Novel proteins and nucleic acids encoding same

FIELD OF THE INVENTION

The present invention relates to novel polypeptides that are targets of small molecule drugs and that have properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions.

BACKGROUND

Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways involve extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells.

Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells and receptor cells in close proximity to each other, for example two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding biochemical or physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect.

Signaling processes may elicit a variety of effects on cells and tissues including by way of nonlimiting example induction of cell or tissue proliferation, suppression of growth or proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue.

Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as diminished or suppressed level of synthesis and secretion of protein effectors. In other classes of pathologies the dysregulation is manifested as increased or up-regulated level of synthesis and secretion of protein effectors: In a clinical setting a subject may be suspected of suffering from a condition brought on by altered or mis-regulated levels of a protein effector of interest. Therefore there is a need to assay for the level of the protein effector of interest in a biological sample from such a subject, and to compare the level with that characteristic of a nonpathological condition. There also is a need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished or suppressed levels of the protein effector of interest. In addition, there is a need for a method of treatment of a pathological condition brought on by a increased or up-regulated levels of the protein effector of interest.

Small molecule targets have been implicated in various disease states or pathologies. These targets may be proteins, and particularly enzymatic proteins, which are acted upon by small molecule drugs for the purpose of altering target function and achieving a desired result. Cellular, animal and clinical studies can be performed to elucidate the genetic contribution to the etiology and pathogenesis of conditions in which small molecule targets are implicated in a variety of physiologic, pharmacologic or native states. These studies utilize the core technologies at CuraGen Corporation to look at differential gene expression, protein-protein interactions, large-scale sequencing of expressed genes and the association of genetic variations such as, but not limited to, single nucleotide polymorphisms (SNPs) or splice variants in and between biological samples from experimental and control groups. The goal of such studies is to identify potential avenues for therapeutic intervention in order to prevent, treat the consequences or cure the conditions.

In order to treat diseases, pathologies and other abnormal states or conditions in which a mammalian organism has been diagnosed as being, or as being at risk for becoming, other than in a normal state or condition, it is important to identify new therapeutic agents. Such a procedure includes at least the steps of identifying a target component within an affected tissue or organ, and identifying a candidate therapeutic agent that modulates the functional attributes of the target. The target component may be any biological macromolecule implicated in the disease or pathology. Commonly the target is a polypeptide or protein with specific functional attributes. Other classes of macromolecule may be a nucleic acid, a polysaccharide, a lipid such as a complex lipid or a glycolipid; in addition a target may be a sub-cellular structure or extra-cellular structure that is comprised of more than one of these classes of macromolecule. Once such a target has been identified, it may be employed in a screening assay in order to identify favorable candidate therapeutic agents from among a large population of substances or compounds.

In many cases the objective of such screening assays is to identify small molecule candidates; this is commonly approached by the use of combinatorial methodologies to develop the population of substances to be tested. The implementation of high throughput screening methodologies is advantageous when working with large, combinatorial libraries of compounds.

SUMMARY OF THE INVENTION

The invention includes nucleic acid sequences and the novel polypeptides they encode. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, etc., nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as “NOVX” nucleic acid, which represents the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 566, or polypeptide sequences, which represents the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 566.

In one aspect, the invention provides an isolated polypeptide comprising a mature form of a NOVX amino acid. One example is a variant of a mature form of a NOVX amino acid sequence, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. The amino acid can be, for example, a NOVX amino acid sequence or a variant of a NOVX amino acid sequence, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also includes fragments of any of these. In another aspect, the invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof.

Also included in the invention is a NOVX polypeptide that is a naturally occurring allelic variant of a NOVX sequence. In one embodiment, the allelic variant includes an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a NOVX nucleic acid sequence. In another embodiment, the NOVX polypeptide is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution. In one embodiment, the invention discloses a method for determining the presence or amount of the NOVX polypeptide in a sample. The method involves the steps of: providing a sample; introducing the sample to an antibody that binds immunospecifically to the polypeptide; and determining the presence or amount of antibody bound to the NOVX polypeptide, thereby determining the presence or amount of the NOVX polypeptide in the sample. In another embodiment, the invention provides a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide in a mammalian subject. This method involves the steps of: measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and comparing the amount of the polypeptide in the sample of the first step to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

In a further embodiment, the invention includes a method of identifying an agent that binds to a NOVX polypeptide. This method involves the steps of: introducing the polypeptide to the agent; and determining whether the agent binds to the polypeptide. In various embodiments, the agent is a cellular receptor or a downstream effector.

In another aspect, the invention provides a method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a NOVX polypeptide. The method involves the steps of: providing a cell expressing the NOVX polypeptide and having a property or function ascribable to the polypeptide; contacting the cell with a composition comprising a candidate substance; and determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent. In another aspect, the invention describes a method for screening for a modulator of activity or of latency or predisposition to a pathology associated with the NOVX polypeptide. This method involves the following steps: administering a test compound to a test animal at increased risk for a pathology associated with the NOVX polypeptide, wherein the test animal recombinantly expresses the NOVX polypeptide. This method involves the steps of measuring the activity of the NOVX polypeptide in the test animal after administering the compound of step; and comparing the activity of the protein in the test animal with the activity of the NOVX polypeptide in a control animal not administered the polypeptide, wherein a change in the activity of the NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the NOVX polypeptide. In one embodiment, the test animal is a recombinant test animal that expresses a test protein transgene or expresses the transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein the promoter is not the native gene promoter of the transgene. In another aspect, the invention includes a method for modulating the activity of the NOVX polypeptide, the method comprising introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide.

The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. In a preferred embodiment, the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant. In another embodiment, the nucleic acid encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence. In one embodiment, the NOVX nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 566, or a complement of the nucleotide sequence. In another aspect, the invention provides a vector or a cell expressing a NOVX nucleotide sequence.

In one embodiment, the invention discloses a method for modulating the activity of a NOVX polypeptide. The method includes the steps of: introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide. In another embodiment, the invention includes an isolated NOVX nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising a NOVX amino acid sequence or a variant of a mature form of the NOVX amino acid sequence, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. In another embodiment, the invention includes an amino acid sequence that is a variant of the NOVX amino acid sequence, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed.

In one embodiment, the invention discloses a NOVX nucleic acid fragment encoding at least a portion of a NOVX polypeptide or any variant of the polypeptide, wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed. In another embodiment, the invention includes the complement of any of the NOVX nucleic acid molecules or a naturally occurring allelic nucleic acid variant. In another embodiment, the invention discloses a NOVX nucleic acid molecule that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the invention discloses a NOVX nucleic acid, wherein the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence.

In another aspect, the invention includes a NOVX nucleic acid, wherein one or more nucleotides in the NOVX nucleotide sequence is changed to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In one embodiment, the invention discloses a nucleic acid fragment of the NOVX nucleotide sequence and a nucleic acid fragment wherein one or more nucleotides in the NOVX nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In another embodiment, the invention includes a nucleic acid molecule wherein the nucleic acid molecule hybridizes under stringent conditions to a NOVX nucleotide sequence or a complement of the NOVX nucleotide sequence. In one embodiment, the invention includes a nucleic acid molecule, wherein the sequence is changed such that no more than 15% of the nucleotides in the coding sequence differ from the NOVX nucleotide sequence or a fragment thereof.

In a further aspect, the invention includes a method for determining the presence or amount of the NOVX nucleic acid in a sample. The method involves the steps of: providing the sample; introducing the sample to a probe that binds to the nucleic acid molecule; and determining the presence or amount of the probe bound to the NOVX nucleic acid molecule, thereby determining the presence or amount of the NOVX nucleic acid molecule in the sample. In one embodiment, the presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.

In another aspect, the invention discloses a method for determining the presence of or predisposition to a disease associated with altered levels of the NOVX nucleic acid molecule of in a first mammalian subject. The method involves the steps of: measuring the amount of NOVX nucleic acid in a sample from the first mammalian subject; and comparing the amount of the nucleic acid in the sample of step (a) to the amount of NOVX nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE FIGURES

FIG. D1: Alignment of CG55806-04 (SEQ ID NO:748), CG55806-02 (SEQ ID NO:752), and 1PFX (SEQ ID NO: 1476).

FIG. D2: Structure of porcine factor IXa (1PFX).

FIG. E1: Data showing effect on cell growth by knockdown of CG59693-01.

FIG. E2: Data showing effect on cell growth by knockdown of CG59693-01 with subsequent treatment with Paclitaxel (48 hr).

FIG. E3: Data showing effect on cell viability by knockdown of CG59693-01 with subsequent treatment with Paclitaxel (48 hr).

FIG. E4: Data showing effect on cell growth by knockdown of CG59693-01 with subsequent treatment with Paclitaxel (72 hr).

FIG. E5: Data showing effect on cell viability by knockdown of CG59693-01 with subsequent treatment with Paclitaxel (72 hr).

FIG. E6: Data showing effect on cell growth by knockdown of CG59693-01 by AS4 antisense oligonucleotide followed by subsequent treatment with Gemcitabine.

FIG. E7: Data showing effect on cell growth by knockdown of CG59693-01 by AS4 antisense oligonucleotide followed by subsequent treatment with Daunorubicin.

FIG. E8: Data showing effect on cell growth by knockdown of CG59693-01 by AS4 antisense oligonucleotide followed by subsequent treatment with Etoposide.

FIG. E9: Data showing effect on cell growth by knockdown of CG59693-01 by AS4 antisense oligonucleotide followed by subsequent treatment with Cisplatin.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as “NOVX nucleic acids” or “NOVX polynucleotides” and the corresponding encoded polypeptides are referred to as “NOVX polypeptides” or “NOVX proteins.” Unless indicated otherwise, “NOVX” is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.

TABLE ASequences and Corresponding SEQ ID NumbersSEQ IDSEQNOID NONOVXInternal(nucleic(aminoAssignmentIdentificationacid)acid)HomologyNOV1aCG101340-0112Putative G protein-coupled receptor92 (Putative G-protein coupledreceptor) - Homo sapiensNOV1bSNP1338246534Putative G protein-coupled receptor92 (Putative G-protein coupledreceptor) - Homo sapiensNOV2aCG101396-0156Glutamate receptor delta-1 subunitprecursor - Rattus norvegicusNOV2b26725322478Glutamate receptor delta-1 subunitprecursor - Rattus norvegicusNOV2c315490179910Glutamate receptor delta-1 subunitprecursor - Rattus norvegicusNOV2dCG101396-021112Glutamate receptor delta-1 subunitprecursor - Rattus norvegicusNOV2eSNP133792111314Glutamate receptor delta-1 subunitprecursor - Rattus norvegicusNOV3aCG102348-011516Complement Clr-like proteinase -Homo sapiensNOV3b1998426451718Complement Clr-like proteinase -Homo sapiensNOV3c1983063431920Complement Clr-like proteinase -Homo sapiensNOV3d1998426652122Complement Clr-like proteinase -Homo sapiensNOV3e1998426612324Complement Clr-like proteinase -Homo sapiensNOV3f1995970242526Complement Clr-like proteinase -Homo sapiensNOV3g1998426532728Complement Clr-like proteinase -Homo sapiensNOV3h1996528302930Complement Clr-like proteinase -Homo sapiensNOV3i1996528353132Complement Clr-like proteinase -Homo sapiensNOV3j1983063083334Complement Clr-like proteinase -Homo sapiensNOV3kCG102348-023536Complement Clr-like proteinase -Homo sapiensNOV3lCG102348-033738Complement Clr-like proteinase -Homo sapiensNOV3mCG102348-043940Complement Clr-like proteinase -Homo sapiensNOV3nCG102348-054142Complement Clr-like proteinase -Homo sapiensNOV3oCG102348-064344Complement Clr-like proteinase -Homo sapiensNOV3pSNP133765704546Complement Clr-like proteinase -Homo sapiensNOV3qSNP133765684748Complement Clr-like proteinase -Homo sapiensNOV3rSNP133824634950Complement Clr-like proteinase -Homo sapiensNOV3sSNP133742455152Complement Clr-like proteinase -Homo sapiensNOV4aCG125860-025354Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4bCG125860-015556Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4cSNP133760125758Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4dSNP133760145960Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4eSNP133760156162Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4fSNP133760166364Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4gSNP133760176566Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4hSNP133760116768Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4iSNP133760186970Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4jSNP133824677172Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV4kSNP133824667374Transmembrane protease, serine 5(EC 3.4.21.—) (Spinesin) - HomosapiensNOV5aCG155759-027576Seven transmembrane helix receptor -Homo sapiensNOV5bCG155759-017778Seven transmembrane helix receptor -Homo sapiensNOV6aCG187667-017980LOC133308 protein - Homo sapiensNOV6bCG187667-028182LOC133308 protein - Homo sapiensNOV7aCG187676-018384Sentrin-specific protease 5 (EC3.4.22.—) (Sentrin/SUMO-specificprotease SENP5) (Protease FKSG45) -Homo sapiensNOV8aCG50235-048586Tolloid-like 2 protein - Homo sapiensNOV8bCG50235-018788Tolloid-like 2 protein - Homo sapiensNOV8cCG50235-028990Tolloid-like 2 protein - Homo sapiensNOV8dCG50235-039192Tolloid-like 2 protein - Homo sapiensNOV8eSNP133773839394Tolloid-like 2 protein - Homo sapiensNOV8fSNP133773849596Tolloid-like 2 protein - Homo sapiensNOV8gSNP133773859798Tolloid-like 2 protein - Homo sapiensNOV8hSNP1337738699100Tolloid-like 2 protein - Homo sapiensNOV8iSNP13377387101102Tolloid-like 2 protein - Homo sapiensNOV9aCG50249-01103104Voltage gated potassium channelKv3.2b (Potassium voltage-gatedpotassium channel subfamily Cmember 2) - Homo sapiensNOV9b207885588105106Voltage gated potassium channelKv3.2b (Potassium voltage-gatedpotassium channel subfamily Cmember 2) - Homo sapiensNOV9cCG50249-02107108Voltage gated potassium channelKv3.2b (Potassium voltage-gatedpotassium channel subfamily Cmember 2) - Homo sapiensNOV9dCG50249-03109110Voltage gated potassium channelKv3.2b (Potassium voltage-gatedpotassium channel subfamily Cmember 2) - Homo sapiensNOV9eCG50249-04111112Voltage gated potassium channelKv3.2b (Potassium voltage-gatedpotassium channel subfamily Cmember 2) - Homo sapiensNOV10aCG50307-03113114Steroid dehydrogenase-like proteinNOV10b275624102115116Steroid dehydrogenase-like proteinNOV10cCG50307-01117118Steroid dehydrogenase-like proteinNOV10dCG50307-02119120Steroid dehydrogenase-like proteinNOV10eSNP13375811121122Steroid dehydrogenase-like proteinNOV11aCG50315-01123124Seven transmembrane helix receptor -Homo sapiensNOV11b207580272125126Seven transmembrane helix receptor -Homo sapiensNOV11c314411778127128Seven transmembrane helix receptor -Homo sapiensNOV11dCG50315-02129130Seven transmembrane helix receptor -Homo sapiensNOV11eCG50315-03131132Seven transmembrane helix receptor -Homo sapiensNOV12aCG50341-01133134Seven transmembrane helix receptor -Homo sapiensNOV12b169475616135136Seven transmembrane helix receptor -Homo sapiensNOV12cCG50341-02137138Seven transmembrane helix receptor -Homo sapiensNOV12dCG50341-03139140Seven transmembrane helix receptor -Homo sapiensNOV12eCG50341-04141142Seven transmembrane helix receptor -Homo sapiensNOV13aCG50365-01143144Carbonic anhydrase XIII (EC 4.2.1.1)(Carbonate dehydratase XIII) (CA-XIII) - Homo sapiensNOV13b278019595145146Carbonic anhydrase XIII (EC 4.2.1.1)(Carbonate dehydratase XIII) (CA-XIII) - Homo sapiensNOV13cCG50365-02147148Carbonic anhydrase XIII (EC 4.2.1.1)(Carbonate dehydratase XIII) (CA-XIII) - Homo sapiensNOV14aCG50367-01149150ADAM 33 precursor (EC 3.4.24.—) (Adisintegrin and metalloproteinasedomain 33) - Homo sapiensNOV14bCG50367-05151152ADAM 33 precursor (EC 3.4.24.—) (Adisintegrin and metalloproteinasedomain 33) - Homo sapiensNOV14cCG50367-06153154ADAM 33 precursor (EC 3.4.24.—) (Adisintegrin and metalloproteinasedomain 33) - Homo sapiensNOV14dCG50367-07155156ADAM 33 precursor (EC 3.4.24.—) (Adisintegrin and metalloproteinasedomain 33) - Homo sapiensNOV14e249356906157158ADAM 33 precursor (EC 3.4.24.—) (Adisintegrin and metalloproteinasedomain 33) - Homo sapiensNOV14fCG50367-02159160ADAM 33 precursor (EC 3.4.24.—) (Adisintegrin and metalloproteinasedomain 33) - Homo sapiensNOV14gCG50367-03161162ADAM 33 precursor (EC 3.4.24.—) (Adisintegrin and metalloproteinasedomain 33) - Homo sapiensNOV14hCG50367-04163164ADAM 33 precursor (EC 3.4.24.—) (Adisintegrin and metalloproteinasedomain 33) - Homo sapiensNOV15aCG50718-02165166Glomerular mesangial cell receptorprotein-tyrosine phosphataseprecursor - Rattus norvegicusNOV15bCG50718-06167168Glomerular mesangial cell receptorprotein-tyrosine phosphataseprecursor - Rattus norvegicusNOV15c258979883169170Glomerular mesangial cell receptorprotein-tyrosine phosphataseprecursor - Rattus norvegicusNOV15dCG50718-01171172Glomerular mesangial cell receptorprotein-tyrosine phosphataseprecursor - Rattus norvegicusNOV15eCG50718-03173174Glomerular mesangial cell receptorprotein-tyrosine phosphataseprecursor - Rattus norvegicusNOV15fCG50718-04175176Glomerular mesangial cell receptorprotein-tyrosine phosphataseprecursor - Rattus norvegicusNOV15gCG50718-05177178Glomerular mesangial cell receptorprotein-tyrosine phosphataseprecursor - Rattus norvegicusNOV16aCG50934-03179180Mast cell protease-11 - Mus musculusNOV16bCG50934-01181182Mast cell protease-11 - Mus musculusNOV16cCG50934-02183184Mast cell protease-11 - Mus musculusNOV16dSNP13381559185186Mast cell protease-11 - Mus musculusNOV16eSNP13381558187188Mast cell protease-11 - Mus musculusNOV16fSNP13376399189190Mast cell protease-11 - Mus musculusNOV16gSNP13378301191192Mast cell protease-11 - Mus musculusNOV16hSNP13378300193194Mast cell protease-11 - Mus musculusNOV17aCG51213-04195196ADAMTS-10 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 10)(ADAM-TS 10) (ADAM-TS10) -Homo sapiens (Human), 1077 aaNOV17bCG51213-01197198ADAMTS-10 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 10)(ADAM-TS 10) (ADAM-TS10) -Homo sapiens (Human), 1077 aaNOV17c306345264199200ADAMTS-10 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 10)(ADAM-TS 10) (ADAM-TS10) -Homo sapiens (Human), 1077 aaNOV17dCG51213-02201202ADAMTS-10 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 10)(ADAM-TS 10) (ADAM-TS10) -Homo sapiens (Human), 1077 aaNOV17eCG51213-03203204ADAMTS-10 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 10)(ADAM-TS 10) (ADAM-TS10) -Homo sapiens (Human), 1077 aaNOV17fCG51213-05205206ADAMTS-10 precursor (EG 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 10)(ADAM-TS 10) (ADAM-TS10) -Homo sapiens (Human), 1077 aaNOV17gCG51213-06207208ADAMTS-10 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 10)(ADAM-TS 10) (ADAM-TS10) -Homo sapiens (Human), 1077 aaNOV17hCG51213-07209210ADAMTS-10 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 10)(ADAM-TS 10) (ADAM-TS10) -Homo sapiens (Human), 1077 aaNOV18aCG51448-05211212Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18bCG51448-01213214Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18c274051198215216Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18d274051170217218Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18eCG51448-02219220Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18fCG51448-03221222Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18gCG51448-04223224Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18hSNP13375535225226Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18iSNP13375536227228Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18jSNP13375537229230Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18kSNP13375538231232Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18lSNP13375539233234Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18mSNP13375540235236Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18nSNP13375541237238Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18oSNP13375542239240Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV18pSNP13375543241242Human cardiac myosin light chainkinase (cMLCK) mutant, G89DNOV19aCG51752-02243244Human FCTR6b polypeptidesequenceNOV19bCG51752-03245246Human FCTR6b polypeptidesequenceNOV19c175069825247248Human FCTR6b polypeptidesequenceNOV19d175069842249250Human FCTR6b polypeptidesequenceNOV19e258076315251252Human FCTR6b polypeptidesequenceNOV19f258076366253254Human FCTR6b polypeptidesequenceNOV19gCG51752-04255256Human FCTR6b polypeptidesequenceNOV19h191887409257258Human FCTR6b polypeptidesequenceNOV19iCG51752-01259260Human FCTR6b polypeptidesequenceNOV19jCG51752-05261262Human FCTR6b polypeptidesequenceNOV19kCG51752-06263264Human FCTR6b polypeptidesequenceNOV19lCG51752-07265266Human FCTR6b polypeptidesequenceNOV19mSNP13374584267268Human FCTR6b polypeptidesequenceNOV19nSNP13374585269270Human FCTR6b polypeptidesequenceNOV20aCG51914-02271272Human kinase polypeptide (PKIN-16)NOV20bCG51914-01273274Human kinase polypeptide (PKIN-16)NOV21aCG51965-01275276Cadherin EGF LAG seven-pass G-type receptor 1 precursor (Flamingohomolog 2) (hFmi2) - Homo sapiensNOV21b258076370277278Cadherin EGF LAG seven-pass G-type receptor 1 precursor (Flamingohomolog 2) (hFmi2) - Homo sapiensNOV21c317619862279280Cadherin EGF LAG seven-pass G-type receptor 1 precursor (Flamingohomolog 2) (hFmi2) - Homo sapiensNOV21d317460050281282Cadherin EGF LAG seven-pass G-type receptor 1 precursor (Flamingohomolog 2) (hFmi2) - Homo sapiensNOV21eSNP13382483283284Cadherin EGF LAG seven-pass G-type receptor 1 precursor (Flamingohomolog 2) (hFmi2) - Homo sapiensNOV21fSNP13382484285286Cadherin EGF LAG seven-pass G-type receptor 1 precursor (Flamingohomolog 2) (hFmi2) - Homo sapiensNOV21gSNP13382485287288Cadherin EGF LAG seven-pass G-type receptor 1 precursor (Flamingohomolog 2) (hFmi2) - Homo sapiensNOV22aCG51983-05289290ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV22bCG51983-01291292ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV22cCG51983-02293294ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV22dCG51983-03295296ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV22eCG51983-04297298ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV22fCG51983-06299300ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV22gSNP13376585301302ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV22hSNP13376586303304ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV23aCG53390-02305306Seven transmembrane helix receptor -Homo sapiensNOV23bCG53390-01307308Seven transmembrane helix receptor -Homo sapiensNOV23cCG53390-03309310Seven transmembrane helix receptor -Homo sapiensNOV24aCG53482-01311312Human odorant receptor (OR)NOV24bCG53482-02313314Human odorant receptor (OR)NOV24cCG53482-03315316Human odorant receptor (OR)NOV24dSNP13373787317318Human odorant receptor (OR)NOV24eSNP13373786319320Human odorant receptor (OR)NOV24fSNP13373785321322Human odorant receptor (OR)NOV25aCG53530-03323324Seven transmembrane helix receptor -Homo sapiensNOV25bCG53530-01325326Seven transmembrane helix receptor -Homo sapiensNOV25cCG53530-02327328Seven transmembrane helix receptor -Homo sapiensNOV26aCG53563-03329330Seven transmembrane helix receptor -Homo sapiensNOV26bCG53563-01331332Seven transmembrane helix receptor -Homo sapiensNOV26cCG53563-02333334Seven transmembrane helix receptor -Homo sapiensNOV27aCG53719-02335336Olfactory receptor MOR106-5 - MusmusculusNOV27bCG53719-01337338Olfactory receptor MOR106-5 - MusmusculusNOV28aCG53746-04339340Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28bCG53746-01341342Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28cCG53746-02343344Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28dCG53746-03345346Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28eSNP13373967347348Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28fSNP13373968349350Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28gSNP13382432351352Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28hSNP13373969353354Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28iSNP13373970355356Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28jSNP13373971357358Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28kSNP13373972359360Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV28lSNP13382433361362Olfactory receptor 5P3 (Olfactoryreceptor-like protein JCG1) - HomosapiensNOV29aCG53767-02363364Seven transmembrane helix receptor -Homo sapiensNOV29bCG53767-01365366Seven transmembrane helix receptor -Homo sapiensNOV29cSNP13382437367368Seven transmembrane helix receptor -Homo sapiensNOV29dSNP13382436369370Seven transmembrane helix receptor -Homo sapiensNOV30aCG53776-02371372Olfactory receptor 5P2 (Olfactoryreceptor-like protein JCG3) - HomosapiensNOV30bCG53776-03373374Olfactory receptor 5P2 (Olfactoryreceptor-like protein JCG3) - HomosapiensNOV30cCG53776-01375376Olfactory receptor 5P2 (Olfactoryreceptor-like protein JCG3) - HomosapiensNOV31aCG53803-02377378Sequence 3 from Patent WO0159113 -Homo sapiensNOV31bCG53803-01379380Sequence 3 from Patent WO0159113 -Homo sapiensNOV32aCG53989-03381382Mast cell protease-11 - Mus musculusNOV32bCG53989-04383384Mast cell protease-11 - Mus musculusNOV32c306076095385386Mast cell protease-11 - Mus musculusNOV32dCG53989-01387388Mast cell protease-11 - Mus musculusNOV32eCG53989-02389390Mast cell protease-11 - Mus musculusNOV32fCG53989-05391392Mast cell protease-11 - Mus musculusNOV32gCG53989-06393394Mast cell protease-11 - Mus musculusNOV32hCG53989-07395396Mast cell protease-11 - Mus musculusNOV32iCG53989-08397398Mast cell protease-11 - Mus musculusNOV32jCG53989-09399400Mast cell protease-11 - Mus musculusNOV32kCG53989-10401402Mast cell protease-11 - Mus musculusNOV32lCG53989-11403404Mast cell protease-11 - Mus musculusNOV32mCG53989-12405406Mast cell protease-11 - Mus musculusNOV32nCG53989-13407408Mast cell protease-11 - Mus musculusNOV33aCG54203-02409410Olfactory receptor 2S2 - HomosapiensNOV33bCG54203-01411412Olfactory receptor 2S2 - HomosapiensNOV33cSNP13382442413414Olfactory receptor 2S2 - HomosapiensNOV33dSNP13373880415416Olfactory receptor 2S2 - HomosapiensNOV33eSNP13373881417418Olfactory receptor 2S2 - HomosapiensNOV33fSNP13382443419420Olfactory receptor 2S2 - HomosapiensNOV33gSNP13373844421422Olfactory receptor 2S2 - HomosapiensNOV33hSNP13373883423424Olfactory receptor 2S2 - HomosapiensNOV34aCG54212-02425426Seven transmembrane helix receptor -Homo sapiensNOV34bCG54212-01427428Seven transmembrane helix receptor -Homo sapiensNOV34cCG54212-03429430Seven transmembrane helix receptor -Homo sapiensNOV34dCG54212-04431432Seven transmembrane helix receptor -Homo sapiensNOV34eSNP13373981433434Seven transmembrane helix receptor -Homo sapiensNOV34fSNP13373982435436Seven transmembrane helix receptor -Homo sapiensNOV34gSNP13373984437438Seven transmembrane helix receptor -Homo sapiensNOV34hSNP13373985439440Seven transmembrane helix receptor -Homo sapiensNOV35aCG54236-01441442Cysteinyl leukotriene receptor 2(CysLTR2) (PSEC0146) (HG57)(HPN321) (hGPCR21) - HomosapiensNOV35bCG54236-02443444Cysteinyl leukotriene receptor 2(CysLTR2) (PSEC0146) (HG57)(HPN321) (hGPCR21) - HomosapiensNOV36aCG54479-06445446Macrophage stimulating 1(Hepatocyte growth factor-like) -Homo sapiensNOV36bCG54479-05447448Macrophage stimulating 1(Hepatocyte growth factor-like) -Homo sapiensNOV36cCG54479-01449450Macrophage stimulating 1(Hepatocyte growth factor-like) -Homo sapiensNOV36dCG54479-02451452Macrophage stimulating 1(Hepatocyte growth factor-like) -Homo sapiensNOV36eCG54479-03453454Macrophage stimulating 1(Hepatocyte growth factor-like) -Homo sapiensNOV36fCG54479-04455456Macrophage stimulating 1(Hepatocyte growth factor-like) -Homo sapiensNOV37aCG54539-02457458Zinc transporter 1 (ZnT-1) - HomosapiensNOV37bCG54539-01459460Zinc transporter 1 (ZnT-1) - HomosapiensNOV37cSNP13382438461462Zinc transporter 1 (ZnT-1) - HomosapiensNOV38aCG54683-05463464Gamma-aminobutyric-acid receptorrho-3 subunit precursor (GABA(A)receptor) - Rattus norvegicusNOV38bCG54683-01465466Gamma-aminobutyric-acid receptorrho-3 subunit precursor (GABA(A)receptor) - Rattus norvegicusNOV38cCG54683-02467468Gamma-aminobutyric-acid receptorrho-3 subunit precursor (GABA(A)receptor) - Rattus norvegicusNOV38dCG54683-03469470Gamma-aminobutyric-acid receptorrho-3 subunit precursor (GABA(A)receptor) - Rattus norvegicusNOV38eCG54683-04471472Gamma-aminobutyric-acid receptorrho-3 subunit precursor (GABA(A)receptor) - Rattus norvegicusNOV39aCG54692-06473474Human G-protein coupled receptor(GCREC-15)NOV39bCG54692-01475476Human G-protein coupled receptor(GCREC-15)NOV39cCG54692-02477478Human G-protein coupled receptor(GCREC-15)NOV39dCG54692-03479480Human G-protein coupled receptor(GCREC-15)NOV39eCG54692-04481482Human G-protein coupled receptor(GCREC-15)NOV39fCG54692-05483484Human G-protein coupled receptor(GCREC-15)NOV40aCG55069-01485486Ten-m3 - Mus musculusNOV40bCG55069-04487488Ten-m3 - Mus musculusNOV40c248993047489490Ten-m3 - Mus musculusNOV40d262802488491492Ten-m3 - Mus musculusNOV40e248993606493494Ten-m3 - Mus musculusNOV40f314411758495496Ten-m3 - Mus musculusNOV40g319067006497498Ten-m3 - Mus musculusNOV40h319506086499500Ten-m3 - Mus musculusNOV40iCG55069-03501502Ten-m3 - Mus musculusNOV40j219937039503504Ten-m3 - Mus musculusNOV40k219937046505506Ten-m3 - Mus musculusNOV40l219937583507508Ten-m3 - Mus musculusNOV40m219937000509510Ten-m3 - Mus musculusNOV40n219937005511512Ten-m3 - Mus musculusNOV40o219937013513514Ten-m3 - Mus musculusNOV40p219937063515516Ten-m3 - Mus musculusNOV40qCG55069-09517518Ten-m3 - Mus musculusNOV40r309327410519520Ten-m3 - Mus musculusNOV40sCG55069-02521522Ten-m3 - Mus musculusNOV40tCG55069-05523524Ten-m3 - Mus musculusNOV40uCG55069-06525526Ten-m3 - Mus musculusNOV40vCG55069-07527528Ten-m3 - Mus musculusNOV40wCG55069-08529530Ten-m3 - Mus musculusNOV40xCG55069-10531532Ten-m3 - Mus musculusNOV40yCG55069-11533534Ten-m3 - Mus musculusNOV40zCG55069-12535536Ten-m3 - Mus musculusNOV40aCG55069-13537538Ten-m3 - Mus musculusNOV40bCG55069-14539540Ten-m3 - Mus musculusNOV40cCG55069-15541542Ten-m3 - Mus musculusNOV40dSNP13374479543544Ten-m3 - Mus musculusNOV40eSNP13382453545546Ten-m3 - Mus musculusNOV40fSNP13382454547548Ten-m3 - Mus musculusNOV40gSNP13382455549550Ten-m3 - Mus musculusNOV40hSNP13378354551552Ten-m3 - Mus musculusNOV41aCG55343-03553554Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41b260568382555556Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41c314361391557558Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41d317286137559560Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41eCG55343-01561562Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41fCG55343-02563564Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41gCG55343-04565566Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41hCG55343-05567568Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41iCG55343-06569570Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41jSNP13373740571572Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41kSNP13376425573574Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41lSNP13376424575576Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV41mSNP13376423577578Olfactory receptor 2B6 (Hs6M1-32)(Olfactory receptor 6-31) (OR6-31) -Homo sapiensNOV42aCG55358-04579580G-protein coupled receptor 4a(GPCR4a)NOV42bCG55358-03581582G-protein coupled receptor 4a(GPCR4a)NOV42c317863291583584G-protein coupled receptor 4a(GPCR4a)NOV42d317863328585586G-protein coupled receptor 4a(GPCR4a)NOV42e317863350587588G-protein coupled receptor 4a(GPCR4a)NOV42f271624076589590G-protein coupled receptor 4a(GPCR4a)NOV42gCG55358-01591592G-protein coupled receptor 4a(GPCR4a)NOV42hCG55358-02593594G-protein coupled receptor 4a(GPCR4a)NOV42iCG55358-05595596G-protein coupled receptor 4a(GPCR4a)NOV42jCG55358-06597598G-protein coupled receptor 4a(GPCR4a)NOV42kCG55358-07599600G-protein coupled receptor 4a(GPCR4a)NOV42lSNP13375122601602G-protein coupled receptor 4a(GPCR4a)NOV42mSNP13375123603604G-protein coupled receptor 4a(GPCR4a)NOV42nSNP13382494605606G-protein coupled receptor 4a(GPCR4a)NOV42oSNP13375124607608G-protein coupled receptor 4a(GPCR4a)NOV42pSNP13375125609610G-protein coupled receptor 4a(GPCR4a)NOV42qSNP13376426611612G-protein coupled receptor 4a(GPCR4a)NOV42rSNP13376427613614G-protein coupled receptor 4a(GPCR4a)NOV42sSNP13375126615616G-protein coupled receptor 4a(GPCR4a)NOV43aCG55604-04617618Seven transmembrane helix receptorNOV43bCG55604-01619620Seven transmembrane helix receptorNOV43cCG55604-02621622Seven transmembrane helix receptorNOV43dCG55604-03623624Seven transmembrane helix receptorNOV43eCG55604-05625626Seven transmembrane helix receptorNOV43fCG55604-06627628Seven transmembrane helix receptorNOV43gCG55604-07629630Seven transmembrane helix receptorNOV43hSNP13019742631632Seven transmembrane helix receptorNOV43iSNP13373776633634Seven transmembrane helix receptorNOV43jSNP13373777635636Seven transmembrane helix receptorNOV43kSNP13373778637638Seven transmembrane helix receptorN0V43lSNP13373838639640Seven transmembrane helix receptorNOV43mSNP13373837641642Seven transmembrane helix receptorNOV43nSNP13373836643644Seven transmembrane helix receptorNOV43oSNP13373780645646Seven transmembrane helix receptorNOV43pSNP13373781647648Seven transmembrane helix receptorNOV43qSNP13373782649650Seven transmembrane helix receptorNOV43rSNP13373783651652Seven transmembrane helix receptorNOV43sSNP13373833653654Seven transmembrane helix receptorNOV43tSNP13373784655656Seven transmembrane helix receptorNOV43uSNP13373832657658Seven transmembrane helix receptorNOV44aCG55752-07659660Glucosidase - Homo sapiens(Human), 769 aaNOV44bCG55752-06661662Glucosidase - Homo sapiens(Human), 769 aaNOV44cCG55752-01663664Glucosidase - Homo sapiens(Human), 769 aaNOV44dCG55752-02665666Glucosidase - Homo sapiens(Human), 769 aaNOV44eCG55752-03667668Glucosidase - Homo sapiens(Human), 769 aaNOV44fCG55752-04669670Glucosidase - Homo sapiens(Human), 769 aaNOV44gCG55752-05671672Glucosidase - Homo sapiens(Human), 769 aaNOV44hSNP13379656673674Glucosidase - Homo sapiens(Human), 769 aaNOV44iSNP13379655675676Glucosidase - Homo sapiens(Human), 769 aaNOV44jSNP13379654677678Glucosidase - Homo sapiens(Human), 769 aaNOV45aCG55778-03679680Aldo-keto reductase related protein 3 -Homo sapiensNOV45bCG55778-06681682Aldo-keto reductase related protein 3 -Homo sapiensNOV45c275480984683684Aldo-keto reductase related protein 3 -Homo sapiensNOV45dCG55778-01685686Aldo-keto reductase related protein 3 -Homo sapiensNOV45eCG55778-02687688Aldo-keto reductase related protein 3 -Homo sapiensNOV45fCG55778-04689690Aldo-keto reductase related protein 3 -Homo sapiensNOV45gCG55778-05691692Aldo-keto reductase related protein 3 -Homo sapiensNOV45hCG55778-07693694Aldo-keto reductase related protein 3 -Homo sapiensNOV45iCG55778-08695696Aldo-keto reductase related protein 3 -Homo sapiensNOV45jSNP13375813697698Aldo-keto reductase related protein 3 -Homo sapiensNOV46aCG55794-03699700Zn-carboxypeptidase - Homo sapiensNOV46b210223559701702Zn-carboxypeptidase - Homo sapiensNOV46c210223626703704Zn-carboxypeptidase - Homo sapiensNOV46d171095097705706Zn-carboxypeptidase - Homo sapiensNOV46e183852229707708Zn-carboxypeptidase - Homo sapiensNOV46f183852264709710Zn-carboxypeptidase - Homo sapiensNOV46g183852410711712Zn-carboxypeptidase - Homo sapiensNOV46h183523337713714Zn-carboxypeptidase - Homo sapiensNOV46iCG55794-01715716Zn-carboxypeptidase - Homo sapiensNOV46jCG55794-02717718Zn-carboxypeptidase - Homo sapiensNOV46kCG55794-04719720Zn-carboxypeptidase - Homo sapiensNOV46lCG55794-05721722Zn-carboxypeptidase - Homo sapiensNOV46mCG55794-06723724Zn-carboxypeptidase - Homo sapiensNOV46nCG55794-07725726Zn-carboxypeptidase - Homo sapiensNOV46oCG55794-08727728Zn-carboxypeptidase - Homo sapiensNOV46pCG55794-09729730Zn-carboxypeptidase - Homo sapiensNOV46qCG55794-10731732Zn-carboxypeptidase - Homo sapiensNOV46rCG55794-11733734Zn-carboxypeptidase - Homo sapiensNOV46sCG55794-12735736Zn-carboxypeptidase - Homo sapiensNOV46tCG55794-13737738Zn-carboxypeptidase - Homo sapiensNOV46uSNP13375362739740Zn-carboxypeptidase - Homo sapiensNOV46vSNP13379598741742Zn-carboxypeptidase - Homo sapiensNOV46wSNP13375066743744Zn-carboxypeptidase - Homo sapiensNOV46xSNP13375067745746Zn-carboxypeptidase - Homo sapiensNOV47aCG55806-04747748FACTOR IX - Homo sapiensNOV47bCG55806-01749750FACTOR IX - Homo sapiensNOV47cCG55806-02751752FACTOR IX - Homo sapiensNOV47dCG55806-03753754FACTOR IX - Homo sapiensNOV47eSNP13382503755756FACTOR IX - Homo sapiensNOV47fSNP13382492757758FACTOR IX - Homo sapiensNOV48aCG55828-02759760Serine/threonine-protein kinase PAK7 (EC 2.7.1.—) (p21-activated kinase 7)(PAK-7) (PAK-5) - Homo sapiensNOV48bCG55828-01761762Serine/threonine-protein kinase PAK7 (EC 2.7.1.—) (p21-activated kinase 7)(PAK-7) (PAK-5) - Homo sapiensNOV48cSNP13379517763764Serine/threonine-protein kinase PAK7 (EC 2.7.1.—) (p21-activated kinase 7)(PAK-7) (PAK-5) - Homo sapiensNOV48dSNP13376535765766Serine/threonine-protein kinase PAK7 (EC 2.7.1.—) (p21-activated kinase 7)(PAK-7) (PAK-5) - Homo sapiensNOV48eSNP13382500767768Serine/threonine-protein kinase PAK7 (EC 2.7.1.—) (p21-activated kinase 7)(PAK-7) (PAK-5) - Homo sapiensNOV48fSNP13375705769770Serine/threonine-protein kinase PAK7 (EC 2.7.1.—) (p21-activated kinase 7)(PAK-7) (PAK-5) - Homo sapiensNOV49aCG55980-02771772Seven transmembrane helix receptor -Homo sapiensNOV49bCG55980-01773774Seven transmembrane helix receptor -Homo sapiensNOV50aCG55988-03775776Organic cation transporter OKB1 -Homo sapiensNOV50bCG55988-04777778Organic cation transporter OKB1 -Homo sapiensNOV50cCG55988-01779780Organic cation transporter OKB1 -Homo sapiensNOV50dCG55988-02781782Organic cation transporter OKB1 -Homo sapiensNOV51aCG56071-01783784Mixed lineage kinase MLK1 - Homosapiens (Human), 1066 aaNOV51b274082270785786Mixed lineage kinase MLK1 - Homosapiens (Human), 1066 aaNOV51cSNP13376041787788Mixed lineage kinase MLK1 - Homosapiens (Human), 1066 aaNOV52aCG56142-01789790Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV52bCG56142-04791792Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV52c276873337793794Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV52d276863970795796Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV52e276863992797798Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV52f276873330799800Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV52gCG56142-02801802Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV52hCG56142-03803804Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV52iCG56142-05805806Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV52jCG56142-06807808Similar to protease, serine, 8(Prostasin) - Homo sapiens (Human),327 aaNOV53aCG56144-01809810Seven transmembrane helix receptor -Homo sapiensNOV53b170645965811812Seven transmembrane helix receptor -Homo sapiensNOV53c168869277813814Seven transmembrane helix receptor -Homo sapiensNOV53d170645981815816Seven transmembrane helix receptor -Homo sapiensNOV53e168869262817818Seven transmembrane helix receptor -Homo sapiensNOV53f168869254819820Seven transmembrane helix receptor -Homo sapiensNOV53gCG56144-02821822Seven transmembrane helix receptor -Homo sapiensNOV53hCG56144-03823824Seven transmembrane helix receptor -Homo sapiensNOV53iCG56144-04825826Seven transmembrane helix receptor -Homo sapiensNOV53jCG56144-05827828Seven transmembrane helix receptor -Homo sapiensNOV53kCG56144-06829830Seven transmembrane helix receptor -Homo sapiensNOV54aCG56146-02831832Seven transmembrane helix receptor -Homo sapiensNOV54bCG56146-01833834Seven transmembrane helix receptor -Homo sapiensNOV54c170646057835836Seven transmembrane helix receptor -Homo sapiensNOV54d170646049837838Seven transmembrane helix receptor -Homo sapiensNOV54e170646053839840Seven transmembrane helix receptor -Homo sapiensNOV54f174307717841842Seven transmembrane helix receptor -Homo sapiensNOV54g168869383843844Seven transmembrane helix receptor -Homo sapiensNOV54hCG56146-03845846Seven transmembrane helix receptor -Homo sapiensNOV54i262939640847848Seven transmembrane helix receptor -Homo sapiensNOV54jCG56146-04849850Seven transmembrane helix receptor -Homo sapiensNOV54kCG56146-05851852Seven transmembrane helix receptor -Homo sapiensNOV54lCG56146-06853854Seven transmembrane helix receptor -Homo sapiensNOV55aCG56258-04855856Na exchanger isoform 3 splice variant2 - Homo sapiensNOV55bCG56258-02857858Na exchanger isoform 3 splice variant2 - Homo sapiensNOV55c258076220859860Na exchanger isoform 3 splice variant2 - Homo sapiensNOV55d248057963861862Na exchanger isoform 3 splice variant2 - Homo sapiensNOV55eCG56258-01863864Na exchanger isoform 3 splice variant2 - Homo sapiensNOV55fCG56258-03865866Na exchanger isoform 3 splice variant2 - Homo sapiensNOV55gCG56258-05867868Na exchanger isoform 3 splice variant2 - Homo sapiensNOV55hCG56258-06869870Na exchanger isoform 3 splice variant2 - Homo sapiensNOV56aCG56262-01871872Putative calcium binding transporter -Homo sapiensNOV56b266120550873874Putative calcium binding transporter -Homo sapiensNOV57aCG56315-01875876Connexin25 - Homo sapiensNOV57b247679382877878Connexin25 - Homo sapiensNOV57c247678321879880Connexin25 - Homo sapiensNOV57d247679418881882Connexin25 - Homo sapiensNOV57e247679395883884Connexin25 - Homo sapiensNOV57f247679328885886Connexin25 - Homo sapiensNOV57gCG56315-02887888Connexin25 - Homo sapiensNOV57hCG56315-03889890Connexin25 - Homo sapiensNOV57iCG56315-04891892Connexin25 - Homo sapiensNOV57jCG56315-05893894Connexin25 - Homo sapiensNOV57kCG56315-06895896Connexin25 - Homo sapiensNOV57lCG56315-07897898Connexin25 - Homo sapiensNOV57mCG56315-08899900Connexin25 - Homo sapiensNOV57nSNP13381650901902Connexin25 - Homo sapiensNOV57oSNP13381651903904Connexin25 - Homo sapiensNOV57pSNP13381652905906Connexin25 - Homo sapiensNOV57qSNP13381653907908Connexin25 - Homo sapiensNOV57rSNP13381654909910Connexin25 - Homo sapiensNOV58aCG56398-01911912Sodium/glucose cotransporter KST1 -Homo sapiensNOV58b265726152913914Sodium/glucose cotransporter KST1 -Homo sapiensNOV58c267254040915916Sodium/glucose cotransporter KST1 -Homo sapiensNOV58dSNP13379242917918Sodium/glucose cotransporter KST1 -Homo sapiensNOV59aCG56605-03919920Protease PRTS-5NOV59bCG56605-01921922Protease PRTS-5NOV59cCG56605-02923924Protease PRTS-5NOV60aCG56645-03925926sodium/glucose cotransporterFbh68723patNOV60bCG56645-04927928sodium/glucose cotransporterFbh68723patNOV60cCG56645-01929930sodium/glucose cotransporterFbh68723patNOV60dCG56645-02931932sodium/glucose cotransporterFbh68723patNOV61aCG56667-01933934Seven transmembrane helix receptor -Homo sapiensNOV61b268952113935936Seven transmembrane helix receptor -Homo sapiensNOV62aCG56868-01937938ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV62b276580332939940ADAM 7 precursor (A disintegrin andmetalloproteinase domain 7) (Spermmaturation-related glycoprotein GP-83) - Homo sapiensNOV63aCG56870-01941942NDRG3 protein - Homo sapiensNOV63bCG56870-06943944NDRG3 protein - Homo sapiensNOV63c276585681945946NDRG3 protein - Homo sapiensNOV63dCG56870-02947948NDRG3 protein - Homo sapiensNOV63eCG56870-03949950NDRG3 protein - Homo sapiensNOV63fCG56870-04951952NDRG3 protein - Homo sapiensNOV63gCG56870-05953954NDRG3 protein - Homo sapiensNOV64aCG57109-01955956Human kinase (PKIN)-4NOV64b260457400957958Human kinase (PKIN)-4NOV64c260457409959960Human kinase (PKIN)-4NOV64dCG57109-05961962Human kinase (PKIN)-4NOV64e267253965963964Human kinase (PKIN)-4NOV64f267254000965966Human kinase (PKIN)-4NOV64g267253987967968Human kinase (PKIN)-4NOV64hCG57109-02969970Human kinase (PKIN)-4NOV64iCG57109-03971972Human kinase (PKIN)-4NOV64jCG57109-04973974Human kinase (PKIN)-4NOV64kCG57109-06975976Human kinase (PKIN)-4NOV65aCG57399-04977978Human phospholipase-like enzymeNOV65bCG57399-01979980Human phospholipase-like enzymeNOV65cCG57399-02981982Human phospholipase-like enzymeNOV65dCG57399-03983984Human phospholipase-like enzymeNOV66aCG57562-02985986cation-transporting ATPase 2 (EC3.6.3.—) (CGI-152) - Homo sapiensNOV66bCG57562-01987988cation-transporting ATPase 2 (EC3.6.3.—) (CGI-152) - Homo sapiensNOV66cSNP13380762989990cation-transporting ATPase 2 (EC3.6.3.—) (CGI-152) - Homo sapiensNOV66dSNP13380787991992cation-transporting ATPase 2 (EC3.6.3.—) (CGI-152) - Homo sapiensNOV67aCG57758-03993994Na+coupled citrate transporter protein -Homo sapiensNOV67b308537854995996Na+coupled citrate transporter protein -Homo sapiensNOV67cCG57758-01997998Na+coupled citrate transporter protein -Homo sapiensNOV67dCG57758-029991000Na+coupled citrate transporter protein -Homo sapiensNOV67eCG57758-0410011002Na+coupled citrate transporter protein -Homo sapiensNOV67fCG57758-0510031004Na+coupled citrate transporter protein -Homo sapiensNOV68aCG58504-0110051006ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68b16964837610071008ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68c16964838810091010ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68d16964836510111012ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68e28406825010131014ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68f30586786610151016ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68g31817639710171018ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68hCG58504-0210191020ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68iCG58504-0310211022ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68jCG58504-0410231024ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68kCG58504-0510251026ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68lCG58504-0610271028ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV68mCG58504-0710291030ADAMTS-12 precursor (EC 3.4.24.—)(A disintegrin and metalloproteinasewith thrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS12) -Homo sapiensNOV69aCG58510-0110311032Cation transport protein YRDONOV70aCG59309-0110331034Human Acyl-CoA thioesteraseNOV70b27890138610351036Human Acyl-CoA thioesteraseNOV71aCG59490-0110371038Mast cell protease-11 - Mus musculusNOV71b20763951210391040Mast cell protease-11 - Mus musculusNOV71c20763947610411042Mast cell protease-11 - Mus musculusNOV71d20763952310431044Mast cell protease-11 - Mus musculusNOV71eCG59490-0210451046Mast cell protease-11 - Mus musculusNOV72aCG59693-0110471048Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)(20 alpha-hydroxysteroiddehydrogenase) - Homo sapiensNOV72bCG59693-0310491050Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)(20 alpha-hydroxysteroiddehydrogenase) - Homo sapiensNOV72c27763725210511052Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)(20 alpha-hydroxysteroiddehydrogenase) - Homo sapiensNOV72dCG59693-0210531054Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)dehydrogenase) - Homo sapiensNOV72eCG59693-0410551056Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)(20 alpha-hydroxysteroiddehydrogenase) - Homo sapiensNOV72fCG59693-0510571058Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)(20 alpha-hydroxysteroiddehydrogenase) - Homo sapiensNOV72gCG59693-0610591060Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)(20 alpha-hydroxysteroiddehydrogenase) - Homo sapiensNOV72hCG59693-0710611062Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)(20 alpha-hydroxysteroiddehydrogenase) - Homo sapiensNOV72iCG59693-0810631064Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)(20 alpha-hydroxysteroiddehydrogenase) - Homo sapiensNOV72jCG59693-0910651066Aldo-keto reductase family 1 memberC1 (EC 1.1.1.—) (Trans-1,2-dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2) (DD2)(20 alpha-hydroxysteroiddehydrogenase) - Homo sapiensNOV73aCG59839-0210671068cation-transporting ATPase 3 (EC3.6.3.—) (ATPase family homolog up-regulated in senescence cells 1) -Homo sapiensNOV73bCG59839-0110691070cation-transporting ATPase 3 (EC3.6.3.—) (ATPase family homolog up-regulated in senescence cells 1) -Homo sapiensNOV74aCG90866-0410711072Human protein kinaseNOV74bCG90866-0310731074Human protein kinaseNOV74cCG90866-0110751076Human protein kinaseNOV74dCG90866-0210771078Human protein kinaseNOV74eCG90866-0510791080Human protein kinaseNOV75aCG91708-0210811082Stromelysin-1 precursor (EC3.4.24.17) (Matrix metalloproteinase-3) (MMP-3) (Transin-1) (SL-1) -Homo sapiensNOV75b26275185610831084Stromelysin-1 precursor (EC3.4.24.17) (Matrix metalloproteinase-3) (MMP-3) (Transin-1) (SL-1) -Homo sapiensNOV75cCG91708-0110851086Stromelysin-1 precursor (EC3.4.24.17) (Matrix metalloproteinase-3) (MMP-3) (Transin-1) (SL-1) -Homo sapiensNOV75dCG91708-0310871088Stromelysin-1 precursor (EC3.4.24.17) (Matrix metalloproteinase-3) (MMP-3) (Transin-1) (SL-1) -Homo sapiensNOV75eCG91708-0410891090Stromelysin-1 precursor (EC3.4.24.17) (Matrix metalloproteinase-3) (MMP-3) (Transin-1) (SL-1) -Homo sapiensNOV75fSNP1338074010911092Stromelysin-1 precursor (EC3.4.24.17) (Matrix metalloproteinase-3) (MMP-3) (Transin-1) (SL-1) -Homo sapiensNOV76aCG92078-0210931094Yolk SAC permease-like YSPL-1form 1 (Yolk SAC permease-likeYSPL-1 form 4) (Yolk SACpermease-like YSPL-1 form 3) (YolkSAC permease-like YSPL-1 form 2) -Mus musculusNOV76bCG92078-0110951096Yolk SAC permease-like YSPL-1form 1 (Yolk SAC permease-likeYSPL-1 form 4) (Yolk SACpermease-like YSPL-1 form 3) (YolkSAC permease-like YSPL-1 form 2) -Mus musculusNOV77aCG93669-0410971098NIMA-related protein kinase 3 -Homo sapiensNOV77bCG93669-0110991100NIMA-related protein kinase 3 -Homo sapiensNOV77cCG93669-0211011102NIMA-related protein kinase 3 -Homo sapiensNOV77dCG93669-0311031104NIMA-related protein kinase 3 -Homo sapiensNOV77eSNP1337646411051106NIMA-related protein kinase 3 -Homo sapiensNOV77fSNP1337646211071108NIMA-related protein kinase 3 -Homo sapiensNOV77gSNP1338252111091110NIMA-related protein kinase 3 -Homo sapiensNOV78aCG94235-0111111112Thymidylate kinase homologueNOV78b25464786411131114Thymidylate kinase homologueNOV78c25434779711151116Thymidylate kinase homologueNOV78dCG94235-0211171118Thymidylate kinase homologueNOV79aCG95175-0111191120Human EphA full length kinaseNOV79b27569711811211122Human EphA full length kinaseNOV79c27569715011231124Human EphA full length kinaseNOV80aCG99638-0111251126Concentrative Na+-nucleosidecotransporter hCNT3NOV81aCG99650-0111271128Concentrative Na+-nucleosidecotransporter hCNT3NOV81bSNP1338252511291130Concentrative Na+-nucleosidecotransporter hCNT3NOV81cSNP1338252611311132Concentrative Na+-nucleosidecotransporter hCNT3

Table A indicates the homology of NOVX polypeptides to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table A will be useful in therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table A.

Pathologies, diseases, disorders and condition and the like that are associated with NOVX sequences include, but are not limited to, e.g., cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, metabolic disturbances associated with obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, diabetes, metabolic disorders, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers, as well as conditions such as transplantation and fertility.

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

Consistent with other known members of the family of proteins, identified in column 5 of Table A, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of, other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A.

The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit diseases associated with the protein families listed in Table A.

The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example C. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g., detection of a variety of cancers. SNP analysis for each NOVX, if applicable, is presented in Example D.

Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

NOVX Clones

The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders.

The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) a biological defense weapon.

In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 566; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 566, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 566; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 566 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d).

In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO: 2n, wherein n is an integer between 1 and 566; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 566 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 566; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 566, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 566 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules.

In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 566; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 566 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 566; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 566 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

NOVX Nucleic Acids and Polypeptides

One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, by way of nonlimiting example, as a result of one or more naturally occurring processing steps that may take place within the cell (e.g., host cell) in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a “mature” form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

The term “probe”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), about 100 nt, or as many as approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single-stranded or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term “isolated” nucleic acid molecule, as used herein, is a nucleic acid that is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′- and 3′-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium, or of chemical precursors or other chemicals.

A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, or a complement of this nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2^ndEd., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template with appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

As used herein, the term “oligonucleotide” refers to a series of linked nucleotide residues. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of a NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, is one that is sufficiently complementary to the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, that it can hydrogen bond with few or no mismatches to the nucleotide sequence shown in SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, thereby forming a stable duplex.

As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

A “fragment” provided herein is defined as a sequence of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, and is at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice.

A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5′ direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3′ direction of the disclosed sequence.

A “derivative” is a nucleic acid sequence or amino acid sequence formed from the native compounds either directly, by modification or partial substitution. An “analog” is a nucleic acid sequence or amino acid sequence that has a structure similar to, but not identical to, the native compound, e.g., they differs from it in respect to certain components or side chains. Analogs may be synthetic or derived from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. A “homolog” is a nucleic acid sequence or amino acid sequence of a particular gene that is derived from different species.

Derivatives and analogs may be full length or other than full length. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the proteins under stringent, moderately stringent, or low stringent conditions. See e.g., Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993, and below.

A “homologous nucleic acid sequence” or “homologous amino acid sequence,” or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences include those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

A NOVX polypeptide is encoded by the open reading frame (“ORF”) of a NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG “start” codon and terminates with one of the three “stop” codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bona fide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g., from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566; or an anti-sense strand nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566; or of a naturally occurring mutant of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566.

Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe has a detectable label attached, e.g. the label can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express a NOVX protein, such as by measuring a level of a NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

“A polypeptide having a biologically-active portion of a NOVX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a “biologically-active portion of NOVX” can be prepared by isolating a portion of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, that encodes a polypeptide having a NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX.

NOVX Nucleic Acid and Polypeptide Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 566.

In addition to the human NOVX nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame (ORF) encoding a NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from a human SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 65% homologous to each other typically remain hybridized to each other.

Homologs (i.e., nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase “stringent hybridization conditions” refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60° C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6×SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65° C., followed by one or more washes in 0.2×SSC, 0.01% BSA at 50° C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6×SSC, 5×Reinhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55° C., followed by one or more washes in 1×SSC, 0.1% SDS at 37° C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Krieger, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5×SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40° C., followed by one or more washes in 2×SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50° C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g. Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. Proc Natl Acad Sci USA 78: 6789-6792.

Conservative Mutations

In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, thereby leading to changes in the amino acid sequences of the encoded NOVX protein, without altering the functional ability of that NOVX protein. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 566. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an “essential” amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are not particularly amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 40% homologous to the amino acid sequences of SEQ ID NO:2n, wherein n is an integer between 1 and 566. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 566; more preferably at least about 70% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 566; still more preferably at least about 80% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 566; even more preferably at least about 90% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 566; and most preferably at least about 95% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 566.

An isolated nucleic acid molecule encoding a NOVX protein homologous to the protein of SEQ ID NO:2n, wherein n is an integer between 1 and 566, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced any one of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis of a nucleic acid of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved “strong” residues or fully conserved “weak” residues. The “strong” group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the “weak” group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and a NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g., avidin proteins).

In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

Interfering RNA

In one aspect of the invention, NOVX gene expression can be attenuated by RNA interference. One approach well-known in the art is short interfering RNA (siRNA) mediated gene silencing where expression products of a NOVX gene are targeted by specific double stranded NOVX derived siRNA nucleotide sequences that are complementary to at least a 19-25 nt long segment of the NOVX gene transcript, including the 5′ untranslated (UT) region, the ORF, or the 3′ UT region. See, e.g., PCT applications WO00/44895, WO99/32619, WO01/75164, WO01/92513, WO 01/29058, WO01/89304, WO02/16620, and WO02/29858, each incorporated by reference herein in their entirety. Targeted genes can be a NOVX gene, or an upstream or downstream modulator of the NOVX gene. Nonlimiting examples of upstream or downstream modulators of a NOVX gene include, e.g., a transcription factor that binds the NOVX gene promoter, a kinase or phosphatase that interacts with a NOVX polypeptide, and polypeptides involved in a NOVX regulatory pathway.

According to the methods of the present invention, NOVX gene expression is silenced using short interfering RNA. A NOVX polynucleotide according to the invention includes a siRNA polynucleotide. Such a NOVX siRNA can be obtained using a NOVX polynucleotide sequence, for example, by processing the NOVX ribopolynucleotide sequence in a cell-free system, such as but not limited to a Drosophila extract, or by transcription of recombinant double stranded NOVX RNA or by chemical synthesis of nucleotide sequences homologous to a NOVX sequence. See, e.g., Tuschl, Zamore, Lehmann, Bartel and Sharp (1999), Genes & Dev. 13: 3191-3197, incorporated herein by reference in its entirety. When synthesized, a typical 0.2 micromolar-scale RNA synthesis provides about 1 milligram of siRNA, which is sufficient for 1000 transfection experiments using a 24-well tissue culture plate format.

The most efficient silencing is generally observed with siRNA duplexes composed of a 21-nt sense strand and a 21-nt antisense strand, paired in a manner to have a 2-nt 3′ overhang. The sequence of the 2-nt 3′ overhang makes an additional small contribution to the specificity of siRNA target recognition. The contribution to specificity is localized to the unpaired nucleotide adjacent to the first paired bases. In one embodiment, the nucleotides in the 3′ overhang are ribonucleotides. In an alternative embodiment, the nucleotides in the 3′ overhang are deoxyribonucleotides. Using 2′-deoxyribonucleotides in the 3′ overhangs is as efficient as using ribonucleotides, but deoxyribonucleotides are often cheaper to synthesize and are most likely more nuclease resistant.

A contemplated recombinant expression vector of the invention comprises a NOVX DNA molecule cloned into an expression vector comprising operatively-linked regulatory sequences flanking the NOVX sequence in a manner that allows for expression (by transcription of the DNA molecule) of both strands. An RNA molecule that is antisense to NOVX mRNA is transcribed by a first promoter (e.g., a promoter sequence 3′ of the cloned DNA) and an RNA molecule that is the sense strand for the NOVX mRNA is transcribed by a second promoter (e.g., a promoter sequence 5′ of the cloned DNA). The sense and antisense strands may hybridize in vivo to generate siRNA constructs for silencing of the NOVX gene. Alternatively, two constructs can be utilized to create the sense and anti-sense strands of a siRNA construct. Finally, cloned DNA can encode a construct having secondary structure, wherein a single transcript has both the sense and complementary antisense sequences from the target gene or genes. In an example of this embodiment, a hairpin RNAi product is homologous to all or a portion of the target gene. In another example, a hairpin RNAi product is a siRNA. The regulatory sequences flanking the NOVX sequence may be identical or may be different, such that their expression may be modulated independently, or in a temporal or spatial manner.

In a specific embodiment, siRNAs are transcribed intracellularly by cloning the NOVX gene templates into a vector containing, e.g., a RNA pol III transcription unit from the smaller nuclear RNA (snRNA) U6 or the human RNase P RNA H1. One example of a vector system is the GeneSuppressor™ RNA Interference kit (commercially available from Imgenex). The U6 and H1 promoters are members of the type III class of Pol III promoters. The +1 nucleotide of the U6-like promoters is always guanosine, whereas the +1 for H1 promoters is adenosine. The termination signal for these promoters is defined by five consecutive thymidines. The transcript is typically cleaved after the second uridine. Cleavage at this position generates a 3′ TU overhang in the expressed siRNA, which is similar to the 3′ overhangs of synthetic siRNAs. Any sequence less than 400 nucleotides in length can be transcribed by these promoter, therefore they are ideally suited for the expression of around 21-nucleotide siRNAs in, e.g., an approximately 50-nucleotide RNA stem-loop transcript.

A siRNA vector appears to have an advantage over synthetic siRNAs where long term knock-down of expression is desired. Cells transfected with a siRNA expression vector would experience steady, long-term mRNA inhibition. In contrast, cells transfected with exogenous synthetic siRNAs typically recover from mRNA suppression within seven days or ten rounds of cell division. The long-term gene silencing ability of siRNA expression vectors may provide for applications in gene therapy.

In general, siRNAs are chopped from longer dsRNA by an ATP-dependent ribonuclease called DICER. DICER is a member of the RNase III family of double-stranded RNA-specific endonucleases. The siRNAs assemble with cellular proteins into an endonuclease complex. In vitro studies in Drosophila suggest that the siRNAs/protein complex (siRNP) is then transferred to a second enzyme complex, called an RNA-induced silencing complex (RISC), which contains an endoribonuclease that is distinct from DICER. RISC uses the sequence encoded by the antisense siRNA strand to find and destroy mRNAs of complementary sequence. The siRNA thus acts as a guide, restricting the ribonuclease to cleave only mRNAs complementary to one of the two siRNA strands.

A NOVX mRNA region to be targeted by siRNA is generally selected from a desired NOVX sequence beginning 50 to 100 nt downstream of the start codon. Alternatively, 5′ or 3′ UTRs and regions nearby the start codon can be used but are generally avoided, as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. An initial BLAST homology search for the selected siRNA sequence is done against an available nucleotide sequence library to ensure that only one gene is targeted. Specificity of target recognition by siRNA duplexes indicate that a single point mutation located in the paired region of an siRNA duplex is sufficient to abolish target mRNA degradation. See, Elbashir et al. 2001 EMBO J. 20(23):6877-88. Hence, consideration should be taken to accommodate SNPs, polymorphisms, allelic variants or species-specific variations when targeting a desired gene.

In one embodiment, a complete NOVX siRNA experiment includes the proper negative control. A negative control siRNA generally has the same nucleotide composition as the NOVX siRNA but lack significant sequence homology to the genome. Typically, one would scramble the nucleotide sequence of the NOVX siRNA and do a homology search to make sure it lacks homology to any other gene.

Two independent NOVX siRNA duplexes can be used to knock-down a target NOVX gene. This helps to control for specificity of the silencing effect. In addition, expression of two independent genes can be simultaneously knocked down by using equal concentrations of different NOVX siRNA duplexes, e.g., a NOVX siRNA and an siRNA for a regulator of a NOVX gene or polypeptide. Availability of siRNA-associating proteins is believed to be more limiting than target mRNA accessibility.

A targeted NOVX region is typically a sequence of two adenines (AA) and two thymidines (TT) divided by a spacer region of nineteen (N19) residues (e.g., AA(N19)TT). A desirable spacer region has a G/C-content of approximately 30% to 70%, and more preferably of about 50%. If the sequence AA(N19)TT is not present in the target sequence, an alternative target region would be AA(N21). The sequence of the NOVX sense siRNA corresponds to (N19)TT or N21, respectively. In the latter case, conversion of the 3′ end of the sense siRNA to TT can be performed if such a sequence does not naturally occur in the NOVX polynucleotide. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3′ overhangs. Symmetric 3′ overhangs may help to ensure that the siRNPs are formed with approximately equal ratios of sense and antisense target RNA-cleaving siRNPs. See, e.g., Elbashir, Lendeckel and Tuschl (2001). Genes & Dev. 15: 188-200, incorporated by reference herein in its entirely. The modification of the overhang of the sense sequence of the siRNA duplex is not expected to affect targeted mRNA recognition, as the antisense siRNA strand guides target recognition.

Alternatively, if the NOVX target mRNA does not contain a suitable AA(N21) sequence, one may search for the sequence NA(N21). Further, the sequence of the sense strand and antisense strand may still be synthesized as 5′ (N19)TT, as it is believed that the sequence of the 3′-most nucleotide of the antisense siRNA does not contribute to specificity. Unlike antisense or ribozyme technology, the secondary structure of the target mRNA does not appear to have a strong effect on silencing. See, Harborth, et al. (2001) J. Cell Science 114: 4557-4565, incorporated by reference in its entirety.

Transfection of NOVX siRNA duplexes can be achieved using standard nucleic acid transfection methods, for example, OLIGOFECTAMINE Reagent (commercially available from Invitrogen). An assay for NOVX gene silencing is generally performed approximately 2 days after transfection. No NOVX gene silencing has been observed in the absence of transfection reagent, allowing for a comparative analysis of the wild-type and silenced NOVX phenotypes. In a specific embodiment, for one well of a 24-well plate, approximately 0.84 μg of the siRNA duplex is generally sufficient. Cells are typically seeded the previous day, and are transfected at about 50% confluence. The choice of cell culture media and conditions are routine to those of skill in the art, and will vary with the choice of cell type. The efficiency of transfection may depend on the cell type, but also on the passage number and the confluency of the cells. The time and the manner of formation of siRNA-liposome complexes (e.g., inversion versus vortexing) are also critical. Low transfection efficiencies are the most frequent cause of unsuccessful NOVX silencing. The efficiency of transfection needs to be carefully examined for each new cell line to be used. Preferred cell are derived from a mammal, more preferably from a rodent such as a rat or mouse, and most preferably from a human. Where used for therapeutic treatment, the cells are preferentially autologous, although non-autologous cell sources are also contemplated as within the scope of the present invention.

For a control experiment, transfection of 0.84 μg single-stranded sense NOVX siRNA will have no effect on NOVX silencing, and 0.84 μg antisense siRNA has a weak silencing effect when compared to 0.84 μg of duplex siRNAs. Control experiments again allow for a comparative analysis of the wild-type and silenced NOVX phenotypes. To control for transfection efficiency, targeting of common proteins is typically performed, for example targeting of lamin A/C or transfection of a CMV-driven EGFP-expression plasmid (e.g., commercially available from Clontech). In the above example, a determination of the fraction of lamin A/C knockdown in cells is determined the next day by such techniques as immunofluorescence, Western blot, Northern blot or other similar assays for protein expression or gene expression. Lamin A/C monoclonal antibodies may be obtained from Santa Cruz Biotechnology.

Depending on the abundance and the half life (or turnover) of the targeted NOVX polynucleotide in a cell, a knock-down phenotype may become apparent after 1 to 3 days, or even later. In cases where no NOVX knock-down phenotype is observed, depletion of the NOVX polynucleotide may be observed by immunofluorescence or Western blotting. If the NOVX polynucleotide is still abundant after 3 days, cells need to be split and transferred to a fresh 24-well plate for re-transfection. If no knock-down of the targeted protein is observed, it may be desirable to analyze whether the target mRNA (NOVX or a NOVX upstream or downstream gene) was effectively destroyed by the transfected siRNA duplex. Two days after transfection, total RNA is prepared, reverse transcribed using a target-specific primer, and PCR-amplified with a primer pair covering at least one exon-exon junction in order to control for amplification of pre-mRNAs. RT/PCR of a non-targeted mRNA is also needed as control. Effective depletion of the mRNA yet undetectable reduction of target protein may indicate that a large reservoir of stable NOVX protein may exist in the cell. Multiple transfection in sufficiently long intervals may be necessary until the target protein is finally depleted to a point where a phenotype may become apparent. If multiple transfection steps are required, cells are split 2 to 3 days after transfection. The cells may be transfected immediately after splitting.

An inventive therapeutic method of the invention contemplates administering a NOVX siRNA construct as therapy to compensate for increased or aberrant NOVX expression or activity. The NOVX ribopolynucleotide is obtained and processed into siRNA fragments, or a NOVX siRNA is synthesized, as described above. The NOVX siRNA is administered to cells or tissues using known nucleic acid transfection techniques, as described above. A NOVX siRNA specific for a NOVX gene will decrease or knockdown NOVX transcription products, which will lead to reduced NOVX polypeptide production, resulting in reduced NOVX polypeptide activity in the cells or tissues.

The present invention also encompasses a method of treating a disease or condition associated with the presence of a NOVX protein in an individual comprising administering to the individual an RNAi construct that targets the mRNA of the protein (the mRNA that encodes the protein) for degradation. A specific RNAi construct includes a siRNA or a double stranded gene transcript that is processed into siRNAs. Upon treatment, the target protein is not produced or is not produced to the extent it would be in the absence of the treatment.

Where the NOVX gene function is not correlated with a known phenotype, a control sample of cells or tissues from healthy individuals provides a reference standard for determining NOVX expression levels. Expression levels are detected using the assays described, e.g., RT-PCR, Northern blotting, Western blotting, ELISA, and the like. A subject sample of cells or tissues is taken from a mammal, preferably a human subject, suffering from a disease state. The NOVX ribopolynucleotide is used to produce siRNA constructs, that are specific for the NOVX gene product. These cells or tissues are treated by administering NOVX siRNA's to the cells or tissues by methods described for the transfection of nucleic acids into a cell or tissue, and a change in NOVX polypeptide or polynucleotide expression is observed in the subject sample relative to the control sample, using the assays described. This NOVX gene knockdown approach provides a rapid method for determination of a NOVX minus (NOVX⁻) phenotype in the treated subject sample. The NOVX⁻ phenotype observed in the treated subject sample thus serves as a marker for monitoring the course of a disease state during treatment.

In specific embodiments, a NOVX siRNA is used in therapy. Methods for the generation and use of a NOVX siRNA are known to those skilled in the art. Example techniques are provided below.

Production of RNAs

Sense RNA (ssRNA) and antisense RNA (asRNA) of NOVX are produced using known methods such as transcription in RNA expression vectors. In the initial experiments, the sense and antisense RNA are about 500 bases in length each. The produced ssRNA and asRNA (0.5 μM) in 10 mM Tris-HCl (pH 7.5) with 20 mM NaCl were heated to 95° C. for 1 min then cooled and annealed at room temperature for 12 to 16 h. The RNAs are precipitated and resuspended in lysis buffer (below). To monitor annealing, RNAs are electrophoresed in a 2% agarose gel in TBE buffer and stained with ethidium bromide. See, e.g., Sambrook et al., Molecular Cloning. Cold Spring Harbor Laboratory Press, Plainview, N.Y. (1989).

Lysate Preparation

Untreated rabbit reticulocyte lysate (Ambion) are assembled according to the manufacturer's directions. dsRNA is incubated in the lysate at 30° C. for 10 min prior to the addition of mRNAs. Then NOVX mRNAs are added and the incubation continued for an additional 60 min. The molar ratio of double stranded RNA and mRNA is about 200:1. The NOVX mRNA is radiolabeled (using known techniques) and its stability is monitored by gel electrophoresis.

In a parallel experiment made with the same conditions, the double stranded RNA is internally radiolabeled with a ³²P-ATP. Reactions are stopped by the addition of 2×-proteinase-K buffer and deproteinized as described previously (Tuschl et al., Genes Dev., 13:3191-3197 (1999)). Products are analyzed by electrophoresis in 15% or 18% polyacrylamide sequencing gels using appropriate RNA standards. By monitoring the gels for radioactivity, the natural production of 10 to 25 nt RNAs from the double stranded RNA can be determined.

The band of double stranded RNA, about 21-23 bps, is eluded. The efficacy of these 21-23 mers for suppressing NOVX transcription is assayed in vitro using the same rabbit reticulocyte assay described above using 50 nanomolar of double stranded 21-23 mer for each assay. The sequence of these 21-23 mers is then determined using standard nucleic acid sequencing techniques.

RNA Preparation

21 nt RNAs, based on the sequence determined above, are chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany). Synthetic oligonucleotides are deprotected and gel-purified (Elbashir, Lendeckel, & Tuschl, Genes & Dev. 15, 188-200 (2001)), followed by Sep-Pak C18 cartridge (Waters, Milford, Mass., USA) purification (Tuschl, et al., Biochemistry, 32:11658-11668 (1993)).

These RNAs (20 μM) single strands are incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90° C. followed by 1 h at 37° C.

Cell Culture

A cell culture known in the art to regularly express NOVX is propagated using standard conditions. 24 hours before transfection, at approx. 80% confluency, the cells are trypsinized and diluted 1:5 with fresh medium without antibiotics (1-3×105 cells/ml) and transferred to 24-well plates (500 ml/well). Transfection is performed using a commercially available lipofection kit and NOVX expression is monitored using standard techniques with positive and negative control. A positive control is cells that naturally express NOVX while a negative control is cells that do not express NOVX. Base-paired 21 and 22 nt siRNAs with overhanging 3′ ends mediate efficient sequence-specific mRNA degradation in lysates and in cell culture. Different concentrations of siRNAs are used. An efficient concentration for suppression in vitro in mammalian culture is between 25 nM to 100 nM final concentration. This indicates that siRNAs are effective at concentrations that are several orders of magnitude below the concentrations applied in conventional antisense or ribozyme gene targeting experiments.

The above method provides a way both for the deduction of NOVX siRNA sequence and the use of such siRNA for in vitro suppression. In vivo suppression may be performed using the same siRNA using well known in-vivo transfection or gene therapy transfection techniques.

Antisense Nucleic Acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a NOVX protein of SEQ ID NO:2n, wherein n is an integer between 1 and 566, or antisense nucleic acids complementary to a NOVX nucleic acid sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding a NOVX protein. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence encoding the NOVX protein. The term “noncoding region” refers to 5′ and 3′ sequences that flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).

Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 5-methoxyuracil, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, 2-thiouracil, 4-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 2-methylthio-N-6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOVX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987. Nucl. Acids Res. 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (See, e.g., Inoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, et al., 1987. FEBS Lett. 215: 327-330.

Ribozymes and PNA Moieties

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for a NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOVX cDNA disclosed herein (i.e., SEQ ID NO:2n−1, wherein n is an integer between 1 and 566). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA. See, e.g., U.S. Pat. No. 4,987,071 to Cech, et al. and U.S. Pat. No. 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418.

Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N.Y. Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15.

In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996. Bioorg Med Chem 4: 5-23. As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleotide bases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomer can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Perry-O'Keefe, et al., 1996. Proc. Natl. Acad. Sci. USA 93: 14670-14675.

PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S₁nucleases (See, Hyrup, et al., 1996.supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra).

In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleotide bases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996. Nucl Acids Res 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)-amino-5′-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5′ end of DNA. See, e.g., Mag, et al., 1989. Nucl Acid Res 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment. See, e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment. See, e.g., Petersen, et al., 1975. Bioorg. Med. Chem. Lett. 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989. Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre, et al., 1987. Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol, et al., 1988. BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988. Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

NOVX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in any one of SEQ ID NO:2n, wherein n is an integer between 1 and 566. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in any one of SEQ ID NO:2n, wherein n is an integer between 1 and 566, while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

In general, a NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An “isolated” or “purified” polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language “substantially free of cellular material” includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a “contaminating protein”), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

The language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 566) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of a NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of a NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

In an embodiment, the NOVX protein has an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 566. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 566, and retains the functional activity of the protein of SEQ ID NO:2n, wherein n is an integer between 1 and 566, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 566, and retains the functional activity of the NOVX proteins of SEQ ID NO:2n, wherein n is an integer between 1 and 566.

Determining Homology Between Two or More Sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid “identity”).

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. J Mol Biol 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566.

The term “sequence identity” refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term “substantial identity” as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

Chimeric and Fusion Proteins

The invention also provides NOVX chimeric or fusion proteins. As used herein, a NOVX “chimeric protein” or “fusion protein” comprises a NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An “NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a NOVX protein of SEQ ID NO:2n, wherein n is an integer between 1 and 566, whereas a “non-NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within a NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of a NOVX protein. In one embodiment, a NOVX fusion protein comprises at least one biologically-active portion of a NOVX protein. In another embodiment, a NOVX fusion protein comprises at least two biologically-active portions of a NOVX protein. In yet another embodiment, a NOVX fusion protein comprises at least three biologically-active portions of a NOVX protein. Within the fusion protein, the term “operatively-linked” is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

In another embodiment, the fusion protein is a NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOVX ligand and a NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g., promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with a NOVX ligand.

A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

NOVX Agonists and Antagonists

The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins. (e.g., for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983. Tetrahedron 39: 3; Itakura, et al., 1984. Annu. Rev. Biochem. 53: 323; Itakura, et al., 1984. Science 198: 1056; Ike, et al., 1983. Nucl. Acids Res. 11: 477.

Polypeptide Libraries

In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of a NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S₁nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. Proc. Natl. Acad. Sci. USA 89: 7811-7815; Delgrave, et al., 1993. Protein Engineering 6:327-331.

Anti-NOVX Antibodies

Included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen-binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_ab, F_ab′ and F_(ab′)2fragments, and an F_abexpression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 566, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. A NOVX polypeptide or a fragment thereof comprises at least one antigenic epitope. An anti-NOVX antibody of the present invention is said to specifically bind to antigen NOVX when the equilibrium binding constant (K_D) is ≦1 μM, preferably ≦100 nM, more preferably ≦10 nM, and most preferably ≦100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., incorporated herein by reference). Some of these antibodies are discussed below.

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen that is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).

Monoclonal Antibodies

The term “monoclonal antibody” (MAb) or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells' is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′)₂or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Pat. No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

Human Antibodies

Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed “human antibodies”, or “fully human antibodies” herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals. For example, mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al, (Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

Fab Fragments and Single Chain Antibodies

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g. U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_(ab′)2fragment produced by pepsin digestion of an antibody molecule; (ii) an F_abfragment generated by reducing the disulfide bridges of an F_(ab′)2fragment; (iii) an F_abfragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_vfragments.

Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab′)₂bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab′)₂fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab′ fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives is then reconverted to the Fab′-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab′-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab′ fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab′)₂molecule. Each Fab′ fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5): 1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab′ portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker that is too short to allow pairing between the two domains on the same chain. Accordingly, the V_Hand V_Ldomains of one fragment are forced to pair with the complementary V_Land V_Hdomains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g., CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Pat. No. 4,676,980.

Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).

Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, and ¹⁸⁶Re.

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a “receptor” (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

Immunoliposomes

The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab′ fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).

Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention

In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme linked immunosorbent assay (ELISA) and other immunologically mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Antibodies directed against a NOVX protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of a NOVX protein (e.g., for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies specific to a NOVX protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain, are utilized as pharmacologically active compounds (referred to hereinafter as “Therapeutics”).

An antibody specific for a NOVX protein of the invention (e.g., a monoclonal antibody or a polyclonal antibody) can be used to isolate a NOVX polypeptide by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation. An antibody to a NOVX polypeptide can facilitate the purification of a natural NOVX antigen from cells, or of a recombinantly produced NOVX antigen expressed in host cells. Moreover, such an anti-NOVX antibody can be used to detect the antigenic NOVX protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic NOVX protein. Antibodies directed against a NOVX protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

Antibody Therapeutics

Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.

Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand that may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

Pharmaceutical Compositions of Antibodies

Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.

If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

ELISA Assay

An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., F_abor F_(ab)2) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term “biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in “ELISA: Theory and Practice: Methods in Molecular Biology”, Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, N.J., 1995; “Immunoassay”, E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, Calif., 1996; and “Practice and Theory of Enzyme Immunoassays”, P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

NOVX Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors”. In general, useful expression vectors in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably-linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term “regulatory sequence” is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 3140), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e.g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSec1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Banerji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the α-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., “Antisense RNA as a molecular tool for genetic analysis,”. Reviews-Trends in Genetics, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

Transgenic NOVX Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing a NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences, i.e., any one of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of any one of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5′- and 3′-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′- and 3′-termini) are included in the vector. See, e.g., Thomas, et al., 1987. Cell 51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e.g., Li, et al., 1992. Cell 69: 915.

The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. Curr. Opin. Biotechnol. 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae. See, O'Gorman, et al., 1991. Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997. Nature 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.

Pharmaceutical Compositions

The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as “active compounds”) of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in a NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.

Screening Assays

The invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e.g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds that bind to or modulate the activity of the membrane-bound form of a NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. Anticancer Drug Design 12: 145.

A “small molecule” as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993. Proc. Natl. Acad. Sci. U.S.A. 90: 6909; Erb, et al., 1994. Proc. Natl. Acad. Sci. U.S.A. 91: 11422; Zuckermann, et al., 1994. J. Med. Chem. 37: 2678; Cho, et al., 1993. Science 261: 1303; Carrell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2059; Carell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2061; and Gallop, et al., 1994. J. Med. Chem. 37: 1233.

Libraries of compounds may be presented in solution (e.g., Houghten, 1992. Biotechniques 13: 412-421), or on beads (Lam, 1991. Nature 354: 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner, U.S. Pat. No. 5,233,409), plasmids (Cull, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990. Science 249: 404-406; Cwirla, et al., 1990. Proc. Natl. Acad. Sci. U.S.A. 87: 6378-6382; Felici, 1991. J. Mol. Biol. 222: 301-310; Ladner, U.S. Pat. No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ¹²⁵I, ³⁵S, ¹⁴C, or ³H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule. As used herein, a “target molecule” is a molecule with which a NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOVX target molecule can be a non-NOVX molecule or a NOVX protein or polypeptide of the invention. In one embodiment, a NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

Determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e., intracellular Ca²⁺, diacylglycerol, IP₃, etc.) detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to a NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate a NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra.

In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of a NOVX target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)_n, N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

In yet another aspect of the invention, the NOVX proteins can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos, et al., 1993. Cell 72: 223-232; Madura, et al., 1993. J. Biol. Chem. 268: 12046-12054; Bartel, et al., 1993. Biotechniques 14: 920-924; Iwabuchi, et al., 1993. Oncogene 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX (“NOVX-binding proteins” or “NOVX-bp”) and modulate NOVX activity. Such NOVX-binding proteins are also involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, et al., 1983. Science 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et al., 1987. Nature, 325: 783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Tissue Typing

The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP (“restriction fragment length polymorphisms,” described in U.S. Pat. No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5′- and 3′-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If coding sequences, such as those of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine

The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in a NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as “pharmacogenomics”). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials.

These and other agents are described in further detail in the following sections.

Diagnostic Assays

An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NO:2n−1, wherein n is an integer between 1 and 566, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′)₂) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (ise., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a “test sample” refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

The methods of the invention can also be used to detect genetic lesions in a NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOVX gene; (ii) an addition of one or more nucleotides to a NOVX gene; (iii) a substitution of one or more nucleotides of a NOVX gene, (iv) a chromosomal rearrangement of a NOVX gene; (v) an alteration in the level of a messenger RNA transcript of a NOVX gene, (vi) aberrant modification of a NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOVX gene, (viii) a non-wild-type level of a NOVX protein, (ix) allelic loss of a NOVX gene, and (x) inappropriate post-translational modification of a NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988. Science 241: 1077-1080; and Nakazawa, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995. Nucl. Acids Res. 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177); Qβ Replicase (see, Lizardi, et al, 1988. BioTechnology 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996. Human Mutation 7: 244-255; Kozal, et al., 1996. Nat. Med. 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. Proc. Natl. Acad. Sci. USA 74: 560 or Sanger, 1977. Proc. Natl. Acad. Sci. USA 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996. Adv. Chromatography 36: 127-162; and Griffin, et al., 1993. Appl. Biochem. Biotechnol. 38: 147-159).

Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985. Science 230: 1242. In general, the art technique of “mismatch cleavage” starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S₁nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988. Proc. Natl. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. Methods Enzymol. 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called “DNA mismatch repair” enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994. Carcinogenesis 15: 1657-1662. According to an exemplary embodiment, a probe based on a NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Appl. 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. Nature 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265:12753.

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3′-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. Tibtech. 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3′-terminus of the 5′ sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOVX gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.

In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol., 23: 983-985; Linder, 1997. Clin. Chem., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome pregnancy zone protein precursor enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a “read out” or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent.

Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.

These methods of treatment will be discussed more fully, below.

Diseases and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are “dysfunctional” (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to “knockout” endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244: 1288-1292); or (v) modulators (i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).

Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, a NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

Therapeutic Methods

Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOVX protein, a peptide, a NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering a NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

Determination of the Biological Effect of the Therapeutic

In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.

Prophylactic and Therapeutic Uses of the Compositions of the Invention

The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.

As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from diseases, disorders, conditions and the like, including but not limited to those listed herein.

Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES
Example A
Polynucleotide and Polypeptide Sequences, and Homology Data Example 1

The NOV1 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 1A.

TABLE 1ANOV1 Sequence AnalysisNOV1a, CG101340-01SEQ ID NO: 11327 bpDNA SequenceORF Start: ATG at 76ORF Stop: TGA at 1192GAGGTGAATGCCATGCCATGATTCTGGTGTGCTCCATGGCATCCCCAGCCTAGCTCCCAATCCCACTTTGGCACGATGTTAGCCAACAGCTCCTCAACCAACAGTTCTGTTCTCCCGTGTCCTGACTACCGACCTACCCACCGCCTGCACTTGGTGGTCTACAGCTTGGTGCTGGCTGCCGGGCTCCCCCTCAACGCGCTAGCCCTCTGGGTCTTCCTGCGCGCGCTGCGCGTGCACTCGGTGGTGAGCGTGTACATGTGTAACCTGGCGGCCAGCGACCTGCTCTTCACCCTCTCGCTGCCCGTTCGTCTCTCCTACTACGCACTGCACCACTGGCCCTTCCCCGACCTCCTGTGCCAGACGACGGGCGCCATCTTCCAGATGAACATGTACGGCAGCTGCATCTTCCTGATGCTCATCAACGTGGACCGCTACGCCGCCATCGTGCACCCGCTGCGACTGCGCCACCTGTGGCGGCCCCGCGTGGCGCGGCTGCTCTACCTGGGCGTGTGGGCGCTCATCCTGGTGTTTGCCGTGCCCGCCGCCCGCGTGCACAGGCCCTCGCGTTGCCGCTACCGGGACCTCGAGGTGCGCCTATGCTTCGAGAGCTTCTGCGACGAGCTGTGGAAAGGCAGGCTGCTGCCCCTCGTGCTGCTGGCCGAGGCGCTGGGCTTCCTGCTGCCCCTGGCGGCGGTGGTCTACTCGTCGGGCCGAGTCTTCTGGACGCTGGCGCGCCCCGACGCCACGCAGAGCCAGCGGCGGTGGAAGACCGTGCGCCTCCTGCTGGCTAACCTCGTCATCTTCCTGCTGTGCTTCGTGCCCTACAACAGCACGCTGGCGGTCTACGGGCTGCTGCGGAGCAAGCTGGTGGCGGCCAGCGTGCCTGCCCGCGATCGCGTGCGCGGGGTGCTGATGGTGATGGTGCTGCTGGCCGGCGCCAACTGCGTGCTGGACCCGCTGGTGTACTACTTTAGCGCCGAGGGCTTCCGCAACACCCTGCGCGGCCTGGGCACTCCGCACCGGGCCAGGACCTCGGCCACCAACGGGACGCGGGCGGCGCTCGCGCAATCCGAAAGGTCCGCCGTCACCACCGACGCCACCAGGCCGGATGCCGCCAGTCAGGGGCTGCTCCGACCCTCCGACTCCCACTCTCTGTCTTCCTTCACACAGTGTCCCCAGGATTCCGCCCTCTGAACACACATGCCATTGCGCTGTCCGTGCCCGACTCCCAACGCCTCTCGTTCTGGGAGGCTTACAGGGCGTACACACAAGAAGGTGGGCTGGGCACTTGGACCTTTGGGTGGCAATTCCAGCTTAGCAACGCAGANOV1a, CG101340-01Protein SequenceSEQ ID NO: 2372 aaMW at 41482.1kDMLANSSSTNSSVLPCPDYRPTHRLHLVVYSLVLAAGLPLNALALWVFLRALRVHSVVSVYMCNLAASDLLFTLSLPVRLSYYALHHWPFPDLLCQTTGAIFQMNMYGSCIFLMLINVDRYAAIVHPLRLRHLWRPRVARLLYLGVWALILVFAVPAARVHRPSRCRYRDLEVRLCFESFCDELWKGRLLPLVLLAEALGFLLPLAAVVYSSGRVFWTLARPDATQSQRRWKTVRLLLANLVIFLLCFVPYNSTLAVYGLLRSKLVAASVPARDRVRGVLMVMVLLAGANCVLDPLVYYFSAEGFRNTLRGLGTPHRARTSATNGTHAALAQSERSAVTTDATRPDAASQGLLRPSDSHSLSSFTQCPQDSALSEQ ID NO: 31327 bpNOV1b, SNP13382465 ofORF Start: ATG at 76ORF Stop: TGA at 1192CG101340-01, DNA SequenceSNP Pos: 472SNP Change: T to CGAGGTGAATGCCATGCCATGATTCTGGTGTGCTCCATGGCATCCCCAGCCTAGCTCCCAATCCCACTTTGGCACGATGTTAGCCAACAGCTCCTCAACCAACAGTTCTGTTCTCCCGTGTCCTGACTACCGACCTACCCACCGCCTGCACTTGGTGGTCTACAGCTTGGTGCTGGCTGCCGGGCTCCCCCTCAACGCGCTAGCCCTCTGGGTCTTCCTGCGCGCGCTGCGCGTGCAcTCGGTGGTGAGCGTGTACATGTGTAACCTGGCGGCCAGCGACCTGCTCTTCACCCTCTCGCTGCCCGTTCGTCTCTCCTACTACGCACTGCACCACTGGCCCTTCCCCGACCTCCTGTGCCAGACGACGGGCGCCATCTTCCAGATGAACATGTACGGCAGCTGCATCTTCCTGATGCTCATCAACGTGGACCGCTACGCCGCCATCGTGCACCCGCTGCGACTGCGCCACCTGCGGCGGCCCCGCGTGGCGCGGCTGCTCTACCTGGGCGTGTGGGCGCTCATCCTGGTGTTTGCCGTGCCCGCCGCCCGCGTGCACAGGCCCTCGCGTTGCCGCTACCGGGACCTCGAGGTGCGCCTATGCTTCGAGAGCTTCTGCGACGAGCTGTGGAAAGGCAGGCTGCTGCCCCTCGTGCTGCTGGCCGAGGCGCTGGGCTTCCTGCTGCCCCTGGCGGCGGTGGTCTACTCGTCGGGCCGAGTCTTCTGGACGCTGGCGCGCCCCGACGCCACGCAGAGCCAGCGGCGGTGGAAGACCGTGCGCCTCCTGCTGGCTAACCTCGTCATCTTCCTGCTGTGCTTCGTGCCCTACAACAGCACGCTGGCGGTCTACGGGCTGCTGCGGAGCAAGCTGGTGGCGGCCAGCGTGCCTGCCCGCGATCGCGTGCGCGGGGTGCTGATGGTGATGGTGCTGCTGGCCGGCGCCAACTGCGTGCTGGACCCGCTGGTGTACTACTTTAGCGCCGAGGGCTTCCGCAACACCCTGCGCGGCCTGGGCACTCCGCACCGGGCCAGGACCTCGGCCACCAACGGGACGCGGGCGGCGCTCGCGCAATCCGAAAGGTCCGCCGTCACCACCGACGCCACCAGGCCGGATGCCGCCAGTCAGGGGCTGCTCCGACCCTCCGACTCCCACTCTCTGTCTTCCTTCACACAGTGTCCCCAGGATTCCGCCCTCTGAACACACATGCCATTGCGCTGTCCGTGCCCGACTCCCAACGCCTCTCGTTCTGGGAGGCTTACAGGGCGTACACACAAGAAGGTGGGCTGGGCACTTGGACCTTTGGGTGGCAATTCCAGCTTAGCAACGCAGANOV1b, SNP13382465 ofSEQ ID NO: 4MW at 41452.1kDCG101340-01, Protein SequenceSNP Pos: 133372 aaSNP Change: Trp to ArgMLANSSSTNSSVLPCPDYRPTHRLHLVVYSLVLAAGLPLNALALWVFLRALRVHSVVSVYMCNLAASDLLFTLSLPVRLSYYALHHWPFPDLLCQTTGAIFQMNNYGSCIFLMLINVDRYAAIVHPLRLRHLRRPRVARLLYLGVWALILVFAVPAARVHRPSRCRYRDLEVRLCFESFCDELWKGRLLPLVLLAEALGFLLPLAAVVYSSGRVFWTLARPDATQSQRRWKTVRLLLANLVIFLLCFVPYNSTLAVYGLLRSKLVAASVPARDRVRGVLMVMVLLAGANCVLDPLVYYFSAEGFRNTLRGLGTPHRARTSATNGTRAALAQSERSAVTTDATRPDAASQGLLRPSDSHSLSSFTQCPQDSAL

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 1B.

TABLE 1BComparison of the NOV1 protein sequences.NOV18aMCSLPMARYYRIKYADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLARTKVPIFLGNOV18bMCSLPMARYYIIKYADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLARTKVPIFLGNOV18c-----LSYCFRIKYADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLARTKVPIFLGNOV18aQGGSRCLACVETEEGPSLQLEPSTLPPQDVNIEELYKGGEEATRFTFFQSSSGSAFRLENOV18bQGGSRCLACVETEEGPSLQLE-------DVNIEELYKGGEEATRFTFFQSSSGSAFRLENOV18cQGGSRCLACVETEEGPSLQLEPSTLPPQDVNIEELYKGGEEATRFTFFQSSSGSAFRLENOV18aAAAWPGWFLCGPAEPQQPVQLTKESEPSARTKFYFEQSWNOV18bAAAWPGWFLCGPAEPQQPVQLTKESEPSARTKFYFEQSWNOV18cAAAWPGWFLCGPAEPQQPVQLTKESEPSARTKFYFEQSWNOV1a(SEQ ID NO: 2)

Further analysis of the NOV1a protein yielded the following properties shown in Table 1C.

TABLE 1CProtein Sequence Properties NOV1aSignalP analysis:Cleavage site between residues 59 and 60PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 16; peak value 3.12PSG score: −1.28GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 0.37possible cleavage site: between 43 and 44>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −4.19Transmembrane 31-47INTEGRALLikelihood = −0.16Transmembrane 99-115INTEGRALLikelihood = −7.01Transmembrane 140-156INTEGRALLikelihood = −6.90Transmembrane 192-208INTEGRALLikelihood = −7.54Transmembrane 232-248INTEGRALLikelihood = −3.82Transmembrane 277-293PERIPHERALLikelihood = 1.43 (at 56)ALOM score:−7.54 (number of TMSs: 6)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 38Charge difference: 0.5 C(2.5) − N(2.0)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment (75):4.95Hyd Moment (95):3.49G content:0D/E content:1S/T content:6Score: −3.65Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 176 CRY|RDNUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 10.2%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23) 55.6%: endoplasmic reticulum 11.1%: Golgi 11.1%: vacuolar 11.1%: vesicles of secretory system 11.1%: mitochondrial>> prediction for CG101340-01 is end (k = 9)

A search of the NOV1a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1D.

TABLE 1DGeneseq Results for NOV1aNOV1aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABP81962Human G protein-coupled1 . . . 372368/372 (98%)0.0receptor GPR92/3 protein SEQ ID1 . . . 372368/372 (98%)NO:410 - Homo sapiens, 372 aa.[WO200261087-A2, 08-AUG-2002]AAM52650Human G protein-coupled1 . . . 372368/372 (98%)0.0receptor TGR4 - Homo sapiens,1 . . . 372368/372 (98%)372 aa. [WO200177326-A1, 18-OCT-2001]AAU11897Human novel G protein-coupled1 . . . 372368/372 (98%)0.0receptor, GPCR9 - Homo sapiens,1 . . . 372368/372 (98%)372 aa. [WO200190187-A2, 29-NOV-2001]AAE16170Human G-protein coupled1 . . . 372368/372 (98%)0.0receptor 1 (GCREC-1) protein -1 . . . 372368/372 (98%)Homo sapiens, 372 aa.[WO200187937-A2, 22-NOV-2001]AAU97915Human HIPHUM00000011 . . . 372368/372 (98%)0.0purinergic receptor protein -1 . . . 372368/372 (98%)Homo sapiens, 372 aa.[GB2360523-A, 26-SEP-2001]

In a BLAST search of public sequence databases, the NOV1a protein was found to have homology to the proteins shown in the BLASTP data in Table 1E.

TABLE 1EPublic BLASTP Results for NOV1aNOV1aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9H1C0Putative G protein-coupled 1 . . . 372368/372 (98%)0.0receptor 92 (Putative G-protein 1 . . . 372368/372 (98%)coupled receptor) - Homo sapiens(Human), 372 aa.CAD38444Sequence 10 from Patent 3 . . . 372294/370 (79%) e-164WO0238607 - Mus musculus123 . . . 488 316/370 (84%)(Mouse), 488 aa.P32250P2Y purinoceptor 5 (P2Y5)22 . . . 302111/284 (39%)1e-51(Purinergic receptor 5) (6H1) -14 . . . 293169/284 (59%)Gallus gallus (Chicken), 308 aa.Q8BMC0P2Y purinoceptor 5 - Mus 7 . . . 309113/306 (36%)1e-49musculus (Mouse), 344 aa. 3 . . . 303178/306 (57%)P43657P2Y purinoceptor 5 (P2Y5)22 . . . 309106/291 (36%)1e-49(Purinergic receptor 5) (RB intron17 . . . 303171/291 (58%)encoded G-protein coupledreceptor) - Homo sapiens(Human), 344 aa.

PFam analysis indicates that the NOV1a protein contains the domains shown in the Table 1F.

TABLE 1FDomain Analysis of NOV1aIdentities/Similarities forExpectPfam DomainNOV1a Match Regionthe Matched RegionValue7tm_139 . . . 297 87/276 (32%)7.2e-53196/276 (71%)

Example 2

The NOV2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 2A.

TABLE 2ANOV2 Sequence AnalysisNOV2a, CG101396-01SEQ ID NO: 53189 bpDNA SequenceORF Start: ATG at 86ORF Stop: TGA at 3113CTGCACCGGGACCAGCGCCTCCCCGCTTCGCGCTGCCCTCGGCCTCGCCCCGGGCCCGGGTGGATGAGCCGCGCGCCCGGGGGACATGGAAGCGCTGACGCTGTGGCTTCTCCCCTGGATATGCCAGTGCGTGTCGGTGCGGGCCGACTCCATCATCCACATCGGTGCCATCTTCGAGGAGAACGCGGCCAAGGACGACAGGGTGTTCCAGTTGGCGGTATCCGACCTGAGCCTCAACGATGACATCCTGCAGAGCGAGAAGATCACCTAGTCCATCAAGGTCATCGAGGCCAACAACCCATTCCAGGCTGTGCAGGAAGCCTGTGACCTCATGACCCAGGGGATTTTGGCCTTGGTCACGTCCACTGGCTGTGCATCTGCCAATGCCCTGCAGTCCCTCACGGATGCCATGCACATCCCACACCTCTTTGTCCAGCGCAACCCGGGAGGGTCGCCACGCACCGCATGCCACCTGAACCCCAGCCCCGATGGTGAGGCCTACACACTGGCTTCGAGACCACCCGTCCGCCTCAATGATGTCATGCTCAGGCTGGTGACGGAGCTGCGCTGGCAGAAGTTCGTCATGTTCTACGACAGCGAGTATGATATCCGTGGGCTTCAAAGCTTTCTGGACCAGGCCTCGCGGCTGGGCCTTGACGTCTCTTTACAAAAGGTGGACAAGAACATTAGCCACGTATTCACCAGCCTCTTCACCACGATGAAGACAGAGGAGCTGAATCGCTACCGGGACACGCTTCGCCGCGCCATCCTGCTGCTCAGCCCACAGGGAGCCCACTCCTTCATCAACGAGGCCGTGGAGACCAACCTGGCTTCCAAGGACAGCCACTGGGTCTTTGTGAATGAGGAAATCAGTGACCCGGAGATCCTGGATCTGGTCCATAGTGCCCTTGGAAGGATGACCGTGGTCCGGCAAATCTTTCCGTCTGCAAAGGACAATCAGAAATGCACGAGGAACAACCACCGCATCTCCTCCCTGCTCTGCGACCCCCAGGAAGGCTACCTCCAGATGCTGCAGATCTCCAACCTCTATCTGTATGACAGTGTTCTGATGCTGGCCAACGCCTTTCACAGGAAGCTGGAGGACCGGAAGTGGCATAGCATGGCGAGCCTCAACTGCATACGGAAATCCACTAAGCCATGGAATGGTGGGAGGTCCATGCTGGATACCATCAAAAAGGGCCACATCACTGGCCTCACTGGGGTGATGGAGTTTCGGGAGGACAGTTCGAATCCCTATGTCCAGTTTGAAATCCTTGGCACTACCTATAGTGAGACTTTTGGCAAAGACATGCGCAAGTTGGCGACATGGGACTCAGAGAAGGGCTTGAATGGCAGCTTGCAAGAGAGGCCCATGGGCAGCCGCCTCCAAGGATTGACTCTTAAAGTGGTGACTGTCTTGGAAGAGCCTTTCGTGATGGTGGCTGAGAACATCCTAGGACAGCCCAAGCGCTACAAAGGGTTCTCCATAGATGTCCTGGATGCACTGGCCAAGGCTCTGGGCTTTAAATATGAGATTTACCAAGCCCCTGATGGCAGGTACGGTCACCAGCTCCATAACACCTCCTGGAACGGGATGATCGGGGAGCTCATCAGCAAGAGAGCAGACTTGGCCATCTCTGCCATCACCATCACCCCAGAGAGGGAGAGCGTTGTGGACTTCAGCAAGCGGTACATGGACTATTCAGTGGGGATTCTAATTAAGAAGCCCGAGGAGAAAATCAGCATCTTCTCCCTCTTTGCTCCATTTGATTTCGCTGTGTGGGCCTGCATTGCAGCAGCCATCCCTGTGGTTGGTGTGCTGATATTTGTGTTGAACAGGATACAGGCTGTGAGGGCTCAGAGTGCTGCCCAGCCCAGGCCGTCAGCTTCTGCCACTCTGCACAGCGCCATCTGGATTGTCTATGGAGCCTTCGTACAGCAAGGTGGCGAATCTTCCGTGAACTCCATGGCCATGCGCATCGTGATGGGCAGCTGGTGGCTCTTCACGCTCATTGTGTGCTCCTCCTACACAGCCAACGTTGCTGCCTTCCTCACAGTGTCCAGGATGGACAACCCCATAAGGACTTTCCAGGACCTGTCCAAACAAGTGGAAATGTCTTATGGCACTGTCCGGGATTCTGCTGTATATGAGTACTTCCGAGCCAAGGGCACCAACCCCCTGGAGCAGGACAGCACGTTTGCTGAACTCTGGCGGACCATCAGCAAGAACGGAGGGGCTGACAACTGCGTGTCCAGTCCTTCAGAAGGCATCAGGAAGGCAAAGAAGGGGAACTACGCCTTCCTGTGGGATGTGGCCGTGGTGGAATACGCAGCCCTGACGGATGACGACTGCTCGGTGACTGTCATCGGCAACAGCATCAGCAGCAAGGGTTACGGGATTGCCCTGCAGCATGGCAGCCCCTACAGGGACCTCTTCTCCCAGAGGATCCTGGAGCTGCAGGACACAGGGGACCTGGATGTGCTGAAGCAGAAGTGGTGGCCGCACATGGGCCGCTGTGACCTCACCAGCCATGCCAGCGCCCAGGCCGACGGCAAATCCCTCAAGCTGCACAGCTTCGCCGGGGTCTTCTGCATCCTGGCCATTGGCCTGCTCCTGGCCTGCCTGGTGGCTGCCCTGGAGTTGTGGTGGAACAGCAACCGGTGCCACCAGGAGACCCCCAAGGAGGACAAAGAAGTGAACTTGGAGCAGGTCCACCGGCGCATGAACAGCCTCATGGATGAAGACATTGCTCACAAGCAGATTTCCCCAGCGTCGATTGAGCTCTCGGCCCTGGAGATGGGGGGCCTGGCTCCCACCCAGACCTTGGAGCCGACACGGGAGTACCAGAACACCCAGCTCTCGGTCAGCACCTTTCTGCCAGAGCAGAGCAGCCATGGCACCAGCCGGACACTCTCATCAGGGCCCAGCAGCAACCTGCCGCTGCCGCTGAGCAGCTCGGCGACCATGCCCTCCATGCAGTGCAAACACAGGTCACCCAACGGGGGGCTGTTCCGGCAGAGCCCGGTGAAGACCCCCATCCCCATGTCCTTCCAGCCCGTGCCTGGAGGCGTCCTTCCAGAGGCTCTGGACACCTCCCACGGGACCTCCATCTGACTGCGCCGCCTGCCCTCCTGCCCACCCTCCCACCCACCCGACCAGCAGAGCTTTTTAATACAAGAAAACAACAANOV2a, CG101396-01Protein SequenceSEQ ID NO: 61009 aaMW at 112129.7kDMEALTLWLLPWICQCVSVRADSIIHIGAIFEENAAKDDRVFQLAVSDLSLNDDILQSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGAHSFINEAVETNLASKDSHWVFVNEEISDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDSEKGLNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMWSLMDEDIAHKQISPASIELSALEMGGLAPTQThEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSINOV2b, 267253224SEQ ID NO: 72986 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGTACCGACTCCATCATCCACATCGGTGCCATCTTCGAGGAGAACGCGGCCAAGGACGACAGGGTGTTCCAGTTGGCGGTATCCGACCTGAGCCTCAACGATGACATCCTGCAGAGCGAGAAGATCACCTACTCCATCAAGGTCATCGAGGCCAACAACCCATTCCAGGCTGTGCAGGAAGCCTGTGACCTCATGACCCAGGGGATTTTGGCCTTGGTCACGTCCACTGGCTGTGCATCTGCCAATGCCCTGCAGTCCCTCACGGATGCCATGCACATCCCACACCTCTTTGTCCAGCGCAACCCGGGAGGGTCGCCACGCACCGCATGCCACCTGAACCCCAGCCCCGATGGTGAGGCCTACACACTGGCTTCGAGACCACCCGTCCGCCTCAATGATGTCATGCTCAGGCTGGTGACGGAGCTGCGCTGGCAGAAGTTCGTCATGTTCTACGACAGCGAGTATGATATCCGTGGGCTTCAAAGCTTTCTGGACCAGGCCTCGCGGCTGGGCCTTGACGTCTCTTTACAAAAGGTGGACAAGAACATTAGCCACGTATTCACCAGCCTCTTCACCACGATGAAGACAGAGGAGCTGAATCGCTACCGGGACACGCTTCGCCGCGCCATCCTGCTGCTCAGCCCACAGGGAGCCCACTCCTTCATCAACGAGGCCGTGGAGACCAACCTGGCTTCCAAGGACAGCCACTGGGTCTTTGTGAATGAGGAAATCAGTGACCCGGAGATCCTGGATCTGGTCCATAGTGCCCTTGGAAGGATGACCGTGGTCCGGCAAATCTTTCCGTCTGCAAAGGACAATCAGAAATGCACGAGGAACAACCACCGCATCTCCTCCCTGCTCTGCGACCCCCAGGAAGGCTACCTCCAGATGCTGCAGATCTCCAACCTCTATCTGTATGACAGTGTTCTGATGCTGGCCAACGCCTTTCACAGGAAGCTGGAGGACCGGAAGTGGCATAGCATGGCGAGCCTCAACTGCATACGGAAATCCACTAAGCCATGGAATGGTGGGAGGTCCATGCTGGATACCATCAAAAAGGGCCACATCACTGGCCTCACTGGGGTGATGGAGTTTCGGGAGGACAGTTCGAATCCCTATGTCCAGTTTGAAATCCTTGGCACTACCTATAGTGAGACTTTTGGCAAAGACATGCGCAAGTTGGCGACATGGGACTCAGAGAAGGGCTTGAATGGCAGCTTGCAAGAGAGGCCCATGGGCAGCCGCCTCCAAGGATTGACTCTTAAAGTGGTGACTGTCTTGGAAGAGCCTTTCGTGATGGTGGCTGAGAACATCCTAGGACAGCCCAAGCGCTACAAAGGGTTCTCCATAGATGTCCTGGATGCACTGGCCAAGGCTCTGGGCTTTAAATATGAGATTTACCAAGCCCCTGATGGCAGGTACGGTCACCAGCTCCATAACACCTCCTGGAACGGGATGATCGGGGAGCTCATCAGCAAGAGAGCAGACTTGGCCATCTCTGCCATCACCATCACCCCAGAGAGGGAGAGCGTTGTGGACTTCAGCAAGCGGTACATGGACTATTCAGTGGGGATTCTAATTAAGAAGCCCGAGGAGAAAATCAGCATCTTCTCCCTCTTTGCTCCATTTGATTTCGCTGTGTGGGCCTGCATTGCAGCAGCCATCCCTGTGGTTGGTGTGCTGATATTTGTGTTGAACAGGATACAGGCTGTGAGGGCTCAGAGTGCTGCCCAGCCCAGGCCGTCAGCTTCTGCCACTCTGCACAGCGCCATCTGGATTGTCTATGGAGCCTTCGTACAGCAAGGTGGCGAATCTTCCGTGAACTCCATGGCCATGCGCATCGTGATGGGCAGCTGGTGGCTCTTCACGCTCATTGTGTGCTCCTCCTACACAGCCAACCTTGCTGCCTTCCTCACAGTGTCCAGGATGGACAACCCCATAAGGACTTTCCAGGACCTGTCCAAACAAGTGGAAATGTCTTATGGCACTGTCCGGGATTCTGCTGTATATGAGTACTTCCGAGCCAAGGGCACCAACCCCCTGGAGCAGGACAGCACGTTTGCTGAACTCTGGCGGACCATCAGCAAGAACGGAGGGGCTGACAACTGCGTGTCCAGTCCTTCAGAAGGCATCAGGAAGGCAAAGAAGGGGAACTACGCCTTCCTGTGGGATGTGGCCGTGGTGGAATACGCAGCCCTGACGGATGACGACTGCTCGGTGACTGTCATCGGCAACAGCATCAGCAGCAAGGGTTACGGGATTGCCCTGCAGCATGGCAGCCCCTACAGGGACCTCTTCTCCCAGAGGATCCTGGAGCTGCAGGACACAGGGGACCTGGATGTGCTGAAGCAGAAGTGGTGGCCGCACATGGGCCGCTGTGACCTCACCAGCCATGCCAGCGCCCAGGCCGACGGCAAATCCCTCAAGCTGCACAGCTTCGCCGGGGTCTTCTGCATCCTGGCCATTGGCCTGCTCCTGGCCTGCCTGGTGGCTGCCCTGGAGTTGTGGTGGAACAGCAACCGGTGCCACCAGGAGACCCCCAAGGAGGACAAAGAAGTGAACTTGGAGCAGGTCCACCGGCGCATGAACAGCCTCATGGATGAAGACATTGCTCACAAGCAGATTTCCCCAGCGTCGATTGAGCTCTCGGCCCTGGAGATGGGGAGCCTGGCTCCCACCCAGACCTTGGAGCCGACACGGGAGTACCAGAACACCCAGCTCTCGGTCAGCACCTTTCTGCCAGAGCAGAGCAGCCATGGCACCAGCCGGACACTCTCATCAGGGCCCAGCAGCAACCTGCCGCTGCCGCTGAGCAGCTCGGCGACCATGCCCTCCATGCAGTGCAAACACAGGTCACCCAACGGGGGGCTGTTCCGGCAGAGCCCGGTGAAGACCCCCATCCCCATGTCCTTCCAGCCCGTGCCTGGAGGCGTCCTTCCAGAGGCTCTGGACACCTCCCACGGGACCTCCATCCTCGAGGGCNOV2b, 267253224Protein SequenceSEQ ID NO: 8995 aaMW at 110403.5kDTGTDSIIHIGAIFEENAAKDDRVFQLAVSDLSLNDDILQSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGAHSFINEAVETNLASKDSHWVFVNEEISDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDSEKGLNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPASIELSALEMGSLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSILEGNOV2c, 315490179SEQ ID NO: 93049 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCACCATGGAAGCGCTGACGCTGTGGCTTCTCCCCTGGATATGCCAGTGCGTGTCGGTGCGGGCCGACTCCATCATCCACATTGGTGCCATCTTCGAGGAGAACGCGGCCAAGGACGACAGGGTGTTCCAGTTGGCGGTATCCGACCTGAGCCTCAACGATGACATCCTGCAGAGCGAGAAGATCACCTACTCCATCAAGGTCATCGAGGCCAACAACCCATTCCAGGCTGTGCAGGAAGCCTGTGACCTCATGACCCAGGGGATTTTGGCCTTGGTCACGTCCACTGGCTGTGCATCTGCCAATGCCCTGCAGTCCCTCACGGATGCCATGCACATCCCACACCTCTTTGTCCAGCGCAACCCGGGAGGGTCGCCACGCACCGCATGCCACCTGAACCCCAGCCCCGATGGTGAGGCCTACACACTGGCTTCGAGACCACCCGTCCGCCTCAATGATGTCATGCTCAGGCTGGTGACGGAGCTGCGCTGGCAGAAGTTCGTCATGTTCTACGACAGCGAGTATGATATCCGTGGGCTTCAAAGCTTTCTGGACCAGGCCTCGCGGCTGGGCCTTGACGTCTCTTTACAAAAGGTGGACAAGAACATTAGCCACGTATTCACCAGCCTCTTCACCACGATGAAGACAGAGGAGCTGAATCGCTACCGGGACACGCTTCGCCGCGCCATCCTGCTGCTCAGCCCACAGGGAGCCCACTCCTTCATCAACGAGGCCGTGGAGACCAACCTGGCTTCCAAGGACAGCCACTGGGTCTTTGTGAATGAGGAAATCAGTGACCCGGAGATCCTGGATCTGGTCCATAGTGCCCTTGGAAGGATGACCGTGGTCCGGCAAATCTTTCCGTCTGCAAAGGACAATCAGAAATGCACGAGGAACAACCACCGCATCTCCTCCCTGCTCTGCGACCCCCAGGAAGGCTACCTCCAGATGCTGCAGATCTCCAACCTCTATCTGTATGACAGTGTTCTGATGCTGGCCAACGCCTTTCACAGGAAGCTGGAGGACCGGAAGTGGCATAGCATGGCGAGCCTCAACTGCATACGGAAATCCACTAAGCCATGGAATGGTGGGAGGTCCATGCTGGATACCATCAAAAAGGGCCACATCACTGGCCTCACTGGGGTGATGGAGTTTCGGGAGGACAGTTCGAATCCCTATGTCCAGTTTGAAATCCTTGGCACTACCTATAGTGAGACTTTTGGCAAAGACATGCGCAAGTTGGCGACATGGGACTCAGAGAAGGGCTTGAATGGCAGCTTGCAAGAGAGGCCCATGGGCAGCCGCCTCCAAGGATTGACTCTTAAAGTGGTGACTGTCTTGGAAGAGCCTTTCGTGATGGTGGCTGAGAACATCCTAGGACAGCCCAAGCGCTACAAAGGGTTCTCCATAGATGTCCTGGATGCACTGGCCAAGGCTCTGGGCTTTAAATATGAGATTTACCAAGCCCCTGATGGCAGGTACGGTCACCAGCTCCATAACACCTCCTGGAACGGGATGATCGGGGAGCTCATCAGCAAGAGAGCAGACTTGGCCATCTCTGCCATCACCATCACCCCAGAGAGGGAGAGCGTTGTGGACTTCAGCAAGCGGTACATGGACTATTCAGTGGGGATTCTAATTAAGAAGCCCGAGGAGAAAATCAGCATCTTCTCCCTCTTTGCTCCATTTGATTTCGCTGTGTGGGCCTGCATTGCAGCAGCCATCCCTGTGGTTGGTGTGCTGATATTTGTGTTGAACAGGATACAGGCTGTGAGGGCTCAGAGTGCTGCCCAGCCCAGGCCGTCAGCTTCTGCCACTCTGCACAGCGCCATCTGGATTGTCTATGGAGCCTTCGTACAGCAAGGTGGCGAATCTTCCGTGAACTCCATGGCCATGCGCATCGTGATGGGCAGCTGGTGGCTCTTCACGCTCATTGTGTGCTCCTCCTACACAGCCAACCTTGCTGCCTTCCTCACAGTGTCCAGGATGGACAACCCCATAAGGACTTTCCAGGACCTGTCCAAACAAGTGGAAATGTCTTATGGCACTGTCCGGGATTCTGCTGTATATGAGTACTTCCGAGCCAAGGGCACCAACCCCCTGGAGCAGGACAGCACGTTTGCTGAACTCTGGCGGACCATCAGCAAGAACGGAGGGGCTGACAACTGCGTGTCCAGTCCTTCAGAAGOCATCAGGAAGGCAAAGAAGGGGAACTACGCCTTCCTGTGGGATGTGGCCGTGGTGGAATACGCAGCCCTGACGGATGACGACTGCTCGGTGACTGTCATCGGCAACAGCATCAGCAGCAAGGGTTACGGGATTGCCCTGCAGCATGGCAGCCCCTACAGGGACCTCTTCTCCCAGAGGATCCTGGAGCTGCAGGACACAGGGGACCTGGATGTGCTGAAGCAGAAGTGGTGGCCGCACATGGGCCGCTGTGACCTCACCAGCCATGCCAGCGCCCAGGCCGACGGCAAATCCCTCAAGCTGCACAGCTTCGCCGGGGTCTTCTGCATCCTGGCCATTGGCCTGCTCCTGGCCTGCCTGGTGGCTGCCCTGGAGTTGTGGTGGAACAGCAACCGGTGCCACCAGGAGACCCCCAAGGAGGACAAAGAAGTGAACTTGGAGCAGGTCCACCGGCGCATGAACAGCCTCATGGATGAAGACATTGCTCACAAGCAGATTTCCCCAGCGTCGATTGAGCTCTCGGCCCTGGAGATGGGGGGCCTGGCTCCCACCCAGACCTTGGAGCCGACACGGGAGTACCAGAACACCCAGCTCTCGGTCAGCACCTTTCTGCCAGAGCAGAGCAGCCATGGCACCAGCCGGACACTCTCATCAGGGCCCAGCAGCAACCTGCCGCTGCCGCTGAGCAGCTCGGCGACCATGCCCTCCATGCAGTGCAAACACAGGTCACCCAACGGGGGGCTGTTCCGGCAGAGCCCGGTGAAGACCCCCATCCCCATGTCCTTCCAGCCCGTGCCTGGAGGCGTCCTTCCAGAGGCTCTGGACACCTCCCACGGGACCTCCATCCTCGAGGGCNOV2c, 315490179Protein SequenceSEQ ID NO: 101016 aaMW at 112775.3kDTGSTMEALTLWLLPWICQCVSVRADSIIHIGAIFEENAAKDDRVFQLAVSDLSLNDDILQSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGAHSFINEAVETNLASKDSHWVFVNEEISDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDSEKGLNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPASIELSALEMGGLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSILEGNOV2d, CG101396-02SEQ ID NO: 113094bpDNA SequenceORF Start: ATG at 56ORF Stop: TAG at 3083TGTCGACGGCGCCAGTGTGATGATATTGCAGATTCGCCTTCACCGCGGCCGCACCATGGAAGCGCTGACGCTGTGGCTTCTCCCCTGGATATGCCAGTGCGTGTCGGTGCGGGCCGACTCCATCATCCACATCGGTGCCATCTTCGAGGAGAACGCGGCCAAGGACGACAGGGTGTTCCAGTTGGCGGTATCCGACCTGAGCCTCAGCGATGACATCCTGCAGAGCGAGAAGATCACCTACTCCATCAAGGTCATCGAGGCCAACAACCCATTCCAGGCTGTGCAGGAAGCCTGTGACCTCATGACCCAGGGGATTTTGGCCTTGGTCACGTCCACTGGCTGTGCATCTGCCAATGCCCTGCAGTCCCTCACGGATGCCATGCACATCCCACACCTCTTTGTCCAGCGCAACCCGGGAGGGTCGCCACGCACCGCATGCCACCTGAACCCCAGCCCCGATGGTGAGGCCTACACACTGGCTTCGAGACCACCCGTCCGCCTCAATGATGTCATGCTCAGGCTGGTGACGGAGCTGCGCTGGCAGAAGTTCGTCATGTTCTACGACAGCGAGTATGATATCCGTGGGCTTCAAAGCTTTCTGGACCAGGCCTCGCGGCTGGGCCTTGACGTCTCTTTACAAAAGGTGGACAAGAACATTAGCCACGTATTCACCAGCCTCTTCACCACGATGAAGACAGAGGAGCTGAATCGCTACCGGGACACGCTTCGCCGCGCCATCCTGCTGCTCAGCCCACAGGGAGCCCACTCCTTCATCAACGAGGCCGTGGAGACCAACCTGGCTTCCAAGGACAGCCACTGGGTCTTTGTGAATGAGGAAATCAGTGACCCGGAGATCCTGGATCTGGTCCATAGTGCCCTTGGAAGGATGACCGTGGTCCGGCAAATCTTTCCGTCTGCAAAGGACAATCAGAAATGCACGAGGAACAACCACCGCATCTCCTCCCTGCTCTGCGACCCCCAGGAAGGCTACCTCCAGATGCTGCAGATCTCCAACCTCTATCTGTATGACAGTGTTCTGATGCTGGCCAACGCCTTTCACAGGAAGCTGGAGGACCGGAAGTGGCATAGCATGGCGAGCCTCAACTGCATACGGAAATCCACTAAGCCATGGAATGGTGGGAGGTCCATGCTGGATACCATCAAAAAGGGCCACATCACTGGCCTCACTGGGGTGATGGAGTTTCGGGAGGACAGTTCGAATCCCTATGTCCAGTTTGAAATCCTTGGCACTACCTATAGTGAGACTTTTGGCAAAGACATGCGCAAGTTGGCGACATGGGACTCAGAGAAGGGCTTGAATGGCAGCTTGCAAGAGAGGCCCATGGGCAGCCGCCTCCAAGGATTGACTCTTAAAGTGGTGACTGTCTTGGAAGAGCCTTTCGTGATGGTGGCTGAGAACATCCTAGGACAGCCCAAGCGCTACAAAGGGTTCTCCATAGATGTCCTGGATGCACTGGCCAAGGCTCTGGGCTTTAAATATGAGATTTACCAAGCCCCTGATGGCAGGTACGGTCACCAGCTCCATAACACCTCCTGGAACGGGATGATCGGGGAGCTCATCAGCAAGAGAGCAGACTTGGCCATCTCTGCCATCACCATCACCCCAGAGAGGGAGAGCGTTGTGGACTTCAGCAAGCGGTACATGGACTATTCAGTGGGGATTCTAATTAAGAAGCCCGAGGAGAAAATCAGCATCTTCTCCCTCTTTGCTCCATTTGATTTCGCTGTGTGGGCCTGCATTGCAGCAGCCATCCCTGTGGTTGGTGTGCTGATATTTGTGTTGAACAGGATACAGGCTGTGAGGGCTCAGAGTGCTGCCCAGCCCAGGCCGTCAGCTTCTGCCACTCTGCACAGCGCCATCTGGATTGTCTATGGAGCCTTCGTACAGCAAGGTGGCGAATCTTCCGTGAACTCCATGGCCATGCGCATCGTGATGGGCAGCTGGTGGCTCTTCACGCTCATTGTGTGCTCCTCCTACACAGCCAACCTTGCTGCCTTCCTCACAGTGTCCAGGATGGACAACCCCATAAGGACTTTCCAGGACCTGTCCAAACAAGTGGAAATGTCTTATGGCACTGTCCGGGATTCTGCTGTATATGAGTACTTCCGAGCCAAGGGCACCAACCCCCTGGAGCAGGACAGCACGTTTGCTGAACTCTGGCGGACCATCAGCAAGAACGGAGGGGCTGACAACTGCGTGTCCAGTCCTTCAGAAGGCATCAGGAAGGCAAAGAAGGGGAACTACGCCTTCCTGTGGGATGTGGCCGTGGTGGAATACGCAGCCCTGACGGATGACGACTGCTCGGTGACTGTCATCGGCAACAGCATCAGCAGCAAGGGTTACGGGATTGCCCTGCAGCATGGCAGCCCCTACAGGGACCTCTTCTCCCAGAGGATCCTGGAGCTGCAGGACACAGGGGACCTGGATGTGCTGAAGCAGAAGTGGTGGCCGCACATGGGCCGCTGTGACCTCACCAGCCATGCCAGCGCCCAGGCCGACGGCAAATCCCTCAAGCTGCACAGCTTCGCCGGGGTCTTCTGCATCCTGGCCATTGGCCTGCTCCTGGCCTGCCTGGTGGCTGCCCTGGAGTTGTGGTGGAACAGCAACCGGTGCCACCAGGAGACCCCCAAGGAGGACAAAGAAGTGAACTTGGAGCAGGTCCACCGGCGCATGAACAGCCTCATGGATGAAGACATTGCTCACAAGCAGATTTCCCCAGCGTCGATTGAGCTCTCGGCCCTGGAGATGGGGGGCCTGGCTCCCACCCAGACCTTGGAGCCGACACGGGAGTACCAGAACACCCAGCTCTCGGTCAGCACCTTTCTGCCAGAGCAGAGCAGCCATGGCACCAGCCGGACACTCTCATCAGGGCCCAGCAGCAACCTGCCGCTGCCGCTGAGCAGCTCGGCGACCATGCCCTCCATGCAGTGCAAACACAGGTCACCCAACGGGGGGCTGTTCCGGCAGAGCCCGGTGAAGACCCCCATCCCCATGTCCTTCCAGCCCGTGCCTGGAGGCGTCCTTCCAGAGGCTCTGGACACCTCCCACGGGACCTCCATCTAGCTCGAGGGCNOV2d, CG101396-02Protein SequenceSEQ ID NO: 121009 aaMW at 112102.6kDMEALTLWLLPWICQCVSVRADSIIHIGAIFEENAAKDDRVFQLAVSDLSLSDDILQSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDANHIPHLFVQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGAHSFINEAVETNLASKDSHWVFVNEEISDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDSEKGLMGSLQERPMGSRLOGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPASIELSALEMGGLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSISEQ ID NO: 133189 bpNOV2e, SNP13379211 ofORF Start: ATG at 86ORF Stop: TGA at 3113CG101396-01, DNA SequenceSNP Pos: 3184SNP Change: C to TCTGCACCGGGACCAGCGCCTCCCCGCTTCGCGCTGCCCTCGGCCTCGCCCCGGGCCCGGGTGGATGAGCCGCGCGCCCGGGGGACATGGAAGCGCTGACGCTGTGGCTTCTCCCCTGGATATGCCAGTGCGTGTCGGTGCGGGCCGACTCCATCATCCACATCGGTGCCATCTTCGAGGAGAACGCGGCCAAGGACGACAGGGTGTTCCAGTTGGCGGTATCCGACCTGAGCCTCAACGATGACATCCTGCAGAGCGAGAAGATCACCTACTCCATCAAGGTCATCGAGGCCAACAACCCATTCCAGGCTGTGCAGGAAGCCTGTGACCTCATGACCCAGGGGATTTTGGCCTTGGTCACGTCCACTGGCTGTGCATCTGCCAATGCCCTGCAGTCCCTCACGGATGCCATGCACATCCCGCACCTCTTTGTCCAGCGCAACCCGGGAGGGTCGCCACGCACCGCATGCCACCTGAACCCCAGCCCCGATGGTGAGGCCTACACACTGGCTTCGAGACCACCCGTCCGCCTCAATGATGTCATGCTCAGGCTGGTGACGGAGCTGCGCTGGCAGAAGTTCGTCATGTTCTACGACAGCGAGTATGATATCCGTGGGCTTCAAAGCTTTCTGGACCAGGCCTCGCGGCTGGGCCTTGACGTCTCTTTACAAAAGGTGGACAAGAACATTAGCCACGTATTCACCAGCCTCTTCACCACGATGAAGACAGAGGAGCTGAATCGCTACCGGGACACGCTTCGCCGCGCCATCCTGCTGCTCAGCCCACAGGGAGCCCACTCCTTCATCAACGAGGCCGTGGAGACCAACCTGGCTTCCAAGGACAGCCACTGGGTCTTTGTGAATGAGGAAATCAGTGACCCGGAGATCCTGGATCTGGTCCATAGTGCCCTTGGAAGGATGACCGTGGTCCGGCAAATCTTTCCGTCTGCAAAGGACAATCAGAAATGCACGAGGAACAACCACCGCATCTCCTCCCTGCTCTGCGACCCCCAGGAAGGCTACCTCCAGATGCTGCAGATCTCCAACCTCTATCTGTATGACAGTGTTCTGATGCTGGCCAACGCCTTTCACAGGAAGCTGGAGGACCGGAAGTGGCATAGCATGGCGAGCCTCAACTGCATACGGAAATCCACTAAGCCATGGAATGGTGGGAGGTCCATGCTGGATACCATCAAAAAGGGCCACATCACTGGCCTCACTGGGGTGATGGAGTTTCGGGAGGACAGTTCGAATCCCTATGTCCAGTTTGAAATCCTTGGCACTACCTATAGTGAGACTTTTGGCAAAGACATGCGCAAGTTGGCGACATGGGACTCAGAGAAGGGCTTGAATGGCAGCTTGCAAGAGAGGCCCATGGGCAGCCGCCTCCAAGGATTGACTCTTAAAGTGGTGACTGTCTTGGAAGAGCCTTTCGTGATGGTGGCTGAGAACATCCTAGGACAGCCCAAGCGCTACAAAGGGTTCTCCATAGATGTCCTGGATGCACTGGCCAAGGCTCTGGGCTTTAAATATGAGATTTACCAAGCCCCTGATGGCAGGTACGGTCACCAGCTCCATAACACCTCCTGGAACGGGATGATCGGGGAGCTCATCAGCAAGAGAGCAGACTTGGCCATCTCTGCCATCACCATCACCCCAGAGAGGGAGAGCGTTGTGGACTTCAGCAAGCGGTACATGGACTATTCAGTGGGGATTCTAATTAAGAAGCCCGAGGAGAAAATCAGCATCTTCTCCCTCTTTGCTCCATTTGATTTCGCTGTGTGGGCCTGCATTGCAGCAGCCATCCCTGTGGTTGGTGTGCTGATATTTGTGTTGAACAGGATACAGGCTGTGAGGGCTCAGAGTGCTGCCCAGCCCAGGCCGTCAGCTTCTGCCACTCTGCACAGCGCCATCTGGATTGTCTATGGAGCCTTCGTACAGCAAGGTGGCGAATCTTCCGTGAACTCCATGGCCATGCGCATCGTGATGGGCAGCTGGTGGCTCTTCACGCTCATTGTGTGCTCCTCCTACACAGCCAACCTTGCTGCCTTCCTCACAGTGTCCAGGATGGACAACCCCATAAGGACTTTCCAGGACCTGTCCAAACAAGTGGAAATGTCTTATGGCACTGTCCGGGATTCTGCTGTATATGAGTACTTCCGAGCCAAGGGCACCAACCCCCTGGAGCAGGACAGCACGTTTGCTGAACTCTGGCGGACCATCAGCAAGAACGGAGGGGCTGACAACTGCGTGTCCAGTCCTTCAGAAGGCATCAGGAAGGCAAAGAAGGGGAACTACGCCTTCCTGTGGGATGTGGCCGTGGTGGAATACGCAGCCCTGACGGATGACGACTGCTCGGTGACTGTCATCGGCAACAGCATCAGCAGCAAGGGTTACGGGATTGCCCTGCAGCATGGCAGCCCCTACAGGGACCTCTTCTCCCAGAGGATCCTGGAGCTGCAGGACACAGGGGACCTGGATGTGCTGAAGCAGAAGTGGTGGCCGCACATGGGCCGCTGTGACCTCACCAGCCATGCCAGCGCCCAGGCCGACGGCAAATCCCTCAAGCTGCACAGCTTCGCCGGGGTCTTCTGCATCCTGGCCATTGGCCTGCTCCTGGCCTGCCTGGTGGCTGCCCTGGAGTTGTGGTGGAACAGCAACCGGTGCCACCAGGAGACCCCCAAGGAGGACAAAGAAGTGAACTTGGAGCAGGTCCACCGGCGCATGAACAGCCTCATGGATGAAGACATTGCTCACAAGCAGATTTCCCCAGCGTCGATTGAGCTCTCGGCCCTGGAGATGGGGGGCCTGGCTCCCACCCAGACCTTGGAGCCGACACGGGAGTACCAGAACACCCAGCTOTCGGTCAGCACCTTTCTGCCAGAGCAGAGCAGCCATGGCACCAGCCGGACACTCTCATCAGGGCCCAGCAGCAACCTGCCGCTGCCGCTGAGCAGCTCGGCGACCATGCCCTCCATGCAGTGCAAACACAGGTCACCCAACGGGGGGCTGTTCCGGCAGAGCCCGGTGAAGACCCCCATCCCCATGTCCTTCCAGCCCGTGCCTGGAGGCGTCCTTCCAGAGGCTCTGGACACCTCCCACGGGACCTCCATCTGACTGCGCCGCCTGCCCTCCTGCCCACCCTCCCACCCACCCGACCAGCAGAGCTTTTTAATACAAGAAAATAACAANOV2e, SNP13379211 ofMW at 112129.7kDCG101396-01, Protein SequencesSEQ ID NO: 141009 aaSNP Change: no changeMEALTLWLLPWICQCVSVRADSIIHIGAIFEENAAKDDRVFQLAVSDLSLNDDILQSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGAHSFINEAVETNLASKDSHWVFVNEEISDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDSEKGLNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPASIELSALEMGGLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSI

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 2B.

TABLE 2BComparison of the NOV2 protein sequences.NOV2a----MEALTLWLLPWICQCVSVRASIIHIGAIFEENAAKDDRVFQLAVSDLSLNDDILQNOV2b---------------------TGTDSIIHIGAIFEENAAKDDRVFQLAVSDLSNDDILQNOV2cTGSTMEALTLWLLPWICQCVSVRADSIIHIGAIFEENAAKDDRVFQLAVSDLSLNDDILQNOV2d----MEALTLWLLPWICQCVSVRADSIIHIGAIFEENAAKDDRVFQLAVSDLSLNDDILQNOV2aSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVNOV2bSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVNOV2cSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVNOV2dSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVNOV2aQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRNOV2bQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRNOV2cQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRNOV2dQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRNOV2aGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGANOV2bGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGANOV2cGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGANOV2dGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGANOV2aHSFINEAVETNLASKDSHWVFVNEEESDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNOV2bHSFINEAVETNLASKDSHWVFVNEEESDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNOV2cHSFINEAVETNLASKDSHWVFVNEEESDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNOV2dHSFINEAVETNLASKDSHWVFVNEEESDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNOV2aNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTNOV2bNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTNOV2cNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTNOV2dNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTNOV2aKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDNOV2bKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDNOV2cKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDNOV2dKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDNOV2aSEKGLNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKNOV2bSEKGLNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKNOV2cSEKGLNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKNOV2dSEKGLNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKNOV2aALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYNOV2bALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYNOV2cALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYNOV2dALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYNOV2aMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQNOV2bMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQNOV2cMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQNOV2dMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQNOV2aPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLNOV2bPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLNOV2cPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLNOV2dPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLNOV2aTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGNOV2bTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGNOV2cTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGNOV2dTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGNOV2aGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHNOV2bGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHNOV2cGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHNOV2dGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHNOV2aGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCNOV2bGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCNOV2cGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCNOV2dGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCNOV2aILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPANOV2bILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPANOV2cILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPANOV2dILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPANOV2aSIELSALEMGGLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSNOV2bSIELSALEMGGLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSNOV2cSIELSALEMGGLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSNOV2dSIELSALEMGGLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSNOV2aSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSI---NOV2bSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSILEGNOV2cSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSILEGNOV2dSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSI---NOV2a(SEQ ID NO: 6)NOV2b(SEQ ID NO: 8)NOV2c(SEQ ID NO: 10)NOV2d(SEQ ID NO: 12)

Further analysis of the NOV2a protein yielded the following properties shown in Table 2C.

TABLE 2CProtein Sequence Properties NOV2aSignalP analysis:Cleavage site between residues 21 and 22PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 2; pos. chg 0; neg. chg 1H-region: length 16; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −1.56possible cleavage site: between 17 and 18>>>Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS (s) for the threshold 0.5: 3INTEGRAL Likelihood = −11.41 Transmembrane 567-583INTEGRAL Likelihood = −0.43 Transmembrane 629-645INTEGRAL Likelihood = −12.79 Transmembrane 834-850PERIPHERAL Likelihood = 1.01 (at 437)ALOM score: −12.79 (number of TMSs: 3)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 574Charge difference: 5.0 C(3.0) − N(−2.0)C > N: C-terminal side will be inside>>>membrane topology: type 3bMITDISC:discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):3.64Hyd Moment (95):6.21G content:0D/E content:2S/T content:2Score: −5.86Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 29 VRA|DSNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: PKRYKGF (5) at 460bipartite: RKWHSMASLNCIRKSTK at 341content of basic residues: 9.5%NLS Score: 0.45KDEL:ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL:peroxisomal targeting signal in the C-terminus: nonePTS2:2nd peroxisomal targeting signal: noneVAC:possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR:N-myristoylation pattern nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 70.6COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):44.4%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: nuclear11.1%: mitochondrial>> prediction for CG101396-01 is end (k = 9)

A search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2D.

TABLE 2DGeneseq Results for NOV2aNOV2aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE13278Human transporters and ion1 . . . 10091008/1009 (99%)0.0channels (TRICH)-5 - Homo1 . . . 10091009/1009 (99%)sapiens, 1009 aa.[WO200177174-A2, 18-OCT-2001]AAM48984Rat glutamate receptor delta-11 . . . 1009 993/1009 (98%)0.0subunit SEQ ID NO: 1 - Rattus1 . . . 10091004/1009 (99%)norvegicus, 1009 aa.[WO2002063 I 3-A2, 24-JAN-2002]AAG77969Human ion channel protein1 . . . 1009 999/1009 (99%)0.0IC32391 - Homo sapiens, 10091 . . . 10091001/1009 (99%)aa. [WO200183752-A2, 08-NOV-2001]AAB40361Human ORFX ORF12583 . . . 1009 927/927 (100%)0.0polypeptide sequence SEQ ID1 . . . 927927/927 (100%)NO:250 - Homo sapiens, 927 aa.[WO200058473-A2, 05-OCT-2000]AAM48988Human glutamate receptor delta-219 . . . 1009 791/791 (100%)0.01 subunit SEQ ID NO: 8 - Homo 1 . . . 791 791/791 (100%)sapiens, 791 aa.[WO200206313-A2, 24-JAN-2002]

In a BLAST search of public sequence databases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2E.

TABLE 2EPublic BLASTP Results for NOV2aNOV2aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ62640Glutamate receptor delta-1 1 . . . 1009 993/1009 (98%)0.0subunit precursor - Rattus 1 . . . 10091004/1009 (99%)norvegicus (Rat), 1009 aa.CAD19379Sequence 4 from Patent 1 . . . 1009 999/1009 (99%)0.0WO0183752 - Homo sapiens 1 . . . 10091001/1009 (99%)(Human), 1009 aa.528857glutamate receptor delta-1 1 . . . 1009 992/1009 (98%)0.0chain precursor - rat, 1009 aa. 1 . . . 10091004/1009 (99%)Q61627Glutamate receptor delta-1 1 . . . 1009 992/1009 (98%)0.0subunit precursor - Mus 1 . . . 10091002/1009 (98%)musculus (Mouse), 1009 aa.Q9ULK0Hypothetical protein219 . . . 1009 791/791 (100%)0.0KIAAI220 - Homo sapiens 1 . . . 791 791/791 (100%)(Human), 791 aa (fragment)

PFam analysis indicates that the NOV2a protein contains the domains shown in the Table 2F.

TABLE 2FDomain Analysis of NOV2aIdentities/NOV2aSimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValueANF_-receptor 17 . . . 410 67/478 (14%)0.00034261/478 (55%)SBP_-bac_-3439 . . . 808 60/404 (15%)8.4e-07 221/404 (55%)lig_-chan562 . . . 852123/325 (38%)6.9e-125250/325 (77%)

Example 3

The NOV3 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 3A.

TABLE 3ANOV3 Sequence AnalysisNOV3a, CG102348-01SEQ ID NO: 153345 bpDNA SequenceORF Start: ATG at 18ORF Stop: TGA at 1479CAGATGTCCAGTTCCAGATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCCCTCACTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGGCTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTTCACAAGGGCTTTCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCGTCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATTGACCCTGGGGGCTTGAACAGGGACTGACCAGCACAGTGGAGGCCCCAGGCAACAGAGGGCCTGGAGTGAGGACTGAACACTGGGGTAGGGGTTGGGGGTGGGGGGTTGGGGGAGGCAGGGAAATCCTATTCACATCACTGTTGCACCAAGCCACTGCAAGAGAAACCCCCACCCGGCAAGCCCGCCCCATCCCAGACAGGAAGCAGAGTCCCACAGACCGCTCCTCCTCACCCTCTACCTCCCTGTGCTCATGCACTAGGCCCCGGGAAGCCTGTACATCTCAACAACTTTCGCCTTGAATGTCCTTAGAACCACCTTCCCCTACTTCATCTGTTGACACAGCTTTTATACTCACCTGTGGAAGAGTCAGCTACTCACCCGCTATTAGAGTATGGAGGAAGGGGTTTTCATTGCATTGCATTTCTGAAACATTCCTAAGACCCTTTAGTTGACCTTCAAATATTCAAGCTATTCTGCAGCTCCAAGATGCAATTATAGAAACAGCTCCTTTTTTATTTTATGTCCTCTATATGCCAGGTGCTTCACCTGTTATTTCACTTAATCCTCATACCATATTTGCAAAGGATGTGTTATTATCTATGTGTGACAAATGAGGAAACTGAGGCTCAGGGGATAAAGGGACTTGCCCAAGTCCCACAGCTGGTGTGTGACTGCAGAGACTGTGCTCTTCCCAGTGTGCTGCAATACTTCTCAACCCTCCTCTAACCTGCTGTGTCACCCGCTTTCCCTCCCAGCCCCCACATCCTTACCATTTTCCCTCCCTGGGAATTCCTGCTTCTGCGAAAATGGTATCCTCTAGCTCACACTTTCCTAATGGCCCCATCTCCTGCAGAAGCCAGGTGAGCCCAGCACTGGACTGAAGTTCTTGCAGACACCCCACCTGTGCCCCTATCATCAGGGGAACTGCTCCACCTGAGAGGACCAACTCTTTAATTTTTAGTAAAACCTGAAGGTGATGGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAACACCTTAGGAGTCCGAGGTGGGTGGATCACGAGGTCAGGAGATCCAGCCCATCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCGGGCGTGGTGACACGTGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCTAAGATCACGCCACTGCACTCCAGCCTGCGGACAGACCAAGACTTCATCCCCCCCAAAAAAAAAAGATTGGAGGTGATTTACAGTGAAAGACACAAATAAAATACAACTGTTCAATGGAAATAGAAAATAAACACCATAAAAGAGAGAAGAGAGGTAATTTGTTAGCATCAAGAGTCAAGTTGCTATATGGTCAAAGGTTAAATTTATCTCTAAAAAATGGCAGGATTCAAAGTTGTACATACATGTGATTACTTCTGTTTTTTACACCCACATACAGTACAAAAGATTATTAAAAATATTCCCAAAAGGCAGGTGCAATGATGCACACTTATACCCCCAGCCACTCAGGAGGCTGATGCAAGAGGATCGCTTGAGCCCAGGAGTTGAAGTCCAGCCTAAGCAACATAGTGAAACCCCATCTCCAAAAATATAATAATAATTCTCTCAAAATACTAAACAGAGGTGGTTTTATTGATAAGATTTTGGCTGTTTGGTTTTCCACTATTCTCTATTGGCTAAAATTTGTTTAATGAGCATGAAATGTTTTTATTTTATTTTGCTTATTTTTATGATTGCAAAAAATGATATGAGTTTCTCCCTGCCAAGGCAAAAAATATATATATATACCTATAAAAAAAAAAAAAAAAAAAAAAAAAAANOV3a, CG102348-01Protein SequenceSEQ ID NO: 16487 aaMW at 53483.9kDMPGPRVWGKYLWRSPHSKGCPGANWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTVYPKDSVSLRKMQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVNNGKNNOV3b, 199842645SEQ ID NO: 171368 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGTTCGTCTTCCAGGACTTCGACCTGGAGTCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCACGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCcTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3b, 199842645Protein SequenceSEQ ID NO: 18456 aaMW at 49986.8kDKLCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRFVFQDFDLESSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQATAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRRSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNKLNOV3c, 198306343SEQ ID NO: 19741 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGAACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCGTGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3c, 198306343Protein SequenceSEQ ID NO: 20247 aaMW at 27566.2kDKLTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKNSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNNFCVGDETQRHSVCQGDSGSVYVVWDNRAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNKLNOV3d, 199842665SEQ ID NO: 211368 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCGTCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3d, 199842665Protein SequenceSEQ ID NO: 22456 aaMW at 49918.7kDKLCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTVYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNKLNOV3e, 199842661SEQ ID NO: 231368 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGGACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGITGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3e, 199842661Protein SequenceSEQ ID NO: 24456 aaMW at 49933.7kDKLCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSEDKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNNFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNKLNOV3f, 199597024SEQ ID NO: 251479 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTCCCACCATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCCCTCACTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGGCTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAGTCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3f, 199597024Protein SequenceSEQ ID NO: 26493 aaMW at 54164.8kDKLPTMPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTVSFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNKLNOV3g, 199842653SEQ ID NO: 271293 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCCGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTCGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3g, 199842653Protein SequenceSEQ ID NO: 28431 aaMW at 47213.7kDKLCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGRLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNKLNOV3h, 199652830SEQ ID NO: 291368 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCCGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGGAAGACAGACAGGATGGGGAAGAGGTTCTTCAGTGTATGCCTGTCTGTGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATGACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3h, 199652830Protein SequenceSEQ ID NO: 30456 aaMW at 49933.7kDKLCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWEDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNHANHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNKNKLNOV3i, 199652835SEQ ID NO: 311368 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCGGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGGGACACAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3i, 199652835Protein SequenceSEQ ID NO: 32456 aaMW at 49888.7kDKLCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKMQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELRHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDGTQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNKLNOV3j, 198306308SEQ ID NO: 33387 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCGGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTTCACAAGGGCTTTCTGGCCCTCTACAAGCTTNOV3j, 198306308Protein SequenceSEQ ID NO: 34129 aaMW at 14001.5kDKLCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYKLNOV3k, CG102348-02SEQ ID NO: 35387 bpDNA SequenceORF Start: at 7ORF Stop: at 382AAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCGGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTTCACAAGGGCTTTCTGGCCCTCTACAAGCTTNOV3k, CG102348-02Protein SequenceSEQ ID NO: 36125 aaMW at 13518.9kDCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYNOV3l, CG102348-03SEQ ID NO: 37741 bpDNA SequenceORF Start: at 7ORF Stop: at 736AAGCTTACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGAACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCGTGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3l, CG102348-03Protein SequenceSEQ ID NO: 38243 aaMW at 27083.5kDTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKNSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNRAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNNOV3m, CG102348-04SEQ ID NO: 391293 bpDNA SequenceORF Start: at 7ORF Stop: at 1288AAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCCGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTCGGGGATGAGACGCAAAGGCACAGTGTCrGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3m, CG102348-04Protein SequenceSEQ ID NO: 40427 aaMW at 46731.0kDCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGOQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGRLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNNOV3n, CG102348-05SEQ ID NO: 411368 bpDNA SequenceORF Start: at 7ORF Stop: at 1363AAGCTTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGTTCGTCTTCCAGGACTTCGACCTGGAGTCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCACGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATAAGCTTNOV3n, CG102348-05Protein SequenceSEQ ID NO: 42452 aaMW at 49504.1kDCPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRFVFQDFDLESSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQATAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNNFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNNOV3o, CG102348-06SEQ ID NO: 431479 bpDNA SequenceORF Start: ATG at 13ORF Stop: at 1474AAGCTTCCCACCATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCCCTCACTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGGCTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTCCACAAGGGCTTCCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCACGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCATCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAAGGGGAGTGATGAATGGCAAGAATAAGCTTNOV3o, CG102348-06Protein SequenceSEQ ID NO: 44487 aaMW at 53528.0kDMPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGORFFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQATAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNSEQ ID NO: 453345 bpNOV3p, SNP 13376570 ofORF Start: ATG at 18ORF Stop: TGA at 1479CG102348-01, DNA SequenceSNP Pos: 343SNP Change: G to ACAGATGTCCAGTTCCAGATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCCCTCACTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGGCTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAACCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTTCACAAGGGCTTTCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCGTCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATTGACCCTGGGGGCTTGAACAGGGACTGACCAGCACAGTGGAGGCCCCAGGCAACAGAGGGCCTGGAGTGAGGACTGAACACTGGGGTAGGGGTTGGGGGTGGGGGGTTGGGGGAGGCAGGGAAATCCTATTCACATCACTGTTGCACCAAGCCACTGCAAGAGAAACCCCCACCCGGCAAGCCCGCCCCATCCCAGACAGGAAGCAGAGTCCCACAGACCGCTCCTCCTCACCCTCTACCTCCCTGTGCTCATGCACTAGGCCCCGGGAAGCCTGTACATCTCAACAACTTTCGCCTTGAATGTCCTTAGAACCACCTTCCCCTACTTCATCTGTTGACACAGCTTTTATACTCACCTGTGGAAGAGTCAGCTACTCACCCGCTATTAGAGTATGGAGGAAGGGGTTTTCATTGCATTGCATTTCTGAAACATTCCTAAGACCCTTTAGTTGACCTTCAAATATTCAAGCTATTCTGCAGCTCCAAGATGCAATTATAGAAACAGCTCCTTTTTTATTTTATGTCCTCTATATGCCAGGTGCTTCACCTGTTATTTCACTTAATCCTCATACCATATTTGCAAAGGATGTGTTATTATCTATGTGTGACAAATGAGGAAACTGAGGCTCAGGGGATAAAGGGACTTGCCCAAGTCCCACAGCTGGTGTGTGACTGCAGAGACTGTGCTCTTCCCAGTGTGCTGCAATACTTCTCAACCCTCCTCTAACCTGCTGTGTCACCCGCTTTCCCTCCCAGCCCCCACATCCTTACCATTTTCCCTCCCTGGGAATTCCTGCTTCTGCGAAAATGGTATCCTCTAGCTCACACTTTCCTAATGGCCCCATCTCCTGCAGAAGCCAGGTGAGCCCAGCACTGGACTGAAGTTCTTGCAGACACCCCACCTGTGCCCCTATCATCAGGGGAACTGCTCCACCTGAGAGGACCAACTCTTTAATTTTTAGTAAAACCTGAAGGTGATGGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAACACCTTAGGAGTCCGAGGTGGGTGGATCACGAGGTCAGGAGATCCAGCCCATCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCGGGCGTGGTGACACGTGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCTAAGATCACGCCACTGCACTCCAGCCTGCGGACAGACCAAGACTTCATCCCCCCCAAAAAAAAAAGATTGGAGGTGATTTACAGTGAAAGACACAAATAAAATACAACTGTTCAATGGAAATAGAAAATAAACACCATAAAAGAGAGAAGAGAGGTAATTTGTTAGCATCAAGAGTCAAGTTGCTATATGGTCAAAGGTTAAATTTATCTCTAAAAAATGGCAGGATTCAAAGTTGTACATACATGTGATTACTTCTGTTTTTTACACCCACATACAGTACAAAAGATTATTAAAAATATTCCCAAAAGGCAGGTGCAATGATGCACACTTATACCCCCAGCCACTCAGGAGGCTGATGCAAGAGGATCGCTTGAGCCCAGGAGTTGAAGTCCAGCCTAAGCAACATAGTGAAACCCCATCTCCAAAAATATAATAATAATTCTCTCAAAATACTAAACAGAGGTGGTTTTATTGATAAGATTTTGGCTGTTTGGTTTTCCACTATTCTCTATTGGCTAAAATTTGTTTAATGAGCATGAAATGTTTTTATTTTATTTTGCTTATTTTTATGATTGCAAAAAATGATATGAGTTTCTCCCTGCCAAGGCAAAAAATATATATATATACCTATAAAAAAAAAAAAAAAAAAAAAAAAANOV3p, SNP13376570 ofSEQ ID NO: 46MW at 53510.9kDCG102348-01, Protein SequenceSNP Pos: 109487 aaSNP Change: Ser to AsnMPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPNQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCOEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTVYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNNOV3q, SNP13376568 ofSEQ ID NO: 473345 bpCG102348-01, DNA SequenceORF Start: ATG at 18ORF Stop: TGA at 1479SNP Pos: 564SNP Change: G to ACAGATGTCCAGTTCCAGATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCCCTCACTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGGCTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTITGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTTCACAAGGGCTTTCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACACACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCGTCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATTGACCCTGGGGGCTTGAACAGGGACTGACCAGCACAGTGGAGGCCCCAGGCAACAGAGGGCCTGGAGTGAGGACTGAACACTGGGGTAGGGGTTGGGGGTGGGGGGTTGGGGGAGGCAGGGAAATCCTATTCACATCACTGTTGCACCAAGCCACTGCAAGAGAAACCCCCACCCGGCAAGCCCGCCCCATCCCAGACAGGAAGCAGAGTCCCACAGACCGCTCCTCCTCACCCTCTACCTCCCTGTGCTCATGCACTAGGCCCCGGGAAGCCTGTACATCTCAACAACTTTCGCCTTGAATGTCCTTAGAACCACCTTCCCCTACTTCATCTGTTGACACAGCTTTTATACTCACCTGTGGAAGAGTCAGCTACTCACCCGCTATTAGAGTATGGAGGAAGGGGTTTTCATTGCATTGCATTTCTGAAACATTCCTAAGACCCTTTAGTTGACCTTCAAATATTCAAGCTATTCTGCAGCTCCAAGATGCAATTATAGAAACAGCTCCTTTTTTATTTTATGTCCTCTATATGCCAGGTGCTTCACCTGTTATTTCACTTAATCCTCATACCATATTTGCAAAGGATGTGTTATTATCTATGTGTGACAAATGAGGAAACTGAGGCTCAGGGGATAAAGGGACTTGCCCAAGTCCCACAGCTGGTGTGTGACTGCAGAGACTGTGCTCTTCCCAGTGTGCTGCAATACTTCTCAACCCTCCTCTAACCTGCTGTGTCACCCGCTTTCCCTCCCAGCCCCCACATCCTTACCATTTTCCCTCCCTGGGAATTCCTGCTTCTGCGAAAATGGTATCCTCTAGCTCACACTTTCCTAATGGCCCCATCTCCTGCAGAAGCCAGGTGAGCCCAGCACTGGACTGAAGTTCTTGCAGACACCCCACCTGTGCCCCTATCATCAGGGGAACTGCTCCACCTGAGAGGACCAACTCTTTAATTTTTAGTAAAACCTGAAGGTGATGGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAACACCTTAGGAGTCCGAGGTGGGTGGATCACGAGGTCAGGAGATCCAGCCCATCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCGGGCGTGGTGACACGTGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCTAAGATCACGCCACTGCACTCCAGCCTGCGGACAGACCAAGACTTCATCCCCCCCAAAAAAAAAAGATTGGAGGTGATTTACAGTGAAAGACACAAATAAAATACAACTGTTCAATGGAAATAGAAAATAAACACCATAAAAGAGAGAAGAGAGGTAATTTGTTAGCATCAAGAGTCAAGTTGCTATATGGTCAAAGGTTAAATTTATCTCTAAAAAATGGCAGGATTCAAAGTTGTACATACATGTGATTACTTCTGTTTTTTACACCCACATACAGTACAAAAGATTATTAAAAATATTCCCAAAAGGCAGGTGCAATGATGCACACTTATACCCCCAGCCACTCAGGAGGCTGATGCAAGAGGATCGCTTGAGCCCAGGAGTTGAAGTCCAGCCTAAGCAACATAGTGAAACCCCATCTCCAAAAATATAATAATAATTCTCTCAAAATACTAAACAGAGGTGGTTTTATTGATAAGATTTTGGCTGTTTGGTTTTCCACTATTCTCTATTGGCTAAAATTTGTTTAATGAGCATGAAATGTTTTTATTTTATTTTGCTTATTTTTATGATTGCAAAAAATGATATGAGTTTCTCCCTGCCAAGGCAAAAAATATATATATATACCTATAAAAAAAAAAAAAAAAAAAAAAAAAAANOV3q, SNP13376568 ofSEQ ID NO: 48MW at 53513.9kDCG102348-01, Protein SequenceSNP Pos: 183487 aaSNP Change: Ala to ThrMPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINTPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTVYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELONSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETRQRHSVCQGDSGSVYVVWDNHAHHWVATGISWGIGCGEGYDFYTKVLSYVDWIKGVNNGKNSEQ ID NO: 493345 bpNOV3r, SNP13382463 ofORF Start: ATG at 18ORF Stop: TGA at 1479CG102348-01, DNA SequenceSNP Pos: 693SNP Change: C to TCAGATGTCCAGTTCCAGATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCCCTCACTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGGCTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTTCACAAGGGCTTTCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTTTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCGTCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGGAGTGATGAATGGCAAGAATTGACCCTGGGGGCTTGAACAGGGACTGACCAGCACAGTGGAGGCCCCAGGCAACAGAGGGCCTGGAGTGAGGACTGAACACTGGGGTAGGGGTTGGGGGTGGGGGGTTGGGGGAGGCAGGGAAATCCTATTCACATCACTGTTGCACCAAGCCACTGCAAGAGAAACCCCCACCCGGCAAGCCCGCCCCATCCCAGACAGGAAGCAGAGTCCCACAGACCGCTCCTCCTCACCCTCTACCTCCCTGTGCTCATGCACTAGGCCCCGGGAAGCCTGTACATCTCAACAACTTTCGCCTTGAATGTCCTTAGAACCACCTTCCCCTACTTCATCTGTTGACACAGCTTTTATACTCACCTGTGGAAGAGTCAGCTACTCACCCGCTATTAGAGTATGGAGGAAGGGGTTTTCATTGCATTGCATTTCTGAAACATTCCTAAGACCCTTTAGTTGACCTTCAAATATTCAAGCTATTCTGCAGCTCCAAGATGCAATTATAGAAACAGCTCCTTTTTTATTTTATGTCCTCTATATGCCAGGTGCTTCACCTGTTATTTCACTTAATCCTCATACCATATTTGCAAAGGATGTGTTATTATCTATGTGTGACAAATGAGGAAACTGAGGCTCAGGGGATAAAGGGACTTGCCCAAGTCCCACAGCTGGTGTGTGACTGCAGAGACTGTGCTCTTCCCAGTGTGCTGCAATACTTCTCAACCCTCCTCTAACCTGCTGTGTCACCCGCTTTCCCTCCCAGCCCCCACATCCTTACCATTTTCCCTCCCTGGGAATTCCTGCTTCTGCGAAAATGGTATCCTCTAGCTCACACTTTCCTAATGGCCCCATCTCCTGCAGAAGCCAGGTGAGCCCAGCACTGGACTGAAGTTCTTGCAGACACCCCACCTGTGCCCCTATCATCAGGGGAACTGCTCCACCTGAGAGGACCAACTCTTTAATTTTTAGTAAAACCTGAAGGTGATGGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAACACCTTAGGAGTCCGAGGTGGGTGGATCACGAGGTCAGGAGATCCAGCCCATCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCGGGCGTGGTGACACGTGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCTAAGATCACGCCACTGCACTCCAGCCTGCGGACAGACCAAGACTTCATCCCCCCCAAAAAAAAAAGATTGGAGGTGATTTACAGTGAAAGACACAAATAAAATACAACTGTTCAATGGAAATAGAAAATAAACACCATAAAAGAGAGAAGAGAGGTAATTTGTTAGCATCAAGAGTCAAGTTGCTATATGGTCAAAGGTTAAATTTATCTCTAAAAAATGGCAGGATTCAAAGTTGTACATACATGTGATTACTTCTGTTTTTTACACCCACATACAGTACAAAAGATTATTAAAAATATTCCCAAAAGGCAGGTGCAATGATGCACACTTATACCCCCAGCCACTCAGGAGGCTGATGCAAGAGGATCGCTTGAGCCCAGGAGTTGAAGTCCAGCCTAAGCAACATAGTGAAACCCCATCTCCAAAAATATAATAATAATTCTCTCAAAATACTAAACAGAGGTGGTTTTATTGATAAGATTTTGGCTGTTTGGTTTTCCACTATTCTCTATTGGCTAAAATTTGTTTAATGAGCATGAAATGTTTTTATTTTATTTTGCTTATTTTTATGATTGCAAAAAATGATATGAGTTTCTCCCTGCCAAGGCAAAAAATATATATATATACCTATAAAAAAAAAAAAAAAAAAAAAAAAAAANOV3r, SNP13382463 ofSEQ ID NO: 50MW at 53517.9kDCG102348-01, Protein SequenceSNP Pos: 226487 aaSNP Change: Leu to PheMPGPRVWGKYLWRSPNSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVFQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTVYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNNFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKGVMNGKNSEQ ID NO: 513345 bpNOV3s, SNP13374245 ofORF Start: ATG at 18ORF Stop: TGA at 1479CG102348-01, DNA SequenceSNP Pos: 1459SNP Change: G to ACAGATGTCCAGTTCCAGATGCCTGGACCCAGAGTGTGGGGGAAATATCTCTGGAGAAGCCCTCACTCCAAAGGCTGTCCAGGCGCAATGTGGTGGCTGCTTCTCTGGGGAGTCCTCCAGGCTTGCCCAACCCGGGGCTCCGTCCTCTTGGCCCAAGAGCTACCCCAGCAGCTGACATCCCCCGGGTACCCAGAGCCGTATGGCAAAGGCCAAGAGAGCAGCACGGACATCAAGGCTCCAGAGGGCTTTGCTGTGAGGCTCGTCTTCCAGGACTTCGACCTGGAGCCGTCCCAGGACTGTGCAGGGGACTCTGTCACAATCTCATTCGTCGGTTCGGATCCAAGCCAGTTCTGTGGTCAGCAAGGCTCCCCTCTGGGCAGGCCCCCTGGTCAGAGGGAGTTTGTATCCTCAGGGAGGAGTTTGCGGCTGACCTTCCGCACACAGCCTTCCTCGGAGAACAAGACTGCCCACCTTCACAAGGGCTTTCTGGCCCTCTACCAAACCGTGGCTGTGAACTATAGTCAGCCCATCAGCGAGGCCAGCAGGGGCTCTGAGGCCATCAACGCACCTGGAGACAACCCTGCCAAGGTCCAGAACCACTGCCAGGAGCCCTATTATCAGGCCGCGGCAGCAGGGGCACTCACCTGTGCAACCCCAGGGACCTGGAAAGACAGACAGGATGGGGAGGAGGTTCTTCAGTGTATGCCTGTCTGCGGACGGCCAGTCACCCCCATTGCCCAGAATCAGACGACCCTCGGTTCTTCCAGAGCCAAGCTGGGCAACTTCCCCTGGCAAGCCTTCACCAGTATCCACGGCCGTGGGGGCGGGGCCCTGCTGGGGGACAGATGGATCCTCACTGCTGCCCACACCGTCTACCCCAAGGACAGTGTTTCTCTCAGGAAGAACCAGAGTGTGAATGTGTTCTTGGGCCACACAGCCATAGATGAGATGCTGAAACTGGGGAACCACCCTGTCCACCGTGTCGTTGTGCACCCCGACTACCGTCAGAATGAGTCCCATAACTTTAGCGGGGACATCGCCCTCCTGGAGCTGCAGCACAGCATCCCCCTGGGCCCCAACGTCCTCCCGGTCTGTCTGCCCGATAATGAGACCCTCTACCGCAGCGGCTTGTTGGGCTACGTCAGTGGGTTTGGCATGGAGATGGGCTGGCTAACTACTGAGCTGAAGTACTCGAGGCTGCCTGTAGCTCCCAGGGAGGCCTGCAACGCCTGGCTCCAAAAGAGACAGAGACCCGAGGTGTTTTCTGACAATATGTTCTGTGTTGGGGATGAGACGCAAAGGCACAGTGTCTGCCAGGGGGACAGTGGCAGCGTCTATGTGGTATGGGACAATCATGCCCATCACTGGGTGGCCACGGGCATTGTGTCCTGGGGCATAGGGTGTGGCGAAGGGTATGACTTCTACACCAAGGTGCTCAGCTATGTGGACTGGATCAAGGAAGTGATGAATGGCAAGAATTGACCCTGGGGGCTTGAACAGGGACTGACCAGCACAGTGGAGGCCCCAGGCAACAGAGGGCCTGGAGTGAGGACTGAACACTGGGGTAGGGGTTGGGGGTGGGGGGTTGGGGGAGGCAGGGAAATCCTATTCACATCACTGTTGCACCAAGCCACTGCAAGAGAAACCCCCACCCGGCAAGCCCGCCCCATCCCAGACAGGAAGCAGAGTCCCACAGACCGCTCCTCCTCACCCTCTACCTCCCTGTGCTCATGCACTAGGCCCCGGGAAGCCTGTACATCTCAACAACTTTCGCCTTGAATGTCCTTAGAACCACCTTCCCCTACTTCATCTGTTGACACAGCTTTTATACTCACCTGTGGAAGAGTCAGTTACTCACCCGCTATTAGAGTATGGAGGAAGGGGTTTTCATTGCATTGCATTTCTGAAACATTCCTAAGACCCTTTAGTTGACCTTCAAATATTCAAGCTATTCTGCAGCTCCAAGATGCAATTATAGAAACAGCTCCTTTTTTATTTTATGTCCTCTATATGCCAGGTGCTTCACCTGTTATTTCACTTAATCCTCATACCATATTTGCAAAGGATGTGTTATTATCTATGTGTGACAAATGAGGAAACTGAGGCTCAGGGGATAAAGGGACTTGCCCAAGTCCCACAGCTGGTGTGTGACTGCAGAGACTGTGCTCTTCCCAGTGTGCTGCAATACTTCTCAACCCTCCTCTAACCTGCTGTGTCACCCGCTTTCCCTCCCAGCCCCCACATCCTTACCATTTTCCCTCCCTGGGAATTCCTGCTTCTGCGAAAATGGTATCCTCTAGCTCACACTTTCCTAATGGCCCCATCTCCTGCAGAAGCCAGGTGAGCCCAGCACTGGACTGAAGTTCTTGCAGACACCCCACCTGTGCCCCTATCATCAGGGGAACTGCTCCACCTGAGAGGACCAACTCTTTAATTTTTAGTAAAACCTGAAGGTGATGGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAACACCTTAGGAGTCCGAGGTGGGTGGATCACGAGGTCAGGAGATCCAGCCCATCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATACAAAATTAGCCGGGCGTGGTGACACGTGCCTGTAGTCCCAGCTACTCGGGAAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCTAAGATCACGCCACTGCACTCCAGCCTGCGGACAGACCAAGACTTCATCCCCCCCAAAAAAAAAAGATTGGAGGTGATTTACAGTGAAAGACACAAATAAAATACAACTGTTCAATGGAAATAGAAAATAAACACCATAAAAGAGAGAAGAGAGGTAATTTGTTAGCATCAAGAGTCAAGTTGCTATATGGTCAAAGGTTAAATTTATCTCTAAAAAATGGCAGGATTCAAAGTTGTACATACATGTGATTACTTCTGTTTTTTACACCCACATACAGTACAAAAGATTATTAAAAATATTCCCAAAAGGCAGGTGCAATGATGCACACTTATACCCCCAGCCACTCAGGAGGCTGATGCAAGAGGATCGCTTGAGCCCAGGAGTTGAAGTCCAGCCTAAGCAACATAGTGAAACCCCATCTCCAAAAATATAATAATAATTCTCTCAAAATACTAAACAGAGGTGGTTTTATTGATAAGATTTTGGCTGTTTGGTTTTCCACTATTCTCTATTGGCTAAAATTTGTTTAATGAGCATGAAATGTTTTTATTTTATTTTGCTTATTTTTATGATTGCAAAAAATGATATGAGTTTCTCCCTGCCAAGGCAAAAAATATATATATATACCTATAAAAAAAAAAAAAAAAAAAAAAAAAAANOV3s, SNP13374245 ofSEQ ID NO: 52MW at 53556.0kDCG102348-01, Protein SequenceSNP Pos: 481487 aaSNP Change: Gly to GluMPGPRVWGKYLWRSPHSKGCPGAMWLLWGVLQACPTRGSVLLAQELPQQLTSPGYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTVYPKDSVSLRKNQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVDWIKEVMNGKN

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 3B.

TABLE 3BComparison of the NOV3 protein sequences.NOV3a----MPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGNOV3b-------------------------------------KLCPTRGSVLLAQELPQQLTSPGNOV3c------------------------------------------------------------NOV3d-------------------------------------KLCPTRGSVLLAQELPQQLTSPGNOV3e-------------------------------------KLCPTRGSVLLAQELPQQLTSPGNOV3fKLPTMPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGNOV3g-------------------------------------KLCPTRGSVLLAQELPQQLTSPGNOV3h-------------------------------------KLCPTRGSVLLAQELPQQLTSPGNOV3i-------------------------------------KLCPTRGSVLLAQELPQQLTSPGNOV3j-------------------------------------KLCPTRGSVLLAQELPQQLTSPGNOV3k---------------------------------------CPTRGSVLLAQELPQQLTSPGNov3l------------------------------------------------------------NOV3m---------------------------------------CPTRGSVLLAQELPQQLTSPGNOV3n---------------------------------------CPTRGSVLLAQELPQQLTSPGNOV3o----MPGPRVWGKYLWRSPHSKGCPGAMWWLLLWGVLQACPTRGSVLLAQELPQQLTSPGNOV3aYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGNOV3bYPEPYGKGQESSTDIKAPEGFAVRFVFQDFDLESSQDCAGDSVTISFVGSDPSQFCGQQGNOV3c------------------------------------------------------------NOV3dYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGNOV3eYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGNOV3fYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTVSFVGSDPSQFCGQQGNOV3gYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGNOV3hYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGNOV3iYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGNOV3jYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGNOV3kYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGNOV3l------------------------------------------------------------NOV3mYPEPYGKGQESSTDIKAPEGFAVRLVFQDFDLEPSQDCAGDSVTISFVGSDPSQFCGQQGNOV3nYPEPYGKGQESSTDIKAPEGFAVRFVFQDFDLESSQDCAGDSVTISFVGSDPSQFCGQQGNOV3oYPEPYGKGQESSTDIKAPEGFAVRFVFQDFDLESSQDCAGDSVTISFVGSDPSQFCGQQGNOV3aSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3bSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3c------------------------------------------------------------NOV3dSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3eSPLGRPPGQREFVSSGRSLRLTFRTQPSSEDKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3fSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3gSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3hSPLGRPPGQREFVSSGRSLRLTFRTQP5SENKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3iSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3jSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYKL--------------NOV3kSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALY----------------NOV3l------------------------------------------------------------NOV3mSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3nSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAELHKGFLALYQTVAVNYSQPISEASRNOV3oSPLGRPPGQREFVSSGRSLRLTFRTQPSSENKTAHLHKGFLALYQTVAVNYSQPISEASRNOV3aGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVNOV3bGSEAINAPGDNPAKVQNHCQEPYYQATAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVNOV3c------------------------------------------------------------NOV3dGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVNOV3eGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVNOV3fGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVNOV3gGSEAINAPGDNPAKVQNHCQEPYYQAAAA-----------------------V--CGRPVNOV3hGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWEDRQDGEEVLQCMPVCGRPVNOV3iGSEAINAPGDNPAKVQNHCQEPYYQAAAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVNOV3j------------------------------------------------------------NOV3k------------------------------------------------------------NOV3l------------------------------------------------------------NOV3mGSEAINAPGDNPAKVQNHCQEPYYQAAAA-----------------------V--CGRPVNOV3nGSEAINAPGDNPAKVQNHCQEPYYQATAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVNOV3oGSEAINAPGDNPAKVQNHCQEPYYQATAAGALTCATPGTWKDRQDGEEVLQCMPVCGRPVNOV3aTPIAQNQTTLGSSPAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTVYPKDSVSLRKNNOV3bTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNNOV3c------KLTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKNSVSLRKNNOV3dTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTVYPKDSVSLRKNNOV3eTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNNOV3fTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNNOV3gTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNNOV3hTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAETIYPKDSVSLRKNNOV3iTPIAQNQTTLGSSRAKLGNFPWOAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNNOV3j------------------------------------------------------------NOV3k------------------------------------------------------------NOV3l--------TLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKNSVSLRKNNOV3mTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNNOV3nTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNNOV3oTPIAQNQTTLGSSRAKLGNFPWQAFTSIHGRGGGALLGDRWILTAAHTIYPKDSVSLRKNNOV3aQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3bQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPIGPNVLNOV3cQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3dQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3eQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3fQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3gQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3hQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3iQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELRHSIPLGPNVLNOV3j------------------------------------------------------------NOV3k------------------------------------------------------------NOV3lQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3mQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3nQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3oQSVNVFLGHTAIDEMLKLGNHPVHRVVVHPDYRQNESHNFSGDIALLELQHSIPLGPNVLNOV3aPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3bPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3cPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3dPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3ePVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREAcNAWLQKRQRPEVFSNOV3fPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3gPVCLPDNETLYRSGLLGYVSGFGMEMGRLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3hPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3iPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3j------------------------------------------------------------NOV3k------------------------------------------------------------NOV3lPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3mPVCLPDNETLYRSGLLGYVSGFGMEMGRLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3nPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3oPVCLPDNETLYRSGLLGYVSGFGMEMGWLTTELKYSRLPVAPREACNAWLQKRQRPEVFSNOV3aDNMFCVGDETQRHSVCQODSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3bDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3cDNMFCVGDETQRHSVCQGDSGSVYVVWDNRAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3dDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3eDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3fDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3gDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3hDNMFCVGDETQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3iDNMFCVGDGTQRHSVCQGDSGSVYVVWDNHAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3j------------------------------------------------------------NOV3k------------------------------------------------------------NOV3lDNMFCVGDETQRHSVCQGDSGSVYVVWDNRAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3mDNMFCVGDETQRHSVCQGDSGSVYVVWDNRAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3nDNMFCVGDETQRHSVCQGDSGSVYVVWDNRAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3oDNMFCVGDETQRHSVCQGDSGSVYVVWDNRAHHWVATGIVSWGIGCGEGYDFYTKVLSYVNOV3aDWIKGVMNGKN--NOV3bDWIKGVMNGKNKLNOV3cDWIKGVMNGKNKLNOV3dDWIKGVMNGKNKLNOV3eDWIKGVMNGKNKLNOV3fDWIKGVMNGKNKLNOV3gDWIKGVMNGKNKLNOV3hDWIKGVMNGKNKLNOV3iDWIKGVMNGKNKLNOV3j-------------NOV3k-------------NOV3lDWIKGVMNGKN--NOV3mDWIKGVMNGKN--NOV3nDWIKGVNNGKN--NOV3oDWIKGVMNGKN--NOV3a(SEQ ID NO: 16)NOV3b(SEQ ID NO: 18)NOV3c(SEQ ID NO: 20)NOV3d(SEQ ID NO: 22)NOV3e(SEQ ID NO: 24)NOV3f(SEQ ID NO: 26)NOV3g(SEQ ID NO: 28)NOV3h(SEQ ID NO: 30)NOV3i(SEQ ID NO: 32)NOV3j(SEQ ID NO: 34)NOV3k(SEQ ID NO: 36)NOV3l(SEQ ID NO: 38)NOV3m(SEQ ID NO: 40)NOV3n(SEQ ID NO: 42)NOV3o(SEQ ID NO: 44)

Further analysis of the NOV3a protein yielded the following properties shown in Table 3C.

TABLE 3CProtein Sequence Properties NOV3aSignalP analysis:Cleavage site between residues 36 and 37PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 9; pos.chg 2; neg.chg 0H-region: length 3; peak value −5.40PSG score: −9.80GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 2.53possible cleavage site: between 35 and 36>>>Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 2.97 (at 20)ALOM score: 2.97 (number of TMSs: 0)MITDISC:discrimination of mitochondrial targeting seqR content:3Hyd Moment (75):7.36Hyd Moment (95):6.26G content:6D/E content:1S/T content:4Score: −3.72Gavel:prediction of cleavage sites for mitochondrial preseqR-2 motif at 49 TRG|SVNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 8.4%NLS Score: −0.47KDEL:ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: PGPRKKXX-like motif in the C-terminus: MNGKSKL:peroxisomal targeting signal in the C-terminus: nonePTS2:2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR:N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 76.7COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23)60.9%: mitochondrial17.4%: cytoplasmic17.4%: nuclear 4.3%: peroxisomal>>prediction for CG102348-01 is mit (k = 23)

A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3D.

TABLE 3DGeneseq Results for NOV3aNOV3aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU08683Human FCTR5a polypeptide 1 . . . 487485/487 (99%)0.0sequence - Homo sapiens, 487 1 . . . 487487/487 (99%)aa. [WO200166747-A2, 13-SEP-2001]AAU08684Human FCTR5b polypeptide 1 . . . 487484/487 (99%)0.0sequence - Homo sapiens, 487 1 . . . 487487/487 (99%)aa. [WO200166747-A2, 13-SEP-2001]AAB23624Human secreted protein SEQ ID24 . . . 487464/464 (100%)0.0NO: 48 - Homo sapiens, 464 aa. 1 . . . 464464/464 (100%)[WO200049134-A1, 24-AUG-2000]AAB95642Human protein sequence SEQ ID 1 . . . 425423/425 (99%)0.0NO: 18384 - Homo sapiens, 438 1 . . . 425423/425 (99%)aa. [EP1074617-A2, 07-FEB-2001]ABG65427Human albumin fusion protein24 . . . 413389/390 (99%)0.0#2102 - Homo sapiens, 396 aa. 1 . . . 390390/390 (99%)[WO200177137-A1, 18-OCT-2001]

In a BLAST search of public sequence databases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3E.

TABLE 3EPublic BLASTP Results for NOV3aNOV3aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9NZP8Complement C1r-like 1 . . . 487487/487 (100%)0.0proteinase - Homo sapiens 1 . . . 487487/487 (100%)(Human), 487 aa.CAC88678Sequence 16 from Patent 1 . . . 487485/487 (99%)0.0WO0166747 - Homo sapiens 1 . . . 487487/487 (99%)(Human), 487 aa.Q9H804Hypothetical protein - Homo 1 . . . 425423/425 (99%)0.0sapiens (Human), 438 aa. 1 . . . 425423/425 (99%)AAH35220Similar to complement189 . . . 483176/303 (58%)e-108component - Homo sapiens400 . . . 701226/303 (74%)(Human), 705 aa.Q8J012Complement component 1, r189 . . . 483176/303 (58%)e-108subcomponent - Homo sapiens144 . . . 445226/303 (74%)(Human), 449 aa (fragment).

PFam analysis indicates that the NOV3a protein contains the domains shown in the Table 3F.

TABLE 3FDomain Analysis of NOV3aIdentities/NOV3aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect ValueCUB 40 . . . 160 41/131 (31%)1.4e-06 88/131 (67%)trypsin245 . . . 479 87/270 (32%)2.1e-43174/270 (64%)

Example 4

The NOV4 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 4A.

TABLE 4ANOV4 Sequence AnalysisNOV4a, CG125860-02SEQ ID NO: 531880 bpDNA SequenceORF Start: ATG at 24ORF Stop: TAA at 1563TTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGGCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4a, CG125860-02Protein SequenceSEQ ID NO: 54513 aaMW at 55531.5kDMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFNOV4b, CG125860-01SEQ ID NO: 551787 bpDNA SequenceORF Start: ATG at 54ORF Stop: TAA at 1470GCGGAACATTGCCTAGTAGACCCTGAGGCTTTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCATTTCTCAGGCGGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGGCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4b, CG125860-01Protein SequenceSEQ ID NO: 56472 aaMW at 50916.3kDMSLMLDDQPPMEAQYAEEGPGPGIFPAEPGDQQHPISQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGAINERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQLCNSSCVYSGALTPRNLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFSEQ ID NO: 571880 bpNOV4c, SNP13376012 ofORF Start: ATG at 24ORF Stop: TAA at 1563CG125860-02, DNA SequenceSNP Pos: 36SNP Change: C to TTTACAACAGTGCCACTGACCCCTATGAGCCTGATGTTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGcTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGGCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4c, SNP13376012 ofSEQ ID NO: 58MW at 55531.5kDCG125860-02, Protein SequenceSNP Pos: 5513 aaSNP Change: Leu to LeuMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPAIPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFSEQ ID NO: 591880 bpNOV4d, SNP13376014 ofORF Start: ATG at 24ORF Stop: TAA at 1563CG125860-02, DNA SequenceSNP Pos: 265SNP Change: G to ATTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCAACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGGCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCcTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4d, SNP13376014 ofSEQ ID NO: 60MW at 55503.5kDCG125860-02, Protein SequenceSNP Pos: 81513 aaSNP Change: Arg to GlnMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMQRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFSEQ ID NO: 611880 bpNOV4e, SNP13376015 ofORF Start: ATG at 24ORF Stop: TAA at 1563CG125860-02, DNA SequenceSNP Pos: 827SNP Change: T to CTTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGcTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGCGGGCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4e, SNP13376015 ofSEQ ID NO: 62MW at 55531.5kDCG125860-02, Protein SequenceSNP Pos: 268513 aaSNP Change: Gly to GlyMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCNHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFSEQ ID NO: 631880 bpNOV4f, SNP13376016 ofORF Start: ATG at 24ORF Stop: TAA at 1563CG125860-02, DNA SequenceSNP Pos: 830SNP Change: G to TTTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGTCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4f, SNP13376016 ofSEQ ID NO: 64MW at 55531.5kDCG125860-02, Protein SequenceSNP Pos: 269513 aaSNP Change: Gly to GlyMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQLCNSSCVYSGALTPRHLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFSEQ ID NO: 651880 bpNOV4g, SNP13376017 ofORF Start: ATG at 24ORF Stop: TAA at 1563CG125860-02, DNA SequenceSNP Pos: 836SNP Change: T to CTTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCITGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGGCAGTCCGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4g, SNP13376017 ofSEQ ID NO: 66MW at 55531.5kDCG125860-02, Protein SequenceSNP Pos: 271513 aaSNP Change: Ser to SerMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFSEQ ID NO: 671880 bpNOV4h, SNP13376011 ofORF Start: ATG at 24ORF Stop: TAA at 1563CG125860-02, DNA SequenceSNP Pos: 869SNP Change: C to TTTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGGCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGTGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4h, SNP13376011 ofSEQ ID NO: 68MW at 55531.5kDCG125860-02, Protein SequenceSNP Pos: 282513 aaSNP Change: Ser to SerMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTOLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFSEQ ID NO: 691880 bpNOV4i, SNP13376018 ofORF Start: ATG at 24ORF Stop: TAA at 1563CG125860-02, DNA SequenceSNP Pos: 975SNP Change: A to GTTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGGCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCGGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4i, SNP13376018 ofSEQ ID NO: 70MW at 55501.5kDCG125860-02, Protein SequenceSNP Pos: 318513 aaSNP Change: Ser to GlyMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSGWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFSEQ ID NO: 711880 bpNOV4j, SNP13382467 ofORF Start: ATG at 24ORF Stop: TAA at 1563CG125860-02, DNA SequenceSNP Pos: 1269SNP Change: C to TTTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGTCTGCCATGAGGGCTGGAGCCCCGCCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCAGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGGCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCTTGCTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4j, SNP13382467 ofSEQ ID NO: 72MW at 55531.5kDCG125860-02, Protein SequenceSNP Pos: 416513 aaSNP Change: Leu to LeuMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPMHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFSEQ ID NO: 731880 bpNOV4k, SNP13382466 ofORF Start: ATG at 24ORF Stop: TAA at 1563CG125860-02, DNA SequenceSNP Pos: 1272SNP Change: C to TTTACAACAGTGCCACTGACCCCTATGAGCCTGATGCTGGATGACCAACCCCCTATGGAGGCCCAGTATGCAGAGGAGGGCCCAGGACCTGGGATCTTCAGAGCAGAGCCTGGAGACCAGCAGCATCCCAGTAGGCCAGACTGGGCCATAGGGGAAATGACAGGGTGGGGACAGTGGAGGGCAATCATCCTACATTCCCCGGATCCTCCTTGGGGTCAGCCCCACATGATTGATGTTTCTCAGGCAGTGTGCTGGCGTTCCATGCGACGTGGCTGTGCAGTGCTGGGAGCCCTGGGGCTGCTGGCCGGTGCAGGTGTTGGCTCATGGCTCCTAGTGCTGTATCTGTGTCCTGCTGCCTCTCAGCCCATTTCCGGGACCTTGCAGGATGAGGAGATAACTTTGAGCTGCTCAGAGGCCAGCGCTGAGGAAGCTCTGCTCCCTGCACTTCCCAAAACACCTGCACTTCCCAAAACAGTATCTTTCAGAATAAACAGCGAAGACTTCTTGCTGGAAGCGCAAGTGAGGGATCAGCCACGCTGGCTCCTGGTCTGCCATGAGGGCTGGAGCCCCGCCCTGGGGCTGCAGATCTGCTGGAGCCTTGGGCATCTCAGACTCACTCACCACAAGGGAGTAAACCTCACTGACATCAAACTCAACAGTTCCCAGGAGTTTGCTCTGCTCTCTCCTAGACTGGGAGGCTTCCTGGAGGAGGCGTGGCAGCCCAGTAGGACTACTGAGGCTGTTAGGAACAACTGCACTTCTGGTCAAGTTGTTTCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCCTGGCTTCCCGGATAGTTGGTGGGCAGTCTGTGGCTCCTGGGCGCTGGCCGTGGCAGGCCAGCGTGGCCCTGGGCTTCCGGCACACGTGTGGGGGCTCTGTGCTAGCGCCACGCTGGGTGGTGACTGCTGCACATTGTATGCACAGTTTCAGGCTGGCCCGCCTGTCCAGCTGGCGGGTTCATGCGGGGCTGGTCAGCCACAGTGCCGTCAGGCCCCACCAAGGGGCTCTGGTGGAGAGGATTATCCCACACCCCCTCTACAGTGCCCAGAATCATGACTACGACGTCGCCCTCCTGAGGCTCCAGACCGCTCTCAACTTCTCAGACACTGTGGGCGCTGTGTGCCTGCCGGCCAAGGAACAGCATTTTCCGAAGGGCTCGCGGTGCTGGGTGTCTGGCTGGGGCCACACCCACCCTAGCCATACTTACAGCTCGGATATGCTCCAGGACACGGTGGTGCCCCTGTTCAGCACTCAGCTCTGCAACAGCTCTTGCGTGTACAGCGGAGCCCTCACCCCCCGCATGCTTTGCGCTGGCTACCTGGACGGAAGGGCTGATGCATGCCAGGGAGATAGCGGGGGCCCCCTAGTGTGCCCAGATGGGGACACATGGCGCCTAGTGGGGGTGGTCAGCTGGGGGCGTGGCTGCGCAGAGCCCAATCACCCAGGTGTCTACGCCAAGGTAGCTGAGTTTCTGGACTGGATCCATGACACTGCTCAGGTGAGTGTGGGGGCAGGAGTAGGGCAGGGAGATTTCTAAAGGACCTGCCCTCGAATGCAAGGAACCTTACCCCTTAGGCCCGGGCCCTGCTGGGGACTGGGGAGGGTGCTAGGACATATTCCCCAGAGTGAGTGGAGGAAGAAGTGAAGCTTAAACATGGAATCCATTGGATTTCTATCAGTTTAAGGATGAACTGGGTAAGAGTATGCCTGAGTTTGTATCCCAGATCTACCATTTCCTGTGTCGACCTTTGGCAAATTTCTAACTTTGTTAAACCTTAATTTCCTGATAATAACCATGATGGCTACTTATATGCTATTGTTATATGCTATTAAATAAGACCCGTACAATGCCNOV4k, SNP13382466 ofSEQ ID NO: 74MW at 55565.5kDCG125860-02, Protein SequenceSNP Pos: 417513 aaSNP Change: Leu to PheMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLFSTQLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDF

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 4B.

TABLE 4BComparison of the NOV4 protein sequences.NOV4aMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHPSRPDWAIGEMTGWGQWRAIILHSPDNOV4bMSLMLDDQPPMEAQYAEEGPGPGIFRAEPGDQQHP-------------------------NOV4aPPWGQPHMIDVSQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQNOV4b----------ISQAVCWRSMRRGCAVLGALGLLAGAGVGSWLLVLYLCPAASQPISGTLQNOV4aDEEITLSCSEASAEEALLPALPKTPALPKTVSFRINSEDFLLEAQVRDQPRWLLVCHEGWNOV4bDEEITLSCSEASAEEALLPALPKT------VSFRINSEDFLLEAQVRDQPRWLLVCHEGWNOV4aSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVNOV4bSPALGLQICWSLGHLRLTHHKGVNLTDIKLNSSQEFAQLSPRLGGFLEEAWQPSRTTEAVNOV4aRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWNOV4bRNNCTSGQVVSLRCSECGARPLASRIVGGQSVAPGRWPWQASVALGFRHTCGGSVLAPRWNOV4aVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLNOV4bVVTAAHCMHSFRLARLSSWRVHAGLVSHSAVRPHQGALVERIIPHPLYSAQNHDYDVALLNOV4aRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQNOV4bRLQTALNFSDTVGAVCLPAKEQHFPKGSRCWVSGWGHTHPSHTYSSDMLQDTVVPLLSTQNOV4aLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNOV4bLCNSSCVYSGALTPRMLCAGYLDGRADACQGDSGGPLVCPDGDTWRLVGVVSWGRGCAEPNOV4aNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFNOV4bNHPGVYAKVAEFLDWIHDTAQVSVGAGVGQGDFNOV4a(SEQ ID NO: 54)NOV4b(SEQ ID NO: 56)

Further analysis of the NOV4a protein yielded the following properties shown in Table 4C.

TABLE 4CProtein Sequence Properties NOV4aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 7; pos.chg 0; neg.chg 2H-region: length 4; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −12.80possible cleavage site: between 13 and 14>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 1Number of TMS(s) for threshold 0.5: 1INTEGRAL Likelihood = −3.40 Transmembrane 89-105PERIPHERAL Likelihood = 5.57 (at 173)ALOM score: −3.40 (number of TMSs: 1)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 96Charge difference: −8.0 C(−6.0) − N( 2.0)N >= C: N-terminal side will be inside>>> membrane topology: type 2 (cytoplasmic tail 1 to 89)MITDISC:discrimination of mitochondrial targeting seqR content:0Hyd Moment (75):8.83Hyd Moment(95):8.90G content:0DIE content:2S/T content:1Score: −6.04Gavel:prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.2%NLS Score: −0.47KDEL:ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL:peroxisomal targeting signal in the C-terminus: nonePTS2:2nd peroxisomal targeting signal: noneVAC:possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR:N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 89COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):34.8%: mitochondrial26.1%: cytoplasmic17.4%: Golgi 8.7%: endoplasmic reticulum 4.3%: extracellular, including cell wall 4.3%: nuclear 4.3%: vesicles of secretory system>> prediction for CG125860-02 is mit (k = 23)

A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4D.

TABLE 4DGeneseq Results for NOV4aNOV4aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABG76906Human hepsin/plasma 1 . . . 513470/513 (91%)0.0transmembrane serine protease- 1 . . . 472472/513 (91%)like protein - Homo sapiens, 472aa. [WO200233087-A2, 25-APR-2002]AAU82752Amino acid sequence of novel 1 . . . 504451/504 (89%)0.0human protease #51 - Homo 1 . . . 456453/504 (89%)sapiens, 457 aa. [WO200200860-A2, 03-JAN-2002]AAB11699Human serine protease BSSP2 1 . . . 504451/504 (89%)0.0(hBSSP2), SEQ ID NO:10 - Homo 1 . . . 456453/504 (89%)sapiens, 457 aa. [WO200031272-A1, 02-JUN-2000]AAB08950Human secreted protein sequence69 . . . 504417/436 (95%)0.0encoded by gene 22 SEQ ID57 . . . 479419/436 (95%)NO:107 - Homo sapiens, 480 aa.[WO200017222-A1, 30-MAR-2000]AAB08912Human secreted protein sequence80 . . . 504409/425 (96%)0.0encoded by gene 22 SEQ ID 1 . . . 412410/425 (96%)NO:69 - Homo sapiens, 414 aa.[WO200017222-A1, 30-MAR-2000]

In a BLAST search of public sequence databases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4E.

TABLE 4EPublic BLASTP Results for NOV4aIdentities/NOV4aSimilaritiesProteinResidues/for the AccessionProtein/MatchMatchedExpectNumberOrganism/LengthResiduesPortionValueQ9H3S3Transmembrane pro- 1 . . . 504451/5040.0tease, serine 5 (EC 1 . . . 456(89%)3.4.21.-) (Spinesin) -453/504Homo sapiens(89%)(Human), 457 aa.Q8CJ17Adrenal mitochondrial 11 . . . 502360/4920.0protease long variant - 1 . . . 444(73%)Rattus norvegicus393/492(Rat), 445 aa.(79%)Q8CDR0Transmembrane pro- 1 . . . 502359/5020.0tease - Mus musculus 1 . . . 454(71%)(Mouse), 455 aa.394/502(77%)Q9ER04Transmembrane pro- 1 . . . 502359/5020.0tease, serine 5 (EC 1 . . . 454(71%)3.4.21.-) (Spinesin) -394/502Mus musculus(77%)(Mouse), 455 aa.Q8CJ16Adrenal mitochondrial151 . . . 502289/352e-177protease short variant - 26 . . . 370(82%)Rattus norvegicus312/352(Rat), 371 aa.(88%)

PFam analysis indicates that the NOV4a protein contains the domains shown in the Table 4F.

TABLE 4FDomain Analysis of NOV4aIdentities/NOV4aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect Valuetrypsin266. . . 496111/265 (42%)3.9e-87198/265 (75%)

Example 5

The NOV5 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 5A.

TABLE 5ANOV5 Sequence AnalysisNOV5a, CG155759-02SEQ ID NO: 75941 bpDNA SequenceORF Start: ATG at 4ORF Stop: TAG at 931GACATGGAACAGGATAATACAACATTGCTGACAGAGTTTGTTCTCACAGGACTTACATATCAGCCAGAGTGGAAAATGCCCCTGTTCTTGGTGTTCTTGGTGATCTATCTCATCACTATTGTGTGGAACCTTGGTCTGATTGCTCTTATCTGGAATGACCCACAACTTCACATCCCCATGTACTTTTTTCTTGGGAGTTTAGCCTTTGTTGATGCTTGGATATCTTCCACAGTAACTCCCAAAATGTTGGTTAATTTCTTGGCCAAAAACAGGATGATATCTCTGTCTGAATGCATGATTCAATTTTTTTCCTTTGCATTTGGTGGAACTACAGAATGTTTTCTCTTGGCAACAATGGCATATGATCGCTATGTAGCCATATGCAAACCTTTACTATATCCAGTGATTATGAACAATTCACTATGCATACGGCTGTTAGCCTTCTCATTTTTAGGTGGCTTCCTCCATGCCTTAATTCATGAAGTCCTTATATTCAGATTAACCTTCTGCAATTCTAACATAATACATCATTTTTACTGTGATATTATACCACTGTTTATGATTTCCTGTACTGACCCTTCTATTAATTTTCTAATGGTTTTTATTTTGTCTGGCTCAATTCAGGTATTCACCATTGTGACAGTTCTTAATTCTTACACATTTGCTCTTTTCACAATCCTAAAAAAGAAGTCTGTTAGAGGCGTAAGGAAAGCCTTTTCCACCTGTGGAGCCCATCTCTTATCTGTCTCTTTATATTATGGCCCACTTATCTTCATGTATTTGCGCCCTGCATCTCCACAAGCAGATGACCAGGATATGATAGACTCTGTCTTTTATACAATCATAATTCCTTTGCTAAATCCCATTATCTACAGTCTGAGAAATAAACAAGTAATAGATTCATTCACAAAAATGGTAAAAAGAAATGTTTAGATTTCATANOV5a, CG155759-02Protein SequenceSEQ ID NO: 76309 aaMW at 35396.8kDMEQDNTTLLTEFVLTGLTYQPEWKMPLFLVFLVIYLITIVWNLGLIALIWNDPQLHIPMYFFLGSLAFVDAWISSTVTPKMLVNFLAKNRMISLSECMIQFFSFAFGGTTECFLLATMAYDRYVAICKPLLYPVIMNNSLCIRLLAFSFLGGFLHALIHEVLIFRLTFCNSNIIHHFYCDIIPLFMISCTDPSINFLMVFILSGSIQVFTIVTVLNSYTFALFTILKKKSVRGVRKAFSTCGAHLLSVSLYYGPLIFMYLRPASPQADDQDMIDSVFYTIIIPLLNPIIYSLRNKQVIDSFTKMVKRNVNOV5b, CG155759-01SEQ ID NO: 77941 bpDNA SequenceORF Start: ATG at 4ORF Stop: TAG at 931GACATGGAACAGGATAATACAACATTGCTGACAGAGTTTGTTCTCACAGGACTTACATATCAGCCAGAGTGGAAAATGCCCCTGTTCTTGGTGTTCTTGGTGATCTATCTCATCACTATTGTGTGGAACCTTGGTCTGATTGCTCTTATCTGGAATGACCCACAACTTCACATCCCCATGTACTTTTTTCTTGGGAGTTTAGCCTTTGTTGATGCTTGGATATCTTCCACAGTAACTCCCAAAATGTTGGTTAATTTCTTGGCCAAAAACAGGATGATATCTCTGTCTGAATGCATGATTCAATTTTTTTCCTTTGCATTTGGTGGAACTACAGAATGTTTTCTCTTGGCAACAATGGCATATGATCGCTATGTAGCCATATGCAAACCTTTACTATATCCAGTGATTATGAACAATTCACTATGCATACGGCTGTTAGCCTTCTCATTTTTAGGTGGCTTCCTCCATGCCTTAATTCATGAAGTCCTTATATTCAGATTAACCTTCTGCAATTCTAACATAATACATCATTTTTACTGTGATATTATACCACTGTTTATGATTTCCTGTACTGACCCTTCTATTAATTTTCTAATGGTTTTTATTTTGTCTGGCTCAATTCAGGTATTCACCATTGTGACAGTTCTTAATTCTTACACATTTGCTCTTTTCACAATCCTAAAAAAGAAGTCTGTTAGAGGCGTAAGGAAAGCCTTTTCCACCTGTGGAGCCCATCTCTTATCTGTCTCTTTATATTATGGCCCACTTATCTTCATGTATTTGCGCCCTGCATCTCCACAAGCAGATGACCAAGATATGATAGACTCTGTCTTTTATACAATCATAATTCCTTTGCTAAATCCCATTATCTACAGTCTGAGAAATAAACAAGTAATAGATTCATTCACAAAAATGGTAAAAAGAAATGTTTAGATTTCATANOV5b, CG155759-01Protein SequenceSEQ ID NO: 78309 aaMW at 35396.8kDMEQDNTTLLTEFVLTGLTYQPEWKMPLFLVFLVIYLITIVWNLGLIALIWNDPQLHIPMYFFLGSLAFVDAWISSTVTPKMLVNFLAKNRNISLSECMIQFFSFAFGGTTECFLLATMAYDRYVAICKPLLYPVIMNNSLCIRLLAFSFLGGFLHALIHEVLIFRLTFCNSNIIHHFYCDIIPLFMISCTDPSINFLMVFILSGSIQVFTIVTVLNSYTFALFTILKKKSVRGVRKAFSTCGAHLLSVSLYYGPLIFMYLRPASPQADDQDMIDSVFYTIIIPLLNPIIYSLRNKQVIDSFTKMVKRNV

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 5B.

TABLE 5BComparison of the NOV5 protein sequences.NOV5aMEQDNTTLLTEFVLTGLTYQPEWKMPLFLVFLVIYLITIVWNLGLIALIWNDPQLHIPMYNOV5bMEQDNTTLLTEFVLTGLTYQPEWKMPLFLVFLVIYLITIVWNLGLIALIWNDPQLHIPMYNOV5aFFLGSLAFVDAWISSTVTPKMLVNFLAKNRMISLSECMIQFFSFAFGGTTECFLLATMAYNOV5bFFLGSLAFVDAWISSTVTPKMLVNFLAKNRMISLSECMIQFFSFAFGGTTECFLLATMAYNOV5aDRYVAICKPLLYPVIMNNSLCIRLLAFSFLGGFLHALIHEVLIFRLTFCNSNIIHHFYCDNOV5bDRYVAICKPLLYPVIMNNSLCIRLLAFSFLGGFLHALIHEVLIFRLTFCNSNIIHHFYCDNOV5aIIPLFMISCTDPSINFLMVFILSGSIQVFTIVTVLNSYTFALFTILKKKSVRGVRKAFSTNOV5bIIPLFMISCTDPSINFLMVFILSGSIQVFTIVTVLNSYTFALFTILKKKSVRGVRKAFSTNOV5aCGAHLLSVSLYYGPLIFMYLRPASPQADDQDMIDSVFYTIIIPLLNPIIYSLRNKQVIDSNOV5bCGAHLLSVSLYYGPLIFMYLRPASPQADDQDMIDSVFYTIIIPLLNPIIYSLRNKQVIDSNOV5aFTKMVKRNVNOV5bFTKMVKRNVNOV5a(SEQ ID NO: 76)NOV5b(SEQ ID NO: 78)

Further analysis of the NOV5a protein yielded the following properties shown in Table 5C.

TABLE 5CProtein Sequence Properties NOV5aSigna1P analysis: Cleavage site between residues 52 and 53PSORT II analysis:PSG: a new signal peptide prediction method N-region: length 11; pos. chg 0; neg. chg 3 H-region: length 10; peak value 0.00 PSG score: −4.40GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −3.77 possible cleavage site: between 38 and 39>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 5 INTEGRAL Likelihood = −9.24 Transmembrane 25-41 INTEGRAL Likelihood = 0.37 Transmernbrane 57-73 INTEGRAL Likelihood = 31 2.02 Transmembrane 142-158 INTEGRAL Likelihood = 31 5.79 Transmembrane 196-212 INTEGRAL Likelihood = 31 1.70 Transmembrane 276-292 PERIPHERAL Likelihood = 0.90 (at 173) ALOM score: −9.24 (number of TMSs: 5)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 32 Charge difference: 0.5 C(−0.5) − N(−1.0). C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment (75): 6.20 Hyd Moment(95): 3.11 G content: 0 D/E content: 2 SIT content: 0 Score: −7.39Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not foundNUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 6.5% NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: KKXX-like motif in the C-terminus: VKRNSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues--------------------------Final Results (k = 9/23) 33.3%: endoplasmic reticulum 11.1%: mitochondrial 11.1%: Golgi 11.1%: vacuolar 11.1%: nuclear 11.1%: vesicles of secretory system 11.1%: cytoplasmic>> prediction for CG155759-02 is end (k=9)

A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5D.

TABLE 5DGeneseq Results for NOV5aNOV5aIdentifies/Residues/Similarities forGenesqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #,Date]ResiduesRegionValueABP72221Human G-protein coupled1 . . . 309309/309 (100%)e-179receptor GCREC-15 (olfactory1 . . . 309309/309 (100%)receptor) - Homo sapiens, 309 aa.[WO2003000859-A2, 03-JAN-2003]AAU85253G-coupled olfactory receptor1 . . . 309309/309 (100%)e-179#114 - Homo sapiens, 314 aa.6 . . . 314309/309 (100%)[WO200198526-A2, 27-DEC-2001]AAU95610Human olfactory and pheromone1 . . . 309309/309 (100%)e-179G protein-coupled receptor #97 -6 . . . 314309/309 (100%)Homo sapiens, 314 aa.[WO200224726-A2, 28-MAR-2002]AAB71190Human GPCRX protein SEQ ID1 . . . 309309/309 (100%)e-17956 - Homo sapiens, 309 aa.1 . . . 309309/309 (100%)[WO200250275-A2, 27-JUN-2002]ABP95748Human GPCR polypeptide SEQ1 . . . 309309/309 (100%)e-179ID NO 306- Homo sapiens, 3146 . . . 314309/309 (100%)aa. [WO200216548-A2, 28-FEB-2002]

In a BLAST search of public sequence databases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5E.

TABLE 5EPublic BLASTP Results for NOV5aIdentities/NOV5aSimilaritiesProteinResidues/for theAccessionProtein/MatchMatchedExpectNumberOrganism/LengthResiduesPortionValueQ8NGV7Seven transmembrane1 . . . 309309/309e-179helix receptor -6 . . . 314(100%)Homo sapiens309/309(Human), 314 aa.(100%)Q8VG48Olfactory receptor4 . . . 308232/305e-141MOR183-1 -4 . . . 308(76%)Mus musculus272/305(Mouse), 309 aa.(89%)Q8VEX5Olfactory receptor1 . . . 309239/309e-139MOR183-1 -1 . . . 309(77%)Mus musculus270/309(Mouse), 309 aa.(87%)CAD-Sequence 195 from1 . . . 309241/309e-13937583Patent WO0224726 -17 . . . 325 (77%)e-139Homo sapiens267/309(Human), 325 aa.(85%)Q8NGV6Seven transmembrane1 . . . 309241/309e-139helix receptor -1 . . . 309(77%)Home sapiens267/309(Human), 309 aa.(85%)

PFam analysis indicates that the NOV5a protein contains the domains shown in the Table 5F.

TABLE 5FDomain Analysis of NOV5aIdentities/NOV5aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect Value7tm_141 . . . 290 43/276 (16%)1.2e-19169/276 (61%)

Example 6

The NOV6 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 6A.

TABLE 6ANOV6 Sequence AnalysisNOV6a, CG187667-01SEQ ID NO: 792680 bpDNA SequenceORF Start: ATG at 873ORF Stop: TAG at 2484GGGCAGGTGTTAAGCGATAAAGGGGGGCAGAACAAGTCTTTTATCCGGCCATTTAATTGGTCACCTTAAGAAAGAATCCTATCTTCCCACCGCAGCTGAGAAGACACTTCTAAGAGGTACAGCTAAAAGGTGGAGGACTGATAGACAACTTAGAGGTTGGTTTCGGGAACGATAAAACAAGTAACGGGCTGCCCGGCCTGCGCCGCGGAGTCCCGAGGAGCCTGCGCTGTGCTCCTCTCGCGGTGTCTCGTCATCTCCGGGAAGACTCGGCGCCTGGGTCCGCGCTCTCTGGGTAAGCTTTCCGGGAAGCTTTCCCGGGAGCTCGCTGGTCCTGGCCCCAGAAGCCTGCGGACCCGCCCAGGGAGGATAAGCAGCTGAAAGACCGCGCGGTGCCGCTCCGAGGCCCCGGGACGTGGGCCCATGGTCGGCCTGGCGCCACCTTTCCGGGGGAAGCCACGCGCACCAGGCATCGCACGCGGCTCTGCACCCGCGCCGCCGGACCTGAAACCCGGCGGAGGGCACACGGGGCTGCCGCTGCGGGCCCCGGACCAACCCATGCTTACTCCGGAGCCTGTACCGGCGCCGACGGGTCGGACCTCCCTGCGCGGTGTCGCCCAGCGGGTTCGTGCGAAAGGCGGGGCCGACTACACGCGGTGCCGCGCCCTGAGACCGTTTATCTGCAGTCAACGCAGCCTCCCGGCTCAGCCTGGGAAGATGCGCGAATCGGGAACCCCAGAGCGCGGTGGCTAGACCGGGCTCCGCCGCCTCCCCCACAGCCCCTTTCCTAATCGTTCAGACGGAGCCTGGTCGACTTCGCCGGAGACTGCCAGATCTCGTTCCTCTTCCCTGTGTCATCTTCTTAATTATAAATAATGGGGGATGAAGATAAAAGAATTACATATGAAGATTCAGAACCATCCACAGGAATGAATTACACGCCCTCCATGCATCAAGAAGCACAGGAGGAGACAGTTATGAAGCTCAAAGGTATAGATGCAAATGAACCAACAGAAGGAAGTATTCTTTTGAAAAGCAGTGAAAAAAAGCTACAAGAAACACCAACTGAAGCAAATCACGTACAAAGACTGAGACAAATGCTGGCTTGCCCTCCACATGGTTTACTGGACAGGGTCATAACAAATGTTACCATCATTGTTCTTCTGTGGGCTGTAGTTTGGTCAATTACTGGCAGTGAATGTCTTCCTGGAGGAAACCTATTTGGAATTATAATCCTATTCTATTGTGCCATCATTGGTGGTAAACTTTTGGGGCTTATTAAGTTACCTACATTGCCTCCACTGCCTTCTCTTCTTGGCATGCTGCTTGCAGGGTTTCTCATCAGAAATATCCCAGTCATCAACGATAATGTGCAGATCAAGCACAAGTGGTCTTCCTCTTTGAGAAGCATAGCCCTGTCTATCATTCTGGTTCGTGCTGGCCTTGGTCTGGATTCAAAGGCCCTGAAGAAGTTAAAGGGCGTTTGTGTAAGACTGTCCATGGGTCCCTGTATTGTGGAGGCGTGCACATCTGCTCTTCTTGCCCATTACCTGCTGGGTTTACCATGGCAATGGGGATTTATACTGGGTTTTGTTTTAGGTGCTGTATCTCCAGCTGTTGTGGTGCCTTCAATGCTCCTTTTGCAGGGAGGAGGCTATGGTGTTGAGAAGGGTGTCCCAACCTTGCTCATGGCAGCTGGCAGCTTCGATGACATTCTGGCCATCACTGGCTTCAACACATGCTTGGGCATAGCCTTTTCCACAGGCTCTACTGTCTTTAATGTCCTCAGAGGAGTTTTGGAGGTGGTAATTGGTGTGGCAACTGGATCTGTTCTTGGATTTTTCATTCAGTACTTTCCAAGCCGTGACCAGGACAAACTTGTGTGTAAGAGAACATTCCTTGTGTTGGGGTTGTCTGTGCTAGCTGTGTTCAGCAGTGTGCATTTTGGTTTCCCTGGATCAGGAGGACTGTGCACGTTGGTCATGGCTTTCCTTGCAGGCATGGGATGGACCAGCGAAAAGGCAGAGGTTGAAAAGATAATTGCAGTTGCCTGGGACATTTTTCAGCCCCTTCTTTTTGGACTAATTGGAGCAGAGGTATCTATTGCATCTCTCAGACCAGAAACTGTAGGCCTTTGTGTTGCCACCGTAGGCATTGCAGTATTGATACGAATTTTGACTACATTTCTGATGGTGTGTTTTGCTGGTTTTAACTTAAAAGAAAAGATATTTATTTCTTTTGCATGGCTTCCAAAGGCCACAGTTCAGGCTGCAATAGGATCTGTGGCTTTGGACACAGCAAGGTCACATGGAGAGAAACAATTAGAAGACTATGGAATGGATGTGTTGACAGTGGCATTTTTGTCCATCCTCATCACAGCCCCAATTGGAAGTCTGCTTATTGGTTTACTGGGCCCCAGGCTTCTGCAGAAAGTTGAACATCAAAATAAAGATGAAGAAGTTCAAGGAGAGACTTCTGTGCAAGTTTAGGAAGCGCGGATTCTATTACTGGAAACTTTGGGACTGAAAGGCCAAAGCTTCTGGGCCCACCATCAACGCAGCTCCGCTTTCATTTCTTTCACATACAACTTTCCACATAAGATTTCATGCGGAAAAAAAAAAAAAACTCACAAAGGTTTTATACTGATAACAGTATATTAAGTGTTTACTTTGTACACAGCGTCNOV6a, CG187667-01Protein SequenceSEQ ID NO: 80537 aaMW at 57563.3kDMGDEDKRITYEDSEPSTGMNYTPSMHQEAQEETVMKLKGIDANEPTEGSILLKSSEKKLQETPTEANHVQRLRQMLACPPHGLLDRVITNVTIIVLLWAVVWSITGSECLPGGNLFGIIILFYCAIIGGKLLGLIKLPTLPPLPSLLGMLLAGFLIRNIPVINDNVQIKHKWSSSLRSIALSIILVRAGLGLDSKALKKLKGVCVRLSMGPCIVEACTSALLAHYLLGLPWQWGFILGFVLGAVSPAVVVPSMLLLQGGGYGVEKGVPTLLMAAGSFDDILAITGFNTCLGIAFSTGSTVFNVLRGVLEVVIGVATGSVLGFFIQYFPSRDQDKLVCKRTFLVLGLSVLAVFSSVHFGFPGSGGLCTLVMAFLAGMGWTSEKAEVEKIIAVAWDIFQPLLFGLIGAEVSIASLRPETVGLCVATVGIAVLIRILTTFLMVCFAGFNLKEKIFISFAWLPKATVQAAIGSVALDTARSHGEKQLEDYGMDVLTVAFLSILITAPIGSLLIGLLGPRLLQKVEHQNKDEEVQGETSVQVNOV6b, CG187667-02SEQ ID NO: 812285 bpDNA SequenceORF Start: ATG at 873ORF Stop: TAA at 2235GGGCAGGTGTTAAGCGATAAAGGGGGGCAGAACAAGTCTTTTATCCGGCCATTTAATTGGTCACCTTAAGAAAGAATCCTATCTTCCCACCGCAGCTGAGAAGACACTTCTAAGAGGTACAGCTAAAAGGTGGAGGACTGATAGACAACTTAGAGGTTGGTTTCGGGAACGATAAAACAAGTAACGGGCTGCCCGGCCTGCGCCGCGGAGTCCCGAGGAGCCTGCGCTGTGCTCCTCTCGCGGTGTCTCGTCATCTCCGGGAAGACTCGGCGCCTGGGTCCGCGCTCTCTGGGTAAGCTTTCCGGGAAGCTTTCCCGGGAGCTCGCTGGTCCTGGCCCCAGAAGCCTGCGGACCCGCCCAGGGAGGATAAGCAGCTGAAAGACCGCGCGGTGCCGCTCCGAGGCCCCGGGACGTGGGCCCATGGTCGGCCTGGCGCCACCTTTCCGGGGGAAGCCACGCGCACCAGGCATCGCACGCGGCTCTGCACCCGCGCCGCCGGACCTGAAACCCGGCGGAGGGCACACGGGGCTGCCGCTGCGGGCCCCGGACCAACCCATGCTTACTCCGGAGCCTGTACCGGCGCCGACGGGTCGGACCTCCCTGCGCGGTGTCGCCCAGCGGGTTCGTGCGAAAGGCGGGGCCGACTACACGCGGTGCCGCGCCCTGAGACCGTTTATCTGCAGTCAACGCAGCCTCCCGGCTCAGCCTGGGAAGATGCGCGAATCGGGAACCCCAGAGCGCGGTGGCTAGACCGGGCTCCGCCGCCTCCCCCACAGCCCCTTTCCTAATCGTTCAGACGGAGCCTGGTCGACTTCGCCGGAGACTGCCIGATCTCGTTCCTCTTCCCTGTGTCATCTTCTTAATTATAAATAATGGGGGATGAAGATAAAAGAATTACATATGAAGATTCAGAACCATCCACAGGAATGAATTACACGCCCTCCATGCATCAAGAAGCACAGGAGGAGACAGTTATGAAGCTCAAAGGTATAGATGCAAATGAACCAACAGAAGGAAGTATTCTTTTGAAAAGCAGTGAAAAAAAGCTACAAGAAACACCAACTGAAGCAAATCACGTACAAAGACTGAGACAAATGCTGGCTTGCCCTCCACATGGTTTACTGGACAGGGTCATAACAAATGTTACCATCATTGTTCTTCTGTGGGCTGTAGTTTGGTCAATTACTGGCAGTGAATGTCTTCCTGGAGGAAACCTATTTGGAATTATAATCCTATTCTATTGTGCCATCATTGGTGGTAAACTTTTGGGGCTTATTAAGTTACCTACATTGCCTCCACTGCCTTCTCTTCTTGGCATGCTGCTTGCAGGGTTTCTCATCAGAAATATCCCAGTCATCAACGATAATGTGCAGATCAAGCACAAGTGGTCTTCCTCTTTGAGAAGCATAGCCCTGTCTATCATTCTGGTTCGTGCTGGCCTTGGTCTGGATTCAAAGGCCCTGAAGAAGTTAAAGGGCGTTTGTGTAAGACTGTCCATGGGTCCCTGTATTGTGGAGGCGTGCACATCTGCTCTTCTTGCCCATTACCTGCTGGGTTTACCATGGCAATGGGGATTTATACTGGGTTTTGTTTTAGGTGCTGTATCTCCAGCTGTTGTGGTGCCTTCAATGCTCCTTTTGCAGGGAGGAGGCTATGGTGTTGAGAAGGGTGTCCCAACCTTGCTCATGGCAGCTGGCAGCTTCGATGACATTCTGGCCATCACTGGCTTCAACACATGCTTGGGCATAGCCTTTTCCACAGGCTCTACTGTCTTTAATGTCCTCAGAGGAGTTTTGGAGGTGGTAATTGGTGTGGCAACTGGATCTGTTCTTGGATTTTTCATTCAGTACTTTCCAAGCCGTGACCAGGACAAACTTGTGTGTAAGAGAACATTCCTTGTGTTGGGGTTGTCTGTGCTAGCTGTGTTCAGCAGTGTGCATTTTGGTTTCCCTGGATCAGGAGGACTGTGCACGTTGGTCATGGCTTTCCTTGCAGGCATGGGATGGACCAGCGAAAAGGCAGAGGTTGAAAAGATAATTGCAGTTGCCTGGGACATTTTTCAGCCCCTTCTTTTTGGACTAATTGGAGCAGAGGTATCTATTGCATCTCTCAGACCAGAAACTGTAGGAAGCGCGGATTCTATTACTGGAAACTTTGGGACTGAAAGGCCAAAGCTTCTGGGCCCACCATCAACGCAGCTCCGCTTTCATTTCTTTCACATACAACTTTCCACATAAGATTTCATGCGGAAAAAAAAAAAAAACTCACAAAGGTTTTATACTGATNOV6b, CG187667-02Protein SequenceSEQ ID NO: 82454 aaMW at 48709.8kDMGDEDKRITYEDSEPSTGMNYTPSMHQEAQEETVMKLKGIDANEPTEGSILLKSSEKKLQETPTEANHVQRLRQMLACPPHGLLDRVITNVTIIVLLWAVVWSITGSECLPGGNLFGIIILFYCAIIGGKLLGLIKLPTLPPLPSLLGMLLAGFLIRNIPVINDNVQIKHKWSSSLRSIALSIILVRAGLGLDSKALKKLKGVCVRLSMGPCIVEACTSALLAHYLLGLPWQWGFILGFVLGAVSPAVVVPSMLLLQGGGYGVEKGVPTLLMAAGSFDDILAITGFNTCLGIAFSTGSTVFNVLRGVLEVVIGVATGSVLGFFIQYFPSRDQDKLVCKRTFLVLGLSVLAVFSSVHFGFPGSGGLCTLVMAFLAGMGWTSEKAEVEKIIAVAWDIFQPLLFGLIGAEVSIASLRPETVGSADSITGNFGTERPKILGPPSTQLRFHFFHIQLST

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 6B.

TABLE 6BComparison of the NOV6 protein sequences.NOV6aMGDEDKRITYEDSEPSTGMNYTPSMHQEAQEETVMKLKGIDANEPTEGSILLKSSEKKLQNOV6bMGDEDKRITYEDSEPSTGMNYTPSMHQEAQEETVMKLKGIDANEPTEGSILLKSSEKKLQNOV6aETPTEANHVQRLRQMLACPPHGLLDRVITNVTIIVLLWAVVWSITGSECLPGGNLFGIIINOV6bETPTEANHVQRLRQMLACPPHGLLDRVITNVTIIVLLWAVVWSITGSECLPGGNLFGIIINOV6aLFYCAIIGGKLLGLIKLPTLPPLPSLLGMLLAGFLIRNIPVINDNVQIKHKWSSSLRSIANOV6bLFYCAIIGGKLLGLIKLPTLPPLPSLLGMLLAGFLIRNIPVINDNVQIKHKWSSSLRSIANOV6aLSIILVRAGLGLDSKALKKLKGVCVRLSMGPCIVEACTSALLAHYLLGLPWQWGFILGFVNOV6bLSIILVRAGLGLDSKALKKLKGVCVRLSMGPCIVEACTSALLAHYLLGLPWQWGFILGFVNOV6aLGAVSPAVVVPSMLLLQGGGYGVEKGVPTLLMAAGSFDDILAITGFNTCLGIAFSTGSTVNOV6bLGAVSPAVVVPSMLLLQGGGYGVEKGVPTLLMAAGSFDDILAITGFNTCLGIAFSTGSTVNOV6aFNVLRGVLEVVIGVATGSVLGFFIQYFPSRDQDKLVCKRTFLVLGLSVLAVFSSVHFGFPNOV6bFNVLRGVLEVVIGVATGSVLGFFIQYFPSRDQDKLVCKRTFLVLGLSVLAVFSSVHFGFPNOV6aGSGGLCTLVMAFLAGMGWTSEKAEVEKIIAVAWDIFQPLLFGLIGAEVSIASLRPETVGLNOV6bGSGGLCTLVMAFLAGMGWTSEKAEVEKIIAVAWDIFQPLLFGLIGAEVSIASLRPETVGSNOV6aCVATVGIAVLIRILTTFLMVCFAGFNLKEKIFISFAWLPKATVQAAIGSVALDTARSHGENOV6bADSITGNFGTERPK--LLG-----------P-------PSTQLRFHFFHIQLST------NOV6aKQLEDYGMDVLTVAFLSILITAPIGSLLIGLLGPRLLQKVEHQNKDEEVQGETSVQVNOV6b---------------------------------------------------------NOV6a(SEQ ID NO: 80)NOV6b(SEQ ID NO: 82)

Further analysis of the NOV6a protein yielded the following properties shown in Table 6C.

TABLE 6CProtein Sequence Properties NOV6aSigna1P analysis: No Known Signal Sequence IndicatedPSORT II analysis:PSG: a new signal peptide prediction method N-region: length 11; pos. chg 2; neg. chg 4 H-region: length 0; peak value 0.00 PSG score: −4.40GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −13.82 possible cleavage site: between 48 and 49>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 10 INTEGRAL Likelihood = −5.20 Transmembrane 88-104 INTEGRAL Likelihood = −6.10 Transmembrane 118-134 INTEGRAL Likelihood = −3.13 Transmembrane 146-162 INTEGRAL Likelihood = −1.06 Transmembrane 176-192 INTEGRAL Likelihood = −6.26 Transmembrane 234-250 INTEGRAL Likelihood = −4.09 Transmembrane 308-324 INTEGRAL Likelihood = −4.94 Transmembrane 341-357 INTEGRAL Likelihood = −3.19 Transmembrane 388-404 INTEGRAL Likelihood = −7.91 Transmembrane 418-434 INTEGRAL Likelihood = −6.69 Transmembrane 493-509 PERIPHERAL Likelihood = 0.63 (at 213) ALOM score: −7.91(number of TMSs: 10)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 95 Charge difference: −2.5 C(−1.0) − N( 1.5) N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 9.18 Hyd Moment(95): 7.68G content: 1 DIE content: 2 S/T content: 0 Score: −6.91Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not foundNUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 7.4% NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues--------------------------Final Results (k = 9/23) 66.7%: endoplasmic reticulum 11.1%: nuclear 11.1%: vesicles of secretory system 11.1%: mitochondrialprediction for CG187667-01 is end (k=9)

A search of the NOV6a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6D.

TABLE 6DGeneseq Results for NOV6aNOV6aIdentifies/Residues/Similarities forGenesqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #,Date]ResiduesRegionValueABU11723Human MDDT polypeptide SEQ1 . . . 537537/537 (100%)0.0ID 670 - Homo sapiens, 538 aa.2 . . . 538537/537 (100%)[WO200279449-A2, 10-OCT-2002]ABP69843Human polypeptide SEQ ID NO1 . . . 537526/537 (97%)0.01890 - Homo sapiens, 537 aa.1 . . . 537530/537 (97%)[WO200270539-A2, 12-SEP-2002]AAY94918Human secreted protein clone100 . . . 464 231/365 (63%)e-137dd504_18 protein sequence SEQ1 . . . 365290/365 (79%)ID NO:42 - Homo sapiens, 396aa. [WO200009552-A1, 24-FEB-2000]AAU01672Human secreted protein encoded153 . . . 519 224/367 (61%)e-130by gene #13 - Homo sapiens, 3701 . . . 366287/367 (78%)aa. [WO200123409-A2, 05-APR-2001]AAU01642Human secreted protein214 . . . 519185/306 (60%)e-106immunogenic epitope encoded by1 . . . 305236/306 (76%)gene #2 - Homo sapiens, 323 aa.[WO200123409-A2, 05-APR-2001]

In a BLAST search of public sequence databases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6E.

TABLE 6EPublic BLASTP Results for NOV6aNOV6aIdentities/ProteinResidues/Similarities forAccessionProtein/Matchthe MatchedExpectNumberOrganism/LengthResiduesPortionValueAAH47447LOC133308 protein - Homo 19 . . . 537519/519(100%)0.0sapiens (Human), 519 aa. 1 . . . 519519/519 (100%)Q96D95Hypothetical protein - Homo101 . . . 426320/326 (98%)0.0sapiens (Human), 354 aa 1 . . . 326321/326 (98%)(fragment).Q8C0X2Hypothetical glutainic acid-rich 53 . . . 521263/470 (55%)e-159region/Na+/H+ exchanger 83 . . . 551359/470 (75%)containing protein - Musmusculus (Mouse), 565 aa.Q95JS4Hypothetical 55.5 kDa protein - 73 . . . 519261/447 (58%)e-157Macaca fascicularis (Crab eating 53 . . . 498347/447 (77%)macaque) (Gynomolgusmonkey), 511 aa.Q8CDX4Hypothetical Na+/H+ exchanger253 . . . 537247/285 (86%)e-138containing protein - Mus 1 . . . 284264/285 (91%)musculus (Mouse), 295 aa.

PFam analysis indicates that the NOV6a protein contains the domains shown in the Table 6F.

TABLE 6FDomain Analysis of NOV6aIdentities/NOV6aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect ValueLrgA114 . . . 19926/114 (23%)0.760/114 (53%)Na_H_—119 . . . 520 85/470 (18%)1.3e-16Exchanger286/470 (61%)

Example 7

The NOV7 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 7A.

TABLE 7ANOV7 Sequence AnalysisNOV7a, CG187676-01SEQ ID NO: 832474 bpDNA SequenceORF Start: ATG at 5ORF Stop: TGA at 2270AAAAATGAAAAAACAGAGGAAAATTCTATGGAGGAAAGGAATCCACTTAGCCTTTTCTGAGAAATGGAATACTGGGTTTGGAGGCTTTAAGAAGTTTTATTTTCACCAACACTTGTGCATTCTGAAAGCTAAGCTGGGAAGGCCAGTTACTTGGAATAGACAGTTGAGACATTTCCAGGGTAGAAAGAAAGCTCTTCAAATCCAGAAAACGTGGATCAAGGATGAACCCCTTTGTGCTAAGACCAAGTTCAATGTGGCTACTCAAAATGTTAGTACTTTGTCCTCTAAAGTGAAAAGAAAGGACGCTAAACACTTCATTTCCTCCTCAAAGACTCTCCTGAGACTCCAAGCAGAGAAGCTGTTGTCATCAGCAAAGAATTCTGACCATGAATACTGCAGAGAGAAAAATCTCTTGAAGGCAGTTACTGACTTTCCATCAAATAGTGCTTTAGGTCAGGCCAATGGTCACAGACCTAGGACAGACCCACAACCTTCTGACTTTCCCATGAAGTTCAATGGGGAGAGCCAAAGTCCAGGTGAGAGTGGCACGATTGTGGTCACCTTGAACAACCATAAGAGAAAGGGCTTTTGTTACGGCTGCTGCCAAGGGCCGGAGCACCACAGGAATGGGGGACCCTTGATTCCAAAAAAGTTCCAACTTAACCAACATAGAAGGATAAAATTATCTCCTCTTATGATGTATGAGAAATTATCCATGATTAGATTTCGGTACAGGATTCTCAGATCCCAGCACTTCAGAACCAAAAGCAAGGTTTGCAAGCTAAGAAAAGCCCAGCGAAGCTGGGTACAGAAAGTCACTGGGGACCATCAAGAGACCCGTAGGGAGAACGGTGAGGGTGGCAGTTGCAGCCCATTTCCTTCCCCAGAACCTAAAGACCCTTCTTGTCGGCATCAGCCGTACTTTCCAGATATGGACAGCAGTGCTGTGGTGAAGGGGACGAACTCTCATGTGCCTGATTGCCACACTAAAGGAAGCTCTTTCTTGGGCAAGGAGCTTAGTTTAGACGAAGCATTCCCTGACCAACAGAATGGCAGTGCCACAAACGCCTGGGACCAGTCATCCTGTTCTTCTCCTAAGTGGGAGTGTACAGAGCTGATTCATGACATCCCCTTACCAGAACATCGTTCTAATACCATGTTCATTTCAGAAACTGAAAGAGAAATTATGACTCTGGGTCAGGAAAATCAGACAAGTTCTGTCAGTGATGACAGAGTAAAACTGTCAGTGTCTGGAGCAGATACATCTGTGAGTAGCGTAGATGGGCCTGTGTCCCAAAAGGCTGTTCAAAATGAGAACTCATACCAGATGGAGGAGGATGGATCTCTCAAGCAGAGCATTCTTAGTTCTGAGTTGCTGGACCACCCTTACTGTAAAAGTCCACTGGAGGCTCCCTTGGTGTGCAGTGGACTCAAACTAGAAAATCAAGTAGGAGGTGGAAAGAACAGTCAGAAAGCCTCTCCAGTGGATGATGAACAGCTGTCAGTCTGTCTTTCTGGATTCCTAGATGAGGTTATGAAGAAGTATGGCAGTTTGGTTCCACTCAGTGAAAAAGAAGTCCTTGGAAGATTAAAAGATGTCTTTAATGAAGACTTTTCTAATAGAAAACCATTTATCAATAGGGAAATAACAAACTATCGGGCCAGACATCAAAAATGTAACTTCCGTATCTTCTATAATAAACACATGCTGGATATGGACGACCTGGCGACTCTGGATGGTCAGAACTGGCTGAATGACCAGGTCATTAATATGTATGGTGAGCTGATAATGGATGCAGTCCCGGACAAAGTTCACTTCTTCAACAGCTTTTTTCATAGACAGCTGGTAACCAAAGGATATAATGGAGTAAAAAGATGGACTAAAAAGGTGGATTTGTTTAAAAAGAGTCTTCTGTTGATTCCTATTCACCTGGAAGTCCACTGGTCTCTCATTACTGTGACACTCTCTAATCGAATTATTTCATTTTATGATTCCCAAGGCATTCATTTTAAGTTTTGTGTAGAGAATATAAGAAAGTATTTGCTGACTGAAGCCAGAGAAAAAAATAGACCTGAATTTCTTCAGGGTTGGCAGACTGCTGTTACGAAGTGTATTCCACAACAGAAAAACGACAGTGACTGTGGAGTCTTTGTGCTCCAGTACTGCAAGTGCCTCGCCTTAGAGCAGCCTTTCCAGTTTTCACAAGAAGACATGCCCCGAGTGCGGAAGAGGATTTACAAGGAGCTATGTGAGTGCCGGCTCATGGACTGAAACTCAGCAGGGACTCTGGGAAGTCTGACCAAGTTGGAGCAGATGGTTTGTTACTTGAATCTCCAAACACTTAGTTGAATTTTTACAGATATTTCAGATCAGTGGTGTTGGGCCACTATTGTTACCTCAAATTTATTTTTTGCCCTTATTCATTTCTCCAGCTACCATGTACTATTGTTTAATGTTCAGTTTGGTTTCAAAANOV7a, CG187676-01Protein SequenceSEQ ID NO: 84755 aaMW at 86692.3kDMKKQRKILWRKGIHLAFSEKWNTGFGGFKKFYFHQHLCILKAKLGRPVTWNRQLRHFQGRKKALQIQKTWIKDEPLCAKTKFNVATQNVSTLSSKVKRKDAKHFISSSKTLLRLQAEKLLSSAKNSDHEYCREKNLLKAVTDFPSNSALGQANGHRPRTDPQPSDFPMKFNGESQSPGESGTIVVTLNNHKRKGFCYGCCQGPEHHRNGGPLIPKKFQLNQHRRIKLSPLMMYEKLSMIRFRYRILRSQHFRTKSKVCKLRKAQRSWVQKVTGDHQETRRENGEGGSCSPFPSPEPKDPSCRHQPYFPDMDSSAVVKGTNSHVPDCHTKGSSFLGKELSLDEAFPDQQNGSATNAWDQSSCSSPKWECTELIHDIPLPEHRSNTMFISETEREIMTLGQENQTSSVSDDRVKLSVSGADTSVSSVDGPVSQKAVQNENSYQMEEDGSLKQSILSSELLDHPYCKSPLEAPLVCSGLKLENQVGGGKNSQKASPVDDEQLSVCLSGFLDEVMKKYGSLVPLSEKEVLGRLKDVFNEDFSNRKPFINREITNYRARHQKCNFRIFYNKHMLDMDDLATLDGQNWLNDQVINNYGELIMDAVPDKVHFFNSFFHRQLVTKGYNGVKRWTKKVDLFKKSLLLIPIHLEVHWSLITVTLSNRIISFYDSQGIHFKFCVENIRKYLLTEAREKNRPEFLQGWQTAVTKCIPQQKNDSDCGVFVLQYCKCLALEQPFQFSQEDMPRVRKRIYKELCECRLMD

Further analysis of the NOV7a protein yielded the following properties shown in Table 7B.

TABLE 7BProtein Sequence Properties NOV7aSigna1P analysis: No Known Signal Sequence IndicatedPSORT II analysis:PSG: a new signal peptide prediction method N-region: length 11; pos. chg 6; neg. chg 0 H-region: length 7; peak value 0.84 PSG score: −3.56GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −10.14 possible cleavage site: between 18 and 19>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 1 Number of TMS(s) for threshold 0.5: 0 PERIPHERAL Likelihood = 6.31 (at 710) ALOM score: −0.06 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seq R content: 2 Hyd Moment(75): 3.21 Hyd Moment(95) : 10.20G content: 1 D/E content: 1 S/T content: 1 Score: −3.27Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 70 GRK|KANUCDISC: discrimination of nuclear localization signals pat4: HKRK (3) at 190 pat7: PRVRKRI (5) at 738 bipartite: none content of basic residues: 15.1% NLS Score: 0.15KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: XXRR-like motif in the N-terminus: KKQRnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 89COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues------------------------------Final Results (k = 9/23) 65.2%: nuclear 26.1%: mitochondrial 4.3%: cytoplasmic 4.3%: peroxisomal>> prediction for CG187676-01 is nuc (k=23)

A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7C.

TABLE 7CGeneseq Results for NOV7aNOV7aIdentifies/Residues/Similarities forGenesqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #,Date]ResiduesRegionValueABJ26650Human protein modification + 1 . . . 755755/755 (100%)0.0maintenance molecule protein 1 . . . 755755/755 (100%)SEQ ID No 4 - Homo sapiens,755 aa. [WO2003000844-A2, 03-JAN-2003]AAB71412Human HIPHUM106 splice 1 . . . 755754/755 (99%)0.0variant SEQ ID 4 - Homo 1 . . . 755755/755 (99%)sapiens, 755 aa. [GB2371801-A,07-AUG-2002]AAB71411Human HIPIIUM106 protein 1 . . . 755727/755 (96%)0.0SEQ ID 2 - Homo sapiens, 727 1 . . . 727727/755 (96%)aa. [GB2371801-A, 07-AUG-2002]ABP69066Human polypeptide SEQ ID NO310 . . . 752413/443 (93%)0.01113 - Homo sapiens, 419 aa. 1 . . . 415413/443 (93%)[WO200270539-A2, 12-SEP-2002]AAM25617Human protein sequence SEQ ID485 . . . 755267/271 (98%)e-157NO:1132 - Homo sapiens, 270 aa. 1 . . . 270268/271 (98%)[WO200153455-A2 , 26-JUL-2001]

In a BLAST search of public sequence databases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7D.

TABLE 7DPublic BLASTP Results for NOV7aNOV7aIdentities/ProteinResidues/Similarities forAccessionProtein/Matchthe MatchedExpectNumberOrganism/LengthResiduesPortionValueQ96H10Sentrin-specific protease 5 (EC 1 . . . 755754/755 (99%)0.03.4.22.-) (Sentrin/SUMO-specific 1 . . . 755754/755 (99%)protease SENP5) (ProteaseFKSG45) - Homo sapiens(Human), 755 aa.Q8WP32Sentrin-specific protease 5 (EG 1 . . . 755714/755 (94%)0.03.4.22.-) (Sentrin/SUMO-specific 1 . . . 755735/755 (96%)protease SENP5) (QtsA-16408) -Macaca fascicularis (Grab eatingmacaque) (Cynomolgus monkey),755 aa.Q8BXW0Hypothetical SUMO/sentrin/Ub11 1 . . . 755619/756 (81%)0.0specific protease containing protein - 1 . . . 749667/756 (87%)Mus musculus (Mouse), 749 aa.Q8BRD5Sentrin/SUMO-specific protease -485 . . . 753148/274 (54%)1e-82Mus musculus(Mouse), 568 aa.294 . . . 566202/274 (73%)Q9EP97Sentrin-specific protease 3 (EC485 . . . 753148/274 (54%)1e-823.4.22.-) (Sentrin/SUMO-specific294 . . . 566202/274 (73%)protease SENP3) (SUMO-1specific protease 3) (Smt3-specific isopeptidase 1) (Smt3ip1) -Mus musculus (Mouse), 568 aa.

PFam analysis indicates that the NOV7a protein contains the domains shown in the Table 7E.

TABLE 7EDomain Analysis of NOV7aIdentities/NOV7aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect ValuePeptifase_—563 . . . 752 62/248 (25%)7e-43C48149/248 (60%)

Example 8

The NOV8 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 8A.

TABLE 8ANOV8 Sequence AnalysisNOV8a, CG50235-04SEQ ID NO: 853120 bpDNA SequenceORF Start: ATG at 256ORF Stop: TGA at 2719TAACCTGTCTCACGACGGTCTAAACCCAGGCAGCCTCGGCCGCCGGGCAAGTAGCTCCGAGCGGCTGCTTCCCGGTTGCCTCGAAGAAGACAGGGGGCGCCGCGCTCCGCTTGCTCCGCGCCTGAGCCATGCCCAGCAGCCCTGTGTAACCACCGAGTCCCGGCCGGAGCCGACCGACCCAGTGTGCGCCGTCTTTCGGCCGAGCTGAGCTTTCGTGCACGCAACTCCCTCTGCCCCAGCCGGCCCCGCGCCACCATGCCCCGGGCGACTGCACTTGGGGCCCTGGTGTCACTGCTGCTGCTGCTGCCGCTGCCTCGCGGCGCCGGGGGACTCGGGGAGCGCCCGGACGCCACCGCAGACTACTCAGAGCTGGACGGCGAGGAGGGCACGGAGCAGCAGCTGGAGCATTACCACGACCCTTGCAAAGCCGCTGTCTTTTGGGGAGACATTGCCTTAGATGAAGATGACTTGAAGCTGTTTCACATTGACAAAGCCAGAGACTGGACCAAGCAGACAGTGGGGGCAACAGGACACAGCACAGGTGGGCTTGAAGAGCAGGCATCTGAGAGCAGCCCAGACACCACAGCCATGGACACTGGCACCAAGGAAGCTGGAAAGGATGGCCGGGAGAATACCACACTCCTGCACAGCCCTGGGACCTTGCATGCCGCAGCCAAGACCTTCTCTCCCCGGGTCCGAAGAGCCACAACCTCAAGGACAGAGAGGATATGGCCTGGAGGAGTCATCCCCTACGTCATTGGAGGGAACTTCACTGGGAGCCAGAGGGCCATTTTTAAGCAGGCCATGAGACACTGGGAGAAGCACACCTGTGTGACCTTCATAGAAAGGACGGATGAGGAAAGCTTTATTGTATTCAGTTACAGAACCTGTGGCTGTTGCTCCTATGTTGGGCGCCGAGGAGGAGGCCCACAGGCCATATCCATTGGGAAGAACTGTGACAAGTTTGGCATTGTGGCTCACGAGCTGGGCCATGTGGTTGGGTTTTGGCATGAACACACCCGGCCAGACAGAGACCAACATGTCACCATCATCAGGGAAAACATCCAGCCAGGTCAGGAGTATAATTTCTTAAAAATGGAAGCTGGGGAAGTGAGCTCTCTGGGAGAGACATACGACTTTGACAGCATCATGCACTACGCCCGGAACACCTTCTCAAGAGGAGTTTTCTTAGACACCATCCTTCCCCGTCAAGATGACAATGGCGTCAGGCCAACCATTGGCCAGCGCGTGCGGCTCAGTCAGGGAGACATAGCTCAAGCCCGGAAGCTGTACAAATGCCCAGCGTGTGGGGAGACCCTGCAGGACACAACGGGAAACTTTTCTGCACCTGGTTTCCCAAATGGGTACCCATCTTACTCCCACTGCGTCTGGAGGATCTCGGTCACCCCAGGGGAAAAGATCGTATTAAACTTCACATCCATGGATTTGTTTAAAAGCCGACTGTGCTGGTATGATTACGTGGAGGTCCGGGATGGTTACTGGAGAAAAGCCCCCCTTTTGGGCAGGTTTTGTGGCGATAAGATCCCGGAGCCCCTCGTCTCCACGGACAGCCGGCTCTGGGTGGAGTTCCGCAGCAGCAGCAACATCTTGGGCAAGGGCTTCTTTGCAGCGTACGAAGCTACCTGCGGGGGAGACATGAACAAAGATGCCGGTCAGATTCAATCTCCCAACTATCCGGATGACTACAGACCTTCCAAGGAATGTGTCTGGAGGATTACGGTTTCGGAGGGGTTTCACGTGGGACTTACCTTCCAAGCTTTTGAGATTGAAAGGCACGACAGCTGTGCATATGACTACCTGGAAGTCCGGGATGGCCCCACGGAAGAGAGTGCCCTGATCGGCCACTTTTGTGGCTATGAGAAGCCGGAGGATGTGAAATCGAGCTCCAACAGACTGTGGATGAAGTTTGTGTCCGATGGCTCTATCAATAAAGCGGGCTTTGCAGCCAATTTTTTCAAGGAGGTGGATGAGTGTTCCTGGCCAGATCACGGCGGGTGCGAACATCGCTGTGTGAACACGCTGGGCAGCTACAAGTGTGCCTGTGACCCTGGCTACGAGCTGGCCGCCGATAAGAAGATGTGTGAAGTGGCCTGTGGCGGTTTCATTACCAAGCTGAATGGAACCATCACCAGCCCTGGGTGGCCGAAGGAGTATCCCACAAACAAAAACTGTGTCTGGCAGGTGGTGGCCCCCGCTCAGTACCGGATCTCCCTTCAGTTTGAAGTGTTTGAACTGGAAGGCAATGACGTCTGTAAGTACGACTTTGTAGAGGTGCGCAGCGGCCTGTCCCCCGACGCCAAGCTGCACGGCAGGTTCTGCGGCTCTGAGACGCCGGAAGTCATCACCTCGCAGAGCAACAACATGCGCGTGGAGTTCAAGTCCGACAACACCGTCTCCAAGCGCGGCTTCAGGGCCCACTTCTTCTCAGATAAGGACGAGTGTGCCAAGGACAACGGCGGGTGTCAGCATGAGTGCGTCAACACCTTCGGGAGCTACCTGTGCAGGTGCAGAAACGGCTACTGGCTCCACGAGAATGGGCATGACTGCAAAGAGGCTGGCTGTGCACACAAGATCAGCAGTGTGGAGGGGACCCTGGCGAGCCCCAACTGGCCTGACAAATACCCCAGCCGGAGGGAGTGTACCTGGAACATCTCTTCGACTGCAGGCCACAGAGTAAAACTCAGTGCGGGGTCAGGCTGAAGGCTGAAGTGCAGACCAAAGAGCTCTATTCCCACGCCCAGTTTGGGGACAACAACTACCCGAGCGAGGCCCGCTGTGACTGGGTGATCGTGGCAGAGGACGGCTACGGCGTGGAGCTGACATTCCGGACCTTTGAGGTTGAGGAGGAGGCCGACTGCGGCTACGACTACATGGAAGCCTACGACGGCTACGACAGCTCAGCGCCCAGGCTCGGCCGCTTCTGTGGCTCTGGGCCATTAGAAGAAATCTACTCTGCAGGTGATTCCCTGATGATTCGATTCCGCACAGATGACACCATCAACAAGAAAGGCTTTCATGCCCGATACACCAGCACCAAGTTCCAGGATGCCCTGCACATGAAGAAATAGTGCTGATGTTCTTGAAAGACAGAAACTGAGANOV8a, CG50235-04Protein SequenceSEQ ID NO: 86821 aaMW at 91404.2kDMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFEIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFAANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTITSPGWPKEYPTNKNCVWQVVAPAQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTAGHRVKLSAGSGNOV8b, CG50235-01SEQ ID NO: 873350 bpDNA SequenceORF Start: ATG at 365ORF Stop: TAG at 3341CGCCCATTGGCTCCTCAGCCAAGCACGTACACCAAATGTCTGAACCTGCGGTTCCTCTCGTACTGAGCAGGATTACCATGGCAACAACACATCATCAGTAGGGTAAAACTAACCTGTCTCACGACGGTCTAAACCCAGGCAGCCTCGGCCGCCGGGCAAGTAGCTCCGAGCGGCTGCTTCCCGGTTGCCTCGAAGAAGACAGGGGGCGCCGCGCTCCGCTTGCTCCGCGCCTGAGCCATGCCCAGCAGCCCTGTGTAACCACCGAGTCCCGGCCGGAGCCGACCGACCCAGTGTGCGCCGTCTTTCGGCCGAGCTGAGCTTTCGTGCACGCAACTCCCTCTGCCCCAGCCGGCCCCGCGCCACCATGCCCCGGGCGACTGCACTTGGGGCCCTGGTGTCACTGCTGCTGCTGCTGCCGCTGCCTCGCGGCGCCGGGGGACTCGGGGAGCGCCCGGACGCCACCGCAGACTACTCAGAGCTGGACGGCGAGGAGGGCACGGAGCAGCAGCTGGAGCATTACCACGACCCTTGCAAAGCCGCTGTCTTTTGGGGAGACATTGCCTTAGATGAAGATGACTTGAAGCTGTTTCACATTGACAAAGCCAGAGACTGGACCAAGCAGACAGTGGGGGCAACAGGACACAGCACAGGTGGGCTTGAAGAGCAGGCATCTGAGAGCAGCCCAGACACCACAGCCATGGACACTGGCACCAAGGAAGCTGGAAAGGATGGCCGGGAGAATACCACACTCCTGCACAGCCCTGGGACCTTGCATGCCGCAGCCAAGACCTTCTCTCCCCGGGTCCGAAGAGCCACAACCTCAAGGACAGAGAGGATATGGCCTGGAGGAGTCATCCCCTACGTCATTGGAGGGAACTTCACTGGGAGCCAGAGGGCCATTTTTAAGCAGGCCATGAGACACTGGGAGAAGCACACCTGTGTGACCTTCATAGAAAGGACGGATGAGGAAAGCTTTATTGTATTCAGTTACAGAACCTGTGGCTGTTGCTCCTATGTTGGGCGCCGAGGAGGAGGCCCACAGGCCATATCCATTGGGAAGAACTGTGACAAGTTTGGCATTGTGGCTCACGAGCTGGGCCATGTGGTTGGGTTTTGGCATGAACACACCCGGCCAGACAGAGACCAACATGTCACCATCATCAGGGAAAACATCCAGCCAGGTCAGGAGTATAATTTCTTAAAAATGGAAGCTGGGGAAGTGAGCTCTCTGGGAGAGACATACGACTTTGACAGCATCATGCACTACGCCCGGAACACCTTCTCAAGAGGAGTTTTCTTAGACACCATCCTTCCCCGTCAAGATGACAATGGCGTCAGGCCAACCATTGGCCAGCGCGTGCGGCTCAGTCAGGGAGACATAGCTCAAGCCCGGAAGCTGTACAAATGCCCAGCGTGTGGGGAGACCCTGCAGGACACAACGGGAAACTTTTCTGCACCTGGTTTCCCAAATGGGTACCCATCTTACTCCCACTGCGTCTGGAGGATCTCGGTCACCCCAGGGGAAAAGATCGTATTAAACTTCACATCCATGGATTTGTTTAAAAGCCGACTGTGCTGGTATGATTACGTGGAGGTCCGGGATGGTTACTGGAGAAAAGCCCCCCTTTTGGGCAGGTTTTGTGGCGATAAGATCCCGGAGCCCCTCGTCTCCACGGACAGCCGGCTCTGGGTGGAGTTCCGCAGCAGCAGCAACATCTTGGGCAAGGGCTTCTTTGCAGCGTACGAAGCTACCTGCGGGGGAGACATGAACAAAGATGCCGGTCAGATTCAATCTCCCAACTATCCGGATGACTACAGACCTTCCAAGGAATGTGTCTGGAGGATTACGGTTTCAGAGGGGTTTCACGTGGGACTTACCTTCCAAGCTTTTGAGATTGAAAGGCACGACAGCTGTGCATATGACTACCTGGAAGTCCGGGATGGCCCCACGGAAGAGAGTGCCCTGATCGGCCACTTTTGTGGCTATGAGAAGCCGGAGGATGTGAAATCGAGCTCCAACAGACTGTGGATGAAGTTTGTGTCCGATGGCTCTATCAATAAAGCGGGCTTTGCAGCCAATTTTTTCAAGGAGGTGGATGAGTGTTCCTGGCCAGATCACGGCGGGTGCGAACATCGCTGTGTGAACACGCTGGGCAGCTACAAGTGTGCCTGTGACCCTGGCTACGAGCTGGCCGCCGATAAGAAGATGTGTGAAGTGGCCTGTGGCGGTTTCATTACCAAGCTGAATGGAACCATCACCAGCCCTGGGTGGCCGAAGGAGTATCCCACAAACAAAAACTGTGTCTGGCAGGTGGTGGCCCCCACTCAGTACCGGATCTCCCTTCAGTTTGAAGTGTTTGAACTGGAAGGCAATGACGTCTGTAAGTACGACTTTGTAGAGGTGCGCAGCGGCCTGTCCCCCGACGCCAAGCTGCACGGCAGGTTCTGCGGCTCTGAGACGCCGGAAGTCATCACCTCGCAGAGCAACAACATGCGCGTGGAGTTCAAGTCCGACAACACCGTCTCCAAGCGCGGCTTCAGGGCCCACTTCTTCTCAGATAAGGACGAGTGTGCCAAGGACAACGGCGGGTGTCAGCATGAGTGCGTCAACACCTTCGGGAGCTACCTGTGCAGGTGCAGAAACGGCTACTGGCTCCACGAGAATGGGCATGACTGCAAAGAGGCTGGCTGTGCACACAAGATCAGCAGTGTGGAGGGGACCCTGGCGAGCCCCAACTGGCCTGACAAATACCCCAGCCGGAGGGAGTGTACCTGGAACATCTCTTCGACTGCAGGCCACAGAGTGAAACTCACCTTTAATGAGTTTGAGATCGAGCAGCACCAGGAATGTGCCTATGACCACCTGGAAATGTATGACGGGCCGGACAGCCTGGCCCCCATTCTGGGCCGTTTCTGCGGCAGCAAGAAACCAGACCCCACGGTGGCTTCCGGCAGCAAGTGCGGGGGCAGGCTGAAGGCTGAAGTGCAGACCAAAGAGCTCTATTCCCACGCCCAGTTTGGGGACAACAACTACCCGAGCGAGGCCCGCTGTGACTGGGTGATCGTGGCAGAGGACGGCTACGGCGTGGAGCTGACATTCCGGACCTTTGAGGTTGAGGAGGAGGCCGACTGCGGCTACGACTACATGGAAGCCTACGACGGCTACGACAGCTCAGCGCCCAGGCTCGGCCGCTTCTGTGGCTCTGGGCCATTAGAAGAAATCTACTCTGCAGGTGATTCCCTGATGATTCGATTCCGCACAGATGACACCATCAACAAGAAAGGCTTTCATGCCCGATACACCAGCACCAAGTTCCAGGATGGCCTGCACATGAAGAAATAGTGCTGATNOV8b, CG50235-01Protein SequenceSEQ ID NO: 88992 aaMW at 110925.6kDMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFKQANRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFEIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWNKFVSDGSINKAGFAANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTITSPGWPKEYPTNKNCVWQVVAPTQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLHGRFCGSETPEVITSQSNNNRVEFKSDNTVSKRGFRAHFFSDKDECAKDMGGCQHECVNTFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTAGHRVKLTFNEFEIEQHQECAYDHLEMYDGPDSLAPILGRFCGSKKPDPTVASGSKCGGRLKAEVQTKELYSHAQFGDNNYPSEARCDWVIVAEDGYGVELTFRTFEVEEEADCGYDYMEAYDGYDSSAPRLGRFCGSGPLEEIYSAGDSLMIRFRTDDTINKKGFHARYTSTKFQDGLHMKKNOV8c, CG50235-02SEQ ID NO: 895006 bpDNA SequenceORF Start: ATG at 365ORF Stop: TAG at 3410CGCCCATTGGCTCCTCAGCCAAGCACGTACACCAAATGTCTGAACCTGCGGTTCCTCTCGTACTGAGCAGGATTACCATGGCAACAACACATCATCAGTAGGGTAAAACTAACCTGTCTCACGACGGTCTAAACCCAGGCAGCCTCGGCCGCCGGGCAAGTAGCTCCGAGCGGCTGCTTCCCGGTTGCCTCGAAGAAGACAGGGGGCGCCGCGCTCCGCTTGCTCCGCGCCTGAGCCATGCCCAGCAGCCCTGTGTAACCACCGAGTCCCGGCCGGAGCCGACCGACCCAGTGTGCGCCGTCTTTCGGCCGAGCTGAGCTTTCGTGCACGCAACTCCCTCTGCCCCAGCCGGCCCCGCGCCACCATGCCCCGGGCGACTGCACTTGGGGCCCTGGTGTCACTGCTGCTGCTGCTGCCGCTGCCTCGCGGCGCCGGGGGACTCGGGGAGCGCCCGGACGCCACCGCAGACTACTCAGAGCTGGACGGCGAGGAGGGCACGGAGCAGCAGCTGGAGCATTACCACGACCCTTGCAAAGCCGCTGTCTTTTGGGGAGACATTGCCTTAGATGAAGATGACTTGAAGCTGTTTCACATTGACAAAGCCAGAGACTGGACCAAGCAGACAGTGGGGGCAACAGGACACAGCACAGGTGGGCTTGAAGAGCAGGCATCTGAGAGCAGCCCAGACACCACAGCCATGGACACTGGCACCAAGGAAGCTGGAAAGGATGGCCGGGAGAATACCACACTCCTGCACAGCCCTGGGACCTTGCATGCCGCAGCCAAGACCTTCTCTCCCCGGGTCCGAAGAGCCACAACCTCAAGGACAGAGAGGATATGGCCTGGAGGAGTCATCCCCTACGTCATTGGAGGGAACTTCACTGGGAGCCAGAGGGCCATTTTTAAGCAGGCCATGAGACACTGGGAGAAGCACACCTGTGTGACCTTCATAGAAAGGACGGATGAGGAAAGCTTTATTGTATTCAGTTACAGAACCTGTGGCTGTTGCTCCTATGTTGGGCGCCGAGGAGGAGGCCCACAGGCCATATCCATTGGGAAGAACTGTGACAAGTTTGGCATTGTGGCTCACGAGCTGGGCCATGTGGTTGGGTTTTGGCATGAACACACCCGGCCAGACAGAGACCAACATGTCACCATCATCAGGGAAAACATCCAGCCAGGTCAGGAGTATAATTTCTTAAAAATGGAAGCTGGGGAAGTGAGCTCTCTGGGAGAGACATACGACTTTGACAGCATCATGCACTACGCCCGGAACACCTTCTCAAGAGGAGTTTTCTTAGACACCATCCTTCCCCGTCAAGATGAGATGGCGTCCAGGCCAACCATTGGCCAGCGCGTGCGGCTCAGTCAGGGAGACATAGCTCAAGCCCGGAAGCTGTACAAATGCCCAGCGTGTGGGGAGACCCTGCAGGACACAACGGGAAACTTTTCTGCACCTGGTTTCCCAAATGGGTACCCATCTTACTCCCACTGCTTCTGGAGGATCTCGGTCACCCCAGGGGAAAAGATCGTATTAAACTTCACATCCATGGATTTGTTTAAAAGCCGACTGTGCTGGTATGATTACGTGGAGGTCCGGGATGGTTACTGGAGAAAAGCCCCCCTTTTGGGCAGGTTTTGTGGCGATAAGATCCCGGAGCCCCTCGTCTCCACGGACAGCCGGCTCTGGGTGGAGTTCCGCAGCAGCAGCAACATCTTGGGCAAGGGCTTCTTTGCAGCGTACGAAGCTACCTGCGGAAGAGACATGAACAAAGATGCCGGTCAGATTCAATCTCCCAACTATCCGGATGACTACAGACCTTCCAAGGAATGTGTCTGGAGGATTACGGTTTCGGAGGGGTTTCACGTGGGACTTACCTTCCAAGCTTTTGAGATTGAAAGGCACGACAGCTGTGCATATGACTACCTGGAAGTCCGGGATGGCCCCACGGAAGAGAGTGCCCTGATCGGCCACTTTTGTGGCTATGAGAAGCCGGAGGATGTGAAATCGAGCTCCAACAGACTGTGGATGAAGTTTGTGTCCGATGGCTCTATCAATAAAAGCGGGCTTTGCAGCCAATTTTTTCAAGGAGGTGGATGAGTGTTCTGGCCAGATCACGGCGGGTGCGAACATCGCTGTGTGAACACGCTGGGCAGCTACAAGTGTGCCTGTGACCCTGGCTACGAGCTGGCCGCCGATAAGAAGATGTGTGAAGTGGCCTGTGGCGGTTTCATTACCAAGCTGAATGGAACCATCACCAGCCCTGGGTGGCCGAAGGAGTATCCCACAAACAAAAACTGTGTCTGGCAGGTGGTGGCCCCCGCTCAGTACCGGATCTCCCTTCAGTTTGAAGTGTTTGAACTGGAAGGCAATGACGTCTGTAAGTACGACTTTGTACAGGTGCGCAGCGGCCTGTCCCCCGACGCCAAGCTGCACGGCAGGTTCTGCGGCTCTGAGACGCCGGAAGTCATCACCTCGCAGAGCAACAACATGCGCGTGGAGTTCAAGTCCGACAACACCGTCTCCAAGCGCGGCTTCAGGGCCCACTTCTTCTCAGATAAGGACGAGTGTGCCAAGGACAACGGCGGGTGTCAGCATGAGTGCGTCAACACCTTCGGGAGCTACCTGTGCAGGTGCAGAAACGGCTACTGGCTCCACGAGAATGGGCATGACTGCAAAGAGGCTGGCTGTGCACACAAGATCAGCAGTGTGGAGGGGACCCTGGCGAGCCCCAACTGGCCTGACAAATACCCCAGCCGGAGGGAGTGTACCTGGAACATCTCTTCGACTGCAGGCCACAGAGTGAAACTCACCTTTAATGAGTTTGAGATCGAGCAGCACCAGGAATGTGCCTATGACCACCTGGAAATGTATGACGGGCCGGACAGCCTGGCCCCCATTCTGGGCCGTTTCTGCGGCAGCAAGAAACCAGACCCCACGGTGGCTTCCGGCAGCAGTATGTTTCTCAGGTTTTATTCGGATGCCTCAGTGCAGAGGAAAGGCTTCCAGGCAGTGCACAGCACAGAGTGCGGGGGCAGGCTGAAGGCTGAAGTGCAGACCAAAGAGCTCTATTCCCACGCCCAGTTTGGGGACAACAACTACCCGAGCGAGGCCCGCTGTGACTGGGTGATCGTGGCAGAGGACGGCTACGGCGTGGAGCTGACATTCCGGACCTTTGAGGTTGAGGAGGAGGCCGACTGCGGCTACGACTACATGGAAGCCTACGACGGCTACGACAGCTCAGCGCCCAGGCTCGGCCGCTTCTGTGGCTCTGGGCCATTAGAAGAAATCTACTCTGCAGGTGATTCCCTGATGATTCGATTCCGCACAGATGACACCATCAACAAGAAAGGCTTTCATGCCCGATACACCAGCACCAAGTTCCAGGATGCCCTGCACATGAAGAAATAGTGCTGATGTTCTTGAAAGACAGAAACTGAGAATTTTTTTGTTTTGTTTTGTTTTTAACAACAATAGCACCTTGAAAATCTGCCCTAAAACAGTGTACAGTATTTTTCTCAAACAAAAACTCAGAATCCAGCCTTAGAGGTATATATTTGAATGAAAGTCTTGTAAGTTTGGCCAACAAGGTGGAGAAAAAAATGTTCTTTTGCTTCTGTCTGCAATGTTGTCATTCATGAACTGTTAAAGTGTTAAAGATTAGGATTGGAGTCACTGACCATTCCGGCTATGCTTCTTCATACCATTCTCCTTGTTGTCCCTTGCTCCTATGTGGCAAAAGGTCAGCCTTGGGGTTGGCCGTTCCTCTAATCTGGACTTGCTTGCTTGGTGCCAGGTGCGTCTTCTGTCCATGTTGGGCATAAGGGATGAAAACTTGGCCGAGACTAATGTGTGGCCCACAGCTTTGGCTGGAATCATTTTCTTTCTCTCTGCCAGGGACATGTCAACCAAGAAACCTGAAAATATGGATGGATGTCAGGACTAAAAAAAGGCATCACAGTGAGCAGTGAGCACAGAGGGAGTTTCGAGTATAAGAATCATTGTCATGAAGTTAGGAGACCACAAAGCCATTTCTCAGAGTCATTCACTCTCCTTGTCCCTTTGGTTTCCCCCCTTCCTTAATTGCAGTGGGGGCTAAGGTATCCATTATGAATACAGCAGAACATTTGCTGGCGAGAGTCCTGTCTGCTGAGAAGACAATATTGTGGCTCGTCCTGATATTTTTTCATTCATTGACTTTGAGAAGACTCCACCTGTGCTTGGAATTCCATGGGCTTCAAAGAACATTTCTTCTTTTAGCTTTGGAGGCACTTGCCGTGGCACACCTGGACTCCTTGACATCCAATTCAAACTGCATTTGCAAAATGTGCAAAGACCTCTTATGAGGGACCAATTCAGGTCCCTTATGGGGTGAACACTGTTGAAGACTGGTTAATTATAAGTTATGTAAGAATCATCGCCTTGTGGAACAAGTCAATCAGTGACTAGCTTCCTGTAGCCAATCAGGTTAAAGAGGGCGTTGGTAATTTTGTTCTGATTTAACTAGTATTCAATCACCAACTTGCAAACAGAATTCATAACACTTGGCACTTGTTCTAGAGAAGTGTAGAGGATGATGTTAACATAATTTTAGCACTTCAAGGTATAATTTAAACAGTGAGGTAGTTTTGAATGGCATTTCATTAAGGCATCTATGGGCATTATGAGCTAAAAGCTGTGGTATGTTAGCTTTAAAAGAGTATTTATGTTGGAATAATTTTTAAATAATGTTTACATAACTGTAAGTCCTGTTTGGTTGTTGTTGGACGCAGGGCGGCACATGAGTGTTTTTGGTTAGAGCCAAGATAGCTCCCATGCACCGGAATTCCTTTGGGATGAATCAGCATCATTTTAAACAAAGTATATGTAAAAGGTGAAAGGTTATATTTTTTACAGATCAGAATGTGGCACCAGAGGACTGTGTCTCATTAAAGTGATTGCTGGGAGCAAAAACTAGAATGATACAAAGAAAGGTCAGAGAAATGCATGGGAATATTTTTTCTTTNOV8c, CG50235-02Protein SequenceSEQ ID NO: 901015 aaMW at 113555.5kDMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFEIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFAANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTITSPGWPKEYPTNKNCVWQVVAPAQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTAGHRVKLTFNEFEIEQHQECAYDHLEMYDGPDSLAPILGRFCGSKKPDPTVASGSSMFLRFYSDASVQRKGFQAVHSTECGGRLKAEVQTKELYSHAQFGDNNYPSEARCDWVIVAEDGYGVELTFRTFEVEEEADCGYDYMEAYDGYDSSAPRLGRFCGSGPLEEIYSAGDSLMIRFRTDDTINKKGFHARYTSTKFQDALHMKKNOV8d, CG50235-03SEQ ID NO: 913146 bpDNA SequenceORF Start: ATG at 227ORF Stop: TAG at 3137GCAGCCTCGGCCGCCGGGCAAGTAGCTCCGAGCGGCTGCTTCCCGGTTGCCTCGACGAAGACAGGGGGCGCCGCGCTCCGCTTGCTCCGCGCCTGAGCCATGCCCAGCAGCCCTGTGTAACCACCGAGTCCCGGCCGGAGCCGACCGACCCAGTGTGCGCCGTCTTTCGGCCGAGCTGAGCTTTCGTGCACGCAACTCCCTCTGCCCCAGCCGGCCCCGCGCCACCATGCCCCGGGCGACTGCACTTGGGGCCCTGGTGTCACTGCTGCTGCTGCTGCCGCTGCCTCGCGGCGCCGGGGGACTCGGGGAGCGCCCGGACGCCACCGCAGACTACTCAGAGCTGGACGGCGAGGAGGGCACGGAGCAGCAGCTGGAGCATTACCACGACCCTTGCAAAGCCGCTGTCTTTTGGGGAGACATTGCCTTAGATGAAGATGACTTGAAGCTGTTTCACATTGACAAAGCCAGAGACTGGACCAAGCAGACAGTGGGGGCAACAGGACACAGCACAGGTGGGCTTGAAGAGCAGGCATCTGAGAGCAGCCCAGACACCACAGCCATGGACACTGGCACCAAGGAAGCTGGAAAGGGGAGCCAGAGGGCCATTTTTAAGCAGGCCATGAGACACTGGGAGAAGCACACCTGTGTGACCTTCATAGAAAGGACGGATGAGGAAAGCTTTATTGTATTCAGTTACAGAACCTGTGGCTGTTGCTCCTATGTTGGGCGCCGAGGAGGAGGCCCACAGGCCATATCCATTGGGAAGAACTGTGACAAGTTTGGCATTGTGGCTCACGAGCTGGGCCATGTGGTTGGGTTTTGGCATGAACACACCCGGCCAGACAGAGACCAACATGTCACCATCATCAGGGAAAACATCCAGCCAGGTCAGGAGTATAATTTCTTAAAAATGGAAGCTGGGGAAGTGAGCTCTCTGGGAGAGACATACGACTTTGACAGCATCATGCACTACGCCCGGAACACCTTCTCAAGAGGAGTTTTTTTAGACACCATCCTTCCCCGTCAAGATGACAATGGCGTCAGGCCAACCATTGGCCAGCGCGTGCGGCTCAGTCAGGGAGACATAGCTCAAGCCCGGAAGCTGTACAAATGCCCAGGTCCTACTTGTGCTTTTGTTAGCCAGAAAACATCAATCTGCTTGCTACACTTCTCACCAACCTGTTCCGAGGGCTTTGGCTGGCAAAGGGCGTGTGGGGAGACCCTGCAGGACACAACGGGAAACTTTTCTGCACCTGGTTTCCCAAATGGGTACCCATCTTACTCCCACTGCGTCTGGAGGATCTCGGTCACCCCAGGGGAAAAGATCGTATTAAACTTCACATCCATGGATTTGTTTAAAAGCCGACTGTGCTGGTATGATTACGTGGAGGTCCGGGATGGTTACTGGAGAAAAGCCCCCCTTTTGGGCAGGTTTTGTGGCGATAAGATCCCGGAGCCCCTCGTCTCCACGGACAGCCGGCTCTGGGTGGAGTTCCGCAGCAGCAGCAACATCTTGGGCAAGGGCTTCTTTGCAGCGTACGAAGCTACCTGCGGGGGAGACATGAACAAAGATGCCGGTCAGATTCAATCTCCCAACTATCCGGATGACTACAGACCTTCCAAGGAATGTGTCTGGAGGATTACGGTTTCAGAGGGGTTTCACGTGGGACTTACCTTCCAAGCTTTTGAGATTGAAAGGCACGACAGCTGTGCATATGACTACCTGGAAGTCCGGGATGGCCCCACGGAAGAGAGTGCCCTGATCGGCCACTTTTGTGGCTATGAGAAGCCGGAGGATGTGAAATCGAGCTCCAACAGACTGTGGATGAAGTTTGTGTCCGATGGCTCTATCAATAAAGCGGGCTTTGCAGCCAATTTTTTCAAGGAGGTGGATGAGTGTTCCTGGCCAGATCACGGCGGGTGCGAGCATCGCTGTGTGAACACGCTGGGCAGCTACAAGTGTGCCTGTGACCCTGGCTACGAGCTGGCCGCCGATAAGAAGATGTGTGAAGTGGCCTGTGGCGGTTTCATTACCAAGCTGAATGGAACCATCACCAGCCCTGGGTGGCCGAAGGAGTATCCCACAAACAAAAACTGTGTCTGGCAGGTGGTGGCCCCCACTCAGTACCGGATCTCCCTTCAGTTTGAAGTGTTTGAACTGGAAGGCAATGACGTCTGTAAGTACGACTTTGTAGAGGTGCGCAGCGGCCTGTCCCCCGACGCCAAGCTGCACGGCAGGTTCTGCGGCTCTGAGACGCCGGAGGTCATCACCTCGCAGAGCAACAACATGCGCGTGGAGTTCAAGTCCGACAACACCGTCTCCAAGCGCGGCTTCAGGGCCCACTTCTTCTCAGATAAGGACGAGTGTGCCAAGGACAACGGCGGGTGTCAGCATGAGTGCGTCAACACCTTCGGGAGCTACCTGTGCAGGTGCAGAAACGGCTACTGGCTCCACGAGAATGGGCATGACTGCAAAGAGGCTGGCTGTGCACACAAGATCAGCAGTGTGGAGGGGACCCTGGCGAGCCCCAACTGGCCTGACAAATACCCCAGCCGGAGGGAGTGTACCTGGAACATCTCTTCGACTGCAGGCCACAGAGTGAAACTCACCTTTAATGAGTTTGAGATCGAGCAGCACCAGGAATGTGCCTATGACCACCTGGAAATGTATGACGGGCCGGACAGCCTGGCCCCCATTCTGGGCCGTTTCTGCGGTAGCAAGAAACCAGACCCCACGGTGGCTTCCGGCAGCAAGTGCGGGGGCAGGCTGAAGGCTGAAGTGCAGACCAAAGAGCTCTATTCCCACGCCCAGTTTGGGGACAACAACTACCCGAGCGAGGCCCGCTGTGACTGGGTGATCGTGGCAGAGGACGGCTACGGCGTGGAGCTGACATTCCGGACCTTTGAGGTTGAGGAGGAGGCCGACTGCGGCTACGACTACATGGAAGCCTACGACGGCTACGACAGCTCAGCGCCCAGGCTCGGCCGCTTCTGTGGCTCTGGGCCATTAGAAGAAATCTACTCTGCAGGTGATTCCCTGATGATTCGATTCCGCACAGATGACACCATCAACAAGAAAGGCTTTCATGCCCGATACACCAGCACCAAGTTCCAGGATGCCCTGCACATGAAGAAATAGTGCTGATNOV8d, CG50235-03Protein SequenceSEQ ID NO: 92970 aaMW at 108564.0kDMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGKGSQRAIFKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSINHYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPGPTCAFVSQKTSICLLHFSPTCSEGFGWQRACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFEIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFAANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTITSPGWPKEYPTNKNCVWQVVAPTQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTAGHRVKLTFNEFEIEQHOECAYDHLEMYDGPDSLAPILGRFCGSKKPDPTVASGSKCGGRLKAEVQTKELYSHAQFGDNNYPSEARCDWVIVAEDGYGVELTFRTFEVEEEADCGYDYMEAYDGYDSSAPRLGRFCGSGPLEEIYSAGDSLMIRFRTDDTINKKGFHARYTSTKFQDALHMKKSEQ ID NO: 933120 bpNOV8e, SNP13377383 ofORF Start: ATG at 256ORF Stop: TGA at 2719CG50235-04, DNA SequenceSNP Pos: 2201SNP Change: A to GTAACCTGTCTCACGACGGTCTAAACCCAGGCAGCCTCGGCCGCCGGGCAAGTAGCTCCGAGCGGCTGCTTCCCGGTTGCCTCGAAGAAGACAGGGGGCGCCGCGCTCCGCTTGCTCCGCGCCTGAGCCATGCCCAGCAGCCCTGTGTAACCACCGAGTCCCGGCCGGAGCCGACCGACCCAGTGTGCGCCGTCTTTCGGCCGAGCTGAGCTTTCGTGCACGCAACTCCCTCTGCCCCAGCCGGCCCCGCGCCACCATGCCCCGGGCGACTGCACTTGGGGCCCTGGTGTCACTGCTGCTGCTGCTGCCGCTGCCTCGCGGCGCCGGGGGACTCGGGGAGCGCCCGGACGCCACCGCAGACTACTCAGAGCTGGACGGCGAGGAGGGCACGGAGCAGCAGCTGGAGCATTACCACGACCCTTGCAAAGCCGCTGTCTTTTGGGGAGACATTGCCTTAGATGAAGATGACTTGAAGCTGTTTCACATTGACAAAGCCAGAGACTGGACCAAGCAGACAGTGGGGGCAACAGGACACAGCACAGGTGGGCTTGAAGAGCAGGCATCTGAGAGCAGCCCAGACACCACAGCCATGGACACTGGCACCAAGGAAGCTGGAAAGGATGGCCGGGAGAATACCACACTCCTGCACAGCCCTGGGACCTTGCATGCCGCAGCCAAGACCTTCTCTCCCCGGGTCCGAAGAGCCACAACCTCAAGGACAGAGAGGATATGGCCTGGAGGAGTCATCCCCTACGTCATTGGAGGGAACTTCACTGGGAGCCAGAGGGCCATTTTTAAGCAGGCCATGAGACACTGGGAGAAGCACACCTGTGTGACCTTCATAGAAAGGACGGATGAGGAAAGCTTTATTGTATTCAGTTACAGAACCTGTGGCTGTTGCTCCTATGTTGGGCGCCGAGGAGGAGGCCCACAGGCCATATCCATTGGGAAGAACTGTGACAAGTTTGGCATTGTGGCTCACGAGCTGGGCCATGTGGTTGGGTTTTGGCATGAACACACCCGGCCAGACAGAGACCAACATGTCACCATCATCAGGGAAAACATCCAGCCAGGTCAGGAGTATAATTTCTTAAAAATGGAAGCTGGGGAAGTGAGCTCTCTGGGAGAGACATACGACTTTGACAGCATCATGCACTACGCCCGGAACACCTTCTCAAGAGGAGTTTTCTTAGACACCATCCTTCCCCGTCAAGATGACAATGGCGTCAGGCCAACCATTGGCCAGCGCGTGCGGCTCAGTCAGGGAGACATAGCTCAAGCCCGGAAGCTGTACAAATGCCCAGCGTGTGGGGAGACCCTGCAGGACACAACGGGAAACTTTTCTGCACCTGGTTTCCCAAATGGGTACCCATCTTACTCCCACTGCGTCTGGAGGATCTCGGTCACCCCAGGGGAAAAGATCGTATTAAACTTCACATCCATGGATTTGTTTAAAAGCCGACTGTGCTGGTATGATTACGTGGAGGTCCGGGATGGTTACTGGAGAAAAGCCCCCCTTTTGGGCAGGTTTTGTGGCGATAAGATCCCGGAGCCCCTCGTCTCCACGGACAGCCGGCTCTGGGTGGAGTTCCGCAGCAGCAGCAACATCTTGGGCAAGGGCTTCTTTGCAGCGTACGAAGCTACCTGCGGGGGAGACATGAACAAAGATGCCGGTCAGATTCAATCTCCCAACTATCCGGATGACTACAGACCTTCCAAGGAATGTGTCTGGAGGATTACGGTTTCGGAGGGGTTTCACGTGGGACTTACCTTCCAAGCTTTTGAGATTGAAAGGCACGACAGCTGTGCATATGACTACCTGGAAGTCCGGGATGGCCCCACGGAAGAGAGTGCCCTGATCGGCCACTTTTGTGGCTATGAGAAGCCGGAGGATGTGAAATCGAGCTCCAACAGACTGTGGATGAAGTTTGTGTCCGATGGCTCTATCAATAAAGCGGGCTTTGCAGCCAATTTTTTCAAGGAGGTGGATGAGTGTTCCTGGCCAGATCACGGCGGGTGCGAACATCGCTGTGTGAACACGCTGGGCAGCTACAAGTGTGCCTGTGACCCTGGCTACGAGCTGGCCGCCGATAAGAAGATGTGTGAAGTGGCCTGTGGCGGTTTCATTACCAAGCTGAATGGAACCATCACCAGCCCTGGGTGGCCGAAGGAGTATCCCACAAACAAAAACTGTGTCTGGCGGGTGGTGGCCCCCGCTCAGTACCGGATCTCCCTTCAGTTTGAAGTGTTTGAACTGGAAGGCAATGACGTCTGTAAGTACGACTTTGTAGAGGTGCGCAGCGGCCTGTCCCCCGACGCCAAGCTGCACGGCAGGTTCTGCGGCTCTGAGACGCCGGAAGTCATCACCTCGCAGAGCAACAACATGCGCGTGGAGTTCAAGTCCGACAACACCGTCTCCAAGCGCGGCTTCAGGGCCCACTTCTTCTCAGATAAGGACGAGTGTGCCAAGGACAACGGCGGGTGTCAGCATGAGTGCGTCAACACCTTCGGGAGCTACCTGTGCAGGTGCAGAAACGGCTACTGGCTCCACGAGAATGGGCATGACTGCAAAGAGGCTGGCTGTGCACACAAGATCAGCAGTGTGGAGGGGACCCTGGCGAGCCCCAACTGGCCTGACAAATACCCCAGCCGGAGGGAGTGTACCTGGAACATCTCTTCGACTGCAGGCCACAGAGTAAAACTCAGTGCGGGGTCAGGCTGAAGGCTGAAGTGCAGACCAAAGAGCTCTATTCCCACGCCCAGTTTGGGGACAACAACTACCCGAGCGAGGCCCGCTGTGACTGGGTGATCGTGGCAGAGGACGGCTACGGCGTGGAGCTGACATTCCGGACCTTTGAGGTTGAGGAGGAGGCCGACTGCGGCTACGACTACATGGAAGCCTACGACGGCTACGACAGCTCAGCGCCCAGGCTCGGCCGCTTCTGTGGCTCTGGGCCATTAGAAGAAATCTACTCTGCAGGTGATTCCCTGATGATTCGATTCCGCACAGATGACACCATCAACAAGAAAGGCTTTCATGCCCGATACACCAGCACCAAGTTCCAGGATGCCCTGCACATGAAGAAATAGTGCTGATGTTCTTGAAAGACAGAAACTGAGANOV8e, SNP13377383 ofSEQ ID NO: 94MW at 91432.3kDCG50235-04, Protein SequenceSNP Pos: 649821 aaSNP Change: Gln to ArgMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAIMDTGTKEAGKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTSSRLWVEFRSSSNILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFEIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFAANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTITSPGWPKEYPTNKNCVWRVVAPAQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTAGHRVKLSAGSGSEQ ID NO: 953120 bpNOV8f, SNP13377384 ofORF Start: ATG at 256ORF Stop: TGA at 2719CG50235-04, DNA SequenceSNP Pos: 2434SNP Change: G to ATAACCTGTCTCACGACGGTCTAAACCCAGGCAGCCTCGGCCGCCGGGCAAGTAGCTCCGAGCGGCTGCTTCCCGGTTGCCTCGAAGAAGACAGGGGGCGCCGCGCTCCGCTTGCTCCGCGCCTGAGCCATGCCCAGCAGCCCTGTGTAACCACCGAGTCCCGGCCGGAGCCGACCGACCCAGTGTGCGCCGTCTTTCGGCCGAGCTGAGCTTTCGTGCACGCAACTCCCTCTGCCCCAGCCGGCCCCGCGCCACCATGCCCCGGGCGACTGCACTTGGGGCCCTGGTGTCACTGCTGCTGCTGCTGCCGCTGCCTCGCGGCGCCGGGGGACTCGGGGAGCGCCCGGACGCCACCGCAGACTACTCAGAGCTGGACGGCGAGGAGGGCACGGAGCAGCAGCTGGAGCATTACCACGACCCTTGCAAAGCCGCTGTCTTTTGGGGAGACATTGCCTTAGATGAAGATGACTTGAAGCTGTTTCACATTGACAAAGCCAGAGACTGGACCAAGCAGACAGTGGGGGCAACAGGACACAGCACAGGTGGGCTTGAAGAGCAGGCATCTGAGAGCAGCCCAGACACCACAGCCATGGACACTGGCACCAAGGAAGCTGGAAAGGATGGCCGGGAGAATACCACACTCCTGCACAGCCCTGGGACCTTGCATGCCGCAGCCAAGACCTTCTCTCCCCGGGTCCGAAGAGCCACAACCTCAAGGACAGAGAGGATATGGCCTGGAGGAGTCATCCCCTACGTCATTGGAGGGAACTTCACTGGGAGCCAGAGGGCCATTTTTAAGCAGGCCATGAGACACTGGGAGAAGCACACCTGTGTGACCTTCATAGAAAGGACGGATGAGGAAAGCTTTATTGTATTCAGTTACAGAACCTGTGGCTGTTGCTCCTATGTTGGGCGCCGAGGAGGAGGCCCACAGGCCATATCCATTGGGAAGAACTGTGACAAGTTTGGCATTGTGGCTCACGAGCTGGGCCATGTGGTTGGGTTTTGGCATGAACACACCCGGCCAGACAGAGACCAACATGTCACCATCATCAGGGAAAACATCCAGCCAGGTCAGGAGTATAATTTCTTAAAAATGGAAGCTGGGGAAGTGAGCTCTCTGGGAGAGACATACGACTTTGACAGCATCATGCACTACGCCCGGAACACCTTCTCAAGAGGAGTTTTCTTAGACACCATCCTTCCCCGTCAAGATGACAATGGCGTCAGGCCAACCATTGGCCAGCGCGTGCGGCTCAGTCAGGGAGACATAGCTCAAGCCCGGAAGCTGTACAAATGCCCAGCGTGTGGGGAGACCCTGCAGGACACAACGGGAAACTTTTCTGCACCTGGTTTCCCAAATGGGTACCCATCTTACTCCCACTGCGTCTGGAGGATCTCGGTCACCCCAGGGGAAAAGATCGTATTAAACTTCACATCCATGGATTTGTTTAAAAGCCGACTGTGCTGGTATGATTACGTGGAGGTCCGGGATGGTTACTGGAGAAAAGCCCCCCTTTTGGGCAGGTTTTGTGGCGATAAGATCCCGGAGCCCCTCGTCTCCACGGACAGCCGGCTCTGGGTGGAGTTCCGCAGCAGCAGCAACATCTTGGGCAAGGGCTTCTTTGCAGCGTACGAAGCTACCTGCGGGGGAGACATGAACAAAGATGCCGGTCAGATTCAATCTCCCAACTATCCGGATGACTACAGACCTTCCAAGGAATGTGTCTGGAGGATTACGGTTTCGGAGGGGTTTCACGTGGGACTTACCTTCCAAGCTTTTGAGATTGAAAGGCACGACAGCTGTGCATATGACTACCTGGAAGTCCGGGATGGCCCCACGGAAGAGAGTGCCCTGATCGGCCACTTTTGTGGCTATGAGAAGCCGGAGGATGTGAAATCGAGCTCCAACAGACTGTGGATGAAGTTTGTGTCCGATGGCTCTATCAATAAAGCGGGCTTTGCAGCCAATTTTTTCAAGGAGGTGGATGAGTGTTCCTGGCCAGATCACGGCGGGTGCGAACATCGCTGTGTGAACACGCTGGGCAGCTACAAGTGTGCCTGTGACCCTGGCTACGAGCTGGCCGCCGATAAGAAGATGTGTGAAGTGGCCTGTGGCGGTTTCATTACCAAGCTGAATGGAACCATCACCAGCCCTGGGTGGCCGAAGGAGTATCCCACAAACAAAAACTGTGTCTGGCAGGTGGTGGCCCCCGCTCAGTACCGGATCTCCCTTCAGTTTGAAGTGTTTGAACTGGAAGGCAATGACGTCTGTAAGTACGACTTTGTAGAGGTGCGCAGCGGCCTGTCCCCCGACGCCAAGCTGCACGGCAGGTTCTGCGGCTCTGAGACGCCGGAAGTCATCACCTCGCAGAGCAACAACATGCGCGTGGAGTTCAAGTCCGACAACACCGTCTCCAAGCGCGGCTTCAGGACCCACTTCTTCTCAGATAAGGACGAGTGTGCCAAGGACAACGGCGGGTGTCAGCATGAGTGCGTCAACACCTTCGGGAGCTACCTGTGCAGGTGCAGAAACGGCTACTGGCTCCACGAGAATGGGCATGACTGCAAAGAGGCTGGCTGTGCACACAAGATCAGCAGTGTGGAGGGGACCCTGGCGAGCCCCAACTGGCCTGACAAATACCCCAGCCGGAGGGAGTGTACCTGGAACATCTCTTCGACTGCAGGCCACAGAGTAAAACTCAGTGCGGGGTCAGGCTGAAGGCTGAAGTGCAGACCAAAGAGCTCTATTCCCACGCCCAGTTTGGGGACAACAACTACCCGAGCGAGGCCCGCTGTGACTGGGTGATCGTGGCAGAGGACGGCTACGGCGTGGAGCTGACATTCCGGACCTTTGAGGTTGAGGAGGAGGCCGACTGCGGCTACGACTACATGGAAGCCTACGACGGCTACGACAGCTCAGCGCCCAGGCTCGGCCGCTTCTGTGGCTCTGGGCCATTAGAAGAAATCTACTCTGCAGGTGATTCCCTGATGATTCGATTCCGCACAGATGACACCATCAACAAGAAAGGCTTTCATGCCCGATACACCAGCACCAGGTTCCAGGATGCCCTGCACATGAAGAAATAGTGCTGATGTTCTTGAAAGACAGAAACTGAGANOV8f, SNP13377384 ofSEQ ID NO: 96MW at 91434.2kDCG50235-04, Protein SequenceSNP Pos: 727821 aaSNP Change: Ala to ThrMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTANDTGTKEAGKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFEIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFAANFFKEVDECSWPDNGGCEHRCVNTLGSYKCACDPGYELAADKKNCEVACGGFITKLNGTITSPGWPKEYPTNKNCVWQVVAPAQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLHGRFCGSETPEVITSQSNMRVEFKSDNTVSKRGFRTHFFSDKDECAKDDNGGCQHECVNTFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTAGHRVKLSAGSGSEQ ID NO: 973120 bpNOV8g, SNP13377385 ofORF Start: ATG at 256ORF Stop: TGA at 2719CG50235-04, DNA SequenceSNP Pos: 2751SNP Change: T to CTAACCTGTCTCACGACGGTCTAAACCCAGGCAGCCTCGGCCGCCGGGCAAGTAGCTCCGAGCGGCTGCTTCCCGGTTGCCTCGAAGAAGACAGGGGGCGCCGCGCTCCGCTTGCTCCGCGCCTGAGCCATGCCCAGCAGCCCTGTGTAACCACCGAGTCCCGGCCGGAGCCGACCGACCCAGTGTGCGCCGTCTTTCGGCCGAGCTGAGCTTTCGTGCACGCAACTCCCTCTGCCCCAGCCGGCCCCGCGCCACCATGCCCCGGGCGACTGCACTTGGGGCCCTGGTGTCACTGCTGCTGCTGCTGCCGCTGCCTCGCGGCGCCGGGGGACTCGGGGAGCGCCCGGACGCCACCGCAGACTACTCAGAGCTGGACGGCGAGGAGGGCACGGAGCAGCAGCTGGAGCATTACCACGACCCTTGCAAAGCCGCTGTCTTTTGGGGAGACATTGCCTTAGATGAAGATGACTTGAAGCTGTTTCACATTGACAAAGCCAGAGACTGGACCAAGCAGACAGTGGGGGCAACAGGACACAGCACAGGTGGGCTTGAAGAGCAGGCATCTGAGAGCAGCCCAGACACCACAGCCATGGACACTGGCACCAAGGAAGCTGGAAAGGATGGCCGGGAGAATACCACACTCCTGCACAGCCCTGGGACCTTGCATGCCGCAGCCAAGACCTTCTCTCCCCGGGTCCGAAGAGCCACAACCTCAAGGACAGAGAGGATATGGCCTGGAGGAGTCATCCCCTACGTCATTGGAGGGAACTTCACTGGGAGCCAGAGGGCCATTTTTAAGCAGGCCATGAGACACTGGGAGAAGCACACCTGTGTGACCTTCATAGAAAGGACGGATGAGGAAAGCTTTATTGTATTCAGTTACAGAACCTGTGGCTGTTGCTCCTATGTTGGGCGCCGAGGAGGAGGCCCACAGGCCATATCCATTGGGAAGAACTGTGACAAGTTTGGCATTGTGGCTCACGAGCTGGGCCATGTGGTTGGGTTTTGGCATGAACACACCCGGCCAGACAGAGACCAACATGTCACCATCATCAGGGAAAACATCCAGCCAGGTCAGGAGTATAATTTCTTAAAAATGGAAGCTGGGGAAGTGAGCTCTCTGGGAGAGACATACGACTTTGACAGCATCATGCACTACGCCCGGAACACCTTCTCAAGAGGAGTTTTCTTAGACACCATCCTTCCCCGTCAAGATGACAATGGCGTCAGGCCAACCATTGGCCAGCGCGTGCGGCTCAGTCAGGGAGACATAGCTCAAGCCCGGAAGCTGTACAAATGCCCAGCGTGTGGGGAGACCCTGCAGGACACAACGGGAAACTTTTCTGCACCTGGTTTCCCAAATGGGTACCCATCTTACTCCCACTGCGTCTGGAGGATCTCGGTCACCCCAGGGGAAAAGATCGTATTAAACTTCACATCCATGGATTTGTTTAAAAGCCGACTGTGCTGGTATGATTACGTGGAGGTCCGGGATGGTTACTGGAGAAAAGCCCCCCTTTTGGGCAGGTTTTGTGGCGATAAGATCCCGGAGCCCCTCGTCTCCACGGACAGCCGGCTCTGGGTGGAGTTCCGCAGCAGCAGCAACATCTTGGGCAAGGGCTTCTTTGCAGCGTACGAAGCTACCTGCGGGGGAGACATGAACAAAGATGCCGGTCAGATTCAATCTCCCAACTATCCGGATGACTACAGACCTTCCAAGGAATGTGTCTGGAGGATTACGGTTTCGGAGGGGTTTCACGTGGGACTTACCTTCCAAGCTTTTGAGATTGAAAGGCACGACAGCTGTGCATATGACTACCTGGAAGTCCGGGATGGCCCCACGGAAGAGAGTGCCCTGATCGGCCACTTTTGTGGCTATGAGAAGCCGGAGGATGTGAAATCGAGCTCCAACAGACTGTGGATGAAGTTTGTGTCCGATGGCTCTATCAATAAAGCGGGCTTTGCAGCCAATTTTTTCAAGGAGGTGGATGAGTGTTCCTGGCCAGATCACGGCGGGTGCGAACATCGCTGTGTGAACACGCTGGGCAGCTACAAGTGTGCCTGTGACCCTGGCTACGAGCTGGCCGCCGATAAGAAGATGTGTGAAGTGGCCTGTGGCGGTTTCATTACCAAGCTGAATGGAACCATCACCAGCCCTGGGTGGCCGAAGGAGTATCCCACAAACAAAAACTGTGTCTGGCAGGTGGTGGCCCCCGCTCAGTACCGGATCTCCCTTCAGTTTGAAGTGTTTGAACTGGAAGGCAATGACGTCTGTAAGTACGACTTTGTAGAGGTGCGCAGCGGCCTGTCCCCCGACGCCAAGCTGCACGGCAGGTTCTGCGGCTCTGAGACGCCGGAAGTCATCACCTCGCAGAGCAACAACATGCGCGTGGAGTTCAAGTCCGACAACACCGTCTCCAAGCGCGGCTTCAGGGCCCACTTCTTCTCAGATAAGGACGAGTGTGCCAAGGACAACGGCGGGTGTCAGCATGAGTGCGTCAACACCTTCGGGAGCTACCTGTGCAGGTGCAGAAACGGCTACTGGCTCCACGAGAATGGGCATGACTGCAAAGAGGCTGGCTGTGCACACAAGATCAGCAGTGTGGAGGGGACCCTGGCGAGCCCCAACTGGCCTGACAAATACCCCAGCCGGAGGGAGTGTACCTGGAACATCTCTTCGACTGCAGGCCACAGAGTAAAACTCAGTGCGGGGTCAGGCTGAAGGCTGAAGTGCAGACCAAAGAGCTCTATCCCCACGCCCAGTTTGGGGACAACAACTACCCGAGCGAGGCCCGCTGTGACTGGGTGATCGTGGCAGAGGACGGCTACGGCGTGGAGCTGACATTCCGGACCTTTGAGGTTGAGGAGGAGGCCGACTGCGGCTACGACTACATGGAAGCCTACGACGGCTACGACAGCTCAGCGCCCAGGCTCGGCCGCTTCTGTGGCTCTGGGCCATTAGAAGAAATCTACTCTGCAGGTGATTCCCTGATGATTCGATTCCGCACAGATGACACCATCAACAAGAAAGGCTTTCATGCCCGATACACCAGCACCAAGTTCCAGGATGCCCTGCACATGAAGAAATAGTGCTGATGTTCTTGAAAGACAGAAACTGAGANOV8g, SNP13377385 of+TL,19MW at 91404.2kDCG50235-04, Protein SequenceSEQ ID NO: 98821 aaSNP Change: no changeMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNILGKGFFAAYEATCGGDNNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFEIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFAANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTITSPGWPKEYPTNKNCVWQVVAPAQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTAGHRVKLSAGSGSEQ ID NO: 993120 bpNOV8h, SNP13377386 ofORF Start: ATG at 256ORF Stop: TGA at 2719CG50235-04, DNA SequenceSNP Pos: 2794SNP Change: G to ATAACCTGTCTCACGACGGTCTAAACCCAGGCAGCCTCGGCCGCCGGGCAAGTAGCTCCGAGCGGCTGCTTCCCGGTTGCCTCGAAGAAGACAGGGGGCGCCGCGCTCCGCTTGCTCCGCGCCTGAGCCATGCCCAGCAGCCCTGTGTAACCACCGAGTCCCGGCCGGAGCCGACCGACCCAGTGTGCGCCGTCTTTCGGCCGAGCTGAGCTTTCGTGCACGCAACTCCCTCTGCCCCAGCCGGCCCCGCGCCACCATGCCCCGGGCGACTGCACTTGGGGCCCTGGTGTCACTGCTGCTGCTGCTGCCGCTGCCTCGCGGCGCCGGGGGACTCGGGGAGCGCCCGGACGCCACCGCAGACTACTCAGAGCTGGACGGCGAGGAGGGCACGGAGCAGCAGCTGGAGCATTACCACGACCCTTGCAAAGCCGCTGTCTTTTGGGGAGACATTGCCTTAGATGAAGATGACTTGAAGCTGTTTCACATTGACAAAGCCAGAGACTGGACCAAGCAGACAGTGGGGGCAACAGGACACAGCACAGGTGGGCTTGAAGAGCAGGCATCTGAGAGCAGCCCAGACACCACAGCCATGGACACTGGCACCAAGGAAGCTGGAAAGGATGGCCGGGAGAATACCACACTCCTGCACAGCCCTGGGACCTTGCATGCCGCAGCCAAGACCTTCTCTCCCCGGGTCCGAAGAGCCACAACCTCAAGGACAGAGAGGATATGGCCTGGAGGAGTCATCCCCTACGTCATTGGAGGGAACTTCACTGGGAGCCAGAGGGCCATTTTTAAGCAGGCCATGAGACACTGGGAGAAGCACACCTGTGTGACCTTCATAGAAAGGACGGATGAGGAAAGCTTTATTGTATTCAGTTACAGAACCTGTGGCTGTTGCTCCTATGTTGGGCGCCGAGGAGGAGGCCCACAGGCCATATCCATTGGGAAGAACTGTGACAAGTTTGGCATTGTGGCTCACGAGCTGGGCCATGTGGTTGGGTTTTGGCATGAACACACCCGGCCAGACAGAGACCAACATGTCACCATCATCAGGGAAAACATCCAGCCAGGTCAGGAGTATAATTTCTTAAAAATGGAAGCTGGGGAAGTGAGCTCTCTGGGAGAGACATACGACTTTGACAGCATCATGCACTACGCCCGGAACACCTTCTCAAGAGGAGTTTTCTTAGACACCATCCTTCCCCGTCAAGATGACAATGGCGTCAGGCCAACCATTGGCCAGCGCGTGCGGCTCAGTCAGGGAGACATAGCTCAAGCCCGGAAGCTGTACAAATGCCCAGCGTGTGGGGAGACCCTGCAGGACACAACGGGAAACTTTTCTGCACCTGGTTTCCCAAATGGGTACCCATCTTACTCCCACTGCGTCTGGAGGATCTCGGTCACCCCAGGGGAAAAGATCGTATTAAACTTCACATCCATGGATTTGTTTAAAAGCCGACTGTGCTGGTATGATTACGTGGAGGTCCGGGATGGTTACTGGAGAAAAGCCCCCCTTTTGGGCAGGTTTTGTGGCGATAAGATCCCGGAGCCCCTCGTCTCCACGGACAGCCGGCTCTGGGTGGAGTTCCGCAGCAGCAGCAACATCTTGGGCAAGGGCTTCTTTGCAGCGTACGAAGCTACCTGCGGGGGAGACATGAACAAAGATGCCGGTCAGATTCAATCTCCCAACTATCCGGATGACTACAGACCTTCCAAGGAATGTGTCTGGAGGATTACGGTTTCGGAGGGGTTTCACGTGGGACTTACCTTCCAAGCTTTTGAGATTGAAAGGCACGACAGCTGTGCATATGACTACCTGGAAGTCCGGGATGGCCCCACGGAAGAGAGTGCCCTGATCGGCCACTTTTGTGGCTATGAGAAGCCGGAGGATGTGAAATCGAGCTCCAACAGACTGTGGATGAAGTTTGTGTCCGATGGCTCTATCAATAAAGCGGGCTTTGCAGCCAATTTTTTCAAGGAGGTGGATGAGTGTTCCTGGCCAGATCACGGCGGGTGCGAACATCGCTGTGTGAACACGCTGGGCAGCTACAAGTGTGCCTGTGACCCTGGCTACGAGCTGGCCGCCGATAAGAAGATGTGTGAAGTGGCCTGTGGCGGTTTCATTACCAAGCTGAATGGAACCATCACCAGCCCTGGGTGGCCGAAGGAGTATCCCACAAACAAAAACTGTGTCTGGCAGGTGGTGGCCCCCGCTCAGTACCGGATCTCCCTTCAGTTTGAAGTGTTTGAACTGGAAGGCAATGACGTCTGTAAGTACGACTTTGTAGAGGTGCGCAGCGGCCTGTCCCCCGACGCCAAGCTGCACGGCAGGTTCTGCGGCTCTGAGACGCCGGAAGTCATCACCTCGCAGAGCAACAACATGCGCGTGGAGTTCAAGTCCGACAACACCGTCTCCAAGCGCGGCTTCAGGGCCCACTTCTTCTCAGATAAGGACGAGTGTGCCAAGGACAACGGCGGGTGTCAGCATGAGTGCGTCAACACCTTCGGGAGCTACCTGTGCAGGTGCAGAAACGGCTACTGGCTCCACGAGAATGGGCATGACTGCAAAGAGGCTGGCTGTGCACACAAGATCAGCAGTGTGGAGGGGACCCTGGCGAGCCCCAACTGGCCTGACAAATACCCCAGCCGGAGGGAGTGTACCTGGAACATCTCTTCGACTGCAGGCCACAGAGTAAAACTCAGTGCGGGGTCAGGCTGAAGGCTGAAGTGCAGACCAAAGAGCTCTATTCCCACGCCCAGTTTGGGGACAACAACTACCCGAGCGAGGCCCACTGTGACTGGGTGATCGTGGCAGAGGACGGCTACGGCGTGGAGCTGACATTCCGGACCTTTGAGGTTGAGGAGGAGGCCGACTGCGGCTACGACTACATGGAAGCCTACGACGGCTACGACAGCTCAGCGCCCAGGCTCGGCCGCTTCTGTGGCTCTGGGCCATTAGAAGAAATCTACTCTGCAGGTGATTCCCTGATGATTCGATTCCGCACAGATGACACCATCAACAAGAAAGGCTTTCATGCCCGATACACCAGCACCAAGTTCCAGGATGCCCTGCACATGAAGAAATAGTGCTGATGTTCTTGAAAGACAGAAACTGAGANOV8h, SNP13377386 ofMW at 91404.2kDCG50235-04, Protein SequenceSEQ ID NO: 100821 aaSNP Change: no changeMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVAHELGHVVGFWHEHTRPDRDQHVTIIRENIOPGQEYNFLKMEAGEVSSLGETYDFDSIMHYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFEIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFAANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTITSPGWPKEYPTNKNCVWQVVAPAQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTNNISSTAGHRVKLSAGSGSEQ ID NO: 1013120 bpNOV8i, SNP13377387 ofORF Start: ATG at 256ORF Stop: TGA at 2719CG50235-04, DNA SequenceSNP Pos: 2983SNP Change: A to GTAACCTGTCTCACGACGGTCTAAACCCAGGCAGCCTCGGCCGCCGGGCAAGTAGCTCCGAGCGGCTGCTTCCCGGTTGCCTCGAAGAAGACAGGGGGCGCCGCGCTCCGCTTGCTCCGCGCCTGAGCCATGCCCAGCAGCCCTGTGTAACCACCGAGTCCCGGCCGGAGCCGACCGACCCAGTGTGCGCCGTCTTTCGGCCGAGCTGAGCTTTCGTGCACGCAACTCCCTCTGCCCCAGCCGGCCCCGCGCCACCATGCCCCGGGCGACTGCACTTGGGGCCCTGGTGTCACTGCTGCTGCTGCTGCCGCTGCCTCGCGGCGCCGGGGGACTCGGGGAGCGCCCGGACGCCACCGCAGACTACTCAGAGCTGGACGGCGAGGAGGGCACGGAGCAGCAGCTGGAGCATTACCACGACCCTTGCAAAGCCGCTGTCTTTTGGGGAGACATTGCCTTAGATGAAGATGACTTGAAGCTGTTTCACATTGACAAAGCCAGAGACTGGACCAAGCAGACAGTGGGGGCAACAGGACACAGCACAGGTGGGCTTGAAGAGCAGGCATCTGAGAGCAGCCCAGACACCACAGCCATGGACACTGGCACCAAGGAAGCTGGAAAGGATGGCCGGGAGAATACCACACTCCTGCACAGCCCTGGGACCTTGCATGCCGCAGCCAAGACCTTCTCTCCCCGGGTCCGAAGAGCCACAACCTCAAGGACAGAGAGGATATGGCCTGGAGGAGTCATCCCCTACGTCATTGGAGGGAACTTCACTGGGAGCCAGAGGGCCATTTTTAAGCAGGCCATGAGACACTGGGAGAAGCACACCTGTGTGACCTTCATAGAAAGGACGGATGAGGAAAGCTTTATTGTATTCAGTTACAGAACCTGTGGCTGTTGCTCCTATGTTGGGCGCCGAGGAGGAGGCCCACAGGCCATATCCATTGGGAAGAACTGTGACAAGTTTGGCATTGTGGCTCACGAGCTGGGCCATGTGGTTGGGTTTTGGCATGAACACACCCGGCCAGACAGAGACCAACATGTCACCATCATCAGGGAAAACATCCAGCCAGGTCAGGAGTATAATTTCTTAAAAATGGAAGCTGGGGAAGTGAGCTCTCTGGGAGAGACATACGACTTTGACAGCATCATGCACTACGCCCGGAACACCTTCTCAAGAGGAGTTTTCTTAGACACCATCCTTCCCCGTCAAGATGACAATGGCGTCAGGCCAACCATTGGCCAGCGCGTGCGGCTCAGTCAGGGAGACATAGCTCAAGCCCGGAAGCTGTACAAATGCCCAGCGTGTGGGGAGACCCTGCAGGACACAACGGGAAACTTTTCTGCACCTGGTTTCCCAAATGGGTACCCATCTTACTCCCACTGCGTCTGGAGGATCTCGGTCACCCCAGGGGAAAAGATCGTATTAAACTTCACATCCATGGATTTGTTTAAAAGCCGACTGTGCTGGTATGATTACGTGGAGGTCCGGGATGGTTACTGGAGAAAAGCCCCCCTTTTGGGCAGGTTTTGTGGCGATAAGATCCCGGAGCCCCTCGTCTCCACGGACAGCCGGCTCTGGGTGGAGTTCCGCAGCAGCAGCAACATCTTGGGCAAGGGCTTCTTTGCAGCGTACGAAGCTACCTGCGGGGGAGACATGAACAAAGATGCCGGTCAGATTCAATCTCCCAACTATCCGGATGACTACAGACCTTCCAAGGAATGTGTCTGGAGGATTACGGTTTCGGAGGGGTTTCACGTGGGACTTACCTTCCAAGCTTTTGAGATTGAAAGGCACGACAGCTGTGCATATGACTACCTGGAAGTCCGGGATGGCCCCACGGAAGAGAGTGCCCTGATCGGCCACTTTTGTGGCTATGAGAAGCCGGAGGATGTGAAATCGAGCTCCAACAGACTGTGGATGAAGTTTGTGTCCGATGGCTCTATCAATAAAGCGGGCTTTGCAGCCAATTTTTTCAAGGAGGTGGATGAGTGTTCCTGGCCAGATCACGGCGGGTGCGAACATCGCTGTGTGAACACGCTGGGCAGCTACAAGTGTGCCTGTGACCCTGGCTACGAGCTGGCCGCCGATAAGAAGATGTGTGAAGTGGCCTGTGGCGGTTTCATTACCAAGCTGAATGGAACCATCACCAGCCCTGGGTGGCCGAAGGAGTATCCCACAAACAAAAACTGTGTCTGGCAGGTGGTGGCCCCCGCTCAGTACCGGATCTCCCTTCAGTTTGAAGTGTTTGAACTGGAAGGCAATGACGTCTGTAAGTACGACTTTGTAGAGGTGCGCAGCGGCCTGTCCCCCGACGCCAAGCTGCACGGCAGGTTCTGCGGCTCTGAGACGCCGGAAGTCATCACCTCGCAGAGCAACAACATGCGCGTGGAGTTCAAGTCCGACAACACCGTCTCCAAGCGCGGCTTCAGGGCCCACTTCTTCTCAGATAAGGACGAGTGTGCCAAGGACAACGGCGGGTGTCAGCATGAGTGCGTCAACACCTTCGGGAGCTACCTGTGCAGGTGCAGAAACGGCTACTGGCTCCACGAGAATGGGCATGACTGCAAAGAGGCTGGCTGTGCACACAAGATCAGCAGTGTGGAGGGGACCCTGGCGAGCCCCAACTGGCCTGACAAATACCCCAGCCGGAGGGAGTGTACCTGGAACATCTCTTCGACTGCAGGCCACAGAGTAAAACTCAGTGCGGGGTCAGGCTGAAGGCTGAAGTGCAGACCAAAGAGCTCTATTCCCACGCCCAGTTTGGGGACAACAACTACCCGAGCGAGGCCCGCTGTGACTGGGTGATCGTGGCAGAGGACGGCTACGGCGTGGAGCTGACATTCCGGACCTTTGAGGTTGAGGAGGAGGCCGACTGCGGCTACGACTACATGGAAGCCTACGACGGCTACGACAGCTCAGCGCCCAGGCTCGGCCGCTTCTGTGGCTCTGGGCCATTAGAAGAAATCTACTCTGCAGGTGGTTCCCTGATGATTCGATTCCGCACAGATGACACCATCAACAAGAAAGGCTTTCATGCCCGATACACCAGCACCAAGTTCCAGGATGCCCTGCACATGAAGAAATAGTGCTGATGTTCTTGAAAGACAGAAACTGAGANOV8i, SNP13377387 ofMW at 91404.2kDCG50235-04, Protein SequenceSEQ ID NO: 102821 aaSNP Change: no changeMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGKDGREMTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFKQANRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFEIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFAANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTITSPGWPKEYPTNKNCVWQVVAPAQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTAGHRVKLSAGSG

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 8B.

TABLE 8BComparison of the NOV8 protein sequences.NOV8aMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVNOV8bMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVNOV8cMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVNOV8dMPRATALGALVSLLLLLPLPRGAGGLGERPDATADYSELDGEEGTEQQLEHYHDPCKAAVNOV8aFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGNOV8bFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGNOV8CFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGNOV8dFWGDIALDEDDLKLFHIDKARDWTKQTVGATGHSTGGLEEQASESSPDTTAMDTGTKEAGNOV8aKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFNOV8bKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFNOV8cKDGRENTTLLHSPGTLHAAAKTFSPRVRRATTSRTERIWPGGVIPYVIGGNFTGSQRAIFNOV8dK----------------------------------------------------GSQRAIFNOV8aKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVNOV8bKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVNOV8cKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVNOV8dKQAMRHWEKHTCVTFIERTDEESFIVFSYRTCGCCSYVGRRGGGPQAISIGKNCDKFGIVNOV8aAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHNOV8bAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHNOV8cAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHNOV8dAHELGHVVGFWHEHTRPDRDQHVTIIRENIQPGQEYNFLKMEAGEVSSLGETYDFDSIMHNOV8aYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCP-----------NOV8bYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCP-----------NOV8cYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCP-----------NOV8dYARNTFSRGVFLDTILPRQDDNGVRPTIGQRVRLSQGDIAQARKLYKCPGPTCAFVSQKTNOV8a-------------------ACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVNOV8b-------------------ACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVNOV8c-------------------ACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVNOV8dSICLLHFSPTCSEGFGWQRACGETLQDTTGNFSAPGFPNGYPSYSHCVWRISVTPGEKIVNQV8aLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNNOV8bLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNNOV8cLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNNOV8dLNFTSMDLFKSRLCWYDYVEVRDGYWRKAPLLGRFCGDKIPEPLVSTDSRLWVEFRSSSNNOV8aILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFENOV8bILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFENOV8cILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFENOV8dILGKGFFAAYEATCGGDMNKDAGQIQSPNYPDDYRPSKECVWRITVSEGFHVGLTFQAFENOV8aIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFANOV8bIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFANOV8cIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFANOV8dIERHDSCAYDYLEVRDGPTEESALIGHFCGYEKPEDVKSSSNRLWMKFVSDGSINKAGFANOV8aANFFKEVDECSWPDHGGCENRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTNOV8bANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTNOV8cANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTNOV8dANFFKEVDECSWPDHGGCEHRCVNTLGSYKCACDPGYELAADKKMCEVACGGFITKLNGTNOV8aITSPGWPKEYPTMKNCVWQVVAPAQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLNOV8bITSPGWPKEYPTNKNCVWQVVAPTQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLNOV8cITSPGWPKEYPTNKNCVWQVVAPAQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLNOV8dITSPGWPKEYPTNKNCVWQVVAPTQYRISLQFEVFELEGNDVCKYDFVEVRSGLSPDAKLNOV8aHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTNOV8bHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTNOV8cHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTNOV8dHGRFCGSETPEVITSQSNNMRVEFKSDNTVSKRGFRAHFFSDKDECAKDNGGCQHECVNTNOV8aFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTANOV8bFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTANOV8cFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTANovadFGSYLCRCRNGYWLHENGHDCKEAGCAHKISSVEGTLASPNWPDKYPSRRECTWNISSTANOV8aGHRVKLSAGSG-------------------------------------------------NOV8bGHRVKLTFNEFEIEQHQECAYDHLEMYDGPDSLAPILGRFCGSKKPDPTVASGSKCGGRLNOV8cGHRVKLTFNEFEIEQHQECAYDHLEMYDGPDSLAPILGRFCGSKKPDPTVASGSSMFLRFNOV8dGHRVKLTFNEFEIEQHQECAYDHLEMYDGPDSLAPILGRFCGSKKPDPTVASGSKCGGRLNOV8a------------------------------------------------------------NOV8bKAEVQTKELYSHAQFGDNNYPSEARCDWVIVAEDGYGVELTFRTFEVEEEADCGYDYMEANOV8cYSDASVQRKGFQAVIISTECGGRLKAEVQTKELYSHAQFGDNNYPSEARCDWVIVAEDGYGNOV8dKAEVQTKELYSHAQFGDNNYPSEARCDWVIVAEDGYGVELTFRTFEVEEEADCGYDYMEANOV8a------------------------------------------------------------NOV8bYDGYDSSAPRLGRFCGSGPLEEIYSAGDSLMIRFRTDDTINKKGFHARYTSTKFQDGLHMNOV8cVELTFRTFEVEEEADCGYDYMEAYDGYDSSAPRLGRFCGSGPLEEIYSAGDSLMIRFRTDNOV8dYDGYDSSAPRLGRFCGSGPLEEIYSAGDSLMIRFRTDDTINKKGFHARYTSTKFQDALHMNOV8a-------------------------NOV8bKK-----------------------NOV8cDTINKKGFHARYTSTKFQDALHMKKNOV8dKK-----------------------NOV8a(SEQ ID NO: 86)NOV8b(SEQ ID NO: 88)NOV8c(SEQ ID NO: 90)NOV8d(SEQ ID NO: 92)

Further analysis of the NOV8a protein yielded the following properties shown in Table 8C.

TABLE 8CProtein Sequence Properties NOV8aSigna1P analysis: Cleavage site between residues 26 and 27PSORT II analysis:PSG: a new signal peptide prediction method N-region: length 3; pos. chg 1; neg. chg 0 H-region: length 17; peak value 10.45 PSG score: 6.05GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): 4.44 possible cleavage site: between 25 and 26>>> Seems to have a cleavable signal peptide (1 to 25)ALOM: Klein et al's method for TM region allocation Init position for calculation: 26 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 6.31 (at 203) ALOM score: 6.31 (number of TMSs: 0)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 12 Charge difference: −3.0 C(−1.0) − N( 2.0) N >= C: N-terminal side will be insideMITDISC: discrimination of mitochondrial targeting seq R content: 2 Hyd Moment(75): 7.80 Hyd Moment(95): 7.61G content: 5 DIE content: 1 S/T content: 2 Score: −4.54Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 31 PRG|AGNUCDISC: discrimination of nuclear localization signals pat4: none pat7: PRVRRAT (5) at 145 bipartite: none content of basic residues: 11.2% NLS Score: −0.04KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: XXRR-like motif in the N-terminus: PRATnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 76.7COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues--------------------------Final Results (k = 9/23) 33.3%: extracellular, including cell wall 22.2%: Golgi 22.2%: vacuolar 11.1%: mitochondrial 11.1%: endoplasmic reticulum>> predictionfor CG50235-04 is exc (k=9)

A search of the NOV8a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8D.

TABLE 8DGeneseq Results for NOV8aNOV8aIdentifies/Residues/Similarities forGenesqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #,Date]ResiduesRegionValueAAY32240Human tolloid-like protein 1 . . . 817816/817 (99%)0.0mT11-2 - Homo sapiens, 1015 1 . . . 817817/817 (99%)aa. [WO9951730-A2, 14-OCT-1999]ABG79187Human tolloid-like 2-like protein 1 . . . 817815/817 (99%)0.0#1 - Homo sapiens, 992 aa. 1 . . . 817816/817 (99%)[WO200264791-A2, 22-AUG-2002]ABG79188Human tolloid-like 2-like protein 1 . . . 817763/847 (90%)0.0#2 - Homo sapiens, 970 aa. 1 . . . 795764/847 (90%)[WO200264791 -A2, 22-AUG-2002]AAY32241Mouse tolloid-like protein mT11- 1 . . . 817728/817 (89%)0.02-Mus musculus, 1012 aa. 1 . . . 814759/817(92%)[WO9951730-A2, 14-OCT-1999]AAW40224Human tolloid-like (T11) protein -35 . . . 817584/783 (74%)0.0Homo sapiens, 1013 aa.34 . . . 815666/783 (84%)[WO9745528-A2, 04-DEC-1997]

In a BLAST search of public sequence databases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8E.

TABLE 8EPublic BLASTP Results for NOV8aIdentities/NOV8aSimilaritiesProteinResidues/for theAccessionProtein/MatchMatchedExpectNumberOrganism/LengthResiduesPortionValueQ9Y6L7Tolloid-like 2 protein - 1 . . . 817816/8170.0Homo sapiens 1 . . . 817(99%)(Human), 1015 aa.817/817(99%)Q9WVM6Tolloid-like-2 protein - 1 . . . 817728/8170.0Mus musculus 1 . . . 814(89%)(Mouse), 1012 aa.759/817(92%)Q9UQ00Hypothetical protein90 . . . 817726/7280.0KIAA0932 - Homo 1 . . . 728(99%)sapiens (Human), 926727/728aa (fragment).(99%)O57382Xolloid - Xenopus52 . . . 816596/7680.0laevis (African clawed52 . . . 819(77%)frog), 1019 aa.680/768(87%)Q8J128Xolloid-like35 . . . 817597/7830.0metalloprotease -29 . . . 810(76%)Xenopus laevis679/783Africian clawed(86%)frog), 1007 aa.

PFam analysis indicates that the NOV8a protein contains the domains shown in the Table 8F.

TABLE 8FDomain Analysis of NOV8aIdentities/NOV8aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect ValueAstacin157 . . . 350100/202 (50%)9.5e-114172/202 (85%)CUB351 . . . 46050/116(43%)2.4e-5299/116 (85%)CUB464 . . . 57362/116 (53%)3.1e-6098/116 (84%)EGF580 . . . 61617/47 (36%)1.2e-0529/47 (62%)CUB620 . . . 729 57/116 (49%)4.7e-58101/116 (87%)EGF736 . . . 77118/47 (38%)7.4e-0731/47 (66%)

Example 9

The NOV9 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 9A.

TABLE 9ANOV9 Sequence AnalysisNOV9a, CG50249-01SEQ ID NO: 1031953 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAA at 1930GTCTGAGTCACAGAGATGGGCAAGATCGAGAACAACGAGAGGGTGATCCTCAATGTCGGGGGCACCCGGCACGAAACCTACCGCAGCACCCTCAAGACCCTGCCTGGAACACGCCTGGCCCTTCTTGCCTCCTCCGAGCCCCCAGGCGACTGCTTGACCACGGCGGGCGACAAGCTGCAGCCGTCGCCGCCTCCACTGTCGCCGCCGCCGAGAGCGCCCCCGCTGTCCCCCGGGCCAGGCGGCTGCTTCGAGGGCGGCGCGGGCAACTGCAGTTCCCGCGGCGGCAGGGCCAGCGACCATCCCGGTGGCGGCCGCGAGTTCTTCTTCGACCGGCACCCGGGCGTCTTCGCCTATGTGCTCAATTACTACCGCACCGGCAAGCTGCACTGCCCCGCAGACGTGTGCGGGCCGCTCTTCGAGGAGGAGCTGGCCTTCTGGGGCATCGACGAGACCGACGTGGAGCCCTGCTGCTGGATGACCTACCGGCAGCACCGCGACGCCGAGGAGGCGCTGGACATCTTCGAGACCCCCGACCTCATTGGCGGCGACCCCGGCGACGACGAGGACCTGGCGGCCAAGAGGCTGGGCATCGAGGACGCGGCGGGGCTCGGGGGCCCGGACGGCAAATCTGGCCGCTGGAGGAGGCTGCAGCCCCGCATGTGGGCCCTCTTCGAAGACCCCTACTCGTCCAGAGCCGCCAGGTTTATTGCTTTTGCTTCTTTATTCTTCATCCTGGTTTCAATTACAACTTTTTGCCTGGAAACACATGAAGCTTTCAATATTGTTAAAAACAAGACAGAACCAGTCATCAATGGCACAAGTGTTGTTCTACAGTATGAAATTGAAACGGATCCTGCCTTGACGTATGTAGAAGGAGTGTGTGTGGTGTGGTTTACTTTTGAATTTTTAGTCCGTATTGTTTTTTCACCCAATAAACTTGAATTCATCAAAAATCTCTTGAATATCATTGACTTTGTGGCCATCCTACCTTTCTACTTAGAGGTGGGACTCAGTGGGCTGTCATCCAAAGCTGCTAAAGATGTGCTTGGCTTCCTCAGGGTGGTAAGGTTTGTGAGGATCCTGAGAATTTTCAAGCTCACCCGCCATTTTGTAGGTCTGAGGGTGCTTGGACATACTCTTCGAGCTAGTACTAATGAATTTTTGCTGCTGATAATTTTCCTGGCTCTAGGAGTTTTGATATTTGCTACCATGATCTACTATGCCGAGAGAGTGGGAGCTCAACCTAACGACCCTTCAGCTAGTGAGCACACACAGTTCAAAAACATTCCCATTGGGTTCTGGTGGGCTGTAGTGACCATGACTACCCTGGGTTATGGGGATATGTACCCCCAAACATGGTCAGGCATGCTGGTGGGAGCCCTGTGTGCTCTGGCTGGAGTGCTGACAATAGCCATGCCAGTGCCTGTCATTGTCAATAATTTTGGAATGTACTACTCCTTGGCAATGGCAAAGCAGAAACTTCCAAGGAAAAGAAAGAAGCACATCCCTCCTGCTCCTCAGGCAAGCTCACCTACTTTTTGCAAGACAGAATTAAATATGGCCTGCAATAGTACACAGAGTGACACATGTCTGGGCAAAGACAATCGACTTCTGGAACATAACAGATCAGTGTTATCAGGTGACGACAGTACAGGAAGTGAGCCGCCACTATCACCCCCAGAAAGGCTCCCCATCAGACGCTCTAGTACCAGAGACAAAAACAGAAGAGGGGAAACATGTTTCCTACTGACGACAGGTGATTACACGTGTGCTTCTGATGGAGGGATCAGGAAAGGTTATGAAAAATCCCGAAGCTTAAACAACATAGCGGGCTTGGCAGGCAATGCTCTGAGGCTCTCTCCAGTAACATCACCCTACAACTCTCCTTGTCCTCTGAGGCGCTCTCGATCTCCCATCCCATCTATCTTGTAAACCAAACAACCAAACTGCATCNOV9a, CG50249-01Protein SequenceSEQ ID NO: 104638 aaMW at 70224.7kDMGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPSPPPLSPPPRAPPLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQFKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYEKSRSLNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSILNOV9b, 207885588SEQ ID NO: 1051815 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAGATCTCCCACCATGGGCAAGATCGAGAACAACGAGAGGGTGATCCTCAATGTCGGGGGCACCCGGCACGAAACCTACCGCAGCACCCTCAAGACCCTGCCTGGAACACGCCTGGCCCTTCTTGCCTCCTCCGAGCCCCCAGGCAACTGCAGTTCCCGCGGCGGCAGGGCCAGCGACCATCCCGGTGGCGGCCGCGAGTTCTTCTTCGACCGGCACCCGGGCGTCTTCGCCTATGTGCTCAATTACTACCGCACCGGCAAGCTGCACTGCCCCGCAGACGTGTGCGGGCCGCTCTTCGAGGAGGAGCTGGCCTTCTGGGGCATCGACGAGACCGACGTGGAGCCCTGCTGCTGGATGACCTACCGGCAGCACCGCGACGCCGAGGAGGCGCTGGACATCTTCGAGACCCCCGACCTCATTGGCGGCGACCCCGGCGACGACGAGGACCTGGCGGCCAAGAGGCTGGGCATCGAGGACGCGGCGGGGCTCGGGGGCCCCGACGGCAAATCTGGCCGCTGGAGGAGGCTGCAGCCCCGCATGTGGGCCCTCTTCGAAGACCCCTACTCGTCCAGAGCCGCCAGGTTTATTGCTTTTGCTTCTTTATTCTTCATCCTGGTTTCAATTACAACTTTTTGCCTGGAAACACATGAAGCTTTCAATATTGTTAAAAACAAGACAGAACCAGTCATCAATGGCACAAGTGTTGTTCTACAGTATGAAATTGAAACGGATCCTGCCTTGACGTATGTAGAAGGAGTGTGTGTGGTGTGGTTTACTTTTGAATTTTTAGTCCGTATTGTTTTTTCACCCAATAAACTTGAATTCATCAAAAATCTCTTGAATATCATTGACTTTGTGGCCATCCTACCTTTCTACTTAGAGGTGGGACTCAGTGGGCTGTCATCCAAAGCTGCTAAAGATGTGCTTGGCTTCCTCAGGGTGGTAAGGTTTGTGAGGATCCTGAGAATTTTCAAGCTCACCCGCCATTTTGTAGGTCTGAGGGTGCTTGGACATACTCTTCGAGCTAGTACTAATGAATTTTTGCTGCTGATAATTTTCCTGGCTCTAGGAGTTTTGATATTTGCTACCATGATCTACTATGCCGAGAGAGTGGGAGCTCAACCTAACGACCCTTCAGCTAGTGAGCACACACAGTTCAAAAACATTCCCATTGGGTTCTGGTGGGCTGTAGTGACCATGACTACCCTGGGTTATGAGGATACGTACCCCCAAACATGGTCAGGCATGCTGGTGGGAGCCCTGTGTGCTCTGGCTGGAGTGCTGACAATAGCCATGCCAGTGCCTGTCATTGTCAATAATTTTGGAATGTACTACTCCTTGGCAATGGCAAAGCAGAAACTTCCAAGGAAAAGAAAGAAGCACATCCCTCCTGCTCCTCAGGCAAGCTCACCTACTTTTTGCAAGACAGAATTAAATATGGCCTGCAATAGTACACAGAGTGACACATGTCTGGGCAAAGACAATCGACTTCTGGAACATAACAGATCAGTGTTATCAGGTGACGACAGTACAGGAAGTGAGCCGCCACTATCACCCCCAGAAAGGCTCCCCATCAGACGCTCTAGTACCAGAGACAAAAACAGAAGAGGGGAAACATGTTTCCTACTGACGACAGGTGATTACACGTGTGCTTCTGATGGAGGGATCAGGAAAGGATATGAAAAATCCCGAAGCTTAAACAACATAGCGGGCTTGGCAGGCAATGCTCTGAGGCTCTCTCCAGTAACATCACCCTACAACTCTCCTTGTCCTCTGAGGCGCTCTCGATCTCCCATCCCATCTATCTTGCTCGAGNOV9b, 207885588Protein SequenceSEQ ID NO: 106605 aaMW at 67228.3kDRSPTMGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQFKNIPIGFWWAVVTMTTLGYEDTYPQTWSGMLVGALCALAGVLTIANPVPVIVNNFGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYEKSRSLNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSILLENOV9c, CG50249-02SEQ ID NO: 107607 bpDNA SequenceORF Start: ATG at 13ORF Stop: at 604AGATTTCCCACCATGGGCAAGATCGAGAACAACGAGAGGGTGATCCTCAATGTCGGGGGCACCCGGCACGAAACCTACCGCAGCACCCTCAAGACCCTGCCTGGAACACGCCTGGCCCTTCTTGCCTCCTCCGAGCCCCCAGGCGACTGCTTGACCACAGCGGGCAACTGCAGTTCCCGCGGCGGCAGGGCCAGCGACCATCCCGGTGGCGGCCGCGAGTTCTTCTTCGACCGGCATCCGGGCGTCTTCGCCTATGTGCTCAATTACTACCGCACCGGCAAGCTGCACTGTCCCGCAGACGTGTGCGGGCCGCTCTTCGAGGAGGAGCTGGCCTTCTGGGGCATCGACGAGACCGACGTGGAGCCCTGCTGCTGGATGACCTACCGGCAGCACCGCGACGCCGAGGAGGCGCTGGACATCTTCGAGACCCCCGACCTCATTGGCGGCGACCCCGGCGACGACGAGGACCTGGCGGCCAAGAGGCTGGGCATCGAGGACGCGGCGGGGCTCGGGGGCCCCGACGGCAAATCTGGCCGCTGGAGGAGGCTGCAGCCCCGCATGTGGGCCCTCTTCGACCCCTACTCGTCCAGAGCCGCCAGGCTCGNOV9c, CG50249-02Protein SequenceSEQ ID NO: 108197 aaMW at 21779.0kDMGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARNOV9d, CG50249-03SEQ ID NO: 1091815 bpDNA SequenceORF Start: ATG at 13ORF Stop: at 1810AGATCTCCCACCATGGGCAAGATCGAGAACAACGAGAGGGTGATCCTCAATGTCGGGGGCACCCGGCACGAAACCTACCGCAGCACCCTCAAGACCCTGCCTGGAACACGCCTGGCCCTTCTTGCCTCCTCCGAGCCCCCAGGCAACTGCAGTTCCCGCGGCGGCAGGGCCAGCGACCATCCCGGTGGCGGCCGCGAGTTCTTCTTCGACCGGCACCCGGGCGTCTTCGCCTATGTGCTCAATTACTACCGCACCGGCAAGCTGCACTGCCCCGCAGACGTGTGCGGGCCGCTCTTCGAGGAGGAGCTGGCCTTCTGGGGCATCGACGAGACCGACGTGGAGCCCTGCTGCTGGATGACCTACCGGCAGCACCGCGACGCCGAGGAGGCGCTGGACATCTTCGAGACCCCCGACCTCATTGGCGGCGACCCCGGCGACGACGAGGACCTGGCGGCCAAGAGGCTGGGCATCGAGGACGCGGCGGGGCTCGGGGGCCCCGACGGCAAATCTGGCCGCTGGAGGAGGCTGCAGCCCCGCATGTGGGCCCTCTTCGAAGACCCCTACTCGTCCAGAGCCGCCAGGTTTATTGCTTTTGCTTCTTTATTCTTCATCCTGGTTTCAATTACAACTTTTTGCCTGGAAACACATGAAGCTTTCAATATTGTTAAAAACAAGACAGAACCAGTCATCAATGGCACAAGTGTTGTTCTACAGTATGAAATTGAAACGGATCCTGCCTTGACGTATGTAGAAGGAGTGTGTGTGGTGTGGTTTACTTTTGAATTTTTAGTCCGTATTGTTTTTTCACCCAATAAACTTGAATTCATCAAAAATCTCTTGAATATCATTGACTTTGTGGCCATCCTACCTTTCTACTTAGAGGTGGGACTCAGTGGGCTGTCATCCAAAGCTGCTAAAGATGTGCTTGGCTTCCTCAGGGTGGTAAGGTTTGTGAGGATCCTGAGAATTTTCAAGCTCACCCGCCATTTTGTAGGTCTGAGGGTGCTTGGACATACTCTTCGAGCTAGTACTAATGAATTTTTGCTGCTGATAATTTTCCTGGCTCTAGGAGTTTTGATATTTGCTACCATGATCTACTATGCCGAGAGAGTGGGAGCTCAACCTAACGACCCTTCAGCTAGTGAGCACACACAGTTCAAAAACATTCCCATTGGGTTCTGGTGGGCTGTAGTGACCATGACTACCCTGGGTTATGAGGATACGTACCCCCAAACATGGTCAGGCATGCTGGTGGGAGCCCTGTGTGCTCTGGCTGGAGTGCTGACAATAGCCATGCCAGTGCCTGTCATTGTCAATAATTTTGGAATGTACTACTCCTTGGCAATGGCAAAGCAGAAACTTCCAAGGAAAAGAAAGAAGCACATCCCTCCTGCTCCTCAGGCAAGCTCACCTACTTTTTGCAAGACAGAATTAAATATGGCCTGCAATAGTACACAGAGTGACACATGTCTGGGCAAAGACAATCGACTTCTGGAACATAACAGATCAGTGTTATCAGGTGACGACAGTACAGGAAGTGAGCCGCCACTATCACCCCCAGAAAGGCTCCCCATCAGACGCTCTAGTACCAGAGACAAAAACAGAAGAGGGGAAACATGTTTCCTACTGACGACAGGTGATTACACGTGTGCTTCTGATGGAGGGATCAGGAAAGGATATGAAAAATCCCGAAGCTTAAACAACATAGCGGGCTTGGCAGGCAATGCTCTGAGGCTCTCTCCAGTAACATCACCCTACAACTCTCCTTGTCCTCTGAGGCGCTCTCGATCTCCCATCCCATCTATCTTGCTCGAGNOV9d, CG50249-03Protein SequenceSEQ ID NO: 110599 aaMW at 66544.6kDMGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQFKNIPIGFWWAVVTMTTLGYEDTYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYEKSRSLNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSILNOV9e, CG50249-04SEQ ID NO: 1113028 bpDNA SequenceORF Start: ATG at 22ORF Stop: TAA at 1861AGTCATGTCTGAGTCACAGAGATGGGCAAGATCGAGAACAACGAGAGGGTGATCCTCAATGTCGGGGGCACCCGGCACGAAACCTACCGCAGCACCCTCAAGACCCTGCCTGGAACACGCCTGGCCCTTCTTGCCTCCTCCGAGCCCCCAGGCGACTGCTTGACCACGGCGGGCGACAAGCTGCAGCCGTCGCCGCCTCCACTGTCGCCGCCGCCGAGAGCGCCCCCGCTGTCCCCCGGGCCAGGCGGCTGCTTCGAGGGCGGCGCGGGCAACTGCAGTTCCCGCGGCGGCAGGGCCAGCGACCATCCCGGTGGCGGCCGCGAGTTCTTCTTCGACCGGCACCCGGGCGTCTTCGCCTATGTGCTCAATTACTACCGCACCGGCAAGCTGCACTGCCCCGCAGACGTGTGCGGGCCGCTCTTCGAGGAGGAGCTGGCCTTCTGGGGCATCGACGAGACCGACGTGGAGCCCTGCTGCTGGATGACCTACCGGCAGCACCGCGACGCCGAGGAGGCGCTGGACATCTTCGAGACCCCCGACCTCATTGGCGGCGACCCCGGCGACGACGAGGACCTGGCGGCCAAGAGGCTGGGCATCGAGGACGCGGCGGGGCTCGGGGGCCCCGACGGCAAATCTGGCCGCTGGAGGAGGCTGCAGCCCCGCATGTGGGCCCTCTTCGAAGACCCCTACTCGTCCAGAGCCGCCAGGTTTATTGCTTTTGCTTCTTTATTCTTCATCCTGGTTTCAATTACAACTTTTTGCCTGGAAACACATGAAGCTTTCAATATTGTTAAAAACAAGACAGAACCAGTCATCAATGGCACAAGTGTTGTTCTACAGTATGAAATTGAAACGGATCCTGCCTTGACGTATGTAGAAGGAGTGTGTGTGGTGTGGTTTACTTTTGAATTTTTAGTCCGTATTGTTTTTTCACCCAATAAACTTGAATTCATCAAAAATCTCTTGAATATCATTGACTTTGTGGCCATCCTACCTTTCTACTTAGAGGTGGGACTCAGTGGGCTGTCATCCAAAGCTGCTAAAGATGTGCTTGGCTTCCTCAGGGTGGTAAGGTTTGTGAGGATCCTGAGAATTTTCAAGCTCACCCGCCATTTTGTAGGTCTGAGGGTGCTTGGACATACTCTTCGAGCTAGTACTAATGAATTTTTGCTGCTGATAATTTTCCTGGCTCTAGGAGTTTTGATATTTGCTACCATGATCTACTATGCCGAGAGAGTGGGAGCTCAACCTAACGACCCTTCAGCTAGTGAGCACACACAGTTCAAAAACATTCCCATTGGGTTCTGGTGGGCTGTAGTGACCATGACTACCCTGGGTTATGGGGATATGTACCCCCAAACATGGTCAGGCATGCTGGTGGGAGCCCTGTGTGCTCTGGCTGGAGTGCTGACAATAGCCATGCCAGTGCCTGTCATTGTCAATAATTTTGGAATGTACTACTCCTTGGCAATGGCAAAGCAGAAACTTCCAAGGAAAAGAAAGAAGCACATCCCTCCTGCTCCTCAGGCAAGCTCACCTACTTTTTGCAAGACAGAATTAAATATGGCCTGCAATAGTACACAGAGTGACACATGTCTGGGCAAAGACAATCGACTTCTGGAACATAACAGATCAGTGTTATCAGGTGACGACAGTACAGGAAGTGAGCCGCCACTATCACCCCCAGAAAGGCTCCCCATCAGACGCTCTAGTACCAGAGACAAAAACAGAAGAGGGGAAACATGTTTCCTACTGACGACAGGTGATTACACGTGTGCTTCTGATGGAGGGATCAGGAAACATAACTGCAAAGAGGTTGTCATTACTGGTTACACGCAAGCCGAGGCCAGATCTCTTACTTAATGACTTGGGGGAAGGCACAAAACATGAGAGAAAGTGTTGTACAGAATTTATCATGGATTATTGACTGCTGAGAAAGGGACAGTGGAATTTAGCCATACAAAGGACTATACTGGAAACAGACTTCTGCTGCTGAATGTGCCCTGATGTGACCAGGTTGCACTTGGAAGAGATCCTCCGCGTCTTCATGAGGCACTTAAAGCTTATAAAAGAACTGCGGCTGGAACTCATCTGGTGCTCCCCATGAGAGTGCTCTGCTTGTAGACTGGCCAGTGTCCATGAAACAACTGTAAATACCAACATGTGTGCATGGGTCAACAGTCTTGGCCATTTCTCATCAAAAGAAGCCAAATTCATGATCAACATCTCTGAAGTTTCAAGTAAGGCCCACACTTCTTTGAATTACTCTTCATGGGCCCACATTAGGTTGTGCTGTGAATTACTTAAGGCAGTGATACTGATGTAGTATAGTTTTGTCTTAATTTCCCTTATTTCTACTTCTTTGGTTGAATCTATGAACTTGATTGTATAATTTTCTTATAAATTACTGATGTAATCAGCTTGTCAATTATGTTGTGAAATTGTTAGTATTCATTTATCAAAAATGACCTATGTTTAGTCACATATTTGTTTAGTTCTGGGAAATTGTTATAGCTTAAATGGAACTCACCAACATTATTCATAGTTTAAGTCTTTTATCATTATTACCTCAATTATAAATATTACAAAAACATAATTCTGGCAATGAGAGTATTTTTTTATTCAATGATCAAGGAGCAATGTCAGTATATAGTAGAATATCAATTAAATTATATCCTAAAATGTATATTTTGCATAAAAGAGATATTCTTTAATCAATTACTTTTTTGTGAGTTTTGTGGCGAATGAAGCTTGTACGTGTCTTTAAAACTGTTGTAGATGAAACTGTATAAGATTTTTACATCTTGCTTAATCAATATTTTCAGAGTCTATTAGTTCCCCTGGGATTCTGAATATAACATATAGCCTATTATAAATCCCTGTATCGTGGACCTTTTGTGAACATTTCAAGGCGCATGCACAACCTTGATGATAACCAGTGGAAATGTAACTAACTGAAATGAAGAATAAAAGGCAAATGAGCTGGGGATAAACTTGAATGTTATCTGATTAAATTACTCAAATTATTNOV9e, CG50249-04Protein SequenceSEQ ID NO: 112613 aaMW at 67598.7kDMGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPSPPPLSPPPRAPPLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQFKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKDNCKEVVITGYTQAEARSLT

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 9B.

TABLE 9BComparison of the NOV9 protein sequences.NOV9a----MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPNOV9bRSPTMGKIENNERVILNVGGTRHETYRSTLKLPGTRRLALLSSEPPG------------NOV9c----MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTA------NOV9d----MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPG------------NOV9e----MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPNOV9aSPPPLSPPPRAPPLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNNOV9b---------------------------NCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNNOV9c--------------------------GNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNNOV9d---------------------------NCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNNQV9eSPPPLSPPPRAPPLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNNOV9aYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGNOV9bYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGNOV9cYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGNOV9dYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGNOV9eYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGNOV9aGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLNOV9bGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLNOV9cGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLNOV9dGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLNOV9eGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLNOV9aFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFENOV9bFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFENOV9c------------------------------------------------------------NOV9dFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFENOV9eFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFENOV9aFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILNOV9bFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILNOV9c------------------------------------------------------------NOV9dFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILNOV9eFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILNOV9aRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASNOV9bRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASNOV9c------------------------------------------------------------NOV9dRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASNOV9eRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASNOV9aEHTQFKNIPIGFWWAVVTMTTLGYEDTYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFNOV9bEHTQFKNIPIGFWWAVVTMTTLGYEDTYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFNOV9c------------------------------------------------------------NOV9dEHTQFKNIPIGFWWAVVTMTTLGYEDTYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFNOV9eEHTQFKNIPIGFWWAVVTMTTLGYEDTYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFNOV9aGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNNOV9bGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNNOV9c------------------------------------------------------------NOV9dGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNNOV9eGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNNOV9aRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYENOV9bRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYENOV9c------------------------------------------------------------NOV9dRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYENOV9eRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYENOV9aKSRSLNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSIL--NOV9bKSRSLNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSILLENOV9c--------------------------------------------NOV9dKSRSLNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSIL--NOV9eKEVVITGYTQAEARSLT---------------------------NOV9a(SEQ ID NO: 104)NOV9b(SEQ ID NO: 106)NOV9c(SEQ ID NO: 108)NOV9d(SEQ ID NO: 110)NOV9e(SEQ ID NO: 112)

Further analysis of the NOV9a protein yielded the following properties shown in Table 9C.

TABLE 9CProtein Sequence Properties NOV9aSigna1P analysis: No Known Signal Sequence IndicatedPSORT II analysis:PSG: a new signal peptide prediction method N-region: length 9; pos. chg 2; neg. chg 2 H-region: length 8; peak value 4.97 PSG score: 0.57GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −3.54 possible cleavage site: between 46 and 47>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 6 INTEGRAL Likelihood = −6.90 Transmembrane 230-246 INTEGRAL Likelihood = −3.24 Transmembrane 287-303 INTEGRAL Likelihood = −2.23 Transmembrane 314-330 INTEGRAL Likelihood = −0.16 Transmembrane 343-359 INTEGRAL Likelihood = −13.00 Transmembrane 382-398 INTEGRAL Likelihood = −7.01 Transmembrafle 451-467 PERIPHERAL Likelihood = 3.61 (at 424) ALOM score: −13.00 (number of TMSs: 6)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 237 Charge difference: −0.5 C(−0.5) − N( 0.0) N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment (75) : 5.56 Hyd Moment (95): 3.52G content: 1 DIE content: 2 S/T content: 0 Score: −7.90Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not foundNUCDISC: discrimination of nuclear vocalization signals pat4: PRKR (4) at 490 pat4: RKRK (5) at 491 pat4: KRKK (5) at 492 pat4: RKKH (3) at 493 pat7: PRKRKKH (5) at 490 pat7: PLRRSRS (4) at 626 bipartite: none content of basic residues: 10.7% NLS Score: 1.37KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 89COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23): 66.7%: endoplasmic reticulum 22.2%: mitochondrial 11.1%: nuclearprediction for CG50249-01 is end (k=9)

A search of the NOV9a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9D.

TABLE 9DGeneseq Results for NOV9aNOV9aIdentifies/Residues/Similarities forGenesqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #,Date]ResiduesRegionValueAA014201Human transporter and ion1 . . . 638638/638 (100%)0.0channel TRICH-18 - Homo1 . . . 638638/638 (100%)sapiens, 638 aa. [WO200204520-A2, 17-JAN-2002]ABP52157Human 53763 transporter protein1 . . . 638638/638 (100%)0.0SEQ ID NO:11 - Homo sapiens,1 . . . 638638/638 (100%)638 aa. [WO200255701-A2, 18-JUL-2002]ABG70285Human novel polypeptide #1 -1 . . . 638638/638 (100%)0.0Homo sapiens, 638 aa.1 . . . 638638/638 (100%)[WO200257452-A2, 25-JUL-2002]ABB78396Longer splice variant of a human1 . . . 638638/638 (100%)0.0voltage-gated potassium channel -1 . . . 638638/638 (100%)Homo sapiens, 638 aa.[GB2372503-A, 28-AUG-2002]ABP52167Rat voltage gated potassium1 . . . 638623/638 (97%)0.0channel protein KV3.2 SEQ ID1 . . . 638625/638 (97%)NO:33 - Rattus norvegicus, 638aa. [WO200255701-A2, 18-JUL-2002]

In a BLAST search of public sequence databases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9E.

TABLE 9EPublic BLASTP Results for NOV9aNOV9aIdentities/ProteinResidues/Similarities forAccessionProtein/Matchthe MatchedExpectNumberOrganism/LengthResiduesPortionValueQ96PR1Voltage gated potassium channel1 . . . 638638/638 (100%)0.0Kv3 .2b (Potassium voltage-gated1 . . . 638638/638 (100%)potassium channel subfamily Cmember 2) - Homo sapiens(Human), 638 aa.P22462Potassium voltage-gated channel1 . . . 638623/638 (97%)0.0subfamily C member 21 . . . 638625/638 (97%)(Potassium channel Kv3.2)(KSHIIIA) - Rattus norvegicus(Rat), 638 aa.AA089503Kv3.2d voltage-gated potassium1 . . . 593593/593 (100%)0.0channel - Homo sapiens1 . . . 593593/593 (100%)(Human), 629 aa.Q96PR0Voltage gated potassium channel1 . . . 593593/593 (100%)0.0Kv3.2a - Homo sapiens (Human),1 . . . 593593/593 (100%)613 aa.A39402potassium channel protein IIIA1 . . . 593578/593 (97%)0.0form 1, shaker-type - rat, 613 aa.1 . . . 593580/593 (97%)

PFam analysis indicates that the NOV9a protein contains the domains shown in the Table 9F.

TABLE 9FDomain Analysis of NOV9aIdentities/NOV9aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect ValueK_tetra 9 . . . 156 50/161 (31%)3.2e-42121/161 (75%)ion_trans281 . . . 472 53/233 (23%)6.3e-43155/233 (67%)

Example 10

The NOV10 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 10A.

TABLE 10ANOV10 Sequence AnalysisNOV10a, CG50307-03SEQ ID NO: 1131162 bpDNA SequenceORF Start: ATG at 97ORF Stop: TGA at 1087ATCTACGGAGTCCCTTTGGCCACATAAGATTGGCCTTAAGAGAAGGACGGAGCCACATACTGCTGACGGCCCAGAACTGGCAGAGAGAAGGTTGCCATGGCTGCTGTTGACAGTTTCTACCTCTTGTACTGGGAAATCGCCAGGTCTTGCAATTGCTATATGGAAGCTCTAGCTTTGGTTGGAGCCTGGTATACGGCCAGAAAAAGCATCACTGTCATCTGTGACTTTTACAGCCTGATCAGGCTGCATTTTATCCCCCGCCTGGGGAGCAGAGCAGACTTGATCAAGCAGTATGGAAGATGGGCCGTTGTCAGCGGTGCAACAGATGGGATTGGAAAAGCCTACGCTGAAGAGTTAGCAAGCCGAGGTCTCAATATAATCCTGATTAGTCGGAACGAGGAGAAGTTGCAGGTTGTTGCTAAAGACATAGCCGACACGTACAAAGTGGAAACTGATATTATAGTTGCGGACTTCAGCAGCGGTCGTGAGATCTACCTTCCAATTCGAGAAGCCCTGAAGGACAAAGACGTTGGCATCTTGGTAAATAACGTGGGTGTGTTTTATCCCTACCCGCAGTATTTCACTCAGCTGTCCGAGGACAAGCTCTGGGACATCATAAATGTGAACATTGCCGCCGCTAGTTTGATGGTCCATGTTGTGTTACCGGGAATGGTGGAGAGAAAGAAAGGTGCCATCGTCACGATCTCTTCTGGCTCCTGCTGCAAACCCACTCCTCAGCTGGCTGCATTTTCTGCTTCTAAGGCTTATTTAGACCACTTCAGCAGAGCCTTGCAATATGAATATGCCTCTAAAGGAATCTTTGTACAGAGTCTAATCCCTTTCTATGTAGCCACCAGCATGACAGCACCCAGCAACTTTCTGCACAGGTGCTCGTGGTTGGTGCCTTCGCCAAAAGTCTATGCACATCATGCTGTTTCTACTCTTGGGATTTCCAAAAGGACCACAGGATATTGGTCCCATTCTATTCAGTTTCTTTTTGCACAGTATATGCCTGAATGGCTCTGGGTGTGGGGAGCAAATATTCTCAACCGTTCACTACGTAAGGAAGCCTTATCCTGCACAGCCTGAGTCTGGATGGCCACTTGAGAAGTTTTGCCAACTCCTGGGAACCTCGATATTCTGACATTTGGAAAAACACATTNOV10a, CG50307-03Protein SequenceSEQ ID NO: 114330 aaMW at 37031.4kDMAAVDSFYLLYWEIARSCNCYMEALALVGAWYTARKSITVICDFYSLIRLHFIPRLGSRADLIKQYGRWAVVSGATDGIGKAYAEELASRGLNIILISRNEEKLQVVAKDIADTYKVETDIIVADFSSGREIYLPIREALKDKDVGILVNNVGVFYPYPQYFTQLSEDKLWDIINVNIAAASLMVHVVLPGMVERKKGAIVTISSGSCCKPTPQLAAFSASKAYLDHFSRALQYEYASKGIFVQSLIPFYVATSMTAPSNFLHRCSWLVPSPKVYAHHAVSTLGISKRTTGYWSHSIQFLFAQYMPEWLWVWGANILNRSLRKEALSCTANOV10b, 275624102SEQ ID NO: 1151012 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCACCATGGCTGCTGTTGACAGTTTCTACCTCTTGTACAGGGAAATCGCCAGGTCTTGCAATTGCTATATGGAAGCTCTAGCTTTGGTTGGAGCCTGGTATACGGCCAGAAAAAGCATCACTGTCATCTGTGACTTTTACAGCCTGATCAGGCTGCATTTTATCCCCCGCCTGGGGAGCAGAGCAGACTTGATCAAGCAGTATGGAAGATGGGCCGTTGTCAGCGGTGCAACAGATGGGATTGGAAAAGCCTACGCTGAAGAGTTAGCAAGCCGAGGTCTCAATATAATCCTGATTAGTCGGAACGAGGAGAAGTTGCAGGTTGTTGCTAAAGACATAGCCGACACGTACAAAGTGGAAACTGATATTATAGTTGCGGACTTCAGCAGCGGTCGTGAGATCTACCTTCCAATTCGAGAAGCCCTGAAGGACAAAGACGTTGGCATCTTGGTAAATAACGTGGGTGTGTTTTATCCCTACCCGCAGTATTTCACTCAGCTGTCCGAGGACAAGCTCTGGGACATCATAAATGTGAACATTGCCGCCGCTAGTTTGATGGTCCATGTTGTGTTACCGGGAATGGTGGAGAGAAAGAAAGGTGCCATCGTCACGATCTCTTCTGGCTCCTGCTGCAAACCCACTCCTCAGCTGGCTGCATTTTCTGCTTCTAAGGCTrATTTAGACCACTTCAGCAGAGCCTTGCAATATGAATATGCCTCTAAAGGAATCTTTGTACAGAGTCTAATCCCTTTCTATGTAGCCACCAGCATGACAGCACCCAGCAACTTTCTGCACAGGTGCTCGTGGTTGGTGCCTTCGCCAAAAGTCTATGCACATCATGCTGTTTCTACTCTTGGGATTTCCAAAAGGACCACAGGATATTGGTCCCATTCTATTCAGTTTCTTTTTGCACAGTATATGCCTGAATGGCTCTGGGTGTGGGGAGCAAATATTCTCAACCGTTCACTACGTAAGGAAGCCTTATCCTGCACAGCCCTCGAGGGCNOV10b, 275624102Protein SequenceSEQ ID NO: 116337 aaMW at 37647.0kDTGSTMAAVDSFYLLYREIARSCNCYMEALALVGAWYTARKSITVICDFYSLIRLHFIPRLGSRADLIKQYGRWAVVSGATDGIGKAYAEELASRGLNIILISRNEEKLQVVAKDIADTYKVETDIIVADFSSGREIYLPIREALKDKDVGILVNNVGVFYPYPQYFTQLSEDKLWDIINVNIAAASLMVHVVLPGMVERKKGAIVTISSGSCCKPTPQLAAFSASKAYLDHFSRALQYEYASKGIFVQSLIPFYVATSMTAPSNFLHRCSWLVPSPKVYAHHAVSTLGISKRTTGYWSHSIQFLFAQYMPEWLWVWGANILNRSLRKEALSCTALEGNOV10c, CG50307-01SEQ ID NO: 1171831 bpDNA SequenceORF Start: ATG at 183ORF Stop: TGA at 1173ACCGGTTTGGAAGACTTTGCCGGCCTGCAGGACACATGATGACATTGGACCCACCCTCCCCAGCTCGGAGTCTTTAACTCAGTCACATCTACGGAGTCCCTTTGGCCACATAAGATTGGCCTTAAGAGAAGGACGGAGCCACATACTGCTGACGGCCCAGAACTGGCAGAGAGAAGGTTGCCATGGCTGCTGTTGACAGTTTCTACCTCTTGTACAGGGAAATCGCCAGGTCTTGCAATTGCTATATGGAAGCTCTAGCTTTGGTTGGAGCCTGGTATACGGCCAGAAAAAGCATCACTGTCATCTGTGACTTTTACAGCCTGATCAGGCTGCATTTTATCCCCCGCCTGGGGAGCAGAGCAGACTTGATCAAGCAGTATGGAAGATGGGCCGTTGTCAGCGGTGCAACAGATGGGATTGGAAAAGCCTACGCTGAAGAGTTAGCAAGCCGAGGTCTCAATATAATCCTGATTAGTCGGAACGAGGAGAAGTTGCAGGTTGTTGCTAAAGACATAGCCGACACGTACAAAGTGGAAACTGATATTATAGTTGCGGACTTCAGCAGCGGTCGTGAGATCTACCTTCCAATTCGAGAAGCCCTGAAGGACAAAGACGTTGGCATCTTGGTAAATAACGTGGGTGTGTTTTATCCCTACCCGCAGTATTTCACTCAGCTGTCCGAGGACAAGCTCTGGGACATCATAAATGTGAACATTGCCGCCGCTAGTTTGATGGTCCATGTTGTGTTACCGGGAATGGTGGAGAGAAAGAAAGGTGCCATCGTCACGATCTCTTCTGGCTCCTGCTGCAAACCCACTCCTCAGCTGGCTGCATTTTCTGCTTCTAAGGCTTATTTAGACCACTTCAGCAGAGCCTTGCAATATGAATATGCCTCTAAAGGAATCTTTGTACAGAGTCTAATNCCTTTCTATGTAGCCACCAGCATGACAGCACCCAGCAACTTTCTGCACAGGTGCTCGTGGTTGGTGCCTTCGCCAAAAGTCTATGCACATCATGCTGTTTCTACTCTTGGGATTTCCAAAAGGACCACAGGATATTGGTCCCATTCTATTCAGTTTCTTTTTGCACAGTATATGCCTGAATGGCTCTGGGTGTGGGGAGCAAATATTCTCAACCGTTCACTACGTAAGGAAGCCTTATCCTGCACAGCCTGAGTCTGGATGGCCACTTGAGAAGTTTTGCCAACTCCTGGGAACCTCGATATTCTGACATTTGGAAAAACACATTTAATTTATCTCCTGTGTTTCATTGCTGATTATTCAGCATACTGTTGATTCGTCATTTGCAAAACACACATAATACCGTCAGAGTGCTGTGAAAAACCTTAAGGGTGTGTGGATGGCACAGGATCAATAATGCCTGAGGCTGATTGACGACATCTACATTTCAGTGCTTTTTCCCTAAGCTGTTTGAAAGTTACGCTTTTCTGTTGTTCTAGAGCCACAGCAGTCTAATATTGAAATATAATATGATTGTCAGGTCTTATAATTTCAGATGTTGTTTTTTAAGGGAAATTGACCATTTCACTAGAGGAGTTGTGCTGGTTTTTACATGTGCATCAAGGAAAGACTACTGGAAAAGTATTTATTTTGGTAACTAAGATTGCTGGCTACTATTAGGGACACACTCCGGGCTGTTTGGTATAGCTCTACCTGGTTTGACTATCTGTCATGGAAATGCTGCCTTCCACTGGTTTTTCCTTTGAGACGGGGTGTGTGCCTGGGTTGTGGGGCCCTTGGGCCCCTTTTTTTTGGTGCCCCTTCTTCCACCCACTTTCGGCCCGCGGGCCCCCTGGCGCTCTGGGTTTCCCNOV10c, CG50307-01Protein SequenceSEQ ID NO: 118330 aaMW at 36888.2kDMAAVDSFYLLYREIARSCNCYMEALALVGAWYTARKSITVICDFYSLIRLHFIPRLGSRADLIKQYGRWAVVSGATDGIGKAYAEELASRGLNIILISRNEEKLQVVAKDIADTYKVETDIIVADFSSGREIYLPIREALKDKDVGILVNNVGVFYPYPQYFTQLSEDKLWDIINVNIAAASLMVHVVLPGMVERKKGAIVTISSGSCCKPTPQLAAFSASKAYLDHFSRALQYEYASKGIFVQSLXPFYVATSMTAPSNFLHRCSWLVPSPKVYAHHAVSTLGISKRTTGYWSHSIQFLFAQYMPEWLWVWGANILNRSLRKEALSCTANOV10d, CG50307-02SEQ ID NO: 1191152 bpDNA SequenceORF Start: ATG at 97ORF Stop: TGA at 1087ATCTACGGAGTCCCTTTGGCCACATAAGATTGGCCTTAAGAGAAGGACGGAGCCACATACTGCTGACGGCCCAGAACTGGCAGAGAGAAGGTTGCCATGGCTGCTGTTGACAGTTTCTACCTCTTGTACAGGGAAATCGCCAGGTCTTGCAATTGCTATATGGAAGCTCTAGCTTTGGTTGGAGCCTGGTATACGGCCAGAAAAAGCATCACTGTCATCTGTGACTTTTACAGCCTGATCAGGCTGCATTTTATCCCCCGCCTGGGGAGCAGAGCAGACTTGATCAAGCAGTATGGAAGATGGGCCGTTGTCAGCGGTGCAACAGATGGGATTGGAAAAGCCTACGCTGAAGAGTTAGCAAGCCGAGGTCTCAATATAATCCTGATTAGTCGGAACGAGGAGAAGTTGCAGGTTGTTGCTAAAGACATAGCCGACACGTACAAAGTGGAAACTGATATTATAGTTGCGGACTTCAGCAGCGGTCGTGAGATCTACCTTCCAATTCGAGAAGCCCTGAAGGACAAAGACGTTGGCATCTTGGTAAATAACGTGGGTGTGTTTTATCCCTACCCGCAGTATTTCACTCAGCTGTCCGAGGACAAGCTCTGGGACATCATAAATGTGAACATTGCCGCCGCTAGTTTGATGGTCCATGTTGTGTTACCGGGAATGGTGGAGAGAAAGAAAGGTGCCATCGTCACGATCTCTTCTGGCTCCTGCTGCAAACCCACTCCTCAGCTGGCTGCATTTTCTGCTTCTAAGGCTTATTTAGACCACTTCAGCAGAGCCTTGCAATATGAATATGCCTCTAAAGGAATCTTTGTACAGAGTCTAATCCCTTTCTATGTAGCCACCAGCATGACAGCACCCAGCAACTTTCTGCACAGGTGCTCGTGGTTGGTGCCTTCGCCAAAAGTCTATGCACATCATGCTGTTTCTACTCTTGGGATTTCCAAAAGGACCACAGGATATTGGTCCCATTCTATTCAGTTTCTTTTTGCACAGTATATGCCTGAATGGCTCTGGGTGTGGGGAGCAAATATTCTCAACCGTTCACTACGTAAGGAAGCCTTATGCTGCACAGCCTGAGTCTGGATGGCCACTTGAGAAGTTTTGCCAACTCCTGGGAACCTCGATATTCTGACATTTGGANOV10d, CG50307-02Protein SequenceSEQ ID NO: 120330 aaMW at 37017.4kDMAAVDSFYLLYREIARSCNCYMEALALVGAWYTARKSITVICDFYSLIRLHFIPRLGSRADLIKQYGRWAVVSGATDGIGKAYAEELASRGLMIILISRNEEKLQVVAKDIADTYKVETDIIVADFSSGREIYLPIREALKDKDVGILVNNVGVFYPYPQYFTQLSEDKLWDIINVNIAAASLMVHVVLPGMVERKKGAIVTISSGSCCKPTPQLAAFSASKAYLDHFSRALQYEYASKGIFVQSLIPFYVATSMTAPSNFLHRCSWLVPSPKVYAHHAVSTLGISKRTTGYWSHSIQFLFAQYMPEWLWVWGANILNRSLRKEALCCTASEQ ID NO: 1211162bpNOV10e, SNP13375811 ofORF Start: ATG at 97ORF Stop: TGA at 1087CG50307-03, DNA SequenceSNP Pos: 1076SNP Change: C to GATCTACGGAGTCCCTTTGGCCACATAAGATTGGCCTTAAGAGAAGGACGGAGCCACATACTGCTGACGGCCCAGAACTGGCAGAGAGAAGGTTGCCATGGCTGCTGTTGACAGTTTCTACCTCTTGTACTGGGAAATCGCCAGGTCTTGCAATTGCTATATGGAAGCTCTAGCTTTGGTTGGAGCCTGGTATACGGCCAGAAAAAGCATCACTGTCATCTGTGACTTTTACAGCCTGATCAGGCTGCATTTTATCCCCCGCCTGGGGAGCAGAGCAGACTTGATCAAGCAGTATGGAAGATGGGCCGTTGTCAGCGGTGCAACAGATGGGATTGGAAAAGCCTACGCTGAAGAGTTAGCAAGCCGAGGTCTCAATATAATCCTGATTAGTCGGAACGAGGAGAAGTTGCAGGTTGTTGCTAAAGACATAGCCGACACGTACAAAGTGGAAACTGATATTATAGTTGCGGACTTCAGCAGCGGTCGTGAGATCTACCTTCCAATTCGAGAAGCCCTGAAGGACAAAGACGTTGGCATCFIGGTAAATAACGTGGGTGTGTTTTATCCCTACCCGCAGTATTTCACTCAGCTGTCCGAGGACAAGCTCTGGGACATCATAAATGTGAACATTGCCGCCGCTAGTTTGATGGTCCATGTTGTGTTACCGGGAATGGTGGAGAGAAAGAAAGGTGCCATCGTCACGATCTCTTCTGGCTCCTGCTGCAAACCCACTCCTCAGCTGGCTGCATTTTCTGCTTCTAAGGCTTATTTAGACCACTTCAGCAGAGCCTTGCAATATGAATATGCCTCTAAAGGAATCTTTGTACAGAGTCTAATCCCTTTCTATGTAGCCACCAGCATGACAGCACCCAGCAACTTTCTGCACAGGTGCTCGTGGTTGGTGCCTTCGCCAAAAGTCTATGCACATCATGCTGTTTCTACTCTTGGGATTTCCAAAAGGACCACAGGATATTGGTCCCATTCTATTCAGTTTCTTTTTGCACAGTATATGCCTGAATGGCTCTGGGTGTGGGGAGCAAATATTCTCAACCGTTCACTACGTAAGGAAGCCTTATGCTGCACAGCCTGAGTCTGGATGGCCACTTGAGAAGTTTTGCCAACTCCTGGGAACCTCGATATTCTGACATTTGGAAAAACACATTNOV10e, SNP13375811 ofSEQ ID NO: 122MW at 37047.4kDCG50307-03, Protein SequenceSNP Pos: 327330 aaSNP Change: Ser to CysMAAVDSFYLLYWEIARSCNCYMEALALVGAWYTARKSITVICDFYSLIRLHFIPRLGSRADLIKQYGRWAVVSGATDGIGKAYAEELASRGLNIILISRNEEKLQVVAKDIADTYKVETDIIVADFSSGREIYLPIREALKDKDVGILVNNVGVFYPYPQYFTQLSEDKLWDIINVNIAAASLMVHVVLPGMVERKKGAIVTISSGSCCKPTPQLAAFSASKAYLDHFSRALQYEYASKGIFVQSLIPFYVATSMTAPSNFLHRCSWLVPSPKVYAHHAVSTLGISKRTTGYWSHSIQFLFAQYMPEWLWVWGANILNRSLRKEALCCTA

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 10B.

TABLE 10BComparison of the NOV10 protein sequences.NOV10a----MAAVDSFYLLYWEIARSCNCYMEALALVGAWYTARKSITVICDFYSLIRLHFIPRLNOV10bTGSTMAAVDSFYLLYREIARSCNCYMEALALVGAWYTARKSITVICDFYSLIRLHFIPRLNOV10c----MAAVDSFYLLYREIARSCNCYMEALALVGAWYTARKSITVICDFYSLIRLHFIPRLNOV10d----MAAVDSFYLLYREIARSCNCYMEALALVGAWYTARKSITVICDFYSLIRLHFIPRLNOV10aGSRADLIKQYGRWAVVSGATDGIGKAYAEELASRGLNIILISRNEEKLQVVAKDIADTYKNOV10bGSRADLIKQYGRWAVVSGATDGIGKAYAEELASRGLNIILISRNEEKLQVVAKDIADTYKNOV10cGSRADLIKQYGRWAVVSGATDGIGKAYAEELASRGLNIILISRNEEKLQVVAKDIADTYKNOV10dGSRADLIKQYGRWAVVSGATDGIGKAYAEELASRGLNIILISRNEEKLQVVAKDIADTYKNOV10aVETDIIVADFSSGREIYLPIREALKDKDVGILVNNVGVFYPYPQYFTQLSEDKLWDIINVNOV10bVETDIIVADFSSGREIYLPIREALKDKDVGILVNNVGVFYPYPQYFTQLSEDKLWDIINVNOV10cVETDIIVADFSSGREIYLPIREALKDKDVGILVNNVGVFYPYPQYFTQLSEDKLWDIINVNOV10dVETDIIVADFSSGREIYLPIREALKDKDVGILVNNVGVFYPYPQYFTQLSEDKLWDIINVNOV10aNIAAASLMVHVVLPGMVERKKGAIVTISSGSCCKPTPQLAAFSASKAYLDHFSRALQYEYNOV10bNIAAASLMVHVVLPGMVERKKGAIVTISSGSCCKPTPQLAAFSASKAYLDHFSRALQYEYNOV10cNIAAASLMVHVVLPGMVERKKGAIVTISSGSCCKPTPQLAAFSASKAYLDHFSRALQYEYNOV10dNIAAASLMVHVVLPGMVERKKGAIVTISSGSCCKPTPQLAAFSASKAYLDHFSRALQYEYNOV10aASKGIFVQSLIPFYVATSMTAPSNFLHRCSWLVPSPKVYAHHAVSTLGISKRTTGYWSHSNOV10bASKGIFVQSLIPFYVATSMTAPSNFLHRCSWLVPSPKVYAHHAVSTLGISKRTTGYWSHSNOV10cASKGIFVQSLIPFYVATSMTAPSNFLHRCSWLVPSPKVYAHHAVSTLGISKRTTGYWSHSNOV10dASKGIFVQSLIPFYVATSMTAPSNFLHRCSWLVPSPKVYAHHAVSTLGISKRTTGYWSHSNOV10aIQFLFAQYMPEWLWVWGANILNRSLRKEALSCTA---NOV10bIQFLFAQYMPEWLWVWGANILNRSLRKEALSCTALEGNOV10cIQFLFAQYMPEWLWVWGANILNRSLRKEALSCTA---NOV10dIQFLFAQYMPEWLWVWGANILNRSLRKEALCCTA---NOV10a(SEQ ID NO: 114)NOV10b(SEQ ID NO: 116)NOV10c(SEQ ID NO: 118)NOV10d(SEQ ID NO: 120)

Further analysis of the NOV10a protein yielded the following properties shown in Table 10C.

TABLE 10CProtein Sequence Properties NOV10aSignalP analysis: No Known Signal Sequence IndicatedPSORT II analysis:PSG: a new signal peptide prediction method N-region: length 5; pos. chg 0; neg. chg 1 H-region: length 7; peak value 0.00 PSG score: −4.40GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −6.54 possible cleavage site: between 58 and 59>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation mit position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 1 Number of TMS(s) for threshold 0.5: 1 INTEGRAL Likelihood = −3.88 Transmembrane 173-189 PERIPHERAL Likelihood = 2.01 (at 37) ALOM score: −3.88 (number of TMSs: 1)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 180 Charge difference: 4.5 C( 2.5) − N(−2.0) C > N: C-terminal side will be inside>>> membrane topology: type lb (cytoplasmic tail 173 to 330)MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75) : 6.52 Hyd Moment(95) : 5.94 G content: 0 D/E content: 2 S/T content: 1 Score: −6.71Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not foundNUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 10.0% NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues--------------------------Final Results (k = 9/23) 34.8%: nuclear 21.7%: mitochondrial 21.7%: cytoplasmic 8.7%: vesicles of secretory system 4.3%: vacuolar 4.3%: peroxisomal 4.3%: endoplasmic reticulumprediction for CG50307-03 is nuc (k=23)

A search of the NOV10a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 10D.

TABLE 10DGeneseq Results for NOV10aNOV10aIdentifies/Residues/Similarities forGenesqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #,Date]ResiduesRegionValueAAE21050Human ding metabolising1 . . . 330329/330 (99%)0.0enzyme (DME-8) protein - Homo1 . . . 330329/330 (99%)sapiens, 330 aa. [WO200212467-A2, 14-FEB-2002]AAE21521Human dehydrogenase DHDR-51 . . . 330329/330 (99%)0.0protein - Homo sapiens, 330 aa.1 . . . 330329/330 (99%)[WO200216562-A2, 28-FEB-2002]ABJ10602Human novel protein NOV10a1 . . . 330329/330 (99%)0.0SEQ ID NO: 32 - Homo sapiens,1 . . . 33029/330 (99%)330 aa. [WO200259315-A2, 01-AUG-2002]AAM41389Human polypeptide SEQ ID NO1 . . . 330329/330 (99%)0.06320 - Homo sapiens, 340 aa.11 . . . 340329/330 (99%)[WO200153312-A1, 26-JUL-2001]AAM39603Human polypeptide SEQ ID NO1 . . . 330329/330 (99%)0.02748 - Homo sapiens, 330 aa.1 . . . 330329/330 (99%)[WO200153312-A1, 26-JUL-2001]

In a BLAST search of public sequence databases, the NOV10a protein was found to have homology to the proteins shown in the BLASTP data in Table 10E.

TABLE 10EPublic BLASTP Results for NOV10aIdentities/NOV10aSimilaritiesProteinResidues/for theAccessionMatchMatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAD28991Sequence 1 from Patent1 . . . 330329/330 (99%)0.0WO0216562 - Homo sapiens1 . . . 330329/330 (99%)(Human), 330 aa.Q8NC98Hypothetical protein FLJ90397 -1 . . . 330328/330 (99%)0.0Homo sapiens (Human), 3301 . . . 330328/330 (99%)aa.Q9BY22Steroid dehydrogenase-like22 . . . 330 309/309 (100%)e−179protein - Homo sapiens1 . . . 309309/309 (100%)(Human), 309 aa.Q8WVE5Steroid dehydrogenase-like -22 . . . 330 308/309 (99%)e−178Homo sapiens (Human), 3091 . . . 309308/309 (99%)aa.Q8BTX9Steroid dehydrogenase-like1 . . . 330289/330 (87%)e−173protein homolog - Mus1 . . . 330310/330 (93%)musculus (Mouse), 330 aa.

PFam analysis indicates that the NOV10a protein contains the domains shown in the Table 10F.

TABLE 10FDomain Analysis of NOV10aNOV10aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Valueadh_short66 . . . 306 73/275 (27%)8e−24166/275 (60%)

Example 11

The NOV11 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 11A.

TABLE 11ANOV11 Sequence AnalysisNOV11a, CG50315-01SEQ ID NO: 123938 bpDNA SequenceORF Start: at 1ORF Stop: TAG at 931AATCTCACCAGAGTAACCGAATTCATTCTCATGGGCTTTATGGACCACCCCAAATTGGAGATTCCCCTCTTTCTGGTGTTTCTGAGTTTCTACCTAGTCACCCTTCTTGGGAATGTGGGGATGATTATGTTAATCCAAGTAGATGTCAAACTCTACACCCCAATGTACTTCTTCCTGAGCCACCTCTCCCTGCTGGATGCCTGTTACACCTCAGTCATCACCCCTCAGATCCTAGCCACATTGGCCACAGGCAAAACGGTCATCTCCTACGGCCACTGTGCTGCCCAGTTCTTTTTATTCACCATCTGTGCAGGCACAGAGTGCTTTCTGCTGGCAGTGATGGCCTATGATCGCTATGCTGCCATTCGCAACCCACTGCTCTATACCGTGGCCATGAATCCCAGGCTCTACTGGAGCCTGGTGGTAGGAGCCTATGTCTGTGGGGTGTCAGGAGCCATCCTGCGTACCACTTGCACCTTCACCCTCTCCTTCTGTAAGGACAATCAAATAAACTTCTTCTTCTGTGACCTCCCACCCCTGCTGAAGCTTGCCTGCAGTGACACAGCAAACATCGAGATTGTCATCATCTTCTTTGGCAATTTTGTGATTTTGGCCAATGCCTCCGTCATCCTGATTTCCTATCTGCTCATCATCAAGACCATTTTGAAAGTGAAGTCTTCAGGTGGCAGGGCCAAGACTTTCTCCACATGTGCCTCTCACATCACTGCTGTGGCCCTTTTCTTTGGAGCCCTTATCTTCATGTATCTGCAAAGTGGCTCAGGCAAATCTCTGGAGGAAGACAAAGTCGTGTCTGTCTTCTATACAGTGGTCATCCCCATGCTGAACCCTCTGATCTACAGCTTAAGAAACAAAGATGTAAAAGACGCCTTCAGAAAGGTCGCTAGGAGACTCCAGGTGTCCCTGAGCATGTAGATTTANOV11a, CG50315-01Protein SequenceSEQ ID NO: 124310 aaMW at 34522.7kDNLTRVTEFILMGFMDHPKLEIPLFLVFLSFYLVTLLGNVGMIMLIQVDVKLYTPMYFFLSHLSLLDACYTSVITPQILAThATGKTVISYGHCAAQFFLFTICAGTECFLLAVMAYDRYAAIRNPLLYTVAMNPRLYWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDVKDAFRKVARRLQVSLSMNOV11b, 207580272SEQ ID NO: 125822 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCATGATTATGTTAATCCAAGTAGATGTCAAACTCTACACCCCAATGTACTTCTTCCTGAGCCACCTCTCCCTGCTGGATGCCTGTTACACCTCAGTCATCACCCCTCAGATCCTAGCCACATTGGCCACAGGCAAAACGGTCATCTCCTACGGCCACTGTGCTGCCCAGTTCTTTTTATTCACCATCTGTGCAGGCACAGAGTGCTTTCTGCTGGCAGTGATGGCCTATGATCGCTATGCTGCCATTCGCAACCCACTGCTCTATACCGTGGCCATGAATCCCAGGCTCTACTGGAGCCTGGTGGTAGGAGCCTATGTCTGTGGGGTGTCAGGAGCCATCCTGCGTACCACTTGCACCTTCACCCTCTCCTTCTGTAAGGACAATCAAATAAACTTCTTCTTCTGTGACCTCCCACCCCTGCTGAAGCTTGCCTGCAGTGACACAGCAAACATCGAGATTGTCATCATCTTCTTTGGCAATTTTGTGATTTTGGCCAATGCCTCCGTCATCCTGATTTCCTATCTGCTCATCATCAAGACCATTTTGAAAGTGAAGTCTTCAGGTGGCAGGGCCAAGACTTTCTCCACATGTGCCTCTCACATCACTGCTGTGGCCCTTTTCTTTGGAGCCCTTATCTTCATGTATCTGCAAAGTGGCTCAGGCAAATCTCTGGAGGAAGACAAAGTCGTGTCTGTCTTCTATACAGTGGTCATCCCCATGCTGAACCCTCTGATCTACAGCTTAAGAAACAAAGATGTAAAAGACGCCTTCAGAAAGGTCGCTAGGAGACTCCAGGTGTTCCTGAGCATGCTCGAGNOV11b, 207580272Protein SequenceSEQ ID NO: 126274 aaMW at 30387.7kDGSMIMLIQVDVKLYTPMYFFLSHLSLLDACYTSVITPQILATLATGKTVISYGHCAAQFFLFTICAGTECFLLAVMAYDRYAAIRNPLLYTVAMNPRLYWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDVKDAFRKVARRLQVFLSMLENOV11c, 314411778SEQ ID NO: 127964 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCACCATGGCCAAGAATAATCTCACCAGAGTAACCGAATTCATTCTCATGGGCTTTATGGACCACCCCAAATTGGAGATTCCCCTCTTTCTGGTGTTTCTGAGTTTCTACCTAGTCACCCTTCTTGGGAATGTGGGGATGATTATGTTAATCCAAGTAGATGTCAAACTCTACACCCCAATGTACTTCTTCCTGAGCCACCTCTCCCTGCTGGATGCCTGTTACACCTCAGTCATCACCCCTCAGATCCTAGCCACATTGGCCACAGGCAAAACGGTCATCTCCTACGGCCACTGTGCTGCCCAGTTCTTTTTATTCACCATCTGTGCAGGCACAGAGTGCTTTCTGCTGGCAGTGATGGCCTATGATCGCTATGCTGCCATTCGCAACCCACTGCTCTATACCGTGGCCATGAATCCCAGGCTCTGCTGGAGCCTGGTGGTAGGAGCCTATGTCTGTGGGGTGTCAGGAGCCATCCTGCGTACCACTTGCACCTTCACCCTCTCCTTCTGTAAGGACAATCAAATAAACTTCTTCTTCTGTGACCTCCCACCCCTGCTGAAGCTTGCCTGCAGTGACACAGCAAACATCGAGATTGTCATCATCTTCTTTGGCAATTTTGTGATTTTGGCCAATGCCTCCGTCATCCTGATTTCCTATCTGCTCATCATCAAGACCATTTTGAAAGTGAAGTCTTCAGGTGGCAGGGCCAAGACTTTCTCCACATGTGCCTCTCACATCACTGCTGTGGCCCTTTTCTTTGGAGCCCTTATCTTCATGTATCTGCAAAGTGGCTCAGGCAAATCTCTGGAGGAAGACAAAGTCGTGTCTGTCTTCTATACAGTGGTCATCCCCATGCTGAACCCTCTGATCTACAGCTTAAGAAACAAAGATGTAAAAGACGCCTTCAGAAAGGTCGCTAGGAGACTCCAGGTGTCCCTGAGCATGCTCGAGGGCNOV11c, 314411778Protein SequenceSEQ ID NO: 128321 aaMW at 35552.9kDTGSTMAKNNLTRVTEFILMGFMDNPKLEIPLFLVFLSFYLVTLLGNVGMIMLIQVDVKLYTPMYFFLSHLSLLDACYTSVITPQILATLATGKTVISYGHCAAQFFLFTICAGTECFLLAVMAYDRYAAIRNPLLYTVANNPRLCWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDVKDAFRKVARRLQVSLSMLEGNOV11d, CG50315-02SEQ ID NO: 129968 bpDNA SequenceORF Start: ATG at 17ORF Stop: TAG at 959AGTCCACATTGTCTCCATGGCCAAGAATAATCTCACCAGAGTAACCGAATTCATTCTCATGGGCTTTATGGACCACCCCAAATTGGAGATTCCCCTCTTTCTGGTGTTTCTGAGTTTCTACCTAGTCACCCTTCTTGGGAATGTGGGGATGATTATGTTAATCCAAGTAGATGTCAAACTCTACACCCCAATGTACTTCTTCCTGAGCCACCTCTCCCTGCTGGATGCCTGTTACACCTCAGTCATCACCCCTCAGATCCTAGCCACATTGGCCACAGGCAAAACGGTCATCTCCTACGGCCACTGTGCTGCCCAGTTCTTTTTATTCACCATCTGTGCAGGCACAGAGTGCTTTCTGCTGGCAGTGATGGCCTATGATCGCTATGCTGCCATTCGCAACCCAOTGCTCTATACCGTGGCCATGAATCCCAGGCTCTGCTGGAGCCTGGTGGTAGGAGCCTATGTCTGTGGGGTGTCAGGAGCCATCCTGCGTACCACTTGCACCTTCACCCTCTCCTTCTGTAAGGACAATCAAATAAACTTCTTCTTCTGTGACCTCCCACCCCTGCTGAAGCTTGCCTGCAGTGACACAGCAAACATCGAGATTGTCATCATCTTCTTTGGCAATTTTGTGATTTTGGCCAATGCCTCCGTCATCCTGATTTCCTATCTGCTCATCATCAAGACCATTTTGAAAGTGAAGTCTTCAGGTGGCAGGGCCAAGACTTTCTCCACATGTGCCTCTCACATCACTGCTGTGGCCCTTTTCTTTGGAGCCCTTATCTTCATGTATCTGCAAAGTGGCTCAGGCAAATCTCTGGAGGAAGACAAAGTCGTGTCTGTCTTCTATACAGTGGTCATCCCCATGCTGAACCCTCTGATCTACAGCTTAAGAAACAAAGATGTAAAAGACGCCTTCAGAAAGGTCGCTAGGAGACTCCAGGTGTCCCTGAGCATGTAGATCTAAGNOV11d, CG50315-02Protein SequenceSEQ ID NO: 130314 aaMW at 34907.2kDMAKNNLTRVTEFILMGFMDHPKLEIPLFLVFLSFYLVTLLGNVGMIMLIQVDVKLYTPMYFFLSHLSLLDACYTSVITPQILATLATGKTVISYGHCAAQFFLFTICAGTECFLLAVMAYDRYAAIRNPLLYTVAMNPRLCWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDVKDAFRKVARRLQVSLSMNOV11e, CG50315-03SEQ ID NO: 131822 bpDNA SequenceORF Start: ATG at 7ORF Stop: at 817GGATCCATGATTATGTTAATCCAAGTAGATGTCAAACTCTACACCCCAATGTACTTCTTCCTGAGCCACCTCTCCCTGCTGGATGCCTGTTACACCTCAGTCATCACCCCTCAGATCCTAGCCACATTGGCCACAGGCAAAACGGTCATCTCCTACGGCCACTGTGCTGCCCAGTTCTTTTTATTCACCATCTGTGCAGGCACAGAGTGCTTTCTGCTGGCAGTGATGGCCTATGATCGCTATGCTGCCATTCGCAACCCACTGCTCTATACCGTGGCCATGAATCCCAGGCTCTACTGGAGCCTGGTGGTAGGAGCCTATGTCTGTGGGGTGTCAGGAGCCATCCTGCGTACCACTTGCACCTTCACCCTCTCCTTCTGTAAGGACAATCAAATAAACTTCTTCTTCTGTGACCTCCCACCCCTGCTGAAGCTTGCCTGCAGTGACACAGCAAACATCGAGATTGTCATCATCTTCTTTGGCAATTTTGTGATTTTGGCCAATGCCTCCGTCATCCTGATTTCCTATCTGCTCATCATCAAGACCATTTTGAAAGTGAAGTCTTCAGGTGGCAGGGCCAAGACTTTCTCCACATGTGCCTCTCACATCACTGCTGTGGCCCTTTTCTTTGGAGCCCTTATCTTCATGTATCTGCAAAGTGGCTCAGGCAAATCTCTGGAGGAAGACAAAGTCGTGTCTGTCTTCTATACAGTGGTCATCCCCATGCTGAACCCTCTGATCTACAGCTTAAGAAACAAAGATGTAAAAGACGCCTTCAGAAAGGTCGCTAGGAGACTCCAGGTGTTCCTGAGCATGCTCGAGNOV11e, CG50315-03Protein SequenceSEQ ID NO: 132270 aaMW at 30001.3kDMIMLIQVDVKLYTPMYFFLSHLSLLDACYTSVITPQILAThATGKTVISYGHCAAQFFLFTICAGTECFLLAVMAYDRYAAIRNPLLYTVAMNPRLYWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDVKDAFRKVARRLQVFLSM

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 11B.

TABLE 11BComparison of the NOV11 protein sequences.NOV11a--------NLTRVTEFILMGFMDHPKLEIPLFLVFLSFYLVTLLGNVGMIMLIQVDVKYLNOV11b----------------------------------------------GSMIMLIQVDVKLYNOV11cTGSTMAKNNLTRVTEFILMGFMDHPKLEIPLFLVFLSFYLVTLLGNVGMIMLIQVDVKYLNOV11d----MAKNNLTRVTEFILMGFMDHPKLEIPLFLVFLSFYLVTLLGNVGMIMLIQVDVKYLNOV11e------------------------------------------------MIMLIQVDVKLYNOV11aTPMYFFLSHLSLLDACYTSVITPQILATLATGKTVISYGHCAAQFFLFTICAGTECFLLANOV11bTPMYFFLSHLSLLDACYTSVITPQILATLATGKTVISYGHCAAQFFLFTICAGTECFLLANOV11cTPMYFFLSHLSLLDACYTSVITPQILATLATGKTVISYGHCAAQFFLFTICAGTECFLLANOV11dTPMYFFLSHLSLLDACYTSVITPQILATLATGKTVISYGHCAAQFFLFTICAGTECFLLANOV11eTPMYFFLSHLSLLDACYTSVITPQILATLATGKTVISYGHCAAQFFLFTICAGTECFLLANOV11aVMAYDRYAAIRNPLLYTVANNPRLYWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFNOV11bVMAYDRYAAIRNPLLYTVANNPRLYWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFNOV11cVMAYDRYAAIRNPLLYTVANNPRLCWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFNOV11dVMAYDRYAAIRNPLLYTVANNPRLCWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFNOV11eVMAYDRYAAIRNPLLYTVANNPRLYWSLVVGAYVCGVSGAILRTTCTFTLSFCKDNQINFNOV11aFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKNOV11bFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKNOV11cFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKNOV11dFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKNOV11eFFCDLPPLLKLACSDTANIEIVIIFFGNFVILANASVILISYLLIIKTILKVKSSGGRAKNOV11aTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDNOV11bTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDNOV11cTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDNOV11dTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDNOV11eTFSTCASHITAVALFFGALIFMYLQSGSGKSLEEDKVVSVFYTVVIPMLNPLIYSLRNKDNOV11aVKDAFRKVARRLQVSLSM---NOV11bVKDAFRKVARRLQVFLSMLE-NOV11cVKDAFRKVARRLQVSLSMLEGNOV11dVKDAFRKVARRLQVSLSM---NOV11eVKDAFRKVARRLQVFLSM---NOV11a(SEQ ID NO: 124)NOV11b(SEQ ID NO: 126)NOV11c(SEQ ID NO: 128)NOV11d(SEQ ID NO: 130)NOV11e(SEQ ID NO: 132)

Further analysis of the NOV11a protein yielded the following properties shown in Table 11C.

TABLE 11CProtein Sequence Properties NOV11aSignalP analysis: Cleavage site between residues 38 and 39PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 7; pos.chg 1; neg.chg 1H-region: length 7; peak value 6.23PSG score: 1.83GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.00possible cleavage site: between 37 and 38>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −6.58 Transmembrane 21-37INTEGRALLikelihood = −4.09 Transmembrane 97-113INTEGRALLikelihood = −1.65 Transmembrane 138-154INTEGRALLikelihood = −8.70 Transmembrane 202-218INTEGRALLikelihood = −4.14 Transmembrane 240-256INTEGRALLikelihood = −3.13 Transmembrane 269-285PERIPHERALLikelihood = 0.85 (at 183)ALOM score: −8.70 (number of TMSs: 6)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 28Charge difference: 2.0 C(0.5) − N(−1.5)C > N: C-terminal side will be inside>>>Caution: Inconsistent mtop result with signal peptide>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):1.96Hyd Moment(95):9.20G content:1D/E content:2S/T content:2Score: −6.22Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 14 TRV|TENUCDISC:discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.7%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: LTRVnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG50315-01 is end (k = 9)

A search of the NOV11a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11D.

TABLE 11DGeneseq Results for NOV11aNOV11aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB06632G protein-coupled receptor1 . . . 310310/310 (100%)e−176GPCR17b protein SEQ ID NO: 74 -1 . . . 310310/310 (100%)Homo sapiens, 310 aa.[WO200212343-A2, 14-FEB-2002]ABB06631G protein-coupled receptor1 . . . 310309/310 (99%)e−175GPCR17a protein SEQ ID NO: 72 -5 . . . 314309/310 (99%)Homo sapiens, 314 aa.[WO200212343-A2, 14-FEB-2002]AAU95529Human olfactory and pheromone1 . . . 310309/310 (99%)e−175G protein-coupled receptor #16 -5 . . . 314309/310 (99%)Homo sapiens, 314 aa.[WO200224726-A2, 28-MAR-2002]ABP95742Human GPCR polypeptide SEQ1 . . . 310309/310 (99%)e−175ID NO 294 - Homo sapiens, 3145 . . . 314309/310 (99%)aa. [WO200216548-A2, 28-FEB-2002]AAG72468Human OR-like polypeptide1 . . . 310309/310 (99%)e−175query sequence, SEQ ID NO:5 . . . 314309/310 (99%)2149 - Homo sapiens, 314 aa.[WO200127158-A2, 19-APR-2001]

In a BLAST search of public sequence databases, the NOV11a protein was found to have homology to the proteins shown in the BLASTP data in Table 11E.

TABLE 11EPublic BLASTP Results for NOV11aNOV11aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8NGQ6Seven transmembrane helix1 . . . 310309/310 (99%)e−175receptor - Homo sapiens5 . . . 314309/310 (99%)(Human), 314 aa.CAD37586Sequence 201 from Patent1 . . . 310308/310 (99%)e−173WO0224726 - Homo sapiens5 . . . 314308/310 (99%)(Human), 314 aa.Q8VG66Olfactory receptor MOR211-1 -1 . . . 307253/307 (82%)e−146Mus musculus (Mouse), 316 aa.5 . . . 311279/307 (90%)Q8VG65Olfactory receptor MOR211-2 -1 . . . 310246/310 (79%)e−144Mus musculus (Mouse), 314 aa.5 . . . 314278/310 (89%)Q96RA8Olfactory receptor - Homo64 . . . 279 215/216 (99%)e−119sapiens (Human), 216 aa1 . . . 216215/216 (99%)(fragment).

PFam analysis indicates that the NOV11a protein contains the domains shown in the Table 11F.

TABLE 11FDomain Analysis of NOV11aNOV11aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_137 . . . 286 55/276 (20%)1.5e−28174/276 (63%)

Example 12

The NOV12 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 12A.

TABLE 12ANOV12 Sequence AnalysisNOV12a, CG50341-01SEQ ID NO: 133997 bpDNA SequenceORF Start: ATG at 21ORF Stop: TAA at 966GGCGCTTATAATTTTGAACTATGACCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGCTCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTTAGTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACTAAAGTTGAAGATGGGAAGTACTTTTTTTGNNNOV12a, CG50341-01Protein SequenceSEQ ID NO: 134315 aaMW at 34934.2kDMTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDNOV12b, 169475616SEQ ID NO: 135819 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACCTCGAGNOV12b, 169475616Protein SequenceSEQ ID NO: 136273 aaMW at 29857.9kDGSMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDLENOV12c, CG50341-02SEQ ID NO: 137996 bpDNA SequenceORF Start: ATG at 21ORF Stop: TAA at 966GGCGCTTATAATTTTGAACTATGACCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGCTCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTTAGTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACTAAAGATTGAAGATGGGAAGTACTTTTTTTGNOV12c, CG50341-02Protein SequenceSEQ ID NO: 138315 aaMW at 34934.2kDMTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDNOV12d, CG50341-03SEQ ID NO: 139819 bpDNA SequenceORF Start: ATG at 7ORF Stop: at 814GGATCCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACCTCGAGNOV12d, CG50341-03Protein SequenceSEQ ID NO: 140269 aaMW at 29471.5kDMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTANSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDNOV12e, CG50341-04SEQ ID NO: 141957 bpDNA SequenceORF Start: ATG at 7ORF Stop: at 952GGATCCATGACCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGCTCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTTAGTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACCTCGAGNOV12e, CG50341-04Protein SequenceSEQ ID NO: 142315 aaMW at 34934.2kDMTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLHRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDD

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 12B.

TABLE 12BComparison of the NOV12 protein sequences.NOV12aMTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFNOV12b--------------------------------------------GSMILDHRLHMAMYFFNOV12cMTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFNOV12d----------------------------------------------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--NOV12bKVLWNVRSSGVMKDDLENOV12cKVLWNVRSSGVMKDD--NOV12dKVLWNVRSSGVMKDD--NOV12eKVLWNVRSSGVMKDD--NOV12a(SEQ ID NO: 134)NOV12b(SEQ ID NO: 136)NOV12c(SEQ ID NO: 138)NOV12d(SEQ ID NO: 140)NOV12e(SEQ ID NO: 142)

Further analysis of the NOV12a protein yielded the following properties shown in Table 12C.

TABLE 12CProtein Sequence Properties NOV12aSignalP analysis: Cleavage site between residues 47 and 48PSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 9; pos.chg 0; neg.chg 1H-region:length 4; peak value 0.00PSG score:−4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.11possible cleavage site: between 36 and 37>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 5INTEGRALLikelihood = −9.87 Transmembrane 32-48INTEGRALLikelihood = −9.66 Transmembrane 90-106INTEGRALLikelihood = −9.71 Transmembrane 198-214INTEGRALLikelihood = −5.79 Transmembrane 239-255INTEGRALLikelihood = 0.16 Transmembrane 267-283PERIPHERALLikelihood = 1.11 (at 56)ALOM score: −9.87 (number of TMSs: 5)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 39Charge difference: 1.0 C(2.5) − N(1.5)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):2.94Hyd Moment(95):4.71G content:0D/E content:2S/T content:3Score: −5.83Gavel:prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 6.7%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: VMKDSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found *** LHALLFSLIYLTAVLMNLVIIL at 24 nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: endoplasmic reticulum11.1%: mitochondrial11.1%: Golgi11.1%: vacuolar11.1%: vesicles of secretory system11.1%: cytoplasmic>> prediction for CG50341-01 is end (k = 9)

A search of the NOV12a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12D.

TABLE 12DGeneseq Results for NOV12aNOV12aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU11100Human novel G protein-coupled1 . . . 315315/315 (100%)e−179receptor, NOV7 - Homo sapiens,1 . . . 315315/315 (100%)315 aa. [WO200177177-A2, 18-OCT-2001]AAU85251G-coupled olfactory receptor1 . . . 315315/315 (100%)e−179#112 - Homo sapiens, 315 aa.1 . . . 315315/315 (100%)[WO200198526-A2, 27-DEC-2001]AAU95586Human olfactory and pheromone1 . . . 315315/315 (100%)e−179G protein-coupled receptor #73 -1 . . . 315315/315 (100%)Homo sapiens, 315 aa.[WO200224726-A2, 28-MAR-2002]AAU24631Human olfactory receptor1 . . . 315315/315 (100%)e−179AOLFR125 - Homo sapiens, 3151 . . . 315315/315 (100%)aa. [WO200168805-A2, 20-SEP-2001]ABP95851Human GPCR polypeptide SEQ1 . . . 313313/313 (100%)e−178ID NO 512 - Homo sapiens, 3141 . . . 313313/313 (100%)aa. [WO200216548-A2, 28-FEB-2002]

In a BLAST search of public sequence databases, the NOV12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12E.

TABLE 12EPublic BLASTP Results for NOV12aNOV12aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8NGZ2Seven transmembrane helix1 . . . 315315/315 (100%) e−179receptor - Homo sapiens1 . . . 315315/315 (100%)(Human), 315 aa.Q96R53Olfactory receptor - Homo66 . . . 282 217/217 (100%) e−120sapiens (Human), 217 aa1 . . . 217217/217 (100%)(fragment).Q8NHC5Seven transmembrane helix1 . . . 303158/307 (51%)9e−88receptor - Homo sapiens1 . . . 302225/307 (72%)(Human), 309 aa.CAD35484Sequence 23 from Patent1 . . . 303155/303 (51%)4e−87WO0208289 - Homo sapiens1 . . . 303211/303 (69%)(Human), 314 aa.Q8VF67Olfactory receptor MOR218-3 -1 . . . 302156/302 (51%)4e−87Mus musculus (Mouse), 3155 . . . 306214/302 (70%)aa.

PFam analysis indicates that the NOV12a protein contains the domains shown in the Table 12F.

TABLE 12FDomain Analysis of NOV12aNOV12aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_139 . . . 288 57/277 (21%)1.8e−14170/277 (61%)

Example 13

The NOV13 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 13A.

TABLE 13ANOV13 Sequence AnalysisNOV13a, CG50365-01SEQ ID NO: 143828 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAA at 802CCACCCCGAGGGACCATGTCGAGGCTCAGCTGGGGATACCGCGAGCACAACGGTCCTATTCACTGGAAGGAATTTTTCCCTATTGCTGATGGTGATCAGCAATCTCCAATTGAGATTAAAACCAAAGAAGTGAAATATGACTCTTCCCTCCGACCACTTAGTATCAAGTATGACCCAAGCTCAGCTAAAATCATCAGCAACAGCGGCCATTCCTTCAATGTTGACTTTGATGACACAGAGAACAAATCAGTTCTGCGTGGTGGTCCTCTCACTGGAAGCTACAGGTTACGGCAGGTTCACCTTCACTGGGGGTCCGCTGATGACCACGGCTCCGAGCACATAGTAGATGGAGTGAGCTATGCTGCAGAGCTCCATGTTGTTCACTGGAATTCAGACAAATACCCCAGCTTTGTTGAGGCAGCTCATGAACCAGATGGACTGGCTGTCTTGGGAGTGTTTTTACAGGTGGGTGAACCTAATTCCCAACTGCAAAAGATTACTGACACTTTGGATTCCATTAAAGAAAAGGGTAAACAAACTCGATTCACAAATTTTGACCTATTGTCTCTGCTTCCACCATCCTGGGACTACTGGACATATCCTGGTTCTCTTACAGTTCCACCTCTTCTTGAGAGTGTCACATGGATTGTTTTAAAGCAACCTATAAACATCAGCTCTCAACAGCTGGCCAAATTTCGCAGTCTCCTGTGCACAGCGGAGGGTGAAGCAGCAGCTTTTCTGGTGAGCAATCACCGCCCACCACAGCCTCTAAAGGGCCGCAAAGTGAGAGCCTCTTTCCATTAAAAATTGTCACCAATGAACTCCCCCNOV13a, CG50365-01Protein SequenceSEQ ID NO: 144262 aaMW at 29428.8kDMSRLSWGYREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFDDTENKSVLRGGPLTGSYRLRQVHLHWGSADDHGSEHIVDGVSYAAELHVVHWNSDKYPSFVEAAHEPDGLAVLGVFLQVGEPNSQLQKITDTLDSIKEKGKQTRFTNFDLLSLLPPSWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLAKFRSLLCTAEGEAAAFLVSNHRPPQPLKGRKVRASFHNOV13b, 278019595SEQ ID NO: 145784 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCAGCTGGGGATACCGCGAGCACAACGGTCCTATTCACTGGAAGGAATTTTTCCCTATTGCTGATGGTGATCAGCAATCTCCAATTGAGATTAAAACCAAAGAAGTGAAATATGACTCTTCCCTCCGACCACTTAGTATCAAGTATGACCCAAGCTCAGCTAAAATCATCAGCAACAGCGGCCATTCCTTCAATGTTGACTTTGATGACACAGAGAACAAATCAGTTCTGCGTGGTGGTCCTCTCACTGGAAGCTACAGGTTACGGCAGGTTCACCTTCACTGGGGGTCCGCTGATGACCACGGCTCCGAGCACATAGTAGATGGAGTGAGCTATGCTGCAGAGCTCCATGTTGTTCACTGGAATTCAGACAAATACCCCAGCTTTGTTGAGGCAGCTCATGAACCAGATGGACTGGCTGTCTTGGGAGTGTTTTTACAGATTGGTGAACCTAATTCCCAACTGCAAAAGATTACTGACACTTTGGATTCCATTAAAGAAAAGGGTAAACAAACTCGATTCACAAATTTTGACCTATTGTCTCTGCTTCCACCATCCTGGGACTACTGGACATATCCTGGTTCTCTTACAGTTCCACCTCTTCTTGAGAGTGTCACATGGATTGTTTTAAAGCAACCTATAAACATCAGCTCTCAACAGCTGGCCAAATTTCGCAGTCTCCTGTGCACAGCGGAGGGTGAAGCAGCAGCTTTTCTGGTGAGCAATCACCGCCCACCACAGCCTCTAAAGGGCCGCAAAGTGAGAGCCCTCGAGGGCNOV13b, 278019595Protein SequenceSEQ ID NO: 146261 aaMW at 29128.4kDTGSSWGYREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFDDTEMKSVLRGGPLTGSYRLRQVHLHWGSADDHGSEHIVDGVSYAAELHVVHWNSDKYPSFVEAAHEPDGLAVLGVFLQIGEPNSOLQKITDTLDSIKEKGKQTRFTNFDLLSLLPPSWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLAKFRSLLCTAEGEAAAFLVSNHRPPQPLKGRKVRALEGNOV13c, CG50365-02SEQ ID NO: 147833 bpDNA SequenceORF Start: ATG at 21ORF Stop: TAA at 807ATGTCGAGGCTCAGCTGGGGATGTCGAGGCTCAGCTGGGGATACCGCGAGCACAACGGTCCTATTCACTGGAAGGAATTTTTCCCTATTGCTGATGGTGATCAGCAATCTCCAATTGAGATTAAAACCAAAGAAGTGAAATATGACTCTTCCCTCCGACCACTTAGTATCAAGTATGACCCAAGCTCAGCTAAAATCATCAGCAACAGCGGCCATTCCTTCAATGTTGACTTTGATGACACAGAGAACAAATCAGTTCTGCGTGGTGGTCCTCTCACTGGAAGCTACAGGTTACGGCAGGTTCACCTTCACTGGGGGTCCGCTGATGACCACGGCTCCGAGCACATAGTAGATGGAGTGAGCTATGCTGCAGAGCTCCATGTTGTTCACTGGAATTCAGACAAATACCCCAGCTTTGTTGAGGCAGCTCATGAACCAGATGGACTGGCTGTCTTGGGAGTGTTTTTACAGATTGGTGAACCTAATTCCCAACTGCAAAAGATTACTGACACTTTGGATTCCATTAAAGAAAAGGGTAAACAAACTCGATTCACAAATTTTGACCTATTGTCTCTGCTTCCACCATCCTGGGACTACTGGACATATCCTGGTTCTCTTACAGTTCCACCTCTTCTTGAGAGTGTCACATGGATTGTTTTAAAGCAACCTATAAACATCAGCTCTCAACAGCTGGCCAAATTTCGCAGTCTCCTGTGCACAGCGGAGGGTGAAGCAGCAGCTTTTCTGGTGAGCAATCACCGCCCACCACAGCCTCTAAAGGGCCGCAAAGTGAGAGCCTCTTTCCATTAAAAATTGTCACCAATGAACTCCCCCNOV13c, CG50365-02Protein SequenceSEQ ID NO: 148262 aaMW at 29442.8kDMSRLSWGYREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFDDTENKSVLRGGPLTGSYRLRQVHLHWGSADDHGSEHIVDGVSYAAELHVVHWNSDKYPSFVEAAHEPDGLAVLGVFLQIGEPNSQLQKITDTLDSIKEKGKQTRFTNFDLLSLLPPSWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLAKFRSLLCTAEGEAAAFLVSNHRPPQPLKGRKVRASFH

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 13B.

TABLE 13BComparison of the NOV13 protein sequences.NOV13aMSRLSWGYREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIINOV13b-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(SEQ ID NO: 144)NOV13b(SEQ ID NO: 146)NOV13c(SEQ ID NO: 148)

Further analysis of the NOV13a protein yielded the following properties shown in Table 13C.

TABLE 13CProtein Sequence Properties NOV13aSignalP analysis: No Known Signal Sequence PredictedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 2; neg.chg 1H-region: length 7; peak value −7.23PSG score: −11.62GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −8.81possible cleavage site: between 57 and 58>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERALLikelihood = 2.97 (at 197)ALOM score: 2.97 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment(75):8.62Hyd Moment(95):7.75G content:2D/E content:2S/T content:2Score: −5.03Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 13 SRL|SWNUCDISC:discrimination of nuclear localization signalspat4: nonepat7: PLKGRKV (4) at 251bipartite: nonecontent of basic residues: 10.3%NLS Score: −0.13KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: SRLSnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 55.5COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):43.5%: cytoplasmic34.8%: mitochondrial21.7%: nuclear>> prediction for CG50365-01 is cyt (k = 23)

A search of the NOV13a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13D.

TABLE 13DGeneseq Results for NOV13aNOV13aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE25377Human NZMS-1 protein - Homo1 . . . 262246/262 (93%)e−143sapiens, 247 aa. [WO200246385-1 . . . 247247/262 (93%)A2, 13-JUN-2002]AAU19418Human diagnostic and therapeutic1 . . . 262246/262 (93%)e−143polypeptide (DITHP) #4 - Homo13 . . . 273 248/262 (93%)sapiens, 274 aa. [WO200162927-A2, 30-AUG-2001]ABB08900Human lyase HLYA-1 protein -1 . . . 242241/242 (99%)e−143Homo sapiens, 242 aa.1 . . . 242242/242 (99%)[WO200200840-A2, 03-JAN-2002]AAB63110Human secreted protein sequence78 . . . 261 181/184 (98%)e−105encoded by gene 27 SEQ ID1 . . . 184183/184 (99%)NO: 120 - Homo sapiens, 184 aa.[WO200061748-A1, 19-OCT-2000]AAO15236Human carbonic anhydrase I1 . . . 261157/261 (60%)5e−94 (Cln115) protein - Homo sapiens,1 . . . 261202/261 (77%)261 aa. [US2002042088-A1, 11-APR-2002]

In a BLAST search of public sequence databases, the NOV13a protein was found to have homology to the proteins shown in the BLASTP data in Table 13E.

TABLE 13EPublic BLASTP Results for NOV13aNOV13aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedNumberProtein/Organism/LengthResiduesPortionExpect ValueQ8N1Q1Carbonic anhydrase XIII (EC1 . . . 262261/262 (99%) e−1554.2.1.1) (Carbonate dehydratase1 . . . 262262/262 (99%)XIII) (CA-XIII) - Homo sapiens(Human), 262 aa.Q9D6N1Carbonic anhydrase XIII (EC1 . . . 262238/262 (90%) e−1414.2.1.1) (Carbonate dehydratase1 . . . 262250/262 (94%)XIII) (CA-XIII) - Mus musculus(Mouse), 262 aa.Q8HY33Carbonic anhydrase 1 -1 . . . 261164/261 (62%)e−99Monodelphis domestica (Short-1 . . . 261210/261 (79%)tailed grey opossum), 262 aa.Q8JG56Erythrocyte carbonic anhydrase -5 . . . 261165/257 (64%)1e−95 Lepisosteus osseus (Long-nosed4 . . . 260198/257 (76%)gar), 261 aa.Q8UWA5Carbonic anhydrase 2 (EC 4.2.1.1)6 . . . 261164/256 (64%)8e−95 (Carbonate dehydratase) -5 . . . 259200/256 (78%)Tribolodon hakonensis, 260 aa.

PFam analysis indicates that the NOV13a protein contains the domains shown in the Table 13F.

TABLE 13FDomain Analysis of NOV13aNOV13aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Valuecarb_anhydrase6 . . . 261172/283 (61%)1.9e−162221/283 (78%)

Example 14

The NOV14 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 14A.

TABLE 14ANOV14 Sequence AnalysisNOV14a, CG50367-01SEQ ID NO: 1492762 bpDNA SequenceORF Start: ATG at 3ORF Stop: TGA at 2745CTATGGGCTGGAGGCCCCGGAGAGCTCGGGGGACCCCGTTGCTGCTGCTGCTACTACTGCTGCTGCTCTGGCCAGTGCCAGGCGCCGGGGTGCTTCAAGGACATATCCCTGGGCAGCCAGTCACCCCGCACTGGGTCCTGGATGGACAACCCTGGCGCACCGTCAGCCTGGAGGAGCCGGTCTCGAAGCCAGACATGGGGCTGGTGGCCCTGGAGGCTGAAGGCCAGGAGCTCCTGCTTGAGCTGGAGAAGAACCACAGGCTGCTGGCCCCAGGATACATAGAAACCCACTACGGCCCAGATGGGCAGCCAGTGGTGCTGGCCCCCAACCACACGGATCATTGCCACTACCAAGGGCGAGTAAGGGGCTTCCCCGACTCCTGGGTAGTCCTCTGCACCTGCTCTGGGATGAGTGGCCTGATCACCCTCAGCAGGAATGCCAGCTATTATCTGCGTCCCTGGCCACCCCGGGGCTCCAAGGACTTCTCAACCCACGAGATCTTTCGGATGGAGCAGCTGCTCACCTGGAAAGGAACCTGTGGCCACAGGGATCCTGGGAACAAAGCGGGCATGACCAGCCTTCCTGGTGGTCCCCAGAGCAGGGGCAGGCGAGAAGCGCGCAGGACCCGGAAGTACCTGGAACTGTACATTGTGGCAGACCACACCCTGTTCTTGACTCGGCACCGAAACTTGAACCACACCAAACAGCGTCTCCTGGAAGTCGCCAACTACGTGGACCAGCTTCTCAGGACTCTGGACATTCAGGTGGCGCTGACCGGCCTGGAGGTGTGGACCGAGCGGGACCGCAGCCGCGTCACGCAGGACGCCAACGCCACGCTCTGGGCCTTCCTGCAGTGGCGCCGGGGGCTGTGGGCGCAGCGGCCCCACGACTCCGCGCAGCTGCTCACGGGCCGCGCCTTCCAGGGCGCCACAGTGGGCCTGGCGCCCGTCGAGGGCATGTGCCGCGCCGAGAGCTCGGGAGGCGTGAGCACGGACCACTCGGAGCTCCCCATCGGCGCCGCAGCCACCATGGCCCATGAGATCGGCCACAGCCTCGGCCTCAGCCACGACCCCGACGGCTGCTGCGTGGAGGCTGCGGCCGAGTCCGGAGGCTGCGTCATGGCTGCGGCCACCGGGCACCCGTTTCCGCGCGTGTTCAGCGCCTGCAGCCGCCGCCAGCTGCGCGCCTTCTTCCGCAAGGGGGGCGGCGCTTGCCTCTCCAATGCCCCGGACCCCGGACTCCCGGTGCCGCCGGCGCTCTGCGGGAACGGCTTCGTGGAAGCGGGCGAGGAGTGTGACTGCGGCCCTGGCCAGGAGTGCCGCGACCTCTGCTGCTTTGCTCACAACTGCTCGCTGCGCCCGGGGGCCCAGTGCGCCCACGGGGACTGCTGCGTGCGCTGCCTGCTGAAGCCGGCTGGAGCGCTGTGCCGCCAGGCCATGGGTGACTGTGACCTCCCTGAGTTTTGCACGGGCACCTCCTCCCACTGTCCCCCAGACGTTTACCTACTGGACGGCTCACCCTGTGCCAGGGGCAGTGGCTACTGCTGGGATGGCGCATGTCCCACGCTGGAGCAGCAGTGCCAGCAGCTCTGGGGGCCTGGCTCCCACCCAGCTCCCGAGGCCTGTTTCCAGGTGGTGAACTCTGCGGGAGATGCTCATGGAAACTGCGGCCAGGACAGCGAGGGCCACTTCCTGCCCTGTGCAGGGAGGGATGCCCTGTGTGGGAAGCTGCAGTGCCAGGGTGGAAAGCCCAGCCTGCTCGCACCGCACATGGTGCCAGTGGACTCTACCGTTCACCTAGATGGCCAGGAAGTGACTTGTCGGGGAGCCTTGGCACTCCCCAGTGCCCAGCTGGACCTGCTTGGCCTGGGCCTGGTAGAGCCAGGCACCCAGTGTGGACCTAGAATGGTGTGCCAGAGCAGGCGCTGCAGGAAGAATGCCTTCCAGGAGCTTCAGCGCTGCCTGACTGCCTGCCACAGCCACGGGGTTTGCAATAGCAACCATAACTGCCACTGTGCTCCAGGCTGGGCTCCACCCITCTGTGACAAGCCAGGCTTTGGTGGCAGCATGGACAGTGGCCCTGTGCAGGCTGAAAACCATGACACCTTCCTGCTGGCCATGCTCCTCAGCGTCCTGCTGCCTCTGCTCCCAGGGGCCGGCCTGGCCTGGTGTTGCTACCGACTCCCAGGAGCCCATCTGCAGCGATGCAGCTGGGGCTGCAGAAGGGACCCTGCGTGCAGTGGCCCCAAAGATGGCCCACACAGGGACCACCCCCTGGGCGGCGITCACCCCATGGAGTTGGGCCCCACAGCCACTGGACAGCCCTGGCCCCTGGCCCCAGGGGCTCCTGCTGACCATATTCACAACATTTACCCTCCACCATTTCTCCCAGACCCTGAGAACTCTCATGAGCCCAGCAGCCACCCTGAGAAGCCTCTGCCAGCAGTCTCGCCTGACCCCCAAGGTGGTTCCCTTGCAGCCTGGGGCCCCAGTCCTTTAGGGGACAACATATCCTCCTCATTCTCAGCAGATCAAGTCCAGATGCCAAGATCCTGCCTCTGTGGCGAACCCTGGGGAGGCCACGTGGGAAGGAAAGAGGGCTCTAAGAGGGGAGGCCCCAGACTGGGGGAGAGGCCTGTCTGGAGCCCAGGATCACCTGGCTGTGCTGCAGAACTGGAGAAGAGAAGCTCAGCAGAAAGGAGCTGGCATGGGGCCAACAGCAGAAAAGCAGGAGGCACGCAGAAGTGACTGGGAAGCAGGAGGNOV14a, CG50367-01Protein SequenceSEQ ID NO: 150914 aaMW at 98055.2kDMGWRPRPARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQPWPLAPGAPADHIHNIYPPPFLPDPENSHEPSSHPEKPLPAVSPDPQGGSLAAWGPSPLGDNISSSFSADQVQMPRSCLCGEPWGGHVGRKEGSKRGGPRLGERPVWSPGSPGCAAELEKRSSAERSWHGANSRKAGGTQKNOV14b, CG50367-05SEQ ID NO: 1513397 bpDNA SequenceORF Start: ATG at 37ORF Stop: TGA at 2398GCGAGCCGCTGCCTAGAGGCCGAGGAGCTCACAGCTATGGGCTGGAGGCCCCGGAGAGCTCGGGGGACCCCGTTGCTGCTGCTGCTACTACTGCTGCTGCTCTGGCCAGTGCCAGTCGCCGGGGTGCTTCAAGGACATATCCCTGGGCAGCCAGTCACCCCGCACTGGGTCCTGGATGGACAACCCTGGCGCACCGTCAGCCTGGAGGAGCCGGTCTCGAAGCCAGACATGGGGCTGGTGGCCCTGGAGGCTGAAGGCCAGGAGCTCCTGCTTGAGCTGGAGAAGAACCACAGGCTGCTGGCCCCAGGATACATAGAAACCCACTACGGCCCAGATGGGCAGCCAGTGGTGCTGGCCCCCAACCACACGGATCATTGCCACTACCAAGGGCGAGTAAGGGGCTTCCCCGACTCCTGGGTAGTCCTCTGCACCTGCTCTGGGATGAGTGGCCTGATCACCCTCAGCAGGAATGCCAGCTATTATCTGCGTCCCTGGCCACCCCGGGGCTCCAAGGACTTCTCAACCCACGAGATCTTTCGGATGGAGCAGCTGCTCACCTGGAAAGGAACCTGTGGCCACAGGGATCCTGGGAACAAAGCGGGCATGACCAGCCTTCCTGGTGGTCCCCAGAGCAGGGGCAGGCGAGAAGCGCGCAGGACCCGGAAGTACCTGGAACTGTACATTGTGGCAGACCACACCCTGTTCTTGACTCGGCACCGAAACTTGAACCACACCAAACAGCGTCTCCTGGAAGTCGCCAACTACGTGGACCAGCTTCTCAGGACTCTGGACATTCAGGTGGCGCTGACCGGCCTGGAGGTGTGGACCGAGCGGGACCGCAGCCGCGTCACGCAGGACGCCAACGCCACGCTCTGGGCCTTCCTGCAGTGGCGCCGGGGGCTGTGGGCGCAGCGGCCCCACGACTCCGCGCAGCTGCTCACGGGCCGCGCCTTCCAGGGCGCCACAGTGGGCCTGGCGCCCGTCGAGGGCATGTGCCGCGCCGAGAGCTCGGGAGGCGTGAGCACGGACCACTCGGAGCTCCCCATCGGCGCCGCAGCCACCATGGCCCATGAGATCGGCCACAGCCTCGGCCTCAGCCACGACCCCGACGGCTGCTGCGTGGAGGCTGCGGCCGAGTCCGGAGGCTGCGTCATGGCTGCGGCCACCGGGCACCCGTTTCCGCGCGTGTTCAGCGCCTGCAGCCGCCGCCAGCTGCGCGCCTTCTTCCGCAAGGGGGGCGGCGCTTGCCTCTCCAATGCCCCGGACCCCGGACTCCCGGTGCCGCCGGCGCTCTGCGGGAACGGCTTCGTGGAAGCGGGCGAGGAGTGTGACTGCGGCCCTGGCCAGGAGTGCCGCGACCTCTGCTGCTTTGCTCACAACTGCTCGCTGCGCCCGGGGGCCCAGTGCGCCCACGGGGACTGCTGCGTGCGCTGCCTGCTGAAGCCGGCTGGAGCGCTGTGCCGCCAGGCCATGGGTGACTGTGACCTCCCTGAGTTTTGCACGGGCACCTCCTCCCACTGTCCCCCAGACGTTTACCTACTGGACGGCTCACCCTGTGCCAGGGGCAGTGGCTACTGCTGGGATGGCGCATGTCCCACGCTGGAGCAGCAGTGCCAGCAGCTCTGGAAGCCTGGCTCCCACCCAGCTCCCGAGGCCTGTTTCCAGGTGGTGAACTCTGCGGGAGATGCTCATGGAAACTGCGGCCAGGACAGCGAGGGCCACTTCCTGCCCTGTGCAGGGAGGGATGCCCTGTGTGGGAAGCTGCAGTGCCAGGGTGGAAAGCCCAGCCTGCTCGCACCGCACATGGTGCCAGTGGACTCTACCGTTCACCTAGATGGCCAGGAAGTGACTTGTCGGGGAGCCTTGGACTCCCCAGTGCCCAGCTGGACCTGCTTGGCCTTGGGCCTGGTAGAGTCAGGCACCCAGTGTGGACCTAGAATGGTTTGCAATAGCAACCATAACTGCCACTGTGCTCCAGGCTGGGCTCCACCCTTCTGTGACAAGCCAGGCTTTGGTGGCAGCATGGACAGTGGCCCTGTGCAGGCTGAAAACCATGACACCTTCCTGCTGGCCATGCTCCTCAGCGTCCTGCTGCCTCTGCTCCCAGGGGCCGGCCTGGCCTGGTGTTGCTACCGACTCCCAGGAGCCCATCTGCAGCGATGCAGCTGGGGCTGCAGAAGGGACCCTGCGTGCAGTGGCCCCAAAGATGGCCCACACAGGGACCACCCCCTGGGCGGCGTTCACCCCATGGAGTTGGGCCCCACAGCCACTGGACAGCCCTGGCCCCTGGACCCTGAGAACTCTCATGAGCCCAGCAGCCACCCTGAGAAGCCTCTGCCAGCAGTCTCGCCCGACCCCCAAGCAGATCAAGTCCAGATGCCAAGATCCTGCCTCTGGTGAGAGGTAGCTCCTAAAATGAACAGATTTAAAGACAGGTGGCCACTGACAGCCACTCCAGGAACTTGAACTGCAGGGGCAGAGCCAGTGAATCACCGGACCTCCAGCACCTGCAGGCAGCTTGGAAGTTTCTTCCCCGAGTGGAGCTTCGACCCACCCACTCCAGGAACCCAGAGCCACACTAGAAGTTCCTGAGGGCTGGAGAACACTGCTGGGCACACTCTCCAGCTCAATAAACCATCAGTCCCAGAAGCAAAGGTCACACAGCCCCTGACCTCCCTCACCAGTGGAGGCTGGGTAGTGCTGGCCATCCCAAAAGGGCTCTGTCCTGGGAGTCTGGTGTGTCTCCTACATGCAATTTCCACGGACCCAGCTCTGTGGAGGGCATGACTGCTGGCCAGAAGCTAGTGGTCCTGGGGCCCTATGGTTCGACTGAGTCCACACTCCCCTGCAGCCTGGCTGGCCTCTGCAAACAAACATAATTTTGGGGACCTTCCTTCCTGTTTCTTCCCACCCTGTCTTCTCCCCTAGGTGGTTCCTGAGCCCCCACCCCCAATCCCAGTGCTACACCTGAGGTTCTGGAGCTCAGAATCTGACAGCCTCTCCCCCATTCTGTGTGTGTCGGGGGGACAGAGGGAACCATTTAAGAAAAGATACCAAAGTAGAAGTCAAAAGAAAGACATGTTGGCTATAGGCGTGGTGGCTCATGCCTATAATCCCAGCACTTTGGGAAGCCGGGGTAGGAGGATCACCAGAGGCCAGCAGGTCCACACCAGCCTGGGCAACACAGCAAGACACCGCATCTACAGAAAAATTTTAAAATTAGCTGGGCGTGGTGGTGTGTACCTGTAGGCCTAGCTGCTCAGGAGGCTGAAGCAGGAGGATCACTTGAGCCTGAGTTCAACACTGCAGTGAGCTATGGTGGCACCACTGCACTCCAGCCTGGGTGACAGAGCAAGACCCTGTCTCTAAAATAAATTTTAAAAAGACATATTACACTNOV14b, CG50367-05Protein SequenceSEQ ID NO: 152787 aaMW at 84713.5kDMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVNLDGQEVTCRGALALPSAQLDLLGLGLVESGTQCGPRNVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQPWPLDPENSHEPSSHPEKPLPAVSPDPQADQVQMPRSCLWNOV14c, CG50367-06SEQ ID NO: 1533351 bpDNA SequenceORF Start: ATG at 37ORF Stop: TGA at 1579GCGAGCCGCTGCCTAGAGGCCGAGGAGCTCACAGCTATGGGCTGGAGGCCCCGGAGAGCTCGGGGGACCCCGTTGCTGCTGCTGCTACTACTGCTGCTGCTCTGGCCAGTGCCAGGCGCCGGGGTGCTTCAAGGACATATCCCTGGGCAGCCAGTCACCCCGCACTGGGTCCTGGATGGACAACCCTGGCGCACCGTCAGCCTGGAGGAGCCGGTCTCGAAGCCAGACATGGGGCTGGTGGCCCTGGAGGCTGAAGGCCAGGAGCTCCTGCTTGAGCTGGAGAAGAACCACAGGCTGCTGGCCCCAGGATACATAGAAACCCACTACGGCCCAGATGGGCAGCCAGTGGTGCTGGCCCCCAACCACACGGATCATTGCCACTACCAAGGGCGAGTAAGGGGCTTCCCCGACTCCTGGGTAGTCCTCTGCACCTGCTCTGGGATGAGTGGCCTGATCACCCTCAGCAGGAATGCCAGCTATTATCTGCGTCCCTGGCCACCCCGGGGCTCCAAGGACTTCTCAACCCACGAGATCTTTCGGATGGAGCAGCTGCTCACCTGGAAAGGAACCTGTGGCCACAGGGATCCTGGGAACAAAGCGGGCATGACCAGCCTTCCTGGTGGTCCCCAGAGCAGGGGCAGGCGAGAAGCGCGCAGGACCCGGAAGTACCTGGAACTGTACATTGTGGCAGACCACACCCTGTTCTTGACTCGGCACCGAAACTTGAACCACACCACACAGCGTCTCCTGGAAGTCGCCAACTACGTGGACCAGCTTCTCAGGACTCTGGACATTCAGGTGGCGCTGACCGGCCTGGAGGTGTGGACCGAGCGGGACCGCAGCCGCGTCACGCAGGACGCCAACGCCACGCTCTGGGCCTTCCTGCAGTGGCGCCGGGGGCTGTGGGCGCAGCGGCCCCACGACTCCGCGCAGCTGCTCACGGGCCGCGCCTTCCAGGGCGCCACAGTGGGCCTGGCGCCCGTCGAGGGCATGTGCCGCGCCGAGAGCTCGGGAGGCGTGAGCACGGACCACTCGGAGCTCCCCATCGGCGCCGCAGCCACCATGGCCCATGAGATCGGCCACAGCCTCGGCCTCAGCCACGACCCCGACGGCTGCTGCGTGGAGGCTGCGGCCGAGTCCGGAGGCTGCGTCATGGCTGCGGCCACCGGGCACCCGTTTCCGCGCGTGTTCAGCGCCTGCAGCCGCCGCCAGCTGCGCGCCTTCTTCCGCAAGGGGGGCGGCGCTTGCCTCTCCAATGCCCCGGACCCCGGACTCCCGGTGCCGCCGGCGCTCTGCGGGAACGGCTTCGTGGAAGCGGGCGAGGAGTGTGACTGCGGCCCTGGCCAGGAGTGCCGCGACCTCTGCTGCTTTGCTCACAACTGCTCGCTGCGCCCGGGGGCCCAGTGCGCCCACGGGGACTGCTGCGTGCGCTGCCTGACGTTTACCTACTGGACGGCTCACCCTGTGCCAGGGGCAGTGGCTACTGCTGGGATGGCGCATGTCCCACGCTGGAGCAGCAGTGCCAGCAGCTCTGGGGGCCTGGCTCCCACCCAGCTCCCGAGGCCTGTTTCCAGGTGGTGAACTCTGCGGGAGATGCTCATGGAAACTGCGGCCAGGACAGCGAGGGCCACTTCCTGCCCTGTGCAGGGAGGGATGCCCTGTGTGGGAAGCTGCAGTGCCAGGGTGGAAAGCCCAGCCTGCTCGCACCGCACATGGTGCCAGTGGACTCTACCGTTCACCTAGATGGCCAGGAAGTGACTTGTCGGGGAGCCTTGGCACTCCCCAGTGCCCAGCTGGACCTGCTTGGCCTGGGCCTGGTAGAGCCAGGCACCCAGTGTGGACCTAGAATGGTGTGCCAGAGCAGGCGCTGCAGGAAGAATGCCTTCCAGGAGCTTCAGCGCTGCCTGACTGCCTGCCACAGCCACGGGGTTTGCAATAGCAACCATAACTGCCACTGTGCTCCAGGCTGGGCTCCACCCTTCTGTGACAAGCCAGGCTTTGGTGGCAGCATGGACAGTGGCCCTGTGCAGGCTGAAAACCATGACACCTTCCTGCTGGCCATGCTCCTCAGCGTCCTGCTGCCTCTGCTCCCAGGGGCCGGCCTGGCCTGGTGTTGCTACCGACTCCCAGGAGCCCATCTGCAGCGATGCAGCTGGGGCTGCAGAAGGGACCCTGCGTGCAGTGGCCCCAAAGATGGCCCACACAGGGACCACCCCCTGGGCGGCGTTCACCCCATGGAGTTGGGCCCCACAGCCACTGGACAGCCCTGGCCCCTGGACCCTGAGAACTCTCATGAGCCCAGCAGCCACCCTGAGAAGCCTCTGCCAGCAGTCTCGCCTGACCCCCAAGATCAAGTCCAGATGCCAAGATCCTGCCTCTGGTGAGAGGTAGCTCCTAAAATGAACAGATTTAAAGACAGGTGGCCACTGACAGCCACTCCAGGAACTTGAACTGCAGGGGCAGAGCCAGTGAATCACCGGACCTCCAGCACCTGCAGGCAGCTTGGAAGTTTCTTCCCCGAGTGGAGCTTCGACCCACCCACTCCAGGAACCCAGAGCCACATTAGAAGTTCCTGAGGGCTGGAGAACACTGCTGGGCACACTCTCCAGCTCAATAAACCATCAGTCCCAGAAGCAAAGGTCACACAGCCCCTGACCTCCCTCACCAGTGGAGGCTGGGTAGTGCTGGCCATCCCAAAAGGGCTCTGTCCTGGGAGTCTGGTGTGTCTCCTACATGCAATTTCCACGGACCCAGCTCTGTGGAGGGCATGACTGCTGGCCAGAAGCTAGTGGTCCTGGGGCCCTATGGTTCGACTGAGTCCACACTCCCCTGGAGCCTGGCTGGCCTCTGCAAACAAACATAATTTTGGGGACCTTCCTTCCTGTTTCTTCCCACCCTGTCTTCTCCCCTAGGTGGTTCCTGAGCCCCCACCCCCAATCCCAGTGCTACACCTGAGGTTCTGGAGCTCAGAATCTGACAGCCTCTCCCCCATTCTGTGTGTGTCGGGGGGACAGAGGGAACCATTTAAGAAAAGATACCAAAGTAGAAGTCAAAAGAAAGACATGTTGGCTATAGGCGTGGTGGCTCATGCCTATAATCCCAGCACTTTGGGAAGCCGGGGTAGGAGGATCACCAGAGGCCAGCAGGTCCACACCAGCCTGGGCAACACAGCAAGACACCGCATCTACAGAAAAATTTTAAAATTAGCTGGGCGTGGTGGTGTGTACCTGTAGGCCTAGCTGCTCAGGAGGCTGAAGCAGGAGGATCACTTGAGCCTGAGTTCAACACTGCAGTGAGCTATGGTGGCACCACTGCACTCCAGCCTGGGTGACAGAGCAAGACCCTGTCTCTNOV14c, CG50367-06Protein SequenceSEQ ID NO: 154514 aaMW at 55996.3kDMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLTFTYWTAHPVPGAVATAGMAHVPRWSSSASSSGGLAPTQLPRPVSRWNOV14d, CG50367-07SEQ ID NO: 1553139 bpDNA SequenceORF Start: ATG at 37ORF Stop: TGA at 1354GCGAGCCGCTGCCTAGAGGCCGAGGAGCTCACAGCTATGGGCTGGAGGCCCCGGAGAGCTCGGGGGACCCCGTTGCTGCTGCTGCTACTACTGCTGCTGCTCTGGCCAGTGCCAGGCGCCGGGGTGCTTCAAGGACATATCCCTGGGCAGCCAGTCACCCCGCACTGGGTCCTGGATGGACAACCCTGGCGCACCGTCAGCCTGGAGGAGCCGGTCTCGAAGCCAGACATGGGGCTGGTGGCCCTGGAGGCTGAAGGCCAGGAGCTCCTGCTTGAGCTGGAGAAGAACCACAGGCTGCTGGCCCCAGGATACATAGAAACCCACTACGGCCCAGATGGGCAGCCAGTGGTGCTGGCCCCCAACCACACGGATCATTGCCACTACCAAGGGCGAGTAAGGGGCTTCCCCGACTCCTGGGTAGTCCTCTGCACCTGCTCTGGGATGAGTGGCCTGATCACCCTCAGCAGGAATGCCAGCTATTATCTGCGTCCCTGGCCACCCCGGGGCTCCAAGGACTTCTCAACCCACGAGATCTTTCGGATGGAGCAGCTGCTCACCTGGAAAGGAACCTGTGGCCACAGGGATCCTGGGAACAAAGCGGGCATGACCAGCCTTCCTGGTGGTCCCCAGAGCAGGGGCAGGCGAGAAGCGCGCAGGACCCGGAAGTACCTGGAACTGTACATTGTGGCAGACCACACCCTGTTCTTGACTCGGCACCGAAACTTGAACCACACCAAACAGCGTCTCCTGGAAGTCGCCAACTACGTGGACCAGCTTCTCAGGACTCTGGACATTCAGGTGGCGCTGACCGGCCTGGAGGTGTGGACCGAGCGGGACCGCAGCCGCGTCACGCAGGACGCCAACGCCACGCTCTGGGCCTTCCTGCAGTGGCGCCGGGGACTGTGGGCGCAGCGGCCCCACGACTCCGCGCAGCTGCTCACGACCACTCGGAGCTCCCCATCGGCGCCGCAGCCACCATGGCCCATGAGATCGGCCACAGCCTCGGCCTCAGCCACGACCCCGACGGCTGCTGCGTGGAGGCTGCGGCCGAGTCCGGAGGCTGCGTCATGGCTGCGGCCACCGGGCACCCGTTTCCGCGCGTGTTCAGCGCCTGCAGCCGCCGCCAGCTGCGCGCCTTCTTCCGCAAGGGGGGCGGCGCTTGCCTCTCCAATGCCCCGGACCCCGGACTCCCGGTGCCGCCGGCGCTCTGCGGGAACGGCTTCGTGGAAGCGGGCGAGGAGTGTGACTGCGGCCCTGGCCAGGAGTGCCGCGACCTCTGCTGCTTTGCTCACAACTGCTCGCTGCGCCCGGGGGCCCAGTGCGCCCACGGGGACTGCTGCGTGCGCTGCCTGCTGAAGCCGGCTGGAGCGCTGTGCCGCCAGGCCATGGGTGACTGTGACCTCCCTGAGTTTTGCACGGGCACCTCCTCCCACTGTCCCCCAGACGTTTACCTACTGGACGGCTCACCCTGTGCCAGGGGCAGTGGCTACTGCTGGGATGGCGCATGTCCCACGCTGGAGCAGCAGTGCCAGCAGCTCTGGGGGCCTGGCTCCCACCCAGCTCCCGAGGCCTGTTTCCAGGTGGTGAACTCTGCGGGAGATGCTCATGGAAACTGCGGCCAGGACAGCGAGGGCCACTTCCTGCCCTGTGCAGGGAGGGATGCCCTGTGTGGGAAGCTGCAGTGCCAGGGTGGAAAGCCCAGCCTGCTCGCACCGCACATGGTGCCAGTGGACTCTACCGTTCACCTAGATGGCCAGGAAGTGACTTGTCGGGGAGCCTTGGCACTCCCCAGTGCCCAGCTGGACCTGCTTGGCCTGGGCCTGGTAGAGCCAGGCACCCAGTGTGGACCTAGAATGGTGTGCCAGAGCAGGCGCTGCAGGAAGAATGCCTTCCAGGAGCTTCAGCGCTGCCTGACTGCCTGCCACAGCCACGGGGTTTGCAATAGCAACCATAACTGCCACTGTGCTCCAGGCTGGGCTCCACCCTTCTGTGACAAGCCAGGCTTTGGTGGCAGCATGGACAGTGGCCCTGTGCAGGCTGAAAACCATGACACCTTCCTGCTGGCCATGCTCCTCAGCGTCCTGCTGCCTCTGCTCCCAGGGGCCGGCCTGGCCTGGTGTTGCTACCGACTCCCAGGAGCCCATCTGCAGCGATGCAGCTGGGGCTGCAGAAGGGACCCTGCGTGCAGTGGCCCCAAAGATGGCCCACACAGGGACCACCCCCTGGGCGGCGTTCACCCCATGGAGTTGGGCCCCACAGCCACTGGACAGCCCTGGCCCCTGGACCCTGAGAACTCTCATGAGCCCAGCAGCCACCCTGAGAAGCCTCTGCCAGCAGTCTCGCCTGACCCCCAAGATCAAGTCCAGATGCCAAGATCCTGCCTCTGGTGAGAGGTAGCTCCTAAAATGAACAGATTTAAAGACAGGTGGCCACTGACAGCCACTCCAGGAACTTGAACTGCAGGGGCAGAGCCAGTGAATCACCGGACCTCCAGCACCTGCAGGCAGCTTGGAAGTTTCTTCCCCGAGTGGAGCTTCGACCCACCCACTCCAGGAACCCAGAGCCACATTAGAAGTTCCTGAGGGCTGGAGAACACTGCTGGGCACACTCTCCAGCTCAATAAACCATCAGTCCCAGAAGCAAAGGTCACACAGCCCCTGACCTCCCTCACCAGTGGAGGCTGGGTAGTGCTGGCCATCCCAAAAGGGCTCTGTCCTGGGAGTCTGGTGTGTCTCCTACATGCAATTTCCACGGACCCAGCTCTGTGGAGGGCATGACTGCTGGCCAGAAGCTAGTGGTCCTGGGGCCCTATGGTTCGACTGAGTCCACACTCCCCTGGAGCCTGGCTGGCCTCTGCAAACAAACATAATTTTGGGGACCTTCCTTCCTGTTTCTTCCCACCCTGTCTTCTCCCCTAGGTGGTTCCTGAGCCCCCACCCCCAATCCCAGTGCTACACCTGAGGTTCTGGAGCTCAGAATCTGACAGCCTCTCCCCCATTCTGTGTGTGTCGGGGGGACAGAGGGAACCATTTAAGAAAAGATACCAAAGTAGAAGTCAAAAGAAAGACATGTTGGCTATAGGCGTGGTGGCTCATGCCTATAATCCCAGCACTTTGGGAAGCCGGGGTAGGAGGATCACNOV14d, CG50367-07Protein SequenceSEQ ID NO: 156439 aaMW at 48163.4kDMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTTTRSSPSAPQPPWPMRSATASASATTPTAAAWRLRPSPEAASWLRPPGTRFRACSAPAAAASCAPSSARGAALASPMPRTPDSRCRRRSAGTASWKRARSVTAALARSAATSAALLTTARCARGPSAPTGTAACAACNOV14e, 249356906SEQ ID NO: 1571278 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTGAGCTGGAGAAGAACCACAGGCTGCTGGCCCCAGGATACATAGAAACCCACTACGGCCCAGATGGGCAGCCAGTGGTGCTGGCCCCCAACCACACGGATCATTGCCACTACCAAGGGCGAGTAAGGGGCTTCCCCGACTCCTGGGTAGTCCTCTGCACCTGCTCTGGGATGAGTGGCCTGATCACCCTCAGCAGGAATGCCAGCTATTATCTGCGTCCCTGGCCACCCCGGGGCTCCAAGGACTTCTCAACCCACGAGATCTTTCGGATGGAGCAGCTGCTCACCTGGAAAGGAACCTGTGGCCACAGGGATCCTGGGAACAAAGCGGGCATGACCAGCCTTCCTGGTGGTCCCCAGAGCAGGGGCAGGCGAGAAGCGCGCAGGACCCGGAAGTACCTGGAACTGTACATTGTGGCAGACCACACCCTGTTCTTGACTCGGCACCGAAACTTGAACCACACCAAACAGCGTCTCCTGGAAGTCGACAACTACGTGGACCAGCTTCTCAGGACTCTGGACATTCAGGTGGCGCTGACCGGCCTGGAGGTGTGGACCGAGCGGGACCGCAGCCGCGTCACGCAGGACGCCAACGCCACGCTCTGGGCCTTCCTGCAGTGGCGCCGGGGACTGTGGGCGCAGCGGCCCCACGACTCCGCGCAGCTGCTCACGGGCCGCGCCTTCCAGGGCGCCACAGTGGGCCTGGCGCCCGTCGAGGGCATGTGCCGCGCCGAGAGCTCGGGAGGCGTGAGCACGGACCACTCGGAGCTCCCCATCGGCGCCGCAGCCACCATGGCCCATGAGATCGGCCACAGCCTCGGCCTCAGCCACGACCCCGACGGCTGCTGCGTGGAGGCTGCGGCCGAGTCCGGAGGCTGCGTCATGGCTGCGGCCACCGGGCACCCGTTTCCGCGCGTGTTCAGCGCCTGCAGCCGCCGCCAGCTGCGCGCCTTCTTCCGCAAGGGGGGCGGCGCTTGCCTCTCCAATGCCCCGGACCCCGGACTCCCGGTGCCGCCGGCGCTCTGCGGGAACGGCTTCGTGGAAGCGGGCGAGGAGTGTGACTGCGGCCCTGGCCAGGAGTGCCGCGACCTCTGCTGCTTTGCTCACAACTGCTCGCTGCGCCCGGGGGCCCAGTGCGCCCACGGGGACTGCTGCGTGCGCTGCCTGCTGAAGCCGGCTGGAGCGCTGTGCCGCCAGGCCATGGGTGACTGTGACCTCCCTGAGTTTTGCACGGGCACCTCCTCCCACTGTCCCCCAGACGTTTACCTACTCGAGNOV14e, 249356906Protein SequenceSEQ ID NO: 158426 aaMW at 46516.2kDKLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVDNYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLENOV14f, CG50367-02SEQ ID NO: 1592705 bpDNA SequenceORF Start: ATG at 3ORF Stop: TGA at 2688CTATGGGCTGGAGGCCCCGGAGAGCTCGGGGGACCCCGTTGCTGCTGCTGCTACTACTGCTGCTGCTCTGGCCAGTGCCAGGCGCCGGGGTGCTTCAAGGACATATCCCTGGGCAGCCAGTCACCCCGCACTGGGTCCTGGATGGACAACCCTGGCGCACCGTCAGCCTGGAGGAGCCGGTCTCGAAGCCAGACATGGGGCTGGTGGCCCTGGAGGCTGAAGGCCAGGAGCTCCTGCTTGAGCTGGAGAAGAACCACAGGCTGCTGGCCCCAGGATACATAGAAACCCACTACGGCCCAGATGGGCAGCCAGTGGTGCTGGCCCCCAACCACACGGATCATTGCCACTACCAAGGGCGAGTAAGGGGCTTCCCCGACTCCTGGGTAGTCCTCTGCACCTGCTCTGGGATGAGTGGCCTGATCACCCTCAGCAGGAATGCCAGCTATTATCTGCGTCCCTGGCCACCCCGGGGCTCCAAGGACTTCTCAACCCACGAGATCTTTCGGATGGAGCAGCTGCTCACCTGGAAAGGAACCTGTGGCCACAGGGATCCTGGGAACAAAGCGGGCATGACCAGCCTTCCTGGTGGTCCCCAGAGCAGGGGCAGGCGAGAAGCGCGCAGGACCCGGAAGTACCTGGAACTGTACATTGTGGCAGACCACACCCTGTTCTTGACTCGGCACCGAAACTTGAACCACACCAAACAGCGTCTCCTGGAAGTCGCCAACTACGTGGACCAGCTTCTCAGGACTCTGGACATTCAGGTGGCGCTGACCGGCCTGGAGGTGTGGACCGAGCGGGACCGCAGCCGCGTCACGCAGGACGCCAACGCCACGCTCTGGGCCTTCCTGCAGTGGCGCCGGGGGCTGTGGGCGCAGCGGCCCCACGACTCCGCGCAGCTGCTCACGGGCCGCGCCTTCCAGGGCGCCACAGTGGGCCTGGCGCCCGTCGAGGGCATGTGCCGCGCCGAGAGCTCGGGAGGCGTGAGCACGGACCACTCGGAGCTCCCCATCGGCGCCGCAGCCACCATGGCCCATGAGATCGGCCACAGCCTCGGCCTCAGCCACGACCCCGACGGCTGCTGCGTGGAGGCTGCGGCCGAGTCCGGAGGCTGCGTCATGGCTGCGGCCACCGGGCACCCGTTTCCGCGCGTGTTCAGCGCCTGCAGCCGCCGCCAGCTGCGCGCCTTCTTCCGCAAGGGGGGCGGCGCTTGCCTCTCCAATGCCCCGGACCCCGGACTCCCGGTGCCGCCGGCGCTCTGCGGGAACGGCTTCGTGGAAGCGGGCGAGGAGTGTGACTGCGGCCCTGGCCAGGAGTGCCGCGACCTCTGCTGCTTTGCTCACAACTGCTCGCTGCGCCCGGGGGCCCAGTGCGCCCACGGGGACTGCTGCGTGCGCTGCCTGCTGCCGCCGGCTGGAGCGCTGTGCCGCCAGGCCATGGGTGACTGTGACCTCCCTGAGTTTTGCACGGGCACCTCCTCCCACTGTCCCCCAGACGTTTACCTACTGGACGGCTCACCCTGTGCCAAGGGCAGTGGCTACTGCTGGGATGGCGCATGTCCCACGCTGGAGCAGCAGTGCCAGCAGCTCTGGGGGCCTGGCTCCCACCCAGCTCCCGAGGCCTGTTTCCAGGTGGTGAACTCTGCGGGAGATGCTCATGGAAACTGCGGCCAGGACAGCGAGGGCCACTTCCTGCCCTGTGCAGGGAGGGATGCCCTGTGTGGGAAGCTGCAGTGCCAGGGTGGAAAGCCCAGCCTGCTCGCACCGCACATGGTGCCAGTGGACTCTACCGTTCACCTAGATGGCCAGGAAGTGACTTGTCGGGGAGCCTTGGCACTCCCCAGTGCCCAGCTGGACCTGCTTGGCCTGGGCCTGGTAGAGCCAGGCACCCAGTGTGGACCTAGAATGGTGTGCCAGAGCAGGCGCTGCAGGAAGAATGCCTTCCAGGAGCTTCAGCGCTGCCTGACTGCCTGCCACAGCCACGGGGTTTGCAATAGCAACCATAACTGCCACTGTGCTCCAGGCTGGGCTCCACCCTTCTGTGACAAGCCAGGCTTTGGTGGCAGCATGGACAGTGGCCCTGTGCAGGCTGALAACCATGACACCTTCCTGCTGGCCATGCTCCTCAGCGTCCTGCTGCCTCTGCTCCCAGGCGCCGGCCTGGCCTGGTGTTGCTACCGACTCCCAGGAGCCCATCTGCAGCGATGCAGCTGGGGCTGCAGAAGGGACCCTGCGTGCAGTGGCCCCAAAGATGGCCCACACAGAGACCACCCCCTGGGCGGCGTTCACCCCATGGAGTTGGGCCCCACAGCCACTGGACAGCCCTGGCCCCTGGACCCTGAGAACTCTCATGAGCCCAGCAGCCACCCTGAGAAGCCTCTGCCAGCAGTCTCGCCTGACCCCCAAGGTGGTTCCCTTGCAGCCTGGGGCCCCAGTCCTTTAGGGGACAACATATCCTCCTCATTCTCAGCAGATCAAGTCCAGATGCCAAGATCCTGCCTCTGTGGCGAACCCTGGGGAGGCCACGTGGGAAGGAAAGAGGGCTCTAAGAGGGGAGGCCCCAGACTGGGGGAGAGGCCTGTCTGGAGCCCAGGATCACCTGGCTGTGCTGCAGAACTGGAGAAGAGAAGCTCAGCAGCAGGGAGCTGGCATGGGGCCAACAGCAGAAAAGCAGGAGGCACGCAGAAGTGACTGGGAAGCAGGAGGNOV14f, CG50367-02Protein SequenceSEQ ID NO: 160895 aaMW at 96021.0kDMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGNSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRNEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCAKGSGYCWDGACPTLEQQCQQLWGPGSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQPWPLDPENSHEPSSHPEKPLPAVSPDPQGGSLAAWGPSPLGDNISSSFSADQVQMPRSCLCGEPWGGHVGRKEGSKRGGPRLGERPVWSPGSPGCAAELEKRSSAERSWHGANSRKAGGTQKNOV14g, CG50367-03SEQ ID NO: 1612642 bpDNA SequenceORF Start: ATG at 3ORF Stop: TGA at 2625CTATGGGCTGGAGGCCCCGGAGAGCTCGGGGGACCCCGTTGCTGCTGCTGCTACTACTGCTGCTGGGCTGGCCAGTGCCAGGCGCCGGGGTGCTTCAAGGACATATCCCTGGGCAGCCAGTCACCCCGCACTGGGTCCTGGATGGACAACCCTGGCGCACCGTCAGCCTGGAGGAGCCGGTCTCGAAGCCAGACATGGGGCTGGTGGCCCTGGAGGCTGAAGGCCAGGAGCTCCTGCTTGAGCTGGAGAAGAACCACAGGCTGCTGGCCCCAGGATACATAGAAACCCACTACGGCCCAGATGGGCAGCCAGTGGTGCTGGCCCCCAACCACACGGATCATTGCCACTACCAAGGGCGAGTAAGGGGCTTCCCCGACTCCTGGGTAGTCCTCTGCACCTGCTCTGGGATGAGTGGCCTGATCACCCTCAGCAGGAATGCCAGCTATTATCTGCGTCCCTGGCCACCCCGGGGCTCCAAGGACTTCTCAACCCACGAGATCTTTCGGATGGAGCAGCTGCTCACCTGGAAAGGAACCTGTGGCCACAGGGATCCTGGGAACAAAGCGGGCATGACCAGCCTTCCTGGTGGTCCCCAGAGCAGGGGCAGGCGAGAAGCGCGCAGGACCCGGAAGTACCTGGAACTGTACATTGTGGCAGACCACACCCTGTTCTTGACTCGGCACCGAAACTTGAACCACACCAAACAGCGTCTCCTGGAAGTCGCCAACTACGTGGACCAGCTTCTCAGGACTCTGGACATTCAGGTGGCGCTGACCGGCCTGGAGGTGTGGACCGAGCGGGACCGCAGCCGCGTCACGCAGGACGCCAACGCCACGCTCTGGGCCTTCCTGCAGTGGCGCCGGGGGCTGTGGGCGCAGCGGCCCCACGACTCCGCGCAGCTGCTCACGGGCCGCGCCTTCCAGGGCGCCACAGTGGGCCTGGCGCCCGTCGAGGGCATGTGCCGCGCCGAGAGCTCGGGAGGCGTGAGCACGGACCACTCGGAGCTCCCCATCGGCGCCGCAGCCACCATGGCCCATGAGATCGGCCACAGCCTCGGCCTCAGCCACGACCCCGACGGCTGCTGCGTGGAGGCTGCGGCCGAGTCCGGAGGCTGCGTCATGGCTGCGGCCACCGGGCACCCGTTTCCGCGCGTGTTCAGCGCCTGCAGCCGCCGCCAGCTGCGCGCCTTCTTCCGCAAGGGGGGCGGCGCTTGCCTCTCCAATGCCCCGGACCCCGGACTCCCGGTGCCGCCGGCGCTCTGCGGGAACGGCTTCGTGGAAGCGGGCGAGGAGTGTGACTGCGGCCCTGGCCAGGAGTGCCGCGACCTCTGCTGCTTTGCTCACAACTGCTCGCTGCGCCCGGGGGCCCAGTGCGCCCACGGGGACTGCTGCGTGCGCTGCCTGCTGAAGCCGGCTGGAGCGCTGTGCCGCCAGGCCATGGGTGACTGTGACCTCCCTGAGTTTTGCACGGGCACCTCCTCCCACTGTCCCCCAGACGTTTACCTACTGGACGGCTCACCCTGTGCCAAGGGCAGTGGCTACTGCTGGGATGGCGCATGTCCCACGCTGGAGCAGCAGTGCCAGCAGCTCTGGGGGCCTGGCTCCCACCCAGCTCCCGAGGCCTGTTTCCAGGTGGTGAACTCTGCGGGAGATGCTCATGGAAACTGCGGCCAGGACAGCGAGGGCCACTTCCTGCCCTGTGCAGGGAGGGATGCCCTGTGTGGGAAGCTGCAGTGCCAGGGTGGAAAGCCCAGCCTGCTCGCACCGCACATGGTGCCAGTGGACTCTACCGTTCACCTAGATGGCCAGGAAGTGACTTGTCGGGGAGCCTTGGCACTCCCCAGTGCCCAGCTGGACCTGCTTGGCCTGGGCCTGGTAGAGCCAGGCACCCAGTGTGGACCTAGAATGGTGTGCCAGAGCAGGCGCTGCAGGAAGAATGCCTTCCAGGAGCTTCAGCGCTGCCTGACTGCCTGCCACAGCCACGGGGTTTGCAATAGCAACCATAACTGCCACTGTGCTCCAGGCTGGGCTCCACCCTTCTGTGACAAGCCAGGCTTTGGTGGCAGCATGGACAGTGGCCCTGTGCAGGCTGAAAACCATGACACCTTCCTGCTGGCCATGCTCCTCAGCGTCCTGCTGCCTCTGCTCCCAGGCGCCGGCCTGGCCTGGTGTTGCTACCGACTCCCAGGAGCCCATCTGCAGCGATGCAGCTGGGGCTGCAGAAGGGACCCTGCGTGCAGTGGCCCCAAAGATGGCCCACACAGAGACCACCCCCTGGGCGGCGTTCACCCCATGGAGTTGGGCCCCACAGCCACTGGACAGCCCTGGCCCCTGGACCCTGAGAACTCTCATGAGCCCAGCAGCCACCCTGAGAAGCCTCTGCCAGCAGTCTCGCCTGACCCCCAAGCAGATCAAGTCCAGATGCCAAGATCCTGCCTCTGTGGCGAACCCTGGGGAGGCCACGTGGGAAGGAAAGAGGGCTCTAAGAGGGGAGGCCCCAGACTGGGGGAGAGGCCTGTCTGGAGCCCAGGATCACCTGGCTGTGCTGCAGAACTGGAGAAGAGAAGCTCAGCAGAAAGGAGCTGGCATGGGGCCAACAGCAGAAAAGCAGGAGGCACGCAGAAGTGACTGGGAAGCAGGAGGNOV14g, CG50367-03Protein SequenceSEQ ID NO: 162874 aaMW at 94031.9kDMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRNEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCAKGSGYCWDGACPTLEQQCQQLWGPGSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLANLLSVLLPLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQPWPLDPENSHEPSSHPEKPLPAVSPDPQADQVQMPRSCLCGEPWGGHVGRKEGSKRGGPRLGERPVWSPGSPGCAAELEKRSSAERSWHGANSRKAGGTQKNOV14h, CG50367-04SEQ ID NO: 1633468 bpDNA SequenceORF Start: ATG at 37ORF Stop: TGA at 2473GCGAGCCGCTGCCTAGAGGCCGAGGAGCTCACAGCTATGGGCTGGAGGCCCCGGAGAGCTCGGGGGACCCCGTTGCTGCTGCTGCTACTACTGCTGCTGCTCTGGCCAGTGCCAGGCGCCGGGGTGCTTCAAGGACATATCCCTGGGCAGCCAGTCACCCCGCACTGGGTCCTGGATGGACAACCCTGGCGCACCGTCAGCCTGGAGGAGCCGGTCTCGAAGCCAGACATGGGGCTGGTGGCCCTGCAGGCTGAAGGCCAGGAGCTCCTGCTTGAGCTGGAGAAGAACCACAGGCTGCTGGCCCCAGGATACATAGAAACCCACTACGGCCCAGATGGGCAGCCAGTGGTGCTGGCCCCCAACCACACGGATCATTGCCACTACCAAGGGCGAGTAAGGGGCTTCCCCGACTCCTGGGTAGTCCTCTGCACCTGCTCTGGGATGAGTGGCCTGATCACCCTCAGCAGGAATGCCAGCTATTATCTGCGTCCCTGGCCACCCCGGGGCTCCAAGGACTTCTCAACCCACGAGATCTTTCGGATGGAGCAGCTGCTCACCTGGAAAGGAACCTGTGGCCACAGGGATCCTGGGAACAAAGCGGGCATGACCAGCCTTCCTGGTGGTCCCCAGAGCAGGGGCAGGCGAGAAGCGCGCAGGACCCGGAAGTACCTGGAACTGTACATTGTGGCAGACCACACCCTGTTCTTGACTCGGCACCGAAACTTGAACCACACCAAACAGCGTCTCCTGGAAGTCGCCAACTACGTGGACCAGCTTCTCAGGACTCTGGACATTCAGGTGGCGCTGACCGGCCTGGAGGTGTGGACCGAGCGGGACCGCAGCCGCGTCACGCAGGACGCCAACGCCACGCTCTGGGCCTTCCTGCAGTGGCGCCGGGGGCTGTGGGCGCAGCGGCCCCACGACTCCGCGCAGCTGCTCACGGGCCGCGCCTTCCAGGGCGCCACAGTGGGCCTGGCGCCCGTCGAGGGCATGTGCCGCGCCGAGAGCTCGGGAGGCGTGAGCACGGACCACTCGGAGCTCCCCATCGGCGCCGCAGCCACCATGGCCCATGAGATCGGCCACAGCCTCGGCCTCAGCCACGACCCCGACGGCTGCTGCGTGGAGGCTGCGGCCGAGTCCGGAGGCTGCGTCATGGCTGCGGCCACCGGGCACCCGTTTCCGCGCGTGTTCAGCGCCTGCAGCCGCCGCCAGCTGCGCGCCTTCTTCCGCAAGGGGGGCGGCGCTTGCCTCTCCAATGCCCCGGACCCCGGACTCCCGGTGCCGCCGGCGCTCTGCGGGAACGGCTTCGTGGAAGCGGGCGAGGAGTGTGACTGCGGCCCTGGCCAGGAGTGCCGCGACCTCTGCTGCTTTGCTCACAACTGCTCGCTGCGCCCGGGGGCCCAGTGCGCCCACGGGGACTGCTGCGTGCGCTGCCTGCTGAAGCCGGCTGGAGCGCTGTGCCGCCAGGCCATGGGTGACTGTGACCTCCCTGAGTTTTGCACGGGCACCTCCTCCCACTGTCCCCCAGACGTTTACCTACTGGACGGCTCACCCTGTGCCAGGGGCAGTGGCTACTGCTGGGATGGCGCATGTCCCACGCTGGAGCAGCAGTGCCAGCAGCTCTGGGGGCCTGGCTCCCACCCAGCTCCCGAGGCCTGTTTCCAGGTGGTGAACTCTGCGGGAGATGCTCATGGAAACTGCGGCCAGGACAGCGAGGGCCACTTCCTGCCCTGTGCAGGGAGGGATGCCCTGTGTGGGAAGCTGCAGTGCCAGGGTGGAAAGCCCAGCCTGCTCGCACCGCACATGGTGCCAGTGGACTCTACCGTTCACCTAGATGGCCAGGAAGTGACTTGTCGGGGAGCCTTGGCACTCCCCAGTGCCCAGCTGGACCTGCTTGGCCTGGGCCTGGTAGAGCCAGGCACCCAGTGTGGACCTAGAATGGTGTGCCAGAGCAGGCGCTGCAGGAAGAATGCCTTCCAGGAGCTTCAGCGCTGCCTGACTGCCTGCCACAGCCACGGGGTTTGCAATAGCAACCATAACTGCCACTGTGCTCCAGGCTGGGCTCCACCCTTCTGTGACAAGCCAGGCTTTGGTGGCAGCATGGACAGTGGCCCTGTGCAGGCTGAAAACCATGACACCTTCCTGCTGGCCATGCTCCTCAGCGTCCTGCTGCCTCTGCTCCCAGGGGCCGGCCTGGCCTGGTGTTGCTACCGACTCCCAGGAGCCCATCTGCAGCGATGCAGCTGGGGCTGCAGAAGGGACCCTGCGTGCAGTGGCCCCAAAGATGGCCCACACAGGGACCACCCCCTGGGCGGCGTTCACCCCATGGAGTTGGGCCCCACAGCCACTGGACAGCCCTGGCCCCTGGACCCTGAGAACTCTCATGAGCCCAGCAGCCACCCTGAGAAGCCTCTGCCAGCAGTCTCGCCTGACCCCCAAGATCAAGTCCAGATGCCAAGATCCTGCCTCTGGTGAGAGGTAGCTCCTAAAATGAACAGATTTAAAGACAGGTGGCCACTGACAGCCACTCCAGGAACTTGAACTGCAGGGGCAGAGCCAGTGAATCACCGGACCTCCAGCACCTGCAGGCAGCTTGGAAGTTTCTTCCCCGAGTGGAGCTTCGACCCACCCACTCCAGGAACCCAGAGCCACATTAGAAGTTCCTGAGGGCTGGAGAACACTGCTGGGCACACTCTCCAGCTCAATAAACCATCAGTCCCAGAAGCAAAGGTCACACAGCCCCTGACCTCCCTCACCAGTGGAGGCTGGGTAGTGCTGGCCATCCCAAAAGGGCTCTGTCCTGGGAGTCTGGTGTGTCTCCTACATGCAATTTCCACGGACCCAGCTCTGTGGAGGGCATGACTGCTGGCCAGAAGCTAGTGGTCCTGGGGCCCTATGGTTCGACTGAGTCCACACTCCCCTGGAGCCTGGCTGGCCTCTGCAAACAAACATAATTTTGGGGACCTTCCTTCCTGTTTCTTCCCACCCTGTCTTCTCCCCTAGGTGGTTCCTGAGCCCCCACCCCCAATCCCAGTGCTACACCTGAGGTTCTGGAGCTCAGAATCTGACAGCCTCTCCCCCATTCTGTGTGTGTCGGGGGGACAGAGGGAACCATTTAAGAAAAGATACCAAAGTAGAAGTCAAAAGAAAGACATGTTGGCTATAGGCGTGGTGGCTCATGCCTATAATCCCAGCACTTTGGGAAGCCGGGGTAGGAGGATCACCAGAGGCCAGCAGGTCCACACCAGCCTGGGCAACACAGCAAGACACCGCATCTACAGAAAAATTTTAAAATTAGCTGGGCGTGGTGGTGTGTACCTGTAGGCCTAGCTGCTCAGGAGGCTGAAGCAGGAGGATCACTTGAGCCTGAGTTCAACACTGCAGTGAGCTATGGTGGCACCACTGCACTCCAGCCTGGGTGACAGAGCAAGACCCTGTCTCTAAAATAAATTTTAAAAAGACATATTANOV14h, CG50367-04Protein SequenceSEQ ID NO: 164812 aaMW at 87666.9kDMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRIVIVCQSRRCRKNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQPWPLDPENSHEPSSHPEKPLPAVSPDPQDQVQMPRSCLW

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 14B.

TABLE 14BComparison of the NOV14 protein sequences.NOV14aMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGOPVTPHWVLDGQPWRTVSLEEPVNOV14bMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVNOV14cMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVNOV14dMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVNOV14e-------------------------------------------------------------NOV14fMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVIDGQPWRTVSLEEPVNOV14gMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVNOV14hMGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVNOV14aSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVNOV14bSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVNOV14cSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVNOV14dSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVNOV14e-----------------KLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVNOV14fSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVNOV14gSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVNOV14hSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVNOV14aRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGNOV14bRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGNOV14cRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGNOV14dRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGNOV14eRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGNOV14fRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGNOV14gRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRNEQLLTWKGTCGNOV14hRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGNOV14aHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVNOV14bHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVNOV14cHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVNOV14dHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVNOV14eHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRKLNHTKQRLLEVNOV14fHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVNOV14gHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVNOV14hHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVNOV14aANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLNOV14bANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLNOV14cANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLNOV14dANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLNOV14eDNYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLNOV14fANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLNOV14gANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLNOV14hANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLNOV14aLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCNOV14bLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCNOV14cLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCNOV14dLTTTRSSPSAP--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------RSAGTASWKRARSVTAALARSAANOV14eCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCNOV14fCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCNOV14gCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCNOV14hCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCNOV14aGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKP-------AGANOV14bGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKP-------AGANOV14cGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLTFTYWTAHPVPGANOV14dTSAALLTTARCARGPSAPTGTAACAAC---------------------------------NOV14eGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKP-------AGANOV14fGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKP-------AGANOV14gGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKP-------AGANOV14hGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKP-------AGANOV14aLCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGNOV14bLCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGNOV14cVATAGMAHVPRWSSSASSSGGLAPTQLPRPVSRW--------------------------NOV14d-------------------------------------------------------------NOV14eLCRQAMGDCDLPEFCTGTSSHCPPDVYLLE------------------------------NOV14fLCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCAKGSGYCWDGACPTLEQQCQQLWGPGNOV14gLCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCAKGSGYCWDGACPTLEQQCQQLWGPGNOV14hLCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGNOV14aSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVNOV14bSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVNOV14c-------------------------------------------------------------NOV14d-------------------------------------------------------------NOV14e-------------------------------------------------------------NOV14fSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVNOV14gSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVNOV14hSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVNOV14aDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRNVCQSRRCRKNAFQELQRCNOV14bDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVESGTQCGPRMVCN---------------NOV14c-------------------------------------------------------------NOV14d-------------------------------------------------------------NOV14e-------------------------------------------------------------NOV14fDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCNOV14gDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCNOV14hDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCNOV14aLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPNOV14b-----------SNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPNOV14c-------------------------------------------------------------NOV14d-------------------------------------------------------------NOV14e-------------------------------------------------------------NOV14fLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPNOV14gLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPNOV14hLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPNOV14aLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQNOV14bLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPNRDHPLGGVHPMELGPTATGQNOV14c-------------------------------------------------------------NOV14d-------------------------------------------------------------NOV14e-------------------------------------------------------------NOV14fLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQNOV14gLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQNOV14hLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQNOV14aPWPLAPGAPADHIHNIYPPPFLPDPENSHEPSSHPEKPLPAVSPDPQGGSLAAWGPSPLGNOV14bPWPLDP-------------------ENSHEPSSHPEKPLPAVSPDPQ-------------NOV14c-------------------------------------------------------------NOV14d-------------------------------------------------------------NOV14e-------------------------------------------------------------NOV14fPWPLDP-------------------ENSHEPSSHPEKPLPAVSPDPQGGSLAAWGPSPLGNOV14gPWPLDP-------------------ENSHEPSSHPEKPLPAVSPDPQ-------------NOV14hPWPLDP-------------------ENSHEPSSHPEKPLPAVSPDPQ-------------NOV14aDNISSSFSADQVQMPRSCLCGEPWGGHVGRKEGSKRGGPRLGERPVWSPGSPGCAAELEKNOV14b--------ADQVQMPRSCLW----------------------------------------NOV14c-------------------------------------------------------------NOV14d-------------------------------------------------------------NOV14e-------------------------------------------------------------NOV14fDNISSSFSADQVQMPRSCLCGEPWGGHVGRKEGSKRGGPRLGERPVWSPGSPGCAAELEKNOV14g--------ADQVQMPRSCLCGEPWGGHVGRKEGSKRGGPRLGERPVWSPGSPGCAAELEKNOV14h---------DQVQMPRSCLW----------------------------------------NOV14aRSSAERSWHGANSRKAGGTQKNOV14b---------------------NOV14c---------------------NOV14d---------------------NOV14e---------------------NOV14fRSSAERSWHGANSRKAGGTQKNOV14gRSSAERSWHGANSRKAGGTQKNOV14h---------------------NOV14a(SEQ ID NO: 150)NOV14b(SEQ ID NO: 152)NOV14C(SEQ ID NO: 154)NOV14d(SEQ ID NO: 156)NOV14e(SEQ ID NO: 158)NOV14f(SEQ ID NO: 160)NOV14g(SEQ ID NO: 162)NOV14h(SEQ ID NO: 164)

Further analysis of the NOV14a protein yielded the following properties-shown in Table 14C.

TABLE 14CProtein Sequence Properties NOV14aSignalP analysis: Cleavage site between residues 30 and 31PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 9; pos.chg 4; neg.chg 0H-region: length 37; peak value 11.70PSG score: 7.30GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 5.85possible cleavage site: between 27 and 28>>> Seems to have a cleavable signal peptide (1 to 27)ALOM:Klein et al's method for TM region allocationInit position for calculation: 28Tentative number of TMS(s) for the threshold 0.5: 2Number of TMS(s) for threshold 0.5: 1INTEGRALLikelihood = −6.16 Transmembrane 702-718PERIPHERALLikelihood = 0.63 (at 126)ALOM score: −6.16 (number of TMSs: 1)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 13Charge difference: −5.0 C(0.0) − N(5.0)N >= C: N-terminal side will be inside>>> membrane topology: type 1a (cytoplasmic tail 719 to 914)MITDISC: discrimination of mitochondrial targeting seqR content:4Hyd Moment(75):2.69Hyd Moment(95):8.42G content:6D/E content:1S/T content:2Score: −3.80Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 19 ARG|TPNUCDISC: discrimination of nuclear localization signalspat4: RPRR (4) at 4pat7: PRRARGT (5) at 5pat7: PQSRGRR (3) at 197bipartite: nonecontent of basic residues: 8.9%NLS Score: 0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: GWRPnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 70.6COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: extracellular, including cell wall22.2%: Golgi22.2%: endoplasmic reticulum11.1%: plasma membrane>> prediction for CG50367-01 is exc (k = 9)

A search of the NOV14a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14D.

TABLE 14DGeneseq Results for NOV14aNOV14aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABJ10597Human novel protein NOV7a 1 . . . 914914/914 (100%)0.0SEQ ID NO: 22 - Homo sapiens, 1 . . . 914914/914 (100%)914 aa. [WO200259315-A2, 01-AUG-2002]ABJ10598Human novel protein NOV7b1 . . . 914894/914 (97%)0.0SEQ ID NO: 24 - Homo sapiens,1 . . . 895895/914 (97%)895 aa. [WO200259315-A2, 01-AUG-2002]ABJ10599Human novel protein NOV7c1 . . . 914873/914 (95%)0.0SEQ ID NO: 26 - Homo sapiens,1 . . . 874874/914 (95%)874 aa. [WO200259315-A2, 01-AUG-2002]ABU58632Human PRO polypeptide #233 -1 . . . 852812/852 (95%)0.0Homo sapiens, 813 aa.1 . . . 812812/852 (95%)[US2003027272-A1, 06-FEB-2003]ABU57163Human PRO polypeptide #233 -1 . . . 852812/852 (95%)0.0Homo sapiens, 813 aa.1 . . . 812812/852 (95%)[US2003027280-A1, 06-FEB-2003]

In a BLAST search of public sequence databases, the NOV14a protein was found to have homology to the proteins shown in the BLASTP data in Table 14E.

TABLE 14EPublic BLASTP Results for NOV14aNOV14aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9BZ11ADAM 33 precursor (EC1 . . . 852812/852 (95%)0.03.4.24.-) (A disintegrin and1 . . . 812812/852 (95%)metalloproteinase domain 33) -Homo sapiens (Human), 813 aa.Q8N0W6A disintegrin and1 . . . 852811/852 (95%)0.0metalloprotease domain 33 -1 . . . 811811/852 (95%)Homo sapiens (Human), 812 aa.CAC33153Sequence 1 from Patent1 . . . 661 661/661 (100%)0.0WO0109293 - Homo sapiens1 . . . 661 661/661 (100%)(Human), 802 aa.Q8R5G5Metalloprotease/disintegrin1 . . . 805571/806 (70%)0.0ADAM33 - Mus musculus1 . . . 784632/806 (77%)(Mouse), 797 aa.Q923W9ADAM 33 precursor (EC1 . . . 805570/806 (70%)0.03.4.24.-) (A disintegrin and1 . . . 784631/806 (77%)metalloproteinase domain 33) -Mus musculus (Mouse), 797 aa.

PFam analysis indicates that the NOV14a protein contains the domains shown in the Table 14F.

TABLE 14FDomain Analysis of NOV14aNOV14aIdentities/Match SimilaritiesExpectPfam DomainRegionfor the Matched RegionValuePep_M12B_propep 80 . . . 19844/122 (36%)1.3e−3193/122 (76%)Reprolysin210 . . . 40984/206 (41%) 3e−88163/206 (79%) disintegrin426 . . . 501 38/76 (50%)2.5e−23 52/76 (68%)EGF653 . . . 680 9/47 (19%)0.43 20/47 (43%)

Example 15

The NOV15 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 15A.

TABLE 15ANOV15 Sequence AnalysisNOV15a, CG50718-02SEQ ID NO: 1656881 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAA at 6859AAAAATGTAATAAAGATGGATTTTCTTATCATTTTTCTTTTACTTTTTATTGGGACTTCAGAGACACAGGTAGATGTTTCCAATGTCGTTCCTGGTACTAGGTACGATATAACCATCTCTTCAATTTCTACAACATACACCTCACCTGTTACTAGAATAGGGGCTTCTAATGAACCAGGGCCTCCAGTCTTCCTAGCCGGGGAAAGAGTCGGATCTGCTGGGATTCTTCTGTCTTGGAATACACCACCTAATCCAAATGGAAGGATTATATCTTACATTGTCAAATATAAGGAAGTTTGTCCGTGGATGCAAACAGTATATACACAAGTCAGATCAAAGCCAGACAGTCTGGAAGTTCTTCTTACTAATCTTAATCCTGGAACAACATATGAAATTAAGGTAGCTGCTGAAAACAGTGCTGGCATTGGAGTGTTTAGTGATCCATTTCTCTTCCAAACTGCAGAAAGTGCTCCAGGAAAAGTGGTGGATTTCACAGGTGAGGCTGTCCCGTTCAGCAGTAAGCTGATGTGGTATACCTCGGCAACCAAAAAAAAAATTACCAGCTTCAAGATTAGTGTCAAGCATAACAGAAGTGGGATAGTAGTGAAAGAAGTGTCAATCAGAGTGGAGTGCATTTTAAGTGCTTCCCTTCCTTTGCACTGCAACGAGAATAGTGAATCTTTTTTATGGAGTACAGCCAGCCCTTCTCCAACCCTTGGTAGAGTTACACCTCCATCGCGTACCACACATTCATCAAGCACGTTGACACAGAATGAGATCAGCTCTGTGAAAGAGCCTATCAGTTTTGTAGTGACACACTTGAGACCTTATACAACATATCTTTTTGAAGTTTCAGCTGCTACAACTGAAGCAGGTTATATTGATAGTACGATTGTCAGAACACCAGAATCAGTGCCTGAAGGACCACCACAAAACTGCGTAACAGGCAACATCACAGGAAAGTCCTTTTCAATTTTATGGGACCCACCAACTATAGTAACAGGGAAATTTAGTTATAGAGTTGAATTATATGGACCATCAGCAGGTCGCATTTTGGATAACAGCACAAAAGACCTCAAGTTTGCATTCACTAACCTAACACCATTTACAATGTATGATGTCTATATTGCGGCTGCGGCCAGTGCAGGGACTGGGCCCAAGTCAAATATTTCAGTATTCACTCCACCAGATGTTCCAGGGGCAGTGTTTGATTTACAACTTGCAGAGGTAGAATCCACGCAAGTAAGAATTACTTGGAAGAAACCACGACAACCAAATGGAATTATTAACCAATACCGAGTGAAAGTGCTAGTTCCAGAGACAGGAATAATTTTGGAAAATACTTTGCTCACTGGAAATAATGAGATAAATGACCCCATGGCTCCAGAATTGTGAACATAGTACAGCCCAATGGTAGGATTATATGAGGGTTCAGCAGAGATGTCGTCTGACCTTCACTCACTTGCTACATTTATATATAACAGCCATCCAGATAAAAACTTTCCTGCAAGGAATAGAGCTGAAGACCAGACTTCACCAGTTGTAACTACAAGGAATCAGTATATTACTGACATTGCAGCTGAACAGCTGACTTATGTTCTTATCAGATTAAGGAGATTTTGGGCTGAGACAATGGGGTTTTCTAGATATACAATCATGTCATCTGCAAGCAGGGACAATTTGACTTCCCCAGGCCCTTTGTCAGCCCAAAATTTCAGAGTTACACATGTTACCATAACAGAAGTATTTTTACACTGGGATCCTCCAGATCCTGTATTTTTTCATCATTACCTTATCACTATTTTGGATGTTGAAAACCAATCCAAGAGTATTATTTTAAGGACATTAAACAGTTTGTCTCTTGTCCTTATAGGGTTAAAGAAATACACAAAATACAAAATGAGAGTGGCAGCCTCAACCCACGTTGGAGAAAGTTCTTTGTCTGAAGAAAATGACATCTTTGTGAGAACTTCAGAAGATGAACCGGAATCATCACCTCAAGATGTCGAAGTAATTGATGTTACCGCAGATGAAATAAGGTTGAAGTGGTCACCACCCGAAAAGCCCAATGGGATCATTATTGCTTATGAAGTGCTATATAAAAATATAGATACTTTATATATGAAGAACACATCAACAACAGACATAATATTAAGGAACTTAAGACCTCACACCCTCTATAACATTTCTGTAAGGTCTTACACCAGATTTGGTCATGGCAATCAGGTATCTTCTTTACTCTCTGTAAGGACTTCGGAGTCAGTGCCTGATAGTGCACCAGAAAATATCACTTACAAAAATATTTCTTCTGGAGAGATTGAGCTATCATTCCTTCCCCCAAGTAGTCCCAATGGAATCATACAAAAATATACAATTTATCTCAAGAGAAGTAATGGAAATGAGGAAAGAACTATAAATACAACCTCTTTAACCCAAAACATTAAAGGTCTGAAGAAATATACCCAATATATCATTGAGGTGTCTGCTAGTACACTCAAAGGTGAAGGAGTTCGGAGTGCTCCCCATAAGTATACTGACGGAGGAAGATGCTCCTGATTCTCCCCCCAAGACTTCTCTGTAAAACAGTTGTCTGGTGTCACGGTGAAGTTGTCATGGCAACCACCCCTGGAGCCAAATGGAATTATCCTTTATTACACAGTTTATGTCTGGAGATCATCATTAAAAACTATTAATGTCACTGAAATCATTGGAGAGTTATCAGATTTGGATTATAATGTTGAATACAGTGCTTATGTAACAGCTAGCACCAGATTTGGTGATGGGAAAACAAGAAGCAATATCATTAGCTTTCAAACACCAGAGGGACCAAGCGATCCTCCCAAAGATGTTTATTATGCAAACCTCAGTTCTTCATCAATAATTCTTTTCTGGACACCTCCTTCAAAACCTAATGGGATTATACAATATTACTCTGTTTATTACAGAAATACTTCAGGTACTTTTATGCAGAATTTTACACTCCATGAAGTAACCAATGACTTTGACAATATGACTGTATCCACAATTATAGATAAACTGACAATATTCAGCTACTATACATTTTGGTTAACAGCAAGTACTTCAGTTGGAAATGGGAATAAAAGCAGTGACATCATTGAAGTATACACAGATCAAGACGTACCTGAAGGGTTTGTTGGAAACCTGACTTACGAATCCATTTCGTCAACTGCAATAAATGTAAGCTGGGTCCCACCGGCTCAACCAAACGGTCTAGTCTTCTACTATGTTTCACTGATCTTACAGCAGACTCCTCGCCATGTGAGACCACCTCTTGTTACATATGAGAGAAGCATATATTTTGATAATCTGGAAAAATACACTGATTATATATTAAAAATTACTCCATCAACAGAAAAGGGATTCTCTGATACCTATACTGCCCAGCTATACATCAAGACTGAAGAAGATATCCCAGAAACTTCACCAATAATCAACACTTTTAAAAACCTTTCCTCTACCTCAGTTCTCTTATCATGGGATCCCCCAGTAAAGCCAAATGGTGCAATAATAAGTTATGATTTAACTTTACAAGGACCAAATGAAAATTATTCTTTCATTACTTCTGATAATTACATAATATTGGAAGAGCTTTCACCATTTACATTATATAGCTTTTTTGCTGCCGCAAGAACTAGAAAAGGACTTGGTCCTTCCAGTATTCTTTTCTTTTACACAGATGAGTCAGTGCCGTTAGCACCTCCACAAAATTTGACTTTAATCAACTGTACTTCAGACTTTGTATGGCTGAAATGGAGCCCAAGTCCTCTTCCAGGTGGTATTGTTAAAGTATATAGTTTTAAAATTCATGAACATGAAACTGACACTATATATTATAAGAATATATCAGGATTTAAAACTGAAGCCAAACTTGTTGGACTGGAACCAGTCAGCACCTACTCTATCCGTGTATCTGCGTTCACCAAAGTTGGAAATGGCAATCAATTTAGTAATGTAGTAAAATTCACAACCCAAGAATCAGTTCCAGATGTCGTGCAGAATATGCAGTGCATGGCAACTAGCTGGCAGTCAGTTTTAGTGAAATGGGATCCACCCAAAAAGGCAAATGGAATAATAACGCAGTATATGGTAACAGTTGAAAGGAATTCTACAAAAGTTTCTCCCCAAGATCACATGTACACTTTCATAAAGCTTCTTGCCAATACCTCATATGTCTTTAAAGTAAGAGCTTCAACCTCAGCTGGTGAAGGTGATGAAAGCACATGCCATGTCAGCACACTACCTGAAACAGTTCCCAGTGTTCCCACAAATATTGCTTTTTCTGATGTTCAGTCAACTAGTGCAACATTGACATGGATAAGACCTGACACTATCCTTGGCTACTTTCAAAATTACAAAATTACCACTCAAGTTCGTGCTCAAAAATGCAAAGAATGGGAATCCGAAGAATGTGTTGAATATCAAAAAATTCAATACCTOTATGAAGCTCACTTAACTGAAGAGACAGTATATGGATTAAAGAAATTTAGATGGTATAGATTCCAAGTGGCTGCCAGCACCAATGCTGGCTATGGCAATGCTTCAAACTGGATTTCTACAAAAACTCTGCCTGGCCCTCCAGATGGTCCTCCTGAAAATGTTCATGTAGTAGCAACATCACCTTTTAGCATCAGCATAAGCTGGAGTGAACCTGCTGTCATTACTGGACCAACATGTTATCTGATTGATGTCAAATCGGTAGATAATGATGAATTTAATATATCCTTCATCAAGTCAAATGAAGAAAATAAAACCATAGAAATTAAAGATTTAGAAATATTCACAAGGTATTCTGTAGTGATCACTGCATTTACTGGGAACATTAGTGCTGCATATGTAGAAGGGAAGTCAAGTGCTGAAATGATTGTTACTACTTTAGAATCAGCCCCAAAGGACCCACCTAACAACATGACATTTCAGAAGATACCAGATGAAGTTACAAAATTTCAATTAACGTTCCTTCCTCCTTCTCAACCTAATGGAAATATCCAAGTATATCAAGCTCTGGTTTACCGAGAAGATGATCCTACTGCTGTCCAGATTCACAACCTCAGTATTATACAGAAAACCAACACATTCGTCATTGCAATGCTAGAAGGACTAAAAGGTGGACATACATACAATATCAGTGTTTACGCAGTCAATAGTGCTGGTGCAGGTCCAAAGGTTCCGATGAGAATAACCATGGATATCAAAGCTCCAGCACGACCAAAAAACAAACCAACCCCTATTTATGATGCCACAGGAAAACTGCTTGTGACTTCAACAACAATTACAATCAGAATGCCAATATGTTACTACAGTGATGATCATGGACCAATAAAAAAAATGTACAAGTGCTTGTGAACAGCAGGAGCTCAGCATGATGGAAATGTAACAAAGTGGTATGATGCATATTTTAATAAAGCAAGGCCATATTTTACAAATGAAGGCTTTCCTAACCCTCCATGTACAGAAGGAAAGACAAAGTTTAGTGGCAATGAAGAAATCTACATCATAGGTGCTGATAATGCATGCATGATTCCTGGCAATGAAGACAAAATTTGCAATGGACCACTGAAACCAAAAAAGCAATACTTATTTAAATTTAGAGCTACAAATATTATGGGACAATTTACTGACTCTGATTATTCTGACCCTGTTAAGACTTTAGGCGAAGGACTTTCAGAAAGAACCGTAGAGATCATTCTTTCCGTCACTTTGTGTATCCTTTCAATAATTCTCCTTGGAACAGCTATTTTTGCATTTGCAAGAATTCGACAGAAGCAGAAAGAAGGTGGCACATACTCTCCTCAGGATGCAGAAATTATTGACACTAAATTGAAGCTGGATCAGCTCATCACAGTGGCAGACCTGGAACTGAAGGACGAGAGATTAACGCGGCCAATAAGCAAGAAATCCTTCCTGCAACATGTTGAAGAGCTTTGCACAAACAACAACCTAAAGTTTCAAGAAGAATTTTCGGAATTACGAAAATTTCTTCAGGATCTTTCTTCAACTGATGCTGATCTGCCTTGGAATAGAGCAAAAAACCGCTTCCCAAACATAAAACCATATAATAATAACAGAGTAAAGCTGATAGCTGACGCTAGTGTTCCAGGTTCGGATTATATTAATGCCAGCTATATTTCTGGTTATTTATGTCCAAATGAATTTATTGCTACTCAAGGTCCACTACCAGGAACAGTTGGAGATTTTTGGAGAATGGTGTGGGAAACCAGAGCAAAAACATTAGTAATGCTAACACAGTGTTTTGAAAAAGGACGGATCAGATGCCATCAGTATTGGCCAGAGGACAACAAGCCAGTTACTGTCTTTGGAGATATAGTGATTACAAAGCTAATGGAGGATGTTCAAATAGATTGGACTATCAGGGATCTGAAAATTGAAAGGCATGGGGATTGCATGACTGTTCGACAGTGTAACTTTACTGCCTGGCCAGAGCATGGGGTTCCTGAGAACAGCGCCCCTCTAATTCACTTTGTGAAGTTGGTTCGAGCAAGCAGGGCACATGACACCACACCTATGATTGTTCACTGCAGTGCTGGAGTTGGAAGAACTGGAGTTTTTATTGCTCTGGACCATTTAACACAACATATAAATGACCATGATTTTGTGGATATATATGGACTAGTAGCTGAACTGAGAAGTGAAAGAATGTGCATGGTGCAGAATCTGGCACAGTATATCTTTTTACACCAGTGCATTCTGGATCTCTTATCAAATAAGGGAAGTAATCAGCCCATCTGTTTTGTTAACTATTCAGCACTTCAGAAGATGGACTCTTTGGACGCCATGGAAGGTGGTGATGTTGAGCTTGAATGGGAAGAAACCACTATGTAAATATTCAGACCAAAGGATACNOV15a, CG50718-02Protein SequenceSEQ ID NO: 1662281 aaMW at 255030.3kDMDFLIIFLLLFIGTSETQVDVSNVVPGTRYDITISSISTTYTSPVTRIGASNEPGPPVFLAGERVGSAGILLSWNTPPNPNGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNPGTTYEIKVAAENSAGIGVFSDPFLFQTAESAPGKVVDFTGEAVPFSSKLMWYTSATKKKITSFKISVKHNRSGIVVKEVSIRVECILSASLPLHCNENSESFLWSTASPSPTLGRVTPPSRTTHSSSTLTQNEISSVKEPISFVVTHLRPYTTYLFEVSAATTEAGYIDSTIVRTPESVPEGPPQNCVTGNITGKSFSILWDPPTIVTGKFSYRVELYGPSAGRILDNSTKDLKFAFTNLTPFTMYDVYIAAETSAGTGPKSNISVFTPPDVPGAVFDLQLAEVESTQVRITWKKPRQPNGIINQYRVKVLVPETGIILENTLLTGNNEINDPMAPEIVNIVQPMVGLYEGSAEMSSDLHSLATFIYNSHPDKNFPARNRAEDQTSPVVTTRNQYITDIAAEQLTYVLIRLRRFWAEThGFSRYTIMSSASRDNLTSPGPLSAQNFRVTHVTITEVFLHWDPPDPVFFHHYLITILDVENQSKSIILRTLNSLSLVLIGLKKYTKYKMRVAASTHVGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNGIIIAYEVLYKNIDTLYMKNTSTTDIILRNLRPHTLYNISVRSYTRFGHGNQVSSLLSVRTSESVPDSAPENITYKNISSGEIELSFLPPSSPNGIIQKYTIYLKRSNGNEERTINTTSLTQNIKGLKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWRSSLKTINVTETSLELSDLDYNVEYSAYVTASTRFGDGKTRSNIISFQTPEGPSDPPKDVYYANLSSSSIILFWTPPSKPNGIIQYYSVYYRNTSGTFMQNFTLHEVTNDFDNMTVSTIIDKLTIFSYYTFWLTASTSVGNGNKSSDIIEVYTDQDVPEGFVGNLTYESISSTAINVSWVPPAQPNGLVFYYVSLILQQTPRHVRPPLVTYERSIYFDNLEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDIPETSPIINTFKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPNENYSFITSDNYIILEELSPFTLYSFFAAARTRKGLGPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKVYSFKIHEHETDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGMQFSNVVKFTTQESVPDVVQNMQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFIKLLANTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDTILGYFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVAASTNAGYGNASNWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLIDVKSVDNDEFNISFIKSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMIVTTLESAPKDPPNNNTFQKIPDEVTKFQLTFLPPSQPNGNIQVYQALVYREDDPTAVQIHNLSIIQKTNTFVIANLEGLKGGHTYNISVYAVNSAGAGPKVPMRITMDIKAPARPKTKPTPIYDATGKLLVTSTTITIRNPICYYSDDHGPIKNVQVLVTETGAQHDGNVTKWYDAYFNKARPYFTNEGFPNPPCTEGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLKPKKQYLFKFRATNIMGQFTDSDYSDPVKTLGEGLSERTVEIILSVTLCILSIILLGTAIFAFARIRQKQKEGGTYSPQDAEIIDTKLKLDQLITVADLELKDERLTRPISKKSFLQHVEELCTNNNLKFQEEFSELPKFLQDLSSTDADLPWNRAKNRFPNIKPYNNNRVKLIADASVPGSDYINASYISGYLCPNEFIATQGPLPGTVGDFWRNVWETRAKTLVMLTQCFEKGRIRCHQYWPEDNKPVTVFGDIVITKLMEDVQIDWTIRDLKIERHGDCMTVRQCNFTAWPEHGVPENSAPLIHFVKLVRASRAHDTTPMIVHCSAGVGRTGVFIALDHLTQHINDHDFVDIYGLVAELRSERMCMVQNLAQYIFLHQCILDLLSNKGSNQPICFVNYSAILQKMDSLDAMEGGDVELEWEETTMNOV15b, CG50718-06SEQ ID NO: 1676900 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAA at 6898ATGGATTTTCTTATCATTTTTCTTTTACTTTTTATTGGGACTTCAGAGACACAGGTAGATGTTTCCAATGTCGTTCCTGGTACTAGGTACGATATAACCATCTCTTCAATTTCTACAACATACACCTCACCTGTTACTAGAATAGTGACAACAAATGTAACAAAACCAGGGCCTCCAGTCTTCCTAGCCGGGGAAAGAGTCGGATCTGCTGGGATTCTTCTGTCTTGGAATACACCACCTAATCCAAATGGAAGGATTATATCTTACATTGTCAAATATAAGGAAGTTTGTCCGTGGATGCAAACAGTATATACACAAGTCAGATCAAAGCCAGACAGTCTGGAAGTTCTTCTTACTAATCTTAATCCTGGAACAACATATGAAATTAAGGTTGCTGCTGAAAACAGTGCTGGCATTGGAGTGTTTAGTGATCCATTTCTCTTCCAAACTGCAGAAAGTGCTCCAGGAAAAGTGGTGAATCTCACAGTTGAGGCCTACAACGCTTCAGCAGTTAAGCTGATTTGGTATTTACCTCGGCAACCAAATGGCAAAATTACCAGCTTCAAGATTAGTGTCAAGCATGCCAGAAGTGGGATAGTAGTGAAAGATGTCTCAATCAGAGTAGAGGACATTTTGACTGGGAAATTGCCAGAATGCAATGAGAATAGTGAATCTTTTTTATGGAGTACAGCCAGCCCTTCTCCAACCCTTGGTAGAGTTACACCTCCATCGCGTACCACACATTCATCAAGCACGTTGACACAGAATGAGATCAGCTCTGTGTGGAAAGAGCCTATCAGTTTTGTAGTGACACACTTGAGACCTTATACAACATATCTTTTTGAAGTTTCAGCTGTTACAACTGAAGCAGGTTATATTGATAGTACGATTGTCAGAACACCAGAATCAGTGCCTGAAGGACCACCACAAAACTGCGTAACAGGCAACATCACAGGAAAGTCCTTTTCAATTTTATGGGACCCACCAACTATAGTAACAGGGAAATTTAGTTATAGAGTTGAATTATATGGACCATCAGGTCGCATTTTGGATAACAGCACAAAAGACCTCAAGTTTGCATTCACTAACCTAACACCATTTACAATGTATGATGTCTATATTTGCGGCTGAAACCAGTGCAGGGACTGGGCCAAGTCAAATATTTCAGTATTCACTCCACCAGATGTTCCAGGGGCAGTGTTTGATTTACAACTTGCAGAGGTAGAATCCACGCAAGTAAGAATTACTTGGAAGAAACCACGACAACCAAATGGAATTATTAACCAATACCGAGTGAAAGTGCTAGTTCCAGAGACAGGAATAATTTTGGAAAATACTTTGCTCACTGGAAATAATGAGTATATAAATGACCCCATGGCTCCAGAAATTGTGAACATAGTAGAGCCAATGGTAGGATTATATGAGGGTTCAGCAGAGATGTCGTCTGACCTTCACTCACTTGCTACATTTATATATAACAGCCATCCAGATAAAAACTTTCCTGCAAGGAATAGAGCTGAAGACCAGACTTCACCAGTTGTAACTACAAGGAATCAGTATATTACTGACATTGCAGCTGAACAGCTGTCTTATGTTATCAGGAGACTTGTACCTTTCACTGAGCACATGATTAGTGTATCTGCTTTCACCATCATGGGAGAAGGACCACCAACAGTTCTCAGTGTTAGGACACGTCAGCAAGTGCCAAGCTCCATTAAAATTATAAACTATAAAAATATTAGTTCTTCATCTATTTTGTTATATTGGGATCCTCCAGAATATCCCAATGGAAAAATAACTCACTATACGATTTATGCAATGGAATTGGATACAAACAGAGCATTCCAGATAACTACCATAGATAACAGCTTTCTCATAACAGGGTTAAAGAAATACACAAAATACAAAATGAGAGTGGCAGCCTCAACCCACGATGGAGAAAGTTCTTTGTCTGAAGAAAATGACATCTTTGTGAGAACTTCAGAAGATGAACCGGAATCATCACCTCAAGATGTCGAAGTAATTGATGTTACCGCAGATGAAATAAGGTTGAAGTGGTCACCACCCGAAAAGCCCAATGGGATCATTATTGCTTATGAAGTGCTATATAAAAATATAGATACTTTATATATGAAGAACACATCAACAACAGACATAATATTAAGGAACTTAAGACCTCACACCCTCTATAACATTTCTGTAAGGTCTTACACCAGATTTGGTCATGGCAATCAGGTATCTTCTTTACTCTCTGTAAGGACTTCGGAGACTGTGCCTGATAGTGCACCAGAAAATATCACTTACAAAAATATTTCTTCTGGAGAGATTGAGCTATCATTCCTTCCCCCAAGTAGTCCCAATGGAATCATAAAAAAATATACAATTTATCTCAAGAGAAGTAATGGAAATGAGGAAAGAACTATAAATACAACCTCTTTAACCCAAAACATTAAAGTACTGAAGAAATATACCCAATATATCATTGAGGTGTCTGCTAGTACACTGAAAGGTGAAGGAGTTCGGAGTGCTCCCATAAGTATACTGACGGAGGAAGATGCTCCTGATTCTCCCCCTCAAGACTTCTCTGTAAAACAGTTGTCTGGTGTCACGGTGAAGTTGTCATGGCAACCACCCCTGGAGCCAAATGGAATTATCCTTTATTACACAGTTTATGTCTGGAATAGATCATCATTAAAAACTATTAATGTCACTGAAACATCATTGGAGTTATCAGATTTGGATTATAATGTTGAATACAGTGCTTATGTAACAGCTAGCACCAGATTTGGTGATGGGAAAACAAGAAGCAATATCATTAGCTTTCAAACACCAGAGGGAGCACCAAGCGATCCTCCCAAAGATGTTTATTATGCAAACCTCAGTTCTTCATCAATAATTCTTTTCTGGACACCTCCTTCAAAACCTAATGGGATTATACAATATTACTCTGTTTATTACAGAAATACTTCAGGTACTTTTATGCAGAATTTTACACTCCATGAAGTAACCAATGACTTTGACAATATGACTGTATCCACAATTATAGATAAACTGACAATATTCAGCTACTATACATTTTGGTTAACAGCAAGTACTTCAGTTGGAAATGGGAATAAAAGCAGTGACATCATTGAAGTATACACAGATCAAGACGTCCCTGAAGGGTTTGTTGGAAACCTGACTTACGAATCCATTTCGTCAACTGCAATAAATGTAAGCTGGGTCCCACCGGCTCAACCAAACGGTCTAGTCTTCTACTATGTTTCACTGATCTTACAGCAGACTCCTCGCCATGTGAGACCACCTCTTGTTACATATGAGAGAAGCATATATTTTGATAATCTGGAAAAATACACTGATTATATATTAAAAATTACTCCATCAACAGAAAAGGGATTCTCTGATACCTATACTGCCCAGCTATACATCAAGACTGAAGAAGATGTCCCAGAAACTTCACCAATAATCAACACTTTTAAAAACCTTTCCTCTACCTCAGTTCTCTTATCATGGGATCCCCCAGTAAAGCCAAATGGTGCAATAATAAGTTATGATTTAACTTTACAAGGACCAAATGAAAATTATTCTTTCATTACTTCTGATAATTACATAATATTGGAAGAGCTTTCACCATTTACATTATATAGCTTTTTTGCTGCCGCAAGAACTAGAAAAGGACTTGGTCCTTCCAGTATTCTTTTCTTTTACACAGATGAGTCAGTGCCGTTAGCACCTCCACAAAATTTGACTTTAATCAACTGTACTTCAGACTTTGTATGGCTGAAATGGAGCCCAAGTCCTCTTCCAGGTGGTATTGTTAAAGTATATAGTTTTAAAATTCATGAACATGAAACTGACACTATATATTATAAGAATATATCAGGATTTAAAACTGAAGCCAAACTTGTTGGACTGGAACCAGTCAGCACCTACTCTATCCGTGTATCTGCGTTCACCAAAGTTGGAAATGGCAATCAATTTAGTAATGTAGTAAAATTCACAACCCAAGAATCAGTTCCAGATGTCGTGCAGAATATGCAGTGCATGGCAACTAGCTGGCAGTCAGTTTTAGTGAAATGGGATCCACCCAAAAAGGCAAATGGAATAATAACGCAGTATATGGTAACAGTTGAAAGGAATTCTACAAAAGTTTCTCCCCAAGATCACATGTACACTTTCATAAAGCTTCTTGCCAATACCTCATATGTCTTTAAAGTAAGAGCTTCAACCTCAGCTGGTGAAGGTGATGAAAGCACATGCCATGTCAGCACACTACCTGAAACAGTTCCCAGTGTTCCCACAAATATTGCTTTTTCTGATGTTCAGTCAACTAGTGCAACATTGACATGGATAAGACCTGACACTATCCTTGGCTACTTTCAAAATTACAAAATTACCACTCAACTTCGTGCTCAAAAATGCAAAGAATGGGAATCCGAAGAATGTGTTGAATATCAAAAAATTCAATACCTCTATGAAGCTCACTTAACTGAAGAGACAGTATATGGATTAAAGAAATTTAGATGGTATAGATTCCAAGTGGCTGCCAGCACCAATGCTGGCTATGGCAATGCTTCAAACTGGATTTCTACAAAAACTCTGCCTGGCCCTCCAGATGGTCCTCCTGAAAATGTTCATGTAGTAGCAACATCACCTTTTAGCATCAGCATAAGCTGGAGTGAACCTGCTGTCATTACTGGACCAACATGTTATCTGATTGATGTCAAATCGGTAGATAATGATGAATTTAATATATCCTTCATCAAGTCAAATGAAGAAAATAAAACCATAGAAATTAAAGATTTAGAAATATTCACAAGGTATTCTGTAGTGATCACTGCATTTACTGGGAACATTAGTGCTGCATATGTAGAAGGGAAGTCAAGTGCTGAAATGATTGTTACTACTTTAGAATCAGCCCCAAAGGACCCACCTAACAACATGACATTTCAGAAGATACCAGATGAAGTTACAAAATTTCAATTAACGTCCCTTCCTCCTTCTCAACCTAATGGAAATATCCAAGTATATCAAGCTCTGGTTTACCGAGAAGATGATCCTACTGCTGTCCAGATTCACAACCTCAGTATTATACAGAAAACCAACACATTCGTCATTGCAATGCTAGAAGGACTAAAAGGTGGACATACATACAATATCAGTGTTTACGCAGTCAATAGTGCTGGTGCAGGTCCAAAGGTTCCGATGAGAATAACCATGGATATCAAAGCTCCAGCACGACCAAAAACCAAACCAACCCCTATTTATGATGCCACAGGAAAACTGCTTGTGACTTCAACAACAATTACAATCAGAATGCCAATATGTTACTACAGTGATGATCATGGACCAATAAAAAATGTACAAGTGCTTGTGACAGAAACAGGAGCTCAGCATGATGGAAATGTAACAAAGTGGTATGATGCATATTTTAATAAAGCAAGGCCATATTTTACAAATGAAGGCTTTCCTAACCCTCCATGTACAGAAGGAAAGACAAAGTTTAGTGGCAATGAAGAAATCTACATCATAGGTGCTGATAATGCATGCATGATTCCTGGCAATGAAGACAAAATTTGCAATGGACCACTGAAACCAAAAAAGCAATACTTATTTAAATTTAGAGCTACAAATATTATGGGACAATTTACTGACTCTGATTATTCTGACCCTGTTAAGACTTTAGGCGAAGGACTTTCAGAAAGAACCCTAGAGATCATTCTTTCCGTCACTTTGTGTATCCTTTCAATAATTCTCCTTGGAACAGCTATTTTTGCATTTGCAAGAATTCGACAGAAGCAGAAAGAAGGTGGCACATACTCTCCTCAGGATGCAGAAATTATTGACACTAAATTGAAGCTGGATCAGCTCATCACAGTGGCAGACCTGGAACTGAAGGACGAGAGATTAACGCGGTTACTTAGTTATAGAAAATCCATCAAGCCAATAAGCAAGAAATCCTTCCTGCAACATGTTGAAGAGCTTTGCACAAACAACAACCTAAAGTTTCAAAGAAGAATTTTCGGAATTACCAAATTTCTTCAGGATCTTTCTTCAACTGATGCTGATCTGCCTTGGAATAGAGCAAAAAACCGCTTCCCAAACATAAAACCATATAATAATAACAGAGTAAAGCTGATAGCTGACGCTAGTGTTCCAGGTTCGGATTATATTAATGCCAGCTATATTTCTGGTTATTTATGTCCAAATGAATTTATTGCTACTCAAGGTCCACTACCAGGAACAGTTGGAGATTTTTGGAGAATGGTGTGGGAAACCAGAGCAAAAACATTAGTAATGCTAACACAGTGTTTTGAAAAAGGACGGATCAGATGCCATCAGTATTGGCCAGAGGACAACAAGCCAGTTACTGTCTTTGGAGATATAGTGATTACAAAGCTAATGGAGGATGTTCAAATAGATTGGACTATCAGGGATCTGAAAATTGAAAGGCATGGGGATTGCATGACTGTTCGACAGTGTAACTTTACTGCCTGGCCAGAGCATGGGGTTCCTGAGAACAGCGCCCCTCTAATTCACTTTGTGAAGTTGGTTCGAGCAAGCAGGGCACATGACACCACACCTATGATTGTTCACTGTAGTGCTGGAGTTGGAAGAACTGGAGTTTTTATTGCTCTGGACCATTTAACACAACATATAAATGACCATGATTTTGTGGATATATATGGACTAGTAGCTGAACTGAGAAGTGAAAGAATGTGCATGGTGCAGAATCTGGCACAGTATATCTTTTTACACCAGTGCATTCTGGATCTCTTATCAAATAAGGGAAGTAATCAGCCCATCTGTTTTGTTAACTATTCAGCACTTCAGAAGATGGACTCTTTGGACGCCATGGAAGGTGATGTTGAGCTTGAATGGGAAAGAAACCACTATGTAANOV15b, CG50718-06Protein SequenceSEQ ID NO: 1682299 aaMW at 257243.9kDMDFLIIFLLLFIGTSETQVDVSNVVPGTRYDITISSISTTYTSPVTRIVTTNVTKPGPPVFLAGERVGSAGILLSWNTPPNPNGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNPGTTYEIKVAAENSAGIGVFSDPFLFQTAESAPGKVVNLTVEAYNASAVKLIWYLPRQPNGKITSFKISVKHARSGIVVKDVSIRVEDILTGKLPECNENSESFLWSTASPSPTLGRVTPPSRTTHSSSTLTQNEISSVWKEPISFVVTHLRPYTTYLFEVSAVTTEAGYIDSTIVRTPESVPEGPPQNCVTGNITGKSFSILWDPPTIVTGKFSYRVELYGPSGRILDNSTKDLKFAFTNLTPFTMYDVYIAAETSAGTGPKSNISVFTPPDVPGAVFDLQLAEVESTQVRITWKKPRQPNGIINQYRVKVLVPETGIILENTLLTGNNEYINDPMAPEIVNIVEPMVGLYEGSAEMSSDLHSLATFIYNSHPDKNFPARNRAEDQTSPVVTTRNQYITDIAAEQLSYVIRRLVPFTEHMISVSAFTIMGEGPPTVLSVRTRQQVPSSIKIINYKNISSSSILLYWDPPEYPNGKITHYTIYAMELDTNRAFQITTIDNSFLITGLKKYTKYKMRVAASTHDGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNGIIIAYEVLYKNIDTLYMKNTSTTDIILRNLRPHTLYNISVRSYTRFGHGNQVSSLLSVRTSETVPDSAPENITYKNISSGEIELSFLPPSSPNGIIKKYTIYLKRSNGNEERTINTTSLTQNIKVLKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWNRSSLKTINVTETSLELSDLDYNVEYSAYVTASTRFGDGKTRSNIISFQTPEGAPSDPPKDVYYANLSSSSIILFWTPPSKPNGIIQYYSVYYRNTSGTFMQNFTLHEVTNDFDNMTVSTIIDKLTIFSYYTFWLTASTSVGNGNKSSDIIEVYTDQDVPEGFVGNLTYESISSTAINVSWVPPAQPNGLVFYYVSLILQQTPRHVRPPLVTYERSIYFDNLEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDVPETSPIINTFKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPNENYSFITSDNYIILEELSPFTLYSFFAAARTRKGLGPPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKVYSFKIHEHTDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGNQFSNVVKFTTQESVPDVVQNMQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFIKLLANTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDTILGYFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVAASTNAGYGNASNWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLIDVKSVDNDEFNISFIKSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMIVTTLESAPKDPPNNMTFQKIPDEVTKFQLTSLPPSQPNGNIQVYQALVYREDDPTAVQIHNLSIIQKTNTFVIAMLEGLKGGHTYNISVYAVMSAGAGPKVPMRITMDIKAPARPKTKPTPIYDATGKLLVTSTTITIRMPICYYSDDHGPIKNVQVLVTETGAQHDGNVTKWYDAYFNKARPYFTNEGFPNPPCTEGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLKPKKQYLFKFRATNIMGQFTDSDYSDPVKTLGEGLSERTLEIILSVTLCILSIILLGTAIFAFARIRQKQKEGGTYSPQDAEIIDTKLKLDQLITVADLELKDERLTRLLSYRKSIKPISKKSFLQHVEELCTNNNLKFQEEFSELPKFLQDLSSTDADLPWNRAKNRFPNIKPYNNNRVKLIADASVPGSDYINASYISGYLCPNEFIATQGPLPGTVGDFWRMVWETRAKTLVMLTQCFEKGRIRCHQYWPEDNKPVTVFGDIVITKLMEDVQIDWTIRDLKIERHGDCMTVRQCNFTAWPEHGVPENSAPLIHFVKLVRASRAHDTTPMIVHCSAGVGRTGVFIALDHLTQHINDHDFVDIYGLVAELRSERMCMVQNLAQYIFLHQCILDLLSNKGSNQPICFVNYSALQKMDSLDAMEGDVELEWEETTMNOV15c, 258979883SEQ ID NO: 1692220 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAGATCTCCTGAAGGACCACCACAAAACTGCGTAACAGGCAACATCACAGGAAAGTCCTTTTCAATTTTATGGGACCCACCAACTATAGTAACAGGGAAATTTAGTTATAGAGTTGAATTATATGGACCATCAGGTCGCATTTTGGATAACAGCACAAAAGACCTCAAGTTTGCATTCACTAACCTAACACCATTTACAATGTATGATGTCTATATTGCGGCTGAAACCAGTGCAGGGACTGGGCCCAAGTCAAATATTTCAGTATTCACTCCACCAGATGTTCCAGGGGCAGTGTTTGATTTACAACTTGCAGAGGTAGAATCCACGCAAGTAAGAATTACTTGGAAGAAACCACGACAACCAAATGGAATTATTAACCAATACCGAGTGAAAGTGCTAGTTCCAGAGACAGGAATAATTTTGGAAAATACTTTGCTCACTGGAAATAATGAGTATATAAATGACCCCATGGCTCCAGAAATTGTGAACATAGTAGAGCCAATGGTAGGATTATATGAGGGTTCAGCAGAGATGTCGTCTGACCTTCACTCACTTGCTACATTTATATATAACAGCCATCCAGATAAAAACTTTCCTGCAAGGAATAGAGCTGAAGACCAGACTTCACCAGTTGTAACTACAAGGAATCAGTATATTACTGACATTGCAGCTGAACAGCTGTCTTATGTTATCAGGAGACTTGTACCTTTCACTGAGCACATGATTAGTGTATCTGCTTTCACCATCATGGGAGAAGGACCACCAACAGTTCTCAGTGTTAGGACACGTCAGCAAGTGCCAAGCTCCATTAAAATTATAAACTATAAAAATATTAGTTCTTCATCTATTTTGTTATATTGGGATCCTCCAGAATATCCCAATGGAAAAATAACTCACTATACGATTTATGCAATGGAATTGGATACAAACAGAGCATTCCAGATAACTACCATAGATAACAGCTTTCTCATAACAGGGTTAAAGAAATACACAAAATACAAAATGAGAGTGGCAGCCTCAACCCACGATGGAGAAAGTTCTTTGTCTGAAGAAAATGACATCTTTGTGAGAACTTCAGAAGATGAACCGGAATCATCACCTCAAGATGTCGAAGTAATTGATGTTACCGCAGATGAAATAAGGTTGAAGTGGTCACCACCCGAAAAGCCCAATGGGATCATTATTGCTTATGAAGTGCTATATAAAAATATAGATACTTTATATATGAAGAACACATCAACAACAGACATAATATTAAGGAACTTAAGACCTCACACCCTCTATAACATTTCTGTAAGGTCTTACACCAGATTTGGTCATGGCAATCAGGTATCTTCTTTACTCTCTGTAAGGACTTCGGAGACTGTGCCTGATAGTGCACCAGAAAATATCACTTACAAAAATATTTCTTCTGGAGAGATTGAGCTATCATTCCTTCCCCCAAGTAGTCCCAATGGAATCATAAAAAAATATACAATTTATCTCAAGAGAAGTAATGGAAATGAGGAAAGAACTATAAATACAACCTCTTTAACCCAAACATTAAAAGTACTGAAGAAATATACCCAATATATCATTGAGGTGTCTGCTAGTACACTGAAAGGTGAAGGAGTTCGGAGTGCTCCCATAAGTATACTGACGGAGGAAGATGCTCCTGATTCTCCCCCTCAAGACTTCTCTGTAAAACAGTTGTCTGGTGTCACGGTGAAGTTGTCATGGCAACCACCCCTGGAGCCAAATGGAATTATCCTTTATTACACAGTTTATGTCTGGAATAGATCATCATTAAAAACTATTAATGTCACTGAAACATCATTGGAGTTATCAGATTTGGATTATAATGTTGAATACAGTGCTTATGTAACAGCTAGCACCAGATTTGGTGATGGGAAAACAAGAAGCAATATCATTAGCTTTCAAACACCAGAGGGAGCACCAAGCGATCCTCCCAAAGATGTTTATTATGCAAACCTCAGTTCTTCATCAATAATTCTTTTCTGGACACCTCCTTCAAAACCTAATGGGATTATACAATATTACTCTGTTTATTACAGAAATACTTCAGGTACTTTTATGCAGAATTTTACACTCCATGAAGTAACCAATGACTTTGACAATATGACTGTATCCACAATTATAGATAAACTGACAATATTCAGCTACTATACATTTTGGTTAACAGCAAGTACTTCAGTTGGAAATGGGAATAAAAGCCTCGAGNOV15c, 258979883Protein SequenceSEQ ID NO: 170740 aaMW at 82862.3kDRSPEGPPQNCVTGNITGKSFSILWDPPTIVTGKFSYRVELYGPSGRILDNSTKDLKFAFTNLTPFTMYDVYIAAETSAGTGPKSNISVFTPPDVPGAVFDLQLAEVESTQVRITWKKPRQPNGIINQYRVKVLVPETGIILENTLLTGNNEYINDPMAPEIVNIVEPMVGLYEGSAEMSSDLHSLATFIYNSHPDKNFPARNRAEDQTSPVVTTRNQYITDIAAEQLSYVIRRLVPFTEHMISVSAFTIMGEGPPTVLSVRTRQQVPSSIKIINYKNISSSSILLYWDPPEYPNGKITHYTIYA4ELDTNRAFQITTIDNSFLITGLKKYTKYKMRVAASTHDGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNGIIIAYEVLYKNIDTLYMKNTSTTDIILRNLRPHTLYNISVRSYTRFGHGNQVSSLLSVRTSETVPDSAPENITYKNISSGEIELSFLPPSSPNGIIKKYTIYLKRSNGNEERTINTTSLTQNIKVLKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWNRSSLKTINVTETSLELSDLDYNVEYSAYVTASTRFGDGKTRSNIISFQTPEGAPSDPPKDVYYANLSSSSIILFWTPPSKPNGIIQYYSVYYRNTSGTFMQNFTLHEVTNDFDNMTVSTIIDKLTIFSYYTFWLTASTSVGNGNKSLENOV5d, CG50718-01SEQ ID NO: 1716994 bpDNA SequenceORF Start: ATG at 31ORF Stop: TAA at 6874TGATTCTACTGGCTGAAAAATGTAATAAAGATGGATTTTCTTATCATTTTTCTTTTACTTTTTATTGGGACTTCAGAGACACAGGTAGATGTTTCCAATGTCGTTCCTGGTACTAGGTACGATATAACCATCTCTTCAATTTCTACAACATACACCTCACCTGTTACTAGAATAGGGGCTTCTAATGAACCAGGGCCTCCAGTCTTCCTAGCCGGGGAAAGAGTCGGATCTGCTGGGATTCTTCTGTCTTGGAATACACCACCTAATCCAAATGGAAGGATTATATCTTACATTGTCAAATATAAGGAAGTTTGTCCGTGGATGCAAACAGTATATACACAAGTCAGATCAAAGCCAGACAGTCTGGAAGTTCTTCTTACTAATCTTAATCCTGGAACAACATATGAAATTAAGGTAGCTGCTGAAAACAGTGCTGGCATTGGAGTGTTTAGTGATCCATTTCTCTTCCAAACTGCAGAAAGTGCTCCAGGAAAAGTGGTGGATTTCACAGGTGAGGCTGTCCCGTTCAGCAGTAAGCTGATGTGGTATACCTCGGCAACCAAAAAAAAAATTACCAGCTTCAAGATTAGTGTCAAGCATAACAGAAGTGGGATAGTAGTGAAAGAAGTGTCAATCAGAGTGGAGTGCATTTTAAGTGCTTCCCTTCCTTTGCACTGCAACGAGAATAGTGAATCTTTTTTATGGAGTACAGCCAGCCCTTCTCCAACCCTTGGTAGAGTTACACCTCCATCGCGTACCACACATTCATCAAGCACGTTGACACAGAATGAGATCAGCTCTGTGAAAGAGCCTATCAGTTTTGTAGTGACACACTTGAGACCTTATACAACATATCTTTTTGAAGTTTCAGCTGCTACAACTGAAGCAGGTTATATTGATAGTACGATTGTCAGAACACCAGAATCAGTGCCTGAAGGACCACCACAAAACTGCGTAACAGGCAACATCACAGGAAAGTCCTTTTCAATTTTATGGGACCCACCAACTATAGTAACAGGGAAATTTAGTTATAGAGTTGAATTATATGGACCATCAGCAGGTCGCATTTTGGATAACAGCACAAAAGACCTCAAGTTTGCATTCACTAACCTAACACCATTTACAATGTATGATGTCTATATTGCGGCTGAAACCAGTGCAGGGACTGGGCCCAAGTCAAATATTTCAGTATTCACTCCACCAGATGTTCCAGGGGCAGTGTTTGATTTACAACTTGCAGAGGTAGAATCCACGCAAGTAAGAATTACTTGGAAGAAACCACGACAACCAAATGGAATTATTAACCAATACCGAGTGAAAGTGCTAGTTCCAGAGACAGGAATAATTTTGGAAAATACTTTGCTCACTGGAAATAATGAGATAAATGACCCCATGGCTCCAGAAATTGTGAACATAGTACAGCCAATGGTAGGATTATATGAGGGTTCAGCAGAGATGTCGTCTGACCTTCACTCACTTGCTACATTTATATATAACAGCCATCCAGATAAAAACTTTCCTGCAAGGAATAGAGCTGAAGACCAGACTTCACCAGTTGTAACTACAAGGAATCAGTATATTACTGACATTGCAGCTGAACAGCTGACTTATGTTCTTATCAGATTAAGGAGATTTTGGGCTGAGACAATGGGGTTTTCTAGATATACAATCATGTCATCTGCAAGCAGGGACAATTTGACTTCCCCAGGCCCTTTGTCAGCCCAAAATTTCAGAGTTACACATGTTACCATAACAGAAGTATTTTTACACTGGGATCCTCCAGATCCTGTATTTTTTCATCATTACCTTATCACTATTTTGGATGTTGAAAACCAATCCAAGAGTATTATTTTAAGGACATTAAACAGTTTGTCTCTTGTCCTTATAGGGTTAAAGAAATACACAAAATACAAAATGAGAGTGGCAGCCTCAACCCACGTTGGAGAAAGTTCTTTGTCTGAAGAAAATGACATCTTTGTGAGAACTTCAGAAGATGAACCGGAATCATCACCTCAAGATGTCGAAGTAATTGATGTTACCGCAGATGAAATAAGGTTGAAGTGGTCACCACCCGAAAAGCCCAATGGGATCATTATTGCTTATGAAGTGCTATATAAAAATATAGATACTTTATATATGAAGAACACATCAACAACAGACATAATATTAAGGAACTTAAGACCTCACACCCTCTATAACATTTCTGTAAGGTCTTACACCAGATTTGGTCATGGCAATCAGGTATCTTCTTTACTCTCTGTAAGGACTTCGGAGTCAGTGCCTGATAGTGCACCAGAAAATATCACTTACAAAAATATTTCTTCTGGAGAGATTGAGCTATCATTCCTTCCCCCAAGTAGTCCCAATGGAATCATACAAAAATATACAATTTATCTCAAGAGAAGTAATGGAAATGAGGAAAGAACTATAAATACAACCTCTTTAACCCAAAACATTAAAGGTCTGAAGAAATATACCCAATATATCATTGAGGTGTCTGCTAGTACACTCAAAGGTGAAGGAGTTCGGAGTGCTCCCATAAGTATACTGACGGAGGAAGATGCTCCTGATTCTCCCCCTCAAGACTTCTCTGTAAAACAGTTGTCTGGTGTCACGGTGAAGTTGTCATGGCAACCACCCCTGGAGCCAAATGGAATTATCCTTTATTACACAGTTTATGTCTGGAGATCATCATTAAAAACTATTAATGTCACTGAAACATCATTGGAGTTATCAGATTTGGATTATAATGTTGAATACAGTGCTTATGTAACAGCTAGCACCAGATTTGGTGATGGGAAAACAAGAAGCAATATCATTAGCTTTCAAACACCAGAGGGACCAAGCGATCCTCCCAAAGATGTTTATTATGCAAACCTCAGTTCTTCATCAATAATTCTTTTCTGGACACCTCCTTCAAAACCTAATGGGATTATACAATATTACTCTGTTTATTACAGAAATACTTCAGGTACTTTTATGCAGAATTTTACACTCCATGAAGTAACCAATGACTTTGACAATATGACTGTATCCACAATTATAGATAAACTGACAATATTCAGCTACTATACATTTTGGTTAACAGCAAGTACTTCAGTTGGAAATGGGAATAAAAGCAGTGACATCATTGAAGTATACACAGATCAAGACGTACCTGAAGGGTTTGTTGGAAACCTGACTTACGAATCCATTTCGTCAACTGCAATAAATGTAAGCTGGGTCCCACCGGCTCAACCAAACGGTCTAGTCTTCTACTATGTTTCACTGATCTTACAGCAGACTCCTCGCCATGTGAGACCACCTCTTGTTACATATGAGAGAAGCATATATTTTGATAATCTGGAAAAATACACTGATTATATATTAAAAATTACTCCATCAACAGAAAAGGGATTCTCTGATACCTATACTGCCCAGCTATACATCAAGACTGAAGAAGATATCCCAGAAACTTCACCAATAATCAACACTTTTAAAAACCTTTCCTCTACCTCAGTTCTCTTATCATGGGATCCCCCAGTAAAGCCAAATGGTGCAATAATAAGTTATGATTTAACTTTACAAGGACCAAATGAAAATTATTCTTTCATTACTTCTGATAATTACATAATATTGGAAGAGCTTTCACCATTTACATTATATAGCTTTTTTGCTGCCGCAAGAACTAGAAAAGGACTTGGTCCTTCCAGTATTCTTTTCTTTTACACAGATGAGTCAGTGCCGTTAGCACCTCCACAAAATTTGACTTTAATCAACTGTACTTCAGACTTTGTATGGCTGAAATGGAGCCCAAGTCCTCTTCCAGGTGGTATTGTTAAAGTATATAGTTTTAAAATTCATGAACATGAAACTGACACTATATATTATAAGAATATATCAGGATTTAAAACTGAAGCCAAACTTGTTGGACTGGAACCAGTCAGCACCTACTCTATCCGTGTATCTGCGTTCACCAAAGTTGGAAATGGCAATCAATTTAGTAATGTAGTAAAATTCACAACCCAAGAATCAGTTCCAGATGTCGTGCAGAATATGCAGTGCATGGCAACTAGCTGGCAGTCAGTTTTAGTGAAATGGGATCCACCCAAAAAGGCAAATGGAATAATAACGCAGTATATGGTAACAGTTGAAAGGAATTCTACAAAAGTTTCTCCCCAAGATCACATGTACACTTTCATAAAGCTTCTTGCCAATACCTCATATGTCTTTAAAGTAAGAGCTTCAACCTCAGCTGGTGAAGGTGATGAAAGCACATGCCATGTCAGCACACTACCTGAAACAGTTCCCAGTGTTCCCACAAATATTGCTTTTTCTGATGTTCAGTCAACTAGTGCAACATTGACATGGATAAGACCTGACACTATCCTTGGCTACTTTCAAAATTACAAAATTACCACTCAACTTCGTGCTCAAAAATGCAAAGAATGGGAATCCGAAGAATGTGTTGAATATCAAAAAATTCAATACCTCTATGAAGCTCACTTAACTGAAGAGACAGTATATGGATTAAAGAAATTTAGATGGTATAGATTCCAAGTGGCTGCCAGCACCAATGCTGGCTATGGCAATGCTTCAAACTGGATTTCTACAAAAACTCTGCCTGGCCCTCCAGATGGTCCTCCTGAAAATGTTCATGTAGTAGCAACATCACCTTTTAGCATCAGCATAAGCTGGAGTGAACCTGCTGTCATTACTGGACCAACATGTTATCTGATTGATGTCAAATCGGTAGATAATGATGAATTTAATATATCCTTCATCAAGTCAAATGAAGAAAATAAAACCATAGAAATTAAAGATTTAGAAATATTCACAAGGTATTCTGTAGTGATCACTGCATTTACTGGGAACATTAGTGCTGCATATGTAGAAGGGAAGTCAAGTGCTGAAATGATTGTTACTACTTTAGAATCAGCCCCAAAGGACCCACCTAACAACATGACATTTCAGAAGATACCAGATGAAGTTACAAAATTTCAATTAACGTTCCTTCCTCCTTCTCAACCTAATGGAAATATCCAAGTATATCAAGCTCTGGTTTACCGAGAAGATGATCCTACTGCTGTCCAGATTCACAACCTCAGTATTATACAGAAAACCAACACATTCGTCATTGCAATGCTAGAAGGACTAAAAGGTGGACATACATACAATATCAGTGTTTACGCAGTCAATAGTGCTGGTGCAGGTCCAAAGGTTCCGATGAGAATAACCATGGATATCAAAGCTCCAGCACGACCAAAAACCAAACCAACCCCTATTTATGATGCCACAGGAAAACTGCTTGTGACTTCAACAACAATTACAATCAGAATGCCAATATGTTACTACAGTGATGATCATGGACCAATAAAAAATGTACAAGTGCTTGTGACAGAAACAGGAGCTCAGCATGATGGAAATGTAACAAAGTGGTATGATGCATATTTTAATAAAGCAAGGCCATATTTTACAAATGAAGGCTTTCCTAACCCTCCATGTACAGAAGGAAAGACAAAGTTTAGTGGCAATGAAGAAATCTACATCATAGGTGCTGATAATGCATGCATGATTCCTGGCAATGAAGACAAAATTTGCAATGGACCACTGAAACCAAAAAAGCAATACTTATTTAAATTTAGAGCTACAAATATTATGGGACAATTTACTGACTCTGATTATTCTGACCCTGTTAAGACTTTAGGCGAAGGACTTTCAGAAAGAACCGTAGAGATCATTCTTTCCGTCACTTTGTGTATCCTTTCAATAATTCTCCTTGGAACAGCTATTTTTGCATTTGCAAGAATTCGACAGAAGCAGAAAGAAGGTGGCACATACTCTCCTCAGGATGCAGAAATTATTGACACTAAATTGAAGCTGGATCAGCTCATCACAGTGGCAGACCTGGAACTGAAGGACGAGAGATTAACGCGGCCAATAAGCAAGAAATCCTTCCTGCAACATGTTGAAGAGCTTTGCACAAACAACAACCTAAAGTTTCAAGAAGAATTTTCGGAATTACCAAAATTTCTTCAGGATCTTTCTTCAACTGATGCTGATCTGCCTTGGAATAGAGCAAAAAACCGCTTCCCAAACATAAAACCATATAATAATAACAGAGTAAAGCTGATAGCTGACGCTAGTGTTCCAGGTTCGGATTATATTAATGCCAGCTATATTTCTGGTTATTTATGTCCAAATGAATTTATTGCTACTCAAGGTCCACTACCAGGAACAGTTGGAGATITTTGGAGAATGGTGTGGGAAACCAGAGCAAAAACATTAGTAATGCTAACACAGTGTTTTGAAAAAGGACGGATCAGATGCCATCAGTATTGGCCAGAGGACAACAAGCCAGTTACTGTCTTTGGAGATATAGTGATTACAAAGCTAATGGAGGATGTTCAAATAGATTGGACTATCAGGGATCTGAAAATTGAAAGGCATGGGGATTGCATGACTGTTCGACAGTGTAACTTTACTGCCTGGCCAGAGCATGGGGTTCCTGAGAACAGCGCCCCTCTAATTCACTTTGTGAAGTTGGTTCGAGCAAGCAGGGCACATGACACCACACCTATGATTGTTCACTGCAGTGCTGGAGTTGGAAGAACTGGAGTTTTTATTGCTCTGGACCATTTAACACAACATATAAATGACCATGATTTTGTGGATATATATGGACTAGTAGCTGAACTGAGAAGTGAAAGAATGTGCATGGTGCAGAATCTGGCACAGTATATCTTTTTACACCAGTGCATTCTGGATCTCTTATCAAATAAGGGAAGTAATCAGCCCATCTGTTTTGTTAACTATTCAGCACTTCAGAAGATGGACTCTTTGGACGCCATGGAAGGTGGTGATGTTGAGCTTGAATGGGAAGAAACCACTATGTAAATATTCAGACCAAAGGATACAATTGGAAGAGATTTTTAAATCCCAGGGGCCAAAGTTACCCCCTCATTCTTCCGAATTGAAATGTGCAACCTTAAAGAAATATCTATGCTTCTCTCACNOV15d, CG50718-01Protein SequenceSEQ ID NO: 1722281 aaMW at 255030.3kDMDFLIIFLLLFIGTSETQVDVSNVVPGTRYDITISSISTTYTSPVTRIGASNEPGPPVFLAGERVGSAGILLSWNTPPNPNGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNPGTTYEIKVAAENSAGIGVFSDPFLFQTAESAPGKVVDFTGEAVPFSSKLMWYTSATKKKITSFKISVKHNRSGIVVKEVSIRVECILSASLPLHCNENSESFLWSTASPSPTLGRVTPPSRTTHSSSTLTQNEISSVKEPISFVVTHLRPYTTYLFEVSAATTEAGYIDSTIVRTPESVPEGPPQNCVTGNITGKSFSILWDPPTIVTGKFSYRVELYGPSAGRILDNSTKDLKFAFTNLTPFTMYDVYIAAETSAGTGPKSNISVFTPPDVPGAVFDLQLAEVESTQVRITWKKPRQPNGIINQYRVKVLVPETGIILENTLLTGNNEINDPMAPEIVNIVQPMVGLYEGSAEMSSDLHSLATFIYNSHPDKNFPARNRAEDQTSPVVTTRNQYITDIAAEQLTYVLIRLRRFWAETMGFSRYTIMSSASRDNLTSPGPLSAQMFRVTHVTITEVFLHWDPPDPVFFHHYLITILDVENQSKSIILRTLNSLSLVLIGLKKYTKYKMRVAASTHVGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNGIIIAYEVLYKNIDTLYMKNTSTTDIILRNLRPHTLYNISVRSYTRFGNGNQVSSLLSVRTSESVPDSAPENITYKNISSGEIELSFLPPSSPNGIIQKYTIYLKRSNGNEERTINTTSLTQNIKGLKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWRSSLKTINVTETSLELSDLDYNVEYSAYVTASTRFGDGKTRSNIISFQTPEGPSDPPKDVYYANLSSSSIILFWTPPSKPNGIIQYYSVYYRNTSGTFMQNFTLHEVTNDFDNMTVSTIIDKLTIFSYYTFWLTASTSVGNGNKSSDIIEVYTDQDVPEGFVGNLTYESISSTAINVSWVPPAQPNGLVFYYVSLILQQTPRHVRPPLVTYERSIYFDNLEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDIPETSPIINTFKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPNENYSFITSDNYIILEELSPFTLYSFFAAARTRKGLGPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKVYSFKIHEHETDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGNQFSNVVKFTTQESVPDVVQNMQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFIKLLANTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDTILGYFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVAASTNAGYGNASNWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLIDVKSVDNDEFNISF1KSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMIVTTLESAPKDPPNNMTFQKIPDEVTKFQLTFLPPSQPNGNIQVYQALVYREDDPTAVQIHNLSIIQKTNTFVIAMLEGLKGGHTYNISVYAVNSAGAGPKVPMRITMDIKAPARPKTKPTPIYDATGKLLVTSTTITIRMPICYYSDDHGPIKNVQVLVTETGAQHDGNVTKWYDAYFNKARPYFTNEGFPNPPCTEGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLKPKKQYLFKFRATNIMGQFTDSDYSDPVKTLGEGLSERTVEIILSVTLCILSIILLGTAIFAFARIRQKQKEGGTYSPQDAEIIDTKLKLDQLITVADLELKDERLTRPISKKSFLQHVEELCTNNNLKFQEEFSELPKFLQDLSSTDADLPWNRAKNRFPNIKPYNNNRVKLIADASVPGSDYINASYISGYLCPNEFIATQGPLPGTVGDFWRMVWETRAKTLVMLTQCFEKGRIRCHQYWPEDNKPVTVFGDIVITKLMEDVOIDWTIRDLKIERHGDCMTVROCNFTAWPEHGVPENSAPLIHFVKLVRASRAHDTTPMIVHCSAGVGRTGVFIALDHLTQHINDHDFVDIYGLVAELRSERNGMVQNLAQYIFLHQCILDLLSNKGSNQPICFVNYSALQKMDSLDAMEGGDVELEWEETTMNOV15e, CG50718-03SEQ ID NO: 1732739 bpDNA SequenceORF Start: at 7ORF Stop: at 2734AGATCTCAGGTAGATGTTTCCAATGTCGTTCCTGGTACTAGGTACGATATAACCATCTCTTCAATTTCTACAACATACACCTCACCTGTTACTAGAATAGTGACAACAAATGTAACAAAACCAGGGCCTCCAGTCTTCCTAGCCGGGGAAAGAGTCGGATCTGCTGGGATTCTTCTGTCTTGGAATACACCACCTAATCCAAATGGAAGGATTATATCTTACATTGTCAAATATAAGGAAGTTTGTCCGTGGATGCAAACAGTATATACACAAGTCAGATCAAAGCCAGACAGTCTGGAAGTTCTTCTTACTAATCTTAATCCTGGAACAACATATGAAATTAAGGTTGCTGCTGAAAACAGTGCTGGCATTGGAGTGTTTAGTGATCCATTTCTCTTCCAAACTGCAGAAAGTGCTCCAGGAAAAGTGGTGAATCTCACAGTTGAGGCCTACAACGCTTCAGCAGTTAAGCTGATTTGGTATTTACCTCGGCAACCAAATGGCAAAATTACCAGCTTCAAGATTAGTGTCAAGCATGCCAGAAGTGGGATAGTAGTGAAAGATGTCTCAATCAGAGTAGAGGACATTTTGACTGGGAAATTGCCAGAATGCAATGAGAATAGTGAATCTTTTTTATGGAGTACAGCCAGCCCTTCTCCAACCCTTGGTAGAGTTACACCTCCATCGCGTACCACACATTCATCAAGCACGTTGACACAGAATGAGATCAGCTCTGTGTGGAAAGAGCCTATCAGTTTTGTAGTGACACACTTGAGACCTTATACAACATATCTTTTTGAAGTTTCAGCTGTTACAACTGAAGCAGGTTATATTGATAGTACGATTGTCAGAACACCAGAATCAGTGCCTGAAGGACCACCACAAAACTGCGTAACAGGCAACATCACAGGAAAGTCCTTTTCAATTTTATGGGACCCACCAACTATAGTAACAGGGAAATTTAGTTATAGAGTTGAATTATATGGACCATCAGGTCGCATTTTGGATAACAGCACAAAAGACCTCAAGTTTGCATTCACTAACCTAACACCATTTACAATGTATGATGTCTATATTGCGGCTGAAACCAGTGCAGGGACTGGGCCCAAGTCAAATATTTCAGTATTCACTCCACCAGATGTTCCAGGGGCAGTGTTTGATTTACAACTTGCAGAGGTAGAATCCACGCAAGTAAGAATTACTTGGAAGAAACCACGACAACCAAATGGAATTATTAACCAATACCGAGTGAAAGTGCTAGTTCCAGAGACAGGAATAATTTTGGAAAATACTTTGCTCACTGGAAATAATGAGTATATAAATGACCCCATGGCTCCAGAAATTGTGAACATAGTAGAGCCAATGGTAGGATTATATGAGGGTTCAGCAGAGATGTCGTCTGACCTTCACTCACTTGCTACATTTATATATAACAGCCATCCAGATAAAAACTTTCCTGCAAGGAATAGAGCTGAAGACCAGACTTCACCAGTTGTAACTACAAGGAATCAGTATATTACTGACATTGCAGCTGAACAGCTGTCTTATGTTATCAGGAGACTTGTACCTTTCACTGAGCACATGATTAGTGTATCTGCTTTCACCATCATGGGAGAAGGACCACCAACAGTTCTCAGTGTTAGGACACGTCAGCAAGTGCCAAGCTCCATTAAAATTATAAACTATAAAAATATTAGTTCTTCATCTATTTTGTTATATTGGGATCCTCCAGAATATCCCAATGGAAAAATAACTCACTATACGATTTATGCAATGGAATTGGATACAAACAGAGCATTCCAGATAACTACCATAGATAACAGCTTTCTCATAACAGGGTTAAAGAAATACACAAAATACAAAATGAGAGTGGCAGCCTCAACCCACGATGGAGAAAGTTCTTTGTCTGAAGAAAATGACATCTTTGTGAGAACTTCAGAAGATGAACCGGAATCATCACCTCAAGATGTCGAAGTAATTGATGTTACCGCAGATGAAATAAGGTTGAAGTGGTCACCACCCGAAAAGCCCAATGGGATCATTATTGCTTATGAAGTGCTATATAAAAATATAGATACTTTATATATGAAGAACACATCAACAACAGACATAATATTAAGGAACTTAAGACCTCACACCCTCTATAACATTTCTGTAAGGTCTTACACCAGATTTGGTCATGGCAATCAGGTATCTTCTTTACTCTCTGTAAGGACTTCGGAGACTGTGCCTGATAGTGCACCAGAAAATATCACTTACAAAAATATTTCTTCTGGAGAGATTGAGCTATCATTCCTTCCCCCAAGTAGTCCCAATGGAATCATACAAAAATATACAATTTATCTCAAGAGAAGTAATGGAAATGAGGAAAGAACTATAAATACAACCTCTTTAACCCAAAACATTAAAGGACTGAAGAAATATACCCAATATATCATTGAGGTGTCTGCTAGTACACTCAAAGGTGAAGGAGTTCGGAGTGCTCCCATAAGTATACTGACGGAGGAAGATGCTCCTGATTCTCCCCCTCAAGACTTCTCTGTAAAACAGTTGTCTGGTGTCACGGTGAAGTTGTCATGGCAACCACCCCTGGAGCCAAATGGAATTATCCTTTATTACACAGTTTATGTCTGGAATAGATCATCATTAAAAACTATTAATGTCACTGAAACATCATTGGAGTTATCAGATTTGGATTATAATGTTGAATACAGTGCTTATGTAACAGCTAGCCTCGAGNOV15e, CG50718-03Protein SequenceSEQ ID NO: 174909 aaMW at 100812.8kDQVDVSNVVPGTRYDITISSISTTYTSPVTRIVTTNVTKPGPPVFLAGERVGSAGILLSWNTPPNPNGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNPGTTYEIKVAAENSAGIGVFSDPFLFQTAESAPGKVVNLTVEAYNASAVKLIWYLPRQPNGKITSFKISVKHARSGIVVKDVSIRVEDILTGKLPECNENSESFLWSTASPSPTLGRVTPPSRTThSSSTLTQNEISSVWKEPISFVVTHLRPYTTYLFEVSAVTTEAGYIDSTIVRTPESVPEGPPQNCVTGNITGKSFSILWDPPTIVTGKFSYRVELYGPSGRILDNSTKDLKFAFTNLTPFTMYDVYIAAETSAGTGPKSNISVFTPPDVPGAVFDLQLAEVESTQVRITWKKPRQPNGIINQYRVKVLVPETGIILENTLLTGNNEYINDPMAPEIVNIVEPMVGLYEGSAEMSSDLHSLATFIYNSHPDKNFPARNRAEDQTSPVVTTRNQYITDIAAEQLSYVIRRLVPFTEHMISVSAFTIMGEGPPTVLSVRTRQQVPSSIKIINYKRNSSSSILLYWDPPEYPNGKITHYTIYAMELDTNRAFQITTIDNSFLITGLKKYTKYKMRVAASTHDGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNGIIIAYEVLYKNIDTLYMKNTSTTDIILRNLRPHTLYNISVRSYTRFGHGNQVSSLLSVRTSETVPDSAPENITYKNISSGEIELSFLPPSSPNGIIQKYTIYLKRSNGNEERTINTTSLTQNIKGLKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDFSVKQLSGVTVKLSWQPPLEPNGIELYYTVYVWNRSSLKTINVTETSLELSDLDYNVEYSAYVTASNOV15f, CG50718-04SEQ ID NO: 1752565 bpDNA SequenceORF Start: at 7ORF Stop: at 2560AGATCTCCTGAAGGGTTTGTTGGAAACCTGACTTACGAATCCATTTCGTCAACTGCAATAAATGTAAGCTGGGTCCCACCGGCTCAACCAAACGGTCTAGTCTTCTACTATGTTTCACTGATCTTACAGCAGACTCCTCGCCATGTGAGACCACCTCTTGTTACATATGAGAGAAGCATATATTTTGATAATCTGGAAAAATACACTGATTATATATTAAAAATTACTCCATCAACAGAAAAGGGATTCTCTGATACCTATACTGCCCAGCTATACATCAAGACTGAAGAAGATGTCCCAGAAACTTCACCAATAATCAACACTTTTAAAAACCTTTCCTCTACCTCAGTTCTCTTATCATGGGATCCCCCAGTAAAGCCAAATGGTGCAATAATAAGTTATGATTTAACTTTACAAGGACCAAATGAAAATTATTCTTTCATTACTTCTGATAATTACATAATATTGGAAGAGCTTTCACCATTTACATTATATAGCTTTTTTGCTGCCGCAAGAACTAGAAAAGGACTTGGTCCTTCCAGTATTCTTTTCTTTTACACAGATGAGTCAGTGCCGTTAGCACCTCCACAAAATTTGACTTTAATCAACTGTACTTCAGACTTTGTATGGCTGAAATGGAGCCCAAGTCCTCTTCCAGGTGGTATTGTTAAAGTATATAGTTrTAAAATTCATGAACATGAAACTGACACTATATATTATAAGAATATATCAGGATTTAAAACTGAAGCCAAACTTGTTGGACTGGAACCAGTCAGCACCTACTCTATCCGTGTATCTGCGTTCACCAAAGTTGGAAATGGCAATCAATTTAGTAATGTAGTAAAATTCACAACCCAAGAATCAGTTCCAGATGTCGTGCAGAATATGCAGTGCATGGCAACTAGCTGGCAGTCAGTTTTAGTGAAATGGGATCCACCCAAAAAGGCAAATGGAATAATAACGCAGTATATGGTAACAGTTGAAAGGAATTCTACAAAAGTTTCTCCCCAAGATCACATGTACACTTTCATAAAGCTTCTTGCCAATACCTCATATGTCTTTAAAGTAAGAGCTTCAACCTCAGCTGGTGAAGGTGATGAAAGCACATGCCATGTCAGCACACTACCTGAAACAGTTCCCAGTGTTCCCACAAATATTGCTTTTTCTGATGTTCAGTCAACTAGTGCAACATTGACATGGATAAGACCTGACACTATCCTTGGCTACTTTCAAAATTACAAAATTACCACTCAACTTCGTGCTCAAAAATGCAAAGAATGGGAATCCGAAGAATGTGTTGAATATCAAAAAATTCAATACCTCTATGAAGCTCACTTAACTGAAGAGACAGTATATGGATTAAAGAAATTTAGATGGTATAGATTCCAAGTGGCTGCCAGCACCAATGCTGGCTATGGCAATGCTTCAAACTGGATTTCTACAAAAACTCTGCCTGGCCCTCCAGATGGTCCTCCTGAAAATGTTCATGTAGTAGCAACATCACCTTTTAGCATCAGCATAAGCTGGAGTGAACCTGCTGTCATTACTGGACCAACATGTTATCTGATTGATGTCAAATCGGTAGATAATGATGAATTTAATATATCCTTCATCAAGTCAAATGAAGAAAATAAAACCATAGAAATTAAAGATTTAGAAATATTCACAAGGTATTCTGTAGTGATCACTGCATTTACTGGGAACATTAGTGCTGCATATGTAGAAGGGAAGTCAAGTGCTGAAATGATTGTTACTACTTTAGAATCAGCCCCAAAGGACCCACCTAACAACATGACATTTCAGAAGATACCAGATGAAGTTACAAAATTTCAATTAACGTCCCTTCCTCCTTCTCAACCTAATGGAAATATCCAAGTATATCAAGCTCTGGTTTACCGAGAAGATGATCCTACTGCTGTCCAGATTCACAACCTCAGTATTATACAGAAAACCAACACATTCGTCATTGCAATGCTAGAAGGACTAAAAGGTGGACATACATACAATATCAGTGTTTACGCAGTCAATAGTGCTGGTGCAGGTCCAAAGGTTCCGATGAGAATAACCATGGATATCAAAGCTCCAGCACGACCAAAAACCAAACCAACCCCTATTTATGATGCCACAGGAAAACTGCTTGTGACTTCAACAACAATTACAATCAGAATGCCAATATGTTACTACAGTGATGATCATGGACCAATAAAAAATGTACAAGTGCTTGTGACAGAAACAGGAGCTCAGCATGATGGAAATGTAACAAAGTGGTATGATGCATATTTTAATAAAGCAAGGCCATATTTTACAAATGAAGGCTTTCCTAACCCTCCATGTACAGAAGGAAAGACAAAGTTTAGTGGCAATGAAGAAATCTACATCATAGGTGCTGATAATGCATGCATGATTCCTGGCAATGAAGACAAAATTTGCAATGGACCACTGAAACCAAAAAAGCAATACTTATTTAAATTTAGAGCTACAAATATTATGGGACAATTTACTGACTCTGATTATTCTGACCCTGTTAAGACTTTAGGCGAAGGACTTTCAGAAAGAACCCTCGAGNOV15f, CG50718-04Protein SequenceSEQ ID NO: 176851 aaMW at 95001.6kDPEGFVGNLTYESISSTAINVSWVPPAQPNGLVFYYVSLILQQTPRHVRPPLVTYERSIYFDNLEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDVPETSPIINTFKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPNENYSFITSDNYIILEELSPFTLYSFFAAARTRKGLGPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKVYSFKIHEHETDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGNQFSNVVKFTTQESVPDVVQNNQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFIKLLANTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDTILGYFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVAASTNAGYGNASNWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLIDVKSVDMDEFNISFIKSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMIVTTLESAPKDPPNNMTFQKIPDEVTKFQLTSLPPSQPNGNIQVYQALVYREDDPTAVQIHNLSIIQKTNTFVIAMLEGLKGGHTYNISVYAVNSAGAGPKVPMRITMDIKAPARPKTKPTPIYDATGKLLVTSTTITIRMPICYYSDDHGPIKNVQVLVTETGAQHDGNVTKWYDAYFNKARPYFTNEGFPNPPCTEGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLKPKKQYLFKFRATNIMGQFTDSDYSDPVKTLGEGLSERTNOV15g, CG50718-05SEQ ID NO: 1776903 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAA at 6901ATGGATTTTCTTATCATTTTTCTTTTACTTTTTATTGGGACTTCAGAGACACAGGTAGATGTTTCCAATGTCGTTCCTGGTACTAGGTACGATATAACCATCTCTTGAATTTCTACAACATACACCTCACCTGTTACTAGAATAGTGACAACAAATGTAACAGAACCAGGGCCTCCAGTCTTCCTAGCCGGGGAAAGAGTCGGATCTGCTGGGATTCTTCTGTCTTGGAATACACCACCTAATCCAAATGGAAGGATTATATCTTACATTGTCAAATATAAGGAAGTTTGTCCGTGGATGCAAACAGTATATACACAAGTCAGATCAAAGCCAGACAGTCTGGAAGTTCTTCTTACTAATCTTAATCCTGGAACAACATATGAAATTAAGGTAGCTGCTGAAAACAGTGCTGGCATTGGAGTGTTTAGTGATCCATTTCTCTTCCAAACTGCAGAAAGTCCAGCTCCAGGAAAAGTGGTGAATCTCACAGTTGAGGCCTACAACGCTTCAGCAGTTAAGCTGATTTGGTATTTACCTCGGCAACCAAATGGCAAAATTACCAGCTTCAAGATTAGTGTCAAGCATGCCAGAAGTGGGATAGTAGTGAAAGATGTCTCAATCAGAGTAGAGGACATTTTGACTGGGAAATTGCCAGAATGCAATGTAGAGAATAGTGAATCTTTTTTATGGAGTACAGCCAGCCCTTCTCCAACCCTTGGTAGAGTTACACCTCCATCGCGTACCACACATTCATCAAGCACGTTGACACAGAATGAGATCAGCTCTGTGTGGAAAGAGCCTATCAGTTTTGTAGTGACACACTTGAGACCTTATACAACATATCTTTTTGAAGTTTCAGCTGCTACAACTGAAGCAGGTTATATTGATAGTACGATTGTCAGAACACCAGAATCAGTGCCTGAAGGACCACCACAAAACTGCGTAACAGGCAACATCACAGGAAAGTCCTTTTCAATTTTATGGGACCCACCAACTATAGTAACAGGGAAATTTAGTTATAGAGTTGAATTATATGGACCATCAGGTCGCATTTTGGATAACAGCACAAAAGACCTCAAGTTTGCATTCACTAACCTAACACCATTTACAATGTATGATGTCTATATTGCGGCTGAAACCAGTGCAGGGACTGGGCCCAAGTCAAATATTTCAGTATTCACTCCACCAGATGTTCCAGGGGCAGTGTTTGATTTACAACTTGCAGAGGTAGAATCCACGCAAGTAAGAATTACTTGGAAGAAACCACGACAACCAAATGGAATTATTAACCAATACCGAGTGAAAGTGCTAGTTCCAGAGACAGGAATAATTTTGGAAAATACTTTGCTCACTGGAAATAATGAGATAAATGACCCCATGGCTCCAGAAATTGTGAACATAGTAGAGCCAATGGTAGGATTATATGAGGGTTCAGCAGAGATGTCGTCTGACCTTCACTCACTTGCTACATTTATATATAACAGCCATCCAGATAAAAACTTTCCTGCAAGGAATAGAGCTGAAGACCAGACTTCACCAGTTGTAACTACAAGGAATCAGTATATTACTGACATTGCAGCTGAACAGCTGTCTTATGTTATCAGGAGACTTGTACCTTTCACTGAGCACATGATTAGTGTATCTGCTTTCACCATCATGGGAGAAGGACCACCAACAGTTCTCAGTGTTAGGACACGTCAGCAAGTGCCAAGCTCCATTAAAATTATAAACTATAAAAATATTAGTTCTTCATCTATTTTGTTATATTGGGATCCTCCAGAATATCCCAATGGAAAAATAACTCACTATACGATTTATGCAATGGAATTGGATACAAACAGAGCATTCCAGATAACTACCATAGATAACAGCTTTCTCATAACAGGTATAGGGTTAAAGAAATACACAAAATACAAAATGAGAGTGGCAGCCTCAACCCACGTTGGAGAAAGTTCTTTGTCTGAAGAAAATGACATCTTTGTGAGAACTTCAGAAGATGAACCGGATCATCACCTCACCGATGTCGAAGTAATTGATGTTACCGCAGATGAAATAAGGTTGAAGTGGTCACCACCCGAAAAGCCCAATGGGATCATTATTGCTTATGAAGTGCTATATAAAAATATAGATACTTTATATATGAAGAACACATCAACAACAGACATAATATTAAGGAACTTAAGACCTCACACCCTCTATAACATTTCTGTAAGGTCTTACACCAGATTTGGTCATGGCAATCAGGTATCTTCTTTACTCTCTGTAAGGACTTCGGAGACTGTGCCTGATAGTGCACCAGAAAATATCACTTACAAAAATATTTCTTCTGGAGAGATTGAGCTATCATTCCTTCCCCCAAGTAGTCCCAATGGAATCATACAAAAATATACAATTTATCTCAAGAGAAGTAATGGAAATGAGGAAAGAACTATAAATACAACCTCTTTAACCCAAAACATTCTGAAGAAATATACCCAATATATCATTGAGGTGTCTGCTAGTACACTCAAAGGTGAAGGAGTTCGGAGTGCTCCCATAAGTATACTGACGGAGGAAGATGCTCCTGATTCTCCCCCTCAAGACTTCTCTGTAAAACAGTTGTCTGGTGTCACGGTGAAGTTGTCATGGCAACCACCCCTGGAGCCAAATGGAATTATCCTTTATTACACAGTTTATGTCTGGAGGAATAGATCATCATTAAAAACTATTAATGTCACTGAAACATCATTGGAGTTATCAGATTTGGATTATAATGTTGAATACAGTGCTTATGTAACAGCTAGCACCAGATTTGGTGATGGGAAAACAAGAAGCAATATCATTAGCTTTCAAACACCAGAGGGACCAAGCGATCCTCCCAAAGATGTTTATTATGCAAACCTCAGTTCTTCATCAATAATTCTTTTCTGGACACCTCCTTCAAAACCTAATGGGATTATACAATATTACTCTGTTTATTACAGAATTACTTCAGGTACTTTTATGCAGAATTTTACACTCCATGAAGTAACCAATGACTTTGACAATATGACTGTATCCACAATTATAGATAAACTGACAATATTCAGCTACTATACATTTTGGTTAACAGCAAGTACTTCAGTTGGAAATGGGAATAAAAGCAGTGACATCATTGAAGTATACACAGATCAAGACGTCCCTGAAGGGTTTGTTGGAAACCTGACTTACGAATCCATTTCGTCAACTGCAATAAATGTAAGCTGGGTCCCACCGGCTCAACCAAACGGTCTAGTCTTCTACTATGTTTCACTGATCTTACAGCAGACTCCTCGCCATGTGAGACCACCTCTTGTTACATATGAGAGAAGCATATATTTTGATAATCTGGAAAAATACACTGATTATATATTAAAAATTACTCCATCAACAGAAAAGGGATTCTCTGATACCTATACTGCCCAGCTATACATCAAGACTGAAGAAGATGTCCCAGAAACTTCACCAATAATCAACACTTTTAAAAACCTTTCCTCTACCTCAGTTCTCTTATCATGGGATCCCCCAGTAAAGCCAAATGGTGCAATAATAAGTTATGATTTAACTTTACAAGGACCAAATGAAAATTATTCTTTCATTACTTCTGATAATTACATAATATTGGAAGAGCTTTCACCATTTACATTATATAGCTTTTTTGCTGCCGCAAGAACTAGAAAAGGACTTGGTCCTTCCAGTATTCTTTTCTTTTACACAGATGAGTCAGTGCCGTTAGCACCTCCACAAAATTTGACTTTAATCAACTGTACTTCAGACTTTGTATGGCTGAAATGGAGCCCAAGTCCTCTTCCAGGTGGTATTGTTAAAGTATATAGTTTTAAAATTCATGAACATGAAACTGACACTATATATTATAAGAATATATCAGGATTTAAAACTGAAGCCAAACTTGTTGGACTGGAACCAGTCAGCACCTACTCTATCCGTGTATCTGCGTTCACCAAAGTTGGAAATGGCAATCAATTTAGTAATGTAGTAAAATTCACAACCCAAGAATCAGTTCCAGATGTCGTGCAGAATATGCAGTGCATGGCAACTAGCTGGCAGTCAGTTTTAGTGAAATGGGATCCACCCAAAAAGGCAAATGGAATAATAACGCAGTATATGGTAACAGTTGAAAGGAATTCTACAAAAGTTTCTCCCCAAGATCACATGTACACTTTCATAAAGCTTCTTGCCAATACCTCATATGTCTTTAAAGTAAGAGCTTCAACCTCAGCTGGTGAAGGTGATGAAAGCACATGCCATGTCAGCACACTACCTGAAACAGTTCCCAGTGTTCCCACAAATATTGCTTTTTCTGATGTTCAGTCAACTAGTGCAACATTGACATGGATAAGACCTGACACTATCCTTGGCTACTTTCAAAATTACAAAATTACCACTCAACTTCGTGCTCAAAAATGCAAAGAATGGGAATCCGAAGAATGTGTTGAATATCAAAAAATTCAATACCTCTATGAAGCTCACTTAACTGAAGAGACAGTATATGGATTAAAGAAATTTAGATGGTATAGATTCCAAGTGGCTGCCAGCACCAATGCTGGCTATGGCAATGCTTCAAACTGGATTTCTACAAAAACTCTGCCTGGCCCTCCAGATGGTCCTCCTGAAAATGTTCATGTAGTAGCAACATCACCTTTTAGCATCAGCATAAGCTGGAGTGAACCTGCTGTCATTACTGGACCAACATGTTATCTGATTGATGTCAAATCGGTAGATAATGATGAATTTAATATATCCTTCATCAAGTCAAATGAAGAAAATAAAACCATAGAAATTAAAGATTTAGAAATATTCACAAGGTATTCTGTAGTGATCACTGCATTTACTGGGAACATTAGTGCTGCATATGTAGAAGGGAAGTCAAGTGCTGAAATGATTGTTACTACTTTAGAATCAGCCCCAAAGGACCCACCTAACAACATGACATTTCAGAAGATACCAGATGAAGTTACAAAATTTCAATTAACGTCCCTTCCTCCTTCTCAACCTAATGGAAATATCCAAGTATATCAAGCTCTGGTTTACCGAGAAGATGATCCTACTGCTGTCCAGATTCACAACCTCAGTATTATACAGAAAACCAACACATTCGTCATTGCAATGCTAGAAGGACTAAAAGGTGGACATACATACAATATCAGTGTTTACGCAGTCAATAGTGCTGGTGCAGGTCCAAAGGTTCCGATGAGAATAACCATGGATATCAAAGCTCCAGCACGACCAAAAACCAAACCAACCCCTATTTATGATGCCACAGGAAAACTGCTTGTGACTTCAACAACAATTACAATCAGAATGCCAATATGTTACTACAGTGATGATCATGGACCAATAAAAAATGTACAAGTGCTTGTGACAGAAACAGGAGCTCAGCATGATGGAAATGTAACAAAGTGGTATGATGCATATTTTAATAAAGCAAGGCCATATTTTACAAATGAAGGCTTTCCTAACCCTCCATGTACAGAAGGAAAGACAAAGTTTAGTGGCAATGAAGAAATCTACATCATAGGTGCTGATAATGCATGCATGATTCCTGGCAATGAAGACAAAATTTGCAATGGACCACTGAAACCAAAAAAGCAATACTTATTTAAATTTAGAGCTACAAATATTATGGGACAATTTACTGACTCTGATTATTCTGACCCTGTTAAGACTTTAGGCGAAGGACTTTCAGAAAGAACCCTAGAGATCATTCTTTCCGTCACTTTGTGTATCCTTTCAATAATTCTCCTTGGAACAGCTATTTTTGCATTTGCAAGAATTCGACAGAAGCAGAAAGAAGGTGGCACATACTCTCCTCAGGATGCAGAAATTATTGACACTAAATTGAAGCTGGATCAGCTCATCACAGTGGCAGACCTGGAACTGAAGGACGAGAGATTAACGCGGTTACTTAGTTATAGAAAATCCATCAAGCCAATAAGCAAGAAATCCTTCCTGCAACATGTTGAAGAGCTTTGCACAAACAACAACCTAAAGTTTCAAGAAGAATTTTCGGAATTACCAAAATTTCTTCAGGATCTTTCTTCAACTGATGCTGATCTGCCTTGGAATAGAGCAAAAAACCGCTTCCCAAACATAAAACCATATAATAATAACAGAGTAAAGCTGATAGCTGACGCTAGTGTTCCAGGTTCGGATTATATTAATGCCAGCTATATTTCTGGTTATTTATGTCCAAATGAATTTATTGCTACTCAAGGTCCACTACCAGGAACAGTTGGAGATTTTTGGAGAATGGTGTGGGAAACCAGAGCAAAAACATTAGTAATGCTAACACAGTGTTTTGAAAAAGGACGGATCAGATGCCATCAGTATTGGCCAGAGGACAACAAGCCAGTTACTGTCTTTGGAGATATAGTGATTACAAAGCTAATGGAGGATGTTCAAATAGATTGGACTATCAGGGATCTGAAAATTGAAAGGCATGGGGATTGCATGACTGTTCGACAGTGTAACTTTACTGCCTGGCCAGAGCATGGGGTTCCTGAGAACAGCGCCCCTCTAATTCACTTTGTGAAGTTGGTTCGAGCAAGCAGGGCACATGACACCACACCTATGATTGTTCACTGTAGTGCTGGAGTTGGAAGAACTGGAGTTTTTATTGCTCTGGACCATTTAACACAACATATAAATGACCATGATTTTGTGGATATATATGGACTAGTAGCTGAACTGAGAAGTGAAAGAATGTGCATGGTGCAGAATCTGGCACAGTATATCTTTTTACACCAGTGCATTCTGGATCTCTTATCAAATAAGGGAAGTAATCAGCCCATCTGTTTTGTTAACTATTCAGCACTTCAGAAGATGGACTCTTTGGACGCCATGGAAGGTGATGTTGAGCTTGAATGGGAAGAAACCACTATGTAANOV15g, CG50718-05Protein SequenceSEQ ID NO: 1782300 aaMW at 257261.9kDMDFLIIFLLLFIGTSETQVDVSNVVPGTRYDITISSISTTYTSPVTRIVTTNVTEPGPPVFLAGERVGSAGILLSWNTPPNPNGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNPGTTYEIKVAAENSAGIGVFSDPFLFQTAESPAPGKVVNLTVEAYNASAVKLIWYLPRQPNGKITSFKISVKHARSGIVVKDVSIRVEDILTGKLPECNVENSESFLWSTASPSPTLGRVTPPSRTTHSSSTLTQNEISSVWKEPISFVVTHLRPYTTYLFEVSAATTEAGYIDSTIVRTPESVPEGPPQNCVTGNITGKSFSILWDPPTIVTGKFSYRVELYGPSGRILDNSTKDLKFAFTNLTPFTMYDVYIAAETSAGTGPKSNISVFTPPDVPGAVFDLQLAEVESTQVRITWKKPRQPNGIINQYRVKVLVPETGIILENTLLTGNNEINDPMAPEIVNIVEPMVGLYEGSAEMSSDLHSLATFIYNSHPDKNFPARNRAEDQTSPVVTTRNQYITDIAAEQLSYVIRRIVPFTEHMISVSAFTIMGEGPPTVLSVRTRQQVPSSIKIINYKNISSSSILLYWDPPEYPNGKITHYTIYAMELDTNRAFQITTIDNSFLITGIGLKKYTKYKMRVAASTHVGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNGIIIAYEVLYKNIDTLYMKNTSTTDIILRNLRPHTLYNISVRSYTRFGHGNQVSSLLSVRTSETVPDSAPENITYKNISSGEIELSFLPPSSPNGIIQKYTIYLKRSNGNEERTINTTSLTQNILKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWRNRSSLKTINVTETSLELSDLDYNVEYSAYVTASTRFGDGKTRSNIISFQTPEGPSDPPKDVYYANLSSSSIILFWTPPSKPNGIIQYYSVYYRNTSGTFMQNFTLHEVTNDFDNMTVSTIIDKLTIFSYYTFWLTASTSVGNGNKSSDIIEVYTDQDVPEGFVGNLTYESISSTAINVSWVPPAQPNGLVFYYVSLILQQTPRHVRPPLVTYERSIYFDNLEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDVPETSPIINTFKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPNENYSFITSDNYIILEELSPFTLYSFFAAARTRKGLGPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKVYSFKIHEHETDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGNQFSNVVKFTTQESVPDVVQNNQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFIKLLANTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDTILGYFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVAASTNAGYGNASNWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLIDVKSVDNDEFNISFIKSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMIVTTLESAPKDPPNNMTFQKIPDEVTKFQLTSLPPSQPNGNIQVYQALVYREDDPTAVQIHNLSIIQKThTFVIAMLEGLKGGHTYNISVYAVNSAGAGPKVPMRITMDIKAPARPKTKPTPIYDATGKLLVTSTTITIRMPICYYSDDHGPIKNVQVLVTETGAQHDGNVTKWYDAYFNKARPYFTNEGFPNPPCTEGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLKPKKQYLFKFRATNIMGQFTDSDYSDPVKTLGEGLSERTLEIILSVTLCILSIILLGTAIFAFARIRQKQKEGGTYSPQDAEIIDTKLKLDQLITVADLELKDERLTRLLSYRKSIKPISKKSFLQHVEELCTNNNLKFQEEFSELPKFLQDLSSTDADLPWNRAKNRFPNIKPYNNNRVKLIADASVPGSDYINASYISGYLCPNEFIATQGPLPGTVGDFWRMVWETRAKTLVMLTQCFEKGRIRCHQYWPEDNKPVTVFGDIVITKLMEDVQIDWTIRDLKIERHGDCMTVRQCNFTAWPEHGVPENSAPLIHFVKLVRASRAHDTTPMIVHCSAGVGRTGVFIALDHLTQHINDHDFVDIYGLVAELRSERMCMVQNLAQYIFLHQCILDLLSNKGSNQPICFVNYSALQKMDSLDAMEGDVELEWEETTM

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 15B.

TABLE 15BComparison of the NOV15 protein sequences.NOV15aMDFLIIFLLLFIGTSETQVDVSNVVPGTRYDITISSISTTYTSPVTRIGASNEPGPPVFLNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dMDFLIIFLLLFIGTSETQVDVSNVVPGTRYDITISSISTTYTSPVTRIGASNEPGPPVFLNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aAGERVGSAGILLSWNTPPNPNGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dAGERVGSAGILLSWNTPPNPNGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aPGTTYEIKVAAENSAGIGVFSDPFLFQTAESAPGKVVDFTGEAVPFSSKLMWYTSATKKKNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dPGTTYEIKVAAENSAGIGVFSDPFLFQTAESAPGKVVDFTGEAVPFSSKLMWYTSATKKKNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aITSFKISVKHNRSGIVVKEVSIRVECILSASLPLHCNENSESFLWSTASPSPTLGRVTPPNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dITSFKISVKHNRSGIVVKEVSIRVECILSASLPLHCNENSESFLWSTASPSPTLGRVTPPNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aSRTTHSSSTLTQNEISSVKEPISFVVTHLRPYTTYLFEVSAATTEAGYIDSTIVRTPESVNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dSRTTHSSSTLTQNEISSVKEPISFVVTHLRPYTTYLFEVSAATTEAGYIDSTIVRTPESVNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aPEGPPQNCVTGNITGKSFSILWDPPTIVTGKFSYRVELYGPSAGRILDNSTKDLKFAFTNNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dPEGPPQNCVTGNITGKSFSILWDPPTIVTGKFSYRVELYGPSAGRILDNSTKDLKFAFTNNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aLTPFTMYDVYIAAETSAGTGPKSNISVFTPPDVPGAVFDLQLAEVESTQVRITWKKPRQPNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dLTPFTMYDVYIAAETSAGTGPKSNISVFTPPDVPGAVFDLQLAEVESTQVRITWKKPRQPNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aNGIINQYRVKVLVPETGIILENTLLTGNNEINDPMAPEIVNIVQPMVGLYEGSAEMSSDLNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dNGIINQYRVKVLVPETGIILENTLLTGNNEINDPMAPEIVNIVQPMVGLYEGSAEMSSDLNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aHSLATFIYNSHPDKNFPARNRAEDQTSPVVTTRNQYITDIAAEQLTYVLIRLRRFWAETMNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dHSLATFIYNSHPDKNFPARNRAEDQTSPVVTTRNQYITDIAAEQLTYVLIRLRRFWAETMNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aGFSRYTIMSSASRDNLTSPGPLSAQNFRVTHVTITEVFLHWDPPDPVFFHHYLITILDVENOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dGFSRYTIMSSASRDNLTSPGPLSAQNFRVTHVTITEVFLHWDPPDPVFFHHYLITILDVENOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aNQSKSIILRTLNSLSLVLIGLKKYTKYKMRVAASTHVGESSLSEENDIFVRTSEDEPESSNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dNQSKSIILRTLNSLSLVLIGLKKYTKYKMRVAASTHVGESSLSEENDIFVRTSEDEPESSNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aPQDVEVIDVTADEIRLKWSPPEKPNGIIIAYEVLYKNIDTLYNKNTSTTDIILRNLRPHTNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dPQDVEVIDVTADEIRLKWSPPEKPNGIIIAYEVLYKNIDTLYNKNTSTTDIILRNLRPHTNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aLYNISVRSYTRFGHGNQVSSLLSVRTSESVPDSAPENITYKNISSGEIELSFLPPSSPNGNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dLYNISVRSYTRFGHGNQVSSLLSVRTSESVPDSAPENITYKNISSGEIELSFLPPSSPNGNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aIIQKYTIYLKRSNGNEERTINTTSLTQNIKGLKKYTQYIIEVSASTLKGEGVRSAPISILNOV15b------------------------------------------------------------NOV15c------------------------------------------------------------NOV15dIIQKYTIYLKRSNGNEERTINTTSLTQNIKGLKKYTQYIIEVSASTLKGEGVRSAPISILNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------------------NOV15aTEEDAPDSPPQDFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWRSSLKTINVTETSLENOV15b------------------------------------------------MDFLIIFLLLFINOV15c------------------------------------------------------------NOV15dTEEDAPDSPPQDFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWRSSLKTINVTETSLENOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15g------------------------------------------------MDFLIIFLLLFINOV15aLSDLDYNVEYSAYVTASTRFGDGKTRSNIISFQTPEGPSDPPKDVYYANLSSSSIILFWTNOV15bGTSETQVDVSNVVPGTRYDITISSISTTYTSPVTRIVTTNVTKPGPPVFLAGERVGSAGINOV15c------------------------------------------------------------NOV15dLSDLDYNVEYSAYVTASTRFGDGKTRSNIISFQTPEGPSDPPKDVYYANLSSSSIILFWTNOV15e-----QVDVSNVVPGTRYDITISSISTTYTSPVTRIVTTNVTKPGPPVFLAGERVGSAGINOV15f------------------------------------------------------------NOV15gGTSETQVDVSNVVPGTRYDITISSISTTYTSPVTRIVTTNVTEPGPPVFLAGERVGSAGINOV15aPPSKPNGIIQYYSVYYRNTSGTFMQNFTLHEVTNDFDNMTVSTIIDKLTIFSYYTFWLTANOV15bLLSWNTPPNPMGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNPGTTYEIKVANOV15c------------------------------------------------------------NOV15dPPSKPNGIIQYYSVYYRNTSGTFMQNFTLHEVTNDFDNMTVSTIIDKLTIFSYYTFWLTANOV15eLLSWNTPPNPMGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNPGTTYEIKVANOV15f------------------------------------------------------------NOV15gLLSWNTPPNPMGRIISYIVKYKEVCPWMQTVYTQVRSKPDSLEVLLTNLNPGTTYEIKVANOV15aSTSVGNGNKSSDIIEVYTDQDVPEGFVGNLTYESISSTAINVSWVPPAQPNG--------NOV15bAENSAGIGVFSDPFLFQTAES-APGKVVNLTVEAYNASAVKLIWYLPRQPNGKITSFKISNOV15c------------------------------------------------------------NOV15dSTSVGNGNKSSDIIEVYTDQDVPEGFVGNLTYESISSTAINVSWVPPAQPNG--------NOV15eAENSAGIGVFSDPFLFQTAES-APGKVVNLTVEAYNASAVKLIWYLPRQPNGKITSFKISNOV15f----------------------PEGFVGNLTYESISSTAINVSWVPPAQPNG--------NOV15gAENSAGIGVFSDPFLFQTAESPAPGKVVNLTVEAYNASAVKLIWYLPRQPNGKITSFKISNOV15a-------------------------LVFYY--------VSLILQQTPRHVRPPLVTYERSNOV15bVKHARSGIVVKDVSIRVEDILTGKLPECNE-NSESFLWSTASPSPTLGRVTPPSRTTHSSNOV15c------------------------------------------------------------NOV15d-------------------------LVFYY--------VSLILQQTPRHVRPPLVTYERSNOV15eVKHARSGIVVKDVSIRVEDILTGKLPECNE-NSESFLWSTASPSPTLGRVTPPSRTTHSSNOV15f-------------------------LVFYY--------VSLILQQTPRHVRPPLVTYERSNOV15gVKHARSGIVVKDVSIRVEDILTGKLPECNVENSESFLWSTASPSPTLGRVTPPSRTTHSSNOV15aIYFDN--------------LEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDIPETSPINOV15bSTLTQNEISSVWKEPISFVVTHLRPYTTYLFEVSAVTTEAGYIDSTIVRTPESVPEGPPQNOV15c----------------------------------------------------RSPEGPPQNOV15dIYFDN--------------LEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDIPETSPINOV15eSTLTQNEISSVWKEPISFVVTHLRPYTTYLFEVSAVTTEAGYIDSTIVRTPESVPEGPPQNOV15fIYFDN--------------LEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDVPETSPINOV15gSTLTQNEISSVWKEPISFVVTHLRPYTTYLFEVSAATTEAGYIDSTIVRTPESVPEGPPQNOV15aINTFKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPN-ENYSFITSDNYIILEELSPFTLNOV15bNCVTGNITGKSFSILWDPPTIVT-GKFSYRVELYGPSGRILDNSTKDLKFAFTNLTPFTMNOV15cNCVTGNITGKSFSILWDPPTIVT-GKFSYRVELYGPSGRILDNSTKDLKFAFTNLTPFTMNOV15dINTFKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPN-ENYSFITSDNYIILEELSPFTLNOV15eNCVTGNITGKSFSILWDPPTIVT-GKFSYRVELYGPSGRILDNSTKDLKFAFTNLTPFTMNOV15fINTFKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPN-ENYSFITSDNYIILEELSPFTLNOV15gNCVTGMITGKSFSILWDPPTIVT-GKFSYRVELYGPSGRILDNSTKDLKFAFThLTPFTMNOV15aYSFFAAARTRKGLGPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKNOV15bYDVYIAAETSAGTGPKSNISVFTPPDVPGA-VFDLQLAEVESTQVRITWKKPRQPNGIINNOV15cYDVYIAAETSAGTGPKSNISVFTPPDVPGA-VFDLQLAEVESTQVRITWKKPRQPNGIINNOV15dYSFFAAARTRKGLGPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKNOV15eYDVYIAAETSAGTGPKSNISVFTPPDVPGA-VFDLQLAEVESTQVRITWKKPRQPNGIINNOV15fYSFFAAARTRKGLGPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKNOV15gYDVYIAAETSAGTGPKSNISVFTPPDVPGA-VFDLQLAEVESTQVRITWKKPRQPNGIINNOV15aVYSFKIHEHETDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGNQFSNVVKFTNOV15bQYRVKVLVPETGIILENTLLTGNNEYINDPMAPEIVNIVEPMVGLYEGSAEMSSDLHSLANOV15cQYRVKVLVPETGIILENTLLTGNNEYINDPMAPEIVNIVEPMVGLYEGSAEMSSDLHSLANOV15dVYSFKIHEHETDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGNQFSNVVKFTNOV15eQYRVKVLVPETGIILENTLLTGNNEYINDPMAPEIVNIVEPMVGLYEGSAEMSSDLHSLANOV15fVYSFKIHEHETDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGNQFSNVVKFTNOV15gQYRVKVLVPETGIILENTLLTGNN-EINDPMAPEIVNIVEPMVGLYEGSAEMSSDLHSLANOV15aTQESVPDVVQNNQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFINOV15bTFIYNSHPDK--------------NFPARNRAEDQTSPVVTTRNQYITDIAAEQLSYVIRNOV15cTFIYNSHPDK--------------NFPARNRAEDQTSPVVTTRNQYITDIAAEQLSYVIRNOV15dTQESVPDVVQNNQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFINOV15eTFIYNSHPDK--------------NFPARNRAEDQTSPVVTTRNQYITDIAAEQLSYVIRNOV15fTQESVPDVVQNMQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFINOV15gTFIYNSHPDK--------------NFPARNRAEDQTSPVVTTRNQYITDIAAEQLSYVIRNOV15aKLLANTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDNOV15bRLVPFTEHMISVSAFTIMGEG-PPTVLSVRTRQQVPSSIKIINYKNISSSSILLYWDPPENOV15cRLVPFTEHMISVSAFTIMGEG-PPTVLSVRTRQQVPSSIKIINYKNISSSSILLYWDPPENOV15dKLLANTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDNOV15eRLVPFTEHMISVSAFTIMGEG-PPTVLSVRTRQQVPSSIKIINYKNISSSSILLYWDPPENOV15fKLLANTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDNOV15gRLVPFTEHMISVSAFTIMGEG-PPTVLSVRTRQQVPSSIKIINYKNISSSSILLYWDPPENOV15aTILGYFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVNOV15bYPNGKITHYTIY------------AMELDTNRAFQITTIDNSFLIT--GLKKYTKYKMRVNOV15cYPNGKITHYTIY------------AMELDTNRAFQITTIDNSFLIT--GLKKYTKYKMRVNOV15dTILGYFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVNOV15eYPNGKITHYTIY------------AMELDTNRAFQITTIDNSFLIT--GLKKYTKYKMRVNOV15fTILGYFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVNOV15gYPNGKITHYTIY------------AMELDTNRAFQITTIDNSFLITGIGLKKYTKYKMRVNOV15aAASTNAGYGNAS--NWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLNOV15bAASTHDGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNG----INOV15cAASTHDGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNG----INOV15dAASTNAGYGNAS--NWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLNOV15eAASTHDGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNG----INOV15fAASTNAGYGNAS--NWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLNOV15gAASTHVGESSLSEENDIFVRTSEDEPESSPQDVEVIDVTADEIRLKWSPPEKPNG----INOV15aIDVKSVDNDEFNISFIKSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMNOV15bIIAYEVLYKNIDTLYNKSNTSTTDIILRNLRPHTLYNISVRSYTRFGHGNQVS----SLLNOV15cIIAYEVLYKNIDTLYMK-NTSTTDIILRNLRPHTLYNISVRSYTRFGHGNQVS----SLLNOV15dIDVKSVDNDEFNISFIKSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMNOV15eIIAYEVLYKNIDTLYMK-NTSTTDIILRNLRPHTLYNISVRSYTRFGHGNQVS----SLLNOV15fIDVKSVDNDEFNISFIKSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMNOV15gIIAYEVLYKNIDTLYMK-NTSTTDIILRNLRPHTLYNISVRSYTRFGHGNQVS----SLLNOV15aIVTTLESAPKDPPNNMTFQKIPDEVTKFQLTFLPPSQPNGNIQVYQALVYREDDPTAVQINOV15bSVRTSETVPDSAPENITYKNIS--SGEIELSFLPPSSPNGIIKKYTIYLKRSNGNEERTINOV15cSVRTSETVPDSAPENITYKNIS--SGEIELSFLPPSSPNGIIKKYTIYLKRSNGNEERTINOV15dIVTTLESAPKDPPNNMTFQKIPDEVTKFQLTFLPPSQPNGNIQVYQALVYREDDPTAVQINOV15eSVRTSETVPDSAPENITYKNIS--SGEIELSFLPPSSPNGIIQKYTIYLKRSNGNEERTINOV15fIVTTLESAPKDPPNNNTFQKIPDEVTKFQLTSLPPSQPNGNIQVYQALVYREDDPTAVQINOV15gSVRTSETVPDSAPENITYKNIS--SGEIELSFLPPSSPNGIIQKYTIYLKRSNGNEERTINOV15aHNLSIIQKTNTFVIAMLEGLKGGHTYNISVYAVNSAG-AGPKVPMRITMDIKAP-ARPKTNOV15bNTTSLTQNIK--------VLKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDNOV15cNTTSLTQNIK--------VLKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDNOV15dHNLSIIQKTNTFVIAMLEGLKGGHTYNISVYAVNSAG-AGPKVPMRITMDIKAP-ARPKTNOV15eNTTSLTQNIK--------GLKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDNOV15fHNLSIIQKTNTFVIAMLEGLKGGHTYNISVYAVNSAG-AGPKVPMRITMDIKAP-ARPKTNOV15gNTTSLTQNI----------LKKYTQYIIEVSASTLKGEGVRSAPISILTEEDAPDSPPQDNOV15aKPTPIYDATGKLLVTSTTITIRMPICYYSDDHGP--IKNVQVLVTETGAQH-DGNVTKWYNOV15bFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWN-RSSLKTINVTETSLELSDLDYNVEYNOV15cFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWN-RSSLKTINVTETSLELSDLDYNVEYNOV15dKPTPIYDATGKLLVTSTTITIRMPICYYSDDHGP--IKNVQVLVTETGAQH-DGNVTKWYNOV15eFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWN-RSSLKTINVTETSLELSDLDYNVEYNOV15fKPTPIYDATGKLLVTSTTITIRMPICYYSDDHGP--IKNVQVLVTETGAQH-DGNVTKWYNOV15gFSVKQLSGVTVKLSWQPPLEPNGIILYYTVYVWRNRSSLKTINVTETSLELSDLDYNVEYNOV15aDAYFNKARPYFTNEGFPNPP--CT-EGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLNOV15bSAYVTASTRFGDGKTRSNIISFQTPEGAPSDPPKDVYYANLSSSSIILFWTPPSKPNGIINOV15cSAYVTASTRFGDGKTRSNIISFQTPEGAPSDPPKDVYYANLSSSSIILFWTPPSKPNGIINOV15dDAYFNKARPYFTNEGFPNPP--CT-EGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLNOV15eSAYVTAS---------------------------------------------------- NOV15fDAYFNKARPYFTNEGFPNPP--CT-EGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLNOV15gSAYVTASTRFGDGKTRSNIISFQTPEGP-SDPPKDVYYANLSSSSIILFWTPPSKPNGIINOV15aKPKKQYLFKFRATNIMGQFTDSDYSDPVKTLGEGLSERTVEIILSVTLCILSIILLGTAINOV15bQYYSVYYRNTSGTFNQNFTLHEVTNDFDNNTVSTIIDKLTIFSYYTFWLTASTSVGNGNKNOV15cQYYSVYYRNTSGTFMQNFTLHEVTNDFDNNTVSTIIDKLTIFSYYTFWLTASTSVGNGNKNOV15dKPKKQYLFKFRATNIMGQFTDSDYSDPVKTLGEGLSERTVEIILSVTLCILSIILLGTAINOV15e------------------------------------------------------------NOV15fKPKKQYLFKFRATNIMGQFTDSDYSDPVKTLGEGLSERT---------------------NOV15gQYYSVYYRNTSGTFMQNFTLHEVTNDFDNMTVSTIIDKLTIFSYYTFWLTASTSVGNGNKNOV15aFAFARIRQKQKEGGTYSPQDAEIIDTKLKLDQLITVADLELKDERLTRPISKKSFLQHVENOV15bSSDIIEVYTDQDVPEGFVGNLTYESISSTAINVSWVPPAQPNGLVFYYVSLILQQTPRHVNOV15cSLE---------------------------------------------------------NOV15dFAFARIRQKQKEGGTYSPQDAEIIDTKLKLDQLITVADLELKDERLTRPISKKSFLQHVENOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gSSDIIEVYTDQDVPEGFVGNLTYESISSTAINVSWVPPAQPNGLVFYYVSLILQQTPRHVNOV15aELCTNNNLKFQEEFSELPKFLQDLSSTDADLPWNRAKNRFPNIKPYNNNRVKLIADASVPNOV15bRPPLVTYERSIYFDNLEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDVPETSPIINTFNOV15c------------------------------------------------------------NOV15dELCTNNNLKFQEEFSELPKFLQDLSSTDADLPWNRAKNRFPNIKPYNNNRVKLIADASVPNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gRPPLVTYERSIYFDNLEKYTDYILKITPSTEKGFSDTYTAQLYIKTEEDVPETSPIINTFNOV15aGSDYINASYISGYLCPNEFIATQGPLPGTVGDFWRMVWETRAKTLVMLTQCFEKGRIRCHNOV15bKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPNENYSFITSDNYIILEELSPFTLYSFFANOV15c------------------------------------------------------------NOV15dGSDYINASYISGYLCPNEFIATQGPLPGTVGDFWRMVWETRAKTLVMLTQCFEKGRIRCHNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gKNLSSTSVLLSWDPPVKPNGAIISYDLTLQGPNENYSFITSDNYIILEELSPFTLYSFFANOV15aQYWPEDNKPVTVFGDIVITKLMEDVQIDWTIRDLKIERHGDCMTVRQCNFTAWPEHGVPENOV15bAARTRKGLGPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKVYSFKNOV15c------------------------------------------------------------NOV15dQYWPEDHKPVTVFGDIVITKLMEDVQIDWTIRDLKIERHGDCMTVRQCNFTAWPEHGVPENOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gAARTRKGLGPSSILFFYTDESVPLAPPQNLTLINCTSDFVWLKWSPSPLPGGIVKVYSFKNOV15aNSAPLIHFVKLVRASRAHDTTPMIVHCSAGVGRTGVFIALDHLTQHINDHDFVDIYGLVANOV15bIHEHETDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGNQFSNVVKFTTQESVNOV15c------------------------------------------------------------NOV15dNSAPLIHFVKLVRASRAHDTTPMIVHCSAGVGRTGVFIALDHLTQHINDHDFVDIYGLVANOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gIHEHETDTIYYKNISGFKTEAKLVGLEPVSTYSIRVSAFTKVGNGNQFSNVVKFTTQESVNOV15aELRSERMCMVQNLAQYIFLHQCILDLLSNKGSNQPICFVNYSALQKMDSLDAMEGGDVELNOV15bPDVVQNMQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFIKLLANNOV15c------------------------------------------------------------NOV15dELRSERMCMVQNLAQYIFLHQCILDLLSNKGSNQPICFVNYSALQKMDSLDAMEGGDVELNOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gPDVVQNMQCMATSWQSVLVKWDPPKKANGIITQYMVTVERNSTKVSPQDHMYTFIKLLANNOV15aEWEETTM-----------------------------------------------------NOV15bTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDTILGYNOV15c------------------------------------------------------------NOV15dEWEETTM-----------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gTSYVFKVRASTSAGEGDESTCHVSTLPETVPSVPTNIAFSDVQSTSATLTWIRPDTILGYNOV15a------------------------------------------------------------NOV15bFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVAASTNNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gFQNYKITTQLRAQKCKEWESEECVEYQKIQYLYEAHLTEETVYGLKKFRWYRFQVAASTNNOV15a------------------------------------------------------------NOV15bAGYGNASNWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLIDVKSVDNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gAGYGNASNWISTKTLPGPPDGPPENVHVVATSPFSISISWSEPAVITGPTCYLIDVKSVDNOV15a------------------------------------------------------------NOV15bNDEFNISFIKSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMIVTTLESNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gNDEFNISFIKSNEENKTIEIKDLEIFTRYSVVITAFTGNISAAYVEGKSSAEMIVTTLESNOV15a------------------------------------------------------------NOV15bAPKDPPNNMTFQKIPDEVTKFQLTSLPPSQPNGNIQVYQALVYREDDPTAVQIHNLSIIQNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gAPKDPPNNMTFQKIPDEVTKFQLTSLPPSQPNGNIQVYQALVYREDDPTAVQIHNLSIIQNOV15a------------------------------------------------------------NOV15bKTNTFVIAMLEGLKGGHTYNISVYAVNSAGAGPKVPMRITMDIKAPARPKTKPTPIYDATNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gKTNTFVIAMLEGLKGGHTYNISVYAVNSAGAGPKVPMRITMDIKAPARPKTKPTPIYDATNOV15a------------------------------------------------------------NOV15bGKLLVTSTTITIRMPICYYSDDHGPIKNVQVLVTETGAQHDGNVTKWYDAYFNKARPYFTNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gGKLLVTSTTITIRMPICYYSDDHGPIKNVQVLVTETGAQHDGNVTKWYDAYFNKARPYFTNOV15a------------------------------------------------------------NOV15bNEGFPNPPCTEGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLKPKKQYLFKFRATNINOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gNEGFPNPPCTEGKTKFSGNEEIYIIGADNACMIPGNEDKICNGPLKPKKQYLFKFRATNINOV15a------------------------------------------------------------NOV15bMGQFTDSDYSDPVKTLGEGLSERTLEIILSVTLCILSIILLGTAIFAFARIRQKQKEGGTNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gMGQFTDSDYSDPVKTLGEGLSERTLEIILSVTLCILSIILLGTAIFAFARIRQKQKEGGTNOV15a------------------------------------------------------------NOV15bYSPQDAEIIDTKLKLDQLITVADLELKDERLTRLLSYRKSIKPISKKSFLQHVEELCTNNNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gYSPQDAEIIDTKLKLDQLITVADLELKDERLTRLLSYRKSIKPISKKSFLQHVEELCTNNNOV15a------------------------------------------------------------NOV15bNLKFQEEFSELPKFLQDLSSTDADLPWNRAKNRFPNIKPYNNNRVKLIADASVPGSDYINNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gNLKFQEEFSELPKFLQDLSSTDADLPWNRAKNRFPNIKPYNNNRVKLIADASVPGSDYINNOV15a------------------------------------------------------------NOV15bASYISGYLCPNEFIATQGPLPGTVGDFWRMVWETRAKTLVMLTQCFEKGRIRCHQYWPEDNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gASYISGYLCPNEFIATQGPLPGTVGDFWRMVWETRAKTLVMLTQCFEKGRIRCHQYWPEDNOV15a------------------------------------------------------------NOV15bNKPVTVFGDIVITKLMEDVQIDWTIRDLKIERHGDCMTVRQCNFTAWPEHGVPENSAPLINOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gNKPVTVFGDIVITKLMEDVQIDWTIRDLKIERHGDCMTVRQCNFTAWPEHGVPENSAPLINOV15a------------------------------------------------------------NOV15bHFVKLVRASRAHDTTPMIVHCSAGVGRTGVFIALDHLTQHINDHDFVDIYGLVAELRSERNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gHFVKLVRASRAHDTTPMIVHCSAGVGRTGVFIALDHLTQHINDHDFVDIYGLVAELRSERNOV15a------------------------------------------------------------NOV15bMCMVQNLAQYIFLHQCILDLLSNKGSNQPICFVNYSALQKMDSLDAMEGDVELEWEETTMNOV15c------------------------------------------------------------NOV15d------------------------------------------------------------NOV15e------------------------------------------------------------NOV15f------------------------------------------------------------NOV15gMCMVQNLAQYIFLHQCILDLLSNKGSNQPICFVNYSALQKMDSLDAMEGDVELEWEETTMNOV15a(SEQ ID NO: 166)NOV15b(SEQ ID NO: 168)NOV15c(SEQ ID NO: 170)NOV15d(SEQ ID NO: 172)NOV15e(SEQ ID NO: 174)NOV15f(SEQ ID NO: 176)NOV15g(SEQ ID NO: 178)

Further analysis of the NOV15a protein yielded the following properties shown in Table 15C.

TABLE 15CProtein Sequence Properties NOV15aSignalP analysis: Cleavage site between residues 18 and 19PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 2; pos.chg 0; neg.chg 1H-region: length 13; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 2.26possible cleavage site: between 17 and 18>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 3INTEGRALLikelihood = −2.55 Transmembrane 3-19INTEGRALLikelihood = −1.12 Transmembrane 605-621INTEGRALLikelihood = −10.46 Transmembrane 1894-1910PERIPHERALLikelihood = 1.59 (at 2178)ALOM score: −10.46 (number of TMSs: 3)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 10Charge difference: −1.0 C(−1.0) − N(0.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):3.60Hyd Moment(95):6.71G content:1D/E content:2S/T content:2Score: −7.20Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: KKPR (4) at 415pat4: KPKK (4) at 1855pat7: PLKPKKQ (4) at 1853bipartite: nonecontent of basic residues: 8.8%NLS Score: 0.37KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 70.6COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):56.5%: endoplasmic reticulum26.1%: mitochondrial17.4%: nuclear>> prediction for CG50718-02 is end (k = 23)

A search of the NOV15a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15D.

TABLE 15DGeneseq Results for NOV15aNOV15aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAO18736Human NOV2a protein - Homo1 . . . 2281 2281/2281 (100%)0.0sapiens, 2281 aa.1 . . . 2281 2281/2281 (100%)[WO200257450-A2, 25-JUL-2002]AAG79724Human KPP-2, Incyte ID No.1 . . . 22812180/2306 (94%)0.07480588CD1 - Homo sapiens,1 . . . 22992214/2306 (95%)2299 aa. [WO200290530-A2,14-NOV-2002]AAO18738Human NOV2c protein - Homo1 . . . 22812177/2305 (94%)0.0sapiens, 2300 aa.1 . . . 23002205/2305 (95%)[WO200257450-A2, 25-JUL-2002]ABP60057Human phosphatase protein1 . . . 22812171/2296 (94%)0.0SEQ ID #2 - Homo sapiens,1 . . . 22912209/2296 (95%)2291 aa. [WO200279452-A2,10-OCT-2002]ABP60058Human phosphatase related1 . . . 22811893/2306 (82%)0.0protein #SEQ ID 4 - Homo1 . . . 23012077/2306 (89%)sapiens, 2301 aa.[WO200279452-A2, 10-OCT-2002]

In a BLAST search of public sequence databases, the NOV15a protein was found to have homology to the proteins shown in the BLASTP data in Table 15E.

TABLE 15EPublic BLASTP Results for NOV15aNOV15aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueO88488Glomerular mesangial cell 1 . . . 22811893/2306 (82%)0.0receptor protein-tyrosine 2 . . . 23022077/2306 (89%)phosphatase precursor - Rattusnorvegicus (Rat), 2302 aa.Q8BY76Hypothetical fibronectin type 1 . . . 1042791/1058 (74%)0.0III domain/fibronectin type III 1 . . . 1053897/1058 (84%)repeat containing protein - Musmusculus (Mouse), 1086 aa(fragment).AAO42638RE52018p - Drosophila1142 . . . 2244311/1133 (27%)2e−99melanogaster (Fruit fly), 1631 497 . . . 1531505/1133 (44%)aa.Q8IR87CG1817-PC - Drosophila1142 . . . 2244311/1133 (27%)2e−99melanogaster (Fruit fly), 1556 497 . . . 1531505/1133 (44%)aa.Q9VYW1CG1817 protein - Drosophila1142 . . . 2244311/1133 (27%)2e−99melanogaster (Fruit fly), 1962 497 . . . 1531505/1133 (44%)aa.

PFam analysis indicates that the NOV15a protein contains the domains shown in the Table 15F.

TABLE 15FDomain Analysis of NOV15aIdentities/NOV15a MatchSimilaritiesExpectPfam DomainRegionfor the Matched RegionValuefn3 54 . . . 14130/91 (33%)1.6e−1463/91 (69%)fn3301 . . . 38325/88 (28%)2.7e−0659/88 (67%)fn3561 . . . 64326/86 (30%)7.9e−0756/86 (65%)fn3657 . . . 73828/87 (32%)4.2e−1462/87 (71%)fn3751 . . . 83429/87 (33%)9.4e−1267/87 (77%)fn3846 . . . 92624/87 (28%)7.6e−1262/87 (71%)fn3 938 . . . 103025/97 (26%)6.8e−0868/97 (70%)fn31043 . . . 112419/87 (22%)0.05856/87 (64%)fn31140 . . . 122128/87 (32%)2.4e−0957/87 (66%)fn31233 . . . 131824/87 (28%)8.3e−0959/87 (68%)fn31330 . . . 140825/86 (29%)6.2e−1158/86 (67%)fn31420 . . . 151629/99 (29%)7.7e−0967/99 (68%)fn31528 . . . 161019/87 (22%)2.1e−0760/87 (69%)fn31631 . . . 172426/97 (27%) 1e−0566/97 (68%)Y_phosphatase2008 . . . 2239116/280 (41%) 5.1e−109190/280 (68%)

Example 16

The NOV16 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 16A.

TABLE 16ANOV16 Sequence AnalysisNOV16a, CG50934-03SEQ ID NO: 179964 bpDNA SequenceORF Start: ATG at 67ORF Stop: TGA at 655GACCATCTGATTGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGGTCAGGAGCAGGACCACTTGGGTGGGATGTGGAGAGATGACCCGGAATGTCGGTGCAGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCATTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV16a, CG50934-03Protein SequenceSEQ ID NO: 180196 aaMW at 21256.7kDMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGGQEQDHLGGMWRDDPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGPSACGRRRNOV16b, CG50934-01SEQ ID NO: 1811171 bpDNA SequenceORF Start: at 187ORF Stop: TGA at 805ATGCTGTGGCTACTGCTCCTGACCCTCCCCTGCCTGATGGGCTCTGTGCCCAGGAACCCAGGCGAGTCCGCCCCACCCAATGCCCCTGCTGCCCAGGACCCCCTCCTTGCCCTGCCCCGGGCTCAGAGTGCCAGCCCTGGGGTGGGTGGGGACCATCTGATTGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGGTCAGGAGCAGGACCACTTGGGTGGGATGTGGAGAGATGACCCGGAATGTCGGTGCAGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGGTGCAGTGGGGTCTGCATGATCCAGGAGGGCCCGTCTTCCTTGTGGACACGCCTGCTNOV1 6b, CG50934-01Protein SequenceSEQ ID NO: 182206 aaMW at 22191.8kDALGRPSSVPLMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGGQEQDHLGGMWRDDPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGPSACGRRRNOV16c, CG50934-02SEQ ID NO: 183843 bpDNA SequenceORF Start: ATG at 26ORF Stop: TAG at 836GAGGTGGAGGTTGCAGTAAGCCAAGATGGCGCCACTGCACTCTAGCCTGTTTCTGCTGAGCGGGACCATGAGCCCAAAAGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGTCAGCCTGAGGTTCTACAGCATGAAGAAGGGTCTGTGGGAGCCCATCTGTGGGGGCTCCCTCATCCACCCAGAGTGGGTGCTGACCGCCGCCCACTGCGTCGAGCTTGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTTGGGGACACGTTTTCCTGCTCCCGCCACCCCACCTCAGGGCAGCGGAAGGTCCAATCATGAGGACCCGAGCTTGCGAGAGGATGTATCACAAAGGCCCCACTGCCCACGTCACCATCATCAAGGCTGCCATGCCGTGTGCAGGGGCTGAGCGCCATCTCTCCCCACAGGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV16c, CG50934-02Protein SequenceSEQ ID NO: 184270 aaMW at 29993.6kDMAPLHSSLFLLSGTMSPKVGITGGCDVSARRHPWQVSLRFYSMKKGLWEPICGGSLIHPEWVLTAAHCVELEELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIWGHVFLLPPPHLRAAEGPIMRTRACERNYHKGPTAHVTIIKAAMPCAGAERHLSPQGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRYPGMYTRVTSYVSWIRQYVPPFPRRSEQ ID NO: 185964 bpNOV16d, SNP13381559 ofORF Start: ATG at 67ORF Stop: TGA at 655CG50934-03, DNA SequenceSNP Pos: 338SNP Change: T to CGACCATCTGATTGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGCCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGGTCAGGAGCAGGACCACTTGGGTGGGATGTGGAGAGATGACCCGGAATGTCGGTGCAGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCATTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV16d, SNP13381559 ofSEQ ID NO: 186MW at 21228.6kDCG50934-03, Protein SequenceSNP Pos: 91196 aaSNP Change: Val to AlaMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPASLPSASRDVPSGKTCWVTGWGVIGRGGQEQDHLGGMWRDDPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGPSACGRRRSEQ ID NO: 187964 bpNOV16e, SNP13381558 ofORF Start: ATG at 67ORF Stop: TGA at 655CG50934-03, DNA SequenceSNP Pos: 359SNP Change: G to TGACCATCTGATTGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGGTCAGGAGCAGGACCACTTGGGTGGGATGTGGAGAGATGACCCGGAATGTCGGTGCAGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCATTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV16e, SNP13381558 ofSEQ ID NO: 188MW at 21213.7kDCG50934-03, Protein SequenceSNP Pos: 98196 aaSNP Change: Arg to LeuMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGGQEQDHLGGMWRDDPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGPSACGRRRSEQ ID NO: 189964 bpNOV16f, SNP13376399 ofORF Start: ATG at 67ORF Stop: TGA at 655CG50934-03, DNA SequenceSNP Pos: 641SNP Change: G to AGACCATCTGATTGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGGTCAGGAGCAGGACCACTTGGGTGGGATGTGGAGAGATGACCCGGAATGTCGGTGCAGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTATGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCATTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV16f, SNP13376399 ofSEQ ID NO: 190MW at 21316.7kDCG50934-03, Protein SequenceSNP Pos: 192196 aaSNP Change: Cys to TyrMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGGQEQDHLGGMWRDDPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGPSAYGRRRSEQ ID NO: 191964 bpNOV16g, SNP13378301 ofORF Start: ATG at 67ORF Stop: TGA at 655CG50934-03, DNA SequenceSNP Pos: 868SNP Change: G to AGACCATCTGATTGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGGTCAGGAGCAGGACCACTTGGGTGGGATGTGGAGAGATGACCCGGAATGTCGGTGCAGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCATTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTACGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV16g, SNP13378301 ofMW at 21256.7kDCG50934-03, Protein SequenceSEQ ID NO: 192196 aaSNP Change: no changeMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGGQEQDHLGGMWRDDPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGPSACGRRRSEQ ID NO: 193964 bpNOV16h, SNP13378300 ofORF Start: ATG at 67ORF Stop: TGA at 655CG50934-03, DNA SequenceSNP Pos: 907SNP Change: C to TGACCATCTGATTGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGGTCAGGAGCAGGACCACTTGGGTGGGATGTGGAGAGATGACCCGGAATGTCGGTGCAGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCATTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGATGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV16h, SNP13378300 ofMW at 21256.7kDCG50934-03, Protein SequenceSEQ ID NO: 194196 aaSNP Change: no changeMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGGQEQDHLGGMWRDDPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGPSACGRRR

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 16B.

TABLE 16BComparison of the NOV16 protein sequences.NOV16a--------------MSPARGVS-----------WWASLGAATSRP-------GGTPGR--NOV16b----ALGRPSSVPLMSPARGVS-----------WWASLGAATSRP-------GGTPGR--NOV16cMAPLHSSLFLLSGTMSPKVGITGGCDVSARRHPWQVSLRFYSMKKGLWEPICGGSLIHPENOV16a-----------EELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALNOV16b-----------EELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALNOV16cWVLTAAHCVELEELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALNOV16aLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIG------RGGQEQDHLGGMWRNOV16bLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIG------RGGQEQDHLGGMWRNOV16cLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIWGHVFLLPPPHLRAAEGPIMRNOV16aD-DPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGNOV16bD-DPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGNOV16cTRACERMYHKGPTAHVTIIKAAMPCAGAERHLSPQGDNGGPLLCRRN--CTWVQVEVVSWNOV16aPSACGRRR------------------------NOV16bPSACGRRR------------------------NOV16cGKLCGLRYPGMYTRVTSYVSWIRQYVPPFPRRNOV16a(SEQ ID NO: 180)NOV16b(SEQ ID NO: 182)NOV16c(SEQ ID NO: 184)

Further analysis of the NOV16a protein yielded the following properties shown in Table 16C.

TABLE 16CProtein Sequence Properties NOV16aSignalP analysis: Cleavage site between residues 19 and 20PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 5; pos.chg 1; neg.chg 0H-region: length 13; peak value 6.79PSG score: 2.39GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.86possible cleavage site: between 18 and 19>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) .. fixedPERIPHERALLikelihood = 4.88 (at 73)ALOM score: 4.88 (number of TMSs: 0)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 6Charge difference: −3.0 C(−1.0) − N(2.0)N >= C: N-terminal side will be insideMITDISC: discrimination of mitochondrial targeting seqR content:3Hyd Moment(75):7.01Hyd Moment(95):6.08G content:5DIE content:1S/T content:6Score: −2.71Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 29 SRP|GGNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 12.2%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: SPARnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 70.6COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: extracellular, including cell wall33.3%: mitochondrial11.1%: cytoplasmic>> prediction for CG50934-03 is exc (k = 9)

A search of the NOV16a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16D.

TABLE 16DGeneseq Results for NOV16aNOV16aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE08591Human NOV12 protein - Homo12 . . . 117106/106 (100%) 2e−56sapiens, 220 aa. [WO200161009- 1 . . . 106106/106 (100%) A2, 23-AUG-2001]AAU82736Amino acid sequence of novel 5 . . . 11797/121 (80%) 3e−47human protease #35 - Homo184 . . . 302 101/121 (83%) sapiens, 948 aa. [WO200200860-A2, 03-JAN-2002]AAE14347Human protease PRTS-12 5 . . . 11797/121 (80%) 3e−47protein - Homo sapiens, 262 aa.30 . . . 148101/121 (83%) [WO2001 83775-A2, 08-NOV-2001]AAE08587Human NOV8 protein - Homo25 . . . 11791/93 (97%)6e−47sapiens, 290 aa. [WO200161009-84 . . . 17691/93 (97%)A2, 23-AUG-2001]AAE08590Human NOV11 protein - Homo27 . . . 11790/91 (98%)2e−46sapiens, 285 aa. [WO200161009-81 . . . 17190/91 (98%)A2, 23-AUG-2001]

In a BLAST search of public sequence databases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16E.

TABLE 16EPublic BLASTP Results for NOV16aNOV16aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueAAP21675Mast cell protease-11 - Mus10 . . . 11463/105 (60%) 3e-27musculus (Mouse), 318 aa.75 . . . 17377/105 (73%) AAA30855Mastin precursor - Canis sp, 25127 . . . 11455/88 (62%)5e-22aa (fragment).53 . . . 14061/88 (68%)P19236Mastocytoma protease precursor27 . . . 11455/88 (62%)5e-22(EC 3.4.21.-) - Canis familiaris71 . . . 15861/88 (68%)(Dog), 269 aa.Q8SQ44Tryptase precursor - Sus scrofa35 . . . 11449/80 (61%)1e-18(Pig), 277 aa.90 . . . 16760/80 (74%)I48685mast cell proteinase 6 (EC34 . . . 11444/81 (54%)2e-163.4.21.-) precursor - mouse, 23087 . . . 16454/81 (66%)aa.

PFam analysis indicates that the NOV16a protein contains the domains shown in the Table 16F.

TABLE 16FDomain Analysis of NOV16aIdentities/SimilaritiesPfamNOV16a Matchfor theExpectDomainRegionMatched RegionValuetrypsin19 . . . 17252/266 (20%)0.00069108/266 (41%)

Example 17

The NOV17 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 17A.

TABLE 17ANOV17 Sequence AnalysisNOV17a, CG51213-04SEQ ID NO: 1952804 bpDNA SequenceORF Start: ATG at 71ORF Stop: TAG at 2636TGGCCAGCCAGGCCTGAAGCGATCGGTCAGCCGAGAGCGCTACGTGGAGACCCTGGTGGTGGCTGACAAGATGATGGTGGCCTATCACGGGCGCCGGGATGTGGAGCAGTATGTCCTGGCCATCATGAACATTCAGGTTGCCAAACTTTTCCAGGACTCGAGTCTGGGAAGCACCGTTAACATCCTCGTAACTCGCCTCATCCTGCTCACGGAGGACCAGCCCACTCTGGAGATCACCCACCATGCCGGGAAGTCCCTGGACAGCTTCTGTAAGTGGCAGAAATCCATCGTGAACCACAGCGGCCATGGCAATGCCATTCCAGAGAACGGTGTGGCTAACCATGACACAGCAGTGCTCATCACACGCTATGACATCTGCATCTACAAGAACAAACCCTGCGGCACACTAGGCCTGGCCCCGGTGGGCGGAATGTGTGAGCGCGAGAGAAGCTGCAGCGTCAATGAGGACATTGGCCTGGCCACAGCGTTCACCATTGCCCACGAGATCGGGCACACATTCGGCATGAACCATGACGGCGTGGGAAACAGCTGTGGGGCCCGTGGTCAGGACCCAGCCAAGCTCATGGCTGCCCACATTACCATGAAGACCAACCCATTCGTGTGGTCATCCTGCAGCCGTGACTACATCACCAGCTTTCTAGACTCGGGCCTGGGGCTCTGCCTGAACAACCGGCCCCCCAGACAGGACTTTGTGTACCCGACAGTGGCACCGGGCCAAGCCTACGATGCAGATGAGCAATGCCGCTTTCAGCATGGAGTCAAATCGCGTCAGTGTAAATACGGGGAGGTCTGCAGCGAGCTGTGGTGTCTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGCCGCCGAGGGCACGCTGTGCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACTGTCTGAGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAGGGGGCGTGAAGGCCTGCTCGCTCACGAGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACCAGGAGTCCCTGCTGCTGGAGGGGCTGCCTGGGACCCCCCAGCCCCACCGTCTGCCTCTAGCTGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCCCTGGGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTGCCCTCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTGCCCCCCTACTCCTGGCACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGTCGCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCACGGAGGCCCTGCGGCCGCCCACCACGCAGCAGTGTGAGGCCAAGTGCGACAGCCCAACCCCCGGGGACGGCCCTGAAGAGTGCAAGGATGTGAACAAGGTCGCCTACTGCCCCCTGGTGCTCAAATTTCAGTTCTGCAGCCGAGCCTACTTCCGCCAGATGTGCTGCAAAACCTGCCAGGGCCACTAGGGGGCGCGCGGCACCCGGAGCCACAGCTGGCGGGGTCTCCGCCGCCAGCCCTGCAGCGGGCCGGCCAAAGGGGGCCCCGGGGGGGCGGGAACTGGGAGGGAAGGGTGAGACGGAGCCGGAAGTTATTTATTGGGAACCCCTGCAGGGCCCTGGCTGGGGGGATGGANOV17a, CG51213-04SEQ ID NO: 196855 aaMW at 93285.7kDProtein SequenceMMVAYHGRRDVEQYVLAINNIQVAKLFQDSSLGSTVNILVTRLILLTEDQPTLEITHHAGKSLDSFCKWQKSIVNHSGHGNAIPENGVANHDTAVLITRYDICIYKNKPCGTLGLAPVGGMCERERSCSVNEDIGLATAFTIAHEIGHTFGMNHDGVGNSCGARGQDPAKLMAAHITMKTNPFVWSSCSRDYITSFLDSGLGLCLNNRPPRQDFVYPTVAPGQAYDADEQCRFQNGVKSRQCKYGEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLSERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTSLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECTEALRPPTTQQCEAKCDSPTPGDGPEECKDVNKVAYCPLVLKFQFCSRAYFRQMCCKTCQGHNOV17b, CG51213-01SEQ ID NO: 1972266 bpDNA SequenceORF Start: ATG at 589ORF Stop: TAG at 2158CTCGGGCCTGGGGCTCTGCCTGAACAACCGGCCCCCCAGACAGGACTTTGTGTACCCGACAGTGGCACCGGGCCAAGCCTACGATGCAGATGAGCAATGCCGCTTTCAGCATGGAGTCAAATCGCGTCAGTTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAAGGTGAGTGTGGGACTCCAAAGGCTGTGGGGCCGTGAAGGGCAGCCGTGGGAGTGTCCAGCAGCAGGTGGATGAATGCAGCATCCCGGGGTCTGCCATGAGCCCTGTCCCCACCCGGGGAGACAGAGTACCTGGGATACGGTACCATGGGGGTTCAACGTGACGCTGGGAGCCCCCACTCCCTCTGCCCAAGCTGCCCTTCCTCTTGGGTCTGGGGTCTGTCCCTCTTGGCCTCACTCCCCCAGGGAGCAAGCAAAGAGTTCCGGGGTGGCCTGGCCCGTGGTGTGACGGGGCCGTGCCCCCCAGGGGGCGTGAAGGCCTGCTCGCTCACGTGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACCAGGAGTCCCTGCTGCTGGAGGGGCTGCCTGGGACCCCCCAGCCCCACCGTCTGCCTCTAGCTGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCCCTGGGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTGCCCTCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTGCCCCCCTACTCCTGGCACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGCCGCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCACGGAGGCCCTGCGGCCGCCCACCACGCAGCAGTGTGAGGCCAAGTGCGACAGCCCAACCCCCGGGGACGGCCCTGAAGAGTGCAAGGATGTGAACAAGGTCGCCTACTGCCCCCTGGTGCTCAAATTTCAGTTCTGCAGCCGAGCCTACTTCCGCCAGATGTGCTGCAAAACCTGCCAGGGCCACTAGGGGGCGCGCGGCACCCGGAGCCACAGCTGGCGGGGTCTCCGCCGCCAGCCCTGCAGCTGGGCCGGCCAGAGGGGGCCCCGGGGGGGCGGGAACTGGGAGGGAAGGGNOV17b, CG51213-01SEQ ID NO: 198523 aaMW at 56126.2kDProtein SequenceMGVQRDAGSPHSLCPSCPSSWVWGLSLLASLPQGASKEFRGGLARGVTGPCPPGGVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASNECTEALRPPTTQQCEAKCDSPTPGDGPEECKDVNKVAYCPLVLKFQFCSRAYFRQMCCKTCQGHNOV17c, 306345264SEQ ID NO: 199706 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCTGGCACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGCCGCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCACGGAGGCCCTGCGGCCGCCCACCACGCAGCAGTGTGAGGCCAAGTGCCTCGAGGGCNOV17c, 306345264SEQ ID NO: 200235 aaMW at 25395.4kDProtein SequenceTGSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECTEALRPPTTQQCEAKCLEGNOV17d, CG51213-02SEQ ID NO: 2013199 bpDNA SequenceORF Start: at 1297ORF Stop: at 3199TAAAGGGTTCAGCCTGGTGCCTGGTCCAGAGATAGTGGTGGTCATTGTTACCCCATAATGGCATTGGTGCAAGTCCTTTCTTATCTATCCTGTCACGTGCCTCATAGCCATTTATATAGGCAAGACAGGCATTAGGCTGCCCATCTTGTAGATGAGTAAACTGAGGCCCAGAGAGGGGAAATATATTGCAAGTTGGTAGCAGAATTGAGGTCTCTGCACAACTCAAATATGCCACAGTGCCTCCTTGTGGAGAGGAGGACAAAAGCAGAGCTGAAATCATTATCTTGAAGAGGTGTCAGAAGTGGGATTGCGACAGGACTGATGTGATATTTTTAGATATGGCCAAGAGGACACAGTCTGAGTTTTTAGCTGAGAAATGTCCTCTATAAGGCAGAAGGCAGAGATTCTAGAGGACCTTTGAGGGAGAATGTATTTGAGAACAACTCTTCCAGCTTCTTACATATGTACAGGTATCTCTCAGGGGCTGACCTAGGAAGGGTCCTTTCCTGTGGCCATTGATCGATCCAGTCCCACATCTGGAAAGCTTACAAGAATTGGGTTCAAAGCGGGGATTACACTTGATAATTACAGAAGGACCACCTACTTCTTAGAGGAAAGACGCTGGGAGGTTGCTTAGGATGTGGGCCAAGAGGGTCAGAGAGGACCACCTACTTTTTAGAGGAAAGACGCTGGGAGGTTGCTTAGGATGTGGGCCAAGAGGGTCAGAGATTTTGCTTCACCTGAACTCACTGGGGCTTCTCCAGGGATATTAACCTGGACTTTAAGAGTCAGAGTGAGTCCCTGGGACTAGTTCAGCCCATCCAGGATTCAGACGGGAAGAAGGTGGGGCTGATTTTTCACCTGGAGAAAGAGAGGCATGTCCCACACAGACCTAACTCGGCATTGTCCCCTCCCAAACTCCCACCCCTCCACATAGCTTAAAAGTGTTGGGGGCTTCTCCAGTTTAGATGGGGGAACAAAGAGAACCAACAGCTGGAAAAAACTAGAGATGAGGCCGTTGGCCTAGTCATCATCCAGGCCGATTTCTCAGAACCACCACTTTCTCTTCGGCTACTTTGCCCATCCCATAAAAGAACCCCAAATCCTTCCTGTTCATTCCTCAGCAGTTCCCACGTTTCCTTCCAGAAACTCAGAAGGCACCAGGAACTGAATTGCAAAGTTCGTTAGAGCACAGACTCTGAATTAAAGAGCTGGGTTAAACTCCAGGCTATTCCCTTAGTAGCTGTGTGACCTTACCTGTCTGAAGCTTGGTTTTCTCCCAGTAAGATGGGGTAGTACTGCCTAAAGAGGTATATGGCATGTATAAAGTGCTCCATAAATGGAGCTTATTGGGAGAGTATAAGTCACAGGCCATGCCCCGCAAGGGGATGCACGAAGACCCACCGCGAGCCAGGAAGGGAGCACCGGGCTCTCTGCTCTGGGACCGGCAGTGAGCCGGACATCTGGGTCCTCCCAAGCCGGGCGGGCTGCCCCAGGGAGGAAGGGAGGGGGGCGAGCCTGAGCGGGCACCTCGGCCCGCAGGAGGTCTGCAGCGAGCTGTGGTGTCTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGCCGCCGAGGGCACGCTGTGCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAGGGGGCGTGAAGGCCTGCTCGCTCACGTGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACCAGGAGTCCCTGCTGCTGGAGGGGCTGCCCGGGACCCCCCAGCCCCACCGTCTGCCTCTAGCTGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCCCTGGGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTGCCCTCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTGCCCCCCTACTCCTGGCACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGCCGCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCACGGAGGCCCTGCNOV17d, CG51213-02SEQ ID NO: 2021634 aaMW at 68853.1kDProtein SequenceYCLKRYMACIKCSINGAYWESISHRPCPARGCTKTHREPGREHRALCSGTGSEPDIWVLPSRAGCPREEGRGASLSGHLGPQEVCSELWCLSKSNRCIThSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECTEALNOV17e, CG51213-03SEQ ID NO: 2033700 bpDNA SequenceORF Start: at 1798ORF Stop: at 3700CTGACATTCCACCCTTGACACCCCCCAACATCCTAACTTAGCTGGTAACTGCAGCACCCTCTAAGGAATTCCTAAAGAATTCTGAAGCTACTCCTCAACATCTGCTGTGACCCAGGTATCCTAACAATGATCATGGTGTCTGACATTTACTGAGCTCTCACTATGGGCTAAGCATGTGCTGTGTGTCACCATCTAAACTCCTGACAATCCTGCTAGCCCCCACGTTACAGAGGAAGGGACTGAGCCATAGCATAGGGAGGATGACTTGTCCAAGGCCACAGTTTGAGACCATGACAGAGCTGGGATTTAAATCCAGGTCTCTCATGACTCTCTAAATTTTACAAAGGGGCAGGGGAGGGGAGGAGCTGTCAAAATATCAAGCTTGGGCTGGCACTGGCTATATGTTGAATTGAGCCTTCCTTTTAGTTTTTGAAGGAACATCTTTCAGGCCATCTTGGCAAAGGGGGATTTATTTACTAAATGTGAACTGGTTAATATATGTAAAGGGTTCAGCCTGGTGCCTGGTCCAGAGATAGTGGTGGTCATTGTTACCCCATAATGGCATTGGTGCAAGTCCTTTCTTATCTATCCTGTCACGTGCCTCATAGCCATTTATATAGGCAAGACAGGCATTAGGCTGCCCATCTTGTAGATGAGTAAACTGAGGCCCAGAGAGGGGAAATATATTGCAAGTTGGTAGCAGAATTGAGGTCTCTGCACAACTCAAATATGCCACAGTGCCTCCTTGTGGAGAGGAGGACAAAAGCAGAGCTGAAATCATTATCTTGAAGAGGTGTCAGAAGTGGGATTGCGACAGGACTGATGTGATATTTTTAGATATGGCCAAGAGGACACAGTCTGAGTTTTTAGCTGAGAAATGTCCTCTATAAGGCAGAAGGCAGAGATTCTAGAGGACCTTTGAGGGAGAATGTATTTGAGAACAACTCTTCCAGCTTCTTACATATGTACAGGTATCTCTCAGGGGCTGACCTAGGAAGGGTCCTTTCCTGTGGCCATTGATCGATCCAGTCCCACATCTGGAAAGCTTACAAGAATTGGGTTCAAAGCGGGGATTACACTTGATAATTACAGAAGGACCACCTACTTCTTAGAGGAAAGACGCTGGGAGGTTGCTTAGGATGTGGGCCAAGAGGGTCAGAGAGGACCACCTACTTTTTAGAGGAAAGACGCTGGGAGGTTGCTTAGGATGTGGGCCAAGAGGGTCAGAGATTTTGCTTCACCTGAACTCACTGGGGCTTCTCCAGGGATATTAACCTGGACTTTAAGAGTCAGAGTGAGTCCCTGGGACTAGTTCAGCCCATCCAGGATTCAGACGGGAAGAAGGTGGGGCTGATTTTTCACCTGGAGAAAGAGAGGCATGTCCCACACAGACCTAACTCGGCATTGTCCCCTCCCAAACTCCCACCCCTCCACATAGCTTAAAAGTGTTGGGGGCTTCTCCAGTTTAGATGGGGGAACAAAGAGAACCAACAGCTGGAAAAAACTAGAGATGAGGCCGTTGGCCTAGTCATCATCCAGGCCGATTTCTCAGAACCACCACTTTCTCTTCGGCTACTTTGCCCATCCCATAAAAGAACCCCAAATCCTTCCTGTTCATTCCTCAGCAGTTCCCACGTTTCCTTCCAGAAACTCAGAAGGCACCAGGAACTGAATTGCAAAGTTCGTTAGAGCACAGACTCTGAATTAAAGAGCTGGGTTAAACTCCAGGCTATTCCCTTAGTAGCTGTGTGACCTTACCTGTCTGAAGCTTGGTTTTCTCCCAGTAAGATGGGGTAGTACTGCCTAAAGAGGTATATGGCATGTATAAAGTGCTCCATAAATGGAGCTTATTGGGAGAGTATAAGTCACAGGCCATGCCCCGCAAGGGGATGCACGAAGACCCACCGCGAGCCAGGAAGGGAGCACGGGGCTCTCTGCTCTGGGACCGGCAGTGAGCCGGACATCTGGGTCCTCCCAAGCCGGGCGGGCTGCCCCAGGGAGGAAGGGAGGGGGGCGAGCCTGAGCGGGCACCTCGGCCCGCAGGAGGTCTGCAGCGAGCTGTGGTGTCTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGCCGCCGAGGGCACGCTGTGCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAGGGGGCGTGAAGGCCTGCTCGCTCACGTGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACCAGGAGTCCCTGCTGCTGGAGGGGCTGCCCGGGACCCCCCAGCCCCACCGTCTGCCTCTAGCTGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCCCTGGGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTGCCCTCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTGCCCCCCTACTCCTGGCACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGCCGCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCACGGAGGCCCTGCNOV17e, CG51213-03SEQ ID NO: 204634 aaMW at 68754.0kDProtein SequenceYCLKRYMACIKCSINGAYWESISHRPCPARGCTKTHREPGREHGALCSGTGSEPDIWVLPSRAGCPREEGRGASLSGHLGPQEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLGERRRBRSCNTDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKPPATMRCNLRRCPPARNVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECTEALNOV17f, CG51213-05SEQ ID NO: 2053400 bpDNA SequenceORF Start: at 1ORF Stop: TAG at 3232CGGTCTCAAGATGAGTTCCTGTCCAGTCTGGAGAGCTATGAGATCGCCTTCCCCACCCGCGTGGACCACAACGGGGCACTGCTGGCCTTCTCGCCACCTCCTCCCCGGAGGCAGCGCCGCGGCACGGGGGCCACAGCCGAGTCCCGCCTCTTCTACAAAGTAGCCTCGCCCAGCACCCACTTCCTGCTGAACCTGACCCGCAGCTCCCGTCTACTGGCAGGGCACGTCTCCGTGGAGTACTGGACACGGGAGGGCCTGGCCTGGCAGAGGGCGGCCCGGCCCCACTGCCTCTACGCTGGTCACCTGCAGGGCCAGGCCAGCAGCTCCCATGTGGCCATCAGCACCTGTGGAGGCCTGCACGGCCTGATCGTGGCAGACGAGGAAGAGTACCTGATTGAGCCCCTGCACGGTGGGCCCAAGGGTTCTCGGAGCCCGGAGGAAAGTGGACCACATGTGGTGTACAAGCGTTCCTCTCTGCGTCACCCCCACCTGGACACAGCCTGTGGAGTGAGAGATGAGAAACCGTGGAAAGGGCGGCCATGGTGGCTGCGGACCTTGAAGCCACCGCCTGCCAGACCCCTGGGGAATGAAACAGAGCGTGGCCAGCCAGGCCTGAAGCGATCGGTCAGCCGAGAGCGCTACGTGGAGACCCTGGTGGTGGCTGACAAGATGATGGTGGCCTATCACGGGCGCCGGGATGTGGAGCAGTATGTCCTGGCCATCATGAACATTGTTGCCAAACTTTTCCAGGACTCGAGTCTGGGAAGCACCGTTAACATCCTCGTAACTCGCCTCATCCTGCTCACGGAGGACCAGCCCACTCTGGAGATCACCCACCATGCCGGGAAGTCCCTAGACAGCTTCTGTAAGTGGCAGAAATCCATCGTGAACCACAGCGGCCATGGCAATGCCATTCCAGAGAACGGTGTGGCTAACCATGACACAGCAGTGCTCATCACACGCTATGACATCTGCATCTACAAGAACAAACCCTGCGGCACACTAGGCCTGGCCCCGGTGGGCGGAATGTGTGAGCGCGAGAGAAGCTGCAGCGTCAATGAGGACATTGGCCTGCCACAAGCGTTCACCATTGCCCACGAGATCGGGCACACATTCGGCATGAACCATGACGGCGTGGGAAACAGCTGTGGGGCCCGTGGTCAGGACCCAGCCAAGCTCATGGCTGCCCACATTACCATGAAGACCAACCCATTCGTGTGGTCATCCTGCAACCGTGACTACATCACCAGCTTTCTAGACTCGGGCCTGGGGCTCTGCCTGAACAACCGGCCCCCCAGACAGGACTTTGTGTACCCGACAGTGGCACCGGGCCAAGCCTACGATGCAGATGAGCAATGCCGCTTTCAGCATGGAGTCAAATCGCGTCAGTGTAAATACGGGGAGGTCTGCAGCGAGCTGTGGTGTCTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGCCGCCGAGGGCACGCTGTGCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGTCGTCACTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAGGGGGCGTGAAGGCCTGCTCGCTCACGAGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACCAGGAGTCCCTGCTGCTGGAGGGGCTGCCTGGGACCCCCCAGCCCCACCGTCTGCCTCTAGCTGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCCCTGGGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTGCCCTCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTGCCCCCCTACTCCTGGCACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGTCGCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCACGGAGGCCCTGCGGCCGCCCACCACGCAGCAGTGTGAGGCCAAGTGCGACAGCCCAACCCCCGGGGACGGCCCTGAAGAGTGCAAGGATGTGAACAAGGTCGCCTACTGCCCCCTGGTGCTCAAATTTCAGTTCTGCAGCCGAGCCTACTTCCGCCAGATGTGCTGCAAAACCTGCCAGGGCCACTAGGGGGCGCGCGGCACCCGGAGCCACAGCTGGCGGGGTCTCCGCCGCCAGCCCTGCAGCGGGCCGGCCAAAGGGGGCCCCGGGGGGGCGGGAACTGGGAGGGAAGGGTGAGACGGAGCCGGAAGTTATTTATTGGGAACCCCTGCAGGGCCCTGGCTGGGGGGATGGANOV17f, CG51213-05SEQ ID NO: 2061077 aaMW at 118071.4kDProtein SequenceRSQDEFLSSLESYEIAFPTRVDHNGALLAFSPPPPRRQRRGTGATAESRLFYKVASPSTHFLLNLTRSSRLLAGHVSVEYWTREGLAWQRAARPHCLYAGHLQGQASSSHVAISTCGGLHGLIVADEEEYLIEPLHGGPKGSRSPEESGPHVVYKRSSLRHPHLDTACGVRDEKPWKGRPWWLRTLKPPPARPLGNETERGQPGLKRSVSRERYVETLVVADKMMVAYHGRRDVEQYVLAIMNIVAKLFQDSSLGSTVNILVTRLILLTEDQPTLEITHHAGKSLDSFCKWQKSIVNHSGHGNAIPENGVANHDTAVLITRYDICIYKNKPCGTLGLAPVGGMCERERSCSVNEDIGLPQAFTIAHEIGHTFGMNHDGVGMSCGARGQDPAKLMAAHITNKTNPFVWSSCNRDYITSFLDSGLGLCLNNRPPRQDFVYPTVAPGQAYDADEQCRFQHGVKSRQCKYGEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTSLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHPATLPPAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECTEALRPPTTQQCEAKCDSPTPGDGPEECKDVNKVAYCPLVLKFQFCSRAYFRQMCCKTCQGHNOV17g, CG51213-06SEQ ID NO: 207978 bpDNA SequenceORF Start: at IORF Stop: end of sequenceTCCATAAATGGAGCTTATTGGGAGAGTATAAGTCACAGGCCATGCCCCGCAAGGGGATGCACGAAGACCCACCGCGAGCCAGGAAGGGAGCACCGGGCTCTCTGCTCTGGGACCGGCAGTGAGCCGGACATCTGGGTCCTCCCAAGCCGGGCGGGCTGCCCCAGGGAGGAAGGGAGGGGGGCGAGCCTGAGCGGGCACCTCGGCCCGCAGGAGGTCTGCAGCGAGCTGTGGTGTCTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGCCGCCGAGGGCACGCTGTGCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAGGGGGCGTGAAGGCCTGCTCGCTCACGTGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAGNOV17g, CG51213-06SEQ ID NO: 208326 aaMW at 35330.2kDProtein SequenceSINGAYWESISHRPCPARGCTKTHREPGREHRALCSGTGSEPDIWVLPSRAGCPREEGRGASLSGHLGPQEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKNOV17h, CG51213-07SEQ ID NO: 2091866 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTCCATAAATGGAGCTTATTGGGAGAGTATAAGTCACAGGCCATGCCCCGCAAGGGGATGCACGAAGACCCACCGCGAGCCAGGAAGGGAGCACCGGGCTCTCTGCTCTGGGACCGGCAGTGAGCCGGACATCTGGGTCCTCCCAAGCCGGGCGGGCTGCCCCAGGGAGGAAGGGAGGGGGGCGAGCCTGAGCGGGCACCTCGGCCCGCAGGAGGTCTGCAGCGAGCTGTGGTGTCTGAGCAAGAGCAACCGGTGCATCACCAACAGCATCCCGGCCGCCGAGGGCACGCTGTGCCAGACGCACACCATCGACAAGGGGTGGTGCTACAAACGGGTCTGTGTCCCCTTTGGGTCGCGCCCAGAGGGTGTGGACGGAGCCTGGGGGCCGTGGACTCCATGGGGCGACTGCAGCCGGACCTGTGGCGGCGGCGTGTCCTCTTCTAGCCGTCACTGCGACAGCCCCAGGCCAACCATCGGGGGCAAGTACTGTCTGGGTGAGAGAAGGCGGCACCGCTCCTGCAACACGGATGACTGTCCCCCTGGCTCCCAGGACTTCAGAGAAGTGCAGTGTTCTGAATTTGACAGCATCCCTTTCCGTGGGAAATTCTACAAGTGGAAAACGTACCGGGGAGGGGGCGTGAAGGCCTGCTCGCTCACGTGCCTAGCGGAAGGCTTCAACTTCTACACGGAGAGGGCGGCAGCCGTGGTGGACGGGACACCCTGCCGTCCAGACACGGTGGACATTTGCGTCAGTGGCGAATGCAAGCACGTGGGCTGCGACCGAGTCCTGGGCTCCGACCTGCGGGAGGACAAGTGCCGAGTGTGTGGCGGTGACGGCAGTGCCTGCGAGACCATCGAGGGCGTCTTCAGCCCAGCCTCACCTGGGGCCGGGTACGAGGATGTCGTCTGGATTCCCAAAGGCTCCGTCCACATCTTCATCCAGGATCTGAACCTCTCTCTCAGTCACTTGGCCCTGAAGGGAGACCAGGAGTCCCTGCTGCTGGAGGGGCTGCCCGGGACCCCCCAGCCCCACCGTCTGCCTCTAGCTGGGACCACCTTTCAACTGCGACAGGGGCCAGACCAGGTCCAGAGCCTCGAAGCCCTGGGACCGATTAATGCATCTCTCATCGTCATGGTGCTGGCCCGGACCGAGCTGCCTGCCCTCCGCTACCGCTTCAATGCCCCCATCGCCCGTGACTCGCTGCCCCCCTACTCCTGGCACTATGCGCCCTGGACCAAGTGCTCGGCCCAGTGTGCAGGCGGTAGCCAGGTGCAGGCGGTGGAGTGCCGCAACCAGCTGGACAGCTCCGCGGTCGCCCCCCACTACTGCAGTGCCCACAGCAAGCTGCCCAAAAGGCAGCGCGCCTGCAACACGGAGCCTTGCCCTCCAGACTGGGTTGTAGGGAACTGGTCGCTCTGCAGCCGCAGCTGCGATGCAGGCGTGCGCAGCCGCTCGGTCGTGTGCCAGCGCCGCGTCTCTGCCGCGGAGGAGAAGGCGCTGGACGACAGCGCATGCCCGCAGCCGCGCCCACCTGTACTGGAGGCCTGCCACGGCCCCACTTGCCCTCCGGAGTGGGCGGCCCTCGACTGGTCTGAGTGCACCCCCAGCTGCGGGCCGGGCCTCCGCCACCGCGTGGTCCTTTGCAAGAGCGCAGACCACCGCGCCACGCTGCCCCCGGCGCACTGCTCACCCGCCGCCAAGCCACCGGCCACCATGCGCTGCAACTTGCGCCGCTGCCCCCCGGCCCGCTGGGTGGCTGGCGAGTGGGGTGAGTGCTCTGCACAGTGCGGCGTCGGGCAGCGGCAGCGCTCGGTGCGCTGCACCAGCCACACGGGCCAGGCGTCGCACGAGTGCACGGAGGCCCTGNOV17h, CG51213-07SEQ ID NO: 210622 aaMW at 67376.2kDProtein SequenceSINGAYWESISHRPCPARGCTKTHREPGREHRALCSGTGSEPDIWVLPSRAGCPREEGRGASLSGHLGPQEVCSELWCLSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFRGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGCDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLSLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMVLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVAPHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPPAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECTEAL

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 17B.

TABLE 17BComparison of the NOV17 protein sequences.NOV17a ------------------------------------------------------------NOV17b ------------------------------------------------------------NOV17c ------------------------------------------------------------NOV17d ------------------------------------------------------------NOV17e ------------------------------------------------------------NOV17f RSQDEFLSSLESYEIAFPTRVDHNGALLAFSPPPPRRQRRGTGATABSRLFYKVASPSTHNOV17g ------------------------------------------------------------NOV17h ------------------------------------------------------------NOV17a ------------------------------------------------------------NOV17b ------------------------------------------------------------NOV17c ------------------------------------------------------------NOV17d ------------------------------------------------------------NOV17e ------------------------------------------------------------NOV17f FLLNLTRSSRLLAGHVSVEYWTREGLAWQRAARPHCLYAGHLQGQASSSHVAISTCGGLHNOV17g ------------------------------------------------------------NOV17h ------------------------------------------------------------NOV17a ------------------------------------------------------------NOV17b ------------------------------------------------------------NOV17c ------------------------------------------------------------NOV17d ------------------------------------------------------------NOV17e ------------------------------------------------------------NOV17f GLIVADEEEYLIEPLHGGPKGSRSPEESGPHVVYKRSSLRHPHLDTACGVRDEKPWKGRPNOV17g ------------------------------------------------------------NOV17h ------------------------------------------------------------NOV17a ------------------------------------------MMVAYHGRRDVEQYVLAINOV17b ------------------------------------------------------------NOV17c ------------------------------------------------------------NOV17d ------------------------------------------------------------NOV17e ------------------------------------------------------------NOV17f WWLRTLKPPPARPLGNETERGQPGLKRSVSRERYVETLVVADKMMVAYHGRRDVEQYVLANOV17g ------------------------------------------------------------NOV17h ------------------------------------------------------------NOV17a MNIQVAKLFQDSSLGSTVNILVTRLILLTEDQPTLEITHHAGKSLDSFCKWQKSIVNHSGNOV17b ------------------------------------------------------------NOV17c ------------------------------------------------------------NOV17d ------------------------------------------------------------NOV17e ------------------------------------------------------------NOV17f IMNIVAKLFQDSSLGSTVNILVTRLILLTEDQPTLEITHHAGKSLDSFCKWQKSIVNHSGNOV17g ------------------------------------------------------------NOV17h ------------------------------------------------------------NOV17a HGNAIPENGVANHDTAVLITRYDICIYKNKPCGTLGLAPVGGMCERERSCSVNEDIGLATNOV17b ------------------------------------------------------------NOV17c ------------------------------------------------------------NOV17d ------------------------------------------------------------NOV17e ------------------------------------------------------------NOV17f HGNAIPENGVANHDTAVLITRYDICIYKNKPCGTLGLAPVGGMCERERSCSVNEDIGLPQNOV17g ------------------------------------------------------------NOV17h ------------------------------------------------------------NOV17a AFTIAHEIGHTFGMNHDGVGMSCGARGQDPAKLMAAHITMKTNPFVWSSCSRDYITSFLDNOV17b ------------------------------------------------------------NOV17c ------------------------------------------------------------NOV17d ------------------------------------------------------------NOV17e ------------------------------------------------------------NOV17f AFTIAHEIGHTFGMNHDGVGNSCGARGQDPAKLMAAHITMKTNPFVWSSCNRDYITSFLDNOV17g ------------------------------------------------------------NOV17h ------------------------------------------------------------NOV17a SGLGLCLNNRPPRQDFVYPTVAPGQAYDADEQCRFQHGVKSRQCKYGEVCSELWCLSKSNNOV17b ------------------------------------------------------------NOV17c ------------------------------------------------------------NOV17d ------------------------------YCLKRYMACIKCSINGAYWESISHRPCPARNOV17e ------------------------------YCLKRYMACIKCSINGAYWESISHRPCPARNOV17f SGLGLCLNNRPPRQDFVYPTVAPGQAYDADEQCRFQHGVKSRQCKYGEVCSELWCLSKSNNOV17g ------------------------------------------SINGAYWESISHRPCPARNOV17h ------------------------------------------SINGAYWESISHRPCPARNOV17a RCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGNOV17b --------------------------------MGVQRD----AGSPHSLCPSCPSSWVWGNOV17c ------------------------------------------------------------NOV17d GCTKTHREPGREHRALCSGTGSEPDIWVLPSRAGCPREEGRGASLSGHLGPQEVCSELWCNOV17e GCTKTHREPGREHGALCSGTGSEPDIWVLPSRAGCPREEGRGASLSGHLGPQEVCSELWCNOV17f RCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRTCGGGNOV17g GCTKTHREPGREHRALCSGTGSEPDIWVLPSRAGCPREEGRGASLSGHLGPQEVCSELWCNOV17h GCTKTHREPGREHRALCSGTGSEPDIWVLPSRAGCPREEGRGASLSGHLGPQEVCSELWCNOV17a VS-----------------------S--SS---------RHCD-----------------NOV17b LS-----------------------L--LA---------SLPQ-----------------NOV17c ------------------------------------------------------------NOV17d LSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRNOV17e LSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRNOV17f VS-----------------------S--SS---------RHCD-----------------NOV17g LSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRNOV17h LSKSNRCITNSIPAAEGTLCQTHTIDKGWCYKRVCVPFGSRPEGVDGAWGPWTPWGDCSRNOV17a ---S-PR--P--------TIGGKYCLSERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFNOV17b ---G-AS--K--------EFRGGLARG--------VTGPCPPG-----------------NOV17c ------------------------------------------------------------NOV17d TCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFNOV17e TCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFNOV17f ---S-PR--P--------TIGGKYCLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFNOV17g TCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFNOV17h TCGGGVSSSSRHCDSPRPTIGGKYCLGERRRHRSCNTDDCPPGSQDFREVQCSEFDSIPFNOV17a RGKFYKWKTYRGGGVKACSLTSLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGNOV17b -------------GVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGNOV17c ------------------------------------------------------------NOV17d RGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGNOV17e RGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGNOV17f RGKFYKWKTYRGGGVKACSLTSLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGNOV17g RGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGNOV17h RGKFYKWKTYRGGGVKACSLTCLAEGFNFYTERAAAVVDGTPCRPDTVDICVSGECKHVGNOV17a CDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLNOV17b CDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLNOV17c ------------------------------------------------------------NOV17d CDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLNOV17e CDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLNOV17f CDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLNOV17g CDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLNOV17h CDRVLGSDLREDKCRVCGGDGSACETIEGVFSPASPGAGYEDVVWIPKGSVHIFIQDLNLNOV17a SLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMNOV17b SLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMNOV17c ------------------------------------------------------------NOV17d SLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMNOV17e SLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMNOV17f SLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMNOV17g SLSHLALK----------------------------------------------------NOV17h SLSHLALKGDQESLLLEGLPGTPQPHRLPLAGTTFQLRQGPDQVQSLEALGPINASLIVMNOV17a VLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVNOV17b VLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVNOV17c ------------------------TGSNHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVNOV17d VLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVNOV17e VLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVNOV17f VLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVNOV17g ------------------------------------------------------------NOV17h VLARTELPALRYRFNAPIARDSLPPYSWHYAPWTKCSAQCAGGSQVQAVECRNQLDSSAVNOV17a APHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKNOV17b APHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKNOV17c APHYCSAHSKLPKRQRACNTEPCPPDNVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKNOV17d APHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKNOV17e APHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKNOV17f APHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKNOV17g ------------------------------------------------------------NOV17h APHYCSAHSKLPKRQRACNTEPCPPDWVVGNWSLCSRSCDAGVRSRSVVCQRRVSAAEEKNOV17a ALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPNOV17b ALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPNOV17d ALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPNOV17d ALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHPATLPNOV17e ALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPNOV17f ALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPNOV17g ------------------------------------------------------------NOV17h ALDDSACPQPRPPVLEACHGPTCPPEWAALDWSECTPSCGPGLRHRVVLCKSADHRATLPNOV17a PAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECNOV17b PAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECNOV17c PAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECNOV17d PAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECNOV17e PAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECNOV17f PAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECNOV17g ------------------------------------------------------------NOV17h PAHCSPAAKPPATMRCNLRRCPPARWVAGEWGECSAQCGVGQRQRSVRCTSHTGQASHECNOV17a TEALRPPTTQQCEAKCDSPTPGDGPEECKDVNKVAYCPLVLKFQFCSRAYFRQMCCKTCQNOV17b TEALRPPTTQQCEAKCDSPTPGDGPEECKDVNKVAYCPLVLKFQFCSRAYFRQMCCKTCQNOV17c TEALRPPTTQQCEAKCLEG-----------------------------------------NOV17d TEAL--------------------------------------------------------NOV17e TEAL--------------------------------------------------------NOV17f TEALRPPTTQQCEAKCDSPTPGDGPEECKDVNKVAYCPLVLKFQFCSRAYFRQMCCKTCQNOV17g ------------------------------------------------------------NOV17h TEAL--------------------------------------------------------NOV17a GHNOV17b GHNOV17c --NOV17d --NOV17e --NOV17f GHNOV17g --NOV17h --NOV17a (SEQ ID NO: 196)NOV17b (SEQ ID NO: 198)NOV17c (SEQ ID NO: 200)NOV17d (SEQ ID NO: 202)NOV17e (SEQ ID NO: 204)NOV17f (SEQ ID NO: 206)NOV17g (SEQ ID NO: 208)NOV17h (SEQ ID NO: 210)

Further analysis of the NOV17a protein yielded the following properties shown in Table 17C.

TABLE 17CProtein Sequence Properties NOV17aSignalP analysis: No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 2; neg.chg 1H-region: length 1; peak value −0.15PSG score: −4.55GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −8.03possible cleavage site: between 33 and 34>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 1Number of TMS(s) for threshold 0.5: 0PERIPHERAL Likelihood = 1.38 (at 31)ALOM score: −1.70 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment(75):5.01Hyd Moment(95):5.34G content:1D/E content:2S/T content:0Score: −5.94Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 18 GRR|DVNUCDISC: discrimination of nuclear localization signalspat4: RRRH (3) at 342pat4: RRHR (3) at 343pat7: PKRQRAC (5) at 625bipartite: nonecontent of basic residues: 10.6%NLS Score: 0.33KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: foundKLPK at 623RNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR:N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found *** LGSTVNILVTRLILLTEDQPTL at 32nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 76.7COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):95.7%: nuclear 4.3%: cytoplasmic>> prediction for CG51213-04 is nuc (k = 23)

A search of the NOV17a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17D.

TABLE 17DGeneseq Results for NOV17aNOV17aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU97888Human aggrecanase protein #2 -1 . . . 855852/855 (99%)0.0Homo sapiens, 1104 aa.250 . . . 1103 852/855 (99%)[WO200234895-A2, 02-MAY-2002]AAB74945Human ADAM type metal1 . . . 855852/855 (99%)0.0protease MDTS2 protein SEQ ID250 . . . 1103 852/855 (99%)NO: 10 - Homo sapiens, 1103 aa.[JP2001008687-A, 16 Jan. 2001]AAU72890Human metalloprotease partial1 . . . 855851/855 (99%)0.0protein sequence #2 - Homo250 . . . 1103 852/855 (99%)sapiens,1103 aa. [WO200183782-A2, 08-NOV-2001]ABG76505DNA encoding protein1 . . . 855851/855 (99%)0.0modification and maintenance250 . . . 1103 852/855 (99%)molecule #9 - Homo sapiens, 1103aa. [WO200260942-A2, 08-AUG-2002]AAB47719ADAMTS-E - Homo sapiens,1 . . . 855852/856 (99%)0.01104 aa. [EP1149903-A1, 31-250 . . . 1104 852/856 (99%)OCT-2001]

In a BLAST search of public sequence databases, the NOV17a protein was found to have homology to the proteins shown in the BLASTP data in Table 17E.

TABLE 17EPublic BLASTP Results for NOV17aNOV17aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9H324ADAMTS-10 precursor (EC1 . . . 855850/855 (99%)0.03.4.24.-) (A disintegrin and224 . . . 1077 851/855 (99%)metalloproteinase withthrombospondin motifs 10)(ADAM-TS 10) (ADAM-TS10) -Homo sapiens (Human), 1077 aa(fragment).Q8CG28Zinc metalloendopeptidase - Mus1 . . . 854809/855 (94%)0.0musculus (Mouse), 1070 aa.216 . . . 1069 824/855 (95%)CAD20434Sequence 8 from Patent1 . . . 796793/796 (99%)0.0WO0188156 - Homo sapiens250 . . . 1044 793/796 (99%)(Human), 1044 aa (fragment).CAC37777Sequence 11 from Patent246 . . . 797 550/552 (99%)0.0WO0123561 - Homo sapiens83 . . . 634 550/552 (99%)(Human), 634 aa (fragment).CAD20435Sequence 11 from Patent1 . . . 557552/557 (99%)0.0WO0188156 - Homo sapiens250 . . . 805 552/557 (99%)(Human), 814 aa.

PFam analysis indicates that the NOV17a protein contains the domains shown in the Table 17F.

TABLE 17FDomain Analysis of NOV17aIdentities/NOV17aSimilaritiesPfamMatchfor the MatchedExpectDomainRegionMatched RegionValueReprolysin 2 . . . 209 59/235 (25%)1.4e-09151/235 (64%)tsp_1303 . . . 35321/53 (40%)2.8e-0737/53 (70%)tsp_1581 . . . 63611/59 (19%)0.05638/59 (64%)tsp_1640 . . . 69614/63 (22%)0.1338/63 (60%)tsp_1698 . . . 75416/57 (28%)0.4334/57 (60%)tsp_1759 . . . 80917/55 (31%)0.234/55 (62%)

Example 18

The NOV18 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 18A.

TABLE 18ANOV18 Sequence AnalysisNOV18a, CG51448-05SEQ ID NO: 2111762 bpDNA SequenceORF Start: ATG at 197ORF Stop: TGA at 1760TTTGAGTTAGACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGTGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGTACATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTATAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGAGGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGTTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18a,CG51448-05SEQ ID NO: 212521 aaMW at 57751.9kDProtein SequenceMPKPLPQRKGMVPWPNPQLAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKMILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSNNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMBYIEGGELFERIVDEDYHLTEVDTNVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18b, CG51448-01SEQ ID NO: 2131788 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786ATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18b, CG51448-01SEQ ID NO: 214595 aaMW at 64501.9kDProtein SequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIEDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQARNNAAQOLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAVSAANRFKKISSSGALMALGVNOV18c, 274051198SEQ ID NO: 215787 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCAAGCTTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGTACATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTATAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGAGGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCGTCGACGGCNOV18c, 274051198SEQ ID NO: 216262 aaMW at 29771.1kDProtein SequenceTKLMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFNHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCLAHPWLVDGNOV18d, 274051170SEQ ID NO: 2171813 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCAAGCTTCCCACCATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGTGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGTACATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTATAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGAGGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCGTCGACGGCNOV18d, 274051170SEQ ID NO: 218604 aaMW at 65496.1kDProtein SequenceTKLPTMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVVDGNOV18e, GG51448-02SEQ ID NO: 2192010 bpDNA SequenceORF Start: ATG at 40ORF Stop: TGA at 1828TTTGAGTTAGACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGTGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGTACATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTATAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGCGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGAGGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGAGCCCTGGGCGCAGCTGAAGCCTGGACGCAGCCACACAGTGGCCGGGGCTGAAGCCACACAGCCCAGAAGGCCAGAAAAGGCAGCCAGATCCCCAGGGCAGCCTCGTTAGGACAAGGCTGTGCCAGGCTGGGAGGCTCGGGGCTCCCCACGCCCCCATGCAGTGACCGCTTCCCCGATGTGNOV18e, GG51448-02SEQ ID NO: 220596 aaMW at 64656.1kDProtein SequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMNKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYNPNEKLKVNFGTPEFLSPEAVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18f, CG51448-03SEQ ID NO: 2211839 bpDNA SequenceORF Start: ATG at 49ORF Stop: TGA at 1837CTAGAAAGACTTGAGTTAGACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGTGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGTACATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTATAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGCGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGAGGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18f, CG51448-03SEQ ID NO: 222596 aaMW at 64656.1kDProtein SequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYNPNEKLKVNFGTPEFLSPEAVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18g, GG51448-04SEQ ID NO: 2232558 bpDNA SequenceORF Start: ATG at 164ORF Stop: TGA at 1949CTTTGCTCCAGGTACCTCTCTCCCCTCAGTTAGCAGGCCTCGGCTTCCTGTCTCACTGCAGCCAGACGAGAGGGGAAATTGGACAGCCTGACACACTCCACTCTTGTTTCTGCAGCTAGAAAGACTTGAGTTAGACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCCGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGTCGGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTGATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTATAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGAGGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGAGCCCTGGGCGCAGCTGAAGCCTGGACGCAGCCACACAGTGGCCGGGGCTGAAGCCACACAGCCCAGAAGGCCAGAAAAGGCAGCCAGATCCCCAGGGCAGCCTCGTTAGGACAAGGCTGTGCCAGGCTGGGAGGCTCGGGGCTCCCCACGCCCCCATGCAGTGACCGCTTCCCCGATGTGAGCCGCCTCGGAGTGTGGCCTGGATCCATCCTGCTAGCACCTCCCCAGACAGGGCTCCAGCCTGTCGGCCACACCCCAGACTCCAGGCCCCCGTTGAAGCCGCTCCCGGTTCCCTCCCCAGCTCCTCGTCTTTGAACTGCCGCCGCCGTGGTGACCCCTGCTTTGCCCCACTGGGAGAGTCCTTAGCCTGGGCCTCCTCCTAGCTGGAGTGCCATGGCTGGGGGGTCTCAGCATGTAGGGCTTCTGTGGTTGTGGATGGGAGGCTCCTGGTGGGGCAGAAAGGCTGCAACGCTGATTCCTAAGGCCCAGCTGCCAGGGAAGACAGAGCAGGCTTTGTGAGAGAGGACCTCCATGCCCCCGCCACCTCCCCACTCCAGCAGATAAGGCCGAGCCCACACCATCTGGCCCAGGCTGGCCCCCACCACCTNOV18g, CG51448-04SEQ ID NO: 224595 aaMW at 64476.9kDProtein SequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRSAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILLMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18h, SNP13375535 ofSEQ ID NO: 2251788 bpCG51448-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786SNP Pos: 102SNP Change: A to GATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAGGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18h, SNP13375535 ofSEQ ID NO: 226595 aaMW at 64501.9kDCG51448-01, ProteinSNP Pos: 34SNP Change: Lys to LysSequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQARNNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18i, SNP13375536 ofSEQ ID NO: 2271788 bpCG51448-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786SNP Pos: 287SNP Change: C to TATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGTCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18i, SNP13375536 ofSEQ ID NO: 228595 aaMW at 64530.0kDCG51448-01, ProteinSNP Pos: 96SNP Change: Ala to ValSequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAVLPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKENVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEEEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18j, SNP13375537 ofSEQ ID NO: 2291788 bpCG51448-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786SNP Pos: 350SNP Change: C to TATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGTCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18j, SNP13375537 ofSEQ ID NO: 230595 aaMW at 64530.0kDCG51448-01, ProteinSNP Pos: 117SNP Change: Ala to ValSequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGVSGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18k, SNP13375538 ofSEQ ID NO: 2311788 bpCG51448-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786SNP Pos: 1249SNP Change: A to TATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCTCCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18k, SNP13375538 ofSEQ ID NO: 232595 aaMW at 64487.9kDCG51448-01, ProteinSNP Pos: 417SNP Change: Thr to SerSequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRNVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTSGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18l, SNP13375539 ofSEQ ID NO: 2331788 bpCG51448-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786SNP Pos: 1358INP Change: T to CATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGCGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18l, SN1P13375539 ofSEQ ID NO: 234595 aaMW at 64473.8kDCG51448-01, ProteinSNP Pos: 453SNP Change: Val to AlaSequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKABEGKNILAESQKBVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEIEGGELFERIVDEDYHLTEVDTNVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEAVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18m, SNP13375540 ofSEQ ID NO: 2351788 bpCG51448-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786SNP Pos: 1391SNP Change: A to GATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGGCATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18m, SNP13375540 ofSEQ ID NO: 236595 aaMW at 64443.9kDCG51448-01, ProteinSNP Pos: 464SNP Change: Asp to GlySequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKMILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFNEIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTGMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQARNNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18n, SNP13375541 ofSEQ ID NO: 2371788 bpCG51448-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786SNP Pos: 1511SNP Change: A to GATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGGGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18n, SNP13375541 ofSEQ ID NO: 238595 aaMW at 64429.8kDCG51448-01, ProteinSNP Pos: 504SNP Change: Glu to GlySequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEGTFEAVSDEAKDFVSNLIVKDQARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18o, SNP13375542 ofSEQ ID NO: 2391788 bpCG51448-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786SNP Pos: 1675SNP Change: C to TATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAAGACCCCTGGCTGCAGGGAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTCACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGTTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGTCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18o, SNP13375542 ofSEQ ID NO: 240595 aaMW at 64535.9kDCG51448-01, ProteinSNP Pos: 559SNP Change: Leu to PheSequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEOGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILFKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGVNOV18p, SNP13375543 ofSEQ ID NO: 2411788 bpCG51448-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1786SNP Pos: 1724SNP Change: T to GATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGACAAGGCACCTAAAGGTCCCACAGGTGAAAGACCCCTGGCTGCAGGGAAAGACCCTGGCCCCCCAGACCCAAAGAAAGCTCCGGATCCACCCACCCTGAAGAAAGATGCCAAAGCCCCTGCCTCAGAGAAAGGGGATGGTACCCTGGCCCAACCCTCAACTAGCAGCCAAGGCCCCAAAGGAGAGGGTGACAGGGGCGGGGGGCCCGCGGAGGGCAGTGCTGGGCCCCCGGCAGCCCTGCCCCAGCAGACTGCGACACCTGAGACCAGCGTCAAGAAGCCCAAGGCTGAGCAGGGAGCCTCAGGCAGCCAGGATCCTGGAAAGCCCAGGGTGGGCAAGAAGGCAGCAGAGGGCCAAGCAGCAGCCAGGAGGGGCTCACCTGCCTTTCTGCATAGCCCCAGCTGTCCTGCCATCATCTCCAGTTCTGAGAAGCTGCTGGCCAAGAAGCCCCCAAGCGAGGCATCAGAGCTGACCTTTGAAGGGGTGCCCATGACCCACAGCCCCACGGATCCCAGGCCAGCCAAGGCAGAAGAAGGAAAGAACATCCTGGCAGAGAGCCAGAAGGAAGTGGGAGAGAAAACCCCAGGCCAGGCTGGCCAGGCTAAGATGCAAGGGGACACCTCGAGGGGGATTGAGTTCCAGGCTGTTCCCTCAGAGAAATCCGAGGTGGGGCAGGCCCTCTGTCTCACAGCCAGGGAGGAGGACTGCTTCCAGATTTTGGATGATTGCCCGCCACCTCCGGCCCCCTTCCCTCACCGCATGGTGGAGCTGAGGACCGGGAATGTCAGCAGTGAATTCAGTATGAACTCCAAGGAGGCGCTCGGAGGGGGCAAGTTTGGGGCAGTCTGTACCTGCATGGAGAAAGCCACAGGCCTCAAGCTGGCAGCCAAGGTCATCAAGAAACAGACTCCCAAAGACAAGGAAATGGTGTTGCTGGAGATTGAGGTCATGAACCAGCTGAACCACCGCAATCTGATCCAGCTGTATGCAGCCATCGAGACTCCGCATGAGATCGTCCTGTTCATGGAGATCGAGGGCGGAGAGCTCTTCGAGAGGATTGTGGATGAGGACTACCATCTGACCGAGGTGGACACCATGGTGTTTGTCAGGCAGATCTGTGACGGGATCCTCTTCATGCACAAGATGAGGGTTTTGCACCTGGACCTCAAGCCAGAGAACATCCTGTGTGTCAACACCACCGGGCATTTGGTGAAGATCATTGACTTTGGCCTGGCACGGAGGTACCACAACCCCAACGAGAAGCTGAAGGTGAACTTTGGGACCCCAGAGTTCCTGTCACCTGAGGTGGTGAATTATGACCAAATCTCCGATAAGACAGACATGTGGAGTATGGGGGTGATCACCTACATGCTGCTGAGCGGCCTCTCCCCCTTCCTGGGAGATGATGACACAGAGACCCTAAACAACGTTCTATCTGGCAACTGGTACTTTGATGAAGAGACCTTTGAGGCCGTATCAGACGAGGCCAAAGACTTTGTCTCCAACCTCATCGTCAAGGACCAGGCCCGGATGAACGCTGCCCAGTGTCTCGCCCATCCCTGGCTCAACAACCTGGCGGAGAAAGCCAAACGCTGTAACCGACGCCTTAAGTCCCAGATCTTGCTTAAGAAATACCTCATGAAGAGGCGCTGGAAGAAAAACTTCATTGCTGGCAGCGCTGCCAACCGCTTCAAGAAGATCAGCAGCTCGGGGGCACTGATGGCTCTGGGGGTCTGANOV18p, SNP13375543 ofSEQ ID NO: 242595 aaMW at 64459.8kDCG51448-01, ProteinSNP Pos: 575SNP Change: Val to GlySequenceMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSNNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLMNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAGSAANRFKKISSSGALMALGV

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 18B.

TABLE 18BComparison of the NOV18 protein sequences.NOV18a ------------------------------------------------------------NOV18b -----MATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKNOV18c ------------------------------------------------------------NOV18d TKLPTMATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKNOV18e -----MATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKNOV18f -----MATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKNOV18g -----MATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKNOV18a -------------------MPKPLPQRKG-MVPWPNPQLAALPQQTATPETSVKKPKAEQNOV18b APASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQNOV18c ------------------------------------------------------------NOV18d APASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQNOV18e APASEKGDGThAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQNOV18f APASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQNOV18g APASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQNOV18a GASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTNOV18b GASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTNOV18c ------------------------------------------------------------NOV18d GASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTNOV18e GASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTNOV18f GASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTNOV18g GASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTNOV18a FEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSNOV18b FEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAXMQGDTSRGIEFQAVPSNOV18c ------------------------------------------------------------NOV18d FEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSNOV18e FEGVPMTHSPTDPRPAKAEEGKNThAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSNOV18f FEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSNOV18g FEGVPMTHSPTDPRSAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSNOV18a EKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKNOV18b EKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKNOV18c ----------------------------------------------TKLMNSKEALGGGKNOV18d EKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKNOV18e EKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKNOV18f EKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKNOV18g EKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKNOV18a FGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAPJETPHEINOV18b FGAVCTCMEKATGLKIAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEINOV18c FGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEINOV18d FGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEINOV18e FGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEINOV18f FGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEINOV18g FGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEINOV18a VLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNOV18b VLFMEIE-GGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNOV18c VLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNOV18d VLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNOV18e VLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNOV18f VLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNOV18g VLFMEIE-GGELFERIVDEDYHLTEVDTMVFVRQICDGILLMHKMRVLHLDLKPENILCVNOV18a NTTGHLVKIIDFGLARRYN-PNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMNOV18b NTTGHLVKIIDFGLARRYHNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMNOV18c NTTGHLVKIIDFGLARRYN-PNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMNOV18d NTTGHLVKIIDFGLARRYN-PNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMNOV18e NTTGHLVKIIDFGLARRYN-PNEKLKVNFGTPEFLSPEAVNYDQISDKTDMWSMGVITYMNOV18f NTTGHLVKIIDFGLARRYN-PNEKLKVNFGTPEFLSPEAVNYDQISDKTDMWSMGVITYMNOV18g NTTGHLVKIIDFGLARRYN-PNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMNOV18a LLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARNNAAQCNOV18b LLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQ-ARNNAAQCNOV18c LLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCNOV18d LLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCNOV18e LLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARNNAAQCNOV18f LLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARNNAAQCNOV18g LLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCNOV18a LAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALNOV18b LAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALNOV18c LAHPWLVDG---------------------------------------------------NOV18d LAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALNOV18e LAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALNOV18f LAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALNOV18g LAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALNOV18a GV---NOV18b GV---NOV18c -----NOV18d GVVDGNOV18e GV---NOV18f GV---NOV18g GV---NOV18a (SEQ ID NO: 212)NOV18b (SEQ ID NO: 214)NOV18c (SEQ ID NO: 216)NOV18d (SEQ ID NO: 218)NOV18e (SEQ ID NO: 220)NOV18f (SEQ ID NO: 222)NOV18g (SEQ ID NO: 224)

Further analysis of the NOV18a protein yielded the following properties shown in Table 18C.

TABLE 18CProtein Sequence Properties NOV18aSignalP analysis: No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 9; pos.chg 3; neg.chg 0H-region: length 20; peak value 1.84PSG score: −2.56GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −10.69possible cleavage site: between 29 and 30>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 1.48 (at 393)ALOM score: 1.48 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):14.68Hyd Moment(95):9.57G content:1D/E content:1S/T content:2Score: —2.37Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 18 QRK|GMNUCDISC: discrimination of nuclear localization signalspat4: KKPK (4) at 34pat7: nonebipartite: RRLKSQILLKKYLMKRR at 477content of basic residues: 12.9%NLS Score: 0.27KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: foundRIVDEDYHL at 295VAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 55.5COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):69.6%: nuclear17.4%: mitochondrial13.0%: cytoplasmic>> prediction for CG51448-05 is nuc (k = 23)

A search of the NOV18a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18D.

TABLE 18DGeneseq Results for NOV18aNOV18aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE22849Human cardiac myosin light20 . . . 521502/502 (100%)0.0chain kinase (cMLCK) mutant,95 . . . 596502/502 (100%)G89D - Homo sapiens, 596 aa.[WO200224889-A2, 28-MAR-2002]AAE22847Human cardiac myosin light20 . . . 521502/502 (100%)0.0chain kinase (cMLCK) mutant,95 . . . 596502/502 (100%)A87V - Homo sapiens, 596 aa.[WO200224889-A2, 28-MAR-2002]AAE22723Human cardiac myosin light20 . . . 521502/502 (100%)0.0chain kinase (cMLCK) protein -95 . . . 596502/502 (100%)Homo sapiens, 596 aa.[WO200224889-A2, 28-MAR-2002]AAU03521Human protein kinase #21 -20 . . . 521502/502 (100%)0.0Homo sapiens, 612 aa.111 . . . 612 502/502 (100%)[WO200138503-A2, 31-MAY-2001]AAE16340Human POLY4 protein - Homo20 . . . 521501/502 (99%)0.0sapiens, 596 aa. [WO200185767-95 . . . 596501/502 (99%)A2, 15-NOV-2001]

In a BLAST search of public sequence databases, the NOV18a protein was found to have homology to the proteins shown in the BLASTP data in Table 18E.

TABLE 18EPublic BLASTP Results for NOV18aNOV18aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAC88318Sequence 7 from Patent20 . . . 521502/502 (100%)0.0WO0164905 - Homo sapiens95 . . . 596502/502 (100%)(Human), 596 aa.Q9H1R3Myosin light chain kinase 2,20 . . . 521502/502 (100%)0.0skeletal/cardiac muscle (EC94 . . . 595502/502 (100%)2.7.1.117) (MLCK2) - Homosapiens (Human), 595 aa.A35021myosin-light-chain kinase (EC20 . . . 521462/504 (91%)0.02.7.1.117), skeletal muscle -105 . . . 608 479/504 (94%)rabbit, 608 aa.P07313Myosin light chain kinase 2,20 . . . 521462/504 (91%)0.0skeletal/cardiac muscle (EC104 . . . 607 479/504 (94%)2.7.1.117) (MLCK2) -Oryctolagus cuniculus (Rabbit),607 aa.A28798myosin-light-chain kinase (EC20 . . . 521429/502 (85%)0.02.7.1.117), skeletal muscle - rat,112 . . . 610 453/502 (89%)610 aa.

PFam analysis inidcates that the NOV18a protein contains the domains shown in the Table 18F.

TABLE 18FDomain Analysis of NOV18aIdentities/SimilaritiesNOV18a Matchfor thePfam DomainRegionMatched RegionExpect Valuepkinase210 . . . 46593/297 (31%)9.3e-76198/297 (67%)

Example 19

The NOV19 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 19A.

TABLE 19ANOV19 Sequence AnalysisNOV19a, CG51752-02SEQ ID NO: 2431042 bpDNA SequenceORF Start: ATG at 207ORF Stop: TGA at 1008AGAGTGCTCTAAACCCAGCTCGGCCTTTGCTGTATTAGACAGAAGCACCTCATTCATATCCCTGGGGCCCCTGATGGTGCAGTGGTCTGGCTGTGGTCTGCACACCAGCTATTCTGTTTTGTTTTGTTTTGTTTTTTCCTACCTTTTTCCAATCCTCACACCTTCTGATCAACAGCCCCAGTAGGGTTTAAAGGTCCTAGAGCTACATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACTGATAATAAAATAGAGGCTATTCTTTCAACCGAAANOV19a, CG51752-02SEQ ID NO: 244267 aaMW at 29498.9kDProtein SequenceMGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEECSKMFPKLTKNNLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYNOV19b, CG51752-03SEQ ID NO: 245888 bpDNA SequenceORF Start: ATG at 79ORF Stop: TGA at 880TTGTTTTTTCCTACCTTTTTCCAATCCTCACACCTTCTGATCAACAGCCCCAGTAGGGTTTAAAGGTCCTAGAGCTACATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGCGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATAACCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCCGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACTGATTATAANOV19b, CG51752-03SEQ ID NO: 246267 aaMW at 29468.8kDProtein SequenceMGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQThAADKNSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIITWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLPLCPLSHVLFRAILYNOV19c, 175069825SEQ ID NO:247816 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCGCTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGCGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATAAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACCTCGAGNOV19c, 175069825SEQ ID NO: 248272 aaMW at 29928.3kDProtein SequenceGSTMGFRFLGTANSAAFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19d, 175069842SEQ ID NO: 249816 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCGCTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGCGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGCGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATAAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACCTCGAGNOV19d, 175069842SEQ ID NO: 250272 aaMW at 29981.3kDProtein SequenceGSTMGFRFLGTANSAAFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLRAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19e, 258076315SEQ ID NO: 251729 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGCGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACCTCGAGNOV19e, 258076315SEQ ID NO: 252243 aaMW at 26802.7kDProtein SequenceGSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19f, 258076366SEQ ID NO: 253729 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACCTCGAGNOV19f, 258076366SEQ ID NO: 254243 aaMW at 26830.8kDProtein SequenceGSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19g, CG51752-04SEQ ID NO: 255852 bpDNA SequenceORF Start: ATG at 46ORF Stop: TGA at 847CTTCTGATCAACAGCCCCAGTAGGGTTTAAAGGTCCTAGAGCTACATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGGCTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCCCCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGCGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAATTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACTGATAANOV19g, CG51752-04SEQ ID NO: 256267 aaMW at 29436.8kDProtein SequenceMGFRFLGTANSATFEASLPLPLAPLWFSAPSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANNDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYNOV19h, 191887409SEQ ID NO: 257816 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACCTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACCTCGAGNOV19h, 191887409SEQ ID NO: 258272 aaMW at 29986.4kDProtein SequenceGSTMGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19i, CG51752-01SEQ ID NO: 2591078 bpDNA SequenceORF Start: ATG at 243ORF Stop: TGA at 1044TTGATCCGTGCCAAGTGGCTTTTTGTGGGCTCTGTAGAGTGCTCTAAACCCAGCTCGGCCTTTGCTGTATTAGACAGAAGCACCTCATTCATATCCCTGGGGCCCCTGATGGTGCAGTGGTCTGGCTGTGGTCTGCACACCAGCTATTCTGTTTTGTTTTGTTTTGTTTTTTTCCTACCTTTTTCCAATCCTCACACCTTCTGATCAACAGCCCCAGTAGGGTTTAAAGGTCCTAGAGCTACATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGATAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGGAGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACTGATAATAAAATAGAGGCTATTCTTTCAACCGAAANOV19i, CG51752-01SEQ ID NO: 260267 aaMW at 29412.8kDProtein SequenceMGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANNDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGDKNTPGIYTSLVNYNLWIEKQLGGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYNOV19j, CG51752-05SEQ ID NO: 261816 bpDNA SequenceORF Start: ATG at 10ORF Stop: at 811GGATCCACCATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCGCTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGCGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATAAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACCTCGAGNOV19j, CG51752-05SEQ ID NO: 262267 aaMW at 29440.8kDProtein SequenceMGFRFLGTANSAAFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANNDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKAPMVIMDWEECSKMFPKLTKNNLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFMAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYNOV19k, CG51752-06SEQ ID NO: 263729 bpDNA SequenceORF Start: at 7ORF Stop: at 724GGATCCGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACCTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACCTCGAGNOV19k, CG51752-06SEQ ID NO: 264239 aaMW at 26444.4kDProtein SequenceATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYNOV19l, CG51752-07SEQ ID NO: 265816 bpDNA SequenceORF Start: ATG at 10ORF Stop: at 811GGATCCACCATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACCTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACCTCGAGNOV19l, GG51752-07SEQ ID NO: 266267 aaMW at 29498.9kDProtein SequenceMGFRFLGThNSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYNOV19m, SNP13374584 ofSEQ ID NO: 2671042 bpCG51752-02, DNA SequenceORF Start: ATG at 207ORF Stop: TGA at 1008SNP Pos: 243SNP Change: A to GAGAGTGCTCTAAACCCAGCTCGGCCTTTGCTGTATTAGACAGAAGCACCTCATTCATATCCCTGGGGCCCCTGATGGTGCAGTGGTCTGGCTGTGGTCTGCACACCAGCTATTCTGTTTTGTTTTGTTTTGTTTTTTCCTACCTTTTTCCAATCCTCACACCTTCTGATCAACAGCCCCAGTAGGGTTTAAAGGTCCTAGAGCTACATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCGCTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGTGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACTGATAATAAAATAGAGGCTATTCTTTCAACCGAAANOV19m, SNP13374584 ofSEQ ID NO: 268267 aaMW at 29468.8kDCG51752-02, ProteinSNP Pos: 13SNP Change: Thr to AlaSequenceMGFRFLGTANSAAFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILYNOV19n, SNP13374585 ofSEQ ID NO: 2691042 bpCG51752-02, DNA SequenceORF Start: ATG at 207ORF Stop: TGA at 1008SNP Pos: 586SNP Change: T to CAGAGTGCTCTAAACCCAGCTCGGCCTTTGCTGTATTAGACAGAAGCACCTCATTCATATCCCTGGGGCCCCTGATGGTGCAGTGGTCTGGCTGTGGTCTGCACACCAGCTATTCTGTTTTGTTTTGTTTTGTTTTTTCCTACCTTTTTCCAATCCTCACACCTTCTGATCAACAGCCCCAGTAGGGTTTAAAGGTCCTAGAGCTACATGGGATTTAGGTTTCTGGGCACAGCCAATTCTGCCACTTTTGAGACTTCCCTTCCCCTTCCACTTGCCCCTCTCTGGTTCTCTGCCACCAGTCCAGAAGAACTGAGTGTCGTGCTGGGGACCAACGACTTAACTAGCCCATCCATGGAAATAAAGGAGGTCGCCAGCATCATTCTTCACAAAGACTTTAAGAGAGCCAACATGGACAATGACATTGCCTTGCTGCTGCTGGCTTCGCCCATCAAGCTCGATGACCTGAAGGTGCCCATCTGCCTCCCCACGCAGCCCGGCCCTGCCACATGGCGCGAATGCTGGGTGGCAGGTTGGGGCCAGACCAATGCTGCTGACAAAAACTCTGTGAAAACGGATCTGATGAAAGCGCCAATGGTCATCATGGACTGGGAGGAGTGTTCAAAGATGTTTCCAAAACTTACCAAAAATATGCTGTGTGCCGGATACAAGAATGAGAGCTATGATGCCTGCAAGGGTGACAGTGGGGGGCCTCTGGTCTGCACCCCAGAGCCTGGTGAGAAGTGGTACCAGGTGGGCATCATCAGCTGGGGAAAGAGCTGTGGAGAGAAGAACACCCCAGGGATATACACCTCGTTGGTGAACTACAACCTCTGGATCGAGAAAGTGACCCAGCTAGAGGGCAGGCCCTTCAATGCAGAGAAAAGGAGGACTTCTGTCAAACAGAAACCTATGGGCTCCCCAGTCTCGGGAGTCCCAGAGCCAGGCAGCCCCAGATCCTGGCTCCTGCTCTGTCCCCTGTCCCATGTGTTGTTCAGAGCTATTTTGTACTGATAATAAAATAGAGGCTATTCTTTCAACCGAAANOV19n, SNP13374585 ofSEQ ID NO: 270267 aaMW at 29470.8kDCG51752-02, ProteinSNP Pos: 127SNP Change: Val to AlaSequenceMGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASIILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGEKWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSPVSGVPEPGSPRSWLLLCPLSHVLFRAILY

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 19B.

TABLE 19BComparison of the NOV19 protein sequences.NOV19a ---MGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19b ---MGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19c GSTMGFRFLGTANSAAFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19d GSTMGFRFLGTANSAAFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19e -----------------------------GSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19f -----------------------------GSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19g ---MGFRFLGTANSATFEASLPLPLAPLWFSAPSPEELSVVLGTNDLTSPSMEIKEVASINOV19h GSTMGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19i ---MGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19j ---MGFRFLGTANSAAFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19k -------------------------------ATSPEELSVVLGTNDLTSPSMEIKEVASINOV19l ---MGFRFLGTANSATFETSLPLPLAPLWFSATSPEELSVVLGTNDLTSPSMEIKEVASINOV19a ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19b ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19c ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19d ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19e ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19f ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19g ILHKDFKRANNDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19h ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19i ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19j ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19k ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19l ILHKDFKRANMDNDIALLLLASPIKLDDLKVPICLPTQPGPATWRECWVAGWGQTNAADKNOV19a NSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19b NSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19c NSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19d NSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLRAGYKNESYDACKGDSGGPLVCTPEPGENOV19e NSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19f NSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19g NSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19h NSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19i NSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19j NSVKTDLMKAPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19k NSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19l NSVKTDLMKVPMVIMDWEECSKMFPKLTKNMLCAGYKNESYDACKGDSGGPLVCTPEPGENOV19a KWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19b KWYQVGIITWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19c KWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19d KWYQVGIISWGKSCGEKMTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19e KWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19f KWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19g KWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19h KWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19i KWYQVGIISWGKSCGDKNTPGIYTSLVNYNLWIEKVTQLGGRPFNAEKRRTSVKQKPMGSNOV19j KWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19k KWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19l KWYQVGIISWGKSCGEKNTPGIYTSLVNYNLWIEKVTQLEGRPFNAEKRRTSVKQKPMGSNOV19a PVSGVPEPGSPRSWLLLCPLSHVLFRAILY--NOV19b PVSGVPEPGSPRSWLPLCPLSHVLFRAILY--NOV19c PVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19d PVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19e PVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19f PVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19g PVSGVPEPGSPRSWLLLCPLSHVLFRAILY--NOV19h PVSGVPEPGSPRSWLLLCPLSHVLFRAILYLENOV19i PVSGVPEPGSPRSWLLLCPLSHVLFRAILY--NOV19j PVSGVPEPGSPRSWLLLCPLSHVLFRAILY--NOV19k PVSGVPEPGSPRSWLLLCPLSHVLFRAILY--NOV19l PVSGVPEPGSPRSWLLLCPLSHVLFRAILY--NOV19a (SEQ ID NO: 244)NOV19b (SEQ ID NO: 246)NOV19c (SEQ ID NO: 248)NOV19d (SEQ ID NO: 250)NOV19e (SEQ ID NO: 252)NQV19f (SEQ ID NO: 254)NOV19g (SEQ ID NO: 256)NOV19h (SEQ ID NO: 258)NOV19i (SEQ ID NO: 260)NOV19j (SEQ ID NO: 262)NOV19k (SEQ ID NO: 264)NOV19l (SEQ ID NO: 266)

Further analysis of the NOV19a protein yielded the following properties shown in Table 19C.

TABLE 19CProtein Sequence Properties NOV19aSignalP analysis: No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 4; pos.chg 1; neg.chg 0H-region: length 10; peak value 4.03PSG score: −0.38GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.06possible cleavage site: between 32 and 33>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0Number of TMS(s) for threshold 0.5: 0PERIPHERAL Likelihood = 2.38 (at 72)ALOM score: 0.05 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):8.51Hyd Moment(95):7.65G content:2D/E content:2S/T content:8Score: −4.16Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 14 FRF|LGNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 10.5%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: GFRFnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs:Bacterial regulatory proteins, gntR family signature(PS00043):*** found *** VASIILHKDFKRANMDNDIALL at 54NNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 70.6COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):43.5%: mitochondrial34.8%: cytoplasmic 8.7%: peroxisomal 4.3%: vacuolar 4.3%: nuclear 4.3%: endoplasmic reticulum>> prediction for CG51752-02 is mit (k = 23)

A search of the NOV19a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 19D.

TABLE 19DGeneseq Results for NOV19aNOV19aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU08686Human FCTR6b polypeptide1 . . . 267267/267 (100%)e-160sequence - Homo sapiens, 2671 . . . 267267/267 (100%)aa. [WO200166747-A2, 13-SEP-2001]AAU08685Human FCTR6a polypeptide1 . . . 267265/267 (99%)e-159sequence - Homo sapiens, 2671 . . . 267266/267 (99%)aa. [WO200166747-A2, 13-SEP-2001]AAU82737Amino acid sequence of novel32 . . . 267235/236 (99%)e-141human protease #36 - Homo117 . . . 352235/236 (99%)sapiens, 352 aa. [WO200200860-A2, 03-JAN-2002]AAB03160Human trypsin family serine32 . . . 267233/236 (98%)e-140protease Tespec PRO-3 - Homo117 . . . 352234/236 (98%)sapiens, 352 aa. [WO200026352-A1, 11-MAY-2000]AAU76529Human LP polypeptide #2 -32 . . . 249214/218 (98%)e-127Homo sapiens, 356 aa.117 . . . 334215/218 (98%)[WO200216578-A2, 28-FEB-2002]

In a BLAST search of public sequence databases, the NOV19a protein was found to have homology to the proteins shown in the BLASTP data in Table 19E.

TABLE 19EPublic BLASTP Results for NOV19aNOV19aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAC88680Sequence 22 from Patent1 . . . 267267/267 (100%)e-160WO0166747 - Homo sapiens1 . . . 267267/267 (100%)(Human), 267 aa.CAC88679Sequence 20 from Patent1 . . . 267265/267 (99%)e-159WO0166747 - Homo sapiens1 . . . 267266/267 (99%)(Human), 267 aa.Q9MZZ6Hypothetical 29.5 kDa protein -1 . . . 267248/267 (92%)e-146Macaca fascicularis (Crab eating1 . . . 267251/267 (93%)macaque) (Cynomolgusmonkey), 267 aa.CAD28997Sequence 3 from Patent32 . . . 249 214/218 (98%)e-127WO0216578 - Homo sapiens117 . . . 334 215/218 (98%)(Human), 356 aa.AAH497141700049K14Rik protein - Mus27 . . . 225 87/200 (43%)5e-45musculus (Mouse), 321 aa.98 . . . 297 119/200 (59%)

PFam analysis indicates that the NOV19a protein contains the domains shown in the Table 19F.

TABLE 19FDomain Analysis of NOV19aIdentities/PfamSimilaritiesExpectDomainNOV19a Match Regionfor the Matched RegionValuetrypsin5 . . . 21075/267 (28%)8.6e-34153/267 (57%)

Example 20

The NOV20 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 20A.

TABLE 20ANOV20 Sequence AnalysisNOV20a, GG51914-02SEQ ID NO: 2713261 bpDNA SequenceORF Start: ATG at 92ORF Stop: TGA at 3146AGCGGGGCTCTGGGGTCTGGGGGCATTGCTCAGCGGTGCTAGGCTGGCGCGGCTTGAGCCGCCGCCGGACTGACAGCTCGGTCTGCGGACCATGGAGACCTGCGCCGGTCCACACCCGCTGCGCCTCTTCCTCTGCCGGATGCAGCTCTGTCTCGCGCTGCTTTTGGGACCCTGGCGGCCTGGGACCGCCGAGGAAGTTATCCTCCTGGATTCCAAAGCCTCCCAGGCCGAGCTGGGCTGGACTGCACTGCCAAGTAATGGGTGGGAGGAGATCAGCGGCGTGGATGAACACGACCGTCCCATCCGCACGTACCAAGTGTGCAATGTGCTGGAGCCCAACCAGGACAACTGGCTGCAGACTGGCTGGATAAGCCGTGGCCGCGGGCAGCGCATCTTCGTGGAACTGCAGTTCACACTCCGTGACTGCAGCAGCATCCCTGGCGCCGCGGGTACCTGCAAGGAGACCTTCAACGTCTACTACCTGGAAACTGAGGCCGACCTGGGCCGTGGGCGTCCCCGCCTAGGCGGCAGCCGGCCCCGCAAAATCGACACGATCGCGGCGGACGAGAGCTTCACGCAGGGCGACCTGGGTGAGCGCAAGATGAAGCTGAACACAGAGGTGCGCGAGATCGGACCGCTCAGCCGGCGGGGTTTCCACCTGGCCTTTCAGGACGTGGGCGCATGCGTGGCGCTTGTCTCGGTGCGCGTCTACTACAAGCAGTGCCGCGCCACCGTGCGGGGCCTGGCCACGTTCCCAGCCACCGCAGCCGAGAGCGCCTTCTCCACACTGGTGGAAGTGGCCGGAACGTGCGTGGCGCACTCGGAAGGGGAGCCTGGCAGCCCCCCACGCATGCACTGCGGCGCCGACGGCGAGTGGCTGGTGCCTGTGGGCCGCTGCAGCTGCAGCGCGGGATTCCAGGAGCGTGGTGACTTCTGCGAATGTCCCCCAGGGTTTTACAAGGTGTCCCCGCGGCGGCCCCTCTGCTCACCGTGCCCAGAGCACAGCCGGGCCCTGGAAAACGCCTCCACCTTCTGCGTGTGCCAGGACAGCTATGCGCGCTCACCCACCGACCCGCCCTCGGCTTCCTGCACCCGTCCGCCGTCGGCGCCGCGGGACCTGCAGTACAGCCTGAGCCGCTCGCCGCTGGTGCTGCGACTGCGCTGGCTGCCGCCGGCCGACTCGGGAGGCCGCTCGGACGTCACCTACTCGCTGCTGTGCCTGCGCTGCGGCCGCGAGGGCCCGGCGGGCGCCTGCGAGCCGTGCGGGCCGCGCGTGGCCTTCCTACCGCGCCAGGCAGGGCTGCGGGAGCGAGCCGCCACGCTGCTGCACCTGCGGCCCGGGGCGCGCTACACCGTGCGCGTGGCCGTGCTCAACGGCGTCTCGTCAGCGCCCTGGGAGGAGGATGAGATCCGCAGGGACCGAGTGGAACCCCAGAGCGTGTCCCTGTCGTGGCGGGAGCCCATCCCTGCCGGAGCCCCTGGGGCCAATGACACGGAGTACGAGATCCGATACTACGAGAAGGGTCAGAGTGAGCAGACTTACTCCATGGTGAAGACGGGGGCGCCCACAGTCACCGTCACCAACCTGAAGCCGGCTACCCGCTACGTCTTTCAGATCCGGGCCGCTTCCCCGGGGCCATCCTGGGAGGCCCAGAGTTTTAACCCCAGCATTGAAGTACAGACCCTGGGGGAGGCTGCCTCAGGGTCCAGGGACCAGAGCCCCGCCATTGTCGTCACCGTAGTGACCATCTCGGCCCTCCTCGTCCTGGGCTCCGTGATGAGTGTGCTGGCCATTTGGAGGAGGCCCTGCAGCTATGGCAAAGGAGGAGGGGATGCCCATGATGAAGAGGAGCTGTATTTCCACTTCAAAGTCCCAACACGTCGCACATTCCTGGACCCCCAGAGCTGTGGGGACCTGCTGCAGGCTGTGCATCTGTTCGCCAAGGAACTGGATGCGAAAAGCGTCACGCTGGAGAGGAGCCTTGGAGGAGGCAAGCTGGGCGCCCAGGAAGCCTTGTCCCCATCTGGAAGCCTCACCCACTCTATAGGCCCCGCCCCTACTCTGTCCACACCTCTATCCGGGCGGTTTGGGGAGCTGTGCTGTGGCTGCTTGCAGCTCCCCGGTCGCCAGGAGCTGCTCGTAGCCGTGCATATGCTGAGGGACAGCGCCTCCGACTCACAGAGGCTCGGCTTCCTGGCCGAGGCCCTCACGCTGGGCCAGTTTGACCATAGCCACATCGTGCGGCTGGAGGGCGTTGTTACCCGAGGTAGGGGAAGCACCTTGATGATTGTCACCGAGTACATGAGCCATGGGGCCCTGGACGGCTTCCTCAGGCGGCACGAGGGGCAGCTGGTGGCTGGGCAACTGATGGGGTTGCTGCCTGGGCTGGCATCAGCCATGAAGTATCTGTCAGAGATGGGCTACGTTCACCGGGGCCTGGCAGCTCGCCATGTGCTGGTCAGCAGCGACCTTGTCTGCAAGATCTCTGGCTTCGGGCGGGGCCCCCGGGACCGATCAGAGGCTGTCTACACCACTGGCCGGAGCCCAGCGCTATGGGCCGCTCCCGAGACACTTCAGTTTGGCCACTTCAGCTCTGCCAGTGACGTGTGGAGCTTCGGCATCATCATGTGGGAGGTGATGGCCTTTGGGGAGCGGCCTTACTGGGACATGTCTGGCCAAGACGTGATCAAGGCTGTGGAGGATGGCTTCCGGCTGCCACCCCCCAGGAACTGTCCTAACCTTCTGCACCGACTAATGCTCGACTGCTGGCAGAAGGACCCAGGTGAGCGGCCCAGGTTCTCCCAGATCCACAGCATCCTGAGCAAGATGGTGCAGGACCCAGAGCCCCCCAAGTGTGCCCTGACTACCTGTCCCAGGCCTCCCACCCCACTAGCGGACCGTGCCTTCTCCACCTTCCCCTCCTTTGGCTCTGTGGGCGCGTGGCTGGAGGCCCTGGACCTGTGCCGCTACAAGGACAGCTTCGCGGCTGCTGGCTATGGGAGCCTGGAGGCCGTGGCCGAGATGACTGCCCAGGACCTGGTGAGCCTAGGCATCTCTTTGGCTGAACATCGAGAGGCCCTCCTCAGCGGGATCAGCGCCCTGCAGGCACGAGTGCTCCAGCTGCAGGGCCAGGGGGTGCAGGTGTGAGTGGACCCCATTCTTCCAAGGCAGGACTCCGGTGGGGGTCCAGTCCCCCAGCCCTGCCCAAGGACCGTGGCAAGCTGCGCTCCAGCAGTGTGGGAGGGAGCGCTCTCTTCCTCNOV20a, CG51914-02SEQ ID NO: 2721018 aaMW at 110851.8kDProtein SequenceMETCAGPHPLRLFLCRNQLCLALLLGPWRPGTAEEVILLDSKASQAELGWTALPSNGWEEISGVDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGTCKETFNVYYLETEADLGRGRPRLGGSRPRKIDTIAADESFTQGDLGERKMKLNTEVREIGPLSRRGFHLAFQDVGACVALVSVRVYYKQCRATVRGLATFPATAAESAFSTLVEVAGTCVAHSEGEPGSPPRMHCGADGEWLVPVGRCSCSAGFQERGDFCECPPGFYKVSPRRPLCSPCPEHSRALENASTFCVCQDSYARSPTDPPSASCTRPPSAPRDLQYSLSRSPLVLRLRWLPPADSGGRSDVTYSLLCLRCGREGPAGACEPCGPRVAFLPRQAGLRYYEATLLHLRPGARYTVRVAVLNGVSSAPWEEDEIRRDRVEPQSVSLSWREPIPAGAPGANDTEYEIRYYEKGQSEQTYSMVKTGAPTVTVTNLKPATRYVFQIRAASPGPSWEAQSFNPSIEVQTLGEAASGSRDQSPAIVVTVVTISALLVLGSVMSVLAIWRRPCSYGKGGGDAHDEEELYFHFKVPTRRTFLDPQSCGDLLQAVHLFAKELDAKSVTLERSLGGGKLGAQEALSPSGSLTHSIGPAPTLSTPLSGRFGELCCGCLQLPGRQELLVAVHMLRDSASDSQRLGFLAEALTLGQFDHSHIVRLEGVVTRGRGSTLMIVTEYMSHGALDGFLRRHEGQLVAGQLMGLLPGLASAMKYLSEMGYVHRGLAARHVLVSSDLVCKISGFGRGPRDRSEAVYTTGRSPALWAAPETLQFGHFSSASDVWSFGIIMWEVMAFGERPYWDMSGQDVIKAVEDGFRLPPPRNCPNLLHRLMLDCWQKDPGERPRFSQIHSILSKMVQDPEPPKCALTTCPRPPTPLADRAFSTFPSFGSVGAWLEALDLCRYKDSFAAAGYGSLEAVAEMTAQDLVSLGISLAEHREALLSGISALQARVLQLQGQGVQVNOV20b, GG51914-01SEQ ID NO: 2733003 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 3001ATGGTATTGACAACTGCTATACCAGCCTGGCTTCTTAGCTGTTCCCTCCCACTCTCATCCTGGGCCCACCATGCGACACCGCCCCTCCGTCTAGTAGTTATCCTCCTGGATTCCAAAGCCTCCCAGGCCGAGCTGGGCTGGACTGCACTGCCAAGTAATGGGTGGGAGGAGATCAGCGGCGTGGATGAACACGACCGTCCCATCCGCACGTACCAAGTGTGCAATGTGCTGGAGCCCAACCAGGACAACTGGCTGCAGACTGGCTGGATAAGCCGTGGCCGCGGGCAGCGCATCTTCGTGGAACTGCAGTTCACACTCCGTGACTGCAGCAGCATCCCTGGCGCCGCGGGTACCTGCAAGGAGACCTTCAACGTCTACTACCTGGAAACTGAGGCCGACCTGGGCCGTGGGCGTCCCCGCCTAGGCGGCAGCCGGCCCCGCAAAATCGACACGATCGCGGCGGACGAGAGCTTCACGCAGGGCGACCTGGGTGAGCGCAAGATGAAGCTGAACACAGAGGTGCGCGAGATCGGACCGCTCAGCCGGCGGGGTTTCCACCTGGCCTTTCAGGACGTGGGCGCATGCGTGGCGCTTGTCTCGGTGCGCGTCTACTACAAGCAGTGCCGCGCCACCGTGCGGGGCCTGGCCACGTTCCCAGCCACCGCAGCCGAGAGCGCCTTCTCCACACTGGTGGAAGTGGCCGGAACGTGCGTGGCGCACTCGGAAGGGGAGCCTGGCAGCCCCCCACGCATGCACTGCGGCGCCGACGGCGAGTGGCTGGTGCCTGTGGGCCGCTGCAGCTGCAGCGCGGGATTCCAGGAGCGTGGTGACTTCTGCGAATGTCCCCCAGGGTTTTACAAGGTGTCCCCGCGGCGGCCCCTCTGCTCACCGTGCCCAGAGCACAGCCGGGCCCTGGAAAACGCCTCCACCTTCTGCGTGTGCCAGGACAGCTATGCGCGCTCACCCACCGACCCGCCCTCGGCTTCCTGCACCCGTCCGCCGTCGGCGCCGCGGGACCTGCAGTACAGCCTGAGCCGCTCGCCGCTGGTGCTGCGACTGCGCTGGCTGCCGCCGGCCGACTCGGGAGGCCGCTCGGACGTCACCTACTCGCTGCTGTGCCTGCGCTGCGGCCGCGAGGGCCCGGCGGGCGCCTGCGAGCCGTGCGGGCCGCGCGTGGCCTTCCTACCGCGCCAGGCAGGGCTGCGGGAGCGAGCCGCCACGCTGCTGCACCTGCGGCCCGGCGCGCGCTACACCGTGCGCGTGGCCGCGCTCAACGGCGTCTCGGGCCCGGCGGCCGCCGCGGGAACCACCTACGCGCAGGTCACCGTCTCCACCGGGCCCTCAGCGCCCTGGGAGGAGGATGAGATCCGCAGGGAACCGAGTGGAACCCCAGAGCGTGTCCCTGTCGTGGCGGGAGCCCATCCTGCCGGAGCCCCTGGGGCCAATGACACGGAGTACGAGATCCGATACTACGAGAAGCAGAGTGAGCAGACTTACTCCATGGTGAAGACAGGGGCGCCCACAGTCACCGTCACCAACCTGAAGCCGGCTACCCGCTACGTCTTTCAGATCCGGGCCGCTTCCCCGGGGCCATCCTGGGAGGCCCAGAGTTTTAACCCCAGCATTGAAGTACAGACCCTGGGGGAGGCTGCCTCAGGGTCCAGGGACCAGAGCCCCGCCATTGTCGTCACCGTAGTGACCATCTCGGCCCTCCTCGTCCTGGGCTCCGTGATGAGTGTGCTGGCCATTTGGAGGAGGAGGCCCTGCAGCTATGGCAAAGGAGGAGGGGATGCCCATGATGAAGAGGAGCTGTATTTCCACTGTAAAGTCCCAACACGTCGCACATTCCTGGACCCCCAGAGCTGTGGGGACCTGCTGCAGGCTGTGCATCTGTTCGCCAAGGAACTGGATGCGAAAAGCGTCACGCTGGAGAGGAGCCTTGGAGGAGGCAAGTTTGGGGAGCTGTGCTGTGGCTGCTTGCAGCTCCCCGGTCGCCAGGAGCTGCTCGTAGCCGTGCACATGCTGAGGGACAGCGCCTCCGACTCACAGAGGCTCGGCTTCCTGGCCGAGGCCCTCACGCTGGGCCAGTTTGACCATAGCCACATCGTGCGGCTGGAGGGCGTTGTTACCCGAGGTAGGACCTTGATGATTGTCACCGAGTACATGAGCCATGGGGCCCTGGACGGCTTCCTCAGGCACGAGGGGCAGCTGGTGGCTGGGCAACTGATGGGGTTGCTGCCTGGGCTGGCATCAGCCATGAAGTATCTGTCAGAGATGGGCTACGTTCACCGGGGCCTGGCAGCTCGCCATGTGCTGGTCAGCAGCGACCTTGTCTGCAAGATCTCTGGCTTCGGGCGGGGCCCCCGGGACCGATCAGAGGCTGTCTACACCACTGGCCGGAGCCCAGCGCTATGGGCCGCTCCCGAGACACTTCAGTTTGGCCACTTCAGCTCTGCCAGTGACGTGTGGAGCTTCGGCATCATCATGTGGGAGGTGATGGCCTTTGGGGAGCGGCCTTACTGGGACATGTCTGGCCAAGACGTGAAGGCTGTGGAGGATGGCTTCCGGCTGCCACCCCCCAGGAACTGTCCTAACCTTCTGCACCGACTAATGCTCGACTGCTGGCAGAAGGACCCAGGTGAGCGGCCCAGGTTCTCCCAGATCCACAGCATCCTGAGCAAGATGGTGCAGGACCCAGAGCCCCCCAAGTGTGCCCTGACTACCTGTCCCAGGCCTCCCACTCCACTAGCCGACCGTGCCTTCTCCACCTTCCCCTCCTTTGGCTCTGTGGGCGCGTGGCTGGAGGCCCTGGACCTGTGCCGCTACAAGGACAGCTTCGCGGCTGCTGGCTATGGGAGCCTGGAGGCCGTGGCCGAGATGACTGCCCAGGACCTGGTGAGCCTAGGCATCTCTTTGGCTGAACATCGAGAGGCCCTCCTCAGCGGGATCAGCGCCCTGCAGGCACGAGTGCTCCAGCTGCAGGGCCAGGGGGTGCAGGTGTGANOV20b, CG51914-01SEQ ID NO: 2741000 aaMW at 108840.5kDProtein SequenceMVLTTAIPAWLLSCSLPLSSWAHHATPPLRLVVILLDSKASQAELGWTALPSNGWEEISGVDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGTCKETFNVYYLETEADLGRGRPRLGGSRPRKIDTIAADESFTQGDLGERKMKLNTEVREIGPLSRRGFHLAFQDVGACVALVSVRVYYKQCRATVRGLATFPATAAESAFSTLVEVAGTCVAHSEGEPGSPPRMHCGADGEWLVPVGRCSCSAGFQERGDFCECPPGFYKVSPRRPLCSPCPEHSRALENASTFCVCQDSYARSPTDPPSASCTRPPSAPRDLQYSLSRSPLVLRLRWLPPADSGGRSDVTYSLLCLRCGREGPAGACEPCGPRVAFLPRQAGLRERAATLLHLRPGARYTVRVAALNGVSGPAAAAGTTYAQVTVSTGPSAPWEEDEIRRDRVEPQSVSLSWREPIPAGAPGANDTEYEIRYYEKQSEQTYSMVKTGAPTVTVTNLKPATRYVFQIRAASPGPSWEAQSFNPSIEVQTLGEAASGSRDQSPAIVVTVVTISALLVLGSVMSVLAIWRRRPCSYGKGGGDAHDEEELYFHCKVPTRRTFLDPQSCGDLLQAVHLFAKELDAKSVTLERSLGGGKFGELCCGCLQLPGRQELLVAVHMLRDSASDSQRLGFLAEALTLGQFDHSHIVRLEGVVTRGRTLMIVTEYMSHGALDGFLRHEGQLVAGQLMGLLPGLASANKYLSEMGYVHRGLAARHVLVSSDLVCKISGFGRGPRDRSEAVYTTGRSPALWAAPETLQFGHFSSASDVWSFGIIMWEVMAFGERPYWDMSGQDVKAVEDGFRLPPPRNCPNLLHRLMLDCWQKDPGERPRFSQIHSILSKMVQDPEPPKCALTTCPRPPTPLADRAFSTFPSFGSVGAWLEALDLCRYKDSFAAAGYGSLEAVAEMTAQDLVSLGISLABHREALLSGISALQARVLQLQGQGVQV

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 20B.

TABLE 20BComparison of the NOV20 protein sequences.NOV20a METCAGPHPLRLFLCRMQLCLALLLGPWRPGTAEEVILLDSKASQAELGWTALPSNGWEENOV20b -MVLTTAIPAWLLSC--SLPLSSWAHHATPPLRLVVILLDSKASQAELGWTALPSNGWEENOV20a ISGVDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGNOV20b ISGVDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGNOV20a TCKETFNVYYLETEADLGRGRPRLGGSRPRKIDTIAADESFTQGDLGERKMKLNTEVREINOV20b TCKETFNVYYLETEADLGRGRPRLGGSRPRKIDTIAADESFTQGDLGERKMKLNTEVREINOV20a GPLSRRGFHLAFQDVGACVALVSVRVYYKQCRATVRGLATFPATAAESAFSTLVEVAGTCNOV20b GPLSRRGFHLAFQDVGACVALVSVRVYYKQCRATVRGLATFPATAAESAFSTLVEVAGTCNOV20a VAHSEGEPGSPPRNHCGADGEWLVPVGRCSCSAGFQERGDFCECPPGFYKVSPRRPLCSPNOV20b VAHSEGEPGSPPRMHCGADGEWLVPVGRCSCSAGFQERGDFCECPPGFYKVSPRRPLCSPNOV20a CPEHSRALENASTFCVCQDSYARSPTDPPSASCTRPPSAPRDLQYSLSRSPLVLRLRWLPNOV20b CPEHSRALENASTFCVCQDSYARSPTDPPSASCTRPPSAPRDLQYSLSRSPLVLRLRWLPNOV20a PADSGGRSDVTYSLLCLRCGREGPAGACEPCGPRVAFLPRQAGLRERAATLLHLRPGARYNOV20b PADSGGRSDVTYSLLCLRCGREGPAGACEPCGPRVAFLPRQAGLRERAATLLHLRPGARYNOV20a TVRVAVLNGVS-------------------SAPWEEDEIRRDRVEPQSVSLSWREPIPAGNOV20b TVRVAALNGVSGPAAAAGTTYAQVTVSTGPSAPWEEDEIRRDRVEPQSVSLSWREPIPAGNOV20a APGANDTEYEIRYYEKGQSEQTYSMVKTGAPTVTVTNLKPATRYVFQIRAASPGPSWEAQNOV20b APGANDTEYEIRYYEK-QSEQTYSMVKTGAPTVTVTNLKPATRYVFQIRAASPGPSWEAQNOV20a SFNPSIEVQTLGEAASGSRDQSPAIVVTVVTISALLVLGSVMSVLAIWRR-PCSYGKGGGNOV20b SFNPSIEVQTLGEAASGSRDQSPAIVVTVVTISALLVLGSVMSVLAIWRRRPCSYGKGGGNOV20a DAHDEEELYFHFKVPTRRTFLDPQSCGDLLQAVHLFAKELDAKSVTLERSLGGGKLGAQENOV20b DAHDEEELYFHFKVPTRRTFLDPQSCGDLLQAVHLFAKELDAKSVTLERSLGGG------NOV20a ALSPSGSLTHSIGPAPTLSTPLSGRFGELCCGCLQLPGRQELLVAVHMLRDSASDSQRLGNOV20b ------------------------KFGELCCGCLQLPGRQELLVAVHMLRDSASDSQRLGNOV20a FLAEALTLGQFDHSHIVRLEGVVTRGRGSTLMIVTEYMSHGALDGFLRRHEGQLVAGQLMNOV20b FLAEALTLGQFDHSHIVRLEGVVTRGR--TLMIVTEYMSHGALDGFLR-HEGQLVAGQLMNOV20a GLLPGLASAMKYLSEMGYVHRGLAARHVLVSSDLVCKISGFGRGPRDRSEAVYTTGRSPANOV20b GLLPGLASAMKYLSEMGYVHRGLAARHVLVSSDLVCKISGFGRGPRDRSEAVYTTGRSPANOV20a LWAAPETLQFGHFSSASDVWSFGIIMWEVMAFGERPYWDMSGQDVIKAVEDGFRLPPPRNNOV20b LWAAPETLQFGHFSSASDVWSFGIIMWEVMAFGERPYWDMSGQD-VKAVEDGFRLPPPRNNOV20a CPNLLHRLMLDCWQKDPGERPRFSQIHSILSKMVQDPEPPKCALTTCPRPPTPLADRAFSNOV20b CPNLLHRLMLDCWQKDPGERPRFSQIHSILSKMVQDPEPPKCALTTCPRPPTPLADRAFSNOV20a TFPSFGSVGAWLEALDLCRYKDSFAAAGYGSLEAVAEMTAQDLVSLGISLAEHREALLSGNOV20b TFPSFGSVGAWLEALDLCRYWDSFAAAGYGSLEAVAEMTAQDLVSLGISLAEHREALLSGNOV20a ISALQARVLQLQGQGVQVNOV20b ISALQARVLQLQGQGVQVNOV20a (SEQ ID NO: 272)NOV20b (SEQ ID NO: 274)

Further analysis of the NOV20a protein yielded the following properties shown in Table 20C.

TABLE 20CProtein Sequence Properties NOV20aSignalP analysis: Cleavage site between residues 34 and 35PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 11; pos.chg 1; neg.chg 1H-region: length 4; peak value 0.56PSG score: −3.84GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 0.06possible cleavage site: between 33 and 34>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 3Number of TMS(s) for threshold 0.5: 1INTEGRAL Likelihood = −9.08Transmembrane 546-562PERIPHERAL Likelihood = 0.85 (at 754)ALOM score: −9.08 (number of TMSs: 1)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 553Charge difference: 3.5 C( 1.5) - N(-2.0)C > N: C-terminal side will be inside>>> membrane topology: type 1b (cytoplasmic tail 546 to 1018)MITDISC: discrimination of mitochondrial targeting seqR content:3Hyd Moment(75):5.96Hyd Moment(95):3.64G content:3D/E content:2S/T content:2Score: −5.44Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 39 WRP|GTNUCDISC: discrimination of nuclear localization signalspat4: RPRK (4) at 148pat7: nonebipartite: nonecontent of basic residues: 10.2%NLS Score: −0.22KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: foundRLFLCRMQL at 11VAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: foundLL at 556LL at 609LL at 682LL at 762LL at 884LL at 997checking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found *** LSGRFGELCCGCLQLPGRQELL at 662 LVSLGISLAEHREALLSGISAL at 983 nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 70.6COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):39.1%: nuclear21.7%: cytoplasmic17.4%: mitochondrial 8.7%: vesicles of secretory system 4.3%: vacuolar 4.3%: peroxisomal 4.3%: endoplasmic reticulum>> prediction for CG51914-02 is nuc (k = 23)

A search of the NOV20a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 20D.

TABLE 20DGeneseq Results for NOV20aNOV20aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB98843Human NEPHA - Homo1 . . . 1018984/1040 (94%)0.0sapiens, 1008 aa.1 . . . 1008984/1040 (94%)[WO200283735-A1, 24-OCT-2002]AAE19158Human kinase polypeptide1 . . . 1018973/1041 (93%)0.0(PKIN-16) - Homo sapiens,1 . . . 1009975/1041 (93%)1009 aa. [WO200208399-A2,31-JAN-2002]AAU03553Human protein kinase #53 -1 . . . 1018973/1041 (93%)0.0Homo sapiens, 1009 aa.1 . . . 1009975/1041 (93%)[WO200138503-A2, 31-MAY-2001]AAU76874Human EphA full length kinase -37 . . . 1018 948/1004 (94%)0.0Homo sapiens, 974 aa.1 . . . 974 948/1004 (94%)[WO200208253-A2, 31-JAN-2002]AAM47209Human NOV3 protein - Homo36 . . . 1018 946/1003 (94%)0.0sapiens, 1000 aa.33 . . . 1000 946/1003 (94%)[WO200174851-A2, 11-OCT-2001]

In a BLAST search of public sequence databases, the NOV20a protein was found to have homology to the proteins shown in the BLASTP data in Table 20E.

TABLE 20EPublic BLASTP Results for NOV20aNOV20aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAD23752Sequence 1 from Patent 37 . . . 1018948/1004 (94%)0.0WO0208253 - Homo sapiens 1 . . . 974948/1004 (94%)(Human), 974 aa (fragment).CAD13085Sequence 5 from Patent 36 . . . 1018946/1003 (94%)0.0WO0174851 - Homo sapiens 33 . . . 1000946/1003 (94%)(Human), 1000 aa.CAD23753Sequence 3 from Patent 37 . . . 1018947/1052 (90%)0.0WO0208253 - Homo sapiens 1 . . . 1022947/1052 (90%)(Human), 1022 aa (fragment).CAD23754Sequence 5 from Patent37 . . . 663625/647 (96%)0.0WO0208253 - Homo sapiens 1 . . . 647625/647 (96%)(Human), 647 aa (fragment).CAD23755Sequence 7 from Patent37 . . . 663624/695 (89%)0.0WO0208253 - Homo sapiens 1 . . . 695624/695 (89%)(Human), 695 aa (fragment).

PFam analysis indicates that the NOV20a protein contains the domains shown in the Table 20F.

TABLE 20FDomain Analysis of NOV20aIdentities/PfamSimilarities forExpectDomainNOV20a Match Regionthe Matched RegionValueEPH_1bd 35 . . . 211116/178 (65%) 8.8e-122159/178 (89%)fn3337 . . . 432 25/100 (25%)1.9e-05 65/100 (65%)fn3437 . . . 51723/88 (26%)7.3e-0958/88 (66%)pkinase656 . . . 910 81/298 (27%)8.3e-38176/298 (59%)SAM 941 . . . 100527/68 (40%)7.1e-1651/68 (75%)

Example 21

The NOV21 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 21A.

TABLE 21ANOV21 Sequence AnalysisNOV21a, CG51965-01SEQ ID NO: 2759087 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 9085ATGGCGCCGCCGCCGCCGCCCGTGCTGCCCGTGCTGCTGCTCCTGGCCGCCGCCGCCGCCCTGCCGGCGATGGGGCTGCGAGCGGCCGCCTGGGAGCCGCGCGTACCCGGCGGGACCCGCGCCTTCGCCCTCCGGCCCGGCTGTACCTACGCGGTGGGCGCCGCTTGCACGCCCCGGGCGCCGCGGGAGCTGCTGGACGTGGGCCGCGATGGGCGGCTGGCAGGACGTCGGCGCGTCTCGGGCGCGGGGCGCCCGCTGCCGCTGCAAGTCCGCTTGGTGGCCCGCAGTGCCCCGACGGCGCTGAGCCGCCGCCTGCGGGCGCGCACGCACCTTCCCGGCTGCGGAGCCCGTGCCCGGCTCTGCGGAACCGGTGCCCGGCTCTGCGGGGCGCTCTGCTTCCCCGTCCCCGGCGGCTGCGCGGCCGCGCAGCATTCGGCGCTCGCAGCTCCGACCACCTTACCCGCCTGCCGCTGCCCGCCGCGCCCCAGGCCCCGCTGTCCCGGCCGTCCCATCTGCCTGCCGCCGGGCGGCTCGGTCCGCCTGCGTCTGCTGTGCGCCCTGCGGCGCGCGGCTGGCGCCGTCCGGGTGGGACTGGCGCTGGAGGCCGCCACCGCGGGGACGCCCTCCGCGTCGCCATCCCCATCGCCGCCCCTGCCGCCGAACTTGCCCGAAGCCCGGGCGGGGCCGGCGCGACGGGCCCGGCGGGGCACGAGCGGCAGAGGGAGCCTGAAGTTTCCGATGCCCAACTACCAGGTGGCGTTGTTTGAGAACGAACCGGCGGGCACCCTCATCCTCCAGCTGCACGCGCACTACACCATCGAGGGCGAGGAGGAGCGCGTGAGCTATTACATGGAGGGGCTGTTCGACGAGCGCTCCCGGGGCTACTTCCGAATCGACTCTGCCACGGGCGCCGTGAGCACGGACAGCGTACTGGACCGCGAGACCAAGGAGACGCACGTCCTCAGGGTGAAAGCCGTGGACTACAGTACGCCGCCGCGCTCGGCCACCACCTACATCACTGTCTTGGTCAAAGACACCAACGACCACAGCCCGGTCTTCGAGCAGTCGGAGTACCGCGAGCGCGTGCGGGAGAACCTGGAGGTGGGCTACGAGGTGCTGACCATCCGCGCCAGCGACCGCGACTCGCCCATCAACGCCAACTTGCGTTACCGCGTGTTGGGGGGCGCGTGGGACGTCTTCCAGCTCAACGAGAGCTCTGGCGTGGTGAGCACACGGGCGGTGCTGGACCGGGAGGAGGCGGCCGAGTACCAGCTCCTGGTGGAGGCCAACGACCAGGGGCGCAATCCGGGCCCGCTCAGTGCCACGGCCACCGTGTACATCGAGGTGGAGGACGAGAACGACAACTACCCCCAGTTCAGCGAGCAGAACTACGTGGTCCAGGTGCCCGAGGACGTGGGGCTCAACACGGCTGTGCTGCGAGTGCAGGCCACGGACCGGGACCAGGGCCAGAACGCGGCCATTCACTACAGCATCCTCAGCGGGAACGTGGCCGGCCAGTTCTACCTGCACTCGCTGAGCGGGATCCTGGATGTGATCAACCCCTTGGATTTCGAGGATGTCCAGAAATACTCGCTGAGCATTAAGGCCCAGGATGGGGGCCGGCCCCCGCTCATCAATTCTTCAGGGGTGGTGTCTGTGCAGGTGCTGGATGTCAACGACAACGAGCCTATCTTTGTGAGCAGCCCCTTCCAGGCCACGGTGCTGGAGAATGTGCCCCTGGGCTACCCCGTGGTGCACATTCAGGCGGTGGACGCGGACTCTGGAGAGAACGCCCGGCTGCACTATCGCCTGGTGGACACGGCCTCCACCTTTCTGGGGGGCGGCAGCGCTGGGCCTAAGAATCCTGCCCCCACCCCTGACTTCCCCTTCCAGATCCACAACAGCTCCGGTTGGATCACAGTGTGTGCCGAGCTGGACCGCGAGGAGGTGGAGCACTACAGCTTCGGGGTGGAGGCGGTGGACCACGGCTCGCCCCCCATGAGCTCCTCCACCAGCGTGTCCATCACGGTGCTGGACGTGAATGACAACGACCCGGTGTTCACGCAGCCCACCTACGAGCTTCGTCTGAATGAGGATGCGGCCGTGGGGAGCAGCGTGCTGACCCTGCAGGCCCGCGACCGTGACGCCAACAGTGTGATTACCTACCAGCTCACAGGCGGCAACACCCGGAACCGCTTTGCACTCAGCAGCCAGAGAGGGGGCGGCCTCATCACCCTGGCGCTACCTCTGGACTACAAGCAGGAGCAGCAGTACGTGCTGGCGGTGACAGCATCCGACGGCACACGGTCGCACACTGCGCATGTCCTAATCAACGTCACTGATGCCAACACCCACAGGCCTGTCTTTCAGAGCTCCCATTACACAGTGAGTGTCAGTGAGGACAGGCCTGTGGGCACCTCCATTGCTACCCTCAGTGCCAACGATGAGGACACAGGAGAGAATGCCCGCATCACCTACGTGATTCAGGACCCCGTGCCGCAGTTCCGCATTGACCCCGACAGTGGCACCATGTACACCATGATGGAGCTGGACTATGAGAACCAGGTCGCCTACACGCTGACCATCATGGCCCAGGACAACGGCATCCCGCAGAAATCAGACACCACCACCCTAGAGATCCTCATCCTCGATGCCAATGACAATGCACCCCAGTTCCTGTGGGATTTCTACCAGGGTTCCATCTTTGAGGATGCTCCACCCTCGACCAGCATCCTCCAGGTCTCTGCCACGGACCGGGACTCAGGTCCCAATGGGCGTCTGCTGTACACCTTCCAGGGTGGGGACGACGGCGATGGGGACTTCTACATCGAGCCCACGTCCGGTGTGATTCGCACCCAGCGCCGGCTGGACCGGGAGAATGTGGCCGTGTACAACCTTTGGGCTCTGGCTGTGGATCGGGGCAGTCCCACTCCCCTTAGCGCCTCGGTAGAAATCCAGGTGACCATCTTGGACATTAATGACAATGCCCCCATGTTTGAGAAGGACGAACTGGAGCTGTTTGTTGAGGAGAACAACCCAGTGGGGTCGGTGGTGGCAAAGATTCGTGCTAACGACCCTGATGAAGGCCCTAATGCCCAGATCATGTATCAGATTGTGGAAGGGGACATGCGGCATTTCTTCCAGCTGGACCTGCTCAACGGGGACCTGCGTGCCATGGTGGAGCTGGACTTTGAGGTCCGGCGGGAGTATGTGCTGGTGGTGCAGGCCACGTCGGCTCCGCTGGTGAGCCGAGCCACGGTGCACATCCTTCTCGTGGACCAGAATGACAACCCGCCTGTGCTGCCCGACTTCCAGATCCTCTTCAACAACTATGTCACCAACAAGTCCAACAGTTTCCCCACCGGCGTGATCGGCTGCATCCCGGCCCATGACCCCGACGTGTCAGACAGCCTCAACTACACCTTCGTGCAGGGCAACGAGCTGCGCCTGTTGCTGCTGGACCCCGCCACGGGCGAACTGCAGCTCAGCCGCGACCTGGACAACAACCGGCCGCTGGAGGCGCTCATGGAGGTGTCTGTGTCTGCAGATGGCATCCACAGCGTCACGGCCTTCTGCACCCTGCGTGTCACCATCATCACGGACGACATGCTGACCAACAGCATCACTGTCCGCCTGGAGAACATGTCCCAGGAGAAGTTCCTGTCCCCGCTGCTGGCCCTCTTCGTGGAGGGGGTGGCCGCCGTGCTGTCCACCACCAAGGACGACGTCTTCGTCTTCAACGTCCAGAACGACACCGACGTCAGCTCCAACATCCTGAACGTGACCTTCTCGGCGCTGCTGCCTGGCGGCGTCCGCGGCCAGTTCTTCCCGTCGGAGGACCTGCAGGAGCAGATCTACCTGAATCGGACGCTGCTGACCACCATCTCCACGCAGCGCGTGCTGCCCTTCGACGACGACATCTGCCTGCGCGAGCCCTGCGAGAACTACATGAAGTGCGTGTCCGTTCTGCGATTCGACAGCTCCGCGCCCTTCCTCAGCTCCACCACCGTGCTCTTCCGGCCCATCCACCCCATCAACGGCCTGCGCTGCCGCTGCCCGCCCGGCTTCACCGGCGACTACTGCGAGACGGAGATCGACCTCTGCTACTCCGACCCGTGCGGCGCCAACGGCCGCTGCCGCAGCCGCGAGGGCGGCTACACCTGCGAGTGCTTCGAGGACTTCACTGGAGAGCACTGTGAGGTGGATGCCCGCTCAGGCCGCTGTGCCAACGGGGTGTGCAAGAACGGGGGCACCTGCGTGAACCTGCTCATCGGCGGCTTCCACTGCGTGTGTCCTCCTGGCGAGTATGAGAGGCCCTACTGTGAGGTGACCACCAGGAGCTTCCCGCCCCAGTCCTTCGTCACCTTCCGGGGCCTGAGACAGCGCTTCCACTTCACCATCTCCCTCACGTTTGCCACTCAGGAAAGGAACGGCTTGCTTCTCTACAACGGCCGCTTCAATGAGAAGCACGACTTCATCGCCCTGGAGATCGTGGACGAGCAGGTGCAGCTCACCTTCTCTGCAGGTGCAGGCGAGACAACAACGACCGTGGCACCGAAGGTTCCCAGTGGTGTGAGTGACGGGCGGTGGCACTCTGTGCAGGTGCAGTACTACAACAAGGTAAGATGGGCCCCACCACTTCCCCCTGGCCCCCAGCCCAATATTGGCCACCTGGGCCTGCCCCATGGGCCGTCCGGGGAAAAGATGGCCGTGGTGACAGTGGATGATTGTGACACAACCATGGCTGTGCGCTTTGGAAAGGACATCGGGAACTACAGCTGCGCTGCCCAGGGCACTCAGACCGGCTCCAAGAAGTCCCTGGATCTGACCGGCCCTCTACTCCTGGGGGGTGTCCCCAACCTGCCAGAAGACTTCCCAGTGCACAACCGGCAGTTCGTGGGCTGCATGCGGAACCTGTCAGTCGACGGCAAAAATGTGGACATGGCCGGATTCATCGCCAACAATGGCACCCGGGAAGGCTGCGCTGCTCGGAGGAACTTCTGCGATGGGAGGCGGTGTCAGAATGGAGGCACCTGTGTCAACAGGTGGAATATGTATCTGTGTGAGTGTCCACTCCGATTCGGCGGGAAGAACTGTGAGCAAGCCATGCCTCACCCCCAGCTCTTCAGCGGTGAGAGCGTCGTGTCCTGGAGTGACCTGAACATCATCATCTCTGTGCCCTGGTACCTGGGGCTCATGTTCCGGACCCGGAAGGAGGACAGCGTTCTGATGGAGGCCACCAGTGGTGGGCCCACCAGCTTTCGCCTCCAGATCCTGAACAACTACCTCCAGTTTGAGGTGTCCCACGGCCCCTCCGATGTGGAGTCCGTGATGCTGTCCGGGTTGCGGGTGACCGACGGGGAGTGGCACCACCTGCTGATCGAGCTGAAGAATGTTAAGGAGGACAGTGAGATGAAGCACCTGGTCACCATGACCTTGGACTATGGGATGGACCAGAACAAGGCAGATATCGGGGGCATGCTTCCCGGGCTGACGGTAAGGAGCGTGGTGGTCGGAGGCGCCTCTGAAGACAAGGTCTCCGTGCGCCGTGGATTCCGAGGCTGCATGCAGGGAGTGAGGATGGGGGGGACGCCCACCAACGTCGCCACCCTGAACATGAACAACGCACTCAAGGTCAGGGTGAAGGACGGCTGTGATGTGGACGACCCCTGTACCTCGAGCCCCTGTCCCCCCAATAGCCGCTGCCACGACGCCTGGGAGGACTACAGCTGCGTCTGTGACAAAGGGTACCTTGGAATAAACTGTGTGGATGCCTGTCACCTGAACCCCTGCGAGAACATGGGGGCCTGCGTGCGCTCCCCCGGCTCCCCGCAGGGCTACGTGTGCGAGTGTGGGCCCAGTCACTACGGGCCGTACTGTGAGAACAAACTCGACCTTCCGTGCCCCAGAGGCTGGTGGGGGAACCCCGTCTGTGGACCCTGCCACTGTGCCGTCAGCAAAGGCTTTGATCCCGACTGTAATAAGACCAACGGCCAGTGCCAATGCAAGGAGAATTACTACAAGCTCCTAGCCCAGGACACCTGTCTGCCCTGCGACTGCTTCCCCCATGGCTCCCACAGCCGCACTTGCGACATGGCCACCGGGCAGTGTGCCTGCAAGCCCGGCGTCATCGGCCGCCAGTGCAACCGCTGCGACAACCCGTTTGCCGAGGTCACCACGCTCGGCTGTGAAGTGATCTACAATGGCTGTCCCAAAGCATTTGAGGCCGGCATCTGGTGGCCACAGACCAAGTTCGGGCAGCCGGCTGCGGTGCCATGCCCTAAGGGATCCGTTGGAAATGCGGTCCGACACTGCAGCGGGGAGAAGGGCTGGCTGCCCCCAGAGCTCTTTAACTGTACCACCATCTCCTTCGTGGACCTCAGGGCCATGAATGAGAAGCTGAGCCGCAATGAGACGCAGGTGGACGGCGCCAGGGCCCTGCAGCTGGTGAGGGCGCTGCGCAGTGCTACACAGCACACGGGCACGCTCTTTGGCAATGACGTGCGCACGGCCTACCAGCTGCTGGGCCACGTCCTTCAGCACGAGAGCTGGCAGCAGGGCTTCGACCTGGCAGCCACGCAGGACGCCGACTTTCACGAGGACGTCATCCACTCGGGCAGCGCCCTCCTGGCCCCAGCCACCAGGGCGGCGTGGGAGCAGATCCAGCGGAGCGAGGGCGGCACGGCACAGCTGCTCCGGCGCCTCGAGGGCTACTTCAGCAACGTGGCACGCAACGTGCGGCGGACGTACCTGCGGCCCTTCGTCATCGTCACCGCCAACATGGTTCTTGCTGTCGACATCTTTGACAAGTTCAACTTTACGGGAGCCAGGGTCCCGCGATTCGACACCATCCATGAAGAGTTCCCCAGGGAGCTGGAGTCCTCCGTCTCCTTCCCAGCCGACTTCTTCAGACCACCTGAAGAAAAAGAAGGCCCCCTGCTGAGGCCGGCTGGCCGGAGGACCACCCCGCAGACCACGCGCCCGGGGCCTGGCACCGAGAGGGAGGCCCCGATCAGCAGGCGGAGGCGACACCCTGATGACGCTGGCCAGTTCGCCGTCGCTCTGGTCATCATTTACCGCACCCTGGGGCAGCTCCTGCCCGAGCGCTACGACCCCGACCGTCGCAGCCTCCGGTTGCCTCACCGGCCCATCATTAATACCCCGATGGTGAGCACGCTGGTGTACAGCGAGGGGGCTCCGCTCCCGAGACCCCTGGAGAGGCCCGTCCTGGTGGAGTTCGCCCTGCTGGAGGTGGAGGAGCGAACCAAGCCTGTCTGCGTGTTCTGGAACCACTCCCTGGCCGTTGGTGGGACGGGAGGGTGGTCTGCCCGGGGCTGCGAGCTCCTGTCCAGGAACCGGACACATGTCGCCTGCCAGTGCAGCCACACAGCCAGCTTTGCGGTGCTCATGGATATCTCCAGGCGTGAGAACGGGGAGGTCCTGCCTCTGAAGATTGTCACCTATGCCGCTGTGTCCTTGTCACTGGCAGCCCTGCTGGTGGCCTTCGTCCTCCTGAGCCTGGTCCGCATGCTGCGCTCCAACCTGCACAGCATTCACAAGCACCTCGCCGTGGCGCTCTTCCTCTCTCAGCTGGTGTTCGTGATTGGGATCAACCAGACGGAAAACCCGTTTCTGTGCACAGTGGTTGCCATCCTCCTCCACTACATCTACATGAGCACCTTTGCCTGGACCCTCGTGGAGAGCCTGCATGTCTACCGCATGCTGACCGAGGTGCGCAACATCGACACGGGGCCCATGCGGTTCTACTACGTCGTGGGCTGGGGCATCCCGGCCATTGTCACAGGACTGGCGGTCGGCCTGGACCCCCAGGGCTACGGGAACCCCGACTTCTGCTGGCTGTCGCTTCAAGACACCCTGATTTGGAGCTTTGCGGGGCCCATCGGAGCTGTTATAATCATCAACACAGTCACTTCTGTCCTATCTGCAAAGGTTTCCTGCCAAAGAAAGCACCATTATTATGGGAAAAAAGGGATCGTCTCCCTGCTGAGGACCGCATTCCTCCTGCTGCTGCTCATCAGCGCCACCTGGCTGCTGGGGCTGCTGGCTGTGAACCGCGATGCACTGAGCTTTCACTACCTCTTCGCCATCTTCAGCGGCTTACAGGGCCCCTTCGTCCTCCTTTTCCACTGCGTGCTCAACCAGGAGGTCCGGAAGCACCTGAAGGGCGTGCTCGGCGGGAGGAAGCTGCACCTGGAGGACTCCGCCACCACCAGGGCCACCCTGCTGACGCGCTCCCTCAACTGCAACACCACCTTCGGTGACGGGCCTGACATGCTGCGCACAGACTTGGGCGAGTCCACCGCCTCGCTGGACAGCATCGTCAGGGATGAAGGGATCCAGAAGCTCGGCGTGTCCTCTGGGCTGGTGAGGGGCAGCCACGGAGAGCCAGACGCGTCCCTCATGCCCAGGAGCTGCAAGGATCCCCCTGGCCACGATTCCGACTCAGATAGCGAGCTGTCCCTGGATGAGCAGAGCAGCTCTTACGCCTCCTCACACTCGTCAGACAGCGAGGACGATGGGGTGGGAGCTGAGGAAAAATGGGACCCGGCCAGGGGCGCCGTCCACAGCACCCCCAAAGGGGACGCTGTGGCCAACCACGTTCCGGCCGGCTGGCCCGACCAGAGCCTGGCTGAGAGTGACAGTGAGGACCCCAGCGGCAAGCCCCGCCTGAAGGTGGAGACCAAGGTCAGCGTGGAGCTGCACCGCGAGGAGCAGGGCAGTCACCGTGGAGAGTACCCCCCGGACCAGGAGAGCGGGGGGCGCAGCCAGGCTTGCTAGCAGCCAGCCCCCAGAGCAGAGGAGCATCTTGAAAAATAAGTCACCTACCCGCCGCCGCTGACGCTGACGGAGCAGACGCTGAAGGGCCGGCTCCGGGAGAAGCTGGCCGACTGTGAGCAGAGCCCCACATCCTCGCGCACGTCTTCCCTGGGCTCTGGCGGCCCCGACTGCGCCATCACAGTCAAGAGCCCTGGGAGGGAGCCGGGGCGTGACCACCTCAACGGGGTGGCCATGAATGTGCGCACTGGAGCGCCCAGGCCGATGGCTCCGACTCTGAGAAACCGTGANOV21a, GG51965-01SEQ ID NO: 2763028 aaMW at 330865.9kDProtein SequenceMAPPPPPVLPVLLLLAAAAALPAMGLRAAAWEPRVPGGTRAFALRPGCTYAVGAACTPRAPRELLDVGRDGRLAGRRRVSGAGRPLPLQVRLVARSAPTALSRRLRARTHLPGCGARARLCGTGARLCGALCFPVPGGCAAAQHSALAAPTTLPACRCPPRPRPRCPGRPICLPPGGSVRLRLLCALRRAAGAVRVGLALEAATAGTPSASPSPSPPLPPNLPEARAGPARRARRGTSGRGSLKFPMPNYQVALFENEPAGTLILQLHAHYTIEGEEERVSYYMEGLFDERSRGYFRIDSATGAVSTDSVLDRETKETHVLRVKAVDYSTPPRSATTYITVLVKDTNDHSPVFEQSEYRERVRENLEVGYEVLTIRASDRDSPINANLRYRVLGGAWDVFQLNESSGVVSTRAVLDREEAAEYQLLVEANDQGRNPGPLSATATVYIEVEDENDNYPQFSEQNYVVQVPEDVGLNTAVLRVQATDRDQGQNAAIHYSILSGNVAGQFYLHSLSGILDVINPLDFEDVQKYSLSIKAQDGGRPPLINSSGVVSVQVLDVNDNEPIFVSSPFQATVLENVPLGYPVVHIQAVDADSGENARLHYRLVDTASTFLGGGSAGPKNPAPTPDFPFQIHNSSGWITVCAELDREEVEHYSFGVEAVDHGSPPMSSSTSVSITVLDVNDNDPVFTQPTYELRLNBDAAVGSSVLTLQARDRDANSVITYQLTGGNTRNRFALSSQRGGGLITLALPLDYKQEQQYVLAVTASDGTRSHTAHVLINVTDANTHRPVFQSSHYTVSVSEDRPVGTSIATLSANDEDTGENARITYVIQDPVPQFRIDPDSGTMYTMMELDYENQVAYTLTIMAQDNGIPQKSDTTTLEILILDANDNAPQFLWDFYQGSIFEDAPPSTSILQVSATDRDSGPNGRLLYTFQGGDDGDGDFYIEPTSGVIRTQRRLDRENVAVYNLWALAVDRGSPTPLSASVEIQVTILDINDNAPMFEKDELELFVEENNPVGSVVAKIRANDPDEGPNAQIMYQIVEGDMRHFFQLDLLNGDLRAMVELDFEVRREYVLVVQATSAPLVSRATVHILLVDQNDNPPVLPDFOILFNNYVTNKSNSFPTGVIGCIPAHDPDVSDSLNYTFVQGNELRLLLLDPATGELQLSRDLDNNRPLEALMEVSVSADGIHSVTAFCTLRVTIITDDMLTNSITVRLENMSQEKFLSPLLALFVEGVAAVLSTTKDDVFVFNVQNDTDVSSNILNVTFSALLPGGVRGQFFPSEDLQEQIYLNRTLLTTISTQRVLPFDDNICLREPCENYMKCVSVLRFDSSAPFLSSTTVLFRPIHPINGLRCRCPPGFTGDYCETEIDLCYSDPCGANGRCRSREGGYTCECFEDFTGEHCEVDARSGRCANGVCKNGGTCVNLLIGGFHCVCPPGEYERPYCEVTTRSFPPQSFVTFRGLRQRFHFTISLTFATQERNGLLLYNGRFNEKHDFIALEIVDEQVQLTFSAGAGETTTTVAPKVPSGVSDGRWHSVQVQYYNKVRWAPPLPPGPQPNIGHLGLPHGPSGEKMAVVTVDDCDTTMAVRFGKDIGNYSCAAQGTQTGSKKSLDLTGPLLLGGVPNLPEDFPVNHRQFVGCMRNLSVDGKNVDMAGFIANNGTREGCAARRNFCDGRRCQNGGTCVNRWNMYLCECPLRFGGKNCEQAMPHPQLFSGESVVSWSDLNIIISVPWYLGLMFRTRKEDSVLMEATSGGPTSFRLQILNNYLQFEVSHGPSDVESVMLSGLRVTDGEWHHLLIELKNVKEDSEMKHLVTMTLDYGMDQNKADIGGMLPGLTVRSVVVGGASEDKVSVRRGFRGCMQGVRMGGTPTNVATLNMNNALKVRVKDGCDVDDPCTSSPCPPNSRCHDAWEDYSCVCDKGYLGIMCVDACHLNPCENMGACVRSPGSPQGYVCECGPSHYGPYCENKLDLPCPRGWWGNPVCGPCHCAVSKGFDPDCNKTNGQCQCKENYYKLLAQDTCLPCDCFPHGSHSRTCDMATGQCACKPGVIGRQCNRCDNPFAEVTTLGCEVIYNGCPKAPEAGIWWPQTKFGQPAAVPCPKGSVGNAVRHCSGEKGWLPPELFNCTTISFVDLRAMNEKLSRNETQVDGARALQLVRALRSATQHTGTLFGNDVRTAYQLLGHVLQHESWQQGFDLAATQDADFHEDVIHSGSALLAPATRAAWEQIQRSEGGTAQLLRPLEGYFSNVARNVRRTYLRPFVIVTANMVLAVDIFDKFNFTGARVPRFDTIHEEFPRELESSVSFPADFFRPPEEKEGPLLRPAGRRTTPQTTRPGPGTEREAPISRRRRHPDDAGQFAVALVIIYRTLGQLLPERYDPDRRSLRLPHRPIINTPMVSTLVYSEGAPLPRPLERPVLVEFALLEVEERTKPVCVFWNHSLAVGGTGGWSARGCELLSRNRTHVACQCSHTASFAVLMDISRRENGEVLPLKIVTYAAVSLSLAALLVAFVLLSLVRMLRSNLHSIHKHLAVALFLSQLVFVIGINQTENPFLCTVVAILLHYIYMSTFAWTLVESLHVYRMLTEVRNIDTGPMRFYYVVGWGIPAIVTGLAVGLDPQGYGNPDFCWLSLQDTLIWSFAGPIGAVIIINTVTSVLSAKVSCQRKHHYYGKKGIVSLLRTAFLLLLLISATWLLGLLAVNRDALSFHYLFAIFSGLQGPFVLLFHCVLNQEVRKHLKGVLGGRKLHLEDSATTRATLLTRSLNCNTTFGDGPDMLRTDLGESTASLDSIVRDEGIQKLGVSSGLVRGSHGEPDASLMPRSCKDPPGHDSDSDSELSLDEQSSSYASSHSSDSEDDGVGAEEKWDPARGAVHSTPKGDAVANHVPAGWPDQSLAESDSEDPSGKPRLKVETKVSVELHREEQGSHRGEYPPDQESGGAARLASSQPPEQRSILKNKVTYPPPLTLTEQTLKGRLREKLADCEQSPTSSRTSSLGSGGPDCAITVKSPGREPGRDHLNGVAMNVRTGSAQADGSDSEKPNOV21b, 258076370SEQ ID NO: 2771263 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceCTCAAGCTTGAAGTGATCTACAATGGCTGTCCCAAAGCATTTGAGGCCGGCATCTGGTGGCCACAGACCAAGTTCGGGCAGCCGGCTGCGGTGCCATGCCCTAAGGGATCCGTTGGAAATGCGGTCCGACACTGCAGCGGGGAGAAGGGCTGGCTGCCCCCAGAGCTCTTTAACTGTACCACCATCTCCTTCGTGGACCTCAGGGCCATGAATGAGAAGCTGAGCCGCAATGAGACGCAGGTGGACGGCGCCAGGGCCCTGCAGCTGGTGAGGGCGCTGCGCAGTGCTACACAGCACACGGGCACGCTCTTTGGCAATGACGTGCGCACGGCCTACCAGCTGCTGGGCCACGTCCTTCAGCACGAGAGCTGGCAGCAGGGCTTCGACCTGGCAGCCACGCAGGACGCCGACTTTCACGAGGACGTCATCCACTCGGGCAGCGCCCTCCTGGCCCCAGCCACCAGGGCGGCGTGGGAGCAGATCCAGCGGAGCGAGGGCGGCACGGCACAGCTGCTCCGGCGCCTCGAGGGCTACTTCAGCAACGTGGCACGCAACGTGCGGCGGACGTACCTGCGGCCCTTCGTCATCGTCACCGCCAACATGATTCTTGCTGTCGACATCTTTGACAAGTTCAACTTTACGGGAGCCAGGGTCCCGCGATTCGACACCATCCATGAAGAGTTCCCCAGGGAGCTGGAGTCCTCCGTCTCCTTCCCAGCCGACTTCTTCAGACCACCTGAAGAAAAAGAAGGCCCCCTGCTGAGGCCGGCTGGCCGGAGGACCACCCCGCAGACCACGCGCCCGGGGCCTGGCACCGAGAGGGAGGCCCCGATCAGCAGGCGGAGGCGACACCCTGATGACGCTGGCCAGTTCGCCGTCGCTCTGGTCATCATTTACCGCACCCTGGGGCAGCTCCTGCCCGAGCGCTACGACCCCGACCGTCGCAGCCTCCGGTTGCCTCACCGGCCCATCATTAATACCCCGATGGTGAGCACGCTGGTGTACAGCGAGGGGGCTCCGCTCCCGAGACCCCTGGAGAGGCCCGTCCTGGTGGAGTTCGCCCTGCTGGAGGTGGAGGAGCGAACCAAGCCTGTCTGCGTGTTCTGGAACCACTCCCTGGCCGTTGGTGGGACGGGAGGGTGGTCTGCCCGGGGCTGCGAGCTCCTGTCCAGGAACCGGACACATGTCGCCTGCCAGTGCAGCCACACAGCCAGCTTTGCGGTGCTCATGGATATCTCCAGGCGTGAGAACGGGGAGAAGCTTNOV21b, 258076370SEQ ID NO: 278421 aaMW at47178.1kDProtein SequenceLKLEVIYNGCPKAFEAGIWWPQTKFGQPAAVPCPKGSVGNAVRHCSGEKGWLPPELFNCTTISFVDLRAMNEKLSRNETQVDGARALQLVRALRSATQHTGTLFGNDVRTAYQLLGHVLQHESWQQGFDLAATQDADFHEDVIHSGSALLAPATRAAWEQIQRSEGGTAQLLRRLEGYFSNVARNVRRTYLRPFVIVTANMILAVDIFDKFNFTGARVPRFDTIHEEFPRELESSVSFPADFFRPPEEKEGPLLRPAGRRTTPQTTRPGPGTEREAPISRRRRHPDDAGQFAVALVIIYRTLGQLLPERYDPDRRSLRLPNRPIINTPMVSTLVYSEGAPLPRPLERPVLVEFALLEVEERTKPVCVFWNHSLAVGGTGGWSARGCELLSRNRTHVACQCSHTASFAVLMDISRRENGEKLNOV21c, 317619862SEQ ID NO: 279750 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceCGCAAGCTTGTCCTGCCTCTGAAGATTGTCACCTATGCCGCTGTGTCCTTGTCACTGGCAGCCCTGCTGGTGGCCTTCGTCCTCCTGAGCCTGGTCCGCATGCTGCGCTCCAACCTGCACAGCATTCACAAGCACCTCGCCGTGGCGCTCTTCCTCTCTCAGCTGGTGTTCGTGATTGGGATCAACCAGACGGAAAACCCGTTTCTGTGCACAGTGGTTGCCATCCTCCTCCACTACATCTACATGAGCACCTTTGCCTGGACCCTCGTGGAGAGCCTGCATGTCTACCGCATGCTGACCGAGGTGCGCAACATCGACACGGGGCCCATGCGGTTCTACTACGTCGTGGGCTGGGGCATCCCGGCCATTGTCACAGGACTGGCGGTCGGCCTGGACCCCCAGGGCTACGGGAACCCCGACTTCTGCTGGCTGTCGCTTCAAGACACCCTGATTTGGAGCTTTGCGGGGCCCATCGGAGCTGTTATAATCATCAACACAGTCACTTCTGTCCTATCTGCAAAGGTTTCCTGCCAAAGAAAGCACCATTATTATGGGAAAAAAGGGATCGTCTCCCTGCTGAGGACCGCATTCCTCCTGCTGCTGCTCATCAGCGCCACCTGGCTGCTGGGGCTGCTGGCTGTGAACCGCGACGCACTGAGCTTTCACTACCTCTTCGCCATCTTCAGCGGCTTACAGGGCCCCTTCGTCCTCCTTTTCCACTGCGTGCTCAACCAGGAGGTCAAGCTTGCGNOV21c, 317619862SEQ ID NO: 280250 aaMW at 27799.9kDProtein SequenceRKLVLPLKIVTYAAVSLSLAALLVAFVLLSLVRMLRSNLHSIHKHLAVALFLSQLVFVIGINQTENPFLCTVVAILLHYIYMSTFAWTLVESLHVYRMLTEVRNIDTGPMRFYYVVGWGIPAIVTGLAVGLDPQGYGNPDFCWLSLQDTLIWSFAGPIGAVIIINTVTSVLSAKVSCQRKHHYYGKKGIVSLLRTAFLLLLLISATWLLGLLAVNRDALSFHYLFAIFSGLQGPFVLLFHCVLNQEVKLANOV21d, 317460050SEQ ID NO: 2812541 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTTACCAGGTGGCGTTGTTTGAGAACGAACCGGCGGGCACCCTCATCCTCCAGCTGCACGCGCACCACACCATCGAGGGCGAGGAGGAGCGCGTGAGCTATTACATGGAGGGGCTGTTCGACGAGCGCTCCCGGGGCTACTTCCGAATCGACTCTGCCGCGGGCGCCGTGAGCACGGACAGCGTACTGGACCGCGAGACCAAGGAGACGCACGTCCTCAGGGTGAAAGCCGTGGACTACAGTACGCCGCCGCGCTCGGCCACCACCTACATCACTGTCTTGGTCAAAGACACCAACGACCACAGCCCGGTCTTCGAGCAGTCGGAGTACCGCGAGCGCGTGCGGGAGAACCTGGAGGTGGGCTACGAGGTGCTGACCATCCGCGCCAGCGACCGCGACTCGCCCATCAACGCCAACTTGCGTTACCGCGTGTTGGGGGGCGCGTGGGACGTCTTCCAGCTCAACGAGAGCTCTGGCGTGGTGAGTACACGGGCGGTGCTGGACCGGGAGGAGGCGGCCGAGTACCAGCTGCTGGTGGAGGCCAACGACCAGGGGCGCAATCCGGGCCCGCTCAGTGCCACGGCCACCGTGTACATCGAGGTGGAGGACGAGAACGACAACTACCCCCAGTTCAGCGAGCAGAACTACGTGGTCCAGGTGCCCGAGGACGTGGGGCTCAACACGGCTGTGCTGCGAGTGCAGGCCACGGACCGGGACCAGGGCCAGAACGCGGCCATTCACTACAGCATCCTCAGCGGGAACGTGGCCGGCCAGTTCTACCTGCACTCGCTGAGCGGGATCCTGGATGTGATCAACCCCTTGGATTTCGAGGATGTCCAGAAATACTCGCTGAGCATTAAGGCCCAGGATGGGGGCCGGCCCCCGCTCATCAATTCTTCAGGGGTGGTGTCTGTGCAGGTGCTGGATGTCAACGACAACGAGCCTATCTTTGTGAGCAGCCCCTTCCAGGCCACGGTGCTGGAGAATGTGCCCCTGGGCTACCCCGTGGTGCACATTCAGGCGGTGGACGCGGACTCTGGAGAGAACGCCCGGCTGCACTATCGCCTGGTGGACACGGCCTCCACCTTTCTGGGGGGCGGCAGCGCTGGGCCTAAGAATCCTGCCCCCACCCCTGACTTCCCCTTCCAGATCCGCAACAGCTCCGGTTGGATCACAGTGTGTGCCGAGCTGGACCGCGAGGAGGTGGAGCACTACAGCTTCGGGGTGGAGGCGGTGGACCACGGCTGGCCCCCCATGAGCTCCTCCACCAGCGTGTCCATCACGGTGCTGGACGTGAATGACAACGACCCGGTGTTCACGCAGCCCACCTACGAGCTTCGTCTGAATGAGGATGCGGCCGTGGGGAGCAGCGTGCTGACCCTGCAGGCCCGCGACCGTGACGCCAACAGTGTGATTACCTACCAGCTCACAGGCGGCAACACCCGGAACCGCTTTGCACTCAGCAGCCAGAGAGGGGGCGGCCTCATCACCCTGGCGCTACCTCTGGACTACAAGCAGGAGCAGCAGTACGTGCTGGCGGTGACAGCATCCGACGGCACACGGTCGCACACTGCGCATGTCCTAATCAACGTCACTGATGCCAACACCCACAGGCCTGTCTTTCAGAGCTCCCATTACACAGTGAGTGTCAGTGAGGACAGGCCTGTGGGCACCTCCATTGCTACCCTCAGTGCCAACGATGAGGACACAGGAGAGAATGCCCGCATCACCTACGTGATTCAGGACCCCGTGCCGCAGTTCCGCATTGACCCCGACAGTGGCACCATGTACACCATGATGGAGCTGGACTATGAGAACCAGGTCGCCTACACGCTGACCATCATGGCCCAGGACAACGGCATCCCGCAGAAATCAGACACCACCACCCTAGAGATCCTCATCCTCGATGCCAATGACAATGCACCCCAGTTCCTGTGGGATTTCTACCAGGGTTCCATCTTTGAGGATGCTCCACCCTCGACCAGCATCCTCCAGGTCTCTGCCACGGACCGGGACTCAGGTCCCAATGGGCGTCTGCTGTACACCTTCCAGGGTGGGGACGACGGCGATGGGGACTTCTACATCGAGCCCACGTCCGGTGTGATTCGCACCCAGCGCCGGCTGGACCGGGAGAATGTGGCCGTGTACAACCTTTGGGCTCTGGCTGTGGATCGGGGCAGTCCCACTCCCCTTAGCGCCTCGGTAGAAATCCAGGTGACCATCTTGGACATTAATGACAATGCCCCCATGTTTGAGAAGGACGAACTGGAGCTGTTTGTTGAGGAGAACAACCCAGTGGGGTCGGTGGTGGCAAAGATTCGTGCTAACGACCCTGATGAAGGCCCTAATGCCCAGATCATGTATCAGATTGTGGAAGGGGACATGCGGCATTTCTTCCAGCTGGACCTGCTCAACGGGGACCTGCGTGCCATGGTGGAGCTGGACTTTGAGGTCCGGCGGGAGTATGTGCTGGTGGTGCAGGCCACGTCGGCTCCGCTGGTGAGCCGAGCCACGGTGCACATCCTTCTCGTGCTCGAGNOV21d, 317460050SEQ ID NO: 282847 aaMW at 93611.5kDProtein SequenceKLYQVALFENEPAGTLILQLHAHHTIEGEEERVSYYMEGLFDERSRGYFRIDSAAGAVSTDSVLDRETKETHVLRVKAVDYSTPPRSATTYITVLVKDTNDHSPVFEQSEYRERVRENLEVGYEVLTIRASDRDSPINANLRYRVLGGAWDVFQLNESSGVVSTRAVLDREEAAEYQLLVEANDQGRNPGPLSATATVYIEVEDENDNYPQFSEQNYVVQVPEDVGLNTAVLRVQATDRDQGQNAAIHYSILSGNVAGQFYLHSLSGILDVINPLDFEDVQKYSLSIKAQDGGRPPLINSSGVVSVQVLDVNDNEPIFVSSPFQATVLENVPLGYPVVHIQAVDADSGENARLHYRLVDTASTFLGGGSAGPKNPAPTPDFPFQIRNSSGWITVCAELDREEVEHYSFGVEAVDHGWPPMSSSTSVSITVLDVNDNDPVFTQPTYELRLNEDAAVGSSVLTLQARDRDANSVITYQLTGGNTRNRFALSSQRGGGLITLALPLDYKQEQQYVLAVTASDGTRSHTAHVLINVTDANTHRPVFQSSHYTVSVSEDRPVGTSIATLSANDEDTGENARITYVIQDPVPQFRIDPDSGTMYTMMELDYENQVAYTLTIMAQDNGIPQKSDTTTLEILILDANDNAPQFLWDFYQGSIFEDAPPSTSILQVSATDRDSGPNGRLLYTFQGGDDGDGDFYIEPTSGVIRTQRRLDRENVAVYNLWALAVDRGSPTPLSASVEIQVTILDINDNAPMFEKDELELFVEENNPVGSVVAKIRANDPDEGPNAQIMYQIVEGDMRHFFQLDLLNGDLRAMVELDFEVRREYVLVVQATSAPLVSRATVHILLVLENOV21e, SNP13382483 ofSEQ ID NO: 2839087 bpCG51965-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 9085SNP Pos: 8435SNP Change: G to CATGGCGCCGCCGCCGCCGCCCGTGCTGCCCGTGCTGCTGCTCCTGGCCGCCGCCGCCGCCCTGCCGGCGATGGGGCTGCGAGCGGCCGCCTGGGAGCCGCGCGTACCCGGCGGGACCCGCGCCTTCGCCCTCCGGCCCGGCTGTACCTACGCGGTGGGCGCCGCTTGCACGCCCCGGGCGCCGCGGGAGCTGCTGGACGTGGGCCGCGATGGGCGGCTGGCAGGACGTCGGCGCGTCTCGGGCGCGGGGCGCCCGCTGCCGCTGCAAGTCCGCTTGGTGGCCCGCAGTGCCCCGACGGCGCTGAGCCGCCGCCTGCGGGCGCGCACGCACCTTCCCGGCTGCGGAGCCCGTGCCCGGCTCTGCGGAACCGGTGCCCGGCTCTGCGGGGCGCTCTGCTTCCCCGTCCCCGGCGGCTGCGCGGCCGCGCAGCATTCGGCGCTCGCAGCTCCGACCACCTTACCCGCCTGCCGCTGCCCGCCGCGCCCCAGGCCCCGCTGTCCCGGCCGTCCCATCTGCCTGCCGCCGGGCGGCTCGGTCCGCCTGCGTCTGCTGTGCGCCCTGCGGCGCGCGGCTGGCGCCGTCCGGGTGGGACTGGCGCTGGAGGCCGCCACCGCGGGGACGCCCTCCGCGTCGCCATCCCCATCGCCGCCCCTGCCGCCGAACTTGCCCGAAGCCCGGGCGGGGCCGGCGCGACGGGCCCGGCGGGGCACGAGCGGCAGAGGGAGCCTGAAGTTTCCGATGCCCAACTACCAGGTGGCGTTGTTTGAGAACGAACCGGCGGGCACCCTCATCCTCCAGCTGCACGCGCACTACACCATCGAGGGCGAGGAGGAGCGCGTGAGCTATTACATGGAGGGGCTGTTCGACGAGCGCTCCCGGGGCTACTTCCGAATCGACTCTGCCACGGGCGCCGTGAGCACGGACAGCGTACTGGACCGCGAGACCAAGGAGACGCACGTCCTCAGGGTGAAAGCCGTGGACTACAGTACGCCGCCGCGCTCGGCCACCACCTACATCACTGTCTTGGTCAAAGACACCAACGACCACAGCCCGGTCTTCGAGCAGTCGGAGTACCGCGAGCGCGTGCGGGAGAACCTGGAGGTGGGCTACGAGGTGCTGACCATCCGCGCCAGCGACCGCGACTCGCCCATCAACGCCAACTTGCGTTACCGCGTGTTGGGGGGCGCGTGGGACGTCTTCCAGCTCAACGAGAGCTCTGGCGTGGTGAGCACACGGGCGGTGCTGGACCGGGAGGAGGCGGCCGAGTACCAGCTCCTGGTGGAGGCCAACGACCAGGGGCGCAATCCGGGCCCGCTCAGTGCCACGGCCACCGTGTACATCGAGGTGGAGGACGAGAACGACAACTACCCCCAGTTCAGCGAGCAGAACTACGTGGTCCAGGTGCCCGAGGACGTGGGGCTCAACACGGCTGTGCTGCGAGTGCAGGCCACGGACCGGGACCAGGGCCAGAACGCGGCCATTCACTACAGCATCCTCAGCGGGAACGTGGCCGGCCAGTTCTACCTGCACTCGCTGAGCGGGATCCTGGATGTGATCAACCCCTTGGATTTCGAGGATGTCCAGAAATACTCGCTGAGCATTAAGGCCCAGGATGGGGGCCGGCCCCCGCTCATCAATTCTTCAGGGGTGGTGTCTGTGCAGGTGCTGGATGTCAACGACAACGAGCCTATCTTTGTGAGCAGCCCCTTCCAGGCCACGGTGCTGGAGAATGTGCCCCTGGGCTACCCCGTGGTGCACATTCAGGCGGTGGACGCGGACTCTGGAGAGAACGCCCGGCTGCACTATCGCCTGGTGGACACGGCCTCCACCTTTCTGGGGGGCGGCAGCGCTGGGCCTAAGAATCCTGCCCCCACCCCTGACTTCCCCTTCCAGATCCACAACAGCTCCGGTTGGATCACAGTGTGTGCCGAGCTGGACCGCGAGGAGGTGGAGCACTACAGCTTCGGGGTGGAGGCGGTGGACCACGGCTCGCCCCCCATGAGCTCCTCCACCAGCGTGTCCATCACGGTGCTGGACGTGAATGACAACGACCCGGTGTTCACGCAGCCCACCTACGAGCTTCGTCTGAATGAGGATGCGGCCGTGGGGAGCAGCGTGCTGACCCTGCAGGCCCGCGACCGTGACGCCAACAGTGTGATTACCTACCAGCTCACAGGCGGCAACACCCGGAACCGCTTTGCACTCAGCAGCCAGAGAGGGGGCGGCCTCATCACCCTGGCGCTACCTCTGGACTACAAGCAGGAGCAGCAGTACGTGCTGGCGGTGACAGCATCCGACGGCACACGGTCGCACACTGCGCATGTCCTAATCAACGTCACTGATGCCAACACCCACAGGCCTGTCTTTCAGAGCTCCCATTACACAGTGAGTGTCAGTGAGGACAGGCCTGTGGGCACCTCCATTGCTACCCTCAGTGCCAACGATGAGGACACAGGAGAGAATGCCCGCATCACCTACGTGATTCAGGACCCCGTGCCGCAGTTCCGCATTGACCCCGACAGTGGCACCATGTACACCATGATGGAGCTGGACTATGAGAACCAGGTCGCCTACACGCTGACCATCATGGCCCAGGACAACGGCATCCCGCAGAAATCAGAAACCACCACCCTAGAGATCCTCATCCTCGATGCCAATGACAATGCACCCCAGTTCCTGTGGGATTTCTACCAGGGTTCCATCTTTGAGGATGCTCCACCCTCGACCAGCATCCTCCAGGTCTCTGCCACGGACCGGGACTCAGGTCCCAATGGGCGTCTGCTGTACACCTTCCAGGGTGGGGACGACGGCGATGGGGACTTCTACATCGAGCCCACGTCCGGTGTGATTCGCACCCAGCGCCGGCTGGACCGGGAGAATGTGGCCGTGTACAACCTTTGGGCTCTGGCTGTGGATCGGGGCAGTCCCACTCCCCTTAGCGCCTCGGTAGAAATCCAGGTGACCATCTTGGACATTAATGACAATGCCCCCATGTTTGAGAAGGACGAACTGGAGCTGTTTGTTGAGGAGAACAACCCAGTGGGGTCGGTGGTGGCAAAGATTCGTGCTAACGACCCTGATGAAGGCCCTAATGCCCAGATCATGTATCAGATTGTGGAAGGGGACATGCGGCATTTCTTCCAGCTGGACCTGCTCAACGGGGACCTGCGTGCCATGGTGGAGCTGGACTTTGAGGTCCGGCGGGAGTATGTGCTGGTGGTGCAGGCCACGTCGGCTCCGCTGGTGAGCCGAGCCACGGTGCACATCCTTCTCGTGGACCAGAATGACAACCCGCCTGTGCTGCCCGACTTCCAGATCCTCTTCAACAACTATGTCACCAACAAGTCCAACAGTTTCCCCACCGGCGTGATCGGCTGCATCCCGGCCCATGACCCCGACGTGTCAGACAGCCTCAACTACACCTTCGTGCAGGGCAACGAGCTGCGCCTGTTGCTGCTGGACCCCGCCACGGGCGAACTGCAGCTCAGCCGCGACCTGGACAACAACCGGCCGCTGGAGGCGCTCATGGAGGTGTCTGTGTCTGCAGATGGCATCCACAGCGTCACGGCCTTCTGCACCCTGCGTGTCACCATCATCACGGACGACATGCTGACCAACAGCATCACTGTCCGCCTGGAGAACATGTCCCAGGAGAAGTTCCTGTCCCCGCTGCTGGCCCTCTTCGTGGAGGGGGTGGCCGCCGTGCTGTCCACCACCAAGGACGACGTCTTCGTCTTCAACGTCCAGAACGACACCGACGTCAGCTCCAACATCCTGAACGTGACCTTCTCGGCGCTGCTGCCTGGCGGCGTCCGCGGCCAGTTCTTCCCGTCGGAGGACCTGCAGGAGCAGATCTACCTGAATCGGACGCTGCTGACCACCATCTCCACGCAGCGCGTGCTGCCCTTCGACGACAACATCTGCCTGCGCGAGCCCTGCGAGAACTACATGAAGTGCGTGTCCGTTCTGCGATTCGACAGCTCCGCGCCCTTCCTCAGCTCCACCACCGTGCTCTTCCGGCCCATCCACCCCATCAACGGCCTGCGCTGCCGCTGCCCGCCCGGCTTCACCGGCGACTACTGCGAGACGGAGATCGACCTCTGCTACTCCGACCCGTGCGGCGCCAACGGCCGCTGCCGCAGCCGCGAGGGCGGCTACACCTGCGAGTGCTTCGAGGACTTCACTGGAGAGCACTGTGAGGTGGATGCCCGCTCAGGCCGCTGTGCCAACGGGGTGTGCAAGAACGGGGGCACCTGCGTGAACCTGCTCATCGGCGGCTTCCACTGCGTGTGTCCTCCTGGCGAGTATGAGAGGCCCTACTGTGAGGTGACCACCAGGAGCTTCCCGCCCCAGTCCTTCGTCACCTTCCGGGGCCTGAGACAGCGCTTCCACTTCACCATCTCCCTCACGTTTGCCACTCAGGAAAGGAACGGCTTGCTTCTCTACAACGGCCGCTTCAATGAGAAGCACGACTTCATCGCCCTGGAGATCGTGGACGAGCAGGTGCAGCTCACCTTCTCTGCAGGTGCAGGCGAGACAACAACGACCGTGGCACCGAAGGTTCCCAGTGGTGTGAGTGACGGGCGGTGGCACTCTGTGCAGGTGCAGTACTACAACAAGGTAAGATGGGCCCCACCACTTCCCCCTGGCCCCCAGCCCAATATTGGCCACCTGGGCCTGCCCCATGGGCCGTCCGGGGAAAAGATGGCCGTGGTGACAGTGGATGATTGTGACACAACCATGGCTGTGCGCTTTGGAAAGGACATCGGGAACTACAGCTGCGCTGCCCAGGGCACTCAGACCGGCTCCAAGAAGTCCCTGGATCTGACCGGCCCTCTACTCCTGGGGGGTGTCCCCGACCTGCCAGAAGACTTCCCAGTGCACAACCGGCAGTTCGTGGGCTGCATGCGGAACCTGTCAGTCGACGGCAAAAATGTGGACATGGCCGGATTCATCGCCAACAATGGCACCCGGGAAGGCTGCGCTGCTCGGAGGAACTTCTGCGATGGGAGGCGGTGTCAGAATGGAGGCACCTGTGTCAACAGGTGGAATATGTATCTGTGTGAGTGTCCACTCCGATTCGGCGGGAAGAACTGTGAGCAAGCCATGCCTCACCCCCAGCTCTTCAGCGGTGAGAGCGTCGTGTCCTGGAGTGACCTGAACATCATCATCTCTGTGCCCTGGTACCTGGGGCTCATGTTCCGGACCCGGAAGGAGGACAGCGTTCTGATGGAGGCCACCAGTGGTGGGCCCACCAGCTTTCGCCTCCAGATCCTGAACAACTACCTCCAGTTTGAGGTGTCCCACGGCCCCTCCGATGTGGAGTCCGTGATGCTGTCCGGGTTGCGGGTGACCGACGGGGAGTGGCACCACCTGCTGATCGAGCTGAAGAATGTTAAGGAGGACAGTGAGATGAAGCACCTGGTCACCATGACCTTGGACTATGGGATGGACCAGAACAAGGCAGATATCGGGGGCATGCTTCCCGGGCTGACGGTAAGGAGCGTGGTGGTCGGAGGCGCCTCTGAAGACAAGGTCTCCGTGCGCCGTGGATTCCGAGGCTGCATGCAGGGAGTGAGGATGGGGGGGACGCCCACCAACGTCGCCACCCTGAACATGAACAACGCACTCAAGGTCAGGGTGAAGGACGGCTGTGATGTGGACGACCCCTGTACCTCGAGCCCCTGTCCCCCCAATAGCCGCTGCCACGACGCCTGGGAGGACTACAGCTGCGTCTGTGACAAAGGGTACCTTGGAATAAACTGTGTGGATGCCTGTCACCTGAACCCCTGCGAGAACATGGGGGCCTGCGTGCGCTCCCCCGGCTCCCCGCAGGGCTACGTGTGCGAGTGTGGGCCCAGTCACTACGGGCCGTACTGTGAGAACAAACTCGACCTTCCGTGCCCCAGAGGCTGGTGGGGGAACCCCGTCTGTGGACCCTGCCACTGTGCCGTCAGCAAAGGCTTTGATCCCGACTGTAATAAGACCAACGGCCAGTGCCAATGCAAGGAGAATTACTACAAGCTCCTAGCCCAGGACACCTGTCTGCCCTGCGACTGCTTCCCCCATGGCTCCCACAGCCGCACTTGCGACATGGCCACCGGGCAGTGTGCCTGCAAGCCCGGCGTCATCGGCCGCCAGTGCAACCGCTGCGACAACCCGTTTGCCGAGGTCACCACGCTCGGCTGTGAAGTGATCTACAATGGCTGTCCCAAAGCATTTGAGGCCGGCATCTGGTGGCCACAGACCAAGTTCGGGCAGCCGGCTGCGGTGCCATGCCCTAAGGGATCCGTTGGAAATGCGGTCCGACACTGCAGCGGGGAGAAGGGCTGGCTGCCCCCAGAGCTCTTTAACTGTACCACCATCTCCTTCGTGGACCTCAGGGCCATGAATGAGAAGCTGAGCCGCAATGAGACGCAGGTGGACGGCGCCAGGGCCCTGCAGCTGGTGAGGGCGCTGCGCAGTGCTACACAGCACACGGGCACGCTCTTTGGCAATGACGTGCGCACGGCCTACCAGCTGCTGGGCCACGTCCTTCAGCACGAGAGCTGGCAGCAGGGCTTCGACCTGGCAGCCACGCAGGACGCCGACTTTCACGAGGACGTCATCCACTCGGGCAGCGCCCTCCTGGCCCCAGCCACCAGGGCGGCGTGGGAGCAGATCCAGCGGAGCGAGGGCGGCACGGCACAGCTGCTCCGGCGCCTCGAGGGCTACTTCAGCAACGTGGCACGCAACGTGCGGCGGACGTACCTGCGGCCCTTCGTCATCGTCACCGCCAACATGGTTCTTGCTGTCGACATCTTTGACAAGTTCAACTTTACGGGAGCCAGGGTCCCGCGATTCGACACCATCCATGAAGAGTTCCCCAGGGAGCTGGAGTCCTCCGTCTCCTTCCCAGCCGACTTCTTCAGACCACCTGAAGAAAAAGAAGGCCCCCTGCTGAGGCCGGCTGGCCGGAGGACCACCCCGCAGACCACGCGCCCGGGGCCTGGGGCCGAGAGGGAGGCCCCGATCAGCAGGCGGAGGCGACACCCTGATGACGCTGGCCAGTTCGCCGTCGCTCTGGTCATCATTTACCGCACCCTGGGGCAGCTCCTGCCCGAGCGCTACGACCCCGACCGTCGCAGCCTCCGGTTGCCTCACCGGCCCATCATTAATACCCCGATGGTGAGCACGCTGGTGTACAGCGAGGGGGCTCCGCTCCCGAGACCCCTGGAGAGGCCCGTCCTGGTGGAGTTCGCCCTGCTGGAGGTGGAGGAGCGAACCAAGCCTGTCTGCGTGTTCTGGAACCACTCCCTGGCCGTTGGTGGGACGGGAGGGTGGTCTGCCCGGGGCTGCGAGCTCCTGTCCAGGAACCGGACACATGTCGCCTGCCAGTGCAGCCACACAGCCAGCTTTGCGGTGCTCATGGATATCTCCAGGCGTGAGAACGGGGAGGTCCTGCCTCTGAAGATTGTCACCTATGCCGCTGTGTCCTTGTCACTGGCAGCCCTGCTGGTGGCCTTCGTCCTCCTGAGCCTGGTCCGCATGCTGCGCTCCAACCTGCACAGCATTCACAAGCACCTCGCCGTGGCGCTCTTCCTCTCTCAGCTGGTGTTCGTGATTGGGATCAACCAGACGGAAAACCCGTTTCTGTGCACAGTGGTTGCCATCCTCCTCCACTACATCTACATGAGCACCTTTGCCTGGACCCTCGTGGAGAGCCTGCATGTCTACCGCATGCTGACCGAGGTGCGCAACATCGACACGGGGCCCATGCGGTTCTACTACGTCGTGGGCTGGGGCATCCCGGCCATTGTCACAGGACTGGCGGTCGGCCTGGACCCCCAGGGCTACGGGAACCCCGACTTCTGCTGGCTGTCGCTTCAAGACACCCTGATTTGGAGCTTTGCGGGGCCCATCGGAGCTGTTATAATCATCAACACAGTCACTTCTGTCCTATCTGCAAAGGTTTCCTGCCAAAGAAAGCACCATTATTATGGGAAAAAAGGGATCGTCTCCCTGCTGAGGACCGCATTCCTCCTGCTGCTGCTCATCAGCGCCACCTGGCTGCTGGGGCTGCTGGCTGTGAACCGCGATGCACTGAGCTTTCACTACCTCTTCGCCATCTTCAGCGGCTTACAGGGCCCCTTCGTCCTCCTTTTCCACTGCGTGCTCAACCAGGAGGTCCGGAAGCACCTGAAGGGCGTGCTCGGCGGGAGGAAGCTGCACCTGGAGGACTCCGCCACCACCAGGGCCACCCTGCTGACGCGCTCCCTCAACTGCAACACCACCTTCGGTGACGGGCCTGACATGCTGCGCACAGACTTGGGCGAGTCCACCGCCTCGCTGGACAGCATCGTCAGGGATGAAGGGATCCAGAAGCTCGGCGTGTCCTCTGGGCTGGTGAGGGGCAGCCACGGAGAGCCAGACGCGTCCCTCATGCCCAGGAGCTCCAAGGATCCCCCTGGCCACGATTCCGACTCAGATAGCGAGCTGTCCCTGGATGAGCAGAGCAGCTCTTACGCCTCCTCACACTCGTCAGACAGCGAGGACGATGGGGTGGGAGCTGAGGAAAAATGGGACCCGGCCAGGGGCGCCGTCCACAGCACCCCCAAAGGGGACGCTGTGGCCAACCACGTTCCGGCCGGCTGGCCCGACCAGAGCCTGGCTGAGAGTGACAGTGAGGACCCCAGCGGCAAGCCCCGCCTGAAGGTGGAGACCAAGGTCAGCGTGGAGCTGCACCGCGAGGAGCAGGGCAGTCACCGTGGAGAGTACCCCCCCGGACAGGAGAGCGGGGGCGCAGCCAGGCTTGCTAGCAGCCAGCCCCCAGAGCAGAGGAGCATCTTGAAAAATAAAGTCACCTACCCGCCGCCGCTGACGCTGACGGAGCAGACGCTGAAGGGCCGGCTCCGGGAGAAGCTGGCCGACTGTGAGCAGAGCCCCACATCCTCGCGCACGTCTTCCCTGGGCTCTGGCGGCCCCGACTGCGCCATCACAGTCAAGAGCCCTGGGAGGGAGCCGGGGCGTGACCACCTCAACGGGGTGGCCATGAATGTGCGCACTGGGAGCGCCCAGGCCGATGGCTCCGACTCTGAGAAACCGTGANOV21e, SNP13382483 ofSEQ ID NO: 2843028 aaMW at 330849.8kDCG51965-01, ProteinSNP Pos: 2812SNP Change: Cys to SerSequenceMAPPPPPVLPVLLLLAAAAALPAMGLRAAAWEPRVPGGTRAFALRPGCTYAVGAACTPRAPRELLDVGRDGRLAGRRRVSGAGRPLPLQVRLVARSAPTALSRRLRARTHLPGCGARARLCGTGARLCGALCFPVPGGCAAAQHSALAAPTTLPACRCPPRPRPRCPGRPICLPPGGSVRLRLLCALRRAAGAVRVGLALEAATAGTPSASPSPSPPLPPNLPEARAGPARRARRGTSGRGSLKFPMPNYQVALFENEPAGTLILQLHAHYTIEGEEERVSYYMEGLFDERSRGYFRIDSATGAVSTDSVLDRETKETHVLRVKAVDYSTPPRSATTYITVLVKDTNDHSPVFEQSEYRERVRENLEVGYEVLTIRASDRDSPINANLRYRVLGGAWDVFQLNESSGVVSTRAVLDREEAAEYQLLVEANDQGRNPGPLSATATVYIEVEDENDNYPQFSEQNYVVQVPEDVGLNTAVLRVQATDRDQGQNAAIHYSILSGNVAGQFYLHSLSGILDVINPLDFEDVQKYSLSIKAQDGGRPPLINSSGVVSVQVLDVNDNEPIFVSSPFQATVLENVPLGYPVVHIQAVDADSGENARLHYRLVDTASTFLGGGSAGPKNPAPTPDFPFQIHNSSGWITVCAELDREEVEHYSFGVEAVDHGSPPMSSSTSVSITVLDVNDNDPVFTQPTYELRLNEDAAVGSSVLTLQARDRDANSVITYQLTGGNTRNRFALSSQRGGGLITLALPLDYKQEQQYVLAVTASDGTRSHTAHVLINVTDANTNRPVFQSSHYTVSVSEDRPVGTSIATLSANDEDTGENARITYVIQDPVPQFRIDPDSGTMYTMMELDYENQVAYTLTIMAQDNGIPQKSDTTTLEILILDANDNAPQFLWDFYQGSIFEDAPPSTSILQVSATDRDSGPNGRLLYTFQGGDDGDGDFYIEPTSGVIRTQRRLDRENVAVYNLWAIAVDRGSPTPLSASVEIQVTILDINDNAPMFEKDELELFVEENNPVGSVVAKIRANDPDEGPNAQIMYQIVEGDMRHFFQLDLLNGDLRAMVELDFEVRREYVLVVQATSAPLVSRATVHILLVDQNDNPPVLPDFQILFNNYVTNKSNSFPTGVIGCIPAHDPDVSDSLNYTFVQGNELRLLLLDPATGELQLSRDLDNNRPLEALMEVSVSADGIHSVTAFCTLRVTIITDDMLTNSITVRLENMSQEKFLSPLLALFVEGVAAVLSTTKDDVFVFNVQNDTDVSSNILNVTFSALLPGGVRGQFFPSEDLQEQIYLNRTLLTTISTQRVLPFDDNICLREPCENYMKCVSVLRFDSSAPFLSSTTVLFRPIHPINGLRCRCPPGFTGDYCETEIDLCYSDPCGANGRCRSREGGYTCECFEDFTGEHCEVDARSGRCANGVCKNGGTCVNLLIGGFHCVCPPGEYERPYCEVTTRSFPPQSFVTFRGLRQRFHFTISLTFATQERNGLLLYNGRFNEKHDFIALEIVDEQVQLTFSAGAGETTTTVAPKVPSGVSDGRWHSVQVQYYNKVRWAPPLPPGPQPNIGHLGLPHGPSGEKMAVVTVDDCDTTMAVRFGKDIGNYSCAAQGTQTGSKKSLDLTGPLLLGGVPNLPEDFPVHNRQFVGCMRNLSVDGKNVDMAGFIANNGTREGCAARRNFCDGRRCQNGGTCVNRWNMYLCECPLRFGGKNCEQANPHPQLFSGESVVSWSDLNIIISVPWYLGLMFRTRKEDSVLMEATSGGPTSFRLQILNNYLQFEVSHGPSDVESVMLSGLRVTDGEWHHLLIELKNVKEDSEMKHLVTMTLDYGMDQNKADIGGMLPGLTVRSVVVGGASEDKVSVRRGFRGCMQGVRMGGTPTNVATLNMNNALKVRVKDGCDVDDPCTSSPCPPNSRCHDAWEDYSCVCDKGYLGINCVDACHLNPCENMGACVRSPGSPQGYVCECGPSHYGPYCENKLDLPCPRGWWGNPVCGPCHCAVSKGFDPDCNKTNGQCQCKENYYKLLAQDTCLPCDCFPHGSHSRTCDMATGQCACKPGVIGRQCNRCDNPFAEVTTLGCEVIYNGCPKAFEAGIWWPQTKFGQPAAVPCPKGSVGNAVRHCSGEKGWLPPELFNCTTISFVDLRAMNEKLSRNETQVDGARALQLVRALRSATQHTGTLFGNDVRTAYQLLGHVLQHESWQQGFDLAATQDADFHEDVIHSGSALLAPATRAAWEQIQRSEGGTAQLLRRLEGYFSNVARNVRRTYLRPFVIVTANMVLAVDIFDKFNFTGARVPRFDTIHEEFPRELESSVSFPADFFRPPEEKEGPLLRPAGRRTTPQTTRPGPGTEREAPISRRRRHPDDAGQFAVALVIIYRTLGOLLPERYDPDRRSLRLPHRPIINTPMVSTLVYSEGAPLPRPLERPVLVEFALLEVEERTKPVCVFWNHSLAVGGTGGWSARGCELLSRNRTHVACQCSHTASFAVLMDISRRENGEVLPLKIVTYAAVSLSLAALLVAFVLLSLVRMLRSNLHSIHKHLAVALFLSQLVFVIGINQTENPFLCTVVAILLHYIYMSTFAWTLVESLHVYRMLTEVRNIDTGPMRFYYVVGWGIPAIVTGLAVGLDPQGYGNPDFCWLSLQDTLIWSFAGPIGAVIIINTVTSVLSAKVSCQRKHHYYGKKGIVSLLRTAFLLLLLISATWLLGLLAVNRDALSFHYLFAIFSGLQGPFVLLFHCVLNQEVRKHLKGVLGGRKLHLEDSATTRATLLTRSLNCNTTFGDGPDMLRTDLGESTASLDSIVRDEGIQKLGVSSGLVRGSHGEPDASLMPRSSKDPPGHDSDSDSELSLDEOSSSYASSHSSDSEDDGVGAEEKWDPARGAVHSTPKGDAVANHVPAGWPDQSLAESDSEDPSGKPRLKVETKVSVELHREEQGSHRGEYPPDQESGGAARLASSQPPEQRSILKNKVTYPPPLTLTEQTLKGRLREKLADCEQSPTSSRTSSLGSGGPDCAITVKSPGREPGRDHLNGVANNVRTGSAQADGSDSEKPNOV21f, SNP13382484 ofSEQ ID NO: 2859087 bpCG51965-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 9085SNP Pos: 8592SNP Change: C to AATGGCGCCGCCGCCGCCGCCCGTGCTGCCCGTGCTGCTGCTCCTGGCCGCCGCCGCCGCCCTGCCGGCGATGGGGCTGCGAGCGGCCGCCTGGGAGCCGCGCGTACCCGGCGGGACCCGCGCCTTCGCCCTCCGGCCCGGCTGTACCTACGCGGTGGGCGCCGCTTGCACGCCCCGGGCGCCGCGGGAGCTGCTGGACGTGGGCCGCGATGGGCGGCTGGCAGGACGTCGGCGCGTCTCGGGCGCGGGGCGCCCGCTGCCGCTGCAAGTCCGCTTGGTGGCCCGCAGTGCCCCGACGGCGCTGAGCCGCCGCCTGCGGGCGCGCACGCACCTTCCCGGCTGCGGAGCCCGTGCCCGGCTCTGCGGAACCGGTGCCCGGCTCTGCGGGGCGCTCTGCTTCCCCGTCCCCGGCGGCTGCGCGGCCGCGCAGCATTCGGCGCTCGCAGCTCCGACCACCTTACCCGCCTGCCGCTGCCCGCCGCGCCCCAGGCCCCGCTGTCCCGGCCGTCCCATCTGCCTGCCGCCGGGCGGCTCGGTCCGCCTGCGTCTGCTGTGCGCCCTGCGGCGCGCGGCTGGCGCCGTCCGGGTGGGACTGGCGCTGGAGGCCGCCACCGCGGGGACGCCCTCCGCGTCGCCATCCCCATCGCCGCCCCTGCCGCCGAACTTGCCCGAAGCCCGGGCGGGGCCGGCGCGACGGGCCCGGCGGGGCACGAGCGGCAGAGGGAGCCTGAAGTTTCCGATGCCCAACTACCAGGTGGCGTTGTTTGAGAACGAACCGGCGGGCACCCTCATCCTCCAGCTGCACGCGCACTACACCATCGAGGGCGAGGAGGAGCGCGTGAGCTATTACATGGAGGGGCTGTTCGACGAGCGCTCCCGGGGCTACTTCCGAATCGACTCTGCCACGGGCGCCGTGAGCACGGACAGCGTACTGGACCGCGAGACCAAGGAGACGCACGTCCTCAGGGTGAAAGCCGTGGACTACAGTACGCCGCCGCGCTCGGCCACCACCTACATCACTGTCTTGGTCAAAGACACCAACGACCACAGCCCGGTCTTCGAGCAGTCGGAGTACCGCGAGCGCGTGCGGGAGAACCTGGAGGTGGGCTACGAGGTGCTGACCATCCGCGCCAGCGACCGCGACTCGCCCATCAACGCCAACTTGCGTTACCGCGTGTTGGGGGGCGCGTGGGACGTCTTCCAGCTCAACGAGAGCTCTGGCGTGGTGAGCACACGGGCGGTGCTGGACCGGGAGGAGGCGGCCGAGTACCAGCTCCTGGTGGAGGCCAACGACCAGGGGCGCAATCCGGGCCCGCTCAGTGCCACGGCCACCGTGTACATCGAGGTGGAGGACGAGAACGACAACTACCCCCAGTTCAGCGAGCAGAACTACGTGGTCCAGGTGCCCGAGGACGTGGGGCTCAACACGGCTGTGCTGCGAGTGCAGGCCACGGACCGGGACCAGGGCCAGAACGCGGCCATTCACTACAGCATCCTCAGCGGGAACGTGGCCGGCCAGTTCTACCTGCACTCGCTGAGCGGGATCCTGGATGTGATCAACCCCTTGGATTTCGAGGATGTCCAGAAATACTCGCTGAGCATTAAGGCCCAGGATGGGGGCCGGCCCCCGCTCATCAATTCTTCAGGGGTGGTGTCTGTGCAGGTGCTGGATGTCAACGACAACGAGCCTATCTTTGTGAGCAGCCCCTTCCAGGCCACGGTGCTGGAGAATGTGCCCCTGGGCTACCCCGTGGTGCACATTCAGGCGGTGGACGCGGACTCTGGAGAGAACGCCCGGCTGCACTATCGCCTGGTGGACACGGCCTCCACCTTTCTGGGGGGCGGCAGCGCTGGGCCTAAGAATCCTGCCCCCACCCCTGACTTCCCCTTCCAGATCCACAACAGCTCCGGTTGGATCACAGTGTGTGCCGAGCTGGACCGCGAGGAGGTGGAGCACTACAGCTTCGGGGTGGAGGCGGTGGACCACGGCTCGCCCCCCATGAGCTCCTCCACACGCGTGTCCATCACGGTGCTGGACGTGAATGACAACGACCCGGTGTTCACGCAGCCCACCTACGAGCTTCGTCTGAATGAGGATGCGGCCGTGGGGAGCAGCGTGCTGACCCTGCAGGCCCGCGACCGTGACGCCAACAGTGTGATTACCTACCAGCTCACAGGCGGCAACACCCGGAACCGCTTTGCACTCAGCAGCCAGAGAGGGGGCGGCCTCATCACCCTGGCGCTACCTCTGGACTACAAGCAGGAGCAGCAGTACGTGCTGGCGGTGACAGCATCCGACGGCACACGGTCGCACACTGCGCATGTCCTAATCAACGTCACTGATGCCAACACCCACAGGCCTGTCTTTCAGAGCTCCCATTACACAGTGAGTGTCAGTGAGGACAGGCCTGTGGGCACCTCCATTGCTACCCTCAGTGCCAACGATGAGGACACAGGAGAGAATGCCCGCATCACCTACGTGATTCAGGACCCCGTGCCGCAGTTCCGCATTGACCCCGACAGTGGCACCATGTACACCATGATGGAGCTGGACTATGAGAACCAGGTCGCCTACACGCTGACCATCATGGCCCAGGACAACGGCATCCCGCAGAAATCAGACACCACCACCCTAGAGATCCTCATCCTCGATGCCAATGACAATGCACCCCAGTTCCTGTGGGATTTCTACCAGGGTTCCATCTTTGAGGATGCTCCACCCTCGACCAGCATCCTCCAGGTCTCTGCCACGGACCGGGACTCAGGTCCCAATGGGCGTCTGCTGTACACCTTCCAGGGTGGGGACGACGGCGATGGGGACTTCTACATCGAGCCCACGTCCGGTGTGATTCGCACCCAGCGCCGGCTGGACCGGGAGAATGTGGCCGTGTACAACCTTTGGGCTCTGGCTGTGGATCGGGGCAGTCCCACTCCCCTTAGCGCCTCGGTAGAAATCCAGGTGACCATCTTGGACATTAATGACAATGCCCCCATGTTTGAGAAGGACGAACTGGAGCTGTTTGTTGAGGAGAACAACCCAGTGGGGTCGGTGGTGGCAAAGATTCGTGCTAACGACCCTGATGAAGGCCCTAATGCCCAGATCATGTATCAGATTGTGGAAGGGGACATGCGGCATTTCTTCCAGCTGGACCTGCTCAACGGGGACCTGCGTGCCATGGTGGAGCTGGACTTTGAGGTCCGGCGGGAGTATGTGCTGGTGGTGCAGGCCACGTCGGCTCCGCTGGTGAGCCGAGCCACGGTGCACATCCTTCTCGTGGACCAGAATGACAACCCGCCTGTGCTGCCCGACTTCCAGATCCTCTTCAACAACTATGTCACCAACAAGTCCAACAGTTTCCCCACCGGCGTGATCGGCTGCATCCCGGCCCATGACCCCGACGTGTCAGACAGCCTCAACTACACCTTCGTGCAGGGCAACGAGCTGCGCCTGTTGCTGCTGGACCCCGCCACGGGCGAACTGCAGCTCAGCCGCGACCTGGACAACAACCGGCCGCTGGAGGCGCTCATGGAGGTGTCTGTGTCTGCAGATGGCATCCACAGCGTCACGGCCTTCTGCACCCTGCGTGTCACCATCATCACGGACGACATGCTGACCAACAGCATCACTGTCCGCCTGGAGAACATGTCCCAGGAGAAGTTCCTGTCCCCGCTGCTGGCCCTCTTCGTGGAGGGGGTGGCCGCCGTGCTGTCCACCACCAAGGACGACGTCTTCGTCTTCAACGTCCAGAACGACACCGACGTCAGCTCCAACATCCTGAACGTGACCTTCTCGGCGCTGCTGCCTGGCGGCGTCCGCGGCCAGTTCTTCCCGTCGGAGGACCTGCAGGAGCAGATCTACCTGAATCGGACGCTGCTGACCACCATCTCCACGCAGCGCGTGCTGCCCTTCGACGACAACATCTGCCTGCGCGAGCCCTGCGAGAACTACATGAAGTGCGTGTCCGTTCTGCGATTCGACAGCTCCGCGCCCTTCCTCAGCTCCACCACCGTGCTCTTCCGGCCCATCCACCCCATCAACGGCCTGCGCTGCCGCTGCCCGCCCGGCTTCACCGGCGACTACTGCGAGACGGAGATCGACCTCTGCTACTCCGACCCGTGCGGCGCCAACGGCCGCTGCCGCAGCCGCGAGGGCGGCTACACCTGCGAGTGCTTCGAGGACTTCACTGGAGAGCACTGTGAGGTGGATGCCCGCTCAGGCCGCTGTGCCAACGGGGTGTGCAAGAACGGGGGCACCTGCGTGAACCTGCTCATCGGCGGCTTCCACTGCGTGTGTCCTCCTGGCGAGTATGAGAGGCCCTACTGTGAGGTGACCACCAGGAGCTTCCCGCCCCAGTCCTTCGTCACCTTCCGGGGCCTGAGACAGCGCTTCCACTTCACCATCTCCCTCACGTTTGCCACTCAGGAAAGGAACGGCTTGCTTCTCTACAACGGCCGCTTCAATGAGAAGCACGACTTCATCGCCCTGGAGATCGTGGACGAGCAGGTGCAGCTCACCTTCTCTGCAGGTGCAGGCGAGACAACAACGACCGTGGCACCGAAGGTTCCCAGTGGTGTGAGTGACGGGCGGTGGCACTCTGTGCAGGTGCAGTACTACAACAAGGTAAGATGGGCCCCACCACTTCCCCCTGGCCCCCAGCCCAATATTGGCCACCTGGGCCTGCCCCATGGGCCGTCCGGGGAAAAGATGGCCGTGGTGACAGTGGATGATTGTGACACAACCATGGCTGTGCGCTTTGGAAAGGACATCGGGAACTACAGCTGCGCTGCCCAGGGCACTCAGACCGGCTCCAAGAAGTCCCTGGATCTGACCGGCCCTCTACTCCTGGGGGGTGTCCCCAACCTGCCAGAAGACTTCCCAGTGCACAACCGGCAGTTCGTGGGCTGCATGCGGAACCTGTCAGTCGACGGCAAAAATGTGGACATGGCCGGATTCATCGCCAACAATGGCACCCGGGAAGGCTGCGCTGCTCGGAGGAACTTCTGCGATGGGAGGCGGTGTCAGAATGGAGGCACCTGTGTCAACAGGTGGAATATGTATCTGTGTGAGTGTCCACTCCGATTCGGCGGGAAGAACTGTGAGCAAGCCATGCCTCACCCCCAGCTCTTCAGCGGTGAGAGCGTCGTGTCCTGGAGTGACCTGAACATCATCATCTCTGTGCCCTGGTACCTGGGGCTCATGTTCCGGACCCGGAAGGAGGACAGCGTTCTGATGGAGGCCACCAGTGGTGGGCCCACCAGCTTTCGCCTCCAGATCCTGAACAACTACCTCCAGTTTGAGGTGTCCCACGGCCCCTCCGATGTGGAGTCCGTGATGCTGTCCGGGTTGCGGGTGACCGACGGGGAGTGGCACCACCTGCTGATCGAGCTGAAGAATGTTAAGGAGGACAGTGAGATGAAGCACCTGGTCACCATGACCTTGGACTATGGGATGGACCAGAACAAGGCAGATATCGGGGGCATGCTTCCCGGGCTGACGGTAAGGAGCGTGGTGGTCGGAGGCGCCTCTGAAGACAAGGTCTCCGTGCGCCGTGGATTCCGAGGCTGCATGCAGGGAGTGAGGATGGGGGGGACGCCCACCAACGTCGCCACCCTGAACATGAACAACGCACTCAAGGTCAGGGTGAAGGACGGCTGTGATGTGGACGACCCCTGTACCTCGAGCCCCTGTCCCCCCAATAGCCGCTGCCACGACGCCTGGGAGGACTACAGCTGCGTCTGTGACAAAGGGTACCTTGGAATAAACTGTGTGGATGCCTGTCACCTGAACCCCTGCGAGAACATGGGGGCCTGCGTGCGCTCCCCCGGCTCCCCGCAGGGCTACGTGTGCGAGTGTGGGCCCAGTCACTACGGGCCGTACTGTGAGAACAAACTCGACCTTCCGTGCCCCAGAGGCTGGTGGGGGAACCCCGTCTGTGGACCCTGCCACTGTGCCGTCAGCAAAGGCTTTGATCCCGACTGTAATAAGACCAACGGCCAGTGCCAATGCAAGGAGAATTACTACAAGCTCCTAGCCCAGGACACCTGTCTGCCCTGCGACTGCTTCCCCCATGGCTCCCACAGCCGCACTTGCGACATGGCCACCGGGCAGTGTGCCTGCAAGCCCGGCGTCATCGGCCGCCAGTGCAACCGCTGCGACAACCCGTTTGCCGAGGTCACCACGCTCGGCTGTGAAGTGATCTACAATGGCTGTCCCAAAGCATTTGAGGCCGGCATCTGGTGGCCACAGACCAAGTTCGGGCAGCCGGCTGCGGTGCCATGCCCTAAGGGATCCGTTGGAAATGCGGTCCGACACTGCAGCGGGGAGAAGGGCTGGCTGCCCCCAGAGCTCTTTAACTGTACCACCATCTCCTTCGTGGACCTCAGGGCCATGAATGAGAAGCTGAGCCGCAATGAGACGCAGGTGGACGGCGCCAGGGCCCTGCAGCTGGTGAGGGCGCTGCGCAGTGCTACACAGCACACGGGCACGCTCTTTGGCAATGACGTGCGCACGGCCTACCAGCTGCTGGGCCACGTCCTTCAGCACGAGAGCTGGCAGCAGGGCTTCGACCTGGCAGCCACGCAGGACGCCGACTTTCACGAGGACGTCATCCACTCGGGCAGCGCCCTCCTGGCCCCAGCCACCAGGGCGGCGTGGGAGCAGATCCAGCGGAGCGAGGGCGGCACGGCACAGCTGCTCCGGCGCCTCGAGGGCTACTTCAGCAACGTGGCACGCAACGTGCGGCGGACGTACCTGCGGCCCTTCGTCATCGTCACCGCCAACATGGTTCTTGCTGTCGACATCTTTGACAAGTTCAACTTTACGGGAGCCAGGGTCCCGCGATTCGACACCATCCATGAAGAGTTCCCCAGGGAGCTGGAGTCCTCCGTCTCCTTCCCAGCCGACTTCTTCAGACCACCTGAAGAAAAAGAAGGCCCCCTGCTGAGGCCGGCTGGCCGGAGGACCACCCCGCAGACCACGCGCCCGGGGCCTGGCACCGAGAGGGAGGCCCCGATCAGCAGGCGGAGGCGACACCCTGATGACGCTGGCCAGTTCGCCGTCGCTCTGGTCATCATTTACCGCACCCTGGGGCAGCTCCTGCCCGAGCGCTACGACCCCGACCGTCGCAGCCTCCGGTTGCCTCACCGGCCCATCATTAATACCCCGATGGTGAGCACGCTGGTGTACAGCGAGGGGGCTCCGCTCCCGAGACCCCTGGAGAGGCCCGTCCTGGTGGAGTTCGCCCTGCTGGAGGTGGAGGAGCGAACCAAGCCTGTCTGCGTGTTCTGGAACCACTCCCTGGCCGTTGGTGGGACGGGAGGGTGGTCTGCCCGGGGCTGCGAGCTCCTGTCCAGGAACCGGACACATGTCGCCTGCCAGTGCAGCCACACAGCCAGCTTTGCGGTGCTCATGGATATCTCCAGGCGTGAGAACGGGGAGGTCCTGCCTCTGAAGATTGTCACCTATGCCGCTGTGTCCTTGTCACTGGCAGCCCTGCTGGTGGCCTTCGTCCTCCTGAGCCTGGTCCGCATGCTGCGCTCCAACCTGCACAGCATTCACAAGCACCTCGCCGTGGCGCTCTTCCTCTCTCAGCTGGTGTTCGTGATTGGGATCAACCAGACGGAAAACCCGTTTCTGTGCACAGTGGTTGCCATCCTCCTCCACTACATCTACATGAGCACCTTTGCCTGGACCCTCGTGGAGAGCCTGCATGTCTACCGCATGCTGACCGAGGTGCGCAACATCGACACGGGGCCCATGCGGTTCTACTACTGTCGTGGGCTGGGGATCCCGGCCATTGTCACAGGACTGGCGGTCGGCCTGGACCCCCAGGGCTACGGGAACCCCGACTTCTGCTGGCTGTCGCTTCAAGACACCCTGATTTGGAGCTTTGCGGGGCCCATCGGAGCTGTTATAATCATCAACACAGTCACTTCTGTCCTATCTGCAAAGGTTTCCTGCCAAAGAAAGCACCATTATTATGGGAAAAAAGGGATCGTCTCCCTGCTGAGGACCGCATTCCTCCTGCTGCTGCTCATCAGCGCCACCTGGCTGCTGGGGCTGCTGGCTGTGAACCGCGATGCACTGAGCTTTCACTACCTCTTCGCCATCTTCAGCGGCTTACAGGGCCCCTTCGTCCTCCTTTTCCACTGCGTGCTCAACCAGGAGGTCCGGAAGCACCTGAAGGGCGTGCTCGGCGGGAGGAAGCTGCACCTGGAGGACTCCGCCACCACCAGGGCCACCCTGCTGACGCGCTCCCTCAACTGCAACACCACCTTCGGTGACGGGCCTGACATGCTGCGCACAGACTTGGGCGAGTCCACCGCCTCGCTGGACAGCATCGTCAGGGATGAAGGGATCCAGAAGCTCGGCGTGTCCTCTGGGCTGGTGAGGGGCAGCCACGGAGAGCCAGACGCGTCCCTCATGCCCAGGAGCTGCAAGGATCCCCCTGGCCACGATTCCGACTCAGATAGCGAGCTGTCCCTGGATGAGCAGAGCAGCTCTTACGCCTCCTCACACTCGTCAGACAGCGAGGACGATGGGGTGGGAGCTGAGGAAAAATGGGACCCGGCCAGGGGCGCCGTCCACAGCACACCCAAAGGGGACGCTGTGGCCAACCACGTTCCGGCCGGCTGGCCCGACCAGAGCCTGGCTGAGAGTGACAGTGAGGACCCCAGCGGCAAGCCCCGCCTGAAGGTGGAGACCAAGGTCAGCGTGGAGCTGCACCGCGAGGAGCAGGGCAGTCACCGTGGAGAGTACCCCCCGGACCAGGAGAGCGGGGGCGCAGCCAGGCTTGCTAGCAGCCAGCCCCCAGAGCAGAGGAGCATCTTGAAAAATAAAGTCACCTACCCGCCGCCGCTGACGCTGACGGAGCAGACGCTGAAGGGCCGGCTCCGGGAGAAGCTGGCCGACTGTGAGCAGAGCCCCACATCCTCGCGCACGTCTTCCCTGGGCTCTGGCGGCCCCGACTGCGCCATCACAGTCAAGAGCCCTGGGAGGGAGCCGGGGCGTGACCACCTCAACGGGGTGGCCATGAATGTGCGCACTGGGAGCGCCCAGGCCGATGGCTCCGACTCTGAGAAACCGTGANOV21f, SNP13382484 ofSEQ ID NO: 2863028 aaMW at 330865.9kDCG51965-01, ProteinSNP Pos: 2864SNP Change: Thr to ThrSequenceMAPPPPPVLPVLLLLAAAAALPAMGLRAAAWEPRVPGGTRAFALRPGCTYAVGAACTPRAPRELLDVGRDGRLAGRRRVSGAGRPLPLQVRLVARSAPTALSRRLRARTHLPGCGARARLCGTGARLCGALCFPVPGGCAAAQHSALAAPTTLPACRCPPRPRPRCPGRPICLPPGGSVRLRLLCALRRAAGAVRVGLALEAATAGTPSASPSPSPPLPPNLPEARAGPARRARRGTSGRGSLKFPMPNYQVALFENEPAGTLILQLHAHYTIEGEEERVSYYMEGLFDERSRGYFRIDSATGAVSTDSVLDRETKETHVLRVKAVDYSTPPRSATTYITVLVKDTNDHSPVFEQSEYRERVRENLEVGYEVLTIRASDRDSPINANLRYRVLGGAWDVFQLNESSGVVSTRAVLDREEAAEYQLLVEANDQGRNPGPLSATATVYIEVEDENDNYPQFSEQNYVVQVPEDVGLNTAVLRVQATDRDQGQNAAIHYSILSGNVAGQFYLHSLSGILDVINPLDFEDVQKYSLSIKAQDGGRPPLINSSGVVSVQVLDVNDNEPIFVSSPFQATVLENVPLGYPVVHIQAVDADSGENARLHYRLVDTASTFLGGGSAGPKNPAPTPDFPFQIHNSSGWITVCAELDREEVEHYSFGVEAVDHGSPPMSSSTSVSITVLDVNDNDPVFTQPTYELRLNEDAAVGSSVLTLQARDRDANSVITYQLTGGNTRNRFALSSQRGGGLITLALPLDYKQEQQYVLAVTASDGTRSHTAHVLINVTDANTNRPVFQSSHYTVSVSEDRPVGTSIATLSANDEDTGENARITYVIQDPVPQFRIDPDSGTMYTMMELDYENQVAYTLTIMAQDNGIPQKSDTTTLEILILDANDNAPQFLWDFYQGSIFEDAPPSTSILQVSATDRDSGPNGRLLYTFQGGDDGDGDFYIEPTSGVIRTQRRLDRENVAVYNLWAIAVDRGSPTPLSASVEIQVTILDINDNAPMFEKDELELFVEENNPVGSVVAKIRANDPDEGPNAQIMYQIVEGDMRHFFQLDLLNGDLRAMVELDFEVRREYVLVVQATSAPLVSRATVHILLVDQNDNPPVLPDFQILFNNYVTNKSNSFPTGVIGCIPAHDPDVSDSLNYTFVQGNELRLLLLDPATGELQLSRDLDNNRPLEALMEVSVSADGIHSVTAFCTLRVTIITDDMLTNSITVRLENMSQEKFLSPLLALFVEGVAAVLSTTKDDVFVFNVQNDTDVSSNILNVTFSALLPGGVRGQFFPSEDLQEQIYLNRTLLTTISTQRVLPFDDNICLREPCENYMKCVSVLRFDSSAPFLSSTTVLFRPIHPINGLRCRCPPGFTGDYCETEIDLCYSDPCGANGRCRSREGGYTCECFEDFTGEHCEVDARSGRCANGVCKNGGTCVNLLIGGFHCVCPPGEYERPYCEVTTRSFPPQSFVTFRGLRQRFHFTISLTFATQERNGLLLYNGRFNEKHDFIALEIVDEQVQLTFSAGAGETTTTVAPKVPSGVSDGRWHSVQVQYYNKVRWAPPLPPGPQPNIGHLGLPHGPSGEKMAVVTVDDCDTTMAVRFGKDIGNYSCAAQGTQTGSKKSLDLTGPLLLGGVPNLPEDFPVHNRQFVGCMRNLSVDGKNVDMAGFIANNGTREGCAARRNFCDGRRCQNGGTCVNRWNMYLCECPLRFGGKNCEQANPHPQLFSGESVVSWSDLNIIISVPWYLGLMFRTRKEDSVLMEATSGGPTSFRLQILNNYLQFEVSHGPSDVESVMLSGLRVTDGEWHHLLIELKNVKEDSEMKHLVTMTLDYGMDQNKADIGGMLPGLTVRSVVVGGASEDKVSVRRGFRGCMQGVRMGGTPTNVATLNMNNALKVRVKDGCDVDDPCTSSPCPPNSRCHDAWEDYSCVCDKGYLGINCVDACHLNPCENMGACVRSPGSPQGYVCECGPSHYGPYCENKLDLPCPRGWWGNPVCGPCHCAVSKGFDPDCNKTNGQCQCKENYYKLLAQDTCLPCDCFPHGSHSRTCDMATGQCACKPGVIGRQCNRCDNPFAEVTTLGCEVIYNGCPKAFEAGIWWPQTKFGQPAAVPCPKGSVGNAVRHCSGEKGWLPPELFNCTTISFVDLRAMNEKLSRNETQVDGARALQLVRALRSATQHTGTLFGNDVRTAYQLLGHVLQHESWQQGFDLAATQDADFHEDVIHSGSALLAPATRAAWEQIQRSEGGTAQLLRRLEGYFSNVARNVRRTYLRPFVIVTANMVLAVDIFDKFNFTGARVPRFDTIHEEFPRELESSVSFPADFFRPPEEKEGPLLRPAGRRTTPQTTRPGPGTEREAPISRRRRHPDDAGQFAVALVIIYRTLGOLLPERYDPDRRSLRLPHRPIINTPMVSTLVYSEGAPLPRPLERPVLVEFALLEVEERTKPVCVFWNHSLAVGGTGGWSARGCELLSRNRTHVACQCSHTASFAVLMDISRRENGEVLPLKIVTYAAVSLSLAALLVAFVLLSLVRMLRSNLHSIHKHLAVALFLSQLVFVIGINQTENPFLCTVVAILLHYIYMSTFAWTLVESLHVYRMLTEVRNIDTGPMRFYYVVGWGIPAIVTGLAVGLDPQGYGNPDFCWLSLQDTLIWSFAGPIGAVIIINTVTSVLSAKVSCQRKHHYYGKKGIVSLLRTAFLLLLLISATWLLGLLAVNRDALSFHYLFAIFSGLQGPFVLLFHCVLNQEVRKHLKGVLGGRKLHLEDSATTRATLLTRSLNCNTTFGDGPDMLRTDLGESTASLDSIVRDEGIQKLGVSSGLVRGSHGEPDASLMPRSSKDPPGHDSDSDSELSLDEOSSSYASSHSSDSEDDGVGAEEKWDPARGAVHSTPKGDAVANHVPAGWPDQSLAESDSEDPSGKPRLKVETKVSVELHREEQGSHRGEYPPDQESGGAARLASSQPPEQRSILKNKVTYPPPLTLTEQTLKGRLREKLADCEQSPTSSRTSSLGSGGPDCAITVKSPGREPGRDHLNGVANNVRTGSAQADGSDSEKPNOV21g, SNP13382485 ofSEQ ID NO: 2879087 bpCG51965-01, DNA SequenceORF Start: ATG at 1ORF Stop: TGA at 9085SNP Pos: 8752SNP Change: G to CATGGCGCCGCCGCCGCCGCCCGTGCTGCCCGTGCTGCTGCTCCTGGCCGCCGCCGCCGCCCTGCCGGCGATGGGGCTGCGAGCGGCCGCCTGGGAGCCGCGCGTACCCGGCGGGACCCGCGCCTTCGCCCTCCGGCCCGGCTGTACCTACGCGGTGGGCGCCGCTTGCACGCCCCGGGCGCCGCGGGAGCTGCTGGACGTGGGCCGCGATGGGCGGCTGGCAGGACGTCGGCGCGTCTCGGGCGCGGGGCGCCCGCTGCCGCTGCAAGTCCGCTTGGTGGCCCGCAGTGCCCCGACGGCGCTGAGCCGCCGCCTGCGGGCGCGCACGCACCTTCCCGGCTGCGGAGCCCGTGCCCGGCTCTGCGGAACCGGTGCCCGGCTCTGCGGGGCGCTCTGCTTCCCCGTCCCCGGCGGCTGCGCGGCCGCGCAGCATTCGGCGCTCGCAGCTCCGACCACCTTACCCGCCTGCCGCTGCCCGCCGCGCCCCAGGCCCCGCTGTCCCGGCCGTCCCATCTGCCTGCCGCCGGGCGGCTCGGTCCGCCTGCGTCTGCTGTGCGCCCTGCGGCGCGCGGCTGGCGCCGTCCGGGTGGGACTGGCGCTGGAGGCCGCCACCGCGGGGACGCCCTCCGCGTCGCCATCCCCATCGCCGCCCCTGCCGCCGAACTTGCCCGAAGCCCGGGCGGGGCCGGCGCGACGGGCCCGGCGGGGCACGAGCGGCAGAGGGAGCCTGAAGTTTCCGATGCCCAACTACCAGGTGGCGTTGTTTGAGAACGAACCGGCGGGCACCCTCATCCTCCAGCTGCACGCGCACTACACCATCGAGGGCGAGGAGGAGCGCGTGAGCTATTACATGGAGGGGCTGTTCGACGAGCGCTCCCGGGGCTACTTCCGAATCGACTCTGCCACGGGCGCCGTGAGCACGGACAGCGTACTGGACCGCGAGACCAAGGAGACGCACGTCCTCAGGGTGAAAGCCGTGGACTACAGTACGCCGCCGCGCTCGGCCACCACCTACATCACTGTCTTGGTCAAAGACACCAACGACCACAGCCCGGTCTTCGAGCAGTCGGAGTACCGCGAGCGCGTGCGGGAGAACCTGGAGGTGGGCTACGAGGTGCTGACCATCCGCGCCAGCGACCGCGACTCGCCCATCAACGCCAACTTGCGTTACCGCGTGTTGGGGGGCGCGTGGGACGTCTTCCAGCTCAACGAGAGCTCTGGCGTGGTGAGCACACGGGCGGTGCTGGACCGGGAGGAGGCGGCCGAGTACCAGCTCCTGGTGGAGGCCAACGACCAGGGGCGCAATCCGGGCCCGCTCAGTGCCACGGCCACCGTGTACATCGAGGTGGAGGACGAGAACGACAACTACCCCCAGTTCAGCGAGCAGAACTACGTGGTCCAGGTGCCCGAGGACGTGGGGCTCAACACGGCTGTGCTGCGAGTGCAGGCCACGGACCGGGACCAGGGCCAGAACGCGGCCATTCACTACAGCATCCTCAGCGGGAACGTGGCCGGCCAGTTCTACCTGCACTCGCTGAGCGGGATCCTGGATGTGATCAACCCCTTGGATTTCGAGGATGTCCAGAAATACTCGCTGAGCATTAAGGCCCAGGATGGGGGCCGGCCCCCGCTCATCAATTCTTCAGGGGTGGTGTCTGTGCAGGTGCTGGATGTCAACGACAACGAGCCTATCTTTGTGAGCAGCCCCTTCCAGGCCACGGTGCTGGAGAATGTGCCCCTGGGCTACCCCGTGGTGCACATTCAGGCGGTGGACGCGGACTCTGGAGAGAACGCCCGGCTGCACTATCGCCTGGTGGACACGGCCTCCACCTTTCTGGGGGGCGGCAGCGCTGGGCCTAAGAATCCTGCCCCCACCCCTGACTTCCCCTTCCAGATCCACAACAGCTCCGGTTGGATCACAGTGTGTGCCGAGCTGGACCGCGAGGAGGTGGAGCACTACAGCTTCGGGGTGGAGGCGGTGGACCACGGCTCGCCCCCCATGAGCTCCTCCACCAGCGTGTCCATCACGGTGCTGGACGTGAATGACAACGACCCGGTGTTCACGCAGCCCACCTACGAGCTTCGTCTGAATGAGGATGCGGCCGTGGGGAGCAGCGTGCTGACCCTGCAGGCCCGCGACCGTGACGCCAACAGTGTGATTACCTACCAGCTCACAGGCGGCAACACCCGGAACCGCTTTGCACTCAGCAGCCAGAGAGGGGGCGGCCTCATCACCCTGGCGCTACCTCTGGACTACAAGCAGGAGCAGCAGTACGTGCTGGCGGTGACAGCATCCGACGGCACACGGTCGCACACTGCGCATGTCCTAATCAACGTCACTGATGCCAACACCCACAGGCCTGTCTTTCAGAGCTCCCATTACACAGTGAGTGTCAGTGAGGACAGGCCTGTGGGCACCTCCATTGCTACCCTCAGTGCCAACGATGAGGACACAGGAGAGAATGCCCGCATCACCTACGTGATTCAGGACCCCGTGCCGCAGTTCCGCATTGACCCCGACAGTGGCACCATGTACACCATGATGGAGCTGGACTATGAGAACCAGGTCGCCTACACGCTGACCATCATGGCCCAGGACAACGGCATCCCGCAGAAATCAGACACCACCACCCTAGAGATCCTCATCCTCGATGCCAATGACAATGCACCCCAGTTCCTGTGGGATTTCTACCAGGGTTCCATCTTTGAGGATGCTCCACCCTCGACCAGCATCCTCCAGGTCTCTGCCACGGACCGGGACTCAGGTCCCAATGGGCGTCTGCTGTACACCTTCCAGGGTGGGGACGACGGCGATGGGGACTTCTACATCGAGCCCACGTCCGGTGTGATTCGCACCCAGCGCCGGCTGGACCGGGAGAATGTGGCCGTGTACAACCTTTGGGCTCTGGCTGTGGATCGGGGCAGTCCCACTCCCCTTAGCGCCTCGGTAGAAATCCAGGTGACCATCTTGGACATTAATGACAATGCCCCCATGTTTGAGAAGGACGAACTGGAGCTGTTTGTTGAGGAGAACAACCCAGTGGGGTCGGTGGTGGCAAAGATTCGTGCTAACGACCCTGATGAAGGCCCTAATGCCCAGATCATGTATCAGATTGTGGAAGGGGACATGCGGCATTTCTTCCAGCTGGACCTGCTCAACGGGGACCTGCGTGCCATGGTGGAGCTGGACTTTGAGGTCCGGCGGGAGTATGTGCTGGTGGTGCAGGCCACGTCGGCTCCGCTGGTGAGCCGAGCCACGGTGCACATCCTTCTCGTGGACCAGAATGACAACCCGCCTGTGCTGCCCGACTTCCAGATCCTCTTCAACAACTATGTCACCAACAAGTCCAACAGTTTCCCCACCGGCGTGATCGGCTGCATCCCGGCCCATGACCCCGACGTGTCAGACAGCCTCAACTACACCTTCGTGCAGGGCAACGAGCTGCGCCTGTTGCTGCTGGACCCCGCCACGGGCGAACTGCAGCTCAGCCGCGACCTGGACAACAACCGGCCGCTGGAGGCGCTCATGGAGGTGTCTGTGTCTGCAGATGGCATCCACAGCGTCACGGCCTTCTGCACCCTGCGTGTCACCATCATCACGGACGACATGCTGACCAACAGCATCACTGTCCGCCTGGAGAACATGTCCCAGGAGAAGTTCCTGTCCCCGCTGCTGGCCCTCTTCGTGGAGGGGGTGGCCGCCGTGCTGTCCACCACCAAGGACGACGTCTTCGTCTTCAACGTCCAGAACGACACCGACGTCAGCTCCAACATCCTGAACGTGACCTTCTCGGCGCTGCTGCCTGGCGGCGTCCGCGGCCAGTTCTTCCCGTCGGAGGACCTGCAGGAGCAGATCTACCTGAATCGGACGCTGCTGACCACCATCTCCACGCAGCGCGTGCTGCCCTTCGACGACAACATCTGCCTGCGCGAGCCCTGCGAGAACTACATGAAGTGCGTGTCCGTTCTGCGATTCGACAGCTCCGCGCCCTTCCTCAGCTCCACCACCGTGCTCTTCCGGCCCATCCACCCCATCAACGGCCTGCGCTGCCGCTGCCCGCCCGGCTTCACCGGCGACTACTGCGAGACGGAGATCGACCTCTGCTACTCCGACCCGTGCGGCGCCAACGGCCGCTGCCGCAGCCGCGAGGGCGGCTACACCTGCGAGTGCTTCGAGGACTTCACTGGAGAGCACTGTGAGGTGGATGCCCGCTCAGGCCGCTGTGCCAACGGGGTGTGCAAGAACGGGGGCACCTGCGTGAACCTGCTCATCGGCGGCTTCCACTGCGTGTGTCCTCCTGGCGAGTATGAGAGGCCCTACTGTGAGGTGACCACCAGGAGCTTCCCGCCCCAGTCCTTCGTCACCTTCCGGGGCCTGAGACAGCGCTTCCACTTCACCATCTCCCTCACGTTTGCCACTCAGGAAAGGAACGGCTTGCTTCTCTACAACGGCCGCTTCAATGAGAAGCACGACTTCATCGCCCTGGAGATCGTGGACGAGCAGGTGCAGCTCACCTTCTCTGCAGGTGCAGGCGAGACAACAACGACCGTGGCACCGAAGGTTCCCAGTGGTGTGAGTGACGGGCGGTGGCACTCTGTGCAGGTGCAGTACTACAACAAGGTAAGATGGGCCCCACCACTTCCCCCTGGCCCCCAGCCCAATATTGGCCACCTGGGCCTGCCCCATGGGCCGTCCGGGGAAAAGATGGCCGTGGTGACAGTGGATGATTGTGACACAACCATGGCTGTGCGCTTTGGAAAGGACATCGGGAACTACAGCTGCGCTGCCCAGGGCACTCAGACCGGCTCCAAGAAGTCCCTGGATCTGACCGGCCCTCTACTCCTGGGGGGTGTCCCCAACCTGCCAGAAGACTTCCCAGTGCACAACCGGCAGTTCGTGGGCTGCATGCGGAACCTGTCAGTCGACGGCAAAAATGTGGACATGGCCGGATTCATCGCCAACAATGGCACCCGGGAAGGCTGCGCTGCTCGGAGGAACTTCTGCGATGGGAGGCGGTGTCAGAATGGAGGCACCTGTGTCAACAGGTGGAATATGTATCTGTGTGAGTGTCCACTCCGATTCGGCGGGAAGAACTGTGAGCAAGCCATGCCTCACCCCCAGCTCTTCAGCGGTGAGAGCGTCGTGTCCTGGAGTGACCTGAACATCATCATCTCTGTGCCCTGGTACCTGGGGCTCATGTTCCGGACCCGGAAGGAGGACAGCGTTCTGATGGAGGCCACCAGTGGTGGGCCCACCAGCTTTCGCCTCCAGATCCTGAACAACTACCTCCAGTTTGAGGTGTCCCACGGCCCCTCCGATGTGGAGTCCGTGATGCTGTCCGGGTTGCGGGTGACCGACGGGGAGTGGCACCACCTGCTGATCGAGCTGAAGAATGTTAAGGAGGACAGTGAGATGAAGCACCTGGTCACCATGACCTTGGACTATGGGATGGACCAGAACAAGGCAGATATCGGGGGCATGCTTCCCGGGCTGACGGTAAGGAGCGTGGTGGTCGGAGGCGCCTCTGAAGACAAGGTCTCCGTGCGCCGTGGATTCCGAGGCTGCATGCAGGGAGTGAGGATGGGGGGGACGCCCACCAACGTCGCCACCCTGAACATGAACAACGCACTCAAGGTCAGGGTGAAGGACGGCTGTGATGTGGACGACCCCTGTACCTCGAGCCCCTGTCCCCCCAATAGCCGCTGCCACGACGCCTGGGAGGACTACAGCTGCGTCTGTGACAAAGGGTACCTTGGAATAAACTGTGTGGATGCCTGTCACCTGAACCCCTGCGAGAACATGGGGGCCTGCGTGCGCTCCCCCGGCTCCCCGCAGGGCTACGTGTGCGAGTGTGGGCCCAGTCACTACGGGCCGTACTGTGAGAACAAACTCGACCTTCCGTGCCCCAGAGGCTGGTGGGGGAACCCCGTCTGTGGACCCTGCCACTGTGCCGTCAGCAAAGGCTTTGATCCCGACTGTAATAAGACCAACGGCCAGTGCCAATGCAAGGAGAATTACTACAAGCTCCTAGCCCAGGACACCTGTCTGCCCTGCGACTGCTTCCCCCATGGCTCCCACAGCCGCACTTGCGACATGGCCACCGGGCAGTGTGCCTGCAAGCCCGGCGTCATCGGCCGCCAGTGCAACCGCTGCGACAACCCGTTTGCCGAGGTCACCACGCTCGGCTGTGAAGTGATCTACAATGGCTGTCCCAAAGCATTTGAGGCCGGCATCTGGTGGCCACAGACCAAGTTCGGGCAGCCGGCTGCGGTGCCATGCCCTAAGGGATCCGTTGGAAATGCGGTCCGACACTGCAGCGGGGAGAAGGGCTGGCTGCCCCCAGAGCTCTTTAACTGTACCACCATCTCCTTCGTGGACCTCAGGGCCATGAATGAGAAGCTGAGCCGCAATGAGACGCAGGTGGACGGCGCCAGGGCCCTGCAGCTGGTGAGGGCGCTGCGCAGTGCTACACAGCACACGGGCACGCTCTTTGGCAATGACGTGCGCACGGCCTACCAGCTGCTGGGCCACGTCCTTCAGCACGAGAGCTGGCAGCAGGGCTTCGACCTGGCAGCCACGCAGGACGCCGACTTTCACGAGGACGTCATCCACTCGGGCAGCGCCCTCCTGGCCCCAGCCACCAGGGCGGCGTGGGAGCAGATCCAGCGGAGCGAGGGCGGCACGGCACAGCTGCTCCGGCGCCTCGAGGGCTACTTCAGCAACGTGGCACGCAACGTGCGGCGGACGTACCTGCGGCCCTTCGTCATCGTCACCGCCAACATGGTTCTTGCTGTCGACATCTTTGACAAGTTCAACTTTACGGGAGCCAGGGTCCCGCGATTCGACACCATCCATGAAGAGTTCCCCAGGGAGCTGGAGTCCTCCGTCTCCTTCCCAGCCGACTTCTTCAGACCACCTGAAGAAAAAGAAGGCCCCCTGCTGAGGCCGGCTGGCCGGAGGACCACCCCGCAGACCACGCGCCCGGGGCCTGGCACCGAGAGGGAGGCCCCGATCAGCAGGCGGAGGCGACACCCTGATGACGCTGGCCAGTTCGCCGTCGCTCTGGTCATCATTTACCGCACCCTGGGGCAGCTCCTGCCCGAGCGCTACGACCCCGACCGTCGCAGCCTCCGGTTGCCTCACCGGCCCATCATTAATACCCCGATGGTGAGCACGCTGGTGTACAGCGAGGGGGCTCCGCTCCCGAGACCCCTGGAGAGGCCCGTCCTGGTGGAGTTCGCCCTGCTGGAGGTGGAGGAGCGAACCAAGCCTGTCTGCGTGTTCTGGAACCACTCCCTGGCCGTTGGTGGGACGGGAGGGTGGTCTGCCCGGGGCTGCGAGCTCCTGTCCAGGAACCGGACACATGTCGCCTGCCAGTGCAGCCACACAGCCAGCTTTGCGGTGCTCATGGATATCTCCAGGCGTGAGAACGGGGAGGTCCTGCCTCTGAAGATTGTCACCTATGCCGCTGTGTCCTTGTCACTGGCAGCCCTGCTGGTGGCCTTCGTCCTCCTGAGCCTGGTCCGCATGCTGCGCTCCAACCTGCACAGCATTCACAAGCACCTCGCCGTGGCGCTCTTCCTCTCTCAGCTGGTGTTCGTGATTGGGATCAACCAGACGGAAAACCCGTTTCTGTGCACAGTGGTTGCCATCCTCCTCCACTACATCTACATGAGCACCTTTGCCTGGACCCTCGTGGAGAGCCTGCATGTCTACCGCATGCTGACCGAGGTGCGCAACATCGACACGGGGCCCATGCGGTTCTACTACGTCGTGGGCTGGGGCATCCCGGCCATTGTCACAGGACTGGCGGTCGGCCTGGACCCCCAGGGCTACGGGAACCCCGACTTCTGCTGGCTGTCGCTTCAAGACACCCTGATTTGGAGCTTTGCGGGGCCCATCGGAGCTGTTATAATCATCAACACAGTCACTTCTGTCCTATCTGCAAAGGTTTCCTGCCAAAGAAAGCACCATTATTATGGGAAAAAAGGGATCGTCTCCCTGCTGAGGACCGCATTCCTCCTGCTGCTGCTCATCAGCGCCACCTGGCTGCTGGGGCTGCTGGCTGTGAACCGCGATGCACTGAGCTTTCACTACCTCTTCGCCATCTTCAGCGGCTTACAGGGCCCCTTCGTCCTCCTTTTCCACTGCGTGCTCAACCAGGAGGTCCGGAAGCACCTGAAGGGCGTGCTCGGCGGGAGGAAGCTGCACCTGGAGGACTCCGCCACCACCAGGGCCACCCTGCTGACGCGCTCCCTCAACTGCAACACCACCTTCGGTGACGGGCCTGACATGCTGCGCACAGACTTGGGCGAGTCCACCGCCTCGCTGGACAGCATCGTCAGGGATGAAGGGATCCAGAAGCTCGGCGTGTCCTCTGGGCTGGTGAGGGGCAGCCACGGAGAGCCAGACGCGTCCCTCATGCCCAGGAGCTGCAAGGATCCCCCTGGCCACGATTCCGACTCAGATAGCGAGCTGTCCCTGGATGAGCAGAGCAGCTCTTACGCCTCCTCACACTCGTCAGACAGCGAGGACGATGGGGTGGGAGCTGAGGAAAAATGGGACCCGGCCAGGGGCGCCGTCCACAGCACCCCCAAAGGGGACGCTGTGGCCAACCACGTTCCGGCCGGCTGGCCCGACCAGAGCCTGGCTGAGAGTGACAGTGAGGACCCCAGCGGCAAGCCCCGCCTGAAGGTGGAGACCAAGGTCAGCGTGGAGCTGCACCGCGAGGAGCAGGGCAGTCACCGTGGACAGTACCCCCCGGACCAGGAGAGCGGGGGCGCAGCCAGGCTTGCTAGCAGCCAGCCCCCAGAGCAGAGGAGCATCTTGAAAAATAAAGTCACCTACCCGCCGCCGCTGACGCTGACGGAGCAGACGCTGAAGGGCCGGCTCCGGGAGAAGCTGGCCGACTGTGAGCAGAGCCCCACATCCTCGCGCACGTCTTCCCTGGGCTCTGGCGGCCCCGACTGCGCCATCACAGTCAAGAGCCCTGGGAGGGAGCCGGGGCGTGACCACCTCAACGGGGTGGCCATGAATGTGCGCACTGGGAGCGCCCAGGCCGATGGCTCCGACTCTGAGAAACCGTGANOV21g, SNP13382485 ofSEQ ID NO: 2883028 aaMW at 330864.9kDCG51965-01, ProteinSNP Pos: 2918SNP Change: Glu to GlnSequenceMAPPPPPVLPVLLLLAAAAALPAMGLRAAAWEPRVPGGTRAFALRPGCTYAVGAACTPRAPRELLDVGRDGRLAGRRRVSGAGRPLPLQVRLVARSAPTALSRRLRARTHLPGCGARARLCGTGARLCGALCFPVPGGCAAAQHSALAAPTTLPACRCPPRPRPRCPGRPICLPPGGSVRLRLLCALRRAAGAVRVGLALEAATAGTPSASPSPSPPLPPNLPEARAGPARRARRGTSGRGSLKFPMPNYQVALFENEPAGTLILQLHAHYTIEGEEERVSYYMEGLFDERSRGYFRIDSATGAVSTDSVLDRETKETHVLRVKAVDYSTPPRSATTYITVLVKDTNDHSPVFEQSEYRERVRENLEVGYEVLTIRASDRDSPINANLRYRVLGGAWDVFQLNESSGVVSTRAVLDREEAAEYQLLVEANDQGRNPGPLSATATVYIEVEDENDNYPQFSEQNYVVQVPEDVGLNTAVLRVQATDRDQGQNAAIHYSILSGNVAGQFYLHSLSGILDVINPLDFEDVQKYSLSIKAQDGGRPPLINSSGVVSVQVLDVNDNEPIFVSSPFQATVLENVPLGYPVVHIQAVDADSGENARLHYRLVDTASTFLGGGSAGPKWPAPTPDFPFQIHNSSGWITVCAELDREEVEHYSFGVEAVDHGSPPMSSSTSVSITVLDVNDNDPVFTQPTYELRINEDAAVGSSVLTLQARDRDANSVITYQLTGGNTRNRFALSSORGGGLITLALPLDYKQEQQYVLAVTASDGTRSHTAHVLINVTDANTHRPVFQSSHYTVSVSEDRPVGTSIATLSANDEDTGENARITYVIQDPVPQFRIDPDSGTMYTMMELDYENQVAYTLTIMAQDNGIPQKSDTTTLEILILDANDNAPQFLWDFYQGSIFEDAPPSTSILQVSATDRDSGPNGRLLYTFQGGDDGDGDFYIEPTSGVIRTQRRLDRENVAVYNLWALAVDRGSPTPLSASVEIQVTILDINDNAPMFEKDELELFVEENNPVGSVVAKIRANDPDEGPNAQIMYQIVEGDMRHFFQLDLLNGDLRAMVELDFEVRREYVLVVQATSAPLVSRATVHILLVDQNDNPPVLPDFQILFNNYVTNKSNSFPTGVIGCIPAHDPDVSDSLNYTFVQGNELRLLLLDPATGELQLSRDLDNNRPLEALMEVSVSADGIHSVTAFCTLRVTIITDDMLTNSITVRLENNSQEKFLSPLLALFVEGVAAVLSTTKDDVFVFNVQNDTDVSSNILNVTFSALLPGGVRGQFFPSEDLQEQIYLNRTLLTTISTQRVLPFDDNICLREPCENYMKCVSVLRFDSSAPFLSSTTVLFRPIHPINGLRCRCPPGFTGDYCETEIDLCYSDPCGANGRCRSREGGYTCECFEDFTGEHCEVDARSGRCANGVCKNGGTCVNLLIGGFHCVCPPGEYERPYCEVTTRSFPPQSFVTFRGLRQRFHFTISLTFATQERNGLLLYNGRFNEKHDFIALEIVDEQVQLTFSAGAGETTTTVAPKVPSGVSDGRWHSVQVQYYNKVRWAPPLPPGPQPNIGHLGLPHGPSGEKMAVVTVDDCDTTMAVRFGKDIGNYSCAAQGTQTGSKKSLDLTGPLLLGGVPNLPEDFPVHNRQFVGCMRNLSVDGKNVDMAGFIANNGTREGCAARRNFCDGRRCQNGGTCVNRWNMYLCECPLRFGGKNCEQAMPHPQLFSGESVVSWSDLNIIISVPWYLGLMFRTRKEDSVLMEATSGGPTSFRLQILNNYLQFEVSHGPSDVESVNLSGLRVTDGEWHHLLIELKNVKEDSEMKHLVTMTLDYGMDQNKADIGGMLPGLTVRSVVVGGASEDKVSVRRGFRGCMQGVRMGGTPTNVATLNNNNALKVRVKDGCDVDDPCTSSPCPPNSRCHDAWEDYSCVCDKGYLGINCVDACHLNPCENNGACVRSPGSPQGYVCECGPSHYGPYCENKLDLPCPRGWWGNPVCGPCHCAVSKGFDPDCNKTNGQCQCKENYYKLLAQDTCLPCDCFPHGSHSRTCDMATGOCACKPGVIGRQCNRCDNPFAEVTTLGCEVIYNGCPKAFEAGIWWPQTKFGQPAAVPCPKGSVGNAVRHCSGEKGWLPPELFNCTTISFVDLRAMNEKLSRNETQVDGARALQLVRALRSATQHTGTLFGNDVRTAYQLLGHVLQHESWQQGFDLAATQDADFHEDVIHSGSALLAPATRAAWEQIQRSEGGTAQLLRRLEGYFSNVARNVRRTYLRPFVIVTANMVLAVDIFDKFNFTGARVPRFDTIHEEFPRELESSVSFPADFFRPPEEKEGPLLRPAGRRTTPQTTRPGPGTEREAPISRRRRHPDDAGQFAVALVIIYRTLGQLLPERYDPDRRSLRLPHRPIINTPMVSTLVYSEGAPLPRPLERPVLVEFALLEVEERTKPVCVFWNHSLAVGGTGGWSARGCELLSRNRTHVACQCSHTASFAVLMDISRRENGEVLPLKIVTYAAVSLSLAALLVAFVLLSLVRMLRSNLHSIHKHLAVALFLSQLVFVIGINQTENPFLCTVVAILLHYIYMSTFAWTLVESLHVYRMLTEVRNIDTGPMRFYYVVGWGIPAIVTGLAVGLDPQGYGNPDFCWLSLQDTLIWSFAGPIGAVIIINTVTSVLSAKVSCQRKHHYYGKKGIVSLLRTAFLLLLLISATWLLGLLAVNRDALSFHYLFAIFSGLQGPFVLLFHCVLMQEVRKHLKGVLGGRKLHLEDSATTRATLLTRSLNCNTTFGDGPDMLRTDLGESTASLDSIVRDEGIQKLGVSSGLVRGSHGEPDASLMPRSCKDPPGHDSDSDSELSLDEQSSSYASSHSSDSEDDGVGAEEKWDPARGAVHSTPKGDAVANHVPAGWPDQSLAESDSEDPSGKPRLKVETKVSVELHREEQGSHRGQYPPDQESGGAARLASSQPPEQRSILKNKVTYPPPLTLTEQTLKGRLREKLADCEQSPTSSRTSSLGSGGPDCAITVKSPGREPGRDHLNGVANNVRTGSAQADGSDSEKP

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 21B.

TABLE 21BComparison of the NOV21 protein sequences.NOV21a MAPPPPPVLPVLLLLAAAAALPANGLRAAAWEPRVPGGTRAFALRPGCTYAVGAACTPRANOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a PRELLDVGRDGRLAGRRRVSGAGRPLPLQVRLVARSAPTALSRRLRARTHLPGCGARARLNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a CGTGARLCGALCFPVPGGCAAAQHSALAAPTTLPACRCPPRPRPRCPGRPICLPPGGSVRNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a LRLLCALRRAAGAVRVGLALEAATAGTPSASPSPSPPLPPNLPEARAGPARRARRGTSGRNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a GSLKFPMPNYQVALFENEPAGTLILQLHAHYTIEGEEERVSYYMEGLFDERSRGYFRIDSNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d -------KLYQVALFENEPAGTLILQLHAHHTIEGEEERVSYYMEGLFDERSRGYFRIDSNOV21a ATGAVSTDSVLDRETKETHVLRVKAVDYSTPPRSATTYITVLVKDTNDHSPVFEQSEYRENOV21b ------------------------------------LKLEVIYNGCPKAFEAGIWWPQTKNOV21c ------------------------------------------------------------NOV21d AAGAVSTDSVLDRETKETHVLRVKAVDYSTPPRSATTYITVLVKDTNDHSPVFEQSEYRENOV21a RVRENLEVGYEVLTIRASDRDSPINANLRYRVLGGAWDVFQLNESSGVVSTRAVLDREEANOV21b FGQPAAVPCPKGSVGNAVRHCSGEKGWLPPELFNCTTISFVDLRAMNEKLSRNETQVDGANOV21c --RK-LVLPLKIVTYAAVS-LS-LAALLVAFVLLSLVRMLRSNLHS-IHKHLAVALF--LNOV21d RVRENLEVGYEVLTIRASDRDSPINANLRYRVLGGAWDVFQLNESSGVVSTRAVLDREEANOV21a AEYQLLVEANDQGRNPGPLSATATVYIEVEDENDNYPQFSEQNYVVQVPEDVGLNTAVLRNOV21b RALQLVRALRSATQHTGTLFGNDVRTAYQLLGHVLQHESWQQGFDLAATQDADFHEDVIHNOV21c SQLVFVIGIN-QTENP-FLCTVVAILLHYIYMS----TFAWT--LVES-------LHVYRNOV21d AEYQLLVEANDQGRNPGPLSATATVYIEVEDENDNYPQFSEQNYVVQVPEDVGLNTAVLRNOV21a VQATDRDQGQNAAIHYSILSGNVAGQFYLHSLSGILDVINPLDFEDVQKYSLSIKAQDGGNOV21b SGSALLAPATRAAWEQIQRSEG-GTAQLLRRLEGYFSNVARNVRRTYLRPFVIVTANMILNOV21c MLTEVRN----------IDTG--PMRFYYVVGWGIPAIVT----G----LAVGLDPQGYGNOV21d VQATDRDQGQNAAIHYSILSGNVAGQFYLHSLSGILDVINPLDFEDVQKYSLSIKAQDGGNOV21a RPPLINSSGVVSVQVLDVNDNEPIFVSSPFQATVLENVPLGYPVVHIQAVDADSGENARLNOV21b AVDIFDKFNFTGARVPRFDTIHEEFPRELESSVSFPADFFRPPEEKEGPLLRPAGRRTTPNOV21c NPDFC----WLSLQDTLI----WSFAG-PIGAVIIINT--------VTSVLSAKVSCQRKNOV21d RPPLINSSGVVSVQVLDVNDNEPIFVSSPFQATVLENVPLGYPVVHIQAVDADSGENARLNOV21a HYRLVDTASTFLGGGSAGPKNPAPTPDFPFQIHNSSGWITVCAELDRE-EVEHYSFGVBANOV21b QTTRPGPGTEREAPISRRRRHPDDAGQFAVALVIIYRTLGQLLPERYD-PDRRSLRLPHRNOV21c HH--------YYG--KKGIVSLLRT-AFLLLLLISATWLLGLLAVNRDALSFHYLFAIFSNOV21d HYRLVDTASTFLGGGSAGPKNPAPTPDFPFQIRNSSGWITVCAELDREEVE-HYSFGVEANOV21a VDHGSPPMSSSTSVSITVLDVNDNDPVFTQPTYELRLNEDAAVGSSVLTLQARDRDANSVNOV21b PIINTPMVSTLVYSEGAPLPRPLERPVLVEFALLEVEERTKPVCVFWNHSLAVGGTGGWSNOV21c GLQG-P------FV-LLFHCV-LNQEVKLA------------------------------NOV21d VDHGWPPMSSSTSVSITVLDVNDNDPVFTQPTYELRLNEDAAVGSSVLTLQARDRDANSVNOV21a ITYQLTGGNTRNRFALSSQRGGGLITLALPLDYKQEQQYVLAVTASDGTRSHTAHVLINVNOV21b ARGCELLSRNRTHVACQCSHTASFAVLMDISRRENGEKL---------------------NOV21c ------------------------------------------------------------NOV21d ITYQLTGGNTRNRFALSSQRGGGLITLALPLDYKQEQQYVLAVTASDGTRSHTAHVLINVNOV21a TDANTHRPVFQSSHYTVSVSEDRPVGTSIATLSANDEDTGENARITYVIQDPVPQFRIDPNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d TDANTHRPVFQSSHYTVSVSEDRPVGTSIATLSANDEDTGENARITYVIQDPVPQFRIDPNOV21a DSGTMYTMMELDYENQVAYTLTIMAQDNGIPQKSDTTTLEILILDANDNAPQFLWDFYQGNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d DSGTMYTMMELDYENQVAYTLTIMAQDNGIPQKSDTTTLEILILDANDNAPQFLWDFYQGNOV21a SIFEDAPPSTSILQVSATDRDSGPNGRLLYTFQGGDDGDGDFYIEPTSGVIRTQRRLDRENOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d SIFEDAPPSTSILQVSATDRDSGPNGRLLYTFQGGDDGDGDFYIEPTSGVIRTQRRLDRENOV21a NVAVYNLWALAVDRGSPTPLSASVEIQVTILDINDNAPMFEKDELELFVEENNPVGSVVANOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d NVAVYNLWALAVDRGSPTPLSASVEIQVTILDINDNAPMFEKDELELFVEENNPVGSVVANOV21a KIRANDPDEGPNAQIMYQIVEGDMRHFFQLDLLNGDLRAMVELDFEVRREYVLVVQATSANOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d KIRANDPDEGPNAQIMYQIVEGDMRHFFQLDLLNGDLRAMVELDFEVRREYVLVVQATSANOV21a PLVSRATVHILLVDQNDNPPVLPDFQILFNNYVTNKSNSFPTGVIGCIPAHDPDVSDSLNNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d PLVSRATVHILLVLE---------------------------------------------NOV21a YTFVQGNELRLLLLDPATGELQLSRDLDNNRPLEALMEVSVSADGIHSVTAFCTLRVTIINOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a TDDMLTNSITVRLENMSQEKFLSPLLALFVEGVAAVLSTTKDDVFVFNVQNDTDVSSNILNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a NVTFSALLPGGVRGQFFPSEDLQEQIYLNRTLLTTISTQRVLPFDDNICLREPCENYMKCNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a VSVLRFDSSAPFLSSTTVLFRPIHPINGLRCRCPPGFTGDYCETEIDLCYSDPCGANGRCNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a RSREGGYTCECFEDFTGEHCEVDARSGRCANGVCKNGGTCVNLLIGGFHCVCPPGEYERPNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a YCEVTTRSFPPQSFVTFRGLRQRFHFTISLTFATQERNGLLLYNGRFNEKHDFIALEIVDNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a EQVQLTFSAGAGETTTTVAPKVPSGVSDGRWHSVQVQYYNKVRWAPPLPPGPQPNIGHLGNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a LPHGPSGEKMAVVTVDDCDTTMAVRFGKDIGNYSCAAQGTQTGSKKSLDLTGPLLLGGVPNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a NLPEDFPVHNRQFVGCMRNLSVDGKNVDMAGFIANNGTREGCAARRNFCDGRRCQNGGTCNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a VNRWNMYLCECPLRFGGKNCEQAMPHPQLFSGESVVSWSDLNIIISVPWYLGLMFRTRKENOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a DSVLMEATSGGPTSFRLQILNNYLQFEVSHGPSDVESVMLSGLRVTDGEWHHLLIELKNVNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a KEDSEMKHLVTMTLDYGMDQNXADIGGMLPGLTVRSVVVGGASEDKVSVRRGFRGCMQGVNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a RNGGTPTNVATLNMNNALKVRVKDGCDVDDPCTSSPCPPNSRCHDAWEDYSCVCDKGYLGNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a INCVDACHLNPCENNGACVRSPGSPQGYVCECGPSHYGPYCENKLDLPCPRGWWGNPVCGNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a PCHCAVSKGFDPDCNKTNGQCQCKENYYKLLAQDTCLPCDCFPHGSHSRTCDMATGQCACNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a KPGVIGRQCNRCDNPFAEVTTLGCEVIYNGCPKAFEAGIWWPQTKFGQPAAVPCPKGSVGNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a NAVRHCSGEKGWLPPELFNCTTISFVDLRAMNEKLSRNETQVDGARALQLVRALRSATQHNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a TGTLFGNDVRTAYQLLGHVLQHESWQQGFDLAATQDADFHEDVIHSGSALLAPATRAAWENOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a QIQRSEGGTAQLLRRLEGYFSNVARNVRRTYLRPFVIVTANNVLAVDIFDKFNFTGARVPNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a RFDTIHEEFPRELESSVSFPADFFRPPEEKEGPLLRPAGRRTTPQTTRPGPGTEREAPISNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a RRRRHPDDAGQFAVALVIIYRTLGQLLPERYDPDRRSLRLPHRPIINTPMVSTLVYSEGANOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a PLPRPLERPVLVEFALLEVEERTKPVCVFWNHSLAVGGTGGWSARGCELLSRNRTHVACQNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a CSHTASFAVLMDISRRENGEVLPLKIVTYAAVSLSLAALLVAFVLLSLVRMLRSNLHSIHNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a KHLAVALFLSQLVFVIGINQTENPFLCTVVAILLHYIYMSTFAWTLVESLHVYRMLTEVRNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a NIDTGPMRFYYVVGWGIPAIVTGLAVGLDPQGYGNPDFCWLSLQDTLIWSFAGPIGAVIINOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a INTVTSVLSAKVSCQRKHHYYGKKGIVSLLRTAFLLLLLISATWLLGLLAVNRDALSFHYNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a LFAIFSGLQGPFVLLFHCVLNQEVRKHLKGVLGGRKLHLEDSATTRATLLTRSLNCNTTFNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a GDGPDMLRTDLGESTASLDSIVRDEGIQKLGVSSGLVRGSHGEPDASLMPRSCKDPPGHDNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a SDSDSELSLDEQSSSYASSHSSDSEDDGVGAEEKWDPARGAVHSTPKGDAVANHVPAGWPNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a DQSLAESDSEDPSGKPRLKVETKVSVELHREEQGSHRGEYPPDQESGGAARLASSQPPEQNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a RSILKNKVTYPPPLTLTEQTLKGRLREKLADCEQSPTSSRTSSLGSGGPDCAITVKSPGRNOV21b ------------------------------------------------------------NOV21c ------------------------------------------------------------NOV21d ------------------------------------------------------------NOV21a EPGRDHLNGVAMNVRTGSAQADGSDSEKPNOV21b -----------------------------NOV21c -----------------------------NOV21d -----------------------------NOV21a (SEQ ID NO: 276)NOV21b (SEQ ID NO: 278)NOV21c (SEQ ID NO: 280)NOV21d (SEQ ID NO: 282)

Further analysis of the NOV21a protein yielded the following properties shown in Table 21C.

TABLE 21CProtein Sequence Properties NOV21aSignalP analysis: Cleavage site between residues 21 and 22PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 26; peak value 9.94PSG score: 5.54GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 3.49possible cleavage site: between 20 and 21>>> Seems to have a cleavable signal peptide (1 to 20)ALOM:Klein et al's method for TM region allocationInit position for calculation: 21Tentative number of TMS(s) for the threshold 0.5: 10INTEGRAL Likelihood = −4.99Transmembrane 1220 −1236INTEGRAL Likelihood = −0.53Transmembrane 2251 −2267INTEGRAL Likelihood = −0.06Transmembrane 2351 −2367INTEGRAL Likelihood = −9.92Transmembrane 2489 −2505INTEGRAL Likelihood = −5.95Tranamembrane 2521 −2537INTEGRAL Likelihood = −1.54Transmembrane 2544 −2560INTEGRAL Likelihood = −2.81Transmembrane 2591 −2607INTEGRAL Likelihood = −1.59Transmembrane 2631 −2647INTEGRAL Likelihood = −8.92Transmembrane 2674 −2690INTEGRAL Likelihood = −1.17Transmembrane 2703 −2719PERIPHERAL Likelihood = 2.81 (at 1076)ALOM score: −9.92 (number of TMSs: 10)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 10Charge difference: 1.0 C( 2.0) - N( 1.0)C > N: C-terminal side will be inside>>> Caution: Inconsistent mtop result with signal peptide>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75)1.33Hyd Moment(95):2.60G content:1D/E content:1S/T content:0Score: −5.63Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 69 PRA|PRNUCDISC: discrimination of nuclear localization signalspat4: RRRR (5) at 2340pat4: RRRH (3) at 2341pat7: PARRARR (4) at 229pat7: PISRRRR (5) at 2337bipartite: nonecontent of basic residues: 9.1%NLS Score: 0.80KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: DSEKSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 70.6COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):66.7%: endoplasmic reticulum11.1%: vacuolar11.1%: mitochondrial11.1%: cytoplasmic>> prediction for CG51965-01 is end (k = 9)

A search of the NOV21a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 21D.

TABLE 21DGeneseq Results for NOV21aNOV21aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE08586Human NOV7 protein - Homo1 . . . 3028 3028/3028 (100%)0.0sapiens, 3028 aa.1 . . . 3028 3028/3028 (100%)[WO200161009-A2, 23-AUG-2001]ABP81979Human GPCR1 . . . 30283011/3029 (99%)0.0CELSR1/Flamingo protein1 . . . 30143012/3029 (99%)SEQ ID NO: 444 - Homosapiens, 3014 aa.[WO200261087-A2, 08-AUG-2002]AAU02196Seven-pass transmembrane1 . . . 30283011/3029 (99%)0.0receptor-like protein, MEM1 -1 . . . 30143012/3029 (99%)Homo sapiens, 3014 aa.[WO200144473-A2, 21-JUN-2001]AAU68533Human novel cytokine encoded1 . . . 30283011/3029 (99%)0.0by cDNA 790C1P2C_4 #1 -1 . . . 30143012/3029 (99%)Homo sapiens, 3014 aa.[WO200175093-A1, 11-OCT-2001]AAW27161Mouse receptor ME2 - Mus256 . . . 2902 2138/2647 (80%)0.0musculus, 2707 aa.35 . . . 2663 2345/2647 (87%)[WO9707209-A2, 27-FEB-1997]

In a BLAST search of public sequence databases, the NOV21a protein was found to have homology to the proteins shown in the BLASTP data in Table 21E.

TABLE 21EPublic BLASTP Results for NOV21aNOV21aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9NYQ6Cadherin EGF LAG seven-pass1 . . . 30283011/3029 (99%)0.0G-type receptor 1 precursor1 . . . 30143012/3029 (99%)(Flamingo homolog 2) (hFmi2) -Homo sapiens (Human), 3014 aa.O35161Cadherin EGF LAG seven-pass1 . . . 30282453/3057 (80%)0.0G-type receptor 1 precursor - Mus1 . . . 30342680/3057 (87%)musculus (Mouse), 3034 aa.E1260972SEQUENCE 3 FROM PATENT256 . . . 2902 2138/2647 (80%)0.0WO9707209 - unidentified, 270735 . . . 2663 2345/2647 (87%)aa.Q9HCU4Cadherin EGF LAG seven-pass223 . . . 3026 1658/2839 (58%)0.0G-type receptor 2 precursor163 . . . 2915 2067/2839 (72%)(Epidermal growth factor-like 2)(Multiple epidermal growthfactor-like domains 3) (Flamingo1) - Homo sapiens (Human), 2923aa.Q9R0M0Cadherin EGF LAG seven-pass2 . . . 30261665/3072 (54%)0.0G-type receptor 2 precursor8 . . . 29122095/3072 (67%)(Flamingo 1) (mFmi1) - Musmusculus (Mouse), 2920 aa.

PFam analysis indicates that the NOV21a protein contains the domains shown in the Table 21F.

TABLE 21FDomain Analysis of NOV21aIdentities/NOV21aSimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValuecadherin250 . . . 34435/110 (32%)1e-1470/110 (64%)cadherin358 . . . 45044/107 (41%)1.8e-2172/107 (67%)cadherin464 . . . 55638/107 (36%) 2e-2474/107 (69%)cadherin570 . . . 67839/124 (31%)3.8e-2387/124 (70%)cadherin692 . . . 78035/107 (33%)7.4e-1971/107 (66%)cadherin794 . . . 88342/107 (39%)1.6e-2873/107 (68%)cadherin897 . . . 99041/108 (38%)2.2e-2776/108 (70%)cadherin1004 . . . 109238/107 (36%)3.8e-2267/107 (63%)EGF1308 . . . 1361 16/61 (26%)0.71 38/61 (62%)EGF1368 . . . 1399 15/47 (32%)1.8e-05 26/47 (55%)EGF1408 . . . 1441 19/47 (40%)5.3e-07 29/47 (62%)laminin_G1471 . . . 164743/206 (21%)5.5e-17138/206 (67%) EGF1668 . . . 1699 17/47 (36%)4.7e-07 24/47 (51%)laminin_G1734 . . . 186726/163 (16%)0.003490/163 (55%)EGF1891 . . . 1922 11/47 (23%)7.7e-05 24/47 (51%)EGF1926 . . . 1960 18/47 (38%)0.0057 24/47 (51%)laminin_EGF1981 . . . 2015 13/60 (22%)0.87 24/60 (40%)laminin_EGF2018 . . . 2063 26/59 (44%)8.8e-09 31/59 (53%)HRM2067 . . . 2124 21/77 (27%)5.1e-17 47/77 (61%)GPS2422 . . . 2475 26/56 (46%)1.6e-21 46/56 (82%)7tm_22480 . . . 272388/274 (32%)6.4e-90210/274 (77%)

Example 22

The NOV22 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 22A.

TABLE 22ANOV22 Sequence AnalysisNOV22a, CG51983-05SEQ ID NO: 2892268 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAG at 2266ATGCTTCCCGGGTGTATATTCTTGATGATTTTACTCATTCCTCAGGTTAAAGAAAAGTTCATCCTTGGAGTAGAGGGTCAACAACTGGTTCGTCCTAAAAAGCTTCCTCTGATACAGAAGCGAGATACTGGACACACCCATGATGATGACATACTGAAAACGTATGAAGAAGAATTGTTGTATGAAATAAAACTAAATAGAAAAACCTTAGTCCTTCATCTTCTAAGATCCAGGGAGTTCCTAGGCTCAAATTACAGTGAAACATTCTACTCCATGAAAGGAGAAGCGTTCACCAGGCATCCTCAGATCATGGAACACTGTTACTATAAAGGAAACATCCTAAATGAAAAGAATTCTGTTGCCAGCATCAGTACTTGTGACGGGTTGAGGGGATTCTTCAGAATAAACGACCAAAGATACCTCATTGAACCAGTGAAATACTCAGATGAGGGAGAACATTTGGTGTTCAAATATAACCTGAGGGTGCCGTATGGTGCCAATTATTCCTGTACAGAGCTTAATTTTACCAGAAAAACTGTTCCAGGGGATAATGAATCTGAAGAAGACTCCAAAATAAAAGGCATCCATGATGAAAAGTATGTTGAATTGTTCATTGTTGCTGATGATACTGTGTATCGCAGAAATGGTCATCCTCACAATAAACTAAGGAACCGAATTTGGGGAATGGTCAATTTTGTCAACATGATTTATAAAACCTTAAACATCCATGTGACGTTGGTTGGCATTGAAATATGGACACATGAAGATAAATAGAACTATATTCAAATATAGAAACTACCTTATTGCGTTTTTTCATTTTGGCAAGAAAAGATCCTTAAAACACGGAAGGATTTTGATCATGTTGTATTACTCAGTGGGAAGTGGCTCTACTCACATGTGCAAGGAATTTCTTATCCAGGGGGTATGTGCCTGCCCTATTATTCCACCAGTATCATTAAGGATCTTTTACCTGACACAAACATAATTGCAAACAGAATGGCACATCAACTGGGGCATAACCTTGGGATGCAGCATGACGAGTTCCCATGCACCTGTCCTTCAGGAAAATGCGTGATGGACAGTGATGGAAGCATTCCTGCACTGAAATTCAGTAAATGCAGCCAAAACCAATACCACCAGTACTTGAAGGATTATAAGCCAACATGCATGCTCAACATTCCATTTCCTTACAATTTTCATGATTTCCAATTTTGTGGAAACAAGAAGTTGGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCAATGGATTTCCTTGCAAGAACTCAGAAGGCTACTGTTTCATGGGGAAATGTCCAACTCGTGAGGATCAGTGCTCTGAACTATTTGATGATGAGGCAATAGAGAGTCATGATATCTGCTACAAGATGAATACAAAAGGAAATAAATTTGGATACTGCAAAAACAAGGAAAACAGATTTCTTCCCTGTGAGGAGAAGGATGTCAGATGTGGAAAGATCTACTGCACTGGAGGGGAGCTTTCCTCTCTCCTTGGAGAAGACAAGACTTATCACCTTAAGGATCCCCAGAAGAATGCTACTGTCAAATGCAAAACTATTTTTTTATACCATGATTCTACAGACATTGGCCTGGTGGCGTCAGGAACAAAATGTGGAGAGGGAATGGTATGCAACAATGGTGAATGTCTAAACATGGAAAAGGTCTATATCTCAACCAATTGCCCCTCTCAGTGCAATGAAAATCCTGTAGATGGCCACGGACTCCAGTGCCACTGTGAGGAAGGACAGGCACCTGTAGCCTGTGAAGAAACCTTACATGTTACCAGTATCACCATCTTGGTTGTTGTGCTTGTCCTGGTTATTGTCGGTATCGGAGTTCTTATACTATTAGTTCGTTACCGAAAATGTATCAAGTTGAAGCAAGTTCAGAGCCCACCTACAGAAACCCTGGGAGTGGAGAACAAAGGATACTTTGGTGATGAGCAGCAGATAAGGACTGAGCCAATCCTGCCAGAAATTCATTTCCTAAATAAACCTGCAAGTAAAGATTCAAGAGGAATCGCAGATCCCAATCAAAGTGCCAAGTGGTAGNOV22a, CG51983-05SEQ ID NO: 290755 aaMW at 85868.5kDProtein SequenceMLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLYEIKLNRKTLVLHLLRSREFLGSNYSETFYSMKGEAFTRHPQIMEHCYYKGNILNEKNSVASISTCDGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVPGDNESEEDSKIKGIHDEKYVELFIVADDTVYRRNGHPHNKLRMRIWGMVNFVNMIYKTLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVMDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCABGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYCKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVACEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDEQQIRTEPILPEIHFLNKPASKDSRGIADPNQSAKWNOV22b, CG51983-01SEQ ID NO: 2912431 bpDNA SequenceORF Start: ATG at 51ORF Stop: TAG at 2385GAACTCCTTTTCTCAAGCACTTCTGCTCTCCTCTACCAGAATCACTCAGAATGCTTCCCGGGTGTATATTCTTGATGATTTTACTCATTCCTCAGGTTAAAGAAAAGTTCATCCTTGGAGTAGAGGGTCAACAACTGGTTCGTCCTAAAAAGCTTCCTCTGATACAGAAGCGAGATACTGGACACACCCATGATGATGACATAAAAACGTATGAAGAAGAATTGTTGTATGAAATAAAACTAAATAGAAAAACCTTAGTCCTTCATCTTCTAAGATCCAGGAGGGAGTTCCTAGGCTCAAATTACAGTGAAACATTCTACTCCATGAAAGGAGAAGCGTTCACCAGGCATCCTCAGATCATGGATCATTGTTTTTACCAAGGATCCATAGTACACGAATATGATTCAGCTGCCAGTATCAGTACGTGTAATGGTCTAAGGGGATTCTTCAGAATAAACGACCAAAGATACCTCATTGAACCAGTGAAATACTCAGATGAGGGAGAACATTTGGTGTTCAAATATAACCTGAGGGTGCCGTATGGTGCCAATTATTCCTGTACAGAGCTTAATTTTACCAGAAAAACTGTTCCAGGGGATAATGAATCTGAAGAAGACTCCAAAATAAAACAGGGCATCCATGATGAAAAGTATGTTGAATTGTTCATTGTTGCTGATGATACTGTGTATCGCAGAAATGGTCATCCTCACAATAAACTAAGGAACCGAATTTGGGGAATGGTCAATTTTGTCAACATGATTTATAAAACCTTAAACATCCATGTGACGTTGGTTGGCATTGAAATATGGACACATGAAGATAAAATAGAACTATATTCAAATATAGAAACTACCTTATTGCGTTTTTCATTTTGGCAAGAAAAGATCCTTAAAACACGGAAGGATTTTGATCATGTTGTATTACTCAGTGGGAAGTGGCTCTACTCACATGTGCAAGGAATTTCTTATCCAGGGGGTATGTGCCTGCCCTATTATTCCACCAGTATCATTAAGGATCTTTTACCTGACACAAACATAATTGCAAACAGAATGGCACATCAACTGGGGCATAACCTTGGGATGCAGCATGACGAGTTCCCATGCACCTGTCCTTCAGGAAAATGCGTGATGGACAGTGATGGAAGCATTCCTGCACTGAAATTCAGTAAATGCAGCCAAAACCAATACCACCAGTACTTGAAGGATTATAAGCCAACATGCATGCTCAACATTCCATTTCCTTACAATTTTCATGATTTCCAATTTTGTGGAAACAAGAAGTTGGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCAATGGATTTCCTTGCAAGAACTCAGAAGGCTACTGTTTCATGGGGAAATGTCCAACTCGTGAGGATCAGTGCTCTGAACTATTTGATGATGAGGCAATAGAGAGTCATGATATCTGCTACAAGATGAATACAAAAGGAAATAAATTTGGATACTGCAAAAACAAGGAAAACAGATTTCTTCCCTGTGAGGAGAAGGATGTCAGATGTGGAAAGATCTACTGCACTGGAGGGGAGCTTTCCTCTCTCCTTGGAGAAGACAAGACTTATCACCTTAAGGATCCCCAGAAGAATGCTACTGTCAAATGCAAAACTATTTTTTTATACCATGATTCTACAGACATTGGCCTGGTGGCGTCAGGAACAAAATGTGGAGAGGGAATGGTATGCAACAATGGTGAATGTCTAAACATGGAAAAGGTCTATATCTCAACCAATTGCCCCTCTCAGTGCAATGAAAATCCTGTAGATGGCCACGGACTCCAGTGCCACTGTGAGGAAGGACAGGCACCTGTAGCCTGTGAAGAAACCTTACATGTTACCAGTATCACCATCTTGGTTGTTGTGCTTGTCCTGGTTATTGTCGGTATCGGAGTTCTTATACTATTAGTTCGTTACCGAAAATGTATCAAGTTGAAGCAAGTTCAGAGCCCACCTACAGAAACCCTGGGAGTGGAGAACAAAGGATACTTTGGTGATGAGCAGCAGATAAGGACTGAGCCAATCCTGCCAGAAATTCATTTCCTAAATCAGAGAACTCCAGAATCCTTGGAAAGCCTGCCCACTAGTTTTTCAAGTCCCCACTACATCACACTGAAACCTGCAAGTAAAGATTCAAGAGGAATCGCAGATCCCAATCAAAGTGCCAAGTGGTAGGTTACCCTGACAGATAGTACCTCCCTTTTTTATTTTTCAAATGCNOV22b, GG51983-01SEQ ID NO: 292778 aaMW at 88471.2kDProtein SequenceMLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDIKTYEEELLYEIKLNRKTLVLHLLRSRREFLGSNYSETFYSMKGEAFTRHPQIMDHCFYQGSIVHEYDSAASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVPGDNESEEDSKIKQGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKTLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVMDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYCKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVACEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDEQQIRTEPILPEIHFLNQRTPESLESLPTSFSSPHYITLKPASKDSRGIADPNQSAKWNOV22c, GG51983-02SEQ ID NO: 2932583 bpDNA SequenceORF Start: ATG at 85ORF Stop: TGA at 2347GATCCCTGCAGTGGAAGTGAGGAGGAAGAAAGGTGAACTCCTTTTCTCAAGCACTTCTGCTCTCCTCTACCAGAATCACTCAGAATGCTTCCCGGGTGTATATTCTTGATGATTTTACTCATTCCTCAGGTTAAAGAAAAGTTCATCCTTGGAGTAGAGGGTCAACAACTGGTTCGTCCTAAAAAGCTTCCTCTGATACAGAAGCGAGATACTGGACACACCCATGATGATGACATACTGAAAACGTATGAAGAAGAATTGTTGTATGAAATAAAACTAAATAGAAAAACCTTAGTCCTTCATCTTCTAAGATCCAGGGAGTTCCTAGGCTCAAATTACAGTGAAACATTCTACTCCATGAAAGGAGGAGCGTTCACCAGGCATCCTCAGATCATGGATCATTGTTTTTACCAAGGATCCATAGTACACGAATATGATTCAGCTGCCAGTATCAGTACGTGTAATGGTCTAAGGGGATTCTTCAGAATAAACGACCAAAGATACCTCATTGAACCAGTGAAATACTCAGATGAGGGAGAACATTTGGTGTTCAAATATAACCTGAGGGTGCCGTATGGTGCCAATTATTCCTGTACAGAGCTTAATTTTACCAGAAAAACTGTTCCAGGGGATAATGAATCTGAAGAAGACTCCAAAATAAAAGGCATCCATGATGAAAAGTATGTTGAATTGTTCATTGTTGCTGATGATACTGTGTATCGCAGAAATGGTCATCCTCACAATAAACTAAGGAACCGAATTTGGGGAATGGTCAATTTTGTCAACATGATTTATAAAACCTTAAACATCCATGTGACGTTGGTTGGCATTGAAATATGGACACATGAAGATAAAATAGAACTATATTCAAATATAGAAACTACCTTATTGCGTTTTTCATTTTGGCAAGAAAAGATCCTTAAAACACGGAAGGATTTTGATCATGTTGTATTACTCAGTGGGAAGTGGCTCTACTCACATGTGCAAGGAATTTCTTATCCAGGGGGTATGTGCCTGCCCTATTATTCCACCAGTATCATTAAGGATCTTTTACCTGACACAAACATAATTGCAAACAGAATGGCACATCAACTGGGGCATAACCTTGGGATGCAGCATGACGAGTTCCCATGCACCTGTCCTTCAGGAAAATGCGTGATGGACAGTGATGGAAGCATTCCTGCACTGAAATTCAGTAAATGCAGCCAAAACCAATACCACCAGTACTTGAAGGATTATAAGCCAACATGCATGCTCAACATTCCATTTCCTTACAATTTTCATGATTTCCAATTTTGTGGAAACAAGAAGTTGGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCAATGGATTTCCTTGCAAGAACTCAGAAGGCTACTGTTTCATGGGGAAATGTCCAACTCGTGAGGATCAGTGCTCTGAACTATTTGATGATGATGCAATAGAGAGTCATGATATCTGCTACAAGATGAATACAAAAGGAAATAAATTTGGATACTGCAAAAACAAGGAAAACAGATTTCTTCCCTGTGAGGAGAAAGATGTCAGATGTGGAAAGATCTACTGCACTGGAGGGGAGCTTTCCTCTCTCCTTGGAGAAGACAAGACTTATCACCTTAAGGATCCCCAGAAGAATGCTACTGTCAAATGCAAAACTATTTTTTTATACCATGATTCTACAGACATTGGCCTGGTGGCGTCAGGAACAAAATGTGGAGAGGGAATGGTGTGCAACAATGGTGAATGTCTAAACATGGAAAAGGTCTATATCTCAACCAATTGCCCCTCTCAGTGCAATGAAAATCCTGTGGATGGCCACGGACTCCAGTGCCACTGTGAGGAAGGACAGGCACCTGTAGCCTGTGAAGAAACCTTACATGTTACCAATATCACCATCTTGGTTGTTGTGCTTGTCCTGGTTATTGTCGGTATCGGAGTTCTTATACTATTAGTTCGTTACCGAAAATGTATCAAGTTGAAGCAAGTTCAGAGCCCACCTACAGAAACCCTGGGAGTGGAGAACAAAGGATACTTTGGTGATGAGCAGCAGATAAGGACTGAGCCAATCCTGCCAGAAATTCATTTCCTAAATAAACCTGCAAGTAAAGATTCAAGAGGAATCGCAGATCCCAATCAAAGTGCCAAGTGAGCTTGAAGTTGGATATCCAAAATGGCCGTGCAAGCTTAGGCTGGGGATTCTGGATGCAACGTCTTTACAACCTTACCTAGATATCTGCTACTCACATTTTTGGTAGTGTTTCAAACGTTCTTTATCCAGACAGACAATGTTTAAGAGAAACAACTTATTTCTGTTAATATTTACCGGTAGAATTCACACCCTCTATCATAAACATATGCTGCAGAAAAAAAAAAAAAAAAAAAANOV22c, CG51983-02SEQ ID NO: 294754 aaMW at 85582.1kDProtein SequenceMLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLYEIKLNRKTLVLHLLRSREFLGSNYSETFYSMKGGAFTRHPQIMDHCFYQGSIVHEYDSAASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVPGDNESEEDSKIKGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKTLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVMDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDDAIESHDICYKMNTKGNKFGYCKWKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVACEETLHVTNITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDEQQIRTEPILPEIHFLNKPASKDSRGIADPNQSAKNOV22d, GG51983-03SEQ ID NO: 2952274 bpDNA SequenceORF Start: ATG at 4ORF Stop: TAG at 2272AGAATGCTTCCCGGGTGTATATTCTTGATGATTTTACTCATTCCTCAGGTTAAAGAAAAGTTCATCCTTGGAGTAGAGGGTCAACAACTGGTTCGTCCTAAAAAGCTTCCTCTGATACAGAAGCGAGATACTGGACACACCCATGATGATGACATAAAAAACGTATGAAGAAGAATTGTTGTATGAATAAAACTAAATAGAAAAACCTTAGTCCTTCATCTTCTAAGATCCAGGAGGGAGTTCCTAGGCTCAAATTACAGTGAAACATTCTACTCCATGAAAGGAGAAGCGTTCACCAGGCATCCTCAGATCATGGATCATTGTTTTTACCAAGGATCCATAGTACACGAATATGATTCAGCTGCCAGTATCAGTACGTGTAATGGTCTAAGGGGATTCTTCAGAATAAACGACCAAAGATACCTCATTGAACCAGTGAAATACTCAGATGAGGGAGAACATTTGGTGTTCAAATATAACCTGAGGGTGCCGTATGGTGCCAATTATTCCTGTACAGAGCTTAATTTTACCAGAAAAACTGTTCCAGGGGATAATGAATCTGAAGAAGACTCCAAAATAAAACAGGGCATCCATGATGAAAAGTATGTTGAATTGTTCATTGTTGCTGATGATACTGTGTATCGCAGAAATGGTCATCCTCACAATAAACTAAGGAACCGAATTTGGGGAATGGTCAATTTTGTCAACATGATTTATAAAACCTTAAACATCCATGTGACGTTGGTTGGCATTGAAATATGGACACATGAAGATAAAATAGAACTATATTCAAATATAGAAACTACCTTATTGCGTTTTTCATTTTGGCAAGAAAAGATCCTTAAAACACGGAAGGATTTTGATCATGTTGTATTACTCAGTGGGAAGTGGCTCTACTCACATGTGCAAGGAATTTCTTATCCAGGGGGTATGTGCCTGCCCTATTATTCCACCAGTATCATTAAGGATCTTTTACCTGACACAAACATAATTGCAAACAGAATGGCACATCAACTGGGGCATAACCTTGGGATGCAGCATGACGAGTTCCCATGCACCTGTCCTTCAGGAAAATGCGTGATGGACAGTGATGGAAGCATTCCTGCACTGAAATTCAGTAAATGCAGCCAAAACCAATACCACCAGTACTTGAAGGATTATAAGCCAACATGCATGCTCAACATTCCATTTCCTTACAATTTTCATGATTTCCAATTTTGTGGAAACAAGAAGTTGGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCAATGGATTTCCTTGCAAGAACTCAGAAGGCTACTGTTTCATGGGGAAATGTCCAACTCGTGAGGATCAGTGCTCTGAACTATTTGATGATGAGGCAATAGAGAGTCATGATATCTGCTACAAGATGAATACAAAAGGAAATAAATTTGGATACTGCAAAAACAAGGAAAACAGATTTCTTCCCTGTGAGGAGAAGGATGTCAGATGTGGAAAGATCTACTGCACTGGAGGGAAGCTTTCCTCTCTCCTTGGAGAAGACAAGACTTATCACCTTAAGGATCCCCAGAAGAATGCTACTGTCAAATGCAAAACTATTTTTTTATACCATGATTCTACAGACATTGGCCTGGTGGCGTCAGGAACAAAATGTGGAGAGGGAATGGTATGCAACAATGGTGAATGTCTAAACATGGAAAAGGTCTATATCTCAACCAATTGCCCCTCTCAGTGCAATGAAAATCCTGTAGATGGCCACGGACTCCAGTGCCACTGTGAGGAAGGACAGGCACCTGTAGCCTGTGAAGAAACCTTACATGTTACCAGTATCACCATCTTGGTTGTTGTGCTTGTCCTGGTTATTGTCGGTATCGGAGTTCTTATACTATTAGTTCGTTACCGAAAATGTATCAAGTTGAAGCAAGTTCAGAGCCCACCTACAGAAACCCTGGGAGTGGAGAACAAAGGATACTTTGGTGATGAGCAGCAGATAAGGACTGAGCCAATCCTGCCAGAAATTCATTTCCTAAATAAACCTGCAAGTAAAGATTCAAGAGGAATCGCAGATCCCAATCAAAGTGCCAAGTGGTAGNOV22d, CG51983-03SEQ ID NO: 296756 aaMW at 85998.5kDProtein SequenceMLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDIKTYEEELLYEIKLNRKTLVLHLLRSRREFLGSNYSETFYSMKGEAFTRHPQIMDHCFYQGSIVHEYDSAASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVPGDNESEEDSKIKQGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKTLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVMDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYCKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVACEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDEQQIRTEPILPEIHFLNKPASKDSRGIADPNQSAKWNOV22e, CG51983-04SEQ ID NO: 2972283 bpDNA SequenceORF Start: ATG at 12ORF Stop: TGA at 2274AATCACTCAGAATGCTTCCCGGGTGTATATTCTTGATGATTTTACTCATTCCTCAGGTTAAAGAAAAGTTCATCCTTGGAGTAGAGGGTCAACAACTGGTTCGTCCTAAAAAGCTTCCTCTGATACAGAAGCGAGATACTGGACACACCCATGATGATGACATACTGAAAACGTATGAAGAAGAATTGTTGTATGAAATAAAACTAAATAGAAAAACCTTAGTCCTTCATCTTCTAAGATCCAGGGAGTTCCTAGGCTCAAATTACAGTGAAACATTCTACTCCATGAAAGGAGGAGCGTTCACCAGGCATCCTCAGATCATGGATCATTGTTTTTACCAAGGATCCATAGTACACGAATATGATTCAGCTGCCAGTATCAGTACGTGTAATGGTCTAAGGGGATTCTTCAGAATAAACGACCAAAGATACCTCATTGAACCAGTGAAATACTCAGATGAGGGAGAACATTTGGTGTTCAAATATAACCTGAGGGTGCCGTATGGTGCCAATTATTCCTGTACAGAGCTTAATTTTACCAGAAAAACTGTTCCAGGGGATAATGAATCTGAAGAAGACTCCAAAATAAAAGGCATCCATGATGAAAAGTATGTTGAATTGTTCATTGTTGCTGATGATACTGTGTATCGCAGAAATGGTCATCCTCACAATAAACTAAGGAACCGAATTTGGGGAATGGTCAATTTTGTCAACATGATTTATAAAACCTTAAACATCCATGTGACGTTGGTTGGCATTGAAATATGGACACATGAAGATAAAATAGAACTATATTCAAATATAGAAACTACCTTATTGCGTTTTTCATTTTGGCAAGAAAAGATCCTTAAAACACGGAAGGATTTTGATCATGTTGTATTACTCAGTGGGAAGTGGCTCTACTCACATGTGCAAGGAATTTCTTATCCAGGGGGTATGTGCCTGCCCTATTATTCCACCAGTATCATTAAGGATCTTTTACCTGACACAAACATAATTGCAAACAGAATGGCACATCAACTGGGGCATAACCTTGGGATGCAGCATGACGAGTTCCCATGCACCTGTCCTTCAGGAAAATGCGTGATGGACAGTGATGGAAGCATTCCTGCACTGAAATTCAGTAAATGCAGCCAAAACCAATACCACCAGTACTTGAAGGATTATAAGCCAACATGCATGCTCAACATTCCATTTCCTTACAATTTTCATGATTTCCAATTTTGTGGAAACAAGAAGTTGGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCAATGGATTTCCTTGCAAGAACTCAGAAGGCTACTGTTTCATGGGGAAATGTCCAACTCGTGAGGATCAGTGCTCTGAACTATTTGATGATGATGCAATAGAGAGTCATGATATCTGCTACAAGATGAATACAAAAGGAAATAAATTTGGATACTGCAAAAACAAGGAAAACAGATTTCTTCCCTGTGAGGAGAAAGATGTCAGATGTGGAAAGATCTACTGCACTGGAGGGGAGCTTTCCTCTCTCCTTGGAGAAGACAAGACTTATCACCTTAAGGATCCCCAGAAGAATGCTACTGTCAAATGCAAAACTATTTTTTTATACCATGATTCTACAGACATTGGCCTGGTGGCGTCAGGAACAAAATGTGGAGAGGGAATGGTGTGCAACAATGGTGAATGTCTAAACATGGAAAAGGTCTATATCTCAACCAATTGCCCCTCTCAGTGCAATGAAAATCCTGTGGATGGCCACGGACTCCAGTGCCACTGTGAGGAAGGACAGGCACCTGTAGCCTGTGAAGAAACCTTACATGTTACCAATATCACCATCTTGGTTGTTGTGCTTGTCCTGGTTATTGTCGGTATCGGAGTTCTTATACTATTAGTTCGTTACCGAAAATGTATCAAGTTGAAGCAAGTTCAGAGCCCACCTACAGAAACCCTGGGAGTGGAGAACAAAGGATACTTTGGTGATGAGCAGCAGATAAGGACTGAGCCAATCCTGCCGGAAATTCATTTCCTAAATAAACCTGCAAGTAAAGATTCAAGAGGAATCGCAGATCCCAATCAAAGTGCCAAGTGAGCTTGAANOV22e, CG51983-04SEQ ID NO: 298754 aaMW at 85582.1kDProtein SequenceMLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLYEIKLNRKTLVLHLLRSREFLGSNYSETFYSMKGGAFTRHPQIMDHCFYQGSIVHEYDSAASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVPGDNESEEDSKIKGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKTLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVMDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDDAIESHDICYKMNTKGNKFGYCKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDIGLVASGTKCGEGMVCNNGECLNNEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVACEETLHVTNITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDEQQIRTEPILPEIHFLNKPASKDSRGIADPNQSAKNOV22f, CG51983-06SEQ ID NO: 2992464 bpDNA SequenceORF Start: ATG at 4ORF Stop: TGA at 2248AGAATGCTTCCCGGGTGTATATTCTTGATGATTTTACTCATTCCTCAGGTTAAAGAAAAGTTCATCCTTGGAGTAGAGGGTCAACAACTGGTTCGTCCTAAAAAGCTTCCTCTGATACAGAAGCGAGATACTGGACACACCCATGATGATGACATACTGAAAACGTATGAAGAAGAATTGTTGTATGAAATAAAACTAAATAGAAAAACCTTAGTCCTTCATCTTCTAAGATCCAGGGAGTTCCTAGGCTCAAATTACAGTGAAACATTCTACTCCATGAAAGGAGAAGCGTTCACCAGGCATCCTCAGATCATGGATCATTGTTTTTACCAAGGATCCATAGTACACGAATATGATTCAGCTGCCAGTATCAGTACGTGTAATGGTCTAAGGGGATTCTTCAGAATAAACGACCAAAGATACCTCATTGAACCAGTGAAATACTCAGATGAGGGAGAACATTTGGTGTTCAAATATAACCTGAGGGTGCCGTATGGTGCCAATTATTCCTGTACAGAGCTTAATTTTACCAGAAAAACTGTTCCAGGGGATAATGAATCTGAAGAAGACTCCAAAATAAAAGGCATCCATGATGAAAAGTATGTTGAATTGTTCATTGTTGCTGATGATACTGTGTATCGCAGAAATGGTCATCCTCACAATAAACTAAGGAACCGAATTTGGGGAATGGTCAATTTTGTCAACATGATTTATAAAACCTTAAACATCCATGTGACGTTGGTTGGCATTGAAATATGGACACATGAAGATAAAATAGAACTATATTCAAATATAGAAACTACCTTATTGCGTTTTTCATTTTGGCAAGAAAAGATCCTTAAAACACGGAAGGATTTTGATCATGTTGTATTACTCAGTGGGAAGTGGCTCTACTCACATGTGCAAGGAATTTCTTATCCAGGGGGTATGTGCCTGCCCTATTATTCCACCAGTATCATTAAGGATCTTTTACCTGACACAAACATAATTGCAAACAGAATGGCACATCAACTGGGGCATAACCTTGGGATGCAGCATGACGAGTTCCCATGCACCTGTCCTTCAGGAAAATGCGTGATGGACAGTGATGGAAGCATTCCTGCACTGAAATTCAGTAAATGCAGCCAAAACCAATACCACCAGTACTTGAAGGATTATAAGCCAACATGCATGCTCAACATTCCATTTCCTTACAATTTTCATGATTTCCAATTTTGTGGAAACAAGAAGTTGGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCAATGGATTTCCTTGCAAGAACTCAGAAGGCTACTGTTTCATGGGGAAATGTCCAACTCGTGAGGATCAGTGCTCTGAACTATTTGATGATGAGGCAATAGAGAGTCATGATATCTGCTACAAGATGAATACAAAAGGAAATAAATTTGGATACTGCAAAAACAAGGAAAACAGATTTCTTCCCTGTGAGGAGAAAGATGTCAGATGTGGAAAGACCTACTGCACTGGAGGGGAGCTTTCCTCTCTCCTTGGAGAAGACAAGACTTATCACCTTAAGGATCCCCAGAAGAATGCTACTGTCAAATGCAAAACTATTTTTTTATACCATGATTCTACAGACATTGGCCTGGTGGCGTCAGGAACAAAATGTGGAGAGGGAATGGTGGATGGCCACGGACTCCAGTGCCACTGTGAGGAAGGACAGGCACCTGTAGCCTGTGAAGAAACCTTACATGTTACCAATATCACCATCTTGGTTGTTGTGCTTGTCCTGGTTATTGTCGGTATCGGAGTTCTTATACTATTAGTTCGTTACCGAAAATGTATCAAGTTGAAGCAAGTTCAGAGCCCACCTACAGAAACCCTGGGAGTGGAGAACAAAGGATACTTTGGTGATGAGCAGCAGATAAGGACTGAGCCAATCCTGCCAGAAATTCATTTCCTAAATAGAACTCCAGAATCCTTGGAAAGCCTGCCCACTAGTTTTTCAAGTCCCCACTACATCACACTGAAACCTGCAAGTAAAGATTCAAGAGGAATCGCAGATCCCAATCAAAGTGCCAAGTGAGCTTGAAGTTGGATATCCAAAATGGCCGTGCAAGCTTAGGCTGGGGATTCTGGATGCAACGTCTTTACAACCTTACCTAGATATCTGCTACTCACATTTTTGGTAGTGTTTCAAACGTTCTTTATCCAGACAGACAATGTTTAAGAGAAACAACTTATTTCTGTTAATATTTACCGGTAGAATTCACACCCTCTATCATAAACATATGCTGCAGNOV22f, CG51983-06SEQ ID NO: 300748 aaMW at 85014.4kDProtein SequenceMLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLYEIKLNRKTLVLHLLRSREFLGSNYSETFYSMKGEAFTRHPQIMDHCFYQGSIVHEYDSAASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVPGDNESEEDSKIKGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKTLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVMDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYCKNKENRFLPCEEKDVRCGKTYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDIGLVASGTKCGEGMVDGHGLQCHCEEGQAPVACEETLHVTNITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDEQQIRTEPILPEIHFLNRTPESLESLPTSFSSPHYITLKPASKDSRGIADPNQSAKNOV22g, SNP13376585SEQ ID NO: 3012268 bpof GG51983-05, DNAORF Start: ATG at 1ORF Stop: TAG at 2266SequenceSNP Pos: 119SNP Change: A to GATGCTTCCCGGGTGTATATTCTTGATGATTTTACTCATTCCTCAGGTTAAAGAAAAGTTCATCCTTGGAGTAGAGGGTCAACAACTGGTTCGTCCTAAAAAGCTTCCTCTGATACAGAGGCGAGATACTGGACACACCCATGATGATGACATACTGAAAACGTATGAAGAAGAATTGTTGTATGAAATAAAACTAAATAGAAAAACCTTAGTCCTTCATCTTCTAAGATCCAGGGAGTTCCTAGGCTCAAATTACAGTGAAACATTCTACTCCATGAAAGGAGAAGCGTTCACCAGGCATCCTCAGATCATGGAACACTGTTACTATAAAGGAAACATCCTAAATGAAAAGAATTCTGTTGCCAGCATCAGTACTTGTGACGGGTTGAGGGGATTCTTCAGAATAAACGACCAAAGATACCTCATTGAACCAGTGAAATACTCAGATGAGGGAGAACATTTGGTGTTCAAATATAACCTGAGGGTGCCGTATGGTGCCAATTATTCCTGTACAGAGCTTAATTTTACCAGAAAAACTGTTCCAGGGGATAATGAATCTGAAGAAGACTCCAAAATAAAAGGCATCCATGATGAAAAGTATGTTGAATTGTTCATTGTTGCTGATGATACTGTGTATCGCAGAAATGGTCATCCTCACAATAAACTAAGGAACCGAATTTGGGGAATGGTCAATTTTGTCAACATGATTTATAAAACCTTAAACATCCATGTGACGTTGGTTGGCATTGAAATATGGACACATGAAGATAAAATAGAACTATATTCAAATATAGAAACTACCTTATTGCGTTTTTCATTTTGGCAAGAAAAGATCCTTAAAACACGGAAGGATTTTGATCATGTTGTATTACTCAGTGGGAAGTGGCTCTACTCACATGTGCAAGGAATTTCTTATCCAGGGGGTATGTGCCTGCCCTATTATTCCACCAGTATCATTAAGGATCTTTTACCTGACACAAACATAATTGCAAACAGAATGGCACATCAACTGGGGCATAACCTTGGGATGCAGCATGACGAGTTCCCATGCACCTGTCCTTCAGGAAAATGCGTGATGGACAGTGATGGAAGCATTCCTGCACTGAAATTCAGTAAATGCAGCCAAAACCAATACCACCAGTACTTGAAGGATTATAAGCCAACATGCATGCTCAACATTCCATTTCCTTACAATTTTCATGATTTCCAATTTTGTGGAAACAAGAAGTTGGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCAATGGATTTCCTTGCAAGAACTCAGAAGGCTACTGTTTCATGGGGAAATGTCCAACTCGTGAGGATCAGTGCTCTGAACTATTTGATGATGAGGCAATAGAGAGTCATGATATCTGCTACAAGATGAATACAAAAGGAAATAAATTTGGATACTGCAAAAACAAGGAAAACAGATTTCTTCCCTGTGAGGAGAAGGATGTCAGATGTGGAAAGATCTACTGCACTGGAGGGGAGCTTTCCTCTCTCCTTGGAGAAGACAAGACTTATCACCTTAAGGATCCCCAGAAGAATGCTACTGTCAAATGCAAAACTATTTTTTTATACCATGATTCTACAGACATTGGCCTGGTGGCGTCAGGAACAAAATGTGGAGAGGGAATGGTATGCAACAATGGTGAATGTCTAAACATGGAAAAGGTCTATATCTCAACCAATTGCCCCTCTCAGTGCAATGAAAATCCTGTAGATGGCCACGGACTCCAGTGCCACTGTGAGGAAGGACAGGCACCTGTAGCCTGTGAAGAAACCTTACATGTTACCAGTATCACCATCTTGGTTGTTGTGCTTGTCCTGGTTATTGTCGGTATCGGAGTTCTTATACTATTAGTTCGTTACCGAAAATGTATCAAGTTGAAGCAAGTTCAGAGCCCACCTACAGAAACCCTGGGAGTGGAGAACAAAGGATACTTTGGTGATGAGCAGCAGATAAGGACTGAGCCAATCCTGCCAGAAATTCATTTCCTAAATAAACCTGCAAGTAAAGATTCAAGAGGAATCGCAGATCCCAATCAAAGTGCCAAGTGGTAGNOV22g, SNP13376585 ofSEQ ID NO: 302755 aaMW at 85896.5k.DCG51983-05, ProteinSNP Pos: 40SNP Change: Lys to ArgSequenceMLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQRRDTGHTHDDDILKTYEEELLYEIKLNRKTLVLHLLRSREFLGSNYSETFYSMKGEAFTRHPQIMEHCYYKGNILNEKNSVASISTCDGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVPGDNESEEDSKIKGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKTLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVMDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCABGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYCKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVACEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDEQQIRTEPILPEIHFLNKPASKDSRGIADPNQSAKWNOV22h, SNP13376586 ofSEQ ID NO: 3032268 bpCG51983-05, DNA SequenceORF Start: ATG at 1ORF Stop: TAG at 2266SNP Pos: 125SNP Change: A to GATGCTTCCCGGGTGTATATTCTTGATGATTTTACTCATTCCTCAGGTTAAAGAAAAGTTCATCCTTGGAGTAGAGGGTCAACAACTGGTTCGTCCTAAAAAGCTTCCTCTGATACAGAAGCGAGGTACTGGACACACCCATGATGATGACATACTGAAAACGTATGAAGAAGAATTGTTGTATGAAATAAAACTAAATAGAAAAACCTTAGTCCTTCATCTTCTAAGATCCAGGGAGTTCCTAGGCTCAAATTACAGTGAAACATTCTACTCCATGAAAGGAGAAGCGTTCACCAGGCATCCTCAGATCATGGAACACTGTTACTATAAAGGAAACATCCTAAATGAAAAGAATTCTGTTGCCAGCATCAGTACTTGTGACGGGTTGAGGGGATTCTTCAGAATAAACGACCAAAGATACCTCATTGAACCAGTGAAATACTCAGATGAGGGAGAACATTTGGTGTTCAAATATAACCTGAGGGTGCCGTATGGTGCCAATTATTCCTGTACAGAGCTTAATTTTACCAGAAAAACTGTTCCAGGGGATAATGAATCTGAAGAAGACTCCAAAATAAAAGGCATCCATGATGAAAAGTATGTTGAATTGTTCATTGTTGCTGATGATACTGTGTATCGCAGAAATGGTCATCCTCACAATAAACTAAGGAACCGAATTTGGGGAATGGTCAATTTTGTCAACATGATTTATAAAACCTTAAACATCCATGTGACGTTGGTTGGCATTGAAATATGGACACATGAAGATAAAATAGAACTATATTCAAATATAGAAACTACCTTATTGCGTTTTTCATTTTGGCAAGAAAAGATCCTTAAAACACGGAAGGATTTTGATCATGTTGTATTACTCAGTGGGAAGTGGCTCTACTCACATGTGCAAGGAATTTCTTATCCAGGGGGTATGTGCCTGCCCTATTATTCCACCAGTATCATTAAGGATCTTTTACCTGACACAAACATAATTGCAAACAGAATGGCACATCAACTGGGGCATAACCTTGGGATGCAGCATGACGAGTTCCCATGCACCTGTCCTTCAGGAAAATGCGTGATGGACAGTGATGGAAGCATTCCTGCACTGAAATTCAGTAAATGCAGCCAAAACCAATACCACCAGTACTTGAAGGATTATAAGCCAACATGCATGCTCAACATTCCATTTCCTTACAATTTTCATGATTTCCAATTTTGTGGAAACAAGAAGTTGGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCAATGGATTTCCTTGCAAGAACTCAGAAGGCTACTGTTTCATGGGGAAATGTCCAACTCGTGAGGATCAGTGCTCTGAACTATTTGATGATGAGGCAATAGAGAGTCATGATATCTGCTACAAGATGAATACAAAAGGAAATAAATTTGGATACTGCAAAAACAAGGAAAACAGATTTCTTCCCTGTGAGGAGAAGGATGTCAGATGTGGAAAGATCTACTGCACTGGAGGGGAGCTTTCCTCTCTCCTTGGAGAAGACAAGACTTATCACCTTAAGGATCCCCAGAAGAATGCTACTGTCAAATGCAAAACTATTTTTTTATACCATGATTCTACAGACATTGGCCTGGTGGCGTCAGGAACAAAATGTGGAGAGGGAATGGTATGCAACAATGGTGAATGTCTAAACATGGAAAAGGTCTATATCTCAACCAATTGCCCCTCTCAGTGCAATGAAAATCCTGTAGATGGCCACGGACTCCAGTGCCACTGTGAGGAAGGACAGGCACCTGTAGCCTGTGAAGAAACCTTACATGTTACCAGTATCACCATCTTGGTTGTTGTGCTTGTCCTGGTTATTGTCGGTATCGGAGTTCTTATACTATTAGTTCGTTACCGAAAATGTATCAAGTTGAAGCAAGTTCAGAGCCCACCTACAGAAACCCTGGGAGTGGAGAACAAAGGATACTTTGGTGATGAGCAGCAGATAAGGACTGAGCCAATCCTGCCAGAAATTCATTTCCTAAATAAACCTGCAAGTAAAGATTCAAGAGGAATCGCAGATCCCAATCAAAGTGCCAAGTGGTAGNOV22h, SNP13376586 ofSEQ ID NO: 304755 aaMW at 85810.5kDCG51983-05, ProteinSNP Pos: 42SNP Change: Asp to GlySequenceMLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRGTGHTHDDDILKTYEEELLYEIKLNRKTLVLHLLRSREFLGSNYSETFYSMKGEAFTRHPQIMEHCYYKGNILNEKNSVASISTCDGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVPGDNESEEDSKIKGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKTLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVMDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYCKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDIGLVASGTKCGEGMVCNNGECLNNEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVACEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDEQQIRTEPILPEIHFLNKPASKDSRGIADPNQSAKW

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 22B.

TABLE 22BComparison of the NOV22 protein sequences.NOV22a MLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLNOV22b MLPGCIFLMILLIPQVKEKFILGVEGOQLVRPKKLPLIQKRDTGHTHDDDIK-TYEEELLNOV22c MLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLNOV22d MLPGCIFLMILLIPOVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDIK-TYEEELLNOV22e MLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLNOV22f MLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLNOV22a YEIKLNRKTLVLHLLRSR-EFLGSNYSETFYSMKGEAFTRHPQIMEHCYYKGNILNEKNSNOV22b YEIKLNRKTLVLHLLRSRREFLGSNYSETFYSMKGEAFTRHPQIMDHCFYQGSIVHEYDSNOV22c YEIKLNRKTLVLHLLRSR-EFLGSNYSETFYSMKGGAFTRHPQIMDHCFYQGSIVHEYDSNOV22d YEIKLNRKTLVLHLLRSRREFLGSNYSETFYSMKGEAFTRHPQIMDHCFYQGSIVHEYDSNOV22e YEIKLNRKTLVLHLLRSR-EFLGSNYSETFYSMKGGAFTRHPQIMDHCFYQGSIVHEYDSNOV22f YEIKLNRKTLVLHLLRSR-EFLGSNYSETFYSMKGEAFTRHPQIMDHCFYQGSIVHEYDSNOV22a VASISTCDGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTNOV22b AASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFYNLKRVPYGANYSCTELNFTRKTNOV22c AASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFYNLKRVPYGANYSCTELNFTRKTNOV22d AASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFYNLKRVPYGANYSCTELNFTRKTNOV22e AASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFYNLKRVPYGANYSCTELNFTRKTNOV22f AASISTCNGLRGFFRINDQRYLIEPVKYSDEGEHLVFYNLKRVPYGANYSCTELNFTRKTNOV22a VPGDNESEEDSKIKG-IHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKNOV22b VPGDNESEEDSKIKQGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKNOV22c VPGDNESEEDSKIKG-IHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKNOV22d VPGDNESEEDSKIKQGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKNOV22e VPGDNESEEDSKIKG-IHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKNOV22f VPGDNESEEDSKIKG-IHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKNOV22a TLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSNOV22b TLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSNOV22c TLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSNOV22d TLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSNOV22e TLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSNOV22f TLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSNOV22a HVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVNOV22b HVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVNOV22c HVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVNOV22d HVQGISYPGGMCLPYYSTSIIKDLLPDTNIEANRMAHQLGHNLGMQHDEFPCTCPSGKCVNOV22e HVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVNOV22f HVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVNOV22a MDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCNOV22b MDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCNOV22c MDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCNOV22d MDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCNOV22e MDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCNOV22f MDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCNOV22a GPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPNOV22b GPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPNOV22c GPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPNOV22d GPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPENCTGHSPNOV22e GPAQECTNPCCDAHTCVLKPGFTCABGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPNOV22f GPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPNOV22a ACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYNOV22b ACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYNOV22c ACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDDAIESHDICYKMNTKGNKFGYNOV22d ACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYNOV22e ACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDDAIESHDICYKMNTKGNKFGYNOV22f ACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYNOV22a CKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSNOV22b CKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSNOV22c CKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSNOV22d CKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSNOV22e CKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSNOV22f CKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSNOV22a TDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQGNENPVDGHGLQCHCEEGQAPVNOV22b TDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVNOV22c TDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQcNENPVDGHGLQCHCEEGQAPVNOV22d TDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVNOV22e TDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVNOV22f TDIGLVASGTKCGEGMVD---------------------------GHGLQCHCEEGQAPVNOV22a ACEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGNOV22b ACEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGNOV22c ACEETLHVTNITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGNOV22d ACEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGNOV22e ACEETLHVTNITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGNOV22f ACEETLHVTNITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGNOV22a DEQQIRTEPILPEIHFLN----------------------KPASKDSRGIADPNQSAKWNOV22b DEQQIRTEPILPEIHFLNQRTPESLESLPTSFSSPHYITLKPASKDSRGIADPNQSAKWNOV22c DEQQIRTEPILPEIHFLN----------------------KPASKDSRGIADPNQSAK-NOV22d DEQQIRTEPILPEIHFLN----------------------KPASKDSRGIADPNQSAKWNOV22e DEQQIRTEPILPEIHFLN----------------------KPASKDSRGIADPNQSAK-NOV22f DEQQIRTEPILPEIHFLN-RTPESLESLPTSFSSPHYITLKPASKDSRGIADPNQSAK-NOV22a (SEQ ID NO: 290)NOV22b (SEQ ID NO: 292)NOV22c (SEQ ID NO: 294)NOV22d (SEQ ID NO: 296)NOV22e (SEQ ID NO: 298)NOV22f (SEQ ID NO: 300)

Further analysis of the NOV22a protein yielded the following properties shown in Table 22C.

TABLE 22CProtein Sequence Properties NOV22aSignalP analysis: Cleavage site between residues 19 and 20PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 16; peak value 12.97PSG score: 8.57GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −5.58possible cleavage site: between 18 and 19>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 2INTEGRAL Likelihood = −2.18Transmembrane 1-17INTEGRAL Likelihood = −18.52Transmembrane 671-687PERIPHERAL Likelihood = 4.35 (at 235)ALOM score: —18.52 (number of TMSs: 2)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 8Charge difference: 0.0 C( 1.0) - N( 1.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):3.80Hyd Moment(95):1.48G content:1D/E content:1S/T content:0Score: −6.33Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: RPKK (4) at 31pat7: nonebipartite: nonecontent of basic residues: 11.5%NLS Score: −0.22KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: QSAKSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs:Bacterial regulatory proteins, gntR family signature (PS00043):*** found *** EEELLYEIKLNRKTLVLHLLRS at 56NNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 55.5COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23)34.8%: nuclear30.4%: endoplasmic reticulum21.7%: mitochondrial 4.3%: vesicles of secretory system 4.3%: cytoplasmic 4.3%: peroxisomal>> prediction for CG51983-05 is nuc (k = 23)

A search of the NOV22a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 22D.

TABLE 22DGeneseq Results for NOV22aNOV22aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAB47567Protease PRTS-9 - Homo sapiens,1 . . . 754749/776 (96%)0.0776 aa. [WO200171004-A2, 27-1 . . . 776751/776 (96%)SEP-2001]AAU77409Human NOV4b protein,1 . . . 755754/780 (96%)0.0homologue of ADAM proteins -1 . . . 779754/780 (96%)Homo sapiens, 779 aa.[WO200206329-A2, 24-JAN-2002]AAU77408Human NOV4a protein,1 . . . 755744/779 (95%)0.0homologue of ADAM proteins -1 . . . 778752/779 (96%)Homo sapiens, 778 aa.[WO200206329-A2, 24-JAN-2002]AAU16950Human novel secreted protein,1 . . . 677664/677 (98%)0.0SEQ ID 191 - Homo sapiens, 69517 . . . 693 675/677 (99%)aa. [WO200155441-A2, 02-AUG-2001]AAB64744Gene 16 human secreted protein336 . . . 710 353/375 (94%)0.0homologous amino acid sequence1 . . . 375364/375 (96%)#138 - Macaca fascicularis, 375aa. [WO200077237-A1, 21-DEC-2000]

In a BLAST search of public sequence databases, the NOV22a protein was found to have homology to the proteins shown in the BLASTP data in Table 22E.

TABLE 22EPublic BLASTP Results for NOV22aNOV22aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9H2U9ADAM 7 precursor (A disintegrin1 . . . 754741/754 (98%)0.0and metalloproteinase domain 7)1 . . . 754751/754 (99%)(Sperm maturation-relatedglycoprotein GP-83) - Homosapiens (Human), 754 aa.Q28475ADAM 7 precursor (A disintegrin1 . . . 754695/776 (89%)0.0and metalloproteinase domain 7)1 . . . 776726/776 (92%)(Epididymal apical protein I) (EAPI) - Macaca fascicularis (Crabeating macaque) (Cynomolgusmonkey), 776 aa.AAH43207Hypothetical protein - Homo212 . . . 736 524/525 (99%)0.0sapiens (Human), 561 aa29 . . . 553 525/525 (99%)(fragment).O35227ADAM 7 precursor (A disintegrin1 . . . 752507/773 (65%)0.0and metalloproteinase domain 7) -1 . . . 771620/773 (79%)Mus musculus (Mouse), 788 aa.Q63180ADAM 7 precursor (A disintegrin1 . . . 752505/773 (65%)0.0and metalloproteinase domain 7)1 . . . 772614/773 (79%)(Epididymal apical protein I) (EAPI) - Rattus norvegicus (Rat), 789aa.

Pam analysis indicates that the NOV22a protein contains the domains shown in the Table 22F.

TABLE 22FDomain Analysis of NOV22aNOV22aIdentities/MatchSimilarities forPfam DomainRegionthe Matched RegionExpect ValuePep_M12B_propep 73 . . . 188 38/119 (32%)6.7e−45100/119 (84%)Reprolysin199 . . . 394 88/203 (43%) 5.5e−104173/203 (85%)disintegrin411 . . . 486 41/76 (54%)1.6e−25 53/76 (70%)

Example 23

The NOV23 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 23A.

TABLE 23ANOV23 Sequence AnalysisNOV23a, CG53390-02SEQ ID NO: 305994 bpDNA SequenceORF Start: ATG at 27ORF Stop: TGA at 969TGCAGCTAAAGTGCATTGTGTAAAACATGGGGGATGTGAATCAGTCGGTGGCCTCAGACTTCATTCTGGTGGGCCTCTTCAGTCACTCAGGATCACGCCAGCTCCTCTTCTCCCTGGTGGCTGTCATGTTTGTCATAGGCCTTCTGGGCAACACCGTTCTTCTCTTCTTGATCCGTGTGGACTCCCGGCTCCATACACCCATGTACTTCCTGCTCAGCCAGCTCTCCCTGTTTGACATTGGCTGTCCCATGGTCACCATCCCCAAGATGGCATCAGACTTTCTGCGGGGAGAAGGTGCCACCTCCTATGGAGGTGGTGCAGCTCAAATATTCTTCCTCACACTGATGGGTGTGGCTGAGGGCGTCCTGTTGGTCCTCATGTCTTATGACCGTTATGTTGCTGTGTGCCAGCCCCTGCAGTATCCTGTACTTATGAGACGCCAGGTATGTCTGCTGATGATGGGCTCCTCCTGGGTGGTAGGTGTGCTCAACGCCTCCATCCAGACCTCCATCACCCTGCATTTTCCCTACTGTGCCTCCCGTATTGTGGATCACTTCTTCTGTGAGGTGCCAGCCCTACTGAAGCTCTCCTGTGCAGATACCTGTGCCTACGAGATGGCGCTGTCCACCTCAGGGGTGCTGATCCTAATGCTCCCTCTTTCCCTCATCGCCACCTCCTACGGCCACGTGTTGCAGGCTGTTCTAAGCATGCGCTCAGAGGAGGCCAGACACAAGGCTGTCACCACCTGCTCCTCGCACATCACGGTAGTGGGGCTCTTTTATGGTGCCGCCGTGTTCATGTACATGGTGCCTTGCGCCTACCACAGTCCACAGCAGGATAACGTGGTTTCCCTCTTCTATAGCCTTGTCACCCCTACACTCAACCCCCTTATCTACAGTCTGAGGAATCCGGAGGTGTGGATGGCTTTGGTCAAAGTGCTTAGCAGAGCTGGACTCAGGCAAATGTGCTGACTACATAGAAACTGCTGGTGAGANOV23a, CG53390-02SEQ ID NO: 306314 aaMW at 34443.4kDProtein SequenceMGDVNQSVASDFILVGLFSHSGSRQLLFSLVAVMFVIGLLGNTVLLFLIRVDSRLHTPMYFLLSQLSLFDIGCPMVTIPKMASDFLRGEGATSYGGGAAQIFFLTLMGVAEGVLLVLMSYDRYVAVCQPLQYPVLMRRQVCLLMMGSSWVVGVLNASIQTSITLHFPYCASRIVDHFFCEVPALLKLSCADTCAYEMALSTSGVLILMLPLSLIATSYGHVLQAVLSMRSEEARHKAVTTCSSHITVVGLFYGAAVFMYMVPCAYHSPQQDNVVSLFYSLVTPTLNPLIYSLRNPEVWMALVKVLSRAGLRQMCNOV23b, CG53390-01SEQ ID NO: 307994 bpDNA SequenceORF Start: ATG at 27ORF Stop: TGA at 969TGCAGCTAAAGTGCATTGTGTAAAACATGGGGGATGTGAATCAGTCGGTGGCCTCAGACTTCATTCTGGTGGGCCTCTTCAGTCACTCAGGATCACGCCAGCTCCTCTTCTCCCTGGTGGCTGTCATGTTTGTCATAGGCCTTCTGGGCAACACCGTTCTTCTCTTCTTGATCCGTGTGGACTCCCGGCTCCATACACCCATGTACTTCCTGCTCAGCCAGCTCTCCCTGTTTGACATTGGCTGTCCCATGGTCACCATCCCCAAGATGGCATCAGACTTTCTGCGGGGAGAAGGTGCCACCTCCTATGGAGGTGGTGCAGCTCAAATATTCTTCCTCACACTGATGGGTGTGGCTGAGGGCGTCCTGTTGGTCCTCATGTCTTATGACCGTTATGTTGCTGTGTGCCAGCCCCTGCAGTATCCTGTACTTATGAGACGCCAGGTATGTCTGCTGATGATGGGCTCCTCCTGGGTGGTAGGTGTGCTCAACGCCTCCATCCAGACCTCCATCACCCTGCATTTTCCCTACTGTGCCTCCCGTATTGTGGATCACTTCTTCTGTGAGGTGCCAGCCCTACTGAAGCTCTCCTGTGCAGATACCTGTGCCTACGAGATGGCGCTGTCCACCTCAGGGGTGCTGATCCTAATGCTCCCTCTTTCCCTCATCGCCACCTCCTACGGCCACGTGTTGCAGGCTGTTCTAAGCATGCGCTCAGAGGAGGCCAGACACAAGGCTGTCACCACCTGCTCCTCGCACATCACGGTAGTGGGGCTCTTTTATGGTGCCGCCGTGTTCATGTACATGGTGCCTTGCGCCTACCACAGTCCACAGCAGGATAACGTGGTTTCCCTCTTCTATAGCCTTGTCACCCCTACACTCAACCCCCTTATCTACAGTCTGAGGAATCCGGAGGTGTGGATGGCTTTGGTCAAAGTGCTTAGCAGAGCTGGACTCAGGCAAATGTGCTGACTACATAGAAACTGCTGGTGAGANOV23b, CG53390-01SEQ ID NO: 308314 aaMW at 34443.4kDProtein SequenceMGDVNQSVASDFILVGLFSHSGSRQLLFSLVAVMFVIGLLGNTVLLFLIRVDSRLHTPMYFLLSQLSLFDIGCPMVTIPKMASDFLRGEGATSYGGGAAQIFFLTLMGVAEGVLLVLMSYDRYVAVCQPLQYPVLMRRQVCLLMMGSSWVVGVLNASIQTSITLHFPYCASRIVDHFFCEVPALLKLSCADTCAYEMALSTSGVLILMLPLSLIATSYGHVLQAVLSMRSEEARHKAVTTCSSHITVVGLFYGAAVFMYMVPCAYHSPQQDNVVSLFYSLVTPTLNPLIYSLRNPEVWMALVKVLSPAGLRQMCNOV23c, CG53390-03SEQ ID NO: 309977 bpDNA SequenceORF Start: ATG at 16ORF Stop: TGA at 958TGCATTGTGTAAAACATGGGGGATGTGAATCAGTCGGTGGCCTCAGACTTCATTCTGGTGGGCCTCTTCAGTCACTCAGGATCACGCCAGCTCCTCTTCTCCCTGGTGGCTGTCATGTTTGTCATAGGCCTTCTGGGCAACACCGTTCTTCTCTTCTTGATCCGTGTGGACTCCCGGCTCCATACACCCATGTACTTCCTGCTCAGCCAGCTCTCCCTGTTTGACATTGGCTGTCCCATGGTCACCATCCCCAAGATGGCATCAGACTTTCTGCGGGGAGAAGGTGCCACCTCCTATGGAGGTGGTGCAGCTCAAATATTCTTCCTCACACTGATGGGTGTGGCTGAGGGCGTCCTGTTGGTCCTCATGTCTTATGACCGTTATGTTGCTGTGTGCCAGCCCCTGCAGTATCCTGTACTTATGAGACGCCAGGTATGTCTGCTGATGATGGGCTCCTCCTGGGTGGTAGGTGTGCTCAACGCCTCCATCCAGACCTCCATCACCCTGCATTTTCCCTACTGTGCCTCCCGTATTGTGGATCACTTCTTCTGTGAGGTGCCAGCCCTACTGAAGCTCTCCTGTGCAGATACCTGTGCCTACGAGATGGCGCTGTCCACCTCAGGGGTGCTGATCCTAATGCTCCCTCTTTCCGTCATCGCCACCTCCTACGGCCACGTGTTGCAGGCTGTTCTAAGCATGCGCTCAGAGGAGGCCAGACACAAGGCTGTCACCACCTGCTCCTCGCACATCACGGTAGTGGGGCTCTTTTATGGTGCCGCCGTGTTCATGTACATGGTGCCTTGCGCCTACCACAGTCCACAGCAGGATAACGTGGTTTCCCTCTTCTATAGCCTTGTCACCCCTACACTCAACCCCCTTATCTACAGTCTGAGGAATCCGGAGGTGTGGATGGCTTTGGTCAAAGTGCTTAGCAGAGCTGGACTCAGGCAAATGTGCTGACTACATAGAAACTGCTGNOV23c, CG53390-03SEQ ID NO: 310314 aaMW at 34443.4kDProtein SequenceMGDVNQSVASDFILVGLFSHSGSRQLLFSLVAVMFVIGLLGNTVLLFLIRVDSRLHTPMYFLLSQLSLFDIGCPMVTIPKMASDFLRGEGATSYGGGAAQIFFLTLMGVAEGVLLVLMSYDRYVAVCQPLQYPVLMRRQVCLLMMGSSWVVGVLNASIQTSITLHFPYCASRIVDHFFCEVPALLKLSCADTCAYEMALSTSGVLILMLPLSLIATSYGHVLQAVLSMRSEEARHKAVTTCSSHITVVGLFYGAAVFMYMVPCAYHSPQQDNVVSLFYSLVTPTLNPLIYSLRNPEVWMALVKVLSRAGLRQMC

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 23B.

TABLE 23BComparison of the NOV23 protein sequences.NOV23a MGDVNQSVASDFILVGLFSHSGSRQLLFSLVAVMFVIGLLGNTVLLFLIRVDSRLHTPMYNOV23b MGDVNQSVASDFILVGLFSHSGSRQLLFSLVAVMFVIGLLGNTVLLFLIRVDSRLHTPMYNOV23c MGDVNQSVASDFILVGLFSHSGSRQLLFSLVAVMFVIGLLGNTVLLFLIRVDSRLHTPMYNOV23a FLLSQLSLFDIGCPMVTIPKMASDFLRGEGATSYGGGAAQIFFLTLMGVAEGVLLVLMSYNOV23b FLLSQLSLFDIGCPMVTIPKMASDFLRGEGATSYGGGAAQIFFLTLMGVAEGVLLVLMSYNOV23c FLLSQLSLFDIGCPMVTIPKMASDFLRGEGATSYGGGAAQIFFLTLMGVAEGVLLVLMSYNOV23a DRYVAVCQPLQYPVLMRRQVCLLMMGSSWVVGVLNASIQTSITLHFPYCASRIVDHFFCENOV23b DRYVAVCQPLQYPVLMRRQVCLLMMGSSWVVGVLNASIQTSITLHFPYCASRIVDHFFCENOV23c DRYVAVCQPLQYPVLNRRQVCLLMMGSSWVVGVLNASIQTSITLHFPYCASRIVDHFFCENOV23a VPALLKLSCADTCAYEMALSTSGVLILMLPLSLIATSYGHVLQAVLSMRSEEARHKAVTTNOV23b VPALLKLSCADTCAYEMALSTSGVLILMLPLSLIATSYGHVLQAVLSMRSEEARHKAVTTNOV23c VPALLKLSCADTCAYEMALSTSGVLILMLPLSLIATSYGHVLQAVLSMRSEEARHKAVTTNOV23a CSSHITVVGLFYGAAVFMYMVPCAYHSPQQDNVVSLFYSLVTPTLNPLIYSLRNPEVWMANOV23b CSSHITVVGLFYGAAVFMYMVPCAYHSPQQDNVVSLFYSLVTPTLNPLIYSLRNPEVWMANOV23c CSSHITVVGLFYGAAVFMYMVPCAYHSPQQDNVVSLFYSLVTPTLNPLIYSLRNPEVWMANOV23a LVKVLSRAGLRQMCNOV23b LVKVLSRAGLRQMCNOV23c LVKVLSRAGLRQMCNOV23a (SEQ ID NO: 306)NOV23b (SEQ ID NO: 308)NOV23c (SEQ ID NO: 310)

Further analysis of the NOV23a protein yielded the following properties shown in Table 23C.

TABLE 23CProtein Sequence Properties NOV23aSignalP analysis:Cleavage site between residues 42 and 43PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 11; pos.chg 0; neg.chg 2H-region: length 12; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −1.30possible cleavage site: between 41 and 42>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 5INTEGRALLikelihood = −8.60Transmembrane 33-49INTEGRALLikelihood = −7.17Transmembrane 101-117INTEGRALLikelihood = −1.38Transmembrane 140-156INTEGRALLikelihood = −4.09Transmembrane 198-214INTEGRALLikelihood = −3.77Transmembrane 245-261PERIPHERALLikelihood = 1.38 (at 62)ALOM score: −8.60 (number of TMSs: 5)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 40Charge difference: 1.0 C(1.5) − N(0.5)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):0.74Hyd Moment(95):7.13G content:1D/E content:2S/T content:2Score: −7.54Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 5.4%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: endoplasmic reticulum11.1%: Golgi11.1%: vacuolar11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG53390-02 is end (k = 9)

A search of the NOV23a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 23D.

TABLE 23DGeneseq Results for NOV23aNOV23aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU85207G-coupled olfactory receptor #68 -1 . . . 314314/314 (100%)e−179Homo sapiens, 314 aa.1 . . . 314314/314 (100%)[WO200198526-A2, 27-DEC-2001]AAU95551Human olfactory and pheromone1 . . . 314314/314 (100%)e−179G protein-coupled receptor #38 -1 . . . 314314/314 (100%)Homo sapiens, 314 aa.[WO200224726-A2, 28-MAR-2002]ABJ04025Human G-protein coupled1 . . . 314314/314 (100%)e−179receptor SEQ ID NO: 116 -1 . . . 314314/314 (100%)Homo sapiens, 314 aa.[WO200255558-A2, 18-JUL-2002]ABP95895Human GPCR polypeptide SEQ1 . . . 314314/314 (100%)e−179ID NO 600 - Homo sapiens, 3141 . . . 314314/314 (100%)aa. [WO200216548-A2, 28-FEB-2002]AAG71902Human olfactory receptor1 . . . 314314/314 (100%)e−179polypeptide, SEQ ID NO: 1583 -1 . . . 314314/314 (100%)Homo sapiens, 314 aa.[WO200127158-A2, 19-APR-2001]

In a BLAST search of public sequence databases, the NOV23a protein was found to have homology to the proteins shown in the BLASTP data in Table 23E.

TABLE 23EPublic BLASTP Results for NOV23aNOV23aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8NG97Seven transmembrane helix1 . . . 314 314/314 (100%)e−179receptor - Homo sapiens1 . . . 314 314/314 (100%)(Human), 314 aa.Q8VFG8Olfactory receptor MOR282-1 -1 . . . 301225/301 (74%)e−126Mus musculus (Mouse), 308 aa.1 . . . 301255/301 (83%)Q96R25Olfactory receptor - Homo68 . . . 284 217/217 (100%)e−122sapiens (Human), 217 aa1 . . . 217 217/217 (100%)(fragment).Q8VGD8Olfactory receptor MOR281-1 -5 . . . 312173/308 (56%)2e−97 Mus musculus (Mouse), 315 aa.7 . . . 313229/308 (74%)Q8VGD7Olfactory receptor MOR277-1 -5 . . . 307170/304 (55%)3e−91 Mus musculus (Mouse), 317 aa.6 . . . 308218/304 (70%)

PFam analysis indicates that the NOV23a protein contains the domains shown in the Table 23F.

TABLE 23FDomain Analysis of NOV23aIdentities/NOV23a MatchSimilarities forPfam DomainRegionthe Matched RegionExpect Value7tm_141 . . . 290 46/276 (17%)5.5e−25167/276 (61%)

Example 24

The NOV24 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 24A.

TABLE 24ANOV24 Sequence AnalysisNOV24a, CG53482-01SEQ ID NO: 3111008 bpDNA SequenceORF Start: ATG at 27ORF Stop: TAG at 999AGCTGGAGATCTGGAACTTCCACAGCATGGAGCTCTGGAACTACCACAGCATGGAGCTCTGGAACTTCACCTTGGGAAGTGGCTTCATTTTGGTGGGGATTCTGAATGACAGTGGGTCTCCTGAACTGCTCTGTGCTACAATTACAATCCTATACTTGTTGGCCCTGATCAGCAATGGCCTACTGCTCCTGGCTATCACCATGGAAGCCCGGCTCCACATGCCCATGTACCTCCTGCTTGGGCAGCTCTCTCTCATGGACCTCCTGTTCACATCTGTTGTCACTCCCAAGGCCCTTGCGGACTTTCTGCGCAGAGAAAACACCATCTCCTTTGGAGGCTGTGCCCTTCAGATGTTCCTGGCACTGACAATGGGTGGTGCTGAGGACCTCCTACTGGCCTTCATGGCCTATGACAGGTATGTGGCCATTTGTCATCCTCTGACATACATGACCCTCATGAGCTCAAGAGCCTGCTGGCTCATGGTGGCCACGTCCTGGATCCTGGCATCCCTAAGTGCCCTAATATATACCGTGTATACCATGCACTATCCCTTCTGCAGGGCCCAGGAGATCAGGCATCTTCTCTGTGAGATCCCACACTTGCTGAAGTTGGCCTGTGCTGATACCTCCAGATATGAGCTCATGGTATATGTGATGGGTGTGACCTTCCTGATTCCCTCTCTTGCTGCTATACTGGCCTCCTATACACAAATTCTACTCACTGTGCTCCATATGCCATCAAATGAGGGGAGGAAGAAAGCCCTTGTCACCTGCTCTTCCCACCTGACTGTGGTTGGGATGTTCTATGGAGCTGCCACATTCATGTATGTCTTGCCCAGTTCCTTCCACAGCACCAGACAAGACAACATCATCTCTGTTTTCTACACAATTGTCACTCCAGCCCTGAATCCACTCATCTACAGCCTGAGGAATAAGGAGGTCATGCGGGCCTTGAGGAGGGTCCTGGGAAAATACATGCTGCCAGCACACTCCACGCTCTAGGGAAGGANOV24a, CG53482-01SEQ ID NO: 312324 aaMW at 36344.8kDProtein SequenceMELWNYHSMELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLLLLAITMEARLHMPMYLLLGQLSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLALTMGGAEDLLLAFMAYDRYVAICHPLTYMTLMSSRACWLMVATSWILASLSALIYTVYTMHYPFCRAQEIRHLLCEIPHLLKLACADTSRYELMVYVMGVTFLIPSLAAILASYTQILLTVLHMPSNEGRKKALVTCSSHLTVVGMFYGAATFMYVLPSSFHSTRQDNIISVFYTIVTPALNPLIYSLRNKEVMRALRRVLGKYMLPAHSTLNOV24b, CG53482-02SEQ ID NO: 3131050 bpDNA SequenceORF Start: ATG at 72ORF Stop: TAG at 1020AAACTAGAGTTCATCTTAGCAPAAATTCATGAAGTATCCATCTTGTTCTAGGTGATGAAAGAAACCACAGCATGGAGCTCTGGAACTTCACCTTGGGAAGTGGCTTCATTTTGGTGGGGATTCTGAATGACAGTGGGTCTCCTGAACTGCTCTGTGCTACAATTACAATCCTATACTTGTTGGCCCTGATCAGCAATGGCCTACTGCTCCTGGCTATCACCATGGAAGCCCGGCTCCACATGCCCATGTACCTCCTGCTTGGGCAGCTCTCTCTCATGGACCTCCTGTTCACATCTGTTGTCACTCCCAAGGCCCTTGCGGACTTTCTGCGCAGAGAAAACACCATCTCCTTTGGAGGCTGTGCCCTTCAGATGTTCCTGGCACTGACAATGGGTGGTGCTGAGGACCTCCTACTGGCCTTCATGGCCTATGACAGGTATGTGGCCATTTGTCATCCTCTGACATACATGACCCTCATGAGCTCAAGAGCCTGCTGGCTCATGGTGGCCACGTCCTGGATCCTGGCATCCCTAAGTGCCCTAATATATACCGTGTATACCATGCACTATCCCTTCTGCAGGGCCCAGGAGATCAGGCATCTTCTCTGTGAGATCCCACACTTGCTGAAGGTGGCCTGTGCTGATACCTCCAGATATGAGCTCATGGTATATGTGATGGGTGTGACCTTCCTGATTCCCTCTCTTGCTGCTATACTGGCCTCCTATACACAAATTCTACTCACTGTGCTCCATATGCCATCAAATGAGGGGAGGAAGAAAGCCCTTGTCACCTGCTCTTCCCACCTGACTGTGGTTGGGATGTTCTATGGAGCTGCCACATTCATGTATGTCTTGCCCAGTTCCTTCCACAGCACCAGACAAGACAACATCATCTCTGTTTTCTACACAATTGTCACTCCAGCCCTGAATCCACTCATCTACAGCCTGAGGAATAAGGAGGTCATGCGGGCCTTGAGGAGGGTCCTGGGAAAATACATGCTGCCAGCACACTCCACGCTCTAGGGAAGGATCATGGCTAGCTTCCAGAATTNOV24b, CG53482-02SEQ ID NO: 314316 aaMW at 35269.6kDProtein SequenceMELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLLLLAITMEARLHMPMYLLLGQLSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLALTMGGAEDLLLAFMAYDRYVAICHPLTYMTLMSSRACWLMVATSWILASLSALIYTVYTNHYPFCRAQEIRHLLCEIPHLLKVACADTSRYELMVYVMGVTFLIPSLAAILASYTQILLTVLHMPSNEGRKKALVTCSSHLTVVGMFYGAATFMYVLPSSFHSTRQDNIISVFYTIVTPALNPLIYSLRNKEVMRALRRVLGKYMLPAHSTLNOV24c, CG53482-03SEQ ID NO: 3151010 bpDNA SequenceORF Start: at 4ORF Stop: TAG at 1000TAGCTGGAGATCTGGAACTTCCACAGCATGGAGCTCTGGAACTACCACAGCATGGAGCTCTGGAACTTCACCTTGGGAAGTGGCTTCATTTTGGTGGGGATTCTGAATGACAGTGGGTCTCCTGAACTGCTCTGTGCTACAATTACAATCCTATACTTGTTGGCCCTGATCAGCAATGGCCTACTGCTCCTGGCTATCACCATGGAAGCCCGGCTCCACATGCCCATGTACCTCCTGCTTGGGCAGCTCTCTCTCATGGACCTCCTGTTCACATCTGTTGTCACTCCCAAGGCCCTTGCGGACTTTCTGCGCAGAGAAAACACCATCTCCTTTGGAGGCTGTGCCCTTCAGATGTTCCTGGCACTGACAATGGGTGGTGCTGAGGACCTCCTACTGGCCTTCATGGCCTATGACAGGTATGTGGCCATTTGTCATCCTCTGACATACATGACCCTCATGAGCTCAAGAGCCTGCTGGCTCATGGTGGCCACGTCCTGGATCCTGGCATCCCTAAGTGCCCTAATATATACCGTGTATACCATGCACTATCCCTTCTGCAGGGCCCAGGAGATCAGGCATCTTCTCTGTGAGATCCCACACTTGCTGAAGTTGGCCTGTGCTGATACCTCCAGATATGAGCTCATGGTATATGTGATGGGTGTGACCTTCCTGATTCCCTCTCTTGCTGCTATACTGGCCTCCTATACACAAATTCTACTCACTGTGCTCCATATGCCATCAAATGAGGGGAGGAAGAAAGCCCTTGTCACCTGCTCTTCCCACCTGACTGTGGTTGGGATGTTCTATGGAGCTGCCACATTCATGTATGTCTTGCCCAGTTCCTTCCACAGCACCAGACAAGACAACATCATCTCTGTTTTCTACACAATTGTCACTCCAGCCCTGAATCCACTCATCTACAGCCTGAGGAATAAGGAGGTCATGCGGGCCTTGAGGAGGGTCCTGGGAAAATACATGCTGCCAGCACACTCCACGCTCTAGGGAAGGAANOV24c, CG53482-03SEQ ID NO: 316332 aaMW at 37371.9kDProtein SequenceLEIWNFHSMELNNYHSMELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLLLLAITMEARLHMPMYLLLGQLSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLALTMGGABDLLLAFMAYDRYVAICHPLTYMTLMSSRACWLMVATSWILASLSALIYTVYTMHYPFCRAQEIRHLLCEIPHLLKLACADTSRYELMVYVMGVTFLIPSLAAILASYTQILLTVLHMPSNEGRKKALVTCSSHLTVVGMFYGAATFMYVLPSSFHSTRQDNIISVFYTIVTPALNPLIYSLRNKEVMRALRRVLGKYMLPAHSTLNOV24d, SNP13373787 ofSEQ ID NO: 3171008 bpCG53482-01, DNA SequenceORF Start: ATG at 27ORF Stop: TAG at 999SNP Pos: 430SNP Change: G to AAGCTGGAGATCTGGAACTTCCACAGCATGGAGCTCTGGAACTACCACAGCATGGAGCTCTGGAACTTCACCTTGGGAAGTGGCTTCATTTTGGTGGGGATTCTGAATGACAGTGGGTCTCCTGAACTGCTCTGTGCTACAATTACAATCCTATACTTGTTGGCCCTGATCAGCAATGGCCTACTGCTCCTGGCTATCACCATGGAAGCCCGGCTCCACATGCCCATGTACCTCCTGCTTGGGCAGCTCTCTCTCATGGACCTCCTGTTCACATCTGTTGTCACTCCCAAGGCCCTTGCGGACTTTCTGCGCAGAGAAAACACCATCTCCTTTGGAGGCTGTGCCCTTCAGATGTTCCTGGCACTGACAATGGGTGGTGCTGAGGACCTCCTACTGGCCTTCATGGCCTATGACAGGTATGTGGCCATTTATCATCCTCTGACATACATGACCCTCATGAGCTCAAGAGCCTGCTGGCTCATGGTGGCCACGTCCTGGATCCTGGCATCCCTAAGTGCCCTAATATATACCGTGTATACCATGCACTATCCCTTCTGCAGGGCCCAGGAGATCAGGCATCTTCTCTGTGAGATCCCACACTTGCTGAAGTTGGCCTGTGCTGATACCTCCAGATATGAGCTCATGGTATATGTGATGGGTGTGACCTTCCTGATTCCCTCTCTTGCTGCTATACTGGCCTCCTATACACAAATTCTACTCACTGTGCTCCATATGCCATCAAATGAGGGGAGGAAGAAAGCCCTTGTCACCTGCTCTTCCCACCTGACTGTGGTTGGGATGTTCTATGGAGCTGCCACATTCATGTATGTCTTGCCCAGTTCCTTCCACAGCACCAGACAAGACAACATCATCTCTGTTTTCTACACAATTGTCACTCCAGCCCTGAATCCACTCATCTACAGCCTGAGGAATAAGGAGGTCATGCGGGCCTTGAGGAGGGTCCTGGGAAAATACATGCTGCCAGCACACTCCACGCTCTAGGGAAGGANOV24d, SNP13373787 ofSEQ ID NO: 318324 aaMW at 36404.8kDCG53482-01, ProteinSNP Pos: 135SNP Change: Cys to TyrSequenceMELWNYHSMELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLLLLAITMEARLHMPMYLLLGQLSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLALTMGGAEDLLLAFMAYDRYVAIYHPLTYMTLMSSRACWLMVATSWILASLSALIYTVYTMHYPFCRAQEIRHLLCEIPHLLKLACADTSRYELMVYVMGVTFLIPSLAAILASYTQILLTVLHMPSNEGRKKALVTCSSHLTVVGMFYGAATFMYVLPSSFHSTRQDNIISVFYTIVTPALNPLIYSLRNKEVMRALRRVLGKYMLPAHSTLNOV24e, SNP13373786 ofSEQ ID NO: 3191008 bpCG53482-01, DNA SequenceORF Start: ATG at 27ORF Stop: TAG at 999SNP Pos: 442SNP Change: C to AAGCTGGAGATCTGGAACTTCCACAGCATGGAGCTCTGGAACTACCACAGCATGGAGCTCTGGAACTTCACCTTGGGAAGTGGCTTCATTTTGGTGGGGATTCTGAATGACAGTGGGTCTCCTGAACTGCTCTGTGCTACAATTACAATCCTATACTTGTTGGCCCTGATCAGCAATGGCCTACTGCTCCTGGCTATCACCATGGAAGCCCGGCTCCACATGCCCATGTACCTCCTGCTTGGGCAGCTCTCTCTCATGGACCTCCTGTTCACATCTGTTGTCACTCCCAAGGCCCTTGCGGACTTTCTGCGCAGAGAAAACACCATCTCCTTTGGAGGCTGTGCCCTTCAGATGTTCCTGGCACTGACAATGGGTGGTGCTGAGGACCTCCTACTGGCCTTCATGGCCTATGACAGGTATGTGGCCATTTGTCATCCTCTGAAATACATGACCCTCATGAGCTCAAGAGCCTGCTGGCTCATGGTGGCCACGTCCTGGATCCTGGCATCCCTAAGTGCCCTAATATATACCGTGTATACCATGCACTATCCCTTCTGCAGGGCCCAGGAGATCAGGCATCTTCTCTGTGAGATCCCACACTTGCTGAAGTTGGCCTGTGCTGATACCTCCAGATATGAGCTCATGGTATATGTGATGGGTGTGACCTTCCTGATTCCCTCTCTTGCTGCTATACTGGCCTCCTATACACAAATTCTACTCACTGTGCTCCATATGCCATCAAATGAGGGGAGGAAGAAAGCCCTTGTCACCTGCTCTTCCCACCTGACTGTGGTTGGGATGTTCTATGGAGCTGCCACATTCATGTATGTCTTGCCCAGTTCCTTCCACAGCACCAGACAAGACAACATCATCTCTGTTTTCTACACAATTGTCACTCCAGCCCTGAATCCACTCATCTACAGCCTGAGGAATAAGGAGGTCATGCGGGCCTTGAGGAGGGTCCTGGGAAATACATGCTGCCAGCACACTCCACGCTCTAGGGAAGGANOV24e, SNP13373786 ofSEQ ID NO: 320324 aaMW at 36371.9kDCG53482-01, ProteinSNP Pos: 139SNP Change: Thr to LysSequenceMELWNYHSMELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLLLLAITMEARLHMPMYLLLGQLSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLALTMGGAEDLLLAFMAYDRYVAICHPLKYMTLMSSRACWLMVATSWILASLSALIYTVYTMHYPFCRAQEIRHLLCEIPHLLKLACADTSRYELMVYVMGVTFLIPSLAAILASYTQILLTVLHMPSNEGRKKALVTCSSHLTVVGMFYGAATFMYVLPSSFHSTRQDNIISVFYTIVTPALNPLIYSLRNKEVMRALRRVLGKYMLPAHSTLNOV24f, SNP13373785 ofSEQ ID NO: 3211008 bpCG53482-01, DNA SequenceORF Start: ATG at 27ORF Stop: TAG at 999SNP Pos: 754SNP Change: A to GAGCTGGAGATCTGGAACTTCCACAGCATGGAGCTCTGGAACTACCACAGCATGGAGCTCTGGAACTTCACCTTGGGAAGTGGCTTCATTTTGGTGGGGATTCTGAATGACAGTGGGTCTCCTGAACTGCTCTGTGCTACAATTACAATCCTATACTTGTTGGCCCTGATCAGCAATGGCCTACTGCTCCTGGCTATCACCATGGAAGCCCGGCTCCACATGCCCATGTACCTCCTGCTTGGGCAGCTCTCTCTCATGGACCTCCTGTTCACATCTGTTGTCACTCCCAAGGCCCTTGCGGACTTTCTGCGCAGAGAAAACACCATCTCCTTTGGAGGCTGTGCCCTTCAGATGTTCCTGGCACTGACAATGGGTGGTGCTGAGGACCTCCTACTGGCCTTCATGGCCTATGACAGGTATGTGGCCATTTGTCATCCTCTGACATACATGACCCTCATGAGCTCAAGAGCCTGCTGGCTCATGGTGGCCACGTCCTGGATCCTGGCATCCCTAAGTGCCCTAATATATACCGTGTATACCATGCACTATCCCTTCTGCAGGGCCCAGGAGATCAGGCATCTTCTCTGTGAGATCCCACACTTGCTGAAGTTGGCCTGTGCTGATACCTCCAGATATGAGCTCATGGTATATGTGATGGGTGTGACCTTCCTGATTCCCTCTCTTGCTGCTATACTGGCCTCCTATACACAAATTCTACTCACTGTGCTCCATATGCCATCAAATGAGGGGAGGAGGAAAGCCCTTGTCACCTGCTCTTCCCACCTGACTGTGGTTGGGATGTTCTATGGAGCTGCCACATTCATGTATGTCTTGCCCAGTTCCTTCCACAGCACCAGACAAGACAACATCATCTCTGTTTTCTACACAATTGTCACTCCAGCCCTGAATCCACTCATCTACAGCCTGAGGAATAAGGAGGTCATGCGGGCCTTGAGGAGGGTCCTGGGAAATACATGCTGCCAGCACACTCCACGCTCTAGGGAAAGGANOV24f, SNP13373785 ofSEQ ID NO: 322324 aaMW at 36372.8kDCG53482-01, ProteinSNP Pos: 243SNP Change: Lys to ArgSequenceMELWNYHSMELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLLLLAITMEARLHMPMYLLLGQLSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLALTMGGAEDLLLAFMAYDRYVAICHPLKYMTLMSSRACWLMVATSWILASLSALIYTVYTMHYPFCRAQEIRHLLCEIPHLLKLACADTSRYELMVYVMGVTFLIPSLAAILASYTQILLTVLHMPSNEGRRKALVTCSSHLTVVGMFYGAATFMYVLPSSFHSTRQDNIISVFYTIVTPALNPLIYSLRNKEVMRALRRVLGKYMLPAHSTL

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 24B.

TABLE 24BComparison of the NOV24 protein sequences.NOV24a --------MELWNYHSMELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLNOV24b ----------------MELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLNOV24c LEIWNFHSMELWNYHSMELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLNOV24a LLLAITMEARLHMPMYLLLGQLSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLANOV24b LLLAITMEARLHMPMYLLLGQLSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLANOV24c LLLAITMEARLHMPMYLLLGQLSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLANOV24a LTMGGAEDLLLAFMAYDRYVAICHPLTYMTLMSSRACWLMVATSWILASLSALIYTVYTMNOV24b LTMGGAEDLLLAFMAYDRYVAICHPLTYMTLMSSRACWLMVATSWILASLSALIYTVYTMNOV24c LTMGGAEDLLLAFMAYDRYVAICHPLTYMTLMSSRACWLMVATSWILASLSALIYTVYTMNOV24a HYPFCRAQEIRHLLCEIPHLLKLACADTSRYELMVYVMGVTFLIPSLAAILASYTQILLTNOV24b HYPFCRAQEIRHLLCEIPHLLKVACADTSRYELMVYVMGVTFLIPSLAAILASYTQILLTNOV24c HYPFCRAQEIRHLLCEIPHLLKLACADTSRYELMVTVMGVTFLIPSLAAILASYTQILLTNOV24a VLHMPSNEGRKKALVTCSSHLTVVGMFYGAATFMYVLPSSFHSTRQDNIISVFYTIVTPANOV24b VLHMPSNEGRKKALVTCSSHLTVVGMFYGAATFMYVLPSSFHSTRQDNIISVFYTIVTPANOV24c VLHMPSNEGRKKALVTCSSHLTVVGMFYGAATFMYVLPSSFHSTRQDNIISVFYTIVTPANOV24a LNPLIYSLRNKEVMRALRRVLGKYMLPAHSTLNOV24b LNPLIYSLRNKEVMRALRRVLGKYMLPAHSTLNOV24c LNPLIYSLRNKEVMRALRRVLGKYMLPAHSTLNOV24a (SEQ ID NO: 312)NOV24b (SEQ ID NO: 314)NOV24c (SEQ ID NO: 316)

Further analysis of the NOV24a protein yielded the following properties shown in Table 24C.

TABLE 24CProtein Sequence Properties NOV24aSignalP analysis:Cleavage site between residues 62 and 63PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 0; neg.chg 2H-region: length 17; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.29possible cleavage site: between 56 and 57>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −7.75Transmembrane 41-57INTEGRALLikelihood = −1.65Transmembrane 69-85INTEGRALLikelihood = −2.07Transmembrane 150-166INTEGRALLikelihood = −5.10Transmembrane 207-223INTEGRALLikelihood = −0.80Transmembrane 253-269INTEGRALLikelihood = −0.80Transmembrane 281-297PERIPHERALLikelihood = 0.85 (at 109)ALOM score: −7.75 (number of TMSs: 6)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 48Charge difference: 2.5 C(0.5) − N(−2.0)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):4.76Hyd Moment(95):6.14G content:0D/E content:2S/T content:1Score: −6.93Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 6.2%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG53482-01 is end (k = 9)

A search of the NOV24a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 24D.

TABLE 24DGeneseq Results for NOV24aNOV24aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU97928Novel odourant receptor NOV71 . . . 324324/324 (100%)0.0protein - Unidentified, 324 aa.1 . . . 324324/324 (100%)[WO200236632-A2, 10-MAY-2002]AAU97927Novel odourant receptor NOV61 . . . 324324/324 (100%)0.0protein - Unidentified, 324 aa.1 . . . 324324/324 (100%)[WO200236632-A2, 10-MAY-2002]AAU07088Human odorant receptor (OR)1 . . . 324324/324 (100%)0.0polypeptide #5 - Homo sapiens,1 . . . 324324/324 (100%)324 aa. [WO200157215-A2, 09-AUG-2001]AAU85234G-coupled olfactory receptor #95 -9 . . . 324315/316 (99%) e−180Homo sapiens, 316 aa.1 . . . 316316/316 (99%) [WO200198526-A2, 27-DEC-2001]AAU95574Human olfactory and pheromone9 . . . 324315/316 (99%) e−180G protein-coupled receptor #61 -1 . . . 316316/316 (99%) Homo sapiens, 316 aa.[WO200224726-A2, 28-MAR-2002]

In a BLAST search of public sequence databases, the NOV24a protein was found to have homology to the proteins shown in the BLASTP data in Table 24E.

TABLE 24EPublic BLASTP Results for NOV24aNOV24aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAD57894Sequence 11 from Patent1 . . . 324 324/324 (100%)0.0WO0236632 - Homo sapiens1 . . . 324 324/324 (100%)(Human), 324 aa.Q9H205Olfactory receptor 2AG19 . . . 324315/316 (99%)e−179(HT3) - Homo sapiens1 . . . 316316/316 (99%)(Human), 316 aa.Q8VGU0Olfactory receptor MOR283-2 -9 . . . 324264/316 (83%)e−149Mus musculus (Mouse), 3161 . . . 316284/316 (89%)aa.Q9EPF7T2 olfactory receptor - Mus9 . . . 324262/316 (82%)e−149musculus (Mouse), 316 aa.1 . . . 316284/316 (88%)Q8VFM5Olfactory receptor MOR283-4 -9 . . . 323253/315 (80%)e−145Mus musculus (Mouse), 3161 . . . 315280/315 (88%)aa.

PFam analysis indicates that the NOV24a protein contains the domains shown in the Table 24F.

TABLE 24FDomain Analysis of NOV24aIdentities/NOV24a MatchSimilarities forPfam DomainRegionthe Matched RegionExpect Value7tm_149 . . . 298 62/277 (22%)1.3e−33173/277 (62%)

Example 25

The NOV25 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 25A.

TABLE 25ANOV25 Sequence AnalysisNOV25a, CG53530-03SEQ ID NO: 3231016 bpDNA SequenceORF Start: ATG at 7ORF Stop: TAG at 961TACCAGATGAATCCAGCAAATCATTCCCAGGTGGCAGGATTTGTTCTACTGGGGCTCTCTCAGGTTTGGGAGCTTCGGTTTGTTTTCTTCACTGTTTTCTCTGCTGTGTATTTTATGACTGTAGTGGGAAACCTTCTTATTGTGGTCATAGTGACCTCCGACCCACACCTGCACACAACCATGTATTTTCTCTTGGGCAATCTTTCTTTCCTGGACTTTTGCTACTCTTCCATCACAGCACCTAGGATGCTGGTTGACTTGCTCTCAGGCAACCCTACCATTTCCTTTGGTGGATGCCTGACTCAACTCTTCTTCTTCCACTTCATTGGAGGCATCAAGATCTTCCTGCTGACTGTCATGGCGTATGACCGCTACATTGCCATTTCCCAGCCCCTGCACTACACGCTCATTATGAATCAGACTGTCTGTGCACTCCTTATGGCAGCCTCCTGGGTGGGGGGCTTCATCCACTCCATAGTACAGATTGCATTGACTATCCAGCTGCCATTCTGTGGGCCTGACAAGCTGGACAACTTTTATTGTGATGTGCCTCAGCTGATCAAATTGGCCTGCACAGATACCTTTGTCTTAGAGCTTTTAATGGTGTCTAACAATGGCCTGGTGACCCTGATGTGTTTTCTGGTGCTTCTGGGATCGTACACAGCACTGCTAGTCATGCTCCGAAGCCACTCACGGGAGGGCCGCAGCAAGGCCCTGTCTACCTGTGCCTCTCACATTGCTGTGGTGACCTTAATCTTTGTGCCTTGCATCTACGTCTATACAAGGCCTTTTCGGACATTCCCCATGGACAAGGCCGTCTCTGTGCTATACACAATTGTCACCCCCATGCTGAATCCTGCCATCTATACCCTGAGAAACAAGGAAGTGATCATGGCCATGAAGAAGCTGTGGAGGAGGAAAAAGGACCCTATTGGTCCCCTGGAGCACAGACCCTTACATTAGCAGAGGCAGTGACCTGAGAATCTGAAAGATGCTACAGGGTATTAGCAGAGGCANOV25a, CG53530-03SEQ ID NO: 324318 aaMW at 35770.3kDProtein SequenceMNPANHSQVAGFVLLGLSQVWELRFVFFTVFSAVYFMTVVGNLLIVVIVTSDPHLHTTMYFLLGNLSFLDFCYSSITAPRMLVDLLSGNPTISFGGCLTQLFFFHFIGGIKIFLLTVMAYDRYIAISQPLHYTLIMNQTVCALLMAASWVGGFIHSIVQIALTIQLPFCGPDKLDNFYCDVPQLIKLACTDTFVLELLMVSNNGLVTLMCFLVLLGSYTALLVMLRSHSREGRSKALSTCASHIAVVTLIFVPCIYVYTRPFRTFPMDKAVSVLYTIVTPHLNPAIYTLRNKEVIMANKKLWRRKKDPIGPLEHRPLHNOV25b, CG53530-01SEQ ID NO: 3251077 bpDNA SequenceORF Start: ATG at 31ORF Stop: TAG at 985CAGGTTCATTGACAAGGTCATACCAACCAGATGAATCCAGCAAATCATTCCCAGGTGGCAGGATTTGTTCTACTGGGGCTCTCTCAGGTTTGGGAGCTTCGGTTTGTTTTCTTCACTGTTTTCTCTGCTGTGTATTTTATGACTGTAGTGGGAAACCTTCTTATTGTGGTCATAGTGACCTCCGACCCACACCTGCACACAACCATGTATTTTCTCTTGGGCAATCTTTCTTTCCTGGACTTTTGCTACTCTTCCATCACAGCACCTAGGATGCTGGTTGACTTGCTCTCAGGCAACCCTACCATTTCCTTTGGTGGATGCCTGACTCAACTCTTCTTCTTCCACTTCATTGGAGGCATCAAGATCTTCCTGCTGACTGTCATGGCGTATGACCGCTACATTGCCATTTCCCAGCCCCTGCACTACACGCTCATTATGAATCAGACTGTCTGTGCACTCCTTATGGCAGCCTCCTGGGTGGGGGGCTTCATCCACTCCATAGTACAGATTGCATTGACTATCCAGCTGCCATTCTGTGGGCCTGACAAGCTGGACAACTTTTATTGTGATGTGCCTCAGCTGATCAAATTGGCCTGCACAGATACCTTTGTCTTAGAGCTTTTAATGGTGTCTAACAATGGCCTGGTGACCCTGATGTGTTTTCTGGTGCTTCTGGGATCGTACACAGCACTGCTAGTCATGCTCCGAAGCCACTCACGGGAGGGCCGCAGCAAGGCCCTGTCTACCTGTGCCTCTCACATTGCTGTGGTGACCTTAATCTTTGTGCCTTGCATCTACGTCTATACAAGGCCTTTTCGGACATTCCCCATGGACAAGGCCGTCTCTGTGCTATACACAATTGTCACCCCCATGCTGAATCCTGCCATCTATACCCTGAGAAACAAGGAAGTGATCATGGCCATGAAGAAGCTGTGGAGGAGGAAAAAGGACCCTATTGGTCCCCTGGAGCACAGACCCTTACATTAGCAGAGGCAGTGACCTGAGAATCTGAAAGATGCTACAGGGTATTAGCAGAGGCAGTGACCTGAGAATCTGAAAGATGCTACAGGGTATTAGNOV25b, CG53530-01SEQ ID NO: 326318 aaMW at 35770.3kDProtein SequenceMNPANHSQVAGFVLLGLSQVWELRFVFFTVFSAVYFMTVVGNLLIVVIVTSDPHLHTTMYFLLGNLSFLDFCYSSITAPRMLVDLLSGNPTISFGGCLTQLFFFHFIGGIKIFLLTVMAYDRYIAISQPLHYTLIMNQTVCALLMAASWVGGFIHSIVQIALTIQLPFCGPDKLDMFYCDVPQLIKLACTDTFVLELLMVSNNGLVTLMCFLVLLGSYTALLVMLRSHSREGRSKALSTCASHIAVVTLIFVPCIYVYTRPFRTFPMDKAVSVLYTIVTPMLNPAIYTLRNIEVIMAHKKLWRRKKDPIGPLEHRPLHNOV25c,CG53530-02SEQ ID NO: 3271077 bpDNA SequenceORF Start: ATG at 31ORF Stop: TAG at 985CAGGTTCATTGACAAGGTCATACCAACCAGATGAATCCAGCAAATCATTCCCAGGTGGCAGGATTTGTTCTACTGGGGCTCTCTCAGGTTTGGGAGCTTCGGTTTGTTTTCTTCACTGTTTTCTCTGCTGTGTATTTTATGACTGTAGTGGGAAACCTTCTTATTGTGGTCATAGTGACCTCCGACCCACACCTGCACACAACCATGTATTTTCTCTTGGGCAATCTTTCTTTCCTGGACTTTTGCTACTCTTCCATCACAGCACCTAGGATGCTGGTTGACTTGCTCTCAGGCAACCCTACCATTTCCTTTGGTGGATGCCTGACTCAACTCTTCTTCTTCCACTTCATTGGAGGCATCAAGATCTTCCTGCTGACTGTCATGGCGTATGACCGCTACATTGCCATTTCCCAGCCCCTGCACTACACGCTCATTATGAATCAGACTGTCTGTGCACTCCTTATGGCAGCCTCCTGGGTGGGGGGCTTCATCCACTCCATAGTACAGATTGCATTGACTATCCAGCTGCCATTCTGTGGGCCTGACAAGCTGGACAACTTTTATTGTGATGTGCCTCAGCTGATCAAATTGGCCTGCACAGATACCTTTGTCTTAGAGCTTTTAATGGTGTCTAACAATGGCCTGGTGACCCTGATGTGTTTTCTGGTGCTTCTGGGATCGTACACAGCACTGCTAGTCATGCTCCGAAGCCACTCACGGGAGGGCCGCAGCAAGGCCCTGTCTACCTGTGCCTCTCACATTGCTGTGGTGACCTTAATCTTTGTGCCTTGCATCTACGTCTATACAAGGCCTTTTCGGACATTCCCCATGGACAAGGCCGTCTCTGTGCTATACACAATTGTCACCCCCATGCTGAATCCTGCCATCTATACCCTGAGAAACAAGGAAGTGATCATGGCCATGAAGAAGCTGTGGAGGAGGAAAAAGGACCCTATTGGTCCCCTGGAGCACAGACCCTTACATTAGCAGAGGCAGTGACCTGAGAATCTGAAAGATGCTACAGGGTATTAGCAGAGGCAGTGACCTGAGAATCTGAAAGATGCTACAGGGTATTAGNOV25c, CG53530-02SEQ ID NO: 328318 aaMW at 35770.3kDProtein SequenceMNPANHSQVAGFVLLGLSQVWELRFVFFTVFSAVYFMTVVGNLLIVVIVTSDPHLHTTMYFLLGNLSFLDFCYSSITAPRNLVDLLSGNPTISFGGCLTQLFFFHFIGGIKIFLLTVMAYDRYIAISQPLHYTLIMNQTVCALLMAASWVGGFIHSIVQIALTIQLPFCGPDKLDNFYCDVPQLIKLACTDTFVLELLMVSNNGLVTLMCFLVLLGSYTALLVMLRSHSREGRSKALSTCASHIAVVTLIFVPCIYVYTRPFRTFPMDKAVSVLYTIVTPMLNPAIYTLRNKEVIMAMKKLWRRKKDPIGPLEHRPLH

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 25B.

TABLE 25BComparison of the NOV25 protein sequences.NOV25a MNPANHSQVAGFVLLGLSQVWELRFVFFTVFSAVYFMTVVGNLLIVVIVTSDPHLHTTMYNOV25b MNPANHSQVAGFVLLGLSQVWELRFVFFTVFSAVYFMTVVGNLLIVVIVTSDPHLHTTMYNOV25c MNPANHSQVAGFVLLGLSQVWELRFVFFTVFSAVYFMTVVGNLLIVVIVTSDPHLHTTMYNOV25a FLLGNLSFLDFCYSSITAPRMLVDLLSGNPTISFGGCLTQLFFFHFIGGIKIFLLTVMAYNOV25b FLLGNLSFLDFCYSSITAPRMLVDLLSGNPTISFGGCLTQLFFFHFIGGIKIFLLTVMAYNOV25c FLLGNLSFLDFCYSSITAPRMLVDLLSGNPTISFGGCLTQLFFFHFIGGIKIFLLTVMAYNOV25a DRYIAISQPLHYTLIMNQTVCALLMAASWVGGFINSIVQIALTIQLPFCGPDKLDNFYCDNOV25b DRYIAISQPLHYTLIMNQTVCALLMAASWVGGFINSIVQIALTIQLPFCGPDKLDNFYCDNOV25c DRYIAISQPLHYTLIMNQTVCALLMAASWVGGFINSIVQIALTIQLPFCGPDKLDNFYCDNOV25a VPQLIKLACTDTFVLELLMVSNNGLVTLMCFLVLLGSYTALLVMLRSHSREGRSKALSTCNOV25b VPQLIKLACTDTFVLELLMVSNNGLVTLMCFLVLLGSYTALLVMLRSHSREGRSKALSTCNOV25c VPQLIKLACTDTFVLELLMVSNNGLVTLMCFLVLLGSYTALLVMLRSHSREGRSKALSTCNOV25a ASHIAVVTLIFVPCIYVYTRPFRTFPMDKAVSVLYTIVTPMLNPAIYTLRNKEVIMAMKKNOV25b ASHIAVVTLIFVPCIYVYTRPFRTFPMDKAVSVLYTIVTPMLNPAIYTLRNKEVIMAMKKNOV25c ASHIAVVTLIFVPCIYVYTRPFRTFPMDKAVSVLYTIVTPMLNPAIYTLRNKEVIMAMKKNOV25a LWRRKKDPIGPLEHRPLHNOV25b LWRRKKDPIGPLENRPLHNOV25c LWRRKKDPIGPLEHRPLHNOV25a (SEQ ID NO: 324)NOV25b (SEQ ID NO: 326)NOV25C (SEQ ID NO: 328)

Further analysis of the NOV25a protein yielded the following properties shown in Table 25C.

TABLE 25CProtein Sequence Properties NOV25aSignalP analysis:Cleavage site between residues 52 and 53PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 21; peak value 9.57PSG score: 5.17GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −5.51possible cleavage site: between 32 and 33>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −8.23Transmembrane 33-49INTEGRALLikelihood = −4.04Transmembrane 101-117INTEGRALLikelihood = −0.90Transmembrane 142-158INTEGRALLikelihood = −0.90Transmembrane 184-200INTEGRALLikelihood = −6.37Transmembrane 208-224INTEGRALLikelihood = −4.51Transmembrane 241-257PERIPHERALLikelihood = 0.79 (at 12)ALOM score: −8.23 (number of TMSs: 6)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 40Charge difference: 0.0 C(0.0) − N(0.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):1.55Hyd Moment(95):4.07G content:2D/E content:1S/T content:2Score: −6.22Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 132 DRY|IANUCDISC: discrimination of nuclear localization signalspat4: RRKK (5) at 303pat7: nonebipartite: nonecontent of basic residues: 6.9%NLS Score: −0.16KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):66.7%: endoplasmic reticulum22.2%: mitochondrial11.1%: nuclear>> prediction for CG53530-03 is end (k = 9)

A search of the NOV25a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 25D.

TABLE 25DGeneseq Results for NOV25aNOV25aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU85175G-coupled olfactory receptor #36 -1 . . . 318318/318 (100%)0.0Homo sapiens, 318 aa.1 . . . 318318/318 (100%)[WO200198526-A2, 27-DEC-2001]AAU95525Human olfactory and pheromone1 . . . 318318/318 (100%)0.0G protein-coupled receptor #12 -1 . . . 318318/318 (100%)Homo sapiens, 318 aa.[WO200224726-A2, 28-MAR-2002]AAU05140Human odorant receptor (OR)-1 . . . 318318/318 (100%)0.0like protein, NOV10 - Homo1 . . . 318318/318 (100%)sapiens, 318 aa.[WO200151632-A2, 19-JUL-2001]AAU10320G-protein coupled receptor1 . . . 318318/318 (100%)0.0(GCREC) #21 - Homo sapiens,1 . . . 318318/318 (100%)318 aa. [WO200166742-A2, 13-SEP-2001]AAG71624Human olfactory receptor1 . . . 315314/315 (99%)0.0polypeptide, SEQ ID NO: 1305 -1 . . . 315314/315 (99%)Homo sapiens, 315 aa.[WO200127158-A2, 19-APR-2001]

In a BLAST search of public sequence databases, the NOV25a protein was found to have homology to the proteins shown in the BLASTP data in Table 25E.

TABLE 25EPublic BLASTP Results for NOV25aNOV25aIdentities/ProteinResidues/SimilaritiesAccessionMatchfor the MatchedNumberProtein/Organism/LengthResiduesPortionExpect ValueQ8NGN0Seven transmembrane helix1 . . . 318 318/318 (100%)0.0receptor - Homo sapiens1 . . . 318 318/318 (100%)(Human), 318 aa.Q8VFN1Olfactory receptor MOR239-6 -1 . . . 314284/314 (90%)e−166Mus musculus (Mouse), 314 aa.1 . . . 314296/314 (93%)Q8VFU8Olfactory receptor MOR239-5 -1 . . . 317200/317 (63%)e−113Mus musculus (Mouse), 314 aa.1 . . . 313241/317 (75%)Q8NGE8Seven transmembrane helix1 . . . 304190/304 (62%)e−110receptor - Homo sapiens1 . . . 304236/304 (77%)(Human), 314 aa.Q8VF58Olfactory receptor MOR240-1 -1 . . . 304186/304 (61%)e−110Mus musculus (Mouse), 311 aa.1 . . . 304237/304 (77%)

PFam analysis indicates that the NOV25a protein contains the domains shown in the Table 25F.

TABLE 25FDomain Analysis of NOV25aIdentities/NOV25a MatchSimilarities forPfam DomainRegionthe Matched RegionExpect Value7tm_141 . . . 287 57/276 (21%)3.3e−28172/276 (62%)

Example 26

The NOV26 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 26A.

TABLE 26ANOV26 Sequence AnalysisNOV26a, CG53563-03SEQ ID NO: 3291028 bpDNA SequenceORF Start: ATG at 28ORF Stop: TAG at 961AGGGAGAGAGACCAAGGGTGAGAAGAAATGTCCAACGCCAGCCTACTGACAGCGTTCATCCTCATGGGCCTTCCCCATGCCCCAGCGCTGGACGCCCCCCTCTTTGGAGTCTTCCTGGTGGTTTACGTGCTCACTGTGCTGGGGAACCTCCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCACCATGTACTACTTCCTCACCAACCTGTCGTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCCAAATTGCTGATGACTTTGGTGTTCCCAAGTGGCAGGGCTATCTCCTTCCACAGCTGCATGGCTCAGCTCTATTTCTTTCACTTCCTAGGGGGCACCGAGTGTTTCCTCTACAGGGTCATGTCCTGTGATCGCTACCTGGCCATCAGTTACCCGCTCAGGTACACCAGCATGATGACTGGGCGCTCGTGTACTCTTCTGGCCACCAGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGGCCATATTGACTTTCCATTTGCCCTACTGTGGACCCAACTGGATCCAGCACTATTTGTGTGATGCACCGCCCATCCTGAAACTGGCCTGTGCAGACACCTCAGCCATAGAGACTGTCATTTTTGTGACTGTTGGAATAGTGGCCTCGGGCTGCTTTGTCCTGATAGTGCTGTCCTATGTGTCCATCGTCTGTTCCATCCTGCGGATCCGCACCTCAGAGGGGAAGCACAGAGCCTTTCAGACCTGTGCCTCCCACTGTATCGTGGTCCTTTGCTTCTTTGGCCCTGGTCTTTTCATTTACCTGAGGCCAGGCTCCAGGAAAGCTGTGGATGGAGTTGTGGCCGTTTTCTACACTGTGCTGACGCCCCTTCTCAACCCTGTTGTGTACACCCTGAGGAACAAGGAGGTGAAGAAAGCTCTGTTGAAGCTGAAAGACAAAGTAGCACATTCTCAGAGCAAATAGACACTAGGGAAGATTACATATCTTAGCTCTTGTGAATAGTGCTGTGAAAAACATACAGGGGCAGGNOV26a, GG53563-03SEQ ID NO: 330311 aaMW at 34518.7kDProtein SequenceMSNASLLTAFILMGLPHAPALDAPLFGVFLVVYVLTVLGNLLILLVIRVDSHLHTTMYYFLTNLSFIDMWFSTVTVPKLLMTLVFPSGRAISFHSCMAQLYFFHFLGGTECFLYRVMSCDRYLAISYPLRYTSMMTGRSCTLLATSTWLSGSLHSAVQAILTFHLPYCGPNWIQHYLCDAPPILKLACADTSAIETVIFVTVGIVASGCFVLIVLSYVSIVCSILRIRTSEGKHRAFQTCASHCIVVLCFFGPGLFIYLRPGSRKAVDGVVAVFYTVLTPLLNPVVYTLRNKEVKKALLKLKDKVAHSQSKNOV26b, CG53563-01SEQ ID NO: 3311038 bpDNA SequenceORF Start: ATG at 28ORF Stop: TAG at 961AGGGAGAGAGACCAAGGGTGAGAAGAAATGTCCAACGCCAGCCTACTGACAGCGTTCATCCTCATGGGCCTTCCCCATGCCCCAGCGCTGGACGCCCCCCTCTTTGGAGTCTTCCTGGTGGTTTACGTGCTCACTGTGCTGGGGAACCTCCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCACCATGTACTACTTCCTCACCAACCTGTCGTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCCAAATTGCTGATGACTTTGGTGTTCCCAAGTGGCAGGGCTATCTCCTTCCACAGCTGCATGGCTCAGCTCTATTTCTTTCACTTCCTAGGGGGCACCGAGTGTTTCCTCTACAGGGTCATGTCCTGTGATCGCTACCTGGCCATCAGTTACCCGCTCAGGTACACCAGCATGATGACTGGGCGCTCGTGTACTCTTCTGGCCACCAGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGGCCATATTGACTTTCCATTTGCCCTACTGTGGACCCAACTGGATCCAGCACTATTTGTGTGATGCACCGCCCATCCTGAAACTGGCCTGTGCAGACACCTCAGCCATAGAGACTGTCATTTTTGTGACTGTTGGAATAGTGGCCTCGGGCTGCTTTGTCCTGATAGTGCTGTCCTATGTGTCCATCGTCTGTTCCATCCTGCGGATCCGCACCTCAGAGGGGAAGCACAGAGCCTTTCAGACCTGTGCCTCCCACTGTATCGTGGTCCTTTGCTTCTTTGGCCCTGGTCTTTTCATTTACCTGAGGCCAGGCTCCAGGAAAGCTGTGGATGGAGTTGTGGCCGTTTTCTACACTGTGCTGACGCCCCTTCTCAACCCTGTTGTGTACACCCTGAGGAACAAGGAGGTGAAGAAAGCTCTGTTGAAGCTGAAAGACAAAGTAGCACATTCTCAGAGCAAATAGACACTAGGGAAGATTACATATCTTAGCTCTTGTGAATAGTGCTGTGAAAAACATACAGGGGCAGGTATCTTTTGGNOV26b, GG53563-01SEQ ID NO: 332311 aaMW at 34518.7kDProtein SequenceMSNASLLTAFILMGLPHAPALDAPLFGVFLVVYVLTVLGNLLILLVIRVDSHLHTTMYYFLTNLSFIDMWFSTVTVPKLLMTLVFPSGRAISFHSCMAQLYFFHFLGGTECFLYRVMSCDRYLAISYPLRYTSMMTGRSCTLLATSTWLSGSLHSAVQAILTFHLPYCGPNWIQHYLCDAPPILKLACADTSAIETVIFVTVGIVASGCFVLIVLSYVSIVCSILRIRTSEGKHRAFQTCASHCIVVLCFFGPGLFIYLRPGSRKAVDGVVAVFYTVLTPLLNPVVYTLRNKEVKKALLKLKDKVAHSQSKNOV26c, CG53563-02SEQ ID NO: 3331040 bpDNA SequenceORF Start: ATG at 36ORF Stop: TAG at 969TTTCTGTAAGAACAGAGCCCCATATATGAGAAGAAATGTCCAACGCCACCCTACTGACAGCGTTCATCCTCACGGGCCTTCCCCATGCCCCAGGGCTGGACGCCCCCCTCTTTGGAATCTTCCTGGTGGTTTACGTGCTCACTGTGCTGGGGAACCTCCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCCCCATGTACTACTTCCTCACCAACCTGTCCTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCCAAAATGCTGATGACCTTGGTGTCCCCAAGCGGCAGGACTATCTCCTTCCACAGCTGCGTGGCTCAGCTCTATTTTTTCCACTTCCTGGGGAGCACCGAGTGTTTCCTCTACACAGTCATGTCCTATGATCGCTACCTGGCCATCAGTTACCCGCTCAGGTACACCAACATGATGACTGGGCGCTCGTGTGCCCTCCTGGCCACCGGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGACCATATTGACTTTCCATTTGCCCTACTGTGGACCCAACCAGATCCAGCACTACTTCTGTGACGCACCGCCCATCCTGAAACTGGCCTGTGCAGACACCTCAGCCAACGAGATGGTCATCTTTGTGAATATTGGGCTAGTGGCCTCGGGCTGCTTTGTCCTGATAGTGCTGTCCTATGTGTCCATCGTCTGTTCCATCCTGCGGATCCGCACCTCAGAGGGGAGGCAGAGAGCCTTTCAGACCTGTGCCTCCCACTGTATCGTGGTCCTTTGCTTCTTTGGCCCTGGTCTTTTCATTTACCTGAGGCCAGGCTCCAGGGACGCCTTGCATGGGGTTGTGGCCGTTTTCTACACCACGCTGACTCCTCTTTTCAACCCTGTTGTGTACACCCTGAGAAACAAGGAGGTAAAGAAAGCTCTGTTGAAGCTGAAAAATGGGTCAGTATTTGCTCAGGGTGAATAGTTAAGAAAGGCCATATATGGCTAACTTTTCTTTTTTTATTTGTAATTAAATTAAACCTTCAACATAAGCNOV26c, CG53563-02SEQ ID NO: 334311 aaMW at 34516.4kDProtein SequenceMSNATLLTAFILTGLPHAPGLDAPLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYYFLTNLSFIDMWFSTVTVPKMLMTLVSPSGRTISFHSCVAQLYFFHFLGSTECFLYTVMSYDRYLAISYPLRYTNMMTGRSCALLATGTWLSGSLHSAVQTILTFHLPYCGPNQIQHYFCDAPPILKLACADTSANEMVIFVNIGLVASGCFVLIVLSYVSIVCSILRIRTSEGRHRAFQTCASHCIVVLCFFGPGLFIYLRPGSRDALHGVVAVFYTTLTPLFNPVVYTLRNKEVKKALLKLKNGSVFAQGE

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 26B.

TABLE 26BComparison of the NOV26 protein sequences.NOV26a MSNASLLTAFILMGLPHAPALDAPLFGVFLVVYVLTVLGNLLILLVIRVDSHLHTTMYYFNOV26b MSNASLLTAFILMGLPHAPALDAPLFGVFLVVYVLTVLGNLLILLVIRVDSHLHTTMYYFNOV26c MSNATLLTAFILTGLPHAPGLDAPLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTTMYYFNOV26a LTNLSFIDMWFSTVTVPKLLMTLVFPSGRAISFHSCMAQLYFFHFLGGTECFLYRVMSCDNOV26b LTNLSFIDMWFSTVTVPKLLMTLVFPSGRAISFHSCMAQLYFFHFLGGTECFLYRVMSCDNOV26c LTNLSFIDMWFSTVTVPKMLMTLVSPSGRTISFHSCVAQLYFFHFLGSTECFLYRVMSYDNOV26a RYLAISYPLRYTSMMTGRSCTLLATSTWLSGSLHSAVQAILTFHLPYCGPNWIQHYLCDANOV26b RYLAISYPLRYTSMMTGRSCTLLATSTWLSGSLHSAVQAILTFHLPYCGPNWIQHYLCDANOV26c RYLAISYPLRYTNMMTGRSCALLATGTWLSGSLHSAVQTILTFHLPYCGPNQIQHYFCDANOV26a PPILKLACADTSAIETVIFVTVGIVASGCFVLIVLSYVSIVCSILRIRTSEGKHRAFQTCNOV26b PPILKLACADTSAIETVIFVTVGIVASGCFVLIVLSYVSIVCSILRIRTSEGKHRAFQTCNOV26c PPILKLACADTSANEMVIFVNIGLVASGCFVLIVLSYVSIVCSILRIRTSEGRHRAFQTCNOV26a ASHCIVVLCFFGPGLFIYLRPGSRKAVDGVVAVFYTVLTPLLNPVVYTLRNKEVKKALLKNOV26b ASHCIVVLCFFGPGLFIYLRPGSRKAVDGVVAVFYTVLTPLLNPVVYTLRNKEVKKALLKNOV26c ASHCIVVLCFFGPGLFIYLRPGSRDALHGVVAVFYTTLTPLFNPVVYTLRNKEVKKALLKNOV26a LKDKVAHSQSKNOV26b LKDKVAHSQSKNOV26c LKNGSVFAQGENOV26a (SEQ ID NO: 330)NOV26b (SEQ ID NO: 332)NOV26c (SEQ ID NO: 334)

Further analysis of the NOV26a protein yielded the following properties shown in Table 26C.

TABLE 26CProtein Sequence Properties NOV26aSignalP analysis:Cleavage site between residues 52 and 53PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 21; peak value 11.19PSG score: 6.79GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.58possible cleavage site: between 51 and 52>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 4INTEGRALLikelihood = −10.61Transmembrane 31-47INTEGRALLikelihood = −10.08Transmembrane 197-213INTEGRALLikelihood = −4.46Transmembrane 243-259INTEGRALLikelihood = −2.60Transmembrane 270-286PERIPHERALLikelihood = 0.85 (at 5)ALOM score: −10.61 (number of TMSs: 4)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 38Charge difference: 1.5 C(1.0) − N(−0.5)C > N: C-terminal side will be inside>>>Caution: Inconsistent mtop result with signal peptide>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):4.41Hyd Moment(95):3.21G content:1D/E content:1S/T content:3Score: −5.14Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 99 GRA|ISNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.4%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG53563-03 is end (k = 9)

A search of the NOV26a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 26D.

TABLE 26DGeneseq Results for NOV26aNOV26aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU85273G-coupled olfactory receptor1 . . . 311311/311 (100%)0.0#134 - Homo sapiens, 311 aa.1 . . . 311311/311 (100%)[WO200198526-A2, 27-DEC-2001]AAU95627Human olfactory and pheromone1 . . . 311311/311 (100%)0.0G protein-coupled receptor #114 -1 . . . 311311/311 (100%)Homo sapiens, 311 aa.[WO200224726-A2, 28-MAR-2002]ABP95802Human GPCR polypeptide SEQ1 . . . 311311/311 (100%)0.0ID NO 414 - Homo sapiens, 3111 . . . 311311/311 (100%)aa. [WO200216548-A2, 28-FEB-2002]AAG66376Partial NOV 15 protein sequence1 . . . 311311/311 (100%)0.0#2 - Unidentified, 311 aa.1 . . . 311311/311 (100%)[WO200155179-A2, 02-AUG-2001]AAG66335Human NOV 15 protein sequence -1 . . . 311311/311 (100%)0.0Homo sapiens, 311 aa.1 . . . 311311/311 (100%)[WO200155179-A2, 02-AUG-2001]

In a BLAST search of public sequence databases, the NOV26a protein was found to have homology to the proteins shown in the BLASTP data in Table 26E.

TABLE 26EPublic BLASTP Results for NOV26aNOV26aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedNumberProtein/Organism/LengthResiduesPortionExpect ValueQ8NGN5Seven transmembrane helix1 . . . 311 311/311 (100%)0.0receptor - Homo sapiens1 . . . 311 311/311 (100%)(Human), 311 aa.CAC69628Sequence 13 from Patent1 . . . 311308/311 (99%)e−179WO0155179 - Homo sapiens1 . . . 311308/311 (99%)(Human), 311 aa.CAC69627Sequence 11 from Patent1 . . . 311308/311 (99%)e−178WO0155179 - Homo sapiens1 . . . 311308/311 (99%)(Human), 311 aa.Q8NGN4Seven transmembrane helix1 . . . 311274/311 (88%)e−159receptor - Homo sapiens1 . . . 311288/311 (92%)(Human), 311 aa.Q8NGN6Seven transmembrane helix1 . . . 311274/311 (88%)e−159receptor - Homo sapiens1 . . . 311286/311 (91%)(Human), 311 aa.

PFam analysis indicates that the NOV26a protein contains the domains shown in the Table 26F.

TABLE 26FDomain Analysis of NOV26aIdentities/NOV26a MatchSimilarities forPfam DomainRegionthe Matched RegionExpect Value7tm_139 . . . 287 52/276 (19%)2.4e−26165/276 (60%)

Example 27

The NOV27 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 27A.

TABLE 27ANOV27 Sequence AnalysisNOV27a, GG53719-02SEQ ID NO: 335993 bpDNA SequenceORF Start: at 256ORF Stop: end of sequenceTATTAGAAGAAGAGTGTCATAGAAGCCAATAACATTTCTGGGCCTGTGAGTGAATTTATCCTCCTGGGCTTCCCCTGCCTGCTGCAGGGAGACCAAGATCCTCCTCTTTGTGGTCTTCTCCCTCATCTACCTTCTGACCCTCATGGGTAACACATCCATCATCTGCGCTGTGTGGTCAAGCCAGAAACTCCACACACCTATGTACATCCTCTTGGCTAATTTCTCTTTCCTGGAGATCTGCTGCATTAGTTCTGATGTCCCAAAATGTTGGCCAATCTCATCTCCCATATCAAGAGCATCTCCTATGCTGGCTGCCTGCTCCAGTTCTTCTACTTCTCCATGTGTGCTGCAGAGGGCTATTTTCTGTCTGTGATGTCCTTTGATCGGTTCCTTACCATCTGTCGACCTTTGCATTATCCCACAGTCATGACTCACCACCTGTGTGTCCGATTAGTGGCCTTCTGCAGGGCAGGTGGTTTTCTATCCATACTGATGCCTGCAGTGCTTATGTCCCGAGTGCCTTTCTGTGGCCCTAACATCACTGACCATTTTTTCTGTAACCTGGGACCATTGCTGGCACTGTCCTGTGCCCCAGTTCCCAAAACTACTCTGACTTGTGCTACAGTAAGCTCTCTCATCATCTTCATCACCTTCCTCTACATTCTTGGGTCCCATATCTTAGTTTTGCGAGCTGTTCTGTGGGTCCCAGCTGGCTCAGGCAGGAACAAAGCTTTCTCTACATGTGCTTCCCATTTCTTGGTTGTTTCTTTCTTCTATGGCTCAGTCATGGTGATGTATGTGAGTCCAGGCTCCAGGAGCCGTCCTGGGACACAGAAATTTGTGACATTGTTTTACTGCACAGCAAACCCATTCTTTAATCCCCTGACCTACAGTCTCTGGAACAAAGATATGACAGATGCCCTTAAAAAAGTGCTGGGAGTGCCATCAAAAGAAATATCTTGGAACACACTGAAATGATATACATTCTTCTACNOV27a, GG53719-02SEQ ID NO: 336321 aaMW at 35567.8kDProtein SequenceMSVIEANNISGPVSELSSWASPACCRETKILLFVVFSLIYLLTLMGNTSIICAVWSSQKLHTPMYILLANFSFLEICCISSDVPMLANLISHIKSISYAGCLLQFFYFSMCAAEGYFLSVMSFDRFLTICRPLHYPTVMTHHLCVRLVAFCRAGGFLSILMPAVLMSRVPFCGPNITDHFFCNLGPLLALSCAPVPKTTLTCATVSSLIIFITFLYILGSHILVLRAVLWVPAGSGRNKAFSTCASHFLVVSFFYGSVMVMYVSPGSRSRPGTQKFVTLFYCTANPFFNPLTYSLWNKDMTDALKKVLGVPSKEISWNTLKNOV27b, CG53719-01SEQ ID NO: 3371012 bpDNA SequenceORF Start: ATG at 25ORF Stop: TGA at 988TCATTTCCTTCATAGATTAGAAGAATGAGTGTCATAGAAGCCAATAACATTTCTGGGCCTGTGAGTGAATTTATCCTCCTGGGCTTCCCTGCCTGCTGCAGGGAGACCAAGATCCTCCTCTTTGTGGTCTTCTCCCTCATCTACCTTCTGACCCTCATGGGTAACACATCCATCATCTGCGCTGTGTGGTCAAGCCAGAAACTCCACACACCTATGTACATCCTCTTGGCTAATTTCTCTTTCCTGGAGATCTGCTGCATTAGTTCTGATGTCCCAATGTTGGCCAATCTCATCTCCCATATCAAGAGCATCTCCTATGCTGGCTGCCTGCTCCAGTTCTTCTACTTCTCCATGTGTGCTGCAGAAGGCTACTTTCTGTCTGTGATGTCCTTTGATCGGTTCCTTACCATCTGTCGACCTTTGCATTATCCCACAGTCATGACTCACCACCTGTGTGTCCGATTAGTGGCCTTCTGCAGGGCAGGTGGTTTTCTATCCATACTGATGCCTGCAGTGCTTATGTCCCGAGTGCCTTTCTGTGGCCCTAACATCACTGACCATTTTTTCTGTAACCTGGGACCATTGCTGGCACTGTCCTGTGCCCCAGTTCCCAAAACTACTCTGACTTGTGCTACAGTAAGCTCTCTCATCATCTTCATCACCTTCCTCTACATTCTTGGGTCCCATATCTTAGTTTTGCGAGCTGTTCTGTGGGTCCCAGCTGGCTCAGGCAGGAACAAAGCTTTCTCTACATGTGCTTCCCATTTCTTGGTTGTTTCTTTCTTCTATGGCTCAGTCATGGTGATGTATGTGAGTCCAGGCTCCAGGAGCCGCCCTGGGACACAGAAATTTGTGACATTGTTTTACTGCACAGCAACCCCATTCTTTAATCCCCTGACCTACAGTCTCTGGAACAAAGATATGACAGATGCCCTTAAAAAAGTGCTGGGAGTGCCATCAAAAGAAATATATTGGAACACACTGAAATGATATACATTCTTCTACAATTATTNOV27b, CG53719-01SEQ ID NO: 338321 aaMW at 35690.1kDProtein SequenceMSVIEANNISGPVSEFILLGFPACCRETKILLFVVFSLIYLLTLMGNTSIICAVWSSQKLHTPMYILLANFSFLEICCISSDVPMLANLISHIKSISYAGCLLQFFYFSMCAAEGYFLSVMSFDRFLTICRPLHYPTVMTHHLCVRLVAFCRAGGFLSILMPAVLMSRVPFCGPNITDHFFCNLGPLLALSCAPVPKTTLTCATVSSLIIFITFLYILGSHILVLRAVLWVPAGSGRNKAFSTCASHFLVVSFFYGSVMVMYVSPGSRSRPGTQKFVTLFYCTATPFFNPLTYSLWNKDMTDALKKVLGVPSKEIYWNTLK

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 27B.

TABLE 27BComparison of the NOV27 protein sequences.NOV27a MSVIEANNISGPVSELSSWASPACCRETKILLFVVFSLIYLLTLMGNTSIICAVWSSQKLNOV27b MSVIEANNISGPVSEFILLGFPACCRETKILLFVVFSLIYLLTLMGNTSIICAVWSSQKLNOV27a HTPMYILLANFSFLEICCISSDVPMLANLISHIKSISYAGCLLQFFYFSMCAAEGYFLSVNOV27b HTPMYILLANFSFLEICCISSDVPMLANLISHIKSISYAGCLLQFFYFSMCAAEGYFLSVNOV27a MSFDRFLTICRPLHYPTVMTHHLCVRLVAFCRAGGFLSILMPAVLMSRVPFCGPNITDHFNOV27b MSFDRFLTICRPLHYPTVMTHHLCVRLVAFCRAGGFLSILMPAVLMSRVPFCGPNITDHFNOV27a FCNLGPLLALSCAPVPKTTLTCATVSSLIIFITFLYILGSHILVLRAVLWVPAGSGRNKANOV27b FCNLGPLLALSCAPVPKTTLTCATVSSLIIFITFLYILGSHILVLRAVLWVPAGSGRNKANOV27a FSTCASHFLVVSFFYGSVMVMYVSPGSRSRPGTQKFVTLFYCTANPFFNPLTYSLWNKDMNOV27b FSTCASHFLVVSFFYGSVMVMYVSPGSRSRPGTQKFVTLFYCTATPFFNPLTYSLWNKDMNOV27a TDALKKVLGVPSKEISWNTLKNOV27b TDALKKVLGVPSKEIYWNTLKNOV27a (SEQ ID NO: 336)NOV27b (SEQ ID NO: 338)

Further analysis of the NOV27a protein yielded the following properties shown in Table 27C.

TABLE 27CProtein Sequence Properties NOV27aSignalP analysis:Cleavage site between residues 47 and 48PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 5; pos.chg 0; neg.chg 1H-region: length 9; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.31possible cleavage site: between 43 and 44>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 5INTEGRALLikelihood = −9.34Transmembrane 30-46INTEGRALLikelihood = −1.28Transmembrane 64-80INTEGRALLikelihood = −0.96Transmembrane 156-172INTEGRALLikelihood = −7.54Transmembrane 208-224INTEGRALLikelihood = −2.50Transmembrane 248-264PERIPHERALLikelihood = 1.48 (at 180)ALOM score: −9.34 (number of TMSs: 5)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 37Charge difference: 1.5 C(1.5) − N(0.0)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):0.86Hyd Moment(95):3.03G content:1D/E content:2S/T content:3Score: −7.70Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 6.5%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG53719-02 is end (k = 9)

A search of the NOV27a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 27D.

TABLE 27DGeneseq Results for NOV27aNOV27aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU07092Human odorant receptor (OR)1 . . . 321313/321 (97%)0.0polypeptide #9 - Homo sapiens,1 . . . 321313/321 (97%)321 aa. [WO200157215-A2, 09-AUG-2001]ABP72226Human G-protein coupled1 . . . 321314/322 (97%)0.0receptor GCREC-20 (odorant1 . . . 322314/322 (97%)receptor) - Homo sapiens, 322 aa.[WO2003000859-A2, 03-JAN-2003]AAG72445Human OR-like polypeptide query1 . . . 321310/322 (96%)0.0sequence, SEQ ID NO: 2126 -1 . . . 322311/322 (96%)Homo sapiens, 322 aa.[WO200127158-A2, 19-APR-2001]AAG72079Human olfactory receptor1 . . . 321309/322 (95%)e−180polypeptide, SEQ ID NO: 1760 -1 . . . 322310/322 (95%)Homo sapiens, 322 aa.[WO200127158-A2, 19-APR-2001]ABP72218Human G-protein coupled29 . . . 321 255/295 (86%)e−149receptor GCREC-12 (olfactory39 . . . 333 270/295 (91%)receptor) - Homo sapiens, 333 aa.[WO2003000859-A2, 03-JAN-2003]

In a BLAST search of public sequence databases, the NOV27a protein was found to have homology to the proteins shown in the BLASTP data in Table 27E.

TABLE 27EPublic BLASTP Results for NOV27aNOV27aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8VFT6Olfactory receptor MOR106-5 - 6 . . . 309181/308 (58%)1e−98Mus musculus (Mouse), 312 aa. 4 . . . 310224/308 (71%)Q8NGC7Seven transmembrane helix26 . . . 310169/287 (58%)2e−93receptor - Homo sapiens39 . . . 325212/287 (72%)(Human), 330 aa.CAD57956Sequence 107 from Patent26 . . . 310169/287 (58%)8e−93WO0250276 - Homo sapiens16 . . . 302211/287 (72%)(Human), 307 aa.Q8VFT9Olfactory receptor MOR106-2 -24 . . . 308168/287 (58%)2e−90Mus musculus (Mouse), 309 aa.21 . . . 307210/287 (72%)Q8VFT8Olfactory receptor MOR106-3 -24 . . . 308166/287 (57%)4e−90Mus musculus (Mouse), 311 aa.23 . . . 309212/287 (73%)

PFam analysis indicates that the NOV27a protein contains the domains shown in the Table 27F.

TABLE 27FDomain Analysis of NOV27aIdentities/NOV27a MatchSimilarities forPfam DomainRegionthe Matched RegionExpect Value7tm_146 . . . 293 47/276 (17%)4.5e−13166/276 (60%)

Example 28

The NOV28 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 28A.

TABLE 28ANOV28 Sequence AnalysisNOV28a, CG53746-04SEQ ID NO: 3391604 bpDNA SequenceORF Start: ATG at 648ORF Stop: TGA at 1581ACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTGGATATTTGGTGTACTTTTCCTCAATTGTGAAATCTCTGGGTGGGGACCACAGCTCAGTGTTGAGTTACTGACCTCTTCTTGGTCCTGTGGATTAGCATGCAGCTAATCTGTTTGACCTCTGTTTGGAATTCGGAATTCTTAATGACTACACATCTTTGATACAATAGATGATACCTCAAACATCCTTTTGAACAGCTGTTCTTTTCCATGAGTCTTGGTCTATTCTGACATTTATGTCTCCCTTCAATCACGTCTTTGGCCTTAGAAGATTGAGTTACTGGATTCTTTATATATTCTAGTGGTCATCTCTGAAATGTGCTCAGAGAGCACCTAAATTAACCATCCAATACGAGTTGAGTGTGTTAAGTTAAAAAAAAAAAAAAGATTTTTCTGAGTATTCCTGACCTTACATCAGTGAACATTTATGTTTTAAAGTCTTACATAAGATACTGTGTGTGAAAGCATTTTCTTCCCAAATTTACATGAGTGCCTAAATTGTTATACTTTTTGGTTAAATAGATATTGGAAAAATAAGTGTGCAATTATAGCATTTAATCCCATTATAATATTCATTTGTTTTTCTTTCAGTTGGCACCATTCCCAATTTAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGATTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTATTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28a, CG53746-04SEQ ID NO: 340311 aaMW at 34309.4kDProtein SequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPIAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28b, GG53746-01SEQ ID NO: 341984 bpDNA SequenceORF Start: ATG at 24ORF Stop: TGA at 957AGTTGGCACCATTCCCAATATAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGGTTATCTGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTGTTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGAATCTNOV28b, CG53746-01SEQ ID NO: 342311 aaMW at 34295.4kDProtein SequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPVAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28c, CG53746-02SEQ ID NO: 343952 bpDNA SequenceORF Start: ATG at 7ORF Stop: TGA at 940ATATAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGGTTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTGTTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTGGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTTTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTNOV28c, CG53746-02SEQ ID NO: 344311 aaMW at 34295.4kDProtein SequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPVAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28d, GG53746-03SEQ ID NO: 345964 bpDNA SequenceORF Start: ATG at 8ORF Stop: TGA at 941TATATAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGGTTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTAQTCCTCATCAGTCACACCTGTCATGAGCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTGTTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTGGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTTTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28d, CG53746-03SEQ ID NO: 346311 aaMW at 34295.4kDProtein SequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPVAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28e, SNP13373967 ofSEQ ID NO: 3471604 bpCG53746-04, DNA SequenceORF Start: ATG at 648ORF Stop: TGA at 1581SNP Pos: 466SNP Change: T to CACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTGGATATTTGGTGTACTTTTCCTCAATTGTGAAATCTCTGGGTGGGGACCACAGCTCAGTGTTGAGTTACTGACCTCTTCTTGGTCCTGTGGATTAGCATGCAGCTAATCTGTTTGACCTCTGTTTGGAATTCGGAATTCTTAATGACTACACATCTTTGATACAATAGATGATACCTCAAACATCCTTTTGAACAGCTGTTCTTTTCCATGAGTCTTGGTCTATTCTGACATTTATGTCTCCCTTCAATCACGTCTTTGGCCTTAGAAGATTGAGTTACTGGATTCTTTATATATTCTAGTGGTCATCTCTGAAATGTGCTCAGAGAGCACCTAAATTAACCATCCAATACGAGTTGAGTGTGTTAAGTTAAAAAAAAAAAAAAGATTTTTCTGAGTATTCCTGACCTTACATCAGTGAACATTTATGCTTTAAAGTCTTACATAAGATACTGTGTGTGAAAGCATTTTCTTCCCAAATTTACATGAGTGCCTAAATTGTTATACTTTTTGGTTAAATAGATATTGGAAAAATAAGTGTGCAATTATAGCATTTAATCCCATTATAATATTCATTTGTTTTTCTTTCAGTTGGCACCATTCCCAATTTAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGATTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTATTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28e, SNP13373967 ofSEQ ID NO: 348311 aaMW at 34309.4kDCG53746-04, ProteinSNP Change: no changeSequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPIAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28f, SNP13373968 ofSEQ ID NO: 3491604 bpCG53746-04, DNA SequenceORF Start: ATG at 648ORF Stop: TGA at 1581SNP Pos: 550SNP Change: T to CACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTGGATATTTGGTGTACTTTTCCTCAATTGTGAAATCTCTGGGTGGGGACCACAGCTCAGTGTTGAGTTACTGACCTCTTCTTGGTCCTGTGGATTAGCATGCAGCTAATCTGTTTGACCTCTGTTTGGAATTCGGAATTCTTAATGACTACACATCTTTGATACAATAGATGATACCTCAAACATCCTTTTGAACAGCTGTTCTTTTCCATGAGTCTTGGTCTATTCTGACATTTATGTCTCCCTTCAATCACGTCTTTGGCCTTAGAAGATTGAGTTACTGGATTCTTTATATATTCTAGTGGTCATCTCTGAAATGTGCTCAGAGAGCACCTAAATTAACCATCCAATACGAGTTGAGTGTGTTAAGTTAAAAAAAAAAAAAAGATTTTTCTGAGTATTCCTGACCTTACATCAGTGAACATTTATGCTTTAAAGTCTTACATAAGATACTGTGTGTGAAAGCATTTTCTTCCCAAATTTACATGAGTGCCTAAATTGTTATACTTTTTGGTTAAATAGATATTGGAAAAATAAGTGTGCAATTATAGCATTTAATCCCATTATAATATTCATTTGTTTTTCTTTCAGTTGGCACCATTCCCAATTTAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGATTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTATTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28f, SNP13373968 ofSEQ ID NO: 350311 aaMW at 34309.4kDCG53746-04, ProteinSNP Change: no changeSequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPIAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28g, SNP13382432 ofSEQ ID NO: 3511604 bpCG53746-04, DNA SequenceORF Start: ATG at 648ORF Stop: TGA at 1581SNP Pos: 644SNP Change: T to AACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTGGATATTTGGTGTACTTTTCCTCAATTGTGAAATCTCTGGGTGGGGACCACAGCTCAGTGTTGAGTTACTGACCTCTTCTTGGTCCTGTGGATTAGCATGCAGCTAATCTGTTTGACCTCTGTTTGGAATTCGGAATTCTTAATGACTACACATCTTTGATACAATAGATGATACCTCAAACATCCTTTTGAACAGCTGTTCTTTTCCATGAGTCTTGGTCTATTCTGACATTTATGTCTCCCTTCAATCACGTCTTTGGCCTTAGAAGATTGAGTTACTGGATTCTTTATATATTCTAGTGGTCATCTCTGAAATGTGCTCAGAGAGCACCTAAATTAACCATCCAATACGAGTTGAGTGTGTTAAGTTAAAAAAAAAAAAAAGATTTTTCTGAGTATTCCTGACCTTACATCAGTGAACATTTATGCTTTAAAGTCTTACATAAGATACTGTGTGTGAAAGCATTTTCTTCCCAAATTTACATGAGTGCCTAAATTGTTATACTTTTTGGTTAAATAGATATTGGAAAAATAAGTGTGCAATTATAGCATTTAATCCCATTATAATATTCATTTGTTTTTCTTTCAGTTGGCACCATTCCCAATTTAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGATTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTATTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28g, SNP13382432 ofSEQ ID NO: 352311 aaMW at 34309.4kDCG53746-04, ProteinSNP Change: no changeSequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPIAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28h, SNP13373969 ofSEQ ID NO: 3531604 bpCG53746-04, DNA SequenceORF Start: ATG at 648ORF Stop: TGA at 1581SNP Pos: 695SNP Change: A to GACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTGGATATTTGGTGTACTTTTCCTCAATTGTGAAATCTCTGGGTGGGGACCACAGCTCAGTGTTGAGTTACTGACCTCTTCTTGGTCCTGTGGATTAGCATGCAGCTAATCTGTTTGACCTCTGTTTGGAATTCGGAATTCTTAATGACTACACATCTTTGATACAATAGATGATACCTCAAACATCCTTTTGAACAGCTGTTCTTTTCCATGAGTCTTGGTCTATTCTGACATTTATGTCTCCCTTCAATCACGTCTTTGGCCTTAGAAGATTGAGTTACTGGATTCTTTATATATTCTAGTGGTCATCTCTGAAATGTGCTCAGAGAGCACCTAAATTAACCATCCAATACGAGTTGAGTGTGTTAAGTTAAAAAAAAAAAAAAGATTTTTCTGAGTATTCCTGACCTTACATCAGTGAACATTTATGCTTTAAAGTCTTACATAAGATACTGTGTGTGAAAGCATTTTCTTCCCAAATTTACATGAGTGCCTAAATTGTTATACTTTTTGGTTAAATAGATATTGGAAAAATAAGTGTGCAATTATAGCATTTAATCCCATTATAATATTCATTTGTTTTTCTTTCAGTTGGCACCATTCCCAATTTAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGGTTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTATTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28h, SNP13373969 ofSEQ ID NO: 354311 aaMW at 34309.4kDCG53746-04, ProteinSNP Pos: 16SNP Change: Gly to GlySequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPIAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28i, SNP13373970 ofSEQ ID NO: 3551604 bpCG53746-04, DNA SequenceORF Start: ATG at 648ORF Stop: TGA at 1581SNP Pos: 927SNP Change: A to GACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTGGATATTTGGTGTACTTTTCCTCAATTGTGAAATCTCTGGGTGGGGACCACAGCTCAGTGTTGAGTTACTGACCTCTTCTTGGTCCTGTGGATTAGCATGCAGCTAATCTGTTTGACCTCTGTTTGGAATTCGGAATTCTTAATGACTACACATCTTTGATACAATAGATGATACCTCAAACATCCTTTTGAACAGCTGTTCTTTTCCATGAGTCTTGGTCTATTCTGACATTTATGTCTCCCTTCAATCACGTCTTTGGCCTTAGAAGATTGAGTTACTGGATTCTTTATATATTCTAGTGGTCATCTCTGAAATGTGCTCAGAGAGCACCTAAATTAACCATCCAATACGAGTTGAGTGTGTTAAGTTAAAAAAAAAAAAAAGATTTTTCTGAGTATTCCTGACCTTACATCAGTGAACATTTATGCTTTAAAGTCTTACATAAGATACTGTGTGTGAAAGCATTTTCTTCCCAAATTTACATGAGTGCCTAAATTGTTATACTTTTTGGTTAAATAGATATTGGAAAAATAAGTGTGCAATTATAGCATTTAATCCCATTATAATATTCATTTGTTTTTCTTTCAGTTGGCACCATTCCCAATTTAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGATTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTGTTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28i, SNP13373970 ofSEQ ID NO: 356311 aaMW at 34295.4kDCG53746-04, ProteinSNP Pos: 94SNP Change: Ile to ValSequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPVAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28j, SNP13373971 ofSEQ ID NO: 3571604 bpCG53746-04, DNA SequenceORF Start: ATG at 648ORF Stop: TGA at 1581SNP Pos: 959SNP Change: A to GACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTGGATATTTGGTGTACTTTTCCTCAATTGTGAAATCTCTGGGTGGGGACCACAGCTCAGTGTTGAGTTACTGACCTCTTCTTGGTCCTGTGGATTAGCATGCAGCTAATCTGTTTGACCTCTGTTTGGAATTCGGAATTCTTAATGACTACACATCTTTGATACAATAGATGATACCTCAAACATCCTTTTGAACAGCTGTTCTTTTCCATGAGTCTTGGTCTATTCTGACATTTATGTCTCCCTTCAATCACGTCTTTGGCCTTAGAAGATTGAGTTACTGGATTCTTTATATATTCTAGTGGTCATCTCTGAAATGTGCTCAGAGAGCACCTAAATTAACCATCCAATACGAGTTGAGTGTGTTAAGTTAAAAAAAAAAAAAAGATTTTTCTGAGTATTCCTGACCTTACATCAGTGAACATTTATGCTTTAAAGTCTTACATAAGATACTGTGTGTGAAAGCATTTTCTTCCCAAATTTACATGAGTGCCTAAATTGTTATACTTTTTGGTTAAATAGATATTGGAAAAATAAGTGTGCAATTATAGCATTTAATCCCATTATAATATTCATTTGTTTTTCTTTCAGTTGGCACCATTCCCAATTTAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGATTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTATTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTGGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28j, SNP13373971 ofSEQ ID NO: 358311 aaMW at 34309.4kDCG53746-04, ProteinSNP Pos: 104SNP Change: Val to ValSequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPIAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28k, SNP13373972 ofSEQ ID NO: 3591604 bpCG53746-04, DNA SequenceORF Start: ATG at 648ORF Stop: TGA at 1581SNP Pos: 1058SNP Change: C to TACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTGGATATTTGGTGTACTTTTCCTCAATTGTGAAATCTCTGGGTGGGGACCACAGCTCAGTGTTGAGTTACTGACCTCTTCTTGGTCCTGTGGATTAGCATGCAGCTAATCTGTTTGACCTCTGTTTGGAATTCGGAATTCTTAATGACTACACATCTTTGATACAATAGATGATACCTCAAACATCCTTTTGAACAGCTGTTCTTTTCCATGAGTCTTGGTCTATTCTGACATTTATGTCTCCCTTCAATCACGTCTTTGGCCTTAGAAGATTGAGTTACTGGATTCTTTATATATTCTAGTGGTCATCTCTGAAATGTGCTCAGAGAGCACCTAAATTAACCATCCAATACGAGTTGAGTGTGTTAAGTTAAAAAAAAAAAAAAGATTTTTCTGAGTATTCCTGACCTTACATCAGTGAACATTTATGCTTTAAAGTCTTACATAAGATACTGTGTGTGAAAGCATTTTCTTCCCAAATTTACATGAGTGCCTAAATTGTTATACTTTTTGGTTAAATAGATATTGGAAAAATAAGTGTGCAATTATAGCATTTAATCCCATTATAATATTCATTTGTTTTTCTTTCAGTTGGCACCATTCCCAATTTAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGATTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTATTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCTCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28k, SNP13373972 ofSEQ ID NO: 360311 aaMW at 34309.4kDCG53746-04, ProteinSNP Pos: 137SNP Change: Ser to SerSequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPIAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGALKRELRIKIFSNOV28l, SNP13382433 ofSEQ ID NO: 3611604 bpCG53746-04, DNA SequenceORF Start: ATG at 648ORF Stop: TGA at 1581SNP Pos: 1482SNP Change: A to GACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTTGGATATTTGGTGTACTTTTCCTCAATTGTGAAATCTCTGGGTGGGGACCACAGCTCAGTGTTGAGTTACTGACCTCTTCTTGGTCCTGTGGATTAGCATGCAGCTAATCTGTTTGACCTCTGTTTGGAATTCGGAATTCTTAATGACTACACATCTTTGATACAATAGATGATACCTCAAACATCCTTTTGAACAGCTGTTCTTTTCCATGAGTCTTGGTCTATTCTGACATTTATGTCTCCCTTCAATCACGTCTTTGGCCTTAGAAGATTGAGTTACTGGATTCTTTATATATTCTAGTGGTCATCTCTGAAATGTGCTCAGAGAGCACCTAAATTAACCATCCAATACGAGTTGAGTGTGTTAAGTTAAAAAAAAAAAAAAGATTTTTCTGAGTATTCCTGACCTTACATCAGTGAACATTTATGCTTTAAAGTCTTACATAAGATACTGTGTGTGAAAGCATTTTCTTCCCAAATTTACATGAGTGCCTAAATTGTTATACTTTTTGGTTAAATAGATATTGGAAAAATAAGTGTGCAATTATAGCATTTAATCCCATTATAATATTCATTTGTTTTTCTTTCAGTTGGCACCATTCCCAATTTAGATGGGGACTGGAAATGACACCACTGTGGTAGAGTTTACTCTTTTGGGATTATCCGAGGATACTACAGTTTGTGCTATTTTATTTCTTGTGTTTCTAGGAATTTATGTTGTCACCTTAATGGGTAATATCAGCATAATTGTATTGATCAGAAGAAGTCATCATCTTCATACACCCATGTACATTTTCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTCATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTATTGCTGGTTGTGTGGCCCAGCTCTGTTCTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTATGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCTTAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATTAAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTTTGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCTATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCTGAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACTGCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTCTACGCCGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATAAAAATATTTTCTTGATGAAACTAGTTAGTTTGAAGANOV28l, SNP13382433 ofSEQ ID NO: 362311 aaMW at 34279.4kDCG53746-04, ProteinSNP Pos: 279SNP Change: Thr to AlaSequenceMGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYIFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPIAGCVAQLCSVVTFGTAECFLLAAMAYDRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDYSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTCTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYAVVIPMLNPLIYSLRNKEIKGALKRELRIKIFS

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 28B.

TABLE 28BComparison of the NOV28 protein sequences.NOV28a MGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYNOV25b MGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYNOV25c MGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLHTPMYNOV25d MGTGNDTTVVEFTLLGLSEDTTVCAILFLVFLGIYVVTLMGNISIIVLIRRSHHLNTPMYNOV28a IFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPIAGCVAQLCSVVTFGTAECFLLAAMAYNOV28b IFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPVAGCVAQLCSVVTFGTAECFLLAAMAYNOV28c IFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPVAGCVAQLCSVVTFGTAECFLLAAMAYNOV28d IFLCHLAFVDIGYSSSVTPVMLMSFLRKETSLPVAGCVAQLCSVVTFGTAECFLLAAMAYNOV28a DRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDNOV28b DRYVAICSPLLYSTcMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDNOV28c DRYVAICSPLLYSTcMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDNOV28d DRYVAICSPLLYSTCMSPGVCIILVGMSYLGGCVNAWTFIGCLLRLSFCGPNKVNHFFCDNOV28a YSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTNOV28b YSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTNOV28c YSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTNOV28d YSPLLKLACSHDFTFEIIPAISSGSIIVATVCVIAISYIYILITILKMHSTKGRHKAFSTNOV28a CTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGANOV28b CTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGANOV28c CTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGANOV28d CTSHLTAVTLFYGTITFIYVMPKSSYSTDQNKVVSVFYTVVIPMLNPLIYSLRNKEIKGANOV28a LKRELRIKIFSNOV28b LKRELRIKIFSNOV28c LKRELRIKIFSNOV28d LKRELRIKIFSNOV28a (SEQ ID NO: 340)NOV28b (SEQ ID NO: 342)NOV28c (SEQ ID NO: 344)NOV28d (SEQ ID NO: 346)

Further analysis of the NOV28a protein yielded the following properties shown in Table 28C.

TABLE 28CProtein Sequence Properties NOV28aSignalP analysis:Cleavage site between residues 42 and 43PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 11; pos.chg 0; neg.chg 2H-region: length 7; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −5.11possible cleavage site: between 38 and 39>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −11.46Transmembrane 23-39INTEGRALLikelihood = −1.49Transmembrane 101-117INTEGRALLikelihood = −2.23Transmembrane 140-156INTEGRALLikelihood = −9.82Transmembrane 206-222INTEGRALLikelihood = −0.85Transmembrane 245-261INTEGRALLikelihood = −3.13Transmembrane 273-289PERIPHERALLikelihood = 1.48 (at 61)ALOM score: −11.46 (number of TMSs: 6)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 30Charge difference: 7.5 C(3.5) − N(−4.0)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):5.92Hyd Moment(95):6.18G content:2D/E content:2S/T content:3Score: −7.11Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 6.8%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: IKIFSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: mitochondrial>> prediction for CG53746-04 is end (k = 9)

A search of the NOV28a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 28D.

TABLE 28DGeneseq Results for NOV28aNOV28aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAG66704Human GPCR2c polypeptide -1 . . . 311 311/311 (100%)e−180Homo sapiens, 311 aa.1 . . . 311 311/311 (100%)[WO200160865-A2, 23-AUG-2001]AAU95624Human olfactory and pheromone1 . . . 311310/311 (99%)e−180G protein-coupled receptor #111 -1 . . . 311311/311 (99%)Homo sapiens, 311 aa.[WO200224726-A2, 28-MAR-2002]AAG66702Human GPCR2a polypeptide -1 . . . 311310/311 (99%)e−180Homo sapiens, 311 aa.1 . . . 311311/311 (99%)[WO200160865-A2, 23-AUG-2001]AAE25068Human G-protein coupled1 . . . 311309/311 (99%)e−180receptor (GCREC)-8 protein -1 . . . 311311/311 (99%)Homo sapiens, 311 aa.[WO200246230-A2, 13-JUN-2002]AAG66703Human GPCR2b polypeptide -1 . . . 311309/311 (99%)e−180Homo sapiens, 311 aa.1 . . . 311310/311 (99%)[WO200160865-A2, 23-AUG-2001]

In a BLAST search of public sequence databases, the NOV28a protein was found to have homology to the proteins shown in the BLASTP data in Table 28E.

TABLE 28EPublic BLASTP Results for NOV28aNOV28aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8WZ94Olfactory receptor 5P31 . . . 311310/311 (99%)e−180(Olfactory receptor-like protein1 . . . 311311/311 (99%)JCG1) - Homo sapiens (Human),311 aa.CAD37573Sequence 175 from Patent1 . . . 311304/311 (97%)e−175WO0224726 - Homo sapiens1 . . . 311307/311 (97%)(Human), 311 aa.Q8NGM2Seven transmembrane helix59 . . . 311 252/253 (99%)e−145receptor - Homo sapiens1 . . . 253253/253 (99%)(Human), 253 aa.Q8VG42Olfactory receptor MOR204-6 -1 . . . 303240/303 (79%)e−138Mus musculus (Mouse), 310 aa.1 . . . 303267/303 (87%)Q8VEZ0Olfactory receptor MOR204-32 -1 . . . 303236/303 (77%)e−136Mus musculus (Mouse), 312 aa.1 . . . 303266/303 (86%)

PFam analysis indicates that the NOV28a protein contains the domains shown in the Table 28F.

TABLE 28FDomain Analysis of NOV28aNOV28aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_141 . . . 290 56/276 (20%)2.5e−34179/276 (65%)

Example 29

The NOV29 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 29A.

TABLE 29ANOV29 Sequence AnalysisNOV29a, CG53767-02SEQ ID NO: 3631378 bpDNA SequenceORF Start: ATG at 473ORF Stop: TAA at 1331TGAAATTGGAGAGTCATACAAAATCCAGAATGGAGAAAAGAGAGATAAACAGTGCTTTTGGGGTAAAATCCAGGTATAGGTATTTGGGCCCACTCTATGTCATCTATACATATTATCATATTAGAATCATTCTTCTCTTCACTCAGGCTCCTGACCTTGACCTCTTTCCAGGTGCATTTAACTCCCTTTCCTCAGGTTCTCTAAGAGTTGCCTGACACTTGCCCAGGTCCCCTGAATAAAATACAGGTAAATCAGTGCATAAGAAGCTTTATACAGTGATCTCAGACTTGTGACCAAGAGCCCCTCTGCACCATTGATAGACAGTGGCCGTGCCCACCAGGAGGATGGGCAATCACACTGCAGTGAGCCTATTCCTTCTGTGGGGATTTTCCAGTTTTTCAGACCTGCAGAGTCTACTTTTTGTGGTGATTCTCTTCTACATGTGACCATCCTAGCTGCAAACGTGTCCATAATGGGGGCCATCAAGCTCAGCCACAACCTTCACACTCCTATGTACTTTTTCCTCTGTGGCCTGTCCTTTTCAGAAACTTGTACCACTGTGGTAGTAATCCCTCGCATGTTGGTGGACTTTCTATCAGAGAGCAAGACCATTTCTCTTCCTGAGTGTGCCACACAGATGTTTTTCTTTCTGGGCTTTGCATCCAACAACTGTTTCATCATGGCCGCTATGTCCTACGACCGCTACACGGCCATCCACAACCCACTGCAGTACCACACCCTTATGACAAGAAAGATCTGCTTGCAGATGATGATGGCTTCTTGGATGGTTGGGTTCCTGTTTTCTCTGTGCATCATCGTCACTGTATTCAACTTGTCTCTTTGCGACTTGAACACTATCCAGCACTATTTCTGTGATATCTCACCAGTGGTCTCCCTTGCTTGTAATTACACTTTCTATCATGAAATGGCTATTTTTGTGCTCTCTGCCTTTGTGTTGGTGGGCAGCTGTATTTTAATTATGATTTCCTATGTCTTCATTGTGTTCATAGTCATAAAGATGCCCTCTGCAAAGGGGAGGTCTAAGGCCTTCTCAACTTGCTCCTCCCACCTCACTGTTGTGTCCATACACTATGGATTTGCTTGCTTTGTCTATTTGAGGCCCAAGAACAGCAACTCCTTCGATGAAGACATGCCGACGGCCATGATATATACAATACTGATGCCTCTGCTTAACCCCATCGTGTACAGTCTGAGAAACAAAGAAATGCAGATAGCCCTAAGAAAAACACTAGGCAGTGTATTTGGGGTTTTCCCTCAGAAGACAAAAAAAGAGCCTGAACATTTAAAAAAATTACACAGCATTGATAAATAAAGGTGAGAAAAGCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGNOV29a, CG53767-02SEQ ID NO: 364286 aaMW at 32538.4kDProtein SequenceMGAIKLSHNLHTPMYFFLCGLSFSETCTTVVVIPRMLVDFLSESKTISLPECATQMFFFLGFASNNCFIMAANSYDRYTAIHNPLQYHTLMTRKICLQMMMASWMVGFLFSLCIIVTVFNLSLCDLNTIQHYFCDISPVVSLACNYTFYHEMAIFVLSAFVLVGSCILIMISYVFIVFIVIKMPSAKGRSKAFSTCSSHLTVVSIHYGFACFVYLRPKNSNSFDEDMPTAMIYTILMPLLNPIVYSLRNKEMQIALRKTLGSVFGVFPQKTKKEPEHLKKLHSIDKNOV29b, CG53767-01SEQ ID NO: 3651028 bpDNA SequenceORF Start: ATG at 23ORF Stop: TAA at 1007AGTGGCCGTGCCCACCAGGAGGATGGGCAATCACACTGCAGTGAGCCTATTCCTTCTGTGGGGATTTTCCAGTTTTTCAGACCTGCAGAGTCTACTTTGTGGTGATTCTCTTCTACATGTGACCATCCTAGCTGCAAACGTGTCCATAATGGGGGCCATCAAGCTCAGCCACAACCTTCACACTCCTATGTACTTTTTCCTCTGTGGCCTGTCCTTTTCAGAAACTTGTACCACTGTGGTAGTAATCCCTCGCATGTTGGTGGACTTTCTATCAGAGAGCAAGACCATTTCTCTTCCTGAGTGTGCCACACAGATGTTTTTCTTTCTGGGCTTTGCATCCAACAACTGTTTCATCATGGCCGCTATGTCCTACGACCGCTACACGGCCATCCACAACCCACTGCAGTACCACACCCTTATGACAAGAAAGATCTGCTTGCAGATGATGATGGCTTCTTGGATGGTTGGGTTCCTGTTTTCTCTGTGCATCATCGTCACTGTATTCAACTTGTCTCTTTGCGACTTGAACACTATCCAGCACTATTTCTGTGATATCTCACCAGTGGTCTCCCTTGCTTGTAATTACACTTTCTATCATGAAATGGCTATTTTTGTGCTCTCTGCCTTTGTGTTGGTGGGCAGCTGTATTTTAATTATGATTTCCTATGTCTTCATTGTGTTCATAGTCATAAAGATGCCCTCTGCAAAGGGGAGGTCTAAGGCCTTCTCAACTTGCTCCTCCCACCTCACTGTTGTGTCCATACACTATGGATTTGCTTGCTTTGTCTATTTGAGGCCCAAGAACAGCAACTCCTTCGATGAAGACATGCTGACGGCCATGATATATACAATACTGATGCCTCTGCTTAACCCCATCGTGTACAGTCTGAGAAACAAAGAAATGCAGATAGCCCTAAGAAAAACACTAGGCAGTGTATTTGGGGTTTTCCCTCAGAAGACAAAAAAAGAGCCTGAACATTTAAAAAAATTACACAGCATTGATAAATAAAGGTGAGAAAAGTGGAGTANOV29b, CG53767-01SEQ ID NO: 366328 aaMW at 37015.5kDProtein SequenceMGNHTAVSLFLLWGFSSFSDLQSLLCGDSLLHVTILAANVSIMGAIKLSHNLHTPMYFFLCGLSFSETCTTVVVIPRMLVDFLSESKTISLPECATQMFFFLGFASNNCFIMAAMSYDRYTAIHNPLQYHTLMTRKICLQMMMASWMVGFLFSLCIIVTVFNLSLCDLNTIQHYFCDISPVVSLACNYTFYHEMAIFVLSAFVLVGSCILIMISYVFIVFIVIKMPSAKGRSKAFSTCSSHLTVVSIHYGFACFVYLRPKNSNSFDEDMLTAMIYTILMPLLNPIVYSLRNKEMQIALRKTLGSVFGVFPQKTKKEPEHLKKLHSIDKNOV29c, SNP13382437 ofSEQ ID NO: 3671378 bpCG53767-02, DNA SequenceORF Start: ATG at 473ORF Stop: TAA at 1331SNP Pos: 961SNP Change: G to ATGAAATTGGAGAGTCATACAAAATCCAGAATGGAGAAAAGAGAGATAAACAGTGCTTTTGGGGTAAAATCCAGGTATAGGTATTTGGGCCCACTCTATGTCATCTATACATATTATCATATTAGAATCATTCTTCTCTTCACTCAGGCTCCTGACCTTGACCTCTTTCCAGGTGCATTTAACTCCCTTTCCTCAGGTTCTCTAAGAGTTGCCTGACACTTGCCCAGGTCCCCTGAATAAAATACAGGTAAATCAGTGCATAAGAAGCTTTATACAGTGATCTCAGACTTGTGACCAAGAGCCCCTCTGCACCATTGATAGACAGTGGCCGTGCCCACCAGGAGGATGGGCAATCACACTGCAGTGAGCCTATTCCTTCTGTGGGGATTTTCCAGTTTTTCAGACCTGCAGAGTCTACTTTTTGTGGTGATTCTCTTCTACATGTGACCATCCTAGCTGCAAACGTGTCCATAATGGGGGCCATCAAGCTCAGCCACAACCTTCACACTCCTATGTACTTTTTCCTCTGTGGCCTGTCCTTTTCAGAAACTTGTACCACTGTGGTAGTAATCCCTCGCATGTTGGTGGACTTTCTATCAGAGAGCAAGACCATTTCTCTTCCTGAGTGTGCCACACAGATGTTTTTCTTTCTGGGCTTTGCATCCAACAACTGTTTCATCATGGCCGCTATGTCCTACGACCGCTACACGGCCATCCACAACCCACTGCAGTACCACACCCTTATGACAAGAAAGATCTGCTTGCAGATGATGATGGCTTCTTGGATGGTTGGGTTCCTGTTTTCTCTGTGCATCATCGTCACTGTATTCAACTTGTCTCTTTGCGACTTGAACACTATCCAGCACTATTTCTGTGATATCTCACCAGTGGTCTCCCTTGCTTGTAATTACACTTTCTATCATGAAATGGCTATTTTTGTGCTCTCTGCCTTTGTGTTGGTAGGCAGCTGTATTTTAATTATGATTTCCTATGTCTTCATTGTGTTCATAGTCATAAAGATGCCCTCTGCAAAGGGGAGGTCTAAGGCCTTCTCAACTTGCTCCTCCCACCTCACTGTTGTGTCCATACACTATGGATTTGCTTGCTTTGTCTATTTGAGGCCCAAGAACAGCAACTCCTTCGATGAAGACATGCCGACGGCCATGATATATACAATACTGATGCCTCTGCTTAACCCCATCGTGTACAGTCTGAGAAACAAAGAAATGCAGATAGCCCTAAGAAAAACACTAGGCAGTGTATTTGGGGTTTTCCCTCAGAAGACAAAAAAAGAGCCTGAACATTTAAAAAAATTACACAGCATTGATAAATAAAGGTGAGAAAGCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGNOV29c, SNP13382437 ofSEQ ID NO: 368286 aaMW at 32538.4kDCG53767-02, ProteinSNP Pos: 163SNP Change: Val to ValSequenceMGAIKLSHNLHTPMYFFLCGLSFSETCTTVVVIPRNLVDFLSESKTISLPECATQMFFFLGFASNNCFIMAANSYDRYTAIHNPLQYHTLMTRKICLQMMMASWMVGFLFSLCIIVTVFNLSLCDLNTIQHYFCDISPVVSLACNYTFYHEMAIFVLSAFVLVGSCILIMISYVFIVFIVIKMPSAKGRSKAFSTCSSHLTVVSIHYGFACFVYLRPKNSNSFDEDMPTAMIYTILMPLLNPIVYSLRNKEMQIALRKTLGSVFGVFPQKTKKEPEHLKKLHSIDKNOV29d, SNP13382436 ofSEQ ID NO: 3691378 bpCG53767-02, DNA SequenceORF Start: ATG at 473ORF Stop: TAA at 1331SNP Pos: 1283SNP Change: A to GTGAAATTGGAGAGTCATACAAAATCCAGAATGGAGAAAAGAGAGATAAACAGTGCTTTTGGGGTAAAATCCAGGTATAGGTATTTGGGCCCACTCTATGTCATCTATACATATTATCATATTAGAATCATTCTTCTCTTCACTCAGGCTCCTGACCTTGACCTCTTTCCAGGTGCATTTAACTCCCTTTCCTCAGGTTCTCTAAGAGTTGCCTGACACTTGCCCAGGTCCCCTGAATAAAATACAGGTAAATCAGTGCATAAGAAGCTTTATACAGTGATCTCAGACTTGTGACCAAGAGCCCCTCTGCACCATTGATAGACAGTGGCCGTGCCCACCAGGAGGATGGGCAATCACACTGCAGTGAGCCTATTCCTTCTGTGGGGATTTTCCAGTTTTTCAGACCTGCAGAGTCTACTTTTTGTGGTGATTCTCTTCTACATGTGACCATCCTAGCTGCAAACGTGTCCATAATGGGGGCCATCAAGCTCAGCCACAACCTTCACACTCCTATGTACTTTTTCCTCTGTGGCCTGTCCTTTTCAGAAACTTGTACCACTGTGGTAGTAATCCCTCGCATGTTGGTGGACTTTCTATCAGAGAGCAAGACCATTTCTCTTCCTGAGTGTGCCACACAGATGTTTTTCTTTCTGGGCTTTGCATCCAACAACTGTTTCATCATGGCCGCTATGTCCTACGACCGCTACACGGCCATCCACAACCCACTGCAGTACCACACCCTTATGACAAGAAAGATCTGCTTGCAGATGATGATGGCTTCTTGGATGGTTGGGTTCCTGTTTTCTCTGTGCATCATCGTCACTGTATTCAACTTGTCTCTTTGCGACTTGAACACTATCCAGCACTATTTCTGTGATATCTCACCAGTGGTCTCCCTTGCTTGTAATTACACTTTCTATCATGAAATGGCTATTTTTGTGCTCTCTGCCTTTGTGTTGGTGGGCAGCTGTATTTTAATTATGATTTCCTATGTCTTCATTGTGTTCATAGTCATAAAGATGCCCTCTGCAAAGGGGAGGTCTAAGGCCTTCTCAACTTGCTCCTCCCACCTCACTGTTGTGTCCATACACTATGGATTTGCTTGCTTTGTCTATTTGAGGCCCAAGAACAGCAACTCCTTCGATGAAGACATGCCGACGGCCATGATATATACAATACTGATGCCTCTGCTTAACCCCATCGTGTACAGTCTGAGAAACAAAGAAATGCAGATAGCCCTAAGAAAAACACTAGGCAGTGTATTTGGGGTTTTCCCTCAGAAGGCAAAAAAAGAGCCTGAACATTTAAAAAAATTACACAGCATTGATAAATAAAGGTGAGAAAAGCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGNOV29d, SNP13382436 ofSEQ ID NO: 370286 aaMW at 32508.4kDCG53767-02, ProteinSNP Pos: 271SNP Change: Thr to AlaSequenceMGAIKLSHNLHTPMYFFLCGLSFSETCTTVVVIPRMLVDFLSESKTISLPECATQMFFFLGFASNNCFIMAANSYDRYTAIHNPLQYHTLMTRKICLQMMMASWMVGFLFSLCIIVTVFNLSLCDLNTIQHYFCDISPVVSLACNYTFYHEMAIFVLSAFVLVGSCILIMISYVFIVFIVIKMPSAKGRSKAFSTCSSHLTVVSIHYGFACFVYLRPKNSNSFDEDMPTAMIYTILMPLLNPIVYSLRNKEMQIALRKTLGSVFGVFPQKAKKEPEHLKKLHSIDK

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 29B.

TABLE 29BComparison of the NOV29 protein sequences.NOV29a ------------------------------------------MGAIKLSHNLHTPMYFFLNOV29b MGNHTAVSLFLLWGFSSFSDLQSLLCGDSLLHVTILAANVSIMGAIKLSHNLHTPMYFFLNOV29a CGLSFSETCTTVVVIPRNLVDFLSESKTISLPECATQMFFFLGFASNNCFIMAAMSYDRYNOV29b CGLSFSETCTTVVVIPRMLVDFLSESKTISLPECATQMFFFLGFASNNCFIMAAMSYDRYNOV29a TAIHNPLQYHTLMTRKICLQMMMASWMVGFLFSLCIIVTVFNLSLCDLNTIQHYFCDISPNOV29b TAIHNPLQYHTLMTRKICLQMMMASWMVGFLFSLCIIVTVFNLSLCDLNTIQHYFCDISPNOV29a VVSLACNYTFYHEMAIFVLSAFVLVGSCILIMISYVFIVFIVIKMPSAKGRSKAFSTCSSNOV29b VVSLACNYTFYMEMAIFVLSAFVLVGSCILIMISYVFIVFIVIKMPSAKGRSKAFSTCSSNOV29a HLTVVSIHYGFACFVYLRPKNSNSFDEDMPTAMIYTILMPLLNPIVYSLRNKEMQIALRKNOV29b HLTVVSIHYGFACFVYLRPKNSNSFDEDMLTAMIYTILMPLLNPIVYSLRNKENQIALRKNOV29a TLGSVFGVFPQKTKKEPEHLKKLHSIDKNOV29b TLGSVFGVFPQKTKKEPEHLKKLHSIDKNOV29a (SEQ ID NO: 364)NOV29b (SEQ ID NO: 366)

Further analysis of the NOV29a protein yielded the following properties shown in Table 29C.

TABLE 29CProtein Sequence Properties NOV29aSignalP analysis:Cleavage site between residues 25 and 26PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 5; pos.chg 1; neg.chg 0H-region: length 19; peak value 10.63PSG score: 6.23GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −2.51possible cleavage site: between 29 and 30>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 4INTEGRALLikelihood = −0.43Transmembrane 17-33INTEGRALLikelihood = −7.17Transmembrane 105-121INTEGRALLikelihood = −1.33Transmembrane 148-164INTEGRALLikelihood = −12.52Transmembrane 165-181PERIPHERALLikelihood = 0.53 (at 231)ALOM score: −12.52 (number of TMSs: 4)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 24Charge difference: −0.5 C(−1.0) − N(−0.5)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):4.10Hyd Moment(95):4.80G content:2D/E content:1S/T content:4Score: −5.17Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 45 PRM|LVNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: PQKTKKE (4) at 268bipartite: RKTLGSVFGVFPQKTKK at 257content of basic residues: 7.7%NLS Score: 0.36KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: endoplasmic reticulum44.4%: mitochondrial>> prediction for CG53767-02 is end (k = 9)

A search of the NOV29a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 29D.

TABLE 29DGeneseq Results for NOV29aNOV29aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABP72224Human G-protein coupled1 . . . 286285/286 (99%)e−166receptor GCREC-18 (olfactory44 . . . 329 285/286 (99%)receptor) - Homo sapiens, 329 aa.[WO2003000859-A2, 03-JAN-2003]ABP95890Human GPCR polypeptide SEQ1 . . . 286285/286 (99%)e−166ID NO 590 - Homo sapiens, 2861 . . . 286285/286 (99%)aa. [WO200216548-A2, 28-FEB-2002]AAG66705Human GPCR3 polypeptide -1 . . . 286285/286 (99%)e−166Homo sapiens, 328 aa.43 . . . 328 285/286 (99%)[WO200160865-A2, 23-AUG-2001]AAG71567Human olfactory receptor1 . . . 271270/271 (99%)e−156polypeptide, SEQ ID NO: 1248 -46 . . . 316 270/271 (99%)Homo sapiens, 316 aa.[WO200127158-A2, 19-APR-2001]ABG59965Human DITHP polypeptide #23 -1 . . . 258257/258 (99%)e−149Homo sapiens, 328 aa.71 . . . 328 257/258 (99%)[WO200220754-A2, 14-MAR-2002]

In a BLAST search of public sequence databases, the NOV29a protein was found to have homology to the proteins shown in the BLASTP data in Table 29E.

TABLE 29EPublic BLASTP Results for NOV29aNOV29aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8NGM4Seven transmembrane helix 1 . . . 286285/286 (99%) e−165receptor - Homo sapiens54 . . . 339285/286 (99%)(Human), 339 aa.Q8VF20Olfactory receptor MOR267-14 - 1 . . . 278187/278 (67%) e−109Mus musculus (Mouse), 32144 . . . 321226/278 (81%)aa.CAD42418Sequence 75 from Patent 1 . . . 261136/261 (52%)3e−75WO0212343 - Homo sapiens46 . . . 306182/261 (69%)(Human), 314 aa.CAD42393Sequence 23 from Patent 1 . . . 261134/261 (51%)1e−73WO0212343 - Homo sapiens44 . . . 304177/261 (67%)(Human), 313 aa.Q8NGX3Seven transmembrane helix 1 . . . 261132/261 (50%)4e−73receptor - Homo sapiens47 . . . 306186/261 (70%)(Human), 314 aa.

PFam analysis indicates that the NOV29a protein contains the domains shown in the Table 29F.

TABLE 29FDomain Analysis of NOV29aNOV29aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_13 . . . 245 47/278 (17%)3.1e−19169/278 (61%)

Example 30

The NOV30 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 30A.

TABLE 30ANOV30 Sequence AnalysisNOV30a, CG53776-02SEQ ID NO: 3711072 bpDNA SequenceORF Start: ATG at 12ORF Stop: TAG at 1047TTAACATTTTAATGTGCTGTTCTCATTTGGGTTCATTTAGTCAGCAGCTACTTCGTCTCATGAATTCCCTGAAGGACGGGAATCACACCGCTCTGACGGGGTTCATCCTATTGGGCTTAACAGATGATCCAATCCTTCGAGTCATCCTCTTCATGATCATCCTATGCATCTACCTGGTAACCATATCTGGTAATCTCAGCATAATTATTCTTATCAGAATTTCTTCTCAGCTCCATCATCCTATGTATTTCTTTCTGAGCCACTTGGCTTTTGCTGACATGGCCTATTCATCTTCTGTCACACCCAACATGCTTGTAAACTTCCTGGTGGAGAGAAATACAGTCTCCTACCTTGGATGTGCCATCCAGCTTGGTTCAGCGGCTTTCTTTGCAACAGTCGAATGCGTCTTTCTGGCTGCCATGGCCTATGACCGCTTTGTGGCAATTTGCAGTCCACTGCTTTATTCAACCAAAATGTCCACACAAGTCAGTGTCCAGCTACTCTTAGTAGTTTACATAGCTGGTTTTCTCATTGCTGTCTCCTATACTACTTCCTTCTATTTTTTACTCTTCTGTGGACCAAATCAAGTCAATCATTTTTTCTGTGATTTCGCTCCCTTACTTGAACTCTCCTGTTCTGATATCAGTGTCTCCACAGTTGTTCTCTCATTTTCTTCTGGATCCATCATTGTGGTCACTGTGTGTGTCATAGCCGTCTGCTACATCTATATCCTCATCACCATCCTGAAGATGCGCTCCACTGAGGGGCACCACAAGGCCTTCTCCACCTGCACTTCCCACCTCACTGTGGTTACCCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAATTTTAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTGTACACAGTGGTGATTCCCATGTTGAACCCCTTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTGTTAGAAAAATACTTTCTCATGATGCTTGTTATTTTAGTAGAACTTCAAATAATGATATTACATAGAACCCTATCTCTTCTCTTGAGAANOV30a, CG53776-02SEQ ID NO: 372345 aaMW at 38430.9kDProtein SequenceMCCSHLGSFSQQLLRLMNSLKDGNHTALTGFILLGLTDDPILRVILFMIILCIYLVTISGNLSIIILIRISSQLHHPMYFFLSHLAFADMAYSSSVTPNMLVNFLVERNTVSYLGCAIQLGSAAFFATVECVFLAAMAYDRFVAICSPLLYSTKMSTQVSVQLLLVVYIAGFLIAVSYTTSFYFLLFCGPNQVNHFFCDFAPLLELSCSDISVSTVVLSFSSGSIIVVTVCVIAVCYIYILITILKMRSTEGHHKAFSTCTSHLTVVTLFYGTITFIYVMPNFSYSTDQNKVVSVLYTVVIPMLNPLIYSLRNKEIKGALKRELVRKILSHDACYFSRTSNNDITNOV30b, CG53776-03SEQ ID NO: 3731050 bpDNA SequenceORF Start: at 207ORF Stop: end of sequenceTTCTCAAGAGAAGAGATAGGGTTCTATGTAATATCATTATTTGAAGTTCTACTAAAATAACAAGCATCATGAGAAAGTATTTTTCTAACAAGCTCTCTCTTCAGAGCCCCCTTAATCTCCTTGTTCCTGAGGCTGTAGATCAGGGGGTTCAACATGGGAATCACCACTGTGTACAACACAGACACCACCTTGTTCTGGTCAGTTGAGTAGCTAAAATTGGGCATCACATAAATGAAGGTAATGGTCCCATAGAACAGGGTAACCACAGTGAGGTGGGAAGTGCAGGTGGAGAAGGCCTTGTGGTGCCCCTCAGTGGAGCGCATCTTCAGGATGGTGATGAGGATATAGATGTAGCAGACGGCTATGACACACACAGTGACCACAATGATGGATCCAGAAGAAAATGAGAGAACAACTGTGGAGACACTGATATCAGAACAGGAGAGTTCAAGTAAGGGAGCGAAATCACAGAAAAAATGATTGACTTGATTTGGTCCACAGAAGAGTAAAAATAGAAGGAAGTAGTATAGGAGACAGCAATGAGAAAACCAGCTATGTAAACTACTAAGAGTAGCTGGACACTGACTTGTGTGGACATTTTGGTTGAATAAAGCAGTGGACTGCAAATTGCCACAAAGCGGTCATAGGCCATGGCAGCCAGAAGGACGCATTCGACTGTTGCAAAGAAAGCCGCTGAACCAAGCTGGATGGCACATCCAAGGTAGGAGACTGTATTTCTCTCCACCAGGAAGTTTACAAGCATGTTGGGTGTGACAGAAGATGAATAGGCCATGTCAGCAAAAGCCAAGTGGCTCAGAAAGAAATACATAGGATGATGGAGCTGAGAAGAAATTCTGATAAGAATAATTATGCTGAGATTACCAGATAGGATGATCATGAAGAGGATGACTCGAAGGATTGGATCATCTGTTAAGCCCAATAGGATGAACCCCGTCAGAGCGGTGTGATTCCCGTCCTTCAGGGAATTCATGAGACGAAGTAGCTGCTGACTAAATGAACCCTAATGAGAACAGCACATTAAAATGTTAANOV30b, CG53776-03SEQ ID NO: 374338 aaMW at 37640.9kDProtein SequenceMCCSHLGSFSQQLLRLMNSLKDGNHTALTGFILLGLTDDPILRVILFMIILCGNLSIIILIRISSQLHHPMYFFLSHLAFADMAYSSSVTPNMLVNFLVERNTVSYLGCAIQLGSAAFFATVECVFLAAMAYDRFVAICSPLLYSTKMSTQVSVQLLLVVYIAGFLIAVSYTTSFYFLLFCGPNQVNHFFCDFAPLLELSCSDISVSTVVLSFSSGSIIVVTVCVIAVCYIYILITILKMRSTEGHHKAFSTCTSHLTVVTLFYGTITFIYVMPNFSYSTDQNKVVSVLYTVVIPMLNPLIYSLRNKEIKGALKRELVRKILSHDACYFSRTSNNDITNOV30c, CG53776-01SEQ ID NO: 3751070 bpDNA SequenceORF Start: ATG at 27ORF Stop: TAG at 1041GAAGCCATCAAATTTATAACATTTTAATGTGCTGTTCTCATTTGGGTTCATTTAGTCAGCAGCTACTTCGTCTCATGAATTCCCTGAAGGACGGGAATCACACCGCTCTGACGGGGTTCATCCTATTGGGCTTAACAGATGATCCAATCCTTCGAGTCATCCTCTTCATGATCATCCTATCTGGTAATCTCAGCATAATTATTCTTATCAGAATTTCTTCTCAGCTCCATCATCCTATGTATTTCTTTCTGAGCCACTTGGCTTTTGCTGACATGGCCTATTCATCTTCTGTCACACCCAACATGCTTGTAAACTTCCTGGTGGAGAGAAATACAGTCTCCTACCTTGGATGTGCCATCCAGCTTGGTTCAGCGGCTTTCTTTGCAACAGTCGAATGCGTCCTTCTGGCTGCCATGGCCTATGACCGCTTTGTGGCAATTTGCAGTCCACTGCTTTATTCAACCAAAATGTCCACACAAGTCAGTGTCCAGCTACTCTTAGTAGTTTACATAGCTGGTTTTCTCATTGCTGTCTCCTATACTACTTCCTTCTATTTTTTACTCTTCTGTGGACCAAATCAAGTCAATCATTTTTTCTGTGATTTCGCTCCCTTACTTGAACTCTCCTGTTCTGATATCAGTGTCTCCACAGTTGTTCTCTCATTTTCTTCTGGATCCATCATTGTGGTCACTGTGTGTGTCATAGCCGTCTGCTACATCTATATCCTCATCACCATCCTGAAGATGCGCTCCACTGAGGGGCACCACAAGGCCTTCTCCACCTGCACTTCCCACCTCACTGTGGTTACCCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAATTTTAGCTACTCAACTGACCAGAACAAGGTGGTGTCTGTGTTGTACACAGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTGTTAGAAAAATACTTTCTCATGATGCTTGTTATTTTAGTAGAACTTCAAATAATGATATTACATAGAACCCTATCTCTTCTCTTGAGAATACTNOV30c, CG53776-01SEQ ID NO: 376338 aaMW at 37590.8kDProtein SequenceMCCSHLGSFSQQLLRLMNSLKDGNHTALTGFILLGLTDDPILRVILFMIILSGNLSIIILIRISSQLHHPMYFFLSHLAFADMAYSSSVTPNMLVNFLVERNTVSYLGCAIQLGSAAFFATVECVLLAAMAYDRFVAICSPLLYSTKMSTQVSVQLLLVVYIAGFLIAVSYTTSFYFLLFCGPNQVNHFFCDFAPLLELSCSDISVSTVVLSFSSGSIIVVTVCVIAVCYIYILITILKMRSTEGHHKAFSTCTSHLTVVTLFYGTITFIYVMPNFSYSTDQNKVVSVLYTVVIPMLNPLIYSLRNKEIKGALKRELVRKILSHDACYFSRTSNNDIT

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 30B.

TABLE 30BComparison of the NOV30 protein sequences.NOV30a MCCSHLGSFSQQLLRLNNSLKDGNHTALTGFILLGLTDDPILRVILFMIILCIYLVTISGNOV30b MCCSHLGSFSQQLLRLMNSLKDGNHTALTGFILLGLTDDPILRVILFMIILC-------GNOV30c MCCSHLGSFSQQLLRLMNSLKDGNHTALTGFILLGLTDDPILRVILFMIILS-------GNOV30a NLSIIILIRISSQLHHPMYFFLSHLAFADMAYSSSVTPNMLVNFLVERNTVSYLGCAIQLNOV30b NLSIIILIRISSQLHHPMYFFLSHLAFADMAYSSSVTPNMLVNFLVERNTVSYLGCAIQLNOV30c NLSIIILIRISSQLHHPMYFFLSHLAFADMAYSSSVTPNMLVNFLVERNTVSYLGCAIQLNOV30a GSAAFFATVECVFLAAMAYDRFVAICSPLLYSTKMSTQVSVQLLLVVYIAGFLIAVSYTTNOV30b GSAAFFATVECVFLAAMAYDRFVAICSPLLYSTKMSTQVSVQLLLVVYIAGFLIAVSYTTNOV30c GSAAFFATVECVLLAAMAYDRFVAICSPLLYSTKMSTQVSVQLLLVVYIAGFLIAVSYTTNOV30a SFYFLLFCGPNQVNHFFCDFAPLLELSCSDISVSTVVLSFSSGSIIVVTVCVIAVCYIYINOV30b SFYFLLFCGPNQVNHFFCDFAPLLELSCSDISVSTVVLSFSSGSIIVVTVCVIAVCYIYINOV30c SFYFLLFCGPNQVNHFFCDFAPLLELSCSDISVSTVVLSFSSGSIIVVTVCVIAVCYIYINOV30a LITILKMRSTEGHHKAFSTCTSHLTVVTLFYGTITFIYVMPNFSYSTDQNKVVSVLYTVVNOV30b LITILKMRSTEGHHKAFSTCTSHLTVVTLFYGTITFIYVMPNFSYSTDQNKVVSVLYTVVNOV30c LITILKMRSTEGHHKAFSTCTSHLTVVTLFYGTITFIYVMPNFSYSTDQNKVVSVLYTVVNOV30a IPMLNPLIYSLRNKEIKGALKRELVRKILSHDACYFSRTSNNDITNOV30b IPMLNPLIYSLRNKEIKGALKRELVRKILSHDACYFSRTSNNDITNOV30c IPMLNPLIYSLRNKEIKGALKRELVRKILSHDACYFSRTSNNDITNOV30a (SEQ ID NO: 372)NOV30b (SEQ ID NO: 374)NOV30c (SEQ ID NO: 376)

Further analysis of the NOV30a protein yielded the following properties shown in Table 30C.

TABLE 30CProtein Sequence Properties NOV30aSignalP analysis:Cleavage site between residues 61 and 62PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 14; peak value 5.07PSG score: 0.67GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −5.40possible cleavage site: between 57 and 58>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −10.56Transmembrane 41-57INTEGRALLikelihood = −2.07Transmembrane 122-138INTEGRALLikelihood = −7.70Transmembrane 159-175INTEGRALLikelihood = −12.68Transmembrane 225-241INTEGRALLikelihood = −2.13Transmembrane 264-280INTEGRALLikelihood = −3.66Transmembrane 292-308PERIPHERALLikelihood = 1.91 (at 58)ALOM score: −12.68 (number of TMSs: 6)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 48Charge difference: 3.0 C(2.0) − N(−1.0)C > N: C-terminal side will be inside>>>Caution: Inconsistent mtop result with signal peptide>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):3.87Hyd Moment(95):1.84G content:1D/E content:1S/T content:4Score: −4.16Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 25 LRL|MNNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 5.5%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG53776-02 is end (k = 9)

A search of the NOV30a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 30D.

TABLE 30DGeneseq Results for NOV30aNOV30aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAG66706Human GPCR4 polypeptide -1 . . . 345337/345 (97%)0.0Homo sapiens, 338 aa.1 . . . 338337/345 (97%)[WO200160865-A2, 23-AUG-2001]ABU11199Human G-protein coupled17 . . . 345 321/329 (97%)e−180receptor GCREC-52 - Homo1 . . . 322321/329 (97%)sapiens, 322 aa. [WO200279448-A2, 10-OCT-2002]AAU85166G-coupled olfactory receptor #27 -17 . . . 345 321/329 (97%)e−180Homo sapiens, 322 aa.1 . . . 322321/329 (97%)[WO200198526-A2, 27-DEC-2001]AAU95576Human olfactory and pheromone17 . . . 345 321/329 (97%)e−180G protein-coupled receptor #63 -1 . . . 322321/329 (97%)Homo sapiens, 322 aa.[WO200224726-A2, 28-MAR-2002]ABP95758Human GPCR polypeptide SEQ17 . . . 345 321/329 (97%)e−180ID NO 326 - Homo sapiens, 3221 . . . 322321/329 (97%)aa. [WO200216548-A2, 28-FEB-2002]

In a BLAST search of public sequence databases, the NOV30a protein was found to have homology to the proteins shown in the BLASTP data in Table 30E.

TABLE 30EPublic BLASTP Results for NOV30aNOV30aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8WZ92Olfactory receptor 5P217 . . . 345321/329 (97%)e−179(Olfactory receptor-like protein 1 . . . 322321/329 (97%)JCG3) - Homo sapiens (Human),322 aa.CAD37572Sequence 173 from Patent17 . . . 345320/329 (97%)e−178WO0224726 - Homo sapiens 1 . . . 322320/329 (97%)(Human), 322 aa.Q8VG09Olfactory receptor MOR204-8 -17 . . . 330253/314 (80%)e−145Mus musculus (Mouse), 314 aa. 1 . . . 314279/314 (88%)Q8VG04Olfactory receptor MOR204-13 -21 . . . 330246/310 (79%)e−141Mus musculus (Mouse), 314 aa. 5 . . . 314272/310 (87%)Q8VFD3Olfactory receptor MOR204-16 -17 . . . 336239/320 (74%)e−137Mus musculus (Mouse), 321 aa. 1 . . . 320271/320 (84%)

PFam analysis indicates that the NOV30a protein contains the domains shown in the Table 30F.

TABLE 30FDomain Analysis of NOV30aNOV30aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect ValueDUF4058 . . . 299 43/277 (16%)0.22152/277 (55%)7tm_160 . . . 309 54/276 (20%)9.4e−32185/276 (67%)

Example 31

The NOV31 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 31A.

TABLE 31ANOV31 Sequence AnalysisNOV31a, GG53803-02SEQ ID NO: 3771049 bpDNA SequenceORF Start: ATG at 54ORF Stop: TGA at 996ATATTTTGCTTTGGCAGGAACAATTCTCTTCAACCCTTCCATTAAAAGGAATTATGATGATGGTTTTAAGGAATCTGAGCATGGAGCCCACCTTTGCCCTTTTAGGTTTCACAGATTACCCAAAGCTTCAGATTCCTCTCTTCCTTGTGTTTCTGCTCATGTATGTTATCACAGTGGTAGGAAACCTTGGGATGATCATAATAATCAAGATTAACCCCAAATTTCACACTCCTATGTACTTTTTCCTTAGTCACCTCTCTTTTGTTGATTTTTGTTACTCTTCCATTGTCACTCCCAAGCTGCTTGAGAACTTGGTAATGGCAGATAAAAGCATCTTCTACTTTAGCTGCATGATGCAGTACTTCCTGTCCTGCACTGCTGTGGTGACAGAGTCTTTCTTGCTGGCAGTGATGGCCTATGACCGCTTTGTGGCCATCTGCAATCCTCTGCTTTATACAGTGGCCATGTCACAGAGGCTCTGTGCCCTGCTGGTGGCTGGGTCATATCTCTGGGGCATGTTTGGCCCCTTGGTACTCCTTTGTTATGCTCTCCGGTTAAACTTCTCTGGACCTAATGTAATCAACCACTTCTTTTGTGAGTATACTGCTCTCATCTCTGTGTCTGGCTCTGATATACTCATCCCCCACCTGCTGCTTTTCAGCTTCGCCACCTTCAATGAGATGTGTACACTACTGATCATCCTCACTTCCTATGTTTTCATTTTTGTGACTGTACTAAAAATCCGTTCTGTTAGTGGGCGCCACAAAGCCTTCTCCACCTGGGCCTCCCACCTGACTGCTATCACCATCTTCCATGGGACCATCCTTTTCCTTTACTGTGTACCCAACTCCAAAAACTCTCGGCAAACAGTCAAAGTGGCCTCTGTATTTTACACAGTTGTCAACCCCATGCTGAACCCTCCGATCTACAGCCTAAGGAATAAAGACGTGAAGGATGCTTTCTGGAAGTTAATACATACACAAGTTCCATTTCACTGAACCAGTCTCAAAAGTTGTTTTCAATCCAAATGAACAACCCANNNNNNNNNNNOV31a, CG53803-02SEQ ID NO: 378314 aaMW at 35790.4kDProtein SequenceMMMVLRNLSMEPTFALLGFTDYPKLQIPLFLVFLLMYVITVVGNLGMIIIIKINPKFHTPMYFFLSHLSFVDFCYSSIVTPKLLENLVMADKSIFYFSCMMQYFLSCTAVVTESFLLAVMAYDRFVAICNPLLYTVAMSQRLCALLVAGSYLWGMFGPLVLLCYALRLNFSGPNVINHFFCEYTALISVSGSDILIPHLLLFSFATFNEMCTLLIILTSYVFIFVTVLKIRSVSGRHKAFSTWASHLTAITIFHGTILFLYCVPNSKNSRQTVKVASVFYTVVNPMLNPPIYSLRNKDVKDAFWKLIHTQVPFHNOV31b,GG53803-01SEQ ID NO: 3791039 bpDNA SequenceORF Start: ATG at 54ORF Stop: TGA at 996ATATTTTGCTTTGGCAGGAACAATTCTCTTCAACCCTTCCATTAAAAGGAATTATGATGATGGTTTTAAGGAATCTGAGCATGGAGCCCACCTTTGCCCTTTTAGGTTTCACAGATTACCCAAAGCTTCAGATTCCTCTCTTCCTTGTGTTTCTGCTCATGTATGTTATCACAGTGGTAGGAAACCTTGGGATGATCATAATAATCAAGATTAACCCCAAATTTCACACTCCTATGTACTTTTTCCTTAGTCACCTCTCTTTTGTTGATTTTTGTTACTCTTCCATTGTCACTCCCAAGCTGCTTGAGAACTTGGTAATGGCAGATAAAAGCATCTTCTACTTTAGCTGCATGATGCAGTACTTCCTGTCCTGCACTGCTGTGGTGACAGAGTCTTTCTTGCTGGCAGTGATGGCCTATGACCGCTTTGTGGCCATCTGCAATCCTCTGCTTTATACAGTGGCCATGTCACAGAGGCTCTGTGCCCTGCTGGTGGCTGGGTCATATCTCTGGGGCATGTTTGGCCCCTTGGTACTCCTTTGTTATGCTCTCCGGTTAAACTTCTCTGGACCTAATGTAATCAACCACTTCTTTTGTGAGTATACTGCTCTCATCTCTGTGTCTGGCTCTGATATACTCATCCCCCACCTGCTGCTTTTCAGCTTCGCCACCTTCAATGAGATGTGTACACTACTGATCATCCTCACTTCCTATGTTTTCATTTTTGTGACTGTACTAAAAATCCGTTCTGTTAGTGGGCGCCACAAAGCCTTCTCCACCTGGGCCTCCCACCTGACTGCTATCACCATCTTCCATGGGACCATCCTTTTCCTTTACTGTGTACCCAACTCCAAAAACTCTCGGCAAACAGTCAAAGTGGCCTCTGTATTTTACACAGTTGTCAACCCCATGCTGAACCCTCCGATCTACAGCCTAAGGAATAAAGACGTGAAGGATGCTTTCTGGAAGTTAATACATACACAAGTTCCATTTCACTGAACCAGTCTCAAAAGTTGTTTTCAATCCAAATGAACAACCCANOV31b, CG53803-01SEQ ID NO: 380314 aaMW at 35790.4kDProtein SequenceMMMVLRNLSMEPTFALLGFTDYPKLQIPLFLVFLLMYVITVVGNLGMIIIIKINPKFHTPMYFFLSHLSFVDFCYSSIVTPKLLENLVMADKSIFYFSCMMQYFLSCTAVVTESFLLAVMAYDRFVAICNPLLYTVAMSQRLCALLVAGSYLWGMFGPLVLLCYALRLNFSGPNVINHFFCEYTALISVSGSDILIPHLLLFSFATFNEMCTLLIILTSYVFIFVTVLKIRSVSGRHKAFSTWASHLTAITIFHGTILFLYCVPNSKNSRQTVKVASVFYTVVNPMLNPPIYSLRNKDVKDAFWKLIHTQVPFH

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 31B.

TABLE 31BComparison of the NOV31 protein sequences.NOV31a MMMVLRNLSMEPTFALLGFTDYPKLQIPLFLVFLLMYVITVVGNLGMIIIIKINPKFHTPNOV31b MMMVLRNLSMEPTFALLGFTDYPKLQIPLFLVFLLMYVITVVGNLGMIIIIKINPKFHTPNOV31a MYFFLSHLSFVDFCYSSIVTPKLLENLVMADKSIFYFSCMMQYFLSCTAVVTESFLLAVMNOV31b MYFFLSHLSFVDFCYSSIVTPKLLENLVMADKSIFYFSCMMQYFLSCTAVVTESFLLAVMNOV31a AYDRFVAICNPLLYTVAMSQRLCALLVAGSYLWGMFGPLVLLCYALRLNFSGPNVINHFFNOV31b AYDRFVAICNPLLYTVAMSQRLCALLVAGSYLWGMFGPLVLLCYALRLNFSGPNVINHFFNOV31a CEYTALISVSGSDILIPHLLLFSFATFNEMCTLLIILTSYVFIFVTVLKIRSVSGRHKAFNOV31b CEYTALISVSGSDILIPHLLLFSFATFNEMCTLLIILTSYVFIFVTVLKIRSVSGRHKAFNOV31a STWASHLTAITIFHGTILFLYCVPNSKNSRQTVKVASVFYTVVNPMLNPPIYSLRNKDVKNOV31b STWASHLTAITIFHGTILFLYCVPNSKNSRQTVKVASVFYTVVNPMLNPPIYSLRNKDVKNOV31a DAFWKLIHTQVPFHNOV31b DAFWKLIHTQVPFHNOV31a (SEQ ID NO: 378)NOV31b (SEQ ID NO: 380)

Further analysis of the NOV31a protein yielded the following properties shown in Table 31C.

TABLE 31CProtein Sequence Properties NOV31aSignalP analysis:Cleavage site between residues 44 and 45PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 11; pos.chg 1; neg.chg 1H-region: length 9; peak value 9.41PSG score: 5.01GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −1.06possible cleavage site: between 43 and 44>>> Seems to have a cleavable signal peptide (1 to 43)ALOM: Klein et al's method for TM region allocationInit position for calculation: 44Tentative number of TMS(s) for the threshold 0.5: 5INTEGRALLikelihood = −2.23Transmembrane 104-120INTEGRALLikelihood = −0.64Transmembrane 145-161INTEGRALLikelihood = −0.80Transmembrane 186-202INTEGRALLikelihood = −8.39Transmembrane 212-228INTEGRALLikelihood = −2.71Transmembrane 247-263PERIPHERALLikelihood = 2.07 (at 63)ALOM score: −8.39 (number of TMSs: 5)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 21Charge difference: 3.0 C(1.0) − N(−2.0)C > N: C-terminal side will be inside>>>Caution: Inconsistent mtop result with signal peptide>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):7.94Hyd Moment(95):8.95G content:1D/E content:2S/T content:3Score: −5.12Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 16 LRN|LSNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 6.4%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found ***LLVAGSYLWGMFGPLVLLCYAL at 145nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: endoplasmic reticulum22.2%: vacuolar22.2%: mitochondrial11.1%: Golgi>> prediction for CG53803-02 is end (k = 9)

A search of the NOV31a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 31D.

TABLE 31DGeneseq Results for NOV31aNOV31aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU85141G-coupled olfactory receptor #2 -1 . . . 314314/314 (100%)0.0Homo sapiens, 314 aa.1 . . . 314314/314 (100%)[WO200198526-A2, 27-DEC-2001]AAG72434Human OR-like polypeptide1 . . . 314314/314 (100%)0.0query sequence, SEQ ID NO:1 . . . 314314/314 (100%)2115 - Homo sapiens, 314 aa.[WO200127158-A2, 19-APR-2001]|AAG71725Human olfactory receptor1 . . . 314314/314 (100%)0.0polypeptide, SEQ ID NO: 1406 -1 . . . 314314/314 (100%)Homo sapiens, 314 aa.[WO200127158-A2, 19-APR-2001]AAE07540Human G-protein coupled1 . . . 314314/314 (100%)0.0receptor 2a (GPCR2a) variant -1 . . . 314314/314 (100%)Homo sapiens, 314 aa.[WO200159113-A2, 16-AUG-2001]AAU24517Human olfactory receptor1 . . . 314314/314 (100%)0.0AOLFR2 - Homo sapiens, 3141 . . . 314314/314 (100%)aa. [WO200168805-A2, 20-SEP-2001]

In a BLAST search of public sequence databases, the NOV31a protein was found to have homology to the proteins shown in the BLASTP data in Table 31E.

TABLE 31EPublic BLASTP Results for NOV31aNOV31aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAC69325Sequence 3 from Patent1 . . . 314314/314 (100%)0.0WO0159113 - Homo sapiens1 . . . 314314/314 (100%)(Human), 314 aa.CAC69326Sequence 5 from Patent1 . . . 314313/314 (99%)0.0WO0159113 - Homo sapiens1 . . . 314313/314 (99%)(Human), 314 aa.Q8NGL3Seven transmembrane helix1 . . . 314312/314 (99%)0.0receptor - Homo sapiens1 . . . 314313/314 (99%)(Human), 314 aa.CAD37508Sequence 39 from Patent10 . . . 314 305/305 (100%)e−177WO0224726 - Homo sapiens1 . . . 305305/305 (100%)(Human), 305 aa.Q8VFR4Olfactory receptor MOR174-8 -7 . . . 313243/307 (79%)e−139Mus musculus (Mouse), 3167 . . . 313267/307 (86%)aa.

PFam analysis indicates that the NOV31a protein contains the domains shown in the Table 31F.

TABLE 31FDomain Analysis of NOV31aNOV31aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_143 . . . 292 58/278 (21%)1.4e−24174/278 (63%)

Example 32

The NOV32 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 32A.

TABLE 32ANOV32 Sequence AnalysisNOV32a, CG53989-03SEQ ID NO: 3811092 bpDNA SequenceORF Start: ATG at 30ORF Stop: TAG at 1047CCGGGACAGTCACCTCCAGCAGCATCCTGATGTTCTGGGGACACTGGTGCTGGGGGGTCAGTGGGGAAGGGCTCCTGGGTCCTCATGACCCTCTCCCTTGGGTGAGCACAAAACACCATGGCACTTTGGGGTCTTGGAAACAGACTAAAGGGGATGTCAAGTCCTCATTCCTTGGAGCTGCTGACGAGTCCAGAATGGGTCATGTTTTCTTGCCCCGACCCCAGCACCTCAGGGCAGCGGAAGGTCCAGAGAGAGGTCGGGGACCGGGGCCGCTCCTTGCATCCTGGGCTTGTGTCTGTTGCCCCCTGGCTGGTGACTTGCACTCTCCTGGAGCTGGTTCTTGCAGCCGAGGCCGTCACGGGGCTGGGATGTCGCTGCTGCTTCTCTTCGTGGTGTTGACCATTTCTCAGACCTCCCCCCGCCCCTGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCGGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAATTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACTCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGGTGCAGTGGGGTCTGCATGATCCAGGAGGGCCCGTCTTNOV32a, CG53989-03SEQ ID NO: 382339 aaMW at 37349.5kDProtein SequenceMFWGHWCWGVSGEGLLGPHDPLPWVSTKHHGTLGSWKQTKGDVKSSFLGAADESRMGHVFLPRPQHLRAAEGPERGRGPGPLLASWACVCCPLAGDLHSPGAGSCSRGRHGAGMSLLLLFVVLTISQTSPRPCREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVSWGKFCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRNOV32b, CG53989-04SEQ ID NO: 383881 bpDNA SequenceORF Start: ATG at 31ORF Stop: TAG at 832GCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCCCGGCCAGGAGGCACCCCTGGTAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAATTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACTCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGGTGCAGTGGGGTCTGCATGATCCAGGAGGGCCCGTCTAAGCGNOV32b, CG53989-04SEQ ID NO: 384267 aaMW at 30126.0kDProtein SequenceMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWAWAPDASWMASCRCRDGWPQARWLRAAGMYYLTALQAERPHSRRGQELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKFCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRNOV32c, 306076095SEQ ID NO: 385819 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceCGCAAGCTTATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGTTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCGTCGACGCGNOV32c, 306076095SEQ ID NO: 386273 aaMW at 30808.8kDProtein SequenceRKLMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRFYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWAWAPDASWMASCRCRDGWPQARWLRAAGMYYLTALQAERPHSRRGQELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRVDANOV32d, CG53989-01SEQ ID NO: 387858 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAG at 856ATGCTGTGGCTACTGCTCCTGACCCTCCCCTGCCTGATGGGCTCTGTGCCCAGGAACCCAGGCGAGGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGTCAGCCTGAGGTTCTACAGCATGAAGAAGGGTCTGTGGGAGCCCATCTGTGGGGGCTCCCTCATCCACCCAGAGTGGGTGCTGACCGCCGCCCACTGCCTTTTGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGNOV32d, CG53989-01SEQ ID NO: 388285 aaMW at 31927.6kDProtein SequenceMLWLLLLTLPCLMGSVPRNPGEGTGRELVGITGGCDVSARRHPWQVSLRFYSMKKGLWEPICGGSLIHPENVLTAAHCLLEELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRNOV32e, CG53989-02SEQ ID NO: 389660 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCNOV32e, CG53989-02SEQ ID NO: 390220 aaMW at 24527.8kDProtein SequenceSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRNOV32f, CG53989-05SEQ ID NO: 3912847 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAG at 2845ATGGTCAGCAAGGGGGGAGTTGCTGCAGAGCCAGAGCCACACTATTGTGAGGACAGTGAAAGAGGCCCCAACACCCTCACAGGTCCGGGCAGCCTTCCTAGAGGAGGTGGCATTGAGGTGGGCATGGAGTTTCCGGGATGCAGCGGTGAAGGGTGCGTGAAGCCCCATGAGGAGGCGGCCCGGGAGGGGGCGGGCAGAGGCAAGAGGGCTGTGCCGGGACCCAAGCGACGGCAGCAGGGGTCAGCAGAGGGGCCTGCGGCGGGGTGGACGCTGGAGCAGGAGACCAGGGGAGATGTCTTAGAGGATAAAAATGAGCGGGCAGATGAAGAGATACTCAGGCTGGCACCAGGGAAAGGCAGGCTCCCAATAGACAGCAAACACCTGAAACCGGTGATCAGCAGCTTCCCGGTAAGATCTCAGGAGCTGGGCGAGGGGGCTGGAGCAGGCACACTAAGAGGCAAAATGGCAGAGTTTAACTGGTCTATGGCCTTCAAGGGACCTGCGGCTGGTCATGAAGAGCGCCTCAACTCTGTGTCCAGCAGGGCCAAGAAGGGCATTGGCTGGGATGTCGCTGCTGCTTCTCTTCGTGGTGTTGACCATTTCTCAGACCTCCCCCCGCCCCTGCAGGTCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGCCATGCCCCTCAGCTCAGACCCCTGCTGTGGTCCGAAGATTTGTGCTCCCCCCAAATCCAGATGTTGAAGCCCTAACTCCCAGTGTGATGGGATCAGGAGCGCCGCTGCCCCCGGCCCCCGACCTGCAAGAGGCCGAGGTCCCCATCATGAGGACCCGAGCTTGCGAGAGGATGTATCACAAAGGCCCCACTGCCCACGGCCAGGTCACCATCATCAAGGCTGCCATGCCGTGTGCAGGGAGGAAGGGGCAGGGTTCCTGCCAGGCCGCTCTGAGGACGGAGGACCTCACCCCAACCACACCCAACACGGAGGTGTCTCCACGTGCAGACCCCAGGCTGAGCCAGCCGGAGGACATCTGGCCAGAGTGGGCTTGGCCAGTTGTGGTGGGCACCACCATGCTGCTGCTGCTGCTGTTCCTGGCTGTCTCCTCCCTGGGGAGCTGTAGCACTGGGAGTCCAGCTCCCGTCCCCGAGAATGACCTGGTGGGCATTGTGGGGGGCCACAACACCCCAGGGGAAGTGGTCGTGGCAGTGGGTGCTGACCGCCGCTCACTGCATTTTCCGGAAGGACACCGACCCGTCCACCTACCGGATTCACACCAGGGATGTGTATCTGTACGGGGGCCGGGGGCTGCTGAATGTCAGCCAGATCGTCGTCCACCCAACTACTCTGTCTTCTTCCTGGGGGCAGACATCGCCCTGCTGAAGCTGGCCACCAGTTCCCTGGAGTTCACTGACAGTGACAACTGCTGGAACACAGGCTGGGGCATGGTCGGCTTGTTGGATATGCTGCCGCCTCCTTACCGCCCGCAGCAGGTGAAGGTCCTCACACTGAGCAATGCAGACTGTGAGCGGCAGACCTACGATGCTTTTCCTGGTGCTGGAGACAGAAAGTTCATCCAGGATGACATGATCTGTGCCGGCCGCACGGGCCGCCGCACCTGGAAGGGTGACTCAGGCGGCCCCCTGGTCTGCAAGAAGAAGGGTACCTGGCTCCAGGCGGGAGTAGTGAGCTGGGGATTTTACAGTGATCGGCCCAGCATTGGCGTCTACACACGCCCAGAGACCAGCTGGCAGGGTGCCAACCATGCAGACGCCCAGAGACCAGCTGGCAGGGTGCCAACCATGCAGAGGCCCAGAGACATGGGCCAGGGCCAGGAGTGGGTCTGCAGGCCCTTCACCCACGTCACCTGCTACCCGACGGCCATCCCCAGGCCCTTCACCCATGTCACCTGCTACCTGATGGCTGTCCCCAGCACCCTCACCCACGTCACCTGCTACCCGACGGCCGTCCCCAGGCCCTTCACCCATGTCACCTGCTACCTGATGGCTGTCCCCAGCACCCTCACCCATCTCACCTGCTACATGATGGCCGTCCCCAGGCCCTTTACCCACATCACCTGCTACCCAATGGCTGTCCCCAGCACCCTTACCCACGTCACCTGCCACCCGACGGCCATCCCCAGGCCCTTCACCCACATCACCTGCTACACGATGGCCATCCCCAGGCCTTCAACCACGCCACCTGCTACACGACGGCCATCCCCAGCACCCTCACCCACGTCACCTGCTACACGATGGCCGTCCCCAGGCCCATCACCCATGTCACCTGCTACACGATAGNOV32f, GG53989-05SEQ ID NO: 392948 aaMW at 102839.3kDProtein SequenceMVSKGGVAAEPEPHYCEDSERGPNTLTGPGSLPRGGGIEVGMEFPGCSGEGCVKPHEEAAREGAGRGKRAVPGPKRRQQGSAEGPAAGWTLEQETRGDVLEDKNERADEEILRLAPGKGRLPIDSKHLKPVISSFPVRSQELGEGAGAGTLRGKMAEFNWSMAFKGPAAGHEERLNSVSSRAKKGIGWDVAAASLRGVDHFSDLPPPLQVREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQPCPSAQTPAVVRRFVLPPNPDVEALTPSVMGSGAPLPPAPDLQEAEVPIMRTRACERMYHKGPTAHGQVTIIKAAMPCAGRKGQGSCQAALRTEDLTPTTPNTEVSPRADPRLSQPEDIWPEWAWPVVVGTTMLLLLLFLAVSSLGSCSTGSPAPVPENDLVGIVGGHNTPGEVVVAVGADRRSLHFPEGHRPVHLPDSHQGCVSVRGPGAAECQPDRRPPNYSVFFLGADIALLKLATSSLEFTDSDNCWNTGWGMVGLLDMLPPPYRPQQVKVLTLSNADCERQTYDAFPGAGDRKFIQDDMICAGRTGRRTWKGDSGGPLVCKKKGTWLQAGVVSWGFYSDRPSIGVYTRPETSWQGANHADAQRPAGRVPTMQRPRDMGQGQEWVCRPFTHVTCYPTAIPRPFTHVTCYLMAVPSTLTHVTCYPTAVPRPFTHVTCYLMAVPSTLTHITCYMMAVPRPFTHITCYPMAVPSTLTHVTCHPTAIPRPFTHITCYTMAIPRPSTTPPATRRPSPAPSPTSPATRWPSPGPSPMSPATRNOV32g, CG53989-06SEQ ID NO: 393660 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCNOV32g, CG53989-06SEQ ID NO: 394220 aaMW at 24527.8kDProtein SequenceSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRNOV32h, CG53989-07SEQ ID NO: 395672 bpDNA SequenceORF Start: at 7ORF Stop: at 667AGATCTTCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCCTCGAGNOV32h, CG53989-07SEQ ID NO: 396220 aaMW at 24484.8kDProtein SequenceSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRNOV32i,CG53989-08SEQ ID NO: 3971171 bpDNA SequenceORF Start: at 187ORF Stop: TGA at 805ATGCTGTGGCTACTGCTCCTGACCCTCCCCTGCCTGATGGGCTCTGTGCCCAGGAACCCAGGCGAGTCCGCCCCACCCAATGCCCCTGCTGCCCAGGACCCCCTCCTTGCCCTGCCCCGGGCTCAGAGTGCCAGCCCTGGGGTGGGTGGGGACCATCTGATTGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGGTCAGGAGCAGGACCACTTGGGTGGGATGTGGAGAGATGACCCGGAATGTCGGTGCAGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGGTGCAGTGGGGTCTGCATGATCCAGGAGGGCCCGTCTTCCTTGTGGACACGCCTGCTNOV32i, CG53989-08SEQ ID NO: 398206 aaMW at 22191.8kDProtein SequenceALGRPSSVPLMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGGQEQDHLGGMWRDDPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGPSACGRRRNOV32j, CG53989-09SEQ ID NO: 399843 bpDNA SequenceORF Start: ATG at 26ORF Stop: TAG at 836GAGGTGGAGGTTGCAGTAAGCCAAGATGGCGCCACTGCACTCTAGCCTGTTTCTGCTGAGCGGGACCATGAGCCCAAAAGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGTCAGCCTGAGGTTCTACAGCATGAAGAAGGGTCTGTGGGAGCCCATCTGTGGGGGCTCCCTCATCCACCCAGAGTGGGTGCTGACCGCCGCCCACTGCGTCGAGCTTGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCCCCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTTGGGGACACGTTTTCCTGCTCCCGCCACCCCACCTCAGGGCAGCGGAAGGTCCAATCATGAGGACCCGAGCTTGCGAGAGGATGTATCACAAAGGCCCCACTGCCCACGTCACCATCATCAAGGCTGCCATGCCGTGTGCAGGGGCTGAGCGCCATCTCTCCCCACAGGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV32j, CG53989-09SEQ ID NO: 400270 aaMW at 29993.6kDProtein SequenceMAPLHSSLFLLSGTMSPKVGITGGCDVSARRHPWQVSLRFYSMKKGLWEPICGGSLIHPEWVLTAAHCVELEELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIWGHVFLLPPPHLRAAEGPIMRTRACERMYHKGPTAHVTIIKAAMPCAGAERHLSPQGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRYPGMYTRVTSYVSWIRQYVPPFPRRNOV32k, CG53989-10SEQ ID NO: 401964 bpDNA SequenceORF Start: ATG at 67ORF Stop: TGA at 655GACCATCTGATTGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGGTCAGGAGCAGGACCACTTGGGTGGGATGTGGAGAGATGACCCGGAATGTCGGTGCAGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGCCACAGGCCAGGTGGCTCAGAGCAGCAGGAATGTACTATCTCACGGCTCTGCAGGCGGAACGTCCACACTCCAGGCGTGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCATTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV32k, CG53989-10SEQ ID NO: 402196 aaMW at 21256.7kDProtein SequenceMSPARGVSWWASLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGGQEQDHLGGMWRDDPECRCRPGLQTRPGWLPAAAETDGHRPGGSEQQECTISRLCRRNVHTPGVGRNYCPGPSACGRRRNOV321, CG53989-11SEQ ID NO: 403948 bpDNA SequenceORF Start: ATG at 61ORF Stop: TAG at 931TGACCCTCCCCTGCCTGATGGGCTCTGTGCCCAGGAACCCAGGCGAGTCCGCCCCACCCAATGCCCCTGCTGCCCAGCCGGTCTCTCCTGGTGCCCCTGAGCTCTGGGAAGACCCTCGTCCGTCCCCCTCATGAGCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGTCAGCCTGAGGTTCTACAGCATGAAGAAGGGTCTGTGGGAGCCCATCTGTGGGGGCTCCCTCATCCACCCAGAGTGGGTGCTGACCGCCGCCCACTGCCTTGGGCCTGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGAGCGCCATCTCTCCCCACAGGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCGTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGGTGCAGTGGGNOV32l, CG53989-11SEQ ID NO: 404290 aaMW at 32449.2kDProtein SequenceMPLLPSRSLLVPLSSGKTLVRPPHEPGTGRELVGITGGCDVSARRHPWQVSLRFYSMKKGLWEPICGGSLIHPEWVLTAAHCLGPEELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDERHLSPQGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRNOV32m, CG53989-12SEQ ID NO: 405843 bpDNA SequenceORF Start: ATG at 11ORF Stop: TAG at 836TGAGAGATAAATGGGCTCCCAGAGATGCCAGGGAGGAGGCCCCGGCACGGGGCGTGAGCTGGTGGGCATCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGTCAGCCTGAGGTTCTACAGCATGAAGAAGGGTCTGTGGGAGCCCATCTGTGGGGGCTCCCTCATCCACCCAGAGTGGGTGCTGACCGCCGCCCACTGCCTTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGCCTGGGCTCCAGACGCGTCCTGGATGGCTTCCTGCCGCTGCCGAGACGGATGGGCAGGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCTAGCTGGGNOV32m, CG53989-12SEQ ID NO: 406275 aaMW at 30683.8kDProtein SequenceMGSQRCQGGGPGTGRELVGITGGCDVSARRHPWQVSLRFYSMKKGLWEPICGGSLIHPEWVLTAAHCLGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRPGLQTRPGWLPAAAETDGQELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRNOV32n, CG53989-13SEQ ID NO: 407870 bpDNA SequenceORF Start: ATG at 43ORF Stop: TAA at 868ATCTGGCCAGAGTGGGCTTGGCCAGTTGTGGTGGGCACCACCATGCTGCTGCTGCTGCTGTTCCTGGCTGTCTCCTCCCTGGGGAGCTGTAGCACTGGGAGTCCAGCTCCCGTCCCCGAGAATGACCTGGTGGGCATTGTGGGGGGCCACAACACCCAGGGGAAGTGGTCGTGGCAGGTCAGCCTGAGGATCTATAGCTACCACTGGGCCTCCTGGGTGCCCATCTGCGGGGGCTCCCTCATCCACCCCCAGTGGGTGCTGACCGCCGCTCACTGCATTTTCCGGAAGGACACCGACCCGTCCACCTACCGGATTCACACCAGGGATGTGTATCTGTACGGGGGCCGGGGGCTGCTGAATGTCAGCCAGATCGTCGTCCACCCCAACTACTCTGTCTTCTTCCTGGGGGCAGACATCGCCCTGCTGAAGCTGGCCACCAGTGTGAGAACAACAAACACTCTCGCGGCAGTCGCCCTGCCGTCATTGTCCCTGGAGTTCACTGACAGTGACAACTGCTGGAACACAGGCTGGGGCATGGTCGGCTTGTTGGATATGCTGCCGCCTCCTTACCGCCCGCAGCAGGTGAAGGTCCTCACACTGAGCAATGCAGACTGTGAGCGGCAGACCTACGATGCTTTTCCTGGTGCTGGAGACAGAAAGTTCATCCAGGATGACATGATCTGTGCCGGCCGCACGGGCCGCCGCACCTGGAAGGGTGACTCAGGCGGCCCCCTGGTCTGCAAGAAGAAGGGTACCTGGCTCCAGGCGGGAGTAGTGAGCTGGGGATTTTACAGTGATCGGCCCAGCATTGGCGTCTACACGTGGGTCCAGACCTATGTGCCCTGGATCCTGCAGCAAATGCACCTCTAANOV32n, CG53989-13SEQ ID NO: 408275 aaMW at 30467.7kDProtein SequenceMLLLLLFLAVSSLGSCSTGSPAPVPENDLVGIVGGHNTQGKWSWQVSLRIYSYHWASWVPICGGSLIHPQWVLTAAHCIFRKDTDPSTYRIHTRDVYLYGGRGLLNVSQIVVHPNYSVFFLGADIALLKLATSVRTTNTLAAVALPSLSLEFTDSDNCWNTGWGMVGLLDMLPPPYRPQQVKVLTLSNADCERQTYDAFPGAGDRKFIQDDMICAGRTGRRTWKGDSGGPLVCKKKGTWLQAGVVSWGFYSDRPSIGVYTWVQTYVPWILQQMHL

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 32B.

TABLE 32BComparison of the NOV32 protein sequences.NOV32a ------------------------------------------------------------NOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d ------------------------------------------------------------NOV32e ------------------------------------------------------------NOV32f MVSKGGVAAEPEPHYCEDSERGPNTLTGPGSLPRGGGIEVGMEFPGCSGEGCVKPHEEAANOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j ------------------------------------------------------------NOV32k ------------------------------------------------------------NOV32l ------------------------------------------------------------NOV32m ------------------------------------------------------------NOV32n ------------------------------------------------------------NOV32a ---------------MFWGMWCWGVSGEGLLGPHDPLPWVSTKHHGTLGSWKQTKGDVKSNOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d --------------------------------------------------MLWLLLLTLPNOV32e ------------------------------------------------------------NOV32f REGAGRGKRAVPGPKRRQQGSAEGPAAGWTLEQETRGDVLEDKNERADEEILRLAPGKGRNOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j -------------------------------------------------------MAPLHNOV32k ------------------------------------------------------------NOV32l -----------------------------------------------------MPLLPSRNOV32m -------------------------------------------------------MGSQRNOV32n --------------------------------------------------------MLLLNOV32a SFLGAADESRMGHVFLPRPQHLRAAEGPERGRGPGPLLASWACVCCPLAGDLHSPGAGSCNOV32b -------------------------MSPARG------VSWWA-----------SLGAATSNOV32c ----------------------RKLMSPARG------VSWWA-----------SLGAATSNOV32d CLMGSVPRNPG-------EGTGRELVGITGGCDVSARRHPWQVS---LR--FYSMKKGLWNOV32e -----------------------------------------------------SLGAATSNOV32f LPIDSKHLKPVISSFPVRSQELGEGAGAGTLRGKMAEFNWSMAFKGPAAGHEERLNSVSSNOV32g -----------------------------------------------------SLGAATSNOV32h -----------------------------------------------------SLGAATSNOV32i --------------ALGRPS-SVPLMSPARG------VSWWA-----------SLGAATSNOV32j SSLFLLS------------GTMSPKVGITGGCDVSARRHPWQVS---LR--FYSMKKGLWNOV32k -------------------------MSPARG------VSWWA-----------SLGAATSNOV32l SLLVPLSSGKTLVRPPHEPGTGRELVGITGGCDVSARRHPWQVS---LR--FYSMKKGLWNOV32m CQGG--G-----------PGTGRELVGITGGCDVSARRHPWQVS---LR--FYSMKKGLWNOV32n LLFLAVSSLGSCSTGSPAPVPENDLVGIVGGHNTQG-KWSWQVSLR-----IYSYHWASWNOV32a SRGR-HGAGMSLLLLFVVLTISQTSPRPC-REELEACAFRVQVGQLRLYEDDQRTKVVEINOV32b RPG---G-----------------TPG---REELEACAFRVQVGQLRLYEDDQRTKVVEINOV32c RPG---G-----------------TPG---REELEACAFRVQVGQLRLYEDDQRTKVVEINOV32d EPIC-GG-------SLIHPEWVLTAAHCL-LEELEACAFRVQVGQLRLYEDDQRTKVVEINOV32e RPG---G-----------------TPG---REELEACAFRVQVGQLRLYEDDQRTKVVEINOV32f RAKKGIGWDVAAASLRGVDHFSDLPPPLQVREELEACAFRVQVGQLRLYEDDQRTKVVEINOV32g RPG--------------------GTPG---REELEACAFRVQVGQLRLYEDDQRTKVVEINOV32h RPG--------------------GTPG---REELEACAFRVQVGQLRLYEDDQRTKVVEINOV32i RPG---G-----------------TPG---REELEACAFRVQVGQLRLYEDDQRTKVVEINOV32j EPIC-GG-------SLIHPEWVLTAAHCVELEELEACAFRVQVGQLRLYEDDQRTKVVEINOV32k RPG---G-----------------TPG---REELEACAFRVQVGQLRLYEDDQRTKVVEINOV32l EPIC-GG-------SLIHPEWVLTAAHCLGPEELEACAFRVQVGQLRLYEDDQRTKVVEINOV32m EPIC-GG-------SLIHPEWVLTAAHCLGREELEACAFRVQVGQLRLYEDDQRTKVVEINOV32n VPIC-GG-------SLIHPQWVLTAAHCIFRKDTDPSTYRIHTRDVYLYGGRGLLNVSQINOV32a VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTG----WNOV32b VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWAWAPDASWNOV32c VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWAWAPDASWNOV32d VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTG----WNOV32e VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTG----WNOV32f VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTG----WNOV32g VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTG----WNOV32h VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTG----WNOV32i VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTG----WNOV32j VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTG----WNOV32k VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTG----WNOV32l VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTG----WNOV32m VRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRPGLQTRPGWLPA----ANOV32n VVHPNYSVFF---LGADIALLKLATSVRTTNTLAAVALPSLSLEFTDSDNCWNTG----WNOV32a GVIG--R-G--------ELLPWP-----------------------LSLWEATVKVRSNVNOV32b MASCRCRDGWPQARWLRAAGMYYLTALQAERPHSR-R-GQELLPWPLSLWEATVKVRSNVNOV32c MASCRCRDGWPQARWLRAAGMYYLTALQAERPHSR-R-GQELLPWPLSLWEATVKVRSNVNOV32d GVIG----R-------GELLPWP-----------------------LSLWEATVKVRSNVNOV32e GVIG--R-G--------ELLPWP-----------------------LSLWEATVKVRSNVNOV32f GVIG---RG--------ELLPWP-----------------------LSLWEATVKVRSNVNOV32g GVIG--R-G--------ELLPWP-----------------------LSLWEATVKVRSNVNOV32h GVIG--R-G--------ELLPWP-----------------------LSLWEATVKVRSNVNOV32i GVIG--RGGQEQD---HLGGMWR------DDPECRCRPGLQTRPGWLPAAAETDGHRPGGNOV32j GVIW----G-------HVFLLPP-----------------------PHLRAAEGPIMR--NOV32k GVIG--RGGQEQD---HLGGMWR------DDPECRCRPGLQTRPGWLPAAAETDGHRPGGNOV32l GVIG----R-------GELLPWP-----------------------LSLWEATVKVRSNVNOV32m AETD----G-------QELLPWP-----------------------LSLWEATVKVRSNVNOV32n GMVG----L---------LDMLP-----------------------PPYRPQQVKVLT--NOV32a LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVNOV32b LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVNOV32c LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVNOV32d LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVNOV32e LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVNOV32f LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVNOV32g LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVNOV32h LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVNOV32i SEQQECT----------ISR-LCRRNVHTPGVG-RNYCPG----PSACGRRR--------NOV32j --TRACERMYHKGPTAHVT--IIKAAMPCAGAERHLSPQGDNGGPLLCRRNCTWVQVEVVNOV32k SEQQECT----------ISR-LCRRNVHTPGVG-RNYCPG----PSACGRRR--------NOV32l LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDERHLSPQGDNGGPLLCRRNCTWVQVEVVNOV32m LCNQTCRRRFPSNHTERFER-LIKDDMLCAGDGNHGSWPGDNGGPLLCGRNCTWVQVEVVNOV32n LSNADCERQTYDAFPGAGDRKFIQDDMICAGRTGRRTWKGDSGGPLVCKKKGTWLQAGVVNOV32a SWGKFCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR-------------------------NOV32b SWGKFCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR-------------------------NOV32c SWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRVDA----------------------NOV32d SWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR-------------------------NOV32e SWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR-------------------------NOV32f SWGKLCGLRGYPGMYTRVTSYVSWIRQPCPSAQTPAVVRRFVLPPNPDVEALTPSVMGSGNOV32g SWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR-------------------------NOV32h SWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR-------------------------NOV32i ------------------------------------------------------------NOV32j SWGKLCGLR-YPGMYTRVTSYVSWIRQYVPPFPRR-------------------------NOV32k ------------------------------------------------------------NOV32l SWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR-------------------------NOV32m SWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR-------------------------NOV32n SWGFYSDRP-SIGVYTWVQTYVPWILQQMHL-----------------------------NOV32a ------------------------------------------------------------NOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d ------------------------------------------------------------NOV32e ------------------------------------------------------------NOV32f APLPPAPDLQEAEVPIMRTRACERMYHKGPTAHGQVTIIKAANPCAGRKGQGSCQAALRTNOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j ------------------------------------------------------------NOV32k ------------------------------------------------------------NOV32l ------------------------------------------------------------NOV32m ------------------------------------------------------------NOV32n ------------------------------------------------------------NOV32a ------------------------------------------------------------NOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d ------------------------------------------------------------NOV32e ------------------------------------------------------------NOV32f EDLTPTTPNTEVSPRADPRLSQPEDIWPEWAWPVVVGTTMLLLLLFLAVSSLGSCSTGSPNOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j ------------------------------------------------------------NOV32k ------------------------------------------------------------NOV32l ------------------------------------------------------------NOV32m ------------------------------------------------------------NOV32n ------------------------------------------------------------NOV32a ------------------------------------------------------------NOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d ------------------------------------------------------------NOV32e ------------------------------------------------------------NOV32f APVPENDLVGIVGGHNTPGEVVVAVGADRRSLHFPEGHRPVHLPDSHQGCVSVRGPGAAENOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j ------------------------------------------------------------NOV32k ------------------------------------------------------------NOV32l ------------------------------------------------------------NOV32m ------------------------------------------------------------NOV32n ------------------------------------------------------------NOV32a ------------------------------------------------------------NOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d ------------------------------------------------------------NOV32e ------------------------------------------------------------NOV32f CQPDRRPPNYSVFFLGADIALLKLATSSLEFTDSDNCWNTGWGMVGLLDMLPPPYRPQQVNOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j ------------------------------------------------------------NOV32k ------------------------------------------------------------NOV32l ------------------------------------------------------------NOV32m ------------------------------------------------------------NOV32n ------------------------------------------------------------NOV32a ------------------------------------------------------------NOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d ------------------------------------------------------------NOV32e ------------------------------------------------------------NOV32f KVLTLSNADCERQTYDAFPGAGDRKFIQDDMICAGRTGRRTWKGDSGGPLVCKKKGTWLQNOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j ------------------------------------------------------------NOV32k ------------------------------------------------------------NOV32l ------------------------------------------------------------NOV32m ------------------------------------------------------------NOV32n ------------------------------------------------------------NOV32a ------------------------------------------------------------NOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d ------------------------------------------------------------NOV32e ------------------------------------------------------------NOV32f AGVVSWGFYSDRPSIGVYTRPETSWQGANHADAQRPAGRVPTMQRPRDMGQGQEWVCRPFNOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j ------------------------------------------------------------NOV32k ------------------------------------------------------------NOV32l ------------------------------------------------------------NOV32m ------------------------------------------------------------NOV32n ------------------------------------------------------------NOV32a ------------------------------------------------------------NOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d ------------------------------------------------------------NOV32e ------------------------------------------------------------NOV32f THVTCYPTAIPRPFTHVTCYLMAVPSTLTHVTCYPTAVPRPFTHVTCYLMAVPSTLTHITNOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j ------------------------------------------------------------NOV32k ------------------------------------------------------------NOV32l ------------------------------------------------------------NOV32m ------------------------------------------------------------NOV32n ------------------------------------------------------------NOV32a ------------------------------------------------------------NOV32b ------------------------------------------------------------NOV32c ------------------------------------------------------------NOV32d ------------------------------------------------------------NOV32e ------------------------------------------------------------NOV32f CYMMAVPRPFTHITCYPMAVPSTLTHVTCHPTAIPRPFTHITCYTMAIPRPSTTPPATRRNOV32g ------------------------------------------------------------NOV32h ------------------------------------------------------------NOV32i ------------------------------------------------------------NOV32j ------------------------------------------------------------NOV32k ------------------------------------------------------------NOV32l ------------------------------------------------------------NOV32m ------------------------------------------------------------NOV32n ------------------------------------------------------------NOV32a ---------------------------NOV32b ---------------------------NOV32c ---------------------------NOV32d ---------------------------NOV32e ---------------------------NOV32f PSPAPSPTSPATRWPSPGPSPMSPATRNOV32g ---------------------------NOV32h ---------------------------NOV32i ---------------------------NOV32j ---------------------------NOV32k ---------------------------NOV32l ---------------------------NOV32m ---------------------------NOV32n ---------------------------NOV32a (SEQ ID NO: 382)NOV32b (SEQ ID NO: 384)NOV32c (SEQ ID NO: 386)NOV32d (SEQ ID NO: 388)NOV32e (SEQ ID NO: 390)NOV32f (SEQ ID NO: 392)NOV32g (SEQ ID NO: 394)NOV32h (SEQ ID NO: 396)NOV32i (SEQ ID NO: 398)NOV32j (SEQ ID NO: 400)NOV32k (SEQ ID NO: 402)NOV32l (SEQ ID NO: 404)NOV32m (SEQ ID NO: 406)NOV32n (SEQ ID NO: 408)

Further analysis of the NOV32a protein yielded the following properties shown in Table 32C.

TABLE 32CProtein Sequence Properties NOV32aSignalP analysis:Cleavage site between residues 13 and 14PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 12; peak value 6.67PSG score: 2.27GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −6.63possible cleavage site: between 34 and 35>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 1Number of TMS(s) for threshold 0.5: 1INTEGRALLikelihood = −2.76Transmembrane 110-126PERIPHERALLikelihood = 1.80 (at 81)ALOM score: −2.76 (number of TMSs: 1)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 117Charge difference: −2.0 C(0.0) − N(2.0)N >= C: N-terminal side will be inside>>> membrane topology: type 2 (cytoplasmic tail 1 to 110)MITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):4.93Hyd Moment(95):1.50G content:5D/E content:2S/T content:1Score: −9.83Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 10.6%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: foundLL at 15LL at 82checking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 89COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):34.8%: cytoplasmic30.4%: mitochondrial13.0%: Golgi 8.7%: endoplasmic reticulum 4.3%: extracellular, including cell wall 4.3%: nuclear 4.3%: vesicles of secretory system>> prediction for CG53989-03 is cyt (k = 23)

A search of the NOV32a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 32D.

TABLE 32DGeneseq Results for NOV32aNOV32aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE14347Human protease PRTS-12 protein -130 . . . 339205/210 (97%)e−123Homo sapiens, 262 aa. 53 . . . 262205/210 (97%)[WO200183775-A2, 08-NOV-2001]AAE08591Human NOV12 protein - Homo126 . . . 339205/214 (95%)e−122sapiens, 220 aa. [WO200161009- 7 . . . 220206/214 (95%)A2, 23-AUG-2001]AAE08590Human NOV11 protein - Homo135 . . . 339203/205 (99%)e−122sapiens, 285 aa. [WO200161009- 81 . . . 285203/205 (99%)A2, 23-AUG-2001]AAU82736Amino acid sequence of novel 9 . . . 334237/368 (64%)e−118human protease #35 - Homo 46 . . . 411252/368 (68%)sapiens, 948 aa. [WO200200860-A2, 03-JAN-2002]AAE08587Human NOV8 protein - Homo135 . . . 339198/205 (96%)e−116sapiens, 290 aa. [WO200161009- 86 . . . 290198/205 (96%)A2, 23-AUG-2001]

In a BLAST search of public sequence databases, the NOV32a protein was found to have homology to the proteins shown in the BLASTP data in Table 32E.

TABLE 32EPublic BLASTP Results for NOV32aNOV32aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueAAP21675Mast cell protease-11 - Mus106 . . . 336 129/231 (55%)2e−60musculus (Mouse), 318 aa.60 . . . 284155/231 (66%)AAA30855Mastin precursor - Canis sp, 25198 . . . 337120/240 (50%)7e−51aa (fragment).22 . . . 249142/240 (59%)P19236Mastocytoma protease precursor98 . . . 337120/240 (50%)7e−51(EC 3.4.21.—) - Canis familiaris40 . . . 267142/240 (59%)(Dog), 269 aa.Q8SQ44Tryptase precursor - Sus scrofa143 . . . 337 106/195 (54%)1e−49(Pig), 277 aa.90 . . . 275128/195 (65%)Q9XSM1Tryptase (EC 3.4.21.59) - Ovis109 . . . 337 95/229 (41%)6e−43aries (Sheep), 273 aa.54 . . . 273129/229 (55%)

PFam analysis indicates that the NOV32a protein contains the domains shown in the Table 32F.

TABLE 32FDomain Analysis of NOV32aNOV32aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Valuetrypsin125 . . . 329 80/272 (29%)5.6e−32156/272 (57%)

Example 33

The NOV33 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 33A.

TABLE 33ANOV33 Sequence AnalysisNOV33a, CG54203-02SEQ ID NO: 4091028 bpDNA SequenceORF Start: ATG at 18ORF Stop: TGA at 975TGCAGAGGGGATATCACATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGGGGCTCTCTGCCCACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGATGATGTACCTCGTGATCCTGCTGGGCAATGGGGTCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTACTTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCACTGGTCCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATGGCACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTTGATCGCTATGTGGCCATCTGCAACCCCCTTAGGTACTCCGTGATCATGAGCAAGGCTGCCTACATGCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTGGCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGGCTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAATGTGATCTTCCTAGGAGTCCCGGTTCTGTTCATCTCTTTCTCCTATGTCTTCATCATCACCACCATCCTGAGGATCCCCTCAGCTGAGGGGAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCACCTCACCGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCTAAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATGGGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGGCTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGATGGTGGAAGGGTCCTCTGTGATTGTCACCCACATGGAAGTAAGGAATCACANOV33a, CG54203-02SEQ ID NO: 410319 aaMW at 35072.3kDProtein Sequence MEKANETSPVMGFVLLGLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMAFDRYVAICNPLRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIIYSLRNKDVKAAVRRLLRPKGFTQNOV33b, CG54203-01SEQ ID NO: 4111031 bpDNA SequenceORF Start: ATG at 22ORF Stop: TGA at 979TGATGGCAGAGGGGATATCACATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGAGGCTCTCTGCCCACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGCTGATGTACCTCGTGATCCTGCTGGGCAATGGGGTCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTACTTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCACTGGTCCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATGGCACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTTGATCGCTATGTGGCCATCTGCAACCCCCTTAGGTACTCCGTGATCATGAGCAAGGCTGCCTACATGCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTGGCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGGCTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAATGTGATCTTCCTAGGAGTCCCGGTTCTGTTCATCTCTTTCTCCTATGTCTTCATCATCACCACCATCCTGAGGATCCCCTCAGCTGAGGGGAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCACCTCACCGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCTAAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATGGGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGGCTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGATGGTGGAAGGGTCCTCTGTGATTGTCACCCACATGGAAGTAAGGAATCACNOV33b, CG54203-01SEQ ID NO: 412319 aaMW at 35171.4kDProtein SequenceMEKANETSPVMGFVLLRLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMAFDRYVAICNPLRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIIYSLRNKDVKAAVRRLLRPKGFTQNOV33c, SNP13382442 ofSEQ ID NO: 4131028 bpCG54203-02, DNA SequenceORF Start: ATG at 18ORF Stop: TGA at 975SNP Pos: 66SNP Change: G to ATGCAGAGGGGATATCACATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGAGGCTCTCTGCCCACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGCTGATGTACCTCGTGATCCTGCTGGGCAATGGGGTCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTACTTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCACTGGTCCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATGGCACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTTGATCGCTATGTGGCCATCTGCAACCCCCTTAGGTACTCCGTGATCATGAGCAAGGCTGCCTACATGCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTGGCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGGCTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAATGTGATCTTCCTAGGAGTCCCGGTTCTGTTCATCTCTTTCTCCTATGTCTTCATCATCACCACCATCCTGAGGATCCCCTCAGCTGAGGGGAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCACCTCACCGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCTAAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATGGGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGGCTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGATGGTGGAAGGGTCCTCTGTGATTGTCACCCACATGGAAGTAAGGAATCACANOV33c, SNP13382442 ofSEQ ID NO: 414319 aaMW at 35171.4kDCG54203-02, ProteinSNP Pos: 17SNP Change: Gly to ArgSequenceMEKANETSPVMGFVLLRLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMAFDRYVAICNPLRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIEYSLRNKDVKAAVRRLLRPKGFTQNOV33d, SNP13373880 ofSEQ ID NO: 4151028 bpCG54203-02, DNA SequenceORF Start: ATG at 18ORF Stop: TGA at 975SNP Pos: 324SNP Change: G to ATGCAGAGGGGATATCACATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGAGGCTCTCTGCCCACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGCTGATGTACCTCGTGATCCTGCTGGGCAATGGGGTCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTACTTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCACTGGTCCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATGACACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTTGATCGCTATGTGGCCATCTGCAACCCCCTTAGGTACTCCGTGATCATGAGCAAGGCTGCCTACATGCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTGGCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGGCTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAATGTGATCTTCCTAGGAGTCCCGGTTCTGTTCATCTCTTTCTCCTATGTCTTCATCATCACCACCATCCTGAGGATCCCCTCAGCTGAGGGGAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCACCTCACCGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCTAAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATGGGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGGCTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGATGGTGGAAGGGTCCTCTGTGATTGTCACCCACATGGAAGTAAGGAATCACANOV33d, SNP13373880 ofSEQ ID NO: 416319 aaMW at 35102.3kDCG54203-02, ProteinSNP Pos: 103SNP Change: Ala to ThrSequenceMEKANETSPVMGFVLLGLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMTLSFAMAGTECLLLSMMAFDRYVAICNPLRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIEYSLRNKDVKAAVRRLLRPKGFTQNOV33e, SNP13373881 ofSEQ ID NO: 4171028 bpCG54203-02, DNA SequenceORF Start: ATG at 18ORF Stop: TGA at 975SNP Pos: 429SNP Change: A to GTGCAGAGGGGATATCACATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGAGGCTCTCTGCCCACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGCTGATGTACCTCGTGATCCTGCTGGGCAATGGGGTCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTACTTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCACTGGTCCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATGGCACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTTGATCGCTATGTGGCCATCTGCAACCCCCTTAGGTACTCCGTGATCATGGGCAAGGCTGCCTACATGCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTGGCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGGCTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAATGTGATCTTCCTAGGAGTCCCGGTTCTGTTCATCTCTTTCTCCTATGTCTTCATCATCACCACCATCCTGAGGATCCCCTCAGCTGAGGGGAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCACCTCACCGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCTAAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATGGGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGGCTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGATGGTGGAAGGGTCCTCTGTGATTGTCACCCACATGGAAGTAAGGAATCACANOV33e, SNP13373881 ofSEQ ID NO: 418319 aaMW at 35042.3kDCG54203-02, ProteinSNP Pos: 138SNP Change: Ser to GlySequenceMEKANETSPVMGFVLLGLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMAFDRYVAICNPLRYSVIMGKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIEYSLRNKDVKAAVRRLLRPKGFTQNOV33f, SNP13382443 ofSEQ ID NO: 4191028 bpCG54203-02, DNA SequenceORF Start: ATG at 18ORF Stop: TGA at 975SNP Pos: 444SNP Change: A to GTGCAGAGGGGATATCACATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGAGGCTCTCTGCCCACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGCTGATGTACCTCGTGATCCTGCTGGGCAATGGGGTCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTACTTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCACTGGTCCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATGGCACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTTGATCGCTATGTGGCCATCTGCAACCCCCTTAGGTACTCCGTGATCATGAGCAAGGCTGCCTACGTGCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTGGCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGGCTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAATGTGATCTTCCTAGGAGTCCCGGTTCTGTTCATCTCTTTCTCCTATGTCTTCATCATCACCACCATCCTGAGGATCCCCTCAGCTGAGGGGAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCACCTCACCGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCTAAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATGGGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGGCTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGATGGTGGAAGGGTCCTCTGTGATTGTCACCCACATGGAAGTAAGGAATCACANOV33f, SNP13382443 ofSEQ ID NO: 420319 aaMW at 35040.2kDCG54203-02, ProteinSNP Pos: 143SNP Change: Met to Val SequenceMEKANETSPVMGFVLLGLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMAFDRYVAICNPLRYSVIMSKAAYVPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIEYSLRNKDVKAAVRRLLRPKGFTQNOV33g, SNP13373844 ofSEQ ID NO: 4211028 bpCG54203-02, DNA SequenceORF Start: ATG at 18ORF Stop: TGA at 975SNP Pos: 719SNP Change: G to ATGCAGAGGGGATATCACATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGAGGCTCTCTGCCCACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGCTGATGTACCTCGTGATCCTGCTGGGCAATGGGGTCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTACTTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCACTGGTCCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATGGCACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTTGATCGCTATGTGGCCATCTGCAACCCCCTTAGGTACTCCGTGATCATGAGCAAGGCTGCCTACATGCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTGGCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGGCTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAATGTGATCTTCCTAGGAGTCCCGGTTCTGTTCATCTCTTTCTCCTATGTCTTCATCATCACCACCATCCTGAGGATCCCCTCAGCTGAGGGAAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCACCTCACCGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCTAAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATGGGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGGCTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGATGGTGGAAGGGTCCTCTGTGATTGTCACCCACATGGAAGTAAGGAATCACANOV33g, SNP13373844 ofSEQ ID NO: 422319 aaMW at 35072.3kDCG54203-02, ProteinSNP Pos: 234SNP Change: Gly to GlySequenceMEKANETSPVMGFVLLGLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMAFDRYVAICNPLRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIEYSLRNKDVKAAVRRLLRPKGFTQNOV33h, SNP13373883 ofSEQ ID NO: 4231028 bpCG54203-02, DNA SequenceORF Start: ATG at 18ORF Stop: TGA at 975SNP Pos: 758SNP Change: C to TTGCAGAGGGGATATCACATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGAGGCTCTCTGCCCACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGCTGATGTACCTCGTGATCCTGCTGGGCAATGGGGTCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTACTTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCACTGGTCCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATGGCACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTTGATCGCTATGTGGCCATCTGCAACCCCCTTAGGTACTCCGTGATCATGAGCAAGGCTGCCTACATGCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTGGCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGGCTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAATGTGATCTTCCTAGGAGTCCCGGTTCTGTTCATCTCTTTCTCCTATGTCTTCATCATCACCACCATCCTGAGGATCCCCTCAGCTGAGGGGAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCACCTCACTGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCTAAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATGGGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGGCTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGATGGTGGAAGGGTCCTCTGTGATTGTCACCCACATGGAAGTAAGGAATCACANOV33h, SNP13373883 ofSEQ ID NO: 424319 aaMW at 35072.3kDCG54203-02, ProteinSNP Pos: 247SNP Change: Thr to ThrSequenceMEKANETSPVMGFVLLGLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMAFDRYVAICNPLRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIEYSLRNKDVKAAVRRLLRPKGFTQ

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 33B.

TABLE 33BComparison of the NOV33 protein sequences.NOV33a MEKANETSPVMGFVLLGLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMNOV33b MEKANETSPVMGFVLLRLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMNOV33a YFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMANOV33b YFFLGNLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMANOV33a FDRYVAICNPLRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCNOV33b FDRYVAICNPLRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIOLPFCGDNVINHFTCNOV33a EILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSNOV33b EILAVLKLACADISINVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSNOV33a TCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIIYSLRNOV33b TCSAHLTVVIVFYGTLFFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIIYSLRNOV33a NKDVKAAVRRLLRPKGFTQNOV33b NKDVKAAVRRLLRPKGFTQNOV33a (SEQ ID NO: 410)NOV33b (SEQ ID NO: 412)

Further analysis of the NOV33a protein yielded the following properties shown in Table 33C.

TABLE 33CProtein Sequence Properties NOV33aSignalP analysis:Cleavage site between residues 45 and 46PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 6; pos.chg 1; neg.chg 2H-region: length 16; peak value 0.00PSG score: −4.40GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.59possible cleavage site: between 44 and 45>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 7INTEGRALLikelihood = −9.50Transmembrane 31-47INTEGRALLikelihood = −0.22Transmembrane 67-83INTEGRALLikelihood = −0.32Transmembrane 93-109INTEGRALLikelihood = −3.77Transmembrane 182-198INTEGRALLikelihood = −6.95Transmembrane 206-222INTEGRALLikelihood = −1.81Transmembrane 242-258INTEGRALLikelihood = −0.22Transmembrane 280-296PERIPHERALLikelihood = 2.38 (at 151)ALOM score: −9.50 (number of TMSs: 7)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 38Charge difference: 1.0 C(0.5) − N(−0.5)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content: 0Hyd Moment(75):6.12Hyd Moment(95):11.03G content:0D/E content: 2S/T content:0Score: −6.47Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.2%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: KGFTSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: endoplasmic reticulum11.1%: mitochondrial11.1%: vacuolar11.1%: vesicles of secretory system11.1%: Golgi>> prediction for CG54203-02 is end (k = 9)

A search of the NOV33a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 33D.

TABLE 33DGeneseq Results for NOV33aNOV33aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU85170G-coupled olfactory receptor #31 -1 . . . 319318/319 (99%)e−179Homo sapiens, 319 aa.1 . . . 319318/319 (99%)[WO200198526-A2, 27-DEC-2001]AAU97924Novel odourant receptor NOV31 . . . 319318/319 (99%)e−179protein - Unidentified, 319 aa.1 . . . 319318/319 (99%)[WO200236632-A2, 10-MAY-2002]AAG71989Human olfactory receptor1 . . . 319318/319 (99%)e−179polypeptide, SEQ ID NO: 1670 -1 . . . 319318/319 (99%)Homo sapiens, 319 aa.[WO200127158-A2, 19-APR-2001]AAU07096Human odorant receptor (OR)1 . . . 319318/319 (99%)e−179polypeptide #13 - Homo sapiens,1 . . . 319318/319 (99%)319 aa. [WO200157215-A2, 09-AUG-2001]AAU07086Human odorant receptor (OR)1 . . . 319318/319 (99%)e−179polypeptide #3 - Homo sapiens,1 . . . 319318/319 (99%)319 aa. [WO200157215-A2, 09-AUG-2001]

In a BLAST search of public sequence databases, the NOV33a protein was found to have homology to the proteins shown in the BLASTP data in Table 33E.

TABLE 33EPublic BLASTP Results for NOV33aNOV33aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedNumberProtein/Organism/LengthResiduesPortionExpect ValueQ9NQN1Olfactory receptor 2S2 - Homo1 . . . 319318/319 (99%)e−179sapiens (Human), 319 aa.1 . . . 319318/319 (99%)CAC88321Sequence 3 from Patent1 . . . 317263/317 (82%)e−151WO0164879 - Homo sapiens1 . . . 317289/317 (90%)(Human), 318 aa.Q9QZ22Olfactory receptor1 . . . 319263/319 (82%)e−150GA_x5J8B7W5BNN-979337-1 . . . 319292/319 (91%)980296 - Mus musculus(Mouse), 319 aa.CAC88320Sequence 1 from Patent1 . . . 317263/318 (82%)e−149WO0164879 - Homo sapiens1 . . . 318288/318 (89%)(Human), 319 aa.Q9QZ19Olfactory receptor (Olfactory1 . . . 317257/317 (81%)e−147receptor MOR262-5) - Mus1 . . . 317283/317 (89%)musculus (Mouse), 319 aa.

PFam analysis indicates that the NOV33a protein contains the domains shown in the Table 33F.

TABLE 33FDomain Analysis of NOV33aNOV33aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_142 . . . 297 57/280 (20%)3.7e−35179/280 (64%)

Example 34

The NOV34 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 34A.

TABLE 34ANOV34 Sequence AnalysisNOV34a, CG54212-02SEQ ID NO: 425953 bpDNA SequenceORF Start: ATG at 11ORF Stop: TGA at 947ACTCTGCAGCATGGAGCCGCTCAACAGAACAGAGGTGTCCGAGTTCTTTCTGAAAGGATTTTCTGGCTACCCAGCCCTGGAGCATCTGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCTCCTGGGGAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCTGTGTACTTCTTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCCACCTTTGTGCCTCTGATGCTGGTCCACCTCCTGTCATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTCTGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTACCTGGCCATCTGCCAGCCACTCAGGTACCGCGTGCTCATGAGCCACCGGCTCTGCGTGCTGCTGATGGGAGCTGCCTGGGTCCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCATGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGTGCTGAAGCTGGCATGCGGCAACACGTCGGTCAGCGAAGACTTCCTGCTGGCGGGCTCCATCCTGCTGCTGCCTGTACCCCTGGCATTCATCTGCCTGTCCTACTTGCTCATCCTGGCCACCATCCTGAGGGTGCCCTCGGCCGCCAGGTGCTGCAAAGCCTTCTCCACCTGCTTGGCACACCTGGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAGGAAGCCCACATCTCTGATGAGGTCTTCACAGTCCTCTATGCCATGGTCACGACCATGCTGAACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGCCAGGAAGGTGTGGGGCAGGAGTCGGGCCTCCAGGTGAGGGANOV34a, GG54212-02SEQ ID NO: 426312 aaMW at 34707.2kDProtein SequenceMEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYFFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYDRYLAICQPLRYRVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTCLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASRNOV34b, GG54212-01SEQ ID NO: 4271050 bpDNA SequenceORF Start: ATG at 59ORF Stop: TGA at 995CCCTGTACCCTCTCTCCTTCCATCCCAGCTGTGGACCATCTCTTCAGAACTCTGCAGCATGGAGCCGCTCAACAGAACAGAGGTGTCCGAGTTCTTTCTGAAAGGATTTTCTGGCTACCCAGCCCTGGAGCATCTGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCTCCTGGGGAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCCGTGTACTTCTTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCCACCTTTGTGCCTCTGATGCTGGTCCACCTCCTGTCATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTCTGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTACCTGGCCATCTGCCAGCCACTCAGGTACCACGTGCTCATGAGCCACCGGCTCTGCGTGCTGCTGATGGGAGCTGCCTGGGTCCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCATGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGTGCTGAAGCTGGCATGCGGCAACACGTCGGTCAGCGAAGACTTCCTGCTGGCGGGCTCCATCCTGCTGCTGCCTGTACCCCTGGCATTCATCTGCCTGTCCTACTTGCTCATCCTGGCCACCATCCTGAGGGTGCCCTCGGCCGCCAGGTGCTGCAAAGCCTTCTCCACCTGCTTGGCACACCTGGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAGGAAGCCCACATCTCTGATGAGGTCTTCACAGTCCTCTATGCCATGGTCACGACCATGCTGAACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGCCAGGAAGGTGTGGGGCAGGAGTCGGGCCTCCAGGTGAGGGAGGGCGGGGCTCTGTACAGACGCAGGTCTCAGGTTAGTAGCTGAGGCCATNOV34b, CG54212-01SEQ ID NO: 428312 aaMW at 34688.2kDProtein SequenceMEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYFFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYDRYLAICQPLRYRVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTCLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASRNOV34c, CG54212-03SEQ ID NO: 429917 bpDNA SequenceORF Start: at 3ORF Stop: TGA at 861TGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCTCCTGGGGAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCCGTGTACTTCTTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCCACCTTTGTGCCTCTGATGCTGGTCCACCTCCTGTCATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTCTGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTACCTGGCCATCTGCCAGCCACTCAGGTACCACGTGCTCATGAGCCACCGGCTCTGCGTGCTGCTGATGGGAGCTGCCTGGGTCCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCATGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGTGCTGAAGCTGGCATGCGGCAACACGTCGGTCAGCGAAGACTTCCTGCTGGCGGGCTCCATCCTGCTGCTGCCTGTACCCCTGGCATTCATCTGCCTGTCCTACTTGCTCATCCTGGCCACCATCCTGAGGGTGCCCTCGGCCGCCAGGTGCTGCAAAGCCTTCTCCACCTGCTTGGCACACCTGGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAGGAAGCCCACATCTCTGATGAGGTCTTCACAGTCCTCTATGCCATGGTCACGACCATGCTGAACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGCCAGGAAGGTGTGGGGCAGGAGTCGGGCCTCCAGGTGAGGGAGGGCGGGGCTCTGTACAGACGCAGGTCTCAGGTTAGTAGCTGAGGCCATCNOV34c, CG54212-03SEQ ID NO: 430286 aa MW at 31693.8kDProtein SequenceLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYFFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYDRYLAICQPLRYHVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTCLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASRNOV34d, CG54212-04SEQ ID NO: 4311025 bpDNA SequenceORF Start: ATG at 33ORF Stop: TGA at 969AGCTGTGGACCATCTCTTCAGAACTCTGCAGCATGGAGCCGCTCAACAGAACAGAGGTGTCCGAGTTCTTTCTGAAAGGATTTTCTGGCTACCCAGCCCTGGAGCATCTGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCTCCTGGGGAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCCGTGTACTTCTTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCCACCTTTGTGCCTCTGATGCTGGTCCACCTCCTGTCATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTCTGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTACCTGGCCATCTGCCAGCCACTCAGGTACCACGTGCTCATGAGCCACCGGCTCTGCGTGCTGCTGATGGGAGCTGCCTGGGTCCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCATGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGTGCTGAAGCTGGCATGCGGCAACACGTCGGTCAGCGAAGACTTCCTGCTGGCGGGCTCCATCCTGCTGCTGCCTGTACCCCTGGCATTCATCTGCCTGTCCTACTTGCTCATCCTGGCCACCATCCTGAGGGTGCCCTCGGCCGCCAGGTGCTGCAAAGCCTTCTCCACCTGCTTGGCACACCTGGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAGGAAGCCCACATCTCTGATGAGGTCTTCACAGTCCTCTATGCCATGGTCACGACCATGCTGAACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGCCAGGAAGGTGTGGGGCAGGAGTCGGGCCTCCAGGTGAGGGAGGGCGGGGCTCTGTACAGACGCAGGTCTCAGGTTAGTAGCTGAGGCCATCNOV34d, CG54212-04SEQ ID NO: 432312 aaMW at 34688.2kDProtein SequenceMEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYFFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYDRYLAICQPLRYRVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTCLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASRNOV34e, SNP13373981 ofSEQ ID NO: 433953 bpCG54212-02, DNA SequenceORF Start: ATG at 11ORF Stop: TGA at 947SNP Pos: 184SNP Change: T to CACTCTGCAGCATGGAGCCGCTCAACAGAACAGAGGTGTCCGAGTTCTTTCTGAAAGGATTTTCTGGCTACCCAGCCCTGGAGCATCTGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCTCCTGGGGAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCCGTGTACTTCTTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCCACCTTTGTGCCTCTGATGCTGGTCCACCTCCTGTCATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTCTGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTACCTGGCCATCTGCCAGCCACTCAGGTACCGCGTGCTCATGAGCCACCGGCTCTGCGTGCTGCTGATGGGAGCTGCCTGGGTCCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCATGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGTGCTGAAGCTGGCATGCGGCAACACGTCGGTCAGCGAAGACTTCCTGCTGGCGGGCTCCATCCTGCTGCTGCCTGTACCCCTGGCATTCATCTGCCTGTCCTACTTGCTCATCCTGGCCACCATCCTGAGGGTGCCCTCGGCCGCCAGGTGCTGCAAAGCCTTCTCCACCTGCTTGGCACACCTGGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAGGAAGCCCACATCTCTGATGAGGTCTTCACAGTCCTCTATGCCATGGTCACGACCATGCTGAACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGCCAGGAAGGTGTGGGGCAGGAGTCGGGCCTCCAGGTGAGGGANOV34e, SNP13373981 ofSEQ ID NO: 434312 aaMW at 34707.2kDCG54212-02, ProteinSNP Pos: 58SNP Change: Pro to ProSequenceMEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYFFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYDRYLAICQPLRYRVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTCLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASRNOV34f, SNP13373982 ofSEQ ID NO: 435953 bpCG54212-02, DNA SequenceORF Start: ATG at 11ORF Stop: TGA at 947SNP Pos: 188SNP Change: T to CACTCTGCAGCATGGAGCCGCTCAACAGAACAGAGGTGTCCGAGTTCTTTCTGAAAGGATTTTCTGGCTACCCAGCCCTGGAGCATCTGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCTCCTGGGGAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCTGTGCACTTCTTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCCACCTTTGTGCCTCTGATGCTGGTCCACCTCCTGTCATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTCTGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTACCTGGCCATCTGCCAGCCACTCAGGTACCGCGTGCTCATGAGCCACCGGCTCTGCGTGCTGCTGATGGGAGCTGCCTGGGTCCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCATGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGTGCTGAAGCTGGCATGCGGCAACACGTCGGTCAGCGAAGACTTCCTGCTGGCGGGCTCCATCCTGCTGCTGCCTGTACCCCTGGCATTCATCTGCCTGTCCTACTTGCTCATCCTGGCCACCATCCTGAGGGTGCCCTCGGCCGCCAGGTGCTGCAAAGCCTTCTCCACCTGCTTGGCACACCTGGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAGGAAGCCCACATCTCTGATGAGGTCTTCACAGTCCTCTATGCCATGGTCACGACCATGCTGAACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGCCAGGAAGGTGTGGGGCAGGAGTCGGGCCTCCAGGTGAGGGANOV34f, SNP13373982 ofSEQ ID NO: 436312 aaMW at 34681.2kDCG54212-02, ProteinSNP Pos: 60SNP Change: Tyr to HisSequenceMEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVHFFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYDRYLAICQPLRYRVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTCLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASRNOV34g, SNP13373984 ofSEQ ID NO: 437953 bpCG54212-02, DNA SequenceORF Start: ATG at 11ORF Stop: TGA at 947SNP Pos: 408SNP Change: G to AACTCTGCAGCATGGAGCCGCTCAACAGAACAGAGGTGTCCGAGTTCTTTCTGAAAGGATTTTCTGGCTACCCAGCCCTGGAGCATCTGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCTCCTGGGGAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCTGTGTACTTCTTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCCACCTTTGTGCCTCTGATGCTGGTCCACCTCCTGTCATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTCTGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTACCTGGCCATCTGCCAGCCACTCAGGTACCACGTGCTCATGAGCCACCGGCTCTGCGTGCTGCTGATGGGAGCTGCCTGGGTCCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCATGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGTGCTGAAGCTGGCATGCGGCAACACGTCGGTCAGCGAAGACTTCCTGCTGGCGGGCTCCATCCTGCTGCTGCCTGTACCCCTGGCATTCATCTGCCTGTCCTACTTGCTCATCCTGGCCACCATCCTGAGGGTGCCCTCGGCCGCCAGGTGCTGCAAAGCCTTCTCCACCTGCTTGGCACACCTGGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAGGAAGCCCACATCTCTGATGAGGTCTTCACAGTCCTCTATGCCATGGTCACGACCATGCTGAACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGCCAGGAAGGTGTGGGGCAGGAGTCGGGCCTCCAGGTGAGGGANOV34g, SNP13373984 ofSEQ ID NO: 438312 aaMW at 34688.2kDCG54212-02, ProteinSNP Pos: 133SNP Change: Arg to HisSequenceMEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYFFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYDRYLAICQPLRYHVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTCLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASRNOV34h, SNP13373985 ofSEQ ID NO: 439953 bpCG54212-02, DNA SequenceORF Start: ATG at 11ORF Stop: TGA at 947SNP Pos: 501SNP Change: T to CACTCTGCAGCATGGAGCCGCTCAACAGAACAGAGGTGTCCGAGTTCTTTCTGAAAGGATTTTCTGGCTACCCAGCCCTGGAGCATCTGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCTCCTGGGGAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCTGTGTACTTCTTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCCACCTTTGTGCCTCTGATGCTGGTCCACCTCCTGTCATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTCTGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTACCTGGCCATCTGCCAGCCACTCAGGTACCGCGTGCTCATGAGCCACCGGCTCTGCGTGCTGCTGATGGGAGCTGCCTGGGTCCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCACGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGTGCTGAAGCTGGCATGCGGCAACACGTCGGTCAGCGAAGACTTCCTGCTGGCGGGCTCCATCCTGCTGCTGCCTGTACCCCTGGCATTCATCTGCCTGTCCTACTTGCTCATCCTGGCCACCATCCTGAGGGTGCCCTCGGCCGCCAGGTGCTGCAAAGCCTTCTCCACCTGCTTGGCACACCTGGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAGGAAGCCCACATCTCTGATGAGGTCTTCACAGTCCTCTATGCCATGGTCACGACCATGCTGAACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGCCAGGAAGGTGTGGGGCAGGAGTCGGGCCTCCAGGTGAGGGANOV34h, SNP13373985 ofSEQ ID NO: 440312 aaMW at 34677.1kDCG54212-02, ProteinSNP Pos: 164SNP Change: Met to ThrSequenceMEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYFFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYDRYLAICQPLRYRVLMSHRLCVLLMGAAWVLCLLKSVTEMVISTRLPFCGHHVVSHFTCKILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTCLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASR

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 34B.

TABLE 34BComparison of the NOV34 protein sequences.NOV34a MEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYNOV34b MEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYNOV34c --------------------------LFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYNOV34d MEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYNOV34a FFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYNOV34b FFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYNOV34c FFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYNOV34d FFLGNLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYNOV34a DRYLAICQPLRYRVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKNOV34b DRYLAICQPLRYHVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKNOV34c DRYLAICQPLRYHVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKNOV34d DRYLAICQPLRYHVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKNOV34a ILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTNOV34b ILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTNOV34c ILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTNOV34d ILAVLKLACGNTSVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTNOV34a CLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEANOV34b CLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEANOV34c CLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEANOV34d CLAHLAVVLLFYGTIIFMYLKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEANOV34a ARKVWGRSRASRNOV34b ARKVWGRSRASRNOV34c ARKVWGRSRASRNOV34d ARKVWGRSRASRNOV34a (SEQ ID NO: 426)NOV34b (SEQ ID NO: 428)NOV34c (SEQ ID NO: 430)NOV34d (SEQ ID NO: 432)

Further analysis of the NOV34a protein yielded the following properties shown in Table 34C.

TABLE 34CProtein Sequence Properties NOV34aSignalP analysis:Cleavage site between residues 48 and 49PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 11; pos.chg 1; neg.chg 3H-region: length 3; peak value 0.00PSG score: −4.40GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −2.43possible cleavage site: between 33 and 34>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −1.86Transmembrane 35-51INTEGRALLikelihood = −0.11Transmembrane 92-108INTEGRALLikelihood = −4.88Transmembrane 141-157INTEGRALLikelihood = −0.27Transmembrane 173-189INTEGRALLikelihood = −7.80Transmembrane 204-220INTEGRALLikelihood = −6.26Transmembrane 241-257PERIPHERALLikelihood = 0.79 (at 71)ALOM score: −7.80 (number of TMSs: 6)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 42Charge difference: 0.5 C(0.0) − N(−0.5)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):6.33Hyd Moment(95):9.16G content:0D/E content:2S/T content:1Score: −5.44Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 8.3%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: endoplasmic reticulum11.1%: Golgi11.1%: vacuolar11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG54212-02 is end (k = 9)

A search of the NOV34a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 34D.

TABLE 34DGeneseq Results for NOV34aNOV34aIdentities/Residues/SimilaritiesGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU85168G-coupled olfactory receptor #29 -1 . . . 312311/312 (99%)e−178Homo sapiens, 312 aa.1 . . . 312311/312 (99%)[WO200198526-A2, 27-DEC-2001]AAU95519Human olfactory and pheromone1 . . . 312311/312 (99%)e−178G protein-coupled receptor #6 -1 . . . 312311/312 (99%)Homo sapiens, 312 aa.[WO200224726-A2, 28-MAR-2002]AAU97925Novel odourant receptor NOV41 . . . 312311/312 (99%)e−178protein - Unidentified, 312 aa.1 . . . 312311/312 (99%)[WO200236632-A2, 10-MAY-2002]AAU97923Novel odourant receptor NOV21 . . . 312311/312 (99%)e−178protein - Unidentified, 312 aa.1 . . . 312311/312 (99%)[WO200236632-A2, 10-MAY-2002]AAU97922Novel odourant receptor NOV11 . . . 312311/312 (99%)e−178protein - Unidentified, 312 aa.1 . . . 312311/312 (99%)[WO200236632-A2, 10-MAY-2002]

In a BLAST search of public sequence databases, the NOV34a protein was found to have homology to the proteins shown in the BLASTP data in Table 34E.

TABLE 34EPublic BLASTP Results for NOV34aNOV34aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedNumberProtein/Organism/LengthResiduesPortionExpect ValueQ8NGT2Seven transmembrane helix1 . . . 312311/312 (99%)e−178receptor - Homo sapiens1 . . . 312311/312 (99%)(Human), 312 aa.CAD57893Sequence 9 from Patent1 . . . 312310/312 (99%)e−177WO0236632 - Homo sapiens1 . . . 312311/312 (99%)(Human), 312 aa.Q9QZ18Olfactory receptor (Olfactory1 . . . 312256/312 (82%)e−146receptor MOR262-4) - Mus1 . . . 312275/312 (88%)musculus (Mouse), 312 aa.Q96R40Olfactory receptor - Homo68 . . . 283 215/216 (99%)e−120sapiens (Human), 216 aa1 . . . 216215/216 (99%)(fragment).CAD42439Sequence 121 from Patent1 . . . 307167/307 (54%)5e−94 WO0212343 - Homo sapiens1 . . . 305225/307 (72%)(Human), 311 aa.

PFam analysis indicates that the NOV34a protein contains the domains shown in the Table 34F.

TABLE 34FDomain Analysis of NOV34aNOV34aIdentities/PfamMatchSimilaritiesDomainRegionfor the Matched RegionExpect Value7tm_141 . . . 290 63/276 (23%)2.8e−34182/276 (66%)

Example 35

The NOV35 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 35A.

TABLE 35ANOV35 Sequence AnalysisNOV35a, CG54236-01SEQ ID NO: 4411260 bpDNA SequenceORF Start: ATG at 105ORF Stop: TAA at 1143TGCTCCCTGTTTCATTAAAACCTAGAGAGATGTAATCAGTAAGCAAGAAGGAAAAAGGGAAATTCACAAAGTAACTTTTTGTGTCTGTTTCTTTTTAACCCAGCATGGAGAGAAAATTTATGTCCTTGCAACCATCCATCTCCGTATCAGAAATGGAACCAAATGGCACCTTCAGCAATAACAACAGCAGGAACTGCACAATTGAAAACTTCAAGAGAGAATTTTTCCCAATTGTATATCTGATAATATTTTTCTGGGGAGTCTTGGGAAATGGGTTGTCCATATATGTTTTCCTGCAGCCTTATAAGAAGTCCACATCTGTGAACGTTTTCATGCTAAATCTGGCCATTTCAGATCTCCTGTTCATAAGCACGCTTCCCTTCAGGGCTGACTATTATCTTAGAGGCTCCAATTGGATATTTGGAGACCTGGCCTGCAGGATTATGTCTTATTCCTTGTATGTCAACATGTACAGCAGTATTTATTTCCTGACCGTGCTGAGTGTTGTGCGTTTCCTGGCAATGGTTCACCCCTTTCGGCTTCTGCATGTCACCAGCATCAGGAGTGCCTGGATCCTCTGTGGGATCATATGGATCCTTATCATGGCTTCCTCAATAATGCTCCTGGACAGTGGCTCTGAGCAGAACGGCAGTGTCACATCATGCTTAGAGCTGAATCTCTATAAAATTGCTAAGCTGCAGACCATGAACTATATTGCCTTGGTGGTGGGCTGCCTGCTGCCATTTTTCACACTCAGCATCTGTTATCTGCTGATCATTCGGGTTCTGTTAAAAGTGGAGGTCCCAGAATCGGGGCTGCGGGTTTCTCACAGGAAGGCACTGACCACCATCATCATCACCTTGATCATCTTCTTCTTGTGTTTCCTGCCCTATCACACACTGAGGACCGTCCACTTGACGACATGGAAAGTGGGTTTATGCAAAGACAGACTGCATAAAGCTTTGGTTATCACACTGGCCTTGGCAGCAGCCAATGCCTGCTTCAATCCTCTGCTCTATTACTTTGCTGGGGAGAATTTTAAGGACAGACTAAAGTCTGCACTCAGAAAAGGCCATCCACAGAAGGCAAAGACAAAGTGTGTTTTCCCTGTTAGTGTGTGGTTGAGAAAGGAAACAAGAGTATAAGGAGCTCTTAGATGAGACCTGTTCTTGTATCCTTGTGTCCATCTTCATTCACTCATAGTCTCCAAATGACTTTGTATTTACATCACTCCCAACAAATGTTGATTCTTAATATTTANOV35a, CG54236-01SEQ ID NO: 442346 aaMW at 39634.7kDProtein SequenceMERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSIYVFLQPYKKSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYVNMYSSIYFLTVLSVVRFLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNGSVTSCLELNLYKIAKLQTMNYIALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRVSHRKALTTIIITLIIFFLCFLPYHTLRTVHLTTWKVGLCKDRLHKALVITLALAAANACFNPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWLRKETRVNOV35b, CG54236-02SEQ ID NO: 4431193 bpDNA SequenceORF Start: ATG at 105ORF Stop: TAA at 1143TGCTCCCTGTTTCATTAAAACCTAGAGAGATGTAATCAGTAAGCAAGAAGGAAAAAGGGAAATTCACAAAGTAACTTTTTGTGTCTGTTTCTTTTTAACCCAGCATGGAGAGAAAATTTATGTCCTTGCAACCATCCATCTCCGTATCAGAAATGGAACCAAATGGCACCTTCAGCAATAACAACAGCAGGAACTGCACAATTGAAAACTTCAAGAGAGAATTTTTCCCAATTGTATATCTGATAATATTTTTCTGGGGAGTCTTGGGAAATGGGTTGTCCATATATGTTTTCCTGCAGCCTTATAAGAAGTCCACATCTGTGAACGTTTTCATGCTAAATCTGGCCATTTCAGATCTCCTGTTCATAAGCACGCTTCCCTTCAGGGCTGACTATTATCTTAGAGGCTCCAATTGGATATTTGGAGACCTGGCCTGCAGGATTATGTCTTATTCCTTGTATGTCAACATGTACAGCAGTATTTATTTCCTGACCGTGCTGAGTGTTGTGCGTTTCCTGGCAATGGTTCACCCCTTTCGGCTTCTGCATGTCACCAGCATCAGGAGTGCCTGGATCCTCTGTGGGATCATATGGATCCTTATCATGGCTTCCTCAATAATGCTCCTGGACAGTGGCTCTGAGCAGAACGGCAGTGTCACATCATGCTTAGAGCTGAATCTCTATAAAATTGCTAAGCTGCAGACCATGAACTATATTGCCTTGGTGGTGGGCTGCCTGCTGCCATTTTTCACACTCAGCATCTGTTATCTGCTGATCATTCGGGTTCTGTTAAAAGTGGAGGTCCCAGAATCGGGGCTGCGGGTTTCTCACAGGAAGGCACTGACCACCATCATCATCACCTTGATCATCTTCTTCTTGTGTTTCCTGCCCTATCACACACTGAGGACCGTCCACTTGACGACATGGAAAGTGGGTTTATGCAAAGACAGACTGCATAAAGCTTTGGTTATCACACTGGCCTTGGCAGCAGCCAATGCCTGCTTCAATCCTCTGCTCTATTACTTTGCTGGGGAGAATTTTAAGGACAGACTAAAGTCTGCACTCAGAAAAGGCCATCCACAGAAGGCAAAGACAAAGTGTGTTTTCCCTGTTAGTGTGTGGTTGAGAAAGGAAACAAGAGTATAAGGAGCTCTTAGATGAGACCTGTTCTTGTATCCTTGTGTCCATCTTCATTCACTCATAGTCTCCAAATGACTTTGTATTTACATCACTCCCAACAAATGTTGATTCTTAATATTTANOV35b, CG54236-02SEQ ID NO: 444346 aaMW at 39634.7kDProtein SequenceMERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSIYVFLQPYKKSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYVNMYSSIYFLTVLSVVRFLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNGSVTSCLELNLYKIAKLQTMNYIALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRVSHRKALTTIIITLIIFFLCFLPYHTLRTVHLTTWKVGLCKDRLHKALVITLALAAANACFNPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWLRKETRV

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 35B.

TABLE 35BComparison of the NOV35 protein sequences.NOV35a MERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSINOV35b MERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSINOV35a YVFLQPYKKSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYVNOV35b YVFLQPYKKSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYVNOV35a NMYSSIYFLTVLSVVRFLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNOV35b NMYSSIYFLTVLSVVRFLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNOV35a NGSVTSCLELNLYKIAKLQTMNYIALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRVNOV35b NGSVTSCLELNLYKIAKLQTMNYIALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRVNOV35a SHRKALTTIIITLIIFFLCFLPYHTLRTVHLTTWKVGLCKDRLHKALVITLALAAANACFNOV35b SHRKALTTIIITLIIFFLCFLPYHTLRTVHLTTWKVGLCKDRLHKALVITLALAAANACFNOV35a NPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWLRKETRVNOV35b NPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWLRKETRVNOV35a (SEQ ID NO: 442)NOV35b (SEQ ID NO: 444)

Further analysis of the NOV35a protein yielded the following properties shown in Table 35C.

TABLE 35CProtein Sequence Properties NOV35aSignalP analysis:Cleavage site between residues 60 and 61PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 4; pos.chg 2; neg.chg 1H-region: length 11; peak value 5.18PSG score: 0.78GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −0.37possible cleavage site: between 55 and 56>>> Seems to have a cleavable signal peptide (1 to 55)ALOM: Klein et al's method for TM region allocationInit position for calculation: 56Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −2.81Transmembrane 75-91INTEGRALLikelihood = −3.72Transmembrane 125-141INTEGRALLikelihood = −8.86Transmembrane 157-173INTEGRALLikelihood = −7.75Transmembrane 204-220INTEGRALLikelihood = −11.36Transmembrane 245-261INTEGRALLikelihood = −1.06Transmembrane 287-303PERIPHERALLikelihood = 2.38 (at 222)ALOM score: −11.36 (number of TMSs: 6)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 27Charge difference: 2.0 C(1.0) − N(−1.0)C > N: C-terminal side will be inside>>>Caution: Inconsistent mtop result with signal peptide>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):11.72Hyd Moment(95):9.21G content:0D/E content:2S/T content:4Score: −3.79Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 13 ERK|FMNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 10.4%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the C-terminus: ERKFKKXX-like motif in the C-terminus: KETRSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):66.7%: endoplasmic reticulum11.1%: Golgi11.1%: vacuolar11.1%: cytoplasmic>> prediction for CG54236-01 is end (k = 9)

A search of the NOV35a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 35D.

TABLE 35DGeneseq Results for NOV35aNOV35aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABU11923Human G-protein coupled1 . . . 346346/346 (100%)0.0receptor HGPRBMY11v1 -1 . . . 346346/346 (100%)Homo sapiens, 346 aa.[WO200286123-A2, 31-OCT-2002]ABP81707Human cysteinyl leukotriene1 . . . 346346/346 (100%)0.0CYSLT2 receptor protein SEQ1 . . . 346346/346 (100%)ID NO: 589 - Homo sapiens, 346aa. [WO200261087-A2, 08-AUG-2002]ABB05229Human LTD4-like G protein-1 . . . 346346/346 (100%)0.0coupled receptor protein SEQ ID1 . . . 346346/346 (100%)NO: 2 - Homo sapiens, 346 aa.[WO200194580-A1, 13-DEC-2001]AAG77965Human G-protein coupled1 . . . 346346/346 (100%)0.0receptor PFI-017* - Homo1 . . . 346346/346 (100%)sapiens, 346 aa. [US2001039037-A1, 08-NOV-2001]AAE17231Human CysLT2 GPCR (G-1 . . . 346346/346 (100%)0.0protein coupled receptor) - Homo1 . . . 346346/346 (100%)sapiens, 346 aa. [WO200192302-A2, 06-DEC-2001]

In a BLAST search of public sequence databases, the NOV35a protein was found to have homology to the proteins shown in the BLASTP data in Table 35E.

TABLE 35EPublic BLASTP Results for NOV35aNOV35aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9NS75Cysteinyl leukotriene receptor 21 . . . 346 346/346 (100%)0.0(CysLTR2) (PSEC0146) (HG57)1 . . . 346 346/346 (100%)(HPN321) (hGPCR21) - Homosapiens (Human), 346 aa.CAC69290Sequence 1 from Patent1 . . . 346344/346 (99%)0.0WO0159118 - Homo sapiens1 . . . 346345/346 (99%)(Human), 346 aa.Q95N03Cysteinyl leukotriene receptor 21 . . . 346275/347 (79%)e−158(CysLTR2) - Sus scrofa (Pig),1 . . . 345300/347 (86%)345 aa.Q8R528Cysteinyl leukotriene 2 receptor -17 . . . 324 226/308 (73%)e−132Mus musculus (Mouse), 309 aa.1 . . . 308256/308 (82%)Q920A1Cysteinyl leukotriene receptor 217 . . . 324 224/308 (72%)e−131(CysLTR2) - Mus musculus1 . . . 308255/308 (82%)(Mouse), 309 aa.

PFam analysis indicates that the NOV35a protein contains the domains shown in the Table 35F.

TABLE 35FDomain Analysis of NOV35aNOV35aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_155 . . . 305 89/277 (32%)6.1e−54185/277 (67%)TAS2R33 . . . 324 64/314 (20%)0.019173/314 (55%)

Example 36

The NOV36 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 36A.

TABLE 36ANOV36 Sequence AnalysisNOV36a, CG54479-06SEQ ID NO: 4452066 bpDNA SequenceORF Start: ATG at 22ORF Stop: TAG at 2032ACAGGTTTCACAACTTCCCGGATGGGGCTGTGGTGGGTCAAGTGCAGCCTCCAGCCAGCCAGGATGGGGTGGCTCCCACTCCTGCTGCTTCTGACTCAATGCTTAGGGGTCCCTGGGCAGCGCTCGCCATTGAATGACTTCCAAGTGCTCCGGGGCACAGAGCTACAGCACCTGCTACATGCGGTGGTGCCCGGGCCTTGGCAGGAGGATGTGGCAGATGCTGAAGAGTGTGCTGGTCGCTGTGGGCCCTTAATGGACTGCCGGGCCTTCCACTACAACGTGAGCAGCCATGGTTGCCAACTGCTGCCATGGACTCAACACTCGCCCCACACGAGGCTGCGGCGTTCTGGGCGCTGTGACCTCTTCCAGAAGAAAQACTACGTACGGACCTGCATCATGAACAATGGGGTTGGGTACCGGGGCACCATGGCCACGACCGTGGGTGGCCTGCCCTGCCAGGCTTGGAGCCACAAGTTCCCGAATGATCACAAGTACACGCCCACTCTCCGGAATGGCCTGGAAGAGAACTTCTGCCGTAACCCTGATGGCGACCCCGGAGGTCCTTGGTGCTACACAACAGACCCTGCTGTGCGCTTCCAGAGCTGCGGCATCAAATCCTGCCGGGAGGCCGCGTGTGTCTGGTGCAATGGCGAGGAATACCGCGGCGCGGTAGACCGCACGGAGTCAGGGCGCGAGTGCCAGCGCTGGGATCTTCAGCACCCGCACCAGCACCCCTTCGAGCCGGGCAAGTTCCTCGACCAAGGTCTGGACGACAACTATTGCCGGAATCCTGACGGCTCCGAGCGGCCATGGTGCTACACTACGGATCCGCAGATCGAGCGAGAGTTCTGTGACCTCCCCCGCTGCGGGTCCGAGGCACAGCCCCGCCAAGAGGCCACAACTGTCAGCTGCTTCCGCGGGAAGGGTGAGGGCTACCGGGGCACAGCCAATACCACCACTGCGGGCGTACCTTGCCAGCGTTGGGACGCGCAAATCCCTCATCAGCACCGATTTACGCCAGAAAAATACGCGTGCAAAGACCTTCGGGAGAACTTCTGCCGGAACCCCGACGGCTCAGAGGCGCCCTGGTGCTTCACACTGCGGCCCGGCATGCGCGCGGCCTTTTGCTACCAGATCCGGCGTTGTACAGACGACGTGCGGCCCCAGGACTGCTACCACGGCGCAGGGGAGCAGTACCGCGGCACGGTCAGCAAGACCCGCAAGGGTGTCCAGTGCCAGCGCTGGTCCGCTGAGACGCCGCACAAGCCGCAGTTCACGTTTACCTCCGAACCGCATGCACAACTGGAGGAGAACTTCTGCCGGAACCCAGATGGGGATAGCCATGGGCCCTGGTGCTACACGATGGACCCAAGGACCCCATTCGACTACTGTGCCCTGCGACGCTGCGCTGATGACCAGCCGCCATCAATCCTGGACCCCCCAGACCAGGTGCAGTTTGAGAAGTGTGGCAAGAGGGTGGATCGGCTGGATCAGCGGCGTTCCAAGCTGCGCGTGGTTGGGGGCCATCCGGGCAACTCACCCTGGACAGTCAGCTTGCGGAATCGGCAGGGCCAGCATTTCTGCGGGGGGTCTCTAGTGAAGGAGCAGTGGATACTGACTGCCCGGCAGTGCTTCTCCTCCTGCCATATGCCTCTCACGGGCTATGAGGTATGGTTGGGCACCCTGTTCCAGAACCCACAGCATGGAGAGCCAAGCCTACAGCGGGTCCCAGTAGCCAAGATGGTGTGTGGGCCCTCAGGCTCCCAGCTTGTCCTGCTCAAGCTGGAGAGATCTGTGACCCTGAACCAGCGTGTGGCCCTGATCTGCCTGCCCCCTGAATGGTATGTGGTGCCTCCAGGGACCAAGTGTGAGGGTGACTACGGGGGCCCACTTGCCTGCTTTACCCACAACTGCTGGGTCCTGGAAGGAATTATAATCCCCAACCGAGTATGCGCAAGGTCCCGCTGGCCAGCTGTCTTCACGCGTGTCTCTGTGTTTGTGGACTGGATTCACAAGGTCATGAGACTGGGTTAGGCCCAGCCTTGATGCCATATGCCTTGGGGAGGNOV36a, CG54479-06SEQ ID NO: 446670 aaMW at 76160.6kDProtein SequenceMGLWWVTVQPPARRNGWLPLLLLLTQCLGVPGQRSPLWDFQVLRGTELQHLLHAVVPGPWQEDVADAEECAGRCGPLMDCRAFHYNVSSHGCQLLPWTQHSPHTRLRRSGRCDLFQKKDYVRTCIMNNGVGYRGTMATTVGGLPCQAWSHKFPMDHKYTPTLRNGLEENFCRNPDGDPGGPWCYTTDPAVRFQSCGIKSCREAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATTVSCFRGKGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLRPGMRAAFCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQCQRWSAETPHKPQFTFTSEPHAQLEENFCRNPDGDSHGPWCYTMDPRTPFDYCALRRCADDQPPSILDPPDQVQFEKCGKRVDRLDQRRSKLRVVGGHPGNSPWTVSLRNRQGQHFCGGSLVKEQWILTARQCFSSCHMPLTGYEVWLGTLFQNPQHGEPSLQRVPVAKMVCGPSGSQLVLLKLERSVTLNQRVALICLPPEWYVVPPGTKCEGDYGGPLACFTHMCWVLEGIIIPNRVCARSRWPAVFTRVSVFVDWIHKVMRLGNOV36b, CG54479-05SEQ ID NO: 4471698 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1696ATGACTTCTAGGTGCTCCGGGGCACAGAGCTACCTACAAGCGGTGGTGCCCGGGCCTTGGCAGGAGGATGTGGCAGATGCTGAAGAGTGTGCTGGTCGCTGTGGGCCCTTAATGGACTGCGCGTTCCACTACAATGTGAGCAGCCATGGTTGCCAACTGCTGCCATGGACTCAACACTCACCCCACACGAGGCTGCGGCATTCTGGGCGCTGTGACCTCTTCCAGGAGAAAGACTACATACGGACCTGCATCATGAACAATGGGGTTGGGTACCGGGGCACCATGGCCACGACCGTGGGTGGCCTGTCCTGCCAGGCTTGGAGCCACAAGTTCCCGAACGATCACCAGTACATGCCCACGCTCCGGAATGGCCTGGAAGAGAACTTCTGCCGTAACCCTGATGGCGACCCCGGAGGTCCTTGGTGCCACACAACAGACCCTGCCGTGCGCTTCCAGAGCTGCGGCATCAAATCCTGCCGGGTGGCCGCGTGTGTCTGGTGCAATGGCGAGGAATACCGCGGCGCGGTAGACCGCACCGAGTCAGGGCGCGAGTGCCAGCGCTGGGATCTTCAGCACCCGCACCAGCACCCCTTCGAGCCGGGCAAGTTCCTCGACCAAGGTCTGGACGACAACTATTGCCGGAATCCTGACGGCTCCGAGCGGCCATGGTGCTACACTACGGATCCGCAGATCGAGCGAGAATTCTGTGACCTCCCCCGCTGCGGTTCCGAGGCACAGCCCCGCCAAGAGGCCACAAGTGTCAGCTGCTTCCGCGGGAAGGGTGAGGGCTACCGGGGCACAGCCAATACCACCACCGCGGGCGTACCTTGCCAGCGTTGGGACGCGCAAATCCCGCATCAGCACCGATTTACGCCAGAAAAATACGCGTGCAAGGACCTTCGGGAGAACTTCTGCCGGAACCCCGACGGCTCAGAGGCGCCCTGGTGCTTCACACTGCGGCCCGGCATGCGCGTGGGCTTTTGCTACCAGATCCGGCGTTGTACAGACGACGTGCGGCCCCAGGACTGCTACCACGGCGCGGGGGAGCAGTACCGCGGCACGGTCAGCAAGACCCGCAAGGGTGTCCAGTGCCAGCGCGGGTCCGCTGAGACGCCGCACAAGCCGCAGTTCACGTTTACCTCCGAACCGCATGCACAACTGGAGGAGAACTTCTGCCAGGACCCAGATGGGGATAGCCATGGGCCCTGGTGCTACACGATGGACCCAAGGACCCCATTCGACTACTGTGCCCTGCGACGCTGCGCTGATGACCAGCCGCCATCAATCCTGGACCCCCCCGACCAGGTGCAGTTTGAGAAGTGTGGCAAGAGGGTGGATCGGCTGGATCAGCGTTGTTCCAAGCTGCGCGTGGCTGGGGGCCATCCGGGCAACTCACCCTGGACAGTCAGCTTGCGGAATAGGCAGGGCCAGCATTTCTGCGGGGGGTCTCTAGTGAAGGAGCAGTGGATACTGACTGCCCGGCAGTGCTTCTCCTCCAGCCATATGCCTCTCACGGGCTATGAGGTATGGTTGGGCACCCTGTTCCAGAACCCACAACATGGAGAGCCAGGCCTACAGCGGGTCCCAGTAGCCAAGATGCTGTGTGGGCCCTCAGGCTCTCAGCTTGTCCTGCTCAAGCTGGAGAGGTCTGTGACCCTGAACCAGCGTGTGGCCCTGATCTGCCTGCCGCCTGAATGANOV36b, CG54479-05SEQ ID NO: 448565 aaMW at 63751.8kDProtein SequenceMTSRCSGAQSYLQAVVPGPWQEDVADAEECAGRCGPLMDCAFHYNVSSHGCQLLPWTQHSPHTRLRHSGRCDLFQEKDYIRTCIMNNGVGYRGTMATTVGGLSCQAWSHKFPNDHQYMPTLRNGLEENFCRNPDGDPGGPWCHTTDPAVRFQSCGIKSCRVAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATSVSCFRGKGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLRPGMRVGFCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQCQRGSABTPHKPQFTFTSEPHAQLEENFCQDPDGDSHGPWCYTNDPRTPFDYCALRRCADDQPPSILDPPDQVQFEKCGKRVDRLDQRCSKLRVAGGHPGNSPWTVSLRNRQGQHFCGGSLVKEQWILTARQCFSSSHMPLTGYEVWLGTLFQNPQHGEPGLQRVPVAKMLCGPSGSQLVLLKLERSVTLNQRVALICLPPENOV36c, CG54479-01SEQ ID NO: 4492200 bpDNA SequenceORF Start: ATG at 21ORF Stop: TAG at 2157TGCAGCCTCCAGCCAGAAGGATGGGGTGGCTCCCACTCCTGCTGCTTCTGACTCAATGCTTAGGGGTCCCTGGGCAGCGCTCGCCATTGAATGACTTCGAGGTGCTCCGGGGCACAGAGCTACAGCGGCTGCTACAAGCGGTGGTGCCCGGGCCTTGGCAGGAGGATGTGGCAGATGCTGAAGAGTGTGCTGGTCGCTGTGGGCCCTTAATGGACTGCCGGGCGTTCCACTACAATGTGAGCAGCCATGGTTGCCAACTGCTGCCATGGACTCAACACTCACCCCACACGAGGCTGCGGCATTCTGGGCGCTGTGACCTCTTCCAGGAGAAAGACTACATACGGACCTGCATCATGAACAATGGGGTTGGGTACCGGGGCACCATGGCCACGACCGTGGGTGGCCTGTCCTGCCAGGCTTGGAGCCACAAGTTCCCGAACGATCACAGGTACATGCCCACGCTCCGGAATGGCCTGGAAGAGAACTTCTGCCGTAACCCTGATGGCGACCCCGGAGGTCCTTGGTGCCACACAACAGACCCTGCCGTGCGCTTCCAGAGCTGCGGCATCAAATCCTGCCGGTCTGCCGCGTGTGTCTGGTGCAATGGCGAGGAATACCGCGGCGCGGTAGACCGCACCGAGTCAGGGCGCGAGTGCCAGCGCTGGGATCTTCAGCACCCGCACCAGCACCCCTTCGAGCCGGGCAAGTACCCCGACCAAGGTCTGGACGACAACTATTGCCGGAATCCTGACGGCTCCGAGCGGCCATGGTGCTACACTACGGATCCGCAGATCGAGCGAGAATTCTGTGACCTCCCCCGCTGCGGTTCCGAGGCACAGCCCCGCCAAGAGGCCACAAGTGTCAGCTGCTTCCGCGGGAAGGGTGAGGGCTACCGGGGCACAGCCAATACCACCACCGCGGGCGTACCTTGCCAGCGTTGGGACGCGCAAATCCCGCATCAGCACCGATTTACGCCAGAAAAATACGCGTGCAAGGACCTTCGGGAGAACTTCTGCCGGAACCCCGACGGCTCAGAGGCGCCCTGGTGCTTCACACTGCGGCCCGGCATGCGCGTGGGCTTTTGCTACCAGATCCGGCGTTGTACAGACGACGTGCGGCCCCAGGGTTGCTACCACGGCGCGGGGGAGCAGTACCGCGGCACGGTCAGCAAGACCCGCAAGGGTGTCCAGTGCCAGCGCGCGTCCGCTGAGACGCCGCACAAGCCGCAGTTTACCTTTACCTCCGAACCGCATGCACAACTGGAGGAGAACTTCTGCCGCGACCCAGATGGGGATAGCTATGGGCCCTGGTGCTACACGATGGACCCAAGGACCCCATTCGACTACTGTGCCCTGCGACGCTGCGCTGATGACCAGCCGCCATCAATCCTGGACCCCCCCGACCAGGTGCAGTTTGAGAAGTGTGGCAAGAGGGTGGATCGGCTGGATCAGCGTTGTTCCAAGCTGCGCGTGGCTGGGGGCCATCCGGGCAACTCACCCTGGACAGTCAGCTTGCGGAATAGGCAGGGCCAGCATTTCTGCGGGGGGTCTCTAGTGAAGGAGCAGTGGATACTGACTGCCCGGCAGTGCTTCTCCTCCAGCCATATGCCTCTCACGGGCTATGAGGTATGGTTGGGCACCCTGTTCCAGAACCCACAACATGGAGAGCCAGGCCTACAGCGGGTCCCAGTAGCCAAGATGCTGTGTGGGCCCTCAGGCTCTCAGCTTGTCCTGCTCAAGCTGGAGAGATCTGTGACCCTGAACCAGCGTGTGGCCCTGATCTGCCTGCCGCCTGAATGGTATGTGGTGCCTCCAGGGACCAAGTGTGAGATTGCAGGCCGGGGTGAGACCAAAGGTACGGGTAATGACACAGTCCTAAATGTGGCCTTGCTGAATGTCATCTCCAACCAGGAGTGTAACATCAAGCACCGAGGACATGTGCGGGAGAGCGAGATGTGCACTGAGGGACTGTTGGCCCCTGTGGGGGCCTGTGAGGGGGGTGACTACGGGGGCCCACTTGCCTGCTTTACCCACAACTGCTGGGTCCTGGAAGGAATTAGAATCCCCAACCGAGTATGCGCAAGGTCGCGCTGGCCAGCCGTCTTCACACGTGTCTCTGTGTTTGTGGACTGGATTCACAAGGTCATGAGACTGGGTTAGGCCCAGCCTTGACGCCATATGCTTTGGGGAGGACAAAACTTNOV36c, CG54479-01SEQ ID NO: 450712 aaMW at 80097.8kDProtein SequenceMGWLPLLLLLTQCLGVPGQRSPLNDFEVLRGTELQRLLQAVVPGPWQEDVADAEECAGRCGPLMDCRAFHYNVSSHGCQLLPWTQHSPHTRLRHSGRCDLFQEKDYIRTCIMNNGVGYRGTMATTVGGLSCQAWSHKFPNDHRYMPTLRNGLEENFCRNPDGDPGGPWCHTTDPAVRFQSCGIKSCRSAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFEPGKYPDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATSVSCFRGKGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLRPGMRVGFCYQIRRCTDDVRPQGCYHGAGEQYRGTVSKTRKGVQCQRASAETPHKPQFTFTSEPHAQLEENFCRDPDGDSYGPWCYTMDPRTPFDYCALRRCADDQPPSILDPPDQVQFEKCGKRVDRLDQRCSKLRVAGGHPGNSPWTVSLRNRQGQHFCGGSLVKEQWILTARQCFSSSHMPLTGYEVWLGTLFQNPQHGEPGLQRVPVAKMLCGPSGSQLVLLKLERSVTLNQRVALICLPPEWYVVPPGTKCEIAGRGETKGTGNDTVLNVALLNVISNQECNIKHRGHVRESEMCTEGLLAPVGACEGGDYGGPLACFTHNCWVLEGIRIPNRVCARSRWPAVFTRVSVFVDWIHKVMRLGNOV36d, CG54479-02SEQ ID NO: 4511710 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1705ATGACTTCCAGGTGCTCCGGGGCACAGAGCTACCTGCTACATGCGGTGGTGCCTGGGCCTTGGCAGGAGGATGTGGCAGATGCTGAAGAGTGTGCTGGTCGCTGTGGGCCCTTAACGGACTGCTGGGCCTTCCACTACAATGTGAGCAGCCATGGTTGCCAACTGCTGCCATGGACTCAACACTCGCCCCACTCAAGGCTGTGGCATTCTGGGCGCTGTGACCTCTTCCAGAAGAAAGACTACATACGGACCTGCATCATGAACAATGGGGTTGGGTACCGGGGCACCATGGCCACGACCGTGGGTGGCCTGTCCTGCCAGGCTTGGAGCCACAAGTTCCCGAATGATCACAAGTACATGCCCACGCTCCGGAATGGCCTGGAAGAGAACTTCTGCCATAACCCTGATGGCGACCCCGGAGGTCCTTGGTGCCACACAACAGACCCTGCCGTGCGCTTCCAGAGCTGCGGCATCAAATCCTGCCGGGTGGCCGCGTGTGTCTGGTGCAATGGCGAGGAATACCGCGGCGCGGTAGACCGCACCGAGTCAGGGCGCGAGTGCCAGCGCTGGGATCTTCAGCACCCGCACCAGCACCCCTTCGAGCCGGGCAAGTACCTCGACCAAGGTCTGGACGACAACTATTGCCGGAATCCTGACGGCTCCGAGCGGCCATGGTGCTACACTACGGATCCGCAGATCGAGCGAGAATTCTGTGACCTCCCCCGCTGCGGTTCCGAGGCACAGCCCCGCCAAGAGGCCACAAGTGTCAGCTGCTTCCGCGGGAAGGGTGAGGGCTACCGGGGCACAGCCAATACCACCACCGCGGGCGTACCTTGCCAGCGTTGGGACGCGCAAATCCCGCATCAGCACCGATTTACGCCAGAAAAATACGCGTGCAAGGACCTTCGGGAGAACTTCTGCCGGAACCCCGACGGCTCAGAGGCGCCCTGGTGCTTCACACTGCGGCCCGGCATGCGCGTGGGCTTTTGCTACCAGATCCGGCGTTGTACAGACGACGTGCGGCCCCAGGACTGCTACCACGGCGCGGGGGAGCAGTACCGCGGCACGGTCAGCAAGACCCGCAAGGGTGTCCAGTGCCAGCGCGCGTCCGCTGAGACGCCGCACAAGCCGCAGTTCACGTTTACCTCCGAACCGCATGCACAACTGGAGGAGAACTTCTGCCAGGACCCAGATGGGGATAGCCATGGGCCCTGGTGCTACACGATGGACCCAAGGACCCCATTCGACTACTGTGCCCTGCGACGCTGCGCTGATGACCAGCCGCCATCAATCCTGGACCCCCCCACAGACCAGGTGCAGTTTGAGAAGTGTGGCAAGAGGGTGGATCGGCTGGATCAGCGTCGTTCCAAGCTGCGCGTGGCTGGGGGCCATCCGGGCAACTCACCCTGGACAGTCAGCTTGGGGAATCGGAGGCAGGGCCAGCATTTCTGCGGGGGGTCTCTAGTGAAGGAGCAGTGGATACTGACTGCCCGGCAGTGCTTCTCCTCCCATATGCCTCTCACGGGCTATGAGGTATGGTTGGGCACCCTGTTCCAGAACCCACAACATGGAGAGCCAGGCCTACAGCGGGTCCCAGTAGCCAAGATGCTGTGTGGGCCCTCAGGCTCCCAGCTTGTCCTGCTCAAGCTGGAGAGATCTGTGACCCTGAACCAGCGTGTGGCCCTGATCTGCCTGCCGCCTGAATGATATNOV36d, CG54479-02SEQ ID NO: 452568 aaMW at 64180.3kDProtein SequenceMTSRCSGAQSYLLHAVVPGPWQEDVADAEECAGRCGPLTDCWAFHYNVSSHGCQLLPWTQHSPHSRLWHSGRCDLFQKKDYIRTCIMNNGVGYRGTMATTVGGLSCQAWSHKFPNDHKYMPTLRNGLEENFCHNPDGDPGGPWCHTTDPAVRFQSCGIKSCRVAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFEPGKYLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATSVSCFRGKGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLRPGMRVGFCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQCQRASAETPHKPQFTFTSEPHAQLEENFCQDPDGDSHGPWCYTMDPRTPFDYCALRRCADDQPPSILDPPTDQVQFEKCGKRVDRLDQRRSKLRVAGGHPGWSPWTVSLGNRRQGQHFCGGSLVKEQWILTARQCFSSHMPLTGYEVWLGTLFQNPOHGEPGLQRVPVAKMLCGPSGSQLVLLKLERSVTLNQRVALICLPPENOV36e, CG54479-03SEQ ID NO: 4531011 bpDNA SequenceORF Start: at 7ORF Stop: at 1006AAGCTTTGCATCATGAACAATGGGGTTGGGTACCGGGGCACCATGGCCACGACCGTGGGTGGCCTGCCCTGCCAGGCTTGGAGCCACAAGTTCCCAAATGATCACAAGTACACGCCCACTCTCCGGAATGGCCTGGAAGAGAACTTCTGCCGTAACCCTGATGGCGACCCCGGAGGTCCTTGGTGCTACACAACAGACCCTGCTGTGCGCTTCCAGAGCTGCGGCATCGAATCCTGCCGGGAGGCCGCGTGTGTCTGGTGCAATGGCGAGGAATACCGCGGCGCGGTAGACCGCACGGAGTCAGGGCGCGAGTGCCAGCGCTGGGATCTTCAGCACCCGCACCAGCACCCCTTCGAGCCGGGCAAGTTCCTCGACCAAGGTCTGGACGACAACTATTGCCGGAATCCTGACGGCTCCGAGCGGCCATGGTGCTACACTACGGATCCGCAGATCGAGCGAGAGTTCTGTGACCTCCCCCGCTGCGGGTCCGAGGCACAGCCCCGCCAAGAGGCCACAACTGTCAGCTGCTTCCGCGGGAAGGGTGAGGGCTACCGGGGCACAGCCAATACCACCACTGCGGGCGTACCTTGCCAGCGTTGGGACGCGCAAATCCCTCATCAGCACCGATTTACGCCAGAAAAATACGCGTGCAAAGACCTTCGGGAGAACTTCTGCCGGAACCCCGACGGCTCAGAGGCGCCCTGGTGCTTCACACTGCGGCCCGGCATGCGCGCGGCCTTTTGCTACCAGATCCGGCGTTGTACAGACGACGTGCGGCCCCAGGGGGAGCAGTACCGCGGCACGGTCAGCAAGACCCGCAAGGGTGTCCAGTGCCAGCGCTGGTCCGCTGAGACGCCGCACAAGCCGCAGTTCACGTTTACCTCCGAACCGCATGCACAACTGGAGGAGAACTTCTGCCGGAACCCAGATGGGGATAGCCATGGGCCCTGGTGCTACACGATGGACCCAAGGACCCCATTCGACTACTGTGCCCTGCGACGCTGCCTCGAGNOV36e, CG54479-03SEQ ID NO: 454333 aaMW at 38129.9kDProtein SequenceCIMNNGVGYRGTMATTVGGLPCQAWSHKFPNDHKYTPTLRNGLEENFCRNPDGDPGGPWCYTTDPAVRFQSCGIESCREAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATTVSCFRGKGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLRPGMRAAFCYQIRRCTDDVRPQGEQYRGTVSKTRKGVQCQRWSAETPHKPQFTFTSEPHAQLEENFCRNPDGDSHGPWCYTMDPRTPFDYCALRRCNOV36f, GG54479-04SEQ ID NO: 4551881 bpDNA SequenceORF Start: ATG at 76ORF Stop: TGA at 1777ACACATTACTGACATGTATGCCCACCTGACCTGCACCCACTCATGCCCACTCTGCAGGGCAGCGCTCG+E,unc CCATTGAATGACTTCCAGGTGCTCCGGGGCACAGAGCTACCTGCTACATGCGGTGGTGCCTGGGCCTTGGCAGGAGGATGTGGCAGATGCTGAAGAGTGTGCTGGTCGCTGTGGGCCCTTAACGGACTGCTGGGCCTTCCACTACAATGTGAGCAGCCATGGTTGCCAACTGCTGCCATGGACTCAACACTCGCCCCACTCAAGGCTGTGGCATTCTGGGCGCTGTGACCTCTTCCAGAAGAAAGACTACATACGGACCTGCATCATGAACAATGGGGTTGGGTACCGGGGCACCATGGCCACGACCGTGGGTGGCCTGTCCTGCCAGGCTTGGAGCCACAAGTTCCCGAATGATCACAAGTACATGCCCACGCTCCGGAATGGCCTGGAAGAGAACTTCTGCCATAACCCTGATGGCGACCCCGGAGGTCCTTGGTGCCACACAACAGACCCTGCCGTGCGCTTCCAGAGCTGCGGCATCAAATCCTGCCGGGTGGCCGCGTGTGTCTGGTGCAATGGCGAGGAATACCGCGGCGCGGTAGACCGCACCGAGTCAGGGCGCGAGTGCCAGCGCTGGGATCTTCAGCACCCGCACCAGCACCCCTTCGAGCCGGGCAGGTTCCTCGACCAAGGTCTGGACGACAACTATTGCCGGAATCCTGACGGCTCCGAGCGGCCATGGTGCTACACTACGGATCCGCAGATCGAGCGAGAATTCTGTGACCTCCCCCGCTGCGGTTCCGAGGCACAGCCCCGCCAAGAGGCCACAAGTGTCAGCTGCTTCCGCGGGAAGGGTGAGGGCTACCGGGGCACAGCCAATACCACCACCGCGGGCGTACCTTGCCAGCGTTGGGACGCGCAAATCCCGCATCAGCACCGATTTACGCCAGAAAAATACGCGTGCAAGGACCTTCGGGAGAACTTCTGCCGGAACCTCGACGGCTCAGAGGCGCCCTGGTGCTTCACACTGCGGCCCGGCATGCGCGTGGGCTTTTGCTACCAGATCCGGCGTTGTACAGACGACGTGCGGCCCCAGGACTGCTACCACGGCGCGGGGGAGCAGTACCGCGGCACGGTCAGCAAGACCCGCAAGGGTGTCCAGTGCCAGCGCGCGTCCGCTGAGACGCCGCACAAGCCGCAGTTCACGTTTACCTCCGAACCGCATGCACAACTGGAGGAGAACTTCTGCCAGACCCCAGATGGGGATAGCCATGGGCCCTGGTGCTACACGATGGACCCAAGGACCCCATTCGACTACTGTGCCCTGCGACGCTGCGCTGATGACCAGCCGCCATCAATCCTGGACCCCCCCGACCAGGTGCAGTTTGAGAAGTGTGGCAAGAGGGTGGATCGGCTGGATCAGCGTCGTTCCAAGCTGCGCGTGGCTGGGGGCCATCCGGGCAACTCACCCTGGACAGTCAGCTTGGGGAATCGGCAGGGCCAGCATTTCTGCGGGGGGTCTCTAGTGAAGGAGCAGTGGATACTGACTGCCCGGCAGTGCTTCTCCTCCCAGCATATGCCTCTCACGGGCTATGAGGTATGGTTGGGCACCCTGTTCCAGAACCCACAACATGGAGAGCCAGGCCTACAGCGGGTCCCAGTAGCCAAGATGCTGTGTGGGCCCTCAGGCTCCCAGCTTGTCCTGCTCAAGCTGGAGAGGTCTGTGACCCTGAACCAGCGTGTGGCCCTGATCTGCCTGCCGCCTGAATGATATGTGGTGCCTCCAGGGACCAAGTGTGAGATTGCAGGCCGGGGTGAGACCAAAGGTAAGAGCATAGTGCACAGGACTGCTGGTGGCCAGGAGGCCCAGCCCNOV36f, CG54479-04SEQ ID NO: 456567 aaMW at 64065.2kDProtein SequenceMTSRCSGAQSYLLHAVVPGPWQEDVADAEECAGRCGPLTDCWAFHYNVSSHGCQLLPWTQHSPHSRLWHSGRCDLFQKKDYIRTCIMNNGVGYRGTMATTVGGLSCQAWSHKFPNDHKYMPTLRNGLEENFCHNPDGDPGGPWCHTTDPAVRFQSCGIKSCRVAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFEPGRFLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATSVSCFRGKGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNLDGSEAPWCFTLRPGMRVGFCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQCQRASAETPHKPQFTFTSEPHAQLEENFCQTPDGDSHGPWCYTMDPRTPFDYCALRRCADDQPPSILDPPDQVQFEKCGKRVDRLDQRRSKLRVAGGHPGNSPWTVSLGNRQGQHFCGGSLVKEQWILTARQCFSSQHMPLTGYEVWLGTLFQNPQHGEPGLQRVPVAKMLCGPSGSQLVLLKLERSVTLNQRVALICLPPE

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 36B.

TABLE 36BComparison of the NOV36 protein sequences.NOV36a MGLWWVTVQPPARRMGWLPLLLLLTQCLGVPGQRSPLNDFQVLRGTELQHLLHAVVPGPWNOV36b ----------------------MTSRCSGAQSY------------------LQAVVPGPWNOV36c --------------MGWLPLLLLLTQCLGVPGQRSPLWDFEVLRGTELQRLLQAVVPGPWNOV36d ----------------------MTSRCSGAQSYL-----------------LHAVVPGPWNOV36e ------------------------------------------------------------NOV36f ----------------------MTSRCSGAQSYL-----------------LHAVVPGPWNOV36a QEDVADAEECAGRCGPLMDCRAFHYNVSSHGCQLLPWTQHSPHTRLRRSGRCDLFQKKDYNOV36b QEDVADAEECAGRCGPLMDC-AFHYNVSSHGCQLLPWTQHSPHTRLRHSGRCDLFQEKDYNOV36c QEDVADAEECAGRCGPLMDCRAFHYNVSSHGCQLLPWTQHSPHTRLRHSGRCDLFQEKDYNOV36d QEDVADAEECAGRCGPLTDCWAFHYNVSSHGCQLLPWTQHSPHSRLWHSGRCDLFQKKDYNOV36e ------------------------------------------------------------NOV36f QEDVADAEECAGRCGPLTDCWAFHYNVSSHGCQLLPWTQHSPHSRLWHSGRCDLFQKKDYNOV36a VRTCIMNNGVGYRGTMATTVGGLPCQAWSHKFPNDHKYTPTLRNGLEENFCRNPDGDPGGNOV36b IRTCIMNNGVGYRGTMATTVGGLSCQAWSHKFPNDHQYMPTLRNGLEENFCRNPDGDPGGNOV36c IRTCIMNNGVGYRGTMATTVGGLSCQAWSHKFPNDHRYMPTLRNGLEENFCRNPDGDPGGNOV36d IRTCIMNNGVGYRGTMATTVGGLSCQAWSHKFPNDHKYMPTLRNGLEENFCHNPDGDPGGNOV36e ---CIMNNGVGYRGTMATTVGGLPCQAWSHKFPNDHKYTPTLRNGLEENFCRNPDGDPGGNOV36f IRTCIMNNGVGYRGTMATTVGGLSCQAWSHKFPNDHKYMPTLRNGLEENFCHNPDGDPGGNOV36a PWCYTTDPAVRFQSCGIKSCREAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFENOV36b PWCHTTDPAVRFQSCGIKSCRVAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFENOV36c PWCHTTDPAVRFQSCGIKSCRSAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFENOV36d PWCHTTDPAVRFQSCGIKSCRVAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFENOV36e PWCYTTDPAVRFQSCGIESCREAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFENOV36f PWCHTTDPAVRFQSCGIKSCRVAACVWCNGEEYRGAVDRTESGRECQRWDLQHPHQHPFENOV36a PGKFLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATTVSCFRGNOV36b PGKFLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATSVSCFRGNOV36c PGKYPDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATSVSCFRGNOV36d PGKYLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATSVSCFRGNOV36e PGKFLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATTVSCFRGNOV36f PGRFLDQGLDDNYCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATSVSCFRGNOV36a KGEGYRGTANTTTAGVPCQRWDAQIPHQRRFTPEKYACKDLRENFCRNPDGSEAPWCFTLNOV36b KGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLNOV36c KGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLNOV36d KGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLNOV36e KGEGYRGTA1TTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAPWCFTLNOV36f KGEGYRGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNLDGSEAPWCFTLNOV36a RPGMRAAFCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQCQRWSAETPHKPQFTFNOV36b RPGMRVGFCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQCQRGSABTPHKPQFTFNOV36c RPGMRVGFCYQIRRCTDDVRPQGCYHGAGEQYRGTVSKTRKGVQCQRASAETPHKPQFTFNOV36d RPGMRVGFCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQCQRASAETPHKPQFTFNOV36e RPGMRAAFCYQIRRCTDDVRPQ-----G-EQYRGTVSKTRKGVQCQRWSAETPHKPQFTFNOV36f RPGMRVGFCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQCQRASAETPHKPQFTFNOV36a TSEPHAQLEENFCRNPDGDSHGPWCYTMDPRTPFDYCALRRCADDQPPSILDPP-DQVQFNOV36b TSEPHAQLEENFCQDPDGDSHGPWCYTMDPRTPFDYCALRRCADDQPPSILDPP-DQVQFNOV36c TSEPHAQLEENFCRDPDGDSYGPWCYTMDPRTPFDYCALRRCADDQPPSILDPP-DQVQFNOV36d TSEPHAQLEENFCQDPDGDSHGPWCYTMDPRTPFDYCALRRCADDQPPSILDPPTDQVQFNOV36e TSEPHAQLEENFCRNPDGDSHGPWCYTMDPRTPFDYCALRRC------------------NOV36f TSEPHAQLEENFCQTPDGDSHGPWCYTMDPRTPFDYCALRRCADDQPPSILDPP-DQVQFNOV36a EKCGKRVDRLDQRRSKLRVVGGHPGNSPWTVSLRNR-QGQHFCGGSLVKEQWILTARQCFNOV36b EKCGKRVDRLDORCSKLRVAGGHPGNSPWTVSLRNR-QGQHFCGGSLVKEQWILTARQCFNOV36c EKCGKRVDRLDQRCSKLRVAGGHPGNSPWTVSLRNR-QGQHFCGGSLVKEQWILTARQCFNOV36d EKCGKRVDRLDQRRSKLRVAGGHPGNSPWTVSLGNRRQGQHFCGGSLVKEQWILTARQCFNOV36e ------------------------------------------------------------NOV36f EKCGKRVDRLDQRRSKLRVAGGHPGNSPWTVSLGNR-QGQHFCGGSLVKEQWILTARQCFNOV36a SSCHMPLTGYEVWLGTLFQNPQHGEPSLQRVPVAKMVCGPSGSQLVLLKLERSVTLNQRVNOV36b SSSHMPLTGYEVWLGTLFQNPQHGEPGLQRVPVAKMLCGPSGSQLVLLKLERSVTLNQRVNOV36c SSSHMPLTGYEVWLGTLFQNPQHGEPGLQRVPVAKMLCGPSGSQLVLLKLERSVTLNQRVNOV36d SS-HMPLTGYEVWLGTLFQNPQHGEPGLQRVPVAKMLCGPSGSQLVLLKLERSVTLNQRVNOV36e ------------------------------------------------------------NOV36f SSQHMPLTGYEVWLGTLFQNPQHGEPGLQRVPVAKMLCGPSGSQLVLLKLERSVTLNQRVNOV36a ALICLPPEWYVVPPGTKCEG----------------------------------------NOV36b ALICLPPE----------------------------------------------------NOV36c ALICLPPEWYVVPPGTKCEIAGRGETKGTGNDTVLNVALLNVISNQECNIKHRGHVRESENOV36d ALICLPPE----------------------------------------------------NOV36e ------------------------------------------------------------NOV36f ALICLPPE----------------------------------------------------NOV36a ----------------DYGGPLACFTHNCWVLEGIIIPNRVCARSRWPAVFTRVSVFVDWNOV36b ------------------------------------------------------------NOV36c MCTEGLLAPVGACEGGDYGGPLACFTHNCWVLEGIRIPNRVCARSRWPAVFTRVSVFVDWNOV36d ------------------------------------------------------------NOV36e ------------------------------------------------------------NOV36f ------------------------------------------------------------NOV36a IHKVMRLGNOV36b --------NOV36c IHKVMRLGNOV36d --------NOV36e --------NOV36f --------NOV36a (SEQ ID NO: 446)NOV36b (SEQ ID NO: 448)NOV36c (SEQ ID NO: 450)NOV36d (SEQ ID NO: 452)NOV36e (SEQ ID NO: 454)NOV36f (SEQ ID NO: 456)

Further analysis of the NOV36a protein yielded the following properties shown in Table 36C.

TABLE 36CProtein Sequence Properties NOV36aSignalP analysis:Cleavage site between residues 30 and 31PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 12; peak value 9.09PSG score: 4.69GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 6.16possible cleavage site: between 29 and 30>>> Seems to have a cleavable signal peptide (1 to 29)ALOM: Klein et al's method for TM region allocationInit position for calculation: 30Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 3.07 (at 623)ALOM score: 3.07 (number of TMSs: 0)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 14Charge difference: −3.0 C(0.0) − N(3.0)N >= C: N-terminal side will be insideMITDISC: discrimination of mitochondrial targeting seqR content:3Hyd Moment(75):1.11Hyd Moment(95):1.26G content:4D/E content:1S/T content:3Score: −4.52Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 44 QRS|PLNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: PHTRLRR (3) at 102bipartite: nonecontent of basic residues: 11.8%NLS Score: −0.22KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 55.5COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):66.7%: extracellular, including cell wall22.2%: mitochondrial11.1%: vacuolar>> prediction for CG54479-06 is exc (k = 9)

A search of the NOV36a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 36D.

TABLE 36DGeneseq Results for NOV36aNOV36aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAW14270Human growth factor L5/3 -15 . . . 670637/711 (89%)0.0Homo sapiens, 711 aa. 1 . . . 711641/711 (89%)[US5606029-A, 25-FEB-1997]AAR66602Human L5/3 tumour suppressor15 . . . 670637/711 (89%)0.0protein - Homo sapiens, 711 aa. 1 . . . 711641/711 (89%)[US5315000-A, 24-MAY-1994]AAY31157Human macrophage stimulating15 . . . 670639/716 (89%)0.0protein - Homo sapiens, 711 aa. 1 . . . 711642/716 (89%)[US5948892-A, 07-SEP-1999]ABB82662Human hepatocyte growth factor-15 . . . 670636/711 (89%)0.0like protein (HGFL) - Homo 1 . . . 711640/711 (89%)sapiens, 711 aa. [WO200283074-A2, 24-OCT-2002]AAB84520Amino acid sequence of human15 . . . 670638/716 (89%)0.0macrophage stimulating protein 1 . . . 710641/716 (89%)(MSP) - Homo sapiens, 710 aa.[WO200144294-A2, 21-JUN-2001]

In a BLAST search of public sequence databases, the NOV36a protein was found to have homology to the proteins shown in the BLASTP data in Table 36E.

TABLE 36EPublic BLASTP Results for NOV36aNOV36aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueAAH48330Macrophage stimulating 115 . . . 670637/711 (89%)0.0(Hepatocyte growth factor-like) - 1 . . . 711641/711 (89%)Homo sapiens (Human), 711 aa.P26927Hepatocyte growth factor-like15 . . . 670636/711 (89%)0.0protein precursor (Macrophage 1 . . . 711640/711 (89%)stimulatory protein) (MSP)(Macrophage stimulating protein) -Homo sapiens (Human), 711 aa.CAD48698Sequence 61 from Patent15 . . . 670612/712 (85%)0.0WO0229058 - Homo sapiens 1 . . . 712626/712 (86%)(Human), 712 aa.CAD48697Sequence 59 from Patent15 . . . 670611/712 (85%)0.0WO0229058 - Homo sapiens 1 . . . 712625/712 (86%)(Human), 712 aa.Q13208Hepatocyte growth factor-like50 . . . 606533/557 (95%)0.0protein homolog - Homo sapiens11 . . . 567543/557 (96%)(Human), 567 aa.

PFam analysis indicates that the NOV36a protein contains the domains shown in the Table 36F.

TABLE 36FDomain Analysis of NOV36aNOV36aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect ValuePAN 32 . . . 120 25/110 (23%)1.3e−16 68/110 (62%)kringle124 . . . 200 46/85 (54%)3.3e−45 70/85 (82%)kringle205 . . . 282 48/85 (56%) 2e−48 73/85 (86%)kringle297 . . . 375 44/85 (52%)3.6e−49 73/85 (86%)kringle384 . . . 462 44/85 (52%)1.5e−50 76/85 (89%)trypsin498 . . . 663 73/263 (28%)7.3e−21126/263 (48%)

Example 37

The NOV37 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 37A.

TABLE 37ANOV37 Sequence AnalysisNOV37a, CG54539-02SEQ ID NO: 4571567 bpDNA SequenceORF Start: ATG at 2ORF Stop: TGA at 1523TATGGGGTGTTGGGGTCGGAACCGGGGCCGGCTGCTGTGCATGCTGGCGCTGACCTTCATGTTCATGGTGCTGGAGGTGGTGGTGAGCCGGGTGACCTCGTCGCTGGCGATGCTCTCCGACTCCTTCCACATGCTGTCGGACGTGCTGGCGCTGGTGGTGGCGCTGGTGGCCGAGCGCTTCGCCCGGCGGACCCACGCCACCCAGAAGAACACGTTCGGCTGGATCCGAGCCGAGGTAATGGGGGCTCTGGTGAACGCCATCTTCCTGACTGGCCTCTGTTTCGCCATCCTGCTGGAGGCCATCGAGCGCTTCATCGAGCCGCACGAGATGCAGCAGCCGCTGGTGGTCCTTGGGGTCGGCGTGGCCGGGCTGCTGGTCAACGTGCTGGGGCTCTGCCTCTTCCACCATCACAGCGGCTTCAGCCAGGACTCCGGCCACGGCCACTCGCACGGGGGTCACGGCTACGGCCACGGCCTCCCCAAGGGGCCTCGCGTTAAGAGCACCCGCCCCGGGAGCAGCGACATCAACGTGGCCCCGGGCGAGCAGGGTCCCGACCAGGAGGAGACCAACACCCTGGTGGCCAATACCAGCCAACTCAACGGGCTGAAATTGGACCCCGCAGACCCAGAAAACCCCAGAAGTGGTGATACAGTGGAAGTACAAGTGAATGGAAATCTTGTCAGAGAACCTGACCATATGGAACTGGAAGAAGATAGGGCTGGACAACTTAACATGCGTGGAGTTTTTCTGCATGTCCTTGGAGATGCCTTGGGTTCAGTGATTGTAGTAGTAAATGCCTTAGTCTTTTACTTTTCTTGGAAAGGTTGTTCTGAAGGGGATTTTTGTGTGAATCCATGTTTCCCTGACCCCTGCAAAGCATTTGTAGAAATAATTAATAGTACTCATGCATCAGTTTATGAGGCTGGTCCTTGCTGGGTGCTATATTTAGATCCAACTCTTTGTGTTGTAATGGTTTGTATACTTCTTTACACAACCTATCCATTACTTAAGGAATCTGCTCTTATTCTTCTACAAACTGTTCCTAAACAAATTGATATCAGAAATTTGATAAAAGAACTTCGAAATGTTGAAGGAGTTGAGGAAGTTCATGAATTACATGTTTGGCAACTTGCTGGAAGCAGAATCATTGCCACTGCTCACATAAAATGTGAAGATCCAACATCATACATGGAGGTGGCTAAAACCATTAAAGACGTTTTTCATAATCACGGAATTCACGCTACTACCATTCAGCCTGAATTTGCTAGTGTAGGCTCTAAATCAAGTGTAGTTCCGTGTGAACTTGCCTGCAGAACCCAGTGTGCTTTGAAGCAATGTTGTGGGACACTACCACAAGCCCCTTCTGGAAAGGATGCAGAAAAGACCCCAGCAGTTAGCATTTCTTGTTTAGAACTTAGTAACAATCTAGAGAAGAAGCCCAGGAGGACTAAAGCTGAAAACATCCCTGCTGTTGTGATAGAGATTAAAAACATGCCAAACAAACAACCTGAATCATCTTTGTGAGTCTTGAAAAAGATGTGATATTTGACTTTTGCTTTAAACTGCNOV37a, CG54539-02SEQ ID NO: 458507 aaMW at 55325.3kDProtein SequenceMGCWGRNRGRLLCMLALTFMFMVLEVVVSRVTSSLAMLSDSFHMLSDVLALVVALVAERFARRTHATQKNTFGWIRAEVMGALVNAIFLTGLCFAILLEAIERFIEPHEMQQPLVVLGVGVAGLLVNVLGLCLFHHHSGFSQDSGHGHSHGGHGYGHGLPKGPRVKSTRPGSSDINVAPGEQGPDQEETNTLVANTSNSNGLKLDPADPENPRSGDTVEVQVNGNLVREPDHMELEEDRAGQLNMRGVFLHVLGDALGSVIVVVNALVFYFSWKGCSEGDFCVNPCFPDPCKAFVEIINSTHASVYEAGPCWVLYLDPTLCVVMVCILLYTTYPLLKESALILLQTVPKQIDIRNLIKELRNVEGVEEVHELHVWQLAGSRIIATAHIKCEDPTSYMEVAKTIKDVFHNHGIHATTIQPEFASVGSKSSVVPCELACRTQCALKQCCGTLPQAPSGKDAEKTPAVSISCLELSNNLEKKPRRTKAENIPAVVIEIKNMPNKQPESSLNOV37b, CG54539-01SEQ ID NO: 4591665 bpDNA SequenceORF Start: ATG at 77ORF Stop: TGA at 1598CGACCCTCCGCGTCCCGCCAACGCCGCCGCTGCACCAGTCTCCGGGCCGGGCTCGGCGGGCCCCGCAGCCGCAGCCATGGGGTGTTGGGGTCGGAACCGGGGCCGGCTGCTGTGCATGCTGGCGCTGACCTTCATGTTCATGGTGCTGGAGGTGGTGGTGAGCCGGGTGACCTCGTCGCTGGCGATGCTCTCCGACTCCTTCCACATGCTGTCGGACGTGCTGGCGCTGGTGGTGGCGCTGGTGGCCGAGCGCTTCGCCCGGCGGACCCACGCCACCCAGAAGAACACGTTCGGCTGGATCCGAGCCGAGGTAATGGGGGCTCTGGTGAACGCCATCTTCCTGACTGGCCTCTGTTTCGCCATCCTGCTGGAGGCCATCGAGCGCTTCATCGAGCCGCACGAGATGCAGCAGCCGCTGGTGGTCCTTGGGGTCGGCGTGGCCGGGCTGCTGGTCAACGTGCTGGGGCTCTGCCTCTTCCACCATCACAGCGGCTTCAGCCAGGACTCCGGCCACGGCCACTCGCACGGGGGTCACGGCCACGGCCACGGCCTCCCCAAGGGGCCTCGCGTTAAGAGCACCCGCCCCGGGAGCAGCGACATCAACGTGGCCCCGGGCGAGCAGGGTCCCGACCAGGAGGAGACCAACACCCTGGTGGCCAATACCAGCAACTCCAACGGGCTGAAATTGGACCCCGCGGACCCAGAAAACCCCAGAAGTGGTGATACAGTGGAAGTACAAGTGAATGGAAATCTTGTCAGAGAACCTGACCATATGGAACTGGAAGAAGATAGGGCTGGACAACTTAACATGCGTGGAGTTTTTCTGCATGTCCTTGGAGATGCCTTGGGTTCAGTGATTGTAGTAGTAAATGCCTTAGTCTTTTACTTTTCTTGGAAAGGTTGTTCTGAAGGGGATTTTTGTGTGAATCCATGTTTCCCTGACCCCTGCAAAGCATTTGTAGAAATAATTAATAGTACTCATGCATCAGTTTATGAGGCTGGTCCTTGCTGGGTGCTATATTTAGATCCAACTCTTTGTGTTGTAATGGTTTGTATACTTCTTTACACAACCTATCCATTACTTAAGGAATCTGCTCTTATTCTTCTACAAACTGTTCCTAAACAAATTGATATCAGAAATTTGATAAAAGAACTTCGAAATGTTGAAGGAGTTGAGGAAGTTCATGAATTACATGTTTGGCAACTTGCTGGAAGCAGAATCATTGCCACTGCTCACATAAAATGTGAAGATCCAACATCATACATGGAGGTGGCTAAAACCATTAAAGACGTTTTTCATAATCACGGAATTCACGCTACTACCATTCAGCCTGAATTTGCTAGTGTAGGCTCTAAATCAAGTGTAGTTCCGTGTGAACTTGCCTGCAGAACCCAGTGTGCTTTGAAGCAATGTTGTGGGACACTACCACAAGCCCCTTCTGGAAAGGATGCAGAAAAGACCCCAGCAGTTAGCATTTCTTGTTTAGAACTTAGTAACAATCTAGAGAAGAAGCCCAGGAGGACTAAAGCTGAAAACATCCCTGCTGTTGTGATAGAGATTAAAAACATGCCAAACAAACAACCTGAATCATCTTTGTGAGTCTTGAAAAAGATGTGATATTTGACTTTTGCTTTAAACTGCAAGAGGAAAAAGACTCCACTGAANOV37b, CG54539-01SEQ ID NO: 460507 aaMW at 55299.3kDProtein SequenceMGCWGRNRGRLLCMLALTFMFMVLEVVVSRVTSSLAMLSDSFHMLSDVLALVVALVAERFARRTHATQKNTFGWIRAEVMGALVNAIFLTGLCFAILLEAIERFIEPHEMQQPLVVLGVGVAGLLVNVLGLCLFHHHSGFSQDSGHGHSHGGHGHGHGLPKGPRVKSTRPGSSDINVAPGEQGPDQEETNTLVANTSNSNGLKLDPADPENPRSGDTVEVQVNGNLVREPDHMELEEDRAGQLNMRGVFLHVLGDALGSVIVVVNALVFYFSWKGCSEGDFCVNPCFPDPCKAFVEIINSTHASVYEAGPCWVLYLDPTLCVVMVCILLYTTYPLLKESALILLQTVPKQIDIRNLIKELRNVEGVEEVHELHVWQLAGSRIIATAHIKCEDPTSYMEVAKTIKDVFHNHGIHATTIQPEFASVGSKSSVVPCELACRTQCALKQCCGTLPQAPSGKDAEKTPAVSISCLELSNNLEKKPRRTKAENIPAVVIEIKNMPNKQPESSLNOV37c, SNP13382438 ofSEQ ID NO: 4611567 bpCG54539-02, DNA SequenceORF Start: ATG at 2ORF Stop: TGA at 1523SNP Pos: 464SNP Change: T to CTATGGGGTGTTGGGGTCGGAACCGGGGCCGGCTGCTGTGCATGCTGGCGCTGACCTTCATGTTCATGGTGCTGGAGGTGGTGGTGAGCCGGGTGACCTCGTCGCTGGCGATGCTCTCCGACTCCTTCCACATGCTGTCGGACGTGCTGGCGCTGGTGGTGGCGCTGGTGGCCGAGCGCTTCGCCCGGCGGACCCACGCCACCCAGAAGAACACGTTCGGCTGGATCCGAGCCGAGGTAATGGGGGCTCTGGTGAACGCCATCTTCCTGACTGGCCTCTGTTTCGCCATCCTGCTGGAGGCCATCGAGCGCTTCATCGAGCCGCACGAGATGCAGCAGCCGCTGGTGGTCCTTGGGGTCGGCGTGGCCGGGCTGCTGGTCAACGTGCTGGGGCTCTGCCTCTTCCACCATCACAGCGGCTTCAGCCAGGACTCCGGCCACGGCCACTCGCACGGGGGTCACGGCCACGGCCACGGCCTCCCCAAGGGGCCTCGCGTTAAGAGCACCCGCCCCGGGAGCAGCGACATCAACGTGGCCCCGGGCGAGCAGGGTCCCGACCAGGAGGAGACCAACACCCTGGTGGCCAATACCAGCAACTCCAACGGGCTGAAATTGGACCCCGCAGACCCAGAAAACCCCAGAAGTGGTGATACAGTGGAAGTACAAGTGAATGGAAATCTTGTCAGAGAACCTGACCATATGGAACTGGAAGAAGATAGGGCTGGACAACTTAACATGCGTGGAGTTTTTCTGCATGTCCTTGGAGATGCCTTGGGTTCAGTGATTGTAGTAGTAAATGCCTTAGTCTTTTACTTTTCTTGGAAAGGTTGTTCTGAAGGGGATTTTTGTGTGAATCCATGTTTCCCTGACCCCTGCAAAGCATTTGTAGAAATAATTAATAGTACTCATGCATCAGTTTATGAGGCTGGTCCTTGCTGGGTGCTATATTTAGATCCAACTCTTTGTGTTGTAATGGTTTGTATACTTCTTTACACAACCTATCCATTACTTAAGGAATCTGCTCTTATTCTTCTACAAACTGTTCCTAAACAAATTGATATCAGAAATTTGATAAAAGAACTTCGAAATGTTGAAGGAGTTGAGGAAGTTCATGAATTACATGTTTGGCAACTTGCTGGAAGCAGAATCATTGCCACTGCTCACATAAAATGTGAAGATCCAACATCATACATGGAGGTGGCTAAAACCATTAAAGACGTTTTTCATAATCACGGAATTCACGCTACTACCATTCAGCCTGAATTTGCTAGTGTAGGCTCTAAATCAAGTGTAGTTCCGTGTGAACTTGCCTGCAGAACCCAGTGTGCTTTGAAGCAATGTTGTGGGACACTACCACAAGCCCCTTCTGGAAAGGATGCAGAAAAGACCCCAGCAGTTAGCATTTCTTGTTTAGAACTTAGTAACAATCTAGAGAAGAAGCCCAGGAGGACTAAAGCTGAAAACATCCCTGCTGTTGTGATAGAGATTAAAAACATGCCAAACAAACAACCTGAATCATCTTTGTGAGTCTTGAAAAAGATGTGATATTTGACTTTTGCTTTAAACTGCNOV37c, SNP13382438 ofSEQ ID NO: 462507 aaMW at 55299.3kDCG54539-02, ProteinSNP Pos: 155SNP Change: Tyr to HisSequenceMGCWGRNRGRLLCMLALTFMFMVLEVVVSRVTSSLAMLSDSFHMLSDVLALVVALVAERFARRTHATQKNTFGWIRAEVMGALVNAIFLTGLCFAILLEAIERFIEPHEMQQPLVVLGVGVAGLLVNVLGLCLFHHHSGFSQDSGHGHSHGGHGHGHGLPKGPRVKSTRPGSSDINVAPGEQGPDQEETNTLVANTSNSNGLKLDPADPENPRSGDTVEVQVNGNLVREPDHMELEEDRAGQLNMRGVFLHVLGDALGSVIVVVNALVFYFSWKGCSEGDFCVNPCFPDPCKAFVEIINSTHASVYEAGPCWVLYLDPTLCVVMVCILLYTTYPLLKESALILLQTVPKQIDIRNLIKELRNVEGVEEVHELHVWQLAGSRIIATAHIKCEDPTSYMEVAKTIKDVFHNHGIHATTIQPEFASVGSKSSVVPCELACRTQCALKQCCGTLPQAPSGKDAEKTPAVSISCLELSNNLEKKPRRTKAENIPAVVIEIKNNPNKQPESSL

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 37B.

TABLE 37BComparison of the NOV37 protein sequences.NOV37a MGCWGRNRGRLLCMLALTFMFMVLEVVVSRVTSSLAMLSDSFHMLSDVLALVVALVAERFNOV37b MGCWGRNRGRLLCMLALTFMFMVLEVVVSRVTSSLAMLSDSFHMLSDVLALVVALVAERFNOV37a ARRTHATQKNTFGWIRAEVMGALVNAIFLTGLCFAILLEAIERFIEPHEMQQPLVVLGVGNOV37b ARRTHATQKNTFGWIRAEVMGALVNAIFLTGLCFAILLEAIERFIEPHEMQQPLVVLGVGNOV37a VAGLLVNVLGLCLFHHHSGFSQDSGHGHSHGGHGYGHGLPKGPRVKSTRPGSSDINVAPGNOV37b VAGLLVNVLGLCLFHHHSGFSQDSGHGHSHGGHGHGHGLPKGPRVKSTRPGSSDINVAPGNOV37a EQGPDQEETNTLVAITSNSNGLKLDPADPENPRSGDTVEVQVNGNLVREPDHMELEEDRANOV37b EQGPDQEETNTLVANTSNSNGLKLDPADPENPRSGDTVEVQVNGNLVREPDHMELEEDRANOV37a GQLNMRGVFLHVLGDALGSVIVVVNALVFYFSWKGCSEGDFCVNPCFPDPCKAFVEIINSNOV37b GQLNMRGVFLHVLGDALGSVIVVVNALVFYFSWKGCSEGDFCVNPCFPDPCKAFVEIINSNOV37a THASVYEAGPCWVLYLDPTLCVVMVCILLYTTYPLLKESALILLQTVPKQIDIRNLIKELNOV37b THASVYEAGPCWVLYLDPTLCVVMVCILLYTTYPLLKESALILLQTVPKQIDIRNLIKELNOV37a RNVEGVEEVHELHVWQLAGSRIIATAHIKCEDPTSYMEVAKTIKDVFHNHGIHATTIQPENOV37b RNVEGVEEVHELHVWQLAGSRIIATAHIKCEDPTSYMEVAKTIKDVFHNHGIHATTIQPENOV37a FASVGSKSSVVPCELACRTQCALKQCCGTLPQAPSGKDAEKTPAVSISCLELSNNLEKKPNOV37b FASVGSKSSVVPCELACRTQCALKQCCGTLPQAPSGKDAEKTPAVSISCLELSNNLEKKPNOV37a RRTKAENIPAVVIEIKNMPNKQPESSLNOV37b RRTKAENIPAVVIEIKNMPNKQPESSLNOV37a (SEQ ID NO: 458)NOV37b (SEQ ID NO: 460)

Further analysis of the NOV37a protein yielded the following properties shown in Table 37C.

TABLE 37CProtein Sequence Properties NOV37aSignalP analysis:Cleavage site between residues 30 and 31PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 10; pos.chg 3; neg.chg 0H-region: length 14; peak value 12.34PSG score: 7.94GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −2.29possible cleavage site: between 29 and 30>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −8.76Transmembrane 12-28INTEGRALLikelihood = −3.66Transmembrane 41-57INTEGRALLikelihood = −7.54Transmembrane 82-98INTEGRALLikelihood = −7.43Transmembrane 114-130INTEGRALLikelihood = −5.57Transmembrane 248-264INTEGRALLikelihood = −7.01Transmembrane 313-329PERIPHERALLikelihood = 6.21 (at 421)ALOM score: −8.76 (number of TMSs: 6)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 19Charge difference: −4.0 C(0.0) − N(4.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:3Hyd Moment(75):5.99Hyd Moment(95):2.66G content:3D/E content:1S/T content:1Score: −3.81Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 40 SRV|TSNUCDISC: discrimination of nuclear localization signalspat4: KKPR (4) at 478pat4: KPRR (4) at 479pat7: PRRTKAE (5) at 480bipartite: nonecontent of basic residues: 8.3%NLS Score: 0.46KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):66.7%: endoplasmic reticulum22.2%: mitochondrial11.1%: nuclear>> prediction for CG54539-02 is end (k = 9)

A search of the NOV37a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 37D.

TABLE 37DGeneseq Results for NOV37aNOV37aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABG73033Human transporter polypeptide -1 . . . 507506/507 (99%)0.0Homo sapiens, 507 aa.1 . . . 507507/507 (99%)[US2002106721-A1, 08-AUG-2002]ABG73033Human transporter polypeptide -1 . . . 507506/507 (99%)0.0Homo sapiens, 507 aa.1 . . . 507507/507 (99%)[US2002106721-A1, 08-AUG-2002]AAG67549Amino acid sequence of a human1 . . . 507504/507 (99%)0.0transporter protein - Homo1 . . . 507506/507 (99%)sapiens, 507 aa. [WO200164878-A2, 07-SEP-2001]AAE16348Human zinc transporter like1 . . . 507506/512 (98%)0.0protein, POLY12 - Homo sapiens,1 . . . 512507/512 (98%)512 aa. [WO200185767-A2, 15-NOV-2001]AAY86241Human secreted protein14 . . . 501 482/488 (98%)0.0HOABR60, SEQ ID NO: 156 -1 . . . 488484/488 (98%)Homo sapiens, 490 aa.[WO9966041-A1, 23-DEC-1999]

In a BLAST search of public sequence databases, the NOV37a protein was found to have homology to the proteins shown in the BLASTP data in Table 37E.

TABLE 37EPublic BLASTP Results for NOV37aNOV37aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9Y6M5Zinc transporter 1 (ZnT-1) -1 . . . 507505/507 (99%)0.0Homo sapiens (Human), 507 aa.1 . . . 507506/507 (99%)Q62720Zinc transporter 1 (ZnT-1) -1 . . . 507437/511 (85%)0.0Rattus norvegicus (Rat), 507 aa.1 . . . 507468/511 (91%)Q60738Zinc transporter 1 (ZnT-1) - Mus1 . . . 507431/509 (84%)0.0musculus (Mouse), 503 aa.1 . . . 503464/509 (90%)AAH46675Similar to solute carrier family 304 . . . 500297/508 (58%) e−156(zinc transporter), member 1 -2 . . . 493366/508 (71%)Xenopus laevis (African clawedfrog), 494 aa.CAD58282Sequence 16 from Patent1 . . . 485183/503 (36%)2e−69 WO0240656 - Homo sapiens1 . . . 454254/503 (50%)(Human), 485 aa.

PFam analysis indicates that the NOV37a protein contains the domains shown in the Table 37F.

TABLE 37FDomain Analysis of NOV37aNOV37aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect ValueCation_efflux11 . . . 426102/435 (23%)4.8e−56323/435 (74%)

Example 38

The NOV38 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 38A.

TABLE 38ANOV38 Sequence AnalysisNOV38a, CG54683-05SEQ ID NO: 4631416 bpDNA SequenceORF Start: ATG at 4ORF Stop: TGA at 1402GAGATGGTCCTGGCTTTCCAGTTAGTCTCCTTCACCTACATCTGGATCATATTGAAACCAAATGTTTGTGCTGCTTCTAACATCAAGATGACACACCAGCGGTGCTCCTCTTCAATGAAACAAACCCAAGAAACTAGAATGAAGAAAGATGACAGTACCAAAGCGCGGCCTCAGAAATATGAGCAACTTCTCCATATAGAGGACAACGATTTCGCAATGAGACCTGGATTTGGAGGGTCTCCAGTGCCAGTAGGTATAGATGTCCATGTTGAAAGCATTGACAGCATTTCAGAGACTAACATGGTAGACTTTACAATGACTTTTTATCTCAGGCATTACTGGAAAGACGAGAGGCTCTCCTTTCCTAGCACAGCAAACAAAAGCATGACATTTGATCATAGATTGACCAGAAAGATCTGGGTGCCTGATATCTTTTTTGTCCACTCTAAAAGATCCTTCATCCATGATACAACTATGGAGAATATCATGCTGCGCGTACACCCTGATGGAAACGTCCTCCTAAGTCTCAGGATAACGGTTTCGGCCATGTGCTTTATGGATTTCAGCAGGTTTCCTCTTGACACTCAAAATTGTTCTCTTGAACTGGAAAGCGCCTACAATGAGGATGACCTAATGCTATACTGGAAACACGGAAACAAGTCCTTAAATACTGAAGAACATATGTCCCTTTCTCAGTTCTTCATTGAAGACTTCAGTGCATCTAGTGGATTAGCTTTCTATAGCAGCACAGGTTGGTACAATAGGCTTTTCATCAACTTTGTGCTAAGGAGGCATGTTTTCTTCTTTGTGCTGCAAACCTATTTCCCAGCCATATTGATGGTGATGCTTTCATGGGTTTCATTTTGGATTGACCGAAGAGCTGTTCCTGCAAGAGTTTCCCTGGGTGGAATCACCACAGTGCTGACCATGTCCACAATCATCACTGCTGTGAGCGCCTCCATGCCCCAGGTGTCCTACCTCAAGGCTGTGGATGTGTACCTGTGGGTCAGCTCCCTCTTTGTGTTCCTGTCAGTCATTGAGTATGCAGCTGTGAACTACCTCACCACAGTGGAAGAGCGGAAACAATTCAAGAAGACAGGAAAGATTTCTAGGATGTACAATATTGATGCAGTTCAAGCTATGGCCTTTGATGGTTGTTACCATGACAGCGAGATTGACATGGACCAGACTTCCCTCTCTCTAAACTCAGAAGACTTCATGAGAAGAAAATCGATATGCAGCCCCAGCACCGATTCATCTCGGATAAAGAGAAGAAAATCCCTAGGAGGACATGTTGGTAGAATCATTCTGGAAAACAACCATGTCATTGACACCTATTCTAGGATTNTATTCCCCATTGTGTATATCTTATTTAATTTGTTTTACTGGGGTGTATATGTATGAAGGGGAATTTCANOV38a, CG54683-05SEQ ID NO: 464466 aaMW at 53919.5kDProtein SequenceMVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTQETRMKKDDSTKARPQKYEQLLHIEDNDFAMRPGFGGSPVPVGIDVHVESIDSISETNMVDFTMTFYLRHYWKDERLSFPSTANKSMTFDHRLTRKIWVPDIFFVHSKRSFIHDTTMENINLRVHPDGNVLLSLRITVSAMCFMDFSRFPLDTQNCSLELESAYNEDDLMLYWKHGNKSLNTEEHMSLSQFFIEDFSASSGLAFYSSTGWYNRLFINFVLRRHVFFFVLQTYFPAILMVMLSWVSFWIDRRAVPARVSLGGITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYAAVNYLTTVEERKQFKKTGKISRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFMRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRIXFPIVYILFNLFYWGVYVNOV38b, CG54683-01SEQ ID NO: 4651875 bpDNA SequenceORF Start: ATG at 10ORF Stop: TGA at 1411TTGGAAGAGATGGTCCTGGCTTTCCAGTTAGTCTCCTTCACCTACATCTGGATCATATTGAAACCAAATGTTTGTGCTGCTTCTAACATCAAGATGACACACCAGCGGTGCTCCTCTTCAATGAAACAAACCTGGATGCAAGAAACTAGAATGAAGAAAGATGACAGTACCAAAGCGCGGCCTCAGAAATATGAGCAACTTCTCCATATAGAGGACAACGATTTCGCAATGAGACCTGGATTTGGAGGTTCTCCAGTGCCAGTAGGTATAGATGTCCATGTTGAAAGCATTGACAGCATTTCAGAGACTAACATGGACTTTACAATGACTTTTTATCTCAGGCATTACTGGAAAGACGAGAGGCTCTCCTTTCCTAGCACAGCAAACAAAAGCATGACATTTGATCATAGACACTTGCGGTATTCGTTATTCATCAGAAGGCTGTATCTGTTATACTGCCAGAGGTCTTTCTTCTCACCCTCATCCATACTTCCCTCATCTCCAGACATCCATGCACCTGGTACATCTAAAAGCAGTTTGTCTGATAGCCTTGTATGTATATCTGAAAAAAACTTGCCAGGACACAGTAAAAACACACCTCTTGCAATGTCAGATGTAGCCTACAATGAGGATGACCTAATGCTATACTGGAAACACGGAAACAAGTCCTTAAATACTGAAGAACATATGTCCCTTTCTCAGTTCTTCATTGAAGACTTCAGTGCATCTAGTGGATTAGCTTTCTATAGCAGCACAGGTACAGCATTTTACATGGGTGATTCATCAGCATTTATTGGACATCTACTGTTTTTGATCTGGAGTTCCAGGAAAAGACCAGGTTTAGAGATGTTGGGTTTGGGAATTCTCAGAATCTGGGTAATAACTAGAGCCATGGATAAGAAAATGGAAATGGGAATCACCACAGTGCTGACCATGTCCACAATCATCACTGCTGTGAGCGCCTCCATGCCCCAGGTGTCCTACCTCAAGGCTGTGGATGTGTACCTGTGGGTCAGCTCCCTCTTTGTGTTCCTGTCAGTCATTGAGTATGCAGCTGTGAACTACCTCACCACAGTGGAAGAGCGGAAACAATTCAAAAAAAGTTTTTCAAAGATTTCTAGGATGTACAATATTGATGCAGTTCAAGCTATGGCCTTTGATGGTTGTTACCATGACAGCGAGATTGACATGGACCAGACTTCCCTCTCTCTAAACTCAGAAGACTTCATGAGAAGAAAATCGATATGCAGCCCCAGCACCGATTCATCTCGGATAAAGAGAAGAAAATCCCTAGGAGGACATGTTGGTAGAATCATTCTGGAAAACAACCATGTCATTGACACCTATTCTAGGATTTTATTCCCCATTGTGTATATCTTTTTTAATTTGTTTTACTGGGGTGTATATGTATGAAGGGGAATTTCAAATGTATACAACTTTAAAGCCAGATGATGTTTAAAAACAAAACTCTTGAATATGAGTTGGATAGTCCTAGATGGAACTGGGAAAGAGCAAGTCACCTCTCCTGCCCTAATGAAAATTTGAAAGCTGTCTGATTTACATCTAAGAAAGAGTTTAGGTCCTAGAAAAGTTTGACTCCATAAATAAGAGTCATAGGCATGTGTATTATGGGAAAAACAGTTTTCCATTGGGAAGGGCTTTATAACTACTTCATCTGAACCCTCCTTCTTTCTTAATGAAATGTTCTTTATTTAACTAGGGAAGAAAGCTGGACTATAACAATAATTCAAAGATATTTTGTTTCTTAGTGCCAGCCAAGTGCCTGGTTATCTACCAGAGCTCAACCGTCCTAGGCAAGAACATCCACATAGAGGTGGTATCATCCACACTCACACAGCTGAGAATCCTATGAAGNOV38b, CG54683-01SEQ ID NO: 466467 aaMW at 53522.9kDProtein SequenceMVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTWMQETRMKKDDSTKARPQKYEQLLHIEDNDFAMRPGFGGSPVPVGIDVHVESIDSISETNMDFTMTFYLRHYWKDERLSFPSTANKSMTFDHRHLRYSLFIRRLYLLYCQRSFFSPSSILPSSPDIHAPGTSKSSLSDSLVCISEKNLPGHSKNTPLAMSDVAYNEDDLMLYWKHGNKSLNTEEHMSLSQFFIEDFSASSGLAFYSSTGTAFYMGDSSAFIGHLLFLIWSSRKRPGLEMLGLGILRIWVITRAMDKKMEMGITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYAAVNYLTTVEERKQFKKSFSKISRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFMRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYIFFNLFYWGVYVNOV38c, GG54683-02SEQ ID NO: 4671444 bpDNA SequenceORF Start: ATG at 21ORF Stop: TGA at 1425GTTTTTTTGTTTTGGAAGAGATGGTCCTGGCTTTCCAGTTAGTCTCCTTCACCTACATCTGGATCATATTGAAACCAAATGTTTGTGCTGCTTCTAACATCAAGATGACACACCAGCGGTGCTCCTCTTCAATGAAACAAACCTGCAAACAAGAAACTAGAATGAAGAAAGATGACAGTACCAAAGCGCGGCCTCAGAAATATGAGCAACTTCTCCATATAGAGGACAACGATTTCGCAATGAGACCTGGATTTGGAGGGTCTCCAGTGCCAGTAGGTATAGATGCCCATGTTGAAAGCATTGACAGCATTTCAGAGACTAACATGGACTTTACAATGACTTTTTATCTCAGGCATTACTGGAAAGACGAGAGGCTCTCCTTTCCTAGCACAGCAAACAAAAGCATGACATTTGATCATAGATTGACCAGAAAGATCTGGGTGCCTGATATCTTTTTTGTCCACTCTAAAAGATCCTTCATCCATGATACAACTATGGAGAATATCATGCTGCGCGTACACCCTGATGGAAACGTCCTCCTAAGTCTCAGGATAACGGTTTCGGCCATGTGCTTTATGGATTTCAGCAGGTTTCCTCTTGACGACACTCAAAATTGTTCTCTTGAACTGGAAAGCTGTGCCTACAATGAGGATGACCTAATGCTATACTGGAAACACGGAAACAAGTCCTTAAATACTGAAGAACATATGTCCCTTTCTCAGTTCTTCATTGAAGACTTCAGTGCATCTAGTGGATTAGCTTTCTATAGCAGCACAGGTTGGTACAATAGGCTTTTCATCAACTTTGTGCTAAGGAGGCATGTTTTCTTCTTTGTGCTGCAAACCTATTTCCCAGCCATATTGATGGTGATGCTTTCATGGGTTTCATTTTGGATTGACCGAAGAGCTGTTCCTGCAAGAGTTTCCCTGGGTATCACCACAGTGCTGACCATGTCCACAATCATCACTGCTGTGAGCGCCTCCATGCCCCAGGTGTCCTACCTCAAGGCTGTGGATGTGTACCTGTGGGTCAGCTCCCTCTTTGTGTTCCTGTCAGTCATTGAGTATGCAGCTGTGAACTACCTCACCACAGTGGAAGAGCGGAAACAATTCAAGAAGACAGGAAAGGTATCTAGGATGTACAATATTGATGCAGTTCAAGCTATGGCCTTTGATGGTTGTTACCATGACAGCGAGATTGACATGGACCAGACTTCCCTCTCTCTAAACTCAGAAGACTTCATGAGAAGAAAATCGATATGCAGCCCCAGCACCGATTCATCTCGGATAAAGAGAAGAAAATCCCTAGGAGGACATGTTGGTAGAATCATTCTGGAAAACAACCATGTCATTGACACCTATTCTAGGATTTTATTCCCCATTGTGTATATTTTATTTAATTTGTTTTACTGGGGTGTATATGTATGAAGGGGAATTTCAAATGTNOV38c, CG54683-02SEQ ID NO: 468468 aaMW at 54283.9kDProtein SequenceMVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTCKQETRMKKDDSTKARPQKYEQLLHIEDNDFAMRPGFGGSPVPVGIDAHVESIDSISETNMDFTMTFYLRHYWKDERLSFPSTANKSMTFDHRLTRKIWVPDIFFVHSKRSFIHDTTMENIMLRVHPDGNVLLSLRITVSAMCFMDFSRFPLDDTQNCSLELESCAYNEDDLMLYWKHGNKSLNTEEHMSLSQFFIEDFSASSGLAFYSSTGWYNRLFINFVLRRHVFFFVLQTYFPAILMVMLSWVSFWIDRRAVPARVSLGITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYAAVNYLTTVEERKQFKKTGKVSRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFMRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYILFNLFYWGVYVNOV38d, CG54683-03SEQ ID NO: 4691438 bpDNA SequenceORF Start: ATG at 21ORF Stop: TGA at 1419GTTTTTTTGTTTTGGAAGAGATGGTCCTGGCTTTCCAGTTAGTCTCCTTCACCTACATCTGGATCATATTGAAACCAAATGTTTGTGCTGCTTCTAACATCAAGATGACACACCAGCGGTGCTCCTCTTCAATGAAACAAACCTGCAAACAAGAAACTAGAATGAAGAAAGATGACAGTACCAAAGCGCGGCCTCAGAAATATGAGCAACTTCTCCATATAGAGGACAACGATTTCGCAATGAGACCTGGATTTGGAGGGTCTCCAGTGCCAGTAGGTATAGATGTCCATGTTGAAAGCATTGACAGCATTTCAGAGACTAACATGGACTTTACAATGACTTTTTATCTCAGGCATTACTGGAAAGACGAGAGGCTCTCCTTTCCTAGCACAGCAAACAAAAGCATGACATTTGATCATAGATTGACCAGAAAGATCTGGGTGCCTGATATCTTTTTTGTCCACTCTAAAAGATCCTTCATCCATGATACAACTATGGAGAATATCATGCTGCGCGTACACCCTGATGGAAACGTCCTCCTAAGTCTCAGGATAACGGTTTCGGCCATGTGCTTTATGGATTTCAGCAGGTTTCCTCTGACTCAAAATTGTTCTCTTGAACTGGAAAGCTGTGCCTACAATGAGGATGACCTAATGCTATACTGGAAACACGGAAACAAGTCCTTAAATACTGAAGAACATATGTCCCTTTCTCAGTTCTTCATTGAAGACTTCAGTGCATCTAGTGGATTAGCTTTCTATAGCAGCACAGGTTGGTACAATAGGCTTTTCATCAACTTTGTGCTAAGGAGGCATGTTTTCTTCTTTGTGCTGCAAACCTATTTCCCAGCCATATTGATGGTGATGCTTTCATGGGTTTCATTTTGGATTGACCGAAGAGCTGTTCCTGCAAGAGTTTCCCTGGGTATCACCACAGTGCTGACCATGTCCACAATCATCACTGCTGTGAGCGCCTCCATGCCCCAGGTGTCCTACCTCAAGGCTGTGGATGTGTACCTGTGGGTCAGCTCCCTCTTTGTGTTCCTGTCAGTCATTGAGTATGCAGCTGTGAACTACCTCACCACAGTGGAAGAGCGGAAACAATTCAAGAAGACAGGAAAGGTATCTAGGATGTACAATATTGATGCAGTTCAAGCTATGGCCTTTGATGGTTGTTACCATGACAGCGAGATTGACATGGACCAGACTTCCCTCTCTCTAAACTCAGAAGACTTCATGAGAAGAAAATCGATATGCAGCCCCAGCACCGATTCATCTCGGATAAAGAGAAGAAAATCCCTAGGAGGACATGTTGGTAGAATCATTCTGGAAAACAACCATGTCATTGACACCTATTCTAGGATTTTATTCCCCATTGTGTATATTTTATTTAATTTGTTTTACTGGGGTGTATATGTATGAAGGGGAATTTCAAATGTNOV38d, GG54683-03SEQ ID NO: 470466 aaMW at 54081.8kDProtein SequenceMVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTCKQETRMKKDDSTKARPQKYEQLLHIEDNDFAMRPGFGGSPVPVGIDVHVESIDSISETNMDFTMTFYLRHYWKDERLSFPSTANKSMTFDHRLTRKIWVPDIFFVHSKRSFIHDTThENIMLRVHPDGNVLLSLRITVSAMCFMDFSRFPLTQNCSLELESCAYNEDDLMLYWKHGNKSLNTEEHMSLSQFFIEDFSASSGLAFYSSTGWYNRLFINFVLRRHVFFFVLQTYFPAILMVMLSWVSFWIDRRAVPARVSLGITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYAAVNYLTTVEERKQFKKTGKVSRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFMRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYILFNLFYWGVYVNOV38e, CG54683-04SEQ ID NO: 4711799 bpDNA SequenceORF Start: ATG at 71ORF Stop: TGA at 1445AAGAAGAAACTGTGATCACAGTATTGGTTGCGTTCACCTGCATCCTTTCTGTTTTTTTGTTTTGGAAGAGATGGTCCTGGCTTTCCAGTTAGTCTCCTTCACCTACATCTGGATCATATTGGTTTGTGCTGCTTCTAACATCAAGATGACACACCAGCGGTGCTCCTCTTCAATGAAACAAACCGTAAGATGCTCAATGAAGAAAGATGACAGTACCAAAGCGCGGCCTCAGAAATATGAGCAACTTCTCCATATAGAGGACAACGATITCGCAATGAGACCTGGATTTGGAGGTTCTCCAGTGCCAGTAGGTATAGATGTCCATGTTGAAAGCATTGACAGCATTTCAGAGACTAACATGGACTTTACAATGACTTTTTATCTCAGGCATTACTGGAAAGACGAGAGGCTCTCCTTTCCTAGCACAGCAAACAAAAGCATGACATTTGATCATAGAAAGAGTATCCCCCGCCCTGAACACTTGCGGTATTCGTTATTCATCAGAAGGCTGTATCTGTTATACTGCCAGAGGTCTTTCTTCTCACCCTCATCCATACTTCCCTCATCTCCAGACATCCATGCACCTGGTACATCTAAAAGCAGTTTGTCTGATAGCCTTGTATGTATATCTGAAAAAAACTTGCCAGGACACAGTAAAAACACACCTCTTGCAATGGCCTACAATGAGGATGACCTAATGCTATACTGGAAACACGGAAACAAGTCCTTAAATACTGAAGAACATATGTCCCTTTCTCAGTTCTTCATTGAAGACTTCAGTGCATCTAGTGGATTAGCTTTCTATAGCAGCACAGGTACAGCATTTTACATGGGTGATTCATCAGCATTTATTGGACATCTACTGTTTTTAAATAGACATTTACATTTCTTCATCATAAATTTTGAAATTACTCAAATATTGATGATTGGAATCACCACAGTGCTGACCATGTCCACAATCATCACTGCTGTGAGCGCCTCCATGCCCCAGGTGTCCTACCTCAAGGCTGTGGATGTGTACCTGTGGGTCAGCTCCCTCTTTGTGTTCCTGTCAGTCATTGAGTATGCAGCTGTGAACTACCTCACCACAGTGGAAGAGCGGAAACAATTCAAGAAGACAGGAAAGGTACAGATTTCTAGGATGTACAATATTGATGCAGTTCAAGCTATGGCCTTTGATGGTTGTTACCATGACAGCGAGATTGACATGGACCAGACTTCCCTCTCTCTAAACTCAGAAGACTTCATGAGAAGAAAATCGATATGCAGCCCCAGCACCGATTCATCTCGGATAAAGAGAAGAAAATCCCTAGGAGGACATGTTGGTAGAATCATTCTGGAAAACAACCATGTCATTGACACCTATTCTAGGATTTTATTCCCCATTGTGTATATCCCATTGTGTATATCTTTATTTAATTTGTTTTACTGGGGTGTATATGTATGAAGGGGAATTTCAAATGTATACAACTTTAAAGCCAGATGATGTTTAAAAACAAAACTCTTGAATATGAGTTGGAATTGAAGACTTCAGTGCATCTAGTGGATTAGCTTTCTATAGCAGCACAGGTACAGCATTTTACATGGGTGATTCATCAGCATTTATTGGACATCTACTGTTTTACTTTTGGTCTTTGATGATGGTGATGTACAGATGGGTTGGAATCACCACAGTGCTGACCATGTCCACAATCATCACTGCTGTGAGCGCCTCCATGCCCCAGGTGTCCTACCTCAAGGCTGTGGATGTGTACCTGTGGGTCAGCTCCCTCTTTGTGTTCCTGTCAGTCATTGAGTATNOV38e, GG54683-04SEQ ID NO: 472458 aaMW at 52330.5kDProtein SequenceMVLAFQLVSFTYIWIILVCAASNIKMTHQRCSSSMKQTVRCSMKKDDSTKARPQKYEQLLHIEDNDFAMRPGFGGSPVPVGIDVHVESIDSISETNMDFTMTFYLRHYWKDERLSFPSTANKSMTFDHRKSIPRPEHLRYSLFIRRLYLLYCQRSFFSPSSILPSSPDIHAPGTSKSSLSDSLVCISEKNLPGHSKNTPLAMAYNEDDLMLYWKHGNKSLNTEEHMSLSQFFIEDFSASSGLAFYSSTGTAFYMGDSSAFIGHLLFLNRHLHFFIINFEITQILMIGITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYAAVNYLTTVEERKQFKKTGKVQISRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFMRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYIPLCISLFNLFYWGVYV

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 38B.

TABLE 38BComparison of the NOV38 protein sequences.NOV38a MVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQT--QETRMKKDDSTKARPQKNOV38b MVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTWMQETRMKKDDSTKARPQKNOV38c MVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTCKQETRMKKDDSTKARPQKNOV38d MVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTCKQETRMKKDDSTKARPQKNOV38e MVLAFQLVSFTYIWIIL---VCAASNIKMTHQRCSSSMKQTVRCS--MKKDDSTKARPQKNOV38a YEQLLHIEDNDFANRPGFGGSPVPVGIDVHVESIDSISETNNVDFTMTFYLRHYWKDERLNOV38b YEQLLHIEDNDFANRPGFGGSPVPVGIDVHVESIDSISETN-MDFTMTFYLRHYWKDERLNOV38c YEQLLHIEDNDFANRPGFGGSPVPVGIDAHVESIDSISETN-MDFTMTFYLRHYWKDERLNOV38d YEQLLHIEDNDFANRPGFGGSPVPVGIDVHVESIDSISETN-MDFTMTFYLRHYWKDERLNOV38e YEQLLHIEDNDFAMRPGFGGSPVPVGIDVHVESIDSISETN-MDFTMTFYLRHYWKDERLNOV38a SFPSTANKSMTFDHR--------LTRKIWVPDIFFVHSKRSFIHDTTMENIMLRVHPDGNNOV38b SFPSTANKSMTFDHR-------HLRYSLFIRRLYLLYCQRSFFSPSSILPSSPDIHAPG-NOV38c SFPSTANKSMTFDHR--------LTRKIWVPDIFFVHSKRSFIHDTTMENIMLRVHPDGNNOV38d SFPSTANKSMTFDHR--------LTRKIWVPDIFFVHSKRSFIHDTTMENIMLRVHPDGNNOV38e SFPSTANKSMTFDHRKSIPRPEHLRYSLFIRRLYLLYCQRSFFSPSSILPSSPDIHAPG-NOV38a VLLSLRITVSAMCFMDFSRFPLD-TQNCSLELES-AYNEDDLMLYWKHGNKSLNTEEHMSNOV38b --TSKSSLSDSLVCISEKNLPG-HSKNTPLAMSDVAYNEDDLMLYWKHGNKSLNTEEHMSNOV38c VLLSLRITVSANCFMDFSRFPLDDTQNCSLELESCAYNEDDLMLYWKHGNKSLNTEEHMSNOV38d VLLSLRITVSANCFMDFSRFPL--TQNCSLELESCAYNEDDLMLYWKHGNKSLNTEEHMSNOV38e --TSKSSLSDSLVCISEKNLPG-HSKNTPLAM---AYNEDDLMLYWKHGNKSLNTEEHNSNOV38a LSQFFIEDFSASSGLAFYSSTGWYNRLFINFVLRRHVFFFVLQT-YFPAILMVMLSWVSFNOV38b LSQFFIEDFSASSGLAFYSSTGTAFYMGDSSAFIGHLLFLIWSSRKRPGLEMLGLGILRINOV38c LSQFFIEDFSASSGLAFYSSTGWYNRLFINFVLRRHVFFFVLQT-YFPAILMVMLSWVSFNOV38d LSQFFIEDFSASSGLAFYSSTGWYNRLFINFVLRRHVFFFVLQT-YFPAILMVMLSWVSFNOV38e LSQFFIEDFSASSGLAFYSSTGTAFYMGDSSAFIGHLLFLN-----R---------HLHFNOV38a WIDRRAVPARVSLGGITTVLTNSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYNOV38b WVITRAMDKKMEMG-ITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYNOV38c WIDRRAVPARVSLG-ITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYNOV38d WIDRRAVPARVSLG-ITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYNOV38e FIINFEITQILMIG-ITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYNOV38a AAVNYLTTVEERKQFKKT--GKISRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFNOV38b AAVNYLTTVEERKQFKKS-FSKISRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFNOV38c AAVNYLTTVEERKQFKKT--GKVSRNYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFNOV38d AAVNYLTTVEERKQFKKT--GKVSRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFNOV38e AAVNYLTTVEERKQFKKTGKVQISRNYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFNOV38a MRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRIXFPIVYI-----LFNLFNOV38b MRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYI-----FFNLFNOV38c MRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYI-----LFNLFNOV38d MRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYI-----LFNLFNOV38e MRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYIPLCISLFNLFNOV38a YWGVYVNOV38b YWGVYVNOV38c YWGVYVNOV38d YWGVYVNOV38e YWGVYVNOV38a (SEQ ID NO: 464)NOV38b (SEQ ID NO: 466)NOV38c (SEQ ID NO: 468)NOV38d (SEQ ID NO: 470)NOV38e (SEQ ID NO: 472)

Further analysis of the NOV38a protein yielded the following properties shown in Table 38C.

TABLE 38CProtein Sequence Properties NOV38aSignalP analysis:Cleavage site between residues 25 and 26PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 17; peak value 9.53PSG score: 5.12GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1) −7.09possible cleavage site: between 24 and 25>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −4.51Transmembrane 1-17INTEGRALLikelihood = −0.43Transmembrane 171-187INTEGRALLikelihood = −3.98Transmembrane 265-281INTEGRALLikelihood = −0.64Transmembrane 300-316INTEGRALLikelihood = −3.98Transmembrane 329-345INTEGRALLikelihood = −0.85Transmembrane 448-464PERIPHERALLikelihood = 7.48 (at 229)ALOM score: −4.51 (number of TMSs: 6)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 8Charge difference: 1.5 C(2.5) − N(1.0)C > N: C-terminal side will be inside>>>Caution: Inconsistent mtop result with signal peptide>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):2.39Hyd Moment(95):3.90G content:0D/E content:1S/T content:8Score: −2.44Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 43 QRC|SSNUCDISC: discrimination of nuclear localization signalspat4: KRRK (5) at 422pat7: nonebipartite: RRKSICSPSTDSSRIKR at 407bipartite: RKSICSPSTDSSRIKRR at 408content of basic residues: 10.3%NLS Score: 0.99KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: endoplasmic reticulum11.1%: vacuolar11.1%: Golgi11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG54683-05 is end (k = 9)

A search of the NOV38a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 38D.

TABLE 38DGeneseq Results for NOV38aNOV38aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE21956Human transporter protein - Homo1 . . . 466463/469 (98%)0.0sapiens, 467 aa. [US2002028773-1 . . . 467463/469 (98%)A1, 07-MAR-2002]AAU04467Human gamma-amino butyric1 . . . 466463/469 (98%)0.0acid (GABA) receptor protein #1 -1 . . . 467463/469 (98%)Homo sapiens, 467 aa.[WO200153489-A1, 26-JUL-2001]ABU12089Novel human gamma1 . . . 466461/470 (98%)0.0aminobutyric acid receptor-like1 . . . 468462/470 (98%)protein #2 - Homo sapiens, 468aa. [US2002123612-A1, 05-SEP-2002]AAG68256Human POLY3 protein sequence1 . . . 466461/470 (98%)0.0SEQ ID NO: 6 - Homo sapiens,1 . . . 468462/470 (98%)468 aa. [WO200179294-A2, 25-OCT-2001]ABU12090Novel human gamma1 . . . 466461/469 (98%)0.0aminobutyric acid receptor-like1 . . . 466462/469 (98%)protein #2 - Homo sapiens, 466aa. [US2002123612-A1, 05-SEP-2002]

In a BLAST search of public sequence databases, the NOV38a protein was found to have homology to the proteins shown in the BLASTP data in Table 38E.

TABLE 38EPublic BLASTP Results for NOV38aNOV38aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueP50573Gamma-aminobutyric-acid 1 . . . 466392/470 (83%)0.0receptor rho-3 subunit precursor 1 . . . 464417/470 (88%)(GABA(A) receptor) - Rattusnorvegicus (Rat), 464 aa.Q9YGQ2Gamma-aminobutyric-acid 1 . . . 465300/478 (62%)e−161receptor rho-3 subunit - Morone 4 . . . 469369/478 (76%)americana (White perch), 470 aa.P50572Gamma-aminobutyric-acid39 . . . 465278/428 (64%)e−155receptor rho-1 subunit precursor50 . . . 473326/428 (75%)(GABA(A) receptor) - Rattusnorvegicus (Rat), 474 aa.P56475Gamma-aminobutyric-acid39 . . . 465278/428 (64%)e−154receptor rho-1 subunit precursor50 . . . 473326/428 (75%)(GABA(A) receptor) - Musmusculus (Mouse), 474 aa.P24046Gamma-aminobutyric-acid39 . . . 465276/428 (64%)e−154receptor rho-1 subunit precursor49 . . . 472325/428 (75%)(GABA(A) receptor) - Homosapiens (Human), 473 aa.

PFam analysis indicates that the NOV38a protein contains the domains shown in the Table 38F.

TABLE 38FDomain Analysis of NOV38aNOV38aIdentities/MatchSimilaritiesExpectPfam DomainRegionfor the Matched RegionValueNeur_chan_LBD 58 . . . 265 74/253 (29%)1.6e−65176/253 (70%)Neur_chan_memb272 . . . 462 45/292 (15%) 9e−37145/292 (50%)

Example 39

The NOV39 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 39A.

TABLE 39ANOV39 Sequence AnalysisNOV39a, CG54692-06SEQ ID NO: 4731125 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1111ATGGAGGCCGCTAGCCTTTCAGTGGCCACCGCCGGCGTTGCCCTTGCCCTGGGACCCGAGACCAGCAGCGGGACCCCAAGCCCGAGAGGGATACTCGGTTCGACCCCGAGCGGCGCCGTCCTGCCGGGCCGAGGGCCGCCCTTCTCTGTCTTCACGGTCCTGGTGGTGACGCTGCTAGTGCTGCTGATCGCTGCCACTTTCCTGTGGAACCTGCTGGTTCCGGTCACCATCCCGCGGGTCCGTGCCTTCCACCGCGTGCCGCATAACTTGGTGGCCTCGACGGCCGTCTCGGACGAACTAGTGGCAGCGCTGGCGATGCCACCGAGCCTGGCGAGTGAGCTGTCGACCGGGCGACGTCGGCTGCTGGGCCGGAGCCTGTGCCACGTGTGGATCTCCTTCGACGCCCTGTGCTGCCCCGCCGGCCTCGGGAACGTGGCGGCCATCGCCCTGGGCCGCGACGGGGCCATCACACGGCACCTGCAGCACACGCTGCGCACCCGCAGCCGCGCCTCGTTGCTCATGATCGCGCTCGCCCGGGTGCCGTCGGCGCTCATCGCCCTCGCGCCGCTGCTCTTTGGCCGGGGCGAGGTGTGCGACGCTCGGCTCCAGCGCTGCCAGGTGAGCCGGGAACCCTCCTATGCCGCCTTCTCCACCCGCGGCGCCTTCCACCTGCCGCTTGGCGTGGTGCCGTTTGTCTACCGGAAGATCTACGAGGCGGCCAAGTTTCGTTTCGGCCGCCGCCGGAGAGCTGTGCTGCCGTTGCCGGCCACCATGCAGGTGAAGGAAGCACCTGATGAGGCTGAAGTGGTGTTCACGGCACATTGCAAAGCAACGGTGTCCTTCCAGGTGAGCGGGGACTCCTGGCGGGAGCAGAAGGAGAGGCGAGCAGCCATGATGGTGGGAATTCTGATTGGCGTGTTTGTGCTGTGCTGGATCCCCTTCTTCCTGACGGAACTCATCAGCCCACTCTGTGCCTGCAGCCTGCCCCCCATCTGGAAAAGCATATTTCTGTGGCTTGGCTACTCCAATTCTTTCTTCAACCCCCTGATTTACACAGCTTTTAACAAGAACTACAACAATGCCTTCAAGAGCCTCTTTACTAAGCAGAGATGAACACAGGGGTTANOV39a, CG54692-06SEQ ID NO: 474370 aaMW at 40243.7kDProtein SequenceMEAASLSVATAGVALALGPETSSGTPSPRGILGSTPSGAVLPGRGPPFSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPPSLASELSTGRRRLLGRSLCHVWISFDALCCPAGLGNVAAIALGRDGAITRHLQHTLRTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLPLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPATMQVKEAPDEAEVVFTAHCKATVSFQVSGDSWREQKERRAANMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGYSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39b, CG54692-01SEQ ID NO: 4751150 bpDNA SequenceORF Start: ATG at 24ORF Stop: TGA at 1134CTGGAGCTGCGATCCCAAGCGCCATGGAGGCCGCTAGCCTTTCAGTGGCCACCGCCGGCGTTGCCCTTGCCCTGGGACCCGAGACCAGCAGCGGGACCCCAAGCCCGAGAGGGATACTCGGTTCGACCCCGAGCGGCGCCGTCCTGCCGGGCCGAGGGCCGCCCTTCTCTGTCTTCACGGTCCTGGTGGTGACGCTGCTAGTGCTGCTGATCGCTGCCACTTTCCTGTGGAACCTGCTGGTTCCGGTCACCATCCCGCGGGTCCGTGCCTTCCACCGCGTGCCGCATAACTTGGTGGCCTCGACGGCCGTCTCGGACGAACTAGTGGCAGCGCTGGCGATGCCACCGAGCCTGGCGAGTGAGCTGTCGACCGGGCGACGTCGGCTGCTGGGCCGGAGCCTGTGCCACGTGTGGATCTCCTTCGACGCCCTGTGCTGCCCCGCCGGCCTCGGGAACGTGGCGGCCATCGCCCTGGGCCGCGACGGGGCCATCACACGGCACCTGCAGCACACGCTGCGCACCCGCAGCCGCGCCTCGTTGCTCATGATCGCGCTCGCCCGGGTGCCGTCGGCGCTCATCGCCCTCGCGCCGCTGCTCTTTGGCCGGGGCGAGGTGTGCGACGCTCGGCTCCAGCGCTGCCAGGTGAGCCGGGAACCCTCCTATGCCGCCTTCTCCACCCGCGGCGCCTTCCACCTGCCGCTTGGCGTGGTGCCGTTTGTCTACCGGAAGATCTACGAGGCGGCCAAGTTTCGTTTCGGCCGCCGCCGGAGAGCTGTGCTGCCGTTGCCGGCCACCTCCAAGGTAAAGGAAGCACCTGATGAGGCTGAAGTGGTGTTCACGGCACATTGCAAAGCAACGGTGTCCTTCCAGGTGAGCGGGGACTCCTGGCGGGAGCAGAAGGAGAGGCGAGCAGCCATGATGGTGGGAATTCTGATTGGCGTGTTTGTGCTGTGCTGGATCCCCTTCTTCCTGACGGAACTCATCAGCCCACTCTGTGCCTGCAGCCTGCCCCCCATCTGGAAAAGCATATTTCTGTGGCTTGGCTACTCCAATTCTTTCTTCAACCCCCTGATTTACACAGCTTTTAACAAGAACTACAACAATGCCTTCAAGAGCCTCTTTACTAAGCAGAGATGAACACAGGGGTTAGANOV39b, CG54692-01SEQ ID NO: 476370 aaMW at 40199.7kDProtein SequenceMEAASLSVATAGVALALGPETSSGTPSPRGILGSTPSGAVLPGRGPPFSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPPSLASELSTGRRRLLGRSLCHVWISFDALCCPAGLGNVAAIALGRDGAITRHLQHTLRTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLPLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPATMQVKEAPDEAEVVFTAHCKATVSFQVSGDSWREQKERRAANMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGYSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39c, CG54692-02SEQ ID NO: 4771150 bpDNA SequenceORF Start: ATG at 24ORF Stop: TGA at 1134CTGGAGCTGCGATCCCAAGCGCCATGGAGGCCGCTAGCCTTTCAGTGGCCACCGCCGGCGTTGCCCTTGCCCTGGGACCCGAGACCAGCAGCGGGACCCCAAGCCCGAGAGGGATACTCGGTTCGACCCCGAGCGGCGCCGTCCTGCCGGGCCGAGGGCCGCCCTTCTCTGTCTTCACGGTCCTGGTGGTGACGCTGCTAGTGCTGCTGATCGCTGCCACTTTCCTGTGGAACCTGCTGGTTCCGGTCACCATCCCGCGGGTCCGTGCCTTCCACCGCGTGCCGCATAACTTGGTGGCCTCGACGGCCGTCTCGGACGAACTAGTGGCAGCGCTGGCGATGCCACCGAGCCTGGCGAGTGAGCTGTCGACCGGGCGACGTCGGCTGCTGGGCCGGAGCCTGTGCCACGTGTGGATCTCCTTCGACGCCCTGTGCTGCCCCGCCGGCCTCGGGAACGTGGCGGCCATCGCCCTGGGCCGCGACGGGGCCATCACACGGCACCTGCAGCACACGCTGCGCACCCGCAGCCGCGCCTCGTTGCTCATGATCGCGCTCGCCCGGGTGCCGTCGGCGCTCATCGCCCTCGCGCCGCTGCTCTTTGGCCGGGGCGAGGTGTGCGACGCTCGGCTCCAGCGCTGCCAGGTGAGCCGGGAACCCTCCTATGCCGCCTTCTCCACCCGCGGCGCCTTCCACCTGCCGCTTGGCGTGGTGCCGTTTGTCTACCGGAAGATCTACGAGGCGGCCAAGTTTCGTTTCGGCCGCCGCCGGAGAGCTGTGCTGCCGTTGCCGGCCACCTCCAAGGTAAAGGAAGCACCTGATGAGGCTGAAGTGGTGTTCACGGCACATTGCAAAGCAACGGTGTCCTTCCAGGTGAGCGGGGACTCCTGGCGGGAGCAGAAGGAGAGGCGAGCAGCCATGATGGTGGGAATTCTGATTGGCGTGTTTGTGCTGTGCTGGATCCCCTTCTTCCTGACGGAACTCATCAGCCCACTCTGTGCCTGCAGCCTGCCCCCCATCTGGAAAAGCATATTTCTGTGGCTTGGCTACTCCAATTCTTTCTTCAACCCCCTGATTTACACAGCTTTTAACAAGAACTACAACAATGCCTTCAAGAGCCTCTTTACTAAGCAGAGATGAACACAGGGGTTAGANOV39c, CG54692-02SEQ ID NO: 478370 aaMW at 40215.7kDProtein SequenceMEAASLSVATAGVALALGPETSSGTPSPRGILGSTPSGAVLPGRGPPFSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPPSLASELSTGRRRLLGRSLCHVWISFDALCCPAGLGNVAAIALGRDGAITRHLQHTLRTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLPLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPATMQVKEAPDEAEVVFTAHCKATVSFQVSGDSWREQKERRAANMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGYSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39d, GG54692-03SEQ ID NO: 4791127 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1117ATGGAGGCCGCTAGCCTTTCAGTGGCCACCGCCGGCGTTGCCCTTGCCCTGGGACCCGAGACCAGCAGCGGGACCCCAAGCCCGAGAGGGATACTCGGTTCGACCCCGAGCGGCGCCGTCCTGCCGGGCCGAGGGCCGCCCTTCTCTGTCTTCACGGTCCTGGTGGTGACGCTGCTAGTGCTGCTGATCGCCGCCACTTTCCTGTGGAACCTGCTGGTTCCGGTCACCATCCCGCGGGTCCGTGCCTTCCACCGCGTGCCGCATAACTTGGTGGCCTCGACGGCCGTCTCGGACGAACTAGTGGCAGCGCTGGCGATGCCACCGAGCCTGGCGAGTGAGCTGTCGACCGGGCGACGTCGGCTGCTGGGCCGGAGCCTGTGCCACGTGTGGATCTCCTTCCACGGCCCACGGCTGTGCTGCCCCGCCGGCCTCGGGAACGTGGCGGCCATCGCCCTGGGCCGCGACGGGGCCATCACACGGCACCTGCAGCACACGCTGCGCACCCGCAGCCGCGCCTCGTTGCTCATGATCGCGCTCACCCGGGTGCCGTCGGCGCTCATCGCCCTCGCGCCGCTGCTCTTTGGCCGGGGCGAGGTGTGCGACGCTCGGCTCCAGCGCTGCCAGGTGAGCCGGGAACCCTCCTATGCCGCCTTCTCCACCCGCGGCGCCTTCCACCTGCCGCTTGGCGTGGTGCCGTTTGTCTACCGGAAGATCTACGAGGCGGCCAAGTTTCGTTTCGGCCGCCGCCGGAGAGCTGTGCTGCCGTTGCCGGCCACCATGCAGGTGAAGGAAGCACCTGATGAGGCTGAAGTGGTGTTCACGGCACATTGCAAAGCAACGGTGTCCTTCCAGGTGAGCGGGGACTCCTGGCGGGAGCAGAAGGAGAGGCGAGCAGCCATGATGGTGGGAATTCTGATTGGCGTGTTTGTGCTGTGCTGGATCCCCTTCTTCCTGACGGAACTCATCAGCCCACTCTGTGCCTGCAGCCTGCCCCCCATCTGGAAAAGCATATTTCTGTGGCTTGGCTACTCCAATTCTTTCTTCAACCCCCTGATTTACACAGCTTTTAACAAGAACTACAACAATGCCTTCAAGAGCCTCTTTACTAAGCAGAGATGAACACAGGGNOV39d, CG54692-03SEQ ID NO: 480372 aaMW at 40535.1kDProtein SequenceMEAASLSVATAGVALALGPETSSGTPSPRGILGSTPSGAVLPGRGPPFSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPPSLASELSTGRRRLLGRSLCHVWISFHGPRLCCPAGLGNVAAIALGRDGAITRHLQHTLRTRSRASLLMIALTRVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLPLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPATMQVKEAPDEAEVVFTAHCKATVSFQVSGDSWREQKERRAAMMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGYSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39e, GG54692-04SEQ ID NO: 4811155 bpDNA SequenceORF Start: ATG at 5ORF Stop: TGA at 1145CGCCATGGAGGCCGCTAGCCTTTCAGTGGCCACCGCCGGCGTTGCCCTTGCCCCCGAGACCAGCAGCCCGGCGTTGCCCTTGCCCTGGGACCCGAGACCAGCAGCAGGACCCGGGACCCCAAGCCCGAGAGGGATACTCGGTTCGACCCCGAGCGGCGCCGTCCTGCCGGGCCGAGGGCCGCCCTTCTCTGTCTTCACGGTCCTGGTGGTGACGCTGCTAGTGCTGCTGATCGCTGCCACTTTCCTGTGGAACCTGCTGGTTCCGGTCACCATCCCGCGGGTCCGTGCCTTCCACCGCGTGCCGCATAACTTGGTGGCCTCGACGGCCGTCTCGGACGAACTAGTGGCAGCGCTGGCGATGCCACCGAGCCTGGCGAGTGAGCTGTCGACCGGGCGACGTCGGCTGCTGGGCCGCCACGTGTGGATCTCCTTCGACGCCCTGTGCTGCCCCGCCGGCCTCGGGAACGTGGCGGCCATCGCCCTGGGCCGCGACGGGGCCATCACACGGCACCTGCAGCACACGCTGCGCACCCGCAGCCGCGCCTCGTTGCTCATGATCGCGCTCGCCCGGGTGCCGTCGGCGCTCATCGCCCTCGCGCCGCTGCTCTTTGGCCGGGGCGAGGTGTGCGACGCTCGGCTCCAGCGCTGCCAGGTGAGCCGGGAACCCTCCTATGCCGCCTTCTCCACCCGCGGCGCCTTCCACCTGCCGCTTGGCGTGGTGCCGTTTGTCTACCGGAAGATCTACGAGGCGGCCAAGTTTCGTTTCGGCCGCCGCCGGAGAGCTGTGCTGCCGTTGCCGGCCACCATGCAGGTGAAGGAAGCACCTGATGAGGCTGAAGTGGTGTTCACGGCACATTGCAAAGCAACGGTGTCCTTCCAGGTGAGCGGGGACTCCTGGCGGGAGCAGAAGGAGAGGCGAGCAGCCATGATGGTGGGAATTCTGATTGGCGTGTTTGTGCTGTGCTGGATCCCCTTCTTCCTGACGGAACTCATCAGCCCACTCTGTGCCTGCAGCCTGCCCCCCATCTGGAAAAGCATATTTCTGTGGCTTGGCTACTCCAATTCTTTCTTCAACCCCCTGATTTACACAGCTTTTAACAAGAACTACAACAATGCCTTCAAGAGCCTCTTTACTAAGCAGAGATGAACACAGGGNOV39e, CG54692-04SEQ ID NO: 482380 aaMW at 41306.9kDProtein SequenceMEAASLSVATAGVALAPETSSPALPLPWDPRPAAGPGTPSPRGILGSTPSGAVLPGRGPPFSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALANPPSLASELSTGRRRLLGRHVWISFDALCCPAGLGNVAAIALGRDGAITRHLQHTLRTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLPLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPATMQVKEAPDEAEVVFTAHCKATVSFQVSGDSWREQKERRAANMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGYSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39f, GG54692-05SEQ ID NO: 4831152 bpDNA SequenceORF Start: ATG at 5ORF Stop: TGA at 1142CGCCATGGAGGCCGCTAGCCTTTCAGTGGCCACCGCCGGCGTTGCCCTTGCCCTGGGACCCGAGACCAGCAGCGGACCCGGGACCCCAAGCCCGAGAGGGATACTCGGTTCGACCCCGAGCGGCGCCGTCCTGCCGGGCCGAGGGCCGCCCTTCTCTGTCTTCACGGTCCTGGTGGTGACGCTGCTAGTGCTGCTGATCGCTGCCACTTTCCTGTGGAACCTGCTGGTTCCGGTCACCATCCCGCGGGTCCGTGCCTTCCACCGCGTGCCGCATAACTTGGTGGCCTCGACGGCCGTCTCGGACGAACTAGTGGCAGCGCTGGCGATGCCACCGAGCCTGGCGAGTGAGCTGTCGACCGGGCGACGTCGGCTGCTGGGCCGGAGCCTGTGCCACGTGTGGATCTCCTTCGACGCCGGAGCCTGTCTGTGCTGCCCCGCCGGCCTCGGGAACGTGGCGGCCATCGCCCTGGGCCGCGACGGGGCCATCACACGGCACCTGCAGCACACGCTGCGCACCCGCAGCCGCGCCTCGTTGCTCATGATCGCGCTCGCCCGGGTGCCGTCGGCGCTCATCGCCCTCGCGCCGCTGCTCTTTGGCCGGGGCGAGGTGTGCGACGCTCGGCTCCAGCGCTGCCAGGTGAGCCGGGAACCCTCCTATGCCGCCTTCTCCACCCGCGGCGCCTTCCACCTGCCGCTTGGCGTGGTGCCGTTTGTCTACCGGAAGATCTACGAGGCGGCCAAGTTTCGTTTCGGCCGCCGCCGGAGAGCTGTGCTGCCGTTGCCGGCCACCATGCAGGTGAGGTCCAAGGTAAAGGAAGCACCTGATGAGGCTGAAGTGGTGTTCACGGCACATTGCAAAGCAACGGTGTCCTTCCAGGTGAGCGGGGACTCCTGGCGGGAGCAGAAGGAGAGGCGAGCAGCCATGATGGTGGGAATTCTGATTGGCGTGTTTGTGCTGTGCTGGATCCCCTTCTTCCTGACGGAACTCATCAGCCCACTCTGTGCCTGCAGCCTGCCCCCCATCTGGAAAAGCATATTTCTGTGGCTTGGCTACTCCAATTCTTTCTTCAACCCCCTGATTTACACAGCTTTTAACAAGAACTACAACAATGCCTTCAAGAGCCTCTTTACTAAGCAGAGATGAACACAGGGNOV39f, CG54692-05SEQ ID NO: 484379 aaMW at 41099.7kDProtein SequenceMEAASLSVATAGVALALGPETSSGPGTPSPRGILGSTPSGAVLPGRGPPFSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPPSLASELSTGRRRLLGRSLCHVWISFDAGACLCCPAGLGNVAAIALGRDGAITRHLQHTLRTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLPLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPATMQVRSKVKEAPDEAEVVFTAHCKATVSFOVSGDSWREQKERRAAMMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGYSNSFFNPLIYTAFNKNYNNAFKSLFTKQR

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 39B.

TABLE 39BComparison of the NOV39 protein sequences.NOV39a MEAASLSVATAGVALA-----------LGPETSSG--TPSPRGILGSTPSGAVLPGRGPPNOV39b MEAASLSVATAGVALA-----------LGPETSSG--TPSPRGILGSTPSGAVLPGRGPPNOV39c MEAASLSVATAGVALA-----------LGPETSSG--TPSPRGILGSTPSGAVLPGRGPPNOV39d MEAASLSVATAGVALA-----------LGPETSSG--TPSPRGILGSTPSGAVLPGRGPPNOV39e MEAASLSVATAGVAIAPETSSPALPLPWDPRPAAGPGTPSPRGILGSTPSGAVLPGRGPPNOV39f MEAASLSVATAGVALA-----------LGPETSSGPGTPSPRGILGSTPSGAVLPGRGPPNOV39a FSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPNOV39b FSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPNOV39c FSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPNOV39d FSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPNOV39e FSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALANPNOV39f FSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPNOV39a PSLASELSTGRRRLLGRSLCHVWISFDA---LCCPAGLGNVAAIALGRDGAITRHLQHTLNOV39b PSLASELSTGRRRLLGRSLCHVWISFDA---LCCPAGLGNVAAIALGRDGAITRHLQHTLNOV39c PSLASELSTGRRRLLGRSLCHVWISFDA---LCCPAGLGNVAAIALGRDGAITRHLQHTLNOV39d PSLASELSTGRRRLLGRSLCHVWISFHG-PRLCCPAGLGNVAAIALGRDGAITRHLQHTLNOV39e PSLASELSTGRRRLLGR---HVWISFDA---LCCPAGLGNVAAIALGRDGAITRHLQHTLNOV39f PSLASELSTGRRRLLGRSLCHVWISFDAGACLCCPAGLGNVAAIALGRDGAITRHLQHTLNOV39a RTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLNOV39b RTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLNOV39c RTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLNOV39d RTRSRASLLMIALTRVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLNOV39e RTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLNOV39f RTRSRASLLMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLNOV39a PLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPAT----MQVKEAPDEAEVVFTAHCKATVSNOV39b PLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPAT----SKVKEAPDEAEVVFTAHCKATVSNOV39c PLGVAPFVYRKIYEAAKFRFGRRRRAVLPLPAT----MQVKEAPDEAEVVFTAHCKATVSNOV39d PLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPAT----MQVKEAPDEAEVVFTAHCKATVSNOV39e PLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPAT----MQVKEAPDEAEVVFTAHCKATVSNOV39f PLGVVPFVYRKIYEAAKFRFGRRRRAVLPLPATMQVRSKVKEAPDEAEVVFTAHCKATVSNOV39a FQVSGDSWREQKERRAANMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGNOV39b FQVSGDSWREQKERRAAMMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGNOV39c FQVSGDSWREQKERRAAMMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGNOV39d FQVSGDSWREQKERRAAMMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGNOV39e FQVSGDSWREQKERRAANMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGNOV39f FQVSGDSWREQKERRAAMMVGILIGVFVLCWIPFFLTELISPLCACSLPPIWKSIFLWLGNOV39a YSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39b YSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39c YSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39d YSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39e YSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39f YSNSFFNPLIYTAFNKNYNNAFKSLFTKQRNOV39a (SEQ ID NO: 474)NOV39b (SEQ ID NO: 476)NOV39c (SEQ ID NO: 478)NOV39d (SEQ ID NO: 480)NOV39e (SEQ ID NO: 482)NOV39f (SEQ ID NO: 484)

Further analysis of the NOV39a protein yielded the following properties shown in Table 39C.

TABLE 39CProtein Sequence Properties NOV39aSignalP analysis:Cleavage site between residues 25 and 26PSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 2; pos.chg 0; neg.chg 1H-region: length 17; peak value 0.00PSG score: −4.40GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −4.24possible cleavage site: between 23 and 24>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 5INTEGRALLikelihood = 0.32Transmembrane 1-17INTEGRALLikelihood = −12.10Transmembrane 48-64INTEGRALLikelihood = −0.48Transmembrane 135-151INTEGRALLikelihood = −4.94Transmembrane 172-188INTEGRALLikelihood = −9.66Transmembrane 300-316PERIPHERALLikelihood = 0.69 (at 90)ALOM score: −12.10 (number of TMSs: 5)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 8Charge difference: 0.0 C(0.0) − N(0.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):3.56Hyd Moment(95):5.35G content:2D/E content:2S/T content:3Score: −7.53Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 95 HRV|PHNUCDISC: discrimination of nuclear localization signalspat4: RRRR (5) at 246pat7: nonebipartite: RKIYEAAKFRFGRRRRA at 234content of basic residues: 10.5%NLS Score: 0.50KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: FTKQSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):66.7%: endoplasmic reticulum22.2%: mitochondrial11.1%: nuclear>> prediction for CG54692-06 is end (k = 9)

A search of the NOV39a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 39D.

TABLE 39DGeneseq Results for NOV39aNOV39aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE18654Human G-protein coupled1 . . . 370 370/370 (100%)0.0receptor (GCREC-15) - Homo1 . . . 370 370/370 (100%)sapiens, 370 aa. [WO200210387-A2, 07-FEB-2002]AAM47212Human NOV5b protein - Homo1 . . . 370369/370 (99%)0.0sapiens, 370 aa. [WO200174851-1 . . . 370369/370 (99%)A2, 11-OCT-2001]AAM47211Human NOV5a protein - Homo1 . . . 370368/370 (99%)0.0sapiens, 370 aa. [WO200174851-1 . . . 370369/370 (99%)A2, 11-OCT-2001]AAE15638Human G-protein coupled1 . . . 370367/372 (98%)0.0receptor-8 (GCREC-8) protein -1 . . . 372367/372 (98%)Homo sapiens, 372 aa.[WO200198351-A2, 27-DEC-2001]ABB78809Human NOV5 protein sequence1 . . . 370370/379 (97%)0.0SEQ ID NO: 16 - Homo sapiens,1 . . . 379370/379 (97%)379 aa. [WO200230974-A2, 18-APR-2002]

In a BLAST search of public sequence databases, the NOV39a protein was found to have homology to the proteins shown in the BLASTP data in Table 39E.

TABLE 39EPublic BLASTP Results for NOV39aNOV39aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAD13088Sequence 11 from Patent1 . . . 370369/370 (99%)0.0WO0174851 - Homo sapiens1 . . . 370369/370 (99%)(Human), 370 aa.CAD13087Sequence 9 from Patent1 . . . 370368/370 (99%)0.0WO0174851 - Homo sapiens1 . . . 370369/370 (99%)(Human), 370 aa.P353655-hydroxytryptamine 5B receptor1 . . . 370296/370 (80%)e−165(5-HT-5B) (Serotonin receptor)1 . . . 370316/370 (85%)(MR22) - Rattus norvegicus(Rat), 370 aa.P313875-hydroxytryptamine 5B receptor1 . . . 370298/370 (80%)e−165(5-HT-5B) (Serotonin receptor) -1 . . . 370317/370 (85%)Mus musculus (Mouse), 370 aa.S38744serotonin receptor 5B - rat, 3691 . . . 370296/370 (80%)e−164aa.1 . . . 369316/370 (85%)

PFam analysis indicates that the NOV39a protein contains the domains shown in the Table 39F.

TABLE 39FDomain Analysis of NOV39aNOV39aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_169 . . . 351 75/314 (24%)1.2e−43197/314 (63%)

Example 40

The NOV40 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 40A.

TABLE 40ANOV40 Sequence AnalysisNOV40a, CG55069-01SEQ ID NO: 4858657 bpDNA SequenceORF Start: ATG at 151ORF Stop: TAA at 8326TTTGGCCTCGGGCCAGAATTCGGCACGAGGGGTCTGGAGCTTGGAGGAGAAGTCTGAACTAAGGATAAACTAAAGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTCCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGGTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAGAAGTTACCGCCTTCCCATACTCAGTCCTCCCCCCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAGCTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGGGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAGTTTAGTCACTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATGAAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCCGCTCACGCCCTGCCCACATTGTCCTGTGGCACAACCCGAGTGGGACTCTCCAACGCCCAAGAGCCTTCCTCCCGGGGGAATGAGACTGCTGTTACGACCCACACCCACACCGCGAAAACAAGGACCGCTTTTTTCCGAATGACCTTAAAGGTGATCGGCTTTAACGAATATGTTTACATATGCATAGCGCTGCACTCAGTCGGACTGAACGTAGCCAGAGGAAAAAAAAATCATCAAGGACAAAGGCCTCGACCTGTTGCGCTGGGCCGTCTGTTCCTTCTAGGCACTGTATTTAACTAACTTTANOV40a, CG55069-01SEQ ID NO: 4862725 aaMW at 303959.6kDProtein SequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIANHLFGLNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKKLPPSHTQSSPQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACSSGYKGESCEEADCIDPGCSNHGVCINGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQANGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNNTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGALALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRNOV40b, CG55069-04SEQ ID NO: 4871783 bpDNA SequenceORF Start: at 7ORF Stop: at 778AAGCTTTGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTCGACNOV40b, CG55069-04SEQ ID NO: 488257 aaMW at 26866.7kDProtein SequenceCPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIEGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDNOV40c, 248993047SEQ ID NO: 4892448 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGTACCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCTTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGAGGGTTGTCCTGGTCTGTCCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTcTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCGTCGACNOV40c, 248993047SEQ ID NO: 490816 aaMW at 89174.1kDProtein SequenceGTNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIEGCPGLSNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSVDNOV40d, 262802488SEQ ID NO: 4912519 bpDNA SequenceORF Start: at 1ORF Stop: TAG at 2515GGTACCAACTGGCAGCTACAGCAGACTGAAAATGACGCATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGCCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGCGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGGCATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCGTCGACCCAGCAGCCTCCAGTCGTGAGTAGCGNOV40d, 262802488SEQ ID NO: 492838 aaMW at 91545.9kDProtein SequenceGTNWQLQQTENDAFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSNTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIvIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCINGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGWHCACQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQGIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNNGGWTLDKMHVLDVQNGILYKGNGENQFISQQPPVVSSVDPAASSRENOV40e, 248993606SEQ ID NO: 4932536 bpDNA SequenceORF Start: at 1ORF Stop: at 2536GGTACCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCTTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGTAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCGTCGACGCTACACACGACTGGAGGCTGCTGGTCATTTTCAGCTCTGCAGTAGCTGCCAGTTGGTACCNOV40e, 248993606SEQ ID NO: 494845 aaMW at 92534.0kDProtein SequenceGTNWQLQQTENDTFENGKVNSDTNPTNTVSLPSGDNGKIGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKEGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGNFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSVDATHDWRLLVIFSSAVAASWYNOV40f, 314411758SEQ ID NO: 4952500 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCAAGCTTAACTGGCAGCTACAGCAGACTGAAAATGACGCATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGCCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGCGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGGCATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCCTCGAGGGCNOV40f, 314411758SEQ ID NO: 496833 aaMW at 91116.5kDProtein SequenceTKLNWQLQQTENDAFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGWHCACQPGWRGAGCDVANETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQGIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNNGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSLEGNOV40g, 319067006SEQ ID NO: 497730 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCTCGCGAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCAGCAGCGCGTGCGCGACGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGGTCGACGGCNOV40g, 319067006SEQ ID NO: 498243 aaMW at 27175.5kDProtein SequenceTSRTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGALALHVRYGMTLDEEKARILEQAQQRVRDGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRVDGNOV40h, 319506086SEQ ID NO: 4991178 bpDNA SequenceORF Start: at 78ORF Stop: end of sequenceCACCTCGCGACCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGOCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCCTCGAGGGCNOV40h, 319506086SEQ ID NO: 500367 aaMW at 40968.5kDProtein SequenceSMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIALEGNOV40i, CG55069-03SEQ ID NO: 5018473 bpDNA SequenceORF Start: ATG at 258ORF Stop: TAA at 8142TTGACAGAAAAAGGCAGTAAACGGGGAATCTCTTTTTTTGAATAAAGAAGAAGAAGAAATAAAGTACCTGTCATCTTGACAAGTGGCGGAGCGGAGGAGTCAAGGATTATAAATGATCACAGCCAGGTCCAGCTCGCCCCGTGATTGGGCTCTCCCGCGATCTGCACCGGGGGAAGCGCATGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCTTGTGCTTGCAACTCAGGATACAAAGGAAAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGGGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAAGTTTAGTGCTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATGAAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCCGCTCACGCCCTGCCCACATTGTCCTGTGGCACAACCCGAGTGGGACTCTCCAACGCCCAAGAGCCTTCCTCCCGGGGGAATGAGACTGCTGTTACGACCCACACCCACACCGCGAAAACAAGGACCGCTTTTTTCCGAATGACCTTAAAGGTGATCGGCTTTAACGAATATGTTTACATATGCATAGCGCTGCACTCAGTCGGACTGAACGTAGCCAGAGGAAAAAAAAATCATCAAGGACAAAGGCCTCGACCTGTTGCGCTGGGCCGTCTGTTCCTTCTAGGCACTGTATTTAACTAACTTTANOV40i, CG55069-03SEQ ID NO: 5022628 aaMW at 293503.3kDProtein SequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIANHLFGLNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKMAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGKSCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVANETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNNGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSMSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNWAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGALALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRNOV40j, 219937039SEQ ID NO: 5031854 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTATGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGTTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATGTCGACNOV40j, 219937039SEQ ID NO: 504618 aaMW at 68016.2kDProtein SequenceKLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKMHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVDNOV40k, 219937046SEQ ID NO: 5051854 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGTTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAGTGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGCGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTATGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTCGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGTTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATGTCGACNOV40k, 219937046SEQ ID NO: 506618 aaMW at 67935.1kDProtein SequenceKLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVASGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHALDVQNGILYKGNGENQFISQQPPVVSSINGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDSTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVDNOV40l, 219937583SEQ ID NO: 5071834 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceTAAGCTTGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTATGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGTTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATGTCGACNOV40l, 219937583SEQ ID NO: 508611 aaMW at 67062.2kDProtein SequenceKLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVASGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHALDVQNGILYKGNGENQFISQQPPVVSSINGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDSTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVDNOV40m, 219937000SEQ ID NO: 5091833 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTATGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGTTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATGTCGACNOV40m, 219937000SEQ ID NO: 510611 aaMW at 67062.2kDProtein SequenceKLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPMLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVAIACGIDGSLYVGDFNYVRRIFPSGNVTSVLELSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVDNOV40n, 219937005SEQ ID NO: 5111833 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTATGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGTTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATGTCGACNOV40n, 219937005SEQ ID NO: 512611 aaMW at 67062.2kDProtein SequenceKLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPMLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVAIACGIDGSLYVGDFNYVRRIFPSGNVTSVLELSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVDNOV40o, 219937013SEQ ID NO: 5131833 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTATGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGTTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATGTCGACNOV40o, 219937013SEQ ID NO: 514611 aaMW at 67034.1kDProtein SequenceKLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPMLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVAIACGIDGSLYVGDFNYVRRIFPSGNVTSVLELSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVDNOV40p,219937063SEQ ID NO: 5151833 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTATGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGTTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATGTCGACNOV40p, 219937063SEQ ID NO: 516611 aaMW at 67026.1kDProtein SequenceKLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPMLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVAIACGIDGSLYVGDFNYVRRIFPSGNVTSVLELSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVDNOV40q, GG55069-09SEQ ID NO: 5172536 bpDNA SequenceORF Start: at 7ORF Stop: at 2470GGTACCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCTTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGTAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCGTCGACGCTACACACGACTGGAGGCTGCTGGTCATTTTCAGCTCTGCAGTAGCTGCCAGTTGGTACCNOV40q, CG55069-09SEQ ID NO: 518821 aaMW at 89886.1kDProtein SequenceNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKEGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQOPPVVSSNOV40r, 309327410SEQ ID NO: 5192482 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCTCGCGAAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCTTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGTAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCCTCGAGGGCNOV40r, 309327410SEQ ID NO: 520827 aaMW at 90529.8kDProtein SequenceTSRNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKIGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKEGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSLEGNOV40s, CG55069-02SEQ ID NO: 5218645 bpDNA SequenceORF Start: ATG at 151ORF Stop: TAA at 8314TTTGGCCTCGGGCCAGAATTCGGCACGAGGGGTCTGGAGCTTGGAGGAGAAGTCTGAACTAAGGATAAACTAAAGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTCCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGGTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAGCTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGGGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAGTTTAGTCACTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATGAAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCCGCTCACGCCCTGCCCACATTGTCCTGTGGCACAACCCGAGTGGGACTCTCCAACGCCCAAGAGCCTTCCTCCCGGGGGAATGAGACTGCTGTTACGACCCACACCCACACCGCGAAAACAAGGACCGCTTTTTTCCGAATGACCTTAAAGGTGATCGGCTTTAACGAATATGTTTACATATGCATAGCGCTGCACTCAGTCGGACTGAACGTAGCCAGAGGAAAAAAAAATCATCAAGGACAAAGGCCTCGACCTGTTGCGCTGGGCCGTCTGTTCCTTCTAGGCACTGTATTTAACTAACTTTANOV40s, CG55069-02SEQ ID NO: 5222721 aaMW at 303489.1kDProtein SequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENEQPASNQGQSTLQPLPPSHKQHSAQHNPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACSSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNNGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGALALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRNOV40t, CG55069-05SEQ ID NO: 523810 bpDNA SequenceORF Start: at 7ORF Stop: at 805AAGCTTTGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCTTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTCGACNOV40t, GG55069-05SEQ ID NO: 524266 aaMW at 27935.0kDProtein SequenceCPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKEGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDNOV40u, CG55069-06SEQ ID NO: 5258204 bpDNA SequenceORF Start: ATG at 4ORF Stop: TAA at 8179AGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTCCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGGTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAGAAGTTACCGCCTTCCCATACTCAGTCCTCCCCCCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAGCTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGGGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAGTTTAGTCACTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATGAAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCNOV40u, CG55069-06SEQ ID NO: 5262725 aaMW at 303959.6kDProtein SequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENEQPASNOGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIANHLFGLNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKKLPPSHTQSSPQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFThDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACSSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISOSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRNPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNNTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTNQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIOYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGALALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRNOV40v, CG55069-07SEQ ID NO: 5271833 bpDNA SequenceORF Start: at 7ORF Stop: at 1828AAGCTTGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTATGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGTTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATGTCGACNOV40v, GG55069-07SEQ ID NO: 528607 aaMW at 66606.6kDProtein SequenceDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGOVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNOV40w, CG55069-08SEQ ID NO: 5298487 bpDNA SequenceORF Start: ATG at 299ORF Stop: TAA at 8138ACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTCCCATTTGACAGAAAAAGGCAGTAAACGGGGAATCTCTTTTTTTGAATAAAGAAGAAGAAGAAATAAAGTACCTGTCATCTTGACAAGTGGCGGAGCGGAGGAGTCAAGGATTATAAATGATCACAGCCAGGTCCAGCTCGCCCCGTGATTGGGCTCTCCCGCGATCTGCACCGGGGGAAGCGCATGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAACCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCATGGCTGGAATGGAGAGCACTGCACTATCGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAGTTTAGTCACTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATAGAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCCGCTCACGCCCTGCCCACATTGTCCTGTGGCACAACCCGAGTGGGACTCTCCAACGCCCAAGAGCCTTCCTCCCGGGGGAATGAGACTGCTGTTACGACCCACACCCACACCGCGAAAACAAGGACCGCTTTTTTCCGAATGACCTTAAAGGTGATCGGCTTTAACGAATATGTTTACATATGCATAGCGCTGCACTCAGTCGGACTGAACGTAGCCAGAGGAAAAAAAAATCATCAAGGACAAAGGCCTCGACCTGTTGCGCTGGGCCGTCTGTTCCTTCTAGGCACTGTATTTAACTAACTTTAAAAAAAAAAAAAAAAAAGNOV40w, CG55069-08SEQ ID NO: 5302613 aaMW at 291899.4kDProtein SequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPTCNQRACHPRCAEHGTCKDGKCECSHGWNGEHCTIEGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNNTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKINWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFANEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLMIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGALALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRNOV40x, CG55069-10SEQ ID NO: 5312519 bpDNA SequenceORF Start: at 7ORF Stop: at 2488GGTACCAACTGGCAGCTACAGCAGACTGAAAATGACGCATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGCCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGCGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGGCATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCGTCGACCCAGCAGCCTCCAGTCGTGAGTAGCGNOV40x, GG55069-10SEQ ID NO: 532827 aaMW at 90474.8kDProtein SequenceNWQLQQTENDAFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGWHCACQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQGIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSPAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQMGILYKGNGENQFISQQPPVVSSNOV40y, CG55069-11SEQ ID NO: 5332482 bpDNA SequenceORF Start: at 11ORF Stop: at 2474CACCTCGCGAAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCTTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGTAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCCTCGAGGGCNOV40y, CG55069-11SEQ ID NO: 534821 aaMW at 89886.1kDProtein SequenceNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGMGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKEGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSNOV40z, CG55069-12SEQ ID NO: 5352500 bpDNA SequenceORF Start: at 11ORF Stop: at 2492CACCAAGCTTAACTGGCAGCTACAGCAGACTGAAAATGACGCATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGCCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGCGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGGCATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCCTCGAGGGCNOV40z, CG55069-12SEQ ID NO: 536827 aaMW at 90474.8kDProtein SequenceNWQLQQTENDAFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGWHCACQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQGIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSNOV40aa, CG55069-13SEQ ID NO: 5372541 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAG at 2530CACCGCGGCCGCACCATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCGAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCQGAAAGGCTTACCGCCTTCCCATACTCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTCTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCTTGTGCTTGCAACTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCTGGCATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGTAAGGACAATGAAGGAGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGAAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCTAGGTCGACGGCNOV40aa, GG55069-13SEQ ID NO: 538838 aaMW at 91589.1kDProtein SequenceMLPGLALLLLAAWTARANWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGSIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGMGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKEGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSNOV40ab, CG55069-14SEQ ID NO: 5391755 bpDNA SequenceORF Start: ATG at 890ORF Stop: TAA at 1532GAGAAAGGAGATTAAAAATAACCTCTGGATATTCCTCTCATGTGATCTTTATTCTGGATGAAGCATTAGGACAGCTAATAGCCGTGTGTCACTGTGTGATTTCTTCCCTAAGACTAAGGACCCATCATTTTAGTGCAACCTTCTTCATTTAAATGGAGAGTTGTAATTGCCAATGCTCACAGCTACTCCTGCTCCGGCAATTTGCTGCCAGAAGTGTGTTTTCCTTTTTAAAAGGCAGTAAATTCAAGATGTTGTGGTGGATGTAGATTTTTGCTGCAAGGAAATAACAGCTGGTGATGGAATTTCATTCTTTTGACTTCTAGATTGCCTGTGAAGAGCTGCTTCCTCGGAAGAGCACCCTAAGGCTGGGTGGCCACTATCCTTTGCCTTGGCAGAGCCAGCCAGAAGGCCTAGGCACAACCCGCTGTGTTTGCTGACAGCCAACCTACCCTGGAGTTCCGGAGCGGCTTCCTAGGAAGACTGGGGAGCGGTAGAAAAATGGCTCTGCTGAGATGAGCTCTTAATTAATGCACTGAGAGCCTGCAAGTCCCACCTCTCAACAGGAATGATTGACGTCCAAGGATACATAAATTACACTAACTGAGCTCTGCCTCTATATAAGCTTTCCACATCCAACTCATCAGAGAAGCTAGGCTTGTACCATAACCAATACCCCTGCTTGGCAACTCTAATGAGCAAACTGCCGCAAAATTGAGAGAGAACACACCTTTTTGATTTCCTGCTCTTCTAAGACACAGTGATTTAGAATTTCTGTTCAAGCAAGAGAACTAAAGACTTCTTTAAAGAAGAGAAGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACACAACTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTCCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGTTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGGAGGGTCAAGCAGTTGGTTCGGTTTTCATTGGAATTTTTATGTGAGTAAAGCTTCCTGTTTGCTGCGCTTGCCTAGGATTTTCTTATCCCACAACTACAATGTGAACAAAGAGATGAGAGAGAAATTATGCTAATGCATTTTGGTGGATCAAATGAGTGTTTCATGAGACAACTCAAATTTTTGTTAGCTATATGGTGTTGGAATATAATTTCAAAGACAACTAAGCCCTAAAATAGGAGATTTATTTAAAACATAACTTTTCCTTGAATGAAAGGATGTTTTTGTTCTTTCTCTGACAAATATGATTTGAGAATAAAAGACCTGCCCGGGCAGCCGCTCGAGCCCTATAGTGAGNOV40ab, CG55069-14SEQ ID NO: 540214 aaMW at 24449.8kDProtein SequenceMDVKERRPYCSLTKSRREEKRRYTNSSADNEECRVPTHNSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPERAMRLWGRGFKSGRSSCLSSRSNSALTLTDTEHENKSDSENGGSSSWFGFHWNFYVSKASCLLRLPRIFLSHNYNVNKEMREKLCNOV40ac, CG55069-15SEQ ID NO: 541768 bpDNA SequenceORF Start: ATG at 65ORF Stop: TAA at 707AGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTCCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGGTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGGAGGGTCAAGCAGTTGGTTCGGTTTTCATTGGAATTTTTATGTGGGTAAAGCTTCCTGTTTGCTGCGCTTGCCTAGGATTTTCTTATCCCACAACTACAATGTGAACAAAGAGATGAGAGAGAAATTATGCTAATGCATTTTGGTGGATCAATGCTAATGCATTTTGGTGGATCAATGCTAATGCATTTTGGTNOV40ac, CG55069-15SEQ ID NO: 542214 aaMW at 24376.8kDProtein SequenceMDVKERRPYCSLTKSRREEKRRYTNSSADNEECRVPTHNSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPERAMRLWGRGFKSGRSSCLSSRSNSALTLTDTEHENKSDSENGGSSSWFGFHWNFYVSKASCLLRLPRIFLSHNYNVNKEMREKLCNOV40ad, SNP13374479 ofSEQ ID NO: 5438657 bpCG55069-01, DNA SequenceORF Start: ATG at 151ORF Stop: TAA at 8326SNP Pos: 465SNP Change: C to TTTTGGCCTCGGGCCAGAATTCGGCACGAGGGGTCTGGAGCTTGGAGGAGAAGTCTGAACTAAGGATAAACTAAAGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTTCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGGTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAGAAGTTACCGCCTTCCCATACTCAGTCCTCCCCCCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAGCTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGTATCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGGGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCAGGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAGTTTAGTCACTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATGAAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCCGCTCACGCCCTGCCCACATTGTCCTGTGGCACAACCCGAGTGGGACTCTCCAACGCCCAAGAGCCTTCCTCCCGGGGGAATGAGACTGCTGTTACGACCCACACCCACACCGCGAAAACAAGGACCGCTTTTTTCCGAATGACCTTAAAGGTGATCGGCTTTAACGAATATGTTTACATATGCATAGCGCTGCACTCAGTCGGACTGAACGTAGCCAGAGGAAAAAAAAATCATCAAGGACAAAGGCCTCGACCTGTTGCGCTGGGCCGTCTGTTCCTTCTAGGCACTGTATTTAACTAACTTTANOV40ad, SNP13374479 ofSEQ ID NO: 5442725 aaMW at 303959.6kDCG55069-01, ProteinSNP Pos: 105SNP Change: Leu to LeuSequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLMWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKKLPPSHTQSSPQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACSSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNOPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGAIALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRNOV40ae, SNP13382453 ofSEQ ID NO: 5458657 bpCG55069-01, DNA SequenceORF Start: ATG at 151ORF Stop: TAA at 8326SNP Pos: 973SNP Change: T to CTTTGGCCTCGGGCCAGAATTCGGCACGAGGGGTCTGGAGCTTGGAGGAGAAGTCTGAACTAAGGATAAACTAAAGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTCCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGGTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCACCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAGAAGTTACCGCCTTCCCATACTCAGTCCTCCCCCCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAGCTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGThTCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGGGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAGTTTAGTCACTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATGAAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCCGCTCACGCCCTGCCCACATTGTCCTGTGGCACAACCCGAGTGGGACTCTCCAACGCCCAAGAGCCTTCCTCCCGGGGGAATGAGACTGCTGTTACGACCCACACCCACACCGCGAAAACAAGGACCGCTTTTTTCCGAATGACCTTAAAGGTGATCGGCTTTAACGAATATGTTTACATATGCATAGCGCTGCACTCAGTCGGACTGAACGTAGCCAGAGGAAAAAAAAATCATCAAGGACAAAGGCCTCGACCTGTTGCGCTGGGCCGTCTGTTCCTTCTAGGCACTGTATTTAACTAACTTTANOV40ae, SNP13382453 ofSEQ ID NO: 5462725 aaMW at 303969.7kDCG55069-01, ProteinSNP Pos: 275SNP Change: Ser to ProSequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMAPGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLMWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKKLPPSHTQSSPQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACSSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNOPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGAIALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRNOV40af, SNP13382454 ofSEQ ID NO: 5478657 bpCG55069-01, DNA SequenceORF Start: ATG at 151ORF Stop: TAA at 8326SNP Pos: 1953SNP Change: C to TTTTGGCCTCGGGCCAGAATTCGGCACGAGGGGTCTGGAGCTTGGAGGAGAAGTCTGAACTAAGGATAAACTAAAGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTCCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGGTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAGAAGTTACCGCCTTCCCATACTCAGTCCTCCCCCCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCTTGTGCTTGCAGCTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGThTCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGGGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAGTTTAGTCACTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATGAAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCCGCTCACGCCCTGCCCACATTGTCCTGTGGCACAACCCGAGTGGGACTCTCCAACGCCCAAGAGCCTTCCTCCCGGGGGAATGAGACTGCTGTTACGACCCACACCCACACCGCGAAAACAAGGACCGCTTTTTTCCGAATGACCTTAAAGGTGATCGGCTTTAACGAATATGTTTACATATGCATAGCGCTGCACTCAGTCGGACTGAACGTAGCCAGAGGAAAAAAAAATCATCAAGGACAAAGGCCTCGACCTGTTGCGCTGGGCCGTCTGTTCCTTCTAGGCACTGTATTTAACTAACTTTANOV40af, SNP13382454 ofSEQ ID NO: 5482725 aaMW at 303959.6kDCG55069-01, ProteinSNP Pos: 601SNP Change: Ser to SerSequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLMWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKKLPPSHTQSSPQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACSSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNOPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGAIALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRNOV40ag, SNP13382455 ofSEQ ID NO: 5498657 bpCG55069-01, DNA SequenceORF Start: ATG at 151ORF Stop: TAA at 8326SNP Pos: 2559SNP Change: C to TTTTGGCCTCGGGCCAGAATTCGGCACGAGGGGTCTGGAGCTTGGAGGAGAAGTCTGAACTAAGGATAAACTAAAGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTCCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGGTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAGAAGTTACCGCCTTCCCATACTCAGTCCTCCCCCCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAGCTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGThTCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGTAAGGACAATGAAGGGGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAGTTTAGTCACTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATGAAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTCAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCCGCTCACGCCCTGCCCACATTGTCCTGTGGCACAACCCGAGTGGGACTCTCCAACGCCCAAGAGCCTTCCTCCCGGGGGAATGAGACTGCTGTTACGACCCACACCCACACCGCGAAAACAAGGACCGCTTTTTTCCGAATGACCTTAAAGGTGATCGGCTTTAACGAATATGTTTACATATGCATAGCGCTGCACTCAGTCGGACTGAACGTAGCCAGAGGAAAAAAAAATCATCAAGGACAAAGGCCTCGACCTGTTGCGCTGGGCCGTCTGTTCCTTCTAGGCACTGTATTTAACTAACTTTANOV40ag, SNP13382455 ofSEQ ID NO: 5502725 aaMW at 303959.6kDCG55069-01, ProteinSNP Pos: 803SNP Change: Ser to SerSequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLMWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKKLPPSHTQSSPQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACSSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNOPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGAIALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRNOV40ah, SNP13378354 ofSEQ ID NO: 5518657 bpCG55069-01, DNA SequenceORF Start: ATG at 151ORF Stop: TAA at 8326SNP Pos: 7770SNP Change: C to TTTTGGCCTCGGGCCAGAATTCGGCACGAGGGGTCTGGAGCTTGGAGGAGAAGTCTGAACTAAGGATAAACTAAAGAGAGGCCAATGAGACTTGAACCCTGAGCCTAAGTTGTCACCAGCAGGACTGATGTGCACACAGAAGGAATGAAGTATGGATGTGAAAGAACGCAGGCCTTACTGCTCCCTGACCAAGAGCAGACGAGAGAAGGAACGGCGCTACACAAATTCCTCCGCAGACAATGAGGAGTGCCGGGTACCCACACAGAAGTCCTACAGTTCCAGCGAGACATTGAAAGCTTTTGATCATGATTCCTCGCGGCTGCTTTACGGCAACAGAGTGAAGGATTTGGTTCACAGAGAAGCAGACGAGTTCACTAGACAAGGACAGAATTTTACCCTAAGGCAGTTAGGAGTTTGTGAACCAGCAACTCGAAGAGGACTGGCATTTTGTGCGGAAATGGGGCTCCCTCACAGAGGTTACTCTATCAGTGCAGGGTCAGATGCTGATACTGAAAATGAAGCAGTGATGTCCCCAGAGCATGCCATGAGACTTTGGGGCAGGGGGGTCAAATCAGGCCGCAGCTCCTGCCTGTCAAGTCGGTCCAACTCAGCCCTCACCCTGACAGATACGGAGCACGAAAACAAGTCCGACAGTGAGAATGAGCAACCTGCAAGCAATCAAGGCCAGTCTACCCTGCAGCCCTTGCCGCCTTCCCATAAGCAGCACTCTGCACAGCATCATCCATCCATCACTTCTCTCAACAGAAACTCCCTGACCAATAGAAGGAACCAGAGTCCGGCCCCGCCGGCTGCTTTGCCCGCCGAGCTGCAAACCACACCCGAGTCCGTCCAGCTGCAGGACAGCTGGGTCCTTGGCAGTAATGTACCACTGGAAAGCAGGCATTTCCTATTCAAAACAGGAACAGGTACAACGCCACTGTTCAGTACTGCAACCCCAGGATACACAATGGCATCTGGCTCTGTTTATTCACCACCTACTCGGCCACTACCTAGAAACACCCTATCAAGAAGTGCTTTTAAATTCAAGAAGTCTTCAAAGTACTGTAGCTGGAAATGCACTGCACTGTGTGCCGTAGGGGTCTCGGTGCTCCTGGCAATACTCCTGTCTTATTTTATAGCAATGCATCTCTTTGGCCTCAACTGGCAGCTACAGCAGACTGAAAATGACACATTTGAGAATGGAAAAGTGAATTCTGATACCATGCCAACAAACACTGTGTCATTACCTTCTGGAGACAATGGAAAATTAGGTGGATTTACGCAAGAAAATAACACCATAGATTCCGGAGAACTTGATATTGGCCGAAGAGCAATTCAAGAGATTCCTCCCGGGATCTTCTGGAGATCACAGCTCTTCATTGATCAGCCACAGTTTCTTAAATTCAATATCTCTCTTCAGAAGGATGCATTGATTGGAGTATATGGCCGGAAGAAGTTACCGCCTTCCCATACTCAGTCCTCCCCCCAGTATGACTTCGTGGAGCTCCTGGATGGCAGCAGGCTGATTGCCAGAGAGCAGCGGAGCCTGCTTGAGACGGAGAGAGCCGGGCGGCAGGCGAGATCCGTCAGCCTTCATGAGGCCGGCTTTATCCAGTACTTGGATTCTGGAATCTGGCATCTGGCTTTTTATAATGATGGGAAAAATGCAGAGCAGGTGTCTTTTAATACCATTGTTATAGAGTCTGTGGTGGAATGTCCCCGAAATTGCCATGGAAATGGAGAATGCGTTTCTGGAACTTGCCATTGTTTTCCAGGATTTCTGGGTCCGGATTGTTCAAGAGCCGCCTGTCCAGTGTTATGTAGTGGCAACGGGCAGTACTCCAAGGGCCGCTGCCTGTGTTTCAGCGGCTGGAAGGGCACCGAGTGTGATGTGCCGACTACCCAGTGTATTGACCCACAGTGTGGGGGTCGTGGGATTTGTATCATGGGCTCCTGTGCTTGCAGCTCAGGATACAAAGGAGAAAGTTGTGAAGAAGCTGACTGTATAGACCCTGGGTGTTCTAATCATGGTGTGTGTATCCACGGGGAATGTCACTGCAGTCCAGGATGGGGAGGTAGCAATTGTGAAATACTGAAGACCATGTGTCCAGACCAGTGCTCCGGCCACGGAACGThTCTTCAAGAAAGTGGCTCCTGCACGTGTGACCCTAACTGGACTGGCCCAGACTGCTCAAACGAAATATGTTCTGTGGACTGTGGCTCACACGGCGTTTGCATGGGGGGGACGTGTCGCTGTGAAGAAGGCTGGACGGGCCCAGCCTGTAATCAGAGAGCCTGCCACCCCCGCTGTGCCGAGCACGGGACCTGCAAGGATGGCAAGTGTGAATGCAGCCAGGGCTGGAATGGAGAGCACTGCACTATCGCTCACTATTTGGATAAGATAGTTAAAGACAAGATAGGATATAAAGAGGGTTGTCCTGGTCTGTGCAACAGCAATGGAAGATGTACCCTGGACCAAAATGGCGGACATTGTGTGTGCCAGCCTGGATGGAGAGGAGCAGGCTGTGACGTAGCCATGGAGACTCTTTGCACAGATAGCAAGGACAATGAAGGGGATGGACTCATTGACTGCATGGATCCCGATTGCTGCCTACAGAGTTCCTGCCAGAATCAGCCCTATTGTCGGGGACTGCCGGATCCTCAGGACATCATTAGCCAAAGCCTTCAATCGCCTTCTCAGCAAGCTGCCAAATCCTTTTATGATCGAATCAGTTTCCTTATAGGATCTGATAGCACCCATGTTATACCTGGAGAAAGTCCTTTCAATAAGAGCCTTGCATCTGTCATCAGAGGCCAAGTACTGACTGCTGATGGAACTCCACTTATTGGAGTAAATGTCTCGTTTTTCCATTACCCAGAATATGGATATACTATTACCCGCCAGGACGGAATGTTTGACTTGGTGGCAAATGGTGGGGCCTCTCTAACTTTGGTATTTGAACGATCCCCATTCCTCACTCAGTATCATACTGTGTGGATTCCATGGAATGTCTTTTATGTGATGGATACCCTAGTCATGGAGAAAGAAGAGAATGACATTCCCAGCTGTGATCTGAGTGGATTCGTGAGGCCAAATCCCATCATTGTGTCATCACCTTTATCCACCTTTTTCAGATCTTCTCCTGAAGACAGTCCCATCATTCCCGAAACACAGGTACTCCACGAGGAAACTACAATTCCAGGAACAGATTTGAAACTCTCCTACTTGAGTTCCAGAGCTGCAGGGTATAAGTCAGTTCTCAAGATCACCATGACCCAGTCTATTATTCCATTTAATTTAATGAAGGTTCATCTTATGGTAGCTGTAGTAGGAAGACTCTTCCAAAAGTGGTTTCCTGCCTCACCAAACTTGGCCTATACTTTCATATGGGATAAAACAGATGCATATAATCAGAAAGTCTATGGTCTATCTGAAGCTGTTGTGTCAGTTGGATATGAGTATGAGTCGTGTTTGGACCTGACTCTGTGGGAAAAGAGGACTGCCATTCTGCAGGGCTATGAATTGGATGCGTCCAACATGGGTGGCTGGACATTAGATAAACATCACGTGCTGGATGTACAGAACGGTATACTGTACAAGGGAAACGGGGAAAACCAGTTCATCTCCCAGCAGCCTCCAGTCGTGAGTAGCATCATGGGCAATGGGCGAAGGCGCAGCATTTCCTGCCCCAGTTGCAATGGTCAAGCTGATGGTAACAAGTTACTGGCCCCAGTGGCGCTAGCTTGTGGGATCGATGGCAGTCTGTACGTAGGCGATTTCAACTACGTGCGGCGGATATTCCCTTCTGGAAATGTAACAAGTGTCTTAGAACTAAGAAATAAAGATTTTAGACATAGCAGCAACCCAGCTCATAGATACTACCTTGCAACGGATCCAGTCACGGGAGATCTGTACGTTTCTGACACAAACACCCGCAGAATTTATCGCCCAAAGTCACTTACGGGGGCAAAAGACTTGACTAAAAATGCAGAAGTCGTCGCAGGGACAGGGGAGCAATGCCTTCCGTTTGACGAGGCGAGATGTGGGGATGGAGGGAAGGCCGTGGAAGCCACACTCATGAGTCCCAAAGGAATGGCAGTTGATAAGAATGGATTAATCTACTTTGTTGATGGAACCATGATTAGGAAAGTTGACCAAAATGGAATCATATCAACTCTTCTGGGCTCTAACGATTTGACTTCAGCCAGACCTTTAACTTGTGACACCAGCATGCACATCAGCCAGGTACGTCTGGAATGGCCCACTGACCTAGCCATTAACCCTATGGATAACTCCATTTATGTCCTGGATAATAATGTAGTTTTACAGATCACTGAAAATCGTCAAGTTCGCATTGCTGCTGGACGGCCCATGCACTGTCAGGTTCCCGGAGTGGAATATCCTGTGGGGAAGCACGCGGTGCAGACAACACTGGAATCAGCCACTGCCATTGCTGTGTCCTACAGTGGGGTCCTGTACATTACTGAAACTGATGAGAAGAAAATTAACCGGATAAGGCAGGTCACAACAGATGGAGAAATCTCCTTAGTGGCCGGAATACCTTCAGAGTGTGACTGCAAAAATGATGCCAACTGTGACTGTTACCAGAGTGGAGATGGCTACGCCAAGGATGCCAAACTCAGTGCCCCATCCTCCCTGGCTGCTTCTCCAGATGGTACACTGTATATTGCAGATCTAGGGAATATCCGGATCCGGGCTGTGTCAAAGAATAAGCCTTTACTTAACTCTATGAACTTCTATGAAGTTGCGTCTCCAACTGATCAAGAACTCTACATCTTTGACATCAATGGTACTCACCAATATACTGTAAGTTTAGTCACTGGTGATTACCTTTACAATTTTAGCTACAGCAATGACAATGATATTACTGCTGTGACAGACAGCAATGGCAACACCCTTAGAATTAGACGGGACCCAAATCGCATGCCAGTTCGAGTGGTGTCTCCTGATAACCAAGTGATATGGTTGACAATAGGAACAAATGGATGTTTGAAAGGCATGACTGCTCAAGGACTGGAATTAGTTTTGTTTACTTACCATGGCAATAGTGGCCTTTTAGCCACTAAAAGTGATGAAACTGGATGGACAACGTTTTTTGACTATGACAGTGAAGGTCGTCTGACAAATGTTACGTTTCCAACTGGAGTGGTCACAAACCTGCATGGGGACATGGACAAGGCTATCACAGTGGACATTGAGTCATCTAGCCGAGAAGAAGATGTCAGCATCACTTCAAATCTGTCCTCGATCGATTCTTTCTACACCATGGTTCAAGATCAGTTAAGAAACAGCTACCAGATTGGTTATGACGGCTCCCTCAGAATTATCTACGCCAGTGGCCTGGACTCACACTACCAAACAGAGCCGCACGTTCTGGCTGGCACCGCTAATCCGACGGTTGCCAAAAGAAACATGACTTTGCCTGGCGAGAACGGTCAAAACTTGGTGGAATGGAGATTCCGAAAAGAGCAAGCCCAAGGGAAAGTCAATGTCTTTGGCCGCAAGCTCAGGGTTAATGGCAGAAACCTCCTTTCAGTTGACTTTGATCGAACAACAAAGACAGAAAAGATCTATGACGACCACCGTAAATTTCTACTGAGGATCGCCTACGACACGTCTGGGCACCCGACTCTCTGGCTGCCAAGCAGCAAGCTGATGGCCGTCAATGTCACCTATTCATCCACAGGTCAAATTGCCAGCATCCAGCGAGGCACCACTAGCGAGAAAGTAGATTATGACGGACAGGGGAGGATCGTGTCTCGGGTCTTTGCTGATGGTAAAACATGGAGTTACACATATTTAGAAAAGTCCATGGTTCTTCTGCTTCATAGCCAGCGGCAGTACATCTTCGAATACGATATGTGGGACCGCCTGTCTGCCATCACCATGCCCAGTGTGGCTCGCCACACCATGCAGACCATCCGATCCATTGGCTACTACCGCAACATATACAACCCCCCGGAAAGCAACGCCTCCATCATCACGGACTACAACGAGGAAGGGCTGCTTCTACAAACAGCTTTCTTGGGTACAAGTCGGAGGGTCTTATTCAAATACAGAAGGCAGACTAGGCTCTCAGAAATTTTATATGATAGCACAAGAGTCAGTTTTACCTATGATGAAACAGCAGGAGTCCTAAAGACAGTAAACCTCCAGAGTGATGGTTTTATTTGCACCATTAGATACAGGCAAATTGGTCCCCTGATTGACAGGCAGATTTTCCGCTTTAGTGAAGATGGGATGGTAAATGCAAGATTTGACTATAGCTATGACAACAGCTTTCGAGTGACCAGCATGCAGGGTGTGATCAATGAAACGCCACTGCCTATTGATCTGTATCAGTTTGATGACATTTCTGGCAAAGTTGAGCAGTTTGGAAAGTTTGGAGTTATATATTATGATATTAACCAGATCATTTCTACAGCTGTAATGACCTATACGAAGCACTTTGATGCTCATGGCCGTATCAAGGAGATTCAATATGAGATATTCAGGTCGCTCATGTACTGGATTACAATTCAGTATGATAACATGGGTCGGGTAACCAAGAGAGAGATTAAAATAGGGCCCTTTGCCAACACCACCAAATATGCTTATGAATATGATGTTGATGGACAGCTCCAAACAGTTTACCTCAATGAAAAGATAATGTGGCGGTACAACTACGATCTGAATGGAAACCTCCATTTACTGAACCCAAGTAACAGTGCGCGTCTGACACCCCTTCGCTATGACCTGCGAGACAGAATCACTCGACTGGGTGATGTTCAATATCGGTTGGATGAAGATGGTTTCCTACGTCAAAGGGGCACGGAAATCTTTGAATATAGCTCCAAGGGGCTTCTAACTCGAGTTTACAGTAAAGGCAGTGGCTGGACAGTGATCTACCGTTATGACGGCCTGGGAAGGCGTGTTTCTAGCAAAACCAGTCTAGGACAGCACCTGCAGTTTTTTTATGCTGACTTAACTTATCCCACTAGGATTACTCATGTCTACAACCATTCGAGTTCAGAAATTACCTCCCTGTATTATGATCTCCAAGGACATCTTTTTGCCATGGAAATCAGCAGTGGGGATGAATTCTATATTGCATCGGATAACACAGGGACACCACTGGCTGTGTTCAGTAGCAATGGGCTTATGCTGAAACAGATTCAGTACACTGCATATGGGGAAATCTATTTTGACTCTAATATTGACTTTCAACTGGTAATTGGATTTCATGGTGGCCTGTATGACCCACTCACCAAATTAATCCACTTTGGAGAAAGAGATTATGACATTTTGGCAGGACGGTGGACAACACCTGACATAGAAATCTGGAAAAGAATTGGGAAGGACCCAGCTCCTTTTAACTTGTACATGTTTAGGAATAACAACCCTGCAAGCAAAATCCATGACGTGAAAGATTACATCACAGATGTTAACAGCTGGCTGGTGACATTTGGTTTCCATCTGCACAATGCTATTCCTGGATTCCCTGTTCCCAAATTTGATTTAACAGAACCTTCTTACGAACTTGTGAAGAGTCAGCAGTGGGATGATATACCGCCCATCTTCGGAGTCCAGCAGCAAGTGGCGCGGCAGGCCAAGGCCTTCCTGTCGCTGGGGAAGATGGCCGAGGTGCAGGTGAGCCGGCGCCGGGCCGGCGGCGCGCAGTCCTGGCTGTGGTTCGCCACGGTCAAGTCGCTGATCGGCAAGGGCGTCATGCTGGCCGTCAGCCAGGGCCGCGTGCAGACCAACGTGCTTAACATCGCCAACGAGGACTGCATCAAGGTGGCGGCCGTGCTCAACAACGCCTTCTACCTGGAGAACCTGCACTTCACCATCGAGGGCAAGGACACGCACTACTTCATCAAGACCACCACGCCCGAGAGCGACCTGGGCACGCTGCGGTTGACCAGCGGCCGCAAGGCGCTGGAGAACGGCATCAACGTGACGGTGTCGCAGTCCACCACGGTGGTGAACGGCAGGACGCGCAGGTTCGCGGACGTGGAGATGCAGTTCGGCGCGCTGGCGCTGCACGTGCGCTACGGCATGACCCTGGACGAGGAGAAGGCGCGCATCCTGGAGCAGGCGCGGCAGCGCGCGCTCGCCCGGGCCTGGGCGCGCGAGCAGCAGCGCGTGCGCGACGGCGAGGAGGGCGCGCGCCTCTGGACGGAGGGCGAGAAGCGGCAGCTGCTGAGCGCCGGCAAGGTGCAGGGCTACGACGGGTACTACGTACTCTCGGTGGAGCAGTACCCCGAGCTGGCCGACAGCGCCAACAACATCCAGTTCCTGCGGCAGAGCGAGATCGGCAGGAGGTAACGCCCGGGCCGCGCCCGCCGAGCCGCTCACGCCCTGCCCACATTGTCCTGTGGCACAACCCGAGTGGGACTCTCCAACGCCCAAGAGCCTTCCTCCCGGGGGAATGAGACTGCTGTTACGACCCACACCCACACCGCGAAAACAAGGACCGCTTTTTTCCGAATGACCTTAAAGGTGATCGGCTTTAACGAATATGTTTACATATGCATAGCGCTGCACTCAGTCGGACTGAACGTAGCCAGAGGAAAAAAAAATCATCAAGGACAAAGGCCTCGACCTGTTGCGCTGGGCCGTCTGTTCCTTCTAGGCACTGTATTTAACTAACTTTANOV40ah, SNP13378354 ofSEQ ID NO: 5522725 aaMW at 303959.6kDCG55069-01, ProteinSNP Pos: 2540SNP Change: Leu to LeuSequenceMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLMWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKKLPPSHTQSSPQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACSSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNOPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGAIALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRR

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 40B.

TABLE 40BComparison of the NOV40 protein sequences.NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wMDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wNRVKDLVHREADEFTRQEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wQSPAPPAALPAELQTTPESVQLQDSNVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTNNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wASGSVYSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wFGLNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40g------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIENOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wSVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wGTCRCEEGWTGPTCNQRACHPRCAEHGTCKDGKCECSHGWNGEHCTIEGCPGLCNSNGRCNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wTLDQNGWHCVCQPGWRGAGCDVANETLCTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPFNKSLASVIRGQVLTNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wADGTPLIGVNVSFFNYPEYGYTITRQDGMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHENOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTAILQGYELDASNMGGNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wWTLDKHHVLDVQNGILYKGNGEMQFISQQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCDTSMHISQVRLEWPTNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wDLAINPMDNSIYVLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKHDANCDCYQSGDGYANOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wNGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40wLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40u---------MDVKERRPYCSLTKSRREKBRRYTNSSADNEECRVPTQKSYSSSETLKAFDNOV40v------------------------------------------------------------NOV40wVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRINOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFCAENGLPHRGYSNOV40v------------------------------------------------------------NOV40wIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFRKEQAQGKVNVFGRKNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40 k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uISAGSDADTENEAVMSPEHAMRLWGRGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENENOV40v------------------------------------------------------------NOV40wLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPENOV40v------------------------------------------------------------NOV40wGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a--------------------MDVKERRPYCSLTKSRREKERRYTNSSADNEECRVPTQKNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uSVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLNOV40v------------------------------------------------------------NOV40wDRLSAITNPSVARHTNQTIRSIGYYRNIYNPPESNASIITDYNEEGLLLQTAFLGTSRRVNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aSYSSSETLKAFDHDSSRLLYGNRVKDLVHREADEFTRQGQNFTLRQLGVCEPATRRGLAFNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------MDVKERNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLNWQLQQTENDTFENGNOV40v------------------------------------------------------------NOV40wLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aCAEMGLPHRGYSISAGSDADTENEAVMSPEHANRLWGRGVKSGRSSCLSSRSNSALTLTDNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iRPYCSLTKSRREKERRYTNSSADNEECRVPTQKSYSSSETLKAFDHDSSRLLYGNRVKDLNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDNOV40v------------------------------------------------------------NOV40wFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGKVEQFGKFGVIYYDINOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aTEHENKSDSENEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iVHREADEFTRQEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uQPQFLKFNISLQKDALIGVYGRKKLPPSHTQSSPQYDFVELLDGSRLIAREQRSLLETERNOV40v------------------------------------------------------------NOV40wNQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRVTKREIKIGPFANTTNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGTGTTPLFSTATPGYTMASGSVYNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGNGENOV40v------------------------------------------------------------NOV40wKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDNOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLNWQNOV40b------------------------------------------------------------NOV40c-------------------------------------------------------GTNWQNOV40d-------------------------------------------------------GTNWQNOV40e-------------------------------------------------------GTNWQNOV40f------------------------------------------------------TKLNWQNOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iSPPTRPLPRNTLSRSAFKFKKSSKYCSWKCTALCAVGVSVLLAILLSYFIAMHLFGLNWQNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q---------------------------------------------------------NWQNOV40r------------------------------------------------------TSRNWQNOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uCVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCNOV40v------------------------------------------------------------NOV40wVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLNOV40x---------------------------------------------------------NWQNOV40y---------------------------------------------------------NWQNOV40z---------------------------------------------------------NWQNOV40aa----------------------------------------MLPGLALLLLAAWTARANWQNOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40b------------------------------------------------------------NOV40cLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40dLQQTENDAFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40eLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40fLQQTENDAFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40qLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40rLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uGGRGICTMGSCACSSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGWGGSNCEILKTMNOV40v------------------------------------------------------------NOV40wQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFANEISSGDEFYIASDNTGTPLAVFNOV40xLQQTENDAFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40yLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40zLQQTENDAFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40aaLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTIDSGELDIGRRAIQEIPNOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKKLPPSHTQSSPQYDFVELLDGSRLINOV40b------------------------------------------------------------NOV40cPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40dPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40ePGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40fPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSNT----QYDFVELLDGSRLINOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40qPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40rPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHG----VCMGGTCRCEEGWTNOV40v------------------------------------------------------------NOV40wSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTNOV40xPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40yPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40zPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40aaPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHT----QYDFVELLDGSRLINOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40b------------------------------------------------------------NOV40cAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40dAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40eAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40fAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40qAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40rAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40s------------------------------------------------------------NOV40t------------------------------------------------------------NOV40uGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKEGCPGLCNNOV40v------------------------------------------------------------NOV40wPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVNOV40xAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40yAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40zAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40aaAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVNOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40b--CPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40cVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40dVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40eVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40fVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40g--TSRTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLG---KMAEVQVSRRRAGGANOV40h--------------------------SMDVKERRPYCSLTKSRREKERRYTNSSADNEECNOV40iVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40j-----KLDQNG-----------------------------------GHCVCQPGWRGAGCNOV40k-----KLDQNG-----------------------------------GHCVCQPGWRGAGCNOV40l-----KLDQNG-----------------------------------GHCVCQPGWRGAGCNOV40m-----KLDQNG-----------------------------------GHCVCQPGWRGAGCNOV40n-----KLDQNG-----------------------------------GHCVCQPGWRGAGCNOV40o-----KLDQNG-----------------------------------GHCVCQPGWRGAGCNOV40p-----KLDQNG-----------------------------------GHCVCQPGWRGAGCNOV40qVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40rVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40s---------------------------MDVKERRPYCSLTKSRREKERRYTNSSADNEECNOV40t--CPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40uSNGRCTLDQNG-----------------------------------GHCVCQPGWRGAGCNOV40v-------DQNG-----------------------------------GHCVCQPGWRGAGCNOV40wPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLG---KMAEVQVSRRRAGGANOV40xVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40yVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40zVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40aaVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNGQYSKGRCLCFSGWKGTECNOV40ab---------------------------MDVKERRPYCSLTKSRREKERRYTNSSADNEECNOV40ac---------------------------MDVKERRPYCSLTKSRREKERRYTNSSADNEECNOV40aDVPTTQCIDPQCGGRGICINGSCACSSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40bDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40cDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40dDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40eDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40fDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40gQSWLWFATVKSLIGKGVMLAVSQG-RVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIENOV40hRVPTQKSYSSSE----------------TLKAFDHDSSRLLYGNRVKDLVHREADEFTRQNOV40iDVPTTQCIDPQCGGRGICIMGSCACNSGYKGKSCEEADCIDPGCSNHGVCIHGECHCSPGNOV40jDVAMETLCTDSK-----------------DNEGDGLIDCMDPDCCLQSSCQN-QPYCRGLNOV40kDVAMETLCTDSK-----------------DNEGDGLIDCMDPDCCLQSSCQN-QPYCRGLNOV40lDVAMETLCTDSK-----------------DNEGDGLIDCMDPDCCLQSSCQN-QPYCRGLNOV40mDVANETLCTDSK-----------------DNEGDGLIDCMDPDCCLQSSCQN-QPYCRGLNOV40nDVAMETLCTDSK-----------------DNEGDGLIDCMDPDCCLQSSCQN-QPYCRGLNOV40oDVAMETLCTDSK-----------------DNEGDGLIDCMDPDCCLQSSCQN-QPYCRGLNOV40pDVAMETLCTDSK-----------------DNEGDGLIDCMDPDCCLQSSCQN-QSYCRGLNOV40qDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40rDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40sRVPTQKSYSSSE----------------TLKAFDHDSSRLLYGNRVKDLVHREADEFTRQNOV40tDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40uDVAMETLCTDSK-----------------DNEGDGLIDCMDPDCCLQSSCQN-QPYCRGLNOV40vDVAMETLCTDSK-----------------DNEGDGLIDCMDPDCCLQSSCQN-QPYCRGLNOV40wQSWLWFATVKSLIGKGVMLAVSQG-RVQTNVLNIANEDCIKVAAVLNNAFYLENLHFTIENOV40xDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40yDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40zDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40aaDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEADCIDPGCSNHGVCIHGECHCSPGNOV40abRVPTHNSYSSSE----------------TLKAFDHDSSRLLYGNRVKDLVHREADEFTRQNOV40acRVPTQKSYSSSE----------------TLKAFDHDSSRLLYGNRVKDLVHREADEFTRQNOV40aWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40bWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40cWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40dWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40eWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40fWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40g-GKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGNOV40hEQPASNQGQSTLQPLPPSHKQHSAQHHPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPNOV40iWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40jPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGES-----PFNKSLASVIRGQNOV40kPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGES-----PFNKSLASVIRGQNOV40lPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGES-----PFNKSLASVIRGQNOV40mPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGES-----PFNKSLASVIRGQNOV40nPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGES-----PFNKSLASVIRGQNOV40oPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGES-----PFNKSLASVIRGQNOV40pPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGES-----PFNKSLASVIRGQNOV40qWGGSNCEILKThCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40rWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40sGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRNOV40tWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40uPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGES-----PFNKSLASVIRGQNOV40vPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGES-----PFNKSLASVIRGQNOV40w-GKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRRFADVEMQFGNOV40xWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40yWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40zWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40aaWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCSNEICSVDCGSHGVCMGGTNOV40abGQNFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRNOV40acGONFTLRQLGVCEPATRRGLAFCAEMGLPHRGYSISAGSDADTENEAVMSPEHAMRLWGRNOV40aCRCEEGWTGPACNORACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKNOV40bCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTI---------------NOV40cCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTI---------------NOV40dCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKNOV40eCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVK------NOV40fCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKNOV40gALALHVRYGMTLDEEKARILEQA------------QQRVRDG------------------NOV40hESVQLQDSWVLG-SNVPLESRHFLFKTGTGTTP---------------------------NOV40iCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKNOV40jVLTADGTPLIGVNVSFFHYPEYGYTITRQ-------------------------------NOV40kVLTADGTPLIGVNVSFFHYPEYGYTITRQ-------------------------------NOV40lVLTADGTPLIGVNVSFFHYPEYGYTITRQ-------------------------------NOV40mVLTADGTPLIGVNVSFFHYPEYGYTITRQ-------------------------------NOV40nVLTADGTPLIGVNVSFFHYPEYGYTITRQ-------------------------------NOV40oVLTADGTPLIGVNVSFFHYPEYGYTITRQ-------------------------------NOV40pVLTADGTPLIGVNVSFFHYPEYGYTITRQ-------------------------------NOV40qCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVK------NOV40rCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLKIVK-------NOV40sGVKSGRSSCLSSRSNSALTLTDTEHENKSDSENEQPASNQGQSTLQPLPPSHKQHSAQHHNOV40tCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVK------NOV40uVLTADGTPLIGVNVSFFHYPEYGYTITRQ-------------------------------NOV40vVLTADGTPLIGVNVSFFHYPEYGYTITRQ-------------------------------NOV40wALALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTEGEKRQL---NOV40xCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKNOV40yCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVK------NOV40zCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGEHCTIAHYLDKIVKDKIGYKNOV40aaCRCEEGWTGPACNQRACHPRCABHGTCKDGKCECSQGWNGEHCTIAHYLDKIVK------NOV40abGFKSGRSSCLSSRSNSALTLTDTEHENKSDSEN---------------------------NOV40acGVKSGRSSCLSSRSNSALTLTDTEHENKSDSEN---------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sPSITSLNRNSLTNRRNQSPAPPAALPAELQTTPESVQLQDSWVLGSNVPLESRHFLFKTGNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a--EGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40b--EGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCD------------------------NOV40c--EGCPGLSNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40d--EGCPGLCNSNGRCTLDQNGWHCACQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40e--EGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40f--EGCPGLCNSNGRCTLDQNGWHCACQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40g------KVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRRVDG--------------NOV40h-----LFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKS-SKYCSWKCTALCAVGNOV40i--EGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40j-----------DGMFDLVANGGASLTLVFERSP---------------------------NOV40k-----------DGMFDLVASGGASLTLVFERSP---------------------------NOV40l-----------DGMFDLVANGGASLTLVFERSP---------------------------NOV40m-----------DGMFDLVANGGASLTLVFERSP---------------------------NOV40n-----------DGMFDLVANGGASLTLVFERSP---------------------------NOV40o-----------DGMFDLVANGGASLTLVFERSP---------------------------NOV40p-----------DGMFDLVANGGASLTLVFERSP---------------------------NOV40q--EGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40r--EGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40sTGTTPLFSTATPGYTMASGSVYSPPTRPLPRNTLSRSAFKFKKS-SKYCSWKCTALCAVGNOV40t--EGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCD------------------------NOV40u-----------DGMFDLVANGGASLTLVFERSP---------------------------NOV40v-----------DGMFDLVANGGASLTLVFERSP---------------------------NOV40w--LSAGKQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRR------------------NOV40x--EGCPGLCNSNGRCTLDQNGWHCACQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40y--EGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40z--EGCPGLCNSNGRCTLDQNGWHCACQPGWRGAGCDVAMETLCTDSKDNEGDGLIDCMDPNOV40aa--EGCPGLCNSNGRCTLDQNGWHCVCQPGWRGAGCDVANETLCTDSKDNEGDGLIDCMDPNOV40ab-----GGSSSWFGFHWNFYVSKASCLLRLPRIFLSHNYNVNKEMREKLC-----------NOV40ac-----GGSSSWFGFHWNFYVGKASCLLRLPRIFLSHNYNVNKEMREKLC-----------NOV40aDCCLQSSCQNQPYCRGLPDPQDIISOSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40b------------------------------------------------------------NOV40cDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40dDCCLQSSCQNQPYCRGLPDPQGIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40eDCCLQSSCQNQPYCRGLPDPODIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40fDCCLQSSCQNQPYCRGLPDPQGIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40g------------------------------------------------------------NOV40hVSVLLAILLSYFIAMHLFGLNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFNOV40iDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40qDCCLQSSCQNQPYCRGLPDPQDIISOSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40rDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40sVSVLLAILLSYFIAMHLFGLNWQLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40xDCCLQSSCQNQPYCRGLPDPQGIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40yDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40zDCCLQSSCQNQPYCRGLPDPQGIISQSLQSPSQQAAKSFYDRISFLIGSDSTHVIPGESPNOV40aaDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQOAAKSFYDRISFLIGSDSTHVIPGESPNOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40b------------------------------------------------------------NOV40cFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40dFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40eFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40fFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40g------------------------------------------------------------NOV40hTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLNOV40iFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40qFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40rFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40sTQENNTIDSGELDIGRRAIQEIPPGIFWRSQLFIDQPQFLKFNISLQKDALIGVYGRKGLNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40xFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40yFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40zFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40aaFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGMFDLVANGGASLTLVFENOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aRSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40b------------------------------------------------------------NOV40cRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40dRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPHPIIVSSPLSTFFRSSNOV40eRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40fRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40g------------------------------------------------------------NOV40hPPSHTQYDFVELLDGSRLIALEG-------------------------------------NOV40iRSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40j---FLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40k---FLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40l---FLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40m---FLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40n---FLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40o---FLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40p---FLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40qRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40rRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40sPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSVSLHEAGFIQYLDSGIWHLAFYNOV40t------------------------------------------------------------NOV40u---FLTQYHTVWIPWNVFYVMDTLVMBKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40v---FLTQYHTVWIPWNVFYVNDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40w------------------------------------------------------------NOV40xRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40yRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40zRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40aaRSPFLTQYHTVWIPWNVFYVMDTLVMKKEENDIPSCDLSGFVRPNPIIVSSPLSTFFRSSNOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLNVNOV40b------------------------------------------------------------NOV40cPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40dPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40ePEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40fPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40jPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40kPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40lPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40mPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40nPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40oPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40pPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40qPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40rPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40sNDGKNAEQVSFNTIVIESVVECPRNCHGNGECVSGTCHCFPGFLGPDCSRAACPVLCSGNNOV40t------------------------------------------------------------NOV40uPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40vPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40w------------------------------------------------------------NOV40xPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40yPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40zPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40aaPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITMTQSIIPFNLMKVHLMVNOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40b------------------------------------------------------------NOV40cAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40dAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40eAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40fAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40jAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40kAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40lAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40mAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40nAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40oAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40pAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40qAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40rAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40sGQYSKGRCLCFSGWKGTECDVPTWQCIDPQCGGRGICIMGSCACSSGYKGESCEEADCIDNOV40t------------------------------------------------------------NOV40uAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40vAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40w------------------------------------------------------------NOV40xAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40yAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40zAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40aaAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVGYEYESCLDLTLWEKRTNOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40b------------------------------------------------------------NOV40cAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSVD--------NOV40dAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSVDPAASSRE-NOV40eAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSVDATHDWRLLNOV40fAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSLEG-------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40jAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40kAILQGYELDASNMGGWTLDKHHALDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40lAILQGYELDASNMGGWTLDKHHALDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40mAILQGYELDASNNGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40nAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40oAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40pAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40qAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSS----------NOV40rAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSLEG-------NOV40sPGCSNHGVCIHGECHCSPGWGGSNCEILKTMCPDQCSGHGTYLQESGSCTCDPNWTGPDCNOV40t------------------------------------------------------------NOV40uAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40vAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSSIMGNGRRRSINOV40w------------------------------------------------------------NOV40xAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSS----------NOV40yAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSS----------NOV40zAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSS----------NOV40aaAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQQPPVVSS----------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40eVIFSSAVAASWY------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNOV40jSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNOV40kSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNOV40lSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELS-------SNOV40mSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELS-------SNOV40nSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELS-------SNOV40oSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELS-------SNOV40pSCPSCNGQADGNKLLAPVALACGIDGSLHVGDFNYVRRIFPSGNVTSVLELS-------SNOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sSNEICSVDCGSHGVCMGGTCRCEEGWTGPACNQRACHPRCAEHGTCKDGKCECSQGWNGENOV40t------------------------------------------------------------NOV40uSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELRNKDFRHSSNOV40vSCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNVTSVLELS-------SNOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40jNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40kNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40lNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40mNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40nNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40oNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40pNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sHCTIAHYLDKIVKDKIGYKEGCPGLCNSNGRCTLDQNGGHCVCQPGWRGAGCDVAMETLCNOV40t------------------------------------------------------------NOV40uNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40vNPAHRYYIATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNAEVVAGTGEQCLPFDEARNOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40jCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40kCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40lCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40mCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40nCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40oCGDGGKAAEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40pCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sTDSKDNEGDGLIDCMDPDCCLQSSCQNQPYCRGLPDPQDIISQSLQSPSQQAAKSFYDRINOV40t------------------------------------------------------------NOV40uCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40vCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIISTLLGSNDLTSARPLTCNOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aDTSMHISQVRLEWPTDLAINPMDNSIYYLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iDTSMHISQVRLEWPTDLAINPMDNSIYYLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYNOV40jDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVD---------------------------NOV40kDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVD---------------------------NOV40lDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVD---------------------------NOV40mDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVD---------------------------NOV40nDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVD---------------------------NOV40oDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVD---------------------------NOV40pDTSMHISQVRLEWPTDLAINPMDNSIYVLDNVD---------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sSFLIGSDSTHVIPGESPFNKSLASVIRGQVLTADGTPLIGVNVSFFHYPEYGYTITRQDGNOV40t------------------------------------------------------------NOV40uDTSMHISQVRLEWPTDLAINPMDNSIYYLDNNVVLQITENRQVRIAAGRPMHCQVPGVEYNOV40vDTSMHISQVRLEWPTDLAINPMDNSIYVLDN-----------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV4Qq------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sMFDLVANGGASLTLVFERSPFLTQYHTVWIPWNVFYVMDTLVMEKEENDIPSCDLSGFVRNOV40t------------------------------------------------------------NOV40uPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTDGEISLVAGIPSECDCKNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sPNPIIVSSPLSTFFRSSPEDSPIIPETQVLHEETTIPGTDLKLSYLSSRAAGYKSVLKITNOV40t------------------------------------------------------------NOV40uNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRIRAVSKNKPLLNSMNFYNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sMTQSIIPFNLMKVHLMVAVVGRLFQKWFPASPNLAYTFIWDKTDAYNQKVYGLSEAVVSVNOV40t------------------------------------------------------------NOV40uEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITAVTDSNGNTLRIRRDPNNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sGYEYESCLDLTLWEKRTAILQGYELDASNMGGWTLDKHHVLDVQNGILYKGNGENQFISQNOV40t------------------------------------------------------------NOV40uRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSGLLATKSDETGWTTFFDNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sQPPVVSSIMGNGRRRSISCPSCNGQADGNKLLAPVALACGIDGSLYVGDFNYVRRIFPSGNOV40t------------------------------------------------------------NOV40uYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSITSNLSSIDSFYTMVQDQNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sNVTSVLELRNKDFRHSSNPAHRYYLATDPVTGDLYVSDTNTRRIYRPKSLTGAKDLTKNANOV40t------------------------------------------------------------NOV40uLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNMTLPGENGQNLVEWRFNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV400------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sEVVAGTGEQCLPFDEARCGDGGKAVEATLMSPKGMAVDKNGLIYFVDGTMIRKVDQNGIINOV40t------------------------------------------------------------NOV40uRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKFLLRIAYDTSGHPTLWLNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sSTLLGSNDLTSARPLTCDTSMHISQVRLEWPTDLAINPMDNSIYVLDNNVVLQITENRQVNOV40t------------------------------------------------------------NOV40uPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFADGKTWSYTYLEKSMVLNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEENOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iLLHSQRQYIFEYDMWDRLSAITMPSVARHTNQTIRSIGYYRNIYNPPESNASIITDYNEENOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sRIAAGRPMHCQVPGVEYPVGKHAVQTTLESATAIAVSYSGVLYITETDEKKINRIRQVTTNOV40t------------------------------------------------------------NOV40uLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNIYNPPESNASIITDYNEENOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTINOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTINOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sDGEISLVAGIPSECDCKNDANCDCYQSGDGYAKDAKLSAPSSLAASPDGTLYIADLGNIRNOV40t------------------------------------------------------------NOV40uGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETAGVLKTVNLQSDGFICTINOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sIRAVSKNKPLLNSMNFYEVASPTDQELYIFDINGTHQYTVSLVTGDYLYNFSYSNDNDITNOV40t------------------------------------------------------------NOV40uRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINETPLPIDLYQFDDISGNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sAVTDSNGNTLRIRRDPNRMPVRVVSPDNQVIWLTIGTNGCLKGMTAQGLELVLFTYHGNSNOV40t------------------------------------------------------------NOV40uKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEIFRSLMYWITIQYDNMGRNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sGLLATKSDETGWTTFFDYDSEGRLTNVTFPTGVVTNLHGDMDKAITVDIESSSREEDVSINOV40t------------------------------------------------------------NOV40uVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDLNGNLHLLNPSNSARLTNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sTSNLSSIDSFYTMVQDQLRNSYQIGYDGSLRIIYASGLDSHYQTEPHVLAGTANPTVAKRNOV40t------------------------------------------------------------NOV40uPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTRVYSKGSGWTVIYRYDGNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDENOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDENOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sNMTLPGENGQNLVEWRFRKEQAQGKVNVFGRKLRVNGRNLLSVDFDRTTKTEKIYDDHRKNOV40t------------------------------------------------------------NOV40uLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYYDLQGHLFAMEISSGDENOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sFLLRIAYDTSGHPTLWLPSSKLMAVNVTYSSTGQIASIQRGTTSEKVDYDGQGRIVSRVFNOV40t------------------------------------------------------------NOV40uFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLVIGFHGGLYDPLTKLIHNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sADGKTWSYTYLEKSMVLLLHSQRQYIFEYDMWDRLSAITMPSVARHTMQTIRSIGYYRNINOV40t------------------------------------------------------------NOV40uFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASKIHDVKDYITDVNSWLVNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMANOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMANOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sYNPPESNASIITDYNEEGLLLQTAFLGTSRRVLFKYRRQTRLSEILYDSTRVSFTYDETANOV40t------------------------------------------------------------NOV40uTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQQQVARQAKAFLSLGKMANOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNANOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNANOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sGVLKTVNLQSDGFICTIRYRQIGPLIDRQIFRFSEDGMVNARFDYSYDNSFRVTSMQGVINOV40t------------------------------------------------------------NOV40uEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNIANEDCIKVAAVLNNANOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sNETPLPIDLYQFDDISGKVEQFGKFGVIYYDINQIISTAVMTYTKHFDAHGRIKEIQYEINOV40t------------------------------------------------------------NOV40uFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGINVTVSQSTTVVNGRTRNOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aRFADVEMQFGALALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTNOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iRFADVEMQFGALALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTNOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sFRSLMYWITIQYDNNGRVTKREIKIGPFANTTKYAYEYDVDGQLQTVYLNEKIMWRYNYDNOV40t------------------------------------------------------------NOV40uRFADVEMQFGALALHVRYGMTLDEEKARILEQARQRALARAWAREQQRVRDGEEGARLWTNOV40V------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40aEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRR------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40iEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRR------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sLNGNLHLLNPSNSARLTPLRYDLRDRITRLGDVQYRLDEDGFLRQRGTEIFEYSSKGLLTNOV40t------------------------------------------------------------NOV40uEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSEIGRR------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sRVYSKGSGWTVIYRYDGLGRRVSSKTSLGQHLQFFYADLTYPTRITHVYNHSSSEITSLYNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sYDLQGHLFAMEISSGDEFYIASDNTGTPLAVFSSNGLMLKQIQYTAYGEIYFDSNIDFQLNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sVIGFHGGLYDPLTKLIHFGERDYDILAGRWTTPDIEIWKRIGKDPAPFNLYMFRNNNPASNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sKIHDVKDYITDVNSWLVTFGFHLHNAIPGFPVPKFDLTEPSYELVKSQQWDDIPPIFGVQNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sQQVARQAKAFLSLGKMAEVQVSRRRAGGAQSWLWFATVKSLIGKGVMLAVSQGRVQTNVLNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sNIANEDCIKVAAVLNNAFYLENLHFTIEGKDTHYFIKTTTPESDLGTLRLTSGRKALENGNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sINVTVSQSTTVVNGRTRRFADVEMQFGALALHVRYGMTLDEEKARILEQARQRALARAWANOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a------------------------------------------------------------NOV40b------------------------------------------------------------NOV40c------------------------------------------------------------NOV40d------------------------------------------------------------NOV40e------------------------------------------------------------NOV40f------------------------------------------------------------NOV40g------------------------------------------------------------NOV40h------------------------------------------------------------NOV40i------------------------------------------------------------NOV40j------------------------------------------------------------NOV40k------------------------------------------------------------NOV40l------------------------------------------------------------NOV40m------------------------------------------------------------NOV40n------------------------------------------------------------NOV40o------------------------------------------------------------NOV40p------------------------------------------------------------NOV40q------------------------------------------------------------NOV40r------------------------------------------------------------NOV40sREQQRVRDGEEGARLWTEGEKRQLLSAGKVQGYDGYYVLSVEQYPELADSANNIQFLRQSNOV40t------------------------------------------------------------NOV40u------------------------------------------------------------NOV40v------------------------------------------------------------NOV40w------------------------------------------------------------NOV40x------------------------------------------------------------NOV40y------------------------------------------------------------NOV40z------------------------------------------------------------NOV40aa------------------------------------------------------------NOV40ab------------------------------------------------------------NOV40ac------------------------------------------------------------NOV40a-----NOV40b-----NOV40c-----NOV40d-----NOV40e-----NOV40f-----NOV40g-----NOV40h-----NOV40i-----NOV40j-----NOV40k-----NOV40l-----NOV40m-----NOV40n-----NOV40o-----NOV40p-----NOV40q-----NOV40r-----NOV40sEIGRRNOV40t-----NOV40u-----NOV40v-----NOV40w-----NOV40x-----NOV40y-----NOV40z-----NOV40aa-----NOV40ab-----NOV40ac-----NOV40a(SEQ ID NO: 486)NOV40b(SEQ ID NO: 488)NOV40c(SEQ ID NO: 490)NOV40d(SEQ ID NO: 492)NOV40e(SEQ ID NO: 494)NOV40f(SEQ ID NO: 496)NOV40g(SEQ ID NO: 498)NOV40h(SEQ ID NO: 500)NOV40i(SEQ ID NO: 502)NOV40j(SEQ ID NO: 504)NOV40k(SEQ ID NO: 506)NOV40l(SEQ ID NO: 508)NOV40m(SEQ ID NO: 510)NOV40n(SEQ ID NO: 512)NOV40o(SEQ ID NO: 514)NOV40p(SEQ ID NO: 516)NOV40q(SEQ ID NO: 518)NOV40r(SEQ ID NO: 520)NOV40s(SEQ ID NO: 522)NOV40t(SEQ ID NO: 524)NOV40u(SEQ ID NO: 526)NOV40v(SEQ ID NO: 528)NOV40w(SEQ ID NO: 530)NOV40x(SEQ ID NO: 532)NOV40y(SEQ ID NO: 534)NOV40z(SEQ ID NO: 536)NOV40aa(SEQ ID NO: 538)NOV40ab(SEQ ID NO: 540)NOV40ac(SEQ ID NO: 542)

Further analysis of the NOV40a protein yielded the following properties shown in Table 40C.

TABLE 40CProtein Sequence Properties NOV40aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG: a new signal peptide prediction methodN-region: length 7; pos.chg 3; neg.chg 2H-region: length 6; peak value −1.30PSG score: −5.70GvH: von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −13.53possible cleavage site: between 60 and 61>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 3Number of TMS(s) for threshold 0.5: 1INTEGRALLikelihood = −9.39Transmembrane 309-325PERIPHERALLikelihood = 2.54 (at 2515)ALOM score: −9.39 (number of TMSs: 1)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 316Charge difference: −6.5 C(−1.5) − N(5.0)N >= C: N-terminal side will be inside>>> membrane topology: type 2 (cytoplasmic tail 1 to 309)MITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):3.03Hyd Moment(95):4.83G content:0D/E content:2S/T content:0Score: −7.62Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: RRPYCSLTKSRREKERR at 6bipartite: RKEQAQGKVNVFGRKLR at 1778content of basic residues: 9.9%NLS Score: 0.51KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: foundLL at 57checking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found ***LTPLRYDLRDRITRLGDVQYRL at 2196nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 55.5COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):34.8%: nuclear26.1%: mitochondrial13.0%: Golgi 8.7%: cytoplasmic 4.3%: plasma membrane 4.3%: vesicles of secretory system 4.3%: extracellular, including cell wall 4.3%: peroxisomal>> prediction for CG55069-01 is nuc (k = 23)

A search of the NOV40a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 40D.

TABLE 40DGeneseq Results for NOV40aNOV40aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABP53586Human NOV15a protein SEQ1 . . . 2725 2725/2725 (100%)0.0ID NO: 36 - Homo sapiens,1 . . . 2725 2725/2725 (100%)2725 aa. [WO200262999-A2,15-AUG-2002]ABP53587Human NOV15b protein SEQ1 . . . 27252720/2725 (99%)0.0ID NO: 38 - Homo sapiens,1 . . . 27212720/2725 (99%)2721 aa. [WO200262999-A2,15-AUG-2002]ABP53588Human NOV15c protein SEQ148 . . . 2725 2553/2579 (98%)0.0ID NO: 40 - Homo sapiens,54 . . . 2628 2558/2579 (98%)2628 aa. [WO200262999-A2,15-AUG-2002]ABP53589Human NOV15d protein SEQ148 . . . 2725 2536/2579 (98%)0.0ID NO: 42 - Homo sapiens,54 . . . 2613 2540/2579 (98%)2613 aa. [WO200262999-A2,15-AUG-2002]ABB98401Human NOV1, a TEN-M4 like1 . . . 27251917/2813 (68%)0.0protein - Homo sapiens, 27941 . . . 27942260/2813 (80%)aa. [WO200255704-A2, 18-JUL-2002]

In a BLAST search of public sequence databases, the NOV40a protein was found to have homology to the proteins shown in the BLASTP data in Table 40E.

TABLE 40EPublic BLASTP Results for NOV40aNOV40aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9WTS6Ten-m3 - Mus musculus 1 . . . 27252663/2725 (97%)0.0(Mouse), 2715 aa. 1 . . . 27152696/2725 (98%)Q9JLC1ODZ3 - Mus musculus354 . . . 27252308/2372 (97%)0.0(Mouse), 2346 aa (fragment). 1 . . . 23462334/2372 (98%)Q9W7R4Ten-m3 - Brachydanio rerio143 . . . 27252116/2598 (81%)0.0(Zebrafish) (Danio rerio), 2590 27 . . . 25902352/2598 (90%)aa.Q9WTS7Ten-m4 - Mus musculus 1 . . . 27251867/2790 (66%)0.0(Mouse), 2771 aa. 1 . . . 27712227/2790 (78%)Q9DER5Teneurin-2 - Gallus gallus173 . . . 27251777/2561 (69%)0.0(Chicken), 2802 aa (fragment).267 . . . 28022138/2561 (83%)

PFam analysis indicates that the NOV40a protein contains the domains shown in the Table 40F.

TABLE 40FDomain Analysis of NOV40aPfamNOV40aIdentities/SimilaritiesExpectDomainMatch Regionfor the Matched RegionValueEGF522 . . . 54812/47 (26%)0.9824/47 (51%)EGF586 . . . 61310/47 (21%)0.4319/47 (40%)EGF618 . . . 64512/47 (26%)0.09322/47 (47%)EGF652 . . . 68012/47 (26%)0.8722/47 (47%)EGF716 . . . 74212/47 (26%)0.02423/47 (49%)EGF762 . . . 79211/47 (23%)0.6621/47 (45%)NHL1497 . . . 152410/29 (34%)0.04322/29 (76%)

Example 41

The NOV41 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 41A.

TABLE 41ANOV41 Sequence AnalysisNOV41a, CG55343-03SEQ ID NO: 553943 bpDNA SequenceORF Start: ATG at 2ORF Stop: TAA at 941TATGAATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGGCCTTGGGGGCTACTGAATATCTTCTCCTGGCCGTCATGTCCTTTGATTGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGTCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATCATATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATAGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCAAGGAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAAGGAAGGCTTTAAAAGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAATAANOV41a, CG55343-03Protein SequenceSEQ ID NO: 554313 aaMW at 35443.7kDMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDWFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKEVKEGFKRLVARVFLIKKNOV41b, 260568382SEQ ID NO: 555946 bpDNA SequenceORF Start: at 3ORF Stop: TAG at 936ATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGGCCTTGGGGGCTACTGAATATCTTCTCCTGGCCGTCATGTCCTTTGATAGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGTCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATCATATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATAGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCAAGGAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAAGGAAGGCTTTAAAAGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAATAGGGATTCGGNOV41b, 260568382Protein SequenceSEQ ID NO: 556311 aaMW at 35168.4kDWVNDSIIQEFILLGFSDRPVVLEFPLLVVFLISYTVTIFGNTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDRFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKEVKEGFKRLVARVFLIKKNOV41c, 314361391SEQ ID NO: 557960 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceCGCGGATCCACCATGAATTGGGTAAATGACAGCATCATACAGGAGTTTATTTTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGGCCAAGGGGGCTACTGAATATCTTCTCCTGGCCGTCATGTCCTTTGATAGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGTCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATCATATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATAGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCAAGGAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAGGAAGGCTTTAAAAGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAACTCGAGGCGNOV41c, 314361391Protein SequenceSEQ ID NO: 558320 aaMW at 36128.5kDRGSTMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDRFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKEVKEGFKRLVARVFLIKKLEANOV41d, 317286137SEQ ID NO: 559321 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceCGCGGATCCACCATGAATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTCGAGGCGNOV41d, 317286137Protein SequenceSEQ ID NO: 560107 aaMW at 12270.4kDRGSTMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLEANOV41e, CG55343-01SEQ ID NO: 561943 bpDNA SequenceORF Start: ATG at 2ORF Stop: TAA at 941TATGAATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGGCCTTGGGGGCTACTGAATATCTTCTCCTGGCCGTCATGTCCTTTGATTGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGTCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATCATATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATAGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCCGGAAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAAGGAAGGCTTTAAAAGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAATAANOV41e, CG55343-01Protein SequenceSEQ ID NO: 562313 aaMW at 35443.7kDMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDWFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWSTLTLQLPLCDPYVIADHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSABGRQKAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKEVKBGFKRLVARVFLIKKNOV41f, CG55343-02SEQ ID NO: 563933 bpDNA SequenceORF Start: ATG at 15ORF Stop: TAA at 954TTGAAACATTAATCATGAATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAACTTCATACCCCCAATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGGCCTTGGGGGCTACTGAATATCTTCTCCTGGCCGTCATGTCCTTTGATAGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGATCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATGTATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATAGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCAAGGAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAAGGAAGGCTTTAAAAGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAATAAGAAATATGCAAATGATAAGCTTTGCTAAAGACAAAATNOV41f, CG55343-02Protein SequenceSEQ ID NO: 564313 aaMW at 35413.7kDMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDRFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKEVKEGFKRLVARVFLIKKNOV41g, CG55343-04SEQ ID NO: 56560 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTNOV41g, CG55343-04Protein SequenceSEQ ID NO: 56620 aaMW at 2425.7kDDSIIQEFILLGFSDRPWLEFNOV41h, CG55343-05SEQ ID NO: 56760 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTANOV41h, GG55343-05Protein SequenceSEQ ID NO: 56720 aaMW at 2130.4kDEVPALLKLSCVETTANEAELNOV41i, CG55343-06SEQ ID NO: 569946 bpDNA SequenceORF Start: at 3ORF Stop: TAG at 936ATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGCCTTGGGGGCTACTGAATATACTTCTCCTGGCCGTCATGTCCTTTGATAGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGTCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATCATATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATAGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCAAGGAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAAGGAAGGCTTTAAAAGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAATAGGGATTCGGNOV41i, CG55343-06Protein SequenceSEQ ID NO: 570311 aaMW at 35168.4kDWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDRFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSABGRQKAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKEVKEGFKRLVARVFLIKKNOV41j,SNP13373740 ofSEQ ID NO: 571943 bpCG55343-03,ORF Start: ATG at 2ORF Stop: TAA at 941DNA SequenceSNP Pos: 568SNP Change: T to CTATGAATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGGCCTTGGGGGCTACTGAATATCTTCTCCTGGCCGTCATGTCCTTTGATTGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGCGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGTCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATCATATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATAGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCAAGGAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAAGGAAGGCTTTAAAAGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAATAANOV41j,SNP13373740 ofCG55343-03,SEQ ID NO: 572MW at 35443.7kDProtein SequenceSNP Pos: 189313 aaSNP Change: Cys to CysMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDWFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKEVKEGFKRLVARVFLIKKNOV41k,SNP13376425 ofSEQ ID NO: 573943 bpCG55343-03,ORF Start: ATG at 2ORF Stop: TAA at 941DNA SequenceSNP Pos: 758SNP Change: A to GTATGAATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGGCCTTGGGGGCTACTGAATATCTTCTCCTGGCCGTCATGTCCTTTGATTGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGTCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATCATATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATGGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCAAGGAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAAGGAAGGCTTTAAAAGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAATAANOV41k,SNP13376425 ofCG55343-03,SEQ ID NO: 574MW at 35413.7kDProtein SequenceSNP Pos: 253313 aaSNP Change: Set to GlyMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDWFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKAFGTCGSHLIVVSLFYGTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKEVKEGFKRLVARVFLIKKNOV41l,SNP13376424 ofSEQ ID NO: 575943 bpCG55343-03,ORF Start: ATG at 2ORF Stop: TAA at 941DNA SequenceSNP Pos: 810SNP Change: A to GTATGAATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGGCCTTGGGGGCTACTGAATATCTTCTCCTGGCCGTCATGTCCTTTGATTGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGTCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATCATATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATAGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCGAGGAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAAGGAAGGCTTTAAAAGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAATAANOV41l,SNP13376424 ofCG55343-03,SEQ ID NO: 576MW at 35471.8kDProtein SequenceSNP Pos: 270313 aaSNP Change: Gln to ArgMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDWFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSABGRQKAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDRGKMVSLFYGIIAPMLNPLIYTLRNKEVKEGFKRLVARVFLIKKNOV41m,SNP13376423 ofSEQ ID NO: 577943 bpCG55343-03,ORF Start: ATG at 2ORF Stop: TAA at 941DNA SequenceSNP Pos: 908SNP Change: A to GTATGAATTGGGTAAATGACAGCATCATACAGGAGTTTATTCTGCTGGGTTTCTCAGATCGACCTTGGCTGGAGTTTCCACTCCTTGTGGTCTTCTTGATTTCTTACACTGTGACCATCTTTGGCAATCTGACCATTATTCTAGTGTCACGCCTGGACACCAAACTTCATACCCCCATGTATTTTTTTCTTACCAATCTATCACTCCTGGATCTTTGTTACACCACATGTACAGTCCCACAAATGCTAGTAAATTTATGCAGCATCAGGAAAGTAATCAGTTATCGTGGCTGTGTAGCCCAGCTTTTCATATTTCTGGCCTTGGGGGCTACTGAATATCTTCTCCTGGCCGTCATGTCCTTTGATTGGTTTGTAGCTATTTGTCGGCCTCTCCATTACTCAGTTATCATGCACCAGAGACTCTGCCTCCAGTTGGCAGCTGCATCCTGGGTTACTGGTTTTAGTAACTCAGTGTGGTTGTCTACCCTGACTCTCCAGCTGCCACTCTGTGACCCCTATGTGATAGATCACTTTCTCTGTGAAGTCCCTGCACTGCTCAAGTTATCTTGTGTTGAGACAACAGCAAATGAGGCTGAACTATTCCTTGTCAGTGAGCTCTTCCATCTAATACCCCTGACACTCATCCTTATATCATATGCTTTTATTGTCCGAGCAGTATTGAGGATACAGTCTGCTGAAGGTCGACAAAAAGCATTTGGGACATGTGGTTCCCATCTAATTGTGGTGTCTCTTTTTTATAGTACAGCCGTCTCTGTGTACCTGCAACCACCTTCGCCCAGCTCCAAGGACCAAGGAAAGATGGTTTCTCTCTTCTATGGAATCATTGCACCCATGCTGAATCCCCTTATATATACACTTAGGAACAAGGAGGTAAAGGAAGGCTTTAAAGGGTTGGTTGCAAGAGTCTTCTTAATCAAGAAATAANOV41m,SNP13376423 of CG55343-03,SEQ ID NO: 578MW at 35344.6kDProtein SequenceSNP Pos: 303313 aaSNP Change: Arg to GlyMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLAVMSFDWFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKEVKEGFKGLVARVFLIKK

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 41B.

TABLE 41BComparison of the NOV41 protein sequences.NOV41a----MNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHNOV41b------WVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHNOV41cRGSTMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHNOV41dRGSTMNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHNOV41e----MNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHNOV41f----MNWVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHNOV41g---------DSIIQEFILLGFSDRPWLEF-------------------------------NOV41h------------------------------------------------------------NOV41i------WVNDSIIQEFILLGFSDRPWLEFPLLVVFLISYTVTIFGNLTIILVSRLDTKLHNOV41aTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLANOV41bTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLANOV41cTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLANOV41dTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLEA-------------NOV41eTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLANOV41fTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLANOV41g------------------------------------------------------------NOV41h------------------------------------------------------------NOV41iTPMYFFLTNLSLLDLCYTTCTVPQMLVNLCSIRKVISYRGCVAQLFIFLALGATEYLLLANOV41aVMSFDWFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHNOV41bVMSFDRFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHNOV41cVMSFDRFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHNOV41d------------------------------------------------------------NOV41eVMSFDWFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHNOV41fVMSFDRFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHNOV41g------------------------------------------------------------NOV41h------------------------------------------------------------NOV41iVMSFDRFVAICRPLHYSVIMHQRLCLQLAAASWVTGFSNSVWLSTLTLQLPLCDPYVIDHNOV41aFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKNOV41bFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKNOV41cFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKNOV41d------------------------------------------------------------NOV41eFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKNOV41fFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKNOV41g------------------------------------------------------------NOV41h---EVPALLKLSCVETTANEAEL-------------------------------------NOV41iFLCEVPALLKLSCVETTANEAELFLVSELFHLIPLTLILISYAFIVRAVLRIQSAEGRQKNOV41aAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKENOV41bAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKENOV41cAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKENOV41d------------------------------------------------------------NOV41eAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKENOV41fAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKENOV41g------------------------------------------------------------NOV41h------------------------------------------------------------NOV41iAFGTCGSHLIVVSLFYSTAVSVYLQPPSPSSKDQGKMVSLFYGIIAPMLNPLIYTLRNKENOV41aVKEGFKRLVARVFLIKK---NOV41bVKEGFKRLVARVFLIKK---NOV41cVKEGFKRLVARVFLIKKLEANOV41d--------------------NOV41eVKEGFKRLVARVFLIKK---NOV41fVKEGFKRLVARVFLIKK---NOV41g--------------------NOV41h--------------------NOV41iVKEGFKRLVARVFLIKK---NOV41a(SEQ ID NO: 554)NOV41b(SEQ ID NO: 556)NOV41c(SEQ ID NO: 558)NOV41d(SEQ ID NO: 560)NOV41e(SEQ ID NO: 562)NOV41f(SEQ ID NO: 564)NOV41g(SEQ ID NO: 566)NOV41h(SEQ ID NO: 568)NOV41i(SEQ ID NO: 570)

Further analysis of the NOV41a protein yielded the following properties shown in Table 41C.

TABLE 41CProtein Sequence Properties NOV41aSignalP analysis:Cleavage site between residues 39 and 40PSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 11; pos.chg 0;neg.chg 2H-region:length 7;peak value0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −4.39possible cleavage site: between 38 and 39>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 5INTEGRALLikelihood =−4.78Transmembrane 25-41INTEGRALLikelihood =−5.15Transmembrane 101-117INTEGRALLikelihood =−5.47Transmembrane 206-222INTEGRALLikelihood =−0.80Transmembrane 244-260INTEGRALLikelihood =−0.75Transmembrane 273-289PERIPHERALLikelihood = 3.02 (at 173)ALOM score: −5.47 (number of TMSs: 5)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 32Charge difference: 3.5 C(1.5) − N(−2.0)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):8.26Hyd Moment(95):10.83G content:0D/E content:2S/T content:1Score: −5.89Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.3%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: FLIKSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: mitochondrial>> prediction for CG55343-03 is end (k = 9)

A search of the NOV41a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 41D.

TABLE 41DGeneseq Results for NOV41aNOV41aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE09961G-protein coupled-receptor1 . . . 313 313/313 (100%)e−180(GPCR)NOV1b protein -1 . . . 313 313/313 (100%)Unidentified, 313 aa.[WO200166746-A2, 13-SEP-2001]AAU95518Human olfactory and pheromone1 . . . 313312/313 (99%)e−178G protein-coupled receptor #5 -1 . . . 313312/313 (99%)Homo sapiens, 313 aa.[WO200224726-A2, 28-MAR-2002]ABP95746Human GPCR polypeptide SEQ1 . . . 313312/313 (99%)e−178ID NO 302 - Homo sapiens, 3131 . . . 313312/313 (99%)aa. [WO200216548-A2, 28-FEB-2002]AAE09960G-protein coupled-receptor1 . . . 313312/313 (99%)e−178(GPCR) NOV1a protein -1 . . . 313312/313 (99%)Unidentified, 313 aa.[WO200166746-A2, 13-SEP-2001]AAG71842Human olfactory receptor1 . . . 313312/313 (99%)e−178polypeptide, SEQ ID NO: 1523 -1 . . . 313312/313 (99%)Homo sapiens, 313 aa.[WO200127158-A2, 19-APR-2001]

In a BLAST search of public sequence databases, the NOV41a protein was found to have homology to the proteins shown in the BLASTP data in Table 41E.

TABLE 41EPublic BLASTP Results for NOV41aNOV41aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueP58173Olfactory receptor 2B6 (Hs6M1-1 . . . 313312/313 (99%)e−17832) (Olfactory receptor 6-31)1 . . . 313312/313 (99%)(OR6-31) - Homo sapiens(Human), 313 aa.Q8VFH1Olfactory receptor MOR256-11 -1 . . . 312254/312 (81%)e−145Mus musculus (Mouse), 313 aa.1 . . . 312273/312 (87%)Q9GZK3Olfactory receptor 2B2 (Olfactory1 . . . 310252/310 (81%)e−143receptor 6-1) (OR6-1) (Hs6M1-1 . . . 310277/310 (89%)10) - Homo sapiens (Human), 357 aa.Q8VFH2Olfactory receptor MOR256-10 -1 . . . 313247/313 (78%)e−140Mus musculus (Mouse), 313 aa.1 . . . 313275/313 (86%)Q63394OL1 receptor - Rattus norvegicus1 . . . 313244/313 (77%)e−139(Rat), 313 aa.1 . . . 313273/313 (86%)

PFam analysis indicates that the NOV41a protein contains the domains shown in the Table 41F.

TABLE 41FDomain Analysis of NOV41aPfamNOV41aIdentities/SimilaritiesExpectDomainMatch Regionfor the Matched RegionValue7tm_141 . . . 290 56/276 (20%)1.3e−33176/276 (64%)TAS2R99 . . . 308 51/309 (17%)0.27126/309 (41%)

Example 42

The NOV42 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 42A.

TABLE 42ANOV42 Sequence AnalysisNOV42a, CG55358-04SEQ ID NO: 579947 bpDNA SequenceORF Start: ATG at 2ORF Stop: TAG at 938TATGGAAAACGATAATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATCATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCTTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGANOV42a,CG55358-04Protein SequenceSEQ ID NO: 580312 aaMW at 34640.9kDMENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIVLAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSODQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEAMKKVLGKGSAEINOV42b, CG55358-03SEQ ID NO: 581932 bpDNA SequenceORF Start: at 3ORF Stop: TAG at 924ATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATTATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42b, CG55358-03Protein SequenceSEQ ID NO: 582307 aaMW at 34051.3kDTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNNTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANKKVLGKGSAEINOV42c, 317863291SEQ ID NO: 583693 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceCGCGGATCCACCATGTACAAGTTCTTTCGAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGCCCTGGGAGGGGTGGAGTGTAGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGTTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCCTCGAGGCGNOV42c, 317863291Protein SequenceSEQ ID NO: 584231 aaMW at 25750.8kDRGSTMYKFFRGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANSLFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVALGGVECVLLAVMAYDRYAAVCKPLHYTAIIMHPRLCGQLVSVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFlILAPLILILISYGYVGGTVLRILEANOV42d, 317863328SEQ ID NO: 585609 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceCGCGGATCCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGTTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCCTCGAGGCGNOV42d, 317863328Protein SequenceSEQ ID NO: 586203 aaMW at 22437.8kDRGSLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLVSVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRILEANOV42e, 317863350SEQ ID NO: 587433 bpDNA SequenceORF Start: at 1ORF Stop: at 433CGCGGATCCGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGTTTCATGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCCTCGAGGCGAAGGGCGAATTCCAGCACACTGNOV42e, 317863350Protein SequenceSEQ ID NO: 588144 aaMW at 15783.9kDFGSAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLVSVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVARILEAKGEFQHTNOV42f, 271624076SEQ ID NO: 589953 bpDNA SequenceORF Start: at 1ORF Stop: TAG at 934GAAAACGATAATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACTGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCAAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTTTTTGTTGTCTCTCTCTTCTATGGTACAATCATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATCGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGGAATTCGGAAGGGCGAANOV42f, 271624076Protein SequenceSEQ ID NO: 590311 aaMW at 34523.7kDENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFAALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEAMKKVLGKGSAEINOV42g, CG55358-01SEQ ID NO: 591945 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAG at 937ATGGAAAACGATAATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATCATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42g, CG55358-01Protein SequenceSEQ ID NO: 592312 aaMW at 34654.9kDMENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYNYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEAMKKVLGKGSAEINOV42h, CG55358-02SEQ ID NO: 593947 bpDNA SequenceORF Start: ATG at 3ORF Stop: TAG at 939GTATGGAAAACGATAATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATCATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42h, CG55358-02Protein SequenceSEQ ID NO: 594312 aaMW at 34654.9kDMENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFlILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANKKVLGKGSAEINOV42i, CG55358-05SEQ ID NO: 59563 bpDNA SequenceORF Start: ATG at 1ORF Stop: end of sequenceATGGAAAACGATAATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCNOV42i, CG55358-05Protein SequenceSEQ ID NO: 59621 aaMW at 2362.5kDMENDNTSSFEGFILVGFSDRPNOV42j, GG55358-06SEQ ID NO: 59760 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCANOV42j, CG55358-06Protein SequenceSEQ ID NO: 59820 aaMW at 2411.9kDTLMLPRCGHRRVDHFLCEMPNOV42k, GG55358-07SEQ ID NO: 599953 bpDNA SequenceORF Start: at 1ORF Stop: TAG at 934GAAAACGATAATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGGAGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCCAAACCCCTGCACTACACCATCATCATGGCCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGTGGGCGAAAGAAAGCCTTCAACACTTGCAGTCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATCATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATCGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGGAATTCGGAAGGGCGAANOV42k, CG55358-07Protein SequenceSEQ ID NO: 600311 aaMW at 34523.7kDENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEAMKKVLGKGSAEINOV42l,+TL,26SNP13375122 ofSEQ ID NO: 601932 bpCG55358-03,ORF Start: at 3ORF Stop: TAG at 924DNA SequenceSNP Pos: 64SNP Change: T to CATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGACCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATTATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42L,SNP13375122 ofCG55358-03,SEQ ID NO: 602MW at 34039.2kDProtein SequenceSNP Pos: 21307 aaSNP Change: Ile to ThrTSSFEGFILVGFSDRPHLELTee VFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFNOV42mCG55358-03,ORF Start: at 3ORF Stop: TAG at 924DNA SequenceSNP Pos: 124SNP Change: T to CATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGCCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGAAATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTAACTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTAATATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGGGTCTTTATCATCCTTAACACCACTCATCCTCATTCTCATTTCTTATGGTTACTTGGAGGAACAGTGCTTAGGATCAAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATTATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42m,SNP13375 123 ofCG55358-03,SEQ ID NO: 604MW at 34023.2kDProtein SequenceSNP Pos: 41307 aaSNP Change: Val to AlaTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIAee LLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIINHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANKKVLGKGSAEINOV42n,SNP13382494 ofSEQ ID NO: 605932 bpCG55358-03,ORF Start: at 3ORF Stop: TAG at 924DNA SequenceSNP Pos: 254SNP Change: T to CATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAAGGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGACee AAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTAAAGTGTGTCCTCCTAACTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACAATCATCATGCACCAACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATTATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTACCCCCTGATCTATACACTAAGAAAACAAAGATGTTAAACAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42n,SNP13382494 ofCG55358-03,SEQ ID NO: 606MW at 34051.3kDProtein SequenceSNP Pos: 84307 aaSNP Change: Asp to AspTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIINHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEAMKKVLGKGSAEINOV42o,SN1P13375124 ofSEQ ID NO: 607932 bpGG55358-03,ORF Start: at 3ORF Stop: TAG at 924DNA SequenceSNP Pos: 283SNP Change: T to CATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCAAAGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGAAATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATAAGCTATGTGGGTTGTGCCACee CCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCAAATGGCAACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAAGAAAGCCTTCAACACTTGCAGTCTCGCATCTAATTGTTGTCTCTCTTCTATGGTACAATTATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42o,SNP13375124 ofCG55358-03,SEQ ID NO: 608MW at 34039.2kDProtein SequenceSNP Pos: 94307 aaSNP Change: Ile to ThrTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCATQLYFVLALGGVECVLLMTMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANKKVLGKGSAEINOV42p, SNP13375125 ofSEQ ID NO: 609932 bpCG55358-03,ORF Start: at 3ORF Stop: TAG at 924DNA SequenceSNP Pos: 336SNP Change: G to AATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTATCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCCTGGCTTTTGCCCTGGCAATCTTTATCATCCTTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATTATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42p,SNP13375125 ofCG55358-03,SEQ ID NO: 610MW at 34065.3kDProtein SequenceSNP Pos: 112307 aaSNP Change: Val to IleTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAIMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRVDHFLCEMPALIGMACVDTMMLEALAAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANKKVLGKGSAEINOV42q,SNP13376426 ofSEQ ID NO: 611932 bpCG55358-03,ORF Start: at 3ORF Stop: TAG at 924DNA SequenceSNP Pos: 415SNP Change: A to GATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACGGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTATTGTTGTCTCTCTCTTCTAATGGTACAATTATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCTGATCTATACACTAAGAAACAAAGATGTTAAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42q,SNP13376426 ofCG55358-03,SEQ ID NO: 612MW at 34079.3kDProtein SequenceSNP Pos: 138307 aaSNP Change: Gln to ArgTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGRLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEAMKKVLGKGSAEINOV42r,SNP13376427 ofSEQ ID NO: 613932 bpCG55358-03,ORF Start: at 3ORF Stop: TAG at 924DNA SequenceSNP Pos: 421SNP Change: C to TATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACGGCTGGTTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTATTGTTGTCTCTCTCTTCTAATGGTACAATTATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCTGATCTATACACTAAGAAACAAAGATGTTAAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42r,SNP13376427 ofCG55358-03,SEQ ID NO: 614MW at 34079.3kDProtein SequenceSNP Pos: 140307 aaSNP Change: Ala to ValTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVBCVLIAVMAYDRYAAVCKPLHYTIIMHPRLCGQLVSVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTITYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANKKVLGKGSAEINOV42s,SNP13375126 ofSEQ ID NO: 615932 bpCG55358-03,ORF Start: at 3ORF Stop: TAG at 924DNA SequenceSNP Pos: 700SNP Change: T to CATACAAGTTCTTTCGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTTGGCAAACCTCTCATTCCTGGACATGTGTTTCACCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCCTGGCCCTGGGAGGGGTGGAGTGTGTCCTCCTGGCTGTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTCTCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCACCACTCATCCTCATTCTCATTTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTCee CAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATTATATACATGTACCTCCAGCCAGCAAATACTTATTCCCAGGACCAGGGCAAGTTTCTTACCCTTTTCTACACAATTGTCACTCCCAGTGTTAACCCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGGNOV42s,SNP13375126 ofCG55358-03,SEQ ID NO: 616MW at 33991.2kDProtein SequenceSNP Pos: 233307 aa SNP Change: Phe to SerTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKASNTCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEAMKKVLGKGSAEI

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 42B.

TABLE 42BComparison of the NOV42 protein sequences.NOV42aMENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYNOV42b-----TSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYNOV42cRGSTMYKFFRGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYNOV42d----------------------------RGSLIFYLLTLLGNMTIVLLSALDSRLHTPMYNOV42e------------------------------------------------------------NOV42f-ENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYNOV42gMENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYNOV42hMENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYNOV42i------------------------------------------------------------NOV42j------------------------------------------------------------NOV42k-ENDNTSSFEGFILVGFSDRPHLELIVFVVVLIFYLLTLLGNMTIVLLSALDSRLHTPMYNOV42aFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYNOV42bFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYNOV42cFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYNOV42dFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYNOV42e----------------------------------RGSAIQLYFVLALGGVECVLLAVMAYNOV42fFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYNOV42gFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYNOV42hFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYNOV42i------------------------------------------------------------NOV42j------------------------------------------------------------NOV42kFFLANLSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYNOV42aDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCENOV42bDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCENOV42cDRYAAVCKPLHYTIIMHPRLCGQLVSVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCENOV42dDRYAAVCKPLHYTIIMHPRLCGQLVSVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCENOV42eDRYAAVCKPLHYTIIMHPRLCGQLVSVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCENOV42fDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCENOV42gDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCENOV42hDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCENOV42i--------------------------------MENDNTSSFEGFILVGFSDRP-------NOV42j------------------------------------------TLMLPRCGHRRVDHFLCENOV42kDRYAAVCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCENOV42aMPALIGMACVDTMMLEALAFALAIFIVLAPLILILISYGYVGGTVLRIKSAAGRKKAFNTNOV42bMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTNOV42cMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRILEA---------NOV42dMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRILEA---------NOV42eMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRILEAKGEFQHT--NOV42fMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTNOV42gMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTNOV42hMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTNOV42i------------------------------------------------------------NOV42jMP----------------------------------------------------------NOV42kMPALIGMACVDTMMLEALAFALAIFIILAPLILILISYGYVGGTVLRIKSAAGRKKAFNTNOV42aCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANOV42bCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANOV42c------------------------------------------------------------NOV42d------------------------------------------------------------NOV42e------------------------------------------------------------NOV42fCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANOV42gCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANOV42hCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANOV42i------------------------------------------------------------NOV42j------------------------------------------------------------NOV42kCSSHLIVVSLFYGTIIYMYLQPANTYSQDQGKFLTLFYTIVTPSVNPLIYTLRNKDVKEANOV42aMKKVLGKGSAEINOV42bMKKVLGKGSAEINOV42c------------NOV42d------------NOV42e------------NOV42fMKKVLGKGSAEINOV42gMKKVLGKGSAEINOV42hMKKVLGKGSAEINOV42i------------NOV42j------------NOV42kMKKVLGKGSAEINOV42a(SEQ ID NO: 580)NOV42b(SEQ ID NO: 582)NOV42c(SEQ ID NO: 584)NOV42d(SEQ ID NO: 586)NOV42e(SEQ ID NO: 588)NOV42f(SEQ ID NO: 590)NOV42g(SEQ ID NO: 592)NOV42h(SEQ ID NO: 594)NOV42i(SEQ ID NO: 596)NOV42j(SEQ ID NO: 598)NOV42k(SEQ ID NO: 600)

Further analysis of the NOV42a protein yielded the following properties shown in Table 42C.

TABLE 42CProtein Sequence Properties NOV42aSignalP analysis:Cleavage site between residues 42 and 43PSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 10; pos.chg 0;neg.chg 3H-region:length 8;peak value0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −2.80possible cleavage site: between 41 and 42>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 5INTEGRALLikelihood =−13.21Transmembrane 25-41INTEGRALLikelihood = −7.11Transmembrane 103-119INTEGRALLikelihood = −0.27Transmembrane 183-199INTEGRALLikelihood =−14.97Transmembrane 200-216INTEGRALLikelihood = −1.12Transmembrane 244-260PERIPHERALLikelihood = 1.80 (at 273)ALOM score: −14.97 (number of TMSs: 5)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 32Charge difference: 2.0 C(0.5) − N(−1.5)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):6.56Hyd Moment(95):3.47G content:0D/E content:2S/T content:0Score: −7.29Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 6.7%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: endoplasmic reticulum22.2%: vacuolar11.1%: vesicles of secretory system11.1%: Golgi>> prediction for CG55358-04 is end (k = 9)

A search of the NOV42a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 42D.

TABLE 42DGeneseq Results for NOV42aNOV42aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE10685G-protein coupled receptor 4a1 . . . 312311/312 (99%)e−180(GPCR4a) - Unidentified, 312 aa.1 . . . 312312/312 (99%)[WO200164879-A2, 07-SEP-2001]AAG72062Human olfactory receptor1 . . . 312310/312 (99%)e−179polypeptide, SEQ ID NO: 1743 -3 . . . 314312/312 (99%)Homo sapiens, 334 aa.[WO200127158-A2, 19-APR-2001]AAE10686G-protein coupled receptor 4b6 . . . 312306/307 (99%)e−177(GPCR4b) - Unidentified, 307 aa.1 . . . 307307/307 (99%)[WO200164879-A2, 07-SEP-2001]ABP95745Human GPCR polypeptide SEQ43 . . . 312 269/270 (99%)e−155ID NO 300 - Homo sapiens, 2701 . . . 270270/270 (99%)aa. [WO200216548-A2, 28-FEB-2002]AAG71998Human olfactory receptor43 . . . 312 269/270 (99%)e−155polypeptide, SEQ ID NO: 1679 -1 . . . 270270/270 (99%)Homo sapiens, 270 aa.[WO200127158-A2, 19-APR-2001]

In a BLAST search of public sequence databases, the NOV42a protein was found to have homology to the proteins shown in the BLASTP data in Table 42E.

TABLE 42EPublic BLASTP Results for NOV42aNOV42aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAC88325Sequence 11 from Patent1 . . . 312311/312 (99%)e−179WO0164879 - Homo sapiens1 . . . 312312/312 (99%)(Human), 312 aa.Q8NHA6Seven transmembrane helix12 . . . 312 300/301 (99%)e−173receptor - Homo sapiens18 . . . 318 301/301 (99%)(Human), 318 aa.Q8VFH0Olfactory receptor MOR256-12 -1 . . . 312295/312 (94%)e−172Mus musculus (Mouse), 3176 . . . 317304/312 (96%)aa.Q8VG14Olfactory receptor MOR256-8 -1 . . . 307212/307 (69%)e−125Mus musculus (Mouse), 308 aa.1 . . . 307251/307 (81%)Q8VFG9Olfactory receptor MOR256-13 -5 . . . 305205/301 (68%)e−120Mus musculus (Mouse), 31411 . . . 311 247/301 (81%)aa.

PFam analysis indicates that the NOV42a protein contains the domains shown in the Table 42F.

TABLE 42FDomain Analysis of NOV42aPfamNOV42aIdentities/SimilaritiesExpectDomainMatch Regionfor the Matched RegionValue7tm_141 . . . 290 57/276 (21%)3.2e−41177/276 (64%)

Example 43

The NOV43 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 43A.

TABLE 43ANOV43 Sequence AnalysisNOV43a, CG55604-04SEQ ID NO: 617968 bpDNA SequenceORF Start: ATG at 8ORF Stop: TGA at 950TATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATATCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATGGAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43a, CG55604-04Protein SequenceSEQ ID NO: 618314 aaMW at 35728.1kDMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43b, GG55604-01SEQ ID NO: 619840 bpDNA SequenceORF Start: ATG at 42ORF Stop: TGA at 810TCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTTCTTAGAAACTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTGTCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTTTTAGAGCTATGGNOV43b, CG55604-01Protein SequenceSEQ ID NO: 620256 aaMW at 29023.1kDMYFFLRNLSFADLCFSTSIVPQVLVHFLVKRTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYAVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPWGQNIINHYFCEPPALLKLASIADTYSTEMAIFSMGVVILLAPVSILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFATYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43c, GG55604-02SEQ ID NO: 621944 bpDNA SequenceORF Start: ATG at 31ORF Stop: TGA at 973TGCCAAACAGGTAAACAGGCAAAAATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATATCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTGTCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTGGGATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCATGACCTCTGAGTCTGACTTTTANOV43c, GG55604-02Protein SequenceSEQ ID NO: 622314 aaMW at 35714.lkDMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43d, CG55604-03SEQ ID NO: 623960 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 943ATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTTATCTGTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATATCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTNOV43d, CG55604-03Protein SequenceSEQ ID NO: 624314 aaMW at 35728.1kDMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43e, GG55604-05SEQ ID NO: 625995 bpDNA SequenceORF Start: ATG at 31ORF Stop: TGA at 973TGCCAAACAGGTAAACAGGCAAAAATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCCGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTTTTAANOV43e, CG55604-05Protein SequenceSEQ ID NO: 626314 aaMW at 35728.1kDMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43f, CG55604-06SEQ ID NO: 627946 bpDNA SequenceORF Start: ATG at 2ORF Stop: TGA at 944TATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATATCTCCTTTGCAGATCTCTGTTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCATTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTCGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTGTCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGANOV43f, CG55604-06Protein SequenceSEQ ID NO: 628314 aaMW at 35614.9kDMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43g, CG55604-07SEQ ID NO: 629962 bpDNA SequenceORF Start: ATG at 2ORF Stop: TGA at 944TATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATATCTCCTTTGCAGATCTCTGTTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCATTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTCGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTGTCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43g, CG55604-07Protein SequenceSEQ ID NO: 630314 aaMW at 35728.1kDMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43h,SNP13019742 ofSEQ ID NO: 631968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 203SNP Change: A to CTATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43h,SNP13019742 ofCG55604-04,SEQ ID NO: 632Protein SequenceSNP Pos: 66314 aaMW at 35728.1kDMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43i, SNP13373776 ofSEQ ID NO: 633968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 355SNP Change: A to CTATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43i,SNP13373776 ofCG55604-04,SEQ ID NO: 634MW at 35728.1kDProtein SequenceSNP Pos: 116314 aaSNP Change: Ala to AlaMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43j,SNP13373777 ofSEQ ID NO: 635968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 372SNP Change: G to ATATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCAGGTTGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43j,SNP13373777 ofCG55604-04,SEQ ID NO: 636MW at 35700.0kDProtein SequenceSNP Pos: 122314 aaSNP Change: Arg to GlnMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDQYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43k,SNP13373778 ofSEQ ID NO: 637968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 422SNP Change: C to TTATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAATGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43k,SNP13373778 ofCG55604-04,SEQ ID NO: 638MW at 35758.1kDProtein SequenceSNP Pos: 139314 aaSNP Change: Arg to TrpMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQWVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43l,SNP13373838 ofSEQ ID NO: 639968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 453SNP Change: G to CTATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTCGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43l,SNP13373838 ofCG55604-04,SEQ ID NO: 640MW at 35628.9kDProtein SequenceSNP Pos: 149314 aaSNP Change: Trp to SerMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSSASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43m,SNP13373837 ofSEQ ID NO: 641968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 461SNP Change: G to ATATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTAGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43m,SNP13373837 ofCG55604-04,SEQ ID NO: 642MW at 35827.2kDProtein SequenceSNP Pos: 152314 aaSNP Change: Gly to ArgMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASRALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43n,SN1P13373836 ofSEQ ID NO: 643968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 587SNP Change: A to GTATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTAGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACGGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43n,SNP13373836 ofCG55604-04,SEQ ID NO: 644MW at 35698.1kDProtein SequenceSNP Pos: 194314 aaSNP Change: Ser to GlyMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYGTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43o,SNP13373780 ofSEQ ID NO: 645968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 615SNP Change: G to ATATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTAGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACGGCACAGAAATGGCCATCTTTTCAATGGACGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43o,SNP13373780 ofCG55604-04,SEQ ID NO: 646MW at 35786.1kDProtein SequenceSNP Pos: 203314 aaSNP Change: Gly to AspMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMDVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43p,SNP13373781 ofSEQ ID NO: 647968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 638SNP Change: A to GTATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTAGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACGGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTGTCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43p,SNP13373781 ofCG55604-04,SEQ ID NO: 648MW at 35714.1kDProtein SequenceSNP Pos: 211314 aaSNP Change: Ile to ValMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43q, SNP13373782 ofSEQ ID NO: 649968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 679SNP Change: T to CTATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTAGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACGGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACCGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43q,SNP13373782 ofCG55604-04,SEQ ID NO: 650MW at 35728.1kDProtein SequenceSNP Pos: 224314 aaSNP Change: Thr to ThrMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNOLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGONIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43r,SNP13373783 ofSEQ ID NO: 6511968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 844SNP Change: A to GTATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTAGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACGGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACGGCGGTGACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43r,SNP13373783 ofCG55604-04,SEQ ID NO: 652MW at 35728.1kDProtein SequenceSNP Pos: 279314 aaSNP Change: Thr to ThrMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNOLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRONOV43s,SNP13373833 ofSEQ ID NO: 653968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 850SNP Change: G to ATATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTAGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACGGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTAACTCCAATGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43s,SNP13373833 ofCG55604-04,SEQ ID NO: 654MW at 35728.1kDProtein SequenceSNP Pos: 281314 aaSNP Change: Val to ValMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNOLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCEPPALLKLASIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKCFSHRONOV43t,SNP13373784 ofSEQ ID NO: 655968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 857SNP Change: A to GTATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTAGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACGGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAGTGTTGAACCCCATAATTTATAGCTTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43t,SNP13373784 ofCG55604-04,SEQ ID NO: 656MW at 35696.0kDProtein SequenceSNP Pos: 284314 aaSNP Change: Met to ValMGEENQTFVSKFIFLGLSQDLQTOILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPWGQNIINHYFCEPPALLKLASAIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPVLNPIIYSLRNKDVKGALRKLVGRKCFSHRQNOV43u,SNP13373832 ofSEQ ID NO: 657968 bpCG55604-04,ORF Start: ATG at 8ORF Stop: TGA at 950DNA SequenceSNP Pos: 885SNP Change: G to ATATATCAATGGGAGAAGAAAACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGATCCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCATCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCTCCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTAAAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTGGGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAAGCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCTGGGCCAGTAGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTGGGGACAGAATATAATCAATCACTACTTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCCATAGACACTTACGGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCCCTATCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCTGGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTTCTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGATAAAATGATATCTGTGTTCTATACAGCGGTGACTCCCGTGTTGAACCCCATAATTTATAGCTTGAAGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCTCATAGGCAGTGACCTCTGAGTCTGACTANOV43u,SNP13373832 ofCG55604-04,SEQ ID NO: 658MW at 35700.1kDProtein SequenceSNP Pos: 293314 aaSNP Change: Arg to LysMGEENQTFVSKFIFLGLSQDLQTOILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYFFLRNISFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAVMSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPWGQNIINHYFCEPPALLKLASAIDTYSTEMAIFSMGVVILLAPISLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLIVVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPVLNPIIYSLKNKDVKGALRKLVGRKCFSHRQ

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 43B.

TABLE 43BComparison of the NOV43 protein sequences.NOV43aMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLDSRLHTPMYNOV43b------------------------------------------------------------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(SEQ ID NO: 618)NOV43b(SEQ ID NO: 620)NOV43c(SEQ ID NO: 622)NOV43d(SEQ ID NO: 624)NOV43e(SEQ ID NO: 626)NOV43f(SEQ ID NO: 628)NOV43g(SEQ ID NO: 630)

Further analysis of the NOV43a protein yielded the following properties shown in Table 43C.

TABLE 43CProtein Sequence Properties NOV43aSignalP analysis:Cleavage site between residues 42 and 43PSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 11; pos.chg 1;neg.chg 2H-region:length 8;peak value0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 0.24possible cleavage site: between 41 and 42>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 5INTEGRALLikelihood =−13.32Transmembrane 25-41INTEGRALLikelihood = −1.75Transmembrane 71-87INTEGRALLikelihood = −8.86Transmembrane 101-117INTEGRALLikelihood = −9.34Transmembrane 199-215INTEGRALLikelihood = −1.65Transmembrane 241-257PERIPHERALLikelihood = 1.59 (at 273)ALOM score: −13.32 (number of TMSs: 5)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 32Charge difference: 1.5 C(1.5) − N(0.0)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):8.77Hyd Moment(95):7.26G content:1D/E content:2S/T content:0Score: −7.02Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 8.0%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found *** LFLIIYLLTVLGNQLIIILIFL at 30 nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG55604-04 is end (k = 9)

A search of the NOV43a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 43D.

TABLE 43DGeneseq Results for NOV43aNOV43aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAG66338Human NOV 18 protein1 . . . 314 314/314 (100%)0.0sequence - Homo sapiens, 314 aa.1 . . . 314 314/314 (100%)[WO200155179-A2, 02-AUG-2001]AAG66331Human NOV 11 protein1 . . . 314 314/314 (100%)0.0sequence - Homo sapiens, 3141 . . . 314 314/314 (100%)aa. [WO200155179-A2, 02-AUG-2001]AAG66337Human NOV 17 protein1 . . . 314313/314 (99%)0.0sequence - Homo sapiens, 3141 . . . 314314/314 (99%)aa. [WO200155179-A2, 02-AUG-2001]AAG66333Human NOV 13 protein1 . . . 314313/314 (99%)0.0sequence - Homo sapiens, 3141 . . . 314314/314 (99%)aa. [WO200155179-A2, 02-AUG-2001]AAG66332Human NOV 12 protein1 . . . 314313/314 (99%)0.0sequence - Homo sapiens, 3141 . . . 314314/314 (99%)aa. [WO200155179-A2, 02-AUG-2001]

In a BLAST search of public sequence databases, the NOV43a protein was found to have homology to the proteins shown in the BLASTP data in Table 43E.

TABLE 43EPublic BLASTP Results for NOV43aNOV43aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAC69632Sequence 21 from Patent1 . . . 314 314/314 (100%)e−180WO0155179 - Homo sapiens1 . . . 314 314/314 (100%)(Human), 314 aa.CAC69634Sequence 25 from Patent1 . . . 314313/314 (99%)e−180WO0155179 - Homo sapiens1 . . . 314314/314 (99%)(Human), 314 aa.CAC69637Sequence 31 from Patent1 . . . 314313/314 (99%)e−180WO0155179 - Homo sapiens1 . . . 314314/314 (99%)(Human), 314 aa.Q8NGH3Seven transmembrane helix1 . . . 314312/314 (99%)e−180receptor - Homo sapiens1 . . . 314314/314 (99%)(Human), 314 aa.Q9EP67B5 olfactory receptor -1 . . . 304253/304 (83%)e−144Mus musculus (Mouse), 307 aa.1 . . . 304275/304 (90%)

PFam analysis indicates that the NOV43a protein contains the domains shown in the Table 43F.

TABLE 43FDomain Analysis of NOV43aPfamNOV43aIdentities/SimilaritiesExpectDomainMatch Regionfor the Matched RegionValue7tm_141 . . . 290 58/277 (21%)8.4e−36179/277 (65%)

Example 44

The NOV44 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 44A.

TABLE 44ANOV44 Sequence AnalysisNOV44a, CG55752-07SEQ ID NO: 6591998 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1969ATGGGCATTTATGGTTCAGTACCTTATCTCCTGGCCCACAAACTGGGCAGAACTATAGGTATTTTCTGGCTGAATGCCTCGGAAACACTGGTGGAGATCAATACAGAGCCTGCAGTAGAGTACACACTGACCCAGATGGGCCCAGTTGCTGCTAAACAAAAGGTCAGATCTCGCACTCATGTGCACTGGATGTCAGAGAGTGGCATCATTGATGTTTTTCTGCTGACAGGACCTACACCTTCTGATGTCTTCAAACAGTACTCACACCTTACAGGTACACAAGCCATGCCCCCTCTTTTCTCTTTGGGATACCACCAGTGCCGCTGGAACTATGAAGATGAGCAGGATGTAAAAGCAGTGGATGCAGGGTTTGATGAGCATGACATTCCTTATGATGCCATGTGGCTGGACATAGAGCACACTGAGGGCAAGAGGTACTTCACCTGGGACAAAAACAGATTCCCAAACCCCAAGAGGATGCAAGAGCTGCTCAGGAGCAAAAAGCGTAAGCTTGTGGTCATCAGTGATCCCCACATCAAGATTGATCCTGACTACTCAGTATATGTGAAGGCCAAAGATCAGGGCTTCTTTGTGAAGAATCGAGGAAGGGAAGACTTTGAAGGGGTGTGTTGGCCAGGTCTCTCCTCTTACCTGGATTTCACCAATCCCAAGGTCAGAGAGTGGTATTCAAGTCTTTTTGCTTTCCCTGTTTATCAGGGATCTACGGACATCCTCTTCCTTTGGAATGACATGAATGAGCCTTCTGTCTTTAGAGGGCCAGAGCAAACCATGCAGAAGAATGCCATTCATCATGGCAATTGGGAGCACAGAGAGCTCCACAACATCTACGGTTTTTATCATCAAATGGCTACTGCAGAAGGACTGATAAAACGATCTAAAGGGAAGGAGAGACCCTTTGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACCAGCCCTTCTTCCGTGGCCATGCCACCATGAACACCAAGCGACGAGAGCCCTGGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAAGCCATCAGAGAGCGCTATGGCCTCCTGCCATATTGGTATTCTCTGTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGCTGGGTAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTATGGTATGACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTAAGGGTTCTTCATGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCACACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATTCCAGTTAAGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGGTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATAATATGACAAAGAACTGCCCCTGGTGATGTGAGCNOV44a, GG55752-07Protein SequenceSEQ ID NO: 660656 aaMW at 74971.6kDMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTLTQMGPVAAKQKVRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQANPPLFSLGYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKMRFPNPKRNQELLRSKXRKLVVISDPHIKIDPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFTNPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHNIYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYGGAVWTGDNTAEWSNLKISIPMLLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEEHTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRPLWVEFPDELKTFDMEDEYMLGSALLVHPVTEPKATTVDVFLPGSNEVWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTKGSSVGELYLDDGHSFQYLHQKQFLHRKFSFCSSVLINSSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSSGDGKDQPVAFTYCAKTSILSLEKLSLNIATDWEVRIINOV44b, CG55752-06SEQ ID NO: 6612001 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1972ATGGGCATTTATGGTTCAGTACCTTATCTCCTGGCCCACAAACTGGGCAGAACTATAGGTATTTTCTGGCTGAATGCCTCGGAAACACTGGTGGAGATCAATACAGAGCCTGCAGTAGAGTACACACTGACCCAGATGGGCCCAGTTGCTGCTAAACAAAAGGTCAGATCTCGCACTCATGTGCACTGGATGTCAGAGAGTGGCATCATTGATGTTTTTCTGCTGACAGGACCTACACCTTCTGATGTCTTCAAACAGTACTCACACCTTACAGGTACACAAGCCATGCCCCCTCTTTTCTCTTTGGGATACCACCAGTGCCGCTGGAACTATGAAGATGAGCAGGATGTAAAAGCAGTGGATGCAGGGTTTGATGAGCATGACATTCCTTATGATGCCATGTGGCTGGACATAGAGCACACTGAGGGCAAGAGGTACTTCACCTGGGACAAAAACAGATTCCCAAACCCCAAGAGGATGCAAGAGCTGCTCAGGAGCAAAAAGCGTAAGGTACTTGTGGTCATCAGTGATCCCCACATCAAGATTGATCCTGACTACTCAGTATATGTGAAGGCCAAAGATCAGGGCTTCTTTGTGAAGAATCAGGAAGGGGAAGACTTTGAAGGGGTGTGTTGGCCAGGTTCTCCTCTTACCTGGATTTCACCAATCCCAAGGTACAGAGAGTGGTATTCAAGTCTTTTTGCTTTCCCTGTTTATCAGGGATCTACGGACATCCTCTTCCTTTGGAATGACATGAATGAGCCTTCTGTCTTTAGAGGGCCAGAGCAAACCATGCAGAAGAATGCCATTCATCATGGCAATTGGGAGCACAGAGAGCTCCACAACATCTACGGTTTTTATCATCAAATGGCTACTGCAGAAGGACTGATAAAACGATCTAAAGGGAAGGAGAGACCCTTTGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACCAGCCCTTCTTCCGTGGCCATGCCACCATGAACACCAAGCGACGAGAGCCCTGGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAAGCCATCAGAGAGCGCTATGGCCTCCTGCCATATTGGATTCTCTGTTCTACCATGCACACGTGGCATTCCCAACCTGTCATGAGGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGCTGGGTTTAGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTTCCAGGATCAAATGAGGTATGGTATGACTATAAGACATTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATTCCAGTTTTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATCATATGACAAAGAACTGCCCCTGGTGATGTGAGCNOV44b, CG55752-06Protein SequenceSEQ ID NO: 662657 aaMW at 75166.9kDMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVETLTQMGPVAAKQKVRSRTHVHWAMSESGIIDVFLLTGPTPSDVFKQYSHLTGIQAMPPLFSLGYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQELLRSKKRKVLVVISDPHIKIDPDYSVYKVAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFTNPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVRGPEQTMQKNAAIHHGNWEHRELHNIYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYGAVWTGDNTAEWSNLKISIPMLLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEEHTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRRPLWVEFPDELKTFDMEDEYMLGLGSALLVHPVTEPKATTVDVFLPGSNEVWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTGSSVGELYDDGHSFQYLHQKQFLHRKFSFCSSVLINSSFADQRGHYPSKCVVEAKILVLGFRKEPSSVTTHSSDGKDQPVAFTYCAKTSILSLEKSLNIATDWEVRIINOV44c, CG55752-01SEQ ID NO: 6633025 bpDNA SequenceORF Start: ATG at 28ORF Stop: TGA at 2929ACAGTGCCTGGGGGTCAGGCTTCCGCATGCGGGCTGCAGTTGCTGGCATTGCCTTCCGCAGGGAGGCGTCAGAAACAGTGGCTTTCCAAGAAGTCCACCTATCAGGCATTATTGGATTCAGTCACAACAGATAAAGACAGCACCAGGTTCCAAATCATCAATGAAGCAAGTAAGGTGAGGCGTCAGAAACAGTGGCTTTCCAAGAAGTCCACCTATCAGGCATTATTGGATTCAGTCACAACAGATGAAGACAGCACCAGGTTCCAAATCATCAATGAAGCAAGTAAGGTGCCTCTCCTGGCTGAAATTTATGGTATAGAAGGAAACATTTTCAGGCTTAAAATTAATGAAGAGACTCCTCTAAAACCCAGATTTGAAGTTCCGGATGTCCTCACAAGCAAGCCAAGCACTGTAAGGATTTCATGCTCTGGGGACACAGGCAGTCTGATATTGGCAGATGGAAAAGGAGACCTGAAGTGCCATATCACAGCAAACCCATTCAAGGTAGACTTGGTGTCTGAAGAAGAGGTTGTGATTAGCATAAATTCCCTGGGCCAATTATACTTTGAGCATGGCAGGGCCCCTAGGGTCTCTTTCTCGGATAAGGTTAATCTCACGCTTGGTAGCATATGGGATAAGATCAAGAACCTTTTCTCTAGGCAAGGATCAAAAGACCCAGCTGAGGGCGATGGGGCCCAGCCTGAGGAAACACCCAGGGATGGCGACAAGCCAGAGGAGACTCAGGGGAAGGCAGAGAAAGATGAGCCAGGAGCCTGGGAGGAGACATTCAAAACTCACTCTGACAGCAAGCCGTATGGCCCTTCTTCTATTGGTTTGGATTTCTCCTTGCATGGATTTGAGCATCTTTATGGGATCCCACAACATGCAGAATCACACCAACTTAAAAATACTGGGGATGGAGATGCTTACCGTCTTTATAACCTGGATGTCTATGGATACCAAATATATGATAAATGGGCATTTATGGTTCAGTACCTTATCTCCTGGCCCAACAAACTGGGCAGAACTATAGGTATTTTCTGGCTGAATGCCTCGGAACACTGGTGGAGATCAATACAGAGCACTGCAGGGATAGTCATCTTTGGTCCTGTCTCTTTGATTTATCAAAGCCAGGGAGATACACCTCTAACAACTCATGTGCACTGGATGTCAGAGAGTGGCATCATTGATGTTTTTCTGCTGACAGGACCTACACCTTCTGATGTCTTCAAACAGTACTCACACCTTACAGGTACACAAGCCATGCCCCCTCTTTTCTCTTTGGGATACCACCAGTGCCGTCGGAACTATGAAGATGAGCAGGATGTAAAAGCAGTGGATGCAGGGTTTGATGAGCATGACATTCCTTATGATGCCATGTGGCTGGACATAGAGCACACTGAGGGCAAGAGGTACTTCACCTGGGACAAAAACAGATTCCCAAACCCCAAGAGGATGCAAGAGCTGCTCAGGAGCAAAAAGCGTAAGCTTGTGGTCATCAGTGATCCCCACATCAAGATTGAACCTGACTACTCAGTATATGTGAAGGCCAAAGATCAGGGCTTCTTTGTGAAGAATCAGGAAGGGGAAGACTTTGAAGGGGTGTGTTGGCCAGGTATGAAATCATACCTGGATTCACCAATCCCAAGGTCAGAGAGTGGTATTCAAGTATGTTCAGTTCCAATTGTGAATGGATCTACGGACATCCTCTTCCTTTGGAATGACATGAATGAGCCTTCTGTCTTTAGAGGGCCAGAGCAAACCATGCAGAAGAATGCCATTCATCATGGCAATTGGGAGCAGAGAGAGCTCCACAACATCTACGGTTTTTATATGGCTACTGCAGAAGGACTGTAAAACGATCTAAAGGGAAGGAGAGACCCTTTGTTCTTAACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGAGCAGAGCTGCTAGTGCGGTGGTACCAGGCTGGGACCTACGCACCTTCTTCCGTGGCCATGCCACCATGAACACCAAGCGCGAGAGCCCTGGCTCTTTGGGGAGGAACACAACCCGACTCATCCGAGAAGCCATCAGAGAGCGCTATGGCCTCCTGCCATATTGGTATTCTCTCTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGTTAGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTAGTCTGGTATGACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTACTGTTACAGATTCCAGTGTTTCAGCGAGGTGGAAGGGGTTGCTCTAAGCACTCTCCAGGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGGTGGCCTCCTCTCCAGTATCTCAAGGACACTTACATACCCCACTCAGCATGACAAAAGCCCTGCTTTTCACTGTATCGTCTCCAGCCAGCGTGAAAATGCGGCTTCACTACAGCCCAGAGAAAAGGGCCAGGTTTAGTCATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATCATATGACAAAGAACTGCCCCTGGTGATGTGAGCAGGGACCTGCCTGCCCCTTTCAACCTTTCCCCTCACCTTTTTTGAGATTTTTGCTGCAATCTGTTTGNOV44c, CG55752-01Protein SequenceSEQ ID NO: 664967 aaMW at 109801.3kDMRAAVAGIAFRRRRQKQWLSKKSTYQALLDSVTTDEDSTRFQIINEASKVRRQKQWLSKKSTYQALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPDVLTSKPSTVRISCSGDTGSLILADGKGDLKCHITANPFKVDLVSEEEVVISINSLGQLYFEHGRAPRVSFSDKVNLTLGSIWDKIKNLFSRQGSKDPAEGDGAQPEETPRDDKPEETQGKAEKDEPGAWEETFKTHSDSKPYGPSSAIGLDFSLHGFEHLYGIPQHAESHQLKNTGDGDAYRLYNLDVYGYQIYDKMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAGIVIFGPVSLIYQSQGDTPLTTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQAMPPLFSLGYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQELLRSKKRKLVVISDPHIKIEPDYSVYVKAKDQGFFVKNQEGEDFEGDVCWPGMKSYLFTNPKVREWYSSMFSSNCDGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHNIYGFYMATEAGLIKRSKGKERPFVLTRSFFAGSQKYGAVWTGDNTAEWSNLKISIPMLLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEEHTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRPLWVEFPDELKTFDMEDEYMLGSALLVHPVTEPKATTVDVFLPGSNEVVWYDYKTFAHWEGGCTVKIPVLLQIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTLQGSSVGELYLDDGHSFQYLHQKQFLHRKFSFCSSVLVASSPVSQGHLHTPLSMTKALLFTVSSPASVKMRLHYSPEKRARFSHCAATSISSLEKLSNIATDWEVRIINOV44d, CG55752-02SEQ ID NO: 6654483 bpDNA SequenceORF Start: ATG at 204ORF Stop: TGA at 2946AACGCTAGTTTGGGCCTGAAAAATTCCAGGAGCAAGAGTCAAGATTTGTCACTCCATGAGAATCTGGAGGGGACTCCCTTCCCAGAAACTTGACGATGAAGTACTGGTTGTAATTTTAGAAAGACACCCAATCGGCTTTTTTAAAAGATCGCCCAGGGCCCTTGTCCTGAGAGCTGGGAGCTGGTCGGAGTGACAGAGAAGCCATGGAAGCAGCAGTGAAAGAGGAAATAAGTGTTGAAGATGAAGCTGTAGATAAAAACATTTTCAGAGACTGTAACAAGATCGCATTTTACAGGCGTCAGAAACAGTGGCTTTCCAAGAAGTCCACCTATCAGGCATTATTGGATTCAGTCACAACAGATGAAGACAGCACCAGGTTCCAAATCATCAATGAAGCAAGTAAGGTTCCTCTCCTGGCTGAAATTTATGGTATAGAAGGAAACATTTTCAGGCTTAAAATTAACGAAGAGACTCCTCTAAAACCCAGATTTGAAGTTCCGGATGTCCTCACAAGCAAGCCAAGCACTGTAAGGCTGATTTCATGCTCTGGGGACACAGGCAGTCTGATATTGGCAGATGGAAAAGGAGACCTGAAGTGCCATATCACAGCAAACCCATTCAAGGTAGACTTGGTGTCTGAAGAAGAGGTTGTGATTAGCATAAATTCCCTGGGCCAATTATACTTTGAGCATCTACAGATTCTTCACAAACAAAGAGCTGCTAAAGAAAATGAGGAGGAGACATCAGTGGACACCTCTCAGGAAAATCAAGAAGATCTGGGCCTGTGGGAAGAGAAATTTGGAAAATTTGTGGATATCAAAGCTAATGGCCCTCTTCTATTGGTTTGGATTTCTCCTTAGCATGGATTTGAGCATCTTTATGGGATCCCACAACATGCAGAATCACACCAACTTAAAAATACTGGTGATGGAGATGCTTACCGTCTTTATAACCTGGATGTCTATGGATACCAAATATATGATAAAATGGGCATTTATGTTCAGTACCTTATCTCCTAGGCCCACAAACTGGGCAGAACTATAGGTATTTTCTGGCTGAATGCCTCGGAAACACTGGTGGAGATCAATACAGAGCCTGCAGTAGAGTACACACTGACCCAGATGGGCCCAGTTGCTGCTAAACAAAAGGTCAGATCTCGCACTCATGTGCACTGGATGTCAGAGAGTGGCATCATTGATGTTTTTCTGCTGACATTACCTACACCTTCTGATGCTTCAAACAGTACTCACACCTTACAGGCACACAAGCCATGCCCCCTCTTTTTCTCTTTGGGATACCACCAGTGCCGCTGGAACTATGAAGATGAGCAGGATGTAAAAGCAGTGGATGCAGGGTTTGATGAGCATGACATTCCTTATGATGCCATGTGGCTGGACATAGAGCACACTGAGGGCAAGAGGTACTTCACCTGGGACAAAAACAGTTCCCAAACCCCAAGAGGATGCAAGAGCTGCTCAGGAGCAAAAAAGCGTAAGCTTGTGGTCATCAGTGAATCCCCACATCAAGATTGATCCTGACTACTCAGTATATGTGAAGGCCAAAGCAGGGATCTACGGACATCCTCTTCCTTTGGAATGACATGAATGAGCCTTCTGTCTTTAGAGGGCCAGAGCAAACCATGCAGAAGAATGCCATTCATCATGGCAATTGGGAGCACAGAGAGCTCCACAACATCTACGGTTTTTATCATCAAATGGCTACTGCAGAAGGACTGATAAAACGATCTAAAGGGAAGGAGAGACCCTTTGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACCAGCCCTTCTTCCGTGGCCATGCACCATGAACACCAAGCGACGAGAGCCCTGAGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAACCATCAGAGAGCGCTATGGCCTCCTGCCATAATTGGTATTCTCTGTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGCTGGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTCTGTATGCACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTAAGGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATAGTTTTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATCATATGACAAAGAACTGCCCCTGGTGATGTGAGCAGGGACCTGCCTGCCCCTTTCAACCTTTCCCCTCACCTTTTTTGAGATTTTTGCTGCAATCTGTTTGCCTTCCCTGAATCAAAATAATCTTTCATTCGTCACCATTATACTAATGAACAATAGATTATCATGTTCAAAATTTCAGATTTTACATGTTAAGATGTACTAACAATATTCCTTGTATCAAACATCTCCTTTTCTCCCTGATACATAGCCCTGAGACATTTATAGCGTTCAGGAGTCTTCTATTGCTTCCATTCCTTCAGCAGGGCTGCGTGGGTCTGTTTTAACGTGGGCCAAGCCTACCTGGGCAGCCCATTTGCCAGGGCTTGCCTCAGGCCATGCAGCATTGGCGCTCTGGCTGCAGCAGCTGAGTTGCTCAAGGCCAGTGTCCAAGTGGACAGCAGCCTCTGGTACTCCCCCCAGTTATCTTCCACCCACATGGACTGGGCAGAGCAGCCCTCTTCTGTGTGCACTGCATACGTGCAGCCCGTGGGAGTTATTCTCCCCTAGAGATCGACTTGGCAGCACGAAGGATTCTTTTCTCTTTCATGCTTCTCAGGCTCAATAGTTTCTAATTAATCTTAAAATCCATGTCTTTTACATTGTTTTTTTAATTAAGTGCTGTTTACTAACCAATAATATTTATAACATGAGTAAGCTATAATTAATAACAATGAAATAAAAATACCATGTACCCACCACTGGACTTCAGAAGTAGAACTCATGACTGGGCTAGGATGAGGCAAGGGAGAACCCTGGCCTTGGGCACAAAATGTAAGGGATGCCAAAAAAATACAGTAATCAAAGTAAGTAATATTTCAATCCAATATGGATTAGTATTACTGAGTTTCCTTTTGTCCCAGGCTTTAAATATGGCTTGGCATGGGGCAGAACATTACAACATACCAGTCGTGTCATGGTGCCCAAGGCTCCACAGACCTCAGTGGCTCCCTGCTGCCTGCCACAGCATCTGTTTTAGCAGCCTCGACTCCTCAGCACTCCTCAGCACACACCTCTTCTTATCAGGCTTCCTCCACTTAGCAACTTGCTAACGGCCACCTCTGTGCCTTCTGATCCCTGGGCGCCAATATCCTCCTGCCCTTACCATCCTTCCAGGCCCAACTTAAATCCCATTTCCCATGAAGCCTAAGCTGAACACCCCTACCAGATCCCATACCATTAGCAGTGATTTTGCCTTCCCCGTAATGCTGTCCCACTTATAACTGTAAGCTCTACTTGCTGTGATTAGTTAGCTGGTGGATTTAATTGATTAAAAAAATTACGATTGAATGTAAAAAAAAANOV44d, CG55752-02Protein SequenceSEQ ID NO: 666914 aaMW at 104319.2kDMEAAVKEEISVEDEAVDKNIFRDCNKIAFYRRQKQWLSKKSTYQALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPDVLTSKPSTVRLISCDGDTGSLILADGKGDLKCHITANPFKVDLVSEEEVVISINSLGQLYFEHLQILHKQRAAKENEEETSVDTSQENQEDLGLWEEKFGKFVDIKANGPSSIGLDFSLHGFEHLYGIPQHAESHQLKNTGDGDAYRLYNLDVYGYQIYDKMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTLTQMGPVAAKQKVRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQAMPPLFSLGYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHEEGKRYFTWDKNRFPNPKRIVIQELLRSKKRKLWISDPHIKIDPDYSVVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFTNPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRILHNIYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYGAVWTGDNTAEWSNLKISIPMLLTLSITGISPCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEEHTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRPLWVEFPDELKTFDMEDEYMLGSALLVHPVTEPKATTVDVFLPGSNEVWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTKGSSVGELYLDDGHSFQYLHQKQFLHRKFSFCSSVLINSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSSDGKDQPVAFTYCAKTSILSLEKLSLNIATDWEVRIINOV44e, CG55752-03SEQ ID NO: 6673015 bpDNA SequenceORF Start: ATG at 204ORF Stop: TGA at 2946AACGCTAGTTTGGGCCTGAAAAATTCCAGGAGCAAGAGTCAAGATTTGTCACTCCATGAGAATCTGGAGGGACTCCCTTCCCAGAAACTTGACGATGAAGTACTGGTTGTAATTTTAGAAAGACACCCAATCAGGCTTTTTTAAAAGATCGCCCAGGGCCCTTGTCCTGAGAGCTGGGAGCTGGTCGGAGTGACAGAGAAGCCATGGAAGCAGCAGTGAAAGAGGAAATAAGTGTTGAAGATGAAGCTGTAGATAAAAACATTTTCAGAGACTGTAACAAGATCGCATTTTACAGGCGTCAGAAACAGTGGCTTTCCAAGAAGTCCACCTATCAGGCATTATTGGATTCAGTCACAACAGATGAAGACAGCACCAGGTTCCAAATCATCAATGAAGCAAGTAAGGTTCCTCTCCTGGCTGAAATTTATGGTATAGAAGGAAACATTTTCAGGCTTAAAATTAACGAAGAGACTCCTCTAAAACCCAGATTTGAAGTTCCGGATGTCCTCACAAGCAAGCCAAGCACTGTAAGGCTGATTTCATGCTCTGGGGACACAGGCAGTCTGATATTGGCAGATGGAAAAGGAGACCTGAAGTGCCATATCACAGCAAACCCATTCAAGGTAGACTTGGTGTCTGAAGAAGAGGTTGTGATTAGCATAAATTCCCTGGGAAAATTAGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACCAGCCCTTCTTCCGTGGCCATGCACCATGAACACCAAGCGACGAGAGCCCTGAGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAACCATCAGAGAGCGCTATGGCCTCCTGCCATAATTGGTATTCTCTGTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGCTGGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTCTGTATGCACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTAAGGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATAGTTTTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACCAGCCCTTCTTCCGTGGCCATGCACCATGAACACCAAGCGACGAGAGCCCTGAGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAACCATCAGAGAGCGCTATGGCCTCCTGCCATAATTGGTATTCTCTGTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGCTGGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTCTGTATGCACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTAAGGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATAGTTTTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGTTCTGATCAATAGTTTTGCTGACCAGAGGGGTCACTATCCAGCAAGTGTGGGTGGAGAAAGATCTATGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATCATATGACAAAGAACTGCCCCTGGTGATGTGAGAGGGACCATGCCTGCCCCTTTCAACCTTTCCCCTCACCTTTNOV44e, CG55752-03Protein SequenceSEQ ID NO: 668914 aaMW at 104206.0kDMEAAVKEEISVEDEAVDKNIFRDCNKIAFYRRQKQWLSKKSTYQALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPDVLTSKPSTVRLISCDGDTGSLILADGKGDLKCHITANPFKVDLVSEEEVVISINSLGQLYFEHLQILHKQRAAKENEEETSVDTSQENQEDLGLWEEKFGKFVDIKANGPSSIGLDFSLHGFEHLYGIPQHAESHQLKNTGDGDAYRLYNLDVYGYQIYDKMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTLTQMGPVAAKQKVRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQAMPPLFSLGYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHEEGKRYFTWDKNRFPNPKRIVIQELLRSKKRKLWISDPHIKIDPDYSVVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFTNPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRILHNIYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYGAVWTGDNTAEWSNLKISIPMLLTLSITGISPCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEEHTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRPLWVEFPDELKTFDMEDEYMLGSALLVHPVTEPKATTVDVFLPGSNEVWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTKGSSVGELYLDDGHSFQYLHQKQFLHRKFSFCSSVLINSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSSDGKDQPVAFTYCAKTSILSLEKLSLNIATDWEVRIINOV44f, CG55752-04SEQ ID NO: 6693102 bpDNA SequenceORF Start: ATG at 103ORF Stop: TGA at 2839TACTGGTTGTAATTTTAGAAAGACACCCAATCGGCTTTTTTAAAAGATCGCCCAGGGCCCTTGTCCTGAGAGCTGGGAGCTGGTCGGAGTGACAGAGAAGCCATGGAAGCAGCAGTGAAAGAGGAAATAAGTGTTGAAGATGAAGCTGTAGATAAAAACATTTTCAGAGACTGTAACAAGATCGCATTTTACAGGCGTCAGAAACAGTGGCTTTCCAAGAAGTCCACCTATCGGGCATTATTGGATTCAGTCACAACAGATGAAGACAGCACCAGGTTCCAAATCATCAATGAAGCAAGTAAGGTTCCTCTCCTGGCTGAAATTTATGGTATAGAAGGAAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTAAGGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATAGTTTTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACCAGCCCTTCTTCCGTGGCCATGCACCATGAACACCAAGCGACGAGAGCCCTGAGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAACCATCAGAGAGCGCTATGGCCTCCTGCCATAATTGGTATTCTCTGTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGCTGGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTCTGTATGCACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTAAGGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATAGTTTTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGTTCTGATCAATAGTTTTGCTGACCAGAGGGGTCACTATCCAGCAAGTGTGGGTGGAGAAAGATCTATGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTCTCTGGGGACACAGGCAGTCTGATATTGGCAGATGGAAAAGGAGACCTGAAGTGCCATATCACAGCAAACCCATTCAAGGTAGACTTGGTGTCTGAAGAAGAGGTTGTGATTAGCATAAATTCCCTGGGAAAATTAGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACCAGCCCTTCTTCCGTGGCCATGCACCATGAACACCAAGCGACGAGAGCCCTGAGCTCTTTTCTTCATGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAAATTTTTGCACAGGAAGTTTTCATTCTGTTCAGTGGCTGATCAATAGTTTTGCTGACCAGAGGAAGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATCATATGACAAAGAACTGCCCCTGGTGATGTGAGCAGGGACCTGCCTGCCCCTTTCAACCTTTCCCCTCACCTTTTTTGAGATTTTTGCTGCAATCTGTTTGTCTTCCCTGAATCAAAATAATCTTTCATTCGTCACCATTATACTAATGAACAATAGATTTCATGTTTCAAAATTTCAGATTTTACATGTTAAGATGTACTAACAATATTCCTTGTATCAAACATCTCCTTTTCTCCCTGATACATAGCCCTGAGACATTATAGCGTCdNOV44f, CG55752-04Protein SequenceSEQ ID NO: 670912 aaMW at 104189.1kDMEAAVKEEISVEDEAVDKNIFRDCNKIAFYRRQKQWLSKKSTYRALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPDVLTSKPSTVRLISCSGDTGSLILADGKGDLKCHITANPFKVDLVSEEEVVISINSLGQLYFEHLQILHKQRAAKENEEETSVDTSQENQEDLGLWEEKFGKFVDIKANGPSSIGLDFSLHGFEHLYGIPQHAESHQLKNTGDAYRLYNLDVYGYQIYDIGGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTLTQMGPVAAKQKVRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTAQANPPLFSLGHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQELLRSKKRKLVVISDPHIKIEPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFThPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHNIYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYGAVWTGDNTAEWSNLKISIPMLLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEEHTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRPLWVEFPDELKTFDMEDEYMLGSALLVHPVTEPKATTVDVFLPGSNEVWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTQGSSVGELYLDDGHSFQYLHQKQFLHRKFSFCSSVLINSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSSDGKDQPVAFTYCAKTSILSLEKLSLNIATDWEVRIINOV44g, CG55752-05SEQ ID NO: 6712951 bpDNA SequenceORF Start: ATG at 210ORF Stop: TGA at 2688TACTGGTTGTAATTTTAGAAAGACACCCAATCGGCTTTTTTAAAAGATCGCCCAGGGCCCTTGTCCTGAGAGCTGGGAGCTGGTCGGAGTGACAGAGAAGCCATGGAAGCAGCAGTGAAAGAGGAAATAAGTGTTGAAGATGAAGCTGTAGATAAAAACATTTTCAGAGACTGTAACAAGATCGCATTTTACAGGAAGAAAAGCGTATTATGTTAATTCTGAACAGGCGTCAGAAACAGTGGCTTTCCAAGAAGTCCACCTATCGGGCATTATTGGATTCAGTCACAACAGATGAAGACAGCACCAGGTTCCAAATCATCAATGAAGCAAGTAAGGTTCCTCTCCTGGCTGAAATTTATGGTATAGAAGGAAACATTTTCAGGCTTAAAATTAACGAAGAGACTCCTCTAAAACCCAGATTTGAAGTTCCGGATGTCCTCACAAGCAAGCCAAGCACTGTAAGAGCTGCTAAAGAAAATGAGGAGGAGACATCAGTGGACACCTCTCAGGAAAATCAAGAAGATCTGGGCCTGTGGGAAGAGAAATTTGGAAAATTTGTGGATATCACAGCTAATGGCCCTTCTTCTATTGGTTTGGATTTCTCCTTGCATGGATTTGAGCATCTTTATGGGATCCCACAACATGCAGAATCACACCAACTTAAAAATACTGGAGATGCTTACCGTCTTTATAACCTGGATGTCTATGGATACCAAATATATGATAAAATGGGCATTTATGGTTCAGTACCTTATCTCCTGGCCCACAAACTGGGCAGAACTATAGGTATTTTCTGGCTGAATGCCTCGGAAACACTGGTGGAGATCAATACAGAGCCTGCAGTAGAGTACACACTGACCCAGATGGGCCCAGTTGCTGCTAAACAAAAGGTCAGATCTCGCACTCATGTGCACTGGATGTCAGAGAGTGGCATCATTGATGTTTTTCTGCTGACAGGACCTACACCTTCTGATGTCTTCAAACAGTACTCACACCTTACAGGTACGCAAGCCATGCCCCCTCTTTTCTCTTTGGGATACCACCAGTGCCGCTGGAACTATGAAGATGAGCAGGATGTAAAAGCAGTGGATGCAGGGTTTGATGAGCATGACATTCCTTATGATGCCATGTGGCTGGACATAGAGCACACTGAGGGCAAGAGGTACTTCACCTGGGACAAAAACAGATTCCCAAACCCCAAGAGGATGCAAGAGCTGCTCAGGAGCAAAAAGCGTAAGCTTGTGGTCATCAGTGATCCCCACATCAAGATTGAACCTGACTACTCAGTATATGTGAAGGCCAAAGATCAGGGCTTCTTTGTGAAGAATCAGGAAGGGGAAGACTTTGAAGGGGTGTGTTGGCCAGGTCTCTCCTCTTACCTGGATTTCACCAATCCCAAGGTCAGAGAGTGGTATTCAAGTCTTTTTGCTTTCCCTGTTTATCAGGGATCTACGGACATCCTCTTCCTTTGGAATGACATGAATGAGCCTTCTGTCTTTAGAGGGCCAGAGCAAACCATGCAGAAGAATGCCATTCATCATGGCAATTGGGAGCACAGAGAGCTCCACAACATCTACGGTTTTTATCATCAAATGGCTACTGCAGAAGGACTGATAAAACGATCTAAAGGGAAGGAGAGACCCTTTGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACCAGCCCTTCTTCCGTGGCCATGCCACCATGAACACCAAGCGACGAGAGCCCTGGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAAGCCATCAGAGAGCGCTATGGCCTCCTGCCATATTGGTATTCTCTGTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGTTAGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTATGGTATGACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTCAGGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATAGTTTTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATCATATGACAAAGAACTGCCCCTGGTGATGTGAGCAGGGACCTGCCTGCCCCTTTCAACGTTTCCCCTCACCTTTTTTGAGATTTTTGCTGCAATCTGTTTGTCTTCCCTGAATCAAAATAATCTTTCATTCGTCACCATTATACTAATGAACAATAGATTTCATGTTTCAAAATTTCAGATTTTACATGTTAAGATGTACTAACAATATTCCTTGTATCAAACATCTCCTTTTCTCCCTGATACATAGCCCTGAGACATTATAGCGTCNOV44g, CG55752-05Protein SequenceSEQ ID NO: 672826 aaMW at 94610.4kDMLILNRRQKQWLSKKSTYRALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPDVLTSKPSTVRAAKENEEETSVDTSQENQEDLGLWEEKFGKFVDITANGPSSIGLDFSLHGFEHLYGIPQHESHQLKNTGDAYRLYNLDVYGYQIYDKMGAIYGSVPYLLANKLGRTIGIFWLNASETLVEINTEPAVEYTLTQMGPVAAKQKVRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQANPPLFSLGYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQELLRSKKRKLVVISDPHIKIEPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFTNPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHNIYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYGAVWTGDNTAEWSNLKISIPMLLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEEHTRILREAIRERYGLLPYWYSLFYHAHVASQPVMRPLWVEFPDELKTFDMEDEYMLGSALLVHPVTEPKATTVDVFLPGSNEVWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTQGSSVGELYLDDGHSFQYLHQKQFLHRKFSFCSSVLINSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSSDGKDQPVAFTYCAKTSILSLEKLSLNIATDWEVRIINOV44h,SNP13379656 ofSEQ ID NO: 6732001 bpCG55752-06,ORF Start: ATG at 1ORF Stop: TGA at 1972DNA SequenceSNP Pos: 617SNP Change: A to GATGGGCATTTATGGTTCAGTACCTTATCTCCTGGCCCACAAACTGGGCAGAACTATAGGTATTTTCTGGCTGAATGCCTCGGAAACACTGGTGGAGATCAATACAGAGCCTGCAGTAGAGTACACACTGACCCAGATGGGCCCAGTTGCTGCTAAACAAAAGGTCAGATCTCGCACTCATGTGCACTGGATGTCAGAGAGTGGCATCATTGATGTTTTTCTGCTGACAGGACCTACACCTTCTGATGTCTTCAAACAGTACTCACACCTTACAGGTATTCAAGCCATGCCCCCTCTTTTCTCTTTGGGATACCACCAGTGCCGCTGGAACTATGAAGATGAGCAGGATGTAAAAGCAGTGGATGCAGGGTTTGATGAGCATGACATTCCTTATGATGCCATGTGGCTGGACATAGAGCACACTGAGGGCAAGAGGTACTTCACCTGGGACAAAAACAGATTCCCAAACCCCAAGAGGATGCAAGAGCTGCTCAGGAGCAAAAAGCGTAAGGTACTTGTGGTCATCAGTGATCCCCACATCAAGATTGATCCTGACTACTCAGTATATGTGAAGGCCAAAGATCAGGGCTTCTTTGTGAAGAATCAGGAAGGGGAAGGCTTTGAAGGGGTGTGTTGGCCAGGTCTCTCCTCTTACCTGGATTTCACCAATCCCAAGGTCAGAGAGTGGTATTCAAGTCTTTTTGCTTTCCCTGTTTATCAGGGATCTACGGACATCCTCTTCCTTTGGAATGACATGAATGAGCCTTCTGTCTTTAGAGGGCCAGAGCAAACCATGCAGAAGAATGCCATTCATCATGGCAATTGGGAGCACAGAGAGCTCCACAACATCTACGGTTTTTATCATCAAATGGCTACTGCAGAAGGACTGATAAAACGATCTAAAGGGAAGGAGAGACCCTTTGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACcAGCCCTTCTTCCGTGGCCATGCCACCATGAACACCAAGCGACGAGAGCCCTGGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAAGCCATCAGAGAGCGCTATGGCCTCCTGCCATATTGGTATTCTCTGTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGCTGGGTTTAGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTATGGTATGACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATTCCAGTITTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATCATATGACAAAGAACTGCCCCTGGTGATGTGAGCNOV44h,SNP13379656 ofCG55752-06,SEQ ID NO: 674MW at 75108.9kDProtein SequenceSNP Pos: 206657 aaSNP Change: Asp to GlyMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTLTQMGPVAAKQKVRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGIQAMPPLFSLGYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQELLRSKKRKVLVVISDPHIKIDPDYSVYVKAKDQGFFVKNQEGEGFEGVCWPGLSSYLDFTNPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHNIYGFYHQMATAEGLIKRSKGKAAERPAFVLTRSQFFAGSQKGTGDNTAEWSNLKISIPMLLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEEHTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRRPLWVEFPDELKTFDMEDEYMLGLGSALLVHPVTEPKATTVDVFLPGSNEVWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTGSSVGELYLDDGHSFQYLHQKQFLHRKFSFCSSVLINSSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSSDGKDQPVAFTYCAKTSILSLEKLSLNIATDWEVRIINOV44i,SNP13379655 ofSEQ ID NO: 6752001 bpCG55752-06,ORF Start: ATG at 1ORF Stop: TGA at 1972DNA SequenceSNP Pos: 1763SNP Change: T to CATGGGCATTTATGGTTCAGTACCTTATCTCCTGGCCCACAAACTGGGCAGAACTATAGGTATTTTCTGGCTGAATGCCTCGGAAACACTGGTGGAGATCAATACAGAGCCTGCAGTAGAGTACACACTGACCCAGATGGGCCCAGTTGCTGCTAAACAAAAGGTCAGATCTCGCACTCATGTGCACTGGATGTCAGAGAGTGGCATCATTGATGTTTTTCTGCTGACAGGACCTACACCTTCTGATGTCTTCAAACAGTACTCACACCTTACAGGATTCAAGCCATGCCCCTCTTTTCTCTTTTGGGATACCACCAGTGCCGCTGGAACTATGAAAGATGAGCAGGATGTAAAAGCAGTGGATGCAGGGTTTGATGAGCATGACATTCCTTATGATGCCATGTAACTGGACATAGAGCACACTGAGGGCAAGAGGTACTTCACCTGGGACAAAAACAGATTCCCAAACCCCAAGAGGATGCAAGAGCTGCTCAGGAGCAAAAAGCGTAAGGTACTTGTGGTCATCAGTGATCCCCACATCAAGATTGATCCTGACTACTCAGTATATGTGAAGGCCAAAGATCAGGGCTTCTTTGTGAAGAATCAGGAAGGGGAAGACTTTGAAGGGGTGTGTTGGCCAGGTCTCTCCTCTTACCTGGATTTCACCAATCCCAAGGTCAGATGACATGAATGAGCCTTCTGTCTTTAGAGGGCCAGAGCAAACCATGCAGAAGAATGCCATTCATCATGGCAATTGGGAGCACAGAGAGCTCCACAACATCTACGGTTTTTATCATCAAATGGCTACTGCAGAAGGACTGATAAAACGATCTAAAGGGAAGGAGAGACCCTTTGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACcAGCCCTTCTTCCGTGGCCATGCCACCATGAACACCAAGCGACGAGAGCCCTGGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAAGCCATCAGAGAGCGCTATGGCCTCCTGCCATATTGGTATTCTCTGTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGCTGGGTTTAGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTATGGTATGACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATTCCAGTTTTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGTCTGGAG44j CCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAACCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATCATATGACAAAGAACTGCCCCTGGTGATGTGAGCNOV44i,SNP13379655 ofCG55752-06,SEQ ID NO: 676MW at 75106.8kDProtein SequenceSNP Pos: 588657 aaSNP Change: Phe to SerMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTLTQMGPVAAKQKVRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGIQAMPPLFSLGYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQELLRSKKRKVLVVISDPHIKIDPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFTNPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHNIYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYGAVWTGDNTAEWSNLKISIPMLLTLSITGISFCGAIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEAEHTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRRPLWVEFPDELKTFDMEDEYMLGLGSALLVHPVTEPKATTVDVFLPGSNEVWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTGSSVGELYLDDGHSFQYLHQKQFLHRKFSFCSSVLINSSSADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSSDGKDQPVAFTYCAKTSILSLEKLSLNIATDWEVRIINOV44j,SNP13379654 ofSEQ ID NO: 6772001 bpCG55752-06,ORF Start: ATG at 1ORF Stop: TGA at 1972DNA SequenceSNP Pos: 1772SNP Change: A to GATGGGCATTTATGGTTCAGTACCTTATCTCCTGGCCCACAAACTGGGCAGAACTATAGGTATTTTCTGGCTGAATGCCTCGGAAACACTGGTGGAGATCAATACAGAGCCTGCATAGAGTACACACTAGACCCAGAATGACATGAATGAGCCTTCTGTCTTTAGAGGGCCAGAGCAAACCATGCAGAAGAATGCCATTCATCATGGCAATTGGGAGCACAGAGAGCTCCACAACATCTACGGTTTTTATCATCAAATGGCTACTGCAGAAGGACTGATAAAACGATCTAAAGGGAAGGAGAGACCCTTTGTTCTTACACGTTCTTTCTTTGCTGGATCACAAAAGTATGGTGCCGTGTGGACAGGCGACAACACAGCAGAATGGAGCAACTTGAAAATTTCTATCCCAATGTTACTCACTCTCAGCATTACTGGGATCTCTTTTTGCGGAGCTGACATAGGCGGGTTCATTGGGAATCCAGAGACAGAGCTGCTAGTGCGTTGGTACCAGGCTGGAGCCTACcAGCCCTTCTTCCGTGGCCATGCCACCATGAACACCAAGCGACGAGAGCCCTGGCTCTTTGGGGAGGAACACACCCGACTCATCCGAGAAGCCATCAGAGAGCGCTATGGCCTCCTGCCATATTGGTATTCTCTGTTCTACCATGCACACGTGGCTTCCCAACCTGTCATGAGGAGGCCTCTGTGGGTAGAGTTCCCTGATGAACTAAAGACTTTTGATATGGAAGATGAATACATGCTGGGTTTAGGGAGTGCATTATTGGTTCATCCAGTCACAGAACCAAAAGCCACCACAGTTGATGTGTTTCTTCCAGGATCAAATGAGGTATGGTATGACTATAAGACATTTGCTCATTGGGAAGGAGGGTGTACTGTAAAGATCCCAGTAGCCTTGGACACTATTCCAGTGTTTCAGCGAGGTGGAAGTGTGATACCAATAAAGACAACTGTAGGAAAATCCACAGGCTGGATGACTGAATCCTCCTATGGACTCCGGGTTGCTCTAAGCACTGGTTCTTCAGTGGGTGAGTTATATCTTGATGATGGCCATTCATTCCAATACCTCCACCAGAAGCAATTTTTGCACAGGAAGTTTTCATTCTGTTCCAGTGTTCTGATCAATTCCAGTTTTGCTGACCAGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAATGGGCCCAGTTGCTGCTAAACAAAAGGTCAGATCTCGCACTCATGTGCACTGGATGTCAGAGAGTGGCATCATTGATGTTTTTCTGCTGACAGGACCTACACCTTCTGATGTCTTCAAACAGTACTCACACCTTACAGGTATTCAAGCCATGCCCCCTCTTTTCTCTTTGGGATACCACCAGTGCCGCTGGAACTATGAAGATGAGCAGGATGTAAAAGCAGTGGATGCAGGGTTTGATGAGCATGACATTCCTTATGATGCCATGTGGCTGGACATAGAGCACACTGAGGGCAAGAGGTACTTCACCTGGGACAAAAACAGATTCCCAAACCCCAAGAGGATGCAAGAGCTGCTCAGGAGCAAAAAGCGTAAGGTACTTGTGGTCATCAGTGATCCCCACATCAAGAACCGGAGGGGTCATTATCCCAGCAAGTGTGTGGTGGAGAAGATCTTGGTCTTAGGCTTCAGGAAGGAGCCATCTTCTGTGACTACCCACTCATCTGATGGTAAAGATCAGCCTGTGGCTTTTACGTATTGTGCCAAAACATCCATCCTGAGCCTGGAGAAGCTCTCACTCAACATTGCCACTGACTGGGAGGTCCGCATCATATGACAAAGAACTGCCCCTGGTGATGTGAGCNOV44j,SNP13379654 ofCG55752-06,SEQ ID NO: 678MW at 75194.9kDProtein SequenceSNP Pos: 591657 aaSNP Change: Gln to ArgMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTLTQMGPVAAKQKVRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGIQAMPPLFSLGYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQELLRSKKRKVLVVISDPHIKIDPDYSVYVKAKDQGFFVKNQEGEGFEGVCWPGLSSYLDFTNPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHNIYGFYHQMATAEGLIKRSKGKAAERPAFVLTRSQFFAGSQKGTGDNTAEWSNLKISIPMLLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEEHTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRRPLWVEFPDELKTFDMEDEYMLGLGSALLVHPVTEPKATTVDVFLPGSNEVWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGSVIPIKTTVGKSTGWMTESSYGLRVALSTGSSVGELYLDDGHSFQYLHQKQFLHRKFSFCSSVLINSSFADRRGHYPSKCVVEKILVLGFRKEPSSVTTHSSDGKDQPVAFTYCAKTSILSLEKLSLNIATDWEVRII

TABLE 44B

Comparison of the NOV44 protein sequences.

NOV44a
------------------------------------------------------------

NOV44b
------------------------------------------------------------

NOV44c
MRAAVAGIAFRRRRQKQWLSKKSTYQALLDSVTTDEDSTRFQIINEASKVRRQKQWLSKK

NOV44d
MEAAVKEEIS------------------VEDEAVDKN--IFRDCNKIAFYRRQKQWLSKK

NOV44e
MEAAVKEEIS------------------VEDEAVDKN--IFRDCNKIAFYRRQKQWLSKK

NOV44f
MEAAVKEEIS------------------VEDEAVDKN--IFRDCNKIAFYRRQKQWLSKK

NOV44g
---------------------------------------------MLILNRRQKQWLSKK

NOV44a
------------------------------------------------------------

NOV44b
------------------------------------------------------------

NOV44c
STYQALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPD

NOV44d
STYQALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPD

NOV44e
STYQALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPD

NOV44f
STYRALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPD

NOV44g
STYRALLDSVTTDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLKINEETPLKPRFEVPD

NOV44a
------------------------------------------------------------

NOV44b
------------------------------------------------------------

NOV44c
VLTSKPSTVR-ISCSGDTGSLILADGKGDLKCHITANPFKVDLVSEEEVVISINSLGQLY

NOV44d
VLTSKPSTVRLISCSGDTGSLILADGKGDLKCHITANPFKVDLVSEEEVVISINSLGQLY

NOV44e
VLTSKPSTVRLISCSGDTGSLILADGKGDLKCHITANPFKVDLVSEEEVVISINSLGQLY

NOV44f
VLTSKPSTVRLISCSGDTGSLILADGKGDLKCHITANPFKVDLVSEEEVVISINSLGQLY

NOV44g
VLTSKP------------------------------------------------------

NOV44a
------------------------------------------------------------

NOV44b
------------------------------------------------------------

NOV44c
FEHGRAPRVSFSDKVNLTLGSIWDKIKNLFSRQGSKDPAEGDGAQPEETPRDGDKPEETQ

NOV44d
FEH----------------------LQILHKQRAAKENEE-------ETSVDTS--QENQ

NOV44e
FEH----------------------LQILHKQRAAKENEE-------ETSVDTS--QENQ

NOV44f
FEH----------------------LQILHKQRAAKENEE-------ETSVDTS--QENQ

NOV44g
---------------------------S--TVRAAKENEE-------ETSVDTS--QENQ

NOV44a
------------------------------------------------------------

NOV44b
------------------------------------------------------------

NOV44c
GKAEKDEPGAWEETFKTHSDSKPYGPSSIGLDFSLHGFEHLYGIPQHAESHQLKNTGDGD

NOV44d
-----EDLGLWEEKFGKFVDIKANGPSSIGLDFSLHGFEHLYGIPQHAESHQLKNTGDGD

NOV44e
-----EDLGLWEEKFGKFVDIKANGPSSIGLDFSLHGFEHLYGIPQHAESHQLKNTGDGD

NOV44f
-----EDLGLWEEKFGKFVDIKANGPSSIGLDFSLHGFEHLYGIPQHAESHQLKNTG--D

NOV44g
-----EDLGLWEEKFGKFVDITANGPSSIGLDFSLHGFEHLYGIPQHAESHQLKNTG--D

NOV44a
-----------------MGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTL

NOV44b
-----------------MGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTL

NOV44c
AYRLYNLDVYGYQIYDKMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAGIVIF

NOV44d
AYRLYNLDVYGYQIYDKMGIYGSVPYLLAHKIGRTIGIFWLNASETLVEINTEPAVEYTL

NOV44e
AYRLYNLDVYGYQIYDKMGIYGSVPYLLAHKIGRTIGIFWLNASETLVEINTEPAVEYTL

NOV44f
AYRLYNLDVYGYQIYDKMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTL

NOV44g
AYRLYNLDVYGYQIYDKMGIYGSVPYLLAHKLGRTIGIFWLNASETLVEINTEPAVEYTL

NOV44a
TQMGPVAAKQK-VRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQAMPPLFSL

NOV44b
TQMGPVAAKQK-VRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGIQAMPPLFSL

NOV44c
GPVSLIYQSQGDTPLTTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQANPPLFSL

NOV44d
TQMGPVAAKQK-VRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQANPPLFSL

NOV44e
TQMGPVAAKQK-VGSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQANPPLFSL

NOV44f
TQMGPVAAKQK-VRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQANPPLFSL

NOV44g
TQMGPVAAKQK-VRSRTHVHWMSESGIIDVFLLTGPTPSDVFKQYSHLTGTQANPPLFSL

NOV44a
GYHQCRNNYEDEQDVKAVDAGFDEHDIPYDANWLDIEHTEGKRYFTWDKNRFPNPKRMQE

NOV44b
GYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQE

NOV44c
GYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAIWLDIEHTEGKRYFTWDKNRFPNPKRMQE

NOV44d
GYHQCRWNYEDEODVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQE

NOV44e
GYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQE

NOV44f
GYHQCRWNYEDEQDVKAVDAGFDEHDIPYDANWLDIEHTEGKRYFTWDKNRFPNPKRMOE

NOV44g
GYHQCRWNYEDEQDVKAVDAGFDEHDIPYDAMWLDIEHTEGKRYFTWDKNRFPNPKRMQE

NOV44a
LLRSKKR-KLVVISDPHIKIDPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFT

NOV44b
LLRSKKRKVLVVISDPHIKIDPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFT

NOV44c
LLRSKKR-KLVVISDPHIKIEPDYSVYVKAKDOGFFVKNQEGEDFEGVCWPGMKSYLDFT

NOV44d
LLRSKKR-KLVVISDPHIKIDPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFT

NOV44e
LLRSKKR-KLVVISDPHIKIDPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFT

NOV44f
LLRSKKR-KLVVISDPHIKIEPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSYLDFT

NOV44g
LLRSKKR-KLVVISDPHIKIEPDYSVYVKAKDQGFFVKNQEGEDFEGVCWPGLSSThDFT

NOV44a
NPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHN

NOV44b
NPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHN

NOV44c
NPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHN

NOV44d
NPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHN

NOV44e
NPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHN

NOV44f
NPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHN

NOV44g
NPKVREWYSSLFAFPVYQGSTDILFLWNDMNEPSVFRGPEQTMQKNAIHHGNWEHRELHN

NOV44a
IYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYGGAVWTGDNTAEWSNLKISIPM

NOV44b
IYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYG-AVWTGDNTAEWSNLKISIPM

NOV44c
IYGFY--MATAEGLIKRSKGKERPFVLTRSFFAGSQKYG-AVWTGDNTAEWSNLKISIPM

NOV44d
IYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYG-AVWTGDNTAEWSNLKISIPM

NOV44e
IYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYG-AVWTGDNTAEWSNLKISIPM

NOV44f
IYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYG-AVWTGDNTAEWSNLKISIPM

NOV44g
IYGFYHQMATAEGLIKRSKGKERPFVLTRSFFAGSQKYG-AVWTGDNTAEWSNLKISIPM

NOV44a
LLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEE

NOV44b
LLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEE

NOV44c
LLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEE

NOV44d
LLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEE

NOV44e
LLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEE

NOV44f
LLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEE

NOV44g
LLTLSITGISFCGADIGGFIGNPETELLVRWYQAGAYQPFFRGHATMNTKRREPWLFGEE

NOV44a
HTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMR-PLWVEFPDELKTFDMEDEYMLG--

NOV44b
HTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMRRPLWVEFPDELKTFDMEDEYMLGLG

NOV44c
HTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMR-PLWVEFPDELKTFDMEDEYMLG--

NOV44d
HTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMR-PLWVEFPDELKTFDMEDEYMLG--

NOV44e
HTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMR-PLWVEFPDELKTFDMEDEYMLG--

NOV44f
HTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMR-PLWVEFPDELKTFDMEDEYMLG--

NOV44g
HTRLIREAIRERYGLLPYWYSLFYHAHVASQPVMR-PLWVEFPDELKTFDMEDEYMLG--

NOV44a
SALLVHPVTEPKATTVDVFLPGSNE-VWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGS

NOV44b
SALLVHPVTEPKATTVDVFLPGSNE-VWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGS

NOV44c
SALLVHPVTEPKATTVDVFLPGSNEVVWYDYKTFAHWEGGCTVKIPVLLQ-IPVFQRGGS

NOV44d
SALLVHPVTEPKATTVDVFLPGSNE-VWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGS

NOV44e
SALLVHPVTEPKATTVDVFLPGSNE-VWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGS

NOV44f
SALLVHPVTEPKATTVDVFLPGSNE-VWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGS

NOV44g
SALLVHPVTEPKATTVDVFLPGSNE-VWYDYKTFAHWEGGCTVKIPVALDTIPVFQRGGS

NOV44a
VIPIKTTVGKSTGWMTESSYGLRVALSTK-GSSVGELYLDDGHSFQYLHQKQFLHRKFSF

NOV44b
VIPIKTTVGKSTGWMTESSYGLRVALST--GSSVGELYLDDGHSFQYLHQKQFLHRKFSF

NOV44c
VIPIKTTVGKSTGWMTESSYGLRVALSTKQGSSVGELYLDDGHSFQYLHQKQFLHRKFSF

NOV44d
VIPIKTTVGKSTGWMTESSYGLRVALSTK-GSSVGELYLDDGHSFQYLHQKQFLHRKFSF

NOV44e
VIPIKTTVGKSTGWMTESSYGLRVALSTK-GSSVGELYLDDGHSFQYLHQKQFLHRKFSF

NOV44f
VIPIKTTVGKSTGWMTESSYGLRVALSTQ-GSSVGELYLDDGHSFQYLHQKQFLHRKFSF

NOV44g
VIPIKTTVGKSTGWMTESSYGLRVALSTQ-GSSVGELYLDDGHSFQYLHQKQFLHRKFSF

NOV44a
CSSVLINSSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSSGDGKDQPVAFTYCAKTS

NOV44b
CSSVLINSSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSS-DGKDQPVAFTYCAKTS

NOV44c
CSSVLI-SSPVSQGHLHTPLSMTKALLLFTVSS-PASVTTHSS-DGKDQPVAFTYCAKTS

NOV44d
CSSVLI-SSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSS-DGKDQPVAFTYCAKTS

NOV44e
CSSVLI-SSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSS-DGKDQPVAFTYCAKTS

NOV44f
CSSVLI-SSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSS-DGKDQPVAFTYCAKTS

NOV44g
CSSVLI-SSFADQRGHYPSKCVVEKILVLGFRKEPSSVTTHSS-DGKDQPVAFTYCAKTS

NOV44a
ILSLEKLSLNIATDWEVRII

NOV44b
ILSLEKLSLNIATDWEVRII

NOV44c
ILSLEKLSLNIATDWEVRII

NOV44d
ILSLEKLSLNIATDWEVRII

NOV44e
ILSLEKLSLNIATDWEVRII

NOV44f
ILSLEKLSLNIATDWEVRII

NOV44g
ILSLEKLSLNIATDWEVRII

NOV44a
(SEQ ID NO: 660)

NOV44b
(SEQ ID NO: 662)

NOV44c
(SEQ ID NO: 664)

NOV44d
(SEQ ID NO: 666)

NOV44e
(SEQ ID NO: 668)

NOV44f
(SEQ ID NO: 670)

NOV44g
(SEQ ID NO: 672)

Further analysis of the NOV44a protein yielded the following properties shown in Table 44C.

TABLE 44CProtein Sequence Properties NOV44aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 0;pos.chg 0;neg.chg 0H-region:length 13; peak value 5.66PSG score: 1.26GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −7.02possible cleavage site: between 51 and 52>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 1Number of TMS(s) for threshold 0.5: 1INTEGRALLikelihood = −2.07Transmembrane 337-353PERIPHERALLikelihood = 3.82 (at 496)ALOM score: −2.07 (number of TMSs: 1)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 344Charge difference: −2.0 C(−3.0) − N(−1.0)N >= C: N-terminal side will be inside>>> membrane topology: type 2 (cytoplasmic tail 1 to 337)MITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment (75):2.91Hyd Moment(95):0.96G content:4D/E content:1S/T content:3Score: −6.13Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 27 GRT|IGNUCDISC: discrimination of nuclear localization signalspat4: KKRK (5) at 167pat7: nonebipartite: nonecontent of basic residues: 10.4%NLS Score: −0.16KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: MGIYGSVPrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: foundLL at 10LL at 74LL at 163checking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):30.4%: cytoplasmic30.4%: mitochondrial17.4%: Golgi 8.7%: endoplasmic reticulum 4.3%: extracellular, including cell wall 4.3%: nuclear 4.3%: vesicles of secretory system>> prediction for CG55752-07 is cyt (k = 23)

A search of the NOV44a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 44D.

TABLE 44DGeneseq Results for NOV44aNOV44aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABG69611Human NOV11b protein - Homo 1 . . . 656653/656 (99%)0.0sapiens, 914 aa. [WO200250277-262 . . . 914653/656 (99%)A2, 27-JUN-2002]ABG69613Human NOV11d protein - Homo 1 . . . 656651/656 (99%)0.0sapiens, 912 aa. [WO200250277-260 . . . 912653/656 (99%)A2, 27-JUN-2002]ABG69612Human NOV11c protein - Homo 1 . . . 656651/656 (99%)0.0sapiens, 914 aa. [WO200250277-262 . . . 914652/656 (99%)A2, 27-JUN-2002]AAG79779Carbohydrate-associated protein 1 . . . 652648/652 (99%)0.0(CHOP)-1 - Homo sapiens, 912262 . . . 910648/652 (99%)aa. [WO200297060-A2, 05-DEC-2002]ABP52437Human carbohydrate metabolism 1 . . . 656634/656 (96%)0.0enzyme CME-2 protein SEQ ID262 . . . 914636/656 (96%)NO: 2 - Homo sapiens, 914 aa.[WO200261059-A2, 08-AUG-2002]

In a BLAST search of public sequence databases, the NOV44a protein was found to have homology to the proteins shown in the BLASTP data in Table 44E.

TABLE 44EPublic BLASTP Results for NOV44aNOV44aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8IWZ0Glucosidase - Homo sapiens 1 . . . 656653/656 (99%)0.0(Human), 769 aa (fragment).117 . . . 769653/656 (99%)Q8TET4FLJ00088 protein - Homo 1 . . . 656653/656 (99%)0.0sapiens (Human), 925 aa273 . . . 925653/656 (99%)(fragment).Q8IZM5Neutral alpha glucosidase C 1 . . . 656653/656 (99%)0.0type 2 - Homo sapiens262 . . . 914653/656 (99%)(Human), 914 aa.AAN74755Neutral alpha glucosidase C - 1 . . . 656652/656 (99%)0.0synthetic construct, 914 aa.262 . . . 914653/656 (99%)Q8IZM4Neutral alpha-glucosidase C 1 . . . 656652/656 (99%)0.0type 3 - Homo sapiens (Human),262 . . . 914653/656 (99%)914 aa.

PFam analysis indicates that the NOV44a protein contains the domains shown in the Table 44F.

TABLE 44FDomain Analysis of NOV44aNOV44aIdentities/SimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValueGlyco_hydro_311 . . . 616259/856 (30%)3.4e−235517/856 (60%)

Example 45

The NOV45 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 45A.

TABLE 45ANOV45 Sequence AnalysisNOV45a, CG55778-03SEQ ID NO: 6791752 bpDNA SequenceORF Start: ATG at 23ORF Stop: TAA at 653GGCGGGGCGGCCGGCGGCGGCCATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGCAGGCTTCTCCAGGTAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCTGTGGTGCACCTGCCATAAGAAGTCCTTGGTGGAAACAGCATGCAGAAAGAGTCTCAAGGCCTTGAAGCTGAACTATTTGGACCTCTACCTCATACACTGGCCCATGGGTTTCAAGCCTCCTCATCCAGAATGGATCATGAGCTGCAGTGAACTTTCCTTCTGCCTCTCACATCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACATGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCTCAGCCTAAACAAGAATCTCCGACTGGCCATGTTCCCCATGTAAATATGGCTCCTTCTTTTTAAAACAGAGGGAAGAATATACAGATTGAATGATTGGTGTCTGAATAGAACTAAAAATCACAAAGACTATCCTTTCCACANOV45a, GG55778-03Protein SequenceSEQ ID NO: 680210 aaMW at 24136.7kDMGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPPHPEWIMSCSELSFCLSHPRVQDLPLDESNNVIPSDTDFLDTWEILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNKNLRLAMFPMNOV45b, CG55778-06SEQ ID NO: 681569 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 550ATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGGCTTCTCCAGGAAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCCTCCTCATCCAGAATGGATCATGAGCTGCAGTGAACTTTCCTTCTGCCTCTCACATCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACATGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCACAGCCTAAACAGGAATCTCCGACTGGCCATGTTCCCCATAACTAAAAATCACAAAGACTATCCTTTCCACATAGAATACTGAGGACGCTTCCCCTTCCTNOV45b, CG55778-06Protein SequenceSEQ ID NO: 682183 aaMW at 21057.81kDMGDIPAVGLSSWKASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKPPHPEWIMSCSELSFCLSHPRVQDLPLDESNMVIPSDTDFLDTWEILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNRNLRLAMFPITKNHKDYPFHIEYNOV45c, 275480984SEQ ID NO: 683655 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCAGATCTCCCACCATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGCAGGCTTCTCCAGGGAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCTGTGGTGCACCTGCCATAAGAAGTCCTTGGTGGAAACAGCATGCAGAAAGAGTCTCAAGGCCTTGAAGCTGAACTATTTGGACCTCTACCTCATACACTGGCCCATGGGTTTCAAGCCTCCTCATCCAGAATGGATCATGAGCTGCAGTGAACTTTCCTTCTGCCTCTCACATCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACGTGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCTCAGCCTAAACAGGAACCTCCGACTGGCCATGTTCCCCATGGTCGACGGCNOV45c, 275480984Protein SequenceSEQ ID NO: 684218 aaMW at 24946.5kDTRSPTMGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPPHPEWIMSCSELSFCLSHPRVQDLPLDESNVVIPSDTDFLDTWEILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNRNLRLAMFPMVDGNOV45d, CG55778-01SEQ ID NO: 6851956 bpDNA SequenceORF Start: ATG at 31ORF Stop: TGA at 937GGCGGGGCGGCGGGGCGGCCGGCGGCGGCCATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGCAGGCTTCTCCAGGGAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCTGTGGTGCACCTGCCATAAGAAGTCCTTGGTGGAAACAGCATGCAGAAAGAGTCTCAAGGCCTTGAAGCTGAACTATTTGGACCTCTACCTCATACACTGGCCCATGGGTTTCAAGCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACATGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGGCCATGGAGGACCTGGTGATCACCGGGCTGGTGAAGAACATCGGGGTGTCAAACTTCAACCATGAACAGCTTGAGAGGCTTTTGAATAAGCCTGGGTTGAGGTTCAAGCCACTAACCAACCAGATTGAGTGCCACCCATATCTTACTCAGAAGAATCTGATCAGTTTTTGCCAATCCAGAGATGTGTCCGTGACTGCTTACCGTCCTCTTGGTGGCTCTAGTGAGGGGGTTGACCTGATAGACAACCCTGTGATCAAGAGGATTGCAAAGGAGCACGGCAAGTCTCCTGCTCAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCTCAGCCTAAACAGGAATCTCCGACTGGCCATGTTCCCCAGAACTAAAAATCACAAAGACTATCCTTTCCACATAGAATACTGAGGACGCTTCCCCTTCCTNOV45d, CG55778-01Protein SequenceSEQ ID NO: 686302 aaMW at 34561.5kDMGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPRVQDLPLDESNMVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHEQLERLLNKPGLRFKPLTNQIECHPYLTQKNLISFCQSRDVSVTAYRPLGGSSEGVDLIDNPVIKRIAKEHGKSPAQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNRNLRLANFPRTKNHKDYPFHIEYNOV45e, CG55778-02SEQ ID NO: 687875 bpDNA SequenceORF Start: ATG at 23ORF Stop: TAA at 776GGCGGGGCGGCCGGCGGCGGCCATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGCAGGCTTCTCCAGGAAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCTGTGGTGCACCTGCCATAAGAAGTCCTTGGTGGAAACAGCATGCAGAAAGGGTCTCAAGGCCTTGAAGCTGAACTATTTGGACCTCTACCTCATACACTGGCCCATGGGTTTCAAGCCTCCTCATCCAGAATGGATCATGAGCTGCAGTGAACTTTCCTTCTGCCTCTCACATCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACATGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGGCCATGGAGGACCTGGTGATCACCGGGCTGGTGAAGAACATCGGGGTGTCAAACTTCAACCATGAACAGCTTGAGAGGCTTTTGAATAAGCCTGGGTTGAGGTTCAAGCCACTAACCAACCAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCTCAGCCTAAACAGGAATCTCCGACTGGCCATGTTCCCCATGTAAATATGGCTCCTTCTTTTTAAAACAGAGGGAAGAATATACAGATTGAATGATTGGTGTCTGAATAGAACTAAAAATCACAAAGACTATCCTTTCCACANOV45e, GG55778-02Protein SequenceSEQ ID NO: 688251 aaMW at 28765.1kDMGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKLWCTCHKKSLVETACRKGLKALKLNYLDLYLIHWPMGFKPPHPEWIMSCSELSFCLSHPRVQDLPLDESNMVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHEQLERLLNKPGLRFKPLThQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNRNLRLAMFPMNOV45f, GG55778-04SEQ ID NO: 689785 bpDNA SequenceORF Start: ATG at 31ORF Stop: TGA at 766GGCGGGGCGGCGGGGCGGCCGGCGGCGGCCATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGCAGGCTTCTCCAGGGAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCTGTGGTGCACCTGCCATAAGAAGTCCTTGGTGGAAACAGCATGCAGAAAGAGTCTCAAGGCCTTGAAGCTGAACTATTTGGACCTCTACCTCATACACTGGCCCATGGGTTTCAAGCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACATGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGGCCATGGAGGACCTGGTGATCACCGGGCTGGTGAAGAACATCGGGGTGTCAAACTTCAACCATGAACAGCTTGAGAGGCTTTTGAATAAGCCTGGGTTGAGGTTCAAGCCACTAACCAACCAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCTCAGCCTAAACAGGAATCTCCGACTGGCCATGTTCCCCAGAACTAAAAATCACAAAGACTATCCTTTCCACATAGAATACTGAGGACGCTTCCCCTTCCTNOV45f, CG55778-04Protein SequenceSEQ ID NO: 690245 aaMW at 28311.4kDMGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPRVQDLPLDESNNVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHEQLERLLNKPGLRFKPLTNQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNRNLRLANFPRTKNHKDYPFHIEYNOV45g, CG55778-05SEQ ID NO: 691937 bpDNA SequenceORF Start: ATG at 31ORF Stop: TAA at 838GGCGGGGCGGCGGGGCGGCCGGCGGCGGCCATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGCAGGCTTCTCCAGGGAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCCTCCTCATCCAGAATGGATCATGAGCTGCAGTGAACTTTCCTTCTGCCTCTCACATCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACATGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGGCCATGGAGGACCTGGTGATCACCGGGCTGGTGAAGAACATCGGGGTGTCAAACTTCAACCATGAACAGCTTGAGAGGCTTTTGAATAAGCCTGGGTTGAGGTTCAAGCCACTAACCAACCAGATTGAGTGCCACCCATATCTTACTCAGAAGAATCTGATCAGTTTTTGCCAATCCAGAGATGTGTCCGTGACTGCTTACCGTCCTCTTGGTGGCTCGTGTGAGGGGGTTGACCTGATAGACAACCCTGTGATCAAGAGGATTGCAAAGGAGCACGGCAAGTCTCCTGCTCAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCTCAGCCTAAACAGGAATCTCCGACTGGCCATGTTCCCCATGTAAATATGGCTCCTTCTTTTTAAAACAGAGGGAAGAATATACAGATTGAATGATTGGTGTCTGAATAGAACTAAAAATCACAAAGACTATCCTTTCCACANOV45g, CG55778-05Protein SequenceSEQ ID NO: 692269 aaMW at 30426.6kDMGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKPPHPEWIMSCSELSFCLSHPRVQDLPLDESNMVIPSDTDFLDTWEANEDLVITGLVKNIGVSNFNHEQLERLLNKPGLRFKPLTNQIECHPYLTQKNLISFCQSRDVSVTAYRPLGGSCEGVDLIDNPVIKRIAKEHGKSPAQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNRNLRLANFPMNOV45h, CG55778-07SEQ ID NO: 6931527 bpDNA SequenceORF Start: ATG at 21ORF Stop: TGA at 981CGGGGCGGCCGGCGGCGGCCATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGGCTTCTCCAGGGAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCTGTGGTGCACCTGCCATAAGAAGTCCTTGGTGGAAACAGCATGCAGAAAGAGTCTCAAGGCCTTGAAGCTGAACTATTTGGACCTCTACCTCATACACTGGCCCATGGGTTTCAAGCCTCCTCATCCAGAATGGATCATGAGCTGCAGTGAACTTTCCTTCTGCCTCTCACATCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACATGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGGCCATGGAGGACCTGGTGATCACCGGGCTGGTGAAGAACATCGGGGTGTCAAACTTCAACCATGAACAGCTTGAGAGGCTTTTGAATAAGCCTGGGTTGAGGTTCAAGCCACTAACCAACCAGATTGAGTGCCACCCATATCTTACTCAGAAGAATCTGATCAGTTTTTGCCAATCCAGAGATGTGTCCGTGACTGCTTACCGTCCTCTTGGTGGCTCGTGTGAGGGGGTTGACCTGATAGACAACCCTGTGATCAAGAGGATTGCAAAGGAGCACGGCAAGTCTCCTGCTCAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCTCAGCCTAAACAGGAATCTCCGACTGGCCATGTTCCCCATAACTAAAAATCACAATGACTATCCTTTCCACATAGAATACTGAGGACGCTTCCCCTTCCTTGTTTCTGCTCAGCCCAGATGCACAGACACTATTGGCAATGTTGACCCTCCTCTGTCATCACAGCGCCAGGGCAGCTGTGCCTGGGACAGGAGCCACACAGTCAGAGGGGGATGTAAGAGCCACCTTCTCTGACAAATCTGGAGAATTGAGTGTGTTCTAAGTGAAGGCAATGGGGTTTCTCCAAGACAGCCTGTGTGGCCTCTACTCTGAACAAATACACTGATGAGTCATCAGTGAAATTTGCCTTCACATTTTAAGAAAACTTTATCTTATGGAGTTATTTAAGCCATCTACAGAGCTGAGGAAACAGTGTAATGTGTCTCTGCCCCATTGCGCAGCTCCACCCATTGTGCCCCAGGCCAGCCCGCGTCACCTACACTTCCTTCTGTGCCCTGCCAGTGACCCCCAGGTTATTCTAAAGCAGAGTCCTTCCCTTCCCCCAGTGAGAAGGAAAATGGGATAAGTCTGGGACACTGTTTCAGTTCAATAAAGAGGCTTTTTTCTTCCTTAAAAAAAAAAAAAAAAANOV45h, CG55778-07Protein SequenceSEQ ID NO: 694320 aaMW at 36574.8kDMGDIPAVGLSSWKASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPPHPEWIMSCSELSFCLSHPRVQDLPLDESNMVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHEQLERLLNKPGLRFKPLTNQIECHPYLTQKNLISFCQSRDVSVTAYRPLGGSCEGVDLIDNPVIKRIAKEHGKSPAQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNRNLRLANFPITKNHNDYPFHIEYNOV45i, CG55778-08SEQ ID NO: 6951680 bpDNA SequenceORF Start: ATG at 101ORF Stop: TAA at 1022GGCACGAGGACGGCGGGTCGCCAGCGCCTCAGTAGCTCGCGCGGTGCCTGTCGGTAGTCGCGTGCGGGGCGGCGGGGCGGCGGGGCGGCCGGCGGCGGCCATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGGCTTCTCCAGGGAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCTGTGGTGCACGTGCCATAAGAAGTCCTTGGTGGAAACAGCATGCAGAAAGAGTCTCAAGGCCTTGAAGCTGAACTATTTGGACCTCTACCTCATACACTGGCCCATGGGTTTCAAGCCTCCTCATCCAGAATGGATCATGAGCTGCAGTGAACTTTCCTTCTGCCTCTCACATCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACATGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGGCCATGGAGGACCTGGTGATCACCGGGCTGGTGAAGAACATCGGGGTGTCAAACTTCAACCATGAACAGCTTGAGAGGCTTTTGAATAAGCCTGGGTTGAGGTTCAAGCCACTAACCAACCAGATTGAGTGCCACCCATATCTTACTCAGAAGAATCTGATCAGTTTTTGCCAATCCAGAGATGTGTCCGTGACTGCTTACCGTCCTCTTGGTGGCTCGTGTGAGGGGGTTGACCTGATAGACAACCCTGTGATCAAGAGGATTGCAAAGGAGCACGGCAAGTCTCCTGCTCAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCTCAGCCTAAACAGGAATCTCCGACTGGCCATGTTCCCCATGTAAATATGGCTCCTTCTTTTTAAAACAGAGGGAAGAATATACAGATTGAATGATTGGTGTCTGAATAGAACTAAAAATCACAAAGACTATCCTTTCCACATAGAATACTGAGGACGCTTCCCCTTCCTTGTTTCTGCTCAGCCCAGATGCACAGACACTATTGGCAATGTTGACCCTCCTCTGTCATCACAGCGCCAGGGCAGCTGTGCCTGGGACAGGAGCCACACAGTCAGAGGGGGATGTAAGAGCCACCTTCTCTGACAAATCTGGAGAATTGAGTGTGTTCTAAGTGAAGGCAATGGGGTTTCTCCAAGACAGCCTGTGTGGCCTCTACTCTGAACAAATACACTGATGAGTCATCAGTGAAATTTGCCTTCACATTTTAAGAAAACTTTATCTTATGGAGTTATTTAAGCCATCTACAGAGCTGAGGAAACAGTGTAATGTGTCTCTGCCCCATTGCGCAGCTCCACCCATTGTGCCCCAGGCCAGCCCGCGTCACCTACACTTCCTTCTGTGCCCTGCCAGTGACCCCCAGGTTATTCTAAAGCAGAGTCCTTCCCTTCCCCCAGTGAGAAGGAAAATGGGATAAGTCTGGGACACTGTTTCAGTTCAATAAGAGGCTTTTTTCTTCCTTAAAAAAAAAAAAAAAAAAAAAANOV45i, CG55778-08Protein SequenceSEQ ID NO: 696307 aaMW at 34933.0kDMGDIPAVGLSSWKASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPPHPEWIMSCSELSFCLSHPRVQDLPLDESNMVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHEQLERLLNKPGLRFKPLTNQIECHPYLTQKLISFCQSRDVSVTAYRPLGGSCEGVDLIDNPAVIKRIAKEHGKSPAQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNRNLRLAMFPMNOV45j,SNP13375813 ofSEQ ID NO: 697752 bpCG55778-03,ORF Start: ATG at 23ORF Stop: TAA at 653DNA Sequence SNP Pos: 624SNP Change: A to GGGCGGGGCGGCCGGCGGCGGCCATGGGAGATATCCCAGCCGTGGGCCTCAGCTCCTGGAAGCAGGCTTCTCCAGGTAAAGTGACCGAGGCAGTGAAAGAGGCCATTGACGCAGGGTACCGGCACTTCGACTGTGCTTACTTTTACCACAATGAGAGGGAGGTTGGAGCAGGGATCCGTTGCAAGATCAAGGAAGGCGCTGTAAGACGGGAGGATCTGTTCATTGCCACTAAGCTGTGGTGCACCTGCCATAAGAAGTCCTTGGTGGAAACAGCATGCAGAAAGAGTCTCAAGGCCTTGAAGCTGAACTATTTGGACCTCTACCTCATACACTGGCCCATGGGTTTCAAGCCTCCTCATCCAGAATGGATCATGAGCTGCAGTGAACTTTCCTTCTGCCTCTCACATCCTCGAGTGCAGGACTTGCCTCTGGACGAGAGCAACATGGTTATTCCCAGTGACACGGACTTCCTGGACACGTGGGAGATTTTGATCCGATTTCAAATCCAGAGGAATGTGATAGTGATCCCCGGATCTATCACCCCAAGTCACATTAAAGAGAATATCCAGGTGTTTGATTTTGAATTAACACAGCACGATATGGATAACATCCTCAGCCTAAACAGGAATCTCCGACTGGCCATGTTCCCCATGTAAATATGGCTCCTTCTTTTTAAAACAGAGGGAAGAATATACAGATTGAATGATTGGTGTCTGAATAGAACTAAAAATCACAAAGACTATCCTTTCCACANOV45j,SNP13375813 ofCG55778-03,SEQ ID NO: 698MW at24164.7kDProtein Sequence SNP Pos: 201210 aaSNP Change: Lys to ArgMGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKIKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPPHPEWIMSCSELSFCLSHPRVQDLPLDESNMVIPSDTDFLDTWEILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILSLNRNLRLAMFPM

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 45B.

TABLE 45BComparison of the NOV45 protein sequences.NOV45a-----MGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKINOV45b-----MGDIPAVGLSSWKAS-PGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKINOV45cTRSPTMGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKINOV45d-----MGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKINOV45e-----MGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKINOV45f-----MGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKINOV45g-----MGDIPAVGLSSWKQASPGKVTEAVKEAIDAGYRJHFDCAYFYHNERVGAGIRCKINOV45h-----MGDIPAVGLSSWKAS-PGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKINOV45i-----MGDIPAVGLSSWKAS-PGKVTEAVKEAIDAGYRHFDCAYFYHNEREVGAGIRCKINOV45aKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPPHPEWNOV45bKEGAVRREDLFIAT---------------------------------------KPPHPEWNOV45cKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPPHPEWNOV45dKEGAVRREDLFIATKLWCTCHKKSLVETACR-------------------KSLKALKLNYNOV45eKEGAVRREDLFIATKLWCTCHKKSLVETACRKGLKALKLNYLDLYLIHWPMGFKPPHPEWNOV45fKEGAVRREDLFIATKLWCTCHKKSLVETACR-------------------KSLKALKLNYNOV45gKEGAVRREDLFIAT---------------------------------------KPPHPEWNOV45hKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPPHPEWNOV45iKEGAVRREDLFIATKLWCTCHKKSLVETACRKSLKALKLNYLDLYLIHWPMGFKPPHPEWNOV45aIMSCSELSFCLSHPRVQDLPLDESNMVIPSDTDFLDTWE---------------------NOV45bIMSCSELSFCLSHPRVQDLPLDESNNVIPSDTDFLDTWE---------------------NOV45cIMSCSELSFCLSHPRVQDLPLDESNVVIPSDTDFLDTWE---------------------NOV45dLDLYLIHWPMGFKPRVQDLPLDESNMVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHNOV45eIMSCSELSFCLSHPRVQDLPLDESNMVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHNOV45fLDLYLIHWPMGFKPRVQDLPLDESNNVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHNOV45gIMSCSELSFCLSHPRVQDLPLDESNMVIPSDTDFLDTWEANEDLVITGLVKNIGVSNFNHNOV45hIMSCSELSFCLSHPRVQDLPLDESNNVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHNOV45iIMSCSELSFCLSHPRVQDLPLDESNNVIPSDTDFLDTWEAMEDLVITGLVKNIGVSNFNHNOV45a------------------------------------------------------------NOV45b---------------------------------------------------------IL-NOV45c------------------------------------------------------------NOV45dEQLERLLNKPGLRFKPLTNQIECHPYLTQKNLISFCQSRDVSVTAYRPLGGSSEGVDLIDNOV45eEQLERLLNKPGLRFKPLTN-----------------------------------------NOV45fEQLERLLNKPGLRFKPLT------------------------------------------NOV45gEQLERLLNKPGLRFKPLTNQIECHPYLTQKNLISFCQSRDVSVTAYRPLGGSCEGVDLIDNOV45hEQLERLLNKPGLRFKPLTNQIECHPYLTQKNLISFCQSRDVSVTAYRPLGGSCEGVDLIDNOV45iEQLERLLNKPGLRFKPLTNQIECHPYLTQKNLISFCQSRDVSVTAYRPLGGSCEGVDLIDNOV45a-----------------ILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILNOV45b---------------I--LIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILNOV45c-----------------ILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILNOV45dNPVIKRIAKEHGKSPAQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILNOV45e----------------QILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILNOV45f--------N-------QILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILNOV45gNPVIKRIAKEHGKSPAQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILNOV45hNPVIKRIAKEHGKSPAQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILNOV45iNPVIKRIAKEHGKSPAQILIRFQIQRNVIVIPGSITPSHIKENIQVFDFELTQHDMDNILNOV45aSLNKNLRLAMFPM-------------NOV45bSLNRNLRLAMFPITKNHKDYPFHIEYNOV45cSLNRNLRLANFPMVDG----------NOV45dSLNRNLRLAMFPRTKNHKDYPFHIEYNOV45eSLNRNLRLANFPM-------------NOV45fSLNRNLRLAMFPRTKNHKDYPFHIEYNOV45gSLNRNLRLAMFPM-------------NOV45hSLNRNLRLAMFPITKNHNDYPFHIEYNOV45iSLNRNLRLAMFPM-------------NOV45a(SEQ ID NO: 680)NOV45b(SEQ ID NO: 682)NOV45C(SEQ ID NO: 684)NOV45d(SEQ ID NO: 686)NOV4Se(SEQ ID NO: 688)NOV45f(SEQ ID NO: 690)NOV45g(SEQ ID NO: 692)NOV45h(SEQ ID NO: 694)NOV45i(SEQ ID NO: 696)

Further analysis of the NOV45a protein yielded the following properties shown in Table 45C.

TABLE 45CProtein Sequence Properties NOV45aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 3;pos.chg 0;neg.chg 1H-region:length 9;peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −6.56possible cleavage site: between 18 and 19>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 6.21 (at 155)ALOM score: 6.21 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):5.33Hyd Moment(95):5.59G content:3D/E content:2S/T content:4Score: −7.44Gavel:prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 11.4%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 89COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):52.2%: cytoplasmic34.8%: nuclear13.0%: mitochondrial>> prediction for CG55778-03 is cyt (k = 23)

A search of the NOV45a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 45D.

TABLE 45DGeneseq Results for NOV45aNOV45aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABP53592Human NOV16c protein SEQ1 . . . 210 210/210 (100%)e−124ID NO: 48 - Homo sapiens, 2101 . . . 210 210/210 (100%)aa. [WO200262999-A2, 15-AUG-2002]ABP53591Human NOV16b protein SEQ1 . . . 210208/251 (82%)e−117ID NO: 46 - Homo sapiens, 2511 . . . 251209/251 (82%)aa. [WO200262999-A2, 15-AUG-2002]AAM79279Human protein SEQ ID NO1 . . . 210205/251 (81%)e−1141941 - Homo sapiens, 263 aa.1 . . . 250207/251 (81%)[WO200157190-A2, 09-AUG-2001]ABU11795Human MDDT polypeptide SEQ1 . . . 156152/156 (97%)5e−89 ID 742 - Homo sapiens, 215 aa.31 . . . 185 154/156 (98%)[WO200279449-A2, 10-OCT-2002]AAM80263Human protein SEQ ID NO1 . . . 156151/156 (96%)3e−88 3909 - Homo sapiens, 264 aa.11 . . . 165 152/156 (96%)[WO200157190-A2, 09-AUG-2001]

In a BLAST search of public sequence databases, the NOV45a protein was found to have homology to the proteins shown in the BLASTP data in Table 45E.

TABLE 45EPublic BLASTP Results for NOV45aNOV45aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueBAC54567Aldo-keto reductase related1 . . . 210207/210 (98%)e−121protein 3 - Homo sapiens1 . . . 209209/210 (98%)(Human), 222 aa.BAC54565Aldo-keto reductase related1 . . . 210208/251 (82%)e−115protein 1 - Homo sapiens1 . . . 250209/251 (82%)(Human), 250 aa.BAC54566Aldo-keto reductase related1 . . . 210207/251 (82%)e−115protein 2 - Homo sapiens1 . . . 250209/251 (82%)(Human), 263 aa.Q9BU71Similar to aldo-keto reductase -1 . . . 156153/156 (98%)6e−89 Homo sapiens (Human), 307 aa.1 . . . 155154/156 (98%)Q96JD6Aldo-keto reductase loopADR -1 . . . 156153/156 (98%)6e−89 Homo sapiens (Human), 320 aa.1 . . . 155154/156 (98%)

PFam analysis indicates that the NOV45a protein contains the domains shown in the Table 45F.

TABLE 45FDomain Analysis of NOV45aNOV45aIdentities/SimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValuealdo_ket_red2 . . . 203 87/369 (24%)8.2e−37157/369 (43%)

Example 46

The NOV46 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 46A.

TABLE 46ANOV46 Sequence AnalysisNOV46a, CG55794-03SEQ ID NO: 6991222 bpDNA SequenceORF Start: ATG at 41ORF Stop: TAA at 1163CCAGAGAGGCCCAGAATTTTCTAACTTACTGTGTGGCAGAATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCAATTCCTAGGAGTGACCTATGAGACCCACCCCATATATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGGATACGCAAGCTCCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCTTCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACATATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGTGCATTCTGCCCAGGCCTGCTCAACCCCAGTGGCATGAGTGTGGCTTGGAGGAACGNOV46a, CG55794-03Protein SequenceSEQ ID NO: 7001374 aaMW at 42580.0kDMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWNREISEKYKEVVTQHFLGVTYETHPIYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRLSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46b, 210223559SEQ ID NO: 7011579 bpDNA SequenceORF Start: at 67ORf Stop: TAA at 1396CCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATTCGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGATGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGATTTCGATGTTGCTGTTTTGCCATTTTCCAACAGCACAAATAACGGGTTATTGTTTATAAATACTACTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTATCTCTCGAGAAAAGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCcTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGCGGCCGCCAGCTTTCTAGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCGTCGACCATCATCATCATCATCATTGAGTTTGTAGCCTTAGACATGACTGTTCCTCAGTTCAAGTTGGGCACTTACGAGAAGACCGGTCTTGCTAGATTCTAATCAAGAGGATGTCAGAATGCCNOV46b, 210223559Protein SequenceSEQ ID NO: 702443 aaMW at 49842.7kDLFETMRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLEKRYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGPFSYTFELRDSGTYGFVLPEAQIQPTCEAETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46c, 210223626SEQ ID NO: 7031607 bpDNA SequenceORF Start: at 74ORF Stop: TAA at 1421ACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATTCGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGATGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGATTTCGATGTTGCTGTTTTGCCATTTTCCAACAGCACAAATAACGGGTTATTGTTTATAAATACTACTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTATCTCTCGAGAAAAGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCAACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAACAGGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGAAAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCCACCATCACCACCATCACTAAGCGGCCGCCAGCTTTCTAGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCGTCGACCATCATCATCATCATCATTGAGTTTGTAGCCTTAGACATGACTGTTCCTCAGTTCAAGTTGGGCACTTACGAGAAGACCGGTCTTGCTAGCATTCTAATCAAGAGGATGTCAGAATGCCATTNOV46c, 210223626Protein SequenceSEQ ID NO: 704449 aaMW at 50665.6kDLFETMRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLEKRYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYENMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46d, 171095097SEQ ID NO: 7051148 bpDNA SequenceORF Start: at 2ORF Stop: TAA at 1127CACCATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGCGGCCGCTCGAGTCTAGANOV46d, 171095097Protein SequenceSEQ ID NO: 706375 aaMW at 42630.1kDTMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46e, 183852229SEQ ID NO: 7071148 bpDNA SequenceORF Start: at 3ORF Stop: TAA at 1146CCACCATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTIGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCCACCATCACCACCATCACTAANOV46e, 183852229Protein SequenceSEQ ID NO: 708381 aaMW at 43452.9kDTMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCOWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSnHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46f, 183852264SEQ ID NO: 7091151 bpDNA SequenceORF Start: at 3ORF Stop: TAA at 1149CCACCATGGGCCACCATCACCACCATCACAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAANOV46f, 183852264Protein SequenceSEQ ID NO: 710382 aaMW at 43510.0kDTMGHHHHHHKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSANILYASSGSSRNWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46g, 183852410SEQ ID NO: 7111162 bpDNA SequenceORF Start: at 2ORF Stop: TAA at 1148CACCATGGGCCACCATCACCACCATCACAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGCGGCCGCTTTCNOV46g, 183852410Protein SequenceSEQ ID NO: 712382 aaMW at 43510.0kDTMGHHHHHHKPLLETLYLLGMLVPGGLGYDRSLAQHRQEEVDKSVSPWSLETYSYNIYHPMGEIYEWNREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46h, 183523337SEQ ID NO: 7131162 bpDNA SequenceORF Start: at 2ORF Stop: TAA at 1148CACCATGGGCCACCATCACCACCATCACAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGCGGCCGCTTTCNOV46h, 183523337Protein SequenceSEQ ID NO: 714382 aaMW at 43510.0kDTMGHHHHHHKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIRAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46i, CG55794-01SEQ ID NO: 7151196 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAA at 1138TTACTGTGTGGCAGAATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCAATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATATATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGGCTGTGGAATTCACGGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGGCAGTTAATTCTCACACTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACATATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGTGCATCCTGCCCAGGCCTGCTCAACCCCAGTGGCATGAGTGTGGCTGGAGGAACGNOV46i, GG55794-01Protein SequenceSEQ ID NO: 716374 aaMW at 42472.9kDMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEINEWMREISEKYKEVVTQHFLGVTYETHPIYYLKISQPSGNPKKIIWMGCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANLAKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46j, CG55794-02SEQ ID NO: 7171008 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTCCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACATATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGNOV46j, CG55794-02Protein SequenceSEQ ID NO: 718336 aaMW at 38597.1kDYDRSLAQHROEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKBVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFTLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRNOV46k, CG55794-04SEQ ID NO: 7191579 bpDNA SequenceORF Start: at 334ORF Stop: TAA at 1396CCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATTCGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGATGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGATTTCGATGTTGCTGTTTTGCCATTTTCCAACAGCACAAATAACGGGTTATTGTTTATAAATACTACTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTATCTCTCGAGAAAAGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATAAAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATAAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACAAGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGAAACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTAAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGCGGCCGCCAGCTTTCTAGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCGTCGACCATCATCATCATCATCATTGAGTTTGTAGCCTTAGACATGACTGTTCCTCAGTTCAAGTTGGGCACTTACGAGAAGACCGGTCTTGCTAGATTCTAATCAAGAGGATGTCAGAATGCCNOV46k, CG55794-04Protein SequenceSEQ ID NO: 720354 aaMW at 40431.3kDYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKWHSDSAGRAVTSATMLLGLLVSCMSLLNOV461, CG55794-05SEQ ID NO: 7211607 bpDNA SequenceORF Start: at 341ORF Stop: at 1403ACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAAAAACAACTAATTATTCGAAACGATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGATGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGATTTCGATGTTGCTGTTTTGCCATTTTCCAACAGCACAAATAACGGGTTATTGTTTATAAATACTACTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTATCTCTCGAGAAAAGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCCACCATCACCACCATCACTAAGCGGCCGCCAGCTTTCTAGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCGTCGACCATCATCATCATCATCATTGAGTTTGTAGCCTTAGACATGACTGTTCCTCAGTTCAAGTTGGGCACTTACGAGAAGACCGGTCTTGCTAGATTCTAATCAAGAGGATGTCAGAATGCCATTNOV461, CG55794-05Protein SequenceSEQ ID NO: 722354 aaMW at 40431.3kDYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46m, GG55794-06SEQ ID NO: 7231977 bpDNA SequenceORF Start: ATG at 41ORF Stop: TAG at 671CCAGAGAGGCCCAGAATTTTCTAACTTACTGTGTGGCAGAATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAAACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCATATATTATCTGAAGATCAGCCAACCATACTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGGATACGCAAGCTCCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCTTCTTGGTGTAATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACATATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCCGAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGTGGGCCTGTCTGGTGTCCTGCATGTCTCTTCTCTAAGTGCATCCTGCCCAGNOV46m, CG55794-06Protein SequenceSEQ ID NO: 724210 aaMW at 24848.2kDMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPIYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCNSSWTEGSKCIESKVWNQLNOV46n, CG55794-07SEQ ID NO: 7251378 bpDNA SequenceORF Start: ATG at 259ORF Stop: TAA at 1225ACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTGAAAATACATCAGCATGTGGGAAAGAGCAACGTTGATCGTCTTCACGGAAAGGCTGAGGACCCTGCGCCTACCACATGTTGGCCAGGGTGAGCAAGCAGTGAAAGAGAAAACACTTTTTTCAAAAAGCCAACTGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATATATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGGATACGCAAGCTCCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCTTCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACATATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGTGCATTCTGCCCAGGCCTGCTCAACCCCAGTGGCATGAGTGTGGCTGGAGGAACGGTGTGTTATGGTTGTAAAGAAACCAAATAATTTAACTAAAAATACTTCCTATTTCAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAANOV46n, CG55794-07Protein SequenceSEQ ID NO: 7261322 aaMW at 36617.2kDMGEIYEWMREISEKYKEVVTQHFLGVTYETHPIYYLKISQPSGMPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWIISDSAGRVRSATMLLGLLVSCMSLLNOV46o, CG55794-08SEQ ID NO: 727128 bpDNA SequenceORF Start: at 1ORF Stop: TAA at 1126ACCATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAATCAAGTAACCACCCAGAAATGATTCAAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAANOV46o, CG55794-08Protein SequenceSEQ ID NO: 728375 aaMW at 42630.1kDTMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46p, CG55794-09SEQ ID NO: 7291151 bpDNA SequenceORF Start: at 3ORF Stop: TAA at 1149CCACCATGGGCCACCATCACCACCATCACAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAANOV46p, CG55794-09Protein SequenceSEQ ID NO: 730382 aaMW at 43510.0kDTMGHHHHHHKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46q, CG55794-10SEQ ID NO: 7311148 bpDNA SequenceORF Start: at 3ORF Stop: TAA at 1146CCACCATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCIAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCCACCATCACCACCATCACTAANOV46q, CG55794-10Protein SequenceSEQ ID NO: 732381 aaMW at 43452.9kDTMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46r,CG55794-11SEQ ID NO: 7331146 bpDNA SequenceORF Start: at 1ORF Stop: TAA at 1144ACCATGGTAAGCGCTATTGTTTTATATGTGCTTTTGGCGGCGGCGGCGCATTCTGCCTTTGCGTATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCCACCATCACCACCATCACTAANOV46r, CG55794-11Protein SequenceSEQ ID NO: 734381 aaMW at 43355.7kDTMVSAIVLYVLLAAAAHSAFAYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46s, CG55794-12SEQ ID NO: 7351161 bpDNA SequenceORF Start: at 1ORF Stop: TAA at 1159ATTATTATACCTCCCACCATCGGGCGCGGATCCACCATGGTAAGCGCTATTGTTTTATATGTGCTTTTGGCGGCGGCGGCGCATTCTGCCTTTGCGTATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAANOV46s, CG55794-12Protein SequenceSEQ ID NO: 736386 aaMW at 43638.1kDIIIPPTIGRGSTMVSAIVLYVLLAAAAHSAFAYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMRBISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46t, CG55794-13SEQ ID NO: 7371212 bpDNA SequenceORF Start: at 1ORF Stop: TAA at 1210CGCGGATCCACCATGGTAAGCGCTATTGTTTTATATGTGCTTTTGGCGGCGGCGGCGCATTCTGCCTTTGCGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATGTATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGTATACGCAAGCTTCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCCACCATCACCACCATCACTAANOV46t, CG55794-13Protein SequenceSEQ ID NO: 738403 aaMW at 45622.4kDRGSTMVSAIVLYVLLAAAAHSAFAKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPMYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSSIRKLLRNLDFYVLPVINIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46u,SNP13375362 ofSEQ ID NO: 7391222 bpCG55794-03,ORF Start: ATG at 41ORF Stop: TAA at 1163DNA Sequence SNP Pos: 240SNP Change: A to GCCAGAGAGGCCCAGAATTTTCTAACTTACTGTGTGGCAGAATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTGCAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATATATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGGATACGCAAGCTCCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCTTCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGTAGACTAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACATATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGTGCATTCTGCCCAGGCCTGCTCAACCCCAGTGGCATGAGTGTGGCTTGGAGGAACGNOV46u,SNP13375362 ofCG55794-03,SEQ ID NO: 740MW at 42520.0kDProtein SequenceSNP Pos: 67374 aaSNP Change: Tyr to CysMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKCKEVVTQHFLGVTYETHPIYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLNOV46v,SNP13379598 ofSEQ ID NO: 7411222 bpCG55794-03,ORF Start: ATG at 41ORF Stop: TAA at 1163DNA SequenceSNP Pos: 988SNP Change: A to GCCAGAGAGGCCCAGAATTTTCTAACTTACTGTGTGGCAGAATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATATATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGGATACGCAAGCTCCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCTTCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACGTATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCTCTAAGTGCATTCTGCCCAGGCCTGCTCAACCCCAGTGGCATGAGTGTGGCTTGGAGGAACGNOV46v,SNP13379598 ofCG55794-03,SEQ ID NO: 742MW at 42580.OkDProtein SequenceSNP Pos: 316374 aaSNP Change: Thr to ThrMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPIYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCNSLLNOV46w,SNP13375066 ofSEQ ID NO: 7431222 bpCG55794-03,ORF Start: ATG at 41ORF Stop: TAA at 1163DNA SequenceSNP Pos: 1152SNP Change: T to CCCAGAGAGGCCCAGAATTTTCTAACTTACTGTGTGGCAGAATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATATATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGGATACGCAAGCTCCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCTTCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGGAACATATGGGTTTGTTCTGCCAGAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCACGTCTCTTCTCTAAGTGCATTCTGCCCAGGCCTGCTCAACCCCAGTGGCATGAGTGTGGCTTGGAGGAACGNOV46w,SNP13375066 ofCG55794-03,SEQ ID NO: 744MW at 42549.9kDProtein SequenceSNP Pos: 371374 aaSNP Change: Met to ThrMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPIYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPAVSEPETKAVASFIESKKDDILCFLTHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCTSLLNOV46x,SNP13375067 ofSEQ ID NO: 7451222 bpCG55794-03,ORF Start: ATG at 41ORF Stop: TAA at 1163DNA SequenceSNP Pos: 1161SNP Change: T to CCCAGAGAGGCCCAGAATTTTCTAACTTACTGTGTGGCAGAATGAAGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCCTGGAGGGTGGGATATGATAGAATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCTAGGAGTGACCTATGAGACCCACCCCATATATTATCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTCTACAAAACCATAAAGACAACTCAAGGATACGCAAGCTCCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACTGATCGTCTTTGGAGGAAATCCCGTTCACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCTTCTTGGTGTAGTATTGGTGCCTCTAGAAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACATATGGGTTTGTTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCCTGCATGTCTCTTCCCTAAGTGCCTGCCCAGGCCTGCTCAACCCCAGTGGCATGAGTGTGGCTTGGAGGAACGNOV46x,SNP13375067 ofCG55794-03,SEQ ID NO: 746MW at 42564.0kDProtein SequenceSNP Pos: 374374 aaSNP Change: Leu to ProMKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWMREISEKYKEVVTQHFLGVTYETHPIYYLKISQPSGNPKKIIWMDCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLRNLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLP

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 46B.

TABLE 46BComparison of the NOV46 protein sequences.NOV46a------------------------------------------------------------NOV46bLFETMRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNOV46cLFETMRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNOV46d------------------------------------------------------------NOV4Ee------------------------------------------------------------NOV46f----------------------------------------------------------TMNOV46g----------------------------------------------------------TMNOV46h------------------------------------------------------------NOV46i------------------------------------------------------------NOV46j------------------------------------------------------------NOV46k------------------------------------------------------------NOV46l------------------------------------------------------------NOV46m------------------------------------------------------------NOV46n------------------------------------------------------------NOV46o------------------------------------------------------------NOV46p----------------------------------------------------------TMNOV46q------------------------------------------------------------NOV46r------------------------------------------------------------NOV46s-----------------------------------------------------IIIPPTINOV46t------------------------------------------------------------NOV46a------MKPLLETLYLLGMLVPG------------------GLGYDRSLAQHRQEIVDKSNOV46bNSTNNGLLFINTTIASIAAKEEGVSL---------------EKRYDRSLAQHRQEIVDKSNOV46cNSTNNGLLFINTTIASIAAKEEGVSL---------------EKRYDRSLAQHRQEIVDKSNOV46d----TMKPLLETLYLLGMLVPGG-------------------LGYDRSLAQHRQEIVDKSNOV46e----TMKPLLETLYLLGMLVPGG-------------------LGYDRSLAQHRQEIVDKSNOV46fGHHHHHHKPLLETLYLLGMLVPG------------------GLGYDRSLAQHRQEIVDKSNOV46gGHHHHHHKPLLETLYLLGMLVPG------------------GLGYDRSLAQHRQEIVDKSNOV46hGHHHHHHKPLLETLYLLGMLVPG------------------GLGYDRSLAQHROEIVDKSNOV46i------MKPLLETLYLLGMLVPG------------------GLGYDRSLAQHRQEIVDKSNOV46j--------------------------------------------YDRSLAQHRQEIVDKSNOV46k--------------------------------------------YDRSLAQHRQEIVDKSNOV46l--------------------------------------------YDRSLAQHRQEIVDKSNOV46m------MKPLLETLYLLGMLVPG------------------GLGYDRSLAQHRQEIVDKSNOV46n------------------------------------------------------------NOV46o----TMKPLLETLYLLGMLVPGG-------------------LGYDRSLAQHRQEIVDKSNOV46pGHHHHHHKPLLETLYLLGMLVPG------------------GLGYDRSLAQHRQEIVDKSNOV46q----TMKPLLETLYLLGMLVPGG-------------------LGYDRSLAQHRQEIVDKSNOV46r----TMVSAIVLYVLLAAAAHS-------------------AFAYDRSLAQHRQEIVDKSNOV46sGRGSTMVSAIVLYVLLAAAAHS-------------------AFAYDRSLAQHRQEIVDKSNOV46t-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----------------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------NOV46nYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKNOV46oYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKNOV46pYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKNOV46qYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKNOV46rYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKNOV46sYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKNOV46tYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKNOV46aAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46bAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46cAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46dAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46eAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46fAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46gAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46hAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46iAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46jAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46kAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46lAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46m------------------------------------------------------------NOV46nAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46oAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46pAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46qAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46rAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46sAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46tAVASFIESKKDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNOV46aNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46bNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46cNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46dNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46eNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46fNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46gNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46hNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46iNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46jNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46kNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46lNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46m------------------------------------------------------------NOV46nNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV4GoNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46pNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46qNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46rNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46sNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46tNYRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFVLPEAQIQPTCEETMEANOV46aVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46bVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46cVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46dVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46eVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46fVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46gVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46hVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46iVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46jVLSVLDDVYAKHWHSDSAGR------------------------NOV46kVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46lVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46m--------------------------------------------NOV46nVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46oVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46pVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46qVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46rVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46sVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL------NOV46tVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLLHHHHHHNOV46a(SEQ ID NO: 700)NOV46b(SEQ ID NO: 702)NOV46c(SEQ ID NO: 704)NOV46d(SEQ ID NO: 706)NOV46e(SEQ ID NO: 708)NOV46f(SEQ ID NO: 710)NOV46g(SEQ ID NO: 712)NOV46h(SEQ ID NO: 714)NOV46i(SEQ ID NO: 716)NOV46j(SEQ ID NO: 718)NOV46k(SEQ ID NO: 720)NOV46l(SEQ ID NO: 722)NOV46m(SEQ ID NO: 724)NOV46n(SEQ ID NO: 726)NOV46o(SEQ ID NO: 728)NOV46p(SEQ ID NO: 730)NOV46q(SEQ ID NO: 732)NOV46r(SEQ ID NO: 734)NOV46s(SEQ ID NO: 736)NOV46t(SEQ ID NO: 738)

Further analysis of the NOV46a protein yielded the following properties shown in Table 46C.

TABLE 46CProtein Sequence Properties NOV46aSignalP analysis:Cleavage site between residues 21 and 22PSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 6;pos.chg 1;neg.chg 1H-region:length 15; peak value 9.15PSG score: 4.75GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −0.52possible cleavage site: between 20 and 21>>> Seems to have a cleavable signal peptide (1 to 20)ALOM:Klein et al's method for TM region allocationInit position for calculation: 21Tentative number of TMS(s) for the threshold 0.5: 1Number of TMS(s) for threshold 0.5: 1INTEGRALLikelihood = −2.34Transmembrane 357-373PERIPHERALLikelihood = 4.08 (at 229)ALOM score: −2.34 (number of TMSs: 1)MTOP: Prediction of membrane topology (Hartmann et al.)Center position for calculation: 10Charge difference: −0.5 C(0.5) − N(1.0)N >= C: N-terminal side will be inside>>> membrane topology: type 1a (cytoplasmic tail 374 to 374)>>> Seems to be GPI anchoredMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):8.63Hyd Moment(95):12.49G content:4D/E content:2S/T content:1Score: −7.55Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 9.9%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 70.6COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: extracellular, including cell wall22.2%: endoplasmic reticulum11.1%: Golgi11.1%: plasma membrane>> prediction for CG55794-03 is exc (k = 9)

A search of the NOV46a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 46D.

TABLE 46DGeneseq Results for NOV46aNOV46aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAG66547Human secreted1 . . . 374 374/374 (100%)0.0metallocarboxypeptidase-like1 . . . 374 374/374 (100%)polypeptide - Homo sapiens, 374aa. [WO200157265-A1, 09-AUG-2001]AAG66565Human secreted1 . . . 374373/374 (99%)0.0metallocarboxypeptidase-like1 . . . 374374/374 (99%)variant polypeptide - Homosapiens, 374 aa. [WO200157265-A1, 09-AUG-2001]AAU82703Amino acid sequence of novel1 . . . 374372/374 (99%)0.0human protease #2 - Homo1 . . . 374373/374 (99%)sapiens, 374 aa. [WO200200860-A2, 03-JAN-2002]AAB74682Human protease and protease13 . . . 374 360/362 (99%)0.0inhibitor PPIM-15 - Homo1 . . . 362361/362 (99%)sapiens, 362 aa. [WO200110903-A2, 15-FEB-2001]AAG66560Human secreted21 . . . 374 354/354 (100%)0.0metallocarboxypeptidase-like1 . . . 354 354/354 (100%)polypeptide - Homo sapiens, 354aa. [WO200157265-A1, 09-AUG-2001]

In a BLAST search of public sequence databases, the NOV46a protein was found to have homology to the proteins shown in the BLASTP data in Table 46E.

TABLE 46EPublic BLASTP Results for NOV46aNOV46aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8IVL8Zn-carboxypeptidase - Homo 1 . . . 374372/374 (99%)0.0sapiens (Human), 374 aa. 1 . . . 374373/374 (99%)Q9PUF2Carboxypeptidase homolog - 13 . . . 337152/326 (46%)7e−87Bothrops jararaca (Jararaca), 416 82 . . . 405219/326 (66%)aa.Q8AXN3Carboxypeptidase B - 41 . . . 337146/297 (49%)8e−86Paralichthys olivaceus (Flounder),100 . . . 396203/297 (68%)408 aa (fragment).CAA03381SEQUENCE 85 FROM PATENT 45 . . . 352148/312 (47%)1e−85WO9620011 - unidentified, 349 26 . . . 336204/312 (64%)aa.Q9JHH6Carboxypeptidase R (Thrombin- 30 . . . 350145/323 (44%)2e−85activatable fibrinolysis inhibitor)103 . . . 417210/323 (64%)(1110032P04Rik protein) - Musmusculus (Mouse), 422 aa.

PFam analysis indicates that the NOV46a protein contains the domains shown in the Table 46F.

TABLE 46FDomain Analysis of NOV46aIdentities/NOV46aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect ValueZn_carbOpept48..24982/215 (38%)1.2e-74168/215 (78%)

Example 47

The NOV47 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 47A.

TABLE 47ANOV47 Sequence AnalysisNOV47a,CG55806-04SEQ ID NO: 7471300 bpDNA SequenceORF Start: ATG at 20ORF Stop: TGA at 1274TGACTGTATCGCCGGATTCATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATTCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAGGAGTTTGTTCATGGGAACCTTGAGAGAGAATGTATGGAAGAAAAGTGCAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAACACTGAAAGAACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAATCCATGTTTAAATGGCGGCAGTTGCAAGGATGTCATTAATTCCTATGAATGTTGGTGTCCCTTTGGATTTGAAGGAAAGAACTGTGAATTAGTGCCATTTCCATGTGGAAGAGTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGACTGTTTTTCCTGATGTGGACTATGTAAATTCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCATTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGGCAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAATGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGTGAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAATTATTCCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTGGAACTGGACGAACCCTTAGTGCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAGGAATACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTCCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCCACATGTCTTGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTAGGCTTCCATGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAAGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAATATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTCACTTGACTGCAGCCAAGCTAATTCCGGAAGNOV47a,GG55806-04Protein SequenceSEQ ID NO: 748418 aaMW at 47031.8kDMQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVHGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDVINSYECWCPFGFEGKNCELVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRIVIRIIPHNNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYLIIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTNOV47b,CG55806-01SEQ ID NO: 7491438 bpDNA SequenceORF Start: ATG at 2ORF Stop: TAA at 1184TATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATTCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGGAACCTTGAGAGAGAATGTCTGGAGGAAAGTGTAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAACACTGAAAGAACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAATCCATGTTTAAATGGCGGCAGTTGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCCCTTTGGATTTGAAGGAAAGAACTGTGAATTAGATGTGGACTATGTAAATTCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCATTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGGCAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAATGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGTGAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAATTATTCCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTGGAACTGGACGAACCCTTAGTGCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAGGAATACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTCCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCCACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTCCATGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAAGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAATATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTCACTTAATGAAAGATGGATTTCCAAGGTTAATTCATTGGAATTGAAAATTAACAGGGCCTCTCACTAACTAATCACTTTCCCATCTTTTGTTAGATTTGAATATATACATTCTATGATCATTGCTTTTTCTCTTTACAGGGGAGAATTTCATATTTTACCTGAGCAAATTGATTAGAAAATGGAACCACTAGAGGAATATAATGTGTTAGGAAATTACAGTCATTTCTAAGGGCCCAGCCTTGACAAATTGTGAGTAAANOV47B, CG55806-01Protein SequenceSEQ ID NO: 750394 aaMW at 44431.7kDMQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNLERECLEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTNOV47c, CG55806-02SEQ ID NO: 7512807 bpDNA SequenceORF Start: ATG at 20ORF Stop: TAA at 1403CAATCTGCTAGCAAAGGTTATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTGATCACCATCTGCCTTTTAGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATTCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTTGAGAGAGAATGTATGGAAGAAAAGTGTAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAACACTGAAAGAACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAATCCATGTTTAAATGGCGGCAGTTGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCCCTTTGGATTTGAAGGAAAGAACTGTGAATTAGATGTAACATGTAACATTAAGAATGGCAGATGAGCAGTTTTGTAAAAATAGTGCTGATAACACAAGGTGGTTTGCTCCTGTACTGAGGGATATCGACTTGCAGAAAACCAGAAGTCCTGTGAACCAGCAGTGCCATTTCCATGTGGAAGAGTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGACTGTTTTTCCTGATGTGGACTATGTAAATTCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCATTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGGCAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAATGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGTGAACATAATATTGAGGAGACAGAACATACAGAGCAAAGCGAAATGTGATTCGAATTATTCCTCACCACAACTACAATGCAGCTAATTAATAAGTACAACCATGCATTGCCCTTCTGGAACTGGACGAACCCTTAGTGCTAAACAGCTACGTTACAACCTATTTGCATTGCTGACAAGGAATACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTCCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCCACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTCCATGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAAGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAATATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTCACTTAATGAAAGATGGATTTCCAAGGTTAATTCATTGGAATTGAAAATTAACAGGGCCTCTCACTAACTAATCACTTTCCCATCTTTTGTTAGATTTGAATATATACATTCTATGATCATTGCTTTTTCTCTTTACAGGGGAGAATTTCATATTTTACCTGAGCAAATTGATTAGAAAATGGAACCACTAGAGGAATATAATGTGTTAGGAAATTACAGTCATTTCTGAAGCCCAGCCCTTGACAAAATTGTGAAGTTAAATTCTCCACTCTGTCCATCAGATACTATGGTTCTCCACTATGGCAACTAACTCACTCAATTTTCCCTCCTTAGCAGCATTCCATCTTCCCGATCTTCTTTGCTTCTCCAACCAAAACATCATGTTTATTAGTTCTGTATACAGTACAGGATCTTTGGTCTACTCTATCACGAGAAGGCTCAGTACCACACTCATGAAGAAAGAACACAGGAGTAGCTGAGAGGCTAAAACTCATCAAAAACACTACTCCTTTTCCTCTACCCTATTCCTCAATCTTTTACCTTTTCCAAATTCCCAATTCCCCAAATCAGTTTTTCTCTTTCTTACTCCCTCTCTCCCTTTTACCCTCCATGGTCGTTAAAGGAGAGATGGGGAGCATCATTCTGTTATACTTCTGTACACAGTTATACATGTCTATCAAACCCAGACTTGCTTCCATAGTGGAGACTTGCTTTTCAGAACATAGGGATGAAGTAAGGTGCCTGAAAAGTTTGGGGGAAAAGTTTCTTTCAGAGAGTTAAGTTATTTTATATATATAATATATATATAAAATATATAATATACAATATAAATATATAGTGTGTGTGTGTATGCGTGTGTGTAGACACACACGCATACACACATATAATGGAAGCAATAAGCCATTCTTAAGAGCTTGTATGGTTATGCAGGTCTGACTAGGCATGATTTCACGAAGGCAAGATTGGCATATCAGTTGTAACTAAAAAAGCTGACATTGACCCAGACATATTGTACTCTTTCTAAAAATAATAATAATAATGCTAACAGAAAGAAGAGAACCGTTCGTTTGCAATCTACAGCTAGTAGAGACTTGAGGAAGAATTCAACAGTGTGTCTTCAGCAGTGTTCAGAGCCAAGCAAGAAGTTGAAGTTGCCTAGACCAGAGGACATAAGTATCATGTCTCCTTTAACTAGCATACCCCGAAGTGGAGAAGGATGCAGCAGGCTCAAAGGCATAAGTCATTCCAATCAGCCAACTAAGTTGTCCTTTTCTGGTTTCGTGTTCACCATGGAACATTTTGATTATAGTTAATCCTTCTATCTTGAATCTTCTAGAGAGTTGCTGACCAACTGACGTATGTTTCCCTTTGTGAATTAATAAACTGGTGTTCTGGTTCAAAAAAAAAANOV47c, CG55806-02Protein SequenceSEQ ID NO: 752461 aaMW at 51778.0kDMQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTNOV47d, CG55806-03SEQ ID NO: 7531612 bpDNA SequenceORF Start: ATG at 22ORF Stop: TAA at 1405TTGACTGTATCGCCGGAATTCATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATTCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTTGAGAGAGAATGTATGGAAGAAAAGTGTAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAACACTGAAAGAACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAATCCATGTTTAAATGGCGGCAGTTGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCCCTTTGGATTTGAAGGAAAGAACTGTGAATTAGATGTAACATGTAACATTAAGAATGGCAGATGCGAGCAGTTTTGTAAAAATAGTGCTGATAACAAGGTGGTTTGCTCCTGTACTGAGGGATATCGACTTGCAGAAAACCAGAAGTCCTGTGAACCAGCAGTGCCATTTCCATGTGGAAGAGTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGACTGTTTTTCCTGATGTGGACTATGTAAATTCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCATTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGGCAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAATGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGTGAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAATTATTCCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTGGAACTGGACGAACCCTTAGTGCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAGGAATACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTCCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCCACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTCCATGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAAGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAATATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTCACTTAATGAAAGATGGATTTCCAAGGTTAATTCATTGAAATTGAAAATTAATAGGGCCTCTCACTAACTAATCACTTTCCCATCTTTTGTTAGATTTGAATATATACATTCTATGATCATTGCTTTTTCTCTTTACAGGGGAGAATTTCATATTTTACCTGAGCAAATTGATTAGAAAATGGAACCACTAGAGGAATATAATGTGTTAGGANOV47d, CG55806-03Protein SequenceSEQ ID NO: 754461 aaMW at 51778.0kDMQRVNNIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTNOV47e,SNP13382503 ofSEQ ID NO: 7551300 bpCG55806-04,ORF Start: ATG at 20ORF Stop: TGA at 1274DNA SequenceSNP Pos: 470SNP Change: A to GTGACTGTATCGCCGGATTCATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATTCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAGGAGTTTGTTCATGGGAACCTTGAGAGAGAATGTATGGAAGAAAAGTGCAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAACACTGAAAGAACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAATCCATGTTTAAATGGCGGCAGTTGCAAGGATGTCATTAATTCCTATGAATGTTGGTGTCCCTTTGGATTTGAAGGAAAGAACTGTGAATTAGTGCCATTTCCATGTGGAAGAGTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGGCTGTTTTTCCTGATGTGGACTATGTAAATTCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCATTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGGCAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAATGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGTGAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAATTATTCCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTGGAACTGGACGAACCCTTAGTGCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAGGAATACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTCCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCCACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTCCATGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAAGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAATATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTCACTTGACTGCAGCCAAGCTAATTCCGGAAGNOV47e,SNP13382503 ofCG55806-04,SEQ ID NO: 756MW at 47001.8kDProtein SequenceSNP Pos: 151418 aaSNP Change: Thr to AlaMQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRAPKRYNSGKLEEFVGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDCESNPCLNGGSCKDVINSAYECWCPFGFEGKNCELVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTAEETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTNOV47f,SNP13382492 ofSEQ ID NO: 7571300 bpCG55806-04,ORF Start: at 2ORF Stop: at 1253DNA SequenceSNP Pos: 673SNP Change: G to ATGACTGTATCGCCGGATTCATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATTCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAGGAGTTTGTTCATGGGAACCTTGAGAGAGAATGTATGGAAGAAAAGTGCAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAACCTGAAAGAAACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGGAGTCCAATCCATGTTTAAATAGGCGGCAGTTGCAAGGATGTCATTAATTCCTATGAATGTTGGTGTCCCTTTGGATTTGAAGGAAAGAACTGTGAATTAGTGCCATTTCCATGTGGAAGAGTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGACTGTTTTTCCTGATGTGGACTATGTAAATTCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCATTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGGCAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAATGAATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGTGAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAATTATTCCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTGGAACTGGACGAACCCTTAGTGCTAAACAGTAACGTTACACCTATTTGCATTGCTGACAAGGAATACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTCCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCCACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTCCATGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAAGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAATATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTCACTTGACTGCAGCCAAGCTAATTCCGGAAGNOV47f,SNP13382492 ofCG55806-04,SEQ ID NO: 758MW at46845.6kDProtein SequenceSNP Pos: 2181417 aaSNP Change: Trp to EndMQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVHGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDVINSYECWCPFGFEGKNCELVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 47B.

TABLE 47BComparison of the NOV47 protein sequences.NOV47aMQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVHGNLNOV47bMQRVNNIMAESPGLITICLLGYLLSABCTVFLDHENANKILNRPKRYNSGKLEEFVQGNLNOV47cMQRVNMIMABSPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNLNOV47dMQRVNNIMABSPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNLNOV47aERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDVINSYECWCPNOV47bERECLEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPNOV47cERECMEEKCSFEEAREVFENTERTTEFWKOYVDGDQCESNPCLNGGSCKDDINSYECWCPNOV47dERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPNOV47aFGFEGKNCELVP-----------------------------------------FP--CGRNOV47bFGFEGKNCELDV-----------------------------------------D------NOV47cFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRNOV47dFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLABNQKSCEPAVPFPCGRNOV47aVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWNOV47b--------------------YVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWNOV47cVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWNOV47dVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWNOV47aQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIINOV47bQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIINOV47cQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIINOV47dQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIINOV47aPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFNOV47bPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFNOV47cPHHNYNAAINKYNHDIALLELDEPLVIMSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFNOV47dPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFNOV47aHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVENOV47bHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVENOV47cHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVENOV47dHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVENOV47aGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTNOV47bGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTNOV47cGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTNOV47dGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTNOV47a(SEQ ID NO: 748)NOV47b(SEQ ID NO: 750)NOV47c(SEQ ID NO: 752)NOV47d(SEQ ID NO: 754)

Further analysis of the NOV47a protein yielded the following properties shown in Table 47C.

TABLE 47CProtein Sequence Properties NOV47aSignalP analysis:Cleavage site between residues 26 and 27PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 1; neg.chg 1H-region: length 16; peak value 9.84PSG score: 5.44GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1) : −2.46possible cleavage site: between 25 and 26>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 1Number of TMS(s) for threshold 0.5: 1INTEGRAL Likelihood = −2.50 Transmembrane 14-30PERIPHERAL Likelihood = 2.07 (at 219)ALOM score: −2.50 (number of TMSs: 1)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 21Charge difference: −2.5 C(−1.5) - N( 1.0)N >= C: N-terminal side will be inside>>> membrane topology: type 2 (cytoplasmic tail 1 to 14)MITDISC:discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):4.83Hyd Moment(95):6.44G content:2D/E content:2S/T content:3Score: −6.32Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 13 QRV|NMNUCDISC: discrimination of nuclear localization signalspat4: RPKR (4) at 43pat7: nonebipartite: nonecontent of basic residues: 10.0%NLS Score: −0.22KDEL:ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: QRVNKKXX-like motif in the C-terminus: KTKLSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regions 58 N 0.51 59 L 0.51 60 E 0.51 61 R 0.51 62 E 0.51 63 C 0.51 64 M 0.51 65 E 0.51 66 E 0.51 67 K 0.51 68 C 0.51 69 S 0.51 70 F 0.51 71 E 0.51 72 E 0.51 73 A 0.51 74 R 0.51 75 E 0.51 76 V 0.51 77 F 0.51 78 E 0.51 79 N 0.51 80 T 0.51 81 E 0.51 82 R 0.51 83 T 0.51 84 T 0.51 85 E 0.51total: 28 residues-------------------------Final Results (k = 9/23):34.8%: mitochondrial30.4%: cytoplasmic 8.7%: Golgi 8.7%: nuclear 4.3%: vacuolar 4.3%: extracellular, including cell wall 4.3%: vesicles of secretory system 4.3%: endoplasmic reticulum>> prediction for CG55806-04 is mit (k = 23)

A search of the NOV47a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 47D.

TABLE 47DGeneseq Results for NOV47aNOV47aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB99529Amino acid sequence of human1..418416/461 (90%)0.0Factor IX - Homo sapiens, 4611..461416/461 (90%)aa. [W020028609]-A2, 31-Oct.-2002]ABB81908Protein relating to the invention1..418416/461 (90%)0.0#1 - Unidentified, 461 aa.1..461416/461 (90%)[RU2181147-C2, 10-Apr.-2002]AAY97295Human clotting factor IX - Homo1..418416/461 (90%)0.0sapiens, 461 aa. [W0200049147-1..461416/461 (90%)A1, 24-Aug.-2000]AAO21524Protein of human factor IX -1..418408/462 (88%)0.0Homo sapiens, 461 aa.1..461409/462 (88%)[WO200240544-A2, 23-May-2002]ABP53571Human NOV3 protein SEQ ID1..418391/418 (93%)0.0NO:6 - Homo sapiens, 394 aa.1..394392/418 (93%)[WO200262999-A2, 15-Aug.-2002]

In a BLAST search of public sequence databases, the NOV47a protein was found to have homology to the proteins shown in the BLASTP data in Table 47E.

TABLE 47EPublic BLASTP Results for NOV47aNOV47aIdentities/ProteinResidues/Similarities forAccessionProtein/Matchthe MatchedExpectNumber/Organism/LengthResiduesPortionValueCAA00205FACTOR IX -1..418416/461 (90%)0.0Homo sapiens1..461416/461 (90%)(Human), 461 aa.Q95ND7Coagulation factor1..418415/461 (90%)0.0XI - Pantroglodytes1..461416/461 (90%)(Chimpanzee),461 aa.P00740Coagulation factor1..418415/461 (90%)0.0IX precursor1..461415/461 (90%)(EC 3.4.21.22)(Christmas factor) -Homo sapiens(Human), 461 aa.Q14316F9 (Coagulation6..418411/456 (90%)0.0factor IX (Plasma1..456411/456 (90%)THROMBO-PLASTICcomponent,christmasdisease,HAEMOPHILIAB))(Factor IX) -Homo sapiens(Human), 456 aa.CAA01607FACTOR IX6..418408/456 (89%)0.0PROTEIN - Homo1..456408/456 (89%)sapiens (Human),456 aa.

PFam analysis indicates that the NOV47a protein contains the domains shown in the Table 47F.

TABLE 47FDomain Analysis of NOV47aIdentities/NOV47aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect Valuegla 52..9326/42 (62%)1.1e-1840/42 (95%)EGF97..12816/47 (34%)1.9e-0625/47 (53%)trypsin184..411109/263 (41%)4.4e-92197/263 (75%)

Example 48

The NOV48 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 48A.

TABLE 48ANOV48 Sequence AnalysisNOV48a, CG55828-02SEQ ID NO: 7591439 bpDNA SequenceORF Start: ATG at 35ORF Stop: TGA at 1406TCATCCACAGCCATCATATAAAGGTTTTGGCATCATGTTTGGGAAGAAAAAGAAAAAGATTGAAATATCTGGCCCGTCCAACTTTGAACACAGGGTTCATACTGGGTTTGATCCACAAGAGCAGAAGTTTACCGGCCTTCCCCAGCAGTGGCACAGCCTGTTAGCAGATACGGCCAACAGGCCAAAGCCTATGGTGGACCCTTCATGCATCACACCCATCCAGCTGGCTCCTATGAAGGTGGATTACGATCGAGCACAGATGGTCCTCAGCCCTCCACTGTCAGGGTCTGACACCTACCCCAGGGGCCCTGCCAAACTACCTCAAAGTCAAAGCAAATCGGGCTATTCCTCAAGCAGTCACCAGTACCCGTCTGGGTACCACAAAGCCACCTTGTACCATCACCCCTCCCTGCAGAGCAGTTCGCAGTACATCTCCACGGCTTCCTACCTGAGCTCCCTCAGCCTCTCATCCAGCACCTACCCGCCGCCCAGCTGGGGCTCCTCCTCCGACCAGCAGCCCTCCAGGGTGTCCCATGAACAGTTTCGGGCGGCCCTGCAGCTGGTGGTCAGCCCAGGAGACCCCAGGGAATACTTGGCCAACTTTATCAAAATCGGGGAAGGCTCAACCGGCATCGTATGCATCGCCACCGAGAAACACACAGGGAAACAAGTTGCAGTGAAGAAAATGGACCTCCGGAAGCAACAGAGACGAGAACTGCTTTTCAATGAGGTCGTGATCATGCGGGATTACCACCATGACAATGTGGTTGACATGTACAGCAGCTACCTTGTCGGCGATGAGCTCTGGGTGGTCATGGAGTTTCTAGAAGGTGGTGCCTTGACAGACATTGTGACTCACACCAGAATGAATGAAGAACAGATAGCTACTGTCTGCCTGTCAGTTCTGAGAGCTCTCTCCTACCTTCATAACCAAGGAGTGATTCACAGGGACATAAAAAGTGACTCCATTCTCCTGACAAGCGATGGCCGGATAAAGTTGTCTGATTTTGGTTTCTGTGCTCAAGTTTCCAAAGAGGTGCCGAAGAGGAAATCATTGGTTGGCACTCCCTACTGGATGGCCCCTGAGGTGATTTCTAGGCTACCTTATGGGACAGAGGTGGACATCTGGTCCCTCGGGATCATGGTGATAGAAATGATTGATGGCGAGCCCCCCTACTTCAATGAGCCTCCCCTCCAGGCGATGCGGAGGATCCGGGACAGTTTACCTCCAAGAGTGAAGGACCTACACAAGGTTTCTTCAGTGCTCCGGGGATTCCTAGACTTGATGTTGGTGAGGGAGCCCTCTCAGAGAGCAACAGCCCAGGAACTCCTCGGACATCCATTCTTAAAACTAGCAGGTCCACCGTCTTGCATCGTCCCCCTCATGAGACAATACAGGCATCACTGAGCAGAGGATTCGTGTAGGTGGCAAAGCTAGANOV48a,CG55828-02Protein SequenceSEQ ID NO: 760457 aaMW at 51352.3kDMFGKKKKKIEISGPSNFEHRVHTGFDPQEQKFTGLPQOWHSLLADTANRPKPMVDPSCITPIQLAPMKVDYDRAQMVLSPPLSGSDTYPRGPAKLPQSQSKSGYSSSSHQYPSGYHKATLYHHPSLQSSSQYISTASYLSSLSLSSSTYPPPSWGSSSDQQPSRVSHEQFRAALQLVVSPGDPREYLANFIKIGEGSTGIVCIATEKHTGKQVAVKKMDLRKQQRRELLFNEVVIMRDYHHDNVVDMYSSYLVGDELWVVMEFLEGGALTDIVTHTRNNEEQIATVCLSVLRALSYLHNQGVIHRDIKSDSILLTSDGRIKLSDFGFCAQVSKEVPKRKSLVGTPYWMAPEVISRLPYGTEVDIWSLGIMVIEMIDGEPPYFNEPPLQAMRRIRDSLPPRVKDLHKVSSVLRGFLDLMLVREPSQRATAQELLGHPFLKLAGPPSCIVPLMRQYRHHNOV48b, CG55828-01SEQ ID NO: 7614796 bpDNA SequenceORF Start: ATG at 549ORF Stop: TGA at 1833NCGAAAACCCGGAGCAGCTGCGTACGCTCATGGACAGTCCTCCGAGGGGCGAAGCCGGGCAGCTGGGCATGCTCAGTAGCTGGGGGAGGTTTGGGTGGAGAGTAGAAAGCTGTGGCTCTGCCTCTCATCCCCTCCCGCTGGCCCCCGCCCCCCTTGCCCCTACCCAGCCAGTAGTAGTTCCCCAGCGTGCGCCCGGGGAGACCGGGAACATGGCGCTGGGAGCGCTGTAGCAGCTGAGAAGGGGCTGAGGCACCGCCGCTTCGCTGACAGCCGGCCACCAGATGTTCATGCATTCTAGAGAAAGTGGAAAACTTAGAAGCCTAATTAATGACTGTCTTCTGGACCTCTGAGACCATGTTTCTAGTGTTTTCCGTGGAATATTATCAGAAATACACTGTGGTGAAATGCTTCCACCTCTTGCTAAAATGAACACTGAGGAAAAATGAAGAAGACTGACAAGCACCAGCGAAAAGTTGCAGAATAGAAATAGCCACACTCCTCTGGAGTCTTTAATTCATCCACAGCCATCATATAAAGGTTTTGGCATCATGTTTGGGAAGAAAAAGAAAAAGATTGAAATATCTGGCCCGTCCAACTTTGAACACAGGGTTCATACTGGGTTTGATCCACAAGAGCAGAAGTTTACCGGCCTTCCCCAGCAGTGGCACAGCCTGTTAGCAGATACGGCCAACAGGCCAAAGCCTATGGTGGACCCTTCATGCATCACACCCATCCAGCTGGCTCCTATGAAGACAATCGTTAGAGGAAACAAACCCTGCAAGGAAACCTCCATCAACGGCCTGCTAGAGGATTTTGACAACATCTCGGTGACTCGCTCCAACTCCCTAAGGAAAGAAAGCCCACCCACCCCAGATCAGGGAGCCTCCAGCCACGGTCCAGGCCACGCGGAAGAAAATGGCTTCATCACCTTCTCCCAGTATTCCAGCGAATCCGATACTACTGCTGACTACACGACCGAAAAGTACAGGGAGAAGAGTCTCTATGGAGATGATCTGGATCCGTATTATAGAGGCAGCCACGCAGCCAAGCAAAATGGGCACGTAATGAAAATGAAGCACGGGGAGGCCTACTATTCTGAGGTGAAGCCTTTGAAATCCGATTTTGCCAGATTTTCTGCCGATTATCACTCACATTTGGACTCACTGAGCAAACCAAGTGAATACAGTGACCTCAAGTGGGAGTATCAGAGAGCCTCGAGTAGCTCCCCTCTGGATTATTCATTCCAATTCACACCTTCTAGAACTGCAGGGCCAGCGGGTGCTCCAAAGGAGAGCCTGGCGTACAGTGAAAGTGAATGGGGACCCAGCCTGGATGACTATGACAGGAGGCCAAAGTCTTCGTACCTGAATCAGACAAGCCCTCAGCCCACCATGCGGCAGAGGTCCAGGTCAGGCTCGGGACTCCAGGAACCGATGATGCCATTTGGAGCAAGTGCATTTAAAACCCATCCCCAAGGACACTCCTACAACTCCTACACCTACCCTCGCTTGTCCGAGCCCACAATGTGCATTCCAAAGGTGGATTACGATCCAGAACAGATGGTCCTCAGCCCTCCACTGTCAGGGTCTGACACCTACCCCAGGGGCCCTGCCAAACTACCTCAAAGTCAAAGCAAATCGGGCTATTCCTCAAGCAGTCACCAGTACCCGTCTGGGTACCACAAAGCCACCTTGTACCATCACCCCTCCCTGCAGAGCAGTTCGCAGTACATCTCCACGGCTTCCTACCTGAGCTCCCTAAGCCTCTCATCCAGCATACCCGCCGCCCAGCTGGGGCTCCTCCTCCGACCAGCAGCCCTCCAGGGTGTCCCATGAACAGTTTCGGGCGGCCCTGCAGCTGGTGGTCAGCCCAGGAGACCCCAGGGAATACTTGGCCAACTTTATCAAAATCGGGGAAGGCTCAACCGGCATCGTATGCATCGCCACCGAGAAACACACAGGGAAACAAGTTGCAGTGAAGAAAATGGACCTCCGGAAGCAACAGAGACGAGAACTGCTTTTCAATGAGGTCGTGATCATGCGGGATTACCACCATGACAATGTGGTTGACATGTACAGCAGCTACCTTGTCGGCGATGAGCTCTGGGTGGTCATGGAGTTTCTAGAAGGTGGTGCCTTGACAGACATTGTGACTCACACCAGAATGAATGAAGAACAGATAGCTACTGTCTGCCTGTCAGTTCTGAGAGCTCTGTCCTACCTTCATAACCAAGGAGTGATTCACAGGGACATAAAAAGTGACTCCATCCTCCTGACAAGCGATGGCCGGATAAAGTTGTCTGATTTTGGTTTCTGTGCTCAAGTTTCCAAAGAGGTGCCGAAGAGGAAATCATTGGTTGGCACTCCCTACTGGATGGCCCCTGAGGTGATTrCTAGGCTACCTTATGGGACAGAGGTGGACATCTGGTCCCTCGGGATCATGGTGATAGAAATGATTGATGGCGAGCCCCCCTACTTCAATGAGCCTCCCCTCCAGGCGATGCGGAGGATCCGGGACAGTTTACCTCCAAGAGTGAAGGACCTACACAAGGTTTCTTCAGTGCTCCGGGGATTCCTAGACTTGATGTTGGTGAGGGAGCCCTCTCAGAGAGCAACAGCCCAGGAACTCCTCGGACATCCATTCTTAAAACTAGCAGGTCCACCGTCTTGCATCGTCCCCCTCATGAGACAATACAGGCATCACTGAGCAGAGGATTCGTGTAGGTGGCAAAGCTAGATGAGGACATGAGAATAATTCAGGAGAACAAAAGGAAACACAGAACATGCAAAAGGCCTGTGCATTCTAGACCAGCCAATTGGTGGGACAGCGTGATGACCGGCAGGGTTCAACAGACCAGGGCATCTTCTTGTGTCTTAAACAGGCATCTCTCCACTGACAGCCGGTGTGGTCACTTGGAGAACGGCTTTAATAAGTCATTATTATATTTTTCAGCCCTTCATCCAGCAAATCAGAAGGACTCAGTACAAACTCCGTTATGATATATCCTAGCCACATGCAGGGTAACATGTAGGATTTTCTATATTGAAAGAATACTTTTCTGGCAAAAAAAAAAAAAAAAAGAAAGAAAGGAAAACAAAAAGCACTTTTTTCTTAATGGTAGCAGTATAATGTATTTTGCAACGAATTTGTAATTTTTCTGTACGATAGTTTTGATAATTTATAGTACTTTGATGTCATGTAGCCATTGTATCAGTTGAAGTAATACTTGTTTACTAGAGGAGTTTGAACAAAGCCTTTCCTACTTTTTTATCCCTTTAAGAGAACCAATGATTCTTTAGGAACTTTGAATACTGAATGACTCTCAATCACCGTCAGCTTTAGTAAAATCTCTTTCTTATCCTAACAAGTGTCTTATTTGGTGGAAGAAGAATTAAGAGTGATGGTGATGGTGTGCACGTTTCATTAATCCAACCAAAAATAATGAAATAAAATTTGAGCCACAGTATACCACTCCTTGGGATAAAGTTAAATATTTTTAAAGATCACATTTTCCATGAACGCCTCTAGTAGCAAACCATTCTTTTGCACACCACAATGTTTCCCTCAGTGCCCTTTCTCAAATGGGTACAATGTTCCCTTGTGGCACAGTATTAATCGCTATTGTTCATGTATCGTGCTGGAAGTCTGAACTGACTCTAGAGGATGAATTAGCAAGAGGGTATTTTACCAGGTATGATCTGACTTCAGTTGTGCCCATGTTATAATGTGTTTCCGACATACATTTGTCACCATTTTTAAACTCTGTATGCTAGCACACCAAACTCTTGTCTATAATTTACCTTTGTACCACAGTATTAATCGCTATTGTTCATGTATCGTGCTGGAAGTCTGAACTGACTCTAGAGGATGAATTAGCAAGAGGGTATTTTACCAGGTATGATCTGACTTCAGTTGTGCCCATGTTATAATGTGTTTCCGACATAGGAGAGTCGTGCTGCTGTCTAGATCTTCTTGAATGTTGATAAAAATGAATGACTACTACAATACATTTTGTGTTGCTTGTTGGATGAATTTGCATGTTAACTGTAGGCCAATATAGATTTGCCTTTAAAACTCTGGAAGAGCTACATAGTCATCATTAGTTTCTATTAATTATGCATCAGACAAAAGCCATTTGTTACCAAACTGGGAAAACAGAGGCTTTTCTTAACTATTTCACATACTGTAACAAATATGAATTTAAATTTGTGATAGCGCTCTGGTTGCTCTAAGCATAATTAAGAATTTTTGTAATTAATAGGTTGCTAATTATTTATCACTGCTAAAAAGGAAAAAAGGCATAAAATGACCTTCTACTGATTAGATTTTCAGTTTTCTTTCAAACTGGAAATGCCTCCATAAATATGATCTATGATTTTGCTTCATAAAACAGCAAATCAATGTTTTATGTAAAATATTAAAGCATTAATATAAATATGTGAGAATAAAAACAATCTAAATCCAGAAAATGGCAGTCCTAAATGTTCATGAGACAGATTGTATTAATTTAACCAGGACTATGTAGAAGTAGAAAGAAAAGAAAAAGAAAATCTTTTTTAAACCAGAATAAACATTAAAAACTATTGCAGAAAATAGTGGATTTTGGATTCCAAACATTTTCGACAGTGTAATGGAAATTTTTCTGTAATTTTCTTACCATCGGGTATTTTTTAAAGTATTCATTGAGTTTACCAAAAGTTACTGTAGCTTAAAAGGTTTTGTGAGCACTAACTATTGGCAGAAACTGCATTTGCAAATAAAAATAAATGTTTGCCTTTTAAAAAAAAAAAAAAAAANOV48b, CG55828-01Protein SequenceSEQ ID NO: 762428 aaMW at 47439.0kDMFGKKKKKIEISGPSNFEHRVHTGFDPQEQKFTGLPQQWHSLLADTANRPKPMVDPSCITPIQLAPMKTIVRGNKPCKETSINGLLEDFDNISVTRSNSLRKESPPTPDQGASSHGPGHAEENGFITFSQYSSESDTTADYTTEKYREKSLYGDDLDPYYRGSHAAKQNGHVMKMKHGEAYYSEVKPLKSDFARFSADYHSHLDSLSKPSEYSDLKWEYQRASSSSPLDYSFQFTPSRTAGTSGCSKESLAYSESEWGPSLDDYDRRPKSSYLNQTSPQPTMRQRSRSGSGLQEPMMPFGASAFICIHPQGHSYNSYTYPRLSEPLCIPKVDYDPAQHVLSPPLSGSDTYPRGPAKLPQSOSKSGYSSSSHQYPSGYHKATLYHHPSLQSSSQYISTASYLSSLSLSSSIPAAQLGLLLRPAALQGVPNOV48c,SNP13379517 ofSEQ ID NO: 7631439 bpCG55828-02,ORF Start: ATG at 35ORF Stop: TGA at 1406DNA SequenceSNP Pos: 149SNP Change: T to CTCATCCACAGCCATCATATAAAGGTTTTGGCATCATGTTTGGGAAGAAAAAGAAAAAGATTGAAATATCTGGCCCGTCCAACTTTGAACACAGGGTTCATACTGGGTTTGATCCACAAGAGCAGAAGTTTACCGGCCTTCCCCAGCAGCGGCACAGCCTGTTAGCAGATACGGCCAACAGGCCAAAGCCTATGGTGGACCCTTCATGCATCACACCCATCCAGCTGGCTCCTATGAAGGTGGATTACGATCGAGCACAGATGGTCCTCAGCCCTCCACTGTCAGGGTCTGACACCTACCCCAGGGGCCCTGCCAAACTACCTCAAAGTCAAAGCAAATCGGGCTATTCCTCAAGCAGTCACCAGTACCCGTCTGGGTACCACAAAGCCACCTTGTACCATCACCCCTCCCTGCAGAGCAGTTCGCAGTACATCTCCACGGCTTCCTACCTGAGCTCCCTCAGCCTCTCATCCAGCACCTACCCGCCGCCCAGCTGGGGCTCCTCCTCCGACCAGCAGCCCTCCAGGGTGTCCCATGAACAGTTTCGGGCGGCCCTGCAGCTGGTGGTCAGCCCAGGAGACCCCAGGGAATACTTGGCCAACTTTATCAAAATCGGGGAAGGCTCAACCGGCATCGTATGCATCGCCACCGAGAAACACACAGGGAAACAAGTTGCAGTGAAGAAAATGGACCTCCGGAAGCAACAGAGACGAGAACTGCTTTTCAATGAGGTCGTGATCATGCGGGATTACCACCATGACAATGTGGTTGACATGTACAGCAGCTACCTTGTCGGCGATGAGCTCTGGGTGGTCATGGAGTTTCTAGAAGGTGGTGCCTTGACAGACATTGTGACTCACACCAGAATGAATGAAGAACAGATAGCTACTGTCTGCCTGTCAGTTCTGAGAGCTCTCTCCTACCTTCATAACCAAGGAGTGATTCACAGGGACATAAAAAGTGACTCCATTCTCCTGACAAGCGATGGCCGGATAAAGTTGTCTGATTTTGGTTTCTGTGCTCAAGTTTCCAAAGAGGTGCCGAAGAGGAAATCATTGGTTGGCACTCCCTACTGGATGGCCCCTGAGGTGATTTCTAGGCTACCTTATGGGACAGAGGTGGACATCTGGTCCCTCGGGATCATGGTGATAGAAATGATTGATGGCGAGCCCCCCTACTTCAATGAGCCTCCCCTCCAGGCGATGCGGAGGATCCGGGACAGTTTACCTCCAAGAGTGAAGGACCTACACAAGGTTTCTTCAGTGCTCCGGGGATTCCTAGACTTGATGTTGGTGAGGGAGCCCTCTCAGAGAGCAACAGCCCAGGAACTCCTCGGACATCCATTCTTAAAACTAGCAGGTCCACCGTCTTGCATCGTCCCCCTCATGAGACAATACAGGCATCACTGAGCAGAGGATTCGTGTAGGTGGCAAAGCTAGANOV48c,SNP13379517 ofCG55828-02,SEQ ID NO: 764MW at 51322.3kDProtein SequenceSNP Pos: 39457 aaSNP Change: Trp to ArgMFGKKKKKIEISGPSNFEHRVHTGFDPQEQKFTGLPQQRHSLLADTANRPKPMVDPSCITPIQLAPMKVDYDRAQMVLSPPLSGSDTYPRGPAKLPQSQSKSGYSSSSHQYPSGYHKATLYHHPSLQSSSQYISTASYLSSLSLSSSTYPPPSWGSSSDQQPSRVSHEQFRAALQLVVSPGDPREYLANFIKIGEGSTGIVCIATEKHTGKQVAVKKMDLRKQQRRELLFNEVVIMRDYHHDNVVDMYSSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIATVCLSVLRALSYLHNQGVUIRDIKSDSILLTSDGRIKLSDFGFCAQVSKEVPKRKSLVGTPYWMAPEVISRLPYGTEVDIWSLGIMVIENIDGEPPYFNEPPLQAMRRIRDSLPPRVKDLHKVSSVLRGFLDLMLVREPSQRATAQELLGHPFLKLAGPPSCIVPLMRQYRHHNOV48d,SNP13376535 ofSEQ ID NO: 7651439 bpCG55828-02,ORF Start: ATG at 35ORF Stop: TGA at 1406DNA SequenceSNP Pos: 222SNP Change: A to GTCATCCACAGCCATCATATAAAGGTTTTGGCATCATGTTTGGGAAGAAAAAGAAAAAGATTGAAATATCTGGCCCGTCCAACTTTGAACACAGGGTTCATACTGGGTTTGATCCACAAGAGCAGAAGTTTACCGGCCTTCCCCAGCAGTGGCACAGCCTGTTAGCAGATACGGCCAACAGGCCAAAGCCTATGGTGGACCCTTCATGCATCACACCCATCCGGCTGGCTCCTATGAAGGTGGATTACGATCGAGCACAGATGGTCCTCAGCCCTCCACTGTCAGGGTCTGACACCTACCCCAGGGGCCCTGCCAAACTACCTCAAAGTCAAAGCAAATCGGGCTATTCCTCAAGCAGTCACCAGTACCCGTCTGGGTACCACAAAGCCACCTTGTACCATCACCCCTCCCTGCAGAGCAGTTCGCAGTACATCTCCACGGCTTCCTACCTGAGCTCCCTCAGCCTCTCATCCAGCACCTACCCGCCGCCCAGCTGGGGCTCCTCCTCCGACCAGCAGCCCTCCAGGGTGTCCCATGAACAGTTTCGGGCGGCCCTGCAGCTGGTGGTCAGCCCAGGAGACCCCAGGGAATACTTGGCCAACTTTATCAAAATCGGGGAAGGCTCAACCGGCATCGTATGCATCGCCACCGAGAAACACACAGGGAAACAAGTTGCAGTGAAGAAAATGGACCTCCGGAAGCAACAGAGACGAGAACTGCTTTTCAATGAGGTCGTGATCATGCGGGATTACCACCATGACAATGTGGTTGACATGTACAGCAGCTACCTTGTCGGCGATGAGCTCTGGGTGGTCATGGAGTTTCTAGAAGGTGGTGCCTTGACAGACATTGTGACTCACACCAGAATGAATGAAGAACAGATAGCTACTGTCTGCCTGTCAGTTCTGAGAGCTCTCTCCTACCTTCATAACCAAGGAGTGATTCACAGGGACATAAAAAGTGACTCCATTCTCCTGACAAGCGATGGCCGGATAAAGTTGTCTGATTTTGGTTTCTGTGCTCAAGTTTCCAAAGAGGTGCCGAAGAGGAAATCATTGGTTGGCACTCCCTACTGGATGGCCCCTGAGGTGATTTCTAGGCTACCTTATGGGACAGAGGTGGACATCTGGTCCCTCGGGATCATGGTGATAGAAATGATTGATGGCGAGCCCCCCTACTTCAATGAGCCTCCCCTCCAGGCGATGCGGAGGATCCGGGACAGTTTACCTCCAAGAGTGAAGGACCTACACAAGGTTTCTTCAGTGCTCCGGGGATTCCTAGACTTGATGTTGGTGAGGGAGCCCTCTCAGAGAGCAACAGCCCAGGAACTCCTCGGACATCCATTCTTAAAACTAGCAGGTCCACCGTCTTGCATCGTCCCCCTCATGAGACAATACAGGCATCACTGAGCAGAGGATTCGTGTAGGTGGCAAAGCTAGANOV48d,SNP13376535 ofCG55828-02,SEQ ID NO: 766MW at 51380.3kDProtein SequenceSNP Pos: 63457 aaSNP Change: Gln to ArgMFGKKKKKIEISGPSNFEHRVHTGFDPQEOKFTGLPQQWHSLLADTANRPKPMVDPSCITPIRLAPMKVDYDRAQMVLSPPLSGSDTYPRGPAKLPQSQSKSGYSSSSHQYPSGYHKATLYHHPSLQSSSQYISTASYLSSLSLSSSTYPPPSWGSSSDQQPSRVSHEQFRAALQLVVSPGDPREYLANFIKIGEGSTGIVCIATEKHTGQVAVKKMDLRKQQRRELLFNEVVIMRDYHHDNVVDMYSSYLVGDELWVVMEFLEGGAALTDIVTHTRNNEEQIATVCLSVLRALSYLHNQGVIHRDIKSDSILLTSDGRIKLSDFGFCAQVSKEVPKRKSLVGTPYWMAPEVISRLPYGTEVDIWSLGIMVIEMIDGEPPYFNEPPLQANRRIRDSLPPRVKDLHKVSSVLRGFLDLMLVREPSQRATAQELLGHPFLKLAGPPSCIVPLMRQYRHHNOV48e,SNP13382500 ofSEQ ID NO: 7671439 bpCG55828-02,ORF Start: ATG at 35ORF Stop: TGA at 1406DNA SequenceSNP Pos: 970SNP Change: T to CTCATCCACAGCCATCATATAAAGGTTTTGGCATCATGTTTGGGAAGAAAAAGAAAAAGATTGAAATATCTGGCCCGTCCAACTTTGAACACAGGGTTCATACTGGGTTTGATCCACAAGAGCAGAAGTTTACCGGCCTTCCCCAGCAGTGGCACAGCCTGTTAGCAGATACGGCCAACAGGCCAAAGCCTATGGTGGACCCTTCATGCATCACACCCATCCAGCTGGCTCCTATGAAGGTGGATTACGATCGAGCACAGATGGTCCTCAGCCCTCCACTGTCAGGGTCTGACACCTACCCCAGGGGCCCTGCCAAACTACCTCAAAGTCAAAGCAAATCGGGCTATTCCTCAAGCAGTCACCAGTACCCGTCTGGGTACCACAAAGCCACCTTGTACCATCACCCCTCCCTGCAGAGCAGTTCGCAGTACATCTCCACGGCTTCCTACCTGAGCTCCCTCAGCCTCTCATCCAGCACCTACCCGCCGCCCAGCTGGGGCTCCTCCTCCGACCAGCAGCCCTCCAGGGTGTCCCATGAACAGTTTCGGGCGGCCCTGCAGCTGGTGGTCAGCCCAGGAGACCCCAGGGAATACTTGGCCAACTTTATCAAAATCGGGGAAGGCTCAACCGGCATCGTATGCATCGCCACCGAGAAACACACACCCAACAAGTTGCAAGTGAAGAAAATGGACCTCCGGAAGCAACAGAGACGAGAACTGCTTTTCAATGAGGTCGTGATCATGCGGGATTACCACCATGACAATGTGGTTGACATGTACAGCAGCTACCTTGTCGGCGATGAGCTCTGGGTGGTCATGGAGTTTCTAGAAGGTGGTGCCTTGACAGACATTGTGACTCACACCAGAATGAATGAAGAACAGATAGCTACTGTCTGCCTGTCAGTTCTGAGAGCTCTCTCCTACCTTCATAACCAAGGAGTGATTCACAGGGACATAAAAAGTGACTCCATCCTCCTGACAAGCGATGGCCGGATAAAGTTGTCTGATTTTGGTTTCTGTGCTCAAGTTTCCAAAGAGGTGCCGAAGAGGAAATCATTGGTTGGCACTCCCTACTGGATGGCCCCTGAGGTGATTTCTAGGCTACCTTATGGGACAGAGGTGGACATCTGGTCCCTCGGGATCATGGTGATAGAAATGATTGATGGCGAGCCCCCCTACTTCAATGAGCCTCCCCTCCAGGCGATGCGGAGGATCCGGGACAGTTTACCTCCAAGAGTGAAGGACCTACACAAGGTTTCTTCAGTGCTCCGGGGATTCCTAGACTTGATGTTGGTGAGGGAGCCCTCTCAGAGAGCAACAGCCCAGGAACTCCTCGGACATCCATTCTTAAAACTAGCAGGTCCACCGTCTTGCATCGTCCCCCTCATGAGACAATACAGGCATCACTGAGCAGAGGATTCGTGTAGGTGGCAAAGCTAGANOV48e,SNP13382500 ofCG55828-02,SEQ ID NO: 768MW at 51352.3kDProtein SequenceSNP Pos: 312457 aaSNP Change: Ile to IleMFGKKKKKIEISGPSNFEHRVHTGFDPQEQKFTGLPQQWHSLLADTANRPKPMVDPSCITPIQLAPMKVDYDRAQMVLSPPLSGSDTYPRGPAKLPQSQSKSGYSSSSHQYPSGYHKATLYHHPSLQSSSQYISTASYLSSLSLSSSTYPPPSWGSSSDQQPSRVSHEQFRAALQLVVSPGDPREYLANFIKIGEGSTGIVCIATEKHTGKQVAVKKMDLRKQQRRELLFNEVVIMRDYHHDNVVDMYSSYLVGDELWVVMEFLEGGALTDIVTHTRNNEEQIATVCLSVLRALSYLHNQGVIHRDIKSDSILLTSDGRIKLSDFGFCAQVSKEVPKRKSLVGTPYWMAPEVISRLPYGTEVDIWSLGIMVIEMIDGEPPYFNEPPLQANRRIRDSLPPRVKDLHKVSSVLRGFLDLMLVREPSQRATAQELLGHPFLKLAGPPSCIVPLMRQYRHHNOV48f,SN1P13375705 ofSEQ ID NO: 7691439 bpCG55828-02,ORF Start: ATG at 35ORF Stop: TGA at 1406DNA SequenceSNP Pos: 1375SNP Change: C to TTCATCCACAGCCATCATATAAAGGTTTTGGCATCATGTTTGGGAAGAAAAAGAAAAAGATTGAAATATCTGGCCCGTCCAACTTTGAACACAGGGTTCATACTGGGTTTGATCCACAAGAGCAGAAGTTTACCGGCCTTCCCCAGCAGTGGCACAGCCTGTTAGCAGATACGGCCAACAGGCCAAAGCCTATGGTGGACCCTTCATGCATCACACCCATCCAGCTGGCTCCTATGAAGGTGGATTACGATCGAGCACAGATGGTCCTCAGCCCTCCACTGTCAGGGTCTGACACCTACCCCAGGGGCCCTGCCAAACTACCTCAAAGTCAAAGCAAATCGGGCTATTCCTCAAGCAGTCACCAGTACCCGTCTGGGTACCACAAAGCCACCTTGTACCATCACCCCTCCCTGCAGAGCAGTTCGCAGTACATCTCCACGGCTTCCTACCTGAGCTCCCTCAGCCTCTCATCCAGCACCTACCCGCCGCCCAGCTGGGGCTCCTCCTCCGACCAGCAGCCCTCCAGGGTGTCCCATGAACAGTTTCGGGCGGCCCTGCAGCTGGTGGTCAGCCCAGGAGACCCCAGGGAATACTTGGCCAACTTTATCAAAATCGGGGAAGGCTCAACCGGCATCGTATGCATCGCCACCGAGAAACACACAGGGAAACAAGTTGCAGTGAAGAAAATGGACCTCCGGAAGCAACAGAGACGAGAACTGCTTTTCAATGAGGTCGTGATCATGCGGGATTACCACCATGACAATGTGGTTGACATGTACAGCAGCTACCTTGTCGGCGATGAGCTCTGGGTGGTCATGGAGTTTCTAGAAGGTGGTGCCTTGACAGACATTGTGACTCACACCAGAATGAATGAAGAACAGATAGCTACTGTCTGCCTGTCAGTTCTGAGAGCTCTCTCCTACCTTCATAACCAAGGAGTGATTCACAGGGACATAAAAAGTGACTCCATTCTCCTGACAAGCGATGGCCGGATAAAGTTGTCTGATTTTGGTTTCTGTGCTCAAGTTTCCAAAGAGGTGCCGAAGAGGAAATCATTGGTTGGCACTCCCTACTGGATGGCCCCTGAGGTGATTTCTAGGCTACCTTATGGGACAGAGGTGGACATCTGGTCCCTCGGGATCATGGTGATAGAAATGATTGATGGCGAGCCCCCCTACTTCAATGAGCCTCCCCTCCAGGCGATGCGGAGGATCCGGGACAGTTTCCTCCAAAGAGTGAAGGACCTACACAAGGTTTCTTCAGTGCTCCGGGGATTCCTAGACTTGATGTTGGTGAGGGAGCCCTCTCAGAGAGCAACAGCCCAGGAACTCCTCGGACATCCATTCTTAAAACTAGCAGGTCCACCGTCTTGCATTGTCCCCCTCATGAGACAATACAGGCATCACTGAGCAGAGGATTCGTGTAGGTGGCAAAGCTAGANOV48f,SNP13375705 ofCG55828-02,SEQ ID NO: 770MW at 51352.3kDProtein SequenceSNP Pos: 447457 aaSNP Change: Ile to IleMFGKKKKKIEISGPSNFEHRVHTGFDPQEQKFTGLPQQWHSLLADTANRPKPMVDPSCITPIQLAPMKVDYDRAQMVLSPPLSGSDTYPRGPAKLPQSQSKSGYSSSSHQYPSGYHKATLYHHPSLQSSSQYISTASYLSSLSLSSSTYPPPSWGSSSDQQPSRVSHEQFRAALQLVVSPGDPREYLANFIKIGEGSTGIVCIATEKHTGKQVAVKKMDLRKQQRRELLFNEVVIMRDYHHDNVVDMYSSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIATVCLSVLRALSYLHNQGVIHRDIKSDSILLTSDGRIKLSDFGFCAQVSKEVPKRKSLVGTPYWMAPEVISRLPYGTEVDIWSLGIMVIEMIDGEPPYFNEPPLQANRRIRDSLPPRVKDLHKVSSVLRGFLDLMILVREPSQRATAQELLGHPFLKLAGPPSCIVPLMRQYRHH

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 48B.

TABLE 48BComparison of the NOV48 protein sequences.NOV48aMFGKKKKKIEISGPSNFEHRVHTGFDPQEQKFTGLPQQWHSLLADTANRPKPMVDPSCITNOV48bMFGKKKKKIEISGPSNFEHRVHTGFDPQEQKFTGLPQQWHSLLADTANRPKPMVDPSCITNOV48aPIQLAPMKVDYDRAQMVLSPPLSGSDTYPRGPAKLPQSQSKSGYSSSSHQYPSGYHKATLNOV48bPIQLAPMKTIVRGNKPCKETSING-LLEDFDNISVTRSNSLRKESPPTPDQGASSHGPGHNOV48aYHHPSLQSSSQYISTASYLSSLSLSSSTYPPPSWGSSSDQQPSRVSHEQFRAALQLVVSPNOV48bAEENGFITFSQYSSESD--TTADYTTEKYREKSLYGDDLDPYYRGSHAAKQNGHVMKMKHNOV48aGDPREYLANFIKIGEGSTGIVCIATEKHTGKQVAVKKMDLRKQQRRELLFNEVVIMRDYHNOV48bG-----EAYYSEVKPLKSDFARFSADYHSHLDSLSKPSEYS-DLKWEYQRASSSSPLDYSNOV48aHDNVVDMYS-SYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIATVCLSVLRALSYLHNNOV48bFQFTPSRTAGTSGCSKESLAYSESEWGPSLDDYDRRPKSS-------------YLNQTSPNOV48aQGVIHRDIKSDSILLTSDGRIKLSDFGFCAQVSKEVPKRKSLVGTPYWMAPEVISRLPYGNOV48bQPTMRQRSRS------GSG-LQEPMMPFGASAFKTHPQGHSYNSYTYPRLSEPTMCIP--NOV48aTEVDIWSLGIMVIEMIDGEPPYFNEPPLQAMRRIRDSLPPRVKDLHKVSSVLRGFLDLMLNOV48b-KVDYDPAQMVLSPPLSGSDTYPRGP--AKLPQSQSKSGYSSSSHQYPSGYHKATLYHHPNOV48aVREPS-QRATAQELLGHPFLKLAGPPSCIVPLMRQYRHH---NOV48bSLQSSSQYISTASYLSSLSLSSSIPAAQLGLLLRPAALQGVPNOV48a(SEQ ID NO: 760)NOV48b(SEQ ID NO: 762)

Further analysis of the NOV48a protein yielded the following properties shown in Table 48C.

TABLE 48CProtein Sequence Properties NOV48aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 5; neg.chg 1H-region: length 7; peak value −2.19PSG score: −6.59GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −7.22possible cleavage site: between 44 and 45>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) .. fixedPERIPHERAL Likelihood = 2.54 (at 257)ALOM score: 2.54 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment (75):3.66Hyd Moment(95):6.70G content:2D/E content:2S/T content:2Score: −7.66Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: KKKK (5) at 4pat4: KKKK (5) at 5pat4: PKRK (4) at 336pat7: PKRKSLV (5) at 336bipartite: nonecontent of basic residues: 11.2%NLS Score: 0.84KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 76.7COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):78.3%: nuclear13.0%: cytoplasmic 4.3%: mitochondrial 4.3%: peroxisomal>> prediction for CG55828-02 is nuc (k = 23)

A search of the NOV48a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 48D.

TABLE 48DGeneseq Results for NOV48aNOV48aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAB65705Novel protein kinase, SEQ ID 56..457393/402 (97%)0.0NO: 234 - Homo sapiens, 719 aa.319..719393/402 (97%)[WO200073469-A2, 07-Dec.-2000]AAM38963Human polypeptide SEQ ID NO 56..457392/402 (97%)0.02108 - Homo sapiens, 719 aa.319..719393/402 (97%)[WO200153312-A1, 26-Jul.-2001]AAE02187Human p2l-activatedkinase 5 56..457391/402 (97%)0.0(PAK5) protein - Homo sapiens,319..719392/402 (97%)719 aa. [WO200136602-A2, 25-May-2001]AAG67825Human P21-active kinase 60 56..457355/402 (88%)0.0protein - Homo sapiens, 547 aa.147..547358/402 (88%)[CN1298009-A, 06-Jun.-2001]ABG19308Novel human diagnostic protein150..455253/306 (82%)e-146#19299 -Homo sapiens, 620 aa.313..618276/306(89%)[WO200175067-A2, 11-Oct.-2001]

In a BLAST search of public sequence databases, the NOV48a protein was found to have homology to the proteins shown in the BLASTP data in Table 48E.

TABLE 48EPublic BLASTP Results for NOV48aNOV48aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9P286Serine/threonine-protein kinase 56..457393/402 (97%)0.0PAK 7 (EC 2.7.1.-) (p21-activated319..719393/402 (97%)kinase 7) (PAK-7) (PAK-5) -Homo sapiens (Human), 719 aa.Q8TB93P21(CDKN1A)-activated kinase 56..457392/402 (97%)0.07 - Homo sapiens (Human),319..719392/402 (97%)719 aa.Q8C015Serine/threonine-protein kinase 56..457382/402 (95%)0.0PAK 5 - Mus musculus (Mouse),319..719389/402 (96%)719 aa.Q8BVB0Serine/threonine-protein kinase 56..457381/402 (94%)0.0PAK 5 - Mus musculus (Mouse),319..719388/402 (95%)719 aa.Q9ULS8Hypothetical protein KIAA1142 - 1..455317/460 (68%)e-174Homo sapiens (Human), 467 aa30..465359/460 (77%)(fragment).

PFam analysis indicates that the NOV48a protein contains the domains shown in the Table 48F.

TABLE 48FDomain Analysis of NOV48aIdentities/PfamSimilaritiesExpectDomainNOV48a Match Regionfor the Matched RegionValuePBD 11..69 22/64(34%)1.3e-10 44/64 (69%)pkinase187..438 91/297 (31%)7.8e-83200/297 (67%)

Example 49

The NOV49 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 49A.

TABLE 49ANOV49 Sequence AnalysisNOV49a, CG55980-02SEQ ID NO: 771972 bpDNA SequenceORF Start: ATG at 18ORF Stop: TAA at 954CTCATATCTCCCTCATTATGTCTGTTCTCAATAACTCCGAAGTCAAGCTTTTCCTTCTGATTGGGATCCCAGGACTGGAACATGCCCACATTTGGTTCTCCATCCCCATTTGCCTCATGTACCTGCTTGCCATCATGGGCAACTGCACCATTCTCTTTATTATAAAGACAGAGCCCTCGCTTCATGAGCCCATGTATTATTTCCTTGCCATGTTGGCTGTCTCTGACATGGGCCTGTCCCTCTCCTCCCTTCCTACCATGTTGAGGGTCTTCTTGTTCAATGCCATGGGAATTTCACCTAATGCCTGCTTTGCTCAAGAATTCTTCATTCATGGATTCACTGTCATGGAATCCTCAGTACTTCTAATTATGTCTTTGGACCGCTTTCTTGCCATTCACAATCCCTTAAGATACAGTTCTATCCTCACTAGCAACAGGGTTGCTAAAATGGGACTTATTTTAGCCATTAGGAGCATTCTCTTAGTGATTCCATTTCCCTTCACCTTAAGGAGATTAAAATATTGTCAAAAGAATCTTCTTTCTCACTCATACTGTCTTCATCAGGATACCATGAAGCTGGCCTGCTCTGACAACAAGACCAATGTCATCTATGGCTTCTTCATTGCTCTCTGTACTATGCTGGACTTGGCACTGATTGTTTTGTCTTATGTGCTGATCTTGAAGACTATACTCAGCATTGCATCTTTGGCAGAGAGGCTTAAGGCCCTAAATACCTGTGTCTCCCACATCTGTGCTGTGCTCACCTTCTATGTGCCCATCATCACCCTGGCTGCCATGCATCACTTTGCCAAGCACAAAAGCCCTCTTGTTGTGATCCTTATTGCAGATATGTTCTTGTTGGTGCCGCCCCTTATGAACCCCATTGTGTACTGTGTAAAGACTCGACAAATCTGGGAGAAGATCTTGGGGAAGTTGCTTAATGTATGTGGGAGATAAGAACTTGAACAATTAGNOV49a, CG55980-02Protein SequenceSEQ ID NO: 772312 aaMW at 35131.1kDMSVLNNSEVKLFLLIGIPGLEHAHIWFSIPICLMYLLAIMGNCTILFIIKTEPSLHEPMYYFLAMLAVSDMGLSLSSLPTMLRVFLFNAMGISPNACFAQEFFIHGFTVMESSVLLIMSLDRFLAIHNPLRYSSILTSNRVAXMGLILAIRSILLVIPFPFTLRRLKYCQKNLLSHSYCLHQDTMKLACSDNKTNVIYGFFIALCTMLDLALIVLSYVLILKTILSIASLAERLKALNTCVSHICAVITFYVPIITLAAMHHFAKHKSPLVVILIADMFLLVPPLNNPIVYCVKTRQIWEKILGKLLNVCGRNOV49b, CG55980-01SEQ ID NO: 773972 bpDNA SequenceORF Start: ATG at 18ORF Stop: TAA at 954CTCATATCTCCCTCATTATGTCTGTTCTCAATAACTCCGAAGTCAAGCTTTTCCTTCTGATTGGGATCCCAGGACTGGAACATGCCCACATTTGGTTCTCCATCCCCATTTGCCTCATGTACCTGCTTGCCATCATGGGCAACTGCACCATTCTCTTTATTATAAAGACAGAGCCCTCGCTTCATGAGCCCATGTATTATTTCCTTGCCATGTTGGCTGTCTCTGACATGGGCCTGTCCCTCTCCTCCCTTCCTACCATGTTGAGGGTCTTCTGTCATGGAATCCTCAGTACTTCTAATTATGTCTTTGGACCGCTTTCTTGCCATTCACAATCCCTTAATGTCATGGAATCCTCAGTACTTCTAATTATGTCTTTGGACCGCTTTCTTGCCATTCACAATCCCTTAAGATACAGTTCTATCCTCACTAGCAACAGGGTTGCTAAAATGGGACTTATTTTAGCCATTAGGAGCATTCTCTTAGTGATTCCATTTCCCTTCACCTTAAGGAGATTAAAATATTGTCAAAAGAATCTTCTTTCTCACTCATACTGTCTTCATCAGGATACCATGAAGCTGGCCTGCTCTGACAACAAGACCAATGTAATCTATGGCTTcTTCATTGCTCTCTGTACTATGCTGGACTTGGCACTGATTGTTTTGTCTTATGTGCTGATCTTGAAGACTATACTCAGCATTGCATCTTTGGCAGAGAGGCTTAAGGCCCTAAATACCTGTGTCTCCCACATCTGTGCTGTGCTCACCTTCTATGTGCCCATCATCACCCTGGCTGCCATGCATCACTTTGCCAAGCACAAAAGCCCTCTTGTTGTGATCCTTATTGCAGATATGTTCTTGTTGGTGCCGCCCCTTATGAACCCCATTGTGTACTGTGTAAAGACTCGACAAATCTGGGAGAAGATCTTGGGGAAGTTGCTTAATGTATGTGGGAGATAAGAACTTGAACAATTAGNOV49b, GG55980-01Protein SequenceSEQ ID NO: 774312 aaMW at 35131.1kDMSVLNNSEVKLFLLIGIPGLEHAHIWFSIPICLMYLLAIMGNCTILFIIKTEPSLHEPMYYFLAMLAVSDMGLSLSSLPTMLRVFLFNANGISPNACFAQEFFIHGFTVMESSVLLIMSLDRFLAIHNPLRYSSILTSNRVAXMGLILAIRSILLVIPFPFTLRRLKYCQKNLLSHSYCLHQDTMKLACSDNKTNVIYGFFIAICTMLDLALIVLSYVLILKTILSIASLAERLKALNTCVSHICAVLTFYVPIITLAAMHHFAKHKSPLVVILIADMFLLVPPLMNPIVYCVKTRQIWEKILGKLLNVCGR

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 49B.

TABLE 49BComparison of the NOV49 protein sequences.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(SEQ ID NO: 772)NOV49b(SEQ ID NO: 774)

Further analysis of the NOV49a protein yielded the following properties shown in Table 49C.

TABLE 49CProtein Sequence Properties NOV49aSignalP analysis:Cleavage site between residues 42 and 43PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 1; neg.chg 1H-region: length 10; peak value 10.00PSG score: 5.60GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.28possible cleavage site: between 23 and 24>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 8INTEGRAL Likelihood = −6.00Transmembrane 33-49INTEGRAL Likelihood = 0.32Transmembrane 62-78INTEGRAL Likelihood = −0.48Transmembrane 102-118INTEGRAL Likelihood = −5.63Transmembrane 141-157INTEGRAL Likelihood = −7.59Transmembrane 199-215INTEGRAL Likelihood = 0.42Transmembrane 218-234INTEGRAL Likelihood = −5.79Transmembrane 244-260INTEGRAL Likelihood = −8.17Transmembrane 270-286PERIPHERAL Likelihood = 2.12 (at 11)ALOM score: −8.17 (number of TMSs: 8)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 40Charge difference: −1.5 C(−0.5) - N( 1.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment (75):0.68Hyd Moment (95):3.43G content:2D/E content:2S/T content:2Score: −8.46Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.7%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found *** LKYCQKNLLSHSYCLHQDTMKL at 166 nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):66.7%: endoplasmic reticulum22.2%: mitochondrial11.1%: vesicles of secretory system>> prediction for CG55980-02 is end (k = 9)

A search of the NOV49a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 49D.

TABLE 49DGeneseq Results for NOV49aNOV49aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU85302G-coupled olfactory1..312312/312 (100%)e-178receptor #163 - Homo1..312312/312 (100%)sapiens, 312 aa.[WO200198526-A2, 27-Dec.-2001]AAU95741Human olfactory and1..312312/312 (100%)e-178pheromone Gprotein-1..312312/312 (100%)coupled receptor #228 -Homo sapiens, 312 aa.[WO200224726-A2, 28-Mar.-2002]AAB71167Human GPCRX protein1..312312/312 (100%)e-178SEQ ID 10 - Homo1..312312/312 (100%)sapiens, 312 aa.[WO200250275-A2, 27-Jun.-2002]AAB71166Human GPGRX protein1..312312/312 (100%)e-178SEQ ID 8 - Homo sapiens,1..312312/312 (100%)312 aa. [WO200250275-A2, 27-Jun.-2002]AAB71344Human GCREC-231..312312/312 (100%)e-178INCYTE ID 7472087GD11..312312/312 (100%)SEQ ID 23 - Homosapiens, 312 aa.[WO200263004-A2, 15-Aug.-2002]

In a BLAST search of public sequence databases, the NOV49a protein was found to have homology to the proteins shown in the BLASTP data in Table 49E.

TABLE 49EPublic BLASTP Results for NOV49aNOV49aIdentities/ProteinResidues/Similarities forEx-AccessionProtein/Matchthe MatchedpectNumber/Organism/LengthResiduesPortionValueQ8NH64Seven trans-1..312312/312 (100%)e-178membrane helix1..312312/312 (100%)receptor - Homosapiens (Human),312 aa.Q8VH16Olfactory receptor1..306242/308 (78%)e-141MOR8-1 -8..315272/308 (87%)Mus musculus(Mouse), 318aa.Q8VH12Olfactory receptor3..306233/306 (76%)e-134MOR8-3 -2..307262/306 (85%)Mus musculus(Mouse), 312aa.GAD37707Sequence 449 from1..306222/308 (72%)e-130Patent1..308268/308 (86%)WO0224726 -Homo sapiens(Human), 313 aa.Q8NGJ6Seven trans-1..306221/308 (71%)e-129membrane helix1..308267/308 (85%)receptor -Homo sapiens(Human), 313 aa.

PFam analysis indicates that the NOV49a protein contains the domains shown in the Table 49F.

TABLE 49FDomain Analysis of NOV49aNOV49aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_1 41..29157/277 (21%)7.4e-13169/277 (61%)

Example 50

The NOV50 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 50A.

TABLE 50ANOV50 Sequence AnalysisNOV50a, CG55988-03SEQ ID NO: 7751630 bpDNA SequenceORF Start: ATG at 1ORF Stop: TGA at 1528ATGGGGTCCCGCCACTTCGAGGGGATTTATGACCACGTGGGGCACTTCGGCAGATTCCAGAGAGTCCTCTATTTCATATGTGCCTTCCAGAACATCTCTTGTGGTATTCACTACTTGGCTTCTGTGTTCATGGGAGTCACCCCTCATCATGTCTGCAGGCCCCCAGGCAATGTGAGTCAGGTTGTTTTCCATAATCACTCTAATTGGAGTTTGGAGGACACCGGGGCCCTGTTGTCTTCAGGCCAGAAAGATTATGTTACGGTGCAGTTGCAGAATGGTGAGATCTGGGAGCTCTCAAGGTGTAGCAGGAATAAGAGGGAGAACACATCGAGTTTGGGCTATGAATACACTGGCAGTAAGAAAGAGTTTCCTTGTGTGGATGGCTACATATATGACCAGAACACATGGAAAAGCACTGCGGTGACCCAGTGGAACCTGGTCTGTGACCGAAAATGGCTTGCAATGCTGATCCAGCCCCTATTTATGTTTGGAGTCCTACTGGGATCGGTGACTTTTGGCTACTTTTCTGAGGCTAAGGAACGCCGGGTGGTCTTGTGGGCCACAAGCAGTAGCATGTTTTTGTTTGGAATAGCAGCGGCGTTTGCAGTTGATTATTACACCTTCATGGCTGCTCGCTTTTTTCTTGCCATGGTTGCAAGTGGCTATCTTGTGGTGGGGTTTGTCTATGTGATGGAATTCATTGGCATGAAGTCTCGGAAATGGGCGTCTGTCCATTTGCATTCCTTTTTTGCAGTTGGAACCCTGCTGGTGGCTTTGACAGGATACTTGGTCAGGACCTGGTGGCTTTACCAGATGATCCTCTCCACAGTGACTGTCCCCTTTATCCTGTGCTGTTGGGTGCTCCCAGAGACACCTTTTTGGCTTCTCTCAGAGGGACGATATGAAGAAGCACAAAAAATAGTTGACATCATGGCCAAGTGGAACAGGGCAAGCTCCTGTAAACTGTCAGAACTTTATCACTGGACCTACAAGGTCCTGTTAGTAATAGCCCCACTGAATGTTCAGAAGCACAACCTATCATATCTGTTTTATAACTGGAGCATTACGAAAAGGACACTTACCGTTTGGCTAATCTGGTTCACTGGAAGTTTGGGATTCTACTCGTTTTCCTTGAATTCTGTTAACTTAGGAGGCAATGAATACTTAAACCTCTTCCTCCTGGGTGTAGTGGAAATTCCCGCCTACACCTTCGTGTGCATCGCCACGGACAAGGTCGGGAGGAGAACAGTCCTGGCCTACTAACTTTTCTGCAGTGCACTGGCCTGTGGTGTCGTTATGGTGATCCCCCAGATCGCTGGCTGTGGGAAGCGGCAGCATGGTGTGTCGCCTGGCCAGCATCCTGGCGCCGTTCTCTGTGGACCTCAGCAGCATTTGGATCTTCATACCACAGTTGTTTGTTGGGACTATGGCCCTCCTGAGTGGAGTGTTAACACTAAAGCTTCCAGAAACCCTTGGGAAACGGCTAGCAACTACTTGGGAGGAGGCTGCAAAACTGGAGTCAGAGAATGAAAGCAAGTCAAGCAAATTACTTCTCACAACTAATAATAGTGGGCTGGAAAAAACGGAAGCGATTACCCCCAGGGATTCTGGTCTTGGTGAATAAATGTGCNOV50a, CG55988-03Protein SequenceSEQ ID NO: 776509 aaMW at 57300.6kDMGSRHFEGIYDHVGHPGRPQRVLYFICAFQNISCGIHYLASVFMGVTPHHVCRPPGNVSQVVFHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKKEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYFSDRLGRRVVLWATSSSMFLFGIAAAFAVDYYTFMAARFFLAMVASGYLVVGFVYVMEFIGMKSRTWASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGRYEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLTVWLIWFTGSLGFYSFSLNSVNLGGNEYLNLFLLGVVEIPAYTFVCIATDKVGRRTVLAYSLFCSALACGVVMVIPQIAGCGKRQHGVSPGQHPGAVLCGPQQHLDLHTTVVCWDYGPPEWSVNTKASRNPWETASNYLGGGCKTGVRENOV50b, GG55988-04SEQ ID NO: 7771599 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAA at 1546ATGGGGTCCCGCCACTTCGAGGGGATTTATGACCACGTGGGGCACTTCGGCAGATTCCAGAGAGTCCTCTATTTCATATGTGCCTTCCAGAACATCTCTTGTGGTATTCACTACTTGGCTTCTGTGTTCATGGGAGTCACCCCTCATCATGTCTGCAGGCCCCCAGGCAATGTGAGTCAGGTTGTTTTCCATAATCACTCTAATTGGAGTTTGGAGGACACCGGGGCCCTGTTGTCTTCAGGCCAGAAAGATTATGTTACGGTGCAGTTGCAGAATGGTGAGATCTGGGAGCTCTCAAGGTGTAGCAGGAATAAGAGGGAGAACACATCGAGTTTGGGCTATGAATACACTGGCAGTAAGAAAGAGTTTCCTTGTGTGGATGGCTACATATATGACCAGAACACATGGAAAAGCACTGCGGTGACCCAGTGGAACCTGGTCTGTGACCGAAAATGGCTTGCAATGCTGATCCAGCCCCTATTTATGTTTGGAGTCCTACTGGGATCGGTGACTTTTGGCTACTTTTCTGACAGGCTAGGACGCCGGGTGGTCTTGTGGGCCACAAGCAGTAGCATGTTTTTGTTTGGAATAGCAGCGGCGTTTGCAGTTGATTATTACACCTTCATGGCTGCTCGCTTTTTTCTTGCCATGGTTGCAAGTGGCTATCTTGTGGTGGGGTTTGTCTATGTGATGGAATTCATTGGCATGAAGTCTCGGACATGGGCGTCTGTCCATTTGCATTCCTTTTTTGCAGTTGGAACCCTGCTGGTGGCTTTGACAGGATACTTGGTCAGGACCTGGTGGCTTTACCAGATGATCCTCTCCACAGTGACTGTCCCCTTTATCCTGTGCTGTTGGGTGCTCCCAGAGACACCTTTTTGGCTTCTCTCAGAGGGACGATATGAAGAAGCACAAAAAATAGTTGACATCATGGCCAAGTGGAACAGGGCAAGCTCCTGTAAACTGTCAGAACTTTTATCACTGGACCTACAAGGTCCTGTTAGTAATAGCCCCACTGAAGTTCAGAACACAACCTATCATATCTGTTTTATAACTGGAGCATTACGAAAAGGACACTTAACCGTTTGGCTAATCTGGTTCACTGGAAGTTTGGGATTCTACTCGTTTTCCTTGAATTCTGTTAACTTAGGAGGCAATGAATACTTAAACCTCTTCCTCCTGGGTGTAGTGGAAATTCCCGCCTACACCTTCGTGTGCATCGCCACGGACAAGGTCGGGAGGAGAACAGTCCTGGCCTACTCTCTTTTCTGCAGTGCACTGGCCTGTGGTGTCGTTATGGTGATCCCCCAGAAACATTATATTTTGGGTGTGGTGACAGCTATGGTTGGAAAATTTGCCATCGGGGCAGCATTTGGTCTCATTTATCTTTATACAGCTGAGCTGTATCCAACCATTGTAAGATCGCTGGCTGTGGGAAGCGGCAGCATGGTGTGTCGCCTGGCCAGCATCCTGGCGCCGTTCTCTGTGGACCTCAGCAGCATTTGGATCTTCATACCACAGCTCCTAGGACAGCACCTTCAGGAGTAATAATGCAGGCAGTCGCTGGCAATTAAGGAGGCGCTCCATGGTGGGTCATGANOV50b, CG55988-04Protein SequenceSEQ ID NO: 778515 aaMW at 58030.0kDMGSRHFEGIYDHVGHFGRFQRVLYFICAFQNISCGIHYLASVFMGVTPHHVCRPPGNVSQVVFHNGSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKKEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYFSDRLGRRVVLWATSSSMFLFGIAAAFAVDYYTFMAARFFLAMVASGYLVVGFVYVMEFIGMKSRTWASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGRYEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLTVWLIWFTGSLGFYSFSLNSVNLGGNEYLNLFLLGVVEIPAYTFVCIATDKVGRRTVLAYSLFCSALACGVVMVIPQKHYILGVVTAMVGKFAIGAAFGLEYLETAELYTIVARSLAVGSGSMVCRLASILAPFSVDLSSIWIFIPQLLGQHLQENOY50c, CG55988-01SEQ ID NO: 7792069 bpDNA SequenceORF Start: ATG at 279ORF Stop: TAA at 1881GCTTCTAGGCCTTCTCAGTAGATGGAGCTAAGTAATATATGTATATATACTAACCCACAGATATAAATATGCTATAATTATTTCTATATTTATCCATTCGTGTATATGTTAAGATAAACATGATGGAGACCCATTCAAATTTGCTTATGTTCTTTTTCAGCCTATAGACCAGATATAATAATTAGCTTTTCTTCTCTTGCAGATTCCAGAGAGTCCTCTATTTCATATGTGCCTTCCAGAACATCTCTTGTGGTATTCACTACTTGGCTTCTGTGTTCATGGGAGTCACCCCTCATCATGTCTGCAGGCCCCCAGGCAATGTGAGTCAGGTTGTTTTCCATAATCACTCTAATTGGAGTTTGGAGGACACCGGGGCCCTGTTGTCTTCAGGCCAGAAAGATTATGTTACGGTGCAGTTGCAGAATGGTGAGATCTGGGAGCTCTCAAGGTGTAGCAGGAATAAGAGGGAGAACACATCGAGTTTGGGCTATGAATACACTGGCAGTAAGAAAGAGTTTCCTTGTGTGGATGGCTACATATATGACCAGAACACATGGAAAAGCACTGCGGTGACCCAGTGGAACCTGGTCTGTGACCGAAATGAGCTTGCAATGCTGATCCAGCCCCTATTTATGTTTGGAGTGCCTACTGGGATCGGTGACTTTTGGCTACTTTCTGACAGGCTAGGACGCCGGGTGGTCTTGTGGGCCACAAGCAGTAGCATGTTTTTGTTTGGAATAGCAGCGGCGTTTGCAGTTGATTATTACACCTTCATGGCTGCTCGCTTTTTTCTTGCCATGGTTGCAAGTGGCTATCTTGTGGTGGGGTTTTGTCTATGTGATGGAATTCATTGGCATGAAGTCTCGGACATGGGCTCTGTCCATTTGCATTCCTTTTTTGCAGTTGGAACCCTGCTGGTGGCTTTGACAGGATACTTGGTCAGGACCTGGTGGCTTTACCAGATGATCCTCTCCACAGTGACTGTCCCCTTTATCCTGTGCTGTTGGGTGCTCCCAGAGACACCTTTTTGGCTTCTCTCAGAGGGACGATATGAAGAAGCACAAAAAATAGTTGACATCATGGCCAAGTGGAACAGGGCAAGCTCCTGTAAACTGTCAGAACTTTTATCACTGGACCTACAAGGTCCTGTTAGTAATAGCCCCACTGAAGTTCAGAAGCACAACCTATCATATCTGTTTTATAACTGGAGCATTACGAAAAGGACACTTACCGTTTGGCTAATCTGGTTCACTGGAAGTTTGGGATTCTACTCGTTTTCCTTGAATTCTGTTAACTTAGGAGGCAATGAATACTTAAACCTCTTCCTCCTGGGTGTAGTGGAAATTCCCGCCTACACCTTCGTGTGCATCGCCATGGACAAGGTCGGGAGGAGAACAGTCCTGGCCTACTCTCTTTTCTGCAGTGCACTGGCCTGTGGTGTCGTTATGGTGATCCCCCAGAAACATTATATTTTGGGTGTGGTGACAGCTATGGTTGGAAAATTTGCCATCGGGGCAGCATTTGGCCTCATTTATCTTTATACAGCTGAGCTGTATCCAACCATTGTAAGATCGCTGGCTGTGGGAACGGCAGCATGGTGTGTCGCCTGGCCAGCATCCTGGCAGCCGTTCTCTGTGGACCTCAGCAGCATTTGGATCTTCATACCACAGTTGTTTGTTGGGACTATGGCCCTCCTGAGTGGAGTGTTAACACTAAAGCTTCCAGAAACCCTTGGGAAACGGCTAGCAACTACTTGGGAGGAGGCTGCAAAACTGGAGTCAGAGAATGAAAGCAAGTCAAGCAAATTACTTCTCACAACTAATAATAGTGGGCTGGAAAAAACGGAAGCGATTACCCCCAGGGATTCTGGTCTTGGTGAATAAATGTGCCATGCCTGGTGTCTAGCACCTGAAATATTATTTACCCCTAATGCCTTTGTATTAGAGGAATCTTATTCTCATCTCCATATGTTGTTTGTATGTCTTTTTAATAAATTTTGTAAGAAAATTTTAAAGCAAATATGTTATAAAAGAAATAAAAACTAAGATGAAAATTCTCAGTTTTAAAAANOV50c, GG55988-01Protein SequenceSEQ ID NO: 780534 aaMW at 59606.7kDMGVTPHHVCRPPGNVSQVVGHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKKEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYFSDRLGRRVVLWATSSSMFLFGIAAAFAVDYYTFMAARFFLAMVASGYLVVGFVYVMEFIGMKSRTWASVHLHRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLTVWLIWFTGSLGFYSFSLNSVMLGGNEYLNLFLLGVVEIPAYTFVCIAMDKVGRRTVLAYSLFCSALACGVVMVIPQKHYILGVVTANVGKFAIGAAGFLIYLYTAELYPTIVRSLAVGSGSMVCRLASILAPFSVDLSSIWIFIPQLFVGTMALLSGVLTLKLPETLGKRLATTWEEAAKLESENESKSSKLLLTTNNSGLEKTEAITPRDSGLGENOV50d, GG55988-02SEQ ID NO: 7811666 bpDNA SequenceORF Start: ATG at 76ORF Stop: TAA at 1654TTCCAGAGAGTCCTCTATTTCATATGTGCCTTCCAGAACATCTCTTGTGGTATTCACTACTTGGCTTCTGTGTTCATGGGAGTCACCCCTCATCATGTCTGCAGGCCCCCAGGCAATGTGAGTCAGGTTGTTTTCCATAATCACTCTAATTGGAGTTTGGAGGACACCGGGGCCCTGTTGTCTTCAGGCCAGAAAGATTATGTTACGGTGCAGTTGCAGAATGGTGAGATCTGGGAGCTCTCAAGGTGCAGATGGAATAAGAGGGAGAACACATCGAGTTTGGGCTATGAATACACTGGCAGTAAGAAAGAGTTTCCTTGTGTGGATGGCTACATATATGACCAGAACACATGGAAAAGCACTGCGGTGACCCAGTGGAACCTGGTCTGTGACCGAAAATCGGTTGCAATGCTGATCCAGCCCCTATTTATGTTTGGAGTCCTACTGGGATGCGGTGACTTTTGGCTACTTTCTGACAGGCTTTTTTGCCTATATGTGATTTGCAATGGGTCAGACTCCTCAATAGTTATAAATGTGAACCTTGAATATAAATCCCTATTATTTGTTTTTCAGGTTGCAAGTGGCTATCTTGTGGTGGGGTTTGTCTATGTGATGGAATTCATTGGCATGAAGTCTCGGACATGGGCGTCTGTCCATTTGCATTCCTTTTTGCAAGTTGGAACCCTGCTGGTGGCTTTGACAGGATACTTGGTCAGGACCTGGTGGCTTTACCAGATGATCCTCTCCACAGTGACTGTCCCCTTTATCCTGTGCTGTTGGGTGCTTCCCAGAGACACCTTTTGGCTTCTCTGCAGAGGACGATATGAAGAAGCACAAAAAATAGTTGACATCATGGCCAAGTGGAACAGGGCAAGCTCCTGTAAACTGTCAGAACTTTTATCACTGGACCTACAAGGTCCTGTTAGTAATAGCCCACTGAAGTTCAGAAGCAACAACCTATCATATCTGTTTTATAACTGGAGCATTACGAAAAGGACACTTACCGTTTGGCTAATCTGGTTCACTGGAAGTTTGGGATTCTACTCGTTTTCCTTGAATTCTGTTAACTTAGGAGGCAATGAATACTTAAACCTCTTCCTCACAGGTGTAGTGGAAATTCCCGCCTACACCTTCGTGTGCATCGCCATGGACAAGGTCGGGAGGAGAACAGTCCTGGCCTACTCTCTTTTCTGCAGTGCACTGGCCTGTGGTGTCGTTATGGTGATCCCCCAGGTGAGTTATCTTCTGGGTGTGGTGACAGCTATGGTTGGAAAATTTGCCATCGGGGCAGCATTTGGCCTCATTTATCTTTATACAGCTGAGCTGTATCCAACCATTGTAAGGTCGCTGGCTGTGGGAAGCGGCAGCATGGTGTGTCGCCTGGCCAGCATCCTGGCGCCGTTCTCTGTGGACCTCAGCAGCATTTGGATCTTCATACCACAGTTGTTTGTTGGGACTATGGCCCTCCTGAGTGGAGTGTTAACACTAAAGCTTCCAGAAACCCTTGGGAAACGGCTAGCAACTACTTGGGACCAGGCTGCAAAACTGGAGTCAGAGAATGAAAGCAAGTCAAGCAAATTACTTCTCACAACTAATAATAGTGGGCTGGAAAAAACGGAAGCGATTACCCCCAGGGATTCTGGTCTTGGTGAATAAATGTGCCATGNOV50d, CG55988-02Protein SequenceSEQ ID NO: 782526 aaMW at 58820.8kDMGVTPHHVCRPPGNVSQVVFHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKKEFPCVDGYIYDQNTWSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYAFSDRLFCLYVICNGVRLLNSYKCDLEYKSLLFVFQVASGYLVVGFVYVMEFIGMKSRTWASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGRYEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLTVWLIWFTGSLGYSFSLNSVNLGGNEYALNLFLTGVVEIPAYTFVCIAMDKVGRRTVLAYSLFCSALACGVVMVIPQVSYLLGVVTAMVGKFAIGAAFGLIYLYTAELYPTIVRSLAVGSGSMVCRLASILAPFSVDLSSIWIFIPQLFVGTMALLSGVLTLKLPETLGKRLATTWEEAAKLESENESKSSKLLLTTNNSGLEKTEAITPRDSGLGE

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 50B.

TABLE 50BComparison of the NOV50 protein sequences.NOV50aMGSRHFEGIYDHVGHFGRFQRVLYFICAFQNISCGIHYLASVFMGVTPHHVCRPPGNVSQNOV50bMGSRHFEGIYDHVGHFGRFQRVLYFICAFQNISCGIHYLASVFMGVTPHHVCRPPGNVSQNOV50c-------------------------------------------MGVTPHHVCRPPGNVSQNOV50d-------------------------------------------MGVTPHHVCRPPGNVSQNOV50aVVFHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKNOV50bVVFHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKNOV50cVVFHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKNOV50dVVFHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKNOV50aKEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYFSDRLGNOV50bKEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYFSDRLGNOV50cKEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYFSDRLGNOV50dKEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLANLIQPLFMFGVLLGSVTFGYFSDRLFNOV50aRRVVLWATSSSMFLFGIAAAFAVDYYTFMAARFFLAMVASGYLVVGFVYVMEFIGMKSRTNOV50bRRVVLWATSSSMFLFGIAAAFAVDYYTFMAARFFLAMVASGYLVVGFVYVMEFIGMKSRTNOV50cRRVVLWATSSSMFLFGIAAAFAVDYYTFMAARFFLANVASGYLVVGFVYVMEFIGMKSRTNOV50dCLYVICN--------GVRLLNSYKCDLEYKSLLFVFQVASGYLVVGFVYVMEFIGMKSRTNOV50aWASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGRNOV50bWASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGRNOV50cWASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGRNOV50dWASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGRNOV50aYEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLNOV50bYEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLNOV50cYEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLNOV50dYEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLNOV50aTVWLIWFTGSLGFYSFSLNSVNLGGNEYLNLFLLGVVEIPAYTFVCIATDKVGRRTVLAYNOV50bTVWLIWFTGSLGFYSFSLNSVNLGGNEYLNLFLLGVVEIPAYTFVCIATDKVGRRTVLAYNOV50cTVWLIWFTGSLGFYSFSLNSVNLGGNEYLNLFLLGVVEIPAYTFVCIAMDKVGRRTVLAYNOV50dTVWLIWFTGSLGFYSFSLNSVNLGGNEYLNLFLTGVVEIPAYTFVCIAMDKVGRRTVLAYNOV50aSLFCSALACGVVMVIPQI--------AGCGKRQHGVSPG--------QHP--------G-NOV50bSLFCSALACGVVMVIPQKHYILGVVTAMVGKFAIGAAFGLIYLYTAELYPTIVRSLAVGSNOV50cSLFCSALACGVVMVIPQKHYILGVVTAMVGKFAIGAAFGLIYLYTAELYPTIVRSLAVGSNOV50dSLFCSALACGVVMVIPQVSYLLGVVTAMVGKFAIGAAFGLIYLYTAELYPTIVRSLAVGSNOV50a-AVLCGPQQHLDLHTTVVC--WDYGP------------------PE---------WSVNTNOV50bGSMVCRLASILAPFSVDLSSIWIFIPQLLGQHLQE-------------------------NOV50cGSMVCRLASILAPFSVDLSSIWIFIPQLFVGTMALLSGVLTLKLPETLGKRLATTWEEAANOV50dGSMVCRLASILAPFSVDLSSIWIFIPQLFVGTMALLSGVLTLKLPETLGKRLATTWEEAANOV50aKASRNPWETASNYLGGGCKTGVRE-------------NOV50b-------------------------------------NOV50cKLESENESKSSKLLLTTNNSGLEKTEAITPRDSGLGENOV50dKLESENESKSSKLLLTTNNSGLEKTEAITPRDSGLGENOV50a(SEQ ID NO: 776)NOV50b(SEQ ID NO: 778)NOV50c(SEQ ID NO: 780)NOV50d(SEQ ID NO: 782)

Further analysis of the NOV50a protein yielded the following properties shown in Table 50C.

TABLE 50CProtein Sequence Properties NOV50aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 11; pos.chg 1; neg.chg 2H-region: length 6; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −1.51possible cleavage site: between 34 and 35>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 7INTEGRAL Likelihood =−3.03Transmembrane 154-170INTEGRAL Likelihood =−1.12Transmembrane 183-199INTEGRAL Likelihood =−4.57Transmembrane 214-230INTEGRAL Likelihood =−3.08Transmembrane 248-264INTEGRAL Likelihood =−5.89Transmembrane 272-288INTEGRAL Likelihood =−4.51Transmembrane 391-407INTEGRAL Likelihood =−5.10Transmembrane 419-435PERIPHERAL Likelihood = 2.81 (at 360)ALOM score: −5.89 (number of TMSs: 7)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 161Charge difference: 0.0 C( 2.0) - N( 2.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment (75):7.38Hyd Moment (95):9.73G content:2D/E content:2S/T content:1Score: −6.19Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 14 SRH|FENUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.5%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: GSRHnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylatiOn pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found *** LVCDRKWLAMLIQPLFMFGVLL at 146 nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):77.8%: endoplasmic reticulum22.2%: mitochondrial>> prediction for CG55988-03 is end (k = 9)

A search of the NOV50a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 50D.

TABLE 50DGeneseq Results for NOV50aNOV50aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABP74100Human TRICH SEQ ID NO 5 - 1..437436/437 (99%)0.0Homo sapiens, 577 aa. 1..437436/437 (99%)[WO200246415-A2, 13-Jun.-2002]AAM00930Human bone marrow protein, 1..437436/437 (99%)0.0SEQ ID NO: 406 - Homo sapiens, 7..443436/437 (99%)584 aa. [WO200153453-A2, 26-Jul.-2001]AAM78367Human protein SEQ ID NO 1029 1..437436/437 (99%)0.0- Homo sapiens, 577 aa. 1..43743 6/437 (99%)[WO200157190-A2, 09-Aug.-2001]AAM79351Human protein SEQ ID NO 2997 1..437432/438 (98%)0.0- Homo sapiens, 585 aa. 7..444432/438 (98%)[WO200157190-A2, 09-Aug.-2001]AAB43038Human OREX 0RiF280218..437419/420 (99%)0.0polypeptide sequence SEQ ID 1..420419/420 (99%)NO:5604 - Homo sapiens, 560 aa.[WO200058473-A2, 05-Oct.-2000]

In a BLAST search of public sequence databases, the NOV50a protein was found to have homology to the proteins shown in the BLASTP data in Table 50E.

TABLE 50EPublic BLASTP Results for NOV50aNOV50aIdentities/ProteinResidues/Similarities forEx-AccessionProtein/Matchthe MatchedpectNumber/Organism/LengthResiduesPortionValueQ96RU0Organic cation 1..437437/437 (100%)0.0transporter 1..437437/437 (100%)OKB1 - Homosapiens (Human),577 aa.AAH47565Organic cation 1..437436/437 (99%)0.0transporter OKB1 - 1..437436/437 (99%)Homo sapiens(Human), 577 aa.Q8IZD5Putative 1..437436/437 (99%)0.0transmembrane 1..437436/437 (99%)transporter FLIPT2 - Homosapiens (Human),577 aa.014567WUGSC:18..437419/420 (99%)0.0RG331P03.1protein -Homo sapiens 1..420419/420 (99%)(Human), 456 aa(fragment).QSIUG8Carnitine transporter18..437387/420 (92%)0.02 - Homo16..403387/420 (92%)sapiens (Human),543 aa.

PFam analysis indicates that the NOV50a protein contains the domains shown in the Table 50F.

TABLE 50FDomain Analysis of NOV50aIdentities/NOV50aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect Valuesugar_tr120..499 67/493 (14%)7.8e-05242/493 (49%)

Example 51

The NOV51 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 51A.

TABLE 51ANOV51 Sequence AnalysisNOV51a, CG56071-01SEQ ID NO: 7833092 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAG at 3073ATGGAGCCCTCCAGAGCGCTTCTCGGCTGCCTAGCGAGCGCCGCCGCTGCCGCCCCGCCGGGGGAGGATGGAGCAGGGGCCGGGGCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGCGGCGGCGGCGGTGGGCCCCGGGGAGCTGGGCTGCGACGCGCCGCTGCCCTACTGGACGGCCGTGTTCGAGTACGAGGCGGCGGGCGAGGACGAGCTGACCCTGCGGCTGGGCGACGTGGTGGAGGTGCTGTCCAAGGACTCGCAGGTGTCCGGCGACGAGGGCTGGTGGACCGGGCAGCTGAACCAGCGGGTGGGCATCTTCCCCAGCAACTACGTGACCCCGCGCAGCGCCTTCTCCAGCCGCTGCCAGCCCGGCGGCGAAATTGATTTTGCGGAGCTCACCTTGGAAGAGATTATTGGCATCGGGGGCTTTGGGAAGGTCTATCGTGCTTTCTGGATAGGGGATGAGGTTGCTGTGAAAGCAGCTCGCCACGACCCTGATGAGGACATCAGCCAGACCATAGAGAATGTTCGCCAAGAGGCCAAGCTCTTCGCCATGCTGAAGCACCCCAACATCATTGCCCTAAGAGGGGTATGTCTGAAGGAGCCCAACCTCTGCTTGGTCATGGAGTTTGCTCGTGGAGGACCTTTGAATAGAGTGTTATCTGGGAAAAGGATTCCCCCAGACATCCTGGTGAATTGGGCTGTGCAGATTGCCAGAGGGATGAACTACTTACATGATGAGGCAATTGTTCCCATCATCCACCGCGACCTTAAGTCCAGCAACGTATTGATCCTCCAGAAGGTGGAGAATGGAGACCTGAGCAACAAGATTCTGAAGATCACTGATTTTGGCCTGGCTCGGGAATGGCACCGAACCACCAAGATGAGTGCGGCAGGGACGTATGCTTGGATGGCACCCGAAGTCATCCGGGCCTCCATGTTTTCCAAAGGCAGTGATGTGTGGAGCTATGGGGTGCTACTTTGGGAGTTGCTGACTGGTGAGGTGCCCTTTCGAGGCATTGATGGCTTAGCAGTCGCTTATGGAGTGGCCATGAACAAACTCGCCCTTCCTATTCCTTCTACGTGCCCAGAACCTTTTGCCAAACTCATGGAAGACTGCTGGAATCCTGATCCCCACTCACGACCATCTTTCACGAATATCCTGGACCAGCTAACCACCATAGAGGAGTCTGGTTTCTTTGAAATGCCCAAGGACTCCTTCCACTGCCTGCAGGACAACTGGAAACACGAGATTCAGGAGATGTTTGACCAACTCAGGGCCAAAGAAAAGGAACTTCGCACCTGGGAGGAGGAGCTGACGCGGGCTGCACTGCAGCAGAAGAACCAGGAGGAACTGCTGCGGCGTCGGGAGCAGGAGCTGGCCGAGCGGGAGATTGACATCCTGGAACGGGAGCTCAACATCATCATCCACCAGCTGTGCCAGGAGAAGCCCCGGGTGAAGAAACGCAAGGGCAAGTTCAGGAAGAGCCGGCTGAAGCTCAAGGATGGCAACCGCATCAGCCTCCCTTCTGGTTTCCAGCACAAGTTCACGGTGCAGGCCTCCCCTACCATGGATAAAAGGAAGAGTCTTATCAACAGCCGCTCCAGTCCTCCTGCAAGCCCCACCATCATTCCTCGCCTTCGAGCCATCCAGTGTGAGACTGTTTCCCAAATTAGCTGGGGCCAGAACACACAGGGGCACCTGTCCGAAAGCAGCAAAACCTGGGGCAGGAGCTCAGTCGTCCCAAAGGAGGAAGGGGAGGAGGAGGAGAAGAGGGCCCCAAAGAAGAAGGGACGGACGTGGGGGCCAGGGACGCTTGGTCAGAAGGAGCTTGCCTCGGGAGATGAACTCAAGTCCCTGGTAGATGGATATAAGCAGTGGTCGTCCAGTGCCCCCAACCTGGTGAAGGGCCCAAGGAGTACCCCGGCCCTGCCAGGGTTCACCAGCCTTATGGAGATGGAGGATGAGGACAGTGAAGGCCCAGGGAGTGGAGAGAGTCGCCTACAGCATTCACCCAGCCAGTCCTACCTCTGTATCCCATTCCCTCGTGGAGAGCCCACCCCAGTCAACTCGGCCACGAGTACCCCTCAGCTGACGCCAACCAACAGCCTCAAGCGGGGCGGTGCCCACCACCGCCGCTGCGAGGTGGCTCTGCTCGGCTGTGGGGCTGTTCTGGCAGCCACAGGCCTAGGGTTTGACTTGCTGGAAGCTGGCAAGTGCCAGCTGCTTCCCCTGGAGGAGCCTGAGCCACCAGCCCGGGAGGAGAAGAAAAGACGGGAGGGTCTTTTTCAGAGGTCCAGCCGTCCTCGTCGGAGCACCAGCCCCCCATCCCGAAAGCTTTTCAAGAAGGAGGAGCCCATGCTGTTGCTAGGAGACCCCTCTGCCTCCCTGACGCTGCTCTCCCTCTCCTCCATCTCCGAGTGCAACTCCACACGCTCCCTGCTGCAGTCCGACAGCGATGAAATTGTCGTGTATGAGATGCCAGTCAGCCCAGTCGAGGCCCCTCCCCTGAGTCCATGTACCCACAACCCCCTGGTCAATGTCCGAGTAGAGCGCTTCAAACGAGATCCTAACCAATCTCTGACTCCCACCCATGTCACCCTCACCACCCCCTCGCAGCCCAGCAGTCACCGGCGGACTCCTTCTGATGGGGCCCTTAAGCCAGAGACTCTCCTAGCCAGCAGGAGCCCCAGTCCCAGCCGAGACCCAGGTGAATTCCCCCGTCTCCCTGACCCCAATGTGGTCTTCCCCCCAACCCCAAGGCGCTGGAACACTCAGCAGGACTCTACCTTGGAGAGACCCAAGACTCTGGAGTTTCTGCCTCGGCCGCGTCCTTCTGCCAACCGGCAACGGCTGGACCCTTGGTGGTTTGTGTCCCCCAGCCATGCCCGCAGCACCTCCCCAGCCAACAGCTCCAGCACAGAGACGCCCGGGCCGCTGCCCCCGACTGAGCGGACGCTCCTGGACCTGGATGCAGAGGGGCAGAGTCAGGACAGCACCGTGCCGCTGTGCAGAGCGGAACTGAACACACACAGGCCTGCCCCTTATGAGATCCAGCAGGAGTTCTGGTCTTAGCACGAAAAGGATTGGGGNOV51a, CG56071-01Protein SequenceSEQ ID NO: 7841024 aaMW at 113682.1kDMEPSRALLGCLASAAAAAPPGEDGAGAGAEEEEEEEEEAAAAVGPGELGCDAPLPYWTAVFEYEAAGEDELTLRLGDVVEVLSKDSQVSGDEGWWTGQLNQRVGIFPSNYVTPRSAFSSRCQPGGEIDFAELTLEEIIGIGGFGKVYRAFWIGDEVAVKAARHDPDEDISQTIENVRQEAKLFAMLKHPNIIALRGVCLKEPNLCLVMEFARGGPLNRVLSGKRIPPDILVNWAVQIARGMNYLHDEAIVPIIHRDLKSSNVLILQKVENGDLSNKILKITDFGLAREWHRTTKMSAAGTYAWMAPEVIRASMFSKGSDVWSYGVLLWELLTGEVPFRGIDGLAVAYGVANNKLALPIPSTCPEPFAKLMEDCWNPDPHSRPSFTNILDQLTTIEESGFFEMPKDSFHCLQDNWKHEIQEMFDQLRAKEKELRTWEEELTRAALQQKNQEELLRRREQELAEREIDILERELNIIIHQLCQEKPRVKKRKGKFRKSRLKLKDGNRISLPSGFQHKFTVQASPTMDKRKSLINSRSSPPASPTIIPRLRAIQCETVSQISWGQNTQGMLSESSKTWGRSSVVPKEEGEEEEKRAPKKKGRTWGPGTLGQKELASGDELKSLVDGYKQWSSSAPNLVKGPRSTPALPGFTSLMEMEDEDSEGPGSGESRLQHSPSQSYLCIPFPRGEPTPVNSATSTPQLTPTNSLKRGGAHHRRCEVALLGCGAVLAATGLGFDLLEAGKCQLLPLEEPEPPAREEKKRREGLFQRSSRPRRSTSPPSRKLFKKEEPMLLLGDPSASLTLLSLSSISECNSTRSLLQSDSDEIVVYEMPVSPVEAPPLSPCTHNPLVNVRVERFKRDPNQSLTPTHVTLTTPSQPSSHRRTPSDGALKPETLLASRSPSPSRDPGEFPRLPDPNVVFPPTPRRWNTQQDSTLERPKTLEFLPRPRPSANRQRLDPWWFVSPSHARSTSPANSSSTETPGPLPPTERTLLDLDAEGOSQDSTVPLCRAELNTHRPAPYEIQQEFWSNOV51b, 274082270SEQ ID NO: 785807 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceACCGGATCCCTCACCTTGGAAGAGATTATTGGCATCGGGGGCTTTGGGAAGGTCTATCGTGCTTTCTGGATAGGGGATGAGGTTGCTGTGAAAGCAGCTCGCCACGACCCTGATGAGGACATCAGCCAGACCATAGAGAATGTTCGCCAAGAGGCCAAGCTCTTCGCCATGCTGAAGCACCCCAACATCATTGCCCTAAGAGGGGTATGTCTGAAGGAGCCCAACCTCTGCTTGGTCATGGAGTTTGCTCGTGGAGGACCTTTGAATAGAGTGTTATCTGGGAAAAGGATTCCCCCAGACATCCTGGTGAATTGGGCTGTGCAGATTGCCAGAGGGATGAACTACTTACATGATGAGGCAATTGTTCCCATCATCCACCGCGACCTTAAGTCCAGCAACATATTGATCCTCCAGAAGGTGGAGAATGGAGACCTGAGCAACAAGATTCTGAAGATCACTGATTTTGGCCTGGCTCGGGAATGGCACCGAACCACCAAGATGAGTGCGGCAGGGACGTATGCTTGGATGGCACCCGAAGTCATCCGGGCCTCCATGTTTTCCAAAGGCAGTGATGTGTGGAGCTATGGGGTGCTACTTTGGGAGTTGCTGACTGGTGAGGTGCCCTTTCGAGGCATTGATGGCTTAGCAGTCGCTTATGGAGTGGCCATGAACAAACTCGCCCTTCCTATTCCTTCTACGTGCCCAGAACCTTTTGCCAAACTCATGGAAGACTGCTGGAATCCTGATCCCCACTCACGACCATCTTTCACGAATATCCTGGACCAGCTAACCACCTACTCGAGGGCNOV51b, 274082270Protein SequenceSEQ ID NO: 786269 aaMW at 29861.3kDTGSLTLEEIIGIGGFGKVYRAFWIGDEVAVKAARHDPDEDISQTIENVRQEAKLFAMLKHPNIIALRGVCLKEPNLCLVMEFARGGPLNRVLSGKRIPPDILVNWAVQIARGMNYLHDEAIVPIIHRDLKSSNILILQKVENGDLSNKILKITDFGLAREWHRTTKMSAAGTYAWMAPEVIRASMFSKGSDVWSYGVLLWELLTGEVPFRGIDGLAVAYGVAMNKLALPIPSTCPEPFAKLMEDCWNPDPHSRPSFTNILDQLTTILEGSEQ ID NO: 7873092 bpNOV51c, SNP13376041 ofORF Start: ATG at 1ORF Stop: TAG at 3073CG56071-01, DNA SequenceSNP Pos: 2712SNP Change: T to CATGGAGCCCTCCAGAGCGCTTCTCGGCTGCCTAGCGAGCGCCGCCGCTGCCGCCCCGCCGGAAGAGGATGGAGCAGGGGCCGGGGCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGCGGCGGCGGCGGTGGGCCCCGGGGAGCTGGGCTGCGACGCGCCGCTGCCCTACTGGACGGCCGTGTTCGAGTACGAGGCGGCGGGCGAGGACGAGCTGACCCTGCGGCTGGGCGACGTGGTGGAGGTGCTGTCCAAGGACTCGCAGGTGTCCGGCGACGAGGGCTGGTGGACCGGGCAGCTGAACCAGCGGGTGGGCATCTTCCCCAGCAACTACGTGACCCCGCGCAGCGCCTTCTCCAGCCGCTGCCAGCCCGGCGGCGAAATTGATTTTGCGGAGCTCACCTTGGAAGAGATTATTGGCATCGGGGGCTTTGGGAAGGTCTATCGTGCTTTCTGGATAGGGGATGAGGTTGCTGTGAAAGCAGCTCGCCACGACCCTGATGAGGACATCAGCCAGACCATAGAGAATGTTCGCCAAGAGGCCAAGCTCTTCGCCATGCTGAAGCACCCCAACATCATTGCCCTAAGAGGGGTATGTCTGAAGGAGCCCAACCTCTGCTTGGTCATGGAGTTTGCTCGTGGAGGACCTTTGAATAGAGTGTTATCTGGGAAAAGGATTCCCCCAGACATCCTGGTGAATTGGGCTGTGCAGATTGCCAGAGGGATGAACTACTTACATGATGAGGCAATTGTTCCCATCATCCACCGCGACCTTAAGTCCAGCAACGTATTGATCCTCCAGAAGGTGGAGAATGGAGACCTGAGCAACAAGATTCTGAAGATCACTGATTTTGGCCTGGCTCGGGAATGGCACCGAACCACCAAGATGAGTGCGGCAGGGACGTATGCTTGGATGGCACCCGAAGTCATCCGGGCCTCCATGTTTTCCAAAGGCAGTGATGTGTGGAGCTATGGGGTGCTACTTTGGGAGTTGCTGACTGGTGAGGTGCCCTTTCGAGGCATTGATGGCTTAGCAGTCGCTTATGGAGTGGCCATGAACAAACTCGCCCTTCCTATTCCTTCTACGTGCCCAGAACCTTTTGCCAAACTCATGGAAGACTGCTGGAATCCTGATCCCCACTCACGACCATCTTTCACGAATATCCTGGACCAGCTAACCACCATAGAGGAGTCTGGTTTCTTTGAAATGCCCAAGGACTCCTTCCACTGCCTGCAGGACAACTGGAAACACGAGATTCAGGAGATGTTTGACCAACTCAGGGCCAAAGAAAAGGAACTTCGCACCTGGGAGGAGGAGCTGACGCGGGCTGCACTGCAGCAGAAGAACCAGGAGGAACTGCTGCGGCGTCGGGAGCAGGAGCTGGCCGAGCGGGAGATTGACATCCTGGAACGGGAGCTCAACATCATCATCCACCAGCTGTGCCAGGAGAAGCCCCGGGTGAAGAAACGCAAGGGCAAGTTCAGGAAGAGCCGGCTGAAGCTCAAGGATGGCAACCGCATCAGCCTCCCTTCTGGTTTCCAGCACAAGTTCACGGTGCAGGCCTCCCCTACCATGGATAAAAGGAAGAGTCTTATCAACAGCCGCTCCAGTCCTCCTGCAAGCCCCACCATCATTCCTCGCCTTCGAGCCATCCAGTGTGAGACTGTTTCCCAAATTAGCTGGGGCCAGAACACACAGGGGCACCTGTCCGAAAGCAGCAAAACCTGGGGCAGGAGCTCAGTCGTCCCAAAGGAGGAAGGGGAGGAGGAGGAGAAGAGGGCCCCAAAGAAGAAGGGACGGACGTGGGGGCCAGGGACGCTTGGTCAGAAGGAGCTTGCCTCGGGAGATGAACTCAAGTCCCTGGTAGATGGATATAAGCAGTGGTCGTCCAGTGCCCCCAACCTGGTGAAGGGCCCAAGGAGTACCCCGGCCCTGCCAGGGTTCACCAGCCTTATGGAGATGGAGGATGAGGACAGTGAAGGCCCAGGGAGTGGAGAGAGTCGCCTACAGCATTCACCCAGCCAGTCCTACCTCTGTATCCCATTCCCTCGTGGAGAGCCCACCCCAGTCAACTCGGCCACGAGTACCCCTCAGCTGACGCCAACCAACAGCCTCAAGCGGGGCGGTGCCCACCACCGCCGCTGCGAGGTGGCTCTGCTCGGCTGTGGGGCTGTTCTGGCAGCCACAGGCCTAGGGTTTGACTTGCTGGAAGCTGGCAAGTGCCAGCTGCTTCCCCTGGAGGAGCCTGAGCCACCAGCCCGGGAGGAGAAGAAAAGACGGGAGGGTCTTTTTCAGAGGTCCAGCCGTCCTCGTCGGAGCACCAGCCCCCCATCCCGAAAGCTTTTCAAGAAGGAGGAGCCCATGCTGTTGCTAGGAGACCCCTCTGCCTCCCTGACGCTGCTCTCCCTCTCCTCCATCTCCGAGTGCAACTCCACACGCTCCCTGCTGCAGTCCGACAGCGATGAAATTGTCGTGTATGAGATGCCAGTCAGCCCAGTCGAGGCCCCTCCCCTGAGTCCATGTACCCACAACCCCCTGGTCAATGTCCGAGTAGAGCGCTTCAAACGAGATCCTAACCAATCTCTGACTCCCACCCATGTCACCCTCACCACCCCCTCGCAGCCCAGCAGTCACCGGCGGACTCCTGCTGATGGGGCCCTTAAGCCAGAGACTCTCCTAGCCAGCAGGAGCCCCAGTCCCAGCCGAGACCCAGGCGAATTCCCCCGTCTCCCTGACCCCAATGTGGTCTTCCCCCCAACCCCAAGGCGCTGGAACACTCAGCAGGACTCTACCTTGGAGAGACCCAAGACTCTGGAGTTTCTGCCTCGGCCGCGTCCTTCTGCCAACCGGCAACGGCTGGACCCTTGGTGGTTTGTGTCCCCCAGCCATGCCCGCAGCACCTCCCCAGCCAACAGCTCCAGCACAGAGACGCCCGGGCCGCTGCCCCCGACTGAGCGGACGCTCCTGGACCTGGATGCAGAGGGGCAGAGTCAGGACAGCACCGTGCCGCTGTGCAGAGCGGAACTGAACACACACAGGCCTGCCCCTTATGAGATCCAGCAGGAGTTCTGGTCTTAGCACGAAAAGGATTGGGGNOV51c, SNP13376041 ofSEQ ID NO: 788MW at 113682.1kDCG56071-01, Protein SequenceSNP Pos: 9041024 aaSNP Change: Gly to GlyMEPSRALLGCLASAAAAAPPGEDGAGAGAEEEEEEEEEAAAAVGPGELGCDAPLPYWTAVFEYEAAGEDELTLRLGDVVEVLSKDSQVSGDEGWWTGQLNQRVGIFPSNYVTPRSAFSSRCQPGGEIDFAELTLEEIIGIGGFGKVYRAFWIGDEVAVKAARHDPDEDISQTIENVRQEAKLFAMLKHPNIIALRGVCLKEPNLCLVMEFARGGPLNRVLSGKRIPPDILVNWAVQIARGMNYLHDEAIVPIIHRDLKSSNVLILQKVENGDLSNKILKITDFGLAREWHRTTKMSAAGTYAWMAPEVIRASMFSKGSDVWSYGVLLWELLTGEVPFRGIDGLAVAYGVANNKLALPIPSTCPEPFAKLMEDCWNPDPHSRPSFTNILDQLTTIEESGFFEMPKDSFHCLQDNWKHEIQEMFDQLRAKEKELRTWEEELTRAALQOKNQEELLRRREQELAEREIDILERELNIIIHQLCQEKPRVKKRKGKFRKSRLKLKDGNRISLPSGFQHKFTVQASPTMDKRKSLINSRSSPPASPTIIPRLRAIQCETVSQISWGQNTQGHLSESSKTWGRSSVVPKEEGEEEEKRAPKKKGRTWGPGTLGQKELASGDELKSLVDGYKQWSSSAPNLVKGPRSTPALPGFTSLMEMEDEDSEGPGSGESRLQHSPSQSYLCIPFPRGEPTPVNSATSTPQLTPTNSLKRGGAHHRRCEVALLGCGAVLAATGLGFDLLEAGKCQLLPLEEPEPPAREEKKRREGLFQRSSRPRRSTSPPSRKLFKKEEPMLLLGDPSASLTLLSLSSISECNSTRSLLQSDSDEIVVYEMPVSPVEAPPLSPCTHNPLVNVRVERFKRDPNQSLTPTHVTLTTPSQPSSHRRTPSDGALKPETLLASRSPSPSRDPGEFPRLPDPNVVFPPTPRRWNTQQDSTLERPKTLEFLPRPRPSANRQRLDPWWFVSPSHARSTSPANSSSTETPGPLPPTERTLLDLDAEGQSQDSTVPLCRAELNTHRPAPYEIQQEFWS

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 51B.

TABLE 51BComparison of the NOV51 protein sequences.NOV51aMEPSRALLGCLASAAAAAPPGEDGAGAGAEEEEEEEEEAAAAVGPGELGCDAPLPYWTAVNOV51b------------------------------------------------------------NOV51aFEYEAAGEDELTLRLGDVVEVLSKDSQVSGDEGWWTGQLNQRVGIFPSNYVTPRSAFSSRNOV51b------------------------------------------------------------NOV51aCQPGGEIDFAELTLEEIIGIGGFGKVYRAFWIGDEVAVKAARHDPDEDISQTIENVRQEANOV51b--------TGSLTLEEIIGIGGFGKVYRAFWIGDEVAVKAARHDPDEDISQTIENVRQEANOV51aKLFANLKHPNIIALRGVCLKEPNLCLVMEFARGGPLNRVLSGKRIPPDILVNWAVQIARGNOV51bKLFANLKHPNIIALRGVCLKEPNLCLVMEFARGGPLNRVLSGKRIPPDILVNWAVQIARGNOV51aMNYLHDEAIVPIIHRDLKSSNVLILQKVENGDLSNKILKITDFGLAREWHRTTKMSAAGTNOV51bMNYLHDEAIVPIIHRDLKSSNILILQKVENGDLSNKILKITDFGLAREWHRTTKMSAAGTNOV51aYAWMAPEVIRASMFSKGSDVWSYGVLLWELLTGEVPFRGIDGLAVAYGVAMNKLALPIPSNOV51bYAWMAPEVIRASMFSKGSDVWSYGVLLWELLTGEVPFRGIDGLaVAYGVAMNKLALPIPSNOV51aTCPEPFAKLMEDCWNPDPHSRPSFTNILDQLTTIEESGFFEMPKDSFHCLQDNWKHEIQENOV51bTCPEPFAKLMEDCWNPDPHSRPSFTNILDQLTTILEG-----------------------NOV51aMFDQLRAKEKELRTWEEELTRAALQQKNQEELLRRREQELAEREIDILERELNIIIHQLCNOV51b------------------------------------------------------------NOV51aQEKPRVKKRKGKFRKSRLKLKDGNRISLPSGFQHKFTVQASPTMDKRKSLINSRSSPPASNOV51b------------------------------------------------------------NOV51aPTIIPRLRAIQCETVSQISWGQNTQGHLSESSKTWGRSSVVPKEEGEEEEKRAPKKKGRTNOV51b------------------------------------------------------------NOV51aWGPGTLGQKELASGDELKSLVDGYKQWSSSAPNLVKGPRSTPALPGFTSLMEMEDEDSEGNOV51b------------------------------------------------------------NOV51aPGSGESRLQHSPSQSYLCIPFPRGEPTPVNSATSTPQLTPTNSLKRGGAHHRRCEVALLGNOV51b------------------------------------------------------------NOV51aCGAVLAATGLGFDLLEAGKCQLLPLEEPEPPAREEKKRREGLFQRSSRPRRSTSPPSRKLNOV51b------------------------------------------------------------NOV51aFKKEEPMLLLGDPSASLTLLSLSSISECNSTRSLLQSDSDEIVVYEMPVSPVEAPPLSPCNOV51b------------------------------------------------------------NOV51aTHNPLVNRVERFKRDPNQSLTPTHVTLTTPSQPSSHRRTPSDGALKPETLLASSRSPSPSNOV51b------------------------------------------------------------NOV51aRDPGEFPRLPDPNVVFPPTPRRWNTQQDSTLERPKTLEFLPRPRPSANRQRLDPWWFVSPNOV51b------------------------------------------------------------NOV51aSHARSTSPANSSSTETPGPLPPTERTLLDLDAEGQSQDSTVPLCRAELNTHRPAPYEIQQNOV51b------------------------------------------------------------NOV51aEFWSNOV51b----NOV51a(SEQ ID NO: 784)NOV51b(SEQ ID NO: 786)

Further analysis of the NOV51a protein yielded the following properties shown in Table 51C.

TABLE 51CProtein Sequence Properties NOV51aSignalP analysis:Cleavage site between residues 18 and 19PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 5; pos.chg 1; neg.chg 1H-region: length 16; peak value 7.95PSG score: 3.55GvH:von.Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 0.45possible cleavage site: between 17 and 18>>> Seems to have a cleavable signal peptide (1 to 17)ALOM:Klein et al's method for TM region allocationInit position for calculation: 18Tentative number of TMS(s) for the threshold 0.5: 1Number of TMS(s) for threshold 0.5: 1INTEGRAL Likelihood = −3.66 Transmembrane 716 - 732PERIPHERAL Likelihood = 2.44 (at 342)ALOM score: −3.66 (number of TMSs: 1)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 8Charge difference: −10.0 C(−9.0) - N( 1.0)N >= C: N-terminal side will be inside>>>membrane topology: type 1a (cytoplasmic tail 733 to 1024)MITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment (75):4.60Hyd Moment (95):9.12G content:2D/E content:2S/T content:2Score: −6.34Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 15 SRA|LLNUCDISC: discrimination of nuclear localization signalspat4: KKRK (5) at 487pat4: PKKK (4) at 594pat4: KKRR (5) at 756pat4: RPRR (4) at 768pat7: PRVKKRK (5) at 484pat7: PTMDKRK (3) at 522pat7: PKKKGRT (5) at 594bipartite: KKRREGLFQRSSRPRRS at 756content of basic residues: 12.1%NLS Score: 2.27KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: EPSRnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: foundLL at 734LL at 742LL at 788LL at 789LL at 799LL at 814LL at 891checking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt≡s method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 89COIL: Lupas's algorithm to detect coiled-coil regions 409 L 0.51 410 Q 0.87 411 D 0.99 412 N 0.99 413 W 0.99 414 K 1.00 415 H 1.00 416 E 1.00 417 I 1.00 418 Q 1.00 419 E 1.00 420 M 1.00 421 F 1.00 422 D 1.00 423 Q 1.00 424 L 1.00 425 R 1.00 426 A 1.00 427 K 1.00 428 E 1.00 429 K 1.00 430 E 1.00 431 L 1.00 432 R 1.00 433 T 1.00 434 W 1.00 435 E 1.00 436 E 1.00 437 E 1.00 438 L 1.00 439 T 1.00 440 R 1.00 441 A 1.00 442 A 0.97 443 L 0.97 444 0 0.96 445 Q 0.96 446 K 0.96 447 N 0.96 448 0 0.96 449 E 0.96 450 E 0.96 451 L 0.81 452 L 0.81 453 R 0.81 454 R 0.81 455 R 0.71 456 E 0.71 457 0 0.71 458 E 0.71 459 L 0.71 460 A 0.71 461 E 0.71 462 R 0.64 463 E 0.64 464 I 0.64 465 D 0.64 466 I 0.64 467 L 0.64 468 E 0.64 469 R 0.64 470 E 0.64 471 L 0.64 472 N 0.64 473 I 0.64 474 I 0.64 475 I 0.64 476 H 0.64 477 0 0.64 478 L 0.64 479 C 0.64 480 Q 0.64 481 E 0.64 482 K 0.64total: 74 residues--------------------------Final Results (k = 9/23):44.4%: extracellular, including cell wall22.2%: Golgi22.2%: endoplasmic reticulum11.1%: plasma membrane>> prediction for CG56071-01 is exc (k = 9)

A search of the NOV51a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 51D.

TABLE 51aGeneseq Results for NOV51aNOV51aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB98408Human NOV7, a mixed lineage 1..10241024/1024 (100%)0.0kinase 2-like protein - Homo 1..10241024/1024 (100%)sapiens, 1024 aa.[WO200255704-A2, 18-Jul.-2002]AAE21717Human PKIN-12 protein- 1..10241003/1111 (90%)0.0Homo sapiens, 1097 aa. 1..10971006/1111(90%)[WO200218557-A2, 07-Mar.-2002]AAE11775Human kinase (PKJN)-9 protein 1..1024994/1072 (92%)0.0- Homo sapiens, 1046 aa. 1..1046997/1072 (92%)[WO200181555-A2, 01-Nov.-2001]ABP61000Novel human protein. SEQ ID24..1024540/1061 (50%)0.087 - Homo sapiens, 1021 aa.19..1021682/1061 (63%)[WO200250105-A1, 27-Jun.-2002]ABB80923Novel human protein (NHP)24.. 1024537/1076 (49%)0.0kinase - Homo sapiens, 1036 aa.19..1036684/1076 (62%)[WO200255685-A2, 18-Jul.-2002]

In a BLAST search of public sequence databases, the NOV51a protein was found to have homology to the proteins shown in the BLASTP data in Table 51E.

TABLE 51EPublic BLASTP Results for NOV51aNOV51aIdentities/ProteinResidues/Similarities forEx-AccessionProtein/Matchthe MatchedpectNumber/Organism/LengthResiduesPortionValueQ9H2N5Mixed lineage kinase 53..1024952/1080 (88%)0.0MLK1 - Homo sapiens 1..1066955/1080 (88%)(Human), 1066 aa(fragment).Q8K2L2Similar to mitogen-341..1024634/746 (84%)0.0activated protein 1..732649/746 (86%)kinase kinase 9 -Mus musculus(Mouse), 732 aa(fragment).Q8BIG8Mixed lineage kinase 1..616572/628 (91%)0.0MLKI homolog - Mus 1..607581/628 (92%)musculus (Mouse),608 aa.Q02779Mitogen-activated 35..1006579/988 (58%)0.0protein kinase 2..950699/988 (70%)kinase kinase 10(EC 2.7.1.37) (Mixedlineage kinase 2)(Protein kinaseMST) - Homo sapiens(Human), 954 aa.Q8WWN1Mixed lineage 24..1024537/1076 (49%)0.0kinase 4beta - 19..1036680/1076 (62%)Homo sapiens(Human), 1036 aa.

PFam analysis indicates that the NOV51a protein contains the domains shown in the Table 51F.

TABLE 51FDomain Analysis of NOV51aIdentities/NOV51aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect ValueSH3 55..11426/63 (41%)4.7e-1550/63 (79%)pkinase132..393100/307 (33%)7e-95216/307 (70%)

Example 52

The NOV52 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 52A.

TABLE 52ANOV52 Sequence AnalysisNOV52a, CG56142-01SEQ ID NO: 789866 bpDNA SequenceORF Start: ATG at 19ORF Stop: TGA at 820CCCAGCCTTGAAGACAGAATGAGAGGGGTTTCCTGTCTCCAGGTCCTGCTCCTTCTGGTGCTGGCCTGCGGGCAGCCCCGCATGTCCAGTCGGATCGTTGGGGGCCGGGATGGCCGGGACGGAGAGTGGCCGTGGCAGGCGAGCATCCAGCATCGTGGGGCACACGTGTGCGGGGGGTCGCTCATCGCCCCCCAGTGGGTGCTGACAGCGGCGCACTGCTTCCCCAGGGCACTGCCAGCTGAGTACCGCGTGCGCCTGGGGGCGCTGCGTCTGGGCTCCACCTCGCCCCGCACGCTCTCGGTGCCCGTGCGACGGGTGCCGCTGCCCCCGGACTACTCCGAGGACGGGGCCCGCGGCGACCTGGCACTGCTGCAGCTGCGTCGCCCGGTGCCCCTGAGCGCTCGCGTCCAACCCGTCTGCCTGCCCGTGCCCGGCGCCCGCCCGCCGCCCGGCACACCATGCCGGGTCACCGGCTGGGGCAGCCTCCGCCCAGGAGTGCCCCTCCCAGAGTGGCGACCGCTACAAGGAGTAAGGGTGCCGCTGCTGGACTCGCGCACCTGCGACGGCCTCTACCACGTGGGCGCGGACGTGCCCCAGGCTGAGCGCATTGTGCTGCCTGGGAGTCTGTGTGCCGGCTACCCCCAGGGCCACAAGGACGCCTGCCAGGTGTGCACCCAGCCTCCCCAGCCTCCGGAGTCCCCTCCCTGTGCCCAGCACCCTCCCTCCCTGAACTCCAGGACCCAGGACATCCCAACTCAGGCTCAGGATCCTGGCCTCCAACCTAGAGGCACCACGCCAGGGGTCTGGAACCCTGAGAACTGAAGTCCTGGGAGGGCTGGGACTTAGGCTCCTCTTTCTCCTGCAGGNOV52a, CG56142-01Protein SequenceSEQ ID NO: 790267 aaMW at 28699.8kDMRGVSCLQVLLLLVLACGQPRNSSRIVGGRDGRDGEWPWQASEQHRGAHVCGGSLIAPQWVLTAAHCFPRALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSEDGARGDLALLQLRRPVPLSARVQPVCLPVPGARPPPGTPCRVTGWGSLRPGVPLPEWRPLQGVRVPLLDSRTCDGLYHVGADVPQAERIVLPGSLCAGYPQGHKDACQVCTQPPQPPESPPCAQHPPSLNSRTQDIPTQAQDPGLQPRGTTPGVWNPENNOV52b, CG56142-04SEQ ID NO: 791638 bpDNA SequenceORF Start: ATG at 14ORF Stop: TGA at 578CCTTGAAGACAGAATGAGAGGGGTTTCCTGTCTCCAGGTCCTGCTCCTTCTGGTGCTGGGAGCTGCTGGGACTCAGGGAAGGAAGTCTGCAGCCTGCGGGCAGCCCCGCATGTCCAGTCGGATCGTTGGGGGCCGGGATGGCCGGGACGGAGAGTGGCCGTGGCAGGCGAGCATCCAGCATCGTGGGGCACACGTGTGCGGGGGGTCGCTCATCGCCCCCCAGTGGGTGCTGACAGCGGCGCACTGCTTCCCCAGTGCCCCTCCAGAGTGGCGACCGCTACAAGGAGTAAGGGTGCCGCTGCTGGACTCGCGCACCTGCGACGGCCTCTACCACGTGGGCGCGGACGTGCCCCAGGCTGAGCGCATTGTGCTGCCTGGGAGTCTGTGTGCCGGCTACCCCCAGGGCCACAAGGACGCCTGCCAGGTGTGCACCCAGCCTCCCCAGCCTCCGGAGTCCCCTCCCTGTGCCCAGCACCCTCCCTCCCTGAACTCCAGGACCCAGGACATCCCAACTCAGGCTCAGGATCCTGGCCTCCAACCTAGAGGCACCACGCCAGGGGTCTGGAACCCTGAGAACTGAAGTCCTGGGAGGGCTGGGACTTAGGCTCCTCTTTCTCCTGGAGGGTGATTCTGGGGGANOV52b, CG56142-04Protein SequenceSEQ ID NO: 792188 aaMW at 19994.5kDMRGVSCLQVLLLLVLGAAGTQGRKSAACGQPRMSSRIVGGRDGRDGEWPWQASIQHRGAHVCGGSLIAPQWVLTAAHCFPSAPPEWRPLQGVRVPLLDSRTCDGLYHVGADVPQAERIVLPGSLCAGYPQGHKDACQVCTQPPQPPESPPCAQHPPSLNSRTQDIPTQAQDPGLQPRGTTPGVWNPENNOV52c, 276873337SEQ ID NO: 7931165 bpDNA SequenceORF Start: at 606ORF Stop: TGA at 948CACCAAGCTTTGGGACTACGAGACGCCCAAGGTGATCGTGGTGAGGAACCGGCGCCTGGGGGTCCTGTACCGCGCCGTGCAGCTGCTCATCCTGCTCTACTTCGTGTGGTACGTATTCATCGTGCAGAAAAGCTACCAGGAGAGCGAGACGGGCCCCGAGAGCTCCATCATCACCAAGGTCAAGGGGATCACCACGTCCGAGCACAAAGTGTGGGACGTGGAGGAGTACGTGAAGCCCCCCGAGGGGGGCAGCGTGTTCAGCATCATCACCAGGGTCGAGGCCACCCACTCCCAGACCCAGGGAACCTGCCCCGAGAGCATAAGGGTCCACAACGCCACCTGCCTCTCCGACGCCGACTGCGTGGCTGGGGAGCTGGACATGCTGGGAAACGGCCTGAGGACCGGGCGCTGTGTGCCCTATTACCAGGGGCCCTCCAAGACCTGCGAGGTGTTCGGCTGGTGCCCGGTGGAAGATGGGGCCTCTGTCAGCGAATTTCTGGGTACGATGGCCCCAAATTTCACCATCCTCATCAAGAACAGCATCCACTACCCCAAATTCCACTTCTCCAAGGGCAACATCGCCGACCGCACAGACGGGTACCTGAAGCGCTGCACGTTCCACGAGGCCTCCGACCTCTACTGCCCCATCTTCAAGCTGGGCTTTATCGTGGAGAAGGCTGGGGAGAGCTTCACAGAGCTCGCACACAAGGGTGGTGTCATCGGGGTCATTATCAACTGGGACTGTGACCTGGACCTGCCTGCATCGGAGTGCAACCCCAAGTACTCCTTCCGGAGGCTTGACCCCAAGCACGTGCCTGCCTCGTCAGGCTACAACTTCAGGTTTGCCAAATACTACAAGATCAATGGCACCACCACCCGCACGCTCATCAAGGCCTACGGGATCCACATTGACGTCATTGTGCATGGACAGGTCGGGAAGTTCAGCCTGATTCCCACCATTATTAATCTGGCCACAGCTCTGACTTCCGTCGGGGTGGTAAGGAACCCTCTCTGGGGTCCCAGCGGGTGCGGGGGGTCCACCAGGCCCTTACACACCGGTCTCTGCTGGCCCCAGGGCTCCTTCCTGTGCGACTGGATCTTGCTAACATTCATGAACAAAAACAAGGTCTACAGCCATAAGAAATTTGACAAGGTGGTCGACGGCNOV52c, 276873337Protein SequenceSEQ ID NO: 794114 aaMW at 11702.8kDSAARSTRPPTSTAPSSSWALSWRRLGRASQSSHTRVVSSGSLSTGTVTWTCLHRSATPSTPSGGLTPSTCLPRQATTSGLPNTTRSMAPPPARSSRPTGSTLTSLCMDRSGSSANOV52d, 276863970SEQ ID NO: 7951164 bpDNA SequenceORF Start: at 605ORF Stop: TGA at 947CACAAGCTTTGGGACTACGAGACGCCCAAGGTGATCGTGGTGAGGAACCGGCGCCTGGGGGTCCTGTACCGCGCCGTGCAGCTGCTCATCCTGCTCTACTTCGTGTGGTACGTATTCATCGTGCAGAAAAGCTACCAGGAGAGCGAGACGGGCCCCGAGAGCTCCATCATCACCAAGGTCAAGGGGATCACCACGTCCGAGCACAAAGTGTGGGACGTGGAGGAGTACGTGAAGCCCCCCGAGGGGGGCAGCGTGTTCAGCATCATCACAGGGGTCGAGGCCACCCACTCCCAGACCCAGGGAACCTGCCCCGAGAGCATAAGGGTCCACAACGCCACCTGCCTCTCCGACGCCGACTGCGTGGCTGGGGAGCTGGACATGCTGGGAAACGGCCTGAGGACCGGGCGCTGTGTGCCCTATTACCAGGGGCCCTCCAAGACCTGCGAGGTGTTCGGCTGGTGCCCGGTGGAAGATGGGGCCTCTGTCAGCCAATTTCTGGGTACGATGGCCCCAAATTTCACCATCCTCATCAAGAACAGCATCCACTACCCCAAATTCCACTTCTCCAAGGGCAACATCGCCGACCGCACAGACGGGTACCTGAAGCGCTGCACGTTCCACGAGGCCTCCGACCTCTACTGCCCCATCTTCAAGCTGGGCTTTATCGTGGAGAAGGCTGGGGAGAGCTTCACAGAGCTCGCACACAAGGGTGGTGTCATCGGGGTCATTATCAACTGGGACTGTGACCTGGACCTGCCTGCATCGGAGTGCAACCCCAAGTACTCCTTCCGGAGGCTTGACCCCAAGCACGTGCCTGCCTCGTCAGGCTACAACTTCAGGTTTGCCAAATACTACAAGATCAATGGCACCACCACCCGCACGCTCATCAAGGCCTACGGGATCCGCATTGACGTCATTGTGCATGGACAGGTCGGGAAGTTCAGCCTGATTCCCACCATTATTAATCTGGCCACAGCTCTGACTTCCGTCGGGGTGGTAAGGAACCCTCTCTGGGGTCCCAGCGGGTGCGGGGGGTCCACCAGGCCCTTACACACCGGTCTCTGCTGGCCCCAGGGCTCCTTCCTGTGCGACTGGATCTTGCTAACATTCATGAACAAAAACAAGGTCTACAGCCATAAGAAATTTGACAAGGTGGTCGACGGCNOV52d, 276863970Protein SequenceSEQ ID NO: 796114 aaMW at 11672.8kDSARSTRPPTSTAPSSSWALSWRRLGRASQSSHTRWSSGSLSTGTVTWTCLHRSATPSTPSGGLTPSTCLPRQATTSGLPNTTRSMAPPPARSSRPTGSALTSLCMDRSGSSANOV52e, 276863992SEQ ID NO: 7971087 bpDNA SequenceORF Start: at 606ORF Stop: TGA at 948CACCAAGCTTTGGGACTACGAGACGCCCAAGGTGATCGTGGTGAGGAACCGGCGCCTGGGGGTCCTGTACCGCGCCGTGCAGCTGCTCATCCTGCTCTACTTCGTGTGGTACGTATTCATCGTGCAGAAAAGCTACCAGGAGAGCGAGACGGGCCCCGAGAGCTCCATCATCACCAAGGTCAAGGGGATCACCACGTCCGAGCACAAAGTGTGGGACGTGGAGGAGTACGTGAAGCCCCCCGAGGGGGGCAGCGTGTTCAGCATCATCACCAGGGTCGAGGCCACCCACTCCCAGACCCAGGGAACCTGCCCCGAGAGCATAAGGGTCCACAACGCCACCTGCCTCTCCGACGCCGACTGCGTGGCTGGGGAGCTGGACATGCTGGGAAACGGCCTGAGGACCGGGCGCTGTGTGCCCTATTACCAGGGGCCCTCCAAGACCTGCGAGGTGTTCGGCTGGTGCCCGGTGGAAGATGGGGCCTCTGTCAGCCAATTTCTGGGTACGATGGCCCCAAATTTCACCATCCTCATCAAGAACAGCATCCACTACCCCAAATTCCACTTCTCCAAGGGCAACATCGCCGACCGCACAGACGGGTACCTGAAGCGCTGCACGTTCCACGAGGCCTCCGACCTCTACTGCCCCATCTTCAAGCTGGGCTTTATCGTGGAGAAGGCTGGGGAGAGCTTCACAGAGCTCGCACAAGAGGGTGGTGTCATCGGGGTCATTATCAACTGGGACTGTGACCTGGACCTGCCTGCATCGGAGTGCAACCCCAAGTACTCCTTCCGGAGGCTTGACCCCAAGCACGTGCCTGCCTCGTCAGGCTACAACTTCAGGTTTGCCAAATACTACAAGATCAATGGCACCACCACCCGCACGCTCATCAAGGCCTACGGGATCCGCATTGACGTCATTGTGCATGGACAGGCCGGGAAGTTCAGCCTGATTCCCACCATTATTAATCTGGCCACAGCTCTGACTTCCGTCGGGGTGGGCTCCTTCCTGTGCGACTGGATCTTGCTAACATTCATGAACAAAAACAAGGTCTACAGCCATAAGAAATTTGACAAGGTGGTCGACGGCNOV52e, 276863992Protein SequenceSEQ ID NO: 798114 aaMW at 11682.8kDSAARSTRPPTSTAPSSSWALSWRRLGRASQSSHTRVVSSGSLSTGTVTWTCLHRSATPSTPSGGLTPSTCLPRQATTSGLPNTTRSMAPPPARSSRPTGSALTSLCMDRPGSSANOV52f, 2768733301SEQ ID NO: 7991087 bpDNA SequenceORF Start: at 606ORF Stop: TGA at 948CACCAAGCTTTGGGACTACGAGACGCCCAAGGTGATCGTGGTGAGGAACCGGCGCCTGGGGGTCCTGTACCGCGCCGTGCAGCTGCTCATCCTGCTCTACTTCGTGTGGTACGTATTCATCGTGCAGAAAAGCTACCAGGAGAGCGAGACGGGCCCCGAGAGCTCCATCATCACCAAGGTCAAGGGGATCACCACGTCCGAGCACAAAGTGTGGGACGTGGAGGAGTACGTGAAGCCCCCCGAGGGGGGCAGCGTGTTCAGCATCATCACCAGGGTCGAGGCCACCCACTCCCAGACCCAGGGAACCTGCCCCGAGAGCATAAGGGTCCACAACGCCACCTGCCTCTCCGACGCCGACTGCGTGGCTGGGGAGCTGGACATGCTGGGAAACGGCCTGAGGACCGGGCGCTGTGTGCCCTATTACCAGGGGCCCTCCAAGACCTGCGAGGTGTTCGGCTGGTGCCCGGTGGAAGATGGGGCCTCTGTCAGCCAATTTCTGGGTACGATGGCCCCAAATTTCACCATCCTCATCAAGAACAGCATCCACTACCCCAAATTCCACTTCTCCAAGGGCAACATCGCCGACCGCACAGACGGGTACCTGAAGCGCTGCACGTTCCACGAGGCCTCCGACCTCTACTGCCCCATCTTCAAGCTGGGCTTTATCGTGGAGAAGGCTGGGGAGAGCTTCACAGAGCTCGCACACAAGGGTGGTGTCATCGGGGTCATTATCAACTGGGACTGTGACCTGGACCTGCCTGCATCGGAGTGCAACCCCAAGTACTCCTTCCGGAGGCTTGACCCCAAGCACGTGCCTGCCTCGTCAGGCTACAACTTCAGGTTTGCCAAATACTACAAGATCAATGGCACCACCACCCGCACGCTCATCAAGGCCTACGGGATCCGCATTGACGTCATTGTGCATGGACAGGCCGGGAAGTTCATCCTGATTCCCACCATTATTAATCTGGCCACAGCTCTGACTTCCGTCGGGGTGGGCTCCTTCCTGTGCGACTGGATCTTGCTAACATTCATGAACAAAAACAAGGTCTACAGCCATAAGAAATTTGACAAGGTGGTCGACGGCNOV52f, 276873330Protein SequenceSEQ ID NO: 800114 aaMW at 11698.8kDSAARSTRPPTSTAPSSSWALSWRRLGRASQSSHTRVVSSGSLSTGTVTWTCLHRSATPSTPSGGLTPSTCLPRQATTSGLPNTTRSMAPPPARSSRPTGSALTSLCMDRPGSSSNOV52g, CG56142-02SEQ ID NO: 8011020 bpDNA SequenceORF Start: ATG at 91ORF Stop: TAA at 931AGGACTCTCCTCTCTTCTCCCTGCTGGCTCCAGACCAGAGTCCAAGCCCTAGGCAGTGCCACCCTTACCCAGCCCAGCCTTGAAGACAGAATGAGAGGGGTTTCCTGTCTCCAGGTCCTGCTCCTTCTGGTGCTGGGAGCTGCTGGGACTCAGGGAAGGAAGTCTGCAGCCTGCGGGCAGCCCCGCATGTCCAGTCGGATCGTTGGGGGCCGGGATGGCCGGGACGGAGAGTGGCCGTGGCAGGCGAGCATCCAGCATCGTGGGGCACACGTGTGCGGGGGGTCGCTCATCGCCCCCCAGTGGGTGCTGACAGCGGCGCACTGCTTCCCCAGGAGGGCACTGCCAGCTGAGTACCGCGTGCGCCTGGGGGCGCTGCGTCTGGGCTCCACCTCGCCCCGCACGCTCTCGGTGCCCGTGCGACGGGTGCTGCTGCCCCCGGACTACTCCGAGGACGGGGCCCGCGGCGACCTGGCACTGCTGCAGCTGCGTCGCCCGGTGCCCCTGAGCGCTCGCGTCCAACCCGTCTGCCTGCCCGTGCCCGGCGCCCGCCCGCCGCCCGGCACACCATGCCGGGTCACCGGCTGGGGCAGCCTCCGCCCAGGAGTGCCCCTCCCAGAGTGGCGACCGCTACAAGGAGTAAGGGTGCCGCTGCTGGACTCGCGCACCTGCGACGGCCTCTACCACGTGGGCGCGGACGTGCCCCAGGCTGAGCGCATTGTGCTGCCTGGGAGTCTGTGTGCCGGCTACCCCCAGGGCCACAAGGACGCCTGCCAGGGTGATTCTGGGGGACCTCTGACCTGCCTGCAGTCTGGGAGCTGGGTCCTGGTGGGCGTGGTGAGCTGGGGCAAGGGTTGTGCCCTGCCCAACCGTCCAGGGGTCTACACCAGTGTGGCCACATATAGCCCCTGGATTCAGGCTCGCGTCAGCTTCTAATGCTAGCCGGTGAGGCTGACCTGGAGCCAGCTGCTGGGGTCCCTCAGCCTCCTGGTTCATCCAGGCACCTGCCTATACCCCACATCCNOV52g, CG56142-02Protein SequenceSEQ ID NO: 802280 aaMW at 29786.2kDMRGVSCLQVLLLLVLGAAGTQGRKSAACGQPRMSSRIVGGRDGRDGEWPWQASIQHRGAHVCGGSLIAPQWVLTAAHCFPRRALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSEDGARGDLALLQLRRPVPLSARVQPVCLPVPGARPPPGTPCRVTGWGSLRPGVPLPEWRPLQGVRVPLLDSRTCDGLYHVGADVPQAERIVLPGSLCAGYPQGHKDACQGDSGGPLTCLQSGSWVLVGVVSWGKGCALPNRPGVYTSVATYSPWIQARVSFNOV52h, CG56142-03SEQ ID NO: 8031606 bpDNA SequenceORF Start: ATG at 69ORF Stop: TGA at 921CCACGCGTCCGACCAGAGTCCAAGCCCTAGGCAGTGCCACCCTTACCCAGCCCAGCCTTGAAGACAGAATGAGAGGGGTTTCCTGTCTCCAGGTCCTGCTCCTTCTGGTGCTGGGAGCTGCTGGGACTCAGGGAAGGAAGTCTGCAGCCTGCGGGCAGCCCCGCATGTCCAGTCGGATCGTTGGGGGCCGGGATGGCCGGGACGGAGAGTGGCCGTGGCAGGCGAGCATCCAGCATCCTGGGGCACACGTGTGCGGGGGGTCGCTCATCGCCCCCCAGTGGGTGCTGACAGCGGCGCACTGCTTCCCCAGGAGGGCACTGCCAGCTGAGTACCGCGTGCGCCTGGGGGCGCTGCGTCTGGGCTCCACCTCGCCCCGCACGCTCTCGGTGCCCGTGCGACGGGTGCTGCTGCCCCCGGACTACTCCGAGGACGGGGCCCGCGGCGACCTGGCACTGCTGCAGCTGCGTCGCCCGGTGCCCCTGAGCGCTCGCGTCCAACCCGTCTGCCTGCCCGTGCCCGGCGCCCGCCCGCCGCCCGGCACACCATGCCGGGTCACCGGCTGGGGCAGCCTCCGCCCAGGAGTGCCCCTCCCAGAGTGGCGACCGCTACAAGGAGTAAGGGTGCCGCTGCTGGACTCGCGCACCTGCGACGGCCTCTACCACGTGGGCGCGGACGTGCCCCAGGCTGAGCGCATTGTGCTGCCTGGGAGTCTGTGTGCCGGCTACCCCCAGGGCCACAAGGACGCCTGCCAGGGTGATTCTGGGGGACCTCTGACCTGCCTGCAGTCTGGGAGCTGGGTCCTGGTGGGCGTGGTGAGCTGGGGCAAGGGTTGTGCCCTGCCCAACCGTCCAGGGGTCTACACCAGTGTGGCCACATATAGCCCCTGGATTCAGGCTCGCGTCACTTCTAATGCTAGCCGGTGAGGCTGACCTGGAGCCAGCTGCTGGGGTCCCTCAGCCTCCTGGTTCATCCAGGCACCTGCCTATACCCCACATCCCTTCTGCCTCGAGGCCAAGATGCCTAAAAAAGCTAAAGGCCACCCCACCCCCCACCCACCACCTTCTGGCTCCTCTCCTCTTTGGGGATCACCAGCTCTGACTCCACCAACCCTCATCCAGGAATCTGCCATGAGTCCCAGGGAGTCACACTCCCCACTCCCTTCCTGGCTTGTATTTACTTTTCTTGGCCCTGGCCAGGGCTGGGCGCAAGGCACGCAGTGATGGGCAAACGAATTGCTGCCCATCTGGCCTGTGTGCCCATCTTTTTCTGGAGAAAGTCAGATTCACAGCATGACAGAGATTTGACACCAGGGAGATCCTCCATAGCTGGCTTTGAGGACACGGGGACCACAGCCATGAGCGGCCTCTAAGAGCTGAGAGACAGCCGGCAGGGAATCGGAACCCTCAGACCCACAGCCGCAAGGCACTGGATTCTGGCAGCACCCTGAAGGAGCTGGGAAGTAAGTTCTTCCCCAGCCTCCAGATAAGAGCCCCGCCGGCCAATCCCTTCATTTCAACCTAAAGAGACCCTAAGCAGAGAACCTAGCTGAGCCACTCCTGACCTACAAAGTTGTGACTTAATAAATGTGTGCTTTAAGCTGCCAAAANOV52h, CG56142-03Protein SequenceSEQ ID NO: 804284 aaMW at 30109.5kDMRGVSCLQVLLLLVLGAAGTQGRKSAACGQPRMSSRIVGGRDGRDGEWPWQASIQHPGAHVCGGSLIAPQWVLTAAHCFPRRALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSEDGARGDLALLQLRRPVPLSARVQPVCLPVPGARPPPGTPCRVTGWGSLRPGVPLPEWRPLQGVRVPLLDSRTCDGLYHVGADVPQAERIVLPGSLCAGYPQGHKDACQGDSGGPLTCLQSGSWVLVGVVSWGKGCALPNRPGVYTSVATYSPWIQARVTSNASRNOV52i, CG56142-05SEQ ID NO: 805762 bpDNA SequenceORF Start: at 7ORF Stop: at 757AGATCTCAGCCCCGCATGTCCAGTCGGATCGTTGGGGGCCGGGATGGCCGGGACGGAGAGTGGCCGTGGCAGGCGAGCATCCAGCATCGTGGGGCACACGTGTGCGGGGGGTCGCTCATCGCCCCCCAGTGGGTGCTGACAGCGGCGCACTGCTTCCCCAGGAGGGCACTGCCAGCTGAGTACCGCGTGCGCCTGGGGGCGCTGCGTCTGGGCTCCACCTCGCCCCGCACGCTCTCGGTGCCCGTGCGACGGGTGCTGCTGCCCCCGGACTACTCCGAGGACGGGGCCCGCGGCGACCTGGCACTGCTGCAGCTGCGTCGCCCGGTGCCCCTGAGCGCTCGCGTCCAACCCGTCTGCCTGCCCGTGCCCGCCGCCCGCCCGCCGCCCGGCACACCATGCCGGGTCACCGGCTGGGGCAGCCTCCGCCCAGGAGTGCCCCTCCCAGAGGGGCGACCGCTACAAGGAGTAAGGGTGCCGCTGCTGGACTCGCGCACCTGCGACGGCCTCTACCACGTGGGCGCGGACGTGCCCCAGGCTGAGCGCATTGTGCTGCCTGGGAGTCTGTGTGCCGGCTACCCCCAGGTCCACAAGGACGCCTGCCAGGTGTGCACCCAGCCTCCCCAGCCTCCGGAGTCCCCTCCCTGTGCCCAGCTCCCTCCCTCCCTGAACTCCAGGACCCAGGACATCCCAACTCAGGCTCAGGATCCTGGCCTCCAACCTAGAGGCACCACGCCAGGGGTCTGGAACCCTGAGAACCTCGAGNOV52i, CG56142-05Protein SequenceSEQ ID NO: 806250 aaMW at 26888.5kDQPRMSSRIVGGRDGRDGEWPWQASIQHRGAHVCGGSLIAPQWVLTAAHCFPRRALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSEDGARGDLALLQLRRPVPLSARVQPVCLPVPAARPPPGTPCRVTGWGSLRPGVPLPEGRPLQGVRVPLLDSRTCDGLYHVGADVPQAERIVLPGSLCAGYPQVHKDACQVCTQPPQPPESPPCAQLPPSLNSRTQDIPTQAQDPGLQPRGTTPGVWNPENNOV52j, CG56142-06SEQ ID NO: 807762 bpDNA SequenceORF Start: at 7ORF Stop: at 757AGATCTCAGCCCCGCATGTCCAGTCGGATCGTTGGGGGCCGGGATGGCCGGGACGGAGAGTGGCCGTGGCAGGCGAGCATCCAGCATCGTGGGGCACACGTGTGCGGGGGGTCGCTCATCGCCCCCCAGTGGGTGCTGACAGCGGCGCACTGCTTCCCCAGGAGGGCACTGCCAGCTGAGTACCGCGTGCGCCTGGGGGCGCTGCGTCTGGGCTCCACCTCGCCCCGCACGCTCTCGGTGCCCGTGCGACGGGTGCTGCTGCCCCCGGACTACTCCGAGGACGGGGCCCGCGGCGACCTGGCACTGCTGCAGCTGCGTCGCCCGGTGCCCCTGAGCGCTCGCGTCCAACCCGTCTGCCTGCCCGTGCCCGGCGCCCGCCCGCCGCCCGGCACACCATGCCGGGTCACCGGCTGGGGCAGCCTCCGCCCAGGAGTGCCCCTCCCAGAGTGGCGACCGCTACAAGGAGTAAGGGTGCCGCTGCTGGACTCGCGCACCTGCGACGGCCTCTACCACGTGGGCGCGGACGTGCCCCAGGCTGAGCGCATTGTGCTGCCTGGGAGTCTGTGTGCCGGCTACCCCCAGGGCCACAAGGACGCCTGCCAGGTGTGCACCCAGCCTCCCCAGCCTCCGGAGTCCCCTCCCTGTGCCCAGCTCCCTCCCTCCCTGAACTCCAGGACCCAGGACATCCCAACTCAGGCTCAGGATCCTGGCCTCCAACCTAGAGGCACCACGCCAGGGGTCTGGAACCCTGAGAACCTCGAGNOV52j, CG56142-06Protein SequenceSEQ ID NO: 808250 aaMW at 26961.6kDQPRMSSRIVGGRDGRDGEWPWQASIQHRGAHVCGGSLIAPQWVLTAAHCFPRRALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSEDGARGDLALLQLRRPVPLSARVQPVCLPVPGARPPPGTPCRVTGWGSLRPGVPLPEWRPLQGVRVPLLDSRTCDGLYHVGADVPQAERIVLPGSLCAGYPQGHKDACQVCTQPPQPPESPPCAQLPPSLNSRTQDIPTQAQDPGLQPRGTTPGVWNPEN

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 52B.

TABLE 52BComparison of the NOV52 protein sequences.NOV52aMRGVSCLQVLLLLVL-----------ACGQPRMSSRIVGGRDGRDGEWPWQASIQHRGAHNOV52bMRGVSCLQVLLLLVLGAAGTQGRKSAACGQPRMSSRIVGGRDGRDGEWPWQASIQHRGAHNOV52c------------------------------------------------------------NOV52d------------------------------------------------------------NOV52e------------------------------------------------------------NOV52f------------------------------------------------------------NOV52gMRGVSCLQVLLLLVLGAAGTQGRKSAACGQPRMSSRIVGGRDGRDGEWPWQASIQHRGAHNOV52hMRGVSCLQVLLLLVLGAAGTQGRKSAACGQPRMSSRIVGGRDGRDGEWPWQASIQHRGAHNOV52i-----------------------------QPRMSSRIVGGRDGRDGEWPWQASIQHRGAHNOV52j-----------------------------QPRMSSRIVGGRDGRDGEWPWQASIQHRGAHNOV52aVCGGSLIAPQWVLTAAHCFPR-ALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSENOV52bVCGGSLIAPQWVLTAAHCFPS---------------------------------------NOV52c------------------------------------------------------------NOV52d------------------------------------------------------------NOV52e------------------------------------------------------------NOV52f------------------------------------------------------------NOV52gVCGGSLIAPQWVLTAAHCFPRRALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSENOV52hVCGGSLIAPQWVLTAAHCFPRRALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSENOV52iVCGGSLIAPQWVLTAAHCFPRRALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSENOV52jVCGGSLIAPQWVLTAAHCFPRRALPAEYRVRLGALRLGSTSPRTLSVPVRRVLLPPDYSENOV52aDGARGDLALLQLRRPVPLSARVQPVCLPVPGARPPPGTPCRVTGWGSLRPGVPLPEWRPLNOV52b---------------------------------------AP-------------PEWRPLNOV52c--------------------------SAARSTRPPTST-APSSSWA--------LSWRRLNOV52d--------------------------SAARSTRPPTST-APSSSWA--------LSWRRLNOV52e--------------------------SAARSTRPPTST-APSSSWA--------LSWRRLNOV52f--------------------------SAARSTRPPTST-APSSSWA--------LSWRRLNOV52gDGARGDLALLQLRRPVPLSARVQPVCLPVPGARPPPGTPCRVTGWGSLRPGVPLPEWRPLNOV52hDGARGDLALLQLRRPVPLSARVQPVCLPVPGARPPPGTPCRVTGWGSLRPGVPLPEWRPLNOV52iDGARGDLALLQLRRPVPLSARVQPVCLPVPGARPPPGTPCRVTGWGSLRPGVPLPEWRPLNOV52jDGARGDLALLQLRRPVPLSARVQPVCLPVPGARPPPGTPCRVTGWGSLRPGVPLPEWRPLNOV52aQGVRVPLLDSRTCDGLYHVG-ADVPQAERIVLPGSLCAGYPQGHKDACQVCTQ-PPQPPENOV52bQGVRVPLLDSRTCDGLYHVG-ADVPQAERIVLPGSLCAGYPQGHKDACQVCTQ-PPQPPENOV52cGRASQSSHTRVVSSGSLSTGTVTWTCLHRSATPSTPSGGLTPSTCLPRQATTSGLPNTTRNOV52dGRASQSSHTRVVSSGSLSTGTVTWTCLHRSATPSTPSGGLTPSTCLPRQATTSGLPNTTRNOV52eGRASQSSHTRVVSSGSLSTGTVTWTCLHRSATPSTPSGGLTPSTCLPRQATTSGLPNTTRNOV52fGRASQSSHTRVVSSGSLSTGTVTWTCLHRSATPSTPSGGLTPSTCLPRQATTSGLPNTTRNOV52gQGVRVPLLDSRTCDGLYHVG-ADVPQAERIVLPGSLCAGYPQGHKDACQGDSGGPLTCLQNOV52hQGVRVPLLDSRTCDGLYHVG-ADVPQAERIVLPGSLCAGYPQGHKDACQGDSGGPLTCLQNOV52iQGVRVPLLDSRTCDGLYHVG-ADVPQAERIVLPGSLCAGYPQVHKDACQVCTQ-PPQPPENOV52jQGVRVPLLDSRTCDGLYHVG-ADVPQAERIVLPGSLCAGYPQGHKDACQVCTQ-PPQPPENOV52aSPPCAQHPPSLNSRTQDIPTQAQDPGLQPRGTTPGVWNPEN-------NOV52bSPPCAQHPPSLNSRTQDIPTQAQDPGLQPRGTTPGVWNPEN-------NOV52cSM--APP-PARSSRPTGSTLTSL-CMDRSGSSA---------------NOV52dSM--APP-PARSSRPTGSTLTSL-CMDRSGSSA---------------NOV52eSM--APP-PARSSRPTGSTLTSL-CMDRSGSSA---------------NOV52fSM--APP-PARSSRPTGSTLTSL-CMDRSGSSA---------------NOV52gSG--SWVLVGVVSWGKGCALPNR-PGVYTSVATYSPWIQARVSF----NOV52hSG--SWVLVGVVSWGKGCALPNR-PGVYTSVATYSPWIQARVTSNASRNOV52iSPPCAQLPPSLNSRTQDIPTQAQDPGLQPRGTTPGVWNPEN-------NOV52jSPPCAQLPPSLNSRTQDIPTQAQDPGLQPRGTTPGVWNPEN-------NOV52a(SEQ ID NO: 790)NOV52b(SEQ ID NO: 792)NOV52c(SEQ ID NO: 794)NOV52d(SEQ ID NO: 796)NOV52e(SEQ ID NO: 798)NOV52f(SEQ ID NO: 800)NOV52g(SEQ ID NO: 802)NOV52h(SEQ ID NO: 804)NOV52i(SEQ ID NO: 806)NOV52j(SEQ ID NO: 808)

Further analysis of the NOV52a protein yielded the following properties shown in Table 52C.

TABLE 52CProtein Sequence Properties NOV52aSignalP analysis:Cleavage site between residues 19 and 20PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 2; pos.chg 1; neg.chg 0H-region: length 18; peak value 10.88PSG score: 6.48GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 1.06possible cleavage site: between 18 and 19>>> Seems to have a cleavable signal peptide (1 to 18)ALOM:Klein et al's method for TM region allocationInit position for calculation: 19Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) .. fixedPERIPHERAL Likelihood = 5.30 (at 48)ALOM score: 5.30 (number of TMSs: 0)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 9Charge difference: 0.0 C( 2.0) - N( 2.0)N >= C: N-terminal side will be insideMITDISC: discrimination of mitochondrial targeting seqR content:4Hyd Moment (75):6.32Hyd Moment (95):5.75G content:4D/E content:1S/T content:3Score: −2.36Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 35 SRI|VGNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 10.1%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: RGVSnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 76.7COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):55.6%: extracellular, including cell wall33.3%: mitochondrial11.1%: nuclear>> prediction for CG56142-01 is exc (k = 9)

A search of the NOV52a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 52D.

TABLE 50DGeneseq Results for NOV52aNOV50aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU74742Human protease PRTS-2 protein 1..267267/279 (95%)e-159sequence - Homo sapiens, 365 aa.87..365267/279 (95%)[WO200 1 98468-A2, 27-Dec.-2001]ABP61012Novel human protein. 1..267267/279 (95%)e-159SEQ ID 99 - 1..279267/279 (95%)Homo sapiens, 279 aa.[WO200250 105-Al, 27-Jun.-2002]AAE00290Human plasminogen-like protein 1..267267/279 (95%)e- 159from clone HEOQBO8 - Homo 1..279267/279 (95%)sapiens, 279 aa. [WO200124815-Al, 12-Apr.-2001]ABB07286Human prostasin-like serine 1..216216/217 (99%)e-127protease - Homo sapiens, 272 aa. 1..217216/217 (99%)[WO2001 98466-A2, 27-Dec.-2001]ABP61010Novel human protein. 1..216216/228 (94%)e-125SEQ ID 97 - 1..228216/228 (94%)Homo sapiens, 280 aa.[WO200250105-A1, 27-Jun.-2002]

In a BLAST search of public sequence databases, the NOV52a protein was found to have homology to the proteins shown in the BLASTP data in Table 52E.

TABLE 52EPublic BLASTP Results for NOV52aNOV52aIdentities/ProteinResidues/Similarities forEx-AccessionProtein/Matchthe MatchedpectNumberOrganism/LengthResiduesPortionValueQ8N171Similar to protease, 1..216216/228 (94%)e-124serine, 848..275216/228 (94%)(Prostasin) -Homo sapiens(Human), 327 aa (fragment).Q8NF86Serine protease 1..216215/228 (94%)e-123EOS - Homo sapiens 1..228215/228 (94%)(Human), 284 aa.AAP20885Tryptase-6 - 1..216175/225 (77%)3e-98Mus musculus 1..225186/225 (81%)(Mouse), 277 aa.Q9ER10Brain-specific serine17..215 91/202 (45%)1e-46protease 4 precursor41..238125/202 (61%)(EG 3.4.21.-)(BSSP-4) -Mus musculus(Mouse), 306 aa.Q9ES87Prostasin precursor16..216 93/202 (46%)1e-46(EC 3.4.21.-) -36..235125/202 (61%)Rattus norvegicus(Rat), 342 aa.

PFam analysis indicates that the NOV52a protein contains the domains shown in the Table 52F.

TABLE 52FDomain Analysis of NOV52aIdentities/NOV52aSimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValuetrypsin26 . . . 241 83/269 (31%)1e−38165/269 (61%)

Example 53

The NOV53 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 53A.

TABLE 53ANOV53 Sequence AnalysisNOV53a, CG56144-01SEQ ID NO: 8091151 bpDNA SequenceORF Start: ATG at 90ORF Stop: TAG at 1056TAATCTTTGCAGGTGGGATAGCACAGGTTGAACTCTAATCATATATACTGTAGAAGGTATATATAGAAGGTGAAGAAGCCCTGTAAAAAATGACAAGGAGATTTCCAGGAGCCATGCTTCCCTCTAATATCACCTCAACACATCCAGCTGTCTTTTTGTTGGTAGGAATTCCTGGTTTGGAACACCTGCATGCCTGGATCTCCATCCCCTTCTGCTTTGCTTATACTCTGGCCCTGCTAGGCAACTGTACCCTTCTCTTCATTATCCAGGCTGATGCAGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTTTAGTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAAGCATTTGGGACATGTGTGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGTAGATGGATAGTTCTCTTTTTTTATCCCACTTGCCAAGTAATGAGAATGCTGGATTGGGGTTGAGGGGAAAAATCTAAATAGGAAAATTGCAGAGTNOV53a, CG56144-01Protein SequenceSEQ ID NO: 810322 aaMW at 36121.9kDMTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQHFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVARAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMFSVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNMNOV53b, 170645965SEQ ID NO: 811981 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGACAAGGAGATTTCCAGGAGCCATGCTTCCCTCTAATATCACCTCAACACATCCAGCTGTCTTTTTGTTGGTAGGAATTCCTGGTTTGGAACACCTGCATGCCTGGATCTCCATCCCCTTCTGCTTTGCTTATACTCTGGCCCTGCTAGGCAACTGTACCCTTCTCTTCATTATCCAGGCTGATGCAGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTTTATTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGCTCGAGNOV53b, 170645965Protein SequenceSEQ ID NO: 812327 aaMW at 36635.5kDGSTMTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVARAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMFIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNMLENOV53c, 168869277SEQ ID NO: 813981 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGACAAGGAGATTTCCAGGAGCCATGCTTCCCTCTAATATCACCTCAACACATCCAGCTGTCTTTTTGTTGGTAGGAATTCCTGGTTTGGAACACCTGCATGCCTGGATCTCCATCCCCTTCTGCTTTGCTTATACTCTGGCCCTGCTAGGCAACTGTACCCTTCTCTTCATTATCCAGGCTGATGCAGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTTTATTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGCGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGCTCGAGNOV53c, 168869277Protein SequenceSEQ ID NO: 814327 aaMW at 36607.4kDGSTMTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVARAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMFIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCASHIGAILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNNLENOV53d, 170645981SEQ ID NO: 815981 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCAAGACAAGGAGATTTCCAGGAGCCATGCTTCCCTCTAATATCACCTCAACACATCCAGCTGTCTTTTTGTTGGTAGGAATTCCTGGTTTGGAACACCTGGATGCCTGGATCTCCATCCCCTTCTGCTTTGCTTATACTCTGGCCCTGCTAGGCAACTGTACCCTTCTCTTCATTATCCAGGCTGATGCAGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGACCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTTTATTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTGTCTCACATAGGTACCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGCTCGAGNOV53d, 170645981Protein SequenceSEQ ID NO: 816327 aaMW at 36720.5kDGSTKTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVARAVTLMTPLPFLLRRFHYCRDPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMFIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGTILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNMLENOV53e, 168869262SEQ ID NO: 817981 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGACAAGGAGATTTCCAGGAGCCATGCTTCCCTCTAATATCACCTCAACACATCCAGCTGTCTTTTTGTTGGTAGGAATTCCTGGTTTGGAACACCTGCATGCCTGGATCTCCATCCCCTTCTGCTTTGCTTATACTCTGGCCCTGCTAGGCAACTGTACCCTTCTCTTCATTATCCGGGCTGATGCAGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCTGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTTTATTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGCTCGAGNOV53e, 168869262Protein SequenceSEQ ID NO: 818327 aaMW at 36693.5kDGSTHTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGMCTLLFIIRADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVAWAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMFIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNMLENOV53f, 168869254SEQ ID NO:819981 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGACAAGGAGATTTCCAGGAGCCATGCTTCCCTCTAATATCACCTCAACACATCCAGCTGTCTTTTTGTTGGTAGGAATTCCTGGTTTGGAACACCTGCATGCCTGGATCTCCATCCCCCTCTGCTTTGCTTATACTCTGGCCCTGCTAGGCAACTGTACCCTTCTCTTCATTATCCAGGCTGATGCAGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTTTATTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGCTCGAGNOV53f, 168869254Protein SequenceSEQ ID NO: 820327 aaMW at 36601.4kDGSTMTRRFPGANLPSNITSTHPAVFLLVGIPGLEHLHAWISIPLCFAYTLALLGNCTLLFIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVARAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVANFIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNMLENOV53g, CG56144-02SEQ ID NO: 821966 bpDNA SequenceORF Start: ATG at 1ORF Stop: end of sequenceATGACAAGGAGATTTCCAGGAGCCATGCTTCCCTCTAATATCACCTCAACACATCCAGCTGTCTTTTTGTTGGTAGGAATTCCTGGTTTGGAACACCTGCATGCCTGGATCTCCATCCCCTTCTGCTTTGCTTATACTCTGGCCCTGCTAGGCAACTGTACCCTTCTCTTCATTATCCAGGCTGATGCAGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTTTATTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTTCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGNOV53g, CG56144-02Protein SequenceSEQ ID NO: 822322 aaMW at 36148.0kDMTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVARAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMFIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNMNOV53h, CG56144-03SEQ ID NO: 823777 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCTGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTCTATTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGNOV53h, CG56144-03Protein SequenceSEQ ID NO: 824259 aaMW at 29252.8kDALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVAWAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMSIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNMNOV53i, CG56144-04SEQ ID NO: 825777 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCTGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTCTATTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGNOV53i, CG56144-04Protein SequenceSEQ ID NO: 826259 aaMW at 29252.8kDALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVAWAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMSIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNMNOV53j, CG56144-05SEQ ID NO: 827789 bpDNA SequenceORF Start: at 7ORF Stop: at 784GGATCCGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTTTATTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGCTCGAGNOV53j, CG56144-05Protein SequenceSEQ ID NO: 828259 aaMW at 29282.9kDALHEPMYLFLAMLATIDLVLSSTTLPKNLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVARAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMFIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVISSVMHRVARHAAPRVHILLAIFYLLFPPMVNPIEYGVKTKQIREYVLSLFQRKNMNOV53k, CG56144-06SEQ ID NO: 829789 bpDNA SequenceORF Start: at 7ORF Stop: at 784GGATCCGCCCTCCATGAACCCATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCCCAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTCCAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTCATCACCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACACATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCTGTGGCCATGTTTATTGTGGTGTTGGACCTGGTCTTTGTTATCCTGTCTTATGTCTTCATCCTTCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTGTCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCGTGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCCCACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCTCAGTCTATTCCAGAGAAAGAACATGCTCGAGNOV53k, CG56144-06Protein SequenceSEQ ID NO: 830259 aaMW at 29282.91WALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKPLHYTTVLTGSLITKIGMAAVARAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDTSFNNIYGIAVAMFIVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVISSVNHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNM

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 53B.

TABLE 53BComparison of the NOV53 protein sequences.NOV53a---MTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFNOV53bGSTMTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFNOV53cGSTMTRRFPGANLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFNOV53dGSTKTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFNOV53eGSTMTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFNOV53fGSTMTRRFPGAMLPSNITSTHPAVFLLVGIPGLENLHAWISIPLCFAYTLALLGNCTLLFNOV53g---MTRRFPGAMLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFNOV53h------------------------------------------------------------NOV53i------------------------------------------------------------NOV53j------------------------------------------------------------NOV53k------------------------------------------------------------NOV53aIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53bIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53cIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53dIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53eIIRAnAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53fIIQADAALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53gIIQADAALHEPMYLFLANLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53h------ALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53i------ALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53j------ALHEPMYLFLAMLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFNOV53k------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--NOV53bNPIIYGVKTKQIREYVLSLFQRKNMLENOV53cNPIIYGVKTKQIREYVLSLFQRKNMLENOV53dNPIIYGVKTKQIREYVLSLFQRKNMLENOV53eNPIIYGVKTKQIREYVLSLFQRKNMLENOV53fNPIIYGVKTKQIREYVLSLFQRKNMLENOV53gNPIIYGVKTKQIREYVLSLFQRKNM--NOV53hNPIIYGVKTKQIREYVLSLFQRKNM--NOV53iNPIIYGVKTKQIREYVLSLFQRKNM--NOV53jNPIIYGVKTKQIREYVLSLFQRKNM--NOV53kNPIIYGVKTKQIREYVLSLFQRKNM--NOV53a(SEQ ID NO: 810)NOV53b(SEQ ID NO: 812)NOV53c(SEQ ID NO: 814)NOV53d(SEQ ID NO: 816)NOV53e(SEQ ID NO: 818)NOV53f(SEQ ID NO: 820)NOV53g(SEQ ID NO: 822)NOV53h(SEQ ID NO: 824)NOV53i(SEQ ID NO: 826)NOV53j(SEQ ID NO: 828)NOV53k(SEQ ID NO: 830)

Further analysis of the NOV53a protein yielded the following properties shown in Table 53C.

TABLE 53CProtein Sequence Properties NOV53aSignalP analysis:Cleavage site between residues 64 and 65PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 4; pos.chg 2; neg.chg 0H-region: length 26; peak value 10.58PSG score: 6.18GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.34possible cleavage site: between 61 and 62>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 7INTEGRALLikelihood = −3.29Transmembrane 43-59INTEGRALLikelihood = −2.07Transmembrane 69-85INTEGRALLikelihood = −1.70Transmembrane 104-120INTEGRALLikelihood = 0.26Transmembrane 157-173INTEGRALLikelihood = −11.09Transmembrane 210-226INTEGRALLikelihood = 0.21Transmembrane 255-271INTEGRALLikelihood = −3.03Transmembrane 284-300PERIPHERALLikelihood = 1.54 (at 21)ALOM score: −11.09 (number of TMSs: 7)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 50Charge difference: −1.5 C(−1.5) − N(0.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content: 2Hyd Moment(75):12.17Hyd Moment(95):11.23G content: 3D/E content: 1S/T content: 5Score: −1.65Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 14 RRF|PGNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 6.8%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: TRRFKKXX-like motif in the C-terminus: QRKNSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: foundTLPK at 87RNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):77.8%: endoplasmic reticulum11.1%: nuclear11.1%: mitochondrial>> prediction for CG56144-01 is end (k = 9)

A search of the NOV53a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 53D.

TABLE 53DGeneseq Results for NOV53aNOV53aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE11904Human G-protein coupled1 . . . 322318/322 (98%)0.0receptor 10b (GPCR10b) protein -1 . . . 322321/322 (98%)Homo sapiens, 322 aa.[WO200181378-A2, 01-NOV-2001]AAE11903Human G-protein coupled1 . . . 322321/322 (99%)0.0receptor 10a (GPCR10a) protein -1 . . . 321321/322 (99%)Homo sapiens, 321 aa.[WO200181378-A2, 01-NOV-2001]AAU85178G-coupled olfactory receptor #39 -9 . . . 322314/314 (100%)e−180Homo sapiens, 314 aa.1 . . . 314314/314 (100%)[WO200198526-A2, 27-DEC-2001]ABP95675Human GPCR polypeptide SEQ9 . . . 322314/314 (100%)e−180ID NO 160 - Homo sapiens, 3141 . . . 314314/314 (100%)aa. [WO200216548-A2, 28-FEB-2002]AAU24558Human olfactory receptor9 . . . 322314/314 (100%)e−180AOLFR45 - Homo sapiens, 3141 . . . 314314/314 (100%)aa. [WO200168805-A2, 20-SEP-2001]

In a BLAST search of public sequence databases, the NOV53a protein was found to have homology to the proteins shown in the BLASTP data in Table 53E.

TABLE 53EPublic BLASTP Results for NOV53aNOV53aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8NGK4Seven transmembrane helix9 . . . 322311/314 (99%)e−178receptor - Homo sapiens1 . . . 314312/314 (99%)(Human), 314 aa.Q8NGK3Seven transmembrane helix9 . . . 322283/314 (90%)e−161receptor - Homo sapiens1 . . . 314290/314 (92%)(Human), 314 aa.Q8VH04Olfactory receptor MOR28-1 -9 . . . 322273/314 (86%)e−157Mus musculus (Mouse), 317 aa.1 . . . 314291/314 (91%)CAD20423Sequence 1 from Patent9 . . . 316276/308 (89%)e−154WO0179295 Homo sapiens1 . . . 307287/308 (92%)(Human), 316 aa.Q8VG23Olfactory receptor MOR29-1 -9 . . . 319172/311 (55%)3e−96 Mus musculus (Mouse), 315 aa.1 . . . 310224/311 (71%)

PFam analysis indicates that the NOV53a protein contains the domains shown in the Table 53F.

TABLE 53FDomain Analysis of NOV53aIdentities/SimilaritiesPfamNOV53afor the MatchedExpectDomainMatch RegionRegionValue7tm_151 . . . 302 50/277 (18%)4.5e−13163/277 (59%)

Example 54

The NOV54 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 54A.

TABLE 54ANOV54 Sequence AnalysisNOV54a, CG56146-02SEQ ID NO: 831807 bpDNA SequenceORF Start: ATG at 1ORF Stop: end of sequenceATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGACACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACNOV54a, CG56146-02Protein SequenceSEQ ID NO: 832269 aaMW at 29515.5kDMILDHRLHMAHYFFLRHLSFLDLCLISDTVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKKNDIKSALSKVLNNVRSSGVMKDDNOV54b, CG56146-01SEQ ID NO: 833995 bpDNA SequenceORF Start: ATG at 21ORF Stop: TAA at 966GGCGCTTATAATTTTGAACTATGACCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGCTCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTTAGTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACTAAAGTTGAAGATGGGAAGTACTTTTTTTGNOV54b, CG56146-01Protein SequenceSEQ ID NO: 834315 aaMW at 34934.2kDMTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTANSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDNOV54c, 170646057SEQ ID NO: 835819 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATACACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACCTCGAGNOV54c, 170646057Protein SequenceSEQ ID NO: 836273 aaMW at 29888.0kDGSMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDTPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDLENOV54d, 170646049SEQ ID NO: 837819 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCGCAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACCTCGAGNOV54d, 170646049Protein SequenceSEQ ID NO: 838273 aaMW at 29827.9kDGSMILDHRLHMAMYFFLRHLSFLDLCLISAAVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDLENOV54e, 170646053SEQ ID NO: 839819 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCCGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGGGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACCTCGAGNOV54e, 170646053Protein SequenceSEQ ID NO: 840273 aaMW at 29799.8kDGSMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLPAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSGAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDLENOV54f, 174307717SEQ ID NO: 841960 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGACCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGCTCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTTAGTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCGAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCCTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTAAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACCTCGAGNOV54f, 174307717Protein SequenceSEQ ID NO: 842320 aaMW at 35404.7kDGSTMTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLNNLVIILLMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGIPTANSYDRYAAICCPLHCKAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDLENOV54g, 168869383SEQ ID NO: 843820 bpDNA SequenceORF Start: at 296ORF Stop: end of sequenceGGATCCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACCTCGAGNOV54g, 168869383Protein SequenceSEQ ID NO: 844175 aaMW at 19239.2kDWLCPGSTEGPWDSCTQLEHSLLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDLENOV54h, CG56146-03SEQ ID NO: 845945 bpDNA SequenceORF Start: ATG at 1ORF Stop: end of sequenceATGACCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGCTCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTTAGTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACNOV54h, CG56146-03Protein SequenceSEQ ID NO: 846315 aaMW at 34934.2kDMTNQTQMNEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDNOV54i, 262939640SEQ ID NO: 847952 bpDNA SequenceORF Start: at 3ORF Stop: TAG at 942CCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGCTCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTTAGTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACTAGCAATTGGGNOV54i, 262939640Protein SequenceSEQ ID NO: 848313 aaMW at 34701.9kDNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPAlLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVIRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDDNOV54j, CG56146-04SEQ ID NO: 84960 bpDNA SequenceORF Start: ATG at 1ORF Stop: end of sequenceATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGCTCCTGAGGCTGCATGCTNOV54j, CG56146-04Protein SequenceSEQ ID NO: 85020 aaMW at 2519.0kDMMEFLLVRFTENWVLLRLHANOV54k, CG56146-05SEQ ID NO: 85160 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTNOV54l, CG561146-06SEQ ID NO: 853952 bpDNA SequenceORF Start: at 3ORF Stop: TAG at 942CCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGCTCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTTAGTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCGACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACTCTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTACTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCATCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGCTCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTGAATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCTCACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCATTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGATATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTCACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTATTCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCTACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAAGCAGTGGGGTAATGAAAGATGACTAGCAATTGGGNOV54l, CG56146-06Protein SequenceSEQ ID NO: 854313 aaMW at 34701.9kDNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTANSYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAIISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDD

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 54B.

TABLE 54BComparison of the NOV54 protein sequences.NOV54a-------------------------------------------------MILDHRLHMAMNOV54b---MTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMNOV54c-----------------------------------------------GSMILDHRLHMAMNOV54d-----------------------------------------------GSMILDHRLHMAMNOV54e-----------------------------------------------GSMILDHRLHMAMNOV54fGSTMTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMNOV54g------------------------------------------------------------NOV54h---MTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMNOV54i-----NQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMNOV54j------------------------------------------------------------NOV54k------------------------------------------------------------NOV54l-----NQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMNOV54aYFFLRHLSFLDLCLISDTVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSNOV54bYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSNOV54cYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSNOV54dYFFLRHLSFLDLCLISAAVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSNOV54eYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLPAGSEIGILTAMSNOV54fYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGIPTAMSNOV54g------------------------------------------------------------NOV54hYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSNOV54iYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSNOV54j------------------------------------------------------------NOV54k------------------------------------------------------------NOV54lYFFLRHLSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSNOV54aYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCNOV54bYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCNOV54cYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCNOV54dYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCNOV54eYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCNOV54fYDRYAAICCPLHCKAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCNOV54g------WLCPGSTEGPWDS--CTQLEHS-----------------LLNFYGSDELHQFFCNOV54hYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCNOV54iYDRYAAICCPLHCEAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCNOV54j--------------------------------------------------MMEFLLVRFTNOV54k------------------------------------------------------------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--------------------------------------------------NOV54kDVPALLKLTCSKEHAIISVS----------------------------------------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------------------------------------------------------------NOV54k------------------------------------------------------------NOV54lNCVPHLIVVTVFLVTGAVAYLKPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSNOV54aALSKVLWNVRSSGVMKDD--NOV54bALSKVLWNVRSSGVMKDD--NOV54cALSKVLWNVRSSGVMKDDLENOV54dALSKVLWNVRSSGVMKDDLENOV54eALSKVLWNVRSSGVMKDDLENOV54fALSKVLWNVRSSGVMKDDLENOV54gALSKVLWNVRSSGVMKDDLENOV54hALSKVLWNVRSSGVMKDD--NOV54iALSKVLWNVRSSGVMKDD--NOV54j--------------------NOV54k--------------------NOV54lALSKVLWNVRSSGVMKDD--NOV54a(SEQ ID NO: 832)NOV54b(SEQ ID NO: 834)NOV54c(SEQ ID NO: 836)NOV54d(SEQ ID NO: 838)NOV54e(SEQ ID NO: 840)NOV54f(SEQ ID NO: 842)NOV54g(SEQ ID NO: 844)NOV54h(SEQ ID NO: 846)NOV54i(SEQ ID NO: 848)NOV54j(SEQ ID NO: 850)NOV54k(SEQ ID NO: 852)NOV54l(SEQ ID NO: 854)

Further analysis of the NOV54a protein yielded the following properties shown in Table 54C.

TABLE 54CProtein Sequence Properties NOV54aSignalP analysis:Cleavage site between residues 70 and 71PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 6; pos.chg 1; neg.chg 1H-region: length 9; peak value 7.79PSG score: 3.39GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −2.72possible cleavage site: between 59 and 60>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 4INTEGRALLikelihood = −9.66Transmembrane 44-60INTEGRALLikelihood = −9.71Transmembrane 152-168INTEGRALLikelihood = −5.79Transmembrane 193-209INTEGRALLikelihood = 0.16Transmembrane 221-237PERIPHERALLikelihood = 1.11 (at 10)ALOM score: −9.71 (number of TMSs: 4)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 51Charge difference: 0.0 C(−1.0) − N(−1.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment(75):6.56Hyd Moment(95):1.99G content:0D/E content:2S/T content:1Score: −5.34Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 26 LRH|LSNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.1%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: VMKDSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):66.7%: endoplasmic reticulum33.3%: mitochondrial>> prediction for CG56146-02 is end (k = 9)

A search of the NOV54a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 54D.

TABLE 54DGeneseq Results for NOV54aNOV54aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU11100Human novel G protein-coupled 1 . . . 269268/269 (99%)e−152receptor, NOV7 - Homo sapiens,47 . . . 315268/269 (99%)315 aa. [WO200177177-A2, 18-OCT-2001]AAU85251G-coupled olfactory receptor #112 - 1 . . . 269268/269 (99%)e−152Homo sapiens, 315 aa.47 . . . 315268/269 (99%)[WO200198526-A2, 27-DEC-2001]AAU95586Human olfactory and pheromone 1 . . . 269268/269 (99%)e−152G protein-coupled receptor #73 -47 . . . 315268/269 (99%)Homo sapiens, 315 aa.[WO200224726-A2, 28-MAR-2002]AAU24631Human olfactory receptor 1 . . . 269268/269 (99%)e−152AOLFR125 - Homo sapiens, 31547 . . . 315268/269 (99%)aa. [WO200168805-A2, 20-SEP-2001]ABP95851Human GPCR polypeptide SEQ 1 . . . 267266/267 (99%)e−151ID NO 512 - Homo sapiens, 31447 . . . 313266/267 (99%)aa. [WO200216548-A2, 28-FEB-2002]

In a BLAST search of public sequence databases, the NOV54a protein was found to have homology to the proteins shown in the BLASTP data in Table 54E.

TABLE 54EPublic BLASTP Results for NOV54aNOV54aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedNumberProtein/Organism/LengthResiduesPortionExpect ValueQ8NGZ2Seven transmembrane helix 1 . . . 269268/269 (99%)e−152receptor - Homo sapiens47 . . . 315268/269 (99%)(Human), 315 aa.Q96R53Olfactory receptor - Homo20 . . . 236216/217 (99%)e−120sapiens (Human), 217 aa 1 . . . 217216/217 (99%)(fragment).CAD35484Sequence 23 from Patent 3 . . . 257134/255 (52%)6e−77WO0208289 - Homo sapiens49 . . . 303181/255 (70%)(Human), 314 aa.Q8NHC5Seven transmembrane helix 3 . . . 257138/259 (53%)2e−76receptor - Homo sapiens49 . . . 302192/259 (73%)(Human), 309 aa.CAD35483Sequence 21 from Patent 3 . . . 257134/255 (52%)3e−76WO0208289 - Homo sapiens49 . . . 303180/255 (70%)(Human), 314 aa.

PFam analysis indicates that the NOV54a protein contains the domains shown in the Table 54F.

TABLE 54FDomain Analysis of NOV54aIdentities/SimilaritiesPfamNOV54afor the MatchedExpectDomainMatch RegionRegionValue7tm_11 . . . 242 53/277 (19%)8.5e−07162/277 (58%)

Example 55

The NOV55 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 55A.

TABLE 55ANOV55 Sequence AnalysisNOV55a, CG56258-04SEQ ID NO: 8552828 bpDNA SequenceORF Start: ATG at 63ORF Stop: TAA at 2826GTCTCTGGCCTATCAGGAGGACAACTGGTGCTGCAATAGAAGCCAGTGGCTAAGTCTCGTGTATGGCGTGGTTAAGGTTGCAGCCTCTCACCTCTGCCTTCCTCCATTTTGGGCTGGTTACCTTTGTGCTCTTCCTGAATGGTCTTCGAGCAGAGGCTGGTGGCTCAGGGGACGTGCCAAGCACAGGGCAGAACAATGAGTCCTGTTCAGGGTCATCGGACTGCAAGGAGGGTGTCATCCTGCCAATCTGGTACCCGGAGAACCCTTCCCTTGGGGACAAGATTGCCAGGGTCATTGTCTATTTTGTGGCCCTGATATACATGTTCCTTGGGGTGTCCATCATTGCTGACCGCTTCATGGCATCTATTGAAGTCATCACCTCTCAAGAGAGGGAGGTGACAATTAAGAAACCCAATGGAGAAACCAGCACAACCACTATTCGGGTCTGGAATGAAACTGTCTCCAACCTGACCCTTATGGCCCTGGGTTCCTCTGCTCCTGAGATACTCCTCTCTTTAATTGAGGTGTGTGGTCATGGGTTCATTGCTGGTGATCTGGGACCTTCTACCATTGTAGGGAGTGCAGCCTTCAACATGTTCATCATCATTGGCATCTGTGTCTACGTGATCCCAGACGGAGAGACTCGCAAGATCAAACATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGTATCTTTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCTCCCCTGGTGTGGTCCAGGTTTGGGAAGGCCTCCTCACTCTCTTCTTCTTTCCAGTGTGTGTCCTTCTGGCCTGGGTGGCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAAGTACCGCACAGACAAACACCGAGGAATTATCATAGAGACAGAGGGTGACCACCCTAAGGGCATTGAGATGGATGGGAAAATGATGAATTCCCATTTTCTGATGGGAACCTGGTGCCCCTGGAAGGGAAGGAAGTGGATGAGTCCCGCAGAGAGATGATCCGGAATTCTCAAGGATCTGAAGCAAAAACACCCAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTTCCCACCAACAGAAGAGCCGCGCCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGCAGGCAATATCCTGAAGAAACATGCAGCAGAACAAGCCAAGAAGGCCTCCAGCATGAGCGAGGTGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTTCTTACCAGTGCCTGGAGAACTGTGGGGCTGTACTCCTGACAGTGGTGAGGAAAGGGGGAGACATGTCAAAGACCATGTATGTGGACTACAAAACAGAGGATGGTTCTGCCAATGCAGGGGCTGACTATGAGTTCACAGAGGGCACGGTGGTTCTGAAGCCAGGAGAGACCCAGAAGGAGTTCTCCGTGGGCATAATTGATGACGACATTTTTGAGGAGGATGAACACTTCTTTGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCAGCAATATTCAACAGTCTTCCCTTGCCTCGGGCTGTCCTAGCCTCCCCTTGTGTGGCCACAGTTACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTTGAATGTGATACTATTCATGTCAGTGAGAGTATTGGTGTTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCCCGGGGTACAGTCATCGTCCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTGAGGACTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAAACTGTGAAAACCATAAGGGTTAAAATAGTAGATGAGGAGGAATACGAAAGGCAAGAGAATTTCTTCATTGCCCTTGGTGAACCGAAATGGATGGAACGTGGAATATCAGATGTGACAGACAGGAAGCTGACTATGGAAGAAGAGGAGGCCAAGAGGATAGCAGAGATGGGAAAGCCAGTATTGGGTGAACACCCCAAACTAGAACTCATCATTGAAGAGTCCTATGAGTTCAAGACTACGGTGGACAAACTGATCAAGAAGACAAACCTGGCCTTGGTTGTGGGGACCCATTCCTGGAGGGACCAGTTCATGGAGGCCATCACCGTCAGTGCAGCAGGGGATGAGGATGAGGATGAATCCGGGGAGGAGAGGCTGCCCTCCTGCTTTGACTACGTCATGCACTTCCTGACTGTCTTCTGGAAGGTGCTGTTTGCCTGTGTGCCCCCCACAGAGTACTGCCACGGCTGGGCCTGCTTCGCCGTCTCCATCCTCATCATTGGCATGCTCACCGCCATCATTGGGGACCTGGCCTCGCACTTCGGCTGCACCATTGGTCTCAAAGATTCAGTCACAGCTGTTGTTTTCGTGGCATTTGGCACCTCTGTCCCAGATACGTTTGCCAGCAAAGCTGCTGCCCTCCAGGATGTATATGCAGACGCCTCCATTGGCAACGTGACGGGCAGCAACGCCGTCAATGTCTTCCTGGGCATCGGCCTGGCCTGGTCCGTGGCCGCCATCTACTGGGCTCTGCAGGGACAGGAGTTCCACGTGTCGGCCGGCACACTGGCCTTCTCCGTCACCCTCTTCACCATCTTTGCATTTGTCTGCATCAGCGTGCTCTTGTACCGAAGGCGGCCGCACCTGGGAGGGGAGCTTGGTGGCCCCCGTGGCTGCAAGCTCGCCACAACATGGCTCTTTGTGAGCCTGTGGCTCCTCTACATACTCTTTGCCACACTAGAGGCCTATTGCTACATCAAGGGGTTCTAANOV55a, CG56258-04Protein SequenceSEQ ID NO: 856921 aaMW at 1024 13.7kDMAWLRLQPLTSAFLHFGLVTFVLFLNGLRAEAGGSGDVPSTGQNNESCSGSSDCKEGVILPIWYPENPSLGDKIARVIVYFVALIYMFLGVSIIADRFMASIEVITSQEREVTIKKPNGETSTTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCGHGFIAGDLGPSTIVGSAAFNMFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVVQVWEGLLTLFFFPVCVLLAWVADKRLLFYKYMHKKYRTDKHRGIIIETEGDHPKGIEMDGKMMNSHFLDGNLVPLEGKEVDESRREMIRILKDLKQKHPEKDLDQLVEMANYYALSHQQKSRAFYRIQATRMMTGAGNILKKHAAEQAKKASSMSEVHTDEPEDFISKVFFDPCSYQCLENCGAVLLTVVRKGGDMSKTMYVDYKTEDGSANAGADYEFTEGTVVLKPGETQKEFSVGIIDDDIFEEDEHFFVRLSNVRIEEEQPEEGMPPAIFNSLPLPRAVLASPCVATVTILDDDHAGIFTFECDTIHVSESIGVMEVKVLRTSGARGTVIVPFRTVEGTAKGGGEDFEDTYGELEFKNDETVKTIRVKIVDEEEYERQENFFIALGEPKWMERGISDVTDRKLTMEEEEAKRIAEMGKPVLGEHPKLEVIIEESYEFKTTVDKLIKKTNLALVVGTHSWRDQFMEAITVSAAGDEDEDESGEERLPSCFDYVMHFLTVFWKVLFACVPPTEYCHGWACFAVSILIIGMLTAIIGDLASHFGCTIGLKDSVTAVVFVAFGTSVPDTFASKAAALQDVYADASIGNVTGSNAVNVFLGIGLAWSVAAIYWALQGQEFHVSAGTLAFSVTLFTIFAFVCISVLLYRRRPHLGGELGGPRGCKLATTWLFVSLWLLYILFATLEAYCYIKGFNOV55b, CG56258-02SEQ ID NO: 8572840 bpDNA SequenceORF Start: ATG at 63ORF Stop: TAA at 2838GTCTCTGGCCTATCAGGAGGACAACTGGTGCTGCAATAGAAGCCAGTGGCTAAGTCTCGTGTATGGCGTGGTTAAGGTTGCAGCCTCTCACCTCTGCCTTCCTCCATTTTGGGCTGGTTACCTTTGTGCTCTTCCTGAATGGTCTTCGAGCAGAGGCTGGTGGCTCAGGGGACGTGCCAAGCACAGGGCAGAACAATGAGTCCTGTTCAGGGTCATCGGACTGCAAGGAGGGTGTCATCCTGCCAATCTGGTACCCGGAGAACCCTTCCCTTGGGGACAAGATTGCCAGGGTCATTGTCTATTTTGTGGCCCTGATATACATGTTCCTTGGGGTGTCCATCATTGCTGACCGCTTCATGGCATCTATTGAAGTCATCACCTCTCAAGAGAGGGAGGTGACAATTAAGAAACCCAATGGAGAAACCAGCACAACCACTATTCGGGTCTGGAATGAAACTGTCTCCAACCTGACCCTTATGGCCCTGGGTTCCTCTGCTCCTGAGATACTCCTCTCTTTAATTGAGGTGTGTGGTCATGGGTTCATTGCTGGTGATCTGGGACCTTCTACCATTGTAGGGAGTGCAGCCTTCAACATGTTCATCATCATTGGCATCTGTGTCTACGTGATCCCAGACGGAGAGACTCGCAAGATCAAGCATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGTATCTTTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCTCCCCTGGTGTGGTCCAGGTTTGGGAAGGCCTCACTGCTCTCTTCTTCTTTCCAGTGTGTGTCCTTCTGGCCTGGGTGGCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAAGTACCGCACAGACAAACACCGAGGAATTATCATAGAGACAGAGGGTGACCACCCTAAGGGCATTGAGATGGGAAAATGGGTGATGAATTCCCATTTTCTAGATGGGAACCTGGTGCCCCTGGAGGGAAGGGAAGTGGATGAGTCCCGCAGAGAGATGATCCGGATTCTCAAGGATCTGAAGCAAAAACACCCAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTTCCCACCAACAGAAGAGCCGTGCCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGCAGGCAATATCCTGAAGAAACATGCAGCAGAACAAGCCAAGAAGGCCTCCAGCATGAGCGAGGTGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTTCTTACCAGTGCCTGGAGAACTGTGGGGCTGTACTCCTGACAGTGGTGAGGAAAGGGGGAGACATGTCAAAGACCATGTATGTGGACTACAAAACAGAGGATGGTTCTGCCAATGCAGGGGCTGACTATGAGTTCACAGAGGGCACGGTGGTTCTGAAGCCAGGAGAGACCCAGAAGGAGTTCTCCGTGGGCATAATTGATGACGACATTTTTGAGGAGGATGAACACTTCTTTGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCAGCAATATTCAACAGTCTTCCCTTGCCTCGGGCTGTCCTAGCCTCCCCTTGTGTGGCCACAGTTACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTTGAATGTGATACTATTCATGTCAGTGAGAGTATTGGTGTTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCCCGGGGTACAGTCATCGTCCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTGAGGACTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAAACTGTCAAAACAATTCACATCAAGGTAATTGATGATGAGGCATATGAGAAAAACAAGAATTACTTCATTGAGATGATGGGCCCCCGCATGGTGGATATGAGTTTTCAGAAAGCGCTCCTGTTATCTCCAGACAGGAAGCTGACTATGGAAGAAGAGGAGGCCAAGAGGATAGCAGAGATGGGAAAGCCAGTATTGGGTGAACACCCCAAACTAGAAGTCATCATTGAAGAGTCCTATGAGTTCAAGACTACGGTGGACAAACTGATCAAGAAGACAAACCTGGCCTTGGTTGTGGGGACCCATTCCTGGAGGGACCAGTTCATGGAGGCCATCACCGTCAGTGCAGCAGGGGATGAGGATGAGGATGAATCCGGGGAGGAGAGGCTGCCCTCCTGCTTTGACTACGTCATGCACTTCCTGACTGTCTTCTGGAAGGTGCTGTTTGCCTGTGTGCCCCCCACAGAGTACTGCCACGGCTGGGCCTGCTTCGCCGTCTCCATCCTCATCATTGGCATGCTCACCGCCATCATTGGGGACCTGGCCTCGCACTTCGGCTGCACCATTGGTCTCAAAGATTCAGTCACAGCTGTTGTTTTCGTGGCATTTGGCACCTCTGTCCCAGATACGTTTGCCAGCAAAGCTGCTGCCCTCCAGGATGTATATGCAGACGCCTCCATTGGCAACGTGACGGGCAGCAACGCCGTCAATGTCTTCCTGGGCATCGGCCTGGCCTGGTCCGTGGCCGCCATCTACTGGGCTCTGCAGGGACAGGAGTTCCACGTGTCGGCCGGCACACTGGCCTTCTCCGTCACCCTCTTCACCATCTTTGCATTTGTCTGCATCAGCGTGCTCTTGTACCGAAGGCGGCCGCACCTGGGAGGGGAGCTTGGTGGCCCCCGTGGCTGCAAGCTCGCCACAACATGGCTCTTTGTGAGCCTGTGGCTCCTCTACATACTCTTTGCCACACTAGAGGCCTATTGCTACATCAAGGGGTTCTAANOV55b, CG56258-02Protein SequenceSEQ ID NO: 858925 aaMW at 102802.3kDMAWLRLQPLTSAFLHFGLVTFVLFLNGLRAEAGGSGDVPSTGQNNESCSGSSDCKEGVILPIWYPENPSLGDKIARVIVYFVALIYMFLGVSIIADRFMASIEVITSQEREVTIKKPNGETSTTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCGHGFIAGDLGPSTIVGSAAFNMFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVVQVWEGLLTLFFFPVCVLLAWVADKRLLFYKYMHKKYRTDKHRGIIIETEGDHPKGIEMDGKMMNSHFLDGNLVPLEGKEVDESRREMIRILKDLKQKHPEKDLDQLVEMANYYALSHQQKSRAFYRIQATRMMTGAGNILKKHAAEQAKKASSMSEVHTDEPEDFISKVFFDPCSYQCLENCGAVLLTVVRKGGDMSKTMYVDYKTEDGSANAGADYEFTEGTVVLKPGETQKEFSVGIIDDDIFEEDEHFFVRLSNVRIEEEQPEEGMPPAIFNSLPLPRAVLASPCVATVTILDDDHAGIFTFECDTIHVSESIGVMEVKVLRTSGARGTVIVPFRTVEGTAKGGGEDFEDTYGELEFKNDETVKTIHIKVIDDEAYEKNKNYFIEMMGPRMVDMSFQKALLLSPDRKLTMEEEEAKRIAEMGKPVLGEHPKLEVIIEESYEFKTTVDKLIKKTNLALVVGTHSWRDQFMEAITVSAAGDEDEDESGEERLPSCFDYVMHFLTVFWKVLFACVPPTEYCHGWACFAVSILIIGMLTAIIGDLASHFGCTIGLKDSVTAVVFVAFGTSVPDTFASKAAALQDVYADASIGNVTGSNAVNVFLGIGLAWSVAAIYWALQGQEFHVSAGTLAFSVTLFTIFAFVCISVLLYRRRPHLGGELGGPRGCKLATTWLFVSLWLLYILFATLEAYCYIKGFNOV55c, 258076220SEQ ID NO: 8592778 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGGCGTGGTTAAGGTTGCAGCCTCTCACCTCTGCCTTCCTCCATTTTGGGCTGGTTACCTTTGTGCTCTTCCTGAATGGTCTTCGAGCAGAGGCTGGTGGCTCAGGGGACGTGCCAAGCACAGGGCAGAACAATGAGTCCTGTTCAGGGTCATCGGACTGCAAGGAGGGTGTCATCCTGCCAATCTGGTACCCGGAGAACCCTTCCCTTGGGGACAAGATTGCCAGGGTCATTGTCTATTTTGTGGCCCTGATATACATGTTCCTTGGGGTGTCCATCATTGCTGACCGCTTCATGGCATCTATTGAAGTCATCACCTCTCAAGAGAGGGAGGTGACAATTAAGAAACCCAATGGAGAAACCAGCACAACCACTATTCGGGTCTGGAATGAAACTGTCTCCAACCTGACCCTTATGGCCCTGGGTTCCTCTGCTCCTGAGATACTCCTCTCTTTAATTGAGGTGTGTGGTCATGGGTTCATTGCTGGTGATCTGGGACCTTCTACCATTGTAGGGAGTGCAGCCTTCAACATGTTCATCATCATTGGCATCTGTGTCTACGTGATCCCAGACGGAGAGACTCGCAAGATCAAGCATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGTATCTTTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCTCCCCTGGTGTGGTCCAGGTTTGGGAAGGCCTCCTCACTCTCTTCTTCTTTCCAGTGTGTGTCCTTCTGGCCTGGGTGGCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAAGTACCGCACAGACAAACACCGAGGAATTATCATAGAGACAGAGGGTGACCACCCTAAGGGCATTGAGATGGATGGGAAAATGATGAATTCCCATTTTCTAGATGGGAACCTGGTGCCCCTGGAAGGGAAGGAAGTGGATGAGTCCCGCAGAGAGATGATCCGGATTCTCAAGGATCTGAAGCAAAAACACCCAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTTCCCACCAACAGAAGAGCCGCGCCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGCAGGCAATATCCTGAAGAAACATGCAGCAGAACAAGCCAAGAAGGCCTCCAGCATGAGCGAGGTGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTTCTTACCAGTGCCTGGAGAACTGTGGGGCTGTACTCCTGACAGTGGTGAGGAAAGGGGGAGACATGTCAAAGACCATGTATGTGGACTACAAAACAGAGGATGGTTCTGCCAATGCAGGGGCTGACTATGAGTTCACAGAGGGCACGGTGGTTCTGAAGCCAGGAGAGACCCAGAAGGAGTTCTCCGTGGGCATAATTGATGACGACATTTTTGAGGAGGATGAACACTTCTTTGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCAGCAATATTCAACAGTCTTCCCTTGCCTCGGGCTGTCCTAGCCTCCCCTTGTGTGGCCACAGTTACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTTGAATGTGATACTATTCATGTCAGTGAGAGTATTGGTGTTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCCCGGGGTACAGTCATCGTCCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTGAGGACTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAAACTGTGAAAACCATAAGGGTTAAAATAGTAGATGAGGAGGAATACGAAAGGCAAGAGAATTTCTTCATTGCCCTTGGTGAACCGAAATGGATGGAACGTGGAATATCAGATGTGACAGACAGGAAGCTGACTATGGAAGAAGAGGAGGCCAAGAGGATAGCAGAGATGGGAAAGCCAGTATTGGGTGAACACCCCAAACTAGAAGTCATCATTGAAGAGTCCTATGAGTTCAAGACTACGGTGGACAAACTGATCAAGAAGACAAACCTGGCCTTGGTTGTGGGGACCCATTCCTGGAGGGACCAGTTCATGGAGGCCATCACCGTCAGTGCAGCAGGGGATGAGGATGAGGATGAATCCGGGGAGGAGAGGCTGCCCTCCTGCTTTGACTACGTCATGCACTTCCTGACTGTCTTCTGGAAGGTGCTGTTTGCCTGTGTGCCCCCCACAGAGTACTGCCACGGCTGGGCCTGCTTCGCCGTCTCCATCCTCATCATTGGCATGCTCACCGCCATCATTGGGGACCTGGCCTCGCACTTCGGCTGCACCATTGGTCTCAAAGATTCAGTCACAGCTGTTGTTTTCGTGGCATTTGGCACCTCTGTCCCAGATACGTTTGCCAGCAAAGCTGCTGCCCTCCAGGATGTATATGCAGACGCCTCCATTGGCAACGTGACGGGCAGCAACGCCGTCAATGTCTTCCTGGGCATCGGCCTGGCCTGGTCCGTGGCCGCCATCTACTGGGCTCTGCAGGGACAGGAGTTCCACGTGTCGGCCGGCACACTGGCCTTCTCCGTCACCCTCTTCACCATCTTTGCATTTGTCTGCATCAGCGTGCTCTTGTACCGAAGGCGGCCGCACCTGGGAGGGGAGCTTGGTGGCCCCCGTGGCTGCAAGCTCGCCACAACATGGCTCTTTGTGAGCCTGTGGCTCCTCTACATACTCTTTGCCACACTAGAGGCCTATTGCTACATCAAGGGGTTCCTCGAGNOV55c, 258076220Protein SequenceSEQ ID NO: 860926 aaMW at 102901.2kDGSTMAWLRLQPLTSAFLHFGLVTFVLFLNGLRAEAGGSGDVPSTGQNNESCSGSSDCKEGVILPIWYPENPSLGDKIARVIVYFVALIYMFLGVSIIADRFMASIEVITSQEREVTIKKPNGETSTTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCGHGFIAGDLGPSTIVGSAAFNMFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVVQVWEGLLTLFFFPVCVLLAWVADKRLLFYKRMHKKYRTDKHRGIIIETEGDHPKGIEMDGKMMNSHFLDGNLVPLEGKEVDESRREMIRILKDLKQKHPEKDLDQLVEMANYYALSHQQKSRAFYRIQATRMMTGAGNILKKHAAEQAKKASSMSEVHTDEPEDFISKVFFDPCSYQCLENCGAVLLTVVRKGGDMSKTMYVDYKTEDGSANAGADYEFTEGTVVLKPGETQKEFSVGIIDDDIFEEDEHFFVRLSNVRIEEEQPEEGMPPAIFNSLPLPRAVLASPCVATVTILDDDHAGIFTFECDTIHVSESIGVMEVKVLRTSGARGTVIVPFRTVEGTAKGGGEDFEDTYGELEFKNDETVKTIRVKIVDEEEYERQENFFIALGEPKWMERGISDVTDRKLTMEEEEAKRIAEMGKPVLGEHPKLEVIIEESYEFKTTVDKLIKKTNLALVVGTHSWRDQFMEAITVSAAGDEDEDESGEERLPSCFDYVMHFLTVFWKVLFACVPPTEYCHGWACFAVSILIIGMLTAIIGDLASHFGCTIGLKDSVTAVVFVAFGTSVPDTFASKAAALQDVYADASIGNVTGSNAVNVFLGIGLAWSVAAIYWALQGQEFHVSAGTLAFSVTLFTIFAFVCISVLLYRRRPHLGGELGGPRGCKLATTWLFVSLWLLYILFATLEAYCYIKGFLENOV55d, 248057963SEQ ID NO: 8612685 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCGAGGCTGGTGGCTCAGGGGACGTGCCAAGCACAGGGCAGAACAATGAGTCCTGTTCAGGGTCATCGGACTGCAAGGAGGGTGTCATCCTGCCAATCTGGTACCCGGAGAACCCTTCCCTTGGGGACAAGATTGCCAGGGTCATTGTCTATTTTGTGGCCCTGATATACATGTTCCTTGGGGTGTCCATCATTGCTGACCGCTTCATGGCATCTATTGAGTCATCACCTCTCAAGAGAGGGAGGTGACAATTAAGAAACCCAATTGGAGAAACCAGCACAACCACTATTCGGGTCTGGAATGAAACTGTCTCCAACCTGACCCTTATGGCCCTGGGTTCCTCTGCTCCTGAGATACTCCTCTCTTTAATTGAGGTGTGTGGTCATGGGTTCATTGCTGGTGATCTGGGACCTTCTACCATTGTAGGGAGTGCAGCCTTCAACATGTTCATCATCATTGGCATCTGTGTCTACGTGATCCCAGACGGAGAGACTCGCAAGATCAAACATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGTATCTTTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCTCCCCTGGTGTGGTCCAGGTTTGGGAAGGCCTCCTCACTCTCTTCTTCTTTCCAGTGTGTGTCCTTCTGGCCTGGGTGGCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAAGTACCGCACAGACAAACACCGAGGAATTATCATAGAGACAGAGGGTGACCACCCTAAGGGCATTGAGATGGATGGGAAAATGATGAATTCCCATTTTCTAGATGGGAACCTGGTGCCCCTGGAAGGGAAGGAAGTGGATGAGTCCCGCAGAGAGATGATCCGGATTCTCAAGGATCTGAAGCAAAAACACCCAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTTCCCACCAACAGAAGAGCCGCGCCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGCAGGCAATATCCTGAAGAAACATGCAGCAGAACAAGCCAAGAAGGCCTCCAGCATGAGCGAGGTGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTTCTTACCAGTGCCTGGAGAACTGTGGGGCTGTACTCCTGACAGTGGTGAGGAAAGGGGGAGACATGTCAAAGACCATGTATGTGGACTACAAAACAGAGGATGGTTCTGCCAATGCAGGGGCTGACTATGAGTTCACAGAGGGCACGGTGGTTCTGAAGCCAGGAGAGACCCAGAAGGAGTTCTCCGTGGGCATAATTGATGACGACATTTTTGAGGAGGATGAACACTTCTTTGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCAGCAATATTCAACAGTCTTCCCTTGCCTCGGGCTGTCCTAGCCTCCCCTTGTGTGGCCACAGTTACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTTGAATGTGATACTATTCATGTCAGTGAGAGTATTGGTGTTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCCCGGGGTACAGTCATCGTCCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTGAGGACTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAAACTGTGAAAACCATAAGGGTTAAAATAGTAGATGAGGAGGAATACGAAAGGCAAGAGAATTTCTTCATTGCCCTTGGTGAACCGAAATGGATGGAACGTGGAATATCAGATGTGACAGACAGGAAGCTGACTATGGAAGAAGAGGAGGCCAAGAGGATAGCAGAGATGGGAAAGCCAGTATTGGGTGAACACCCCAAACTAGAAGTCATCATTGAAGAGTCCTATGAGTTCAAGACTACGGTGGACAAACTGATCAAGAAGACAAACCTGGCCTTGGTTGTGGGGACCCATTCCTGGAGGGACCAGTTCATGGAGGCCATCACCGTCAGTGCAGCAGGGGATGAGGATGAGGATGAATCCGGGGAGGAGAGGCTGCCCTCCTGCTTTGACTACGTCATGCACTTCCTGACTGTCTTCTGGAAGGTGCTGTTTGCCTGTGTGCCCCCCACAGAGTACTGCCACGGCTGGGCCTGCTTCGCCGTCTCCATCCTCATCATTGGCATGCTCACCGCCATCATTGGGGACCTGGCCTCGCACTTCGGCTGCACCATTGGTCTCAAAGATTCAGTCACAGCTGTTGTTTTCGTGGCATTTGGCACCTCTGTCCCAGATACGTTTGCCAGCAAAGCTGCTGCCCTCCAGGATGTATATGCAGACGCCTCCATTGGCAACGTGACGGGCAGCAACGCCGTCAATGTCTTCCTGGGCATCGGCCTGGCCTGGTCCGTGGCCGCCATCTACTGGGCTCTGCAGGGACAGGAGTTCCACGTGTCGGCCGGCACACTGGCCTTCTCCGTCACCCTCTTCACCATCTTTGCATTTGTCTGCATCAGCGTGCTCTTGTACCGAAGGCGGCCGCACCTGGGAGGGGAGCTTGGTGGCCCCCGTGGCTGCAAGCTCGCCACAACATGGCTCTTTGTGAGCCTGTGGCTCCTCTACATACTCTTTGCCACACTAGAGGCCTATTGCTACATCAAGGGGTTCCTCGAGNOV55d, 248057963Protein SequenceSEQ ID NO: 862895 aaMW at 99385.0kDGSEAGGSGDVPSTGQNNESCSGSSDCKEGVILPIWYPENPSLGDKIARVIVYFVALIYMFLGVSIIADRFMASIEVITSQEREVTIKKPNGETSTTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCGHGFIAGDLGPSTIVGSAAFNNFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVVQVWEGLLTLFFFPVCVLLAWVADKRLLFYKYMHKKYRTDKHRGIIIETEGDHPKGIEMDGKMMNSHFLDGNLVPLEGKEVDESRREMIRILKDLKQKHPEKDLDQLVEMANYYALSHQQKSRAFYRIQATRNMTGAGNILKKHAAEQAKKASSMSEVNTDEPEDFISKVFFDPCSYQCLENCGAVLLTVVRKGGDMSKTMYVDYKTEDGSANAGADYEFTEGTVVLKPGETQKEFSVGIIDDDIFEEDEHFFVRLSNVRIEEEQPEEGMPPAIFNSLPLPRAVLASPCVATVTILDDDHAGIFTFECDTIHVSESIGVMEVKVLRTSGARGTVIVPFRTVEGTAKGGGEDFEDTYGELEFKNDETVKTIRVKIVDEEEYERQENFFIALGEPKWMERGISDVTDRKLTMEEEEAKRIAEMGKPVLGEHPKLEVIIEESYEFKTTVDKLIKKTNLALVVGTHSWRDQFMEAITVSAAGDEDEDESGEERLPSCFDYVMHFLTVFWKVLFACVPPTEYCHGWACFAVSILIIGMLTAIIGDLASHFGCTIGLKDSVTAVVFVAFGTSVPDTFASKAAALQDVYADASIGNVTGSNAVNVFLGIGLAWSVAAIYWALQGQEFHVSAGTLAFSVTLFTIFAFVCISVLLYRRRPHLGGELGGPRGCKLATTWLFVSLWLLYILFATLEAYCYIKGFLENOV55e, CG56258-01SEQ ID NO: 8632813 bpDNA SequenceORF Start: ATG at 9ORF Stop: TAG at 2793TCTCGTGTATGGCGTGGTTAAGGTTGCAGCCTCTCACCTCTGCCTTCCTCCATTTTGGGCTGGTTACCTTTGTGCTCTTCCTGAATGGTCTTCGAGCAGAGGCTGGTGGCTCAGGGGACGTGCCAAGCACAGGGCAGAACAATGAGTCCTGTTCAGGGTCATCGGACTGCAAGGAGGGTGTCATCCTGCCAATCTGGTACCCGGAGAACCCTTCCCTTGGGGACAAGATTGCCAGGGTCATTGTCTATTTTGTGGCCCTGATATACATGTTCCTTGGGGTGTCCATCATTGCTGACCGCTTCATGGCATCTATTGAAGTCATCACCTCTCAAGAGAGGGAGGTGACAATTAAGAAACCCAATGGAGAAACCAGCACAACCACTATTCGGGTCTGGAATGAAACTGTCTCCAACCTGACCCTTATGGCCCTGGGTTCCTCTGCTCCTGAGATACTCCTCTCTTTAATTGAGGTGTGTGGTCATGGGTTCATTGCTGGTGATCTGGGACCTTCTACCATTGTAGGGAGTGCAGCCTTCAACATGTTCATCATCATTGGCATCTGTGTCTACGTGATCCCAGACGGAGAGACTCGCAAGATCAAGCATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGTATCTTTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCCCCCCTGGTGTGGTCCAGGTTTGGGAAGGCCTCCTCACTCTCTTCTTCTTTCCAGTGTGTGTCCTTCTGGCCTGGGTGGCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAAGTACCGCACAGACAAACACCGAGGAATTATCATAGAGACAGAGGGTGACCACCCTAAGGGCATTGAGATGGATGGGAAAATGATGAATTCCCATTTTCTAGATGGGAACCTGGTGCCCCTGGAAGGGAAGGAAGTGGATGAGTCCCGCAGAGAGATGATCCGGATTCTCAAGGATCTGAAGCAAAAACACCCAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTTCCCACCAACAGAAGAGCCGTGCCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGCAGGCAATATCCTGAAGAAACATGCAGCAGAACAAGCCAAGAAGGCCTCCAGCATGAGCGAGGTGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTTCTTACCAGTGCCTGGAGAACTGTGGGGCTGTACTCCTGACAGTGGTGAGGAAAGGGGGAGACATGTCAAAGACCATGTATGTGGACTACAAAACAGAGGATGGTTCTGCCAATGCAGGGGCTGACTATGAGTTCACAGAGGGCACGGTGGTTCTGAAGCCAGGAGAGACCCAGAAGGAGTTCTCCGTGGGCATAATTGATGACGACATTTTTGAGGAGGATGAACACTTCTTTGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCAGCAATATTCAACAGTCTTCCCTTGCCTCGGGCTGTCCTAGCCTCCCCTTGTGTGGCCACAGTTACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTTGAATGTGATACTATTCATGTCAGTGAGAGTATTGGTGTTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCCCGGGGTACAGTCATCGTCCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTGAGGACTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAAACTGTGAAAACTCTTCAGGTGAAGATAGTTGATGACGAGGAATATGAGAAAAAGGATAATTTCTTCATTGAGCTGGGCCAGCCCCAGTGGCTTAAGCGAGGGATTTCAGCTCTGCTACTCAATCAAGGGGATGGGGACAGGAAGCTAACAGCCGAGGAGGAGGAGGCTCGGAGGATAGCAGAGATGGGCAAGCCAGTTCTTGGGGAGAACTGCCGGCTGGAGGTCATCATCGAGGAGTCATATGATTTTAAGAACACGGTGGATAAACTCATCAAGAAAACGAACTTGGCCTTGGTAATTGGGACCCATTCATGGAGGGAGCAGTTTTTAGAGGCAATTACGGTGAGCGCAGGGGACGAGGAGGAGGAGGAGGACGGGTCCCGGGAGGAGCGGCTGCCGTCGTGCTTTGACTACGTGATGCACTTCCTGACGGTGTTCTGGAAGGTGCTCTTCGCCTGTGTGCCCCCCACCGAGTACTGCCACGGCTGGGCCTGCTTTGGTGTCTCCATCCTGGTCATCGGCCTGCTCACCGCCCTCATTGGGGACCTCGCCTCCCACTTCGGCTGCACCGTTGGCCTCAAGGACTCTGTCAATGCTGTTGTCTTCGTTGCCCTGGGCACCTCCATCCCTGACACGTTCGCCAGCAAGGTGGCGGCGCTGCAGGACCAGTGCGCCGACGCGTCCATCGGCAACGTGACCGGCTCCAACGCGGTGAACGTGTTCCTTGGCCTGGGCGTCGCCTGGTCTGTGGCCGCCGTGTACTGGGCGGTGCAGGGCCGCCCCTTCGAGGTGCGCACTGGCACGCTGGCCTTCTCCGTCACGCTCTTCACCGTCTTCGCCTTCGTGGGCATTGCCGTGCTGCTGTACCGGCGCCGGCCGCACATCGGCGGCGAGCTGGGCGGCCCGCGCGGACCCAAGCTCGCCACCACCGCGCTCTTCCTGGGCCTCTGGCTCCTGTACATCCTCTTCGCCAGCCTGGAGGCGTACTGCCACATCCGGGGCTTCTAGGGCCTCGCGCAGAGACTCNOV55e, CG56258-01Protein SequenceSEQ ID NO: 864928 aaMW at 102900.1kDMAWLRLQPLTSAFLHFGLVTFVLFLNGLRAEAGGSGDVPSTGQNNESCSGSSDCKEGVILPIWYPENPSLGDKIARVIVYFVALIYMFLGVSIIADRFMASIEVITSQEREVTIKKPNGETSTTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCGHGFIAGDLGPSTIVGSAAFNNFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVVQVWEGLLTLFFFPVCVLLAWVADKRLLFYKYMHKKYRTDKHRGIIIETEGDHPKGIEMDGKMMNSHFLDGNLVPLEGKEVDESRREMIRILKDLKQKHPEKDLDQLVEMANYYALSHQQKSRAFYRIQATRMMTGAGNILKKHAAEQAKKASSMSEVHTDEPEDFISKVFFDPCSYQCLENCGAVLLTVVRKGGDMSKTMYVDYKTEDGSANAGADYEFTEGTVVLKPGETQKEFSVGIIDDDIFEEDEHFFVRLSNVRIEEEQPEEGMPPAIFNSLPLPRAVLASPCVATVTILDDDHAGIFTFECDTIHVSESIGVMEVKVLRTSGARGTVIVPFRTVEGTAKGGGEDFEDTYGELEFKNDETVKTLQVKIVDDEEYEKKDNFFIELGQPQWLKRGISALLLNQGDGDRKLTAEEEEARRIAEMGKPVLGENCRLEVIIEESYDFKNTVDKLIKKTNLALVIGTHSWREQFLEAITVSAGDEEEEEDGSREERLPSCFDYVMHFLTVFWKVLFACVPPTEYCHGWACFGVSILVIGLLTALIGDLASHFGCTVGLKDSVNAVVFVALGTSIPDTFASKVAALQDQCADASIGNVTGSNAVNVFLGLGVAWSVAAVYWAVQGRPFEVRTGTLAFSVTLFTVFAFVGIAVLLYRRRPHIGGELGGPRGPKLATTALFLGLWLLYILFASLEAYCHIRGFNOV55f, CG56258-03SEQ ID NO: 8652685 bpDNA SequenceORF Start: at 7ORF Stop: at 2680GGATCCGAGGCTGGTGGCTCAGGGGACGTGCCAAGCACAGGGCAGAACAATGAGTCCTGTTCAGGGTCATCGGACTGCAAGGAGGGTGTCATCCTGCCAATCTGGTACCCGGAGAACCCTTCCCTTGGGGACAAGATTGCCAGGGTCATTGTCTATTTTGTGGCCCTGATATACATGTTCCTTGGGGTGTCCATCATTGCTGACCGCTTCATGGCATCTATTGAAGTCATCACCTCTCAAGAGAGGGAGGTGACAATTAAGAAACCCAATGGAGAAACCAGCACAACCACTATTCGGGTCTGGAATGAAACTGTCTCCAACCTGACCCTTATGGCCCTGGGTTCCTCTGCTCCTGAGATACTCCTCTCTTTAATTGAGGTGTGTGGTCATGGGTTCATTGCTGGTGATCTGGGACCTTCTACCATTGTAGGGAGTGCAGCCTTCAACATGTTCATCATCATTGGCATCTGTGTCTACGTGATCCCAGACGGAGAGACTCGCAAGATCAAACATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGTATCTTTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCTCCCCTGGTGTGGTCCAGGTTTGGGAAGGCCTCCTCACTCTCTTCTTCTTTCCAGTGTGTGTCCTTCTGGCCTGGGTGGCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAAGTACCGCACAGACAAACACCGAGGAATTATCATAGAGACAGAGGGTGACCACCCTAAGGGCATTGAGATGGATGGGAAAATGATGAATTCCCATTTTCTAGATGGGAACCTGGTGCCCCTGGAAGGGAAGGAAGTGGATGAGTCCCGCAGAGAGATGATCCGGATTCTCAAGGATCTGAAGCAAAAACACCCAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTTCCCACCAACAGAAGAGCCGCGCCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGCAGGCAATATCCTGAAGAAACATGCAGCAGAACAAGCCAAGAAGGCCTCCAGCATGAGCGAGGTGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTTCTTACCAGTGCCTGGAGAACTGTGGGGCTGTACTCCTGACAGTGGTGAGGAAAGGGGGAGACATGTCAAAGACCATGTATGTGGACTACAAAACAGAGGATGGTTCTGCCAATGCAGGGGCTGACTATGAGTTCACAGAGGGCACGGTGGTTCTGAAGCCAGGAGAGACCCAGAAGGAGTTCTCCGTGGGCATAATTGATGACGACATTTTTGAGGAGGATGAACACTTCTTTGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCAGCAATATTCAACAGTCTTCCCTTGCCTCGGGCTGTCCTAGCCTCCCCTTGTGTGGCCACAGTTACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTTGAATGTGATACTATTCATGTCAGTGAGAGTATTGGTGTTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCCCGGGGTACAGTCATCGTCCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTGAGGACTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAAACTGTGAAAACCATAAGGGTTAAAATAGTAGATGAGGAGGAATACGAAAGGCAAGAGAATTTCTTCATTGCCCTTGGTGAACCGAAATGGATGGAACGTGGAATATCAGATGTGACAGACAGGAAGCTGACTATGGAAGAAGAGGAGGCCAAGAGGATAGCAGAGATGGGAAAGCCAGTATTGGGTGAACACCCCAAACTAGAAGTCATCATTGAAGAGTCCTATGAGTTCAAGACTACGGTGGACAAACTGATCAAGAAGACAAACCTGGCCTTGGTTGTGGGGACCCATTCCTGGAGGGACCAGTTCATGGAGGCCATCACCGTCAGTGCAGCAGGGGATGAGGATGAGGATGAATCCGGGGAGGAGAGGCTGCCCTCCTGCTTTGACTACGTCATGCACTTCCTGACTGTCTTCTGGAAGGTGCTGTTTGCCTGTGTGCCCCCCACAGAGTACTGCCACGGCTGGGCCTGCTTCGCCGTCTCCATCCTCATCATTGGCATGCTCACCGCCATCATTGGGGACCTGGCCTCGCACTTCGGCTGCACCATTGGTCTCAAAGATTCAGTCACAGCTGTTGTTTTCGTGGCATTTGGCACCTCTGTCCCAGATACGTTTGCCAGCAAAGCTGCTGCCCTCCAGGATGTATATGCAGACGCCTCCATTGGCAACGTGACGGGCAGCAACGCCGTCAATGTCTTCCTGGGCATCGGCCTGGCCTGGTCCGTGGCCGCCATCTACTGGGCTCTGCAGGGACAGGAGTTCCACGTGTCGGCCGGCACACTGGCCTTCTCCGTCACCCTCTTCACCATCTTTGCATTTGTCTGCATCAGCGTGCTCTTGTACCGAAGGCGGCCGCACCTGGGAGGGGAGCTTGGTGGCCCCCGTGGCTGCAAGCTCGCCACAACATGGCTCTTTGTGAGCCTGTGGCTCCTCTACATACTCTTTGCCACACTAGAGGCCTATTGCTACATCAAGGGGTTCCTCGAGNOV55f, CG56258-03Protein SequenceSEQ ID NO: 866891 aaMW at 98998.6kDEAGGSGDVPSTGQNNESCSGSSDCKEGVILPIWYPENPSLGDKIARVIVYFVALIYMFLGVSIIADRFMASIEVITSQEREVTIKKPNGETSTTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCGHGFIAGDLGPSTIVGSAAFNMFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVVQVWEGLLTLFFFPVCVLLAWVADKRLLFYKYMHKKYRTDKHRGIIIETEGDHPKGIEMDGKMMNSHFLDGNLVPLEGKEVDESRREMIRILKDLKQKHPEKDLDQLVEMANYYALSHQQKSRAFYRIQATRNMTGAGNILKKHAAEQAKKASSMSEVHTDEPEDFISKVFFDPCSYQCLENCGAVLLTVVRKGGDMSKTMYVDYKTEDGSANAGADYEFTEGTVVLKPGETQKEFSVGIIDDDIFEEDEHFFVRLSNVRIEEEQPEEGMPPAIFNSLPLPRAVLASPCVATVTILDDDHAGIFTFECDTIHVSESIGVMEVKVLRTSGARGTVIVPFRTVEGTAKGGGEDFEDTYGELEFKNDETVKTIRVKIVDEEEYERQENFFIALGEPKWMERGISDVTDRKLTMEEEEAKRIAEMGKPVLGEHPKLEVIIEESYEFKTTVDKLIKKTNLALVVGTHSWRDQFMEAITVSAAGDEDEDESGEERLPSCFDYVMHFLTVFWKVLFACVPPTEYCHGWACFAVSILlIGMLTAIIGDLASHFGCTIGLKDSVTAVVFVAFGTSVPDTFASKAAALQDVYADASIGNVTGSNAVNVFLGIGLAWSVAAIYWALQGQEFHVSAGTLAFSVTLFTIFAFVCISVLLYRRRPHLGGELGGPRGCKLATTWLFVSLWLLYILFATLEAYCYIKGFNOV55g, CG56258-05SEQ ID NO: 8672778 bpDNA SequenceORF Start: ATG at 10ORF Stop: at 2773GGATCCACCATGGCGTGGTTAAGGTTGCAGCCTCTCACCTCTGCCTTCCTCCATTTTGGGCTGGTTACCTTTGTGCTCTTCCTGAATGGTCTTCGAGCAGAGGCTGGTGGCTCAGGGGACGTGCCAAGCACAGGGCAGAACAATGAGTCCTGTTCAGGGTCATCGGACTGCAAGGAGGGTGTCATCCTGCCAATCTGGTACCCGGAGAACCCTTCCCTTGGGGACAAGATTGCCAGGGTCATTGTCTATTTTGTGGCCCTGATATACATGTTCCTTGGGGTGTCCATCATTGCTGACCGCTTCATGGCATCTATTGAAGTCATCACCTCTCAAGAGAGGGAGGTGACAATTAAGAAACCCAATGGAGAAACCAGCACAACCACTATTCGGGTCTGGAATGAAACTGTCTCCAACCTGACCCTTATGGCCCTGGGTTCCTCTGCTCCTGAGATACTCCTCTCTTTAATTGAGGTGTGTGGTCATGGGTTCATTGCTGGTGATCTGGGACCTTCTACCATTGTAGGGAGTGCAGCCTTCAACATGTTCATCATCATTGGCATCTGTGTCTACGTGATCCCAGACGGAGAGACTCGCAAGATCAAGCATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGTATCTTTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCTCCCCTGGTGTGGTCCAGGTTTGGGAAGGCCTCCTCACTCTCTTCTTCTTTCCAGTGTGTGTCCTTCTGGCCTGGGTGGCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAAGTACCGCACAGACAAACACCGAGGAATTATCATAGAGACAGAGGGTGACCACCCTAAGGGCATTGAGATGGATGGGAAAATGATGAATTCCCATTTTCTAGATGGGAACCTGGTGCCCCTGGAAGGGAAGGAAGTGGATGAGTCCCGCAGAGAGATGATCCGGATTCTCAAGGATCTGAAGCAAAAACACCCAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTTCCCACCAACAGAAGAGCCGCGCCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGCAGGCAATATCCTGAAGAAACATGCAGCAGAACAAGCCAAGAAGGCCTCCAGCATGAGCGAGGTGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTTCTTACCAGTGCCTGGAGAACTGTGGGGCTGTACTCCTGACAGTGGTGAGGAAAGGGGGAGACATGTCAAAGACCATGTATGTGGACTACAAAACAGAGGATGGTTCTGCCAATGCAGGGGCTGACTATGAGTTCACAGAGGGCACGGTGGTTCTGAAGCCAGGAGAGACCCAGAAGGAGTTCTCCGTGGGCATAATTGATGACGACATTTTTGAGGAGGATGAACACTTCTTTGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCAGCAATATTCAACAGTCTTCCCTTGCCTCGGGCTGTCCTAGCCTCCCCTTGTGTGGCCACAGTTACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTTGAATGTGATACTATTCATGTCAGTGAGAGTATTGGTGTTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCCCGGGGTACAGTCATCGTCCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTGAGGACTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAAACTGTGAAAACCATAAGGGTTAAAATAGTAGATGAGGAGGAATACGAAAGGCAAGAGAATTTCTTCATTGCCCTTGGTGAACCGAAATGGATGGAACGTGGAATATCAGATGTGACAGACAGGAAGCTGACTATGGAAGAAGAGGAGGCCAAGAGGATAGCAGAGATGGGAAAGCCAGTATTGGGTGAACACCCCAAACTAGAAGTCATCATTGAAGAGTCCTATGAGTTCAAGACTACGGTGGACAAACTGATCAAGAAGACAAACCTGGCCTTGGTTGTGGGGACCCATTCCTGGAGGGACCAGTTCATGGAGGCCATCACCGTCAGTGCAGCAGGGGATGAGGATGAGGATGAATCCGGGGAGGAGAGGCTGCCCTCCTGCTTTGACTACGTCATGCACTTCCTGACTGTCTTCTGGAAGGTGCTGTTTGCCTGTGTGCCCCCCACAGAGTACTGCCACGGCTGGGCCTGCTTCGCCGTCTCCATCCTCATCATTGGCATGCTCACCGCCATCATTGGGGACCTGGCCTCGCACTTCGGCTGCACCATTGGTCTCAAAGATTCAGTCACAGCTGTTGTTTTCGTGGCATTTGGCACCTCTGTCCCAGATACGTTTGCCAGCAAAGCTGCTGCCCTCCAGGATGTATATGCAGACGCCTCCATTGGCAACGTGACGGGCAGCAACGCCGTCAATGTCTTCCTGGGCATCGGCCTGGCCTGGTCCGTGGCCGCCATCTACTGGGCTCTGCAGGGACAGGAGTTCCACGTGTCGGCCGGCACACTGGCCTTCTCCGTCACCCTCTTCACCATCTTTGCATTTGTCTGCATCAGCGTGCTCTTGTACCGAAGGCGGCCGCACCTGGGAGGGGAGCTTGGTGGCCCCCGTGGCTGCAAGCTCGCCACAACATGGCTCTTTGTGAGCCTGTGGCTCCTCTACATACTCTTTGCCACACTAGAGGCCTATTGCTACATCAAGGGGTTCCTCGAGNOV55g, CG56258-05Protein SequenceSEQ ID NO: 868921 aaMW at 102413.7kDMAWLRLQPLTSAFLHFGLVTFVLFLNGLRAEAGGSGDVPSTGQNNESCSGSSDCKEGVILPIWYPENPSLGDKIARVIVYFVALIYMFLGVSIIADRFMASIEVITSOEREVTIKKPNGETSTTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCGHGFIAGDLGPSTIVGSAAFNMFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVVQVWEGLLTLFFFPVCVLIAWVADKRLLFYKYMHKKYRTDKHRGIIIETEGDHPKGIEMDGKMMNSHFLDGNLVPLEGKEVDESRREMIRILKDLKQKHPEKDLDQLVEMANYYALSHQQKSRAFYRIQATRMMTGAGNILKKHAAEQAKKASSMSEVHTDEPEDFISKVFFDPCSYQCLENCGAVLLTVVRKGGDMSKTMYVDYKTEDGSANAGADYEFTEGTVVLKPGETQKEFSVGIIDDDIFEEDEHFFVRLSNVRIEEEQPEEGMPPAIFNSLPLPRAVLASPCVATVTILDDDHAGIFTFECDTIHVSESIGVMEVKVLRTSGARGTVIVPFRTVEGTAKGGGEDFEDTYGELEFKNDETVKTIRVKIVDEEEYERQENFFIALGEPKWMERGISDVTDRKLTMEEEEAKRIAEMGKPVLGEHPKLEVIIEESYEFKTTVDKLIKKTNLALVVGTHSWRDQFMEAITVSAAGDEDEDESGEERLPSCFDYVMHFLTVFWKVLFACVPPTEYCHGWACFAVSILIIGMLTAIIGDLASHFGCTIGLKDSVTAVVFVAFGTSVPDTFASKAAALQDVYADASIGNVTGSNAVNVFLGIGLAWSVAAIYWALQGQEFHVSAGTLAFSVTLFTIFAFVCISVLLYRRRPHLGGELGGPRGCKLATTWLFVSLWLLYILFATLEAYCYIKGFNOV55h, CG56258-06SEQ ID NO: 8692813 bpDNA SequenceORF Start: ATG at 9ORF Stop: TAG at 2793TCTCGTGTATGGCGTGGTTAAGGTTGCAGCCTCTCACCTCTGCCTTCCTCCATTTTGGGCTGGTTACCTTTGTGCTCTTCCTGAATGGTCTTCGAGCAGAGGCTGGTGGCTCAGGGGACGTGCCAAGCACAGGGCAGAACAATGAGTCCTGTTCAGGGTCATCGGACTGCAAGGAGGGTGTCATCCTGCCAATCTGGTACCCGGAGAACCCTTCCCTTGGGGACAAGATTGCCAGGGTCATTGTCTATTTTGTGGCCCTGATATACATGTTCCTTGGGGTGTCCATCATTGCTGACCGCTTCATGGCATCTATTGAAGTCATCACCTCTCAAGAGAGGGAGGTGACAATTAAGAAACCCAATGGAGAAACCAGCACAACCACTATTCGGGTCTGGAATGAAACTGTCTCCAACCTGACCCTTATGGCCCTGGGTTCCTCTGCTCCTGAGATACTCCTCTCTTTAATTGAGGTGTGTGGTCATGGGTTCATTGCTGGTGATCTGGGACCTTCTACCATTGTAGGGAGTGCAGCCTTCAACATGTTCATCATCATTGGCATCTGTGTCTACGTGATCCCAGACGGAGAGACTCGCAAGATCAAGCATCTACGAGTCTTCTTCATCACCGCTGCTTGGAGTATCTTTGCCTACATCTGGCTCTATATGATTCTGGCAGTCTTCTCCCCTGGTGTGGTCCAGGTTTGGGAAGGCCTCCTCACTCTCTTCTTCTTTCCAGTGTGTGTCCTTCTGGCCTGGGTGGCAGATAAACGACTGCTCTTCTACAAATACATGCACAAAAAGTACCGCACAGACAAACACCGAGGAATTATCATAGAGACAGAGGGTGACCACCCTAAGGGCATTGAGATGGATGGGAAAATGATGAATTCCCATTTTCTAGATGGGAACCTGGTGCCCCTGGAAGGGAAGGAAGTGGATGAGTCCCGCAGAGAGATGATCCGGATTCTCAAGGATCTGAAGCAAAAACACCCAGAGAAGGACTTAGATCAGCTGGTGGAGATGGCCAATTACTATGCTCTTTCCCACCAACAGAAGAGCCGTGCCTTCTACCGTATCCAAGCCACTCGTATGATGACTGGTGCAGGCAATATCCTGAAGAAACATGCAGCAGAACAAGCCAAGAAGGCCTCCAGCATGAGCGAGGTGCACACCGATGAGCCTGAGGACTTTATTTCCAAGGTCTTCTTTGACCCATGTTCTTACCAGTGCCTGGAGAACTGTGGGGCTGTACTCCTGACAGTGGTGAGGAAAGGGGGAGACATGTCAAAGACCATGTATGTGGACTACAAAACAGAGGATGGTTCTGCCAATGCAGGGGCTGACTATGAGTTCACAGAGGGCACGGTGGTTCTGAAGCCAGGAGAGACCCAGAAGGAGTTCTCCGTGGGCATAATTGATGACGACATTTTTGAGGAGGATGAACACTTCTTTGTAAGGTTGAGCAATGTCCGCATAGAGGAGGAGCAGCCAGAGGAGGGGATGCCTCCAGCAATATTCAACAGTCTTCCCTTGCCTCGGGCTGTCCTAGCCTCCCCTTGTGTGGCCACAGTTACCATCTTGGATGATGACCATGCAGGCATCTTCACTTTTGAATGTGATACTATTCATGTCAGTGAGAGTATTGGTGTTATGGAGGTCAAGGTTCTGCGGACATCAGGTGCCCGGGGTACAGTCATCGTCCCCTTTAGGACAGTAGAAGGGACAGCCAAGGGTGGCGGTGAGGACTTTGAAGACACATATGGGGAGTTGGAATTCAAGAATGATGAAACTGTGAAAACTCTTCAGGTGAAGATAGTTGATGACGAGGAATATGAGAAAAAGGATAATTTCTTCATTGAGCTGGGCCAGCCCCAGTGGCTTAAGCGAGGGATTTCAGCTCTGCTACTCAATCAAGGGGATGGGGACAGGAAGCTAACAGCCGAGGAGGAGGAGGCTCGGAGGATAGCAGAGATGGGCAAGCCAGTTCTTGGGGAGAACTGCCGGCTGGAGGTCATCATCGAGGAGTCATATGATTTTAAGAACACGGTGGATAAACTCATCAAGAAAACGAACTTGGCCTTGGTAATTGGGACCCATTCATGGAGGGAGCAGTTTTTAGAGGCAATTACGGTGAGCGCAGGGGACGAGGAGGAGGAGGAGGACGGGTCCCGGGAGGAGCGGCTGCCGTCGTGCTTTGACTACGTGATGCACTTCCTGACGGTGTTCTGGAAGGTGCTCTTCGCCTGTGTGCCCCCCACCGAGTACTGCCACGGCTGGGCCTGCTTTGGTGTCTCCATCCTGGTCATCGGCCTGCTCACCGCCCTCATTGGGGACCTCGCCTCCCACTTCGGCTGCACCGTTGGCCTCAAGGACTCTGTCAATGCTGTTGTCTTCGTTGCCCTGGGCACCTCCATCCCTGACACGTTCGCCAGCAAGGTGGCGGCGCTGCAGGACCAGTGCGCCGACGCGTCCATCGGCAACGTGACCGGCTCCAACGCGGTGAACGTGTTCCTTGGCCTGGGCGTCGCCTGGTCTGTGGCCGCCGTGTACTGGGCGGTGCAGGGCCGCCCCTTCGAGGTGCGCACTGGCACGCTGGCCTTCTCCGTCACGCTCTTCACCGTCTTCGCCTTCGTGGGCATTGCCGTGCTGCTGTACCGGCGCCGGCCGCACATCGGCGGCGAGCTGGGCGGCCCGCGCGGACCCAAGCTCGCCACCACCGCGCTCTTCCTGGGCCTCTGGCTCCTGTACATCCTCTTCGCCAGCCTGGAGGCGTACTGCCACATCCGGGGCTTCTAGGGCCTCGCGCAGAGACTCNOV55h, CG56258-06Protein SequenceSEQ ID NO: 870928 aaMW at 102900.1kDMAWLRLQPLTSAFLHFGLVTFVLFLNGLRAEAGGSGDVPSTGQNNESCSGSSDCKEGVILPIWYPENPSLGKDIARVIVYFVALIYMFLGVSIIADRFMASIEVITSQEREVTIKKPNGETSTTTIRVWNETVSNLTLMALGSSAPEILLSLIEVCGHGFIAGDLGPSTIVGSAAFNMFIIIGICVYVIPDGETRKIKHLRVFFITAAWSIFAYIWLYMILAVFSPGVVQVWEGLLTLFFFPVCVLLAWVADKRLLFYKYMHKKYRTDKHRGIIIETEGDHPKGIEMDGKMMNSHFLDGNLVPLEGKEVDESRREMIRILKDLKQKHPEKDLDQLVEMANYYALSHQQKSRAFYRIQATRMMTGAGNILKKHAAEQAKKASSMSEVHTDEPEDFISKVFFDPCSYQCLENCGAVLLTVVRKGGDMSKTMYVDYKTEDGSANAGADYEFTEGYVVLKPGETQKEFSVGIIDDDIFEEDEHFFVRLSNVRIEEEQPEEGMPPAIFNSLPLPRAVLASPCVATVTILDDDHAGIFTFECDTIHVSESIGVMEVKVLRTSGARGTVIVPFRTVEGTAKGGGEDFEDTYGELEFKNDETVKTLQVKIVDDEEYEKKDNFFIELGQPQWLKRGISALLLNQGDGDRKLTAEEEEARRIAEMGKPVLGENCRLEVIIEESYDFKNTVDKLIKKTNLALVIGTHSWREQFLEAITVSAGDEEEEEDGSREERLPSCFDYVMHFLTVFWKVLFACVPPTEYCHGWACFGVSILVIGLLTALIGDLASHFGCTVGLKDSVNAVVFVALGTSIPDTFASKVAALQDQCADASIGNVTGSNAVNVFLGLGVAWSVAAVYWAVQGRPFEVRTGTLAFSVTLFTVFAFVGIAVLLYRRRPHIGGELGGPRGPKLATTALFLGLWLLYILFASLEAYCHIRGF

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 55B.

TABLE 55BComparison of the NOV55 protein sequences.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(SEQ ID NO: 856)NOV55b(SEQ ID NO: 858)NOV55C(SEQ ID NO: 860)NOV55d(SEQ ID NO: 862)NOV55e(SEQ ID NO: 864)NOV55f(SEQ ID NO: 866)NOV55g(SEQ ID NO: 868)NOV55h(SEQ ID NO: 870)

Further analysis of the NOV55a protein yielded the following properties shown in Table 55C.

TABLE 55CProtein Sequence Properties NOV55aSignalP analysis:Cleavage site between residues 31 and 32PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 5; pos.chg 1; neg.chg 0H-region: length 23; peak value 11.61PSG score: 7.21GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 0.67possible cleavage site: between 30 and 31>>> Seems to have a cleavable signal peptide (1 to 30)ALOM: Klein et al's method for TM region allocationInit position for calculation: 31Tentative number of TMS(s) for the threshold 0.5: 11INTEGRALLikelihood = −8.92Transmembrane 78-94INTEGRALLikelihood = −6.64Transmembrane 170-186INTEGRALLikelihood = −3.24Transmembrane 208-224INTEGRALLikelihood = −8.49Transmembrane 235-251INTEGRALLikelihood = 0.21Transmembrane 508-524INTEGRALLikelihood = −1.12Transmembrane 724-740INTEGRALLikelihood = −9.61Transmembrane 750-766INTEGRALLikelihood = 0.05Transmembrane 775-791INTEGRALLikelihood = −3.35Transmembrane 823-839INTEGRALLikelihood = −8.39Transmembrane 858-874INTEGRALLikelihood = −3.56Transmembrane 893-909PERIPHERALLikelihood = 1.06 (at 137)ALOM score: −9.61 (number of TMSs: 11)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 15Charge difference: −3.5 C(−1.0) − N(2.5)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment(75):4.35Hyd Moment(95):3.78G content:2D/E content:1S/T content:3Score: −3.73Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 39 LRA|EANUCDISC: discrimination of nuclear localization signalspat4: RRRP (4) at 876pat7: nonebipartite: nonecontent of basic residues: 9.0%NLS Score: −0.22KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: AWLRKKXX-like motif in the C-terminus: YIKGSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: foundILPI at 59RNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):66.7%: endoplasmic reticulum11.1%: nuclear11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG56258-04 is end (k = 9)

A search of the NOV55a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 55D.

TABLE 55DGeneseq Results for NOV55aNOV55aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB83246Human transporter protein -1 . . . 921921/921 (100%)0.0Homo sapiens, 921 aa.1 . . . 921921/921 (100%)[WO200233086-A2, 25-APR-2002]ABB81913Human ion exchanger protein #1 -1 . . . 921921/921 (100%)0.0Homo sapiens, 921 aa.1 . . . 921921/921 (100%)[WO200259316-A2, 01-AUG-2002]ABP74104Human TRICH SEQ ID NO 9 -1 . . . 921921/921 (100%)0.0Homo sapiens, 921 aa.1 . . . 921921/921 (100%)[WO200246415-A2, 13-JUN-2002]ABB81915Human ion exchanger protein #11 . . . 921920/921 (99%)0.0Asp/Gly mutant - Homo sapiens,1 . . . 921920/921 (99%)921 aa. [WO200259316-A2, 01-AUG-2002]ABB81916Human ion exchanger protein #11 . . . 921921/922 (99%)0.0Ala mutant - Homo sapiens, 9221 . . . 922921/922 (99%)aa. [WO200259316-A2, 01-AUG-2002]

In a BLAST search of public sequence databases, the NOV55a protein was found to have homology to the proteins shown in the BLASTP data in Table 55E.

TABLE 55EPublic BLASTP Results for NOV55aNOV55aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8IUF0Na+/Ca2+ exchanger isoform 31 . . . 921921/921 (100%)0.0splice variant 2 - Homo sapiens1 . . . 921921/921 (100%)(Human), 921 aa.CAD12716Sequence 1 from Patent1 . . . 921921/927 (99%)0.0WO0183744 - Homo sapiens1 . . . 927921/927 (99%)(Human), 927 aa (fragment).Q8NFI7Na+/Ca2+ exchanger isoform 3 -1 . . . 921921/927 (99%)0.0Homo sapiens (Human), 927 aa.1 . . . 927921/927 (99%)Q96QG1Sodium/calcium exchanger1 . . . 921918/924 (99%)0.0SCL8A3 - Homo sapiens1 . . . 924919/924 (99%)(Human), 924 aa.P70549Sodium/calcium exchanger 31 . . . 921897/927 (96%)0.0precursor (Na(+)/Ca(2+)-1 . . . 927911/927 (97%)exchange protein 3) - Rattusnorvegicus (Rat), 927 aa.

PFam analysis indicates that the NOV55a protein contains the domains shown in the Table 55F.

TABLE 55FDomain Analysis of NOV55aIdentities/PfamNOV55aSimilaritiesDomainMatch Regionfor the Matched RegionExpect ValueNa_Ca_Ex 89 . . . 248 41/181 (23%)1.6e−33134/181 (74%)Calx-beta386 . . . 485 50/106 (47%)1.4e−45 88/106 (83%)Calx-beta519 . . . 619 51/106 (48%)3.5e−46 95/106 (90%)Na_Ca_Ex757 . . . 910 44/178 (25%)8.7e−31128/178 (72%)

Example 56

The NOV56 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 56A.

TABLE 56ANOV56 Sequence AnalysisNOV56a, CG56262-01SEQ ID NO: 8711551 bpDNA SequenceORF Start: ATG at 108ORF Stop: TGA at 1512GCGGCCGCGGGAGCTGACCCTGCGGGGTCCCGGGGGGGGAGGGGGAGCCGCGAAGCCCCCACTGACGCCGCCGCTGCCGGGCCTCCCCTCCCCCCCGGGCGGGCGCCATGCGGGGGAGCCCGGGCGACGCGGAGCGGCGGCAGCGCTGGGGTCGCCTGTTCGAGGAGCTGGACAGTAACAAGGATGGCCGCGTGGACGTGCACGAGTTGCGCCAGGGGCTGGCCAGGCTGGGCGGGGGCAACCCAGACCCCGGCGCCCAACAGGGTATCTCCTCTGAGGGTGATGCTGACCCAGATGGCGGGCTCGACCTGGAGGAATTTTCCCGCTATCTGCAGGAGCGGGAACAGCGTCTGCTGCTCATGTTTCACAGTCTTGACCGGAACCAGGATGGTCACATTGATGTCTCTGAGATCCAACAGAGTTTCCGAGCTCTGGGCATTTCCATCTCGCTGGAGCAGGCTGAGAAAATTTTGCACAGCATGGACCGAGACGGCACAATGACCATTGACTGGCAAGAATGGCGCGACCACTTCCTGTTGCATTCGCTGGAAAATGTGGAGGACGTGCTGTATTTCTGGAAGCATTCCACGGTCCTGGACATTGGCGAGTGCCTGACAGTGCCGGACGAGTTCTCAAAGCAAGAGAAGCTGACGGGCATGTGGTGGAAACAGCTGGTGGCCGGCGCAGTGGCAGGTGCCGTGTCACGGACAGGCACGGCCCCTCTGGACCGCCTCAAGGTCTTCATTCAGGTCCATGCCTCAAAGACCAACCGGCTGAACATCCTTGGGGGGCTTCGAAGCATGGTCCTTGAGGGAGGCATCCGCTGCCTGTGGCGCGGCAATGGTATTAATGTACTCAAGATTGCCCCCGAGTCAGCTATCAAGTTCATGGCCTATGAACAGGTGAGGAGGGCCATCCTGGGGCAGCAGGAGACACTGCATGTGCAGGAGCGCTTCGTGGCTGGCTCCCTGGCTGGTGCCACAGCCCAAACCATCATTTACCCTATGGAGGTGCTGAAGACGCGGCTGACCTTGCGCCGGACGGGCCAGTATAAGGGGCTGCTGGACTGCGCCAGGCGTATCCTGGAGAGGGAGGGGCCCCGTGCCTTCTACCGCGGCTACCTCCCCAACGTGCTGGGCATCATCCCCTATGCGGGCATCGACCTGGCCGTCTACGAGGTCCTGAAGAACTGGTGGCTTCAGCAGTACAGCCACGACTCGGCAGACCCAGGCATCCTCGTGCTCCTGGCCTGCGGTACCATATCCAGCACCTGCGGCCAGATAGCCAGTTACCCGCTGGCCCTGGTCCGGACCCGCATGCAGGCACAAGCCTCCATCGAGGGTGGCCCCCAGCTGTCCATGCTGGGTCTGCTACGTCACATCCTGTCCCAGGAGGGCATGCGGGGCCTCTACCGGGGGATCGCCCCCAACTTCATGAAGGTTATTCCAGCTGTGAGCATCTCCTATGTGGTCTACGAGAACATGAAGCAGGCCTTGGGGGTCACGTCCAGGTGAGGGACCCGGAGCCCGTCCCCCCAATCCCTCACCCCCCNOV56a, CG56262-01Protein SequenceSEQ ID NO: 872468 aaMW at 52387.5kDMRGSPGDAERRQRWGRLFEELDSNKDGRVDVHELRQGLARLGGGNPDPGAQQGISSEGDADPDGGLDLEEFSRYLQEREQRLLLMFHSLDRNQDGHIDVSEIQQSFRALGISISLEQAEKILHSMDRDGTMTIDWQEWRDHFLLHSLENVEDVLYFWKHSTVLDIGECLTVPDEFSKQEKLTGMWWKQLVAGAVAGAVSTRGTAPLDRLKVFIQVHASKTNRLNILGGLRSMVLEGGIRCLWRGNGINVLKIAPESAIKFMAYEQVRRAILGQQETLHVQERFVAGSLAGATAQTIIYPMEVLKTRLTLRRTGQYKGLLDCARRILEREGPRAFTRGYLPNVLGIIPYAGIDLAVYEVLKNWWLQQYSHDSADPGILVLLACGTISSTCGQIASYPLALVRTRMQAQASIEGGPQLSMLGLLRHILSQEGMRGLYRGIAPNFMKVIPAVSISYVVYENMKQALGVTSRNOV56b, 266120550SEQ ID NO: 8731426 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCACCATGCGGGGGAGCCCGGGCGACGCGGAGCGGCGGCAGCGCTGGGGTCGCCTGTTCGAGGAGCTGGACAGTAACAAGGATGGCCGCGTGGACGTGCACGAGTTGCGCCAGGGGCTGGCCAGGCTGGGCGGGGGCAACCCAGACCCCGGCGCCCAACAGGGTATCTCCTCTGAGGGTGATGCTGACCCAGATGGCGGGCTCGACCTGGAGGAATTTTCCCGCTATCTGCAGGAGCGGGAACAGCGTCTGCTGCTCATGTTTCACAGTCTTGACCGGAACCAGGATGGTCACATTGATGTCTCTGAGATCCAACAGAGTTTCCGAGCTCTGGGCATTTCCATCTCGCTGGAGCAGGCTGAGAAAATTTTGCACAGCATGGACCGAGACGGCACAATGACCATTGACTGGCAAGAATGGCGCGACCACTTCCTGTTGCATTCGCTGGAAAATGTGGAGGACGTGCTGTATTTCTGGAAGCATTCCACGGTCCTGGACATTGGCGAGTGCCTGACAGTGCCGGACGAGTTCTCAAAGCAAGAGAAGCTGACGGGCATGTGGTGGAAACAGCTGGTGGCCGGCGCAGTGGCAGGTGCCGTGTCACGGACAGGCACGGCCCCTCTGGACCGCCTCAAGGTCTTCATGCAGGTCCATGCCTCAAAGACCAACCGGCTGAACATCCTTGGGGGGCTTCGAAGCATGGTCCTTGAGGGAGGCATCCGCTCCCTGTGGCGCGGCAATGGTATTAATGTACTCAAGATTGCCCCCGAGTCAGCTATCAAGTTCATGGCCTATGAACAGATCAAGAGGGCCATCCTGGGGCAGCAGGAGACACTGCATGTGCAGGAGCGCTTCGTGGCTGGCTCCCTGGCTGGTGCCACAGCCCAAACCATCATTTACCCTATGGAGGTGCTGAAGACGCGGCTGACCTTGCGCCGGACGGGCCAGTATAAGGGGCTGCTGGACTGCGCCAGGCGTATCCTGGAGAGGGAGGGGCCCCGTGCCTTCTACCGCGGCTACCTCCCCAACGTGCTGGGCATCATCCCCTATGCGGGCATCGACCTGGCCGTCTACGAGACTCTGAAGAACTGGTGGCTTCAGCAGTACAGCCACGACTCGGCAGACCCAGGCATCCTCGTGCTCCTGGCCTGCGGTACCATATCCAGCACCTGCGGCCAGATAGCCAGTTACCCGCTGGCCCTGGTCCGGACCCGCATGCAGGCACAAGCCTCCATCGAGGGTGGCCCCCAGCTGTCCATGCTGGGTCTGCTACGTCACATCCTGTCCCAGGAGGGCATGCGGGGCCTCTACCGGGGGATCGCCCCCAACTTCATGAAGGTTATTCCAGCTGTGAGCATCTCCTATGTGGTCTACGAGAACATGAAGCAGGCCTTGGGGGTCACGTCCAGGCTCGAGGGCNOV56b, 266120550Protein SequenceSEQ ID NO: 874475 aaMW at 53023.1kDTGSTMRGSPGDAERRQRWGRLFEELDSNKDGRVDVHELRQGLARLGGGNPDPGAQQGISSEGDADPDGGLDLEEFSRYLQEREQRLLLMFHSLDRNQDGHIDVSEIQQSFRALGISISLEQAEKILHSMDRDGTMTIDWQEWRDHFLLHSLENVEDVLYFWKHSTVLDIGECLTVPDEFSKQEKLTGMWWKQLVAGAVAGAVSRTGTAPLDRLKVFMQVHASKTNRLNILGGLRSMVLEGGIRSLWRGNGINVLKIAPESAIKFMAYEQIKRAILGQQETLHVQERFVAGSLAGATAQTIIYPMEVLKTRLTLRRTGQYKGLLDCARRILEREGPRAFYRGYLPNVLGIIPYAGIDLAVYETLKNWWLQQYSHDSADPGILVLLACGTISSTCGQIASYPLALVRTRMQAQASIEGGPQLSMLGLLRHILSQEGMRGLYRGIAPNFMKVIPAVSISYVVYENMKQALGVTSRLEG

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 56B.

TABLE 56BComparison of the NOV56 protein sequences.NOV56a----MRGSPGDAERRQRWGRLFEELDSNKDGRVDVHELRQGLARLGGGNPDPGAQQGISSNOV56bTGSTMRGSPGDAERRQRWGRLFEELDSNKDGRVDVHELRQGLARLGGGNPDPGAQQGISSNOV56aEGDADPDGGLDLEEFSRYLQEREQRLLLMFHSLDRNQDGHIDVSEIQQSFRALGISISLENOV56bEGDADPDGGLDLEEFSRYLQEREQRLLLMFHSLDRNQDGHIDVSEIQQSFRALGISISLENOV56aQAEKILHSMDRDGTMTIDWQEWRDHFLLHSLENVEDVLYFWKHSTVLDIGECLTVPDEFSNOV56bQAEKILHSMDRDGTMTIDWQEWRDHFLLHSLENVEDVLYFWKHSTVLDIGECLTVPDEFSNOV56aKQEKLTGNWWKQLVAGAVAGAVSRTGTAPLDRLKVFIQVHASKTNRLNILGGLRSMVLEGNOV56bKQEKLTGNWWKQLVAGAVAGAVSRTGTAPLDRLKVFIQVHASKTNRLNILGGLRSMVLEGNOV56aGIRCLWRGNGINVLKIAPESAIKFMAYEQVRRAILGQQETLHVQERFVAGSLAGATAQTINOV56bGIRSLWRGNGINVLKIAPESAIKFMAYEQIKRAILGQQETLHVQERFVAGSLAGATAQTINOV56aIYPMEVLKTRLTLRRTGQYKGLLDCARRILEREGPRAFYRGYLPNVLGIIPYAGIDLAVYNOV56bIYPMEVLKTRLTLRRTGQYKGLLDCARRILEREGPRAFYRGYLPNVLGIIPYAGIDLAVYNOV56aEVLKNWWLQQYSHDSADPGILVLLACGTISSTCGQIASYPLALVRTRMQAQASIEGGPQLNOV56bETLKNWWLQQYSHDSADPGILVLLACGTISSTCGQIASYPLALVRTRMQAQASIEGGPQLNOV56aSMLGLLRHILSQEGMRGLYRGIAPNFMKVIPAVSISYVVYENMKQALGVTSR---NOV56bSMLGLLRHILSQEGMRGLYRGIAPNFMKVIPAVSISYVVYENMKQALGVTSRLEGNOV56a(SEQ ID NO: 872)NOV56b(SEQ ID NO: 874)

Further analysis of the NOV56a protein yielded the following properties shown in Table 56C.

TABLE 56CProtein Sequence Properties NOV56aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 11; pos.chg 3; neg.chg 2H-region: length 1; peak value −14.40PSG score: −18.80GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −7.60possible cleavage site: between 46 and 47>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 1Number of TMS(s) for threshold 0.5: 0PERIPHERAL Likelihood = 0.85 (at 342)ALOM score: −0.90 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment(75):10.59Hyd Moment(95):7.77G content: 2D/E content:2S/T content: 1Score: −5.97Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 12 MRG|SPNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 11.3%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: RGSPnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found ***LEEFSRYLQEREQRLLLMFHSL at 68 nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):52.2%: cytoplasmic30.4%: nuclear 8.7%: mitochondrial 4.3%: vacuolar 4.3%: vesicles of secretory system>> prediction for CG56262-01 is cyt (k = 23)

A search of the NOV56a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 56D.

TABLE 56DGeneseq Results for NOV56aNOV56aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE22927Human transporter and ion 1 . . . 468463/468 (98%)0.0channel (TRICH) 26 - Homo 1 . . . 468466/468 (98%)sapiens, 468 aa. [WO200222684-A2, 21-MAR-2002]AAU27869Human contig polypeptide 1 . . . 468463/468 (98%)0.0sequence #22 - Homo sapiens, 50939 . . . 506466/468 (98%)aa. [WO200164834-A2, 07-SEP-2001]AAU27697Human full-length polypeptide 1 . . . 468463/468 (98%)0.0sequence #22 - Homo sapiens, 471 1 . . . 468466/468 (98%)aa. [WO200164834-A2, 07-SEP-2001]ABG22637Novel human diagnostic protein 1 . . . 468442/470 (94%)0.0#22628 - Homo sapiens, 508 aa.39 . . . 508450/470 (95%)[WO200175067-A2, 11-OCT-2001]ABG30434Human protein sequence #2 used 1 . . . 409403/409 (98%)0.0for determining sequence of 1 . . . 409406/409 (98%)unknown gene - Homo sapiens,456 aa. [JP2002176980-A, 25-JUN-2002]

In a BLAST search of public sequence databases, the NOV56a protein was found to have homology to the proteins shown in the BLASTP data in Table 56E.

TABLE 56EPublic BLASTP Results for NOV56aNOV56aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAD55563Putative calcium binding 1 . . . 407402/407 (98%)0.0transporter - Homo sapiens 1 . . . 407405/407 (98%)(Human), 438 aa.Q96NQ4Hypothetical protein FLJ30339 -85 . . . 468379/384 (98%)0.0Homo sapiens (Human), 384 aa. 1 . . . 384382/384 (98%)CAD20531Sequence 1 from Patent 1 . . . 407374/407 (91%)0.0WO0174854 - Homo sapiens 1 . . . 406388/407 (94%)(Human), 460 aa (fragment).AAH43834Similar to hypothetical protein 6 . . . 468302/463 (65%)e−177MGC36388 - Xenopus laevis53 . . . 514368/463 (79%)(African clawed frog), 514 aa.Q8BHG0Weakly similar to peroxisomal 6 . . . 468305/463 (65%)e−176CA-dependent solute carrier -41 . . . 502366/463 (78%)Mus musculus (Mouse), 502 aa.

PFam analysis indicates that the NOV56a protein contains the domains shown in the Table 56F.

TABLE 56FDomain Analysis of NOV56aIdentities/SimilaritiesPfamNOV56afor the MatchedExpectDomainMatch RegionRegionValueefhand 13 . . . 41 8/29 (28%)0.00022 26/29 (90%)efhand 81 . . . 109 8/29 (28%)0.012 21/29 (72%)mito_carr184 . . . 27638/124 (31%)2.1e−2478/124 (63%)mito_carr278 . . . 36938/124 (31%)3.4e−3281/124 (65%)mito_carr375 . . . 46831/124 (25%)2.4e−2376/124 (61%)

Example 57

The NOV57 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 57A.

TABLE 57ANOV57 Sequence AnalysisNOV57a, CG56315-01SEQ ID NO: 875728 bpDNA SequenceORF Start: ATG at 28ORF Stop: TGA at 697AGTCTTGCCTTCTTTTGAGCCTAAGTCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGACTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATGGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACCTCATGCTTGTGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGGTTCTCAAGTGCTTTATTAAGTGCTGTCTCCAAAAATATTTAAAAAAACCTCAAGTCCTCAGTGTGTGAGTGCCACAGCCTCAGATATGTTGAATGTGNOV57a, CG56315-01Protein SequenceSEQ ID NO: 876223 aaMW at 25859.7kDMSWMFLRDLLSGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHVWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSVNOV57b, 247679382SEQ ID NO: 877700 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceAGGCTCCGCGGCCGCCCCCTTCACCGGATCCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGATTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCGTACAACTGATAATGGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACCTCATGCTTGCGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGCTCGAGGGCAAGGGTGGGCGCGCCGACCCAGCTTTCTTGTACAAAAGTTGGCATTTTATAAGAAAANOV57b, 247679382Protein SequenceSEQ ID NO: 878233 aaMW at 26752.3kDGSAAAPFTGSMSWMFLRDLLSGVNKYSTGIGWIWLAVVFVFRLLVYMVAAEHVWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWAVQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLRIVLNFIELSFLLEGKGGRADPAFLYKSWHFIRKNOV57c, 247678321SEQ ID NO: 879724 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceAGGCTCCGCGGCCGCCCCCTTCACCGGATCCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGATTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATGGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACCTCATGCTTGCGTATTGTGTTGAATTCCATTGAACTGAGTTTTTTGGTTCTCAAGTGCCTTATTAAGTGCTGTCTCCAAAAATATTTAAAAAAACCTCAAGTCCTCAGTGTGCTCGAGGGCAAGGGTGGGCGCGCCNOV57c, 247678321Protein SequenceSEQ ID NO: 880241 aaMW at 27446.4kDGSAAAPFTGSMSWMFLRDLLSGVMKYSTGIGWIWLAVVFVFRLLVYMVAAEHVWKDEQKEFEGNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLRIVLNSIELSFLVLKCLIKCCLQKYLKKPQVLSVLEGKGGRANOV57d, 247679418SEQ ID NO: 881538 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceAGGCTCCGCGGCCGCCCCCTTCACCGGATCCGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATGGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTA2AAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACCTCATGCTTGCGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGCTCGAGGGCAAGGGTGGGCGCGCCNOV57d, 247679418Protein SequenceSEQ ID NO: 882179 aaMW at 20339.7kDGSAAAPFTGSEHVWKDEQKEFECNSRQPGCIQNCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLRIVLNFIELSFLLEGKGGRANOV57e, 247679395SEQ ID NO: 883658 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceAGGCTCCGCGGCCGCCCCCTTCACCGGATCCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGATTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATGGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACCTCATGCTTGCGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGCTCGAGGGCAAGGGTGGGCGCGCCNOV57e, 247679395Protein SequenceSEQ ID NO: 884219 aaMW at 24976.2kDGSAAAPFTGSMSWMFLRDLLSGVNKYSTGIGWIWLAVVFVFRLLVYMVAAEHVWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLRIVLNFIELSFLLEGKGGRANOV57f, 247679328SEQ ID NO: 885604 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceAGGCTCCGCGGCCGCCCCCTTCACCGGATCCGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATGGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACCTCATGCTTGCGTATTGTGTTGAATTCCATTGAACTGAGTTTTTTGGTTCTCAAGTGCCTTATTAAGTGCTGTCTCCAAAAATATTTAAAAAAACCTCAAGTCCTCAGTGTGCTCGAGGGCAAGGGTGGGCGCGCCNOV57f, 247679328Protein SequenceSEQ ID NO: 886201 aaMW at 22809.8kDGSAAAPFTGSEHVWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLRIVLNSIELSFLVLKCLIKCCLQKYLKKPQVLSVLEGKGGHANOV57g, CG56315-02SEQ ID NO: 887727 bpDNA SequenceORF Start: ATG at 27ORF Stop: TGA at 696AGTCTTGCTTCTTTTGAGCCTAAGTCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGATTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATGGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACCTCATGCTTGTGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGGTTCTCAAGTGCTTTATTAAGTGCTGTCTCCAAAAATATTTAAAAAAACCTCAAGTCCTCAGTGTGTGAGTGCCACAGCCTCAGATATGTTGAATGTGNOV57g, CG56315-02Protein SequenceSEQ ID NO: 888223 aaMW at 25871.7kDMSWMFLRDLLSGVNKYSTGIGWIWLAVVFVFRLLVYMVAAEHVWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSVNOV57h, CG56315-03SEQ ID NO: 88924 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTTTGAGCAAAACAGAAGACAGCCCNOV57h, CG56315-03Protein SequenceSEQ ID NO: 8908 aaMW at 1074.2kDFEQNRRQPNOV57i, CG56315-04SEQ ID NO: 89124 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTTTGAGTGCAACAGGAGACAGCCCNOV57i, CG56315-04Protein SequenceSEQ ID NO: 8928 aaMW at 1049.2kDFECNRRQPNOV57j, CG56315-05SEQ ID NO: 89324 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTTTGAGCAAAACAGTAGACAGCCCNOV57j, CG56315-05Protein SequenceSEQ ID NO: 8948 aaMW at 1005.1kDFEQNSRQPNOV57k, CG56315-06SEQ ID NO: 89524 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTTTGAGTGCAACAGTAGACAGCCCNOV57k, CG56315-06Protein SequenceSEQ ID NO: 8968 aaMW at 980.1kDFECNSRQPNOV57l, CG56315-07SEQ ID NO: 89724 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTTTGAGCAAAACAGTAGACAGGCCNOV57l, CG56315-07Protein SequenceSEQ ID NO: 8988 aaMW at 979.0kDFEQNSRQANOV57m, CG56315-08SEQ ID NO: 89924 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTTTGAGTGCAACAGTAGACAGGCCNOV57m, CG56315-08Protein SequenceSEQ ID NO: 9008 aaMW at 954.0kDFECNSRQASEQ ID NO: 901728 bpNOV57n, SNP13381650 ofORF Start: ATG at 28ORF Stop: TGA at 697CG56315-01, DNA SequenceSNP Pos: 86SNP Change: C to TAGTCTTGCCTTCTTTTGAGCCTAAGTCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGATTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATGGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTcTTGGTCATCACCTCATGCTTGTGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGGTTCTCAAGTGCTTTATTAAGTGCTGTCTCCAAAAATATTTAAAAAAACCTCAAGTCCTCAGTGTGTGAGTGCCACAGCCTCAGATATGTTGAATGTGNOV57n, SNP13381650 ofSEQ ID NO: 902MW at 25871.7kDCG56315-01, Protein SequenceSNP Pos: 20223 aaSNP Change: Thr to IleMSWMFLRDLLSGVNKYSTGIGWIWLAVVFVFRLLVYMVAAEHVWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSVSEQ ID NO: 903728 bpNOV57o, SNP13381651 ofORF Start: ATG at 28ORF Stop: TGA at 697CG56315-01, DNA SequenceSNP Pos: 154SNP Change: G to AAGTCTTGCCTTCTTTTGAGCCTAAGTCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGACTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACATGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATGGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACCTCATGCTTGTGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGGTTCTCAAGTGCTTTATTAAGTGCTGTCTCCAAAAATATTTAAAAAAACCTCAAGTCCTCAGTGTGTGAGTGCCACAGCCTCAGATATGTTGAATGTGNOV57o, SNP13381651 ofSEQ ID NO: 904MW at 25891.7kDCG56315-01, Protein SequenceSNP Pos: 43223 aaSNP Change: Val to MetMSWMFLRDLLSGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHMWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSVSEQ ID NO: 905728 bpNOV57p, SNP13381652 ofORF Start: ATG at 28ORF Stop: TGA at 697CG56315-01, DNA SequenceSNP Pos: 276SNP Change: G to AAGTCTTGCCTTCTTTTGAGCCTAAGTCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGACTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATAGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACcTCATGCTTGTGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGGTTCTCAAGTGCTTTATTAAGTGCTGTCTCCAAAAATATTTAAAAAAACCTCAAGTCCTCAGTGTGTGAGTGCCACAGCCTCAGATATGTTGAATGTGNOV57p, SNP13381652 ofSEQ ID NO: 906MW at 25841.6kDCG56315-01, Protein SequenceSNP Pos: 83223 aaSNP Change: Met to IleMSWMFLRDLLSGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHMWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSVSEQ ID NO: 907728 bpNOV57q, SNP13381653 ofORF Start: ATG at 28ORF Stop: TGA at 697CG56315-01, DNA SequenceSNP Pos: 557SNP Change: C to TAGTCTTGCCTTCTTTTGAGCCTAAGTCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGACTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATAGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACcTCATGCTTGTGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGGTTCTCAAGTGCTTTATTAAGTGCTGTCTCCAAAAATATTTAAAAAAACCTCAAGTCCTCAGTGTGTGAGTGCCACAGCCTCAGATATGTTGAATGTGNOV57q, SNP13381653 ofSEQ ID NO: 908MW at 25889.8kDCG56315-01, Protein SequenceSNP Pos: 177223 aaSNP Change: Thr to MetMSWMFLRDLLSGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHMWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKMIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSVSEQ ID NO: 909728 bpNOV57r, SNP13381654 ofORF Start: ATG at 28ORF Stop: TGA at 697CG56315-01, DNA SequenceSNP Pos: 643SNP Change: T to CAGTCTTGCCTTCTTTTGAGCCTAAGTCATGAGTTGGATGTTCCTCAGAGATCTCCTGAGTGGAGTAAATAAATACTCCACTGGGACTGGATGGATTTGGCTGGCTGTCGTGTTTGTCTTCCGTTTGCTGGTCTACATGGTGGCAGCAGAGCACGTGTGGAAAGATGAGCAGAAAGAGTTTGAGTGCAACAGTAGACAGCCCGGTTGCAAAAATGTGTGTTTTGATGACTTCTTCCCCATTTCCCAAGTCAGACTTTGGGCCTTACAACTGATAATAGTCTCCACACCTTCACTTCTGGTGGTTTTACATGTAGCCTATCATGAGGGTAGAGAGAAAAGGCACAGAAAGAAACTCTATGTCAGCCCAGGTACAATGGATGGGGGCCTATGGTACGCTTATCTTATCAGCCTCATTGTTAAAACTGGTTTTGAAATTGGCTTCCTTGTTTTATTTTATAAGCTATATGATGGCTTTAGTGTTCCCTACCTTATAAAGTGTGATTTGAAGCCTTGTCCCAACACTGTGGACTGCTTCATCTCCAAACCCACTGAGAAGACGATCTTCATCCTCTTCTTGGTCATCACCTCATGCTTGTGTATTGTGTTGAATTTCATTGAACTGAGTTTTTTGGTTCTCAAGTGCCTTATTAAGTGCTGTCTCCAAAAATATTTAAAAAAACCTCAAGTCCTCAGTGTGTGAGTGCCACAGCCTCAGATATGTTGAATGTGNOV57r, SNP13381654 ofSEQ ID NO: 910MW at 25825.6kDCG56315-01, Protein SequenceSNP Pos: 206223 aaSNP Change: Phe to LeuMSWMFLRDLLSGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHMWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCLIKCCLQKYLKKPQVLSV

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 57B.

TABLE 57BComparison of the NOV57 protein sequences.NOV57a----------MSWMFLRDLLGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHVWKDEQKENOV57bGSAAAPFTGSMSWMFLRDLLGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHVWKDEQKENOV57cGSAAAPFTGSMSWMFLRDLLGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHVWKDEQKENOV57dGSAAAPFTG---------------------------------------SEHVWKDEQKENOV57eGSAAAPFTGSMSWMFLRDLLGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHVWKDEQKENOV57fGSAAAPFTG---------------------------------------SEHVWKDEQKENOV57g----------MSWMFLRDLLGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHVWKDEQKENOV57h------------------------------------------------------------NOV57i------------------------------------------------------------NOV57j------------------------------------------------------------NOV57k------------------------------------------------------------NOV57l------------------------------------------------------------NOV57m------------------------------------------------------------NOV57aFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYNOV57bFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYNOV57cFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYNOV57dFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYNOV57eFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYNOV57fFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYNOV57gFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYNOV57hFEQNRRQP----------------------------------------------------NOV57iFECNRRQP----------------------------------------------------NOV57jFEQNSRQP----------------------------------------------------NOV57kFECNSRQP----------------------------------------------------NOV57lFEQNSRQA----------------------------------------------------NOV57mFECNSRQA----------------------------------------------------NOV57aVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFINOV57bVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFINOV57cVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFINOV57dVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFINOV57eVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFINOV57fVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFINOV57gVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFINOV57h------------------------------------------------------------NOV57i------------------------------------------------------------NOV57j------------------------------------------------------------NOV57k------------------------------------------------------------NOV57l------------------------------------------------------------NOV57m------------------------------------------------------------NOV57aSKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSV-------NOV57bSKPTEKTIFILFLVITSCLRIVLNFIELSFLLEGKGGRADPAFLYKSWHFIRK-------NOV57cSKPTEKTIFILFLVITSCLRIVLNSIELSFLVLKCLIKCCLQKYLKKPQVLSVLEGKGGRNOV57dSKPTEKTIFILFLVITSCLRIVLNFIELSFLLEGKGGRA---------------------NOV57eSKPTEKTIFILFLVITSCLRIVLNFIELSFLLEGKGGRA---------------------NOV57fSKPTEKTIFILFLVITSCLRIVLNSIELSFLVLKCLIKCCLQKYLKKPQVLSVLEGKGGRNOV57gSKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSV-------NOV57h------------------------------------------------------------NOV57i------------------------------------------------------------NOV57j------------------------------------------------------------NOV57k------------------------------------------------------------NOV57l------------------------------------------------------------NOV57m------------------------------------------------------------NOV57a-NOV57b-NOV57cANOV57d-NOV57e-NOV57fANOV57g-NOV57h-NOV57i-NOV57j-NOV57k-NOV57l-NOV57m-NOV57a(SEQ ID NO: 876)NOV57b(SEQ ID NO: 878)NOV57c(SEQ ID NO: 880)NOV57d(SEQ ID NO: 882)NOV57e(SEQ ID NO: 884)NOV57f(SEQ ID NO: 886)NOV57g(SEQ ID NO: 888)NOV57h(SEQ ID NO: 890)NOV57i(SEQ ID NO: 892)NOV57j(SEQ ID NO: 894)NOV57k(SEQ ID NO: 896)NOV57l(SEQ ID NO: 898)NOV57m(SEQ ID NO: 900)

Further analysis of the NOV57a protein yielded the following properties shown in Table 57C.

TABLE 57CProtein Sequence Properties NOV57aSignalP analysis:Cleavage site between residues 41 and 42PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 8; pos.chg 1; neg.chg 1H-region: length 6; peak value −2.35PSG score: −6.75GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −4.71possible cleavage site: between 40 and 41>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 5INTEGRALLikelihood = −7.64Transmembrane 23-39INTEGRALLikelihood = −2.60Transmembrane 81-97INTEGRALLikelihood = −3.24Transmembrane 125-141INTEGRALLikelihood = −12.26Transmembrane 177-193INTEGRALLikelihood = −2.81Transmembrane 195-211PERIPHERALLikelihood = 6.36 (at 63)ALOM score: −12.26 (number of TMSs: 5)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 30Charge difference: −1.5 C(0.5) − N(2.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment(75):11.62Hyd Moment(95):9.22G content: 3D/E content:2S/T content: 5Score: −4.01Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 42 FRL|LVNUCDISC: discrimination of nuclear localization signalspat4: KRHR (3) at 103pat4: RHRK (3) at 104pat4: HRKK (3) at 105pat7: nonebipartite: nonecontent of basic residues: 11.2%NLS Score: 0.09KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):55.6%: endoplasmic reticulum33.3%: mitochondrial11.1%: nuclear>> prediction for CG56315-01 is end (k = 9)

A search of the NOV57a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 57D.

TABLE 57DGeneseq Results for NOV57aNOV57aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE26418Human transmembrane protein1 . . . 223221/223 (99%) e−131(TMP)-4 protein - Homo sapiens,1 . . . 223221/223 (99%)223 aa. [WO200234783-A2, 02-MAY-2002]ABU56673Lung cancer-associated1 . . . 209123/216 (56%)6e−73polypeptide #266 - Unidentified,1 . . . 216161/216 (73%)273 aa. [WO200286443-A2, 31-OCT-2002]ABU56449Lung cancer-associated1 . . . 209123/216 (56%)6e−73polypeptide #42 - Unidentified,1 . . . 216161/216 (73%)273 aa. [WO200286443-A2, 31-OCT-2002]AAY36192Human secreted protein #64 -1 . . . 209123/216 (56%)6e−73Homo sapiens, 273 aa.1 . . . 216161/216 (73%)[WO9925825-A2, 27-MAY-1999]AAY36145Human secreted protein #17 -1 . . . 209123/216 (56%)6e−73Homo sapiens, 273 aa.1 . . . 216161/216 (73%)[WO9925825-A2, 27-MAY-1999]

In a BLAST search of public sequence databases, the NOV57a protein was found to have homology to the proteins shown in the BLASTP data in Table 57E.

TABLE 57EPublic BLASTP Results for NOV57aNOV57aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ96KP0Connexin25 - Homo sapiens1 . . . 223222/223 (99%) e−131(Human), 223 aa.1 . . . 223223/223 (99%)Q91XA4Similar to gap junction membrane1 . . . 209123/214 (57%)6e−73channel protein beta 5 (Gap1 . . . 214166/214 (77%)junction protein) (Connexin) -Mus musculus (Mouse), 271 aa.Q02739Gap junction beta-5 protein1 . . . 209123/214 (57%)6e−73(Connexin 31.1) (Cx31.1) - Mus1 . . . 214166/214 (77%)musculus (Mouse), 271 aa.O95377Gap junction beta-5 protein1 . . . 209123/216 (56%)2e−72(Connexin 31.1) (Cx31.1) - Homo1 . . . 216161/216 (73%)sapiens (Human), 273 aa.P28232Gap junction beta-5 protein1 . . . 213122/218 (55%)4e−72(Connexin 31.1) (Cx31.1) - Rattus1 . . . 218167/218 (75%)norvegicus (Rat), 271 aa.

PFam analysis indicates that the NOV57a protein contains the domains shown in the Table 57F.

TABLE 57FDomain Analysis of NOV57aIdentities/SimilaritiesPfamNOV57afor the MatchedExpectDomainMatch RegionRegionValueconnexin2 . . . 201109/247 (44%)2.2e−111166/247 (67%)

Example 58

The NOV58 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 58A.

TABLE 58ANOV58 Sequence AnalysisNOV58a, CG56398-01SEQ ID NO: 9112105 bpDNA SequenceORF Start: ATG at 31ORF Stop: TAG at 2056CCTCAGGATCCAGAGGTCTCGTTCAGGACCATGGAGAGCGGCACCAGCAGCCCTCAGCCTCCACAGTTAGATCCCCTGGATGCGTTTCCCCAGAAGGGCTTGGAGCCTGGGGACATCGCGGTGCTAGTTCTGTACTTCCTCTTTGTCCTGGCTGTTGGACTATGGTCCACAGTGAAGACCAAAAGAGACACAGTGAAAGGCTACTTCCTGGCTGGAGGGGACATGGTGTGGTGGCCAGTGGGTGCATCCTTGTTTGCCAGCAATGTTGGAAGTGGACATTTCATTGGCCTGGCAGGGTCAGGTGCTGCTACGGGCATTTCTGTATCAGCTTATGAACTTAATGGCTTGTTTTCTGTGCTGATGTTGGCCTGGATCTTCCTACCCATCTACATTGCTGGTCAGGTGACCACGATGCCAGAATACCTACGGAAGCGCTTCGGTGGCATCAGAATCCCCATCATCCTGGCTGTACTCTACCTATTTATCTACATCTTCACCAAGATCTCGGTAGACATGTATGCAGGTGCCATCTTCATCCAGCAGTCTTTGCACCTGGATCTGTACCTGGCCATAGTTGGGCTACTGGCCATCACTGCTGTATACACGGTTGCTGGTGGCCTGGCTGCTGTGATCTACACGGATGCCCTGCAGACGCTGATCATGCTTATAGGAGCGCTCACCTTGATGGGCTACAGTTTCGCCGCGGTTGGTGGGATGGAAGGACTGAAGGAGAAGTACTTCTTGGCCCTGGCTAGCAACCGGAGTGAGAACAGCAGCTGCGGGCTGCCCCGGGAAGATGCCTTCCATATTTTCCGAGATCCGCTGACATCTGATCTCCCGTGGCCGGGGGTCCTATTTGGAATGTCCATCCCATCCCTCTGGTACTGGTGCACGGATCAGGTAATTGTCCAGCGGACTCTGGCTGCCAAGAACCTGTCCCATGCCAAAGGAGGTGCTCTGATGGCTGCATACCTGAAGGTGCTGCCCCTCTTCATAATGGTGTTCCCTGGGATGGTCAGCCGCATCCTCTTCCCAGATCAAGTGGCCTGTGCAGATCCAGAGATCTGCCAGAAGATCTGCAGCAACCCCTCAGGCTGTTCGGACATCGCGTATCCCAAACTCGTGCTGGAACTCCTGCCCACAGGTCTCCGTGGGCTGATGATGGCTGTGATGGTGGCGGCTCTCATGTCCTCCCTCACCTCCATCTTTAACAGTGCCAGCACCATCTTCACCATGGACCTCTGGAATCACCTCCGGCCTCGGGCATCTGAGAAGGAGCTCATGATTGTGGGCAGGGTGTTTGTGCTGCTGCTGGTCCTGGTCTCCATCCTCTGGATCCCTGTGGTCCAGGCCAGCCAGGGCGGCCAGCTCTTCATCTATATCCAGTCCATCAGCTCCTACCTGCAGCCGCCTGTGGCGGTGGTCTTCATCATGGGATGTTTCTGGAAGAGGACCAATGAAAAGGGTGCCTTCTGGGGCCTGATCTCGGGCCTGCTCCTGGGCTTGGTTAGGCTGGTCCTGGACTTTATTTACGTGCAGCCTCGATGCGACCAGCCAGATGAGCGCCCGGTCCTGGTGAAGAGCATTCACTACCTCTACTTCTCCATGATCCTGTCCACGGTCACCCTCATCACTGTCTCCACCGTGAGCTGGTTCACAGAGCCACCCTCCAAGGAGATGGTCAGCCACCTGACCTGGTTTACTCGTCACGACCCCGTGGTCCAGAAGGAACAAGCACCACCAGCAGCTCCCTTGTCTCTTACCCTCTCTCAGAACGGGATGCCAGAGGCCAGCAGCAGCAGCAGCGTCCAGTTCGAGATGGTTCAAGAAAACACGTCTAAAACCCACAGCGGTGACATGACCCCAAAGCAGTCCAAAGTGGTGAAGGCCATCCTGTGGCTCTGTGGAATACAGGAGAAGGGCAAGGAAGAGCTCCCGGCCAGAGCAGAAGCCATCATAGTTTCCCTGGAAGAAAACCCCTTGGTGAAGACCCTCCTGGACGTCAACCTCATTTTCTGCGTGAGCTGCGCCATCTTTATCTGGGGCTATTTTGCTTAGTGTGGGGTGAACCCAGGGGTCCAAACTCTGTTTCTCTTCAGTGCTCCNOV58a, CG56398-01Protein SequenceSEQ ID NO: 912675 aaMW at 73989.3kDMESGTSSPQPPQLDPLDAFPQKGLEPGDIAVLVLYFLFVLAVGLWSTVKTKRDTVKGYFLAGGDMVWWPVGASLFASNVGSGHFIGLAGSGAATGISVSAYELNGLFSVLMLAWIFLPIYIAGQVTTMPEYLRKRFGGIRIPIILAVLYLFIYIFTKISVDMYAGAIFIQQSLHLDLYLAIVGLLAITAVYTVAGGLAAVIYRDALQTLIMLIGALTLMGYSFAAVGGMEGLKEKYFLALASNRSENSSCGLPREDAFHIFRDPLTSDLPWPGVLFGMSIPSLWYWCTDQVIVQRTIAAKNLSHAKGGALMAAYLKVLPLFIMVFPGMVSRILFPDQVACADPEICQKICSNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIFTMDLWNHLRPRASEKELMIVGRVFVLLLVLVSILWIPVVQASQGGQLFIYIQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDFIYVQPRCDQPDERPVLVKSIHYLYFSMILSTVTLITVSTVSWFTEPPSKEMVSHLTWFTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQENTSKTHSGDMTPKQSKVVKAILWLCGIQEKGKEELPARAEAIIVSLEENPLVKTLLDVNLIFCVSCAIFIWGYFANOV58b, 265726152SEQ ID NO: 9131309 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCTACTTCCTGGCTGGAGGGGACATGGTGTGGTGGCCAGTGGGTGCATCCTTGTTTGCCAGCAATGTTGGAAGTGGACATTTCATTGGCCTGGCAGGGTCAGGTGCTGCTACGGGCATTTCTGTATCAGCTTATGAACTTAATGGCTTGTTTTCTGTGCTGATGTTGGCCTGGATCTTCCTACCCATCTACATTGCTGGTCAGGTCACCACGATGCCAGAATACCTACGGAAGCGCTTCGGTGGCATCAGAATCCCCATCATCCTGGCTGTACTCTACCTATTTATCTACATCTTCACCAAGATCTCGGTAGACATGTATGCAGGTGCCATCTTCATCCAGCAGTCTTTGCACCTGGATCTGTACCTGGCCATAGTTGGGCTACTGGCCATCACTGCTGTATACACGGTTGCTGGTGGCCTGGCTGCTGTGATCTACACGGATGCCCTGCAGACGCTGATCATGCTTATAGGAGCGCTCACCTTGATGGGCTACAGTTTCGCCGCGGTTGGTGGGATGGAAGGACTGAAGGAGAAGTACTTCTTGGCCCTGGCTAGCAACCGGAGTGAGAACAGCAGCTGCGGGCTGCCCCGGGAAGATGCCTTCCATATTTTCCGAGATCCGCTGACATCTGATCTCCCGTGGCCGGGGGTCCTATTTGGAATGTCCATCCCATCCCTCTGGTACTGGTGCACGGATCAGGTGATTGTCCAGCGGACTCTGGCTGCCAAGAACCTGTCCCATGCCAAAGGAGGTGCTCTGATGGCTGCATACCTGAAGGTGCTGCCCCTCTTCATAATGGTGTTCCCTGGGATGGTCAGCCGCATCCTCTTCCCAGATCAAGTGGCCTGTGCAGATCCAGAGATCTGCCAGAAGATCTGCAGCAACCCCTCAGGCTGTTCGGACATCGCGTATCCCAAACTCGTGCTGGAACTCCTGCCCACAGGGCTCCGTGGGCTGATGATGGCTGTGATGGTGGCGGCTCTCATGTCCTCCCTCACCTCCATCTTTAACAGTGCCAGCACCATCTTCACCATGGACCTCTGGAATCACCTCCGGCCTCGGGCATCTGAGAAGGAGCTCATGATTGTGGGCAGGGTGTTTGTGCTGCTGCTGGTCCTGGTCTCCATCCTCTGGATCCCTGTGGTCCAGGCCAGCCAGGGCGGCCAGCTCTTCATCTATATCCAGTCCATCAGCTCCTACCTGCAGCCGCCTGTGGCGGTGGTCTTCATCATGGGATGTTTCTGGAAGAGGACCAATGAAAAGGGTGCCTTCTGGGGCCTGATCTCGGGCCTCGAGGGCNOV58b, 265726152Protein SequenceSEQ ID NO: 914436 aaMW at 47358.5kDTGSYFLAGGDMVWWPVGASLFASNVGSGHFIGLAGSGAATGISVSAYELNGLFSVLMLAWIFLPIYIAGQVTTMPEYLRKRFGGIRIPIILAVLYLFIYIFTKISVDMYAGAIFIQQSLHLDLYLAIVGLLAITAVYTVAGGLAAVIYTDALQTLIMLIGALTLMGYSFAAVGGMEGLKEKYFLALASNRSENSSCGLPREDAFHIFRDPLTSDLPWPGVLFGMSIPSLWYWCTDQVIVQRTLAAKNLSHAKGGALMAAYLKVLPLFIMVFPGMVSRILFPDQVACADPEICQKICSNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIFTMDLWNHLRPRASEKELMIVGRVFVLLLVLVSILWIPVVQASQGGQLFIYIQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLEGNOV58c, 267254040SEQ ID NO: 9151912 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceAGAATTCGCCTTCACCGGATCCAAAAGAGACACAGTGAAAGGCTACTTCCTGGCTGGAGGGGACATGGTGTGGTGGCCAGTGGGTGCATCCTTGTTTGCCAGCAATGTTGGAAGTGGACATTTCATTGGCCTGGCAGGGTCAGGTGCTGCTACGGGCATTTCTGTATCAGCTTATGAACTTAATGGCTTGTTTTCTGTGCTGATGTTGGCCTGGATCTTCCTACCCATCTACATTGCTGGTCAGGTCACCACGATGCCAGAATACCTACGGAAGCGCTTCGGTGGCATCAGAATCCCCATCATCCTGGCTGTACTCTACCTATTTATCTACATCTTCACCAAGATCTCGGTAGACATGTATGCAGGTGCCATCTTCATCCAGCAGTCTTTGCACCTGGATCTGTACCTGGCCATAGTTGGGCTACTGGCCATCACTGCTGTATACACGGTTGCTGGTGGCCTGGCTGGTGTGATCTACACGGATGCCCTGCAGACGCTGATCATGCTTATAGGAGCGCTCACCTTGATGGGCTACAGTTTCGCCGCGGTTGGTGGGATGGAAGGACTGAAGGAGAAGTACTTCTTGGCCCTGGCTAGCAACCGGAGTGAGAACAGCAGCTGCGGGCTGCCCCGGGAAGATGCCTTCCATATTTTCCGAGATCCGCTGACATCTGATCTCCCGTGGCCGGGGGTCCTATTTGGAATGTCCATCCCATCCCTCTGGTACTGGTGCACGGATCAGGTGATTGTCCAGCGGACTCTGGCTGCCAAGAACCTGTCCCATGCCAAAGGAGGTGCTCTGATGGCTGCATACCTGAAGGTGCTGCCCCTCTTCATAATGGTGTTCCCTGGGATGGTCAGCCGCATCCTCTTCCCAGATCAAGTGGCCTGTGCAGATCCAGAGATCTGCCAGAAGATCTGCAGCAACCCCTCAGGCTGTTCGGACATCGCGTATCCCAAACTCGTGCTGGAACTCCTGCCCACAGGGCTCCGTGGGCTGATGATGGCTGTGATGGTGGCGGCTCTCATGTCCTCCCTCACCTCCATCTTTAACAGTGCCAGCACCATCTTCACCATGGACCTCTGGAATCACCTCCGGCCTCGGGCATCTGAGAAGGAGCTCATGATTGTGGGCAGGGTGTTTGTGCTGCTGCTGGTCCTGGTCTCCATCCTCTGGATCCCTGTGGTCCAGGCCAGCCAGGGCGGCCAGCTCTTCATCTATATCCAGTCCATCAGCTCCTACCTGCAGCCGCCTGTGGCGGTGGTCTTCATCATGGGATGTTTCTGGAAGAGGACCAATGAAAAGGGTGCCTTCTGGGGCCTGATCTCGGGCCTGCTCCTGGGCTTGGTTAGGCTGGTCCTGGACTTTATTTACGTGCAGCCTCGATGCGACCAGCCAGATGAGCGCCCGGTCCTGGTGAAGAGCATTCACTACCTCTACTTCTCCATGATCCTGTCCACGGTCACCCTCATCACTGTCTCCACCGTGAGCTGGTTCACAGAGCCACCCTCCAAGGAGATGGTCAGCCACCTGACCTGGTTTACTCGTCACGACCCCGTGGTCCAGAAGGAACAAGCACCACCAGCAGCTCCCTTGTCTCTTACCCTCTCTCAGAACGGGATGCCAGAGGCCAGCAGCAGCAGCAGCGTCCAGTTCGAGATGGTTCAAGAAAACACGTCTAAAACCCACAGCTGTGACATGACCCCAAAGCAGTCCAAAGTGGTGAAGGCCATCCTGTGGCTCTGTGGAATACAGGAGAAGGGCAAGGAAGAGCTCCCGGCCAGAGCAGAAGCCATCATAGTTTCCCTGGAAGAAAACCCCTTGGTGAAGACCCTCCTGGACGTCAACCTCATTTTCTGCGTGAGCTGCGCCATCTTTATCTGGGGCTATTTTGCTCTCGAGGGCAGGGCGNOV58c, 267254040Protein SequenceSEQ ID NO: 916637 aaMW at 69945.6kDEFAFTGSKRDTVKGYFLAGGDMVWWPVGASLFASNVGSGHFIGLAGSGAATGISVSAYELNGLFSVLMLAWIFLPIYIAGQVTTMPEYLRKRFGGIRIPIILAVLYLFIYIFTKISVDMYAGAIFIQQSLHLDLYLAIVGLLAITAVYTVAGGLAAVIYTDALQTLIMLIGALTLMGYSFAAVGGMEGLKEKYFLALASNRSENSSCGLPREDAFHIFRDPLTSDLPWPGVLFGMSIPSLWYWCTDQVIVQRTLAAKNLSHAKGGALMAAYLKVLPLFIMVFPGMVSRILFPDQVACADPEICQKICSNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIFTMDLWNHLRPRASEKELMIVGRVFVLLLVLVSIILWIPWQASQGGQLFIYIQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDFIYVQPRCDQPDERPVLVKSIHYLYFSMILSTVTLITVSTVSWFTEPPSKEMVSHLTWFTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQENTSKTHSCDMTPKQSKVVKAILWLCGIQEKGKEELPARAEAIIVSLEENPLVKTLLDVNLIFCVSCAIFIWGYFALEGRASEQ ID NO: 9172105 bpNOV58d, SNP13379242 ofORF Start: ATG at 31ORF Stop: TAG at 2056CG56398-01, DNA SequenceSNP Pos: 804SNP Change: C to GCCTCAGGATCCAGAGGTCTCGTTCAGGACCATGGAGAGCGGCACCAGCAGCCCTCAGCCTCCACAGTTAGATCCCCTGGATGCGTTTCCCCAGAAGGGCTTGGAGCCTGGGGACATCGCGGTGCTAGTTCTGTACTTCCTCTTTGTCCTGGCTGTTGGACTATGGTCCACAGTGAAGACCAAAAGAGACACAGTGAAAGGCTACTTCCTGGCTGGAGGGGACATGGTGTGGTGGCCAGTGGGTGCATCCTTGTTTGCCAGCAATGTTGGAAGTGGACATTTCATTGGCCTGGCAGGGTCAGGTGCTGCTACGGGCATTTCTGTATCAGCTTATGAACTTAATGGCTTGTTTTCTGTGCTGATGTTGGCCTGGATCTTCCTACCCATCTACATTGCTGGTCAGGTGACCACGATGCCAGAATACCTACGGAAGCGCTTCGGTGGCATCAGAATCCCCATCATCCTGGCTGTACTCTACCTATTTATCTACATCTTCACCAAGATCTCGGTAGACATGTATGCAGGTGCCATCTTCATCCAGCAGTCTTTGCACCTGGATCTGTACCTGGCCATAGTTGGGCTACTGGCCATCACTGCTGTATACACGGTTGCTGGTGGCCTGGCTGCTGTGATCTACACGGATGCCCTGCAGACGCTGATCATGCTTATAGGAGCGCTCACCTTGATGGGCTACAGTTTCGCCGCGGTTGGTGGGATGGAAGGACTGAAGGAGAAGTACTTCTTGGCCCTGGCTAGCAACCGGAGTGAGAACAGCAGCTGCGGGCTGCCCCGGGAAGATGCCTTGCATATTTTCCGAGATCCGCTGACATCTGATCTCCCGTGGCCGGGGGTCCTATTTGGAATGTCCATCCCATCCCTCTGGTACTGGTGCACGGATCAGGTAATTGTCCAGCGGACTCTGGCTGCCAAGAACCTGTCCCATGCCAAAGGAGGTGCTCTGATGGCTGCATACCTGAAGGTGCTGCCCCTCTTCATAATGGTGTTCCCTGGGATGGTCAGCCGCATCCTCTTCCCAGATCAAGTGGCCTGTGCAGATCCAGAGATCTGCCAGAAGATCTGCAGCAACCCCTCAGGCTGTTCGGACATCGCGTATCCCAAACTCGTGCTGGAACTCCTGCCCACAGGTCTCCGTGGGCTGATGATGGCTGTGATGGTGGCGGCTCTCATGTCCTCCCTCACCTCCATCTTTAACAGTGCCAGCACCATCTTCACCATGGACCTCTGGAATCACCTCCGGCCTCGGGCATCTGAGAAGGAGCTCATGATTGTGGGCAGGGTGTTTGTGCTGCTGCTGGTCCTGGTCTCCATCCTCTGGATCCCTGTGGTCCAGGCCAGCCAGGGCGGCCAGCTCTTCATCTATATCCAGTCCATCAGCTCCTACCTGCAGCCGCCTGTGGCGGTGGTCTTCATCATGGGATGTTTCTGGAAGAGGACCAATGAAAAGGGTGCCTTCTGGGGCCTGATCTCGGGCCTGCTCCTGGGCTTGGTTAGGCTGGTCCTGGACTTTATTTACGTGCAGCCTCGATGCGACCAGCCAGATGAGCGCCCGGTCCTGGTGAAGAGCATTCACTACCTCTACTTCTCCATGATCCTGTCCACGGTCACCCTCATCACTGTCTCCACCGTGAGCTGGTTCACAGAGCCACCCTCCAAGGAGATGGTCAGCCACCTGACCTGGTTTACTCGTCACGACCCCGTGGTCCAGAAGGAACAAGCACCACCAGCAGCTCCCTTGTCTCTTACCCTCTCTCAGAACGGGATGCCAGAGGCCAGCAGCAGCAGCAGCGTCCAGTTCGAGATGGTTCAAGAAAACACGTCTAAAACCCACAGCGGTGACATGACCCCAAAGCAGTCCAAAGTGGTGAAGGCCATCCTGTGGCTCTGTGGAATACAGGAGAAGGGCAAGGAAGAGCTCCCGGCCAGAGCAGAAGCCATCATAGTTTCCCTGGAAGAAAACCCCTTGGTGAAGACCCTCCTGGACGTCAACCTCATTTTCTGCGTGAGCTGCGCCATCTTTATCTGGGGCTATTTTGCTTAGTGTGGGGTGAACCCAGGGGTCCAAACTCTGTTTCTCTTCAGTGCTCCNOV58d, SNP13379242 ofSEQ ID NO: 918MW at 73955.2kDCG56398-01, Protein SequenceSNP Pos: 258675 aaSNP Change: Phe to LeuMESGTSSPQPPQLDPLDAFPQKGLEPGDIAVLVLYFLFVLAVGLWSTVKTKRDTVKGYFLAGGDMVWWPVGASLFASNVGSGHFIGLAGSGAATGISVSAYELNGLFSVLMLAWIFLPIYIAGQVTTMPEYLRKRFGGIRIPIILAVLYLFIYIFTKISVDMYAGAIFIQQSLHLDLYLAIVGLLAITAVYTVAGGLAAVIYTDALQTLIMLIGALTLMGYSFAAVGGMEGLKEKYFLALASNRSENSSCGLPREDALHIFRDPLTSDLPWPGVLFGMSIPSLWYWCTDQVIVQRTLAAKNLSHAKGGALMAAYLKVLPLFIMVFPGMVSRILFPDQVACADPEICQKICSNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIFTMDLWNHLRPRASEKELMIVGRVFVLLLVLVSILWIPVVQASQGGQLFIYIQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDFIYVQPRCDQPDERPVLVKSIHYLYFSMILSTVTLITVSTVSWFTEPPSKENVSHLTWFTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQENTSKTHSGDMTPKQSKVVKAILWLCGIQEKGKEELPARAEAIIVSLEENPLVKTLLDVNLIFCVSCAIFIWGYFA

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 58B.

TABLE 58BComparison of the NOV58 protein sequences.NOV58aMESGTSSPQPPQLDPLDAFPQKGLEPGDIAVLVLYFLFVLAVGLWSTVKTKRDTVKGYFLNOV58b------------------------------------------------------TGSYFLNOV58c-------------------------------------------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--------------------------------------------------NOV58cFWGLISGLLLGLVRLVLDFIYVQPRCDQPDERPVLVKSIHYLYFSMILSTVTLITVSTVSNOV58aWFTEPPSKEMVSHLTWFTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQENOV58b------------------------------------------------------------NOV58cWFTEPPSKEMVSHLTWFTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQENOV58aNTSKTHSGDMTPKQSKVVKAILWLCGIQEKGKEELPARAEAIIVSLEENPLVKTLLDVNLNOV58b------------------------------------------------------------NOV58cNTSKTHSCDMTPKQSKVVKAILWLCGIQEKGKEELPARAEAIIVSLEENPLVKTLLDVNLNOV58aIFCVSCAIFIWGYFA-----NOV58b--------------------NOV58cIFCVSCAIFIWGYFALEGRANOV58a(SEQ ID NO: 912)NOV58b(SEQ ID NO: 914)NOV58c(SEQ ID NO: 916)

Further analysis of the NOV58a protein yielded the following properties shown in Table 58C.

TABLE 58CProtein Sequence Properties NOV58aSignalP analysis:Cleavage site between residues 51 and 52PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 2; pos.chg 0; neg.chg 1H-region: length 11; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −0.94possible cleavage site: between 41 and 42>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 11INTEGRALLikelihood = −10.61Transmembrane 29-45INTEGRALLikelihood = −6.64Transmembrane 106-122INTEGRALLikelihood = −7.64Transmembrane 139-155INTEGRALLikelihood = −5.79Transmembrane 177-193INTEGRALLikelihood = −3.24Transmembrane 210-226INTEGRALLikelihood = −4.88Transmembrane 309-325INTEGRALLikelihood = −3.88Transmembrane 376-392INTEGRALLikelihood = −13.69Transmembrane 423-439INTEGRALLikelihood = −5.47Transmembrane 484-500INTEGRALLikelihood = −0.53Transmembrane 524-540INTEGRALLikelihood = −5.47Transmembrane 654-670PERIPHERALLikelihood = 1.32 (at 454)ALOM score: −13.69 (number of TMSs: 11)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 36Charge difference: 6.0 C(3.0) − N(−3.0)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):4.59Hyd Moment(95):4.89G content:1D/E content:2S/T content:4Score: −6.67Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: PEYLRKR (3) at 129bipartite: nonecontent of basic residues: 6.7%NLS Score: −0.22KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):66.7%: endoplasmic reticulum11.1%: vacuolar11.1%: mitochondrial11.1%: Golgi>> prediction for CG56398-01 is end (k = 9)

A search of the NOV58a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 58D.

TABLE 58DGeneseq Results for NOV58aNOV58aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB80599Human sbg1007026SGLT protein -1 . . . 675674/675 (99%)0.0Homo sapiens, 675 aa.1 . . . 675674/675 (99%)[WO200222802-A1, 21-MAR-2002]AAB60093Human transport protein TPPT-13 -1 . . . 675674/675 (99%)0.0Homo sapiens, 675 aa.1 . . . 675674/675 (99%)[WO200078953-A2, 28-DEC-2000]AAB85102Novel human transporter protein1 . . . 675673/675 (99%)0.0(NHP) - Homo sapiens, 675 aa.1 . . . 675673/675 (99%)[WO200142469-A1, 14-JUN-2001]ABP69833Human polypeptide SEQ ID NO1 . . . 675672/675 (99%)0.01880 - Homo sapiens, 675 aa.1 . . . 675672/675 (99%)[WO200270539-A2, 12-SEP-2002]AAU77134Human sodium-sugar symporter1 . . . 675671/675 (99%)0.032620 polypeptide - Homo1 . . . 675672/675 (99%)sapiens, 675 aa. [WO200216582-A2, 28-FEB-2002]

In a BLAST search of public sequence databases, the NOV58a protein was found to have homology to the proteins shown in the BLASTP data in Table 58E.

TABLE 58EPublic BLASTP Results for NOV58aNOV58aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedNumberProtein/Organism/LengthResiduesPortionExpect ValueQ8WWX8Sodium/glucose cotransporter1 . . . 675674/675 (99%)0.0KST1 - Homo sapiens (Human),1 . . . 675674/675 (99%)675 aa.CAC83728Sodium-dependent glucose1 . . . 675673/675 (99%)0.0transporter - Homo sapiens1 . . . 675673/675 (99%)(Human), 675 aa.Q96PP5Putative sodium-coupled1 . . . 675672/675 (99%)0.0cotransporter RKST1 - Homo1 . . . 675672/675 (99%)sapiens (Human), 675 aa.CAD43585Sequence 1 from Patent1 . . . 675671/675 (99%)0.0WO0216582 - Homo sapiens1 . . . 675672/675 (99%)(Human), 675 aa.Q8K0E3Similar to putative sodium-1 . . . 675583/675 (86%)0.0coupled cotransporter RKST1 -1 . . . 673627/675 (92%)Mus musculus (Mouse), 673 aa.

PFam analysis indicates that the NOV58a protein contains the domains shown in the Table 58F.

TABLE 58FDomain Analysis of NOV58aNOV58aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect ValueSSF58 . . . 487199/447 (45%)1.9e−199370/447 (83%)

Example 59

The NOV59 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 59A.

TABLE 59ANOV59 Sequence AnalysisNOV59a, CG56605-03SEQ ID NO: 919557 bpDNA SequenceORF Start: ATG at 26ORF Stop: TAG at 524ATGGTGGCAGAGTCTACATAGAACTATGCTTCGTGGTGTTCTGGGGAAAACCTTTCGACTTGTTGGCTATACTATTCAATATGGCTGTATAGCTCATTGTGCTTTTGAATACGTTGGTGGTGTTGTCATGTGTTCTGGACCATCAATGGAGCCTACAATTCAAAATTCAGATATTGTCTTTGCAGAAAATCTTAGTCGACATTTTTATGGTATCCAAAGAGGTGACATTGTGATTGCAAAAAGCCCAAGTGATCCAAAATCAAATATTTGTAAAAGAGTAATTGGTTTGGAAGGAGACAAAATCCTCACCACTAGTCCATCAGATTTCTTTAAAAGCCATAGTTATGTGCCAATGGGTCATGTTTGGTTAGAAGGTGACAATCTACAGAATTCTACAGATTCCAGGTGCTATGGACCTATTCCATATGGACTAATAAGAGGACGAATCTTCTTTAAGATTTGGCCTCTGAGTGATTTTGGATTTTTACGTGCCAGCCCTAATGGCCACAGATTTTCTGATGATTAGTAAGCATTTATTCTTTTGACTTGATTATTGTNOV59a, CG56605-03Protein SequenceSEQ ID NO: 920166 aaMW at 18504.0kDMLRGVLGKTFRLVGYTIQYGCIAHCAFEYVGGVVMCSGPSMETPIQNSDIVFAENLSRHFYGIQRGDIVIAKSPSDPKSNICKRVIGLEGDKILTTSPSDFFKSHSYVPMGHVWLEGDNLQNSTDSRCYGPIPYGLIRGRIFFKIWPLSDFGFLRASPNGHRFSDDNOV59b, CG56605-01SEQ ID NO: 921513 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAA at 445AGTCTACATAGAACTATGCTTCGTGGTGCTCTGGGGAAACCTTCTGACCTTGTTGGCTATGCTATTCAGTATGGCTGTATAGCTCACTGTGCTTCTGAATACGTTGGTGGTGTTGTCATGTGTTCTGGACCATCAATGGAGCCTACAATTCAAAATTCAGATACTGTCTTTGCACAAAATCTTAGTCGACATTTTGATAGTATCCAAAGAGGTGACATTGTGATTGCAAAAAGCCCAAGTGATCCAACATCAAATATTTGTAAAAGAGTAACTGGTTTGGAAGGAGACAAAATCCTCACCACTAGTCCATCAGATTTCTTTAAAAGCTACAGTTATGTCCCAGTGGGTCATGTTTGGTTAGAAGGTGATAATCTACAGAATTCTACAGATTCCAGTTACTATGGACCTATTCCATATGAACTAATAAGAGGACGAATCTTCTTTTAAGATTCGGCCTCTGAGTGATTTTGGATTTTTATGTGCCAGCCTTAATGGCCACAGATTTTCTGATGANOV59b, CG56605-01Protein SequenceSEQ ID NO: 922143 aaMW at 15622.4kDMLRGAIGKPSDLVGYAIQYGCIAHCASEYVGGVVMCSGPSMEPTIQNSDTVFAQNLSRHFDSIQRGDIVIAKSPSDPTSNICKRVTGLEGDKILTTSPSDFFKSYSYVPVGHVWLEGDNLQNSTDSSYYGPIPYELIRGRIFFNOV59c, CG56605-02SEQ ID NO: 923507 bpDNA SequenceORF Start: ATG at 11ORF Stop: at 506ACATAGAACTATGCTTCGTGGTGCTCTGGGGAAAACCTTTCGACTTGTTGGCTATACTATTCAATATGGCTGTATAGCTCATTGTGCTTTTGAATACGTTGGTGGTGTTGTCATGTGTTCTGGACCATCAATGGAGCCTACAATTCAAAATTCAGATATTGTCTTTGCAGAAAATCTTAGTCGACATTTTTATGGTATCCAAAGAGGTGACATTGTGATTGCAAAAAGCCCAAGTGATCCAAAATCAAATATTTGTAAAAGAGTAATTGGTTTGGAAGGAGACAAAATCCTCACCACTAGTCCATCAGATTTCTTTAAAAGCCATAGTTATGTGCCAATGGGTCATGTTTGGTTAGAAGGTGACAATCTACAGAATTCTACAGATTCCAGGTGCTATGGACCTATTCCATATGGACTAATAAGAGGACGAATCTTCTTTAAGATTTGGCCTCTGAGTGATTTTGGATTTTTACGTGCCAGCCTTAATGGCCACAGATTTTCTGATGANOV59c, CG56605-02Protein SequenceSEQ ID NO: 924165 aaMW at 18376.9kDMLRGALGKTFRLVGYTIQYGCIAHCAFEYVGGVVMCSGPSMEPTIQNSDIVFAENLSRHFYGIQRGDIVIAKSPSDPKSNICKRVIGLEGDKILTTSPSDFFKSHSYVPMGHVWLEGDNLQNSTDSRCYGPIPYGLIRGRIFFKIWPLSDFGFLRASLNGHRFSD

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 59B.

TABLE 59BComparison of the NOV59 protein sequences.NOV59aMLRGVLGKTFRLVGYTIQYGCIAHCAFEYVGGVVMCSGPSMEPTIQNSDIVFAENLSRHFNOV59bMLRGALGKPSDLVGYAIQYGCIAHCASEYVGGVVMCSGPSMEPTIQNSDTVFAQNLSRHFNOV59cMLRGVLGKTFRLVGYTIQYGCIAHCAFEYVGGVVMCSGPSMEPTIQNSDIVFAENLSRHFNOV59aYGIQRGDIVIAKSPSDPKSNICKRVIGLEGDKILTTSPSDFFKSHSYVPMGHVWLEGDNLNOV59bDSIQRGDIVIAKSPSDPTSNICKRVTGLEGDKILTTSPSDFFKSYSYVPVGHVWLEGDNLNOV59cYGIQRGDIVIAKSPSDPKSNICKRVIGLEGDKILTTSPSDFFKSHSYVPMGHVWLEGDNLNOV59aQNSTDSRCYGPIPYGLIRGRIFFKIWPLSDFGFLRASPNGHRFSDDNOV59bQNSTDSSYYGPIPYELIRGRIFF-----------------------NOV59cQNSTDSRCYGPIPYGLIRGRIFFKIWPLSDFGFLRASLNGHRFSD-NOV59a(SEQ ID NO: 920)NOV59b(SEQ ID NO: 922)NOV59c(SEQ ID NO: 924)

Further analysis of the NOV59a protein yielded the following properties shown in Table 59C.

TABLE 59CProtein Sequence Properties NOV59aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG: a new signal peptide prediction method N-region: length 11; pos.chg 3; neg.chg 0 H-region: length 16; peak value 6.29 PSG score: 1.89GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −7.69 possible cleavage site: between 32 and 33>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 1.70 (at 20) ALOM score: 1.70 (number of TMSs: 0)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 6 Charge difference: 0.0 C(2.0) − N(2.0) N >= C: N-terminal side will be insideMITDISC: discrimination of mitochondrial targeting seq R content:2Hyd Moment(75):14.36 Hyd Moment(95):9.31G content: 4 D/E content:1S/T content: 2 Score: −2.96Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 21 FRL|VGNUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 10.2% NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: XXRR-like motif in the N-terminus: LRGVnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 89COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residuesFinal Results (k = 9/23): 43.5%: cytoplasmic 34.8%: mitochondrial 8.7%: nuclear 8.7%: peroxisomal 4.3%: plasma membrane>> prediction for CG56605-03 is cyt (k = 23)

A search of the NOV59a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 59D.

TABLE 59DGeneseq Results for NOV59aNOV59aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABG70899Human S26 signal peptidase1 . . . 166166/166 (100%)2e−97family member 33449 - Homo1 . . . 166166/166 (100%)sapiens, 166 aa. [US2002115630-A1, 22-AUG-2002]AAB47563Protease PRTS-5 - Homo sapiens,1 . . . 166166/166 (100%)2e−97166 aa. [WO200171004-A2, 27-1 . . . 166166/166 (100%)SEP-2001]ABG08149Novel human diagnostic protein1 . . . 166166/166 (100%)2e−97#8140 - Homo sapiens, 166 aa.1 . . . 166166/166 (100%)[WO200175067-A2, 11-OCT-2001]ABB64326Drosophila melanogaster5 . . . 15076/160 (47%)2e−38polypeptide SEQ ID NO 19770 -3 . . . 162100/160 (62%) Drosophila melanogaster, 166 aa.[WO200171042-A2, 27-SEP-2001]AAB74688Human protease and protease108 . . . 166 58/59 (98%)6e−30inhibitor PPIM-21 - Homo36 . . . 94 58/59 (98%)sapiens, 94 aa. [WO200110903-A2, 15-FEB-2001]

In a BLAST search of public sequence databases, the NOV59a protein was found to have homology to the proteins shown in the BLASTP data in Table 59E.

TABLE 59EPublic BLASTP Results for NOV59aNOV59aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ96LU5Hypothetical protein FLJ25059 -1 . . . 166166/166 (100%)5e−97Homo sapiens (Human), 166 aa.1 . . . 166166/166 (100%)Q9CQU81500034J20Rik protein1 . . . 166156/166 (93%) 1e−89(2610528O17Rik protein)1 . . . 166157/166 (93%) (RIKEN cDNA 1500034J20 gene)(Unknown EST) - Mus musculus(Mouse), 166 aa.Q96SH9DJ1137O17.1 (Similar to putative1 . . . 144144/144 (100%)2e−82mitochondrial inner membrane1 . . . 144144/144 (100%)protease subnunit 2) - Homosapiens (Human), 144 aa(fragment).Q9VXR8CG9240 protein - Drosophila5 . . . 15076/160 (47%)5e−38melanogaster (Fruit fly), 166 aa.3 . . . 162100/160 (62%) Q8SZ24RE22928p - Drosophila5 . . . 15076/160 (47%)1e−37melanogaster (Fruit fly), 166 aa.3 . . . 16299/160 (61%)

PFam analysis indicates that the NOV59a protein contains the domains shown in the Table 59F.

TABLE 59FDomain Analysis of NOV59aNOV59aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect ValuePeptidase_S261 . . . 152 37/221 (17%)9.1e−07104/221 (47%)

Example 60

The NOV60 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 60A.

TABLE 60ANOV60 Sequence AnalysisNOV60a, CG56645-03SEQ ID NO: 9251862 bpDNA SequenceORF Start: ATG at 35ORF Stop: TGA at 1829CGGGCTCATACCTAGTGCCTGCGGCAGGACAGCCATGGCCGCCAACTCCACCAGCGACCTCCACACTCCCGGGACGCAGCTGAGCGTGGCTGACATCATCGTCATCACTGTGTATTTTGCTCTGAACGTGGCCGTGGGCATATGGTCCTCTTGTCGGGCCAGTAGGAACACGGTGAATGGCTACTTCCTGGCAGGCCGGGACATGACGTGGTGGCCGATTGGAGCCTCCCTCTTCGCCAGCAGCGAGGGCTCTGGCCTCTTCATTGGACTGGCGGGCTCAGGCGCGGCAGGAGGTCTGGCCGTGGCAGGCTTCGAGTGGAATGCCACGTACGTGCTGCTGGCACTGGCATGGGTGTTCGTGCCCATCTACATCTCCTCAGAGATCGTCACCTTACCTGAGTACATTCAGAAGCGCTACGGGGGCCAGCGGATCCGCATGTACCTGTCTGTCCTGTCCCTGCTACTGTCTGTCTTCACCAAGATATCGCTGGACCTGTACGCGGGGGCTCTGTTTGTGCACATCTGCCTGGGCTGGAACTTCTACCTCTCCACCATCCTCACGCTCGGCATCACAGCCCTGTACACCATCGCAGGGGGCCTGGCTGCTGTAATCTACACGGACGCCCTGCAGACGCTCATCATGGTGGTGGGGGCTGTCATCCTGACAATCAAAGCTTTTGACCAGATCGGTGGTTACGGGCAGCTGGAGGCAGCCTACGCCCAGGCCATTCCCTCCAGGACCATTGCCAACACCACCTGCCACCTGCCACGTACAGACGCCATGCACATGTTTCGAGACCCCCACACAGGGGACCTGCCGTGGACCGGGATGACCTTTGGCCTGACCATCATGGCCACCTGGTACTGGTGCACCGACCAGGTCATCGTGCAGCGATCACTGTCAGCCCGGGACCTGAACCATGCCAAGGCGGGCTCCATCCTGGCCAGCTACCTCAAGATGCTCCCCATGGGCCTGATCATCATGCCGGGCATGATCAGCCGCGCATTGTTCCCAGGTGCTCATGTCTATGAGGAGAGACACCAAGTGTCCGTCTCTCGAACAGATGATGTGGGCTGCGTGGTGCCGTCCGAGTGCCTGCGGGCCTGCGGGGCCGAGGTCGGCTGCTCCAACATCGCCTACCCCAAGCTGGTCATGGAACTGATGCCCATCGGTCTGCGGGGGCTGATGATCGCAGTGATGCTGGCGGCGCTCATGTCGTCGCTGACCTCCATCTTCAACAGCAGCAGCACCCTCTTCACTATGGACATCTGGAGGCGGCTGCGTCCCCGCTCCGGCGAGCGGGAGCTCCTGCTGGTGGGACGGCTGGTCATAGTGGCACTCATCGGCGTGAGTGTGGCCTGGATCCCCGTCCTGCAGGACTCCAACAGCGGGCAACTCTTCATCTACATGCAGTCAGTGACCAGCTCCCTGGCCCCACCAGTGACTGCAGTCTTTGTCCTGGGCCTGATAGCAGGGCTGGTGGTGGGGGCCACGAGGCTGGTCCTGGAATTCCTGAACCCAGCCCCACCGTGCGGAGAGCCAGACACGCGGCCAGCCGTCCTGGGGAGCATCCACTACCTGCACTTCGCTGTCGCCCTCTTTGCACTCAGTGGTGCTGTTGTGGTGGCTGGAAGCCTGCTGACCCCACCCCCACAGAGTGTCCAGATTGAGAACCTTACCTGGTGGAACCTGGCTCAGGATGTGCCCTTGGGAACTAAAGCAGGTGATGGCCAAACACCCCAGAAACACGCCTTCTGGGCCCGTGTCTGTGGCTTCAATGCCATCCTCCTCATGTGTGTCAACATATTCTTTTATGCCTACTTCGCCTGACACTGCCATCCTGGACAGAAAGGCAGGAGCTNOV60a, CG56645-03Protein SequenceSEQ ID NO: 926598 aaMW at 64485.7kDMAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCRASRNTVNGYFLAGRDMTWWPIGASLFASSEGSGLFIGLAGSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLPEYIQKRYGGQRIRNYLSVLSLLLSVFTKISLDLYAGALFVHICLGWNFYLSTILTLGITALYTIAGGLAAVIYTDALQTLIMVVGAVILTIKAFDQIGGYGQLEAAYAQAIPSRTIANTTCHLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTDQVIVQRSLSARDLNHAKAGSILASYLKMLPMGLIIMPGMISRALFPGAHVYEERHQVSVSRTDDVGCVVPSECLRACGAEVGCSNIAYPKLVMELMPIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRLRPRSGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFIYMQSVTSSLAPPVTAVFVLGLIAGLVVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALFALSGAVVVAGSLLTPPPQSVQIENLTWWNLAQDVPLGTKAGDGQTPQKHAFWARVCGFNAILLMCVNIFFYAYFANOV60b, CG56645-04SEQ ID NO: 9271801 bpDNA SequenceORF Start: ATG at 35ORF Stop: TGA at 1790CGGGCTCATACCTAGTGCCTGCGGCAGGACAGCCATGGCCGCCAACTCCACCAGCGACCTCCACACTCCCGGGACGCAGCTGAGCGTGGCTGACATCATCGTCATCACTGTGTATTTTGCTCTGAACGTGGCCGTGGGCATATGGTCCTCTTGTCGGGCCAGTAGGAACACGGTGAATGGCTACTTCCTGGCAGGCCGGGACATGACGTGGTGGCCGGATTGGAGCCTCCCTCTTCGCCAGCGCGAGGGCTCTGGCCTCTTCATTGGACTGGCGGGCTCAGGCGCGGCAGGAGGTCTGGCCGTGGCAGGCTTCGAGTGGAATGCCACGTACGTGCTGCTGGCACTGGCATGGGTGTTCGTGCCCATCTACATCTCCTCAGAGATCGTCACCTTACCTGAGTACATTCAGAAGCGCTACGGGGGCCAGCGGATCCGCATGTACCTGTCTGTCCTGTCCCTGCTACTGTCTGTCTTCACCAAGATATCGCTGGACCTGTACGCGGGGGCTCTGTTTGTGCACATCTGCCTGGGCTGGAACTTCTACCTCTCCACCATCCTCACGCTCGGCATCACAGCCCTGTACACCATCGCAGCTTTTGACCAGATCGGTGGTTACGGGCAGCTGGAGGCAGCCTACGCCCAGGCCATTCCCTCCAGGACCATTGCCAACACCACCTGCCAGCTGCCACGTACAGACGCCATGCACATGTTTCGAGACCCCCACACAGGGGACCTGCCGTGGACCGGGATGACCTTTGGCCTGACCATCATGGCCACCTGGTACTGGTGCACCGACCAGGTCATCGTGGAGGGATCACTGTCAGCCCGGGACCTGAACCATGCCAAGGGGGGCTCCATCCTGGGCAGCTACCTCAAGATGCTCCCCATGGGCCTGATCATCATGCCGGGCATGATCAGCCGCGCATTGTTCCCAGGTGCTCATGTCTATGAGGAGAGACACCAAGTGTCCGTCTCTCGAACAGATGATGTGGGCTGCGTGGTGCCGTCCGAGTGCCTGCGGGCCTGCGGGGCCGAGGTCGGCTGCTCCAACATCGCCTACCCCAAGCTGGTCATGGAACTGATGCCCATCGGTCTGCGGGGGCTGATGATCGCAGTGATGCTGGCGGCGCTCATGTCGTCGCTGACCTCCATCTTCAACAGCAGCAGCACCCTCTTCACTATGGACATCTGGAGGCGGCTGCGTCCCCGCTCCGGCGAGCGGGAGCTCCTGCTGGTGGGACGGCTGGTCATAGTGGCACTCATCGGCGTGAGTGTGGCCTGGATCCCCGTCCTGCAGGACTCCAACAGCGGGCAACTCTTCATCTACATGCAGTCAGTGACCAGCTCCCTGGCCCCACCAGTGACTGCAGTCTTTGTCCTGGGCGTCTTCTGGCGACGTGCCAACGAGCAGGGGGCCTTCTGGGGCCTGATAGCAGGGCTGGTGGTGGGGGCCACGAGGCTGGTCCTGGAATTCCTGAACCCGGCCCCACCGTGCGGAGAGCCAGACACGCGGCCAGCCGTCCTGGGGAGCATCCACTACCTGCACTTCGCTGTCGCCCTCTTTGCACTCAGTGGTGCTGTTGTGGTGGCTGGAAGCCTGCTGACCCCACCCCCACAGAGTGTCCAGATTGAGAACCTTACCTGGTGGACCCTGGCTCAGGATGTGCCCTTGGGAACTAAAGCAGGTGATGGCCAAACACCCCAGAAACACGCCTTCTGGGCCCGTGTCTGTGGCTTCAATGCCATCCTCCTCATGTGTGTCAACATATTCTTTTATGCCTACTTCGCCTGACACTGCCATNOV60b, CG56645-04Protein SequenceSEQ ID NO: 928585 aaMW at 63317.1kDMAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCRASRNTVNGYFLAGRDMTWWPIGASLFASSEGSGLFIGLAGSGAAGGLAVAGFEWNATYVLLALANVFVPIYISSEIVTLPEYIQKRYGGQRIRMYLSVLSLLLSVFTKISLDLYAGALFVHICLGWNFYLSTILTLGITALYTIAAFDQIGGYGOLEAAYAQAIPSRTIANTTCQLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTDQVIVEGSLSARDLNHAKGGSILGSYLKMLPMGLIIMPGMISRALFPGAHVYEERHQVSVSRTDDVGCVVPSECLRACGAEVGCSNIAYPKLVMELMPIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRLRPRSGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFIYMQSVTSSLAPPVTAVFVLGVFWRRANEQGAFWGLIAGLVVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALFALSGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTKAGDGQTPQKHAFWARVCGFNAILLMCVNIFFYAYFANOV60c, CG56645-01SEQ ID NO: 9291914 bpDNA SequenceORF Start: ATG at 51ORF Stop: TGA at 1839TTGCCCCTCAGTCCCTCGGGCTCATACCTAGTGCCTGCGGCAGGACAGCCATGGCCGCCAACTCCACCAGCGACCTCCACACTCCCGGGACGCAGCTGAGCGTGGCTGACATCATCGTCATCACTGTGTATTTTGCTCTGAACGTGGCCGTGGGCATATGGTCCTCTTGTCGGGCCAGTAGGAACACGGTGAATGGCTACTTCCTGGCAGGCCGGGACATGACGTGGTGGCCGATTGGAGCCTCCCTCTTCGCCAGCAGCGAGGGCTCTGGCCTCTTCATTGGACTGGCGGGCTCAGGCGCGGCAGGAGGTCTGGCCGTGGCAGGCTTCGAGTGGAATGCCACGTACGTGCTGCTGGCACTGGCATGGGTGTTCGTGCCCATCTACATCTCCTCAGAGATCGTCACCTTACCTGAGTACATTCAGAAGCGCTACGGGGGCCAGCGGATCCGCATGTACCTGTCTGTCCTGTCCCTGCTACTGTCTGTCTTCACCAAGATATCGCTGGACCTGTACGCGGGGGCTCTGTTTGTGCACATCTGCCTGGGCTGGAACTTCTACCTCTCCACCATCCTCACGCTCGGCATCACAGCCCTGTACACCATCGCAGGGGGCCTGGCTGCTGTAATCTACACGGACGCCCTGCAGACGCTCATCATGGTGGTGGGGGCTGTCATCCTGACAATCAAAGCTTTTGACCAGATCGGTGGTTACGGGCAGCTGGAGGCAGCCTACGCCCAGGCCATTCCCTCCAGGACCATTGCCAACACCACCTGCCACCTGCCACGTACAGACGCCATGCACATGTTTCGAGACCCCCACACAGGGGACCTGCCGTGGACCGGGATGACCTTTGGCCTGACCATCATGGCCACCTGGTACTGGTGCACCGACCAGGTGATCGTGCAGCGATCACTGTCAGCCCGGGACCTGAACCATGCCAAGGCGGGCTCCATCCTGGCCAGCTACCTCAAGATGCTCCCCATGGGCCTGATCATAATGCCGGGCATGATCAGCCGCGCATTGTTCCCAGATGATGTGGGCTGCGTGGTGCCGTCCGAGTGCCTGCGGGCCTGCGGGGCCGAGGTCGGCTGCTCCAACATCGCCTACCCCAAGCTGGTCATGGAACTGATGCCCATCGGTCTGCGGGGGCTGATGATCGCAGTGATGCTGGCGGCGCTCATGTCGTCGCTGACCTCCATCTTCAACAGCAGCAGCACCCTCTTCACTATGGACATCTGGAGGCGGCTGCGTCCCCGCTCCGGCGAGCGGGAGCTCCTGCTGGTGGGACGGCTGGTCATAGTGGCACTCATCGGCGTGAGTGTGGCCTGGATCCCCGTCCTGCAGGACTCCAACAGCGGGCAACTCTTCATCTACATGCAGTCAGTGACCAGCTCCCTGGCCCCACCAGTGACTGCAGTCTTTGTCCTGGGCGTCTTCTGGCGACGTGCCAACGAGCAGGGGGCCTTCTGGGGCCTGATAGCAGGGCTGGTGGTGGGGGCCACGAGGCTGGTCCTGGAATTCCTGAACCCAGCCCCACCGTGCGGAGAGCCAGACACGCGGCCAGCCGTCCTGGGGAGCATCCACTACCTGCACTTCGCTGTCGCCCTCTTTGCACTCAGTGGTGCTGTTGTGGTGGCTGGAAGCCTGCTGACCCCACCCCCACAGAGTGTCCAGATTGAGAACCTTACCTGGTGGACCCTGGCTCAGGATGTGCCCTTGGGAACTAAAGCAGGTGATGGCCAAACACCCCAGAAACACGCCTTCTGGGCCCGTGTCTGTGGCTTCAATGCCATCCTCCTCATGTGTGTCAACATATTCTTTTATGCCTACTTCGCCTGACACTGCCATCCTGGACAGAAAGGCAGGAGCTCTGAGTCCTCAGGTCCACCCATTTCCCTCATGGGGATCCCGANOV60c, CG56645-01Protein SequenceSEQ ID NO: 930596 aaMW at 64341.6kDMAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCRASRNTVNGYFLAGRDMTWWPIGASLFASSEGSGLFIGLAGSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLPEYIQKRYGGQRIRNYLSVLSLLLSVFTKISLDLYAGALFVHICLGWNFYLSTILTLGITAIYTIAGGLAAVIYTDALQTLIMVVGAVILTIKAFDQIGGYGQLEAAYAQAIPSRTIANTTCHLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTDQVIVQRSLSARDLNHAKAGSILASYLKMLPMGLIIMPGMISRALFPDDVGCVVPSECLRACGAEVGCSNIAYPKLVMELMPIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRLRPRSGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFIYMQSVTSSLAPPVTAVFVLGVFWRRANEQGAFWGLIAGLVVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALFALSGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTKAGDGQTPQKIIAFWARVCGFNAILLMCVNIFFYAYFANOV60d, CG56645-02SEQ ID NO: 9311912 bpDNA SequenceORF Start: ATG at 35ORF Stop: TGA at 1871CGGGCTCATACCTAGTGCCTGCGGCAGGACAGCCATGGCCGCCAACTCCACCAGCGACCTCCACACTCCCGGGACGCAGCTGAGCGTGGCTGACATCATCGTCATCACTGTGTATTTTGCTCTGAACGTGGCCGTGGGCATATGGTCCTCTTGTCGGGCCAGTAGGAACACGGTGAATGGCTACTTCCTGGCAGGCCGGGACATGACGTGGTGGCCGATTGGAGCCTCCCTCTTCGCCAGCAGCGAGGGCTCTGGCCTCTTCATTGGACTGCCGGGCTCAGGCGCGGCAGGAGGTCTGGCCGTGGCAGGCTTCGAGTGGAATGCCACGTACGTGCTGCTGGCACTGGCATGGGTGTTCGTGCCCATCTACATCTCCTCAGAGATCGTCACCTTACCTGAGTACATTCAGAAGCGCTACGGGGGCCAGCGGATCCGCATGTACCTGTCTGTCCTGTCCCTGCTACTGTCTGTCTTCACCAAGATATCGCTGGACCTGTACGCGGGGGCTCTGTTTGTGCACATCTGCCTGGGCTGGAACTTCTACCTCTCCACCATCCTCACGCTCGGCATCACAGCCCTGTACACCATCGCAGGGGGCCTGGCTGCTGTAATCTACACGGACGCCCTGCAGACGCTCATCATGGTGGTGGGGGCTGTCATCCTGACAATCAAAGCTTTTGACCAGATCGGTGGTTACGGGCAGCTGGAGGCAGCCTACGCCCAGGCCATTCCCTCCAGGACCATTGCCAACACCACCTGCCACCTGCCACGTACAGACGCCATGCACATGTTTCGAGACCCCCACACAGGGGACCTGCCGTGGACCGGGATGACCTTTGGCCTGACCATCATGGCCACCTGGTACTGGTGCACCGACCAGGTCATCGTGCAGCGATCACTGTCAGCCCGGGACCTGAACCATGCCAAGGCGGGCTCCATCCTGGCCAGCTACCTCAAGATGCTCCCCATGGGCCTGATCATCATGCCGGGCATGATCAGCCGCGCATTGTTCCCAGGTGCTCATGTCTATGAGGAGAGACACCAAGTGTCCGTCTCTCGAACAGATGATGTGGGCTGCGTGGTGCCGTCCGAGTGCCTGCGGGCCTGCGGGGCCGAGGTCGGCTGCTCCAACATCGCCTACCCCAAGCTGGTCATGGAACTGATGCCCATCGGTCTGCGGGGGCTGATGATCGCAGTGATGCTGGCGGCGCTCATGTCGTCGCTGACCTCCATCTTCAACAGCAGCAGCACCCTCTTCACTATGGACATCTGGAGGCGGCTGCGTCCCCGCTCCGGCGAGCGGGAGCTCCTGCTGGTGGGACGGCTGGTCATAGTGGCACTCATCGGCGTGAGTGTGGCCTGGATCCCCGTCCTGCAGGACTCCAACAGCGGGCAACTCTTCATCTACATGCAGTCAGTGACCAGCTCCCTGGCCCCACCAGTGACTGCAGTCTTTGTCCTGGGCGTCTTCTGGCGACGTGCCAACGAGCAGGGGGCCTTCTGGGGCCTGATAGCAGGGCTGGTGGTGGGGGCCACGAGGCTGGTCCTGGAATTCCTGAACCCAGCCCCACCGTGCGGAGAGCCAGACACGCGGCCAGCCGTCCTGGGGAGCATCCACTACCTGCACTTCGCTGTCGCCCTCTTTGCACTCAGTGGTGCTGTTGTGGTGGCTGGAAGCCTGCTGACCCCACCCCCACAGAGTGTCCAGATTGAGAACCTTACCTGGTGGACCCTGGCTCAGGATGTGCCCTTGGGAACTAAAGCAGGTGATGGCCAAACACTCCAGAAACACGCCTTCTGGGCCCGTGTCTGTGGCTTCAATGCCATCCTCCTCATGTGTGTCAACATATTCTTTTATGCCTACTTCGCCTGACACTGCCATCCTGGACAGAAAGGCAGGAGCTCTGAGTCCNOV60d, CG56645-02Protein SequenceSEQ ID NO: 932612 aaMW at 66194.7kDMAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCRASRNTVNGYFLAGRDMTWWPIGASLFASSEGSGLFIGLAGSGAAGGLAVAGFEWNATYVLLAIAWVFVPIYISSEIVTLPEYIQKRYGGQRIRMYLSVLSLLLSVFTKISLDLYAGALFVHICLGWNFYLSTILTLGITALYTIAGGLAAVIYTDALQTLIMVVGAVILTIKAFDQIGGYGQLEAAYAQAIPSRTIANTTCHLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTDQVIVQRSLSARDLNHAKAGSSILASYLKMLPNGLIIMPGMISRALFPGANVYEERHQVSVSRTDDVGCVVPSECLRACGAEVGCSNIAYPKLVMELMPIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRLRPRSGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFIYMQSVTSSLAPPVTAVFVLGVFWRRANEQGAFWGLIAGLVVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALFALSGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTKAGDGQTLQKHAFWARVCGFNAILLMCVMIFFYAYFA

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 60B.

TABLE 60BComparison of the NOV60 protein sequences.NOV60aMAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCRASRNTVNGYFLAGRDMTWWNOV60bMAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCRASRNTVNGYFLAGRDMTWWNOV60cMAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCRASRNTVNGYFLAGRDMTWWNOV60dMAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCRASRNTVNGYFLAGRDMTWWNOV60aPIGASLFASSEGSGLFIGLAGSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLNOV60bPIGASLFASSEGSGLFIGLAGSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLNOV60cPIGASLFASSEGSGLFIGLAGSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLNOV60dPIGASLFASSEGSGLFIGLAGSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLNOV60aPEYIQKRYGGQRIRMYLSVLSLLLSVFTKISLDLYAGALFVHICLGWNFYLSTILTLGITNOV60bPEYIQKRYGGQRIRMYLSVLSLLLSVFTKISLDLYAGALFVHICLGWNFYLSTILTLGITNOV60cPEYIQKRYGGQRIRMYLSVLSLLLSVFTKISLDLYAGALFVHICLGWNFYLSTILTLGITNOV60dPEYIQKRYGGQRIRMYLSVLSLLLSVFTKISLDLYAGALFVHICLGWNFYLSTILTLGITNOV60aALYTIAGGLAAVIYTDALQTLIMVVGAVILTIKAFDQIGGYGQLEAAYAQAIPSRTIANTNOV60bALYTIA---------------------------AFDQIGGYGQLEAAYAQAIPSRTIANTNOV60cALYTIAGGLAAVIYTDALQTLIMVVGAVILTIKAFDQIGGYGQLEAAYAQAIPSRTIANTNOV60dALYTIAGGLAAVIYTDALQTLIMVVGAVILTIKAFDQIGGYGQLEAAYAQAIPSRTIANTNOV60aTCHLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTDQVIVQRSLSARDLNHAKAGNOV60bTCQLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTDQVIVEGSLSARDLNHAKAGNOV60cTCHLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTDQVIVQRSLSARDLNHAKAGNOV60dTCHLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTDQVIVQRSLSARDLNHAKAGNOV60aSILASYLKMLPMGLIIMPGMISRALFPGAHVYEERHQVSVSRTDDVGCVVPSECLRACGANOV60bSILASYLKMLPMGLIIMPGMISRALFPGAHVYEERHQVSVSRTDDVGCVVPSECLRACGANOV60cSILASYLKMLPMGLIIMPGMISRALFP----------------DDVGCVVPSECLRACGANOV60dSILASYLKMLPMGLIIMPGMISRALFPGAHVYEERHQVSVSRTDDVGCVVPSECLRACGANOV60aEVGCSNIAYPKLVMELMPIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRLRPRSNOV60bEVGCSNIAYPKLVMELMPIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRLRPRSNOV60cEVGCSNIAYPKLVMELMPIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRLRPRSNOV60dEVGCSNIAYPKLVMELMPIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRLRPRSNOV60aGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFIYMQSVTSSLAPPVTAVFVL----NOV60bGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFIYMQSVTSSLAPPVTAVFVLGVFWNOV60cGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFIYMQSVTSSLAPPVTAVFVLGVFWNOV60dGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFIYMQSVTSSLAPPVTAVFVLGVFWNOV60a----------GLIAGLVVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALFALSNOV60bRRANEQGAFWGLIAGLVVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALFALSNOV60cRRANEQGAFWGLIAGLVVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALFALSNOV60dRRANEQGAFWGLIAGLVVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALFALSNOV60aGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTKAGDGQTPQKHAFWARVCGFNAILLNOV60bGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTKAGDGQTPQKHAFWARVCGFNAILLNOV60cGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTKAGDGQTPQKHAFWARVCGFNAILLNOV60dGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTKAGDGQTPQKHAFWARVCGFNAILLNOV60aMCVNIFFYAYFANOV60bMCVNIFFYAYFANOV60cMCVNIFFYAYFANOV60dMCVNIFFYAYFANOV60a(SEQ ID NO: 926)NOV60b(SEQ ID NO: 928)NOV60c(SEQ ID NO: 930)NOV60d(SEQ ID NO: 932)

Further analysis of the NOV60a protein yielded the following properties shown in Table 60C.

TABLE 60CProtein Sequence Properties NOV60aSignalP analysis:Cleavage site between residues 43 and 44PSORT II analysis:PSG: a new signal peptide prediction method N-region: length 8; pos.chg 0; neg.chg 1 H-region: length 11; peak value 0.00 PSG score: −4.40GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −2.19 possible cleavage site: between 42 and 43>>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 12 INTEGRALLikelihood = −6.00Transmembrane 21-37 INTEGRALLikelihood = −1.17Transmembrane 75-91 INTEGRALLikelihood = −4.51Transmembrane 97-113 INTEGRALLikelihood = −1.33Transmembrane 136-152 INTEGRALLikelihood = −2.92Transmembrane 177-193 INTEGRALLikelihood = −3.88Transmembrane 196-212 INTEGRALLikelihood = −0.27Transmembrane 301-317 INTEGRALLikelihood = −5.04Transmembrane 384-400 INTEGRALLikelihood = −10.03Transmembrane 431-447 INTEGRALLikelihood = −8.65Transmembrane 470-486 INTEGRALLikelihood = −6.74Transmembrane 520-536 INTEGRALLikelihood = −3.45Transmembrane 578-594 PERIPHERALLikelihood = 0.63 (at 159) ALOM score: −10.03 (number of TMSs: 12)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 28 Charge difference: 4.5 C(3.0) − N(−1.5) C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seq R content:0Hyd Moment(75):8.68 Hyd Moment(95):8.07G content:1 D/E content:2S/T content:6 Score: −5.13Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not foundNUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 5.5% NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residuesFinal Results (k = 9/23): 77.8%: endoplasmic reticulum 11.1%: mitochondrial 11.1%: vacuolar>> prediction for CG56645-03 is end (k = 9)

A search of the NOV60a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 60D.

TABLE 60DGeneseq Results for NOV60aNOV60aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB99496Amino acid sequence of1 . . . 598597/612 (97%)0.0sodium/glucose cotransporter48 . . . 659 597/612 (97%)Fbh68723pat - Homo sapiens, 664aa. [WO200283857-A2, 24-OCT-2002]ABB99497Amino acid sequence of1 . . . 598581/612 (94%)0.0sodium/glucose cotransporter48 . . . 643 581/612 (94%)h68723 - Homo sapiens, 643 aa.[WO200283857-A2, 24-OCT-2002]AAO14199Human transporter and ion1 . . . 598581/612 (94%)0.0channel TRICH-16 - Homo1 . . . 596581/612 (94%)sapiens, 596 aa. [WO200204520-A2, 17-JAN-2002]ABB80588Human sbg1020829SGLT protein -1 . . . 598581/612 (94%)0.0Homo sapiens, 596 aa.1 . . . 596581/612 (94%)[WO200222802-A1, 21-MAR-2002]ABG31594Human transporter protein - Homo1 . . . 598581/612 (94%)0.0sapiens, 596 aa. [US2002081678-1 . . . 596581/612 (94%)A1, 27-JUN-2002]

In a BLAST search of public sequence databases, the NOV60a protein was found to have homology to the proteins shown in the BLASTP data in Table 60E.

TABLE 60EPublic BLASTP Results for NOV60aNOV60aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAC51188Sequence 144 from Patent1 . . . 598581/612 (94%)0.0WO0149728 - Homo sapiens1 . . . 596581/612 (94%)(Human), 596 aa.Q28610Na+/glucose cotransporter-1 . . . 598518/612 (84%)0.0related protein - Oryctolagus2 . . . 597544/612 (88%)cuniculus (Rabbit), 597 aa.Q96LQ1Hypothetical protein FLJ25217 -157 . . . 598 441/456 (96%)0.0Homo sapiens (Human), 517 aa.62 . . . 517 441/456 (96%)Q8BZW1Weakly similar to NA+-glucose6 . . . 551339/560 (60%)0.0cotransporter type 1 - Mus19 . . . 562 425/560 (75%)musculus (Mouse), 685 aa.Q8BGU9Weakly similar to NA+-glucose6 . . . 551338/560 (60%)0.0cotransporter type 1 - Mus19 . . . 562 424/560 (75%)musculus (Mouse), 685 aa.

PFam analysis indicates that the NOV60a protein contains the domains shown in the Table 60F.

TABLE 60FDomain Analysis of NOV60aNOV60aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect ValueSSF50 . . . 485187/463 (40%)1.3e−167362/463 (78%)

Example 61

The NOV61 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 61A.

TABLE 61ANOV61 Sequence AnalysisNOV61a, CG56667-01SEQ ID NO: 9331027 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAG at 940ATGATCTGCTCAGCTATCAACCTACACTTACTACTGGCAGTTAAGATGATTCACCCTGTCTGGATTCTTTGCAGTCATCACTCTCGATCAGCATCTTCACACACCCATGTACTTCTTCCTGAAGAACCTCTCCGTTTTGGATCTGTGCTACATCTCAGTCACTGTGCCTAAATCCATCCGTAACTCCCTGACTCGCAGAAGCTCCATCTCTTATCTTGGCTGTGTGGCTCAAGTCTATTTTTTCTCTGCCTTTGCATCTGCTGAGCTGGCCTTCCTTACTGTCATGTCTTATGACCGCTATGTTGCCATTTGCCACCCCCTCCAATACAGAGCCGTGATGACATCAGGAGGGTGCTATCAGATGGCAGTCACCACCTGGCTAAGCTGCTTTTCCTACGCAGCCGTCCACACTGGCAACATGTTTCGGGAGCACGTTTGCAGATCCAGTGTGATCCACCAGTTCTTCCGTGACATCCCTCATGTGTTGGCCCTGGTTTCCTGTGAGGTTTTCTTTGTAGAGTTTTTGACCCTGGCCCTGAGCTCATGCTTGGTTCTGGGATGCTTTATTCTCATGATGATCTCCTATTTCCAAATCTTCTCAACGGTGCTCAGAATCCCTTCAGGACAGAGTCGAGCAAAAGCCTTCTCCACCTGCTCCCCCCAGCTCATTGTCATCATGCTCTTTCTTACCACAGGGCTCTTTGCTGCCTTAGGACCAATTGCAAAAGCTCTGTCCATTCAGGATTTAGTGATTGCTCTGACATACACAGTTTTGCCTCCCTTCCTCAATCCCATCATATATAGTCTTAGGAATAAGGAGATTAAAACAGCCATGTGGAGACTCTTTGTGAAGATATATTTTCTGCAAAAGTAGAACATCCTGGTCTTTACTATAGAAGATCTGCAACAAAACCCCAAAAAAGCATAAATACTTTATGACAAAAAAAGATGAAAAAATTNOV61a, CG56667-01Protein SequenceSEQ ID NO: 934313 aaMW at 35319.9kDMICSAINLHLLLAVKMIHPVWILAPREQGLFLLIYLAVLVGNLLIIAVITLDQHLHTPMYFFLKNLSVLDLCYISVTVPKSIRNSLTRRSSISYLGCVAQVYFFSAFASAELAFLTVMSYDRYVAICHPLQYRAVMTSGGCYQMAVTTWLSCFSYAAVHTGNMFREHVCRSSVIHQFFRDIPHVLALVSCEVFFVEFLTLALSSCLVLGCFILMMISYFQIFSTVLRIPSGQSRAKAFSTCSPQLIVIMLFLTTGLFAALGPIAKALSIQDLVIALTYTVLPPFLNPIIYSLRNKEIKTANWRLFVKIYFLQKNOV61b, 268952113SEQ ID NO: 935817 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCGTCATCACTCTCGATCAGCATCTTCACACACCCATGTACTTCTTCCTGAAGAACCTCTCTGTTTTGGATCTGTGCTACATCTCAGTCACTGTGCCTAAATCCATCCGTAACTCCCTGACTCGCAGAAGCTCCATCTCTTATCTTGGCTGTGTGGCTCAAGTCTATTTTTTCTCTGCCTTTGCATCTGCTGAGCTGGCCTTCCTTACTGTCATGTCTTATGACCGCTATGTTGCCATTTGCCACCCCCTCCAATACAGAGCCGTGATGACATCAGGAGGGTGCTATCAGATGGCAGTCACCACCTGGCTAAGCTGCTTTTCCTACGCAGCCGTCCACACTGGCAACATGTTTCGGGAGCACGTTTGCAGATCCAATGTGATCCACCAGTTCTTCCGTGACATCCCTCATGTGTTGGCCCTGGTTTCCTGTGAGGTTTTCTTTGTAGAGTTTTTGACCCTGGCCCTGAGCTCATGCTTGGTTCTGGGATGCTTTATTCTCATGATGATCTCCTATTTCCAAATCTTCTCAACGGTGCTCAGAATCCCTTCAGGACAGAGTCGAGCAAAAGCCTTCTCCACCTGCTCCCCCCAGCTCATTGTCATCATGCTCTTTCTTACCACAGGGCTCTTTGCTGCCTTAGGACCAATTGCAAAAGCTCTGTCCATTCAGGATTTAGTGATTGCTCTGACATACACAGTTTTGCCTCCCTTCCTCAATCCCATCATATATAGTCTTAGGAAATAAGGAGATTAAACAGCCATGTGGAGACTCTTTGTGAAGATATATTTTCTGCAAAAGCTCGAGGGCNOV61b, 268952113Protein SequenceSEQ ID NO: 936272 aaMW at 30688.0kDTGSVITLDQHLHTPNYFFLKNLSVLDLCYISVTVPKSIRNSLTRRSSISYLGCVAQVYFFSAFASAELAFLTVMSYDRYVAICHPLQYRAVMTSGGCYQMAVTTWLSCFSYAAVHTGNMFREHVCRSNVIHQFFRDIPHVLALVSCEVFFVEFLTLALSSCLVLGCFILMMISYFQIFSTVLRIPSGQSRAKAFSTCSPQLIVIMLFLTTGLFAALGPIAKALSIQDLVIALTYTVLPPFLNPIIYSLRNKEIKTAMWRLFVKIYFLQKLEG

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 61B.

TABLE 61BComparison of the NOV61 protein sequences.NOV61aMICSAINLHLLLAVKMIHPVWILAPREQGLFLLIYLAVLVGNLLIIAVITLDQHLHTPMYNOV61b--------------------------------------------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---NOV61bMWRLFVKIYFLQKLEGNOV61a(SEQ ID NO: 934)NOV61b(SEQ ID NO: 936)

Further analysis of the NOV61a protein yielded the following properties shown in Table 61C.

TABLE 61CProtein Sequence Properties NOV61aSignalP analysis:Cleavage site between residues 48 and 49PSORT II analysis:PSG: a new signal peptide prediction method N-region: length 0; pos.chg 0; neg.chg 0 H-region: length 14; peak value 6.18 PSG score: 1.78GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −3.68 possible cleavage site: between 41 and 42>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 7 INTEGRALLikelihood = −2.39Transmembrane 1-17 INTEGRALLikelihood = −11.20Transmembrane 33-49 INTEGRALLikelihood = −0.22Transmembrane 101-117 INTEGRALLikelihood = −1.22Transmembrane 183-199 INTEGRALLikelihood = −8.86Transmembrane 200-216 INTEGRALLikelihood = −7.54Transmembrane 245-261 INTEGRALLikelihood = −0.00Transmembrane 273-289 PERIPHERALLikelihood = 2.01 (at 62) ALOM score: −11.20 (number of TMSs: 7)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 8 Charge difference: 0.5 C(2.0) − N(1.5) C > N: C-terminal side will be inside>>>Caution: Inconsistent mtop result with signal peptide>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seq R content:1Hyd Moment(75):1.74 Hyd Moment(95):4.81G content:0 D/E content:1S/T content:1 Score: −4.54Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 99 RRS|SINUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 7.0% NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residuesFinal Results (k = 9/23): 55.6%: endoplasmic reticulum 11.1%: mitochondrial 11.1%: vacuolar 11.1%: vesicles of secretory system 11.1%: Golgi>> prediction for CG56667-01 is end (k = 9)

A search of the NOV61a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 61D.

TABLE 61DGeneseq Results for NOV61aNOV61aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAG72316Human olfactory receptor47 . . . 219149/173 (86%)2e−80polypeptide, SEQ ID NO: 1997 - 1 . . . 173151/173 (87%)Homo sapiens, 177 aa.[WO200127158-A2, 19-APR-2001]ABB77320Human G-protein coupled30 . . . 304148/275 (53%)8e−78receptor SEQ ID NO 4 - Homo28 . . . 301189/275 (67%)sapiens, 309 aa. [WO200198323-A2, 27-DEC-2001]AAU95571Human olfactory and pheromone30 . . . 304148/275 (53%)8e−78G protein-coupled receptor #58 -28 . . . 301189/275 (67%)Homo sapiens, 309 aa.[WO200224726-A2, 28-MAR-2002]ABP51618Human G protein coupled receptor30 . . . 304149/275 (54%)8e−78SEQ ID NO: 118 - Homo sapiens,28 . . . 300191/275 (69%)308 aa. [WO200250276-A2, 27-JUN-2002]ABG76784Human G-protein coupled30 . . . 304148/275 (53%)8e−78receptor (GPCR) protein #18 -28 . . . 301189/275 (67%)Homo sapiens, 309 aa.[WO200259313-A2, 01-AUG-2002]

In a BLAST search of public sequence databases, the NOV61a protein was found to have homology to the proteins shown in the BLASTP data in Table 61E.

TABLE 61EPublic BLASTP Results for NOV61aNOV61aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8NHC8Seven transmembrane helix20 . . . 307164/291 (56%)3e−81receptor - Homo sapiens18 . . . 308200/291 (68%)(Human), 309 aa.Q8VF67Olfactory receptor MOR218-3 -30 . . . 305146/276 (52%)1e−78Mus musculus (Mouse), 315 aa.32 . . . 307182/276 (65%)CAD57961Sequence 117 from Patent30 . . . 304149/275 (54%)2e−77WO0250276 - Homo sapiens28 . . . 300191/275 (69%)(Human), 308 aa.Q8NHC5Seven transmembrane helix30 . . . 304148/275 (53%)2e−77receptor - Homo sapiens28 . . . 301189/275 (67%)(Human), 309 aa.Q8VEU5Olfactory receptor MOR218-8 -30 . . . 313143/284 (50%)4e−75Mus musculus (Mouse), 320 aa.27 . . . 310185/284 (64%)

PFam analysis indicates that the NOV61a protein contains the domains shown in the Table 61F.

TABLE 61FDomain Analysis of NOV61aNOV61aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Value7tm_141 . . . 290 53/278 (19%)3.9e−31174/278 (63%)

Example 62

The NOV62 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 62A.

TABLE 62ANOV62 Sequence AnalysisNOV62a, CG56868-01SEQ ID NO: 9372422 bpDNA SequenceORF Start: ATG at 51ORF Stop: TAG at 2382GAACTCCTTTTCTCAAGCACTTCTGCTCTCCTCTACCAGAATCACTCAGAATGCTTCCCGGGTGTATATTCTTGATGATTTTACTCATTCCTCAGGTTAAAGAAAAGTTCATCCTTGGAGTAGAGGGTCAACAACTGGTTCGTCCTAAAAAGCTTCCTCTGATACAGAAGCGAGATACTGGACACACCCATGATGATGACATACTGAAAACGTATGAAGAAGAATTGTTGTATGAAATAAAACTAAATAGAAAAACCTTAGTCCTTCATCTTCTAAGATCCAGGGAGTTCCTAGGCTCAAATTACAGTGAAACATTCTACTCCATGAAAGGAGAAGCGTTCACCAGGCATCCTCAGATCATGGAACACTGTTACTATAAAGGAAACATCCTAAATGAAAAGAATTCTGTTGCCAGCATCAGTACTTGTGACGGGTTGAGGGGATTCTTCAGAATAAACGACCAAAGATACCTCATTGAACCAGTGAAATACTCAGATGAGGGAGAACATTTGGTGTTCAAATATAACCTGAGGGTGCCGTATGGTGCCAATTATTCCTGTACAGAGCTTAATTTTACCAGAAAAACTGTTCCAGGGGATAATGAATCTGAAGAAGACTCCAAAATAAAAGGCATCCATGATGAAAAGTATGTTGAATTGTTCATTGTTGCTGATGATACTGTGTATCGCAGAAATGGTCATCCTCACAATAAACTAAGGAACCGAATTTGGGGAATGGTCAATTTTGTCAACATGATTTATAAAACCTTAAACATCCATGTGACGTTGGTTGGCATTGAAATATGGACACATGAAGATAAAATAGAACTATATTCAAATATAGAAACTACCTTATTGCGTTTTTCATTTTGGCAAGAAAAGATCCTTAAAACACGGAAGGATTTTGATCATGTTGTATTACTCAGTGGGAAGTGGCTCTACTCACATGTGCAAGGAATTTCTTATCCAGGGGGTATGTGCCTGCCCTATTATTCCACCAGTATCATTAAGGATCTTTTACCTGACACAAACATAATTGCAAACAGAATGGCACATCAACTGGGGCATAACCTTGGGATGCAGCATGACGAGTTCCCATGCACCTGTCCTTCAGGAAAATGCGTGATGGACAGTGATGGAAGCATTCCTGCACTGAAATTCAGTAAATGCAGCCAAAACCAATACCACCAGTACTTGAAGGATTATAAGCCAACATGCATGCTCAACATTCCATTTCCTTACAATTTTCATGATTTCCAATTrTGTGGAAACAAGAAGTTGGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCAATGGATTTCCTTGCAAGAACTCAGAAGGCTACTGTTTCATGGGGAAATGTCCAACTCGTGAGGATCAGTGCTCTGAACTATTTGATGATGAGGCAATAGAGAGTCATGATATCTGCTACAAGATGAATACAAAAGGAAATAAATTTGGATACTGCAAAAACAAGGAAAACAGATTTCTTCCCTGTGAGGAGAAGGATGTCAGATGTGGAAAGATCTACTGCACTGGAGGGGAGCTTTCCTCTCTCCTTGGAGAAGACAAGACTTATCACCTTAAGGATCCCCAGAAGAATGCTACTGTCAAATGCAAAACTATTTTTTTATACCATGATTCTACAGACATTGGCCTGGTGGCGTCAGGAACAAAATGTGGAGAGGGAATGGTGTGCAACAATGGTGAATGTCTAAACATGGAAAAGGTCTATATCTCAACCAATTGCCCCTCTCAGTGCAATGAAAATCCTGTGGATGGCCACGGACTCCAGTGCCACTGTGAGGAAGGACAGGCACCTGTAGCCTGTGAAGAAACCTTACATGTTACCAGTATCACCATCTTGGTTGTTGTGCTTGTCCTGGTTATTGTCGGTATCGGAGTTCTTATACTATTAGTTCGTTACCGAAAATGTATCAAGTTGAAGCAAGTTCAGAGCCCACCTACAGAAACCCTGGGAGTGGAGAACAAAGGATACTTTGGTGATGAGCAGCAGATAAGGACTGAGCCAATCCTGCCAGAAATTCATTTCCTAAATCAGAGAACTCCAGAATCCTTGGAAAGCCTGCCCACTAGTTTTTCAAGTCCCCACTACATCACACTGAAACCTGCAAGTAAAGATTCAAGAGGAATCGCAGATCCCAATCAAAGTGCCAAGTGGTAGGTTACCCTGACAGATAGTACCTCCCTTTTTTATTTTTCNOV62a, CG56868-01Protein SequenceSEQ ID NO: 938777 aaMW at 88341.2kDMLPGCIFLMILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLYEIKLNRKTLVLNLLRSREFLGSNYSETFYSMKGEAFTRHPQIMEHCYYKGNILNEKNSVASISTCDGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVPGDNESEEDSKIKGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNNIYKTLNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGNQHDEFPCTCPSGKCVMDSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYCKNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDIGLVASGTKCGEGMVCNNGECLNMEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVACEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDEQQIRTEPILPEIHFLNQRTPESLESLPTSFSSPHYITLKPASKDSRGIADPNQSAKWNOV62b, 276580332SEQ ID NO: 939247 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGTACCGATGAGGGTGAAGAGTGTGACTGTGGCCCTGCTCAGGAGTGTACTAATCCTTGCTGTGATGCACACACATGTGTACTGAAGCCAGGATTTACTTGTGCAGAAGGAGAATGCTGTGAATCTTGTCAGATAAAAAAAGCAGGGTCCATATGCAGACCGGCGAAAGATGAATGTGATTTTCCTGAGATGTGCACTGGCCACTCGCCTGCCTGTCCTAAGGACCAGTTCAGGGTCGACGGCNOV62b, 276580332Protein SequenceSEQ ID NO: 94082 aaMW at 8696.6kDTGTDEGEECDCGPAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACPKDQFRVDG

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 62B.

TABLE 62BComparison of the NOV62 protein sequences.NOV62aMLPGCIFLNILLIPQVKEKFILGVEGQQLVRPKKLPLIQKRDTGHTHDDDILKTYEEELLNOV62b------------------------------------------------------------NOV62aYEIKLNRKTLVLHLLRSREFLGSNYSETFYSMKGEAFTRHPQIMEHCYYKGNILNEKNSVNOV62b------------------------------------------------------------NOV62aASISTCDGLRGFFRINDQRYLIEPVKYSDEGEHLVFKYNLRVPYGANYSCTELNFTRKTVNOV62b------------------------------------------------------------NOV62aPGDNESEEDSKIKGIHDEKYVELFIVADDTVYRRNGHPHNKLRNRIWGMVNFVNMIYKTLNOV62b------------------------------------------------------------NOV62aNIHVTLVGIEIWTHEDKIELYSNIETTLLRFSFWQEKILKTRKDFDHVVLLSGKWLYSHVNOV62b------------------------------------------------------------NOV62aQGISYPGGMCLPYYSTSIIKDLLPDTNIIANRMAHQLGHNLGMQHDEFPCTCPSGKCVMDNOV62b------------------------------------------------------------NOV62aSDGSIPALKFSKCSQNQYHQYLKDYKPTCMLNIPFPYNFHDFQFCGNKKLDEGEECDCGPNOV62b-----------------------------------------------TGTDEGEECDCGPNOV62aAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACNOV62bAQECTNPCCDAHTCVLKPGFTCAEGECCESCQIKKAGSICRPAKDECDFPEMCTGHSPACNOV62aPKDQFRVNGFPCKNSEGYCFMGKCPTREDQCSELFDDEAIESHDICYKMNTKGNKFGYCKNOV62bPKDQFRVDG---------------------------------------------------NOV62aNKENRFLPCEEKDVRCGKIYCTGGELSSLLGEDKTYHLKDPQKNATVKCKTIFLYHDSTDNOV62b------------------------------------------------------------NOV62aIGLVASGTKCGEGMVCNNGECLNNEKVYISTNCPSQCNENPVDGHGLQCHCEEGQAPVACNOV62b------------------------------------------------------------NOV62aEETLHVTSITILVVVLVLVIVGIGVLILLVRYRKCIKLKQVQSPPTETLGVENKGYFGDENOV62b------------------------------------------------------------NOV62aQQIRTEPILPEIHFLNQRTPESLESLPTSFSSPHYITLKPASKDSRGIADPNQSAKWNOV62b---------------------------------------------------------NOV62a(SEQ ID NO: 938)NOV62b(SEQ ID NO: 940)

Further analysis of the NOV62a protein yielded the following properties shown in Table 62C.

TABLE 62CProtein Sequence Properties NOV62aSignalP analysis:Cleavage site between residues 19 and 20PSORT II analysis:PSG: a new signal peptide prediction method N-region: length 0; pos.chg 0; neg.chg 0 H-region: length 16; peak value 12.97PSG sc ore: 8.57GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −5.58 possible cleavage site: between 18 and 19>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 2 INTEGRALLikelihood = −2.18Transmembrane 1-17 INTEGRALLikelihood = −18.52Transmembrane 671-687 PERIPHERALLikelihood = 4.35 (at 235) ALOM score: −18.52 (number of TMSs: 2)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 8 Charge difference: 0.0 C(1.0) − N(1.0) N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seq R content:0Hyd Moment(75):3.80 Hyd Moment(95):1.48G content:1 D/E content:1S/T content:0 Score: −6.33Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not foundNUCDISC: discrimination of nuclear localization signals pat4: RPKK (4) at 31 pat7: none bipartite: none content of basic residues: 11.3% NLS Score: −0.22KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: KKXX-like motif in the C-terminus: QSAKSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: Bacterial regulatory proteins, gntR family signature (PS00043):***found*** EEELLYEIKLNRKTLVLHLLRS at 56NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 55.5COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residuesFinal Results (k = 9/23): 34.8%: nuclear 30.4%: endoplasmic reticulum 21.7%: mitochondrial 4.3%: vesicles of secretory system 4.3%: cytoplasmic 4.3%: peroxisomal>> prediction for CG56868-01 is nuc (k = 23)

A search of the NOV62a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 62D.

TABLE 62DGeneseq Results for NOV62aNOV62aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAB47567Protease PRTS-9 - Homo sapiens,1 . . . 776771/776 (99%)0.0776 aa. [WO200171004-A2, 27-1 . . . 776773/776 (99%)SEP-2001]AAU77409Human NOV4b protein,1 . . . 777776/780 (99%)0.0homologue of ADAM proteins -1 . . . 779776/780 (99%)Homo sapiens, 779 aa.[WO200206329-A2, 24-JAN-2002]AAU77408Human NOV4a protein,1 . . . 777766/779 (98%)0.0homologue of ADAM proteins -1 . . . 778774/779 (99%)Homo sapiens, 778 aa.[WO200206329-A2, 24-JAN-2002]AAU16950Human novel secreted protein,1 . . . 677664/677 (98%)0.0SEQ ID 191 - Homo sapiens, 69517 . . . 693 675/677 (99%)aa. [WO200155441-A2, 02-AUG-2001]AAB64744Gene 16 human secreted protein336 . . . 710 353/375 (94%)0.0homologous amino acid sequence1 . . . 375364/375 (96%)#138 - Macaca fascicularis, 375aa. [WO200077237-A1, 21-DEC-2000]

In a BLAST search of public sequence databases, the NOV62a protein was found to have homology to the proteins shown in the BLASTP data in Table 62E.

TABLE 62EPublic BLASTP Results for NOV62aNOV62aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9H2U9ADAM 7 precursor (A disintegrin1 . . . 776741/776 (95%)0.0and metalloproteinase domain 7)1 . . . 754751/776 (96%)(Sperm maturation-relatedglycoprotein GP-83) - Homosapiens (Human), 754 aa.Q28475ADAM 7 precursor (A disintegrin1 . . . 776717/776 (92%)0.0and metalloproteinase domain 7)1 . . . 776748/776 (95%)(Epididymal apical protein I) (EAPI) - Macaca fascicularis (Crabeating macaque) (Cynomolgusmonkey), 776 aa.O35227ADAM 7 precursor (A disintegrin1 . . . 774523/774 (67%)0.0and metalloproteinase domain 7) -1 . . . 771638/774 (81%)Mus musculus (Mouse), 788 aa.AAH43207Hypothetical protein - Homo212 . . . 736 524/525 (99%)0.0sapiens (Human), 561 aa29 . . . 553 525/525 (99%)(fragment).Q63180ADAM 7 precursor (A disintegrin1 . . . 774520/774 (67%)0.0and metalloproteinase domain 7)1 . . . 772632/774 (81%)(Epididymal apical protein I) (EAPI) - Rattus norvegicus (Rat), 789aa.

PFam analysis indicates that the NOV62a protein contains the domains shown in the Table 62F.

TABLE 62FDomain Analysis of NOV62aNOV62aIdentities/MatchSimilaritiesExpectPfam DomainRegionfor the Matched RegionValuePep_M12B_propep 73 . . . 18838/119 (32%)6.7e−45100/119 (84%) Reprolysin199 . . . 39488/203 (43%) 5.5e−104173/203 (85%) disintegrin411 . . . 48641/76 (54%)1.6e−2553/76 (70%)

Example 63

The NOV63 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 63A.

TABLE 63ANOV63 Sequence AnalysisNOV63a, CG56870-01SEQ ID NO: 9411268 bpDNA SequenceORF Start: ATG at 71ORF Stop: TAA at 1196ACTTCTTTCTTTTCTGTTTCAGAGTTACTGATTTATTCTTGAGATTCCTCTACTCTCGTTATCTGACCTCATGGATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTCTAAATGATAAGAATGGTACAAGAAACTTCCAGGACTTTGACTGTCAGGAACATGATATAGAAACAACTCATGGTGTGGTCGACGTCACTATAAGAGGCTTACCCAAAGGAAACAGACCAGTTATACTAACATATCATGACATTGGCCTCAACCGTAAATCCTGTTTCAATGCATTCTTTAACTTTGAGGATATGCAAGAGATCACCCAGCACTTTGCTGTCTGTCATGTGGATGCCCCAGGCCAGCAGGAAGGTGCACCCTCTTTCCCAACAGGGTATCAGTACCCCACAATGGATGAGCTGGCTGAAATGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCATCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCATCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGGATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTTTGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTACAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCCTACAATGGGCGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACAAATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGTTGAGGCTGTGGTCGAATGCAATTCCCGCCTGAACCCTATAAATACAACTTTGCTAAAGATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGCTCACCGAGGCCTTCAAGTACTTTTTGCAGGGAATGGGCTACGTCCCGTCTGCCAGCATGACTCGGCTCGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTCAGCCGGTCTGTCACCAGCAATCAGTCAGATGGAACTCAAGAATCCTGTGAGTCCCCTGATGTCCTGGACAGACACCAGACCATGGAGGTGTCCTGCTAAGCAGATGCTCCTCCCCTGGACCATTGCAAGTCCATCCTTCAAATGACCACTCCATAATATAACATTTCATNOV63a, CG56870-01Protein SequenceSEQ ID NO: 942375 aaMW at 41413.3kDMDELQDVQLTEIKPLLNDKNGTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVILTYHDIGLNRKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEMLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCESPDVLDRHQTMEVSCNOV63b, CG56870-06SEQ ID NO: 9431041 bpDNA SequenceORF Start: ATG at 120ORF Stop: TAA at 969ACTTCTTTCTTTTCTGTTTCAGAGTTACTGATTTATTCTTGAGATTCCTCTACTCTCGTTATCTGACCTCATGGATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTCTAAATGATAAGAATGGTACAAGAAACTTCCAGGACTTTGACTGTCAGGTATCAGTACCCCACAATGGATGAGCTGGCTGAAATGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCATCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCATCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGGATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTTTGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTACAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCCTACAATGGGCGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACAAATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGTTGAGGCTGTGGTCGAATGCAATTCCCGCCTGAACCCTATAAATACAACTTTGCTAAAGATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGCTCACCGAGGCCTTCAAGTACTTTTTGCAGGGAATGGGCTACGTCCCGTCTGCCAGCATGACTCGGCTCGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTCAGCCGGTCTGTCACCAGCAATCAGTCAGATGGAACTCAAGAATCCTGTGAGTCCCCTGATGTCCTGGACAGACACCAGACCATGGAGGTGTCCTGCTAAGCAGATGCTCCTCCCCTGGACCATTGCAAGTCCATCCTTCAAATGACCACTCCATAATATAACATTTCATNOV63b, CG56870-06Protein SequenceSEQ ID NO: 944283 aaMW at 31109.1kDMIRMVQETSRTLTVRYQYPTMDELAEMLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCESPDVLDRHQTMEVSCNOV63c, 276585681SEQ ID NO: 945994 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCAAGCTTACAAGAAACTTCCAGGACTTTGACTGTCAGGAACATGATATAGAAACAACTCATGGTGTGGTCCACGTCACTATAAGAGGCTTACCCAAAGGAAACAGACCAGTTATACTAACATATCATGACATTGGCCTCAACCATAAATCCTGTTTCAATGCATTCTTTAACTTTGAGGATATGCAAGAGATCACCCAGCACTTTGCTGTCTGTCATGTGGATGCCCCAGGCCAGCAGGAAGGTGCACCCTCTTTCCCAACAGGGTATCAGTACCCCACAATGGATGAGCTGGCTGAAGTGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCATCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCATCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGGATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTTTGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTACAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCCTACAATGGACGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACAAATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGTTGAGGCTGTGGTCGAATGCAATTCCCGCCTGAACCCTATAAATACAACTTTGCTAAAGATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGCTCACCGAGGCCTTCAAGTACTTTTTGCAGGGAATGGGCTACATACCATCTGCCAGCATGACTCGGCTCGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTCAGCCGGTCTGTCGACGGCNOV63c, 276585681Protein SequenceSEQ ID NO: 946331 aaMW at 36428.9kDTKLTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVILTYHDIGLNHKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTNDELAEVLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGKLTEAFKYFLQGMGYIPSASMTRLARSRTHSTSSSLGSGESPFSRSVDGNOV63d, CG56870-02SEQ ID NO: 9471175 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAA at 1141TCGTTATCTGACCTCATGGATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTCTAAATGATAAGAATGGTACAAGAAACTTCCAGGACTTTGACTGTCAGGAACATGATATAGAAACAACTCATGGTGTGGTCCACGTCACTATAAGAGGCTTACCCAAAGGAAACAGACCAGTTATACTAACATATCATGACATTGGCCTCAACCATAAATCCTGTTTCAATGCATTCTTTAACTTTGAGGATATGCAAGAGATCACCCAGCACTTTGCTGTCTGTCATGTGGATGCCCCAGGCCAGCAGGAAGGTGCACCCTCTTTCCCAACAGGGTATCAGTACCCCACAATGGATGAGCTGGCTGAAGTGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCATCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCATCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGGATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTTTGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTACAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCCTACAATGGACGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACAAATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGTTGAGGCTGTGGTCGAATGCAATTCCCGCCTGAACCCTATAAATACAACTTTGCTAAAGATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGCTCACCGAGGCCTTCAAGTACTTTTTGCAGGGAATGGGCTACATACCATCTGCCAGCATGACTCGGCTCGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTCAGCCGGTCTGTCACCAGCAATCAGTCACATGGAACTCAAGAATCCTGTGAGTCCCCTGATGTCCTGGACAGACACCAGACCATGGAGGTGTCCTGCTAAGCAGATGCTCCTCCCCTGGACCATTGCAAGTCNOV63d, CG56870-02Protein SequenceSEQ ID NO: 948375 aaMW at 41376.2kDMDELQDVQLTEIKPLLNDKNGTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVILTYHDIGLNHKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEVLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRNHIAQDINQDNLQLFLNSYNGRRNLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGKLTEAFKYFLQGMGYIPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCESPDVLDRHQTMEVSCNOV63e, CG56870-03SEQ ID NO: 9491232 bpDNA SequenceORF Start: ATG at 71ORF Stop: TAA at 1160ACTTCTTTCTTTTCTGTTTCAGAGTTACTGATTTATTCCTGAGATTCCTCTACTCTCGTTATCTGACCTCATGGATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTCTAAATGATAAGGAACATGATATAGAAACAACTCATGGTGTGGTCCACGTCACTATAAGAGGCTTACCCAAAGGAAACAGACCAGTTATACTAACATATCATGACATTGGCCTCAACCATAAATCCTGTTTCAATGCATTCTTTAACTTTGAGGATATGCAAGAGATCACCCAGCACTTTGCTGTCTGTCATGTGGATGCCCCAGGCCAGCAGGAAGGTGCACCCTCTTTCCCAACAGGGTATCAGTACCCCACAATGGATGAGCTGGCTGAAATGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCATCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCATCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGGATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTTTGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTACAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCCTACAATGGGCGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACAAATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGTTGAGGCTGTGGTCGAATGCAATTCCCGCCTGAACCCTATAAATACAACTTTGCTAAAGATGGCGGACTGTGGGAAACTGCCCCAGGTAGTTCAGCCTGGGAAGCTCACCGAGGCCTTCAAGTACTTTTTGCAGGGAATGGGCTACGTCCCGTCTGCCAGCATGACTCGGCTCGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTCAGCCGGTCTGTCACCAGCAATCAGTCAGATGGAACTCAAGAATCCTGTGAGTCCCCTGATGTCCTGGACAGACACCAGACCATGGAGGTGTCCTGCTAAGCAGATGCTCCTCCCCTGGACCATTGCAAGTCCATCCTTCAAATGACCACTCCATAATATAA CATTTCATNOV63e, CG56870-03Protein SequenceSEQ ID NO: 950363 aaMW at 39967.8kDMDELQDVQLTEIKPLLNDKEHDIETTHGVVHVTIRGLPKGNRPVILTYHDIGLNHKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEMLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGKLTEAFKYFLQGMGYVPSASMTRLATSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCESPDVLDRHQTMEVSCNOV63f, CG56870-04SEQ ID NO: 9511220 bpDNA SequenceORF Start: ATG at 71ORF Stop: TAA at 1148ACTTCTTTCTTTTCTGTTTCAGAGTTACTGATTTATTCTTGAGATTCCTCTACTCTCGTTATCTGACCTCATGGATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTCTAAATGATAAGAATGGTACAAGAAACTTCCAGGACTTTGACTGTCAGGAACATGATATAGAAACAACTCATGGTGTGGTCCACGTCACTATAAGAGGCTTACCCAAAGGAAACAGACCAGTTATACTAACATATCATGACATTGGCCTCAACCGTAAATCCTGTTTCAATGCATTCTTTAACTTTGAGGATATGCAAGAGATCACCCAGCACTTTGCTGTCTGTCATGTGGATGCCCCAGGCCAGCAGGAAGGTGCACCCTCTTTCCCAACAGGGTATCAGTACCCCACAATGGATGAGCTGGCTGAAATGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCATCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCATCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGGATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTTTGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTACAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCCTACAATGGACGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACAAATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGTTGAGGCTGTGATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGTTCACCGAGGCCTTCAAGTACTTTTTGCAGGGAATGGGCTACACACCATCTGCCAGCATGACTCGGCTCGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTCAGCCGGTCTGTCACCAGCAATCAGTCAGATGGAACTCAAGAATCCTGTGAGTCCCCTGATGTCCTGGACAGACACCAGACCATGGAGGTGTCCTGCTAAGCAGATGCTCCTCCCCTGGACCATTGCAAGTCCATCCTTCAAATGACCACTCCATAATATAACATTTCATNOV63f, CG56870-04Protein SequenceSEQ ID NO: 952359 aaMW at 39652.2kDMDELQDVQLTEIKPLLNDKNGTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVILTYHDIGLNRKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEMLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRNHIAQDINQDNLQLFLNSYNGRRDLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVMADCGGLPQVVQPGKFTEAFKYFLQGMGYTPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCESPDVLDRHQTMEVSCNOV63g, CG56870-05SEQ ID NO: 9531970 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAA at 898ATGGATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTCTAAATGATAAGAATGGTACAAGAAACTTCCAGGACTTTGACTGTCAGTATCAGTACCCCACAATGGATGAGCTGGCTGAAATGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCATCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCATCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGGATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTTTGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTACAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCCTACAATGGGCGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACAAATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGTTGAGGCTGTGGTCGAATGCAATTCCCGCCTGAACCCTATAAATACAACTTTGCTAAAGATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGCTCACCGAGGCCTTCAAGTACTTTTTGCAGGGAATGGGCTACGTCCCGTCTGCCAGCATGACTCGGCTCGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTCAGCCGGTCTGTCACCAGCAATCAGTCAGATGGAACTCAAGAATCCTGTGAGTCCCCTGATGTCCTGGACAGACACCAGACCATGGAGGTGTCCTGCTAAGCAGATGCTCCTCCCCTGGACCATTGCAAGTCCATCCTTCAAATGACCACTCCATAATATAACATTTCATNOV63g, CG56870-05Protein SequenceSEQ ID NO: 954299 aaMW at 32956.9kDMDELQDVQLTEIKPLLNDKNGTRNFQDFDCQYQYPTMDELAEMLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCESPDVLDRHQTMEVSC

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 63B.

TABLE 63BComparison of the NOV63 protein sequences.NOV63aMDELQDVQLTEIKPLLNDKNGTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVILTYNOV63b------------------------------------------------------------NOV63c------------------TKLTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVILTYNOV63dMDELQDVQLTEIKPLLNDKNGTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVILTYNOV63e------------MDELQDVQLTEIKPLLNDKEHDIETTHGVVHVTIRGLPKGNRPVILTYNOV63fMDELQDVQLTEIKPLLNDKNGTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVILTYNOV63g------------------------------------------------------------NOV63aHDIGLNRKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEMLNOV63b---------------------------MIRMVQETS-----RTLTVRYQYPTMDELAEMLNOV63cHDIGLNHKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEVLNOV63dHDIGLNHKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEVLNOV63eHDIGLNHKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEVLNOV63fHDIGLNRKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEVLNOV63g----------------MDELQDVQLTEIKPLLNDKNGTRNFQDFDCQYQYPTMDELAEVLNOV63aPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGNOV63bPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGNOV63cPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGNOV63dPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGNOV63ePPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGNOV63fPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGNOV63gPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGNOV63aLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPNOV63bLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPNOV63cLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPNOV63dLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPNOV63eLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPNOV63fLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPNOV63gLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPNOV63aILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGNOV63bILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGNOV63cILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGNOV63dILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGNOV63eILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGNOV63fILGQNDNKSKTLKCSTLLVVGDNSPAVEAV----------------MADCGGLPQVVQPGNOV63gILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGNOV63aKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCENOV63bKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCENOV63cKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVDG-----------NOV63dKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCENOV63eKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCENOV63fKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCENOV63gKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCENOV63aSPDVLDRHQTMEVSCNOV63bSPDVLDRHQTMEVSCNOV63c---------------NOV63dSPDVLDRHQTMEVSCNOV63eSPDVLDRHQTMEVSCNOV63fSPDVLDRHQTMEVSCNOV63gSPDVLDRHQTMEVSCNOV63a(SEQ ID NO: 942)NOV63b(SEQ ID NO: 944)NOV63c(SEQ ID NO: 946)NOV63d(SEQ ID NO: 948)NOV63e(SEQ ID NO: 950)NOV63f(SEQ ID NO: 952)NOV63g(SEQ ID NO: 954)

Further analysis of the NOV63a protein yielded the following properties shown in Table 63C.

TABLE 63CProtein Sequence Properties NOV63aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG: a new signal peptide prediction method N-region: length 11; pos.chg 0; neg.chg 4 H-region: length 1; peak value 0.00 PSG score: −4.40GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −14.03 possible cleavage site: between 48 and 49>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 1 Number of TMS(s) for threshold 0.5: 0 PERIPHERAL Likelihood = 4.67 (at 174) ALOM score: 0.47 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seq R content:0Hyd Moment(75):8.01 Hyd Moment(95):7.59G content:0 D/E content:2S/T content:0 Score: −6.61Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not foundNUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 7.5% NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 55.5COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residuesFinal Results (k = 9/23): 39.1%: cytoplasmic 39.1%: nuclear 13.0%: mitochondrial 4.3%: Golgi 4.3%: endoplasmic reticulum>> prediction for CG56870-01 is cyt (k = 23)

A search of the NOV63a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 63D.

TABLE 63DGeneseq Results for NOV63aNOV63aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAB94494Human protein sequence SEQ ID1 . . . 375360/375 (96%)0.0NO: 15186 - Homo sapiens, 3631 . . . 363361/375 (96%)aa. [EP1074617-A2, 07-FEB-2001]AAG64392Human reducing agent and1 . . . 375360/375 (96%)0.0tunicamycin-responsive protein1 . . . 363361/375 (96%)40 - Homo sapiens, 363 aa.[WO200155375-A1, 02-AUG-2001]AAM94019Human stomach cancer expressed1 . . . 375360/375 (96%)0.0polypeptide SEQ ID NO 108 -1 . . . 363361/375 (96%)Homo sapiens, 363 aa.[WO200109317-A1, 08-FEB-2001]ABG10563Novel human diagnostic protein68 . . . 374 283/323 (87%)e−155#10554 - Homo sapiens, 382 aa.1 . . . 307287/323 (88%)[WO200175067-A2, 11-OCT-2001]AAU31598Novel human secreted protein68 . . . 374 282/323 (87%)e−154#2089 - Homo sapiens, 395 aa.1 . . . 307286/323 (88%)[WO200179449-A2, 25-OCT-2001]

In a BLAST search of public sequence databases, the NOV63a protein was found to have homology to the proteins shown in the BLASTP data in Table 63E.

TABLE 63EPublic BLASTP Results for NOV63aNOV63aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9UGV2NDRG3 protein - Homo sapiens1 . . . 375373/375 (99%)0.0(Human), 375 aa.1 . . . 375374/375 (99%)Q9QYF9NDRG3 protein (Ndr3 protein) -1 . . . 375358/375 (95%)0.0Mus musculus (Mouse), 375 aa.1 . . . 375368/375 (97%)Q8VCV2Similar to N-myc downstream1 . . . 375359/388 (92%)0.0regulated 3 - Mus musculus1 . . . 388368/388 (94%)(Mouse), 388 aa.Q96SM2Hypothetical protein FLJ14759 -1 . . . 375360/375 (96%)0.0Homo sapiens (Human), 363 aa.1 . . . 363361/375 (96%)AAH44139Similar to N-myc downstream1 . . . 375290/375 (77%)e−169regulated 3 - Brachydanio rerio2 . . . 371324/375 (86%)(Zebrafish) (Danio rerio), 371 aa.

PFam analysis indicates that the NOV63a protein contains the domains shown in the Table 63F.

TABLE 63FDomain Analysis of NOV63aNOV63aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect Valueabhydrolase87 . . . 307 46/237 (19%)0.0014142/237 (60%)Ndr32 . . . 317181/301 (60%)5.6e−186275/301 (91%)

Example 64

The NOV64 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 64A.

TABLE 64ANOV64 Sequence AnalysisNOV64a, CG57109-01SEQ ID NO: 9552536 bpDNA SequenceORF Start: ATG at 150ORF Stop: TAG at 2094GGGACACTGACATGGACTGAAGGAGTAGAAAAGAAGCCTTGGGCTCTCCCAGATGGAAGAATGACCGTGTGAGGAAACTGTTTAACCTCAAGGGCAGGGAAATCAGGAGCGTCTCTGATTTCTTCAGGGAAGGGGATGCTTTCATAGCTATGGGCAAAGAACCACTGACACTGAAGAGCATTCAGGTGGCTGTAGAAGAACTGTACCCCAACAAAGCCCGGGCCCTGACACTGGCCCAGCACAGCCGTGCCCCTTCTCCAAGGCTGAGGAGCAGGCTGTTTAGCAAGGCTCTGAAAGGAGACCACCGCTGTGGGGAGACCGAGACCCCCAAGAGCTGCAGCGAAGTTGCAGGATGCAAGGCAGCCATGAGGCACCAGGGGAAGATCCCCGAGGAGCTTTCACTAGATGACAGAGCGAGGACCCAGAAGAAGTGGGGGAGGGGGAAATGGGAGCCAGAACCCAGTAGCAAGCCCCCCACAGAGCGAGGACCCAGAAGAAGTGGGGGAGGGGGAAATGGGAGCCAGAACCCAGTAGCAAGCCCCCCCTCGGGTGAAATTATCAGATGCGAGAAGTGCAAGAGAGAGAGGGAGCTTCAGCAGAGCCTGGAGCGTGAGAGGCTTTCTCTGGGGACCAGTGAGCTGGATATGGGGAAGGGCCCAATGTATGATGTGGAGAAGCTGGTGAGGACCAGAAGCTGCAGGAGGTCTCCCGAGGCAAATCCTGCAAGTGGGGAGGAAGGGTGGAAGGGTGACAGCCACAGGAGCAGCCCCAGGAATCCCACTCAAGAGCTGAGGAGACCCAGCAAGAGCATGGACAAGAAAGAGGACAGAGGCCCAGAGGATCAAGAAAGCCATGCTCAGGGAGCAGCCAAGGCCAAGAAGGACCTTGTGGAAGTTCTTCCTGTCACAGAGGAGGGGCTGAGGGAGGTGAAGAAGGACACCAGGCCCATGAGCAGGAGCAAACATGGTGGCTGGCTCCTGAGAGAGCACCAGGCGGGCTTTGAGAAGCTCCGCAGGACCCGAGGAGAAGAGAAGGAGGCAGAGAAGGAGAAAAAGCCATGTATGTCTGGAGGCAGAAGGATGACTCTCAGAGATGACCAACCTGCAAAGCTAGAAAAGGAGCCCAAGACGAGGCCAGAAGAGAACAAGCCAGAGCGGCCCAGCGGTCGGAAGCCACGGCCCATGGGCATCATTGCCGCCAATGTGGAAAAGCATTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGACATGTGGGCGGCTGGCGTGATCCTCTATATCCTGCTGTGTGGCTTTCCCCCATTCCGCAGCCCTGAGAGGGACCAGGACGAGCTCTTTAACATCATCCAGCTGGGCCACTTTGAGTTCCTCCCCCCTTACTGGGACAATATCTCTGATGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCAGGTTCTTCAGCACCCCTGGATCGAAACAGCTGGCAAGACCAATACAGTGAAACGACAGAAGCAGGTGTCCCCCAGCAGCGAGGGTCACTTCCGGAGCCAGCACAAGAGGGTTGTGGAGCAGGTATCATAGTCACCACCTTGGGAATCTGTCCAGCCCCCAGTTCTGCTCAAGGACAGAGAAAAGGATAGAAGTTTGAGAGAAAAACAATGAAAGAGGCTTCTTCACATAATTGGTGAATCAGAGGGAGAGACACTGAGTATATTTTAAAGCATATTAAAAAAATTAAGTCAATGTTAAATGTCACAACATATTTTTAGATTTGTATATTTAAAGCCTTTAATACATTTTTGGGGGGTAAGCATTGTCATCAGTGAGGAATTTTGGTAATAATGATGTGTTTTGCTTCCCCTTTGTAACCAAGTTTATTCTGTACTACAGGAGTGGTGCTTACCAGGGTCTAAACTCCCCCTGTGAGATTAATAAGGTGCATTGTGGTCTTTCTGTGTTAATAAAATGTGCTCTGAATAACAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGG+TL, NOV64a, CG57109-01Protein SequenceSEQ ID NO: 956648 aaMW at 73813.6kDMGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVSNOV64b, 260457400SEQ ID NO: 957793 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGACATGTGGGCTGCTGGCGTGATCCTCTATATCCTGCTGTGTGGCTTTCCCCCATTCCGCAGCCCTGAGAGGGACCAGGACGAGCTCTTTAACATCATCCAGCTGGGCCACTTTGAGTTCCTCCCCCCTTACTGGGACAATATCTCTGATGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCAGGTTCTTCAGCACCCCTGGATCCTCGAGGGCNOV64b, 260457400Protein SequenceSEQ ID NO: 958264 aaMW at 30106.4kDTGSYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVLQHPWILEGNOV64c, 260457409SEQ ID NO: 959625 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCAGGTTCTTCAGCACCCCTGGATCCTCGAGGGCNOV64c, 260457409Protein SequenceSEQ ID NO: 960208 aaMW at 23605.1kDTGSYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKAAKDLVSRLLVVDPKKRYTAHQVLQHPWILEGNOV64d, CG57109-05SEQ ID NO: 9612133 bpDNA SequenceORF Start: ATG at 90ORF Stop: TAG at 2034TTGACCGTGTGAGGAAACTGTTTAACCTCAAGGGCAGGGAAATCAGGAGCGTCTCTGATTTCTTCAGGGAAGGGGATGCTTTCATAGCTATGGGCAAAGAACCACTGACACTGAAGAGCATTCAGGTGGCTGTAGAAGAACTGTACCCCAACAAAGCCCGGGCCCTGACACTGGCCCAGCACAGCCGTGCCCCTTCTCCAAGGCTGAGGAGCAGGCTGTTTAGCAAGGCTCTGAAAGGAGACCACCGCTGTGGGGAGACCGAGACCCCCAAGAGCTGCAGCGAAGTTGCAGGATGCAAGGCAGCCATGAGGCACCAGGGGAAGATCCCCGAGGAGCTTTCACTAGATGACAGAGCGAGGACCCAGAAGAAGTGGGGGAGGGGGAAATGGGAGCCAGAACCCAGTAGCAAGCCCCCCAGGGAAGCCACTCTGGAAGAGAGGCACGCAAGGGGAGAGAAGCATCTTGGGGTGGAGATTGAAAAGACCTCGGGTGAAATTATCAGATGCGAGAAGTGCAAGAGAGAGAGGGAGCTCCAGCAGAGCCTGGAGCGTGAGAGGCTTTCTCTGGGGACCAGTGAGCTGGATATGGGGAAGGGCCCAATGTATGATGTGGAGAAGCTGGTGAGGACCAGAAGCTGCAGGAGGTCTCCCGAGGCAAATCCTGCAAGTGGGGAGGAAGGGTGGAAGGGTGACAGCCACAGGAGCAGCCCCAGGAATCCCACTCAAGAGCTGAGGAGACCCAGCAAGAGCATGGACAAGAAAGAGGACAGAGGCCCAGAGGATCAAGAAAGCCATGCTCAGGGAGCGGCCAAGGCCAAGAAGGACCTTGTGGAAGTTCTTCCTGTCACAGAGGAGGGGCTGAGAGAGGTGAAGAAGGACACCAGGCCCATGAGCAGGAGCAAACATGGTGGCTGGCTCCTGAGAGAGCACCAGGCGGGCTTTGAGAAGCTCCGCAGGACCCGAGGAGAAGAGAAGGAGGCAGAGAAGGAGAAAAAGCCATGTATGTCTGGAGGCAGAAGGATGACTCTCAGAGACGACCAACCTGCAAAGCTAGAAAAGGAGCCCAAGACGAGGCCAGAAGAGAACAAGCCAGAGCGGCCCAGCGGTCGGAAGCCACGGCCCATGGGCATCATTGCCGCCAATGTGGAAAAGCATTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGACATGTGGGCTGCTGGCGTGATCCTCTATATCCTGCTGTGTGGCTTTCCCCCATTCCGCAGCCCTGAGAGGGACCAGGACGAGCTCTTTAACATCATCCAGCTGGGCCACTTTGAGTTCCTCCCCCCTTACTGGGACAATATCTCTGATGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCAGGTTCTTCAGCACCCCTGGATCGAAACAGCTGGCAAGACCAATACAGTGAAACGACAGAAGCAGGTGTCCCCCAGCAGCGAGGGTCACTTCCGGAGCCAGCACAAGAGGGTTGTGGAGCAGGTATCATAGTCACCACCTTGGGAATCTGTCCAGCCCCCAGTTCTGCTCAAGGACAGAGAAAAGGATAGAAGTTTGAGAGAAAAACAATGAAAGAGGCTTCTTCACANOV64d, CG57109-05Protein SequenceSEQ ID NO: 962648 aaMW at 73813.6kDMGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKISGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFMIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVSNOV64e, 267253965SEQ ID NO: 9631966 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCACCATGGGCAAAGAACCACTGACACTGAAGAGCATTCAGGTGGCTGTAGAAGAACTGTACCCCAACAAAGCCCGGGCCCTGACACTGGCCCAGCACAGCCGTGCCCCTTCTCCAAGGCTGAGGAGCAGGCTGTTTAGCAAGGCTCTGAAAGGAGACCACCGCTGTGGGGAGACCGAGACCCCCAAGAGCTGCAGCGAAGTTGCAGGATGCAAGGCAGCCATGAGGCACCAGGGGAAGATCCCCGAGGAGCTTTCACTAGATGACAGAGCGAGGACCCAGAAGAAGTGGGGGAGGGGGAAATGGGAGCCAGAACCCAGTAGCAAGCCCCCCAGGGAAGCCACTCTGGAAGAGAGGCACGCAAGGGGAGAGAAGCATCTTGGGGTGGAGATTGAAAAGACCTCGGGTGAAATTATCAGATGCGAGAAGTGCAAGAGAGAGAGGGAGCTCCAGCAGAGCCTGGAGCGTGAGAGGCTTTCTCTGGGGACCAGTGAGCTGGATATGGGGAAGGGCCCAATGTATGATGTGGAGAAGCTGGTGAGGACCAGAAGCTGCAGGAGGTCTCCCGAGGCAAATCCTGCAAGTGGGGAGGAAGGGTGGAAGGGTGACAGCCACAGGAGCAGCCCCAGGAATCCCACTCAAGAGCTGAGGAGACCCAGCAAGAGCATGGACAAGAAAGAGGACAGAGGCCCAGAGGATCAAGAAAGCCATGCTCAGGGAGCGGCCAAGGCCAAGAAGGACCTTGTGGAAGTTCTTCCTGTCACAGAGGAGGGGCTGAGAGAGGTGAAGAAGGACACCAGGCCCATGAGCAGGAGCAAACATGGTGGCTGGCTCCTGAGAGAGCACCAGGCGGGCTTTGAGAAGCTCCGCAGGACCCGAGGAGAAGAGAAGGAGGCAGAGAAGGAGAAAAAGCCATGTATGTCTGGAGGCAGAAGGATGACTCTCAGAGACGACCAACCTGCAAAGCTAGAAAAGGAGCCCAAGACGAGGCCAGAAGAGAACAAGCCAGAGCGGCCCAGCGGTCGGAAGCCACGGCCCATGGGCATCATTGCCGCCAATGTGGAAAAGCATTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGACATGTGGGCTGCTGGCGTGATCCTCTATATCCTGCTGTGTGGCTTTCCCCCATTCCGCAGCCCTGAGAGGGACCAGGACGAGCTCTTTAACATCATCCAGCTGGGCCACTTTGAGTTCCTCCCCCCTTACTGGGACAATATCTCTGATGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCAGGTTCTTCAGCACCCCTGGATCGAAACAGCTGGCAAGACCAATACAGTGAAACGACAGAAGCAGGTGTCCCCCAGCAGCGAGGGTCACTTCCGGAGCCAGCACAAGAGGGTTGTGGAGCAGGTATCACTCGAGGGCNOV64e, 267253965Protein SequenceSEQ ID NO: 964655 aaMW at 74459.2kDTGSTMGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYANKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVSLEGNOV64f, 267254000SEQ ID NO: 9651621 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCACCATGGGCAAAGAACCACTGACACTGAAGAGCATTCAGGTGGCTGTAGAAGAACTGTACCCCAACAAAGCCCGGGCCCTGACACTGGCCCAGCACAGCCGTGCCCCTTCTCCAAGGCTGAGGAGCAGGCTGTTTAGCAAGGCTCTGAAAGGAGACCACCGCTGTGGGGAGACCGAGACCCCCAAGAGCTGCAGCGAAGTTGCAGGATGCAAGGCAGCCATGAGGCACCAGGGGAAGATCCCCGAGGAGCTTTCACTAGATGACAGAGCGAGGACCCAGAAGAAGTGGGGGAGGGGGAAATGGGAGCCAGAACCCAGTAGCAAGCCCCCCAGGGAAGCCACTCTGGAAGAGAGGCACGCAAGGGGAGAGAAGCATCTTGGGGTGGAGATTGAAAAGACCTCGGGTGAAATTATCAGATGCGAGAAGTGCAAGAGAGAGAGGGAGCTCCAGCAGAGCCTGGAGCGTGAGAGGCTTTCTCTGGGGACCAGTGAGCTGGATATGGGGAAGGGCCCAATGTATGATGTGGAGAAGCTGGTGAGGACCAGAAGCTGCAGGAGGTCTCCCGAGGCAAATCCTGCAAGTGGGGAGGAAGGGTGGAAGGGTGACAGCCACAGGAGCAGCCCCAGGAATCCCACTCAAGAGCTGAGGAGACCCAGCAAGAGCATGGACAAGAAAGAGGACAGAGGCCCAGAGGATCAAGAAAGCCATGCTCAGGGAGCGGCCAAGGCCAAGAAGGACCTTGTGGAAGTTCTTCCTGTCACAGAGGAGGGGCTGAGAGAGGTGAAGAAGGACACCAGGCCCATGAGCAGGAGCAAACATGGTGGCTGGCTCCTGAGAGAGCACCAGGCGGGCTTTGAGAAGCTCCGCAGGACCCGAGGAGAAGAGAAGGAGGCAGAGAAGGAGAAAAAGCCATGTATGTCTGGAGGCAGAAGGATGACTCTCAGAGACGACCAACCTGCAAAGCTAGAAAAGGAGCCCAAGACGAGGCCAGAAGAGAACAAGCCAGAGCGGCCCAGCGGTCGGAAGCCACGGCCCATGGGCATCATTGCCGCCAATGTGGAAAAGCATTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGCTCGAGGGCNOV64f, 267254000Protein SequenceSEQ ID NO: 966540 aaMW at 61179.2kDTGSTMGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKCDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYANKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLELEGNOV64g, 267253987SEQ ID NO: 967793 bpDNA SequenceORF Start: at 1ORF Stop: at 793ACCGGATCCTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGACATGTGGGCTGCTGGCGTGATCCTCTATATCCTGCTGTGTGGCTTTCCCCCATTCCGCAGCCCTGAGAGGGACCAGGACGAGCTCTTTAACATCATCCAGCTGGGCCACTTTGAGTTCCTCCCCCCTTACTGGGACAATATCTCTGATGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCAGGTTCTTCAGCACCCCTGGATCCTCGAGGGCCNOV64g, 267253987Protein SequenceSEQ ID NO: 968264 aaMW at 30106.4kDTGSYETGRVIGDGNFAVVKECRHRETRQAYANKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVLQHPWILEGNOV64h, CG57109-02SEQ ID NO: 9692808 bpDNA SequenceORF Start: ATG at 151ORF Stop: TAG at 2659TTTACAGAGTCAGGCCTCACCGTGAGAGGGCTCCTGTATTAGTCCCTTTTCATGCTGCTTATAGAGACATACCTGAGACTGGGCAATTTGCAGAGAAAGGTTTTCTTGGACTTACAGTTAGTTCCACGTGGCTGGGGAAGCCTCACAATCATGGCGGAAGGCAAGGAAGGGCAAGTCCCATCTTACATGGATGGCAGCAGGCAAAGAGAGAATGAGGAAGATGCAAAAGCGGAAACCCCTGATGTAACCATCAGATCTTATGAGATTTATTCACTACCATGGAACAGACAGCAAGGCGTATGTGACCATTCTCTAGAATATTTAAGCTCGAGAATCTCAGAGCGGAAGCTGCAAGGCTCCTGGCTGCCTGCCAGCCGAGGGAATCTGGAGAAACCATTCCTGGGGCCGCGTGGCCCCGTCGTGCCCTTGTTCTGCCCTCGGAATGGCCTTCACTCAGCACATCCTGAGAACAGCCCTCTGAAGCCCAGGGTCGTGACCGTAGTGAAGCTGGGTGGGCAGCGCCCCCGAAAGATCACTCTGCTCCTCAACAGGCGATCAGTGCAGACGTTCGAGCAGCTCTTAGCTGACATCTCAGAAGCCTTGGGCTCTCCCAGATGGAAGAATGACCGTGTGAGGAAACTGTTTAACCTCAAGGGCAGGGAAATCAGGAGCGTCTCTGATTTCTTCAGGGAAGGGGATGCTTTCATAGCTATGGGCAAAGAACCACTGACACTGAAGAGCATTCAGGTGGCTGTAGAAGAACTGTACCCCAACAAAGCCCGGGCCCTGACACTGGCCCAGCACAGCCGTGCCCCTTCTCCAAGGCTGAGGAGCAGGCTGTTTAGCAAGGCTCTGAAAGGAGACCACCGCTGTGGGGAGACCGAGACCCCCAAGAGCTGCAGCGAAGTTGCAGGATGCAAGGCAGCCATGAGGCACCAGGGGAAGATCCCCGAGGAGCTTTCACTAGATGACAGAGCGAGGACCCAGAAGAAGTGGGGGAGGGGGAAATGGGAGCCAGAACCCAGTAGCAAGCCCCCCAGGGAAGCCACTCTGGAAGAGAGGCACGCAAGGGGAGAGAAGCATCTTGGGGTGGAGATTGAAAAGACCTCGGGTGAAATTATCAGATGCGAGAAGTGCAAGAGAGAGAGGGAGCTCCAGCAGAGCCTGGAGCGTGAGAGGCTTTCTCTGGGGACCAGTGAGCTGGATATGGGGAAGGGCCCAATGTATGATGTGGAGAAGCTGGTGAGGACCAGAAGCTGCAGGAGGTCTCCCGAGGCAAATCCTGCAAGTGGGGAGGAAGGGTGGAAGGGTGACAGCCACAGGAGCAGCCCCAGGAATCCCACTCAAGAGCTGAGGAGACCCAGCAAGAGCATGGACAAGAAAGAGGACAGAGGCCCAGAGGATCAAGAAAGCCATGCTCAGGGAGCAGCCAAGGCCAAGAAGGACCTTGTGGAAGTTCTTCCTGTCACAGAGGAGGGGCTGAGGGAGGTGAAGAAGGACACCAGGCCCATGAGCAGGAGCAAACATGGTGGCTGGCTCCTGAGAGAGCACCAGGCGGGCTTTGAGAAGCTCCGCAGGACCCGAGGAGAAGAGAAGGAGGCAGAGAAGGAGAAAAAGCCATGTATGTCTGGAGGCAGAAGGATGACTCTCAGAGATGACCAACCTGCAAAGCTAGAAAAGGAGCCCAAGACGAGGCCAGAAGAGAACAAGCCAGAGCGGCCCAGCGGTCGGAAGCCACGGCCCATGGGCATCATTGCCGCCAATGTGGAAAAGCATTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGACATGTGGGCTGCTGGCGTGATCCTCTATATCCTGCTGTGTGGCTTTCCCCCATTCCGCAGCCCTGAGAGGGACCAGGACGAGCTCTTTAACATCATCCAGCTGGGCCACTTTGAGTTCCTCCCCCCTTACTGGGACAATATCTCTGATACAGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCAGGTTCTTCAGCACCCCTGGATCGAAACAGCTGGCAAGACCAATACAGTGAAACGACAGAAGCAGGTGTCCCCCAGCAGCGAGGGTCACTTCCGGAGCCAGCACAAGAGGGTTGTGGAGCAGGTATCATAGTCACCACCTTGGGAATCTGTCCAGCCCCCAGTTCTGCTCAAGGACAGAGAAAAGGATAGAAGTTTGAGAGAAAAACAATGAAAGAGGCTTCTTCACATAATTGGTGAATCAGAGGGAGAGACACTGAGTATATTTTAAAGCATATTANOV64h, CG57109-02Protein SequenceSEQ ID NO: 970836 aaMW at 95152.6kDMAEGKEGQVPSYMDGSRQRENEEDAKAETPDVTIRSYEIYSLPWNRQQGVCDHSLEYLSSRISERKLQGSWLPASRGNLEKPFLGPRGPVVPLFCPRNGLHSAHPENSPLKPRVVTVVKLGGQRPRKITLLLNRRSVQTFEQLLADISEALGSPRWKNDRVRKLFNLKGREIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRNTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETHRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMDDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDTAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVSNOV64i, CG57109-03SEQ ID NO: 9713016 bpDNA SequenceORF Start: ATG at 52ORF Stop: TAG at 2617TTTACAGAGTCAGGCCTCACCGTGAGAGGGCTCCTGTATTAGTCCCTTTTCATGCTGCTTATAGAGACATACCTGAGACTGGGCAATTTGCAGAGAAAGGTTTTCTTGGACTTACAGTTAGTTCCACGTGGCTGGGGAAGCCTCACAATCATGGCGGAAGGCAAGGAAGGGCAAGTCCCATCTTACATGGATGGCAGCAGGCAAAGAGAGAATGAGGAAGATGCAAAAGCGGAAACCCCTGATGTAACCATCAGATCTTATGAGATTTATTCACTACCATGGAACAGACAGCAAGGCGTATGTGACCATTCTCTAGAATATTTAAGCTCGAGAATCTCAGAGCGGAAGCTGCAAGGCTCCTGGCTGCCTGCCAGCCGAGGGAATCTGGAGAAACCATTCCTGGGGCCGCGTGGCCCCGTCGTGCCCTTGTTCTGCCCTCGGAATGGCCTTCACTCAGCACATCCTGAGAACAGCCCTCTGAAGCCCAGGGTCGTGACCGTAGTGAAGCTGGGTGGGCAGCGCCCCCGAAAGATCACTCTGCTCCTCAACAGGCGATCAGTGCAGACGTTCGAGCAGCTCTTAGCTGACATCTCAGAAGCCTTGGGCTCTCCCAGATGGAAGAATGACCGTGTGAGGAAACTGTTTAACCTCAAGGGCAGGGAAATCAGGAGCGTCTCTGATTTCTTCAGGGAAGGGGATGCTTTCATAGCTATGGGCAAAGAACCACTGACACTGAAGAGCATTCAGGTGGCTGTAGAAGAACTGTACCCCAACAAAGCCCGGGCCCTGACACTGGCCCAGCACAGCCGTGCCCCTTCTCCAAGGCTGAGGAGCAGGCTGTTTAGCAAGGCTCTGAAAGGAGACCACCGCTGTGGGGAGACCGAGACCCCCAAGAGCTGCAGCGAAGTTGCAGGATGCAAGGCAGCTATGAGGCACCAGGGGAAGATCCCCGAGGAGCTTTCACTAGATGACAGAGCGAGGACCCAGAAGAAGTGGGGGAGGGGGAAATGGGAGCCAGAACCCAGTAGCAAGCCCCCCAGGGAAGCCACTCTGGAAGAGAGGCACGCAAGGGGAGAGAAGCATCTTGGGGTGGAGATTGAAAAGACCTCGGGTGAAATTATCAGATGCGAGAAGTGCAAGAGAGAGAGGGAGCTTCAGCAGAGCCTGGAGCGTGAGAGGCTTTCTCTGGGGACCAGTGAGCTGGATATGGGGAAGGGCCCAATGTATGATGTGGAGAAGCTGGTGAGGACCAGAAGCTGCAGGAGGTCTCCCGAGGCAAATCCTGCAAGTGGGGAGGAAGGGTGGAAGGGTGACAGCCACAGGAGCAGCCCCAGGAATCCCACTCAAGAGCTGAGGAGACCCAGCAAGAGCATGGACAAGAAAGAGGACAGAGGCCCAGAGGATCAAGAAAGCCATGCTCAGGGAGCAGCCAAGGCCAAGAAGGACCTTGTGGAAGTTCTTCCTGTCACAGAGGAGGGGCTGAGGGAGGTGAAGAAGGACACCAGGCCCATGAGCAGGAGCAAACATGGTGGCTGGCTCCTGAGAGAGCACCAGGCGGGCTTTGAGAAGCTCCGCAGGACCCGAGGAGAAGAGAAGGAGGCAGAGAAGGAGAAAAAGCCATGTATGTCTGGAGGCAGAAGGATGACTCTCAGAGATGACCAACCTGCAAAGCTAGAAAAGGAGCCCAAGACGAGGCCAGAAGAGAACAAGCCAGAGCGGCCCAGCGGTCGGAAGCCACGGCCCATGGGCATCATTGCCGCCAATGTGGAAAAGCATTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGACATGTGGGCTGCTGGCGTGATCCTCTATATCCTGCTGTGTGGCTTTCCCCCATTCCGCAGCCCTGAGAGGGACCAGGACGAGCTCTTTAACATCATCCAGCTGGGCCACTTTGAGTTCCTCCCCCCTTACTGGGACAATATCTCTGATGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCAGGTTCTTCAGCACCCCTGGATCGAAACAGCTGGCAAGACCAATACAGTGAAACGACAGAAGCAGGTGTCCCCCAGCAGCGAGGGTCACTTCCGGAGCCAGCACAAGAGGGTTGTGGAGCAGGTATCATAGTCACCACCTTGGGAATCTGTCCAGCCCCCAGTTCTGCTCAAGGACAGAGAAAAGGATAGAAGTTTGAGAGAAAAACAATGAAAGAGGCTTCTTCACATAATTGGTGAATCAGAGGGAGAGACACTGAGTATATTTTAAAGCATATTAAAAAAATTAAGTCAATGTTAAATGTCACAACATATTTTTAGATTTGTATATTTAAAGCCTTTAATACATTTTTGGGGGGTAAGCATTGTCATCAGTGAGGAATTTTGGTAATAATGATGTGTTTTGCTTCCCCTTTGTAACCAAGTTTATTCTGTACTACAGGAGTGGTGCTTACCAGGGTCTAAACTCCCCCTGTGAGATTAATAAGGTGCACTGTGGTCTTTCTGTGTTAATAAAATGTGCTCTGAATNOV64i, CG57109-03Protein SequenceSEQ ID NO: 972855 aaMW at 97447.3kDMLLIETYLRLGNLQRKVFLDLQLVPRGWGSLTIMAEGKEGQVPSYMDGSRQRENEEDAKAETPDVTIRSYEIYSLPWNRQQGVCDHSLEYLSSRISERKLQGSWLPASRGNLEKPFLGPRGPVVPLFCPRNGLHSAHPENSPLKPRVVTVVKLGGQRPRKITLLLNRRSVQTFEQLLADISEALGSPRWKNDRVRKLFNLKGREIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRNTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVSNOV64j, CG57109-04SEQ ID NO: 9732433 bpDNA SequenceORF Start: ATG at 52ORF Stop: TAG at 2284TTTACAGAGTCAGGCCTCACCGTGAGAGGGCTCCTGTATTAGTCCCTTTTCATGCTGCTTATAGAGACATACCTGAGACTGGGCAATTTGCAGAGAAAGGTTTTCTTGGACTTACAGTTAGTTCCACGTGGCTGGGGAAGCCTCACAATCATGGCGGAAGGCAAGGAAGGGCAAGTCCCATCTTACATGGATGGCAGCAGGCAAAGAGAGAATGAGGAAGATGCAAAAGCGGAAACCCCTGATGTAACCATCAGATCTTATGAGATTTATTCACTACCATGGAACAGACAGCAAGGCGTATGTGACCATTCTCTAGAATATTTAAGCTCGAGAATCTCAGAGCGGAAGCTGCAAGGCTCCTGGCTGCCTGCCAGCCGAGGGAATCTGGAGAAACCATTCCTGGGGCCGCGTGGCCCCGTCGTGCCCTTGTTCTGCCCTCGGAATGGCCTTCACTCAGCACATCCTGAGAACAGCCCTCTGAAGCCCAGGGTCGTGACCGTAGTGAAGCTGGGTGGGCAGCGCCCCCGAAAGATCACTCTGCTCCTCAACAGGCGATCAGTGCAGACGTTCGAGCAGCTCTTAGCTGACATCTCAGAAGCCTTGGGCTCTCCCAGATGGAAGAATGACCGTGTGAGGAAACTGTTTAACCTCAAGGGCAGGGAAATCAGGAGCGTCTCTGATTTCTTCAGGGAAGGGGATGCTTTCATAGCTATGGGCAAAGAACCACTGACACTGAAGAGCATTCAGGTGGCTGTAGAAGAACTGTACCCCAACAAAGCCCGGGCCCTGACACTGGCCCAGCACAGCCGTGCCCCTTCTCCAAGGCTGAGGAGCAGGCTGTTTAGCAAGGCTCTGAAAGGAGACCACCGCTGTGGGGAGACCGAGACCCCCAAGAGCTGCAGCGAAGTTGCAGGATGCAAGGCAGCCATGAGGCACCAGGGGAAGATCCCCGAGGAGCTTTCACTAGATGACAGAGCGAGGACCCAGAAGAAGTGGGGGAGGGGGAAATGGGAGCCAGAACCCAGTAGCAAGCCCCCCAGGGAAGCCACTCTGGAAGAGAGGCACGCAAGGGGAGAGAAGCATCTTGGGGTGGAGATTGAAAAGACCTCGGGTGAAATTATCAGATGCGAGAAGTGCAAGAGAGAGAGGGAGCTCCAGCAGAGCCTGGAGCGTGAGAGGCTTTCTCTGGGGACCAGTGAGCTGGATATGGGGAAGGGCCCAATGTATGATGTGGAGAAAAAGCCATGTATGTCTGGAGGCAGAAGGATGACTCTCAGAGATGACCAACCTGCAAAGCTAGAAAAGGAGCCCAAGACGAGGCCAGAAGAGAACAAGCCAGAGCGGCCCAGCGGTCGGAAGCCACGGCCCATGGGCATCATTGCCGCCAATGTGGAAAAGCATTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTTTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGACATGTGGGCTGCTGGCGTGATCCTCTATATCCTGCTGTGTGGCTTTCCCCCATTCCGCAGCCCTGAGAGGGACCAGGACGAGCTCTTTAACATCATCCAGCTGGGCCACTTTGAGTTCCTCCCCCCTTACTGGGACAATATCTCTGATACAGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCAGGTTCTTCAGCACCCCTGGATCGAAACAGCTGGCAAGACCAATACAGTGAAACGACAGAAGCAGGTGTCCCCCAGCAGCGAGGGTCACTTCCGGAGCCAGCACAAGAGGGTTGTGGAGCAGGTATCATAGTCACCACCTTGGGAATCTGTCCAGCCCCCAGTTCTGCTCAAGGACAGAGAAAAGGATAGAAGTTTGAGAGAAAAACAATGAAAGAGGCTTCTTCACATAATTGGTGAATCAGAGGGAGAGACACTGAGTATATTTTAAAGCATATTANOV64j, CG57109-04Protein SequenceSEQ ID NO: 974744 aaMW at 84729.4kDMLLIETYLRLGNLQRKVFLDLQLVPRGWGSLTIMAEGKEGQVPSYMDGSRQRENEEDAKAETPDVTIRSYEIYSLPWNRQQGVCDHSLEYLSSRISERKLQGSWLPASRGNLEKPFLGPRGPVVPLFCPRNGLHSAHPENSPLKPRVVTVVKLGGQRPRKITLLINRRSVQTFEQLLADISEALGSPRWKNDRVRKLFNLKGREIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIEAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDTAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVSNOV64k, CG57109-06SEQ ID NO: 9752720 bpDNA SequenceORF Start: ATG at 149ORF Stop: TGA at 1826GGACACTGACATGGACTGAAGGAGTAGAAAAGAAGCCTTGGGCTCTCCCAGATGGAAGAATGACCGTGTGAGGAAACTGTTTAACCTCAAGGGCAGGGAAATCAGGAGCGTCTCTGATTTCTTCAGGGAAGGGGATGCTTTCATAGCTATGGGCAAAGAACCACTGACACTGAAGAGCATTCAGGTGGCTGTAGAAGAACTGTACCCCAACAAAGCCCGGGCCCTGACACTGGCCCAGCACAGCCGTGCCCCTTCTCCAAGGCTGAGGAGCAGGCTGTTTAGCAAGGCTCTGAAAGGAGACCACCGCTGTGGGGAGACCGAGACCCCCAAGAGCTGCAGCGAAGTTGCAGGATGCAAGGCAGCTATGAGGCACCAGGGGAAGATCCCCGAGGAGCTTTCACTAGATGACAGAGCGAGGACCCAGAAGAAGTGGGGGAGGGGGAAATGGGAGCCAGAACCCAGTAGCAAGCCCCCCAGGGAAGCCACTCTGGAAGAGAGGCACGCAAGGGGAGAGAAGCATCTTGGGGTGGAGATTGAAAAGACCTCGGGTGAAATTATCAGATGCGAGAAGTGCAAGAGAGAGAGGGAGCTTCAGCAGAGCCTGGAGCGTGAGAGGCTTTCTCTGGGGACCAGTGAGCTGGATATGGGGAAGGGCCCAATGTATGATGTGGAGAAGCTGGTGAGGACCAGAAGCTGCAGGAGGTCTCCCGAGGCAAATCCTGCAAGTGGGGAGGAAGGGTGGAAGGGTGACAGCCACAGGAGCAGCCCCAGGAATCCCACTCAAGAGCTGAGGAGACCCAGCAAGAGCATGGACAAGAAAGAGGACAGAGGCCCAGAGGATCAAGAAAGCCATGCTCAGGGAGCAGCCAAGGCCAAGAAGGACCTTGTGGAAGTTCTTCCTGTCACAGAGGAGGGGCTGAGGGAGGTGAAGAAGGACACCAGGCCCATGAGCAGGAGCAAACATGGTGGCTGGCTCCTGAGAGAGCACCAGGCGGGCTTTGAGAAGCTCCGCAGGACCCGAGGAGAAGAGAAGGAGGCAGAGAAGGAGAAAAAGCCATGTATGTCTGGAGGCAGAAGGATGACTCTCAGAGATGACCAACCTGCAAAGCTAGAAAAGGAGCCCAAGACGAGGCCAGAAGAGAACAAGCCAGAGCGGCCCAGCGGTCGGAAGCCACGGCCCATGGGCATCATTGCCGCCAATGTGGAAAAGCATTATGAGACTGGCCGGGTCATTGGGGATGGGAACTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATCTTGCATGAAGTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAAAGCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTTTTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTAAGTGTTACACATCGATCTGTGGGACTCTAGTTCCCTTACTAACAAATGTTTCATTTGTCATATTTACTAGTTTTCAATATGGAATAAATCTCAGAGAACTGACACTTAGGCTTGGATTTGGACTTCAATGAAAATATTTGAAGTAGGCTTGACCAAAGCATGAGAGCTTTCTCCTCATTAGGGCTGCCCTTGTTACAGTCAATGGATCAGTGTGTGTGCATGTGTGTGTGTGTGTGTGTGTTTATTGTGTTTAGGCAGGACAGTGAGATGAAAGATGATGGAGAATTGGGTGGGGAACTCAAGCAAGCAAGGCTACTTGACCCAAGGCTATCTCTAATAGGAGAGAATTGAAGCAGTCCTTATGGTACTTGGTTTAAAAATTTCTTCACCAACCTTGCATTTAAAGGAAAAGGATCCCATTTTCCTCCATGAACTCTATGAATATTTATTACCTACTTGTATATTATGCAAGGATCCAATGAGCTGTTTTAGTGACAAACTTTCTAAAACATTTAAAAAGGAAATAATAGTTATGATATGGCTCTAAATATATGAATGACTATTTGACTACTGTGGCACTCCAGGAGAAACCAATTTACCCACCATTGGTAAGATGGGAAGACTCTCATTGGGTTGCAGGGTTGGTGACAGGGAGAAGGGATGGACGGATAGTTTCCCAGCAGCAGAAGCATCAGGATAATTAAGATGAGGAGATGGCCAGGGATGGTGGCTCATGCCTGTAATCCCAGCTCTTTGGGAGGCTGAGGCAGGTGGATCACCTGAGGTCAGGCGTTTGAAACCATCCTGGCCAACATGGTGAAACCCTGTCTGTACTAAAACTACAAAAAAATTAGCTGGGCGTGGTGGCACATGCCTGTAATCTGAGCTACTCGGGAGGCTGAGGCAGGAGAATTGCTTGAACCGGGGAGGTGGAGTTTGCAGTGAGCCAAGATCGTGCCATTGCACTCCAGCCTGGGCAACAAGAGTGAAACTTCATCTCAAAAAAAAAAAAAAAAAAAAAACNOV64k, CG57109-06Protein SequenceSEQ ID NO: 976559 aaMW at 63436.9kDMGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILHEVYETDMEIYLILEYVQGGDLFDAIEESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGKCYTSICGTLVPLLTNVSFVIFTSFQYGINLRELTLRLGFGLQ

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 64B.

TABLE 64BComparison of the NOV64 protein sequences.NOV64a------------------------------------------------------------NOV64b------------------------------------------------------------NOV64c------------------------------------------------------------NOV64d------------------------------------------------------------NOV64e------------------------------------------------------------NOV64f------------------------------------------------------------NOV64g------------------------------------------------------------NOV64h---------------------------------MAEGKEGQVPSYMDGSRQRENEEDAKANOV64iMLLIETYLRLGNLQRKVFLDLQLVPRGWGSLTIMAEGKEGQVPSYMDGSRQRENEEDAKANOV64jMLLIETYLRLGNLQRKVFLDLQLVPRGWGSLTIMAEGKEGQVPSYMDGSRQRENEEDAKANOV64k------------------------------------------------------------NOV64a------------------------------------------------------------NOV64b------------------------------------------------------------NOV64c------------------------------------------------------------NOV64d------------------------------------------------------------NOV64e------------------------------------------------------------NOV64f------------------------------------------------------------NOV64g------------------------------------------------------------NOV64hETPDVTIRSYEIYSLPWNRQQGVCDHSLEYLSSRISERKLQGSWLPASRGNLEKPFLGPRNOV64iETPDVTIRSYEIYSLPWNRQQGVCDHSLEYLSSRISERKLQGSWLPASRGNLEKPFLGPRNOV64jETPDVTIRSYEIYSLPWNRQQGVCDHSLEYLSSRISERKLQGSWLPASRGNLEKPFLGPRNOV64k------------------------------------------------------------NOV64a------------------------------------------------------------NOV64b------------------------------------------------------------NOV64c------------------------------------------------------------NOV64d------------------------------------------------------------NOV64e------------------------------------------------------------NOV64f------------------------------------------------------------NOV64g------------------------------------------------------------NOV64hGPVVPLFCPRNGLHSAHPENSPLKPRVVTVVKLGGQRPRKITLLLNRRSVQTFEQLLADINOV64iGPVVPLFCPRNGLHSAHPENSPLKPRVVTVVKLGGQRPRKITLLLNRRSVQTFEQLLADINOV64jGPVVPLFCPRNGLHSAHPENSPLKPRVVTVVKLGGQRPRKITLLLNRRSVQTFEQLLADINOV64k------------------------------------------------------------NOV64a----------------------------------------MGKEPLTLKSIQVAVEELYPNOV64b------------------------------------------------------------NOV64c------------------------------------------------------------NOV64d----------------------------------------MGKEPLTLKSIQVAVEELYPNOV64e------------------------------------TGSTMGKEPLTLKSIQVAVEELYPNOV64f------------------------------------TGSTMGKEPLTLKSIQVAVEELYPNOV64g------------------------------------------------------------NOV64hSEALGSPRWKNDRVRKLFNLKGREIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNOV64iSEALGSPRWKNDRVRKLFNLKGREIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNOV64jSEALGSPRWKNDRVRKLFNLKGREIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNOV64k----------------------------------------MGKEPLTLKSIQVAVEELYPNOV64aNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPNOV64b------------------------------------------------------------NOV64c------------------------------------------------------------NOV64dNKARALTLAQHSRAPSPRLRSRLFSKALKGDNRCGETETPKSCSEVAGCKAAMRHQGKIPNOV64eNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAANRHQGKIPNOV64fNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPNOV64g------------------------------------------------------------NOV64hNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPNOV64iNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAANRHQGKIPNOV64jNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAANRHQGKIPNOV64kNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAANRHQGKIPNOV64aEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCENOV64b------------------------------------------------------------NOV64c------------------------------------------------------------NOV64dEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCENOV64eEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCENOV64fEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCENOV64g------------------------------------------------------------NOV64hEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCENOV64iEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCENOV64jEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCENOV64kEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCENOV64aKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGNOV64b------------------------------------------------------------NOV64c------------------------------------------------------------NOV64dKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGNOV64eKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGNOV64fKCKRERELQQSLERERLSLGTSELDNGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGNOV64g------------------------------------------------------------NOV64hKCKRERELQQSLERERLSLGTSELDNGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGNOV64iKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGNOV64jKCKRERELQQSLERERLSLGTSELDMGKGPMYDVE-------------------------NOV64kKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGNOV64aDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVNOV64b------------------------------------------------------------NOV64c------------------------------------------------------------NOV64dDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVNOV64eDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVNOV64fDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVNOV64g------------------------------------------------------------NOV64hDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVNOV64iDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVNOV64j------------------------------------------------------------NOV64kDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVNOV64aKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRNTLRDDQPAKNOV64b------------------------------------------------------------NOV64c------------------------------------------------------------NOV64dKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKNOV64eKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKNOV64fKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKNOV64g------------------------------------------------------------NOV64hKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKNOV64iKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKNOV64j----------------------------------------KKPCMSGGRRMTLRDDQPAKNOV64kKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRNTLRDDQPAKNOV64aLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQNOV64b--------------------------------TGSYETGRVIGDGNFAVVKECRHRETRQNOV64c--------------------------------TGSYETGRVIGDGNFAVVKECRHRETRQNOV64dLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQNOV64eLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQNOV64fLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQNOV64g--------------------------------TGSYETGRVIGDGNFAVVKECRHRETRQNOV64hLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAWKECRHRETRQNOV64iLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQNOV64jLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQNOV64kLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQNOV64aAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFNOV64bAYANKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFNOV64cAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFNOV64dAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFNOV64eAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFNOV64fAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFNOV64gAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFNOV64hAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFNOV64iAYAMKIIDKSRLKGKEDMVDSEI-------------LHEVYETDMEIYLILEYVQGGDLFNOV64jAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFNOV64kAYANKIIDKSRLKGKEDMVDSEIL-------------HEVYETDMEIYLILEYVQGGDLFNOV64aDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64bDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64cDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64dDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64eDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64fDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64gDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFWOV64hDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64iDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64jDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64kDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFNOV64aGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQNOV64bGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQNOV64cGLAKHVVRPIFTVCGTPTYVAPEILSEK--------------------------------NOV64dGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQNOV64eGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQNOV64fGLAKHVVRPIFTVCGTPTYVAPEILSEKG-------------------------------NOV64gGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQNOV64hGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQNOV64iGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQNOV64jGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQNOV64aDELFNIIQLGHFEFLPPYWDNISD-AAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNOV64bDELFNIIQLGHFEFLPPYWDNISD-AAKDLVSRLLVVDPKKRYTAHQVLQHPWILEG---NOV64c---------------------AAK----DLVSRLLVVDPKKRYTAHQVLQHPWILEG---NOV64dDELFNIIQLGHFEFLPPYWDNISD-AAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNOV64eDELFNIIQLGHFEFLPPYWDNISD-AAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNOV64f-------------------------------YGLELEG----------------------NOV64gDELFNIIQLGHFEFLPPYWDNISD-AAKDLVSRLLVVDPKKRYTAHQVLQHPWILEG---NOV64hDELFNIIQLGHFEFLPPYWDNISDTAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNOV64iDELFNIIQLGHFEFLPPYWDNISD-AAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNOV64jDELFNIIQLGHFEFLPPYWDNISDTAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNOV64k--------T-----LVPLLTNVSFVIFTSFQYGINLRELTLRLGFGLQ------------NOV64aNTVKRQKQVSPSSEGHFRSQHKRVVEQVS---NOV64b--------------------------------NOV64c--------------------------------NOV64dNTVKRQKQVSPSSEGHFRSQHKRVVEQVS---NOV64eNTVKRQKQVSPSSEGHFRSQHKRVVEQVSLEGNOV64f--------------------------------NOV64g--------------------------------NOV64hNTVKRQKQVSPSSEGHFRSQHKRVVEQVS---NOV64iNTVKRQKQVSPSSEGHFRSQHKRVVEQVS---NOV64jNTVKRQKQVSPSSEGHFRSQHKRVVEQVS---NOV64k--------------------------------NOV64a(SEQ ID NO: 956)NOV64b(SEQ ID NO: 958)NOV64c(SEQ ID NO: 960)NOV64d(SEQ ID NO: 962)NOV64e(SEQ ID NO: 964)NOV64f(SEQ ID NO: 966)NOV64g(SEQ ID NO: 968)NOV64h(SEQ ID NO: 970)NOV64i(SEQ ID NO: 972)NOV64j(SEQ ID NO: 974)NOV64k(SEQ ID NO: 976)

Further analysis of the NOV64a protein yielded the following properties shown in Table 64C.

TABLE 64CProtein Sequence Properties NOV64aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG: a new signal peptide prediction method N-region: length 9; pos.chg 2; neg.chg 1 H-region: length 6; peak value −5.22 PSG score: −9.62GvH: von Heijne's method for signal seq. recognition GvH score (threshold: −2.1): −7.85 possible cleavage site: between 34 and 35>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 1 Number of TMS(s) for threshold 0.5: 1 INTEGRALLikelihood = −3.29Transmembrane 534-550 PERIPHERALLikelihood = 4.72 (at 452) ALOM score: −3.29 (number of TMSs: 1)MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 541 Charge difference: 1.0 C(−2.0) − N(−3.0) C > N: C-terminal side will be inside>>> Single TMS is located near the C-terminus>>> membrane topology: type Nt (cytoplasmic tail 1 to 533)MITDISC: discrimination of mitochondrial targeting seq R content:0Hyd Moment(75):9.28 Hyd Moment(95):7.07G content:1 D/E content:2S/T content:2 Score: −6.37Gavel: prediction of cleavage sites for mitochondrial preseq R-10 motif at 52 SRL FSNUCDISC: discrimination of nuclear localization signals pat4: RKPR (4) at 340 pat4: PKKR (4) at 598 pat7: PSGRKPR (3) at 337 pat7: PKKRYTA (5) at 598 bipartite: none content of basic residues: 17.9% NLS Score: 0.72KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif: type 1: none type 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: found LL at 276 LL at 483checking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 89COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residuesFinal Results (k = 9/23): 30.4%: nuclear 26.1%: cytoplasmic 13.0%: Golgi 8.7%: mitochondrial 8.7%: vesicles of secretory system 8.7%: endoplasmic reticulum 4.3%: peroxisomal>> prediction for CG57109-01 is nuc (k = 23)

A search of the NOV64a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 64D.

TABLE 64DGeneseq Results for NOV64aNOV64aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE24133Human kinase (PKIN)-4 protein - 1 . . . 648648/648 (100%)0.0Homo sapiens, 835 aa.188 . . . 835648/648 (100%)[WO200233099-A2, 25-APR-2002]ABB82471Human serine/threonine protein 1 . . . 648648/648 (100%)0.0kinase - Homo sapiens, 835 aa.188 . . . 835648/648 (100%)[WO200270678-A2, 12-SEP-2002]AAO15419Novel human kinase protein 2 - 1 . . . 648647/648 (99%) 0.0Homo sapiens, 817 aa.170 . . . 817648/648 (99%) [WO200242438-A2, 30-MAY-2002]ABB82474Human serine/threonine protein 1 . . . 484484/484 (100%)0.0kinase fragment - Homo sapiens,188 . . . 671484/484 (100%)751 aa. [WO200270678-A2, 12-SEP-2002]AAY42696Rat serine-threonine protein 1 . . . 648495/649 (76%)0.0kinase PK80 sequence - Rattus 98 . . . 733535/649 (82%)norvegicus, 733 aa.[WO9950395-A1, 07-OCT-1999]

In a BLAST search of public sequence databases, the NOV64a protein was found to have homology to the proteins shown in the BLASTP data in Table 64E.

TABLE 64EPublic BLASTP Results for NOV64aNOV64aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9C098Hypothetical protein KIAA1765 - 41 . . . 648 608/608 (100%)0.0Homo sapiens (Human), 608 aa 1 . . . 608 608/608 (100%)(fragment).Q8BWQ5Hypothetical eukaryotic protein 1 . . . 632467/633 (73%)0.0kinase containing protein - Mus 1 . . . 619510/633 (79%)musculus (Mouse), 619 aa.O15075Serine/threonine-protein kinase348 . . . 641155/294 (52%)3e−87DCAMKL1 (EC 2.7.1.-)382 . . . 674212/294 (71%)(Doublecortin-like and CAMkinase-like 1) - Homo sapiens(Human), 740 aa.Q8BQN2Double cortin and348 . . . 641154/294 (52%)1e−86calcium/calmodulin-dependent 75 . . . 367212/294 (71%)protein kinase-like 1 - Musmusculus (Mouse), 452 aa.Q8CCN4Double cortin and348 . . . 641154/294 (52%)1e−86calcium/calmodulin-dependent 91 . . . 383212/294 (71%)protein kinase-like 1 - Musmusculus (Mouse), 449 aa.

PFam analysis indicates that the NOV64a protein contains the domains shown in the Table 64F.

TABLE 64FDomain Analysis of NOV64aIdentities/NOV64aSimilaritiesMatchfor thePfam DomainRegionMatched RegionExpect Valuepkinase356 . . . 613109/301 (36%)8.1e-102220/301 (73%)

Example 65

The NOV65 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 65A.

TABLE 65ANOV65 Sequence AnalysisNOV65a, CG57399-04SEQ ID NO: 977947 bpDNA SequenceORF Start: ATG at 7ORF Stop: TGA at 937GACCTGATGAAGAATGACACGAGGATACACTTTCAGGAAGACTGGAAGATAATAACCCTGTTTATAGGCGGCAATGACCTCTGTGATTTCTGCAATGATCTGGTCCACTATTCTCCCCAGAACTTCACAGACAACATTGGAAAGGCCCTGGACATCCTCCATGCTGAGGTTCCTCGGGCATTTGTGAACCTGGTGACGGTGCTTGAGATCGTCAACCTGAGGGAGCTGTACCAGGAGAAAAAAGTCTACTGCCCAAGGATGATCCTCAGGTCTCTGTGTCCCTGTGTCCTGAAGTTTGATGATAACTCAACAGAACTTGCTACCCTCATCGAATTCAACAAGAAGTTTCAGGAGAAGACCCACCAACTGATTGAGAGTGGGCGATATGACACAAGGGAAGATTTTACTGTGGTTGTGCGGCCGTTCTTTGAAAACGTGGACATGCCAAAGACCTCGGAAGGATTGCCTGACAACTCTTTCTTCGCTCCTGACTGTTTCCACTTCAGCAGCAAGTCTCACTCCCGAGCAGCCAGTGCTCTCTGGAACAATATGCTGGAGCCTGTTGGCCAGAAGACGACTCGTCATAAGTTTGAAAACAAGATCAATATCACATGTCCGAACCAGGTCCAGCCGTTTCTGAGGACCTACAAGAACAGCATGCAGGGTCATGGGACCTGGCTGCCATGCAGGGACAGAGCCCCTTCTGCCTTGCACCCTACCTCAGTGCATGCCCTGAGACCTGCAGACATCCAAGTTGTGGCTGCTCTGGGGGATTCTCTGACCGCTGGCAATGGAATTGGCTCCAAACCAGACGACCTCCCCGATGTCACCACACAGTATCGGGGACTGTCATACAGAGAAAGTAAACCAGGGTTCTTATCAGACTCCTGGGTCAGCAAATCCAACAGGAAATGCACCAGAAAAGCACCAAATCCCTGAATCTACACNOV65a, CG57399-04+TL,14Protein SequenceSEQ ID NO: 978310 aaMW at 35268.7kDMKNDTRIHFQEDWKIITLFIGGNDLCDFCNDLVHYSPQNFTDNIGKALDILHAEVPRAFVNLVTVLEIVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFNKKFQEKTHQLIESGRYDTREDFTVVVRPFFENVDMPKTSEGLPDNSFFAPDCFHFSSKSHSRAASALWNNMLEPVGQKTTRHKFENKINITCPNQVQPFLRTYKNSMQGHGTWLPCRDRAPSALHPTSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYRESKPGFLSDSWVSKSNRKCTRKAPNPNOV65b, CG57399-01SEQ ID NO: 9794268 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAG at 4258ATGACCTGGGACACAGCTCTCTGGACCTCAGTTTTTCTGATTGGGCTCCTTCCTACCCTTGGTTTCGCTAATTGCATCCTCCAGACTTCTGGTAAAATGTGTACTTTAAGAGGTAGATACCCCCAGCCCCCACAACCACCTCTCTGCTTGTCTCCCCTAGTCCACCAGCTCCGACCAGCAGACATCAAAGTGGTGGCCGCCCTGGGTAATGATGAAACCTTCCAGGAAAGTGGTGCAGGGCAGCTAAGTGAGCCTGACCCCAGGCAGTGGTCCTGGCCACAGGCCTGCTTGCCTGGGGTAAAAAAGGAAATGCAAGATGTGGTAGGTGAGAGAACGCCGAGCCGTCGCCGCAGCCTCCGCCGCCGAGAAGCCCTTGTTCCCGCTGCTGGGAAGGAGAGTCTGTGCCGACAAGATATTTTCATTTCCTTGTTGGAAATTATCAAGCATTTTCCTCCCTCCCCTCAGGACATCAACCTGGAGAAAGACTGGAAGCTGGTCACACTCTTCATTGGGGTCAACGACTTGTGTCATTACTGTCCACTTGTTCAGGGCCCCGTTATAGACCTGGGTGGGATGGATACCCTCCACTCCCTGCAGCTCCCAAGGGCTTTCGTCAACGTGGTGGAGGTCATGGAGCTGGCTAGCCTGTACCAGGGCCAAGGCGGGAAATGTGCCATGCTGGCAGCTCAGGAAGCCTGGAACAGCCTCCTGGCCTCCAGCAGGTACAGTGAGCAGGAGTCCTTCACCGTGGTTTTCCAGCCTTTCTTCTATGAGACCACCCCATCTGACCCCCGACTCCAGGATTCTACCACGCTGGCCTGGCATCTCTGGAATAGGATGATGGAGCCAGCAGGAGAGAAAGATGAGCCATTGAGTGTAAAACACGGGAGGCCAATGAAGTGTCCCTCTCAGGAGAGCCCCTATCTGTTCAGCTACAGAAACAGCAACTACCTGACCAGACTGCAGAAACCCCAAGACAAGCTTGTAAGAGAAGGAGCGGAAATCAGATGTCCTGACAAAGACCCCTCCGATACGGTTCCCACCTCAGTTCATAGGCTGAAGCCGGCTGACATCAACGTAATTGGAGCCCTGGGTGACTCTCTCACGGCAGGCAATGGGGCCGGGTCCACACCTGGGAACGTCTTGGACGTCTTGACTCAGTACCGAGGCCTGTCCTGGAGCGTCGGCGGAGATGAGAACATCGGCACCGTTACCACCCTGGCAGACATCCTCCGGGAATTCAACCCTTCCCTGAAGGGCTTCTCTGTTGGCACTGGGAAAGAAACCAGTCCTAATGCCTTCTTAAACCAGGCTGTGGCAGGAGGCCGAGCTGAGCAGGCCAGGAGGCTGGTGGACCTGATGAAGAATGACACGAGGATACACTTTCAGGAAGACTGGAAGATAATAACCCTGTTTATAGGCGGCAATGACCTCTGTGATTTCTGCAATGATCTGGTACACTATTCTCCCCAGAACTTCACAGACAACATTGGAAAGGCCCTGGACATCCTCCATGCTGAGTCTCAGGTTCCTCGGGCATTTGTGAACCTGGTGACGGTGCTTGAGATCGTCAACCTGAGGGAGCTGTACCAGGAGAAAAAAGTCTACTGCCCAAGGATGATCCTCAGGTCACTGTGTCCCTGTGTCCTGAAGTTTGATGATAACTCAACAGAACTTGCTACCCTCATCGAATTCAACAAGAAGTTTCAGGAGAAGACCCACCAACTGATTGAGAGTGGGCGATATGACACAAGGGAAGATTTTACTGTGGTTGTGCAGCCGTTCTTTGAAAACGTGGACATGCCAAAGACCCAGGAAGGATTGCCTGACAACTCTTTCTTCGCTCCTGACTGTTTCCACTTCAGCAGCAAGTCTCACTCCCGAGCAGCCAGTGCTCTCTGGAACAATATGCTGGAGCCTGTTGGCCAGAAGACGACTCGTCATAAGTTTGAAAACAAGATCAATATCACATGTCCGTCACAGGTCCAGCCGTTTCTGAGGACCTACAAGAACAGCATGCAGGGTCATGGGACCTGGCTGCCATGCAGGGACAGAGCCCCTTCTGCCTTGCACCCTACCTCAGTGCATGCCCTGAGACCTGCAGACATCCAAGTTGTGGCTGCTCTGGGGGATTCTCTGACCGCTGGCAATGGAATTGGCTCCAAACCAGACGACCTCCCCGATGTCACCACACAGTATCGGGGACTGTCATACAGTGCAGGAGGGGACGGCTCCCTGGAGAATGTGACCACCTTACCTAGTTCTATCCTTCGGGAGTTTAACAGAAACCTCACAGGCTACGCCGTGGGCACGGGTGATGCCAATGACACGAATGCATTCCTCAATCAAGCTGTTCCCGGAGCAAAGGCTAGGGATCTTATGAGCCAAGTCCAAACTCTGATGCAGAAGATGAAAGATGATCATAGAGTAAATTTCCATGAAGACTGGAAGGTCATCACAGTGCTGATCGGAGGCAGCGATTTATGTGACTACTGCACAGATTCGAATCTGTATTCTGCAGCCAACTTTGTTCACCATCTCCGCAATGCCTTGGACGTCCTGCATAGAGAGGTGCCCAGAGTCCTGGTCAACCTCGTGGACTTCCTGAACCCCACTATCATGCGGCAGGTGTTCCTGGGAAACCCAGACAAGTGCCCAGTGCAGCAGGCCAGCGTTTTGTGTAACTGCGTTCTGACCCTGCGGGAGAACTCCCAAGAGCTAGCCAGGCTGGAGGCCTTCAGCCGAGCCTACCAGAGCAGCATGCGCGAGCTGGTGGGGTCAGGCCGCTATGACACGCAGGAGGACTTCTCTGTGGTGCTGCAGCCCTTCTTCCAGAACATCCAGCTCCCTGTCCTGCAGGATGGGCTCCCAGATACGTCCTTCTTTGCCCCAGACTGCATCCACCCAAATCAGAAATTCCACTCCCAGCTGGCCAGAGCCCTTTGGACCAATATGCTTGAACCACTTGGAAGCAAAACAGAGACCCTGGACCTGAGAGCAGAGATGCCCATCACCTGTCCCACTCAGAATGAGCCCTTCCTGAGAACCCCTCGGAATAGTAACTACACGTACCCCATCAAGCCAGCCATTGAGAACTGGGGCAGTGACTTCCTGTGTACAGAGTGGAAGGCTTCCAATAGTGTTCCAACCTCTGTCCACCAGCTCCGACCAGCAGACATCAAAGTGGTGGCCGCCCTGGGTGACTCTCTGACTACAGCAGTGGGAGCTCGACCAAACAACTCCAGTGACCTACCCACATCTTGGAGGGGACTCTCTTGGAGCATTGGAGGGGATGGGAACTTGGAGACTCACACCACACTGCCCAGTATTCTGAAGAAGTTCAACCCTTACCTCCTTGGCTTCTCTACCAGCACCTGGGAGGGGACAGCAGGACTAAATGTGGCAGCGGAAGGGGCCAGAGCTAGGAGGGACATGCCAGCCCAGGCCTGGGACCTGGTAGAGCGAATGAAAAACAGCCCCATACACTTTCAGGAAGACTGGAAGATAATAACCCTGTTTATAGGCGGCAATGACCTCTGTGATTTCTGCAATGATCTGGTAGGTGAATATGTTCAGCACATCCAACAGGCCCTGGACATCCTCTCTGAGGAGCTCCCAAGGGCTTTCGTCAACGTGGTGGAGGTCATGGAGCTGGCTAGCCTGTACCAGGGCCAAGGCGGGAAATGTGCCATGCTGGCAGCTCAGAACAACTGCACTTGCCTCAGACACTCGCAAAGCTCCCTGGAGAAGCAAGAACTGAAGAAAGTGAACTGGAACCTCCAGCATGGCATCTCCAGTTTCTCCTACTGGCACCAATACACACAGCGTGAGGACTTTGCGGTTGTGGTGCAGCCTTTCTTCCAAAACACACTCACCCCACTGAACAGAGGGGACACTGACCTCACCTTCTTCTCCGAGGACTGTTTTCACTTCTCAGACCGCGGGCATGCCGAGATGGCCATCGCACTCTGGAACAACATGCTGGAACCAGTGGGCCGCAAGACTACCTCCAACAACTTCACCCACAGCCGAGCCAAACTCAAGTGCCCCTCTCCTGTGAGTCCTTACCTCTACACCCTGCGGAACAGCCGATTGCTCCCAGACCAGGCTGAAGAAGCCCCCGAGGTGCTCTACTGGGCTGTCCCAGTGGCAGCGGGAGTCGGCCTTGTGGTGGGCATCATCGGGACAGTGGTCTGGAGGTGCAGGAGAGGTGGCCGGAGGGAAGATCCTCCAATGAGCCTGCGCACTGTGGCCCTCTAGGCCCGGGGNOV65b, CG57399-01Protein SequenceSEQ ID NO: 9801419 aaMW at 158435.1kDMTWDTALWTSVFLIGLLPTLGFANCILQTSGKMCTLRGRYPQPPQPPLCLSPLVHQLRPADIKVVAALGNDETFQESGAGQLSEPDPRQWSWPQACLPGVKKEMQDVVGERTPSRRRSLRRREALVPAAGKESLCRQDIFISLLEIIKHFPPSPQDINLEKDWKLVTLFIGVNDLCHYCPLVQGPVIDLGGMDTLHSLQLPRAFVNVVEVMELASLYQGQGGKCAMLAAQEAWNSLLASSRYSEQESFTVVFQPFFYETTPSDPRLQDSTTLAWHLWNRMMEPAGEKDEPLSVKHGRPMKCPSQESPYLFSYRNSNYLTRLQKPQDKLVREGAEIRCPDKDPSDTVPTSVHRLKPADINVIGALGDSLTAGNGAGSTPGNVLDVLTQYRGLSWSVGGDENIGTVTTLADILREFNPSLKGFSVGTGKETSPNAFLNQAVAGGRAEQARRLVDLMKNDTRIHFQEDWKIITLFIGGNDLCDFCNDLVHYSPQNFTDNIGKALDILHAESQVPRAFVNLVTVLEIVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFNKKFQEKTHQLIESGRYDTREDFTVVVQPFFENVDMPKTQEGLPDNSFFAPDCFHFSSKSHSRAASALWNNNLEPVGQKTTRHKFENKINITCPSQVQPFLRTYKNSMQGHGTWLPCRDRAPSALHPTSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYSAGGDGSLENVTTLPSSILREFNRNLTGYAVGTGDANDTNAFLNQAVPGAKARDLMSQVQTLMQKMKDDHRVNFHEDWKVITVLIGGSDLCDYCTDSNLYSAANFVHHLRNALDVLHREVPRVLVNLVDFLNPTIMRQVFLGNPDKCPVQQASVLCNCVLTLRENSQELARLEAFSRAYQSSMRELVGSGRYDTQEDFSVVLQPFFQNIQLPVLQDGLPDTSFFAPDCIHPNQKFHSQLARALWTNMLEPLGSKTETLDLRAEMPITCPTQNEPFLRTPRNSNYTYPIKPAIENWGSDFLCTEWKASNSVPTSVHQLRPADIKVVAALGDSLTTAVGARPNNSSDLPTSWRGLSWSIGGDGNLETHTTLPSILKKFNPYLLGFSTSTWEGTAGLNVAAEGARARRDMPAQAWDLVERMKNSPIHFQEDWKIITLFIGGNDLCDFCNDLVGEYVQHIQQALDILSEELPRAFVNVVEVMELASLYQGQGGKCAMLAAQNNCTCLRHSQSSLEKQELKKVNWNLQHGISSFSYWHQYTQREDFAVVVQPFFQNTLTPLNRGDTDLTFFSEDCFHFSDRGHAEMAIALWNNMLEPVGRKTTSNNFTHSRAKLKCPSPVSPYLYTLRNSRLLPDQAEEAPEVLYWAVPVAAGVGLVVGIIGTVVWRCRRGGRREDPPMSLRTVALNOV65c, CG57399-02SEQ ID NO: 9811624 bpDNA SequenceORF Start: ATG at 311ORF Stop: TGA at 1241GCCGGCTGACATCAATGTAATTGGAGCCCTGGGTGACTCTCTCACGGCAGGCAATGGGGCCGGGTCCACACCTGGGAACGTCTTGGACGTCTTGACTCAGTACCGAGGCCTGTCCTGGAGCGTCGGCGGAGATGAGAACATCGGCACCGTTACCACCCTGGCGAACATCCTCCGGGAATTCAACCCTTCCCTGAAGGGCTTCTCTGTTGGCACTGGGAAAGAAACCAGTCCTAATGCCTTCTTAAACCAGGCTGTGGCAGGAGGCCGAGCTGAGGATCTACCTGTCCAGGCCAGGAGGCTGGTGGACCTGATGAAGAATGACACGAGGATACACTTTCAGGAAGACTGGAAGATAATAACCCTGTTTATAGGCGGCAATGACCTCTGTGATTTcTGCAATGATCTGGTCCACTATTCTCCCCAGAACTTCACAGACAACATTGGAAAGGCCCTGGACATCCTCCATGCTGAGGTTCCTCGGGCATTTGTGAACCTGGTGACGGTGCTTGAGATCGTCAACCTGAGGGAGCTGTACCAGGAGAAAAAAGTCTACTGCCCAAGGATGATCCTCAGGTCTCTGTGTCCCTGTGTCCTGAAGTTTGATGATAACTCAACAGAACTTGCTACCCTCATCGAATTCAACAAGAAGTTTCAGGAGAAGACCCACCAACTGATTGAGAGTGGGCGATATGACACAAGGGAAGATTTTACTGTGGTTGTGCAGCCGTTCTTTGAAAACGTGGACATGCCAAAGACCTCGGAAGGATTGCCTGACAACTCTTTCTTCGCTCCTGACTGTTTCCACTTCAGCAGCAAGTCTCACTCCCGAGCAGCCAGTGCTCTCTGGAACAATATGCTGGAGCCTGTTGGCCAGAAGACGACTCGTCATAAGTTTGAAAACAAGATCAATATCACATGTCCGAACCAGGTCCAGCCGTTTCTGAGGACCTACAAGAACAGCATGCAGGGTCATGGGACCTGGCTGCCATGCAGGGACAGAGCCCCTTCTGCCTTGCACCCTACCTCAGTGCATGCCCTGAGACCTGCAGACATCCAAGTTGTGGCTGCTCTGGGGGATTCTCTGACCGCTGGCAATGGAATTGGCTCCAAACCAGACGACCTCCCCGATGTCACCACACAGTATCGGGGACTGTCATACAGAGAAAGTAAACCAGGGTTCTTATCAGACTCCTGGGTCAGCAAATCCAACAGGAAATGCACCAGAAAAGCACCAAATCCCTGAATCTTCACCTCCCCGCTTGCATGTATACGTGTACACGTGGTGTTCCTACGTCTCTGTTTACTGTCTTTATGTGTTTATTCATGTTGTCTTGTAGTCACACAGCTGCCTTTACATATATGTACACATCTGCACAGAAAACCTCTGAAACCCATCGCACACTTCGAGAGGCCATAACCAAGACACAATCACAATCAGCCATGTCTTGAAAGATTAGCAATTCGACAAGAGGAAAGGGTGAGAAAGGGCATCCCGAACACGGAAGTGGAGAAGCTCAGGGTGTGTCAGGCGAGCGGTTGCGTGTAGATATTCTCAAGTTTCTTTCTCTCCTAATAAAGTTCTCATTCCTGTAGGCTTCAAAGTAAGTGGCGAGTAGCTCAGAATNOV65c, CG57399-02Protein SequenceSEQ ID NO: 982310 aaMW at 35240.6kDMKNDTRIHFQEDWKIITLFIGGNDLCDFCNDLVHYSPQNFTDNIGKALDILHAEVPRAFVNLVTVLEIVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFNKKFQEKTHQLIESGRYDTREDFTVVVQPFFENVDMPKTSEGLPDNSFFAPDCFHFSSKSHSRAASALWNNMLEPVGQKTTRHKFEMKINITCPNQVQPFLRTYKNSMQGHGTWLPCRDRAPSALHPTSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYRESKPGFLSDSWVSKSNRKCTRKAPNPNOV65d, CG57399-03SEQ ID NO: 9834425 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAG at 4285CTGGAGCATTCTGGCATGGGGCTGCGGCCAGGCATTTTCCTCCTGGAGCTGCTGCTGCTTCTGGGGCAAGGTACCCCTCAGATCCATACCTCTCCTAGAAAGAGTACATTGGAAGGGCAGCTATGGCCAGAGACAGTTCACTCTCTGAAGCCTTCTGATATTAAATTTGTGGCAGCCATTGGCAATCTGGAAATTGTGCCAGACCCAGGGACGGGCGATCTGGAGAAGCAAGACGAAAGGCCACAGCAGGTGTGCATGGGAGTGATGACAGTCCTTTCAGACATCATCAGATATTTCAGTCCTTCTGTTCCAATGCCTGTGTGCCACACTGGAAAGAGAGTCATACCCCACGATGGTGCTGAGGACTTGTGGATTCAGGCTCAAGAACTGGTGAGAAACATGAAAGAGAACCAACTTGACTTTCAATTTGACTGGAAGCTCATCAATGTGTTCTTCAGTAATGCAAGCCAGTGTTACCTGTGCCCCTCTGCTCAACAGAATGGGCTTGCGGCGGGCGGCGTGGATGAGCTGATGGGGGTGCTGGACTACCTGCAGCAGGAGGTGCCCAGAGCATTTGTAAACCTGGTGGACCTCTCTGAGGTTGCAGAGGTCTCTCGTCAGTATCACGGCACTTGGCTCAGCCCTGCACCAGAGCCCTGTAATTGCTCAGAGGAGACCACCCGGCTGGCCAAGGTGGTGATGCAGTGGTCTTATCAGGAAGCCTGGAACAGCCTCCTGGCCTCCAGCAGGTACAGTGAGCAGGAGTCCTTCACCGTGGTTTTCCAGCCTTTCTTCTATGAGACCACCCCATCTGACCCCCGACTCCAGGATTCTACCACGCTGGCCTGGCATCTCTGGAATAGGATGATGGAGCCAGCAGGAGAGAAAGATGAGCCATTGAGTGTAAAACACGGGAGGCCAATGAAGTGTCCCTCTCAGGAGAGCCCCTATCTGTTCAGCTACAGAAACAGCAACTACCTGACCAGACTGCAGAAACCCCAAGACAAGCTTGAGGTAAGAGAAGGAGCGGAAATCAGATGTCCTGACAAAGACCCCTCCGATACGGTTCCCACCTCAGTTCATAGGCTGAAGCCGGCTGACATCAACGTAATTGGAGCCCTGGGTGACTCTCTCACGGCAGGCAATGGGGCCGGGTCCACACCTGGGAACGTCTTGGACGTCTTGACTCAGTACCGAGGCCTGTCCTGGAGCGTCGGCGGAGATGAGAACATCGGCACCGTTACCACCCTGGCGGACATCCTCCGGGAATTCAACCCTTCCCTGAAGGGCTTCTCTGTTGGCACTGGGAAAGAAACCAGTCCTAATGCCTTCTTAAACCAGGCTGTGGCAGGAGGCCGAGCTGAGCAGGCCAGGAGGCTGGTGGACCTGATGAAGAATGACACGAGGATACACTTTCAGGAAGACTGGAAGATAATAACCCTGTTTATAGGCGGCAATGACCTCTGTGATTTCTGCAATGATCTGGTACACTATTCTCCCCAGAACTTCACAGACAACATTGGAAAGGCCCTGGACATCCTCCATGCTGAGGTTCCTCGGGCATTTGTGAACCTGGTGACGGTGCTTGAGATCGTCAACCTGAGGGAGCTGTACCAGGAGAAAAAAGTCTACTGCCCAAGGATGATCCTCAGGTCACTGTGTCCCTGTGTCCTGAAGTTTGATGATAACTCAACAGAACTTGCTACCCTCATCGAATTCAACAAGAAGTTTCAGGAGAAGACCCACCAACTGATTGAGAGTGGGCGATATGACACAAGGGAAGATTTTACTGTGGTTGTGCAGCCGTTCTTTGAAAACGTGGACATGCCAAAGACCCAGGAAGGATTGCCTGACAACTCTTTCTTCGCTCCTGACTGTTTCCACTTCAGCAGCAAGTCTCACTCCCGAGCAGCCAGTGCTCTCTGGAACAATATGCTGGAGCCTGTTGGCCAGAAGACGACTCGTCATAAGTTTGAAAACAAGATCAATATCACATGTCCGAACCAGGTAGAGTGGCCGTTTCTGAGGACCTACAAGAACAGCATGCAGGGTCATGGGACCTGGCTGCCATGCAGGGACAGAGCCCCTTCTGCCTTGCACCCTACCTCAGTGCATGCCCTGAGACCTGCAGACATCCAAGTTGTGGCTGCTCTGGGGGATTCTCTGACCGCTGGCAATGGAATTGGCTCCAAACCAGACGACCTCCCCGATGTCACCACACAGTATCGGGGACTGTCATACAGTGCAGGAGGGGACGGCTCCCTGGAGAATGTGACCACCTTACCTGATATCCTTCGGGAGTTTAACAGAAACCTCACAGGCTACGCCGTGGGCACGGGTGATGCCAATGACACGAATGCATTCCTCAATCAAGCTGTTCCCGGAGCAAAGGCTAGGGATCTTATGAGCCAAGTCCAAACTCTGATGCAGAAGATGAAAGATGATCATAGAGTAAATTTCCATGAAGACTGGAAGGTCATCACAGTGCTGATCGGAGGCAGCGATTTATGTGACTACTGCACAGATTCGAATCTGTATTCTGCAGCCAACTTTGTTCACCATCTCCGCAATGCCTTGGACGTCCTGCATAGAGAGGTGCCCAGAGTCCTGGTCAACCTCGTGGACTTCCTGAACCCCACTATCATGCGGCAGGTGTTCCTGGGAAACCCAGACAAGTGCCCAGTGCAGCAGGCCAGCGTTTTGTGTAACTGCGTTCTGACCCTGCGGGAGAACTCCCAAGAGCTAGCCAGGCTGGAGGCCTTCAGCCGAGCCTACCAGAGCAGCATGCGCGAGCTGGTGGGGTCAGGCCGCTATGACACGCAGGAGGACTTCTCTGTGGTGCTGCAGCCCTTCTTCCAGAACATCCAGCTCCCTGTCCTGCAGGATGGGCTCCCAGATACGTCCTTCTTTGCCCCAGACTGCATCCACCCAAATCAGAAATTCCACTCCCAGCTGGCCAGAGCCCTTTGGACCAATATGCTTGAACCACTTGGAAGCAAAACAGAGACCCTGGACCTGAGAGCAGAGATGCCCATCACCTGTCCCACTCAGAATGAGCCCTTCCTGAGAACCCCTCGGAATAGTAACTACACGTACCCCATCAAGCCAGCCATTGAGAACTGGGGCAGTGACTTCCTGTGTACAGAGTGGAAGGCTTCCAATAGTGTTCCAACCTCTGTCCACCAGCTCCGACCAGCAGACATCAAAGTGGTGGCCGCCCTGGGTGACTCTCTGACTGTGGCAGTGGGAGCTCGACCAAACAACTCCAGTGACCTACCCACATCTTGGAGGGGACTCTCTTGGAGCATTGGAGGGGATGGGAACTTGGAGACTCACACCACACTGCCCGACATTCTGAAGAAGTTCAACCCTTACCTCCTTGGCTTCTCTACCAGCACCTGGGAGGGGACAGCAGGACTAAATGTGGCAGCGGAAGGGGCCAGAGCTAGGGACATGCCAGCCCAGGCCTGGGACCTGGTAGAGCGAATGAAAAACAGCCCCCAGGACATCAACCTGGAGAAAGACTGGAAGCTGGTCACACTCTTCATTGGGGTCAACGACTTGTGTCATTACTGTGAGAATCCGGTAGGCGAATATGTTCAGCACATCCAACAGGCCCTGGACATCCTCTCTGAGGAGCTCCCAAGGGCTTTCGTCAACGTGGTGGAGGTCATGGAGCTGGCTAGCCTGTACCAGGGCCAAGGCGGGAAATGTGCCATGCTGGCAGCTCAGAACAACTGCACTTGCCTCAGACACTCGCAAAGCTCCCTGGAGAAGCAAGAACTGAAGAAAGTGAACTGGAACCTCCAGCATGGCATCTCCAGTTTCTCCTACTGGCACCAATACACACAGCGTGAGGACTTTGCGGTTGTGGTGCAGCCTTTCTTCCAAAACACACTCACCCCACTGAACAGAGGGGACACTGACCTCACCTTCTTCTCCGAGGACTGTTTTCACTTCTCAGACCGCGGGCATGCCGAGATGGCCATCGCACTCTGGAACAACATGCTGGAACCAGTGGGCCGCAAGACTACCTCCAACAACTTCACCCACAGCCGAGCCAAACTCAAGTGCCCCTCTCCTGAGAGCCCTTACCTCTACACCCTGCGGAACAGCCGATTGCTCCCAGACCAGGCTGAAGAAGCCCCCGAGGTGCTCTACTGGGCTGTCCCAGTGGCAGCGGGAGTCGGCCTTGTGGTGGGCATCATCGGGACAGTGGTCTGGAGGTGCAGGAGAGGTGGCCGGAGGGAAGATCCTCCAATGAGCCTGCGCACTGTGGCCCTCTAGGCCCGGGGGTGGGTCCTCACCCTAAACTCCCTATAGCCACTCTCTTCACCGCCCTCTGCCCCAGCCACTCCCGGCCACCAGGACATGCTTCAATGCCTGGTGCCATAGGAAGCCCAGGGGACAGTCACAACTTCTTGGNOV65d, CG57399-03Protein SequenceSEQ ID NO: 9841423 aaMW at 159352.7kDMGLRPGIFLLELLLLLGQGTPQIHTSPRKSTLEGQLWPETVHSLKPSDIKFVAAIGNLEIVPDPGTGDLEKQDERPQQVCMGVMTVLSDIIRYFSPSVPMPVCHTGKRVIPHDGAEDLWIQAQELVRNMKENQLDFQFDWKLINVFFSNASQCYLCPSAQQNGLAAGGVDELNGVLDYLQQEVPRAFVNLVDLSEVAEVSRQYHGTWLSPAPEPCNCSEETTRLAKVVMQWSYQEAWNSLLASSRYSEQESFTVVFQPFFYETTPSDPRLQDSTTLAWHLWNRMMEPAGEKDEPLSVKHGRPMKCPSQESPYLFSYRNSNYLTRLQKPQDKLEVREGAEIRCPDKDPSDTVPTSVHRLKPADINVIGALGDSLTAGNGAGSTPGNVLDVLTQYRGLSWSVGGDENIGTVTTLADILREFNPSLKGFSVGTGKETSPNAFLNQAVAGGRAEQARRLVDLMKNDTRIHFQEDWKIITLFIGGNDLCDFCNDLVHYSPQNFTDNIGKALDILHAEVPRAFVNLVTVLEIVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFNKKFQEKTEQLIESGRYDTREDFTVVVQPFFENVDMPKTQEGLPDNSFFAPDCFHFSSKSHSRAASALWNNMLEPVGQKTTRHKFENKINITCPNQVEWPFLRTYKNSMQGHGTWLPCRDRAPSALHPTSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYSAGGDGSLENVTTLPDILREFNRNLTGYAVGTGDANDTNAFLNQAVPGAKARDLMSQVQTLMQKMKDDHRVNFHEDWKVITVLIGGSDLCDYCTDSNLYSAANFVHHLRNALDVLHREVPRVLVNLVDFLNPTIMRQVFLGNPDKCPVQQASVLCNCVLTLRENSQELARLEAFSRAYQSSMRELVGSGRYDTQEDFSVVLQPFFQNIQLPVLQDGLPDTSFFAPDCIHPNQKFHSQLARALWTNNLEPLGSKTETLDLRAEMPITCPTQMEPFLRTPRNSNYTYPIKPAIENWGSDFLCTEWKASNSVPTSVHQLRPADIKVVAALGDSLTVAVGARPNNSSDLPTSWRGLSWSIGGDGNLETHTTLPDILKKFNPYLLGFSTSTWEGTAGLNVAAEGARARDMPAQAWDLVERMKNSPQDINLEKDWKLVTLFIGVNDLCHYCENPVGEYVQHIQQALDILSEELPRAFVNVVEVMELASLYQGQGGKCANLAAQNNCTCLRHSQSSLEKQELKKVNWNLQHGISSFSYWHQYTQREDFAVVVQPFFQNTLTPLNRGDTDLTFFSEDCFHFSDRGHAEMAIALWNNMLEPVGRKTTSNNFTHSRAKLKCPSPESPYLYTLRNSRLLPDQAEEAPEVLYWAVPVAAGVGLVVGIIGTVVWRCRRGGRREDPPMSLRTVAL

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 65B.

TABLE 65BComparison of the NOV65 protein sequences.NOV65a------------------------------------------------------------NOV65bMTWDTALWTSVFLIGLLPTLGFANCILQTSGKMCTLRGRYPQPPQPPLCLSPLVHQLRPANOV65c------------------------------------------------------------NOV65d----MGLRPGIFLLELLLLLGQGTPQIHTSPRKSTLEGQLWP---------ETVHSLKPSNOV65a------------------------------------------------------------NOV65bDIKVVAALGNDETFQESGAGQLSEPDPRQWSWPQACLPGVKKEMQDVVGERTPSRRRSLRNOV65c------------------------------------------------------------NOV65dDIKFVAAIGNLEIVPDPGTGDLEKQDER----PQQVCMGVMTVLSDIIRYFSPSVPMPVCNOV65a------------------------------------------------------------NOV65bRR-EALVPAAGKESLCRQDIFISLLEIIKHFPPSPQDINLEKDWKLVTLFIGVNDLCHYCNOV65c------------------------------------------------------------NOV65dHTGKRVIPHDG-----AEDLWIQAQELVRNMKEN--QLDFQFDWKLINVFFSNASQCYLCNOV65a------------------------------------------------------------NOV65bPLVQGPVIDLGGMDTLH-----S-LQLPRAFVNVVEVMELASLYQGQGG-----------NOV65c------------------------------------------------------------NOV65dPSAQQNGLAAGGVDELMGVLDYLQQEVPRAFVNLVDLSEVAEVSRQYHGTWLSPAPEPCNNOV65a------------------------------------------------------------NOV65b-------K---CAMLAAQEAWNSLLASSRYSEQESFTVVFQPFFYETTPSDPRLQDSTTLNOV65c------------------------------------------------------------NOV65dCSEETTRLAKVVMQWSYQEAWNSLLASSRYSEQESFTVVFQPFFYETTPSDPRLQDSTTLNOV65a------------------------------------------------------------NOV65bAWHLWNRMMEPAGEKDEPLSVKHGRPMKCPSQESPYLFSYRNSNYLTRLQKPQDK-LVRENOV65c------------------------------------------------------------NOV65dAWHLWNRMMEPAGEKDEPLSVKHGRPMKCPSQESPYLFSYRNSNYLTRLQKPQDKLEVRENOV65a------------------------------------------------------------NOV65bGAEIRCPDKDPSDTVPTSVHRLKPADINVIGALGDSLTAGNGAGSTPGNVLDVLTQYRGLNOV65c------------------------------------------------------------NOV65dGAEIRCPDKDPSDTVPTSVHRLKPADINVIGALGDSLTAGNGAGSTPGNVLDVLTQYRGLNOV65a------------------------------------------------------------NOV65bSWSVGGDENIGTVTTLADILREFNPSLKGFSVGTGKETSPNAFLNQAVAGGRAEQARRLVNOV65c------------------------------------------------------------NOV65dSWSVGGDENIGTVTTLADILREFNPSLKGFSVGTGKETSPNAFLNQAVAGGRAEQARRLVNOV65a--MKNDTRIHFQEDWKIITLFIGGNDLCDFCNDLVHYSPQNFTDNIGKALDILHAE--VPNOV65bDLMKNDTRIHFQEDWKIITLFIGGNDLCDFCNDLVHYSPQNFTDNIGKALDILHAESQVPNOV65c--MKNDTRIHFQEDWKIITLFIGGNDLCDFCNDLVHYSPQNFTDNIGKALDILHAE--VPNOV65dDLMKNDTRIHFQEDWKIITLFIGGNDLCDFCNDLVHYSPQNFTDNIGKALDILHAE--VPNOV65aRAFVNLVTVLEIVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFNKKFQENOV65bRAFVNLVTVLEIVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFNKKFQENOV65cRAFVNLVTVLEIVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFNKKFQENOV65dRAFVNLVTVLEIVNLRELYQEKKVYCPRNILRSLCPCVLKFDDNSTELATLIEFNKKFQENOV65aKTHQLIESGRYDTREDFTVVVRPFFENVDMPKTSEGLPDNSFFAPDCFHFSSKSHSRAASNOV65bKTHQLIESGRYDTREDFTVVVQPFFENVDMPKTQEGLPDNSFFAPDCFHFSSKSHSRAASNOV65cKTHQLIESGRYDTREDFTVVVQPFFENVDMPKTSEGLPDNSFFAPDCFHFSSKSHSRAASNOV65dKTHQLIESGRYDTREDFTVVVQPFFENVDMPKTQEGLPDNSFFAPDCFHFSSKSHSRAASNOV65aALWNNMLEPVGQKTTRHKFENKINITCPNQVQP-FLRTYKNSMQGHGTWLPCRDRAPSALNOV65bALWNNMLEPVGQKTTRHKFENKINITCPSQVQP-FLRTYKNSMQGHGTWLPCRDRAPSALNOV65cALWNNMLEPVGQKTTRHKFENKINITCPNQVQP-FLRTYKNSMQGHGTWLPCRDRAPSALNOV65dALWNNMLEPVGQKTTRHKFENKINITCPNQVEWPFLRTYKNSMQGHGTWLPCRDRAPSALNOV65aHPTSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYRESKPG------NOV65bHPTSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYSAGGDGSLENVTNOV65cHPTSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYRESKPG------NOV65dHPTSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYSAGGDGSLENV-NOV65aFLSDSWVSKSNRKCTRKAPNP---------------------------------------NOV65bTLPSSILREFNRNLTGYAVGTGDANDTNAFLNQAVPGAKARDLMSQVQTLMQKMKDDHRVNOV65cFLSDSWVSKSNRKCTRKAPNP---------------------------------------NOV65dTTLPDILREFNRLTGYAVGTGDANDTNAFLNQAVPGAKARDLMSQVQTLMQKMKDDHRVNOV65a------------------------------------------------------------NOV65bNFHEDWKVITVLIGGSDLCDYCTDSNLYSAANFVHHLRNALDVLHREVPRVLVNLVDFLNNOV65c------------------------------------------------------------NOV65dNFHEDWKVITVLIGGSDLCDYCTDSNLYSAANFVHHLRNALDVLHREVPRVLVNLVDFLNNOV65a------------------------------------------------------------NOV65bPTIMRQVFLGNPDKCPVQQASVLCNCVLTLRENSQELARLEAFSRAYQSSMRELVGSGRYNOV65c------------------------------------------------------------NOV65dPTIMRQVFLGNPDKCPVQQASVLCNCVLTLRENSQELARLEAFSRAYQSSMRELVGSGRYNOV65a------------------------------------------------------------NOV65bDTQEDFSVVLQPFFQNIQLPVLQDGLPDTSFFAPDCIHPNQKFHSQLARALWTNMLEPLGNOV65c------------------------------------------------------------NOV65dDTQEDFSVVLQPFFQNIQLPVLQDGLPDTSFFAPDCIHPNQKFHSQLARALWTNMLEPLGNOV65a------------------------------------------------------------NOV65bSKTETLDLRAEMPITCPTQNEPFLRTPRNSNYTYPIKPAIENWGSDFLCTEWKASNSVPTNOV65c------------------------------------------------------------NOV65dSKTETLDLRAEMPITCPTQNEPFLRTPRNSNYTYPIKPAIENWGSDFLCTEWKASNSVPTNOV65a------------------------------------------------------------NOV65bSVHQLRPADIKVVAALGDSLTTAVGARPNNSSDLPTSWRGLSWSIGGDGNLETHTTLPSINOV65c------------------------------------------------------------NOV65dSVHQLRPADIKVVAALGDSLTVAVGARPNNSSDLPTSWRGLSWSIGGDGNLETHTTLPDINOV65a------------------------------------------------------------NOV65bLKKFNPYLLGFSTSTWEGTAGLNVAAEGARARRDMPAQAWDLVERMKNSP--IHFQEDWKNOV65c------------------------------------------------------------NOV65dLKKFNPYLLGFSTSTWEGTAGLNVAAEGARAR-DMPAQAWDLVERMKNSPQDINLEKDWKNOV65a------------------------------------------------------------NOV65bIITLFIGGNDLCDFCNDLVGEYVQHIQQALDILSEELPRAFVNVVEVMELASLYQGQGGKNOV65c------------------------------------------------------------NOV65dLVTLFIGVNDLCHYCENPVGEYVQHIQQALDILSEELPRAFVNVVEVMELASLYQGQGGKNOV65a------------------------------------------------------------NOV65bCAMLAAQNNCTCLRHSQSSLEKQELKKVNWNLQHGISSFSYWHQYTQREDFAVVVQPFFQNOV65c------------------------------------------------------------NOV65dCAMLAAQNNCTCLRHSQSSLEKQELKKVNWNLQHGISSFSYWHQYTQREDFAVVVQPFFQNOV65a------------------------------------------------------------NOV65bNTLTPLNRGDTDLTFFSEDCFHFSDRGHAEMAIALWNNMLEPVGRKTTSNNFTHSRAKLKNOV65c------------------------------------------------------------NOV65dNTLTPLNRGDTDLTFFSEDCFHFSDRGHAEMAIALWNNMLEPVGRKTTSNNFTHSRAKLKNOV65a------------------------------------------------------------NOV65bCPSPVSPYLYTLRNSRLLPDQAEEAPEVLYWAVPVAAGVGLVVGIIGTVVWRCRRGGRRENOV65c------------------------------------------------------------NOV65dCPSPESPYLYTLRNSRLLPDQAEEAPEVLYWAVPVAAGVGLVVGIIGTVVWRCRRGGRRENOV65a-----------NOV65bDPPMSLRTVALNOV65c-----------NOV65dDPPMSLRTVALNOV65a(SEQ ID NO: 978)NOV65b(SEQ ID NO: 980)NOV65c(SEQ ID NO: 982)NOV65d(SEQ ID NO: 984)

Further analysis of the NOV65a protein yielded the following properties shown in Table 65C.

TABLE 65CProtein Sequence Properties NOV65aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 11; pos.chg 2; neg.chg 2H-region: length 0; peak value −1.15PSG score: −5.55GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −10.77possible cleavage site: between 28 and 29>>> Seems to have no N-terminal signal peptideALOM: Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 1.43 (at 55)ALOM score: 1.43 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment (75):3.74Hyd Moment (95):6.40G content:0D/E content:2S/T content:1Score: −6.13Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 12.3%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: KAPNSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 70.6COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):87.0%: nuclear 8.7%: mitochondrial 4.3%: peroxisomal>> prediction for CG57399-04 is nuc (k = 23)

A search of the NOV65a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 65D.

TABLE 65DGeneseq Results for NOV65aNOV65aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB09556Human lipase NHL (Val 1318 1 . . . 293284/293 (96%)e-170variant) - Homo sapiens, 1458 aa.491 . . . 783286/293 (96%)[WO200259328-A1, 01-Aug.-2002]ABB09555Human lipase NHL (Ala 1318 1 . . . 293284/293 (96%)e-170variant) - Homo sapiens, 1458 aa.491 . . . 783286/293 (96%)[WO200259328-A1, 01-Aug.-2002]AAE22860Human phospholipase-like 1 . . . 293273/298 (91%)e-160enzyme - Homo sapiens, 1216 aa.247 . . . 544279/298 (93%)[WO200231 161-A2, 18-Apr.-2002]AAW30751Rat phospholipase-Bllipase - 1 . . . 293203/293 (69%)e-118Rattus rattus, 1450 aa.495 . . . 787236/293 (80%)[JP09248190-A, 22-Sep.-1997]ABP53556Human phospholipase protein 1 . . . 217 92/218 (42%)8e-44SEQ ID NO:2 - Homo sapiens,203 . . . 416130/218 (59%)472 aa. [WO200262977-A2, 15-Aug.-2002]

In a BLAST search of public sequence databases, the NOV65a protein was found to have homology to the proteins shown in the BLASTP data in Table 65E.

TABLE 65EPublic BLASTP Results for NOV65aNOV65aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ96DP9Hypothetical protein FLJ30866 - 1 . . . 259258/259 (99%)e-154Homo sapiens (Human), 270 aa. 1 . . . 259259/259 (99%)Q05017Phospholipase ADRAB-B 1 . . . 293238/293 (81%)e-140precursor (EC 3.1.-.-)-491 . . . 783260/293 (88%)Oryctolagus cuniculus (Rabbit),1458 aa.070320Phospholipase B - Cavia 1 . . . 291221/291 (75%)e-131porcellus (Guinea pig), 1463 aa.490 . . . 780254/291 (86%)054728Phospholipase B - Rattus 1 . . . 293203/293 (69%)e-117norvegicus (Rat), 1450 aa.495 . . . 787236/293 (80%)Q8IUP7Similar to phospholipase B - 1 . . . 217 92/218 (42%)2e-43Homo sapiens (Human), 423 aa.154 . . . 367130/218 (59%)

PFam analysis indicates that the NOV65a protein contains the domains shown in the Table 65F.

TABLE 65FDomain Analysis of NOV65aNOV65aIdentities/MatchSimilaritiesPfam DomainRegionfor the Matched RegionExpect ValueLipase_GDSL1 . . . 17839/370 (11%)1.3e-10141/370 (38%)

Example 66

The NOV66 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 66A.

TABLE 66ANOV66 Sequence AnalysisNOV66a, CG57562-02SEQ ID NO: 9853517 bpDNA SequenceORF Start: ATG at 5ORF Stop: TGA at 3506AAAGATGGCGGCAGCGGCGGCGGTGGGCAACGCGGTGCCCTGCGGGGCCCGGCCTTGCGGGGTCCGGCCTGACGGGCAGCCCAAGCCCGGGCCGCAGCCGCGCGCGCTCCTTGCCGCCGGGCCGGCGCTCATAGCGAACGGTGACGAGCTGGTGGCTGCCGTGTGGCCGTACCGGCGGTTGGCGCTGTTGCGGCGCCTCACGGTGCTGCCATTCGCCGGGCTGCTTTACCCGGCCTGGTTGGGTGCCGCAGCCGCTGGCTGCTGGGGCTGGGGCAGCAGTTGGGTGCAGATCCCCGAAGCTGCGCTGCTCGTGCTTGCCACCATCTGCCTCGCGCACGCGCTCACTGTCCTCTCGGGGCATTGGTCTGTGCACGCGCATTGCGCGCTCACCTGCACCCCGGAGTACGACCCCAGCAAAGCGACCTTTGTGAAGGTGGTGCCAACCCCCAACAATGGCTCCACGGAGCTCGTGGCCCTGCACCGCAATGAGGGCGAAGACGGGCTTGAGGTGCTGTCCTTCGAATTCCAGAAGATCAAGTATTCCTACGATGCCCTGGAGAAGAAGCAGTTTCTCCCCGTGGCCTTTCCTGTGGGAAACGCCTTCTCATACTATCAGAGCAACAGAGGCTTCCAGGAAGACTCAGAGATCCGAGCAGCTGAGAAGAAATTTGGGAGCAACAAGGCCGAGATGGTGGTGCCTGACTTCTCGGAGCTTTTCAAGGAGAGAGCCACAGCCCCCTTCTTTGTATTTCAGGTGTTCTGTGTGGGGCTCTGGTGCCTGGATGAGTACTGGTACTACAGCGTCTTTACGCTATCCATGCTGGTGGCGTTCGAGGCCTCGCTGGTGCAGCAGCAGATGCGGAACATGTCGGAGATCCGGAAGATGGGCAACAAGCCCCACATGATCCAGGTCTACCGAAGCCGCAAGTGGAGGCCCATTGCCAGTGATGAGATCGTACCAGGGGACATCGTCTCCATCGGCCGCTCCCCACAGGAGAACCTGGTGCCATGTGACGTGCTTCTGCTGCGAGGCCGCTGCATCGTAGACGAGGCCATGCTCACGGGGGAGTCCGTGCCACAGATGAAGGAGCCCATCGAAGACCTCAGCCCAGACCGGGTGCTGGACCTCCAGGCTGATTCCCGGCTGCACGTCATCTTCGGGGGCACCAAGGTGGTGCAGCACATCCCCCCACAGAAAGCCACCACGGGCCTGAAGCCGGTTGACAGCGGGTGCGTGGCCTACGTCCTGCGGACCGGATTCAACACATCCCAGGGCAAGCTGCTGCGCACCATCCTCTTCGGGGTCAAGAGGGTGACTGCGAACAACCTGGAGACCTTCATCTTCATCCTCTTCCTCCTGGTGTTTGCCATCGCTGCAGCTGCCTATGTATGGATTGAAGGTACCAAGGACCCCAGCCGGAACCGCTACAAGCTGTTTCTGGAGTGCACCCTGATCCTCACCTCGGTCGTGCCTCCTGAGCTGCCCATCGAGCTGTCCCTGGCCGTCAACACCTCCCTCATCGCCCTGGCCAAGCTCTACATGTACTGCACAGAGCCCTTCCGGATCCCCTTTGCTGGCAAGGTCGAGGTGTGCTGCTTTGACAAGACGGGGACGTTGACCAGTGACAGCCTGGTGGTGCGCGGTGTGGCCGGGCTGAGAGACGGGAAGGAGGTGACCCCAGTGTCCAGCATCCCTGTAGAAACACACCGGGCCCTGGCCTCGTGCCACTCGCTCATGCAGCTGGACGACGGCACCCTCGTGGGTGACCCTCTAGAGAAGGCCATGCTGACGGCCGTGGACTGGACGCTGACCAAAGATGAGAAAGTATTCCCCCGAAGTATTAAAACTCAGGGGCTGAAAATTCACCAGCGCTTTCATTTTGCCAGTGCCCTGAAGCGAATGTCCGTGCTTGCCTCGTATGAGAAGCTGGGCTCCACCGACCTTTGTTACATCGCGGCCGTGAAGGGGGCCCCCGAAACTCTGCACTCCATGGCCCGGGAGGTCAAGCGGGAGGCCCTGGAGTGCAGCCTCAAGTTCGTCGGCTTCATTGTGGTCTCCTGCCCGCTCAAGGCTGACTCGAAGGCCGTGATCCGGGAGATCCAGAATGCGTCCCACCGGGTGTTCATGATCACGGGAGACAACCCGCTCACTGCATGCCACGTGGCCCAGGAGCTGCACTTCATTGAAAAGGCCCACACGCTGATCCTGCAGCCTCCCTCCGAGAAAGGCCGGCAGTGCGAGTGGCGCTCCATTGACGGCAGCATCGTGCTGCCCCTGGCCCGGGGCTCCCCAAAGGCACTGGCCCTGGAGTACGCACTGTGCCTCACAGGCGACGGCTTGGCCCACCTGCAGGCCACCGACCCCCAGCAGCTGCTCCGCCTCATCCCCCATGTGCAGGTGTTCGCCCGTGTGGCTCCCAAGCAGAAGGAGTTTGTCATCACCAGCCTGAAGGAGCTGGGCTACGTGACCCTCATGTGTGGGGATGGCACCAACGACGTGGGCGCCCTGAAGCATGCTGACGTGGGTGTGGCGCTCTTGGCCAATGCCCCTGAGCGGGTTGTCGAGCGGCGACGGCGGCCCCGGGACAGCCCAACCCTGAGCAACAGTGGCATCAGAGCCACCTCCAGGACAGCCAAGCAGCGGTCGGGGCTCCCTCCCTCCGAGGAGCAGCCAACCTCCCAGAGGGACCGCCTGAGCCAGGTGCTGCGAGACCTCGAGGACGAGAGTACGCCCATTGTGAAACTGGGGGATGCCAGCATCGCAGCACCCTTCACCTCCAAGCTCTCATCCATCCAGTGCATCTGCCACGTGATCAAGCAGGGCCGCTGCACGCTGGTGACCACGCTACAGATGTTCAAGATCCTGGCGCTCAATGCCCTCATCCTGGCCTACAGCCAGAGCGTCCTCTACCTGGAGGGAGTCAAGTTCAGTGACTTCCAGGCCACCCTACAGGGGCTGCTGCTGGCCGGCTGCTTCCTCTTCATCTCCCGTTCCAAGCCCCTCAAGACCCTCTCCCGAGAACGGCCCCTGCCCAACATCTTCAACCTGTACACCATCCTCACCGTCATGCTCCAGTTCTTTGTGCACTTCCTGAGCCTTGTCTACCTGTACCGTGAGGCCCAGGCCCGGAGCCCCGAGAAGCAGGAGCAGTTCGTGGACTTGTACAAGGAGTTTGAGCCAAGCCTGGTCAACAGCACCGTCTACATCATGGCCATGGCCATGCAGATGGCCACCTTCGCCATCAATTACAAAGGCCCGCCCTTCATGGAGAGCCTGCCCGAGAACAAGCCCCTGGTGTGGAGTCTGGCAGTTTCACTCCTGGCCATCATTGGCCTGCTCCTCGGCTCCTCGCCCGACTTCAACAGCCAGTTTGGCCTCGTGGACATCCCTGTGGAGTTCAAGCTGGTCATTGCCCAGGTCCTGCTCCTGGACTTCTGCCTGGCGCTCCTGGCCGACCGCGTCCTGCAGTTCTTCCTGGGGACCCCGAAGCTGAAAGTGCCTTCCTGAGATGGCAGTNOV66a, CG57562-02Protein SequenceSEQ ID NO: 9861167 aaMW at 128749.4kDMAAAAAVGNAVPCGARPCGVRPDGQPKPGPQPRALLAAGPALIANGDELVAAVWPYRRLALLRRLTVLPFAGLLYPAWLGAAAAGCWGWGSSWVQIPEAALLVLATICLAHALTVLSGHWSVHAHCALTCTPEYDPSKATFVKVVPTPNNGSTELVALHRNEGEDGLEVLSFEFQKIKYSYDALEKKQFLPVAFPVGNAFSYYQSNRGFQEDSEIRAAEKKFGSNKAEMVVPDFSELFKERATAPFFVFQVFCVGLWCLDEYWYYSVFTLSMLVAFEASLVQQQMRNMSEIRKMGNKPHMIQVYRSRKWRPIASDEIVPGDIVSIGRSPQENLVPCDVLLLRGRCIVDEAMLTGESVPQMKEPIEDLSPDRVLDLQADSRLHVIFGGTKVVQHIPPQKATTGLKPVDSGCVAYVLRTGFNTSQGKLLRTILFGVKRVTANNLETFIFILFLLVFAIAAAAYVWIEGTKDPSRNRYKLFLECTLILTSVVPPELPIELSLAVNTSLIALAKLYMYCTEPFRIPFAGKVEVCCFDKTGTLTSDSLVVRGVAGLRDGKEVTPVSSIPVETHRALASCHSLMQLDDGTLVGDPLEKAMLTAVDWTLTKDEKVFPRSIKTQGLKIHQRFHFASALKRNSVLASYEKLGSTDLCYIAAVKGAPETLHSMAREVKREALECSLKFVGFIVVSCPLKADSKAVIREIQNASHRVFMITGDNPLTACHVAQELHFIEKAHTLILQPPSEKGRQCEWRSIDGSIVLPLARGSPKALALEYALCLTGDGLAHLQATDPQQLLRLIPHVQVFARVAPKQKEFVITSLKELGYVTLMCGDGTNDVGALKHADVGVALLANAPERVVERRRRPRDSPTLSNSGIRATSRTAKQRSGLPPSEEQPTSQRDRLSQVLRDLEDESTPIVKLGDASIAAPFTSKLSSIQCICHVIKQGRCTLVTTLQMFKILALNALILAYSQSVLYLEGVKFSDFQATLQGLLLAGCFLFISRSKPLKTLSRERPLPNIFNLYTILTVHLQFFVHFLSLVYLYREAQARSPEKQEQFVDLYKEFEPSLVNSTVYIMAMAMQMATFAINYKGPPFMESLPENKPLVWSLAVSLLAIIGLLLGSSPDFNSQFGLVDIPVEFKLVIAQVLLLDFCLALLADRVLQFFLGTPKLKVPSNOV66b, CG57562-01SEQ ID NO: 9873904 bpDNA SequenceORF Start: ATG at 68ORF Stop: TGA at 3680TTACCGGAAGTAAAACTTCGGAAGTGAGGCGTTCCTCTGCCCGGAAGTGAGCGCGGCGCTAGGAAAGATGGCGGCAGCGGCGGCGGTGGGCAACGCGGTGCCCTGCGGGGCCCGGCCTTGCGGGGTCCGGCCTGACGGGCAGCCCAAGCCCGGGCGCAGCCGGCGCGCGCTCCTTGCCGCCGGGCCGGCGCTCATAGCGAACGGTGACGAGCTGGTGGCTGCCGTGTGGCCGTACCGGCGGTTGGCGCTGTTGCGGCGCCTCACGGTGCTGCCATTCGCCGGGCTGCTTTACCCGGCCTGGTTGGGTGCCGCAGCCGCTGGCTGCTGGGGCTGGGGCAGCAGTTGGGTGCAGATCCCCGAAGCTGCGCTGCTCGTGCTTGCCACCATCTGCCTCGCGCACGCGCTCACTGTCCTCTCGGGGCATTGGTCTGTGCACGCGCATTGCGCGCTCACCTGCACCCCGGAGTACGACCCCAGCAAAGCGACCTTTGTGAAGGTGGTGCCAACCCCCAACAATGGCTCCACGGAGCTCGTGGCCCTGCACCGCAATGAGGGCGAAGACGGGCTTGAGGTGCTGTCCTTCGAATTCCAGAAGATCAAGTATTCCTACGATGCCCTGGAGAAGAAGCAGTTTCTCCCCGTGGCCTTTCCTGTGGGAAACGCCTTCTCATACTATCAGAGCAACAGAGGCTTCCAGGAAGACTCAGAGATCCGAGCAGCTGAGAAGAAATTTGGGAGCAACAAGGCCGAGATGGTGGTGCCTGACTTCTCGGAGCTTTTCAAGGAGAGAGCCACAGCCCCCTTCTTTGTATTTCAGGTGTTCTGTGTGGGGCTCTGGTGCCTGGATGAGTACTGGTACTACAGCGTCTTTACGCTATCCATGCTGGTGGCGTTCGAGGCCTCGCTGGTGCAGCAGCAGATGCGGAACATGTCGGAGATCCGGAAGATGGGCAACAAGCCCCACATGATCCAGGTCTACCGAAGCCGCAAGTGGAGGCCCATTGCCAGTGATGAGATCGTACCAGGGGACATCGTCTCCATCGGCCGCTCCCCACAGGAGAACCTGGTGCCATGTGACGTGCTTCTGCTGCGAGGCCGCTGCATCGTAGACGAGGCCATGCTCACGGGGGAGTCCGTGCCACAGATGAAGGAGCCCATCGAAGACCTCAGCCCAGACCGGGTGCTGGACCTCCAGGCTGATTCCCGGCTGCACGTCATCTTCGGGGGCACCAAGGTGGTGCAGCACATCCCCCCACAGAAAGCCACCACGGGCCTGAAGCCGGTTGACAGCGGGTGCGTGGCCTACGTCCTGCGGACCGGATTCAACACATCCCAGGGCAAGCTGCTGCGCACCATCCTCTTCGGGGTCAAGAGGGTGACTGCGAACAACCTGGAGACCTTCATCTTCATCCTCTTCCTCCTGGTGTTTGCCATCGCTGCAGCTGCCTATGTATGGATTGAAGGTACCAAGGACCCCAGCCGGAACCGCTACAAGCTGTTTCTGGAGTGCACCCTGATCCTCACCTCGGTCGTGCCTCCTGAGCTGCCCATCGAGCTGTCCCTGGCCGTCAACACCTCCCTCATCGCCCTGGCCAAGCTCTACATGTACTGCACAGAGCCCTTCCGGATCCCCTTTGCTGGCAAGGTCGAGGTGTGCTGCTTTGACAAGACGGGGACGTTGACCAGTGACAGCCTGGTGGTGCGCGGTGTGGCCGGGCTGAGAGACGGGAAGGAGGTGACCCCAGTGTCCAGCATCCCTGTAGAAACACACCGGGCCCTGGCCTCGTGCCACTCGCTCATGCAGCTGGACGACGGCACCCTCGTGGGTGACCCTCTAGAGAAGGCCATGCTGACGGCCGTGGACTGGACGCTGACCAAAGATGAGAAAGTATTCCCCCGAAGTATTAAAACTCAGGGGCTGAAAATTCACCAGCGCTTTCATTTTGCCAGTGCCCTGAAGCGAATGTCCGTGCTTGCCTCGTATGAGAAGCTGGGCTCCACCGACCTCTGCTACATCGCGGCCGTGAAGGGGGCCCCCGAAACTCTGCACTCCATGTTCTCCCAGTGCCCGCCCGACTACCACCACATCCACACCGAGATCTCCCGGGAAGGAGCCCGCGTCCTGGCGCTGGGGTACAAGGAGCTGGGACACCTCACTCACCAGCAGGCCCGGGAGGTCAAGCGGGAGGCCCTGGAGTGCAGCCTCAAGTTCGTCGGCTTCATTGTGGTCTCCTGCCCGCTCAAGGCTGACTCCAAGGCCGTGATCCGGGAGATCCAGAATGCGTCCCACCGGGTGGTCATGATCACGGGAGACAACCCGCTCACTGCATGCCACGTGGCCCAGGAGCTGCACTTCATTGAAAAGGCCCACACGCTGATCCTGCAGCCTCCCTCCGAGAAAGGCCGGCAGTGCGAGTGGCGCTCCATTGACGGCAGCATCGTGCTGCCCCTGGCCCGGGGCTCCCCAAAGGCACTGGCCCTGGAGTACGCACTGTGCCTCACAGGCGACGGCTTGGCCCACCTGCAGGCCACCGACCCCCAGCAGCTGCTCCGCCTCATCCCCCATGTGCAGGTGTTCGCCCGTGTGGCTCCCAAGCAGAAGGAGTTTGTCATCACCAGCCTGAAGGAGCTGGGCTACGTGACCCTCATGTGTGGGGATGGCACCAACGACGTGGGCGCCCTGAAGCATGCTGACGTGGGTGTGGCGCTCTTGGCCAATGCCCCTGAGCGGGTTGTCGAGCGGCGACGGCGGCCCCGGGACAGCCCAACCCTGAGCAACAGTGGCATCAGAGCCACCTCCAGGACAGCCAAGCAGCGGTCGGGGCTCCCTCCCTCCGAGGAGCAGCCAACCTCCCAGAGGGACCGCCTGAGCCAGGTGCTGCGAGACCTCGAGGACGAGAGTACGCCCATTGTGAAACTGGGGGATGCCAGCATCGCAGCACCCTTCACCTCCAAGCTCTCATCCATCCAGTGCATCTGCCACGTGATCAAGCAGGGCCGCTGCACGCTGGTGACCACGCTACAGATGTTCAAGATCCTGGCGCTCAATGCCCTCATCCTGGCCTACAGCCAGAGCGTCCTCTACCTGGAGGGAGTCAAGTTCAGTGACTTCCAGGCCACCCTACAGGGGCTGCTGCTGGCCGGCTGCTTCCTCTTCATCTCCCGTTCCAAGCCCCTCAAGACCCTCTCCCGAGAACGGCCCCTGCCCAACATCTTCAACCTGTACACCATCCTCACCGTCATGCTCCAGTTCTTTGTGCACTTCCTGAGCCTTGTCTACCTGTACCGTGAGGCCCAGGCCCGGAGCCCCGAGAAGCAGGAGCAGTTCGTGGACTTGTACAAGGAGTTTGAGCCAAGCCTGGTCAACAGCACCGTCTACATCATGGCCATGGCCATGCAGATGGCCACCTTCGCCATCAATTACAAAGGCCCGCCCTTCATGGAGAGCCTGCCCGAGAACAAGCCCCTGGTGTGGAGTCTGGCAGTTTCACTCCTGGCCATCATTGGCCTGCTCCTCGGCTCCTCGCCCGACTTCAACAGCCAGTTTGGCCTCGTGGACATCCCTGTGGAGTTCAAGCTGGTCATTGCCCAGGTCCTGCTCCTGGACTTCTGCCTGGCGCTCCTGGCCGACCGCGTCCTGCAGTTCTTCCTGGGGACCCCGAAGCTGAAAGTGCCTTCCTGAGATGGCAGTGCTGGTACCCACTGCCCACCCTGGCTGCCGCTGGGCGGGAACCCCAACAGGGCCCCGGGAGGGAACCCTGCCCCCAACCCCCCACAGCAAGGCTGTACAGTCTCGCCCTTGGAAGACTGAGCTGGGACCCCCACAGCCATCCGCTGGCTTGGCCAGCAGAACCAGCCCCAAGCCAGCACCTTTGGTAAATAAAGCAGCATCTGAGATTTTAAANOV66b, CG57562-01Protein SequenceSEQ ID NO: 9881204 aaMW at 133030.2kDMAAAAAVGNAVPCGARPCGVRPDGQPKPGRSRRALLAAGPALIANGDELVAAVWPYRRLALLRRLTVLPFAGLLYPAWLGAAAAGCWGWGSSWVQIPEAALLVLATICLAHALTVLSGHWSVHAHCALTCTPEYDPSKATFVKVVPTPNNGSTELVALHRNEGEDGLEVLSFEFQKIKYSYDALEKKQFLPVAFPVGNAFSYYQSNRGFQEDSEIRAAEKKFGSNKAEMVVPDFSELFKERATAPFFVFQVFCVGLWCLDEYWYYSVFTLSMLVAFEASLVQQQMRNMSEIRKMGNKPHMIQVYRSRKWRPIASDEIVPGDIVSIGRSPQENLVPCDVLLLRGRCIVDEAMLTGESVPQMKEPIEDLSPDRVLDLQADSRLHVIFGGTKVVQHIPPQKATTGLKPVDSGCVAYVLRTGFNTSQGKLLRTILFGVKRVTANNLETFIFILFLLVFAIAAAAYVWIEGTKDPSRNRYKLFLECTLILTSVVPPELPIELSLAVNTSLIALAKLYMYCTEPFRIPFAGKVEVCCFDKTGTLTSDSLVVRGVAGLRDGKEVTPVSSIPVETHRALASCHSLMQLDDGTLVGDPLEKAMLTAVDWTLTKDEKVFPRSIKTQGLKIHQRFHFASALKRMSVLASYEKLGSTDLCYIAAVKGAPETLHSMFSQCPPDYHHIHTEISREGARVLALGYKELGHLTHQQAREVKREALECSLKFVGFIVVSCPLKADSKAVIREIQNASHRVVMITGDNPLTACHVAQELHFIEKAHTLILQPPSEKGRQCEWRSIDGSIVLPLARGSPKALALEYALCLTGDGLAHLQATDPQQLLRLIPHVQVFARVAPKQKEFVITSLKELGYVTLMCGDGTNDVGALKHADVGVALLANAPERVVERRRRPRDSPTLSNSGIRATSRTAKQRSGLPPSEEQPTSQRDRLSQVLRDLEDESTPIVKLGDASIAAPFTSKLSSIQCICHVIKQGRCTLVTTLQMFKILALNALILAYSQSVLYLEGVKFSDFQATLQGLLLAGCFLFISRSKPLKTLSRERPLPNIFNLYTILTVMLQFFVHFLSLVYLYREAQARSPEKQEQFVDLYKEFEPSLVNSTVYIMAMAMQMATFAINYKGPPFMESLPENKPLVWSLAVSLLAIIGLLLGSSPDFNSQFGLVDIPVEFKLVIAQVLLLDFCLALLADRVLQFFLGTPKLKVPSSEQ ID NO: 9893517 bpNOV66c, SNP13380762 ofORF Start: ATG at 5ORF Stop: TGA at 3506CG57562-02, DNA SequenceSNP Pos: 756SNP Change: T to CAAAGATGGCGGCAGCGGCGGCGGTGGGCAACGCGGTGCCCTGCGGGGCCCGGCCTTGCGGGGTCCGGCCTGACGGGCAGCCCAAGCCCGGGCCGCAGCCGCGCGCGCTCCTTGCCGCCGGGCCGGCGCTCATAGCGAACGGTGACGAGCTGGTGGCTGCCGTGTGGCCGTACCGGCGGTTGGCGCTGTTGCGGCGCCTCACGGTGCTGCCATTCGCCGGGCTGCTTTACCCGGCCTGGTTGGGTGCCGCAGCCGCTGGCTGCTGGGGCTGGGGCAGCAGTTGGGTGCAGATCCCCGAAGCTGCGCTGCTCGTGCTTGCCACCATCTGCCTCGCGCACGCGCTCACTGTCCTCTCGGGGCATTGGTCTGTGCACGCGCATTGCGCGCTCACCTGCACCCCGGAGTACGACCCCAGCAAAGCGACCTTTGTGAAGGTGGTGCCAACCCCCAACAATGGCTCCACGGAGCTCGTGGCCCTGCACCGCAATGAGGGCGAAGACGGGCTTGAGGTGCTGTCCTTCGAATTCCAGAAGATCAAGTATTCCTACGATGCCCTGGAGAAGAAGCAGTTTCTCCCCGTGGCCTTTCCTGTGGGAAACGCCTTCTCATACTATCAGAGCAACAGAGGCTTCCAGGAAGACTCAGAGATCCGAGCAGCTGAGAAGAAATTTGGGAGCAACAAGGCCGAGATGGTGGTGCCTGACTTCTCGGAGCTTTTCAAGGAGAGAGCCACAGCCCCCTTCTTTGTATTTCAGGCGTTCTGTGTGGGGCTCTGGTGCCTGGATGAGTACTGGTACTACAGCGTCTTTACGCTATCCATGCTGGTGGCGTTCGAGGCCTCGCTGGTGCAGCAGCAGATGCGGAACATGTCGGAGATCCGGAAGATGGGCAACAAGCCCCACATGATCCAGGTCTACCGAAGCCGCAAGTGGAGGCCCATTGCCAGTGATGAGATCGTACCAGGGGACATCGTCTCCATCGGCCGCTCCCCACAGGAGAACCTGGTGCCATGTGACGTGCTTCTGCTGCGAGGCCGCTGCATCGTAGACGAGGCCATGCTCACGGGGGAGTCCGTGCCACAGATGAAGGAGCCCATCGAAGACCTCAGCCCAGACCGGGTGCTGGACCTCCAGGCTGATTCCCGGCTGCACGTCATCTTCGGGGGCACCAAGGTGGTGCAGCACATCCCCCCACAGAAAGCCACCACGGGCCTGAAGCCGGTTGACAGCGGGTGCGTGGCCTACGTCCTGCGGACCGGATTCAACACATCCCAGGGCAAGCTGCTGCGCACCATCCTCTTCGGGGTCAAGAGGGTGACTGCGAACAACCTGGAGACCTTCATCTTCATCCTCTTCCTCCTGGTGTTTGCCATCGCTGCAGCTGCCTATGTATGGATTGAAGGTACCAAGGACCCCAGCCGGAACCGCTACAAGCTGTTTCTGGAGTGCACCCTGATCCTCACCTCGGTCGTGCCTCCTGAGCTGCCCATCGAGCTGTCCCTGGCCGTCAACACCTCCCTCATCGCCCTGGCCAAGCTCTACATGTACTGCACAGAGCCCTTCCGGATCCCCTTTGCTGGCAAGGTCGAGGTGTGCTGCTTTGACAAGACGGGGACGTTGACCAGTGACAGCCTGGTGGTGCGCGGTGTGGCCGGGCTGAGAGACGGGAAGGAGGTGACCCCAGTGTCCAGCATCCCTGTAGAAACACACCGGGCCCTGGCCTCGTGCCACTCGCTCATGCAGCTGGACGACGGCACCCTCGTGGGTGACCCTCTAGAGAAGGCCATGCTGACGGCCGTGGACTGGACGCTGACCAAAGATGAGAAAGTATTCCCCCGAAGTATTAAAACTCAGGGGCTGAAAATTCACCAGCGCTTTCATTTTGCCAGTGCCCTGAAGCGAATGTCCGTGCTTGCCTCGTATGAGAAGCTGGGCTCCACCGACCTTTGTTACATCGCGGCCGTGAAGGGGGCCCCCGAAACTCTGCACTCCATGGCCCGGGAGGTCAAGCGGGAGGCCCTGGAGTGCAGCCTCAAGTTCGTCGGCTTCATTGTGGTCTCCTGCCCGCTCAAGGCTGACTCGAAGGCCGTGATCCGGGAGATCCAGAATGCGTCCCACCGGGTGTTCATGATCACGGGAGACAACCCGCTCACTGCATGCCACGTGGCCCAGGAGCTGCACTTCATTGAAAAGGCCCACACGCTGATCCTGCAGCCTCCCTCCGAGAAAGGCCGGCAGTGCGAGTGGCGCTCCATTGACGGCAGCATCGTGCTGCCCCTGGCCCGGGGCTCCCCAAAGGCACTGGCCCTGGAGTACGCACTGTGCCTCACAGGCGACGGCTTGGCCCACCTGCAGGCCACCGACCCCCAGCAGCTGCTCCGCCTCATCCCCCATGTGCAGGTGTTCGCCCGTGTGGCTCCCAAGCAGAAGGAGTTTGTCATCACCAGCCTGAAGGAGCTGGGCTACGTGACCCTCATGTGTGGGGATGGCACCAACGACGTGGGCGCCCTGAAGCATGCTGACGTGGGTGTGGCGCTCTTGGCCAATGCCCCTGAGCGGGTTGTCGAGCGGCGACGGCGGCCCCGGGACAGCCCAACCCTGAGCAACAGTGGCATCAGAGCCACCTCCAGGACAGCCAAGCAGCGGTCGGGGCTCCCTCCCTCCGAGGAGCAGCCAACCTCCCAGAGGGACCGCCTGAGCCAGGTGCTGCGAGACCTCGAGGACGAGAGTACGCCCATTGTGAAACTGGGGGATGCCAGCATCGCAGCACCCTTCACCTCCAAGCTCTCATCCATCCAGTGCATCTGCCACGTGATCAAGCAGGGCCGCTGCACGCTGGTGACCACGCTACAGATGTTCAAGATCCTGGCGCTCAATGCCCTCATCCTGGCCTACAGCCAGAGCGTCCTCTACCTGGAGGGAGTCAAGTTCAGTGACTTCCAGGCCACCCTACAGGGGCTGCTGCTGGCCGGCTGCTTCCTCTTCATCTCCCGTTCCAAGCCCCTCAAGACCCTCTCCCGAGAACGGCCCCTGCCCAACATCTTCAACCTGTACACCATCCTCACCGTCATGCTCCAGTTCTTTGTGCACTTCCTGAGCCTTGTCTACCTGTACCGTGAGGCCCAGGCCCGGAGCCCCGAGAAGCAGGAGCAGTTCGTGGACTTGTACAAGGAGTTTGAGCCAAGCCTGGTCAACAGCACCGTCTACATCATGGCCATGGCCATGCAGATGGCCACCTTCGCCATCAATTACAAAGGCCCGCCCTTCATGGAGAGCCTGCCCGAGAACAAGCCCCTGGTGTGGAGTCTGGCAGTTTCACTCCTGGCCATCATTGGCCTGCTCCTCGGCTCCTCGCCCGACTTCAACAGCCAGTTTGGCCTCGTGGACATCCCTGTGGAGTTCAAGCTGGTCATTGCCCAGGTCCTGCTCCTGGACTTCTGCCTGGCGCTCCTGGCCGACCGCGTCCTGCAGTTCTTCCTGGGGACCCCGAAGCTGAAAGTGCCTTCCTGAGATGGCAGTNOV66c, SNP13380762 ofSEQ ID NO: 990MW at 128721.4kDCG57562-02, Protein SequenceSNP Pos: 2511167 aaSNP Change: Val to AlaMAAAAAVGNAVPCGARPCGVRPDGQPKPGPQPRALLAAGPALIANGDELVAAVWPYRRLALLRRLTVLPFAGLLYPAWLGAAAAGCWGWGSSWVQIPEAALLVLATICLAHALTVLSGHWSVHAHCALTCTPEYDPSKATFVKVVPTPNNGSTELVALHRNEGEDGLEVLSFEFQKIKYSYDALEKKQFLPVAFPVGNAFSYYQSNRGFQEDSEIRAAEKKFGSNKAEMVVPDFSELFKERATAPFFVFQAFCVGLWCLDEYWYYSVFTLSMLVAFEASLVQQQMRNMSEIRKMGNKPHMIQVYRSRKWRPIASDEIVPGDIVSIGRSPQENLVPCDVLLLRGRCIVDEANLTGESVPQMKEPIEDLSPDRVLDLQADSRLHVIFGGTKVVQHIPPQKATTGLKPVDSGCVAYVLRTGFNTSQGKLLRTILFGVKRVTANNLETFIFILFLLVFAIAAAAYVWIEGTKDPSRNRYKLFLECTLILTSVVPPELPIELSLAVNTSLIALAKLYMYCTEPFRIPFAGKVEVCCFDKTGTLTSDSLVVRGVAGLRDGKEVTPVSSIPVETHRALASCHSLMQLDDGTLVGDPLEKAMLTAVDWTLTKDEKVFPRSIKTQGLKIHQRFHFASALKRMSVLASYEKLGSTDLCYIAAVKGAPETLHSMAREVKREALECSLKFVGFIVVSCPLKADSKAVIREIQNASHRVFMITGDNPLTACHVAQELHFIEKAHTLILQPPSEKGRQCEWRSIDGSIVLPLARGSPKALALEYALCLTGDGLAHLQATDPQQLLRLIPHVQVFARVAPKQKEFVITSLKELGYVTLMCGDGTNDVGALKHADVGVALLANAPERVVERRRRPRDSPTLSNSGIRATSRTAKQRSGLPPSEEQPTSQRDRLSQVLRDLEDESTPIVKLGDASIAAPFTSKLSSIQCICHVIKQGRCTLVTTLQMFKILALNALILAYSQSVLYLEGVKFSDFQATLQGLLLAGCFLFISRSKPLKTLSRERPLPNIFNLYTILTVMLQFFVHFLSLVYLYREAQARSPEKQEQFVDLYKEFEPSLVNSTVYIMAMANQMATFAINYKGPPFMESLPENKPLVWSLAVSLLAIIGLLLGSSPDFNSQFGLVDIPVEFKLVIAQVLLLDFCLALLADRVLQFFLGTPKLKVPSSEQ ID NO: 9913517 bpNOV66d, SNP13380787 ofORF Start: ATG at 5ORF Stop: TGA at 3506CG57562-02, DNA SequenceSNP Pos: 2732SNP Change: C to AAAAGATGGCGGCAGCGGCGGCGGTGGGCAACGCGGTGCCCTGCGGGGCCCGGCCTTGCGGGGTCCGGCCTGACGGGCAGCCCAAGCCCGGGCCGCAGCCGCGCGCGCTCCTTGCCGCCGGGCCGGCGCTCATAGCGAACGGTGACGAGCTGGTGGCTGCCGTGTGGCCGTACCGGCGGTTGGCGCTGTTGCGGCGCCTCACGGTGCTGCCATTCGCCGGGCTGCTTTACCCGGCCTGGTTGGGTGCCGCAGCCGCTGGCTGCTGGGGCTGGGGCAGCAGTTGGGTGCAGATCCCCGAAGCTGCGCTGCTCGTGCTTGCCACCATCTGCCTCGCGCACGCGCTCACTGTCCTCTCGGGGCATTGGTCTGTGCACGCGCATTGCGCGCTCACCTGCACCCCGGAGTACGACCCCAGCAAAGCGACCTTTGTGAAGGTGGTGCCAACCCCCAACAATGGCTCCACGGAGCTCGTGGCCCTGCACCGCAATGAGGGCGAAGACGGGCTTGAGGTGCTGTCCTTCGAATTCCAGAAGATCAAGTATTCCTACGATGCCCTGGAGAAGAAGCAGTTTCTCCCCGTGGCCTTTCCTGTGGGAAACGCCTTCTCATACTATCAGAGCAACAGAGGCTTCCAGGAAGACTCAGAGATCCGAGCAGCTGAGAAGAAATTTGGGAGCAACAAGGCCGAGATGGTGGTGCCTGACTTCTCGGAGCTTTTCAAGGAGAGAGCCACAGCCCCCTTCTTTGTATTTCAGGTGTTCTGTGTGGGGCTCTGGTGCCTGGATGAGTACTGGTACTACAGCGTCTTTACGCTATCCATGCTGGTGGCGTTCGAGGCCTCGCTGGTGCAGCAGCAGATGCGGAACATGTCGGAGATCCGGAAGATGGGCAACAAGCCCCACATGATCCAGGTCTACCGAAGCCGCAAGTGGAGGCCCATTGCCAGTGATGAGATCGTACCAGGGGACATCGTCTCCATCGGCCGCTCCCCACAGGAGAACCTGGTGCCATGTGACGTGCTTCTGCTGCGAGGCCGCTGCATCGTAGACGAGGCCATGCTCACGGGGGAGTCCGTGCCACAGATGAAGGAGCCCATCGAAGACCTCAGCCCAGACCGGGTGCTGGACCTCCAGGCTGATTCCCGGCTGCACGTCATCTTCGGGGGCACCAAGGTGGTGCAGCACATCCCCCCACAGAAAGCCACCACGGGCCTGAAGCCGGTTGACAGCGGGTGCGTGGCCTACGTCCTGCGGACCGGATTCAACACATCCCAGGGCAAGCTGCTGCGCACCATCCTCTTCGGGGTCAAGAGGGTGACTGCGAACAACCTGGAGACCTTCATCTTCATCCTCTTCCTCCTGGTGTTTGCCATCGCTGCAGCTGCCTATGTATGGATTGAAGGTACCAAGGACCCCAGCCGGAACCGCTACAAGCTGTTTCTGGAGTGCACCCTGATCCTCACCTCGGTCGTGCCTCCTGAGCTGCCCATCGAGCTGTCCCTGGCCGTCAACACCTCCCTCATCGCCCTGGCCAAGCTCTACATGTACTGCACAGAGCCCTTCCGGATCCCCTTTGCTGGCAAGGTCGAGGTGTGCTGCTTTGACAAGACGGGGACGTTGACCAGTGACAGCCTGGTGGTGCGCGGTGTGGCCGGGCTGAGAGACGGGAAGGAGGTGACCCCAGTGTCCAGCATCCCTGTAGAAACACACCGGGCCCTGGCCTCGTGCCACTCGCTCATGCAGCTGGACGACGGCACCCTCGTGGGTGACCCTCTAGAGAAGGCCATGCTGACGGCCGTGGACTGGACGCTGACCAAAGATGAGAAAGTATTCCCCCGAAGTATTAAAACTCAGGGGCTGAAAATTCACCAGCGCTTTCATTTTGCCAGTGCCCTGAAGCGAATGTCCGTGCTTGCCTCGTATGAGAAGCTGGGCTCCACCGACCTTTGTTACATCGCGGCCGTGAAGGGGGCCCCCGAAACTCTGCACTCCATGGCCCGGGAGGTCAAGCGGGAGGCCCTGGAGTGCAGCCTCAAGTTCGTCGGCTTCATTGTGGTCTCCTGCCCGCTCAAGGCTGACTCGAAGGCCGTGATCCGGGAGATCCAGAATGCGTCCCACCGGGTGTTCATGATCACGGGAGACAACCCGCTCACTGCATGCCACGTGGCCCAGGAGCTGCACTTCATTGAAAAGGCCCACACGCTGATCCTGCAGCCTCCCTCCGAGAAAGGCCGGCAGTGCGAGTGGCGCTCCATTGACGGCAGCATCGTGCTGCCCCTGGCCCGGGGCTCCCCAAAGGCACTGGCCCTGGAGTACGCACTGTGCCTCACAGGCGACGGCTTGGCCCACCTGCAGGCCACCGACCCCCAGCAGCTGCTCCGCCTCATCCCCCATGTGCAGGTGTTCGCCCGTGTGGCTCCCAAGCAGAAGGAGTTTGTCATCACCAGCCTGAAGGAGCTGGGCTACGTGACCCTCATGTGTGGGGATGGCACCAACGACGTGGGCGCCCTGAAGCATGCTGACGTGGGTGTGGCGCTCTTGGCCAATGCCCCTGAGCGGGTTGTCGAGCGGCGACGGCGGCCCCGGGACAGCCCAACCCTGAGCAACAGTGGCATCAGAGCCACCTCCAGGACAGCCAAGCAGCGGTCGGGGCTCCCTCCCTCCGAGGAGCAGCCAACCTCCCAGAGGGACCGCCTGAGCCAGGTGCTGCGAGACCTCGAGGACGAGAGTACGACCATTGTGAAACTGGGGGATGCCAGCATCGCAGCACCCTTCACCTCCAAGCTCTCATCCATCCAGTGCATCTGCCACGTGATCAAGCAGGGCCGCTGCACGCTGGTGACCACGCTACAGATGTTCAAGATCCTGGCGCTCAATGCCCTCATCCTGGCCTACAGCCAGAGCGTCCTCTACCTGGAGGGAGTCAAGTTCAGTGACTTCCAGGCCACCCTACAGGGGCTGCTGCTGGCCGGCTGCTTCCTCTTCATCTCCCGTTCCAAGCCCCTCAAGACCCTCTCCCGAGAACGGCCCCTGCCCAACATCTTCAACCTGTACACCATCCTCACCGTCATGCTCCAGTTCTTTGTGCACTTCCTGAGCCTTGTCTACCTGTACCGTGAGGCCCAGGCCCGGAGCCCCGAGAAGCAGGAGCAGTTCGTGGACTTGTACAAGGAGTTTGAGCCAAGCCTGGTCAACAGCACCGTCTACATCATGGCCATGGCCATGCAGATGGCCACCTTCGCCATCAATTACAAAGGCCCGCCCTTCATGGAGAGCCTGCCCGAGAACAAGCCCCTGGTGTGGAGTCTGGCAGTTTCACTCCTGGCCATCATTGGCCTGCTCCTCGGCTCCTCGCCCGACTTCAACAGCCAGTTTGGCCTCGTGGACATCCCTGTGGAGTTCAAGCTGGTCATTGCCCAGGTCCTGCTCCTGGACTTCTGCCTGGCGCTCCTGGCCGACCGCGTCCTGCAGTTCTTCCTGGGGACCCCGAAGCTGAAAGTGCCTTCCTGAGATGGCAGTNOV66d, SNP13380787 ofSEQ ID NO: 992MW at 128753.4kDCG57562-02, Protein SequenceSNP Pos: 9101167 aaSNP Change: Pro to ThrMAAAAAVGNAVPCGARPCGVRPDGQPKPGPQPRALLAAGPALIANGDELVAAVWPYRRLALLRRLTVLPFAGLLYPAWLGAAAAGCWGWGSSWVQIPEAALLVLATICLAHALTVLSGHWSVHAHCALTCTPEYDPSKATFVKVVPTPNNGSTELVALHRNEGEDGLEVLSFEFQKIKYSYDALEKKQFLPVAFPVGNAFSYYQSNRGFQEDSEERAAEKKFGSNKAEMVVPDFSELFKERATAPFFVFQVFCVGLWCLDEYWYYSVFTLSMLVAFEASLVQQQMRNMSEIRKMGNKPHMIQVYRSRKWRPIASDEIVPGDIVSIGRSPQENLVPCDVLLLRGRCIVDEAMLTGESVPQMKEPIEDLSPDRVLDLQADSRLHVIFGGTKVVQHIPPQKATTGLKPVDSGCVAYVLRTGFNTSQGKLLRTILFGVKRVTANNLETFIFILFLLVFAIAAAAYVWIEGTKDPSRNRYKLFLECTLILTSVVPPELPIELSLAVNTSLIALAKLYMYCTEPFRIPFAGKVEVCCFDKTGTLTSDSLVVRGVAGLRDGKEVTPVSSIPVETHRALASCHSLMQLDDGTLVGDPLEKAMLTAVDWTLTKDEKVFPRSIKTQGLKIHQRFHFASALKRMSVLASYEKLGSTDLCYIAAVKGAPETLHSMAREVKREALECSLKFVGFIVVSCPLKADSKAVIREIQNASHRVFMITGDNPLTACHVAQELHFIEKAHTLILQPPSEKGRQCEWRSIDGSIVLPLARGSPKALALEYALCLTGDGLAHLQATDPQQLLRLIPHVQVFARVAPKQKEFVITSLKELGYVTLMCGDGTNDVGALKHADVGVALLANAPERVVERRRRPRDSPTLSNSGIRATSRTAKQRSGLPPSEEQPTSQRDRLSQVLRDLEDESTTIVKLGDASIAAPFTSKLSSIQCICHVIKQGRCTLVTTLQMFKILALNALILAYSQSVLYLEGVKFSDFQATLQGLLLAGCFLFISRSKPLKTLSRERPLPNIFNLYTILTVMLQFFVHFLSLVYLYREAQARSPEKQEQFVDLYKEFEPSLVNSTVYIMAMANQMATFAINYKGPPFMESLPENKPLVWSLAVSLLAIIGLLLGSSPDFNSQFGLVDIPVEFKLVIAQVLLLDFCLALLADRVLQFFLGTPKLKVPS

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 66B.

TABLE 66BComparison of the NOV66 protein sequences.NOV66aMAAAAAVGNAVPCGARPCGVRPDGQPKPGPQPRALLAAGPALIANGDELVAAVWPYRRLANOV66bMAAAAAVGNAVPCGARPCGVRPDGQPKPGRSRRALLAAGPALIANGDELVAAVWPYRRLANOV66aLLRRLTVLPFAGLLYPAWLGAAAAGCWGWGSSWVQIPEAALLVLATICLAHALTVLSGHWNOV66bLLRRLTVLPFAGLLYPAWLGAAAAGCWGWGSSWVQIPEAALLVLATICLAHALTVLSGHWNOV66aSVHAHCALTCTPEYDPSKATFVKVVPTPNNGSTELVALHRNEGEDGLEVLSFEFQKIKYSNOV66bSVRAHCALTCTPEYDPSKATFVKVVPTPNNGSTELVALHRNEGEDGLEVLSFEFQKIKYSNOV66aYDALEKKQFLPVAFPVGNAFSYYQSNRGFQEDSEIRAAEKKFGSNKAEMVVPDFSELFKENOV66bYDALEKKQFLPVAFPVGNAFSYYQSNRGFQEDSEIRAAEKKFGSNKAEMVVPDFSELFKENOV66aRATAPFFVFQVFCVGLWCLDEYWYYSVFTLSMLVAFEASLVQQQMRNMSEIRKMGNKPHMNOV66bRATAPFFVFQVFCVGLWCLDEYWYYSVFTLSMLVAFEASLVQQQMRNMSEIRKMGNKPHMNOV66aIQVYRSRKWRPIASDEIVPGDIVSIGRSPQENLVPCDVLLLRGRCIVDEANLTGESVPQMNOV66bIQVYRSRKWRPIASDEIVPGDIVSIGRSPQENLVPCDVLLLRGRCIVDEAMLTGESVPQMNOV66aKEPIEDLSPDRVLDLQADSRLHVIFGGTKVVQHIPPQKATTGLKPVDSGCVAYVLRTGFNNOV66bKEPIEDLSPDRVLDLQADSRLHVIFGGTKVVQHIPPQKATTGLKPVDSGCVAYVLRTGFNNOV66aTSQGKLLRTILFGVKRVTANNLETFIFILFLLVFAIAAAAYVWIEGTKDPSRNRYKLFLENOV66bTSQGKLLRTILFGVKRVTANNLETFIFILFLLVFAIAAAAYVWIEGTKDPSRNRYKLFLENOV66aCTLILTSVVPPELPIELSLAVNTSLIALAKLYMYCTEPFRIPFAGKVEVCCFDKTGTLTSNOV66bCTLILTSVVPPELPIELSLAVNTSLIALAKLYMYCTEPFRIPFAGKVEVCCFDKTGTLTSNOV66aDSLVVRGVAGLRDGKEVTPVSSIPVETHRALASCHSLMQLDDGTLVGDPLEKAMLTAVDWNOV66bDSLVVRGVAGLRDGKEVTPVSSIPVETHRALASCHSLMQLDDGTLVGDPLEKAMLTAVDWNOV66aTLTKDEKVFPRSIKTQGLKIHQRFHFASALKRMSVLASYEKLGSTDLCYIAAVKGAPETLNOV66bTLTKDEKVFPRSIKTQGLKIHQRFHFASALKRMSVLASYEKLGSTDLCYIAAVKGAPETLNOV66aHSM-------------------------------------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(SEQ ID NO: 986)NOV66b(SEQ ID NO: 988)

Further analysis of the NOV66a protein yielded the following properties shown in Table 66C.

TABLE 66CProtein Sequence Properties NOV66aSignalP analysis:Cleavage site between residues 16 and 17PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 15; peak value 7.85PSG score: 3.45GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −4.35possible cleavage site: between 46 and 47>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 11INTEGRAL Likelihood = −7.38 Transmembrane 100-116INTEGRAL Likelihood = −2.23 Transmembrane 243-259INTEGRAL Likelihood = −0.16 Transmembrane 265-281INTEGRAL Likelihood = −11.94 Transmembrane 446-462INTEGRAL Likelihood = 0.10 Transmembrane 493-509INTEGRAL Likelihood = −0.64 Transmembrane 672-688INTEGRAL Likelihood = −0.69 Transmembrane 944-960INTEGRAL Likelihood = −1.38 Transmembrane 978-994INTEGRAL Likelihood = −3.61 Transmembrane 1017-1033INTEGRAL Likelihood = −9.45 Transmembrane 1097-1113INTEGRAL Likelihood = −8.65 Transmembrane 1134-1150PERIPHERAL Likelihood = 1.01 (at 67)ALOM score: −11.94 (number of TMSs: 11)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 107Charge difference: 3.0 C( 2.0) - N(−l.0)C > N: C-terminal side will be inside>>> Caution: Inconsistent mtop result with signal peptide>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment (75):2.14Hyd Moment (95):0.67G content:3D/E content:1S/T content:0Score: −5.79Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 43 PRA|LLNUCDISC: discrimination of nuclear localization signalspat4: RRRR (5) at 855pat4: RRRP (4) at 856pat4: RRPR (4) at 857pat7: nonebipartite: RKMGNKPHMIQVYRSRK at 292content of basic residues: 10.4%NLS Score: 0.83KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: LKVPSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):77.8%: endoplasmic reticulum11.1%: mitochondrial11.1%: vacuolar>> prediction for CG57562-02 is end (k = 9)

A search of the NOV66a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 66D.

TABLE 66DGeneseq Results for NOV66aNOV66aIdentities/Residues/Similarities forEx-GeneseqProtein/Organism/LengthMatchthe MatchedpectIdentifier[Patent #, Date]ResiduesRegionValueAAU91186Human HEAT-3 polypeptide - 1 . . . 11671165/1204 (96%)0.0Homo sapiens, 1204 aa. 1 . . . 12041165/1204 (96%)[WO200216591-A2, 28-Feb.-2002]AAE16780Human transporter and ion 1 . . . 11671159/1204 (96%)0.0channel-17 (TRIGH-17) protein - 1 . . . 11971159/1204 (96%)Homo sapiens, 1197 aa.[WO200192304-A2, 06-Dec.-2001]ABG30096Novel human diagnostic protein328 . . . 1167 829/915 (90%)0.0#30087 - Homo sapiens, 914 aa. 7 . . . 914 830/915 (90%)[WO200175067-A2, 11-Oct.-2001]AAB42279Human ORFX ORF2043418 . . . 1167 734/789 (93%)0.0polypeptide sequence SEQ ID 1 . . . 789 737/789 (93%)NO:4086 - Homo sapiens, 789aa. [WO200058473-A2, 05-Oct.-2000]AAM93412Human polypeptide, SEQ ID633 . . . 1167 530/572 (92%)0.0NO: 3024 - Homo sapiens, 572 1 . . . 572 530/572 (92%)aa. [EP1130094-A2, 05-Sep.-2001]

In a BLAST search of public sequence databases, the NOV66a protein was found to have homology to the proteins shown in the BLASTP data in Table 66E.

TABLE 66EPublic BLASTP Results for NOV66aNOV66aIdentities/ProteinResidues/Similarities forEx-AccessionMatchthe MatchedpectNumberProtein/Organism/LengthResiduesPortionValueQ9HD20Probable cation-transporting 1..11671166/1204 (96%)0.0ATPase 2 (EC 3.6.3.-) (CGI- 1 . . . 12041166/1204 (96%)152) - Homo sapiens (Human),1204 aa.CAD29018Sequence 8 from Patent 1 . . . 11671165/1204 (96%)0.0WO0216591 - Homo sapiens 1 . . . 12041165/1204 (96%)(Human), 1204 aa.Q9EPE9Probable cation-transporting 5 . . . 11671103/1200 (91%)0.0ATPase 2 (EC 3.6.3.-) (CATP) - 2 . . . 12001127/1200 (93%)Mus musculus (Mouse), 1200aa.Q9VKJ6BCDNA:GH06032 protein - 98 . . . 1164 594/1123 (52%)0.0Drosophila melanogaster (Fruit105 . . . 1219 770/1123 (67%)fly), 1225 aa.Q8NC73Hypothetical protein FLJ90439 -633 . . . 1167 530/572 (92%)0.0Homo sapiens (Human), 572 1 . . . 572 530/572 (92%)aa.

PFam analysis indicates that the NOV66a protein contains the domains shown in the Table 66F.

TABLE 66FDomain Analysis of NOV66aIdentities/NOV66aSimilaritiesMatchfor theRegionMatched RegionExpect ValueE1-E2_ATPase266..511 62/284 (22%)7.4e-05166/284 (58%)Hydrolase527 . . . 848 35/327 (11%)2.8e-06199/327 (61%)

Example 67

The NOV67 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 67A.

TABLE 67ANOV67 Sequence AnalysisNOV67a, CG57758-03SEQ ID NO: 9933147 bpDNA SequenceORF Start: ATG at 2ORF Stop: TAG at 1706GATGGCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTGCCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGGCCAAGGAGCTGCCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCTCCAGTTTGTTTACATGAGATTCAATTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGTTGGGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGAAAGGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGTCTCGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCTCCTTTGCCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAGGTTGCTGACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTGAGACTTAGGAAGAGCCACAAGACCACACACACAGCCCTTACCCTCCTCAGGACTACCGAACCTTCTGGCACACCTTGTACAGAGTTTTGGGGTTCACACCCCAAAATGACCCAACGATGTCCACACACCACCAAAACCCAGCCAATGGGCCACCTCTTCCTCCAAGCCCAGATGCAGAGATGGTCATGGGCAGCTGGAGGGTAGGCTCAGAAATGAAGGGAACCCCTCAGTGGGCTGCTGGACCCATCTTTCCCAAGCCTTGCCATTATCTCTGTGAGGGAGGCCAGGTAGCCGAGGGATCAGGATGCAGGCTGCTGTACCCGCTCTGCCTCAAGCATCCCCCACACAGGGCTCTGGTTTTCACTCGCTTCGTCCTAGATAGTTTAAATGGGAATCGGATCCCCTGGTTGAGAGCTAAGACAACCACCTACCAGTGCCCATGTCCCTTCCAGCTCACCTTGAGCAGCCTCAGATCATCTCTGTCACTCTGGAAGGGACACCCCAGCCAGGGACGGAATGCCTGGTCTTGAGCAACCTCCCACTGCTGGAGTGCGAGTGGGAATCAGAGCCTCCTGAAGCCTCTGGGAACTCCTCCTGTGGCCACCACCAAAGGATGAGGAATCTGAGTTGCCAACTTCAGGACGACACCTGGCTTGCCACCCACAGTGCACCACAGGCCAACCTACGCCCTTCATCACTTGGTTCTGTTTTAATCGACTGGCCCCCTGTCCCACCTCTCCAGTGAGCCTCCTTCAACTCCTTGGTCCCCTGTTGTCTGGGTCAACATTTGCCGAGACGCCTTGGCTGGCACCCTCTGGGGTCCCCCTTTTCTCCCAGGCAGGTCATCTTTTCTGGGAGATGCTTCCCCTGCCATCCCCAAATAGCTAGGATCACACTCCAAGTATGGGCAGTGATGGCGCTCTGGGGGCCACAGTGGGCTATCTAGGCCCTCCCTCACCTGAGGCCCAGAGTGGACACAGCTGTTAATTTCCACTGGCTATGCCACTTCAGAGTCTTTCATGCCAGCGTTTGAGCTCCTCTGGGTAAAATCTTCCCTTTGTTGACTGGCCTTCACAGCCATGGCTGGTGACAACAGAGGATCGTTGAGATTGAGCAGCGCTTGGTGATCTCTCAGCAAACAACCCCTGCCCGTGGGCCAATCTACTTGAAGTTACTCGGACAAAGACCCCAAAGTGGGGCAACAACTCCAGAGAGGCTGTGGGAATCTTCAGAAGCCCCCCTGTAAGAGACAGACATGAGAGACAAGCATCTTCTTTCCCCCGCAAGTCCATTTTATTTCCTTCTTGTGCTGCTCTGGAAGAGAGGCAGTAGCAAAGAGATGAGCTCCTGGATGGCATTTTCCAGGGCAGGAGAAAGTATGAGAGCCTCAGGAAACCCCATCAAGGACCGAGTATGTGTCTGGTTCCTTTGGTGGTTGGCTTCTGGCNOV67a, CG57758-03Protein SequenceSEQ ID NO: 994568 aaMW at 63061.4kDMASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQOEDQERKRLCKANTLCICYAASIGGTATLTGTGPNVVLLGQNNELFPDSKDLVNFASWFAFAFPNMLVNLLFAWLWLQFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIETNOV66b, 308537854SEQ ID NO: 9951729 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCAGATCTCCCACCATGGCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTGCCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGGCCAAGGAGCTGCCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCTCCAGTTTGTTTACATGAGATTCAATTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGTTGGGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGAAAGGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGTCTCGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCTCCTTTGCCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAGGTTGCTGACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTGAGACTCTCGAGGGCNOV67b, 308537854Protein SequenceSEQ ID NO: 996576 aaMW at 63903.4kDTRSPTMASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLSMWISNTATTANNVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLGQMNELFPDSKDLVNFASWFAFAFPPNMLVMLLFAWLWLQFVYNRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIETLEGNOV67c, CG57758-01SEQ ID NO: 9971790 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAG at 1720TCTCCCTCCCGCGCGATGGCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGGTCAGTTGTGCCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGGCCAAGGAGCTGCCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCTCCAGTTTGTTTACATGTTCTCCAGTTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGCTGGGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGGTAAGTCTCCTGTTCTGATCGCCCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGTCTCGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCTCCTTTGCCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAGGTTGCTGACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTGAGACTTAGGAAGAGCCACAAGACCACACACACAGCCCTTACCCTCCTCAGGACTACCGAACCTTCTGGCACACCTTNOV67c, CG57758-01Protein SequenceSEQ ID NO: 998568 aaMW at 62592.9kDMASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVSCAYVIILMAIYWCTEVIPLAVTSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLSMWISNTATTANMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNNLVMLLFAWLWLQFVYMFSSFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIETNOV67d, CG57758-02SEQ ID NO: 9991899 bpDNA SequenceORF Start: ATG at 31ORF Stop: TAG at 1879CGTCTCGCCCGCCAGTCTCCCTCCCGCGCGATGGCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGGTCAGTTGCTGTGCCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGGGACAAGGTACCACAATAAACAACCTGAATGCACTGGAGGATGATACAGTGAAAGCAGTACTAGGAGGAAAGTGTGTAGCTATAATAAGCACTTACGTCAAAAAAGTAGAAAAACTTCAAATAAACAATCTAATGACACCTCTTAAAAAACTAGAAAAGCAAGAGCAACAGGACCTAGGGCCTGGCATCAGGCCTCAGGACTCTGCCCAGTGCCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCTCCAGTTTGTTTACATGTTCTCCAGTTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGCTGGGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTCAGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGGTAAGTCTCCTGTTCTGATCGCCCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGTCTCGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCTCCTTTGCCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAGGTTGCTGACATGGTAAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTGAGACTTAGGAAGAGCCACAAGACCACNOV67d, CG57758-02Protein SequenceSEQ ID NO: 1000616 aaMW at 67816.9kDMASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVSCCAYVIILMAIYWCTEVIPLAVTSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARIMLGFMGVTALLSMWISNTATTANMVPIVEAILQQMEATSAATEAGLEGQGTTINNLNALEDDTVKAVLGGKCVAIISTYVKKVEKLQINNLMTPLKKLEKQEQQDLGPGIRPQDSAQCQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMFSSFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKSVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIETNOV67e, CG57758-04SEQ ID NO: 10011606 bpDNA SequenceORF Start: ATG at 2ORF Stop: TAG at 1568GATGGCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTGCCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGGCCAAGGAGCTGCCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCTCCAGTTTGTTTACATGAGATTCAATTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGTTGGGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGAAAGGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTGAGACTTAGGAAGAGCCACAAGACCACACACATAGCCCTTACCCTNOV67e, CG57758-04Protein SequenceSEQ ID NO: 1002522 aaMW at 58109.6kDMASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRLCKANTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIETNOV67f, CG57758-05SEQ ID NO: 10031781 bpDNA SequenceORF Start: ATG at 2ORF Stop: TGA at 1550GATGGCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTGCCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGGCCAAGGAGCTGCCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCTCCAGTTTGTTTACATGAGATTCAATTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGTTGGGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGAAAGGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGAATCACGTCCCCAAGAGCTTCTGTGTTCTGTACGGTGATGTTGCAGTGCTGTCTTTCCGCAGTCTCGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCTCCTTTGCCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAGGTTGCTGACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTGAGACTTAGGAAGAGCCACANOV67f, CG57758-05Protein SequenceSEQ ID NO: 1004516 aaMW at 57173.5kDMASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLSMWISNTATTANMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMNHVPKSFCVLYGDVAVLSFRSLAPSASIRCTSCCPVP

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 67B.

TABLE 67BComparison of the NOV67 protein sequences.NOV67a-----MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPNOV67bTRSPTMASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPNOV67c-----MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVS-CAYVIILMAIYWCTEVIPNOV67d-----MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVSCCAYVIILMAIYWCTEVIPNOV67e-----MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPNOV67f-----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-----------------------------------------AKELPGSQVIFEGPTLGNOV67bGK-----------------------------------------AKELPGSQVIFEGPTLGNOV67cGK-----------------------------------------AKELPGSQVIFEGPTLGNOV67dTINNLNALEDDTVKAVLGGKCVAIISTYVKKVEKLQINNLMTPLKKLEKQEQQDLGPGIRNOV67eGK-----------------------------------------AKELPGSQVIFEGPTLGNOV67fGK-----------------------------------------AKELPGSQVIFEGPTLGNOV67a-Q-----QEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNOV67b-Q-----QEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNOV67c-Q-----QEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNOV67dPQDSAQCQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNOV67e-Q-----QEDQERKRLCKANTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNOV67f-Q-----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-TPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASNOV67bIVPSQKPKFNFRSQTEEERK-TPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASNOV67cIVPSQKPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASNOV67dIVPSQKPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASNOV67eIVPSQKPKFNFRSQTEEERK-TPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASNOV67fIVPSQKPKFNFRSQTEEERK-TPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASNOV67aGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSR---SIGNOV67bGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSR---SIGNOV67cGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSR---SIGNOV67dGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSR---SIGNOV67eGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMVKTGVIMNNOV67fGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMN------HNOV67aLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNOV67bLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNOV67cLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNOV67dLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNOV67eIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIET-------------------------NOV67fVPKSFCVLYGD----VAVLSFRSLAPSASIRCTSCCPVP---------------------NOV67aNTWGRAIFDLDHFPDWANVTHIET---NOV67bNTWGRAIFDLDHFPDWANVTHIETLEGNOV67cNTWGRAIFDLDHFPDWANVTHIET---NOV67dNTWGRAIFDLDHFPDWANVTHIET---NOV67e---------------------------NOV67f---------------------------NOV67a(SEQ ID NO: 994)NOV67b(SEQ ID NO: 996)NOV67c(SEQ ID NO: 998)NOV67d(SEQ ID NO: 1000)NOV67e(SEQ ID NO: 1002)NOV67f(SEQ ID NO: 1004)

Further analysis of the NOV67a protein yielded the following properties shown in Table 67C.

TABLE 67CProtein Sequence Properties NOV67aSignalP analysis:Cleavage site between residues 39 and 40PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 1; neg.chg 0H-region: length 1; peak value 5.97PSG score: 1.57GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −2.36possible cleavage site: between 30 and 31>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 11INTEGRAL Likelihood = −12.21Transmembrane 14-30INTEGRAL Likelihood = −1.81Transmembrane 35-51INTEGRAL Likelihood = −4.99Transmembrane 53-69INTEGRAL Likelihood = −1.75Transmembrane 124-140INTEGRAL Likelihood = −3.72Transmembrane 261-277INTEGRAL Likelihood = −8.01Transmembrane 312-328INTEGRAL Likelihood = −6.26Transmembrane 354-370INTEGRAL Likelihood = 0.21Transmembrane 405-421INTEGRAL Likelihood = −7.11Transmembrane 443-459INTEGRAL Likelihood = −1.70Transmembrane 490-506INTEGRAL Likelihood = −7.43Transmembrane 528-544PERIPHERAL Likelihood = 0.74 (at 89)ALOMscore: −12.21 (number of TMSs: 11)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 21Charge difference: −1.0 C( 2.0) - N( 3.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment (75):1.18Hyd Moment (95):3.95G content:0D/E content:1S/T content:6Score: −3.21Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 47 VRC|AYNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.7%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):66.7%: endoplasmic reticulum22.2%: mitochondrial11.1%: nuclear>> prediction for CG57758-03 is end (k = 9)

A search of the NOV67a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 67D.

TABLE 67DGeneseq Results for NOV67aNOV67aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU79946Human transporter protein1 . . . 568566/568 (99%)0.0sequence - Homo sapiens, 568 aa.1 . . . 568566/568 (99%)[US2002019028-A1, 14-Feb.-2002]AAE21181Human TRICH-25 protein - Homo1 . . . 568531/576 (92%)0.0sapiens, 539 aa. [WO200212340-1 . . . 539531/576 (92%)A2, 14-Feb.-2002]ABB82951Human SLC13A related protein1 . . . 561317/579 (54%)0.0(GenBank Identifier No.1 . . . 572423/579 (72%)GI#4506979) - Homo sapiens, 592aa. [WO200298468-A1, 12-Dec.-2002]ABB82950Human SLC13A related protein1 . . . 561317/579 (54%)0.0(GenBank Identifier No.1 . . . 572423/579 (72%)GI#2499523) - Homo sapiens, 592aa. [WO200298468-A1, 12-Dec.-2002]ABB82952Human SLC13A related protein1 . . . 563284/591 (48%)e-156(GenBank Identifier No.4 . . . 582387/591 (65%)GI#13653602) - Homo sapiens,602 aa. [WO200298468-A1, 12-Dec.-2002]

In a BLAST search of public sequence databases, the NOV67a protein was found to have homology to the proteins shown in the BLASTP data in Table 67E.

TABLE 67EPublic BLASTP Results for NOV67aNOV67aIdentities/ProteinResidues/Similarities forEx-AccessionMatchthe MatchedpectNumberProtein/Organism/LengthResiduesPortionValueAAN86530Na+−coupled citrate transporter 1 . . . 568568/568 (100%)0.0protein - Homo sapiens (Human), 1 . . . 568568/568 (100%)568 aa.Q8CJ44Sodium-coupled citrate 1 . . . 568442/572 (77%)0.0transporter - Rattus norvegicus 1 . . . 572502/572 (87%)(Rat), 572 aa.AAH44437Similar to solute carrier family 5 . . . 564331/598 (55%)0.013, member 2 - Brachydanio rerio10 . . . 605437/598 (72%)(Zebrafish) (Danio rerio), 613 aa.AA027449Sodium dicarboxylate co-11 . . . 563318/582 (54%)0.0transporter - Didelphis11 . . . 587422/582 (71%)marsupialis virginiana (NorthAmerican opossum), 605 aa.Q13183Solute carrier family 13, member 1 . . . 561317/579 (54%)0.02 (Renal sodium/dicarboxylate 1 . . . 572423/579 (72%)cotransporter)(Na(+)/dicarboxylatecotransporter 1) (NaDC-1) -Homo sapiens (Human), 592 aa.

PFam analysis indicates that the NOV67a protein contains the domains shown in the Table 67F.

TABLE 67FDomain Analysis of NOV67aIdentities/NOV67aSimilaritiesMatchfor thePfam DomainRegionMatched RegionExpect ValueDcuC30 . . . 548 88/593 (15%)0.73324/593 (55%)Na_sulph_symp 6 . . . 554159/603 (26%)2e-143423/603 (70%)

Example 68

The NOV68 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 68A.

TABLE 68ANOV68 Sequence AnalysisNOV68a, CG58504-01SEQ ID NO: 10055115 bpDNA SequenceORF Start: ATG at 327ORF Stop: TAA at 5106GAATTCCGGGAGCGGGCGGGCTGCGAGGCCGCGGGGCATGCGGGAGGCGGAGGGGTGGGACCGGGTGGCTGCGCCCATTCCACACCCGCCGAAAGCGGACACTGTCAGCTGAATCACTCCCCTTTTAGGAGGAGGGAGGGGGAAAAGGTGTCTAGCTAATTTCTGCTTAAAAAAGCACAGGAGATCGCGGGTCAGCTTTGCAGTCGCTGCCTTCTCGCGCCTGACCATGCACCCCTGCATCTTCCTGCTGGGCACAGGCGAGCGCTTTATTTCTGGAGCTGAGGGCTAAAACTTTTTTCACTTTTCTTCTCCTCAACATCTGAATCATGCCATGTGCCCAGAGGAGCTGGCTTGCAAACCTTTCCGTGGTGGCTCAGCTCCTTAACTTTGGGGCGCTTTGCTATGGGAGACAGCCTCAGCCAGGCCCGGTTCGCTTCCCGGACAGGAGGCAAGAGCATTTTATCAAGGGCCTGCCAGAATACCACGTGGTGGGTCCAGTCCGAGTAGATGCCAGTGGGCATTTTTTGTCATATGGCTTGCACTATCCCATCACGAGCAGCAGGAGGAAGAGAGATTTGGATGGCTCAGAGGACTGGGTGTACTACAGAATTTCTCACGAGGAGAAGGACCTGTTTTTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCCTCTGCCCCCCTCTGCCATCTCAGTGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGACGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAACTTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTACATCCTCACCATCATGAACATGGTCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACCAGAAAGGACATCTGTGCTGGTTTCAATCGCCCCTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTAAAAAGAAAGGCTTGAAGTCCAAGGTCATTGCCCCCGGAGTGATCTATGATGTTCACCACCAGTGCCAGCTACAATATGGACCCAATGCTACCTTCTGCCAGGAAGTAGAAAACGTCTGCCAGACACTGTGGTGCTCCGTGAAGGGCTTTTGTCGCTCTAAGCTGGACGCTGCTGCAGATGGAACTCAATGTGGTGAGAAGAAGTGGTGTATGGCAGGCAAGTGCATCACAGTGGGGAAGAAACCAGAGAGCATTCCTGGAGGCTGGGGCCGCTGGTCACCCTGGTCCCACTGTTCCAGGACCTGTGGGGCTGGAGTCCAGAGCGCAGAGAGGCTCTGCAACAACCCCGAGCCAAAGTTTGGAGGGAAATATTGCACTGGAGAAAGAAAACGCTATCGCTTGTGCAACGTCCACCCCTGTCGCTCAGAGGCACCAACATTTCGGCAGATGCAGTGCAGTGAATTTGACACTGTTCCCTACAAGAATGAACTCTACCACTGGTTTCCCATTTTTAACCCAGCACATCCTTGTGAGCTCTACTGCCGACCCATAGATGGCCAGTTTTCTGAGAAAATGCTGGATGCTGTCATTGATGGTACCCCTTGCTTTGAAGGCGGCAACAGCAGAAATGTCTGTATTAATGGCATATGTAAGATGGTTGGCTGTGACTATGAGATCGATTCCAATGCCACCGAGGATCGCTGCGGTGTGTGCCTGGGAGATGGCTCTTCCTGCCAGACTGTGAGAAAGATGTTTAAGCAGAAGGAAGGATCTGGTTATGTTGACATTGGGCTCATTCCAAAAGGAGCAAGGGACATAAGAGTGATGGAAATTGAGGGAGCTGGAAACTTCCTGGCCATCAGGAGTGAAGATCCTGAAAAATATTACCTGAATGGAGGGTTTATTATCCAGTGGAACGGGAACTATAAGCTGGCAGGGACTGTCTTTCAGTATGACAGGAAAGGAGACCTGGAAAAGCTGATGGCCACAGGTCCCACCAATGAGTCTGTGTGGATCCAGCTTCTATTCCAGGTGACTAACCCTGGCATCAAGTATGAGTACACAATCCAGAAAGATGGCCTTGACAATGATGTTGAGCAGATGTACTTCTGGCAGTACGGCCACTGGACAGAGTGCAGTGTGACCTGCGGGACAGGTATCCGCCGCCAAACTGCCCATTGCATAAAGAAGGGCCGCGGGATGGTGAAAGCTACATTCTGTGACCCAGAAACACAGCCCAATGGGAGACAGAAGAAGTGCCATGAAAAGGCTTGTCCACCCAGGTGGTGGGCAGGGGAGTGGGAAGCATGCTCGGCGACATGCGGGCCCCACGGGGAGAAGAAGCGAACCGTGCTGTGCATCCAGACCATGGTCTCTGACGAGCAGGCTCTCCCGCCCACAGACTGCCAGCACCTGCTGAAGCCCAAGACCCTCCTTTCCTGCAACAGAGACATCCTGTGCCCCTCGGACTGGACAGTGGGCAACTGGAGTGAGTGTTCTGTTTCCTGTGGTGGTGGAGTGCGGATTCGCAGTGTCACATGTGCCAAGAACCATGATGAACCTTGCGATGTGACAAGGAAACCCAACAGCCGAGCTCTGTGTGGCCTCCAGCAATGCCCTTCTAGCCGGAGAGTTCTGAAACCAAACAAAGGCACTATTTCCAATGGAAAAAACCCACCAACACTAAAGCCCGTCCCTCCACCTACATCCAGGCCCAGAATGCTGACCACACCCACAGGGCCTGAGTCTATGAGCACAAGCACTCCAGCAATCAGCAGCCCTAGTCCTACCACAGCCTCCAAAGAAGGAdACCTGGGTGGGAAACAGTGGCAAGATAGCTCAACCCAACCTGAGCTGAGCTCTCGCTATCTCATTTCCACTGGAAGCACTTCCCAGCCCATCCTCACTTCCCAATCCTTGAGCATTCAGCCAAGTGAGGAAAATGTTTCCAGTTCAGATACTGGTCCTACCTCGGAGGGAGGCCTTGTAGCTACAACAACAAGTGGTTCTGGCTTGTCATCTTCCCGCAACCCTATCACTTGGCCTGTGACTCCATTTTACAATACCTTGACCAAAGGTCCAGAAATGGAGATTCACAGTGGCTCAGGGGAAGAAAGAGAACAGCCTGAGGACAAAGATGAAAGCAATCCTGTAATATGGACCAAGATCAGAGTACCTGGAAATGACGCTCCAGTGGAAAGTACAGAAATGCCACTTGCACCTCCACTAACACCAGATCTCAGCAGGGAGTCCTGGTGGCCACCCTTCAGCACAGTAATGGAAGGACTGCTCCCCAGCCAAAGGCCCACTACTTCCGAAACTGGGACACCCAGAGTTGAGGGGATGGTTACTGAAAAGCCAGCCAACACTCTGCTCCCTCTGGGAGGAGACCACCAGCCAGAACCCTCAGGAAAGACGGCAAACCGTAACCACCTGAAACTTCCAAACAACATGAACCAAACAAAAAGTTCTGAACCAGTCCTGACTGAGGAGGATGCAACAAGTCTGATTACTGAGGGCTTTTTGCTAAATGCCTCCAATTACAAGCAGCTCACAAACGGCCACGGCTCTGCACACTGGATCGTCGGAAACTGGAGCGAGTGCTCCACCACATGTGGCCTGGGGGCCTACTGGAAAAGGGTGGAGTGCACCACCCAGATGGATTCTGACTGTGCGGCCATCCAGAGACCTGACCCTGCAAAAAGATGCCACCTCCGTCCCTGTGCTGGCTGGAAAGTGGGAAACTGGAGCAAGTGCTCCAGAAACTGCAGTGGGGGCTTCAAGATACGCGAGATTCAGTGCGTGGACAGCCGGGACCACCGGAACCTGAGGCCATTTCACTGCCAGTTCCTGGCCGGCATTCCTCCCCCATTGAGCATGAGCTGTAACCCGGAGCCCTGTGAGGCGTGGCAGGTGGAGCCTTGGAGCCAGTGCTCCAGGTCCTGTGGAGGTGGAGTTCAGGAGAGAGGAGTGTTCTGTCCAGGAGGCCTCTGTGATTGGACAAAAAGACCCACATCCACCATGTCTTGCAATGAGCACCTGTGCTGTCACTGGGCCACTGGGAACTGGGACCTGTGTTCCACTTCCTGTGGAGGTGGCTTTCAGAAGAGGATTGTCCAATGTGTGCCCTCAGAGGGCAATAAAACTGAAGACCAAGACCAATGTCTATGTGATCACAAACCCAGACCTCCAGAATTCAAAAAATGCAACCAGCAGGCCTGCAAGAAAAGTGCCGATTTACTTTGCACTAAGGACAAACTGTCAGCCAGTTTCTGCCAGACACTGAAAGCCATGAAGAAATGTTCTGTGCCCACCGTGAGGGCTGAGTGCTGCTTCTCGTGTCCCCAGACACACATCACACACACCCAAAGGCAAAGAAGGCAACGGTTGCTCCAAAAGTCAAAAGAACTCTAAGCCCAAANOV68a, CG58504-01Protein SequenceSEQ ID NO: 10061593 aaMW at 177543.9kDMPCAQRSWLANLSVVAQLLNFGALCYGRQPQPGPVRFPDRRQEHFIKGLPEYHVVGPVRVDASGHFLSYGLHYPITSSRRKRDLDGSEDWWIYRISHEEKDLFFNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESYILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPKKKGLKSKVIAPGVIYDVHHQCQLQYGPNATFCQEVENVCQTLWCSVKGFCRSKLDAAADGTQCGEKKWCMAGKCITVGKKPESIPGGWGRWSPWSHCSRTCGAGVQSAERLCNNPEPKFGGKYCTGERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVPYKNELYHWFPIFNPAHPCELYCRPIDGQFSEKMLDAVIDGTPCFEGGNSRNVCINGICKMVGCDYEIDSNATEDRCGVCLGDGSSCQTVRKMFKQKEGSGYVDIGLIPKGARDIRVMEIEGAGNFLAIRSEDPEKYYLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWIQLLFQVTNPGIKYEYTIQKDGLDNDVEQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKGRGMVKATFCDPETQPNGRQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMVSDEQALPPTDCQHLLKPKTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNHDEPCDVTRKPNSRALCGLQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTPTGPESMSTSTPAISSPSPTTASKEGDLGGKQWQDSSTQPELSSRYLISTGSTSQPILTSQSLSIQPSEENVSSSDTGPTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMEIHSGSGEEREQPEDKDESNPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSTVMEGLLPSQRPTTSETGTPRVEGMVTEKPANTLLPLGGDHQPEPSGKTANRNHLKLPNNMNQTKSSEPVLTEEDATSLITEGFLLNASNYKQLTNGHGSAHWIVGNWSECTTCGLAGAYWKRVECTTQMDSDCAAIQRPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSRDHRNLRPFHCQFLAGIPPPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVQERGVFCPGGLCDWTKRPTSTMSCNEHLCCHWATGNWDLCSTSCGGGFQKRIVQCVPSEGNKTEDQDQCLCDHKPRPPEFKKCNQQACKKSADLLCTKDKLSASFCQTLKAMKKCSVPTVRAECCFSCPQTHITHTQRQRRQRLLQKSKELNOV68b, 169648376SEQ ID NO: 10071068 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCCTCTGCCCCCCTCTGCCATCTCAGTGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGATGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAACTTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTGCATCCTCACCATCATGAACATGGTCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACCAGAAAGGACATCTGTGCTGGTTTCAATCGCCCCTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTCTCGAGNOV68b, 169648376Protein SequenceSEQ ID NO: 1008356 aaMW at 40336.9kDKLNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGMAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESCILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPLENOV68c, 169648388SEQ ID NO: 10091068 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCCTCTGCCCCCCTCTGCCATCTCAGTGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGACGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAACTTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTACATCCTCACCATCATGAACATGATCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACCAGAAAGGACATCTGTGCTGGTTTCAATCGCCCCTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTCTCGAGNOV68c, 169648388Protein SequenceSEQ ID NO: 1010356 aaMW at 40380.8kDKLNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESYILTIMNMITGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPLENOV68d, 169648365SEQ ID NO: 10111068 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCCTCTGCCCCCCTCTGCCATCICAGTGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGACGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAAATTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTACATCCTCACCATCATGAACATGGTCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACCAGAAAGGACATCTGTGCTGGTTTCAATCGCCCCTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTCTCGAGNOV68d, 169648365Protein SequenceSEQ ID NO: 1012356 aaMW at 40366.8kDKLNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESYILTINNMVTGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPLENOV68e, 284068250SEQ ID NO: 10134777 bpDNA SequenceORF Start: at 1ORF Stop: TGA at 4729AGATCTTATGGGAGACAGCCTCAGCCAGGCCCGGTTCGCTTCCCGGACAGGAGGCAAGAGCATTTTATCAAGGGCCTGCCAGAATACCACGTGGTGGGTCCAGTCCGAGTAGATGCCAGTGGGCATTTTTTGTCATATGGCTTGCACTATCCCATCACGAGCAGCAGGAGGAAGAGAGATTTGGATGGCTCAGAGGACTGGGTGTACTACAGAATTTCTCACGAGGAGAAGGACCTGTTTTTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCTTCTGCCCCCCTCTGCCATCTCAATGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGACGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAACTTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTACATCCTCACCATCATGAACATGGTCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACCAGAAAGGACATCTGTGCTGGTTTCAATCGCCCGTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTAAAAAGAAAGGCTTGAAGTCCAAGGTCATTGCCCCCGGAGTGATCTATGATGTTCACCACCAGTGCCAGCTACAATATGGACCCAATGCTACCCTCTGCCAGGAAGTAGAAAACGTCTGCCAGACACTGTGGTGCTCCGTGAAGGGCTTTTGTCGCTCTAAGCTGGACGCTGCTGCAGATGGAACTCAATGTGGTGAGAAGAAGTGGTGTATGGCAGGCAAGTGCATCACAGTGGGGAAGAAACCAGAGAGCATTCCTGGAGGCTGGGGCCGCTGGTCACCCTGGTCCCACTGTTCCAGGACCTGTGGGGCTGGAGTCCAGAGCGCAGAGAGGCTCTGCAACAACCCCGAGCCAAAGTTTGGAGGGAAATATTGCACTGGAGAAAGAAAACGCTATCGCTTGTGCAACGTCCACCCCTGTCGCTCAGAGGCACCAACATTTCGGCAGATGCAGTGCAGTGAATTTGACACTGTTCCCTACAAGAATGAACTCTACCACTGGTTTCCCATTTTTAACCCAGCACATCCTTGTGAGCTCTACTGCCGACCCATAGATGGCCAGTTTTCTGAGAAAATGCTGGATGCTGTCATTGATGGTACCCCTTGCTTTGAAGGCGGCAACAGCAGAAATGTCTGTATTAATGGCATATGTAAGATGGTTGGCTGTGACTATGAGATCGATTCCAATGCCACCGAGGATCGCTGCGGTGTGTGCCTGGGAGATGGCTCTTCCTGCCAGACTGTGAGAAAGATGTTTAAGCAGAAGGAAGGATCTGGTTATGTTGACATTGGGCTCATTCCAAAAGGAGCAAGGGACATAAGAGTGATGGAAATTGAGGGAGCTGGAAACTTCCTGGCCATCAGGAGTGAAGATCCTGAAAAATATTACCTGAATGGAGGGTTTATTATCCAGTGGAACGGGAACTATAAGCTGGCAGGGACTGTCTTTCAGTATGACAGGAAAGGAGACCTGGAAAAGCTGATGGCCACAGGTCCCACCAATGAGTCTGTGTGGATCCAGCTTCTATTCCAGGTGACTAACCCTGGCATCAAGTATGAGTACACAATCCAGAAAGATGGCCTTGACAATGATGTTGAGCAGCAGATGTACTTCTGGCAGTACGGCCACTGGACAGAGTGCAGTGTGACCTGCGGGACAGGTATCCGCCGCCAAACTGCCCATTGCATAAAGAAGGGCCGCGGGATGGTGAAAGCTACATTCTGTGACCCAGAAACACAGCCCAATGGGAGACAGAAGAAGTGCCATGAAAAGGCTTGTCCACCCAGGTGGTGGGCAGGGGAGTGGGAAGCATGCTCGGCGACATGCGGGCCCCACGGGGAGAAGAAGCGAACCGTGCTGTGCATCCAGACCATGGTCTCTGACGAGCAGGCTCTCCCGCCCACAGACTGCCAGCACCTGCTGAAGCCCAAGACCCTCCTTTCCTGCAACAGAGACATCCTGTGCCCCTCGGACTGGACAGTGGGCAACTGGAGTGAGTGTTCTGTTTCCTGTGGTGGTGGAGTGCGGATTCGCAGTGTCACATGTGCCAAGAACCATGATGAACCTTGCGATGTGACAAGGAAACCCAACAGCCGAGCTCTGTGTGGCCTCCAGCAATGCCCTTCTAGCCGGAGAGTTCTGAAACCAAACAAAGGCACTATTTCCAATGGAAAAAACCCACCAACACTAAAGCCCGTCCCTCCACCTACATCCAGGCCCAGAATGCTGACCACACCCACAGGGCCTGAGTCTATGAGCACAAGCACTCCAGCAATCAGCAGCCCTAGTCCTACCACAGCCTCCAAAGAAGGAGACCTGGGTGGGAAACAGTGGCAAGATAGCTCAACCCAACCTGAGCTGAGCTCTCGCTATCTCATTTCCACTGGAAGCACTTCCCAGCCCATCCTCACTTCCCAATCCTTGAGCATTCAGCCAAGTGAGGAAAATGTTTCCAGTTCAGATACTGGTCCTACCTCGGAGGGAGGCCTTGTAGCTACAACAACAAGTGGTTCTGGCTTGTCATCTTCCCGCAACCCTATCACTTGGCCTGTGACTCCATTTTACAATACCTTGACCAAAGGTCCAGAAATGGAGATTCACAGTGGCTCAGGGGAAGAAAGAGAACAGCCTGAGGACAAAGATGAAAGCAATCCTGTAATATGGACCAAGATCAGAGTACCTGGAAATGACGCTCCAGTGGAAAGTACAGAAATGCCACTTGCACCTCCACTAACACCAGATCTCAGCAGGGAGTCCTGGTGGCCACCCTTCAGCACAGTAATGGAAGGACTGCTCCCCAGCCAAAGGCCCACTACTTCCGAAACTGGGACACCCAGAGTTGAGGGGATGGTTACTGAAAAGCCAGCCAACACTCTGCTCCCTCTGGGAGGAGACCACCAGCCAGAACCCTCAGGAAAGACGGCAAACCGTAACCACCTGAAACTTCCAAACAACATGAACCAAACAAAAAGTTCTGAACCAGTCCTGACTGAGGAGGATGCAACAAGTCTGATTACTGAGGGCTTTTTGCTAAATGCCTCCAATTACAAGCAGCTCACAAACGGCCACGGCTCTGCACACTGGATCGTCGGAAACTGGAGCGAGTGCTCCACCACATGTGGCCTGGGGGCCTACTGGAGAAGGGTGGAGTGCAGCACCCAGATGGATTCTGACTGTGCGGCCATCCAGAGACCTGACCCTGCAAAAAGATGCCACCTCCGTCCCTGTGCTGGCTGGAAAGTGGGAAACTGGAGCAAGTGCTCCAGAAACTGCAGTGGGGGCTTCAAGATACGCGAGATTCAGTGCGTGGACAGCCGGGACCACCGGAACCTGAGGCCATTTCACTGCCAGTTCCTGGCCGGCATTCGTCCCCCATTGAGCATGAGCTGTAACCCGGAGCCCTGTGAGGCGTGGCAGGTGGAGCCTTGGAGCCAGTGCTCCAGGTCCTGTGGAGGTGGAGTTCAGGAGAGAGGAGTGTTCTGTCCAGGAGGCCTCTGTGATTGGACAAAAAGACCCACATCCACCATGTCTTGCAATGAGCACCTGTGCTGTCACTGGGCCACTGGGAACTGGGACCTGTGTTCCACTTCCTGTGGAGGTGGCTTTCAGAAGAGGACTGTCCAATGTGTGCCCTCAGAGGGCAATAAAACTGAAGACCAAGACCAATGTCTATGTGATCACAAACCCAGACCTCCAGAATTCAAAAAATGCAACCAGCAGGCCTGCAAGAAAAGTGCCGATTTACTTTGCACTAAGGACAAACTGTCAGCCAGTTTCTGCCAGACACTGAAAGCCATGAAGAAATGTTCTGTGCCCACCGTGAGGGCTGAGTGCTGCTTCTCGTGTCCCCAGACACACATCACACACACCCAAAGGCAAAGAAGGCAACGGTTGCTCCAAAAGTCAAAAGAACTCCTCGAGGAGTTCTTTTGACTTTTGGAGCAACCGGGCCTGGCTGAGGCTGTCTCCCATAAGATCTNOV68e, 284068250Protein SequenceSEQ ID NO: 10141576 aaMW at 175887.8kDRSYGRQPQPGPVRFPDRRQEHFIKGLPEYHVVGPVRVDASGHFLSYGLHYPITSSRRKRDLDGSEDWVYYRISHEEKDLFFNLTVNQGFLSNSYIMEKRYGNLSHVKNMASSAPLCHLNGTVLQQGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESYILTINNMVTGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPKKKGLKSKVIAPGVIYDVHHQCQLQYGPNATLCQEVENVCQTLWCSVKGFCRSKLDAAADGTQCGEKKWCMAGKCITVGKKPESIPGGWGRWSPWSHCSRTCGAGVQSAERLCNNPEPKFGGKYCTGERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVPYKNELYHWFPIFNPAHPCELYCRPIDGQFSEKMLDAVIDGTPCFEGGNSRNVCINGICKMVGCDYEIDSNATEDRCGVCLGDGSSCQTVRKMFKQKEGSGYVDIGLIPKGARDIRVMEIEGAGNFLAIRSEDPEKYYLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWIQLLFQVTNPGIKYEYTIQKDGLDNDVEQQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKGRGMVKATFCDPETQPNGRQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMVSDEQALPPTDCQHLLKPKTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNHDEPCDVTRKPNSRALCGLQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTPTGPESMSTSTPAISSPSPTTASKEGDLGGKQWQDSSTQPELSSRYLISTGSTSQPILTSQSLSIQPSEENVSSSDTGPTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMEIHSGSGEEREQPEDKDESNPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSTVMEGLLPSQRPTTSETGTPRVEGMVTEKPANTLLPLGGDHQPEPSGKTANRNHLKLPNNMNQTKSSEPVLTEEDATSLITEGFLLNASNYKQLTNGHGSAHWIVGNWSECSTTCGLGAYWRRVECSTQMDSDCAAIQRPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSRDHRNLRPFHCQFLAGIPPPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVQERGVFCPGGLCDWTKRPTSTMSCNEHLCCHWATGNWDLCSTSCGGGFQKRTVQCVPSEGNKTEDQDQCLCDHKPRPPEFKKCNQQACKKSADLLCTKDKLSASFCQTLKAMKKCSVPTVRAECCFSCPQTHITHTQRQRRQRLLQKSKELLEEFFNOV68f, 305867866SEQ ID NO: 10154777 bpDNA SequenceORF Start: at 1ORF Stop: TGA at 4729AGATCTTATGGGAGACAGCCTCAGCCAGGCCCGGTTCGCTTCCCGGACAGGAGGCAAGAGCATTTTATCAAGGGCCTGCCAGAATACCACGTGGTGGGTCCAGTCCGAGTAGATGCCAGTGGGCATTTTTTGTCATATGGCTTGCACTATCCCATCACGAGCAGCAGGAGGAAGAGAGATTTGGATGGCTCAGAGGACTGGGTGTACTACAGAATTTCTCACGAGGAGAAGGACCTGTTTTTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCCTCTGCCCCCCTCTGCCATCTCAGTGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGACGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAACTTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTACATCCTCACCATCATGAACATGGTCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACTAGAAAGGACATCTGTGCTGGTTTCAATCGCCCCTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTAAAAAGAAAGGCTTGAAGTCCAAGGTCATTGCCCCCGGAGTGATCTATGATGTTCACCACCAGTGCCAGCTACAATATGGACCCAATGCTACCTTCTGCCAGGAAGTAGAAAACGTCTGCCAGACACTGTGGTGCTCCGTGAAGGGCTTTTGTCGCTCTAAGCTGGACGCTGCTGCAGATGGAACTCAATGTGGTGAGAAGAAGTGGTGTATGGCAGGCAAGTGCATCACAGTGGGGAAGAAACCAGAGAGCATTCCTGGAGGCTGGGGCCGCTGGTCACCCTGGTCCCACTGTTCCAGGACCTGTGGGGCTGGAGTCCAGAGCGCAGAGAGGCTCTGCAACAACCCCGAGCCAAAGTTTGGAGGGAAATATTGCACTGGAGAAAGAAAACGCTATCGCTTGTGCAACGTCCACCCCTGTCGCTCAGAGGCACCAACATTTCGGCAGATGCAGTGCAGTGAATTTGACACTGTTCCCTACAAGAATGAACTCTACCACTGGTTTCCCATTTTTAACCCAGCACATCCTTGTGAGCTCTACTGCCGACCCATAGATGGCCAGTTTTCTGAGAAAATGCTGGATGCTGTCATTGATGGTACCCCTTGCTTTGAAGGCGGCAACAGCAGAAATGTCTGTATTAATGGCATATGTAAGATGGTTGGCTGTGACTATGAGATCGATTCCAATGCCACCGAGGATCGCTGCGGTGTGTGCCTGGGAGATGGCTCTTCCTGCCAGACTGTGAGAAAGATGTTTAAGCAGAAGGAAGGATCTGGTTATGTTGACATTGGGCTCATTCCAAAAGGAGCAAGGGACATAAGAGTGATGGAAATTGAGGGAGCTGGAAACTTCCTGGCCATCAGGAGTGAAGATCCTGAAAAATATTACCTGAATGGAGGGTTTATTATCCAGTGGAACGGGAACTATAAGCTGGCAGGGACTGTCTTTCAGTATGACAGGAAAGGAGACCTGGAAAAGCTGATGGCCACAGGTCCCACCAATGAGTCTGTGTGGATCCAGCTTCTATTCCAGGTGACTAACCCTGGCATCAAGTATGAGTACACAATCCAGAAAGATGGCCTTGACAATGATGTTGAGCAGCAGATGTACTTCTGGCAGTACGGCCACTGGACAGAGTGCAGTGTGACCTGCGGGACAGGTATCCGCCGCCAAACTGCCCATTGCATAAAGAAGGGCCGCGGGATGGTGAAAGCTACATTCTGTGACCCAGAAACACAGCCCAATGGGAGACAGAAGAAGTGCCATGAAAAGGCTTGTCCACCCAGGTGGTGGGCAGGGGAGTGGGAAGCATGCTCGGCGACATGCGGGCCCCACGGGGAGAAGAAGCGAACCGTGCTGTGCATCCAGACCATGGTCTCTGACGAGCAGGCTCTCCCGCCCACAGACTGCCAGCACCTGCTGAAGCCCAAGACCCTCCTTTCCTGCAACAGAGACATCCTGTGCCCCTCGGACTGGACAGTGGGCAACTGGAGTGAGTGTTCTGTTTCCTGTGGTGGTGGAGTGCGGATTCGCAGTGTCACATGTGCCAAGAACCATGATGAACCTTGCGATGTGACAAGGAAACCCAACAGCCGAGCTCTGTGTGGCCTCCAGCAATGCCCTTCTAGCCGGAGAGTTCTGAAACCAAACAAAGGCACTATTTCCAATGGAAAAAACCCACCAACACTAAAGCCCGTCCCTCCACCTACATCCAGGCCCAGAATGCTGACCACACCCACAGGGCCTGAGTCTATGAGCACAAGCACTCCAGCAATCAGCAGCCCTAGTCCTACCACAGCCTCCAAAGAAGGAGACCTGGGTGGGAAACAGTGGCAAGATAGCTCAACCCAACCTGAGCTGAGCTCTCGCTATCTCATTTCCACTGGAAGCACTTCCCAGCCCATCCTCACTTCCCAATCCTTGAGCATTCAGCCAAGTGAGGAAAATGTTTCCAGTTCAGATACTGGTCCTACCTCGGAGGGAGGCCTTGTAGCTACAACAACAAGTGGTTCTGGCTTGTCATCTTCCCGCAACCCTATCACTTGGCCTGTGACTCCATTTTACAATACCTTGACCAAAGGTCCAGAAATGGAGATTCACAGTGGCTCAGGGGAAGAAAGAGAACAGCCTGAGGACAAAGATGAAAGCAATCCTGTAATATGGACCAAGATCAGAGTACCTGGAAATGACGCTCCAGTGGAAAGTACAGAAATGCCACTTGCACCTCCACTAACACCAGATCTCAGCAGGGAGTCCTGGTGGCCACCCTTCAGCACAGTAATGGAAGGACTGCTCCCCAGCCAAAGGCCCACTACTTCCGAAACTGGGACACCCAGAGTTGAGGGGATGGTTACTGAAAAGCCAGCCAACACTCTGCTCCCTCTGGGAGGAGACCACCAGCCAGAACCCTCAGGAAAGACGGCAAACCGTAACCACCTGAAACTTCCAAACAACATGAACCAAACAAAAAGTTCTGAACCAGTCCTGACTGAGGAGGATGCAACAAGTCTGATTACTGAGGGCTTTTTGCTAAATGCCTCCAATTACAAGCAGCTCACAAACGGCCACGGCTCTGCACACTGGATCGTCGGAAACTGGAGCGAGTGCTCCACCACATGTGGCCTGGGGGCCTACTGGAGAAGGGTGGAGTGCAGCACCCAGATGGATTCTGACTGTGCGGCCATCCAGAGACCTGACCCTGCAAAAAGATGCCACCTCCGTCCCTGTGCTGGCTGGAAAGTGGGAAACTGGAGCAAGTGCTCCAGAAACTGCAGTGGGGGCTTCAAGATACGCGAGATTCAGTGCGTGGACAGCCGGGACCACCGGAACCTGAGGCCATTTCACTGCCAGTTCCTGGCCGGCATTCCTCCCCCATTGAGCATGAGCTGTAACCCGGAGCCCTGTGAGGCGTGGCAGGTGGAGCCTTGGAGCCAGTGCTCCAGGTCCTGTGGAGGTGGAGTTCAGGAGAGAGGAGTGTTCTGTCCAGGAGGCCTCTGTGATTGGACAAAAAGACCCACATCCACCATGTCTTGCAATGAGCACCTGTGCTGTCACTGGGCCACTGGGAACTGGGACCTGTGTTCCACTTCCTGTGGAGGTGGCTTTCAGAAGAGGACTGTCCAATGTGTGCCCTCAGAGGGCAATAAAACTGAAGACCAAGACCAATGTCTATGTGATCACAAACCCAGACCTCCAGAATTCAAAAAATGCAACCAGCAGGCCTGCAAGAAAAGTGCCGATTTACTTTGCACTAAGGACAAACTGTCAGCCAGTTTCTGCCAGACACTGAAAGCCATGAAGAAATGTTCTGTGCCCACCGTGAGGGCTGAGTGCTGCTTCTCGTGTCCCCAGACACACATCACACACACCCAAAGGCAAAGAAGGCAACGGTTGCTCCAAAAGTCAAAAGGACTCCTCGAGGAGTTCTTTTGACTTTTGGAGCAACCGGGCCTGGCTGAGGCTGTCTCCCATAAGATCTNOV68f, 305867866Protein SequenceSEQ ID NO: 10161576 aaMW at 175822.7kDRSYGRQPQPGPVRFPDRRQEHFIKGLPEYHVVGPVRVDASGHFLSYGLHYPITSSRRKRDLDGSEDWVYYRISHEEKDLFFNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESYILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPKKKGLKSKVIAPGVIYDVHHQCQLQYGPNATFCQEVENVCQTLWCSVKGFCRSKLDAAADGTQCGEKKWCMAGKCITVGKKPESIPGGWGRWSPWSHCSRTCGAGVQSAERLCNNPEPKFGGKYCTGERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVPYKNELYHWFPIFNPAHPCELYCRPIDGQFSEKMLDAVIDGTPCFEGGNSRNVCINGICKMVGCDYEIDSNATEDRCGVCLGDGSSCQTVRKMFKQKEGSGYVDIGLIPKGARDIRVMEIEGAGNFLAIRSEDPEKYYLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWIQLLFQVTNPGIKYEYTIQKDGLDNDVEQQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKGRGNVKATFCDPETQPNGRQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMVSDEQALPPTDCQHLLKPKTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNHDEPCDVTRKPNSRALCGLQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTPTGPESMSTSTPAISSPSPTTASKEGDLGGKQWQDSSTQPELSSRYLISTGSTSQPILTSQSLSIQPSEENVSSSDTGPTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMEIHSGSGEEREQPEDKDESNPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSTVMEGLLPSQRPTTSETGTPRVEGMVTEKPAWILLPLGGDHQPEPSGKTANRNHLKLPNNMNQTKSSEPVLTEEDATSLITEGFLLNASNYKQLTNGHGSAHWIVGNWSECSTTCGLGAYWRRVECSTQMDSDCAAIQRPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSRDHRNLRPFHCQFLAGIPPPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVQERGVFCPGGLCDWTKRPTSTMSCNEHLCCHWATGNWDLCSTSCGGGFQKRTVQCVPSEGNKTEDQDQCLCDHKPRPPEFKKCNQQACKKSADLLCTKDKLSASFCQTLKAMKKCSVPTVRAECCFSCPQTHITHTQRQRRQRLLQKSKGLLEEFFNOV68g, 318176397SEQ ID NO: 10173174 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceCTGGAATGCGCCCTTAGATCTGGCCGCTGGTCACCCTGGTCCCACTGTTCCAGGACCTGTGGGGCTGGAGTCCAGAGCGCAGAGAGGCTCTGCAACAACCCCGAGCCAAAGTTTGGAGGGAAATATTGCACTGGAGAAAGAAAACGCTATCGCTTGTGCAACGTCCACCCCTGTCGCTCAGAGGCACCAACATTTCGGCAGATGCAGTGCAGTGAATTTGACACTGTTCCCTACAAGAATGAACTCTACCACTGGTTTCCCATTTTTAACCCAGCACATCCTTGTGAGCTCTACTGCCGACCCATAGATGGCCAGTTTTCTGAGAAAATGCTGGATGCTGTCATTGATGGTACCCCTTGCTTTGAAGGCGGCAACAGCAGAAATGTCTGTATTAATGGCATATGTAAGATGGTTGGCTGTGACTATGAGATCGATTCCAATGCCACCGAGGATCGCTGCGGTGTGTGCCTGGGAGATGGCTCTTCCTGCCAGACTGCGAGAAAGATGTTTAAGCAGAAGGAAGGATCTGGTTATGTTGACATTGGGCTCATTCCAAAAGGAGCAAGGGACATAAGAGTGATGGAAATTGAGGGAGCTGGAAACTTCCTGGCCATCAGGAGTGAAGATCCTGAAAAATATTACCTGAATGGAGGGTTTATTATCCAGTGGAACGGGAACTATAAGCTGGCAGGGACTGTCTTTCAGTATGACAGGAAAGGAGACCTGGAAAAGCTGATGGCCACAGGTCCCACCAATGAGTCTGTGTGGATCCAGCTTCTATTCCAGGTGACTAACCCTGGCATCAAGTATGAGTACACAATCCAGAAAGATGGCCTTGACAATGATGTTGAGCAGCAGATGTACTTCTGGCAGTACGGCCACTGGACAGAGTGCAGTGTGACCTGCGGGACAGGTATCCGCCGCCAAACTGCCCATTGCATAAAGAAGGGCCGCGGGATGGTGAAAGCTACATTCTGTGACCCAGAAACACAGCCCAATGGGAGACAGAAGAAGTGCCATGAAAAGGCTTGTCCACCCAGGTGGTGGGCAGGGGAGTGGGAAGCATGCTCGGCGACATGCGGGCCCCACGGGGAGAAGAAGCGAACCGTGcTGTGCATCCAGACCATGGTCTCTGACGAGCAGGCTCTCCCGCCCACAGACTGCCAGCACCTGCTGAAGCCCAAGACCCTCCTTTCCTGCAACAGAGACATCCTGTGCCCCTCGGACTGGACAGTGGGCAACTGGAGTGAGTGTTCTGTTTCCTGTGGTGGTGGAGTGCGGATTCGCAGTGTCACATGTGCCAAGAACCATGATGAACCTTGCGATGTGACAAGGAAACCCAACAGCCGAGCTCTGTGTGGCCTCCAGCAATGCCCTTCTAGCCGGAGAGTTCTGAAACCAAACAAAGGCACTATTTCCAATGGAAAAAACCCACCAACACTAAAGCCCGTCCCTCCACCTACATCCAGGCCCAGAATGCTGACCACACCCACAGGGCCTGAGTCTATGAGCACAAGCACTCCGGCAATCAGCAGCCCTAGTCCTACCACAGCCTCCAAAGAAGGAGACCTGGGTGGGAAACAGTGGCAAGATAGCTCAACCCAACCTGAGCTGAGCTCTCGCTATCTCATTTCCACTGGAAGCACTTCCCAGCCCATCCTCACTTCCCAATCCTTGAGCATTCAGCCAAGTGAGGAAAATGTTTCCAGTTCAGATACTGGTCCTACCTCGGAGGGAGGCCTTGTAGCTACAACAACAAGTGGTTCTGGCTTGTCATCTTCCCGCAACCCTATCACTTGGCCTGTGACTCCATTTTACAATACCTTGACCAAAGGTCCAGAAATGGAGATTCACAGTGGCTCAGGGGAAGAAAGAGAACAGCCTGAGGACAAAGATGAAAGCAATCCTGTAATATGGACCAAGATCAGAGTACCTGGAAATGACGCTCCAGTGGAAAGTACAGAAATGCCACTTGCACCTCCACTAACACCAGATCTCAGCAGGGAGTCCTGGTGGCCACCCTTCAGCACAGTAATGGAAGGACTGCTCCCCAGCCAAAGGCCCACTACTTCCGAAACTGGGACACCCAGAGTTGAGGGGATGGTTACTGAAAAGCCAGCCAACACTCTGCTCCCTCTGGGAGGAGACCACCAGCCAGAACCCTCAGGAAAGACGGCAAACCGTAACCACCTGAAACTTCCAAACAACATGAACCAAACAAAAAGTTCTGAACCAGTCCTGACTGAGGAGGATGCAACAAGTCTGATTACTGAGGGCTTTTTGCTAAATGCCTCCAATTACAAGCAGCTCACAAACGGCTACGGCTCTGCACACTGGATCGTCGGAAACTGGAGCGAGTGCTCCACCACATGTGGCCTGGGGGCCTACTGGAGAAGGGTGGAGTGCAGCACCCAGATGGATTCTGACTGTGCGGCCATCCAGAGACCTGACCCTGCAAAAAGATGCCACCTCCGTCCCTGTGCTGGCTGGAAAGTGGGAAACTGGAGCAAGTGCTCCAGAAACTGCAGTGGGGGCTTCAAGATACGCGAGATTCAGTGCGTGGACAGCCGGGACCACCGGAACCTGAGGCCATTTCACTGCCAGTTCCTGGCCGGCATTCCTCCCCCATTGAGCATGAGCTGTAACCCGGAGCCCTGTGAGGCGTGGCAGGTGGAGCCTTGGAGCCAGTGCTCCAGGTCCTGTGGAGGTGGAGTTCAGGAGAGAGGAGTGTTCTGTCCAGGAGGCCTCTGTGATTGGACAAAAAGACCCACATCCACCATGTCTTGCAATGAGCACCTGTGCTGTCACTGGGCCACTGGGAACTGGGACCTGTGTTCCACTTCCTGTGGAGGCGGCTTTCAGAAGAGGACTGTCCAATGTGTGCCCTCAGAGGGCAATAAAACTGAAGACCAAGACCAATGTCTATGTGATCACAAACCCAGACCTCCAGAATTCAAAAAATGCAACCAGCAGGCCTGCAAGAAAAGTGCCGATTTACTTTGCACTAAGGACAAACTGTCAGCCAGTTTCTGCCAGACACTGAAAGCCATGAAGAAATGTTCTGTGCCCACCGTGAGGGCTGAGTGCTGCTTCTCGTGTCCCCAGACACACATCACACACACCCAAAGGCAAAGAAGGCAACGGTTGCTCCAAAAGTCAAAAGAACTCCTCGAGNOV68g, 318176397Protein SequenceSEQ ID NO: 10181058 aaMW at 117062.0kDLECALRSGRWSPWSHCSRTCGAGVQSAERLCNNPEPKFGGKYCTGERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVPYKNELYHWFPIFNPAHPCELYCRPIDGQFSEKMLDAVIDGTPCFEGGNSRNVCINGICKMVGCDYEIDSNATEDRCGVCLGDGSSCQTARKMFKQKEGSGYVDIGLIPKGARDIRVMEIEGAGNFLAIRSEDPEKYYLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWIQLLFQVTNPGIKYEYTIQKDGLDNDVEQQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKGRGMVKATFCDPETQPNGRQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMVSDEQALPPTDCQHLLKPKTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNHDEPCDVTRKPNSRALCGLQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTPTGPESMSTSTPAISSPSPTTASKEGDLGGKQWODSSTQPELSSRYLISTGSTSQPILTSQSLSIQPSEENVSSSDTGPTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMEIHSGSGEEREOPEDKDESNPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSTVMEGLLPSQRPTTSETGTPRVEGMVTEKPANTLLPLGGDHQPEPSGKTANRNHLKLPNNMNQTKSSEPVLTEEDATSLITEGFLLNASNYKQLTNGYGSAHWIVGNWSECSTTCGLGAYWRRVECSTQMDSDCAAIQRPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSRDHRNLRPFHCQFLAGIPPPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVQERGVFCPGGLCDWTKRPTSTMSCNEHLCCHWATGNWDLCSTSCGGGFQKRTVQCVPSEGNKTEDQDQCLCDHKPRPPEFKKCNQQACKKSADLLCTKDKLSASFCQTLKANKKCSVPTVRAECCFSCPQTHITHTQRQRRQRLLQKSKELLENOV68h, CG58504-02SEQ ID NO: 10191068 bpDNA SequenceORF Start: at 7ORF Stop: at 1063AAGCTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCCTCTGCCCCCCTCTGCCATCTCAGTGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGATGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAACTTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTGCATCCTCACCATCATGAACATGGTCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACCAGAAAGGACATCTGTGCTGGTTTCAATCGCCCCTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTCTCGAGNOV68h, CG58504-02Protein SequenceSEQ ID NO: 1020352 aaMW at 39853.3kDNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGMAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESCILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPNOV68i, CG58504-03SEQ ID NO: 10211068 bpDNA SequenceORF Start: at 7ORF Stop: at 1063AAGCTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCCTCTGCCCCCCTCTGCCATCTCAGTGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGACGGCAGCCCTCAGTGCcTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAACTTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTACATCCTCACCATCATGAACATGATCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACCAGAAAGGACATCTGTGCTGGTTTCAATCGCCCCTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTCTCGAGNOV68i, CG58504-03Protein SequenceSEQ ID NO: 1022352 aaMW at 39897.2kDNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESYILTIMNNITGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPNOV68j, CG58504-04SEQ ID NO: 1023252 bpDNA SequenceORF Start: at 7ORF Stop: at 247AAGCTTCACCAGTGCCAGCTACAATATGGACCCAATGCTACCTTCTGCCAGGAAGTAGAAAACGTCTGCCAGACACTGTGGTGCTCCGTGAAGGGCTTTTGTCGCTCTAAGCTGGACGCTGCTGCAGATGGAACTCAATGTGGTGAGAAGAAGTGGTGTATGGCAGGCAAGTGCATCACAGTGGGGAAGAAACCAGAGAGCATTCCTGGAGGCTGCGGCCGCTGGTCACCCTGGTCCCACTGTTCCCTCGAGNOV68j, CG58504-04Protein SequenceSEQ ID NO: 102480 aaMW at 8757.0kDHQCQLQYGPNATFCQEVENVCQTLWCSVKGFCRSKLDAAADGTQCGEKKWCMAGKCITVGKKPESIPGGCGRWSPWSHCSNOV68k, CG58504-05SEQ ID NO: 10254777 bpDNA SequenceORF Start: at 7ORF Stop: TGA at 4729AGATCTTATGGGAGACAGCCTCAGCCAGGCCCGGTTCGCTTCCCGGACAGGAGGCAAGAGCATTTTATCAAGGGCCTGCCAGAATACCACGTGGTGGGTCCAGTCCGAGTAGATGCCAGTGGGCATTTTTTGTCATATGGCTTGCACTATCCCATCACGAGCAGCAGGAGGAAGAGAGATTTGGATGGCTCAGAGGACTGGGTGTACTACAGAATTTCTCACGAGGAGAAGGACCTGTTTTTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCCTCTGCCCCCCTCTGCCATCTCAGTGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGACGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCAcTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAACTTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTACATCCTCACCATCATGAACATGGTCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACTAGAAAGGACATCTGTGCTGGTTTCAATCGCCCCTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTAAAAAGAAAGGCTTGAAGTCCAAGGTCATTGCCCCCGGAGTGATCTATGATGTTCACCACCAGTGCCAGCTACAATATGGACCCAATGCTACCTTCTGCCAGGAAGTAGAAAACGTCTGCCAGACACTGTGGTGCTCCGTGAAGGGCTTTTGTCGCTCTAAGCTGGACGCTGCTGCAGATGGAACTCAATGTGGTGAGAAGAAGTGGTGTATGGCAGGCAAGTGCATCACAGTGGGGAAGAAACCAGAGAGCATTCCTGGAGGCTGGGGCCGCTGGTCACCCTGGTCCCACTGTTCCAGGACCTGTGGGGCTGGAGTCCAGAGCGCAGAGAGGCTCTGCAACAACCCCGAGCCAAAGTTTGGAGGGAAATATTGCACTGGAGAAAGAAAACGCTATCGCTTGTGCAACGTCCACCCCTGTCGCTCAGAGGCACCAACATTTCGGCAGATGCAGTGCAGTGAATTTGACACTGTTCCCTACAAGAATGAACTCTACCACTGGTTTCCCATTTTTAACCCAGCACATCCTTGTGAGCTCTACTGCCGACCCATAGATGGCCAGTTTTCTGAGAAAATGCTGGATGCTGTCATTGATGGTACCCCTTGCTTTGAAGGCGGCAACAGCAGAAATGTCTGTATTAATGGCATATGTAAGATGGTTGGCTGTGACTATGAGATCGATTCCAATGCCACCGAGGATCGCTGCGGTGTGTGCCTGGGAGATGGCTCTTCCTGCCAGACTGTGAGAAAGATGTTTAAGCAGAAGGAAGGATCTGGTTATGTTGACATTGGGCTCATTCCAAAAGGAGCAAGGGACATAAGAGTGATGGAAATTGAGGGAGCTGGAAACTTCCTGGCCATCAGGAGTGAAGATCCTGAAAAATATTACCTGAATGGAGGGTTTATTATCCAGTGGAACGGGAACTATAAGCTGGCAGGGACTGTCTTTCAGTATGACAGGAAAGGAGACCTGGAAAAGCTGATGGCCACAGGTCCCACCAATGAGTCTGTGTGGATCCAGCTTCTATTCCAGGTGACTAACCCTGGCATCAAGTATGAGTACACAATCCAGAAAGATGGCCTTGACAATGATGTTGAGCAGCAGATGTACTTCTGGCAGTACGGCCACTGGACAGAGTGCAGTGTGACCTGCGGGACAGGTATCCGCCGCCAAACTGCCCATTGCATAAAGAAGGGCCGCGGGATGGTGAAAGCTACATTCTGTGACCCAGAAACACAGCCCAATGGGAGACAGAAGAAGTGCCATGAAAAGGCTTGTCCACCCAGGTGGTGGGCAGGGGAGTGGGAAGCATGCTCGGCGACATGCGGGCCCCACGGGGAGAAGAAGCGAACCGTGCTGTGCATCCAGACCATGGTCTCTGACGAGCAGGCTCTCCCGCCCACAGACTGCCAGCACCTGCTGAAGCCCAAGACCCTCCTTTCCTGCAACAGAGACATCCTGTGCCCCTCGGACTGGACAGTGGGCAACTGGAGTGAGTGTTCTGTTTCCTGTGGTGGTGGAGTGCGGATTCGCAGTGTCACATGTGCCAAGAACCATGATGAACCTTGCGATGTGACAAGGAAACCCAACAGCCGAGCTCTGTGTGGCCTCCAGCAATGCCCTTCTAGCCGGAGAGTTCTGAAACCAAACAAAGGCACTATTTCCAATGGAAAAAACCCACCAACACTAAAGCCCGTCCCTCCACCTACATCCAGGCCCAGAATGCTGACCACACCCACAGGGCCTGAGTCTATGAGCACAAGCACTCCAGCAATCAGCAGCCCTAGTCCTACCACAGCCTCCAAAGAAGGAGACCTGGGTGGGAAACAGTGGCAAGATAGCTCAACCCAACCTGAGCTGAGCTCTCGCTATCTCATTTCCACTGGAAGCACTTCCCAGCCCATCCTCACTTCCCAATCCTTGAGCATTCAGCCAAGTGAGGAAAATGTTTCCAGTTCAGATACTGGTCCTACCTCGGAGGGAGGCCTTGTAGCTACAACAACAAGTGGTTCTGGCTTGTCATCTTCCCGCAACCCTATCACTTGGCCTGTGACTCCATTTTACAATACCTTGACCAAAGGTCCAGAAATGGAGATTCACAGTGGCTCAGGGGAAGAAAGAGAACAGCCTGAGGACAAAGATGAAAGCAATCCTGTAATATGGACCAAGATCAGAGTACCTGGAAATGACGCTCCAGTGGAAAGTACAGAAATGCCACTTGCACCTCCACTAACACCAGATCTCAGCAGGGAGTCCTGGTGGCCACCCTTCAGCACAGTAATGGAAGGACTGCTCCCCAGCCAAAGGCCCACTACTTCCGAAACTGGGACACCCAGAGTTGAGGGGATGGTTACTGAAAAGCCAGCCAACACTCTGCTCCCTCTGGGAGGAGACCACCAGCCAGAACCCTCAGGAAAGACGGCAAACCGTAACCACCTGAAACTTCCAAACAACATGAACCAAACAAAAAGTTCTGAACCAGTCCTGACTGAGGAGGATGCAACAAGTCTGATTACTGAGGGCTTTTTGCTAAATGCCTCCAATTACAAGCAGCTCACAAACGGCCACGGCTCTGCACACTGGATCGTCGGAAACTGGAGCGAGTGCTCCACCACATGTGGCCTGGGGGCCTACTGGAGAAGGGTGGAGTGCAGCACCCAGATGGATTCTGACTGTGCGGCCATCCAGAGACCTGACCCTGCAAAAAGATGCCACCTCCGTCCCTGTGCTGGCTGGAAAGTGGGAAACTGGAGCAAGTGCTCCAGAAACTGCAGTGGGGGCTTCAAGATACGCGAGATTCAGTGCGTGGACAGCCGGGACCACCGGAACCTGAGGCCATTTCACTGCCAGTTCCTGGCCGGCATTCCTCCCCCATTGAGCATGAGCTGTAACCCGGAGCCCTGTGAGGCGTGGCAGGTGGAGCCTTGGAGCCAGTGCTCCAGGTCCTGTGGAGGTGGAGTTCAGGAGAGAGGAGTGTTCTGTCCAGGAGGCCTCTGTGATTGGACAAAAAGACCCACATCCACCATGTCTTGCAATGAGCACCTGTGCTGTCACTGGGCCACTGGGAACTGGGACCTGTGTTCCACTTCCTGTGGAGGTGGCTTTCAGAAGAGGACTGTCCAATGTGTGCCCTCAGAGGGCAATAAAACTGAAGACCAAGACCAATGTCTATGTGATCACAAACCCAGACCTCCAGAATTCAAAAAATGCAACCAGCAGGCCTGCAAGAAAAGTGCCGATTTACTTTGCACTAAGGACAAACTGTCAGCCAGTTTCTGCCAGACACTGAAAGCCATGAAGAAATGTTCTGTGCCCACCGTGAGGGCTGAGTGCTGCTTCTCGTGTCCCCAGACACACATCACACACACCCAAAGGCAAAGAAGGCAACGGTTGCTCCAAAAGTCAAAAGGACTCCTCGAGGAGTTCTTTTGACTTTTGGAGCAACCGGGCCTGGCTGAGGCTGTCTCCCATAAGATCTNOV68k, CG58504-05Protein SequenceSEQ ID NO: 10261574 aaMW at 175579.4kDYGRQPQPGPVRFPDRRQEHFIKGLPEYHVVGPVRVDASGHFLSYGLHYPITSSRRKRDLDGSEDWVYYRISHEEKDLFFNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESYILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPKKKGLKSKVIAPGVIYDVHHQCQLQYGPNATFCQEVENVCQTLWCSVKGFCRSKLDAAADGTQCGEKKWCMAGKCITVGKKPESIPGGWGRWSPWSHCSRTCGAGVOSAERLCNNPEPKFGGKYCTGERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVPYKNELYHWFPIFNPAHPCELYCRPIDGQFSEKMLDAVIDGTPCFEGGNSRNVCINGICKMVGCDYEIDSNATEDRCGVCLGDGSSCQTVRKMFKQKEGSGYVDIGLIPKGARDIRVMEIEGAGNFLAIRSEDPEKYYLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWIQLLFQVTNPGIKYEYTIQKDGLDNDVEQQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKGRGMVKATFCDPETQPNGRQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMVSDEQALPPTDCQHLLKPKTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNHDEPCDVTRKPNSRALCGLQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTPTGPESMSTSTPAISSPSPTTASKEGDLGGKQWQDSSTQPELSSRYLISTGSTSQPILTSQSLSIQPSEENVSSSDTGPTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMEIHSGSGEEREQPEDKDESNPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSTVMEGLLPSQRPTTSETGTPRVEGMVTEKPANTLLPLGGDHQPEPSGKTANRNHLKLPNNNNQTKSSEPVLTEEDATSLITEGFLLNASNYKQLTNGHGSAHWIVGNWSECSTTCGLGAYWRRVECSTQMDSDCAAIQRPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSRDHRNLRPFHCQFLAGIPPPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVQERGVFCPGGLCDWTKRPTSTMSCNEHLCCHWATGNWDLCSTSCGGGFQKRTVQCVPSEGNKTEDQDQCLCDHKPRPPEFKKCNQQACKKSADLLCTKDKLSASFCQTLKAMKKCSVPTVRAECCFSCPQTHITHTQRQRRQRLLQKSKGLLEEFFNOV68l, CG58504-06SEQ ID NO: 10271068 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTAACTTGACGGTCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATGTTAAGATGATGGCTTCCTCTGCCCCCCTCTGCCATCTCAGTGGCACGGTTCTACAGCAGGGCACCAGAGTTGGGACGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTCCAACTACCACATGGAGACTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGCACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGACAGTGTTAACATCTCCCAGAAGCAAGAGCTATGGCGGGAGAAGTGGGAGAGGCACAACTTGCCAAGCAGAAGCCTCTCTCGGCGTTCCATCAGCAAGGAGAGATGGGTGGAGACACTGGTGGTGGCCGACACAAAGATGATTGAATACCATGGGAGTGAGAATGTGGAGTCCTACATCCTCACCATCATGAACATGGTCACTGGGTTGTTCCATAACCCAAGCATTGGCAATGCAATTCACATTGTTGTGGTTCGGCTCATTCTACTCGAAGAAGAAGAGCAAGGACTGAAAATAGTTCACCATGCAGAAAAGACACTGTCTAGCTTCTGCAAGTGGCAGAAGAGTATCAATCCCAAGAGTGACCTCAATCCTGTTCATCACGACGTGGCTGTCCTTCTCACCAGAAAGGACATCTGTGCTGGTTTCAATCGCCCCTGCGAGACCCTGGGCCTGTCTCACCTTTCAGGAATGTGTCAGCCTCACCGCAGTTGTAACATCAATGAAGATTCGGGACTCCCTCTGGCTTTCACAATTGCCCATGAGCTAGGACACAGCTTCGGCATCCAGCATGATGGGAAAGAAAATGACTGTGAGCCTGTGGGCAGACATCCGTACATCATGTCCCGCCAGCTCCAGTACGATCCCACTCCGCTGACATGGTCCAAGTGCAGCGAGGAGTACATCACCCGCTTCTTGGACCGAGGCTGGGGGTTCTGTCTTGATGACATACCTCTCGAGNOV68l, CG58504-06Protein SequenceSEQ ID NO: 1028356 aaMW at 40366.8kDKLNLTVNQGFLSNSYIMEKRYGNLSHVKNMASSAPLCHLSGTVLQOGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGSENVESYILTIMNNVTGLFHNPSIGNAIHIVVVRLILLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPLENOV68m, CG58504-07SEQ ID NO: 1029252 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAAGCTTCACCAGTGCCAGCTACAATATGGACCCAATGCTACCTTCTGCCAGGAAGTAGAAAACGTCTGCCAGACACTGTGGTGCTCCGTGAAGGGCTTTTGTCGCTCTAAGCTGGACGCTGCTGCAGATGGAACTCAATGTGGTGAGAAGAAGTGGTGTATGGCAGGCAAGTGCATCACAGTGGGGAAGAAACCAGAGAGCATTCCTGGAGGCTGGGGCCGCTGGTCACCCTGGTCCCACTGTTCCCTCGAGNOV68m, CG58504-07Protein SequenceSEQ ID NO: 103084 aaMW at 9323.7kDKLHQCQLQYGPNATFCQEVENVCQTLWCSVKGFCRSKLDAAADGTQCGEKKWCMAGKCITVGKKPESIPGGWGRWSPWSHCSLE

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 68B.

TABLE 68BComparison of the NOV68 protein sequences.NOV68aMPCAQRSWLANLSVVAQLLNFGALCYGRQPQPGPVRFPDRRQEHFIKGLPEYHVVGPVRVNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68e------------------------------------------------------------NOV68f------------------------------------------------------------NOV68g------------------------------------------------------------NOVS8h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68k------------------------------------------------------------NOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aDASGHFLSYGLHYPITSSRRKRDLDGSEDWVYYRISHEEKDLFFNLTVNQGFLSNSYIMENOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68e------------------------------------------------------------NOV68f------------------------------------------------------------NOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68k------------------------------------------------------------NOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68e------------------------------------------------------------NOV68f------------------------------------------------------------NOV68g--------------------------------LECALRSGRWSPWSHCSRTCGAGVQSAENOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68k------------------------------------------------------------NOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aKHPLVEGGYHPHIVYRRQKVPETKEPTCGLKDSVNISQKQELWREKWERHNLPSRSLSRRNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68e------------------------------------------------------------NOV68f------------------------------------------------------------NOV68gRLCNNPEPKFGGKYCTGERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVPYKNELYHWFPINOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68k------------------------------------------------------------NOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aSISKERWVETLVVADTKMIEYHGSENVESYILTIMNMVTGLFHNPSIGNAIHIVVVRLILNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68e------------------------------------------------------------NOV68f------------------------------------------------------------NOV68gFNPAHPCELYCRPIDGQFSEKMLDAVIDGTPCFEGGNSRNVCINGICKMVGCDYEIDSNANOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68k------------------------------------------------------------NOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aLEEEEQGLKIVHHAEKTLSSFCKWQKSINPKSDLNPVHHDVAVLLTRKDICAGFNRPCETNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68e-----------------------------------------RSYGRQPQPGPVRFPDRRQNOV68f-----------------------------------------RSYGRQPQPGPVRFPDRRQNOV68gTEDRCGVCLGDGSSCQTARKMFKQKEGSGYVDIGLIPKGARDIRVHEIEGAGNFLAIRSENOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68k-------------------------------------------YGRQPQPGPVRFPDRRQNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aLGLSHLSGMCQPHRSCNINEDSGLPLAFTIAHELGHSFGIQHDGKENDCEPVGRHPYIMSNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eEHFIKGLPEYHVVGPVRVDASGHFLSYGLHYPITSSRRKRDLDGSEDWVYYRISHEEKDLNOV68fENFIKGLPEYHVVGPVRVDASGHFLSYGLHYPITSSRRKRDLDGSEDWVYYRISHEEKDLNOV68gDPEKYYLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWIQLLFQVTNPGINOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kEHFIKGLPEYHVVGPVRVDASGHFLSYGLHYPITSSRRKRDLDGSEDWVYYRISHEEKDLNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aRQLQYDPTPLTWSKCSEEYITRFLDRGWGFCLDDIPKKKGLKSKVIAPGVIYDVHHQCQLNOV68bKLNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGMAALSACHGNOV68cKLNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGNOV68dKLNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGNOV68eFFNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLNGTVLQQGTRVGTAALSACHGNOV68fFFNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGNOV68gKYEYTIQKDGLDNDVEQQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKGRGMVKATFCDPNOV68h--NLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGMAALSACHGNOV68i--NLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGNOV68j-------------------------------------------------------HQCQLNOV68kFFNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGNOV68lKLNLTVNQGFLSNSYIMEKRYGNLSHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGNOV68m-----------------------------------------------------KLHQCQLNOV68aQYGPNATFCQEVENVCQTLWCSVKGFCRSKLDAAA-------------------------NOV68bLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRR-------------------------NOV68cLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRR-------------------------NOV68dLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRR-------------------------NOV68eLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRR-------------------------NOV68fLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRR-------------------------NOV68gETQPNGRQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMVSDEQALPPTDCNOV68hLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRR-------------------------NOV68iLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRR-------------------------NOV68jQYGPNATFCQEVENVCQTLWCSVKGFCRSKLDAAA-------------------------NOV68kLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRR-------------------------NOV68lLTGFFQLPHGDFFIEPVKKHPLVEGGYHPHIVYRR-------------------------NOV68mQYGPNATFCQEVENVCQTLWCSVKGFCRSKLDAAA-------------------------NOV68a--------------------------------------------------DGTQCGEKK-NOV68b--------------------------------------------------QKVPETKEP-NOV68c--------------------------------------------------QKVPETKEP-NOV68d--------------------------------------------------QKVPETKEP-NOV68e--------------------------------------------------QKVPETKEP-NOV68f--------------------------------------------------QKVPETKEP-NOV68gQHLLKPKTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNHDEPCDVTRKPNNOV68h--------------------------------------------------QKVPETKEP-NOV68i--------------------------------------------------QKVPETKEP-NOV68j--------------------------------------------------DGTQCGEKK-NOV68k--------------------------------------------------QKVPETKEP-NOV68l--------------------------------------------------QKVPETKEP-NOV68m--------------------------------------------------DGTQCGEKK-NOV68a---WCMAGKC--------------------------------------------------NOV68b---TCGLKDS--------------------------------------------------NOV68c---TCGLKDS--------------------------------------------------NOV68d---TCGLKDS--------------------------------------------------NOV68e---TCGLKDS--------------------------------------------------NOV68f---TCGLKDS--------------------------------------------------NOV68gSRALCGLQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTPTGPESMSTSTPNOV68h---TCGLKDS--------------------------------------------------NOV68i---TCGLKDS--------------------------------------------------NOV68j---WCMAGKC--------------------------------------------------NOV68k---TCGLKDS--------------------------------------------------NOV68l---TCGLKDS--------------------------------------------------NOV68m---WCMAGKC--------------------------------------------------NOV68a-------ITVGKKPESIPGGWGRWSPWSHCSRTCGAGVQSAERLCNNPEPKFGGKYCT--NOV68b-------VNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGS--NOV68c-------VNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGS--NOV68d-------VNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGS--NOV68e-------VNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGS--NOV68f-------VNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGS--NOV68gAISSPSPTTASKEGDLGGKQWQDSSTQPELSSRYLISTGSTSQPILTSQSLSIQPSEENVNOV68h-------VNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGS--NOV68i-------VNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGS--NOV68j-------ITVGKKPESIPGGCGRWSPWSHCS-----------------------------NOV68k-------VNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGS--NOV68l-------VNISQKQELWREKWERHNLPSRSLSRRSISKERWVETLVVADTKMIEYHGS--NOV68m-------ITVGKKPESIPGGWGRWSPWSHCSLE---------------------------NOV68a--------------------GERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVPYKNELYHNOV68b--------------------ENVESCILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEENOV68c--------------------ENVESYILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEENOV68d--------------------ENVESYILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEENOV68e--------------------ENVESYILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEENOV68f--------------------ENVESYILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEENOV68gSSSDTGPTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMEIHSGSGEEREQPNOV68h--------------------ENVESCILTIMNMVTGLFMNPSIGNAIHIVVVRLILLEEENOV68i--------------------ENVESYILTIMNMITGLFHNPSIGNAIHIVVVRLILLEEENOV68j------------------------------------------------------------NOV68k--------------------ENVESYILTIMNMVTGLFHNPSIGNAIHIVVVRLILLEEENOV68l--------------------ENVESYILTIMNNVTGLFHNPSIGNAIHIVVVRLILLEEENOV68m------------------------------------------------------------NOV68aWFP---------------------------------------------------------NOV68bEQG---------------------------------------------------------NOV68cEQG---------------------------------------------------------NOV68dEQG---------------------------------------------------------NOV68eEQG---------------------------------------------------------NOV68fEQG---------------------------------------------------------NOV68gEDKDESNPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSTVMEGLLPSQRPNOV68hEQG---------------------------------------------------------NOV68iEQG---------------------------------------------------------NOV68j------------------------------------------------------------NOV68kEQG---------------------------------------------------------NOV68lEQG---------------------------------------------------------NOV68m------------------------------------------------------------NOV68a------------------------------------------IFNPAHPCELYCR-----NOV68b------------------------------------------LKIVHHAEKTLSS-----NOV68c------------------------------------------LKIVNHAEKTLSS-----NOV68d------------------------------------------LKIVHHAEKTLSS-----NOV68e------------------------------------------LKIVHHAEKTLSS-----NOV68f------------------------------------------LKIVHHAEKTLSS-----NOV68gTTSETGTPRVEGMVTEKPANTLLPLGGDHQPEPSGKTANRNHLKLPNNMNQTKSSEPVLTNOV68h------------------------------------------LKIVHHAEKTLSS-----NOV68i------------------------------------------LKIVHHAEKTLSS-----NOV68j------------------------------------------------------------NOV68k------------------------------------------LKIVHHAEKTLSS-----NOV68l------------------------------------------LKIVHHAEKTLSS-----NOV68m------------------------------------------------------------NOV68a----------------------------------------------------------PIDGQFSEKMLDNOV68b----------------------------------------------------------FCKWQKSINPKSNOV68c----------------------------------------------------------FCKWQKSINPKSNOV68d----------------------------------------------------------FCKWQKSINPKSNOV68e----------------------------------------------------------FCKWQKSINPKSNOV68f----------------------------------------------------------FCKWQKSINPKSNOV68gEEDATSLITEGFLLNASNYKQLTNGYGSAHWIVGNWSECSTTCGLGAYWRRVECSTQMDSNOV68h----------------------------------------------------------FCKWQKSINPKSNOV68i----------------------------------------------------------FCKWQKSINPKSNOV68j------------------------------------------------------------NOV68k----------------------------------------------------------FCKWQKSINPKSNOV68l----------------------------------------------------------FCKWQKSINPKSNOV68m------------------------------------------------------------NOV68aAVIDGTPCFEGGNSRNVCINGICKMVGCDYEIDSNATEDRCGVCLGDG-SSCQTVRKMFKNOV68bDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINE-DSGLPLAFTIANOV68cDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINE-DSGLPLAFTIANOV68dDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGNCQPHRSCNINE-DSGLPLAFTIANOV68eDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINE-DSGLPLAFTIANOV68fDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINE-DSGLPLAFTIANOV68gDCAAIQRPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSRDHRNLRPFHCQNOV68hDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINE-DSGLPLAFTIANOV68iDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINE-DSGLPLAFTIANOV68j------------------------------------------------------------NOV68kDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINE-DSGLPLAFTIANOV68lDLNPVHHDVAVLLTRKDICAGFNRPCETLGLSHLSGMCQPHRSCNINE-DSGLPLAFTIANOV68m------------------------------------------------------------NOV68aQKEGSGYVDIGLIPKGARDIRVMEIEGAGNFLAIRSE-----------------DPEKYYNOV68bHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPT-----------------PLTWSKNOV68cHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPT-----------------PLTWSKNOV68dHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPT-----------------PLTWSKNOV68eHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPT-----------------PLTWSKNOV68fHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPT-----------------PLTWSKNOV68gFLAGIPPPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVOERGVFCPGGLCDWTKRPTSThSNOV68hHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPT-----------------PLTWSKNOV68iHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPT-----------------PLTWSKNOV68j------------------------------------------------------------NOV68kHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPT-----------------PLTWSKNOV68lHELGHSFGIQHDGKENDCEPVGRHPYIMSRQLQYDPT-----------------PLTWSKNOV68m------------------------------------------------------------NOV68aLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWIQLLFQVTNPGIKYEYTINOV68bCSEEYITRFLDRGWGFCLDDIPLE------------------------------------NOV68cCSEEYITRFLDRGWGFCLDDIPLE------------------------------------NOV68dCSEEYITRFLDRGWGFCLDDIPLE------------------------------------NOV68eCSEEYITRFLDRGWGFCLDDIPKKKGLKSKVIAPGVIYDVHHQCQLQYGPNATLCQEVENNOV68fCSEEYITRFLDRGWGFCLDDIPKKKGLKSKVIAPGVIYDVHHQCQLQYGPNATLCQEVENNOV68gCNEHLCCHWATGNWDLCSTSCGGGFQKRTVQCVPSEGNKTEDQDQCLCDHKPRPPEFKKCNOV68hCSEEYITRFLDRGWGFCLDDIP--------------------------------------NOV68iCSEEYITRFLDRGWGFCLDDIP--------------------------------------NOV68j------------------------------------------------------------NOV68kCSEEYITRFLDRGWGFCLDDIPKKKGLKSKVIAPGVIYDVHHQCQLQYGPNATFCQEVENNOV68lCSEEYITRFLDRGWGFCLDDIPLE------------------------------------NOV68m------------------------------------------------------------NOV68aQKDGLDNDVEQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKGRGMVKATFCDPETQPNGRNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eVCQTLWCSVKGFCRSKLDAAADGTQCGEKKWCMAGKCITVGKKPESIPGGWGRWSPWSHCNOV68fVCQTLWCSVKGFCRSKLDAAADGTQCGEKKWCMAGKCITVGKKPESIPGGWGRWSPWSHCNOV68gNQQACKKSADLLCTKDKLSASFCQTLKAMKKCSVPTVRAECCFSCPQTHITHTQRQRRQRNOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kVCQTLWCSVKGFCRSKLDAAADGTQCGEKKWCMAGKCITVGKKPESIPGGWGRWSPWSHCNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMVSDEQALPPTDCQHLLKPKNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eSRTCGAGVQSAERLCNNPEPKFGGKYCTGERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVNOV68fSRTCGAGVQSAERLCNNPEPKFGGKYCTGERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVNOV68gLLQKSKELLE--------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kSRTCGAGVQSAERLCNNPEPKFGGKYCTGERKRYRLCNVHPCRSEAPTFRQMQCSEFDTVNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNHDEPCDVTRKPNSRALCGLNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68ePYKNELYHWFPIFNPAHPCELYCRPIDGQFSEKMLDAVIDGTPCFEGGNSRNVCINGICKNOV68fPYKNELYHWFPIFNPAHPCELYCRPIDGQFSEKMLDAVIDGTPCFEGGNSRNVCINGICKNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kPYKNELYHWFPIFNPAHPCELYCRPIDGQFSEKMLDAVIDGTPCFEGGNSRNVCINGICKNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTPTGPESMSTSTPAISSPSPNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eMVGCDYEIDSNATEDRCGVCLGDGSSCQTVRKMFKQKEGSGYVDIGLIPKGARDIRVMEINOV68fMVGCDYEIDSNATEDRCGVCLGDGSSCQTVRKMFKQKEGSGYVDIGLIPKGARDIRVMEINOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kMVGCDYEIDSNATEDRCGVCLGDGSSCQTVRKMFKQKEGSGYVDIGLIPKGARDIRVMEINOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aTTASKEGDLGGKQWQDSSTQPELSSRYLISTGSTSQPILTSQSLSIQPSEENVSSSDTGPNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eEGAGNFLAIRSEDPEKYYLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWNOV68fEGAGNFLAIRSEDPEKYYLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kEGAGNFLAIRSEDPEKYYLNGGFIIQWNGNYKLAGTVFQYDRKGDLEKLMATGPTNESVWNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMEIHSGSGEEREQPEDKDESNNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eIQLLFQVTNPGIKYEYTIQKDGLDNDVEQQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKNOV68fIQLLFQVTNPGIKYEYTIQKDGLDNDVEQQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kIQLLFQVTNPGIKYEYTIQKDGLDNDVEQQMYFWQYGHWTECSVTCGTGIRRQTAHCIKKNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSTVMEGLLPSQRPTTSETGTNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eGRGMVKATFCDPETQPNGRQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMNOV68fGRGMVKATFCDPETQPNGRQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kGRGMVKATFCDPETQPNGRQKKCHEKACPPRWWAGEWEACSATCGPHGEKKRTVLCIQTMNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aPRVEGMVTEKPANTLLPLGGDHQPEPSGKTANRNHLKLPNNMNQTKSSEPVLTEEDATSLNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eVSDEQALPPTDCQHLLKPKTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNNOV68fVSDEQALPPTDCQHLLKPKTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kVSDEQALPPTDCQHLLKPKTLLSCNRDILCPSDWTVGNWSECSVSCGGGVRIRSVTCAKNNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aITEGFLLNASNYKQLTNGHGSAHWIVGNWSECSTTCGLGAYWKRVECTTQMDSDCAAIQRNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eHDEPCDVTRKPNSRALCGLQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTNOV68fHDEPCDVTRKPNSRALCGLQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kHDEPCDVTRKPNSRALCGLQQCPSSRRVLKPNKGTISNGKNPPTLKPVPPPTSRPRMLTTNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSRDHRNLRPFHCQFLAGIPPNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68ePTGPESMSTSTPAISSPSPTTASKEGDLGGKQWQDSSTQPELSSRTLISTGSTSQPILTSNOV68fPTGPESMSTSTPAISSPSPTTASKEGDLGGKQWQDSSTQPELSSRYLISTGSTSQPILTSNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kPTGPESMSTSTPAISSPSPTTASKEGDLGGKQWQDSSTQPELSSRYLISTGSTSQPILTSNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVQERGVFCPGGLCDWTKRPTSTMSCNEHLCCNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eQSLSIQPSEENVSSSDTGPTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMENOV68fQSLSIQPSEENVSSSDTGPTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMENOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kQSLSIQPSEENVSSSDTGPTSEGGLVATTTSGSGLSSSRNPITWPVTPFYNTLTKGPEMENOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aHWATGNWDLCSTSCGGGFQKRIVQCVPSEGNKTEDQDQCLCDHKPRPPEFKKCNQQACKKNOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eIHSGSGEEREQPEDKDESNPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSNOV68fIHSGSGEEREQPEDKDESNPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kIHSGSGEEREQPEDKDESNPVIWTKIRVPGNDAPVESTEMPLAPPLTPDLSRESWWPPFSNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aSADLLCTKDKLSASFCQTLKAMKKCSVPTVRAECCFSCPQTHITHTQRQRRQRLLQKSKENOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eTVMEGLLPSQRPTTSETGTPRVEGMVTEKPANTLLPLGGDHQPEPSGKTANRNHLKLPNNNOV68fTVMEGLLPSQRPTTSETGTPRVEGMVTEKPANTLLPLGGDHQPEPSGKTANRNHLKLPNNNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kTVMEGLLPSQRPTTSETGTPRVEGMVTEKPANTLLPLGGDHQPEPSGKTANRNHLKLPNNNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68aL-----------------------------------------------------------NOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eMNQTKSSEPVLTEEDATSLITEGFLLNASNYKQLTNGHGSAHWIVGNWSECSTTCGLGAYNOV68fMNQTKSSEPVLTEEDATSLITEGFLLNASNYKQLTNGHGSAHWIVGNWSECSTTCGLGAYNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kMNQTKSSEPVLTEEDATSLITEGFLLNASNYKQLTNGHGSAHWIVGNWSECSTTCGLGAYNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68a------------------------------------------------------------NOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eWRRVECSTQMDSDCAAIQRPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSNOV68fWRRVECSTQMDSDCAAIQRPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kWRRVECSTQMDSDCAAIQRPDPAKRCHLRPCAGWKVGNWSKCSRNCSGGFKIREIQCVDSNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68a------------------------------------------------------------NOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eRDHRNLRPFHCQFLAGIPPPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVQERGVFCPGGLNOV68fRDHRNLRPFHCQFLAGIPPPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVQERGVFCPGGLNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kRDHRNLRPFHCQFLAGIPPPLSMSCNPEPCEAWQVEPWSQCSRSCGGGVQERGVFCPGGLNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68a------------------------------------------------------------NOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eCDWTKRPTSTMSCNEHLCCHWATGNWDLCSTSCGGGFQKRTVQCVPSEGNKTEDQDQCLCNOV68fCDWTKRPTSTMSCNEHLCCHWATGNWDLCSTSCGGGFQKRTVQCVPSEGNKTEDQDQCLCNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kCDWTKRPTSTMSCNEHLCCHWATGNWDLCSTSCGGGFQKRTVQCVPSEGNKTEDQDQCLCNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68a------------------------------------------------------------NOV68b------------------------------------------------------------NOV68c------------------------------------------------------------NOV68d------------------------------------------------------------NOV68eDHKPRPPEFKKCNQQACKKSADLLCTKDKLSASFCQTLKAMKKCSVPTVRAECCFSCPQTNOV68fDHKPRPPEFKKCNQQACKKSADLLCTKDKLSASFCQTLKAMKKCSVPTVRAECCFSCPQTNOV68g------------------------------------------------------------NOV68h------------------------------------------------------------NOV68i------------------------------------------------------------NOV68j------------------------------------------------------------NOV68kDHKPRPPEFKKCNQQACKKSADLLCTKDKLSASFCQTLKAMKKCSVPTVRAECCFSCPQTNOV68l------------------------------------------------------------NOV68m------------------------------------------------------------NOV68a-------------------------NOV68b-------------------------NOV68c-------------------------NOV68d-------------------------NOV68eHITHTQRQRRQRLLQKSKELLEEFFNOV68fHITHTQRQRRQRLLQKSKGLLEEFFNOV68g-------------------------NOV68h-------------------------NOV68i-------------------------NOV68j-------------------------NOV68kHITHTQRQRRQRLLQKSKGLLEEFFNOV68l-------------------------NOV68m-------------------------NOV68a(SEQ ID NO: 1006)NOV68b(SEQ ID NO: 1008)NOV68c(SEQ ID NO: 1010)NOV68d(SEQ ID NO: 1012)NOV68e(SEQ ID NO: 1014)NOV68f(SEQ ID NO: 1016)NOV68g(SEQ ID NO: 1018)NOV68h(SEQ ID NO: 1020)NOV68i(SEQ ID NO: 1022)NOV68j(SEQ ID NO: 1024)NOV68k(SEQ ID NO: 1026)NOV68l(SEQ ID NO: 1028)NOV68m(SEQ ID NO: 1030)

Further analysis of the NOV68a protein yielded the following properties shown in Table 68C.

TABLE 68CProtein Sequence Properties NOV68aSignalP analysis:Cleavage site between residues 26 and 27PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 6; pos.chg 1; neg.chg 0H-region: length 21; peak value 6.23PSG score: 1.83GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −3.11possible cleavage site: between 27 and 28>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 2Number of TMS(s) for threshold 0.5: 0PERIPHERAL Likelihood = 4.98 (at 267)ALOM score: −1.54 (number of TMSs: 0)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 6Charge difference: 1.0 C( 3.0) - N( 2.0)C > N: C-terminal side will be inside>>>Caution: Inconsistent mtop result with signal peptideMITDISC: discrimination of mitochondrial targeting seqR content:3Hyd Moment (75):8.02Hyd Moment (95):8.85G content:3D/E content:1S/T content:2Score: −2.50Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 46 VRF|PDNUCDISC: discrimination of nuclear localization signalspat4: RRKR (5) at 79pat4: PKKK (4) at 456pat7: PKKKGLK (5) at 456pat7: PNGRQKK (3) at 869pat7: PHGEKKR (3) at 899bipartite: nonecontent of basic residues: 11.5%NLS Score: 1.04KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: KSKESKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: foundKLPN at 1269RNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 89COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):65.2%: nuclear21.7%: mitochondrial13.0%: cytoplasmic>> prediction for CG58504-01 is nuc (k = 23)

A search of the NOV68a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 68D.

TABLE 68DGeneseq Results for NOV68aNOV68aIdentities/Residues/Similarities forEx-GeneseqProtein/Organism/LengthMatchthe MatchedpectIdentifier[Patent #, Date]ResiduesRegionValueAAB74944Human ADAM type metal24 . . . 1574733/1718 (42%)0.0protease MDTS1 protein SEQ ID21 . . . 1673941/1718 (54%)NO:1 - Homo sapiens, 1686 aa.[JP2001008687-A, 16-Jan.-2001]AAE00913Human 27875 ADAM-TS24 . . . 1574731/1718 (42%)0.0protein, alternative version -21 . . . 1673939/1718 (54%)Homo sapiens, 1686 aa.[WO200131034-A1, 03-May-2001]AAE00934Human 27875 ADAM-TS24 . . . 1574731/1718 (42%)0.0disintegrin and metalloproteinase) -21 . . . 1673939/1718 (54%)Homo sapiens, 1686 aa.[WO200131034-A1, 03-May-2001]AAB86949Human metalloprotease MPTS-24 . . . 1574731/1718 (42%)0.019 protein - Homo sapiens, 169025 . . . 1677938/1718 (54%)aa. [DE10107360-A1, 06-Sep.-2001]AAB72283Human ADAMTS-7 amino acid24 . . . 903483/935 (51%)0.0sequence - Homo sapiens, 997 aa.21 . . . 936609/935 (64%)[WO200111074-A2, 15-Feb.-2001]

In a BLAST search of public sequence databases, the NOV68a protein was found to have homology to the proteins shown in the BLASTP data in Table 68E.

TABLE 68EPublic BLASTP Results for NOV68aNOV68aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueP58397ADAMTS-12 precursor (EC 1 . . . 15931593/1593 (100%)0.03.4.24.-) (A disintegrin and 1 . . . 15931593/1593 (100%)metalloproteinase withthrombospondin motifs 12)(ADAM-TS 12) (ADAM-TS 12) -Homo sapiens (Human), 1593aa.CAD60967Metalloprotease disintegrin 12 1 . . . 15881283/1600 (80%)0.0protein - Mus musculus 1 . . . 15951399/1600 (87%)(Mouse), 1600 aa.Q8BKYIADAMTS-12 precursor - Mus 1 . . . 1004 889/1009 (88%)0.0musculus (Mouse), 1009 aa 1 . . . 1009 939/1009 (92%)(fragment).CAC38921Sequence 2 from Patent24 . . . 1574 731/1718 (42%)0.0W0013 1034 - Homo sapiens21 . . . 1673 939/1718 (54%)(Human), 1686 aa.Q9UKP4ADAMTS-7 precursor (EC24 . . . 903 485/935 (51%)0.03.4.24.-) (A disintegrin and21 . . . 936 611/935 (64%)metalloproteinase withthrombospondin motifs 7)(ADAM-TS 7) (ADAM-TS7) -Homo sapiens (Human), 997 aa.

PFam analysis indicates that the NOV68a protein contains the domains shown in the Table 68F.

TABLE 68FDomain Analysis of NOV68aIdentities/SimilaritiesPfam DomainNOV68a Match Regionfor the Matched RegionExpect ValuePep_M12B_propep 105 . . . 222 27/128(21%)9.2e-05 80/128 (62%)Reprolysin 246 . . . 456 66/224 (29%)1.3e-15 149/224 (67%)tsp_1 546 . . . 596 23/53 (43%)2.2e-13 38/53 (72%)tsp_1 827 . . . 881 15/64 (23%)0.054 39/64 (61%)tsp_1 945 . . . 995 17/58(29%)7.1e-05 39/58 (67%)tsp_11314 . . . 1364 13/56 (23%)0.036 29/56 (52%)tsp_11426 . . . 1471 14/54 (26%)0.055 32/54 (59%)tsp_11474 . . . 1530 14/63 (22%)0.0045 40/63 (63%)

Example 69

The NOV69 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 69A.

TABLE 69ANOV69 Sequence AnalysisNOV69a, CG58510-01SEQ ID NO: 1031933 bpDNA SequenceORF Start: ATG at 8ORF Stop: at 932GGATTAAATGGAAAACGATCACAATCATAATCATACACATGGCGCGAACAAAAAGACTTTATTAATTAGTTTTATTATTATTACAAGTTACATGATTGTAGAAGGGTTAGGTGGTTTCTTTACTAACAGTCTTGCGTTAATTTCAGATGCTGGTCATATGTTAAGTGATTCTATTTCTTTAGGTATTGCTTTAATTGCATTTACTTTAGGAGCGAAGCAAGCTAATACAAATAAAACTTTTGGCTACAAAAGGTTTGAAATACTAGCAGCTGTACTTAATGGTATTACTTTGATGTTAATAGCTATCTATATTTTTTATGAAGCTATTGAGAGATTTAAAAACCCCCCTGAGGTAGCTTCTACAGGCATGTTAATTATCGCCTTGGTAGGCTTGTTTATTAATATTATTGTGGCTTGGATAATGCTGCGCGGGAGCGATGTAGAAGAAAACTTAAATATGCGTGGAGCATATTTGCATGTAATAAGCGACATGCTTGGATCTATAGGTGCAGTTATAGCAGCCCTTCTCATTATATTTTTTAGATGGGGGTGGGCGGATCCTTTAGCAAGTGTGATTGTAGCAATTTTAGTACTACGTAGCGGCTTTTATGTAACAAAATCAAGTCTTCATGTATTAATGGAGGGAGCACCAAGCAATATAAATACAAAAGACATTATTAAAACTATTAAAAAATTCAAAGAAGTTAAAAATATTCATGACTTTCATGTTTGGTCAGTAACTAGCGGATTAAACGCGTTATCTTGTCATATTGTTGTAGAAGATACAATGACCATTACTGAAAATGAGTTTTTACTTAAACGTATAGAACATGAATTCAATCATCAAAATATTCAACATGTCACAATACAGACTGAAACTTCTAACAATAATCATAGTGAAAAATTGTTTTGTATCGTGAAAGAAGAAGACAGNOV69a, CG58510-01Protein SequenceSEQ ID NO: 1032308 aaMW at 34326.6kDMENDHNHNHTHGANKKTLLISFIIITSYMIVEGLGGFFTNSLALISDAGHMLSDSISLGIALIAFTLGAKQANTNKTFGYKRFEILAAVLNGITLMLIAIYIFYEAIERFKNPPEVASTGMLIIALVGLFINIIVAWIMLRGSDVEENLNMRGAYLHVISDMLGSIGAVIAALLIIFFRWGWADPLASVIVAILVLRSGFYVTKSSLHVLMEGAPSNINTKDIIKTIKKFKEVKNIHDFHVWSVTSGLNALSCHIVVEDTMTITENEFLLKRIEHEFNHQNIQHVTIQTETSNNNHSEKLFCIVKEED

Further analysis of the NOV69a protein yielded the following properties shown in Table 69B.

TABLE 69BProtein Sequence Properties NOV69aSignalP analysis:Cleavage site between residues 34 and 35PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 4; pos.chg 0; neg.chg 2H-region: length 10; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −6.24possible cleavage site: between 43 and 44>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRAL Likelihood = −4.46Transmembrane 18-34INTEGRAL Likelihood = −1.65Transmembrane 51-67INTEGRAL Likelihood = −6.32Transmembrane 85-101INTEGRAL Likelihood = −11.41Transmembrane 122-138INTEGRAL Likelihood = −9.55Transmembrane 162-178INTEGRAL Likelihood = −4.73Transmembrane 186-202PERIPHERAL Likelihood = 2.54 (at 241)ALOM score: −11.41 (number of TMSs: 6)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 25Charge difference: −3.0 C(−1.0) - N( 2.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment (75):6.56Hyd Moment (95):3.47G content:0D/E content:2S/T content:0Score: −7.29Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 7.5%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KKXX-like motif in the C-terminus: VKEESKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction.: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):66.7%: endoplasmic reticulum22.2%: mitochondrial11.1%: vesicles of secretory system>> prediction for CG58510-01 is end (k = 9)

A search of the NOV69a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 69C.

TABLE 69CGeneseq Results for NOV69aNOV69aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB48454Listeria monocytogenes protein 5 . . . 296163/294 (55%)2e-91#1158 - Listeria monocytogenes,11 . . . 299225/294 (76%)303 aa. [WO200177335-A2, 18-Oct.-2001]ABP39345Staphylococcus epidermidis ORF 3 . . . 302157/300 (52%)3e-91amino acid sequence SEQ ID35 . . . 334220/300 (73%)NO:4190 - Staphylococcusepidermidis, 342 aa. [US6380370-B1, 30-Apr.-2002]ABP40773Staphylococcus epidermidis ORF 1 . . . 299112/305 (36%)4e-56amino acid sequence SEQ ID47 . . . 351188/305 (60%)NO:5618 - Staphylococcusepidermidis, 359 aa. [US6380370-B1, 30-Apr.-2002]AAU61849Propionibacterium acnes 6 . . . 298108/299 (36%)8e-52immunogenic protein #22745 -10 . . . 306185/299 (61%)Propionibacterium acnes, 310 aa.[WO200181581-A2, 01-Nov.-2001]AAB76797Corynebacterium glutamicum 3 . . . 300107/302 (35%)2e-51MCT protein SEQ ID NO:576 -18 . . . 317180/302 (59%)Corynebacterium glutamicum, 318aa. [WO200100805-A2, 04-Jan.-2001]

In a BLAST search of public sequence databases, the NOV69a protein was found to have homology to the proteins shown in the BLASTP data in Table 69D.

TABLE 69DPublic BLASTP Results for NOV69aNOV69aIdentities/ProteinResidues/Similarities forEx-AccessionMatchthe MatchedpectNumberProtein/Organism/LengthResiduesPortionValueO07084Cation transport protein YRDO -7 . . . 307206/301 (68%)e-122Bacillus subtilis, 311 aa.3 . . . 303253/301 (83%)P71023CzcD - Bacillus subtilis, 295 aa21 . . . 307194/287 (67%)e-115(fragment).1 . . . 287242/287 (83%)Q8NVF2CzrB protein - Staphylococcus3 . . . 302161/300 (53%)2e-95aureus (strain MW2), 326 aa.8 . . . 307225/300 (74%)Q99SB4CzrB protein (Cation-efflux3 . . . 302161/300 (53%)2e-95system membrane protein7 . . . 306225/300 (74%)homolog) - Staphylococcus aureus(strain Mu50 / ATCC 700699),and, 325 aa.Q9ZNF5CzrB protein - Staphylococcus3 . . . 302161/300 (53%)2e-95aureus, 325 aa.7 . . . 306225/300 (74%)

PFam analysis indicates that the NOV69a protein contains the domains shown in the Table 69E.

TABLE 69EDomain Analysis of NOV69aIdentities/NOV69aSimilaritiesMatchfor thePfam DomainRegionMatched RegionExpect ValueCation_efflux18 . . . 296102/303 (34%)1.5e-106245/303 (81%)

Example 70

The NOV70 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 70A.

TABLE 70ANOV70 Sequence AnalysisNOV70a, CG59309-01SEQ ID NO: 10331375 bpDNA SequenceORF Start: ATG at 96ORF Stop: TAA at 1362GGGACGCCGGACGCCGTCCGGACATTCGGCGCGCTTGCCACGATCTTGGACGGGTCTCGGGCCTCGACCTTTGAATTCCCCGCTCCGGCTCCAAGATGTCAGCAACGCTGATCCTGGAGCCCCCAGGCCGCTGCTGCTGGAACGAGCCGGTGCGCATTGCCGTGCGCGGCCTGGCCCCGGAGCAGCGGGTTACGCTGCGCGCGTCCCTGCGCGACGAGAAGGGCGCGCTCTTCCGGGCCCACGCGCGCTACTGCGCCGACGCCCGCGGCGAGCTGGACCTGGAGCGCGCACCCGCGCTGGGCGGCAGCTTCGCGGGACTCGAGCCCATGGGGCTGCTCTGGGCCCTGGAACCCGAGAAGCCTTTTTGGCGCTTCCTGAAGCGGGACGTACAGATTCCTTTTGTCGTGGAGTTGGAGGTGCTGGACGGCCACGACCCCGAGCCTGGACGGCTGCTGTGCCAGGCGCAGCACGAGCGCCACTTCCTCCCGCCAGGGGTGCGGCGCCAGTCGGTGCGAGCGGGCCGGGTGCGCGCCACGCTCTTCCTGCCGCCAGGTGAGCCTGGACCCTTCCCAGGGATCATTGACATCTTTGGTATTGGAGGGGGCCTCTTGGAATATCGAGCCAGCCTCCTTGCTGGCCATGGCTTTGCCACGTTGGCTCTAGCTTATTATAACTTTGAAGATCTCCCCAATAACATGGACAACATATCCCTGGAGTACTTCGAAGAAGCCGTATGCTACATGCTTCAACATCCCCAGGTTAAAGGCCCAGGCATTGGGCTTTTGGGCATTTCTCTAGGAGCTGATATTTGTCTCTCAATGGCCTCATTCTTGAAGAATGTCTCAGCCACAGTTTCCATCAATGGATCTGGGATCAGTGGGAACACAGCCATCAACTATAAGCACAGTAGCATTCCACCATTGGGCTATGACCTGAGGAGAATCAAGGTAGCTTTCTCAGGCCTCGTGGACATTGTGGATATAAGGAATGCTCTCGTAGGAGGGTACAAGAACCCCAGCATGATTCCAATAGAGAAGGCCCAGGGGCCCATCCTGCTCATTGTTGGTCAGGATGACCATAACTGGAGAAGTGAGTTGTATGCCCAAACAGTCTCTGAACGGTTACAGGCCCATGGAAAGGAAAAACCCCAGATCATCTGTTACCCTGGGACTGGGCATTACATCGAGCCTCCTTACTTCCCCCTGTGCCCAGCTTCCCTTCACAGATTACTGAACAAACATGTTATATGGGGTGGGGAGCCCAGGGCTCATTCTAAGGCCCAGGAAGATGCCTGGAAGCAAATTCTAGCCTTCTTCTGCAAACACCTGGGAGGTACCCAGAAAACAGCTGTCCCTAAATTGTAATGCATTTGTCTNOV70a, CG59309-01Protein SequenceSEQ ID NO: 1034422 aaMW at 46455.1kDMSATLILEPPGRCCWNEPVRIAVRGLAPEQRVTLRASLRDEKGALFRAHARYCADARGELDLERAPALGGSFAGLEPMGLLWALEPEKPFWRFLKRDVQIPFVVELEVLDGHDPEPGRLLCQAQHERHFLPPGVRRQSVRAGRVRATLFLPPGEPGPFPGIIDIFGIGGGLLEYRASLLAGHGFATLALAYYNFEDLPNNMDNISLEYFEEAVCYMLQHPQVKGPGIGLLGISLGADICLSMASFLKNVSATVSINGSGISGNTAINYKHSSIPPLGYDLRRIKVAFSGLVDIVDIRNALVGGYKNPSMIPIEKAQGPILLIVGQDDHNWRSELYAQTVSERLQAHGKEKPQIICYPGTGHYIEPPYFPLCPASLHRLLNKHVIWGGEPRAHSKAOEDAWKQILAFFCKHLGGTQKTAVPKLNOV70b, 278901386SEQ ID NO: 10351285 bpDNA SequenceORF Start: at 2ORF Stop: end of sequenceCACCGGATCCACCATGTCAGCAACGCTGATCCTGGAGCCCCCAGGCCGCTGCTGCTGGAACGAGCCGGTGCGCATTGCCGTGCGCGGCCTGGCCCCGGAGCAGCGGGTTACGCTGCGCGCGTCCCTGCGCGACGAGAAGGGCGCGCTCTTCCGGGCCCACGCGCGCTACTGCGCCGACGCCTGCGGCGAGCTGGACCTGGAGCGCGCACCCGCGCTGGGCGGCAGCTTCGCGGGACTCGAGCCCATGGGGCTGCTCTGGGCCCTGGAACCCGAGAAGCCTTTTTGGCGCTTCCTGAAGCGGGACGTACAGATTCCTTTTGTCGTGGAGTTGGAGGTGCTGGACGGCCACGACCCCGAGCCTGGACGGCTGCTGTGCCAGGCGCAGCACGAGCGCCACTTCCTCCCGCCAGGGGTGCGGCGCCAGTCGGTGCGAGCGGGCCGGGTGCGCGCCACGCTCTTCCTGCCGCCAGGACCTGGACCCTTCCCAGGGATCATTGACATCTTTGGTATTGGAGGGGGCCTCTTGGAATATCGAGCCAGCCTCCTTGCTGGCCATGGCTTTGCCACGTTGGCTCTAGCTTATTATAACTTTGAAGATCTCCCCAATAACATGGACAACATATCCCTGGAGTACTTCGAAGAAGCCGTATGCTACATGCTTCAACATCCCCAGGTAAAAGGCCCAGGCATTGGGCTTTTGGGCATTTCTCTAGGAGCTGATATTTGTCTCTCAATGGCCTCATTCTTGAAGAATGTCTCAGCCACAGTTTCCATCAATGGATCTGGGATCAGTGGGAACACAGCCATCAACTATAAGCACAGTAGCATTCCACCATTGGGCTATGACCTGAGGAGAATCAAGGTAGCTTTCTCAGGCCTCGTGGACATCGTGGATATAAGGAATGCTCTCGTAGGAGGGTACAAGAACCCCAGCATGATTCCAATAGAGAAGGCCCAGGGGCCCATCCTGCTCATTGTTGGTCAGGATGACCATAACTGGAGAAGTGAGTTGTATGCCCAAACAGTCTCTGAACGGTTACAGGCCCATGGAAAGGAAAAACCCCAGATCATCTGTTACCCTGGGACTGGGCATTACATCGAGCCTCCTTACTTCCCCCTGTGCCCAGCTTCCCTTCACAGATTACTGAACAAACATGTTATATGGGGTGGGGAGCCCAGGGCTCATTCTAAGGCCCAGGAAGATGCCTGGAAGCAAATTCTAGCCTTCTTCTGCAAACACCTGGGAGGTACCCAGAAAACAGCTGTCCCTAAATTGGTCGACGGCNOV70b, 278901386Protein SequenceSEQ ID NO: 1036428 aaMW at 46890.5kDTGSTMSATLILEPPGRCCWNEPVRIAVRGLAPEQRVTLRASLRDEKGALFRAHARYCADACGELDLERAPALGGSFAGLEPMGLLWALEPEKPFWRFLKRDVQIPFVVELEVLDGHDPEPGRLLCQAQHERHFLPPGVRRQSVRAGRVRATLFLPPGPGPFPGIIDIFGIGGGLLEYRASLLAGHGFATLALAYYNFEDLPNNMDNISLEYFEEAVCYMLQHPQVKGPGIGLLGISLGADICLSMASFLKNVSATVSINGSGISGNTAINYKHSSIPPLGYDLRRIKVAFSGLVDIVDIRNALVGGYKNPSMIPIEKAQGPILLIVGQDDHNWRSELYAQTVSERLQAHGKEKPQIICYPGTGHYIEPPYFPLCPASLHRLLNKNVIWGGEPRAHSKAQEDAWKQILAFFCKHLGGTQKTAVPKLVDG

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 70B.

TABLE 70BComparison of the NOV70 protein sequences.NOV70a----MSATLILEPPGRCCWNEPVRIAVRGLAPEQRVTLRASLRDEKGALFRAHARYCADANOV70bTGSTMSATLILEPPGRCCWNEPVRIAVRGLAPEQRVTLRASLRDEKGALFRAHARYCADANOV7caRGELDLERAPALGGSFAGLEPMGLLWALEPEKPFWRFLKRDVQIPFVVELEVLDGHDPEPNOV70bCGELDLERAPALGGSFAGLEPMGLLWALEPEKPFWRFLKRDVQIPFVVELEVLDGHDPEPNOV70aGRLLCQAQHERHFLPPGVRRQSVRAGRVRATLFLPPGEPGPFPGIIDIFGIGGGLLEYRANOV70bGRLLCQAQHERHFLPPGVRRQSVRAGRVRATLFLPPG-PGPFPGIIDIFGIGGGLLEYRANOV70aSLLAGHGFATLALAYYNFEDLPNNNDNISLEYFEEAVCYMLQHPQVKGPGIGLLGISLGANOV70bSLLAGHGFATLALAYYNFEDLPNNMDNISLEYFEEAVCYMLQHPQVKGPGIGLLGISLGANOV70aDICLSMASFLKNVSATVSINGSGISGNTAINYKHSSIPPLGYDLRRIKVAFSGLVDIVDINOV70bDICLSMASFLKNVSATVSINGSGISGNTAINYKHSSIPPLGYDLRRIKVAFSGLVDIVDINOV70aRNALVGGYKNPSMIPIEKAQGPILLIVGQDDHNWRSELYAQTVSERLQAHGKEKPQIICYNOV70bRNALVGGYKNPSMIPIEKAQGPILLIVGQDDHNWRSELYAQTVSERLQAHGKEKPQIICYNOV70aPGTGHYIEPPYFPLCPASLHRLLNKHVIWGGEPRAHSKAQEDAWKQILAFFCKHLGGTQKNOV70bPGTGHYIEPPYFPLCPASLHRLLNKHVIWGGEPRAHSKAQEDAWKQILAFFCKHLGGTQKNOV70aTAVPKL---NOV70bTAVPKLVDGNOV70a(SEQ ID NO: 1034)NOV70b(SEQ ID NO: 1036)

Further analysis of the NOV70a protein yielded the following properties shown in Table 70C.

TABLE 70CProtein Sequence Properties NOV7OaSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 8; pos..chg 0; neg.chg 1H-region: length 3; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −7.81possible cleavage site: between 13 and 14>>> Seems to have no N-terminal signal peptideALOM:Klein et al≡s method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 1Number of TMS(s) for threshold 0.5: 0PERIPHERAL Likelihood = 1.75 (at 285)ALOM score: −1.86 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:1Hyd Moment (75):7.13Hyd Moment (95):4.74G content:1D/E content:2S/T content:2Score: −6.03Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 10.4%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:KXXX-like motif in the C-terminus: AVPKSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR:N-myristoylation pattern : nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationprediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residues--------------------------Final Results (k = 9/23):65.2%: cytoplasmic13.0%: nuclear 8.7%: mitochondrial 8.7%: peroxisomal 4.3%: plasma membrane>> prediction for CG59309-01 is cyt (k = 23)

A search of the NOV70a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 70D.

TABLE 70DGeneseq Results for NOV70aNOV70aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE25382Human NZMS-6 protein - Homo 1 . . . 422421/422 (99%)0.0sapiens, 421 aa. [WO200246385- 1 . . . 421421/422 (99%)A2, 13-Jun.-2002]AAU76350Human Acyl-CoA thioesterase 1 . . . 422420/422 (99%)0.056939 - Homo sapiens, 421 aa. 1 . . . 421420/422 (99%)[WO200208274-A2, 31-Jan.-2002]AAM41490Human polypeptide SEQ ID NO 1 . . . 422296/422 (70%)e-1786421 - Homo sapiens, 494 aa.74 . . . 494341/422 (80%)[WO2001533 12-A1, 26-Jul.-2001]AAM39704Human polypeptide SEQ ID NO 1 . . . 422296/422 (70%)e-1782849 - Homo sapiens, 483 aa.63 . . . 483341/422 (80%)[WO2001 53312-A1, 26-Jul.-2001]AAY71112Human Hydrolase protein- 10 1 . . . 422296/422 (70%)e- 178(HYDRL-10) - Homo sapiens,63 . . . 483341/422 (80%)483 aa. [WO200028045-A2, 18-May-2000]

In a BLAST search of public sequence databases, the NOV70a protein was found to have homology to the proteins shown in the BLASTP data in Table 70E.

TABLE 70EPublic BLASTP Results for NOV70aNOV70aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAD35497Sequence 1 from Patent 1 . . . 422420/422 (99%)0.0WO0208274 - Homo sapiens 1 . . . 421420/422 (99%)(Human), 421 aa.Q8N9L9Hypothetical protein FLJ36904 - 1 . . . 422417/422 (98%)0.0Homo sapiens (Human), 421 aa. 1 . . . 421417/422 (98%)CAD62354Human full-length cDNA clone70 . . . 422352/353 (99%)0.0CSODIO29YHO6 of Placenta of 1 . . . 352352/353 (99%)Homo sapiens (human) - Homosapiens (Human), 352 aa(fragment).Q8BWN8Peroxisomal long chain acyl-CoA 1 . . . 422313/422 (74%)0.0thioesterase IB - Mus musculus 1 . . . 421363/422 (85%)(Mouse), 421 aa.Q8BL20Peroxisomal long chain acyl-CoA 1 . . . 422313/422 (74%)0.0thioesterase IB - Mus musculus 1 . . . 421362/422 (85%)(Mouse), 421 aa.

PFam analysis indicates that the NOV70a protein contains the domains shown in the Table 70F.

TABLE 70FDomain Analysis of NOV70aNOV70aIdentities/SimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValueBile_Hydr_Trans 3 . . . 152 84/157 (54%)1.9e−82140/157 (89%)DLH144 . . . 411 65/309 (21%)0.33170/309 (55%)

Example 71

The NOV71 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 71A.

TABLE 71ANOV71 Sequence AnalysisNOV71a, CG59490-01SEQ ID NO: 1037660 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceTCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCGGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCNOV71a, CG59490-01Protein SequenceSEQ ID NO: 1038220 aaMW at 24527.8kDSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNOTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRNOV71b, 207639512SEQ ID NO: 1039672 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAGATCTTCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAGCGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCCTCGAGNOV71b, 207639512Protein SequenceSEQ ID NO: 1040224 aaMW at 24943.3kDRSSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSSVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRLENOV71c, 207639476SEQ ID NO: 1041672 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAGATCTTCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCCTCGAGNOV71c, 207639476Protein SequenceSEQ ID NO: 1042224 aaMW at 24970.3kDRSSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRLENOV71d, 207639523SEQ ID NO: 1043672 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceAGATCTTCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGCCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTTGAGCTCATCCACCCGGTCTCGTCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCCTTCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCCTCGAGNOV71d, 207639523Protein SequenceSEQ ID NO: 1044224 aaMW at 24984.3kDRSSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQAGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRLENOV71e, CG59490-02SEQ ID NO: 1045672 bpDNA SequenceORF Start: at 7ORF Stop: at 667AGATCTTCACTGGGGGCTGCGACGTCTCGGCCAGGAGGCACCCCTGGCAGGGAGGAGTTGGAGGCTTGCGCGTTTAGAGTGCAGGTGGGGCAGCTGAGGCTCTATGAGGACGACCAGCGGACGAAGGTGGTTGAGATCGTCCGTCACCCCCAGTACAACGAGAGCCTGTCTGCCCAGGGCGGTGCGGACATCGCCCTGCTGAAGCTGGAGGCCCCGGTGCCGCTGTCTGAGCTCATCCACCCGGTCTCGCTCCCGTCTGCCTCCCTGGACGTGCCCTCGGGGAAGACCTGCTGGGTGACCGGCTGGGGTGTCATTGGACGTGGAGAACTACTGCCCTGGCCCCTCAGCTTGTGGGAGGCGACGGTGAAGGTCAGGAGCAACGTCCTCTGTAACCAGACCTGTCGCCGCCGCTTTCCTTCCAACCACACTGAGCGGTTTGAGCGGCTCATCAAGGACGACATGCTGTGTGCCGGGGACGGGAACCACGGCTCCTGGCCAGGCGACAACGGGGGCCCCCTCCTGTGCAGGCGGAATTGCACCTGGGTCCAGGTGGAGGTGGTGAGCTGGGGCAAACTCTGCGGCTATCGCGGCTATCCCGGCATGTACACCCGCGTGACGAGCTACGTGTCCTGGATCCGCCAGTACGTCCCGCCGTTCCCCAGACGCCTCGAGNOV71e, CG59490-02Protein SequenceSEQ ID NO: 1046220 aaMW at 24484.8kDSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGGADIALLKLEAPVPLSELIHPVSLPSASLDVPSGKTCWVTGWGVIGRGELLPWPLSLWEATVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 71B.

TABLE 71BComparison of the NOV71 protein sequences.NOV71a--SLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGNOV71bRSSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGNOV71cRSSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGNOV71dRSSLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGNOV71e--SLGAATSRPGGTPGREELEACAFRVQVGQLRLYEDDQRTKVVEIVRHPQYNESLSAQGNOV71aGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGELLPWPLSLWEANOV71bGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGELLPWPLSLWEANOV71cGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGELLPWPLSLWEANOV71dGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGELLPWPLSLWEANOV71eGADIALLKLEAPVPLSELIHPVSLPSASRDVPSGKTCWVTGWGVIGRGELLPWPLSLWEANOV71aTVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTNOV71bTVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTNOV71cTVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTNOV71dTVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTNOV71eTVKVRSNVLCNQTCRRRFPSNHTERFERLIKDDMLCAGDGNHGSWPGDNGGPLLCRRNCTNOV71aWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR--NOV71bWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRLENOV71cWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRLENOV71dWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRRLENOV71eWVQVEVVSWGKLCGLRGYPGMYTRVTSYVSWIRQYVPPFPRR--NOV71a(SEQ ID NO: 1038)NOV71b(SEQ ID NO: 1040)NOV71c(SEQ ID NO: 1042)NOV71d(SEQ ID NO: 1044)NOV71e(SEQ ID NO: 1046)

Further analysis of the NOV71a protein yielded the following properties shown in Table 71C.

TABLE 71CProtein Sequence Properties NOV71aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 8;pos.chg 1;neg.chg 0H-region:length 6;peak value−8.72PSG score:−13.12GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −7.58possible cleavage site: between 14 and 15>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 4.88 (at 62)ALOM score: 4.88 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment (75):6.94Hyd Moment (95):7.43G content:4D/E content:1S/T content:4Score: −3.60Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 18 SRP|GGNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 12.3%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 89COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23): 39.1%: cytoplasmic 30.4%: mitochondrial 17.4%: nuclear 8.7%: vesicles of secretory system 4.3%: vacuolar>> prediction for CG59490-01 is cyt (k = 23)

A search of the NOV71a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 71D.

TABLE 71DGeneseq Results for NOV71aNOV71aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE08591Human NOV12 protein - Homo 1 . . . 220 220/220 (100%)e−133sapiens, 220 aa. [WO200161009- 1 . . . 220 220/220 (100%)A2, 23-AUG-2001]AAE14347Human protease PRTS-12 15 . . . 220205/206 (99%)e−123protein - Homo sapiens, 262 aa. 57 . . . 262205/206 (99%)[WO200183775-A2, 08-NOV-2001]AAE08590Human NOV11 protein - Homo 16 . . . 220204/205 (99%)e−123sapiens, 285 aa. [WO200161009- 81 . . . 285204/205 (99%)A2, 23-AUG-2001]AAU82736Amino acid sequence of novel 15 . . . 215198/201 (98%)e−118human protease #35 - Homo211 . . . 411198/201 (98%)sapiens, 948 aa. [WO200200860-A2, 03-JAN-2002]AAE08587Human NOV8 protein - Homo 14 . . . 220200/207 (96%)e−118sapiens, 290 aa. [WO200161009- 84 . . . 290200/207 (96%)A2, 23-AUG-2001]

In a BLAST search of public sequence databases, the NOV71a protein was found to have homology to the proteins shown in the BLASTP data in Table 71E.

TABLE 71EPublic BLASTP Results for NOV71aNOV71aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueAAP21675Mast cell protease-11 - Mus16 . . . 217118/202 (58%)2e−59musculus (Mouse), 318 aa.86 . . . 284142/202 (69%)AAA30855Mastin precursor - Canis sp, 25116 . . . 218110/203 (54%)9e−51aa (fragment).53 . . . 249127/203 (62%)P19236Mastocytoma protease precursor16 . . . 218110/203 (54%)9e−51(EC 3.4.21.—) - Canis71 . . . 267127/203 (62%)familiaris (Dog), 269 aa.Q8SQ44Tryptase precursor - Sus scrofa24 . . . 218105/195 (53%)7e−49(Pig), 277 aa.90 . . . 275127/195 (64%)Q9XSM1Tryptase (EC 3.4.21.59) - Ovis14 . . . 218 89/205 (43%)1e−43aries (Sheep), 273 aa.75 . . . 273120/205 (58%)

PFam analysis indicates that the NOV71a protein contains the domains shown in the Table 71F.

TABLE 71FDomain Analysis of NOV71aPfamNOV71aIdentities/SimilaritiesExpectDomainMatch Regionfor the Matched RegionValuetrypsin8 . . . 210 81/272 (30%)1.9e−32152/272 (56%)

Example 72

The NOV72 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 72A.

TABLE 72ANOV72 Sequence AnalysisNOV72a, CG59693-01SEQ ID NO: 1047972 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAA at 970ATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATTAANOV72a, CG59693-01Protein SequenceSEQ ID NO: 1048323 aaMW at 36787.9kDMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYNOV72b, CG59693-03SEQ ID NO: 1049972 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAA at 970ATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGATACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATTAANOV72b, CG59693-03Protein SequenceSEQ ID NO: 1050323 aaMW at 36857.0kDMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKRYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYNOV72c, 277637252SEQ ID NO: 10511001 bpDNA SequenceORF Start: at 8ORF Stop: TAA at 989CATCTAGGCCACCATGGCCATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAAGTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATTAAACGCGTGATCNOV72c, 277637252Protein SequenceSEQ ID NO: 1052327 aaMW at 37162.4kDATMAMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYNOV72d, CG59693-02SEQ ID NO: 1053983 bpDNA SequenceORF Start: ATG at 30ORF Stop: TAA at 981ATGGATTCGATATCAGTGTGTGAAGCTGAATGATGGTCACTTCGTGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTACTCCCCCAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAGTGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGCCAAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGGTTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATTAANOV72d, CG59693-02Protein SequenceSEQ ID NO: 1054317 aaMW at 36217.5kDMMVTSCLSWDLAPMRLQRLLPQVPKSKALEATKLAIEAGRFHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDESGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGIKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALVALRYQLQRGVVVIAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYNOV72e, CG59693-04SEQ ID NO: 1055994 bpDNA SequenceORF Start: ATG at 16ORF Stop: at 979GCCAGATCTCCCACCATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATGTCGAGGGTGNOV72e, CG59693-04Protein SequenceSEQ ID NO: 1056321 aaMW at 36495.6kDMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVIVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDNOV72f, CG59693-05SEQ ID NO: 10571219 bpDNA SequenceORF Start: ATG at 24ORF Stop: TAA at 993TGCTAACCAGGCCAGTGACAGAAATGGATTCGAAATACCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTCTAGAGGCCGTCAAATTGGCAATAGAAGCCGGGTTCCACCATATTGATTCTGCACATGTTTACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGAGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGACTATGTTGACCTCTATCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCATGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCACAGGCTGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCATCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATTAACATGGAGGGCATTGCATGAGGTCTGCCAGAAGGCCCTGCGTGTGGATGGTGACACAGAGGATGGCTCTATGCTGGTGACTGGACACATCGCCTCTGGTTAAATCTCTCCTGCTTGGCGACTTCAGTAAGCTACAGCTAAGCCCATCGGCCGGAAAAGAAAGACAATAATTTTGTTTTTTCATTTTGAAAAAATTAAATGCTCTCTCCTAAAGATTCTTCACCTANOV72f, CG59693-05Protein SequenceSEQ ID NO: 1058323 aaMW at 36734.9kDMDSKYQCVKLNDGHFNPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHIDSAHVYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNHRLLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYNOV72g, CG59693-06SEQ ID NO: 10591001 bpDNA SequenceORF Start: at 11ORF Stop: at 983CATCTAGGCCACCATGGCCATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATTAAACGCGTGATCNOV72g, CG59693-06Protein SequenceSEQ ID NO: 1060324 aaMW at 36799.0kDTMAMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDNOV72h, CG59693-07SEQ ID NO: 10611012 bpDNA SequenceORF Start: at 1ORF Stop: at 1012GCCGGTACCACCATGGGCCACCATCACCACCATCACGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATCTCGAGGGTGNOV72h, CG59693-07Protein SequenceSEQ ID NO: 1062337 aaMW at 38297.5kDAGTTMGHHHHHHDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYLEGNOV72i, CG59693-08SEQ ID NO: 10631225 bp DNA SequenceORF Start: ATG at 24ORF Stop: TAA at 993TGCTAACCAGGCCAGTGACAGAAATGGATTCGAAATACCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTCTAGAGGCCGTCAAATTGGCAATAGAAGCCGGGTTCCACCATATTGATTCTGCACATGTTTACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGAGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGACTATGTTGACCTCTATCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCATGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCACAGGCTGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCATCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATTAACATGGAGGGCATTGCATGAGGTCTGCCAGAAGGCCCTGCGTGTGGATGGTGACACAGAGGATGGCTCTATGCTGGTGACTGGACACATCGCCTCTGGTTAAATCTCTCCTGCTTGGCGACTTCAGTAAGCTACAGCTAAGCCCATCGGCCGGAAAAGAAAGACAATAATTTTGTTTTTTCATTTTGAAAAAATTAAATGCTCTCTCCTAAAGATTCTTCACCTAAAAAAANOV72i, CG59693-08Protein SequenceSEQ ID NO: 1064323 aaMW at 36734.9kDMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHIDSAHVYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLDYVDLTLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNHRLLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYNOV72j, CG59693-09SEQ ID NO: 1065996 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAG at 985CACCGCGGCCGCACCATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATTAGGTCGACGGCNOV72j, CG59693-09Protein SequenceSEQ ID NO: 1066323 aaMW at 36787.9kDMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNEEQVGLAIRSKIADGSVKREDIFYTSKLWNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 72B.

TABLE 72BComparison of the NOV72 protein sequences.NOV72a-----------MDSKYQCVKLNDGHFNPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHINOV72b-----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHINOV72c-------ATMAMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHINOV72d----------------MMVTSCLSWDLAPMRLQRLLP-QVPKSKALEATKLAIEAGFRHINOV72e-----------MDSKYQCVKLNDGHFNPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHINOV72f-----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFHHINOV72g--------TMAMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHINOV72hAGTTMGHHHHHHDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHINOV72i-----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHINOV72j-----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHINOV72aDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72bDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72cDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72dDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72eDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72fDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72gDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72hDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72iDSAHVYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72jDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDNOV72aYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNNOV72bYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNNOV72cYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNNOV72dYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNNOV72eYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNNOV72fYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNNOV72gYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNNOV72hYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNNOV72iYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNNOV72jYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNNOV72aRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72bRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72cRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72dRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72eRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72fHRLLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72gRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72hRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72iHRLLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72jRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDNOV72aPNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTNOV72bPNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKRYNEQRIRQNVQVFEFQLTNOV72cPNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTNOV72dPNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTNOV72ePNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTNOV72fPNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTNOV72gPNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTNOV72hPNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTNOV72iPNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTNOV72jPNSPVLLEDPVLCALADDHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTNOV72aSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---NOV72bSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---NOV72cSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---NOV72dSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---NOV72eSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSD-----NOV72fSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---NOV72gSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSD-----NOV72hSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYLEGNOV72iSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---NOV72jSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---NOV72a(SEQ ID NO: 1048)NOV72b(SEQ ID NO: 1050)NOV72c(SEQ ID NO: 1052)NOV72d(SEQ ID NO: 1054)NOV72e(SEQ ID NO: 1056)NOV72f(SEQ ID NO: 1058)NOV72g(SEQ ID NO: 1060)NOV72h(SEQ ID NO: 1062)NOV72i(SEQ ID NO: 1064)NOV72j(SEQ ID NO: 1066)

Further analysis of the NOV72a protein yielded the following properties shown in Table 72C.

TABLE 72CProtein Sequence Properties NOV72aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 9;pos.chg 2;neg.chg 1H-region:length 2;peak value−3.30PSG score:−7.70GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −5.32possible cleavage site: between 27 and 28>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 3.66 (at 253)ALOM score: 3.66 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):0.10Hyd Moment(95):4.27G content:0D/E content:2S/T content:1Score: −7.79Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: KKHK (3) at 246pat4: KHKR (3) at 247pat7: nonebipartite: nonecontent of basic residues: 13.3%NLS Score: −0.10KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 76.7COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23): 34.8%: cytoplasmic 30.4%: mitochondrial 30.4%: nuclear 4.3%: vacuolar>> prediction for CG59693-01 is cyt (k = 23)

A search of the NOV72a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 72D.

TABLE 72DGeneseq Results for NOV72aNOV72aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAB43444Human cancer associated protein 1 . . . 323318/323 (98%)0.0sequence SEQ ID NO: 889 - Homo14 . . . 336318/323 (98%)sapiens, 336 aa. [WO200055350-A1, 21-SEP-2000]AAU85559Clone #59314 (L1426P) of lung 1 . . . 323311/323 (96%)0.0tumour protein - Homo sapiens, 1 . . . 323316/323 (97%)323 aa. [WO200204514-A2, 17-JAN-2002]ABB75050Human lung tumour L773P29 . . . 323288/295 (97%)e−168recombinant protein sequence77 . . . 371290/295 (97%)SEQ ID NO: 433 - Homo sapiens,371 aa. [WO200200174-A2, 03-JAN-2002]ABB74958Human lung tumour L773P29 . . . 323288/295 (97%)e−168protein sequence SEQ ID NO: 172 -70 . . . 364290/295 (97%)Homo sapiens, 364 aa.[WO200200174-A2, 03-JAN-2002]AAU85520L773P lung tumour protein -29 . . . 323288/295 (97%)e−168Homo sapiens, 364 aa.70 . . . 364290/295 (97%)[WO200204514-A2, 17-JAN-2002]

In a BLAST search of public sequence databases, the NOV72a protein was found to have homology to the proteins shown in the BLASTP data in Table 72E.

TABLE 72EPublic BLASTP Results for NOV72aNOV72aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ04828Aldo-keto reductase family 11 . . . 323 323/323 (100%)0.0member C1 (EC 1.1.1.—) (Trans-1,2-1 . . . 323 323/323 (100%)dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20) (High-affinity hepatic bile acid-bindingprotein) (HBAB) (Chlordeconereductase homolog HAKRC)(Dihydrodiol dehydrogenase 2)(DD2) (20 alpha-hydroxysteroiddehydrogenase) - Homo sapiens(Human), 323 aa.P52895Aldo-keto reductase family 11 . . . 323316/323 (97%)0.0member C2 (EC 1.1.1.—) (Trans-1,2-1 . . . 323318/323 (97%)dihydrobenzene-1,2-dioldehydrogenase) (EC 1.3.1.20)(Chlordecone reductase homologHAKRD) (Dihydrodioldehydrogenase/bile acid-bindingprotein) (DD/BABP) (Dihydrodioldehydrogenase 2) (DD2) - Homosapiens (Human), 323 aa.I73676chlordecone reductase homolog1 . . . 323313/323 (96%)0.0(clone HAKRd) - human, 323 aa.1 . . . 323317/323 (97%)I73675chlordecone reductase homolog4 . . . 323312/320 (97%)0.0(clone HAKRc) - human, 320 aa1 . . . 320313/320 (97%)(fragment).Q95JH63(20)alpha-1 . . . 323304/323 (94%)0.0hydroxysteroid/dihydrodiol/indanol1 . . . 323319/323 (98%)dehydrogenase (EC 1.1.1.112) -Macaca fuscata (Japanese macaque),323 aa.

PFam analysis indicates that the NOV72a protein contains the domains shown in the Table 72F.

TABLE 72FDomain Analysis of NOV72aNOV72aIdentities/SimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValuealdo_ket_red10 . . . 303164/369 (44%)3.4e−156274/369 (74%)

Example 73

The NOV73 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 73A.

TABLE 73ANOV73 Sequence AnalysisNOV73a, CG59839-02SEQ ID NO: 10674052 bpDNA SequenceORF Start: ATG at 786ORF Stop: TAG at 4023CTTCTGCCTCAGCCTCCCGAGTAGCTGGGATGGGACTACAGATGCACGCCACCACACCTGGCAATTTTTTTTAGTTTTGTGGAGACAAGGTCCCATGTGAGCCACTGTGCCCCACCTTTTAAAGAAATTACCATAAGGAAGCAACTGTCTTTAGCAAATAGAAGATCATAAACATCCTTCTGGAGATCTTGAGATGTTGACTGCGGTTTATAGGGCAATGAAAATCTGCCTACCTGAGTGGGCAATGAGACGGGAGTGCCACCTGTGATCCTTCCAGGGAGCAATTCTTTCTGGTGCCAGGAGCCCAAAGGAAACTCAGTCAACAAGCTACAGATGGGCTTGCTCCGAGTTTGTTCTAGAAGTCAGAACTGCCAGCTCTGAAAATAGGTCACAAGTGACAGGCCGTCCCTGGGCTGCTCACAGGAAGTAGCTGCAAAGGTCAGGGAAAGTTTTTAACGACTATACAGGCCAGTGAATGACAGGCTTTGAGGAGCTTCTCTTCTTGGCATCTGAAACAGCATACTTTCTGACTACCGCTGTGTGCTGTGAGGGGCTGAGGATCCAGACGTGGCTGAGGAAGGTCCCGGCTCATGAGGAGGTGGAAGCCTGGGTGCTTAAACAGATAATCCAGAGTTTGGATGTGAGGTGGTGAATCACTCTGGCTTCATTTGGTTATACTGGTCAAGAGTTTGGCTCTGGAGCAACGTGTCTGGGTTTGAATCCTGGCTGTGCTTTTGGTGATCCTCCATTGTTTTGAAGCACAAGACCTTTAAACCACTGTAGGTATGGACAAGGAAGAAAGGAAGATCATCAATCAGGGTCAAGAAGATGAAATGGAGATTTATGGTTACAATTTGAGTCGCTGGAAGCTTGCCATAGTTTCTTTAGGAGTGATTTGCACTGGTGGGTTTCTCCTCCTCCTCCTCTATTGGATGCCTGAGTGGCGGGTGAAAGCGACCTGTGTCAGAGCTGCAATTAAAGACTGTGACGTAGTGCTGCTGAGGACTACTGATGAATTCAAAATGTGGTTTTGTGCAAAAATTCGCGTTCTTTCTTTGGAAACTCACCCAATTTCAAGTCCAAAATCTATGTCTAATAAGCTTTCAAATGGCCATGCAGTTTGTTTAACTGAGAATCCCACTGGAGAAAATAGGCACGGGATCAGTAAATATTCACAGGCTGAATCACAACAGATTCGTTATTTCACCCATCATAGTGTAAAATATTTCTGGAATGATACCATTCACAATTTTGATTTCTTAAAGGGACTGGATGAAGGTGTTTCTTGTACGTCAATTTATGAAAAGCATAGTGCAGGACTGACAAAGGGGATGCATGCCTACAGAAAACTGCTTTATGGAGTAAATGAAATTGCTGTAAAAGTGCCTTCTGTTTTTAAGCTTCTAATTAAAGAGGTTCTCAACCCATTTTACATTTTCCAGCTGTTCAGTGTTATACTGTGGAGCACTGATGAATACTATTACTATGCTCTAGCTATTGTGGTTATGTCCATAGTATCAATCTGTAGCTCACTGTATTCCATTAGAAAGCAATATGTTATGTTGCATGACATGGTGGCAACTCATAGTACTGTAAGAGTTTCAGTTTGTAGAGTAAATGAAGAAATAGAAGAAATCTTTTCTACTGACCTTGTGCCAGGAGATGTCATGGTCATTCCATTAAATGGGACAATAATGCCTTGCGATGCTGTACTTATTAATGGTACCTGCATTGTAAATGAAAGCATGTTAACAGGAGAAAGTGTTCCAGTGACAAAGACTAACTTGCCAAATCCTTCGGTGGATGTGAAAGGAATAGGAGATGAATTATATAATCCAGAAACACATAAACGACATACTTTGTTTTGTGGGACAACTGTTATTCAGACTCGTTTCTACACCGGAGAACTCGTCAAAGCCATAGTTGTTAGAACAGGATTTAGTACTTCCAAAGGACAGCTTGTTCGTTCCATATTGTATCCCAAACCAACTGATTTTAAACTCTACAGAGATGCCTACTTGTTTCTACTATGTCTTGTGGCAGTTGCTGGCATTGGGTTTATCTACACTATTATTAATAGCATTTTAAATGAGGTACAAGTTGGGGTCATAATTATCGAGTCTCTTGATATTATCACAATTACTGTGCCCCCTGCACTTCCTGCTGCAATGACTGCTGGTATTGTGTATGCTCAGAGAAGACTGAAAAAAATCGGTATTTTCTGTATCAGTCCTCAAAGAATAAATATTTGTGGACAGCTCAATCTTGTTTGCTTTGACAAGACTGGAACTCTAACTGAAGATGGTTTAAATCTTTGGGGGATTCAACGAGTGGAAAATGCACGGTTTCTTTCACCAGAAGAAAATGTGTGCAATGAGATGTTGGTAAAATCCCAGTTTGTTGCTTGTATGGCTACTTGTCATTCACTTACAAAAATTGAAGGAGTGCTCTCTGGTGATCCACTTGATCTGAAAATGTTTGAGGCTATTGGATGGATTCTGGAAGAAGCAACTGAAGAAGAAACAGCACTTCATAATCGAATTATGCCCACAGTGGTTCGTCCTCCCAAACAACTGCTTCCTGAATCTACCCCTGCAGGAAACCAAGAAATGGCTACTTATGAGATAGGAATTGTTCGCCAGTTCCCATTTTCTTCTGCTTTGCAACGTATGAGTGTGGTTGCCAGGGTGCTGGGGGATAGGAAAATGGACGCCTACATGAAAGGAGCGCCCGAGGCCATTGCCGGTCTCTGTAAACCTGAAACAGTTCCTGTCGATTTTCAAAACGTTTTGGAAGACTTCACTAAACAGGGCTTCCGTGTGATTGCTCTTGCACACAGAAAATTGGAGTCAAAACTGACATGGCATAAAGTACAGAATATTAGCAGGGATGCAATTGAGAACAACATGGATTTTATGGGATTAATTATAATGCAGAACAAATTAAAGCAAGAAACCCCTGCAGTACTTGAAGATTTGCATAAAGCCAACATTCGCACCGTCATGGTCACAGGTGACAGTATGTTGACTGCTGTCTCTGTGGCCAGAGATTGTGGAATGATTCTACCTCAGGATAAAGTGATTATTGCTGAAGCATTACCTCCAAAGGATGGGAAAGTTGCCAAAATAAATTGGCATTATGCAGACTCCCTCACGCAGTGCAGTCATCCATCAGCAATTGACCCAGAGGCTATTCCGGTTAAATTGGTCCATGATAGCTTAGAGGATCTTCAAATGACTCGTTATCATTTTGCAATGAATGGAAAATCATTCTCAGTGATACTGGAGCATTTTCAAGACCTTGTTCCTAAGTTGATGTTGCATGGCACCGTGTTTGCCCGTATGGCACCTGATCAGAAGACACAGTTGATAGAAGCATTGCAAAATGTTGAGTATTTTGTTGGGATGTGTGGTGATGGCGCAAATGATTGTGGTGCTTTGAAGAGGGCACACGGAGGCATTTCCTTATCGGAGCTCGAAGCTTCAGTGGCATCTCCCTTTACCTCTAAGACTCCTAGTATTTCCTGTGTGCCAAACCTTATCAGGGAAGGCCGTGCTGCTTTAATAACTTCCTTCTGTGTGTTTAAATTCATGGCATTGTACAGCATTATCCAGTACTTCAGTGTTACTCTGCTGTATTCTATCTTAAGTAACCTAGGAGACTTCCAGTTTCTCTTCATTGATCTGGCAATCATTTTGGTAGTGGTATTTACAGTGAGTTTAAATCCTGCCTGGAAAGAACTTGTGGCACAAAGACCACCTTCGGGTCTTATATCTGGGGCCCTTCTCTTCTCCGTTTTGTCTCAGATTATCATCTGCATTGGATTTCAATCTTTGGGTTTTTTTTGGGTCAAACAGCAACCTTGGTATGAAGTGTGGCATCCAAAATCAGAGGCTTGTAATACAACAGGAAGCGGGTTTTGGAATTCTTCACACGTAGACAATGAAACCGAACTTGATGAAATAATATACAAAATTATGAAAATACCACAGTGTTTTTTATTTCCAGTTTTCAGTACCTCATAGTGGCAATTGCCTTTTCAAAAGGAAAACNOV73a, CG59839-02Protein SequenceSEQ ID NO: 10681079 aaMW at 120773.2kDMDKEERKIINQGQEDEMEIYGYNLSRWKLAIVSLGVICTGGFLLLLLYWMPEWRVKATCVRAAIKDCDVVLLRTTDEFKMWFCAKIRVLSLETHPISSPKSMSNKLSNGHAVCLTENPTGENRHGISKYSQAESQQIRYFTHHSVKYFWNDTIHNFDFLKGLDEGVSCTSIYEKHSAGLTKGMHAYRKLLYGVNEIAVKVPSVFKLLIKEVLNPFYIFQLFSVILWSTDEYYYYALAIVVMSIVSIVSSLYSIRKQYVMLHDMVATHSTVRVSVCRVNEEIEEIFSTDLVPGDVMVIPLNGTIMPCDAVLINGTCIVNESMLTGESVPVTKTNLPNPSVDVKGIGDELYNPETHKRHTLFCGTTVIQTRFYTGELVKAIVVRTGFSTSKGQLVRSILYPKPTDFKLYRDAYLFLLCLVAVAGIGFIYTIINSILNEVQVGVIIIESLDIITITVPPALPAAMTAGIVYAQRRLKKIGIFCISPQRINICGOLNLVCFDKTGTLTEDGLNLWGIQRVENARFLSPEENVCNEMLVKSQFVACMATCHSLTKIEGVLSGDPLDLKMFEAIGWILEEATEEETALHNRIMPTVVRPPKQLLPESTPAGNQEMATYEIGIVRQFPFSSALQRMSVVARVLGDRKMDAYMKGAPEAIAGLCKPETVPVDFQNVLEDFTKQGFRVIALAHRKLESKLTWHKVQNISRDAIENNMDFMGLIIMQNKLKQETPAVLEDLHKANIRTVMVTGDSMLTAVSVARDCGMILPQDKVIIAEALPPKDGKVAKINWHYADSLTQCSHPSAIDPEAIPVKLVHDSLEDLQMTRYHFAMNGKSFSVILEHFQDLVPKLMLHGTVFARMAPDQKTQLIEALQNVEYFVGMCGDGANDCGALKRAHGGISLSELEASVASPFTSKTPSISCVPNLIREGRAALITSFCVFKFMALYSIIQYFSVTLLYSILSNLGDFQFLFIDLAIILVVVFTVSLNPAWKELVAQRPPSGLISGALLFSVLSQIIICIGFQSLGFFWVKQQPWYEVWHPKSEACNTTGSGFWNSSHVDNETELDEIIYKIMKIPQCFLFPVFSTSNOV73b, CG59839-01SEQ ID NO: 10692649 bpDNA SequenceORF Start: ATG at 183ORF Stop: TAG at 2055CAACTGATTTTAAACTCTACAGAGATGCCTACTTGTTTCTACTATGTCTTGTGGCAGTTGCTGGCATTGGGTTTATCTACACTATTATTAATAGCATTTTAAATGAGGTACAAGTTGGGGTCATAATTATCGAGTCTCTTGATATTATCACAATTACTGTGCCCCCTGCACTTCCTGCTGCAATGACTGCTGGTATTGTGTATGCTCAGAGAAGACTGAAAAAAATCGGTATTTTCTGTATCAGTCCTCAAAGAATAAATATTTGTGGACAGCTCAATCTTGTTTGCTTTGACAAGACTGGAACTCTAACTGAAGATGGTTTAGATCTTTGGGGGATTCAACGAGTGGAAAATGCACGATTTCTTTCACCAGAAGAAAATGTGTGCAATGAGATGTTGGTAAAATCCCAGTTTGTTGCTTGTATGGCTACTTGTCATTCACTTACAAAAATTGAAGGAGTGCTCTCTGGTGATCCACTTGATCTGAAAATGTTTGAGGCTATTGGATGGATTCTGGAAGAAGCAACTGAAGAAGAAACAGCACTTCATAATCGAATTATGCCCACAGTGGTTCGTCCTCCCAAACAACTGCTTCCTGAATCTACCCCTGCAGGAAACCAAGAAATGGAGCTGTTTGAACTTCCAGCTACTTATGAGATAGGAATTGTTCGCCAGTTCCCATTTTCTTCTGCTTTGCAACGTATGAGTGTGGTTGCCAGGGTGCTGGGGGATAGGAAAATGGACGCCTACATGAAAGGAGCGCCCGAGGCCATTGCCGGTCTCTGTAAACCTGAAACAGTTCCTGTCGATTTTCAAAACGTTTTGGAAGACTTCACTAAACAGGGCTTCCGTGTGATTGCTCTTGCACACAGAAAATTGGAGTCAAAACTGACATGGCATAAAGTACAGAATATTAGCAGAGATGCAATTGAGAACAACATGGATTTTATGGGATTAATTATAATGCAGAACAAATTAAAGCAAGAAACCCCTGCAGTACTTGAAGATTTGCATAAAGCCAACATTCGCACCGTCATGGTCACAGGTGACAGTATGTTGACTGCTGTCTCTGTGGCCAGAGATTGTGGAATGATTCTACCTCAGGATAAAGTGATTATTGCTGAAGCATTACCTCCAAAGGATGGGAAAGTTGCCAAAATAAATTGGCATTATGCAGACTCCCTCACGCAGTGCAGTCATCCATCAGCAATTGACCCAGAGGCTATTCCGGTTAAATTGGTCCATGATAGCTTAGAGGATCTTCAAATGACTCGTTATCATTTTGCAATGAATGGAAAATCATTCTCAGTGATACTGGAGCATTTTCAAGACCTTGTTCCTAAGTTGATGTTGCATGGCACCGTGTTTGCCCGTATGGCACCTGATCAGAAGACACAGTTGATAGAAGCATTGCAAAATGTTGATTATTTTGTTGGGATGTGTGGTGATGGCGCAAATGATTGTGGTGCTTTGAAGAGGGCACACGGAGGCATTTCCTTATCGGAGCTCGAAGCTTCAGTGGCATCTCCCTTTACCTCTAAGACTCCTAGTATTTCCTGTGTGCCAAACCTTATCAGGGAAGGCCGTGCTGCTTTAATAACTTCCTTCTGTGTGTTTAAATTCATGGCATTGTACAGCATTATCCAGTACTTCAGTGTTACTCTGCTGTATTCTATCTTAAGTAACCTAGGAGACTTCCAGTTTCTCTTCATTGATCTGGCAATCATTTTGGTAGTGGTATTTACAATGAGTTTAAATCCTGCCTGGAAAGAACTTGTGGCACAAAGACCACCTTCGGGTCTTATATCTGGGGCCCTTCTCTTCTCCGTTTTGTCTCAGATTATCATCTGCATTGGATTTCAATCTTTGGGTTTTTTTTGGGTCAAACAGCAACCTTGGTATGAAGTGTGGCATCCAAAATCAGATGCTTGTAATACAACAGGAAGCGGGTTTTGGAATTCTTCACACGTAGACAATGAAACCGAACTTGATGAACTAATATACAAAATTATGAAAATACCACAGTGTTTTTTATTTCCAGTTTTCAGTACCTCATAGTGGCAATTGCCTTTTCAAAAGGAAAACCCTTCAGGCAACCTTGCTACAAAAATTATTTTTTTGTTTTTTCTGTGATTTTTTTATATATTTTTATATTATTCATCATGTTGTATCCAGTTGCCTCTGTTGACCAGGTTCTTCAGATAGTGTGTGTACCATATCAGTGGCGTGTAACTATGCTCATCATTGTTCTTGTCAATGCCTTTGTGTCTATCACAGTGGAGGAGTCAGTGGATCGGTGGGGAAAATGCTGCTTACCCTGGGCCCTGGGCTGTAGAAAGAAGACACCAAAGGCAAAGTACATGTATCTGGCGCAGGAGCTCTTGGTTGATCCAGAATGGCCACCAAAACCTCAGACAACCACAGAAGCTAAAGCTTTAGTTAAGGAGAATGGATCATGTCAAATCATCACCATAACATAGCAGTGAATCAGTCTCAGTGGTATTGCTGATAGCAGTATTCAGGAATATGTGATTTTAGGAGTTTCTGATCCTGTGTGTCAGAATGGCACTAGTTCAGTTTATGTC CCTTCTGATATAGTAGCTTATTTGACAGCTTTGCTCTTCCTTAAAATAAAAAAAAAAAAAAAAAANOV73b, CG59839-01Protein SequenceSEQ ID NO: 1070624 aaMW at 69590.1kDMTAGIVYAQRRLKKIGIFCISPQRINICGQLNLVCFDKTGTLTEDGLDLWGIQRVENARFLSPEENVCNEMLVKSQFVACMATCHSLTKIEGVLSGDPLDLKMFEAIGWILEEATEEETALHNRIMPTVVRPPKQLLPESTPAGNQEMELFELPATYEIGIVRQFPFSSALQRMSVVARVLGDRKMDAYMKGAPEAIAGLCKPETVPVDFQNVLEDFTKQGFRVIALAHRKLESKLTWHKVQNISRDAIENNMDFMGLIIMQNKLKQETPAVLEDLHKANIRTVMVTGDSMLTAVSVARDCGMILPQDKVIIAEALPPKDGKVAKINWHYADSLTQCSHPSAIDPEAIPVKLVHDSLEDLQMTRYHFAMNGKSFSVILEHFQDLVPKLMLHGTVFARMAPDQKTGLIEALQNVDYFVGMCGDGANDCGALKRAHGGISLSELEASVASPFTSKTPSISCVPNLIREGRAALITSFCVFKFMALYSIIQYFSVTLLYSILSNLGDFQFLFIDLAIILVVVFTMSLNPAWKELVAQRPPSGLISGALLFSVLSQIIICIGFQSLGFFWVKQQPWYEVWHPKSDACNTTGSGFWNSSHVDNETELDELIYKIMKIPQCFLFPVFSTS

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 73B.

TABLE 73BComparison of the NOV73 protein sequences.NOV73aMDKEERKIINQGQEDEMEIYGYNLSRWKLAIVSLGVICTGGFLLLLLYWMPEWRVKATCVNOV73b------------------------------------------------------------NOV73aRAAIKDCDVVLLRTTDEFKMWFCAKIRVLSLETHPISSPKSMSNKLSNGHAVCLTENPTGNOV73b------------------------------------------------------------NOV73aENRHGISKYSQAESQQIRYFTHHSVKYFWNDTIHNFDFLKGLDEGVSCTSIYEKHSAGLTNOV73b------------------------------------------------------------NOV73aKGMHAYRKLLYGVNEIAVKVPSVFKLLIKEVLNPFYIFQLFSVILWSTDEYYYYALAIVVNOV73b------------------------------------------------------------NOV73aMSIVSIVSSLYSIRKQYVMLHDMVATHSTVRVSVCRVNEEIEEIFSTDLVPGDVMVIPLNNOV73b------------------------------------------------------------NOV73aGTIMPCDAVLINGTCIVNESMLTGESVPVTKTNLPNPSVDVKGIGDELYNPETHKRHTLFNOV73b------------------------------------------------------------NOV73aCGTTVIQTRFYTGELVKAIVVRTGFSTSKGQLVRSILYPKPTDFKLYRDAYLFLLCLVAVNOV73b------------------------------------------------------------NOV73aAGIGFIYTIINSILNEVQVGVIIIESLDIITITVPPALPAAMTAGIVYAQRRLKKIGIFCNOV73b-----------------------------------------MTAGIVYAQRRLKKIGIFCNOV73aISPQRINICGQLNLVCFDKTGTLTEDGLNLWGIQRVENARFLSPEENVCNEMLVKSQFVANOV73bISPQRINICGQLNLVCFDKTGTLTEDGLDLWGIQRVENARFLSPEENVCNEMLVKSQFVANOV73aCMATCHSLTKIEGVLSGDPLDLKMFEAIGWILEEATEEETALHNRIMPTVVRPPKQLLPENOV73bCMATCHSLTKIEGVLSGDPLDLKMFEAIGWILEEATEEETALHNRIMPTVVRPPKQLLPENOV73aSTPAGNQ------EMATYEIGIVRQFPFSSALQRMSVVARVLGDRKMDAYMKGAPEAIAGNOV73bSTPAGNQEMELFELPATYEIGIVRQFPFSSALQRMSVVARVLGDRKMDAYMKGAPEAIAGNOV73aLCKPETVPVDFQNVLEDFTKQGFRVIALAHRKLESKLTWHKVQNISRDAIENNMDFMGLINOV73bLCKPETVPVDFQNVLEDFTKQGFRVIALAHRKLESKLTWHKVQNISRDAIENNMDFMGLINOV73aIMQNKLKQETPAVLEDLHKANIRTVMVTGDSMLTAVSVARDCGMILPQDKVIIAEALPPKNOV73bIMQNKLKQETPAVLEDLHKANIRTVMVTGDSMLTAVSVARDCGMILPQDKVIIAEALPPKNOV73aDGKVAKINWHYADSLTQCSHPSAIDPEAIPVKLVHDSLEDLQMTRYHFANNGKSFSVILENOV73bDGKVAKINWHYADSLTQCSHPSAIDPEAIPVKLVHDSLEDLQMTRYHFANNGKSFSVILENOV73aHFQDLVPKLMLHGTVFARMAPDQKTQLIEALQNVDYFVGMCGDGANDCGALKRAHGGISLNOV73bHFQDLVPKLMLHGTVFARMAPDQKTQLIEALQNVDYFVGMCGDGANDCGALKRAHGGISLNOV73aSELEASVASPFTSKTPSISCVPNLIREGRAALITSFCVFKFMALYSIIQYFSVTLLYSILNOV73bSELEASVASPFTSKTPSISCVPNLIREGRAALITSFCVFKFMALYSIIQYFSVTLLYSILNOV73aSNLGDFQFLFIDLAIILVVVFTVSLNPAWKELVAQRPPSGLISGALLFSVLSQIIICIGFNOV73bSNLGDFQFLFIDLAIILVVVFTMSLNPAWKELVAQRPPSGLISGALLFSVLSQIIICIGFNOV73aQSLGFFWVKQQPWYEVWHPKSEACNTTGSGFWNSSHVDNETELDEIIYKIMKIPQCFLFPNOV73bQSLGFFWVKQQPWYEVWHPKSDACNTTGSGFNNSSHVDNETELDELIYKIMKIPQCFLFPNOV73aVFSTSNOV73bVFSTSNOV73a(SEQ ID NO: 1068)NOV73b(SEQ ID NO: 1070)

Further analysis of the NOV73a protein yielded the following properties shown in Table 73C.

TABLE 73CProtein Sequence Properties NOV73aSignalP analysis:Cleavage site between residues 58 and 59PSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 7;pos.chg 3;neg.chg 3H-region:length 6;peak value−12.14PSG score:−16.54GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −4.30possible cleavage site: between 41 and 42>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 8INTEGRALLikelihood = −8.44 Transmembrane 31-47 INTEGRALLikelihood = −6.37 Transmembrane 234-250INTEGRALLikelihood = 0.32 Transmembrane 295-311INTEGRALLikelihood = −9.08 Transmembrane 410-426INTEGRALLikelihood = −2.81 Transmembrane 439-455INTEGRALLikelihood = −2.92 Transmembrane 926-942INTEGRALLikelihood =−11.15 Transmembrane 963-979INTEGRALLikelihood = −6.37 Transmembrane 996-1012PERIPHERALLikelihood = 1.11 (at 211)ALOM score:−11.15 (number of TMSs: 8)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 38Charge difference: 4.0 C(2.0) − N(−2.0)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):8.50Hyd Moment(95):5.62G content:0D/E content:2S/T content:0Score: −6.77Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 9.1%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23): 55.6%: endoplasmic reticulum 11.1%: mitochondrial 11.1%: vacuolar 11.1%: vesicles of secretory system 11.1%: Golgi>> prediction for CG59839-02 is end (k = 9)

A search of the NOV73a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 73D.

TABLE 73DGeneseq Results for NOV73aNOV73aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU91185Human HEAT-2 polypeptide - 1 . . . 10591044/1065 (98%)0.0Homo sapiens, 1256 aa. 1 . . . 10651053/1065 (98%)[WO200216591-A2, 28-FEB-2002]AAO14197Human transporter and ion 1 . . . 10591039/1065 (97%)0.0channel TRICH-14 - Homo 1 . . . 10651049/1065 (97%)sapiens, 1256 aa.[WO200204520-A2, 17-JAN-2002]ABU11063Human protein NOV27 - Homo183 . . . 1059 784/883 (88%)0.0sapiens, 973 aa. 1 . . . 812 792/883 (88%)[WO200281629-A2, 17-OCT-2002]ABP69451Human polypeptide SEQ ID NO462 . . . 1059 593/604 (98%)0.01498 - Homo sapiens, 765 aa. 1 . . . 604 598/604 (98%)[WO200270539-A2, 12-SEP-2002]AAB40996Human ORFX ORF760509 . . . 1059 547/557 (98%)0.0polypeptide sequence SEQ ID 2 . . . 558 551/557 (98%)NO: 1520 - Homo sapiens, 692aa. [WO200058473-A2, 05-OCT-2000]

In a BLAST search of public sequence databases, the NOV73a protein was found to have homology to the proteins shown in the BLASTP data in Table 73E.

TABLE 73EPublic BLASTP Results for NOV73aNOV73aProteinResidues/Identities/AccessionMatchSimilarities for theExpectNumberProtein/Organism/LengthResiduesMatched PortionValueQ9H7F0Probable cation- 1 . . . 10591045/1065 (98%) 0.0transporting ATPase 3 (EC 1 . . . 10651054/1065 (98%) 3.6.3.—) (ATPase familyhomolog up-regulated insenescence cells 1) - Homosapiens (Human), 1130 aa.CAD29017Sequence 5 from Patent 1 . . . 10591044/1065 (98%) 0.0WO0216591 - Homo 1 . . . 10651053/1065 (98%) sapiens (Human), 1256 aa.Q96KS1Hypothetical protein -280 . . . 954 655/681 (96%) 0.0Homo sapiens (Human), 3 . . . 680 662/681 (97%) 701 aa.Q95JN5Hypothetical 56.9 kDa 1 . . . 492 492/492 (100%)0.0protein - Macaca 1 . . . 492 492/492 (100%)fascicularis (Crab eatingmacaque) (Cynomolgusmonkey), 504 aa(fragment).Q95JN5Probable cation- 1 . . . 492 492/492 (100%)0.0transporting ATPase 3 (EC 1 . . . 492 492/492 (100%)3.6.3.—) (ATPase familyhomolog up-regulated insenescence cells 1) -Macaca fascicularis (Crabeating macaque)(Cynomolgus monkey),492 aa (fragment).

PFam analysis indicates that the NOV73a protein contains the domains shown in the Table 73F.

TABLE 73FDomain Analysis of NOV73aIdentities/NOV73aSimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValueCation_ATPase_N160 . . . 227 15/87 (17%)0.041 41/87 (47%)E1-E2_ATPase239 . . . 488 58/267 (22%)4.3e−07162/267 (61%)Hydrolase492 . . . 898 40/417 (10%)0.0073243/417 (58%)

Example 74

The NOV74 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 74A.

TABLE 74ANOV74 Sequence AnalysisNOV74a, CG90866-04SEQ ID NO: 10712937 bpDNA SequenceORF Start: ATG at 1ORF Stop: TAA at 2935ATGCAGCCCCTGGACTTTAGTTCAGGGGGAAGTGACCCCAACATCAGCCTCTCAGAAAAGATCCGAGATCAGCTTGTTGTTGGACAGCTGATTCCAGACTGCTATGTAGAACTTGAAAAAATCATTTTATCGGAGCGTAAAAATGTGCCAATTGAATTTCCCGTAATTGACCGGAAACGATTATTACAACTAGTGAGAGAAAATCAGCTGCAGTTAGATGAAAATGAGCTTCCTCACGCAGTTCACTTTCTAAATGAATCAGGAGTCCTTCTTCATTTTCAAGACCCAGCACTGCAGTTAAGTGACTTGTACTTTGTGGAACCCAAGTGGCTTTGTAAAATCATGGCACAGGATGTTAGCAGCATTTTTGGCCTTTATATTCGAGACATTTTGACAGTGAAAGTGGAAGGTTGTCCAAAACACCCTAAGGGCATTATTTCGCGTAGAGATGTGGAAAAATTTCTTTCAAAAAAAAGGAAATTTCCAAAGAACTACATGTCACAGTATTTTAAGCTCCTAGAAAAATTCCAGATTGCTTTGCCAATAGGAGAAGAATATTTGCTGGTTCCAAGCATTTTGTCTGACCACAGGCCTGTGATAGAGCTTCCCCATTGTGAGAACTCTGAAATTATCATCCGACTATATGAAATGCCTTATTTTCCAATGGGATTTTGGTCAAGATTAATCAATCGATTACTTGAGATTTCACCTTACATGCTTTCAGGGAGAGGCTGTATTCTTTTGGGCCAAGTTGTGGACCACATTGATTCTCTCATGGAAGAATGGTTTCCTGGGTTGCTGGAGATTGATATTTGTGGTGAAGGAGAAACTCTGTTGAAGAAATGGGCATTATATAGTTTTAATGATGGTGAAGAACATCAAAAAATCTTACTTGATGACTTGATGAAGAAAGCAGAGGAAGGAGATCTCTTAGTAAATCCAGATCAACCAAGGCTCACCATTCCAATATCTCAGATTGCCCCTGACTTGATTTTGGCTGACCCGCCTAGAAATATTATGTTGAATAATGATGAGTTGGAATTTGAACAAGCTCCAGAGTTTCTCCTAGACTGTTTTGTGTGTATTCACTTATATCCATCAAGTGACTACATTTCAAGGCACTATATGAGAACCATAAATATTGTACAAACAGGATTTGCTAAATGTCGGTGGAGAGTAACAGTCCACGGGGCTGATCATGGTGATGGCAGTTTTGGATCAGTTTACCGAGCAGCCTATGAAGGAGAAGAAGTGGCTGTGAAGATTTTTAATAAACATACATCACTCAGGCTGTTAAGACAAGAGCTTGTGGTGCTTTGCCACCTCCACCACCCCAGTTTGATATCTTTGCTGGCAGCTGGGATTCGTCCCCGGATGTTGGTGATGGAGTTAGCCTCCAAGGGTTCCTTGGATCGCCTGCTTCAGCAGGACAAAGCCAGCCTCACTAGAACCCTACAGCACAGGATTGCACTCCACGTAGCTGATGGTTTGAGATACCTCCACTCAGCCATGATTATATACCGAGACCTGAAACCCCACAATGTGCTGCTTTTCACACTGTATCCCAATGCTGCCATCATTGCAAAGATTGCTGACTACGGCATTGCTCAGTACTGCTGTAGAATGGGGATAAAAACATCAGAGGGCACACCAGGTTTTCGTGCACCTGAAGTTGCCAGAGGAAATGTCATTTATAACCAACAGGCTGATGTTTATTCATTTGGTTTACTACTCTATGACATTTTGACAACTGGAGGTAGAATAGTAGAGGGTTTGAAGTTTCCAAATGAGTTTGATGAATTAGAAATACAAGGAAAATTACCTGATCCAGTTAAAGAATATGGTTGTGCCCCATGGCCTATGGTTGAGAAATTAATTAAACAGTGTTTGAAAGAAAATCCTCAAGAAAGGCCTACTTCTGCCCAGGTATTCGACATTTTGAATTCAGCTGAATTAGTCTGTCTGACGAGACGCATTTTATTACCTAAAAACGTAATTGTTGAATGCATGGTTGCTACACATCACAACAGCAGGAATGCAAGCATTTGGCTGGGCTGTGGGCACACCGACAGAGGACAGCTCTCATTTCTTGACTTAAATACTGAAGGATACACTTCTGAGAGCAAACAAAAAAATTTTCTTTTGGTTGGAACCGCTGATGGCAAGTTAGCAATTTTTGAAGATAAGACTGTTAAGCTTAAAGGAGCTGCTCCTTTGAAGATACTAAATATAGGAAATGTCAGTACTCCATTGATGTGTTTGAGTGAATCCACAAATTCAACGGAAAGAAATGTAATGTGGGGAGGATGTGGCACAAAGATTTTCTCCTTTTCTAATGATTTCACCATTCAGAAACTCATTGAGACAAGAACAAGCCAACTGTTTTCTTATGCAGCTTTCAGTGATTCCAACATCATAACAGTGGTGGTAGACACTGCTCTCTATATTGCTAAGCAAAATAGCCCTGTTGTGGAAGTGTGGGATAAGAAAACTGAAAAACTCTGTGGACTAATAGACTGCGTGCACTTTTTAAGGGAGGTAATGGTAAAAGAAAACAAGGAATCAAAACACAAAATGTCTTATTCTGGGAGAGTGAAAACCCTCTGCCTTCAGAAGAACACTGCTCTTTGGATAGGAACTGGAGGAGGCCATATTTTACTCCTGGATCTTTCAACTCGTCGACTTATACGTGTAATTTACAACTTTTGTAATTCGGTCAGAGTCATGATGACAGCACAGCTAGGCAGCCTTAAAAATGTCATGCTGGTATTGGGCTACAACCGGAAAAATACTGAAGGTACACAAAAGCAGAAGAGATACAATCTTGCTTGACCGTTTGGGACATCCAATCTTCCACATGAAGTGCAAAATTTAGAAAAACACATTGAAGTGAGAAAAGAATTAGCTGAAAAAATGAGACGAACATCTGTTGAGTAANOV74a, CG90866-04Protein SequenceSEQ ID NO: 1072978 aaMW at 111173.8kDMQPLDFSSGGSDPNISLSEKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQDVSSIFGLYIRDILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADPPRNIMLNNDELEFEQAPEFLLDCFVCIHLYPSSDYISRHYMRTINIVQTGFAKCRWRVTVHGADHGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRNLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSESKQKNFLLVGTADGKIAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVENOV74b, CG90866-03SEQ ID NO: 10732687 bpDNA SequenceORF Start: ATG at 108ORF Stop: TAA at 2658ACGCAGTTCACTTTCTAAATGAATCAGGAGTCCTTCTTCATTTTCAAGACCCAGCACTGCAGTTAAGTGACTTGTACTTTGTGGAACCCAAGTGGCTTTGTAAAATCATGGCACAGATTTTGACAGTGAAAGTGGAAGGTTGTCCAAAACACCCTAAGGGCATTATTTCGCGTAGAGATGTGGAAAAATTTCTTTCAAAAAAAAGGAAATTTCCAAAGAACTACATGTCACAGTATTTTAAGCTCCTAGAAAAATTCCAGATTGCTTTGCCAATAGGAGAAGAATATTTGCTGGTTCCAAGCAGTTTGTCTGACCACAGGCCTGTGATAGAGCTTCCCCATTGTGAGAACTCTGAAATTATCATCCGACTATATGAAATGCCTTATTTTCCAATGGGATTTTGGTCAAGATTAATCAATCGATTACTTGAGATTTCACCTTACATGCTTTCAGGGAGAGAACGAGCACTTCGCCCAAACAGAATGTATTGGCGACAAGGCATTTACTTAAATTGGTCTCCTGAAGCTTATTGTCTGGTAGGATCTGAAGTCTTAGACAATCATCCAGAGAGTTTCTTAAAAATTACAGTTCTTCTTCTTGTAGAAAACTGTATTCTTTTGGGCCAAGTTGTGGACCACATTGATTCTCTCATGGAAGAATGGTTTCCTGGGTTGCTGGAGATTGATATTTGTGGTGAAGGAGAAACTCTGTTGAAGAAATGGGCATTATATAGTTTTAATGATGGCGAAGAACATCAAAAAATCTTACTTGATGACTTGATGAAGAAAGCAGAGGAAGGAGATCTCTTAGTAAATCCAGATCAACCAAGGCTCACCATTCCAATATCTCAGATTGCCCCTGACTTGATTTTGGCTGACCTGCCTAGAAATATTATGTTGAATAATGATGAGTTGGAATTTGAACAAGCTCCAGAGTTTCTCCTAGGTGATGGCAGTTTTGGATCAGTTTACCGAGCAGCCTATGAAGGAGAAGAAGTGGCTGTGAAGATTTTTAATAAACATACATCACTCAGGCTGTTAAGACAAGAGCTTGTGGTGCTTTGCCACCTCCACCACCCCAGTTTGATATCTTTGCTGGCAGCTGGGATTCGTCCCCGGATGTTGGTGATGGAGTTAGCCTCCAAGGGTTCCTTGGATCGCCTGCTTCAGCAGGACAAAGCCAGCCTCACTAGAACCCTACAGCACAGGATTGCACTCCACGTAGCTGATGGTTTGAGATACCTCCACTCAGCCATGATTATATACCGAGACCTGAAACCCCACAATGTGCTGCTTTTCACACTGTATCCCAATGCTGCCATCATTGCAAAGATTGCTGACTACGGCATTGCTCAGTACTGCTGTAGAATGGGGATAAAAACATCAGAGGGCACACCAGGTTTTCGTGCACCTGAAGTTGCCAGAGGAAATGTCATTTATAACCAACAGGCTGATGTTTATTCATTTGGTTTACTACTCTATGACATTTTGACAACTGGAGGTAGAATAGTAGAGGGTTTGAAGTTTCCAAATGAGTTTGATGAATTAGAAATACAAGGAAAATTACCTGATCCAGTTAAAGAATATGGTTGTGCCCCATGGCCTATGGTTGAGAAATTAATTAAACAGTGTTTGAAAGAAAATCCTCAAGAAAGGCCTACTTCTGCCCAGGTATTCGACATTTTGAATTCAGCTGAATTAGTCTGTCTGACGAGACGCATTTTATTACCTAAAAACGTAATTGTTGAATGCATGGTTGCTACACATCACAACAGCAGGAATGCAAGCATTTGGCTGGGCTGTGGGCACACCGACAGAGGACAGCTCTCATTTCTTGACTTAAATACTGAAGGATACACTTCTGAGGAAGTTGCTGATAGTAGAATATTGTGCTTAGCCTTGGTGCATCTTCCTGTTGAAAAGGAAAGCTGGATTGTGTCTGGGACACAGTCTGGTACTCTCCTGGTCATCAATACCGAAGATGGGAAAAAGAGACATACCCTAGAAAAGATGACTGATTCTGTCACTTGTTTGTATTGCAATTCCTTTTCCAAGCAAAGCAAACAAAAAAATTTTCTTTTGGTTGGAACCGCTGATGGCAAGTTAGCAATTTTTGAAGATAAGACTGTTAAGCTTAAAGGAGCTGCTCCTTTGAAGATACTAAATATAGGAAATGTCAGTACTCCATTGATGTGTTTGAGTGAATCCACAAATTCAACGGAAAGAAATGTAATGTGGGGAGGATGTGGCACAAAGATTTTCTCCTTTTCTAATGATTTCACCATTCAGAAACTCATTGAGACAAGAACAAGCCAACTGTTTTCTTATGCAGCTTTCAGTGATTCCAACATCATAACAGTGGTGGTAGACACTGCTCTCTATATTGCTAAGCAAAATAGCCCTGTTGTGGAAGTGTGGGATAAGAAAACTGAAAAACTCTGTGGACTAATAGACTGCGTGCACTTTTTAAGCCTTAAAAATGTCATGCTGGTATTGGGCTACAACCGGAAAAATACTGAAGGTACACAAAAGCAGAAAGAGATACAATCTTGCTTGACCGTTTGGGACATCAATCTTCCACATGAAGTGCAAAATTTAGAAAAACACATTGAAGTGAGAAAAGAATTAGCTGAAAAAATGAGACGAACATCTGTTGAGTAAGAGAGAAATAGGAATTGTCTTTGGATANOV74b, CG90866-03Protein SequenceSEQ ID NO: 1074850 aaMW at 96332.5kDMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVALGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKICGLIDCVHFLSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKMIEVRKELAEKMRRTSVENOV74c, CG90866-01SEQ ID NO: 10753052 bpDNA SequenceORF Start: ATG at 108ORF Stop: TAA at 2853ACGCAGTTCACTTTCTAAATGAATCAGGAGTCCTTCTTCATTTTCAAGACCCAGCACTGCAGTTAAGTGACTTGTACTTTGTGGAACCCAAGTGGCTTTGTAAAATCATGGCACAGATTTTGACAGTGAAAGTGGAAGGTTGTCCAAAACACCCTAAGGGCATTATTTCGCGTAGAGATGTGGAAAAATTTCTTTCAAAAAAAAGGAAATTTCCAAAGAACTACATGTCACAGTATTTTAAGCTCCTAGAAAAATTCCAGATTGCTTTGCCAATAGGAGAAGAATATTTGCTGGTTCCAAGCAGTTTGTCTGACCACAGGCCTGTGATAGAGCTTCCCCATTGTGAGAACTCTGAAATTATCATCCGACTATATGAAATGCCTTATTTTCCAATGGGATTTTGGTCAAGATTAATCAATCGATTACTTGAGATTTCACCTTACATGCTTTCAGGGAGAGAACGAGCACTTCGCCCAAACAGAATGTATTGGCGACAAGGCATTTACTTAAATTGGTCTCCTGAAGCTTATTGTCTGGTAGGATCTGAAGTCTTAGACAATCATCCAGAGAGTTTCTTAAAAATTACAGTTCTTCTTCTTGTAGAAAACTGTATTCTTTTGGGCCAAGTTGTGGACCACATTGATTCTCTCATGGAAGAATGGTTTCCTGGGTTGCTGGAGATTGATATTTGTGGTGAAGGAGAAACTCTGTTGAAGAAATGGGCATTATATAGTTTTAATGATGGCGAAGAACATCAAAAAATCTTACTTGATGACTTGATGAAGAAAGCAGAGGAAGGAGATCTCTTAGTAAATCCAGATCAACCAAGGCTCACCATTCCAATATCTCAGATTGCCCCTGACTTGATTTTGGCTGACCTGCCTAGAAATATTATGTTGAATAATGATGAGTTGGAATTTGAACAAGCTCCAGAGTTTCTCCTAGGTGATGGCAGTTTTGGATCAGTTTACCGAGCAGCCTATGAAGGAGAAGAAGTGGCTGTGAAGATTTTTAATAAACATACATCACTCAGGCTGTTAAGACAAGAGCTTGTGGTGCTTTGCCACCTCCACCACCCCAGTTTGATATCTTTGCTGGCAGCTGGGATTCGTCCCCGGATGTTGGTGATGGAGTTAGCCTCCAAGGGTTCCTTGGATCGCCTGCTTCAGCAGGACAAAGCCAGCCTCACTAGAACCCTACAGCACAGGATTGCACTCCACGTAGCTGATGGTTTGAGATACCTCCACTCAGCCATGATTATATACCGAGACCTGAAACCCCACAATGTGCTGCTTTTCACACTGTATCCCAATGCTGCCATCATTGCAAAGATTGCTGACTACGGCATTGCTCAGTACTGCTGTAGAATGGGGATAAAAACATCAGAGGGCACACCAGGTTTTCGTGCACCTGAAGTTGCCAGAGGAAATGTCATTTATAACCAACAGGCTGATGTTTATTCATTTGGTTTACTACTCTATGACATTTTGACAACTGGAGGTAGAATAGTAGAGGGTTTGAAGTTTCCAAATGAGTTTGATGAATTAGAAATACAAGGAAAATTACCTGATCCAGTTAAAGAATATGGTTGTGCCCCATGGCCTATGGTTGAGAAATTAATTAAACAGTGTTTGAAAGAAAATCCTCAAGAAAGGCCTACTTCTGCCCAGGTATTCGACATTTTGAATTCAGCTGAATTATCAGCTGAATTAGTCTGTCTGACGAGACGCATTTTATTACCTAAAAACGTAATTGTTGAATGCATGGTTGCTACACATCACAACAGCAGGAATGCAAGCATTTGGCTGGGCTGTGGGCACACCGACAGAGGACAGCTCTCATTTCTTGACTTAAATACTGAAGGATACACTTCTGAGGAAGTTGCTGATAGTAGAATATTGTGCTTAGCCTTGGTGCATCTTCCTGTTGAAAAGGAAAGCTGGATTGTGTCTGGGACACAGTCTGGTACTCT ACGCAGTTCACTTTCTAAATGAATCAGGAGTCCTTCTTCATTTTCAAGACCCAGCACTGCAGTTAAGTGACTTGTACTTTGTGGAACCCAAGTGGCTTTGTAAAATCATGGCACAGATTTTGACAGTGAAAGTGGAAGGTTGTCCAAAACACCCTAAGGGCATTATTTCGCGTAGAGATGTGGAAAAATTTCTTTCAAAAAAAAGGAAATTTCCAAAGAACTACATGTCACAGTATTTTAAGCTCCTAGAAAAATTCCAGATTGCTTTGCCAATAGGAGAAGAATATTTGCTGGTTCCAAGCAGTTTGTCTGACCACAGGCCTGTGATAGAGCTTCCCCATTGTGAGAACTCTGAAATTATCATCCGACTATATGAAATGCCTTATTTTCCAATGGGATTTTGGTCAAGATTAATCAATCGATTACTTGAGATTTCACCTTACATGCTTTCAGGGAGAGAACGAGCACTTCGCCCAAACAGAATGTATTGGCGACAAGGCATTTACTTAAATTGGTCTCCTGAAGCTTATTGTCTGGTAGGATCTGAAGTCTTAGACAATCATCCAGAGAGTTTCTTAAAAATTACAGTTCTTCTTCTTGTAGAAAACTGTATTCTTTTGGGCCAAGTTGTGGACCACATTGATTCTCTCATGGAAGAATGGTTTCCTGGGTTGCTGGAGATTGATATTTGTGGTGAAGGAGAAACTCTGTTGAAGAAATGGGCATTATATAGTTTTAATGATGGCGAAGAACATCAAAAAATCTTACTTGATGACTTGATGAAGAAAGCAGAGGAAGGAGATCTCTTAGTAAATCCAGATCAACCAAGGCTCACCATTCCAATATCTCAGATTGCCCCTGACTTGATTTTGGCTGACCTGCCTAGAAATATTATGTTGAATAATGATGAGTTGGAATTTGAACAAGCTCCAGAGTTTCTCCTAGGTGATGGCAGTTTTGGATCAGTTTACCGAGCAGCCTATGAAGGAGAAGAAGTGGCTGTGAAGATTTTTAATAAACATACATCACTCAGGCTGTTAAGACAAGAGCTTGTGGTGCTTTGCCACCTCCACCACCCCAGTTTGATATCTTTGCTGGCAGCTGGGATTCGTCCCCGGATGTTGGTGATGGAGTTAGCCTCCAAGGGTTCCTTGGATCGCCTGCTTCAGCAGGACAAAGCCAGCCTCACTAGAACCCTACAGCACAGGATTGCACTCCACGTAGCTGATGGTTTGAGATACCTCCACTCAGCCATGATTATATACCGAGACCTGAAACCCCACAATGTGCTGCTTTTCACACTGTATCCCAATGCTGCCATCATTGCAAAGATTGCTGACTACGGCATTGCTCAGTACTGCTGTAGAATGGGGATAAAAACATCAGAGGGCACACCAGGTTTTCGTGCACCTGAAGTTGCCAGAGGAAATGTCATTTATAACCAACAGGCTGATGTTTATTCATTTGGTTTACTACTCTATGACATTTTGACAACTGGAGGTAGAATAGTAGAGGGTTTGAAGTTTCCAAATGAGTTTGATGAATTAGAAATACAAGGAAAATTACCTGATCCAGTTAAAGAATATGGTTGTGCCCCATGGCCTATGGTTGAGAAATTAATTAAACAGTGTTTGAAAGAAAATCCTCAAGAAAGGCCTACTTCTGCCCAGGTATTCGACATTTTGAATTCAGCTGAATTACCTGGTCATCAATACCGAAGATGGGAAAAAGAGACATACCCTAGAAAAGATGACTGATTCTGTCACTTGTTTGTATTGCAATTCCTTTTCCAAGCAAAGCAAACAAAAAAATTTTCTTTTGGTTGGAACCGCTGATGGCAAGTTAGCAATTTTTGAAGATAAGACTGTTAAGCTTAAAGGAGCTGCTCCTTTGAAGATACTAAATATAGGAAATGTCAGTACTCCATTGATGTGTTTGAGTGAATCCACAAATTCAACGGAAAGAAATGTAATGTGGGGAGGATGTGGCACAAAGATTTTCTCCTTTTCTAATGATTTCACCATTCAGAAACTCATTGAGACAAGAACAAGCCAACTGTTTTCTTATGCAGCTTTCAGTGATTCCAACATCATAACAGTGGTGGTAGACACTGCTCTCTATATTGCTAAGCAAAATAGCCCTGTTGTGGAAGTGTGGGATAAGAAAACTGAAAAACTCTGTGGACTAATAGACTGCGTGCACTTTTTAAGGTTAGTAAAACCAAATAGAAAAAAATTATCTAACCTTATGATGTCTTTGGCTTTACATCCTATATGTTTAAAATCAAAGTTAAGATGCAGTTCATCCAAAGGAAGATCCCATATTTTGCTTCGTGTAATTTACAACTTTTGTAATTCGGTCAGAGTCATGATGACAGCACAGCTAGGCGGAAGCCTTAAAAATGTCATGCTGGTATTGGGCTACAACCGGAAAAATACTGAAGGTACACAAAAGCAGAAAGAGATACAATCTTGCTTGACCGTTTGGGACATCAATCTTCCACATGAAGTGCAAAATTTAGAAAAACACATTGAAGTGAGAAAAGAATTAGCTGAAAAAATGAGACGAACATCTGTTGAGTAAGAGAGAAATAGGAATTGTCTTTGGATAGGAAAATTATTCTCTCCTCTTGTAAATATTTATTTTAAAAATGTTCACATGGAAAGGGTACTCACATTTTTTGAAATAGCTCGTGTGTATGAAGGAATGTTATTATTTTTAATTTAAATATATGTAAAAATACTTACCAGTAAATGTGTATTTTAAAGAACTATTTAAAANOV74c, CG90866-01Protein SequenceSEQ ID NO: 1076915 aaMW at 103676.4kDMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFSQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKTEKLCGLIDCVHFLRLVKPNRKKLSNLMMSLALHPICKLKSKLRCSSSKGRSHILLRVIYNFCNSVRVMMTAQLGGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRTSVENOV74d, CG90866-02SEQ ID NO: 10773040 bpDNA SequenceORF Start: ATG at 108ORF Stop: TAA at 2841ACGCAGTTCACTTTCTAAATGAATCAGGAGTCCTTCTTCATTTTCAAGACCCAGCACTGCAGTTAAGTGACTTGTACTTTGTGGAACCCAAGTGGCTTTGTAAAATCATGGCACAGATTTTGACAGTGAAAGTGGAAGGTTGTCCAAAACACCCTAAGGGCATTATTTCGCGTAGAGATGTGGAAAAATTTCTTTCAAAAAAAAGGAAATTTCCAAAGAACTACATGTCACAGTATTTTAAGCTCCTAGAAAAATTCCAGATTGCTTTGCCAATAGGAGAAGAATATTTGCTGGTTCCAAGCAGTTTGTCTGACCACAGGCCTGTGATAGAGCTTCCCCATTGTGAGAACTCTGAAATTATCATCCGACTATATGAAATGCCTTATTTTCCAATGGGATTTTGGTCAAGATTAATCAATCGATTACTTGAGATTTCACCTTACATGCTTTCAGGGAGAGAACGAGCACTTCGCCCAAACAGAATGTATTGGCGACAAGGCATTTACTTAAATTGGTCTCCTGAAGCTTATTGTCTGGTAGGATCTGAAGTCTTAGACAATCATCCAGAGAGTTTCTTAAAAATTACAGTTCTTCTTCTTGTAGAAAACTGTATTCTTTTGGGCCAAGTTGTGGACCACATTGATTCTCTCATGGAAGAATGGTTTCCTGGGTTGCTGGAGATTGATATTTGTGGTGAAGGAGAAACTCTGTTGAAGAAATGGGCATTATATAGTTTTAATGATGGCGAAGAACATCAAAAAATCTTACTTGATGACTTGATGAAGAAAGCAGAGGAAGGAGATCTCTTAGTAAATCCAGATCAACCAAGGCTCACCATTCCAATATCTCAGATTGCCCCTGACTTGATTTTGGCTGACCTGCCTAGAAATATTATGTTGAATAATGATGAGTTGGAATTTGAACAAGCTCCAGAGTTTCTCCTAGGTGATGGCAGTTTTGGATCAGTTTACCGAGCAGCCTATGAAGGAGAAGAAGTGGCTGTGAAGATTTTTAATAAACATACATCACTCAGGCTGTTAAGACAAGAGCTTGTGGTGCTTTGCCACCTCCACCACCCCAGTTTGATATCTTTGCTGGCAGCTGGGATTCGTCCCCGGATGTTGGTGATGGAGTTAGCCTCCAAGGGTTCCTTGGATCGCCTGCTTCAGCAGGACAAAGCCAGCCTCACTAGAACCCTACAGCACAGGATTGCACTCCACGTAGCTGATGGTTTGAGATACCTCCACTCAGCCATGATTATATACCGAGACCTGAAACCCCACAATGTGCTGCTTTTCACACTGTATCCCAATGCTGCCATCATTGCAAAGATTGCTGACTACGGCATTGCTCAGTACTGCTGTAGAATGGGGATAAAAACATCAGAGGGCACACCAGGTTTTCGTGCACCTGAAGTTGCCAGAGGAAATGTCATTTATAACCAACAGGCTGATGTTTATTCATTTGGTTTACTACTCTATGACATTTTGACAACTGGAGGTAGAATAGTAGAGGGTTTGAAGTTTCCAAATGAGTTTGATGAATTAGAAATACAAGGAAAATTACCTGATCCAGTTAAAGAATATGGTTGTGCCCCATGGCCTATGGTTGAGAAATTAATTAAACAGTGTTTGAAAGAAAATCCTCAAGAAAGGCCTACTTCTGCCCAGGTATTCGACATTTTGAATTCAGCTGAATTAGTCTGTCTGACGAGACGCATTTTATTACCTAAAAACGTAATTGTTGAATGCATGGTTGCTACACATCACAACAGCAGGAATGCAAGCATTTGGCTGGGCTGTGGGCACACCGACAGAGGACAGCTCTCATTTCTTGACTTAAATACTGAAGGATACACTTCTGAGGAAGTTGCTGATAGTAGAATATTGTGCTTAGCCTTGGTGCATCTTCCTGTTGAAAAGGAAAGCTGGATTGTGTCTGGGACACAGTCTGGTACTCTCCTGGTCATCAATACCGAAGATGGGAAAAAGAGACATACCCTAGAAAAGATGACTGATTCTGTCACTTGTTTGTATTGCAATTCCTTTTCCAAGCAAAGCAAACAAAAAAATTTTCTTTTGGTTGGAACCGCTGATGGCAAGTTAGCAATTTTTGAAGATAAGACTGTTAAGCTTAAAGGAGCTGCTCCTTTGAAGATACTAAATATAGGAAATGTCAGTACTCCATTGATGTGTTTGAGTGAATCCACAAATTCAACGGAAAGAAATGTAATGTGGGGAGGATGTGGCACAAAGATTTTCTCCTTTTCTAATGATTTCACCATTCAGAAACTCATTGAGACAAGAACAAGCCAACTGTTTTCTTATGCAGCTTTCAGTGATTCCAACATCATAACAGTGGTGGTAGACACTGCTCTCTATATTGCTAAGCAAAATAGCCCTGTTGTGGAAGTGTGGGATAAGAAAACTGAAAAACTCTGTGGACTAATAGACTGCGTGCACTTTTTAAGCCTTAAAAATGTCATGCTGGTATTGGGCTACAACCGGAAAAATACTTTGGCTTTACATCCTATATGTTTAAAATCAAAGTTAAGATGCAGTTCATCCAAAGGAAGATCCCATATTTTGCTTCGTGTAATTTACAACTTTTGTAATTCGGTCAGAGTCATGATGACAGCACAGCTAGGCGGAAGCCTTAAAAATGTCATGCTGGTATTGGGCTACAACCGGAAAAATACTGAAGGTACACAAAAGCAGAAAGAGATACAATCTTGCTTGACCGTTTGGGACATCAATCTTCCACATGAAGTGCAAAATTTAGAAAAACACATTGAAGTGAGAAAAGAATTAGCTGAAAAAATGAGACGAACATCTGTTGAGTAAGAGAGAAATAGGAATTGTCTTTGGATAGGAAAATTATTCTCTCCTCTTGTAAATATTTATTTTAAAAATGTTCACATGGAAAGGGTACTCACATTTTTTGAAATAGCTCGTGTGTATGAAGGAATGTTATTATTTTTAATTTAAATATATGTAAAAATACTTACCAGTAAATGTGTATTTTAAAGAACTATTTAAAANOV74d, CG90866-02Protein SequenceSEQ ID NO: 1078911 aaMW at 103214.9kDMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVALGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLRLVKPNRKKLSNLMMSLALHPICLKSKLRCSSSKGRSHILLRVIYNFCNSVRVMMTAQLGGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVENOV74e, CG90866-05SEQ ID NO: 10792955 bpDNA SequenceORF Start: ATG at 81ORF Stop: TAA at 2844GAGTCCTTCTTCATTTTCAAGACCCAGCACTGCAGTTAAGTGACTTGTACTTTGTGGAACCCAAGTGGCTTTGTAAAATCATGGCACAGATTTTGACAGTGAAAGTGGAAGGTTGTCCAAAACACCCTAAGGGAATTATTTCGCGTAGAGATGTGGAAAAATTTCTTTCAAAAAAAAGGAAATTTCCAAAGAACTACATGTCACAGTATTTTAAGCTCCTAGAAAAATTCCAGATTGCTTTGCCAATAGGAGAAGAATATTTGCTGGTTCCAAGCAGTTTGTCTGACCACAGGCCTGTGATAGAGCTTCCCCATTGTGAGAACTCTGAAATTATCATCCGAGCAGTTTGTCTGACCACAGGCCTGTGATAGAGCTTCCCCATTGTGAGAACTCTGAAATTATCATCCGACTATATGAAATGCCTTATTTTCCAATGGGATTTTGGTCAAGATTAATCAATCGATTACTTGAGATTTCACCTTACATGCTTTCAGGGAGAGAACGAGCACTTCGCCCAAACAGAATGTATTGGCGACAAGGCATTTACTTAAATTGGTCTCCTGAAGCTTATTGTCTGGTAGGATCTGAAGTCTTAGACAATCATCCAGAGAGTTTCTTAAAAATTACAGTTCCTTCTTGTAGAAAAGGCTGTATTCTTTTGGGCCAAGTTGTGGACCACATTGATTCTCTCATGGAAGAATGGTTTCCTGGGTTGCTGGAGATTGATATTTGTGGTGAAGGAGAAACTCTGTTGAAGAAATGGGCATTATATAGTTTTAATGATGGTGAAGAACATCAAAAAATCTTACTTGATGACTTGATGAAGAAAGCAGAGGAAGGAGATCTCTTAGTAAATCCAGATCAACCAAGGCTCACCATTCCAATATCTCAGATTGCCCCTGACTTGATTTTGGCTGACCTGCCTAGAAATATTATGTTGAATAATGATGAGTTGGAATTTGAACAAGCTCCAGAGTTTCTCCTAGGTGATGGCAGTTTTGGATCAGTTTACCGAGCAGCCTATGAAGGAGAAGAAGTGGCTGTGAAGATTTTTAATAAACATACATCACTCAGGCTGTTAAGACAAGAGCTTGTGGTGCTTTGCCACCTCCACCACCCCAGTTTGATATCTTTGCTGGCAGCTGGGATTCGTCCCCGGATGTTGGTGATGGAGTTAGCCTCCAAGGGTTCCTTGGATCGCCTGCTTCAGCAGGACAAAGCCAGCCTCACTAGAACCCTACAGCACAGGATTGCACTCCACGTAGCTGATGGTTTGAGATACCTCCACTCAGCCATGATTATATACCGAGACCTGAAACCCCACAATGTGCGGCTTTTCACACTGTATCCCAATGCTGCCATCATTGCAAAGATTGCTGACTACGGCATTGCTCAGTACTGCTGTAGAATGGGGATAAAAACATCAGAGGGCACACCAGGGTTTCGTGCACCTGAAGTTGCCAGAGGAAATGTCATTTATAACCAACAGGCTGATGTTTATTCATTTGGTTTACTACTCTATGACATTTTGACAACTGGAGGTAGAATAGTAGAGGGTTTGAAGTTTCCAAATGAGTTTGATGAATTAGAAATACAAGGAAAATTACCTGATCCAGTTAAAGAATATGGTTGTGCCCCATGGCCTATGGTTGAGAAATTAATTAAACAGTGTTTGAAAGAAAATCCTCAAGAAAGGCCTACTTCTGCCCAGGTCTTTGACATTTTGAATTCAGCTGATTAGTCTGTCTGACGAGACGCATTTTTATTACCTAAAAACGTAATTGTTGAATGCATGGTTGCTACACATCACAACAGCAGGAATGCAAGCATTTGGCTGGGCTGTGGGCACACCGACAGAGGACAGCTCTCATTTCTTGACTTAAATACTGAAGGATACACTTCTGAGGAAGTTGCTGATAGTAGAATATTGTGCTTAGCCTTGGTGCATCTTCCTGTTGAAAAGGAAAGCTGGATTGTGTCTGGGACACAGTCTGGTACTCTCCTGGTCATCAATACCGAAGATGGGAAAAAGAGACATACCCTAGAAAAGATGACTGATTCTGTCACTTGTTTGTATTGCAATTCCTTTTCCAAGCAAAGCAAACAAAAAAATTTTCTTTTGGTTGGAACCGCTGATGGCAAGTTAGCAATTTTTGAAGATAAGACTGTTAAGCTTAAAGGAGCTGCTCCTTTGAAGATACTAAATATAGGAATGTCAGGTACTCCATTGATGTGTTTGAGTGAATCCACAAATTCAACGGAAAGAAATGTAATGTGGGGAGGATGTGGCACAAAGATTTTCTCCTTTTCTAATGATTTCACCATTCAGAAACTCATTGAGACAAGAACAAGCCAACTGTTTTCTTATGCAGCTTTCAGTGATTCCAACATCATAACAGTGGTGGTAGACACTGCTCTCTATATTGCTAAGCAAAATAGCCCTGTTGTGGAAGTGTGGGATAAGAAAACTGAAAAACTCTGTGGGCTAATAGACTGCGTGCACTTTTTAAGGGAGGTAACGGTAAAAGAAAACAAGGAATCAAAACACAAAATGTCTTATTCTGGGAGAGTGAAAACCCTCTGCCTTCAGAAGAACACTGCTCTTTGGATAGGAACTGGAGGAGGCCATATTTTACTCCTGGATCTTTCAACTCGTCGACTTATACGTGTAATTTACAACTTTTGTAATTCGGTCAGAGTCATGATGACAGCACAGCTAGGAAGCCTTAAAAATGTCATGCTGGTATTGGGCTACAACCGGAAAAATACTGAAGGTACACAAAAGCAGAAAGAGATACAATCTTGCTTGACCGTTTGGGACATCAATCTTCCACATGAAGTGCAAAATTTAGAAAAACACATTGAAGTGAGAAAAGAATTAGCTGAAAAAATGAGACGAACATCTGTTGAGTAAGAGAGAAATAGGAATTGTCTTTGGATAGGAAAATTATTCTCTCCTCTTGTAAATATTTATTTTAAAAATGTTCACATGGAAAGGGTACTCACATTTTTAAGGGCGAATCNOV74e, CG90866-05Protein SequenceSEQ ID NO: 1080921 aaMW at 104423.0kDMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVALGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKICGLIDCVHFLSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKMIEVRKELAEKMRRTSVE

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 74B.

TABLE 74BComparison of the NOV74 protein sequences.NOV74aMQPLDFSSGGSDPNISLSEKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRNOV74b------------------------------------------------------------NOV74c------------------------------------------------------------NOV74d------------------------------------------------------------NOV74e------------------------------------------------------------NOV74aLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSKLYFVEPKWLCKIMAQDVSNOV74b------------------------------------------------------MAQ---NOV74c------------------------------------------------------MAQ---NOV74d------------------------------------------------------MAQ---NOV74e------------------------------------------------------MAQ---NOV74aSIFGLYIRDILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALNOV74b---------ILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKMYMSQYFKLLEKFQIALNOV74c---------ILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKMYMSQYFKLLEKFQIALNOV74d---------ILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKMYMSQYFKLLEKFQIALNOV74e---------ILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKMYMSQYFKLLEKFQIALNOV74aPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLNOV74bPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLNOV74cPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLNOV74dPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRIINRLLEISPYMLNOV74ePIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRIINRLLEISPYMLNOV74aSG--R-----------------------------------------------GCILLGQVNOV74bSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVNOV74cSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVNOV74dSGRERALRPNRNYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVNOV74eSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVNOV74aVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLNOV74bVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLNOV74cVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLNOV74dVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLNOV74eVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLNOV74aVNPDQPRLTIPISQIAPDLILADPPRNIMLNNDELEFEQAPEFLLDCFVCIHLYPSSDYINOV74bVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLL---------------NOV74cVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLL---------------NOV74dVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLL---------------NOV74eVNPDQPRITIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLL---------------NOV74aSRHYMRTINIVQTGFAKCRWRVTVHGADHGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLNOV74b-----------------------------GDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLNOV74c-----------------------------GDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLNOV74d-----------------------------GDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLNOV74e-----------------------------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----DILNSAELVCLTRRILLPKNVIVNOV74bKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVF----DILNSAELVCLTRRILLPKNVIVNOV74cKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFSQVFDILNSAELVCLTRRILLPKNVIVNOV74dKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVF----DILNSAELVCLTRRILLPKNVIVNOV74eKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVF----DILNSAELVCLTRRILLPKNVIVNOV74aECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSE--------------------NOV74bECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKENOV74cECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKENOV74dECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKENOV74eECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKENOV74a--------------------------------------------SKQKNFLLVGTADGKLNOV74bSWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLNOV74cSWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLNOV74dSWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLNOV74eSWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLNOV74aAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTINOV74bAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTINOV74cAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTINOV74dAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTINOV74eAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTINOV74aQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFNOV74bQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFNOV74cQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFNOV74dQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFNOV74eQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFNOV74aLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNOV74bL----------S------------------------------------------------NOV74cLRLVKPNRKKLSNLMMSLA--LHPICLKSKLRCSSSKGRSHILL---------RVIYNFCNOV74dLRLVKPNRKKLSNLMMSLA--LHPICLKSKLRCSSSKGRSHILL---------RVIYNFCNOV74eLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNOV74aNSVRVMMTAQLG-SLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHINOV74b--------------LKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHINOV74cNSVRVMMTAQLGGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHINOV74dNSVRVMMTAQLGGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHINOV74eNSVRVMMTAQLG-SLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHINOV74aEVRKELAEKMRRTSVENOV74bEVRKELAEKMRRTSVENOV74cEVRKELAEKMRRTSVENOV74dEVRKELAEKMRRTSVENOV74eEVRKELAEKMRRTSVENOV74a(SEQ ID NO: 1072)NOV74b(SEQ ID NO: 1074)NOV74c(SEQ ID NO: 1076)NOV74d(SEQ ID NO: 1078)NOV74e(SEQ ID NO: 1080)

Further analysis of the NOV74a protein yielded the following properties shown in Table 74C.

TABLE 74CProtein Sequence Properties NOV74aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 5;pos.chg 0;neg.chg 1H-region:length 6;peak value0.00PSG score:−4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −11.05possible cleavage site: between 13 and 14>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 2Number of TMS(s) for threshold 0.5: 0PERIPHERAL Likelihood = 1.96 (at 794)ALOM score: −0.64 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment (75):1.98Hyd Moment(95):4.87G content:2D/E content:2S/T content:3Score: −7.81Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: KKRK (5) at 157pat7: PVIDRKR (3) at 54bipartite: RKNVPIEFPVIDRKRLL at 46content of basic residues: 11.6%NLS Score: 0.59KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): ***found*** LQLDENELPHAVHFLNESGVLL at 70Regulator of chromosome condensation (RCC1) signature 2(PS00626): ***found*** IGTGGGHILLL at 878checking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 89COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23): 52.2%: cytoplasmic 39.1%: nuclear 8.7%: mitochondrial>> prediction for CG90866-04 is cyt (k = 23)

A search of the NOV74a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 74D.

TABLE 74DGeneseq Results for NOV74aNOV74aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAU03554Human protein kinase #54 1 . . . 845835/909 (91%)0.0Homo sapiens, 909 aa. 1 . . . 909839/909 (91%)[WO200138503-A2, 31-MAY-2001]ABU11054Human protein NOV19b - Homo130 . . . 978754/963 (78%)0.0sapiens, 911 aa. [WO200281629- 4 . . . 911765/963 (79%)A2, 17-OCT-2002]ABU11053Human protein NOV19a - Homo130 . . . 978754/967 (77%)0.0sapiens, 915 aa. [WO200281629- 4 . . . 915765/967 (78%)A2, 17-OCT-2002]AAE16259Human kinase PKIN-5 protein -401 . . . 978567/642 (88%)0.0Homo sapiens, 656 aa. 15 . . . 656571/642 (88%)[WO200196547-A2, 20-DEC-2001]AAU11287Human transducin polypeptide670 . . . 978298/373 (79%)e−16241 - Homo sapiens, 373 aa. 1 . . . 373302/373 (80%)[CN1306988-A, 08-AUG-2001]

In a BLAST search of public sequence databases, the NOV74a protein was found to have homology to the proteins shown in the BLASTP data in Table 74E.

TABLE 74EPublic BLASTP Results for NOV74aNOV74aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8K062Similar to RIKEN cDNA208 . . . 978642/884 (72%)0.04921513O20 gene - Mus 1 . . . 840694/884 (77%)musculus (Mouse), 840 aa(fragment).Q9CQG84921513O20Rik protein - Mus499 . . . 978401/545 (73%)0.0musculus (Mouse), 561 aa. 18 . . . 561441/545 (80%)Q8NCX9Hypothetical protein - Homo643 . . . 978326/400 (81%)e−178sapiens (Human), 400 aa 1 . . . 400330/400 (82%)(fragment).Q8CI84Hypothetical protein - Mus669 . . . 978239/329 (72%)e−133musculus (Mouse), 327 aa 1 . . . 327269/329 (81%)(fragment).Q8BZJ6Hypothetical serine/threonine 14 . . . 224183/211 (86%)1e−99protein kinase containing protein -345 . . . 543190/211 (89%)Mus musculus (Mouse), 546 aa.

PFam analysis indicates that the NOV74a protein contains the domains shown in the Table 74F.

TABLE 74FDomain Analysis of NOV74aNOV74aIdentities/SimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValuepkinase394 . . . 644 90/302 (30%)1.4e−33169/302 (56%)

Example 75

The NOV75 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 75A.

TABLE 75ANOV75 Sequence AnalysisNOV75a, CG91708-02SEQ ID NO: 10811580 bpDNA SequenceORF Start: ATG at 51ORF Stop: TGA at 1482CAAGACAGCAAGGCATAGAGACAACATAGAGCTAAGTAAAGCCAGTGGAAATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGCAGTTTGCTCAGCCTATCCATTGGATGGAGCTGCAAGGGGTGAGGACACCAGCATGAACCTTGTTCAGAAATATCTAGAAAACTACTACGACCTCGAAAAAGATGTGAAACAGTTTGTTAGGAGAAAGGACAGTGGTCCTGTTGTTAAAAAAATCCGAGAAATGCAGAAGTTCCTTGGATTGGAGGTGACGGGGAAGCTGGACTCCGACACTCTGGAGGTGATGCGCAAGCCCATGTGTGGAGTTCCTGACGTTGGTCACTTCAGAACCTTTCCTGGCATCCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAATTATACACCAGATTTGCCAAAAGATGCTGTTGATTCTGCTGTTGAGAAAGCTCTGAAAGTCTGGGAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGACTGATATAATGATCTCTTTTGCAGTTAGAGAACATGGAGACTTTTACCCTTTTGATGGACCTGGAAATGTTTTGGCCCATGCCTATGCCCCTGGGCCAGGGATTAATGGAGATGCCCACTTTGATGATGATGAACAATGGACAAAGGATACAACAGGGACCAATTTATTTCTCGTTGCTGCTCATGAAATTGGCCACTCCCTGGGTCTCTTTCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTATCACTCACTCACAGACCTGACTCGGTTCCGCCTGTCTCAAGATGATATAAATGGCATTCAGTCCCTCTATGGACCTCCCCCTGACTCCCCTGAGACCCCCCTGGTACCCACGGAACCTGTCCCTCCAGAACCTGGGACGCCAGCCAACTGTGATCCTGCTTTGTCCTTTGATGCTGTCAGCACTCTGAGGGGAGAAATCCTGATCTTTAAAGACAGGCACTTTTGGCGCAAATCCCTCAGGAAGCTTGAACCTGAATTGCATTTGATCTCTTCATTTTGGCCATCTCTTCCTTCAGGCGTGGATGCCGCATATGAAGTTACTAGCAAGGACCTCGTTTTCATTTTTAAAGGAAATCAATTCTGGGCCATCAGAGGAAATGAGGTACGAGCTGGATACCCAAGAGGCATCCACACCCTAGGTTTCCCTCCAACCGTGAGGAAAATCGATGCAGCCATTTCTGATAAGGAAAAGAACAAAACATATTTCTTTGTAGAGGACAAATACTGGAGATTTGATGAGAAGAGAAATTCCATGGAGCCAGGCTTTCCCAAGCAAATAGCTGAAGACTTTCCAGGGATTGACTCAAAGATTGATGCTGTTTTTGAAGAATTTGGGTTCTTTTATTTCTTTACTGGATCTTCACAGTTGGAGTTTGACCCAAATGCAAAGAAAGTGACACACACTTTGAAGAGTAACAGCTGGCTTAATTGTTGAAAGAGATATGTAGAAGGCACAATATGGGCACTTTAAATGAAGCTAATAATTCTTCACCTAAGTCTCTGTGAATTGAAATGTTCGTTTTCTCCTGCTNOV75a, CG91708-02Protein SequenceSEQ ID NO: 1082477 aaMW at 53982.7kDMKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLEKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPMCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGETDIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSARTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNCNOV75b, 262751856SEQ ID NO: 10831446 bpDNA SequenceORF Start: at 1ORF Stop: end of sequenceGGATCCACCATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGCAGTTTGCTCAGCCTATCCATTGGATGGAGCTGCAAGGGGTGAGGACACCAGCATGAACCTTGTTCAGAAATATCTAGAAAACTACTACGACCTCGAAAAAGATGTGAAACAGTTTGTTAGGAGAAAGGACAGTGGTCCTGTTGTTAAAAAAATCCGAGAAATGCAGAAGTTCCTTGGATTGGAGGTGACGGGGAAGCTGGACTCCGACACTCTGGAGGTGATGCGCAAGCCCAGGTGTGGAGTTCCTGACGTTGGTCACTTCAGAACCTTTCCTGGCATCCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAATTATACACCAGATTTGCCAAAAGATGCTGTTGATTCTGCTGTTGAGAAAGCTCTGAAAGTCTGGGAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGGCTGATATAATGATCTCTTTTGCAGTTAGAGAACATGGAGACTTTTACCCTTTTGATGGACCTGGAAATGTTTTGGCCCATGCCTATGCCCCTGGGCCAGGGATTAATGGAGATGCCCACTTTGATGATGATGAACAATGGACAAAGGATACAACAGGGACCAATTTATTTCTCGTTGCTGCTCATGAAATTGGCCACTCCCTGGGTCTCTTTCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTATCACTCACTCACAGACCTGACTCGGTTCCGCCTGTCTCAAGATGATATAAATGGCATTCAGTCCCTCTATGGACCTCCCCCTGACTCCCCTGAGACCCCCCTGGTACCCACGGAACCTGTCCCTCCAGAACCTGGGACGCCAGCCAACTGTGATCCTGCTTTGTCCTTTGATGCTGTCAGCACTCTGAGGGGAGAAATCCTGATCTTTAAAGACAGGCACTTTTGGCGCAAATCCCTCAGGAAGCTTGAACCTGAATTGCATTTGATCTCTTCATTTTGGCCATCTCTTCCTTCAGGCGTGGATGCCGCATATGAAGTTACTAGCAAGGACCTCGTTTTCATTTTTAAAGGAAATCAATTCTGGGCCATCAGAGGAAATGAGGTACGAGCTGGATACCCAAGAGGCATCCACACCCTAGGTTTCCCTCCAACCGTGAGGAAAATCGATGCAGCCATTTCTGATAAGGAAAAGAACAAAACATATTTCTTTGTAGAGGACAAATACTGGAGATTTGATGAGAAGAGAAATTCCATGGAGCCAGGCTTTCCCAAGCAAATAGCTGAAGACTTTCCAGGGATTGACTCAAAGATTGATGCTGTTTTTGAAGAATTTGGGTTCTTTTATTTCTTTACTGGATCTTCACAGTTGGAGTTTGACCCAAATGCAAAGAAAGTGACACACACTTTGAAGAGTAACAGCTGGCTTAATTGTCTCGAGNOV75b, 262751856Protein SequenceSEQ ID NO: 1084482 aaMW at 54465.2kDGSTMKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLEKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPAMCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNCLENOV75c, CG91708-01SEQ ID NO: 10851821 bpDNA SequenceORF Start: ATG at 64ORF Stop: TGA at 1495ACAAGGAGGCAGGCAAGACAGCAAGGCATAGAGACAACATAGAGCTAAGTAAAGCCAGTGGAAATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGCAGTTTGCTCAGCCTATCCATTGGATGGAGCTGCAAGGGGTGAGGACACCAGCATGAACCTTGTTCAGAAATATCTAGAAAACTACTACGACCTCAAAAAAGATGTGAAACAGTTTGTTAGGAGAAAGGACAGTGGTCCTGTTGTTAAAAAAATCCGAGAAATGCAGAAGTTCCTTGGATTGGAGGTGACGGGGAAGCTGGACTCCGACACTCTGGAGGTGATGCGCAAGCCCAGGTGTGGAGTTCCTGATGTTGGTCACTTCAGAACCTTTCCTGGCATCCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAATTATACACCAGATTTGCCAAAAGATGCTGTTGATTCTGCTGTTGAGAAAGCTCTGAAAGTCTGGGAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGGCTGATATAATGATCTCTTTTGCAGTTAGAGAACATGGAGACTTTTACCCTTTTGATGGACCTGGAAATGTTTTGGCCCATGCCTATGCCCCTGGGCCAGGGATTAATGGAGATGCCCACTTTGATGATGATGAACAATGGACAAAGGATACAACAGGGACCAATTTATTTCTCGTTGCTGCTCATGAAATTGGCCACTCCCTGGGTCTCTTTCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTATCACTCACTCACAGACCTGACTCGGTTCCGCCTGTCTCAAGATGATATAAATGGCATTCAGTCCCTCTATGGACCTCCCCCTGACTCCCCTGAGACCCCCCTGGTACCCACGGAACCTGTCCCTCCAGAACCTGGGACGCCAGCCAACTGTGATCCTGCTTTGTCCTTTGATGCTGTCAGCACTCTGAGGGGAGAAATCCTGATCTTTAAAGACAGGCACTTTTGGCGCAAATCCCTCAGGAAGCTTGAACCTGAATTGCATTTGATCTCTTCATTTTGGCCATCTCTTCCTTCAGGCGTGGATGCCGCATATGAAGTTACTAGCAAGGACCTCGTTTTCATTTTTAAAGGAAATCAATTCTGGGCCATCAGAGGAAATGAGGTACGAGCTGGATACCCAAGAGGCATCCACACCCTAGGTTTCCCTCCAACCGTGAGGAAAATCGATGCAGCCATTTCTGATAAGGAAAAGAACAAAACATATrTCTTTGTAGAGGACAAATACTGGAGATTTGATGAGAAGAGAAATTCCATGGAGCCAGGCTTTCCCAAGCAAATAGCTGAAGACTTTCCAGGGATTGACTCAAAGATTGATGCTGTTTTTGAAGAATTTGGGTTCTTTTATTTCTTTACTGGATCTTCACAGTTGGAGTTTGACCCAAATGCAAAGAAAGTGACACACACTTTGAAGAGTAACAGCTGGCTTAATTGTTGAAAGAGATATGTAGAAGGCACAATATGGGCACTTTAAATGAAGCTAATAATTCTTCACCTAAGTCTCTGTGAATTGAAATGTTCGTTTTCTCCTGCCTGTGCTGTGACTCGAGTCACACTCAAGGGAACTTGAGCGTGAATCTGTATCTTGCCGGTCATTTTTATGTTATTACAGGGCATTCAAATGGGCTGCTGCTTAGCTTGCACCTTGTCACATAGAGTGATCTTTCCCAAGAGAAGGGGAAGCACTCGTGTGCAACAGACAAGTGACTGTATCTGTGTAGACTATTTGCTTATTTAATAAAGACGATTTGTCAGTTGTTTTNOV75c, CG91708-01Protein SequenceSEQ ID NO: 1086477 aaMW at 53976.7kDMKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLEKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPMCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGETDIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSARTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNCNOV75d, CG91708-03SEQ ID NO: 10871446 bpDNA SequenceORF Start: ATG at 10ORF Stop: at 1441GGATCCACCATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGCAGTTTGCTCAGCCTATCCATTGGATGGAGCTGCAAGGGGTGAGGACACCAGCATGAACCTTGTTCAGAAATATCTAGAAAACTACTACGACCTCGAAAAAGATGTGAAACAGTTTGTTAGGAGAAAGGACAGTGGTCCTGTTGTTAAAAAAATCCGAGAAATGCAGAAGTTCCTTGGATTGGAGGTGACGGGGAAGCTGGACTCCGACACTCTGGAGGTGATGCGCAAGCCCAGGTGTGGAGTTCCTGACGTTGGTCACTTCAGAACCTTTCCTGGCATCCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAATTATACACCAGATTTGCCAAAAGATGCTGTTGATTCTGCTGTTGAGAAAGCTCTGAAAGTCTGGGAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGGCTGATATAATGATCTCTTTTGCAGTTAGAGAACATGGAGACTTTTACCCTTTTGATGGACCTGGAAATGTTTTGGCCCATGCCTATGCCCCTGGGCCAGGGATTAATGGAGATGCCCACTTTGATGATGATGAACAATGGACAAAGGATACAACAGGGACCAATTTATTTCTCGTTGCTGCTCATGAAATTGGCCACTCCCTGGGTCTCTTTCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTATCACTCACTCACAGACCTGACTCGGTTCCGCCTGTCTCAAGATGATATAAATGGCATTCAGTCCCTCTATGGACCTCCCCCTGACTCCCCTGAGACCCCCCTGGTACCCACGGAACCTGTCCCTCCAGAACCTGGGACGCCAGCCAACTGTGATCCTGCTTTGTCCTTTGATGCTGTCAGCACTCTGAGGGGAGAAATCCTGATCTTTAAAGACAGGCACTTTTGGCGCAAATCCCTCAGGAAGCTTGAACCTGAATTGCATTTGATCTCTTCATTTTGGCCATCTCTTCCTTCAGGCGTGGATGCCGCATATGAAGTTACTAGCAAGGACCTCGTTTTCATTTTTAAAGGAAATCAATTCTGGGCCATCAGAGGAAATGAGGTACGAGCTGGATACCCAAGAGGCATCCACACCCTAGGTTTCCCTCCAACCGTGAGGAAAATCGATGCAGCCATTTCTGATAAGGAAAAGAACAAAACATATTTCTTTGTAGAGGACAAATACTGGAGATTTGATGAGAAGAGAAATTCCATGGAGCCAGGCTTTCCCAAGCAAATAGCTGAAGACTTTCCAGGGATTGACTCAAAGATTGATGCTGTTTTTGAAGAATTTGGGTTCTTTTATTTCTTTACTGGATCTTCACAGTTGGAGTTTGACCCAAATGCAAAGAAAGTGACACACACTTTGAAGAGTAACAGCTGGCTTAATTGTCTCGAGNOV75d, CG91708-03Protein SequenceSEQ ID NO: 1088477 aaMW at 53977.6kDMKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLEKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNCNOV75e, CG91708-04SEQ ID NO: 10891446 bpDNA SequenceORF Start: ATG at 10ORF Stop: at 1441GGATCCACCATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGCAGTTTGCTCAGCCTATCCATTGGATGGAGCTGCAAGGGGTGAGGACACCAGCATGAACCTTGTTCAGAAATATCTAGAAAACTACTACGACCTCAAAAAAGATGTGAAACAGTTTGTTAGGAGAAAGGACAGTGGTCCTGTTGTTAAAAAAATCCGAGAAATGCAGAAGTTCCTTGGATTGGAGGTGACGGGGAAGCTGGACTCCGACACTCTGGAGGTGATGCGCAAGCCCAGGTGTGGAGTTCCTGACGTTGGTCACTTCAGAACCTTTCCTGGCATCCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAATTATACACCAGATTTGCCAAAAGATGCTGTTGATTCTGCTGTTGAGAAAGCTCTGAAAGTCTGGGAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGGCTGATATAATGATCTCTTTTGCAGTTAGAGAACATGGAGACTTTTACCCTTTTGATGGACCTGGAAATGTTTTGGCCCATGCCTATGCCCCTGGGCCAGGGATTAATGGAGATGCCCACTTTGATGATGATGAACAATGGACAAAGGATACAACAGGGACCAATTTATTTCTCGTTGCTGCTCATGAAATTGGCCACTCCCTGGGTCTCTTTCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTATCACTCACTCACAGACCTGACTCGGTTCCGCCTGTCTCAAGATGATATAAATGGCATTCAGTCCCTCTATGGACCTCCCCCTGACTCCCCTGAGACCCCCCTGGTACCCACGGAACCTGTCCCTCCAGAACCTGGGACGCCAGCCAACTGTGATCCTGCTTTGTCCTTTGATGCTGTCAGCACTCTGAGGGGAGAAATCCTGATCTTTAAAGACAGGCACTTTTGGCGCAAATCCCTCAGGAAGCTTGAACCTGAATTGCATTTGATCTCTTCATTCTGGCCATCTCTTCCTTCAGGCGTGGATGCCGCATATGAAGTTACTAGCAAGGACCTCGTTTTCATTTTTAAAGGAAATCAATTCTGGGCCATCAGAGGAAATGAGGTACGAGCTGGATACCCAAGAGGCATCCACACCCTAGGTTTCCCTCCAACCGTGAGGAAAATCGATGCAGCCATTTCTGATAAGGAAAAGAACAAAACATATTTCTTTGTAGAGGACAAATACTGGAGATTTGATGAGAAGAGAAATTCCATGGAGCCAGGCTTTCCCAAGCAAATAGCTGAAGACTTTCCAGGGATTGACTCAAAGATTGATGCTGTTTTTGAAGAATTTGGGTTCTTTTATTTCTTTACTGGATCTTCACAGTTGGAGTTTGACCCAAATGCAAAGAAAGTGACACACACTTTGAAGAGTAACAGCTGGCTTAATTGTCTCGAGNOV75e, CG91708-04Protein SequenceSEQ ID NO: 1090477 aaMW at 53976.7kDMKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNCSEQ ID NO: 10911580 bpNOV75f, SNP13380740 ofORF Start: ATG at 51ORF Stop: TGA at 1482CG91708-02, DNA SequenceSNP Pos: 183SNP Change: G to ACAAGACAGCAAGGCATAGAGACAACATAGAGCTAAGTAAAGCCAGTGGAAATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGCAGTTTGCTCAGCCTATCCATTGGATGGAGCTGCAAGGGGTGAGGACACCAGCATGAACCTTGTTCAGAAATATCTAGAAAACTACTACGACCTCAAAAAAGATGTGAAACAGTTTGTTAGGAGAAAGGACAGTGGTCCTGTTGTTAAAAAAATCCGAGAAATGCAGAAGTTCCTTGGATTGGAGGTGACGGGGAAGCTGGACTCCGACACTCTGGAGGTGATGCGCAAGCCCATGTGTGGAGTTCCTGACGTTGGTCACTTCAGAACCTTTCCTGGCATCCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAATTATACACCAGATTTGCCAAAAGATGCTGTTGATTCTGCTGTTGAGAAAGCTCTGAAAGTCTGGGAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGACTGATATAATGATCTCTTTTGCAGTTAGAGAACATGGAGACTTTTACCCTTTTGATGGACCTGGAAATGTTTTGGCCCATGCCTATGCCCCTGGGCCAGGGATTAATGGAGATGCCCACTTTGATGATGATGAACAATGGACAAAGGATACAACAGGGACCAATTTATTTCTCGTTGCTGCTCATGAAATTGGCCACTCCCTGGGTCTCTITCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTATCACTCACTCACAGACCTGACTCGGTTCCGCCTGTCTCAAGATGATATAAATGGCATTCAGTCCCTCTATGGACCTCCCCCTGACTCCCCTGAGACCCCCCTGGTACCCACGGAACCTGTCCCTCCAGAACCTGGGACGCCAGCCAACTGTGATCCTGCTTTGTCCTTTGATGCTGTCAGCACTCTGAGGGGAGAAATCCTGATCTTTAAAGACAGGCACTTTTGGCGCAAATCCCTCAGGAAGCTTGAACCTGAATTGCATTTGATCTCTTCATTTTGGCCATCTCTTCCTTCAGGCGTGGATGCCGCATATGAAGTTACTAGCAAGGACCTCGTTTTCATTTTTAAAGGAAATCAATTCTGGGCCATCAGAGGAAATGAGGTACGAGCTGGATACCCAAGAGGCATCCACACCCTAGGTTTCCCTCCAACCGTGAGGAAAATCGATGCAGCCATTTCTGATAAGGAAAAGAACAAAACATATTTCTTTGTAGAGGACAAATACTGGAGATTTGATGAGAAGAGAAATTCCATGGAGCCAGGCTTTCCCAAGCAAATAGCTGAAGACTTTCCAGGGATTGACTCAAAGATTGATGCTGTTTTTGAAGAATTTGGGTTCTTTTATTTCTTTACTGGATCTTCACAGTTGGAGTTTGACCCAAATGCAAAGAAAGTGACACACACTTTGAAGAGTAACAGCTGGCTTAATTGTTGAAAGAGATATGTAGAAGGCACAATATGGGCACTTTAAATGAAGCTAATAATTCTTCACCTAAGTCTCTGTGAATTGAAATGTTCGTTTTCTCCTGCTNOV75f, SNP13380740 ofSEQ ID NO: 1092MW at 53981.8kDCG91708-02, Protein SequenceSNP Pos: 45477 aaSNP Change: Glu to LysMKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPMCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGETDIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNC

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 75B.

TABLE 75BComparison of the NOV75 protein sequences.NOV75a---MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLEKDVKQFVRRKDSNOV75bGSTMKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLEKDVKQFVRRKDSNOV75c---MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQFVRRKDSNOV75d---MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLEKDVKQFVRRKDSNOV75e---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--NOV75bLENOV75c--NOV75d--NOV75e--NOV75a(SEQ ID NO: 1082)NOV75b(SEQ ID NO: 1084)NOV75c(SEQ ID NO: 1086)NOV75d(SEQ ID NO: 1088)NOV75e(SEQ ID NO: 1090)

Further analysis of the NOV75a protein yielded the following properties shown in Table 75C.

TABLE 75CProtein Sequence Properties NOV75aSignalP analysis:Cleavage site between residues 18 and 19PSORT II analysis:PSG:a new signal peptide prediction methodN-region:length 2;pos.chg 1;neg.chg 0H-region:length 18; peak value 10.73PSG score: 6.33GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): 3.45possible cleavage site: between 17 and 18>>> Seems to have a cleavable signal peptide (1 to 17)ALOM:Klein et al's method for TM region allocationInit position for calculation: 18Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 3.87 (at 293)ALOM score: 3.87 (number of TMSs: 0)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 8Charge difference: −4.0 C(−2.0) − N(2.0)N >= C: N-terminal side will be insideMITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment (75):3.04Hyd Moment (95):6.62G content:0D/E content:1S/T content:2Score: −4.76Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: PVVKKIR (3) at 59pat7: PKWRKTH (5) at 107bipartite: nonecontent of basic residues: 11.3%NLS Score: 0.22KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23): 33.3%: extracellular, including cell wall 22.2%: mitochondrial 22.2%: endoplasmic reticulum 11.1%: Golgi 11.1%: vacuolar>> prediction for CG91708-02 is exc (k = 9)

A search of the NOV75a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 75D.

TABLE 75DGeneseq Results for NOV75aNOV75aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB04752Human MMP3 protein SEQ ID1 . . . 477475/477 (99%)0.0NO: 3 - Homo sapiens, 477 aa.1 . . . 477475/477 (99%)[WO200179238-A2, 25-OCT-2001]AAB84608Amino acid sequence of matrix1 . . . 477475/477 (99%)0.0metalloproteinase-3 stromelysin 1 -1 . . . 477475/477 (99%)Homo sapiens, 477 aa.[WO200149309-A2, 12-JUL-2001]AAO20482Prostromelysin protein - Homo1 . . . 477475/477 (99%)0.0sapiens, 477 aa. [US6284513-B1,1 . . . 477475/477 (99%)04-SEP-2001]ABP54461Matrix metalloproteinase 3 amino1 . . . 477474/477 (99%)0.0acid sequence SEQ ID NO: 2919 -1 . . . 477475/477 (99%)Homo sapiens, 477 aa.[WO200278516-A2, 10-OCT-2002]ABU03473Angiogenesis-associated human1 . . . 477474/477 (99%)0.0protein sequence #18 - Homo1 . . . 477475/477 (99%)sapiens, 477 aa. [WO200279492-A2, 10-OCT-2002]

In a BLAST search of public sequence databases, the NOV75a protein was found to have homology to the proteins shown in the BLASTP data in Table 75E.

TABLE 75EPublic BLASTP Results for NOV75aNOV75aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueP08254Stromelysin-1 precursor (EC1 . . . 477474/477 (99%)0.03.4.24.17) (Matrix1 . . . 477475/477 (99%)metalloproteinase-3) (MMP-3)(Transin-1) (SL-1) - Homo sapiens(Human), 477 aa.P28863Stromelysin-1 precursor (EC1 . . . 477401/478 (83%)0.03.4.24.17) (Matrix1 . . . 478433/478 (89%)metalloproteinase-3) (MMP-3)(Transin-1) (SL-1) - Oryctolaguscuniculus (Rabbit), 478 aa.Q28397Stromelysin-1 precursor (EC1 . . . 477386/477 (80%)0.03.4.24.17) (Matrix1 . . . 477427/477 (88%)metalloproteinase-3) (MMP-3) -Equus caballus (Horse), 477 aa.P09238Stromelysin-2 precursor (EC1 . . . 477372/477 (77%)0.03.4.24.22) (Matrix1 . . . 476418/477 (86%)metalloproteinase-10) (MMP-10)(Transin-2) (SL-2) - Homo sapiens(Human), 476 aa.Q922W6Matrix metalloproteinase 3 - Mus1 . . . 477366/477 (76%)0.0musculus (Mouse), 479 aa.3 . . . 479413/477 (85%)

PFam analysis indicates that the NOV75a protein contains the domains shown in the Table 75F.

TABLE 75FDomain Analysis of NOV75aNOV75aIdentities/SimilaritiesExpectPfam DomainMatch Regionfor the Matched RegionValuePeptidase_M10_N18 . . . 96 44/84 (52%)1.2e−42 75/84 (89%)Peptidase_M10102 . . . 208 78/107 (73%)1.6e−80105/107 (98%)Astacin107 . . . 267 37/230 (16%)0.17106/230 (46%)hemopexin296 . . . 338 16/50 (32%)5.1e−12 37/50 (74%)hemopexin340 . . . 383 16/50 (32%)5.6e−13 39/50 (78%)hemopexin388 . . . 435 25/50 (50%)6.6e−19 41/50 (82%)hemopexin437 . . . 477 17/50 (34%)1.5e−09 33/50 (66%)

Example 76

The NOV76 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 76A.

TABLE 76ANOV76 Sequence AnalysisNOV76a, CG92078-02SEQ ID NO: 10931983 bpDNA SequenceORF Start: ATG at 6ORF Stop: TGA at 1836GCAGCATGAGCCGATCACCCCTCAATCCCAGCCAACTCCGATCAGTGGGCTCCCAGGATGCCCTGGCCCCCTTGCCTCCACCTGCTCCCCAGAATCCCTCCACCCACTCTTGGGACCCTTTGTGTGGATCTCTGCCTTGGGGCCTCAGCTGTCTTCTGGCTCTGCAGCATGTCTTGGTCATGGCTTCTCTGCTCTGTGTCTCCCACCTGCTCCTGCTTTGCAGTCTCTCCCCAGGAGGACTCTCTTACTCCCCTTCTCAGCTCCTGGCCTCCAGCTTCTTTTCATGTGGTATGTCTACCATCCTGCAAACTTGGATGGGCAGCAGGCTGCCTCTTGTCCAGGCTCCATCCTTAGAGTTCCTTATCCCTGCTCTGGTGCTGACCAGCCAGAAGCTACCCCGGGCCATCCAGACACCTGGAAACTCCTCCCTCATGCTGCACCTTTGTAGGGGACCTAGCTGCCATGGCCTGGGGCACTGGAACACTTCTCTCCAGGAGGTGTCCGGGGCAGTGGTAGTATCTGGGCTGCTGCAGGGCATGATGGGGCTGCTGGGGAGTCCCGGCCACGTGTTCCCCCACTGTGGGCCCCTGGTGCTGGCTCCCAGCCTGGTTGTGGCAGGGCTCTCTGCCCACAGGGAGGTAGCCCAGTTCTGCTTCACACACTGGGGGTTGGCCTTGCTGGTTATCCTGCTCATGGTGGTCTGTTCTCAGCACCTGGGCTCCTGCCAGTTTCATGTGTGCCCCTGGAGGCGAGCTTCAACGTCATCAACTCACACTCCTCTCCCTGTCTTCCGGCTCCTTTCGGTGCTGATCCCAGTGGCCTGTGTGTGGATTGTTTCTGCCTTTGTGGGATTCAGTGTTATCCCCCAGGAACTGTCTGCCCCCACCAAGGCACCATGGATTTGGCTGCCTCACCCAGGTGAGTGGAATTGGCCTTTGCTGACGCCCAGAGCTCTGGCTGCAGGCATCTCCATGGCCTTGGCAGCCTCCACCAGTTCCCTGGGCTGCTATGCCCTGTGTGGCCGGCTGCTGCATTTGCCTCCCCCACCTCCACATGCCTGCAGTCGAGGGCTGAGCCTGGAGGGGCTGGGCAGTGTGCTGGCCGGGCTGCTGGGAAGCCCCATGGGCACTGCATCCAGCTTCCCCAGCGTGGGCAAAGTGGGTCTTATCCAGGCTGGATCTCAGCAAGTGGCTCACTTAGTGGGGCTACTCTGCGTGGGGCTTGGACTCTCCCCCAGGTTGGCTCAGCTCCTCACCACCATCCCACTGCCTGTTGTTGGTGGGGTGCTGGGCGTGACCCAGGCTGTGGTTTTGTCTGCTGGATTCTCCAGCTTCTACCTGGCTGACATAGACTCTGGGCGAAATATCTTCATTGTGGGCTTCTCCATCTTCATGGCCTTGCTGCTGCCAAGATGGTTTCGGGAAGCCCCAGTCCTGTTCAGCACAGGCTGGAGCCCCTTGGATGTATTACTGCACTCACTGCTGACACAGCCCATCTTCCTGGCTGGACTCTCAGGCTTCCTACTAGAGAACACGATTCCTGGCACACAGCTTGAGCGAGGCCTAGGTCAAGGGCTACCATCTCCTTTCACTGCCCAAGAGGCTCGAATGCCTCAGAAGCCCAGGGAGAAGGCTGCTCAAGTGTACAGACTTCCTTTCCCCATCCAAAACCTCTGTCCCTGCATCCCCCAGCCTCTCCACTGCCTCTGCCCACTGCCTGAAGACCCTGGGGATGAGGAAGGAGGCTCCTCTGAGCCAGAAGAGATGGCAGACTTGCTGCCTGGCTCAGGGGAGCCATGCCCTGAATCTAGCAGAGAAGGGTTTAGGTCCCAGAAATGACCAGAACGCCTACTTCTGCCCTGGTTAATTTAGCCCTAACTCTCATCTGCTGGAGAGTCAGCTCCCAAACTGTTCTTTCTTGTAGGCAGAGGATATGTGTGTGTGTATTACATGGGACTGTCTAGAGGTTCCATTTCCCAATAGGNOV76a, CG92078-02Protein SequenceSEQ ID NO: 1094610 aaMW at 64502.7kDMSRSPLNPSQLRSVGSQDALAPLPPPAPQNPSTHSWDPLCGSLPWGLSCLLALQHVLVMASLLCVSHLLLLCSLSPGGLSYSPSQLLASSFFSCGMSTILQTWNGSRLPLVQAPSLEFLIPALVLTSQKLPRAIQTPGNSSLMLHLCRGPSCHGLGHWNTSLQEVSGAVVVSGLLQGMMGLLGSPGHVFPHCGPLVLAPSLVVAGLSAHREVAQFCFTHWGLALLVILLMVVCSQHLGSCQFHVCPWRRASTSSTHTPLPVFRLLSVLIPVACVWIVSAFVGFSVIPQELSAPTKAPWIWLPHPGEWNWPLLTPRALAAGISMALAASTSSLGCYALCGRLLHLPPPPPHACSRGLSLEGLGSVLAGLLGSPMGTASSFPSVGKVGLIQAGSQQVAHLVGLLCVGLGLSPRLAQLLTTIPLPVVGGVLGVTQAVVLSAGFSSFYLADIDSGRNIFIVGFSIFMALLLPRWFREAPVLFSTGWSPLDVLLHSLLTQPIFLAGLSGFLLENTIPGTQLERGLGQGLPSPFTAQEARMPQKPREKAAQVYRLPFPIQNLCPCIPQPLHCLCPLPEDPGDEEGGSSEPEEMADLLPGSGEPCPESSREGFRSQKNOV76b, CG92078-01SEQ ID NO: 10952014 bpDNA SequenceORF Start: ATG at 6ORF Stop: TAG at 1992GCAGCATGAGCCGATCACCCCTCAATCCCAGCCAACTCCGATCAGTGGGCTCCCAGGATGCCCTGGCCCCCTTGCCTCCACCTGCTCCCCAGAATCCCTCCACCCACTCTTGGGACCCTTTGTGTGGATCTCTGCCTTGGGGCCTCAGCTGTCTTCTGGCTCTGCAGCATGTCTTGGTCATGGCTTCTCTGCTCTGTGTCTCCCACCTGCTCCTGCTTTGCAGTCTCTCCCCAGGAGGACTCTCTTACTCCCCTTCTCAGCTCCTGGCCTCCAGCTTCTTTTCATGTGGTATGTCTACCATCCTGCAAACTTGGATGGGCAGCAGGAGGCTGCCTCTTGTCCAGGCTCCATCCTTAGAGTTCCTTATCCCTGCTCTGGTGCTGACCAGCCAGAAGCTACCCCGGGCCATCCAGACACCTGGAAACGCCTCCCTCATGCTGCACCTTTGTAGGGGACCTAGCTGCCATGGCCTGGGGCACTGGAACACTTCTCTCCAGGAGGTGGTGGTAGTATCTGGGCTGCTGCAGGGCATGATGGGGCTGCTGGGGAGTCCCGGCCACGTGTTCCCCCACTGTGGGCCCCTGGTGCTGGCTCCCAGCCTGGTTGTGGCAGGGCTCTCTGCCTTTCCCCAAGAGGGAGTTTTGCTCCTGTCACCCAGCCTGGAGTGCAATGGCATGATCTCGGCTCACCACTGGGGAGAAGCCAGCCAGCTCTGCCTCCTGGCCCTGGAGTGCTCACTCCATCCCCTACCTTTTGGCTTCTGTCTACCCCTGCAAGGCTGGCTCAGAAGGTTCTGGGGGAGGAGTTCTTTTCTCAGTCTCGCCCCTCAGGTGCTGATCCCAGTGGCCTGTGTGTGGATTGTTTCTGCCTTTGTGGGATTCAGTGTTATCCCCCAGGAACTGTCTGCCCCCACCAAGGCACCATGGATTTGGCTGCCTCACCCAGGTGTGTGGAATTGGCCTTTGCTGACGCCCAGAGCTCTGGCTGCAGGCATCTCCATGGCCTTGGCAGCCTCCACCAGTTCCCTGGGCTGCTATGCCCTGTGTGGCCGGCTGCTGCATTTGCCTCCCCCACCTCCACATGCCTGCAGTCGAGGGCTGAGCCTGGAGGGGCTGGGCAGTGTGCTGGCCGGGCTGCTGGGAAGCCCCATGGGCACTGCATCCAGCTTCCCCAACGTGGGCAAAGTGGGTCTTATCCAGCAGGCTGGATCTCAGCAAGTGGCTCACTTAGTGGGGCTACTCTGCGTGGGGCTTGGACTCTCCCCCAGGTTGGCTCAGCTCCTCACCACCATCCCACTGCCTGTTGTTGGTGGTGGGGTGCTGGGGGTGACCCAGGCTGTGGTTTTGTCTGCTGGATTCTCCAGCTTCTACCTGGCTGACATAGACTCTGGGCGAAATATCTTCATTGTGGGCTTCTCCATCTTCATGGCCTTGCTGCTGCCAAGATGGTTTCGGGAAGCCCCAGTCCTGTTCAGCACAGGTCACTCACTGCTGATGGAGCCCCTTGGATGTATTACTGCACAGCCCATCTTCCTGGCTGGACTCTCAGGCTTCCTACTAGAGAACACGATTCGGGGCACACAGCTTGAGCGAGGCCTAGGTCAAGGGCTACCATCTCCTTTCACTGCCCAAGAGGCTCGAATGCCTCAGAAGCCCAGGGAGAAGGCTGCTCAAGTGTACAGACTTCCTTTCCCCATCCAAAACCTCTGTCCCTGCATCCCCCAGCCTCTCCACTGCCTCTGCCCACTGCCTGAAGACCCTGGGGATGAGGAAGGAGGCTCCTCTGAGCAGCAAGAGATGGCAGACTTGCTGCGTGGCTCAGGGGAGCATGCCCTGAATCTAGCAGAGAAGGGTTTAGGTCCAGAAATGACCAGAACGCGTACTTCTGCCCTGGTTAATTTAGCCCTAACTCTCATCTGCTGGAGAGTCAGCTCCCAAACTGTTCTTTCTTGTAGGCAGAGGATATGTGTGTGTGTATTACATGGGACTGTCTAGAGGTTCCATTTCCCAATAGGNOV76b, CG92078-01Protein SequenceSEQ ID NO: 1096662 aaMW at 70138.5kDMSRSPLNPSQLRSVGSQDALAPLPPPAPQNPSTHSWDPLCGSLPWGLSCLLALQHVLVMASLLCVSHLLLLCSLSPGGLSYSPSQLLASSFFSCGMSTILQTWMGSRRLPLVQAPSLEFLIPALVLTSQKLPRAIQTPGNASLMLHLCRGPSCHGLGHWNTSLQEVVVVSGLLQGMMGLLGSPGHVFPHCGPLVLAPSLVVAGLSAFPQEGVLLLSPSLECNGMISAHHWGEASQLCLLALECSLHPLPFGFCLPLQGWLRRFWGRSSFLSLAPQVLIPVACVWIVSAFVGFSVIPQELSAPTKAPWIWLPHPGVWNWPLLTPRALAAGISMAIAASTSSLGCYALCGRLLHLPPPPPHACSRGLSLEGLGSVLAGLLGSPMGTASSFPNVGKVGLIQQAGSQQVAHLVGLLCVGLGLSPRLAQLLTTIPLPVVGGGVLGVTQAVVLSAGFSSFYLADIDSGRNIFlVGFSIFMALLLPRWFREAPVLFSTGHSLLMEPLGCITAQPIFLAGLSGFLLENTIRGTQLERGLGQGLPSPFTAQEARMPQKPREKAAQVYRLPFPIQNLCPCIPQPLHCLCPLPEDPGDEEGGSSEQQEMADLLRGSGEHALNLAEKGLGPEMTRTRTSALVNLALTLICWRVSSQTVLSCRQRICVCVLHGTV

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 76B.

TABLE 76BComparison of the NOV76 protein sequences.NOV76aMSRSPLNPSQLRSVGSQDALAPLPPPAPQNPSTHSWDPLCGSLPWGLSCLLALQHVLVMANOV76bMSRSPLNPSQLRSVGSQDALAPLPPPAPQNPSTHSWDPLCGSLPWGLSCLLALQHVLVMANOV76aSLLCVSHLLLLCSLSPGGLSYSPSQLLASSFFSCGMSTILQTWMGSRRLPLVQAPSLEFLNOV76bSLLCVSHLLLLCSLSPGGLSYSPSQLLASSFFSCGMSTILQTWMGSRRLPLVQAPSLEFLNOV76aIPALVLTSQKLPRAIQTPGNSSLMLHLCRGPSCHGLGNWNTSLQEVSGAVVVSGLLQGMMNOV76bIPALVLTSQKLPRAIQTPGNASLMLHLCRGPSCHGLGHWNTSLQEV---VVVSGLLQGMMNOV76aGLLGSPGHVFPHCGPLVLAPSLVVAGLSAHREVAQFCFT------------HWGLALLVINOV76bGLLGSPGHVFPHCGPLVLAPSLVVAGLSAFPQEGVLLLSPSLECNGMISAHHWGEASQLCNOV76aLLMVVCSQH---LGSCQFHVCPWRRASTSSTHTPLPVFRLLSVLIPVACVWIVSAFVGFSNOV76bLLALECSLHPLPFGFCLPLQGWLRRFWGRSSFLSLAP----QVLIPVACVWIVSAFVGFSNOV76aVIPQELSAPTKAPWIWLPHPGEWNWPLLTPRALAAGISMALAASTSSLGCYALCGRLLHLNOV76bVIPQELSAPTKAPWIWLPHPGVWNWPLLTPRALAAGISMALAASTSSLGCYALCGRLLHLNOV76aPPPPPHACSRGLSLEGLGSVLAGLLGSPMGTASSFPSVGKVGLIQAG-SQQVAHLVGLLCNOV76bPPPPPHACSRGLSLEGLGSVLAGLLGSPMGTASSFPNVGKVGLIQQAGSQQVAHLVGLLCNOV76aVGLGLSPRLAQLLTTIPLPVVGG-VLGVTQAVVLSAGFSSFYLADIDSGRNIFIVGFSIFNOV76bVGLGLSPRLAQLLTTIPLPVVGGGVLGVTQAVVLSAGFSSFYLADIDSGRNIFIVGFSIFNOV76aMALLLPRWFREAPVLFSTGWSPLDVLLHSLLTQPIFLAGLSGFLLENTIPGTQLERGLGQNOV76bMALLLPRWFREAPVLFSTGHSLLMEPLGCITAQPIFLAGLSGFLLENTIRGTQLERGLGQNOV76aGLPSPFTAQEARMPQKPREKAAQVYRLPFPIQNLCPCIPQPLHCLCPLPEDPGDEEGGSSNOV76bGLPSPFTAQEARMPQKPREKAAQVYRLPFPIQNLCPCIPQPLHCLCPLPEDPGDEEGGSSNOV76aEPEEMADLLPGSGEPCPESSREGFRSQK--------------------------------NOV76bEQQEMADLLRGSGEHALNLAEKGLGPEMTRTRTSALVNLALTLICWRVSSQTVLSCRQRINOV76a---------NOV76bCVCVLHGTVNOV76a(SEQ ID NO: 1094)NOV76b(SEQ ID NO: 1096)

Further analysis of the NOV76a protein yielded the following properties shown in Table 76C.

TABLE 76CProtein Sequence Properties NOV76aSignalP analysis:Cleavage site between residues 17 and 18PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 3; pos.chg 1; neg.chg 0H-region: length 8; peak value −1.31PSG score: −5.71GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −4.74possible cleavage site: between 48 and 49>>> Seems to have no N-terminal signal peptide.ALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 9INTEGRALLikelihood = −8.60Transmembrane 56-72INTEGRALLikelihood = 0.16Transmembrane 110-126INTEGRALLikelihood = −0.11Transmembrane 167-183INTEGRALLikelihood = −1.70Transmembrane 192-208INTEGRALLikelihood = −6.90Transmembrane 216-232INTEGRALLikelihood = −8.23Transmembrane 265-281INTEGRALLikelihood = −1.97Transmembrane 421-437INTEGRALLikelihood = −3.24Transmembrane 454-470INTEGRALLikelihood = 0.21Transmembrane 491-507PERIPHERALLikelihood = 0.69 (at 394)ALOM score: −8.60 (number of TMSs: 9)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 63Charge difference: 0.0 C(0.5) − N(0.5)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment(75):10.11Hyd Moment(95):10.29G content:1D/E content:1S/T content:5Score: −1.10Gavel: prediction of cleavage sites for mitochondrial preseqR-2 motif at 421 PRL|AQNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 4.6%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: SRSPnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found ***LDVLLHSLLTQPIFLAGLSGFL at 485 nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 76.7COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):77.8%: endoplasmic reticulum11.1%: nuclear11.1%: mitochondrial>> prediction for CG92078-02 is end (k = 9)

A search of the NOV76a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 76D.

TABLE 76DGeneseq Results for NOV76aNOV76aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE22904Human transporter and ion channel1 . . . 610609/610 (99%)0.0(TRICH) 3 - Homo sapiens, 6101 . . . 610610/610 (99%)aa. [WO200222684-A2, 21-MAR-2002]ABB77088Human transporter protein related1 . . . 610609/610 (99%)0.0to permease subfamily - Homo1 . . . 610610/610 (99%)sapiens, 610 aa. [US2002028915-A1, 07-MAR-2002]AAE29905Human transporter and ion channel1 . . . 610607/618 (98%)0.0(TRICH) protein #5 - Homo1 . . . 618609/618 (98%)sapiens, 618 aa. [WO200277237-A2, 03-OCT-2002]AAW73924Nucleobase permease Yspl1 - Mus1 . . . 609476/613 (77%)0.0sp, 611 aa. [US5858707-A, 12-1 . . . 611519/613 (84%)JAN-1999]ABG70340Human MDDT protein Incyte ID1 . . . 610390/611 (63%)0.0No: LI:230711.5.orf2:2001JAN12 -12 . . . 519 413/611 (66%)Homo sapiens, 519 aa.[WO200255738-A2, 18-JUL-2002]

In a BLAST search of public sequence databases, the NOV76a protein was found to have homology to the proteins shown in the BLASTP data in Table 76E.

TABLE 76EPublic BLASTP Results for NOV76aNOV76aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ60850Yolk SAC permease-like YSPL-11 . . . 609476/613 (77%)0.0form 1 (Yolk SAC permease-like1 . . . 611519/613 (84%)YSPL-1 form 4) (Yolk SACpermease-like YSPL-1 form 3)(Yolk SAC permease-like YSPL-1form 2) - Mus musculus (Mouse),611 aa.CAC51146Sequence 22 from Patent1 . . . 227225/227 (99%)e−130WO0149728 - Homo sapiens1 . . . 227226/227 (99%)(Human), 243 aa.AAH30243Similar to sodium-coupled1 . . . 225 225/225 (100%)e−130ascorbic acid transporter 2 - Homo1 . . . 225 225/225 (100%)sapiens (Human), 492 aa.Q96NA6Hypothetical protein FLJ31168 -1 . . . 227194/227 (85%)e−107Homo sapiens (Human), 212 aa.1 . . . 196195/227 (85%)Q9WTW8Solute carrier family 23, member44 . . . 520 163/496 (32%)3e−762 (Sodium-dependent vitamin C42 . . . 523 271/496 (53%)transporter 2) (Na(+)/L-ascorbicacid transporter 2) - Rattusnorvegicus (Rat), 592 aa.

PFam analysis indicates that the NOV76a protein contains the domains shown in the Table 76F.

TABLE 76FDomain Analysis of NOV76aIdentities/SimilaritiesPfam DomainNOV76a Match Regionfor the Matched RegionExpect Valuexan_ur_permease46 . . . 473116/461 (25%)5e−87336/461 (73%)

Example 77

The NOV77 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 77A.

TABLE 77ANOV77 Sequence AnalysisNOV77a, CG93669-04SEQ ID NO: 10971542 bpDNA SequenceORF Start: ATG at 1ORF Stop: at 1468ATGGATGACTACATGGTCCTGAGAATGATTGGGGAGGGCTCCTTCGGCAGAGCTCTTTTGGTTCAGCATGAAAGCAGTAATCAGATGTTTGCCATGAAAGAAATAAGGCTTCCCAAGTCTAATACACAGAATTCTAGGAAGGAGGCTGTTCTTTTAGCCAAAATGAAACACCCTAATATTGTTGCCTTCAAAGAATCATTTGAAGCTGAAGGACACTTGTATATTGTGATGGAATACTGTGATGGAGGGGATCTAATGCAAAAGATTAAACAGCAGAAAGGAAAGTTATTTCCTGAAGACATACTTAATTGGTTTACCCAAATGTGCCTTGGAGTAAATCACATTCACAAGAAACGTGTGCTACACAGAGATATCAAGTCCAAGAATATCTTCCTCACTCAGAATGGAAAAGTGAAATTGGGAGACTTTGGATCTGCCCGTCTTCTCTCCAGTCCGATGGCATTTGCTTGTACCTATGTGGGAACTCCTTATTATGTGCCTCCAGAAATTTGGGAAAACCTGCCTTATAACAATAAAAGTGACATCTGGTCCTTGGGTTGCATCCTGTATGAACTCTGTACCCTTAAGCATCCATTTCAGGCAAATAGTTGGAAAAATCTTATCCTCAAAGTATGTCAAGGGTGCATCAGTCCACTGCCGTCTCATTACTCCTATGAACTTCAGTTCCTAGTCAAGCAGATGTTTAAAAGGAATCCCTCACATCGCCCCTCGGCTACAACGCTTCTCTCTCGAGGCATCGTAGCTCGGCTTGTCCAGAAGTGCTTACCCCCCCAGATCATCATGGAATATGGTGAGGAAGTATTAGAAGAAATAAAAAATTCGAAGCATAACACACCAAGAAAAAAATCTCTTTTAAAGCAAGAGGAAGAACAAGATAGAAAGGGTAGCCATACTGATTTGGAAAGCATTAATGAAAATTTAGTTGAAAGTGCATTGAGAAGAGTAAACAGAAAATCAGGTAATAAGTCAGTCCATCTGAGGAAAGCCAGTTCACCAAATCTTCATAGACGACAGTGGGAGAAAAATGTACCCAATACAGCTCTTACAGCTTTGGAAAATGCATCCATACTCACCTCCAGTTTAACAGCAGAGGACGATAGAGGTGGTGGTTCTGTAATAAAGTACAGCAAAAATACTACTCGTAAGCAGTGGCTCAAAGAGACCCCTGACACTTTGTTGAACATCCTTAAGAATGCTGATCTCAGCTTGGCTTTTCAAACATACACAATATATAGACCAGGTTCAGAAGGGTTCTTGAAAGGCCCCCTGTCTGAAGAAACAGAAGCATCGGACAGTGTTGATGGAGGTCACGATTCTGTCATTTTGGATCCAGAGCGACTTGAGCCTGGGCTAGATGAGGAGGACACGGACTTTGAGGAGGAAGATGACAACCCCGACTGGGTGTCAGAGCTGAAGAAGCGAGCTGGATGGCAAGGCCTGTGCGACAGATAATGCCTGAGGAAATGTTCCTGAGTCACGCTGAGGAGAGGCTTCACTCAGGAGTTCATGCTGAGATGATCANOV77a, CG93669-04SEQ ID NO: 1098489 aaMW at 55700.9kDProtein SequenceMDDYMVLRMIGEGSFGRALLVQHESSNQMFANKEIRLPKSNTQNSRKEAVLLAKMKHPNIVAFKESFEAEGHLYIVMEYCDGGDLMQKIKQQKGKLFPEDILNWFTQMCLGVNHIHKKRVLHRDIKSKNIFLTQNGKVKLGDFGSARLLSSPMAFACTYVGTPYYVPPEIWENLPYNNKSDIWSLGCILYELCTLKHPFQANSWKNLILKVCQGCISPLPSHYSYELQFLVKQMFKRNPSHRPSATTLLSRGIVARLVQKCLPPQIIMEYGEEVLEEIKNSKHNTPRKKSLLKQEEEQDRKGSHTDLESINENLVESALRRVNRKSGNKSVHLRKASSPNLHRRQWEKNVPNTALTALENASILTSSLTAEDDRGGGSVIKYSKNTTRKQWLKETPDTLLNILKNADLSLAFQTYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPGLDEEDTDFEEEDDNPDWVSELKKRAGWQGLCDNOV77b, CG93669-01SEQ ID NO: 10992257 bpDNA SequenceORF Start: ATG at 246ORF Stop: TAA at 1764CCGCAAGTCCCTCGCCGCCTTGGGGTCTGGGCGCGCGGTCCGTGGGGGTCAGCAGGGCGAGCGGCTTTTCCAGGAGAAAGGGCCCTCACGGGTGAGCGGGGCGACTGGGCTCCCCCGCGGTGCAGTTGCCCCGCGCGACCGGCCCCGGCTTCAACGGATTCTTCTCGCTCGCTGCCCGGAAAGAACCATTTGGGAGAGCCCATGGTGACTGCGTGAGTGGAGCCCAGCTGTGTGGATGCCCCAGCATGGATGACTACATGGTCCTGAGAATGATTGGGGAGGGCTCCTTCGGCAGAGCTCTTTTGGTTCAGCATGAAAGCAGTAATCAGATGTTTGCCATGAAAGAAATAAGGCTTCCCAAGGTCACTACTAATACACAGAATTCTAGGAAGGAGGCTGTTCTTTTAGCCAAAATGAAACACCCTAATATTGTTGCCTTCAAAGAATCATTTGAAGCTGAAGGACACTTGTATATTGTGATGGAATACTGTGATGGAGGGGATCTAATGCAAAAGATTAAACAGCAGAAAGGAAAGTTATTTCCTGAAGACCAGATACTTAATTGGTTTACCCAAATGTGCCTTGGAGTAAATCACATTCACAAGAAACGTGTGCTACACAGAGATATCAAGTCCCAGAATATCTTCCTCACTCAGAATGGAAAAGTGAAATTGGGAGACTTTGGATCTGCCCGTCTTCTCTCCAATCCGATGGCATTTGCTTGTACCTATGTGGGAACTCCTTATTATGTGCCTCCAGAAATTTGGGAAAACCTGCCTTATAACAATAAAAGTGACATCTGGTCCTTGGGTTGCATCCTGTATGAACTCTGTACCCTTAAGCATCCATTTCAGGCAAATAGTTGGAAAAATCTTATCCTCAAAGTATGTCAAGGGTGCATCAGTCCACTGCCGTCTCATTACTCCTATGAACTTCAGTTCCTAGTCAAGCAGATGTTTAAAAGGAATCCCTCACATCGCCCCTCGGCTACAACGCTTCTCTCTCGAGGCATCGTAGCTCGGCTTGTCCAGAAGTGCTTACCCCCCGAGATCATCATGGAATATGGTGAGGAAGTATTAGAAGAAATAAAAAATTCGAAGCATAACACACCAAGAAAAAAAACAAACCCCAGCAGAATCAGGATAGCTTTGGGAAATGAAGCAAGCACAGTGCAAGAGGAAGAACAAGATAGAAAGGGTAGCCATACTGATTTGGAAAGCATTAATGAAAATTTAGTTGAAAGTGCATTGAGAAGAGTAAACAGAGAAGAAAAAGGTAATAAGTCAGTCCATCTGAGGAAAGCCAGTTCACCAAATCTTCATAGACGACAGTGGGAGAAAAATGTACCCAATACAGCTCTTACAGCTTTGGAAAATGCATCCATACTCACCTCCAGTTTAACAGCAGAGGACGATAGAGGTGGTTCTGTAATAAAGTACAGCAAAAATACTACTCGTAAGCAGTGGCTCAAAGAGACCCCTGACACTTTGTTGAACATCCTTAAGAATGCTGATCTCAGCTTGGCTTTTCAAACATACACAATATATAGACCAGGTTCAGAAGGGTTCTTGAAAGGCCCCCTGTCTGAAGAAACAGAAGCATCGGACAGTGTTGATGGAGGTCACGATTCTGTCATTTTGGATCCAGAGCGACTTGAGCCTGGGCTAGATGAGGAGGACACGGACTTTGAGGAGGAAGATGACAACCCCGACTGGGTGTCAGAGCTGAAGAAGCGAGCTGGATGGCAAGGCCTGTGCGACAGATAATGCCTGAGGAAATGTTCCTGAGTCACGCTGAGGAGAGCCTTCACTCAGGAGTTCATGCTGAGATGATCATGAGTTCATGCGACGTATATTTTCCTTTGGAAACAGAATGAAGCAGAGGAAACTCTTAATACTTAAAATCGTTCTTGATTAGTATCGTGAGTTTGAAAAGTCTAGAACTCCTGTAAGTTTTTGAACTCAAGGGAGAAGGTATAGTGGAATGAGTGTGAGCATCGGGCTTTGCAGTCCCATAGAACAGAAATGGGATGCTAGCGTGCCACTACCTACTTGTGTGATTGTGGGAAATTACTTAACCTCTTCAAGCCCCAATTTCCTCAACCATAAAATGAAGATAATAATGCCTACCTCAGAGGGATGCTGACCACAGACCTTTATAGCAGCCCGTATGATATTATTCACATTATGATATGTGTTTATTATTATGTGACTCTTTTTACATTTCCTAAAGGTTTGAGAATTAAATATATTTAATTNOV77b, CG93669-01SEQ ID NO: 1100506 aaMW at 57681.0kDProtein SequenceMDDYMVLRMIGEGSFGRALLVQHESSNQMFA4KEIRLPKVTTNTQMSRKEAVLLAKMKHPNIVAFKESFEAEGHLYIVMEYCDGGDLMQKIKQQKGKLFPEDQILNWFTQMCLGVNHIHKKRVLHRDIKSQNIFLTQNGKVKLGDFGSAPLLSNPMAFACTYVGTPYYVPPEIWENLPYNNKSDIWSLGCILYELCTLKHPFQANSWKNLILKVCQGCISPLPSHYSYELQFLVKQMFKRNPSHRPSATTLLSRGIVARLVQKCLPPEIIMEYGEEVLEEIKNSKHNTPRKKTNPSRIRIALGNEASTVQEEEQDRKGSHTDLESINENLVESALRRVNREEKGNKSVHLRKASSPNLHRRQWEKNVPNTALTALENASILTSSLTAEDDRGGSVIKYSKNTTRKQWLKETPDTLLNILKNADLSLAFQTYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPGLDEEDTDFEEEDDNPDWVSELKKRAGWQGLCDRNOV77c,CG93669-02SEQ ID NO: 11011781 bpDNA SequenceORF Start: ATG at 246ORF Stop: TAA at 1713CCGCAAGTCCCTCGCCGCCTTGGGGTCTGGGCGCGCGGTCCGTGGGGGTCAGCAGGGCGAGCGGCTTTTCCAGGAGAAAGGGCCCTCACGGGTGAGCGGGGCGACTGGGCTCCCCCGCGGTGCAGTTGCCCCGCGCGACCGGCCCCGGCTTCAACGGATTCTTCTCGCTCGCTGCCCGGAAAGAACCATTTGGGAGAGCCCATGGTGACTGCGTGAGTGGAGCCCAGCTGTGTGGATGCCCCAGCATGGATGACTACATGGTCCTGAGAATGATTGGGGAGGGCTCCTTCGGCAGAGCTCTTTTGGTTCAGCATGAAAGCAGTAATCAGATGTTTGCCATGAAAGAAATAAGGCTTCCCAAGGTCACTACTAATACACAGAATTCTAGGAAGGAGGCTGTTCTTTTAGCCAAAATGAAACACCCTAATATTGTTGCCTTCAAAGAATCATTTGAAGCTGAAGGACACTTGTATATTGTGATGGAATACTGTGATGGAGGGGATCTAATGCAAAAGATTAAACAGCAGAAAGGAAAGTTATTTCCTGAAGACCAGATACTTAATTGGTTTACCCAAATGTGCCTTGGAGTAAATCACATTCACAAGAAACGTGTGCTACACAGAGATATCAAGTCCCAGAATATCTTCCTCACTCAGAATGGAAAAGTGAAATTGGGAGACTTTGGATCTGCCCGTCTTCTCTCCAATCCGATGGCATTTGCTTGTACCTATGTGGGAACTCCTTATTATGTGCCTCCAGAAATTTGGGAAAACCTGCCTTATAACAATAAAAGTGACATCTGGTCCTTGGGTTGCATCCTGTATGAACTCTGTACCCTTAAGCATCCATTTCAGGCAAATAGTTGGAAAAATCTTATCCTCAAAGTATGTCAAGGGTGCATCAGTCCACTGCCGTCTCATTACTCCTATGAACTTCAGTTCCTAGTCAAGCAGATGTTTAAAAGGAATCCCTCACATCGCCCCTCGGCTACAACGCTTCTCTCTCGAGGCATCGTAGCTCGGCTTGTCCAGAAGTGCTTACCCCCCGAGATCATCATGGAATATGGTGAGGAAGTATTAGAAGAAATAAAAAATTCGAAGCATAACACACCAAGAAAAAAACAAGAGGAAGAACAAGATAGAAAGGGTAGCCATACTGATTTGGAAAGCATTAATGAAAATTTAGTTGAAAGTGCATTGAGAAGAGTAAACAGAGAAGAAAAAGGTAATAAGTCAGTCCATCTGAGGAAAGCCAGTTCACCAAATCTTCATAGACGACAGTGGGAGAAAAATGTACCCAATACAGCTCTTACAGCTTTGGAAAATGCATCCATACTCACCTCCAGTTTAACAGCAGAGGACGATAGAGGTGGTTCTGTAATAAAGTACAGCAAAAATACTACTCGTAAGCAGTGGCTCAAAGAGACCCCTGACACTTTGTTGAACATCCTTAAGAATGCTGATCTCAGCTTGGCTTTTCAAACATACACAATATATAGACCAGGTTCAGAAGGGTTCTTGAAAGGCCCCCTGTCTGAAGAAACAGAAGCATCGGACAGTGTTGATGGAGGTCACGATTCTGTCATTTTGGATCCAGAGCGACTTGAGCCTGGGCTAGATGAGGAGGACACGGACTTTGAGGAGGAAGATGACAACCCCGACTGGGTGTCAGAGCTGAAGAAGCGAGCTGGATGGCAAGGCCTGTGCGACAGATAATGCCTGAGGAAATGTTCCTGAGTCACGCTGAGGAGAGGCTTCACTCTAGGAGTTCATGCTGAGATGNOV77c, CG93669-02SEQ ID NO: 1102489 aaMW at 55900.0kDProtein SequenceMDDYMVLRMIGEGSFGRALLVQHESSNQMFANKEIRLPKVTTNTQNSRKEAVLLAKMKHPNIVAFKESFEAEGHLYIVMEYCDGGDLMQKIKQQKGKLFPEDQILNWFTQMCLGVNHIHKKRVLHRDIKSQNIFLTQNGKVKLGDFGSARLLSNPMAFACTYVGTPYYVPPEIWENLPYNNKSDIWSLGCILYELCTLKHPFQANSWKNLILKVCQGCISPLPSHYSYELQFLVKQNFKRNPSHRPSATTLLSRGIVARLVQKCLPPEIIMEYGEEVLEEIKNSKHNTPRKKQEEEQDRKGSHTDLESINENLVESALRRVNREEKGNKSVHLRKASSPNLHRRQWEKNVPNTALTALENASILTSSLTAEDDRGGSVIKYSKNTTRKQWLKETPDTLLNILKNADLSLAFQTYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPGLDEEDTDFEEEDDNPDWVSELKKRAGWQGLCDRNOV77d, GG93669-03SEQ ID NO: 11031588 bpDNA SequenceORF Start: ATG at 246ORF Stop: TAA at 1521CCGCAAGTCCCTCGCCGCCTTGGGGTCTGGGCGCGCGGTCCGTGGGGGTCAGCAGGGCGAGCGGCTTTTCCAGGAGAAAGGGCCCTCACGGGTGAGCGGGGCGACTGGGCTCCCCCGCGGTGCAGTTGCCCCGCGCGACCGGCCCCGGCTTCAACGGATTCTTCTCGCTCGCTGCCCGGAAAGAACCATTTGGGAGAGCCCATGGTGACTGCGTGAGTGGAGCCCAGCTGTGTGGATGCCCCAGCATGGATGACTACATGGTCCTGAGAATGATTGGGGAGGGCTCCTTCGGCAGAGCTCTTTTGGTTCAGCATGAAAGCAGTAATCAGATGTTTGCCATGAAAGAAATAAGGCTTCCCAAGGTCACTACTAATACACAGAATTCTAGGAAGGAGGCTGTTCTTTTAGCCAAAATGAAACACCCTAATATTGTTGCCTTCAAAGAATCATTTGAAGCTGAAGGACACTTGTATATTGTGATGGAATACTGTGATGGAGGGGATCTAATGCAAAAGATTAAACAGCAGAAAGGAAAGTTATTTCCTGAAGACCAGATACTTAATTGGTTTACCCAAATGTGCCTTGGAGTAAATCACATTCACAAGAAACGTGTGCTACACAGAGATATCAAGTCCCAGAATATCTTCCTCACTCAGAATGGAAAAGTGAAATTGGGAGACTTTGGATCTGCCCGTCTCCTCTCCAATCCGATGGCATTTGCTTGTACCTATGTGGGAACTCCTTATTATGTGCCTCCAGAAATTTGGGAAAACCTGCCTTATAACAATAAAAGTGACATCTGGTCCTTGGGTTGCATCCTGTATGAACTCTGTACCCTTAAGCATCCATTTCAGGCAAATAGTTGGAAAAATCTTATCCTCAAAGTATGTCAAGGGTGCATCAGTCCACTGCCGTCTCATTACTCCTATGAACTTCAGTTCCTAGTCAAGCAGATGTTTAAAAGGAATCCCTCACATCGCCCCTCGGCTACAGCGCTTCTCTCTCGAGGCATCGTAGCTCGGCTTGTCCAGAAGTGCTTACCCCCCGAGATCATCATGGAATATGGTGAGGAAGTATTAGAAGAAATAAAAAATTCGAAGCATAACACACCAAGAAAAAAACAAGAGGAAGAACAAGATAGAAAGGGTAGCCATACTGATTTGGAAAGCATTAATGAAAATTTAGTTGAAAGTGCATTGAGAAGAGTAAACAGAGAAGAAAAAGGTAATAAGTCAGTCCATCTGAGGAAAGCCAGTTCACCAAATCTTCATAGACGACAGTGGGAGAAAAATGTACCCAATACAGCTCTTACAGCTTTGGAAAATGCATCCATACTCACCTCCAGTTTAACAGCAGAGGACGATAGAGGTTCAGAAGGGTTCTTGAAAGGCCCCCTGTCTGAAGAAACAGAAGCATCGGACAGTGTTGAGGAGGACACGGACTTTGAGGAGGAAGATGACAACCCCGACTGGGTGTCAGAGCTGAAGAAGCGAGCTGGATGGCAAGGCCTGTGCGACAGATAATGCCTGAGGAAATGTACCTGAGTCACGCTGAGGAGAGGCTTCACTCAGGAGTTCATGCTGAGATGNOV77d, CG93669-03SEQ ID NO: 1104425 aaMW at 48684.0kDProtein SequenceMDDYMVLRMIGEGSFGRALLVQHESSNQMFAMKEIRLPKVTTNTQNSRKEAVLLAKMKHPNIVAFKESFEAEGHLYIVMEYCDGGDLMQKIKQQKGKLFPEDQILNWFTQMCLGVNHIHKKRVLHRDIKSQNIFLTQNGKVKLGDFGSARLLSNPMAFACTYVGTPYYVPPEIWENLPYNNKSDIWSLGCILYELCTLKHPFQANSWKNLILKVCQGCISPLPSHYSYELQFLVKQMFKRNPSHRPSATALLSRGIVARLVQKCLPPEIIMEYGEEVLEEIKNSKHNTPRKKQEEEQDRKGSHTDLESINENLVESALRRVNREEKGNKSVHLRKASSPNLHRRQWEKNVPNTALTALENASILTSSLTAEDDRGSEGFLKGPLSEETEASDSVEEDTDFEEEDDNPDWVSELKKRAGWQGLCDRNOV77e, SNP13376464SEQ ID NO: 11051542 bpof CG93669-04,ORF Start: ATG at 1ORF Stop: at 1468DNA SequenceSNP Pos: 94SNP Change: A to GATGGATGACTACATGGTCCTGAGAATGATTGGGGAGGGCTCCTTCGGCAGAGCTCTTTTGGTTCAGCATGAAAGCAGTAATCAGATGTTTGCCGTGAAAGAAATAAGGCTTCCCAAGTCTAATACACAGAATTCTAGGAAGGAGGCTGTTCTTTTAGCCAAAATGAAACACCCTAATATTGTTGCCTTCAAAGAATCATTTGAAGCTGAAGGACACTTGTATATTGTGATGGAATACTGTGATGGAGGGGATCTAATGCAAAAGATTAAACAGCAGAAAGGAAAGTTATTTCCTGAAGACATACTTAATTGGTTTACCCAAATGTGCCTTGGAGTAAATCACATTCACAAGAAACGTGTGCTACACAGAGATATCAAGTCCAAGAATATCTTCCTCACTCAGAATGGAAAAGTGAAATTGGGAGACTTTGGATCTGCCCGTCTTCTCTCCAGTCCGATGGCATTTGCTTGTACCTATGTGGGAACTCCTTATTATGTGCCTCCAGAAATTTGGGAAAACCTGCCTTATAACAATAAAAGTGACATCTGGTCCTTGGGTTGCATCCTGTATGAACTCTGTACCCTTAAGCATCCATTTCAGGCAAATAGTTGGAAAAATCTTATCCTCAAAGTATGTCAAGGGTGCATCAGTCCACTGCCGTCTCATTACTCCTATGAACTTCAGTTCCTAGTCAAGCAGATGTTTAAAAGGAATCCCTCACATCGCCCCTCGGCTACAACGCTTCTCTCTCGAGGCATCGTAGCTCGGCTTGTCCAGAAGTGCTTACCCCCCCAGATCATCATGGAATATGGTGAGGAAGTATTAGAAGAAATAAAAAATTCGAAGCATAACACACCAAGAAAAAAATCTCTTTTAAAGCAAGAGGAAGAACAAGATAGAAAGGGTAGCCATACTGATTTGGAAAGCATTAATGAAAATTTAGTTGAAAGTGCATTGAGAAGAGTAAACAGAAAATCAGGTAATAAGTCAGTCCATCTGAGGAAAGCCAGTTCACCAAATCTTCATAGACGACAGTGGGAGAAAAATGTACCCAATACAGCTCTTACAGCTTTGGAAAATGCATCCATACTCACCTCCAGTTTAACAGCAGAGGACGATAGAGGTGGTGGTTCTGTAATAAAGTACAGCAAAAATACTACTCGTAAGCAGTGGCTCAAAGAGACCCCTGACACTTTGTTGAACATCCTTAAGAATGCTGATCTCAGCTTGGCTTTTCAAACATACACAATATATAGACCAGGTTCAGAAGGGTTCTTGAAAGGCCCCCTGTCTGAAGAAACAGAAGCATCGGACAGTGTTGATGGAGGTCACGATTCTGTCATTTTGGATCCAGAGCGACTTGAGCCTGGGCTAGATGAGGAGGACACGGACTTTGAGGAGGAAGATGACAACCCCGACTGGGTGTCAGAGCTGAAGAAGCGAGCTGGATGGCAAGGCCTGTGCGACAGATAATGCCTGAGGAAATGTTCCTGAGTCACGCTGAGGAGAGGCTTCACTCAGGAGTTCATGCTGAGATGATCANOV77e, SNP13376464SEQ ID NO: 1106489 aaMW at 55668.8kDof CG93669-04,SNP Change: 32SNP Change: Met to ValProtein SequenceMDDYMVLRMIGEGSFGRALLVQHESSNQMFAVKEIRLPKSNTQNSRKEAVLLAKMKHPNIVAFKESFEAEGHLYIVMEYCDGGDLMOKIKQQKGKLFPEDILNWFTQMCLGVNHIHKKRVLHRDIKSKNIFLTQNGKVKLGDFGSARLLSSPMAFACTYVGTPYYVPPEIWENLPYNNKSDIWSLGCILYELCTLKHPFQANSWKNLILKVCQGCISPLPSHYSYELQFLVKQMFKRNPSHRPSATTLLSRGIVARLVQKCLPPQIIMEYGEEVLEEIKNSKHNTPRKKSLLKQEEEQDRKGSRTDLESINENLVESALRRVNRKSGNKSVHLRKASSPNLHRRQWEKNVPNTALTALENASILTSSLTAEDDRGGGSVIKYSKNTTRKQWLKETPDTLLNILKNADLSLAFQTYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPGLDEEDTDFEEEDDNPDWVSELKKRAGWQGLCDNOV77f, SNP13376462SEQ ID NO: 11071542 bpof CG93669-04,ORF Start: ATG at 1ORF Stop: at 1468DNA SequenceSNP Pos: 284SNP Change: A to GATGGATGACTACATGGTCCTGAGAATGATTGGGGAGGGCTCCTTCGGCAGAGCTCTTTTGGTTCAGCATGAAAGCAGTAATCAGATGTTTGCCATGAAAGAAATAAGGCTTCCCAAGTCTAATACACAGAATTCTAGGAAGGAGGCTGTTCTTTTAGCCAAAATGAAACACCCTAATATTGTTGCCTTCAAAGAATCATTTGAAGCTGAAGGACACTTGTATATTGTGATGGAATACTGTGATGGAGGGGATCTAATGCAAAAGATTAAACAGCAGAAAGGAAGGTTATTTCCTGAAGACATACTTAATTGGTTTACCCAAATGTGCCTTGGAGTAAATCACATTCACAAGAAACGTGTGCTACACAGAGATATCAAGTCCAAGAATATCTTCCTCACTCAGAATGGAAAAGTGAAATTGGGAGACTTTGGATCTGCCCGTCTTCTCTCCAGTCCGATGGCATTTGCTTGTACCTATGTGGGAACTCCTTATTATGTGCCTCCAGAAATTTGGGAAAACCTGCCTTATAACAATAAAAGTGACATCTGGTCCTTGGGTTGCATCCTGTATGAACTCTGTACCCTTAAGCATCCATTTCAGGCAAATAGTTGGAAAAATCTTATCCTCAAAGTATGTCAAGGGTGCATCAGTCCACTGCCGTCTCATTACTCCTATGAACTTCAGTTCCTAGTCAAGCAGATGTTTAAAAGGAATCCCTCACATCGCCCCTCGGCTACAACGCTTCTCTCTCGAGGCATCGTAGCTCGGCTTGTCCAGAAGTGCTTACCCCCCCAGATCATCATGGAATATGGTGAGGAAGTATTAGAAGAAATAAAAAATTCGAAGCATAACACACCAAGAAAAAAATCTCTTTTAAAGCAAGAGGAAGAACAAGATAGAAAGGGTAGCCATACTGATTTGGAAAGCATTAATGAAAATTTAGTTGAAAGTGCATTGAGAAGAGTAAACAGAAAATCAGGTAATAAGTCAGTCCATCTGAGGAAAGCCAGTTCACCAAATCTTCATAGACGACAGTGGGAGAAAAATGTACCCAATACAGCTCTTACAGCTTTGGAAAATGCATCCATACTCACCTCCAGTTTAACAGCAGAGGACGATAGAGGTGGTGGTTCTGTAATAAAGTACAGCAAAAATACTACTCGTAAGCAGTGGCTCAAAGAGACCCCTGACACTTTGTTGAACATCCTTAAGAATGCTGATCTCAGCTTGGCTTTTCAAACATACACAATATATAGACCAGGTTCAGAAGGGTTCTTGAAAGGCCCCCTGTCTGAAGAAACAGAAGCATCGGACAGTGTTGATGGAGGTCACGATTCTGTCATTTTGGATCCAGAGCGACTTGAGCCTGGGCTAGATGAGGAGGACACGGACTTTGAGGAGGAAGATGACAACCCCGACTGGGTGTCAGAGCTGAAGAAGCGAGCTGGATGGCAAGGCCTGTGCGACAGATAATGCCTGAGGAAATGTTCCTGAGTCACGCTGAGGAGAGGCTTCACTCAGGAGTTCATGCTGAGATGATCANOV77f, SNP13376462SEQ ID NO: 1108489 aaMW at 55728.9kDof CG93669-04,SNP Pos: 95SNP Change: Lys to ArgProtein SequenceMDDYMVLRMIGEGSFGRALLVQHESSNQMFANKEIRLPKSNTQNSRKEAVLLAKMKHPNIVAFKESFEAEGHLYIVMEYCDGGDLMQKIKQQKGRLFPEDILNWFTQMCLGVNHIHKKRVLHRDIKSKNIFLTQNGKVKLGDFGSARLLSSPMAFACTYVGTPYYVPPEIWENLPYNNKSDIWSLGCILYELCTLKHPFQANSWKNLILKVCQGCISPLPSHYSYELQFLVKQMFKRNPSHRPSATTLLSRGIVARLVQKCLPPQIIMEYGEEVLEEIKNSKHNTPRKKSLLKQEEEQDRKGSHTDLESINENLVESALRRVNRKSGNKSVHLRKASSPNLHRRQWEKNVPNTALTALENASILTSSLTAEDDRGGGSVIKYSKNTTRKQWLKETPDTLLNILKNADLSLAFQTYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPGLDEEDTDFEEEDDNPDWVSELKKRAGWQGLCDNOV77g, SNP13382521SEQ ID NO: 11091542 bpof CG93669-04,ORF Start: ATG at 1ORF Stop: at 1468DNA SequenceSNP Pos: 1511SNP Change: G to CATGGATGACTACATGGTCCTGAGAATGATTGGGGAGGGCTCCTTCGGCAGAGCTCTTTTGGTTCAGCATGAAAGCAGTAATCAGATGTTTGCCATGAAAGAAATAAGGCTTCCCAAGTCTAATACACAGAATTCTAGGAAGGAGGCTGTTCTTTTAGCCAAAATGAAACACCCTAATATTGTTGCCTTCAAAGAATCATTTGAAGCTGAAGGACACTTGTATATTGTGATGGAATACTGTGATGGAGGGGATCTAATGCAAAAGATTAAACAGCAGAAAGGAAAGTTATTTCCTGAAGACATACTTAATTGGTTTACCCAAATGTGCCTTGGAGTAAATCACATTCACAAGAAACGTGTGCTACACAGAGATATCAAGTCCAAGAATATCTTCCTCACTCAGAATGGAAAAGTGAAATTGGGAGACTTTGGATCTGCCCGTCTTCTCTCCAGTCCGATGGCATTTGCTTGTACCTATGTGGGAACTCCTTATTATGTGCCTCCAGAAATTTGGGAAAACCTGCCTTATAACAATAAAAGTGACATCTGGTCCTTGGGTTGCATCCTGTATGAACTCTGTACCCTTAAGCATCCATTTCAGGCAAATAGTTGGAAAAATCTTATCCTCAAAGTATGTCAAGGGTGCATCAGTCCACTGCCGTCTCATTACTCCTATGAACTTCAGTTCCTAGTCAAGCAGATGTTTAAAAGGAATCCCTCACATCGCCCCTCGGCTACAACGCTTCTCTCTCGAGGCATCGTAGCTCGGCTTGTCCAGAAGTGCTTACCCCCCCAGATCATCATGGAATATGGTGAGGAAGTATTAGAAGAAATAAAAAATTCGAAGCATAACACACCAAGAAAAAAATCTCTTTTAAAGCAAGAGGAAGAACAAGATAGAAAGGGTAGCCATACTGATTTGGAAAGCATTAATGAAAATTTAGTTGAAAGTGCATTGAGAAGAGTAAACAGAAAATCAGGTAATAAGTCAGTCCATCTGAGGAAAGCCAGTTCACCAAATCTTCATAGACGACAGTGGGAGAAAAATGTACCCAATACAGCTCTTACAGCTTTGGAAAATGCATCCATACTCACCTCCAGTTTAACAGCAGAGGACGATAGAGGTGGTGGTTCTGTAATAAAGTACAGCAAAAATACTACTCGTAAGCAGTGGCTCAAAGAGACCCCTGACACTTTGTTGAACATCCTTAAGAATGCTGATCTCAGCTTGGCTTTTCAAACATACACAATATATAGACCAGGTTCAGAAGGGTTCTTGAAAGGCCCCCTGTCTGAAGAAACAGAAGCATCGGACAGTGTTGATGGAGGTCACGATTCTGTCATTTTGGATCCAGAGCGACTTGAGCCTGGGCTAGATGAGGAGGACACGGACTTTGAGGAGGAAGATGACAACCCCGACTGGGTGTCAGAGCTGAAGAAGCGAGCTGGATGGCAAGGCCTGTGCGACAGATAATGCCTGAGGAAATGTTCCTGAGTCACGCTGAGGAGAGCCTTCACTCAGGAGTTCATGCTGAGATGATCANOV77g, SNP13382521SEQ ID NO: 1110489 aaMW at 55700.9kDof CG93669-04,SNP Change: no changeProtein SequenceMDDYMVLRNIGEGSFGRALLVQHESSNQMFAMKEIRLPKSNTQNSRKEAVLLAKMKHPNIVAFKESFEAEGHLYIVMEYCDGGDLMQKIKQQKGKLFPEDILNWFTQMCLGVNHIHKKRVLHRDIKSKNIFLTQNGKVKLGDFGSARLLSSPMAFACTYVGTPYYVPPEIWENLPYNNCSDIWSLGCILYELCTLKHPFQANSWKNLILKVCQGCISPLPSHYSYELQFLVKQMFKRNPSHRPSATTLLSRGIVARLVQKCLPPQIIMEYGEEVLEEIKNSKHNTPRKKSLLKQEEEQDRKGSHTDLESINENLVESALRRVNRKSGNKSVHLRKASSPNLHRRQWEKNVPNTALTALENASILTSSLTAEDDRGGGSVIKYSKNTTRKQWLKETPDTLLNILKNADLSLAFQTYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPGLDEEDTDFEEEDDNPDWVSELKKRAGWQGLCD

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 77B.

TABLE 77BComparison of the NOV77 protein sequences.NOV77aMDDYMVLRMIGEGSFGRALLVQHESSNQMFAMKEIRLPKS--NTQNSRKEAVLLAKMKHPNOV77bMDDYMVLRMIGEGSFGRALLVQHESSNQMFAMKEIRLPKVTTNTQNSRKEAVLLAKMKMPNOV77cMDDYMVLRMIGEGSFGRALLVQHESSNQMFAMKEIRLPKVTTNTQNSRKEAVLLAKMKHPNOV77dMDDYMVLRMIGEGSFGRALLVOHESSNQMFAMKEIRLPKVTTNTQNSRKEAVLLAKMKHPNOV77aNIVAFKESFEAEGHLYIVMEYCDGGDLMQKIKQQKGKIFPED-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----NOV77bNPSHRPSATTLLSRGIVARLVQKCLPPEIIMEYGEEVLEEIKNSKHNTPRKKTNPSRIRINOV77cNPSHRPSATTLLSRGIVARLVQKCLPPEIIMEYGEEVLEEIKNSKHNTPRKKQ-------NOV77dNPSHRPSATTLLSRGIVARLVQKCLPPEIIMEYGEEVLEEIKNSKHNTPRKKQ-------NOV77a---------QEEEQDRKGSHTDLESINENLVESALRRVNRKS-GNKSVHLRKASSPNLHRNOV77bALGNEASTVQEEEQDRKGSHTDLESINENLVESALRRVNREEKGNKSVHLRKASSPNLHRNOV77c----------EEEQDRKGSHTDLESINENLVESALRRVNREEKGNKSVHLRKASSPNLHRNOV77d----------EEEQDRKGSHTDLESINENLVESALRRVNREEKGNKSVHLRKASSPNLHRNOV77aRQWEKNVPNTALTALENASILTSSLTAEDDRGGGSVIKYSKNTTRKQWLKETPDTLLNILNOV77bRQWEKNVPNTALTALENASILTSSLTAEDDRGG-SVIKYSKNTTRKQWLKETPDTLLNILNOV77cRQWEKNVPNTALTALENASILTSSLTABDDRGG-SVIKYSKNTTRKQWLKETPDTLLNILNOV77dRQWEKNVPNTALTALENASILTSSLTAEDDRG----------------------------NOV77aKNADLSLAFQTYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPGLDEEDTNOV77bKNADLSLAFQTYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPGLDEEDTNOV77cKNADLSLAFQTYTIYRPGSEGFLKGPLSEETEASDSVDGGHDSVILDPERLEPGLDEEDTNOV77d------------------SEGFLKGPLSEETEASDSVE-------------------EDTNOV77aDFEEEDDNPDWVSELKKRAGWQGLCD-NOV77bDFEEEDDNPDWVSELKKRAGWQGLCDRNOV77cDFEEEDDNPDWVSELKKRAGWQGLCDRNOV77dDFEEEDDNPDWVSELKKRAGWQGLCDRNOV77a(SEQ ID NO: 1098)NOV77b(SEQ ID NO: 1100)NOV77c(SEQ ID NO: 1102)NOV77d(SEQ ID NO: 1104)

Further analysis of the NOV77a protein yielded the following properties shown in Table 77C.

TABLE 77CProtein Sequence Properties NOV77aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 8; pos.chg 1; neg.chg 2H-region: length 3; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −8.46possible cleavage site: between 16 and 17>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 4.61 (at 5)ALOM score: 4.61 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):8.48Hyd Moment(95):7.98G content:0D/E content:2S/T content:0Score: −6.50Gavel:prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: HKKR (3) at 116pat4: PRKK (4) at 286pat7: PRKKSLL (5) at 286bipartite: nonecontent of basic residues: 13.3%NLS Score: 0.40KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: nuclearReliability: 76.7COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):69.6%: nuclear21.7%: cytoplasmic 4.3%: mitochondrial 4.3%: peroxisomal>> prediction for CG93669-04 is nuc (k = 23)

A search of the NOV77a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 77D.

TABLE 77DGeneseq Results for NOV77aNOV77aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABP60668Human serine/threonine protein1 . . . 489480/506 (94%)0.0kinase 55.66 - Homo sapiens, 5061 . . . 505484/506 (94%)aa. [CN1360042-A, 24-JUL-2002]AAM78344Human protein SEQ ID NO 1006 -1 . . . 489480/506 (94%)0.0Homo sapiens, 506 aa.1 . . . 505484/506 (94%)[WO200157190-A2, 09-AUG-2001]ABB97224Novel human protein SEQ ID1 . . . 489479/506 (94%)0.0NO: 492 - Homo sapiens, 527 aa.22 . . . 526 483/506 (94%)[WO200222660-A2, 21-MAR-2002]AAM79328Human protein SEQ ID NO 2974 -1 . . . 489479/506 (94%)0.0Homo sapiens, 527 aa.22 . . . 526 483/506 (94%)[WO200157190-A2, 09-AUG-2001]AAE24136Human kinase (PKIN)-7 protein -1 . . . 489479/506 (94%)0.0Homo sapiens, 506 aa.1 . . . 505483/506 (94%)[WO200233099-A2, 25-APR-2002]

In a BLAST search of public sequence databases, the NOV77a protein was found to have homology to the proteins shown in the BLASTP data in Table 77E.

TABLE 77EPublic BLASTP Results for NOV77aNOV77aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ8J023NIMA-related protein kinase 3 -1 . . . 489479/493 (97%)0.0Homo sapiens (Human), 489 aa.1 . . . 488482/493 (97%)P51956Serine/threonine-protein kinase1 . . . 489480/506 (94%)0.0NEK3 (EC 2.7.1.37) (NimA-1 . . . 505484/506 (94%)related protein kinase 3) (HSPK36) - Homo sapiens (Human), 506aa.CAD34740Sequence 48 from Patent1 . . . 489479/506 (94%)0.0WO0222660 - Homo sapiens22 . . . 526 483/506 (94%)(Human), 527 aa.Q9R0A5Serine/threonine-protein kinase1 . . . 484368/501 (73%)0.0NEK3 (EC 2.7.1.37) (NimA-1 . . . 498413/501 (81%)related protein kinase 3) - Musmusculus (Mouse), 511 aa.Q99K72Similar to NIMA (never in mitosis1 . . . 484367/499 (73%)0.0gene a)-related expressed kinase 3 -1 . . . 496411/499 (81%)Mus musculus (Mouse), 509 aa.

PFam analysis indicates that the NOV77a protein contains the domains shown in the Table 77F.

TABLE 77FDomain Analysis of NOV77aIdentities/NOV77a MatchSimilaritiesExpectPfam DomainRegionfor the Matched RegionValuepkinase4 . . . 254 97/297 (33%)5.4e−87207/297 (70%)

Example 78

The NOV78 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 78A.

TABLE 78ANOV78 Sequence AnalysisNOV78a, CG94235-01SEQ ID NO: 11112856 bpDNA SequenceORF Start: ATG at 28ORF Stop: TAG at 1294GGGCGGCGCGGGGTCTGCGCTGGGGCCATGGCTCCGCCGCGCCGCTTCGTCCTGGAGCTTCCCGACTGCACCCTGGCTCACTTCGCCCTAGGCGCCGACGCCCCCGGCGACGCAGACGCCCCCGACCCCCGCCTGGCGGCGCTGCTGGGGCCCCCGGAGCGCAGCTACTCGCTGTGCGTGCCCGTGACCCCGGACGCCGGCTGCGGGGCCCGGGTCCGGGCGGCGCGGCTGCACCAGCGCCTGCTGCACCAGCTGCGCCGCGGCCCCTTCCAGCGGTGCCAGCTGCTCAGGCTGCTCTGCTACTGCCCGGGCGGCCAGGCCGGCGGCGCACAGCAAGGCTTCCTGCTGCGCGACCCCCTGGATGACCCTGACACCCGGCAAGCGCTGCTCGAGCTGCTGGGCGCCTGTCAGGAGGCACCACGCCCGCACTTGGGCGAGTTCGAGGCCGACCCGCGCGGCCAGCTGTGGCAGCGCCTCTGGGAGGTGCAAGACGGCAGGCGGCTGCAGGTGGGCTGCGCACAGGTCGTGCCCGTCCCGGAGCCCCCGCTGCACCCGGTGGTGCCAGACTTGCCCAGTTCCGTGGTCTTCCCGGACCGGGAAGCCGCCCGGGCCGTTTTGGAGGAGTGTACCTCCTTTATTCCTGAAGCCCGGGCAGTGCTTGACCTGGTCGACCAGTGCCCAAAACAGATCCAGAAAGGAAAGTTCCAGGTTGTTGCCATCGAAGGACTGGATGCCACGGGTGGTAAAACCACGGTGACCCAGTCAGTGGCAGATTCACTTAAGGCTGTCCTCTTAAAGTCACCACCCTCTTGCATTGGCCAGTGGAGGAAGATCTTTGATGATGAACCAACTATCATTAGAAGAGCTTTTTACTCTTTGGGCAATTATATTGTGGCCTCCGAAATAGCTAAAGAATCTGCCAAATCTCCTGTGATTGTAGACAGGCACAGCACGGCCACCTATGCCATAGCCACTGAGGTGAGTGGGGGTCTCCAGCACCTGCCCCCAGCCCATCACCCTGTGTACCAGTGGCCAGAGGACCTGCTCAAACCTGACCTTATCCTGCTGCTCACTGTGAGTCCTGAGGAGAGGTTGCAGAGGCTGCAGGGCCGGGGCATGGAGAAGACCAGGGAAGAAGCAGAACTTGAGGCCAACAGTGTGTTTCGTCAAAAGGTAGAAATGTCCTACCAGCGGATGGAGAATCCTGGCTGCCATGTGGTTGATGCCAGCCCCTCCAGAGAAAAGGTCCTGCAGACGGTATTAAGCCTAATCCAGAATAGTTTTAGTGAACCGTAGTTACTCTGGCCAGGTGCCACGTCTAACTAGATTAGATGTTGTTTGAAACATCTACATCCACCATTTGTTATGCAGTGTTCCCAAATTTCTGTTCTACAAGCATGTTGTGTGGCAGAAAACTGGAGACCAGGCATCTTAATTTTACTTCAGCCATCGTACCCTCTTCTGACTGATGGACCCGTCATCACAAAGGTCCCTCTCATCATGTTCCAGTGAGAGGCCAGCGATTGCTTTCTTCCTGGCATAGTAAACATTTTCTTGGAACATATGTTTCACTTAATCACTACCAAATATCTGGAAGACCTGTCTTACTCAGACAGCACCAGGTGTACAGAAGCAGCAGACAAGATCTTCCAGATCAGCAGGGAGACCCCGGAGCCTCTGCTTCTCCTACACTGGCATGCTGATGAGATCGTGACATGCCCACATTGGCTTCTTCCACATCTGGTTGCACTCGTCATGATGGGCTCGCTGCATCTCCCTCAGTCCCAAATTCTAGAGCCAAGTGTTCCTGCAGAGGCTGTCTATGTGTCCTGGCTGCCCAAGGACACTCCTGCAGAGCCATTTTTGGGTAAGGAACACTTACAAAGAAGGCATTGATCTTGTGTCTGAGGCTCAGAGCCCTTTTGATAGGCTTCTGAGTCATATATAAAGACATTCAAGCCAAGATGCTCCAACTGCAAATATACCAACCTTCTCTGAATTATATTTTGCTTATTTATATTTCTTTTCTTTTTTTCTAAAGTATGGCTCTGAATAGAATGCACATTTTCCATTGAACTGGATGCATTTCATTTAGCCAATCCAGTAATTTATTTATATTAATCTATACATAATATGTTTCCTCAGCATAGGAGCTATGATTCATTAATTAAAAGTGGAGTCAAAACGCTAAATGCAATGTTTGTTGTGTATTTTCATTACACAAACTTAATTTGTCTTGTTAAATAAGTACAGTGGATCTTGGAGTGGGATTTCTTGGTAAATTATCTTGCACTTGAATGTCTCATGATTACATATGAAATCGCTTTGACATATCTTTAGACAGAAAAAAGTAGCTGAGTGAGGGGGAAATTATAGAGCTGTGTGACTTTAGGGAGTAGGTTGAACCAGGTGATTACCTAAAATTCCTTCCAGTTCAAAGGCAGATAAATCTGTAAATTATTTTATCCTATCTACCATTTCTTAAGAAGACATTACTCCAAAATAATTAAATTTAAGGCTTTATCAGGTCTGCATATAGAATCTTAAATTCTAATAAAGTTTCATGTTAATGTCATAGGATTTTTAAAAGAGCTATAGGTAATTTCTATATAATATGTGTATATTAAAATGTAATTGATTTCAGTTGAAAGTATTTTAAAGCTGATAAATAGCATTAGGGTTCTTTGCAATGTGGTATCTAGCTGTATTATTGGTTTTATTTACTTTAAACATTTTGAAAAGCTTATACTGGCAGCCTAGAAAAACAAACAATTAATGTATCTTTATGTCCCTGGCACATGAATAAACTTTGCTGTGGTTTACTAATCTAAAAAAAAAAAAAAAAGGGCGGCCGCTNOV78a, CG94235-01SEQ ID NO: 1112422 aaMW at 46476.6kDProtein SequenceMAPPRRFVLELPDCTLAHFALGADAPGDADAPDPRLAALLGPPERSYSLCVPVTPDAGCGARVRAARLHQRLLHQLRRGPFQRCQLLRLLCYCPGGQAGGAQQGFLLRDPLDDPDTRQALLELLGACQEAPRPHLGEFEADPRGQLWQRLWEVQDGRRLQVGCAQVVPVPEPPLHPVVPDLPSSVVFPDREAARAVLEECTSFIPEARAVLDLVDQCPKQIQKGKFQVVAIEGLDATGGKTTVTQSVADSLKAVLLKSPPSCIGQWRKIFDDEPTIIRRAFYSLGNYIVASEIAKESAKSPVIVDRHSTATYAIATEVSGGLQHLPPAHHPVYQWPEDLLKPDLILLLTVSPEERLQRLQGRGMEKTREEAELEANSVFRQKVEMSYQRMENPGCHVVDASPSREKVLQTVLSLIQNSFSEPNOV78b, 254647864SEQ ID NO: 1113601 bpDNA SequenceORF Start: at 2ORF Stop:end of sequenceCACCGGATCCATCGAAGGACTGGATGCCACGGGTGGTAAAACCACGGTGACCCAGTCAGTGGCAGATTCACTTAAGGCTGTCCTCTTAAAGTCACCACCCTCTTGCATTGGCCAGTGGAGGAAGATCTTTGATGATGAACCAACTATCATTAGAAGAGCTTTTTACTCTTTGGGCAATTATATTGTGGCCTCCGAAATAGCTAAAGAATCTGCCAAATCTCCTGTGATTGTAGACAGGTACTGGCACAGCACGGCCACCTATGCCATAGCCACTGAGGTGAGTGGGGGTCTCCAGCACCTGCCCCCAGCCCATCACCCTGTGTACCAGTGGCCAGAGGACCTGCTCAAACCTGACCTTATCCTGCTGCTCACTGTGAGTCCTGAGGAGAGGTTGCAGAGGCTGCAGGGCCGGGGCATGGAGAAGACCAGGGAAGAAGCAGAACTTGAGGCCAACAGTGTGTTTCGTCAAAAGGTAGAAATGTCCTACCAGCGGATGGAGAATCCTGGCTGCCATGTGGTTGATGCCAGCCCCTCCAGAGAAAAGGTCCTGCAGACGGTATTAAGCCTAATCCAGAATAGTTTTAGTGAACCGGGTACCGGCNOV78b, 254647864SEQ ID NO: 1114200 aaMW at 22132.8kDProtein SequenceTGSIEGLDATGGKTTVTQSVADSLKAVLLKSPPSCIGQWRKIFDDEPTIIRRAFYSLGNYIVASEIAKESAKSPVIVDRYWHSTATYAIATEVSGGLQHLPPAHHPVYQWPEDLLKPDLILLLTVSPEERLQRLQGRGMEKTREEABLEANSVFRQKVEMSYQRMENPGCHVVDASPSREKVLQTVLSLIQNSFSEPGTGNOV78c, 254347797SEQ ID NO: 1115601 bpDNA SequenceORF Start: at 2ORF Stop:end of sequenceCACCGGATCCATCGAAGGACTGGATGCCACGGGTGGTAAAACCACGGTGACCCAGTCAGTGGCAGATTCACTTAAGGCTGTCCTCTTAAAGTCACCACCCTCTTGCATTGGCCAGTGGAGGAAGATCTTTGATGATGAACCAACTATCATTAGAAGAGCTTTTTACTCTTTGGGCAATTATATTGTGGCCTCCGAAATAGCTAAAGAATCTGCCAAATCTCCTGTGATTGTAGACAGGTACTGGCACAGCACGGCCACCTATGCCATAGCCACTGAGGTGAGTGGGGGTCTCCAGCACCTGCCCCCAGCCCATCACCCTGTGTACCAGTGGCCAGAGGACCTGCTCAAACCTGACCTTATCCTGCTGCTCACTGTGAGTCCTGAGGAGAGGTTGCAGAGGCTGCAGGGCCGGGGCATGGAGAAGACCAGGGAAGAAGCAGAACTTGAGGCCAACAGTGTGTTTCGTCAAAAGGTAGAAATGTCCTACCAGCGGATGGAGAATCCTGGCTGCCATGTGGTTGATGCCAGCCCCTCCAGAGAAAAGGTCCTGCAGACGGTATTAAGCCTAATCCAGAATAGTTTTAGTGAACCGGGTACCGGCNOV78c, 254347797SEQ ID NO: 1116200 aaMW at 22132.8kDProtein SequenceTGSIEGLDATGGKTTVTQSVADSLKAVLLKSPPSCIGQWRKIFDDEPTIIRRAFYSLGNYIVASEIAKESAKSPVIVDRYNHSTATYAIATEVSGGLQHLPPAHHPVYQWPEDLLKPDLILLLTVSPEERLQRLQGRGMEKTREEAELEANSVFRQKVEMSYQRNENPGCHVVDASPSREKVLQTVLSLIQNSFSEPGTGNOV78d, CG94235-02SEQ ID NO: 11172331 bpDNA SequenceORF Start: ATG at 16ORF Stop: TAG at 769GTCTGCGCTGGGGCCATGGCTCCGCCGCGCCGCTTCGTCCTGGAGCTTCCTGACTGCACCCTGGCTCACTTCGCCCTAGGCGCCGTTTTGGAGGAGTGTACCTCCTTTATTCCTGAAGCCCGGGCAGTGCTTGACCTGGTCGACCAGTGCCCAAAACAGATCCAGAAAGGAAAGTTCCAGGTTGTTGCCATCGAAGGACTGGATGCCACGGGTAAAACCACGGTGACCCAGTCAGCGGCAGATTCACTTAAGGCTGTCCTCTTAAAGTCACCACCCTCTTGCATTGGCCAGTGGAGGAAGATCTTTGATGATGAACCAACTATCATTAGAAGAGCTTTTTACTCTTTGGGCAATTATATTGTGGCCTCCGAAATAGCTAAAGAATCTGCCAAATCTCCTGTGATTGTAGACAGGTACTGGCACAGCACGGCCACCTATGCCATAGCCACTGAGGTGAGTGGGGGTCTCCAGCACCTGCCCCCAGCCCATCACCCTGTGTACCAGTGGCCAGAGGACCTGCTCAAACCTGACCTTATCCTGCTGCTCACTGTGAGTCCTGAGGAGAGGTTGCAGAGGCTGCAGGGCCGGGGCATGGAGAAGACCAGGGAAGAAGCAGAACTTGAGGCCAACAGTGTGTTTCGTCAAAAGGTAGAAATGTCCTACCAGCGGATGGAGAATCCTGGCTGCCATGTGGTTGATGCCAGCCCCTCCAGAGAAAAGGTCCTGCAGACGGTATTAAGCCTAATCCAGAATAGTTTTAGTGAACCGTAGTTACTCTGGCCAGGTGCCACGTCTAACTAGATTAGATGTTGTTTGAAACATCTACATCCACCATTTGTTATGCAGTGTTCCCAAATTTCTGTTCTACAAGCATGTTGTGTGGCAGAAAACTGGAGACCAGGCATCTTAAGTTTACTTCAGCCATCGTACCCTCTTCTGACTGATGGACCCGTCATCACAAAGGTCCCTCTCATCATGTTCCAGTGAGAGGCCAGCGATTGCTTTCTTCCTGGCATAGTAAACATTTTCTTGGAACATATGTTTCACTTAATCACTACCAAATATCTGGAAGACCTGTCTTACTCAGACAGCACCAGGTGTACAGAAGCAGCAGACAAGATCTTCCAGATCAGCAGGGAGACCCCGGAGCCTCTGCTTCTCCTACACTGGCATGCTGATGAGATCGTGACATGCCCACATTGGCTTCTTCCACATCTGGTTGCACTCGTCATGATGGGCTCGCTGCATCTCCCTCAGTCCCAAATTCTAGAGCCAAGTGTTCCTGCAGAGGCTGTCTATGTGTCCTGGCTGCCCAAGGACACTCCTGCAGAGCCATTTTTGGGTAAGGAACACTTACAAAGAAGGCATTGATCTTGTGTCTGAGGCTCAGAGCCCTTTTGATAGGCTTCTGAGTCATATATAAAGACATTCAAGCCAAGATGCTCCAACTGCAAATATACCAACCTTCTCTGAATTATATTTTGCTTATTTATATTTCTTTTCTTTTTTTCTAAAGTATGGCTCTGAATAGAATGCACATTTTCCATTGAACTGGATGCATTTCATTTAGCCAATCCAGTAATTTATTTATATTAATCTATACATAATATGTTTCCTCAGCATAGGAGCTATGATTCATTAATTAAAAGTGGAGTCAAAACGCTAAATGCAATGTTTGTTGTGTATTTTCATTACACAAACTTAATTTGTCTTGTTAAATAAGTACAGTGGATCTTGGAGTGGGATTTCTTGGTAAATTATCTTGCACTTGAATGTCTCATGATTACATATGAAATCGCTTTGACATATCTTTAGACAGAAAAAAGTAGCTGAGTGAGGGGGAAATTATAGAGCTGTGTGACTTTAGGGAGTAGGTTGAACCAGGTGATTACCTAAAATTCCTTCCAGTTCAAAGGCAGATAAATCTGTAAATTATTTTATCCTATCTACCATTTCTTAAGAAGACATTACTCCAAAATAATTAAATTTAAGGCTTTATCAGGTCTGCATATAGAATCTTAAATTCTAATAAAGTTTCATGTTAATGTCATAGGATTTTTAAAAGAGCTATAGGTAATTTCTGTATAATATGTGTATATTAAAATGTAATTGATTTCAGTTGAAAGTATTTTAAAGCTGATAAATAGCATTAGGGTTCTTTGCAATGTGGTATCTAGCTGTATTATTGGTTTTATTTACTTTAAACATTTTGAAAAGCTTATACTGGCAGCCTAGAAAAACAAACAATTAATGTATCTTTATGTCCCTGGCACATGAATAAACTTTGCTGTGGTTTACTAAAAAAAAAAAAAAAAAAAAAGGGCGGCCGCTNOV78d, CG94235-02SEQ ID NO: 1118251 aaMW at 27980.8kDProtein SequenceMAPPRRFVLELPDCTLAHFALGAVLEECTSFIPEARAVLDLVDQCPKQIQKGKFQVVAIEGLDATGKTTVTQSAADSLKAVLLKSPPSCIGQWRKIFDDEPTIIRRAFYSLGNYIVASEIAKESAKSPVIVDRYWHSTATYAIATEVSGGLQHLPPAHHPVYQWPEDLLKPDLILLLTVSPEERLQRLQGRGMEKTREEAELEANSVFRQKVEMSYQRMENPGCHVVDASPSREKVLQTVLSLIQNSFSEP

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 78B.

TABLE 78BComparison of the NOV78 protein sequences.NOV78aMAPPRRFVLELPDCTLAHFALGADAPGDADAPDPRLAALLGPPERSYSLCVPVTPDAGCGNOV78b------------------------------------------------------------NOV78c------------------------------------------------------------NOV78d------------------------------------------------------------NOV78aARVRAARLHQRLLHQLRRGPFQRCQLLRLLCYCPGGQAGGAQQGFLLRDPLDDPDTRQALNOV78b------------------------------------------------------------NOV78c------------------------------------------------------------NOV78d------------------------------------------------------------NOV78aLELLGACQEAPRPHLGEFEADPRGQLWQRLWEVQDGRRLQVGCAQVVPVPEPPLHPVVPDNOV78b------------------------------------------------------------NOV78c------------------------------------------------------------NOV78d--------------------------------------------------MAPPRRFVLENOV78aLPSSVVFPDREAARAVLEECTSFIPEARAVLDLVDQCPKQIQKGKFQVVAIEGLDATGGKNOV78b-----------------------------------------------TGSIEGLDATGGKNOV78c-----------------------------------------------TGSIEGLDATGGKNOV78dLPDCTLA--HFALGAVLEECTSFIPEARAVLDLVDQCPKQIQKGKFQVVAIEGLDATG-KNOV78aTTVTQSVADSLKAVLLKSPPSCIGQWRKIFDDEPTIIRRAFYSLGNYIVASEIAKESAKSNOV78bTTVTQSVADSLKAVLLKSPPSCIGQWRKIFDDEPTIIRRAFYSLGNYIVASEIAKESAKSNOV78cTTVTQSVADSLKAVLLKSPPSCIGQWRKIFDDEPTIIRRAFYSLGNYIVASEIAKESAKSNOV78dTTVTQSAADSLKAVLLKSPPSCIGQWRKIFDDEPTIIRRAFYSLGNYIVASEIAKESAKSNOV78aPVIVDR--HSTATYAIATEVSGGLQHLPPAHHPVYQWPEDLLKPDLILLLTVSPEERLQRNOV78bPVIVDRYWHSTATYAIATEVSGGLQHLPPAHHPVYQWPEDLLKPDLILLLTVSPEERLQRNOV78cPVIVDRYWHSTATYAIATEVSGGLQHLPPAHHPVYQWPEDLLKPDLILLLTVSPEERLQRNOV78dPVIVDRYWHSTATYAIATEVSGGLQHLPPAHHPVYQWPEDLLKPDLILLLTVSPEERLQRNOV78aLQGRGMEKTREEAELEANSVFRQKVEMSYQRMENPGCHVVDASPSREKVLQTVLSLIQNSNOV78bLQGRGMEKTREEAELEANSVFRQKVEMSYQRMENPGCHVVDASPSREKVLQTVLSLIQNSNOV78cLQGRGMEKTREEAELEANSVFRQKVEMSYQRMENPGCHVVDASPSREKVLQTVLSLIQNSNOV78dLQGRGMEKTREEAELEANSVFRQKVEMSYQRMENPGCHVVDASPSREKVLQTVLSLIQNSNOV78aFSEP---NOV78bFSEPGTGNOV78cFSEPGTGNOV78dFSEP---NOV78a(SEQ ID NO: 1112)NOV78b(SEQ ID NO: 1114)NOV78c(SEQ ID NO: 1116)NOV78d(SEQ ID NO: 1118)

Further analysis of the NOV78a protein yielded the following properties shown in Table 78C.

TABLE 78CProtein Sequence Properties NOV78aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 2; neg.chg 1H-region: length 2; peak value −1.05PSG score: −5.45GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −5.20possible cleavage site: between 22 and 23>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 0number of TMS(s) . . . fixedPERIPHERAL Likelihood = 3.66 (at 7)ALOM score: 3.66 (number of TMSs: 0)MITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment(75):11.11Hyd Moment(95):9.49G content:0D/E content:2S/T content:0Score: −4.13Gavel: prediction of cleavage sites for mitochondrial preseqR-3 motif at 48 ERSY|SNUCDISC: discrimination of nuclear localization signalspat4: nonepat7: nonebipartite: nonecontent of basic residues: 10.9%NLS Score: −0.47KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: APPRnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 70.6COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):47.8%: cytoplasmic26.1%: mitochondrial17.4%: nuclear 8.7%: peroxisomal>> prediction for CG94235-01 is cyt (k = 23)

A search of the NOV78a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 78D.

TABLE 78DGeneseq Results for NOV78aNOV78aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB57297Mouse ischaemic condition related199 . . . 384131/193 (67%) 3e−64protein sequence SEQ ID NO: 834 -157 . . . 344150/193 (76%) Mus musculus, 431 aa.[WO200188188-A2, 22-NOV-2001]AAB72201E. coli thymidylate kinase amino229 . . . 42151/212 (24%)0.062acid sequence - Escherichia coli, 6 . . . 21088/212 (41%)213 aa. [WO200111025-A2, 15-FEB-2001]AAU34536E. coli cellular proliferation229 . . . 42151/212 (24%)0.062protein #117 - Escherichia coli, 6 . . . 21088/212 (41%)213 aa. [WO200170955-A2, 27-SEP-2001]AAY28786E. coli thymidylate kinase-1 -229 . . . 42151/212 (24%)0.062Escherichia coli, 213 aa. 6 . . . 21088/212 (41%)[WO9941404-A2, 19-AUG-1999]AAY23912Amino acid sequence of a heat183 . . . 277 26/97 (26%)0.71 shock protein - Mycobacterium199 . . . 293 49/97 (49%)leprae, 537 aa. [WO9935270-A1,15-JUL-1999]

In a BLAST search of public sequence databases, the NOV78a protein was found to have homology to the proteins shown in the BLASTP data in Table 78E.

TABLE 78EPublic BLASTP Results for NOV78aNOV78aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueQ9DC341200004E04Rik protein - Mus 42 . . . 418292/379 (77%) e−168musculus (Mouse), 395 aa. 16 . . . 393328/379 (86%)Q62316Thymidylate kinase homologue -199 . . . 384131/193 (67%)1e−63Mus musculus (Mouse), 431 aa.157 . . . 344150/193 (76%)Q96AL8Hypothetical protein - Homo365 . . . 422 58/58 (100%)4e−25sapiens (Human), 58 aa 1 . . . 58 58/58 (100%)(fragment).O60970TKRP1 - Leishmania major, 274199 . . . 418 73/220 (33%)1e−21aa. 44 . . . 254108/220 (48%)Q8P3Y6Thymidylate kinase (EC 2.7.4.9)228 . . . 415 53/204 (25%)2e−04(dTMP kinase) - Xanthomonas 11 . . . 196 89/204 (42%)campestris (pv. campestris), 227aa.

PFam analysis indicates that the NOV78a protein contains the domains shown in the Table 78F.

TABLE 78FDomain Analysis of NOV78aNOV78aIdentities/MatchSimilarities forPfam DomainRegionthe Matched RegionExpect ValueThymidylate_kin231 . . . 411 54/210 (26%)2.2e−07131/210 (62%)

Example 79

The NOV79 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 79A.

TABLE 79ANOV79 Sequence AnalysisNOV79a, CG95175-01SEQ ID NO: 11193117 bpDNA SequenceORF Start: ATG at 21ORF Stop: TGA at 3078CCTCCCCAGTAGCTGGGACTATGGGAGCGTGCCACCATGCCTGGTTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCTTGTCTTCCCCTCTCCTTAGTTATCCTCCTGGATTCCAAAGCCTCCCAGGCCGAGCTGGGCTGGACTGCACTGCCAAGTAATGGGTGGGAGGAGATCAGCGGCGTGGATGAACACGACCGTCCCATCCGCACGTACCAAGTGTGCAATGTGCTGGAGCCCAACCAGGACAACTGGCTGCAGACTGGCTGGATAAGCCGTGGCCGCGGGCAGCGCATCTTCGTGGAACTGCAGTTCACACTCCGTGACTGCAGCAGCATCCCTGGCGCCGCGGGTACCTGCAAGGAGACCTTCAACGTCTACTACCTGGAAACTGAGGCCGACCTGGGCCGTGGGCGTCCCCGCCTAGGCGGCAAAATCGACACGATCGCGGCGGACGAGAGCTTCACGCAGGGCGACCTGGGTGAGCGCAAGATGAAGCTGAACACAGAGGTGCGCGAGATCGGACCGCTCAGCCGGCGGGGTTTCCACCTGGCCTTTCAGGACGTGGGCGCATGCGTGGCGCTTGTCTCGGTGCGCGTCTACTACAAGCAGTGCCGCGCCACCGTGCGGGGCCTGGCCACGTTCCCAGCCACCGCAGCCGAGAGCGCCTTCTCCACACTGGTGGAAGTGGCCGGAACGTGCGTGGCGCACTCGGAAGGGGAGCCTGGCAGCCCCCCACGCATGCACTGCGGCGCCGACGGCGAGTGGCTGGTGCCTGTGGGCCGCTGCAGCTGCAGCGCGGGATTCCAGGAGCGTGGTGACTTCTGCGAAGGTATCTGTCCCCCAGGGTTTTACAAGGTGTCCCCGCGGCGGCCCCTCTGCTCACCGTGCCCAGAGCACAGCCGGGCCCTGGAAAACGCCTCCACCTTCTGCGTGTGCCAGGACAGCTATGCGCGCTCACCCACCGACCCGCCCTCGGCTTCCTGCACCCGTCCGCCGTCGGCGCCGCGGGACCTGCAGTACAGCCTGAGCCGCTCGCCGCTGGTGCTGCGACTGCGCTGGCTGCCGCCGGCCGACTCGGGAGGCCGCTCGGACGTCACCTACTCGCTGCTGTGCCTGCGCTGCGGCCGCGAGGGCCCGGCGGGCGCCTGCGAGGGGCCGCGCGTGGCCTTCCTACCGCGCCAGGCAGGGCTGCGGGAGCGAGCCGCCACGCTGCTGCACCTGCGGCCCGGCGCGCGCTACACCGTGCGCGTGGCCGCGCTCAACGGCGTCTCGGGCCCGGCGGCCGCCGCGGGAACCACCTACGCGCAGGTCACCGTCTCCACCGGGCCCGGGGGTAAGGCCGTCCGCGCCCCCCACCCCGAGGCCACCGCGCCTGCCGCCCCTGCGCCCTCTTGGGGCCGCCCCGTCGGTCCTGCGGGATCAGCGCCCTGGGAGGAGGATGAGATCCGCAGGGACCGAGTGGAACCCCAGAGCGTGTCCCTGTCGTGGCGGGAGCCCATCCCTGCCGGAGCCCCTGGGGCCAATGACACGGAGTACGAGATCCGATACTACGAGAAGGTGAGTGCGCAGAGTGAGCAGACTTACTCCATGGTGAAGACAGGGGCGCCCACAGTCACCGTGATTTTCCTCCCAGCTGCCTCAGGGTCCAGGGACCAGAGCCCCGCCATTGTCGTCACCGTAGTGACCATCTCGGCCCTCCTCGTCCTGGGCTCCGTGATGAGTGTGCTGGCCATTTGGAGGAGGAGGCCCTGCAGCTATGGCAAAGGAGGAGGGGATGCCCATGATGAAGAGGAGCTGTATTTCCACTGTGAGTTGGCTGGGAAAGTCCCAACACGTCGCACATTCCTGGACCCCCAGAGCTGTGGGGACCTGCTGCAGGCTGTGCATCTGTTCGCCAAGGAACTGGATGCGAAAAGCGTCACGCTGGAGAGGAGCCTTGGAGGAGGCAAGCTGGGCGGGCGGTTTGGGGAGCTGTGCTGTGGCTGCTTGCAGCTCCCCGGTCGCCAGGAGCTGCTCGTAGCCGTGCACATGCTGAGGGACAGCGCCTCCGACTCACAGAGGCTCGGCTTCCTGGCCGAGGCCCTCACGCTGGGCCAGTTTGACCATAGCCACATCGTGCGGCTGGAGGGCGTTGTTACCCGAGGTAGGGGAAGCACCTTGATGATTGTCACCGAGTACATGAGCCATGGGGCCCTGGACGGCTTCCTCAGGCAGCGGCACGAGGGGCAGCTGGTGGCTGGGCAACTGATGGGGTTGCTGCCTGGGCTGGCATCAGCCATGAAGTATCTGTCAGAGATGGGCTACGTTCACCGGGGCCTGGCAGCTCGCCATGTGCTGGTCAGCAGCGACCTTGTCTGCAAGATCTCTGGCTTCGGGCGGGGCCCCCGGGACCGATCAGAGGCTGTCTACACCACTATGGTGAGGCTACAGAGTGGCCGGAGCCCAGCGCTATGGGCCGCTCCCGAGACACTTCAGTTTGGCCACTTCAGCTCTGCCAGTGACGTGTGGAGCTTCGGCATCATCATGTGGGAGGTGATGGCCTTTGGGGAGCGGCCTTACTGGGACATGTCTGGCCAAGACGTGGTGATCAAGGCTGTGGAGGATGGCTTCCGGCTGCCACCCCCCAGGAACTGTCCTAACCTTCTGCACCGACTAATGCTCGACTGCTGGCAGAAGGACCCAGGTGAGCGGCCCAGGTTCTCCCAGATCCACAGCATCCTGAGCAAGATGGTGCAGGACCCAGAGCCCCCCAAGTGTGCCCTGACTACCTGTCCCAGGCCTCTGACCCGCAGGCCTCCCACTCCACTAGCCGACCGTGCCTTCTCCACCTTCCCCTCCTTTGGCTCTGTGGGCGCGTGGCTGGAGGCCCTGGACCTGTGCCGCTACAAGGACAGCTTCGCGGCTGCTGGCTATGGGAGCCTGGAGGCCGTGGCCGAGATGACTAGCCAGGACCTGGTGAGCCTAGGCATCTCTTTGGCTGAACATCGAGAGGCCCTCCTCAGCGGGATCAGCGCCCTGCAGGCACGAGTGCTCCAGCTGCAGGGCCAGGGGGTGCAGGTGTGAGTGGACCCCATTCTTCCAAGGCAGGACTCCGGTGGGGNOV79a, CG95175-01SEQ ID NO: 11201019 aaMW at 110412.5kDProtein SequenceMGACHHAWLIFVFLVEMGFHHVGQACLPLSLVILLDSKASQAELGWTALPSNGWEEISGVDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGTCKETFNVYYLETEADLGRGRPRLGGKIDTIAADESFTQGDLGERKMKLNTEVREIGPLSRRGFHLAFQDVGACVALVSVRVYYKQCRATVRGLATFPATAAESAFSTLVEVAGTCVAHSEGEPGSPPRMHCGADGEWLVPVGRCSCSAGFQERGDFCEGICPPGFYKVSPRRPLCSPCPEHSRALENASTFCVCQDSYARSPTDPPSASCTRPPSAPRDLQYSLSRSPLVLRLRWLPPADSGGRSDVTYSLLCLRCGREGPAGACEGPRVAFLPRQAGLRERAATLLHLRPGARYTVRVAALNGVSGPAAAAGTTYAQVTVSTGPGGKAVRAPHPEATAPAAPAPSWGRPVGPAGSAPWEEDEIRRDRVEPQSVSLSWREPIPAGAPGANDTEYEIRYYEKVSAQSEQTYSMVKTGAPTVTVIFLPAASGSRDQSPAIVVTVVTISALLVLGSVMSVLAIWRRRPCSYGKGGGDAHDEEELYFHCELAGKVPTRRTFLDPQSCGDLLQAVHLFAKELDAKSVTLERSLGGGKLGGRFGELCCGCLQLPGRQELLVAVHMLRDSASDSQRLGFLABALTLGQFDHSHIVRLEGVVTRGRGSTLMIVTEYMSHGALDGFLRQRHEGQLVAGQLMGLLPGLASAMKYLSEMGYVHRGLAARHVLVSSDLVCKISGFGRGPRDRSEAVYTTMVRLQSGRSPALWAAPETLQFGHFSSASDVWSFGIIMWEVMAFGERPYWDMSGQDVVIKAVEDGFRLPPPRNCPMLLHRLMLDCWQKDPGERPRFSQIHSILSKMVODPEPPKCALTTCPRPLTRRPPTPLADRAFSTFPSFGSVGAWLEALDLCRYKDSFAAAGYGSLEAVAEMTSQDLVSLGISLAEHREALLSGISALQARVLQLQGQGVQVNOV79b, 275697118SEQ ID NO: 1121547 bpDNA SequenceORF Start: at 2ORF Stop:end of sequenceCACCGGATCCGTTATCCTCCTGGATTCCAAAGCCTCCCAGGCCGAGCTGGGCTGGACTGCACTGCCAAGTAATGGGTGGGAGGAGATCAGCGGCGTGGATGAACACGACCGTCCCATCCGCACGTACCAAGTGTGCAATGTGCTGGAGCCCAACCAGGACAACTGGCTGCAGACTGGCTGGATAAGCCGTGGCCGCGGGCAGCGCATCTTCGTGGAACTGCAGTTCACACTCCGTGACTGCAGCAGCATCCCTGGCGCCGCGGGTACCTGCAAGGAGACCTTCAACGTCTACTACCTGGAAACTGAGGCCGACCTGGGCCGTGGGCGTCCCCGCCTAGGCGGCAGCCGGCCCCGCAAAATCGACACGATCGCGGCGGACGAGAGCTTCACGCAGGGCGACCTGGGTGAGCGCAAGATGAAGCTGAACACAGAGGTGCGCGAGATCGGACCGCTCAGCCGGCGGGGTTTCCACCTGGCCTTTCAGGACGTGGGCGCATGCGTGGCGCTTGTCTCGGTGCGCGTCTACTACAAGCAGTGCGTCGACGGCNOV79b, 275697118SEQ ID NO: 1122182 aaMW at 20253.6kDProtein SequenceTGSVILLDSKASQAELGWTALPSNGWEEISGVDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGTCKETFNVYYLETEADLGRGRPRLGGSRPRKIDTIAADESFTQGDLGERKMKLNTEVREIGPLSRRGFHLAFQDVGACVALVSVRVYYKQCVDGNOV79c, 275697150SEQ ID NO: 1123694 bpDNA SequenceORF Start: at 2ORF Stop:end of sequenceCACCGGATCCCTCGTAGCCGTGCACATGCTGAGGGACAGCGCCTCCGACTCACAGAGGCTCGGCTTCCTGGCCGAGGCCCTCACGCTGGGCCAGTTTGACCATAGCCACATCGTGCGGCTGGAGGGCGTTGTTACCCGAGGAAGCACCTTGATGATTGTCACCGAGTACATGAGCCATGGGGCCCTGGACGGCTTCCTCAGGCGGCACGAGGGGCAGCTGGTGGCTGGGCAACTGATGGGGTTGCTGCCTGGGCTGGCATCAGCCATGAAGTATCTGTCAGAGATGGGCTACGTTCACCGGGGCCTGGCAGCTCGCCATGTGCTGGTCAGCAGCGACCTTGTCTGCAAGATCTCTGGCTTCGGGCGGGGCCCCCGGGACCGATCAGAGGCTGTCTACACCACTATGAGTGGCCGGAGCCCAGCGCTATGGGCCGCTCCCGAGACACTTCAGTTTGGCCACTTCAGCTCTGCCAGTGACGTGTGGAGCTTCGGCATCATCATGTGGGAGGTGATGGCCTTTGGGGAGCGGCCTTACTGGGACATGTCTGGCCAAGACGTGATCAAGGCTGTGGAGGATGGCTTCCGGCTGCCACCCCCCAGGAACTGTCCTAACCTTCTGCACCGACTAATGCTCGACTGCTGGCAGAAGGACCCAGGTGAGCGGCCCAGGTTCTCCCAGATCCACGTCGACGGCNOV79c, 275697150SEQ ID NO: 1124231 aaMW at25557.0kDProtein SequenceTGSLVAVHNLRDSASDSQRLGFLAEALTLGQFDHSHIVRLEGVVTRGSTLMIVTEYMSHGALDGFLRRHEGQLVAGQLMGLLPGLASAMKYLSEMGYVHRGLAARHVLVSSDLVCKISGFGRGPRDRSEAVYTTMSGRSPALWAAPETLQFGHFSSASDVWSFGIIMWEVMAFGERPYWDMSGQDVIKAVEDGFRLPPPRNCPNLLHRLMLDCWQKDPGERPRFSQIHVDG

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 79B.

TABLE 79BComparison of the NOV79 protein sequences.NOV79aMGACHHAWLIFVFLVEMGFHHVGQACLPLSLVILLDSKASQAELGWTALPSNGWEEISGVNOV79b----------------------------TSGVILLDSKASQAELGWTALPSNGWEEISGVNOV79c------------------------------------------------------------NOV79aDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGTCKENOV79bDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGTCKENOV79c------------------------------------------------------------NOV79aTFNVYYLETEADLGRGRPRLGG----KIDTIAADESFTQGDLGERKMKLNTEVREIGPLSNOV79bTFNVYYLETEADLGRGRPRLGGSRPRKIDTIAADESFTQGDLGERKMKLNTEVREIGPLSNOV79c------------------------------------------------------------NOV79aRRGFHLAFQDVGACVALVSVRVYYKQCRATVRGLATFPATAAESAFSTLVEVAGTCVAHSNOV79bRRGFHLAFQDVGACVALVSVRVYYKQCVDG------------------------------NOV79c------------------------------------------------------------NOV79aEGEPGSPPRMHCGADGEWLVPVGRCSCSAGFQERGDFCEGICPPGFYKVSPRRPLCSPCPNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aEHSRALENASTFCVCQDSYARSPTDPPSASCTRPPSAPRDLQYSLSRSPLVLRLRWLPPANOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aDSGGRSDVTYSLLCLRCGREGPAGACEGPRVAFLPRQAGLRERAATLLHLRPGARYTVRVNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aAALNGVSGPAAAAGTTYAQVTVSTGPGGKAVRAPHPEATAPAAPAPSWGRPVGPAGSAPWNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aEEDEIRRDRVEPQSVSLSWREPIPAGAPGANDTEYEIRYYEKVSAQSEQTYSMVKTGAPTNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aVTVIFLPAASGSRDQSPAIVVTVVTISALLVLGSVMSVLAIWRRRPCSYGKGGGDAHDEENOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aELYFHCELAGKVPTRRTFLDPQSCGDLLQAVHLFAKELDAKSVTLERSLGGGKLGGRFGENOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aLCCGCLQLPGRQELLVAVHMLRDSASDSQRLGFLAEALTLGQFDHSHIVRLEGVVTRGRGNOV79b------------------------------------------------------------NOV79c-----------TGSLVAVHMLRDSASDSQRLGFLAEALTLGQFDHSHIVRLEGVVTRGRGNOV79aSTLMIVTEYMSHGALDGFLRQRHEGQLVAGQLMGLLPGLASAMKYLSEMGYVHRGLAARHNOV79b------------------------------------------------------------NOV79cSTLMIVTEYMSHGALDGFLRR-HEGQLVAGQLMGLLPGLASAMKYLSEMGYVHRGLAARHNOV79aVLVSSDLVCKISGFGRGPRDRSEAVYTTMVRLQSGRSPALWAAPETLQFGHFSSASDVWSNOV79b------------------------------------------------------------NOV79cVLVSSDLVCKISGFGRGPRDRSEAVYTTMS----GRSPALWAAPETLQFGHFSSASDVWSNOV79aFGIIMWEVMAFGERPYWDMSGQDVVIKAVEDGFRLPPPRNCPNLLHRLMLDCWQKDPGERNOV79b------------------------------------------------------------NOV79cFGIIMWEVMAFGERPYWDMSGQ-DVIKAVEDGFRLPPPRNCPNLLHRLMLDCWQKDPGERNOV79aPRFSQIHSILSKMVQDPEPPKCALTTCPRPLTRRPPTPLADRAFSTFPSFGSVAGWLEALNOV79b------------------------------------------------------------NOV79cPRFSQIHVDGNOV79aDLCRYKDSFAAAGYGSLEAVAEMTSQDLVSLGISLAEHREALLSGISALQARVLQLQGQGNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aVQVNOV79b---NOV79c---NOV79a(SEQ ID NO: 1120)NOV79b(SEQ ID NO: 1122)NOV79c(SEQ ID NO: 1124)

Further analysis of the NOV79a protein yielded the following properties shown in Table 79C.

TABLE 79CProtein Sequence Properties NOV79aSignalP analysis:Cleavage site between residues 43 and 44PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 0; pos.chg 0; neg.chg 0H-region: length 15; peak value 12.14PSG score: 7.74GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −2.44possible cleavage site: between 41 and 42>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 3Number of TMS(s) for threshold 0.5: 1INTEGRALLikelihood = −9.08 Transmembrane 555-571PERIPHERALLikelihood = 0.85 (at 743)ALOM score: −9.08 (number of TMSs: 1)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 562Charge difference: 3.5 C(3.5) − N(0.0)C > N: C-terminal side will be inside>>>Caution: Inconsistent mtop result with signal peptide>>>membrane topology: type 1b (cytoplasmic tail 555 to 1019)MITDISC: discrimination of mitochondrial targeting seqR content:0Hyd Moment(75):3.60Hyd Moment(95):3.84G content:1D/E content:1S/T content:0Score: −6.09Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: RRRP (4) at 579pat7: nonebipartite: nonecontent of basic residues: 10.1%NLS Score: −0.22KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: too long tailDileucine motif in the tail: foundLL at 565LL at 623LL at 670LL at 751LL at 880LL at 998checking 63 PROSITE DNA binding motifs:Leucine zipper pattern (PS00029): *** found ***LGGRFGELCCGCLQLPGRQELL at 650LVSLGISLAEHREALLSGISAL at 984 nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN: Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 89COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):34.8%: nuclear21.7%: mitochondrial21.7%: cytoplasmic 8.7%: vesicles of secretory system 4.3%: vacuolar 4.3%: peroxisomal 4.3%: endoplasmic reticulum>> prediction for CG95175-01 is nuc (k = 23)

A search of the NOV79a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 79D.

TABLE 79DGeneseq Results for NOV79aNOV79aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAM47209Human NOV3 protein - Homo 7 . . . 1019933/1054 (88%)0.0sapiens, 1000 aa. 9 . . . 1000936/1054 (88%)[WO200174851-A2, 11-OCT-2001]AAU76874Human EphA full length kinase -33 . . . 1019925/1027 (90%)0.0Homo sapiens, 974 aa.1 . . . 974926/1027 (90%)[WO200208253-A2, 31-JAN-2002]ABB98843Human NEPHA - Homo24 . . . 1019931/1046 (89%)0.0sapiens, 1008 aa.18 . . . 1008932/1046 (89%)[WO200283735-A1, 24-OCT-2002]AAE19158Human kinase polypeptide24 . . . 1019913/1048 (87%)0.0(PKIN-16) - Homo sapiens,18 . . . 1009916/1048 (87%)1009 aa. [WO200208399-A2,31-JAN-2002]AAU03553Human protein kinase #53 -24 . . . 1019913/1048 (87%)0.0Homo sapiens, 1009 aa.18 . . . 1009916/1048 (87%)[WO200138503-A2, 31-MAY-2001]

In a BLAST search of public sequence databases, the NOV79a protein was found to have homology to the proteins shown in the BLASTP data in Table 79E.

TABLE 79EPublic BLASTP Results for NOV79aNOV79aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAD13085Sequence 5 from Patent 7 . . . 1019933/1054 (88%)0.0WO0174851 - Homo sapiens 9 . . . 1000936/1054 (88%)(Human), 1000 aa.CAD23752Sequence 1 from Patent33 . . . 1019925/1027 (90%)0.0WO0208253 - Homo sapiens1 . . . 974926/1027 (90%)(Human), 974 aa (fragment).CAD23753Sequence 3 from Patent33 . . . 1019930/1071 (86%)0.0WO0208253 - Homo sapiens 1 . . . 1022931/1071 (86%)(Human), 1022 aa (fragment).CAD23754Sequence 5 from Patent33 . . . 653 575/661 (86%)0.0WO0208253 - Homo sapiens1 . . . 623 576/661 (86%)(Human), 647 aa (fragment).CAD23755Sequence 7 from Patent33 . . . 653 580/705 (82%)0.0WO0208253 - Homo sapiens1 . . . 671 581/705 (82%)(Human), 695 aa (fragment).

PFam analysis indicates that the NOV79a protein contains the domains shown in the Table 79F.

TABLE 79FDomain Analysis of NOV79aIdentities/NOV79a MatchSimilarities forPfam DomainRegionthe Matched RegionExpect ValueEPH_lbd 32 . . . 203115/177 (65%) 2.6e−119156/177 (88%)fn3331 . . . 426 25/98 (26%) 2e−06 66/98 (67%)pkinase639 . . . 906 78/309 (25%)1.7e−37186/309 (60%)SAM 942 . . . 1006 27/68 (40%)2.9e−15 50/68 (74%)

Example 80

The NOV80 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 80A.

TABLE 80ANOV80 Sequence AnalysisNOV80a, CG99638-01SEQ ID NO: 11252131 bpDNA SequenceORF Start: ATG at 93ORF Stop: TGA at 2088CTAAATGAAGAGCGCTTGGGACCTGAACAACCAGCAGCGATACCCAGGTACAAAGGACCTCCAGACCAGAGCCAGCCAGCAGCAAAAAGAGCATGGAGCTGAGGAGTACAGCAGCCCCCAGAGCTGAGGGCTACAGCAACGTGGGCTTCCAGAATGAAGAAAACTTTCTTGAGAACGAGAACACATCAGGAAACAACTCAATAAGAAGCAGAGCTGTGCAAAGCAGGGAGCACACAAACACCAAACAGGATGAAGAACAGGTCACAGTTGAGCAGGATTCTCCAAGAAACAGAGAACACATGGAGGATGATGATGAGGAGATGCAACAAAAAGGGTGTTTGGAAAGGAGGTATGACACAGTATGTGGTTTCTGTAGGAAACACAAAACAACTCTTCGGCACATCATCTGGGGCATTTTATTAGCAGGTTATCTGGTTATGGTGATTTCGGCCTGTGTGCTGAACTTTCACAGAGCCCTTCCTCTTTTTGTGATCACCGTGGCTGCCATCTTCTTTGTTGTCTGGGATCACCTGATGGCCAAATACGAACATCGAATTGATGAGATGCTGTCTCCTGGCAGAAGGCTTCTAAACAGCCATTGGTTCTGGCTGAAGTGGGTGATCTGGAGCTCCCTGGTCCTAGCAGTTATTTTCTGGTTGGCCTTTGACACTGCCAAATTGGGTCAACAGCAGCTGGTGTCCTTCGGTGGGCTCATAATGTACATTGTCCTGTTATTTCTATTTTCCAAGTACCCAACCAGAGTTTACTGGAGACCTGTCTTATGGGGAATCGGGCTACAGTTTCTTCTTGGGCTCTTGATTCTAAGGACTGACCCTGGATTTATAGCTTTTGATTGGTTGGGCAGACTAGTTCAGGTCCTGCCGATCGTGGTTTTCTTCAGCACTGTGATGTCCATGCTGTACTACCCTGGACTGATGCAGTGGATTATTAGAAAGGTTGGATGGATCATGCTAGTTACTACGGGATCATCTCCTATTGAATCTGTAGTTGCTTCTGGGCATATATTTGTTGGACAAACGGAGTCTCCACTGCTGGTCCGACCATATTTACCTTACATCACCAAGTCTGAACTCCACGCCATCATGACCGCCGGGTTCTCTACCATTGCTAGGTGCGTGCTAGGTGCATACATTTCTTTTGGGGTTCCATCCTCCCACTTGTTAACAGCGTCAGTTATGTCAGCACCTGCGTCATTGGCTGCTGCTAAACTCTTTTGGCCTGAGACAGAAAAACCTAAAATAACCCTCAAGAATGCCATGAAAATGGAAAGTGGTGATTCAGGGAATCTTCTAGAAGCTGCAACACAGGGAGCATCCTCCTCCATCTCCCTGGTGGCCAACATCGCTGTGAATCTGATTGCCTTCCTGGCCCTGCTGTCTTTTATGAATTCAGCCCTGTCCTGGTTTGGAAACATGTTTGACTACCCACAGCTGAGTTTTGAGCTAATCTGCTCCTACATCTTCATGCCCTTTTCCTTCATGATGGGAGTGGAATGGCAGGACAGCTTTATGGTTGCCAGACTCATAGGTTATAAGACCTTCTTCAATGAATTTGTGGCTTATGAGCACCTCTCAAAATGGATCCACTTGAGGAAAGAAGGTGGACCCAAATTTGTAAACGGTGTGCAGCAATATATATCAATTCGTTCTGAGATAATCGCCACTTACGCTCTCTGTGGTTTTGCCAATATCGGGTCCCTAGGAATCGTGATCGGCGGACTCACATCCATGGCTCCTTCCAGAAAGCGTGATATCGCCTCGGGGGCAGTGAGAGCTCTGATTGCGGGGACCGTGGCCTGCTTCATGACAGCCTGCATCGCAGGCATACTCTCCAGCACTCCTGTGGACATCAACTGCCATCACGTTTTAGAGAATGCCTTCAACTCCACTTTCCCTGGAAACACAACCAAGGTGATAGCTTGTTGCCAAAGTCTGTTGAGCAGCACTGTTGCCAAGGGTCCTGGTGAAGTCATCCCAGGAGGAAACCACAGTCTGTATTCTTTGAAGGGCTGCTGCACATTGTTGAATCCATCGACCTTTAACTGCAATGGGATCTCTAATACATTTTGAGGTCAGCCACTTCTCCAGTGGAACTCTGAAGTACAGATGCTNOV80a, CG99638-01SEQ ID NO: 1126665 aaMW at 73873.1kDProtein SequenceMELRSTAAPRABGYSNVGFQNEENFLENBNTSGNNSIRSRAVQSREHTNTKQDEEQVTVEQDSPRNREHMEDDDEEMQQKGCLERRYDTVCGFCRKHKTTLRHIIWGILLAGYLVMVISACVLNFHRALPLFVITVAAIFFVVWDHLMAKYEHRIDEMLSPGRRLLNSHWFWLKWVIWSSLVLAVIFWLAFDTAKLGQQQLVSFGGLIMYIVLLFLFSKYPTRVYWRPVLWGIGLQFLLGLLILRTDPGFIAFDWLGRLVQVLPIVVFFSTVMSMLYYPGLMQWIIRKVGWIMLVTTGSSPIESVVASGHIFVGQTESPLLVRPYLPYITKSELHAIMTAGFSTIAGSVLGAYISFGVPSSHLLTASVMSAPASLAAAKLFWPETEKPKITLKNAMKMESGDSGNLLEAATQGASSSISLVANIAVNLIAFLALLSFMNSALSWFGNNFDYPQLSFELICSYIFMPFSFMMGVEWQDSFMVARLIGYKTFFNEFVAYEHLSKWIHLRKEGGPKFVNGVQQYISIRSEIIATYALCGFANIGSLGIVIGGLTSMAPSRKRDIASGAVRALIAGTVACFMTACIAGILSSTPVDINCHHVLENAFNSTFPGNTTKVIACCQSLLSSTVAKGPGEVIPGGNHSLYSLKGCCTLLNPSTFNCNGISNTF

Further analysis of the NOV80a protein yielded the following properties shown in Table 80B.

TABLE 80BProtein Sequence Properties NOV80aSignalP analysis:No Known Signal Sequence IndicatedPSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 2; neg.chg 1H-region: length 1; peak value −3.60PSG score: −8.00GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −9.75possible cleavage site: between 13 and 14>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 9INTEGRALLikelihood = −7.96Transmembrane 107-123INTEGRALLikelihood = −9.08Transmembrane 128-144INTEGRALLikelihood = −5.84Transmembrane 175-191INTEGRALLikelihood = −8.97Transmembrane 201-217INTEGRALLikelihood = −4.51Transmembrane 228-244INTEGRALLikelihood = −4.35Transmembrane 259-275INTEGRALLikelihood = −6.58Transmembrane 418-434INTEGRALLikelihood = −1.59Transmembrane 534-550INTEGRALLikelihood = −4.94Transmembrane 569-585PERIPHERALLikelihood = 0.85 (at 454)ALOM score:−9.08 (number of TMSs: 9)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 114Charge difference: −3.5 C(1.5) − N(5.0)N >= C: N-terminal side will be inside>>> membrane topology: type 3aMITDISC: discrimination of mitochondrial targeting seqR content:2Hyd Moment(75):4.42Hyd Moment(95):1.72G content:0D/E content:2S/T content:2Score: −5.36Gavel: prediction of cleavage sites for mitochondrial preseqcleavage site motif not foundNUCDISC: discrimination of nuclear localization signalspat4: RKHK (3) at 95pat7: PSRKRDI (5) at 555bipartite: nonecontent of basic residues: 7.5%NLS Score: 0.15KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals:XXRR-like motif in the N-terminus: ELRSnoneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL: Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):77.8%: endoplasmic reticulum11.1%: vesicles of secretory system11.1%: nuclear>> prediction for CG99638-01 is end (k = 9)

A search of the NOV80a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 80C.

TABLE 80CGeneseq Results for NOV80aNOV80aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueAAE21150Human 52991 protein - Homo1 . . . 665661/665 (99%)0.0sapiens, 665 aa. [WO200218439-1 . . . 665662/665 (99%)A2, 07-MAR-2002]ABP69062Human polypeptide SEQ ID NO1 . . . 665662/691 (95%)0.01109 - Homo sapiens, 691 aa.1 . . . 691663/691 (95%)[WO200270539-A2, 12-SEP-2002]AAE22915Human transporter and ion1 . . . 665661/691 (95%)0.0channel (TRICH) 14 - Homo1 . . . 691662/691 (95%)sapiens, 691 aa. [WO200222684-A2, 21-MAR-2002]AAW49106Rat jejunal concentrative93 . . . 652 261/588 (44%)e−139nucleoside transporter 1 (CNT1) -74 . . . 643 372/588 (62%)Rattus sp, 648 aa. [WO9835990-A1, 20-AUG-1998]AAW70260Human concentrative nucleoside93 . . . 652 261/589 (44%)e−138transporter 1 hCNT1c - Homo74 . . . 643 369/589 (62%)sapiens, 649 aa. [WO9835990-A1, 20-AUG-1998]

In a BLAST search of public sequence databases, the NOV80a protein was found to have homology to the proteins shown in the BLASTP data in Table 80D.

TABLE 80DPublic BLASTP Results for NOV80aNOV80aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueCAD42381Sequence 1 from Patent1 . . . 665661/665 (99%)0.0WO0218439 - Homo sapiens1 . . . 665662/665 (99%)(Human), 665 aa.Q9HAS3Concentrative Na+-nucleoside1 . . . 665662/691 (95%)0.0cotransporter hCNT3 - Homo1 . . . 691663/691 (95%)sapiens (Human), 691 aa.Q9ERH8Concentrative Na+-nucleoside1 . . . 663514/689 (74%)0.0cotransporter mCNT3 - Mus19 . . . 701 584/689 (84%)musculus (Mouse), 703 aa.Q8BWE2Solute carrier family 28 - Mus1 . . . 663513/689 (74%)0.0musculus (Mouse), 703 aa.19 . . . 701 583/689 (84%)Q91VD7Solute carrier family 28 (Sodium-1 . . . 663511/689 (74%)0.0coupled nucleoside transporter),19 . . . 701 584/689 (84%)member 3 (Concentrative Na+-nucleoside cotransporter) - Musmusculus (Mouse), 703 aa.

PFam analysis indicates that the NOV80a protein contains the domains shown in the Table 80E.

TABLE 80EDomain Analysis of NOV80aIdentities/NOV80aSimilarities forPfam DomainMatch Regionthe Matched RegionExpect ValueNrfD 97 . . . 357 67/387 (17%)0.23179/387 (46%)Nucleoside_tra2198 . . . 587175/427 (41%)1.1e−157312/427 (73%)

Example 81

The NOV81 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 81A.

TABLE 81ANOV81 Sequence AnalysisNOV81a, CG99650-01SEQ ID NO: 11271258 bpDNA SequenceORF Start: ATG at 83ORF Stop: TGA at 1160TGTTACCTGGAGACCCTCTGAGCTCTCACCTGCTACTTCIGCCGCTGCTTCTGCACAGAGCCCGGGCGAGGACCCCTCCAGGATGCAGGTCCCGAACAGCACCGGCCCGGACAACGCGACGCTGCAGATGCTGCGGAACCCGGCGATCGCGGTGGCCCTGCCCGTGGTGTACTCGCTGGTGGCGGCGGTCAGCATCCCGGGCAACCTCTTCTCTCTGTGGGTGCTGTGCCGGCGCATGGGGCCCAGATCCCCGTCGGTCATCTTCATGATCAACCTGAGCGTCACGGACCTGATGCTGGCCAGCGTGTTGCCTTTCCAAATCTACTACCATTGCAACCGCCACCACTGGGTATTCGGGGTGCTGCTTTGCAACGTGGTGACCGTGGCCTTTTACGCAAACATGTATTCCAGCATCCTCACCATGACCTGTATCAGCGTGGAGCGCTTCCTGGGGGTCCTGTACCCGCTCAGCTCCAAGCGCTGGCGCCGCCGTCGTTACGCGGTGGCCGCGTGTGCAGGGACCTGGCTGCTGCTCCTGACCGCCCTGTCCCCGCTGGCGCGCACCGATCTCACCTACCCGGTGCACGCCCTGGGCATCATCACCTGCTTCGACGTCCTCAAGTGGACGATGCTCCCCAGCGTGGCCATGTGGGCCGTGTTCCTCTTCACCATCTTCATCCTGCTGTTCCTCATCCCGTTCGTGATCACCGTGGCTTGTTACACGGCCACCATCCTCAAGCTGTTGCGCACGGAGGAGGCGCACGGCCGGGAGCAGCGGAGGCGCGCGGTGGGCCTGGCCGCGGTGGTCTTGCTGGCCTTTGTCACCTGCTTCGCCCCCAACAACTTCGTGCTCCTGGCGCACATCGTGAGCCGCCTGTTCTACGGCAAGAGCTACTACCACGTGTACAAAGTCACGCTGTGTCTCAGCTGCCTCAACAACTGTCTGGACCCGTTTGTTTATTACTTTGCGTCCCGGGAATTCCAGCTGCGCCTGCGGGAATATTTGGGCTGCCGCCGGGTGCCCAGAGACACCCTGGACACGCGCCGCGAGAGCCTCTTCTCCGCCAGGACCACGTCCGTGCGCTCCGAGGCCGGTGCGCACCCTGAAGGGATGGAGGGAGCCACCAGGCCCGGCCTCCAGAGGCAGGAGAGTGTGTTCTGAGTCCCGGGGGCGCAGCTTGGAGAGCCGGGGGCGCAGCTTGGAGATCCAGGGGCGCATGGAGAGGCCACGGTGCCAGAGGTTCAGGGAGAACAGCTGNOV81a, CG99650-01SEQ ID NO: 1128359 aaMW at 40620.4kDProtein SequenceMQVPNSTGPDNATLQMLRNPAIAVALPVVYSLVAAVSIPGNLFSLWVLCRRNGPRSPSVIFMINLSVTDLMLASVLPFQIYYHCNRHHWVFGVLLCNVVTVAFYANMYSSILTMTCISVERFLGVLYPLSSKRWRRRRYAVAACAGTWLLLLTALSPLARTDLTYPVHALGIITCFDVLKWTMLPSVAMWAVFLFTIFILLFLIPFVITVACYTATILKLLRTEEAHGREQRRRAVGLAAVVLLAFVTCFAPNNFVLLAHIVSRLFYGKSYYHVYKVTLCLSCLNNCLDPFVYYFASREFQLRLREYLGCRRVPRDTLDTRRESLFSARTTSVRSEAGAHPEGMEGATRPGLQRQESVFNOV81b, SNP13382525SEQ ID NO: 11291258 bpof CG99650-01,ORF Start: ATG at 83ORF Stop: TGA at 1160DNA SequenceSNP Pos: 910SNP Change: A to GTGTTACCTGGAGACCCTCTGAGCTCTCACCTGCTACTTCTGCCGCTGCTTCTGCACAGAGCCCGGGCGAGGACCCCTCCAGGATGCAGGTCCCGAACAGCACCGGCCCGGACAACGCGACGCTGCAGATGCTGCGGAACCCGGCGATCGCGGTGGCCCTGCCCGTGGTGTACTCGCTGGTGGCGGCGGTCAGCATCCCGGGCAACCTCTTCTCTCTGTGGGTGCTGTGCCGGCGCATGGGGCCCAGATCCCCGTCGGTCATCTTCATGATCAACCTGAGCGTCACGGACCTGATGCTGGCCAGCGTGTTGCCTTTCCAAATCTACTACCATTGCAACCGCCACCACTGGGTATTCGGGGTGCTGCTTTGCAACGTGGTGACCGTGGCCTTTTACGCAAACATGTATTCCAGCATCCTCACCATGACCTGTATCAGCGTGGAGCGCTTCCTGGGGGTCCTGTACCCGCTCAGCTCCAAGCGCTGGCGCCGCCGTCGTTACGCGGTGGCCGCGTGTGCAGGGACCTGGCTGCTGCTCCTGACCGCCCTGTCCCCGCTGGCGCGCACCGATCTCACCTACCCGGTGCACGCCCTGGGCATCATCACCTGCTTCGACGTCCTCAAGTGGACGATGCTCCCCAGCGTGGCCATGTGGGCCGTGTTCCTCTTCACCATCTTCATCCTGCTGTTCCTCATCCCGTTCGTGATCACCGTGGCTTGTTACACGGCCACCATCCTCAAGCTGTTGCGCACGGAGGAGGCGCACGGCCGGGAGCAGCGGAGGCGCGCGGTGGGCCTGGCCGCGGTGGTCTTGCTGGCCTTTGTCACCTGCTTCGCCCCCAACAACTTCGTGCTCCTGGCGCACATCGTGAGCCGCCTGTTCTACGGCAAGAGCTACTACCACGTGTACAAGGTCACGCTGTGTCTCAGCTGCCTCAACAACTGTCTGGACCCGTTTGTTTATTACTTTGCGTCCCGGGAATTCCAGCTGCGCCTGCGGGAATATTTGGGCTGCCGCCGGGTGCCCAGAGACACCCTGGACACGCGCCGCGAGAGCCTCTTCTCCGCCAGGACCACGTCCGTGCGCTCCGAGGCCGGTGCGCACCCTGAAGGGATGGAGGGAGCCACCAGGCCCGGCCTCCAGAGGCAGGAGAGTGTGTTCTGAGTCCCGGGGGCGCAGCTTGGAGAGCCGGGGGCGCAGCTTGGAGATCCAGGGGCGCATGGAGAGGCCACGGTGCCAGAGGTTCAGGGAGAACAGCTGNOV81b, SNP13382525SEQ ID NO: 1130359 aaMW at 40620.4kDof CG99650-01,SNP Pos: 276SNP Change: Lys to LysProtein SequenceMQVPNSTGPDNATLQMLRNPAIAVALPVVYSLVAAVSIPGNLFSLWVLCRRMGPRSPSVIFMINLSVTDLMLASVLPFQIYYHCNRHHWVFGVLLCNVVTVAFYANNYSSILTMTCISVERFLGVLYPLSSKRWRRRRYAVAACAGTWLLLLTALSPLARTDLTYPVHALGIITCFDVLKWTMLPSVAMWAVFLFTIFILLFLIPFVITVACYTATILKLLRTEEAHGREQRRRAVGLAAVVLLAFVTCFAPNNFVLLAHIVSRLFYGKSYYHVYKVTLCLSCLNNCLDPFVYYFASREFQLRLREYLGCRRVPRDTLDTRRESLFSARTTSVRSEAGAHPEGMEGATRPGLQRQESVFNOV81c, SNP13382526SEQ ID NO: 11311258 bpof CG99650-01,ORF Start: ATG at 83ORF Stop: TGA at 1160DNA SequenceSNP Pos: 911SNP Change: G to CTGTTACCTGGAGACCCTCTGAGCTCTCACCTGCTACTTCTGCCGCTGCTTCTGCACAGAGCCCGGGCGAGGACCCCTCCAGGATGCAGGTCCCGAACAGCACCGGCCCGGACAACGCGACGCTGCAGATGCTGCGGAACCCGGCGATCGCGGTGGCCCTGCCCGTGGTGTACTCGCTGGTGGCGGCGGTCAGCATCCCGGGCAACCTCTTCTCTCTGTGGGTGCTGTGCCGGCGCATGGGGCCCAGATCCCCGTCGGTCATCTTCATGATCAACCTGAGCGTCACGGACCTGATGCTGGCCAGCGTGTTGCCTTTCCAAATCTACTACCATTGCAACCGCCACCACTGGGTATTCGGGGTGCTGCTTTGCAACGTGGTGACCGTGGCCTTTTACGCAAACATGTATTCCAGCATCCTCACCATGACCTGTATCAGCGTGGAGCGCTTCCTGGGGGTCCTGTACCCGCTCAGCTCCAAGCGCTGGCGCCGCCGTCGTTACGCGGTGGCCGCGTGTGCAGGGACCTGGCTGCTGCTCCTGACCGCCCTGTCCCCGCTGGCGCGCACCGATCTCACCTACCCGGTGCACGCCCTGGGCATCATCACCTGCTTCGACGTCCTCAAGTGGACGATGCTCCCCAGCGTGGCCATGTGGGCCGTGTTCCTCTTCACCATCTTCATCCTGCTGTTCCTCATCCCGTTCGTGATCACCGTGGCTTGTTACACGGCCACCATCCTCAAGCTGTTGCGCACGGAGGAGGCGCACGGCCGGGAGCAGCGGAGGCGCGCGGTGGGCCTGGCCGCGGTGGTCTTGCTGGCCTTTGTCACCTGCTTCGCCCCCAACAACTTCGTGCTCCTGGCGCACATCGTGAGCCGCCTGTTCTACGGCAAGAGCTACTACCACGTGTACAAACTCACGCTGTGTCTCAGCTGCCTCAACAACTGTCTGGACCCGTTTGTTTATTACTTTGCGTCCCGGGAATTCCAGCTGCGCCTGCGGGAATATTTGGGCTGCCGCCGGGTGCCCAGAGACACCCTGGACACGCGCCGCGAGAGCCTCTTCTCCGCCAGGACCACGTCCGTGCGCTCCGAGGCCGGTGCGCACCCTGAAGGGATGGAGGGAGCCACCAGGCCCGGCCTCCAGAGGCAGGAGAGTGTGTTCTGAGTCCCGGGGGCGCAGCTTGGAGAGCCGGGGGCGCAGCTTGGAGATCCAGGGGCGCATGGAGAGGCCACGGTGCCAGAGGTTCAGGGAGAACAGCTGNOV81c, SNP13382526SEQ ID NO: 1132359 aaMW at 40634.5kDof CG99650-01,SNP Pos: 277SNP Change: Val to LeuProtein SequenceMQVPNSTGPDNATLQMLRNPAIAVALPVVYSLVAAVSIPGNLFSLWVLCRRNGPRSPSVIFMINLSVTDLMLASVLPFQIYYHCNRHHWVFGVLLCNVVTVAFYANMYSSILTMTCISVBRFLGVLYPLSSKRWRRRRYAVAACAGTWLLLLTALSPLARTDLTYPVHALGIITCFDVLKWTMLPSVAMWAVFLFTIFILLFLIPFVITVACYTATILKLLRTEEAHGREQRRRAVGLAAVVLLAFVTCFAPNNFVLLAHIVSRLFYGKSYYHVYKLTLCLSCLNNCLDPFVYYFASREFQLRLREYLGCRRVPRDTLDTRRESLFSARTTSVRSEAGAHPEGMEGATRPGLQRQESVF

A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 81B.

TABLE 81BComparison of the NOV81 protein sequences.NOV79aMGACHHAWLIFVFLVEMGFHHVGQACLPLSLVILLDSKASQAELGWTALPSNGWEEISGVNOV79b----------------------------TGSVILLDSKASQAELGWTALPSNGWEEISGVNOV79c------------------------------------------------------------NOV79aDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGTCKENOV79bDEHDRPIRTYQVCNVLEPNQDNWLQTGWISRGRGQRIFVELQFTLRDCSSIPGAAGTCKENOV79c------------------------------------------------------------NOV79aTFNVYYLETEADLGRGRPRLGG----KIDTIAADESFTQGDLGERKMKLNTEVREIGPLSNOV79bTFNVYYLETEADLGRGRPRLGGSRPRKIDTIAADESFTQGDLGERKMKLNTEVREIGPLSNOV79c------------------------------------------------------------NOV79aRRGFHLAFQDVGACVALVSVRVYYKQCRATVRGLATFPATAAESAFSTLVEVAGTCVAHSNOV79bRRGFHLAFQDVGACVALVSVRVYYKQCVDG------------------------------NOV79c------------------------------------------------------------NOV79aEGEPGSPPRMHCGADGEWLVPVGRCSCSAGFQERGDFCEGICPPGFYKVSPRRPLCSPCPNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aEHSRALENASTFCVCQDSYARSPTDPPSASCTRPPSAPRDLQYSLSRSPLVLRLRWLPPANOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aDSGGRSDVTYSLLCLRCGREGPAGACEGPRVAFLPRQAGLRERAATLLHLRPGARYTVRVNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aAALNGVSGPAAAAGTTYAQVTVSTGPGGKAVRAPHPEATAPAAPAPSWGRPVGPAGSAPWNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aEEDEIRRDRVEPQSVSLSWREPIPAGAPGANDTEYEIRYYEKVSAQSEQTYSMVKTGAPTNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aVTVIFLPAASGSRDQSPAIVVTVVTISALLVLGSVMSVLAIWRRRPCSYGKGGGDAHDEENOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aELYFHCELAGKVPTRRTFLDPQSCGDLLQAVHLFAKELDAKSVTLERSLGGGKLGGRFGENOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aLCCGCLQLPGRQELLVAVHMLRDSASDSQRLGFLAEALTLGQFDHSHIVRLEGVVTRGRGNOV79b------------------------------------------------------------NOV79c-----------TGSLVAVHMLRDSASDSQRLGFLAEALTLGQFDHSHIVRLEGVVTRG--NOV79aSTLMIVTEYMSHGALDGFLRQRHEGQLVAGQLMGLLPGLASAMKYLSEMGYVHRGLAARHNOV79b------------------------------------------------------------NOV79cSTLMIVTEYMSHGALDGFLRR-HEGQLVAGQLMGLLPGLASAMKYLSEMGYVHRGLAARHNOV79aVLVSSDLVCKISGFGRGPRDRSEAVYTTMVRLQSGRSPALWAAPETLQFGHFSSASDVWSNOV79b------------------------------------------------------------NOV79cVLVSSDLVCKISGFGRGPRDRSEAVYTTMS----GRSPALWAAPETLQFGHFSSASDVWSNOV79aFGIIMWEVMAFGERPYWDMSGQDVVIKAVEDGFRLPPPRNCPNLLHRLMLDCWQKDPGERNOV79b------------------------------------------------------------NOV79cFGIIMWEVMAFGERPYWDMSGQ-DVIKAVEDGFRLPPPRNCPNLLHRLMLDCWQKDPGERNOV79aPRFSQIHSILSKMVQDPEPPKCALTTCPRPLTRRPPTPLADRAFSTFPSFGSVGAWLEALNOV79b------------------------------------------------------------NOV79cPRFSQIHVDG--------------------------------------------------NOV79aDLCRYKDSFAAAGYGSLEAVAEMTSQDLVSLGISLAEHREALLSGISALQARVLQLQGQGNOV79b------------------------------------------------------------NOV79c------------------------------------------------------------NOV79aVQVNOV79b---NOV79c---NOV81a(SEQ ID NO: 1128)

Further analysis of the NOV81a protein yielded the following properties shown in Table 81C.

TABLE 81CProtein Sequence Properties NOV81aSignalP analysis:Cleavage site between residues 38 and 39PSORT II analysis:PSG:a new signal peptide prediction methodN-region: length 10; pos.chg 0; neg.chg 1H-region: length 7; peak value 0.00PSG score: −4.40GvH:von Heijne's method for signal seq. recognitionGvH score (threshold: −2.1): −4.98possible cleavage site: between 49 and 50>>> Seems to have no N-terminal signal peptideALOM:Klein et al's method for TM region allocationInit position for calculation: 1Tentative number of TMS(s) for the threshold 0.5: 6INTEGRALLikelihood = −7.11Transmembrane 22-38INTEGRALLikelihood = −2.76Transmembrane 59-75INTEGRALLikelihood = −3.50Transmembrane 89-105INTEGRALLikelihood = −2.28Transmembrane 140-156INTEGRALLikelihood = −14.01Transmembrane 192-208INTEGRALLikelihood = −9.18Transmembrane 235-251PERIPHERALLikelihood = 1.22 (at 110)ALOM score: −14.01 (number of TMSs: 6)MTOP:Prediction of membrane topology (Hartmann et al.)Center position for calculation: 29Charge difference: 3.0 C(3.0) − N(0.0)C > N: C-terminal side will be inside>>> membrane topology: type 3bMITDISC: discrimination of mitochondrial targeting seqR content:4Hyd Moment(75):2.17Hyd Moment(95):4.19G content:3D/E content:2S/T content:10Score: −2.58Gavel:prediction of cleavage sites for mitochondrial preseqR-2 motif at 232 LRT|EENUCDISC: discrimination of nuclear localization signalspat4: RRRR (5) at 135pat7: nonebipartite: nonecontent of basic residues: 9.7%NLS Score: −0.16KDEL: ER retention motif in the C-terminus: noneER Membrane Retention Signals: noneSKL: peroxisomal targeting signal in the C-terminus: nonePTS2: 2nd peroxisomal targeting signal: noneVAC: possible vacuolar targeting motif: noneRNA-binding motif: noneActinin-type actin-binding motif:type 1: nonetype 2: noneNMYR: N-myristoylation pattern: nonePrenylation motif: nonememYQRL: transport motif from cell surface to Golgi: noneTyrosines in the tail: noneDileucine motif in the tail: nonechecking 63 PROSITE DNA binding motifs: nonechecking 71 PROSITE ribosomal protein motifs: nonechecking 33 PROSITE prokaryotic DNA binding motifs: noneNNCN:Reinhardt's method for Cytoplasmic/Nuclear discriminationPrediction: cytoplasmicReliability: 94.1COIL:Lupas's algorithm to detect coiled-coil regionstotal: 0 residuesFinal Results (k = 9/23):44.4%: endoplasmic reticulum22.2%: vacuolar11.1%: Golgi11.1%: vesicles of secretory system11.1%: mitochondrial>> prediction for CG99650-01 is end (k = 9)

A search of the NOV81a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 81D.

TABLE 81DGeneseq Results for NOV81aNOV81aIdentities/Residues/Similarities forGeneseqProtein/Organism/LengthMatchthe MatchedExpectIdentifier[Patent #, Date]ResiduesRegionValueABB82503Human TGR341 polypeptide -1 . . . 359358/359 (99%)0.0Homo sapiens, 359 aa.1 . . . 359359/359 (99%)[WO200277001-A2, 03-OCT-2002]ABG73502Human G protein coupled1 . . . 359358/359 (99%)0.0receptor HGPRBMY1 - Homo1 . . . 359359/359 (99%)sapiens, 359 aa. [WO200268591-A2, 06-SEP-2002]ABP81677Human LS160435 receptor1 . . . 359358/359 (99%)0.0protein SEQ ID NO: 530 - Homo1 . . . 359359/359 (99%)sapiens, 359 aa. [WO200261087-A2, 08-AUG-2002]ABG93784Human G protein-coupled1 . . . 359358/359 (99%)0.0receptor protein, nGPCR-5-1 . . . 359359/359 (99%)Homo sapiens, 359 aa.[WO200264789-A1, 22-AUG-2002]AAB62285Human G-protein coupled1 . . . 359358/359 (99%)0.0receptor, PAUL - Homo sapiens,1 . . . 359359/359 (99%)359 aa. [WO200125280-A1, 12-APR-2001]

In a BLAST search of public sequence databases, the NOV81a protein was found to have homology to the proteins shown in the BLASTP data in Table 81E.

TABLE 81EPublic BLASTP Results for NOV81aNOV81aIdentities/ProteinResidues/Similarities forAccessionMatchthe MatchedExpectNumberProtein/Organism/LengthResiduesPortionValueAAH43610Hypothetical protein - Homo 1 . . . 359358/359 (99%)0.0sapiens (Human), 359 aa. 1 . . . 359359/359 (99%)Q8NH25Seven transmembrane helix 16 . . . 218200/203 (98%) e−112receptor - Homo sapiens 1 . . . 203200/203 (98%)(Human), 258 aa.P47749Proteinase activated receptor 1 15 . . . 313111/300 (37%)4e−54precursor (PAR-1) (Thrombin 93 . . . 386172/300 (57%)receptor) - Xenopus laevis(African clawed frog), 420 aa.A37912thrombin receptor precursor - 22 . . . 311106/292 (36%)5e−53human, 425 aa.101 . . . 389167/292 (56%)P56488Proteinase activated receptor 1 22 . . . 311106/292 (36%)9e−53precursor (PAR-1) (Thrombin101 . . . 389166/292 (56%)receptor) - Papio hamadryas(Hamadryas baboon), 425 aa.

PFam analysis indicates that the NOV81a protein contains the domains shown in the Table 81F.

TABLE 81FDomain Analysis of NOV81aIdentities/NOV81a MatchSimilarities forPfam DomainRegionthe Matched RegionExpect ValueAcyl_transf_3 9 . . . 27444/468 (9%)0.76178/468 (38%)7tm_140 . . . 293 76/276 (28%)5.3e−50193/276 (70%)

Example B
Sequencing Methodology and Identification of NOVX Clones

1. GeneCalling™ Technology: This is a proprietary method of performing differential gene expression profiling between two or more samples developed at CuraGen and described by Shimkets, et al., “Gene expression analysis by transcript profiling coupled to a gene database query” Nature Biotechnology 17:198-803 (1999). cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then digested with up to as many as 120 pairs of restriction enzymes and pairs of linker-adaptors specific for each pair of restriction enzymes were ligated to the appropriate end. The restriction digestion generates a mixture of unique cDNA gene fragments. Limited PCR amplification is performed with primers homologous to the linker adapter sequence where one primer is biotinylated and the other is fluorescently labeled. The doubly labeled material is isolated and the fluorescently labeled single strand is resolved by capillary gel electrophoresis. A computer algorithm compares the electropherograms from an experimental and control group for each of the restriction digestions. This and additional sequence-derived information is used to predict the identity of each differentially expressed gene fragment using a variety of genetic databases. The identity of the gene fragment is confirmed by additional, gene-specific competitive PCR or by isolation and sequencing of the gene fragment.

2. SeqCalling™ Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then sequenced using CuraGen's proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.

3. PathCalling™ Technology: The NOVX nucleic acid sequences are derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, are sequenced. In silico prediction was based on sequences available in CuraGen Corporation's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

The laboratory screening was performed using the methods summarized below: cDNA libraries were derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then directionally cloned into the appropriate two-hybrid vector (Gal4-activation domain (Gal4-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, Calif.) were then transferred from E. coli into a CuraGen Corporation proprietary yeast strain (disclosed in U.S. Pat. Nos. 6,057,101 and 6,083,693, incorporated herein by reference in their entireties).

Gal4-binding domain (Gal4-BD) fusions of a CuraGen Corportion proprietary library of human sequences was used to screen multiple Gal4-AD fusion cDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Gal4-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non-specific primers at the cDNA insert boundaries. Such PCR product was sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.

Physical clone: the cDNA fragment derived by the screening procedure, covering the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) used to make the cDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by the mating of both CuraGen Corporation proprietary yeast strains N106′ and YULH (U.S. Pat. Nos. 6,057,101 and 6,083,693).

4. RACE: Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the sequence of the cDNA of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. Various human tissue samples from different donors were used for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in preceding paragraphs.

5. Exon Linking: The NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain—amygdala, brain—cerebellum, brain—hippocampus, brain—substantia nigra, brain—thalamus, brain—hole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma—Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

6. Physical Clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clones used for expression and screening purposes.

Example C
Quantitative Expression Analysis of Clones in Various Cells and Tissues

The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoinflammatory diseases), Panel CNSD.01 (containing samples from normal and diseased brains) and CNS_neurodegeneration panel (containing samples from normal and Alzheimer's diseased brains).

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.

In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 μg of total RNA were performed in a volume of 20 μl and incubated for 60 minutes at 42° C. This reaction can be scaled up to 50 μg of total RNA in a final volume of 100 μl. sscDNA samples are then normalized to reference nucleic acids as described previously, using 1× TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration=250 nM, primer melting temperature (T_m) range=58°-60° C., primer optimal T_m=59° C., maximum primer difference=2° C., probe does not have 5′ G, probe T_mmust be 10° C. greater than primer T_m, amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, Tex., USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5′ and 3′ ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200 nM.

PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 48° C. for 30 minutes followed by amplification/PCR cycles as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100. CT values below 28 indicate high expression, CT values between 28 and 32 indicate moderate expression, and CT values between 32 and 35 indicate low expression. CT values above 35 reflect levels of expression that are too low to be reliably measured.

When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1× TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification was performed as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were analyzed and processed as described previously.

Panels 1, 1.1, 1.2, and 1.3D

The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:

- ca.=carcinoma,
- *=established from metastasis,
- met=metastasis,
- s cell var=small cell variant,
- non-s=non-sm=non-small,
- squam=squamous,
- pl. eff=pl effusion=pleural effusion,
- glio=glioma,
- astro=astrocytoma, and
- neuro=neuroblastoma.
  
  General_Screening_Panel_V1.4, V1.5, V1.6 and 1.7

The plates for Panels 1.4, 1.5, 1.6 and 1.7 include 2 control wells (genomic DNA control and chemistry control) and 88 to 94 wells containing cDNA from various samples. The samples in Panels 1.4, 1.5, 1.6 and 1.7 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panels 1.4, 1.5, 1.6 and 1.7 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panels 1.4, 1.5, 1.6 and 1.7 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.

Panels 2D, 2.2, 2.3, and 2.4

The plates for Panels 2D, 2.2, 2.3 and 2.4 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI) or from Ardais or Clinomics). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have “matched margins” obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted “NAT” in the results below. The tumor tissue and the “matched margins” are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI/CHTN/Ardais/Clinomics). Unmatched RNA samples from tissues without malignancy (normal tissues) were also obtained from Ardais or Clinomics. This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, Calif.), Research Genetics, and Invitrogen.

HASS Panel V 1.0

The HASS panel v 1.0 plates are comprised of 93 cDNA samples and two controls. Specifically, 81 of these samples are derived from cultured human cancer cell lines that had been subjected to serum starvation, acidosis and anoxia for different time periods as well as controls for these treatments, 3 samples of human primary cells, 9 samples of malignant brain cancer (4 medulloblastomas and 5 glioblastomas) and 2 controls. The human cancer cell lines are obtained from ATCC (American Type Culture Collection) and fall into the following-tissue groups: breast cancer, prostate cancer, bladder carcinomas, pancreatic cancers and CNS cancer cell lines. These cancer cells are all cultured under standard recommended conditions. The treatments used (serum starvation, acidosis and anoxia) have been previously published in the scientific literature. The primary human cells were obtained from Clonetics (Walkersville, Md.) and were grown in the media and conditions recommended by Clonetics. The malignant brain cancer samples are obtained as part of a collaboration (Henry Ford Cancer Center) and are evaluated by a pathologist prior to CuraGen receiving the samples. RNA was prepared from these samples using the standard procedures. The genomic and chemistry control wells have been described previously.

ARDAIS Panel V 1.0

The plates for ARDAIS panel v 1.0 generally include 2 control wells and 22 test samples composed of RNA isolated from human tissue procured by surgeons working in close cooperation with Ardais Corporation. The tissues are derived from human lung malignancies (lung adenocarcinoma or lung squamous cell carcinoma) and in cases where indicated many malignant samples have “matched margins” obtained from noncancerous lung tissue just adjacent to the tumor. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue) in the results below. The tumor tissue and the “matched margins” are evaluated by independent pathologists (the surgical pathologists and again by a pathologist at Ardais). Unmatched malignant and non-malignant RNA samples from lungs were also obtained from Ardais. Additional information from Ardais provides a gross histopathological assessment of tumor differentiation grade and stage. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical state of the patient.

ARDAIS Prostate V 1.0

The plates for ARDAIS prostate 1.0 generally include 2 control wells and 68 test samples composed of RNA isolated from human tissue procured by surgeons working in close cooperation with Ardais Corporation. The tissues are derived from human prostate malignancies and in cases where indicated malignant samples have “matched margins” obtained from noncancerous prostate tissue just adjacent to the tumor. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue) in the results below. The tumor tissue and the “matched margins” are evaluated by independent pathologists (the surgical pathologists and again by a pathologist at Ardais). RNA from unmatched malignant and non-malignant prostate samples were also obtained from Ardais. Additional information from Ardais provides a gross histopathological assessment of tumor differentiation grade and stage. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical state of the patient.

ARDAIS Kidney V 1.0

The plates for ARDAIS kidney 1.0 generally include 2 control wells and 44 test samples composed of RNA isolated from human tissue procured by surgeons working in close cooperation with Ardais Corporation. The tissues are derived from human prostate malignancies and in cases where indicated malignant samples have “matched margins” obtained from noncancerous prostate tissue just adjacent to the tumor. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue) in the results below. The tumor tissue and the “matched margins” are evaluated by independent pathologists (the surgical pathologists and again by a pathologist at Ardais). RNA from unmatched malignant and non-malignant prostate samples were also obtained from Ardais. Additional information from Ardais provides a gross histopathological assessment of tumor differentiation grade and stage. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical state of the patient.

Panel 3D and 3.1 and 3.2

The plates of Panel 3D, 3.1, and 3.2 are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D, 3.1, 3.2, 1, 1.1, 1.2, 1.3D, 1.4, 1.5, and 1.6 are of the most common cell lines used in the scientific literature.

Panels 4D, 4R, and 4.1D

Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, Calif.) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, Calif.). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, Pa.).

Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, Md.) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco/Life Technologies, Rockville, Md.), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μg/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μg/ml. Samples were taken at 24,48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×10⁶cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10⁻⁵M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, Utah), 100 4M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μg/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), and 10 mM Hepes (Gibco) and plated at 10⁶cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μg/ml anti-CD28 (Pharmingen) and 3 ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 10⁶cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μg/ml or anti-CD40 (Pharmingen) at approximately 10 μg/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μg/ml anti-CD28 (Pharmingen) and 2 μg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes 6 (Poietic Systems, German Town, Md.) were cultured at 10⁵-10⁶cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL-4 (1 μg/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μg/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μg/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×10⁵cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10⁵cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10⁻⁵M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately 10⁷cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at −20 degrees C. overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μl of RNAse-free water and 35 μl buffer (Promega) 5 μl DTT, 7 μl RNAsin and 8 μl DNAse were added. The tube was incubated at 37 degrees C. for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at −80 degrees C.

AI_comprehensive panel_v1.0

The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, Md.). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.

Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.

Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.

Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-lanti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:

- AI=Autoimmunity
- Syn=Synovial
- Normal=No apparent disease
- Rep22/Rep20=individual patients
- RA=Rheumatoid arthritis
- Backus=From Backus Hospital
- OA=Osteoarthritis
- (SS) (BA) (MF)=Individual patients
- Adj=Adjacent tissue
- Match control=adjacent tissues
- −M=Male
- −F=Female
- COPD=Chronic obstructive pulmonary disease
  
  AI.05 Chondrosarcoma

The AI.05 chondrosarcoma plates are comprised of SW1353 cells that had been subjected to serum starvation and treatment with cytokines that are known to induce MMP (1, 3 and 13) synthesis (eg. IL1beta). These treatments include: IL-1β (10 ng/ml), IL-1β, +TNF-α (50 ng/ml), IL-1β+Oncostatin (50 ng/ml) and PMA (100 ng/ml). The SW1353 cells were obtained from the ATCC (American Type Culture Collection) and were all cultured under standard recommended conditions. The SW1353 cells were plated at 3×10⁵cells/ml (in DMEM medium-10% FBS) in 6-well plates. The treatment was done in triplicate, for 6 and 18 h. The supernatants were collected for analysis of MMP 1, 3 and 13 production and for RNA extraction. RNA was prepared from these samples using the standard procedures.

Panels 5D and 5I

The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

In the Gestational Diabetes study subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:

- Patient 2 Diabetic Hispanic, overweight, not on insulin
- Patient 7-9 Nondiabetic Caucasian and obese (BMI>30)
- Patient 10 Diabetic Hispanic, overweight, on insulin
- Patient 11 Nondiabetic African American and overweight
- Patient 12 Diabetic Hispanic on insulin

Adipocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr. 2, 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:

Donor 2 and 3 UMesenchymalUndifferentiated AdiposeStem cellsDonor 2 and 3 AMAdiposeAdiposeMidway DifferentiatedDonor 2 and 3 ADAdiposeAdipose Differentiated

Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.

Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.

In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:

GO Adipose=Greater Omentum Adipose
SK=Skeletal Muscle
UT=Uterus
PL=Placenta
AD=Adipose Differentiated
AM=Adipose Midway Differentiated.
U=Undifferentiated Stem Cells

Human Metabolic RTQ-PCR Panel

The plates for the Human Metabolic RTQ-PCR Panel include two control wells (genomic DNA control and chemistry control) and 211 cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. This panel is useful for establishing the tissue and cellular expression profiles for genes believed to play a role in the etiology and pathogenesis of obesity and/or diabetes and to confirm differential expression of such genes derived from other methods.

Metabolic tissues were obtained from patients enrolled in the CuraGen Gestational Diabetes study and from autopsy tissues from Type II diabetics and age, sex and race-matched control patients. One or more of the following were used to characterize the patients: body mass index [BMI=wt (kg)/ht (m²)], serum glucose, HgbA1c. Cell lines used in this panel are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines. RNA from human Pancreatic Islets was also obtained.

In the Gestational Diabetes study, subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarian section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted, and then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus), and subcutaneous adipose. Patient descriptions are as follows:

- Patient 7 Non-diabetic Caucasian and obese
- Patient 8 Non-diabetic Caucasian and obese
- Patient 12 Diabetic Caucasian with unknown BMI and on insulin
- Patient 13 Diabetic Caucasian, overweight, not on insulin
- Patient 15 Diabetic Caucasian, obese, not on insulin
- Patient 17 Diabetic Caucasian, normal weight, not on insulin
- Patient 18 Diabetic Hispanic, obese, not on insulin
- Patient 19 Non-diabetic Caucasian and normal weight
- Patient 20 Diabetic Caucasian, overweight, and on insulin
- Patient 21 Non-diabetic Caucasian and overweight
- Patient 22 Diabetic Caucasian, normal weight, on insulin
- Patient 23 Non-diabetic Caucasian and overweight
- Patient 25 Diabetic Caucasian, normal weight, not on insulin
- Patient 26 Diabetic Caucasian, obese, on insulin
- Patient 27 Diabetic Caucasian, obese, on insulin

Total RNA was isolated from metabolic tissues of 12 Type II diabetic patients and 12 matched control patients included hypothalamus, liver, pancreas, small intestine, psoas muscle, diaphragm muscle, visceral adipose, and subcutaneous adipose. The diabetics and non-diabetics were matched for age, sex, ethnicity, and BMI where possible.

The panel also contains pancreatic islets from a 22 year old male patient (with a BMI of 35) obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at CuraGen.

Cell lines used in this panel are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured at an outside facility. The RNA was extracted at CuraGen according to CuraGen protocols. All samples were then processed at CuraGen to produce single stranded cDNA.

In the labels used to identify tissues in the Human Metabolic panel, the following abbreviations are used:

Pl=placenta
Go=greater omentum
Sk=skeletal muscle
Ut=uterus
CC=Caucasian
HI=Hispanic
AA=African American
AS=Asian
Diab=Type H diabetic
Norm=Non-diabetic
Overwt=Overweight; med BMI
Obese=Hi BMI
Low BM=20-25
Med BM=26-30
Hi BMI=Greater than 30
M=Male
#=Patient identifier
Vis.=Visceral
SubQ=Subcutaneous

Panel CNSD.01

The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supernuclear Palsy, Depression, and “Normal controls”. Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

PSP=Progressive supranuclear palsy
Sub Nigra=Substantia nigra
Glob Palladus=Globus palladus
Temp Pole=Temporal pole
Cing Gyr=Cingulate gyrus
BA 4=Brodman Area 4

Panel CNS_Neurodegeneration_V1.0

The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from “Normal controls” who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0=no evidence of plaques, 3=severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a “control” region within AD patients. Not all brain regions are represented in all cases.

In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:

- AD=Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy
- Control=Control brains; patient not demented, showing no neuropathology
- Control (Path)=Control brains; pateint not demented but showing sever AD-like pathology
- SupTemporal Ctx=Superior Temporal Cortex
- Inf Temporal Ctx=Inferior Temporal Cortex

The expression of the gene was analyzed after normalization using scaling factor. The scaling factor is calculated from the Grand mean of CT values for a panel and the Well mean which is specific to the tissue. The Grand mean is the average CT value for all wells across all runs. For example, if a panel has 50 samples and has had 100 probe/primer sets run on it, the grand mean would be the average of these 5000 CT scores. The well mean is tissue-specific. On the above described panel there would be 50 different well means, each taking the average of the 100 CT values generated for each sample on the panel from the 100 probe/primer sets.

The asumption is that across a large number of genes, all samples should have the same CT value. If a well is lower than the average across a large number of genes, it is “scaled up” by that difference or the “scaling factor”.

Scaling Factor=Grand mean−Well mean

The new CT value for the well is:

Scaled CT value=Raw CT+Scaling Factor.

Statistical Analysis of CNS_Neurodegeneration_V1.0 Data

All data were analyzed by analysis of covariance (ANCOVA). As a covariate, the average CT value (or number of rounds of PCR until signal from the well was detected) was calculated for 1000 PCR runs on different genes. This number is therefore an estimate of total cDNA quantity and quality for each sample. When RTQ PCR is run for a given gene, CT values are therefore compared to these average values to correct for differences in well loading or original RNA quality. Stats were run on data from the temporal cortex, as this regions shows sever neurodegeneration in the mid to late stages of the disease, and because the largest number of samples were available for this region giving the most statistical power. Covariates for each well corresponding to Temporal Cortex samples are listed below. The well numbers (10-25) are listed under “Order” in the table of CT values given for each gene run. For this analysis, Controls and Control (Path) cases were grouped together as the intention was to find genes associated with dementia as opposed to amyloid deposition.

10AD133.01411AD232.30912AD334.19513AD432.68914AD5 Inf30.82915AD5 Sup31.51916AD6 Inf31.51717AD6 Sup31.41518Con134.23619Con232.35220Con333.21521Con433.66122Con5 (Path)31.68523Con6 (Path)32.18724Con7 (Path)34.42725Con8 (Path)32.238

Panel CNS_Neurodegeneration_V2.0

The plates for Panel CNS_Neurodegeneration_V2.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains sixteen brains from Alzheimer's disease (AD) patients, and twenty-nine brains from “Normal controls” who showed no evidence of dementia prior to death. The twenty-nine normal control brains are divided into two categories: Fourteen controls with no dementia and no Alzheimer's like pathology (Controls) and fifteen controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0=no evidence of plaques, 3=severe AD senile plaque load). Tissue from the temporal cotex (Broddmann Area 21) was selected for all samples from the Harvard Brain Tissue Resource Center; from the two sample from the Human Brain and Spinal Fluid Resource Center (samples 1 and 2) tissue from the inferior and superior temporal cortex was used; each sample on the panel represents a pool of inferior and superior temporal cortex from an individual patient. The temporal cortex was chosen as it shows a loss of neurons in the intermediate stages of the disease. Selection of a region which is affected in the early stages of Alzheimer's disease (e.g., hippocampus or entorhinal cortex) could potentially result in the examination of gene expression after vulnerable neurons are lost, and missing genes involved in the actual neurodegeneration process.

In the labels employed to identify tissues in the CNS_Neurodegeneration_V2.0 panel, the following abbreviations are used:

- AD=Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy
- Control=Control brains; patient not demented, showing no neuropathology
- AH3=Control brains; pateint not demented but showing sever AD-like pathology
- Inf & Sup Temp Ctx Pool=Pool of inferior and superior temporal cortex for a given individual

A. CG101340-01: Putative G Protein-Coupled Receptor 92

Expression of full-length physical clone CG101340-01 was assessed using the primer-probe set Gpcr41, described in Table AA. Results of the RTQ-PCR runs are shown in Tables AB and AC.

TABLE AAProbe Name Gpcr41StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ggtggtgagcgtgtacatgtg-3′212401133ProbeTET-5′-cagcgacctgctcttcaccctctcg-3′-252731134TAMRAReverse5′-gtaggagagacgaacgggca-3′202991135

TABLE AB

Panel 1.3D

Column A - Rel. Exp.(%) Gpcr41, Run 158144249

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
4.6
Kidney (fetal)
0.7

Pancreas
0.9
Renal ca. 786-0
0.3

Pancreatic ca. CAPAN 2
21.2
Renal ca. A498
0.4

Adrenal gland
8.1
Renal ca. RXF 393
0.7

Thyroid
13.0
Renal ca. ACHN
0.0

Salivary gland
6.2
Renal ca. UO-31
0.0

Pituitary gland
5.5
Renal ca. TK-10
0.0

Brain (fetal)
3.4
Liver
1.0

Brain (whole)
14.9
Liver (fetal)
8.4

Brain (amygdala)
39.2
Liver ca. (hepatoblast) HepG2
3.6

Brain (cerebellum)
6.7
Lung
10.2

Brain (hippocampus)
100.0
Lung (fetal)
2.2

Brain (substantia nigra)
13.7
Lung ca. (small cell) LX-1
21.2

Brain (thalamus)
21.0
Lung ca. (small cell) NCI-H69
0.4

Cerebral Cortex
22.8
Lung ca. (s. cell var.) SHP-77
0.5

Spinal cord
22.4
Lung ca. (large cell)NCI-H460
0.0

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
1.5

glio/astro U-118-MG
0.4
Lung ca. (non-s. cell) NCI-H23
0.3

astrocytoma SW 1783
0.8
Lung ca. (non-s. cell) HOP-62
3.4

neuro*; met SK-N-AS
1.0
Lung ca. (non-s. cl) NCI-H522
0.0

astrocytoma SF-539
2.9
Lung ca. (squam.) SW 900
0.0

astrocytoma SNB-75
0.5
Lung ca. (squam.) NCI-H596
0.0

glioma SNB-19
0.0
Mammary gland
7.2

glioma U251
0.0
Breast ca.* (pl. ef) MCF-7
0.4

glioma SF-295
1.5
Breast ca.* (pl. ef)
11.8

MDA-MB-231

Heart (Fetal)
45.1
Breast ca.* (pl. ef) T47D
0.0

Heart
4.2
Breast ca. BT-549
2.5

Skeletal muscle (Fetal)
36.6
Breast ca. MDA-N
0.5

Skeletal muscle
1.5
Ovary
29.5

Bone marrow
7.7
Ovarian ca. OVCAR-3
0.3

Thymus
10.2
Ovarian ca. OVCAR-4
0.0

Spleen
50.0
Ovarian ca. OVCAR-5
12.6

Lymph node
17.9
Ovarian ca. OVCAR-8
6.9

Colorectal
95.9
Ovarian ca. IGROV-1
0.5

Stomach
18.6
Ovarian ca. (ascites) SK-OV-3
0.4

Small intestine
25.5
Uterus
2.6

Colon ca. SW480
21.9
Placenta
17.0

Colon ca.* SW620
9.9
Prostate
1.9

(SW480 met)

Colon ca. HT29
1.7
Prostate ca.* (bone met) PC-3
1.6

Colon ca. HCT-116
9.9
Testis
15.3

Colon ca. CaCo-2
1.0
Melanoma Hs688(A).T
0.0

CC Well to Mod Diff
72.7
Melanoma* (met) Hs688(B).T
0.0

(ODO3866)

Colon ca. HCC-2998
31.2
Melanoma UACC-62
0.0

Gastric ca. (liver met)
51.4
Melanoma M14
0.0

NCI-N87

Bladder
10.8
Melanoma LOX IMVI
1.4

Trachea
20.0
Melanoma* (met) SK-MEL-5
1.2

Kidney
1.1
Adipose
16.7

TABLE AC

Panel 4D

Column A - Rel. Exp. (%) Gpcr41, Run 142878269

Column B - Rel. Exp. (%) Gpcr41, Run 144060624

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
19.6
72.7
HUVEC IL-1beta
0.0
0.0

Secondary Th2 act
20.2
76.8
HUVEC IFN gamma
0.0
1.8

Secondary Tr1 act
20.7
39.2
HUVEC TNF alpha + IFN gamma
0.0
0.0

Secondary Th1 rest
23.0
22.5
HUVEC TNF alpha +IL4
0.0
1.3

Secondary Th2 rest
44.4
31.0
HUVEC IL-11
0.6
0.2

Secondary Tr1 rest
20.9
18.8
Lung Microvascular EC none
0.7
1.7

Primary Th1 act
14.9
8.7
Lung Microvascular EC TNF alpha +
0.2
1.1

IL-1beta

Primary Th2 act
33.7
17.4
Microvascular Dermal EC none
0.0
0.0

Primary Tr1 act
25.7
12.2
Microsvasular Dermal EC TNFalpha
0.0
0.0

+ IL-1beta

Primary Th1 rest
89.5
36.6
Bronchial epithelium TNFalpha +
25.5
18.4

IL1beta

Primary Th2 rest
56.3
19.5
Small airway epithelium none
8.3
6.3

Primary Tr1 rest
64.2
35.8
Small airway epithelium TNFalpha +
71.7
29.9

IL-1beta

CD45RA CD4
4.6
18.6
Coronery artery SMG rest
0.0
0.0

lymphocyte act

CD45RO CD4
18.2
57.4
Coronery artery SMC TNFalpha +
0.0
0.0

lymphocyte act

IL-1beta

CD8 lymphocyte act
20.3
48.3
Astrocytes rest
0.2
0.0

Secondary CD8
13.9
18.0
Astrocytes TNFalpha + IL-1beta
0.7
1.0

lymphocyte rest

Secondary CD8
17.7
14.2
KU-812 (Basophil) rest
18.3
34.2

lymphocyte act

CD4 lymphocyte none
7.4
6.3
KU-812 (Basophil) PMA/ionomycin
68.3
71.2

2ry Th1/Th2/Tr1 anti-
59.5
49.3
CCD1106 (Keratinocytes) none
17.2
21.9

CD95 CH11

LAK cells rest
23.5
10.2
93580 CCD1106 (Keratinocytes)
100.0
43.5

TNFa and IFNg

LAK cells IL-2
30.4
20.4
Liver cirrhosis
2.7
2.8

LAK cells IL-2 + IL-12
24.8
15.7
Lupus kidney
3.0
2.1

LAK cells IL-2 + IFN
45.1
16.3
NCI-H292 none
21.3
16.4

gamma

LAK cells IL-2 + IL-18
23.2
12.2
NCI-H292 IL-4
16.2
15.3

LAK cells PMA/
2.1
11.9
NCI-H292 IL-9
21.3
9.5

ionomycin

NK Cells IL-2 rest
31.0
100.0
NCI-H292 IL-13
14.8
69.7

Two Way MLR 3 day
21.9
42.3
NCI-H292 IFN gamma
9.6
36.9

Two Way MLR 5 day
14.2
12.6
HPAEC none
0.3
2.0

Two Way MLR 7 day
14.8
9.6
HPAEC TNF alpha + IL-1 beta
0.0
0.5

PBMC rest
10.2
9.1
Lung fibroblast none
0.0
0.0

PBMC PWM
34.6
19.8
Lung fibroblast TNF alpha + IL-1
0.0
0.0

beta

PBMC PHA-L
45.1
32.1
Lung fibroblast IL-4
0.5
0.0

Ramos (B cell) none
18.0
18.8
Lung fibroblast IL-9
0.0
0.0

Ramos (B cell)
37.9
11.0
Lung fibroblast IL-13
0.3
0.0

ionomycin

B lymphocytes PWM
51.8
14.0
Lung fibroblast IFN gamma
0.1
0.6

B lymphocytes CD40L
32.3
20.2
Dermal fibroblast CCD1070 rest
0.4
0.0

and IL-4

EOL-1 dbcAMP
7.3
18.6
Dermal fibroblast CCD1070 TNF
30.8
13.8

alpha

EOL-1 dbcAMP
0.2
2.5
Dermal fibroblast CCD1070 IL-1
0.0
0.0

PMA/ionomycin

beta

Dendritic cells none
2.0
4.8
Dermal fibroblast IFN gamma
0.0
0.0

Dendritic cells LPS
0.4
0.0
Dermal fibroblast IL-4
0.2
0.0

Dendritic cells anti-CD40
0.3
0.6
IBD Colitis 2
4.0
5.5

Monocytes rest
0.8
0.0
IBD Crohn's
2.0
4.5

Monocytes LPS
2.1
1.5
Colon
22.5
20.2

Macrophages rest
10.4
5.2
Lung
5.8
5.7

Macrophages LPS
0.5
1.8
Thymus
2.5
2.0

HUVEC none
0.0
0.0
Kidney
7.7
7.0

HUVEC starved
0.0
0.0

Panel 1.3D Summary: Gpcr41 Expression of the CG101340-01 gene was highest in hippocampus (CT=29.1) and occured at moderate to low levels throughout the brain. This gene encodes a putative GPCR. Several neurotransmitter receptors are GPCRs, including the dopamine receptor family, the serotonin receptor family, the GABAB receptor, muscarinic acetylcholine receptors, and others; thus this GPCR represents novel neurotransmitter receptor. Targeting various neurotransmitter receptors (dopamine, serotonin) has proven to be an effective therapy in psychiatric illnesses such as schizophrenia, bipolar disorder, and depression. Furthermore, the cerebral cortex and hippocampus are regions of the brain that are known to be involved in Alzheimer's disease, seizure disorders, and in the normal process of memory formation. Therapeutic modulation of this gene or its protein product is beneficial in the treatment of one or more of these diseases, as is stimulation and/or blockade of the receptor coded for by the gene.

This gene was also moderately expressed in a number of other normal tissues including colon, ovary and spleen. Expression of this gene was higher in normal cells than in cancer cell lines and CG101340-01 expression was downregulated in ovarian and brain cancer cell lines. Expression of this gene or its protein product is useful as a marker to distinguish normal tissue from ovarian or brain tumors.

Among tissues with metabolic or endocrine function, this gene was expressed at low levels in adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, and liver. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

In addition, expression of the CG101340-01 gene was upregulated in fetal skeletal muscle and heart when compared to adult tissues. The overexpression of this gene in fetal tissue shows that the protein product enhances skeletal muscle or heart growth and development in the fetus and also acts in a regenerative capacity in the adult. Therapeutic modulation of this gene or its protein product is useful in the treatment of muscular dystrophies or heart disease.

Panel 4D Summary: Gpcr41 Expression of the CG101340-01 gene was upregulated in several tissues and cell types after activation, including lymphocytes, keratinocytes, basophils, small airway epithelium and T cells. The GPCR encoded by this gene functions in the inflammatory process by promoting leukocyte extravasation or initiating a signaling cascade that results in the release of immunomodulatory products such as cytokines. Antibody or small molecule therapeutics designed against the protein encoded by this gene are useful for the reduction or inhibition of inflammation due to psoriasis, delayed type hypersensitivity, asthma, or emphysema.

B. CG101396-01: Glutamate Receptor Delta-1

Expression of gene CG101396-01 was assessed using the primer-probe set Ag4211, described in Table BA. Results of the RTQ-PCR runs are shown in Tables BB, BC and BD.

TABLE BAProbe Name Ag4211StartSEQ IDPrimersSequencesLengthPositionNoForward5′-aggacagttcgaatccctatgt-3′2212391136ProbeTET-5′-ccagtttgaaatccttggcactacct-3′-2612611137TAMRAReverse5′-gcatgtctttgccaaaagtct3′2112931138

TABLE BB

General_screening_panel_v1.4

Column A - Rel. Exp.(%) Ag4211, Run 221252466

Tissue Name
A
Tissue Name
A

Adipose
4.6
Renal ca. TK-10
0.0

Melanoma* Hs688(A).T
2.2
Bladder
6.2

Melanoma* Hs688(B).T
1.8
Gastric ca. (liver met.) NCI-N87
0.0

Melanoma* M14
0.0
Gastric ca. KATO III
0.1

Melanoma* LOXIMVI
0.0
Colon ca. SW-948
0.0

Melanoma* SK-MEL-5
18.6
Colon ca. SW480
14.2

Squamous cell carcinoma
0.2
Colon ca.* (SW480 met) SW620
0.0

SCC-4

Testis Pool
5.2
Colon ca. HT29
0.0

Prostate ca.* (bone met)
0.2
Colon ca. HCT-116
19.2

PC-3

Prostate Pool
3.2
Colon ca. CaCo-2
58.6

Placenta
6.0
Colon cancer tissue
2.6

Uterus Pool
6.0
Colon ca. SW1116
0.0

Ovarian ca. OVCAR-3
3.3
Colon ca. Colo-205
0.0

Ovarian ca. SK-OV-3
97.3
Colon ca. SW-48
0.0

Ovarian ca. OVCAR-4
0.1
Colon Pool
4.6

Ovarian ca. OVCAR-5
10.6
Small Intestine Pool
6.9

Ovarian ca. IGROV-1
16.6
Stomach Pool
7.2

Ovarian ca. OVCAR-8
3.2
Bone Marrow Pool
7.9

Ovary
2.9
Fetal Heart
15.6

Breast ca. MCF-7
0.2
Heart Pool
5.3

Breast ca. MDA-MB-231
0.0
Lymph Node Pool
20.6

Breast ca. BT 549
1.0
Fetal Skeletal Muscle
5.8

Breast ca. T47D
15.0
Skeletal Muscle Pool
2.5

Breast ca. MDA-N
0.1
Spleen Pool
0.0

Breast Pool
3.8
Thymus Pool
6.8

Trachea
3.3
CNS cancer (glio/astro)
0.1

U87-MG

Lung
1.2
CNS cancer (glio/astro)
0.3

U-118-MG

Fetal Lung
52.5
CNS cancer (neuro; met)
2.5

SK-N-AS

Lung ca. NCI-N417
1.0
CNS cancer (astro) SF-539
0.0

Lung ca. LX-1
0.2
CNS cancer (astro) SNB-75
9.7

Lung ca. NCI-H146
14.3
CNS cancer (glio) SNB-19
17.6

Lung ca. SHP-77
0.0
CNS cancer (glio) SF-295
3.1

Lung ca. A549
2.0
Brain (Amygdala) Pool
63.3

Lung ca. NCI-H526
0.5
Brain (cerebellum)
60.7

Lung ca. NCI-H23
21.8
Brain (fetal)
100.0

Lung ca. NCI-H460
1.0
Brain (Hippocampus) Pool
52.1

Lung ca. HOP-62
0.0
Cerebral Cortex Pool
83.5

Lung ca. NCI-H522
6.0
Brain (Substantia nigra) Pool
74.7

Liver
0.1
Brain (Thalamus) Pool
90.8

Fetal Liver
0.6
Brain (whole)
77.9

Liver ca. HepG2
0.0
Spinal Cord Pool
64.6

Kidney Pool
21.5
Adrenal Gland
13.7

Fetal Kidney
4.3
Pituitary gland Pool
1.5

Renal ca. 786-0
0.0
Salivary Gland
1.0

Renal ca. A498
14.7
Thyroid (female)
26.1

Renal ca. ACHN
0.1
Pancreatic ca. CAPAN2
26.1

Renal ca. UO-31
0.0
Pancreas Pool
9.9

TABLE BC

Panel 4.1D

Column A - Rel. Exp.(%) Ag4211, Run 174261196

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1 beta
0.0

Secondary Th2 act
1.1
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
2.5

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
58.6

Primary Th1 act
2.5
Lung Microvascular EC TNFalpha + IL-
41.2

1 beta

Primary Th2 act
0.0
Microvascular Dermal EC none
8.1

Primary Tr1 act
0.0
Microsvasular Dermal EC TNFalpha + IL-
0.0

1 beta

Primary Th1 rest
0.0
Bronchial epithelium TNFalpha + IL1 beta
0.0

Primary Th2 rest
0.0
Small airway epithelium none
1.7

Primary Tr1 rest
0.0
Small airway epithelium TNFalpha + IL-
0.0

1 beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNFalpha + IL-1 beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
9.2

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNFalpha + IL-1 beta
6.6

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
1.3

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNFalpha + IL-
0.0

1 beta

LAK cells IL-2
0.0
Liver cirrhosis
3.2

LAK cells IL-2 + IL-12
1.4
NCI-H292 none
0.0

LAK cells IL-2 + IFN gamma
1.4
NCI-H292 IL-4
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-9
0.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-13
2.7

NK Cells IL-2 rest
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 3 day
0.0
HPAEC none
0.0

Two Way MLR 5 day
0.0
HPAEC TNF alpha + IL-1 beta
2.0

Two Way MLR 7 day
0.0
Lung fibroblast none
4.2

PBMC rest
0.0
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PWM
0.0
Lung fibroblast IL-4
1.6

PBMC PHA-L
0.0
Lung fibroblast IL-9
4.6

Ramos (B cell) none
29.1
Lung fibroblast IL-13
2.5

Ramos (B cell) ionomycin
14.4
Lung fibroblast IFN gamma
1.4

B lymphocytes PWM
0.0
Dermal fibroblast CCD1070 rest
5.3

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 TNF alpha
2.7

EOL-1 dbcAMP
5.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

EOL-1 dbcAMP
4.2
Dermal fibroblast IFN gamma
1.3

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells LPS
0.0
Dermal Fibroblasts rest
4.4

Dendritic cells anti-CD40
1.0
Neutrophils TNFa + LPS
0.0

Monocytes rest
0.0
Neutrophils rest
2.6

Monocytes LPS
0.0
Colon
9.5

Macrophages rest
0.8
Lung
77.4

Macrophages LPS
0.0
Thymus
18.7

HUVEC none
0.0
Kidney
100.0

HUVEC starved
0.0

TABLE BD

general oncology screening panel_v_2.4

Column A - Rel. Exp.(%) Ag4211, Run 268624930

Tissue Name
A
Tissue Name
A

Colon cancer 1
21.0
Bladder NAT 2
0.0

Colon NAT 1
7.5
Bladder NAT 3
0.0

Colon cancer 2
4.2
Bladder NAT 4
4.9

Colon NAT 2
6.9
Prostate adenocarcinoma 1
40.1

Colon cancer 3
8.2
Prostate adenocarcinoma 2
6.1

Colon NAT 3
17.0
Prostate adenocarcinoma 3
13.7

Colon malignant cancer 4
20.9
Prostate adenocarcinoma 4
5.7

Colon NAT 4
6.1
Prostate NAT 5
0.7

Lung cancer 1
5.3
Prostate adenocarcinoma 6
9.2

Lung NAT 1
4.1
Prostate adenocarcinoma 7
5.6

Lung cancer 2
20.7
Prostate adenocarcinoma 8
0.8

Lung NAT 2
6.9
Prostate adenocarcinoma 9
18.3

Squamous cell carcinoma 3
9.9
Prostate NAT 10
1.6

Lung NAT 3
0.0
Kidney cancer 1
27.2

Metastatic melanoma 1
46.7
Kidney NAT 1
20.9

Melanoma 2
2.4
Kidney cancer 2
100.0

Melanoma 3
8.1
Kidney NAT 2
9.8

Metastatic melanoma 4
37.9
Kidney cancer 3
12.1

Metastatic melanoma 5
94.0
Kidney NAT 3
1.4

Bladder cancer 1
0.7
Kidney cancer 4
21.6

Bladder NAT 1
0.0
Kidney NAT 4
7.5

Bladder cancer 2
0.0

General_screening_panel_v1.4 Summary: Ag4211 Highest expression of the CG101396-01 gene was seen in the fetal brain (CT=29). This gene was expressed at moderate levels in all regions of the CNS examined. This gene encodes a protein that is homologous to the delta2 glutamate receptor, which is expressed in the cerebellum. This receptor is involved in motor learning and coordination, and synapse plasticity. Based on the prominent expression of this gene product in the CNS, therapeutic modulation of the expression or function of this gene product is useful for the treatment of CNS disorders involving memory deficits, including Alzheimer's disease and aging as well as for motor impairments and learning following stroke-related brain damage.

Among tissues with metabolic function, this gene was expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle and heart. This widespread expression among these tissues shows that this gene product plays a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene contributes to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

In addition, moderate levels of expression were seen in a cluster of samples derived from ovarian, colon, melanoma and lung cancer cell lines. Thus, expression of this gene is useful as a marker to detect the presence of these cancers. Therapeutic modulation of the expression or function of this gene or gene product is effective in the treatment of ovarian, colon, melanoma and lung cancers.

This gene was also expressed at much higher levels in fetal lung tissue (CT=30) when compared to expression in the adult counterpart (CT=35.5). Expression of this gene is useful as a marker to differentiate between the fetal and adult source of this tissue.

Panel 4.1D Summary: Ag4211 Highest expression of this gene was seen in the kidney (CT=30.8). Moderate levels of expression were also seen in the lung and untreated lung microvascular endothelial cells. Low but significant levels of expression were seen in untreated and treated astrocytes and Ramos B cells and activated lung microvascular endothelial cells. Expression in astrocytes was in agreement with the prominent CNS expression seen in Panel 1.4. This expression demonstrates that this gene product is involved in the homeostasis of the lung and kidney. Therapeutic modulation of the expression of this protein is useful for restoring or maintaining function in these organs during inflammation.

general oncology screening panel_v_—2.4 Summary: Ag4211 Expression of the CG101396-01 gene was detected in a kidney cancer sample (CT=31). Moderate to low expression of this gene was detected in melanoma and prostate cancers. Expression of this gene or its protein product is useful as a marker to detect the presence of these cancers. Therapeutic modulation of the expression or function of this gene product is effective in the treatment of melanoma, kidney and lung cancers.

C. CG102348-01: C1r-Like Proteinase Precursor

Expression of gene CG102348-01 was assessed using the primer-probe set Ag650, described in Table CA. Results of the RTQ-PCR runs are shown in Table CB.

TABLE GAProbe Name Ag650StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gttttcattgcattgcatttct-3′2218831139ProbeTET-5′-cattcctaagaccctttagttgaccttca-29190911403′-TAMRAReverse5′-atcttggagctgcagaatagct-3′2219461141

TABLE CB

Panel 1.1

Column A - Rel. Exp.(%) Ag650, Run 109485832

Tissue Name
A
Tissue Name
A

Adrenal gland
39.2
Renal ca. UO-31
8.8

Bladder
42.6
Renal ca. RXF 393
2.2

Brain (amygdala)
0.7
Liver
76.8

Brain (cerebellum)
2.1
Liver (fetal)
17.4

Brain (hippocampus)
2.8
Liver ca. (hepatoblast) HepG2
4.0

Brain (substantia nigra)
6.0
Lung
9.0

Brain (thalamus)
2.3
Lung (fetal)
19.9

Cerebral Cortex
4.0
Lung ca. (non-s. cell) HOP-62
100.0

Brain (fetal)
2.9
Lung ca. (large cell)
11.3

NCI-H460

Brain (whole)
2.4
Lung ca. (non-s. cell)
23.0

NCI-H23

glio/astro U-118-MG
5.4
Lung ca. (non-s. cl)
56.3

NCI-H522

astrocytoma SF-539
11.6
Lung ca. (non-sm. cell) A549
22.5

astrocytoma SNB-75
2.9
Lung ca. (s. cell var.) SHP-77
0.5

astrocytoma SW1783
1.5
Lung ca. (small cell) LX-1
14.3

glioma U251
6.9
Lung ca. (small cell)
10.3

NCI-H69

glioma SF-295
19.5
Lung ca. (squam.) SW 900
10.0

glioma SNB-19
5.4
Lung ca. (squam.) NCI-H596
5.5

glio/astro U87-MG
6.3
Lymph node
11.1

neuro*; met SK-N-AS
11.9
Spleen
6.6

Mammary gland
18.0
Thymus
2.8

Breast ca. BT-549
1.4
Ovary
13.6

Breast ca. MDA-N
6.6
Ovarian ca. IGROV-1
5.5

Breast ca.* (pl. ef) T47D
3.5
Ovarian ca. OVCAR-3
12.7

Breast ca.* (pl. ef) MCF-7
0.0
Ovarian ca. OVCAR-4
3.2

Breast ca.* (pl. ef)
0.9
Ovarian ca. OVCAR-5
19.3

MDA-MB-231

Small intestine
17.2
Ovarian ca. OVCAR-8
8.0

Colorectal
3.3
Ovarian ca. (ascites)
6.3

SK-OV-3

Colon ca. HT29
6.6
Pancreas
72.7

Colon ca. CaCo-2
14.8
Pancreatic ca. CAPAN 2
2.8

Colon ca. HCT-15
4.7
Pituitary gland
14.7

Colon ca. HCT-116
2.6
Placenta
5.7

Colon ca. HCC-2998
11.7
Prostate
12.1

Colon ca. SW480
4.3
Prostate ca.* (bone met) PC-3
5.7

Colon ca.* SW620
6.4
Salivary gland
49.3

(SW480 met)

Stomach
10.4
Trachea
12.1

Gastric ca. (liver met)
27.7
Spinal cord
5.1

NCI-N87

Heart
17.4
Testis
2.2

Skeletal muscle (Fetal)
5.2
Thyroid
11.5

Skeletal muscle
11.3
Uterus
15.6

Endothelial cells
12.1
Melanoma M14
2.1

Heart (Fetal)
1.2
Melanoma LOX IMVI
0.3

Kidney
20.9
Melanoma UACC-62
4.4

Kidney (fetal)
11.6
Melanoma SK-MEL-28
9.3

Renal ca. 786-0
10.8
Melanoma* (met) SK-MEL-5
1.6

Renal ca. A498
9.0
Melanoma Hs688(A).T
1.6

Renal ca. ACHN
8.1
Melanoma* (met) Hs688(B).T
4.6

Renal ca. TK-10
11.5

Panel 1.1 Summary: Ag650 Highest expression of this gene was detected in a lung cancer HOP-62 cell line (CT=22). High levels of expression of this gene were also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, melanoma and brain cancers. Epression of this gene is useful as a marker to detect the presence of these cancers. Therapeutic modulation of the expression or function of this gene is effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

Among tissues with metabolic or endocrine function, this gene was expressed at high levels in pancreas, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

In addition, this gene was expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therapeutic modulation of this gene product is useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

D. CG125860-02: Transmembrane Protease, Serine 5

Expression of gene CG125860-02 was assessed using the primer-probe set Ag1674, described in Table DA. Results of the RTQ-PCR runs are shown in Tables DC, DD, DE and DF.

TABLE DAProbe Name Ag1674StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ctcactcaccacaagggagtaa-3′226121142ProbeTET-5′-tgacatcaaactcaacagttcccagga-2764111433′-TAMRAReverse5′-gtctaggagagagctgagcaaa-3′226691144

TABLE DB

Ardais Prostate 1.0

Column A - Rel. Exp.(%) Ag1674, Run 370302285

Tissue Name
A

151135 Prostate NAT(B87)
31.2

151143 Prostate NAT(B8A)
27.7

153669 Prostate NAT(D5E)
26.4

153677 Prostate NAT(D66)
12.8

153685 Prostate NAT(D6E)
14.7

145905 Prostate NAT(A0C)
4.0

153670 Prostate NAT(D5F)
18.0

153678 Prostate NAT(D67)
24.0

153686 Prostate NAT(D6F)
6.1

145906 Prostate NAT(A09)
28.7

151129 Prostate NAT(B93)
44.8

151137 Prostate NAT(B86)
42.3

153671 Prostate NAT(D60)
18.0

151145 Prostate NAT(B91)
30.8

153679 Prostate NAT(D68)
12.9

153687 Prostate NAT(D70)
31.4

153672 Prostate NAT(D61)
23.8

153680 Prostate NAT(D69)
35.1

151131 Prostate NAT(B85)
7.4

153673 Prostate NAT(D62)
12.0

153681 Prostate NAT(D6A)
11.5

145910 Prostate NAT(9C3)
27.4

153674 Prostate NAT(D63)
28.7

153682 Prostate NAT(D6B)
14.4

151133 Prostate NAT(B94)
31.9

153675 Prostate NAT(D64)
20.6

153683 Prostate NAT(D6C)
31.9

153668 Prostate NAT(D5D)
39.5

153676 Prostate NAT(D65)
18.7

153684 Prostate NAT(D6D)
30.4

145904 Prostate cancer(9E2)
40.3

149776 Prostate cancer(AD5)
100.0

153653 Prostate cancer(D4E)
26.1

153661 Prostate cancer(D56)
48.3

151128 Prostate cancer(B8C)
47.3

151136 Prostate cancer(B8B)
86.5

151144 Prostate cancer(B8F)
25.3

153654 Prostate cancer(D4F)
45.7

153662 Prostate cancer(D57)
16.0

153655 Prostate cancer(D50)
44.8

145907 Prostate cancer(A0A)
18.3

153663 Prostate cancer(D58)
20.7

151130 Prostate cancer(B90)
54.7

153648 Prostate cancer(D49)
24.7

153656 Prostate cancer(D51)
11.1

153664 Prostate cancer(D59)
26.2

155799 Prostate cancer(EA8)
14.8

145909 Prostate cancer(9E7)
18.6

153649 Prostate cancer(D4A)
16.8

153657 Prostate cancer(D52)
28.7

153665 Prostate cancer(D5A)
25.7

151132 Prostate cancer(B88)
60.7

153650 Prostate cancer(D4B)
14.9

153658 Prostate cancer(D53)
23.8

153666 Prostate cancer(D5B)
22.5

153651 Prostate cancer(D4C)
22.4

153659 Prostate cancer(D54)
41.8

153667 Prostate cancer(D5C)
43.5

151134 Prostate cancer(B92)
51.1

151142 Prostate cancer(B89)
33.7

153652 Prostate cancer(D4D)
36.3

153660 Prostate cancer(D55)
18.3

149773 Prostate NAT(AD8)
0.0

149774 Prostate cancer(AD7)
34.9

151139 Prostate NAT(B8E)
35.8

151138 Prostate cancer(B8D)
30.4

115141 Prostate NAT(B96)
24.5

151140 Prostate cancer(B95)
24.0

TABLE DC

Panel 1.3D

Column A - Rel. Exp.(%) Ag1674, Run 158189117

Tissue Name
A

Liver adenocarcinoma
2.7

Pancreas
0.7

Pancreatic ca. CAPAN 2
0.4

Adrenal gland
1.3

Thyroid
0.2

Salivary gland
5.4

Pituitary gland
3.4

Brain (fetal)
3.4

Brain (whole)
7.1

Brain (amygdala)
28.1

Brain (cerebellum)
3.6

Brain (hippocampus)
100.0

Brain (substantia nigra)
6.9

Brain (thalamus)
20.0

Cerebral Cortex
9.7

Spinal cord
21.9

glio/astro U87-MG
0.6

glio/astro U-118-MG
4.1

astrocytoma SW1783
0.8

neuro*; met SK-N-AS
3.6

astrocytoma SF-539
1.6

astrocytoma SNB-75
3.1

glioma SNB-19
19.6

glioma U251
1.9

glioma SF-295
1.9

Heart (Fetal)
0.7

Heart
0.4

Skeletal muscle (Fetal)
40.3

Skeletal muscle
0.8

Bone marrow
0.7

Thymus
1.4

Spleen
2.4

Lymph node
0.9

Colorectal
1.0

Stomach
1.8

Small intestine
1.6

Colon ca. SW480
0.6

Colon ca.* SW620 (SW480 met)
11.8

Colon ca. HT29
0.4

Colon ca. HCT-116
1.7

Colon ca. CaCo-2
1.3

CC Well to Mod Diff (ODO3866)
1.6

Colon ca. HCC-2998
2.1

Gastric ca. (liver met) NCI-N87
1.7

Bladder
0.5

Trachea
7.4

Kidney
0.4

Kidney (fetal)
1.6

Renal ca. 786-0
0.4

Renal ca. A498
2.6

Renal ca. RXF 393
0.3

Renal ca. ACHN
0.0

Renal ca. UO-31
0.3

Renal ca. TK-10
0.2

Liver
0.1

Liver (fetal)
0.8

Liver ca. (hepatoblast) HepG2
1.1

Lung
2.9

Lung (fetal)
3.1

Lung ca. (small cell) LX-1
5.2

Lung ca. (small cell) NCI-H69
4.5

Lung ca. (s. cell var.) SHP-77
0.7

Lung ca. (large cell)NCI-H460
0.3

Lung ca. (non-sm. cell) A549
0.9

Lung ca. (non-s. cell) NCI-H23
0.8

Lung ca. (non-s. cell) HOP-62
0.7

Lung ca. (non-s. cl) NCI-H522
0.2

Lung ca. (squam.) SW 900
0.4

Lung ca. (squam.) NCI-H596
0.0

Mammary gland
2.9

Breast ca.* (pl. ef) MCF-7
0.9

Breast ca.* (pl. ef) MDA-MB-231
2.8

Breast ca.* (pl. ef) T47D
0.9

Breast ca. BT-549
4.5

Breast ca. MDA-N
9.7

Ovary
0.5

Ovarian ca. OVCAR-3
0.3

Ovarian ca. OVCAR-4
1.0

Ovarian ca. OVCAR-5
0.9

Ovarian ca. OVCAR-8
3.4

Ovarian ca. IGROV-l
0.7

Ovarian ca. (ascites) SK-OV-3
3.2

Uterus
1.3

Placenta
0.2

Prostate
0.9

Prostate ca.* (bone met) PC-3
0.5

Testis
6.2

Melanoma Hs688(A).T
0.0

Melanoma* (met) Hs688(B).T
0.0

Melanoma UACC-62
2.8

Melanoma M14
0.7

Melanoma LOX IMVI
0.4

Melanoma* (met) SK-MEL-5
0.4

Adipose
0.1

TABLE DD

Panel 2D

Column A - Rel. Exp.(%) Ag1674, Run 158191134

Tissue Name
A
Tissue Name
A

Normal Colon
7.8
Kidney Margin 8120608
0.3

CC Well to Mod Diff (ODO3866)
1.9
Kidney Cancer 8120613
5.4

CC Margin (ODO3866)
1.1
Kidney Margin 8120614
1.6

CC Gr.2 rectosigmoid (ODO3868)
2.9
Kidney Cancer 9010320
3.1

CC Margin (ODO3868)
0.4
Kidney Margin 9010321
4.2

CC Mod Diff (ODO3920)
46.7
Normal Uterus
1.4

CC Margin (ODO3920)
2.7
Uterine Cancer 064011
13.3

CC Gr.2 ascend colon (ODO3921)
24.8
Normal Thyroid
1.9

CC Margin (ODO3921)
1.2
Thyroid Cancer
1.0

CC from Partial Hepatectomy
10.0
Thyroid Cancer A302152
1.3

(ODO4309) Mets

Liver Margin (ODO4309)
2.4
Thyroid Margin A302153
4.8

Colon mets to lung (OD04451-01)
50.3
Normal Breast
10.4

Lung Margin (OD04451-02)
2.1
Breast Cancer
8.4

Normal Prostate 6546-1
1.0
Breast Cancer (OD04590-01)
6.0

Prostate Cancer (OD04410)
2.3
Breast Cancer Mets (0D04590-03)
6.2

Prostate Margin (OD04410)
3.3
Breast Cancer Metastasis
20.9

Prostate Cancer (OD04720-01)
11.4
Breast Cancer
4.7

Prostate Margin (OD04720-02)
6.5
Breast Cancer
6.2

Normal Lung
6.0
Breast Cancer 9100266
3.7

Lung Met to Muscle (ODO4286)
0.7
Breast Margin 9100265
3.3

Muscle Margin (ODO4286)
6.4
Breast Cancer A209073
5.7

Lung Malignant Cancer (OD03126)
3.1
Breast Margin A209073
6.7

Lung Margin (OD03126)
3.3
Normal Liver
1.3

Lung Cancer (OD04404)
1.5
Liver Cancer
3.1

Lung Margin (OD04404)
3.2
Liver Cancer 1025
1.5

Lung Cancer (OD04565)
1.1
Liver Cancer 1026
0.8

Lung Margin (OD04565)
2.3
Liver Cancer 6004-T
0.4

Lung Cancer (OD04237-01)
100.0
Liver Tissue 6004-N
2.3

Lung Margin (OD04237-02)
2.9
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (ODO4310)
7.9
Liver Tissue 6005-N
0.3

Liver Margin (OD04310)
0.4
Normal Bladder
5.4

Melanoma Metastasis
47.3
Bladder Cancer
5.0

Lung Margin (OD04321)
3.5
Bladder Cancer
2.0

Normal Kidney
10.2
Bladder Cancer (OD04718-01)
1.7

Kidney Ca, Nuclear grade 2 (OD04338)
4.7
Bladder Normal Adjacent
2.4

(OD04718-03)

Kidney Margin (OD04338)
4.9
Normal Ovary
0.4

Kidney Ca Nuclear grade 1/2 (OD04339)
3.5
Ovarian Cancer
5.6

Kidney Margin (OD04339)
1.6
Ovarian Cancer (OD04768-07)
2.8

Kidney Ca, Clear cell type (OD04340)
4.2
Ovary Margin (OD04768-08)
2.1

Kidney Margin (OD04340)
5.0
Normal Stomach
3.2

Kidney Ca, Nuclear grade 3 (OD04348)
2.4
Gastric Cancer 9060358
2.6

Kidney Margin (OD04348)
3.2
Stomach Margin 9060359
2.4

Kidney Cancer (OD04622-01)
1.4
Gastric Cancer 9060395
0.5

Kidney Margin (OD04622-03)
0.7
Stomach Margin 9060394
1.3

Kidney Cancer (OD04450-01)
0.2
Gastric Cancer 9060397
3.0

Kidney Margin (OD04450-03)
2.0
Stomach Margin 9060396
0.0

Kidney Cancer 8120607
0.4
Gastric Cancer 064005
6.6

TABLE DE

Panel 4D

Column A - Rel. Exp.(%) Ag1674, Run 158191436

Tissue Name
A
Tissue Name
A

Secondary Th1 act
18.4
HUVEC IL-1 beta
4.2

Secondary Th2 act
22.7
HUVEC IFN gamma
34.2

Secondary Tr1 act
33.2
HUVEC TNF alpha + IFN gamma
22.1

Secondary Th1 rest
10.5
HUVEC TNF alpha + IL4
14.9

Secondary Th2 rest
6.9
HUVEC IL-11
6.8

Secondary Tr1 rest
24.8
Lung Microvascular EC none
26.2

Primary Th1 act
28.1
Lung Microvascular EC TNFalpha + IL-
22.7

1 beta

Primary Th2 act
21.6
Microvascular Dermal EC none
33.7

Primary Tr1 act
29.5
Microsvasular Dermal EC TNFalpha + IL-
21.3

1 beta

Primary Th1 rest
77.4
Bronchial epithelium TNFalpha + IL1 beta
31.4

Primary Th2 rest
31.9
Small airway epithelium none
5.9

Primary Tr1 rest
22.2
Small airway epithelium TNFalpha + IL-
40.3

1 beta

CD45RA CD4 lymphocyte act
22.4
Coronery artery SMC rest
10.5

CD45RO CD4 lymphocyte act
57.8
Coronery artery SMC TNFalpha + IL-1 beta
5.4

CD8 lymphocyte act
20.2
Astrocytes rest
22.1

Secondary CD8 lymphocyte rest
31.2
Astrocytes TNFalpha + IL-1 beta
6.9

Secondary CD8 lymphocyte act
10.7
KU-812 (Basophil) rest
48.3

CD4 lymphocyte none
17.0
KU-812 (Basophil) PMA/ionomycin
79.6

2ry Th1/Th2/Tr1 anti-CD95
40.6
CCD1106 (Keratinocytes) none
14.7

CH11

LAK cells rest
26.1
CCD1106 (Keratinocytes) TNFalpha + IL-
16.8

1 beta

LAK cells IL-2
22.2
Liver cirrhosis
20.6

LAK cells IL-2 + IL-12
17.1
Lupus kidney
4.1

LAK cells IL-2 + IFN gamma
16.0
NCI-H292 none
75.3

LAK cells IL-2 + IL-18
23.5
NCI-H292 IL-4
70.2

LAK cells PMA/ionomycin
7.2
NCI-H292 IL-9
27.9

NK Cells IL-2 rest
19.9
NCI-H292 IL-13
40.3

Two Way MLR 3 day
35.1
NCI-H292 IFN gamma
33.7

Two Way MLR 5 day
5.8
HPAEC none
12.1

Two Way MLR 7 day
11.0
HPAEC TNF alpha + IL-1 beta
19.9

PBMC rest
10.7
Lung fibroblast none
9.3

PBMC PWM
57.4
Lung fibroblast TNF alpha + IL-1 beta
15.8

PBMC PHA-L
18.3
Lung fibroblast IL-4
20.3

Ramos (B cell) none
14.4
Lung fibroblast IL-9
14.8

Ramos (B cell) ionomycin
11.9
Lung fibroblast IL-13
18.3

B lymphocytes PWM
35.4
Lung fibroblast IFN gamma
16.0

B lymphocytes CD40L and IL-4
29.3
Dermal fibroblast CCD1070 rest
21.0

EOL-1 dbcAMP
39.8
Dermal fibroblast CCD1070 TNF alpha
38.7

EOL-1 dbcAMP
39.0
Dermal fibroblast CCD1070 IL-1 beta
9.3

PMA/ionomycin

Dendritic cells none
6.3
Dermal fibroblast IFN gamma
17.4

Dendritic cells LPS
7.4
Dermal fibroblast IL-4
35.4

Dendritic cells anti-CD40
6.8
IBD Colitis 2
9.2

Monocytes rest
13.9
IBD Crohn's
1.2

Monocytes LPS
8.4
Colon
35.4

Macrophages rest
37.6
Lung
18.9

Macrophages LPS
2.3
Thymus
43.5

HUVEC none
15.2
Kidney
100.0

HUVEC starved
35.8

Ardais Prostate 1.0 Summary: Ag1674 Expression of the CG125860-02 gene was highest in a prostate cancer sample (CT=29.3). This gene was expressed at moderate levels in the majority of samples on this panel, with no apparent disregulation in prostate cancer.

Panel 1.3D Summary: Ag1674 Expression of this gene was highest in the hippocampus (CT=29.3). In addition, this gene was expressed at moderate levels in all other regions of the central nervous system examined, including amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Expression of this gene or its protein product is useful as a marker for brain tissue. Therapeutic modulation of the activity of this gene or its protein product plays a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

Expression of the CG125860-02 gene was also upregulated in fetal skeletal muscle compared to adult skeletal muscle. The relative overexpression of this gene in fetal tissue demonstrated that the protein product enhances skeletal muscle growth or development in the fetus and also acts in a regenerative capacity in the adult. Therapeutic modulation of this gene or its protein product is useful in the treatment of muscle degenerative diseases, such as muscular dystrophy.

Panel 2D Summary: Ag1674 Expression of this gene was highest in a lung cancer sample (CT=29.1) and was significantly downregulated (about 50-fold) in the normal adjacent lung tissue. The CG125860-02 gene was also overexpressed in 4 colon cancer samples when compared to the appropriate normal matched colon tissue. Therefore, the CG125860-02 gene or protein expression levels are useful as a marker for lung or colon cancer. Gene, protein, antibody or small molecule therapeutics targeting this gene or its protein product are useful in the treatment of lung or colon cancer. Expression of this gene was higher in a number of metastatic tumor samples on this panel, showing that it plays a role in metastasis and is useful as a marker of disease prognosis.

Panel 4D Summary: Ag1674 Expression of this gene was highest in normal kidney (CT=31.8). This gene was expressed at low but ubiquitous levels in the majority of the samples on this panel.

E. CG50235-04: Tolloid-Like 2

Expression of gene CG50235-04 was assessed using the primer-probe set Ag4737, described in Table EA. Results of the RTQ-PCR runs are shown in Tables EB and EC.

TABLE EBGeneral_screening_panel_v1.4Column A - Rel. Exp.(%) Ag4737, Run 222904895Tissue NameATissue NameAAdipose0.0Renal ca. TK-101.1Melanoma* Hs688(A).T4.3Bladder6.8Melanoma* Hs688(B).T1.3Gastric ca. (liver met.) NCI-N875.2Melanoma* M140.0Gastric ca. KATO III2.0Melanoma* LOXIMVI0.0Colon ca. SW-9480.0Melanoma* SK-MEL-51.0Colon ca. SW4809.9Squamous cell carcinoma7.3Colon ca.* (SW480 met) SW6200.3SCC-4Testis Pool0.9Colon ca. HT290.0Prostate ca.* (bone met)0.5Colon ca. HCT-1168.6PC-3Prostate Pool5.6Colon ca. CaCo-20.5Placenta2.0Colon cancer tissue0.5Uterus Pool0.8Colon ca. SW111616.2Ovarian ca. OVCAR-39.1Colon ca. Colo-2051.1Ovarian ca. SK-OV-367.8Colon ca. SW-480.0Ovarian ca. OVCAR-488.3Colon Pool0.0Ovarian ca. OVCAR-50.0Small Intestine Pool6.9Ovarian ca. IGROV-16.6Stomach Pool1.2Ovarian ca. OVCAR-88.7Bone Marrow Pool0.0Ovary3.3Fetal Heart26.1Breast ca. MCF-70.8Heart Pool21.9Breast ca. MDA-MB-2311.1Lymph Node Pool1.6Breast ca. BT 5490.0Fetal Skeletal Muscle2.7Breast ca. T47D3.1Skeletal Muscle Pool17.3Breast ca. MDA-N0.0Spleen Pool2.4Breast Pool0.3Thymus Pool1.4Trachea5.5CNS cancer (glio/astro)0.0U87-MGLung0.9CNS cancer (glio/astro)0.0U-118-MGFetal Lung0.5CNS cancer (neuro; met)2.9SK-N-ASLung ca. NCI-N4170.0CNS cancer (astro) SF-5390.5Lung ca. LX-10.5CNS cancer (astro) SNB-751.4Lung ca. NCI-H1460.9CNS cancer (glio) SNB-195.3Lung ca. SHP-7744.4CNS cancer (glio) SF-2950.0Lung ca. A5490.9Brain (Amygdala) Pool7.8Lung ca. NCI-H52654.7Brain (cerebellum)3.6Lung ca. NCI-H238.8Brain (fetal)1.1Lung ca. NCI-H4600.3Brain (Hippocampus) Pool7.2Lung ca. HOP-620.0Cerebral Cortex Pool5.6Lung ca. NCI-H5228.0Brain (Substantia nigra) Pool19.2Liver0.5Brain (Thalamus) Pool18.0Fetal Liver2.0Brain (whole)6.3Liver ca. HepG21.0Spinal Cord Pool42.0Kidney Pool1.4Adrenal Gland0.0Fetal Kidney1.2Pituitary gland Pool7.8Renal ca. 786-0100.0Salivary Gland7.4Renal ca. A49817.0Thyroid (female)1.8Renal ca. ACHN45.1Pancreatic ca. CAPAN20.0Renal ca. UO-3182.9Pancreas Pool2.8

TABLE EC

Panel 4.1D

Column A - Rel. Exp.(%) Ag4737, Run 204154022

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1 beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
3.3

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNFalpha + IL-
0.0

1 beta

Primary Th2 act
2.5
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.0
Microsvasular Dermal EC TNFalpha + IL-
0.0

1 beta

Primary Th1 rest
0.0
Bronchial epithelium TNFalpha + IL1 beta
39.8

Primary Th2 rest
0.0
Small airway epithelium none
43.2

Primary Tr1 rest
0.0
Small airway epithelium TNFalpha + IL-
12.3

1 beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNFalpha + IL-1 beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
73.7

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNFalpha + IL-1 beta
100.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
2.7

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
29.5

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNFalpha + IL-
5.6

1 beta

LAK cells IL-2
0.0
Liver cirrhosis
0.0

LAK cells IL-2 + IL-12
0.0
NCI-H292 none
12.5

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 IL-4
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-9
11.3

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-13
0.0

NK Cells IL-2 rest
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 3 day
0.0
HPAEC none
0.0

Two Way MLR 5 day
0.0
HPAEC TNF alpha + IL-1 beta
2.9

Two Way MLR 7 day
0.0
Lung fibroblast none
0.0

PBMC rest
0.0
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PWM
3.6
Lung fibroblast IL-4
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-9
4.9

Ramos (B cell) none
3.0
Lung fibroblast IL-13
0.0

Ramos (B cell) ionomycin
2.4
Lung fibroblast IFN gamma
3.4

B lymphocytes PWM
0.0
Dermal fibroblast CCD1070 rest
0.0

B lymphocytes CD40L and IL-4
3.1
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast IFN gamma
0.0

PMA/ionomycin

Dendritic cells none
2.7
Dermal fibroblast IL-4
0.0

Dendritic cells LPS
0.0
Dermal Fibroblasts rest
0.0

Dendritic cells anti-CD40
0.0
Neutrophils TNFa + LPS
0.0

Monocytes rest
0.0
Neutrophils rest
0.0

Monocytes LPS
0.0
Colon
4.1

Macrophages rest
0.8
Lung
0.0

Macrophages LPS
0.0
Thymus
2.5

HUVEC none
0.0
Kidney
2.7

HUVEC starved
0.0

General_screening_panel_v1.4 Summary: Ag4737 Highest expression of this gene was seen in a sample derived from a renal cancer cell line (CT=29.9). This gene showed specific expression restricted to cell lines derived from renal cancer, ovarian cancer and lung cancer. The expression of this gene is useful as marker to detect these cancers. Modulation of this gene, encoded protein and use of small molecule drugs or antibodies is useful in the treatment of renal, ovarian or lung cancer.

This gene was also moderately expressed in several metabolic tissues including adult and fetal heart, pituitary, and skeletal muscle. Thus, this gene is important for the pathogenesis, diagnosis and/or treatment of metabolic diseases, including obesity.

This gene was expressed at low levels in the CNS, except in the spinal cord where expression levels were moderate. Thus, modulation of this gene is useful in treating spinal cord related disorders including spinal cord trauma or spinocerebellar ataxia.

Panel 4.1D Summary: Ag4737 This gene was expressed at moderate levels in TNF-alpha and IL-1 beta treated and resting astrocytes (CTs=32). It was also expressed at a low level in small airway epithelium, and keratinocytes. Expression of this gene was down regulated in both cell types upon treatment with the inflammatory cytokines TNF-alpha and IL-1 beta. This gene encodes for a tolloid like 2 protein, a BMP-1-related proteinase which was shown to play a role in extracellular matrix biosynthesis (Uzel M I, J Biol Chem 276(25):22537-43). Therefore, modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful to reduce or eliminate the symptoms of inflammatory reactions that occur in multiple sclerosis, and also in chronic obstructive pulmonary disease, asthma, or emphysema, and in inflammatory skin diseases.

F. CG50249-01: Voltage-Gated Potassium Channel Protein KV3.2 (KSHIIIA)

Expression of gene CG50249-01 was assessed using the primer-probe set Ag2503, described in Table FA. Results of the RTQ-PCR runs are shown in Tables FB, FC, FD, FE, FF and FG.

TABLE FAProbe Name Ag2503StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gaggctctctccagtaacatca-3′2218511148ProbeTET-5′-actctccttgtcctctgaggcgctct-3′-2618801149TAMRAReverse5′-gcagtttggttgtttggtttac-3′2219291150

TABLE FB

Ardais Breast 1.0

Column A - Rel. Exp.(%) Ag2503, Run 399643618

Tissue Name
A
Tissue Name
A

111297 Breast cancer metastasis (9369)*
0.0
153636 Breast cancer (D3D)
0.0

108830 Breast cancer metastasis (OD06855)*
0.0
164668 Breast cancer (6314)
0.0

97764 Breast cancer node metastasis (OD06083)
0.0
164677 Breast cancer (5272)
0.3

97739 Breast cancer (CHTN20676)
0.0
164685 Breast cancer (0170)
0.0

145848 Breast cancer (9B6)
0.2
98857 Breast cancer (OD06397-12)
0.0

145859 Breast cancer (9EC)
0.0
153628 Breast cancer (D35)
0.0

153632 Breast cancer (D39)
0.0
153637 Breast cancer (D3E)
0.5

153643 Breast cancer (D44)
0.1
164669 Breast cancer (6992)
0.0

164672 Breast cancer (7464)
0.0
164678 Breast cancer (5297)
0.2

164681 Breast cancer (5787)
97.3
164686 Breast cancer (0732)
0.0

97748 Breast cancer (CHTN20931)
0.8
145857 Breast cancer (9F0)
0.0

145850 Breast cancer (9C7)
0.0
153630 Breast cancer (D37)
0.1

149844 Breast cancer (24178)
0.0
153638 Breast cancer (D3F)
27.4

153633 Breast cancer (D3A)
0.1
164670 Breast cancer (7078)
0.0

153644 Breast cancer (D45)
0.3
164679 Breast cancer (5486)
0.0

164673 Breast cancer (8452)
0.6
164687 Breast cancer (5881)
0.0

164682 Breast cancer (6342)*
0.1
145846 Breast cancer (9B7)
0.1

97751 Breast cancer (CHTN21053)
0.0
145858 Breast cancer (9B4)
0.0

116417 Breast cancer (3367)*
0.0
153631 Breast cancer (D38)
0.0

145852 Breast cancer (A1A)
0.0
153639 Breast cancer (D40)
100.0

151097 Breast cancer (CHTN24298)
0.0
164671 Breast cancer (7082)
0.0

153634 Breast cancer (D3B)
0.0
164680 Breast cancer (5705)
0.0

155797 Breast cancer (EA6)
0.0
164688 Breast cancer (7222)
0.0

164674 Breast cancer (8811)
0.2
111288 Breast NAT (3367)
0.0

164683 Breast cancer (6470)
0.0
111302 Breast NAT (6314)
0.4

97763 Breast cancer (OD06083)
0.1
105687 Breast cancer 1B
0.0

116418 Breast cancer (3378)*
0.0
105688 Breast NAT 1A
0.0

145853 Breast cancer (9F3)
0.0
105689 Breast cancer 2B
0.0

153432 Breast cancer (CHTN 24652)
0.2
105690 Breast NAT 2A
0.0

153635 Breast cancer (D3C)
0.0
111289 Breast cancer 3B*
0.0

164667 Breast cancer (5785)
0.0
111290 Breast NAT 3A*
0.0

164676 Breast cancer (5070)
1.4
116424 Breast cancer 4B*
0.0

164684 Breast cancer (6509)
0.2
116425 Breast NAT 4A
0.0

116421 Breast cancer (6314)
0.0
108847 Breast cancer
0.0

145854 Breast cancer (9B8)
0.0
105694 Breast NAT
0.0

153627 Breast cancer (D34)
0.0

TABLE FC

Ardais Panel v.1.0

Column A - Rel. Exp.(%) Ag2503, Run 263526557

Tissue Name
A
Tissue Name
A

136799 Lung cancer(362)
0.0
136787 lung cancer(356)
0.0

136800 LungNAT(363)
1.1
136788 lung NAT(357)
0.2

136813 Lung cancer(372)
0.1
136804 Lung cancer(369)
100.0

136814 Lung NAT(373)
0.0
136805 Lung NAT(36A)
0.0

136815 Lung cancer(374)
0.1
136806 Lung cancer(36B)
0.0

136816 Lung NAT(375)
0.1
136807 Lung NAT(36C)
0.0

136791 Lung cancer(35A)
0.2
136789 lung cancer(358)
0.2

136795 Lung cancer(35E)
0.1
136802 Lung cancer(365)
0.1

136797 Lung cancer(360)
0.1
136803 Lung cancer(368)
0.0

136794 lung NAT(35D)
0.2
136811 Lung cancer(370)
0.0

136818 Lung NAT(377)
10.0
136810 Lung NAT(36F)
0.2

TABLE FD

Ardais Prostate 1.0

Column A - Rel. Exp.(%) Ag2503, Run 320416115

Tissue Name
A
Tissue Name
A

151135 Prostate NAT(B87)
0.8
151128 Prostate cancer(B8C)
0.3

151143 Prostate NAT(B8A)
2.5
151136 Prostate cancer(B8B)
100.0

153669 Prostate NAT(D5E)
2.3
151144 Prostate cancer(B8F)
0.1

153677 Prostate NAT(D66)
2.5
153654 Prostate cancer(D4F)
10.2

153685 Prostate NAT(D6E)
1.7
153662 Prostate cancer(D57)
2.9

145905 Prostate NAT(A0C)
8.6
153655 Prostate cancer(D50)
8.8

153670 Prostate NAT(D5F)
1.2
145907 Prostate cancer(A0A)
1.0

153678 Prostate NAT(D67)
4.2
153663 Prostate cancer(D58)
1.0

153686 Prostate NAT(D6F)
1.2
151130 Prostate cancer(B90)
27.7

145906 Prostate NAT(A09)
6.0
153648 Prostate cancer(D49)
0.2

151129 Prostate NAT(B93)
4.1
153656 Prostate cancer(D51)
8.8

151137 Prostate NAT(B86)
2.1
153664 Prostate cancer(D59)
0.1

153671 Prostate NAT(D60)
0.7
155799 Prostate cancer(EA8)
0.1

151145 Prostate NAT(B91)
1.4
145909 Prostate cancer(9E7)
0.7

153679 Prostate NAT(D68)
5.9
153649 Prostate cancer(D4A)
11.0

153687 Prostate NAT(D70)
4.1
153657 Prostate cancer(D52)
36.3

153672 Prostate NAT(D61)
1.0
153665 Prostate cancer(D5A)
0.3

153680 Prostate NAT(D69)
6.1
151132 Prostate cancer(B88)
41.5

151131 Prostate NAT(B85)
3.5
153650 Prostate cancer(D4B)
3.1

153673 Prostate NAT(D62)
6.9
153658 Prostate cancer(D53)
12.3

153681 Prostate NAT(D6A)
0.8
153666 Prostate cancer(D5B)
26.8

145910 Prostate NAT(9C3)
7.5
153651 Prostate cancer(D4C)
0.5

153674 Prostate NAT(D63)
5.3
153659 Prostate cancer(D54)
25.0

153682 Prostate NAT(D6B)
0.1
153667 Prostate cancer(D5C)
3.5

151133 Prostate NAT(B94)
4.0
151134 Prostate cancer(B92)
4.7

153675 Prostate NAT(D64)
0.2
151142 Prostate cancer(B89)
0.2

153683 Prostate NAT(D6C)
0.5
153652 Prostate cancer(D4D)
1.7

153668 Prostate NAT(D5D)
1.5
153660 Prostate cancer(D55)
0.1

153676 Prostate NAT(D65)
0.9
149773 Prostate NAT(AD8)
2.3

153684 Prostate NAT(D6D)
9.3
149774 Prostate cancer(AD7)
2.8

145904 Prostate cancer(9E2)
0.0
151139 Prostate NAT(B8E)
4.3

149776 Prostate cancer(AD5)
2.0
151138 Prostate cancer(B8D)
0.1

153653 Prostate cancer(D4E)
1.0
115141 Prostate NAT(B96)
4.2

153661 Prostate cancer(D56)
1.7
151140 Prostate cancer(B95)
1.2

TABLE FE

General_screening_panel_v1.4

Column A - Rel. Exp.(%) Ag2503, Run 208015585

Column B - Rel. Exp.(%) Ag2503, Run 212142287

Tissue Name
A
B
Tissue Name
A
B

Adipose
0.0
0.0
Renal ca. TK-10
0.0
0.0

Melanoma* Hs688(A).T
0.0
0.0
Bladder
0.1
0.1

Melanoma* Hs688(B).T
0.0
0.0
Gastric ca. (liver met.) NCI-N87
0.1
0.1

Melanoma* M14
0.0
0.0
Gastric ca. KATO III
0.0
0.0

Melanoma* LOXIMVI
0.0
0.1
Colon ca. SW-948
0.0
0.0

Melanoma* SK-MEL-5
0.0
0.1
Colon ca. SW480
0.0
0.1

Squamous cell carcinoma SCC-4
0.0
0.0
Colon ca.* (SW480 met) SW620
0.0
0.0

Testis Pool
0.2
0.3
Colon ca. HT29
0.1
0.1

Prostate ca.* (bone met) PC-3
0.0
0.0
Colon ca. HCT-116
0.0
0.0

Prostate Pool
6.4
7.8
Colon ca. CaCo-2
0.0
0.0

Placenta
0.0
0.0
Colon cancer tissue
0.1
0.2

Uterus Pool
0.0
0.0
Colon ca. SW1116
0.0
0.0

Ovarian ca. OVCAR-3
0.0
0.0
Colon ca. Colo-205
0.0
0.0

Ovarian ca. SK-OV-3
0.0
0.1
Colon ca. SW-48
0.0
0.0

Ovarian ca. OVCAR-4
0.0
0.0
Colon Pool
0.2
0.1

Ovarian ca. OVCAR-5
8.4
7.2
Small Intestine Pool
0.2
0.4

Ovarian ca. IGROV-1
0.0
0.0
Stomach Pool
0.2
0.0

Ovarian ca. OVCAR-8
0.0
0.0
Bone Marrow Pool
0.0
0.0

Ovary
0.0
0.1
Fetal Heart
0.0
0.0

Breast ca. MCF-7
0.0
0.2
Heart Pool
0.0
0.1

Breast ca. MDA-MB-231
0.0
0.0
Lymph Node Pool
0.1
0.1

Breast ca. BT 549
0.0
0.0
Fetal Skeletal Muscle
0.1
0.0

Breast ca. T47D
8.1
15.4
Skeletal Muscle Pool
0.0
0.1

Breast ca. MDA-N
0.0
0.0
Spleen Pool
0.0
0.0

Breast Pool
0.9
0.5
Thymus Pool
0.4
0.7

Trachea
0.2
0.4
CNS cancer (glio/astro) U87-MG
0.0
0.0

Lung
0.0
0.0
CNS cancer (glio/astro) U-118-MG
0.1
0.1

Fetal Lung
0.0
0.1
CNS cancer (neuro; met) SK-N-AS
0.0
0.0

Lung ca. NCI-N417
0.0
0.0
CNS cancer (astro) SF-539
0.0
0.0

Lung ca. LX-1
0.0
0.0
CNS cancer (astro) SNB-75
0.0
0.0

Lung ca. NCI-H146
1.8
1.8
CNS cancer (glio) SNB-19
0.0
0.0

Lung ca. SHP-77
0.5
0.5
CNS cancer (glio) SF-295
0.0
0.0

Lung ca. A549
0.0
0.0
Brain (Amygdala) Pool
55.9
49.7

Lung ca. NCI-H526
0.0
0.0
Brain (cerebellum)
1.1
1.1

Lung ca. NCI-H23
0.0
0.9
Brain (fetal)
25.9
38.4

Lung ca. NCI-H460
2.0
0.1
Brain (Hippocampus) Pool
31.0
35.8

Lung ca. HOP-62
0.1
0.0
Cerebral Cortex Pool
100.0
80.7

Lung ca. NCI-H522
0.0
0.0
Brain (Substantia nigra) Pool
64.2
64.6

Liver
0.1
0.0
Brain (Thalamus) Pool
97.3
100.0

Fetal Liver
0.0
0.3
Brain (whole)
66.9
65.5

Liver ca. HepG2
0.0
0.0
Spinal Cord Pool
6.4
5.3

Kidney Pool
0.0
0.1
Adrenal Gland
0.0
0.0

Fetal Kidney
1.1
2.2
Pituitary gland Pool
6.6
5.5

Renal ca. 786-0
0.0
0.0
Salivary Gland
0.2
0.1

Renal ca. A498
0.0
0.0
Thyroid (female)
0.0
0.0

Renal ca. ACHN
0.4
0.0
Pancreatic ca. CAPAN2
0.0
0.1

Renal ca. UO-31
0.0
0.0
Pancreas Pool
0.2
0.7

TABLE FF

Panel 2D

Column A - Rel. Exp.(%) Ag2503, Run 160838287

Column B - Rel. Exp.(%) Ag2503, Run 164993346

Tissue Name
A
B
Tissue Name
A
B

Normal Colon
2.7
2.3
Kidney Margin 8120608
0.0
0.0

CC Well to Mod Diff (ODO3866)
0.1
0.2
Kidney Cancer 8120613
0.0
0.0

CC Margin (ODO3866)
0.1
0.3
Kidney Margin 8120614
0.0
0.1

CC Gr.2 rectosigmoid (ODO3868)
0.1
0.0
Kidney Cancer 9010320
0.0
0.1

CC Margin (ODO3868)
0.0
0.1
Kidney Margin 9010321
0.0
0.0

CC Mod Diff (ODO3920)
0.1
0.1
Normal Uterus
0.0
0.0

CC Margin (ODO3920)
0.0
0.1
Uterine Cancer 064011
0.0
0.0

CC Gr.2 ascend colon (ODO3921)
0.1
0.2
Normal Thyroid
0.0
0.1

CC Margin (ODO3921)
0.2
0.0
Thyroid Cancer
0.0
0.0

CC from Partial Hepatectomy
0.2
0.1
Thyroid Cancer A302152
0.0
0.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.1
0.1
Thyroid Margin A302153
0.0
0.0

Colon mets to lung (ODO4451-01)
0.0
0.0
Normal Breast
3.1
2.4

Lung Margin (ODO4451-02)
0.0
0.0
Breast Cancer
0.0
0.0

Normal Prostate 6546-1
2.8
15.9
Breast Cancer (ODO4590-01)
100.0
71.7

Prostate Cancer (ODO4410)
22.4
30.1
Breast Cancer Mets
39.8
33.9

(ODO4590-03)

Prostate Margin (ODO4410)
9.7
9.9
Breast Cancer Metastasis
4.5
7.1

Prostate Cancer (ODO4720-01)
6.0
8.5
Breast Cancer
0.4
0.0

Prostate Margin (ODO4720-02)
3.9
3.7
Breast Cancer
1.2
0.9

Normal Lung
0.0
0.0
Breast Cancer 9100266
93.3
100.0

Lung Met to Muscle (ODO4286)
0.0
0.0
Breast Margin 9100265
28.7
33.0

Muscle Margin (ODO4286)
0.0
0.0
Breast Cancer A209073
2.9
3.4

Lung Malignant Cancer
0.0
0.1
Breast Margin A209073
5.9
7.0

(ODO3126)

Lung Margin (ODO3126)
0.0
0.0
Normal Liver
0.4
0.4

Lung Cancer (ODO4404)
0.0
0.0
Liver Cancer
0.0
0.0

Lung Margin (ODO4404)
0.0
0.0
Liver Cancer 1025
0.0
0.1

Lung Cancer (ODO4565)
0.0
0.0
Liver Cancer 1026
0.0
0.0

Lung Margin (ODO4565)
0.1
0.0
Liver Cancer 6004-T
0.1
0.0

Lung Cancer (ODO4237-01)
0.0
0.1
Liver Tissue 6004-N
0.7
0.4

Lung Margin (ODO4237-02)
0.1
0.0
Liver Cancer 6005-T
0.0
0.0

Ocular Mel Met to Liver
0.0
0.0
Liver Tissue 6005-N
0.2
0.0

(ODO4310)

Liver Margin (ODO4310)
0.0
0.1
Normal Bladder
0.0
0.2

Melanoma Metastasis
0.0
0.0
Bladder Cancer
0.1
0.0

Lung Margin (ODO4321)
0.0
0.0
Bladder Cancer
0.2
0.4

Normal Kidney
0.0
0.0
Bladder Cancer (ODO4718-
0.0
0.0

01)

Kidney Ca, Nuclear grade 2
0.1
0.3
Bladder Normal Adjacent
0.0
0.0

(ODO4338)

(ODO4718-03)

Kidney Margin (ODO4338)
0.1
0.0
Normal Ovary
0.0
0.0

Kidney Ca Nuclear grade 1/2
0.1
0.3
Ovarian Cancer
0.0
0.0

(ODO4339)

Kidney Margin (ODO4339)
0.0
0.0
Ovarian Cancer (ODO4768-
0.0
0.0

07)

Kidney Ca, Clear cell type
0.0
0.1
Ovary Margin (ODO4768-08)
0.0
0.0

(ODO4340)

Kidney Margin (ODO4340)
0.0
0.0
Normal Stomach
0.0
0.1

Kidney Ca, Nuclear grade 3
0.0
0.0
Gastric Cancer 9060358
0.0
0.0

(ODO4348)

Kidney Margin (ODO4348)
0.0
0.0
Stomach Margin 9060359
0.0
0.2

Kidney Cancer (ODO4622-01)
0.0
0.0
Gastric Cancer 9060395
0.0
0.0

Kidney Margin (ODO4622-03)
0.0
0.1
Stomach Margin 9060394
0.0
0.0

Kidney Cancer (ODO4450-01)
0.0
0.0
Gastric Cancer 9060397
0.0
0.3

Kidney Margin (ODO4450-03)
0.0
0.0
Stomach Margin 9060396
0.0
0.0

Kidney Cancer 8120607
0.0
0.0
Gastric Cancer 064005
0.1
0.7

Table FG

Panel 3D

Column A - Rel. Exp.(%) Ag2503, Run 164629451

Column B - Rel. Exp.(%) Ag2503, Run 182113494

Tissue Name
A
B
Tissue Name
A
B

94905 Daoy
0.0
0.0
94954 Ca Ski Cervical
0.0
17.9

Medulloblastoma/Cerebellum

epidermoid carcinoma

(metastasis

94906 TE671
0.0
0.0
94955 ES-2 Ovarian clear cell
0.0
0.0

Medulloblastoni/Cerebellum

carcinoma

94907 D283 Med
7.7
12.2
94957 Ramos Stimulated with
0.0
0.0

Medulloblastoma/Cerebellum

PMA/ionomycin 6h

94908 PFSK-1 Primitive
10.5
57.0
94958 Ramos Stimulated with
0.0
0.0

Neuroectodermal/Cerebellum

PMA/ionomycin 14h

94909 XF-498 CNS
0.0
0.0
94962 MEG-01 Chronic
5.9
12.3

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
0.0
0.0
94963 Raji Burkitt's lymphoma
0.0
0.0

94911 SF-268 CNS/glioblastoma
0.0
0.0
94964 Daudi Burkitt's
0.0
0.0

lymphoma

94912 T98G Glioblastoma
0.0
0.0
94965 U266 B-cell
0.0
0.0

plasmacytoma/myeloma

96776 SK-N-SH Neuroblastoma
0.0
7.9
94968 CA46 Burkitt's
0.0
0.0

(metastasis)

lymphoma

94913 SF-295 CNS/glioblastoma
0.0
0.0
94970 RL non-Hodgkin's B-
0.0
0.0

cell lymphoma

94914 Cerebellum
24.5
63.3
94972 JM1 pre-B-cell
0.0
0.0

lymphoma/leukemia

96777 Cerebellum
8.5
12.9
94973 Jurkat T cell leukemia
0.0
0.0

94916 NCI-H292
0.0
0.0
94974 TF-1 Erythroleukemia
2.0
0.0

Mucoepidermoid lung carcinoma

94917 DMS-114 Small cell lung
4.1
0.0
94975 HUT 78 T-cell
2.7
0.0

cancer

lymphoma

94918 DMS-79 Small cell lung
1.9
0.0
94977 U937 Histiocytic
0.0
0.0

cancer/neuroendocrine

lymphoma

94919 NCI-H146 Small cell lung
100.0
100.0
94980 KU-812 Myelogenous
0.0
0.0

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
0.0
0.0
769-P-Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94921 NCI-N417 Small cell lung
0.0
6.3
94983 Caki-2 Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
0.0
1.7
94984 SW 839 Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell
0.0
0.0
94986 G401 Wilms' tumor
0.0
0.0

lung cancer (metastasis)

94925 NCI-H1155 Large cell lung
30.6
23.7
94987 Hs766T Pancreatic
0.0
0.0

cancer/neuroendocrine

carcinoma (LN metastasis)

94926 NCI-H1299 Large cell lung
0.0
0.0
94988 CAPAN-1 Pancreatic
0.0
0.0

cancer/neuroendocrine

adenocarcinoma (liver

metastasis)

94927 NCI-H727 Lung carcinoid
0.0
0.0
94989 SU86.86 Pancreatic
0.0
0.0

carcinoma (liver metastasis)

94928 NCI-UMC-11 Lung
13.3
6.4
94990 BxPC-3 Pancreatic
0.0
0.0

carcinoid

adenocarcinoma

94929 LX-1 Small cell lung
0.0
57
94991 HPAC Pancreatic
0.0
0.0

cancer

adenocarcinoma

94930 Colo-205 Colon cancer
0.0
0.0
94992 MIA PaCa-2 Pancreatic
0.0
0.0

carcinoma

94931 KM12 Colon cancer
1.2
0.0
94993 CFPAC-1 Pancreatic
3.8
16.0

ductal adenocarcinoma

94932 KM20L2 Colon cancer
0.0
0.0
94994 PANG-1 Pancreatic
0.0
0.0

epithelioid ductal carcinoma

94933 NCI-H716 Colon cancer
2.8
0.0
94996 T24 Bladder carcinma
1.9
0.0

(transitional cell

94935 SW-48 Colon
0.0
0.0
5637- Bladder carcinoma
0.0
0.0

adenocarcinoma

94936 SW1116 Colon
0.0
0.0
94998 HT-1197 Bladder
0.0
0.0

adenocarcinoma

carcinoma

94937 LS 174T Colon
0.0
0.0
94999 UM-UC-3 Bladder
0.0
0.0

adenocarcinoma

carcinma (transitional cell)

94938 SW-948 Colon
0.0
0.0
95000 A204
0.0
0.0

adenocarcinoma

Rhabdomyosarcoma

94939 SW-480 Colon
0.0
0.0
95001 HT-1080 Fibrosarcoma
0.0
0.0

adenocarcinoma

94940 NCI-SNU-5 Gastric
0.0
0.0
95002 MG-63 Osteosarcoma
0.0
0.0

carcinoma

(bone)

KATO III- Gastric carcinoma
5.5
15.3
95003 SK-LMS-1
1.3
0.0

Leiomyosarcoma (vulva)

94943 NCI-SNU-16 Gastric
0.0
0.0
95004 SJRH30
2.5
0.0

carcinoma

Rhabdomyosarcoma (met to

bone marrow)

94944 NCI-SNU-1 Gastric
0.0
0.0
95005 A431 Epidermoid
0.0
0.0

carcinoma

carcinoma

94946 RF-1 Gastric
0.0
0.0
95007 WM266-4 Melanoma
1.6
0.0

adenocarcinoma

94947 RF-48 Gastric
0.0
0.0
DU 145- Prostate carcinoma
0.0
0.0

adenocarcinoma

(brain metastasis)

96778 MKN-45 Gastric carcinoma
0.0
0.0
95012 MDA-MB-468 Breast
0.0
0.0

adenocarcinoma

94949 NCI-N87 Gastric
0.0
0.0
SCC-4- Squamous cell
0.0
0.0

carcinoma

carcinoma of tongue

94951 OVCAR-5 Ovarian
3.1
0.0
SCC-9- Squamous cell
0.0
0.0

carcinoma

carcinoma of tongue

94952 RL95-2 Uterine carcinoma
0.0
0.0
SCC-15 Squamous cell
0.0
0.0

carcinoma of tongue

94953 HelaS3 Cervical
0.0
0.0
95017 CAL 27 Squamous cell
0.0
0.0

adenocarcinoma

carcinoma of tongue

Ardais Breast1.0 Summary: Ag2503 Highest expression of this gene was seen in three breast cancer samples (CTs=23.9-25). Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is of use in the treatment of breast cancers.

Ardais Panel v.1.0 Summary: Ag2503 Highest expression of this gene was seen in a lung cancer (369) sample (CT=25). Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is of use in the treatment of lung cancers.

Ardais Prostate 1.0 Summary: Ag2503 Highest expression of this gene was seen in a prostate cancer (B8B) sample (CT=21). This gene showed relatively higher expression in the prostate cancer samples compared to the other samples on this panel. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is of use in the treatment of prostate cancers.

General_screening_panel_v1.4 Summary: Ag2503 Highest expression of this gene was detected in the thalamus and the cerebral cortex (CTs=25). This gene showed brain preferential expression, with high expression in hippocampus, cortex, amygdala, substantia nigra and thalamus. These regions are susceptible to the neurodegeneration associated with Alzheimer's Disease, Parkinson's disease, Huntington's disease and other pathological neurodegenerative conditions. This gene encodes a protein that is homologous to a potassium channel. Potassium channels play a role in neurodegenerative diseases, including Alzheimer's Disease (Chi X Neurosci Lett 2000 Aug. 18; 290(1):9-12; Yu SP Neurobiol Dis 1998 August; 5(2):81-8). Therefore, modulation of this gene or its protein product is useful to reduce the neuronal degeneration in patients with Alzheimer's Disease and other neurodegenerative diseases. Defective potassium channels are known to cause several CNS disorders, including epilepsy and episodic ataxia with myokymia. Therefore, modulation of this gene and/or expressed protein is useful as a treatment for the symptoms produced by ataxia and epilepsy.

Moderate to low expression was also seen in normal prostate and in cell lines derived from breast, lung, and ovarian cancer. Thus, expression of this gene is useful as a diagnostic marker to detect the presence of these cancers. Use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of these cancers.

This gene showed significantly higher levels of expression in the fetal kidney (CTs=30-31) relative to the adult kidney (CTs=35-36). The higher levels of expression in the fetal kidney demonstrate that this gene product is involved in the development of this organ. Modulation of this gene and/or encoded protein is useful in the treatment of kidney related diseases such as lupus erythematus and glomerulonephritis.

Among tissues with metabolic function, the expression of this potassium channel homolog was highest in the pituitary gland. Potassium channels are involved in regulation of secretion in pituitary cells and their modulation by use of small molecule inhibitors or antibodies is important to modulate specific secretory activities in the pituitary.

Panel 2D Summary: Ag2503 The highest level of expression was seen in a breast cancer sample (CTs=25-27). Higher expression of this gene was seen in breast and prostate cancer samples compared to the corresponding normal adjacent tissue. Expression of this gene is useful as a diagnostic marker of these cancers and use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of these cancers.

Panel 3D Summary: Ag2503 The highest level of expression was seen in a lung cancer cell line (NCI-H146) (CTs=30-33.4). Low expression of this gene was observed in normal cerebellum and cell lines derived from lung cancer, and medulloblastoma. The expression of this gene is useful as a diagnostic marker for lung cancer and use of antibodies, protein therapeutics or small molecule drug is beneficial in the treatment of lung cancer.

G. CG50307-03: Steroid Dehydrogenase

Expression of full-length physical clone CG50307-03 was assessed using the primer-probe sets Ag2248 and Ag2548, described in Tables GA and GB. Results of the RTQ-PCR runs are shown in Tables GC, GD, GE, GF and GG.

TABLE GAProbe Name Ag2248StartSEQ IDPrimersSequencesLengthPositionNoForward5′-agcctacgctgaagagttagc-3′218041151ProbeTET-5′-aagccgaggtctcaatataatcctga-3′-267781152TAMRAReverse5′-acctgcaacttctcctcgtt-3′207501153

TABLE GC

Panel 1.3D

Column A - Rel. Exp.(%) Ag2248, Run 159035206

Column B - Rel. Exp.(%) Ag2548, Run 162292266

Tissue Name
A
B
Tissue Name
A
B

Liver adenocarcinoma
8.7
25.5
Kidney (fetal)
5.0
14.1

Pancreas
1.1
1.7
Renal Ca. 786-0
5.3
7.5

Pancreatic ca. CAPAN-2
2.2
6.3
Renal Ca. A498
10.2
9.0

Adrenal gland
6.6
6.0
Renal Ca. RXF 393
1.5
9.0

Thyroid
9.0
19.3
Renal ca. ACHN
1.7
12.8

Salivary gland
2.9
3.7
Renal ca. UO-31
5.4
15.1

Pituitary gland
19.8
16.2
Renal Ca. TK-10
1.5
6.7

Brain (fetal)
28.3
14.3
Liver
1.3
0.4

Brain (whole)
22.7
25.2
Liver (fetal)
3.1
2.3

Brain (amygdala)
24.7
24.3
Liver ca. (hepatoblast) HepG2
8.1
18.7

Brain (cerebellum)
11.6
14.6
Lung
10.2
7.4

Brain (hippocampus)
100.0
45.1
Lung (fetal)
9.5
12.5

Brain (substantia nigra)
5.1
7.2
Lung Ca. (small cell) LX-1
11.0
16.0

Brain (thalamus)
19.2
25.2
Lung Ca. (small cell) NCI-H69
7.5
6.3

Cerebral Cortex
44.8
100.0
Lung Ca. (s.cell var.) SHP-77
42.9
73.7

Spinal cord
4.8
14.9
Lung Ca. (large cell) NCI-H460
2.7
10.1

glio/astro U87-MG
11.7
42.3
Lung Ca. (non-sm. cell) A549
1.8
4.1

glio/astro U-118-MG
20.7
12.0
Lung Ca. (non-s.cell) NCI-H23
11.7
28.5

astrocytoma SW1783
8.1
38.2
Lung Ca. (non-s.cell) HOP-62
5.3
24.0

neuro*; met SK-N-AS
14.2
6.5
Lung Ca. (non-s.cl) NCI-H522
5.0
15.1

astrocytoma SF-539
3.9
15.2
Lung Ca. (squam.) SW 900
3.4
12.6

astrocytoma SNB-75
8.8
11.3
Lung Ca. (squam.) NCI-H596
1.5
1.9

glioma SNB-19
4.1
20.0
Mammary gland
7.5
9.6

glioma U251
2.5
5.8
Breast ca.* (pl.ef) MCF-7
25.3
88.9

glioma SF-295
3.4
24.0
Breast ca.* (pl.ef) MDA-MB-
21.8
6.4

231

Heart (Fetal)
9.7
35.1
Breast ca.* (pl.ef) T47D
13.6
29.3

Heart
3.6
11.4
Breast ca. BT-549
22.1
7.4

Skeletal muscle (Fetal)
8.2
44.1
Breast Ca. MDA-N
5.7
11.1

Skeletal muscle
5.6
47.6
Ovary
5.4
26.6

Bone marrow
3.2
1.7
Ovarian Ca. OVCAR-3
2.5
4.8

Thymus
3.5
40.6
Ovarian Ca. OVCAR-4
0.6
3.6

Spleen
5.4
10.9
Ovarian Ca. OVCAR-5
3.8
13.1

Lymph node
2.8
4.4
Ovarian Ca. OVCAR-8
5.9
21.2

Colorectal
1.9
9.4
Ovarian Ca. IGROV-1
1.4
3.1

Stomach
2.2
2.7
Ovarian Ca. (ascites) SK-OV-3
5.3
13.1

Small intestine
5.0
7.3
Uterus
3.9
6.0

Colon Ca. SW480
6.0
12.6
Placenta
5.2
8.8

Colon Ca.* SW620 (SW480
4.7
11.1
Prostate
2.0
6.7

met)

Colon Ca. HT29
2.6
7.1
Prostate Ca.* (bone met) PC-3
5.4
9.7

Colon Ca. HCT-116
9.5
22.4
Testis
7.7
24.8

Colon Ca. CaCo-2
6.7
18.0
Melanoma Hs688(A).T
3.3
7.7

CC Well to Mod Duff
4.8
13.2
Melanoma* (met) Hs688(B).T
1.2
6.9

(ODO3866)

Colon Ca. HCC-2998
17.2
10.2
Melanoma UACC-62
1.5
5.6

Gastric ca. (liver met) NCI-N87
10.8
14.7
Melanoma M14
4.3
8.1

Bladder
2.6
11.0
Melanoma LOX IMVI
4.8
2.9

Trachea
6.4
13.8
Melanoma* (met) SK-MEL-5
6.9
10.4

Kidney
1.7
14.1
Adipose
2.3
6.0

TABLE GD

Panel 2D

Column A - Rel. Exp.(%) Ag2248, Run 159035545

Column B - Rel. Exp.(%) Ag2548, Run 162326203

Tissue Name
A
B
Tissue Name
A
B

Normal Colon
49.3
39.5
Kidney Margin 8120608
4.7
6.3

CC Well to Mod Diff (ODO3866)
14.2
10.7
Kidney Cancer 8120613
7.1
14.0

CC Margin (ODO3866)
10.7
8.9
Kidney Margin 8120614
8.8
10.7

CC Gr.2 rectosigmoid (ODO3868)
6.5
5.9
Kidney Cancer 9010320
10.9
13.7

CC Margin (ODO3868)
5.8
6.9
Kidney Margin 9010321
9.7
18.4

CC Mod Diff (ODO3920)
38.4
21.5
Normal Uterus
6.5
8.0

CC Margin (ODO3920)
14.5
9.5
Uterine Cancer 064011
42.9
24.1

CC Gr.2 ascend colon (ODO3921)
25.5
15.8
Normal Thyroid
40.3
31.0

CC Margin (ODO3921)
7.7
5.9
Thyroid Cancer
21.0
21.0

CC from Partial Hepatectomy
32.5
28.5
Thyroid Cancer A302152
21.9
18.4

(ODO4309) Mets

Liver Margin (ODO4309)
12.2
9.0
Thyroid Margin A302153
37.9
39.0

Colon mets to lung (ODO4451-01)
15.6
8.5
Normal Breast
18.9
23.8

Lung Margin (ODO4451-02)
12.6
9.2
Breast Cancer
14.2
20.2

Normal Prostate 6546-1
6.6
57.4
Breast Cancer (ODO4590-01)
100.0
100.0

Prostate Cancer (ODO4410)
40.3
30.1
Breast Cancer Mets
87.1
90.1

(ODO4590-03)

Prostate Margin (ODO4410)
27.0
21.8
Breast Cancer Metastasis
37.6
37.4

Prostate Cancer (ODO4720-01)
28.5
18.3
Breast Cancer
14.6
14.1

Prostate Margin (ODO4720-02)
35.8
25.0
Breast Cancer
27.4
28.9

Normal Lung
56.6
39.0
Breast Cancer 9100266
46.7
41.5

Lung Met to Muscle (ODO4286)
33.4
22.7
Breast Margin 9100265
15.5
16.7

Muscle Margin (ODO4286)
22.1
12.3
Breast Cancer A209073
42.3
42.9

Lung Malignant Cancer
33.4
27.0
Breast Margin A209073
21.3
17.2

(ODO3126)

Lung Margin (ODO3126)
27.5
21.9
Normal Liver
5.4
4.6

Lung Cancer (ODO4404)
13.3
14.9
Liver Cancer
3.8
3.0

Lung Margin (ODO4404)
12.0
11.6
Liver Cancer 1025
4.2
2.3

Lung Cancer (ODO4565)
14.1
14.3
Liver Cancer 1026
3.0
1.3

Lung Margin (ODO4565)
6.9
11.0
Liver Cancer 6004-T
3.6
1.6

Lung Cancer (ODO4237-01)
95.9
82.4
Liver Tissue 6004-N
11.7
9.0

Lung Margin (ODO4237-02)
15.5
13.7
Liver Cancer 6005-T
2.2
2.9

Ocular Mel Met to Liver
27.4
19.9
Liver Tissue 6005-N
4.4
3.8

(ODO4310)

Liver Margin (ODO4310)
5.1
3.4
Normal Bladder
26.6
16.0

Melanoma Metastasis
24.8
18.8
Bladder Cancer
5.0
3.0

Lung Margin (ODO4321)
23.8
20.0
Bladder Cancer
17.1
8.8

Normal Kidney
40.1
48.0
Bladder Cancer (ODO4718-
22.2
15.5

01)

Kidney Ca, Nuclear grade 2
30.6
41.8
Bladder Normal Adjacent
21.2
15.6

(ODO4338)

(ODO4718-03)

Kidney Margin (ODO4338)
16.4
15.9
Normal Ovary
12.6
8.8

Kidney Ca Nuclear grade 1/2
11.3
15.8
Ovarian Cancer
21.6
16.5

(ODO4339)

Kidney Margin (ODO4339)
19.6
24.5
Ovarian Cancer (ODO4768-
40.1
33.9

07)

Kidney Ca, Clear cell type
20.4
30.8
Ovary Margin (ODO4768-08)
11.3
4.0

(ODO4340)

Kidney Margin (ODO4340)
18.4
13.9
Normal Stomach
12.2
8.8

Kidney Ca, Nuclear grade 3
13.3
6.1
Gastric Cancer 9060358
5.0
3.0

(ODO4348)

Kidney Margin (ODO4348)
21.2
19.3
Stomach Margin 9060359
16.0
11.0

Kidney Cancer (ODO4622-01)
19.3
19.2
Gastric Cancer 9060395
16.3
12.6

Kidney Margin (ODO4622-03)
4.4
5.3
Stomach Margin 9060394
13.9
10.6

Kidney Cancer (ODO4450-01)
23.8
27.0
Gastric Cancer 9060397
24.0
12.1

Kidney Margin (ODO4450-03)
15.2
20.0
Stomach Margin 9060396
6.4
7.1

Kidney Cancer 8120607
5.6
4.2
Gastric Cancer 064005
37.1
20.3

TABLE GE

Panel 3D

Column A - Rel. Exp.(%) Ag2548, Run 164886193

Tissue Name
A
Tissue Name
A

94905 Daoy
8.7
94954 Ca Ski Cervical epidermoid
10.6

Medulloblastoma/Cerebellum

carcinoma (metastasis

94906 TE671
10.7
94955 ES-2 Ovarian clear cell
11.3

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
40.6
94957 Ramos Stimulated with
2.0

Medulloblastoma/Cerebellum

PMA/ionomycin 6 h

94908 PFSK-l Primitive
9.0
94958 Ramos Stimulated with
8.8

Neuroectodermal/Cerebellum

PMA/ionomycin 14 h

94909 XF-498 CNS
9.3
94962 MEG-01 Chronic
11.5

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
12.9
94963 Raji Burkitt's lymphoma
4.5

94911 SF-268 CNS/glioblastoma
9.4
94964 Daudi Burkitt's lymphoma
12.0

94912 T98G Glioblastoma
13.7
94965 U266 B-cell
28.1

plasmacytoma/myeloma

96776 SK-N-SH Neuroblastoma
14.9
94968 CA46 Burkitt's lymphoma
9.2

(metastasis)

94913 SF-295 CNS/glioblastoma
9.9
94970 RL non-Hodgkin's B-cell
2.2

lymphoma

94914 Cerebellum
21.5
94972 JM1 pre-B-cell
6.3

lymphoma/leukemia

96777 Cerebellum
6.0
94973 Jurkat T cell leukemia
18.7

94916 NCI-H292 Mucoepidermoid
25.7
94974 TF-l Erythroleukemia
9.7

lung carcinoma

94917 DMS-114 Small cell lung
16.3
94975 HUT 78 T-cell lymphoma
17.1

cancer

94918 DMS-79 Small cell lung
100.0
94977 U937 Histiocytic lymphoma
11.2

cancer/neuroendocrine

94919 NCI-H146 Small cell lung
20.9
94980 KU-812 Myelogenous
5.3

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
36.6
769-P-Clear cell renal carcinoma
6.2

cancer/neuroendocrine

94921 NCI-N417 Small cell lung
9.7
94983 Caki-2 Clear cell renal
8.1

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
14.2
94984 SW 839 Clear cell renal
2.9

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell lung
19.6
94986 G401 Wilms' tumor
8.8

cancer (metastasis)

94925 NCI-H1155 Large cell lung
34.6
94987 Hs766T Pancreatic carcinoma
13.3

cancer/neuroendocrine

(LN metastasis)

94926 NCI-H1299 Large cell lung
19.9
94988 CAPAN-1 Pancreatic
7.7

cancer/neuroendocrine

adenocarcinoma (liver metastasis)

94927 NCI-H727 Lung carcinoid
14.2
94989 SU86.86 Pancreatic carcinoma
10.0

(liver metastasis)

94928 NCI-UMC-11 Lung carcinoid
12.6
94990 BxPC-3 Pancreatic
4.3

adenocarcinoma

94929 LX-1 Small cell lung cancer
20.0
94991 HPAC Pancreatic
6.6

adenocarcinoma

94930 Colo-205 Colon cancer
15.8
94992 MIA PaCa-2 Pancreatic
4.6

carcinoma

94931 KM12 Colon cancer
9.3
94993 CFPAC-1 Pancreatic ductal
19.5

adenocarcinoma

94932 KM20L2 Colon cancer
3.0
94994 PANC-1 Pancreatic epithelioid
9.5

ductal carcinoma

94933 NCI-H716 Colon cancer
19.1
94996 T24 Bladder carcinma
9.9

(transitional cell

94935 SW-48 Colon adenocarcinoma
7.9
5637- Bladder carcinoma
4.7

94936 SW1116 Colon
7.4
94998 HT-1197 Bladder carcinoma
6.1

adenocarcinoma

94937 LS 174T Colon
4.6
94999 UM-UC-3 Bladder carcimia
2.8

adenocarcinoma

(transitional cell)

94938 SW-948 Colon
1.1
95000 A204 Rhabdomyosarcoma
3.4

adenocarcinoma

94939 SW-480 Colon
2.7
95001 HT-1080 Fibrosarcoma
10.7

adenocarcinoma

94940 NCI-SNU-5 Gastric carcinoma
9.3
95002 MG-63 Osteosarcoma (bone)
1.3

KATO III-Gastric carcinoma
24.0
95003 SK-LMS-1 Leiomyosarcoma
9.5

(vulva)

94943 NCI-SNU-16 Gastric
9.5
95004 SJRH30 Rhabdomyosarcoma
10.2

carcinoma

(met to bone marrow)

94944 NCI-SNU-1 Gastric carcinoma
12.2
95005 A431 Epidermoid carcinoma
5.0

94946 RF-1 Gastric adenocarcinoma
5.1
95007 WM266-4 Melanoma
10.5

94947 RF-48 Gastric adenocarcinoma
8.1
DU 145-Prostate carcinoma (brain
0.0

metastasis)

96778 MKN-45 Gastric carcinoma
5.3
95012 MDA-MB-468 Breast
20.7

adenocarcinoma

94949 NCI-N87 Gastric carcinoma
7.4
SCC-4-Squamous cell carcinoma of
0.0

tongue

94951 OVCAR-5 Ovarian carcinoma
2.7
SCC-9-Squamous cell carcinoma of
0.0

tongue

94952 RL95-2 Uterine carcinoma
3.8
SCC-15-Squamous cell carcinoma of
0.0

tongue

94953 HelaS3 Cervical
10.7
95017 CAL 27 Squamous cell
5.5

adenocarcinoma

carcinoma of tongue

TABLE GF

Panel 4D

Column A - Rel. Exp.(%) Ag2248, Run 159034717

Tissue Name
A
Tissue Name
A

Secondary Th1 act
27.2
HUVEC IL-1 beta
8.4

Secondary Th2 act
33.4
HUVEC IFN gamma
14.4

Secondary Tr1 act
37.4
HUVEC TNF alpha + IFN gamma
7.4

Secondary Th1 rest
11.7
HUVEC TNF alpha + IL4
6.6

Secondary Th2 rest
10.4
HUVEC IL-11
11.8

Secondary Tr1 rest
12.5
Lung Microvascular EC none
9.9

Primary Th1 act
28.5
Lung Microvascular EC TNFalpha + IL-
18.2

1 beta

Primary Th2 act
29.3
Microvascular Dermal EC none
28.9

Primary Tr1 act
29.3
Microsvasular Dermal EC TNFalpha + IL-
20.2

1 beta

Primary Th1 rest
62.4
Bronchial epithelium TNFalpha + IL1 beta
20.7

Primary Th2 rest
39.8
Small airway epithelium none
6.9

Primary Tr1 rest
15.3
Small airway epithelium TNFalpha + IL-
40.3

1 beta

CD45RA CD4 lymphocyte act
18.6
Coronery artery SMC rest
15.4

CD45RO CD4 lymphocyte act
20.9
Coronery artery SMC TNFalpha + IL-1 beta
6.8

CD8 lymphocyte act
14.7
Astrocytes rest
20.0

Secondary CD8 lymphocyte rest
11.9
Astrocytes TNFalpha + IL-1 beta
15.8

Secondary CD8 lymphocyte act
19.9
KU-812 (Basophil) rest
8.1

CD4 lymphocyte none
8.2
KU-812 (Basophil) PMA/ionomycin
20.2

2ry Th1/Th2/Tr1 anti-CD95
17.4
CCD1106 (Keratinocytes) none
11.5

CH11

LAK cells rest
19.2
CCD1106 (Keratinocytes) TNFalpha + IL-
5.3

1 beta

LAK cells IL-2
18.2
Liver cirrhosis
2.4

LAK cells IL-2 + IL-12
11.0
Lupus kidney
1.8

LAK cells IL-2 + IFN gamma
19.5
NCI-H292 none
39.5

LAK cells IL-2 + IL-18
17.7
NCI-H292 IL-4
38.2

LAK cells PMA/ionomycin
3.6
NCI-H292 IL-9
40.1

NK Cells IL-2 rest
11.0
NCI-H292 IL-13
18.2

Two Way MLR 3 day
19.2
NCI-H292 IFN gamma
14.7

Two Way MLR 5 day
8.9
HPAEC none
19.2

Two Way MLR 7 day
6.7
HPAEC TNF alpha + IL-1 beta
28.5

PBMC rest
5.8
Lung fibroblast none
17.4

PBMC PWM
40.6
Lung fibroblast TNF alpha + IL-1 beta
17.1

PBMC PHA-L
25.9
Lung fibroblast IL-4
30.4

Ramos (B cell) none
26.6
Lung fibroblast IL-9
20.2

Ramos (B cell) ionomycin
100.0
Lung fibroblast IL-13
16.3

B lymphocytes PWM
35.6
Lung fibroblast LFN gamma
28.1

B lymphocytes CD40L and IL-4
29.7
Dermal fibroblast CCD1070 rest
32.3

EOL-1 dbcAMP
10.5
Dermal fibroblast CCD1070 TNF alpha
57.0

EOL-1 dbcAMP
7.5
Dermal fibroblast CCD1070 IL-1 beta
15.3

PMA/ionomycin

Dendritic cells none
11.6
Dermal fibroblast IFN gamma
12.1

Dendritic cells LPS
7.7
Dermal fibroblast IL-4
20.3

Dendritic cells anti-CD40
9.6
IBD Colitis 2
2.3

Monocytes rest
12.6
IBD Crohn's
2.6

Monocytes LPS
21.0
Colon
11.5

Macrophages rest
24.5
Lung
16.2

Macrophages LPS
14.8
Thymus
38.7

HUVEC none
25.9
Kidney
71.2

HUVEC starved
40.9

TABLE GG

Panel 5 Islet

Column A - Rel. Exp.(%) Ag2248, Run 233070521

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
23.7
94709 Donor 2 AM - A adipose
10.5

97476 Patient-07sk skeletal muscle
12.3
94710 Donor 2 AM - B adipose
5.0

97477 Patient-07ut uterus
18.9
94711 Donor 2 AM - C adipose
5.3

97478 Patient-07pl placenta
35.6
94712 Donor 2 AD - A adipose
14.5

99167 Bayer Patient 1
25.0
94713 Donor 2 AD - B adipose
25.2

97482 Patient-08ut uterus
23.2
94714 Donor 2 AD - C adipose
18.7

97483 Patient-08pl placenta
25.5
94742 Donor 3 U - A Mesenchymal
7.4

Stem Cells

97486 Patient-09sk skeletal muscle
0.7
94743 Donor 3 U - B Mesenchymal
11.2

Stem Cells

97487 Patient-09ut uterus
23.0
94730 Donor 3 AM - A adipose
14.6

97488 Patient-09pl placenta
15.3
94731 Donor 3 AM - B adipose
4.5

97492 Patient-10ut uterus
15.1
94732 Donor 3 AM - C adipose
10.5

97493 Patient-10pl placenta
52.9
94733 Donor 3 AD - A adipose
40.1

97495 Patient-11go adipose
9.1
94734 Donor 3 AD - B adipose
16.0

97496 Patient-11sk skeletal muscle
10.2
94735 Donor 3 AD - C adipose
14.0

97497 Patient-11ut uterus
21.8
77138 Liver HepG2untreated
100.0

97498 Patient-11pl placenta
36.3
73556 Heart Cardiac stromal cells
9.5

(primary)

97500 Patient-12go adipose
21.0
81735 Small Intestine
8.7

97501 Patient-12sk skeletal muscle
35.4
72409 Kidney Proximal Convoluted
16.7

Tubule

97502 Patient-12ut uterus
15.5
82685 Small intestine Duodenum
5.1

97503 Patient-12p1 placenta
9.5
90650 Adrenal Adrenocortical
18.0

adenoma

94721 Donor 2 U - A Mesenchymal
8.3
72410 Kidney HRCE
42.0

Stem Cells

94722 Donor 2 U - B Mesenchymal
8.3
72411 Kidney HRE
27.0

Stem Cells

94723 Donor 2 U - C Mesenchymal
20.4
73139 Uterus Uterine smooth muscle
41.5

Stem Cells

cells

Panel 1.3D Summary: Ag2248/Ag2548 Highest expression of this gene was detected seen in regions of the brain (CTs=28-29).

This gene encodes a protein that is homologous to steroid dehydrogenase. Steroid treatment is used in a number of clinical conditions including Alzheimer's disease (estrogen), treatment of symptoms associated with menopause (estrogen), multiple sclerosis (glucocorticoids), and spinal cord injury (methylprednisolone). Treatment with an antagonst of this gene product, or reduction of the levels of this gene product is useful for the inhibition of steroid degredation and for lowering the necessary amount given for a therapeutic effect, thus reducing peripheral side effects.

This gene was moderately expressed in a variety of metabolic tissues including pancreas, adrenal, thyroid, pituitary, adult and fetal heart, adult and fetal skeletal muscle, fetal liver, and adipose. This gene product is a small molecule drug target for the treatment of metabolic disease, including obesity and Types 1 and 2 diabetes.

The ubiquitous expression of this gene in this panel also showed that the protein encoded by this gene plays a role in cell survival and proliferation for a majority of cell types. There are significant levels of expression in the lung cancer cell line SHP-77. Expression of this gene is of use as a diagnostic marker for lung cancer. Modulation of the gene product is useful in the treatment of lung cancer

Panel 2D Summary: Ag2248/Ag2548 The highest level of expression was seen in a breast cancer sample (CTs=27-29). In addition, this gene was overexpressed in ovarian, gastric, breast, uterine, lung and colon cancers relative to the normal adjacent tissues from these patients. The expression of this gene is of use as a diagnostic marker for the presence of these cancers. Therapeutic inhibition of the activity of this gene product is effective in the treatment of these cancers.

Panel 3D Summary: Ag2548 This gene was expressed at a low to moderate level in most of the cells and tissues used in this panel, with highest expression in the small cell lung cancer cell line DMS-79 (CT=27.79). This ubiquitous expression showed that the gene product plays a role in cell survival and proliferation for a majority of cell types except cell lines derived from tongue squamous cell carcinoma.

Panel 4D Summary: Ag2248 This gene encodes a steroid dehydrogenase-like protein and was expressed at moderate levels (CT=28-32) in numerous immune cell types and tissues. Small molecule antagonists that block the function of the steroid dehydrogenase-like protein encoded by this gene are useful as therapeutics that reduce or eliminate the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, or rheumatoid arthritis.

Panel 5 Islet Summary: Ag2248 The expression of this novel steroid dehydrogenase-like gene was highest in the liver HepG2 cell line, (CT=32.1). Lower but still significant levels of expression were seen in several placenta samples, uterine smooth muscle, adipose samples, differentiated mesenchymal stem cells, and kidney and skeletal muscle from a diabetic patient. Expression in liver cells and placenta showed that the role of this novel steroid dehydrogenase is similar to the role of other steroid dehydrogenases which are involved in steroid and bile acid metabolism. Very low expression of this gene was also seen in a human pancreatic islet sample. Therefore, small molecule therapeutics against this gene product are effective in disorders in which expression of this gene is dysregulated.

H. CG50315-01: Olfactory Receptor

Expression of full-length physical clone CG50315-01 was assessed using the primer-probe sets Ag1665 and Ag2542, described in Tables HA and HB. Results of the RTQ-PCR runs are shown in Tables HC, HD, and HE.

TABLE HAProbe Name Ag1665StartSEQ IDPrimersSequencesLengthPositionNoForward5′-atcttctttggcaattttgtga-3′223321157ProbeTET-5′-aatgcctccgtcatcctgatttcct-3′-252991158TAMRAReverse5′-atggtcttgatgatgagcagat-3′222771159

TABLE HB

Probe Name Ag2542

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-ggaatgtggggatgattatgtt-3′
22
808
1160

Probe
TET-5′-tccaagtagatgtcaaactctacacccca-
29
777
1161

3′-TAMRA

Reverse
5′-gaggtggctcaggaagaagtac-3′
22
753
1162

TABLE HC

PGI1.0

Column A - Rel. Exp.(%) Ag2542, Run 395549579

Tissue Name
A
Tissue Name
A

162191 Normal Lung 1 (IBS)
0.2
162185 Emphysema Lung 12 (Ardais)
2.4

160468 MD lung
1.9
162184 Emphysema Lung 13 (Ardais)
1.5

156629 MD Lung 13
2.7
162183 Emphysema Lung 14 (Ardais)
2.0

162570 Normal Lung 4 (Aastrand)
1.6
162188 Emphysema Lung 15 (Genomic
41.2

Collaborative)

162571 Normal Lung 3 (Aastrand)
0.5
162177 NAT UC Colon 1(Ardais)
0.0

162187 Fibrosis Lung 2 (Genomic
100.0
162176 UC Colon 1(Ardais)
0.5

Collaborative)

151281 Fibrosis lung 11(Ardais)
3.0
162179 NAT UC Colon 2(Ardais)
1.6

162186 Fibrosis Lung 1 (Genomic
34.6
162178 UC Colon 2(Ardais)
0.0

Collaborative)

162190 Asthma Lung 4 (Genomic
70.7
162181 NAT UC Colon 3(Ardais)
1.7

Collaborative)

160467 Asthma Lung 13 (MD)
1.5
162180 UC Colon 3(Ardais)
0.0

137027 Emphysema Lung 1
0.0
162182 NAT UC Colon 4 (Ardais)
1.2

(Ardais)

137028 Emphysema Lung 2
0.0
137042 UC Colon 1108
1.3

(Ardais)

137040 Emphysema Lung 3
1.7
137029 UC Colon 8215
1.1

(Ardais)

137041 Emphysema Lung 4
5.4
137031 UC Colon 8217
1.6

(Ardais)

137043 Emphysema Lung 5
6.0
137036 UC Colon 1137
0.0

(Ardais)

142817 Emphysema Lung 6
3.5
137038 UC Colon 1491
2.4

(Ardais)

142818 Emphysema Lung 7
6.3
137039 UC Colon 1546
2.8

(Ardais)

142819 Emphysema Lung 8
4.6
162593 Crohn's 47751 (NDRI)
0.0

(Ardais)

142820 Emphysema Lung 9
3.9
162594 NAT Crohn's 47751 (NDRI)
0.0

(Ardais)

142821 Emphysema Lung 10
6.5

(Ardais)

TABLE HD

Panel 2D

Column A - Rel. Exp.(%) Ag2542, Run 165910338

Tissue Name
A
Tissue Name
A

Normal Colon
0.0
Kidney Margin 8120608
5.5

CC Well to Mod Diff (ODO3866)
5.1
Kidney Cancer 8120613
0.0

CC Margin (ODO3866)
0.0
Kidney Margin 8120614
5.9

CC Gr.2 rectosigmoid (ODO3868)
0.0
Kidney Cancer 9010320
0.0

CC Margin (ODO3868)
0.0
Kidney Margin 9010321
5.1

CC Mod Diff (ODO3920)
0.0
Normal Uterus
0.0

CC Margin (ODO3920)
0.0
Uterine Cancer 064011
0.0

CC Gr.2 ascend colon (ODO3921)
0.0
Normal Thyroid
0.0

CC Margin (ODO3921)
9.9
Thyroid Cancer
8.1

CC from Partial Hepatectomy
0.0
Thyroid Cancer A302152
0.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.0
Thyroid Margin A302153
0.0

Colon mets to lung (OD04451-01)
0.0
Normal Breast
0.0

Lung Margin (OD04451-02)
4.0
Breast Cancer
0.0

Normal Prostate 6546-1
0.0
Breast Cancer (OD04590-01)
0.0

Prostate Cancer (OD04410)
0.0
Breast Cancer Mets (0D04590-03)
9.3

Prostate Margin (OD04410)
0.0
Breast Cancer Metastasis
4.8

Prostate Cancer (OD04720-01)
0.0
Breast Cancer
0.0

Prostate Margin (OD04720-02)
0.0
Breast Cancer
0.0

Normal Lung
0.0
Breast Cancer 9100266
0.0

Lung Met to Muscle (ODO4286)
5.1
Breast Margin 9100265
0.0

Muscle Margin (ODO4286)
0.0
Breast Cancer A209073
3.1

Lung Malignant Cancer (OD03126)
0.0
Breast Margin A209073
0.0

Lung Margin (OD03126)
0.0
Normal Liver
0.0

Lung Cancer (OD04404)
22.8
Liver Cancer
0.0

Lung Margin (OD04404)
0.0
Liver Cancer 1025
0.0

Lung Cancer (OD04565)
0.0
Liver Cancer 1026
0.0

Lung Margin (OD04565)
0.0
Liver Cancer 6004-T
0.0

Lung Cancer (OD04237-01)
0.0
Liver Tissue 6004-N
7.7

Lung Margin (OD04237-02)
0.0
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (ODO4310)
7.9
Liver Tissue 6005-N
0.0

Liver Margin (OD04310)
0.0
Normal Bladder
15.7

Melanoma Metastasis
0.0
Bladder Cancer
0.0

Lung Margin (OD04321)
0.0
Bladder Cancer
12.6

Normal Kidney
100.0
Bladder Cancer (OD04718-01)
0.0

Kidney Ca, Nuclear grade 2 (OD04338)
0.0
Bladder Normal Adjacent
0.0

(OD04718-03)

Kidney Margin (OD04338)
0.0
Normal Ovary
4.8

Kidney Ca Nuclear grade 1/2 (OD04339)
16.6
Ovarian Cancer
0.0

Kidney Margin (OD04339)
37.6
Ovarian Cancer (OD04768-07)
0.0

Kidney Ca, Clear cell type (OD04340)
11.2
Ovary Margin (OD04768-08)
0.0

Kidney Margin (OD04340)
4.8
Normal Stomach
0.0

Kidney Ca, Nuclear grade 3 (OD04348)
0.0
Gastric Cancer 9060358
0.0

Kidney Margin (OD04348)
3.9
Stomach Margin 9060359
0.0

Kidney Cancer (OD04622-01)
0.0
Gastric Cancer 9060395
0.0

Kidney Margin (OD04622-03)
0.0
Stomach Margin 9060394
0.0

Kidney Cancer (OD04450-01)
0.0
Gastric Cancer 9060397
0.0

Kidney Margin (OD04450-03)
11.2
Stomach Margin 9060396
0.0

Kidney Cancer 8120607
0.0
Gastric Cancer 064005
8.7

TABLE HE

Panel 4D

Column A - Rel. Exp.(%) Ag1665, Run 165974950

Column B - Rel. Exp.(%) Ag1665, Run 165974996

Column C - Rel. Exp.(%) Ag2542, Run 164392485

Column D - Rel. Exp.(%) Ag2542, Run 165871865

Tissue Name
A
B
C
D

Secondary Th1 act
0.0
0.0
0.0
0.0

Secondary Th2 act
0.0
0.0
0.0
0.0

Secondary Tr1 act
3.5
4.2
0.0
0.0

Secondary Th1 rest
0.0
0.0
0.0
0.0

Secondary Th2 rest
0.0
0.0
0.0
0.0

Secondary Tr1 rest
0.0
0.0
0.0
0.0

Primary Th1 act
0.0
0.0
0.0
0.0

Primary Th2 act
0.0
0.0
0.0
0.0

Primary Tr1 act
0.0
7.3
0.0
0.0

Primary Th1 rest
0.0
0.0
0.0
0.0

Primary Th2 rest
0.0
0.0
0.0
0.0

Primary Tr1 rest
0.0
8.4
0.0
0.0

CD45RA CD4 lymphocyte act
0.0
14.3
0.0
0.0

CD45RO CD4 lymphocyte act
0.0
0.0
0.0
0.0

CD8 lymphocyte act
0.0
0.0
0.0
0.0

Secondary CD8 lymphocyte rest
0.0
5.4
0.0
0.0

Secondary CD8 lymphocyte act
0.0
13.3
0.0
0.0

CD4 lymphocyte none
0.0
0.0
0.0
0.0

2ry Th1/Th2/Tr1 anti-CD95 CH11
0.0
9.0
0.0
0.0

LAK cells rest
0.0
0.0
0.0
0.0

LAK cells IL-2
0.0
0.0
0.0
0.0

LAK cells IL-2 + IL-12
0.0
0.0
0.0
0.0

LAK cells IL-2 + IFN gamma
0.0
0.0
0.0
0.0

LAK cells IL-2 + IL-18
0.0
0.0
0.0
0.0

LAK cells PMA/ionomycin
0.0
0.0
0.0
0.0

NK Cells IL-2 rest
0.0
0.0
0.0
0.0

Two Way MLR 3 day
0.0
7.3
0.0
0.0

Two Way MLR 5 day
0.0
20.2
0.0
0.0

Two Way MLR 7 day
0.0
0.0
0.0
0.0

PBMC rest
0.0
0.0
0.1
0.0

PBMC PWM
0.0
0.0
0.0
0.0

PBMC PHA-L
3.1
0.0
0.0
0.0

Ramos (B cell) none
0.0
6.5
0.0
0.0

Ramos (B cell) ionomycin
0.0
49.3
0.0
0.0

B lymphocytes PWM
0.0
0.0
0.0
6.3

B lymphocytes CD40L and IL-4
0.0
0.0
0.0
0.0

EOL-1 dbcAMP
0.0
0.0
0.0
0.0

EOL-1 dbcAMP PMA/ionomycin
0.0
0.0
0.0
0.0

Dendritic cells none
0.0
7.5
0.0
0.0

Dendritic cells LPS
0.0
0.0
0.0
0.0

Dendritic cells anti-CD40
0.0
0.0
0.0
0.0

Monocytes rest
0.0
0.0
0.0
0.0

Monocytes LPS
0.0
0.0
0.0
0.0

Macrophages rest
0.0
14.4
0.0
0.0

Macrophages LPS
0.0
12.6
0.0
0.0

HUVEC none
0.0
0.0
7.6
0.0

HUVEC starved
0.0
0.0
0.0
0.0

HUVEC IL-1 beta
0.0
0.0
0.0
10.4

HUVEC IFN gamma
0.0
0.0
0.0
0.0

HUVEC TNF alpha + IFN gamma
0.0
0.0
0.0
0.0

HUVEC TNF alpha + IL4
0.0
0.0
0.0
0.0

HUVEC IL-11
0.0
0.0
0.0
0.0

Lung Microvascular EC none
0.0
0.0
0.0
1.5

Lung Microvascular EC TNFalpha +
0.0
0.0
0.0
0.0

IL-1 beta

Microvascular Dermal EC none
0.0
10.5
0.0
0.0

Microsvasular Dermal EC TNFalpha +
0.0
0.0
0.0
0.0

IL-1 beta

Bronchial epithelium TNFalpha + IL1 beta
3.5
0.0
0.0
23.0

Small airway epithelium none
2.9
4.4
100.0
0.0

Small airway epithelium TNFalpha +
6.2
9.2
0.1
25.2

IL-1 beta

Coronery artery SMC rest
0.0
20.4
0.0
0.0

Coronery artery SMC TNFalpha + IL-1 beta
2.9
8.2
0.1
13.0

Astrocytes rest
0.0
0.0
0.0
0.0

Astrocytes TNFalpha + IL-1 beta
0.0
0.0
0.0
0.0

KU-812 (Basophil) rest
0.0
0.0
0.0
0.0

KU-812 (Basophil) PMA/ionomycin
0.0
0.0
0.0
0.0

CCD1106 (Keratinocytes) none
0.0
0.0
0.0
0.0

CCD1106 (Keratinocytes) TNFalpha +
7.1
0.0
0.0
7.8

IL-1 beta

Liver cirrhosis
100.0
100.0
0.2
100.0

Lupus kidney
3.0
0.0
0.0
4.0

NCI-H292 none
0.0
0.0
0.0
0.0

NCI-H292 IL-4
0.0
4.8
0.0
0.0

NCI-H292 IL-9
0.0
0.0
0.0
5.7

NCI-H292 IL-13
0.0
0.0
0.0
0.0

NCI-H292 IFN gamma
0.0
0.0
0.0
0.0

HPAEC none
0.0
0.0
0.0
0.0

HPAEC TNF alpha + IL-1 beta
0.0
0.0
0.0
0.0

Lung fibroblast none
0.0
0.0
0.0
0.0

Lung fibroblast TNF alpha + IL-1 beta
2.1
0.0
0.0
0.0

Lung fibroblast IL-4
0.0
0.0
0.0
0.0

Lung fibroblast IL-9
0.0
0.0
0.0
4.3

Lung fibroblast IL-13
0.0
0.0
0.0
0.0

Lung fibroblast IFN gamma
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 rest
0.0
0.0
0.0
6.2

Dermal fibroblast CCD1070 TNF alpha
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 IL-1 beta
0.0
0.0
0.0
0.0

Dermal fibroblast IFN gamma
0.0
0.0
0.0
0.0

Dermal fibroblast IL-4
0.0
0.0
0.0
0.0

IBD Colitis 2
20.2
38.7
0.0
16.8

IBD Crohn's
4.0
16.8
0.0
0.0

Colon
2.8
12.9
0.0
10.4

Lung
3.8
0.0
0.0
4.7

Thymus
20.6
35.6
0.2
27.0

Kidney
0.0
0.0
0.0
0.0

PGI1.0 Summary: Ag2542 Expression of this gene was highest in a lung fibrosis sample (CT=31). Expression of this gene was also significantly upregulated in another lung fibrosis sample as well as an asthmatic lung sample; more modest overexpression was seen in lung samples from patients with emphysema. Thus, gene or protein levels are useful for the detection of lung diseases such as lung fibrosis, emphysema and asthma. Furthermore, therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of lung fibrosis, emphysema or asthma.

Panel 2D Summary: Ag1665 The expression of this gene was low in the samples on Panel 2D. The highest expression was associated with a sample of normal kidney (CT=32.9). In addition, there was a cluster of expression associated with normal kidney tissue when compared to malignant kidney tissue. Thus, the loss of expression of this gene was associated with kidney cancer, and as such, therapeutic application of the protein or its replacement by gene therapy is of use in the treatment of kidney cancer.

Panel 4D Summary: Ag1665/Ag2542 Mmoderate expression of this gene was seen in one IBD colitis sample, with lower expression in a second colitis sample in 3 (of 4 possible) experiments. In addition, low expression was detected in liver cirrhosis (CT=32.7) and thymus (CT=35) in 3 (of 4 possible) determinations. The function of the GPCR encoded by this gene is important in the disease processes in both inflammatory bowel disease and in liver cirrhosis. Therefore, blocking antibodies or small molecule antagonists targeted to this GPCR are useful as therapeutics in colitis and in cirrhosis.

I. CG50341-01: GPCR

Expression of gene CG50341-01 was assessed using the primer-probe set Ag1201, described in Table IA. Results of the RTQ-PCR runs are shown in Tables IB, IC and ID.

TABLE IAProbe Name Ag1201StartSEQ IDPrimersSequencesLengthPositionNoForward5′-agagacaatccaaagccttttc-3′227091163ProbeTET-5′-caactgtgtgcctcacctcattgttg-3′-267311164TAMRAReverse5′-agaccctggctttaaataagca-3′227851165

TABLE IB

Panel 1.3D

Column A - Rel. Exp.(%) Ag1201, Run 147490505

Column B - Rel. Exp.(%) Ag1201, Run 152628232

Column C - Rel. Exp.(%) Ag1201, Run 165528215

Tissue Name
A
B
C
Tissue Name
A
B
C

Liver adenocarcinoma
0.0
13.7
0.0
Kidney (fetal)
15.7
19.6
0.0

Pancreas
0.0
0.0
0.0
Renal Ca. 786-0
0.0
0.0
0.0

Pancreatic ca. CAPAN 2
0.0
0.0
66.9
Renal ca. A498
0.0
0.0
0.0

Adrenal gland
0.0
0.0
0.0
Renal ca. RXF 393
0.0
0.0
0.0

Thyroid
0.0
26.2
0.0
Renal ca. ACHN
0.0
0.0
0.0

Salivary gland
0.0
14.7
0.0
Renal ca. UO-31
0.0
0.0
0.0

Pituitary gland
7.5
0.0
0.0
Renal ca. TK-10
0.0
0.0
0.0

Brain (fetal)
0.0
0.0
0.0
Liver
0.0
0.0
0.0

Brain (whole)
3.3
0.0
0.0
Liver (fetal)
0.0
0.0
0.0

Brain (amygdala)
0.0
0.0
0.0
Liver ca. (hepatoblast)
0.0
0.0
0.0

HepG2

Brain (cerebellum)
0.0
0.0
21.0
Lung
9.2
0.0
0.0

Brain (hippocampus)
0.0
0.0
0.0
Lung (fetal)
0.0
0.0
11.4

Brain (substantia nigra)
0.0
0.0
0.0
Lung ca. (small cell) LX-
0.0
0.0
0.0

1

Brain (thalamus)
0.0
0.0
0.0
Lung ca. (small cell) NCI-
0.0
0.0
0.0

Cerebral Cortex
0.0
0.0
0.0
Lung ca. (s.cell var.)
0.0
0.0
0.0

SHP-77

Spinal cord
8.3
0.0
21.2
Lung ca. (large cell) NCI-
0.0
0.0
0.0

H460

glio/astro U87-MG
0.0
0.0
0.0
Lung ca. (non-sm. cell)
1.5
0.0
0.0

A549

glio/astro U-118-MG
0.0
0.0
0.0
Lung Ca. (non-s.cell)
6.2
94.0
0.0

NCI-H23

astrocytoma SW1783
0.0
0.0
0.0
Lung Ca. (non-s.cell)
20.9
27.0
17.9

HOP-62

neuro*; met SK-N-AS
0.0
0.0
0.0
Lung Ca. (non-s.cl) NCI-
0.0
0.0
0.0

H522

astrocytoma SF-539
0.0
15.6
0.0
Lung ca. (squam.) SW
0.0
0.0
0.0

900

astrocytoma SNB-75
0.0
0.0
0.0
Lung Ca. (squam.) NCI-
0.0
0.0
0.0

H596

glioma SNB-19
0.0
12.0
0.0
Mammary gland
15.6
12.9
0.0

glioma U251
0.0
0.0
27.0
Breast ca.* (pl.ef) MCF-7
0.0
0.0
0.0

glioma SF-295
0.0
0.0
0.0
Breast ca.* (pl.ef) MDA-
0.0
0.0
0.0

MB-231

Heart (Fetal)
0.0
0.0
0.0
Breast ca.* (pl.ef) T47D
0.0
0.0
0.0

Heart
7.7
0.0
0.0
Breast Ca. BT-549
6.7
0.0
0.0

Skeletal muscle (Fetal)
11.2
10.7
0.0
Breast Ca. MDA-N
0.0
0.0
0.0

Skeletal muscle
0.0
0.0
0.0
Ovary
0.0
0.0
0.0

Bone marrow
0.0
20.7
15.5
Ovarian ca. OVCAR-3
6.2
0.0
0.0

Thymus
8.6
0.0
0.0
Ovarian ca. OVCAR-4
0.0
0.0
0.0

Spleen
11.3
28.1
14.0
Ovarian ca. OVCAR-5
0.0
0.0
0.0

Lymph node
7.4
0.0
17.3
Ovarian ca. OVCAR-8
33.7
83.5
28.1

Colorectal
10.8
0.0
0.0
Ovarian ca. IGROV-1
0.0
15.3
0.0

Stomach
5.9
12.4
33.9
Ovarian ca. (ascites) SK-
0.0
0.0
0.0

OV-3

Small intestine
0.0
11.7
0.0
Uterus
0.0
0.0
0.0

Colon ca. SW480
0.0
0.0
0.0
Placenta
0.0
0.0
0.0

Colon ca.* SW620 (SW480
0.0
0.0
0.0
Prostate
0.0
22.2
30.1

met)

Colon ca. HT29
0.0
0.0
0.0
Prostate ca.* (bone met)
14.4
19.5
85.3

PC-3

Colon ca. HCT-116
0.0
0.0
0.0
Testis
100.0
100.0
100.0

Colon ca. CaCo-2
0.0
0.0
0.0
Melanoma Hs688(A).T
0.0
0.0
0.0

CC Well to Mod Duff
0.0
0.0
0.0
Melanoma* (met)
6.9
0.0
0.0

(ODO3866)

Hs688(B).T

Colon ca. HCC-2998
0.0
0.0
0.0
Melanoma UACC-62
0.0
0.0
0.0

Gastric ca. (liver met) NCI-
0.0
0.0
0.0
Melanoma M14
0.0
0.0
0.0

N87

Bladder
0.0
0.0
0.0
Melanoma LOX IMVI
0.0
0.0
11.3

Trachea
71.2
0.0
0.0
Melanoma* (met) SK-
0.0
0.0
0.0

MEL-5

Kidney
0.0
0.0
0.0
Adipose
0.0
12.0
0.0

TABLE IC

Panel 2D

Column A - Rel. Exp.(%) Ag1201, Run 147490530

Column B - Rel. Exp.(%) Ag1201, Run 148032505

Tissue Name
A
B
Tissue Name
A
B

Normal Colon
14.2
12.9
Kidney Margin 8120608
0.0
0.0

CC Well to Mod Diff (ODO3866)
10.1
14.6
Kidney Cancer 8120613
0.0
4.0

CC Margin (ODO3866)
0.0
10.7
Kidney Margin 8120614
0.0
0.0

CC Gr.2 rectosigmoid (ODO3868)
0.0
4.5
Kidney Cancer 9010320
0.0
0.0

CC Margin (ODO3868)
0.0
4.9
Kidney Margin 9010321
0.0
0.0

CC Mod Diff (ODO3920)
0.1
5.4
Normal Uterus
0.0
3.6

CC Margin (ODO3920)
13.4
5.6
Uterine Cancer 064011
66.4
54.0

CC Gr.2 ascend colon (ODO3921)
4.0
3.3
Normal Thyroid
9.5
0.0

CC Margin (ODO3921)
5.1
18.7
Thyroid Cancer
0.0
3.4

CC from Partial Hepatectomy
0.0
0.0
Thyroid Cancer A302152
11.9
33.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.0
0.0
Thyroid Margin A302153
28.5
39.5

Colon mets to lung (ODO4451-01)
4.3
0.0
Normal Breast
18.2
28.3

Lung Margin (ODO4451-02)
5.0
0.0
Breast Cancer
42.3
65.5

Normal Prostate 6546-1
0.0
12.8
Breast Cancer (ODO4590-01)
0.0
0.0

Prostate Cancer (ODO4410)
100.0
100.0
Breast Cancer Mets
0.0
0.0

(ODO4590-03)

Prostate Margin (ODO4410)
8.0
9.6
Breast Cancer Metastasis
31.6
35.6

Prostate Cancer (ODO4720-01)
50.0
64.2
Breast Cancer
18.4
28.7

Prostate Margin (ODO4720-02)
47.0
29.7
Breast Cancer
37.6
35.8

Normal Lung
2.8
10.6
Breast Cancer 9100266
31.4
36.9

Lung Met to Muscle (ODO4286)
3.9
11.1
Breast Margin 9100265
14.5
48.3

Muscle Margin (ODO4286)
0.0
0.0
Breast Cancer A209073
51.8
68.3

Lung Malignant Cancer
0.0
0.0
Breast Margin A209073
41.5
22.7

(ODO3126)

Lung Margin (ODO3126)
0.0
5.2
Normal Liver
13.5
0.0

Lung Cancer (ODO4404)
28.5
6.0
Liver Cancer
0.0
0.0

Lung Margin (ODO4404)
5.4
19.2
Liver Cancer 1025
4.7
5.0

Lung Cancer (ODO4565)
0.0
0.0
Liver Cancer 1026
0.0
0.0

Lung Margin (ODO4565)
1.8
0.0
Liver Cancer 6004-T
0.0
3.8

Lung Cancer (ODO4237-01)
0.0
0.0
Liver Tissue 6004-N
3.6
0.0

Lung Margin (ODO4237-02)
6.2
4.9
Liver Cancer 6005-T
0.0
0.0

Ocular Mel Met to Liver
0.0
10.4
Liver Tissue 6005-N
0.0
0.0

(ODO4310)

Liver Margin (ODO4310)
2.5
3.5
Normal Bladder
9.8
11.2

Melanoma Metastasis
0.0
0.0
Bladder Cancer
0.0
0.0

Lung Margin (ODO4321)
0.0
0.0
Bladder Cancer
5.5
24.1

Normal Kidney
6.3
11.7
Bladder Cancer (ODO4718-
0.0
0.0

01)

Kidney Ca, Nuclear grade 2
4.7
13.1
Bladder Normal Adjacent
5.0
13.6

(ODO4338)

(ODO4718-03)

Kidney Margin (ODO4338)
29.5
94.6
Normal Ovary
20.6
0.0

Kidney Ca Nuclear grade 1/2
29.5
94.6
Ovarian Cancer
92.7
99.3

(ODO4339)

Kidney Margin (ODO4339)
0.0
17.1
Ovarian Cancer (ODO4768-
0.0
9.5

07)

Kidney Ca, Clear cell type
3.6
0.0
Ovary Margin (ODO4768-08)
0.0
5.3

(ODO4340)

Kidney Margin (ODO4340)
0.0
0.0
Normal Stomach
0.0
0.0

Kidney Ca, Nuclear grade 3
7.9
5.1
Gastric Cancer 9060358
0.0
0.0

(ODO4348)

Kidney Margin (ODO4348)
7.4
0.0
Stomach Margin 9060359
10.4
0.0

Kidney Cancer (ODO4622-01)
0.0
0.0
Gastric Cancer 9060395
2.6
0.0

Kidney Margin (ODO4622-03)
0.0
0.1
Stomach Margin 9060394
4.3
0.0

Kidney Cancer (ODO4450-01)
0.0
0.0
Gastric Cancer 9060397
0.0
0.0

Kidney Margin (ODO4450-03)
0.0
0.0
Stomach Margin 9060396
0.0
0.0

Kidney Cancer 8120607
0.0
0.0
Gastric Cancer 064005
4.8
0.7

TABLE ID

Panel 4D

Column A - Rel. Exp. (%) Ag1201, Run 140237534

Column B - Rel. Exp. (%) Ag1201, Run 144180636

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
0.0
0.0
HUVEC IL-1beta
0.0
0.0

Secondary Th2 act
0.0
0.0
HUVEC IFN gamma
0.0
0.0

Secondary Tr1 act
0.0
0.0
HUVEC TNF alpha + IFN gamma
0.0
0.0

Secondary Th1 rest
0.0
0.0
HUVEC TNF alpha +IL4
0.0
0.0

Secondary Th2 rest
0.0
0.0
HUVEC IL-11
0.0
0.0

Secondary Tr1 rest
0.0
0.0
Lung Microvascular EC none
0.0
0.0

Primary Th1 act
0.0
0.0
Lung Microvascular EC TNF alpha +
0.0
0.0

IL-1beta

Primary Th2 act
0.0
0.0
Microvascular Dermal EC none
0.0
0.0

Primary Tr1 act
0.0
0.0
Microsvasular Dermal EC TNFalpha
0.0
0.0

+ IL-1beta

Primary Th1 rest
0.0
0.0
Bronchial epithelium TNFalpha +
0.0
0.0

IL1beta

Primary Th2 rest
0.0
0.0
Small airway epithelium none
0.0
0.0

Primary Tr1 rest
0.0
0.0
Small airway epithelium TNFalpha +
0.0
0.0

IL-1beta

CD45RA CD4
0.0
0.0
Coronery artery SMG rest
0.0
0.0

lymphocyte act

CD45RO CD4
0.0
0.0
Coronery artery SMC TNFalpha +
0.0
0.0

lymphocyte act

IL-1beta

CD8 lymphocyte act
2.3
0.0
Astrocytes rest
0.0
0.0

Secondary CD8
0.0
0.0
Astrocytes TNFalpha + IL-1beta
4.3
0.0

lymphocyte rest

Secondary CD8
0.0
0.0
KU-812 (Basophil) rest
7.9
29.1

lymphocyte act

CD4 lymphocyte none
0.0
0.0
KU-812 (Basophil) PMA/ionomycin
100.0
100.0

2ry Th1/Th2/Tr1 anti-
0.0
0.0
CCD1106 (Keratinocytes) none
0.0
0.0

CD95 CH11

LAK cells rest
3.3
4.4
93580 CCD1106 (Keratinocytes)
0.0
0.0

TNFa and IFNg

LAK cells IL-2
0.0
0.0
Liver cirrhosis
11.3
15.2

LAK cells IL-2 + IL-12
0.0
0.0
Lupus kidney
0.0
0.0

LAK cells IL-2 + IFN
0.0
0.0
NCI-H292 none
0.0
0.0

gamma

LAK cells IL-2 + IL-18
0.0
0.0
NCI-H292 IL-4
0.0
0.0

LAK cells PMA/
0.0
0.0
NCI-H292 IL-9
0.0
0.0

ionomycin

NK Cells IL-2 rest
0.0
0.0
NCI-H292 IL-13
0.0
0.0

Two Way MLR 3 day
3.4
0.0
NCI-H292 IFN gamma
0.0
0.0

Two Way MLR 5 day
8.3
0.0
HPAEC none
0.0
0.0

Two Way MLR 7 day
0.0
0.0
HPAEC TNF alpha + IL-1 beta
0.0
0.0

PBMC rest
0.0
0.0
Lung fibroblast none
0.0
0.0

PBMC PWM
0.0
0.0
Lung fibroblast TNF alpha + IL-1
0.0
0.0

beta

PBMC PHA-L
0.0
0.0
Lung fibroblast IL-4
0.0
0.0

Ramos (B cell) none
0.0
0.0
Lung fibroblast IL-9
0.0
0.0

Ramos (B cell)
0.0
0.0
Lung fibroblast IL-13
0.0
0.0

ionomycin

B lymphocytes PWM
0.0
0.0
Lung fibroblast IFN gamma
0.0
0.0

B lymphocytes CD40L
0.0
0.0
Dermal fibroblast CCD1070 rest
0.0
0.0

and IL-4

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 TNF
0.0
0.0

alpha

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 IL-1
0.0
0.0

PMA/ionomycin

beta

Dendritic cells none
0.0
4.5
Dermal fibroblast IFN gamma
0.0
0.0

Dendritic cells LPS
0.0
0.0
Dermal fibroblast IL-4
0.0
0.0

Dendritic cells anti-CD40
7.9
4.7
IBD Colitis 2
5.3
0.0

Monocytes rest
0.0
0.0
IBD Crohn's
0.0
0.0

Monocytes LPS
0.0
0.0
Colon
0.0
0.0

Macrophages rest
3.7
13.4
Lung
3.1
0.0

Macrophages LPS
0.0
4.2
Thymus
7.4
12.0

HUVEC none
0.0
0.0
Kidney
3.9
3.6

HUVEC starved
0.0
0.0

Panel 1.3D Summary: Ag1201 Tissue expression of this was detected at a low level in many tissues. The highest expression was seen in testis. Expression of this gene or its protein product is useful as a marker for male germ cells and has therapeutic applications in fertility disorders as a potential target.

Panel 2D Summary: Ag1201 This gene was overexpressed in tumors derived from tissues responsive to steroid hormones—ovarian, uterine and prostate cancers as shown by panel 2D. It is therefore a marker for cells, especially tumor cells responsive to steroid hormones. Expression of this gene or its protein product are used to differentiate hormone-responsive and non-hormone responsive tumors, that are known to lead to different clinical outcomes. Being a GPCR, the protein is useful to screen candidate therapeutics for molecules able to modulate tumor growth, preferably small molecule therapeutic and human monoclonal antibodies.

Panel 4D Summary: Ag1201 The pattern of expression in panel 4 showed that Ag1201 has a potential role in inflammation, since this gene was expressed in activated basophils. Basophils are one of the key cell mediators of inflammation during asthma and allergy (Oliver J, Immunopharmacology 2000 Jul. 25; 48(3):269-81). This molecule is important in allowing these cells to extravasate into the site of inflammation and/or in the activation of these cells. Antibody therapeutics to Ag1201 are useful for the inhibition of nasal and lung inflammation due to basophil activation and effectively reduce or eliminate symptoms of asthma, emphysema, and allergic rhinitis.

J. CG50365-01: Carbonate Dehydratase

Expression of gene CG50365-01 was assessed using the primer-probe sets Ag2575 and Ag2644, described in Tables JA and JB. Results of the RTQ-PCR runs are shown in Tables JC, JD, JE and JF.

TABLE JAProbe Name Ag2575StartSEQ IDPrimersSequencesLengthPositionNoForward5′-tcagcaatctccaattgagatt-3′22961166ProbeTET-5′-tgaaatatgactcttccctccgacca-3′-261311167TAMRAReverse5′-ttttagctgagcttgggtcata-3′221691168

TABLE JB

Probe Name Ag2644

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-tcagcaatctccaattgagatt-3′
22
96
1169

Probe
TET-5′-tgaaatatgactcttccctccgacca-3′-
26
131
1170

TAMRA

Reverse
5′-ttttagctgagcttgggtcata-3′
22
169
1171

TABLE JC

Panel 1.3D

Column A - Rel. Exp.(%) Ag2575, Run 162430827

Column B - Rel. Exp.(%) Ag2575, Run 162431039

Tissue Name
A
B
Tissue Name
A
B

Liver adenocarcinoma
0.4
0.4
Kidney (fetal)
6.0
6.0

Pancreas
0.4
0.4
Renal Ca. 786-0
13.5
13.5

Pancreatic ca. CAPAN-2
4.0
4.0
Renal Ca. A498
11.2
11.2

Adrenal gland
1.5
1.5
Renal Ca. RXF 393
1.0
1.0

Thyroid
5.4
5.4
Renal ca. ACHN
2.9
2.9

Salivaxy gland
0.9
0.9
Renal ca. UO-31
5.8
5.8

Pituitary gland
4.8
4.8
Renal Ca. TK-10
6.9
6.9

Brain (fetal)
1.2
1.2
Liver
0.9
0.9

Brain (whole)
1.2
1.2
Liver (fetal)
3.7
3.7

Brain (amygdala)
3.1
3.1
Liver ca. (hepatoblast) HepG2
10.0
10.0

Brain (cerebellum)
5.6
5.6
Lung
6.3
6.3

Brain (hippocampus)
5.4
5.4
Lung (fetal)
6.7
6.7

Brain (substantia nigra)
0.3
0.3
Lung Ca. (small cell) LX-1
0.0
0.0

Brain (thalamus)
1.7
1.7
Lung Ca. (small cell) NCI-H69
6.7
6.7

Cerebral Cortex
21.2
21.2
Lung Ca. (s.cell var.) SHP-77
21.2
21.2

Spinal cord
2.8
2.8
Lung Ca. (large cell) NCI-H460
4.4
4.4

glio/astro U87-MG
25.9
25.9
Lung Ca. (non-sm. cell) A549
2.7
2.7

glio/astro U-118-MG
9.5
9.5
Lung Ca. (non-s.cell) NCI-H23
3.0
3.0

astrocytoma SW1783
17.4
17.4
Lung Ca. (non-s.cell) HOP-62
4.8
4.8

neuro*; met SK-N-AS
0.0
0.0
Lung Ca. (non-s.cl) NCI-H522
0.4
0.4

astrocytoma SF-539
12.9
12.9
Lung Ca. (squam.) SW 900
3.4
3.4

astrocytoma SNB-75
2.8
2.8
Lung Ca. (squam.) NCI-H596
2.7
2.7

glioma SNB-19
27.0
27.0
Mammary gland
4.0
4.0

glioma U251
4.6
4.6
Breast ca.* (pl.ef) MCF-7
0.0
0.0

glioma SF-295
5.2
5.2
Breast ca.* (pl.ef) MDA-MB-
7.5
7.5

231

Heart (Fetal)
2.1
2.1
Breast ca.* (pl.ef) T47D
0.7
0.7

Heart
3.1
3.1
Breast ca. BT-549
0.5
0.5

Skeletal muscle (Fetal)
3.6
3.6
Breast Ca. MDA-N
8.2
8.2

Skeletal muscle
0.0
0.0
Ovary
2.7
2.7

Bone marrow
0.8
0.8
Ovarian Ca. OVCAR-3
5.9
5.9

Thymus
6.8
6.8
Ovarian Ca. OVCAR-4
0.5
0.5

Spleen
1.6
1.6
Ovarian Ca. OVCAR-5
35.1
35.1

Lymph node
1.4
1.4
Ovarian Ca. OVCAR-8
12.8
12.8

Colorectal
5.7
5.7
Ovarian Ca. IGROV-1
0.0
0.0

Stomach
2.6
2.6
Ovarian Ca. (ascites) SK-OV-3
2.0
2.0

Small intestine
8.8
8.8
Uterus
1.4
1.4

Colon Ca. SW480
0.0
0.0
Placenta
0.0
0.0

Colon Ca.* SW620 (SW480
0.0
0.0
Prostate
0.8
0.8

met)

Colon Ca. HT29
8.4
8.4
Prostate Ca.* (bone met) PC-3
7.0
7.0

Colon Ca. HCT-116
5.7
5.7
Testis
2.2
2.2

Colon Ca. CaCo-2
84.1
84.1
Melanoma Hs688(A).T
2.3
2.3

CC Well to Mod Duff
40.3
40.3
Melanoma* (met) Hs688(B).T
2.8
2.8

(ODO3866)

Colon Ca. HCC-2998
14.7
14.7
Melanoma UACC-62
1.5
1.5

Gastric ca. (liver met) NCI-N87
100.0
100.0
Melanoma M14
4.3
4.3

Bladder
11.2
11.2
Melanoma LOX IMVI
7.6
7.6

Trachea
9.9
9.9
Melanoma* (met) SK-MEL-5
13.0
13.0

Kidney
8.9
8.9
Adipose
11.0
11.0

TABLE JD

Panel 2D

Column A - Rel. Exp.(%) Ag2644, Run 162423326

Tissue Name
A
Tissue Name
A

Normal Colon
36.1
Kidney Margin 8120608
2.9

CC Well to Mod Diff (ODO3866)
27.9
Kidney Cancer 8120613
4.0

CC Margin (ODO3866)
11.1
Kidney Margin 8120614
3.7

CC Gr.2 rectosigmoid (ODO3868)
19.1
Kidney Cancer 9010320
10.2

CC Margin (ODO3868)
2.2
Kidney Margin 9010321
8.0

CC Mod Diff (ODO3920)
21.0
Normal Uterus
0.0

CC Margin (ODO3920)
18.3
Uterine Cancer 064011
12.2

CC Gr.2 ascend colon (ODO3921)
37.9
Normal Thyroid
12.8

CC Margin (ODO3921)
7.8
Thyroid Cancer
53.2

CC from Partial Hepatectomy
74.7
Thyroid Cancer A302152
33.7

(ODO4309) Mets

Liver Margin (ODO4309)
15.7
Thyroid Margin A302153
13.6

Colon mets to lung (OD04451-01)
5.0
Normal Breast
27.7

Lung Margin (OD04451-02)
8.2
Breast Cancer
1.7

Normal Prostate 6546-1
21.5
Breast Cancer (OD04590-01)
2.7

Prostate Cancer (OD04410)
10.7
Breast Cancer Mets (0D04590-03)
2.8

Prostate Margin (OD04410)
4.0
Breast Cancer Metastasis
35.1

Prostate Cancer (OD04720-01)
8.7
Breast Cancer
13.2

Prostate Margin (OD04720-02)
12.1
Breast Cancer
7.0

Normal Lung
24.8
Breast Cancer 9100266
2.9

Lung Met to Muscle (ODO4286)
15.4
Breast Margin 9100265
4.8

Muscle Margin (ODO4286)
1.5
Breast Cancer A209073
18.6

Lung Malignant Cancer (OD03126)
7.9
Breast Margin A209073
14.4

Lung Margin (OD03126)
22.4
Normal Liver
6.2

Lung Cancer (OD04404)
3.8
Liver Cancer
1.8

Lung Margin (OD04404)
10.6
Liver Cancer 1025
3.4

Lung Cancer (OD04565)
2.2
Liver Cancer 1026
3.6

Lung Margin (OD04565)
5.5
Liver Cancer 6004-T
4.8

Lung Cancer (OD04237-01)
14.7
Liver Tissue 6004-N
1.8

Lung Margin (OD04237-02)
18.0
Liver Cancer 6005-T
3.3

Ocular Mel Met to Liver (ODO4310)
1.0
Liver Tissue 6005-N
2.1

Liver Margin (OD04310)
5.4
Normal Bladder
10.7

Melanoma Metastasis
4.3
Bladder Cancer
1.3

Lung Margin (OD04321)
18.7
Bladder Cancer
4.6

Normal Kidney
35.4
Bladder Cancer (OD04718-01)
7.2

Kidney Ca, Nuclear grade 2 (OD04338)
26.6
Bladder Normal Adjacent
10.2

(OD04718-03)

Kidney Margin (OD04338)
14.6
Normal Ovary
2.0

Kidney Ca Nuclear grade 1/2 (OD04339)
23.7
Ovarian Cancer
23.3

Kidney Margin (OD04339)
30.4
Ovarian Cancer (OD04768-07)
48.3

Kidney Ca, Clear cell type (OD04340)
19.3
Ovary Margin (OD04768-08)
2.7

Kidney Margin (OD04340)
22.7
Normal Stomach
21.0

Kidney Ca, Nuclear grade 3 (OD04348)
1.4
Gastric Cancer 9060358
3.8

Kidney Margin (OD04348)
20.3
Stomach Margin 9060359
15.8

Kidney Cancer (OD04622-01)
13.9
Gastric Cancer 9060395
17.0

Kidney Margin (OD04622-03)
2.7
Stomach Margin 9060394
15.8

Kidney Cancer (OD04450-01)
16.6
Gastric Cancer 9060397
49.0

Kidney Margin (OD04450-03)
17.8
Stomach Margin 9060396
12.2

Kidney Cancer 8120607
2.9
Gastric Cancer 064005
100.0

TABLE JE

Panel 3D

Column A - Rel. Exp.(%) Ag2644, Run 164886194

Tissue Name
A
Tissue Name
A

94905 Daoy
5.5
94954 Ca Ski Cervical epidermoid
16.5

Medulloblastoma/Cerebellum

carcinoma (metastasis

94906 TE671
0.0
94955 ES-2 Ovarian clear cell
24.7

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
15.3
94957 Ramos Stimulated with
0.0

Medulloblastoma/Cerebellum

PMA/ionomycin 6 h

94908 PFSK-1 Primitive
1.6
94958 Ramos Stimulated with
2.2

Neuroectodermal/Cerebellum

PMA/ionomycin 14 h

94909 XF-498 CNS
4.9
94962 MEG-01 Chronic
30.8

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
8.8
94963 Raji Burkitt's lymphoma
3.4

94911 SF-268 CNS/glioblastoma
1.7
94964 Daudi Burkitt's lymphoma
3.6

94912 T98G Glioblastoma
0.0
94965 U266 B-cell
5.9

plasmacytoma/myeloma

96776 SK-N-SH Neuroblastoma
0.0
94968 CA46 Burkitt's lymphoma
3.2

(metastasis)

94913 SF-295 CNS/glioblastoma
10.3
94970 RL non-Hodgkin's B-cell
0.0

lymphoma

94914 Cerebellum
8.1
94972 JM1 pre-B-cell
0.0

lymphoma/leukemia

96777 Cerebellum
2.0
94973 Jurkat T cell leukemia
3.3

94916 NCI-H292 Mucoepidermoid
22.2
94974 TF-1 Erythroleukemia
28.3

lung carcinoma

94917 DMS-114 Small cell lung
1.1
94975 HUT 78 T-cell lymphoma
1.8

cancer

94918 DMS-79 Small cell lung
100.0
94977 U937 Histiocytic lymphoma
4.4

cancer/neuroendocrine

94919 NCI-H146 Small cell lung
4.9
94980 KU-812 Myelogenous
2.2

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
6.9
769-P-Clear cell renal carcinoma
3.8

cancer/neuroendocrine

94921 NCI-N417 Small cell lung
6.2
94983 Caki-2 Clear cell renal
1.8

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
0.0
94984 SW 839 Clear cell renal
4.1

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell lung
30.6
94986 G401 Wilms' tumor
0.0

cancer (metastasis)

94925 NCI-H1155 Large cell lung
14.9
94987 Hs766T Pancreatic carcinoma
26.2

cancer/neuroendocrine

(LN metastasis)

94926 NCI-H1299 Large cell lung
33.9
94988 CAPAN-1 Pancreatic
14.4

cancer/neuroendocrine

adenocarcinoma (liver metastasis)

94927 NCI-H727 Lung carcinoid
1.2
94989 SU86.86 Pancreatic carcinoma
39.8

(liver metastasis)

94928 NCI-UMC-11 Lung carcinoid
4.1
94990 BxPC-3 Pancreatic
3.3

adenocarcinoma

94929 LX-1 Small cell lung cancer
0.0
94991 HPAC Pancreatic
1.4

adenocarcinoma

94930 Colo-205 Colon cancer
1.4
94992 MIA PaCa-2 Pancreatic
2.1

carcinoma

94931 KM12 Colon cancer
31.9
94993 CFPAC-1 Pancreatic ductal
32.8

adenocarcinoma

94932 KM20L2 Colon cancer
15.1
94994 PANC-1 Pancreatic epithelioid
22.4

ductal carcinoma

94933 NCI-H716 Colon cancer
17.1
94996 T24 Bladder carcinma
2.8

(transitional cell

94935 SW-48 Colon adenocarcinoma
28.5
5637-Bladder carcinoma
11.4

94936 SW1116 Colon
13.5
94998 HT-1197 Bladder carcinoma
0.0

adenocarcinoma

94937 LS 174T Colon
56.3
94999 UM-UC-3 Bladder carcinma
1.9

adenocarcinoma

(transitional cell)

94938 SW-948 Colon
2.9
95000 A204 Rhabdomyosarcoma
0.0

adenocarcinoma

94939 SW-480 Colon
10.9
95001 HT-1080 Fibrosarcoma
4.5

adenocarcinoma

94940 NCI-SNU-5 Gastric carcinoma
0.0
95002 MG-63 Osteosarcoma (bone)
2.2

KATO III-Gastric carcinoma
59.0
95003 SK-LMS-1 Leiomyosarcoma
13.3

(vulva)

94943 NCI-SNU-16 Gastric
29.5
95004 SJRH30 Rhabdomyosarcoma
5.6

carcinoma

(met to bone marrow)

94944 NCI-SNU-1 Gastric carcinoma
15.8
95005 A431 Epidermoid carcinoma
0.0

94946 RE-1 Gastric adenocarcinoma
4.8
95007 WM266-4 Melanoma
7.4

94947 RF-48 Gastric adenocarcinoma
6.8
DU 145-Prostate carcinoma (brain
0.0

metastasis)

96778 MKN-45 Gastric carcinoma
1.8
95012 MDA-MB-468 Breast
0.0

adenocarcinoma

94949 NCI-N87 Gastric carcinoma
24.7
SCC-4-Squamous cell carcinoma of
0.0

tongue

94951 OVCAR-5 Ovarian carcinoma
19.9
SCC-9-Squamous cell carcinoma of
0.0

tongue

94952 RL95-2 Uterine carcinoma
0.0
SCC-15-Squamous cell carcinoma of
0.0

tongue

94953 HelaS3 Cervical
0.0
95017 CAL 27 Squamous cell
4.0

adenocarcinoma

carcinoma of tongue

TABLE JF

Panel 4D

Column A - Rel. Exp.(%) Ag2644, Run 158664089

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.5
HUVEC IL-1beta
3.3

Secondary Th2 act
0.4
HUVEC IFN gamma
14.4

Secondary Tr1 act
0.4
HUVEC TNF alpha + IFN gamma
27.7

Secondary Th1 rest
0.9
HUVEC TNF alpha + IL4
12.2

Secondary Th2 rest
0.7
HUVEC IL-11
1.0

Secondary Tr1 rest
0.9
Lung Microvascular EC none
1.1

Primary Th1 act
0.6
Lung Microvascular EC TNF alpha + IL-
6.2

1beta

Primary Th2 act
1.6
Microvascular Dermal EC none
1.9

Primary Tr1 act
1.4
Microsvasular Dermal EC TNF alpha + IL-
2.0

1beta

Primary Th1 rest
4.6
Bronchial epithelium TNF alpha + IL1beta
3.3

Primary Th2 rest
1.0
Small airway epithelium none
2.4

Primary Tr1 rest
1.8
Small airway epithelium TNF alpha + IL-
33.9

1beta

CD45RA CD4 lymphocyte act
1.9
Coronery artery SMC rest
6.1

CD45RO CD4 lymphocyte act
2.4
Coronery artery SMC TNF alpha + IL-1beta
2.4

CD8 lymphocyte act
1.0
Astrocytes rest
3.9

Secondary CD8 lymphocyte rest
1.4
Astrocytes TNF alpha + IL-1beta
2.1

Secondary CD8 lymphocyte act
0.8
KU-812 (Basophil) rest
1.3

CD4 lymphocyte none
0.8
KU-812 (Basophil) PMA/ionomycin
17.8

2ry Th1/Th2/Tr1 anti-CD95
0.6
CCD1106 (Keratinocytes) none
9.2

CH11

LAK cells rest
2.0
CCD1106 (Keratinocytes) TNF alpha + IL-
6.0

1beta

LAK cells IL-2
5.4
Liver cirrhosis
2.1

LAK cells IL-2 + IL-12
0.8
Lupus kidney
4.2

LAK cells IL-2 + IFN gamma
3.5
NCI-H292 none
35.8

LAK cells IL-2 + IL-18
6.6
NCI-H292 IL-4
52.9

LAK cells PMA/ionomycin
7.4
NCI-H292 IL-9
45.1

NK Cells IL-2 rest
4.4
NCI-H292 IL-13
25.7

Two Way MLR 3 day
3.4
NCI-H292 IFN gamma
42.9

Two Way MLR 5 day
1.4
HPAEC none
5.2

Two Way MLR 7 day
0.8
HPAEC TNF alpha + IL-1beta
16.3

PBMC rest
2.6
Lung fibroblast none
6.3

PBMC PWM
14.5
Lung fibroblast TNF alpha + IL-1beta
3.3

PBMC PHA-L
6.2
Lung fibroblast IL-4
25.3

Ramos (B cell) none
4.9
Lung fibroblast IL-9
7.6

Ramos (B cell) ionomycin
10.7
Lung fibroblast IL-13
11.3

B lymphocytes PWM
9.1
Lung fibroblast IFN gamma
75.8

B lymphocytes CD40L and IL-4
4.6
Dermal fibroblast CCD1070 rest
9.2

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
11.0

EOL-1 dbcAMP
1.5
Dermal fibroblast CCD1070 IL-1beta
4.3

PMA/ionomycin

Dendritic cells none
1.4
Dermal fibroblast IFN gamma
17.8

Dendritic cells LPS
1.1
Dermal fibroblast IL-4
10.0

Dendritic cells anti-CD40
0.9
IBD Colitis 2
2.5

Monocytes rest
5.3
IBD Crohn's
15.8

Monocytes LPS
10.5
Colon
100.0

Macrophages rest
0.9
Lung
14.1

Macrophages LPS
1.1
Thymus
55.5

HUVEC none
7.3
Kidney
17.6

HUVEC starved
4.2

Panel 1.3D Summary: Ag2575 The expression of the CG50365-01 gene highest in a sample derived from a gastric cancer cell line (NCI-H87)(CTs=31). In addition, there was substantial expression in several colon cancer cell lines, ovarian cancer cell lines and brain cancer cell lines. Thus, the expression of this gene is useful as a marker to distinguish NCI-H87 cells from other samples in the panel. Therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics is of benefit in the treatment of colon cancer, brain cancer or ovarian cancer.

In addition, this gene was expressed at low levels in the cerebral cortex. Carbonate dehydratase plays an important role in modulating excitatory synaptic transmission in brain. (Parkkila S. Proc Natl Acad Sci USA 2001 Feb. 13; 98(4): 1918-23) Therefore, this molecule is of use in the treatment of schizophrenia, epilepsy, Alzheimer's disease, bipolar disorder, depression, or any clinical condition associated with impaired or altered neurotransmission.

Panel 2D Summary: Ag2644 The expression of the CG50365-01 gene was highest in a sample derived from a gastric cancer. In addition there was substantial expression associated with other gastric cancers, when compared to their adjacent normal tissues, as well as expression associated with ovarian cancer, breast cancer, thyroid cancer and colon cancer. This expression conformed with expression in Panel 1.3D. Expression of this is useful as a marker to distinguish this gastric cancer sample from other samples in the panel. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics is of benefit in the treatment of colon cancer, breast cancer, ovarian cancer, gastric cancer or thyroid cancer.

Panel 3D Summary: Ag2644 The expression of the CG50365-01 gene was highest in a sample derived from a lung cancer cell line (DMS-79). In addition there was expression associated with a colon cancer cell line, a gastric cancer cell line and a pancreatic cancer cell line. Thus, the expression of this gene is useful as a marker to distinguish DMS-79 cells from other samples in the panel. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics is of benefit in the treatment of colon cancer, pancreatic cancer, gastric cancer or lung cancer.

Panel 4D Summary: Ag2644 The CG50365-01 transcript was expressed in lung fibroblasts treated with gamma interferon, NCI-H292 cells regardless of treatment, activated basophil cell line, and gamma interferon treated HUVECs. It was also expressed in normal colon and thymus. The regulation of the transcript expression in fibroblasts and HUVECs showed that the protein encoded by this transcript contributes to the inflammatory changes due to gamma interferon. Therefore, therapies designed with the protein encoded by this transcript are important for the treatment of emphysema, psoriasis, arthritis and IBD.

K. CG50367-01: adam13

Expression of gene CG50367-01 was assessed using the primer-probe set Ag2425, described in Table KA. Results of the RTQ-PCR runs are shown in Tables KB, KC, KD and KE.

TABLE KAProbe Name Ag2425StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ggctcctgctgaccatattc-3′2023421172ProbeTET-5′-catttaccctccaccatttctcccag-3′-2623661173TAMRAReverse5′-gctgggctcatgagagttct-3′2023981174

TABLE KB

Ardais Prostate 1.0

Column A - Rel. Exp.(%) Ag2425, Run 321632641

Tissue Name
A
Tissue Name
A

151135 Prostate NAT(B87)
22.8
151128 Prostate cancer(B8C)
8.2

151143 Prostate NAT(B8A)
28.5
151136 Prostate cancer(B8B)
1.3

153669 Prostate NAT(D5E)
18.8
151144 Prostate cancer(B8F)
8.1

153677 Prostate NAT(D66)
8.1
153654 Prostate cancer(D4F)
3.5

153685 Prostate NAT(D6E)
14.0
153662 Prostate cancer(D57)
0.9

145905 Prostate NAT(A0C)
14.8
153655 Prostate cancer(D50)
27.2

153670 Prostate NAT(D5F)
3.3
145907 Prostate cancer(A0A)
13.0

153678 Prostate NAT(D67)
12.2
153663 Prostate cancer(D58)
100.0

153686 Prostate NAT(D6F)
1.8
151130 Prostate cancer(B90)
9.1

145906 Prostate NAT(A09)
9.1
153648 Prostate cancer(D49)
9.9

151129 Prostate NAT(B93)
60.3
153656 Prostate cancer(D51)
9.8

151137 Prostate NAT(B86)
18.7
153664 Prostate cancer(D59)
1.8

153671 Prostate NAT(D60)
4.4
155799 Prostate cancer(EA8)
6.2

151145 Prostate NAT(B91)
26.8
145909 Prostate cancer(9E7)
4.9

153679 Prostate NAT(D68)
19.2
153649 Prostate cancer(D4A)
2.4

153687 Prostate NAT(D70)
10.2
153657 Prostate cancer(D52)
1.3

153672 Prostate NAT(D61)
8.1
153665 Prostate cancer(D5A)
3.9

153680 Prostate NAT(D69)
23.7
151132 Prostate cancer(B88)
3.2

151131 Prostate NAT(B85)
5.2
153650 Prostate cancer(D4B)
1.8

153673 Prostate NAT(D62)
8.2
153658 Prostate cancer(D53)
1.8

153681 Prostate
7.4
153666 Prostate cancer(D5B)
0.4

NAT(D6A)

145910 Prostate NAT(9C3)
18.8
153651 Prostate cancer(D4C)
2.4

153674 Prostate NAT(D63)
24.0
153659 Prostate cancer(D54)
7.2

153682 Prostate NAT(D6B)
6.4
153667 Prostate cancer(D5C)
7.6

151133 Prostate NAT(B94)
7.6
151134 Prostate cancer(B92)
1.4

153675 Prostate NAT(D64)
3.6
151142 Prostate cancer(B89)
5.5

153683 Prostate NAT(D6C)
5.1
153652 Prostate cancer(D4D)
7.1

153668 Prostate
4.7
153660 Prostate cancer(D55)
0.9

NAT(D5D)

153676 Prostate NAT(D65)
1.2
149773 Prostate NAT(AD8)
0.0

153684 Prostate
6.9
149774 Prostate cancer(AD7)
6.5

NAT(D6D)

145904 Prostate
21.2
151139 Prostate NAT(B8E)
15.1

cancer(9E2)

149776 Prostate
4.5
151138 Prostate cancer(B8D)
2.2

cancer(AD5)

153653 Prostate
2.7
151141 Prostate NAT(B96)
6.8

cancer(D4E)

153661 Prostate
6.2
151140 Prostate cancer(B95)
4.7

cancer(D56)

TABLE KC

Panel 1.3D

Column A - Rel. Exp.(%) Ag2425, Run 155561580

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
0.0
Kidney (fetal)
3.9

Pancreas
1.8
Renal ca. 786-0
0.0

Pancreatic ca.
0.0
Renal ca. A498
0.0

CAPAN 2

Adrenal gland
0.9
Renal ca. RXF 393
0.0

Thyroid
2.7
Renal ca. ACHN
1.6

Salivary gland
1.1
Renal ca. UO-31
0.0

Pituitary gland
0.5
Renal ca. TK-10
0.0

Brain (fetal)
4.6
Liver
0.0

Brain (whole)
2.3
Liver (fetal)
1.2

Brain (amygdala)
4.2
Liver ca. (hepatoblast) HepG2
0.0

Brain (cerebellum)
0.0
Lung
2.8

Brain (hippocampus)
25.3
Lung (fetal)
17.9

Brain
2.4
Lung ca. (small cell) LX-1
0.0

(substantia nigra)

Brain (thalamus)
9.4
Lung ca. (small cell) NCI-H69
0.0

Cerebral Cortex
1.5
Lung ca. (s. cell var.) SHP-77
1.0

Spinal cord
3.9
Lung ca. (large cell)NCI-H460
0.0

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
1.7

glio/astro U-118-MG
1.1
Lung ca. (non-s. cell) NCI-H23
1.8

astrocytoma SW1783
0.0
Lung ca. (non-s. cell) HOP-62
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (non-s. cl) NCI-H522
0.0

astrocytoma SF-539
0.0
Lung ca. (squam.) SW 900
0.0

astrocytoma SNB-75
0.0
Lung ca. (squam.) NCI-H596
0.0

glioma SNB-19
0.8
Mammary gland
13.5

glioma U251
0.0
Breast ca.* (pl.ef) MCF-7
0.0

glioma SF-295
0.0
Breast ca.* (pl.ef) MDA-MB-231
0.0

Heart (Fetal)
3.4
Breast ca.* (pl.ef) T47D
0.0

Heart
1.1
Breast ca. BT-549
1.6

Skeletal muscle (Fetal)
100.0
Breast ca. MDA-N
0.0

Skeletal muscle
0.9
Ovary
1.9

Bone marrow
3.3
Ovarian ca. OVCAR-3
0.0

Thymus
4.1
Ovarian ca. OVCAR-4
0.0

Spleen
2.7
Ovarian ca. OVCAR-5
0.0

Lymph node
4.6
Ovarian ca. OVCAR-8
0.0

Colorectal
5.9
Ovarian ca. IGROV-1
0.0

Stomach
7.3
Ovarian ca. (ascites) SK-OV-3
0.0

Small intestine
18.4
Uterus
37.4

Colon ca. SW480
0.0
Placenta
1.8

Colon ca.* SW620
0.0
Prostate
8.8

(SW480 met)

Colon ca. HT29
0.0
Prostate ca.* (bone met) PC-3
0.0

Colon ca. HCT-116
0.0
Testis
7.5

Colon ca. CaCo-2
0.0
Melanoma Hs688(A).T
5.0

CC Well to Mod Diff
0.0
Melanoma* (met) Hs688(B).T
3.3

(ODO3866)

Colon ca. HCC-2998
0.0
Melanoma UACC-62
0.0

Gastric ca. (liver met)
0.0
Melanoma M14
0.0

NCI-N87

Bladder
0.0
Melanoma LOX IMVI
0.0

Trachea
15.8
Melanoma* (met) SK-MEL-5
0.0

Kidney
1.8
Adipose
1.6

TABLE KD

Panel 2D

Column A - Rel. Exp.(%) Ag2425, Run 155562155

Tissue Name
A
Tissue Name
A

Normal Colon
100.0
Kidney Margin 8120608
0.0

CC Well to Mod Diff (ODO3866)
5.6
Kidney Cancer 8120613
0.0

CC Margin (ODO3866)
4.5
Kidney Margin 8120614
2.1

CC Gr.2 rectosigmoid (ODO3868)
20.7
Kidney Cancer 9010320
2.2

CC Margin (ODO3868)
21.9
Kidney Margin 9010321
6.1

CC Mod Diff (ODO3920)
6.7
Normal Uterus
49.3

CC Margin (ODO3920)
61.6
Uterine Cancer 064011
92.7

CC Gr.2 ascend colon (ODO3921)
1.0
Normal Thyroid
18.3

CC Margin (ODO3921)
6.2
Thyroid Cancer
0.0

CC from Partial Hepatectomy
0.0
Thyroid Cancer A302152
2.8

(ODO4309) Mets

Liver Margin (ODO4309)
0.0
Thyroid Margin A302153
20.4

Colon mets to lung (OD04451-01)
0.0
Normal Breast
53.2

Lung Margin (OD04451-02)
0.0
Breast Cancer
0.0

Normal Prostate 6546-1
66.4
Breast Cancer (OD04590-01)
2.6

Prostate Cancer (OD04410)
25.9
Breast Cancer Mets (OD04590-03)
11.5

Prostate Margin (OD04410)
72.7
Breast Cancer Metastasis
0.0

Prostate Cancer (OD04720-01)
45.4
Breast Cancer
24.7

Prostate Margin (OD04720-02)
33.7
Breast Cancer
51.8

Normal Lung
84.1
Breast Cancer 9100266
3.1

Lung Met to Muscle (ODO4286)
9.4
Breast Margin 9100265
12.9

Muscle Margin (ODO4286)
0.0
Breast Cancer A209073
17.3

Lung Malignant Cancer (OD03126)
0.0
Breast Margin A209073
99.3

Lung Margin (OD03126)
10.6
Normal Liver
0.0

Lung Cancer (OD04404)
0.0
Liver Cancer
4.0

Lung Margin (OD04404)
0.0
Liver Cancer 1025
4.9

Lung Cancer (OD04565)
13.7
Liver Cancer 1026
0.0

Lung Margin (OD04565)
10.6
Liver Cancer 6004-T
0.0

Lung Cancer (OD04237-01)
0.0
Liver Tissue 6004-N
8.5

Lung Margin (OD04237-02)
0.0
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (ODO4310)
0.0
Liver Tissue 6005-N
0.0

Liver Margin (ODO4310)
0.0
Normal Bladder
11.1

Melanoma Metastasis
0.0
Bladder Cancer
3.1

Lung Margin (OD04321)
2.9
Bladder Cancer
14.6

Normal Kidney
9.7
Bladder Cancer (OD04718-01)
2.4

Kidney Ca, Nuclear grade 2 (OD04338)
0.0
Bladder Normal Adjacent
10.6

(OD04718-03)

Kidney Margin (OD04338)
6.0
Normal Ovary
0.0

Kidney Ca Nuclear grade ½ (OD04339)
0.0
Ovarian Cancer
0.0

Kidney Margin (OD04339)
0.0
Ovarian Cancer (OD04768-07)
3.2

Kidney Ca, Clear cell type (OD04340)
0.0
Ovary Margin (OD04768-08)
6.0

Kidney Margin (OD04340)
4.0
Normal Stomach
12.7

Kidney Ca, Nuclear grade 3 (OD04348)
0.0
Gastric Cancer 9060358
9.9

Kidney Margin (OD04348)
6.7
Stomach Margin 9060359
0.0

Kidney Cancer (OD04622-01)
0.0
Gastric Cancer 9060395
39.2

Kidney Margin (OD04622-03)
7.4
Stomach Margin 9060394
26.4

Kidney Cancer (OD04450-01)
0.0
Gastric Cancer 9060397
6.2

Kidney Margin (OD04450-03)
0.0
Stomach Margin 9060396
3.3

Kidney Cancer 8120607
0.0
Gastric Cancer 064005
25.3

TABLE KE

Panel 4D

Column A - Rel. Exp.(%) Ag2425, Run 155562267

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tr1 act
1.3
Microsvasular Dermal EC TNF alpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNF alpha + IL1beta
0.0

Primary Th2 rest
0.0
Small airway epithelium none
0.0

Primary Tr1 rest
0.0
Small airway epithelium TNF alpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
1.8
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
1.4
Coronery artery SMC TNF alpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNF alpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
1.3
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
3.9
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNF alpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
4.9

LAK cells IL-2 + IL-12
0.0
Lupus kidney
0.0

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
0.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
0.0

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
0.0

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1beta
0.0

PBMC rest
0.0
Lung fibroblast none
13.0

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1beta
2.7

PBMC PHA-L
0.0
Lung fibroblast IL-4
3.4

Ramos (B cell) none
0.0
Lung fibroblast IL-9
10.7

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
5.9

B lymphocytes PWM
0.0
Lung fibroblast IFN gamma
3.3

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
23.7

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
5.6

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1beta
12.5

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
64.6

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
100.0

Dendritic cells anti-CD40
0.0
IBD Colitis 2
0.0

Monocytes rest
0.0
IBD Crohn's
0.0

Monocytes LPS
0.0
Colon
28.3

Macrophages rest
0.0
Lung
21.6

Macrophages LPS
0.0
Thymus
0.0

HUVEC none
0.0
Kidney
0.0

HUVEC starved
0.0

Ardais Prostate 1.0 Summary: Ag2425 Expression of the CG50367-01 gene was highest in a prostate cancer sample (CT=28.3), with expression of this gene slightly downregulated in most of the prostate cancer samples.

Panel 1.3D Summary: Ag2425 Highest expression of the CG50367-01 gene was seen in fetal skeletal muscle (CT=31.1). This gene was highly expressed in fetal skeletal muscle when compared to expression in adult skeletal muscle (CT=40). Thus expression of this gene is useful as a marker differentiate between fetal and adult skeletal muscle. Furthermore, the higher levels of expression in the fetal source of the tissue show that the protein encoded by this gene is involved in the development of the skeletal muscle in the fetus. Therapeutic modulation of the expression or function of this gene is useful for restoring muscle mass or function to weak or dystrophic muscle in the adult.

This gene was expressed at a very low level in all the cancer cell lines used in this panel. The absence of exprssion of this gene in the cancer cell lines showed that modulation of the function of the gene product through the use of peptides, polypeptides, chimeric molecules or small molecule drugs, aree useful in the therapy of cancer.

This gene is a cell-surface metalloprotease expressed at low levels in the hippocampus. It is useful in the treatment of diseases in which the hippocampus is involved, such as Alzheimer's disease, Parkinson's disease, schizophrenia, bipolar disorder, or temporal lobe epilepsy.

Panel 2D Summary: Ag2425 The CG50367-01 gene was expressed at low levels in this panel, with highest expression in the colon (CT=32.2). Moderately higher levels of expression were seen in normal breast, uterine and thyroid tissues compared to the adjacent cancers. Expression of this gene is useful as a marker to identify normal tissue from cancerous tissue in these organs. Therapeutic modulation of the activity of the product of this gene, through the use of peptides, polypeptides, chimeric molecules or small molecule drugs, is useful in the therapy of these cancers.

Panel 4D Summary: Ag2425 The CG50367-01 transcript was most highly expressed in dermal fibroblast upon treatment with either Il-4 or IFN gamma (CTs=31-32) and at lower levels in resting dermal fibroblasts. This transcript was also expressed in lung fibroblasts and normal lung and thymus. This transcript encodes for a ADAM like protein, a member of membrane-anchored glycoproteins that play a role in diverse cellular processes from cell-cell interaction to shedding of cell surface proteases. The expression of this transcript in dermal and lung fibroblasts showed that the protein encoded by this transcript is involved in diseases associated with fibrosis or fibroplasia. Modulation of the expression or the function of this molecule is useful for the treatment of psoriasis, chronic obstructive pulmonary diseases and potentially for osteoarthritis and rheumatoid arthritis.

L. CG50718-02 and CG50718-06: Glomerular Mesangial Cell Receptor Protein-Tyrosine Phosphatase Precursor,

Expression of gene CG50718-02 and variant CG50718-06 was assessed using the primer-probe sets Ag1555 and Ag2315, described in Tables LA and LB. Results of the RTQ-PCR runs are shown in Tables LC, LD, LE, and LF.

TABLE LAProbe Name Ag1555StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gaagtgaaagaatgtgcatggt-3′2267071175ProbeTET-5′-caccagtgcattctggatctcttatca-27675711763′-TAMRAReverse5′-tgggctgattacttcccttatt-3′2267841177

TABLE LB

Probe Name Ag2315

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-agatgagtcagtgccgttagc-3′
21
3711
1178

Probe
TET-5′-cctccacaaaatttgactttaatcaactg-
29
3733 1179

3′-TAMRA

Reverse
5′-tccatttcagccatacaaagtc-3′
22
3769
1180

TABLE LC

Panel 1.3D

Column A - Rel. Exp.(%) Ag1555, Run 146380268

Column B - Rel. Exp.(%) Ag1555, Run 147775028

Tissue Name
A
B
Tissue Name
A
B

Liver adenocarcinoma
0.0
0.0
Kidney (fetal)
33.9
37.6

Pancreas
5.8
1.6
Renal Ca. 786-0
0.0
0.0

Pancreatic ca. CAPAN 2
0.0
0.0
Renal Ca. A498
0.0
0.0

Adrenal gland
0.0
1.9
Renal Ca. RXF 393
0.0
0.0

Thyroid
8.3
24.7
Renal ca. ACHN
0.0
0.0

Salivary gland
1.0
0.0
Renal ca. UO-31
0.0
1.4

Pituitary gland
0.0
0.0
Renal Ca. TK-10
0.0
0.0

Brain (fetal)
0.6
0.0
Liver
0.0
0.0

Brain (whole)
1.3
1.6
Liver (fetal)
0.0
3.6

Brain (amygdala)
3.4
4.0
Liver ca. (hepatoblast) HepG2
0.0
0.0

Brain (cerebellum)
0.0
0.0
Lung
51.1
52.5

Brain (hippocampus)
1.2
0.6
Lung (fetal)
100.0
100.0

Brain (substantia nigra)
0.0
0.0
Lung Ca. (small cell) LX-1
0.0
0.0

Brain (thalamus)
3.2
1.3
Lung Ca. (small cell) NCI-H69
2.4
0.0

Cerebral Cortex
0.0
0.0
Lung Ca. (s.cell var.) SHP-77
0.0
0.0

Spinal cord
1.1
0.0
Lung Ca. (large cell) NCI-H460
0.0
0.0

glio/astro U87-MG
0.0
2.7
Lung Ca. (non-sm. cell) A549
0.0
0.0

glio/astro U-118-MG
27.2
34.6
Lung Ca. (non-s.cell) NCI-H23
0.0
0.0

astrocytoma SW1783
5.4
13.8
Lung Ca. (non-s.cell) HOP-62
0.7
0.9

neuro*; met SK-N-AS
0.0
0.6
Lung Ca. (non-s.cl) NCI-H522
9.9
5.4

astrocytoma SF-539
0.8
0.0
Lung Ca. (squam.) SW 900
0.0
0.0

astrocytoma SNB-75
0.0
0.0
Lung Ca. (squam.) NCI-H596
1.3
2.2

glioma SNB-19
0.0
0.0
Mammary gland
13.0
26.6

glioma U251
0.0
0.0
Breast ca.* (pl.ef) MCF-7
3.9
0.9

glioma SF-295
1.3
3.3
Breast ca.* (pl.ef) MDA-MB-
0.0
0.0

231

Heart (Fetal)
0.0
0.0
Breast ca.* (pl.ef) T47D
0.0
0.0

Heart
0.0
5.7
Breast ca. BT-549
0.0
0.0

Skeletal muscle (Fetal)
3.5
1.6
Breast Ca. MDA-N
0.0
0.0

Skeletal muscle
0.0
1.4
Ovary
5.2
1.6

Bone marrow
1.0
4.1
Ovarian Ca. OVCAR-3
0.0
0.0

Thymus
1.0
0.0
Ovarian Ca. OVCAR-4
0.0
0.0

Spleen
0.0
0.0
Ovarian Ca. OVCAR-5
0.0
0.0

Lymph node
3.7
4.8
Ovarian Ca. OVCAR-8
0.0
0.0

Colorectal
0.0
0.0
Ovarian Ca. IGROV-1
0.0
0.0

Stomach
1.2
2.3
Ovarian Ca. (ascites) SK-OV-3
0.0
0.0

Small intestine
2.2
6.7
Uterus
0.0
0.9

Colon Ca. SW480
0.0
0.0
Placenta
11.8
27.7

Colon Ca.* SW620 (SW480
0.0
0.0
Prostate
3.5
0.9

met)

Colon Ca. HT29
0.0
0.0
Prostate Ca.* (bone met) PC-3
0.0
0.0

Colon Ca. HCT-116
0.0
0.0
Testis
58.2
67.4

Colon Ca. CaCo-2
0.0
0.0
Melanoma Hs688(A).T
22.7
52.1

CC Well to Mod Duff
0.0
0.0
Melanoma* (met) Hs688(B).T
4.8
4.2

(ODO3866)

Colon Ca. HCC-2998
0.0
0.0
Melanoma UACC-62
0.0
1.5

Gastric ca. (liver met) NCI-N87
0.0
0.0
Melanoma M14
0.0
0.0

Bladder
2.0
0.0
Melanoma LOX IMVI
0.0
0.0

Trachea
2.4
3.6
Melanoma* (met) SK-MEL-5
0.0
0.0

Kidney
15.5
17.8
Adipose
38.2
40.6

TABLE LD

Panel 2D

Column A - Rel. Exp.(%) Ag1555, Run 147775063

Column B - Rel. Exp.(%) Ag1555, Run 159601974

Column C - Rel. Exp.(%) Ag2315, Run 159200827

Tissue Name
A
B
C
Tissue Name
A
B
C

Normal Colon
3.8
7.1
12.4
Kidney Margin 8120608
2.9
1.2
1.7

CC Well to Mod Diff
1.0
0.0
2.3
Kidney Cancer 8120613
0.0
0.0
0.0

(ODO3866)

CC Margin (ODO3866)
0.0
0.0
0.7
Kidney Margin 8120614
1.2
2.6
1.8

CC Gr.2 rectosigmoid
0.0
0.0
0.0
Kidney Cancer 9010320
2.7
2.6
2.1

(ODO3868)

CC Margin (ODO3868)
0.0
0.7
0.0
Kidney Margin 9010321
6.6
5.9
4.9

CC Mod Diff (ODO3920)
0.0
0.0
0.0
Normal Uterus
0.0
0.0
1.8

CC Margin (ODO3920)
0.0
0.0
2.2
Uterine Cancer 064011
0.0
0.0
4.5

CC Gr.2 ascend colon
0.0
0.0
0.0
Normal Thyroid
34.9
27.4
11.4

(ODO3921)

CC Margin (ODO3921)
0.0
0.0
0.0
Thyroid Cancer
2.9
7.2
7.9

CC from Partial
1.6
1.1
0.0
Thyroid Cancer
1.3
3.3
2.0

Hepatectomy (ODO4309)

A302152

Mets

Liver Margin (ODO4309)
0.0
0.0
2.0
Thyroid Margin
49.7
69.7
72.2

A302153

Colon mets to lung
2.0
1.0
0.5
Normal Breast
10.0
8.9
25.3

(ODO4451-01)

Lung Margin (ODO4451-02)
8.6
10.0
10.9
Breast Cancer
10.2
3.0
1.1

Normal Prostate 6546-1
4.2
12.2
1.4
Breast Cancer
0.0
2.8
3.9

(ODO4590-01)

Prostate Cancer (ODO4410)
0.0
0.0
3.4
Breast Cancer Mets
7.8
7.3
7.9

(ODO4590-03)

Prostate Margin (ODO4410)
0.8
6.4
2.2
Breast Cancer
4.1
8.0
3.5

Metastasis

Prostate Cancer (ODO4720-
9.5
11.7
19.6
Breast Cancer
0.0
0.0
1.2

01)

Prostate Margin (ODO4720-
10.0
11.3
24.5
Breast Cancer
3.7
2.9
0.9

02)

Normal Lung
59.9
61.1
87.7
Breast Cancer 9100266
2.2
1.1
1.5

Lung Met to Muscle
0.0
0.0
0.0
Breast Margin 9100265
0.0
0.0
0.5

(ODO4286)

Muscle Margin (ODO4286)
0.9
0.0
1.8
Breast Cancer A209073
0.7
1.1
1.9

Lung Malignant Cancer
1.9
2.8
1.7
Breast Margin A209073
0.0
1.2
0.9

(ODO3126)

Lung Margin (ODO3126)
36.3
3.6
43.8
Normal Liver
0.0
0.0
0.0

Lung Cancer (ODO4404)
2.2
4.4
4.3
Liver Cancer
0.0
0.0
0.6

Lung Margin (ODO4404)
9.5
4.2
8.4
Liver Cancer 1025
0.0
0.0
0.0

Lung Cancer (ODO4565)
0.0
0.0
00
Liver Cancer 1026
0.0
0.0
0.0

Lung Margin (ODO4565)
10.8
9.7
14.1
Liver Cancer 6004-T
0.0
1.0
0.6

Lung Cancer (OD04237-01)
0.0
0.0
0.0
Liver Tissue 6004-N
0.0
0.0
0.0

Lung Margin (ODO4237-02)
30.1
18.4
29.3
Liver Cancer 6005-T
0.0
0.0
0.0

Ocular Mel Met to Liver
0.0
0.0
0.6
Liver Tissue 6005-N
0.0
0.0
0.0

(ODO4310)

Liver Margin (ODO4310)
1.0
2.0
0.0
Normal Bladder
4.7
2.2
2.9

Melanoma Metastasis
0.0
0.0
0.0
Bladder Cancer
0.0
0.0
0.0

Lung Margin (ODO4321)
25.7
47.0
49.0
Bladder Cancer
0.0
4.2
5.5

Normal Kidney
86.5
100.0
100.0
Bladder Cancer
0.7
1.6
1.1

(ODO4718-01)

Kidney Ca, Nuclear grade 2
2.2
0.0
1.1
Bladder Normal
4.4
0.9
6.3

(ODO4338)

Adjacent (ODO4718-03)

Kidney Margin (ODO4338)
55.1
35.8
58.2
Normal Ovary
1.7
0.0
0.9

Kidney Ca Nuclear grade 1/2
0.0
0.0
0.0
Ovarian Cancer
0.0
4.2
3.3

(ODO4339)

Kidney Margin (ODO4339)
77.9
63.7
77.9
Ovarian Cancer
0.0
0.0
0.0

(ODO4768-07)

Kidney Ca, Clear cell type
1.7
0.0
0.0
Ovary Margin
9.4
5.5
6.9

(ODO4340)

(ODO4768-08)

Kidney Margin (ODO4340)
100.0
53.2
62.4
Normal Stomach
0.0
0.0
0.0

Kidney Ca, Nuclear grade 3
25.9
23.2
0.0
Gastric Cancer 9060358
0.0
0.0
1.5

(ODO4348)

Kidney Margin (ODO4348)
40.9
50.3
54.7
Stomach Margin
0.0
0.0
2.0

9060359

Kidney Cancer (ODO4622-
0.6
0.0
0.0
Gastric Cancer 9060395
0.9
1.2
1.8

01)

Kidney Margin (ODO4622-
0.0
0.0
1.4
Stomach Margin
0.0
1.0
0.7

03)

9060394

Kidney Cancer (ODO4450-
0.0
0.0
0.0
Gastric Cancer 9060397
0.0
0.0
0.0

01)

Kidney Margin (ODO4450-
40.3
51.1
50.7
Stomach Margin
0.0
0.0
0.0

03)

9060396

Kidney Cancer 8120607
0.0
0.0
0.0
Gastric Cancer 064005
0.0
0.0
2.5

TABLE LE

Panel 4D

Column A - Rel. Exp. (%) Ag1555, Run 147775116

Column B - Rel. Exp. (%) Ag2315, Run 159202089

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
0.0
0.0
HUVEC IL-1beta
0.0
0.0

Secondary Th2 act
0.0
0.0
HUVEC IFN gamma
0.0
0.0

Secondary Tr1 act
0.0
0.7
HUVEC TNF alpha + IFN gamma
0.0
0.0

Secondary Th1 rest
0.0
0.0
HUVEC TNF alpha +IL4
0.0
0.0

Secondary Th2 rest
0.0
0.0
HUVEC IL-11
0.0
0.0

Secondary Tr1 rest
0.0
0.0
Lung Microvascular EC none
0.0
0.0

Primary Th1 act
0.0
0.0
Lung Microvascular EC TNF alpha +
0.0
0.0

IL-1beta

Primary Th2 act
0.0
0.0
Microvascular Dermal EC none
0.0
0.0

Primary Tr1 act
0.0
0.0
Microsvasular Dermal EC TNFalpha
0.0
0.0

+ IL-1beta

Primary Th1 rest
0.0
0.0
Bronchial epithelium TNFalpha +
0.0
0.0

IL1beta

Primary Th2 rest
0.0
0.0
Small airway epithelium none
0.0
0.0

Primary Tr1 rest
0.0
0.0
Small airway epithelium TNFalpha +
0.0
0.0

IL-1beta

CD45RA CD4
3.3
5.0
Coronery artery SMG rest
1.0
2.3

lymphocyte act

CD45RO CD4
0.0
0.0
Coronery artery SMC TNFalpha +
3.7
1.2

lymphocyte act

IL-1beta

CD8 lymphocyte act
0.0
0.0
Astrocytes rest
3.2
0.5

Secondary CD8
0.0
0.0
Astrocytes TNFalpha + IL-1beta
1.0
1.5

lymphocyte rest

Secondary CD8
0.0
0.0
KU-812 (Basophil) rest
0.0
0.0

lymphocyte act

CD4 lymphocyte none
0.0
0.0
KU-812 (Basophil) PMA/ionomycin
0.0
0.0

2ry Th1/Th2/Tr1 anti-
0.0
0.0
CCD1106 (Keratinocytes) none
0.0
0.0

CD95 CH11

LAK cells rest
0.0
0.0
93580 CCD1106 (Keratinocytes)
0.0
0.0

TNFa and IFNg

LAK cells IL-2
0.0
0.0
Liver cirrhosis
1.4
3.8

LAK cells IL-2 + IL-12
0.0
0.0
Lupus kidney
0.0
0.8

LAK cells IL-2 + IFN
0.0
0.0
NCI-H292 none
0.0
0.0

gamma

LAK cells IL-2 + IL-18
0.0
0.0
NCI-H292 IL-4
0.0
2.3

LAK cells PMA/
0.0
0.0
NCI-H292 IL-9
0.0
0.5

ionomycin

NK Cells IL-2 rest
0.0
0.0
NCI-H292 IL-13
0.0
1.3

Two Way MLR 3 day
0.0
0.0
NCI-H292 IFN gamma
0.0
0.0

Two Way MLR 5 day
0.0
0.0
HPAEC none
0.0
0.0

Two Way MLR 7 day
0.0
0.0
HPAEC TNF alpha + IL-1 beta
0.0
0.0

PBMC rest
0.0
0.0
Lung fibroblast none
0.0
0.9

PBMC PWM
0.0
0.0
Lung fibroblast TNF alpha + IL-1
0.0
0.0

beta

PBMC PHA-L
0.0
0.0
Lung fibroblast IL-4
0.0
0.0

Ramos (B cell) none
0.0
0.0
Lung fibroblast IL-9
5.7
1.3

Ramos (B cell)
0.0
0.0
Lung fibroblast IL-13
1.5
1.5

ionomycin

B lymphocytes PWM
0.0
0.0
Lung fibroblast IFN gamma
0.0
1.7

B lymphocytes CD40L
0.0
0.0
Dermal fibroblast CCD1070 rest
12.9
17.2

and IL-4

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 TNF
18.6
12.0

alpha

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 IL-1
6.1
2.9

PMA/ionomycin

beta

Dendritic cells none
0.0
0.0
Dermal fibroblast IFN gamma
0.0
0.0

Dendritic cells LPS
0.0
0.0
Dermal fibroblast IL-4
1.4
0.6

Dendritic cells anti-CD40
0.0
0.0
IBD Colitis 2
0.0
1.4

Monocytes rest
0.0
0.0
IBD Crohn's
0.0
0.0

Monocytes LPS
0.0
0.0
Colon
0.6
0.0

Macrophages rest
0.0
0.0
Lung
4.0
11.7

Macrophages LPS
0.0
0.0
Thymus
100.0
100.0

HUVEC none
0.0
0.0
Kidney
4.2
5.3

HUVEC starved
0.0
0.0

TABLE LF

Panel 5D

Column A - Rel. Exp.(%) Ag2315, Run 169275446

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
84.1
94709 Donor 2 AM - A adipose
13.6

97476 Patient-07sk skeletal muscle
0.6
94710 Donor 2 AM - B adipose
9.3

97477 Patient-07ut uterus
0.0
94711 Donor 2 AM - C adipose
3.6

97478 Patient-07pl placenta
7.2
94712 Donor 2 AD - A adipose
8.7

97481 Patient-08sk skeletal muscle
4.4
94713 Donor 2 AD - B adipose
17.1

97482 Patient-08ut uterus
0.5
94714 Donor 2 AD - C adipose
21.6

97483 Patient-08pl placenta
6.5
94742 Donor 3 U - A Mesenchymal
9.0

Stem Cells

97486 Patient-09sk skeletal muscle
0.0
94743 Donor 3 U - B Mesenchymal
7.3

Stem Cells

97487 Patient-09ut uterus
0.5
94730 Donor 3 AM - A adipose
14.8

97488 Patient-09pl placenta
6.1
94731 Donor 3 AM - B adipose
13.9

97492 Patient-10ut uterus
0.0
94732 Donor 3 AM - C adipose
5.9

97493 Patient-10pl placenta
7.8
94733 Donor 3 AD - A adipose
5.4

97495 Patient-11go adipose
100.0
94734 Donor 3 AD - B adipose
4.7

97496 Patient-11sk skeletal muscle
0.6
94735 Donor 3 AD - C adipose
9.3

97497 Patient-11ut uterus
1.0
77138 Liver HepG2untreated
6.9

97498 Patient-11pl placenta
7.3
73556 Heart Cardiac stromal cells
0.0

(primary)

97500 Patient-12go adipose
61.6
81735 Small Intestine
1.5

97501 Patient-12sk skeletal muscle
3.2
72409 Kidney Proximal Convoluted
0.0

Tubule

97502 Patient-12ut uterus
1.4
82685 Small intestine Duodenum
0.0

97503 Patient-12pl placenta
1.5
90650 Adrenal Adrenocortical
0.0

adenoma

94721 Donor 2 U - A Mesenchymal
14.4
72410 Kidney HRCE
0.0

Stem Cells

94722 Donor 2 U - B Mesenchymal
6.7
72411 Kidney HRE
0.0

Stem Cells

94723 Donor 2 U - C Mesenchymal
6.0
73139 Uterus Uterine smooth muscle
0.0

Stem Cells

cells

Panel 1.3D Summary: Ag1555 Highest expression of this gene was seen in the fetal lung (CTs=32). Modulation of this gene is useful in the treatment of lung related diseases.

Low but significant expression was also seen in the thyroid. Biologic cross-talk between the thyroid and adipose tissue is believed to be a component of some forms of obesity. Modulation of this gene and/or encoded protein is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

Panel 2D Summary: Ag1555/2315 Highest expression of this gene was detected in normal kidney tissue (CTs=30.7-32.4). Significant levels of expression of this was also seen in samples derived from normal lung tissue. This gene was preferentially expressed in healthy tissue relative to adjacent cancerous tissue. Modulation of this gene, encoded protein and/or use of small molecule drugs or antibodies targeting this gene is useful in the treatment of kidney cancer and lung cancer.

Panel 4D Summary: Ag1555/Ag2315 This gene was detected at significant levels in the thymus (CT=31.5) and dermal fibroblasts (CT=34). Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in maintaining or restoring the normal function to these organs during inflammation.

Panel 5D Summary: Ag2315 This gene showed significant expression in human adipose tissue and in cultured human adipocytes (CT=31-34). Modulation of this gene or gene product is useful in the treatment of obesity.

M. CG50934-03: Mastocytoma Protease Precursor

Expression of full-length physical clone CG50934-03 was assessed using the primer-probe set Ag6974, described in Table MA. Results of the RTQ-PCR runs are shown in Table MB.

TABLE MAProbe Name Ag6974StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gagacggatggccacag-3′175201181ProbeTET-5′-ccaggtggctcagagcagcaggaatgtac-2953811823′-TAMRAReverse5′-cgttccgcctgcagag-3′165771183

TABLE MB

General_screening_panel_v1.6

Column A - Rel. Exp.(%) Ag6974, Run 278389211

Tissue Name
A
Tissue Name
A

Adipose
0.0
Renal ca. TK-10
0.0

Melanoma*
0.0
Bladder
0.2

Hs688(A).T

Melanoma*
0.0
Gastric ca. (liver met.) NCI-N87
34.4

Hs688(B).T

Melanoma* M14
0.0
Gastric ca. KATO III
0.0

Melanoma* LOXIMVI
0.0
Colon ca. SW-948
0.0

Melanoma*
0.0
Colon ca. SW480
1.2

SK-MEL-5

Squamous cell
0.0
Colon ca.* (SW480 met) SW620
1.8

carcinoma SCC-4

Testis Pool
0.0
Colon ca. HT29
0.2

Prostate ca.*
0.0
Colon ca. HCT-116
0.0

(bone met) PC-3

Prostate Pool
0.0
Colon ca. CaCo-2
0.9

Placenta
0.6
Colon cancer tissue
11.9

Uterus Pool
0.0
Colon ca. SW1116
0.0

Ovarian ca. OVCAR-3
0.0
Colon ca. Colo-205
2.7

Ovarian ca. SK-OV-3
0.0
Colon ca. SW-48
0.0

Ovarian ca. OVCAR-4
0.1
Colon Pool
0.3

Ovarian ca. OVCAR-5
100.0
Small Intestine Pool
0.3

Ovarian ca. IGROV-1
0.0
Stomach Pool
0.0

Ovarian ca. OVCAR-8
0.0
Bone Marrow Pool
0.1

Ovary
0.0
Fetal Heart
0.0

Breast ca. MCF-7
9.3
Heart Pool
0.0

Breast ca.
0.0
Lymph Node Pool
0.2

MDA-MB-231

Breast ca. BT 549
0.0
Fetal Skeletal Muscle
0.0

Breast ca. T47D
0.4
Skeletal Muscle Pool
0.0

Breast ca. MDA-N
0.0
Spleen Pool
0.0

Breast Pool
0.0
Thymus Pool
0.0

Trachea
0.0
CNS cancer (glio/astro) U87-MG
0.0

Lung
0.0
CNS cancer (glio/astro) U-118-MG
0.2

Fetal Lung
0.0
CNS cancer (neuro; met) SK-N-AS
0.0

Lung ca. NCI-N417
0.0
CNS cancer (astro) SF-539
0.0

Lung ca. LX-1
21.5
CNS cancer (astro) SNB-75
0.0

Lung ca. NCI-H146
0.0
CNS cancer (glio) SNB-19
0.0

Lung ca. SHP-77
4.0
CNS cancer (glio) SF-295
0.5

Lung ca. A549
0.0
Brain (Amygdala) Pool
0.0

Lung ca. NCI-H526
0.0
Brain (cerebellum)
0.0

Lung ca. NCI-H23
0.2
Brain (fetal)
0.2

Lung ca. NCI-H460
0.0
Brain (Hippocampus) Pool
0.0

Lung ca. HOP-62
0.0
Cerebral Cortex Pool
0.1

Lung ca. NCI-H522
0.0
Brain (Substantia nigra) Pool
0.0

Liver
0.0
Brain (Thalamus) Pool
0.0

Fetal Liver
1.5
Brain (whole)
0.0

Liver ca. HepG2
1.1
Spinal Cord Pool
0.0

Kidney Pool
0.1
Adrenal Gland
0.0

Fetal Kidney
0.4
Pituitary gland Pool
1.3

Renal ca. 786-0
0.0
Salivary Gland
0.0

Renal ca. A498
0.0
Thyroid (female)
0.0

Renal ca. ACHN
0.0
Pancreatic ca. CAPAN2
8.5

Renal ca. UO-31
0.0
Pancreas Pool
0.0

General_screening_panel_v1.6 Summary: Ag6974 Highest expression of this gene was detected in an ovarian cancer OVCAR-5 cell line (CT=28). This gene showed preferential expression in colon cancer tissue and a number of cancer cell lines derived from pancreatic, colon, gastric, lung, breast and ovarian cancers. Expression of this gene is useful as diagnostic marker to detect these cancers and also, modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of these cancers.

N. CG51213-01 and CG51213-04: Zinc Metalloendopeptidase

Expression of gene CG51213-01 and CG51213-04 was assessed using the primer-probe sets Ag813, and Ag3985, described in Tables NA and NB. Results of the RTQ-PCR runs are shown in Tables NC, ND NE and NF. Please note that the primer-probe set Ag3985 is specific for CG51213-04 only.

TABLE NAProbe Name Ag813StartSEQ IDPrimersSequencesLengthPositionNoForward5′-tgtagaatttcccacggaaag-3′2111851184ProbeTET-5′-cactgcacttctctgaagtcctggga-3′-2611391185TAMRAReverse5′-ctgcaacacggatgactgt-3′1911111186

TABLE NB

Probe Name Ag3985

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-tgggaaattctacaagtggaaa-3′
22
1192
1187

Probe
TET-5′-ctcgctcacgagcctagcggaag-3′-
23
1243
1188

TAMRA

Reverse
5′-cctctccgtgtagaagttgaag-3′
22
1267
1189

TABLE NC

AI_comprehensive panel_v1.0

Column A - Rel. Exp.(%) Ag3985, Run 226203363

Column B - Rel. Exp.(%) Ag813, Run 234222162

Column C - Rel. Exp.(%) Ag813, Run 246953625

Tissue Name
A
B
C
Tissue Name
A
B
C

110967 COPD-F
14.1
5.4
8.8
112427 Match Control
31.6
0.0
30.6

Psoriasis-F

110980 COPD-F
8.5
5.9
9.2
112418 Psoriasis-M
8.8
8.6
8.7

110968 COPD-M
18.4
12.9
11.9
112723 Match Control
8.9
11.0
8.8

Psoriasis-M

110977 COPD-M
0.0
18.8
25.7
112419 Psoriasis-M
4.7
10.7
8.1

110989 Emphysema-F
37.1
19.3
26.4
112424 Match Control
5.0
7.4
4.1

Psoriasis-M

110992 Emphysema-F
22.1
13.5
30.8
112420 Psoriasis-M
40.3
37.4
36.3

110993 Emphysema-F
22.8
10.5
13.2
112425 Match Control
16.2
11.7
6.2

Psoriasis-M

110994 Emphysema-F
10.2
10.4
7.3
104689 (MF) OA Bone-
94.6
100.0
100.0

Backus

110995 Emphysema-F
60.3
25.5
25.9
104690 (MF) Adj “Normal”
90.1
62.0
65.5

Bone-Backus

110996 Emphysema-F
7.0
3.7
6.5
104691 (ME) OA
100.0
73.7
74.7

Synovium-Backus

110997 Asthma-M
4.1
2.5
2.4
104692 (BA) OA Cartilage-
24.5
15.8
15.0

Backus

111001 Asthma-F
21.8
16.3
21.0
104694 (BA) OA Bone-
85.9
69.3
79.0

Backus

111002 Asthma-F
27.9
24.0
22.1
104695 (BA) Adj “Normal”
78.5
68.3
44.1

Bone-Back

111003 Atopic Asthma-F
25.5
14.9
35.4
104696 (BA) OA
33.9
29.5
27.9

Synovium-Backus

111004 Atopic Asthma-F
46.0
31.6
147.0
104700 (SS) OA Bone-
42.3
55.1
43.2

Backus

111005 Atopic Asthma-F
27.4
18.4
20.2
104701 (SS) Adj “Normal”
75.3
72.2
95.3

Bone-Backus

111006 Atopic Asthma-F
8.4
2.6
5.6
104702 (SS) OA
48.0
36.3
37.9

Synovium-Backus

111417 Allergy-M
21.8
13.4
8.5
117093 OA Cartilage Rep 7
7.5
4.9
11.3

112347 Allergy-M
0.5
0.0
0.0
112672 OA Bone5
34.6
25.3
25.0

112349 Normal Lung-F
0.0
0.0
0.0
112673 OA Synovium5
12.3
8.4
12.6

112357 Normal Lung-F
25.2
15.5
16.4
112674 OA Synovial Fluid
21.2
18.8
16.2

cells5

112354 Normal Lung-M
6.2
3.7
1.5
117100 OA Cartilage
11.8
8.0
10.5

Rep14

112374 Crohns-F
12.2
16.6
21.6
112756 OA Bone9
7.7
3.6
11.2

112389 Match Control
9.3
10.3
6.3
112757 OA Synovium9
5.4
6.0
5.4

Crohns-F

112375 Crohns-F
19.5
0.0
32.8
112758 OA Synovial Fluid
12.2
9.9
9.4

Cells9

112732 Match Control
15.4
10.4
9.7
117125 RA Cartilage Rep2
12.4
5.3
9.3

Crohns-F

112725 Crohns-M
1.0
2.2
0.8
113492 Bone2 RA
6.8
4.0
4.1

112387 Match Control
12.9
8.4
10.5
113493 Synovium2 RA
0.2
1.0
1.7

Crohns-M

112378 Crohns-M
0.5
0.0
0.0
113494 Syn Fluid Cells RA
3.5
2.6
5.6

112390 Match Control
50.0
38.7
38.2
113499 Cartilage4 RA
5.5
4.7
5.2

Crohns-M

112726 Crohns-M
31.2
27.4
22.8
113500 Bone4 RA
6.4
4.0
4.6

112731 Match Control
23.5
7.6
13.6
113501 Synovium4 RA
4.2
3.6
3.1

Crohns-M

112380 Ulcer Col-F
18.6
15.9
20.4
113502 Syn Fluid Cells4
2.6
2.3
1.9

RA

112734 Match Control
28.3
13.5
26.4
113495 Cartilage3 RA
1.3
3.3
5.4

Ulcer Col-F

112384 Ulcer Col-F
47.0
21.6
18.8
113496 Bone3 RA
0.9
4.6
6.4

112737 Match Control
8.5
5.6
5.8
113497 Synovium3 RA
1.1
3.1
1.6

Ulcer Col-F

112386 Ulcer Col-F
8.6
0.7
1.1
113498 Syn Fluid Cells3
4.9
6.9
6.0

RA

112738 MatchControl
3.6
3.0
4.3
117106 Normal Cartilage
16.4
13.7
13.0

Ulcer Col-F

Rep20

112381 Ulcer Col-M
2.5
0.0
0.1
113663 Bone3 Normal
0.0
0.0
0.0

112735 Match Control
2.2
2.1
0.8
113664 Synovium3 Normal
0.0
0.0
0.0

Ulcer Col-M

112382 Ulcer Col-M
3.7
8.7
8.5
113665 Syn Fluid Cells3
0.0
0.0
0.1

Normal

112394 Match Control
3.7
1.5
4.7
117107 Normal Cartilage
2.3
2.3
0.3

Ulcer Col-M

Rep22

112383 Ulcer Col-M
52.5
45.7
54.7
113667 Bone4 Normal
11.0
8.6
4.7

112736 Match Control
3.2
6.1
6.4
113668 Synovium4 Normal
2.9
3.0
6.4

Ulcer Col-M

112423 Psoriasis-F
9.2
7.7
5.2
113669 Syn Fluid Cells4
13.9
12.7
11.0

Normal

TABLE ND

General_screening_panel_v1.5

Column A - Rel. Exp.(%) Ag813, Run 247945092

Tissue Name
A
Tissue Name
A

Adipose
15.2
Renal ca. TK-10
50.3

Melanoma*
26.2
Bladder
88.3

Hs688(A).T

Melanoma*
42.6
Gastric ca. (liver met.) NCI-N87
0.0

Hs688(B).T

Melanoma* M14
0.0
Gastric ca. KATO III
0.0

Melanoma* LOXIMVI
4.7
Colon ca. SW-948
0.0

Melanoma*
0.0
Colon ca. SW480
0.3

SK-MEL-5

Squamous cell
0.0
Colon ca.* (SW480 met) SW620
0.0

carcinoma SCC-4

Testis Pool
9.6
Colon ca. HT29
0.0

Prostate ca.*
0.0
Colon ca. HCT-116
3.2

(bone met) PC-3

Prostate Pool
4.6
Colon ca. CaCo-2
0.4

Placenta
36.6
Colon cancer tissue
30.1

Uterus Pool
5.4
Colon ca. SW1116
0.0

Ovarian ca. OVCAR-3
0.0
Colon ca. Colo-205
0.0

Ovarian ca. SK-OV-3
1.9
Colon ca. SW-48
0.0

Ovarian ca. OVCAR-4
1.2
Colon Pool
29.7

Ovarian ca. OVCAR-5
14.3
Small Intestine Pool
9.5

Ovarian ca. IGROV-1
9.7
Stomach Pool
16.3

Ovarian ca. OVCAR-8
24.1
Bone Marrow Pool
7.9

Ovary
20.6
Fetal Heart
11.8

Breast ca. MCF-7
0.0
Heart Pool
10.9

Breast ca.
0.0
Lymph Node Pool
31.4

MDA-MB-231

Breast ca. BT 549
15.7
Fetal Skeletal Muscle
15.7

Breast ca. T47D
1.0
Skeletal Muscle Pool
4.1

Breast ca. MDA-N
0.0
Spleen Pool
12.3

Breast Pool
30.1
Thymus Pool
37.1

Trachea
6.0
CNS cancer (glio/astro) U87-MG
0.0

Lung
4.9
CNS cancer (glio/astro) U-118-MG
0.7

Fetal Lung
59.5
CNS cancer (neuro; met) SK-N-AS
0.6

Lung ca. NCI-N417
0.0
CNS cancer (astro) SF-539
15.0

Lung ca. LX-1
0.0
CNS cancer (astro) SNB-75
100.0

Lung ca. NCI-H146
0.0
CNS cancer (glio) SNB-19
10.7

Lung ca. SHP-77
1.5
CNS cancer (glio) SF-295
14.8

Lung ca. A549
75.3
Brain (Amygdala) Pool
13.7

Lung ca. NCI-H526
0.0
Brain (cerebellum)
8.5

Lung ca. NCI-H23
30.6
Brain (fetal)
95.9

Lung ca. NCI-H460
0.3
Brain (Hippocampus) Pool
12.9

Lung ca. HOP-62
19.9
Cerebral Cortex Pool
20.0

Lung ca. NCI-H522
17.7
Brain (Substantia nigra) Pool
10.5

Liver
0.4
Brain (Thalamus) Pool
22.2

Fetal Liver
6.3
Brain (whole)
12.0

Liver ca. HepG2
0.0
Spinal Cord Pool
21.0

Kidney Pool
36.6
Adrenal Gland
19.2

Fetal Kidney
36.6
Pituitary gland Pool
1.6

Renal ca. 786-0
0.0
Salivary Gland
0.4

Renal ca. A498
55.5
Thyroid (female)
4.0

Renal ca. ACHN
0.0
Pancreatic ca. CAPAN2
1.1

Renal ca. UO-31
7.0
Pancreas Pool
45.7

TABLE NE

Panel 4.1D

Column A - Rel. Exp. (%) Ag3985, Run 170721255

Column B - Rel. Exp. (%) Ag813, Run 237369996

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
6.7
4.8
HUVEC IL-1beta
6.0
11.6

Secondary Th2 act
21.3
11.7
HUVEC IFN gamma
23.2
6.9

Secondary Tr1 act
14.8
5.3
HUVEC TNF alpha + IFN gamma
10.4
2.7

Secondary Th1 rest
33.2
4.9
HUVEC TNF alpha +IL4
4.9
1.3

Secondary Th2 rest
46.3
2.1
HUVEC IL-11
2.9
20.0

Secondary Tr1 rest
61.6
0.0
Lung Microvascular EC none
100.0
95.9

Primary Th1 act
27.2
0.0
Lung Microvascular EC TNF alpha +
54.3
39.0

IL-1beta

Primary Th2 act
17.2
61.1
Microvascular Dermal EC none
23.7
2.8

Primary Tr1 act
12.4
25.9
Microsvasular Dermal EC TNFalpha
15.2
6.7

+ IL-1beta

Primary Th1 rest
40.1
14.7
Bronchial epithelium TNFalpha +
0.0
0.0

IL1beta

Primary Th2 rest
28.1
15.8
Small airway epithelium none
11.9
0.0

Primary Tr1 rest
59.9
4.1
Small airway epithelium TNFalpha +
0.0
0.0

IL-1beta

CD45RA CD4
10.9
5.4
Coronery artery SMG rest
23.5
33.4

lymphocyte act

CD45RO CD4
9.9
22.2
Coronery artery SMC TNFalpha +
43.8
31.4

lymphocyte act

IL-1beta

CD8 lymphocyte act
14.3
0.9
Astrocytes rest
83.5
20.4

Secondary CD8
0.0
6.0
Astrocytes TNFalpha + IL-1beta
63.3
6.9

lymphocyte rest

Secondary CD8
17.4
0.0
KU-812 (Basophil) rest
0.0
0.0

lymphocyte act

CD4 lymphocyte none
27.4
6.0
KU-812 (Basophil) PMA/ionomycin
2.6
11.0

2ry Th1/Th2/Tr1 anti-
74.7
7.1
CCD1106 (Keratinocytes) none
0.0
0.0

CD95 CH11

LAK cells rest
8.8
11.3
93580 CCD1106 (Keratinocytes)
0.0
0.0

TNFa and IFNg

LAK cells IL-2
22.7
0.0
Liver cirrhosis
27.9
32.5

LAK cells IL-2 + IL-12
8.4
0.0
Lupus kidney
0.0
0.0

LAK cells IL-2 + IFN
11.0
0.0
NCI-H292 none
0.0
0.0

gamma

LAK cells IL-2 + IL-18
12.2
0.0
NCI-H292 IL-4
0.0
0.0

LAK cells PMA/
13.0
10.7
NCI-H292 IL-9
0.0
5.4

ionomycin

NK Cells IL-2 rest
47.3
100.0
NCI-H292 IL-13
0.0
0.0

Two Way MLR 3 day
48.0
13.9
NCI-H292 IFN gamma
14.5
5.3

Two Way MLR 5 day
17.7
0.0
HPAEC none
2.6
4.9

Two Way MLR 7 day
5.5
0.0
HPAEC TNF alpha + IL-1 beta
11.2
10.7

PBMC rest
38.7
2.9
Lung fibroblast none
2.6
9.4

PBMC PWM
14.5
0.0
Lung fibroblast TNF alpha + IL-1
7.9
7.8

beta

PBMC PHA-L
0.0
0.0
Lung fibroblast IL-4
6.0
6.8

Ramos (B cell) none
0.0
0.0
Lung fibroblast IL-9
22.8
0.0

Ramos (B cell)
0.0
0.0
Lung fibroblast IL-13
7.5
16.5

ionomycin

B lymphocytes PWM
0.0
2.4
Lung fibroblast IFN gamma
11.9
12.2

B lymphocytes CD40L
7.1
2.9
Dermal fibroblast CCD1070 rest
7.3
25.5

and IL-4

EOL-1 dbcAMP
48.3
80.1
Dermal fibroblast CCD1070 TNF
10.7
20.3

alpha

EOL-1 dbcAMP
60.7
0.0
Dermal fibroblast CCD1070 IL-1
29.9
9.9

PMA/ionomycin

beta

Dendritic cells none
4.2
0.0
Dermal fibroblast IFN gamma
59.9
57.8

Dendritic cells LPS
0.0
0.0
Dermal fibroblast IL-4
14.3
13.0

Dendritic cells anti-CD40
0.0
0.0
IBD Colitis 2
3.3
0.0

Monocytes rest
0.0
0.0
IBD Crohn's
0.0
2.5

Monocytes LPS
0.0
0.0
Colon
9.0
0.0

Macrophages rest
4.7
0.0
Lung
4.5
0.0

Macrophages LPS
0.0
0.0
Thymus
15.6
4.8

HUVEC none
0.6
0.0
Kidney
11.3
21.9

HUVEC starved
8.7
14.2

TABLE NF

Panel 5 Islet

Column A - Rel. Exp.(%) Ag813, Run 254387841

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
45.7
94709 Donor 2 AM - A adipose
49.3

97476 Patient-07sk skeletal muscle
11.7
94710 Donor 2 AM - B adipose
15.8

97477 Patient-07ut uterus
33.2
94711 Donor 2 AM - C adipose
8.4

97478 Patient-07pl placenta
11.7
94712 Donor 2 AD - A adipose
52.9

99167 Bayer Patient 1
14.4
94713 Donor 2 AD - B adipose
36.3

97482 Patient-08ut uterus
45.7
94714 Donor 2 AD - C adipose
35.6

97483 Patient-08pl placenta
7.0
94742 Donor 3 U - A Mesenchymal
27.4

Stem Cells

97486 Patient-09sk skeletal muscle
0.0
94743 Donor 3 U - B Mesenchymal
33.9

Stem Cells

97487 Patient-09ut uterus
16.3
94730 Donor 3 AM - A adipose
17.2

97488 Patient-09pl placenta
13.8
94731 Donor 3 AM - B adipose
21.2

97492 Patient-10ut uterus
24.3
94732 Donor 3 AM - C adipose
4.9

97493 Patient-10pl placenta
5.1
94733 Donor 3 AD - A adipose
100.0

97495 Patient-11go adipose
9.7
94734 Donor 3 AD - B adipose
40.3

97496 Patient-11sk skeletal muscle
15.0
94735 Donor 3 AD - C adipose
69.7

97497 Patient-11ut uterus
43.2
77138 Liver HepG2untreated
0.0

97498 Patient-11pl placenta
7.9
73556 Heart Cardiac stromal cells
7.9

(primary)

97500 Patient-12go adipose
36.3
81735 Small Intestine
54.3

97501 Patient-12sk skeletal muscle
33.2
72409 Kidney Proximal Convoluted
0.0

Tubule

97502 Patient-12ut uterus
55.1
82685 Small intestine Duodenum
0.0

97503 Patient-12pl placenta
0.0
90650 Adrenal Adrenocortical
26.2

adenoma

94721 Donor 2 U - A Mesenchymal
66.0
72410 Kidney HRCE
0.0

Stem Cells

94722 Donor 2 U - B Mesenchymal
32.1
72411 Kidney HRE
0.0

Stem Cells

94723 Donor 2 U - C Mesenchymal
62.0
73139 Uterus Uterine smooth muscle
6.3

Stem Cells

cells

AI_comprehensive panel_v1.0 Summary: Ag3985/Ag813 Highest expression of this gene was detected in samples from an osteoarthritic bone sample and synovium (CTs=30). Significant expression of this gene was detected in samples derived from orthoarthitis bone, cartilage, synovium and synovial fluid samples, from normal lung, COPD lung, emphysema, atopic asthma, asthma, allergy, Crohn's disease (normal matched control and diseased), ulcerative colitis (normal matched control and diseased), and psoriasis (normal matched control and diseased). Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful for the amelioration of symptoms/conditions associated with autoimmune and inflammatory disorders including psoriasis, allergy, asthma, inflammatory bowel disease, and osteoarthritis.

General_screening_panel_v1.5 Summary: Ag813 Highest expression of this gene was detected in fetal brain and a brain cancer SNB-75 cell line (CTs=31). In addition, moderate expression of this gene was seen in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. This gene codes for a variant of ADAMTS-10, a member of Matrix metalloproteinases (MMPs). MMPs are a gene family of neutral proteases that are important in normal development, wound healing, and a wide variety of pathological processes, including the spread of metastatic cancer cells, arthritic destruction of joints, atherosclerosis, and neuroinflammation. In the central nervous system (CNS), MMPs have been shown to degrade components of the basal lamina, leading to disruption of the blood-brain barrier (BBB), and to contribute to the neuroinflammatory response in many neurological diseases (Rosenberg G A, 2002, Glia 39(3):279-91, PMID: 12203394). Modulation of this gene, encoded protein and/or use of antibodies of small molecule drug targeting this gene or gene product is useful in the treatment of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia, depression, allergic encephalomyelitis (EAE), allergic neuritis (EAN), and cerebral ischemia.

Moderate to low levels of expression of this gene were also detected in tissues with metabolic/endocrine function including pancreas, adipose, adrenal gland, skeletal muscle, heart, fetal liver and the gastrointestinal tract. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

This gene was expressed at moderate to low levels in number of cancer cell lines derived from melanoma, ovarian, breast, lung, renal, colon and brain cancers. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of these cancers.

Panel 4.1D Summary: Ag813/Ag3985 Highest expression of this gene was detected in IL-2 treated resting NK cells and lung microvascular endothelial cells (CTs=31-32.8). Moderate to low levels of expression of this gene were also detected in activated primary polarized T cells, eosinophils, lung microvascular endothelial cells, coronery artery SMC, liver cirrhosis and activated dermal fibroblasts. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of autoimmune and inflammatory diseases including asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

Panel 5 Islet Summary: Ag813 Highest expression of this gene was detected in differentiated adipose cells (CT=33.5). Low expression of this gene was seen mainly in adipose and small intestine. Therefore, modulation of this gene and/or encoded protein is useful in the treatment of obesity and diabetes, including Type II diabetes.

O. CG51448-01 and CG51448-05: Myosin, Light Polypeptide Kinase

Expression of gene CG51448-05 was assessed using the primer-probe sets Ag1289 and Ag764, described in Tables OA and OB. Results of the RTQ-PCR runs are shown in Tables OC, OD and OE.

TABLE OAProbe Name Ag1289StartSEQ IDPrimersSequencesLengthPositionNoForward5′-aacgagaagctgaaggtgaact-3′2212771190ProbeTET-5′-accccagagttcctgtcacctgaggt-3′-2613041191TAMRAReverse5′-tcggagatttggtcataattca-3′2213321192

TABLE OB

Probe Name Ag764

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-aacgagaagctgaaggtgaact-3′
22
1277
1193

Probe
TET-5′-accccagagttcctgtcacctgaggt-3′-
26
1304
1194

TAMRA

Reverse
5′-tcggagatttggtcataattca-3′
22
1332
1195

TABLE OC

AI_comprehensive panel_v1.0

Column A - Rel. Exp.(%) Ag1289, Run 219421496

Column B - Rel. Exp.(%) Ag1289, Run 224054768

Column C - Rel. Exp.(%) Ag764, Run 219421440

Tissue Name
A
B
C
Tissue Name
A
B
C

110967 COPD-F
0.0
0.0
0.0
112427 Match Control
0.1
0.0
0.2

Psoriasis-F

110980 COPD-F
0.5
0.7
1.0
112418 Psoriasis-M
0.0
0.0
0.0

110968 COPD-M
0.0
0.1
0.0
112723 Match Control
0.1
0.1
0.0

Psoriasis-M

110977 COPD-M
0.8
0.9
1.5
112419 Psoriasis-M
0.0
0.1
0.0

110989 Emphysema-F
0.4
0.1
0.2
112424 Match Control
0.0
0.0
0.2

Psoriasis-M

110992 Emphysema-F
0.4
0.3
0.4
112420 Psoriasis-M
0.2
0.1
0.0

110993 Emphysema-F
0.4
0.3
0.2
112425 Match Control
0.1
0.3
0.2

Psoriasis-M

110994 Emphysema-F
0.1
0.0
0.2
104689 (MF) OA Bone-
0.6
0.7
0.6

Backus

110995 Emphysema-F
0.7
0.5
0.4
104690 (MF) Adj “Normal”
0.0
0.2
0.2

Bone-Backus

110996 Emphysema-F
0.1
0.1
1.3
104691 (ME) OA
0.6
0.3
1.5

Synovium-Backus

110997 Asthma-M
0.2
0.0
0.0
104692 (BA) OA Cartilage-
0.0
0.0
0.0

Backus

111001 Asthma-F
0.0
0.2
0.0
104694 (BA) OA Bone-
0.1
0.2
0.5

Backus

111002 Asthma-F
0.2
0.0
0.7
104695 (BA) Adj “Normal”
0.2
0.0
0.4

Bone-Back

111003 Atopic Asthma-F
0.2
0.0
0.2
104696 (BA) OA
0.0
0.1
0.0

Synovium-Backus

111004 Atopic Asthma-F
0.8
0.9
1.3
104700 (SS) OA Bone-
0.1
0.1
0.2

Backus

111005 Atopic Asthma-F
0.4
0.5
0.6
104701 (SS) Adj “Normal”
0.1
0.2
0.2

Bone-Backus

111006 Atopic Asthma-F
0.1
0.3
0.2
104702 (SS) OA
0.0
0.2
0.2

Synovium-Backus

111417 Allergy-M
0.2
0.0
0.0
117093 OA Cartilage Rep 7
0.0
0.0
0.2

112347 Allergy-M
0.1
0.1
0.0
112672 OA Bone5
0.3
0.2
0.5

112349 Normal Lung-F
0.0
0.1
0.1
112673 OA Synovium5
0.2
0.0
0.3

112357 Normal Lung-F
0.4
0.1
0.5
112674 OA Synovial Fluid
0.1
0.1
0.2

cells5

112354 Normal Lung-M
0.2
0.0
0.0
117100 OA Cartilage
0.0
0.1
0.3

Rep14

112374 Crohns-F
0.5
0.1
0.0
112756 OA Bone9
0.7
1.5
1.5

112389 Match Control
0.0
0.0
0.2
112757 OA Synovium9
100.0
100.0
100.0

Crohns-F

112375 Crohns-F
0.3
0.0
45.1
112758 OA Synovial Fluid
0.0
0.0
0.4

Cells9

112732 Match Control
0.1
0.1
0.1
117125 RA Cartilage Rep2
0.0
0.0
0.0

Crohns-F

112725 Crohns-M
0.1
0.0
0.0
113492 Bone2 RA
0.1
0.0
0.0

112387 Match Control
0.1
0.0
0.0
113493 Synovium2 RA
0.0
0.0
0.0

Crohns-M

112378 Crohns-M
0.1
0.1
0.4
113494 Syn Fluid Cells RA
0.2
0.0
0.0

112390 Match Control
0.9
0.8
1.6
113499 Cartilage4 RA
0.0
0.0
0.0

Crohns-M

112726 Crohns-M
0.1
0.0
0.0
113500 Bone4 RA
0.0
0.0
0.0

112731 Match Control
0.0
0.0
0.0
113501 Synovium4 RA
0.0
0.0
0.2

Crohns-M

112380 Ulcer Col-F
0.1
0.0
0.2
113502 Syn Fluid Cells4
0.0
0.0
0.0

RA

112734 Match Control
3.8
4.1
6.4
113495 Cartilage3 RA
0.0
0.0
0.0

Ulcer Col-F

112384 Ulcer Col-F
0.9
0.5
0.7
113496 Bone3 RA
0.0
0.1
0.0

112737 Match Control
0.0
0.0
0.0
113497 Synovium3 RA
0.0
0.0
0.0

Ulcer Col-F

112386 Ulcer Col-F
0.0
0.0
0.2
113498 Syn Fluid Cells3
0.0
0.0
0.0

RA

112738 MatchControl
0.1
0.0
0.4
117106 Normal Cartilage
0.0
0.0
0.5

Ulcer Col-F

Rep20

112381 Ulcer Col-M
0.0
0.0
0.0
113663 Bone3 Normal
0.1
0.0
0.0

112735 Match Control
0.1
0.3
0.0
113664 Synovium3 Normal
0.0
0.0
0.0

Ulcer Col-M

112382 Ulcer Col-M
0.0
0.0
0.0
113665 Syn Fluid Cells3
0.0
0.1
0.0

Normal

112394 Match Control
0.1
0.0
0.0
117107 Normal Cartilage
0.0
0.0
0.3

Ulcer Col-M

Rep22

112383 Ulcer Col-M
0.3
0.9
1.0
113667 Bone4 Normal
0.0
0.0
0.3

112736 Match Control
0.1
0.0
0.0
113668 Synovium4 Normal
0.1
0.8
0.5

Ulcer Col-M

112423 Psoriasis-F
0.0
0.0
0.3
113669 Syn Fluid Cells4
0.1
0.1
0.7

Normal

TABLE OD

Panel 1.3D

Column A - Rel. Exp.(%) Ag1289, Run 146789972

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
0.1
Kidney (fetal)
0.0

Pancreas
0.2
Renal ca. 786-0
0.0

Pancreatic ca.
0.0
Renal ca. A498
0.0

CAPAN 2

Adrenal gland
0.0
Renal ca. RXF 393
0.0

Thyroid
1.4
Renal ca. ACHN
0.0

Salivary gland
0.2
Renal ca. UO-31
0.0

Pituitary gland
0.0
Renal ca. TK-10
0.1

Brain (fetal)
0.0
Liver
0.0

Brain (whole)
0.1
Liver (fetal)
0.0

Brain (amygdala)
0.2
Liver ca. (hepatoblast) HepG2
0.0

Brain (cerebellum)
0.0
Lung
0.0

Brain (hippocampus)
0.1
Lung (fetal)
0.1

Brain
0.1
Lung ca. (small cell) LX-1
0.0

(substantia nigra)

Brain (thalamus)
0.0
Lung ca. (small cell) NCI-H69
0.1

Cerebral Cortex
0.4
Lung ca. (s. cell var.) SHP-77
0.2

Spinal cord
0.1
Lung ca. (large cell)NCI-H460
0.0

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
0.0

glio/astro U-118-MG
0.0
Lung ca. (non-s. cell) NCI-H23
0.0

astrocytoma SW1783
0.0
Lung ca. (non-s. cell) HOP-62
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (non-s. cl) NCI-H522
0.0

astrocytoma SF-539
0.0
Lung ca. (squam.) SW 900
0.0

astrocytoma SNB-75
0.1
Lung ca. (squam.) NCI-H596
0.0

glioma SNB-19
0.0
Mammary gland
0.0

glioma U251
0.0
Breast ca.* (pl.ef) MCF-7
0.0

glioma SF-295
0.0
Breast ca.* (pl.ef) MDA-MB-231
0.0

Heart (Fetal)
0.0
Breast ca.* (pl.ef) T47D
0.0

Heart
0.0
Breast ca. BT-549
0.1

Skeletal muscle (Fetal)
100.0
Breast ca. MDA-N
0.0

Skeletal muscle
28.7
Ovary
0.1

Bone marrow
0.2
Ovarian ca. OVCAR-3
0.0

Thymus
0.0
Ovarian ca. OVCAR-4
0.0

Spleen
0.0
Ovarian ca. OVCAR-5
0.0

Lymph node
0.0
Ovarian ca. OVCAR-8
0.0

Colorectal
0.0
Ovarian ca. IGROV-1
0.0

Stomach
0.0
Ovarian ca. (ascites) SK-OV-3
0.1

Small intestine
0.0
Uterus
0.0

Colon ca. SW480
0.0
Placenta
0.0

Colon ca.* SW620
0.0
Prostate
0.0

(SW480 met)

Colon ca. HT29
0.0
Prostate ca.* (bone met) PC-3
0.0

Colon ca. HCT-116
0.0
Testis
0.2

Colon ca. CaCo-2
0.0
Melanoma Hs688(A).T
0.0

CC Well to Mod Diff
0.0
Melanoma* (met) Hs688(B).T
0.0

(ODO3866)

Colon ca. HCC-2998
0.0
Melanoma UACC-62
0.0

Gastric ca. (liver met)
0.0
Melanoma M14
0.0

NCI-N87

Bladder
0.0
Melanoma LOX IMVI
0.0

Trachea
0.1
Melanoma* (met) SK-MEL-5
0.0

Kidney
0.0
Adipose
0.4

TABLE OE

Panel 4D

Column A - Rel. Exp.(%) Ag764, Run 145632998

Tissue Name
A
Tissue Name
A

Secondary Th1 act
6.6
HUVEC IL-1beta
6.8

Secondary Th2 act
5.4
HUVEC IFN gamma
4.3

Secondary Tr1 act
4.2
HUVEC TNF alpha + IFN gamma
1.3

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
4.4

Secondary Th2 rest
1.1
HUVEC IL-11
8.3

Secondary Tr1 rest
0.0
Lung Microvascular EC none
43.8

Primary Th1 act
5.0
Lung Microvascular EC TNF alpha + IL-
14.0

1beta

Primary Th2 act
2.6
Microvascular Dermal EC none
100.0

Primary Tr1 act
4.4
Microvasular Dermal EC TNF alpha + IL-
10.4

1beta

Primary Th1 rest
7.4
Bronchial epithelium TNF alpha + IL1beta
0.0

Primary Th2 rest
3.5
Small airway epithelium none
0.0

Primary Tr1 rest
3.0
Small airway epithelium TNF alpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
3.9
Coronery artery SMC rest
17.0

CD45RO CD4 lymphocyte act
2.6
Coronery artery SMC TNF alpha + IL-1beta
5.6

CD8 lymphocyte act
2.5
Astrocytes rest
0.7

Secondary CD8 lymphocyte rest
4.7
Astrocytes TNF alpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
2.3
KU-812 (Basophil) rest
3.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
2.6
CCD1106 (Keratinocytes) none
2.5

CH11

LAK cells rest
1.8
CCD1106 (Keratinocytes) TNF alpha + IL-
0.9

1beta

LAK cells IL-2
3.3
Liver cirrhosis
2.3

LAK cells IL-2 + IL-12
3.4
Lupus kidney
1.9

LAK cells IL-2 + IFN gamma
2.6
NCI-H292 none
2.1

LAK cells IL-2 + IL-18
2.0
NCI-H292 IL-4
3.1

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
3.6

NK Cells IL-2 rest
3.1
NCI-H292 IL-13
5.3

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
0.6

Two Way MLR 5 day
3.3
HPAEC none
3.4

Two Way MLR 7 day
1.2
HPAEC TNF alpha + IL-1beta
1.6

PBMC rest
0.0
Lung fibroblast none
0.0

PBMC PWM
4.5
Lung fibroblast TNF alpha + IL-1beta
0.0

PBMC PHA-L
7.0
Lung fibroblast IL-4
0.0

Ramos (B cell) none
7.5
Lung fibroblast IL-9
0.0

Ramos (B cell) ionomycin
8.6
Lung fibroblast IL-13
0.0

B lymphocytes PWM
2.1
Lung fibroblast IFN gamma
0.0

B lymphocytes CD40L and IL-4
4.6
Dermal fibroblast CCD1070 rest
5.6

EOL-1 dbcAMP
0.8
Dermal fibroblast CCD1070 TNF alpha
19.8

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1beta
5.7

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
4.7

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
2.4

Dendritic cells anti-CD40
0.0
IBD Colitis 2
0.0

Monocytes rest
0.0
IBD Crohn′s
0.0

Monocytes LPS
1.0
Colon
3.6

Macrophages rest
0.5
Lung
3.0

Macrophages LPS
0.0
Thymus
0.0

HUVEC none
15.9
Kidney
3.8

HUVEC starved
47.6

AI_comprehensive panel_v1.0 Summary: Ag1289/Ag764 This gene was moderately expressed in a synovium sample from an osteoarthritis patient. Therefore, therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of osteoarthritis.

The gene variant recognized by probe Ag764 was expressed in a Crohn's disease sample. Therefore, therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of Crohn's disease.

Panel 1.3D Summary: Ag1289 Expression of this gene was highest among normal tissues in skeletal muscle, where it is expressed at roughly 10-fold higher levels than fetal skeletal muscle. Therefore, this gene is useful as a marker to differentiate between adult and fetal skeletal muscle.

This gene was also expressed at low levels in thyroid. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of endocrine or metabolically related diseases, such as obesity and diabetes.

Panel 4D Summary: Ag764 This gene was highly expressed in untreated endothelial cells including the microvascular endothelium, human umbilical vein endothelial cells (HUVECS) and lung endothelial cells. This transcript was highly expressed in normal tissue and down regulated in activated endothelium. This gene encodes a protein important for a pathway that is involved in maintaining cellular homeostasis with in a tissue. A protein therapeutic designed with the protein encoded for by this transcript is useful for the reduction or elimination of inflammation in endothelium. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of asthma, allergy, psoriasis and arthritis.

P. CG51752-01 and CG51752-02 and CG51752-03: Trypsin Family Serine Protease Tespec PRO-3

Expression of gene CG51752-01, variant CG51752-02 and full-length physical clone CG51752-03 was assessed using the primer-probe sets Ag1541 and Ag346, described in Tables PA and PB. Results of the RTQ-PCR runs are shown in Tables PC and PD. Please not that the primer-probe set Ag1541 is specific for CG51752-01 and CG51752-02 only.

TABLE PAProbe Name Ag1541StartSEQ IDPrimersSequencesLengthPositionNoForward5′-agaagaacaccccagggatata-3′222381196ProbeTET-5′-cctcgttggtgaactacaacctctgg-3′-262101197TAMRAReverse5′-cctctagctgggtcactttctc-3′221851198

TABLE PB

Probe Name Ag346

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-ctctgggactcccgagactg-3′
20
105
1199

Probe
TET-5′-cccataggtttctgtttgacagaagtcct
32
130
1200

cct-3′-TAMRA

Reverse
5′-aggcccttcaatgcagagaa-3′
20
163
1201

TABLE PC

Panel 1.3D

Column A - Rel. Exp.(%) Ag1541, Run 146287841

Column B - Rel. Exp.(%) Ag1541, Run 150033538

Column C - Rel. Exp.(%) Ag346, Run 153910033

Tissue Name
A
B
C
Tissue Name
A
B
C

Liver adenocarcinoma
0.0
0.0
0.0
Kidney (fetal)
0.5
0.6
0.0

Pancreas
0.0
0.0
1.2
Renal Ca. 786-0
0.0
0.0
0.0

Pancreatic ca. CAPAN 2
0.0
0.0
1.4
Renal ca. A498
0.0
0.0
0.0

Adrenal gland
0.0
0.0
0.0
Renal ca. RXF 393
0.0
0.0
0.0

Thyroid
0.0
0.0
0.0
Renal ca. ACHN
0.0
0.0
0.0

Salivary gland
0.0
0.0
0.0
Renal ca. UO-31
0.0
0.0
0.0

Pituitary gland
0.0
0.0
0.8
Renal ca. TK-10
0.0
0.0
0.0

Brain (fetal)
0.5
0.4
1.2
Liver
0.0
0.0
0.0

Brain (whole)
1.1
1.7
6.3
Liver (fetal)
0.2
0.0
0.0

Brain (amygdala)
0.0
1.7
1.5
Liver ca. (hepatoblast)
0.0
0.0
0.0

HepG2

Brain (cerebellum)
0.6
1.9
3.4
Lung
0.0
0.0
0.0

Brain (hippocampus)
3.3
3.4
6.7
Lung (fetal)
0.0
0.0
0.0

Brain (substantia nigra)
0.5
0.6
0.0
Lung ca. (small cell) LX-
1.7
2.3
5.2

1

Brain (thalamus)
1.0
1.2
0.0
Lung ca. (small cell) NCI-
0.0
0.0
0.0

Cerebral Cortex
1.6
2.6
7.7
Lung ca. (s.cell var.)
1.3
2.5
0.0

SHP-77

Spinal cord
2.5
0.4
2.1
Lung ca. (large cell) NCI-
0.0
0.0
0.0

H460

glio/astro U87-MG
0.0
0.0
0.0
Lung ca. (non-sm. cell)
0.0
0.0
1.0

A549

glio/astro U-118-MG
0.0
0.0
0.0
Lung Ca. (non-s.cell)
1.2
0.4
2.6

NCI-H23

astrocytoma SW1783
0.0
0.0
0.0
Lung Ca. (non-s.cell)
0.0
0.0
0.0

HOP-62

neuro*; met SK-N-AS
0.0
0.0
0.0
Lung Ca. (non-s.cl) NCI-
0.0
0.0
0.9

H522

astrocytoma SF-539
0.0
0.0
0.0
Lung ca. (squam.) SW
0.0
0.7
0.0

900

astrocytoma SNB-75
0.7
0.0
0.0
Lung Ca. (squam.) NCI-
0.0
1.3
0.0

H596

glioma SNB-19
0.0
0.0
2.7
Mammary gland
0.0
1.5
0.0

glioma U251
0.0
0.0
0.0
Breast ca.* (pl.ef) MCF-7
0.0
0.0
0.0

glioma SF-295
0.0
0.8
1.0
Breast ca.* (pl.ef) MDA-
5.8
0.5
2.7

MB-231

Heart (Fetal)
0.0
0.0
0.0
Breast ca.* (pl.ef) T47D
1.2
0.3
6.1

Heart
0.0
0.0
0.0
Breast Ca. BT-549
0.5
0.0
2.1

Skeletal muscle (Fetal)
0.6
1.6
1.4
Breast Ca. MDA-N
0.0
0.0
0.1

Skeletal muscle
0.0
0.0
0.0
Ovary
0.0
0.0
0.0

Bone marrow
0.0
0.0
2.1
Ovarian ca. OVCAR-3
0.0
0.0
1.7

Thymus
0.0
0.0
0.0
Ovarian ca. OVCAR-4
0.0
0.0
0.0

Spleen
0.0
0.0
1.6
Ovarian ca. OVCAR-5
3.6
0.7
3.2

Lymph node
0.0
0.0
0.0
Ovarian ca. OVCAR-8
0.0
0.0
0.0

Colorectal
0.0
0.6
2.2
Ovarian ca. IGROV-1
0.0
0.0
0.0

Stomach
1.9
0.0
0.0
Ovarian ca. (ascites) SK-
0.0
0.0
0.0

OV-3

Small intestine
0.0
1.0
0.0
Uterus
0.0
0.0
1.6

Colon ca. SW480
0.0
0.0
0.0
Placenta
0.0
0.0
0.0

Colon ca.* SW620 (SW480
0.0
0.0
0.0
Prostate
0.0
0.7
1.5

met)

Colon ca. HT29
0.0
0.0
0.0
Prostate ca.* (bone met)
0.0
0.0
0.0

PC-3

Colon ca. HCT-116
0.6
0.4
0.0
Testis
100.0
100.0
100.0

Colon ca. CaCo-2
1.5
0.0
0.0
Melanoma Hs688(A).T
0.0
0.0
0.0

CC Well to Mod Duff
0.0
0.0
0.0
Melanoma* (met)
0.0
0.0
0.0

(ODO3866)

Hs688(B).T

Colon ca. HCC-2998
0.0
0.0
0.0
Melanoma UACC-62
0.0
0.0
0.0

Gastric ca. (liver met) NCI-
1.2
0.0
0.0
Melanoma M14
0.0
0.0
0.0

N87

Bladder
0.0
0.0
0.0
Melanoma LOX IMVI
0.0
0.0
0.0

Trachea
0.0
0.4
0.0
Melanoma* (met) SK-
0.0
0.0
0.0

MEL-5

Kidney
0.8
1.2
2.6
Adipose
0.5
0.0
0.0

TABLE PD

Panel 2D

Column A - Rel. Exp.(%) Ag1541, Run 149802457

Column B - Rel. Exp.(%) Ag1541, Run 150033539

Column C - Rel. Exp.(%) Ag1541, Run 162624512

Tissue Name
A
B
C
Tissue Name
A
B
C

Normal Colon
5.4
2.4
0.0
Kidney Margin 8120608
0.0
0.0
0.0

CC Well to Mod Diff
7.3
0.0
5.1
Kidney Cancer 8120613
0.0
0.0
0.0

(ODO3866)

CC Margin (ODO3866)
5.8
1.5
0.0
Kidney Margin 8120614
20.6
22.8
16.6

CC Gr.2 rectosigmoid
3.4
0.0
0.0
Kidney Cancer 9010320
0.0
0.0
0.0

(ODO3868)

CC Margin (ODO3868)
0.0
0.0
0.0
Kidney Margin 9010321
3.4
26.4
14.8

CC Mod Diff (ODO3920)
11.0
1.4
2.0
Normal Uterus
0.0
0.0
0.0

CC Margin (ODO3920)
0.0
0.0
3.4
Uterine Cancer 064011
14.9
0.0
4.4

CC Gr.2 ascend colon
6.2
2.5
6.1
Normal Thyroid
0.0
0.0
0.0

(ODO3921)

CC Margin (ODO3921)
10.2
0.0
6.0
Thyroid Cancer
0.0
0.0
0.0

CC from Partial
3.6
0.0
4.5
Thyroid Cancer
0.0
0.0
0.0

Hepatectomy (ODO4309)

A302152

Mets

Liver Margin (ODO4309)
0.0
2.4
4.7
Thyroid Margin
0.0
0.0
5.1

A302153

Colon mets to lung
7.2
4.4
7.6
Normal Breast
5.2
3.5
7.0

(ODO4451-01)

Lung Margin (ODO4451-02)
0.0
0.0
0.0
Breast Cancer
0.0
0.0
2.4

Normal Prostate 6546-1
4.8
2.9
22.1
Breast Cancer
0.0
0.0
0.0

(ODO4590-01)

Prostate Cancer (ODO4410)
3.5
0.0
0.0
Breast Cancer Mets
0.0
0.0
0.0

(ODO4590-03)

Prostate Margin (ODO4410)
3.4
0.0
0.0
Breast Cancer
0.0
0.0
0.0

Metastasis

Prostate Cancer (ODO4720-
9.0
8.5
43.8
Breast Cancer
0.0
2.5
0.0

01)

Prostate Margin (ODO4720-
0.0
0.0
0.0
Breast Cancer
52.5
27.5
55.5

02)

Normal Lung
17.7
6.5
0.0
Breast Cancer 9100266
6.2
0.0
0.0

Lung Met to Muscle
0.0
2.3
9.9
Breast Margin 9100265
0.0
0.0
1.9

(ODO4286)

Muscle Margin (ODO4286)
0.0
0.0
0.0
Breast Cancer A209073
1.5
2.5
3.5

Lung Malignant Cancer
6.5
5.7
4.9
Breast Margin A209073
24.3
26.2
61.1

(ODO3126)

Lung Margin (ODO3126)
0.0
0.0
0.0
Normal Liver
10.5
2.7
4.2

Lung Cancer (ODO4404)
0.0
0.0
0.0
Liver Cancer
5.9
1.7
3.2

Lung Margin (ODO4404)
0.0
0.0
3.4
Liver Cancer 1025
21.6
11.0
13.6

Lung Cancer (ODO4565)
0.0
0.0
0.0
Liver Cancer 1026
0.0
0.0
0.0

Lung Margin (ODO4565)
0.0
0.0
0.0
Liver Cancer 6004-T
3.3
13.5
2.7

Lung Cancer (OD04237-01)
0.0
0.0
0.0
Liver Tissue 6004-N
3.2
1.4
0.0

Lung Margin (ODO4237-02)
0.0
0.0
0.0
Liver Cancer 6005-T
0.0
0.0
0.0

Ocular Mel Met to Liver
4.3
0.0
3.2
Liver Tissue 6005-N
0.0
0.0
0.0

(ODO4310)

Liver Margin (ODO4310)
0.0
0.0
0.0
Normal Bladder
0.0
0.0
5.9

Melanoma Metastasis
0.0
0.0
0.0
Bladder Cancer
0.0
0.0
0.0

Lung Margin (ODO4321)
0.0
0.0
0.0
Bladder Cancer
4.6
2.3
7.5

Normal Kidney
28.1
39.2
54.0
Bladder Cancer
17.9
11.4
17.8

(ODO4718-01)

Kidney Ca, Nuclear grade 2
0.0
3.0
0.0
Bladder Normal
0.0
0.0
0.0

(ODO4338)

Adjacent (ODO4718-03)

Kidney Margin (ODO4338)
22.7
31.6
24.1
Normal Ovary
0.0
0.0
0.0

Kidney Ca Nuclear grade 1/2
0.0
3.1
2.9
Ovarian Cancer
1.7
4.8
8.2

(ODO4339)

Kidney Margin (ODO4339)
97.3
100.0
100.0
Ovarian Cancer
0.0
2.1
0.0

(ODO4768-07)

Kidney Ca, Clear cell type
0.0
0.0
0.0
Ovary Margin
0.0
0.0
0.0

(ODO4340)

(ODO4768-08)

Kidney Margin (ODO4340)
100.0
34.4
33.4
Normal Stomach
3.3
2.9
0.0

Kidney Ca, Nuclear grade 3
2.0
4.9
3.1
Gastric Cancer 9060358
0.0
0.0
0.0

(ODO4348)

Kidney Margin (ODO4348)
30.1
19.9
20.9
Stomach Margin
0.0
0.0
0.0

9060359

Kidney Cancer (ODO4622-
0.0
2.4
0.0
Gastric Cancer 9060395
0.0
0.0
0.0

01)

Kidney Margin (ODO4622-
8.4
7.2
13.9
Stomach Margin
0.0
0.0
0.0

03)

9060394

Kidney Cancer (ODO4450-
0.0
0.0
0.0
Gastric Cancer 9060397
0.0
0.0
0.0

01)

Kidney Margin (ODO4450-
47.3
12.9
30.6
Stomach Margin
0.0
0.0
0.0

03)

9060396

Kidney Cancer 8120607
0.0
0.0
0.0
Gastric Cancer 064005
6.3
3.8
2.4

Panel 1.3D Summary: Ag346/Ag1541 The expression of this gene was only detected in the testis (CT=31). Gene or protein expression levels of this gene are useful as a marker for the detection of testis tissue. Therapeutic modulation of the activity of this gene or its protein product is useful for the treatment of male infertility.

Panel 2D Summary: Ag1541 Expression of this gene was highest in normal kidney (CT=31-32). This gene was significantly overexpressed in 8/9 normal kidney samples when compared to the adjacent tumor samples. Therefore, the gene or protein expression levels are useful as a marker to distinguish normal kidney from kidney tumors. Therapeutic modulation of the activity of this gene or its protein product using protein, antibody or small molecule drugs is useful in the treatment of kidney cancer.

Q. CG51914-02: Ephrin Type-A Receptor 7 Precursor

Expression of gene CG51914-02 was assessed using the primer-probe set Ag612, described in Table QA. Results of the RTQ-PCR runs are shown in Tables QB, QC and QD.

TABLE QAProbe Name Ag612StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gccgctcccgagacactt-3′1825581202ProbeTET-5′-ccacttcagctctgccagtgacgtg-3′-2525841203TAMRAReverse5′-cccacatgatgatgccgaa-3′1926151204

TABLE QB

CNS_neurodegeneration_v1.0

Column A - Rel. Exp.(%) Ag612, Run 309606071

Tissue Name
A
Tissue Name
A

AD 1 Hippo
46.0
AH3 4624
31.0

AD 2 Hippo
37.1
AH3 4640
100.0

AD 3 Hippo
9.5
AD 1 Occipital Ctx
11.0

AD 4 Hippo
33.9
AD 2 Occipital Ctx (Missing)
6.8

AD 5 Hippo
59.5
AD 3 Occipital Ctx
8.3

AD 6 Hippo
41.8
AD 4 Occipital Ctx
35.6

Control 2 Hippo
40.9
AD 5 Occipital Ctx
43.5

Control 4 Hippo
21.6
AD 5 Occipital Ctx
21.5

Control (Path) 3 Hippo
15.9
Control 1 Occipital Ctx
8.2

AD 1 Temporal Ctx
26.1
Control 2 Occipital Ctx
36.6

AD 2 Temporal Ctx
28.9
Control 3 Occipital Ctx
29.5

AD 3 Temporal Ctx
12.3
Control 4 Occipital Ctx
20.3

AD 4 Temporal Ctx
62.9
Control (Path) 1 Occipital Ctx
81.2

AD 5 Inf Temporal Ctx
57.4
Control (Path) 2 Occipital Ctx
37.4

AD 5 Sup Temporal Ctx
33.7
Control (Path) 3 Occipital Ctx
17.8

AD 6 Inf Temporal Ctx
50.7
Control (Path) 4 Occipital Ctx
29.9

AD 6 Sup Temporal Ctx
68.8
Control 1 Parietal Ctx
37.6

Control 1 Temporal Ctx
9.7
Control 2 Parietal Ctx
41.5

Control 2 Temporal Ctx
54.7
Control 3 Parietal Ctx
54.0

Control 3 Temporal Ctx
40.3
Control (Path) 1 Parietal Ctx
99.3

Control 3 Temporal Ctx
43.2
Control (Path) 2 Parietal Ctx
52.9

AH3 3975
97.3
Control (Path) 3 Parietal Ctx
11.6

AH3 3954
86.5
Control (Path) 4 Parietal Ctx
56.6

TABLE QC

Panel 1.1

Column A - Rel. Exp.(%) Ag612, Run 109649311

Tissue Name
A
Tissue Name
A

Adrenal gland
0.7
Renal ca. UO-31
0.0

Bladder
25.0
Renal ca. RXF 393
1.0

Brain (amygdala)
12.9
Liver
0.0

Brain (cerebellum)
7.7
Liver (fetal)
0.0

Brain (hippocampus)
39.8
Liver ca. (hepatoblast) HepG2
0.3

Brain (substantia nigra)
50.0
Lung
0.0

Brain (thalamus)
20.9
Lung (fetal)
0.0

Cerebral Cortex
65.5
Lung ca. (non-s. cell) HOP-62
0.3

Brain (fetal)
44.1
Lung ca. (large cell)NCI-H460
1.9

Brain (whole)
36.3
Lung ca. (non-s. cell) NCI-H23
18.3

glio/astro U-118-MG
0.0
Lung ca. (non-s. cl) NCI-H522
100.0

astrocytoma SF-539
0.0
Lung ca. (non-sm. cell) A549
10.5

astrocytoma SNB-75
0.0
Lung ca. (s. cell var.) SHP-77
3.4

astrocytoma SW1783
0.0
Lung ca. (small cell) LX-1
1.5

glioma U251
0.0
Lung ca. (small cell) NCI-H69
3.5

glioma SF-295
0.0
Lung ca. (squam.) SW 900
24.1

glioma SNB-19
0.0
Lung ca. (squam.) NCI-H596
0.7

glio/astro U87-MG
0.0
Lymph node
0.3

neuro*; met SK-N-AS
0.0
Spleen
0.0

Mammary gland
4.3
Thymus
0.0

Breast ca. BT-549
0.0
Ovary
0.1

Breast ca. MDA-N
0.1
Ovarian ca. IGROV-1
1.8

Breast ca.* (pl.ef) T47D
18.6
Ovarian ca. OVCAR-3
4.0

Breast ca.* (pl.ef)
14.9
Ovarian ca. OVCAR-4
0.0

MCF-7

Breast ca.* (pl.ef)
0.1
Ovarian ca. OVCAR-5
36.6

MDA-MB-231

Small intestine
14.8
Ovarian ca. OVCAR-8
11.3

Colorectal
44.1
Ovarian ca. (ascites) SK-OV-3
22.5

Colon ca. HT29
0.7
Pancreas
64.2

Colon ca. CaCo-2
3.4
Pancreatic ca. CAPAN 2
1.1

Colon ca. HCT-15
34.2
Pituitary gland
33.4

Colon ca. HCT-116
6.1
Placenta
0.0

Colon ca. HCC-2998
24.5
Prostate
3.3

Colon ca. SW480
3.7
Prostate ca.* (bone met) PC-3
4.2

Colon ca.* SW620
4.9
Salivary gland
15.7

(SW480 met)

Stomach
10.6
Trachea
1.6

Gastric ca. (liver met)
33.7
Spinal cord
5.8

NCI-N87

Heart
1.6
Testis
65.5

Skeletal muscle (Fetal)
0.0
Thyroid
0.0

Skeletal muscle
0.0
Uterus
0.0

Endothelial cells
0.0
Melanoma M14
0.0

Heart (Fetal)
0.0
Melanoma LOX IMVI
0.0

Kidney
1.0
Melanoma UACC-62
0.0

Kidney (fetal)
0.0
Melanoma SK-MEL-28
0.0

Renal ca. 786-0
0.0
Melanoma* (met) SK-MEL-5
0.7

Renal ca. A498
0.3
Melanoma Hs688(A).T
0.0

Renal ca. ACHN
7.3
Melanoma* (met) Hs688(B).T
0.0

Renal ca. TK-10
42.6

TABLE QD

Panel 4D

Column A - Rel. Exp.(%) Ag612, Run 145645058

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
12.2
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.0
Microsvasular Dermal EC TNF alpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNF alpha + IL1beta
0.0

Primary Th2 rest
0.0
Small airway epithelium none
0.0

Primary Tr1 rest
0.0
Small airway epithelium TNF alpha + IL-
4.6

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
4.6
Coronery artery SMC TNF alpha + IL-1beta
0.0

CD8 lymphocyte act
5.3
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
5.3
Astrocytes TNF alpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
9.7
CCD1106 (Keratinocytes) TNF alpha + IL-
1.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
61.6

LAK cells IL-2 + IL-12
0.0
Lupus kidney
0.0

LAK cells IL-2 + IFN gamma
5.1
NCI-H292 none
32.5

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
46.7

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
58.6

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
89.5

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
100.0

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.0

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1beta
0.0

PBMC PHA-L
8.9
Lung fibroblast IL-4
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-9
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
9.0

B lymphocytes PWM
8.5
Lung fibroblast IFN gamma
0.0

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1beta
0.0

PMA/ionomycin

Dendritic cells none
5.3
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
4.5
Dermal fibroblast IL-4
0.0

Dendritic cells anti-CD40
0.0
IBD Colitis 2
10.7

Monocytes rest
0.0
IBD Crohn's
0.0

Monocytes LPS
1.2
Colon
51.8

Macrophages rest
0.0
Lung
24.7

Macrophages LPS
0.0
Thymus
4.1

HUVEC none
0.0
Kidney
4.6

HUVEC starved
0.0

CNS_neurodegeneration_v1.0 Summary: Ag612 This gene was found to be down-regulated in the temporal cortex of Alzheimer's disease patients. Therefore, up-regulation of this gene, encoded protein, and/or use of agonists for this receptor is useful in reversing the dementia/memory loss associated with this disease and neuronal death.

Panel 1.1 Summary: Ag612 Highest expression of this gene was detected in a lung cancer NCI-H522 cell line (CT=24). High expression of this gene was also seen in cluster of lung cancer, colon cancer, renal cancer, a liver cancer, two breast cancer and a melanoma cell lines. Levels of expression of this gene are useful as diagnostic markers and modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatments of this cancers.

In addition, high expression of this gene was seen in all the regions of the central nervous system (CNS) examined including, amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. This gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of CNS disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression and therapeutic modulation of this gene product may be useful in the treatment of these disorders.

Among tissues with metabolic or endocrine function, this gene was expressed at high to moderate levels in pancreas, adrenal gland, pituitary gland, and the gastrointestinal tract. Modulation of this gene is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes

Panel 4D Summary: Ag612 Highest expression of this gene was detected in IFN gamma treated NCI-H292 cells (CT=33). Moderate to low expression of this gene was also seen in cytokine treated and untreated NCI-H292 cells, liver cirrhosis and colon tissue samples. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene is useful for the treatment of chronic obstructive pulmonary disease, asthma, allergy, and emphysema, liver cirrhosis, autoimmune and inflammatory disease affecting colon including Crohn's disease and ulcerative colitis.

R. CG51965-01: Protocadherin Flamingo 2 Like

Expression of gene CG51965-01 was assessed using the primer-probe sets Ag1989 and Ag1990, described in Tables RA and RB. Results of the RTQ-PCR runs are shown in Tables RC, RD, RE and RF.

TABLE RAProbe Name Ag1989StartSEQ IDPrimersSequencesLengthPositionNoForward5′-cctagagatcctcatcctcgat-3′2226311205ProbeTET-5′-aatgacaatgcaccccagttcctgt-3′-2526561206TAMRAReverse5′-aaagatggaaccctggtagaaa-3′2226851207

TABLE RB

Probe Name Ag1990

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-cctagagatcctcatcctcgat-3′
22
2631
1208

Probe
TET-5′-aatgacaatgcaccccagttcctgt-3′-
25
2656
1209

TAMRA

Reverse
5′-aaagatggaaccctggtagaaa-3′
22
2685
1210

TABLE RC

AI_comprehensive panel_v1.0

Column A - Rel. Exp.(%) Ag1989, Run 248122025

Column B - Rel. Exp.(%) Ag1990, Run 228059649

Tissue Name
A
B
Tissue Name
A
B

110967 COPD-F
4.9
5.3
112427 Match Control Psoriasis-F
23.0
25.5

110980 COPD-F
3.8
5.7
112418 Psoriasis-M
2.0
3.8

110968 COPD-M
2.2
2.6
112723 Match Control Psoriasis-
1.1
1.4

M

110977 COPD-M
9.4
17.9
112419 Psonasis-M
4.8
5.1

110989 Emphysema-F
19.5
24
1112424 Match Control Psoriasis-
3.4
6.0

M

110992 Emphysema-F
35.4
42.3
112420 Psoriasis-M
31.9
30.1

110993 Emphysema-F
6.3
6.7
112425 Match Control Psoriasis-
31.0
31.2

M

110994 Emphysema-F
4.1
6.3
104689 (MF) OA Bone-Backus
12.7
22.1

110995 Emphysema-F
54.7
59.9
104690 (MF) Adj “Normal” Bone-
7.7
9.7

Backus

110996 Emphysema-F
18.6
21.5
104691 (MF) OA Synovium-
3.7
6.8

Backus

110997 Asthma-M
14.1
19.5
104692 (BA) OA Cartilage-
29.9
27.7

Backus

111001 Asthma-F
17.4
23.3
104694 (BA) OA Bone-Backus
11.3
14.5

111002 Asthma-F
32.1
31.6
104695 (BA) Adj “Normal” Bone-
14.0
10.8

Backus

111003 Atopic Asthma-F
24.0
28.1
104696 (BA) OA Synovium-
10.5
6.2

Backus

111004 Atopic Asthma-F
79.0
73.7
104700 (SS) OA Bone-Backus
7.9
11.4

111005 Atopic Asthma-F
34.6
42.0
104701 (SS) Adj “Normal” Bone-
14.3
17.8

Backus

111006 Atopic Asthma-F
4.6
10.9
104702 (SS) OA Synovium-
14.8
19.1

Backus

111417 Allergy-M
27.9
39.0
117093 OA Cartilage Rep7
29.1
28.1

112347 Allergy-M
0.5
1.4
112672 OA Bone5
12.3
12.1

112349 Normal Lung-F
0.6
0.4
112673 OA Synovium5
4.3
6.9

112357 Normal Lung-F
2.5
5.7
112674 OA Synovial Fluid cells
3.1
5.4

112354 Normal Lung-M
2.4
3.1
117100 OA Cartilage Rep14
1.0
4.3

112374 Crohns-F
6.0
6.3
112756 OA Bone9
100.0
100.0

112389 Match Control
40.6
41.8
112757 OA Synovium9
0.4
0.0

Crohns-F

112375 Crohns-F
5.9
5.6
112758 OA Synovial Fluid Cells9
2.7
6.1

112732 Match Control
23.2
20.9
117125 RA Cartilage Rep2
5.3
5.6

Crohns-F

112725 Crobns-M
1.1
1.7
113492 Bone2 RA
53.2
64.6

112387 Match Control
10.2
17.2
113493 Synovium2 RA
28.9
22.4

Crohns-M

112378 Crohns-M
10.2
1.72
113494 Syn Fluid Cells RA
29.7
45.4

112390 Match Control
51.4
58.6
113499 Cartilage4 RA
32.5
37.4

Crohns-M

112726 Crohns-M
19.5
22.4
113500 Bone4 RA
35.6
48.3

112731 Match Control
14.1
21.5
113501 Synovium4 RA
21.6
27.7

Crohns-M

112380 Ulcer Col-F
21.2
27.7
113502 Syn Fluid Cells4 RA
13.3
15.2

Col-F

112384 Ulcer Col-F
38.7
35.4
113496 Bone3 RA
35.4
52.9

112737 Match Control Ulcer
3.1
11.7
113497 Synovium3 RA
16.4
25.7

Col-F

112386 Ulcer Col-F
4.9
6.9
113498 Syn Fluid Cells3 RA
41.5
55.5

112738 Match Control Ulcer
4.2
6.6
117106 Normal Cartilage Rep20
9.9
14.2

Col-F

112381 Ulcer Col-M
1.1
1.0
113663 Bone3 Normal
1.2
0.9

112735 Match Control Ulcer
9.9
11.3
113664 Synovium3 Normal
0.2
0.5

Col-M

112382 UlcerCol-M
21.5
27.5
113665 SynFluid Cells3 Normal
0.6
0.6

112394 Match Control Ulcer
1.2
1.6
117107 Normal Cartilage Rep22
2.7
5.6

Col-M

112383 Ulcer Col-M
34.4
39.5
113667 Bone4 Normal
10.4
9.9

112736 Match Control Ulcer
16.2
17.8
113668 Synovium4 Normal
5.2
9.7

Col-M

112423 Psoriasis-F
1.9
3.6
113669 Syn Fluid Cells4 Normal
12.3
18.2

TABLE RD

Panel 1.3D

Column A - Rel. Exp.(%) Ag1989, Run 147796849

Column B - Rel. Exp.(%) Ag1989, Run 153940861

Column C - Rel. Exp.(%) Ag1990, Run 147797262

Tissue Name
A
B
C
Tissue Name
A
B
C

Liver adenocarcinoma
37.6
54.7
37.4
Kidney (fetal)
7.2
14.3
7.6

Pancreas
0.1
1.1
0.1
Renal Ca. 786-0
30.4
48.0
32.8

Pancreatic ca. CAPAN 2
8.4
15.0
10.0
Renal ca. A498
52.9
65.5
65.5

Adrenal gland
0.7
0.7
0.4
Renal ca. RXF 393
29.7
34.9
34.9

Thyroid
7.3
9.5
6.9
Renal ca. ACHN
89.5
49.0
65.5

Salivary gland
4.0
8.2
6.4
Renal ca. UO-31
18.9
17.7
18.4

Pituitary gland
3.1
4.2
4.2
Renal ca. TK-10
18.3
27.0
14.4

Brain (fetal)
0.4
0.5
0.2
Liver
0.0
0.0
0.0

Brain (whole)
0.6
0.3
0.1
Liver (fetal)
0.1
0.8
0.1

Brain (amygdala)
0.0
0.5
0.0
Liver ca. (hepatoblast)
0.0
0.2
0.1

HepG2

Brain (cerebellum)
0.0
0.0
0.0
Lung
11.0
25.2
9.3

Brain (hippocampus)
0.9
1.7
0.4
Lung (fetal)
14.7
12.1
13.9

Brain (substantia nigra)
0.0
0.0
0.0
Lung ca. (small cell) LX-
4.0
4.8
6.5

1

Brain (thalamus)
0.1
0.0
0.5
Lung ca. (small cell) NCI-
3.4
5.3
3.1

Cerebral Cortex
0.1
0.0
0.4
Lung ca. (s.cell var.)
0.8
0.5
1.1

SHP-77

Spinal cord
0.1
0.1
0.1
Lung ca. (large cell) NCI-
8.1
8.1
11.2

H460

glio/astro U87-MG
14.4
16.6
19.6
Lung ca. (non-sm. cell)
13.5
17.6
13.9

A549

glio/astro U-118-MG
5.8
5.1
7.4
Lung Ca. (non-s.cell)
29.3
49.7
27.2

NCI-H23

astrocytoma SW1783
12.2
14.5
19.5
Lung Ca. (non-s.cell)
33.4
46.7
39.8

HOP-62

neuro*; met SK-N-AS
0.0
0.0
0.0
Lung Ca. (non-s.cl) NCI-
18.6
33.2
22.8

H522

astrocytoma SF-539
20.4
31.4
15.4
Lung ca. (squam.) SW
18.6
16.7
22.4

900

astrocytoma SNB-75
40.6
26.4
47.6
Lung Ca. (squam.) NCI-
1.0
0.6
0.7

H596

glioma SNB-19
1.7
1.9
0.9
Mammary gland
15.3
10.4
16.6

glioma U251
1.6
2.4
1.5
Breast ca.* (pl.ef) MCF-7
60.7
11.2
67.8

glioma SF-295
35.1
62.9
30.6
Breast ca.* (pl.ef) MDA-
9.2
5.5
13.0

MB-231

Heart (Fetal)
74.2
63.3
72.7
Breast ca.* (pl.ef) T47D
9.3
100.0
76.8

Heart
2.4
3.7
2.1
Breast Ca. BT-549
10.7
7.3
11.0

Skeletal muscle (Fetal)
6.3
12.9
7.0
Breast Ca. MDA-N
0.0
0.0
0.0

Skeletal muscle
0.0
0.0
0.0
Ovary
11.7
18.8
10.1

Bone marrow
0.7
0.7
0.6
Ovarian ca. OVCAR-3
47.3
42.0
49.3

Thymus
0.9
1.6
1.6
Ovarian ca. OVCAR-4
19.1
41.5
23.3

Spleen
0.4
0.8
0.5
Ovarian ca. OVCAR-5
49.7
49.3
49.3

Lymph node
7.0
11.1
8.1
Ovarian ca. OVCAR-8
15.7
25.9
19.6

Colorectal
4.2
7.6
6.9
Ovarian ca. IGROV-1
12.8
21.8
21.6

Stomach
10.8
16.7
10.7
Ovarian ca. (ascites) SK-
66.0
64.6
100.0

OV-3

Small intestine
1.0
2.7
0.9
Uterus
2.6
3.5
1.4

Colon ca. SW480
16.7
18.8
16.0
Placenta
2.9
3.3
2.7

Colon ca.* SW620 (SW480
6.0
5.5
3.9
Prostate
2.5
11.2
4.5

met)

Colon ca. HT29
0.5
0.2
0.6
Prostate ca.* (bone met)
20.4
24.0
14.7

PC-3

Colon ca. HCT-116
9.2
12.2
5.4
Testis
3.6
3.8
3.7

Colon ca. CaCo-2
23.7
14.2
16.4
Melanoma Hs688(A).T
0.8
0.2
0.4

CC Well to Mod Duff
20.6
15.8
16.4
Melanoma* (met)
0.1
0.0
0.6

(ODO3866)

Hs688(B).T

Colon ca. HCC-2998
35.1
26.6
31.4
Melanoma UACC-62
4.4
5.8
4.2

Gastric ca. (liver met) NCI-
100.0
62.9
92.7
Melanoma M14
16.8
20.0
11.9

N87

Bladder
1.8
3.3
1.7
Melanoma LOX IMVI
0.1
0.0
0.0

Trachea
27.0
48.0
26.2
Melanoma* (met) SK-
20.3
35.1
17.4

MEL-5

Kidney
8.2
12.7
5.2
Adipose
2.5
3.0
1.6

TABLE RE

Panel 2D

Column A - Rel. Exp.(%) Ag1989, Run 149988692

Column B - Rel. Exp.(%) Ag1990, Run 152494531

Tissue Name
A
B
Tissue Name
A
B

Normal Colon
2.7
3.7
Kidney Margin 8120608
9.4
8.5

CC Well to Mod Diff (ODO3866)
4.4
2.8
Kidney Cancer 8120613
0.3
0.3

CC Margin (ODO3866)
0.1
0.1
Kidney Margin 8120614
13.1
15.9

CC Gr.2 rectosigmoid (ODO3868)
0.91
0.8
Kidney Cancer 9010320
7.9
7.5

CC Margin (ODO3868)
0.3
0.2
Kidney Margin 9010321
12.3
12.8

CC Mod Diff (ODO3920)
4.0
3.8
Normal Uterus
0.3
0.2

CC Margin (ODO3920)
0.7
0.8
Uterine Cancer 064011
8.7
9.8

CC Gr.2 ascend colon (ODO3921)
2.5
3.7
Normal Thyroid
2.8
2.8

CC Margin (ODO3921)
0.4
0.3
Thyroid Cancer
10.7
10.5

CC from Partial Hepatectomy
2.8
3.4
Thyroid Cancer A302152
1.4
1.1

(ODO4309) Mets

Liver Margin (ODO4309)
0.1
0.0
Thyroid Margin A302153
4.0
4.2

Colon mets to lung (ODO4451-01)
4.4
5.3
Normal Breast
8.5
8.7

Lung Margin (ODO4451-02)
4.8
5.8
Breast Cancer
9.9
13.1

Normal Prostate 6546-1
3.1
3.6
Breast Cancer (ODO4590-01)
25.7
27.7

Prostate Cancer (ODO4410)
5.9
5.4
Breast Cancer Mets
23.5
28.9

(ODO4590-03)

Prostate Margin (ODO4410)
4.0
4.9
Breast Cancer Metastasis
100.0
100.0

Prostate Cancer (ODO4720-01)
6.0
7.2
Breast Cancer
20.9
20.7

Prostate Margin (ODO4720-02)
8.1
7.6
Breast Cancer
9.3
7.9

Normal Lung
9.0
10.2
Breast Cancer 9100266
27.5
28.1

Lung Met to Muscle (ODO4286)
4.4
5.5
Breast Margin 9100265
7.7
7.9

Muscle Margin (ODO4286)
0.1
0.1
Breast Cancer A209073
14.4
12.3

Lung Malignant Cancer
20.2
20.9
Breast Margin A209073
8.1
7.0

(ODO3126)

Lung Margin (ODO3126)
9.2
10.4
Normal Liver
0.0
0.0

Lung Cancer (ODO4404)
33.0
28.7
Liver Cancer
0.1
0.1

Lung Margin (ODO4404)
7.3
9.8
Liver Cancer 1025
0.1
0.2

Lung Cancer (ODO4565)
17.8
18.2
Liver Cancer 1026
2.7
2.5

Lung Margin (ODO4565)
3.0
4.1
Liver Cancer 6004-T
0.1
0.0

Lung Cancer (ODO4237-01)
4.2
4.5
Liver Tissue 6004-N
0.2
0.3

Lung Margin (ODO4237-02)
5.3
5.6
Liver Cancer 6005-T
2.3
2.2

Ocular Mel Met to Liver
1.2
1.4
Liver Tissue 6005-N
0.1
0.1

(ODO4310)

Liver Margin (ODO4310)
0.0
0.0
Normal Bladder
2.0
2.5

Melanoma Metastasis
3.1
3.7
Bladder Cancer
2.8
2.6

Lung Margin (ODO4321)
9.6
9.0
Bladder Cancer
5.4
7.4

Normal Kidney
21.6
18.4
Bladder Cancer (ODO4718-
1.2
0.6

01)

Kidney Ca, Nuclear grade 2
10.2
9.6
Bladder Normal Adjacent
1.0
0.9

(ODO4338)

(ODO4718-03)

Kidney Margin (ODO4338)
10.2
9.0
Normal Ovary
1.2
1.2

Kidney Ca Nuclear grade 1/2
11.2
10.4
Ovarian Cancer
7.3
8.6

(ODO4339)

Kidney Margin (ODO4339)
18.2
19.2
Ovarian Cancer (ODO4768-
16.6
14.1

07)

Kidney Ca, Clear cell type
13.2
16.0
Ovary Margin (ODO4768-08)
0.9
0.6

(ODO4340)

Kidney Margin (ODO4340)
16.4
15.7
Normal Stomach
2.2
2.1

Kidney Ca, Nuclear grade 3
2.3
1.5
Gastric Cancer 9060358
0.7
0.6

(ODO4348)

Kidney Margin (ODO4348)
9.2
9.8
Stomach Margin 9060359
1.8
2.0

Kidney Cancer (ODO4622-01)
7.7
9.9
Gastric Cancer 9060395
3.8
3.5

Kidney Margin (ODO4622-03)
2.7
3.0
Stomach Margin 9060394
2.2
2.3

Kidney Cancer (ODO4450-01)
10.4
9.2
Gastric Cancer 9060397
10.9
9.0

Kidney Margin (ODO4450-03)
5.9
4.5
Stomach Margin 9060396
0.5
0.6

Kidney Cancer 8120607
1.2
0.8
Gastric Cancer 064005
2.0
1.6

TABLE RF

Panel 4.1D

Column A - Rel. Exp.(%) Ag1989, Run 248122213

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.5
HUVEC IL-1beta
2.4

Secondary Th2 act
1.3
HUVEC IFN gamma
11.0

Secondary Tr1 act
0.4
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.4

Secondary Th2 rest
0.0
HUVEC IL-11
2.7

Secondary Tr1 rest
0.0
Lung Microvascular EC none
20.4

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-
4.8

1beta

Primary Th2 act
0.4
Microvascular Dermal EC none
0.9

Primary Tr1 act
0.7
Microsvasular Dermal EC TNF alpha + IL-
2.2

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNF alpha + IL1beta
50.7

Primary Th2 rest
0.0
Small airway epithelium none
43.2

Primary Tr1 rest
0.0
Small airway epithelium TNF alpha + IL-
85.9

1beta

CD45RA CD4 lymphocyte act
1.0
Coronery artery SMC rest
0.4

CD45RO CD4 lymphocyte act
0.2
Coronery artery SMC TNF alpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
6.0

Secondary CD8 lymphocyte rest
0.2
Astrocytes TNF alpha + IL-1beta
5.5

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.2

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
92.0

CH11

LAK cells rest
1.7
CCD1106 (Keratinocytes) TNF alpha + IL-
57.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
1.5

LAK cells IL-2 + IL-12
0.0
NCI-H292 none
24.7

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 IL-4
25.2

LAK cells IL-2 + IL-18
0.2
NCI-H292 IL-9
25.7

LAK cells PMA/ionomycin
1.6
NCI-H292 IL-13
40.9

NK Cells IL-2 rest
1.4
NCI-H292 IFN gamma
14.1

Two Way MLR 3 day
0.1
HPAEC none
0.8

Two Way MLR 5 day
0.0
HPAEC TNF alpha + IL-1beta
1.0

Two Way MLR 7 day
0.0
Lung fibroblast none
0.6

PBMC rest
0.1
Lung fibroblast TNF alpha + IL-1beta
0.0

PBMC PWM
0.0
Lung fibroblast IL-4
0.1

PBMC PHA-L
0.2
Lung fibroblast IL-9
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-13
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IFN gamma
0.3

B lymphocytes PWM
0.0
Dermal fibroblast CCD1070 rest
3.2

B lymphocytes CD40L and IL-4
0.1
Dermal fibroblast CCD1070 TNF alpha
2.1

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1beta
0.6

EOL-1 dbcAMP
0.0
Dermal fibroblast IFN gamma
0.4

PMA/ionomycin

Dendritic cells none
14.1
Dermal fibroblast IL-4
0.3

Dendritic cells LPS
1.6
Dermal Fibroblasts rest
1.7

Dendritic cells anti-CD40
3.0
Neutrophils TNFa + LPS
0.0

Monocytes rest
0.0
Neutrophils rest
0.0

Monocytes LPS
2.9
Colon
0.5

Macrophages rest
6.0
Lung
2.9

Macrophages LPS
0.9
Thymus
1.0

HUVEC none
3.0
Kidney
100.0

HUVEC starved
3.1

AI_comprehensive panel_v1.0 Summary: Ag1989/Ag1990 The highest expression of this gene was detected in an osteoarthritic bone sample (CT=29). The expression of this gene was upregulated in bone, synovium, synovial fluid, and cartilage in patients with rheumatoid arthritis (RA) (CTs=29-30) compared to normal controls (CTs=32-38). In addition, expression of this gene was upregulated in lung samples from patients with asthma compared to normal lung controls (CT values=29-30 for patients with asthma versus 34-36 for normal controls). Therefore, expression of this gene is useful as a marker to identify samples from patients with rheumatoid arthritis or asthma. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of rheumatoid arthritis or asthma.

Panel 1.3D Summary: Ag1989/Ag1990 This gene was strongly expressed in most tumor cell lines in this panel, while the expression in most normal tissues was moderate or low. Expression of this gene was up-regulated in a subset of glioma, astrocytoma, pancreatic, colon, kidney, lung, breast and ovarian cancer cell lines. Therefore, expression of this gene is useful in the detection and diagnosis of these types of cancer. Therefore, therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of brain, pancreatic, colon, kidney, lung, breast and ovarian cancer.

Panel 2D Summary: Ag1989/Ag1990 The highest expression of this gene was detected in a metastatic breast cancer sample (CT=25). For all tumor sites there were several cases where the tumor tissues strongly overexpressed the CG53971-01 gene as compared to the normal adjacent controls, especially for lung, breast and ovarian cancers, indicating a role in tumorgenesis. Therefore, therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of cancers including brain, pancreatic, colon, kidney, lung, breast and ovarian cancers.

Panel 4.1D Summary: Ag1989 Expression of this gene was highest in kidney (CT=28.2). In addition, this gene was expressed at moderate levels in the lung cell line NCI-H292 and keratinocytes, irrespective of treatment. Expression of this gene was also up-regulated approximately two-fold in activated small airway epithelium, consistent with a potential role for the CG53971-01 gene in asthma and emphysema. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of asthma or emphysema.

S. CG51983-05: A Disintegrin and Metalloproteinase

Expression of gene CG51983-05 was assessed using the primer-probe set Ag1322, described in Table SA. Results of the RTQ-PCR runs are shown in Table SB.

TABLE SAProbe Name Ag1322StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ggtatgtgcctgccctattatt-3′229221211ProbeTET-5′-ccaccagtatcattaaggatcttttacc309441212tg-3′-TAMRAReverse5′-gccattctgtttgcaattatgt-3′229801213

TABLE SB

Panel 1.2

Column A - Rel. Exp.(%) Ag1322, Run 133804727

Tissue Name
A
Tissue Name
A

Endothelial cells
0.0
Renal ca. 786-0
0.0

Heart (Fetal)
0.0
Renal ca. A498
0.0

Pancreas
0.2
Renal ca. RXF 393
0.0

Pancreatic ca. CAPAN 2
0.0
Renal ca. ACHN
0.0

Adrenal gland
0.2
Renal ca. UO-31
0.0

Thyroid
0.0
Renal ca. TK-10
0.0

Salivary gland
0.1
Liver
0.0

Pituitary gland
0.0
Liver (fetal)
0.2

Brain (fetal)
0.0
Liver ca. (hepatoblast) HepG2
0.0

Brain (whole)
0.0
Lung
0.0

Brain (amygdala)
0.0
Lung (fetal)
0.1

Brain (cerebellum)
0.0
Lung ca. (small cell) LX-1
0.0

Brain (hippocampus)
0.0
Lung ca. (small cell) NCI-H69
0.0

Brain (thalamus)
0.0
Lung ca. (s. cell var.) SHP-77
0.0

Cerebral Cortex
0.0
Lung ca. (large cell) NCI-H460
0.0

Spinal cord
0.1
Lung ca. (non-sm. cell) A549
0.0

glio/astro U87-MG
0.0
Lung ca. (non-s. cell) NCI-H23
0.0

glio/astro U-118-MG
0.0
Lung ca. (non-s. cell) HOP-62
0.0

astrocytoma SW1783
0.0
Lung ca. (non-s. cl) NCI-H522
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (squam.) SW 900
0.0

astrocytoma SF-539
0.0
Lung ca. (squam.) NCI-H596
0.0

astrocytoma SNB-75
0.0
Mammary gland
0.0

glioma SNB-19
0.0
Breast ca.* (pl.ef) MCF-7
0.0

glioma U251
0.1
Breast ca.* (pl.ef) MDA-MB-231
0.0

glioma SF-295
0.0
Breast ca.* (pl.ef) T47D
0.0

Heart
0.0
Breast ca. BT-549
0.0

Skeletal muscle
0.0
Breast ca. MDA-N
0.0

Bone marrow
0.0
Ovary
0.0

Thymus
0.0
Ovarian ca. OVCAR-3
0.0

Spleen
0.0
Ovarian ca. OVCAR-4
0.0

Lymph node
0.1
Ovarian ca. OVCAR-5
0.0

Colorectal
0.0
Ovarian ca. OVCAR-8
0.0

Stomach
0.1
Ovarian ca. IGROV-1
0.0

Small intestine
0.0
Ovarian ca. (ascites) SK-OV-3
0.0

Colon ca. SW480
0.0
Uterus
0.0

Colon ca.* SW620
0.0
Placenta
0.0

(SW480 met)

Colon ca. HT29
0.0
Prostate
2.1

Colon ca. HCT-116
0.0
Prostate ca.* (bone met) PC-3
0.0

Colon ca. CaCo-2
0.0
Testis
100.0

CC Well to Mod Diff
0.0
Melanoma Hs688(A).T
0.0

(ODO3866)

Colon ca. HCC-2998
0.0
Melanoma* (met) Hs688(B).T
0.0

Gastric ca. (liver met)
0.0
Melanoma UACC-62
0.0

NCI-N87

Bladder
0.1
Melanoma M14
0.0

Trachea
0.0
Melanoma LOX IMVI
0.0

Kidney
0.0
Melanoma* (met) SK-MEL-5
0.0

Kidney (fetal)
0.0

Panel 1.2 Summary: Ag1322 Expression of this gene was highest in testis (CT value=29). Low expression was also seen in prostate (CT value=34.6). The gene or encoded protein is useful as a marker for these tissues. This gene encodes a protein with homology to ADAM proteins, which are membrane disintegrin-metalloproteases. The expression of several other ADAM proteins has been shown to be testis-specific and these proteins are thought to play a role in fertilization (Hooft van Huijsduijnen R. (1998) Gene 206: 273-282). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of diseases of the prostate and testis, including infertility.

T. CG53390-02: Olfactory Receptor

Expression of gene CG53390-02 was assessed using the primer-probe sets Ag1588 and Ag2015, described in Tables TA and TB. Results of the RTQ-PCR runs are shown in Tables TC, TD and TE.

TABLE TAProbe Name Ag1588StartSEQ IDPrimersSequencesLengthPositionNoForward5′-aagctctcctgtgcagatacct-3′225821214ProbeTET-5′-ctacgagatggcgctgtccacct-3′-236081215TAMRAReverse5′-aaagagggagcattaggatcag-3′226391216

TABLE TB

Probe Name Ag2015

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-aagctctcctgtgcagatacct-3′
22
582
1217

Probe
TET-5′-ctacgagatggcgctgtccacct-3′-
23
608
1218

TAMRA

Reverse
5′-aaagagggagcattaggatcag-3′
22
639
1219

TABLE TC

Panel 1.3D

Column A - Rel. Exp. (%) Ag1588, Run 165529897

Column B - Rel. Exp. (%) Ag2015, Run 147837991

Column C - Rel. Exp. (%) Ag2015, Run 152152893

Tissue Name
A
B
C
Tissue Name
A
B
C

Liver adenocarcinoma
0.0
0.0
0.0
Kidney (fetal)
0.0
0.0
0.0

Pancreas
0.0
0.0
0.0
Renal ca. 786-0
0.0
0.0
0.0

Pancreatic ca. CAPAN 2
0.0
0.0
0.0
Renal ca. A498
0.0
0.0
0.0

Adrenal gland
0.0
0.0
0.6
Renal ca. RXF 393
0.0
0.8
0.0

Thyroid
0.0
0.0
0.0
Renal ca. ACHN
0.0
0.0
1.2

Salivary gland
0.0
0.0
0.0
Renal ca. UO-31
0.0
0.0
0.0

Pituitary gland
0.0
0.0
0.0
Renal ca. TK-10
0.0
0.0
1.2

Brain (fetal)
0.0
0.0
0.0
Liver
0.0
0.0
0.0

Brain (whole)
0.0
0.0
0.0
Liver (fetal)
0.0
0.0
0.0

Brain (amygdala)
0.0
0.0
0.0
Liver ca. (hepatoblast)
0.0
0.0
0.0

HepG2

Brain (cerebellum)
0.0
0.0
0.0
Lung
0.0
0.3
0.0

Brain (hippocampus)
0.0
0.0
0.0
Lung (fetal)
0.0
0.0
0.0

Brain (substantia nigra)
0.0
0.0
0.0
Lung ca. (small cell) LX-1
0.0
0.0
0.0

Brain (thalamus)
0.0
0.0
0.0
Lung ca. (small cell) NCI-
0.0
0.0
0.0

H69

Cerebral Cortex
0.0
0.0
2.6
Lung ca. (s. cell var.) SHP-
100.0
100.0
100.0

77

Spinal cord
0.0
0.0
0.0
Lung ca. (large cell) NCI-
0.0
0.0
0.0

H460

glio/astro U87-MG
0.0
0.0
0.0
Lung ca. (non-sm. cell)
0.0
0.0
0.0

A549

glio/astro U-118-MG
0.0
0.0
1.1
Lung ca. (non-s. cell) NCI-
1.7
1.6
2.1

H23

astrocytoma SW1783
1.4
0.3
0.0
Lung ca. (non-s. cell) HOP-
0.0
0.0
0.0

62

neuro*; met SK-N-AS
0.0
0.0
0.0
Lung ca. (non-s. cl) NCI-
0.0
0.0
0.0

H522

astrocytoma SF-539
0.0
0.0
0.0
Lung ca. (squam.) SW 900
0.0
0.0
0.0

astrocytoma SNB-75
0.0
0.0
1.1
Lung ca. (squam.) NCI-
0.0
0.0
0.0

H596

glioma SNB-19
0.0
0.3
2.0
Mammary gland
0.0
0.0
1.3

glioma U251
0.7
0.0
0.0
Breast ca.* (pl. ef) MCF-7
0.0
0.5
0.0

glioma SF-295
0.0
0.0
0.0
Breast ca.* (pl. ef) MDA-
0.0
0.0
0.0

MB-231

Heart (Fetal)
0.0
0.0
0.0
Breast ca.* (pl. ef) T47D
0.0
0.4
0.0

Heart
0.0
0.0
0.7
Breast ca. BT-549
0.0
0.0
0.6

Skeletal muscle (Fetal)
0.0
0.0
0.6
Breast ca. MDA-N
0.0
0.9
0.0

Skeletal muscle
0.0
0.0
0.0
Ovary
0.0
0.0
0.0

Bone marrow
0.0
0.0
0.0
Ovarian ca. OVCAR-3
0.0
0.8
0.0

Thymus
0.0
0.3
0.0
Ovarian ca. OVCAR-4
0.0
0.0
0.0

Spleen
0.8
0.0
0.0
Ovarian ca. OVCAR-5
0.0
0.4
0.0

Lymph node
0.0
0.0
0.0
Ovarian ca. OVCAR-8
0.7
0.0
0.0

Colorectal
0.8
0.7
2.1
Ovarian ca. IGROV-1
0.0
0.0
0.0

Stomach
0.0
0.0
0.0
Ovarian ca. (ascites) SK-
0.0
0.0
0.0

OV-3

Small intestine
0.0
0.0
0.6
Uterus
0.0
0.4
0.0

Colon ca. SW480
0.0
0.0
0.0
Placenta
0.0
0.8
2.4

Colon ca.* SW620 (SW480
0.0
0.0
1.9
Prostate
0.0
0.0
0.0

met)

Colon ca. HT29
0.0
0.0
0.0
Prostate ca.* (bone met)
0.0
0.0
0.0

PC-3

Colon ca. HCT-116
0.0
0.7
0.0
Testis
0.0
1.6
0.5

Colon ca. CaCo-2
0.0
0.0
38.7
Melanoma Hs688(A).T
0.0
0.0
0.0

CC Well to Mod Diff
0.0
0.0
1.6
Melanoma* (met)
0.0
0.0
0.0

(ODO3866)

Hs688(B).T

Colon ca. HCC-2998
0.0
0.0
0.6
Melanoma UACC-62
0.0
0.0
0.0

Gastric ca. (liver met) NCI-
0.0
0.0
0.7
Melanoma M14
0.0
0.0
0.0

N87

Bladder
0.0
0.0
0.0
Melanoma LOX IMVI
0.0
0.0
1.1

Trachea
0.0
0.0
0.0
Melanoma* (met) SK-
0.0
0.0
1.4

MEL-5

Kidney
0.0
0.0
0.0
Adipose
0.0
0.0
0.0

TABLE TD

Panel 2D

Column A - Rel. Exp.(%) Ag2015, Run 152152937

Tissue Name
A
Tissue Name
A

Normal Colon
10.6
Kidney Margin 8120608
0.0

CC Well to Mod Diff (ODO3866)
32.5
Kidney Cancer 8120613
0.0

CC Margin (ODO3866)
1.1
Kidney Margin 8120614
25.9

CC Gr.2 rectosigmoid (ODO3868)
20.6
Kidney Cancer 9010320
0.0

CC Margin (ODO3868)
0.0
Kidney Margin 9010321
0.0

CC Mod Diff (ODO3920)
0.0
Normal Uterus
0.0

CC Margin (ODO3920)
0.0
Uterine Cancer 064011
0.0

CC Gr.2 ascend colon (ODO3921)
0.0
Normal Thyroid
0.0

CC Margin (ODO3921)
48.6
Thyroid Cancer
0.0

CC from Partial Hepatectomy
0.0
Thyroid Cancer A302152
0.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.0
Thyroid Margin A302153
0.0

Colon mets to lung (OD04451-01)
0.0
Normal Breast
0.0

Lung Margin (OD04451-02)
0.0
Breast Cancer
0.0

Normal Prostate 6546-1
0.0
Breast Cancer (OD04590-01)
0.0

Prostate Cancer (OD04410)
0.0
Breast Cancer Mets (OD04590-03)
0.0

Prostate Margin (OD04410)
0.0
Breast Cancer Metastasis
0.0

Prostate Cancer (OD04720-01)
0.0
Breast Cancer
0.0

Prostate Margin (OD04720-02)
0.0
Breast Cancer
0.0

Normal Lung
25.0
Breast Cancer 9100266
0.0

Lung Met to Muscle (ODO4286)
0.0
Breast Margin 9100265
0.0

Muscle Margin (ODO4286)
0.0
Breast Cancer A209073
21.3

Lung Malignant Cancer (OD03126)
0.0
Breast Margin A209073
9.7

Lung Margin (OD03126)
0.0
Normal Liver
0.0

Lung Cancer (OD04404)
0.0
Liver Cancer
0.8

Lung Margin (OD04404)
0.0
Liver Cancer 1025
0.0

Lung Cancer (OD04565)
0.0
Liver Cancer 1026
0.0

Lung Margin (OD04565)
0.0
Liver Cancer 6004-T
11.9

Lung Cancer (OD04237-01)
0.0
Liver Tissue 6004-N
100.0

Lung Margin (OD04237-02)
0.0
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (ODO4310)
0.0
Liver Tissue 6005-N
0.0

Liver Margin (ODO4310)
0.0
Normal Bladder
23.7

Melanoma Metastasis
0.0
Bladder Cancer
19.9

Lung Margin (OD04321)
0.0
Bladder Cancer
60.7

Normal Kidney
0.0
Bladder Cancer (OD04718-01)
0.0

Kidney Ca, Nuclear grade 2 (OD04338)
0.0
Bladder Normal Adjacent
0.0

(OD04718-03)

Kidney Margin (OD04338)
0.0
Normal Ovary
0.0

Kidney Ca Nuclear grade ½ (OD04339)
0.0
Ovarian Cancer
0.0

Kidney Margin (OD04339)
0.0
Ovarian Cancer (OD04768-07)
26.1

Kidney Ca, Clear cell type (OD04340)
0.0
Ovary Margin (OD04768-08)
0.0

Kidney Margin (OD04340)
0.0
Normal Stomach
0.0

Kidney Ca, Nuclear grade 3 (OD04348)
0.0
Gastric Cancer 9060358
21.0

Kidney Margin (OD04348)
0.0
Stomach Margin 9060359
0.0

Kidney Cancer (OD04622-01)
0.0
Gastric Cancer 9060395
0.0

Kidney Margin (OD04622-03)
0.0
Stomach Margin 9060394
0.0

Kidney Cancer (OD04450-01)
0.0
Gastric Cancer 9060397
0.0

Kidney Margin (OD04450-03)
24.7
Stomach Margin 9060396
0.0

Kidney Cancer 8120607
0.0
Gastric Cancer 064005
19.8

TABLE TE

Panel 4D

Column A - Rel. Exp. (%) Ag1588, Run 165373604

Column B - Rel. Exp. (%) Ag2015, Run 152153145

Column C - Rel. Exp. (%) Ag2015, Run 152685551

Tissue Name
A
B
C
Tissue Name
A
B
C

Secondary Th1 act
0.0
0.0
40.1
HUVEC IL-1beta
0.0
0.0
0.0

Secondary Th2 act
26.4
25.3
26.1
HUVEC IFN gamma
0.0
0.0
0.0

Secondary Tr1 act
12.3
58.6
0.0
HUVEC TNFalpha + IFN
0.0
0.0
0.0

gamma

Secondary Th1 rest
0.0
11.5
0.0
HUVEC TNFalpha + IL4
0.0
0.0
0.0

Secondary Th2 rest
16.6
43.8
31.0
HUVEC IL-11
0.0
0.0
0.0

Secondary Tr1 rest
42.6
24.5
14.2
Lung Microvascular EC none
0.0
0.0
0.0

Primary Th1 act
0.0
17.3
25.0
Lung Microvascular EC
0.0
0.0
0.0

TNFalpha + IL-1beta

Primary Th2 act
0.0
0.0
0.0
Microvascular Dermal EC
0.0
0.0
0.0

none

Primary Tr1 act
0.0
27.5
0.0
Microsvasular Dermal EC
0.0
0.0
24.0

TNFalpha + IL-1beta

Primary Th1 rest
18.6
69.7
12.3
Bronchial epithelium
0.0
0.0
0.0

TNFalpha + IL1beta

Primary Th2 rest
13.9
31.6
0.0
Small airway epithelium none
0.0
0.0
0.0

Primary Tr1 rest
0.0
0.0
0.0
Small airway epithelium
0.0
0.0
0.0

TNFalpha + IL-1beta

CD45RA CD4
0.0
0.0
12.6
Coronery artery SMC rest
0.0
44.4
0.0

lymphocyte act

CD45RO CD4
23.0
0.0
0.0
Coronery artery SMC
0.0
0.0
0.0

lymphocyte act

TNFalpha + IL-1beta

CD8 lymphocyte act
0.0
0.0
0.0
Astrocytes rest
0.0
0.0
27.5

Secondary CD8
0.0
0.0
0.0
Astrocytes TNFalpha + IL-
0.0
0.0
0.0

lymphocyte rest

1beta

Secondary CD8
27.5
0.0
0.0
KU-812 (Basophil) rest
0.0
0.0
0.0

lymphocyte act

CD4 lymphocyte none
13.1
0.0
13.2
KU-812 (Basophil)
0.0
0.0
41.8

PMA/ionomycin

2ry Th1/Th2/Tr1 anti-
0.0
23.2
29.5
CCD1106 (Keratinocytes)
0.0
0.0
0.0

CD95 CH11

none

LAK cells rest
15.2
12.0
0.0
CCD1106 (Keratinocytes)
0.0
0.0
24.7

TNFalpha + IL-1beta

LAK cells IL-2
0.0
31.6
0.0
Liver cirrhosis
100.0
100.0
100.0

LAK cells IL-2 + IL-12
16.6
33.2
0.0
Lupus kidney
0.0
0.0
0.0

LAK cells IL-2 + IFN
0.0
0.0
15.6
NCI-H292 none
0.0
0.0
0.0

gamma

LAK cells IL-2 + IL-18
0.0
0.0
25.3
NCI-H292 IL-4
0.0
26.6
0.0

LAK cells
0.0
0.0
29.7
NCI-H292 IL-9
0.0
0.0
0.0

PMA/ionomycin

NK Cells IL-2 rest
35.6
25.5
20.3
NCI-H292 IL-13
0.0
0.0
0.0

Two Way MLR 3 day
0.0
0.0
0.0
NCI-H292 IFN gamma
0.0
23.3
0.0

Two Way MLR 5 day
0.0
0.0
24.1
HPAEC none
0.0
0.0
0.0

Two Way MLR 7 day
0.0
0.0
0.0
HPAEC TNFalpha + IL-1
0.0
0.0
0.0

beta

PBMC rest
0.0
12.3
0.0
Lung fibroblast none
0.0
14.2
0.0

PBMC PWM
10.1
0.0
0.0
Lung fibroblast TNFalpha +
0.0
0.0
0.0

IL-1 beta

PBMC PHA-L
0.0
0.0
24.3
Lung fibroblast IL-4
0.0
25.7
0.0

Ramos (B cell) none
0.0
0.0
0.0
Lung fibroblast IL-9
0.0
0.0
0.0

Ramos (B cell)
0.0
16.3
0.0
Lung fibroblast IL-13
0.0
19.3
0.0

ionomycin

B lymphocytes PWM
0.0
13.7
43.2
Lung fibroblast IFN gamma
0.0
0.0
0.0

B lymphocytes CD40L
0.0
20.2
0.0
Dermal fibroblast CCD1070
0.0
0.0
30.1

and IL-4

rest

EOL-1 dbcAMP
0.0
0.0
0.0
Dermal fibroblast CCD1070
57.4
40.9
25.7

TNFalpha

EOL-1 dbcAMP
0.0
11.0
0.0
Dermal fibroblast CCD1070
0.0
0.0
0.0

PMA/ionomycin

IL-1 beta

Dendritic cells none
0.0
0.0
0.0
Dermal fibroblast
0.0
0.0
0.0

gamma

Dendritic cells LPS
0.0
0.0
0.0
Dermal fibroblast IL-4
0.0
0.0
0.0

Dendritic cells anti-
0.0
22.5
0.0
IBD Colitis 2
0.0
0.0
0.0

CD40

Monocytes rest
0.0
0.0
23.2
IBD Crohn's
0.0
0.0
24.8

Monocytes LPS
0.0
0.0
22.7
Colon
0.0
0.0
29.9

Macrophages rest
0.0
0.0
24.5
Lung
0.0
22.5
56.3

Macrophages LPS
0.0
0.0
0.0
Thymus
14.7
0.0
0.0

HUVEC none
0.0
18.7
0.0
Kidney
0.0
0.0
0.0

HUVEC starved
0.0
0.0
0.0

Panel 1.3D Summary: Ag1588/Ag2015 Highest expression was detected in a lung cancer cell line (CTs=29).

Panel 2D Summary: Ag2015 Highest expression was detected in normal liver tissue (CT=33)

Panel 4D Summary: Ag2015 Highest expression was detected in liver cirrhosis (CTs=32-34).

U. CG53530-03: Olfactory Receptor

Expression of full-length physical clone CG53530-03 was assessed using the primer-probe set g1194 described in Table UA. Results of the RTQ-PCR runs are shown in Table UB

TABLE UAProbe Name Ag1194StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gggaaaccttcttattgtggtca-3′231261220ProbeTET-5′-tgacctccgacccacacctgca-3′-221521221TAMRAReverse5′-gattgcccaagagaaaatacatgg-3′241791222

TABLE UB

Panel 1.3D

Column A - Rel. Exp.(%) Ag1194, Run 153594145

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
0.0
Kidney (fetal)
0.0

Pancreas
56.3
Renal ca. 786-0
0.0

Pancreatic ca.
0.0
Renal ca. A498
0.0

CAPAN 2

Adrenal gland
0.0
Renal ca. RXF 393
0.0

Thyroid
0.0
Renal ca. ACHN
0.0

Salivary gland
0.0
Renal ca. UO-31
0.0

Pituitary gland
5.2
Renal ca. TK-10
0.0

Brain (fetal)
7.0
Liver
0.0

Brain (whole)
0.0
Liver (fetal)
0.0

Brain (amygdala)
10.7
Liver ca. (hepatoblast) HepG2
10.5

Brain (cerebellum)
0.0
Lung
0.0

Brain (hippocampus)
0.0
Lung (fetal)
0.0

Brain (substantia
0.0
Lung ca. (small cell) LX-1
0.0

nigra)

Brain (thalamus)
0.0
Lung ca. (small cell) NCI-H69
0.0

Cerebral Cortex
9.5
Lung ca. (s. cell var.) SHP-77
5.5

Spinal cord
0.0
Lung ca. (large cell) NCI-H460
0.0

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
0.0

glio/astro U-118-MG
0.0
Lung ca. (non-s. cell) NCI-H23
0.0

astrocytoma SW1783
0.0
Lung ca. (non-s. cell) HOP-62
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (non-s. cl) NCI-H522
0.0

astrocytoma SF-539
0.0
Lung ca. (squam.) SW 900
0.0

astrocytoma SNB-75
0.0
Lung ca. (squam.) NCI-H596
0.0

glioma SNB-19
0.0
Mammary gland
0.0

glioma U251
0.0
Breast ca.* (pl.ef) MCF-7
0.0

glioma SF-295
0.0
Breast ca.* (pl.ef) MDA-MB-231
0.0

Heart (Fetal)
0.0
Breast ca.* (pl.ef) T47D
0.0

Heart
0.0
Breast ca. BT-549
0.0

Skeletal muscle (Fetal)
18.3
Breast ca. MDA-N
0.0

Skeletal muscle
0.0
Ovary
7.5

Bone marrow
0.0
Ovarian ca. OVCAR-3
0.0

Thymus
0.0
Ovarian ca. OVCAR-4
0.0

Spleen
14.8
Ovarian ca. OVCAR-5
0.0

Lymph node
0.0
Ovarian ca. OVCAR-8
0.0

Colorectal
100.0
Ovarian ca. IGROV-1
0.0

Stomach
0.0
Ovarian ca. (ascites) SK-OV-3
0.0

Small intestine
0.0
Uterus
0.0

Colon ca. SW480
0.0
Placenta
4.4

Colon ca.* SW620
0.0
Prostate
0.0

(SW480 met)

Colon ca. HT29
0.0
Prostate ca.* (bone met) PC-3
0.0

Colon ca. HCT-116
0.0
Testis
28.5

Colon ca. CaCo-2
0.0
Melanoma Hs688(A).T
0.0

CC Well to Mod Diff
0.0
Melanoma* (met) Hs688(B).T
0.0

(ODO3866)

Colon ca. HCC-2998
0.0
Melanoma UACC-62
0.0

Gastric ca. (liver met)
0.0
Melanoma M14
0.0

NCI-N87

Bladder
57.4
Melanoma LOX IMVI
4.7

Trachea
0.0
Melanoma* (met) SK-MEL-5
0.0

Kidney
0.0
Adipose
0.0

Panel 1.3D Summary: Ag1194 Expression of the CG53530-03 gene was highest in colon (CT=32.4) and was primarily associated with normal tissue. Significant gene expression was also detected in bladder, pancreas, and testis. Expression of this gene was downregulated in colon and pancreatic cancer cell lines when compared to the appropriate normal controls. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of colon or pancreatic cancer.

Panel 2D Summary: Ag1194 Prominent expression was detected in normal colon and bladder tissues, in agreement with the results in Panel 1.3D. This gene was expressed at higher levels in normal colon and bladder tissues than in malignant colon and bladder tissues. Targeting this gene or its protein product with small molecule, antibody, or protein therapeutics is useful in the treatment of colon and bladder cancers.

V. CG53719-02: Olfactory Receptor

Expression of gene CG53719-02 was assessed using the primer-probe set Ag379, described in Table VA. Results of the RTQ-PCR runs are shown in Tables VB and VC.

TABLE VAProbe Name Ag379StartSEQ IDPrimersSequencesLengthPositionNoForward5′-tgtgtccgattagtggccttc-3′214421223ProbeTET-5′-catcagtatggatagaaaaccacctgccc314651224tg-3′-TAMRAReverse5′-ctcgggacataagcactgca-3′204981225

TABLE VB

Panel 1.3D

Column A - Rel. Exp. (%) Ag379, Run 153691589

Column B - Rel. Exp. (%) Ag379, Run 153789843

Tissue Name
A
B
Tissue Name
A
B

Liver adenocarcinoma
0.0
4.6
Kidney (fetal)
1.4
0.0

Pancreas
0.0
0.0
Renal ca. 786-0
0.0
3.3

Pancreatic ca. CAPAN 2
0.0
0.0
Renal ca. A498
6.3
0.0

Adrenal gland
0.0
0.0
Renal ca. RXF 393
4.3
0.0

Thyroid
4.5
0.0
Renal ca. ACHN
4.8
0.0

Salivary gland
0.0
0.0
Renal ca. UO-31
2.0
0.0

Pituitary gland
0.0
0.0
Renal ca. TK-10
0.0
3.2

Brain (fetal)
2.4
0.0
Liver
0.0
3.1

Brain (whole)
2.3
7.4
Liver (fetal)
0.0
0.0

Brain (amygdala)
0.0
0.0
Liver ca. (hepatoblast) HepG2
0.0
0.0

Brain (cerebellum)
2.1
0.0
Lung
1.9
3.3

Brain (hippocampus)
2.4
2.2
Lung (fetal)
0.0
0.0

Brain (substantia nigra)
0.0
0.0
Lung ca. (small cell) LX-1
2.6
0.0

Brain (thalamus)
0.0
2.1
Lung ca. (small cell) NCI-H69
0.0
0.0

Cerebral Cortex
2.2
28.1
Lung ca. (s. cell var.) SHP-77
2.2
0.0

Spinal cord
3.1
3.1
Lung ca. (large cell) NCI-H460
2.2
5.0

glio/astro U87-MG
0.0
3.5
Lung ca. (non-sm. cell) A549
2.3
3.1

glio/astro U-118-MG
0.8
9.6
Lung ca. (non-s. cell) NCI-H23
0.0
0.0

astrocytoma SW1783
2.0
0.0
Lung ca. (non-s. cell) HOP-62
28.1
2.8

neuro*; met SK-N-AS
4.5
0.0
Lung ca. (non-s. cl) NCI-H522
7.1
0.0

astrocytoma SF-539
4.5
18.4
Lung ca. (squam.) SW 900
1.9
0.0

astrocytoma SNB-75
9.2
0.0
Lung ca. (squam.) NCI-H596
0.0
0.0

glioma SNB-19
6.0
15.4
Mammary gland
0.0
0.0

glioma U251
4.0
3.5
Breast ca.* (pl. ef) MCF-7
8.0
2.1

glioma SF-295
5.4
0.0
Breast ca.* (pl. ef) MDA-MB-
2.4
7.9

231

Heart (Fetal)
9.0
0.0
Breast ca.* (pl. ef) T47D
0.0
0.0

Heart
0.0
0.0
Breast ca. BT-549
0.0
0.0

Skeletal muscle (Fetal)
0.0
3.4
Breast ca. MDA-N
2.3
0.0

Skeletal muscle
2.9
2.4
Ovary
2.6
0.0

Bone marrow
5.9
0.0
Ovarian ca. OVCAR-3
0.0
0.0

Thymus
0.0
0.0
Ovarian ca. OVCAR-4
0.0
0.0

Spleen
0.0
0.0
Ovarian ca. OVCAR-5
4.9
0.0

Lymph node
1.7
4.0
Ovarian ca. OVCAR-8
7.1
6.4

Colorectal
8.8
6.8
Ovarian ca. IGROV-1
2.2
0.0

Stomach
0.0
0.0
Ovarian ca. (ascites) SK-OV-3
0.0
5.8

Small intestine
0.0
0.0
Uterus
1.8
0.0

Colon ca. SW480
0.0
4.2
Placenta
0.0
0.0

Colon ca.* SW620 (SW480 met)
4.5
0.0
Prostate
2.0
3.7

Colon ca. HT29
4.9
0.0
Prostate ca.* (bone met) PC-3
3.6
3.2

Colon ca. HCT-116
2.8
0.0
Testis
100.0
100.0

Colon ca. CaCo-2
0.0
0.0
Melanoma Hs688(A).T
0.0
3.4

CC Well to Mod Diff
0.0
0.0
Melanoma* (met) Hs688(B).T
0.0
0.0

(ODO3866)

Colon ca. HCC-2998
2.3
0.0
Melanoma UACC-62
2.1
0.0

Gastric ca. (liver met) NCI-N87
0.0
0.0
Melanoma M14
0.0
4.1

Bladder
0.0
4.7
Melanoma LOX IMVI
2.5
0.0

Trachea
6.6
0.0
Melanoma* (met) SK-MEL-5
0.0
0.0

Kidney
0.0
0.0
Adipose
2.0
0.0

TABLE VC

Panel 4.1D

Column A - Rel. Exp.(%) Ag379, Run 169827850

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
5.3
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-
0.0

1beta

Primary Th2 act
16.6
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.0
Microsvasular Dermal EC TNF alpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNF alpha + IL1beta
0.0

Primary Th2 rest
0.0
Small airway epithelium none
0.0

Primary Tr1 rest
0.0
Small airway epithelium TNF alpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNF alpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNF alpha + IL-1beta
4.5

Secondary CD8 lymphocyte act
6.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNF alpha + IL-
5.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
13.2

LAK cells IL-2 + IL-12
0.0
NCI-H292 none
97.3

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 IL-4
50.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-9
47.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-13
56.6

NK Cells IL-2 rest
0.0
NCI-H292 IFN gamma
100.0

Two Way MLR 3 day
0.0
HPAEC none
0.0

Two Way MLR 5 day
9.3
HPAEC TNF alpha + IL-1beta
0.0

Two Way MLR 7 day
0.0
Lung fibroblast none
0.0

PBMC rest
0.0
Lung fibroblast TNF alpha + IL-1beta
0.0

PBMC PWM
0.0
Lung fibroblast IL-4
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-9
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-13
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IFN gamma
0.0

B lymphocytes PWM
0.0
Dermal fibroblast CCD1070 rest
0.0

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1beta
11.5

EOL-1 dbcAMP
0.0
Dermal fibroblast IFN gamma
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells LPS
0.0
Dermal Fibroblasts rest
0.0

Dendritic cells anti-CD40
0.0
Neutrophils TNFa + LPS
0.0

Monocytes rest
0.0
Neutrophils rest
0.0

Monocytes LPS
0.0
Colon
0.0

Macrophages rest
6.2
Lung
0.0

Macrophages LPS
0.0
Thymus
8.0

HUVEC none
0.0
Kidney
0.0

HUVEC starved
0.0

Panel 1.3D Summary: Ag379 Highest expression of this gene was detected in testis (CTs=32-33). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of disorders of the testis, such as infertility.

Panel 4.1D Summary: Ag379 Highest expression of this gene was detected in NCI-H292 cells stimulated by IFN-gamma (CT=34). The gene was also expressed in untreated samples from the NCI-H292 cell line, a human airway epithelial cell line that produces mucins. Mucus overproduction is an important feature of bronchial asthma and chronic obstructive pulmonary disease samples. The expression of the transcript in a mucoepidermoid cell line that is often used as a model for airway epithelium (NCI-H292 cells) showed that this transcript may be important in the proliferation or activation of airway epithelium. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of inflammation in lung epithelia in chronic obstructive pulmonary disease, asthma, allergy, and emphysema.

W. CG53746-04: Odorant Receptor S25

Expression of full-length physical clone CG53746-04 was assessed using the primer-probe set Ag2690, described in Table WA. Results of the RTQ-PCR runs are shown in Tables WB and WC.

TABLE WAProbe Name Ag2690StartSEQ IDPrimersSequencesLengthPositionNoForward5′-agaacaaggtggtgtctgtgtt-3′2214561226ProbeTET-5′-ctacaccgtggtgattcccatgttga-3′-2614781227TAMRAReverse5′-cttgttcctgaggctgtagatc-3′2215111228

TABLE WB

Panel 2D

Column A - Rel. Exp.(%) Ag2690, Run 153131447

Tissue Name
A
Tissue Name
A

Normal Colon
8.4
Kidney Margin 8120608
0.0

CC Well to Mod Diff (ODO3866)
0.0
Kidney Cancer 8120613
0.0

CC Margin (ODO3866)
0.0
Kidney Margin 8120614
1.9

CC Gr.2 rectosigmoid (ODO3868)
0.0
Kidney Cancer 9010320
0.0

CC Margin (ODO3868)
0.2
Kidney Margin 9010321
0.6

CC Mod Diff (ODO3920)
0.0
Normal Uterus
0.0

CC Margin (ODO3920)
1.1
Uterine Cancer 064011
3.4

CC Gr.2 ascend colon (ODO3921)
0.0
Normal Thyroid
0.0

CC Margin (ODO3921)
0.0
Thyroid Cancer
0.8

CC from Partial Hepatectomy
0.0
Thyroid Cancer A302152
0.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.0
Thyroid Margin A302153
0.0

Colon mets to lung (OD04451-01)
2.6
Normal Breast
66.9

Lung Margin (OD04451-02)
10.0
Breast Cancer
0.0

Normal Prostate 6546-1
10.0
Breast Cancer (OD04590-01)
0.7

Prostate Cancer (OD04410)
4.2
Breast Cancer Mets (OD04590-03)
0.0

Prostate Margin (OD04410)
13.7
Breast Cancer Metastasis
0.0

Prostate Cancer (OD04720-01)
62.4
Breast Cancer
10.1

Prostate Margin (OD04720-02)
27.4
Breast Cancer
85.3

Normal Lung
100.0
Breast Cancer 9100266
13.3

Lung Met to Muscle (ODO4286)
0.5
Breast Margin 9100265
22.2

Muscle Margin (ODO4286)
0.0
Breast Cancer A209073
51.4

Lung Malignant Cancer (OD03126)
5.9
Breast Margin A209073
78.5

Lung Margin (OD03126)
39.8
Normal Liver
0.0

Lung Cancer (OD04404)
4.0
Liver Cancer
2.0

Lung Margin (OD04404)
17.9
Liver Cancer 1025
0.1

Lung Cancer (OD04565)
1.1
Liver Cancer 1026
0.0

Lung Margin (OD04565)
19.8
Liver Cancer 6004-T
0.5

Lung Cancer (OD04237-01)
0.0
Liver Tissue 6004-N
0.9

Lung Margin (OD04237-02)
25.0
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (ODO4310)
0.0
Liver Tissue 6005-N
0.0

Liver Margin (ODO4310)
0.0
Normal Bladder
4.1

Melanoma Metastasis
0.0
Bladder Cancer
0.0

Lung Margin (OD04321)
47.0
Bladder Cancer
4.0

Normal Kidney
6.0
Bladder Cancer (OD04718-01)
9.9

Kidney Ca, Nuclear grade 2 (OD04338)
2.9
Bladder Normal Adjacent
0.6

(OD04718-03)

Kidney Margin (OD04338)
8.6
Normal Ovary
0.0

Kidney Ca Nuclear grade ½ (OD04339)
0.0
Ovarian Cancer
0.6

Kidney Margin (OD04339)
2.3
Ovarian Cancer (OD04768-07)
4.7

Kidney Ca, Clear cell type (OD04340)
0.0
Ovary Margin (OD04768-08)
0.5

Kidney Margin (OD04340)
0.5
Normal Stomach
1.3

Kidney Ca, Nuclear grade 3 (OD04348)
0.0
Gastric Cancer 9060358
0.0

Kidney Margin (OD04348)
2.6
Stomach Margin 9060359
2.5

Kidney Cancer (OD04622-01)
0.6
Gastric Cancer 9060395
0.0

Kidney Margin (OD04622-03)
0.8
Stomach Margin 9060394
1.7

Kidney Cancer (OD04450-01)
0.0
Gastric Cancer 9060397
0.0

Kidney Margin (OD04450-03)
2.8
Stomach Margin 9060396
2.2

Kidney Cancer 8120607
0.0
Gastric Cancer 064005
2.4

TABLE WC

Panel 4D

Column A - Rel. Exp.(%) Ag2690, Run 153131451

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.1
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-
0.2

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.3

Primary Tr1 act
0.0
Microsvasular Dermal EC TNF alpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNF alpha + IL1beta
0.1

Primary Th2 rest
0.0
Small airway epithelium none
6.4

Primary Tr1 rest
0.0
Small airway epithelium TNF alpha + IL-
22.1

1beta

CD45RA CD4 lymphocyte act
0.2
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNF alpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
3.5

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNF alpha + IL-1beta
1.8

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
4.4

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNF alpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
1.1

LAK cells IL-2 + IL-12
0.0
Lupus kidney
1.1

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
42.9

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
100.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
41.8

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
37.4

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
15.7

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.3

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1beta
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-4
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-9
0.3

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
0.4

B lymphocytes PWM
0.2
Lung fibroblast IFN gamma
0.6

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
0.6

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1beta
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells anti-CD40
0.0
IBD Colitis 2
0.5

Monocytes rest
0.0
IBD Crohn's
0.1

Monocytes LPS
0.0
Colon
0.0

Macrophages rest
0.0
Lung
4.5

Macrophages LPS
0.0
Thymus
2.0

HUVEC none
0.0
Kidney
1.5

HUVEC starved
0.0

Panel 2D Summary: Ag2690 Highest expression of this gene was seen in normal lung tissue (CT=30)/. In addition, this gene was overexpressed in normal lung tissue when compared to expression in adjacent malignant tissue. Thus, expression of this gene is useful as a marker of lung cancer. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of lung cancer.

Panel 4D Summary: Ag2690 Highest expression of this gene was seen in IL-4 treated NCI-H292 cells, a human airway epithelial cell line that produces mucins (CT=28). This gene was also expressed in a cluster of treated and untreated samples derived from the NCI-H292 cell line. Mucus overproduction is an important feature of bronchial asthma and chronic obstructive pulmonary disease samples. The transcript was also expressed at lower but still significant levels in small airway epithelium treated with IL-1 beta and TNF-alpha. The expression of the transcript in this mucoepidermoid cell line that is often used as a model for airway epithelium (NCI-H292 cells) showed that this transcript is important in the proliferation or activation of airway epithelium. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of inflammation in lung epithelia in chronic obstructive pulmonary disease, asthma, allergy, and emphysema.

X. CG53767-02: Olfactory Receptor

Expression of full-length physical clone CG53767-02 was assessed using the primer-probe sets Ag2687 and Ag440, described in Tables XA and XB. Results of the RTQ-PCR runs are shown in Table XC.

TABLE XAProbe Name Ag2687StartSEQ IDPrimersSequencesLengthPositionNoForward5′-tgtgcatcatcgtcactgtatt-3′228071229ProbeTET-5′-tctttgcgacttgaacactatccagca-2783812303′-TAMRAReverse5′-ggagaccactggtgagatatca-3′228741231

TABLE XB

Probe Name Ag440

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-tgctcctcccacctcactg-3′
19
1058
1232

Probe
TET-5′-tgtccatacactatggatttgcttgctttg
34
1080
1233

tcta-3′-TAMRA

Reverse
5′-tgctgttcttgggcctcaa-3′
19
1115
1234

TABLE XC

Panel 4D

Column A - Rel. Exp.(%) Ag2687, Run 153112357

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.2

Primary Tr1 act
0.0
Microsvasular Dermal EC TNF alpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNF alpha + IL1beta
0.5

Primary Th2 rest
0.0
Small airway epithelium none
2.2

Primary Tr1 rest
0.0
Small airway epithelium TNF alpha + IL-
17.7

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.2

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNF alpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
1.4

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNF alpha + IL-1beta
1.3

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.2

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
1.7

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNF alpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
1.2

LAK cells IL-2 + IL-12
0.0
Lupus kidney
0.7

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
54.7

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
100.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
40.1

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
38.2

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
9.9

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.4

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1beta
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-4
0.6

Ramos (B cell) none
0.2
Lung fibroblast IL-9
0.4

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
0.3

B lymphocytes PWM
0.4
Lung fibroblast IFN gamma
0.0

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
0.4

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
0.4

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1beta
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
0.4

Dendritic cells anti-CD40
0.0
IBD Colitis 2
0.0

Monocytes rest
0.1
IBD Crohn's
0.0

Monocytes LPS
0.0
Colon
0.4

Macrophages rest
0.0
Lung
3.6

Macrophages LPS
0.0
Thymus
10.9

HUVEC none
0.0
Kidney
0.8

HUVEC starved
0.0

Panel 4D Summary: Ag2687 Highest expression of this gene was seen in IL-4 treated NCI-H292 cells, a human airway epithelial cell line that produces mucins (CT=28.8). The gene was also expressed in a cluster of treated and untreated samples derived from the NCI-H292 cell line. Mucus overproduction is an important feature of bronchial asthma and chronic obstructive pulmonary disease samples. The transcript was also expressed at lower but significant levels in small airway epithelium treated with IL-1 beta and TNF-alpha. CG53767-02 gene expression in a mucoepidermoid cell line that is often used as a model for airway epithelium (NCI-H292 cells) showed that this gene is important in the proliferation or activation of airway epithelium. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in reducing or eliminating the symptoms caused by inflammation in lung epithelia in chronic obstructive pulmonary disease, asthma, allergy, and emphysema.

Y. CG53776-02: Olfactory Receptor

Expression of full-length physical clone CG53776-02 was assessed using the primer-probe set Ag7081, described in Table YA. Results of the RTQ-PCR runs are shown in Table YB.

TABLE YAProbe Name Ag7081StartSEQ IDPrimersSequencesLengthPositionNoForward5′-atctacctggtaaccatatctggtaat-3′271681235ProbeTET-5′-ttcttatcagaatttcttctcagctcca-2820812363′-TAMRAReverse5′-gctcagaaagaaatacataggatga-3′252361237

TABLE YB

General_screening_panel_v1.6

Column A - Rel. Exp.(%) Ag7081, Run 283147418

Tissue Name
A
Tissue Name
A

Adipose
0.0
Renal ca. TK-10
0.0

Melanoma* Hs688(A).T
0.0
Bladder
0.0

Melanoma* Hs688(B).T
0.0
Gastric ca. (liver met.) NCI-N87
0.0

Melanoma* M14
0.0
Gastric ca. KATO III
0.0

Melanoma* LOXIMVI
0.0
Colon ca. SW-948
0.0

Melanoma* SK-MEL-5
0.0
Colon ca. SW480
0.0

Squamous Cell
0.0
Colon ca.* (SW480 met) SW620
0.0

carcinoma SCC-4

Testis Pool
0.0
Colon ca. HT29
0.0

Prostate ca.* (bone met)
0.0
Colon ca. HCT-116
0.0

PC-3

Prostate Pool
2.3
Colon ca. CaCo-2
3.6

Placenta
11.2
Colon cancer tissue
0.0

Uterus Pool
0.0
Colon ca. SW1116
0.0

Ovarian ca. OVCAR-3
0.0
Colon ca. Colo-205
0.0

Ovarian ca. SK-OV-3
0.0
Colon ca. SW-48
0.0

Ovarian ca. OVCAR-4
0.0
Colon Pool
0.0

Ovarian ca. OVCAR-5
3.6
Small Intestine Pool
0.0

Ovarian ca. IGROV-1
0.0
Stomach Pool
0.0

Ovarian ca. OVCAR-8
0.0
Bone Marrow Pool
0.0

Ovary
0.0
Fetal Heart
0.0

Breast ca. MCF-7
0.0
Heart Pool
0.0

Breast ca. MDA-MB-231
0.0
Lymph Node Pool
0.0

Breast ca. BT 549
3.3
Fetal Skeletal Muscle
0.0

Breast ca. T47D
0.0
Skeletal Muscle Pool
0.0

Breast ca. MDA-N
0.0
Spleen Pool
0.0

Breast Pool
0.0
Thymus Pool
2.5

Trachea
3.6
CNS cancer (glio/astro) U87-MG
0.0

Lung
0.0
CNS cancer (glio/astro) U-118-MG
3.0

Fetal Lung
100.0
CNS cancer (neuro; met) SK-N-AS
0.0

Lung ca. NCI-N417
0.0
CNS cancer (astro) SF-539
0.0

Lung ca. LX-1
0.0
CNS cancer (astro) SNB-75
0.0

Lung ca. NCI-H146
0.0
CNS cancer (glio) SNB-19
0.0

Lung ca. SHP-77
0.0
CNS cancer (glio) SF-295
0.0

Lung ca. A549
0.0
Brain (Amygdala) Pool
0.0

Lung ca. NCI-H526
0.0
Brain (cerebellum)
0.0

Lung ca. NCI-H23
0.0
Brain (fetal)
0.0

Lung ca. NCI-H460
0.0
Brain (Hippocampus) Pool
0.0

Lung ca. HOP-62
0.0
Cerebral Cortex Pool
0.0

Lung ca. NCI-H522
0.0
Brain (Substantia nigra) Pool
0.0

Liver
0.0
Brain (Thalamus) Pool
0.0

Fetal Liver
0.0
Brain (whole)
0.0

Liver ca. HepG2
0.0
Spinal Cord Pool
0.0

Kidney Pool
0.0
Adrenal Gland
0.0

Fetal Kidney
0.0
Pituitary gland Pool
0.0

Renal ca. 786-0
0.0
Salivary Gland
0.0

Renal ca. A498
0.0
Thyroid (female)
0.0

Renal ca. ACHN
0.0
Pancreatic ca. CAPAN2
0.0

Renal ca. UO-31
0.0
Pancreas Pool
0.0

General_screening_panel_v1.6 Summary: Ag7081 Low but significant expression of this gene was detected in fetal lung (CT=34.3). The relative overexpression of this gene in fetal lung showed that the protein enhances lung growth or development in the fetus and also acts in a regenerative capacity in the adult.

Z. CG53803-02: Olfactory Receptor

Expression of full-length physical clone CG53803-02 was assessed using the primer-probe set Ag2018, described in Table ZA. Results of the RTQ-PCR runs are shown in Tables ZB and ZC.

TABLE ZAProbe Name Ag2018StartSEQ IDPrimersSequencesLengthPositionNoForward5′-atgctctccggttaaacttctc-3′225441238ProbeTET-5′-tggacctaatgtaatcaaccacttcttt305661239tg-3′-TAMRAReverse5′-agagccagacacagagatgaga-3′226081240

TABLE ZB

Panel 2D

Column A - Rel. Exp.(%) Ag2018, Run 152517542

Tissue Name
A
Tissue Name
A

Normal Colon
0.0
Kidney Margin 8120608
0.0

CC Well to Mod Diff (ODO3866)
0.0
Kidney Cancer 8120613
0.0

CC Margin (ODO3866)
0.8
Kidney Margin 8120614
0.0

CC Gr.2 rectosigmoid (ODO3868)
0.0
Kidney Cancer 9010320
0.0

CC Margin (ODO3868)
0.0
Kidney Margin 9010321
0.0

CC Mod Diff (ODO3920)
0.0
Normal Uterus
0.0

CC Margin (ODO3920)
0.0
Uterine Cancer 064011
0.0

CC Gr.2 ascend colon (ODO3921)
0.0
Normal Thyroid
0.0

CC Margin (ODO3921)
0.2
Thyroid Cancer
0.0

CC from Partial Hepatectomy
0.0
Thyroid Cancer A302152
0.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.0
Thyroid Margin A302153
0.0

Colon mets to lung (OD04451-01)
0.0
Normal Breast
0.0

Lung Margin (OD04451-02)
0.0
Breast Cancer
0.0

Normal Prostate 6546-1
0.0
Breast Cancer (OD04590-01)
0.0

Prostate Cancer (OD04410)
0.0
Breast Cancer Mets (OD04590-03)
0.0

Prostate Margin (OD04410)
0.0
Breast Cancer Metastasis
0.0

Prostate Cancer (OD04720-01)
0.0
Breast Cancer
0.0

Prostate Margin (OD04720-02)
0.0
Breast Cancer
0.0

Normal Lung
0.0
Breast Cancer 9100266
0.0

Lung Met to Muscle (ODO4286)
0.1
Breast Margin 9100265
100.0

Muscle Margin (ODO4286)
0.0
Breast Cancer A209073
0.2

Lung Malignant Cancer (OD03126)
0.0
Breast Margin A209073
0.0

Lung Margin (OD03126)
0.0
Normal Liver
0.0

Lung Cancer (OD04404)
0.0
Liver Cancer
0.0

Lung Margin (OD04404)
0.0
Liver Cancer 1025
0.0

Lung Cancer (OD04565)
0.0
Liver Cancer 1026
0.0

Lung Margin (OD04565)
0.0
Liver Cancer 6004-T
0.0

Lung Cancer (OD04237-01)
0.0
Liver Tissue 6004-N
0.0

Lung Margin (OD04237-02)
0.0
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (ODO4310)
0.0
Liver Tissue 6005-N
0.0

Liver Margin (ODO4310)
0.0
Normal Bladder
0.0

Melanoma Metastasis
0.0
Bladder Cancer
0.0

Lung Margin (OD04321)
0.0
Bladder Cancer
0.8

Normal Kidney
0.0
Bladder Cancer (OD04718-01)
0.0

Kidney Ca, Nuclear grade 2 (OD04338)
0.0
Bladder Normal Adjacent
0.0

(OD04718-03)

Kidney Margin (OD04338)
0.0
Normal Ovary
0.0

Kidney Ca Nuclear grade ½ (OD04339)
0.0
Ovarian Cancer
0.0

Kidney Margin (OD04339)
0.0
Ovarian Cancer (OD04768-07)
0.0

Kidney Ca, Clear cell type (OD04340)
0.0
Ovary Margin (OD04768-08)
0.0

Kidney Margin (OD04340)
0.0
Normal Stomach
0.0

Kidney Ca, Nuclear grade 3 (OD04348)
0.0
Gastric Cancer 9060358
0.2

Kidney Margin (OD04348)
0.0
Stomach Margin 9060359
0.0

Kidney Cancer (OD04622-01)
0.0
Gastric Cancer 9060395
0.0

Kidney Margin (OD04622-03)
0.0
Stomach Margin 9060394
0.0

Kidney Cancer (OD04450-01)
0.0
Gastric Cancer 9060397
0.0

Kidney Margin (OD04450-03)
0.0
Stomach Margin 9060396
0.0

Kidney Cancer 8120607
0.0
Gastric Cancer 064005
0.0

TABLE ZC

Panel 4D

Column A - Rel. Exp.(%) Ag2018, Run 152784446

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
1.4
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.0
Microsvasular Dermal EC TNF alpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNF alpha + IL1beta
0.0

Primary Th2 rest
0.0
Small airway epithelium none
0.0

Primary Tr1 rest
0.0
Small airway epithelium TNF alpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNF alpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNF alpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNF alpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
100.0

LAK cells IL-2 + IL-12
0.0
Lupus kidney
0.0

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
0.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
0.0

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
0.0

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.0

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1beta
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-4
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-9
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
0.0

B lymphocytes PWM
0.0
Lung fibroblast IFN gamma
0.0

B lymphocytes CD40L and IL-4
4.5
Dermal fibroblast CCD1070 rest
2.1

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1beta
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells anti-CD40
0.0
IBD Colitis 2
31.4

Monocytes rest
0.0
IBD Crohn's
3.8

Monocytes LPS
0.0
Colon
0.0

Macrophages rest
0.0
Lung
0.0

Macrophages LPS
0.0
Thymus
0.0

HUVEC none
0.0
Kidney
0.0

HUVEC starved
0.0

Panel 2D Summary: Ag2018 Significant expression of this gene was seen in a single normal breast sample (CT=27.6). Expression was down-regulated in the matched adjacent breast tumor tissue (CT=40). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product is useful in the treatment of breast cancer.

Panel 4D Summary: Ag2018 Significant expression of this gene was detected in a liver cirrhosis sample (CT=33.7). Epression of this gene was not detected in normal liver in Panel 1.3D, demonstrating that expression of this gene is unique to liver cirrhosis. This gene encodes a GPCR; therefore, antibodies or small molecule therapeutics will reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, antibodies to this GPCR are useful for the diagnosis of liver cirrhosis.

AA. CG53989-04: Mastocytoma Protease Precursor-Like.

Expression of gene CG53989-04 was assessed using the primer-probe sets Ag1038, Ag1590, Ag1918, Ag2899, Ag720, Ag730, Ag443, Ag5819, Ag6974 and Ag8406, described in Tables AAA, AAB, AAC, AAD, AAE, AAF, AAG, AAH, AAI and AAJ. Results of the RTQ-PCR runs are shown in Tables AAK, AAL, AAM, AAN and AAO.

TABLE AAAProbe Name Ag1038StartSEQ IDPrimersSequencesLengthPositionNoForward5′-aggagcaacgtcctctgtaac-3′215381241ProbeTET-5′-cttccaaccacactgagcggtttgag-3′-265811242TAMRAReverse5′-agcatgtcgtccttgatgag-3′206101243

TABLE AAB

Probe Name Ag1590

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-aggagcaacgtcctctgtaac-3′
21
538
1244

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′-
26
581
1245

TAMRA

Reverse
5′-agcatgtcgtccttgatgag-3′
20
610
1246

TABLE AAC

Probe Name Ag1918

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-aggagcaacgtcctctgtaac-3′
21
538
1247

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′-
26
581
1248

TAMRA

Reverse
5′-agcatgtcgtccttgatgag-3′
20
610
1249

TABLE AAD

Probe Name Ag2899

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-aggagcaacgtcctctgtaac-3′
21
538
1250

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′-
26
581
1251

TAMRA

Reverse
5′-agcatgtcgtccttgatgag-3′
20
610
1252

TABLE AAE

Probe Name Ag720

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-aggagcaacgtcctctgtaac-3′
21
538
1253

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′-
26
581
1254

TAMRA

Reverse
5′-acagcatgtcgtccttgatg-3′
20
612
1255

TABLE AAF

Probe Name Ag730

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-caggagcaacgtcctctgta-3′
20
537
1256

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′-
26
581
1257

TAMRA

Reverse
5′-cacacagcatgtcgtcctt-3′
19
616
1258

TABLE AAG

Probe Name Ag443

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gacggtgaaggtcaggagca-3′
20
525
1259

Probe
TET-5′-cctgtcgccgccgctttcc-3′-TAMRA
19
563
1260

Reverse
5′-aaccgctcagtgtggttgg-3′
19
584
1261

TABLE AAH

Probe Name Ag5819

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-cctggtagggaggagttgga-3′
20
100
1262

Probe
TET-5′-ctgaggctctatgaggacgaccagcggac-
29
151
1263

3′-TAMRA

Reverse
5′-ccaggcccagcaggtcttc-3′
19
339
1264

TABLE AAI

Probe Name Ag6974

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gagacggatggccacag-3′
17
395
1265

Probe
TET-5′-ccaggtggctcagagcagcaggaatgtac-
29
413
1266

3′-TAMRA

Reverse
5′-cgttccgcctgcagag-3′
16
452
1267

TABLE AAJ

Probe Name Ag8406

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gtgagctggtgggcatc-3′
17
49
1268

Probe
TET-5′-ctccctaccaggggtgcctcctg-3′-
23
89
1269

TAMRA

Reverse
5′-cactctaaacgcgcaagc-3′
18
121
1270

TABLE AAK

Ardais Breast1.0

Column A - Rel. Exp.(%) Ag720, Run 389241931

Tissue Name
A
Tissue Name
A

111297 Breast cancer metastasis (9369)*
0.0
153636 Breast cancer (D3D)
0.4

108830 Breast cancer metastasis
1.1
164668 Breast cancer (6314)
0.1

(OD06855)*

97764 Breast cancer node metastasis
1.3
164677 Breast cancer (5272)
12.4

(OD06083)

97739 Breast cancer (CHTN20676)
0.1
164685 Breast cancer (0170)
11.3

145848 Breast cancer (9B6)
8.4
98857 Breast cancer (OD06397-
0.0

12)

145859 Breast cancer (9EC)
1.2
153628 Breast cancer (D35)
0.8

153632 Breast cancer (D39)
0.0
153637 Breast cancer (D3E)
5.4

153643 Breast cancer (D44)
10.7
164669 Breast cancer (6992)
6.0

164672 Breast cancer (7464)
26.1
164678 Breast cancer (5297)
68.8

164681 Breast cancer (5787)
9.7
164686 Breast cancer (0732)
0.5

97748 Breast cancer (CHTN20931)
2.2
145857 Breast cancer (9F0)
15.2

145850 Breast cancer (9C7)
0.1
153630 Breast cancer (D37)
0.6

149844 Breast cancer (24178)
2.5
153638 Breast cancer (D3F)
23.7

153633 Breast cancer (D3A)
0.4
164670 Breast cancer (7078)
1.1

153644 Breast cancer (D45)
9.0
164679 Breast cancer (5486)
4.3

164673 Breast cancer (8452)
29.1
164687 Breast cancer (5881)
0.5

164682 Breast cancer (6342)*
7.7
145846 Breast cancer (9B7)
22.5

97751 Breast cancer (CHTN21053)
0.8
145858 Breast cancer (9B4)
0.0

116417 Breast cancer (3367)*
0.1
153631 Breast cancer (D38)
1.6

145852 Breast cancer (A1A)
13.0
153639 Breast cancer (D40)
22.2

151097 Breast cancer (CHTN24298)
0.4
164671 Breast cancer (7082)
0.3

153634 Breast cancer (D3B)
0.8
164680 Breast cancer (5705)
0.0

155797 Breast cancer (EA6)
2.2
164688 Breast cancer (7222)
0.0

164674 Breast cancer (8811)
8.2
111288 Breast NAT (3367)
0.3

164683 Breast cancer (6470)
2.4
111302 Breast NAT (6314)
0.6

97763 Breast cancer (OD06083)
0.8
105687 Breast cancer 1B
0.0

116418 Breast cancer (3378)*
1.3
105688 Breast NAT 1A
0.0

145853 Breast cancer (9F3)
0.4
105689 Breast cancer 2B
0.0

153432 Breast cancer (CHTN 24652)
16.6
105690 Breast NAT 2A
0.0

153635 Breast cancer (D3C)
1.1
111289 Breast cancer 3B*
0.0

164667 Breast cancer (5785)
1.6
111290 Breast NAT 3A*
0.0

164676 Breast cancer (5070)
100.0
116424 Breast cancer 4B*
0.1

164684 Breast cancer (6509)
24.8
116425 Breast NAT 4A
0.0

116421 Breast cancer (6314)
0.0
108847 Breast cancer
0.0

145854 Breast cancer (9B8)
5.9
105694 Breast NAT
0.0

153627 Breast cancer (D34)
0.2

TABLE AAL

Panel 1.3D

Column A - Rel. Exp.(%) Ag1590, Run 152059684

Column B - Rel. Exp.(%) Ag1590, Run 155330156

Column C - Rel. Exp.(%) Ag2899, Run 160943164

Column D - Rel. Exp.(%) Ag2899, Run 165518181

Tissue Name
A
B
C
D

Liver adenocarcinoma
0.0
1.1
1.7
0.0

Pancreas
0.0
0.0
0.0
6.9

Pancreatic ca. CAPAN 2
8.7
2.5
5.6
10.5

Adrenal gland
0.0
0.8
0.0
0.0

Thyroid
0.0
0.0
0.0
0.0

Salivary gland
0.0
0.0
0.0
2.4

Pituitary gland
34.2
34.2
16.7
42.0

Brain (fetal)
0.0
0.0
0.0
1.9

Brain (whole)
0.0
0.0
0.0
0.0

Brain (amygdala)
0.0
0.0
0.0
0.0

Brain (cerebellum)
0.0
0.0
0.0
0.0

Brain (hippocampus)
0.0
0.0
0.0
0.0

Brain (substantia nigra)
0.0
0.0
0.0
0.0

Brain (thalamus)
0.0
0.0
0.0
0.0

Cerebral Cortex
1.2
0.0
0.0
0.0

Spinal cord
0.0
0.0
0.0
0.0

glio/astro U87-MG
0.0
0.0
0.0
0.0

glio/astro U-118-MG
0.0
0.0
0.0
0.0

astrocytoma SW1783
0.3
1.0
0.0
2.3

neuro*; met SK-N-AS
0.0
0.0
0.0
0.0

astrocytoma SF-539
0.0
0.0
0.0
0.0

astrocytoma SNB-75
0.7
0.0
0.0
4.5

glioma SNB-19
0.0
0.0
0.0
2.5

glioma U251
0.0
0.0
0.0
0.0

glioma SF-295
0.0
0.0
0.0
0.0

Heart (Fetal)
0.0
1.4
0.0
0.0

Heart
0.0
0.0
0.0
0.0

Skeletal muscle (Fetal)
0.0
0.0
0.0
0.0

Skeletal muscle
0.0
0.0
0.0
0.0

Bone marrow
0.9
0.0
1.0
0.0

Thymus
0.7
0.9
1.4
3.7

Spleen
0.6
1.7
0.0
0.0

Lymph node
0.0
0.0
0.0
0.0

Colorectal
3.9
2.4
1.6
8.8

Stomach
0.0
2.4
0.0
0.0

Small intestine
0.0
0.0
0.0
2.0

Colon ca. SW480
0.8
1.5
0.0
0.0

Colon ca.* SW620 (SW480 met)
0.9
0.9
3.4
0.0

Colon ca. HT29
0.0
0.0
0.0
0.0

Colon ca. HCT-116
0.0
1.0
0.0
1.0

Colon ca. CaCo-2
0.0
1.4
0.0
0.0

CC Well to Mod Diff (ODO3866)
8.8
8.1
15.2
26.8

Colon ca. HCC-2998
32.3
29.3
29.9
22.2

Gastric ca. (liver met) NCI-N87
32.1
31.6
36.9
70.7

Bladder
0.8
0.0
0.0
0.0

Trachea
0.8
1.1
0.0
0.0

Kidney
1.8
0.0
1.7
1.0

Kidney (fetal)
3.8
0.9
7.6
0.0

Renal ca. 786-0
0.0
0.0
0.0
0.0

Renal ca. A498
0.8
0.0
0.0
0.0

Renal ca. RXF 393
0.0
0.0
0.0
3.2

Renal ca. ACHN
2.1
0.0
0.0
0.0

Renal ca. UO-31
0.0
0.0
0.0
0.0

Renal ca. TK-10
0.0
0.0
0.0
0.0

Liver
4.7
5.2
3.5
33.9

Liver (fetal)
9.0
6.0
3.7
18.3

Liver ca. (hepatoblast) HepG2
2.4
1.2
1.8
0.0

Lung
0.0
0.0
3.2
0.0

Lung (fetal)
0.4
0.0
0.0
0.0

Lung ca. (small cell) LX-1
6.9
13.1
9.5
10.5

Lung ca. (small cell) NCI-H69
2.2
1.3
0.8
0.0

Lung ca. (s. cell var.) SHP-77
3.3
1.1
6.5
6.3

Lung ca. (large cell) NCI-H460
0.0
0.0
0.0
0.0

Lung ca. (non-sm. cell) A549
0.0
0.0
0.0
0.0

Lung ca. (non-s. cell) NCI-H23
0.0
0.0
0.0
0.0

Lung ca. (non-s. cell) HOP-62
0.8
0.0
0.0
0.0

Lung ca. (non-s. cl) NCI-H522
0.0
0.5
0.0
0.0

Lung ca. (squam.) SW 900
0.8
0.0
0.0
0.0

Lung ca. (squam.) NCI-H596
0.4
0.5
0.0
0.0

Mammary gland
2.7
4.2
0.0
7.9

Breast ca.* (pl.ef) MCF-7
4.1
0.0
0.0
2.5

Breast ca.* (pl.ef) MDA-MB-231
0.0
0.0
1.7
0.0

Breast ca.* (pl.ef) T47D
6.5
5.3
0.7
4.3

Breast ca. BT-549
0.0
0.0
0.0
0.0

Breast ca. MDA-N
0.0
1.1
1.7
0.0

Ovary
0.0
0.0
0.0
0.0

Ovarian ca. OVCAR-3
0.0
0.0
0.0
0.0

Ovarian ca. OVCAR-4
0.0
0.0
0.0
0.0

Ovarian ca. OVCAR-5
100.0
100.0
100.0
100.0

Ovarian ca. OVCAR-8
2.5
0.0
0.0
2.5

Ovarian ca. IGROV-1
0.0
0.0
0.0
0.0

Ovarian ca. (ascites) SK-OV-3
0.0
0.0
0.0
0.0

Uterus
0.0
0.0
0.0
0.0

Placenta
9.2
6.9
8.0
14.0

Prostate
1.9
5.2
1.8
4.1

Prostate ca.* (bone met) PC-3
0.0
0.0
0.0
0.0

Testis
6.3
9.3
8.9
8.8

Melanoma Hs688(A).T
0.0
0.0
0.0
0.0

Melanoma* (met) Hs688(B).T
0.0
0.0
0.0
0.0

Melanoma UACC-62
0.0
0.0
0.0
0.0

Melanoma M14
0.0
0.0
0.0
0.0

Melanoma LOX IMVI
0.0
0.0
0.0
0.0

Melanoma* (met) SK-MEL-5
0.0
0.0
0.0
0.0

Adipose
0.0
0.0
0.0
0.0

TABLE AAM

Panel 2D

Column A - Rel. Exp. (%) Ag1590, Run 152060853

Column B - Rel. Exp. (%) Ag1590, Run 155330182

Column C - Rel. Exp. (%) Ag2899, Run 160999416

Column D - Rel. Exp. (%) Ag2899, Run 164988403

Column E - Rel. Exp. (%) Ag720, Run 145375720

Tissue Name
A
B
C
D
E

Normal Colon
0.1
0.0
0.1
0.3
0.0

CC Well to Mod Diff (ODO3866)
9.2
11.3
5.5
8.5
2.2

CC Margin (ODO3866)
0.2
0.0
0.0
0.3
0.0

CC Gr.2 rectosigmoid (ODO3868)
0.0
0.2
0.0
0.3
0.0

CC Margin (ODO3868)
0.0
0.0
0.0
0.0
0.0

CC Mod Diff (ODO3920)
0.2
0.1
0.0
0.5
0.0

CC Margin (ODO3920)
0.0
0.0
0.0
0.0
0.0

CC Gr.2 ascend colon (ODO3921)
0.0
0.0
0.1
0.1
0.0

CC Margin (ODO3921)
0.3
0.2
0.1
0.1
0.0

CC from Partial Hepatectomy (ODO4309) Mets
1.4
1.4
0.2
1.8
0.3

Liver Margin (ODO4309)
1.8
0.9
0.6
2.0
0.4

Colon mets to lung (OD04451-01)
0.2
0.2
0.3
0.4
0.2

Lung Margin (OD04451-02)
0.0
0.0
0.0
0.0
0.0

Normal Prostate 6546-1
0.4
0.7
0.2
1.6
0.4

Prostate Cancer (OD04410)
0.0
0.0
0.0
0.0
0.0

Prostate Margin (OD04410)
0.0
0.0
0.0
0.4
0.0

Prostate Cancer (OD04720-01)
0.9
1.2
0.3
0.5
0.4

Prostate Margin (OD04720-02)
0.3
0.4
0.3
0.0
0.1

Normal Lung
0.0
0.0
0.1
0.0
0.0

Lung Met to Muscle (ODO4286)
0.0
0.3
0.0
0.0
0.2

Muscle Margin (ODO4286)
0.2
0.0
0.0
0.1
0.0

Lung Malignant Cancer (OD03126)
0.0
0.3
0.0
0.2
0.2

Lung Margin (OD03126)
0.0
0.1
0.0
0.0
0.0

Lung Cancer (OD04404)
0.0
0.0
0.0
0.0
0.1

Lung Margin (OD04404)
0.0
0.0
0.0
0.0
0.0

Lung Cancer (OD04565)
0.2
0.0
0.0
0.4
0.1

Lung Margin (OD04565)
0.0
0.0
0.0
0.0
0.0

Lung Cancer (OD04237-01)
0.0
0.2
0.0
0.5
0.0

Lung Margin (OD04237-02)
0.0
0.0
0.0
0.0
0.0

Ocular Mel Met to Liver (ODO4310)
0.0
0.0
0.0
0.0
0.0

Liver Margin (ODO4310)
1.0
1.1
0.0
1.0
0.5

Melanoma Metastasis
0.0
0.0
0.0
0.0
0.0

Lung Margin (OD04321)
0.0
0.0
0.0
0.0
0.0

Normal Kidney
0.3
1.1
0.1
0.7
0.3

Kidney ca, Nuclear grade 2 (OD04338)
0.0
0.0
0.1
0.1
0.0

Kidney Margin (OD04338)
0.2
0.7
0.2
0.2
0.1

Kidney Ca Nuclear grade 1/2 (OD04339)
0.1
0.1
0.3
0.4
0.0

Kidney Margin (OD04339)
0.6
0.3
0.7
1.4
0.3

Kidney Ca, Clear cell type (OD04340)
0.0
0.0
0.0
0.0
0.0

Kidney Margin (OD04340)
1.2
0.8
0.4
0.9
0.5

Kidney Ca, Nuclear grade 3 (OD04348)
0.0
0.0
0.0
0.6
0.0

Kidney Margin (OD04348)
0.4
0.4
0.4
0.0
0.3

Kidney Cancer (OD04622-01)
0.0
0.0
0.0
0.0
0.0

Kidney Margin (OD04622-03)
0.4
0.1
0.0
0.0
0.2

Kidney Cancer (OD04450-01)
0.3
0.2
0.1
0.0
0.0

Kidney Margin (OD04450-03)
0.0
0.2
0.0
0.3
0.2

Kidney Cancer 8120607
0.0
0.0
0.0
0.0
0.0

Kidney Margin 8120608
0.0
0.4
0.1
0.0
0.1

Kidney Cancer 8120613
0.1
0.9
0.3
0.6
0.2

Kidney Margin 8120614
0.3
0.3
0.0
0.0
0.0

Kidney Cancer 9010320
0.0
0.1
0.0
0.0
0.0

Kidney Margin 9010321
0.1
0.0
0.0
0.0
0.1

Normal Uterus
0.0
0.0
0.0
0.0
0.0

Uterine Cancer 064011
0.0
0.0
0.0
0.0
0.0

Normal Thyroid
0.0
0.1
0.0
0.0
0.0

Thyroid Cancer
0.0
0.3
0.3
0.0
0.0

Thyroid Cancer A302152
0.1
0.0
0.0
0.0
0.1

Thyroid Margin A302153
0.0
0.0
0.0
0.0
0.0

Normal Breast
0.3
0.4
0.1
1.2
0.5

Breast Cancer
33.4
34.6
22.7
55.9
47.0

Breast Cancer (OD04590-01)
100.0
100.0
100.0
100.0
30.6

Breast Cancer Mets (OD04590-03)
63.3
72.7
73.7
88.9
100.0

Breast Cancer Metastasis
2.8
2.6
2.0
2.6
2.9

Breast Cancer
3.6
5.2
2.2
6.4
3.1

Breast Cancer
1.0
1.9
2.2
1.9
0.5

Breast Cancer 9100266
3.5
3.3
1.1
7.1
4.1

Breast Margin 9100265
0.0
0.3
0.1
0.2
0.3

Breast Cancer A209073
2.3
1.6
0.7
2.0
1.7

Breast Margin A209073
0.7
1.3
0.7
0.9
0.2

Normal Liver
0.1
0.5
0.4
2.2
0.9

Liver Cancer
0.3
0.3
0.4
0.3
0.1

Liver Cancer 1025
0.4
0.7
0.5
1.3
0.5

Liver Cancer 1026
0.7
0.1
0.3
1.1
0.2

Liver Cancer 6004-T
0.9
1.1
1.4
2.8
0.6

Liver Tissue 6004-N
0.0
0.0
0.1
0.0
0.0

Liver Cancer 6005-T
0.8
0.8
1.2
0.7
0.2

Liver Tissue 6005-N
0.1
0.0
0.2
0.5
0.0

Normal Bladder
0.0
0.0
0.1
0.4
0.1

Bladder Cancer
0.0
0.1
0.0
0.0
0.1

Bladder Cancer
0.1
0.4
0.3
0.0
0.1

Bladder Cancer (OD04718-01)
0.2
0.2
0.3
0.0
0.4

Bladder Normal Adjacent (OD04718-03)
0.0
0.0
0.0
0.0
0.0

Normal Ovary
0.0
0.0
0.0
0.0
0.0

Ovarian Cancer
0.0
0.0
0.0
0.2
0.0

Ovarian Cancer (OD04768-07)
0.1
0.0
0.1
0.0
0.0

Ovary Margin (OD04768-08)
0.0
0.0
0.0
0.0
0.0

Normal Stomach
0.0
0.1
0.0
0.2
0.0

Gastric Cancer 9060358
0.0
0.0
0.0
0.0
0.0

Stomach Margin 9060359
0.0
0.0
0.0
0.0
0.0

Gastric Cancer 9060395
0.0
0.0
0.0
0.0
0.0

Stomach Margin 9060394
0.0
0.0
0.0
0.0
0.0

Gastric Cancer 9060397
1.5
0.7
0.6
0.3
0.2

Stomach Margin 9060396
0.0
0.0
0.0
0.0
0.0

Gastric Cancer 064005
0.1
0.3
0.0
0.2
0.2

TABLE AAN

Panel 3D

Column A - Rel. Exp. (%) Ag2899, Run 164633619

Column B - Rel. Exp. (%) Ag720, Run 164843791

Tissue Name
A
B
Tissue Name
A
B

94905 Daoy
0.0
0.0
94954 Ca Ski Cervical
0.0
3.2

Medulloblastoma/Cerebellum

epidermoid carcinoma

(metastasis

94906 TE671
0.0
0.0
94955 ES-2 Ovarian clear cell
0.0
0.0

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
0.0
0.0
94957 Ramos Stimulated with
0.0
0.0

Medulloblastoma/Cerebellum

PMA/ionomycin 6 h

94908 PFSK-1 Primitive
0.0
1.4
94958 Ramos Stimulated with
0.0
0.0

Neuroectodermal/Cerebellum

PMA/ionomycin 14 h

94909 XF-498 CNS
0.0
0.0
94962 MEG-01 Chronic
0.0
0.0

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
0.0
0.0
94963 Raji Burkitt's
0.0
0.0

lymphoma

94911 SF-268 CNS/glioblastoma
0.0
0.0
94964 Daudi Burkitt's
0.0
0.0

lymphoma

94912 T98G Glioblastoma
0.0
0.0
94965 U266 B-cell
14.7
17.6

plasmacytoma/myeloma

96776 SK-N-SH Neuroblastoma
0.0
0.0
94968 CA46 Burkitt's
0.0
0.0

(metastasis)

lymphoma

94913 SF-295 CNS/glioblastoma
0.0
0.0
94970 RL non-Hodgkin's B-
0.0
0.0

cell lymphoma

94914 Cerebellum
0.0
0.0
94972 JM1 pre-B-cell
0.0
0.0

lymphoma/leukemia

96777 Cerebellum
1.2
0.0
94973 Jurkat T cell leukemia
0.0
0.0

94916 NCI-H292
0.0
0.0
94974 TF-1 Erythroleukemia
0.0
0.0

Mucoepidermoid lung carcinoma

94917 DMS-114 Small cell lung
0.0
0.0
94975 HUT 78 T-cell
0.0
0.0

cancer

lymphoma

94918 DMS-79 Small cell lung
100.0
100.0
94977 U937 Histiocytic
0.0
0.0

cancer/neuroendocrine

lymphoma

94919 NCI-H146 Small cell lung
0.0
0.0
94980 KU-812 Myelogenous
0.0
0.0

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
0.0
0.0
769-P- Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94921 NCI-N417 Small cell lung
0.0
0.0
94983 Caki-2 Clear cell renal
0.8
1.9

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
0.0
0.0
94984 SW 839 Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell
0.0
0.0
94986 G401 Wilms' tumor
0.0
0.0

lung cancer (metastasis)

94925 NCI-H1155 Large cell
0.0
0.0
94987 Hs766T Pancreatic
1.2
5.5

lung cancer/neuroendocrine

carcinoma (LN metastasis)

94926 NCI-H1299 Large cell
0.0
0.0
94988 CAPAN-l Pancreatic
0.0
0.0

lung cancer/neuroendocrine

adenocarcinoma (liver

metastasis)

94927 NCI-H727 Lung carcinoid
0.0
0.0
94989 SU86.86 Pancreatic
0.0
0.0

carcinoma (liver metastasis)

94928 NCI-UMC-11 Lung
0.0
4.9
94990 BxPC-3 Pancreatic
0.0
2.9

carcinoid

adenocarcinoma

94929 LX-1 Small cell lung
3.2
3.7
94991 HPAC Pancreatic
1.2
5.1

cancer

adenocarcinoma

94930 Colo-205 Colon cancer
7.5
29.3
94992 MIA PaCa-2 Pancreatic
0.0
0.0

carcinoma

94931 KM12 Colon cancer
0.2
1.6
94993 CFPAC-1 Pancreatic
29.1
47.6

ductal adenocarcinoma

94932 KM20L2 Colon cancer
1.2
0.0
94994 PANC-1 Pancreatic
0.0
0.0

epithelioid ductal carcinoma

94933 NCI-H716 Colon cancer
0.0
0.0
94996 T24 Bladder carcinma
0.0
0.0

(transitional cell

94935 SW-48 Colon
0.0
0.0
5637-Bladder carcinoma
0.0
0.0

adenocarcinoma

94936 SW1116 Colon
0.0
0.0
94998 HT-1197 Bladder
5.1
7.6

adenocarcinoma

carcinoma

94937 LS 174T Colon
1.1
0.0
94999 UM-UC-3 Bladder
0.0
0.0

adenocarcinoma

carcinma (transitional cell)

94938 SW-948 Colon
0.0
0.0
95000 A204
0.0
0.0

adenocarcinoma

Rhabdomyosarcoma

94939 SW-480 Colon
0.0
0.0
95001 HT-1080 Fibrosarcoma
0.0
0.0

adenocarcinoma

94940 NCI-SNU-5 Gastric
0.0
1.1
95002 MG-63 Osteosarcoma
0.0
0.0

carcinoma

(bone)

KATO III-Gastric carcinoma
0.0
1.9
95003 SK-LMS-1
0.0
0.0

Leiomyosarcoma (vulva)

94943 NCI-SNU-16 Gastric
2.2
0.0
95004 SJRH30
0.0
0.0

carcinoma

Rhabdomyosarcoma (met to

bone marrow)

94944 NCI-SNU-1 Gastric
0.0
0.0
95005 A431 Epidermoid
1.8
1.6

carcinoma

carcinoma

94946 RF-1 Gastric
0.0
0.0
95007 WM266-4 Melanoma
0.0
0.0

adenocarcinoma

94947 RF-48 Gastric
0.0
0.0
DU 145-Prostate carcinoma
0.0
0.0

adenocarcinoma

(brain metastasis)

96778 MKN-45 Gastric
0.0
0.0
95012 MDA-MB-468 Breast
1.1
0.0

carcinoma

adenocarcinoma

94949 NCI-N87 Gastric
0.0
3.8
SCC-4-Squamous cell
0.0
0.0

carcinoma

carcinoma of tongue

94951 OVCAR-5 Ovarian
29.7
62.0
SCC-9-Squamous cell
0.0
0.0

carcinoma

carcinoma of tongue

94952 RL95-2 Uterine carcinoma
19.3
21.8
SCC-15-Squamous cell
0.0
0.0

carcinoma of tongue

94953 HelaS3 Cervical
0.0
0.0
95017 CAL 27 Squamous cell
0.0
0.0

adenocarcinoma

carcinoma of tongue

TABLE AAO

Panel 4D

Column A - Rel. Exp.(%) Ag1590, Run 152061102

Column B - Rel. Exp.(%) Ag1590, Run 155330411

Column C - Rel. Exp.(%) Ag1918, Run 147288180

Column D - Rel. Exp.(%) Ag2899, Run 159633215

Tissue Name
A
B
C
D

Secondary Th1 act
0.0
0.0
0.0
0.0

Secondary Th2 act
0.0
0.0
0.0
4.3

Secondary Tr1 act
0.0
0.0
0.0
6.6

Secondary Th1 rest
0.0
0.0
0.0
0.0

Secondary Th2 rest
0.0
0.0
0.0
0.0

Secondary Tr1 rest
0.0
0.0
0.0
0.0

Primary Th1 act
0.0
0.0
0.0
0.0

Primary Th2 act
0.0
0.0
0.0
0.0

Primary Tr1 act
0.0
0.0
0.0
0.0

Primary Th1 rest
0.0
0.0
0.0
0.0

Primary Th2 rest
0.0
0.0
0.0
0.0

Primary Tr1 rest
0.0
0.0
0.0
0.0

CD45RA CD4 lymphocyte act
0.0
0.0
0.0
0.0

CD45RO CD4 lymphocyte act
0.0
0.0
0.0
0.0

CD8 lymphocyte act
0.0
0.0
0.0
0.0

Secondary CD8 lymphocyte rest
0.0
0.0
0.0
0.0

Secondary CD8 lymphocyte act
0.0
0.0
0.0
0.0

CD4 lymphocyte none
0.0
0.0
0.0
0.0

2ry Th1/Th2/Tr1 anti-CD95 CH11
0.0
0.0
0.0
0.0

LAK cells rest
0.0
0.0
0.0
0.0

LAK cells IL-2
0.0
0.0
0.0
0.0

LAK cells IL-2 + IL-12
0.0
0.0
0.0
0.0

LAK cells IL-2 + IFN gamma
0.0
0.0
0.0
0.0

LAK cells IL-2 + IL-18
0.0
0.0
0.0
0.0

LAK cells PMA/ionomycin
0.0
0.0
0.0
0.0

NK Cells IL-2 rest
0.0
0.0
0.0
0.0

Two Way MLR 3 day
0.0
0.0
0.0
0.0

Two Way MLR 5 day
0.0
0.0
0.0
0.0

Two Way MLR 7 day
0.0
0.0
0.0
0.0

PBMC rest
6.3
0.0
0.0
0.0

PBMC PWM
0.0
0.0
0.0
0.0

PBMC PHA-L
0.0
0.0
0.0
0.0

Ramos (B cell) none
0.0
0.0
0.0
0.0

Ramos (B cell) ionomycin
0.0
0.0
0.0
0.0

B lymphocytes PWM
0.0
0.0
0.0
0.0

B lymphocytes CD40L and IL-4
0.0
0.0
0.0
0.0

EOL-1 dbcAMP
0.0
0.0
0.0
0.0

EOL-1 dbcAMP PMA/ionomycin
0.0
0.0
0.0
0.0

Dendritic cells none
0.0
0.0
0.0
0.0

Dendritic cells LPS
0.0
0.0
0.0
0.0

Dendritic cells anti-CD40
0.0
0.0
0.0
0.0

Monocytes rest
0.0
0.0
0.0
12.9

Monocytes LPS
0.0
0.0
0.0
0.0

Macrophages rest
0.0
0.0
0.0
0.0

Macrophages LPS
0.0
0.0
0.0
0.0

HUVEC none
0.0
0.0
0.0
0.0

HUVEC starved
0.0
0.0
0.0
0.0

HUVEC IL-1beta
0.0
0.0
0.0
0.0

HUVEC IFN gamma
0.0
0.0
0.0
0.0

HUVEC TNF alpha + IFN gamma
0.0
0.0
0.0
0.0

HUVEC TNF alpha + IL4
0.0
0.0
0.0
0.0

HUVEC IL-11
0.0
0.0
0.0
0.0

Lung Microvascular EC none
0.0
0.0
0.0
0.0

Lung Microvascular EC TNF alpha +
0.0
0.0
0.0
0.0

IL-1beta

Microvascular Dermal EC none
0.0
0.0
0.0
0.0

Microsvasular Dermal EC TNF alpha +
0.0
0.0
0.0
0.0

IL-1beta

Bronchial epithelium TNF alpha + IL1beta
13.9
0.0
30.1
3.4

Small airway epithelium none
0.0
0.0
0.0
0.0

Small airway epithelium TNF alpha +
0.0
0.0
0.0
0.0

IL-1beta

Coronery artery SMC rest
0.0
0.0
0.0
0.0

Coronery artery SMC TNF alpha + IL-1beta
0.0
0.0
0.0
0.0

Astrocytes rest
0.0
0.0
0.0
0.0

Astrocytes TNF alpha + IL-1beta
0.0
0.0
0.0
0.0

KU-812 (Basophil) rest
0.0
0.0
0.0
0.0

KU-812 (Basophil) PMA/ionomycin
10.8
0.0
0.0
5.4

CCD1106 (Keratinocytes) none
0.0
0.0
0.0
0.0

CCD1106 (Keratinocytes) TNF alpha +
0.0
0.0
0.0
0.0

IL-1beta

Liver cirrhosis
22.7
80.1
63.7
100.0

Lupus kidney
0.0
7.4
0.0
0.0

NCI-H292 none
60.3
92.7
36.3
28.9

NCI-H292 IL-4
55.9
6.5
28.7
14.3

NCI-H292 IL-9
100.0
41.8
40.1
29.7

NCI-H292 IL-13
35.8
6.7
9.4
23.7

NCI-H292 IFN gamma
0.0
23.8
1.2
0.0

HPAEC none
0.0
0.0
0.0
0.0

HPAEC TNF alpha + IL-1beta
0.0
0.0
0.0
0.0

Lung fibroblast none
0.0
0.0
0.0
0.0

Lung fibroblast TNF alpha + IL-1beta
0.0
0.0
0.0
0.0

Lung fibroblast IL-4
0.0
0.0
0.0
0.0

Lung fibroblast IL-9
0.0
0.0
0.0
0.0

Lung fibroblast IL-13
0.0
0.0
0.0
0.0

Lung fibroblast IFN gamma
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 rest
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 TNF alpha
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 IL-1beta
0.0
0.0
0.0
0.0

Dermal fibroblast IFN gamma
0.0
0.0
0.0
0.0

Dermal fibroblast IL-4
0.0
0.0
0.0
0.0

IBD Colitis 2
0.0
0.0
0.0
0.0

IBD Crohn's
13.8
0.0
0.0
0.0

Colon
79.6
100.0
100.0
74.7

Lung
77.9
66.0
53.6
85.3

Thymus
62.0
21.6
0.7
23.0

Kidney
0.0
0.0
0.0
0.0

Ardais Breast1.0 Summary: Ag720 Expression of this gene was highest in a breast cancer sample (CT=27.1). Significant CG53989-03 gene expression was detected in 45/64 breast cancer samples but only 1/7 normal breast samples. Gene or protein expression levels are useful for the detection of breast cancer. Therapeutic modulation of this gene, encoded protein and/or use of antibodies or small molecule drugs targeting this gene or gene product is useful in the treatment of breast cancer.

This gene encodes a protein with homology to mastocytoma protease precursor. Mast cell tryptase is a secretory granule associated serine protease with trypsin-like specificity. It is released extracellularly during mast cell degranulation. Mast cells (MC) have been associated with diverse human cancers. The primary function of these cells is to store and release a number of biologically active mediators, including the serine proteases tryptase and chymase. These proteases have been closely related with angiogenesis and tumor invasion, two critical steps during tumor progression. Malignant breast tumors have two to three times more tryptase-containing than chymase-containing mast cells, with the number of mast cells with trptase activity being significantly higher (p<0.02) than in benign lesions. In malignant lesions, tryptase-containing mast cells were concentrated at the tumor edge, i.e. the invasion zone (Kankkunen J P, Harvima I T, Naukkarinen A. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer. 1997 Jul. 29; 72(3): 385-8). Therefore, the protease encoded by this gene plays a role in tumor invasion and metastasis.

General_screening_panel_v1.6 Summary: Ag6974 Highest expression of this gene was detected in a ovarian cancer OVCAR-5 cell line (CT=28). This gene showed preferential expression in colon cancer tissue and a number of cancer cell lines derived from pancreatic, colon, gastric, lung, breast and ovarian cancers. Expression of this gene is useful as diagnostic marker to detect these cancers and also, modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of these cancers.

Panel 1.3D Summary: Ag1590/2899 The expression of the CG56242-01 gene was assessed in four independent runs using two different probe/primer sets. All of the runs show excellent concordance. The expression of this gene was highest in a sample derived from an ovarian cancer cell line (OVCAR-5) (CTs=31-32). There was significant expression associated with a colon cancer cell line, a gastric cancer cell line and pituitary tissue. Therapeutic modulation of this gene, encoded protein and/or use of small molecule or antibodies targeting this gene or gene product is useful in the treatment of ovarian cancer, gastric cancer or colon cancers.

Panel 2D Summary: Ag720/1590/2899 The expression of this gene was highest and exclusive to breast cancer samples (CTs=26-28). Thus, the expression of this gene is useful as marker for breast cancer. Therapeutic modulation of this gene, encoded protein and/or use of small molecule or antibodies targeting this gene or gene product is useful in the treatment of breast cancer.

Panel 3D Summary: Ag720/2899 The expression of this gene was highest in a sample derived from a lung cancer cell line (DMS-79)(CTs=29-31). There was low but significant expression associated with samples derived from an ovarian cancer cell line, a uterine cancer cell line and a pancreatic cancer cell line. The expression of this gene or expressed protein is useful in the detection of lung cancer. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of lung cancer, ovarian cancer, pancreatic cancer or uterine cancer.

Panel 4D Summary: Ag1590/Ag1918/Ag2899 This gene, a tryptase homolog, was expressed at significant levels in IL-9-activated NCI-H292 cells, pulmonary mucoepidermoid cells. Colon, lung, and thymus tissues also showed low levels of expression of this gene. The expression in lung and in the activated NCI-H292 cell line, often used as a model for airway epithelium was consistent with published reports of tryptase in the lung (Walls A F, Bennett A R, Godfrey R C, Holgate S T, Church M K. Mast cell tryptase and histamine concentrations in bronchoalveolar lavage fluid from patients with interstitial lung disease. Clin Sci (Lond) 1991 August; 81(2):183-8). In addition, tryptase has been shown to be up-regulated in lungs affected by disease and specifically in COPD (Grashoff W F, Sont J K, Sterk P J, Hiemstra P S, de Boer W I, Stolk J, Han J, van Krieken J M. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol 1997 December; 151(6):1785-90). Tryptase has also been implicated in the recruitment of granulocytes and epithelial repair (Cairns J A, Walls A F. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 1996 Jan. 1; 156(1):275-83). Based on these observations, therapeutic modulation of this gene, encoded protein and/use of small molecule or antibodies targeting this gene is useful in the reduction or elimination of symptoms in patients with lung diseases including asthma, allergy, or chronic obstructive pulmonary disease.

AB. CG54212-02: GPCR.

Expression of gene CG54212-02 was assessed using the primer-probe set Ag431, described in Table ABA. Results of the RTQ-PCR runs are shown in Tables ABB, ABC and ABD.

TABLE ABAProbe Name Ag431StartSEQ IDPrimersSequencesLengthPositionNoForward5′-agtcacttcacctgcaagatcct-3′235331271ProbeTET-5′-ccgcatgccagcttcagcactg-3′-225581272TAMRAReverse5′-cttcgctgaccgacgtgtt-3′195811273

TABLE ABB

Panel 1

Column A - Rel. Exp.(%) Ag431, Run 98747695

Tissue Name
A
Tissue Name
A

Endothelial cells
0.0
Renal ca. 786-0
0.0

Endothelial cells
0.0
Renal ca. A498
1.5

(treated)

Pancreas
0.0
Renal ca. RXF 393
0.0

Pancreatic ca.
0.0
Renal ca. ACHN
0.0

CAPAN 2

Adrenal gland
2.0
Renal ca. UO-31
0.1

Thyroid
0.0
Renal ca. TK-10
0.2

Salivary gland
0.1
Liver
0.1

Pituitary gland
0.4
Liver (fetal)
0.2

Brain (fetal)
27.5
Liver ca. (hepatoblast) HepG2
0.0

Brain (whole)
21.9
Lung
1.3

Brain (amygdala)
36.1
Lung (fetal)
0.6

Brain (cerebellum)
28.5
Lung ca. (small cell) LX-1
9.9

Brain (hippocampus)
36.1
Lung ca. (small cell) NCI-H69
18.4

Brain (substantia
17.1
Lung ca. (s. cell var.) SHP-77
0.0

nigra)

Brain (thalamus)
36.1
Lung ca. (large cell) NCI-H460
5.3

Brain (hypothalamus)
13.5
Lung ca. (non-sm. cell) A549
8.4

Spinal cord
6.7
Lung ca. (non-s. cell) NCI-H23
0.4

glio/astro U87-MG
0.0
Lung ca. (non-s. cell) HOP-62
0.1

glio/astro U-118-MG
0.0
Lung ca. (non-s. cl) NCI-H522
5.8

astrocytoma SW1783
0.0
Lung ca. (squam.) SW 900
13.5

neuro*; met SK-N-AS
0.1
Lung ca. (squam.) NCI-H596
6.6

astrocytoma SF-539
0.1
Mammary gland
25.2

astrocytoma SNB-75
0.1
Breast ca.* (pl.ef) MCF-7
0.9

glioma SNB-19
2.6
Breast ca.* (pl.ef) MDA-MB-231
0.0

glioma U251
8.2
Breast ca.* (pl.ef) T47D
4.3

glioma SF-295
2.6
Breast ca. BT-549
0.3

Heart
4.0
Breast ca. MDA-N
0.2

Skeletal muscle
32.1
Ovary
0.4

Bone marrow
0.0
Ovarian ca. OVCAR-3
1.4

Thymus
2.5
Ovarian ca. OVCAR-4
0.1

Spleen
0.1
Ovarian ca. OVCAR-5
17.9

Lymph node
0.0
Ovarian ca. OVCAR-8
17.6

Colon (ascending)
16.0
Ovarian ca. IGROV-1
8.1

Stomach
0.6
Ovarian ca. (ascites) SK-OV-3
0.9

Small intestine
0.5
Uterus
1.0

Colon ca. SW480
0.0
Placenta
0.5

Colon ca.* SW620
0.0
Prostate
7.2

(SW480 met)

Colon ca. HT29
4.5
Prostate ca.* (bone met) PC-3
2.0

Colon ca. HCT-116
0.0
Testis
20.9

Colon ca. CaCo-2
0.0
Melanoma Hs688(A).T
0.0

Colon ca. HCT-15
10.5
Melanoma* (met) Hs688(B).T
1.6

Colon ca. HCC-2998
9.6
Melanoma UACC-62
1.9

Gastric ca. (liver met)
8.5
Melanoma M14
0.1

NCI-N87

Bladder
5.3
Melanoma LOX IMVI
0.0

Trachea
0.0
Melanoma* (met) SK-MEL-5
0.0

Kidney
1.0
Melanoma SK-MEL-28
100.0

Kidney (fetal)
3.2

TABLE ABC

Panel 2D

Column A - Rel. Exp.(%) Ag431, Run 153681087

Tissue Name
A
Tissue Name
A

Normal Colon
2.0
Kidney Margin 8120608
0.0

CC Well to Mod Diff (ODO3866)
1.4
Kidney Cancer 8120613
0.0

CC Margin (ODO3866)
0.0
Kidney Margin 8120614
0.0

CC Gr.2 rectosigmoid (ODO3868)
1.6
Kidney Cancer 9010320
0.0

CC Margin (ODO3868)
2.0
Kidney Margin 9010321
20.7

CC Mod Diff (ODO3920)
0.8
Normal Uterus
1.8

CC Margin (ODO3920)
1.1
Uterine Cancer 064011
4.9

CC Gr.2 ascend colon (ODO3921)
1.9
Normal Thyroid
0.0

CC Margin (ODO3921)
2.1
Thyroid Cancer
0.0

CC from Partial Hepatectomy
0.0
Thyroid Cancer A302152
0.0

(ODO4309) Mets

Liver Margin (ODO4309)
1.2
Thyroid Margin A302153
1.9

Colon mets to lung (OD04451-01)
9.2
Normal Breast
0.9

Lung Margin (OD04451-02)
0.7
Breast Cancer
29.5

Normal Prostate 6546-1
3.6
Breast Cancer (OD04590-01)
2.8

Prostate Cancer (OD04410)
3.1
Breast Cancer Mets (OD04590-03)
0.0

Prostate Margin (OD04410)
7.0
Breast Cancer Metastasis
14.6

Prostate Cancer (OD04720-01)
6.9
Breast Cancer
9.4

Prostate Margin (OD04720-02)
7.9
Breast Cancer
100.0

Normal Lung
0.6
Breast Cancer 9100266
4.0

Lung Met to Muscle (ODO4286)
0.0
Breast Margin 9100265
1.3

Muscle Margin (ODO4286)
0.6
Breast Cancer A209073
1.4

Lung Malignant Cancer (OD03126)
2.0
Breast Margin A209073
2.7

Lung Margin (OD03126)
4.2
Normal Liver
0.0

Lung Cancer (OD04404)
0.0
Liver Cancer
0.7

Lung Margin (OD04404)
0.9
Liver Cancer 1025
0.0

Lung Cancer (OD04565)
0.0
Liver Cancer 1026
0.0

Lung Margin (OD04565)
0.0
Liver Cancer 6004-T
2.2

Lung Cancer (OD04237-01)
0.5
Liver Tissue 6004-N
2.4

Lung Margin (OD04237-02)
0.0
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (OD04310)
0.0
Liver Tissue 6005-N
0.0

Liver Margin (OD04310)
0.0
Normal Bladder
3.6

Melanoma Metastasis
0.0
Bladder Cancer
2.8

Lung Margin (OD04321)
2.5
Bladder Cancer
2.8

Normal Kidney
2.5
Bladder Cancer (OD04718-01)
0.8

Kidney Ca, Nuclear grade 2 (OD04338)
0.9
Bladder Normal Adjacent
3.2

(OD04718-03)

Kidney Margin (OD04338)
0.0
Normal Ovary
0.0

Kidney Ca Nuclear grade ½ (OD04339)
0.0
Ovarian Cancer
2.0

Kidney Margin (OD04339)
3.1
Ovarian Cancer (OD04768-07)
0.0

Kidney Ca, Clear cell type (OD04340)
0.0
Ovary Margin (OD04768-08)
0.0

Kidney Margin (OD04340)
0.0
Normal Stomach
4.8

Kidney Ca, Nuclear grade 3 (OD04348)
0.0
Gastric Cancer 9060358
0.0

Kidney Margin (OD04348)
2.7
Stomach Margin 9060359
0.0

Kidney Cancer (OD04622-01)
1.1
Gastric Cancer 9060395
2.9

Kidney Margin (OD04622-03)
0.0
Stomach Margin 9060394
0.6

Kidney Cancer (OD04450-01)
0.0
Gastric Cancer 9060397
0.6

Kidney Margin (OD04450-03)
5.0
Stomach Margin 9060396
0.0

Kidney Cancer 8120607
0.0
Gastric Cancer 064005
0.6

TABLE ABD

Panel 4D

Column A - Rel. Exp.(%) Ag431, Run 153681094

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.1
HUVEC IFN gamma
0.1

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.1

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-
0.0

1beta

Primary Th2 act
0.2
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.0
Microsvasular Dermal EC TNF alpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNF alpha + IL1beta
0.3

Primary Th2 rest
0.0
Small airway epithelium none
0.0

Primary Tr1 rest
0.1
Small airway epithelium TNF alpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNF alpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNF alpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
1.8
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNF alpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
0.5

LAK cells IL-2 + IL-12
0.0
Lupus kidney
0.0

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
0.4

LAK cells PMA/ionomycin
0.1
NCI-H292 IL-9
0.2

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
0.0

Two Way MLR 3 day
5.1
NCI-H292 IFN gamma
100.0

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.0

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1beta
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-4
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-9
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
0.2

B lymphocytes PWM
0.1
Lung fibroblast IFN gamma
0.0

B lymphocytes CD40L and IL-4
0.4
Dermal fibroblast CCD1070 rest
0.1

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
0.2

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1beta
0.0

PMA/ionomycin

Dendritic cells none
0.2
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells anti-CD40
0.0
IBD Colitis 2
0.1

Monocytes rest
0.0
IBD Crohn's
0.0

Monocytes LPS
0.0
Colon
0.2

Macrophages rest
0.0
Lung
0.2

Macrophages LPS
0.0
Thymus
0.1

HUVEC none
0.0
Kidney
0.2

HUVEC starved
0.0

Panel 1 Summary: Ag431 Expression of this gene was highest in a melanoma cell line (CT=27.1). Significant expression was also detected in ovarian, lung, and colon cancer cell lines. Modulation of this gene, encoded protein and/or use of small molecule drugs or antibodies targeting this gene or gene product is useful in the treatment of melanoma and lung, colon or ovarian cancers.

Among tissues with metabolic function, this gene was expressed in the pituitary and adrenal glands, the hypothalamus, heart and skeletal muscle. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of metabolic/endocrine diseases such as diabetes and obesity.

This gene was also expressed at moderate levels in all the regions of the central nervous system examined including the fetal brain, cerebellum, amygdala, hippocampus, substantia nigra, thalamus, hypothalamus, and spinal cord. This gene codes for a GPCR. Neurotransmitter receptors belong to GPCR family of proteins. Thus, this protein may represent a novel neurotransmitter receptor. Neurotransmitter receptors that are GPCRs include the dopamine receptor family, the serotonin receptor family, the GABA receptor, and muscarinic acetylcholine receptors. The selected targeting of dopamine and serotonin receptors has proven to be effective in the treatement of psychiatric illnesses such as schizophrenia, bipolar disorder and depression. Furthermore, the cerebral cortex and hippocampus regions of the brain are known to play critical roles in Alzheimer's disease, seizure disorders, and in the normal process of memory formation. Therefore, modulation of this gene and/or encoded protein is useful in the treatment of any of these diseases.

Panel 2D Summary: Ag431 Expression of this gene was highest in breast cancer (CT=32.3) and was not detected at significant levels in normal breast tissue. There was significant expression in number of breast cancer samples. Modulation of this gene and encoded protein is useful in the treatment of breast cancer.

Panel 4D Summary: Ag431 This gene was expressed in IFN-gamma-stimulated mucoepidermoid (mucus-producing) NCI-H292 cells, but not in resting NCI-H292 cells, or in IL-4-, IL-9-, or IL-13-stimulated NCI-H292 cells. The gene was also expressed at low but significant levels at the three-day time point in a two-way mixed lymphocyte reaction with cells from normal human donors. Thus, modulation of this gene, encoded protein and/or use of antibody or small molecule drug targeting this gene or gene product is useful int he treatment of inflammatory diseases such as colitis, chronic obstructive pulmonary disease, asthma, allergy and emphysema.

AC. CG5423601: Cysteinyl Leukotriene Receptor 2.

Expression of gene CG54236-01 was assessed using the primer-probe set Ag2695, described in Table ACA. Results of the RTQ-PCR runs are shown in Tables ACB, ACC, ACD, ACE and ACF.

TABLE ACAProbe Name Ag2695StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gggaaatgggttgtccatatat-3′222661274ProbeTET-5′-tcctgcagccttataagaagtccaca-3′-262921275TAMRAReverse5′-atctgaaatggccagatttagc-3′223351276

TABLE ACB

AI_comprehensive panel_v1.0

Column A - Rel. Exp. (%) Ag2695, Run 249247284

Column B - Rel. Exp. (%) Ag2695, Run 249259794

Tissue Name
A
B
Tissue Name
A
B

110967 COPD-F
7.1
2.5
112427 Match Control Psoriasis-F
54.0
53.2

110980 COPD-F
6.2
0.0
112418 Psoriasis-M
0.0
6.4

110968 COPD-M
6.9
7.9
112723 Match Control Psoriasis-
0.0
0.0

M

110977 COPD-M
12.3
15.2
112419 Psoriasis-M
12.5
12.5

110989 Emphysema-F
45.1
28.5
112424 Match Control Psoriasis-
19.5
11.0

M

110992 Emphysema-F
15.4
7.6
112420 Psoriasis-M
85.9
75.3

110993 Emphysema-F
11.9
4.8
112425 Match Control Psoriasis-
48.0
58.2

M

110994 Emphysema-F
2.5
0.0
104689 (MF) OA Bone-Backus
39.0
59.9

110995 Emphysema-F
12.9
38.4
104690 (MF) Adj “Normal” Bone-
21.8
27.7

Backus

110996 Emphysema-F
12.2
0.0
104691 (ME) OA Synovium-
77.4
68.3

Backus

110997 Asthma-M
4.2
3.2
104692 (BA) OA Cartilage-
0.0
0.0

Backus

111001 Asthma-F
46.3
25.2
104694 (BA) OA Bone-Backus
48.3
47.0

111002 Asthma-F
52.5
27.5
104695 (BA) Adj “Normal” Bone-
24.8
21.5

Backus

111003 Atopic Asthma-F
58.2
46.0
104696 (BA) OA Synovium-
81.8
49.7

Backus

111004 Atopic Asthma-F
42.3
53.2
104700 (SS) OA Bone-Backus
26.8
15.2

111005 Atopic Asthma-F
26.4
26.8
104701 (SS) Adj “Normal” Bone-
13.5
11.4

Backus

111006 Atopic Asthma-F
7.1
13.7
104702 (SS) OA Synovium-
62.0
49.0

Backus

111417 Allergy-M
20.0
18.8
117093 OA Cartilage Rep7
89.5
59.0

112347 Allergy-M
0.0
0.0
112672 OA Bone5
16.7
38.2

112349 Normal Lung-F
0.0
0.0
112673 OA Synovium5
15.7
11.3

112357 Normal Lung-F
34.4
28.9
112674 OA Synovial Fluid cells5
0.0
12.9

112354 Normal Lung-M
98.6
55.5
117100 OA Cartilage Rep14
7.6
6.1

112374 Crohns-F
5.6
7.2
112756 OA Bone9
22.5
7.9

112389 Match Control
11.0
5.2
112757 OA Synovium9
1.7
0.0

Crohns-F

112375 Crohns-F
7.8
2.5
112758 OA Synovial Fluid Cells9
6.7
20.4

112732 Match Control
43.5
18.6
117125 RA Cartilage Rep2
2.3
4.7

Crohns-F

112725 Crohns-M
3.2
0.0
113492 Bone2 RA
42.3
26.8

112387 Match Control
2.1
8.0
113493 Synovium2 RA
16.6
3.7

Crohns-M

112378 Crohns-M
0.0
0.0
113494 Syn Fluid Cells RA
31.2
23.0

112390 Match Control
28.1
32.5
113499 Cartilage4 RA
20.9
20.0

Crohns-M

112726 Crohns-M
23.2
25.3
113500 Bone4 RA
22.8
39.5

112731 Match Control
20.0
15.3
113501 Synovium4 RA
26.6
24.8

Crohns-M

112380 Ulcer Col-F
11.3
20.7
113502 Syn Fluid Cells4 RA
26.2
19.2

12734 Match Control Ulcer
82.9
43.2
113495 Cartilage3 RA
22.4
16.5

Col-F

112384 Ulcer Col-F
24.7
25.9
113496 Bone3 RA
13.0
18.4

112737 Match Control Ulcer
8.3
3.7
113497 Synovium3 RA
7.0
9.9

Col-F

112386 Ulcer Col-F
2.2
3.6
113498 Syn Fluid Cells3 RA
25.9
27.4

112738 Match Control Ulcer
10.5
4.1
117106 Normal Cartilage Rep20
6.9
1.9

Col-F

112381 Ulcer Col-M
1.5
0.0
113663 Bone3 Normal
0.0
0.0

112735 Match Control Ulcer
11.7
4.5
113664 Synovium3 Normal
0.0
0.0

Col-M

112382 Ulcer Col-M
25.5
16.6
113665 Syn Fluid Cells3 Normal
1.2
0.0

112394 Match Control Ulcer
1.3
2.9
117107 Normal Cartilage Rep22
12.9
0.0

Col-M

112383 Ulcer Col-M
12.2
11.7
113667 Bone4 Normal
50.7
45.4

112736 Match Control Ulcer
15.7
5.6
113668 Synovium4 Normal
50.0
64.6

Col-M

112423 Psoriasis-F
21.2
18.2
113669 Syn Fluid Cells4 Normal
100.0
100.0

TABLE ACC

CNS_neurodegeneration_v1.0

Column A - Rel. Exp. (%) Ag2695, Run 209751330

Column B - Rel. Exp. (%) Ag2695, Run 219966626

Tissue Name
A
B
Tissue Name
A
B

AD 1 Hippo
24.8
15.5
AH3 4624
100.0
47.6

AD 2 Hippo
37.6
34.4
AH3 4640
58.6
63.3

AD 3 Hippo
27.0
19.1
AD 1 Occipital Ctx
20.9
31.0

AD 4 Hippo
28.5
20.4
AD 2 Occipital Ctx
7.8
16.7

(Missing)

AD 5 Hippo
40.3
43.2
AD 3 Occipital Ctx
31.9
19.1

AD 6 Hippo
15.0
13.4
AD 4 Occipital Ctx
51.8
40.6

Control 2 Hippo
18.3
20.9
AD 5 Occipital Ctx
12.9
24.3

Control 4 Hippo
56.3
31.9
AD 5 Occipital Ctx
35.4
32.1

Control (Path)
43.2
20.9
Control 1
100.0
97.3

3 Hippo

Occipital Ctx

AD 1 Temporal Ctx
27.7
39.5
Control 2
44.1
37.9

Occipital Ctx

AD 2 Temporal Ctx
21.9
35.8
Control 3
50.0
49.0

Occipital Ctx

AD 3 Temporal Ctx
13.0
31.2
Control 4
62.9
22.8

Occipital Ctx

AD 4 Temporal Ctx
37.6
45.4
Control (Path) 1
35.6
41.8

Occipital Ctx

AD 5 Inf Temporal
32.3
44.1
Control (Path) 2
67.4
50.0

Ctx

Occipital Ctx

AD 5 Sup Temporal
31.4
26.6
Control (Path) 3
99.3
72.7

Ctx

Occipital Ctx

AD 6 Inf Temporal
16.8
15.3
Control (Path) 4
88.9
90.8

Ctx

Occipital Ctx

AD 6 Sup Temporal
18.2
18.0
Control 1
97.3
94.0

Ctx

Parietal Ctx

Control 1 Temporal
88.3
100.0
Control 2
30.4
27.0

Ctx

Parietal Ctx

Control 2 Temporal
36.3
36.1
Control 3
25.0
14.4

Ctx

Parietal Ctx

Control 3 Temporal
32.1
43.2
Control (Path) 1
46.3
33.4

Ctx

Parietal Ctx

Control 3 Temporal
32.3
62.4
Control (Path) 2
66.0
48.3

Ctx

Parietal Ctx

AH3 3975
48.6
45.4
Control (Path) 3
58.2
80.1

Parietal Ctx

AH3 3954
44.1
41.8
Control (Path) 4
52.5
54.0

Parietal Ctx

TABLE ACD

Panel 1.3D

Column A - Rel. Exp. (%) Ag2695, Run 153140732

Column B - Rel. Exp. (%) Ag2695, Run 153830081

Tissue Name
A
B
Tissue Name
A
B

Liver adenocarcinoma
0.0
0.0
Kidney (fetal)
0.0
3.9

Pancreas
2.1
4.2
Renal ca. 786-0
0.0
0.0

Pancreatic ca. CAPAN 2
0.0
0.0
Renal ca. A498
0.0
1.9

Adrenal gland
67.4
100.0
Renal ca. RXF 393
0.0
0.0

Thyroid
5.1
2.0
Renal ca. ACHN
0.0
0.0

Salivary gland
5.1
3.5
Renal ca. UO-31
0.0
0.0

Pituitary gland
1.0
4.9
Renal ca. TK-10
0.0
0.0

Brain (fetal)
3.5
0.0
Liver
1.5
3.9

Brain (whole)
20.3
16.0
Liver (fetal)
0.0
2.5

Brain (amygdala)
22.2
12.5
Liver ca. (hepatoblast) HepG2
0.0
0.0

Brain (cerebellum)
2.1
4.5
Lung
18.8
16.2

Brain (hippocampus)
61.1
35.1
Lung (fetal)
3.7
3.7

Brain (substantia nigra)
9.2
8.8
Lung ca. (small cell) LX-1
0.0
0.0

Brain (thalamus)
8.7
18.6
Lung ca. (small cell) NCI-H69
0.0
0.0

Cerebral Cortex
45.1
53.2
Lung ca. (s. cell var.) SHP-77
0.0
0.0

Spinal cord
11.3
8.0
Lung ca. (large cell) NCI-H460
0.0
0.0

glio/astro U87-MG
0.0
0.0
Lung ca. (non-sm. cell) A549
0.0
0.0

glio/astro U-118-MG
4.2
0.0
Lung ca. (non-s. cell) NCI-H23
0.0
1.8

astrocytoma SW1783
0.0
0.0
Lung ca. (non-s. cell) HOP-62
0.0
0.0

neuro*; met SK-N-AS
0.0
0.0
Lung ca. (non-s. cl) NCI-H522
0.0
0.0

astrocytoma SF-539
9.0
0.0
Lung ca. (squam.) SW 900
0.0
0.0

astrocytoma SNB-75
0.0
0.0
Lung ca. (squam.) NCI-H596
2.3
0.0

glioma SNB-19
0.0
2.9
Mammary gland
5.2
9.0

glioma U251
0.0
0.0
Breast ca.* (pl. ef) MCF-7
0.0
0.0

glioma SF-295
0.0
2.0
Breast ca.* (pl. ef) MDA-MB-
0.0
0.0

231

Heart (Fetal)
17.4
16.5
Breast ca.* (pl. ef) T47D
0.0
0.0

Heart
41.5
33.0
Breast ca. BT-549
0.0
0.0

Skeletal muscle (Fetal)
8.6
5.2
Breast ca. MDA-N
0.0
0.0

Skeletal muscle
0.0
0.0
Ovary
16.2
9.1

Bone marrow
3.5
11.7
Ovarian ca. OVCAR-3
0.0
0.0

Thymus
1.4
6.8
Ovarian ca. OVCAR-4
0.0
0.0

Spleen
100.0
59.0
Ovarian ca. OVCAR-5
0.0
0.0

Lymph node
32.3
26.8
Ovarian ca. OVCAR-8
0.0
0.0

Colorectal
17.9
20.2
Ovarian ca. IGROV-1
0.0
0.0

Stomach
9.5
0.0
Ovarian ca. (ascites) SK-OV-3
0.0
0.0

Small intestine
13.4
39.0
Uterus
6.5
4.3

Colon ca. SW480
0.0
0.0
Placenta
49.0
32.5

Colon ca.* SW620 (SW480 met)
0.0
0.0
Prostate
15.0
2.2

Colon ca. HT29
0.0
1.9
Prostate ca.* (bone met) PC-3
0.0
0.0

Colon ca. HCT-116
0.0
0.0
Testis
2.4
1.0

Colon ca. CaCo-2
0.0
0.0
Melanoma Hs688(A).T
0.0
0.0

CC Well to Mod Diff
11.0
3.4
Melanoma* (met) Hs688(B).T
0.0
0.0

(ODO3866)

Colon ca. HCC-2998
0.6
0.0
Melanoma UACC-62
0.0
0.0

Gastric ca. (liver met) NCI-N87
0.0
1.9
Melanoma M14
0.0
0.0

Bladder
0.0
2.4
Melanoma LOX IMVI
0.0
0.0

Trachea
4.2
0.0
Melanoma* (met) SK-MEL-5
14.0
4.3

Kidney
2.4
0.0
Adipose
15.5
16.7

TABLE ACE

Panel 2D

Column A - Rel. Exp. (%) Ag2695, Run 153140795

Column B - Rel. Exp. (%) Ag2695, Run 153789847

Tissue Name
A
B
Tissue Name
A
B

Normal Colon
3.8
3.3
Kidney Margin 8120608
1.4
0.5

CC Well to Mod Diff (ODO3866)
1.5
0.6
Kidney Cancer 8120613
0.1
0.1

CC Margin (ODO3866)
2.7
0.5
Kidney Margin 8120614
0.6
0.0

CC Gr.2 rectosigmoid (ODO3868)
0.1
0.2
Kidney Cancer 9010320
4.0
2.5

CC Margin (ODO3868)
0.9
0.3
Kidney Margin 9010321
0.4
1.1

CC Mod Diff (ODO3920)
0.6
0.2
Normal Uterus
0.4
0.3

CC Margin (ODO3920)
0.5
0.3
Uterine Cancer 064011
1.2
0.9

CC Gr.2 ascend colon (ODO3921)
3.2
2.2
Normal Thyroid
0.6
0.8

CC Margin (ODO3921)
0.8
0.6
Thyroid Cancer
7.3
5.7

CC from Partial Hepatectomy
1.6
2.0
Thyroid Cancer A302152
7.1
8.9

(ODO4309) Mets

Liver Margin (ODO4309)
1.3
1.5
Thyroid Margin A302153
1.3
1.1

Colon mets to lung (OD04451-01)
0.3
1.2
Normal Breast
1.1
1.8

Lung Margin (OD04451-02)
2.9
1.7
Breast Cancer
0.2
1.3

Normal Prostate 6546-1
2.0
0.8
Breast Cancer (OD04590-01)
2.2
2.0

Prostate Cancer (OD04410)
1.9
1.7
Breast Cancer Mets

(OD04590-03)
6.7
8.5

Prostate Margin (OD04410)
3.5
3.9
Breast Cancer Metastasis
2.7
2.7

Prostate Cancer (OD04720-01)
1.7
0.5
Breast Cancer
0.6
0.6

Prostate Margin (OD04720-02)
5.0
4.4
Breast Cancer
0.7
0.6

Normal Lung
6.9
7.8
Breast Cancer 9100266
0.1
0.3

Lung Met to Muscle (ODO4286)
2.2
2.0
Breast Margin 9100265
0.2
0.5

Muscle Margin (ODO4286)
0.3
0.5
Breast Cancer A209073
2.3
1.7

Lung Malignant Cancer
2.4
3.7
Breast Margin A209073
0.4
0.3

(OD03126)

Lung Margin (OD03126)
6.9
6.7
Normal Liver
0.6
0.2

Lung Cancer (OD04404)
5.5
2.1
Liver Cancer
0.8
0.0

Lung Margin (OD04404)
1.6
1.9
Liver Cancer 1025
0.2
0.2

Lung Cancer (OD04565)
0.6
0.5
Liver Cancer 1026
0.8
0.6

Lung Margin (OD04565)
1.0
2.0
Liver Cancer 6004-T
0.4
0.5

Lung Cancer (OD04237-01)
4.5
3.8
Liver Tissue 6004-N
0.9
0.3

Lung Margin (OD04237-02)
3.9
5.2
Liver Cancer 6005-T
0.2
0.2

Ocular Mel Met to Liver
0.0
0.2
Liver Tissue 6005-N
0.3
0.3

(ODO4310)

Liver Margin (ODO4310)
1.7
0.7
Normal Bladder
0.9
1.5

Melanoma Metastasis
100.0
100.0
Bladder Cancer
0.1
0.4

Lung Margin (OD04321)
7.3
6.5
Bladder Cancer
0.5
1.2

Normal Kidney
6.4
5.0
Bladder Cancer (OD04718-
1.8
1.2

01)

Kidney Ca, Nuclear grade 2
34.2
33.9
Bladder Normal Adjacent
2.2
1.9

(OD04338)

(OD04718-03)

Kidney Margin (OD04338)
5.2
5.6
Normal Ovary
0.6
0.2

Kidney Ca Nuclear grade 1/2
1.4
0.8
Ovarian Cancer
2.9
1.7

(OD04339)

Kidney Margin (OD04339)
0.9
2.0
Ovarian Cancer (OD04768-
14.4
10.8

07)

Kidney Ca, Clear cell type
8.5
10.3
Ovary Margin (OD04768-08)
1.4
1.0

(OD04340)

Kidney Margin (OD04340)
11.3
6.6
Normal Stomach
0.6
1.5

Kidney Ca, Nuclear grade 3
1.4
1.9
Gastric Cancer 9060358
0.5
0.7

(OD04348)

Kidney Margin (OD04348)
5.4
7.3
Stomach Margin 9060359
0.6
0.6

Kidney Cancer (OD04622-01)
49.0
63.7
Gastric Cancer 9060395
1.1
1.2

Kidney Margin (OD04622-03)
0.7
1.2
Stomach Margin 9060394
1.2
0.4

Kidney Cancer (OD04450-01)
1.4
1.4
Gastric Cancer 9060397
0.9
0.9

Kidney Margin (OD04450-03)
5.7
4.6
Stomach Margin 9060396
1.7
1.1

Kidney Cancer 8120607
0.2
0.0
Gastric Cancer 064005
3.0
2.6

TABLE ACF

Panel 4D

Column A - Rel. Exp. (%) Ag2695, Run 153140809

Column B - Rel. Exp. (%) Ag2695, Run 153766369

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
1.0
1.6
HUVEC IL-1beta
0.0
0.0

Secondary Th2 act
21.0
29.5
HUVEC IFN gamma
0.0
0.0

Secondary Tr1 act
5.0
10.8
HUVEC TNFalpha + IFN gamma
0.0
0.0

Secondary Th1 rest
0.6
3.8
HUVEC TNFalpha + IL4
0.0
0.0

Secondary Th2 rest
13.9
15.4
HUVEC IL-11
0.0
0.0

Secondary Tr1 rest
6.1
5.0
Lung Microvascular EC none
0.0
0.0

Primary Th1 act
0.0
2.6
Lung Microvascular EC TNFalpha +
0.0
0.0

IL-1beta

Primary Th2 act
39.0
54.3
Microvascular Dermal EC none
0.0
0.0

Primary Tr1 act
10.7
21.6
Microsvasular Dermal EC TNFalpha +
0.0
0.0

IL-1beta

Primary Th1 rest
21.0
24.7
Bronchial epithelium TNFalpha +
0.0
0.0

IL1beta

Primary Th2 rest
26.1
21.2
Small airway epithelium none
0.0
0.0

Primary Tr1 rest
11.7
19.1
Small airway epithelium TNFalpha +
0.0
0.0

IL-1beta

CD45RA CD4 lymphocyte
9.6
7.1
Coronery artery SMC rest
0.0
0.0

act

CD45RO CD4 lymphocyte
15.6
17.3
Coronery artery SMC TNFalpha +
0.0
0.0

act

IL-1beta

CD8 lymphocyte act
11.7
9.3
Astrocytes rest
0.0
0.5

Secondary CD8 lymphocyte
8.4
9.0
Astrocytes TNFalpha + IL-1beta
0.0
0.0

rest

Secondary CD8 lymphocyte
22.2
18.3
KU-812 (Basophil) rest
0.5
2.4

act

CD4 lymphocyte none
18.6
9.1
KU-812 (Basophil) PMA/ionomycin
2.9
1.7

2ry Th1/Th2/Tr1 anti-CD95
3.8
7.6
CCD1106 (Keratinocytes) none
0.0
0.7

CH11

LAK cells rest
43.2
32.5
CCD1106 (Keratinocytes) TNFalpha +
0.0
0.0

IL-1beta

LAK cells IL-2
15.9
18.0
Liver cirrhosis
4.8
6.3

LAK cells IL-2 + IL-12
32.3
30.8
Lupus kidney
0.6
0.0

LAK cells IL-2 + IFN
62.9
57.8
NCI-H292 none
0.0
0.0

gamma

LAK cells IL-2 + IL-18
39.2
52.1
NCI-H292 IL-4
0.0
0.0

LAK cells PMA/ionomycin
43.5
52.9
NCI-H292 IL-9
0.0
0.0

NK Cells IL-2 rest
37.4
35.6
NCI-H292 IL-13
0.0
0.0

Two Way MLR 3 day
26.1
23.0
NCI-H292 IFN gamma
0.0
0.0

Two Way MLR 5 day
17.0
10.7
HPAEC none
0.0
0.5

Two Way MLR 7 day
2.1
7.4
HPAEC TNFalpha + IL-1 beta
0.0
0.0

PBMC rest
19.9
28.3
Lung fibroblast none
0.0
0.0

PBMC PWM
28.3
31.4
Lung fibroblast TNFalpha + IL-1
0.0
0.0

beta

PBMC PHA-L
10.9
14.4
Lung fibroblast IL-4
0.0
0.0

Ramos (B cell) none
0.0
0.1
Lung fibroblast IL-9
0.0
0.0

Ramos (B cell) ionomycin
0.0
0.0
Lung fibroblast IL-13
0.0
0.0

B lymphocytes PWM
9.0
9.5
Lung fibroblast IFN gamma
0.0
0.0

B lymphocytes CD40L and
9.5
11.1
Dermal fibroblast CCD1070 rest
0.0
0.0

IL-4

EOL-1 dbcAMP
1.1
0.0
Dermal fibroblast CCD1070 TNF
17.1
20.3

alpha

EOL-1 dbcAMP
3.7
0.6
Dermal fibroblast CCD1070 IL-1
0.0
0.0

PMA/ionomycin

beta

Dendritic cells none
3.7
10.3
Dermal fibroblast IFN gamma
0.0
0.0

Dendritic cells LPS
6.1
8.1
Dermal fibroblast IL-4
1.1
0.0

Dendritic cells anti-CD40
4.9
3.6
IBD Colitis 2
1.1
0.0

Monocytes rest
100.0
100.0
IBD Crohn's
2.2
3.5

Monocytes LPS
0.0
0.3
Colon
21.5
15.6

Macrophages rest
0.6
3.7
Lung
17.6
14.4

Macrophages LPS
1.0
3.1
Thymus
11.8
7.1

HUVEC none
0.0
0.0
Kidney
33.7
20.3

HUVEC starved
0.0
0.0

AI_comprehensive panel_v1.0 Summary: Ag2695 The highest expression of this gene was detected in synovial fluid cells. Low expression of this gene is also seen in orthoarhritis bone, cartilage, synovium, RA bone, normal lung and a psoriasis sample. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of orthoarthritis, rheumatoid arthritis and psoriasis.

CNS_neurodegeneration_v1.0 Summary: Ag2695 This gene was down-regulated in the temporal cortex of Alzheimer's disease patients. Up-regulation of this gene or its protein product, or treatment with specific agonists for this protein encoded by this gene is useful in reversing the dementia/memory loss associated with this disease and neuronal death.

Panel 1.3D Summary: Ag2695 Highest expression of this gene was seen in adrenal gland and spleen (CTS=31.7). Significant expression of this gene is seen mainly in the normal tissues including brain, lymphnode, heart, gastrointestinal tract, lung, ovary, placenta and adipose tissue. Expression of this gene was low or undetectable in any of the cancer cell lines. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of cancer, metabolic and CNS disorders.

Panel 2D Summary: Ag2695 The expression of this gene was detected in metastatic melanoma (CTs=26-27.8). High to moderate expression of this gene was also seen in normal and cancer samples from colon, lung, prostate, liver, prostate, thyroid, uterus, breast, ovary and stomach. Expression of this gene is upregulated in ovarian, thyroid and kidney cancers compared to corresponding normal adjacent normal tissues. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of ovarian, thyroid and kidney cancers.

Panel 4D Summary: Ag2695 Highest expression of this gene was seen in resting monocytes (CT=29.6). This gene was expressed by T lymphocytes prepared under a number of conditions at moderate levels and is expressed at significant levels in treated and untreated dendritic cells, LAK cells, PBMC, activated B lymphocytes, activated dermal fibroblasts, liver cirrhosis sample and normal tissues represented by colon, lung, thymus and kidney. Dendritic cells are powerful antigen-presenting cells (APC) whose function is pivotal in the initiation and maintenance of normal immune responses. Autoimmunity and inflammation may also be reduced by suppression of this function. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of autoimmune and inflammatory diseases, such as lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.

AD. CG54479-05: Hepatocyte Growth Factor-Like Protein Precursor.

Expression of gene CG54479-05 was assessed using the primer-probe sets Ag3086 and Ag3797, described in Tables ADA and ADB. Results of the RTQ-PCR runs are shown in Tables ADC, ADD, ADE and ADF.

TABLE ADAProbe Name Ag3086StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ggaccccattcgactactgt-3′2012291277ProbeTET-5′-ctgatgaccagccgccatcaatc-3′-2312651278TAMRAReverse5′-ttctcaaactgcacctggtc-3′2013001279

TABLE ADB

Probe Name Ag3797

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-tctggacgacaactattgcc-3′
20
621
1280

Probe
TET-5′-atggtgctacactacggatccgcag-3′-
25
666
1281

TAMRA

Reverse
5′-gtcacagaattctcgctcga-3′
20
692
1282

TABLE ADC

General_screening_panel_v1.4

Column A - Rel. Exp.(%) Ag3797, Run 217309613

Tissue Name
A
Tissue Name
A

Adipose
1.4
Renal ca. TK-10
28.9

Melanoma*
0.4
Bladder
8.4

Hs688(A).T

Melanoma*
0.5
Gastric ca. (liver met.) NCI-N87
2.7

Hs688(B).T

Melanoma* M14
0.3
Gastric ca. KATO III
1.4

Melanoma* LOXIMVI
0.3
Colon ca. SW-948
1.0

Melanoma*
0.5
Colon ca. SW480
3.9

SK-MEL-5

Squamous cell
0.8
Colon ca.* (SW480 met) SW620
1.2

carcinoma SCC-4

Testis Pool
2.0
Colon ca. HT29
0.2

Prostate ca.* PC-3
1.5
Colon ca. HCT-116
4.3

(bone met)

Prostate Pool
1.8
Colon ca. CaCo-2
11.5

Placenta
1.7
Colon cancer tissue
2.8

Uterus Pool
0.5
Colon ca. SW1116
2.9

Ovarian ca. OVCAR-3
1.0
Colon ca. Colo-205
0.5

Ovarian ca. SK-OV-3
0.8
Colon ca. SW-48
0.2

Ovarian ca. OVCAR-4
0.3
Colon Pool
1.6

Ovarian ca. OVCAR-5
6.4
Small Intestine Pool
2.0

Ovarian ca. IGROV-1
4.6
Stomach Pool
1.9

Ovarian ca. OVCAR-8
2.9
Bone Marrow Pool
0.4

Ovary
1.9
Fetal Heart
0.8

Breast ca. MCF-7
2.3
Heart Pool
0.7

Breast ca.
2.2
Lymph Node Pool
1.7

MDA-MB-231

Breast ca. BT 549
3.0
Fetal Skeletal Muscle
0.7

Breast ca. T47D
18.6
Skeletal Muscle Pool
1.1

Breast ca. MDA-N
0.7
Spleen Pool
2.5

Breast Pool
1.5
Thymus Pool
2.4

Trachea
1.2
CNS cancer (glio/astro) U87-MG
2.7

Lung
0.4
CNS cancer (glio/astro) U-118-MG
3.1

Fetal Lung
2.3
CNS cancer (neuro; met) SK-N-AS
2.1

Lung ca. NCI-N417
0.2
CNS cancer (astro) SF-539
0.6

Lung ca. LX-1
3.3
CNS cancer (astro) SNB-75
1.8

Lung ca. NCI-H146
0.5
CNS cancer (glio) SNB-19
4.1

Lung ca. SHP-77
2.5
CNS cancer (glio) SF-295
2.1

Lung ca. A549
0.6
Brain (Amygdala) Pool
0.9

Lung ca. NCI-H526
0.6
Brain (cerebellum)
1.9

Lung ca. NCI-H23
3.7
Brain (fetal)
2.8

Lung ca. NCI-H460
0.9
Brain (Hippocampus) Pool
1.0

Lung ca. HOP-62
1.2
Cerebral Cortex Pool
0.7

Lung ca. NCI-H522
1.7
Brain (Substantia nigra) Pool
0.9

Liver
26.6
Brain (Thalamus) Pool
1.0

Fetal Liver
45.7
Brain (whole)
1.6

Liver ca. HepG2
100.0
Spinal Cord Pool
1.7

Kidney Pool
1.7
Adrenal Gland
3.1

Fetal Kidney
11.1
Pituitary gland Pool
1.7

Renal ca. 786-0
1.0
Salivary Gland
1.0

Renal ca. A498
0.3
Thyroid (female)
2.8

Renal ca. ACHN
1.4
Pancreatic ca. CAPAN2
0.8

Renal ca. UO-31
1.8
Pancreas Pool
7.5

TABLE ADD

Panel 1.3D

Column A - Rel. Exp.(%) Ag3086, Run 165552724

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
0.7
Kidney (fetal)
31.2

Pancreas
17.9
Renal ca. 786-0
0.2

Pancreatic ca.
0.6
Renal ca. A498
0.5

CAPAN 2

Adrenal gland
2.7
Renal ca. RXF 393
0.7

Thyroid
3.3
Renal ca. ACHN
0.8

Salivary gland
1.2
Renal ca. UO-31
0.4

Pituitary gland
3.6
Renal ca. TK-10
0.2

Brain (fetal)
3.2
Liver
94.6

Brain (whole)
3.4
Liver (fetal)
100.0

Brain (amygdala)
2.1
Liver ca. (hepatoblast) HepG2
58.6

Brain (cerebellum)
1.5
Lung
2.8

Brain (hippocampus)
3.0
Lung (fetal)
12.9

Brain (substantia
1.7
Lung ca. (small cell) LX-1
1.3

nigra)

Brain (thalamus)
3.1
Lung ca. (small cell) NCI-H69
0.2

Cerebral Cortex
0.9
Lung ca. (s. cell var.) SHP-77
1.2

Spinal cord
2.9
Lung ca. (large cell) NCI-H460
1.4

glio/astro U87-MG
0.7
Lung ca. (non-sm. cell) A549
0.2

glio/astro U-118-MG
0.9
Lung ca. (non-s. cell) NCI-H23
0.9

astrocytoma SW1783
0.4
Lung ca. (non-s. cell) HOP-62
0.5

neuro*; met SK-N-AS
0.7
Lung ca. (non-s. cl) NCI-H522
0.6

astrocytoma SF-539
0.5
Lung ca. (squam.) SW 900
0.4

astrocytoma SNB-75
1.2
Lung ca. (squam.) NCI-H596
0.5

glioma SNB-19
1.6
Mammary gland
3.1

glioma U251
2.4
Breast ca.* (pl.ef) MCF-7
0.7

glioma SF-295
0.7
Breast ca.* (pl.ef) MDA-MB-231
0.7

Heart (Fetal)
0.6
Breast ca.* (pl.ef) T47D
2.7

Heart
0.5
Breast ca. BT-549
0.7

Skeletal muscle (Fetal)
0.2
Breast ca. MDA-N
0.1

Skeletal muscle
1.4
Ovary
0.4

Bone marrow
2.0
Ovarian ca. OVCAR-3
0.6

Thymus
1.2
Ovarian ca. OVCAR-4
0.4

Spleen
4.0
Ovarian ca. OVCAR-5
0.4

Lymph node
3.1
Ovarian ca. OVCAR-8
0.7

Colorectal
1.6
Ovarian ca. IGROV-1
0.7

Stomach
10.3
Ovarian ca. (ascites) SK-OV-3
0.1

Small intestine
29.7
Uterus
3.3

Colon ca. SW480
0.7
Placenta
4.6

Colon ca.* SW620
0.2
Prostate
2.1

(SW480 met)

Colon ca. HT29
0.2
Prostate ca.* (bone met) PC-3
0.9

Colon ca. HCT-116
1.2
Testis
12.5

Colon ca. CaCo-2
2.4
Melanoma Hs688(A).T
0.1

CC Well to Mod Diff
2.1
Melanoma* (met) Hs688(B).T
0.2

(ODO3866)

Colon ca. HCC-2998
1.4
Melanoma UACC-62
0.4

Gastric ca. (liver met)
1.8
Melanoma M14
0.8

NCI-N87

Bladder
4.5
Melanoma LOX IMVI
0.0

Trachea
2.6
Melanoma* (met) SK-MEL-5
0.4

Kidney
26.1
Adipose
2.2

TABLE ADE

Panel 2.2

Column A - Rel. Exp.(%) Ag3086, Run 174268933

Tissue Name
A
Tissue Name
A

Normal Colon
1.4
Kidney Margin (OD04348)
40.9

Colon cancer (OD06064)
0.1
Kidney malignant cancer
0.4

(OD06204B)

Colon Margin (OD06064)
0.0
Kidney normal adjacent tissue
5.1

(OD06204E)

Colon cancer (OD06159)
0.1
Kidney Cancer (OD04450-01)
5.8

Colon Margin (OD06159)
1.4
Kidney Margin (OD04450-03)
15.0

Colon cancer (OD06297-04)
0.0
Kidney Cancer 8120613
0.2

Colon Margin (OD06297-05)
1.1
Kidney Margin 8120614
6.0

CC Gr.2 ascend colon (ODO3921)
0.4
Kidney Cancer 9010320
0.4

CC Margin (ODO3921)
0.2
Kidney Margin 9010321
1.5

Colon cancer metastasis (OD06104)
0.1
Kidney Cancer 8120607
0.1

Lung Margin (OD06104)
0.6
Kidney Margin 8120608
3.5

Colon mets to lung (OD04451-01)
1.3
Normal Uterus
0.2

Lung Margin (OD04451-02)
0.4
Uterine Cancer 064011
0.1

Normal Prostate
0.6
Normal Thyroid
0.5

Prostate Cancer (OD04410)
0.2
Thyroid Cancer
0.3

Prostate Margin (OD04410)
0.5
Thyroid Cancer A302152
2.1

Normal Ovary
0.4
Thyroid Margin A302153
0.4

Ovarian cancer (OD06283-03)
0.2
Normal Breast
0.7

Ovarian Margin (OD06283-07)
1.2
Breast Cancer
2.3

Ovarian Cancer
1.5
Breast Cancer
1.9

Ovarian cancer (OD06145)
0.9
Breast Cancer (OD04590-01)
5.1

Ovarian Margin (OD06145)
1.8
Breast Cancer Mets (OD04590-03)
1.3

Ovarian cancer (OD06455-03)
0.6
Breast Cancer Metastasis
0.7

Ovarian Margin (OD06455-07)
0.2
Breast Cancer
0.5

Normal Lung
0.8
Breast Cancer 9100266
0.2

Invasive poor diff. lung adeno
0.3
Breast Margin 9100265
0.5

(ODO4945-01

Lung Margin (ODO4945-03)
1.1
Breast Cancer A209073
0.2

Lung Malignant Cancer (OD03126)
1.6
Breast Margin A209073
1.4

Lung Margin (OD03126)
0.3
Breast cancer (OD06083)
0.7

Lung Cancer (OD05014A)
0.5
Breast cancer node metastasis
0.2

(OD06083)

Lung Margin (OD05014B)
0.6
Normal Liver
28.7

Lung cancer (OD06081)
0.5
Liver Cancer 1026
7.5

Lung Margin (OD06081)
1.2
Liver Cancer 1025
45.1

Lung Cancer (OD04237-01)
0.3
Liver Cancer 6004-T
35.8

Lung Margin (OD04237-02)
1.1
Liver Tissue 6004-N
5.1

Ocular Mel Met to Liver (ODO4310)
0.2
Liver Cancer 6005-T
14.8

Liver Margin (ODO4310)
21.6
Liver Tissue 6005-N
65.1

Melanoma Metastasis
0.2
Liver Cancer
100.0

Lung Margin (OD04321)
0.2
Normal Bladder
2.8

Normal Kidney
5.6
Bladder Cancer
0.2

Kidney Ca, Nuclear grade 2
20.6
Bladder Cancer
0.7

(OD04338)

Kidney Margin (OD04338)
4.5
Normal Stomach
2.5

Kidney Ca Nuclear grade ½
6.6
Gastric Cancer 9060397
0.0

(OD04339)

Kidney Margin (OD04339)
6.0
Stomach Margin 9060396
0.1

Kidney Ca, Clear cell type (OD04340)
0.4
Gastric Cancer 9060395
0.1

Kidney Margin (OD04340)
8.8
Stomach Margin 9060394
0.3

Kidney Ca, Nuclear grade 3
0.3
Gastric Cancer 064005
2.8

(OD04348)

TABLE ADF

Panel 4.1D

Column A - Rel. Exp. (%) Ag3797, Run 170132421

Column B - Rel. Exp. (%) Ag3797, Run 170275745

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
8.9
1.3
HUVEC IL-1beta
2.4
0.1

Secondary Th2 act
2.6
1.3
HUVEC IFN gamma
2.6
1.2

Secondary Tr1 act
3.1
0.9
HUVEC TNFalpha + IFN gamma
0.0
0.3

Secondary Th1 rest
1.5
1.6
HUVEC TNFalpha + IL4
1.6
0.4

Secondary Th2 rest
3.3
0.7
HUVEC IL-11
2.2
0.4

Secondary Tr1 rest
3.4
0.9
Lung Microvascular EC none
1.8
0.9

Primary Th1 act
3.2
0.3
Lung Microvascular EC TNFalpha +
2.2
0.3

IL-1beta

Primary Th2 act
2.0
1.1
Microvascular Dermal EC none
1.4
0.5

Primary Tr1 act
2.7
1.0
Microsvasular Dermal EC TNFalpha +
2.2
0.3

IL-1beta

Primary Th1 rest
3.2
0.4
Bronchial epithelium TNFalpha +
17.8
0.5

IL1beta

Primary Th2 rest
4.5
0.0
Small airway epithelium none
1.5
0.2

Primary Tr1 rest
2.3
0.7
Small airway epithelium TNFalpha +
3.0
0.6

IL-1beta

CD45RA CD4 lymphocyte
2.0
0.7
Coronery artery SMC rest
1.1
0.6

act

CD45RO CD4 lymphocyte
1.8
2.0
Coronery artery SMC TNFalpha + IL-
1.9
0.8

act

1beta

CD8 lymphocyte act
5.6
0.9
Astrocytes rest
2.5
1.5

Secondary CD8 lymphocyte
4.6
1.1
Astrocytes TNFalpha + IL-1beta
0.5
1.2

rest

Secondary CD8 lymphocyte
1.8
0.2
KU-812 (Basophil) rest
4.3
0.8

act

CD4 lymphocyte none
7.2
1.3
KU-812 (Basophil) PMA/ionomycin
3.0
0.6

2ry Th1/Th2/Trl anti-CD95
6.6
1.1
CCD1106 (Keratinocytes) none
1.6
0.9

CH11

LAK cells rest
7.6
0.4
CCD1106 (Keratinocytes) TNFalpha +
2.4
0.0

IL-1beta

LAK cells IL-2
4.8
0.3
Liver cirrhosis
76.8
9.8

LAK cells IL-2 + IL-12
5.7
0.8
NCI-H292 none
5.4
4.1

LAK cells IL-2 + IFN gamma
5.5
0.2
NCI-H292 IL-4
10.3
0.6

LAK cells IL-2 + IL-18
1.6
0.4
NCI-H292 IL-9
16.5
1.3

LAK cells PMA/ionomycin
2.7
1.3
NCI-H292 IL-13
8.5
3.6

NK Cells IL-2 rest
5.6
2.0
NCI-H292 IFN gamma
5.8
3.4

Two Way MLR 3 day
4.9
2.0
HPAEC none
1.2
1.0

Two Way MLR 5 day
0.5
0.8
HPAEC TNFalpha + IL-1 beta
1.5
0.3

Two Way MLR 7 day
6.0
0.2
Lung fibroblast none
2.5
0.8

PBMC rest
1.3
0.4
Lung fibroblast TNFalpha + IL-1 beta
5.7
0.9

PBMC PWM
7.9
0.5
Lung fibroblast IL-4
2.9
0.4

PBMC PHA-L
5.1
0.5
Lung fibroblast IL-9
2.5
0.4

Ramos (B cell) none
5.7
0.6
Lung fibroblast IL-13
2.7
1.9

Ramos (B cell) ionomycin
4.4
0.3
Lung fibroblast IFN gamma
0.0
2.2

B lymphocytes PWM
1.1
0.2
Dermal fibroblast CCD1070 rest
6.1
3.4

B lymphocytes CD40L and
4.3
0.6
Dermal fibroblast CCD1070 TNF
2.1
3.8

IL-4

alpha

EOL-1 dbcAMP
8.4
3.5
Dermal fibroblast CCD1070 IL-1 beta
4.0
1.5

EOL-1 dbcAMP
7.2
5.1
Dermal fibroblast IFN gamma
1.6
0.9

PMA/ionomycin

Dendritic cells none
3.4
1.0
Dermal fibroblast IL-4
1.4
1.3

Dendritic cells LPS
5.5
0.5
Dermal Fibroblasts rest
2.3
1.5

Dendritic cells anti-CD40
2.6
0.3
Neutrophils TNFa + LPS
0.0
1.7

Monocytes rest
1.1
0.9
Neutrophils rest
0.8
0.6

Monocytes LPS
2.6
0.3
Colon
21.6
6.7

Macrophages rest
5.2
0.2
Lung
3.7
10.6

Macrophages LPS
1.4
0.3
Thymus
11.7
27.0

HUVEC none
1.2
0.2
Kidney
100.0
100.0

HUVEC starved
3.4
0.2

General_screening_panel_v1.4 Summary: Ag3797 Highest expression of this gene was detected in liver cancer HepG2 cell line (CT=25.3). High expression of this gene was also seen in fetal and adult liver. Therapeutic modulation of this gene is useful in the treatment of liver related disorders.

Moderate levels of expression of this gene was also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene is useful as a marker to detect these cancers. Therapeutic modulation of this gene, encoded protein and/or use of antibodies or small molecule targeting this gene or gene product is useful in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

Among tissues with metabolic or endocrine function, this gene was expressed at moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

In addition, this gene is expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene, encoded protein and/or use of antibodies or small molecule targeting this gene or gene product is useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

Panel 1.3D Summary: Ag3086 This gene was highly expressed in both fetal and adult liver tissue (CTs=26) and liver cancer cell lines (CT=27). The gene was also expressed at moderate to low levels in most of the other tissues in the panel. Therapeutic modulation of this gene is useful in the treatment of liver related disorders.

In tissues involved in the central nervous system, this gene was moderately expressed in the fetal and adult brain, including the adult thalamus, substantia nigra, hippocampus, amygdala and is also expressed at low but significant levels in the cerebellum and cerebral cortex. This expression profile suggests that this gene has functional significance in the CNS. This gene codes for a homolog of hepatocyte growth factor, which has numerous therapeutic applications in the CNS, including prevention of neuronal death in animal models of stroke and ischemia. Hepatocyte growth factor has mitogenic activity and thus has potential application as a protein therapeutic to treat brain pathologies when administered directly to the cortico spinal fluid or systemically when the blood brain barrier is disrupted. Hepatocyte growth factor-like protein is a neurotrophic factor useful in the prevention of motoneuron atrophy upon axotomy. Therefore, this gene, expressed protein and/or use of antibodies or small molecule targeting this gene or gene product is useful as a therapeutic agent in treating stroke and neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The potential role of the this gene or its protein product in brain plasticity and regeneration affords utility in treating brain damage and aging related disorders, such as memory impairment that has hippocampal dysfunction as its primary focus.

Panel 2.2 Summary: Ag3086 The expression of this gene was highest in a sample derived from a liver cancer specimen (CT=26) and was expressed at significant levels in a number of samples derived from liver tissue. There was significant expression of this gene associated with normal kidney tissue (CT=27.2) relative to adjacent kidney cancer specimens therapeutic modulation of this gene, encoded protein and/or use of antibodies or small molecule targeting this gene or gene product is useful in the treatment of kidney cancer.

Panel 4.1D Summary: Ag3797 Highest expression of this gene was detected in kidney (CTs=27.4-29). Moderate levels of expression of this gene was also seen in liver cirrhosis sample. This gene was expressed at moderate to low levels in a wide range of cell types of significance in the immune response in health and disease. These cells included members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression indicates that this gene is involved in homeostatic processes for these and other cell types and tissues. Therefore, modulation of this gene, encoded protein and/or use of antibodies or small molecule targeting this gene or gene product is useful in the treatment autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

AE. CG54479-06: Macrophage Stimulatory Protein.

Expression of gene CG54479-06 was assessed using the primer-probe set Ag6711, described in Table AEA. Results of the RTQ-PCR runs are shown in Table AEB.

TABLE AEAProbe Name Ag6711StartSEQ IDPrimersSequencesLengthPositionNoForward5′-accaagtgtgagggtgacta-3′2018611283ProbeTET-5′-tcctggaaggaattataatccccaacc-27191912843′-TAMRAReverse5′-ccagtccacaaacacagaga-3′2019881285

TABLE AEB

General_screening_panel_v1.6

Column A - Rel. Exp.(%) Ag6711, Run 277261482

Tissue Name
A
Tissue Name
A

Adipose
3.5
Renal ca. TK-10
60.7

Melanoma*
1.8
Bladder
11.4

Hs688(A).T

Melanoma*
4.2
Gastric ca. (liver met.) NCI-N87
5.6

Hs688(B).T

Melanoma* M14
1.1
Gastric ca. KATO III
1.4

Melanoma* LOXIMVI
0.7
Colon ca. SW-948
0.9

Melanoma*
3.3
Colon ca. SW480
12.7

SK-MEL-5

Squamous cell
0.5
Colon ca.* (SW480 met) SW620
3.4

carcinoma SCC-4

Testis Pool
4.3
Colon ca. HT29
0.3

Prostate ca.*
2.6
Colon ca. HCT-116
0.5

(bone met) PC-3

Prostate Pool
1.1
Colon ca. CaCo-2
28.7

Placenta
1.4
Colon cancer tissue
9.4

Uterus Pool
0.8
Colon ca. SW1116
4.4

Ovarian ca. OVCAR-3
5.1
Colon ca. Colo-205
0.0

Ovarian ca. SK-OV-3
1.0
Colon ca. SW-48
1.0

Ovarian ca. OVCAR-4
0.5
Colon Pool
3.0

Ovarian ca. OVCAR-5
10.2
Small Intestine Pool
2.1

Ovarian ca. IGROV-1
12.9
Stomach Pool
4.6

Ovarian ca. OVCAR-8
8.3
Bone Marrow Pool
4.1

Ovary
3.8
Fetal Heart
1.1

Breast ca. MCF-7
3.5
Heart Pool
1.2

Breast ca.
1.9
Lymph Node Pool
4.7

MDA-MB-231

Breast ca. BT 549
2.9
Fetal Skeletal Muscle
2.5

Breast ca. T47D
0.0
Skeletal Muscle Pool
1.0

Breast ca. MDA-N
0.3
Spleen Pool
2.4

Breast Pool
6.0
Thymus Pool
7.9

Trachea
1.5
CNS cancer (glio/astro) U87-MG
4.8

Lung
12.9
CNS cancer (glio/astro) U-118-MG
4.6

Fetal Lung
3.5
CNS cancer (neuro; met) SK-N-AS
3.3

Lung ca. NCI-N417
0.0
CNS cancer (astro) SF-539
1.3

Lung ca. LX-1
7.2
CNS cancer (astro) SNB-75
1.7

Lung ca. NCI-H146
1.7
CNS cancer (glio) SNB-19
7.7

Lung ca. SHP-77
6.3
CNS cancer (glio) SF-295
8.1

Lung ca. A549
1.8
Brain (Amygdala) Pool
1.2

Lung ca. NCI-H526
0.0
Brain (cerebellum)
6.9

Lung ca. NCI-H23
11.3
Brain (fetal)
4.1

Lung ca. NCI-H460
5.9
Brain (Hippocampus) Pool
1.5

Lung ca. HOP-62
3.8
Cerebral Cortex Pool
1.2

Lung ca. NCI-H522
8.3
Brain (Substantia nigra) Pool
2.2

Liver
18.8
Brain (Thalamus) Pool
3.9

Fetal Liver
28.7
Brain (whole)
5.4

Liver ca. HepG2
100.0
Spinal Cord Pool
4.4

Kidney Pool
7.3
Adrenal Gland
2.6

Fetal Kidney
7.7
Pituitary gland Pool
2.7

Renal ca. 786-0
4.4
Salivary Gland
0.3

Renal ca. A498
0.6
Thyroid (female)
4.0

Renal ca. ACHN
3.8
Pancreatic ca. CAPAN2
1.4

Renal ca. UO-31
8.8
Pancreas Pool
1.9

General_screening_panel_v1.6 Summary: Ag6711 Highest expression of this gene was detected in a liver cancer HepG2 cell line (CT=30.6). Significant expression of this gene was also seen in number of cancer cell lines derived from ovarian, lung, renal, colon and brain cancers. Thus, expression levels of this gene is useful as a marker to detect these cancers. Therapeutic modulation of this gene, encoded protein and/or use of antibodies or small molecule targeting this gene or gene product is useful in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

Moderate levels of expression of this gene was also seen in fetal and adult liver. Therapeutic modulation of this gene is useful in the treatment of liver related disorders such as obesity, liver cirrhosis and other liver inflammatory diseases.

AF. CG54539-02: Zinc Transporter 1.

Expression of gene CG54539-02 was assessed using the primer-probe set Ag1160, described in Table AFA. Results of the RTQ-PCR runs are shown in Tables AFB, AFC and AFD. CG54539-02 represents a full length physical clone.

TABLE AFAProbe Name Ag1160StartSEQ IDPrimersSequencesLengthPositionNoForward5′-atacatggaggtggctaaaacc-3′2211861286ProbeTET-5′-tcataatcacggaattcacgctactacca-29122212873′-TAMRAReverse5′-acactagcaaattcaggctgaa-3′2212511288

TABLE AFB

General_screening_panel_v1.4

Column A - Rel. Exp.(%) Ag1160, Run 214691191

Tissue Name
A
Tissue Name
A

Adipose
46.0
Renal ca. TK-10
35.4

Melanoma*
31.2
Bladder
35.4

Hs688(A).T

Melanoma*
30.6
Gastric ca. (liver met.) NCI-N87
32.1

Hs688(B).T

Melanoma* M14
23.0
Gastric ca. KATO III
31.2

Melanoma* LOXIMVI
14.1
Colon ca. SW-948
8.8

Melanoma*
15.9
Colon ca. SW480
17.6

SK-MEL-5

Squamous Cell
16.5
Colon ca.* (SW480 met) SW620
18.0

carcinoma SCC-4

Testis Pool
62.4
Colon ca. HT29
8.5

Prostate ca.*
13.9
Colon ca. HCT-116
16.0

(bone met) PC-3

Prostate Pool
4.5
Colon ca. CaCo-2
38.4

Placenta
5.3
Colon cancer tissue
18.6

Uterus Pool
5.1
Colon ca. SW1116
4.7

Ovarian ca. OVCAR-3
42.6
Colon ca. Colo-205
11.5

Ovarian ca. SK-OV-3
80.1
Colon ca. SW-48
12.6

Ovarian ca. OVCAR-4
8.5
Colon Pool
17.8

Ovarian ca. OVCAR-5
36.9
Small Intestine Pool
9.3

Ovarian ca. IGROV-1
15.4
Stomach Pool
9.7

Ovarian ca. OVCAR-8
4.3
Bone Marrow Pool
6.8

Ovary
9.9
Fetal Heart
7.3

Breast ca. MCF-7
37.4
Heart Pool
5.2

Breast ca.
32.1
Lymph Node Pool
17.0

MDA-MB-231

Breast ca. BT 549
12.7
Fetal Skeletal Muscle
3.2

Breast ca. T47D
66.0
Skeletal Muscle Pool
1.8

Breast ca. MDA-N
15.3
Spleen Pool
100.0

Breast Pool
13.5
Thymus Pool
7.1

Trachea
8.5
CNS cancer (glio/astro) U87-MG
29.3

Lung
6.2
CNS cancer (glio/astro) U-118-MG
41.8

Fetal Lung
78.5
CNS cancer (neuro; met) SK-N-AS
28.5

Lung ca. NCI-N417
4.7
CNS cancer (astro) SF-539
7.0

Lung ca. LX-1
29.1
CNS cancer (astro) SNB-75
14.3

Lung ca. NCI-H146
1.7
CNS cancer (glio) SNB-19
15.1

Lung ca. SHP-77
8.8
CNS cancer (glio) SF-295
14.2

Lung ca. A549
26.4
Brain (Amygdala) Pool
4.8

Lung ca. NCI-H526
4.0
Brain (cerebellum)
5.1

Lung ca. NCI-H23
12.8
Brain (fetal)
7.4

Lung ca. NCI-H460
19.9
Brain (Hippocampus) Pool
7.3

Lung ca. HOP-62
10.9
Cerebral Cortex Pool
13.0

Lung ca. NCI-H522
3.8
Brain (Substantia nigra) Pool
7.1

Liver
3.4
Brain (Thalamus) Pool
9.6

Fetal Liver
70.2
Brain (whole)
9.1

Liver ca. HepG2
30.4
Spinal Cord Pool
5.9

Kidney Pool
17.6
Adrenal Gland
24.7

Fetal Kidney
8.0
Pituitary gland Pool
2.7

Renal ca. 786-0
20.9
Salivary Gland
3.7

Renal ca. A498
20.7
Thyroid (female)
9.3

Renal ca. ACHN
29.9
Pancreatic ca. CAPAN2
46.7

Renal ca. UO-31
17.6
Pancreas Pool
17.4

TABLE AFC

Panel 2D

Column A - Rel. Exp.(%) Ag1160, Run 164339479

Tissue Name
A
Tissue Name
A

Normal Colon
63.3
Kidney Margin 8120608
18.3

CC Well to Mod Diff (ODO3866)
17.0
Kidney Cancer 8120613
3.9

CC Margin (ODO3866)
8.9
Kidney Margin 8120614
10.6

CC Gr.2 rectosigmoid (ODO3868)
7.8
Kidney Cancer 9010320
13.9

CC Margin (ODO3868)
2.0
Kidney Margin 9010321
20.7

CC Mod Diff (ODO3920)
9.8
Normal Uterus
8.2

CC Margin (ODO3920)
15.2
Uterine Cancer 064011
33.2

CC Gr.2 ascend colon (ODO3921)
28.9
Normal Thyroid
9.0

CC Margin (ODO3921)
6.4
Thyroid Cancer
52.9

CC from Partial Hepatectomy
51.8
Thyroid Cancer A302152
20.7

(ODO4309) Mets

Liver Margin (ODO4309)
65.5
Thyroid Margin A302153
33.0

Colon mets to lung (OD04451-01)
8.4
Normal Breast
13.1

Lung Margin (OD04451-02)
13.5
Breast Cancer
19.5

Normal Prostate 6546-1
26.8
Breast Cancer (OD04590-01)
29.7

Prostate Cancer (OD04410)
18.7
Breast Cancer Mets (OD04590-03)
27.0

Prostate Margin (OD04410)
15.1
Breast Cancer Metastasis
30.8

Prostate Cancer (OD04720-01)
17.2
Breast Cancer
16.2

Prostate Margin (OD04720-02)
18.3
Breast Cancer
15.0

Normal Lung
34.9
Breast Cancer 9100266
48.3

Lung Met to Muscle (ODO4286)
39.0
Breast Margin 9100265
15.5

Muscle Margin (ODO4286)
8.1
Breast Cancer A209073
36.3

Lung Malignant Cancer (OD03126)
28.5
Breast Margin A209073
11.5

Lung Margin (OD03126)
19.5
Normal Liver
39.0

Lung Cancer (OD04404)
20.0
Liver Cancer
14.6

Lung Margin (OD04404)
11.9
Liver Cancer 1025
18.8

Lung Cancer (OD04565)
13.8
Liver Cancer 1026
11.0

Lung Margin (OD04565)
3.9
Liver Cancer 6004-T
35.1

Lung Cancer (OD04237-01)
17.8
Liver Tissue 6004-N
13.1

Lung Margin (OD04237-02)
33.0
Liver Cancer 6005-T
12.7

Ocular Mel Met to Liver (ODO4310)
5.8
Liver Tissue 6005-N
8.0

Liver Margin (ODO4310)
100.0
Normal Bladder
33.4

Melanoma Metastasis
7.3
Bladder Cancer
7.0

Lung Margin (OD04321)
13.8
Bladder Cancer
11.5

Normal Kidney
37.4
Bladder Cancer (OD04718-01)
38.7

Kidney Ca, Nuclear grade 2 (OD04338)
46.0
Bladder Normal Adjacent
17.3

(OD04718-03)

Kidney Margin (OD04338)
18.8
Normal Ovary
4.6

Kidney Ca Nuclear grade ½ (OD04339)
17.3
Ovarian Cancer
33.7

Kidney Margin (OD04339)
71.2
Ovarian Cancer (OD04768-07)
28.3

Kidney Ca, Clear cell type (OD04340)
69.3
Ovary Margin (OD04768-08)
5.7

Kidney Margin (OD04340)
23.3
Normal Stomach
19.5

Kidney Ca, Nuclear grade 3 (OD04348)
9.8
Gastric Cancer 9060358
4.5

Kidney Margin (OD04348)
32.8
Stomach Margin 9060359
18.6

Kidney Cancer (OD04622-01)
10.5
Gastric Cancer 9060395
34.2

Kidney Margin (OD04622-03)
5.4
Stomach Margin 9060394
13.9

Kidney Cancer (OD04450-01)
27.7
Gastric Cancer 9060397
48.6

Kidney Margin (OD04450-03)
20.4
Stomach Margin 9060396
3.4

Kidney Cancer 8120607
6.2
Gastric Cancer 064005
30.6

TABLE AFD

Panel 4D

Column A - Rel. Exp.(%) Ag1160, Run 140155352

Tissue Name
A
Tissue Name
A

Secondary Th1 act
14.0
HUVEC IL-1beta
9.7

Secondary Th2 act
24.0
HUVEC IFN gamma
15.5

Secondary Tr1 act
18.7
HUVEC TNF alpha + IFN gamma
1.9

Secondary Th1 rest
2.3
HUVEC TNF alpha + IL4
7.0

Secondary Th2 rest
4.3
HUVEC IL-11
5.8

Secondary Tr1 rest
2.8
Lung Microvascular EC none
16.6

Primary Th1 act
21.3
Lung Microvascular EC TNFalpha + IL-
7.1

1beta

Primary Th2 act
20.6
Microvascular Dermal EC none
58.6

Primary Tr1 act
31.4
Microsvasular Dermal EC TNFalpha + IL-
16.8

1beta

Primary Th1 rest
16.4
Bronchial epithelium TNFalpha + IL1beta
40.3

Primary Th2 rest
10.3
Small airway epithelium none
14.6

Primary Tr1 rest
14.2
Small airway epithelium TNFalpha + IL-
92.0

1beta

CD45RA CD4 lymphocyte act
13.3
Coronery artery SMC rest
22.1

CD45RO CD4 lymphocyte act
11.7
Coronery artery SMC TNFalpha + IL-1beta
7.5

CD8 lymphocyte act
6.8
Astrocytes rest
8.0

Secondary CD8 lymphocyte
5.9
Astrocytes TNFalpha + IL-1beta
16.7

rest

Secondary CD8 lymphocyte act
10.5
KU-812 (Basophil) rest
18.3

CD4 lymphocyte none
11.4
KU-812 (Basophil) PMA/ionomycm
69.3

2ry Th1/Th2/Tr1 anti-CD95
11.5
CCD1106 (Keratinocytes) none
13.7

CH11

LAK cells rest
66.0
93580 CCD1106 (Keratinocytes) TNFa and
56.6

IFNg

LAK cells IL-2
13.8
Liver cirrhosis
7.6

LAK cells IL-2 + IL-12
24.0
Lupus kidney
4.5

LAK cells IL-2 + IFN gamma
24.5
NCI-H292 none
37.9

LAK cells IL-2 + IL-18
20.7
NCI-H292 IL-4
51.8

LAK cells PMA/ionomycin
14.1
NCI-H292 IL-9
48.0

NK Cells IL-2 rest
5.9
NCI-H292 IL-13
26.2

Two Way MLR 3 day
35.6
NCI-H292 IFN gamma
27.9

Two Way MLR 5 day
23.2
HPAEC none
14.0

Two Way MLR 7 day
7.7
HPAEC TNF alpha + IL-1 beta
7.3

PBMC rest
7.4
Lung fibroblast none
14.7

PBMC PWM
100.0
Lung fibroblast TNF alpha + IL-1 beta
9.9

PBMC PHA-L
31.6
Lung fibroblast IL-4
36.1

Ramos (B cell) none
29.5
Lung fibroblast IL-9
27.9

Ramos (B cell) ionomycin
47.0
Lung fibroblast IL-13
65.1

B lymphocytes PWM
36.6
Lung fibroblast IFN gamma
66.9

B lymphocytes CD40L and IL-
8.5
Dermal fibroblast CCD1070 rest
38.2

4

EOL-1 dbcAMP
4.7
Dermal fibroblast CCD1070 TNF alpha
50.3

EOL-1 dbcAMP
15.8
Dermal fibroblast CCD1070 IL-1 beta
27.2

PMA/ionomycin

Dendritic cells none
30.1
Dermal fibroblast IFN gamma
7.6

Dendritic cells LPS
34.4
Dermal fibroblast IL-4
16.0

Dendritic cells anti-CD40
39.5
IBD Colitis 2
1.1

Monocytes rest
26.1
IBD Crohn's
3.5

Monocytes LPS
88.9
Colon
38.7

Macrophages rest
96.6
Lung
24.1

Macrophages LPS
68.8
Thymus
94.0

HUVEC none
15.9
Kidney
10.2

HUVEC starved
26.6

General_screening_panel_v1.4 Summary: Ag1160 Highest expression was detected in spleen (CT=27). This gene was widely expressed in this panel, demonstrating a role for this gene product in cell survival and proliferation. Moderate expression was also seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. Modulation of this gene product is useful in the treatment of these cancers.

Among tissues with metabolic function, this gene was expressed at moderte to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues shows that this gene product plays a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene contributes to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

This gene was expressed at much higher levels in fetal lung and liver tissue (CTs=27) when compared to expression in the adult counterparts (CTs=30-31). Expression of this gene is useful as a marker to differentiate between the fetal and adult sources of these tissues. The relative overexpression of this gene in fetal lung shows that the protein product enhances lung and liver growth or development in the fetus and also acts in a regenerative capacity in the adult. Therapeutic modulation of the protein encoded by this gene is useful in treatment of lung and liver related diseases.

This gene was also expressed at moderate to low in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therapeutic modulation of the expression or function of this gene is useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

Panel 2D Summary: Ag1160 Highest expression of this gene was detected in normal liver (CT=27). This gene was over expressed in gastric, colon, breast and lung cancers samples compared to the normal adjacent tissues. Targeting this gene or its protein product with a small molecule, antibody or protein therapeutic is useful in the treatment of these cancers.

Panel 4D Summary: Ag1160 This gene was upregulated in several normal and activated tissues. This gene was particularly high in activated monocytes and both activated and resting macrophages. Antibodies targeting this gene or gene product is useful to detect monocytes which are differentiating into macrophages. Antagonistic therapeutics to this molecule will inhibit the differentiation process, activation of the epithelium or keratinocytes in the skin and block or reduce inflammation in diseases such as asthma, allergy, psoriasis and emphysema.

AG. CG54683-05: Gamma-Aminobutyric-Acid Receptor RHO-3 Subunit Precursor.

Expression of gene CG54683-05 was assessed using the primer-probe sets Ag1130, Ag1198, Ag1253, Ag1603 and Ag3363, described in Tables AGA, AGB, AGC, AGD and AGE. Results of the RTQ-PCR runs are shown in Tables AGF and AGG.

TABLE AGAProbe Name Ag1130StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gtcctggctttccagttagtct-3′2271289ProbeTET-5′-tcacctacatctggatcatattgaaacca-293212903′-TAMRAReverse5′-ttgatgttagaagcagcacaaa-3′22651291

TABLE AGB

Probe Name Ag1198

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gtcctggctttccagttagtct-3′
22
7
1292

Probe
TET-5′-tcacctacatctggatcatattgaaacca-
29
32
1293

3′-TAMRA

Reverse
5′-ttgatgttagaagcagcacaaa-3′
22
65
1294

TABLE AGC

Probe Name Ag1253

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-atctgggtgcctgatatctttt-3′
22
415
1295

Probe
TET-5′-tgtccactctaaaagatccttcatccat
30
438
1296

ga-3′-TAMRA

Reverse
5′-cgcagcatgatattctccatag-3′
22
473
1297

TABLE AGD

Probe Name Ag1603

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gtcctggctttccagttagtct-3′
22
7
1298

Probe
TET-5′-tcacctacatctggatcatattgaaacca-
29
32
1299

3′-TAMRA

Reverse
5′-ttgatgttagaagcagcacaaa-3′
22
65
1300

TABLE AGE

Probe Name Ag3363

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-tggctttccagttagtctcctt-3′
22
11
1301

Probe
TET-5′-cacctacatctggatcatattgaaacca-
28
33
1302

3′-TAMRA

Reverse
5′-ttgatgttagaagcagcacaaa-3′
22
65
1303

TABLE AGF

Panel 1.2

Column A - Rel. Exp.(%) Ag1130, Run 125117140

Column B - Rel. Exp.(%) Ag1130, Run 126566764

Column C - Rel. Exp.(%) Ag1198, Run 129140506

Tissue Name
A
B
C
Tissue Name
A
B
C

Endothelial cells
0.0
0.0
0.0
Renal ca. 786-0
0.0
0.0
0.0

Heart (Fetal)
0.0
0.0
0.0
Renal ca. A498
7.3
4.7
0.0

Pancreas
0.0
0.0
0.0
Renal ca. RXF 393
0.0
0.0
0.0

Pancreatic ca. CAPAN 2
9.0
0.0
0.0
Renal ca. ACHN
0.0
0.0
0.0

Adrenal gland
0.0
2.6
0.0
Renal ca. UO-31
3.9
0.0
0.0

Thyroid
0.0
0.0
0.0
Renal ca. TK-10
0.0
0.0
0.0

Salivary gland
0.0
0.0
0.0
Liver
26.6
0.0
0.0

Pituitary gland
0.0
0.0
0.0
Liver (fetal)
25.3
0.0
0.0

Brain (fetal)
0.0
0.0
0.0
Liver ca. (hepatoblast)
0.0
0.0
0.0

HepG2

Brain (whole)
2.6
20.0
0.0
Lung
0.0
0.0
0.0

Brain (amygdala)
1.3
32.1
0.0
Lung (fetal)
0.0
0.0
0.0

Brain (cerebellum)
1.5
3.8
0.0
Lung ca. (small cell) LX-1
3.4
0.0
0.0

Brain (hippocampus)
0.0
27.0
0.0
Lung ca. (small cell) NCI-
28.5
74.2
0.0

H69

Brain (thalamus)
9.9
22.5
9.8
Lung ca. (s.cell var.) SHP-
3.8
9.7
0.0

77

Cerebral Cortex
0.0
0.0
0.0
Lung ca. (large cell) NCI-
8.8
4.1
5.3

H460

Spinal cord
4.4
0.0
0.0
Lung ca. (non-sm. cell)
51.4
9.5
7.2

A549

glio/astro U87-MG
0.0
0.0
0.0
Lung ca. (non-s.cell) Nd-
0.0
0.0
0.0

H23

glio/astro U-118-MG
0.0
0.0
0.0
Lung ca. (non-s.cell)
8.4
2.7
9.6

HOP-62

astrocytoma SW1783
2.9
0.0
0.0
Lung ca. (non-s.cl) NCI-
0.0
0.0
0.0

H522

neuro*; met SK-N-AS
0.0
0.0
0.0
Lung ca. (squam.) SW
3.2
8.7
0.0

900

astrocytoma SF-539
5.1
0.0
0.0
Lung ca. (squam.) NCI
2.3
15.9
0.0

astrocytoma SNB-75
2.3
0.0
0.0
Mammary gland
0.0
0.0
0.0

glioma SNB-19
6.3
20.7
9.0
Breast ca.* (pl.ef) MCF-7
0.0
0.0
0.0

glioma U251
1.4
0.0
1.8
Breast ca.* (pl.ef) MDA-
0.0
0.0
0.0

MB-231

glioma SF-295
0.0
0.0
0.0
Breast ca.* (pl.ef) T47D
14.1
37.4
0.0

Heart
0.0
0.0
0.0
Breast ca. BT-549
12.5
21.0
12.3

Skeletal muscle
2.3
0.0
0.0
Breast ca. MDA-N
0.0
0.0
0.0

Bone marrow
0.0
0.0
0.0
Ovary
0.0
0.0
0.0

Thymus
0.0
0.0
0.0
Ovarian ca. OVCAR-3
0.0
0.0
0.0

Spleen
2.2
0.0
0.0
Ovarian ca. OVCAR-4
0.0
0.0
0.0

Lymph node
0.0
0.0
0.0
Ovarian ca. OVCAR-5
66.9
35.4
4.4

Colorectal
11.3
27.7
21.8
Ovarian ca. OVCAR-8
2.7
0.0
0.0

Stomach
0.0
0.0
0.0
Ovarian ca. IGROV-1
6.0
0.0
0.0

Small intestine
5.4
0.0
0.0
Ovarian ca. (ascites) SK-
30.8
0.0
0.0

OV-3

Colon ca. SW480
3.2
0.0
0.0
Uterus
0.0
0.0
0.0

Colon ca.* SW620
0.0
0.0
0.0
Placenta
0.0
0.0
0.0

(SW480 met)

Colon ca. HT29
1.9
14.4
0.0
Prostate
6.9
0.0
0.0

Colon ca. HCT-116
0.0
0.0
0.0
Prostate ca.* (bone met)
100.0
0.0
0.0

PC-3

Colon ca. CaCo-2
0.0
0.0
0.0
Testis
54.7
100.0
36.9

CC Well to Mod Duff
72.2
75.8
100.0
Melanoma Hs688(A).T
4.2
0.0
0.0

(ODO3866)

Colon ca. HCC-2998
5.3
4.8
0.0
Melanoma* (met)
2.7
34.2
13.3

Hs688(B).T

Gastric ca. (liver met) NCI-
50.3
0.0
0.0
Melanoma UACC-62
0.0
0.0
0.0

N87

Bladder
6.0
22.1
0.0
Melanoma M14
31.4
36.3
20.2

Trachea
0.0
0.0
0.0
Melanoma LOX IMVI
0.0
0.0
0.0

Kidney
2.0
0.0
0.0
Melanoma* (met) SK-
2.4
0.0
0.0

MEL-5

Kidney (fetal)
1.1
2.5
0.0

TABLE AGG

Panel 4R

Column A - Rel. Exp.(%) Ag1198, Run 142014937

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
2.5
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNFalpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tn act
0.0
Microsvasular Dermal EC TNFalpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNFalpha + IL1beta
0.0

Primary Th2 rest
0.0
Small airway epithelium none
0.0

Primary Tr1 rest
0.0
Small airway epithelium TNFalpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNFalpha + IL-Ibeta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNFalpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
93580 CCD1106 (Keratinocytes) TNFa and
0.0

IFNg

LAK cells IL-2
0.0
Liver cirrhosis
16.4

LAK cells IL-2 + IL-12
0.0
Lupus kidney
0.0

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
0.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
0.0

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
0.0

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1 beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.0

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-4
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-9
0.0

Ramos (B cell) ionomycm
0.0
Lung fibroblast IL-13
0.0

B lymphocytes PWM
0.0
Lung fibroblast IFN gamma
0.0

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP

PMA/ionomycin
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells anti-CD40
0.0
IBD Colitis 1
100.0

Monocytes rest
10.0
IBD Colitis 2
0.0

Monocytes LPS
0.0
IBD Crohn's
0.0

Macrophages rest
0.0
Colon
0.0

Macrophages LPS
0.0
Lung
0.0

HUVEC none
0.0
Thymus
0.0

HUVEC starved
0.0
Kidney
0.0

Panel 1.2 Summary: Ag1130/Ag1198—Significant expression of this gene was seen in testis, a colon cancer and prostate cancer cell line (CTs=33-34). Therefore, modulation of this gene is useful in the treatment of colon and prostate cancers.

Panel 4R Summary: Ag1198 Significant expression of this gene was seen only in the IBD colitis 1 sample (CT=34.2). Modulation of this gene is useful in the treatment of IBD colitis.

AH. CG54692-06: 5-Hydroxytryptamine 5A Receptor.

Expression of gene CG54692-06 was assessed using the primer-probe sets Ag1507, Ag1558 and Ag1602, described in Tables AHA, AHB and AHC. Results of the RTQ-PCR runs are shown in Tables AHD and AHE.

TABLE AHAProbe Name Ag1507StartSEQ IDPrimersSequencesLengthPositionNoForward5′-cccctgatttacacagctttta-3′2210421304ProbeTET-5′-acaacaatgccttcaagagcctcttt-3′-2610731305TAMRAReverse5′-ccctgtgttcatctctgcttag-3′2211001306

TABLE AHB

Probe Name Ag1558

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-cccctgatttacacagctttta-3′
22
1042
1307

Probe
TET-5′-acaacaatgccttcaagagcctcttt-3′-
26
1073
1308

TAMRA

Reverse
5′-ccctgtgttcatctctgcttag-3′
22
1100
1309

TABLE AHC

Probe Name Ag1602

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-cccctgatttacacagctttta-3′
22
1042
1310

Probe
TET-5′-acaacaatgccttcaagagcctcttt-3′-
26
1073
1311

TAMRA

Reverse
5′-ccctgtgttcatctctgcttag-3′
22
1100
1312

TABLE AHD

Panel 1.2

Column A - Rel. Exp.(%) Ag1507, Run 142131135

Tissue Name
A
Tissue Name
A

Endothelial cells
7.5
Renal ca. 786-0
0.9

Heart (Fetal)
5.3
Renal ca. A498
27.4

Pancreas
8.7
Renal ca. RXF 393
2.3

Pancreatic ca. CAPAN 2
3.0
Renal ca. ACHN
15.5

Adrenal Gland
4.4
Renal ca. UO-31
19.2

Thyroid
2.3
Renal ca. TK-10
39.8

Salivary gland
12.9
Liver
5.8

Pituitary gland
0.0
Liver (fetal)
0.0

Brain (fetal)
0.0
Liver ca. (hepatoblast) HepG2
27.2

Brain (whole)
4.0
Lung
0.0

Brain (amygdala)
20.3
Lung (fetal)
1.0

Brain (cerebellum)
3.2
Lung ca. (small cell) LX-1
9.0

Brain (hippocampus)
13.0
Lung ca. (small cell) NCI-H69
34.6

Brain (thalamus)
3.6
Lung ca. (s.cell var.) SHP-77
2.0

Cerebral Cortex
16.6
Lung ca. (large cell) NCI-H460
4.9

Spinal cord
0.0
Lung ca. (non-sm. cell) A549
19.6

gilo/astro U87-MG
10.6
Lung ca. (non-s.cell) NCI-H23
25.7

glio/astro U-118-MG
3.8
Lung ca. (non-s.cell) HOP-62
35.8

astrocytoma SW1783
2.0
Lung ca. (non-s.cl) NCI-H522
21.6

neuro*; met SK-N-AS
1.6
Lung ca. (squam.) SW 900
21.2

astrocytoma SF-539
4.7
Lung ca. (squam.) NCI-H596
3.3

astrocytoma SNB-75
2.1
Mammary gland
1.1

glioma SNB-19
16.4
Breast ca.* (pl.ef) MCF-7
2.0

glioma U251
9.2
Breast ca.* (pl.ef) MDA-MB-231
2.9

glioma SF-295
3.2
Breast ca.* (pl.ef) T47D
20.7

Heart
19.2
Breast ca. BT-549
11.4

Skeletal Muscle
1.4
Breast ca. MDA-N
30.1

Bone marrow
0.9
Ovary
17.0

Thymus
0.0
Ovarian ca. OVCAR-3
5.3

Spleen
3.9
Ovarian ca. OVCAR-4
13.9

Lymph node
1.2
Ovarian ca. OVCAR-5
100.0

Colorectal
6.0
Ovarian ca. OVCAR-8
72.7

Stomach
0.9
Ovarian ca. IGROV-1
49.3

Small intestine
6.0
Ovarian ca. (ascites) SK-OV-3
36.1

Colon ca. SW480
2.3
Uterus
1.0

Colon ca.* SW620 (SW480 met)
0.0
Placenta
0.0

Colon ca. HT29
14.6
Prostate
3.0

Colon ca. HCT-116
13.5
Prostate ca.* (bone met) PC-3
16.0

Colon ca. CaCo-2
3.5
Testis
30.8

CC Well to Mod Diff (ODO3866)
17.8
Melanoma Hs688(B).T
2.0

Colon ca. HCC-2998
35.1
Melanoma* (met) Hs688(B).T
7.3

Gastric ca. (liver met) NCI-N87
14.6
Melanoma UACC-62
6.0

Bladder
38.4
Melanoma M14
57.4

Trachea
0.0
Melanoma LOX IMVI
12.2

Kidney
28.5
Melanoma* (met) SK-MEL-5
3.7

Kidney (fetal)
8.4

TABLE AHE

Panel 2D

Column A - Rel. Exp. (%) Ag1507, Run 165723610

Column B - Rel. Exp. (%) Ag1558, Run 157982934

Column C - Rel. Exp. (%) Ag1602, Run 162381799

Tissue Name
A
B
C
Tissue Name
A
B
C

Normal Colon
11.9
23.8
35.6
Kidney Margin 8120608
0.0
0.0
0.0

CC Well to Mod Diff
47.0
19.5
47.3
Kidney Cancer 8120613
0.0
0.0
3.8

(ODO3866)

CC Margin (ODO3866)
41.5
9.9
11.3
Kidney Margin 8120614
0.0
0.0
0.0

CC Gr.2 rectosigmoid
24.0
8.2
27.2
Kidney Cancer 9010320
0.0
0.0
14.2

(ODO3868)

CC Margin (ODO3868)
16.5
0.0
4.0
Kidney Margin 9010321
11.9
0.0
18.3

CC Mod Diff (ODO3920)
62.0
17.6
0.0
Normal Uterus
0.0
13.1
0.0

CC Margin (ODO3920)
11.2
16.4
9.0
Uterine Cancer 064011
0.0
8.9
18.2

CC Gr.2 ascend colon
6.9
28.9
0.0
Normal Thyroid
14.0
0.0
0.0

(ODO3921)

CC Margin (ODO3921)
49.3
17.9
27.9
Thyroid Cancer
0.0
0.0
0.0

CC from Partial
12.5
9.3
8.1
Thyroid Cancer
0.0
0.0
5.0

Hepatectomy (ODO4309)

A302152

Mets

Liver Margin (ODO4309)
0.0
0.0
8.7
Thyroid Margin
19.2
30.4
18.7

A302153

Colon mets to lung
13.7
0.0
9.0
Normal Breast
0.0
21.9
0.0

(OD04451-01)

Lung Margin (OD04451-02)
12.2
0.0
15.5
Breast Cancer
0.0
8.1
31.0

Normal Prostate 6546-1
10.5
0.0
22.7
Breast Cancer
0.0
24.7
7.7

(OD04590-01)

Prostate Cancer (OD04410)
0.0
8.4
0.0
Breast Cancer Mets
10.8
20.3
10.9

(OD04590-03)

Prostate Margin (OD04410)
0.0
8.0
10.8
Breast Cancer
0.0
11.7
40.9

Metastasis

Prostate Cancer (OD04720-
9.8
9.3
25.9
Breast Cancer
34.9
25.2
8.5

01)

Prostate Margin (OD04720-
39.0
33.7
25.7
Breast Cancer
30.6
8.5
0.0

02)

Normal Lung
24.5
60.3
100.0
Breast Cancer 9100266
19.9
0.0
0.0

Lung Met to Muscle
7.0
7.1
27.2
Breast Margin 9100265
0.0
7.4
0.0

(ODO4286)

Muscle Margin (ODO4286)
0.0
0.0
28.5
Breast Cancer A209073
44.8
25.3
9.0

Lung Malignant Cancer
0.0
9.8
11.5
Breast Margin A209073
11.6
8.8
25.9

(OD03126)

Lung Margin (OD03126)
20.0
35.6
11.2
Normal Liver
40.6
19.6
17.3

Lung Cancer (OD04404)
9.5
4.7
10.1
Liver Cancer
0.0
16.6
13.6

Lung Margin (OD04404)
0.0
8.9
0.0
Liver Cancer 1025
0.0
8.6
10.2

Lung Cancer (OD04565)
0.0
0.0
0.0
Liver Cancer 1026
0.0
9.5
0.0

Lung Margin (OD04565)
10.4
11.3
7.4
Liver Cancer 6004-T
0.0
24.7
9.3

Lung Cancer (OD04237-01)
10.4
8.1
0.0
Liver Tissue 6004-N
0.0
9.3
0.0

Lung Margin (OD04237-02)
18.7
7.6
17.7
Liver Cancer 6005-T
0.0
0.0
10.0

Ocular Mel Met to Liver
0.0
0.0
0.0
Liver Tissue 6005-N
0.0
0.0
0.0

(ODO4310)

Liver Margin (ODO4310)
0.0
0.0
0.0
Normal Bladder
10.4
9.9
0.0

Melanoma Metastasis
0.0
6.7
0.0
Bladder Cancer
0.0
9.0
0.0

Lung Margin (OD04321)
0.0
0.0
27.4
Bladder Cancer
54.7
54.7
32.1

Normal Kidney
11.3
36.1
9.5
Bladder Cancer
0.0
8.0
9.3

(OD04718-0l)

Kidney Ca, Nuclear grade 2
0.0
0.0
0.0
Bladder Normal
0.0
17.2
6.3

(OD04338)

Adjacent (OD04718-03)

Kidney Margin (OD04338)
14.4
0.0
0.0
Normal Ovary
0.0
0.0
8.5

Kidney Ca Nuclear grade 1/2
0.0
15.9
27.5
Ovarian Cancer
11.1
17.6
10.2

(OD04339)

Kidney Margin (OD04339)
21.0
8.6
28.5
Ovarian Cancer
0.0
9.4
27.0

(OD04768-07)

Kidney Ca, Clear cell type
0.0
14.0
16.0
Ovary Margin
0.0
0.0
0.0

(OD04340)

(OD04768-08)

Kidney Margin (OD04340)
18.6
0.0
17.9
Normal Stomach
24.5
7.7
5.0

Kidney Ca, Nuclear grade 3
0.0
16.8
0.0
Gastric Cancer 9060358
0.0
0.0
0.0

(OD04348)

Kidney Margin (OD04348)
6.3
29.3
9.0
Stomach Margin
0.0
8.5
0.0

9060359

Kidney Cancer (OD04622-
0.0
0.0
0.0
Gastric Cancer 9060395
57.4
4.9
3.9

01)

Kidney Margin (OD04622-
0.0
0.0
0.0
Stomach Margin
0.0
32.8
18.2

03)

9060394

Kidney Cancer (OD04450-
0.0
0.0
14.0
Gastric Cancer 9060397
24.1
10.2
9.9

01)

Kidney Margin (OD04450-
0.0
5.5
0.0
Stomach Margin
15.1
0.0
0.0

03)

9060396

Kidney Cancer 8120607
0.0
0.0
0.0
Gastric Cancer 064005
100.0
100.0
50.7

Panel 1.2 Summary: Ag1507 Low but significant expression of this gene was detected in ovarian cancer cell lines (CT=32.5). In general, expression of this gene was seen in cancer cell lines rather than in normal tissues, with low but significant expression also detectable in melanoma, breast cancer, lung cancer, and renal cancer cell lines. Thus, expression levels of this gene is useful to detect melanoma, breast, lung, renal and colon cancers. Therapeutic inhibition of the this gene or gene product, and/or use of antibodies, small molecule or protein drugs, is effective in the treatment of the afore mentioned cancers.

Panel 2D Summary: Ag1558 Significant expression of this gene was detected in a gastric cancer tissue sample (CT=34.7). Thus, expression of the gene is useful to distinguish between gastric cancer and normal tissue. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of gastric cancer.

AI. CG55069-01, CG55069-03, CG55069-04, CG55069-09: Ten-m3.

Expression of gene CG55069-01, CG55069-03, CG55069-04, and CG55069-09 were assessed using the primer-probe sets Ag1479, Ag2674, and Ag2820, described in Tables AIA, AIB, and AIC. Results of the RTQ-PCR runs are shown in Tables AID, AIE, and AIF. CG55069-04, and CG55069-09 represent a physical clone for EGF domain. Probe-primer set Ag2820 is specific for variant CG55069-01.

TABLE AIAProbe Name Ag1479StartSEQ IDPrimersSequencesLengthPositionNoForward5′-cacggaacgtatcttcaagaaa-3′2221251313ProbeTET-5′-ctgcacgtgtgaccctaactggactg-3′-2621541314TAMRAReverse5′-gccacagtccacagaacatatt-3′2221991315

TABLE AIB

Probe Name Ag2674

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-acctactcggccactacctaga-3′
22
993
1316

Probe
TET-5′-caccctatcaagaagtgcttttaaattca-
29
1017
1317

3′-TAMRA

Reverse
5′-cagtgcatttccagctacagta-3′
22
1060
1318

TABLE AIC

Probe Name Ag2820

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-cagagaagcagacgagttcact-3′
22
354
1319

Probe
TET-5′-caaggacagaattttaccctaaggca-3′-
26
379
1320

TAMRA

Reverse
5′-gttgctggttcacaaactccta-3′
22
407
1321

TABLE AID

Panel 1.3D

Column A - Rel. Exp.(%) Ag1479, Run 165520101

Column B - Rel. Exp.(%) Ag2674, Run 162554642

Column C - Rel. Exp.(%) Ag2820, Run 165527000

Column D - Rel. Exp.(%) Ag2820, Run 165544916

Tissue Name
A
B
C
D

Liver adenocarcinoma
16.0
15.9
17.2
8.2

Pancreas
0.5
0.1
0.0
0.1

Pancreatic ca. CAPAN 2
16.2
4.9
10.4
6.3

Adrenal gland
4.1
0.8
4.9
2.7

Thyroid
2.0
0.8
0.6
0.2

Salivary gland
0.2
0.1
0.0
0.1

Pituitary gland
3.5
0.6
0.8
0.1

Brain (fetal)
8.7
0.6
2.3
1.1

Brain (whole)
10.4
2.0
1.7
2.1

Brain (amygdala)
12.8
3.0
2.0
2.0

Brain (cerebellum)
10.0
1.8
0.3
0.3

Brain (hippocampus)
17.7
5.0
3.5
2.1

Brain (substantia nigra)
1.8
0.0
0.4
0.1

Brain (thalamus)
19.3
2.2
2.2
3.2

Cerebral Cortex
8.0
100.0
4.8
3.6

Spinal cord
1.4
1.1
0.4
1.0

glio/astro U87-MG
13.6
12.0
18.8
26.1

glio/astro U-118-MG
82.4
20.9
100.0
100.0

asirocytoma SW1783
27.9
21.5
24.8
19.3

neuro*; met SK-N-AS
31.2
8.7
18.8
16.3

astrocytoma SF-539
25.2
19.8
22.2
19.3

astrocytoma SNB-75
20.6
5.2
27.2
15.7

glioma SNB-19
4.7
1.6
4.0
3.4

glioma U251
100.0
7.9
88.3
76.8

glioma SF-295
5.6
3.3
5.6
3.5

Heart (Fetal)
1.0
4.3
0.3
0.3

Heart
0.7
0.3
0.0
0.0

Skeletal muscle (Fetal)
1.0
32.8
2.3
1.3

Skeletal muscle
6.0
2.0
0.0
0.2

Bone marrow
0.0
0.0
0.0
0.0

Thymus
0.2
0.7
0.5
0.6

Spleen
0.7
0.3
1.0
0.9

Lymph node
2.0
0.2
2.4
2.0

Colorectal
0.3
3.2
0.5
0.1

Stomach
3.4
0.1
2.2
0.1

Small intestine
3.5
0.6
1.3
0.7

Colon ca. SW480
1.6
0.7
2.4
2.0

Colon ca.* SW620 (SW480 met)
0.0
0.0
0.0
0.0

Colon ca. HT29
0.7
0.7
0.6
0.8

Colon ca. HCT-116
0.3
0.0
0.0
0.1

Colon ca. CaCo-2
8.6
14.3
9.7
7.4

CC Well to Mod Duff (ODO3866)
2.6
2.5
2.6
1.4

Colon ca. HCC-2998
1.0
0.4
2.4
1.2

Gastric ca. (liver met) NCI-N87
0.9
0.3
2.4
0.6

Bladder
0.9
2.5
2.3
0.4

Trachea
0.8
0.3
0.0
0.2

Kidney
0.8
0.5
0.0
0.0

Kidney (fetal)
2.8
1.4
2.5
1.3

Renal ca. 786-0
11.2
6.4
19.9
9.5

Renal ca. A498
13.1
4.3
13.2
7.2

Renal ca. RXF 393
21.5
7.2
21.3
26.1

Renal ca. ACHN
10.1
5.1
7.6
7.5

Renal ca. UO-31
10.2
3.3
13.8
9.5

Renal ca. TK-10
0.0
0.0
0.0
0.0

Liver
0.0
0.0
0.0
0.0

Liver (fetal)
0.1
0.0
0.0
0.0

Liver ca. (hepatoblast) HepG2
0.2
0.2
0.0
0.4

Lung
0.4
0.1
0.2
0.0

Lung (fetal)
0.3
0.3
0.0
0.7

Lung ca. (small cell) LX-1
0.0
0.0
0.0
0.0

Lung ca. (small cell) NCI-H69
3.1
11.6
5.4
11.2

Lung ca. (s.cell var.) SHP-77
2.4
1.7
0.0
0.0

Lung ca. (large cell) NCI-H460
18.6
2.6
26.1
12.9

Lung ca. (non-sm. cell) A549
0.4
0.1
0.6
0.2

Lung ca. (non-s.cell) NCI-H23
1.4
2.1
1.2
0.1

Lung ca. (non-s.cell) HOP-62
9.5
3.9
16.0
6.8

Lung ca. (non-s.cl) NCI-H522
28.1
36.9
15.3
5.8

Lung ca. (squam.) SW 900
0.6
0.1
0.2
0.1

Lung ca. (squam.) NGI-H596
16.5
8.0
19.2
12.3

Mammary gland
0.7
0.5
0.5
0.2

Breast ca.* (pl.ef) MCF-7
5.0
8.8
5.1
2.1

Breast ca.* (pl.ef) MDA-MB-231
2.4
0.3
0.5
0.4

Breast ca.* (pl.ef) T47D
53.6
26.1
1.9
1.1

Breast ca. BT-549
0.0
0.0
0.0
0.0

Breast ca. MDA-N
0.8
1.1
1.5
1.1

Ovary
0.8
2.8
0.3
0.0

Ovarian ca. OVCAR-3
58.6
19.3
26.8
20.0

Ovarian ca. OVCAR-4
2.4
0.4
3.1
2.0

Ovarian ca. OVCAR-5
0.0
0.0
0.0
0.0

Ovarian ca. OVCAR-8
8.7
6.7
1.7
2.8

Ovarian ca. IGROV-l
3.1
1.5
0.0
0.4

Ovarian ca. (ascites) SK-OV-3
27.9
6.7
22.2
0.0

Uterus
2.4
0.4
1.2
0.9

Placenta
8.1
4.4
7.7
4.1

Prostate
2.1
0.1
0.0
0.0

Prostate ca.* (bone met) PC-3
0.7
1.1
0.0
0.0

Testis
4.5
1.1
0.0
0.1

Melanoma Hs688(A).T
10.0
20.4
12.8
7.5

Melanoma* (met) Hs688(B).T
12.5
18.9
12.0
4.2

Melanoma UACC-62
1.2
0.3
0.4
0.3

Melanoma M14
13.7
2.1
14.4
7.8

Melanoma LOX IMVI
1.2
1.2
0.0
0.0

Melanoma* (met) SK-MEL-5
3.7
4.5
3.8
1.8

Adipose
3.6
4.5
12.9
0.6

TABLE AIE

Panel 2D

Column A - Rel. Exp. (%) Ag2674, Run 162455917

Column B - Rel. Exp. (%) Ag2820, Run 163578010

Column C - Rel. Exp. (%) Ag2820, Run 165910586

Tissue Name
A
B
C
Tissue Name
A
B
C

Normal Colon
47.6
12.4
15.7
Kidney Margin 8120608
6.9
1.7
3.7

CC Well to Mod Diff
8.4
7.2
7.4
Kidney Cancer 8120613
0.5
0.0
0.0

(ODO3866)

CC Margin (ODO3866)
8.0
0.8
0.4
Kidney Margin 8120614
2.8
1.6
0.0

CC Gr.2 rectosigmoid
5.4
3.8
2.3
Kidney Cancer 9010320
22.4
39.5
36.1

(ODO3868)

CC Margin (ODO3868)
12.4
2.2
1.2
Kidney Margin 9010321
14.1
22.5
11.6

CC Mod Diff (ODO3920)
0.4
0.7
0.0
Normal Uterus
7.1
4.1
7.0

CC Margin (ODO3920)
12.2
1.6
1.4
Uterine Cancer 064011
38.4
5.5
2.3

CC Gr.2 ascend colon
3.8
2.9
3.6
Normal Thyroid
13.9
4.7
1.1

(ODO3921)

CC Margin (ODO3921)
8.9
1.3
0.0
Thyroid Cancer
30.4
36.3
40.9

CC from Partial
6.0
12.3
12.5
Thyroid Cancer
8.3
5.8
2.8

Hepatectomy (ODO4309)

A302152

Mets

Liver Margin (ODO4309)
0.4
0.4
0.0
Thyroid Margin
88.3
10.0
7.2

A302153

Colon mets to lung
1.4
1.5
1.1
Normal Breast
26.4
9.5
11.3

(OD04451-01)

Lung Margin (OD04451-02)
0.7
0.0
0.8
Breast Cancer
2.0
0.7
0.8

Normal Prostate 6546-1
14.1
6.3
2.0
Breast Cancer
13.7
4.0
2.9

(OD04590-01)

Prostate Cancer (OD04410)
26.8
4.9
4.1
Breast Cancer Mets
55.1
32.5
15.9

(OD04590-03)

Prostate Margin (OD04410)
27.0
6.0
1.9
Breast Cancer
24.8
12.2
2.9

Metastasis

Prostate Cancer (OD04720-
18.8
3.2
1.2
Breast Cancer
11.2
7.5
5.5

01)

Prostate Margin (OD04720-
41.2
8.0
3.9
Breast Cancer
11.1
1.8
1.3

02)

Normal Lung
16.0
13.4
11.8
Breast Cancer 9100266
11.8
3.5
1.2

Lung Met to Muscle
25.5
64.2
39.2
Breast Margin 9100265
13.2
4.9
1.7

(ODO4286)

Muscle Margin (ODO4286)
14.1
1.3
1.1
Breast Cancer A209073
19.2
3.5
1.7

Lung Malignant Cancer
44.8
66.9
57.8
Breast Margin A209073
25.3
0.6
2.0

(OD03126)

Lung Margin (OD03126)
11.7
10.6
5.9
Normal Liver
1.7
1.2
0.3

Lung Cancer (OD04404)
13.7
10.4
11.6
Liver Cancer
0.5
0.0
0.0

Lung Margin (OD04404)
11.4
10.7
14.4
Liver Cancer 1025
0.0
0.0
0.0

Lung Cancer (OD04565)
13.1
8.5
4.5
Liver Cancer 1026
0.7
0.0
0.0

Lung Margin (OD04565)
3.1
5.3
6.2
Liver Cancer 6004-T
0.5
0.0
0.0

Lung Cancer (OD04237-01)
7.4
13.6
4.5
Liver Tissue 6004-N
0.6
1.0
0.3

Lung Margin (OD04237-02)
4.8
5.3
3.8
Liver Cancer 6005-T
1.1
0.0
0.0

Ocular Mel Met to Liver
0.9
0.0
0.0
Liver Tissue 6005-N
0.0
0.0
0.0

(ODO4310)

Liver Margin (ODO4310)
5.0
0.0
0.3
Normal Bladder
26.1
14.7
12.7

Melanoma Metastasis
29.7
57.4
31.6
Bladder Cancer
6.0
9.2
2.0

Lung Margin (OD04321)
4.3
7.0
3.5
Bladder Cancer
6.0
3.9
2.3

Normal Kidney
27.7
18.9
14.4
Bladder Cancer
41.8
89.5
82.4

(OD04718-01)

Kidney Ca, Nuclear grade 2
2.9
5.6
2.9
Bladder Normal
22.4
3.5
3.9

(OD04338)

Adjacent (OD04718-03)

Kidney Margin (OD04338)
11.8
10.8
9.0
Normal Ovary
10.1
2.1
0.6

Kidney Ca Nuclear grade 1/2
48.3
82.4
67.8
Ovarian Cancer
100.0
36.3
100.0

(OD04339)

Kidney Margin (OD04339)
15.9
17.7
8.8
Ovarian Cancer
0.3
0.0
0.4

(OD04768-07)

Kidney Ca, Clear cell type
0.8
0.0
0.3
Ovary Margin
8.2
6.9
4.4

(OD04340)

(OD04768-08)

Kidney Margin (OD04340)
21.6
13.9
8.0
Normal Stomach
5.7
2.2
1.9

Kidney Ca, Nuclear grade 3
33.4
84.7
58.2
Gastric Cancer 9060358
7.2
3.0
2.8

(OD04348)

Kidney Margin (OD04348)
12.9
4.6
11.1
Stomach Margin
4.9
0.7
1.5

9060359

Kidney Cancer (OD04622-
1.4
0.0
4.6
Gastric Cancer 9060395
6.5
1.9
1.8

01)

Kidney Margin (OD04622-
7.3
3.9
1.1
Stomach Margin
7.2
2.2
2.3

03)

9060394

Kidney Cancer (OD04450-
84.7
100.0
78.5
Gastric Cancer 9060397
46.7
22.7
28.5

01)

Kidney Margin (OD04450-
19.9
12.0
6.9
Stomach Margin
4.7
0.7
0.0

03)

9060396

Kidney Cancer 8120607
12.7
4.9
4.2
Gastric Cancer 064005
5.6
9.2
6.5

TABLE AIF

Panel 4D

Column A - Rel. Exp.(%) Ag1479, Run 162599612

Column B - Rel. Exp.(%) Ag2674, Run 160645450

Column C - Rel. Exp.(%) Ag2820, Run 162350531

Column D - Rel. Exp.(%) Ag2820, Run 164329602

Tissue Name
A
B
C
D

Secondary Th1 act
0.3
0.0
0.0
0.0

Secondary Th2 act
0.0
0.0
0.0
0.5

Secondary Tr1 act
0.0
0.0
0.0
0.3

Secondary Th1 rest
0.0
0.0
0.0
0.0

Secondary Th2 rest
0.0
0.0
0.0
0.0

Secondary Tr1 rest
0.0
0.0
0.0
0.0

Primary Th1 act
0.0
0.0
0.0
0.0

Primary Th2 act
0.0
0.0
0.0
0.0

Primary Tr1 act
0.0
0.0
0.0
0.0

Primary Th1 act
0.0
0.5
0.0
0.0

Primary Th2 act
0.0
0.0
0.0
0.0

Primary Tr1 act
0.0
0.0
0.0
0.0

CD45RA GD4 lymphocyte act
1.8
1.0
1.6
0.8

CD45RO CD4 lymphocyte act
0.0
0.0
0.0
0.0

CD8 lymphocyte act
0.0
0.0
0.0
0.0

Secondary CD8 lymphocyte rest
0.0
0.0
0.0
0.0

Secondary CD8 lymphocyte act
0.0
0.0
0.0
0.0

CD4 lymphocyte none
0.0
0.0
0.0
0.0

2ry Th1/Th2/Tr1 anti-CD95 CH11
0.0
0.0
0.0
0.0

LAK cells rest
0.0
0.0
0.0
0.0

LAK cells IL-2
0.0
0.0
0.3
0.0

LAX cells IL-2 + IL-12
0.0
0.0
0.0
0.7

LAK cells IL-2 + IFN gamma
0.0
0.0
0.0
0.0

LAK cells IL-2 + IL-18
0.0
0.0
0.0
0.0

LAK cells PMA/ionomycin
0.0
0.0
0.0
0.5

NK Cells IL-2 rest
0.0
0.0
0.0
0.0

Two Way MLR 3 day
0.0
0.0
0.0
0.0

Two Way MLR 5 day
0.0
0.0
0.0
0.0

Two Way MLR 7 day
0.0
0.0
0.0
0.0

PBMC rest
0.0
0.0
0.0
0.0

PBMC PWM
0.0
0.0
0.0
0.0

PBMC PHA-L
0.0
0.0
0.0
0.0

Ramos (B cell) none
0.0
0.0
0.0
0.0

Ramos (B cell) ionomycin
0.0
0.0
0.0
0.0

B lymphocytes PWM
0.0
0.0
0.3
2.5

B lymphocytes CD40L and IL-4
0.2
0.4
0.0
0.0

EOL-1 dbcAMP
0.2
0.2
0.3
0.7

EOL-1 dbcAMP PMA/ionomycin
0.1
0.2
0.9
0.0

Dendritic cells none
0.0
0.0
0.0
0.0

Dendritic cells LPS
0.0
0.0
0.0
0.0

Dendritic cells anti-CD40
0.0
0.0
0.0
0.0

Monocytes rest
0.0
0.0
0.0
0.0

Monocytes LPS
0.0
0.0
0.0
0.0

Macrophages rest
0.0
0.0
0.0
0.0

Macrophages LPS
0.0
0.0
0.0
0.0

HUVEC none
23.0
17.7
0.0
0.0

HUVEC starved
25.0
26.1
0.0
0.0

HUVEC IL-1beta
8.1
7.1
0.0
0.0

HUVEC IFN gamma
14.8
13.8
0.0
0.3

HUVEC TNF alpha + IFN gamma
8.5
6.7
0.0
0.0

HUVEC TNF alpha + IL4
12.0
10.2
0.0
0.0

HUVEC IL-11
8.5
7.0
0.0
0.0

Lung Microvascular EC none
11.1
14.2
0.0
0.0

Lung Microvascular EC TNFalpha +
9.3
11.0
0.0
0.2

IL-1beta

Microvascular Dermal EC none
100.0
75.3
0.0
0.0

Microsvasular Dermal EC TNFalpha +
29.7
26.8
0.0
0.0

IL-1beta

Bronchial epithelium TNFalpha + IL-1beta
0.2
1.3
2.4
19.9

Small airway epithelium none
2.2
1.1
1.0
1.7

Small airway epithelium TNFalpha +
0.3
0.2
0.0
0.0

IL-1beta

Coronery artery SMC rest
8.3
8.0
1.9
2.6

Coronery artery SMC TNFalpha + IL-1beta
4.6
3.1
3.0
1.2

Astrocytes rest
85.9
70.2
100.0
100.0

Astrocytes TNFalpha + IL-1beta
59.0
100.0
71.7
65.5

KU-812 (Basophil) rest
0.0
0.3
0.0
0.0

KU-812 (Basophil) PMA/ionomycin
0.0
0.0
0.0
0.0

CCD1106 (Keratinocytes) none
19.8
17.2
35.6
70.2

CCD1106 (Keratinocytes) TNFalpha +
1.7
1.3
13.4
29.3

IL-1beta

Liver cirrhosis
0.0
0.5
0.3
0.0

Lupus kidney
1.8
2.9
6.2
8.1

NCI-H292 none
0.0
0.0
0.0
0.0

NCI-H292 IL-4
0.0
0.0
0.3
0.4

NCI-H292 IL-9
0.0
0.0
0.0
0.0

NCI-H292 IL-13
0.0
0.0
0.0
0.0

NCI-H292 IFN gamma
0.0
0.0
0.0
0.0

HPAEC none
15.1
12.2
0.0
0.0

HPAEC TNF alpha + IL-1 beta
6.2
7.5
0.6
0.0

Lung fibroblast none
0.9
0.4
0.0
0.4

Lung fibroblast TNF alpha + IL-1 beta
0.6
0.0
0.0
0.0

Lung fibroblast IL-4
2.1
2.9
1.7
3.7

Lung fibroblast IL-9
1.2
0.5
1.2
2.0

Lung fibroblast IL-13
1.2
0.9
1.6
3.3

Lung fibroblast IFN gamma
2.1
1.9
2.3
0.2

Dermal fibroblast CCD1070 rest
10.5
9.8
10.3
8.4

Dermal fibroblast CCD1070 TNF alpha
11.6
4.6
10.0
11.3

Dermal fibroblast CCD1070 IL-1 beta
4.9
2.2
4.5
3.8

Dermal fibroblast IFN gamma
1.2
1.7
0.3
1.6

Dermal fibroblast IL-4
28.3
27.9
12.1
13.4

IBD Colitis 2
0.7
1.6
0.3
0.0

IBD Crohn's
1.6
0.4
0.8
3.7

Colon
8.6
7.6
1.7
1.9

Lung
2.0
2.9
3.8
6.3

Thymus
7.0
13.7
4.1
4.4

Kidney
17.0
27.5
13.0
20.2

This gene codes for TenM3 protein. Ten-M proteins have been shown to be involved in cell migration. This gene was upregulated in a variety of cancers. It was highly expressed in glioma, astrocytoma, lung, renal, ovarian and breast cancer cell lines. It was also expressed at high levels in primary lung, kidney, bladder, ovarian, gastric, melanoma and breast cancer tissues. This EGF repeat domain (CG55069-04 and CG55069-09 variants) of Ten-M3 is known to be involved in dimerization of the full length protein in vivo. Treatment of cells expressing Ten-M3 with this purified protein fragment will interfere with the normal function of endogenous Ten-M3 and inhibit cell migration.

Panel 1.3D Summary: Ag1479/2674/Ag2820 Highest expression of this gene was seen in the brain and in brain cancer cell lines (CTs=28-31). Thus, inhibitors of this gene or gene product is useful for the treatment of diseases involving neurite outgrowth or organization, such as neurodegenerative diseases.

There was substantial expression in other samples derived from cancer cell lines, such as breast cancer, lung cancer ovarian cancer. Thus, therapeutic modulation of this gene, encoded protein and/or use of antibodies or small molecule targeting this gene or gene product is useful in the treatment of brain cancer, lung cancer, or ovarian cancer.

This gene was also moderately expressed in metabolic tissues including adrenal, thyroid, pituitary, fetal heart, adult and fetal skeletal muscle, and adipose. Thus, this geen product may be an antibody target for the treatment of any or all diseases in these tissues, including obesity and diabetes.

Panel 2D Summary: Ag2674/2820 The highest expression of this gene is generally associated with kidney cancers. Of particular note is the consistent absence of expression in normal kidney tissue adjacent to malignant kidney. In addition, there is substantial expression associated with ovarian cancer, bladder cancer and lung cancer. Thus, the expression of this gene could be used to distinguish the above listed malignant tissue from other tissues in the panel. Particularly, the expression of this gene could be used to distinguish malignant kidney tissue from normal kidney. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics might be of benefit in the treatment of kidney cancer, ovarian cancer, bladder cancer or lung cancer.

Panel 4D Summary: Ag1479/Ag2674/Ag2820 The expression of this gene was highest in astrocytes and microvascular dermal endothelial cells (CTs=29-30), with low but significant expression in keratinocytes, and dermal fibroblasts. Expression was not modulated by any treatment, indicating that this protein is important in normal homeostasis. Therefore, modulation of this gene, expressed protein and/or use of antibodies or small molecule targeting this gene or gene product is useful in the treatmen of autoimmune and inflammatory diseases such as asthma, IBD, psoriasis, multiple sclerosis or other inflammatory diseases of the CNS.

AJ. CG55343-03: Olfactory Receptor.

Expression of gene CG55343-03 was assessed using the primer-probe sets Ag1592 and Ag457, described in Tables AJA and AJB. Results of the RTQ-PCR runs are shown in Tables AJC, AJD, AJE and AJF. CG55343-03 represents the full-length physical clone.

TABLE AJAProbe Name Ag1592StartSEQ IDPrimersSequencesLengthPositionNoForward5′-aggaccaaggaaagatggttt-3′218041322ProbeTET-5′-tgcacccatgctgaatccccttatat-3′-268441323TAMRAReverse5′-aagccttcctttacctccttgt-3′228821324

TABLE AJB

Probe Name Ag457

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gccgtctctgtgtacctgca-3′
20
764
1325

Probe
TET-5′-ttcgcccagctccaaggaccaa-3′-
22
790
1326

TAMRA

Reverse
5′-ttccatagaagagagaaaccatctttc-3′
27
813
1327

TABLE AJC

Panel 1.3D

Column A - Rel. Exp. (%) Ag1592, Run 152066536

Column B - Rel. Exp. (%) Ag457, Run 146581824

Column C - Rel. Exp. (%) Ag457, Run 151104452

Tissue Name
A
B
C
Tissue Name
A
B
C

Liver adenocarcinoma
0.0
0.8
0.0
Kidney (fetal)
1.3
0.0
2.1

Pancreas
0.0
0.0
4.0
Renal ca. 786-0
0.0
0.0
0.0

Pancreatic ca. CAPAN 2
0.0
1.3
2.1
Renal ca. A498
8.5
9.5
10.6

Adrenal gland
3.5
1.4
0.0
Renal ca. RXF 393
0.0
0.0
0.0

Thyroid
0.0
0.0
0.9
Renal ca. ACHN
0.0
0.6
0.0

Salivary gland
0.0
0.0
2.3
Renal ca. UO-31
0.0
0.0
0.0

Pituitary gland
0.0
0.0
0.0
Renal ca. TK-10
1.7
1.6
0.9

Brain (fetal)
0.0
0.0
0.0
Liver
2.5
2.0
1.8

Brain (whole)
0.0
1.5
0.0
Liver (fetal)
6.3
5.7
12.7

Brain (amygdala)
1.4
1.5
0.0
Liver ca. (hepatoblast)
9.5
5.3
6.1

HepG2

Brain (cerebellum)
1.8
0.0
2.0
Lung
1.5
0.7
1.9

Brain (hippocampus)
1.2
0.0
0.0
Lung (fetal)
2.3
4.0
5.6

Brain (substantia nigra)
1.2
0.0
2.5
Lung ca. (small cell) LX-
3.4
2.9
4.0

1

Brain (thalamus)
0.0
0.0
0.0
Lung ca. (small cell) NCI-
10.8
15.6
14.4

H69

Cerebral Cortex
0.0
1.5
2.1
Lung ca. (s. cell var.)
21.2
33.9
21.3

SHP-77

Spinal cord
0.0
0.0
0.0
Lung ca. (large cell) NCI-
5.2
2.0
2.6

H460

glio/astro U87-MG
4.5
1.5
1.4
Lung ca. (non-sm. cell)
0.0
3.6
4.5

A549

glio/astro U-118-MG
18.9
11.4
20.2
Lung ca. (non-s. cell)
18.3
7.6
14.6

NCI-H23

astrocytoma SW1783
5.3
2.0
3.0
Lung ca. (non-s. cell)
0.0
0.0
0.0

HOP-62

neuro*; met SK-N-AS
7.1
4.5
14.1
Lung ca. (non-s. cl) NCI-
18.0
7.0
17.3

H522

astrocytoma SF-539
2.6
0.7
2.9
Lung ca. (squam.) SW
0.0
1.5
1.5

900

astrocytoma SNB-75
9.5
22.7
17.4
Lung ca. (squam.) NCI-
14.0
17.4
26.2

H596

glioma SNB-19
0.0
1.8
0.0
Mammary gland
1.6
0.0
0.0

glioma U251
0.0
1.3
0.0
Breast ca.* (pl. ef) MCF-7
100.0
100.0
100.0

glioma SF-295
4.6
1.2
4.5
Breast ca.* (pl. ef) MDA-
21.0
24.5
19.8

MB-231

Heart (Fetal)
5.6
0.4
3.1
Breast ca.* (pl. ef) T47D
5.9
2.1
1.7

Heart
0.0
0.0
1.2
Breast ca. BT-549
13.8
22.8
16.0

Skeletal muscle (Fetal)
4.1
5.0
6.2
Breast ca. MDA-N
3.5
3.3
7.7

Skeletal muscle
0.0
0.0
0.9
Ovary
4.1
0.0
1.0

Bone marrow
8.5
3.7
2.2
Ovarian ca. OVCAR-3
8.7
10.5
5.3

Thymus
3.1
5.3
0.8
Ovarian ca. OVCAR-4
0.0
0.0
0.0

Spleen
1.6
0.7
1.1
Ovarian ca. OVCAR-5
11.7
6.3
4.9

Lymph node
1.1
1.4
2.3
Ovarian ca. OVCAR-8
1.5
2.2
2.9

Colorectal
4.0
0.4
5.5
Ovarian ca. IGROV-1
1.8
0.0
0.9

Stomach
1.4
1.4
6.5
Ovarian ca. (ascites) SK-
1.2
1.3
0.8

OV-3

Small intestine
0.0
0.0
1.7
Uterus
0.0
1.4
3.3

Colon ca. SW480
27.0
34.2
34.6
Placenta
11.1
9.5
11.4

Colon ca.* SW620 (SW480
2.5
6.1
11.8
Prostate
0.0
0.0
0.9

met)

Colon ca. HT29
4.1
1.6
2.1
Prostate ca.* (bone met)
6.5
5.8
7.2

PC-3

Colon ca. HCT-116
2.8
0.7
0.0
Testis
1.2
2.1
1.3

Colon ca. CaCo-2
4.6
6.2
6.3
Melanoma Hs688(A).T
0.0
0.0
1.3

CC Well to Mod Diff
2.4
0.8
0.0
Melanoma* (met)
1.8
0.0
2.2

(ODO3866)

Hs688(B).T

Colon ca. HCC-2998
4.9
5.9
1.6
Melanoma UACC-62
0.0
0.0
0.0

Gastric ca. (liver met) NCI-
42.0
86.5
65.1
Melanoma M14
1.6
0.0
2.0

N87

Bladder
3.2
1.4
3.2
Melanoma LOX IMVI
0.0
2.6
2.6

Trachea
0.0
0.0
0.0
Melanoma* (met) SK-
0.0
0.0
0.0

MEL-5

Kidney
1.5
0.0
0.0
Adipose
0.0
0.0
0.0

TABLE AID

Panel 2D

Column A - Rel. Exp.(%) Ag1592, Run 152066737

Column B - Rel. Exp.(%) Ag457, Run 146087098

Column C - Rel. Exp.(%) Ag457, Run 146581925

Column D - Rel. Exp.(%) Ag457, Run 158141680

Tissue Name
A
B
C
D

Normal Colon
0.0
1.6
0.8
3.6

CC Well to Mod Diff (ODO3866)
1.3
0.5
0.6
0.0

CC Margin (OD03866)
0.0
2.4
2.0
2.5

CC Gr.2 rectosigmoid (ODO3868)
1.3
4.3
2.3
0.8

CC Margin (ODO3868)
0.9
0.0
0.7
1.1

CC Mod Diff(ODO3920)
4.3
6.3
6.7
4.0

CC Margin (ODO3920)
0.9
2.7
0.5
1.0

CC Gr.2 ascend colon (ODO3921)
2.7
1.6
1.7
0.0

CC Margin (ODO3921)
2.1
0.4
1.5
1.3

CC from Partial Hepatectomy (ODO4309)
3.5
1.8
1.5
0.6

Mets

Liver Margin (ODO4309)
2.0
0.8
0.8
2.1

Colon mets to lung (OD04451-01)
4.1
0.0
0.4
0.6

Lung Margin (OD04451-02)
0.0
0.0
0.7
0.0

Normal Prostate 6546-1
2.2
3.4
3.1
1.4

Prostate Cancer (OD04410)
14.5
12.4
16.2
7.3

Prostate Margin (OD04410)
9.0
4.7
6.4
5.9

Prostate Cancer (OD04720-01)
0.0
0.1
0.4
1.1

Prostate Margin (OD04720-02)
0.0
1.0
0.9
2.9

Normal Lung
2.2
1.2
2.5
1.7

Lung Met to Muscle (OD04286)
3.5
4.2
3.4
4.2

Muscle Margin (OD04286)
0.9
0.0
0.5
0.0

Lung Malignant Cancer (OD03126)
0.0
1.5
1.4
1.7

Lung Margin (OD03 126)
0.0
0.9
2.6
1.5

Lung Cancer (OD04404)
6.0
4.1
3.5
6.8

Lung Margin (OD04404)
0.0
1.3
0.0
0.9

Lung Cancer (OD04565)
1.1
0.6
0.9
0.0

Lung Margin (OD04565)
0.0
1.2
0.4
0.7

Lung Cancer (OD04237-01)
17.9
15.9
14.0
15.7

Lung Margin (OD04237-02)
0.9
0.0
1.4
0.8

Ocular Mel Met to Liver (ODO4310)
0.0
0.3
0.0
0.0

Liver Margin (ODO4310)
0.0
0.7
1.6
2.9

Melanoma Metastasis
9.7
10.1
9.7
8.2

Lung Margin (OD04321)
0.0
2.3
1.0
0.0

Normal Kidney
1.6
0.6
0.7
0.0

Kidney Ca, Nuclear grade 2 (OD04338)
0.8
0.0
0.4
0.7

Kidney Margin (OD04338)
1.4
0.0
0.0
0.0

Kidney Ca Nuclear grade 1/2 (OD04339)
0.0
0.6
0.0
1.4

Kidney Margin (OD04339)
0.0
0.0
0.7
0.0

Kidney Ca, Clear cell type (OD04340)
3.0
1.8
3.0
0.9

Kidney Margin (OD04340)
0.0
0.9
0.4
0.0

Kidney Ca, Nuclear grade 3 (OD04348)
0.0
3.1
2.2
1.3

Kidney Margin (OD04348)
0.0
2.4
0.0
0.0

Kidney Cancer (OD04622-01)
0.0
0.9
0.8
1.6

Kidney Margin (OD04622-03)
0.0
0.8
0.0
0.0

Kidney Cancer (OD04450-0l)
0.0
0.7
0.0
2.7

Kidney Margin (OD04450-03)
0.9
0.9
0.8
0.6

Kidney Cancer 8120607
0.0
0.0
0.4
0.0

Kidney Margin 8120608
0.0
0.5
0.3
0.8

Kidney Cancer 8120613
1.1
0.0
0.0
0.6

Kidney Margin 8120614
0.0
0.0
0.0
0.0

Kidney Cancer 9010320
0.0
0.4
1.3
0.0

Kidney Margin 9010321
0.0
0.8
0.0
0.0

Normal Uterus
0.0
0.0
0.0
0.0

Uterine Cancer 064011
0.8
1.2
2.8
1.6

Normal Thyroid
0.0
0.4
2.6
0.0

Thyroid Cancer
1.1
0.0
1.5
0.0

Thyroid Cancer A302152
2.0
3.2
2.2
1.9

Thyroid Margin A302153
0.8
0.0
0.7
0.0

Normal Breast
0.0
0.2
0.4
1.5

Breast Cancer
4.6
8.4
9.9
15.3

Breast Cancer (OD04590-01)
87.1
100.0
87.2
59.9

Breast Cancer Mets (OD04590-03)
36.3
38.7
55.9
14.8

Breast Cancer Metastasis
17.3
17.6
22.4
8.1

Breast Cancer
6.3
5.4
3.4
4.3

Breast Cancer
17.3
20.6
20.9
18.7

Breast Cancer 9100266
3.8
5.4
2.7
3.7

Breast Margin 9100265
3.0
0.8
0.4
2.5

Breast Cancer A209073
2.2
2.7
1.3
0.0

Breast Margin A209073
0.7
0.0
1.7
0.9

Normal Liver
1.8
0.5
0.9
0.0

Liver Cancer
2.0
0.4
0.8
0.0

Liver Cancer 1025
1.1
0.7
0.6
0.0

Liver Cancer 1026
0.0
0.9
0.0
0.0

Liver Cancer 6004-T
1.3
0.0
0.0
0.9

Liver Tissue 6004-N
3.6
0.8
1.4
1.1

Liver Cancer 6005-T
0.0
0.6
2.4
0.0

Liver Tissue 6005-N
2.3
0.4
1.2
1.8

Normal Bladder
7.9
7.1
3.4
2.0

Bladder Cancer
0.0
0.0
0.0
1.0

Bladder Cancer
4.2
4.2
1.8
11.9

Bladder Cancer (OD04718-01)
97.3
62.0
100.0
100.0

Bladder Normal Adjacent (OD04718-03)
0.0
0.9
0.4
0.0

Normal Ovary
1.1
0.0
0.0
0.8

Ovarian Cancer
3.4
1.8
1.1
3.7

Ovarian Cancer (OD04768-07)
100.0
76.3
89.5
85.3

Ovary Margin (OD04768-08)
1.4
0.0
0.0
0.0

Normal Stomach
1.1
0.6
1.4
0.0

Gastric Cancer 9060358
0.0
0.3
0.0
0.9

Stomach Margin 9060359
2.4
0.5
0.8
0.0

Gastric Cancer 9060395
1.9
2.4
1.8
2.1

Stomach Margin 9060394
2.1
1.9
0.0
1.7

Gastric Cancer 9060397
10.9
11.7
10.0
8.7

Stomach Margin 9060396
0.0
1.0
0.5
1.2

Gastric Cancer 064005
4.9
0.6
5.6
2.8

TABLE AJE

Panel 4D

Column A - Rel. Exp. (%) Ag1592, Run 152066880

Column B - Rel. Exp. (%) Ag457, Run 151104533

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
29.9
8.7
HUVEC IL-1beta
0.0
3.1

Secondary Th2 act
4.7
3.8
HUVEC IFN gamma
10.2
7.2

Secondary Tr1 act
15.3
4.8
HUVEC TNFalpha + IFN gamma
0.0
0.0

Secondary Th1 rest
12.2
16.2
HUVEC TNFalpha + IL4
0.0
6.8

Secondary Th2 rest
0.0
5.4
HUVEC IL-11
0.0
2.0

Secondary Tr1 rest
8.3
0.0
Lung Microvascular EC none
0.0
12.9

Primary Th1 act
0.0
9.2
Lung Microvascular EC TNFalpha +
0.0
0.0

IL-1beta

Primary Th2 act
4.4
7.5
Microvascular Dermal EC none
5.0
6.4

Primary Tr1 act
0.0
3.7
Microsvasular Dermal EC TNFalpha +
0.0
4.2

IL-1beta

Primary Th1 rest
18.2
7.8
Bronchial epithelium TNFalpha +
0.0
7.9

IL1beta

Primary Th2 rest
15.4
3.6
Small airway epithelium none
4.6
5.9

Primary Tr1 rest
2.9
0.0
Small airway epithelium TNFalpha +
5.1
0.0

IL-1beta

CD45RA CD4 lymphocyte
0.0
0.0
Coronery artery SMC rest
0.0
4.1

act

CD45RO CD4 lymphocyte
19.6
6.7
Coronery artery SMC TNFalpha +
0.0
3.5

act

IL-1beta

CD8 lymphocyte act
0.0
8.1
Astrocytes rest
0.0
7.8

Secondary CD8 lymphocyte
14.2
10.4
Astrocytes TNFalpha + IL-1beta
0.0
0.0

rest

Secondary CD8 lymphocyte
0.0
3.8
KU-812 (Basophil) rest
3.7
23.2

act

CD4 lymphocyte none
0.0
0.0
KU-812 (Basophil) PMA/ionomycin
100.0
83.5

2ry Th1/Th2/Tr1 anti-CD95
15.4
9.0
CCD1106 (Keratinocytes) none
0.0
7.0

CH11

LAK cells rest
5.1
0.0
CCD1106 (Keratinocytes) TNFalpha +
0.0
3.7

IL-1beta

LAK cells IL-2
5.1
6.8
Liver cirrhosis
17.1
44.8

LAK cells IL-2 + IL-12
0.0
3.8
Lupus kidney
0.0
0.0

LAK cells IL-2 + IFN
16.6
0.0
NCI-H292 none
9.2
4.1

gamma

LAK cells IL-2 + IL-18
0.0
0.0
NCI-H292 IL-4
10.4
4.3

LAK cells PMA/ionomycin
0.0
0.0
NCI-H292 IL-9
23.5
4.1

NK Cells IL-2 rest
0.0
8.7
NCI-H292 IL-13
0.0
0.0

Two Way MLR 3 day
0.0
2.7
NCI-H292 IFN gamma
6.6
37.6

Two Way MLR 5 day
10.9
3.6
HPAEC none
0.0
0.0

Two Way MLR 7 day
4.1
0.0
HPAEC TNFalpha + IL-1 beta
4.7
4.3

PBMC rest
5.1
9.6
Lung fibroblast none
5.5
6.3

PBMC PWM
12.0
36.1
Lung fibroblast TNFalpha + IL-1
21.3
10.2

beta

PBMC PHA-L
0.0
14.6
Lung fibroblast IL-4
6.6
0.0

Ramos (B cell) none
0.0
10.3
Lung fibroblast IL-9
0.0
4.3

Ramos (B cell) ionomycin
18.4
36.1
Lung fibroblast IL-13
0.0
18.6

B lymphocytes PWM
31.4
59.0
Lung fibroblast IFN gamma
0.0
16.2

B lymphocytes CD40L and
27.7
12.1
Dermal fibroblast CCD1070 rest
18.3
11.7

IL-4

EOL-1 dbcAMP
7.6
4.5
Dermal fibroblast CCD1O7O TNF
19.5
9.8

alpha

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 IL-1
4.9
0.0

PMA/ionomycin

beta

Dendritic cells none
0.0
2.8
Dermal fibroblast IFN gamma
0.0
3.9

Dendritic cells LPS
3.5
4.5
Dermal fibroblast IL-4
14.0
4.5

Dendritic cells anti-CD40
0.0
3.0
IBD Colitis 2
6.0
23.8

Monocytes rest
0.0
0.0
IBD Crohn's
0.0
0.0

Monocytes LPS
0.0
0.0
Colon
0.0
2.4

Macrophages rest
0.0
3.0
Lung
5.3
3.5

Macrophages LPS
1.8
11.7
Thymus
0.0
13.6

HUVEC none
4.2
0.0
Kidney
41.5
100.0

HUVEC starved
6.6
4.8

TABLE AJF

general oncology screening panel_v_2.4

Column A - Rel. Exp.(%) Ag457, Run 259804332

Tissue Name
A
Tissue Name
A

Colon cancer 1
1.1
Bladder NAT 2
0.0

CC Margin (ODO3921)
0.0
Bladder NAT 3
0.3

Colon cancer 2
2.1
Bladder NAT 4
0.0

Colon NAT 2
0.0
Prostate adenocarcinoma 1
1.0

Colon cancer 3
2.1
Prostate adenocarcinoma 2
0.0

Colon NAT 3
0.0
Prostate adenocarcinoma 3
0.8

Colon malignant cancer 4
5.5
Prostate adenocarcinoma 4
2.8

Colon NAT 4
0.0
Prostate NAT 5
0.6

Lung cancer 1
0.0
Prostate adenocarcinoma 6
2.6

Lung NAT 1
0.0
Prostate adenocarcinoma 7
2.5

Lung cancer 2
100.0
Prostate adenocarcinoma 8
1.2

Lung NAT 2
0.4
Prostate adenocarcinoma 9
1.6

Squamous cell carcinoma 3
0.5
Prostate NAT 10
0.8

Lung NAT 3
0.0
Kidney cancer 1
1.1

Metastatic melanoma 1
0.0
Kidney NAT 1
0.0

Melanoma 2
0.6
Kidney cancer 2
9.9

Melanoma 3
0.0
Kidney NAT 2
1.6

Metastatic melanoma 4
0.6
Kidney cancer 3
2.4

Metastatic melanoma 5
1.0
Kidney NAT 3
0.0

Bladder cancer 1
0.0
Kidney cancer 4
0.0

Bladder NAT 1
0.0
Kidney NAT 4
0.0

Bladder cancer 2
0.3

Panel 1.3D Summary: Ag457/Ag1592 Expression of this gene, encoding a protein with homology to olfactory receptors, was highest in breast cancer cell line MCF-7 (CTs=32-32.8). In general, this gene was more highly expressed in cancer cell lines relative to normal tissues. Expression of this gene was significantly upregulated in 3/5 breast cancer cell lines, 2/6 ovarian cancer cell lines, and 7/10 lung cancer cell lines. Thus, expression of this gene is useful as a marker for breast, ovarian and lung cancers. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of breast, ovarian and lung cancers.

Panel 2D Summary: Ag457/Ag1592 Expression of this gene was upregulated in 6/8 breast cancer samples. Expression of this gene was higher in one ovarian and one bladder cancer sample relative to the normal adjacent tissue. These results are consistent with what was observed on Panel 1.3D. Thus, expression of this gene is useful as a marker for these cancers. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of breast, ovarian and bladder cancers.

Panel 4D Summary: Ag1592/Ag457 This gene showed preferential expression in activated basophils (CTs=33.9). Basophils release histamines and other biological modifiers in reponse to allergens and play an important role in the pathology of asthma and hypersensitivity reactions. These cells are a good model for the inflammatory cells that take part in various inflammatory lung and bowel diseases, such as asthma, Crohn's disease, and ulcerative colitis. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful to reduce or eliminate the symptoms of patients suffering from asthma, Crohn's disease, and ulcerative colitis.

general oncology screening panel_v_—2.4 Summary: Ag457 Moderate levels of expression of this gene was detected in a lung cancer sample (CT=30.8). Low but significant expression of this gene was also seen in a kidney cancer sample. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of lung and kidney cancers.

AK. CG55358-03, CG55358-04: Olfactory Receptor.

Expression of gene CG55358-03 and CG55358-04 were assessed using the primer-probe sets Ag1593, Ag455b and Ag455, described in Tables AKA, AKB and AKC. Results of the RTQ-PCR runs are shown in Tables AKD, AKE, AKF, AKG and AKH. CG55358-03 and CG55358-04 represent full-length physical clones.

TABLE AKAProbe Name Ag1593StartSEQ IDPrimersSequencesLengthPositionNoForward5′-cctagagctgatcgtctttgtg-3′22531328ProbeTET-5′-tcatcttttatctgctgactcttcttgg30821329ca-3′-TAMRAReverse5′-gaaagcaagacaatggtcatgt-3′221121330

TABLE AKB

Probe Name Ag455b

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-cctggctgtcatggcatatg-3′
20
329
1331

Probe
TET-5′-tgctgcagtctgcaaacccctgc-3′-
23
356
1332

TAMRA

Reverse
5′-gacgtgggtgcatgatgatg-3′
20
386
1333

TABLE AKC

Probe Name Ag455

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-cctggctgtcatggcatatg-3′
20
329
1334

Probe
TET-5′-ctatgctgcagtctgcaaacccctgc-3′-
26
353
1335

TAMRA

Reverse
5′-gacgtgggtgcatgatgatg-3′
20
386
1336

TABLE AKD

Ardais Breast 1.0

Column A - Rel. Exp. (%) Ag1593, Run 399643616

Column B - Rel. Exp. (%) Ag455b, Run 399643480

Tissue Name
A
B
Tissue Name
A
B

111297 Breast cancer metastasis
1.2
1.2
153636 Breast cancer
0.8
1.2

(9369)*

(D3D)

108830 Breast cancer metastasis
2.0
3.1
164668 Breast cancer
12.5
14.4

(OD06855)*

(6314)

97764 Breast cancer node metastasis
0.0
0.1
164677 Breast cancer
0.6
0.6

(OD06083)

(5272)

97739 Breast cancer (CHTN20676)
1.5
1.8
164685 Breast cancer
0.0
0.4

(0170)

145848 Breast cancer (9B6)
100.0
100.0
98857 Breast cancer
5.8
7.3

(OD06397-12)

145849 Breast cancer (9EC)
1.3
1.5
153628 Breast cancer
0.5
0.3

(D35)

153632 Breast cancer (D39)
14.8
20.9
153637 Breast cancer
1.6
1.2

(D3E)

153643 Breast cancer (D44)
0.3
0.1
164669 Breast cancer
3.0
3.1

(6992)

164672 Breast cancer (7464)
12.8
17.6
164678 Breast cancer
2.9
36.3

(5297)

164681 Breast cancer (5787)
1.5
2.1
164686 Breast cancer
9.8
10.6

(0732)

97748 Breast cancer (CHTN20931)
0.3
0.1
145857 Breast cancer (9F0)
1.3
1.3

145850 Breast cancer (9C7)
42.0
57.8
153630 Breast cancer
28.3
27.2

(D37)

149844 Breast cancer (24178)
0.5
0.5
153638 Breast cancer
8.0
8.5

(D3F)

153633 Breast cancer (D3A)
1.0
1.9
164670 Breast cancer
17.2
25.9

(7078)

153644 Breast cancer (D45)
0.2
0.2
164679 Breast cancer
0.5
0.7

(5486)

164673 Breast cancer (8452)
6.8
5.8
164687 Breast cancer
4.1
4.5

(5881)

164682 Breast cancer (6342)*
10.2
13.0
145846 Breast cancer
0.9
1.0

(9B7)

97751 Breast cancer (CHTN21053)
1.8
2.9
145858 Breast cancer
5.9
0.0

(9B4)

116417 Breast cancer (3367)*
1.6
3.2
153631 Breast cancer
1.4
1.1

(D38)

145852 Breast cancer (A1A)
5.7
7.9
153639 Breast cancer
1.7
1.5

(D40)

151097 Breast cancer (CHTN24298)
0.2
0.5
164671 Breast cancer
6.5
7.3

(7082)

153634 Breast cancer (D3B)
9.8
14.7
164680 Breast cancer
14.5
13.1

(5705)

155797 Breast cancer (EA6)
1.0
0.9
164688 Breast cancer
9.9
10.6

(7222)

164674 Breast cancer (8811)
8.4
12.2
111288 Breast NAT (3367)
0.1
0.1

164683 Breast cancer (6470)
22.2
25.5
111302 Breast NAT (6314)
0.5
0.2

97763 Breast cancer (OD06083)
0.7
0.1
105687 Breast cancer 1B
0.1
0.0

116418 Breast cancer (3378)*
0.7
0.8
105688 Breast NAT 1A
0.0
0.0

145853 Breast cancer (9F3)
13.3
22.8
105689 Breast cancer 2B
0.0
0.0

153432 Breast cancer (CHTN 24652)
7.0
9.8
105690 Breast NAT 2A
0.0
0.0

153635 Breast cancer (D3C)
0.2
0.5
111289 Breast cancer 3B*
7.9
7.9

164667 Breast cancer (5785)
21.0
19.3
111290 Breast NAT A*
5.6
7.4

164676 Breast cancer (5070)
4.2
5.1
116424 Breast cancer 4B*
0.1
0.1

164684 Breast cancer (6509)
1.4
1.5
116425 Breast NAT 4A
0.0
0.0

116421 Breast cancer (6314)
0.1
0.0
108847 Breast cancer
0.0
0.0

145854 Breast cancer (9B8)
3.4
3.0
105694 Breast NAT
0.3
0.3

153627 Breast cancer (D34)
4.3
3.9

TABLE AKE

Panel 1.3D

Column A - Rel. Exp. (%) Ag1593, Run 152078944

Column B - Rel. Exp. (%) Ag455b, Run 165974813

Tissue Name
A
B
Tissue Name
A
B

Liver adenocarcinoma
0.0
0.0
Kidney (fetal)
2.8
0.0

Pancreas
0.0
5.1
Renal ca. 786-0
3.6
0.0

Pancreatic ca. CAPAN 2
0.0
0.0
Renal ca. A498
8.5
0.0

Adrenal gland
0.0
0.0
Renal ca. RXF 393
1.8
0.0

Thyroid
0.0
0.0
Renal ca. ACHN
2.5
0.7

Salivary gland
0.0
0.0
Renal ca. UO-31
0.0
0.0

Pituitary gland
0.0
0.0
Renal ca. TK-10
0.0
0.0

Brain (fetal)
0.0
0.0
Liver
0.0
5.6

Brain (whole)
0.0
0.0
Liver (fetal)
0.0
0.0

Brain (amygdala)
0.0
0.0
Liver ca. (hepatoblast) HepG2
8.7
3.9

Brain (cerebellum)
0.0
0.0
Lung
0.0
0.0

Brain (hippocampus)
0.0
0.0
Lung (fetal)
2.0
0.0

Brain (substantia nigra)
0.0
0.0
Lung ca. (small cell) LX-1
4.2
0.0

Brain (thalamus)
0.0
0.0
Lung ca. (small cell) NCI-H69
11.9
17.2

Cerebral Cortex
0.0
0.0
Lung ca. (s. cell var.) SHP-77
28.1
33.4

Spinal cord
0.0
0.0
Lung ca. (large cell) NCI-H460
3.8
0.0

glio/astro U87-MG
2.1
0.0
Lung ca. (non-sm. cell) A549
1.9
0.0

glio/astro U-118-MG
27.7
14.5
Lung ca. (non-s. cell) NCI-H23
24.7
17.1

astrocytoma SW1783
6.0
0.0
Lung ca. (non-s. cell) HOP-62
5.8
4.1

neuro*; met SK-N-AS
20.4
0.0
Lung ca. (non-s. cl) NCI-H522
25.3
0.0

astrocytoma SF-539
0.0
0.0
Lung ca. (squam.) SW 900
0.0
5.0

astrocytoma SNB-75
6.3
10.6
Lung ca. (squam.) NCI-H596
32.8
31.9

glioma SNB-19
1.7
0.0
Mammary gland
0.0
0.0

glioma U251
0.0
0.0
Breast ca.* (pl. ef) MCF-7
100.0
100.0

glioma SF-295
14.3
6.2
Breast ca.* (pl. ef) MDA-MB-
25.7
29.1

231

Heart (Fetal)
2.4
0.0
Breast ca.* (pl. ef) T47D
8.5
5.8

Heart
0.0
0.0
Breast ca. BT-549
26.6
11.3

Skeletal muscle (Fetal)
3.8
4.7
Breast ca. MDA-N
6.7
0.0

Skeletal muscle
0.0
0.0
Ovary
0.0
0.0

Bone marrow
0.0
0.0
Ovarian ca. OVCAR-3
6.5
17.3

Thymus
0.0
3.3
Ovarian ca. OVCAR-4
3.6
0.0

Spleen
0.0
0.0
Ovarian ca. OVCAR-5
6.1
9.7

Lymph node
0.0
0.0
Ovarian ca. OVCAR-8
2.0
0.0

Colorectal
5.6
4.5
Ovarian ca. IGROV-1
0.0
8.1

Stomach
0.0
0.0
Ovarian ca. (ascites) SK-OV-3
2.7
0.0

Small intestine
2.0
0.0
Uterus
3.6
0.0

Colon ca. SW480
22.4
8.5
Placenta
4.1
27.0

Colon ca.* SW620 (SW480 met)
8.4
10.8
Prostate
0.0
5.2

Colon ca. HT29
8.2
0.0
Prostate ca.* (bone met) PC-3
6.9
0.0

Colon ca. HCT-116
1.7
6.5
Testis
9.3
17.1

Colon ca. CaCo-2
7.4
0.0
Melanoma Hs688(A).T
0.0
0.0

CC Well to Mod Diff
3.7
0.0
Melanoma* (met) Hs688(B).T
0.0
0.0

(ODO3866)

Colon ca. HCC-2998
9.1
23.2
Melanoma UACC-62
1.6
0.0

Gastric ca. (liver met) NCI-N87
64.6
43.5
Melanoma M14
0.0
0.0

Bladder
0.0
0.0
Melanoma LOX IMVI
2.4
0.0

Trachea
0.0
6.3
Melanoma* (met) SK-MEL-5
1.9
0.0

Kidney
0.0
0.0
Adipose
0.0
0.0

TABLE AKF

Panel 2D

Column A - Rel. Exp. (%) Ag1593, Run 152079595

Column B - Rel. Exp. (%) Ag455, Run 145367170

Column C - Rel. Exp. (%) Ag455, Run 145492233

Tissue Name
A
B
C
Tissue Name
A
B
C

Normal Colon
2.5
0.5
2.5
Kidney Margin 8120608
0.0
0.0
0.0

CC Well to Mod Diff
1.1
0.0
0.6
Kidney Cancer 8120613
0.0
0.0
0.0

(ODO3866)

CC Margin (ODO3866)
2.1
1.2
1.0
Kidney Margin 8120614
0.0
0.0
0.0

CC Gr.2 rectosigmoid
3.2
1.3
3.2
Kidney Cancer 9010320
0.9
0.0
2.5

(ODO3868)

CC Margin (ODO3868)
0.0
0.0
0.0
Kidney Margin 9010321
0.0
0.0
1.0

CC Mod Diff (ODO3920)
8.7
3.0
2.4
Normal Uterus
0.0
0.0
0.6

CC Margin (ODO3920)
1.9
0.0
0.0
Uterine Cancer 064011
0.4
0.4
0.0

CC Gr.2 ascend colon
3.0
1.7
1.4
Normal Thyroid
0.0
0.5
0.6

(ODO3921)

CC Margin (ODO3921)
0.5
0.4
0.0
Thyroid Cancer
0.4
1.5
0.9

CC from Partial Hepatectomy
1.7
2.6
0.0
Thyroid Cancer A302152
3.0
2.9
0.8

(ODO4309) Mets

Liver Margin (ODO4309)
0.5
1.2
0.6
Thyroid Margin
0.0
0.8
0.5

A302153

Colon mets to lung
0.0
0.0
0.5
Normal Breast
0.0
0.3
2.1

(OD04451-01)

Lung Margin (OD04451-02)
0.9
0.0
0.0
Breast Cancer
6.2
7.1
4.9

Normal Prostate 6546-1
0.9
0.5
1.4
Breast Cancer
100.0
49.3
57.0

(OD04590-01)

Prostate Cancer (OD04410)
16.3
11.9
2.9
Breast Cancer Mets
37.4
100.0
40.3

(OD04590-03)

Prostate Margin (OD04410)
5.6
3.8
0.9
Breast Cancer Metastasis
13.8
27.4
11.0

Prostate Cancer (OD04720-
0.5
1.1
0.0
Breast Cancer
3.3
5.1
0.8

01)

Prostate Margin (OD04720-
0.5
1.8
0.0
Breast Cancer
8.2
8.1
13.1

02)

Normal Lung
2.8
1.5
0.0
Breast Cancer 9100266
1.0
3.0
1.4

Lung Met to Muscle
3.6
10.4
1.1
Breast Margin 9100265
1.7
0.0
1.7

(ODO4286)

Muscle Margin (ODO4286)
0.0
0.0
0.7
Breast Cancer A209073
1.5
3.2
0.7

Lung Malignant Cancer
0.0
1.8
0.7
Breast Margin A209073
0.4
0.8
1.4

(OD03126)

Lung Margin (OD03126)
0.0
1.4
0.7
Normal Liver
0.0
2.9
0.0

Lung Cancer (OD04404)
2.2
0.7
2.5
Liver Cancer
0.0
0.4
0.9

Lung Margin (OD04404)
0.0
0.0
1.5
Liver Cancer 1025
2.1
0.4
0.7

Lung Cancer (OD04565)
0.4
0.4
1.9
Liver Cancer 1026
0.0
0.0
0.0

Lung Margin (OD04565)
0.0
0.0
0.0
Liver Cancer 6004-T
0.4
0.0
0.0

Lung Cancer (OD04237-01)
7.6
5.4
5.5
Liver Tissue 6004-N
4.2
0.7
2.9

Lung Margin (OD04237-02)
0.4
0.4
0.0
Liver Cancer 6005-T
0.7
0.0
2.4

Ocular Mel Met to Liver
0.0
0.0
0.7
Liver Tissue 6005-N
0.0
0.4
0.0

(ODO4310)

Liver Margin (ODO4310)
0.0
0.0
0.0
Normal Bladder
3.6
5.4
0.8

Melanoma Metastasis
3.6
6.8
0.8
Bladder Cancer
0.7
0.5
1.8

Lung Margin (OD04321)
1.0
3.1
0.0
Bladder Cancer
4.5
2.1
5.4

Normal Kidney
0.0
0.4
0.0
Bladder Cancer
33.4
64.2
20.4

(OD04718-01)

Kidney Ca, Nuclear grade 2
0.9
0.0
2.3
Bladder Normal
0.0
0.7
0.0

(OD04338)

Adjacent (OD04718-03)

Kidney Margin (OD04338)
1.2
0.8
0.8
Normal Ovary
0.0
0.0
0.0

Kidney Ca Nuclear grade 1/2
1.9
0.7
1.5
Ovarian Cancer
2.6
2.4
0.7

(OD04339)

Kidney Margin (OD04339)
0.0
0.0
0.0
Ovarian Cancer
97.9
65.1
100.0

(OD04768-07)

Kidney Ca, Clear cell type
0.4
0.0
0.0
Ovary Margin
0.0
0.5
0.0

(OD04340)

(OD04768-08)

Kidney Margin (OD04340)
0.8
0.0
0.9
Normal Stomach
0.0
1.2
1.5

Kidney Ca, Nuclear grade 3
0.5
3.3
0.0
Gastric Cancer 9060358
0.0
0.0
2.2

(OD04348)

Kidney Margin (OD04348)
2.0
2.4
3.0
Stomach Margin
0.4
0.0
0.0

9060359

Kidney Cancer (OD04622-
0.0
1.7
0.0
Gastric Cancer 9060395
0.0
0.0
0.0

01)

Kidney Margin (OD04622-
0.4
0.9
0.0
Stomach Margin
0.0
1.0
0.0

03)

9060394

Kidney Cancer (OD04450-
0.0
0.4
0.0
Gastric Cancer 9060397
4.1
2.3
1.0

01)

Kidney Margin (OD04450-
0.0
0.0
0.0
Stomach Margin
0.0
1.3
1.1

03)

9060396

Kidney Cancer 8120607
0.0
0.0
0.0
Gastric Cancer 064005
2.9
0.4
1.6

TABLE AKG

Panel 3D

Column A - Rd. Exp.(%) Ag455, Run 164730890

Tissue Name
A
Tissue Name
A

94905 Daoy
18.2
94954 Ca Ski Cervical epidermoid
33.9

Medulloblastoma/Cerebellum

carcinoma (metastasis

94906 TE671
0.8
94955 ES-2 Ovarian clear cell
0.0

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
3.8
94957 Ramos Stimulated with
1.3

Medulloblastoma/Cerebellum

PMA/ionomycin 6h

94908 PFSK-1 Primitive
4.5
94958 Ramos Stimulated with
1.5

Neuroectodermal/Cerebellum

PMA/ionomycin 14h

94909 XF-498 CNS
4.5
94962 MEG-01 Chronic
100.0

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
2.0
94963 Raji Burkitt's lymphoma
0.0

94911 SF-268 CNS/glioblastoma
0.0
94964 Daudi Burkitt's lymphoma
0.0

94912 T98G Glioblastoma
7.9
94965 U266 B-cell
40.3

plasmacytomalmyeloma

96776 SK-N-SH Neuroblastoma
0.0
94968 CA46 Burkitt's lymphoma
1.6

(metastasis)

94913 SF-295 CNS/glioblastoma
1.9
94970 RL non-Hodgkin's B-cell
0.0

lymphoma

94914 Cerebellum
1.2
94972 JM1 pre-B-cell
3.7

lymphoma/leukemia

96777 Cerebellum
2.1
94973 Jurkat T cell leukemia
0.0

94916 NCI-H292 Mucoepidermoid
2.4
94974 TF-1 Erythroleukemia
10.6

lung carcinoma

94917 DMS-114 Small cell lung
0.2
94975 HUT 78 T-cell lymphoma
3.0

cancer

94918 DMS-79 Small cell lung
97.9
94977 U937 Histiocytic lymphoma
12.2

cancer/neuroendocrine

94919 NCI-H146 Small cell lung
22.5
94980 KU-812 Myelogenous
17.6

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
2.3
769-P- Clear cell renal carcinoma
0.0

cancer/neuroendocrine

94921 NCI-N417 Small cell lung
14.4
94983 Caki-2 Clear cell renal
0.0

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
3.6
94984 SW 839 Clear cell renal
1.6

cancer/neuroendocnne

carcinoma

94924 NCI-H157 Squamous cell lung
34.2
94986 G401 Wilms' tumor
0.0

cancer (metastasis)

94925 NCI-H1155 Large cell lung
9.8
94987 Hs766T Pancreatic carcinoma
11.6

cancer/neuroendocrine

(LN metastasis)

94926 NCI-H1299 Large cell lung
18.2
94988 CAPAN-1 Pancreatic
6.6

cancer/neuroendocnne

adenocarcinoma (liver metastasis)

94927 NCI-H727 Lung carcinoid
1.8
94989 SU86.86 Pancreatic carcinoma
3.0

(liver metastasis)

94928 NCI-UMC-11 Lung carcinoid
7.9
94990 BxPC-3 Pancreatic
13.3

adenocarcinoma

94929 LX-1 Small cell lung cancer
1.3
94991 HPAC Pancreatic
2.8

adenocarcinoma

94930 Colo-205 Colon cancer
0.0
94992 MIA PaCa-2 Pancreatic
0.0

carcinoma

94931 KM12 Colon cancer
23.7
94993 CFPAC-1 Pancreatic ductal
17.7

adenocarcinoma

94932 KM20L2 Colon cancer
0.0
94994 PANC-1 Pancreatic epithelioid
5.5

ductal carcinoma

94933 NCI-H716 Colon cancer
40.6
94996 T24 Bladder carcinma
5.0

(transitional cell

94935 SW-48 Colon adenocarcinoma
1.8
5637- Bladder carcinoma
0.0

94936 SW1116 Colon
2.4
94998 HT-1197 Bladder carcinoma
15.2

adenocarcinoma

94937 LS 174T Colon
0.0
94999 UM-UC-3 Bladder carcinma
0.0

adenocarcinoma

(transitional cell)

94938 SW-948 Colon
1.1
95000 A204 Rhabdomyosarcoma
5.6

adenocarcinoma

94939 SW-480 Colon
0.0
95001 HT-1080 Fibrosarcoma
0.0

adenocarcinoma

94940 NCI-SNU-5 Gastric carcinoma
11.0
95002 MG-63 Osteosarcoma (bone)
2.0

KATO III- Gastric carcinoma
9.7
95003 SK-LMS-1 Leiomyosarcoma
10.7

(vulva)

94943 NCI-SNU-16 Gastric
11.6
95004 SJRH30 Rhabdomyosarcoma
1.6

carcinoma

(met to bone marrow)

94944 NCI-SNU-1 Gastric carcinoma
6.0
95005 A431 Epidermoid carcinoma
4.6

94946 RF-1 Gastric adenocarcinoma
2.6
95007 WM266-4 Melanoma
1.3

94947 RF-48 Gastric adenocarcinoma
6.0
DU 145- Prostate carcinoma (brain
0.0

metastasis)

96778 MKLN-45 Gastric carcinoma
0.0
95012 MDA-MB-468 Breast
8.5

adenocarcinoma

94949 NCI-N87 Gastric carcinoma
1.4
SCC-4- Squamous cell carcinoma of
0.0

tongue

94951 OVCAR-5 Ovarian carcinoma
0.0
SCC-9- Squamous cell carcinoma of
1.2

tongue

94952 RL95-2 Uterine carcinoma
3.7
SCC-15- Squamous cell carcinoma of
1.8

tongue

94953 HelaS3 Cervical
29.9
95017 CAL 27 Squamous cell
0.0

adenocarcinoma

carcinoma of tongue

TABLE AKH

Panel 4D

Column A - Rel. Exp. (%) Ag1593, Run 152080690

Column B - Rel. Exp. (%) Ag455, Run 138083105

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
7.5
4.0
HUVEC IL-1beta
0.0
0.0

Secondary Th2 act
9.9
5.5
HUVEC IFN gamma
6.3
0.0

Secondary Tr1 act
5.0
7.7
HUVEC TNF alpha + IFN gamma
0.0
0.0

Secondary Th1 rest
7.2
5.1
HUVEC TNF alpha +IL4
0.0
0.0

Secondary Th2 rest
5.3
4.6
HUVEC IL-11
0.0
3.4

Secondary Tr1 rest
0.0
8.1
Lung Microvascular EC none
0.0
0.0

Primary Th1 act
0.0
6.6
Lung Microvascular EC TNFalpha +
0.0
1.6

IL-1beta

Primary Th2 act
5.1
0.0
Microvascular Dermal EC none
0.0
3.6

Primary Tr1 act
0.0
1.5
Microsvasular Dermal EC TNFalpha +
7.1
0.0

IL-1beta

Primary Th1 rest
14.8
6.4
Bronchial epithelium TNFalpha +
0.0
0.0

IL1beta

Primary Th2 rest
4.3
4.1
Small airway epithelium none
0.0
3.8

Primary Tr1 rest
4.5
0.9
Small airway epithelium TNFalpha +
0.0
2.3

IL-1beta

CD45RA CD4 lymphocyte
6.3
10.4
Coronery artery SMC rest
0.0
1.6

act

CD45RO CD4 lymphocyte
1.6
3.8
Coronery artery SMC TNFalpha +
0.0
6.4

act

IL-1beta

CD8 lymphocyte act
0.0
1.5
Astrocytes rest
6.8
0.0

Secondary CD8 lymphocyte
0.0
1.5
Astrocytes TNFalpha + IL-1beta
1.7
6.0

rest

Secondary CD8 lymphocyte
0.0
5.3
KU-812 (Basophil) rest
13.7
25.9

act

CD4 lymphocyte none
0.0
0.0
KU-812 (Basophil) PMA/ionomycin
100.0
100.0

2ry Th1/Th2/Tr1 anti-CD95
8.8
5.1
CCD1106 (Keratinocytes) none
4.5
2.1

CH11

LAK cells rest
0.0
3.1
CCD1106 (Keratinocytes) TNFalpha +
0.0
12.1

IL-1beta

LAK cells IL-2
5.2
14.0
Liver cirrhosis
3.5
14.9

LAK cells IL-2 + IL-12
1.6
6.7
Lupus kidney
0.0
0.0

LAK cells IL-2 + IFN
8.9
6.7
NCI-H292 none
2.5
3.3

gamma

LAK cells IL-2 + IL-18
7.0
1.2
NCI-H292 IL-4
13.8
7.5

LAK cells PMA/ionomycin
1.6
0.0
NCI-H292 IL-9
9.7
7.9

NK Cells IL-2 rest
3.8
5.2
NCI-H292 IL-13
1.7
5.4

Two Way MLR 3 day
6.3
4.3
NCI-H292 IFN gamma
6.8
10.9

Two Way MLR 5 day
1.7
3.4
HPAEC none
0.0
0.0

Two Way MLR 7 day
0.0
1.7
HPAEC TNFalpha + IL-1beta
9.6
3.3

PBMC rest
0.0
1.3
Lung fibroblast none
3.0
0.0

PBMC PWM
28.1
25.7
Lung fibroblast TNFalpha + IL-1
6.8
0.0

beta

PBMC PHA-L
1.1
10.1
Lung fibroblast IL-4
1.5
0.0

Ramos (B cell) none
6.7
3.6
Lung fibroblast IL-9
2.9
0.0

Ramos (B cell) ionomycin
9.1
16.0
Lung fibroblast IL-13
0.0
2.6

B lymphocytes PWM
37.6
47.6
Lung fibroblast IFN gamma
0.0
2.5

B lymphocytes CD40L and
6.4
14.4
Dermal fibroblast CCD1070 rest
2.5
12.4

IL-4

EOL-1 dbcAMP
0.0
2.8
Dermal fibroblast CCD1070 TNF
4.9
12.4

alpha

EOL-l dbcAMP
1.2
1.8
Dermal fibroblast CCD1070 IL-1
0.0
5.2

PMA/ionomycin

beta

Dendritic cells none
0.0
0.0
Dermal fibroblast IFN gamma
0.0
0.0

Dendritic cells LPS
0.0
0.0
Dermal fibroblast IL-4
1.6
4.3

Dendritic cells anti-CD40
0.0
0.0
IBD Colitis 2
3.4
1.4

Monocytes rest
0.0
0.0
IBD Crohn's
1.5
1.6

Monocytes LPS
0.0
4.7
Colon
6.9
2.0

Macrophages rest
0.0
0.0
Lung
2.2
0.0

Macrophages LPS
0.0
1.7
Thymus
0.0
0.0

HUVEC none
3.0
0.0
Kidney
36.6
62.0

HUVEC starved
3.1
3.3

Ardais Breast1.0 Summary: Ag1593/Ag455 Highest expression of this gene is detected in breast cancer 9B6 samples (CTs=25-27). Significant expression of this gene is seen in number of cancer breast cancer samples. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of breast cancer.

Panel 1.3D Summary: Ag1593/Ag455b The expression of this gene was detected in a number of the cancer cell lines and not in the normal tissues. The highest expression was found in MCF-7 breast cancer cells, which are estrogen receptor positive. Low expression of this gene was also seen in cell lines derived from lung, colon, breast and gastric cancers. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of breast, lung, colon and gastric cancers.

Panel 2D Summary: Ag1593/Ag455 Highest expression of this gene was detected in breast cancer samples (CTs=29-30.5). Significant expression of this gene was seen in number of cancer samples derived from breast, ovarian, bladder, colon, and lung cancers. Expression of this gene is useful as marker to detect these cancers and modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of breast, ovarian, bladder, colon, and lung cancers.

Panel 3D Summary: Ag455 This gene was expressed widely, but at a low level, across of all of the samples in panel 3D. Highest expression was detected in a chronic myelogenous leukemia (megokaryoblast) (CT value=30), indicating a potential role for the gene in this disease.

Panel 4D Summary: Ag1593/Ag455 This gene was highly induced the KU-812 basophil cell line and was expressed at lower levels in pokeweed mitogen-activated B cells and PBMC (CTs=31-34). Activated basophils release a number of potent bioresponse modifiers that can damage surrounding tissues. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product will reduce or block inflammation or tissue damage caused by inflammation by blocking activation of basophils and is useful for the treatment of asthma, emphysema, and allergy.

AL. CG55604-04: Olfactory Receptor.

Expression of gene CG55604-04 was assessed using the primer-probe set Ag1240, described in Table ALA. Results of the RTQ-PCR runs are shown in Tables ALB, ALC, ALD and ALE.

TABLE ALAProbe Name Ag1240StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ttccctactggggacagaatat-3′225041337ProbeTET-5′-tacttttgtgaacctcctgccctcct-3′-265361338TAMRAReverse5′-gccatttctgtgctgtaagtgt-3′225791339

TABLE ALB

AI_comprehensive panel_v1.0

Column A - Rel. Exp.(%) Ag1240, Run 306266935

Tissue Name
A
Tissue Name
A

110967 COPD-F
15.2
112427 Match Control Psoriasis-F
41.2

110980 COPD-F
26.1
112418 Psoriasis-M
4.9

110968 COPD-M
26.1
112723 Match Control Psoriasis-M
29.1

110977 COPD-M
85.9
112419 Psoriasis-M
15.0

110989 Emphysema-F
25.5
112424 Match Control Psonasis-M
34.6

110992 Emphysema-F
12.9
112420 Psoriasis-M
54.3

110993 Emphysema-F
17.9
112425 Match Control Psoriasis-M
37.6

110994 Emphysema-F
15.2
104689 (MF) OA Bone-Backus
54.3

110995 Emphysema-F
66.9
104690 (MF) Adj “Normal” Bone-
31.2

Backus

110996 Emphysema-F
8.8
104691 (ME) OA Synovium-Backus
42.3

110997 Asthma-M
1.5
104692 (BA) OA Cartilage-Backus
0.0

111001 Asthma-F
38.4
104694 (BA) OA Bone-Backus
20.4

111002 Asthma-F
56.3
104695 (BA) Adj “Normal” Bone-
28.1

Backus

111003 Atopic Asthma-F
50.7
104696 (BA) OA Synovium-Backus
23.2

111004 Atopic Asthma-F
70.2
104700 (SS) QA Bone-Backus
15.4

111005 Atopic Asthma-F
46.7
104701 (SS) Adj “Normal” Bone-Backus
18.3

111006 Atopic Asthma-F
9.3
104702 (SS) OA Synovium-Backus
25.9

111417 Allergy-M
44.1
117093 OA Cartilage Rep7
53.2

112347 Allergy-M
0.0
112672 OA BoneS
5.6

112349 Normal Lung-F
0.0
112673 OA SynoviumS
4.3

112357 Normal Lung-F
20.3
112674 OA Synovial Fluid cells 5
8.6

112354 NormalLung-M
15.1
117100 OA Cartilage Rep14
1.2

112374 Crohns-F
54.0
1112756 OA Bone9
23.2

112389 Match Control Crohns-F
21.3
112757 OA Synovium9
0.9

112375 Crohns-F
26.8
112758 OA Synovial Fluid Cells9
13.2

112732 Match Control Crohns-F
38.2
117125 RA Cartilage Rep2
5.1

112725 Crohns-M
9.0
113492 Bone2 RA
6.7

112387 Match Control Crohns-M
5.4
113493 Synovium2 RA
3.4

112378 Crohns-M
0.2
113494 Syn Fluid Cells RA
6.9

112390 Match Control Crohns-M
60.7
113499 Cartilage4 RA
4.4

112726 Crohns-M
41.5
113500 Bone4 RA
6.7

112731 Match Control Crohns-M
13.8
113501 Synovium4 RA
4.1

112380 Ulcer Col-F
4S.1
113502 Syn Fluid Cells4 RA
4.1

112734 Match Control Ulcer Col-F
82.9
113495 Cartilage3 RA
3.4

112384 Ulcer Col-F
86.5
113496 Bone3 RA
5.0

112737 Match Control Ulcer Col-F
7.3
113497 Synovium3 RA
1.9

112386 Ulcer Col-F
12.9
113498 Syn Fluid Cells3 RA
6.8

112738 Match Control Ulcer Col-F
10.4
117106 Normal Cartilage Rep20
1.0

112381 Ulcer CoI-M
0.0
113663 Bone3 Normal
0.0

112735 Match Control Ulcer Col-
4.4
113664 Synovium3 Normal
0.0

112382 Ulcer Col-M
24.1
113665 Syn Fluid Cells3 Normal
0.7

112394 Match Control Ulcer Col-
5.3
117107 Normal Cartilage Rep22
21.6

112383 Ulcer Col-M
100.0
113667 Bone4 Normal
32.1

112736 Match Control Ulcer Col-
5.6
113668 Synovium4 Normal
27.2

M

112423 Psoriasis-F
17.9
113669 Syn Fluid Cells4 Normal
60.7

TABLE ALC

General_screening_panel_v1.4

Column A - Rel. Exp.(%) Ag1240, Run 212696338

Tissue Name
A
Tissue Name
A

Adipose
0.0
Renal ca. TK-10
12.8

Melanoma* Hs688(A).T
2.8
Bladder
3.4

Melanoma* Hs688(B).T
0.9
Gastric ca. (liver met.)
0.0

NCI-N87

Melanoma* M14
28.1
Gastric ca. KATO III
1.6

Melanoma* LOXIMVI
15.6
Colon ca. SW-948
7.0

Melanoma* SK-MEL-5
46.3
Colon ca. SW480
65.1

Squamous cell carcinoma
6.7
Colon ca.* (SW480 met)
100.0

SCC-4

SW620

Testis Pool
63.7
Colon ca. HT29
15.5

Prostate ca.* (bone met)
16.6
Colon ca. HCT-116
51.4

PC-3

Prostate Pool
10.7
Colon ca. CaCo-2
0.0

Placenta
0.0
Colon cancer tissue
9.9

Uterus Pool
2.6
Colon ca. SW116
16.0

Ovarian ca. OVCAR-3
52.5
Colon ca. Colo-205
0.0

Ovarian ca. SK-OV-3
54.3
Colon ca. SW-48
7.3

Ovarian ca. OVCAR-4
0.0
Colon Pool
26.6

Ovarian ca. OVCAR-5
29.5
Small Intestine Pool
16.4

Ovarian ca. IGROV-1
0.0
Stomach Pool
23.5

Ovarian ca. OVCAR-8
8.0
Bone Marrow Pool
4.0

Ovary
1.6
Fetal Heart
3.7

Breast ca. MCF-7
0.0
Heart Pool
3.4

Breast ca. MDA-MB-231
35.6
Lymph Node Pool
12.3

Breast ca. BT 549
0.0
Fetal Skeletal Muscle
1.2

Breast ca. T47D
26.8
Skeletal Muscle Pool
0.0

Breast ca. MDA-N
50.7
Spleen Pool
12.5

Breast Pool
53.2
Thymus Pool
18.9

Trachea
6.5
CNS cancer (glio/astro)
36.9

U87-MG

Lung
6.5
CNS cancer (glio/astro)
28.9

U-118-MG

Fetal Lung
1.3
CNS cancer (neuro;met)
2.4

SK-N-AS

Lung ca. NCI-N417
0.0
CNS cancer (astro) SF-539
0.0

Lung ca. LX-1
99.3
CNS cancer (astro) SNB-75
0.0

Lung ca. NCI-H146
18.8
CNS cancer (glio) SNB-19
0.0

Lung ca. SHP-77
1.2
CNS cancer (glio) SF-295
44.4

Lung ca. A549
3.0
Brain (Amygdala) Pool
12.9

Lung ca. NCI-H526
14.6
Brain (cerebellum)
1.4

Lung ca. NCI-H523
40.9
Brain (fetal)
26.4

Lung ca. NCI-H460
13.5
Brain (Hippocampus) Pool
11.9

Lung ca. HOP-62
11.9
Cerebral Cortex Pool
29.9

Lung ca. NCI-H522
0.0
Brain (Substantia nigra) Pool
8.8

Liver
0.0
Brain (Thalamus) Pool
0.0

Fetal Liver
17.9
Brain (whole)
15.9

Liver ca. HepG2
0.0
Spinal Cord Pool
8.3

Kidney Pool
47.6
Adrenal Gland
6.4

Fetal Kidney
37.6
Pituitary gland Pool
1.6

Renal ca. 786-0
22.5
Salivary Gland
0.0

Renal ca. A498
8.5
Thyroid (female)
0.0

Renal ca. ACHN
6.3
Pancreatic ca. CAPAN2
0.0

Renal ca. UO-31
17.2
Pancreas Pool
22.8

TABLE ALD

Panel 1.2

Column A - Rel. Exp.(%) Ag1240, Run 129121683

Tissue Name
A
Tissue Name
A

Endothelial cells
0.0
Renal ca. 786-0
0.0

Heart (Fetal)
0.0
Renal ca. A498
0.0

Pancreas
0.0
Renal ca. RXF 393
0.0

Pancreatic ca. CAPAN 2
0.0
Renal ca. ACHN
0.0

Adrenal gland
0.0
Renal ca. UO-31
0.0

Thyroid
0.0
Renal ca. TK-10
0.0

Salivary gland
0.0
Liver
0.0

Pituitary gland
0.0
Liver (fetal)
0.0

Brain (fetal)
0.0
Liver ca. (hepatoblast) HepG2
0.0

Brain (whole)
0.0
Lung
0.0

Brain (amygdala)
0.0
Lung (fetal)
0.0

Brain (cerebellum)
0.0
Lung ca. (small cell) LX-1
39.5

Brain (hippocampus)
0.0
Lung ca. (small cell)
0.0

NCI-H69

Brain (thalamus)
0.0
Lung ca. (s.celI var.) SHP-77
0.0

Cerebral Cortex
0.0
Lung ca. (large cell)
0.0

NCI-H460

Spinal cord
100.0
Lung ca. (non-sm. cell) A549
0.0

glio/astro U87-MG
0.0
Lung ca. (non.s.cell)
0.0

NGI-H23

glio/astro U-118-MG
0.0
Lung ca. (non-s.cell) HOP-62
0.0

astrocytoma 5W1783
0.0
Lung ca. (non-s.cl) NCI-H522
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (squam.) SW 900
0.0

astrocytoma SF-539
0.0
Lung ca. (squam.) NCI-H596
0.0

astrocytoma SNB-75
0.0
Mammary gland
0.0

glioma SNB-19
0.0
Breast ca.* (pl.ef) MCF-7
0.0

glioma U25
0.0
Breast ca.* (pl.ef)
0.0

MDA-MB-231

glioma SF-295
0.0
Breast ca.* (pl. ef) T47D
0.0

Heart
0.0
Breast ca. BT-549
0.0

Skeletal muscle
0.0
Breast ca. MDA-N
77.4

Bone marrow
0.0
Ovary
0.0

Thymus
0.0
Ovarian ca. OVCAR-3
0.0

Spleen
0.0
Ovarian ca. OVCAR-4
0.0

Lymph node
0.0
Ovarian ca. OVCAR-5
17.7

Colorectal
7.5
Ovarian ca. OVCAR-8
0.0

Stomach
0.0
Ovarian ca. IGROV-1
0.0

Small intestine
0.0
Ovarian ca. (ascites)
0.0

SK-OV-3

Colon ca. SW480
0.0
Uterus
0.0

Colon ca.* SW620
58.2
Placenta
0.0

(SW480 met)

Colon ca. HT29
0.0
Prostate
0.0

Colon ca. HCT-116
0.0
Prostate ca.* (bone met) PC-3
0.0

Colon ca. CaCo-2
0.0
Testis
0.0

CC Well to Mod Diff
57.0
Melanoma Hs688(A).T
0.0

(OD03866)

Colon ca. HCC-2998
0.0
Melanoma* (met) Hs688(B).T
0.0

Gastric ca. (liver met)
0.0
Melanoma UACC-62
0.0

NCI-N87

Bladder
0.0
Melanoma M14
54.0

Trachea
0.0
Melanoma LOX IMYI
0.0

Kidney
0.0
Melanoma* (met) SK-MEL-5
0.0

Kidney (fetal)
0.0

TABLE ALE

Panel 4D

Column A - Rel. Exp.(%) Ag1240, Run 140461898

Column B - Rel. Exp.(%) Ag1240, Run 145779979

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
18.9
15.8
HUVEC IL-1beta
1.6
11.2

Secondary Th2 act
49.3
62.0
HUVEC IFN gamma
3.8
6.3

Secondary Tr1 act
51.4
52.9
HUVEC TNF alpha + IFN gamma
1.8
7.2

Secondary Th1 rest
1.4
0.0
HUVEC TNF alpha + IL4
7.2
12.4

Secondary Th2 rest
2.8
4.6
HUVEC IL-11
3.2
2.1

Secondary Tr1 rest
1.4
7.0
Lung Microvascular EC none
16.5
17.3

Primary Th1 act
52.1
46.3
Lung Microvascular EC TNFalpha +
9.6
10.6

IL-1beta

Primary Th2 act
39.5
39.5
Microvascular Dermal EC none
4.8
8.0

Primary Tr1 act
73.7
69.3
Microsvasular Dermal EC TNFalpha
1.7
2.2

+ IL-1beta

Primaiy Th1 rest
11.2
12.6
Bronchial epithelium TNFalpha +
4.6
0.0

IL1beta

Primary Th2 rest
4.5
11.0
Small airway epithelium none
2.1
2.8

Primary Tr1 rest
2.9
9.5
Small airway epithelium TNFalpha +
28.5
26.6

IL-1beta

CD45RA CD4 lymphocyte
9.1
7.0
Coronery artery SMC rest
0.5
1.8

CD45RO CD4 lymphocyte
23.0
14.6
Coronery artery SMC TNFalpha +
1.8
2.8

IL-1beta

CD8 lymphocyte act
2.5
8.9
Astrocytes rest
1.2
0.8

Secondary CD8
2.3
3.7
Astrocytes TNFalpha + IL-1beta
0.8
0.0

lymphocyte rest

Secondary CD8
15.6
8.2
KU-812 (Basophil) rest
9.2
7.3

lymphocyte act

CD4 lymphocyte none
0.4
1.8
KU-812 (Basophil) PMA/ionomycin
33.9
31.4

2ry Th1/Th2/Tr1 anti-
1.4
2.9
CCD1106 (Keratinocytes) none
11.4
5.6

CD95 CH11

LAK cells rest
0.0
0.0
93580 CCD1106 (Keratinocytes)
22.7
0.8

TNFa and IFNg

LAK cells IL-2
0.9
0.0
Liver cirrhosis
3.5
8.3

LAK cells IL-2 + IL-12
8.6
4.1
Lupus kidney
2.6
1.0

LAK cells IL-2 + IFN
2.5
2.5
NCI-H292 none
24.7
15.6

gamma

LAK cells IL-2 + IL-18
5.4
4.9
NCI-H292 IL-4
13.8
34.2

LAK cells PMA/ionomycin
0.0
4.9
NCI-H292 IL-9
15.4
28.7

NK Cells IL-2 rest
0.9
0.9
NCI-H292 IL-13
8.5
19.3

Two Way MLR 3 day
0.0
3.5
NCI-H292 IFN gamma
4.9
12.8

Two Way MLR 5 day
1.2
2.6
HPAEC none
12.5
12.9

Two Way MLR 7 day
3.5
7.3
HPAEC TNF alpha + IL-1 beta
12.9
19.5

PBMC rest
0.0
1.6
Lung fibroblast none
2.9
2.9

PBMC PWM
3.4
3.8
Lung fibroblast TNF alpha + IL-1
2.0
1.0

beta

PBMC PHA-L
12.2
10.4
Lung fibroblast IL-4
4.0
2.9

Ramos (B cell) none
82.9
50.7
Lung fibroblast IL-9
8.2
6.0

Ramos (B cell) ionomycin
100.0
100.0
Lung fibroblast IL-13
5.0
3.3

B lymphocytes PWM
3.6
7.0
Lung fibroblast IFN gamma
2.5
5.6

B lymphocytes CD40L and
4.3
7.9
Dermal fibroblast CCD1070 rest
29.1
35.4

IL-4

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 TNF
42.6
57.0

alpha

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 IL-1
17.8
31.4

PMA/ionomycin

beta

Dendritic cells none
0.0
0.0
Dermal fibroblast IFN gamma
0.9
0.8

Dendritic cells LPS
0.0
42.9
Dermal fibroblast IL-4
1.8
3.1

Dendritic cells anti-CD40
0.0
0.0
IBD Colitis 2
1.8
0.6

Monocytes rest
0.0
0.0
IBD Crohn's
0.0
0.9

Monocytes LPS
0.0
0.0
Colon
0.9
2.2

Macrophages rest
7.6
4.5
Lung
1.8
5.3

Macrophages LPS
1.2
0.0
Thymus
16.6
7.0

HUVEC none
11.5
11.3
Kidney
17.2
18.8

HUVEC starved
14.2
19.8

AI_comprehensive panel_v1.0 Summary: Ag1240 The highest expression of this gene was detected in an ulcerative colitis sample. Moderate levels of expression of this gene were detected in samples derived from normal and orthoarthitis/rheumatoid arthritis bone and adjacent bone, cartilage, synovium and synovial fluid samples, from normal lung, COPD lung, emphysema, atopic asthma, asthma, allergy, Crohn's disease (normal matched control and diseased), ulcerative colitis (normal matched control and diseased), and psoriasis (normal matched control and diseased). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of autoimmune and inflammatory disorders including psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.

General_screening_panel_v1.4 Summary: Ag1240 The highest expression of this gene was detected in a colon cancer cell line (CT=31). Significant expression of this gene was seen in pancreas, melanoma, lymph node, spleen, thymus, brain, testis, prostate (both normal and cancer), breast (both normal and cancer), kidney (fetal, and adult normal and cancer). The expression of this gene was upregulated in several ovarian and lung cancer cell lines, and downregulated in stomach and breast cancer cell lines. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of ovarian, lung, stomach and breast cancers.

Panel 1.2 Summary: Ag1240 The highest exoression of this gene was detected in spinal cord. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of disorders and injuries of the spinal cord.

Panel 4D Summary: Ag1240 The highest expression of this gene was seen in the B cell lymphoma Ramos (CT=29). This gene was highly expressed in activated T cells, particularly in activated T cells which have been cultured under conditions which skew their development into Th1, Th2 or Tr1 cells, but not in resting T cells. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of inflammation resulting from T cell activation and T cell-mediated autoimmune diseases such as arthritis, Crohn's disease, asthma/allergy, diabetes and psoriasis. These therapeutics is also important in preventing organ rejection due to T cell activation.

AM. CG55752406 and CG55752-07: Glucosidase.

Expression of genes CG55752-06 and CG55752-07 were assessed using the primer-probe set Ag401, described in Table AMA. Results of the RTQ-PCR runs are shown in Tables AMB and AMC.

TABLE AMAProbe Name Ag401StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ttgtgccaaaacatccatcct-3′2118961340ProbeTET-5′-agcctggagaagctctcactcaacattgc-29191813413′-TAMRAReverse5′-tatgatgcggacctcccagt-3′2019521342

TABLE AMB

Panel 1.3D

Column A - Rel. Exp.(%) Ag401, Run 165518174

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
2.9
Kidney (fetal)
13.8

Pancreas
10.1
Renal ca. 786-0
14.8

Pancreatic ca. CAPAN 2
10.2
Renal ca. A498
13.9

Adrenal gland
16.2
Renal ca. RXF 393
18.2

Thyroid
18.9
Renal ca. ACHN
12.7

Salivary gland
24.7
Renal ca. UO-31
12.2

Pituitary gland
20.2
Renal ca. TK-10
5.7

Brain (fetal)
23.5
Liver
16.7

Brain (whole)
52.1
Liver (fetal)
90

Brain (amygdala)
16.2
Liver ca. (hepatoblast) HepG2
9.6

Brain (cerebellum)
47.6
Lung
19.5

Brain (hippocampus)
54.3
Lung (fetal)
11.2

Brain (substantia nigra)
20.0
Lung ca. (small cell) LX-1
18.7

Brain (thalamus)
41.5
Lung ca. (small cell) NCI-H69
0.0

Cerebral Cortex
15.0
Lung ca. (s.cell var.) SHP-77
10.9

Spinal cord
38.7
Lung ca. (large cell) NCI-H460
19.5

glio/astro U87-MG
9.5
Lung ca. (non-sm. cell) A549
1.6

glio/astro U-118-MG
49.7
Lung ca. (non-s.cell) NCI-H23
9.3

astrocytoma SW1783
10.4
Lung ca. (non-s.cell) HOP-62
17.8

neuro*; met SK-N-AS
20.2
Lung ca. (non-s.cl) NCI-H522
9.0

astrocytoma SF-539
25.7
Lung ca. (squam.) SW 900
4.5

astrocytoma SNB-75
22.4
Lung ca. (squam.) NCI-H596
3.1

glioma SNB-19
25.9
Mammary gland
27.0

glioma U251
59.9
Breast ca.* (pl.ef) MCF-7
4.3

glioma SF-295
15.4
Breast ca.* (pl.ef)
47.3

MDA-MB-231

Heart (Fetal)
0.5
Breast ca.* (pl.ef) T47D
6.4

Heart
14.0
Breast ca. BT-549
12.9

Skeletal muscle (Fetal)
7.0
Breast ca. MDA-N
6.2

Skeletal muscle
100.0
Ovary
6.3

Bone marrow
33.9
Ovarian ca. OVCAR-3
10.5

Thymus
32.1
Ovarian ca. OVCAR-4
7.2

Spleen
27.9
Ovarian ca. OVCAR-5
13.6

Lymph node
76.8
Ovarian ca. OVCAR-8
4.6

Colorectal
38.7
Ovarian ca. IGROV-1
2.5

Stomach
21.0
Ovarian ca. (ascites) SK-OV-3
17.3

Small intestine
60.7
Utems
61.6

Colon ca. SW480
7.6
Placenta
2.9

Colon ca.* SW620
2.9
Prostate
17.8

(SW480 met)

Colon ca. HT29
0.8
Prostate ca.* (bone met) PC-3
19.6

Colon ca. HCT-116
3.6
Testis
50.7

Colon ca. CaCo-2
3.1
Melanoma Hs688(A).T
9.5

CC Well to Mod Diff
7.9
Melanoma* (met) Hs688(B).T
15.8

(OD03866)

Colon ca. HCC-2998
10.3
Melanoma UACC-62
7.6

Gastric ca. (liver met)
55.1
Melanoma M14
89.5

NCI-N87

Bladder
22.2
Melanoma LOX IMVI
2.2

Trachea
17.4
Melanoma* (met) SK-MEL-5
1.9

Kidney
19.5
Adipose
15.5

TABLE AMC

Panel 5 Islet

Column A - Rel. Exp.(%) Ag401, Run 304686255

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
1.5
94709 Donor 2 AM - A adipose
16.8

97476 Patient-07sk skeletal muscle
0.0
94710 Donor 2 AM - B adipose
11.3

97477 Patient-07ut uterus
2.8
94711 Donor 2 AM - C adipose
14.2

97478 Patient-07pl placenta
0.8
94712 Donor 2 AD - A adipose
28.1

99167 Bayer Patient 1
0.0
94713 Donor 2 AD - B adipose
50.7

97482 Patient-08ut uterus
0.0
94714 Donor 2 AD - C adipose
25.0

97483 Patient-08pl placenta
2.2
94742 Donor 3 U - A Mesenchymal
8.2

Stem Cells

97486 Patient-09sk skeletal muscle
10.7
94743 Donor 3 U - B Mesenchymal
5.2

Stem Cells

97487 Patient-09ut uterus
7.8
94730 Donor 3 AM - A adipose
33.4

97488 Patient-09pl placenta
2.0
94731 Donor 3 AM - B adipose
100.0

97492 Patient-10ut uterus
7.0
94732 Donor 3 AM - C adipose
52.5

97493 Patient-10pl placenta
9.3
94733 Donor 3 AD - A adipose
47.6

97495 Patient-11go adipose
24.1
94734 Donor 3 AD - B adipose
29.5

97496 Patient-11sk skeletal muscle
8.2
94735 Donor 3 AD - C adipose
10.7

97497 Patient-11ut uterus
18.2
77138 Liver HepG2untreated
46.3

97498 Patient-11pl placenta
0.0
73556 Heart Cardiac stromal cells
12.0

(primary)

97500 Patient-12go adipose
25.2
81735 Small Intestine
34.6

97501 Patient-12sk skeletal muscle
17.9
72409 Kidney Proximal Convoluted
70.2

Tubule

97502 Patient-12ut uterus
16.2
82685 Small intestine Duodenum
9.9

97503 Patient-12pl placenta
6.0
90650 Adrenal Adrenocortical
5.6

adenoma

94721 Donor 2 U - A Mesenchymal
25.2
72410 Kidney HRCE
44.1

94722 Donor 2 U - B Mesenchymal
9.5
72411 Kidney HRE
14.5

Stem Cells

94723 Donor 2 U - C Mesenchymal
19.1
73139 Uterus Uterine smooth muscle
37.1

Stem Cells

cells

Panel 1.3D Summary: Ag401 The highest expression of this gene was detected in skeletal muscle. It was expressed in a variety of metabolic tissues, including pancreas, adipose, adrenal, thyroid, pituitary, adult and fetal heart, adult and fetal skeletal muscle, and adult and fetal liver. This gene encodes an alpha-glucosidase. Alpha-glucosidase inhibitors are currently used in the treatment of Type 2 diabetes to decrease glucose absorption from the gut (Raptis S A, Dimitriadis G D. Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. Exp Clin Endocrinol Diabetes. 2001; 109 Suppl 2:S265-87). Thus, this gene, encoded protein and/or use of small molecule targeting this gene or gene product is useful for the treatment of metabolic diseases, including obesity and Types 1 and 2 diabetes.

This gene was expressed in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of central nervous system disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

Panel 5 Islet Summary: Ag401 The highest expression of this gene was detected during adipocyte differention (CT=32). This gene was upregulated during adipocyte differentiation. It was expressed in a variety of metabolic tissues, including adipose, heart, small intestine, kidney, uterus, skeletal muscle. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of obesity and diabetes.

AN. CG55778-03 and CG55778-06: Aldo-Keto Reductase.

Expression of gene CG55778-03 and CG55778-06 were assessed using the primer-probe set Ag7193, described in Table ANA. Results of the RTQ-PCR runs are shown in Table ANB. CG55778-03 and CG55778-06 represent full length physical clones.

TABLE ANAProbe Name Ag7193StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gacacgtgggagattttgatc-3′214731343ProbeTET-5′-agtgatccccggatctatcaccccaa-3′-265201344TAMRAReverse5′-acacctggatattctctttaatgtga-3′265471345

TABLE ANB

General_screening_panel_v1.7

Column A - Rel. Exp.(%) Ag7193, Run 318040434

Tissue Name
A
Tissue Name
A

Adipose
5.0
Gastric ca. (liver met.) NCI-N87
0.0

HUVEC
1.9
Stomach
0.2

Melanoma* Hs688(A).T
0.0
Colon ca. SW-948
0.4

Melanoma* Hs688(B).T
4.5
Colon ca. SW480
0.0

Melanoma (met) SK-MEL-5
0.5
Colon ca. (SW480 met) SW620
12.9

Testis
3.7
Colon ca. HT29
1.6

Prostate ca. (bone met) PC-3
0.0
Colon ca. HCT-116
1.2

Prostate ca. DU145
1.4
Colon cancer tissue
0.0

Prostate pool
0.5
Colon ca. SW1116
0.0

Uterus pool
0.6
Colon ca. Colo-205
0.0

Ovarian ca. OVCAR-3
0.1
Colon ca. SW-48
1.8

Ovarian ca. (ascites) SK-OV-3
0.2
Colon
1.1

Ovarian ca. OVCAR-4
2.0
Small Intestine
0.3

Ovarian ca. OVCAR-5
2.7
Fetal Heart
0.9

Ovarian ca. IGROV-1
0.0
Heart
0.2

Ovarian ca. OVCAR-8
3.5
Lymph Node Pool
0.3

Ovary
1.2
Lymph Node pool 2
2.1

Breast ca. MCF-7
2.3
Fetal Skeletal Muscle
0.8

Breast ca. MDA-MB-231
3.1
Skeletal Muscle pool
0.1

Breast ca. BT 549
0.4
Skeletal Muscle
0.6

Breast ca. T47D
1.1
Spleen
1.4

113452 mammary gland
0.4
Thymus
0.8

Trachea
2.4
CNS cancer (glio/astro) SF-268
0.0

Lung
9.5
CNS cancer (glio/astro) T98G
0.0

Fetal Lung
2.1
CNS cancer (neuro;met) SK-N-AS
0.0

Lung ca. NCI-N417
0.0
CNS cancer (astro) SF-539
0.0

Lung ca. LX-1
3.0
CNS cancer (astro) SNB-75
0.0

Lung ca. NCI-H146
0.0
CNS cancer (glio) SNB-19
0.0

Lung ca. SHP-77
0.9
CNS cancer (glio) SF-295
0.4

Lung ca. NCI-H23
0.5
Brain (Amygdala)
0.8

Lung ca. NCI-H460
0.3
Brain (Cerebellum)
5.3

Lung ca. HOP-62
10.0
Brain (Fetal)
8.1

Lung ca. NCI-H522
100.0
Brain (Hippocampus)
1.1

Lung ca. DMS-114
7.6
Cerebral Cortex pool
1.0

Liver
0.2
Brain (Substantia nigra)
0.4

Fetal Liver
0.6
Brain (Thalamus)
0.8

Kidney pool
2.7
Brain (Whole)
4.6

Fetal Kidney
1.2
Spinal Cord
0.4

Renal ca. 786-0
0.1
Adrenal Gland
1.7

Renal ca. A498
1.2
Pituitary Gland
1.3

Renal ca. ACHN
0.2
Salivary Gland
0.8

Renal ca. UO-31
0.2
Thyroid
4.6

Renal ca. TK-10
0.0
Pancreatic ca. PANC-1
0.3

Bladder
1.8
Pancreas pool
0.3

General_screening_panel_v1.7 Summary: Ag7193 Among tissues with metabolic or endocrine function, this gene was expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

AO. CG55794-03: Novel Carboxypeptidase B Like Protein.

Expression of gene CG55794-03 was assessed using the primer-probe sets Ag2622 and Ag3953, described in Tables AOA and AOB. Results of the RTQ-PCR runs are shown in Tables AOC, AOD, AOE and AOF. This gene represents a full-length physical clone.

TABLE AOAProbe Name Ag2622StartSEQ IDPrimersSequencesLengthPositionNoForward5′-catcagggtcttcaagagattg-3′229091346ProbeTET-5′-ccgagacattgggattcccttctcat-3′-269341347TAMRAReverse5′-acaaacccatatgttccactgt-3′229781348

TABLE AOB

Probe Name Ag3953

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-acagtggaacatatgggtttgt-3′
22
978
1349

Probe
TET-5′-agaagctcagatccagcccacctgt-3′-
25
1006
1350

TAMRA

Reverse
5′-catacacatcatccaggactga-3′
22
1055
1351

TABLE AOC

Panel 1.3D

Column A - Rel. Exp.(%) Ag2622, Run 162554681

Column B - Rel. Exp.(%) Ag2622, Run 165672349

Tissue Name
A
B
Tissue Name
A
B

Liver adenocarcinoma
0.0
0.0
Kidney (fetal)
10.5
0.0

Pancreas
0.0
0.0
Renal ca. 786-0
0.0
0.0

Pancreatic ca. CAPAN 2
20.0
10.3
Renal ca. A498
7.0
22.2

Adrenal gland
7.4
33.7
Renal ca. RXF 393
0.0
8.5

Thyroid
46.7
7.7
Renal ca. ACHN
0.0
0.0

Salivary gland
0.0
21.2
Renal ca. UO-31
0.0
0.0

Pituitary gland
14.8
40.9
Renal ca. TK-10
0.0
0.0

Brain (fetal)
13.8
0.0
Liver
0.0
0.0

Brain (whole)
60.3
75.3
Liver (fetal)
6.8
0.0

Brain (amygdala)
61.6
28.9
Liver ca. (hepatoblast) HepG2
0.0
0.0

Brain (cerebellum)
6.2
0.0
Lung
19.8
10.8

Brain (hippocampus)
47.3
97.9
Lung (fetal)
23.2
48.6

Brain (substantia nigra)
28.5
82.9
Lung ca. (small cell) LX-1
0.0
0.0

Brain (thalamus)
54.0
100.0
Lung ca. (small cell) NCI-H69
0.0
0.0

Cerebral Cortex
0.0
27.7
Lung ca. (s.cell var.) SHP-77
0.0
0.0

Spinal cord
77.4
28.7
Lung ca. (large cell) NCI-H460
0.0
0.0

glio/astro U87-MG
0.0
0.0
Lung ca. (non-sm. cell) A549
0.0
0.0

gilo/astro U-118-MG
6.5
10.7
Lung ca. (non-s.cell) NCI-H23
0.0
23.7

astrocytoma SW1783
8.3
0.0
Lung ca. (non-s.cell) HOP-62
0.0
10.2

neuro*; met SK-N-AS
0.0
0.0
Lung ca. (non-s.cl) NCI-H522
0.0
14.8

astrocytoma SF-539
0.0
0.0
Lung ca. (squam.) SW 900
0.0
26.4

astrocytoma SNB-75
7.6
19.8
Lung ca. (squam.) NCI-H596
0.0
0.0

glioma SNB-19
13.2
14.4
Mammary gland
13.0
0.0

glionia U251
7.5
0.0
Breast ca.* (pl.ef) MCF-7
0.0
0.0

glioma SF-295
0.0
0.0
Breast ca.* (pl.ef) MDA-MB
0.0
0.0

231

Heart (Fetal)
0.0
0.0
Breast ca.* (pl.ef) T47D
0.0
0.0

Heart
0.0
0.0
Breast ca. BT-549
2.6
27.2

Skeletal muscle (Fetal)
7.1
11.3
Breast ca. MDA-N
0.0
0.0

Skeletal muscle
84.7
57.0
Ovary
24.1
0.0

Bone marrow
0.0
0.0
Ovarian ca. OVCAR-3
0.0
5.8

Thymus
19.6
0.0
Ovarian ca. OVCAR-4
0.0
0.0

Spleen
0.0
13.2
Ovarian ca. OVCAR-5
0.0
0.0

Lymph node
0.0
0.0
Ovarian ca. OVCAR-8
0.0
0.0

Colorectal
5.8
28.3
Ovarian ca. IGROV-l
0.0
0.0

Stomach
0.0
0.0
Ovarian ca. (ascites) SK-OV-3
11.3
62.9

Small intestine
7.6
24.5
Uterus
0.0
33.9

Colon ca. SW480
0.0
0.0
Placenta
0.0
0.0

Colon ca.* SW620 (SW480 met)
0.0
10.2
Prostate
13.3
0.0

Colon ca. HT29
0.0
0.0
Prostate ca.* (bone met) PC-3
0.0
0.0

Colon ca. HCT-116
19.9
0.0
Testis
22.2
23.0

Colon ca. CaCo-2
0.0
0.0
Melanoma Hs688(A).T
0.0
0.0

CC Well to Mod Diff
16.8
9.0
Melanoma* (met) Hs688(B).T
0.0
0.0

(ODO3866)

Colon ca. HCC-2998
12.5
0.0
Melanoma UACC-62
0.0
0.0

Gastric ca. (liver met) NCI-N87
27.0
13.3
Melanoma M14
0.0
0.0

Bladder
28.9
12.4
Melanoma LOX IMVI
0.0
0.0

Trachea
13.6
0.0
Melanoma* (met) SK-MEL-5
0.0
0.0

Kidney
100.0
28.5
Adipose
14.0
9.7

TABLE AOD

Panel 2D

Column A - Ret. Exp.(%) Ag2622, Run 163578215

Column B - Ret. Exp.(%) Ag2622, Run 165910584

Tissue Name
A
B
Tissue Name
A
B

Normal Colon
7.3
20.4
Kidney Margin 8120608
0.8
0.0

CC Well to Mod Diff (ODO3866)
0.4
0.0
Kidney Cancer 8120613
0.0
1.4

CC Margin (ODO3866)
2.7
2.7
Kidney Margin 8120614
1.6
3.3

CC Gr.2 rectosigmoid (ODO3868)
3.3
0.0
Kidney Cancer 9010320
0.9
1.9

CC Margin (ODO3868)
0.5
6.6
Kidney Margin 9010321
5.2
12.4

CC Mod Diff (ODO3920)
0.0
0.0
Normal Uterus
0.5
0.0

CC Margin (ODO3920)
3.4
10.4
Uterine Cancer 064011
4.6
9.4

CC Gr.2 ascend colon (ODO3921)
2.8
4.7
Normal Thyroid
8.2
9.7

CC Margin (ODO3921)
1.9
5.5
Thyroid Cancer
1.2
10.2

CC from Partial Hepatectomy
1.2
2.0
Thyroid Cancer A302152
2.8
2.1

(ODO4309) Mets

Liver Margin (ODO4309)
1.0
4.5
Thyroid Margin A302153
7.4
19.2

Colon mets to lung (OD04451-01)
0.0
0.0
Normal Breast
1.9
4.7

Lung Margin (OD04451-02)
0.7
1.8
Breast Cancer
4.7
6.1

Normal Prostate 6546-1
30.4
27.7
Breast Cancer (OD04590-01)
1.3
5.2

Prostate Cancer (OD04410)
7.9
15.9
Breast Cancer Mets
100.0
4.0

(OD04590-03)

Prostate Margin (OD04410)
13.9
47.3
Breast Cancer Metastasis
17.3
33.9

Prostate Cancer (OD04720-01)
5.5
8.7
Breast Cancer
16.6
14.3

Prostate Margin (OD04720-02)
9.2
37.6
Breast Cancer
8.2
39.8

Normal Lung
4.6
5.3
Breast Cancer 9100266
1.0
2.4

Lung Met to Muscle (ODO4286)
0.7
2.6
Breast Margin 9100265
0.5
2.0

Muscle Margin (ODO4286)
5.3
19.6
Breast Cancer A209073
0.0
17.0

Lung Malignant Cancer
2.4
3.7
Breast Margin A209073
2.3
5.3

(OD03126)

Lung Margin (OD03126)
4.6
7.2
Normal Liver
3.1
9.3

Lung Cancer (OD04404)
1.2
1.7
Liver Cancer
0.3
0.0

Lung Margin (OD04404)
1.5
3.6
Liver Cancer 1025
0.8
0.0

Lung Cancer (OD04565)
0.0
0.0
Liver Cancer 1026
0.0
0.0

Lung Margin (OD04565)
0.0
1.5
Liver Cancer 6004-T
0.4
4.6

Lung Cancer (OD04237-01)
3.9
17.4
Liver Tissue 6004-N
10.0
0.0

Lung Margin (OD04237-02)
0.6
6.5
Liver Cancer 6005-T
0.5
10.0

Ocular Mel Met to Liver
0.0
2.4
Liver Tissue 6005-N
0.0
0.0

(ODO4310)

Liver Margin (ODO4310)
1.4
1.3
Normal Bladder
2.0
10.0

Melanoma Metastasis
1.0
2.5
Bladder Cancer
0.6
0.0

Lung Margin (OD04321)
0.9
8.5
Bladder Cancer
6.9
9.0

Normal Kidney
34.4
100.0
Bladder Cancer (OD04718-
1.0
1.7

01)

Kidney Ca, Nuclear grade 2
4.8
16.5
Bladder Normal Adjacent
3.1
10.2

(OD04338)

(OD04718-03)

Kidney Margin (OD04338)
3.9
27.4
Normal Ovary
1.6
4.2

Kidney Ca Nuclear grade 1/2
10.81
26.4
Ovarian Cancer
2.2
8.3

(OD04339)

Kidney Margin (OD04339)
21.8
55.1
Ovarian Cancer (OD04768-
0.0
0.0

07)

Kidney Ca, Clear cell type
0.8
1.8
Ovary Margin (OD04768-08)
0.0
3.2

(OD04340)

Kidney Margin (OD04340)
11.8
41.2
Normal Stomach
2.1
0.0

Kidney Ca, Nuclear grade 3
0.0
0.0
Gastric Cancer 9060358
0.0
0.0

(OD04348)

Kidney Margin (OD04348)
17.9
28.3
Stomach Margin 9060359
0.0
4.5

Kidney Cancer (OD04622-01)
1.9
2.3
Gastric Cancer 9060395
2.0
0.0

Kidney Margin (OD04622-03)
4.6
2.4
Stomach Margin 9060394
3.4
10.8

Kidney Cancer (OD04450-01)
2.1
6.5
Gastric Cancer 9060397
1.3
0.0

Kidney Margin (OD04450-03)
16.5
47.3
Stomach Margin 9060396
0.0
2.7

Kidney Cancer 8120607
0.6
0.0
Gastric Cancer 064005
1.8
13.6

TABLE AOE

Panel 4D

Column A - Rel. Exp.(%) Ag2622, Run 162554700

Column B - Rel. Exp.(%) Ag2622, Run 165806297

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
0.0
0.1
HUVEC IL-1beta
0.0
0.0

Secondary Th2 act
0.1
0.0
HUVEC IFN gamma
0.3
0.0

Secondary Tr1 act
0.0
0.0
HUVEC TNF alpha + IFN gamma
0.0
0.0

Secondary Th1 rest
0.0
0.0
HUVEC TNF alpha + IL4
0.0
0.0

Secondary Th2 rest
0.0
0.0
HUVEC IL-11
0.0
0.0

Secondary Tr1 rest
0.0
0.0
Lung Microvascular EC none
0.4
0.1

Primary Th1 act
0.0
0.0
Lung Microvascular EC TNFalpha +
0.0
0.0

Primary Th2 act
0.2
0.0
Microvascular Dermal EC none
0.0
0.0

Primary Tr1 act
0.0
0.0
Microsvasular Dermal EC TNFalpha
0.1
0.0

+ IL-1beta

Primary Th1 rest
0.0
0.0
Bronchial epithelium TNFalpha +
0.0
0.1

IL1beta

Primary Th2 rest
0.1
0.0
Small airway epithelium none
0.0
0.1

Primary Tr1 rest
0.2
0.0
Small airway epithelium TNFalpha +
1.1
0.4

IL-1beta

CD45RA CD4 lymphocyte
0.0
0.0
Coronery artery SMG rest
0.0
0.0

act

CD45RO CD4 lymphocyte
0.1
0.1
Coronery artery SMC TNFalpha + IL-
0.0
0.0

1beta

CD8 lymphocyte act
0.0
0.0
Astrocytes rest
0.0
0.0

Secondary CD8 lymphocyte
0.0
0.0
Astrocytes TNFalpha + IL-1beta
0.2
0.2

rest

Secondary CD8 lymphocyte
0.0
0.0
KU-812 (Basophil) rest
0.0
0.0

act

CD4 lymphocyte none
0.2
0.0
KU-812 (Basophil) PMA/ionomycin
0.1
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
0.0
CCD1106 (Keratinocytes) none
0.0
0.0

CH11

LAK cells rest
0.0
0.0
CCD1106 (Keratinocytes) TNFalpha
0.0
0.1

+ IL-1beta

LAK cells IL-2
0.0
0.0
Liver cirrhosis
0.8
0.6

LAK cells IL-2 + IL-12
0.0
0.0
Lupus kidney
0.2
0.4

LAK cells IL-2 + IFN gamma
0.1
0.1
NCI-H292 none
0.0
0.0

LAK cells IL-2 + IL-18
0.1
0.0
NCI-H292 IL-4
0.0
0.0

LAK cells PMA/ionomycin
0.0
0.0
NCI-H292 IL-9
0.0
0.1

NK Cells IL-2 rest
0.1
0.0
NCI-H292 IL-13
0.0
0.0

Two Way MLR 3 day
0.0
0.0
NCI-H292 IFN gamma
0.1
0.0

Two Way MLR 5 day
0.0
0.0
HPAEC none
0.1
0.0

Two Way MLR 7 day
0.0
0.0
HPAEC TNF alpha + IL-1 beta
0.0
0.0

PBMC rest
0.0
0.0
Lung fibroblast none
0.1
0.0

PBMC PWM
0.3
0.1
Lung fibroblast TNF alpha + IL-1 beta
0.1
0.0

PBMC PHA-L
0.1
0.0
Lung fibroblast IL-4
0.0
0.1

Ramos (B cell) none
0.0
0.0
Lung fibroblast IL-9
0.4
0.1

Ramos (B cell) ionomycin
0.0
0.0
Lung fibroblast IL-13
0.1
0.0

B lymphocytes PWM
0.1
0.0
Lung fibroblast IFN gamma
0.5
0.1

B lymphocytes CD40L and
0.0
0.0
Dermal fibroblast CCD1070 rest
0.1
0.1

IL-4

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 TNF
0.0
0.0

alpha

EOL-1 dbcAMP
0.2
0.1
Dermal fibroblast CCD1070 IL-1 beta
0.0
0.0

PMA/ionomycin

Dendritic cells none
0.0
0.0
Dermal fibroblast IFN gamma
0.1
0.0

Dendritic cells LPS
0.0
0.1
Dermal fibroblast IL-4
0.0
0.1

Dendritic cells anti-CD40
0.0
0.0
IBD Colitis 2
0.0
0.0

Monocytes rest
0.0
0.0
IBD Crohn's
1.0
2.2

Monocytes LPS
0.0
0.0
Colon
100.0
100.0

Macrophages rest
0.0
0.0
Lung
0.2
0.0

Macrophages LPS
0.0
0.0
Thymus
1.3
0.9

HUVEC none
10.0
0.0
Kidney
0.5
0.0

HUVEC starved
0.0
0.0

TABLE AOF

Panel 5 Islet

Column A - Rel. Exp.(%) Ag3953, Run 223846464

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
0.0
94709 Donor 2 AM - A adipose
0.0

97476 Patient-07sk skeletal muscle
0.0
94710 Donor 2 AM - B adipose
0.0

97477 Patient-07ut uterus
0.0
94711 Donor 2 AM - C adipose
0.0

97478 Patient-07pl placenta
0.0
94712 Donor 2 AD - A adipose
0.0

99167 Bayer Patient 1
0.0
94713 Donor 2 AD - B adipose
0.0

97482 Patient-08ut uterus
0.0
94714 Donor 2 AD - C adipose
0.0

97483 Patient-08pl placenta
3.7
94742 Donor 3 U - A Mesenchymal
0.0

Stem Cells

97486 Patient-09sk skeletal muscle
0.0
94743 Donor 3 U - B Mesenchymal
0.0

Stem Cells

97487 Patient-09ut uterus
3.8
94730 Donor 3 AM - A adipose
4.4

97488 Patient-09pl placenta
0.0
94731 Donor 3 AM - B adipose
0.0

97492 Patient-10ut uterus
0.0
94732 Donor 3 AM - C adipose
0.0

97493 Patient-10pl placenta
0.0
94733 Donor 3 AD - A adipose
0.0

97495 Patient-11go adipose
0.0
94734 Donor 3 AD - B adipose
0.0

97496 Patient-11sk skeletal muscle
3.3
94735 Donor 3 AD - C adipose
3.6

97497 Patient-11ut uterus
0.0
77138 Liver HepG2untreated
0.0

97498 Patient-11pl placenta
4.0
73556 Heart Cardiac stromal cells
0.0

(primary)

97500 Patient-12go adipose
4.2
81735 Small Intestine
100.0

97501 Patient-12sk skeletal muscle
3.5
72409 Kidney Proximal Convoluted
0.0

Tubule

97502 Patient-12ut uterus
0.0
82685 Small intestine Duodenum
0.0

97503 Patient-12pl placenta
0.0
90650 Adrenal Adrenocortical
0.0

adenoma

94721 Donor 2 U - A Mesenchymal
0.0
72410 Kidney HRCE
0.0

Stem Cells

94722 Donor 2 U - B Mesenchymal
4.0
72411 Kidney HRE
0.0

Stem Cells

94723 Donor 2 U - C Mesenchymal
0.0
73139 Uterus Uterine smooth muscle
0.0

Stem Cells

cells

Panel 1.3D Summary: Ag2622 The highest expression of this gene was detected in the brain and the kidney. There was significantly lower expression in the brain cancer cell lines than normal brain samples. This indicates that downregulation of this gene is important in cell proliferation. Hence this expression profile is useful as a diagnostic marker for brain cancer.

This gene was also expressed at low levels in the CNS. Carboxypeptidase is believed to have a role in the degradation of APP and A-beta, the major component of senile plaques in Alzheimer's disease (Matsumoto A, Itoh K, Matsumoto R. A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. Eur J Neurosci 2000 January; 12(1):227-38). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of Alzheimer's disease.

Panel 2D Summary: Ag2622 This gene was expressed at low levels in the tissues. There was increased expression in normal prostate and kidney compared to the adjacent tumor tissues. There was also increased expression in breast cancer tissues compared to normal breast tissue. Hence, expression of this gene useful as a diagnostic marker in breast, prostate and kidney cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of breast, prostate and kidney cancer.

Panel 4D Summary: Ag2622 This gene encoding a putative carboxypeptidase, was expressed in the colon (CT=25-27) and down regulated in colon tissue isolated from Crohn's and colitis patients (CTs>31). The carboxypeptidase family of enzymes has been found in the colon and is associated with colon disease (Sommer H, Schweisfurth H, Schulz M. Serum angiotensin-1-converting enzyme and carboxypeptidase N in Crohn's disease and ulcerative colitis. Enzyme 1986; 35(4):181-8). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of IBD.

Panel 5 Islet Summary: Ag3953 This gene, a carboxypeptidase B1 homolog, showed moderate expression in small intestine (CT=32.6). Carboxypeptidase B1 is an endocrine tissue-specific protein and is a useful serum marker for acute pancreatitis and dysfunction of pancreatic transplants (Yamamoto, K. K.; Pousette, A.; Chow, P.; Wilson, H.; El Shami, S.; French, C. K. Isolation of a cDNA encoding a human serum marker for acute pancreatitis: identification of pancreas-specific protein as pancreatic procarboxypeptidase B. J. Biol. Chem. 1992 267: 2575-2581 PMID: 1370825). This class of peptidase has been implicated in hormone maturation and/or degradation of secreted peptides such as insulin, GLP-1, and PACAP. PACAP latter has a major role in metabolic processes. Several carboxypeptidases, like CPE or PC1, have been shown to be involved in development of diabetes and obesity. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of diabetes and also, diseases associated with the GI tract and metabolism.

AP. CG55806-04: Factor-IX.

Expression of gene CG55806-04 was assessed using the primer-probe set Ag2613, described in Table APA. Results of the RTQ-PCR runs are shown in Tables APB, APC and APD.

TABLE APAProbe Name Ag2613StartSEQ IDPrimersSequencesLengthPositionNoForward5′-agccacatgtcttcgatctaca-3′222531352ProbeTET-5′-acaacatgttctgtgctggcttccat-3′-262111353TAMRAReverse5′-cccactatctccttgacatgaa-3′221751354

TABLE APB

Panel 1.3D

Column A - Rel. Exp.(%) Ag2613, Run 165672326

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
0.0
Kidney (fetal)
10.7

Pancreas
0.0
Renal ca. 786-0
0.0

Pancreatic ca. CAPAN 2
0.0
Renal ca. A498
0.0

Adrenal gland
0.0
Renal ca. RXF 393
0.0

Thyroid
0.0
Renal ca. ACHN
0.0

Salivary gland
0.0
Renal ca. UO-31
0.0

Pituitary gland
0.0
Renal ca. TK-10
0.0

Brain (fetal)
0.0
Liver
100.0

Brain (whole)
0.0
Liver (fetal)
76.3

Brain (amygdala)
0.0
Liver ca. (hepatoblast) HepG2
0.0

Brain (cerebellum)
0.0
Lung
0.0

Brain (hippocampus)
0.0
Lung (fetal)
0.0

Brain (substantia nigra)
0.0
Lung ca. (small cell) LX-1
0.0

Brain (thalamus)
0.0
Lung ca. (small cell) NCI-H69
0.0

Cerebral Cortex
0.0
Lung ca. (s.cell var.) SHP-77
0.3

Spinal cord
0.0
Lung ca. (large cell) NCI-H460
0.0

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
0.0

glio/astro U-118-MG
0.0
Lung ca. (non-s.cell) NCI-H23
0.0

astrocytoma SW1783
0.0
Lung ca. (non-s.cell) HOP-62
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (non-s.cl) NCI-H522
0.0

astTocytoma SF-539
0.0
Lung ca. (squam.) SW 900
0.0

astrocytoma SNB-75
0.0
Lung ca. (squam.) NCI-H596
0.0

glioma SNB-19
0.0
Mammary gland
0.0

glioma U251
0.0
Breast ca.* (pl.ef) MCF-7
0.0

glioma SF-295
0.0
Breast ca.* (pl.ef)
0.2

MDA-MB-231

Heart (Fetal)
0.0
Breast ca.* (pl.ef) T47D
0.0

Heart
0.0
Breast ca. BT-549
0.0

Skeletal muscle (Fetal)
0.0
Breast ca. MDA-N
0.0

Skeletal muscle
0.0
Ovary
0.0

Bone marrow
0.0
Ovarian ca. OVCAR-3
0.0

Thymus
0.0
Ovarian ca. OVCAR-4
0.0

Spleen
0.0
Ovarian ca. OVCAR-5
0.0

Lymph node
0.0
Ovarian ca. OVCAR-8
0.0

Colorectal
0.0
Ovarian ca. IGROV-1
0.0

Stomach
0.0
Ovarian ca. (ascites) SK-OV-3
0.0

Small intestine
0.0
Uterus
0.0

Colon ca. SW480
0.0
Placenta
0.0

Colon ca.* SW620
0.0
Prostate
0.0

(SW480 met)

Colon ca. HT29
0.0
Prostate ca.* (bone met) PC-3
0.0

Colon ca. HCT-116
0.0
Testis
0.0

Colon ca. CaCo-2
0.0
Melanoma Hs688(A).T
0.0

CC Well to Mod Diff
0.0
Melanoma* (met) Hs688(B).T
0.0

(OD03866)

Colon ca. HCC-2998
0.0
Melanoma UACC-62
0.0

Gastric ca. (liver met)
0.0
Melanoma M14
0.0

NCI-N87

Bladder
0.0
Melanoma LOX IMVI
0.0

Trachea
0.0
Melanoma* (met)
0.0

SK-MEL-5

Kidney
0.0
Adipose
0.0

TABLE APC

Panel 2.2

Column A - Rel. Exp.(%) Ag2613, Run 175128272

Tissue Name
A
Tissue Name
A

Normal Colon
0.4
Kidney Margin (OD04348)
0.0

Colon cancer (OD06064)
0.0
Kidney malignant cancer
0.0

(OD06204B)

Colon Margin (OD06064)
0.0
Kidney normal adjacent tissue
0.0

(OD06204E)

Colon cancer (OD06159)
0.0
Kidney Cancer (OD04450-01)
0.0

Colon Margin (OD06159)
0.0
Kidney Margin (OD04450-03)
0.0

Colon cancer (OD06297-04)
0.0
Kidney Cancer 8120613
0.0

Colon Margin (OD06297-05)
0.0
Kidney Margin 8120614
0.0

CC Gr.2 ascend colon (OD03921)
0.0
Kidney Cancer 9010320
0.0

CC Margin (OD03921)
0.0
Kidney Margin 9010321
0.0

Colon cancer metastasis (OD06104)
0.0
Kidney Cancer 8120607
0.0

Lung Margin (OD06104)
0.0
Kidney Margin 8120608
0.0

Colon mets to lung (OD04451-01)
0.1
Normal Uterus
0.1

Lung Margin (OD04451-02)
0.0
Uterine Cancer 064011
0.0

Normal Prostate
0.0
Normal Thyroid
0.0

Prostate Cancer (OD04410)
0.0
Thyroid Cancer
0.0

Prostate Margin (OD04410)
0.0
Thyroid Cancer A302152
0.0

Normal Ovary
0.0
Thyroid Margin A302153
0.0

Ovarian cancer (OD06283-03)
0.0
Normal Breast
0.0

Ovarian Margin (OD06283-07)
0.0
Breast Cancer
1.5

Ovarian Cancer
2.1
Breast Cancer
0.0

Ovarian cancer (OD06145)
1.0
Breast Cancer (OD04590-01)
0.2

Ovarian Margin (OD06145)
0.2
Breast Cancer Mets (OD04590-03)
0.0

Ovarian cancer (OD06455-03)
0.0
Breast Cancer Metastasis
0.0

Ovarian Margin (OD06455-07)
0.0
Breast Cancer
0.1

Normal Lung
0.2
Breast Cancer 9100266
0.0

Invasive poor diff. lung adeno
0.0
Breast Margin 9100265
0.0

(OD04945-01

Lung Margin (OD04945-03)
0.0
Breast Cancer A209073
0.0

Lung Malignant Cancer (OD03126)
0.0
Breast Margin A209073
0.0

Lung Margin (OD03126)
0.0
Breast cancer (OD06083)
0.0

Lung Cancer (OD05014A)
0.0
Breast cancer node metastasis
0.0

(OD06083)

Lung Margin (OD05014B)
0.4
Normal Liver
100.0

Lung cancer (OD06081)
0.0
Liver Cancer 1026
1.9

Lung Margin (OD06081)
0.0
Liver Cancer 1025
60.3

Lung Cancer (OD04237-01)
0.0
Liver Cancer 6004-T
42.6

Lung Margin (OD04237-02)
0.0
Liver Tissue 6004-N
1.4

Ocular Mel Met to Liver (OD04310)
0.0
Liver Cancer 6005-T
3.3

Liver Margin (OD04310)
51.4
Liver Tissue 6005-N
33.7

Melanoma Metastasis
0.0
Liver Cancer
59.0

Lung Margin (OD04321)
0.0
Normal Bladder
0.0

Normal Kidney
0.0
Bladder Cancer
0.0

Kidney Ca, Nuclear grade 2
0.0
Bladder Cancer
0.0

(OD04338)

Kidney Margin (OD04338)
0.0
Normal Stomach
0.1

Kidney Ca Nuclear grade 1/2
0.0
Gastric Cancer 9060397
0.0

(OD04339)

Kidney Margin (OD04339)
0.0
Stomach Margin 9060396
0.0

Kidney Ca, Clear cell type (OD04340)
0.0
Gastric Cancer 9060395
0.2

Kidney Margin (OD04340)
0.0
Stomach Margin 9060394
0.0

Kidney Ca, Nuclear grade 3
0.0
Gastric Cancer 064005
0.0

(OD04348)

TABLE APD

Panel 4D

Column A - Rel. Exp.(%) Ag2613, Run 164399517

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNFalpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.0
Microsyasular Dermal EC TNFalpha + IL-
0.0

1beta

Primary Th1 rest
10.0
Bronchial epithelium TNFalpha + IL1beta
0.0

Primary Th2 rest
10.0
Small airway epithelium none
0.0

Primary Tr1 rest
10.0
Small airway epithelium TNFalpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNFalpha +IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CDS lymphocyte rest
0.0
Astrocytes TNFaIpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNFalpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
100.0

LAK cells IL-2 + IL-12
0.0
Lupus kidney
0.0

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
0.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
0.0

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
0.0

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1 beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.0

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-4
0.0

Ramos (B cell) none
10.0
Lung fibroblast IL-9
10.0

Ramos (B cell) ionomycin
10.0
Lung fibroblast IL-13
0.0

B lymphocytes PWM
0.0
Lung fibroblast IFN gamma
0.0

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells anti-CD40
0.0
IBD Colitis 2
0.0

Monocytes rest
0.0
IBD Crohn's
0.0

Monocytes LPS
0.0
Colon
0.0

Macrophages rest
0.0
Lung
1.0

Macrophages LPS
0.0
Thymus
0.0

HUVEC none
0.0
Kidney
0.0

HUVEC starved
0.0

Panel 1.3D Summary: Ag2613 The highest expression of this gene was found in adult liver. Expression of this gene was also detected in fetal liver and fetal kidney samples on this panel (CTs=27-31). This gene encodes a protein that is homologous to factor IX. The secreted form of the protein may be present in the circulatory sysytem and exhibit effects that are unrelated to the site of synthesis. Measurement of the expression level of this gene or expressed protein is useful to test liver function. Measurement of the expression level of this gene or expressed protein can be used to differentiate between liver derived tissue and other tissues. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are effective in increasing the levels of factor IX in the blood, and useful in the treatment of hemophilia and liver related disease.

Panel 2.2 Summary: Ag2613 Expression of this gene was highest in samples derived from liver (CT=27.9), consistant with the results seen in Panel 1.3D. Therefore, expression of this gene is useful to differentiate between normal sections of liver as compared to tumors that are secordary metastases from other sites (such as melanoma).

Panel 4D Summary: Ag2613 This transcript was highly expressed in cirrhotic liver tissue (CT=27.8). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of liver cirrhosis.

AQ. CG55828-02: Serine/Threonine-Protein Kinase PAK 5.

Expression of gene CG55828-02 was assessed using the primer-probe set Ag7281, described in Table AQA. Results of the RTQ-PCR runs are shown in Table AQB. Gene CG55828-02 represents full-length physical clone.

TABLE AQAProbe Name Ag7281StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gtgtcccatgaacagtttcg-3′208941355ProbeTET-5′-agcccaggagaccccagggaatactt-3′-268461356TAMRAReverse5′-tccccgattttgataaagttg-3′218221357

TABLE AQB

General_screening_panel_v1.7

Column A - Rel. Exp.(%) Ag7281, Run 318350125

Tissue Name
A
Tissue Name
A

Adipose
0.0
Gastric Ca. (liver met.)
0.0

NCI-N87

HUVEC
0.0
Stomach
0.0

Melanoma* Hs688(A).T
0.0
Colon ca. SW-948
0.0

Melanoma* Hs688(B).T
0.0
Colon ca. SW480
0.0

Melanoma (met) SK-MEL-5
0.0
Colon ca. (SW480 met)
0.0

SW620

Testis
0.2
Colon ca. HT29
0.0

Prostate ca. (bone met) PC-3
0.0
Colon ca. HCT-116
0.0

Prostate ca. DU145
0.0
Colon cancer tissue
0.0

Prostate pool
0.2
Colon ca. SW1116
0.0

Uterus pool
0.0
Colon ca. Colo-205
0.0

Ovarian ca. OVCAR-3
0.0
Colon ca. SW-48
0.0

Ovarian ca. (ascites) SK-OV-3
0.0
Colon
0.0

Ovarian ca. OVCAR-4
0.0
Small Intestine
0.0

Ovarian ca. OVCAR-5
0.0
Fetal Heart
0.0

Ovarian ca. IGROV-1
0.0
Heart
0.0

Ovarian ca. OVCAR-8
0.0
Lymph Node Pool
0.0

Ovary
0.3
Lymph Node pool 2
0.0

Breast ca. MCF-7
0.0
Fetal Skeletal Muscle
0.0

Breast ca. MDA-MB-231
0.0
Skeletal Muscle pool
0.0

Breast ca. BT 549
0.0
Skeletal Muscle
0.0

Breast ca. T47D
0.0
Spleen
0.3

113452 mammary gland
0.0
Thymus
0.1

Trachea
0.5
CNS cancer (glio/astro)
0.0

SF-268

Lung
0.1
CNS cancer (glio/astro)
0.0

T98G

Fetal Lung
0.1
CNS cancer (neuro; met)
0.0

SK-N-AS

Lung ca. NCI-N417
0.1
CNS cancer (astro)
0.0

SF-539

Lung ca. LX-1
0.0
CNS cancer (astro)
0.0

SNB-75

Lung ca. NCI-H146
11.2
CNS cancer (glio)
0.0

SNB-19

Lung ca. SHP-77
3.8
CNS cancer (glio)
0.0

SF-295

Lung ca. NCI-H23
0.0
Brain (Amygdala)
11.7

Lung ca. NCI-H460
0.0
Brain (Cerebellum)
80.1

Lung ca. HOP-62
0.0
Brain (Fetal)
100.0

Lung ca. NCI-H522
0.0
Brain (Hippocampus)
8.1

Lung ca. DMS-114
0.0
Cerebral Cortex pool
9.7

Liver
0.0
Brain (Substantia nigra)
5.9

Fetal Liver
0.0
Brain (Thalamus)
17.8

Kidney pool
0.6
Brain (Whole)
81.8

Fetal Kidney
0.0
Spinal Cord
0.5

Renal ca. 786-0
0.0
Adrenal Gland
5.6

Renal ca. A498
0.0
Pituitary Gland
2.3

Renal ca. ACHN
0.0
Salivary Gland
0.3

Renal ca. UO-31
0.0
Thyroid
0.1

Renal ca. TK-10
0.0
Pancreatic ca. PANC-1
0.0

Bladder
0.1
Pancreas pool
0.4

General_screening_panel_v1.7 Summary: Ag7281 The highest expression of this gene was detected in fetal brain (CT=25). This gene was expressed in all central nervous system samples on this panel. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of disorders of the central nervous system including Alzheimer's disease, Parkinson's disease, trauma, stroke, epilepsy, pain, multiple sclerosis, schizophrenia, bipolar disorder, depression, anxiety, obsessive compulsive disorder, ataxia, autism, drug and alcohol addiction.

AR. CG55988-04: Organic Cation Transporter OKB1.

Expression of gene CG55988-04 was assessed using the primer-probe set Ag6389, described in Table ARA. Results of the RTQ-PCR runs are shown in Table ARB.

TABLE ARAProbe Name Ag6389StartSEQ IDPrimersSequencesLengthPositionNoForward5′-tatggttggaaaatttgcc-3′1913411358ProbeTET-5′-atacagctgagctgtatccaaccattgt3013911359aa-3′-TAMRAReverse5′-ctgtcctaggagctgtggta-3′2015141360

TABLE ARB

General_screening_panel_v1.6

Column A - Rel. Exp.(%) Ag6389, Run 277246969

Tissue Name
A
Tissue Name
A

Adipose
0.0
Renal ca. TK-10
0.0

Melanoma* Hs688(A).T
0.0
Bladder
0.0

Melanoma* Hs688(B).T
0.0
Gastric ca. (liver met.) NCI-N87
0.0

Melanoma* M14
0.0
Gastric ca. KATO III
0.0

Melanoma* LOXIMVI
0.0
Colon ca. SW-948
0.0

Melanoma* SK-MEL-5
0.0
Colon ca. SW480
0.0

Squamous cell carcinoma
0.0
Colon ca.* (SW480 met) SW620
0.0

SCC-4

Testis Pool
100.0
Colon ca. HT29
0.0

Prostate ca.* (bone met)
0.0
Colon ca. HCT-116
0.0

PC-3

Prostate Pool
0.0
Colon ca. CaCo-2
0.0

Placenta
0.0
Colon cancer tissue
0.0

Uterus Pool
0.0
Colon ca. SW1116
0.0

Ovarian ca. OVCAR-3
0.0
Colon ca. Colo-205
0.0

Ovarian ca. SK-OV-3
1.6
Colon ca. SW-48
0.0

Ovarian ca. OVCAR-4
0.0
Colon Pool
5.5

Ovarian ca. OVCAR-5
0.0
Small Intestine Pool
0.0

Ovarian ca. IGROV-1
0.0
Stomach Pool
0.0

Ovarian ca. OVCAR-8
0.0
Bone Marrow Pool
0.0

Ovary
0.0
Fetal Heart
0.0

Breast ca. MCF-7
0.0
Heart Pool
2.5

Breast ca. MDA-MB-231
0.0
Lymph Node Pool
1.5

Breast ca. BT 549
0.0
Fetal Skeletal Muscle
0.0

Breast ca. T47D
0.0
Skeletal Muscle Pool
0.0

Breast ca. MDA-N
0.0
Spleen Pool
0.0

Breast Pool
0.0
Thymus Pool
0.0

Trachea
2.5
CNS cancer (glio/astro) U87-MG
0.0

Lung
0.0
CNS cancer (glio/astro) U-118-MG
0.0

Fetal Lung
2.7
CNS cancer (neuro; met) SK-N-AS
0.0

Lung ca. NCI-N417
2.5
CNS cancer (astro) SF-539
0.0

Lung ca. LX-1
0.0
CNS cancer (astro) SNB-75
0.0

Lung Ca. NCI-H146
0.0
CNS cancer (glio) SNB-19
0.0

Lung ca. SHP-77
0.0
CNS cancer (glio) SF-295
0.0

Lung ca. A549
0.0
Brain (Amygdala) Pool
0.0

Lung ca. NCI-H526
0.0
Brain (cerebellum)
0.0

Lung ca. NCI-H23
0.0
Brain (fetal)
0.0

Lung ca. NCI-H460
0.0
Brain (Hippocampus) Pool
0.0

Lung ca. HOP-62
0.0
Cerebral Cortex Pool
2.3

Lung ca. NCI-H522
0.0
Brain (Substantia nigra) Pool
0.0

Liver
0.0
Brain (Thalamus) Pool
0.0

Fetal Liver
20.3
Brain (whole)
0.0

Liver ca. HepG2
0.0
Spinal Cord Pool
0.0

Kidney Pool
0.0
Adrenal Gland
0.0

Fetal Kidney
5.0
Pituitary gland Pool
0.0

Renal ca. 786-0
0.0
Salivary Gland
0.0

Renal ca. A498
0.0
Thyroid (female)
0.0

Renal ca. ACHN
0.0
Pancreatic ca. CAPAN2
0.0

Renal ca. UO-31
0.0
Pancreas Pool
0.0

General_screening_panel_v1.6 Summary: Ag6389 Low expression of this gene was detected in testis. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product will be useful in the treatment testis related disorders including fertility and hypogonadism.

AS. CG56071-01: Mixed Lineage Kinase 2-Like.

Expression of gene CG56071-01 was assessed using the primer-probe sets Ag2872 and Ag4847, described in Tables ASA and ASB. Results of the RTQ-PCR runs are shown in Tables ASC, ASD, ASE, ASF, ASG, ASH and ASI.

TABLE ASAProbe Name Ag2872StartSEQ IDPrimersSequencesLengthPositionNoForward5′-tcagccagaccatagagaatgt-3′225061361ProbeTET-5′-atgctgaagcaccccaacatcattg-3′-255531362TAMRAReverse5′-ctccttcagacatacccctctt-3′225821363

TABLE ASB

Probe Name Ag4847

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-catagagaatgttcgccaagag-3′
22
516
1364

Probe
TET-5′-atgctgaagcaccccaacatcattg-3′-
25
553
1365

TAMRA

Reverse
5′-ctccttcagacatacccctctt-3′
22
582
1366

TABLE ASC

General_screening_panel_v1.5

Column A - Rel. Exp.(%) Ag4847, Run 228796410

Tissue Name
A
Tissue Name
A

Adipose
1.0
Renal ca. TK-10
13.9

Melanoma* Hs688(A).T
0.1
Bladder
5.8

Melanoma* Hs688(B).T
0.0
Gastric ca. (liver met.) NCI-N87
21.5

Melanoma* M14
5.4
Gastric ca. KATO III
14.7

Melanoma* LOXIMVI
1.6
Colon ca. SW-948
4.3

Melanoma* SK-MEL-5
9.2
Colon ca. SW480
16.2

Squamous cell carcinoma
28.9
Colon ca.* (SW480 met) SW620
5.4

SCC-4

Testis Pool
2.8
Colon ca. HT29
4.8

Prostate ca.* (bone met)
7.2
Colon ca. HCT-116
13.4

PC-3

Prostate Pool
1.5
Colon ca. CaCo-2
13.6

Placenta
5.3
Colon cancer tissue
3.0

Uterus Pool
1.0
Colon ca. SW1116
2.3

Ovarian ca. OVCAR-3
10.1
Colon ca. Colo-205
2.7

Ovarian ca. SK-OV-3
23.5
Colon ca. SW-48
2.1

Ovarian ca. OVCAR-4
7.1
Colon Pool
0.6

Ovarian ca. OVCAR-5
24.0
Small Intestine Pool
1.3

Ovarian ca. IGROV-1
29.5
Stomach Pool
1.3

Ovarian ca. OVCAR-8
3.7
Bone Marrow Pool
0.9

Ovary
1.0
Fetal Heart
0.9

Breast ca. MCF-7
10.5
Heart Pool
0.3

Breast ca. MDA-MB-231
10.9
Lymph Node Pool
0.9

Breast ca. BT 549
0.4
Fetal Skeletal Muscle
0.1

Breast ca. T47D
11.7
Skeletal Muscle Pool
2.9

Breast ca. MDA-N
1.6
Spleen Pool
2.4

Breast Pool
1.1
Thymus Pool
2.5

Trachea
3.9
CNS cancer (glio/astro)
13.3

U87-MG

Lung
0.3
CNS cancer (glio/astro)
0.5

U-118-MG

Fetal Lung
4.2
CNS cancer (neuro; met)
3.7

SK-N-AS

Lung ca. NCI-N417
2.1
CNS cancer (astro) SF-539
0.8

Lung ca. LX-1
8.8
CNS cancer (astro) SNB-75
0.2

Lung ca. NCI-H146
5.6
CNS cancer (glio) SNB-19
4.0

Lung ca. SHP-77
13.1
CNS cancer (glio) SF-295
2.8

Lung ca. A549
13.4
Brain (Amygdala) Pool
8.2

Lung ca. NCI-H526
4.0
Brain (cerebellum)
100.0

Lung ca. NCI-H23
7.3
Brain (fetal)
15.9

Lung ca. NCI-H460
1.1
Brain (Hippocampus) Pool
8.1

Lung ca. HOP-62
4.7
Cerebral Cortex Pool
18.3

Lung ca. NCI-H522
7.1
Brain (Substantia nigra) Pool
24.0

Liver
0.4
Brain (Thalamus) Pool
13.7

Fetal Liver
1.2
Brain (whole)
18.8

Liver ca. HepG2
6.0
Spinal Cord Pool
3.5

Kidney Pool
0.5
Adrenal Gland
2.6

Fetal Kidney
2.6
Pituitary gland Pool
2.3

Renal ca. 786-0
10.8
Salivary Gland
1.8

Renal ca. A498
9.5
Thyroid (female)
1.0

Renal ca. ACHN
11.0
Pancreatic ca. CAPAN2
19.2

Renal ca. UO-31
15.9
Pancreas Pool
2.5

TABLE ASD

Panel 1.3D

Column A - Rel. Exp.(%) Ag2872, Run 161971644

Column B - Rel. Exp.(%) Ag2872, Run 165721686

Column C - Rel. Exp.(%) Ag2872, Run 166006455

Tissue Name
A
B
C
Tissue Name
A
B
C

Liver adenocarcinoma
16.7
22.5
21.8
Kidney (fetal)
1.9
2.9
1.1

Pancreas
0.3
4.3
5.4
Renal ca. 786-0
2.8
17.6
15.0

Pancreatic ca. CAPAN 2
5.5
45.4
44.8
Renal ca. A498
4.5
36.1
12.7

Adrenal gland
0.5
2.2
0.3
Renal ca. RXF 393
13.5
85.9
77.9

Thyroid
0.9
1.7
1.6
Renal ca. ACHN
6.4
17.8
17.8

Salivary gland
0.5
3.7
5.4
Renal ca. UO-31
5.0
27.0
19.3

Pituitaiy gland
1.7
11.4
4.3
Renal ca. TK-10
2.3
7.9
10.0

Brain (fetal)
2.9
24.5
22.1
Liver
0.2
0.0
1.0

Brain (whole)
6.1
66.4
79.6
Liver (fetal)
0.4
0.8
0.7

Brain (amygdala)
6.4
49.7
41.8
Liver ca. (hepatoblast)
4.3
14.7
18.6

HepG2

Brain (cerebellum)
13.1
82.9
100.0
Lung
0.5
6.0
9.0

Brain (hippocampus)
10.2
32.8
29.3
Lung (fetal)
0.5
4.3
0.7

Brain (substantia nigra)
2.0
14.5
12.2
Lung ca. (small cell) LX-
3.4
16.0
11.6

1

Brain (thalamus)
7.4
42.6
63.3
Lung ca. (small cell) NCI
3.6
26.1
26.4

H69

Cerebral Cortex
100.0
84.1
90.1
Lung ca. (s.cell var.)
11.1
25.0
13.8

SHP-77

Spinal cord
0.9
3.1
3.6
Lung ca. (large cell)NCI-
0.3
4.3
43.2

H460

glio/astro U87-MG
13.2
14.5
15.7
Lung ca. (non-sm. cell)
3.9
8.0
9.9

A549

glio/astro U-118-MG
0.0
0.0
0.0
Lung ca. (non-s.cell)
3.0
6.8
3.6

NCI-H23

astrocytoma SW1783
7.3
7.9
10.3
Lung ca. (non-s.cell)
2.0
8.7
6.4

HOP-62

neuro*; met SK-N-AS
1.2
5.9
2.2
Lung ca. (non-s.cl) NCI-
2.6
5.0
3.1

H522

astrocytoma SF-539
1.0
3.7
6.0
Lung ca. (squam.) SW
15.6
58.2
94.0

900

astrocytoma SNB-75
9.7
100.0
21.3
Lung ca. (squam.) NCI-
2.5
16.5
19.3

H596

glioma SNB-19
2.5
6.4
6.7
Mammary gland
0.7
6.2
2.0

glioma U251
2.8
22.2
8.9
Breast ca.* (pl.ef) MCF-7
11.3
21.9
16.7

glioma SF-295
1.2
3.7
6.3
Breast ca.* (pl.ef) MDA-
4.1
32.3
6.7

MB-231

Heart (Fetal)
0.5
0.6
1.7
Breast ca.* (pl.ef) T47D
3.5
17.0
14.4

Heart
0.1
1.1
0.0
Breast ca. BT-549
0.3
4.7
0.8

Skeletal muscle (Fetal)
0.8
0.7
0.3
Breast ca. MDA-N
1.0
0.9
3.3

Skeletal muscle
1.0
4.4
2.5
Ovary
2.3
1.4
0.0

Bone marrow
0.4
1.4
0.9
Ovarian ca. OVCAR-3
3.9
19.1
10.2

Thymus
2.5
0.7
2.3
Ovarian ca. OVCAR-4
1.6
25.2
22.1

Spleen
0.7
6.0
3.3
Ovarian ca. OVCAR-5
6.3
27.7
40.6

Lymph node
1.4
8.7
3.2
Ovarian ca. OVCAR-8
3.3
14.0
6.2

Colorectal
7.5
6.7
6.8
Ovarian ca. IGROV-1
1.4
4.6
11.2

Stomach
0.9
8.3
2.8
Ovarian ca. (ascites) SK-
6.4
46.7
39.2

OV-3

Small intestine
0.8
3.2
2.1
Uterus
0.1
1.1
0.0

Colon ca. SW480
2.5
6.4
18.9
Placenta
2.2
6.8
9.7

Colon ca.* SW620 (SW480
3.1
13.8
9.9
Prostate
0.5
2.6
2.8

met)

Colon ca. HT29
3.2
3.1
4.2
Prostate ca.* (bone met)
4.4
39.2
16.6

PC-3

Colon ca. HCT-116
2.9
15.0
4.8
Testis
2.9
7.3
3.7

Colon ca. CaCo-2
9.0
11.7
9.9
Melanoma Hs688(A).T
0.1
0.0
0.0

CC Well to Mod Duff
4.0
6.9
4.8
Melanoma* (met)
0.0
0.0
0.0

(ODO3866)

Hs688(B).T

Colon ca. HCC-2998
3.1
12.6
11.1
Melanoma UACC-62
1.6
6.3
9.3

Gastric ca. (liver met) NCI-
11.7
54.3
23.2
Melanoma M14
0.9
11.9
2.1

N87

Bladder
7.3
14.7
6.6
Melanoma LOX IMVI
0.4
0.0
0.4

Trachea
2.8
5.9
2.0
Melanoma* (met) SK-
2.1
8.4
6.0

MEL-S

Kidney
2.0
5.8
0.4
Adipose
0.7
2.4
2.4

TABLE ASE

Panel 2.2

Column A - Rel. Exp.(%) Ag2872, Run 175149214

Tissue Name
A
Tissue Name
A

Normal Colon
17.4
Kidney Margin (OD04348)
100.0

Colon cancer (OD06064)
26.6
Kidney malignant cancer
14.1

(OD06204B)

Colon Margin (OD06064)
16.2
Kidney normal adjacent tissue
8.5

(OD06204E)

Colon cancer (OD06159)
4.4
Kidney Cancer (OD04450-01)
29.1

Colon Margin (OD06159)
11.5
Kidney Margin (OD04450-03)
21.3

Colon cancer (OD06297-04)
1.1
Kidney Cancer 8120613
2.3

Colon Margin (OD06297-05)
19.6
Kidney Margin 8120614
16.7

CC Gr.2 ascend colon (ODO3921)
4.4
Kidney Cancer 9010320
0.0

CC Margin (ODO3921)
3.5
Kidney Margin 9010321
10.4

Colon cancer metastasis (ODO6104)
0.0
Kidney Cancer 8120607
16.3

Lung Margin (OD06104)
6.6
Kidney Margin 8120608
7.5

Colon mets to lung (OD04451-01)
33.0
Normal Uterus
0.0

Lung Margin (OD04451-02)
10.8
Uterine Cancer 064011
2.2

Normal Prostate
7.3
Normal Thyroid
0.0

Prostate Cancer (OD04410)
8.0
Thyroid Cancer
5.8

Prostate Margin (OD04410)
5.8
Thyroid Cancer A302152
20.0

Normal Ovary
2.4
Thyroid Margin A302153
3.4

Ovarian cancer (OD06283-03)
4.2
Normal Breast
21.6

Ovarian Margin (OD06283-07)
8.2
Breast Cancer
8.3

Ovarian Cancer
12.2
Breast Cancer
22.5

Ovarian cancer (OD06145)
4.3
Breast Cancer (OD04590-01)
41.2

Ovarian Margin (OD06145)
8.7
Breast Cancer Mets (OD04590-03)
26.1

Ovarian cancer (OD06455-03)
20.2
Breast Cancer Metastasis
46.0

Ovarian Margin (OD06455-07)
0.0
Breast Cancer
15.8

Normal Lung
7.6
Breast Cancer 9100266
9.6

Invasive poor diff. lung adeno
27.5
Breast Margin 9100265
1.7

ODO4945-01

Lung Margin (ODO4945-03)
14.1
Breast Cancer A209073
9.9

Lung Malignant Cancer (OD03126)
16.0
Breast Margin A209073
17.2

Lung Margin (OD03126)
4.3
Breast cancer (OD06083)
50.3

Lung Cancer (OD05014A)
7.5
Breast cancer node metastasis
42.0

(0D06083)

Lung Margin (OD05014B)
16.2
Normal Liver
12.2

Lung cancer (OD06081)
23.8
Liver Cancer 1026
3.2

Lung Margin (OD06081)
12.3
Liver Cancer 1025
10.4

Lung Cancer (OD04237-01)
9.9
Liver Cancer 6004-T
0.3

Lung Margin (OD04237-02)
25.5
Liver Tissue 6004-N
6.8

Ocular Mel Met to Liver (ODO4310)
4.3
Liver Cancer 6005-T
13.6

Liver Margin (ODO4310)
3.7
Liver Tissue 6005-N
8.8

Melanoma Metastasis
5.8
Liver Cancer
21.2

Lung Margin (OD04321)
15.1
Normal Bladder
17.4

Normal Kidney
1.8
Bladder Cancer
4.6

Kidney Ca, Nuclear grade 2
41.8
Bladder Cancer
22.4

(OD04338)

Kidney Margin (OD04338)
10.4
Normal Stomach
27.7

Kidney Ca Nuclear grade 1/2
52.1
Gastric Cancer 9060397
3.6

(OD04339)

Kidney Margin (OD04339)
15.3
Stomach Margin 9060396
14.2

Kidney Ca, Clear cell type (OD04340)
0.0
Gastric Cancer 9060395
5.1

Kidney Margin (OD04340)
16.8
Stomach Margin 9060394
10.2

Kidney Ca, Nuclear grade 3
0.0
Gastric Cancer 064005
12.1

(OD04348)

TABLE ASF

Panel 2D

Column A - Rel. Exp.(%) Ag2872, Run 161971795

Tissue Name
A
Tissue Name
A

Normal Colon
30.8
Kidney Margin 8120608
2.9

CC Well to Mod Diff (ODO3866)
13.0
Kidney Cancer 8120613
7.6

CC Margin (ODO3866)
5.9
Kidney Margin 8120614
15.3

CC Gr.2 rectosigmoid (ODO3868)
16.2
Kidney Cancer 9010320
10.9

CC Margin (ODO3868)
3.4
Kidney Margin 9010321
23.0

CC Mod Diff(ODO3920)
16.3
Normal Uterus
0.0

CC Margin (ODO3920)
10.9
Uterine Cancer 064011
23.5

CC Gr.2 ascend colon (ODO3921)
20.4
Normal Thyroid
4.0

CC Margin (ODO3921)
4.8
Thyroid Cancer
14.5

CC from Partial Hepatectomy
21.6
Thyroid Cancer A302152
15.0

(ODO4309) Mets

Liver Margin (ODO4309)
6.2
Thyroid Margin A302153
11.7

Colon mets to lung (OD04451-01)
24.0
Normal Breast
21.3

Lung Margin (OD04451-02)
9.5
Breast Cancer
25.9

Normal Prostate 6546-1
1.8
Breast Cancer (OD04590-01)
42.3

Prostate Cancer (OD04410)
19.1
Breast Cancer Mets (OD04590-03)
39.2

Prostate Margin (OD04410)
15.2
Breast Cancer Metastasis
40.9

Prostate Cancer (OD04720-01)
17.2
Breast Cancer
15.9

Prostate Margin (OD04720-02)
18.3
Breast Cancer
24.8

Normal Lung
31.0
Breast Cancer 9100266
23.8

Lung Met to Muscle (ODO4286)
12.1
Breast Margin 9100265
7.9

Muscle Margin (ODO4286)
4.6
Breast Cancer A209073
23.2

Lung Malignant Cancer (OD03126)
35.4
Breast Margin A209073
17.2

Lung Margin (OD03126)
24.8
Normal Liver
4.2

Lung Cancer (OD04404)
43.2
Liver Cancer
10.1

Lung Margin (OD04404)
14.2
Liver Cancer 1025
3.3

Lung Cancer (OD04565)
26.6
Liver Cancer 1026
5.3

Lung Margin (OD04565)
8.1
Liver Cancer 6004-T
4.6

Lung Cancer (OD04237-01)
25.2
Liver Tissue 6004-N
8.5

Lung Margin (OD04237-02)
16.6
Liver Cancer 6005-T
5.6

Ocular Mel Met to Liver (ODO4310)
7.0
Liver Tissue 6005-N
1.6

Liver Margin (ODO4310)
9.2
Normal Bladder
28.7

Melanoma Metastasis
8.0
Bladder Cancer
15.1

Lung Margin (OD04321)
32.1
Bladder Cancer
27.4

Normal Kidney
32.5
Bladder Cancer (OD04718-01)
32.1

Kidney Ca, Nuclear grade 2 (OD04338)
30.8
Bladder Normal Adjacent
0.9

(OD04718-03)

Kidney Margin (OD04338)
32.8
Normal Ovary
2.9

Kidney Ca Nuclear grade 1/2 (OD04339)
31.6
Ovarian Cancer
17.1

Kidney Margin (OD04339)
23.3
Ovarian Cancer (OD04768-07)
100.0

Kidney Ca, Clear cell type (OD04340)
5.5
Ovary Margin (OD04768-08)
1.5

Kidney Margin (OD04340)
29.5
Normal Stomach
15.8

Kidney Ca, Nuclear grade 3 (OD04348)
0.5
Gastric Cancer 9060358
2.5

Kidney Margin (OD04348)
27.9
Stomach Margin 9060359
7.5

Kidney Cancer (OD04622-01)
6.0
Gastric Cancer 9060395
8.8

Kidney Margin (OD04622-03)
4.5
Stomach Margin 9060394
14.4

Kidney Cancer (OD04450-01)
16.5
Gastric Cancer 9060397
33.0

Kidney Margin (OD04450-03)
19.2
Stomach Margin 9060396
7.9

Kidney Cancer 8120607
11.5
Gastric Cancer 064005
23.0

TABLE ASG

Panel 3D

Column A - Rel. Exp.(%) Ag2872, Run 164543502

Column B - Rel. Exp.(%) Ag2872, Run 164828587

Tissue Name
A
B
Tissue Name
A
B

94905 Daoy
2.5
1.9
94954 Ca Ski Cervical
8.2
9.7

Medulloblastoma/Cerebellum

epidermoid carcinoma

(metastasis

94906 TE671
1.5
2.0
94955 ES-2 Ovarian clear cell
0.6
0.5

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
6.3
8.8
94957 Ramos Stimulated with
3.0
3.3

Medulloblastoma/Cerebellum

PMA/ionomycin 6h

94908 PFSK-1 Primitive
1.3
1.6
94958 Ramos Stimulated with
3.0
3.8

Neuroectodermal/Cerebellum

PMA/ionomycin 14h

94909 XF-498 CNS
0.3
0.4
94962 MEG-01 Chronic
0.4
0.8

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
0.0
0.0
94963 Raji Burkitt's
1.2
1.1

lymphoma

94911 SF-268 CNS/glioblastoma
0.7
0.9
94964 Daudi Burkitt's
2.2
2.4

lymphoma

94912 T98G Glioblastoma
0.7
1.2
94965 U266 B-cell
1.5
1.1

plasmacytoma/myeloma

96776 SK-N-SH Neuroblastoma
1.2
2.0
94968 CA46 Burkitt's
1.4
0.8

(metastasis)

lymphoma

94913 SF-295 CNS/glioblastoma
0.4
0.6
94970 RL non-Hodgkin's B-
0.7
0.9

cell lymphoma

94914 Cerebellum
7.0
10.4
94972 JM1 pre-B-cell
1.2
1.7

lymphoma/leukemia

96777 Cerebellum
7.9
12.1
94973 Jurkat T cell leukemia
1.7
1.8

94916 NCI-H292
20.9
25.5
94974 TF-1 Erythroleukemia
0.2
0.2

Mucoepidermoid lung carcinoma

94917 DMS-114 Small cell lung
1.6
1.7
94975 HUT 78 T-cell
0.9
1.6

cancer

lymphoma

94918 DMS-79 Small cell lung
100.0
100.0
94977 U937 Histiocytic
0.6
1.4

cancer/neuroendocrine

lymphoma

94919 NCI-H146 Small cell lung
8.5
8.9
94980 KU-812 Myelogenous
0.1
0.2

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
9.7
13.6
769-P- Clear cell renal
1.7
2.2

cancer/neuroendocrine

carcinoma

94921 NCI-N417 Small cell lung
2.5
2.9
94983 Caki-2 Clear cell renal
1.8
2.6

cancer/neuroendocrine carcinoma

94923 NCI-H82 Small cell lung
1.5
1.7
94984 SW 839 Clear cell renal
2.1
2.2

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell
7.4
10.1
94986 G401 Wilms' tumor
0.8
1.6

lung cancer (metastasis)

94925 NCI-H1155 Large cell
8.7
10.8
94987 Hs766T Pancreatic
2.8
3.1

lung cancer/neuroendocrine

carcinoma (LN metastasis)

94926 NCI-H1299 Large cell
5.1
5.1
94988 CAPAN-1 Pancreatic
3.3
3.4

lung cancer/neuroendocrine

adenocarcinoma (liver

metastasis)

94927 NCI-H727 Lung carcinoid
6.2
6.7
94989 SU86.86 Pancreatic
5.7
7.4

carcinoma (liver metastasis)

94928 NCI-UMC-11 Lung
17.8
15.4
94990 BxPC-3 Pancreatic
7.1
10.0

carcinoid

adenocarcinoma

94929 LX-1 Small cell lung
5.1
4.3
94991 HPAC Pancreatic
4.4
3.2

cancer

adenocarcinoma

94930 Colo-205 Colon cancer
3.5
4.5
94992 MIA PaCa-2 Pancreatic
0.8
1.6

carcinoma

94931 KM12 Colon cancer
5.2
6.0
94993 CFPAC-1 Pancreatic
30.4
28.5

ductal adenocarcinoma

94932 KM20L2 Colon cancer
1.3
0.9
94994 PANC-1 Pancreatic
3.8
3.7

epithelioid ductal carcinoma

94933 NCI-H716 Colon cancer
10.8
13.9
94996 T24 Bladder carcinma
2.5
2.4

(transitional cell

94935 SW-48 Colon
1.6
1.3
5637- Bladder carcinoma
5.7
6.0

adenocarcinoma

94936 SW1116 Colon
2.9
2.9
94998 HT-1197 Bladder
6.0
6.3

adenocarcinoma

carcinoma

94937 LS 174T Colon
6.2
6.9
94999 UM-UC-3 Bladder
0.8
0.6

adenocarcinoma

carcinma (transitional cell)

94938 SW-948 Colon
0.7
0.6
95000 A204

adenocarcinoma

Rhabdomyosarcoma
0.9
1.2

94939 SW-480 Colon
2.2
0.2
95001 HT-1080 Fibrosarcoma
8.2
11.8

adenocarcinoma

94940 NCI-SNU-5 Gastric
2.8
3.4
95002 MG-63 Osteosarcoma
0.0
0.0

carcinoma

(bone)

KATO III- Gastric carcinoma
3.3
6.3
95003 SK-LMS-1
1.7
1.8

Leiomyosarcoma (vulva)

94943 NCI-SNU-16 Gastric
3.9
3.8
95004 SJRH30
1.4
0.7

carcinoma

Rhabdomyosarcoma (met to

bone marrow)

94944 NCI-SNU-1 Gastric
6.0
8.0
95005 A431 Epidermoid
4.1
5.6

carcinoma

carcinoma

94946 RF-1 Gastric
1.6
2.3
95007 WM266-4 Melanoma
2.0
2.1

adenocarcinoma

94947 RF-48 Gastric
2.3
1.8
DU 145- Prostate carcinoma
0.3
0.1

adenocarcinoma

(brain metastasis)

96778 MKN-45 Gastric
7.0
7.6
95012 MDA-MB-468 Breast
4.6
7.5

carcinoma

adenocarcinoma

94949 NCI-N87 Gastric
4.4
4.8
SCC-4- Squamous cell
0.8
0.4

carcinoma

carcinoma of tongue

94951 OVCAR-5 Ovarian
0.9
1.4
SCC-9- Squamous cell
0.7
0.5

carcinoma

carcinoma of tongue

94952 RL95-2 Uterine carcinoma
2.3
3.0
SGC-15- Squamous cell
0.4
0.3

carcinoma of tongue

94953 HelaS3 Cervical
1.4
2.2
95017 CAL 27 Squamous cell
3.1
3.4

adenocarcinoma

carcinoma of tongue

TABLE ASH

Panel 4.1D

Column A - Rel. Exp.(%) Ag4847, Run 223335762

Tissue Name
A
Tissue Name
A

Secondary Th1 act
12.2
HUVEC IL-1beta
0.0

Secondary Th2 act
14.8
HUVEC IFN gamma
0.0

Secondary Tr1 act
9.5
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
2.6
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
8.7
HUVEC IL-11
0.0

Secondary Tr1 rest
9.9
Lung Microvascular EC none
0.0

Primary Th1 act
2.1
Lung Microvascular EC TNFalpha + IL-
0.0

1beta

Primary Th2 act
14.2
Microvascular Dermal EC none
0.0

Primary Tr1 act
2.8
Microsvasular Dermal EC TNFalpha + IL-
0.0

1beta

Primary Th1 rest
2.7
Bronchial epithelium TNFalpha + IL1beta
51.8

Primary Th2 rest
3.6
Small airway epithelium none
28.7

Primary Tr1 rest
19.1
Small airway epithelium TNFalpha + IL-
52.5

1beta

CD45RA CD4 lymphocyte act
5.3
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
9.1
Coronery artery SMC TNFalpha + IL-1beta
0.1

CD8 lymphocyte act
3.9
Astrocytes rest
16.7

Secondary CD8 lymphocyte rest
6.6
Astrocytes TNFalpha + IL-1beta
9.7

Secondary CD8 lymphocyte act
2.4
KU-812 (Basophil) rest
0.3

CD4 lymphocyte none
0.5
KU-812 (Basophil) PMA/ionomycin
0.2

2ry Th1/Th2/Tr1 anti-CD95
7.0
CCD1106 (Keratinocytes) none
68.8

CH11

LAK cells rest
1.9
CCD1106 (Keratinocytes) TNFalpha + IL-
29.5

1beta

LAK cells IL-2
6.3
Liver cirrhosis
4.1

LAK cells IL-2 + IL-12
6.2
NCI-H292 none
27.7

LAK cells IL-2 + IFN gamma
4.0
NCI-H292 IL-4
87.1

LAK cells IL-2 + IL-18
3.5
NCI-H292 IL-9
81.2

LAK cells PMA/ionomycin
3.3
NCI-H292 IL-13
74.7

NK Cells IL-2 rest
5.1
NCI-H292 IFN gamma
35.4

Two Way MLR 3 day
1.6
HPAEC none
0.0

Two Way MLR 5 day
1.3
HPAEC TNF alpha + IL-1 beta
0.0

Two Way MLR 7 day
1.6
Lung fibroblast none
0.4

PBMC rest
3.8
Lung fibroblast TNF alpha + IL-1 beta
0.5

PBMC PWM
5.6
Lung fibroblast IL-4
0.0

PBMC PHA-L
13.0
Lung fibroblast IL-9
0.0

Ramos (B cell) none
15.1
Lung fibroblast IL-13
0.0

Ramos (B cell) ionomycin
15.5
Lung fibroblast IFN gamma
0.0

B lymphocytes PWM
9.2
Dermal fibroblast CCD1070 rest
0.0

B lymphocytes CD40L and IL-4
42.0
Dermal fibroblast CCD1070 TNF alpha
6.2

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast IFN gamma
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells LPS
0.0
Dermal Fibroblasts rest
0.0

Dendritic cells anti-CD40
0.0
Neutrophils TNFa + LPS
0.0

Monocytes rest
0.0
Neutrophils rest
0.0

Monocytes LPS
0.0
Colon
0.7

Macrophages rest
0.0
Lung
8.8

Macrophages LPS
0.0
Thymus
32.5

HUVEC none
0.0
Kidney
100.0

HUVEC starved
0.0

TABLE ASI

Panel 5 Islet

Column A - Rel. Exp.(%) Ag2872, Run 237228677

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
5.1
94709 Donor 2 AM - A adipose
1.8

97476 Patient-07sk skeletal muscle
2.7
94710 Donor 2 AM - B adipose
0.0

97477 Patient-07ut uterus
0.0
94711 Donor 2 AM - C adipose
0.0

97478 Patient-07pl placenta
39.5
94712 Donor 2 AD - A adipose
0.0

99167 Bayer Patient 1
97.9
94713 Donor 2 AD - B adipose
0.0

97482 Patient-08ut uterus
0.0
94714 Donor 2 AD - C adipose
0.0

97483 Patient-08pl placenta
21.9
94742 Donor 3 U - A Mesenchymal
0.0

Stem Cells

97486 Patient-09sk skeletal muscle
2.5
94743 Donor 3 U - B Mesenchymal
0.0

Stem Cells

97487 Patient-09ut uterus
0.0
94730 Donor 3 AM - A adipose
0.0

97488 Patient-09pl placenta
19.3
94731 Donor 3 AM - B adipose
0.0

97492 Patient-10ut uterus
1.9
94732 Donor 3 AM - C adipose
0.0

97493 Patient-10pl placenta
100.0
94733 Donor 3 AD - A adipose
0.0

97495 Patient-11go adipose
4.0
94734 Donor 3 AD - B adipose
0.0

97496 Patient-11sk skeletal muscle
3.2
94735 Donor 3 AD - C adipose
0.0

97497 Patient-11ut uterus
1.7
77138 Liver HepG2untreated
46.0

97498 Patient-11pl placenta
23.8
73556 Heart Cardiac stromal cells
0.0

(primary)

97500 Patient-12go adipose
1.6
81735 Small Intestine
13.5

97501 Patient-12sk skeletal muscle
4.0
72409 Kidney Proximal Convoluted
17.1

Tubule

97502 Patient-12ut uterus
0.0
82685 Small intestine Duodenum
1.4

97503 Patient-12pl placenta
20.3
90650 Adrenal Adrenocortical
1.6

adenoma

94721 Donor 2 U - A Mesenchymal
0.0
72410 Kidney HRCE
90.1

Stem Cells

94722 Donor 2 U - B Mesenchymal
0.0
72411 Kidney HRE
48.6

Stem Cells

94723 Donor 2 U - C Mesenchymal
0.0
73139 Uterus Uterine smooth muscle
2.9

Stem Cells

cells

General_screening_panel_v1.5 Summary: Ag4847 Expression of this gene was highest in the cerebellum (CT=25.4). This gene was also expressed at more moderate levels in other central nervous system tissues, including amygdala, hippocampus, cerebral cortex, substantia nigra, thalamus and spinal cord (CTs=27-30). This gene encodes a protein with homology to mixed lineage kinase 2. Mixed lineage kinase 2 is a mammalian protein kinase that activates stress-activated protein kinases/c-jun N-terminal kinases (SAPK/JNKs) through direct phosphorylation of their upstream activator, SEK1/JNKK. MAP kinase signaling pathways are important mediators of cellular responses to a wide variety of stimuli. Signals pass along these pathways via kinase cascades in which three protein kinases are sequentially phosphorylated and activated, initiating a range of cellular programs including cellular proliferation, endocrine, immune and inflammatory responses, and apoptosis. Mixed lineage kinases have been implicated in neuronal apoptosis (Xu Z, Maroney A C, Dobrzanski P, Kukekov N V, Greene L A. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol 2001 July; 21(14):4713-24). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in slowing neuronal apoptosis in the treatment of neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's diseases.

This gene also showed significant expression in cell lines drived from ovarian cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of ovarian cancer.

This gene was expressed at low to moderate levels in endocrine and metabolic tissues including adipose, adrenal gland, liver, pancreas, pituitary gland, skeletal muscle and thyroid. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of endocrine/metabolic-related disorders, such as obesity and diabetes.

Panel 1.3D Summary: Ag2872 This gene showed highest expression in samples derived from brain tissue, either normal tissue or cell lines derived from malignant brain tissue. Please see panel General_Screening_V1.5 for a discussion of this gene in the central nervous system.

There was substantial expression of this gene in a number of cancer cell lines, including ovarian cancer, breast cancer and renal cancer cell lines. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of ovarian, breast or renal cancer.

There was limited expression of this gene in endocrine/metabolic related tissues. Low expression of this gene was seen in adipose, pancreas, reproductive tissues (testes and ovaries) and skeletal muscle. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of different endocrine/metabolic diseases, such as diabetes and obesity.

Panel 2.2 Summary: Ag2872 Expression of this gene was highest in a sample derived from normal kidney tissue adjacent to a kidney cancer (CT=31.2). In addition, there was substantial expression of this gene in samples derived from a cluster of breast cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of breast cancer.

Panel 2D Summary: Ag2872 Expression of this gene was highest in a sample derived from an ovarian cancer (CT=28.4). Thus, expression of this gene can be used to distinguish ovarian cancer tissue from the other tissues in the panel. There was substantial expression of this gene in samples derived from a cluster of breast cancers and well as a small but appreciable difference in expression between a set of colon cancers and their respective normal adjacent tissues. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of breast cancer, ovarian cancer or colon cancer.

Panel 3D Summary: Ag2872 This gene showed highest expression in a sample derived from a small cell lung cancer derived cell line (CT=26.1). There was substantial expression of this gene in two other lung cancer derived cell lines and a pancreatic cancer derived cell line. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of lung cancer.

Panel 4.1D Summary: Ag4847 Expression of this gene was highest in kidney (CT=28.3). This gene was also highly expressed in small airway epithelium treated with TNF-a and IL-1b, and to a lower extent in the same non treated tissue and also in the mucoepidermoid cell line H292 upon treatment with the Th2 cytokines IL-4 and Il-9, cytokines that are responsible for increasing mucus production in this cell line. Expression of this gene was up-regulated in bronchial epithelium upon TNF-a and IL-1 treatment. Moderate expression of this gene was also seen in activated B cells. This gene encodes for a mixed lineage kinase 2 (MLK2) like molecule which was reported to activate JNK pathway (Hirai S, Noda K, Moriguchi T, Nishida E, Yamashita A, Deyama T, Fukuyama K, Ohno S. Differential activation of two JNK activators, MKK7 and SEK1, by MKN28-derived nonreceptor serine/threonine kinase/mixed lineage kinase 2. J Biol Chem 1998 Mar. 27; 273(13):7406-12). Activation of this pathway has been associated to many inflammatory reactions in many cell types. Il-1b which is produced during airway inflammation, has been shown to regulate JNK pathway, for example (Hallsworth M P, Moir L M, Lai D, Hirst S J. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle. Am J Respir Crit Care Med 2001 Aug. 15; 164(4):688-97). The role of Il-4 and IL-13 in airway remodeling appears also to use JNK pathway (Hashimoto S, Gon Y, Takeshita I, Maruoka S, Horie T. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway. J Allergy Clin Immunol 2001 June; 107(6):1001-8). Finally, JNK is required for the production of metalloproteinases (Han Z, Boyle D L, Chang L, Bennett B, Karin M, Yang L, Manning A M, Firestein G S. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001 July; 108(1):73-81), molecules that play an important role in inflammatory disesease such as rheumatoid arthritis, asthma, and inflammatory bowel disease (IBD). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of inflammatory diseseas such as in chronic obstructive pulmonary disease, asthma, emphysema and also rheumatoid arthritis/osteoarthritis, IBD and psoriasis.

Panel 5 Islet Summary: Ag2872 This gene was expressed at low to moderate levels in pancreatic islet cells and placenta in panel 5I. Please refer to General_screening_panel_v1.5 for a synopsis of the the potential function of this MLK2-like gene in endocrine and metabolic disorders.

AT. CG56142-01 and CG56142-04: Prostasin.

Expression of gene CG56142-01 and CG56142-04 were assessed using the primer-probe sets Ag2888 and Ag4095, respectively, described in Table ATA and ATB. Results of the RTQ-PCR runs are shown in Tables ATC, ATD, ATE, ATF, ATG and ATH.

TABLE ATAProbe Name Ag2888StartSEQ IDPrimersSequencesLengthPositionNoForward5′-aatgagaggggtttcctgtct-3′21181368ProbeTET-5′-caggtcctgctccttctggtgctg-3′-24401369TAMRAReverse5′-caacgatccgactggacat-3′19821370

TABLE ATB

Probe Name Ag4095

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-aatgagaggggtttcctgtct-3′
21
13
1371

Probe
TET-5′-caggtcctgctccttctggtgctg-3′-
24
35
1372

TAMRA

Reverse
5′-gcagacttccttccctgagt-3′
20
71
1373

TABLE ATC

General_screening_panel_v1.4

Column A - Rel. Exp.(%) Ag4095, Run 219575329

Tissue Name
A
Tissue Name
A

Adipose
0.0
Renal ca. TK-10
0.2

Melanoma* Hs688(A).T
0.0
Bladder
0.0

Melanoma* Hs688(B).T
0.0
Gastric ca. (liver met.) NCI-N87
0.1

Melanoma* M14
0.0
Gastric ca. KATO III
1.3

Melanoma* LOXIMVI
0.0
Colon ca. SW-948
0.2

Melanoma* SK-MEL-5
0.0
Colon ca. SW480
2.9

Squamous cell carcinoma
0.0
Colon ca.* (SW480 met) SW620
0.0

SCC-4

Testis Pool
0.0
Colon ca. HT29
0.0

Prostate ca.* (bone met)
0.0
Colon ca. HCT-116
0.0

PC-3

Prostate Pool
0.0
Colon ca. CaCo-2
0.0

Placenta
0.0
Colon cancer tissue
100.0

Uterus Pool
0.0
Colon ca. SW1116
0.1

Ovarian ca. OVCAR-3
0.0
Colon ca. Colo-205
0.0

Ovarian ca. SK-OV-3
0.0
Colon ca. SW-48
0.1

Ovarian ca. OVCAR-4
0.0
Colon Pool
0.0

Ovarian ca. OVCAR-5
0.0
Small Intestine Pool
0.0

Ovarian ca. IGROV-1
7.5
Stomach Pool
0.0

Ovarian ca. OVCAR-8
2.0
Bone Marrow Pool
0.0

Ovary
0.0
Fetal Heart
0.0

Breast ca. MCF-7
0.0
Heart Pool
0.0

Breast ca. MDA-MB-231
0.2
Lymph Node Pool
0.0

Breast ca. BT 549
0.0
Fetal Skeletal Muscle
0.0

Breast ca. T47D
0.5
Skeletal Muscle Pool
0.0

Breast ca. MDA-N
0.2
Spleen Pool
0.0

Breast Pool
0.0
Thymus Pool
0.0

Trachea
0.0
CNS cancer (glio/astro) U87-MG
0.0

Lung
1.2
CNS cancer (glio/astro) U-118-MG
0.0

Fetal Lung
0.0
CNS cancer (neuro; met) SK-N-AS
0.0

Lung ca. NCI-N417
0.0
CNS cancer (astro) SF-539
0.0

Lung ca. LX-1
0.0
CNS cancer (astro) SNB-75
0.2

Lung Ca. NCI-H146
0.0
CNS cancer (glio) SNB-19
6.3

Lung ca. SHP-77
0.7
CNS cancer (glio) SF-295
0.5

Lung ca. A549
0.0
Brain (Amygdala) Pool
0.0

Lung ca. NCI-H526
0.0
Brain (cerebellum)
0.0

Lung ca. NCI-H23
0.0
Brain (fetal)
0.0

Lung ca. NCI-H460
0.0
Brain (Hippocampus) Pool
0.0

Lung ca. HOP-62
0.0
Cerebral Cortex Pool
0.0

Lung ca. NCI-H522
0.0
Brain (Substantia nigra) Pool
0.1

Liver
0.0
Brain (Thalamus) Pool
0.0

Fetal Liver
0.1
Brain (whole)
0.0

Liver ca. HepG2
0.0
Spinal Cord Pool
0.0

Kidney Pool
0.0
Adrenal Gland
0.0

Fetal Kidney
0.1
Pituitary gland Pool
0.0

Renal ca. 786-0
0.0
Salivary Gland
0.0

Renal ca. A498
0.0
Thyroid (female)
0.0

Renal ca. ACHN
0.0
Pancreatic ca. CAPAN2
0.0

Renal ca. UO-31
0.0
Pancreas Pool
0.0

TABLE ATD

General_screening_panel_v1.5

Column A - Rel. Exp.(%) Ag2888, Run 258495050

Tissue Name
A
Tissue Name
A

Adipose
0.0
Renal ca. TK-10
0.0

Melanoma* Hs688(A).T
0.0
Bladder
0.0

Melanoma* Hs688(B).T
0.0
Gastric ca. (liver met.) NCI-N87
0.0

Melanoma* M14
0.2
Gastric ca. KATO III
1.3

Melanoma* LOXIMVI
0.0
Colon ca. SW-948
0.5

Melanoma* SK-MEL-5
0.0
Colon ca. SW480
2.7

Squamous cell carcinoma
0.0
Colon ca.* (SW480 met) SW620
0.0

SCC-4

Testis Pool
0.0
Colon ca. HT29
0.0

Prostate ca.* (bone met)
0.0
Colon ca. HCT-116
0.0

PC-3

Prostate Pool
0.0
Colon ca. CaCo-2
0.0

Placenta
0.0
Colon cancer tissue
100.0

Uterus Pool
0.0
Colon ca. SW1116
0.0

Ovarian ca. OVCAR-3
0.0
Colon ca. Colo-205
0.2

Ovarian ca. SK-OV-3
0.0
Colon ca. SW-48
0.0

Ovarian ca. OVCAR-4
0.0
Colon Pool
0.0

Ovarian ca. OVCAR-5
0.0
Small Intestine Pool
0.0

Ovarian ca. IGROV-1
6.6
Stomach Pool
0.0

Ovarian ca. OVCAR-8
1.4
Bone Marrow Pool
0.0

Ovary
0.0
Fetal Heart
0.0

Breast ca. MCF-7
0.0
Heart Pool
0.0

Breast ca. MDA-MB-231
0.0
Lymph Node Pool
0.0

Breast ca. BT 549
0.0
Fetal Skeletal Muscle
0.0

Breast ca. T47D
0.0
Skeletal Muscle Pool
0.0

Breast ca. MDA-N
0.3
Spleen Pool
0.0

Breast Pool
0.0
Thymus Pool
0.0

Trachea
0.2
CNS cancer (glio/astro) U87-MG
0.0

Lung
0.0
CNS cancer (glio/astro) U-118-MG
0.3

Fetal Lung
0.0
CNS cancer (neuro; met) SK-N-AS
0.0

Lung ca. NCI-N417
0.0
CNS cancer (astro) SF-539
0.0

Lung ca. LX-1
0.0
CNS cancer (astro) SNB-75
0.0

Lung Ca. NCI-H146
0.0
CNS cancer (glio) SNB-19
11.8

Lung ca. SHP-77
0.0
CNS cancer (glio) SF-295
0.1

Lung ca. A549
0.0
Brain (Amygdala) Pool
0.0

Lung ca. NCI-H526
0.0
Brain (cerebellum)
0.0

Lung ca. NCI-H23
0.0
Brain (fetal)
0.0

Lung ca. NCI-H460
0.0
Brain (Hippocampus) Pool
0.0

Lung ca. HOP-62
0.0
Cerebral Cortex Pool
0.0

Lung ca. NCI-H522
0.0
Brain (Substantia nigra) Pool
0.0

Liver
0.0
Brain (Thalamus) Pool
0.0

Fetal Liver
0.0
Brain (whole)
0.0

Liver ca. HepG2
0.0
Spinal Cord Pool
0.0

Kidney Pool
0.0
Adrenal Gland
0.0

Fetal Kidney
0.0
Pituitary gland Pool
0.0

Renal ca. 786-0
0.0
Salivary Gland
0.0

Renal ca. A498
0.0
Thyroid (female)
0.0

Renal ca. ACHN
0.0
Pancreatic ca. CAPAN2
0.0

Renal ca. UO-31
0.0
Pancreas Pool
0.0

TABLE ATE

Panel 2D

Column A - Rel. Exp.(%) Ag2888, Run 160897960

Tissue Name
A
Tissue Name
A

Normal Colon
0.0
Kidney Margin 8120608
0.0

CC Well to Mod Diff (ODO3866)
100.0
Kidney Cancer 8120613
0.0

CC Margin (ODO3866)
1.1
Kidney Margin 8120614
0.0

CC Gr.2 rectosigmoid (ODO3868)
0.0
Kidney Cancer 9010320
0.5

CC Margin (ODO3868)
0.0
Kidney Margin 9010321
0.0

CC Mod Diff(ODO3920)
3.5
Normal Uterus
0.0

CC Margin (ODO3920)
0.0
Uterine Cancer 064011
0.0

CC Gr.2 ascend colon (ODO3921)
1.2
Normal Thyroid
0.0

CC Margin (ODO3921)
0.1
Thyroid Cancer
0.0

CC from Partial Hepatectomy
14.2
Thyroid Cancer A302152
0.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.2
Thyroid Margin A302153
0.0

Colon mets to lung (OD04451-01)
3.5
Normal Breast
0.0

Lung Margin (OD04451-02)
0.0
Breast Cancer
0.0

Normal Prostate 6546-1
0.0
Breast Cancer (OD04590-01)
0.0

Prostate Cancer (OD04410)
0.0
Breast Cancer Mets (OD04590-03)
0.0

Prostate Margin (OD04410)
0.0
Breast Cancer Metastasis
0.0

Prostate Cancer (OD04720-01)
0.0
Breast Cancer
0.0

Prostate Margin (OD04720-02)
0.0
Breast Cancer
0.0

Normal Lung
0.0
Breast Cancer 9100266
0.0

Lung Met to Muscle (ODO4286)
0.0
Breast Margin 9100265
0.0

Muscle Margin (ODO4286)
0.0
Breast Cancer A209073
0.0

Lung Malignant Cancer (OD03126)
0.2
Breast Margin A209073
0.0

Lung Margin (OD03126)
0.0
Normal Liver
0.0

Lung Cancer (OD04404)
0.0
Liver Cancer
0.0

Lung Margin (OD04404)
0.0
Liver Cancer 1025
0.2

Lung Cancer (OD04565)
0.0
Liver Cancer 1026
0.0

Lung Margin (OD04565)
0.0
Liver Cancer 6004-T
0.0

Lung Cancer (OD04237-01)
0.2
Liver Tissue 6004-N
0.0

Lung Margin (OD04237-02)
0.0
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (ODO4310)
0.0
Liver Tissue 6005-N
0.0

Liver Margin (ODO4310)
0.0
Normal Bladder
0.0

Melanoma Metastasis
0.7
Bladder Cancer
0.0

Lung Margin (OD04321)
0.0
Bladder Cancer
0.0

Normal Kidney
0.0
Bladder Cancer (OD04718-01)
0.3

Kidney Ca, Nuclear grade 2 (OD04338)
0.0
Bladder Normal Adjacent
0.0

(OD04718-03)

Kidney Margin (OD04338)
0.0
Normal Ovary
0.4

Kidney Ca Nuclear grade 1/2 (OD04339)
0.0
Ovarian Cancer
0.0

Kidney Margin (OD04339)
0.0
Ovarian Cancer (OD04768-07)
0.1

Kidney Ca, Clear cell type (OD04340)
0.0
Ovary Margin (OD04768-08)
0.0

Kidney Margin (OD04340)
0.0
Normal Stomach
0.7

Kidney Ca, Nuclear grade 3 (OD04348)
0.3
Gastric Cancer 9060358
0.0

Kidney Margin (OD04348)
0.0
Stomach Margin 9060359
0.5

Kidney Cancer (OD04622-01)
0.0
Gastric Cancer 9060395
0.0

Kidney Margin (OD04622-03)
0.0
Stomach Margin 9060394
0.0

Kidney Cancer (OD04450-01)
0.0
Gastric Cancer 9060397
17.6

Kidney Margin (OD04450-03)
0.0
Stomach Margin 9060396
0.0

Kidney Cancer 8120607
0.0
Gastric Cancer 064005
0.0

TABLE ATF

Panel 3D

Column A - Rel. Exp.(%) Ag2888, Run 164629839

Tissue Name
A
Tissue Name
A

94905 Daoy
0.0
94954 Ca Ski Cervical epidermoid
0.0

Medulloblastoma/Cerebellum

carcinoma (metastasis

94906 TE671
0.0
94955 ES-2 Ovarian clear cell
0.0

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
0.0
94957 Ramos Stimulated with
0.0

Medulloblastoma/Cerebellum

PMA/ionomycin 6 h

94908 PFSK-1 Primitive
0.0
94958 Ramos Stimulated with
0.0

Neuroectodermal/Cerebellum

PMA/ionomycin 14 h

94909 XF-498 CNS
0.0
94962 MEG-01 Chronic
0.0

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
0.0
94963 Raji Burkitt's lymphoma
0.0

94911 SF-268 CNS/glioblastoma
0.0
94964 Daudi Burkitt's lymphoma
0.0

94912 T98G Glioblastoma
0.0
94965 U266 B-cell
0.0

plasmacytoma/myeloma

96776 SK-N-SH Neuroblastoma
0.0
94968 CA46 Burkitt's lymphoma
0.0

(metastasis)

94913 SF-295 CNS/glioblastoma
0.0
94970 RL non-Hodgkin's B-cell
0.0

lymphoma

94914 Cerebellum
0.0
94972 JM1 pre-B-cell
0.0

lymphoma/leukemia

96777 Cerebellum
0.0
94973 Jurkat T cell leukemia
0.0

94916 NCI-H292 Mucoepidermoid
0.0
94974 TF-l Erythroleukemia
0.0

lung carcinoma

94917 DMS-114 Small cell lung
0.0
94975 HUT 78 T-cell lymphoma
0.0

cancer

94918 DMS-79 Small cell lung
0.0
94977 U937 Histiocytic lymphoma
0.0

cancer/neuroendocrine

94919 NCI-H146 Small cell lung
0.0
94980 KU-812 Myelogenous
0.0

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
0.0
769-P-Clear cell renal carcinoma
0.0

cancer/neuroendocrine

94921 NCI-N417 Small cell lung
0.0
94983 Caki-2 Clear cell renal
0.0

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
0.0
94984 SW 839 Clear cell renal
0.0

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell lung
0.0
94986 G401 Wilms'tumor
0.0

cancer (metastasis)

94925 NCI-H1155 Large cell lung
0.0
94987 Hs766T Pancreatic carcinoma
77.9

cancer/neuroendocrine

(LN metastasis)

94926 NCI-H1299 Large cell lung
0.0
94988 CAPAN-1 Pancreatic

cancer/neuroendocrine

adenocarcinoma (liver metastasis)
1.6

94927 NCI-H727 Lung carcinoid
0.0
94989 SU86.86 Pancreatic carcinoma
2.5

(liver metastasis)

94928 NCI-UMC-11 Lung carcinoid
0.0
94990 BxPC-3 Pancreatic
0.0

adenocarcinoma

94929 LX-1 Small cell lung cancer
0.0
94991 HPAC Pancreatic
0.0

adenocarcinoma

94930 Colo-205 Colon cancer
0.0
94992 MIA PaCa-2 Pancreatic
0.0

carcinoma

94931 KM12 Colon cancer
0.0
94993 CFPAC-1 Pancreatic ductal
0.0

adenocarcinoma

94932 KM20L2 Colon cancer
0.0
94994 PANC-1 Pancreatic epithelioid
0.0

ductal carcinoma

94933 NCI-H716 Colon cancer
0.0
94996 T24 Bladder carcinma
0.0

(transitional cell

94935 SW-48 Colon adenocarcinoma
0.0
5637-Bladder carcinoma
0.0

94936 SW1116 Colon
0.0
94998 HT-1197 Bladder carcinoma
0.0

adenocarcinoma

94937 LS 174T Colon
0.0
94999 UM-UC-3 Bladder carcinma
0.0

adenocarcinoma

(transitional cell)

94938 SW-948 Colon
0.0
95000 A204 Rhabdomyosarcoma
0.0

adenocarcinoma

94939 SW-480 Colon
0.0
95001 HT-1080 Fibrosarcoma
0.0

adenocarcinoma

94940 NCI-SNU-5 Gastric carcinoma
100.0
95002 MG-63 Osteosarcoma (bone)
0.0

KATO III-Gastric carcinoma
0.0
95003 SK-LMS-1 Leiomyosarcoma
0.0

(vulva)

94943 NCI-SNU-16 Gastric
0.0
95004 SJRH30 Rhabdomyosarcoma
0.0

carcinoma

(met to bone marrow)

94944 NCI-SNU-1 Gastric carcinoma
0.0
95005 A431 Epidermoid carcinoma
0.0

94946 RF-1 Gastric adenocarcinoma
0.0
95007 WM266-4 Melanoma
0.0

94947 RF-48 Gastric adenocarcinoma
0.0
DU 145-Prostate carcinoma (brain
0.0

metastasis)

96778 MKN-45 Gastric carcinoma
0.0
95012 MDA-MB-468 Breast
0.0

adenocarcinoma

94949 NCI-N87 Gastric carcinoma
27.9
SCC-4-Squamous cell carcinoma of
0.0

tongue

94951 OVCAR-5 Ovarian carcinoma
0.0
SCC-9-Squamous cell carcinoma of
0.0

tongue

94952 RL95-2 Uterine carcinoma
0.0
SCC-15-Squamous cell carcinoma of
0.0

tongue

94953 HelaS3 Cervical
0.0
95017 CAL 27 Squamous cell
0.0

adenocarcinoma

carcinoma of tongue

TABLE ATG

Panel 4.1D

Column A - Rel. Exp.(%) Ag4095, Run 172383943

Column B - Rel. Exp.(%) Ag4095, Run 268719443

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
0.0
0.0
HUVEC IL-1beta
0.0
0.0

Secondary Th2 act
0.0
0.0
HUVEC IFN gamma
0.0
0.0

Secondary Tr1 act
0.0
0.0
HUVEC TNF alpha + IFN gamma
0.0
0.0

Secondary Th1 rest
0.0
0.0
HUVEC TNF alpha + IL4
0.0
0.0

Secondary Th2 rest
0.0
0.0
HUVEC IL-11
0.0
0.0

Secondary Tr1 rest
0.0
0.0
Lung Microvascular EC none
0.0
0.0

Primary Th1 act
0.0
0.0
Lung Microvascular EC TNFalpha +
0.0
0.0

IL-1beta

Primary Th2 act
0.0
0.0
Microvascular Dermal EC none
0.0
0.0

Primary Tr1 act
0.0
0.0
Microsvasular Dermal EC TNFalpha +
0.0
0.0

+IL-1beta

Primary Th1 rest
0.0
0.0
Bronchial epithelium TNFalpha +
0.0
0.0

IL1beta

Primary Th2 rest
0.0
0.0
Small airway epithelium none
0.0
0.0

Primary Tr1 rest
0.0
0.0
Small airway epithelium TNFalpha +
0.0
0.0

IL-1beta

CD45RA CD4 lymphocyte
0.0
0.0
Coronery artery SMC rest
0.0
0.0

act

CD45RO CD4 lymphocyte
0.0
0.0
Coronery artery SMG TNFalpha + IL-
0.0
0.0

act

1beta

CD8 lymphocyte act
0.0
0.0
Astrocytes rest
8.3
0.0

Secondary CD8 lymphocyte
0.0
0.0
Astrocytes TNFalpha + IL-1beta
0.0
0.0

rest

Secondary CD8 lymphocyte
0.0
0.0
KU-812 (Basophil) rest
0.0
0.0

act

CD4 lymphocyte none
0.0
0.0
KU-812 (Basophil) PMA/ionomycin
0.0
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
0.0
CCD1106 (Keratinocytes) none
0.0
0.0

CH11

LAK cells rest
0.0
0.0
CCD1106 (Keratinocytes) TNFalpha
0.0
0.0

+ IL-1beta

LAK cells IL-2
0.0
0.0
Liver cirrhosis
0.0
0.0

LAK cells IL-2 + IL-12
0.0
0.0
NCI-H292 none
0.0
0.0

LAK cells IL-2 + IFN gamma
0.0
0.0
NCI-H292 IL-4
0.0
0.0

LAK cells IL-2 + IL-18
0.0
0.0
NCI-H292 IL-9
0.0
0.0

LAK cells PMA/ionomycin
0.0
0.0
NCI-H292 IL-13
0.0
0.0

NK Cells IL-2 rest
0.0
0.3
NCI-H292 IFN gamma
0.0
0.0

Two Way MLR 3 day
0.0
0.0
HPAEC none
0.0
0.0

Two Way MLR 5 day
0.0
0.0
HPAEC TNF alpha + IL-1 beta
0.0
0.0

Two Way MLR 7 day
0.0
0.0
Lung fibroblast none
0.0
0.0

PBMC rest
0.0
0.0
Lung fibroblast TNF alpha + IL-1 beta
0.0
0.0

PBMC PWM
0.0
0.0
Lung fibroblast IL-4
0.0
0.0

PBMC PHA-L
0.0
0.0
Lung fibroblast IL-9
0.0
0.0

Ramos (B cell) none
0.0
0.0
Lung fibroblast IL-13
0.0
0.0

Ramos (B cell) ionomycin
0.0
0.0
Lung fibroblast IFN gamma
0.0
0.0

B lymphocytes PWM
0.0
0.0
Dermal fibroblast CCD1070 rest
0.0
0.0

B lymphocytes CD40L and
0.0
0.0
Dermal fibroblast CCD1070 TNF
0.0
0.0

IL-4

alpha

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0
0.0

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast IFN gamma
0.0
0.0

PMA/ionomycin

Dendritic cells none
0.0
0.0
Dermal fibroblast IL-4
3.9
0.0

Dendritic cells LPS
0.0
0.0
Dermal Fibroblasts rest
0.0
0.0

Dendritic cells anti-CD40
0.0
0.0
Neutrophils TNFa + LPS
17.9
0.0

Monocytes rest
0.0
0.0
Neutrophils rest
100.0
100.0

Monocytes LPS
0.0
0.0
Colon
0.0
0.0

Macrophages rest
0.0
0.0
Lung
0.0
0.0

Macrophages LPS
0.0
0.0
Thymus
0.0
0.0

HUVEC none
0.0
0.0
Kidney
0.0
0.0

HUVEC starved
0.0
0.0

TABLE ATH

general oncology screening panel_v_2.4

Column A - Rel. Exp.(%) Ag4095, Run 268389981

Tissue Name
A
Tissue Name
A

Colon cancer 1
50.7
Bladder NAT 2
0.0

CC Margin (ODO3921)
0.0
Bladder NAT 3
2.1

Colon cancer 2
0.0
Bladder NAT 4
0.0

Colon NAT 2
0.0
Prostate adenocarcinoma 1
0.0

Colon cancer 3
21.9
Prostate adenocarcinoma 2
0.0

Colon NAT 3
0.0
Prostate adenocarcinoma 3
0.0

Colon malignant cancer 4
5.1
Prostate adenocarcinoma 4
100.0

Colon NAT 4
4.3
Prostate NAT 5
0.0

Lung cancer 1
0.0
Prostate adenocarcinoma 6
0.0

Lung NAT 1
0.0
Prostate adenocarcinoma 7
0.0

Lung cancer 2
0.0
Prostate adenocarcinoma 8
0.0

Lung NAT 2
0.0
Prostate adenocarcinoma 9
0.0

Squamous cell carcinoma 3
0.0
Prostate NAT 10
0.0

Lung NAT 3
0.0
Kidney cancer 1
3.2

Metastatic melanoma 1
11.0
Kidney NAT 1
0.0

Melanoma 2
0.0
Kidney cancer 2
0.0

Melanoma 3
0.0
Kidney NAT 2
0.0

Metastatic melanoma 4
0.0
Kidney cancer 3
0.0

Metastatic melanoma 5
7.0
Kidney NAT 3
0.0

Bladder cancer 1
0.0
Kidney cancer 4
0.0

Bladder NAT 1
0.0
Kidney NAT 4
0.0

Bladder cancer 2
0.0

General_screening_panel_v1.4 Summary: Ag4095 The expression of this gene was highest and almost exclusive to a sample derived from a colon cancer tissue (CT=27). Low to moderate levels of expression of this gene was also detected in two ovarian, two colon and a brain cancer cell lines. Expression levels of this gene is useful as marker to detect colon, ovarian, and brain cancers. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drugs targeting this gene or gene product is useful in the treatment of colon ovarian, and brain cancers.

General_screening_panel_v1.5 Summary: Ag2888 Significant expression of the CG56142-01 gene was limited to cancer cell lines, with highest expression in a colon cancer cell line (CT=27.9). This gene encodes a putative prostasin, which has been identified as a potential marker of epithelial ovarian cancer. Based on the expression in these panels, expression of this gene will be used as a marker for colon cancer. Therapeutic modulation this gene, encoded protein and/or use of antibodies or small molecule targeting this gene or gene product is useful in the treatment of colon cancer.

Panel 2D Summary: Ag2888 The expression of the CG56142-01 gene appears to be highest and almost exclusive to a sample derived from a colon cancer (CT=30). Therapeutic modulation this gene, encoded protein and/or use of antibodies or small molecule targeting this gene or gene product is useful in the treatment of colon cancer.

Panel 3D Summary: Ag2888 The expression of the CG56142-01 gene was highest and almost exclusive to a sample derived from a gastric cancer cell line (CT=34.1). Thus, the expression of this gene is useful as marker for gastric cancer. Moreover, therapeutic modulation of this gene, throguh the use of small molecule drugs, antibodies or protein therapeutics might be beneficial in the treatment of gastric cancer.

Panel 4.1D Summary: Ag4095 This gene, which encodes a prostasin homolog, was expressed almost exclusively in resting neutrophils (CTs=31). This expression was down regulated in neutrophils activated by TNF-alpha and LPS. Modulation of this gene, encoded protein and/or use of agonist to activated this gene or gene product is useful to reduce activation of these inflammatory cells and eliminate the symptoms in patients with Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis, AIDS or other immunodeficiencies.

general oncology screening panel_v_—2.4 Summary: Ag4095 Expression of this gene was highest in a prostate adenocarcinoma sample (CT=33). Expression of this gene was upregulated in 2/4 colon cancer samples compared to normal adjacent tissue. Therefore, expression of this gene is useful as a marker for colon cancer. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drugs targeting this gene or gene product are beneficial in the treatment of colon cancer.

AV. CG56144-01: 7 Transmembrane Receptor.

Expression of gene CG56144-01 was assessed using the primer-probe sets Ag1221, Ag1221b and Ag1608, described in Tables AVA, AVB and AVC. Results of the RTQ-PCR runs are shown in Tables AVD, AVE, AVF and AVG.

TABLE AVAProbe Name Ag1221StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ctacaaagcatttgggacatgt-3′228211374ProbeTET-5′-cataggtgccatcctgtccacctaca-3′-268511375TAMRAReverse5′-ggtgcatgactgaagagatgac-3′228851376

TABLE AVB

Probe Name Ag1221b

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-ctacacgacggtcctgactgggt-3′
23
512
1377

Probe
TET-5′-catcaccaagattggcatggctgctgtg
30
539
1378

gc-3′-TAMRA

Reverse
5′-aaggggagtggagtcattagtg-3′
22
580
1379

TABLE AVC

Probe Name Ag1608

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-catattctggttcagggatcag-3′
22
368
1380

Probe
TET-5′-caacttctttgcctgtctggtccaga-3′-
26
395
1381

TAMRA

Reverse
5-′atggagaaggagtgaaggaaga-3′
22
424
1382

TABLE AVD

AI_comprehensive panel_v1.0

Column A - Rel. Exp.(%) Ag1221b, Run 228397224

Tissue Name
A
Tissue Name
A

110967 COPD-F
10.8
112427 Match Control Psoriasis-F
21.8

110980 COPD-F
4.2
112418 Psoriasis-M
43.8

110968 COPD-M
10.0
112723 Match Control Psoriasis-M
50.0

110977 COPD-M
19.8
112419 Psoriasis-M
18.3

110989 Emphysema-F
22.8
112424 Match Control Psoriasis-M
0.0

110992 Emphysema-F
16.6
112420 Psoriasis-M
34.2

110993 Emphysema-F
42.3
112425 Match Control Psoriasis-M
3.5

110994 Emphysema-F
11.0
104689 (MF) OA Bone-Backus
12.4

110995 Emphysema-F
23.7
104690 (MF) Adj “Normal” Bone-Backus
5.4

110996 Emphysema-F
20.2
104691 (MF) OA Synovium-Backus
42.0

110997 Asthma-M
0.0
104692 (BA) OA Cartilage-Backus
0.0

111001 Asthma-F
9.9
104694 (BA) OA Bone-Backus
11.5

111002 Asthma-F
8.4
104695 (BA) Adj “Normal” Bone-Backus
4.0

111003 Atopic Asthma-F
6.0
104696 (BA) OA Synovium-Backus
22.7

111004 Atopic Asthma-F
0.0
104700 (SS) OA Bone-Backus
85.9

111005 Atopic Asthma-F
6.7
104701 (SS) Adj “Normal” Bone-Backus
2.6

111006 Atopic Asthma-F
0.0
104702 (SS) OA Synovium-Backus
0.0

111417 Allergy-M
1.8
117093 OA Cartilage Rep7
33.7

112347 Allergy-M
1.8
112672 OA Bone5
16.3

112349 Normal Lung-F
1.4
112673 OA Synovium5
13.9

112357 Normal Lung-F
29.9
112674 OA Synovial Fluid cells5
12.1

112354 Normal Lung-M
69.7
117100 OA Cartilage Rep14
0.0

112374 Crohns-F
9.7
112756 OA Bone9
7.3

112389 Match Control Crohns-F
9.0
112757 OA Synovium9
0.0

112375 Crohns-F
0.0
112758 OA Synovial Fluid Cells9
0.0

112732 Match Control Crohns-F
0.0
117125 RA Cartilage Rep2
19.3

112725 Crohns-M
6.1
113492 Bone2 RA
62.4

112387 Match Control Crohns-M
9.2
113493 Synovium2 RA
37.6

112378 Crohns-M
13.4
113494 Syn Fluid Cells RA
87.1

112390 Match Control Crohns-M
11.0
113499 Cartilage4 RA
89.5

112726 Crohns-M
6.9
113500 Bone4 RA
92.0

112731 Match Control Crohns-M
22.7
113501 Synovium4 RA
37.1

112380 Ulcer Col-F
27.2
113502 Syn Fluid Cells4 RA
24.8

112734 Match Control Ulcer Col-F
25.2
113495 Cartilage3 RA
53.2

112384 Ulcer Col-F
45.1
113496 Bone3 RA
59.5

112737 Match Control Ulcer Col-F
10.0
113497 Synovium3 RA
35.6

112386 Ulcer Col-F
21.0
113498 Syn Fluid Cells3 RA
100.0

112738 Match Control Ulcer Col-F
15.4
117106 Normal Cartilage Rep20
0.0

112381 Ulcer Col-M
2.6
113663 Bone3 Normal
2.1

112735 Match Control Ulcer Col-M
8.8
113664 Synovium3 Normal
2.1

112382 Ulcer Col-M
16.6
113665 Syn Fluid Cells3 Normal
1.2

112394 Match Control Ulcer Col-M
7.1
117107 Normal Cartilage Rep22
9.9

112383 Ulcer Col-M
30.4
113667 Bone4 Normal
3.5

112736 Match Control Ulcer Col-M
4.5
113668 Synovium4 Normal
11.8

112423 Psoriasis-F
26.8
113669 Syn Fluid Cells4 Normal
3.1

TABLE AVE

Panel 1.3D

Column A - Rel. Exp.(%) Ag1221b, Run 147341937

Column B - Rel. Exp.(%) Ag1221b, Run 152570853

Column C - Rel. Exp.(%) Ag1608, Run 147327901

Tissue Name
A
B
C
Tissue Name
A
B
C

Liver adenocarcinoma
0.0
0.0
0.0
Kidney (fetal)
1.6
0.0
0.0

Pancreas
0.0
0.0
0.0
Renal ca. 786-0
0.0
0.0
0.0

Pancreatic ca. CAPAN 2
0.0
0.0
0.0
Renal ca. A498
1.6
2.5
0.9

Adrenal gland
1.2
4.2
0.0
Renal ca. RXF 393
0.0
0.0
0.0

Thyroid
1.2
0.0
0.4
Renal ca. ACHN
0.0
0.0
0.0

Salivary gland
0.7
0.0
0.0
Renal ca. UO-31
0.8
1.5
1.1

Pituitaiy gland
0.0
2.4
0.3
Renal ca. TK-10
0.0
0.0
1.3

Brain (fetal)
0.0
0.0
0.0
Liver
2.3
5.2
1.2

Brain (whole)
1.6
3.6
0.0
Liver (fetal)
1.7
4.0
0.0

Brain (amygdala)
1.3
3.0
1.9
Liver ca. (hepatoblast)
0.0
0.0
0.0

HepG2

Brain (cerebellum)
0.0
1.3
0.0
Lung
6.3
16.7
5.8

Brain (hippocampus)
2.3
6.5
0.9
Lung (fetal)
2.0
8.1
3.0

Brain (substantia nigra)
2.4
3.9
2.6
Lung ca. (small cell) LX-1
0.0
0.0
0.0

Brain (thalamus)
2.2
2.6
0.7
Lung ca. (small cell) NCI-
0.3
1.9
0.0

H69

Cerebral Cortex
1.6
5.5
0.7
Lung ca. (s.cell var.) SHP-
0.0
0.0
0.0

77

Spinal cord
4.1
3.4
2.1
Lung ca. (large cell) NCI-
0.0
0.9
0.0

H460

glio/astro U87-MG
0.0
0.0
0.0
Lung ca. (non-sm. cell)
0.0
0.0
1.7

A549

glio/astro U-118-MG
0.5
0.0
2.7
Lung ca. (non-s.cell) NCI-
0.0
1.2
0.7

H23

astrocytoma SW1783
0.0
0.0
0.0
Lung ca. (non-s.cell) HOP-
0.0
0.0
0.9

62

neuro*; met SK-N-AS
0.3
0.0
0.0
Lung ca. (non-s.cl) NCI-
0.0
0.0
0.0

H522

astrocytoma SF-539
0.0
2.4
0.0
Lung ca. (squam.) SW 900
0.0
0.0
1.4

astrocytoma SNB-75
0.6
0.0
0.0
Lung ca. (squam.) NCI-
1.1
0.0
0.0

H596

glioma SNB-19
0.0
1.3
0.0
Mammary gland
0.6
0.0
1.1

glioma U251
0.0
0.5
0.0
Breast ca.* (pl.ef) MCF-7
0.0
0.0
0.0

glioma SF-295
0.6
0.0
0.0
Breast ca.* (pl.ef) MDA-
0.0
0.0
0.0

MB-231

Heart (Fetal)
0.0
0.0
0.0
Breast ca.* (pl.ef) T47D
0.0
0.0
0.0

Heart
0.0
1.3
0.0
Breast ca. BT-549
1.6
0.0
0.9

Skeletal muscle (Fetal)
2.9
7.7
2.0
Breast ca. MDA-N
0.0
0.0
0.4

Skeletal muscle
0.0
0.0
0.0
Ovary
4.4
6.3
3.4

Bone marrow
19.1
56.6
32.5
Ovarian ca. OVCAR-3
0.0
0.0
0.0

Thymus
0.9
6.3
0.4
Ovarian ca. OVCAR-4
0.0
0.0
0.0

Spleen
7.7
36.6
8.4
Ovarian ca. OVCAR-5
0.4
0.0
2.2

Lymph node
0.7
1.5
0.6
Ovarian ca. OVCAR-8
0.6
0.0
0.0

Colorectal
1.8
6.6
1.3
Ovarian ca. IGROV-1
0.0
2.1
0.4

Stomach
0.3
0.8
0.5
Ovarian ca. (ascites) SK-
0.0
0.0
0.0

OV-3

Small intestine
1.0
1.2
0.7
Uterus
0.0
0.0
2.6

Colon ca. SW480
0.0
0.0
0.0
Placenta
3.1
7.1
1.5

Colon ca.* SW620 (SW480
0.0
0.0
0.0
Prostate
0.0
1.4
1.6

met)

Colon ca. HT29
0.5
1.2
0.0
Prostate ca.* (bone met)
0.0
0.0
0.0

PC-3

Colon ca. HGT-116
0.0
1.1
0.0
Testis
1.2
2.4
1.0

Colon ca. CaCo-2
0.0
3.4
0.0
Melanoma Hs688(A).T
0.0
0.0
0.0

CC Well to Mod Duff
3.1
3.8
3.9
Melanoma* (met)
0.6
0.0
0.0

(ODO3866)

Hs688(B).T

Colon ca. HCC-2998
0.5
3.6
1.7
Melanoma UACC-62
0.0
0.0
0.0

Gastric ca. (liver met) NCI-
100.0
100.0
100.0
Melanoma M14
0.0
0.0
0.0

N87

Bladder
1.4
3.8
4.1
Melanoma LOX IMVI
1.1
0.0
0.0

Trachea
1.9
3.8
1.9
Melanoma* (met) SK-
0.0
0.0
0.0

MEL-5

Kidney
1.2
0.0
0.0
Adipose
0.9
14.1
8.4

TABLE AVF

Panel 2D

Column A - Rel. Exp.(%) Ag1221b, Run 150783273

Column B - Rel. Exp.(%) Ag1221b, Run 152570968

Tissue Name
A
B
Tissue Name
A
B

Normal Colon
27.4
12.9
Kidney Margin 8120608
6.2
0.5

CC Well to Mod Diff (OD03866)
11.8
17.0
Kidney Cancer 8120613
0.3
0.9

CC Margin (ODO3866)
20.2
7.0
Kidney Margin 8120614
2.7
1.0

CC Gr.2 rectosigmoid (ODO3868)
0.0
2.0
Kidney Cancer 9010320
30.8
20.6

CC Margin (ODO3868)
2.4
2.9
Kidney Margin 9010321
5.3
2.8

CC Mod Diff (ODO3920)
12.9
2.5
Normal Uterus
0.0
0.0

CC Margin (ODO3920)
5.4
3.8
Uterine Cancer 064011
11.7
5.3

CC Gr.2 ascend colon (ODO3921)
10.4
3.4
Normal Thyroid
2.7
0.0

CC Margin (ODO3921)
2.9
6.2
Thyroid Cancer
2.6
3.5

CC from Partial Hepatectomy
16.7
6.9
Thyroid Cancer A302152
4.0
4.5

(ODO4309) Mets

Liver Margin (ODO4309)
14.8
6.7
Thyroid Margin A302153
3.7
5.2

Colon mets to lung (OD04451-01)
6.3
7.6
Normal Breast
5.4
6.8

Lung Margin (OD04451-02)
15.7
6.3
Breast Cancer
33.2
18.4

Normal Prostate 6546-1
0.0
3.7
Breast Cancer (OD04590-01)
22.4
27.0

Prostate Cancer (OD04410)
7.8
10.4
Breast Cancer Mets
24.0
27.9

(OD04590-03)

Prostate Margin (OD04410)
23.2
26.6
Breast Cancer Metastasis
5.1
6.1

Prostate Cancer (OD04720-01)
13.9
7.9
Breast Cancer
12.9
15.0

Prostate Margin (OD04720-02)
27.9
12.5
Breast Cancer
1.9
2.2

Normal Lung
100.0
100.0
Breast Cancer 9100266
2.9
2.1

Lung Met to Muscle (OD04286)
15.9
7.1
Breast Margin 9100265
2.4
1.2

Muscle Margin (OD04286)
13.9
13.9
Breast Cancer A209073
13.7
5.8

Lung Malignant Cancer
29.3
24.0
Breast Margin A209073
1.0
3.8

(OD03126)

Lung Margin (OD03126)
61.6
53.6
Normal Liver
19.6
9.6

Lung Cancer (OD04404)
20.7
12.0
Liver Cancer
10.2
5.6

Lung Margin (OD04404)
28.7
25.7
Liver Cancer 1025
2.9
5.0

Lung Cancer (OD04565)
1.3
2.8
Liver Cancer 1026
13.7
14.7

Lung Margin (OD04565)
27.4
28.3
Liver Cancer 6004-T
3.2
11.3

Lung Cancer (OD04237-01)
2.5
8.5
Liver Tissue 6004-N
13.9
18.8

Lung Margin (OD04237-02)
39.0
36.9
Liver Cancer 6005-T
9.7
24.8

Ocular Mel Met to Liver
0.0
0.0
Liver Tissue 6005-N
2.1
3.4

(ODO4310)

Liver Margin (ODO4310)
0.0
2.6
Normal Bladder
22.5
19.3

Melanoma Metastasis
0.0
1.1
Bladder Cancer
6.6
7.3

Lung Margin (OD04321)
33.4
31.2
Bladder Cancer
17.1
15.0

Normal Kidney
5.5
3.8
Bladder Cancer (OD04718-
39.0
29.5

01)

Kidney Ca, Nuclear grade 2
45.7
22.7
Bladder Normal Adjacent
12.5
12.9

(OD04338)

(OD04718-03)

Kidney Margin (OD04338)
12.7
7.6
Normal Ovary
3.7
5.5

Kidney Ca Nuclear grade 1/2
5.6
4.9
Ovarian Cancer
12.0
14.4

(OD04339)

Kidney Margin (OD04339)
0.7
0.9
Ovarian Cancer (OD04768-
14.4
10.7

07)

Kidney Ca, Clear cell type
22.5
24.8
Ovary Margin (OD04768-08)
4.1
1.0

(OD04340)

Kidney Margin (OD04340)
6.4
5.6
Normal Stomach
6.3
1.9

Kidney Ca, Nuclear grade 3
17.6
21.2
Gastric Cancer 9060358
1.4
3.4

(OD04348)

Kidney Margin (OD04348)
26.6
24.8
Stomach Margin 9060359
9.9
11.3

Kidney Cancer (OD04622-01)
53.6
59.0
Gastric Cancer 9060395
12.7
7.7

Kidney Margin (OD04622-03)
2.2
1.9
Stomach Margin 9060394
13.0
7.0

Kidney Cancer (OD04450-01)
1.3
0.0
Gastric Cancer 9060397
28.3
18.9

Kidney Margin (OD04450-03)
2.5
7.3
Stomach Margin 9060396
2.2
1.9

Kidney Cancer 8120607
0.0
2.0
Gastric Cancer 064005
31.9
27.2

TABLE AVG

Panel 4D

Column A - Rel. Exp.(%) Ag1221, Run 140237638

Column B - Ret. Exp.(%) Ag1221, Run 142014678

Column C - Ret. Exp.(%) Ag1221b, Run 150811715

Column D - Ret. Exp.(%) Ag1221b, Run 152571072

Column E - Ret. Exp.(%) Ag1221b, Run 158141668

Column F - Rel. Exp.(%) Ag1608, Run 149925800

Tissue Name
A
B
C
D
E
F

Secondary Th1 act
0.0
4.7
0.0
0.2
0.0
0.0

Secondary Th2 act
0.0
0.0
2.2
1.9
0.4
2.2

Secondary Tr1 act
0.0
0.0
0.0
0.3
0.0
0.7

Secondary Th1 rest
0.6
0.0
0.2
0.0
0.0
0.0

Secondary Th2 rest
0.0
0.0
0.0
0.0
0.0
0.0

Secondary Tr1 rest
0.0
0.0
0.0
0.0
0.0
0.8

Primary Th1 act
0.0
0.0
0.0
0.0
0.3
0.0

Primary Th2 act
0.0
0.0
0.0
0.0
0.0
0.4

Primary Tr1 act
0.0
2.6
0.2
0.0
0.1
0.0

Primary Th1 rest
3.1
0.0
0.7
0.6
0.6
0.6

Primary Th2 rest
0.0
2.7
0.0
0.0
0.0
0.0

Primary Tr1 rest
0.0
0.0
0.1
0.0
0.0
0.0

CD45RA CD4 lymphocyte act
1.4
0.0
0.9
3.6
0.8
2.1

CD45RO CD4 lymphocyte act
0.0
1.9
3.2
2.0
1.4
1.1

CD8 lymphocyte act
0.0
0.0
0.5
0.3
0.5
0.5

Secondary CD8 lymphocyte rest
0.0
0.0
0.7
2.8
1.2
1.6

Secondary CD8 lymphocyte act
0.0
0.0
0.0
0.0
0.0
0.0

CD4 lymphocyte none
1.8
0.0
0.9
0.0
0.9
3.5

2ry Th1/Th2/Tr1 anti-CD95 CH11
0.0
0.0
0.2
0.0
0.3
0.0

LAK cells rest
4.7
10.9
4.5
3.7
7.6
3.3

LAK cells IL-2
0.0
2.3
1.3
3.5
1.9
2.1

LAK cells IL-2 + IL-12
8.9
12.4
2.3
5.5
1.3
3.6

LAK cells IL-2 + IFN gamma
10.7
0.0
6.5
8.8
9.0
11.4

LAK cells IL-2 + IL-18
5.8
5.31
2.5
9.6
4.8
7.3

LAK cells PMA/ionomycin
5.6
6.8
9.7
13.5
17.6
12.2

NK Cells IL-2 rest
1.5
2.2
0.4
0.7
0.0
0.2

Two Way MLR 3 day
21.9
33.0
17.3
20.4
32.1
19.6

Two Way MLR 5 day
4.3
7.0
4.9
5.2
6.7
1.8

Two Way MLR 7 day
2.7
0.0
0.7
1.8
0.9
0.8

PBMC rest
5.3
8.5
6.6
7.3
11.9
6.0

PBMC PWM
13.0
19.5
6.5
6.7
4.5
7.7

PBMC PHA-L
1.3
0.0
1.4
0.4
1.3
0.0

Ramos (B cell) none
0.0
0.0
0.0
0.0
0.7
0.0

Ramos (B cell) ionomycin
0.0
0.0
0.0
0.0
0.0
0.0

B lymphocytes PWM
4.2
4.7
0.7
0.3
0.5
1.9

B lymphocytes CD40L and IL-4
0.0
0.0
0.0
0.1
0.2
0.3

EOL-1 dbcAMP
20.6
24.8
10.9
10.6
8.8
9.0

EOL-1 dbcAMP PMA/ionomycin
1.2
12.2
0.9
2.1
2.5
1.6

Dendntic cells none
0.0
0.0
0.8
0.9
1.4
1.1

Dendritic cells LPS
5.4
3.4
6.0
7.2
3.9
3.6

Dendritic cells anti-CD40
4.9
19.2
6.0
6.4
4.3
6.7

Monocytes rest
100.0
94.6
100.0
100.0
100.0
100.0

Monocytes LPS
25.3
45.7
9.1
9.2
6.6
8.8

Macrophages rest
0.0
5.0
2.3
4.9
0.8
1.8

Macrophages LPS
58.2
100.0
25.0
32.5
25.9
21.0

HUVEC none
0.0
0.0
0.0
0.0
0.8
0.0

HUVEC starved
0.0
0.0
0.0
0.0
0.0
0.0

HUVEC IL-1beta
0.0
0.0
0.0
0.0
0.0
0.0

HUVEC IFN gamma
0.0
0.0
0.5
1.1
0.7
0.4

HUVEC TNF alpha + IFN gamma
0.0
0.0
0.2
0.5
0.3
0.3

HUVEC TNF alpha + IL4
0.0
0.0
0.0
0.3
0.0
0.0

HUVEC IL-11
0.0
0.0
0.0
0.0
0.0
0.0

Lung Microvascular EC none
0.0
0.0
0.2
0.0
1.3
0.0

Lung Microvascular EC TNFalpha + IL-1beta
0.0
0.0
0.4
0.6
0.3
0.3

Microvascular Dermal EC none
0.0
0.0
0.0
0.3
0.0
0.2

Microsvasular Dermal EC TNFalpha + IL-1beta
0.0
0.0
0.0
0.0
0.0
0.0

Bronchial epithelium TNFalpha + IL1beta
0.0
0.0
0.0
0.0
0.0
0.6

Small airway epithelium none
0.0
0.0
0.0
0.3
1.0
0.3

Small airway epithelium TNFalpha + IL-1beta
1.3
0.0
0.4
0.8
0.3
0.5

Coronery artery SMC rest
0.0
0.0
0.0
0.6
1.7
0.4

Coronery artery SMC TNFalpha + IL-1beta
0.0
0.0
0.0
0.0
0.0
0.4

Astrocytes rest
0.0
0.0
0.2
1.0
0.0
0.0

Astrocytes TNFalpha + IL-1beta
0.0
0.0
0.4
0.6
0.1
0.2

KU-812 (Basophil) rest
2.7
0.0
0.2
0.0
0.3
0.0

KU-812 (Basophil) PMA/ionomycin
1.2
1.4
0.7
0.6
0.5
0.6

CCD1106 (Keratinocytes) none
0.0
2.1
0.0
0.0
0.0
0.0

93580 CCD1106 (Keratinocytes) TNFa and IFNg
6.3
13.3
0.2
0.0
1.1
0.4

Liver cirrhosis
15.1
20.0
4.6
10.2
7.4
5.0

Lupus kidney
0.0
0.0
0.0
0.0
0.0
0.0

NCI-H292 none
0.0
0.0
0.0
0.4
0.9
0.0

NCI-H292 IL-4
0.0
0.0
0.0
0.0
0.0
0.1

NCI-H292 IL-9
0.0
0.0
0.0
0.0
0.0
0.0

NCI-H292 IL-13
0.0
0.0
0.0
0.0
0.0
0.0

NCI-H292 IFN gamma
0.0
1.7
0.4
1.0
0.4
0.4

HPAEC none
0.0
0.0
0.0
0.0
0.0
0.0

HPAEC TNF alpha + IL-1 beta
0.0
0.0
0.0
0.0
0.0
0.0

Lung fibroblast none
0.0
0.0
0.0
0.0
0.0
0.0

Lung fibroblast TNF alpha + IL-1 beta
0.9
0.0
0.2
0.6
0.3
0.5

Lung fibroblast IL-4
0.0
0.0
0.0
0.3
0.3
0.0

Lung fibroblast IL-9
0.0
0.0
0.0
0.0
0.3
0.0

Lung fibroblast IL-13
0.0
0.0
0.0
0.6
0.0
0.0

Lung fibroblast IFN gamma
0.0
2.6
1.3
1.2
1.4
1.1

Dermal fibroblast CCD1070 rest
0.0
0.0
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 TNF alpha
0.0
0.0
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 IL-1 beta
0.0
0.0
0.0
0.0
0.0
0.0

Dermal fibroblast IFN gamma
1.6
0.0
0.2
1.1
0.3
0.9

Dermal fibroblast IL-4
0.0
0.0
0.2
0.0
0.0
0.2

IBD Colitis 2
0.0
0.0
0.0
0.0
0.0
0.0

IBD Crohn's
0.0
0.0
0.0
0.0
0.0
0.0

Colon
0.0
0.0
0.7
0.3
0.6
0.3

Lung
0.0
0.0
2.4
3.1
2.6
2.0

Thymus
0.0
0.0
0.4
0.6
1.0
0.4

Kidney
0.0
2.7
0.4
0.6
0.3
0.3

AI_comprehensive panel_v1.0 Summary: Ag1221b Highest expression of this gene was detected in synovial fluid from a rheumatoid arthritis (RA) patient (CT=33). This gene showed preferential expression in rheumatoid arthritis bone, cartilage, synovium and synovial fluid samples. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of rheumatoid arthritis.

Panel 1.3D Summary: Ag1221b/Ag1608 The expression of this gene was seen predominantly in one gastric cancer cell line derived from a metastasis (CTs=30-32). This expression profile indicates that this gene plays a role in liver cancer metastasis to gastric. Significant expression was also seen in bone marrow and spleen indicating that this gene is also important in the hematopoietic system. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug are useful in treatment of gastric cancer, and disorders related to hematopoietic system.

Panel 2D Summary: Ag1221b Highest expression of this gene was detected in normal lung (CTs=31). Expression of this gene was downregulated in the lung cancers. Upregulation of this gene and/or use of agonist is useful in the treatment of lung cancers.

Significant expression of this gene was also seen in breast cancer, thyroid cancer, gastric cancer, ovarian cancer and renal cell carcinoma. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of breast cancer, thyroid cancer, gastric cancer, ovarian cancer and renal cell carcinoma.

Panel 4D Summary: Ag1221b/Ag1608 Highest expression of this gene was detected in resting monocytes and LPS activated macrophages (CTs=28-33). The expression of this gene in resting monocytes indicated that this gene encoded a differentation antigen. Signalling through this molecule will stimulate activation. This gene was down regulated during activation of monocytes, but upregulated in activated macrophages indicating a role in antigen presentation. Significant expression of this gene was also detected in resting and activated LAK cells, two way MLR, resting eosinophils, activated PBMC and liver cirrhosis samples. Modulation of this gene, encoded protein and/or use of antibodies or small molecule targeting this gene or gene product will help reduce or eliminate inflammatory and autoimmune diseases such as asthma/allergy, emphysema, psoriasis, arthritis, IBD Colitis, liver cirrhosis.

AW. CG56146-01, CG56146-02 and CG5614603: 7 Transmembrane Receptor.

Expression of gene CG56146-01, CG56146-02 and CG56146-03 were assessed using the primer-probe sets Ag1175 and Ag1201, described in Tables AWA and AWB. Results of the RTQ-PCR runs are shown in Tables AWC, AWD, AWE and AWF. CG56146-02 and CG56146-03 represent full-length physical clones.

TABLE AWAProbe Name Ag1175StartSEQ IDPrimersSequencesLengthPositionNoForward5′-agagacaatccaaagccttttc-3′225511383ProbeTET-5′-caactgtgtgcctcacctcattgttg-3′-265731384TAMRAReverse5′-agaccctggctttaaataagca-3′226271385

TABLE AWB

Probe Name Ag1201

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-agagacaatccaaagccttttc-3′
22
551
1386

Probe
TET-5′-caactgtgtgcctcacctcattgttg-3′-
26
573
1387

TAMRA

Reverse
5′-agaccctggctttaaataagca-3′
22
627
1388

TABLE AWC

AI_comprehensive panel_v1.0

Column A - Rel. Exp.(%) Ag1175, Run 248064523

Column B - Rel. Exp.(%) Ag1201, Run 211193563

Column C - Rel. Exp.(%) Ag1201, Run 212308358

Tissue Name
A
B
C
Tissue Name
A
B
C

110967 COPD-F
5.6
1.2
2.5
112427 Match Control
76.3
42.9
98.6

Psoriasis-F

110980 COPD-F
5.0
0.0
0.0
112418 Psoriasis-M
12.3
1.4
10.2

110968 COPD-M
0.0
6.1
0.0
112723 Match Control
0.0
0.0
0.0

Psoriasis-M

110977 COPD-M
14.7
12.5
9.5
112419 Psoriasis-M
19.2
6.5
19.1

110989 Emphysema-F
21.6
5.5
6.7
112424 Match Control
5.6
1.8
9.4

Psoriasis-M

110992 Emphysema-F
0.0
8.7
3.6
112420 Psoriasis-M
33.4
24.5
16.6

110993 Emphysema-F
20.4
3.0
5.2
112425 Match Control
58.6
100.0
87.7

Psoriasis-M

110994 Emphysema-F
8.1
0.0
0.0
104689 (MF) OA Bone-
9.2
5.0
4.8

Backus

110995 Emphysema-F
18.9
4.1
10.1
104690 (MF) Adj “Normal”
18.2
4.0
5.8

Bone-Backus

110996 Emphysema-F
3.7
0.0
0.0
104691 (MF) OA
0.0
8.4
0.0

Synovium-Backus

110997 Asthma-M
20.9
0.0
13.5
104692 (BA) OA Cartilage-
0.0
0.0
0.0

Backus

111001 Asthma-F
34.2
8.4
17.0
104694 (BA) OA Bone-
7.7
0.0
8.1

Backus

111002 Asthma-F
30.8
5.9
23.8
104695 (BA) Adj “Normal”
14.5
5.7
6.2

Bone-Backus

111003 Atopic Asthma-F
14.8
11.3
8.7
104696 (BA) OA
13.4
19.2
6.3

Synovium-Backus

111004 Atopic Asthma-F
21.6
10.2
11.6
104700 (SS) OA Bone
17.4
4.1
13.4

Backus

111005 Atopic Asthma-F
22.1
0.0
13.0
104701 (SS) Adj “Normal”
13.7
7.6
3.3

Bone-Backus

111006 Atopic Asthma-F
5.8
0.0
4.7
104702 (SS) OA Synovium-
8.6
12.5
4.0

Backus

111417 Allergy-M
1.5
11.7
17.9
117093 OA Cartilage Rep7
17.2
22.2
14.8

112347 Allergy-M
0.0
0.0
0.0
112672 OA Bone5
15.0
3.0
14.6

112349 Normal Lung-F
0.0
0.0
0.0
112673 OA Synovium5
26.8
2.7
3.8

112357 Normal Lung-F
12.8
1.6
8.7
1112674 OA Synovial Fluid
6.2
9.3
6.4

112354 Normal Lung-M
10.5
0.0
11.8
17100 OA Cartilage
1.9
11.0
4.2

Rep14

112374 Crohns-F
12.7
10.7
12.6
112756 OA Bone9
100.0
60.3
100.0

112389 Match Control
0.0
3.5
0.0
112757 OA Synovium9
0.0
0.0
0.0

Crohns-F

112375 Crohns-F
27.9
8.4
19.9
112758 OA Synovial Fluid
0.0
7.2
12.2

Cells9

112732 Match Control
0.0
1.8
5.4
117125 RA Cartilage Rep2
0.0
3.4
0.0

112725 Crohns-M
5.4
3.3
4.1
113492 Bone2 RA
0.0
6.8
0.0

112387 Match Control
6.9
0.0
4.9
113493 Synovium2 RA
0.0
0.0
0.0

112378 Crohns-M
0.0
0.0
0.0
113494 Syn Fluid Cells RA
0.0
0.0
4.2

112390 Match Control
37.1
22.2
6.9
113499 Cartilage4 RA
6.0
0.0
0.0

Crohns-M

112726 Crohns-M
3.3
0.0
0.0
113500 Bone4RA
0.0
2.6
0.0

112731 Match Control
0.0
3.1
15.8
113501 Synovium4 RA
0.0
0.0
0.0

Crohns-M

112380 Ulcer Col-F
17.1
9.8
22.4
113502 Syn Fluid Cells4
0.0
5.1
3.6

RA

112734 Match Control
5.8
1.2
0.0
113495 Cartilage3 RA
0.0
1.2
3.6

Ulcer Col-F

112384 Ulcer Col-F
39.2
6.1
11.3
113496 Bone3 RA
3.5
0.0
0.0

112737 Match Control
4.1
0.0
12.7
113497 Synovium3 RA
0.0
0.0
0.0

Ulcer Col-F

112386 Ulcer Col-F
0.0
5.9
0.0
113498 Syn Fluid Cells3
0.0
0.0
0.0

RA

112738 Match Control
0.0
0.0
6.3
117106 Normal Cartilage
0.0
3.9
0.0

Ulcer Col-F

Rep20

112381 Ulcer Col-M
0.0
0.4
0.6
113663 Bone3 Normal
0.0
0.0
0.0

112735 Match Control
3.6
1.0
6.6
113664 Synovium3 Normal
0.0
0.0
0.0

Ulcer Col-M

112382 Ulcer Col-M
5.1
4.7
3.9
113665 Syn Fluid Cells3
0.0
0.0
0.7

Normal

112394 Match Control
0.0
2.1
0.0
117107 Normal Cartilage
8.7
9.7
11.9

Ulcer Col-M

Rep22

112383 Ulcer Col-M
2.5
0.0
0.0
113667 Bone4 Normal
6.3
10.2
15.0

112736 Match Control
0.0
0.0
0.0
113668 Synovium4 Normal
0.0
0.0
10.8

Ulcer Col-M

112423 Psoriasis-F
17.9
24.8
44.1
113669 SynFluid Cells4
21.8
9.6
23.2

Normal

TABLE AWD

Panel 1.3D

Column A - Rel. Exp.(%) Ag1201, Run 147490505

Column B - Rel. Exp.(%) Ag1201, Run 148438245

Column C - Rel. Exp.(%) Ag1201, Run 152628232

Tissue Name
A
B
C
Tissue Name
A
B
C

Liver adenocarcinoma
0.0
0.0
13.7
Kidney (fetal)
15.7
0.0
19.6

Pancreas
0.0
0.0
0.0
Renal ca. 786-0
0.0
0.0
0.0

Pancreatic ca. CAPAN 2
0.0
0.0
0.0
Renal ca. A498
0.0
0.0
0.0

Adrenal gland
0.0
0.0
0.0
Renal ca. RXF 393
0.0
0.0
0.0

Thyroid
0.0
0.0
26.2
Renal ca. ACHN
0.0
0.0
0.0

Salivary gland
0.0
0.0
14.7
Renal ca. UO-31
0.0
0.0
0.0

Pituitary gland
7.5
25.3
0.0
Renal ca. TK-10
0.0
0.0
0.0

Brain (fetal)
0.0
13.5
0.0
Liver
0.0
0.0
0.0

Brain (whole)
3.3
0.0
0.0
Liver (fetal)
0.0
0.0
0.0

Brain (amygdala)
0.0
0.0
0.0
Liver ca. (hepatoblast)
0.0
0.0
0.0

HepG2

Brain (cerebellum)
0.0
0.0
0.0
Lung
9.2
0.0
0.0

Brain (hippocampus)
0.0
10.6
0.0
Lung (fetal)
0.0
0.0
0.0

Brain (substantia nigra)
0.0
0.0
0.0
Lung ca. (small cell) LX-1
0.0
0.0
0.0

Brain (thalamus)
0.0
0.0
0.0
Lung ca. (small cell) NCI-H69
0.0
0.0
0.0

Cerebral Cortex
0.0
0.0
0.0
Lung ca. (s.cell var.) SHP-77
0.0
0.0
0.0

Spinal cord
8.3
0.0
0.0
Lung ca. (large cell) NCI-H460
0.0
0.0
0.0

glio/astro U87-MG
0.0
0.0
0.0
Lung ca. (non-sm. cell) A549
1.5
0.0
0.0

gilo/astro U-118-MG
0.0
0.0
0.0
Lung ca. (non-s.cell) NCI-H23
6.2
26.6
94.0

astrocytoma SW1783
0.0
0.0
0.0
Lung ca. (non-s.cell) HOP-62
20.9
23.8
27.0

neuro*; met SK-N-AS
0.0
0.0
0.0
Lung ca. (non-s.cl) NCI-H522
0.0
0.0
0.0

astrocytoma SF-539
0.0
0.0
15.6
Lung ca. (squam.) SW 900
0.0
0.0
0.0

astrocytoma SNB-75
0.0
0.0
0.0
Lung ca. (squam.) NCI-H596
0.0
0.0
0.0

glioma SNB-19
0.0
0.0
12.0
Mammary gland
15.6
0.0
12.9

glioma U251
0.0
0.0
0.0
Breast ca.* (pl.ef) MCF-7
0.0
0.0
0.0

glioma SF-295
0.0
0.0
0.0
Breast ca.* (pl.ef) MDA-
0.0
0.0
0.0

MB-231

Heart (Fetal)
0.0
0.0
0.0
Breast ca.* (pl. ef) T47D
0.0
0.0
0.0

Heart
7.7
0.0
0.0
Breast ca. BT-549
6.7
0.0
0.0

Skeletal muscle (Fetal)
11.2
28.1
10.7
Breast ca. MDA-N
0.0
0.0
0.0

Skeletal muscle
0.0
0.0
0.0
Ovary
0.0
0.0
0.0

Bone marrow
0.0
9.9
20.7
Ovarian ca. OVCAR-3
6.2
0.0
0.0

Thymus
8.6
0.0
0.0
Ovarian ca. OVCAR-4
0.0
0.0
0.0

Spleen
11.3
0.0
28.1
Ovarian ca. OVCAR-5
0.0
0.0
0.0

Lymph node
7.4
0.0
0.0
Ovarian ca. OVCAR-8
33.7
36.3
83.5

Colorectal
10.8
30.1
0.0
Ovarian ca. IGROV-1
0.0
0.0
15.3

Stomach
5.9
0.0
12.4
Ovarian ca. (ascites) SK-
0.0
5.9
0.0

OV-3

Small intestine
0.0
9.8
11.7
Uterus
0.0
20.0
0.0

Colon ca. SW480
0.0
0.0
0.0
Placenta
0.0
0.0
0.0

Colon ca.* SW620
0.0
0.0
0.0
Prostate
0.0
12.6
22.2

(SW480 met)

Colon ca. HT29
0.0
0.0
0.0
Prostate ca.* (bone met)
14.4
50.0
19.5

PC-3

Colon ca. HCT-116
0.0
0.0
0.0
Testis
100.0
100.0
100.0

Colon ca. CaCo-2
0.0
0.0
0.0
Melanoma Hs688(A).T
0.0
0.0
0.0

CC Well to Mod Diff
0.0
13.6
0.0
Melanoma* (met)
6.9
0.0
0.0

(ODO3866)

Hs688(B).T

Colon ca. HCC-2998
0.0
0.0
0.0
Melanoma UACC-62
0.0
0.0
0.0

Gastric ca. (liver met)
0.0
0.0
0.0
Melanoma M14
0.0
0.0
0.0

NCI-N87

Bladder
0.0
0.0
0.0
Melanoma LOX IMVI
0.0
8.0
0.0

Trachea
71.2
0.0
0.0
Melanoma* (met) SK-MEL-5
0.0
0.0
0.0

Kidney
0.0
0.0
0.0
Adipose
0.0
15.0
12.0

TABLE AWE

Panel 2D

Column A - Rel. Exp.(%) Ag1201, Run 147490530

Column B - Rel. Exp.(%) Ag1201, Run 148032505

Tissue Name
A
B
Tissue Name
A
B

Normal Colon
14.2
12.9
Kidney Margin 8120608
0.0
10.0

CC Well to Mod Diff (ODO3866)
10.1
14.6
Kidney Cancer 8120613
0.0
4.0

CC Margin (ODO3866)
0.0
10.7
Kidney Margin 8120614
0.0
0.0

CC Gr.2 rectosigmoid (ODO3868)
0.0
4.5
Kidney Cancer 9010320
0.0
0.0

CC Margin (ODO3868)
0.0
4.9
Kidney Margin 9010321
0.0
0.0

CC Mod Diff (ODO3920)
0.0
5.4
Normal Uterus
0.0
3.6

CC Margin (ODO3920)
13.4
5.6
Uterine Cancer 064011
66.4
54.0

CC Gr.2 ascend colon (ODO3921)
4.0
3.3
Normal Thyroid
9.5
0.0

CC Margin (ODO3921)
5.1
18.7
Thyroid Cancer
0.0
3.4

CC from Partial Hepatectomy
0.0
0.0
Thyroid Cancer A302152
11.9
33.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.0
0.0
Thyroid Margin A302153
28.5
39.5

Colon mets to lung (OD04451-01)
4.3
0.0
Normal Breast
18.2
28.3

Lung Margin (OD04451-02)
5.0
0.0
Breast Cancer
42.3
65.5

Normal Prostate 6546-1
0.0
12.8
Breast Cancer (OD04590-01)
0.0
0.0

Prostate Cancer (OD04410)
100.0
100.0
Breast Cancer Mets
0.0
0.0

(OD04590-03)

Prostate Margin (OD04410)
8.0
9.6
Breast Cancer Metastasis
31.6
35.6

Prostate Cancer (OD04720-01)
50.0
64.2
Breast Cancer
18.4
28.7

Prostate Margin (OD04720-02)
47.0
29.7
Breast Cancer
37.6
35.8

Normal Lung
2.8
10.6
Breast Cancer 9100266
31.4
36.9

Lung Met to Muscle (OD04286)
3.9
11.1
Breast Margin 9100265
14.5
48.3

Muscle Margin (OD04286)
0.0
0.0
Breast Cancer A209073
51.8
68.3

Lung Malignant Cancer
0.0
0.0
Breast Margin A209073
41.5
22.7

(OD03126)

Lung Margin (OD03126)
0.0
5.2
Normal Liver
113.5
0.0

Lung Cancer (OD04404)
28.5
6.0
Liver Cancer
0.0
0.0

Lung Margin (OD04404)
5.4
19.2
Liver Cancer 1025
4.7
5.0

Lung Cancer (OD04565)
0.0
0.0
Liver Cancer 1026
0.0
0.0

Lung Margin (OD04565)
1.8
0.0
Liver Cancer 6004-T
0.0
3.8

Lung Cancer (OD04237-01)
0.0
0.0
Liver Tissue 6004-N
3.6
0.0

Lung Margin (OD04237-02)
6.2
4.9
Liver Cancer 6005-T
0.0
0.0

Ocular Mel Met to Liver
0.0
10.4
Liver Tissue 6005-N
0.0
0.0

(ODO4310)

Liver Margin (ODO4310)
2.5
3.5
Normal Bladder
9.8
11.2

Melanoma Metastasis
0.0
0.0
Bladder Cancer
0.0
0.0

Lung Margin (OD04321)
0.0
0.0
Bladder Cancer
5.5
24.1

Normal Kidney
6.3
11.7
Bladder Cancer (OD04718-
0.0
0.0

01)

Kidney Ca, Nuclear grade 2
47
13.1
Bladder Normal Adjacent
50
13.6

(OD04338)

(OD04718-03)

Kidney Margin (OD04338)
0.0
0.0
Normal Ovary
0.0
0.0

Kidney Ca Nuclear grade 1/2
29.5
94.6
Ovarian Cancer
20.6
0.0

(OD04339)

Kidney Margin (OD04339)
0.0
4.9
Ovarian Cancer (OD04768-
92.7
99.3

07)

Kidney Ca, Clear cell type
0.0
17.1
Ovary Margin (OD04768-08)
0.0
9.5

(OD04340)

Kidney Margin (OD04340)
3.6
0.0
Normal Stomach
0.0
5.3

Kidney Ca, Nuclear grade 3
0.0
0.0
Gastric Cancer 9060358
0.0
0.0

(OD04348)

Kidney Margin (OD04348)
7.9
5.1
Stomach Margin 9060359
0.0
0.0

Kidney Cancer (OD04622-01)
7.4
0.0
Gastric Cancer 9060395
10.4
0.0

Kidney Margin (OD04622-03)
0.0
0.0
Stomach Margin 9060394
2.6
0.0

Kidney Cancer (OD04450-01)
0.0
0.0
Gastric Cancer 9060397
4.3
0.0

Kidney Margin (OD04450-03)
0.0
0.0
Stomach Margin 9060396
0.0
0.0

Kidney Cancer 8120607
0.0
0.0
Gastric Cancer 064005
4.8
0.0

TABLE AWF

Panel 4D

Column A - Rel. Exp.(%) Ag1175, Run 139801091

Column B - Rel. Exp.(%) Ag1201, Run 140237534

Column C - Rel. Exp.(%) Ag1201, Run 144180636

Tissue Name
A
B
C
Tissue Name
A
B
C

Secondary Th1 act
0.0
0.0
0.0
HUVEC IL-1beta
0.0
0.0
0.0

Secondary Th2 act
0.0
0.0
0.0
HUVEC IFN gamma
0.0
0.0
0.0

Secondary Tr1 act
0.0
0.0
0.0
HUVEC TNF alpha + IFN
0.0
0.0
0.0

gamma

Secondary Th1 rest
0.0
0.0
0.0
HUVEC TNF alpha + IL4 0.0
0.0
0.0

Secondary Th2 rest
0.0
0.0
0.0
HUVEC IL-11
0.0
0.0
0.0

Secondary Tr1 rest
0.0
0.0
0.0
Lung Microvascular EC none
0.0
0.0
0.0

Primary Th1 act
0.0
0.0
0.0
Lung Microvascular EC
0.0
0.0
0.0

TNFalpha + IL-1beta

Primary Th2 act
0.0
0.0
0.0
Microvascular Dermal EC
0.0
5.4
0.0

Primary Tr1 act
0.0
0.0
0.0
Microsvasular Dermal EC
0.0
0.0
0.0

TNFalpha + IL-1beta

Primary Th1 rest
0.0
0.0
0.0
Bronchial epithelium
0.0
0.0
0.0

TNFalpha + IL1beta

Primary Th2 rest
0.0
0.0
0.0
Small airway epithelium none
0.0
0.0
0.0

Primary Tr1 rest
0.0
0.0
0.0
Small airway epithelium
0.0
0.0
0.0

TNFalpha + IL-1beta

CD45RA CD4
0.0
0.0
0.0
Coronery artery SMC rest 0.0
0.0
0.0

lymphocyte act

CD45RO CD4
0.0
0.0
0.0
Coronery artery SMC
0.0
0.0
0.0

lymphocyte act

TNFalpha + IL-1beta

CD8 lymphocyte act
0.0
2.3
0.0
Astrocytes rest
0.0
0.0
0.0

Secondary CD8
3.6
0.0
0.0
Astrocytes TNFalpha + IL-
0.0
4.3
0.0

lymphocyte rest

1beta

Secondary CD8
0.0
0.0
0.0
KU-812 (Basophil) rest
15.8
7.9
29.1

lymphocyte act

CD4 lymphocyte none
0.0
0.0
0.0
KU-812 (Basophil)
100.0
100.0
100.0

PMA/ionomycin

2ry Th1/Th2/Tr1 anti-
0.0
0.0
0.0
CCD1106 (Keratinocytes)
0.0
0.0
0.0

CD95 CH11

none

LAK cells rest
0.0
3.3
4.4
93580 CCD1106
0.0
0.0
0.0

(Keratinocytes) TNFa and

IFNg

LAK cells IL-2
3.4
0.0
0.0
Liver cirrhosis
16.4
11.3
15.2

LAK cells IL-2 + IL-12
0.0
0.0
0.0
Lupus kidney
0.0
0.0
0.0

LAX cells IL-2 + IFN
0.0
0.0
0.0
NCI-H292 none
0.0
0.0
0.0

gamma

LAK cells IL-2 + IL-18
0.0
0.0
0.0
NCI-H292 IL-4
0.0
0.0
0.0

LAK Cells
3.5
0.0
0.0
NCI-H292 IL-9
0.0
0.0
0.0

PMA/ionomycin

NK Cells IL-2 rest
0.0
0.0
0.0
NCI-H292 IL-13
0.0
0.0
0.0

Two Way MLR 3 day
0.0
3.4
0.0
NCI-H292 IFN gamma
0.0
0.0
0.0

Two Way MLR 5 day
0.0
8.3
0.0
HPAEC none
0.0
0.0
0.0

Two Way MLR 7 day
0.0
0.0
0.0
HPAEC TNF alpha + IL-1
0.0
0.0
0.0

beta

PBMC rest
0.0
0.0
0.0
Lung fibroblast none
0.0
0.0
0.0

PBMC PWM
0.0
0.0
0.0
Lung fibroblast TNF alpha +
0.0
0.0
0.0

IL-1 beta

PBMC PHA-L
0.0
0.0
0.0
Lung fibroblast IL-4
0.0
0.0
0.0

Ramos (B cell) none
0.0
0.0
0.0
Lung fibroblast IL-9
0.0
0.0
0.0

Ramos (B cell)
0.0
0.0
0.0
Lung fibroblast IL-13
0.0
0.0
0.0

ionomycin

B lymphocytes PWM
0.0
0.0
0.0
Lung fibroblast IFN gamma
0.0
0.0
0.0

B lymphocytes CD40L
0.0
0.0
0.0
Dermal fibroblast CCD1070
6.2
0.0
0.0

and IL-4

rest

EOL-1 dbcAMP
0.0
0.0
0.0
Dermal fibroblast CCD1070
0.0
0.0
0.0

TNF alpha

EOL-1 dbcAMP
0.0
0.0
0.0
Dermal fibroblast CCD1070
0.0
0.0
0.0

PMA/ionomycin

IL-1 beta

Dendritic cells none
0.0
0.0
4.5
Dermal fibroblast IFN gamma
0.0
0.0
0.0

Dendritic cells LPS
0.0
10.0
0.0
Dermal fibroblast IL-4
0.0
0.0
0.0

Dendritic cells anti
0.0
7.9
4.7
IBD Colitis 2
3.1
5.3
0.0

CD40

Monocytes rest
0.0
0.0
0.0
IBD Crohn's
0.0
0.0
0.0

Monocytes LPS
0.0
0.0
0.0
Colon
2.4
0.0
0.0

Macrophages rest
4.1
3.7
13.4
Lung
14.9
3.1
0.0

Macrophages LPS
10.3
0.0
4.2
Thymus
9.6
7.4
12.0

HUVEC none
0.0
0.0
0.0
Kidney
0.0
3.9
3.6

HUVEC starved
6.3
0.0
0.0

AI_comprehensive panel_v1.0 Summary: Ag1175/Ag1201 Highest expression of this gene was detected in orthoarthritis bone and matched control psoriasis sample (CTs=32-33.5). Significant expression of this gene was also seen in psoriasis and asthma samples. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of orthoarthritis, asthma and psoriasis.

Panel 1.3D Summary: Ag1201 This gene showed significant expression mainly in testis (CTs=33-34). Modulation of this gene and encoded protein is useful in the treatment of testis related disorders such as fertility and hypogonadism.

Panel 2D Summary: Ag1201 Highest expression of this gene was detected in prostate cancer sample (CTs=32). This gene was over-expressed in tumors derived from tissues responsive to steroid hormones—ovarian, uterine and prostate cancers. Expression level of this gene is useful as a marker to detect tumor cells responsive to steroid hormones and to differentiate hormone-responsive and non-hormone responsive tumors that are known to lead to different clinical outcomes. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of ovarian, uterine and prostate cancers.

Panel 4D Summary: Ag1201 This gene showed low expression in activated basophils (CTs=32-33). Basophils are one of the key cell mediators of inflammation during asthma and allergy (Oliver J M, Kepley C L, Ortega E, Wilson B S, 2000, Immunologically mediated signaling in basophils and mast cells: finding therapeutic targets for allergic diseases in the human Fcvar epsilonR1 signaling pathway. Immunopharmacology 48(3):269-81). This expression indicated that this gene has a potential role in inflammation and helps the basophils to extravasate into the site of inflammation and/or in the activation of these cells. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful to inhibit nasal and lung inflammation caused by basophil activation and effectively reduce or eliminate symptoms of asthma, emphysema, and allergic rhinitis.

AX. CG56258-02: Sodium/Calcium Exchanger.

Expression of gene CG56258-02 was assessed using the primer-probe sets Ag2903, Ag5035 and Ag6163, described in Tables AXA, AXB and AXC. Results of the RTQ-PCR runs are shown in Tables AXD, AXE, AXF, AXG, AXH, AXI and AXJ.

TABLE AXAProbe Name Ag2903StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gactcgcaagatcaagcatcta-3′226411389ProbeTET-5′-cttcttcatcaccgctgcttggagta-3′-266681390TAMRAReverse5′-tagagccagatgtaggcaaaga-3′226941391

TABLE AXB

Probe Name Ag5035

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gaaagccagtattgggtgaac-3′
21
2023
1392

Probe
TET-5′-ccccaaactagaagtcatcattgaaga-
27
2045
1393

3′-TAMRA

Reverse
5′-tttgtccaccgtagtcttgaac-3′
22
2081
1394

TABLE AXC

Probe Name Ag6163

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-ggggagttggaattcaagaat-3′
21
1815
1395

Probe
TET-5′-tgaaactgtcaaaacaattcacatcaag-
28
1838
1396

3′-TAMRA

Reverse
5′-tctcatatgcctcatcatcaattac-3′
25
1866
1397

TABLE AXD

AI_comprehensive panel_v1.0

Column A - Rel. Exp.(%) Ag2903, Run 225410015

Column B - Rel. Exp.(%) Ag5035, Run 244570389

Tissue Name
A
B
Tissue Name
A
B

110967 COPD-F
0.6
0.3
112427 Match Control Psoriasis-F
4.1
4.8

110980 COPD-F
0.4
0.6
112418 Psoriasis-M
0.8
0.5

110968 COPD-M
0.9
1.2
112723 Match Control Psoriasis-M
0.1
0.0

110977 COPD-M
0.9
0.8
112419 Psoriasis-M
1.3
0.9

110989 Emphysema-F
0.6
0.0
112424 Match Control Psoriasis-M
1.1
0.5

110992 Emphysema-F
0.4
0.7
112420 Psoriasis-M
2.1
2.2

110993 Emphysema-F
1.1
1.4
112425 Match Control Psoriasis-M
2.9
5.8

110994 Emphysema-F
1.0
0.7
104689 (MF) OA Bone-Backus
68.3
44.4

110995 Emphysema-F
1.1
0.8
104690 (ME) Adj “Normal” Bone-
8.8
5.2

Backus

110996 Emphysema-F
0.0
0.0
104691 (ME) OA Synovium-
2.1
1.7

Backus

110997 Asthma-M
1.5
0.6
104692 (BA) OA Cartilage-Backus
3.3
3.6

111001 Asthma-F
1.8
1.5
104694 (BA) OA Bone-Backus
100.0
100.0

111002 Asthma-F
1.9
1.9
104695 (BA) Adj “Normal” Bone-
36.3
28.7

Backus

111003 Atopic Asthma-F
2.7
2.4
104696 (BA) OA Synovium-
1.4
0.5

Backus

111004 Atopic Asthma-F
0.9
1.2
104700 (SS) OA Bone-Backus
54.0
37.6

111005 Atopic Asthma-F
0.9
1.1
104701 (SS) Adj “Normal” Bone-
60.3
34.9

Backus

111006 Atopic Asthma-F
0.4
0.3
104702 (SS) OA Synovium-Backus
2.9
2.1

111417 Allergy-M
2.2
2.8
117093 OA Cartilage Rep7
1.4
0.4

112347 Allergy-M
0.6
0.0
112672 OA Bone5
4.8
3.3

112349 Normal Lung-F
0.9
0.0
112673 OA Synovium5
1.6
1.7

112357 Normal Lung-F
0.1
0.3
112674 OA Synovial Fluid cells5
2.6
2.6

112354 Normal Lung-M
0.0
0.3
117100 OA Cartilage Rep14
0.0
0.0

112374 Crohns-F
0.2
0.0
112756 OA Bone9
5.6
0.4

112389 Match Control Crohns-
0.2
1.1
112757 OA Synovium9
32.3
37.4

F

112375 Crobns-F
0.0
0.0
112758 OA Synovial Fluid Cells9
1.1
0.6

112732 Match Control Crohns-
0.8
0.8
117125 RA Cartilage Rep2
2.8
1.1

F

112725 Crohns-M
0.1
0.0
113492 Bone2 RA
3.0
1.2

112387 Match Control Crohns-
1.6
1.1
113493 Synovium2 RA
1.6
0.8

M

112378 Crohns-M
0.6
0.0
113494 Syn Fluid Cells RA
1.8
0.8

112390 Match Control Crohns-
1.0
0.8
113499 Cartilage4 RA
1.7
1.9

M

112726 Crohns-M
0.8
0.7
113500 Bone4 RA
2.6
2.2

112731 Match Control Crohns-
0.9
0.3
113501 Synovium4 RA
2.0
0.7

M

112380 Ulcer Col-F
0.4
0.5
113502 Syn Fluid Cells4 RA
0.6
0.6

112734 Match Control Ulcer
3.5
1.8
113495 Cartilage3 RA
1.6
0.6

Col-F

112384 Ulcer Col-F
2.7
1.9
113496 Bone3 RA
1.9
0.7

112737 Match Control Ulcer
0.5
0.6
113497 Synovium3 RA
1.4
0.8

Col-F

112386 Ulcer Col-F
2.0
1.4
113498 Syn Fluid Cells3 RA
2.6
2.7

112738 Match Control Ulcer
0.1
0.3
117106 Normal Cartilage Rep20
0.4
0.0

Col-F

112381 Ulcer Col-M
1.3
0.0
113663 Bone3 Normal
0.6
0.0

112735 Match Control Ulcer
3.3
1.2
113664 Synovium3 Normal
0.2
0.0

Col-M

112382 Ulcer Col-M
1.2
0.6
113665 Syn Fluid Cells3 Normal
0.2
0.0

112394 Match Control Ulcer
0.9
0.8
117107 Normal Cartilage Rep22
2.9
0.4

Col-M

112383 Ulcer Col-M
0.7
0.0
113667 Bone4 Normal
1.1
0.0

112736 Match Control Ulcer
0.7
0.3
113668 Synovium4 Normal
1.3
0.5

Col-M

112423 Psoriasis-F
0.7
0.3
113669 Syn Fluid Cells4 Normal
1.1
0.5

TABLE AXE

Cellular OA/RA

Column A - Rel. Exp.(%) Ag2903, Run 406107093

Tissue Name
A
Tissue Name
A

158667 Nhost medium 1 h
0.0
164336 SW1353 + TNF-a (100 ng/ml) 6 h
54.3

158670 Nhost + IL-1b (10
4.2
164337 SW1353 medium alone 18 h
74.2

ng/ml), 1 h

158673 Nhost + PGE2 (10-6 M)
0.0
164338 SW1353 + IL-1b (1 ng/ml) 18 h
62.9

1 h

158668 Nhost medium alone 6 h
2.3
164339 SW1353 + IL-1b (10 ng/ml) 18 h
41.5

158671 Nhost + IL-1b (10
29.1
164340 SW1353 + TNF-a (10 ng/ml) 18 h
49.3

ng/ml) 6 h

158674 Nhost + PGE2 (10-6 M)
2.5
164341 SW1353 + IL-1b (100 ng/ml) 18 h
74.2

6 h

158669 Nhost medium alone 24 h
1.4
173326 HFLS-RA (cell aplication) medium
0.0

alone 18 h

158672 Nhost + IL-1b (10
5.4
173327 HFLS-RA (cell aplication) + TNF-a
12.9

ng/ml) 24 h

18 h

158675 Nhost + PGE2 (10-6 M)
1.2
173331 MH7A (synoviocyte cell line)
46.7

24 h

medium 1 h

164327 SW1353 medium alone
95.3
173332 MH7A (synoviocyte cell line) +
29.1

1 h

IL1b 1 h

164328 SW1353 + IL-1b (1
88.3
173334 MH7A (synoviocyte cell line) TNFa
0.0

ng/ml) 1 h

1 h

164329 SW1353 + IL-1b (10
68.8
173336 MH7A (synoviocyte cell line)
63.7

ng/ml) 1 h

medium alone 6 h

164330 SW1353 + TNF-a (10
82.9
173339 MH7A (synoviocyte cell line) +
61.6

ng/ml) 1 h

IL1b 6 h

164331 SW1353 + TNF-a (100
100.0
173341 MH7A (synoviocyte cell line) TNFa
37.9

ng/ml) 1 h

6 h

164332 SW1353 medium alone
54.7
173342 MH7A (synoviocyte cell line)
37.4

6 h

medium alone 18 h

164333 SW1353 + IL-1b (1
41.5
173344 MH7A (synoviocyte cell line) +
73.7

ng/ml) 6 h

IL1b 18 h

164334 SW1353 + IL-1b (10
29.1
173346 MH7A (synoviocyte cell line) TNF-a
32.1

ng/ml) 6 h

18 h

164335 SW1353 + TNF-a (10
88.3

ng/ml) 6 h

TABLE AXF

PGI1.0

Column A - Rel. Exp.(%) Ag2903, Run 398125347

Tissue Name
A
Tissue Name
A

162191 Normal Lung 1 (IBS)
1.4
162185 Emphysema Lung 12 (Ardais)
41.5

160468 MD lung
13.7
162184 Emphysema Lung 13 (Ardais)
23.2

156629 MD Lung 13
5.8
162183 Emphysema Lung 14 (Ardais)
70.7

162570 Normal Lung 4 (Aastrand)
18.6
162188 Emphysema Lung 15 (Genomic
51.4

Collaborative)

162571 Normal Lung 3 (Aastrand)
6.1
162177 NAT UC Colon 1 (Ardais)
7.6

162187 Fibrosis Lung 2 (Genomic
100.0
162176 UC Colon 1 (Ardais)
7.7

Collaborative)

151281 Fibrosis lung 11 (Ardais)
25.7
162179 NAT UC Colon 2 (Ardais)
11.0

162186 Fibrosis Lung 1 (Genomic
67.8
162178 UC Colon 2 (Ardais)
19.5

Collaborative)

162190 Asthma Lung 4 (Genomic
38.4
162181 NAT UC Colon 3 (Ardais)
3.1

Collaborative)

160467 Asthma Lung 13 (MD)
10.9
162180 UC Colon 3 (Ardais)
2.9

137027 Emphysema Lung 1
13.8
162182 NAT UC Colon 4 (Ardais)
6.5

(Ardais)

137028 Emphysema Lung 2
11.4
137042 UC Colon 1108
8.0

(Ardais)

137040 Emphysema Lung 3
14.8
137029 UC Colon 8215
5.2

(Ardais)

137041 Emphysema Lung 4
23.3
137031 UC Colon 8217
4.9

(Ardais)

137043 Emphysema Lung 5
12.9
137036 UC Colon 1137
9.2

(Ardais)

l428l7 Emphysema Lung 6
17.3
137038 UC Colon 1491
27.2

(Ardais)

142818 Emphysema Lung 7
36.6
137039 UC Colon 1546
12.3

(Ardais)

142819 Emphysema Lung 8
36.1
162593 Crohn's 47751 (NDRI)
3.5

(Ardais)

142820 Emphysema Lung 9
18.0
162594 NAT Crohn's 47751 (NDRI)
3.1

(Ardais)

142821 Emphysema Lung 10
49.3

(Ardais)

TABLE AXG

Panel 1.3D

Column A - Rel. Exp.(%) Ag2903, Run 162556420

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
0.0
Kidney (fetal)
0.3

Pancreas
0.0
Renal ca. 786-0
0.0

Pancreatic ca. CAPAN 2
0.0
Renal ca. A498
0.0

Adrenal gland
0.1
Renal ca. RXF 393
0.0

Thyroid
0.2
Renal ca. ACHN
0.0

Salivary gland
0.1
Renal ca. UO-31
0.1

Pituitary gland
0.4
Renal ca. TK-10
0.0

Brain (fetal)
2.0
Liver
0.0

Brain (whole)
3.9
Liver (fetal)
0.4

Brain (amygdala)
3.7
Liver ca. (hepatoblast) HepG2
0.0

Brain (cerebellum)
3.3
Lung
0.0

Brain (hippocampus)
5.6
Lung (fetal)
0.4

Brain (substantia nigra)
0.9
Lung ca. (small cell) LX-1
0.0

Brain (thalamus)
5.9
Lung ca. (small cell) NCI-H69
0.2

Cerebral Cortex
80.7
Lung ca. (s. cell var.) SHP-77
3.4

Spinal cord
1.7
Lung ca. (large cell) NCI-H460
0.0

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
0.1

glio/astro U-118-MG
0.0
Lung ca. (non-s. cell) NCI-H23
0.0

astrocytoma SW1783
0.6
Lung ca. (non-s. cell) HOP-62
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (non-s. cl) NCI-H522
0.0

astrocytoma SF-539
0.0
Lung ca. (squam.) SW 900
0.0

astrocytoma SNB-75
0.0
Lung ca. (squam.) NCI-H596
0.2

glioma SNB-19
0.1
Mammary gland
0.1

glioma U251
0.0
Breast ca.* (pl. ef) MCF-7
0.0

glioma SF-295
0.0
Breast ca.* (pl. ef) MDA-MB-231
0.0

Heart (Fetal)
5.2
Breast ca.* (pl. ef) T47D
0.0

Heart
0.3
Breast ca. BT-549
0.0

Skeletal muscle (Fetal)
100.0
Breast ca. MDA-N
0.0

Skeletal muscle
21.2
Ovary
0.2

Bone marrow
0.2
Ovarian ca. OVCAR-3
0.0

Thymus
0.6
Ovarian ca. OVCAR-4
0.3

Spleen
0.0
Ovarian ca. OVCAR-5
0.0

Lymph node
0.3
Ovarian ca. OVCAR-8
0.0

Colorectal
1.1
Ovarian ca. IGROV-1
0.0

Stomach
0.1
Ovarian ca. (ascites) SK-OV-3
0.0

Small intestine
0.2
Uterus
0.1

Colon ca. SW480
0.0
Placenta
0.0

Colon ca.* SW620
0.0
Prostate
0.0

(SW480 met)

Colon ca. HT29
0.0
Prostate ca.* (bone met) PC-3
0.0

Colon ca. HCT-116
0.0
Testis
0.3

Colon ca. CaCo-2
0.0
Melanoma Hs688(A).T
0.0

CC Well to Mod Diff
0.5
Melanoma* (met) Hs688(B).T
0.0

(ODO3866)

Colon ca. HCC-2998
0.0
Melanoma UACC-62
0.2

Gastric ca. (liver met)
0.0
Melanoma M14
0.0

NCI-N87

Bladder
0.2
Melanoma LOXIMVI
0.0

Trachea
0.3
Melanoma* (met) SK-MEL-5
0.0

Kidney
0.0
Adipose
0.3

TABLE AXH

Panel 2D

Column A - Rel. Exp.(%) Ag2903, Run 162345106

Tissue Name
A
Tissue Name
A

Normal Colon
8.1
Kidney Margin 8120608
0.5

CC Well to Mod Diff (ODO3866)
0.3
Kidney Cancer 8120613
0.0

CC Margin (ODO3866)
0.3
Kidney Margin 8120614
0.1

CC Gr.2 rectosigmoid (ODO3868)
0.1
Kidney Cancer 9010320
0.5

CC Margin (ODO3868)
0.2
Kidney Margin 9010321
0.0

CC Mod Diff(ODO3920)
0.3
Normal Uterus
1.0

CC Margin (ODO3920)
0.4
Uterine Cancer 064011
0.5

CC Gr.2 ascend colon (ODO3921)
1.1
Normal Thyroid
1.0

CC Margin (ODO3921)
0.9
Thyroid Cancer
0.0

CC from Partial Hepatectomy
0.4
Thyroid Cancer A302152
0.1

(ODO4309) Mets

Liver Margin (ODO4309)
0.1
Thyroid Margin A302153
0.1

Colon mets to lung (OD04451-01)
0.1
Normal Breast
3.0

Lung Margin (OD04451-02)
1.3
Breast Cancer
0.4

Normal Prostate 6546-1
2.3
Breast Cancer (OD04590-01)
0.8

Prostate Cancer (OD04410)
1.2
Breast Cancer Mets (OD04590-03)
1.5

Prostate Margin (OD04410)
4.2
Breast Cancer Metastasis
0.2

Prostate Cancer (OD04720-01)
1.2
Breast Cancer
0.5

Prostate Margin (OD04720-02)
4.6
Breast Cancer
1.2

Normal Lung
5.8
Breast Cancer 9100266
1.8

Lung Met to Muscle (ODO4286)
0.0
Breast Margin 9100265
1.1

Muscle Margin (ODO4286)
100.0
Breast Cancer A209073
0.6

Lung Malignant Cancer (OD03126)
0.8
Breast Margin A209073
0.0

Lung Margin (OD03126)
7.7
Normal Liver
0.0

Lung Cancer (OD04404)
1.4
Liver Cancer
0.0

Lung Margin (OD04404)
4.1
Liver Cancer 1025
0.0

Lung Cancer (OD04565)
0.3
Liver Cancer 1026
0.0

Lung Margin (OD04565)
1.2
Liver Cancer 6004-T
0.1

Lung Cancer (OD04237-01)
0.7
Liver Tissue 6004-N
0.5

Lung Margin (OD04237-02)
2.4
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (ODO4310)
0.0
Liver Tissue 6005-N
0.0

Liver Margin (ODO4310)
0.1
Normal Bladder
0.6

Melanoma Metastasis
0.1
Bladder Cancer
0.2

Lung Margin (OD04321)
2.4
Bladder Cancer
1.4

Normal Kidney
1.5
Bladder Cancer (OD04718-01)
0.5

Kidney Ca, Nuclear grade 2 (OD04338)
0.5
Bladder Normal Adjacent
4.9

(OD04718-03)

Kidney Margin (OD04338)
1.4
Normal Ovary
0.1

Kidney Ca Nuclear grade 1/2 (OD04339)
1.8
Ovarian Cancer
1.9

Kidney Margin (OD04339)
0.6
Ovarian Cancer (OD04768-07)
0.0

Kidney Ca, Clear cell type (OD04340)
1.0
Ovary Margin (OD04768-08)
0.2

Kidney Margin (OD04340)
0.8
Normal Stomach
4.5

Kidney Ca, Nuclear grade 3 (OD04348)
1.3
Gastric Cancer 9060358
1.7

Kidney Margin (OD04348)
0.7
Stomach Margin 9060359
1.5

Kidney Cancer (OD04622-01)
0.7
Gastric Cancer 9060395
1.2

Kidney Margin (OD04622-03)
0.0
Stomach Margin 9060394
2.0

Kidney Cancer (OD04450-01)
0.0
Gastric Cancer 9060397
0.6

Kidney Margin (OD04450-03)
0.1
Stomach Margin 9060396
1.7

Kidney Cancer 8120607
0.1
Gastric Cancer 064005
2.9

TABLE AXI

Panel 4.1D

Column A - Rel. Exp.(%) Ag5035, Run 223740981

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
2.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
1.9

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNFalpha + IL-
100.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tr1 act
2.0
Microsvasular Dermal EC TNFalpha + IL-
55.5

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNFalpha +IL1beta
2.2

Primary Th2 rest
0.0
Small airway epithelium none
4.2

Primary Tr1 rest
0.0
Small airway epithelium TNFalpha + IL-
3.7

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
2.3

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNFalpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNFalpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
10.6

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
13.6

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNFalpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
0.0

LAK cells IL-2 + IL-12
8.4
NCI-H292 none
0.0

LAK cells IL-2 + IFN gamma
2.9
NCI-H292 IL-4
0.0

LAK cells IL-2 + IL-18
3.8
NCI-H292 IL-9
0.0

LAK cells PMA/ionomycin
2.3
NCI-H292 IL-13
2.5

NK Cells IL-2 rest
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 3 day
2.1
HPAEC none
0.0

Two Way MLR 5 day
2.3
HPAEC TNF alpha + IL-1 beta
8.8

Two Way MLR 7 day
1.8
Lung fibroblast none
0.0

PBMC rest
6.7
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PWM
0.0
Lung fibroblast IL-4
0.0

PBMC PHA-L
6.3
Lung fibroblast IL-9
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-13
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IFN gamma
0.0

B lymphocytes PWM
9.2
Dermal fibroblast CCD1070 rest
0.0

B lymphocytes CD40L and IL-4
1.9
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast IFN gamma
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells LPS
2.4
Dermal Fibroblasts rest
2.0

Dendritic cells anti-CD40
0.0
Neutrophils TNFa + LPS
0.0

Monocytes rest
0.0
Neutrophils rest
0.0

Monocytes LPS
31.6
Colon
5.4

Macrophages rest
1.7
Lung
8.1

Macrophages LPS
6.5
Thymus
5.1

HUVEC none
0.0
Kidney
0.0

HUVEC starved
0.0

TABLE AXJ

Panel 5 Islet

Column A - Rel. Exp.(%) Ag2903, Run 242321748

Column B - Rel. Exp.(%) Ag2903, Run 258900739

Column C - Rel. Exp.(%) Ag5035, Run 244908253

Tissue Name
A
B
C
Tissue Name
A
B
C

97457 Patient-02go adipose
0.7
0.8
1.4
94709 Donor 2 AM - A
0.4
0.4
0.0

adipose

97476 Patient-07sk skeletal
9.9
15.2
3.2
94710 Donor 2 AM - B
0.9
1.2
0.0

muscle

adipose

97477 Patient-07ut uterus
0.6
1.4
0.0
94711 Donor2 AM - C
0.0
0.4
0.0

adipose

97478 Patient-07pl placenta
1.4
0.0
1.1
94712 Donor 2 AD - A
0.0
0.0
0.0

adipose

99167 Bayer Patient 1
26.6
26.4
24.8
94713 Donor2 AD - B
0.4
0.3
0.0

adipose

97482 Patient-08ut uterus
0.0
0.3
0.0
94714 Donor 2 AD - C
0.0
0.8
0.0

adipose

97483 Patient-08pl placenta
0.0
0.7
0.0
94742 Donor 3 U - A
0.0
0.0
0.0

Mesenchymal Stem Cells

97486 Patient-09sk skeletal
10.4
19.5
11.1
94743 Donor 3 U - B
0.9
0.0
0.0

muscle

Mesenchymal Stem Cells

97487 Patient-09ut uterus
0.6
2.8
1.7
94730 Donor 3 AM - A
0.9
0.3
0.0

adipose

97488 Patient-09pl placenta
0.3
1.1
1.1
94731 Donor 3 AM - B
0.0
0.0
0.0

adipose

97492 Patient-10ut uterus
0.2
0.4
0.0
94732 Donor 3 AM - C
0.0
0.7
0.0

adipose

97493 Patient-10pl placenta
0.8
0.4
1.1
94733 Donor 3 AD - A
1.0
0.3
0.0

adipose

97495 Patient-11go adipose
1.4
3.1
0.0
94734 Donor 3 AD - B
0.0
0.4
0.0

adipose

97496 Patient-11sk skeletal
29.1
59.9
33.9
94735 Donor 3 AD - C
0.0
0.0
0.0

muscle

adipose

97497 Patient-11ut uterus
0.5
0.4
0.0
77138 Liver HepG2untreated
0.0
0.4
0.0

97498 Patient-11pl placenta
0.0
0.0
0.0
73556 Heart Cardiac stromal
0.5
0.4
0.0

cells (primary)

97500 Patient-12go adipose
0.5
2.8
0.0
81735 Small Intestine
2.3
0.7
0.0

97501 Patient-12sk skeletal
100.0
100.0
100.0
72409 Kidney Proximal
0.0
0.4
0.0

muscle

Convoluted Tubule

97502 Patient-12ut uterus
1.0
0.3
0.0
82685 Small intestine
0.0
1.7
1.1

Duodenum

97503 Patient-12pl placenta
0.0
0.0
0.0
90650 Adrenal
0.0
0.0
0.0

Adrenocortical adenoma

94721 Donor 2 U - A
0.4
0.0
0.0
72410 Kidney HRCE
0.0
0.0
1.6

Mesenchymal Stem Cells

94722 Donor 2 U - B
0.4
1.4
0.0
72411 Kidney HRE
0.4
1.1
0.0

Mesenchymal Stem Cells

94723 Donor 2 U - C
0.0
0.0
0.0
73139 Uterus Uterine smooth
0.0
0.0
0.0

Mesenchymal Stem Cells

muscle cells

AI_comprehensive panel_v1.0 Summary: Ag2903/Ag5035 The highest expression of this gene was detected in an OA bone sample. Expression of the CG56258-01 gene was highly associated with synovium and bone samples from patients with osteoarthritis when compared to expression in the control samples. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of osteoarthritis.

Cellular OA/RA Summary: Ag2903 Moderate expression of this gene was detected in chondrosarcoma cell line (SW1353) and synoviocyte cell line (CTs=31-32). Significant expression of this gene was also detected in cells treated with IL-1-beta, a potent activator of pro-inflammatory cytokines and matrix metalloproteinases which participate in the destruction of cartilage observed in Osteoarthritis (OA). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the prevention or treatment of the degeneration of cartilage observed in OA.

PGI1.0 Summary: Ag2903 The highest expression level of this gene was detected in a lung fibrosis sample (CT=26). It was upregulated in lung fibrosis and several emphysema samples. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of lung fibrosis and emphysema.

Panel 1.3D Summary: Ag2903 Expression of this gene was highest in fetal skeletal muscle (CT=26.8). Significant levels of expression are also seen in adult skeletal muscle and fetal heart. This gene encodes a putative sodium/calcium exchanger. Altered levels of intracellular calcium have been implicated in many diseases, including type 2 diabetes. Based on its expression profile and homology to a calcium transport protein, therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of type 2 diabetes.

Moderate to low levels of expression were seen in all regions of the CNS examined. Inhibition of calcium uptake has been shown to decrease neuronal death in response to cerebral ischemia. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of stroke by decreasing the total infarct volume.

Panel 2D Summary: Ag2903 The expression of the CG56258-01 gene was consistent with the profile seen in Panel 1.3D. Expression was highest and most prominent in a normal muscle sample (CT=28.7). Please see Panel 1.3D for discussion of this gene in metabolic disease.

Panel 4.1D Summary: Ag5035 Expression of the CG56258-02 gene was restricted to TNF-alpha and IL-1 beta treated lung and dermal microvasculature (CTs=33-34). Endothelial cells are known to play important roles in inflammatory responses by altering the expression of surface proteins that are involved in activation and recruitment of effector inflammatory cells. The expression of this gene in dermal microvascular endothelial cells indicated that this protein product is involved in inflammatory responses to skin disorders, including psoriasis. Expression in lung microvascular endothelial cells indicated that the protein encoded by this gene is involved in lung disorders including asthma, allergies, chronic obstructive pulmonary disease, and emphysema. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of psoriasis, asthma, allergies, chronic obstructive pulmonary disease, and emphysema.

Panel 5 Islet Summary: Ag2903/Ag5035 The expression of this gene in this panel was consistent with the profile seen in Panel 1.3D. Expression was highest and most prominent in sampels derived from skeletal muscle (CTs=29-33). Please see Panel 1.3D for discussion of this gene in metabolic disease.

AY. CG56258-04: SCL8A3 Splice Form B-Like.

Expression of gene CG56258-04 was assessed using the primer-probe sets Ag5035 and Ag6142, described in Tables AYA and AYB. Results of the RTQ-PCR runs are shown in Tables AYC, AYD, AYE and AYF.

TABLE AYAProbe Name Ag5035StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gaaagccagtattgggtgaac-3′2120111398ProbeTET-5′-ccccaaactagaagtcatcattgaaga-27203313993′-TAMRAReverse5′-tttgtccaccgtagtcttgaac-3′2220691340

TABLE AYB

Probe Name Ag6142

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gtagatgaggaggaatacgaaagg-3′
24
1869
1341

Probe
TET-5′-aatttcttcattgcccttggtgaacc-3′-
26
1899
1342

TAMRA

Reverse
5′-gatattccacgttccatccatt-3′
22
1927
1343

TABLE AYC

AI_comprehensive panel_v1.0

Column A - Rel. Exp.(%) Ag5035, Run 244570389

Column B - Rel. Exp.(%) Ag6142, Run 253050665

Tissue Name
A
B
Tissue Name
A
B

110967 COPD-F
0.3
1.5
112427 Match Control Psoriasis-F
4.8
9.8

110980 COPD-F
0.6
0.0
112418 Psoriasis-M
0.5
1.0

110968 COPD-M
1.2
0.8
112723 Match Control Psoriasis-M
0.0
0.0

110977 COPD-M
0.8
1.3
112419 Psoriasis-M
0.9
1.7

110989 Emphysema-F
0.0
0.6
112424 Match Control Psoriasis-M
0.5
0.8

110992 Emphysema-F
0.7
0.7
112420 Psoriasis-M
2.2
1.6

110993 Emphysema-F
1.4
0.0
112425 Match Control Psoriasis-M
5.8
4.4

110994 Emphysema-F
0.7
0.6
104689 (MF) OA Bone-Backus
44.4
52.9

110995 Emphysema-F
0.8
0.7
104690 (MF) Adj “Normal” Bone

Backus
5.2
2.8

110996 Emphysema-F
0.0
0.0
104691 (MF) OA Synovium-

Backus
1.7
1.5

110997 Asthma-M
0.6
1.2
104692 (BA) OA Cartilage-Backus
3.6
3.0

111001 Asthma-F
1.5
0.8
104694 (BA) OA Bone-Backus
100.0
100.0

111002 Asthma-F
1.9
0.0
104695 (BA) Adj “Normal” Bone-
28.7
33.7

Backus

111003 Atopic Asthma-F
2.4
1.9
104696 (BA) OA Synovium-
0.5
0.7

Backus

111004 Atopic Asthma-F
1.2
0.8
104700 (55) OA Bone-Backus
37.6
28.9

111005 Atopic Asthma-F
1.1
1.5
104701 (SS) Adj “Normal” Bone-
34.9
27.5

Backus

111006 Atopic Asthma-F
0.3
0.0
104702 (SS) OA Synovium-Backus
2.1
2.5

111417 Allergy-M
2.8
0.0
117093 OA Cartilage Rep7
0.41
0.6

112347 Allergy-M
0.0
0.0
112672 OA Bone5
3.3
3.7

112349 Normal Lung-F
0.0
0.0
112673 OA Synovium5
1.7
1.7

112357 Normal Lung-F
0.3
0.0
112674 OA Synovial Fluid cells5
2.6
1.0

112354 Normal Lung-M
0.3
0.0
117100 OA Cartilage Rep 14
0.0
0.0

112374 Crohns-F
0.0
0.9
112756 OA Bone9
0.4
0.0

112389 Match Control Crohns-
1.1
0.0
112757 OA Synovium9
37.4
25.0

F

112375 Crohns-F
0.0
0.0
112758 OA Synovial Fluid Cells9
0.6
1.2

112732 Match Control Crohns-
0.8
0.7
1117125 RA Cartilage Rep2
1.1
1.4

F

112725 Crohns-M
0.0
0.6
113492 Bone2 RA
1.2
1.4

112387 Match Control Crohns-
1.1
1.1
113493 Synovium2 RA
0.8
1.0

M

112378 Crohns-M
0.0
0.0
1113494 Syn Fluid Cells RA
0.8
1.0

1112390 Match Control Crohns-
0.8
1.2
1113499 Cartilage4 RA
1.9
2.6

M

112726 Crohns-M
0.7
1.6
113500 Bone4 RA
2.2
1.8

112731 Match Control Crohns-
0.3
1.7
113501 Synovium4 RA
0.7
1.0

M

112380 UlcerCol-F
0.5
1.7
113502 Syn Fluid Cells4 RA
0.6
1.3

112734 Match Control Ulcer
1.8
2.2
113495 Cartilage3 RA
0.6
1.4

Col-F

112384 UlcerCol-F
1.9
1.4
113496 Bone3 RA
0.7
1.3

112737 Match Control Ulcer
0.6
0.0
113497 Synovium3 RA
0.8
0.9

Col-F

112386 Ulcer Col-F
1.4
1.1
113498 Syn Fluid Cells3 RA
2.7
2.5

112738 Match Control Ulcer
0.3
0.0
117106 Normal Cartilage Rep20
0.0
0.0

Col-F

112381 Ulcer Col-M
0.0
0.0
113663 Bone3 Normal
0.0
0.0

112735 Match Control Ulcer
1.2
1.5
113664 Synovium3 Normal
0.0
0.0

Col-M

112382 Ulcer Col-M
0.6
1.0
113665 Syn Fluid Cells3 Normal
0.0
0.0

112394 Match Control Ulcer
0.8
0.0
117107 Normal Cartilage Rep22
0.4
1.4

Col-M

112383 Ulcer Col-M
0.0
0.0
113667 Bone4 Normal
0.0
0.0

112736 Match Control Ulcer
0.3
0.7
113668 Synovium4 Normal
0.5
0.9

Col-M

112423 Psoriasis-F
0.3
0.0
113669 Syn Fluid Cells4 Normal
0.5
1.8

TABLE AYD

General_screening_panel v1.5

Column A - Rel. Exp.(%) Ag5035, Run 228967202

Column B - Rel. Exp.(%) Ag5035, Run 244373096

Column C - Rel. Exp.(%) Ag6142, Run 258495052

Column D - Rel. Exp.(%) Ag6142, Run 258496099

Tissue Name
A
B
C
D

Adipose
1.6
2.2
1.4
0.7

Melanoma* Hs688(A).T
0.0
0.0
0.0
0.0

Melanoma* Hs688(B).T
0.0
0.0
0.0
0.0

Melanoma* M14
0.0
0.0
0.0
0.0

Melanoma* LOXIMVI
0.0
0.0
0.0
0.0

Melanoma* SK-MEL-5
0.0
0.0
0.0
0.0

Squamous cell carcinoma SCC-4
0.0
0.0
0.0
0.0

Testis Pool
0.0
0.1
0.6
0.5

Prostate ca.* (bone met) PC-3
0.0
0.0
0.0
0.0

Prostate Pool
1.4
2.0
2.3
1.9

Placenta
0.3
0.1
0.3
0.0

Uterus Pool
2.1
1.6
1.1
0.8

Ovarian ca. OVCAR-3
0.0
0.0
0.0
0.0

Ovarian ca. SK-OV-3
0.0
0.0
0.0
0.8

Ovarian ca. OVCAR-4
0.3
0.0
0.5
0.0

Ovarian ca. OVCAR-5
0.0
0.0
0.2
0.2

Ovarian ca. IGROV-1
0.0
0.0
0.2
0.0

Ovarian ca. OVCAR-8
0.0
0.0
0.0
0.0

Ovary
0.3
0.3
0.1
0.0

Breast ca. MCF-7
0.0
0.0
0.0
0.0

Breast ca. MDA-MB-231
0.0
0.0
0.4
0.0

Breast ca. BT 549
0.0
0.0
0.0
0.0

Breast ca. T47D
0.0
0.0
0.0
0.0

Breast ca. MDA-N
0.0
0.0
0.4
0.0

Breast Pool
2.6
3.5
2.5
3.4

Trachea
0.8
1.1
2.6
2.2

Lung
0.0
0.0
0.0
0.0

Fetal Lung
14.3
14.5
21.3
17.7

Lung ca. NCI-N417
0.0
0.0
0.0
0.0

Lung ca. LX-1
0.0
0.0
0.0
0.0

Lung ca. NCI-H146
0.0
0.0
0.2
0.0

Lung ca. SHP-77
9.3
12.7
19.9
11.7

Lung ca. A549
0.0
0.0
0.0
0.0

Lung ca. NCI-H526
0.2
0.2
0.0
0.0

Lung ca. NCI-H23
0.0
0.0
0.2
0.0

Lung ca. NCI-H460
0.0
0.0
5.4
2.5

Lung Ca. HOP-62
0.0
0.0
0.0
0.0

Lung Ca. NCI-H522
0.0
0.0
0.2
0.0

Liver
0.0
0.0
0.0
0.0

Fetal Liver
2.1
2.0
1.1
1.6

Liver ca. HepG2
0.0
2.0
0.2
0.0

Kidney Pool
1.8
0.0
1.7
2.6

Fetal Kidney
0.8
0.7
1.4
0.0

Renal ca. 786-0
0.0
0.0
0.0
0.0

Renal ca. A498
0.0
0.0
0.0
0.0

Renal ca. ACHN
0.0
0.0
0.0
0.0

Renal ca. UO-31
0.0
0.0
0.0
0.0

Renal ca. TK-10
0.0
0.0
0.2
0.2

Bladder
0.6
0.3
2.0
1.3

Gastric ca. (liver met.) NCI-N87
0.0
0.0
0.2
0.0

Gastric ca. KATO III
0.0
0.0
0.5
0.0

Colon ca. SW-948
0.0
0.0
0.2
0.0

Colon ca. SW480
0.0
0.0
0.1
0.0

Colon ca.* (SW480 met) SW620
0.0
0.0
0.0
0.0

Colon ca. HT29
0.0
0.0
0.0
0.0

Colon ca. HCT-116
0.0
0.0
0.0
0.0

Colon ca. CaCo-2
0.2
0.2
0.0
0.0

Colon cancer tissue
0.7
0.1
0.9
0.0

Colon ca. SW1116
0.0
0.0
0.0
0.0

Colon ca. Colo-205
0.0
0.0
0.0
0.0

Colon ca. SW-48
0.0
0.0
0.0
0.0

Colon Pool
3.5
3.1
3.2
1.9

Small Intestine Pool
1.1
1.3
1.8
0.7

Stomach Pool
0.2
1.4
0.4
0.3

Bone Marrow Pool
2.3
1.8
1.4
2.4

Fetal Heart
0.3
0.6
0.8
0.6

Heart Pool
0.8
0.0
2.2
0.7

Lymph Node Pool
2.6
2.0
3.0
4.8

Fetal Skeletal Muscle
17.9
22.2
20.9
27.0

Skeletal Muscle Pool
100.0
83.5
96.6
79.0

Spleen Pool
0.6
0.0
0.2
0.5

Thymus Pool
0.6
0.4
1.5
1.1

CNS cancer (glio/astro) U87-MG
0.0
0.0
1.5
1.2

CNS cancer (glio/astro) U-118-MG
0.2
0.0
0.0
0.0

CNS cancer (neuro; met) SK-N-AS
0.0
0.0
0.0
0.0

CNS cancer (astro) SF-539
0.0
0.0
0.0
0.0

CNS cancer (astro) SNB-75
0.0
0.2
0.9
1.0

CNS cancer (glio) SNB-19
0.0
0.0
0.0
0.0

CNS cancer (glio) SF-295
0.0
0.0
0.0
0.0

Brain (Amygdala) Pool
32.8
31.0
36.3
26.2

Brain (cerebellum)
69.7
76.3
61.1
49.3

Brain (fetal)
90.1
100.0
100.0
100.0

Brain (Hippocampus) Pool
27.9
31.0
32.1
29.3

Cerebral Cortex Pool
36.3
48.3
39.5
42.3

Brain (Substantia nigra) Pool
31.0
32.1
28.3
24.8

Brain (Thalamus) Pool
50.0
50.3
54.7
51.1

Brain (whole)
46.0
38.2
50.7
46.7

Spinal Cord Pool
17.6
18.4
25.2
17.7

Adrenal Gland
2.5
2.5
3.1
2.1

Pituitary gland Pool
1.3
1.2
1.4
3.2

Salivary Gland
0.0
0.2
0.2
0.0

Thyroid (female)
0.0
0.0
0.3
0.2

Pancreatic ca. CAPAN2
0.0
0.0
0.0
0.0

Pancreas Pool
1.6
7.9
1.3
1.6

TABLE AYE

Panel 4.1D

Column A - Rel. Exp.(%) Ag5035, Run 223740981

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
2.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
1.9

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNFalpha + IL-
100.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tr1 act
2.0
Microsvasular Dermal EC TNFalpha + IL-
55.5

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNFalpha +IL1beta
2.2

Primary Th2 rest
0.0
Small airway epithelium none
4.2

Primary Tr1 rest
0.0
Small airway epithelium TNFalpha + IL-
3.7

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
2.3

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNFalpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNFalpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
10.6

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
13.6

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNFalpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
0.0

LAK cells IL-2 + IL-12
8.4
NCI-H292 none
0.0

LAK cells IL-2 + IFN gamma
2.9
NCI-H292 IL-4
0.0

LAK cells IL-2 + IL-18
3.8
NCI-H292 IL-9
0.0

LAK cells PMA/ionomycin
2.3
NCI-H292 IL-13
2.5

NK Cells IL-2 rest
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 3 day
2.1
HPAEC none
0.0

Two Way MLR 5 day
2.3
HPAEC TNF alpha + IL-1 beta
8.8

Two Way MLR 7 day
1.8
Lung fibroblast none
0.0

PBMC rest
6.7
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PWM
0.0
Lung fibroblast IL-4
0.0

PBMC PHA-L
6.3
Lung fibroblast IL-9
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-13
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IFN gamma
0.0

B lymphocytes PWM
9.2
Dermal fibroblast CCD1070 rest
0.0

B lymphocytes CD40L and IL-4
1.9
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast IFN gamma
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells LPS
2.4
Dermal Fibroblasts rest
2.0

Dendritic cells anti-CD40
0.0
Neutrophils TNFa + LPS
0.0

Monocytes rest
0.0
Neutrophils rest
0.0

Monocytes LPS
31.6
Colon
5.4

Macrophages rest
1.7
Lung
8.1

Macrophages LPS
6.5
Thymus
5.1

HUVEC none
0.0
Kidney
0.0

HUVEC starved
0.0

TABLE AYF

Panel 5 Islet

Column A - Rel. Exp.(%) Ag5035, Run 244908253

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
1.4
94709 Donor 2 AM - A adipose
0.0

97476 Patient-07sk skeletal muscle
3.2
94710 Donor 2 AM - B adipose
0.0

97477 Patient-07ut uterus
0.0
94711 Donor 2 AM - C adipose
0.0

97478 Patient-07pl placenta
1.1
94712 Donor 2 AD - A adipose
0.0

99167 Bayer Patient 1
24.8
94713 Donor 2 AD - B adipose
0.0

97482 Patient-08ut uterus
0.0
94714 Donor 2 AD - C adipose
0.0

97483 Patient-08pl placenta
0.0
94742 Donor 3 U - A Mesenchymal
0.0

Stem Cells

97486 Patient-09sk skeletal muscle
11.1
94743 Donor 3 U - B Mesenchymal
0.0

Stem Cells

97487 Patient-09ut uterus
1.7
94730 Donor 3 AM - A adipose
0.0

97488 Patient-09pl placenta
1.1
94731 Donor 3 AM - B adipose
0.0

97492 Patient-10ut uterus
0.0
94732 Donor 3 AM - C adipose
0.0

97493 Patient-10pl placenta
1.1
94733 Donor 3 AD - A adipose
0.0

97495 Patient-11go adipose
0.0
94734 Donor 3 AD - B adipose
0.0

97496 Patient-11sk skeletal muscle
33.9
94735 Donor 3 AD - C adipose
0.0

97497 Patient-11ut uterus
0.0
77138 Liver HepG2untreated
0.0

97498 Patient-11pl placenta
0.0
73556 Heart Cardiac stromal cells
0.0

(primary)

97500 Patient-12go adipose
0.0
81735 Small Intestine
0.0

97501 Patient-12sk skeletal muscle
100.0
72409 Kidney Proximal Convoluted
0.0

Tubule

97502 Patient-12ut uterus
0.0
82685 Small intestine Duodenum
1.1

97503 Patient-12pl placenta
0.0
90650 Adrenal Adrenocortical
0.0

adenoma

94721 Donor 2 U - A Mesenchymal
0.0
72410 Kidney HRCE
1.6

Stem Cells

94722 Donor 2 U - B Mesenchymal
0.0
72411 Kidney HRE
0.0

Stem Cells

94723 Donor 2 U - C Mesenchymal
0.0
73139 Uterus Uterine smooth muscle
0.0

Stem Cells

cells

AI_comprehensive panel_v1.0 Summary: Ag5035/Ag6142 The highest expression of this gene was detected in an OA bone sample. Expression of the The expression of this gene was highly associated with synovium and bone samples from patients with osteoarthritis when compared to expression in the control samples. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of osteoarthritis.

General_screening_panel_v1.5 Summary: Ag5035/Ag6142 This gene showed highly brain preferential expression (CTs=30-31). Inhibition of calcium uptake has been shown to decrease neuronal death in response to cerebral ischemia. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of stroke by decreasing the total infarct volume.

Moderate levels of expression were seen in fetal and adult skeletal muscle (CTs=30-31). This gene encodes a putative sodium/calcium exchanger. Altered levels of intracellular calcium have been implicated in many diseases, including type 2 diabetes. Based on its expression profile and homology to a calcium transport protein, therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of type 2 diabetes.

Panel 4.1D Summary: Ag5035 Expression of this gene was restricted to TNF-alpha and IL-1 beta treated lung and dermal microvasculature (CTs=33-34). Endothelial cells are known to play important roles in inflammatory responses by altering the expression of surface proteins that are involved in activation and recruitment of effector inflammatory cells. The expression of this gene in dermal microvascular endothelial cells indicated that this protein product may be involved in inflammatory responses to skin disorders, including psoriasis. Expression in lung microvascular endothelial cells indicated that the protein encoded by this transcript may also be involved in lung disorders including asthma, allergies, chronic obstructive pulmonary disease, and emphysema. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of psoriasis, asthma, allergies, chronic obstructive pulmonary disease, and emphysema.

Panel 5 Islet Summary: Ag5035 Expression of this gene was highest and most prominent in sampels derived from skeletal muscle (CTs=29-33). Please see Panel 1.5 for discussion of this gene in metabolic disease.

AZ. CG56262-01: Ca-Binding Transporter.

Expression of gene CG56262-01 was assessed using the primer-probe sets Ag2896 and Ag2920, described in Tables AZA and AZB. Results of the RTQ-PCR runs are shown in Tables AZC, AZD, AZE, AZF and AZG.

TABLE AZAProbe Name Ag2896StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gtcagcttctcttgctttgaga-3′229001344ProbeTET-5′-cactgtcaggcactcgccaatgt-3′-239321345TAMRAReverse5′-ctgtatttctggaagcattcca-3′229641346

TABLE AZB

Probe Name Ag2920

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-ttgatgtctctgagatccaaca-3′
22
1134
1347

Probe
TET-5′-agtttccgagctctgggcatttccat-3′-
26
1107
1348

TAMRA

Reverse
5′-catgctgtgcaaaattttctc-3′
21
1070
1349

TABLE AZC

CNS_neurodegeneration_v1.0

Column A - Rel. Exp.(%) Ag2896, Run 209734744

Column B - Rel. Exp.(%) Ag2920, Run 209779301

Tissue Name
A
B
Tissue Name
A
B

AD 1 Hippo
46.2
55.1
AH3 4624
45.4
64.6

AD 2 Hippo
65.1
62.0
AH3 4640
61.6
56.6

AD 3 Hippo
49.0
64.2
AD 1 Occipital Ctx
24.3
30.1

AD 4 Hippo
34.2
37.6
AD 2 Occipital Ctx (Missing)
0.3
0.3

AD 5 Hippo
52.5
46.3
AD 3 Occipital Ctx
32.1
35.4

AD 6 Hippo
59.9
67.8
AD 4 Occipital Ctx
46.0
53.2

Control 2 Hippo
76.3
87.1
AD 5 Occipital Ctx
60.3
29.5

Control 4 Hippo
38.7
48.3
AD 5 Occipital Ctx
28.7
55.9

Control (Path) 3 Hippo
38.7
47.0
Control 1 Occipital Ctx
32.5
40.9

AD 1 Temporal Ctx
38.2
41.5
Control 2 Occipital Ctx
60.3
66.4

AD 2 Temporal Ctx
62.9
65.1
Control 3 Occipital Ctx
29.9
42.6

AD 3 Temporal Ctx
39.0
49.7
Control 4 Occipital Ctx
38.4
43.8

AD 4 Temporal Ctx
55.5
52.5
Control (Path) 1 Occipital Ctx
67.8
85.3

AD 5 Inf Temporal Ctx
59.9
61.1
Control (Path) 2 Occipital Ctx
31.6
32.3

AD 5 Sup Temporal Ctx
49.7
45.7
Control (Path) 3 Occipital Ctx
29.9
40.1

AD 6 Inf Temporal Ctx
48.6
48.0
Control (Path) 4 Occipital Ctx
30.4
27.2

AD 6 Sup Temporal Ctx
45.1
52.5
Control 1 Parietal Ctx
46.7
51.8

Control 1 Temporal Ctx
55.5
62.9
Control 2 Parietal Ctx
48.3
46.7

Control 2 Temporal Ctx
81.2
99.3
Control 3 Parietal Ctx
6.5
40.9

Control 3 Temporal Ctx
55.1
54.0
Control (Path) 1 Parietal Ctx
100.0
100.0

Control 3 Temporal Ctx
52.9
47.3
Control (Path) 2 Parietal Ctx
43.2
42.0

AH3 3975
94.6
99.3
Control (Path) 3 Parietal Ctx
33.0
47.3

AH3 3954
64.2
72.2
Control (Path) 4 Parietal Ctx
57.4
62.0

TABLE AZD

Panel 1.3D

Column A - Rel. Exp.(%) Ag2896, Run 167660338

Column B - Rel. Exp.(%) Ag2920, Run 167646813

Tissue Name
A
B
Tissue Name
A
B

Liver adenocarcinoma
36.6
40.1
Kidney (fetal)
23.2
21.6

Pancreas
4.2
7.4
Renal ca. 786-0
15.5
19.6

Pancreatic ca. CAPAN 2
10.1
9.3
Renal ca. A498
9.5
9.4

Adrenal gland
3.3
2.8
Renal ca. RXF 393
17.3
16.6

Thyroid
11.8
18.9
Renal ca. ACHN
10.5
14.5

Salivary gland
6.7
6.6
Renal ca. UO-31
7.7
9.9

Pituitary gland
2.2
2.7
Renal ca. TK-10
12.4
14.7

Brain (fetal)
27.0
27.7
Liver
4.3
3.5

Brain (whole)
81.2
74.2
Liver (fetal)
1.8
2.6

Brain (amygdala)
40.1
40.3
Liver ca. (hepatoblast) HepG2
4.7
4.9

Brain (cerebellum)
30.8
33.0
Lung
5.4
3.2

Brain (hippocampus)
44.8
42.0
Lung (fetal)
4.8
4.7

Brain (substantia nigra)
23.0
21.5
Lung ca. (small cell) LX-1
6.7
6.2

Brain (thalamus)
25.5
31.6
Lung ca. (small cell) NCI-H69
0.0
0.1

Cerebral Cortex
100.0
100.0
Lung ca. (s.cell var.) SHP-77
26.1
31.9

Spinal cord
12.6
12.9
Lung ca. (large cell) NCI-H460
1.2
1.4

glio/astro U87-MG
2.2
2.4
Lung ca. (non-sm. cell) A549
10.4
8.9

glio/astro U-118-MG
9.9
8.1
Lung ca. (non-s.cell) NCI-H23
11.0
12.7

astrocytoma SW1783
8.8
10.1
Lung ca. (non-s.cell) HOP-62
4.9
4.7

neuro*; met SK-N-AS
4.2
3.3
Lung ca. (non-s.cl) NCI-H522
11.4
11.4

astrocytoma SF-539
5.8
5.4
Lung ca. (squam.) SW 900
7.9
8.6

astrocytoma SNB-75
10.2
10.5
Lung ca. (squam.) NCI-H596
0.3
0.4

glioma SNB-19
10.1
11.0
Mammary gland
8.3
8.5

glioma U251
14.1
15.8
Breast ca.* (pl.ef) MCF-7
7.5
8.1

glioma SF-295
6.0
5.9
Breast ca.* (pl.ef) MDA-MB-
6.6
7.1

231

Heart (Fetal)
38.7
40.1
Breast ca.* (pl.ef) T47D
16.2
17.0

Heart
10.7
9.9
Breast ca. BT-549
5.8
5.1

Skeletal muscle (Fetal)
16.0
11.8
Breast ca. MDA-N
19.5
22.5

Skeletal muscle
31.2
28.7
Ovary
10.4
10.3

Bone marrow
0.4
0.6
Ovarian ca. OVCAR-3
11.5
9.2

Thymus
2.5
2.5
Ovarian ca. OVCAR-4
35.6
32.5

Spleen
1.1
1.4
Ovarian ca. OVCAR-5
31.0
34.2

Lymph node
2.6
1.7
Ovarian ca. OVCAR-8
5.4
5.5

Colorectal
14.0
12.3
Ovarian ca. IGROV-1
10.3
10.2

Stomach
4.4
4.0
Ovarian ca. (ascites) SK-OV-3
13.8
18.0

Small intestine
4.4
4.9
Uterus
6.3
8.4

Colon ca. SW480
5.1
5.3
Placenta
0.0
0.0

Colon ca.* SW620 (SW480 met)
14.9
18.7
Prostate
3.2
3.8

Colon ca. HT29
6.8
7.2
Prostate ca.* (bone met) PC-3
16.5
18.3

Colon ca. HCT-116
10.7
10.4
Testis
1.4
1.3

Colon ca. CaCo-2
17.0
21.9
Melanoma Hs688(A).T
2.8
2.6

CC Well to Mod Duff
2.4
2.4
Melanoma* (met) Hs688(B).T
2.6
3.8

(ODO3866)

Colon ca. HCC-2998
9.3
7.6
Melanoma UACC-62
10.9
11.2

Gastric ca. (liver met) NCI-N87
5.7
5.5
Melanoma M14
8.6
5.8

Bladder
5.1
5.1
Melanoma LOX IMVI
12.2
10.8

Trachea
1.9
2.8
Melanoma* (met) SK-MEL-5
24.0
25.2

Kidney
12.4
17.0
Adipose
6.1
6.4

TABLE AZE

Panel 4D

Column A - Rel. Exp.(%) Ag2896, Run 164401737

Column B - Rel. Exp.(%) Ag2920, Run 164403312

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
5.6
7.3
HUVEC IL-1beta
4.9
4.3

Secondary Th2 act
6.8
6.0
HUVEC IFN gamma
19.6
19.8

Secondary Tr1 act
7.4
7.7
HUVEC TNF alpha + IFN gamma
7.8
8.9

Secondary Th1 rest
6.4
6.7
HUVEC TNF alpha + IL4
6.1
7.9

Secondary Th2 rest
7.6
7.1
HUVEC IL-11
10.4
11.8

Secondary Tr1 rest
12.2
9.7
Lung Microvascular EC none
7.5
9.8

Primary Th1 act
12.7
14.5
Lung Microvascular EC TNFalpha +
5.5
6.1

IL-1beta

Primary Th2 act
16.0
15.1
Microvascular Dermal EC none
13.7
12.6

Primary Tr1 act
26.4
22.1
Microsvasular Dermal EC TNFalpha
5.7
6.6

+ IL-1beta

Primary Th1 rest
31.6
33.4
Bronchial epithelium TNFalpha +
15.9
11.9

IL1beta

Primary Th2 rest
19.3
18.7
Small airway epithelium none
4.7
5.3

Primary Tr1 rest
14.7
16.5
Small airway epithelium TNFalpha
35.6
37.1

+ IL-1beta

CD45RA CD4 lymphocyte
6.2
5.1
Coronery artery SMC rest
7.1
6.7

act

CD45RO CD4 lymphocyte
11.2
12.3
Coronery artery SMC TNFalpha +
4.6
5.9

act

IL-1beta

CD8 lymphocyte act
11.6
10.8
Astrocytes rest
27.0
23.8

Secondary CD8 lymphocyte
8.2
9.9
Astrocytes TNFalpha + IL-1beta
30.8
28.1

rest

Secondary CD8 lymphocyte
3.0
3.3
KU-812 (Basophil) rest
8.2
6.3

act

CD4 lymphocyte none
2.8
3.4
KU-812 (Basophil) PMA/ionomycin
22.5
19.9

2ry Th1/Th2/Tr1 anti-CD95
7.3
7.4
CCD1106 (Keratinocytes) none
11.11
1.7

CH11

LAK cells rest
7.1
6.7
CCD1106 (Keratinocytes) TNFalpha
6.8
6.3

+ IL-1beta

LAK cells IL-2
14.7
17.0
Liver cirrhosis
3.0
3.0

LAK cells IL-2 + IL-12
6.9
7.0
Lupus kidney
6.5
6.2

LAK cells IL-2 + IFN
12.8
11.0
NCI-H292 none
63.3
72.7

gamma

LAK cells IL-2 + IL-18
6.7
9.0
NCI-H292 IL-4
57.4
69.7

LAK cells PMA/ionomycin
0.9
0.6
NCI-H292 IL-9
57.0
65.5

NK Cells IL-2 rest
7.2
6.5
NCI-H292 IL-13
30.8
35.6

Two Way MLR 3 day
6.3
6.8
NCI-H292 IFN gamma
29.3
34.4

Two Way MLR 5 day
3.5
3.0
HPAEC none
10.8
11.7

Two Way MLR 7 day
4.2
4.5
HPAEC TNF alpha + IL-1 beta
6.9
6.4

PBMC rest
2.0
1.6
Lung fibroblast none
16.8
17.4

PBMC PWM
27.9
26.2
Lung fibroblast TNF alpha + IL-1
7.4
8.0

beta

PBMC PHA-L
27.5
26.8
Lung fibroblast IL-4
30.6
34.6

Ramos (B cell) none
16.8
16.0
Lung fibroblast IL-9
24.8
24.1

Ramos (B cell) ionomycm
100.0
100.0
Lung fibroblast IL-13
19.6
21.8

B lymphocytes PWM
36.6
22.8
Lung fibroblast IFN gamma
31.4
37.6

B lymphocytes CD40L and
13.5
14.9
Dermal fibroblast CCD1070 rest
10.7
12.0

IL-4

EOL-1 dbcAMP
14.5
15.5
Dermal fibroblast CCD1070
20.6
21.3

alpha

EOL-1 dbcAMP
7.1
6.3
Dermal fibroblast CCD1070 IL-1
6.5
5.9

PMA/ionomycin

beta

Dendritic cells none
0.8
1.5
Dermal fibroblast IFN gamma
10.1
11.3

Dendritic cells LPS
0.1
0.2
Dermal fibroblast IL-4
23.0
23.2

Dendritic cells anti-CD40
0.9
0.7
IBD Colitis 2
2.0
2.3

Monocytes rest
0.1
0.0
IBD Crohn's
3.4
4.8

Monocytes LPS
0.2
0.0
Colon
41.5
50.7

Macrophages rest
4.0
3.4
Lung
15.8
17.2

Macrophages LPS
0.5
0.4
Thymus
57.8
55.5

HUVEC none
12.2
12.8
Kidney
5.0
8.5

HUVEC starved
21.6
20.4

TABLE AZF

Panel 5 Islet

Column A - Rel. Exp.(%) Ag2896, Run 268363565

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
19.6
94709 Donor 2 AM - A adipose
8.3

97476 Patient-07sk skeletal muscle
6.6
94710 Donor 2 AM - B adipose
8.1

97477 Patient-07ut uterus
31.6
94711 Donor 2 AM - C adipose
5.0

97478 Patient-07pl placenta
2.6
94712 Donor 2 AD - A adipose
17.6

99167 Bayer Patient 1
32.5
94713 Donor 2 AD - B adipose
29.5

97482 Patient-08ut uterus
26.6
94714 Donor 2 AD - C adipose
25.7

97483 Patient-08pl placenta
1.2
94742 Donor 3 U - A Mesenchymal
5.7

Stem Cells

97486 Patient-09sk skeletal muscle
8.3
94743 Donor 3 U - B Mesenchymal
5.1

Stem Cells

97487 Patient-09ut uterus
47.6
94730 Donor 3 AM - A adipose
8.7

97488 Patient-09pl placenta
1.3
94731 Donor 3 AM - B adipose
4.4

97492 Patient-10ut uterus
28.3
94732 Donor 3 AM - C adipose
3.4

97493 Patient-10pl placenta
3.0
94733 Donor 3 AD - A adipose
9.9

97495 Patient-11go adipose
47.6
94734 Donor 3 AD - B adipose
4.4

97496 Patient-11sk skeletal muscle
35.1
94735 Donor 3 AD - C adipose
4.6

97497 Patient-11ut uterus
100.0
77138 Liver HepG2untreated
54.7

97498 Patient-11pl placenta
0.4
73556 Heart Cardiac stromal cells
10.6

(primary)

97500 Patient-12go adipose
17.3
81735 Small Intestine
60.7

97501 Patient-12sk skeletal muscle
37.4
72409 Kidney Proximal Convoluted
24.1

Tubule

97502 Patient-12ut uterus
76.3
82685 Small intestine Duodenum
18.8

97503 Patient-12pl placenta
0.9
90650 Adrenal Adrenocortical
3.8

adenoma

94721 Donor 2 U - A Mesenchymal
15.2
72410 Kidney HRCE
70.2

Stem Cells

94722 Donor 2 U - B Mesenchymal
11.9
72411 Kidney HRE
59.5

Stem Cells

94723 Donor 2 U - C Mesenchymal
9.7
73139 Uterus Uterine smooth muscle
8.7

Stem Cells

cells

TABLE AZG

general oncology screening panel_v_2.4

Column A - Rel. Exp. (%) Ag2896, Run 260442400

Column B - Rel. Exp. (%) Ag2920, Run 260443377

Tissue Name
A
B
Tissue Name
A
B

Colon cancer 1
26.6
28.1
Bladder NAT 2
0.5
0.5

CC Margin (ODO3921)
29.9
29.1
Bladder NAT 3
0.2
0.1

Colon cancer 2
26.6
18.0
Bladder NAT 4
13.4
11.0

Colon NAT 2
25.7
20.2
Prostate adenocarcinoma 1
35.8
18.4

Colon cancer 3
52.5
59.0
Prostate adenocarcinoma 2
3.3
2.0

Colon NAT 3
74.7
71.2
Prostate adenocarcinoma 3
19.1
16.0

Colon malignant cancer 4
54.0
53.2
Prostate adenocarcinoma 4
13.2
13.1

Colon NAT 4
28.7
16.0
Prostate NAT 5
2.4
2.8

Lung cancer 1
11.4
9.9
Prostate adenocarcinoma 6
7.9
5.3

Lung NAT 1
1.6
0.5
Prostate adenocarcinoma 7
8.0
5.2

Lung cancer 2
64.2
66.0
Prostate adenocarcinoma 8
1.7
1.4

Lung NAT 2
1.5
0.6
Prostate adenocarcinoma 9
39.8
29.1

Squamous cell carcinoma 3
25.9
25.2
Prostate NAT 10
2.5
0.8

Lung NAT 3
0.6
0.4
Kidney cancer 1
18.9
18.4

Metastatic melanoma 1
32.8
22.5
Kidney NAT 1
15.7
12.5

Melanoma 2
1.8
0.8
Kidney cancer 2
100.0
100.0

Melanoma 3
2.1
1.2
Kidney NAT 2
29.7
29.7

Metastatic melanoma 4
37.6
44.8
Kidney cancer 3
18.0
22.8

Metastatic melanoma 5
79.6
72.7
Kidney NAT 3
15.3
14.7

Bladder cancer 1
1.0
0.3
Kidney cancer 4
31.0
28.3

Bladder NAT 1
0.0
0.0
Kidney NAT 4
19.6
21.9

Bladder cancer 2
8.3
5.7

CNS_neurodegeneration_v1.0 Summary: Ag2896/Ag2920 This gene was found to be down-regulated in the temporal cortex of Alzheimer's disease patients. Up-regulation of this gene or its protein product, or treatment with specific agonists for this receptor is of use in reversing the dementia, memory loss and neuronal death associated with this disease.

Panel 1.3D Summary: Ag2896/Ag2920 Highest expression of this gene was detected in the cerebral cortex (CTs=26). High expression of this gene was seen predominantly in all the regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. This gene encodes a Ca binding transporter. Ca++ is critical for synaptic vesicle release (Kovacs I, Neurochem Int 1998 November; 33(5):399-405). Targeting this gene with a small molecule drug, protein therapeutic or antibody is useful for the treatment of diseases resulting from altered/inappropriate synaptic transmission such as epilepsy, schizophrenia, bipolar disorder, depression, and mania.

This gene also had moderate levels of expression adult and fetal heart, skeletal muscle and liver, and adipose. This gene product is homologous to a mitochondrial calcium-dependent transporter. Since intracellular calcium homeostasis is critically important for energy metabolism and signal transduction, modulation of this gene or gene product is useful as a therapeutic for metabolic and endocrine diseases.

Moderate expression was also seen in almost all the cancer cell lines on this panel. This shows that expression of this gene product is required for cell growth and proliferaton in almost all cell types.

Panel 4D Summary: Ag2896/Ag2920 Moderate to low expression of this gene was detected across a wide range of cells on this panel including epithelium, fibroblasts, and endothelial cells. Lower but still significant levels of expression were also seen in monocytes/macrophages, T and B cells, which all play an importan role in both innate and adaptive immunity. Expression of this gene was highest in the B cell lymphoma cell line, and the NCI H292 mucoepidermoid cell line (CTs=26.4-27). Inhibition of the function of the protein encoded by this transcript with a small molecule drug, protein therapeutic, or antibody is useful for the reduction of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, COPD, emphysema, psoriasis, inflammatory bowel disease, lupus erythematosus, or rheumatoid arthritis.

Panel 5 Islet Summary: Ag2896 This gene showed widespread expression in this panel with highest expression seen in uterus from a non-diabetic patient (CT=28.8). Significant expression of this gene was seen in adipose, skeletal muscle, uterus, kidney, small intestine and a liver cancer cell line, which is in agreement with expression seen in panel 1.3D.

general oncology screening panel_v_—2.4 Summary: Ag2896/Ag2920 Highest expression of this gene was detected in a kidney cancer sample (CTs=27). Prominent expression of this gene was also seen in melanoma and prostate cancer samples. This gene was overexpressed in lung cancer samples when compared to expression in matched normal adjacent tissue. Expression of this gene or its protein product is useful as a marker of lung cancers. Targeting this gene or its protein product with a small molecule drug, protein therapeutic, or antibody is useful in the treatment of these cancers.

BA. CG56398-01: Na/Glucose Cotransporter.

Expression of gene CG56398-01 was assessed using the primer-probe set Ag2925, described in Table BAA. Results of the RTQ-PCR runs are shown in Tables BAB, BAC, BAD and BAE.

TABLE BAAProbe Name Ag2925StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ctccctcacctccatctttaac-3′2211911350ProbeTET-5′-ccatcttcaccatggacctctggaat-3′-2612231351TAMRAReverse5′-atcatgagctccttctcagatg-3′2212651352

TABLE BAB

CNS_neurodegeneration_v1.0

Column A - Rel. Exp.(%) Ag2925, Run 209777392

Tissue Name
A
Tissue Name
A

AD 1 Hippo
51.8
AH3 4624
2.3

AD 2 Hippo
31.9
AH3 4640
10.7

AD 3 Hippo
27.7
AD 1 Occipital Ctx
100.0

AD 4 Hippo
5.7
AD 2 Occipital Ctx (Missing)
5.0

AD 5 Hippo
49.3
AD 3 Occipital Ctx
48.0

AD 6 Hippo
19.6
AD 4 Occipital Ctx
40.3

Control 2 Hippo
50.3
AD 5 Occipital Ctx
28.1

Control 4 Hippo
7.5
AD 5 Occipital Ctx
50.3

Control (Path) 3 Hippo
9.3
Control 1 Occipital Ctx
13.6

AD 1 Temporal Ctx
100.0
Control 2 Occipital Ctx
79.6

AD 2 Temporal Ctx
45.7
Control 3 Occipital Ctx
18.2

AD 3 Temporal Ctx
11.3
Control 4 Occipital Ctx
49.7

AD 4 Temporal Ctx
24.1
Control (Path) 1 Occipital Ctx
55.1

AD 5 Inf Temporal Ctx
92.7
Control (Path) 2 Occipital Ctx
28.1

AD 5 Sup Temporal Ctx
43.2
Control (Path) 3 Occipital Ctx
31.4

AD 6 Inf Temporal Ctx
29.7
Control (Path) 4 Occipital Ctx
13.9

AD 6 Sup Temporal Ctx
17.6
Control 1 Parietal Ctx
25.0

Control 1 Temporal Ctx
2.1
Control 2 Parietal Ctx
52.1

Control 2 Temporal Ctx
35.8
Control 3 Parietal Ctx
34.4

Control 3 Temporal Ctx
13.6
Control (Path) 1 Parietal Ctx
18.2

Control 3 Temporal Ctx
4.8
Control (Path) 2 Parietal Ctx
35.4

AH3 3975
16.2
Control (Path) 3 Parietal Ctx
2.8

AH3 3954
10.0
Control (Path) 4 Parietal Ctx
21.5

TABLE BAC

Panel 1.3D

Column A - Rel. Exp.(%) Ag2925, Run 158046924

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
0.4
Kidney (fetal)
1.2

Pancreas
0.0
Renal ca. 786-0
0.0

Pancreatic ca. CAPAN 2
0.0
Renal ca. A498
0.1

Adrenal gland
0.3
Renal ca. RXF 393
0.0

Thyroid
0.0
Renal ca. ACHN
0.0

Salivary gland
0.0
Renal ca. UO-31
0.0

Pituitary gland
0.4
Renal ca. TK-10
0.0

Brain (fetal)
0.3
Liver
0.2

Brain (whole)
19.5
Liver (fetal)
3.8

Brain (amygdala)
10.5
Liver ca. (hepatoblast) HepG2
0.6

Brain (cerebellum)
4.6
Lung
0.2

Brain (hippocampus)
100.0
Lung (fetal)
0.0

Brain (substantia nigra)
22.2
Lung ca. (small cell) LX-1
0.0

Brain (thalamus)
45.4
Lung ca. (small cell) NCI-H69
0.0

Cerebral Cortex
13.0
Lung ca. (s. cell var.) SHP-77
0.0

Spinal cord
25.9
Lung ca. (large cell) NCI-H460
0.0

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
0.8

glio/astro U-118-MG
0.4
Lung ca. (non-s. cell) NCI-H23
0.0

astrocytoma SW1783
0.1
Lung ca. (non-s. cell) HOP-62
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (non-s. cl) NCI-H522
0.0

astrocytoma SF-539
0.1
Lung ca. (squam.) SW 900
0.0

astrocytoma SNB-75
0.1
Lung ca. (squam.) NCI-H596
0.0

glioma SNB-19
0.0
Mammary gland
0.1

glioma U251
0.0
Breast ca.* (pl. ef) MCF-7
0.0

glioma SF-295
0.0
Breast ca.* (pl. ef) MDA-MB-231
0.5

Heart (Fetal)
0.1
Breast ca.* (pl. ef) T47D
0.0

Heart
0.0
Breast ca. BT-549
0.3

Skeletal muscle (Fetal)
0.1
Breast ca. MDA-N
0.2

Skeletal muscle
0.0
Ovary
0.1

Bone marrow
0.0
Ovarian ca. OVCAR-3
0.0

Thymus
0.0
Ovarian ca. OVCAR-4
0.0

Spleen
0.1
Ovarian ca. OVCAR-5
0.0

Lymph node
0.1
Ovarian ca. OVCAR-8
0.3

Colorectal
0.1
Ovarian ca. IGROV-1
0.0

Stomach
0.0
Ovarian ca. (ascites) SK-OV-3
0.0

Small intestine
1.0
Uterus
0.0

Colon ca. SW480
0.2
Placenta
0.4

Colon ca.* SW620
84.7
Prostate
0.2

(SW480 met)

Colon ca. HT29
0.2
Prostate ca.* (bone met) PC-3
0.0

Colon ca. HCT-116
0.0
Testis
0.3

Colon ca. CaCo-2
0.2
Melanoma Hs688(A).T
0.0

CC Well to Mod Diff
0.1
Melanoma* (met) Hs688(B).T
0.0

(ODO3866)

Colon ca. HCC-2998
0.7
Melanoma UACC-62
0.1

Gastric ca. (liver met)
0.0
Melanoma M14
0.0

NCI-N87

Bladder
0.0
Melanoma LOXIMVI
0.0

Trachea
0.0
Melanoma* (met) SK-MEL-5
0.0

Kidney
2.6
Adipose
0.0

TABLE BAD

Panel 2D

Column A - Rel. Exp.(%) Ag2925, Run 158047169

Tissue Name
A
Tissue Name
A

Normal Colon
2.6
Kidney Margin 8120608
63.7

CC Well to Mod Diff (ODO3866)
0.6
Kidney Cancer 8120613
0.0

CC Margin (ODO3866)
0.5
Kidney Margin 8120614
100.0

CC Gr.2 rectosigmoid (ODO3868)
0.0
Kidney Cancer 9010320
0.4

CC Margin (ODO3868)
0.4
Kidney Margin 9010321
14.2

CC Mod Diff (ODO3920)
2.0
Normal Uterus
0.9

CC Margin (ODO3920)
0.7
Uterine Cancer 064011
0.7

CC Gr.2 ascend colon (ODO3921)
0.0
Normal Thyroid
0.0

CC Margin (ODO3921)
1.2
Thyroid Cancer
0.0

CC from Partial Hepatectomy
1.5
Thyroid Cancer A302152
0.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.7
Thyroid Margin A302153
0.4

Colon mets to lung (OD04451-01)
0.0
Normal Breast
0.6

Lung Margin (OD04451-02)
0.9
Breast Cancer
0.9

Normal Prostate 6546-1
0.6
Breast Cancer (OD04590-01)
1.2

Prostate Cancer (OD04410)
1.2
Breast Cancer Mets (OD04590-03)
0.5

Prostate Margin (OD04410)
1.2
Breast Cancer Metastasis
0.9

Prostate Cancer (OD04720-01)
0.9
Breast Cancer
0.0

Prostate Margin (OD04720-02)
1.1
Breast Cancer
0.9

Normal Lung
0.4
Breast Cancer 9100266
1.4

Lung Met to Muscle (ODO4286)
0.0
Breast Margin 9100265
0.0

Muscle Margin (ODO4286)
0.0
Breast Cancer A209073
44.1

Lung Malignant Cancer (OD03126)
1.4
Breast Margin A209073
1.4

Lung Margin (OD03126)
0.0
Normal Liver
0.0

Lung Cancer (OD04404)
0.8
Liver Cancer
0.0

Lung Margin (OD04404)
0.0
Liver Cancer 1025
0.6

Lung Cancer (OD04565)
0.0
Liver Cancer 1026
1.2

Lung Margin (OD04565)
0.4
Liver Cancer 6004-T
0.3

Lung Cancer (OD04237-01)
0.0
Liver Tissue 6004-N
3.3

Lung Margin (OD04237-02)
0.0
Liver Cancer 6005-T
0.3

Ocular Mel Met to Liver (ODO4310)
0.0
Liver Tissue 6005-N
0.4

Liver Margin (ODO4310)
0.1
Normal Bladder
1.2

Melanoma Metastasis
0.0
Bladder Cancer
0.9

Lung Margin (OD04321)
0.1
Bladder Cancer
0.4

Normal Kidney
48.3
Bladder Cancer (OD04718-01)
0.7

Kidney Ca, Nuclear grade 2 (OD04338)
0.9
Bladder Normal Adjacent
0.0

(OD04718-03)

Kidney Margin (OD04338)
3.8
Normal Ovary
0.0

Kidney Ca Nuclear grade 1/2 (OD04339)
0.4
Ovarian Cancer
0.1

Kidney Margin (OD04339)
70.7
Ovarian Cancer (OD04768-07)
1.6

Kidney Ca, Clear cell type (OD04340)
3.0
Ovary Margin (OD04768-08)
0.0

Kidney Margin (OD04340)
11.7
Normal Stomach
1.0

Kidney Ca, Nuclear grade 3 (OD04348)
0.2
Gastric Cancer 9060358
0.0

Kidney Margin (OD04348)
2.1
Stomach Margin 9060359
0.0

Kidney Cancer (OD04622-01)
0.0
Gastric Cancer 9060395
0.4

Kidney Margin (OD04622-03)
2.3
Stomach Margin 9060394
0.7

Kidney Cancer (OD04450-01)
0.0
Gastric Cancer 9060397
2.4

Kidney Margin (OD04450-03)
5.0
Stomach Margin 9060396
0.4

Kidney Cancer 8120607
0.3
Gastric Cancer 064005
0.6

TABLE BAE

Panel 4D

Column A - Rel. Exp.(%) Ag2925, Run 158047348

Tissue Name
A

Secondary Th1 act
1.7

Secondary Th2 act
0.0

Secondary Tr1 act
0.6

Secondary Th1 rest
0.0

Secondary Th2 rest
0.8

Secondary Tr1 rest
0.0

Primary Th1 act
0.6

Primary Th2 act
0.7

Primary Tr1 act
0.6

Primary Th1 rest
0.8

Primary Th2 rest
1.9

Primary Tr1 rest
1.6

CD45RA CD4 lymphocyte act
0.5

CD45RO CD4 lymphocyte act
0.6

CD8 lymphocyte act
0.5

Secondary CD8 lymphocyte rest
0.3

Secondary CD8 lymphocyte act
0.0

CD4 lymphocyte none
0.1

2ry Th1/Th2/Tr1 anti-CD95
1.2

CH11

LAK cells rest
1.1

LAK cells IL-2
1.1

LAK cells IL-2 + IL-12
1.1

LAK cells IL-2 + IFN gamma
0.0

LAK cells IL-2 + IL-18
0.4

LAK cells PMA/ionomycin
1.4

NK Cells IL-2 rest
0.7

Two Way MLR 3 day
2.3

Two Way MLR 5 day
0.8

Two Way MLR 7 day
0.5

PBMC rest
0.0

PBMC PWM
1.1

PBMC PHA-L
0.0

Ramos (B cell) none
0.0

Ramos (B cell) ionomycin
0.0

B lymphocytes PWM
0.6

B lymphocytes CD40L and IL-4
0.4

EOL-1 dbcAMP
0.0

EOL-1 dbcAMP
0.0

PMA/ionomycin

Dendritic cells none
1.1

Dendritic cells LPS
1.0

Dendritic cells anti-CD40
1.1

Monocytes rest
0.6

Monocytes LPS
0.0

Macrophages rest
2.2

Macrophages LPS
0.0

HUVEC none
0.8

HUVEC starved
1.6

HUVEC IL-1beta
0.0

HUVEC IFN gamma
0.0

HUVEC TNF alpha + IFN gamma
0.0

HUVEC TNF alpha + IL4
0.0

HUVEC IL-11
0.6

Lung Microvascular EC none
0.2

Lung Microvascular EC TNFalpha + IL-
0.0

1beta

Microvascular Dermal EC none
0.0

Microsvasular Dermal EC TNFalpha + IL-
0.0

1beta

Bronchial epithelium TNFalpha + IL1beta
0.0

Small airway epithelium none
0.0

Small airway epithelium TNFalpha + IL-
0.0

1beta

Coronery artery SMC rest
0.0

Coronery artery SMC TNFalpha + IL-1beta
0.0

Astrocytes rest
0.0

Astrocytes TNFalpha + IL-1beta
0.0

KU-812 (Basophil) rest
0.0

KU-812 (Basophil) PMA/ionomycin
0.0

CCD1106 (Keratinocytes) none
0.0

CCD1106 (Keratinocytes) TNFalpha + IL-
0.0

1beta

Liver cirrhosis
2.8

Lupus kidney
1.2

NCI-H292 none
0.5

NCI-H292 IL-4
0.2

NCI-H292 IL-9
1.1

NCI-H292 IL-13
0.6

NCI-H292 IFN gamma
0.6

HPAEC none
1.3

HPAEC TNF alpha + IL-1 beta
0.1

Lung fibroblast none
0.7

Lung fibroblast TNF alpha + IL-1 beta
0.0

Lung fibroblast IL-4
0.3

Lung fibroblast IL-9
0.0

Lung fibroblast IL-13
0.0

Lung fibroblast IFN gamma
0.0

Dermal fibroblast CCD1070 rest
0.0

Dermal fibroblast CCD1070 TNF alpha
0.0

Dermal fibroblast CCD1070 IL-1 beta
0.0

Dermal fibroblast IFN gamma
0.0

Dermal fibroblast IL-4
0.0

IBD Colitis 2
0.0

IBD Crohn's
2.9

Colon
100.0

Lung
2.1

Thymus
85.3

Kidney
2.9

CNS_neurodegeneration_v1.0 Summary: Ag2925 This gene was found to be upregulated in the temporal cortex of Alzheimer's disease patients. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful for decreasing neuronal death and as a treatment for this disease.

Panel 1.3D Summary: Ag2925 Expression of this gene was brain-specific. Highest expression was detected in the hippocampus (CT=28) a region that degenerates in Alzheimer's disease. Expression of this gene or its protein product is useful for distinguishing brain tissue from non-neural tissue. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of neurodegenerative diseases.

Panel 2D Summary: Ag2925 This gene was most highly expressed in a normal kidney sample (CT=28.95). Expression of this gene was lost in the adjacent cancer samples. The loss of expression of this gene or its protein product is useful as a marker for kidney cancer. This gene was also expressed at low levels in breast and bladder cancer samples and was absent or extremely low in normal adjacent tissue. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of breast and bladder cancer and as a diagnostic marker for the presence of these cancers.

Panel 4D Summary: Ag2925 Expression of this transcript was almost exclusively restricted to colon and thymus, with highest expression in normal colon (CT=29). This gene was expressed at much lower levels in IBD colon. The protein encoded by this transcript is involved in normal tissue/cellular functions in the kidney and colon. Loss-of-expression of this protein is useful as a diagnostic marker for lupus or IBD.

BB. CG56645-03 and CG56645-04: Sodium Glucose Cotransporter.

Expression of genes CG56645-03 and CG56645-04 were assessed using the primer-probe sets Ag2966 and Ag6497, described in Tables BBA and BBB. Results of the RTQ-PCR runs are shown in Tables BBC, BBD and BBE.

TABLE BBAProbe Name Ag2966StartSEQ IDPrimersSequencesLengthPositionNoForward5′-agcgggcaactcttcatcta-3′2013881353ProbeTET-5′-atgcagtcagtgaccagctccctg-3′-2414091354TAMRAReverse5′-caggacaaagactgcagtcact-3′2214411355

TABLE BBB

Probe Name Ag6497

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-tcatagtggcactcatcgg-3′
19
1329
1356

Probe
TET-5′-aactcttcatctacatgcagtcagtgac
30
1395
1357

ca-3′-TAMRA

Reverse
5′-ctatcaggcccaggacaaa-3′
19
1454
1358

TABLE BBC

Panel 1.3D

Column A - Rel. Exp. (%) Ag2966, Run 160658385

Column B - Rel. Exp. (%) Ag2966, Run 165701959

Tissue Name
A
B
Tissue Name
A
B

Liver adenocarcinoma
0.0
0.0
Kidney (fetal)
1.0
0.0

Pancreas
0.2
1.3
Renal ca. 786-0
0.2
0.0

Pancreatic ca. CAPAN 2
0.0
0.0
Renal ca. A498
0.0
0.3

Adrenal gland
0.2
0.0
Renal ca. RXF 393
0.0
0.5

Thyroid
0.3
0.0
Renal ca. ACHN
0.3
0.0

Salivary gland
0.1
0.4
Renal ca. UO-31
0.0
0.0

Pituitary gland
0.0
0.0
Renal ca. TK-10
0.0
0.0

Brain (fetal)
0.0
0.0
Liver
0.6
0.9

Brain (whole)
0.0
0.3
Liver (fetal)
0.4
0.0

Brain (amygdala)
0.0
0.0
Liver ca. (hepatoblast) HepG2
0.3
0.0

Brain (cerebellum)
0.0
0.0
Lung
0.8
0.6

Brain (hippocampus)
0.5
0.3
Lung (fetal)
1.4
1.4

Brain (substantia nigra)
0.0
0.0
Lung ca. (small cell) LX-1
0.6
0.0

Brain (thalamus)
0.0
0.5
Lung ca. (small cell) NCI-H69
0.0
0.0

Cerebral Cortex
0.0
0.0
Lung ca. (s. cell var.) SHP-77
0.3
0.4

Spinal cord
0.2
0.2
Lung ca. (large cell) NCI-H460
0.2
0.0

glio/astro U87-MG
0.0
0.0
Lung ca. (non-sm. cell) A549
0.8
0.7

glio/astro U-118-MG
0.0
0.0
Lung ca. (non-s. cell) NCI-H23
0.0
0.0

astrocytoma SW1783
0.0
0.0
Lung ca. (non-s. cell) HOP-62
1.6
2.2

neuro*; met SK-N-AS
0.0
0.4
Lung ca. (non-s. cl) NCI-H522
0.5
0.0

astrocytoma SF-539
0.0
0.0
Lung ca. (squam.) SW 900
0.0
0.0

astrocytoma SNB-75
0.0
0.0
Lung ca. (squam.) NCI-H596
0.0
0.0

glioma SNB-19
0.0
0.4
Mammary gland
0.3
0.7

glioma U251
0.0
0.4
Breast ca.* (pl. ef) MCF-7
0.2
0.0

glioma SF-295
0.0
0.0
Breast ca.* (pl. ef) MDA-MB-231
0.0
0.0

Heart (Fetal)
0.0
0.0
Breast ca.* (pl. ef) T47D
0.0
0.0

Heart
0.0
0.0
Breast ca. BT-549
0.2
0.0

Skeletal muscle (Fetal)
3.9
0.3
Breast ca. MDA-N
0.0
0.0

Skeletal muscle
0.0
0.0
Ovary
0.5
0.0

Bone marrow
6.9
2.5
Ovarian ca. OVCAR-3
0.0
0.0

Thymus
1.9
0.9
Ovarian ca. OVCAR-4
0.0
0.4

Spleen
4.2
1.0
Ovarian ca. OVCAR-5
0.3
0.0

Lymph node
3.0
5.4
Ovarian ca. OVCAR-8
0.0
0.0

Colorectal
0.5
0.0
Ovarian ca. IGROV-1
0.0
0.0

Stomach
0.9
0.0
Ovarian ca. (ascites) SK-OV-3
0.0
0.0

Small intestine
1.5
0.5
Uterus
0.0
0.5

Colon ca. SW480
0.8
0.0
Placenta
0.0
0.0

Colon ca.* SW620 (SW480 met)
0.0
0.0
Prostate
0.0
0.0

Colon ca. HT29
0.0
0.0
Prostate ca.* (bone met) PC-3
0.0
0.0

Colon ca. HCT-116
0.0
0.0
Testis
1.6
0.8

Colon ca. CaCo-2
0.0
0.0
Melanoma Hs688(A).T
0.0
0.0

CC Well to Mod Diff (ODO3866)
0.3
0.3
Melanoma* (met) Hs688(B).T
0.0
0.0

Colon ca. HCC-2998
0.3
0.0
Melanoma UACC-62
0.0
0.0

Gastric ca. (liver met) NCI-N87
0.2
0.7
Melanoma M14
0.0
0.0

Bladder
0.2
0.3
Melanoma LOX IMVI
0.0
0.0

Trachea
0.6
0.0
Melanoma* (met) SK-MEL-5
0.0
0.0

Kidney
100.0
100.0
Adipose
0.1
0.6

TABLE BBD

Panel 2D

Column A - Rel. Exp.(%) Ag2966, Run 160658389

Tissue Name
A
Tissue Name
A

Normal Colon
0.2
Kidney Margin 8120608
91.4

CC Well to Mod Diff (ODO3866)
0.1
Kidney Cancer 8120613
0.1

CC Margin (ODO3866)
0.3
Kidney Margin 8120614
100.0

CC Gr.2 rectosigmoid (ODO3868)
0.3
Kidney Cancer 9010320
0.4

CC Margin (ODO3868)
0.1
Kidney Margin 9010321
66.9

CC Mod Diff (ODO3920)
0.6
Normal Uterus
0.2

CC Margin (ODO3920)
0.4
Uterine Cancer 064011
0.4

CC Gr.2 ascend colon (ODO3921)
0.4
Normal Thyroid
0.1

CC Margin (ODO3921)
0.3
Thyroid Cancer
0.0

CC from Partial Hepatectomy
0.4
Thyroid Cancer A302152
0.0

(ODO4309) Mets

Liver Margin (ODO4309)
0.2
Thyroid Margin A302153
0.5

Colon mets to lung (OD04451-01)
0.5
Normal Breast
0.8

Lung Margin (OD04451-02)
0.1
Breast Cancer
0.3

Normal Prostate 6546-1
0.0
Breast Cancer (OD04590-01)
0.8

Prostate Cancer (OD04410)
0.2
Breast Cancer Mets (OD04590-03)
0.8

Prostate Margin (OD04410)
0.0
Breast Cancer Metastasis
0.9

Prostate Cancer (OD04720-01)
0.1
Breast Cancer
0.2

Prostate Margin (OD04720-02)
0.2
Breast Cancer
0.4

Normal Lung
1.5
Breast Cancer 9100266
0.1

Lung Met to Muscle (ODO4286)
0.2
Breast Margin 9100265
0.0

Muscle Margin (ODO4286)
0.0
Breast Cancer A209073
0.2

Lung Malignant Cancer (OD03126)
0.2
Breast Margin A209073
0.3

Lung Margin (OD03126)
0.4
Normal Liver
0.1

Lung Cancer (OD04404)
0.4
Liver Cancer
0.1

Lung Margin (OD04404)
0.4
Liver Cancer 1025
0.2

Lung Cancer (OD04565)
0.2
Liver Cancer 1026
0.0

Lung Margin (OD04565)
0.4
Liver Cancer 6004-T
0.1

Lung Cancer (OD04237-01)
0.1
Liver Tissue 6004-N
0.1

Lung Margin (OD04237-02)
0.0
Liver Cancer 6005-T
0.0

Ocular Mel Met to Liver (ODO4310)
1.8
Liver Tissue 6005-N
0.0

Liver Margin (ODO4310)
0.0
Normal Bladder
0.2

Melanoma Metastasis
0.1
Bladder Cancer
0.1

Lung Margin (OD04321)
0.4
Bladder Cancer
0.1

Normal Kidney
29.9
Bladder Cancer (0D04718-01)
0.1

Kidney Ca, Nuclear grade 2 (OD04338)
9.4
Bladder Normal Adjacent

(OD04718-03)
0.1

Kidney Margin (OD04338)
26.2
Normal Ovary
0.0

Kidney Ca Nuclear grade 1/2 (OD04339)
1.3
Ovarian Cancer
0.1

Kidney Margin (OD04339)
75.8
Ovarian Cancer (OD04768-07)
0.0

Kidney Ca, Clear cell type (OD04340)
29.5
Ovary Margin (OD04768-08)
0.0

Kidney Margin (OD04340)
27.5
Normal Stomach
0.1

Kidney Ca, Nuclear grade 3 (OD04348)
0.7
Gastric Cancer 9060358
0.1

Kidney Margin (OD04348)
11.4
Stomach Margin 9060359
0.1

Kidney Cancer (OD04622-01)
0.9
Gastric Cancer 9060395
0.1

Kidney Margin (OD04622-03)
9.6
Stomach Margin 9060394
0.1

Kidney Cancer (OD04450-01)
0.8
Gastric Cancer 9060397
0.1

Kidney Margin (OD04450-03)
8.2
Stomach Margin 9060396
0.0

Kidney Cancer 8120607
0.6
Gastric Cancer 064005
0.3

TABLE BBE

Panel 4D

Column A - Rel. Exp.(%) Ag2966, Run 160660646

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.3

Secondary Th2 act
0.0
HUVEC IFN gamma
0.9

Secondary Tr1 act
0.7
HUVEC TNF alpha + IFN gamma
0.3

Secondary Th1 rest
0.2
HUVEC TNF alpha + IL4
0.5

Secondary Th2 rest
1.6
HUVEC IL-11
0.8

Secondary Tr1 rest
1.5
Lung Microvascular EC none
2.0

Primary Th1 act
0.3
Lung Microvascular EC TNFalpha + IL-
0.8

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
1.9

Primary Tr1 act
0.3
Microsvasular Dermal EC TNFalpha + IL-
1.7

1beta

Primary Th1 rest
4.8
Bronchial epithelium TNFalpha + IL1beta
0.0

Primary Th2 rest
2.1
Small airway epithelium none
0.0

Primary Tr1 rest
3.4
Small airway epithelium TNFalpha + IL-
0.3

1beta

CD45RA CD4 lymphocyte act
0.6
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
1.1
Coronery artery SMC TNFalpha + IL-1beta
0.3

CD8 lymphocyte act
0.3
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
1.3
Astrocytes TNFalpha + IL-1beta
0.3

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.3

CD4 lymphocyte none
1.7
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.8
CCD1106 (Keratinocytes) none
0.1

CH11

LAK cells rest
2.1
CCD1106 (Keratinocytes) TNFalpha + IL-
0.0

1beta

LAK cells IL-2
0.4
Liver cirrhosis
0.4

LAK cells IL-2 + IL-12
0.3
Lupus kidney
1.0

LAK cells IL-2 + IFN gamma
0.6
NCI-H292 none
0.6

LAK cells IL-2 + IL-18
0.6
NCI-H292 IL-4
0.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
0.0

NK Cells IL-2 rest
0.6
NCI-H292 IL-13
0.0

Two Way MLR 3 day
1.1
NCI-H292 IFN gamma
0.0

Two Way MLR 5 day
1.0
HPAEC none
0.6

Two Way MLR 7 day
0.5
HPAEC TNF alpha + IL-1 beta
0.0

PBMC rest
0.6
Lung fibroblast none
0.0

PBMC PWM
1.1
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PHA-L
0.2
Lung fibroblast IL-4
0.0

Ramos (B cell) none
1.7
Lung fibroblast IL-9
0.0

Ramos (B cell) ionomycin
1.1
Lung fibroblast IL-13
0.0

B lymphocytes PWM
1.4
Lung fibroblast IFN gamma
0.2

B lymphocytes CD40L and IL-4
4.7
Dermal fibroblast CCD1070 rest
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
1.4

EOL-1 dbcAMP
0.1
Dermal fibroblast CCD1070 IL-1 beta
0.0

PMA/ionomycin

Dendritic cells none
0.5
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells anti-CD40
0.5
IBD Colitis 2
0.2

Monocytes rest
1.2
IBD Crohn's
0.0

Monocytes LPS
0.0
Colon
4.9

Macrophages rest
0.2
Lung
3.1

Macrophages LPS
0.0
Thymus
100.0

HUVEC none
0.5
Kidney
4.6

HUVEC starved
0.3

Panel 1.3D Summary: Ag2966 Expression of this gene, a sodium-glucose cotransporter homolog, was limited to the kidney (CTs=29). This restricted expression was in agreement with published data, where secondary active transport of glucose in the kidney is mediated by sodium glucose cotransporter. (Bissonnette P. J Physiol 1999 Oct. 15; 520 Pt 2:359-71). Expression of this gene or its protein product is useful as a marker of kidney tissue. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of diseases that affect the kidney, including diabetes.

Panel 2D Summary: Ag2966 Expression of this gene was predominantly limited to the kidney. The expression was downregulated in kidney cancer samples. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of diseases that affect the kidney, including kidney cancer.

Panel 4D Summary: Ag2966 Expression of this gene was predominantly found in normal tissue from thymus, lung, colon and kidney. This expression profile indicates that the protein product is involved in glucose transport and normal homeostasis in these tissues. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful for maintaining or restoring normal function to these organs during inflammation.

BC. CG56667-01: GPCR.

Expression of gene CG56667-01 was assessed using the primer-probe set Ag2973, described in Table BCA. Results of the RTQ-PCR runs are shown in Table BCB.

TABLE BCAProbe Name Ag2973StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gctgtgtggctcaagtctattt-3′222871359ProbeTET-5′-ttctctgcctttgcatctgctgagct-3′-263101360TAMRAReverse5′-agcggtcataagacatgacagt-3′223461361

TABLE BCB

Panel 4D

Column A - Rel. Exp.(%) Ag2973, Run 164329850

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
11.7
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNFalpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.0
Microsvasular Dermal EC TNFalpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNFalpha + IL1beta
0.0

Primary Th2 rest
6.0
Small airway epithelium none
0.0

Primary Tr1 rest
0.0
Small airway epithelium TNFalpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNFalpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNFalpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNFalpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
100.0

LAK cells IL-2 + IL-12
0.0
Lupus kidney
9.7

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
0.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
0.0

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
0.0

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1 beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.0

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-4
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-9
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
0.0

B lymphocytes PWM
0.0
Lung fibroblast IFN gamma
0.0

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells anti-CD40
0.0
IBD Colitis 2
0.0

Monocytes rest
0.0
IBD Crohn's
0.0

Monocytes LPS
0.0
Colon
8.7

Macrophages rest
0.0
Lung
6.6

Macrophages LPS
0.0
Thymus
13.9

HUVEC none
0.0
Kidney
0.0

HUVEC starved
0.0

Panel 4D Summary: Ag2973 Significant expression of the CG56667-01 gene was detected in a liver cirrhosis sample (CT=32.7). Expression of this gene was not detected in normal liver in Panel 1.3D, suggesting that its expression is unique to liver cirrhosis. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of fibrosis that occurs in liver cirrhosis. Expression of this gene or expressed protein is useful in the diagnosis of liver cirrhosis.

BD. CG56868-01: ADAM7.

Expression of gene CG56868-01 was assessed using the primer-probe sets Ag1322, Ag1322b, Ag2071 and Ag2098, described in Tables BDA, BDB, BDC and BDD. Results of the RTQ-PCR runs are shown in Table BDE.

TABLE BDAProbe Name Ag1322StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ggtatgtgcctgccctattatt-3′229721362ProbeTET-5′-ccaccagtatcattaaggatcttttacc309941363tg-3′-TAMRAReverse5′-gccattctgtttgcaattatgt-3′2210301364

TABLE BDB

Probe Name Ag1322b

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-ggtatgtgcctgccctattatt-3′
22
972
1365

Probe
TET-5′-ccaccagtatcattaaggatcttttacc
30
994
1366

tg-3′-TAMRA

Reverse
5′-gccattctgtttgcaattatgt-3′
22
1030
1367

TABLE BDC

Probe Name Ag2071

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-tgccagaaattcatttcctaaa-3′
22
2236
1368

Probe
TET-5′-ccttggaaagcctgcccactagtttt-3′-
26
2275
1369

TAMRA

Reverse
5′-agtgtgatgtagtggggacttg-3′
22
2302
1370

TABLE BDD

Probe Name Ag2098

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-tgccagaaattcatttcctaaa-3′
22
2236
1371

Probe
TET-5′-ccttggaaagcctgcccactagtttt-3′-
26
2275
1372

TAMRA

Reverse
5′-agtgtgatgtagtggggacttg-3′
22
2302
1373

TABLE BDE

Panel 1.2

Column A - Rel. Exp.(%) Ag1322, Run 133804727

Tissue Name
A
Tissue Name
A

Endothelial cells
0.0
Renal ca. 786-0
0.0

Heart (Fetal)
0.0
Renal ca. A498
0.0

Pancreas
0.2
Renal ca. RXF 393
0.0

Pancreatic ca. CAPAN 2
0.0
Renal ca. ACHN
0.0

Adrenal gland
0.2
Renal ca. UO-31
0.0

Thyroid
0.0
Renal ca. TK-10
0.0

Salivary gland
0.1
Liver
0.0

Pituitary gland
0.0
Liver (fetal)
0.2

Brain (fetal)
0.0
Liver ca. (hepatoblast) HepG2
0.0

Brain (whole)
0.0
Lung
0.0

Brain (amygdala)
0.0
Lung (fetal)
0.1

Brain (cerebellum)
0.0
Lung ca. (small cell) LX-1
0.0

Brain (hippocampus)
0.0
Lung ca. (small cell) NCI-H69
0.0

Brain (thalamus)
0.0
Lung ca. (s. cell var.) SHP-77
0.0

Cerebral Cortex
0.0
Lung ca. (large cell)NCI-H460
0.0

Spinal cord
0.1
Lung ca. (non-sm. cell) A549
0.0

glio/astro U87-MG
0.0
Lung ca. (non-s. cell) NCI-H23
0.0

glio/astro U-118-MG
0.0
Lung ca. (non-s. cell) HOP-62
0.0

astrocytoma SW1783
0.0
Lung ca. (non-s. cl) NCI-H522
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (squam.) SW 900
0.0

astrocytoma SF-539
0.0
Lung ca. (squam.) NCI-H596
0.0

astrocytoma SNB-75
0.0
Mammary gland
0.0

glioma SNB-19
0.0
Breast ca.* (pl. ef) MCF-7
0.0

glioma U251
0.1
Breast ca.* (pl. ef) MDA-MB-231
0.0

glioma SF-295
0.0
Breast ca.* (pl. ef) T47D
0.0

Heart
0.0
Breast ca. BT-549
0.0

Skeletal muscle
0.0
Breast ca. MDA-N
0.0

Bone marrow
0.0
Ovary
0.0

Thymus
0.0
Ovarian ca. OVCAR-3
0.0

Spleen
0.0
Ovarian ca. OVCAR-4
0.0

Lymph node
0.1
Ovarian ca. OVCAR-5
0.0

Colorectal
0.0
Ovarian ca. OVCAR-8
0.0

Stomach
0.1
Ovarian ca. IGROV-1
0.0

Small intestine
0.0
Ovarian ca. (ascites) SK-OV-3
0.0

Colon ca. SW480
0.0
Uterus
0.0

Colon ca.* SW620 (SW480 met)
0.0
Placenta
0.0

Colon ca. HT29
0.0
Prostate
2.1

Colon ca. HCT-116
0.0
Prostate ca.* (bone met) PC-3
0.0

Colon ca. CaCo-2
0.0
Testis
100.0

CC Well to Mod Diff (ODO3866)
0.0
Melanoma Hs688(A).T
0.0

Colon ca. HCC-2998
0.0
Melanoma* (met) Hs688(B).T
0.0

Gastric ca. (liver met) NCI-N87
0.0
Melanoma UACC-62
0.0

Bladder
0.1
Melanoma M14
0.0

Trachea
0.0
Melanoma LOX IMVI
0.0

Kidney
0.0
Melanoma* (met) SK-MEL-5
0.0

Kidney (fetal)
0.0

Panel 1.2 Summary: Ag1322 Expression of this gene was highest in testis (CT value=29). Low expression was also seen in prostate (CT value=34.6). The gene or encoded protein is useful as a marker for these tissues. This gene encodes a protein with homology to ADAM proteins, which are membrane disintegrin-metalloproteases. The expression of several other ADAM proteins has been shown to be testis-specific and these proteins are thought to play a role in fertilization (Hooft van Huijsduijnen R. (1998) ADAM 20 and 21; two novel human testis-specific membrane metalloproteases with similarity to fertilin-alpha. Gene 206: 273-282). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of diseases of the prostate and testis, including infertility.

BE. CG56870-01: NDR3.

Expression of genes CG56870-01 and CG56870-06 was assessed using the primer-probe set Ag2075, described in Table BEA. Results of the RTQ-PCR runs are shown in Tables BEB, BEC, BED and BEE.

TABLE BEAProbe Name Ag2075StartSEQ IDPrimersSequencesLengthPositionNoForward5′-catggatgaacttcaggatgtt-3′22701374ProbeTET-5′-cagctcacagagatcaaaccacttct-3′-26921375TAMRAReverse5′-tgacagtcaaagtcctggaagt-3′221411376

TABLE BEB

Panel 1.3D

Column A - Rel. Exp.(%) Ag2075, Run 152355202

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
11.9
Kidney (fetal)
1.4

Pancreas
0.8
Renal ca. 786-0
3.5

Pancreatic ca. CAPAN 2
1.6
Renal ca. A498
12.9

Adrenal gland
2.4
Renal ca. RXF 393
1.5

Thyroid
1.8
Renal ca. ACHN
1.7

Salivary gland
1.2
Renal ca. UO-31
6.8

Pituitary gland
2.4
Renal ca. TK-10
2.8

Brain (fetal)
3.2
Liver
0.4

Brain (whole)
25.2
Liver (fetal)
0.8

Brain (amygdala)
14.1
Liver ca. (hepatoblast) HepG2
6.7

Brain (cerebellum)
10.8
Lung
2.1

Brain (hippocampus)
39.8
Lung (fetal)
3.2

Brain (substantia nigra)
2.7
Lung ca. (small cell) LX-1
4.1

Brain (thalamus)
12.4
Lung ca. (small cell) NCI-H69
3.8

Cerebral Cortex
100.0
Lung ca. (s. cell var.) SHP-77
3.8

Spinal cord
3.5
Lung ca. (large cell)NCI-H460
0.6

glio/astro U87-MG
6.4
Lung ca. (non-sm. cell) A549
3.0

glio/astro U-118-MG
10.4
Lung ca. (non-s. cell) NCI-H23
7.7

astrocytoma SW1783
5.1
Lung ca. (non-s. cell) HOP-62
3.1

neuro*; met SK-N-AS
6.2
Lung ca. (non-s. cl) NCI-H522
6.3

astrocytoma SF-539
5.4
Lung ca. (squam.) SW 900
1.4

astrocytoma SNB-75
6.7
Lung ca. (squam.) NCI-H596
1.4

glioma SNB-19
3.1
Mammary gland
2.4

glioma U251
2.0
Breast ca.* (pl. ef) MCF-7
1.8

glioma SF-295
3.4
Breast ca.* (pl. ef) MDA-MB-231
11.6

Heart (Fetal)
6.7
Breast ca.* (pl. ef) T47D
9.0

Heart
1.4
Breast ca. BT-549
4.8

Skeletal muscle (Fetal)
18.0
Breast ca. MDA-N
4.2

Skeletal muscle
0.7
Ovary
13.4

Bone marrow
0.9
Ovarian ca. OVCAR-3
1.8

Thymus
0.9
Ovarian ca. OVCAR-4
1.6

Spleen
3.7
Ovarian ca. OVCAR-5
1.8

Lymph node
1.9
Ovarian ca. OVCAR-8
4.9

Colorectal
3.3
Ovarian ca. IGROV-1
1.6

Stomach
2.7
Ovarian ca. (ascites) SK-OV-3
5.8

Small intestine
2.5
Uterus
2.4

Colon ca. SW480
10.4
Placenta
1.2

Colon ca.* SW620 (SW480 met)
3.7
Prostate
6.0

Colon ca. HT29
4.6
Prostate ca.* (bone met) PC-3
4.5

Colon ca. HCT-116
3.6
Testis
1.7

Colon ca. CaCo-2
10.3
Melanoma Hs688(A).T
3.8

CC Well to Mod Diff (ODO3866)
3.2
Melanoma* (met) Hs688(B).T
4.4

Colon ca. HCC-2998
2.6
Melanoma UACC-62
1.4

Gastric ca. (liver met) NCI-N87
3.1
Melanoma M14
1.8

Bladder
0.8
Melanoma LOX IMVI
3.3

Trachea
2.0
Melanoma* (met) SK-MEL-5
2.4

Kidney
1.3
Adipose
1.2

TABLE BEC

Panel 2.2

Column A - Rel. Exp.(%) Ag2075, Run 174255357

Tissue Name
A
Tissue Name
A

Normal Colon
27.7
Kidney Margin (OD04348)
46.3

Colon cancer (OD06064)
52.9
Kidney malignant cancer
19.2

(OD06204B)

Colon Margin (OD06064)
30.1
Kidney normal adjacent tissue
14.3

(OD06204E)

Colon cancer (OD06159)
5.5
Kidney Cancer (OD04450-01)
66.0

Colon Margin (OD06159)
21.0
Kidney Margin (OD04450-03)
19.8

Colon cancer (OD06297-04)
22.2
Kidney Cancer 8120613
3.0

Colon Margin (OD06297-05)
41.8
Kidney Margin 8120614
11.0

CC Gr.2 ascend colon (ODO3921)
4.0
Kidney Cancer 9010320
6.8

CC Margin (ODO3921)
6.7
Kidney Margin 9010321
9.7

Colon cancer metastasis (OD06104)
11.1
Kidney Cancer 8120607
35.6

Lung Margin (OD06104)
42.6
Kidney Margin 8120608
13.7

Colon mets to lung (OD04451-01)
117.8
Normal Uterus
59.5

Lung Margin (OD04451-02)
9.3
Uterine Cancer 064011
9.7

Normal Prostate
51.4
Normal Thyroid
8.8

Prostate Cancer (OD04410)
23.0
Thyroid Cancer
11.2

Prostate Margin (OD04410)
19.3
Thyroid Cancer A302152
17.9

Normal Ovary
22.8
Thyroid Margin A302153
5.5

Ovarian cancer (OD06283-03)
9.9
Normal Breast
33.2

Ovarian Margin (OD06283-07)
17.1
Breast Cancer
8.5

Ovarian Cancer
18.0
Breast Cancer
36.1

Ovarian cancer (OD06145)
6.6
Breast Cancer (OD04590-01)
18.4

Ovarian Margin (OD06145)
12.5
Breast Cancer Mets (OD04590-03)
31.9

Ovarian cancer (OD06455-03)
14.7
Breast Cancer Metastasis
45.4

Ovarian Margin (OD06455-07)
21.8
Breast Cancer
11.5

Normal Lung
21.9
Breast Cancer 9100266
20.9

Invasive poor diff. lung adeno
17.6
Breast Margin 9100265
35.1

(ODO4945-01

Lung Margin (ODO4945-03)
12.2
Breast Cancer A209073
9.7

Lung Malignant Cancer (OD03126)
8.7
Breast Margin A209073
22.2

Lung Margin (OD03126)
7.4
Breast cancer (OD06083)
100.0

Lung Cancer (OD05014A)
9.9
Breast cancer node metastasis
63.7

(OD06083)

Lung Margin (OD05014B)
21.8
Normal Liver
9.9

Lung cancer (OD06081)
5.1
Liver Cancer 1026
5.6

Lung Margin (OD06081)
7.9
Liver Cancer 1025
13.5

Lung Cancer (OD04237-01)
17.4
Liver Cancer 6004-T
4.8

Lung Margin (OD04237-02)
24.0
Liver Tissue 6004-N
9.3

Ocular Mel Met to Liver (ODO4310)
9.7
Liver Cancer 6005-T
15.7

Liver Margin (ODO4310)
4.6
Liver Tissue 6005-N
20.4

Melanoma Metastasis
19.8
Liver Cancer
10.7

Lung Margin (OD04321)
21.6
Normal Bladder
8.0

Normal Kidney
11.0
Bladder Cancer
10.5

Kidney Ca, Nuclear grade 2
37.6
Bladder Cancer
17.3

(OD04338)

Kidney Margin (OD04338)
22.1
Normal Stomach
37.9

Kidney Ca Nuclear grade 1/2
21.6
Gastric Cancer 9060397
11.1

(OD04339)

Kidney Margin (OD04339)
12.9
Stomach Margin 9060396
20.6

Kidney Ca, Clear cell type (OD04340)
6.5
Gastric Cancer 9060395
22.7

Kidney Margin (OD04340)
18.4
Stomach Margin 9060394
36.1

Kidney Ca, Nuclear grade 3
12.9
Gastric Cancer 064005
8.1

(OD04348)

TABLE BED

Panel 3D

Column A - Rel. Exp.(%) Ag2075, Run 164750734

Tissue Name
A
Tissue Name
A

94905 Daoy
6.7
94954 Ca Ski Cervical epidermoid
50.3

Medulloblastoma/Cerebellum

carcinoma (metastasis

94906 TE671
9.0
94955 ES-2 Ovarian clear cell
13.9

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
35.4
94957 Ramos Stimulated with
2.7

Medulloblastoma/Cerebellum

PMA/ionomycin 6 h

94908 PFSK-1 Primitive
15.4
94958 Ramos Stimulated with
3.3

Neuroectodermal/Cerebellum

PMA/ionomycin 14 h

94909 XF-498 CNS
4.4
94962 MEG-01 Chronic
3.4

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
23.3
94963 Raji Burkitt's lymphoma
3.7

94911 SF-268 CNS/glioblastoma
13.6
94964 Daudi Burkitt's lymphoma
6.5

94912 T98G Glioblastoma
18.6
94965 U266 B-cell
8.4

plasmacytoma/myeloma
8.4

96776 SK-N-SH Neuroblastoma
17.0
94968 CA46 Burkitt's lymphoma
7.2

(metastasis)

94913 SF-295 CNS/glioblastoma
8.4
94970 RL non-Hodgkin's B-cell
3.5

lymphoma

94914 Cerebellum
74.7
94972 JM1 pre-B-cell
3.1

lymphoma/leukemia

96777 Cerebellum
62.4
94973 Jurkat T cell leukemia
11.6

94916 NCI-H292 Mucoepidermoid
45.7
94974 TF-1 Erythroleukemia
13.4

lung carcinoma

94917 DMS-114 Small cell lung
10.9
94975 HUT 78 T-cell lymphoma
10.0

cancer

94918 DMS-79 Small cell lung
100.0
94977 U937 Histiocytic lymphoma
18.2

cancer/neuroendocrine

94919 NCI-H146 Small cell lung
30.6
94980 KU-812 Myelogenous
6.0

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
57.4
769-P-Clear cell renal carcinoma
11.3

cancer/neuroendocrine

94921 NCI-N417 Small cell lung
15.2
94983 Caki-2 Clear cell renal
10.4

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
36.9
94984 SW 839 Clear cell renal
2.2

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell lung
51.1
94986 G401 Wilms' tumor
6.2

cancer (metastasis)

94925 NCI-H1155 Large cell lung
26.6
94987 Hs766T Pancreatic carcinoma
42.9

cancer/neuroendocrine

(LN metastasis)

94926 NCI-H1299 Large cell lung
44.4
94988 CAPAN-1 Pancreatic

cancer/neuroendocrine

adenocarcinoma (liver metastasis)
5.0

94927 NCI-H727 Lung carcinoid
47.0
94989 SU86.86 Pancreatic carcinoma
28.1

(liver metastasis)

94928 NCI-UMC-11 Lung carcinoid
60.3
94990 BxPC-3 Pancreatic
6.3

adenocarcinoma

94929 LX-1 Small cell lung cancer
23.5
94991 HPAC Pancreatic
7.4

adenocarcinoma

94930 Colo-205 Colon cancer
29.5
94992 MIA PaCa-2 Pancreatic
3.6

carcinoma

94931 KM12 Colon cancer
24.0
94993 CFPAC-1 Pancreatic ductal
40.9

adenocarcinoma

94932 KM20L2 Colon cancer
8.4
94994 PANC-1 Pancreatic epithelioid
20.9

ductal carcinoma

94933 NCI-H716 Colon cancer
23.3
94996 T24 Bladder carcinma
13.1

(transitional cell

94935 SW-48 Colon adenocarcinoma
27.0
5637- Bladder carcinoma
11.0

94936 SW1116 Colon
10.0
94998 HT-1197 Bladder carcinoma
9.2

adenocarcinoma

94937 LS 174T Colon
9.9
94999 UM-UC-3 Bladder carcinma
7.2

adenocarcinoma

(transitional cell)

94938 SW-948 Colon
1.1
95000 A204 Rhabdomyosarcoma
7.0

adenocarcinoma

94939 SW-480 Colon
8.8
95001 HT-1080 Fibrosarcoma
16.6

adenocarcinoma

94940 NCI-SNU-5 Gastric carcinoma
7.2
95002 MG-63 Osteosarcoma (bone)
16.7

KATO III- Gastric carcinoma
32.8
95003 SK-LMS-1 Leiomyosarcoma
26.4

(vulva)

94943 NCI-SNU-16 Gastric
13.6
95004 SJRH30 Rhabdomyosarcoma
16.8

carcinoma

(met to bone marrow)

94944 NCI-SNU-1 Gastric carcinoma
16.0
95005 A431 Epidermoid carcinoma
9.8

94946 RF-1 Gastric adenocarcinoma
2.1
95007 WM266-4 Melanoma
12.0

94947 RF-48 Gastric adenocarcinoma
4.0
DU 145- Prostate carcinoma (brain
0.1

(metastasis)

96778 MKN-45 Gastric carcinoma
28.7
95012 MDA-MB-468 Breast
14.7

adenocarcinoma

94949 NCI-N87 Gastric carcinoma
13.3
SCC-4- Squamous cell carcinoma of
0.9

tongue

94951 OVCAR-5 Ovarian carcinoma
2.6
SCC-9- Squamous cell carcinoma of
0.3

tongue

94952 RL95-2 Uterine carcinoma
7.2
SCC-15- Squamous cell carcinoma of
0.5

tongue

94953 HelaS3 Cervical
13.4
95017 CAL 27 Squamous cell
21.2

adenocarcinoma

carcinoma of tongue

TABLE BEE

Panel 4D

Column A - Rel. Exp.(%) Ag2075, Run 152787491

Tissue Name
A
Tissue Name
A

Secondary Th1 act
46.3
HUVEC IL-1beta
25.0

Secondary Th2 act
39.2
HUVEC IFN gamma
33.0

Secondary Tr1 act
31.9
HUVEC TNF alpha + IFN gamma
13.1

Secondary Th1 rest
11.7
HUVEC TNF alpha + IL4
20.7

Secondary Th2 rest
13.9
HUVEC IL-11
20.0

Secondary Tr1 rest
21.6
Lung Microvascular EC none
22.7

Primary Th1 act
30.1
Lung Microvascular EC TNFalpha + IL-
15.0

1beta

Primary Th2 act
39.2
Microvascular Dermal EC none
26.8

Primary Tr1 act
54.7
Microsvasular Dermal EC TNFalpha + IL-
16.6

1beta

Primary Th1 rest
84.1
Bronchial epithelium TNFalpha + IL1beta
4.9

Primary Th2 rest
48.6
Small airway epithelium none
19.9

Primary Tr1 rest
39.0
Small airway epithelium TNFalpha + IL-
72.7

1beta

CD45RA CD4 lymphocyte act
21.8
Coronery artery SMC rest
27.9

CD45RO CD4 lymphocyte act
33.0
Coronery artery SMC TNFalpha + IL-1beta
19.6

CD8 lymphocyte act
25.5
Astrocytes rest
26.4

Secondary CD8 lymphocyte rest
21.5
Astrocytes TNFalpha + IL-1beta
13.2

Secondary CD8 lymphocyte act
29.3
KU-812 (Basophil) rest
6.3

CD4 lymphocyte none
12.7
KU-812 (Basophil) PMA/ionomycin
16.0

2ry Th1/Th2/Tr1 anti-CD95
25.5
CCD1106 (Keratinocytes) none
46.0

CH11

LAK cells rest
26.1
CCD1106 (Keratinocytes) TNFalpha + IL-
4.3

1beta

LAK cells IL-2
30.6
Liver cirrhosis
2.7

LAK cells IL-2 + IL-12
18.2
Lupus kidney
3.0

LAK cells IL-2 + IFN gamma
31.0
NCI-H292 none
76.8

LAX cells IL-2 + IL-18
31.2
NCI-H292 IL-4
94.6

LAK cells PMA/ionomycin
9.5
NCI-H292 IL-9
97.3

NK Cells IL-2 rest
37.4
NCI-H292 IL-13
59.5

Two Way MLR 3 day
24.0
NCI-H292 IFN gamma
51.8

Two Way MLR 5 day
23.0
HPAEC none
23.3

Two Way MLR 7 day
19.6
HPAEC TNF alpha + IL-1 beta
15.8

PBMC rest
11.4
Lung fibroblast none
18.4

PBMC PWM
72.2
Lung fibroblast TNF alpha + IL-1 beta
12.0

PBMC PHA-L
33.9
Lung fibroblast IL-4
35.8

Ramos (B cell) none
19.6
Lung fibroblast IL-9
25.5

Ramos (B cell) ionomycin
100.0
Lung fibroblast IL-13
18.7

B lymphocytes PWM
81.8
Lung fibroblast IFN gamma
38.4

B lymphocytes CD40L and IL-4
42.3
Dermal fibroblast CCD1070 rest
48.0

EOL-1 dbcAMP
23.7
Dermal fibroblast CCD1070 TNF alpha
83.5

EOL-1 dbcAMP
13.5
Dermal fibroblast CCD1070 IL-1 beta
13.6

PMA/ionomycin

Dendritic cells none
20.9
Dermal fibroblast IFN gamma
13.1

Dendritic cells LPS
11.5
Dermal fibroblast IL-4
36.6

Dendritic cells anti-CD40
23.2
IBD Colitis 2
1.8

Monocytes rest
19.2
IBD Crohn's
2.4

Monocytes LPS
6.5
Colon
26.8

Macrophages rest
36.1
Lung
21.3

Macrophages LPS
13.3
Thymus
41.5

HUVEC none
37.6
Kidney
24.3

HUVEC starved
58.6

Panel 1.3D Summary: Ag2075 Highest expression of the CG56870-01 and CG56870-06 genes was detected in the cerebral cortex (CT=24.2). Thus expression of this gene is useful in distinguishing this sample from other samples in the panel. Significant expression of this gene is observed throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. The CG56870-01 and CG56870-06 genes encode an Ndr3 homolog which is a putative member of Ndr family. This family consists of proteins from different gene families: Ndr1/RTP/Drg1/NDRG1, Ndr2, and Ndr3 (PFAM: IPR004142). NDRG1 is a cytoplasmic protein involved in stress responses, hormone responses, cell growth, and differentiation. Mutation of this gene was reported to be causative for hereditary motor and sensory neuropathy-Lom. Recently, NDRG4, another memember of Ndr family, was shown to be expressed in neurons of the brain and spinal cord. Its expression was markedly decreased in the brain of Alzheimer's disease patient (Zhou R H, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. (2001) Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 73(1):86-97). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

This gene also showed moderate levels of expression in adipose, adrenal, thyroid, liver, heart, thyroid and skeletal muscle. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of metabolic and endocrine disease, including Types 1 and 2 diabetes and obesity.

In addition, there was significant expression in other samples derived from breast cancer cell lines, lung cancer cell lines, renal cancer cell lines and colon cancer cell lines. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of breast, lung, renal or colon cancer.

Panel 2.2 Summary: Ag2075 Highest expression of the CG56870-01 and CG56870-06 genes was detected in breast cancer sample (CT=29.89). Expression of this gene is useful as a marker for breast cancer. There was significant expression in other samples derived from breast cancers, kidney cancers and colon cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of breast, kidney or colon cancer.

Panel 3D Summary: Ag2075 The expression of this gene was highest in a sample derived from a lung cancer cell line (DMS-79)(CT=26.4). There was significant expression in other samples derived from pancreatic cancer cell lines, lung cancer cell lines, brain cancer cell lines and cervical cancer cell lines. Expression of this gene is useful as a marker for pancreatic, lung, brain and cervical cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of pancreatic, lung, brain or cervical cancer.

Panel 4D Summary: Ag2075 Expression of the CG56870-01 and CG56870-06 genes was ubiquitous througout this panel, with highest expression in samples derived from ionomycin treated Ramos (B cell) cells (CT=26.1). Expression was also detected in PWM treated PBMC cells and PWM treated B lymphocytes. Therapeutic modulation of these gene, expressed proteins and/or use of antibodies or small molecule drugs targeting the genes or gene products are useful in the treatment of autoimmune and inflammatory diseases in which B cells play a part in the initiation or progression of the disease process, such as systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.

BF. CG57109-01 and CG57109-05: Doublecortin/CAMkinase.

Expression of genes CG57109-01 and CG57109-05 was assessed using the primer-probe sets Ag1137, Ag1150, Ag1860, Ag3112 and Ag4281, described in Tables BFA, BFB, BFC, BFD and BFE. Results of the RTQ-PCR runs are shown in Tables BFF, BFG, BFH, BFI, BFJ, BFK, BFL and BFM. CG57109-05 represents a full-length physical clone of the CG57109-01 gene.

TABLE BFAProbe Name Ag1137StartSEQ IDPrimersSequencesLengthPositionNoForward5′-gacatggtggacagtgagatct-3′2213381377ProbeTET-5′-cctctctcaccccaacatcgtgaaat-3′-2613731378TAMRAReverse5′-tctgtttcgtagacttcatgca-3′2213991379

TABLE BFB

Probe Name Ag1150

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gaaattggctgattttggactt-3′
22
1634
1380

Probe
TET-5′-cctatatttactgtgtgtgggacccca-
27
1674
1381

3′-TAMRA

Reverse
5′-agaatttcgggagctacgtaag-3′
22
1702
1382

TABLE BFC

Probe Name Ag1860

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gacatggtggacagtgagatct-3′
22
1338
1383

Probe
TET-5′-cctctctcaccccaacatcgtgaaat-3′-
26
1373
1384

TAMRA

Reverse
5′-tctgtttcgtagacttcatgca-3′
22
1399
1385

TABLE BFD

Probe Name Ag3112

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gaaattggctgattttggactt-3′
22
1634
1386

Probe
TET-5′-cctatatttactgtgtgtgggacccca-
27
1674
1387

3′-TAMRA

Reverse
5′-agaatttcgggagctacgtaag-3′
22
1702
1388

TABLE BFE

Probe Name Ag4281

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-gacatggtggacagtgagatct-3′
22
1338
1389

Probe
TET-5′-atccagagcctctctcaccccaacat-3′-
26
1365
1390

TAMRA

Reverse
5′-tcgtagacttcatgcaatttca-3′
22
1393
1391

TABLE BFF

AI.05 chondrosarcoma

Column A - Rel. Exp.(%) Ag1860, Run 306913837

Tissue Name
A
Tissue Name
A

138353 PMA (18 hrs)
1.6
138346 IL-1beta + Oncostatin M
21.2

(6 hrs)

138352 IL-1beta + Oncostatin M
2.6
138345 IL-1beta + TNFa (6 hrs)
95.9

(18 hrs)

138351 IL-1beta + TNFa (18 hrs)
100.0
138344 IL-1beta (6 hrs)
29.9

138350 IL-1beta (18 hrs)
6.1
138348 Untreated-complete medium
0.0

(6 hrs)

138354 Untreated-complete medium
1.3
138349 Untreated-serum starved
0.0

(18 hrs)

(6 hrs)

138347 PMA (6 hrs)
7.7

TABLE BFG

AI_{—comprehensive}panel_v1.0

Column A - Rel. Exp.(%) Ag1860, Run 225404259

Tissue Name
A
Tissue Name
A

110967 COPD-F
3.7
112427 Match Control Psoriasis-F
7.9

110980 COPD-F
0.0
112418 Psoriasis-M
13.1

110968 COPD-M
20.0
112723 Match Control Psoriasis-M
17.9

110977 COPD-M
3.0
112419 Psoriasis-M
26.8

110989 Emphysema-F
26.2
112424 Match Control Psoriasis-M
19.5

110992 Emphysema-F
4.2
112420 Psoriasis-M
36.9

110993 Emphysema-F
11.0
112425 Match Control Psoriasis-M
23.3

110994 Emphysema-F
19.8
104689 (ME) OA Bone-Backus
13.0

110995 Emphysema-F
8.5
104690 (ME) Adj “Normal” Bone-
3.9

Backus

110996 Emphysema-F
0.0
104691 (ME) OA Synovium-Backus
29.5

110997 Asthma-M
17.2
104692 (BA) OA Cartilage-Backus
0.0

111001 Asthma-F
38.4
104694 (BA) OA Bone-Backus
17.3

111002 Asthma-F
27.9
104695 (BA) Adj “Normal” Bone-
0.0

Backus

111003 Atopic Asthma-F
50.7
104696 (BA) OA Synovium-Backus
93.3

111004 Atopic Asthma-F
68.3
104700 (SS) OA Bone-Backus
11.7

111005 Atopic Asthma-F
56.6
104701 (SS) Adj “Normal” Bone-Backus
15.3

111006 Atopic Asthma-F
17.9
104702 (SS) OA Synovium-Backus
100.0

111417 Allergy-M
31.0
117093 OA Cartilage Rep7
19.1

112347 Allergy-M
8.3
112672 OA Bone5
6.8

112349 Normal Lung-F
2.5
112673 OA Synovium5
4.8

112357 Normal Lung-F
4.4
112674 OA Synovial Fluid cells5
13.9

112354 Normal Lung-M
0.0
117100 OA Cartilage Rep14
4.5

112374 Crohns-F
27.5
112756 OA Bone9
63.7

112389 Match Control Crohns-F
9.0
112757 OA Synovium9
17.7

112375 Crohns-F
36.6
112758 OA Synovial Fluid Cells9
11.7

112732 Match Control Crohns-F
0.0
117125 RA Cartilage Rep2
27.5

112725 Crohns-M
4.4
113492 Bone2 RA
20.0

112387 Match Control Crohns-M
17.1
113493 Synovium2 RA
6.8

112378 Crohns-M
4.2
113494 Syn Fluid Cells RA
8.8

112390 Match Control Crohns-M
49.3
113499 Cartilage4 RA
4.7

112726 Crohns-M
30.1
113500 Bone4 RA
8.8

112731 Match Control Crohns-M
0.0
113501 Synovium4 RA
3.5

112380 Ulcer Col-F
37.9
113502 Syn Fluid Cells4 RA
4.0

112734 Match Control Ulcer Col-F
17.9
113495 Cartilage3 RA
10.4

112384 Ulcer Col-F
29.7
113496 Bone3 RA
4.2

112737 Match Control Ulcer Col-F
9.0
113497 Synovium3 RA
0.0

112386 Ulcer Col-F
5.0
113498 Syn Fluid Cells3 RA
7.9

112738 Match Control Ulcer Col-F
9.8
117106 Normal Cartilage Rep20
0.0

112381 Ulcer Col-M
0.0
113663 Bone3 Normal
0.0

112735 Match Control Ulcer Col-M
28.7
113664 Synovium3 Normal
0.0

112382 Ulcer Col-M
10.0
113665 Syn Fluid Cells3 Normal
0.0

112394 Match Control Ulcer Col-M
0.0
117107 Normal Cartilage Rep22
0.0

112383 Ulcer Col-M
35.4
113667 Bone4 Normal
13.3

112736 Match Control Ulcer Col-M
6.3
113668 Synovium4 Normal
0.0

112423 Psoriasis-F
21.5
113669 Syn Fluid Cells4 Normal
9.4

TABLE BFH

General_screening_panel_v1.4

Column A - Rel. Exp.(%) Ag4281, Run 222183233

Tissue Name
A
Tissue Name
A

Adipose
0.5
Renal ca.TK-10
0.0

Melanoma* Hs688(A).T
0.0
Bladder
5.4

Melanoma* Hs688(B).T
0.0
Gastric ca. (liver met.) NCI-N87
0.0

Melanoma* M14
0.0
Gastric ca. KATO III
0.0

Melanoma* LOXIMVI
0.0
Colon ca. SW-948
0.0

Melanoma* SK-MEL-5
0.0
Colon ca. SW480
0.2

Squamous cell carcinoma SCC-4
0.0
Colon ca.* (SW480 met) SW620
0.0

Testis Pool
34.2
Colon ca. HT29
0.0

Prostate ca.* (bone met) PC-3
0.0
Colon ca. HCT-116
0.0

Prostate Pool
0.9
Colon ca. CaCo-2
2.6

Placenta
2.0
Colon cancer tissue
5.6

Uterus Pool
0.8
Colon ca. SW1116
0.0

Ovarian ca. OVCAR-3
0.7
Colon ca. Colo-205
0.0

Ovarian ca. SK-OV-3
0.6
Colon ca. SW-48
0.0

Ovarian ca. OVCAR-4
0.0
Colon Pool
4.0

Ovarian ca. OVCAR-5
0.0
Small Intestine Pool
0.5

Ovarian ca. IGROV-1
0.0
Stomach Pool
0.4

Ovarian ca. OVCAR-8
0.0
Bone Marrow Pool
1.1

Ovary
0.6
Fetal Heart
4.5

Breast ca. MCF-7
0.0
Heart Pool
2.7

Breast ca. MDA-MB-231
0.0
Lymph Node Pool
5.9

Breast ca. BT 549
0.0
Fetal Skeletal Muscle
22.1

Breast ca. T47D
1.0
Skeletal Muscle Pool
9.3

Breast ca. MDA-N
0.0
Spleen Pool
2.4

Breast Pool
3.1
Thymus Pool
3.1

Trachea
1.7
CNS cancer (glio/astro) U87-MG
0.0

Lung
0.0
CNS cancer (glio/astro) U-118-MG
0.0

Fetal Lung
14.4
CNS cancer (neuro; met) SK-N-AS
0.8

Lung ca. NCI-N417
0.0
CNS cancer (astro) SF-539
0.0

Lung ca. LX-1
0.0
CNS cancer (astro) SNB-75
0.0

Lung ca. NCI-H146
0.9
CNS cancer (glio) SNB-19
0.0

Lung ca. SHP-77
0.0
CNS cancer (glio) SF-295
0.0

Lung ca. A549
0.0
Brain (Amygdala) Pool
25.5

Lung ca. NCI-H526
0.0
Brain (cerebellum)
5.4

Lung ca. NCI-H23
2.1
Brain (fetal)
100.0

Lung ca. NCI-H460
0.0
Brain (Hippocampus) Pool
59.0

Lung ca. HOP-62
0.0
Cerebral Cortex Pool
14.1

Lung ca. NCI-H522
0.7
Brain (Substantia nigra) Pool
15.1

Liver
0.3
Brain (Thalamus) Pool
28.9

Fetal Liver
1.0
Brain (whole)
33.9

Liver ca. HepG2
0.0
Spinal Cord Pool
25.2

Kidney Pool
4.2
Adrenal Gland
2.3

Fetal Kidney
4.6
Pituitary gland Pool
36.6

Renal ca. 786-0
0.0
Salivary Gland
0.4

Renal ca. A498
0.0
Thyroid (female)
0.4

Renal ca. ACHN
0.0
Pancreatic ca. CAPAN2
0.0

Renal ca. UO-31
0.0
Pancreas Pool
2.1

TABLE BFI

PGI1.0

Column A - Rel. Exp.(%) Ag3112, Run 395549582

Tissue Name
A
Tissue Name
A

162191 Normal Lung 1 (IBS)
0.5
162185 Emphysema Lung 12 (Ardais)
5.4

160468 MD lung
6.8
162184 Emphysema Lung 13 (Ardais)
6.5

156629 MD Lung 13
2.3
162183 Emphysema Lung 14 (Ardais)
13.3

162570 Normal Lung 4 (Aastrand)
2.0
162188 Emphysema Lung 15 (Genomic
42.9

Collaborative)

162571 Normal Lung 3 (Aastrand)
0.8
162177 NAT UC Colon 1 (Ardais)
15.3

162187 Fibrosis Lung 2 (Genomic
99.3
162176 UC Colon 1 (Ardais)
21.0

Collaborative)

151281 Fibrosis lung 11(Ardais)
24.0
162179 NAT UC Colon 2(Ardais)
5.8

162186 Fibrosis Lung 1 (Genomic
35.6
162178 UC Colon 2(Ardais)
38.2

Collaborative)

162190 Asthma Lung 4 (Genomic
53.2
162181 NAT UC Colon 3(Ardais)
3.9

Collaborative)

160467 Asthma Lung 13 (MD)
0.6
162180 UC Colon 3(Ardais)
20.3

137027 Emphysema Lung 1
2.3
162182 NAT UC Colon 4 (Ardais)
5.1

(Ardais)

137028 Emphysema Lung 2
0.0
137042 UC Colon 1108
27.4

(Ardais)

137040 Emphysema Lung 3
4.4
137029 UC Colon 8215
100.0

(Ardais)

137041 Emphysema Lung 4
4.0
137031 UC Colon 8217
66.4

(Ardais)

137043 Emphysema Lung 5
15.0
137036 UC Colon 1137
43.5

(Ardais)

142817 Emphysema Lung 6
7.6
137038 UC Colon 1491
62.4

(Ardais)

142818 Emphysema Lung 7
5.9
137039 UC Colon 1546
78.5

(Ardais)

142819 Emphysema Lung 8
8.2
162593 Crohn's 47751 (NDRI)
9.4

(Ardais)

142820 Emphysema Lung 9
4.0
162594 NAT Crohn's 47751 (NDRI)
3.9

(Ardais)

142821 Emphysema Lung 10
6.7

(Ardais)

TABLE BFK

Panel 3D

Column A - Rel. Exp.(%) Ag3112, Run 182114339

Tissue Name
A
Tissue Name
A

94905 Daoy
0.0
94954 Ca Ski Cervical epidermoid
0.0

Medulloblastoma/Cerebellum

carcinoma (metastasis

94906 TE671
0.0
94955 ES-2 Ovarian clear cell
0.0

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
0.0
94957 Ramos Stimulated with
0.0

Medulloblastoma/Cerebellum

PMA/ionomycin 6 h

94908 PFSK-1 Primitive
0.0
94958 Ramos Stimulated with
0.0

Neuroectodermal/Cerebellum

PMA/ionomycin 14 h

94909 XF-498 CNS
0.0
94962 MEG-01 Chronic myelogenous
0.0

leukemia (megokaryoblast)

94910 SNB-78 CNS/glioma
0.0
94963 Raji Burkitt's lymphoma
0.0

94911 SF-268 CNS/glioblastoma
0.0
94964 Daudi Burkitt's lymphoma
0.0

94912 T98G Glioblastoma
0.0
94965 U266 B-cell
0.0

plasmacytoma/myeloma

96776 SK-N-SH Neuroblastoma
0.0
94968 CA46 Burkitt's lymphoma
0.0

(metastasis)

94913 SF-295 CNS/glioblastoma
0.0
94970 RL non-Hodgkin's B-cell
0.0

lymphoma

94914 Cerebellum
6.5
94972 JM1 pre-B-cell
0.0

lymphoma/leukemia

96777 Cerebellum
2.4
94973 Jurkat T cell leukemia
7.3

94916 NCI-H292 Mucoepidermoid
0.0
94974 TF-1 Erythroleukemia
0.0

lung carcinoma

94917 DMS-114 Small cell lung
0.0
94975 HUT 78 T-cell lymphoma
0.0

cancer

94918 DMS-79 Small cell lung
100.0
94977 U937 Histiocytic lymphoma
0.0

cancer/neuroendocrine

94919 NCI-H146 Small cell lung
0.0
94980 KU-812 Myelogenous
0.0

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
0.0
769-P- Clear cell renal carcinoma
0.0

cancer/neuroendocrine

94921 NCI-N417 Small cell lung
0.0
94983 Caki-2 Clear cell renal
0.0

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
0.0
94984 SW 839 Clear cell renal
0.0

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell lung
0.0
94986 G401 Wilims' tumor
0.0

cancer (metastasis)

94925 NCI-H1155 Large cell lung
3.6
94987 Hs766T Pancreatic carcinoma
0.0

cancer/neuroendocrine

(LN metastasis)

94926 NCI-H1299 Large cell lung
0.0
94988 CAPAN-1 Pancreatic
0.0

cancer/neuroendocrine

adenocarcinoma (liver metastasis)

94927 NCI-H727 Lung carcinoid
0.0
94989 SU86.86 Pancreatic carcinoma
0.0

(liver metastasis)

94928 NCI-UMC-11 Lung carcinoid
0.0
94990 BxPC-3 Pancreatic
0.0

adenocarcinoma

94929 LX-1 Small cell lung cancer
0.0
94991 HPAC Pancreatic
0.0

adenocarcinoma

94930 Colo-205 Colon cancer
0.0
94992 MIA PaCa-2 Pancreatic
0.0

carcinoma

94931 KM12 Colon cancer
0.0
94993 CFPAC-1 Pancreatic ductal
0.0

adenocarcinoma

94932 KM20L2 Colon cancer
0.0
94994 PANC-1 Pancreatic epithelioid
0.0

ductal carcinoma

94933 NCI-H716 Colon cancer
0.0
94996 T24 Bladder carcinma
0.0

(transitional cell

94935 SW-48 Colon adenocarcinoma
0.0
5637- Bladder carcinoma
0.0

94936 SW1116 Colon adenocarcinoma
0.0
94998 HT-1197 Bladder carcinoma
0.0

94937 LS 174T Colon
0.0
94999 UM-UC-3 Bladder carcinma
0.0

adenocarcinoma

(transitional cell)

94938 SW-948 Colon adenocarcinoma
0.0
95000 A204 Rhabdomyosarcoma
0.0

94939 SW-480 Colon adenocarcinoma
0.0
95001 HT-1080 Fibrosarcoma
0.0

94940 NCI-SNU-5 Gastric carcinoma
0.0
95002 MG-63 Osteosarcoma (bone)
0.0

KATO III- Gastnc carcinoma
0.0
95003 SK-LMS-1 Leiomyosarcoma
0.0

(vulva)

94943 NCI-SNU-16 Gastric carcinoma
0.0
95004 SJRH30 Rhabdomyosarcoma
0.0

(met to bone marrow)

94944 NCI-SNU-1 Gastric carcinoma
0.0
95005 A431 Epidermoid carcinoma
0.0

94946 RE-1 Gastric adenocarcinoma
0.0
95007 WM266-4 Melanoma
0.0

94947 RF-48 Gastric adenocarcinoma
0.0
DU 145- Prostate carcinoma (brain
0.0

metastasis)

96778 MKN-45 Gastric carcinoma
0.0
95012 MDA-MB-468 Breast
0.0

adenocarcinoma

94949 NCI-N87 Gastric carcinoma
0.0
SCC-4- Squamous cell carcinoma of
0.0

tongue

94951 OVCAR-5 Ovarian carcinoma
0.0
SCC-9- Squamous cell carcinoma of
0.0

tongue

94952 RL95-2 Uterine carcinoma
0.0
SCC-15- Squamous cell carcinoma of
0.0

tongue

94953 Hela53 Cervical
0.0
95017 CAL 27 Squamous cell
0.0

adenocarcinoma

carcinoma of tongue

TABLE BFM

Panel 4D

Column A - Rel. Exp. (%) Ag1860, Run 165828919

Column B - Rel. Exp. (%) Ag3112, Run 164526081

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
0.0
0.0
HUVEC IL-1 beta
6.5
2.2

Secondary Th2 act
0.0
0.0
HUVEC IFN gamma
0.0
0.0

Secondary Tr1 act
0.8
0.0
HUVEC TNF alpha + IFN gamma
0.6
0.0

Secondary Th1 rest
0.0
1.7
HUVEC TNF alpha + IL4
0.6
0.0

Secondary Th2 rest
0.0
0.0
HUVEC IL-11
0.0
0.0

Secondary Tr1 rest
0.6
0.0
Lung Microvascular EC none
0.0
0.0

Primary Th1 act
0.0
0.0
Lung Microvascular EC TNF alpha +
9.7
9.7

IL-1 beta

Primary Th2 act
0.0
0.0
Microvascular Dermal EC none
0.0
0.0

Primary Tr1 act
0.7
0.0
Microsvasular Dermal EC TNF alpha +
1.4
5.9

IL-1 beta

Primary Th1 rest
0.7
0.0
Bronchial epithelium TNF alpha +
0.6
0.0

IL1 beta

Primary Th2 rest
0.6
0.0
Small airway epithelium none
0.0
0.0

Primary Tr1 rest
0.0
0.0
Small airway epithelium TNF alpha +
0.0
0.0

IL-1 beta

CD45RA CD4 lymphocyte
6.7
2.9
Coronery artery SMC rest
9.7
10.4

act

CD45RO CD4 lymphocyte
0.0
0.0
Coronery artery SMC TNF alpha +
23.7
32.8

act

IL-1 beta

CD8 lymphocyte act
1.4
0.0
Astrocytes rest
0.0
0.0

Secondary CD8 lymphocyte
0.0
0.0
Astrocytes TNF alpha + IL-1 beta
11.7
0.0

rest

Secondary CD8 lymphocyte
0.0
1.9
KU-812 (Basophil) rest
0.0
0.0

act

CD4 lymphocyte none
0.0
0.0
KU-812 (Basophil) PMA/ionomycin
0.0
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
2.0
CCD1106 (Keratinocytes) none
0.0
0.0

CH11

LAK cells rest
0.9
0.0
CCD1106 (Keratinocytes) TNF alpha +
0.0
0.0

IL-1 beta

LAK cells IL-2
2.7
0.0
Liver cirrhosis
20.0
6.4

LAK cells IL-2 + IL-12
0.0
0.0
Lupus kidney
0.0
0.0

LAK cells IL-2 + IFN
0.4
0.0
NCI-H292 none
0.0
0.0

gamma

LAK cells IL-2 + IL-18
0.0
0.0
NCI-H292 IL-4
0.0
0.0

LAK cells PMA/ionomycin
1.8
0.0
NCI-H292 IL-9
0.0
2.6

NK Cells IL-2 rest
1.7
0.0
NCI-H292 IL-13
0.0
1.7

Two Way MLR 3 day
1.6
0.0
NCI-H292 IFN gamma
0.0
0.0

Two Way MLR 5 day
0.0
0.0
HPAEC none
0.0
0.0

Two Way MLR 7 day
0.0
0.0
HPAEC TNF alpha + IL-1 beta
100.0
69.3

PBMC rest
0.8
0.0
Lung fibroblast none
0.0
0.0

PBMC PWM
1.5
1.2
Lung fibroblast TNF alpha + IL-1
16.4
3.5

beta

PBMC PHA-L
0.0
0.0
Lung fibroblast IL-4
0.0
0.0

Ramos (B cell) none
0.0
0.0
Lung fibroblast IL-9
0.0
0.0

Ramos (B cell) ionomycin
0.0
0.0
Lung fibroblast IL-13
0.7
0.0

B lymphocytes PWM
0.0
2.5
Lung fibroblast IFN gamma
0.0
0.0

B lymphocytes CD40L and
0.0
1.7
Dermal fibroblast CCD1070 rest
2.3
4.1

IL-4

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 TNF
28.7
42.6

alpha

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast CCD1070 IL-1
49.7
100.0

PMA/ionomycin

beta

Dendritic cells none
4.6
0.0
Dermal fibroblast IFN gamma
0.0
0.9

Dendritic cells LPS
4.2
2.9
Dermal fibroblast IL-4
0.3
0.0

Dendritic cells anti-CD40
15.8
11.5
IBD Colitis 2
1.9
0.0

Monocytes rest
0.0
0.0
IBD Crohn's
2.7
5.1

Monocytes LPS
2.3
0.0
Colon
15.6
3.2

Macrophages rest
5.7
3.4
Lung
23.0
27.7

Macrophages LPS
6.8
3.4
Thymus
0.0
1.7

HUVEC none
0.0
0.0
Kidney
26.8
27.5

HUVEC starved
0.0
0.0

AI.05 chondrosarcoma Summary: Ag1860 Highest expression was detected in IL-1TNF-a treated chondrosarcoma cells (SW1353 cell lines). Expression of this gene was up-regulated upon IL-1 treatment, a potent activator of pro-inflammatory cytokines and matrix metalloproteinases, which participate in the destruction of cartilage observed in Osteoarthritis (OA). Therapeutic modulation of these genes, expressed proteins and/or use of antibodies or small molecule drugs targeting the genes or gene products are useful in the treatment of the degeneration of cartilage observed in OA.

AI_comprehensive panel_v1.0 Summary: Ag1860 Highest expression in this panel was seen in synovium from an OA patient (CT=33.7). Overall, the CG57109-01 and CG57109-05 genes were expressed in OA tissue but not in normal joint tissue and were expressed in pulmonary tissue from patients with atopic asthma but not in normal lung tissue. Therapeutic modulation of these genes, expressed proteins and/or use of antibodies or small molecule drugs targeting the genes or gene products are useful in the treatment of inflammatory diseases including OA and asthma.

General_screening_panel_v1.4 Summary: Ag4281 Highest expression of the CG57109-01 and CG57109-05 genes was detected in the fetal brain (CT=29.5). Overall, expression of this gene was highly brain-specific in this panel, with moderate levels of expression in the amygdala, hippocampus, thalamus and spinal cord and low but significant levels in the cerebral cortex and the substantia nigra. CG57109-01 and CG57109-05 encode a novel doublecortin/CAM kinase like protein. Other members of this family have been implicated in the calcium-signaling pathway that controls neuronal migration in the developing brain. In addition, CAM kinase has been shown to play a crucial role in hippocampal Long Term Potentiation (LTP) from studies in transgenic and knock-out mice, and may also play a role in memory formation in the mature nervous system as well as the developing brain. CAM kinases have also been shown to phosporylate tau, an integral component of the neurofibrillary tangles seen in Alzheimer's, in a manner which shifts tau electrophorytic motility to that seen in the AD brain. Furthermore, tau from AD brains shows aberrent phosphorylation. Therapeutic modulation of these gene, expressed protein and/or use of antibodies or small molecule drugs targeting the genes or gene products are useful in the treatment of learning and memory deficits that are a result of aging or neurodegenerative disease and also in the treatment of neurologic disorders themselves, including Alzheimer's disease.

Moderate to low levels of expression were also seen in a variety of samples from normal tissues, including testis, fetal and adult heart and skeletal muscle and fetal lung.

Expression was much higher in fetal lung (CT=32.3) when compared to expression in the adult counterpart (CT=40). Expression of this gene is useful for distinguishing between the fetal and adult source of this tissue.

PGI1.0 Summary: Ag3112 Highest expression was detected in a colon sample from an ulcerative colitis patient (CT=30.7). Strong expression was observed in a cluster of colon samples derived from ulcerative colitis patients and in fibrotic lung samples. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of inflammatory conditions of the colon and lung.

Panel 3D Summary: Ag3112 Expression was restricted to a sample derived from a lung cancer cell line (CT=32.6). Expression of this gene or expressed protein could be used to detect the presence of lung cancer. Therapeutic modulation of these genes, expressed proteins and/or use of antibodies or small molecule drugs targeting the genes or gene products are useful in the treatment of lung cancer.

Panel 4D Summary: Ag1860 This transcript was highly expressed in activated dermal fibroblasts, endothelial cells, and astrocytes after treatment with IL-1 or TNFalpha, with highest expression in TNF alpha and IL-1 beta treated HPAECs (CT=30.9). The proteins encoded by the CG57109-01 and CG57109-05 genes have homology to protein kinase and may be involved in leukocyte extravasation from the peripheral blood into tissues (Borbiev T, Am J Physiol Lung Cell Mol Physiol 2001 May; 280(5):L983-90). Therapeutic modulation of these genes, expressed proteins and/or use of antibodies or small molecule drugs targeting the genes or gene products are useful in the treatment of inflammation due to asthma, allergy, emphysema, osteoarthritis, colitis, psoriasis, or delayed type hypersensitivity. Agonistic therapies are useful for directing leukocyte traffic into tumors or sites of infection.

Ag3112 Highest expression of the transcript was seen in IL-1 beta treated dermal fibroblasts (CT=30.4). Expression was in agreement with the profile seen with Ag1860, except no expression was seen in astrocytes.

BG. CG57399-04: Phospholipase ADRAB-B Precursor.

Expression of gene CG57399-04 was assessed using the primer-probe set Ag3952, described in Table BGA. Results of the RTQ-PCR runs are shown in Tables BGB and BGC. CG57399-04 represents a full-length physical clone of the CG57399-02 gene.

TABLE BGAProbe Name Ag3952StartSEQ IDPrimersSequencesLengthPositionNoForward5′-ctgtgtccctgtgtcctgaa-3′202741392ProbeTET-5′-tcaacagaacttgctaccctcatcga-3′-263071393TAMRAReverse5′-gtgggtcttctcctgaaacttc-3′223421394

TABLE BGB

General_screening_panel_v1.4

Column A - Rel. Exp.(%) Ag3952, Run 213856126

Tissue Name
A
Tissue Name
A

Adipose
9.0
Renal ca. TK-10
15.0

Melanoma* Hs688(A).T
3.0
Bladder
22.7

Melanoma* Hs688(B).T
3.4
Gastric ca. (liver met.) NCI-N87
13.0

Melanoma* M14
0.9
Gastric ca. KATO III
75.3

Melanoma* LOXIMVI
11.7
Colon ca. SW-948
4.3

Melanoma* SK-MEL-5
1.5
Colon ca. SW480
97.3

Squamous cell Carcinoma SCC-4
8.7
Colon ca.* (SW480 met) SW620
4.4

Testis Pool
12.8
Colon ca. HT29
0.4

Prostate ca.* (bone met) PC-3
10.5
Colon ca. HCT-116
1.2

Prostate Pool
12.9
Colon ca. CaCo-2
60.7

Placenta
5.1
Colon cancer tissue
28.7

Uterus Pool
6.5
Colon ca. SW1116
0.0

Ovarian ca. OVCAR-3
7.3
Colon ca. Colo-205
0.9

Ovarian ca. SK-OV-3
26.4
Colon ca. SW-48
26.1

Ovarian ca. OVCAR-4
1.9
Colon Pool
18.8

Ovarian ca. OVCAR-5
6.7
Small Intestine Pool
5.3

Ovarian ca. IGROV-1
9.2
Stomach Pool
7.9

Ovarian ca. OVCAR-8
4.2
Bone Marrow Pool
8.4

Ovary
10.0
Fetal Heart
1.2

Breast ca. MCF-7
0.4
Heart Pool
5.7

Breast ca. MDA-MB-231
92.0
Lymph Node Pool
32.1

Breast ca. BT 549
5.5
Fetal Skeletal Muscle
1.2

Breast ca. T47D
2.5
Skeletal Muscle Pool
4.7

Breast ca. MDA-N
1.6
Spleen Pool
18.2

Breast Pool
19.6
Thymus Pool
19.3

Trachea
10.3
CNS cancer (glio/astro) U87-MG
38.2

Lung
1.2
CNS cancer (glio/astro) U-118-MG
12.2

Fetal Lung
8.3
CNS cancer (neuro; met) SK-N-AS
0.9

Lung ca. NCI-N417
0.9
CNS cancer (astro) SF-539
7.6

Lung ca. LX-1
27.2
CNS cancer (astro) SNB-75
17.1

Lung ca. NCI-H146
10.7
CNS cancer (glio) SNB-19
6.8

Lung ca. SHP-77
47.3
CNS cancer (glio) SF-295
5.7

Lung ca. A549
5.1
Brain (Amygdala) Pool
7.0

Lung ca. NCI-H526
0.0
Brain (cerebellum)
3.2

Lung ca. NCI-H23
4.1
Brain (fetal)
19.3

Lung ca. NCI-H460
0.5
Brain (Hippocampus) Pool
13.1

Lung ca. HOP-62
2.7
Cerebral Cortex Pool
14.8

Lung ca. NCI-H522
1.3
Brain (Substantia nigra) Pool
6.3

Liver
0.0
Brain (Thalamus) Pool
15.2

Fetal Liver
1.7
Brain (whole)
10.4

Liver ca. HepG2
0.5
Spinal Cord Pool
5.3

Kidney Pool
21.2
Adrenal Gland
100.0

Fetal Kidney
1.6
Pituitary gland Pool
4.3

Renal ca. 786-0
1.7
Salivary Gland
3.4

Renal ca. A498
1.3
Thyroid (female)
14.5

Renal ca. ACHN
4.3
Pancreatic ca. CAPAN2
1.7

Renal ca. UO-31
17.4
Pancreas Pool
24.5

TABLE BGC

Panel 5 Islet

Column A - Rel. Exp.(%) Ag3952, Run 323591168

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
39.8
94709 Donor 2 AM - A adipose
20.9

97476 Patient-07sk skeletal muscle
0.0
94710 Donor 2 AM - B adipose
9.5

97477 Patient-07ut uterus
27.5
94711 Donor 2 AM - C adipose
3.9

97478 Patient-07pl placenta
2.8
94712 Donor 2 AD - A adipose
5.7

99167 Bayer Patient 1
16.0
94713 Donor 2 AD - B adipose
23.3

97482 Patient-08ut uterus
6.3
94714 Donor 2 AD - C adipose
5.5

97483 Patient-08pl placenta
4.9
94742 Donor 3 U - A Mesenchymal
6.9

Stem Cells

97486 Patient-09sk skeletal muscle
8.3
94743 Donor 3 U - B Mesenchymal
0.0

Stem Cells

97487 Patient-09ut uterus
19.8
94730 Donor 3 AM - A adipose
10.7

97488 Patient-09pl placenta
8.0
94731 Donor 3 AM - B adipose
23.5

97492 Patient-10ut uterus
20.4
94732 Donor 3 AM - C adipose
18.2

97493 Patient-10pl placenta
18.0
94733 Donor 3 AD - A adipose
9.3

97495 Patient-11go adipose
49.7
94734 Donor 3 AD - B adipose
0.0

97496 Patient-11sk skeletal muscle
2.4
94735 Donor 3 AD - C adipose
5.1

97497 Patient-11ut uterus
26.8
77138 Liver HepG2untreated
4.5

97498 Patient-11pl placenta
12.9
73556 Heart Cardiac stromal cells
0.0

(primary)

97500 Patient-12go adipose
31.6
81735 Small Intestine
100.0

97501 Patient-12sk skeletal muscle
11.2
72409 Kidney Proximal Convoluted
7.3

Tubule

97502 Patient-12ut uterus
16.4
82685 Small intestine Duodenum
17.2

97503 Patient-12p1 placenta
30.1
90650 Adrenal Adrenocortical

adenoma

94721 Donor 2 U - A Mesenchymal
5.4
72410 Kidney HRCE
10.2

Stem Cells

94722 Donor 2 U - B Mesenchymal
36.1
72411 Kidney HRE
14.5

Stem Cells

94723 Donor 2 U - C Mesenchymal
5.2
73139 Uterus Uterine smooth muscle
36.3

Stem Cells

cells

General_screening_panel_v1.4 Summary: Ag3952 Highest expression of this gene was seen in the adrenal gland (CT=29). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of Addison's disease and other adrenalopathies. This gene showed significant expression in adipose, heart, skeletal muscle, pituitary, thyroid, and pancreas. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of endocrine or metabolic disease, including Types 1 and 2 diabetes, obesity and pancreatitis.

Expression of this gene was detected in samples derived from colon, gastric, lung and breast cancers. Expression of this gene is useful for detecting the presence of these cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of colon, gastric, lung and breast cancers.

Low but significant levels of expression were seen for all regions of the CNS examined. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of CNS disorders such as Alzheimer's disease, Parkinson's disease, stroke, epilepsy, schizophrenia and multiple sclerosis.

Panel 5 Islet Summary: Ag3952 Highest expression was detected in small intestine (CT=32.5). Low but significant expression was also detected in adipose.

BH. CG57562-02: Cation-Transporting ATPase.

Expression of gene CG57562-02 was assessed using the primer-probe sets Ag1179, Ag3287 and Ag6477, described in Tables BHA, BHB and BHC. Results of the RTQ-PCR runs are shown in Tables BHD, BHE and BHF.

TABLE BHAProbe Name Ag1179StartSEQ IDPrimersSequencesLengthPositionNoForward5′-cgctacagatgttcaagatcct-3′2228441395ProbeTET-5′-ctacagccagagcgtcctctacctgg-3′-2628901396TAMRAReverse5′-cctggaagtcactgaacttgac-3′2229211397

TABLE BHB

Probe Name Ag3287

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-cgctacagatgttcaagatcct-3′
22
2844
1398

Probe
TET-5′-ctacagccagagcgtcctctacctgg-3′-
26
2890
1399

TAMRA

Reverse
5′-cctggaagtcactgaacttgac-3′
22
2921
1400

TABLE BHC

Probe Name Ag6477

Start
SEQ ID

Primers
Sequences
Length
Position
No

Forward
5′-ctctgcactccatggccc-3′
18
1980
1401

Probe
TET-5′-cctggagtgcagcctcaagttcgtc-3′-
25
2017
1402

TAMRA

Reverse
5′-gtctcccgtgatcatgaaca-3′
20
2121
1403

TABLE BHD

General_screening_panel_v1.4

Column A - Rel. Exp.(%) Ag3287, Run 216516908

Tissue Name
A
Tissue Name
A

Adipose
4.8
Renal ca.TK-10
26.4

Melanoma* Hs688(A).T
23.0
Bladder
19.9

Melanoma* Hs688(B).T
27.9
Gastric ca. (liver met.) NCI-N87
44.4

Melanoma* M14
31.6
Gastric ca. KATO III
39.8

Melanoma* LOXIMVI
33.7
Colon ca. SW-948
24.3

Melanoma* SK-MEL-5
31.0
Colon ca. SW480
39.8

Squamous cell carcinoma SCC-4
18.4
Colon ca.* (SW480 met) SW620
33.0

Testis Pool
12.2
Colon ca. HT29
10.0

Prostate ca.* (bone met) PC-3
49.7
Colon ca. HCT-116
48.3

Prostate Pool
6.8
Colon ca. CaCo-2
46.7

Placenta
23.0
Colon cancer tissue
19.1

Uterus Pool
4.5
Colon ca. SW1116
11.7

Ovarian ca. OVCAR-3
22.7
Colon ca. Colo-205
15.9

Ovarian ca. SK-OV-3
48.0
Colon ca. SW-48
10.9

Ovarian ca. OVCAR-4
20.6
Colon Pool
16.5

Ovarian ca. OVCAR-5
38.4
Small Intestine Pool
14.5

Ovarian ca. IGROV-1
34.2
Stomach Pool
9.2

Ovarian ca. OVCAR-8
13.5
Bone Marrow Pool
6.8

Ovary
11.7
Fetal Heart
18.0

Breast ca. MCF-7
33.0
Heart Pool
5.2

Breast ca. MDA-MB-231
49.3
Lymph Node Pool
19.8

Breast ca. BT 549
100.0
Fetal Skeletal Muscle
10.5

Breast ca. T47D
76.8
Skeletal Muscle Pool
5.8

Breast ca. MDA-N
24.0
Spleen Pool
12.0

Breast Pool
18.4
Thymus Pool
19.1

Trachea
16.6
CNS cancer (glio/astro) U87-MG
36.1

Lung
5.5
CNS cancer (glio/astro) U-118-MG
65.5

Fetal Lung
42.6
CNS cancer (neuro; met) SK-N-AS
69.3

Lung ca. NCI-N417
18.3
CNS cancer (astro) SF-539
22.4

Lung ca. LX-1
26.1
CNS cancer (astro) SNB-75
49.0

Lung ca. NCI-H146
17.8
CNS cancer (glio) SNB-19
31.9

Lung ca. SHP-77
37.9
CNS cancer (glio) SF-295
84.7

Lung ca. A549
24.1
Brain (Amygdala) Pool
7.5

Lung ca. NCI-H526
7.3
Brain (cerebellum)
42.3

Lung ca. NCI-H23
41.8
Brain (fetal)
26.8

Lung ca. NCI-H460
34.6
Brain (Hippocampus) Pool
8.2

Lung ca. HOP-62
13.4
Cerebral Cortex Pool
9.1

Lung ca. NCI-H522
17.6
Brain (Substantia nigra) Pool
9.1

Liver
5.3
Brain (Thalamus) Pool
13.1

Fetal Liver
21.6
Brain (whole)
18.4

Liver ca. HepG2
23.0
Spinal Cord Pool
6.6

Kidney Pool
22.1
Adrenal Gland
24.0

Fetal Kidney
24.1
Pituitary gland Pool
6.0

Renal ca. 786-0
20.9
Salivary Gland
13.3

Renal ca. A498
23.2
Thyroid (female)
9.5

Renal ca. ACHN
12.4
Pancreatic ca. CAPAN2
44.8

Renal ca. UO-31
27.7
Pancreas Pool
21.6

TABLE BHE

Panel 4D

Column A - Rel. Exp. (%) Ag1179, Run 139820117

Column B - Rel. Exp. (%) Ag3287, Run 164633941

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
46.0
55.5
HUVEC IL-1 beta
5.9
9.9

Secondary Th2 act
76.3
71.7
HUVEC IFN gamma
21.3
65.1

Secondary Tr1 act
38.4
49.7
HUVEC TNF alpha + IFN gamma
10.7
25.9

Secondary Th1 rest
15.0
18.2
HUVEC TNF alpha + IL4
17.1
23.5

Secondary Th2 rest
18.8
18.8
HUVEC IL-11
9.3
14.4

Secondary Tr1 rest
10.7
23.5
Lung Microvascular EC none
17.6
26.8

Primary Th1 act
59.5
52.1
Lung Microvascular EC TNF alpha +
10.9
21.0

IL-1 beta

Primary Th2 act
47.0
40.1
Microvascular Dermal EC none
37.9
26.1

Primary Tr1 act
75.3
68.8
Microsvasular Dermal EC TNF alpha +
21.3
17.7

IL-1 beta

Primary Th1 rest
52.1
60.3
Bronchial epithelium TNF alpha +
32.5
33.4

IL1 beta

Primary Th2 rest
30.1
33.9
Small airway epithelium none
11.9
19.8

Primary Tr1 rest
25.3
25.7
Small airway epithelium TNF alpha +
58.6
73.2

IL-1 beta

CD4SRA CD4 lymphocyte
25.0
40.1
Coronery artery SMC rest
15.6
22.5

act

CD45RO CD4 lymphocyte
56.3
63.7
Coronery artery SMC TNF alpha +
14.9
13.6

act

IL-1 beta

CD8 lymphocyte act
35.6
53.6
Astrocytes rest
15.2
21.8

Secondary CD8
44.4
48.3
Astrocytes TNF alpha + IL-1 beta
17.3
19.6

lymphocyte rest

Secondary CD8
29.1
21.3
KU-812 (Basophil) rest
39.0
59.9

lymphocyte act

CD4 lymphocyte none
16.5
22.5
KU-812 (Basophil) PMA/ionomycin
83.5
83.5

2ry Th1/Th2/Tr1 anti-
31.4
25.2
CCD1106 (Keratinocytes) none
16.4
24.1

CD95 CH11

LAK cells rest
40.6
43.8
93580 CCD1106 (Keratinocytes)
54.7
25.0

TNFa and IFNg

LAK cells IL-2
37.1
42.6
Liver cirrhosis
6.0
6.8

LAK cells IL-2 + IL-12
35.8
34.2
Lupus kidney
17.1
10.4

LAK cells IL-2 + IFN
39.8
42.0
NCI-H292 none
29.5
35.4

gamma

LAK cells IL-2 + IL-18
28.3
42.0
NCI-H292 IL-4
41.8
73.2

LAK cells PMA/ionomycin
18.4
19.8
NCI-H292 IL-9
35.4
48.6

NK Cells IL-2 rest
18.3
26.2
NCI-H292 IL-13
39.8
40.9

Two Way MLR 3 day
27.9
50.0
NCI-H292 IFN gamma
24.5
48.3

Two Way MLR 5 day
21.9
29.5
HPAEC none
20.0
29.5

Two Way MLR 7 day
19.3
19.6
HPAEC TNF alpha + IL-1 beta
18.9
23.7

PBMC rest
10.8
11.5
Lung fibroblast none
20.0
22.8

PBMC PWM
100.0
94.6
Lung fibroblast TNF alpha + IL-1
9.9
15.5

beta

PBMC PHA-L
62.0
49.0
Lung fibroblast IL-4
26.2
42.0

Ramos (B cell) none
69.7
39.8
Lung fibroblast IL-9
19.3
28.5

Ramos (B cell) ionomycin
93.3
100.0
Lung fibroblast IL-13
41.5
27.9

B lymphocytes PWM
79.6
91.4
Lung fibroblast IFN gamma
34.6
43.5

B lymphocytes CD40L and
40.6
59.0
Dermal fibroblast CCD1070 rest
47.3
48.3

IL-4

EOL-1 dbcAMP
43.2
76.3
Dermal fibroblast CCD1070 TNF
47.6
67.4

alpha

EOL-1 dbcAMP
28.9
23.8
Dermal fibroblast CCD1070 IL-1
31.4
34.6

PMA/ionomycin

beta

Dendritic cells none
30.8
36.3
Dermal fibroblast IFN gamma
10.2
18.6

Dendritic cells LPS
32.8
44.4
Dermal fibroblast IL-4
23.7
24.8

Dendritic cells anti-CD40
35.6
38.4
IBD Colitis 2
2.6
2.8

Monocytes rest
28.1
37.9
IBD Crohn's
1.1
1.4

Monocytes LPS
37.9
24.3
Colon
17.0
23.7

Macrophages rest
58.2
67.4
Lung
13.9
21.6

Macrophages LPS
69.3
40.9
Thymus
39.0
31.6

HUVEC none
18.7
23.5
Kidney
40.6
63.3

HUVEC starved
24.8
34.9

TABLE BHF

general oncology screening panel_v_2.4

Column A - Rel. Exp.(%) Ag3287, Run 268695261

Tissue Name
A

Colon cancer 1
36.1

Colon NAT 1
11.3

Colon cancer 2
34.6

Colon NAT 2
20.0

Colon cancer 3
100.0

Colon NAT 3
22.2

Colon malignant cancer 4
100.0

Colon NAT 4
15.1

Lung cancer 1
48.6

Lung NAT 1
5.4

Lung cancer 2
95.9

Lung NAT 2
4.6

Squamous cell carcinoma 3
51.4

Lung NAT 3
3.5

Metastatic melanoma 1
28.9

Melanoma 2
5.6

Melanoma 3
4.9

Metastatic melanoma 4
76.8

Metastatic melanoma 5
59.5

Bladder cancer 1
2.4

Bladder NAT 1
0.0

Bladder cancer 2
9.5

Bladder NAT 2
0.8

Bladder NAT 3
1.4

Bladder NAT 4
5.3

Prostate adenocarcinoma 1
30.1

Prostate adenocarcinoma 2
6.3

Prostate adenocarcinoma 3
15.6

Prostate adenocarcinoma 4
21.6

Prostate NAT 5
14.3

Prostate adenocarcinoma 6
12.4

Prostate adenocarcinoma 7
10.8

Prostate adenocarcinoma 8
3.8

Prostate adenocarcinoma 9
31.9

Prostate NAT 10
3.3

Kidney cancer 1
31.9

Kidney NAT 1
21.8

Kidney cancer 2
78.5

Kidney NAT 2
23.5

Kidney cancer 3
30.6

Kidney NAT 3
7.7

Kidney cancer 4
16.0

Kidney NAT 4
11.3

General_screening_panel_v1.4 Summary: Ag3287—This gene showed moderate to high expression in all samples on this panel, with the highest level of expression in breast cancer cell line BT 549 (CT=25.0). The widespread expression of this gene indicates that the gene product may be involved in cell differentiation and growth.

This gene was widely expressed among tissues with metabolic function, including adipose, adult and fetal skeletal muscle and heart, the pancreas, fetal liver, and the adrenal, thyroid, and pituitary glands. This expression profile indicates that this gene product is involved in metabolic function. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of metabolic disorders, such as obesity and diabetes.

This gene showed widespread expression of this gene in the brain. This indicates that the protein encoded by this gene is important for normal neurological function. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Panel 4D Summary: Ag1179/Ag3287 This gene was expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression indicates that this gene product may be involved in homeostatic processes for these and other cell types and tissues.

This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also indicates a role for the gene product in cell survival and proliferation.

Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

general oncology screening panel_v_—2.4 Summary: Ag3287 Highest expression was detected in a colon cancer sample (CT=26.4), with prominent expression seen in squamous cell carcinoma and melanoma samples. This gene was overexpressed in colon and lung cancers when compared to expression in the normal adjacent tissues. Expression of this gene is useful as a marker of colon and lung cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of colon and lung cancers.

BI. CG57758-03: Renal Sodium/Dicarboxylate Cotransporter.

Expression of gene CG57758-03 was assessed using the primer-probe sets Ag3326 and Ag3692, described in Tables BIA and BIB. Results of the RTQ-PCR runs are shown in Tables BIC, BID and BIE. CG57758-03 represents a full-length physical clone of the CG57758-01 gene.

TABLE BIAProbe Name Ag3326SEQStartIDPrimersSequencesLengthPositionNoForward5′-ccatttactggtgcacagaagt-3′221381404ProbeTET-5′-atccctctggctgtcacctctctcat-3′-261611405TAMRAReverse5′-ggagtccagaatctggaagagt-3′222051406

TABLE BIB

Probe Name Ag3692

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-ccatttactggtgcacagaagt-3′
22
138
1407

Probe
TET-5′-atccctctggctgtcacctctctcat-3′-
26
161
1408

TAMRA

Reverse
5′-ggagtccagaatctggaagagt-3′
22
205
1409

TABLE BIC

General_screening_panel_v1.4

Column A - Rel. Exp. (%) Ag3326, Run 215678613

Column B - Rel. Exp. (%) Ag3692, Run 217131191

Tissue Name
A
B
Tissue Name
A
B

Adipose
0.0
0.0
Renal Ca. TK-10
11.4
12.0

Melanoma* Hs688(A).T
0.0
0.0
Bladder
0.0
0.1

Melanoma* Hs688(B).T
0.1
0.0
Gastric ca. (liver met.) NCI-N87
0.0
0.0

Melanoma* M14
0.0
0.0
Gastric ca. KATO III
0.0
0.0

Melanoma* LOXIMVI
0.0
0.0
Colon ca. SW-948
0.0
0.0

Melanoma* SK-MEL-5
0.0
0.0
Colon ca. SW480
0.0
0.0

Squamous cell carcinoma
0.9
0.7
Colon ca.* (SW480 met) SW620
0.0
0.0

SCC-4

Testis Pool
0.1
0.2
Colon ca. HT29
0.0
0.0

Prostate ca.* (bone met) PC-3
0.0
0.0
Colon ca. HCT-116
0.0
0.0

Prostate Pool
0.0
0.0
Colon ca. CaCo-2
0.0
0.0

Placenta
0.0
0.0
Colon cancer tissue
0.1
0.0

Uterus Pool
0.0
0.0
Colon ca. SW1116
0.0
0.0

Ovarian ca. OVCAR-3
0.0
0.0
Colon ca. Colo-205
0.0
0.0

Ovarian ca. SK-OV-3
0.0
0.0
Colon ca. SW-48
0.0
0.0

Ovarian ca. OVCAR-4
0.1
0.0
Colon Pool
0.6
0.0

Ovarian ca. OVCAR-5
0.0
0.0
Small Intestine Pool
0.1
0.0

Ovarian ca. IGROV-1
0.0
0.0
Stomach Pool
0.0
0.0

Ovarian ca. OVCAR-8
2.8
2.2
Bone Marrow Pool
0.0
0.1

Ovary
0.7
0.6
Fetal Heart
0.0
0.0

Breast ca. MCF-7
0.0
0.0
Heart Pool
0.0
0.0

Breast ca. MDA-MB-231
0.0
0.0
Lymph Node Pool
0.1
0.0

Breast ca. BT 549
0.6
0.8
Fetal Skeletal Muscle
0.0
0.0

Breast ca. T47D
0.0
0.0
Skeletal Muscle Pool
0.0
0.0

Breast ca. MDA-N
0.0
0.0
Spleen Pool
0.4
0.2

Breast Pool
0.0
0.1
Thymus Pool
0.0
0.0

Trachea
0.2
0.1
CNS cancer (glio/astro) U87-MG
0.0
0.0

Lung
0.0
0.0
CNS cancer (glio/astro) U-118-
0.0
0.0

MG

Fetal Lung
0.2
0.1
CNS cancer (neuro; met) SK-N-
0.0
0.0

AS

Lung ca. NCI-N417
0.0
0.0
CNS cancer (astro) SF-539
0.0
0.0

Lung ca. LX-1
0.0
0.0
CNS cancer (astro) SNB-75
0.0
0.0

Lung ca. NCI-H146
0.0
0.0
CNS cancer (glio) SNB-19
0.0
0.0

Lung ca. SHP-77
0.0
0.0
CNS cancer (glio) SF-295
0.1
0.1

Lung ca. A549
0.0
0.1
Brain (Amygdala) Pool
0.4
0.4

Lung ca. NCI-H526
2.0
0.0
Brain (cerebellum)
1.4
1.0

Lung ca. NCI-H23
0.7
0.6
Brain (fetal)
0.7
0.4

Lung ca. NCI-H460
0.0
0.0
Brain (Hippocampus) Pool
0.5
0.7

Lung ca. HOP-62
0.1
0.2
Cerebral Cortex Pool
1.4
1.5

Lung ca. NCI-H522
0.0
0.0
Brain (Substantia nigra) Pool
1.4
1.4

Liver
28.7
24.1
Brain (Thalamus) Pool
1.1
0.9

Fetal Liver
100.0
100.0
Brain (whole)
4.1
3.7

Liver ca. HepG2
29.5
26.2
Spinal Cord Pool
0.1
0.2

Kidney Pool
0.0
0.0
Adrenal Gland
2.6
1.9

Fetal Kidney
0.1
0.1
Pituitary gland Pool
0.0
0.2

Renal ca. 786-0
0.0
0.0
Salivary Gland
40.9
35.1

Renal ca. A498
0.0
0.0
Thyroid (female)
0.0
0.0

Renal ca. ACHN
0.0
0.0
Pancreatic ca. CAPAN2
0.5
0.8

Renal ca. UO-31
0.0
0.0
Pancreas Pool
0.0
0.0

TABLE BID

Panel 4.1D

Column A - Rel. Exp.(%) Ag3692, Run 169987356

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNFalpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
11.3

Primary Tr1 act
4.2
Microsvasular Dermal EC TNFalpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNFalpha + IL1beta
28.5

Primary Th2 rest
0.0
Small airway epithelium none
5.7

Primary Tr1 rest
0.0
Small airway epithelium TNFalpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
3.9
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNFalpha + IL-1beta
0.0

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNFalpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
3.6

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
4.3

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
10.7

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNFalpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
94.0

LAK cells IL-2 + IL-12
0.0
NCI-H292 none
0.0

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 IL-4
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-9
0.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-13
0.0

NK Cells IL-2 rest
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 3 day
0.0
HPAEC none
0.0

Two Way MLR 5 day
3.2
HPAEC TNF alpha + IL-1 beta
0.0

Two Way MLR 7 day
0.0
Lung fibroblast none
0.0

PBMC rest
0.0
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PWM
0.0
Lung fibroblast IL-4
0.0

PBMC PHA-L
0.0
Lung fibroblast IL-9
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-13
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IFN gamma
0.0

B lymphocytes PWM
0.0
Dermal fibroblast CCD1070 rest
0.0

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast IFN gamma
0.0

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IL-4
0.0

Dendritic cells LPS
0.0
Dermal Fibroblasts rest
0.0

Dendritic cells anti-CD40
0.0
Neutrophils TNFa + LPS
0.0

Monocytes rest
0.0
Neutrophils rest
0.0

Monocytes LPS
0.0
Colon
0.0

Macrophages rest
0.0
Lung
0.0

Macrophages LPS
0.0
Thymus
2.4

HUVEC none
0.0
Kidney
100.0

HUVEC starved
0.0

General_screening_panel_v1.4 Summary: This gene was highly expressed in fetal liver (CT=26.5-27.0) and moderately expressed in adult liver and liver cancer cell line HepG2. This result agrees with the results seen in Panel 5 (expression in HepG2). These results are in agreement with published data that show a novel sodium dicarboxylate transporter in brain, choroid plexus kidney, intestine and liver (Chen X Z, Shayakul C, Berger U V, Tian W, Hediger M A. Characterization of a rat Na+-dicarboxylate cotransporter. J Biol Chem 1998 Aug. 14; 273(33):20972-81; Pajor A M, Gangula R, Yao X. Cloning and functional characterization of a high-affinity Na(+)/dicarboxylate cotransporter from mouse brain. Am J Physiol Cell Physiol 2001 May; 280(5):C 1215-23). Expression of this gene is useful as a marker for liver derived tissue.

This gene was expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, and cerebral cortex. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of central nervous system disorders such as Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

Low but significant levels of expression were also seen in the adrenal gland. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of metabolic disorders of the adrenal gland, including adrenoleukodystrophy and congenital adrenal hyperplasia.

Panel 4.1D Summary: Ag3692 Significant expression of this gene was seen only in kidney and a liver cirrhosis sample (CTs=34.0). These results confirm that this gene was expressed in liver derived samples. The presence in the kidney was also in agreement with published results. Please see Panel 1.4. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of kidney inflammation.

BJ. CG58504-01: ADAMTS12.

Expression of gene CG58504-01 was assessed using the primer-probe set Ag2475, described in Table BJA. Results of the RTQ-PCR runs are shown in Tables BJB, BJC, BJD, BJE and BJF.

TABLE BJAProbe Name Ag2475SEQStartIDPrimersSequencesLengthPositionNoForward5′-agagtgacctcaatcctgttca-3′2213181410ProbeTET-5′-acgtggctgtccttctcaccagaaag-3′-2613451411TAMRAReverse5′-gattgaaaccagcacagatgtc-3′2213711412

TABLE BJB

HASS Panel v1.0

Column A - Rel. Exp.(%) Ag2475, Run 268366853

Tissue Name
A

MGF-7 C1
0.1

MCF-7 C2
0.0

MCF-7 C3
0.0

MCF-7 C4
0.0

MCF-7 C5
0.0

MCF-7 C6
0.0

MCF-7 C7
0.0

MCF-7 C9
0.0

MCF-7 C10
0.0

MCF-7 C11
0.0

MCF-7 C12
0.0

MCF-7 C13
0.0

MCF-7 C15
0.0

MCF-7 C16
0.0

MCF-7 C17
0.0

T24 D1
16.2

T24 D2
14.4

T24 D3
40.1

T24 D4
28.1

T24 D5
31.4

T24 D6
23.2

T24 D7
8.0

T24 D9
7.2

T24 D10
10.3

T24 D11
9.5

T24 D12
14.8

T24 D13
3.8

T24 D15
4.6

T24 D16
6.7

T24 D17
13.0

CAPaN B1
0.0

CAPaN B2
0.0

CAPaN B3
0.1

CAPaN B4
0.2

CAPaN B5
0.1

CAPaN B6
0.2

CAPaN B7
0.0

CAPaN B8
0.1

CAPaN B9
0.1

CAPaN B10
0.4

CAPaN B11
0.1

CAPaN B12
0.3

CAPaN B13
0.1

CAPaN B14
0.0

CAPaN B15
0.0

CAPaN B16
0.2

CAPaN B17
0.3

U87-MG F1 (B)
17.3

U87-MG F2
12.9

U87-MG F3
17.4

U87-MG F4
27.4

U87-MG F5
66.0

U87-MG F6
84.7

U87-MG F7
9.2

U87-MG F8
10.6

U87-MG F9
5.4

U87-MG F10
61.1

U87-MG F11
87.7

U87-MG F12
45.7

U87-MG F13
15.7

U87-MG F14
25.2

U87-MG F15
16.3

U87-MG F16
56.6

U87-MG F17
73.2

LnCAP A1
0.0

LnCAP A2
0.0

LnCAP A3
0.0

LnCAP A4
0.1

LnGAP A5
0.0

LnCAP A6
0.0

LnCAP A7
0.0

LnCAP A8
0.0

LnCAP A9
0.1

LnCAP A10
0.0

LnCAP A11
0.0

LnCAP A12
0.0

LnCAP A13
0.1

LnCAP A14
0.0

LnCAP A15
0.0

LnCAP A16
0.0

LnCAP A17
0.1

Primary Astrocytes
100.0

Primary Renal Proximal Tubule Epithelial cell A2
4.4

Primary melanocytes A5
4.5

126443 - 341 medullo
0.0

126444 - 487 medullo
0.0

126445 - 425 medullo
0.3

126446 - 690 medullo
1.0

126447 - 54 adult glioma
17.6

126448 - 245 adult glioma
13.2

126449 - 317 adult glioma
0.2

126450 - 212 glioma
4.4

126451 - 456 glioma
0.3

TABLE BJC

Panel 1.3D

Column A - Rel. Exp.(%) Ag2475, Run 162401130

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
0.0
Kidney (fetal)
5.4

Pancreas
0.0
Renal ca. 786-0
0.0

Pancreatic ca. CAPAN 2
0.1
Renal ca. A498
8.1

Adrenal gland
0.5
Renal ca. RXF 393
5.5

Thyroid
0.0
Renal ca. ACHN
0.0

Salivary gland
0.0
Renal ca. UO-31
23.8

Pituitary gland
0.0
Renal ca. TK-10
1.5

Brain (fetal)
0.0
Liver
0.2

Brain (whole)
0.1
Liver (fetal)
0.8

Brain (amygdala)
0.0
Liver ca. (hepatoblast) HepG2
0.0

Brain (cerebellum)
0.0
Lung
1.9

Brain (hippocampus)
0.0
Lung (fetal)
4.3

Brain (substantia nigra)
0.1
Lung ca. (small cell) LX-1
2.0

Brain (thalamus)
0.5
Lung ca. (small cell) NCI-H69
0.0

Cerebral Cortex
0.3
Lung ca. (s. cell var.) SHP-77
0.0

Spinal cord
0.2
Lung ca. (large cell)NCI-H460
0.2

glio/astro U87-MG
14.9
Lung ca. (non-sm. cell) A549
0.3

glio/astro U-118-MG
2.6
Lung ca. (non-s. cell) NCI-H23
0.0

astrocytoma SW1783
67.8
Lung ca. (non-s. cell) HOP-62
37.1

neuro*; met SK-N-AS
0.0
Lung ca. (non-s. cl) NCI-H522
0.0

astrocytoma SF-539
2.9
Lung ca. (squam.) SW 900
0.0

astrocytoma SNB-75
6.5
Lung ca. (squam.) NCI-H596
0.0

glioma SNB-19
1.1
Mammary gland
3.9

glioma U251
0.7
Breast ca.* (pl. ef) MCF-7
0.0

glioma SF-295
0.4
Breast ca.* (pl. ef) MDA-MB-231
17.1

Heart (Fetal)
7.7
Breast ca.* (p1. ef) T47D
0.0

Heart
0.5
Breast ca. BT-549
6.0

Skeletal muscle (Fetal)
100.0
Breast ca. MDA-N
0.0

Skeletal muscle
0.3
Ovary
13.7

Bone marrow
0.0
Ovarian ca. OVCAR-3
0.0

Thymus
0.3
Ovarian ca. OVCAR-4
0.0

Spleen
0.2
Ovarian ca. OVCAR-5
0.0

Lymph node
0.0
Ovarian ca. OVCAR-8
3.5

Colorectal
1.3
Ovarian ca. IGROV-1
0.0

Stomach
0.3
Ovarian ca. (ascites) SK-OV-3
0.5

Small intestine
0.4
Uterus
0.4

Colon ca. SW480
0.0
Placenta
2.0

Colon ca.* SW620 (SW480 met)
0.3
Prostate
0.2

Colon ca. HT29
0.0
Prostate ca.* (bone met) PC-3
0.0

Colon ca. HCT-116
0.0
Testis
1.3

Colon ca. CaCo-2
0.0
Melanoma Hs688(A).T
9.5

CC Well to Mod Diff(ODO3866)
24.8
Melanoma* (met) Hs688(B).T
22.1

Colon ca. HCC-2998
0.0
Melanoma UACC-62
0.0

Gastric ca. (liver met) NCI-N87
0.0
Melanoma M14
0.0

Bladder
6.7
Melanoma LOX IMVI
1.8

Trachea
0.1
Melanoma (met) SK-MEL-5
0.0

Kidney
0.2
Adipose
7.9

TABLE BJD

Panel 2D

Column A - Rel. Exp.(%) Ag2475, Run 165296233

Tissue Name
A
Tissue Name
A

Normal Colon
21.2
Kidney Margin 8120608
1.2

CC Well to Mod Diff(ODO3866)
40.3
Kidney Cancer 8120613
2.8

CC Margin (ODO3866)
4.7
Kidney Margin 8120614
4.1

CC Gr.2 rectosigmoid (ODO3868)
29.1
Kidney Cancer 9010320
42.6

CC Margin (ODO3868)
4.7
Kidney Margin 9010321
11.3

CC Mod Diff (ODO3920)
8.8
Normal Uterus
6.9

CC Margin (ODO3920)
6.6
Uterine Cancer 064011
27.5

CC Gr.2 ascend colon (ODO3921)
60.3
Normal Thyroid
2.2

CC Margin (ODO3921)
13.6
Thyroid Cancer
0.8

CC from Partial Hepatectomy
53.2
Thyroid Cancer A302152
7.4

(ODO4309) Mets

Liver Margin (ODO4309)
6.7
Thyroid Margin A302153
6.3

Colon mets to lung (OD04451-01)
18.3
Normal Breast
59.9

Lung Margin (OD04451-02)
5.8
Breast Cancer
42.0

Normal Prostate 6546-1
1.0
Breast Cancer (OD04590-01)
51.4

Prostate Cancer (OD04410)
7.4
Breast Cancer Mets (OD04590-03)
65.1

Prostate Margin (OD04410)
14.5
Breast Cancer Metastasis
4.3

Prostate Cancer (OD04720-01)
7.1
Breast Cancer
67.8

Prostate Margin (OD04720-02)
14.2
Breast Cancer
86.5

Normal Lung
23.0
Breast Cancer 9100266
19.6

Lung Met to Muscle (ODO4286)
15.5
Breast Margin 9100265
48.3

Muscle Margin (ODO4286)
9.7
Breast Cancer A209073
93.3

Lung Malignant Cancer (OD03126)
100.0
Breast Margin A209073
53.6

Lung Margin (OD03126)
27.2
Normal Liver
5.8

Lung Cancer (OD04404)
78.5
Liver Cancer
1.5

Lung Margin (OD04404)
25.3
Liver Cancer 1025
4.8

Lung Cancer (OD04565)
54.7
Liver Cancer 1026
16.5

Lung Margin (OD04565)
24.0
Liver Cancer 6004-T
5.7

Lung Cancer (OD04237-01)
54.7
Liver Tissue 6004-N
5.9

Lung Margin (OD04237-02)
38.7
Liver Cancer 6005-T
14.0

Ocular Mel Met to Liver (ODO4310)
0.4
Liver Tissue 6005-N
5.9

Liver Margin (ODO4310)
10.8
Normal Bladder
32.3

Melanoma Metastasis
4.7
Bladder Cancer
29.7

Lung Margin (OD04321)
15.1
Bladder Cancer
15.0

Normal Kidney
19.2
Bladder Cancer (OD04718-01)
48.0

Kidney Ca, Nuclear grade 2 (OD04338)
3.1
Bladder Normal Adjacent
17.6

(OD04718-03)

Kidney Margin (OD04338)
6.7
Normal Ovary
9.5

Kidney Ca Nuclear grade 1/2
1.4
Ovarian Cancer
71.7

(OD04339)

Kidney Margin (OD04339)
9.9
Ovarian Cancer (OD04768-07)
2.7

Kidney Ca, Clear cell type (OD04340)
4.9
Ovary Margin (OD04768-08)
10.2

Kidney Margin (OD04340)
9.9
Normal Stomach
9.0

Kidney Ca, Nuclear grade 3 (OD04348)
17.0
Gastric Cancer 9060358
4.0

Kidney Margin (OD04348)
6.1
Stomach Margin 9060359
2.5

Kidney Cancer (OD04622-O1)
9.2
Gastric Cancer 9060395
17.2

Kidney Margin (OD04622-03)
0.8
Stomach Margin 9060394
5.7

Kidney Cancer (OD04450-01)
2.5
Gastric Cancer 9060397
56.6

Kidney Margin (OD04450-03)
9.2
Stomach Margin 9060396
1.8

Kidney Cancer 8120607
3.2
Gastric Cancer 064005
22.1

TABLE BJF

Panel 4D

Column A - Rel. Exp.(%) Ag2475, Run 163583185

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.2

Secondary Th2 act
0.0
HUVEC IFN gamma
0.3

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.1

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.1

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNFalpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.7

Primary Tr1 act
0.0
Microsvasular Dermal EC TNFalpha + IL-
0.2

1beta

Primary Th1 rest
0.1
Bronchial epithelium TNFalpha + IL1beta
0.0

Primary Th2 rest
0.0
Small airway epithelium none
1.8

Primary Trl rest
0.0
Small airway epithelium TNFalpha + IL-
0.1

1beta

CD45RA CD4 lymphocyte act
3.9
Coronery artery SMC rest
100.0

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNFalpha + IL-1beta
29.9

CD8 lymphocyte act
0.0
Astrocytes rest
22.2

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNFalpha + IL-1beta
24.5

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.5

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNFalpha + IL-
0.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
1.9

LAK cells IL-2 + IL-12
0.1
Lupus kidney
0.6

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
1.7

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
1.9

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
6.2

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
1.9

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
0.9

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1 beta
0.0

PBMC rest
0.0
Lung fibroblast none
4.3

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1 beta
7.0

PBMC PHA-L
0.0
Lung fibroblast IL-4
20.2

Ramos (B cell) none
0.0
Lung fibroblast IL-9
13.4

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
9.2

B lymphocytes PWM
0.0
Lung fibroblast IFN gamma
7.7

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
13.4

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
51.4

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
12.9

PMA/ionomycin

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
3.0

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
37.9

Dendritic cells anti-CD40
0.0
IBD Colitis 2
0.0

Monocytes rest
0.0
IBD Crohn's
0.2

Monocytes LPS
0.0
Colon
1.9

Macrophages rest
0.0
Lung
20.7

Macrophages LPS
0.0
Thymus
0.6

HUVEC none
0.0
Kidney
0.1

HUVEC starved
0.1

HASS Panel v1.0 Summary: Ag2475 This gene was expressed in glioma samples and primary astrocytes in culture (highest expression CT=27.8) indicating a role in cell growth. Expression of this gene in U87-MG (a mixed glial/astrocytoma cell line) was repressed by reducing the oxygen content of the environment. Serum starvation of these cells induces expression. This effect was not observed in T24 (bladder cancer) cells and thus may reflect tissue specific regulation of this gene.

Panel 1.3D Summary: Ag2475 Highest expression of the CG58504-01 gene was seen in fetal skeletal muscle (CT=28.4). This expression was significantly higher than expression seen in the corresponding adult tissue (CT=36.9). In addition, the relative overexpression of this gene in fetal skeletal muscle indicates that the protein product may enhance muscular growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in restoring muscle mass or function in the treatment of muscle related diseases.

Low levels of expression were also seen in other metabolic tissues, including adipose and fetal heart, indicating a potential role for this gene in obesity and/or diabetes.

Moderate levels of expression were also seen in cell lines derived from brain cancer, breast cancer, renal cancer, lung cancer, colon cancer and melanoma. Since cell lines and fetal tissues are, on the whole, more proliferative than normal tissues, this expression profile indicates that this gene might be involved in cell proliferation. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of cancer or other diseases that involve cell proliferation. Furthermore, therapeutic targeting of this gene product with a monoclonal antibody is anticipated to limit or block the extent of tumor cell migration and invasion and tumor metastasis, particularly in brain cancer, breast cancer, renal cancer, lung cancer, colon cancer and melanoma. Expression of this gene or expressed protein is useful in the diagnosis and detection of these cancers.

Panel 2D Summary: Ag2475 Highest expression of the CG58504-01 gene was seen in a lung cancer (CT=28.3). This gene encodes a putative member of the ADAMS family. The ADAMS family of proteins has multiple domains associated with function; A fibronectin domain involved cell/extracellular matrix interaction, a thrombospondin domain involved in angiogenesis and a metalloproteinase domain involved in matrix degredation. This multi-domain structure has implications for this molecule in several tumorigenic processes, including invasion and metastasis and proliferation and cell survival. Thus, the metalloproteinase domain might play a role in cell invasion and metastasis, the fibronectin domain may play a role in cell adhesion or survival and the thrombospondin domain might play a role in angiogenesis. ADAM 12-S cleaves insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 enhances the p53-dependent apoptotic response of colorectal cells to DNA damage. IGF-BP3 is inversely, associated with risk for colorectal cancer. Expression of IGFBP-3 induces growth inhibition and differentiation of the human colon carcinoma cell line, Caco-2. All these data indicate that the protein encoded by CG58504-01 acts by cleaving and inactivating IGFBP-3 limiting its anti-tumor activity.

Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of those cancer types, like colon, lung, kidney, bladder ovarian and gastric tumors where the gene is overexpressed in the tumor compared to the normal adjacent tissue.

Panel 4D Summary: Ag2475 Highest expression of the CG58504-01 gene was seen in resting coronary artery smooth muscle cells (CT=2,7.3). Moderate to low levels of expression were seen in resting astrocytes and TNFalpha+IL-1beta treated astrocytes and coronary artery smooth muscle cells, TNF alpha and IL-4 treated dermal fibroblasts, and lung. Lower levels of expression were seen in treated and untreated lung fibroblasts. This expression indicates that this gene is a marker of smooth muscle. In addition, expression in fibroblasts and astrocytes indicates that this gene product may be involved in inflammatory conditions that involve these cells. This gene encodes a putative ADAMTS molecule which has been implicated in extracellular proteolysis and may play a critical role in the tissue degradation seen in arthritis and other inflammatory conditions (Kuno K.: J Biol Chem 1997 Jan. 3; 272(1):556-62). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of pathological and inflammatory lung and skin disorders that include chronic obstructive pulmonary disease, asthma, allergy, psoriasis and emphysema.

BK. CG59309-01: Acyl-Coenzyme a Thioester Hydrolase.

Expression of gene CG59309-01 was assessed using the primer-probe set Ag3540, described in Table BKA. Results of the RTQ-PCR runs are shown in Tables BKB, BKC, BKD and BKE.

TABLE BKAProbe Name Ag3540SEQStartIDPrimersSequencesLengthPositionNoForward5′-ccacgttggctctagcttatta-3′226491413ProbeTET-5′-tgaagatctccccaataacatggaca-3′-266771414TAMRAReverse5′-ttcgaagtactccagggatatg-3′227041415

TABLE BKB

General_screening_panel_v1.4

Column A - Rel. Exp. (%) Ag3540, Run 217049291

Tissue Name
A

Adipose
1.3

Melanoma* Hs688(A).T
0.7

Melanoma* Hs688(B).T
0.5

Melanoma* M14
0.2

Melanoma* LOXIMVI
0.0

Melanoma* SK-MEL-5
0.0

Squamous cell carcinoma SCC-4
0.3

Testis Pool
0.3

Prostate ca.* (bone met) PC-3
0.8

Prostate Pool
0.3

Placenta
1.4

Uterus Pool
0.1

Ovarian ca. OVCAR-3
1.6

Ovarian ca. SK-OV-3
3.6

Ovarian ca. OVCAR-4
0.4

Ovarian ca. OVCAR-5
23.7

Ovarian ca. IGROV-1
0.0

Ovarian ca. OVCAR-8
0.0

Ovary
0.1

Breast ca. MCF-7
0.0

Breast ca. MDA-MB-231
2.5

Breast ca. BT 549
3.0

Breast ca. T47D
100.0

Breast ca. MDA-N
0.0

Breast Pool
0.3

Trachea
0.4

Lung
0.0

Fetal Lung
0.2

Lung ca. NCI-N417
0.0

Lung ca. LX-1
3.5

Lung ca. NCI-H146
0.0

Lung ca. SHP-77
0.1

Lung ca. A549
1.4

Lung ca. NCI-H526
0.7

Lung ca. NCI-H23
1.3

Lung ca. NCI-H460
0.8

Lung ca. HOP-62
1.2

Lung ca. NCI-H522
0.0

Liver
2.6

Fetal Liver
0.8

Liver ca. HepG2
0.1

Kidney Pool
0.7

Fetal Kidney
0.6

Renal ca. 786-0
0.0

Renal ca. A498
0.0

Renal ca. ACHN
0.0

Renal ca. UO-31
1.1

Renal ca. TK-10
0.1

Bladder
1.1

Gastric ca. (liver met.) NCI-N87
5.6

Gastric ca. KATO III
0.0

Colon ca. SW-948
0.0

Colon ca. SW480
10.3

Colon ca.* (SW480 met) SW620
2.8

Colon ca. HT29
0.8

Colon ca. HCT-116
0.0

Colon ca. CaCo-2
3.5

Colon cancer tissue
1.4

Colon ca. SW1116
0.0

Colon ca. Colo-205
3.3

Colon ca. SW-48
1.7

Colon Pool
0.2

Small Intestine Pool
0.3

Stomach Pool
0.1

Bone Marrow Pool
0.2

Fetal Heart
0.4

Heart Pool
0.2

Lymph Node Pool
0.3

Fetal Skeletal Muscle
0.1

Skeletal Muscle Pool
0.4

Spleen Pool
0.2

Thymus Pool
0.3

CNS cancer (glio/astro) U87-MG
0.0

CNS cancer (glio/astro) U-118-MG
0.3

CNS cancer (neuro; met) SK-N-AS
1.0

CNS cancer (astro) SF-539
0.6

CNS cancer (astro) SNB-75
3.1

CNS cancer (glio) SNB-19
0.0

CNS cancer (glio) SF-295
0.2

Brain (Amygdala) Pool
0.7

Brain (cerebellum)
2.1

Brain (fetal)
0.5

Brain (Hippocampus) Pool
1.0

Cerebral Cortex Pool
0.9

Brain (Substantia nigra) Pool
1.3

Brain (Thalamus) Pool
1.1

Brain (whole)
1.4

Spinal Cord Pool
0.5

Adrenal Gland
0.8

Pituitary gland Pool
0.1

Salivary Gland
0.2

Thyroid (female)
0.7

Pancreatic ca. CAPAN2
9.4

Pancreas Pool
0.9

TABLE BKC

Panel 4D

Column A - Rel. Exp. (%) Ag3540, Run 166447040

Tissue Name
A
Tissue Name
A

Secondary Th1 act
4.8
HUVEC IL-1 beta
1.7

Secondary Th2 act
10.2
HUVEC IFN gamma
0.9

Secondary Tr1 act
12.9
HUVEC TNF alpha + IFN gamma
1.5

Secondary Th1 rest
2.1
HUVEC TNF alpha + IL4
0.8

Secondary Th2 rest
1.4
HUVEC IL-11
1.5

Secondary Tr1 rest
1.6
Lung Microvascular EC none
0.6

Primary Th1 act
4.7
Lung Microvascular EC TNF alpha + IL-1
0.8

beta

Primary Th2 act
6.8
Microvascular Dermal EC none
1.5

Primary Tr1 act
7.3
Microsvasular Dermal EC TNF alpha + IL-1
0.8

beta

Primary Th1 rest
6.6
Bronchial epithelium TNF alpha + IL1beta
1.3

Primary Th2 rest
2.6
Small airway epithelium none
0.6

Primary Tr1 rest
4.2
Small airway epithelium TNF alpha + IL-1
0.0

beta

CD45RA CD4 lymphocyte act
4.1
Coronery artery SMC rest
0.9

CD45RO CD4 lymphocyte act
10.9
Coronery artery SMC TNF alpha + IL-1 beta
0.0

CD8 lymphocyte act
6.6
Astrocytes rest
2.6

Secondary CD8 lymphocyte rest
17.0
Astrocytes TNF alpha + IL-1 beta
2.1

Secondary CD8 lymphocyte act
6.0
KU-812 (Basophil) rest
2.2

CD4 lymphocyte none
2.0
KU-812 (Basophil) PMA/ionomycin
10.2

2ry Th1/Th2/Tr1 anti-CD95
2.4
CCD1106 (Keratinocytes) none
6.8

CH11

LAK cells rest
2.0
CCD1106 (Keratinocytes) TNF alpha + IL-1
25.7

beta

LAK cells IL-2
16.2
Liver cirrhosis
12.0

LAK cells IL-2 + IL-12
12.8
Lupus kidney
5.1

LAK cells IL-2 + IFN gamma
15.6
NCI-H292 none
44.8

LAK cells IL-2 + IL-18
7.4
NCI-H292 IL-4
37.6

LAK cells PMA/ionomycin
3.4
NCI-H292 IL-9
41.2

NK Cells IL-2 rest
9.0
NCI-H292 IL-13
19.8

Two Way MLR 3 day
10.5
NCI-H292 IFN gamma
30.1

Two Way MLR 5 day
7.2
HPAEC none
1.2

Two Way MLR 7 day
8.9
HPAEC TNF alpha + IL-1 beta
3.3

PBMC rest
0.5
Lung fibroblast none
0.9

PBMC PWM
3.8
Lung fibroblast TNF alpha + IL-1 beta
0.7

PBMC PHA-L
1.0
Lung fibroblast IL-4
0.5

Ramos (B cell) none
0.0
Lung fibroblast IL-9
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
0.9

B lymphocytes PWM
10.3
Lung fibroblast IFN gamma
1.2

B lymphocytes CD40L and IL-4
3.8
Dermal fibroblast CCD1070 rest
1.1

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
18.9

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
1.9

PMA/ionomycin

Dendritic cells none
14.9
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
8.9
Dermal fibroblast IL-4
1.5

Dendritic cells anti-CD40
7.9
IBD Colitis 2
2.9

Monocytes rest
0.0
IBD Crohn's
1.9

Monocytes LPS
0.6
Colon
82.9

Macrophages rest
40.3
Lung
9.7

Macrophages LPS
6.1
Thymus
100.0

HUVEC none
1.1
Kidney
1.8

HUVEC starved
1.4

TABLE BKD

Panel 5 Islet

Column A - Rel. Exp. (%) Ag3540, Run 242386396

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
3.3
94709 Donor 2 AM - A adipose
9.1

97476 Patient-07sk skeletal muscle
0.8
94710 Donor 2 AM - B adipose
1.6

97477 Patient-07ut uterus
0.0
94711 Donor 2 AM - C adipose
1.4

97478 Patient-07pl placenta
12.9
94712 Donor 2 AD - A adipose
2.8

99167 Bayer Patient 1
15.5
94713 Donor 2 AD - B adipose
5.8

97482 Patient-08ut uterus
3.4
94714 Donor 2 AD - C adipose
4.2

97483 Patient-08pl placenta
3.4
94742 Donor 3 U - A Mesenchymal
3.0

Stem Cells

97486 Patient-09sk skeletal muscle
100.0
94743 Donor 3 U - B Mesenchymal
1.1

Stem Cells

97487 Patient-09ut uterus
1.6
94730 Donor 3 AM - A adipose
4.3

97488 Patient-09pl placenta
2.6
94731 Donor 3 AM - B adipose
2.0

97492 Patient-10ut uterus
3.1
94732 Donor 3 AM - C adipose
2.0

97493 Patient-10pl placenta
23.2
94733 Donor 3 AD - A adipose
10.7

97495 Patient-11go adipose
0.8
94734 Donor 3 AD - B adipose
3.0

97496 Patient-11sk skeletal muscle
0.0
94735 Donor 3 AD - C adipose
4.0

97497 Patient-11ut uterus
2.5
77138 Liver HepG2untreated
0.7

97498 Patient-11pl placenta
6.7
73556 Heart Cardiac stromal cells
0.0

(primary)

97500 Patient-12go adipose
6.5
81735 Small Intestine
4.8

97501 Patient-12sk skeletal muscle
4.5
72409 Kidney Proximal Convoluted
0.7

Tubule

97502 Patient-12ut uterus
6.7
82685 Small intestine Duodenum
3.6

97503 Patient-12p1 placenta
2.4
90650 Adrenal Adrenocortical
0.6

adenoma

94721 Donor 2 U - A Mesenchymal
2.2
72410 Kidney HRCE
8.0

Stem Cells

94722 Donor 2 U - B Mesenchymal
0.6
72411 Kidney HRE
8.5

Stem Cells

94723 Donor 2 U - C Mesenchymal
3.1
73139 Uterus Uterine smooth muscle
0.0

Stem Cells

cells

TABLE BKE

general oncology screening panel_v_2.4

Column A - Rel. Exp. (%) Ag3540, Run 267294323

Tissue Name
A
Tissue Name
A

Colon cancer 1
2.8
Bladder NAT 2
0.0

CC Margin (ODO3921)
2.9
Bladder NAT 3
0.0

Colon cancer 2
6.9
Bladder NAT 4
0.0

Colon NAT 2
3.3
Prostate adenocarcinoma 1
3.5

Colon cancer 3
7.9
Prostate adenocarcinoma 2
0.0

Colon NAT 3
5.0
Prostate adenocarcinoma 3
1.1

Colon malignant cancer 4
7.1
Prostate adenocarcinoma 4
0.8

Colon NAT 4
0.9
Prostate NAT 5
0.4

Lung cancer 1
1.9
Prostate adenocarcinoma 6
0.6

Lung NAT 1
0.0
Prostate adenocarcinoma 7
0.0

Lung cancer 2
0.0
Prostate adenocarcinoma 8
0.0

Lung NAT 2
0.0
Prostate adenocarcinoma 9
0.8

Squamous cell carcinoma 3
2.6
Prostate NAT 10
0.0

Lung NAT 3
0.0
Kidney cancer 1
5.1

Metastatic melanoma 1
2.4
Kidney NAT 1
2.3

Melanoma 2
0.4
Kidney cancer 2
100.0

Melanoma 3
0.0
Kidney NAT 2
5.1

Metastatic melanoma 4
2.7
Kidney cancer 3
7.7

Metastatic melanoma 5
6.9
Kidney NAT 3
1.3

Bladder cancer 1
0.0
Kidney cancer 4
1.3

Bladder NAT 1
0.0
Kidney NAT 4
13.1

Bladder cancer 2
0.4

General_screening_panel_v1.4 Summary: Ag3540 This gene was most highly expressed in a breast cancer cell line (CT=27.1). Expression of this gene is useful as a marker to detect the presence of breast cancer. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of breast cancer.

Among metabolic tissues, this gene, an acyl coA thioesterase homolog, had a low level of expression in adipose, adult and fetal liver, adrenal, thyroid and pancreas. Acyl CoA thioesterases have multiple roles in lipid homeostasis (Hunt M C, Alexson S E. The role Acyl-CoA thioesterases play in mediating intracellular lipid metabolism. Prog Lipid Res. 2002 March; 41(2):99-130; Hunt M C, Nousiainen S E, Huttunen M K, Orii K E, Svensson L T, Alexson S E. Peroxisome proliferator-induced long chain acyl-CoA thioesterases comprise a highly conserved novel multi-gene family involved in lipid metabolism. J Biol. Chem. 1999 Nov. 26; 274(48):34317-26). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of endocrine and metabolic disease, including Types 1 and 2 diabetes and obesity.

In addition, this gene was expressed in all CNS regions examined. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of neurologic disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, stroke, schizophrenia and multiple sclerosis.

Panel 4D Summary: Ag3540 Highest expression of the CG59309-01 gene was seen in the thymus and colon (CTs=31.5). Significant levels of expression were also seen in a cluster of treated and untreated samples derived from the NCI-H292 mucoepidermoid cell line. Expression of this gene is useful as a marker for thymus and colon tissue. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in regulating T cell development in the thymus or in the treatment of T cell mediated autoimmune or inflammatory diseases, including asthma, allergies, inflammatory bowel disease, lupus erythematosus, or rheumatoid arthritis. Small molecule or antibody therapeutics designed against this protein disrupts T cell development in the thymus and functions as an immunosuppresant for tissue transplants.

Panel 5 Islet Summary: Ag3540 This gene had moderate expression in skeletal muscle (highest expression CT=30.5). Acyl CoA thioesterases function in peroxisomal fatty acid oxidation (Hunt M C, Solaas K, Kase B F, Alexson S E. Characterization of an acyl-coA thioesterase that functions as a major regulator of peroxisomal lipid metabolism. J Biol. Chem. 2002 Jan. 11; 277(2): 1128-38). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in increasing fatty acid oxidation in muscle, and in the treatment of Type 2 diabetes and obesity.

general oncology screening panel_v_—2.4 Summary: Ag3540 Prominent expression was detected in a kidney cancer sample (CT=31.8). Expression of this gene is useful as a marker of this cancer. Targeting this gene or gene product with small molecule, antibody, or protein therapeutics is useful in the treatment of kidney cancer.

BL. CG59490-01: S562_F7.

Expression of gene CG59490-01 was assessed using the primer-probe sets Ag1038, Ag1590, Ag1918, Ag2899, Ag720, Ag730 and Ag443, described in Tables BLA, BLB, BLC, BLD, BLE, BLF and BLG. Results of the RTQ-PCR runs are shown in Tables BLH, BLI, BLJ, BLK and BLL.

TABLE BLAProbe Name Ag1038SEQStartIDPrimersSequencesLengthPositionNoForward5′-aggagcaacgtcctctgtaac-3′213671416ProbeTET-5′-cttccaaccacactgagcggtttgag-3′-264101417TAMRAReverse5-agcatgtcgtccttgatgag-3′204391418

TABLE BLB

Probe Name Ag1590

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-aggagcaacgtcctctgtaac-3′
21
367
1419

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′-
26
410
1420

TAMRA

Reverse
5′-agcatgtcgtccttgatgag-3′
20
439
1421

TABLE BLC

Probe Name Ag1918

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-aggagcaacgtcctctgtaac-3′
21
367
1422

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′-
26
410
1423

TAMRA

Reverse
5′-agcatgtcgtccttgatgag-3′
20
439
1424

TABLE BLD

Probe Name Ag2899

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-aggagcaacgtcctctgtaac-3′
21
367
1425

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′
26
410
1426

TAMRA

Reverse
5′-agcatgtcgtccttgatgag-3′
20
439
1427

TABLE BLE

Probe Name Ag720

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-aggagcaacgtcctctgtaac-3′
21
367
1428

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′-
26
410
1429

TAMRA

Reverse
5′-acagcatgtcgtccttgatg-3′
20
441
1430

TABLE BLF

Probe Name Ag730

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-caggagcaacgtcctctgta-3′
20
366
1431

Probe
TET-5′-cttccaaccacactgagcggtttgag-3′-
26
410
1432

TAMRA

Reverse
5′-cacacagcatgtcgtcctt-3′
19
445
1433

TABLE BLG

Probe Name Ag443

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-gacggtgaaggtcaggagca-3′
20
354
1434

Probe
TET-5′-cctgtcgccgccgctttcc-3′-TAMRA
19
392
1435

Reverse
5′-aaccgctcagtgtggttgg-3′
19
413
1436

TABLE BLH

Ardais Breast1.0

Column A - Rel. Exp. (%) Ag720, Run 389241931

Tissue Name
A

111297 Breast cancer metastasis (9369)*
0.0

108830 Breast cancer metastasis (OD06855)*
1.1

97764 Breast cancer node metastasis (OD06083)
1.3

97739 Breast cancer (CHTN20676)
0.1

145848 Breast cancer (9B6)
8.4

145859 Breast cancer (9EC)
1.2

153632 Breast cancer (D39)
0.0

153636 Breast cancer (D3D)
0.4

164668 Breast cancer (6314)
0.1

164677 Breast cancer (5272)
12.4

164685 Breast cancer (0170)
11.3

98857 Breast cancer (OD06397-12)
0.0

153628 Breast cancer (D35)
0.8

153637 Breast cancer (D3E)
5.4

153643 Breast cancer (D44)
10.7

164672 Breast cancer (7464)
26.1

164681 Breast cancer (5787)
9.7

97748 Breast cancer (CHTN20931)
2.2

145850 Breast cancer (9C7)
0.1

149844 Breast cancer (24178)
2.5

153633 Breast cancer (D3A)
0.4

153644 Breast cancer (D45)
9.0

164673 Breast cancer (8452)
29.1

164682 Breast cancer (6342)*
7.7

97751 Breast cancer (CHTN21053)
0.8

116417 Breast cancer (3367)*
0.1

145852 Breast cancer (A1A)
13.0

151097 Breast cancer (CHTN24298)
0.4

153634 Breast cancer (D3B)
0.8

155797 Breast cancer (EA6)
2.2

164674 Breast cancer (8811)
8.2

164683 Breast cancer (6470)
2.4

97763 Breast cancer (OD06083)
0.8

116418 Breast cancer (3378)*
1.3

145853 Breast cancer (9F3)
0.4

153432 Breast cancer (CHTN 24652)
16.6

153635 Breast cancer (D3C)
1.1

164667 Breast cancer (5785)
1.6

164676 Breast cancer (5070)
100.0

164684 Breast cancer (6509)
24.8

116421 Breast cancer (6314)
0.0

145854 Breast cancer (9B8)
5.9

153627 Breast cancer (D34)
0.2

164669 Breast cancer (6992)
6.0

164678 Breast cancer (5297)
68.8

164686 Breast cancer (0732)
0.5

145857 Breast cancer (9F0)
15.2

153630 Breast cancer (D37)
0.6

153638 Breast cancer (D3F)
23.7

164670 Breast cancer (7078)
1.1

164679 Breast cancer (5486)
4.3

164687 Breast cancer (5881)
0.5

145846 Breast cancer (9B7)
22.5

145858 Breast cancer (9B4)
0.0

153631 Breast cancer (D38)
1.6

153639 Breast cancer (D40)
22.2

164671 Breast cancer (7082)
0.3

164680 Breast cancer (5705)
0.0

164688 Breast cancer (7222)
0.0

111288 Breast NAT (3367)
0.3

111302 Breast NAT (6314)
0.6

105687 Breast cancer 1B
0.0

105688 Breast NAT 1A
0.0

105689 Breast cancer 2B
0.0

105690 Breast NAT 2A
0.0

111289 Breast cancer 3B*
0.0

111290 Breast NAT 3A*
0.0

116424 Breast cancer 4B*
0.1

116425 Breast NAT 4A
0.0

108847 Breast cancer
0.0

105694 Breast NAT
0.0

TABLE BLI

Panel 1.3D

Column A - Rel. Exp. (%) Ag1590, Run 152059684

Column B - Rel. Exp. (%) Ag1590, Run 155330156

Column C - Rel. Exp. (%) Ag2899, Run 160943164

Column D - Rel. Exp. (%) Ag2899, Run 165518181

Tissue Name
A
B
C
D

Liver adenocarcinoma
0.0
1.1
1.7
0.0

Pancreas
0.0
0.0
0.0
6.9

Pancreatic ca. CAPAN 2
8.7
2.5
5.6
10.5

Adrenal gland
0.0
0.8
0.0
0.0

Thyroid
0.0
0.0
0.0
0.0

Salivary gland
0.0
0.0
0.0
2.4

Pituitaiy gland
34.2
34.2
16.7
42.0

Brain (fetal)
0.0
0.0
0.0
1.9

Brain (whole)
0.0
0.0
0.0
0.0

Brain (amygdala)
0.0
0.0
0.0
0.0

Brain (cerebellum)
0.0
0.0
0.0
0.0

Brain (hippocampus)
0.0
0.0
0.0
0.0

Brain (substantia nigra)
0.0
0.0
0.0
0.0

Brain (thalamus)
0.0
0.0
0.0
0.0

Cerebral Cortex
1.2
0.0
0.0
0.0

Spinal cord
0.0
0.0
0.0
0.0

glio/astro U87-MG
0.0
0.0
0.0
0.0

glio/astro U-118-MG
0.0
0.0
0.0
0.0

astrocytoma SW1783
0.3
1.0
0.0
2.3

neuro*; met SK-N-AS
0.0
0.0
0.0
0.0

astrocytoma SF-539
0.0
0.0
0.0
0.0

astrocytoma SNB-75
0.7
0.0
0.0
4.5

glioma SNB-19
0.0
0.0
0.0
2.5

glioma U251
0.0
0.0
0.0
0.0

glioma SF-295
0.0
0.0
0.0
0.0

Heart (Fetal)
0.0
1.4
0.0
0.0

Heart
0.0
0.0
0.0
0.0

Skeletal muscle (Fetal)
0.0
0.0
0.0
0.0

Skeletal muscle
0.0
0.0
0.0
0.0

Bone marrow
0.9
0.0
1.0
0.0

Thymus
0.7
0.9
1.4
3.7

Spleen
0.6
1.7
0.0
0.0

Lymph node
0.0
0.0
0.0
0.0

Colorectal
3.9
2.4
1.6
8.8

Stomach
0.0
2.4
0.0
0.0

Small intestine
0.0
0.0
0.0
2.0

Colon ca. SW480
0.8
1.5
0.0
0.0

Colon ca.* SW620 (SW480 met)
0.9
0.9
3.4
0.0

Colon ca. HT29
0.0
0.0
0.0
0.0

Colon ca. HCT-116
0.0
1.0
0.0
1.0

Colon ca. CaCo-2
0.0
1.4
0.0
0.0

CC Well to Mod Diff (ODO3866)
8.8
8.1
15.2
26.8

Colon ca. HCC-2998
32.3
29.3
29.9
22.2

Gastric ca. (liver met) NCI-N87
32.1
31.6
36.9
70.7

Bladder
0.8
0.0
0.0
0.0

Trachea
0.8
1.1
0.0
0.0

Kidney
1.8
0.0
1.7
1.0

Kidney (fetal)
3.8
0.9
7.6
0.0

Renal ca. 786-0
0.0
0.0
0.0
0.0

Renal ca. A498
0.8
0.0
0.0
0.0

Renal ca. RXF 393
0.0
0.0
0.0
3.2

Renal ca. ACHN
2.1
0.0
0.0
0.0

Renal ca. UO-31
0.0
0.0
0.0
0.0

Renal ca. TK-10
0.0
0.0
0.0
0.0

Liver
4.7
5.2
3.5
33.9

Liver (fetal)
9.0
6.0
3.7
18.3

Liver ca. (hepatoblast) HepG2
2.4
1.2
1.8
0.0

Lung
0.0
0.0
3.2
0.0

Lung (fetal)
0.4
0.0
0.0
0.0

Lung ca. (small cell) LX-1
6.9
13.1
9.5
10.5

Lung ca. (small cell) NCI-H69
2.2
1.3
0.8
0.0

Lung ca. (s. cell var.) SHP-77
3.3
1.1
6.5
6.3

Lung ca. (large cell) NCI-H460
0.0
0.0
0.0
0.0

Lung ca. (non-sm. cell) A549
0.0
0.0
0.0
0.0

Lung ca. (non-s.cell) NCI-H23
0.0
0.0
0.0
0.0

Lung ca. (non-s.cell) HOP-62
0.8
0.0
0.0
0.0

Lung ca. (non-s.cl) NCI-H522
0.0
0.5
0.0
0.0

Lung ca. (squam.) SW 900
0.8
0.0
0.0
0.0

Lung ca. (squam.) NCI-H596
0.4
0.5
0.0
0.0

Mammary gland
2.7
4.2
0.0
7.9

Breast ca.* (pl.ef) MCF-7
4.1
0.0
0.0
2.5

Breast ca.* (pl.ef) MDA-MB-231
0.0
0.0
1.7
0.0

Breast ca.* (p1. ef) T47D
6.5
5.3
0.7
4.3

Breast ca. BT-549
0.0
0.0
0.0
0.0

Breast ca. MDA-N
0.0
1.1
1.7
0.0

Ovary
0.0
0.0
0.0
0.0

Ovarian ca. OVCAR-3
0.0
0.0
0.0
0.0

Ovarian ca. OVCAR-4
0.0
0.0
0.0
0.0

Ovarian ca. OVCAR-5
100.0
100.0
100.0
100.0

Ovarian ca. OVCAR-8
2.5
0.0
0.0
2.5

Ovarian ca. IGROV-1
0.0
0.0
0.0
0.0

Ovarian ca. (ascites) SK-OV-3
0.0
0.0
0.0
0.0

Uterus
0.0
0.0
0.0
0.0

Placenta
9.2
6.9
8.0
14.0

Prostate
1.9
5.2
1.8
4.1

Prostate ca.* (bone met) PC-3
0.0
0.0
0.0
0.0

Testis
6.3
9.3
8.9
8.8

Melanoma Hs688(A).T
0.0
0.0
0.0
0.0

Melanoma* (met) Hs688(B).T
0.0
0.0
0.0
0.0

Melanoma UACC-62
0.0
0.0
0.0
0.0

Melanoma M14
0.0
0.0
0.0
0.0

Melanoma LOX IMVI
0.0
0.0
0.0
0.0

Melanoma* (met) SK-MEL-5
0.0
0.0
0.0
0.0

Adipose
0.0
0.0
0.0
0.0

TABLE BLJ

Panel 2D

Column A - Rel. Exp. (%) Ag1590, Run 152060853

Column B - Rel. Exp. (%) Ag1590, Run 155330182

Column C - Rel. Exp. (%) Ag2899, Run 160999416

Column D - Rel. Exp. (%) Ag2899, Run 164988403

Column E - Rel. Exp. (%) Ag720, Run 145375720

Tissue Name
A
B
C
D
E

Normal Colon
0.1
0.0
0.1
0.3
0.0

CC Well to Mod Diff (ODO3866)
9.2
11.3
5.5
8.5
2.2

CC Margin (ODO3866)
0.2
0.0
0.0
0.3
0.0

CC Gr. 2 rectosigmoid (ODO3868)
0.0
0.2
0.0
0.3
0.0

CC Margin (ODO3868)
0.0
0.0
0.0
0.0
0.0

CC Mod Diff (ODO3920)
0.2
0.1
0.0
0.5
0.0

CC Margin (ODO3920)
0.0
0.0
0.0
0.0
0.0

CC Gr. 2 ascend colon (ODO3921)
0.0
0.0
0.1
0.1
0.0

CC Margin (ODO3921)
0.3
0.2
0.1
0.1
0.0

CC from Partial Hepatectomy (ODO4309) Mets
1.4
1.4
0.2
1.8
0.3

Liver Margin (ODO4309)
1.8
0.9
0.6
2.0
0.4

Colon mets to lung (ODO4451-01)
0.2
0.2
0.3
0.4
0.2

Lung Margin (OD04451-02)
0.0
0.0
0.0
0.0
0.0

Normal Prostate 6546-1
0.4
0.7
0.2
1.6
0.4

Prostate Cancer (OD04410)
0.0
0.0
0.0
0.0
0.0

Prostate Margin (OD04410)
0.0
0.0
0.0
0.4
0.0

Prostate Cancer (OD04720-01)
0.9
1.2
0.3
0.5
0.4

Prostate Margin (OD04720-02)
0.3
0.4
0.3
0.0
0.1

Normal Lung
0.0
0.0
0.1
0.0
0.0

Lung Met to Muscle (ODO4286)
0.0
0.3
0.0
0.0
0.2

Muscle Margin (ODO4286)
0.2
0.0
0.0
0.1
0.0

Lung Malignant Cancer (OD03126)
0.0
0.3
0.0
0.2
0.2

Lung Margin (OD03126)
0.0
0.1
0.0
0.0
0.0

Lung Cancer (OD04404)
0.0
0.0
0.0
0.0
0.1

Lung Margin (OD04404)
0.0
0.0
0.0
0.0
0.0

Lung Cancer (OD04565)
0.2
0.0
0.0
0.4
0.1

Lung Margin (OD04565)
0.0
0.0
0.0
0.0
0.0

Lung Cancer (OD04237-01)
0.0
0.2
0.0
0.5
0.0

Lung Margin (OD04237-02)
0.0
0.0
0.0
0.0
0.0

Ocular Mel Met to Liver (ODO4310)
0.0
0.0
0.0
0.0
0.0

Liver Margin (ODO4310)
1.0
1.1
0.0
1.0
0.5

Melanoma Metastasis
0.0
0.0
0.0
0.0
0.0

Lung Margin (OD04321)
0.0
0.0
0.0
0.0
0.0

Normal Kidney
0.3
1.1
0.1
0.7
0.3

Kidney Ca, Nuclear grade 2 (OD04338)
0.0
0.0
0.1
0.1
0.0

Kidney Margin (OD04338)
0.2
0.7
0.2
0.2
0.1

Kidney Ca Nuclear grade 1/2 (OD04339)
0.1
0.1
0.3
0.4
0.0

Kidney Margin (OD04339)
0.6
0.3
0.7
1.4
0.3

Kidney Ca, Clear cell type (OD04340)
0.0
0.0
0.0
0.0
0.0

Kidney Margin (OD04340)
1.2
0.8
0.4
0.9
0.5

Kidney Ca, Nuclear grade 3 (OD04348)
0.0
0.0
0.0
0.6
0.0

Kidney Margin (OD04348)
0.4
0.4
0.4
0.0
0.3

Kidney Cancer (OD04622-01)
0.0
0.0
0.0
0.0
0.0

Kidney Margin (OD04622-03)
0.4
0.1
0.0
0.0
0.2

Kidney Cancer (OD04450-01)
0.3
0.2
0.1
0.0
0.0

Kidney Margin (OD04450-03)
0.0
0.2
0.0
0.3
0.2

Kidney Cancer 8120607
0.0
0.0
0.0
0.0
0.0

Kidney Margin 8120608
0.0
0.4
0.1
0.0
0.1

Kidney Cancer 8120613
0.1
0.9
0.3
0.6
0.2

Kidney Margin 8120614
0.3
0.3
0.0
0.0
0.0

Kidney Cancer 9010320
0.0
0.1
0.0
0.0
0.0

Kidney Margin 9010321
0.1
0.0
0.0
0.0
0.1

Normal Uterus
0.0
0.0
0.0
0.0
0.0

Uterine Cancer 064011
0.0
0.0
0.0
0.0
0.0

Normal Thyroid
0.0
0.1
0.0
0.0
0.0

Thyroid Cancer
0.0
0.3
0.3
0.0
0.0

Thyroid Cancer A302152
0.1
0.0
0.0
0.0
0.1

Thyroid Margin A302153
0.0
0.0
0.0
0.0
0.0

Normal Breast
0.3
0.4
0.1
1.2
0.5

Breast Cancer
33.4
34.6
22.7
55.9
47.0

Breast Cancer (OD04590-01)
100.0
100.0
100.0
100.0
30.6

Breast Cancer Mets (OD04590-03)
63.3
72.7
73.7
88.9
100.0

Breast Cancer Metastasis
2.8
2.6
2.0
2.6
2.9

Breast Cancer
3.6
5.2
2.2
6.4
3.1

Breast Cancer
1.0
1.9
2.2
1.9
0.5

Breast Cancer 9100266
3.5
3.3
1.1
7.1
4.1

Breast Margin 9100265
0.0
0.3
0.1
0.2
0.3

Breast Cancer A209073
2.3
1.6
0.7
2.0
1.7

Breast Margin A209073
0.7
1.3
0.7
0.9
0.2

Normal Liver
0.1
0.5
0.4
2.2
0.9

Liver Cancer
0.3
0.3
0.4
0.3
0.1

Liver Cancer 1025
0.4
0.7
0.5
1.3
0.5

Liver Cancer 1026
0.7
0.1
0.3
1.1
0.2

Liver Cancer 6004-T
0.9
1.1
1.4
2.8
0.6

Liver Tissue 6004-N
0.0
0.0
0.1
0.0
0.0

Liver Cancer 6005-T
0.8
0.8
1.2
0.7
0.2

Liver Tissue 6005-N
0.1
0.0
0.2
0.5
0.0

Normal Bladder
0.0
0.0
0.1
0.4
0.1

Bladder Cancer
0.0
0.1
0.0
0.0
0.1

Bladder Cancer
0.1
0.4
0.3
0.0
0.1

Bladder Cancer (OD04718-01)
0.2
0.2
0.3
0.0
0.4

Bladder Normal Adjacent (OD04718-03)
0.0
0.0
0.0
0.0
0.0

Normal Ovary
0.0
0.0
0.0
0.0
0.0

Ovarian Cancer
0.0
0.0
0.0
0.2
0.0

Ovarian Cancer (OD04768-07)
0.1
0.0
0.1
0.0
0.0

Ovary Margin (OD04768-08)
0.0
0.0
0.0
0.0
0.0

Normal Stomach
0.0
0.1
0.0
0.2
0.0

Gastric Cancer 9060358
0.0
0.0
0.0
0.0
0.0

Stomach Margin 9060359
0.0
0.0
0.0
0.0
0.0

Gastric Cancer 9060395
0.0
0.0
0.0
0.0
0.0

Stomach Margin 9060394
0.0
0.0
0.0
0.0
0.0

Gastric Cancer 9060397
1.5
0.7
0.6
0.3
0.2

Stomach Margin 9060396
0.0
0.0
0.0
0.0
0.0

Gastric Cancer 064005
0.1
0.3
0.0
0.2
0.2

TABLE BLK

Panel 3D

Column A - Rel. Exp. (%) Ag2899, Run 164633619

Column B - Rel. Exp. (%) Ag720, Run 164843791

Tissue Name
A
B
Tissue Name
A
B

94905 Daoy
0.0
0.0
94954 Ca Ski Cervical
0.0
3.2

Medulloblastoma/Cerebellum

epidermoid carcinoma

(metastasis

94906 TE671
0.0
0.0
94955 ES-2 Ovarian clear cell
0.0
0.0

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
0.0
0.0
94957 Ramos Stimulated with
0.0
0.0

Medulloblastoma/Cerebellum

PMA/ionomycin 6 h

94908 PFSK-1 Primitive
0.0
1.4
94958 Ramos Stimulated with
0.0
0.0

Neuroectodermal/Cerebellum

PMA/ionomycin 14 h

94909 XF-498 CNS
0.0
0.0
94962 MEG-01 Chronic
0.0
0.0

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
0.0
0.0
94963 Raji Burkitt's
0.0
0.0

lymphoma

94911 SF-268 CNS/glioblastoma
0.0
0.0
94964 Daudi Burkitt's
0.0
0.0

lymphoma

94912 T98G Glioblastoma
0.0
0.0
94965 U266 B-cell
14.7
17.6

plasmacytoma/myeloma

96776 SK-N-SH Neuroblastoma
0.0
0.0
94968 CA46 Burkitt's
0.0
0.0

(metastasis)

lymphoma

94913 SF-295 CNS/glioblastoma
0.0
0.0
94970 RL non-Hodgkin's B-
0.0
0.0

cell lymphoma

94914 Cerebellum
0.0
0.0
94972 JM1 pre-B-cell
0.0
0.0

lymphoma/leukemia

96777 Cerebellum
1.2
0.0
94973 Jurkat T cell leukemia
0.0
0.0

94916 NCI-H292
0.0
0.0
94974 TF-1 Erythroleukemia
0.0
0.0

Mucoepidermoid lung carcinoma

94917 DMS-114 Small cell lung
0.0
0.0
94975 HUT 78 T-cell
0.0
0.0

cancer

lymphoma

94918 DMS-79 Small cell lung
100.0
100.0
94977 U937 Histiocytic
0.0
0.0

cancer/neuroendocrine

lymphoma

94919 NCI-H146 Small cell lung
0.0
0.0
94980 KU-812 Myelogenous
0.0
0.0

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
0.0
0.0
769-P- Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94921 NCI-N417 Small cell lung
0.0
0.0
94983 Caki-2 Clear cell renal
0.8
1.9

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
0.0
0.0
94984 SW 839 Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell
0.0
0.0
94986 G401 Wilms' tumor
0.0
0.0

lung cancer (metastasis)

94925 NCI-H1155 Large cell
0.0
0.0
94987 Hs766T Pancreatic
1.2
5.5

lung cancer/neuroendocrine

carcinoma (LN metastasis)

94926 NCI-H1299 Large cell
0.0
0.0
94988 CAPAN-1 Pancreatic
0.0
0.0

lung cancer/neuroendocrine

adenocarcinoma (liver

metastasis)

94927 NCI-H727 Lung carcinoid
0.0
0.0
94989 SU86.86 Pancreatic
0.0
0.0

carcinoma (liver metastasis)

94928 NCI-UMC-11 Lung
0.0
4.9
94990 BxPC-3 Pancreatic
0.0
2.9

carcinoid

adenocarcinoma

94929 LX-1 Small cell lung
3.2
3.7
94991 HPAC Pancreatic
1.2
5.1

cancer

adenocarcinoma

94930 Colo-205 Colon cancer
7.5
29.3
94992 MIA PaCa-2 Pancreatic
0.0
0.0

carcinoma

94931 KM12 Colon cancer
0.2
1.6
94993 CFPAC-1 Pancreatic
29.1
47.6

ductal adenocarcinoma

94932 KM20L2 Colon cancer
1.2
0.0
94994 PANC-1 Pancreatic
0.0
0.0

epithelioid ductal carcinoma

94933 NCI-H716 Colon cancer
0.0
0.0
94996 T24 Bladder carcinma
0.0
0.0

(transitional cell

94935 SW-48 Colon
0.0
0.0
5637- Bladder carcinoma
0.0
0.0

adenocarcinoma

94936 SW1116 Colon
0.0
0.0
94998 HT-1197 Bladder
5.1
7.6

adenocarcinoma

carcinoma

94937 LS 174T Colon
1.1
0.0
94999 UM-UC-3 Bladder
0.0
0.0

adenocarcinoma

carcinma (transitional cell)

94938 SW-948 Colon
0.0
0.0
95000 A204
0.0
0.0

adenocarcinoma

Rhabdomyosarcoma

94939 SW-480 Colon
0.0
0.0
95001 HT-1080 Fibrosarcoma
0.0
0.0

adenocarcinoma

94940 NCI-SNU-5 Gastric
0.0
1.1
95002 MG-63 Osteosarcoma
0.0
0.0

carcinoma

(bone)

KATO III- Gastric carcinoma
0.0
1.9
95003 SK-LMS-1
0.0
0.0

Leiomyosarcoma (vulva)

94943 NCI-SNU-16 Gastric
2.2
0.0
95004 SJRH30
0.0
0.0

carcinoma

Rhabdomyosarcoma (met to

bone marrow)

94944 NCI-SNU-1 Gastric
0.0
0.0
95005 A431 Epidermoid
1.8
1.6

carcinoma

carcinoma

94946 RF-1 Gastric
0.0
0.0
95007 WM266-4 Melanoma
0.0
0.0

adenocarcinoma

94947 RF-48 Gastric
0.0
0.0
DU 145- Prostate carcinoma
0.0
0.0

adenocarcinoma

(brain metastasis)

96778 MKN-45 Gastric
0.0
0.0
95012 MDA-MB-468 Breast
1.1
0.0

carcinoma

adenocarcinoma

94949 NCI-N87 Gastric
0.0
3.8
SCC-4- Squamous cell
0.0
0.0

carcinoma

carcinoma of tongue

94951 OVCAR-5 Ovarian
29.7
62.0
SCC-9- Squamous cell
0.0
0.0

carcinoma

carcinoma of tongue

94952 RL95-2 Uterine carcinoma
19.3
21.8
SCC-15- Squamous cell
0.0
0.0

carcinoma of tongue

94953 HelaS3 Cervical
0.0
0.0
95017 CAL 27 Squamous cell
0.0
0.0

adenocarcinoma

carcinoma of tongue

TABLE BLL

Panel 4D

Column A - Rel. Exp. (%) Ag1590, Run 152061102

Column B - Rel. Exp. (%) Ag1590, Run 155330411

Column C - Rel. Exp. (%) Ag1918, Run 147288180

Column D - Rel. Exp. (%) Ag2899, Run 159633215

Tissue Name
A
B
C
D

Secondary Th1 act
0.0
0.0
0.0
0.0

Secondary Th2 act
0.0
0.0
0.0
4.3

Secondary Tr1 act
0.0
0.0
0.0
6.6

Secondary Th1 rest
0.0
0.0
0.0
0.0

Secondary Th2 rest
0.0
0.0
0.0
0.0

Secondary Tr1 rest
0.0
0.0
0.0
0.0

Primary Th1 act
0.0
0.0
0.0
0.0

Primaiy Th2 act
0.0
0.0
0.0
0.0

Primary Tr1 act
0.0
0.0
0.0
0.0

Primary Th1 rest
0.0
0.0
0.0
0.0

Primary Th2 rest
0.0
0.0
0.0
0.0

Primary Tr1 rest
0.0
0.0
0.0
0.0

CD45RA CD4 lymphocyte act
0.0
0.0
0.0
0.0

CD45RO CD4 lymphocyte act
0.0
0.0
0.0
0.0

CD8 lymphocyte act
0.0
0.0
0.0
0.0

Secondary CD8 lymphocyte rest
0.0
0.0
0.0
0.0

Secondary CD8 lymphocyte act
0.0
0.0
0.0
0.0

CD4 lymphocyte none
0.0
0.0
0.0
0.0

2ry Th1/Th2/Tr1 anti-CD95 CH11
0.0
0.0
0.0
0.0

LAK cells rest
0.0
0.0
0.0
0.0

LAK cells IL-2
0.0
0.0
0.0
0.0

LAK cells IL-2 + IL-12
0.0
0.0
0.0
0.0

LAK cells IL-2 + IFN gamma
0.0
0.0
0.0
0.0

LAK cells IL-2 + IL-18
0.0
0.0
0.0
0.0

LAK cells PMA/ionomycin
0.0
0.0
0.0
0.0

NK cells IL-2 rest
0.0
0.0
0.0
0.0

Two Way MLR 3 day
0.0
0.0
0.0
0.0

Two Way MLR 5 day
0.0
0.0
0.0
0.0

Two Way MLR 7 day
0.0
0.0
0.0
0.0

PBMC rest
6.3
0.0
0.0
0.0

PBMC PWM
0.0
0.0
0.0
0.0

PBMC PHA-L
0.0
0.0
0.0
0.0

Ramos (B cell) none
0.0
0.0
0.0
0.0

Ramos (B cell) ionomycin
0.0
0.0
0.0
0.0

B lymphocytes PWM
0.0
0.0
0.0
0.0

B lymphocytes CD40L and IL-4
0.0
0.0
0.0
0.0

EOL-1 dbcAMP
0.0
0.0
0.0
0.0

EOL-1 dbcAMP PMA/ionomycin
0.0
0.0
0.0
0.0

Dendritic cells none
0.0
0.0
0.0
0.0

Dendritic cells LPS
0.0
0.0
0.0
0.0

Dendnitic cells anti-CD40
0.0
0.0
0.0
0.0

Monocytes rest
0.0
0.0
0.0
12.9

Monocytes LPS
0.0
0.0
0.0
0.0

Macrophages rest
0.0
0.0
0.0
0.0

Macrophages LPS
0.0
0.0
0.0
0.0

HUVEC none
0.0
0.0
0.0
0.0

HUVEC starved
0.0
0.0
0.0
0.0

HUVEC IL-1beta
0.0
0.0
0.0
0.0

HUVEC IFN gamma
0.0
0.0
0.0
0.0

HUVEC TNF alpha + IFN gamma
0.0
0.0
0.0
0.0

HUVEC TNF alpha + IL4
0.0
0.0
0.0
0.0

HUVEC IL-11
0.0
0.0
0.0
0.0

Lung Microvascular EC none
0.0
0.0
0.0
0.0

Lung Microvascular EC TNFalpha +
0.0
0.0
0.0
0.0

IL-1beta

Microvascular Dermal EC none
0.0
0.0
0.0
0.0

Microsvasular Dermal EC TNFalpha +
0.0
0.0
0.0
0.0

IL-1beta

Bronchial epithelium TNFalpha + IL-1beta
13.9
0.0
30.1
3.4

Small airway epithelium none
0.0
0.0
0.0
0.0

Small airway epithelium TNFalpha +
0.0
0.0
0.0
0.0

IL-1beta

Coronery artery SMC rest
0.0
0.0
0.0
0.0

Coronety artery SMG TNFalpha + IL-1beta
0.0
0.0
0.0
0.0

Astrocytes rest
0.0
0.0
0.0
0.0

Astrocytes TNFalpha + IL-1beta
0.0
0.0
0.0
0.0

KU-812 (Basophil) rest
0.0
0.0
0.0
0.0

KU-812 (Basophil) PMA/ionomycin
10.8
0.0
0.0
5.4

CCD1106 (Keratinocytes) none
0.0
0.0
0.0
0.0

CCD1106 (Keratinocytes) TNFalpha +
0.0
0.0
0.0
0.0

IL-1beta

Liver cirrhosis
22.7
80.1
63.7
100.0

Lupus kidney
0.0
7.4
0.0
0.0

NCI-H292 none
60.3
92.7
36.3
28.9

NCI-H292 IL-4
55.9
6.5
28.7
14.3

NCI-H292 IL-9
100.0
41.8
40.1
29.7

NCI-H292 IL-13
35.8
6.7
9.4
23.7

NCI-H292 IFN gamma
0.0
23.8
1.2
0.0

HPAEC none
0.0
0.0
0.0
0.0

HPAEC TNF alpha + IL-1 beta
0.0
0.0
0.0
0.0

Lung fibroblast none
0.0
0.0
0.0
0.0

Lung fibroblast TNF alpha + IL-1 beta
0.0
0.0
0.0
0.0

Lung fibroblast IL-4
0.0
0.0
0.0
0.0

Lung fibroblast IL-9
0.0
0.0
0.0
0.0

Lung fibroblast IL-13
0.0
0.0
0.0
0.0

Lung fibroblast IFN gamma
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 rest
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 TNF alpha
0.0
0.0
0.0
0.0

Dermal fibroblast CCD1070 IL-1 beta
0.0
0.0
0.0
0.0

Dermal fibroblast IFN gamma
0.0
0.0
0.0
0.0

Dermal fibroblast IL-4
0.0
0.0
0.0
0.0

IBD Colitis 2
0.0
0.0
0.0
0.0

IBD Crohn's
13.8
0.0
0.0
0.0

Colon
79.6
100.0
100.0
74.7

Lung
77.9
66.0
53.6
85.3

Thymus
62.0
21.6
0.7
23.0

Kidney
0.0
0.0
0.0
0.0

Ardais Breast1.0 Summary: Ag720 Expression of this gene was highest in a breast cancer sample (CT=27.1). Significant expression of this gene was detected in 45/64 breast cancer samples but only 1/7 normal breast samples. Gene or protein expression levels are useful for the detection of breast cancer. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs are useful in the treatment of breast cancer.

This gene encodes a protein with homology to mastocytoma protease precursor. Mast cell tryptase is a secretory granule associated serine protease with trypsin-like specificity. It is released extracellularly during mast cell degranulation. Mast cells (MC) have been associated with diverse human cancers. The primary function of these cells is to store and release a number of biologically active mediators, including the serine proteases tryptase and chymase. These proteases have been closely related with angiogenesis and tumor invasion, two critical steps during tumor progression. Malignant breast tumors have two to three times more tryptase-containing than chymase-containing mast cells, with the number of mast cells with trptase activity being significantly higher (p<0.02) than in benign lesions. In malignant lesions, tryptase-containing mast cells were concentrated at the tumor edge, i.e. the invasion zone (Kankkunen J P, Harvima I T, Naukkarinen A. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer. 1997 Jul. 29; 72(3): 385-8). It is therefore likely that this protein has a role in tumor invasion and metastasis.

Panel 1.3D Summary: Ag1590/2899 The expression of this gene was assessed in four independent runs using two different probe/primer sets. All of the runs show excellent concordance. The expression of this gene appears to be highest in a sample derived from an ovarian cancer cell line (OVCAR-5) (CTs=31-32). In addition, there appears to be substantial expression associated with a colon cancer cell line, a gastric cancer cell line and pituitary tissue. Thus, the expression of this gene could be used to distinguish OVCAR-5 cells from the other samples in the panel. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, protein therapeutics or antibodies might be of benefit in the treatment of ovarian cancer, gastric cancer or colon cancer

Panel 2D Summary: Ag720/1590/2899 The expression of this gene was assessed in five independent runs in panel 2D using three different primer/probe paris. There is excellent concordance of between these runs. The expression of this gene was highest and exclusive to breast cancer samples (CTs=26-28). Thus, the expression of this gene could be used to distinguish breast cancer samples from other samples in the panel. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, protein therapeutics or antibodies might be of benefit in the treatment of breast cancer.

Panel 3D Summary: Ag720/2899 The expression of this gene was highest and almost exclusive to a sample derived from a lung cancer cell line (DMS-79)(CTs=29-31). In addition, there was low but substantial expression associated with samples derived from an ovarian cancer cell line, a uterine cancer cell line and a pancreatic cancer cell line. The expression of this gene or expressed protein is useful in the detection of lung cancer. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of lung cancer, ovarian cancer, pancreatic cancer or uterine cancer.

Panel 4D Summary: Ag1590/Ag1918/Ag2899 This gene, a tryptase homolog, was expressed at significant levels in IL-9-activated NCI-H292 cells, pulmonary mucoepidermoid cells. Colon, lung, and thymus tissues also showed low levels of expression of this gene. The expression in lung and in the activated NCI-H292 cell line—often used as a model for airway epithelium—is consistent with published reports of tryptase in the lung (Walls A F, Bennett A R, Godfrey R C, Holgate S T, Church M K. Mast cell tryptase and histamine concentrations in bronchoalveolar lavage fluid from patients with interstitial lung disease. Clin Sci (Lond) 1991 August; 81(2):183-8). In addition, tryptase has been shown to be up-regulated in lungs affected by disease and specifically in COPD (Grashoff W F, Sont J K, Sterk P J, Hiemstra P S, de Boer W I, Stolk J, Han J, van Krieken J M. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol 1997 December; 151(6):1785-90). Tryptase has also been implicated in the recruitment of granulocytes and epithelial repair (Cairns J A, Walls A F. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 1996 Jan. 1; 156(1):275-83). Based On these observations, small molecule antagonists or antagonist antibodies are useful in the reduction or elimination of symptoms in patients with lung diseases including asthma, allergy, or chronic obstructive pulmonary disease.

BM. CG59693-01 and CG59693-03: 20 Alpha-Hydroxysteroid Dehydrogenase.

Expression of genes CG59693-01 and CG59693-03 was assessed using the primer-probe set Ag3562, described in Table BMA. Results of the RTQ-PCR runs are shown in Tables BMB, BMC, BMD, BME, BMF, BMG, BMH and BMI. CG59693-03 represents a full-length physical clone of the CG59693-01 gene.

TABLE BMAProbe Name Ag3562SEQStartIDPrimersSequencesLengthPositionNoForward5′-ctggccaagagctacaatga-3′208021437ProbeTET-5′-catcagacagaacgtgcaggtgtttg-3′-268281438TAMRAReverse5′-aggccatctatggctttcat-3′208771439

TABLE BMB

Ardais Panel v.1.0

Column A - Rel. Exp. (%) Ag3562, Run 263525399

Tissue Name
A

136799 Lung cancer(362)
52.9

136800 Lung NAT(363)
0.8

136813 Lung cancer(372)
100.0

136814 Lung NAT(373)
0.4

136815 Lung cancer(374)
1.1

136816 Lung NAT(375)
1.6

136791 Lung cancer(35A)
0.4

136795 Lung cancer(35E)
1.6

136797 Lung cancer(360)
0.4

136794 lung NAT(35D)
1.2

136818 Lung NAT(377)
0.5

136787 lung cancer(356)
0.1

136788 lung NAT(357)
1.1

136806 Lung cancer(36B)
0.1

136807 Lung NAT(36C)
0.4

136789 lung cancer(358)
0.4

136802 Lung cancer(365)
1.6

136803 Lung cancer(368)
0.5

136804 Lung cancer(369)
1.4

136811 Lung cancer(370)
64.2

136810 Lung NAT(36F)
3.9

TABLE BMC

CNS_neurodegeneration_v1.0

Column A - Rel. Exp. (%) Ag3562, Run 210629741

Column B - Rel. Exp. (%) Ag3562, Run 224078542

Tissue Name
A
B
Tissue Name
A
B

AD 1 Hippo
100.0
100.0
AH3 4624
16.5
24.3

AD 2 Hippo
37.9
33.9
AH3 4640
22.7
21.3

AD 3 Hippo
28.1
35.6
AD 1 Occipital Ctx
42.0
65.5

AD 4 Hippo
26.8
25.7
AD 2 Occipital Ctx (Missing)
0.7
1.2

AD 5 Hippo
37.1
41.5
AD 3 Occipital Ctx
32.8
27.7

AD 6 Hippo
76.8
66.4
AD 4 Occipital Ctx
20.6
11.2

Control 2 Hippo
30.6
32.3
AD 5 Occipital Ctx
26.1
27.0

Control 4 Hippo
30.8
34.9
AD 5 Occipital Ctx
39.0
48.0

Control (Path) 3 Hippo
24.1
21.0
Control 1 Occipital Ctx
18.2
16.6

AD 1 Temporal Ctx
57.8
64.2
Control 2 Occipital Ctx
16.7
24.0

AD 2 Temporal Ctx
34.4
29.9
Control 3 Occipital Ctx
18.4
19.8

AD 3 Temporal Ctx
25.7
27.7
Control 4 Occipital Ctx
20.4
22.1

AD 4 Temporal Ctx
23.0
24.1
Control (Path) 1 Occipital Ctx
21.8
18.0

AD 5 Inf Temporal Ctx
33.7
44.1
Control (Path) 2 Occipital Ctx
11.9
15.7

AD 5 Sup Temporal Ctx
54.7
54.3
Control (Path) 3 Occipital Ctx
34.4
22.1

AD 6 Inf Temporal Ctx
47.3
48.0
Control (Path) 4 Occipital Ctx
18.0
18.6

AD 6 Sup Temporal Ctx
45.4
46.7
Control 1 Parietal Ctx
16.5
19.1

Control 1 Temporal Ctx
22.8
23.8
Control 2 Parietal Ctx
62.9
55.9

Control 2 Temporal Ctx
18.4
29.1
Control 3 Parietal Ctx
35.8
29.7

Control 3 Temporal Ctx
25.5
19.3
Control (Path) 1 Parietal Ctx
24.0
24.7

Control 3 Temporal Ctx
18.2
16.8
Control (Path) 2 Parietal Ctx
15.9
15.6

AH3 3975
21.5
22.1
Control (Path) 3 Parietal Ctx
22.1
26.1

AH3 3954
17.4
17.3
Control (Path) 4 Parietal Ctx
23.0
24.1

TABLE BMD

General_screening_panel_v1.4

Column A - Rel. Exp. (%) Ag3562, Run 217240778

Tissue Name
A

Adipose
2.1

Melanoma* Hs688(A).T
0.2

Melanoma* Hs688(B).T
0.3

Melanoma* M14
0.0

Melanoma* LOXIMVI
0.0

Melanoma* SK-MEL-5
0.0

Squamous cell carcinoma SCC-4
0.5

Testis Pool
0.2

Prostate ca.* (bone met) PC-3
0.0

Prostate Pool
0.1

Placenta
0.0

Uterus Pool
0.1

Ovarian ca. OVCAR-3
0.0

Ovarian ca. SK-OV-3
11.8

Ovarian ca. OVCAR-4
0.0

Ovarian ca. OVCAR-5
0.3

Ovarian ca. IGROV-1
0.5

Ovarian ca. OVCAR-8
0.2

Ovary
0.2

Breast ca. MCF-7
0.5

Breast ca. MDA-MB-231
1.1

Breast ca. BT 549
1.2

Breast ca. T47D
0.6

Breast ca. MDA-N
0.0

Breast Pool
0.1

Trachea
1.3

Lung
0.2

Fetal Lung
0.3

Lung ca. NCI-N417
0.0

Lung ca. LX-1
1.6

Lung ca. NCI-H146
1.0

Lung ca. SHP-77
14.7

Lung ca. A549
100.0

Lung ca. NCI-H526
0.0

Lung ca. NCI-H23
0.2

Lung ca. NCI-H460
11.1

Lung ca. HOP-62
0.1

Lung ca. NCI-H522
0.6

Liver
0.7

Fetal Liver
4.1

Liver ca. HepG2
2.4

Kidney Pool
0.2

Fetal Kidney
0.1

Renal ca. 786-0
0.3

Renal ca. A498
11.2

Renal ca. ACHN
0.2

Renal ca. UO-31
0.1

Renal ca. TK-10
1.5

Bladder
0.8

Gastric ca. (liver met.) NCI-N87
0.1

Gastric ca. KATO III
0.4

Colon ca. SW-948
0.6

Colon ca. SW480
0.1

Colon ca.* (SW480 met) SW620
0.5

Colon ca. HT29
0.5

Colon ca. HCT-116
0.0

Colon ca. CaCo-2
2.6

Colon cancer tissue
0.4

Colon ca. SW1116
0.0

Colon ca. Colo-205
3.0

Colon ca. SW-48
0.9

Colon Pool
0.1

Small Intestine Pool
0.1

Stomach Pool
0.1

Bone Marrow Pool
0.1

Fetal Heart
0.0

Heart Pool
0.1

Lymph Node Pool
0.2

Fetal Skeletal Muscle
0.1

Skeletal Muscle Pool
0.7

Spleen Pool
0.0

Thymus Pool
0.2

CNS cancer (glio/astro)
0.9

U87-MG

CNS cancer (glio/astro)
1.0

U-118-MG

CNS cancer (neuro; met)
0.3

SK-N-AS

CNS cancer (astro) SF-539
0.1

CNS cancer (astro) SNB-75
10.2

CNS cancer (glio) SNB-19
0.4

CNS cancer (glio) SF-295
4.0

Brain (Amygdala) Pool
0.2

Brain (cerebellum)
0.1

Brain (fetal)
0.5

Brain (Hippocampus) Pool
0.1

Cerebral Cortex Pool
0.1

Brain (Substantia nigra) Pool
0.2

Brain (Thalamus) Pool
0.2

Brain (whole)
0.4

Spinal Cord Pool
0.3

Adrenal Gland
0.2

Pituitary gland Pool
0.0

Salivary Gland
0.1

Thyroid (female)
0.1

Pancreatic ca. CAPAN2
0.2

Pancreas Pool
0.2

TABLE BME

HASS Panel v1.0

Column A - Rel. Exp. (%) Ag3562, Run 276044499

Tissue Name
A

MCF-7 C1
8.5

MCF-7 C2
12.0

MCF-7 C3
15.7

MGF-7 C4
13.2

MGF-7 C5
20.2

MCF-7 C6
10.4

MCF-7 C7
8.8

MGF-7 C9
6.9

MCF-7 C10
10.2

MCF-7 C11
5.8

MCF-7 C12
8.7

MGF-7 C13
7.6

MCF-7 C15
3.6

MGF-7 C16
13.2

MCF-7 C17
9.8

T24 D1
32.8

T24 D2
12.2

T24 D3
26.4

T24 D4
48.3

T24 D5
18.2

T24 D6
0.2

T24 D7
1.0

T24 D9
0.0

T24 D10
23.7

T24 D11
2.7

T24 D12
0.1

T24 D13
0.3

T24 D15
0.3

T24 D16
0.2

T24 D17
0.5

CAPaN B1
4.4

CAPaN B2
6.3

CAPaN B3
4.3

CAPaN B4
3.4

CAPaN B5
14.9

CAPaN B6
2.1

CAPaN B7
1.8

CAPaN B8
10.7

CAPaN B9
2.6

CAPaN B10
6.4

CAPaN B11
16.3

CAPaN B12
1.7

CAPaN B13
1.3

CAPaN B14
7.4

CAPaN B15
11.2

CAPaN B16
4.2

CAPaN B17
14.2

U87-MG F1 (B)
19.6

U87-MG F2
5.2

U87-MG F3
15.8

U87-MG F4
10.2

U87-MG F5
40.3

U87-MG F6
92.7

U87-MG F7
5.9

U87-MG F8
9.1

U87-MG F9
1.9

U87-MG F10
57.4

U87-MG F11
100.0

U87-MG F12
30.4

U87-MG F13
10.2

U87-MG F14
16.7

U87-MG F15
9.5

U87-MG F16
66.4

U87-MG F17
67.4

LnCAP A1
0.2

LnCAP A2
0.2

LnCAP A3
0.1

LnCAP A4
0.1

LnCAP A5
0.2

LnCAP A6
0.2

LnCAP A7
0.4

LnCAP A8
0.6

LnCAP A9
0.8

LnCAP A10
0.2

LnCAP A11
0.4

LnCAP A12
0.1

LnCAP A13
0.0

LnCAP A14
0.2

LnCAP A15
0.3

LnCAP A16
0.2

LnCAP A17
0.5

Primary Astrocytes
0.4

Primary Renal Proximal Tubule Epithelial cell A2
25.0

Primary melanocytes A5
1.7

126443 - 341 medullo
0.1

126444 - 487 medullo
0.0

126445 - 425 medullo
0.0

126446 - 690 medullo
0.2

126447 - 54 adult glioma
3.8

126448 - 245 adult glioma
0.0

126449 - 317 adult glioma
0.0

126450 - 212 glioma
0.1

126451 - 456 glioma
0.0

TABLE BMF

Oncology cell_line_screening_panel_v3.1

Column A - Rel. Exp. (%) Ag3562, Run 222546381

Tissue Name
A

94905 Daoy Medulloblastoma/Cerebellum
0.0

94906 TE671 Medulloblastom/Cerebellum
0.2

94907 D283 Med Medulloblastoma/Cerebellum
0.0

94908 PFSK-1 Primitive Neuroectodermal/Cerebellum
0.1

94909 XF-498 CNS
0.0

94910 SNB-78 CNS/glioma
0.3

94911 SF-268 CNS/glioblastoma
0.0

94912 T98G Glioblastoma
33.2

96776 SK-N-SH Neuroblastoma (metastasis)
0.0

94913 SF-295 CNS/glioblastoma
2.3

94914 Cerebellum
0.4

96777 Cerebellum
0.1

94916 NCI-H292 Mucoepidermoid lung carcinoma
0.3

94917 DMS-114 Small cell lung cancer
0.0

94918 DMS-79 Small cell lung cancer/neuroendocrine
0.0

94919 NCI-H146 Small cell lung cancer/neuroendocrine
2.2

94920 NCI-H526 Small cell lung cancer/neuroendocrine
0.0

94921 NCI-N417 Small cell lung cancer/neuroendocrine
0.0

94923 NCI-H82 Small cell lung cancer/neuroendocrine carcinoma
0.0

94924 NCI-H157 Squamous cell lung cancer (metastasis)
0.0

94925 NCI-H1155 Large cell lung cancer/neuroendocrine
0.0

94926 NCI-H1299 Large cell lung cancer/neuroendocrine
0.0

94927 NCI-H727 Lung carcinoid
1.3

94928 NCI-UMC-11 Lung carcinoid
100.0

94929 LX-1 Small cell lung cancer
1.6

94930 Colo-205 Colon cancer
7.5

94931 KM12 Colon cancer
0.1

94932 KM20L2 Colon cancer
0.1

94933 NCI-H716 Colon cancer
19.2

94935 SW-48 Colon adenocarcinoma
2.3

94936 SW1116 Colon adenocarcinoma
0.0

94937 LS 174T Colon adenocarcinoma
0.9

94938 SW-948 Colon adenocarcinoma
0.3

94939 SW-480 Colon adenocarcinoma
0.5

94940 NCI-SNU-5 Gastric carcinoma
0.0

112197 KATO III Stomach
0.1

94943 NCI-SNU-16 Gastric carcinoma
2.7

94944 NCI-SNU-1 Gastric carcinoma
16.8

94946 RF-1 Gastric adenocarcinoma
0.5

94947 RF-48 Gastric adenocarcinoma
0.0

96778 MKN-45 Gastric carcinoma
1.6

94949 NCI-N87 Gastric carcinoma
0.8

94951 OVCAR-5 Ovarian carcinoma
0.4

94952 RL95-2 Uterine carcinoma
0.5

94953 HelaS3 Cervical adenocarcinoma
0.9

94954 Ca Ski Cervical epidermoid carcinoma (metastasis
0.3

94955 ES-2 Ovarian clear cell carcinoma
0.0

94957 Ramos Stimulated with PMA/ionomycin 6h
0.0

94958 Ramos Stimulated with PMA/ionomycin 14h
0.0

94962 MEG-01 Chronic myelogenous leukemia (megokaryoblast)
0.1

94963 Raji Burkitt's lymphoma
0.0

94964 Daudi Burkitt's lymphoma
0.0

94965 U266 B-cell plasmacytoma/myeloma
0.0

94968 CA46 Burkitt's lymphoma
0.0

94970 RL non-Hodgkin's B-cell lymphoma
0.0

94972 JM1 pre-B-cell lymphoma/leukemia
0.0

94973 Jurkat T cell leukemia
0.0

94974 TF-1 Erythroleukemia
1.6

94975 HUT 78 T-cell lymphoma
0.0

94977 U937 Histiocytic lymphoma
0.0

94980 KU-812 Myelogenous leukemia
0.9

769-P- Clear cell renal carcinoma
1.0

94983 Caki-2 Clear cell renal carcinoma
63.7

94984 SW 839 Clear cell renal
0.4

94986 G401 Wilms' tumor
0.0

94987 Hs766T Pancreatic carcinoma (LN metastasis)
0.2

94988 CAPAN-1 Pancreatic adenocarcinoma (liver metastasis)
0.3

94989 SU86.86 Pancreatic carcinoma (liver metastasis)
1.2

94990 BxPC-3 Pancreatic adenocarcinoma
3.6

94991 HPAC Pancreatic adenocarcinoma
3.1

94992 MIA PaCa-2 Pancreatic carcinoma
0.0

94993 CFPAC-1 Pancreatic ductal adenocarcinoma
3.9

94994 PANC-1 Pancreatic epitheliold ductal carcinoma
0.0

94996 T24 Bladder carcinma (transitional cell
2.0

5637- Bladder carcinoma
0.1

94998 HT-1197 Bladder carcinoma
0.0

94999 UM-UC-3 Bladder carcinma (transitional cell)
0.1

95000 A204 Rhabdomyosarcoma
0.8

95001 HT-1080 Fibrosarcoma
0.0

95002 MG-63 Osteosarcoma (bone)
0.0

95003 SK-LMS-1 Leiomyosarcoma (vulva)
0.0

95004 SJRH30 Rhabdomyosarcoma (met to bone marrow)
0.1

95005 A431 Epidermoid carcinoma
3.8

95007 WM266-4 Melanoma
0.1

112195 DU 145 Prostate
0.1

95012 MDA-MB-468 Breast adenocarcinoma
0.5

112196 SSC-4 Tongue
0.4

112194 SSC-9 Tongue
0.2

112191 SSC-15 Tongue
0.3

95017 CAL 27 Squamous cell carcinoma of
0.1

tongue

TABLE BMG

Panel 2D

Column A - Rel. Exp. (%) Ag3562, Run 170858350

Tissue Name
A

Normal Colon
5.0

CC Well to Mod Diff (OD03866)
1.5

CC Margin (OD03866)
2.0

CC Gr.2 rectosigmoid (OD03868)
0.5

CC Margin (OD03868)
0.5

CC Mod Duff (OD03920)
0.5

CC Margin (OD03920)
1.2

CC Gr.2 ascend colon (OD03921)
2.1

CC Margin (OD03921)
1.4

CC from Partial Hepatectomy (OD04309) Mets
5.5

Liver Margin (OD04309)
27.0

Colon mets to lung (OD04451-01)
0.4

Lung Margin (OD04451-02)
1.8

Normal Prostate 6546-1
1.3

Prostate cancer (OD04410)
0.4

Prostate Margin (OD04410)
0.5

Prostate cancer (OD04720-01)
0.6

Prostate Margin (OD04720-02)
1.6

Normal Lung
4.1

Lung Met to Muscle (OD04286)
41.8

Muscle Margin (OD04286)
1.7

Lung Malignant cancer (OD03126)
2.0

Lung Margin (OD03126)
2.1

Lung cancer (OD04404)
100.0

Lung Margin (OD04404)
1.7

Lung cancer (OD04565)
43.2

Lung Margin (OD04565)
0.7

Lung cancer (OD04237-01)
0.5

Lung Margin (OD04237-02)
2.2

Ocular Mel Met to Liver (OD04310)
0.1

Liver Margin (OD04310)
14.8

Melanoma Metastasis
0.1

Lung Margin (OD04321)
2.3

Normal Kidney
5.0

Kidney Ca, Nuclear grade 2 (OD04338)
29.1

Kidney Margin (OD04338)
3.1

Kidney Ca Nuclear grade 1/2 (OD04339)
3.7

Kidney Margin (OD04339)
5.1

Kidney Ca, Clear cell type (OD04340)
6.3

Kidney Margin (OD04340)
3.6

Kidney Ca, Nuclear grade 3 (OD04348)
0.1

Kidney Margin (OD04348)
1.8

Kidney cancer (OD04622-01)
1.9

Kidney Margin (OD04622-03)
1.5

Kidney cancer (OD04450-01)
12.0

Kidney Margin (OD04450-03)
4.5

Kidney cancer 8120607
34.2

Kidney Margin 8120608
2.3

Kidney cancer 8120613
4.4

Kidney Margin 8120614
4.2

Kidney cancer 9010320
1.5

Kidney Margin 9010321
2.6

Normal Uterus
0.4

Uterine cancer 064011
0.5

Normal Thyroid
1.2

Thyroid cancer
0.1

Thyroid cancer A302152
0.2

Thyroid Margin A302153
1.6

Normal Breast
5.3

Breast cancer
0.2

Breast cancer (OD04590-01)
1.4

Breast cancer Mets (OD04590-03)
5.2

Breast cancer Metastasis
1.1

Breast cancer
0.3

Breast cancer
0.8

Breast cancer 9100266
0.3

Breast Margin 9100265
0.5

Breast cancer A209073
0.6

Breast Margin A209073
0.5

Normal Liver
11.9

Liver cancer
5.0

Liver cancer 1025
14.7

Liver cancer 1026
3.9

Liver cancer 6004-T
14.0

Liver Tissue 6004-N
20.9

Liver cancer 6005-T
3.7

Liver Tissue 6005-N
6.3

Normal Bladder
5.6

Bladder cancer
0.3

Bladder cancer
0.8

Bladder cancer (OD04718-01)
0.1

Bladder Normal Adjacent (OD04718-03)
0.9

Normal Ovary
0.4

Ovarian cancer
0.5

Ovarian cancer (OD04768-07)
0.6

Ovary Margin (OD04768-08)
0.3

Normal Stomach
5.5

Gastric cancer 9060358
1.0

Stomach Margin 9060359
11.7

Gastric cancer 9060395
14.4

Stomach Margin 9060394
15.3

Gastric cancer 9060397
2.1

Stomach Margin 9060396
6.7

Gastric cancer 064005
7.6

TABLE BMH

Panel 4.1D

Column A - Rel. Exp. (%) Ag3562, Run 169990867

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.7

Secondary Th2 act
0.1
HUVEC IFN gamma
2.1

Secondary Tr1 act
0.2
HUVEC TNF alpha + IFN gamma
0.7

Secondary Th1 rest
0.2
HUVEC TNF alpha + IL4
0.5

Secondary Th2 rest
0.1
HUVEC IL-11
2.4

Secondary Tr1 rest
0.1
Lung Microvascular EC none
13.1

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-1
10.1

beta

Primary Th2 act
0.1
Microvascular Dermal EC none
11.8

Primary Tr1 act
0.0
Microsvasular Dermal EC TNF alpha + IL-1
12.8

beta

Primary Th1 rest
0.4
Bronchial epithelium TNF alpha + IL1beta
92.7

Primary Th2 rest
0.2
Small airway epithelium none
29.9

Primary Tr1 rest
0.1
Small airway epithelium TNF alpha + IL-1
50.3

beta

CD45RA CD4 lymphocyte act
6.7
Coronery artery SMC rest
5.4

CD45RO CD4 lymphocyte act
0.4
Coronery artery SMC TNF alpha + IL-1 beta
7.0

CD8 lymphocyte act
0.3
Astrocytes rest
0.6

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNF alpha + IL-1 beta
0.7

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
16.4

CD4 lymphocyte none
0.6
KU-812 (Basophil) PMA/ionomycin
33.2

2ry Th1/Th2/Tr1 anti-CD95
0.2
CCD1106 (Keratinocytes) none
2.9

CH11

LAK cells rest
0.5
CCD1106 (Keratinocytes) TNF alpha + IL-1
2.3

beta

LAK cells IL-2
1.3
Liver cirrhosis
38.2

LAK cells IL-2 + IL-12
0.5
NCI-H292 none
11.8

LAK cells IL-2 + IFN gamma
1.1
NCI-H292 IL-4
7.1

LAK cells IL-2 + IL-18
0.7
NCI-H292 IL-9
22.5

LAK cells PMA/ionomycin
1.2
NCI-H292 IL-13
5.2

NK Cells IL-2 rest
3.5
NCI-H292 IFN gamma
4.7

Two Way MLR 3 day
1.4
HPAEC none
5.1

Two Way MLR 5 day
0.6
HPAEC TNF alpha + IL-1 beta
7.6

Two Way MLR 7 day
0.3
Lung fibroblast none
6.8

PBMC rest
0.8
Lung fibroblast TNF alpha + IL-1 beta
48.6

PBMC PWM
15.0
Lung fibroblast IL-4
7.5

PBMC PHA-L
0.3
Lung fibroblast IL-9
7.2

Ramos (B cell) none
0.0
Lung fibroblast IL-13
8.8

Ramos (B cell) ionomycin
0.0
Lung fibroblast IFN gamma
6.8

B lymphocytes PWM
0.2
Dermal fibroblast CCD1070 rest
13.9

B lymphocytes CD40L and IL-4
0.3
Dermal fibroblast CCD1070 TNF alpha
19.9

EOL-1 dbcAMP
0.1
Dermal fibroblast CCD1070 IL-1 beta
24.7

EOL-1 dbcAMP
0.1
Dermal fibroblast IFN gamma
38.4

PMA/ionomycin

Dendritic cells none
0.8
Dermal fibroblast IL-4
100.0

Dendritic cells LPS
2.9
Dermal Fibroblasts rest
68.3

Dendritic cells anti-CD40
0.6
Neutrophilis TNFa + LPS
0.2

Monocytes rest
0.1
Neutrophilis rest
0.1

Monocytes LPS
9.7
Colon
14.0

Macrophages rest
2.4
Lung
5.8

Macrophages LPS
2.9
Thymus
6.6

HUVEC none
1.0
Kidney
20.7

HUVEC starved
0.9

TABLE BMI

Panel 5 Islet

Column A - Rel. Exp. (%) Ag3562, Run 242386397

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
12.8
94709 Donor 2 AM - A adipose
10.2

97476 Patient-07sk skeletal muscle
12.4
94710 Donor 2 AM - B adipose
7.1

97477 Patient-07ut uterus
1.6
94711 Donor 2 AM - C adipose
6.4

97478 Patient-07pl placenta
0.3
94712 Donor 2 AD - A adipose
17.9

99167 Bayer Patient 1
100.0
94713 Donor 2 AD - B adipose
15.6

97482 Patient-08ut uterus
0.7
94714 Donor 2 AD - C adipose
19.1

97483 Patient-08pl placenta
0.0
94742 Donor 3 U - A Mesenchymal
2.0

Stem Cells

97486 Patient-09sk skeletal muscle
7.6
94743 Donor 3 U - B Mesenchymal
3.4

Stem Cells

97487 Patient-09ut uterus
3.9
94730 Donor 3 AM - A adipose
17.6

97488 Patient-09pl placenta
0.4
94731 Donor 3 AM - B adipose
7.6

97492 Patient-10ut uterus
1.9
94732 Donor 3 AM - C adipose
9.7

97493 Patient-10pl placenta
0.5
94733 Donor 3 AD - A adipose
32.5

97495 Patient-11go adipose
7.4
94734 Donor 3 AD - B adipose
6.7

97496 Patient-11sk skeletal muscle
8.0
94735 Donor 3 AD - C adipose
23.2

97497 Patient-11ut uterus
2.8
77138 Liver HepG2untreated
82.9

97498 Patient-11pl placenta
0.1
73556 Heart Cardiac stromal cells
1.9

(primary)

97500 Patient-12go adipose
11.3
81735 Small Intestine
13.4

97501 Patient-12sk skeletal muscle
33.2
72409 Kidney Proximal Convoluted
3.6

Tubule

97502 Patient-12ut uterus
3.1
82685 Small intestine Duodenum
2.5

97503 Patient-12p1 placenta
0.4
90650 Adrenal Adrenocortical
2.4

adenoma

94721 Donor 2 U - A Mesenchymal
3.8
72410 Kidney HRCE
11.6

Stem Cells

94722 Donor 2 U - B Mesenchymal
4.3
72411 Kidney HRE
1.3

Stem Cells

94723 Donor 2 U - C Mesenchymal
6.0
73139 Uterus Uterine smooth muscle
0.4

Stem Cells

cells

Ardais Panel v.1.0 Summary: Ag3562 Highest expression of this gene was seen in lung cancer (CT=19.1). In addition, this gene was more highly expressed in three lung cancer samples than in the corresponding normal adjacent tissue. Thus, expression of this gene is useful as a marker of this cancer. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of lung cancer.

CNS_neurodegeneration_v1.0 Summary: Ag3562 This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. This gene was found to be upregulated in the temporal cortex of Alzheimer's disease patients when analyzed by ANCOVA, (p=0.002). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in prevention or slowing the progression of Alzheimer's disease.

General_screening_panel_v1.4 Summary: Ag3562 Highest expression of this gene was detected in lung cancer A549 cell line (CT=20.01). High expression of this gene was also seen in cluster of cancer cell lines derived from gastric, colon, lung, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene is useful as a marker to detect the presence of these cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of gastric, colon, lung, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

Among tissues with metabolic or endocrine function, this gene was expressed at moderate to high levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

In addition, this gene was expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

HASS Panel v1.0 Summary: Ag3562. The expression of this gene was not increased by oxygen deprivation, acidic or a serum starved environment in the breast, bladder, pancreatic and prostate cell line in this panel.

However expression was increased in a glioblastoma/astrocytoma cell line when these cells are subjected to an acidic environment (Maximum expression U87-MG F11; CT=23.96) which indicates that expression may also be upregulated in the acidic regions of brain cancers. Moderate to low-expression was also shown in 2 of 5 glioma and 2 of 4 medulloblastoma tissue samples in this panel. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of brain cancer.

Oncology_cell_line_screening_panel_v3.1 Summary: Ag3562 Highest expression of this gene was detected in lung carcinoid sample (CT=21.7). High to moderate levels of expression of this gene was also seen in number of cancer samples including tongue, breast, prostate, melanoma, bone marrow, bladder, pancreatic, renal, lymphoma, ovarian, cervical, uterine, gastric, lung and brain cancer. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of cancers, including tongue, breast, prostate, melanoma, bone marrow, bladder, pancreatic, renal, lymphoma, ovarian, cervical, uterine, gastric, lung and brain cancer.

Panel 2D Summary: Ag3562 Highest expression of this gene was detected in lung cancer (CT=23.5). High expression of this gene was seen in number o f lung cancer samples. Expression of this gene was higher in cancer sample as compared to corresponding adjacent control samples. Therefore, expression of this gene is useful as marker to detect the presence of lung cancer. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of lung cancer.

High to moderate levels of expression of this gene was also seen in number of cancer samples including colon, gastric, ovarian, liver, breast, thyroid, kidney, and prostate cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of these cancers.

Panel 4.1D Summary: Ag3562 Highest expression of this gene was detected in IL-4 treated dermal fibroblasts (CT=25.2). This gene was expressed at moderate to low levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression indicates that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also indicates a role for the gene product in cell survival and proliferation. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

Panel 5 Islet Summary: Ag3562 Highest expression of this gene was detected in islet cells (Bayer patient 1) (CT=25.3). High to moderate levels of expression of this gene were also seen in adipose, skeletal muscle, placenta, uterus, liver, heart, small intestine and kidney. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

BN. CG59839-02: Cation-Transporting Atpase.

Expression of gene CG59839-02 was assessed using the primer-probe sets Ag1417, Ag3604 and Ag3956, described in Tables BNA, BNB and BNC. Results of the RTQ-PCR runs are shown in Tables BND, BNE and BNF.

TABLE BNAProbe Name Ag1417SEQStartIDPrimersSequencesLengthPositionNoForward5′-ataggaaaatggacgcctacat-3′2226981440ProbeTET-5′-ccattgccggtctctgtaaacctgaa-3′-2627371441TAMRAReverse5′-ttttgaaaatcgacaggaactg-3′2227641442

TABLE BNC

Probe Name Ag3956

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-cagcttgttcgttccatattgt-3
22
1956
1446

Probe
TET-5′-tcccaaaccaactgattttaaactctaca-
29
1979
1447

3′-TAMRA

Reverse
5′-agcaactgccacaagacatagt-3′
22
2027
1448

TABLE BND

General_screening_panel v1.4

Column A - Rel. Exp. (%) Ag3604, Run 217674539

Column B - Rel. Exp. (%) Ag3956, Run 213856332

Tissue Name
A
B
Tissue Name
A
B

Adipose
5.6
9.2
Renal ca. TK-10
17.9
28.5

Melanoma* Hs688(A).T
17.9
29.1
Bladder
10.9
14.4

Melanoma* Hs688(B).T
24.0
37.1
Gastric ca. (liver met.) NCI-N87
17.0
22.4

Melanoma* M14
12.3
21.9
Gastric ca. KATO III
38.7
55.9

Melanoma* LOXIMVI
13.4
22.1
Colon ca. SW-948
4.4
6.9

Melanoma* SK-MEL-5
17.8
24.1
Colon ca. SW480
31.9
46.3

Squamous cell carcinoma
11.9
21.0
Colon ca.* (SW480 met) SW620
17.0
25.3

SCC-4

Testis Pool
1.3
2.1
Colon ca. HT29
9.1
14.1

Prostate ca.* (bone met) PC-3
15.5
22.8
Colon ca. HCT-116
27.9
45.1

Prostate Pool
1.4
2.1
Colon ca. CaCo-2
14.8
22.8

Placenta
0.9
1.0
Colon cancer tissue
10.2
13.6

Uterus Pool
1.4
3.2
Colon ca. SW1116
1.5
1.7

Ovarian ca. OVCAR-3
12.4
20.9
Colon ca. Colo-205
4.1
6.7

Ovarian ca. SK-OV-3
24.3
35.6
Colon ca. SW-48
5.8
4.3

Ovarian ca. OVCAR-4
10.8
17.7
Colon Pool
4.0
7.7

Ovarian ca. OVCAR-5
50.3
52.1
Small Intestine Pool
2.5
4.3

Ovarian ca. IGROV-1
9.0
11.4
Stomach Pool
3.0
5.2

Ovarian ca. OVCAR-8
5.4
5.8
Bone Marrow Pool
1.2
2.7

Ovary
2.1
4.9
Fetal Heart
5.6
7.3

Breast ca. MCF-7
12.0
16.2
Heart Pool
2.1
2.8

Breast ca. MDA-MB-231
15.3
23.2
Lymph Node Pool
4.7
7.5

Breast ca. BT 549
9.2
14.7
Fetal Skeletal Muscle
0.6
1.0

Breast ca. T47D
100.0
100.0
Skeletal Muscle Pool
1.7
2.4

Breast ca. MDA-N
15.2
16.6
Spleen Pool
4.8
4.8

Breast Pool
3.9
7.9
Thymus Pool
2.9
5.4

Trachea
3.0
6.4
CNS cancer (glio/astro) U87-MG
84.7
98.6

Lung
0.5
0.8
CNS cancer (glio/astro) U-118-
30.8
51.4

MG

Fetal Lung
8.0
10.6
CNS cancer (neuro; met) SK-N-
14.5
22.1

AS

Lung ca. NCI-N417
1.5
1.9
CNS cancer (astro) SF-539
13.1
18.6

Lung ca. LX-1
10.9
15.3
CNS cancer (astro) SNB-75
39.8
50.0

Lung ca. NCI-H146
11.7
20.0
CNS cancer (glio) SNB-19
9.8
9.5

Lung ca. SHP-77
5.3
8.1
CNS cancer (glio) SF-295
30.6
43.8

Lung ca. A549
9.6
15.3
Brain (Amygdala) Pool
1.9
2.7

Lung ca. NCI-H526
4.5
5.3
Brain (cerebellum)
1.4
1.8

Lung ca. NCI-H23
25.7
40.6
Brain (fetal)
4.4
7.4

Lung ca. NCI-H460
5.9
7.2
Brain (Hippocampus) Pool
2.1
2.9

Lung ca. HOP-62
5.8
7.0
Cerebral Cortex Pool
2.7
3.8

Lung ca. NCI-H522
8.8
13.3
Brain (Substantia nigra) Pool
1.9
2.4

Liver
0.6
0.9
Brain (Thalamus) Pool
2.8
3.8

Fetal Liver
11.1
14.5
Brain (whole)
2.4
3.4

Liver ca. HepG2
6.2
10.5
Spinal Cord Pool
1.9
2.1

Kidney Pool
5.2
10.8
Adrenal Gland
2.5
3.8

Fetal Kidney
4.2
6.4
Pituitary gland Pool
0.7
0.9

Renal ca. 786-0
44.1
56.3
Salivary Gland
0.8
1.1

Renal ca. A498
10.2
13.3
Thyroid (female)
5.0
7.5

Renal ca. ACHN
6.4
11.4
Pancreatic ca. CAPAN2
12.0
18.4

Renal ca. UO-31
37.9
49.0
Pancreas Pool
5.6
7.8

TABLE BNE

Panel 4.1D

Column A - Rel. Exp. (%) Ag3604, Run 169910577

Column B - Rel. Exp. (%) Ag3956, Run 170729090

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
14.2
11.5
HUVEC IL-1 beta
8.5
5.0

Secondary Th2 act
18.0
13.5
HUVEC IFN gamma
5.2
4.1

Secondary Tr1 act
17.9
10.2
HUVEC TNF alpha + IFN gamma
7.4
4.6

Secondary Th1 rest
1.6
1.1
HUVEC TNF alpha + IL4
11.3
6.8

Secondary Th2 rest
3.8
2.7
HUVEC IL-11
1.8
1.5

Secondary Tr1 rest
2.5
1.8
Lung Microvascular EC none
8.0
5.8

Primary Th1 act
11.8
9.0
Lung Microvascular EC TNF alpha +
24.1
17.0

IL-1 beta

Primary Th2 act
13.6
10.2
Microvascular Dermal EC none
4.1
2.6

Primary Tr1 act
12.1
8.8
Microsvasular Dermal EC TNF alpha +
12.2
6.7

IL-1 beta

Primary Th1 rest
3.6
2.0
Bronchial epithelium TNF alpha +
11.7
7.7

IL1 beta

Primary Th2 rest
3.4
1.2
Small airway epithelium none
4.2
2.5

Primary Tr1 rest
3.4
3.0
Small airway epithelium TNF alpha +
13.6
9.3

IL-1 beta

CD45RA CD4 lymphocyte
13.5
9.2
Coronery artery SMC rest
37.1
24.7

act

CD45RO CD4 lymphocyte
14.8
10.4
Coronery artery SMC TNF alpha +
48.6
31.6

act

IL-1 beta

CD8 lymphocyte act
14.1
8.7
Astrocytes rest
6.7
3.7

Secondary CD8 lymphocyte
11.9
9.3
Astrocytes TNF alpha + IL-1 beta
15.1
7.9

rest

Secondary CD8 lymphocyte
7.2
5.1
KU-812 (Basophil) rest
9.3
6.5

act

CD4 lymphocyte none
1.6
1.2
KU-812 (Basophil) PMA/ionomycin
23.0
17.1

2ry Th1/Th2/Tr1 anti-CD95
2.8
2.5
CCD1106 (Keratinocytes) none
10.6
7.6

CH11

LAK cells rest
15.7
15.3
CCD1106 (Keratinocytes) TNF alpha +
16.2
10.1

IL-1 beta

LAK cells IL-2
6.7
5.3
Liver cirrhosis
3.5
1.8

LAK cells IL-2 + IL-12
7.2
4.5
NCI-H292 none
6.0
4.0

LAK cells IL-2 + IFN
10.4
4.3
NCI-H292 IL-4
13.3
7.4

gamma

LAK cells IL-2 + IL-18
9.4
4.9
NCI-H292 IL-9
13.6
8.3

LAK cells PMA/ionomycin
60.7
34.2
NCI-H292 IL-13
12.5
8.6

NK Cells IL-2 rest
7.2
5.0
NCI-H292 IFN gamma
13.7
8.1

Two Way MLR 3 day
15.1
7.0
HPAEC none
5.3
6.9

Two Way MLR 5 day
13.1
8.5
HPAEC TNF alpha + IL-1 beta
54.7
38.7

Two Way MLR 7 day
8.7
6.3
Lung fibroblast none
11.1
9.4

PBMC rest
1.6
1.2
Lung fibroblast TNF alpha + IL-1
7.4
7.5

beta

PBMC PWM
12.8
7.5
Lung fibroblast IL-4
18.6
10.2

PBMC PHA-L
10.1
6.1
Lung fibroblast IL-9
24.7
19.1

Ramos (B cell) none
10.0
5.0
Lung fibroblast IL-13
13.8
10.2

Ramos (B cell) ionomycin
8.4
5.1
Lung fibroblast IFN gamma
20.4
14.6

B lymphocytes PWM
9.7
6.5
Dermal fibroblast CCD1070 rest
11.8
10.6

B lymphocytes CD40L and
6.7
3.8
Dermal fibroblast CCD1070 TNF
23.2
16.7

IL-4

alpha

EOL-1 dbcAMP
7.9
5.1
Dermal fibroblast CCD1070 IL-1
25.7
13.3

beta

EOL-1 dbcAMP
24.0
16.0
Dermal fibroblast IFN gamma
12.2
8.4

PMA/ionomycin

Dendritic cells none
23.3
13.4
Dermal fibroblast IL-4
12.6
8.5

Dendritic cells LPS
28.7
20.7
Dermal Fibroblast rest
8.7
8.6

Dendritic cells anti-CD40
18.6
12.9
Neutrophils TNFa + LPS
7.5
6.4

Monocytes rest
2.8
1.8
Neutrophils rest
0.6
0.7

Monocytes LPS
100.0
100.0
Colon
1.6
1.0

Macrophages rest
27.7
27.4
Lung
3.7
3.3

Macrophages LPS
24.8
15.5
Thymus
5.7
3.5

HUVEC none
3.5
2.3
Kidney
6.6
4.6

HUVEC starved
4.2
2.8

TABLE BKE

general oncology screening panel_v_2.4

Column A - Rel. Exp. (%) Ag3540, Run 267294323

Tissue Name
A
Tissue Name
A

Colon cancer 1
39.2
Bladder NAT 2
0.2

CC Margin (ODO3921)
10.2
Bladder NAT 3
0.3

Colon cancer 2
45.4
Bladder NAT 4
3.4

Colon NAT 2
18.2
Prostate adenocarcinoma 1
23.2

Colon cancer 3
71.7
Prostate adenocarcinoma 2
2.8

Colon NAT 3
28.9
Prostate adenocarcinoma 3
15.5

Colon malignant cancer 4
92.0
Prostate adenocarcinoma 4
33.4

Colon NAT 4
10.4
Prostate NAT 5
2.3

Lung cancer 1
15.3
Prostate adenocarcinoma 6
4.2

Lung NAT 1
2.1
Prostate adenocarcinoma 7
6.5

Lung cancer 2
100.0
Prostate adenocarcinoma 8
2.0

Lung NAT 2
4.5
Prostate adenocarcinoma 9
20.3

Squamous cell carcinoma 3
91.4
Prostate NAT 10
0.8

Lung NAT 3
1.2
Kidney cancer 1
60.3

Metastatic melanoma 1
21.8
Kidney NAT 1
13.6

Melanoma 2
1.8
Kidney cancer 2
71.2

Melanoma 3
1.8
Kidney NAT 2
26.1

Metastatic melanoma 4
72.2
Kidney cancer 3
55.5

Metastatic melanoma 5
84.7
Kidney NAT 3
8.7

Bladder cancer 1
1.4
Kidney cancer 4
54.7

Bladder NAT 1
0.0
Kidney NAT 4
17.6

Bladder cancer 2
5.0

General_screening_panel_v1.4 Summary: Ag3604/Ag3956 Highest expression of this gene was seen in a breast cancer cell line (CTs=24-25). High levels of expression were also seen in all the cell lines on this panel. Significant levels of expression were seen in the fetal tissue samples. Expression in fetal liver and lung (CTs=27) was significantly higher than in the adult liver and lung (CTs=31.5). Furthermore, this expression profile indicates a role for this gene product in cell growth and proliferation.

Among tissues with metabolic function, this gene was expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues indicates that this gene product plays a role in normal neuroendocrine and metabolic tissues. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

This gene was also expressed at moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

The CG94820-02 gene codes for a cation-transporting ATPase A, P type. A P-type cation transporting ATPase has been implicated in Menkes disease, a disorder of copper transport characterized by progressive neurological degeneration and death in early childhood (Harrison M D, Dameron C T. (1999) Molecular mechanisms of copper metabolism and the role of the Menkes disease protein. J Biochem Mol Toxicol 1999; 13(2):93-106). Thus, the CG94820-02 gene product may play a role in this disease. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of Menkes disease.

Panel 4.1D Summary: Ag3604/Ag3956 Highest expression of the CG94820-02 gene was seen in LPS stimulated monocytes (CTs=25-26). The protein encoded by this gene may therefore be involved in the activation of monocytes in their function as antigen-presenting cells. This indicates that therapeutics that block the function of this membrane protein are useful as anti-inflammatory therapeutics for the treatment of autoimmune and inflammatory diseases. Antibodies or small molecule therapeutics that stimulate the function of this protein may be useful therapeutics for the treatment of immunosupressed individuals.

This gene was expressed at moderate to low levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression indicates that this gene product is involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also indicates a role for the gene product in cell survival and proliferation. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

general oncology screening panel_v_—2.4 Summary: Ag3604 Highest expression was detected in a lung cancer sample, with prominent expression seen in prostate and melanoma cancer samples. This gene was more highly expressed in lung, kidney, and colon cancers than in the normal adjacent tissues. Expression of this gene is useful as a marker of these cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of lung, colon, kidney, melanoma and prostate cancers.

BO. CG90866-03 and CG90866-04: Serine/Threonine-Protein Kinase.

Expression of genes CG90866-03 and CG90866-04 was assessed using the primer-probe sets Ag1088, Ag941 and Ag3771, described in Tables BOA, BOB and BOC. Results of the RTQ-PCR runs are shown in Tables BOD, BOE, BOF and BOG.

TABLE BOAProbe Name Ag1088SEQStartIDPrimersSequencesLengthPositionNoForward5′-cttgatgaagaaagcagaggaa-3′227761449ProbeTET-5′-atccagatcaaccaaggctcaccatt-3′-268141450TAMRAReverse5′-agtcaggggcaatctgagatat-3′228431451

TABLE BOB

Probe Name Ag941

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-cctccactcagccatgatta-3′
20
1241
1452

Probe
TET-5′-ataccgagacctgaaaccccacaatg-3′-
26
1262
1453

TAMRA

Reverse
5′-gcagcattgggatacagtgt-3′
20
1299
1454

TABLE BOG

Probe Name Ag3771

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-ggcacaaagattttctcctttt-3
22
2247
1455

Probe
TET-5′-tgatttcaccattcagaaactcattga-3′-
27
2273
1456

TAMRA

Reverse
5′-gaaaacagttggcttgttcttg-3′
22
2302
1457

TABLE BOD

AI_comprehensive panel_v1.0

Column A - Rel. Exp. (%) Ag3771, Run 311756509

Tissue Name
A
Tissue Name
A

110967 COPD-F
6.6
1112427 Match Control Psoriasis-F
39.5

110980 COPD-F
12.2
112418 Psoriasis-M
5.7

110968 COPD-M
9.1
112723 Match Control Psoriasis-M
8.1

110977 COPD-M
32.3
1112419 Psoriasis-M
12.2

110989 Emphysema-F
17.8
1112424 Match Control Psoriasis-M
9.8

110992 Emphysema-F
4.4
112420 Psoriasis-M
23.0

110993 Emphysema-F
8.5
112425 Match Control Psoriasis-M
36.3

110994 Emphysema-F
4.9
104689 (ME) OA Bone-Backus
10.8

110995 Emphysema-F
7.4
104690 (ME) Adj “Normal” Bone-
9.7

Backus

110996 Emphysema-F
1.0
104691 (ME) OA Synovium-Backus
17.7

110997 Asthma-M
3.1
104692 (BA) OA Cartilage-Backus
0.0

111001 Asthma-F
10.7
104694 (BA) OA Bone-Backus
8.5

111002 Asthma-F
15.1
104695 (BA) Adj “Normal” Bone-
9.9

Backus

111003 Atopic Asthma-F
10.5
104696 (BA) OA Synovium-Backus
14.4

111004 Atopic Asthma-F
8.0
104700 (55) OA Bone-Backus
20.0

111005 Atopic Asthma-F
9.5
104701 (SS) Adj “Normal” Bone-Backus
9.3

111006 Atopic Asthma-F
1.4
104702 (SS) OA Synovium-Backus
22.5

111417 Allergy-M
7.7
117093 OA Cartilage Rep7
7.7

112347 Allergy-M
0.1
112672 OA Bone5
18.6

112349 Normal Lung-F
0.1
112673 OA Synovium5
10.0

112357 Normal Lung-F
20.2
1112674 OA Synovial Fluid Cells5
11.0

112354 Normal Lung-M
11.4
117100 OA Cartilage Rep14
1.3

112374 Crohns-F
5.1
112756 OA Bone9
1.6

112389 Match Control Crohns-F
6.4
112757 OA Synovium9
22.7

112375 Crohns-F
3.0
112758 OA Synovial Fluid Cells9
7.5

112732 Match Control Crohns-F
8.4
117125 RA Cartilage Rep2
2.7

112725 Crohns-M
2.4
113492 Bone2 RA
85.3

112387 Match Control Crohns-M
2.4
113493 Synovium2 RA
26.4

112378 Crohns-M
0.2
113494 Syn Fluid Cells RA
48.0

112390 Match Control Crohns-M
16.8
113499 Cartilage4 RA
75.3

112726 Crohns-M
12.4
113500 Bone4 RA
100.0

112731 Match Control Crohns-M
12.9
113501 Synovium RA
85.9

112380 Ulcer Col-F
11.5
113502 Syn Fluid Cells4 RA
54.7

112734 Match Control Ulcer Col-F
20.3
113495 Cartilage3 RA
60.3

112384 Ulcer Col-F
12.9
113496 Bone3 RA
70.2

112737 Match Control Ulcer Col-F
4.4
113497 Synovium3 RA
45.4

112386 Ulcer Col-F
5.4
113498 Syn Fluid Cells3 RA
92.7

112738 Match Control Ulcer Col-F
2.3
117106 Normal Cartilage Rep20
0.5

112381 Ulcer Col-M
0.2
113663 Bone3 Normal
0.0

112735 Match Control Ulcer Col-
1.2
113664 Synovium3 Normal
0.0

M

112382 Ulcer Col-M
8.5
113665 Syn Fluid Cells3 Normal
0.1

112394 Match Control Ulcer Col-
2.8
117107 Normal Cartilage Rep22
4.0

M

112383 Ulcer Col-M
3.6
113667 Bone4 Normal
10.0

112736 13667 Match Control Ulcer
4.0
113668 Synovium4 Normal
9.3

Col-M

112423 Psoriasis-F
11.1
113669 Syn Fluid Cells4 Normal
14.4

TABLE BOE

General_screening_panel_v1.4

Column A - Rel. Exp. (%) Ag3771, Run 218982528

Tissue Name
A

Adipose
11.7

Melanoma* Hs688(A).T
2.3

Melanoma* Hs688(B).T
0.9

Melanoma* M14
23.0

Melanoma* LOXIMVI
0.6

Melanoma* SK-MEL-5
23.7

Squamous cell carcinoma SCC-4
0.0

Testis Pool
3.8

Prostate ca.* (bone met) PC-3
1.3

Prostate Pool
4.3

Placenta
0.2

Uterus Pool
7.4

Ovarian ca. OVCAR-3
0.3

Ovarian ca. SK-OV-3
3.8

Ovarian ca. OVCAR-4
0.0

Ovarian ca. OVCAR-5
1.7

Ovarian ca. IGROV-1
0.1

Ovarian ca. OVCAR-8
0.1

Ovary
5.5

Breast ca. MCF-7
0.0

Breast ca. MDA-MB-231
0.1

Breast ca. BT 549
0.0

Breast ca. T47D
5.0

Breast ca. MDA-N
4.5

Breast Pool
13.9

Trachea
5.3

Lung
5.0

Fetal Lung
100.0

Lung ca. NCI-N417
0.2

Lung ca. LX-1
0.0

Lung ca. NCI-H146
0.0

Lung ca. SHP-77
0.1

Lung ca. A549
21.3

Lung ca. NCI-H526
0.0

Lung ca. NCI-H23
1.9

Lung ca. NCI-H460
0.7

Lung ca. HOP-62
0.4

Lung ca. NCI-H522
0.0

Liver
0.3

Fetal Liver
9.3

Liver ca. HepG2
0.0

Kidney Pool
23.2

Fetal Kidney
27.7

Renal ca. 786-0
17.9

Renal ca. A498
4.8

Renal ca. ACHN
9.0

Renal ca. UO-31
4.0

Renal ca. TK-10
5.6

Bladder
8.0

Gastric ca. (liver met.) NCI-N87
0.0

Gastric ca. KATO III
0.0

Colon ca. SW-948
0.0

Colon ca. SW480
0.0

Colon ca.* (SW480 met) SW620
0.0

Colon ca. HT29
0.0

Colon ca. HCT-116
0.1

Colon ca. CaCo-2
0.2

Colon cancer tissue
4.6

Colon ca. SW1116
0.0

Colon ca. Colo-205
0.0

Colon ca. SW-48
0.0

Colon Pool
15.6

Small Intestine Pool
13.3

Stomach Pool
8.5

Bone Marrow Pool
5.9

Fetal Heart
2.0

Heart Pool
6.7

Lymph Node Pool
12.8

Fetal Skeletal Muscle
2.0

Skeletal Muscle Pool
5.9

Spleen Pool
16.6

Thymus Pool
7.2

CNS cancer (glio/astro)
4.7

U87-MG

CNS cancer (glio/astro)
11.7

U-118-MG

CNS cancer (neuro; met)
0.6

SK-N-AS

CNS cancer (astro) SF-539
0.1

CNS cancer (astro) SNB-75
0.0

CNS cancer (glio) SNB-19
0.5

CNS cancer (glio) SF-295
3.1

Brain (Amygdala) Pool
4.9

Brain (cerebellum)
1.1

Brain (fetal)
2.9

Brain (Hippocampus) Pool
6.2

Cerebral Cortex Pool
12.5

Brain (Substantia nigra) Pool
7.6

Brain (Thalamus) Pool
13.8

Brain (whole)
5.7

Spinal Cord Pool
6.3

Adrenal Gland
3.7

Pituitary gland Pool
2.0

Salivary Gland
1.3

Thyroid (female)
7.7

Pancreatic ca. CAPAN2
0.0

Pancreas Pool
9.7

TABLE BOF

Panel 4.1D

Column A - Rel. Exp. (%) Ag3771, Run 170130259

Column B - Rel. Exp. (%) Ag3771, Run 311582828

Tissue Name
A
B
Tissue Name
A
B

Secondary Th1 act
0.0
0.0
HUVEC IL-1 beta
0.1
0.0

Secondary Th2 act
0.0
0.0
HUVEC IFN gamma
0.7
0.5

Secondary Tr1 act
0.0
0.0
HUVEC TNF alpha + IFN gamma
0.1
0.0

Secondary Th1 rest
0.0
0.0
HUVEC TNF alpha + IL4
0.0
0.0

Secondary Th2 rest
0.0
0.0
HUVEC IL-11
0.2
0.1

Secondary Tr1 rest
0.0
0.0
Lung Microvascular EC none
0.0
0.1

Primary Th1 act
0.0
0.0
Lung Microvascular EC TNF alpha +
0.0
0.0

IL-1 beta

Primary Th2 act
0.0
0.0
Microvascular Dermal EC none
0.0
0.0

Primary Tr1 act
0.0
0.0
Microsvasular Dermal EC TNF alpha +
0.0
0.0

IL-1 beta

Primary Th1 rest
0.0
0.0
Bronchial epithelium TNF alpha +
0.3
0.1

IL1 beta

Primary Th2 rest
0.0
0.0
Small airway epithelium none
0.1
0.0

Primary Tr1 rest
0.0
0.0
Small airway epithelium TNF alpha +
0.0
0.0

IL-1 beta

CD45RA CD4 lymphocyte
0.6
0.7
Coronery artery SMC rest
1.0
0.9

act

CD45RO CD4 lymphocyte
0.2
0.3
Coronery artery SMC TNF alpha +
0.8
0.7

act

IL-1 beta

CD8 lymphocyte act
0.1
0.0
Astrocytes rest
0.1
0.0

Secondary CD8 lymphocyte
0.0
0.0
Astrocytes TNF alpha + IL-1 beta
0.0
0.0

rest

Secondary CD8 lymphocyte
0.0
0.0
KU-812 (Basophil) rest
0.0
0.0

act

CD4 lymphocyte none
0.7
0.1
KU-812 (Basophil) PMA/ionomycin
0.1
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
0.0
CCD1106 (Keratinocytes) none
0.0
0.0

CH11

LAK cells rest
25.9
5.6
CCD1106 (Keratinocytes) TNF alpha +
0.0
0.0

IL-1 beta

LAK cells IL-2
0.7
0.3
Liver cirrhosis
3.2
0.4

LAK cells IL-2 + IL-12
0.6
0.1
NCI-H292 none
1.9
0.5

LAK cells IL-2 + IFN
1.3
0.2
NCI-H292 IL-4
1.5
0.8

gamma

LAK cells IL-2 + IL-18
0.8
0.2
NCI-H292 IL-9
2.1
1.8

LAK cells PMA/ionomycin
7.3
4.6
NCI-H292 IL-13
1.3
1.0

NK Cells IL-2 rest
0.7
0.6
NCI-H292 IFN gamma
2.5
0.8

Two Way MLR 3 day
23.0
7.9
HPAEC none
0.8
0.3

Two Way MLR 5 day
7.7
0.0
HPAEC TNF alpha + IL-1 beta
0.7
0.4

Two Way MLR 7 day
1.7
0.2
Lung fibroblast none
1.4
1.0

PBMC rest
10.0
1.6
Lung fibroblast TNF alpha + IL-1
3.9
4.2

beta

PBMC PWM
2.0
0.1
Lung fibroblast IL-4
0.5
0.3

PBMC PHA-L
3.0
1.1
Lung fibroblast IL-9
1.2
0.3

Ramos (B cell) none
0.2
0.0
Lung fibroblast IL-13
0.4
0.2

Ramos (B cell) ionomycin
0.1
0.0
Lung fibroblast IFN gamma
0.9
0.7

B lymphocytes PWM
1.6
0.8
Dermal fibroblast CCD1070 rest
0.5
0.3

B lymphocytes CD40L and
6.6
4.7
Dermal fibroblast CCD1070 TNF
0.4
0.3

IL-4

alpha

EOL-1 dbcAMP
0.1
0.1
Dermal fibroblast CCD1070 IL-1
0.7
0.5

beta

EOL-1 dbcAMP
0.0
0.0
Dermal fibroblast IFN gamma
2.2
1.6

PMA/ionomycin

Dendritic cells none
11.1
2.4
Dermal fibroblast IL-4
1.6
0.8

Dendritic cells LPS
10.5
2.0
Dermal Fibroblasts rest
2.0
1.3

Dendritic cells anti-CD40
8.1
1.5
Neutrophils TNFa + LPS
21.8
16.2

Monocytes rest
63.7
17.3
Neutrophils rest
100.0
100.0

Monocytes LPS
3.5
1.6
Colon
1.4
0.3

Macrophages rest
6.1
1.3
Lung
27.9
3.9

Macrophages LPS
6.6
2.9
Thymus
3.1
0.4

HUVEC none
0.2
0.0
Kidney
14.2
8.8

HUVEC starved
0.3
0.3

TABLE BOG

general oncology screening panel_v_2.4

Column A - Rel. Exp. (%) Ag3771, Run 267820396

Column B - Rel. Exp. (%) Ag941, Run 262229106

Tissue Name
A
B
Tissue Name
A
B

Colon cancer 1
0.8
1.1
Bladder NAT 2
0.2
0.2

CC Margin (ODO3921)
0.9
1.4
Bladder NAT 3
0.2
0.1

Colon cancer 2
1.1
1.3
Bladder NAT 4
1.6
2.3

Colon NAT 2
0.7
0.9
Prostate adenocarcinoma 1
13.4
14.9

Colon cancer 3
1.8
1.8
Prostate adenocarcinoma 2
0.6
0.5

Colon NAT 3
2.6
2.9
Prostate adenocarcinoma 3
2.0
2.8

Colon malignant cancer 4
1.9
2.9
Prostate adenocarcinoma 4
1.0
2.2

Colon NAT 4
0.6
0.5
Prostate NAT 5
0.3
0.2

Lung cancer 1
5.8
6.2
Prostate adenocarcinoma 6
0.3
0.2

Lung NAT 1
5.1
8.4
Prostate adenocarcinoma 7
0.7
0.9

Lung cancer 2
20.3
23.0
Prostate adenocarcinoma 8
0.4
0.4

Lung NAT 2
14.8
17.3
Prostate adenocarcinoma 9
4.3
4.0

Squamous cell carcinoma 3
21.2
26.8
Prostate NAT 10
0.2
0.2

Lung NAT 3
5.6
0.8
Kidney cancer 1
25.3
24.5

Metastatic melanoma 1
7.2
6.6
Kidney NAT 1
9.6
8.5

Melanoma 2
0.1
0.1
Kidney cancer 2
100.0
100.0

Melanoma 3
0.4
0.5
Kidney NAT 2
10.7
10.4

Metastatic melanoma 4
12.4
12.2
Kidney cancer 3
51.8
36.6

Metastatic melanoma 5
11.0
12.1
Kidney NAT 3
3.0
4.6

Bladder cancer 1
0.6
0.7
Kidney cancer 4
5.5
11.0

Bladder NAT 1
0.0
0.0
Kidney NAT 4
3.8
6.1

Bladder cancer 2
1.4
1.1

AI_comprehensive panel_v1.0 Summary: Ag3771 Highest expression of this gene was detected in a bone sample from a rheumatoid arthritis patient (CT=26). Prominent expression was detected in a cluster of rheumatoid arthritis samples, including samples from bone, synovium, and cartilage. Targeting this gene or gene product with small molecule, antibody, or protein therapeutics is useful in the treatment of rheumatoid arthritis.

General_screening_panel_v1.4 Summary: Ag3771 Highest expression of this gene was detected in fetal lung sample (CT=27.5). The expression of this gene is much higher in fetal (27-31) as compared to adult lung and liver (CT=32-35). Therefore, expression of this gene can be used to distinguish these fetal from adult tissues. In addition, the relative overexpression of this gene in these fetal tissues indicates that the protein product enhances growth or development of these tissues in the fetus and thus may also act in a regenerative capacity in the adult. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of lung and liver related diseases.

Among tissues with metabolic or endocrine function, this gene was expressed at moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

In addition, this gene was expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

Panel 4.1D Summary: Ag3771 Highest expression of this gene was detected in resting neutropils (CT=27.3). In addition, this gene was expressed in TNFalpha+LPS treated neutrophils. Therefore, the gene product may reduce activation of these inflammatory cells and be useful as a protein therapeutic to reduce or eliminate the symptoms in patients with Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in increasing the immune response in patients with AIDS or other immunodeficiencies.

In addition, expression of this gene was down-regulated in cytokine stimulated LAK cells and LPS-treated monocytes. Therefore, expression of this gene is useful for distinguishing these stimulated versus resting cells.

In addition, low to moderate expression of this gene was also seen in B cells, dendritic cells, endothelial cells, fibroblasts and normal tissues represented by kidney, thymus, lung, and colon. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of cancer, Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis, microbial and viral infections.

general oncology screening panel_v_—2.4 Summary: Ag941/Ag3771 Highest expression of this gene was detected in a kidney cancer sample (CTs=27). Prominent expression was also seen in prostate and melanoma cancer samples. This gene was overexpressed in the kidney cancer samples when compared to expression in the normal adjacent tissue. Expression of this gene is useful as a marker of kidney cancer. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of kidney, melanoma and prostate cancers.

BP. CG9170802: Stromelysin-1.

Expression of gene CG91708-02 was assessed using the primer-probe set Ag3395, described in Table BPA. Results of the RTQ-PCR runs are shown in Tables BPB, BPC, BPD, BPE, BPF, BPG, BPH, BPI and BPJ. CG91708-02 represents a full-length physical clone of the CG91708-01 gene.

TABLE BPAProbe Name Ag3395SEQStartIDPrimersSequencesLengthPositionNoForward5′-gtaaagccagtggaaatgaaga-3′22361458ProbeTET-5′-tcttccaatcctactgttgctgtgcg-3-26591459TAMRAReverse5′-caatggataggctgagcaaac-3′21901460

TABLE BPB

AI.05 chondrosarcoma

Column A - Rel. Exp. (%) Ag3395, Run 306941365

Tissue Name
A

138353 PMA (18 hrs)
1.2

138352 IL-1beta + Oncostatin M (18 hrs)
37.4

138351 IL-1beta + TNFa (18 hrs)
100.0

138350 IL-1beta (18 hrs)
31.9

138354 Untreated-complete medium (18 hrs)
0.2

138347 PMA (6 hrs)
4.0

138346 IL-1beta + Oncostatin M (6 hrs)
29.5

138345 IL-1beta + TNFa (6 hrs)
20.6

138344 IL-1beta (6 hrs)
8.4

138348 Untreated-complete medium (6 hrs)
0.9

138349 Untreated-serum starved (6 hrs)
1.8

TABLE BPC

AI_comprehensive panel_v1.0

Column A - Rel. Exp. (%) Ag3395, Run 217700657

Tissue Name
A
Tissue Name
A

110967 COPD-F
0.0
1112427 Match Control Psoriasis-F
0.0

110980 COPD-F
0.0
112418 Psoriasis-M
0.0

110968 COPD-M
0.0
112723 Match Control Psoriasis-M
0.0

110977 COPD-M
0.0
1112419 Psoriasis-M
0.0

110989 Emphysema-F
0.0
1112424 Match Control Psoriasis-M
0.0

110992 Emphysema-F
0.0
112420 Psoriasis-M
0.0

110993 Emphysema-F
0.0
112425 Match Control Psoriasis-M
0.0

110994 Emphysema-F
0.0
104689 (ME) OA Bone-Backus
1.0

110995 Emphysema-F
0.0
104690 (ME) Adj “Normal” Bone-
2.3

Backus

110996 Emphysema-F
0.0
104691 (ME) OA Synovium-Backus
4.9

110997 Asthma-M
0.0
104692 (BA) OA Cartilage-Backus
27.9

111001 Asthma-F
0.0
104694 (BA) OA Bone-Backus
2.6

111002 Asthma-F
0.0
104695 (BA) Adj “Normal” Bone-
90.1

Backus

111003 Atopic Asthma-F
0.0
104696 (BA) OA Synovium-Backus
100.0

111004 Atopic Asthma-F
0.0
104700 (SS) OA Bone-Backus
0.7

111005 Atopic Asthma-F
0.0
104701 (SS) Adj “Normal” Bone-Backus
14.1

111006 Atopic Asthma-F
0.0
104702 (SS) OA Synovium-Backus
1.6

111417 Allergy-M
0.0
117093 OA Cartilage Rep7
0.3

112347 Allergy-M
0.0
112672 OA Bone5
0.6

112349 Normal Lung-F
0.0
112673 OA Synovium5
0.3

112357 Normal Lung-F
0.0
1112674 OA Synovial Fluid Cells5
0.3

112354 Normal Lung-M
0.0
117100 OA Cartilage Rep14
0.0

112374 Crohns-F
0.0
112756 OA Bone9
0.0

112389 Match Control Crohns-F
0.1
112757 OA Synovium9
0.0

112375 Crohns-F
0.0
112758 OA Synovial Fluid Cells9
0.0

112732 Match Control Crohns-F
0.0
117125 RA Cartilage Rep2
0.0

112725 Crohns-M
0.1
113492 Bone2 RA
0.0

112387 Match Control Crohns-M
0.2
113493 Synovium2 RA
0.0

112378 Crohns-M
0.0
113494 Syn Fluid Cells RA
0.0

112390 Match Control Crohns-M
0.0
113499 Cartilage4 RA
0.0

112726 Crohns-M
0.0
113500 Bone4 RA
0.0

112731 Match Control Crohns-M
0.0
113501 Synovium RA
0.0

112380 Ulcer Col-F
0.0
113502 Syn Fluid Cells4 RA
0.0

112734 Match Control Ulcer Col-F
0.3
113495 Cartilage3 RA
0.0

112384 Ulcer Col-F
0.0
113496 Bone3 RA
0.0

112737 Match Control Ulcer Col-F
0.0
113497 Synovium3 RA
0.0

112386 Ulcer Col-F
0.3
113498 Syn Fluid Cells3 RA
0.1

112738 Match Control Ulcer Col-F
3.0
117106 Normal Cartilage Rep20
0.0

112381 Ulcer Col-M
0.0
113663 Bone3 Normal
0.0

112735 Match Control Ulcer Col-
0.2
113664 Synovium3 Normal
0.0

M

112382 Ulcer Col-M
0.0
113665 Syn Fluid Cells3 Normal
0.0

112394 Match Control Ulcer Col-
0.1
117107 Normal Cartilage Rep22
0.0

M

112736 13667 Match Control Ulcer
0.0
113668 Synovium4 Normal
0.0

Col-M

112383 Ulcer Col-M
0.0
113667 Bone4 Normal
0.0

112423 Psoriasis-F
0.0
113669 Syn Fluid Cells4 Normal
0.0

TABLE BPD

Ardais Panel v.1.0

Column A - Rel. Exp. (%) Ag3395, Run 263151265

Tissue Name
A

136799 Lung cancer(362)
0.8

136800 Lung NAT(363)
0.4

136813 Lung cancer(372)
77.9

136814 Lung NAT(373)
0.2

136815 Lung cancer(374)
1.1

136816 Lung NAT(375)
100.0

136791 Lung cancer(35A)
0.5

136795 Lung cancer(35E)
9.9

136797 Lung cancer(360)
0.1

136794 lung NAT(35D)
0.1

136818 Lung NAT(377)
0.3

136787 lung cancer(356)
0.1

136788 lung NAT(357)
0.1

136804 Lung cancer(369)
0.6

136805 Lung NAT(36A)
0.1

136806 Lung cancer(36B)
4.3

136807 Lung NAT(36C)
0.1

136789 lung cancer(358)
0.0

136802 Lung cancer(365)
0.2

136803 Lung cancer(368)
0.2

136811 Lung cancer(370)
31.2

136810 Lung NAT(36F)
0.9

TABLE BPE

Ardais Prostate 1.0

Column A - Rel. Exp. (%) Ag3395, Run 320416133

Tissue Name
A
Tissue Name
A

151135 Prostate NAT(B87)
1.7
151128 Prostate cancer(B8C)
34.4

151143 Prostate NAT(B8A)
7.9
151136 Prostate cancer(B8B)
34.4

153669 Prostate NAT(D5E)
5.8
151144 Prostate cancer(B8F)
3.4

153677 Prostate NAT(D66)
0.8
153654 Prostate cancer(D4F)
100.0

153685 Prostate NAT(D6E)
5.1
153662 Prostate cancer(D57)
2.8

145905 Prostate NAT(A0C)
3.5
153655 Prostate cancer(D50)
89.5

153670 Prostate NAT(D5F)
5.3
145907 Prostate cancer(A0A)
15.5

153678 Prostate NAT(D67)
13.3
153663 Prostate cancer(D58)
2.6

153686 Prostate NAT(D6F)
6.0
151130 Prostate cancer(B90)
69.3

145906 Prostate NAT(A09)
15.4
153648 Prostate cancer(D49)
2.8

151129 Prostate NAT(B93)
4.0
153656 Prostate cancer(D51)
5.8

151137 Prostate NAT(B86)
3.7
153664 Prostate cancer(D59)
0.1

153671 Prostate NAT(D60)
10.4
155799 Prostate cancer(EA8)
6.4

151145 Prostate NAT(B91)
25.3
145909 Prostate cancer(9E7)
23.8

153679 Prostate NAT(D68)
2.7
153649 Prostate cancer(D4A)
4.9

153687 Prostate NAT(D70)
2.0
153657 Prostate cancer(D52)
9.0

153672 Prostate NAT(D61)
12.4
153665 Prostate cancer(D5A)
5.5

153680 Prostate NAT(D69)
5.9
151132 Prostate cancer(B88)
23.8

151131 Prostate NAT(B85)
1.8
153650 Prostate cancer(D4B)
3.9

153673 Prostate NAT(D62)
4.8
153658 Prostate cancer(D53)
3.5

153681 Prostate NAT(D6A)
1.3
153666 Prostate cancer(D5B)
9.7

145910 Prostate NAT(9G3)
0.9
153651 Prostate cancer(D4C)
0.7

153674 Prostate NAT(D63)
26.2
153659 Prostate cancer(D54)
7.1

153682 Prostate NAT(D6B)
10.7
153667 Prostate cancer(D5C)
33.9

151133 Prostate NAT(B94)
12.2
151134 Prostate cancer(B92)
31.4

153675 Prostate NAT(D64)
9.8
151142 Prostate cancer(B89)
1.6

153683 Prostate NAT(D6C)
15.7
153652 Prostate cancer(D4D)
2.1

153668 Prostate NAT(D5D)
34.9
153660 Prostate cancer(D55)
3.4

153676 Prostate NAT(D65)
6.4
149773 Prostate NAT(AD8)
16.5

153684 Prostate NAT(D6D)
2.7
149774 Prostate cancer(AD7)
6.4

145904 Prostate cancer(9E2)
2.3
151139 Prostate NAT(B8E)
6.5

149776 Prostate cancer(AD5)
49.3
151138 Prostate cancer(B8D)
8.5

153653 Prostate cancer(D4E)
5.4
151141 Prostate NAT(B96)
2.8

153661 Prostate cancer(D56)
4.2
151140 Prostate cancer(B95)
4.1

TABLE BPF

General_screening_panel_v1.4

Column A - Rel. Exp. (%) Ag3395, Run 208034252

Column B - Rel. Exp. (%) Ag3395, Run 212141064

Tissue Name
A
B
Tissue Name
A
B

Adipose
0.1
0.1
Renal ca. TK-10
0.0
0.0

Melanoma* Hs688(A).T
1.2
1.9
Bladder
0.1
0.1

Melanoma* Hs688(B).T
0.3
0.5
Gastric ca. (liver met.) NCI-N87
0.5
0.8

Melanoma* M14
0.1
0.1
Gastric ca. KATO III
0.4
0.8

Melanoma* LOXIMVI
3.2
6.6
Colon ca. SW-948
0.0
0.0

Melanoma* SK-MEL-5
0.0
0.0
Colon ca. SW480
0.0
0.0

Squamous cell carcinoma
0.0
0.1
Colon ca.* (SW480 met) SW620
0.0
0.0

SCC-4

Testis Pool
0.8
1.2
Colon ca. HT29
0.0
0.0

Prostate ca.* (bone met) PC-3
0.1
0.1
Colon ca. HCT-116
0.0
0.0

Prostate Pool
0.1
0.2
Colon ca. CaCo-2
0.1
0.1

Placenta
0.0
0.0
Colon cancer tissue
30.1
37.1

Uterus Pool
0.0
0.0
Colon ca. SW1116
0.0
0.0

Ovarian ca. OVCAR-3
0.0
0.1
Colon ca. Colo-205
0.0
0.0

Ovarian ca. SK-OV-3
0.0
0.3
Colon ca. SW-48
0.0
0.0

Ovarian ca. OVCAR-4
0.0
0.0
Colon Pool
0.0
0.0

Ovarian ca. OVCAR-5
0.2
0.4
Small Intestine Pool
0.6
1.2

Ovarian ca. IGROV-1
0.0
0.1
Stomach Pool
2.2
3.7

Ovarian ca. OVCAR-8
0.0
0.0
Bone Marrow Pool
0.0
0.0

Ovary
0.0
0.0
Fetal Heart
0.0
0.0

Breast ca. MCF-7
0.0
0.0
Heart Pool
0.0
0.0

Breast ca. MDA-MB-231
0.0
0.0
Lymph Node Pool
0.0
0.0

Breast ca. BT 549
0.1
0.2
Fetal Skeletal Muscle
0.0
0.0

Breast ca. T47D
0.1
0.3
Skeletal Muscle Pool
0.1
0.2

Breast ca. MDA-N
0.1
0.2
Spleen Pool
0.1
0.1

Breast Pool
0.1
0.3
Thymus Pool
0.0
0.1

Trachea
1.6
1.8
CNS cancer (glio/astro) U87-MG
100.0
100.0

Lung
0.0
0.0
CNS cancer (glio/astro) U-118-
52.5
72.7

MG

Fetal Lung
0.1
0.1
CNS cancer (neuro; met) SK-N-AS
0.0
0.0

Lung ca. NCI-N417
0.0
0.0
CNS cancer (astro) SF-539
0.1
0.2

Lung ca. LX-1
0.0
0.0
CNS cancer (astro) SNB-75
0.3
0.7

Lung ca. NCI-H146
0.0
0.0
CNS cancer (glio) SNB-19
0.1
0.2

Lung ca. SHP-77
0.0
0.0
CNS cancer (glio) SF-295
21.2
54.0

Lung ca. A549
0.0
0.0
Brain (Amygdala) Pool
0.0
0.0

Lung ca. NCI-H526
0.0
0.0
Brain (cerebellum)
0.0
0.0

Lung ca. NCI-H23
0.0
0.4
Brain (fetal)
0.0
0.0

Lung ca. NCI-H460
0.0
0.2
Brain (Hippocampus) Pool
0.1
0.2

Lung ca. HOP-62
0.0
0.0
Cerebral Cortex Pool
0.0
0.0

Lung ca. NCI-H522
0.1
0.3
Brain (Substantia nigra) Pool
0.0
0.0

Liver
0.0
0.0
Brain (Thalamus) Pool
0.0
0.0

Fetal Liver
0.0
0.0
Brain (whole)
0.0
0.1

Liver ca. HepG2
0.0
0.0
Spinal Cord Pool
0.0
0.0

Kidney Pool
0.0
0.0
Adrenal Gland
0.0
0.1

Fetal Kidney
0.3
0.5
Pituitary gland Pool
0.0
0.0

Renal ca. 786-0
0.0
0.0
Salivary Gland
0.1
0.0

Renal ca. A498
0.0
0.0
Thyroid (female)
0.0
0.0

Renal ca. ACHN
0.0
0.8
Pancreatic ca. CAPAN2
0.1
0.1

Renal ca. UO-31
0.0
0.0
Pancreas Pool
0.0
0.1

TABLE BPG

Panel 2D

Column A - Rel. Exp. (%) Ag3395, Run 165469036

Tissue Name
A

Normal Colon
4.4

CC Well to Mod Diff (OD03866)
48.6

CC Margin (OD03866)
4.6

CC Gr.2 rectosigmoid (OD03868)
9.0

CC Margin (OD03868)
0.3

CC Mod Duff (OD03920)
10.9

CC Margin (OD03920)
1.8

CC Gr.2 ascend colon (OD03921)
100.0

CC Margin (OD03921)
3.1

CC from Partial Hepatectomy (OD04309) Mets
1.4

Liver Margin (OD04309)
0.3

Colon mets to lung (OD04451-01)
0.1

Lung Margin (OD04451-02)
0.0

Normal Prostate 6546-1
1.9

Prostate cancer (OD04410)
0.3

Prostate Margin (OD04410)
0.0

Prostate cancer (OD04720-01)
0.5

Prostate Margin (OD04720-02)
0.9

Normal Lung
0.4

Lung Met to Muscle (OD04286)
0.4

Muscle Margin (OD04286)
9.3

Lung Malignant cancer (OD03126)
2.6

Lung Margin (OD03126)
0.3

Lung cancer (OD04404)
25.9

Lung Margin (OD04404)
0.2

Lung cancer (OD04565)
21.9

Lung Margin (OD04565)
0.4

Lung cancer (OD04237-01)
1.4

Lung Margin (OD04237-02)
0.3

Ocular Mel Met to Liver (OD04310)
0.1

Liver Margin (OD04310)
0.1

Melanoma Metastasis
0.2

Lung Margin (OD04321)
0.3

Normal Kidney
1.7

Kidney Ca, Nuclear grade 2 (OD04338)
0.1

Kidney Margin (OD04338)
1.0

Kidney Ca Nuclear grade 1/2 (OD04339)
0.1

Kidney Margin (OD04339)
1.4

Kidney Ca, Clear cell type (OD04340)
0.0

Kidney Margin (OD04340)
0.5

Kidney Ca, Nuclear grade 3 (OD04348)
0.0

Kidney Margin (OD04348)
1.2

Kidney cancer (OD04622-01)
0.1

Kidney Margin (OD04622-03)
0.3

Kidney cancer (OD04450-01)
0.3

Kidney Margin (OD04450-03)
0.2

Kidney cancer 8120607
0.5

Kidney Margin 8120608
0.0

Kidney cancer 8120613
0.0

Kidney Margin 8120614
0.2

Kidney cancer 9010320
0.6

Kidney Margin 9010321
1.1

Normal Uterus
0.5

Uterine cancer 064011
0.9

Normal Thyroid
0.2

Thyroid cancer
0.0

Thyroid cancer A302152
0.9

Thyroid Margin A302153
0.0

Normal Breast
5.8

Breast cancer
3.8

Breast cancer (OD04590-01)
2.7

Breast cancer Mets (OD04590-03)
2.5

Breast cancer Metastasis
0.3

Breast cancer
17.7

Breast cancer
4.1

Breast cancer 9100266
18.2

Breast Margin 9100265
30.4

Breast cancer A209073
16.8

Breast Margin A209073
19.3

Normal Liver
0.1

Liver cancer
0.1

Liver cancer 1025
0.0

Liver cancer 1026
0.0

Liver cancer 6004-T
0.0

Liver Tissue 6004-N
1.6

Liver cancer 6005-T
0.0

Liver Tissue 6005-N
0.0

Normal Bladder
0.5

Bladder cancer
0.6

Bladder cancer
4.3

Bladder cancer (OD04718-01)
13.4

Bladder Normal Adjacent (OD04718-03)
35.4

Normal Ovary
0.0

Ovarian cancer
1.3

Ovarian cancer (OD04768-07)
0.0

Ovary Margin (OD04768-08)
1.7

Normal Stomach
1.3

Gastric cancer 9060358
6.9

Stomach Margin 90603591
1.4

Gastric cancer 90603951
10.2

Stomach Margin 90603941
1.3

Gastric cancer 9060397
25.0

Stomach Margin 9060396
1.0

Gastric cancer 064005
60.7

TABLE BPH

Panel 3D

Column A - Rel. Exp. (%) Ag3395, Run 165924467

Column B - Rel. Exp. (%) Ag3395, Run 167542915

Tissue Name
A
B
Tissue Name
A
B

94905 Daoy
0.0
0.0
94954 Ca Ski Cervical
0.3
0.2

Medulloblastoma/Cerebellum

epidermoid carcinoma

(metastasis

94906 TE671
0.0
0.0
94955 ES-2 Ovarian clear cell
3.1
4.0

Medulloblastom/Cerebellum

carcinoma

94907 D283 Med
0.0
0.0
94957 Ramos Stimulated with
0.0
0.0

Medulloblastoma/Cerebellum

PMA/ionomycin 6 h

94908 PFSK-1 Primitive
0.0
0.0
94958 Ramos Stimulated with
0.0
0.0

Neuroectodermal/Cerebellum

PMA/ionomycin 14 h

94909 XF-498 CNS
0.1
0.1
94962 MEG-01 Chronic
0.0
0.0

myelogenous leukemia

(megokaryoblast)

94910 SNB-78 CNS/glioma
0.3
0.2
94963 Raji Burkitt's
0.0
0.0

lymphoma

94911 SF-268 CNS/glioblastoma
0.0
0.1
94964 Daudi Burkitt's
0.0
0.0

lymphoma

94912 T98G Glioblastoma
0.8
1.3
94965 U266 B-cell
0.0
0.0

plasmacytoma/myeloma

96776 SK-N-SH Neuroblastoma
12.9
16.7
94968 CA46 Burkitt's
0.0
0.0

(metastasis)

lymphoma

94913 SF-295 CNS/glioblastoma
100.0
100.0
94970 RL non-Hodgkin's B-
0.0
0.0

cell lymphoma

94914 Cerebellum
0.0
0.0
94972 JM1 pre-B-cell
0.0
0.0

lymphoma/leukemia

96777 Cerebellum
0.0
0.0
94973 Jurkat T cell leukemia
0.0
0.0

94916 NCI-H292
0.0
0.0
94974 TF-1 Erythroleukemia
0.0
0.0

Mucoepidermoid lung carcinoma

94917 DMS-114 Small cell lung
0.2
0.3
94975 HUT 78 T-cell
0.0
0.0

cancer

lymphoma

94918 DMS-79 Small cell lung
0.0
0.0
94977 U937 Histiocytic
0.0
0.0

cancer/neuroendocrine

lymphoma

94919 NCI-H146 Small cell lung
0.0
0.0
94980 KU-812 Myelogenous
0.0
0.2

cancer/neuroendocrine

leukemia

94920 NCI-H526 Small cell lung
0.0
0.0
769-P- Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94921 NCI-N417 Small cell lung
0.0
0.0
94983 Caki-2 Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94923 NCI-H82 Small cell lung
0.0
0.0
94984 SW 839 Clear cell renal
0.0
0.0

cancer/neuroendocrine

carcinoma

94924 NCI-H157 Squamous cell
0.0
0.0
94986 G401 Wilms' tumor
0.0
0.0

lung cancer (metastasis)

94925 NCI-H1155 Large cell
0.0
0.0
94987 Hs766T Pancreatic
0.0
0.0

lung cancer/neuroendocrine

carcinoma (LN metastasis)

94926 NCI-H1299 Large cell
0.0
0.0
94988 CAPAN-1 Pancreatic
0.0
0.0

lung cancer/neuroendocrine

adenocarcinoma (liver

metastasis)

94927 NCI-H727 Lung carcinoid
0.0
0.0
94989 SU86.86 Pancreatic
0.0
0.1

carcinoma (liver metastasis)

94928 NCI-UMC-11 Lung
0.1
0.0
94990 BxPC-3 Pancreatic
0.2
0.1

carcinoid

adenocarcinoma

94929 LX-1 Small cell lung
0.0
0.0
94991 HPAC Pancreatic
0.0
0.0

cancer

adenocarcinoma

94930 Colo-205 Colon cancer
0.0
0.0
94992 MIA PaCa-2 Pancreatic
0.0
0.0

carcinoma

94931 KM12 Colon cancer
0.0
0.0
94993 CFPAC-1 Pancreatic
0.0
0.1

ductal adenocarcinoma

94932 KM20L2 Colon cancer
0.0
0.0
94994 PANC-1 Pancreatic
0.0
0.0

epithelioid ductal carcinoma

94933 NCI-H716 Colon cancer
0.0
0.0
94996 T24 Bladder carcinma
0.0
0.0

(transitional cell

94935 SW-48 Colon
0.0
0.0
5637- Bladder carcinoma
0.0
0.0

adenocarcinoma

94936 SW1116 Colon
0.0
0.0
94998 HT-1197 Bladder
0.0
0.1

adenocarcinoma

carcinoma

94937 LS 174T Colon
0.0
0.0
94999 UM-UC-3 Bladder
0.2
0.2

adenocarcinoma

carcinma (transitional cell)

94938 SW-948 Colon
0.0
0.0
95000 A204
0.2
0.2

adenocarcinoma

Rhabdomyosarcoma

94939 SW-480 Colon
0.0
0.0
95001 HT-1080 Fibrosarcoma
0.0
0.1

adenocarcinoma

94940 NCI-SNU-5 Gastric
0.0
0.0
95002 MG-63 Osteosarcoma
0.3
0.5

carcinoma

(bone)

KATO III- Gastric carcinoma
0.0
0.0
95003 SK-LMS-1
23.7
38.4

Leiomyosarcoma (vulva)

94943 NCI-SNU-16 Gastric
0.1
0.2
95004 SJRH30
0.0
0.0

carcinoma

Rhabdomyosarcoma (met to

bone marrow)

94944 NCI-SNU-1 Gastric
0.0
0.0
95005 A431 Epidermoid
0.0
0.0

carcinoma

carcinoma

94946 RF-1 Gastric
0.0
0.0
95007 WM266-4 Melanoma
0.0
0.0

adenocarcinoma

94947 RF-48 Gastric
0.0
0.0
DU 145- Prostate carcinoma
0.0
0.0

adenocarcinoma

(brain metastasis)

96778 MKN-45 Gastric
0.0
0.0
95012 MDA-MB-468 Breast
0.0
0.0

carcinoma

adenocarcinoma

94949 NCI-N87 Gastric
0.0
0.0
SCC-4- Squamous cell
0.0
0.0

carcinoma

carcinoma of tongue

94951 OVCAR-5 Ovarian
0.0
0.0
SCC-9- Squamous cell
0.0
0.0

carcinoma

carcinoma of tongue

94952 RL95-2 Uterine carcinoma
0.0
0.0
SCC-15- Squamous cell
0.0
0.0

carcinoma of tongue

94953 HelaS3 Cervical
0.0
0.0
95017 CAL 27 Squamous cell
0.0
4.3

adenocarcinoma

carcinoma of tongue

TABLE BPI

Panel 4D

Column A - Rel. Exp. (%) Ag3395, Run 166447040

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1 beta
0.0

Secondary Th2 act
0.0
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNF alpha + IL-1
0.0

beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.0
Microsvasular Dermal EC TNF alpha + IL-1
0.0

beta

Primary Th1 rest
0.0
Bronchial epithelium TNF alpha + IL1beta
4.0

Primary Th2 rest
0.0
Small airway epithelium none
0.8

Primary Tr1 rest
0.0
Small airway epithelium TNF alpha + IL-1
7.7

beta

CD45RA CD4 lymphocyte act
23.3
Coronery artery SMC rest
0.6

CD45RO CD4 lymphocyte act
0.0
Coronery artery SMC TNF alpha + IL-1 beta
0.8

CD8 lymphocyte act
0.0
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNF alpha + IL-1 beta
0.3

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
0.0
CCD1106 (Keratinocytes) TNF alpha + IL-1
0.1

beta

LAK cells IL-2
0.0
Liver cirrhosis
0.0

LAK cells IL-2 + IL-12
0.0
Lupus kidney
0.0

LAK cells IL-2 + IFN gamma
0.0
NCI-H292 none
0.0

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
0.0

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
0.0

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
0.0

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
0.0

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1 beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.3

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1 beta
56.6

PBMC PHA-L
0.0
Lung fibroblast IL-4
0.2

Ramos (B cell) none
0.0
Lung fibroblast IL-9
1.7

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
0.1

B lymphocytes PWM
0.0
Lung fibroblast IFN gamma
0.2

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
16.5

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
57.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
100.0

PMA/ionomycin
0.0

Dendritic cells none
0.0
Dermal fibroblast IFN gamma
1.7

Dendritic cells LPS
0.0
Dermal fibroblast IL-4
2.9

Dendritic cells anti-CD40
0.0
IBD Colitis 2
0.1

Monocytes rest
0.0
IBD Crohn's
0.0

Monocytes LPS
0.0
Colon
0.1

Macrophages rest
0.0
Lung
0.0

Macrophages LPS
0.0
Thymus
0.1

HUVEC none
0.0
Kidney
0.0

HUVEC starved
0.0

TABLE BPJ

Panel 5 Islet

Column A - Rel. Exp. (%) Ag3395, Run 259154756

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
0.0
94709 Donor 2 AM - A adipose
8.0

97476 Patient-07sk skeletal muscle
15.3
94710 Donor 2 AM - B adipose
4.1

97477 Patient-07ut uterus
0.0
94711 Donor 2 AM - C adipose
4.5

97478 Patient-07pl placenta
0.0
94712 Donor 2 AD - A adipose
0.3

99167 Bayer Patient 1
100.0
94713 Donor 2 AD - B adipose
0.5

97482 Patient-08ut uterus
2.3
94714 Donor 2 AD - C adipose
1.0

97483 Patient-08pl placenta
0.4
94742 Donor 3 U - A Mesenchymal
0.6

Stem Cells

97486 Patient-09sk skeletal muscle
0.5
94743 Donor 3 U - B Mesenchymal
0.3

Stem Cells

97487 Patient-09ut uterus
0.1
94730 Donor 3 AM - A adipose
21.6

97488 Patient-09pl placenta
0.0
94731 Donor 3 AM - B adipose
12.7

97492 Patient-10ut uterus
0.4
94732 Donor 3 AM - C adipose
13.2

97493 Patient-10pl placenta
0.0
94733 Donor 3 AD - A adipose
2.9

97495 Patient-11go adipose
0.0
94734 Donor 3 AD - B adipose
3.0

97496 Patient-11sk skeletal muscle
0.3
94735 Donor 3 AD - C adipose
0.6

97497 Patient-11ut uterus
1.0
77138 Liver HepG2untreated
0.3

97498 Patient-11pl placenta
0.0
73556 Heart Cardiac stromal cells
0.3

(primary)

97500 Patient-12go adipose
0.0
81735 Small Intestine
1.9

97501 Patient-12sk skeletal muscle
0.0
72409 Kidney Proximal Convoluted
0.3

Tubule

97502 Patient-12ut uterus
0.2
82685 Small intestine Duodenum
1.8

97503 Patient-12p1 placenta
0.3
90650 Adrenal Adrenocortical
0.0

adenoma

94721 Donor 2 U - A Mesenchymal
0.3
72410 Kidney HRCE
1.2

Stem Cells

94722 Donor 2 U - B Mesenchymal
0.7
72411 Kidney HRE
0.3

Stem Cells

94723 Donor 2 U - C Mesenchymal
0.0
73139 Uterus Uterine smooth muscle
22.1

Stem Cells

cells

AI.05 chondrosarcoma Summary: Ag3395 Highest expression of this gene was detected in IL-1 and TNF alpha treated chondrosarcoma cell line (SW1353) (CT=18.8). Expression of this gene was upregulated upon IL-1 treatment, a potent activator of pro-inflammatory cytokines and matrix metalloproteinases. This gene codes for matrix metalloproteinase 3 (MMP3), which is capable of degrading proteoglycan, fibronectin, laminin, and type IV collagen. MMPs are known to participate in the destruction of cartilage observed in Osteoarthritis (OA). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the prevention of the degeneration of cartilage observed in OA.

AI_comprehensive panel_v1.0 Summary: Ag3395 This gene was expressed in orthoarthritis (OA) tissues but not in control tissue. This gene encodes MMP3 protein, which has been shown to be present in OA joint (Bluteau G, Conrozier T, Mathieu P, Vignon E, Herbage D, Mallein-Gerin F. Matrix metalloproteinase-1, -3, -13 and aggrecanase-1 and -2 are differentially expressed in experimental osteoarthritis. Biochim Biophys Acta 2001 May 3; 1526(2):147-58) tissue and may contribute to the pathology of this disease. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of OA.

Ardais Panel v.1.0 Summary: Ag3395 Highest expression of this gene was detected in a normal adjacent lung (375) sample (CT=24.7). Significant expression of this gene was seen in normal and cancer samples from lung. This gene shows up-regulated expression in 4/6 cancer samples relative to corresponding normal adjacent samples. Therefore, modulation of this, expressed protein, and/or use of antibodies or small molecule drug targeting this gene or gene product will be of use to treat lung cancer.

Ardais Prostate 1.0 Summary: Ag3395 Highest expression of this gene was detected in prostate cancer (D4F) sample (CT=27). Significant expression of this gene was seen in normal and cancer samples from prostate. The expression of this gene was relatively higher in number of prostate cancer samples. Therefore, modulation of this, expressed protein, and/or use of antibodies or small molecule drug targeting this gene or gene product will be of use to treat prostate cancer.

General_screening_panel_v1.4 Summary: Ag3395 The expression of this gene was highest in a sample derived a brain cancer cell line (U87-MG) (CTs=22-24). Significant expression of this gene was also seen in brain cancer cell lines, colon cancer cell lines and melanoma cell lines. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of brain or colon cancer or melanoma.

Among tissues with metabolic function, this gene was expressed at low levels in pancreas, adipose, and fetal skeletal muscle. This expression indicates that this gene product plays a role in normal neuroendocrine and metabolic and that disregulated expression of this gene will contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

This gene was also expressed at low but significant levels in the hippocampus, a structure critical for learning and memory. The hippocampus-preferential expression of this gene indicate that it plays a role in learning and memory processes. Modulation of this gene is useful in treatment of CNS disorders involving memory deficits, including Alzheimer's disease and aging.

Panel 2D Summary: Ag3395 Highest expression of this gene was detected in a sample derived from a colon cancer (CT=26.8). Significant expression was also seen in gastric cancer, bladder cancer, breast cancer, lung cancer and colon cancer. Expression levels of this gene is useful as marker to detect these cancers. Therapeutic modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of gastric, bladder, breast, lung or colon cancers.

Panel 3D Summary: Ag3395 The expression of this gene was highest in a sample derived from a brain cancer cell line (SF-295) (CTs=24-26). Significant levels of expression of this gene was also seen in cell lines derived from brain, lung, ovarian, cervical, pancreatic, vulval, and bone cancers. Therapeutic modulation of this gene, encoded protein and/or use of antibodies or small molecule drugs is useful in the treatment of brain lung, ovarian, cervical, pancreatic, vulval, and bone cancers.

Panel 4D Summary: Ag3395 The expression level of this gene was up-regulated in lung and dermal fibroblasts after treatment with IL-1 beta and/or TNF alpha (CTs=21.5-22.5). High expression of this gene was also seen in activated small airway and bronchial epithelium, activated naive T cells (CD45RA CD4 lymphocyte), activated asatrocytes, resting and activated coronary artery SMC cells. This expression profile indicates that the stromolysin protein encoded by this gene may facilitate tissue destruction, remodeling and participate in cell:cell interactions that prevent the resolution of the inflammatory response. Modulation of this gene, encoded protein and/or use of antibodies or small molecule drug targeting this gene or gene product will help to reduce or eliminate inflammation in the skin and lung resulting from psoriasis, allergy, asthma, emphysema, promote wound healing and prevent delayed type hypersensitivity type reactions.

Panel 5 Islet Summary: Ag3395 Highest expression of this gene was detected in islet cells (bayer patient 1) (CT=27.9). Significant expression of this gene was also seen in adipose, skeletal muscle and uterus. Modulation of this gene or expressed protein is useful in the treatment of metabolic disorders, including type II diabetes and obesity.

BQ. CG94235-01: Thymidylate Kinase.

Expression of gene CG94235-01 was assessed using the primer-probe sets Ag1980 and Ag3909, described in Tables BQA and BQB. Results of the RTQ-PCR runs are shown in Tables BQC, BQD, BQE, BQF, BQG, BQH, BQI and BQJ.

TABLE BOAProbe Name Ag1980SEQStartIDPrimersSequencesLengthPositionNoForward5′-gggtacgatggctgaagtaaa-3′2114371461ProbeTET-5′-ccagttttctgccacacaacatgctt-3′-2613941462TAMRAReverse5′-ttatgcagtgttcccaaatttc-3′2213641463

TABLE BOB

Probe Name Ag3909

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-caggtgccacgtctaactagat-3′
22
1307
1464

Probe
TET-5′-tgttgtttgaaacatctacatccacca-3′-
27
1333
1465

TAMRA

Reverse
5′-gaaatttgggaacactgcataa-3′
22
1364
1466

TABLE BQG

AI.05 chondrosarcoma

Column A - Rel. Exp.(%) Ag1980, Run 306913835

Tissue Name
A
Tissue Name
A

138353 PMA (18 hrs)
0.3
138346 IL-1beta + Oncostatin M
9.9

(6 hrs)

138352 IL-1beta + Oncostatin M
0.8
138345 IL-1beta + TNFa (6 hrs)
19.2

(18 hrs)

138351 IL-1beta + TNFa (18 hrs)
100.0
138344 IL-1beta (6 hrs)
7.5

138350 IL-1beta (18 hrs)
13.7
138348 Untreated-complete medium
0.1

(6 hrs)

138354 Untreated-complete medium
0.0
138349 Untreated-serum starved
0.4

(18 hrs)

(6 hrs)

138347 PMA (6 hrs)
0.4

TABLE BQD

AI_comprehensive panel_v1.0

Column A - Rel. Exp. (%) Ag1980, Run 211061884

Column B - Rel. Exp. (%) Ag1980, Run 212317511

Tissue Name
A
B
Tissue Name
A
B

110967 COPD-F
10.1
11.6
112427 Match Control Psoriasis-F
100.0
100.0

110980 COPD-F
12.5
16.8
112418 Psoriasis-M
19.1
18.7

110968 COPD-M
13.9
13.5
112723 Match Control Psoriasis-
6.6
7.2

M

110977 COPD-M
50.3
32.8
112419 Psoriasis-M
35.6
17.0

110989 Emphysema-F
20.7
24.5
112424 Match Control Psoriasis-
7.6
10.1

M

110992 Emphysema-F
12.2
6.0
112420 Psoriasis-M
54.0
53.2

110993 Emphysema-F
12.9
8.7
112425 Match Control Psoriasis-
62.4
72.7

M

110994 Emphysema-F
7.0
5.8
104689 (MF) OA Bone-Backus
66.0
56.3

110995 Emphysema-F
17.0
17.6
104690 (MF) Adj “Normal” Bone-
34.6
24.0

Backus

110996 Emphysema-F
3.3
7.0
104691 (MF) OA Synovium-
36.6
40.9

Backus

110997 Asthma-M
8.0
3.1
104692 (BA) OA Cartilage-
12.1
6.8

Backus

111001 Asthma-F
21.8
15.8
104694 (BA) OA Bone-Backus
51.8
36.3

111002 Asthma-F
24.0
13.1
104695 (BA) Adj “Normal” Bone-
26.4
19.5

Backus

111003 Atopic Asthma-F
20.3
22.5
104696 (BA) OA Synovium-
63.7
40.9

Backus

111004 Atopic Asthma-F
26.1
28.5
104700 (SS) OA Bone-Backus
20.9
62.0

111005 Atopic Asthma-F
24.5
10.3
104701 (SS) Adj “Normal” Bone-
28.7
25.7

Backus

111006 Atopic Asthma-F
11.0
8.1
104702 (SS) OA Synovium-
80.1
59.5

Backus

111417 Allergy-M
8.7
7.7
117093 OA Cartilage Rep7
17.8
20.9

112347 Allergy-M
0.0
0.0
112672 OA Bone5
36.6
33.9

112349 Normal Lung-F
0.0
0.0
112673 OA Synovium5
21.3
22.4

112357 Normal Lung-F
67.4
64.6
112674 OA Synovial Fluid cells5
20.3
20.0

112354 Normal Lung-M
9.8
15.6
117100 OA Cartilage Rep14
9.6
6.9

112374 Crohns-F
11.1
15.0
112756 OA Bone9
95.3
66.0

112389 Match Control
10.4
18.4
112757 OA Synovium9
17.4
19.2

Crohns-F

112375 Crohns-F
14.5
9.9
112758 OA Synovial Fluid Cells9
14.1
17.8

112732 Match Control
29.3
28.5
117125 RA Cartilage Rep2
19.9
22.5

Crohns-F

112725 Crohns-M
5.1
3.6
113492 Bone2 RA
76.3
66.0

112387 Match Control
14.4
15.7
113493 Synovium2 RA
20.9
19.3

Crohns-M

112378 Crohns-M
0.0
0.0
113494 Syn Fluid Cells RA
48.0
43.2

112390 Match Control
33.7
48.6
113499 Cartilage4 RA
40.3
49.7

Crohns-M

112726 Crohns-M
25.0
19.9
113500 Bone4 RA
63.3
50.3

112731 Match Control
19.1
16.8
113501 Synovium4 RA
44.8
36.6

Crohns-M

112380 Ulcer Col-F
14.8
15.9
113502 Syn Fluid Cells4 RA
33.7
21.5

112734 Match Control Ulcer
74.2
59.9
113495 Cartilage3 RA
48.3
29.3

Col-F

112384 Ulcer Col-F
26.2
28.9
113496 Bone3 RA
51.8
45.1

112737 Match Control Ulcer
8.8
4.1
113497 Synovium3 RA
21.9
25.3

Col-F

112386 Ulcer Col-F
11.8
10.9
113498 Syn Fluid Cells3 RA
44.1
47.6

112738 Match Control Ulcer
27.0
15.0
117106 Normal Cartilage Rep20
2.0
5.3

Col-F

112381 Ulcer Col-M
0.0
0.0
113663 Bone3 Normal
0.0
0.2

112735 Match Control Ulcer
6.3
6.5
113664 Synovium3 Normal
0.0
0.0

Col-M

112382 Ulcer Col-M
13.5
10.8
113665 Syn Fluid Cells3 Normal
0.0
0.0

112394 Match Control Ulcer
1.6
7.7
117107 Normal Cartilage Rep22
10.6
11.8

Col-M

112383 Ulcer Col-M
18.7
26.6
113667 Bone4 Normal
10.1
8.4

112736 Match Control Ulcer
12.9
6.7
113668 Synovium4 Normal
10.6
8.1

Col-M

112423 Psoriasis-F
20.7
18.6
113669 Syn Fluid Cells4 Normal
15.8
21.3

TABLE BQE

General_screening_panel_v1.4

Column A - Rel. Exp. (%) Ag3909, Run 217235826

Column B - Rel. Exp. (%) Ag3909, Run 219173644

Tissue Name
A
B
Tissue Name
A
B

Adipose
0.6
0.6
Renal ca. TK-10
0.0
0.0

Melanoma* Hs688(A).T
0.0
0.0
Bladder
9.7
11.7

Melanoma* Hs688(B).T
0.0
0.0
Gastric ca. (liver met.) NCI-N87
100.0
100.0

Melanoma* M14
0.3
0.4
Gastric ca. KATO III
0.5
0.6

Melanoma* LOXIMVI
0.1
0.2
Colon ca. SW-948
0.5
0.5

Melanoma* SK-MEL-5
0.2
0.2
Colon ca. SW480
0.1
0.1

Squamous Cell carcinoma
0.5
0.5
Colon ca.* (SW480 met) SW620
0.0
0.0

SCC-4

Testis Pool
0.6
0.5
Colon ca. HT29
0.1
0.1

Prostate ca.* (bone met) PC-3
0.1
0.1
Colon ca. HCT-116
0.3
0.3

Prostate Pool
0.3
0.3
Colon ca. CaCo-2
0.1
0.0

Placenta
0.4
0.5
Colon cancer tissue
0.6
0.5

Uterus Pool
0.2
0.2
Colon ca. SW1116
0.2
0.1

Ovarian ca. OVCAR-3
0.2
0.2
Colon ca. Colo-205
0.0
0.0

Ovarian ca. SK-OV-3
0.5
0.4
Colon ca. SW-48
0.0
0.0

Ovarian ca. OVCAR-4
0.1
0.1
Colon Pool
0.4
0.5

Ovarian ca. OVCAR-5
0.6
0.5
Small Intestine Pool
0.4
0.4

Ovarian ca. IGROV-1
0.0
0.0
Stomach Pool
0.1
0.3

Ovarian ca. OVCAR-8
0.0
0.0
Bone Marrow Pool
0.2
0.2

Ovary
0.8
0.6
Fetal Heart
0.2
0.2

Breast ca. MCF-7
0.0
0.0
Heart Pool
0.5
0.5

Breast ca. MDA-MB-231
0.2
0.2
Lymph Node Pool
0.4
0.4

Breast ca. BT 549
2.3
3.1
Fetal Skeletal Muscle
0.2
0.2

Breast ca. T47D
1.1
1.0
Skeletal Muscle Pool
1.7
1.9

Breast ca. MDA-N
0.2
0.2
Spleen Pool
2.3
2.6

Breast Pool
0.3
0.4
Thymus Pool
0.5
0.5

Trachea
0.9
1.0
CNS cancer (glio/astro) U87-MG
0.0
0.0

Lung
0.1
0.1
CNS cancer (glio/astro) U-118-
1.0
1.3

MG

Fetal Lung
0.9
0.9
CNS cancer (neuro; met) SK-N-AS
1.2
1.5

Lung ca. NCI-N417
0.0
0.0
CNS cancer (astro) SF-539
0.3
0.4

Lung ca. LX-1
0.0
0.0
CNS cancer (astro) SNB-75
0.1
0.1

Lung ca. NCI-H146
0.9
1.1
CNS cancer (glio) SNB-19
0.0
0.0

Lung ca. SHP-77
0.5
0.5
CNS cancer (glio) SF-295
0.2
0.2

Lung ca. A549
0.0
0.0
Brain (Amygdala) Pool
0.6
0.5

Lung ca. NCI-H526
0.0
0.0
Brain (cerebellum)
0.1
0.2

Lung ca. NCI-H23
0.0
0.0
Brain (fetal)
0.8
0.7

Lung ca. NCI-H460
0.0
0.0
Brain (Hippocampus) Pool
0.5
0.5

Lung ca. HOP-62
0.0
0.0
Cerebral Cortex Pool
0.7
0.7

Lung ca. NCI-H522
0.0
0.0
Brain (Substantia nigra) Pool
0.8
0.7

Liver
0.1
0.1
Brain (Thalamus) Pool
0.8
0.9

Fetal Liver
4.7
4.1
Brain (whole)
1.3
1.3

Liver ca. HepG2
0.0
0.0
Spinal Cord Pool
0.4
0.5

Kidney Pool
0.7
0.8
Adrenal Gland
0.7
0.8

Fetal Kidney
0.2
0.2
Pituitary gland Pool
0.3
0.3

Renal ca. 786-0
0.0
0.0
Salivary Gland
0.5
0.4

Renal ca. A498
0.2
0.2
Thyroid (female)
0.4
0.2

Renal ca. ACHN
0.0
0.0
Pancreatic ca. CAPAN2
0.3
0.3

Renal ca. UO-31
0.1
0.0
Pancreas Pool
0.4
0.3

TABLE BQF

Panel 1.3D

Column A - Rel. Exp.(%) Ag198O, Run 165534458

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
1.4
Kidney (fetal)
0.4

Pancreas
0.4
Renal ca. 786-0
0.0

Pancreatic ca. CAPAN 2
0.0
Renal ca. A498
2.0

Adrenal gland
0.6
Renal ca. RXF 393
0.7

Thyroid
0.7
Renal ca. ACHN
0.0

Salivary gland
1.0
Renal ca. UO-31
0.0

Pituitary gland
0.5
Renal ca. TK-10
0.1

Brain (fetal)
0.8
Liver
0.5

Brain (whole)
3.8
Liver (fetal)
5.3

Brain (amygdala)
2.9
Liver ca. (hepatoblast) HepG2
0.0

Brain (cerebellum)
0.6
Lung
1.5

Brain (hippocampus)
3.2
Lung (fetal)
2.5

Brain (substantia nigra)
1.6
Lung ca. (small cell) LX-1
0.0

Brain (thalamus)
5.1
Lung ca. (small cell) NCI-H69
0.4

Cerebral Cortex
1.9
Lung ca. (s.cell var.) SHP-77
0.5

Spinal cord
1.6
Lung ca. (large cell)NCI-H460
0.0

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
0.0

glio/astro U-118-MG
1.8
Lung ca. (non-s.cell) NCI-H23
0.0

astrocytoma SW1783
0.0
Lung ca. (non-s.cell) HOP-62
0.0

neuro*; met SK-N-AS
1.1
Lung ca. (non-s.cl) NCI-H522
0.0

astrocytoma SF-539
7.9
Lung ca. (squam.) SW 900
1.5

astrocytoma SNB-75
1.7
Lung ca. (squam.) NCI-H596
0.1

glioma SNB-19
0.0
Mammary gland
0.7

glioma U251
0.7
Breast ca.* (pl.ef) MCF-7
0.1

glioma SF-295
0.0
Breast ca.* (pl.ef) MDA-MB-231
0.3

Heart (Fetal)
0.1
Breast ca.* (pl.ef) T47D
0.0

Heart
1.2
Breast ca. BT-549
1.1

Skeletal muscle (Fetal)
0.0
Breast ca. MDA-N
0.0

Skeletal muscle
1.0
Ovary
0.3

Bone marrow
4.5
Ovarian ca. OVCAR-3
0.1

Thymus
1.2
Ovarian ca. OVCAR-4
0.1

Spleen
1.4
Ovarian ca. OVCAR-5
0.3

Lymph node
2.9
Ovarian ca. OVCAR-8
0.0

Colorectal
0.3
Ovarian ca. IGROV-1
0.0

Stomach
1.4
Ovarian ca. (ascites) SK-OV-3
0.4

Small intestine
1.2
Uterus
1.8

Colon ca. SW480
0.0
Placenta
1.3

Colon ca.* SW620 (SW480 met)
0.0
Prostate
0.3

Colon ca. HT29
0.0
Prostate ca.* (bone met) PC-3
0.1

Colon ca. HCT-116
0.1
Testis
1.2

Colon Ca. CaCo-2
0.0
Melanoma Hs688(A).T
0.1

CC Well to Mod Diff (ODO3866)
0.6
Melanoma* (met) Hs688(B).T
0.1

Colon Ca. HCC-2998
12.0
Melanoma UACC-62
1.0

Gastric ca. (liver met) NCI-N87
100.0
Melanoma M14
0.3

Bladder
8.2
Melanoma LOX IMVI
0.1

Trachea
2.0
Melanoma* (met) SK-MEL-5
0.1

Kidney
0.4
Adipose
0.6

TABLE BQG

Panel 2D

Column A - Rel. Exp.(%) Ag1980, Run 169484147

Tissue Name
A
Tissue Name
A

Normal Colon
14.7
Kidney Margin 8120608
1.1

CC Well to Mod Duff (ODO3866)
3.2
Kidney Cancer 8120613
1.4

CC Margin (ODO3866)
6.3
Kidney Margin 8120614
1.5

CC Gr.2 rectosigmoid (ODO3868)
3.5
Kidney Cancer 9010320
6.2

CC Margin (ODO3868)
3.3
Kidney Margin 9010321
2.6

CC Mod Diff (ODO3920)
1.3
Normal Uterus
1.2

CC Margin (ODO3920)
1.5
Uterine Cancer 064011
3.4

CC Gr.2 ascend colon (ODO3921)
3.7
Normal Thyroid
4.7

CC Margin (ODO3921)
1.8
Thyroid Cancer
12.1

CC from Partial Hepatectomy
5.0
Thyroid Cancer A302152
1.6

(ODO4309) Mets

Liver Margin (ODO4309)
16.7
Thyroid Margin A302153
4.4

Colon mets to lung (OD04451-01)
15.0
Normal Breast
4.5

Lung Margin (OD04451-02)
18.4
Breast Cancer
8.1

Normal Prostate 6546-1
5.2
Breast Cancer (OD04590-01)
11.8

Prostate Cancer (OD04410)
9.1
Breast Cancer Mets (OD04590-03)
7.9

Prostate Margin (OD04410)
3.1
Breast Cancer Metastasis
5.3

Prostate Cancer (OD04720-01)
3.2
Breast Cancer
18.0

Prostate Margin (OD04720-02)
6.4
Breast Cancer
2.7

Normal Lung
14.8
Breast Cancer 9100266
6.2

Lung Met to Muscle (ODO4286)
3.4
Breast Margin 9100265
1.9

Muscle Margin (ODO4286)
2.8
Breast Cancer A209073
6.5

Lung Malignant Cancer (OD03126)
5.2
Breast Margin A209073
1.5

Lung Margin (OD03126)
21.5
Normal Liver
2.3

Lung Cancer (OD04404)
53.6
Liver Cancer
6.2

Lung Margin (OD04404)
6.8
Liver Cancer 1025
6.5

Lung Cancer (OD04565)
6.8
Liver Cancer 1026
2.1

Lung Margin (OD04565)
3.6
Liver Cancer 6004-T
6.0

Lung Cancer (OD04237-01)
10.1
Liver Tissue 6004-N
2.9

Lung Margin (OD04237-02)
24.5
Liver Cancer 6005-T
3.3

Ocular Mel Met to Liver (ODO4310)
0.2
Liver Tissue 6005-N
1.7

Liver Margin (ODO4310)
3.5
Normal Bladder
100.0

Melanoma Metastasis
1.8
Bladder Cancer
0.6

Lung Margin (OD04321)
10.3
Bladder Cancer
6.3

Normal Kidney
11.4
Bladder Cancer (OD04718-01)
74.2

Kidney Ca, Nuclear grade 2 (OD04338)
5.3
Bladder Normal Adjacent
5.1

(OD04718-03)

Kidney Margin (OD04338)
4.2
Normal Ovary
3.5

Kidney Ca Nuclear grade ½ (OD04339)
1.5
Ovarian Cancer
11.7

Kidney Margin (OD04339)
4.6
Ovarian Cancer (OD04768-07)
99.3

Kidney Ca, Clear cell type (OD04340)
11.1
Ovary Margin (OD04768-08)
0.9

Kidney Margin (OD04340)
3.5
Normal Stomach
10.7

Kidney Ca, Nuclear grade 3 (OD04348)
59.9
Gastric Cancer 9060358
3.0

Kidney Margin (OD04348)
81.2
Stomach Margin 9060359
9.9

Kidney Cancer (OD04622-01)
6.1
Gastric Cancer 9060395
6.9

Kidney Margin (OD04622-03)
1.1
Stomach Margin 9060394
7.7

Kidney Cancer (OD04450-01)
1.5
Gastric Cancer 9060397
7.2

Kidney Margin (OD04450-03)
1.7
Stomach Margin 9060396
10.4

Kidney Cancer 8120607
0.9
Gastric Cancer 064005
19.9

TABLE BQH

Panel 4.1D

Column A - Rel. Exp.(%) Ag3909, Run 170127176

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.9
HUVEC IL-1beta
0.1

Secondary Th2 act
32.3
HUVEC IFN gamma
0.9

Secondary Tr1 act
3.6
HUVEC TNF alpha + IFN gamma
10.5

Secondary Th1 rest
5.5
HUVEC TNF alpha + IL4
0.4

Secondary Th2 rest
2.0
HUVEC IL-11
0.0

Secondary Tr1 rest
4.8
Lung Microvascular EC none
0.2

Primary Th1 act
1.3
Lung Microvascular EC TNFalpha + IL-
0.6

1beta

Primary Th2 act
2.0
Microvascular Dermal EC none
0.1

Primary Tr1 act
1.1
Microsvasular Dermal EC TNFalpha + IL-
0.4

1beta

Primary Th1 rest
3.5
Bronchial epithelium TNFalpha + IL1beta
0.0

Primary Th2 rest
0.3
Small airway epithelium none
0.0

Primary Tr1 rest
2.5
Small airway epithelium TNFalpha + IL-
0.0

1beta

CD45RA CD4 lymphocyte act
9.3
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
12.4
Coronery artery SMC TNFalpha + IL-1beta
0.0

CD8 lymphocyte act
1.2
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
4.7
Astrocytes TNFalpha + IL-1beta
0.5

Secondary CD8 lymphocyte act
0.7
KU-812 (Basophil) rest
1.4

CD4 lymphocyte none
0.5
KU-812 (Basophil) PMA/ionomycin
4.7

2ry Th1/Th2/Tr1 anti-CD95
1.2
CCD1106 (Keratinocytes) none
0.4

CH11

LAK cells rest
2.8
CCD1106 (Keratinocytes) TNFalpha + IL-
7.7

1beta

LAK cells IL-2
7.5
Liver cirrhosis
0.1

LAK cells IL-2 + IL-12
7.1
NCI-H292 none
0.1

LAK cells IL-2 + IFN gamma
9.5
NCI-H292 IL-4
0.3

LAK cells IL-2 + IL-18
11.7
NCI-H292 IL-9
0.4

LAK cells PMA/ionomycin
6.9
NCI-H292 IL-13
0.5

NK Cells IL-2 rest
11.3
NCI-H292 IFN gamma
2.0

Two Way MLR 3 day
14.0
HPAEC none
0.0

Two Way MLR 5 day
5.3
HPAEC TNF alpha + IL-1 beta
2.9

Two Way MLR 7 day
1.7
Lung fibroblast none
0.0

PBMC rest
0.4
Lung fibroblast TNF alpha + IL-1 beta
9.5

PBMC PWM
2.7
Lung fibroblast IL-4
0.0

PBMC PHA-L
1.1
Lung fibroblast IL-9
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-13
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IFN gamma
3.6

B lymphocytes PWM
0.9
Dermal fibroblast CCD1070 rest
0.0

B lymphocytes CD40L and IL-4
0.5
Dermal fibroblast CCD1070 TNF alpha
1.1

EOL-1 dbcAMP
0.6
Dermal fibroblast CCD1070 IL-1 beta
0.8

EOL-1 dbcAMP
0.0
Dermal fibroblast IFN gamma
6.3

PMA/ionomycin

Dendritic cells none
0.6
Dermal fibroblast IL-4
0.3

Dendritic cells LPS
20.0
Dermal Fibroblasts rest
0.1

Dendritic cells anti-CD40
0.3
Neutrophils TNFa + LPS
0.1

Monocytes rest
2.7
Neutrophils rest
0.3

Monocytes LPS
100.0
Colon
0.5

Macrophages rest
0.9
Lung
0.9

Macrophages LPS
36.9
Thymus
1.0

HUVEC none
0.0
Kidney
0.4

HUVEC starved
0.1

TABLE BQJ

Panel 5 Islet

Column A - Rel. Exp.(%) Ag3909, Run 242413199

Tissue Name
A
Tissue Name
A

97457 Patient-02go adipose
90.1
94709 Donor 2 AM - A adipose
0.0

97476 Patient-07sk skeletal muscle
22.2
94710 Donor 2 AM - B adipose
1.8

97477 Patient-07ut uterus
18.2
94711 Donor 2 AM - C adipose
0.0

97478 Patient-07pl placenta
53.6
94712 Donor 2 AD - A adipose
1.6

99167 Bayer Patient 1
100.0
94713 Donor 2 AD - B adipose
1.2

97482 Patient-08ut uterus
44.8
94714 Donor 2 AD - C adipose
0.0

97483 Patient-08pl placenta
74.2
94742 Donor 3 U - A Mesenchymal
3.1

Stem Cells

97486 Patient-09sk skeletal muscle
9.3
94743 Donor 3 U - B Mesenchymal
3.7

Stem Cells

97487 Patient-09ut uterus
24.1
94730 Donor 3 AM - A adipose
1.7

97488 Patient-09pl placenta
44.1
94731 Donor 3 AM - B adipose
3.6

97492 Patient-10ut uterus
47.0
94732 Donor 3 AM - C adipose
0.0

97493 Patient-10pl placenta
68.3
94733 Donor 3 AD - A adipose
0.0

97495 Patient-11go adipose
17.4
94734 Donor 3 AD - B adipose
0.0

97496 Patient-11sk skeletal muscle
22.8
94735 Donor 3 AD - C adipose
0.0

97497 Patient-11ut uterus
24.3
77138 Liver HepG2untreated
1.8

97498 Patient-11pl placenta
15.4
73556 Heart Cardiac stromal cells
0.0

(primary)

97500 Patient-12go adipose
62.4
81735 Small Intestine
97.3

97501 Patient-12sk skeletal muscle
79.6
72409 Kidney Proximal Convoluted
5.6

Tubule

97502 Patient-12ut uterus
30.6
82685 Small intestine Duodenum
54.3

97503 Patient-12pl placenta
29.7
90650 Adrenal Adrenocortical
10.0

adenoma

94721 Donor 2 U - A Mesenchymal
0.0
72410 Kidney HRCE
8.3

Stem Cells

94722 Donor 2 U - B Mesenchymal
0.0
72411 Kidney HRE
28.3

Stem Cells

94723 Donor 2 U - C Mesenchymal
0.0
73139 Uterus Uterine smooth muscle
0.0

Stem Cells

cells

AI.05 chondrosarcoma Summary: Ag1980 Highest expression of this gene was detected in the IL-1 beta/TNF-a treated chondrosarcoma cell line (SW1353). Expression of this gene was up-regulated upon IL-1 treatment, a potent activator of pro-inflammatory cytokines and matrix metalloproteinases, which participate in the destruction of cartilage observed in Osteoarthritis (OA). Modulation of the expression of this transcript in chondrocytes by either small molecules, antibody, or protein therapeutics is useful for preventing the degeneration of cartilage observed in OA.

AI_comprehensive panel_v1.0 Summary: Ag1980 Highest expression was detected in normal tissue adjacent to psoriasis (CTs=30.5-31.2). Expression of this gene was induced in bone tissue, synovial fluid, synovial fluid cells and synovium from arthritis patients (rheumatoid-RA and osteoarthritis-OA), while the expression of this transcript in these samples from normal patients was much lower. Other tissues including skin and lung also expressed this transcript. However, a consistent expression in diseased tissue, as compared to adjacent tissue or normal lung, is not apparent. This may be due to contamination with activated monocytes which highly express this transcript (see panel 4.1D) Modulation of the expression of this transcript in chondrocytes by either small molecules, antibody, or protein therapeutics is useful for treating rheumatoid arthritis and preventing the degeneration of cartilage observed in OA.

General_screening_panel_v1.4 Summary: Ag3909 Highest expression of the CG94235-01 gene was detected in a gastric cancer cell line (CTs=23.6-24.4). Thus, expression of this gene is useful as a marker of gastric cancer. This gene encodes a putative thymidylate kinase, a DNA synthesis enzyme necessary for cell growth. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of gastric cancer.

Among tissues with metabolic function, this gene was expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. The widespread expression among these tissues indicates that this gene product may play a role in normal neuroendocrine and metabolic disorders. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

In addition, this gene was expressed at much higher levels in fetal lung, liver and skeletal muscle tissue (CTs=28-30) when compared to expression in the adult counterpart (CTs=32.5-35). Thus, expression of this gene is useful for distinguishing between the fetal and adult source of these tissues.

This gene was also expressed at moderate to low levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

Panel 1.3D Summary: Ag1980 Highest expression of the CG94235-01 gene in this panel was seen in a gastric cancer cell line (CT=26). Overall, expression was in reasonable agreement with the results in Panel 1.4. Moderate to low levels of expression were seen in metabolic tissues including adipose, adult and fetal liver, skeletal muscle, heart, pituitary, thyroid, adrenal and pituitary. Moderate to low levels of expression were seen in all CNS regions examined.

In addition, higher levels of expression were seen in fetal liver (CT=30.2) when compared to expression in adult liver (CT=33.7). Thus, expression of this gene is useful for distinguishing between the adult and fetal sources of this tissue.

Panel 2D Summary: Ag1980 Highest expression of the CG94235-01 gene was seen in normal bladder (CT=27.3). In addition, higher levels of expression were seen in ovarian, bladder and lung cancers when compared to expression in normal adjacent tissue. Thus, expression of this gene is useful as a marker of these cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of ovarian, bladder and lung cancers.

Panel 4.1D Summary: Ag3909 Highest expression of the CG94235-01 gene was seen in LPS treated monocytes (CT=25.4). Prominent levels of expression were also seen in LPS activated macrophages and dendritic cells. This transcript encodes a protein that may be important in the normal regulation of cytokines. Inappropriate regulation of the protein encoded by this gene may result in the enhanced and uncontrolled expression of inflammatory cytokines. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of osteoarthritis and rheumatoid arthritis.

Panel 5 Islet Summary: Ag3909 Highest expression of the CG94235-01 gene was seen in islet cells (CT=33.4). Low but significant levels of expression were seen in other metabolic tissues, including adipose, placenta and skeletal muscle. Please see Panel 1.4 for discussion of this gene in metabolic disease.

BR. CG95175-01: Ephrin Type-A Receptor 7 Precursor.

Expression of gene CG95175-01 was assessed using the primer-probe sets Ag3992 and Ag612, described in Tables BRA and BRB. Results of the RTQ-PCR runs are shown in Tables BRC, BRD, BRE and BRF.

TABLE BRAProbe Name Ag3992SEQStartIDPrimersSequencesLengthPositionNoForward5′-accactatggtgaggctacaga-3′2224271467ProbeTET-5′-ctatgggccgctcccgagacact-3′-2324661468TAMRAReverse5′-agagctgaagtggccaaact-3′2024911469

TABLE BRB

Probe Name Ag612

SEQ

Start
ID

Primers
Sequences
Length
Position
No

Forward
5′-gccgctcccgagacactt-3′
18
2472
1470

Probe
TET-5′-ccacttcagctctgccagtgacgtg-3′
25
2498
1471

TAMRA

Reverse
5′-cccacatgatgatgccgaa-3′
19
2529
1472

TABLE BRC

CNS_neurodegeneration_v1.0

Column A - Rel. Exp.(%) Ag612, Run 309606071

Tissue Name
A

AD 1 Hippo
46.0

AD 2 Hippo
37.1

AD 3 Hippo
9.5

AD 4 Hippo
33.9

AD 5 Hippo
59.5

AD 6 Hippo
41.8

Control 2 Hippo
40.9

Control 4 Hippo
21.6

Control (Path) 3 Hippo
15.9

AD 1 Temporal Ctx
26.1

AD 2 Temporal Ctx
28.9

AD 3 Temporal Ctx
12.3

AD 4 Temporal Ctx
62.9

AD 5 Inf Temporal Ctx
57.4

AD 5 Sup Temporal Ctx
33.7

AD 6 Inf Temporal Ctx
50.7

AD 6 Sup Temporal Ctx
68.8

Control 1 Temporal Ctx
9.7

Control 2 Temporal Ctx
54.7

Control 3 Temporal Ctx
40.3

Control 3 Temporal Ctx
43.2

AH3 3975
97.3

AH3 3954
86.5

AH3 4624
31.0

AH3 4640
100.0

AD 1 Occipital Ctx
11.0

AD 2 Occipital Ctx (Missing)
6.8

AD 3 Occipital Ctx
8.3

AD 4 Occipital Ctx
35.6

AD 5 Occipital Ctx
43.5

AD 5 Occipital Ctx
21.5

Control 1 Occipital Ctx
8.2

Control 2 Occipital Ctx
36.6

Control 3 Occipital Ctx
29.5

Control 4 Occipital Ctx
20.3

Control (Path) 1 Occipital Ctx
81.2

Control (Path) 2 Occipital Ctx
37.4

Control (Path) 3 Occipital Ctx
17.8

Control (Path) 4 Occipital Ctx
29.9

Control 1 Parietal Ctx
37.6

Control 2 Parietal Ctx
41.5

Control 3 Parietal Ctx
54.0

Control (Path) 1 Parietal Ctx
99.3

Control (Path) 2 Parietal Ctx
52.9

Control (Path) 3 Parietal Ctx
11.6

Control (Path) 4 Parietal Ctx
56.6

TABLE BRE

Panel 1.3D

Column A - Rel. Exp.(%) Ag612, Run 165720641

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
8.0
Kidney (fetal)
0.0

Pancreas
2.8
Renal ca. 786-0
0.0

Pancreatic ca. CAPAN 2
0.7
Renal ca. A498
0.0

Adrenal gland
0.0
Renal ca. RXF 393
1.7

Thyroid
0.0
Renal ca. ACHN
5.9

Salivary gland
4.0
Renal ca. UO-31
0.0

Pituitary gland
16.0
Renal ca. TK-10
6.7

Brain (fetal)
67.8
Liver
0.0

Brain (whole)
17.9
Liver (fetal)
0.0

Brain (amygdala)
32.5
Liver ca. (hepatoblast) HepG2
0.0

Brain (cerebellum)
7.6
Lung
0.0

Brain (hippocampus)
41.2
Lung (fetal)
0.0

Brain (substantia nigra)
10.5
Lung ca. (small cell) LX-1
1.6

Brain (thalamus)
22.1
Lung ca. (small cell) NCI-H69
0.6

Cerebral Cortex
27.7
Lung ca. (s. cell var.) SHP-77
4.6

Spinal cord
5.9
Lung ca. (large cell)NCI-H460
2.4

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
0.0

glio/astro U-118-MG
0.0
Lung ca. (non-s. cell) NCI-H23
5.2

astrocytoma SW1783
0.0
Lung ca. (non-s. cell) HOP-62
0.0

neuro*; met SK-N-AS
0.6
Lung ca. (non-s. cl) NCI-H522
10.7

astrocytoma SF-539
0.0
Lung ca. (squam.) SW 900
6.9

astrocytoma SNB-75
13.7
Lung ca. (squam.) NCI-H596
0.0

glioma SNB-19
0.0
Mammary gland
4.2

glioma U251
0.0
Breast ca.* (pl. ef) MCF-7
7.9

glioma SF-295
0.0
Breast ca.* (pl. ef) MDA-MB-231
0.6

Heart (Fetal)
0.0
Breast ca.* (pl. ef) T47D
1.9

Heart
0.7
Breast ca. BT-549
0.0

Skeletal muscle (Fetal)
0.0
Breast ca. MDA-N
0.0

Skeletal muscle
0.0
Ovary
0.7

Bone marrow
0.0
Ovarian ca. OVCAR-3
7.1

Thymus
0.1
Ovarian ca. OVCAR-4
0.1

Spleen
1.3
Ovarian ca. OVCAR-5
2.7

Lymph node
0.9
Ovarian ca. OVCAR-8
3.5

Colorectal
24.3
Ovarian ca. IGROV-1
0.0

Stomach
9.5
Ovarian ca. (ascites) SK-OV-3
12.4

Small intestine
11.3
Uterus
0.0

Colon ca. SW480
3.7
Placenta
0.0

Colon ca.* SW620 (SW480 met)
1.8
Prostate
4.2

Colon ca. HT29
0.0
Prostate ca.* (bone met) PC-3
2.9

Colon ca. HCT-116
0.8
Testis
100.0

Colon Ca. CaCo-2
1.7
Melanoma Hs688(A).T
0.0

CC Well to Mod Diff (ODO3866)
8.7
Melanoma* (met) Hs688(B).T
0.0

Colon ca. HCC-2998
9.6
Melanoma UACC-62
0.0

Gastric ca. (liver met) NCI-N87
15.1
Melanoma M14
0.0

Bladder
3.3
Melanoma LOX IMVI
0.0

Trachea
3.8
Melanoma* (met) SK-MEL-5
0.7

Kidney
0.0
Adipose
0.6

TABLE BRF

Panel 4D

Column A - Rel. Exp.(%) Ag612, Run 145645058

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.0
HUVEC IL-1beta
0.0

Secondary Th2 act
12.2
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.0
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.0
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.0
Lung Microvascular EC TNFalpha + IL-
0.0

1beta

Primary Th2 act
0.0
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.0
Microsvasular Dermal EC TNFalpha + IL-
0.0

1beta

Primary Th1 rest
0.0
Bronchial epithelium TNFalpha + IL1beta
0.0

Primary Th2 rest
0.0
Small airway epithelium none
0.0

Primary Tn rest
0.0
Small airway epithelium TNFalpha + IL-
4.6

1beta

CD45RA CD4 lymphocyte act
0.0
Coronery artery SMC rest
0.0

CD45RO CD4 lymphocyte act
4.6
Coronery artery SMC TNFalpha + IL-1beta
0.0

CD8 lymphocyte act
5.3
Astrocytes rest
0.0

Secondary CD8 lymphocyte rest
5.3
Astrocytes TNFalpha + IL-1beta
0.0

Secondary CD8 lymphocyte act
0.0
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.0

2ry Th1/Th2/Tr1 anti-CD95
0.0
CCD1106 (Keratinocytes) none
0.0

CH11

LAK cells rest
9.7
CCD1106 (Keratinocytes) TNFalpha + IL-
1.0

1beta

LAK cells IL-2
0.0
Liver cirrhosis
61.6

LAK cells IL-2 + IL-12
0.0
Lupus kidney
0.0

LAK cells IL-2 + IFN gamma
5.1
NCI-H292 none
32.5

LAK cells IL-2 + IL-18
0.0
NCI-H292 IL-4
46.7

LAK cells PMA/ionomycin
0.0
NCI-H292 IL-9
58.6

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
89.5

Two Way MLR 3 day
0.0
NCI-H292 IFN gamma
100.0

Two Way MLR 5 day
0.0
HPAEC none
0.0

Two Way MLR 7 day
0.0
HPAEC TNF alpha + IL-1 beta
0.0

PBMC rest
0.0
Lung fibroblast none
0.0

PBMC PWM
0.0
Lung fibroblast TNF alpha + IL-1 beta
0.0

PBMC PHA-L
8.9
Lung fibroblast IL-4
0.0

Ramos (B cell) none
0.0
Lung fibroblast IL-9
0.0

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
9.0

B lymphocytes PWM
8.5
Lung fibroblast IFN gamma
0.0

B lymphocytes CD40L and IL-4
0.0
Dermal fibroblast CCD1070 rest
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
0.0

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.0

PMA/ionomycin

Dendritic cells none
5.3
Dermal fibroblast IFN gamma
0.0

Dendritic cells LPS
4.5
Dermal fibroblast IL-4
0.0

Dendritic cells anti-CD40
0.0
IBD Colitis 2
10.7

Monocytes rest
0.0
IBD Crohn's
0.0

Monocytes LPS
1.2
Colon
51.8

Macrophages rest
0.0
Lung
24.7

Macrophages LPS
0.0
Thymus
4.1

HUVEC none
0.0
Kidney
4.6

HUVEC starved
0.0

CNS_neurodegeneration_v1.0 Summary: Ag612 This gene was found to be down-regulated in the temporal cortex of Alzheimer's disease patients. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of dementia/memory loss associated with this disease and neuronal death.

Panel 1.3D Summary: Ag612 Highest expression of the CG95175-01 gene was detected in testis (CT=29). In addition, high expression of this gene was also detected in all the region of the central nervous system examined, and in a cluster of lung cancer, colon cancer, renal cancer, a liver cancer, breast cancer, ovarian cancer and an astrocytoma cell lines, pancreas, pituitary gland, and the gastrointestinal tract. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of diseases of the central nervous system including Alzheimer's disease.

Panel 4D Summary: Ag612 Highest expression of this gene was detected in IFN gama treated NCI-H292 cells (CT=33). Moderate to low expression of this gene was also seen in cytokine treated and untreated NCI-H292 cells, liver cirrhosis and colon tissue samples. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of chronic obstructive pulmonary disease, asthma, allergy, and emphysema, liver cirrhosis, autoimmune and inflammatory disease affecting colon including Crohn's disease and ulcerative colitis.

BS. CG9963801: Sodium/Nucleoside Cotransporter 1.

Expression of gene CG99638-01 was assessed using the primer-probe set Ag1521, described in Table BSA. Results of the RTQ-PCR runs are shown in Tables BSB, BSC and BSD.

TABLE BSAProbe Name Ag1521SEQStartIDPrimersSequencesLengthPositionNoForward5′-tggttttcttcagcactgtgat-3′228891473ProbeTET-5′-catgctgtactaccctggactgatgca-3′-279141474TAMRAReverse5′-catgatccatccaacctttcta-3′229501475

TABLE BSB

Panel 1.3D

Column A - Rel. Exp.(%) Ag1521, Run 165544920

Tissue Name
A
Tissue Name
A

Liver adenocarcinoma
0.0
Kidney (fetal)
2.6

Pancreas
29.3
Renal ca. 786-0
0.0

Pancreatic ca. CAPAN 2
0.0
Renal ca. A498
0.0

Adrenal gland
0.0
Renal ca. RXF 393
0.0

Thyroid
0.0
Renal ca. ACHN
0.0

Salivary gland
1.6
Renal ca. UO-31
0.9

Pituitary gland
1.9
Renal ca. TK-10
0.0

Brain (fetal)
0.0
Liver
0.0

Brain (whole)
1.2
Liver (fetal)
1.6

Brain (amygdala)
0.0
Liver ca. (hepatoblast) HepG2
0.0

Brain (cerebellum)
0.0
Lung
0.6

Brain (hippocampus)
3.1
Lung (fetal)
3.3

Brain (substantia nigra)
0.0
Lung ca. (small cell) LX-1
0.0

Brain (thalamus)
1.8
Lung ca. (small cell) NCI-H69
0.0

Cerebral Cortex
0.0
Lung ca. (s. cell var.) SHP-77
0.0

Spinal cord
0.7
Lung ca. (large cell)NCI-H460
0.0

glio/astro U87-MG
0.0
Lung ca. (non-sm. cell) A549
0.0

glio/astro U-118-MG
4.2
Lung ca. (non-s. cell) NCI-H23
0.0

astrocytoma SW1783
4.9
Lung ca. (non-s. cell) HOP-62
0.0

neuro*; met SK-N-AS
0.0
Lung ca. (non-s. cl) NCI-H522
0.0

astrocytoma SF-539
0.3
Lung ca. (squam.) SW 900
0.0

astrocytoma SNB-75
0.0
Lung ca. (squam.) NCI-H596
0.0

glioma SNB-19
0.0
Mammary gland
7.8

glioma U251
0.0
Breast ca.* (pl. ef) MCF-7
0.6

glioma SF-295
3.3
Breast ca.* (pl. ef) MDA-MB-231
1.1

Heart (Fetal)
0.0
Breast ca.* (pl. ef) T47D
0.0

Heart
0.0
Breast ca. BT-549
0.0

Skeletal muscle (Fetal)
0.0
Breast ca. MDA-N
0.0

Skeletal muscle
0.0
Ovary
0.0

Bone marrow
100.0
Ovarian ca. OVCAR-3
3.1

Thymus
0.7
Ovarian ca. OVCAR-4
2.8

Spleen
1.4
Ovarian ca. OVCAR-5
2.1

Lymph node
2.9
Ovarian ca. OVCAR-8
0.0

Colorectal
5.3
Ovarian ca. IGROV-l
0.0

Stomach
5.3
Ovarian ca. (ascites) SK-OV-3
0.6

Small intestine
4.6
Uterus
1.8

Colon ca. SW480
0.0
Placenta
0.0

Colon ca.* SW620 (SW480 met)
0.0
Prostate
0.4

Colon ca. HT29
5.4
Prostate ca.* (bone met) PC-3
0.0

Colon ca. HCT-116
0.0
Testis
2.0

Colon ca. CaCo-2
0.5
Melanoma Hs688(A).T
0.0

CC Well to Mod Diff (ODO3866)
13.9
Melanoma* (met) Hs688(B).T
0.0

Colon ca. HCC-2998
0.0
Melanoma UACC-62
0.0

Gastric ca. (liver met) NCI-N87
2.2
Melanoma M14
0.0

Bladder
36.3
Melanoma LOX IMVI
0.0

Trachea
22.5
Melanoma* (met) SK-MEL-5
0.0

Kidney
0.0
Adipose
14.5

TABLE BSC

Panel 2.2

Column A - Rel. Exp.(%) Ag1521, Run 173816642

Tissue Name
A
Tissue Name
A

Normal Colon
3.2
Kidney Margin (OD04348)
1.0

Colon cancer (OD06064)
9.9
Kidney malignant cancer
1.3

(OD06204B)

Colon Margin (OD06064)
2.6
Kidney normal adjacent tissue
0.0

(OD06204E)

Colon cancer (OD06159)
0.0
Kidney Cancer (OD04450-01)
0.0

Colon Margin (OD06159)
1.9
Kidney Margin (OD04450-03)
0.0

Colon cancer (OD06297-04)
1.1
Kidney Cancer 8120613
0.0

Colon Margin (OD06297-05)
2.3
Kidney Margin 8120614
0.0

CC Gr.2 ascend colon (ODO3921)
0.0
Kidney Cancer 9010320
0.0

CC Margin (ODO3921)
1.7
Kidney Margin 9010321
2.8

Colon cancer metastasis (OD06104)
9.5
Kidney Cancer 8120607
0.0

Lung Margin (OD06104)
6.0
Kidney Margin 8120608
0.0

Colon mets to lung (OD04451-01)
13.1
Normal Uterus
0.0

Lung Margin (OD04451-02)
3.0
Uterine Cancer 064011
9.7

Normal Prostate
2.2
Normal Thyroid
0.0

Prostate Cancer (OD04410)
0.0
Thyroid Cancer
0.0

Prostate Margin (OD04410)
0.0
Thyroid Cancer A302152
10.7

Normal Ovary
0.0
Thyroid Margin A302153
0.0

Ovarian cancer (OD06283-03)
6.7
Normal Breast
100.0

Ovarian Margin (OD06283-07)
6.0
Breast Cancer
0.0

Ovarian Cancer
1.8
Breast Cancer
9.3

Ovarian cancer (OD06145)
6.9
Breast Cancer (OD04590-01)
1.3

Ovarian Margin (OD06145)
16.4
Breast Cancer Mets (OD04590-03)
0.0

Ovarian cancer (OD06455-03)
6.7
Breast Cancer Metastasis
1.4

Ovarian Margin (0D06455-07)
0.0
Breast Cancer
1.6

Normal Lung
0.0
Breast Cancer 9100266
0.0

Invasive poor diff. lung adeno
13.9
Breast Margin 9100265
6.9

(ODO4945-01

Lung Margin (ODO4945-03)
6.0
Breast Cancer A209073
0.0

Lung Malignant Cancer (OD03126)
5.3
Breast Margin A209073
22.4

Lung Margin (OD03126)
1.5
Breast cancer (OD06083)
20.6

Lung Cancer (OD05014A)
20.7
Breast cancer node metastasis
1.1

(OD06083)

Lung Margin (OD05014B)
12.1
Normal Liver
1.5

Lung cancer (OD06081)
0.0
Liver Cancer 1026
0.0

Lung Margin (OD06081)
1.4
Liver Cancer 1025
0.0

Lung Cancer (OD04237-01)
1.8
Liver Cancer 6004-T
0.0

Lung Margin (OD04237-02)
3.6
Liver Tissue 6004-N
0.0

Ocular Mel Met to Liver (ODO4310)
0.0
Liver Cancer 6005-T
2.5

Liver Margin (ODO4310)
0.0
Liver Tissue 6005-N
3.1

Melanoma Metastasis
0.0
Liver Cancer
0.0

Lung Margin (OD04321)
0.0
Normal Bladder
15.2

Normal Kidney
0.0
Bladder Cancer
1.6

Kidney Ca, Nuclear grade 2
0.0
Bladder Cancer
8.2

(OD04338)

Kidney Margin (OD04338)
0.0
Normal Stomach
3.3

Kidney Ca Nuclear grade 1/2
3.8
Gastric Cancer 9060397
1.7

(OD04339)

Kidney Margin (OD04339)
0.0
Stomach Margin 9060396
0.0

Kidney Ca, Clear cell type (OD04340)
0.0
Gastric Cancer 9060395
0.0

Kidney Margin (OD04340)
0.0
Stomach Margin 9060394
8.2

Kidney Ca, Nuclear grade 3
0.0
Gastric Cancer 064005
0.0

(OD04348)

TABLE BSD

Panel 4D

Column A - Rel. Exp.(%) Ag1521, Run 165725922

Tissue Name
A
Tissue Name
A

Secondary Th1 act
0.4
HUVEC IL-1beta
0.0

Secondary Th2 act
0.1
HUVEC IFN gamma
0.0

Secondary Tr1 act
0.1
HUVEC TNF alpha + IFN gamma
0.0

Secondary Th1 rest
0.2
HUVEC TNF alpha + IL4
0.0

Secondary Th2 rest
0.0
HUVEC IL-11
0.0

Secondary Tr1 rest
0.0
Lung Microvascular EC none
0.0

Primary Th1 act
0.4
Lung Microvascular EC TNFalpha + IL-
0.1

1beta

Primary Th2 act
0.1
Microvascular Dermal EC none
0.0

Primary Tr1 act
0.4
Microsvasular Dermal EC TNFalpha + IL-
0.0

1beta

Primary Th1 rest
2.5
Bronchial epithelium TNFalpha + IL1beta
2.6

Primary Th2 rest
0.6
Small airway epithelium none
1.1

Primary Tr1 rest
0.2
Small airway epithelium TNFalpha + IL-
15.1

1beta

CD45RA CD4 lymphocyte act
0.9
Coronery artery SMC rest
0.2

CD45RO CD4 lymphocyte act
0.6
Coronery artery SMG TNFalpha + IL-1beta
0.2

CD8 lymphocyte act
1.0
Astrocytes rest
0.6

Secondary CD8 lymphocyte rest
0.0
Astrocytes TNFalpha + IL-1beta
2.3

Secondary CD8 lymphocyte act
0.8
KU-812 (Basophil) rest
0.0

CD4 lymphocyte none
0.0
KU-812 (Basophil) PMA/ionomycin
0.1

2ry Th1/Th2/Tr1 anti-CD95
1.0
CCD1106 (Keratinocytes) none
0.2

CH11

LAK cells rest
5.4
CCD1106 (Keratinocytes) TNFalpha + IL-
16.3

1beta

LAK cells IL-2
0.2
Liver cirrhosis
4.2

LAK cells IL-2 + IL-12
1.3
Lupus kidney
0.2

LAK cells IL-2 + IFN gamma
3.6
NCI-H292 none
1.1

LAK cells IL-2 + IL-18
0.7
NCI-H292 IL-4
3.8

LAK cells PMA/ionomycin
5.5
NCI-H292 IL-9
0.6

NK Cells IL-2 rest
0.0
NCI-H292 IL-13
1.7

Two Way MLR 3 day
0.7
NCI-H292 IFN gamma
0.3

Two Way MLR 5 day
2.4
HPAEC none
0.0

Two Way MIR 7 day
2.4
HPAEC TNF alpha + IL-1 beta
0.0

PBMC rest
0.2
Lung fibroblast none
0.4

PBMC PWM
0.3
Lung fibroblast TNF alpha + IL-1 beta
0.1

PBMC PHA-L
0.1
Lung fibroblast IL-4
0.3

Ramos (B cell) none
0.0
Lung fibroblast IL-9
0.6

Ramos (B cell) ionomycin
0.0
Lung fibroblast IL-13
0.2

B lymphocytes PWM
0.5
Lung fibroblast IFN gamma
0.5

B lymphocytes CD40L and IL-4
0.1
Dermal fibroblast CCD1070 rest
0.7

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 TNF alpha
4.4

EOL-1 dbcAMP
0.0
Dermal fibroblast CCD1070 IL-1 beta
0.4

PMA/ionomycin

Dendritic cells none
35.6
Dermal fibroblast IFN gamma
0.5

Dendritic cells LPS
8.4
Dermal fibroblast IL-4
0.4

Dendritic cells anti-CD40
19.3
IBD Colitis 2
0.0

Monocytes rest
0.8
IBD Crohn's
0.7

Monocytes LPS
0.2
Colon
5.8

Macrophages rest
100.0
Lung
0.1

Macrophages LPS
20.9
Thymus
0.0

HUVEC none
0.0
Kidney
0.6

HUVEC starved
0.0

Panel 1.3D Summary: Ag1521 Highest expression of this gene was detected in the bone marrow (CT=30.5). Moderate to low expression was also detected in other normal tissues, including pancreas, adipose, bladder and trachea. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of diseases of the bone marrow, pancreas, adipose, bladder and trachea.

Panel 2.2 Summary: Ag1521 Prominent expression was detected in the breast (CT=33), but not in malignant breast samples. Expression of this gene or its protein product was useful as a marker of this tissue pancreas, adipose, bladder and trachea breast cancer.

Panel 4D Summary: AG1521 Highest expression was detected in resting macrophages (CT=27). Prominent expression was also detected in a cluster of treated and untreated dendritic cells. The protein encoded by this gene was down regulated in macrophages after LPS stimulation. This gene product responds to inflammatory stimuli and becomes down regulated after 12-24 hr exposure. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of inflammation in diseases such as asthma, IBD, psoriasis, arthritis and allergy. Agonistic (ligand-like) therapeutics designed with this protein product are useful for stimulating the immune response and improving the efficacy of vaccines and antiviral or antibacterial treatments. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in immune modulation, organ/bone marrow transplantation, and the treatment of diseases where antigen presentation, a function of mature dendritic cells, plays an important role such as asthma, rheumatoid arthritis, IBD, and psoriasis.

Example D
CG5580604, NOV47a

Coagulation Factor IX is one of the many proteins involved in the cascade of reactions leading to blood coagulation. This protein exists as a zymogen which is processed by either factor VIIa or factor XIa to yield the activated version, IXa which then binds with factor VIIIa to convert factor X to its active form (factor Xa). Factor IXa exists as a complex of a disulfide-linked heavy and light chain with removal of the activation peptide. The heavy chain contains a serine protease domain which is used to activate factor X. The enzymatic activity of IXa by itself is very low, but the catalytic efficiency is increased by about 7 orders of magnitude higher when bound to factor VIIIa.

The light chain contains a γ-carboxyglutamic acid (Gla) domain followed by two EGF domains. The EGF1 domain binds Ca++ and has been shown, along with a small portion of the serine protease domain, to interact with factor VIIIa (Mathur, A. and Bajaj, S. P., 1999, J. Biol. Chem., 274, 18477-18486). The Gla domain is essential for interaction with phospholipid vesicles which help to increase the catalytic efficiency of the serine protease domain of factor IXa (Freedman, S. J., Blostein, M. D., Baleja, J. D., Jacobs, M., Furie, B. C., and Furie, B., 1996, J. Biol. Chem., 271, 16227-16236). A series of experiments have shown that the EGF2 domain is essential for factor IXa binding to surface of activated platelets (Wong, M. Y., Gurr, J. A., and Walsh, P. N., 1999, Biochemistry, 38, 8948-8960). This platelet binding is essential for efficient catalysis to activate factor X.

Figure D1 shows the alignment of CG55806-02 (wild type factor IX), the splice variant CG55806-04 and the sequence of the porcine factor IXa denoted as 1PFX. Figure D2 shows the structure of porcine factor IXa (1PFX) (Brandstetter, H., Bauer, M., Huber, R., Lollar, P., and Bode, W., 1995, Proc. Natl. Acad. Sci. USA, 92, 9796-9800). The deleted portion of CG55806-04 corresponds to the EGF2 domain. Since EGF2 domain has been shown to be essential for platelet binding, the CG55806-04 splice variant may prevent blood clotting.

Example E
CG59693-01, NOV72A Knockdown Cell Validation

Knockdown Oligonucleotides. All oligonucleotides were mixed-backbone oligonucleotides containing modified phosphorothioate segments at 5′ and 3′ ends and 2′-O-methyl RNA oligoribonucleotide segments located in the middle synthesized by Midland, Inc. All oligonucleotides were desalted and gel purified. The purity of the oligonucleotides was confirmed by Mass spectroscopy. The antisense oligonucleotide sequences for CG59693-01 used were:

AS1-5′ GATATTTCGAATCCATTTCTGG 3′(SEQ ID NO:1477)AS2-5′ CATCATTCAGCTTCACACAC 3′(SEQ ID NO:1478)AS3-5′ GAACCTCTGCAGGCGCATAG 3′(SEQ ID NO:1479)AS4-5′ CACTGGAAAATGAATAAGGTA 3′(SEQ ID NO:1480)AS5-5′ CCATGTTAATATTCATCAGA 3′(SEQ ID NO:1481)A17-mer targeted to human immunodeficiency viruswas used as a scramble control(5′ GAGCTCCCAGGCTCAGA 3′).(SEQ ID NO:1482)

Oligonucleotide Transfection. Ten thousand cells were seeded in each well of the 96 well plate in complete medium 24 h before transfection to reach 50% confluency on the day of transfection. Oligonucleotides were diluted with Optimen to 400 nM, and mixed with Oligofectamine (Invitrogen) according to manufacturer's instructions. Cells were first washed with serum-free medium. The oligo and liposome mixture was then added to cells. After 4 h incubation period, serum was added back to cells. Readout assays were performed 24 and 48 h after transfection.

Cell Proliferation Assay. CELLTITER 96® AQueous Non-Radioactive Cell Porliferation Assay (MTS) Kit from PROMEGA was used to determine the number of viable cells in the proliferation assay. Briefly, 20 μl of combined MTS/PMS solution were diluted with 100 μl complete medium and added to each well of the 96 well plate. After 1 h incubation at 37° C., the absorbance at 490 nm was recorded using an ELISA plate reader.

Chemosensitivity Analysis. MCF-7 cells were transfected with 400 nM CG59693-01 knockdown oligonucleotides. Four hours after transfection, different chemotherapeutic agents were added to the cells at indicated concentration. Drug-treated cells were collected 2 days after and analyzed by MTS assay.

Knockdown Results.

Transfection with antisense oligonucleotides had minimal inhibitory effect (about 10-20%) on NCI-H460 cell proliferation when compared with the results of untransfected (UC), liposome (LC) and scrambled oligonucleotide transfected (SC) controls, as shown in Figure E1.

The antisense oligonucleotides transfected cells and control cells were then treated with different chemotherapeutic agents that are used clinically for NSCLC. In the control cells, the chemoagents resulted in less than 40% inhibitory effect on cell growth at indicated concentrations, as shown in Figures E2-E9.

However, up to 90% of growth inhibition was observed in CG59693-01 antisense oligonucleotide transfected cells treated with different chemotherapeutic agents, as shown in Figures E2-E9. Therefore, knockdown of CG59693-01 expression sensitized NCI-H460 cells to chemotherapeutic agents, such as paclitaxel, gemcitabine, etoposide, daunorubicin and cisplatin.

Role(s) of CG59693-01 in Tumorgenesis: Some lung tumors, especially non-small cell lung tumors, are known to be especially detrimental to health. Such characteristic is strongly associated with the ability of these tumors to have acquired resistance to chemotherapy. As shown above, CG59693-01 gene is over expressed in that subset of lung tumors (see differential expression data, also referred to as RTQ PCR data or as TAQMAN data; see also Hsu et al., Cancer Res 2001 Mar. 15; 61(6):2727-31, Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer). Additionally, over expression of this gene has been linked to chemotherapy resistance in human ovarian carcinoma (Deng H B, Parekh H K, Chow K, Simpkins H., J Biol Chem 2002 Feb. 12; [epub ahead of print], Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells).

The antisense experiments showed that decreasing activity of the enzyme encoded by the CG59693-01 gene reduces the level of drug resistance. This reduction should correlate with an improved clinical outcome in patients treated with chemotherapy.

Impact of therapeutic targeting of CG59693-01: Therapeutic targeting of the enzymatic activity of the protein encoded by CG59693-01 with a small molecule inhibitor is anticipated to reduce or eliminate resistance to chemotherapy in lung cancers, especially non-small cell lung tumors. Additionally, targeting of the enzymatic activity of the CG59693-01 protein with a small molecule inhibitor may be effective in reduction of resistrance to chemotherapy in other types of cancers.

Other Embodiments

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims.

Number	Date	Country
60385615	Jun 2002	US
60402268	Aug 2002	US
60387606	Jun 2002	US
60386357	Jun 2002	US
60385755	Jun 2002	US
60386355	Jun 2002	US
60385490	Jun 2002	US
60420718	Oct 2002	US
60386447	Jun 2002	US
60386465	Jun 2002	US
60420627	Oct 2002	US
60386459	Jun 2002	US
60410505	Sep 2002	US
60420852	Oct 2002	US
60386796	Jun 2002	US
60387078	Jun 2002	US
60387083	Jun 2002	US
60387081	Jun 2002	US
60386041	Jun 2002	US
60386701	Jun 2002	US
60387610	Jun 2002	US
60387540	Jun 2002	US
60387429	Jun 2002	US
60410085	Sep 2002	US
60389120	Jun 2002	US
60386931	Jun 2002	US
60387866	Jun 2002	US
60387859	Jun 2002	US
60387659	Jun 2002	US
60387934	Jun 2002	US
60387696	Jun 2002	US
60390006	Jun 2002	US
60389604	Jun 2002	US
60387668	Jun 2002	US
60386864	Jun 2002	US
60401628	Aug 2002	US
60406182	Aug 2002	US
60412955	Sep 2002	US
60415195	Sep 2002	US
60422750	Oct 2002	US
60390144	Jun 2002	US
60388022	Jun 2002	US
60402822	Aug 2002	US
60388096	Jun 2002	US
60389123	Jun 2002	US
60390209	Jun 2002	US
60388479	Jun 2002	US
60403458	Aug 2002	US
60389884	Jun 2002	US
60389146	Jun 2002	US
60387960	Jun 2002	US
60388432	Jun 2002	US
60403617	Aug 2002	US
60423095	Nov 2002	US
60423748	Nov 2002	US
60391726	Jun 2002	US
60403732	Aug 2002	US
60389742	Jun 2002	US
60156217	Sep 1999	US

	Number	Date	Country
Parent	09669360	Sep 2000	US
Child	10455772	Jun 2003	US

Novel proteins and nucleic acids encoding same

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

Provisional Applications (59)

Continuation in Parts (1)